data_2lmq_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lmq _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 . . . . . 0 N--CA 1.463 0.199 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -126.01 131.52 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.033 0.444 . . . . 0.0 110.467 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.6 p-80 -98.93 162.15 13.24 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.926 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 49.5 p-80 -86.39 169.5 12.85 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.805 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -129.5 151.28 50.29 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.45 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -96.54 124.35 40.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.773 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 91.4 mt -123.94 120.94 33.98 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-O 121.11 0.481 . . . . 0.0 110.76 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -127.41 133.47 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.874 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -133.41 124.43 27.1 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.822 0.344 . . . . 0.0 110.53 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 55.1 p90 -124.21 132.25 53.59 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.91 140.48 32.83 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 41.3 tp10 -107.07 158.35 17.12 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 114.071 -1.422 . . . . 0.0 107.491 177.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 t70 . . . . . 0 C--N 1.33 -0.268 0 C-N-CA 119.594 -0.842 . . . . 0.0 112.455 -178.655 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.547 HD22 ' C ' ' B' ' 27' ' ' ASN . 13.8 t-20 . . . . . 0 CA--C 1.534 0.359 0 CA-C-O 120.409 0.147 . . . . 0.0 110.811 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -73.32 -49.25 28.48 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.96 59.69 0.5 Allowed Glycine 0 CA--C 1.543 1.83 0 C-N-CA 119.976 -1.107 . . . . 0.0 110.372 -175.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.57 92.42 9.08 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 123.513 1.625 . . . . 0.0 113.491 -175.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.43 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 1.1 pt -142.3 122.81 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 111.789 -2.46 . . . . 0.0 106.322 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.443 ' O ' ' O ' ' B' ' 33' ' ' GLY . 58.8 mt -104.83 110.12 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.77 92.08 0.58 Allowed Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 104.609 -3.396 . . . . 0.0 104.609 176.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 82.0 mt -146.45 169.62 18.52 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-O 122.954 1.359 . . . . 0.0 112.814 -175.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 53.3 mtp -141.75 119.31 11.66 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.781 -2.009 . . . . 0.0 108.735 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.7 m -124.74 113.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.05 -123.95 1.19 Allowed Glycine 0 C--N 1.305 -1.185 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.441 ' O ' ' CG1' ' B' ' 39' ' ' VAL . . . 80.73 -67.39 3.56 Favored Glycine 0 CA--C 1.535 1.318 0 C-N-CA 120.387 -0.911 . . . . 0.0 111.328 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.23 156.11 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.145 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 87.7 t80 -87.5 126.34 34.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.341 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.04 140.78 34.32 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.555 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 62.4 t -127.6 132.78 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.044 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 86.0 m-70 -143.02 94.08 2.58 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.831 0.348 . . . . 0.0 110.695 179.344 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.609 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 6.9 t60 -158.56 170.18 22.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.813 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.609 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 51.3 tt0 -155.42 141.18 18.06 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.898 0.38 . . . . 0.0 110.213 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -89.0 124.42 34.25 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.27 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 tp -120.96 117.52 27.5 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 177.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.5 129.38 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.787 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -128.78 121.75 29.04 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.717 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.611 ' CD2' ' CD1' ' C' ' 20' ' ' PHE . 7.4 m-85 -122.46 129.03 51.6 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.17 137.4 34.36 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.527 0.68 . . . . 0.0 112.793 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' A' ' 22' ' ' GLU . 86.8 mt-10 -96.09 118.82 33.45 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.303 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -143.43 51.71 1.36 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.316 -179.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 71.3 t -75.7 143.49 13.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.957 0.884 . . . . 0.0 110.807 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.65 38.23 3.99 Favored Glycine 0 CA--C 1.525 0.656 0 CA-C-N 113.813 -1.539 . . . . 0.0 109.373 -178.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.9 t 73.18 120.01 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 115.241 -0.479 . . . . 0.0 110.608 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.748 HD22 ' H ' ' B' ' 30' ' ' ALA . 3.8 p30 -83.07 163.78 20.7 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 119.571 -0.851 . . . . 0.0 108.809 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -46.98 -37.06 8.5 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.249 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' B' ' 31' ' ' ILE . . . 179.53 77.05 0.06 OUTLIER Glycine 0 CA--C 1.531 1.068 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.823 -177.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.748 ' H ' HD22 ' B' ' 27' ' ' ASN . . . -51.77 91.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 119.371 1.586 . . . . 0.0 110.776 -179.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.455 ' N ' ' O ' ' B' ' 29' ' ' GLY . 66.8 mt -132.98 133.51 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.742 -177.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -107.96 109.7 29.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -113.29 97.05 0.84 Allowed Glycine 0 CA--C 1.507 -0.465 0 N-CA-C 104.19 -3.564 . . . . 0.0 104.19 176.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 40.1 tp -141.71 147.29 37.2 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 122.978 1.371 . . . . 0.0 113.47 -173.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 11.6 mtp -116.6 112.62 21.56 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 112.662 -2.063 . . . . 0.0 108.826 178.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 30.1 m -127.24 123.07 61.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 142.77 -113.52 0.79 Allowed Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.428 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 73.77 -72.74 1.27 Allowed Glycine 0 CA--C 1.535 1.29 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.441 ' CG1' ' O ' ' A' ' 38' ' ' GLY . 14.7 p -158.65 138.58 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 178.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.48 ' CG1' ' CD2' ' D' ' 13' ' ' HIS . 1.9 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.504 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -107.85 131.81 54.1 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.32 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -129.59 125.16 35.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.151 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -130.24 134.45 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.083 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.577 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 3.9 t60 -139.95 139.85 36.22 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.544 ' HE2' ' CB ' ' D' ' 16' ' ' LYS . 52.5 t60 -155.56 168.78 26.04 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.508 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.441 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.1 tt0 -138.74 140.81 38.82 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -130.4 113.47 14.37 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 35.6 mt -118.79 110.94 17.82 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.745 178.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 23.1 t -109.15 110.88 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -106.53 108.64 20.25 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.611 ' CD1' ' CD2' ' B' ' 20' ' ' PHE . 14.6 t80 -114.91 124.71 52.41 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 122.424 -0.173 . . . . 0.0 111.273 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 139.57 26.98 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.447 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 98.0 mt-10 -89.89 143.2 26.99 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.481 178.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.447 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 0.0 OUTLIER -164.66 50.44 0.12 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -177.893 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 37.6 t -80.87 149.37 5.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 122.83 1.3 . . . . 0.0 112.417 -174.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.6 36.92 5.69 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 112.052 -2.34 . . . . 0.0 110.28 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' D' ' 24' ' ' VAL . 19.8 t 72.64 120.12 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.789 0.835 . . . . 0.0 110.028 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.664 ' ND2' ' H ' ' B' ' 30' ' ' ALA . 25.9 t30 -83.18 161.99 21.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 116.991 -1.884 . . . . 0.0 110.284 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -47.41 -37.03 10.66 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.421 ' H ' ' ND2' ' C' ' 27' ' ' ASN . . . -178.76 78.16 0.06 OUTLIER Glycine 0 CA--C 1.538 1.508 0 CA-C-O 119.294 -0.726 . . . . 0.0 112.343 -173.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.635 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . -79.18 119.04 21.71 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 123.299 1.524 . . . . 0.0 112.997 -175.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 78.4 mt -139.1 139.89 39.22 Favored 'Isoleucine or valine' 0 C--N 1.353 0.724 0 CA-C-N 112.32 -2.218 . . . . 0.0 113.426 -176.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.405 HD13 HG22 ' C' ' 32' ' ' ILE . 64.1 mt -109.11 112.36 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.31 98.43 0.93 Allowed Glycine 0 C--O 1.238 0.392 0 N-CA-C 106.069 -2.812 . . . . 0.0 106.069 177.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 13.0 tp -133.26 134.59 44.14 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 122.495 1.14 . . . . 0.0 113.931 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.5 mtp -104.88 106.83 17.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 175.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 12.6 p -123.02 122.98 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.97 -113.11 0.55 Allowed Glycine 0 C--N 1.312 -0.801 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -177.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.51 ' O ' ' O ' ' C' ' 39' ' ' VAL . . . 55.73 64.98 3.89 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 119.789 -1.196 . . . . 0.0 112.61 178.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' C' ' 38' ' ' GLY . 33.8 m 16.08 114.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.491 179.972 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 t . . . . . 0 N--CA 1.466 0.338 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 3.5 t60 -143.89 122.72 12.68 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 110.372 -0.233 . . . . 0.0 110.372 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.663 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -118.77 161.53 19.96 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.114 0.483 . . . . 0.0 110.316 178.714 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -85.05 157.04 20.84 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.544 ' CB ' ' HE2' ' C' ' 14' ' ' HIS . 87.0 tttt -160.31 102.21 1.4 Allowed 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.321 177.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 3.1 mt -126.73 121.51 32.22 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -112.4 112.31 39.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -107.64 107.02 17.63 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.545 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 32.5 t80 -110.56 120.56 42.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 -178.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.87 144.99 27.26 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 118.748 -1.181 . . . . 0.0 113.687 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.434 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 98.1 mt-10 -96.05 136.36 36.61 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.99 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' E' ' 22' ' ' GLU . 12.3 m-20 -160.13 49.95 0.29 Allowed 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.647 -178.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' C' ' 26' ' ' SER . 35.7 m -81.67 150.65 4.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 122.601 1.191 . . . . 0.0 113.49 -176.096 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' E' ' 24' ' ' VAL . . . 93.94 36.97 5.59 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-N 112.59 -2.096 . . . . 0.0 111.705 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.461 ' O ' ' OG ' ' C' ' 26' ' ' SER . 0.7 OUTLIER 72.77 120.11 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.333 -0.434 . . . . 0.0 111.544 175.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.635 ' ND2' ' H ' ' C' ' 30' ' ' ALA . 13.4 t30 -83.07 162.3 21.4 Favored 'General case' 0 C--O 1.231 0.103 0 C-N-CA 117.94 -1.504 . . . . 0.0 107.997 176.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.614 ' NZ ' ' ND1' ' Q' ' 13' ' ' HIS . 83.1 tttt -47.53 -37.45 12.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.489 177.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.79 0.06 OUTLIER Glycine 0 CA--C 1.539 1.589 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.554 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.77 119.67 4.47 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -125.5 125.17 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.517 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 mt -106.82 112.71 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 173.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.13 114.71 2.01 Favored Glycine 0 N--CA 1.462 0.429 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -160.78 158.16 28.08 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 123.21 1.481 . . . . 0.0 113.595 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mmm -110.72 111.64 22.97 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 111.967 -2.378 . . . . 0.0 108.882 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 9.0 t -106.09 112.74 40.62 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.714 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -179.09 -121.96 0.74 Allowed Glycine 0 C--N 1.304 -1.22 0 C-N-CA 118.331 -1.89 . . . . 0.0 111.643 -179.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 63.63 61.55 6.12 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 119.65 -1.262 . . . . 0.0 111.347 -178.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.46 ' CG2' ' O ' ' E' ' 39' ' ' VAL . 5.6 p -18.62 122.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.992 179.112 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.144 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -83.73 139.8 32.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.799 0.333 . . . . 0.0 110.758 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.467 ' OE2' ' NE2' ' D' ' 14' ' ' HIS . 79.4 tt0 -155.22 151.24 27.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.988 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.565 ' O ' ' CE1' ' D' ' 14' ' ' HIS . 59.0 t -140.51 168.01 17.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.778 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.499 ' CB ' ' O ' ' D' ' 13' ' ' HIS . 20.8 p-80 -64.34 140.85 58.91 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.601 ' HE2' ' CG1' ' F' ' 12' ' ' VAL . 65.0 m80 -150.63 166.43 30.33 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.697 177.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -89.82 150.99 22.0 Favored 'General case' 0 CA--C 1.522 -0.114 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -152.24 99.18 2.49 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 176.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.549 ' CD2' ' N ' ' E' ' 17' ' ' LEU . 1.3 mm? -118.33 114.11 22.46 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -110.18 106.65 21.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -103.15 103.75 13.84 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 30.3 t80 -110.39 118.52 36.52 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 121.138 -0.225 . . . . 0.0 111.027 -178.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.48 137.01 28.24 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 118.907 -1.117 . . . . 0.0 113.155 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' D' ' 23' ' ' ASP . 97.7 mt-10 -88.37 115.57 25.97 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 177.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' F' ' 22' ' ' GLU . 0.0 OUTLIER -148.57 48.85 1.02 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -175.485 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' D' ' 25' ' ' GLY . 67.2 t -71.9 160.1 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 118.007 -1.477 . . . . 0.0 108.199 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.08 -36.62 4.12 Favored Glycine 0 N--CA 1.464 0.541 0 N-CA-C 108.097 -2.001 . . . . 0.0 108.097 -178.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.469 ' HG ' ' H ' ' D' ' 27' ' ' ASN . 4.2 m -65.79 112.52 3.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 113.22 -1.49 . . . . 0.0 110.622 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -148.98 162.33 40.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.758 0.789 . . . . 0.0 110.922 -178.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 29.84 43.11 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.785 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.19 59.69 0.13 Allowed Glycine 0 CA--C 1.543 1.803 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.484 173.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.72 141.26 40.97 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.534 -0.746 . . . . 0.0 110.322 177.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 1.6 tt -132.52 125.33 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 CA-C-N 119.606 1.094 . . . . 0.0 110.232 176.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 87.1 mt -127.45 127.29 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.851 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.96 107.04 0.86 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 7.3 tt -122.9 123.86 41.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 86.1 mtp -134.08 145.57 49.49 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 119.958 -0.697 . . . . 0.0 112.391 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -124.23 136.85 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.885 0.85 . . . . 0.0 110.659 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.78 103.28 0.39 Allowed Glycine 0 C--N 1.315 -0.63 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' E' ' 39' ' ' VAL . . . 127.12 75.75 0.21 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.157 -178.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.46 ' O ' ' CG2' ' D' ' 39' ' ' VAL . 7.3 t . . . . . 0 N--CA 1.479 1.012 0 C-N-CA 123.628 0.771 . . . . 0.0 112.981 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 C--O 1.231 0.102 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.601 ' CG1' ' HE2' ' E' ' 14' ' ' HIS . 18.2 t -132.64 133.33 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.505 0.669 . . . . 0.0 111.379 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.511 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 0.3 OUTLIER -146.05 117.26 7.87 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.992 179.417 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 76.9 m80 -156.71 165.52 36.02 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.672 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -84.19 155.28 22.61 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.743 178.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -159.98 100.18 1.4 Allowed 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 121.291 0.567 . . . . 0.0 109.865 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.5 mp -125.62 114.92 19.35 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.331 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 12.4 t -99.83 102.61 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.919 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 178.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -95.16 95.22 8.4 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.413 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 64.8 t80 -111.16 113.52 26.1 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-O 121.548 0.69 . . . . 0.0 109.202 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.74 134.76 17.95 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 120.361 -0.536 . . . . 0.0 109.581 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' E' ' 23' ' ' ASP . 96.3 mt-10 -76.74 85.02 3.36 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 178.466 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 51.1 p30 . . . . . 0 CA--C 1.517 -0.306 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.488 -175.178 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.912 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 85.9 mt -115.59 112.12 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 120.667 1.576 . . . . 0.0 111.562 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.412 HD11 HG22 ' F' ' 32' ' ' ILE . 90.7 mt -123.97 123.19 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.89 119.55 3.03 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 38.4 mt -122.87 119.7 31.31 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mtp -140.6 151.38 44.62 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 -178.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 m -127.41 164.55 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.421 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.36 -102.82 0.09 OUTLIER Glycine 0 CA--C 1.525 0.664 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.653 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.09 -77.83 1.24 Allowed Glycine 0 CA--C 1.536 1.38 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.473 ' CG2' ' N ' ' F' ' 40' ' ' VAL . 3.4 p -125.78 162.48 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 117.208 0.504 . . . . 0.0 111.266 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.473 ' N ' ' CG2' ' F' ' 39' ' ' VAL . 9.6 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.58 -178.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 77.5 t . . . . . 0 N--CA 1.463 0.198 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -145.38 131.6 19.48 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.42 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.6 p-80 -152.02 167.49 28.25 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.805 178.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -157.53 142.91 17.13 Favored 'General case' 0 CA--C 1.52 -0.202 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -81.53 126.2 31.41 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.584 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.7 mt -126.52 118.23 24.48 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -141.88 139.79 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 121.026 0.441 . . . . 0.0 110.999 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -134.74 131.84 38.07 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.58 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.498 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 55.1 p90 -131.06 130.34 43.12 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.93 0.395 . . . . 0.0 111.042 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.12 117.37 26.98 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.016 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -143.31 147.44 34.74 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.462 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 C--N 1.327 -0.373 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.035 179.776 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.527 ' C ' ' HZ1' ' H' ' 28' ' ' LYS . 9.1 m120 . . . . . 0 N--CA 1.483 1.187 0 N-CA-C 115.41 1.634 . . . . 0.0 115.41 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -173.86 -21.04 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.419 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.539 ' N ' ' OD2' ' H' ' 23' ' ' ASP . . . 71.66 -97.9 0.73 Allowed Glycine 0 N--CA 1.465 0.624 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.61 97.02 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.112 0.482 . . . . 0.0 111.487 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 91.2 mt -123.03 110.83 27.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -113.76 107.32 22.63 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.78 100.08 0.92 Allowed Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 104.393 -3.483 . . . . 0.0 104.393 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 48.3 tp -150.36 149.28 29.86 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-O 123.034 1.397 . . . . 0.0 113.954 -174.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 mtp -105.64 106.32 16.76 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 112.183 -2.281 . . . . 0.0 106.015 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.468 ' O ' ' CG1' ' G' ' 36' ' ' VAL . 3.8 p -128.47 113.95 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.43 -124.9 1.95 Allowed Glycine 0 C--N 1.307 -1.061 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.1 -66.89 3.7 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.995 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.495 ' CG2' ' H ' ' G' ' 40' ' ' VAL . 12.6 p -108.08 176.01 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . 0.528 ' O ' ' CE1' ' I' ' 13' ' ' HIS . 2.5 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.116 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.347 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -105.64 132.44 51.78 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -159.48 114.43 2.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.069 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.453 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 79.6 t -126.66 128.9 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.483 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 43.4 m-70 -147.61 114.97 6.28 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.462 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.489 ' CE1' ' H ' ' I' ' 14' ' ' HIS . 12.9 m-70 -149.74 169.07 21.92 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -156.52 141.58 17.24 Favored 'General case' 0 CA--C 1.518 -0.278 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 177.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -86.85 120.5 28.2 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.218 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.418 ' C ' ' CD1' ' H' ' 17' ' ' LEU . 0.6 OUTLIER -117.22 113.91 22.89 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.007 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.1 t -122.17 131.03 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 120.867 0.365 . . . . 0.0 111.386 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 37.7 t80 -126.98 116.81 21.33 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.614 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 8.0 t80 -122.63 127.2 49.05 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.95 134.84 32.11 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 112.754 0.649 . . . . 0.0 112.754 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -107.71 121.24 44.31 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.272 178.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.539 ' OD2' ' N ' ' G' ' 29' ' ' GLY . 93.6 m-20 -140.33 46.38 1.82 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.012 -178.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.622 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 20.6 t -81.68 177.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.36 -177.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.622 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . 92.72 -33.92 4.77 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.426 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.55 ' O ' ' O ' ' H' ' 27' ' ' ASN . 37.0 t -162.52 120.31 2.09 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 119.062 1.431 . . . . 0.0 113.502 177.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.55 ' O ' ' O ' ' H' ' 26' ' ' SER . 53.4 p-10 -22.41 153.23 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.946 0 O-C-N 124.266 0.979 . . . . 0.0 112.05 175.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.527 ' HZ1' ' C ' ' G' ' 27' ' ' ASN . 61.7 tttt -165.43 26.42 0.05 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 118.392 -1.323 . . . . 0.0 114.162 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.561 ' H ' ' H ' ' I' ' 28' ' ' LYS . . . 82.03 108.01 0.4 Allowed Glycine 0 CA--C 1.525 0.717 0 C-N-CA 118.987 -1.578 . . . . 0.0 114.448 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.433 ' HB3' HD21 ' I' ' 27' ' ' ASN . . . -120.49 106.49 11.86 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 122.118 0.961 . . . . 0.0 109.273 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 tt -141.45 132.66 27.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 CA-C-N 114.687 -1.142 . . . . 0.0 111.83 -177.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.13 111.69 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.48 103.18 1.42 Allowed Glycine 0 N--CA 1.46 0.248 0 N-CA-C 105.543 -3.023 . . . . 0.0 105.543 177.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.47 145.12 30.08 Favored 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 117.92 -1.512 . . . . 0.0 114.271 -174.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.4 mtp -111.12 112.34 24.07 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 112.935 -1.938 . . . . 0.0 107.02 176.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -119.69 102.88 13.43 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.88 -151.56 20.16 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.97 -56.55 0.54 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.448 ' CG1' ' C ' ' G' ' 39' ' ' VAL . 6.3 p -153.69 161.12 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 177.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.441 ' N ' ' CG2' ' H' ' 39' ' ' VAL . 14.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.787 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -111.89 133.94 53.76 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.731 0.301 . . . . 0.0 110.557 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -155.39 144.95 21.19 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.895 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -127.37 118.67 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.108 0.48 . . . . 0.0 109.946 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' O ' ' G' ' 40' ' ' VAL . 2.9 t-80 -147.83 120.2 8.43 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.588 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.489 ' H ' ' CE1' ' H' ' 14' ' ' HIS . 4.8 m170 -122.48 162.74 21.15 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 120.794 -0.362 . . . . 0.0 110.823 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.03 153.94 20.19 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.728 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -145.47 97.07 2.93 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.646 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -121.14 121.91 38.86 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.347 178.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -117.11 110.16 30.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -107.76 108.97 20.43 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 28.0 t80 -115.68 126.33 53.98 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.91 135.82 34.83 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -94.09 140.6 29.54 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.532 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 7.4 p-10 -176.83 52.14 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.697 0.284 . . . . 0.0 110.442 -175.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 p -74.52 143.16 13.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 122.653 1.216 . . . . 0.0 112.637 -175.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.452 ' O ' ' OG ' ' I' ' 26' ' ' SER . . . 99.53 38.22 3.77 Favored Glycine 0 CA--C 1.529 0.961 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.434 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 7.0 p 73.17 120.2 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.131 -0.535 . . . . 0.0 111.907 176.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.609 ' O ' ' N ' ' I' ' 29' ' ' GLY . 2.4 m-20 -83.93 152.68 24.36 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 118.257 -1.377 . . . . 0.0 108.669 175.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.561 ' H ' ' H ' ' H' ' 29' ' ' GLY . 30.1 mtmt -50.68 43.66 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.862 0 CA-C-O 116.966 -1.492 . . . . 0.0 114.178 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 120.94 77.44 0.47 Allowed Glycine 0 N--CA 1.487 2.04 0 CA-C-N 122.555 2.434 . . . . 0.0 113.013 -178.229 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.22 112.12 18.25 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.316 1.558 . . . . 0.0 111.8 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 12.7 tt -145.74 141.67 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -177.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 38.3 mt -111.16 113.19 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 176.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.01 99.93 0.95 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 177.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 5.9 mp -136.22 148.22 47.98 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 123.411 1.577 . . . . 0.0 114.124 -176.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -116.59 106.31 13.41 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 111.724 -2.489 . . . . 0.0 104.526 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' J' ' 36' ' ' VAL . 38.6 t -126.58 142.75 42.25 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.74 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.152 -175.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.73 -101.99 0.71 Allowed Glycine 0 C--N 1.312 -0.768 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.41 ' O ' ' CG2' ' J' ' 39' ' ' VAL . . . 66.69 -80.09 0.12 Allowed Glycine 0 CA--C 1.533 1.204 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.665 -179.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 40' ' ' VAL . 21.9 t -116.28 131.3 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 C-N-CA 123.068 0.547 . . . . 0.0 109.998 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 39' ' ' VAL . 8.8 p . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 118.038 -0.982 . . . . 0.0 111.43 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -108.39 136.28 48.29 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.741 0.305 . . . . 0.0 110.24 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -78.13 108.98 11.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.96 129.72 68.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.757 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' K' ' 14' ' ' HIS . 67.1 m80 -124.88 127.31 46.91 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.823 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.629 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 12.7 t60 -152.09 170.43 19.96 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.228 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.629 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 32.8 tt0 -138.5 140.65 39.25 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -130.57 104.28 7.13 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.464 ' CD1' ' CG ' ' J' ' 15' ' ' GLN . 6.3 mp -122.8 120.2 32.85 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.736 177.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -113.7 112.25 39.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.911 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.441 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 43.7 m-85 -109.4 108.13 18.55 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 37.2 t80 -116.66 125.12 51.29 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.58 0.228 . . . . 0.0 110.955 -179.278 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.94 133.49 33.8 Favored 'General case' 0 C--O 1.241 0.627 0 CA-C-O 121.452 0.644 . . . . 0.0 111.842 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.453 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 80.1 tt0 -90.47 119.75 31.01 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.534 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.537 ' CG ' HD22 ' I' ' 27' ' ' ASN . 0.2 OUTLIER -147.39 52.05 1.06 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.443 -0.799 . . . . 0.0 108.901 -178.14 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.89 143.14 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 122.448 1.118 . . . . 0.0 112.793 -175.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.09 38.16 3.9 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 112.699 -2.046 . . . . 0.0 112.197 178.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 22.0 t 72.68 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.453 0.701 . . . . 0.0 111.11 176.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -83.18 161.75 21.46 Favored 'General case' 0 C--N 1.34 0.194 0 C-N-CA 117.18 -1.808 . . . . 0.0 110.221 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -47.7 -37.28 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 175.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.03 78.06 0.06 OUTLIER Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.741 -1.033 . . . . 0.0 112.236 -172.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.84 116.87 19.45 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 120.076 1.938 . . . . 0.0 111.66 -175.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 5.0 tt -134.01 136.91 53.04 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 CA-C-N 112.253 -2.249 . . . . 0.0 113.134 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.444 HD11 HG21 ' J' ' 32' ' ' ILE . 89.4 mt -113.09 122.66 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 120.999 0.428 . . . . 0.0 110.609 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.85 104.42 0.97 Allowed Glycine 0 N--CA 1.462 0.396 0 N-CA-C 106.339 -2.704 . . . . 0.0 106.339 176.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.42 ' CD2' ' N ' ' J' ' 35' ' ' MET . 5.0 tt -144.46 142.85 30.57 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-O 122.578 1.18 . . . . 0.0 112.47 -175.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.42 ' N ' ' CD2' ' J' ' 34' ' ' LEU . 28.6 mtp -116.32 115.05 25.21 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.145 -1.843 . . . . 0.0 108.779 178.367 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' I' ' 36' ' ' VAL . 0.1 OUTLIER -97.62 111.35 27.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.512 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 178.956 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.52 131.49 42.96 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.331 -177.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.95 63.51 3.16 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 121.279 -0.486 . . . . 0.0 111.938 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.41 ' CG2' ' O ' ' I' ' 38' ' ' GLY . 42.7 t -124.62 126.36 71.54 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 CA-C-O 121.461 0.648 . . . . 0.0 110.029 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.589 -179.208 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.66 135.76 48.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.657 0.265 . . . . 0.0 110.506 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.16 111.65 16.76 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.334 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 4.5 m -130.67 126.56 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.185 0.517 . . . . 0.0 111.03 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.622 ' CE1' ' HZ2' ' P' ' 28' ' ' LYS . 56.7 m170 -110.16 157.58 19.24 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.699 ' CD2' ' H ' ' K' ' 15' ' ' GLN . 29.1 t60 -158.01 178.02 10.68 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 119.434 -0.906 . . . . 0.0 112.826 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.699 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 31.6 tt0 -160.37 140.57 11.48 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 114.197 -1.365 . . . . 0.0 107.54 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -159.48 115.97 2.58 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.947 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -128.07 125.03 38.49 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 114.395 -1.275 . . . . 0.0 109.196 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 26.3 m -116.03 121.09 66.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.441 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 24.1 m-85 -109.16 109.85 20.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.695 -178.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -111.92 118.67 36.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 122.357 -0.214 . . . . 0.0 111.04 -179.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.66 126.74 27.94 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 110.315 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' J' ' 23' ' ' ASP . 75.4 mt-10 -87.8 140.58 29.36 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.406 -179.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.522 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 7.0 p-10 178.52 48.87 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 17.8 m -72.16 160.61 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 119.309 -0.956 . . . . 0.0 109.887 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.22 -33.25 5.95 Favored Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.149 177.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 1.7 p -72.23 129.98 39.73 Favored 'General case' 0 N--CA 1.465 0.325 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 46.5 t-20 -90.86 143.65 26.5 Favored 'General case' 0 C--O 1.232 0.154 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 176.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.48 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 51.7 tttp 43.52 42.84 4.22 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' L' ' 23' ' ' ASP . . . -101.69 60.48 0.58 Allowed Glycine 0 N--CA 1.476 1.308 0 CA-C-O 119.269 -0.74 . . . . 0.0 114.111 -178.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.86 119.95 4.94 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 119.204 1.502 . . . . 0.0 111.772 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 74.3 mt -121.6 116.83 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -124.17 128.3 73.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.22 103.18 0.79 Allowed Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.024 -2.03 . . . . 0.0 108.024 177.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 30.2 tp -117.11 121.4 41.17 Favored 'General case' 0 C--O 1.24 0.58 0 CA-C-O 121.265 0.555 . . . . 0.0 110.007 -178.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 18.5 ttm -120.86 129.86 53.69 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.16 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' K' ' 37' ' ' GLY . 54.9 t -115.78 131.93 66.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.886 178.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -45.03 -111.73 0.0 OUTLIER Glycine 0 CA--C 1.529 0.915 0 CA-C-N 115.519 -0.764 . . . . 0.0 112.349 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -107.15 -71.69 0.77 Allowed Glycine 0 CA--C 1.534 1.223 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 54.1 t . . . . . 0 CA--C 1.506 -0.719 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.766 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.562 0.22 . . . . 0.0 110.488 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 m -129.93 135.78 60.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.081 0.467 . . . . 0.0 111.567 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 5.1 p80 -146.85 97.97 2.98 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.275 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -154.69 162.59 41.06 Favored 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -89.95 159.24 17.01 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.203 0.525 . . . . 0.0 111.632 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -140.06 110.6 6.72 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.791 177.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 mt -118.09 112.19 19.89 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.555 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 9.0 t -104.21 100.67 10.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -94.44 99.87 11.97 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -116.24 112.17 21.22 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.466 0.651 . . . . 0.0 110.984 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.1 135.41 32.52 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 107.842 -1.169 . . . . 0.0 107.842 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.447 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 80.3 mm-40 -73.39 108.89 6.51 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 118.627 -1.229 . . . . 0.0 108.401 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' L' ' 24' ' ' VAL . 64.9 m-20 -164.03 61.39 0.16 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.514 -176.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' L' ' 23' ' ' ASP . 8.9 t 55.63 155.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.153 -177.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.24 24.2 0.19 Allowed Glycine 0 CA--C 1.521 0.413 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 40.3 t -81.86 -120.93 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' L' ' 29' ' ' GLY . 99.3 m-20 -93.05 -165.61 1.37 Allowed 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.754 -0.778 . . . . 0.0 109.502 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -47.98 47.68 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 115.732 1.753 . . . . 0.0 115.732 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.64 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.31 56.86 0.89 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-N 119.253 0.933 . . . . 0.0 112.339 177.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.62 169.8 9.97 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 8.3 mm -112.98 111.31 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 176.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -125.75 130.1 72.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.594 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.0 116.48 2.73 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 56.9 tp -118.32 123.08 44.47 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttm -125.66 124.99 42.35 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.24 132.45 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.8 112.13 3.6 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.193 -178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.97 -71.17 0.01 OUTLIER Glycine 0 CA--C 1.538 1.521 0 N-CA-C 115.216 0.847 . . . . 0.0 115.216 177.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' K' ' 38' ' ' GLY . 54.1 t . . . . . 0 C--O 1.214 -0.765 0 CA-C-N 117.96 0.88 . . . . 0.0 112.007 -178.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.814 0.34 . . . . 0.0 110.784 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -122.01 131.29 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.01 0.434 . . . . 0.0 110.07 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -119.27 130.35 55.38 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.273 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.598 ' HE2' ' CG1' ' N' ' 12' ' ' VAL . 13.6 m-70 -83.23 167.09 18.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.138 0.494 . . . . 0.0 111.126 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -93.38 159.98 15.01 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.425 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.145 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 88.7 mt -130.1 130.75 45.24 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.965 0.412 . . . . 0.0 111.465 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 67.3 t -133.75 132.2 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.963 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -138.67 136.71 36.14 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.171 0.51 . . . . 0.0 112.001 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -121.11 125.15 46.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.063 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.62 113.75 25.49 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 121.345 0.593 . . . . 0.0 111.224 -179.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . 0.418 ' OE1' ' OE2' ' N' ' 22' ' ' GLU . 12.4 pt-20 -173.16 150.31 1.92 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.724 179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 56.03 46.95 20.77 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.158 178.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -101.03 -170.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.12 -32.43 84.01 Favored Glycine 0 N--CA 1.468 0.822 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.241 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 47.6 t -152.88 125.11 8.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.366 0.583 . . . . 0.0 109.789 177.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . 0.427 ' N ' ' OD1' ' M' ' 27' ' ' ASN . 1.9 m-20 -38.93 134.58 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.956 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.67 -39.54 4.84 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 122.192 0.996 . . . . 0.0 108.39 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.89 -69.29 3.09 Favored Glycine 0 CA--C 1.534 1.261 0 CA-C-N 113.348 -1.751 . . . . 0.0 110.753 -178.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.6 82.38 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 117.335 0.568 . . . . 0.0 111.009 176.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 14.6 tt -121.4 104.58 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 119.592 1.087 . . . . 0.0 109.482 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -124.39 116.59 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 CA-C-O 121.402 0.62 . . . . 0.0 111.618 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.83 104.93 0.86 Allowed Glycine 0 N--CA 1.464 0.529 0 N-CA-C 106.086 -2.806 . . . . 0.0 106.086 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 85.7 mt -145.28 159.81 42.46 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 123.3 1.524 . . . . 0.0 114.214 -176.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 35.4 tpp -107.08 108.5 20.01 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.844 -2.435 . . . . 0.0 105.85 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 4.7 m -119.57 123.06 70.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 119.055 0.843 . . . . 0.0 109.68 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.25 -113.7 0.9 Allowed Glycine 0 C--N 1.31 -0.897 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.43 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . 95.48 -72.13 0.95 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 112.318 -0.313 . . . . 0.0 112.318 179.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 40' ' ' VAL . 2.4 t -122.29 159.23 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 O-C-N 122.691 -0.3 . . . . 0.0 110.621 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 39' ' ' VAL . 2.9 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.827 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -108.21 132.48 53.61 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.835 0.35 . . . . 0.0 110.401 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -125.88 126.86 45.11 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.027 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . 0.598 ' CG1' ' HE2' ' M' ' 14' ' ' HIS . 59.2 t -127.73 130.33 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-O 120.871 0.367 . . . . 0.0 110.994 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.497 ' O ' ' CD2' ' M' ' 14' ' ' HIS . 29.8 t-80 -79.66 161.31 25.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.813 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . . . . . . . . . 29.8 p-80 -93.26 163.18 13.71 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.216 0.531 . . . . 0.0 111.322 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -89.88 160.12 16.61 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.61 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.22 131.6 28.48 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -132.59 127.37 34.86 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.348 0.594 . . . . 0.0 111.199 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.5 130.77 72.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.613 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -132.43 122.41 24.93 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.086 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 5.7 t80 -121.15 127.6 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.285 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.49 117.3 25.6 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.418 ' OE2' ' OE1' ' M' ' 22' ' ' GLU . 97.7 mt-10 -81.59 179.63 7.76 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 119.811 -0.755 . . . . 0.0 109.297 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.489 ' O ' ' CB ' ' N' ' 24' ' ' VAL . 62.3 t0 -60.53 -46.91 88.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 119.193 -1.003 . . . . 0.0 108.494 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.727 ' CG1' ' H ' ' N' ' 25' ' ' GLY . 9.4 t 99.81 -161.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.727 ' H ' ' CG1' ' N' ' 24' ' ' VAL . . . -71.32 -33.4 64.53 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' N' ' 27' ' ' ASN . 34.2 t -162.55 120.55 2.1 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.577 ' O ' ' O ' ' N' ' 26' ' ' SER . 41.2 t-20 -22.0 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 114.682 -1.145 . . . . 0.0 112.443 177.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.518 ' N ' ' OD1' ' N' ' 27' ' ' ASN . 69.9 tttt -163.03 24.39 0.09 Allowed 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.9 107.68 1.25 Allowed Glycine 0 N--CA 1.476 1.35 0 C-N-CA 117.506 -2.283 . . . . 0.0 113.929 177.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.53 102.69 11.52 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 123.637 1.684 . . . . 0.0 109.912 -178.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 20.7 mt -130.19 130.48 65.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 112.388 -2.187 . . . . 0.0 110.824 -176.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 10.1 tt -123.6 116.3 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.805 0.812 . . . . 0.0 109.844 176.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.1 111.58 3.26 Favored Glycine 0 C--N 1.333 0.411 0 N-CA-C 107.02 -2.432 . . . . 0.0 107.02 178.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -137.88 139.22 39.75 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 122.633 1.206 . . . . 0.0 113.636 -176.094 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 95.7 mmm -106.36 111.56 24.19 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -117.19 123.15 71.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -178.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.38 -113.0 0.55 Allowed Glycine 0 C--N 1.306 -1.12 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.747 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.78 -73.16 2.71 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' M' ' 40' ' ' VAL . 62.8 t -138.17 138.39 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.062 0.545 . . . . 0.0 109.777 179.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' O' ' 40' ' ' VAL . 46.5 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.538 -0.744 . . . . 0.0 111.681 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.96 137.4 46.03 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.873 0.368 . . . . 0.0 110.521 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -93.23 113.31 25.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.374 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -125.28 128.72 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 120.781 0.324 . . . . 0.0 110.167 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -131.29 138.27 49.18 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.612 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 83.2 t60 -154.64 153.85 32.02 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 118.346 -1.342 . . . . 0.0 112.836 179.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 33.8 tt0 -90.63 164.44 14.18 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.721 177.19 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 102.18 0.33 Allowed 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mt -122.86 119.59 30.98 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.414 179.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 15.6 t -106.96 115.32 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.401 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -113.87 105.48 13.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 12.5 t80 -107.2 125.46 51.14 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.39 135.59 44.77 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -177.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -112.19 139.87 47.37 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.452 177.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -156.41 46.52 0.44 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.814 0.34 . . . . 0.0 110.127 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.503 ' CG1' ' H ' ' O' ' 25' ' ' GLY . 3.0 t -82.64 174.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 122.314 1.054 . . . . 0.0 112.552 -176.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.503 ' H ' ' CG1' ' O' ' 24' ' ' VAL . . . 92.59 -35.91 3.88 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-N 113.228 -1.805 . . . . 0.0 112.661 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.647 ' O ' ' O ' ' O' ' 27' ' ' ASN . 21.6 p -172.28 113.74 0.3 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 118.974 1.387 . . . . 0.0 112.218 175.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.647 ' O ' ' O ' ' O' ' 26' ' ' SER . 25.2 p30 -10.59 153.34 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 0 O-C-N 124.55 1.157 . . . . 0.0 113.994 176.428 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.513 ' NZ ' ' O ' ' N' ' 27' ' ' ASN . 32.2 tttt -166.33 26.19 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 118.457 -1.297 . . . . 0.0 113.843 172.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.65 107.33 0.37 Allowed Glycine 0 CA--C 1.53 0.982 0 C-N-CA 119.318 -1.42 . . . . 0.0 112.474 178.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . 0.696 ' H ' HD21 ' P' ' 27' ' ' ASN . . . -120.97 112.48 18.81 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 83.6 mt -131.68 131.85 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -176.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . 0.421 HG23 HD11 ' O' ' 32' ' ' ILE . 88.6 mt -108.22 106.06 19.96 Favored 'Isoleucine or valine' 0 C--N 1.344 0.351 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 174.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.58 101.58 1.23 Allowed Glycine 0 N--CA 1.464 0.541 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mp -139.78 146.46 39.49 Favored 'General case' 0 CA--C 1.508 -0.638 0 CA-C-O 123.14 1.447 . . . . 0.0 113.329 -176.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 12.3 mtp -113.24 108.66 17.57 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 111.828 -2.442 . . . . 0.0 106.371 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -124.13 102.85 11.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.03 -151.6 21.01 Favored Glycine 0 C--N 1.302 -1.332 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.062 179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.29 -57.1 1.45 Allowed Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' O' ' 40' ' ' VAL . 33.4 m -129.07 159.3 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 123.253 0.621 . . . . 0.0 110.633 -178.342 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.441 ' OXT' ' O ' ' N' ' 40' ' ' VAL . 3.5 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.069 -0.967 . . . . 0.0 111.648 -178.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.462 0.169 0 CA-C-O 120.951 0.405 . . . . 0.0 109.943 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.631 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 18.0 m170 -120.63 110.83 16.89 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.834 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.612 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 0.2 OUTLIER -160.69 166.99 27.86 Favored 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.17 177.771 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.496 ' NE2' HE21 ' Q' ' 15' ' ' GLN . 15.6 pt20 -89.94 151.6 21.63 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.733 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . 0.506 ' CB ' ' HE2' ' O' ' 14' ' ' HIS . 86.7 tttt -149.79 119.26 6.91 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.47 0.653 . . . . 0.0 110.727 177.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mp -138.99 132.37 30.12 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.218 178.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.02 120.98 65.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.515 ' CD1' ' CE1' ' Q' ' 19' ' ' PHE . 13.4 m-85 -110.78 112.19 23.89 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 22.4 t80 -119.84 127.76 53.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -175.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.81 127.25 48.84 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.577 ' CG ' ' H ' ' P' ' 23' ' ' ASP . 19.1 tt0 -72.07 177.06 4.6 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 115.75 1.759 . . . . 0.0 115.75 -173.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.577 ' H ' ' CG ' ' P' ' 22' ' ' GLU . 55.3 t0 -45.31 47.42 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 112.349 -2.205 . . . . 0.0 116.731 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.558 ' CG1' ' H ' ' P' ' 25' ' ' GLY . 49.0 t -60.88 -179.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 117.903 -1.519 . . . . 0.0 107.317 177.385 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.558 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . -102.08 34.97 5.27 Favored Glycine 0 N--CA 1.469 0.898 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 0.8 OUTLIER 74.53 120.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 -177.535 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.696 HD21 ' H ' ' O' ' 30' ' ' ALA . 12.2 p-10 -82.79 172.7 12.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 122.125 0.964 . . . . 0.0 113.312 -177.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.622 ' HZ2' ' CE1' ' K' ' 13' ' ' HIS . 87.6 tttt -49.2 -36.25 19.32 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.462 -1.699 . . . . 0.0 111.572 177.389 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.48 ' C ' HD22 ' P' ' 27' ' ' ASN . . . -178.42 78.01 0.07 OUTLIER Glycine 0 CA--C 1.541 1.688 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.336 -174.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . 0.569 ' N ' HD22 ' P' ' 27' ' ' ASN . . . -79.85 139.32 37.21 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 121.752 0.787 . . . . 0.0 111.132 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 9.5 tt -149.98 141.83 17.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 -176.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 75.3 mt -105.72 109.55 28.24 Favored 'Isoleucine or valine' 0 C--N 1.349 0.55 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.2 99.58 1.71 Allowed Glycine 0 C--O 1.24 0.492 0 N-CA-C 105.39 -3.084 . . . . 0.0 105.39 176.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 5.4 tp -128.41 134.77 48.86 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 -175.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 35' ' ' MET . . . . . 0.487 ' SD ' ' O ' ' Q' ' 35' ' ' MET . 60.0 tpp -112.69 110.98 21.45 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.006 -1.452 . . . . 0.0 107.62 176.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . 0.473 ' O ' ' CG1' ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -105.09 111.79 36.01 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.228 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.341 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.433 ' O ' ' NE2' ' R' ' 15' ' ' GLN . . . -63.75 131.99 40.53 Favored Glycine 0 N--CA 1.465 0.588 0 CA-C-N 115.868 -0.606 . . . . 0.0 113.204 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.435 ' CA ' ' H ' ' Q' ' 39' ' ' VAL . . . -77.92 64.15 3.41 Favored Glycine 0 CA--C 1.541 1.669 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.42 154.28 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 123.44 0.696 . . . . 0.0 110.266 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.419 -179.762 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -82.02 137.29 35.12 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.814 0.34 . . . . 0.0 110.753 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -74.03 150.1 40.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.664 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . 0.531 ' O ' ' CD2' ' Q' ' 14' ' ' HIS . 27.0 m -128.69 -175.84 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.107 0.479 . . . . 0.0 111.04 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.631 ' CD2' ' H ' ' P' ' 13' ' ' HIS . 2.9 m170 -67.44 105.31 1.77 Allowed 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -176.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.559 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 4.7 m-70 -114.53 160.91 18.7 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 175.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.496 HE21 ' NE2' ' P' ' 15' ' ' GLN . 42.8 tt0 -89.99 157.32 17.88 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.251 178.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -142.19 94.8 2.7 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.606 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -127.76 115.5 18.77 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.923 177.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 t -112.54 110.63 32.91 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.672 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.515 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 57.7 m-85 -107.92 102.1 11.32 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 178.057 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 33.5 t80 -111.25 124.19 51.72 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.345 -0.243 . . . . 0.0 110.345 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.8 128.57 24.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.203 0.525 . . . . 0.0 111.779 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -86.92 104.14 15.97 Favored 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD2' ' R' ' 23' ' ' ASP . 39.5 p-10 -135.05 52.27 2.05 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.562 -1.199 . . . . 0.0 111.517 -175.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 86.8 t -73.75 142.57 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.537 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -177.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.88 37.69 3.59 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 106.846 -2.502 . . . . 0.0 106.846 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 11.2 t -70.4 103.65 2.49 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.644 -0.778 . . . . 0.0 111.281 -178.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -117.97 -151.93 0.49 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.905 -178.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -39.8 -42.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.391 -1.277 . . . . 0.0 113.468 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.9 61.74 0.7 Allowed Glycine 0 CA--C 1.545 1.942 0 N-CA-C 115.793 1.077 . . . . 0.0 115.793 -174.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.24 107.85 5.34 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 87.3 mt -132.97 133.45 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -176.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.72 123.03 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 177.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.85 119.86 3.29 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 46.3 mt -120.56 119.86 34.15 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 120.692 0.282 . . . . 0.0 110.273 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . 0.487 ' O ' ' SD ' ' P' ' 35' ' ' MET . 94.0 mmm -116.52 123.71 48.09 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.473 ' CG1' ' O ' ' P' ' 36' ' ' VAL . 6.5 t -140.04 163.8 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.18 93.38 0.1 Allowed Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 119.513 -1.327 . . . . 0.0 111.382 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.23 -81.98 0.11 Allowed Glycine 0 CA--C 1.533 1.182 0 C-N-CA 119.709 -1.234 . . . . 0.0 113.41 176.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.435 ' H ' ' CA ' ' P' ' 38' ' ' GLY . 10.6 m -147.0 162.09 8.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 120.858 0.361 . . . . 0.0 110.425 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.984 -1.007 . . . . 0.0 110.481 -179.855 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -108.5 134.71 50.9 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.765 0.316 . . . . 0.0 110.328 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.512 ' N ' ' OE1' ' R' ' 11' ' ' GLU . 57.2 mp0 -77.04 135.7 38.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . 0.559 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 40.7 t -139.0 163.31 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.133 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -89.04 119.6 29.7 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.553 178.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -149.51 171.15 17.07 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.797 0.332 . . . . 0.0 111.675 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.433 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 32.8 mt-30 -83.64 154.65 23.6 Favored 'General case' 0 N--CA 1.456 -0.139 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . 0.417 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 70.4 tttt -159.75 104.6 1.57 Allowed 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.637 0.732 . . . . 0.0 109.573 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 mp -126.14 119.71 28.24 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.325 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 26.7 t -101.72 107.9 22.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -103.04 99.51 9.4 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 178.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -118.48 119.58 34.98 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-O 121.731 0.777 . . . . 0.0 111.457 -177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.99 134.11 52.73 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' R' ' 23' ' ' ASP . 83.0 mt-10 -68.72 103.96 1.88 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.226 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' R' ' 22' ' ' GLU . 5.3 p30 140.46 48.44 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 O-C-N 125.107 1.504 . . . . 0.0 108.519 -178.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 36.0 m -72.32 161.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.341 0.591 . . . . 0.0 111.579 -177.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . 0.405 ' O ' ' OG ' ' R' ' 26' ' ' SER . . . 111.7 -29.79 8.3 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.219 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.42 ' O ' ' OG ' ' R' ' 26' ' ' SER . 6.3 p 61.68 109.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.638 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.732 ' O ' ' N ' ' R' ' 29' ' ' GLY . 66.0 t30 -129.72 -179.93 5.47 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.313 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . 0.534 ' H ' ' CG ' ' R' ' 27' ' ' ASN . 98.9 mttt -29.6 47.81 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 126.325 1.85 . . . . 0.0 115.927 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.732 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -170.05 -59.03 0.04 OUTLIER Glycine 0 CA--C 1.539 1.554 0 C-N-CA 120.045 -1.074 . . . . 0.0 113.686 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.0 153.98 27.16 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 117.644 0.722 . . . . 0.0 112.132 -177.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 97.9 mt -121.93 132.37 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.31 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -123.69 128.41 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.313 -0.403 . . . . 0.0 109.929 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.51 120.29 3.65 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 35.9 mt -110.15 115.3 29.49 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.3 tpp -128.26 122.9 32.8 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 21.8 t -136.35 171.55 16.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -167.93 94.4 0.11 Allowed Glycine 0 C--N 1.309 -0.931 0 C-N-CA 119.598 -1.287 . . . . 0.0 111.439 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.0 -81.44 0.14 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 177.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 19.0 m -154.96 151.16 11.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.29 179.812 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.232 0.159 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.2 t -121.79 128.87 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.095 0.474 . . . . 0.0 110.421 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -119.55 163.59 17.09 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.485 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.45 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 3.0 m-70 -83.51 164.71 19.67 Favored 'General case' 0 C--N 1.332 -0.157 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.231 -179.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -130.56 152.51 49.86 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.319 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -94.37 116.6 29.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 30.3 tp -122.28 115.68 22.77 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.195 0.521 . . . . 0.0 110.017 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.1 t -128.48 132.03 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.529 -178.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -136.62 139.15 41.88 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.986 0.422 . . . . 0.0 110.305 178.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -139.19 132.83 30.52 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.23 119.18 24.68 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.862 0.839 . . . . 0.0 111.141 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -152.12 142.63 22.66 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.89 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 53.3 t0 . . . . . 0 CA--C 1.534 0.362 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 177.624 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 10.5 m120 . . . . . 0 N--CA 1.454 -0.27 0 CA-C-O 120.667 0.27 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.411 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 98.4 mttt -62.74 -38.94 92.49 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.835 1.302 . . . . 0.0 107.579 174.272 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.91 -69.48 3.3 Favored Glycine 0 CA--C 1.533 1.174 0 CA-C-N 112.021 -2.354 . . . . 0.0 111.641 -177.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.73 61.27 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 118.64 1.22 . . . . 0.0 112.764 175.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 83.7 mt -131.99 102.05 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.558 0 CA-C-N 119.904 1.229 . . . . 0.0 108.257 179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 80.8 mt -108.32 113.69 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.749 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.74 94.61 0.55 Allowed Glycine 0 N--CA 1.463 0.439 0 N-CA-C 104.748 -3.341 . . . . 0.0 104.748 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 87.5 mt -143.22 157.75 44.22 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 122.788 1.28 . . . . 0.0 114.055 -175.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 4.7 mtp -115.99 106.07 13.37 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 112.435 -2.166 . . . . 0.0 107.154 177.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 43.6 t -124.25 112.03 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.31 -131.89 8.57 Favored Glycine 0 C--N 1.322 -0.246 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.83 -62.69 0.4 Allowed Glycine 0 CA--C 1.534 1.259 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.267 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.444 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 26.9 m -108.34 162.78 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.189 0.495 . . . . 0.0 110.261 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 44.6 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.829 -1.081 . . . . 0.0 110.699 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -105.52 130.95 53.48 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 110.403 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -106.89 116.35 31.78 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.999 0.428 . . . . 0.0 110.729 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.31 128.95 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.373 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.614 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 6.2 t-160 -127.78 106.97 9.49 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.964 0.411 . . . . 0.0 110.468 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.588 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 4.3 t60 -152.82 168.68 24.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.99 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.588 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 54.5 tt0 -155.96 141.42 17.7 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt -85.65 123.71 31.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.944 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 tt -126.01 115.85 20.53 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.006 0.431 . . . . 0.0 110.221 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 m -123.98 131.84 72.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.382 179.297 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 71.9 t80 -125.76 122.32 35.91 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.251 -178.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -115.71 123.68 48.94 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.95 143.33 31.93 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 114.185 1.179 . . . . 0.0 114.185 -178.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.9 mt-10 -91.46 154.75 18.93 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' B' ' 22' ' ' GLU . 70.0 m-20 -139.18 46.5 1.93 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.555 1.317 . . . . 0.0 114.555 -176.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.545 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 60.7 t -111.72 177.03 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 C-N-CA 118.562 -1.255 . . . . 0.0 108.291 177.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.545 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . 62.39 28.35 70.91 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.291 -0.727 . . . . 0.0 111.531 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 24.5 p -170.55 -131.55 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.674 0 CA-C-N 118.558 1.179 . . . . 0.0 113.596 -176.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.529 ' N ' ' OG ' ' B' ' 26' ' ' SER . 90.9 m-20 -30.79 173.01 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 112.803 -1.999 . . . . 0.0 115.449 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -161.28 -21.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.451 -178.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.8 110.73 3.1 Favored Glycine 0 CA--C 1.532 1.123 0 CA-C-N 113.85 -1.523 . . . . 0.0 109.722 177.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -129.86 110.25 11.56 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 123.025 1.393 . . . . 0.0 112.814 -176.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 71.9 mt -142.73 139.85 28.09 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-N 113.824 -1.535 . . . . 0.0 112.134 -178.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.0 mt -106.9 114.34 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 107.157 -1.424 . . . . 0.0 107.157 174.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.08 106.32 1.42 Allowed Glycine 0 N--CA 1.461 0.312 0 N-CA-C 106.677 -2.569 . . . . 0.0 106.677 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.18 141.81 31.26 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.376 -1.33 . . . . 0.0 113.064 -175.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -108.88 109.31 20.38 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 112.455 -2.157 . . . . 0.0 106.637 177.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 32.8 m -133.7 151.69 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.073 0.463 . . . . 0.0 110.091 -177.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.81 -101.85 2.67 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -178.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.08 -80.74 0.58 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.187 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 38.6 t -111.47 135.15 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.602 ' H ' ' CG2' ' C' ' 39' ' ' VAL . 64.1 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.131 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . 0.467 ' OH ' ' NE2' ' E' ' 13' ' ' HIS . 90.1 t80 -73.55 132.52 42.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.986 0.422 . . . . 0.0 110.691 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.42 ' O ' ' CE2' ' C' ' 10' ' ' TYR . 96.3 mt-10 -75.54 136.85 40.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.24 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.471 ' CG2' ' O ' ' C' ' 12' ' ' VAL . 16.7 m -129.45 108.16 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.828 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' B' ' 13' ' ' HIS . 15.4 m-70 -142.64 135.6 28.28 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -178.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.575 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.6 p-80 -153.6 156.19 37.5 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.24 176.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.5 tp60 -99.44 154.2 18.41 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 174.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -121.58 109.68 15.09 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 173.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 34.5 mt -118.45 112.99 20.66 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.112 178.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -116.64 111.39 35.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 106.862 -1.532 . . . . 0.0 106.862 175.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 71.8 m-85 -102.79 108.84 20.22 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' C' ' 20' ' ' PHE . 26.0 t80 -110.7 123.94 50.98 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.565 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.22 138.99 35.52 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -90.79 108.31 19.75 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 176.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -100.28 46.7 0.95 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -176.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.433 ' CG1' ' N ' ' C' ' 25' ' ' GLY . 54.3 t -101.12 162.23 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 176.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.433 ' N ' ' CG1' ' C' ' 24' ' ' VAL . . . 69.98 30.64 69.92 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 176.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.77 ' O ' ' O ' ' C' ' 27' ' ' ASN . 20.6 p -173.06 -118.73 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.406 1.103 . . . . 0.0 113.307 -177.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.77 ' O ' ' O ' ' C' ' 26' ' ' SER . 61.4 t30 21.35 172.91 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 126.0 1.72 . . . . 0.0 114.446 -176.589 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -159.97 -29.54 0.06 Allowed 'General case' 0 N--CA 1.466 0.372 0 O-C-N 121.334 -0.853 . . . . 0.0 112.648 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.69 81.59 0.09 OUTLIER Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.294 -173.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -78.42 130.7 36.4 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 122.798 1.285 . . . . 0.0 113.057 -175.07 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -130.31 134.18 62.86 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 113.022 -1.899 . . . . 0.0 111.581 -178.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.446 HG21 HD12 ' C' ' 32' ' ' ILE . 87.7 mt -107.91 121.99 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.3 102.24 0.63 Allowed Glycine 0 N--CA 1.469 0.848 0 N-CA-C 107.845 -2.102 . . . . 0.0 107.845 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 5.9 mp -139.13 146.65 40.91 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 123.219 1.485 . . . . 0.0 113.538 -176.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -106.69 109.64 21.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 112.19 -2.277 . . . . 0.0 106.798 177.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.411 ' CG1' ' OE1' ' E' ' 15' ' ' GLN . 18.5 t -121.33 131.06 73.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 120.957 0.408 . . . . 0.0 111.695 -176.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.03 -110.85 3.1 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.575 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.32 -73.12 0.68 Allowed Glycine 0 CA--C 1.544 1.849 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -177.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.602 ' CG2' ' H ' ' B' ' 40' ' ' VAL . 1.3 m -132.32 179.77 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 176.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.434 ' OXT' ' O ' ' I' ' 28' ' ' LYS . 46.8 t . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.696 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.472 0.632 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.54 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 22.4 t-80 -61.9 121.22 12.39 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.595 -177.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.77 ' CD2' ' H ' ' E' ' 14' ' ' HIS . 35.3 m170 -150.45 162.55 40.37 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 68.2 tp60 -85.99 156.85 20.28 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 175.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -159.78 102.21 1.49 Allowed 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.29 -0.964 . . . . 0.0 109.914 177.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 16.2 mt -132.16 122.35 25.17 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.361 0.601 . . . . 0.0 111.478 -179.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 91.2 t -113.36 107.56 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.449 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 80.8 m-85 -104.22 106.87 17.53 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -126.69 128.59 46.94 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -176.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.82 124.03 41.22 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.345 177.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -89.27 153.35 20.97 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 122.059 0.933 . . . . 0.0 113.262 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 40.59 55.25 2.95 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 113.631 -1.622 . . . . 0.0 113.257 177.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 98.4 t -66.06 135.12 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 177.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.32 -32.54 1.79 Allowed Glycine 0 N--CA 1.468 0.798 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.414 ' OG ' ' O ' ' C' ' 27' ' ' ASN . 26.8 m -71.25 120.34 16.69 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.147 0.499 . . . . 0.0 110.231 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.506 ' ND2' ' H ' ' E' ' 25' ' ' GLY . 3.9 m120 -103.41 -151.82 0.44 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.184 -178.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.459 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 26.2 pttm 31.72 41.84 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.432 -1.258 . . . . 0.0 114.074 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -173.36 60.89 0.14 Allowed Glycine 0 CA--C 1.54 1.594 0 C-N-CA 119.672 -1.252 . . . . 0.0 113.63 174.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.661 ' N ' ' ND2' ' E' ' 27' ' ' ASN . . . -107.95 109.88 21.48 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 117.717 0.759 . . . . 0.0 109.508 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -134.09 128.59 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 118.952 -1.099 . . . . 0.0 112.186 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -112.55 119.29 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 177.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.43 98.88 0.8 Allowed Glycine 0 C--O 1.239 0.453 0 N-CA-C 105.895 -2.882 . . . . 0.0 105.895 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 11.3 tp -131.47 136.45 47.94 Favored 'General case' 0 C--O 1.244 0.81 0 CA-C-O 122.658 1.218 . . . . 0.0 113.795 -175.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -109.54 110.0 20.96 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 113.064 -1.88 . . . . 0.0 108.217 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.5 122.87 67.25 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.5 -113.58 0.71 Allowed Glycine 0 C--N 1.307 -1.031 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 96.11 -71.98 0.86 Allowed Glycine 0 CA--C 1.53 1.022 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.554 ' CG2' ' O ' ' J' ' 29' ' ' GLY . 0.3 OUTLIER -141.4 163.06 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 178.005 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' D' ' 39' ' ' VAL . 21.2 t . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 118.215 -0.897 . . . . 0.0 111.746 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.75 136.07 46.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.953 0.406 . . . . 0.0 110.686 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -113.72 119.75 38.47 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.301 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.55 ' C ' ' HE2' ' D' ' 14' ' ' HIS . 50.9 t -127.17 134.21 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 121.395 0.617 . . . . 0.0 110.025 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.48 ' CA ' ' HE2' ' D' ' 14' ' ' HIS . 38.1 m-70 -129.23 106.4 8.8 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.934 -178.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.77 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 3.3 p80 -151.87 161.35 42.79 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 177.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.411 ' OE1' ' CG1' ' C' ' 36' ' ' VAL . 79.1 mm-40 -90.01 158.12 17.5 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -141.1 100.03 3.72 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -133.38 126.1 30.56 Favored 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.643 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -113.62 106.66 21.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.505 178.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.449 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 89.8 m-85 -105.79 106.05 16.38 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.303 -1.739 . . . . 0.0 106.303 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -133.53 135.13 44.18 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.091 1.145 . . . . 0.0 114.091 -176.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.32 129.91 46.99 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.988 177.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -91.25 166.26 13.03 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 25.99 47.27 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 112.293 -2.23 . . . . 0.0 115.835 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.461 ' N ' ' O ' ' F' ' 22' ' ' GLU . 53.4 t -67.43 171.43 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 174.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.506 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . -117.75 37.41 3.3 Favored Glycine 0 N--CA 1.48 1.581 0 C-N-CA 119.433 -1.365 . . . . 0.0 111.264 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 72.52 119.99 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.499 . . . . 0.0 110.236 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.661 ' ND2' ' N ' ' D' ' 30' ' ' ALA . 81.4 m-20 -83.19 163.62 20.68 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.952 176.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.402 ' H ' ' HA ' ' D' ' 28' ' ' LYS . 97.4 mttt -46.93 -36.93 8.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 122.022 0.915 . . . . 0.0 108.946 175.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 77.42 0.06 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 113.694 -1.594 . . . . 0.0 110.558 -177.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.73 149.26 4.8 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.775 0.787 . . . . 0.0 110.648 -178.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.44 137.14 56.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.67 122.11 68.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 114.491 -1.231 . . . . 0.0 109.784 178.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.37 106.76 1.36 Allowed Glycine 0 N--CA 1.465 0.607 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 27.0 tp -126.16 125.52 42.61 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.872 0.367 . . . . 0.0 111.313 -177.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.445 ' CG ' ' N ' ' E' ' 36' ' ' VAL . 27.3 ttp -146.29 158.85 43.92 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.614 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.445 ' N ' ' CG ' ' E' ' 35' ' ' MET . 1.3 m -115.02 162.93 12.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.1 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.77 -102.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.371 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -78.47 1.05 Allowed Glycine 0 CA--C 1.534 1.243 0 C-N-CA 121.659 -0.305 . . . . 0.0 112.781 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 9.3 p . . . . . 0 N--CA 1.469 0.508 0 CA-C-N 116.952 0.376 . . . . 0.0 111.107 -179.086 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 pt-20 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 120.74 0.305 . . . . 0.0 110.813 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -124.32 132.83 70.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.018 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.482 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 8.5 p80 -144.74 114.69 7.37 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 121.206 0.526 . . . . 0.0 112.337 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.437 ' ND1' ' O ' ' F' ' 15' ' ' GLN . 54.8 t-80 -151.35 164.35 36.87 Favored 'General case' 0 C--O 1.217 -0.609 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.437 ' O ' ' ND1' ' F' ' 14' ' ' HIS . 88.7 mt-30 -89.91 158.33 17.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 119.113 0.87 . . . . 0.0 111.383 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.53 95.78 2.92 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -130.4 119.31 22.52 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -107.32 105.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.442 ' CE1' ' CD2' ' E' ' 19' ' ' PHE . 78.9 m-85 -107.59 109.0 20.53 Favored 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 20.3 t80 -147.21 137.62 23.42 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 118.618 -1.233 . . . . 0.0 113.826 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.33 130.48 49.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.08 -1.418 . . . . 0.0 107.468 177.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' E' ' 24' ' ' VAL . 96.9 mt-10 -82.29 115.79 21.52 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.043 -0.663 . . . . 0.0 111.653 -178.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 9.6 p-10 . . . . . 0 CA--C 1.529 0.155 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.7 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.402 HD13 HG21 ' F' ' 31' ' ' ILE . 96.3 mt -121.2 127.24 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 118.486 0.585 . . . . 0.0 109.79 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 95.1 mt -128.2 131.7 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-O 120.865 0.364 . . . . 0.0 111.45 -178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.3 116.86 2.67 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.1 tp -122.75 126.13 46.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 5.0 ttp -140.19 139.81 35.75 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 122.365 1.079 . . . . 0.0 113.845 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.478 ' O ' ' O ' ' F' ' 37' ' ' GLY . 43.8 t -117.31 131.95 68.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 CA-C-N 113.758 -1.565 . . . . 0.0 109.523 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -41.25 -111.62 0.0 OUTLIER Glycine 0 CA--C 1.531 1.046 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.907 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -71.7 0.6 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 111.767 -0.533 . . . . 0.0 111.767 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 94.6 t -76.99 131.53 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 117.3 0.55 . . . . 0.0 110.325 179.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 14.9 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.148 -0.929 . . . . 0.0 110.608 -179.754 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.466 0.326 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -138.2 117.34 12.61 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 121.006 0.432 . . . . 0.0 111.546 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.505 ' O ' ' NE2' ' G' ' 15' ' ' GLN . 49.1 p-80 -151.74 168.05 26.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.099 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.505 ' NE2' ' O ' ' G' ' 14' ' ' HIS . 97.7 mm-40 -156.98 143.23 18.07 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.046 0.45 . . . . 0.0 110.07 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -81.27 118.23 22.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 178.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.0 tp -136.76 118.92 15.48 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.313 0.577 . . . . 0.0 111.349 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 m -137.0 153.44 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.965 178.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -146.51 130.74 17.48 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-O 120.964 0.411 . . . . 0.0 111.195 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -123.04 132.2 54.02 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 126.94 35.6 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.467 0.651 . . . . 0.0 112.685 -178.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -96.36 145.31 25.73 Favored 'General case' 0 C--N 1.34 0.159 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 10.2 t70 . . . . . 0 C--N 1.322 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.717 -176.896 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.594 ' OD1' ' N ' ' G' ' 28' ' ' LYS . 31.7 t-20 . . . . . 0 N--CA 1.47 0.535 0 CA-C-O 120.677 0.275 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.594 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 88.5 tttt -69.43 -48.36 61.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.28 0.562 . . . . 0.0 110.411 178.073 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.542 ' N ' ' OD1' ' G' ' 27' ' ' ASN . . . 129.81 59.92 0.1 Allowed Glycine 0 CA--C 1.54 1.633 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 -176.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.09 89.28 0.82 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 87.3 mt -137.27 117.84 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-N 113.315 -1.766 . . . . 0.0 106.857 177.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.484 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.4 mt -106.17 110.64 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 94.86 0.67 Allowed Glycine 0 CA--C 1.508 -0.399 0 N-CA-C 105.097 -3.201 . . . . 0.0 105.097 177.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 79.7 mt -147.49 168.44 21.91 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-O 123.254 1.502 . . . . 0.0 113.766 -175.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 94.5 mmm -120.96 114.39 21.46 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 112.064 -2.335 . . . . 0.0 107.16 178.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 41.4 t -124.6 131.53 72.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.54 -111.31 3.3 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.719 -0.953 . . . . 0.0 110.719 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.4 -73.79 1.33 Allowed Glycine 0 CA--C 1.536 1.395 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.252 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -87.02 171.55 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 117.401 0.6 . . . . 0.0 110.381 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.243 179.273 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -107.62 129.71 54.97 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.711 0.291 . . . . 0.0 110.346 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -154.85 148.76 25.66 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-O 121.166 0.508 . . . . 0.0 111.552 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.648 ' CG1' ' HE2' ' H' ' 14' ' ' HIS . 55.7 t -124.5 130.03 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.459 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 26.0 p-80 -147.46 142.81 27.37 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 119.48 -0.888 . . . . 0.0 113.131 -179.245 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.648 ' HE2' ' CG1' ' H' ' 12' ' ' VAL . 1.5 m-70 -146.23 170.36 16.91 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 114.512 -1.222 . . . . 0.0 108.217 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -155.83 141.28 17.72 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.366 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -87.94 108.67 19.3 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.973 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -121.13 110.71 16.54 Favored 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 72.0 t -122.13 130.62 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.192 -178.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -126.52 118.98 26.0 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -122.35 125.93 46.98 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.61 131.26 39.42 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.457 0.646 . . . . 0.0 112.677 -179.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -97.68 127.1 43.38 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.541 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.574 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 97.1 m-20 -139.25 46.55 1.92 Allowed 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.598 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.59 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 21.5 t -82.8 173.34 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-O 122.697 1.237 . . . . 0.0 113.06 -176.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.59 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . 92.74 -35.16 4.17 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 112.596 -2.093 . . . . 0.0 114.26 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' H' ' 27' ' ' ASN . 32.2 t -162.55 117.38 1.82 Allowed 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 120.691 2.246 . . . . 0.0 114.192 175.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' H' ' 26' ' ' SER . 45.0 p-10 -22.55 153.13 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.116 0.566 . . . . 0.0 112.297 173.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 7.7 tttm -165.95 26.38 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 117.948 -1.501 . . . . 0.0 114.887 173.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 107.77 0.38 Allowed Glycine 0 CA--C 1.532 1.11 0 C-N-CA 119.004 -1.57 . . . . 0.0 113.944 177.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.7 111.47 17.65 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 87.4 mt -130.22 133.61 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.445 ' O ' ' O ' ' I' ' 33' ' ' GLY . 93.6 mt -105.71 108.46 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -109.44 101.92 1.54 Allowed Glycine 0 N--CA 1.465 0.623 0 N-CA-C 105.897 -2.881 . . . . 0.0 105.897 177.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.431 HD11 ' H ' ' H' ' 35' ' ' MET . 47.2 tp -152.53 145.62 24.59 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 117.306 -1.758 . . . . 0.0 114.612 -173.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.431 ' H ' HD11 ' H' ' 34' ' ' LEU . 3.8 ttm -106.9 117.02 32.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.71 177.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.19 102.49 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.801 -178.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.27 -163.93 26.78 Favored Glycine 0 CA--C 1.524 0.617 0 C-N-CA 120.354 -0.926 . . . . 0.0 112.655 177.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.412 ' HA2' ' H ' ' I' ' 38' ' ' GLY . . . 156.2 -54.55 0.41 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -141.31 164.21 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 176.072 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.538 ' OXT' ' NZ ' ' N' ' 28' ' ' LYS . 1.3 p . . . . . 0 N--CA 1.467 0.377 0 CA-C-O 117.802 -1.094 . . . . 0.0 111.353 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.25 135.41 46.67 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.691 0.281 . . . . 0.0 110.387 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' NE2' ' I' ' 13' ' ' HIS . 45.7 tp10 -147.11 100.9 3.35 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.908 0.385 . . . . 0.0 110.256 179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.405 ' H ' HG21 ' H' ' 12' ' ' VAL . 4.9 m -141.75 127.41 18.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.986 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' CE1' ' H' ' 13' ' ' HIS . 49.5 m170 -113.59 136.24 53.03 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.829 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.527 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 70.7 m80 -156.64 176.04 13.26 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.29 0.567 . . . . 0.0 110.515 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 40.8 tp60 -159.33 139.09 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 174.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -105.39 113.61 27.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 118.999 -0.524 . . . . 0.0 111.5 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -129.5 112.48 13.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 m -119.43 124.87 73.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -112.16 116.76 30.98 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 114.752 -1.113 . . . . 0.0 108.673 -178.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -119.08 129.14 54.92 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.767 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.87 138.19 30.08 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.436 -0.506 . . . . 0.0 112.165 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -131.91 130.95 42.23 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 120.458 -0.497 . . . . 0.0 112.261 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.521 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 0.3 OUTLIER -130.98 -49.94 1.03 Allowed 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.188 0.518 . . . . 0.0 110.477 178.644 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.424 ' CG2' ' C ' ' I' ' 23' ' ' ASP . 2.0 t 77.7 143.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.939 176.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.496 ' H ' ' CG2' ' J' ' 24' ' ' VAL . . . 92.08 37.46 5.99 Favored Glycine 0 CA--C 1.525 0.662 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.372 174.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 3.0 p 72.69 120.15 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 117.744 0.772 . . . . 0.0 110.237 177.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.629 ' H ' ' ND2' ' J' ' 27' ' ' ASN . 13.8 p30 -83.03 161.3 21.75 Favored 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 117.598 -1.641 . . . . 0.0 109.192 177.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.434 ' O ' ' OXT' ' C' ' 40' ' ' VAL . 95.8 mttt -48.63 -39.54 24.49 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 176.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.45 0.04 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -175.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.61 139.15 51.32 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 119.027 1.413 . . . . 0.0 114.281 -174.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 61.2 mt -141.57 143.78 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 113.529 -1.669 . . . . 0.0 113.026 -178.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 9.8 mt -104.31 109.72 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 175.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -109.51 100.75 1.38 Allowed Glycine 0 N--CA 1.463 0.454 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.14 143.27 38.13 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.928 1.347 . . . . 0.0 113.681 -175.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 87.7 mmm -117.12 108.71 16.03 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 111.939 -2.391 . . . . 0.0 104.61 175.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 24.4 m -126.14 130.94 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 118.695 -1.202 . . . . 0.0 112.77 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.88 111.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 113.048 -1.887 . . . . 0.0 113.477 177.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.412 ' H ' ' HA2' ' H' ' 38' ' ' GLY . . . -80.81 -60.53 2.29 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.206 -1.157 . . . . 0.0 110.206 175.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.3 p -146.2 150.08 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 121.407 0.622 . . . . 0.0 110.407 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.51 ' OXT' ' NE2' ' L' ' 13' ' ' HIS . 21.3 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.659 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -105.31 133.5 49.98 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . 0.602 ' CG ' ' HE2' ' J' ' 13' ' ' HIS . 80.4 tt0 -153.34 114.81 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.005 0.431 . . . . 0.0 110.645 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.635 ' CG2' ' HE2' ' J' ' 14' ' ' HIS . 2.2 p -138.83 138.34 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.847 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.602 ' HE2' ' CG ' ' J' ' 11' ' ' GLU . 19.7 m-70 -139.19 147.83 42.34 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.814 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.635 ' HE2' ' CG2' ' J' ' 12' ' ' VAL . 56.9 m-70 -151.97 160.92 43.35 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.615 177.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 tp60 -90.46 158.35 17.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 177.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -141.48 90.82 2.32 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.288 176.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 mp -128.54 129.86 46.61 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 118.813 0.733 . . . . 0.0 110.688 177.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 18.4 t -125.64 116.83 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.682 179.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 12.6 m-85 -109.31 106.95 16.97 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 6.3 t80 -114.01 121.91 45.32 Favored 'General case' 0 N--CA 1.478 0.973 0 O-C-N 122.263 -0.273 . . . . 0.0 110.337 -178.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.24 138.73 37.07 Favored 'General case' 0 C--O 1.253 1.259 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 52.7 tt0 -66.92 149.6 50.39 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.697 ' O ' ' O ' ' J' ' 24' ' ' VAL . 65.1 t0 -168.38 64.5 0.07 Allowed 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -168.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.697 ' O ' ' O ' ' J' ' 23' ' ' ASP . 58.7 t -43.06 -104.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 CA-C-O 113.942 -2.932 . . . . 0.0 103.809 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 166.75 -48.18 0.26 Allowed Glycine 0 N--CA 1.482 1.754 2 CA-C-N 127.32 4.6 . . . . 0.0 119.696 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 41.0 t -65.8 101.0 0.6 Allowed 'General case' 0 C--N 1.322 -0.596 1 CA-C-N 125.567 4.683 . . . . 0.0 105.867 -179.531 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.629 ' ND2' ' H ' ' I' ' 27' ' ' ASN . 1.1 m-20 -129.48 160.88 31.79 Favored 'General case' 0 C--N 1.348 0.504 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.75 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.407 ' C ' ' O ' ' J' ' 27' ' ' ASN . 70.3 mmtt -29.61 -39.42 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.785 -1.098 . . . . 0.0 113.44 174.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.554 ' O ' ' CG2' ' D' ' 39' ' ' VAL . . . 140.93 74.87 0.04 OUTLIER Glycine 0 CA--C 1.552 2.371 0 C-N-CA 119.668 -1.253 . . . . 0.0 112.341 -175.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.03 155.54 40.44 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 120.631 2.215 . . . . 0.0 113.061 -174.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' D' ' 38' ' ' GLY . 57.6 mt -138.2 148.53 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 3.9 mt -109.84 110.99 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 173.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.4 103.81 1.71 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 33.4 tp -143.44 132.58 23.08 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 115.695 1.739 . . . . 0.0 115.695 -173.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 78.4 mmm -103.75 123.75 47.62 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 112.78 -2.009 . . . . 0.0 106.886 176.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -135.25 155.68 37.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-O 121.549 0.69 . . . . 0.0 112.441 -176.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.741 ' H ' HE22 ' L' ' 15' ' ' GLN . . . 79.76 -101.42 1.92 Allowed Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.933 176.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.6 -80.31 1.61 Allowed Glycine 0 CA--C 1.537 1.451 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -176.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 59.2 t -124.06 131.57 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-N 117.742 0.771 . . . . 0.0 109.624 177.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.516 ' OXT' ' CD2' ' L' ' 13' ' ' HIS . 27.6 t . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.27 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.442 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . 0.441 ' CD2' ' O ' ' K' ' 11' ' ' GLU . 52.6 t80 -70.69 134.95 47.96 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.883 0.373 . . . . 0.0 110.523 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.441 ' O ' ' CD2' ' K' ' 10' ' ' TYR . 68.8 mm-40 -75.22 154.68 37.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.746 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 27.8 m -122.91 129.59 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.363 0.602 . . . . 0.0 111.847 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.56 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 2.9 t60 -148.99 138.09 21.48 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.129 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.531 ' NE2' ' O ' ' L' ' 12' ' ' VAL . 15.3 m-70 -134.51 158.86 42.85 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -90.17 159.51 16.72 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 57.4 tttt -140.47 95.13 2.82 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 120.041 -0.664 . . . . 0.0 109.758 177.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 37.2 mt -118.47 111.67 18.95 Favored 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 177.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -108.29 107.25 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 84.7 m-85 -104.03 105.68 15.93 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.9 t80 -110.74 114.91 28.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.38 135.93 20.6 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 122.023 0.916 . . . . 0.0 111.867 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.558 ' O ' ' CB ' ' K' ' 23' ' ' ASP . 98.3 mt-10 -69.15 -174.92 0.69 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 118.145 -1.422 . . . . 0.0 107.97 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.564 ' HA ' ' O ' ' J' ' 24' ' ' VAL . 10.5 t0 144.98 46.6 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.474 0.654 . . . . 0.0 109.927 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.526 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 25.4 t -84.03 172.16 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.862 -178.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.526 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . 95.71 -29.68 9.46 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 178.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.485 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 92.07 114.02 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 114.446 -0.877 . . . . 0.0 109.06 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' K' ' 30' ' ' ALA . 1.4 p30 -74.3 174.48 8.76 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.361 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.28 -36.75 43.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.97 76.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.541 0 CA-C-O 119.679 -0.512 . . . . 0.0 112.67 -177.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.518 ' N ' ' OD1' ' K' ' 27' ' ' ASN . . . -80.12 149.7 30.5 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 118.745 1.272 . . . . 0.0 110.527 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 59.1 mt -130.77 135.97 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.547 -0.752 . . . . 0.0 112.14 -177.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.33 119.24 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.74 109.77 1.53 Allowed Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 70.7 mt -122.78 118.38 27.86 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.248 0.547 . . . . 0.0 110.626 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 95.9 mmm -110.74 122.27 47.4 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.004 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.11 132.37 67.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.318 -179.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.24 112.1 3.45 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 178.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -76.65 73.18 1.9 Allowed Glycine 0 CA--C 1.532 1.148 0 C-N-CA 120.243 -0.98 . . . . 0.0 113.498 -178.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 22.1 t . . . . . 0 N--CA 1.467 0.425 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.499 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 C--O 1.232 0.147 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . 0.61 ' CG2' ' H ' ' L' ' 13' ' ' HIS . 11.3 p -138.98 -179.18 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.911 0.386 . . . . 0.0 111.07 -178.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.61 ' H ' ' CG2' ' L' ' 12' ' ' VAL . 0.3 OUTLIER -122.81 108.52 13.11 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.525 -179.941 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.436 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 40.8 t-80 -150.38 165.52 32.85 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.741 HE22 ' H ' ' J' ' 37' ' ' GLY . 51.3 tt0 -89.74 158.73 17.4 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.643 0.259 . . . . 0.0 110.788 -179.03 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -140.01 107.56 5.59 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.252 0.548 . . . . 0.0 111.256 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mt -115.97 109.15 17.16 Favored 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -105.09 103.55 15.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -100.46 100.54 11.31 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.603 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 52.2 t80 -106.41 95.95 6.11 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.84 145.07 31.46 Favored 'General case' 0 CA--C 1.495 -1.138 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.655 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' K' ' 23' ' ' ASP . 80.8 mm-40 -82.6 96.04 7.96 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.728 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 91.8 m-20 -132.56 62.63 1.64 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 112.052 -177.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.449 ' CG1' ' H ' ' L' ' 25' ' ' GLY . 1.5 t 60.51 -141.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.207 0.527 . . . . 0.0 110.871 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.449 ' H ' ' CG1' ' L' ' 24' ' ' VAL . . . 156.63 -29.53 0.55 Allowed Glycine 0 CA--C 1.519 0.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 87.8 p -63.21 -123.66 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.191 -0.505 . . . . 0.0 110.868 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.542 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 5.9 t-20 -156.97 -154.14 0.45 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.856 -178.492 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.542 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 68.6 mttm 28.32 41.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.09 -62.59 0.04 OUTLIER Glycine 0 CA--C 1.537 1.445 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.723 178.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.83 148.08 29.02 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.785 0.792 . . . . 0.0 110.488 178.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 6.7 mm -114.76 125.89 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -120.18 124.6 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.72 115.46 1.7 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.7 tp -126.2 120.73 30.81 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mtp -135.38 147.55 49.09 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -177.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 33.6 m -119.36 159.29 20.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.132 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.643 178.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' K' ' 38' ' ' GLY . . . -61.89 -102.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.487 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.96 -75.14 0.11 Allowed Glycine 0 CA--C 1.534 1.237 0 C-N-CA 121.83 -0.224 . . . . 0.0 112.88 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' K' ' 38' ' ' GLY . 3.0 m . . . . . 0 N--CA 1.466 0.373 0 CA-C-O 121.296 0.57 . . . . 0.0 111.399 -178.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 N--CA 1.466 0.344 0 CA-C-O 121.145 0.498 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.42 130.66 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.158 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 m80 -128.65 113.18 15.07 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 17.9 p-80 -152.56 168.23 26.25 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.548 178.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -129.23 150.65 50.52 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.085 178.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -97.56 116.25 29.4 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.3 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -124.97 114.07 18.65 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 118.154 0.434 . . . . 0.0 110.093 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 19.1 m -131.67 132.52 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.641 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -135.7 133.99 38.67 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-O 121.077 0.465 . . . . 0.0 111.745 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -121.61 129.39 52.8 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.98 131.81 44.62 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.332 0.587 . . . . 0.0 112.164 -178.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -120.23 142.27 49.18 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.557 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 37.42 54.68 1.39 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.306 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 45.6 t -67.79 135.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.76 -33.49 2.04 Favored Glycine 0 N--CA 1.47 0.901 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 62.8 p -82.31 -121.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.131 0.491 . . . . 0.0 111.206 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -93.22 -160.5 0.76 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.063 -178.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 35.28 40.37 0.06 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.38 -64.37 1.22 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.26 49.74 0.44 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.043 0.922 . . . . 0.0 111.772 175.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 97.0 mt -138.49 106.84 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 CA-C-N 114.157 -1.383 . . . . 0.0 107.474 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.2 mt -102.7 104.43 16.53 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.335 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.09 95.71 0.75 Allowed Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 104.071 -3.612 . . . . 0.0 104.071 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . 0.401 ' O ' ' CD2' ' N' ' 34' ' ' LEU . 43.1 tp -146.07 150.4 35.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 122.843 1.306 . . . . 0.0 113.809 -173.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -110.02 106.95 16.66 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 112.65 -2.068 . . . . 0.0 106.228 177.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . 0.476 ' O ' ' CG1' ' M' ' 36' ' ' VAL . 4.0 p -127.35 114.07 34.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.6 -124.61 1.88 Allowed Glycine 0 C--N 1.309 -0.958 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.96 -67.11 3.29 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.043 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 13.0 m -78.4 169.1 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-O 121.041 0.448 . . . . 0.0 110.472 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.458 179.981 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -115.44 142.01 47.29 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.87 0.367 . . . . 0.0 110.52 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . 0.526 ' O ' ' NE2' ' O' ' 13' ' ' HIS . 82.4 tt0 -69.18 120.64 15.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.095 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.51 120.45 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.618 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.474 ' CE1' ' OE2' ' N' ' 11' ' ' GLU . 60.4 m170 -113.68 150.71 32.85 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.901 -178.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.555 ' CE1' ' O ' ' O' ' 12' ' ' VAL . 75.2 m-70 -141.92 172.01 13.28 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 121.19 0.519 . . . . 0.0 110.403 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 68.4 tp60 -138.25 140.87 39.86 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttm -130.17 107.0 8.97 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 5.9 tt -122.6 116.33 23.66 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 80.0 t -121.01 126.22 74.95 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.333 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -127.03 122.02 33.25 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -125.32 125.21 43.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.032 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.95 131.4 53.56 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 179.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -81.05 -166.81 1.22 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.325 0.583 . . . . 0.0 112.53 -177.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.518 ' N ' ' OE1' ' O' ' 22' ' ' GLU . 66.2 t0 -61.97 47.51 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 114.765 -1.107 . . . . 0.0 112.394 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.628 ' CG1' ' H ' ' N' ' 25' ' ' GLY . 30.3 t -61.04 -179.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.019 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.628 ' H ' ' CG1' ' N' ' 24' ' ' VAL . . . -100.96 29.31 12.77 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 121.636 -0.316 . . . . 0.0 112.718 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 10.7 t -81.05 112.86 18.82 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 72.1 m-20 -89.75 -175.06 4.52 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.538 ' NZ ' ' OXT' ' H' ' 40' ' ' VAL . 59.3 mttp 49.29 37.64 11.9 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 111.525 -2.58 . . . . 0.0 114.824 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' N' ' 30' ' ' ALA . . . 92.01 -77.98 1.28 Allowed Glycine 0 N--CA 1.469 0.851 0 N-CA-C 114.517 0.567 . . . . 0.0 114.517 172.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . 0.495 ' CB ' ' O ' ' N' ' 29' ' ' GLY . . . 150.87 162.64 0.0 OUTLIER 'General case' 0 C--O 1.238 0.464 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 28.8 pt -141.32 126.92 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.029 178.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -113.04 114.55 47.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.47 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.95 105.95 1.66 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 104.936 -3.266 . . . . 0.0 104.936 175.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . 0.401 ' CD2' ' O ' ' M' ' 34' ' ' LEU . 0.4 OUTLIER -146.32 144.32 29.73 Favored 'General case' 0 CA--C 1.51 -0.581 0 C-N-CA 117.716 -1.594 . . . . 0.0 114.512 -174.18 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 36.3 tpp -106.97 107.77 18.95 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 174.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.52 143.68 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 -178.216 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.452 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 113.26 -102.68 1.29 Allowed Glycine 0 C--N 1.316 -0.55 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 178.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.69 -80.3 1.81 Allowed Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -178.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 43.4 t -153.03 123.54 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 177.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . 0.408 ' OXT' ' CG2' ' O' ' 40' ' ' VAL . 9.1 m . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.724 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -115.44 141.51 47.95 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.876 0.369 . . . . 0.0 110.687 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -83.11 116.78 22.48 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.233 -0.439 . . . . 0.0 109.933 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.555 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 2.9 m -138.44 160.66 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.823 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 94.3 m-70 -76.74 113.39 14.35 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.529 178.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.572 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 83.6 t60 -148.02 153.23 38.68 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 119.576 -0.849 . . . . 0.0 111.875 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.563 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 42.1 tt0 -98.65 169.61 9.38 Favored 'General case' 0 C--N 1.345 0.396 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -158.57 104.44 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.681 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 31.5 mt -122.29 116.02 23.35 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 177.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -125.0 117.59 50.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-O 121.883 0.849 . . . . 0.0 109.576 178.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -112.31 115.08 28.19 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.429 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -114.63 133.93 55.46 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 122.523 0.329 . . . . 0.0 110.524 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.58 142.11 27.64 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 113.68 0.993 . . . . 0.0 113.68 -178.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' N' ' 23' ' ' ASP . 95.9 mt-10 -78.99 104.98 10.0 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 104.481 -2.415 . . . . 0.0 104.481 175.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.519 ' N ' ' O ' ' P' ' 22' ' ' GLU . 17.6 p30 -83.27 49.03 1.48 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 117.736 2.495 . . . . 0.0 117.736 -172.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 89.9 t -71.56 160.44 5.24 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 C-N-CA 114.803 -2.759 . . . . 0.0 104.221 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.481 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.92 -30.8 8.31 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 -175.065 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 2.5 m 100.59 111.13 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 112.932 -1.634 . . . . 0.0 112.072 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.563 ' CG ' ' H ' ' O' ' 28' ' ' LYS . 12.7 t-20 -70.48 -179.43 2.09 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.702 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.563 ' H ' ' CG ' ' O' ' 27' ' ' ASN . 51.9 tttt 65.53 -47.29 0.38 Allowed 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' O' ' 27' ' ' ASN . . . -81.95 59.38 4.87 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 107.039 -2.424 . . . . 0.0 107.039 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . 0.443 ' H ' ' C ' ' O' ' 28' ' ' LYS . . . -140.31 -171.02 3.11 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 109.739 -3.231 . . . . 0.0 105.513 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.423 HD13 HG23 ' O' ' 31' ' ' ILE . 81.5 mt -128.81 125.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 119.509 -0.876 . . . . 0.0 113.342 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . 0.451 HD13 HG22 ' O' ' 32' ' ' ILE . 88.9 mt -104.33 104.54 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 174.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.05 109.92 2.78 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 105.553 -3.019 . . . . 0.0 105.553 177.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -162.98 150.0 12.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 115.737 -2.385 . . . . 0.0 114.742 -174.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.0 mmm -110.08 105.05 14.02 Favored 'General case' 0 CA--C 1.496 -1.102 0 CA-C-N 111.604 -2.544 . . . . 0.0 106.199 179.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 11.9 p -118.64 142.12 35.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -178.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.04 -102.08 0.21 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 120.076 -1.059 . . . . 0.0 110.549 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.507 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . 73.99 64.75 2.36 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 120.571 -0.823 . . . . 0.0 113.182 -178.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.507 ' O ' ' O ' ' O' ' 38' ' ' GLY . 9.1 p -10.79 140.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.414 ' CG1' ' OXT' ' P' ' 40' ' ' VAL . 7.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.059 177.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.413 HG13 ' H ' ' Q' ' 12' ' ' VAL . 6.2 m . . . . . 0 N--CA 1.463 0.223 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.598 ' H ' ' CE1' ' Q' ' 13' ' ' HIS . 0.6 OUTLIER -129.54 115.67 17.79 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.055 0.455 . . . . 0.0 112.008 -178.991 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.572 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 4.5 p80 -156.11 167.16 31.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.359 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.452 HE22 ' N ' ' N' ' 37' ' ' GLY . 53.2 tt0 -89.78 158.48 17.49 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -140.32 115.08 9.54 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.636 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 14.4 mt -119.47 122.28 41.34 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -119.63 107.56 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 47.8 m-85 -110.03 107.95 18.0 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 178.197 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -116.4 125.56 52.22 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.596 0.236 . . . . 0.0 110.694 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . 0.49 ' CB ' ' ND2' ' O' ' 27' ' ' ASN . . . -129.59 127.78 41.36 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.141 0.496 . . . . 0.0 110.231 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' O' ' 23' ' ' ASP . 16.6 pt-20 -122.03 158.77 28.45 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.433 ' C ' ' OD1' ' O' ' 23' ' ' ASP . 29.8 m-20 76.43 55.98 0.05 OUTLIER 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 113.439 -1.709 . . . . 0.0 112.859 178.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 m -77.4 129.21 37.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.21 -35.41 4.48 Favored Glycine 0 CA--C 1.536 1.383 0 C-N-CA 118.854 -1.641 . . . . 0.0 112.127 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.652 ' O ' ' O ' ' P' ' 27' ' ' ASN . 16.4 t -173.97 125.82 0.36 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 119.562 1.681 . . . . 0.0 114.179 175.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.652 ' O ' ' O ' ' P' ' 26' ' ' SER . 44.6 m-20 -2.86 145.73 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.25 1.42 . . . . 0.0 114.683 173.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -160.31 32.23 0.17 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.73 80.95 0.89 Allowed Glycine 0 N--CA 1.482 1.748 0 C-N-CA 117.768 -2.158 . . . . 0.0 112.939 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' O' ' 28' ' ' LYS . . . -101.94 131.41 48.35 Favored 'General case' 0 CA--C 1.508 -0.651 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -176.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 91.1 mt -133.47 122.49 44.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.164 178.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 mt -107.17 110.43 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 175.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.03 102.88 0.86 Allowed Glycine 0 N--CA 1.462 0.369 0 N-CA-C 107.788 -2.125 . . . . 0.0 107.788 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 pp -157.35 162.35 39.09 Favored 'General case' 0 CA--C 1.493 -1.224 0 C-N-CA 117.664 -1.615 . . . . 0.0 113.621 -177.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 23.3 mtp -119.89 123.19 42.98 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 112.215 -2.266 . . . . 0.0 109.628 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . 0.609 ' O ' ' O ' ' P' ' 37' ' ' GLY . 0.1 OUTLIER -98.17 101.95 12.81 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.965 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.609 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 28.42 172.77 0.0 OUTLIER Glycine 0 N--CA 1.468 0.78 0 C-N-CA 126.04 1.781 . . . . 0.0 116.491 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.03 -58.21 0.59 Allowed Glycine 0 CA--C 1.536 1.378 0 CA-C-N 113.45 -1.375 . . . . 0.0 112.678 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' P' ' 40' ' ' VAL . 72.7 t -105.58 131.4 55.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 CA-C-O 121.195 0.521 . . . . 0.0 111.091 -178.307 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' P' ' 39' ' ' VAL . 5.6 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.3 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -106.58 133.83 50.66 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.02 139.25 37.78 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.758 0.313 . . . . 0.0 110.549 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . 0.455 ' C ' ' CD2' ' Q' ' 13' ' ' HIS . 29.0 m -137.13 158.1 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 121.085 0.469 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.598 ' CE1' ' H ' ' P' ' 13' ' ' HIS . 44.8 m-70 -147.5 115.18 6.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.91 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.631 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 83.2 m-70 -131.89 160.38 35.89 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 48.8 tt0 -90.09 159.18 16.94 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -140.68 92.39 2.51 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.836 178.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mt -115.01 115.12 26.33 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -119.49 107.77 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.397 -179.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.585 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 35.4 m-85 -110.1 101.95 10.7 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 104.311 -2.477 . . . . 0.0 104.311 175.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -123.45 133.37 54.06 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.139 -0.482 . . . . 0.0 112.286 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.09 154.65 49.23 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.528 ' O ' ' N ' ' Q' ' 24' ' ' VAL . 75.4 tt0 -72.58 163.05 28.66 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 65.7 t0 0.78 54.28 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 116.317 1.969 . . . . 0.0 116.317 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' Q' ' 22' ' ' GLU . 0.3 OUTLIER -66.56 137.17 25.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 176.425 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' Q' ' 26' ' ' SER . . . -118.04 -28.34 2.25 Favored Glycine 0 CA--C 1.542 1.745 0 CA-C-O 118.94 -0.922 . . . . 0.0 110.919 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 0.7 OUTLIER 91.11 116.81 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 118.895 1.348 . . . . 0.0 114.607 173.656 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -72.96 174.81 7.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.232 0.539 . . . . 0.0 111.086 177.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -53.84 -38.88 65.1 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.688 178.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.04 69.21 0.21 Allowed Glycine 0 CA--C 1.537 1.438 0 N-CA-C 115.517 0.967 . . . . 0.0 115.517 -175.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.14 121.45 41.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.837 0.819 . . . . 0.0 109.151 178.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 86.1 mt -125.81 132.52 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 121.101 0.477 . . . . 0.0 111.646 -178.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -122.53 121.93 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.521 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.69 108.16 1.15 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 15.7 mt -117.68 122.4 43.43 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -136.12 144.46 45.09 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.447 ' CG1' ' N ' ' Q' ' 37' ' ' GLY . 63.7 t -117.99 168.28 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.447 ' N ' ' CG1' ' Q' ' 36' ' ' VAL . . . -169.15 93.81 0.1 Allowed Glycine 0 C--N 1.314 -0.672 0 C-N-CA 118.915 -1.612 . . . . 0.0 112.932 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.0 -81.51 0.1 OUTLIER Glycine 0 CA--C 1.536 1.391 0 CA-C-N 118.74 1.27 . . . . 0.0 113.373 177.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -171.99 136.81 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 118.299 1.05 . . . . 0.0 110.293 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.094 -0.955 . . . . 0.0 110.634 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.06 142.03 38.85 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 110.315 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -131.18 148.71 52.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.946 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . 0.454 ' C ' ' CD2' ' R' ' 13' ' ' HIS . 2.6 p -129.51 135.85 60.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-O 121.434 0.635 . . . . 0.0 110.857 -179.695 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.489 ' N ' ' CD2' ' R' ' 13' ' ' HIS . 1.3 m-70 -139.9 133.13 29.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.631 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 83.7 t60 -153.55 161.56 42.1 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.453 ' O ' ' CD2' ' R' ' 14' ' ' HIS . 18.4 tt0 -90.14 158.87 17.06 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.306 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 37.7 tttp -140.52 104.6 4.79 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 177.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . 0.428 ' HB2' ' CE2' ' R' ' 19' ' ' PHE . 0.1 OUTLIER -118.58 114.05 22.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.477 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -117.36 107.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.028 0.442 . . . . 0.0 110.439 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.546 ' O ' ' CD2' ' R' ' 20' ' ' PHE . 16.2 m-85 -113.4 101.45 9.39 Favored 'General case' 0 N--CA 1.461 0.118 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . 0.546 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 63.0 m-85 -157.59 -177.75 6.82 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.695 1.236 . . . . 0.0 113.801 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.02 154.41 41.17 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.05 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -82.15 148.9 28.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.111 0.482 . . . . 0.0 111.7 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 58.14 48.14 13.37 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.753 179.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 15.3 t -66.52 166.56 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.812 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.76 15.96 0.04 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.5 p -83.11 140.82 32.41 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.607 ' O ' ' N ' ' R' ' 29' ' ' GLY . 71.5 m-80 -73.15 150.99 41.74 Favored 'General case' 0 C--O 1.223 -0.297 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.299 177.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -51.32 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.81 58.33 0.8 Allowed Glycine 0 CA--C 1.541 1.681 0 CA-C-N 118.611 0.641 . . . . 0.0 112.479 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -147.59 170.14 18.12 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 117.454 0.627 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 87.9 mt -119.89 123.95 71.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -121.57 130.22 74.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.665 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.08 111.44 1.16 Allowed Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 8.0 tt -119.27 121.42 39.6 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 87.9 mtp -141.64 145.16 34.63 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.384 0.611 . . . . 0.0 112.117 -178.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 p -144.01 143.4 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 119.526 -0.869 . . . . 0.0 111.623 177.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.03 -102.62 1.02 Allowed Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 174.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 23.23 73.5 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 112.758 -1.721 . . . . 0.0 115.48 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 96.8 t -49.39 134.4 7.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 117.008 0.404 . . . . 0.0 110.41 178.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.848 179.818 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 . . . . . 0 N--CA 1.466 0.34 0 CA-C-O 121.071 0.462 . . . . 0.0 111.461 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 m -136.22 157.57 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 178.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.427 ' C ' ' CG ' ' A' ' 14' ' ' HIS . 64.8 t-80 -145.32 124.06 12.59 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.712 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.513 ' CE1' ' H ' ' B' ' 14' ' ' HIS . 29.4 m-70 -151.47 165.97 32.55 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.133 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.9 tp60 -159.72 143.36 14.43 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.942 0.401 . . . . 0.0 110.053 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -80.44 120.37 24.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.352 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.8 mt -129.71 112.36 13.57 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.5 t -125.52 131.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.377 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -122.99 124.02 42.21 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.4 p90 -132.48 130.59 40.68 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.765 0.317 . . . . 0.0 110.382 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.19 132.69 40.05 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.068 0.461 . . . . 0.0 110.299 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 23' ' ' ASP . 13.2 pt-20 -83.87 -170.47 3.09 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.989 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 23' ' ' ASP . 21.3 p-10 . . . . . 0 N--CA 1.466 0.366 0 O-C-N 123.258 0.349 . . . . 0.0 111.15 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.56 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 14.5 t-20 . . . . . 0 CA--C 1.529 0.151 0 CA-C-O 121.749 0.785 . . . . 0.0 112.129 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.64 ' HZ1' ' CE1' ' O' ' 13' ' ' HIS . 71.4 tttt -54.4 -38.23 65.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.491 178.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.52 71.42 0.2 Allowed Glycine 0 CA--C 1.536 1.395 0 CA-C-N 114.937 -1.029 . . . . 0.0 114.137 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.474 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -95.65 98.43 10.48 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-O 124.367 2.032 . . . . 0.0 111.036 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 6.0 pt -134.76 139.56 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 111.538 -2.574 . . . . 0.0 108.685 -179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.4 mt -108.57 112.45 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.5 96.8 0.76 Allowed Glycine 0 N--CA 1.463 0.434 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.403 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 77.2 mt -147.08 169.87 18.35 Favored 'General case' 0 CA--C 1.506 -0.721 0 CA-C-O 122.622 1.201 . . . . 0.0 111.834 -176.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 23.5 mtp -124.68 119.42 28.92 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 113.403 -1.726 . . . . 0.0 108.894 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.551 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 2.5 t -108.95 111.9 38.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.52 -131.72 7.97 Favored Glycine 0 C--N 1.32 -0.356 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.6 -62.51 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.439 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 25.2 m -122.96 163.34 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.439 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 99.0 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . 0.527 ' CE1' ' O ' ' C' ' 9' ' ' GLY . 97.2 m-85 -106.12 132.89 51.65 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.541 ' N ' ' OE1' ' B' ' 11' ' ' GLU . 56.9 mp0 -110.31 124.0 50.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.465 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 53.7 t -124.73 128.15 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.522 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 41.2 t60 -131.44 122.24 25.91 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 120.941 0.4 . . . . 0.0 111.595 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.521 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 74.2 t60 -157.78 168.36 27.43 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.593 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.435 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 83.6 mt-30 -154.77 141.81 19.29 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.277 0.56 . . . . 0.0 110.747 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -87.09 110.9 20.41 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.712 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -121.52 112.72 18.85 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -121.65 131.8 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.718 0.294 . . . . 0.0 110.676 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -122.96 116.27 23.29 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.364 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -119.11 126.07 50.76 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.7 136.65 31.05 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.842 1.052 . . . . 0.0 113.842 -178.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -111.53 117.52 33.23 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 176.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.525 ' OD2' ' ND2' ' B' ' 27' ' ' ASN . 65.5 t0 -107.0 46.31 0.94 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -177.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' B' ' 25' ' ' GLY . 61.8 t -83.57 173.26 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.454 ' N ' ' CG1' ' B' ' 24' ' ' VAL . . . 93.6 -28.17 10.71 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.905 177.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.812 ' O ' ' O ' ' B' ' 27' ' ' ASN . 78.0 p 178.61 -129.35 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.524 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.825 -178.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.812 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.1 t30 10.16 152.06 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.503 ' HB3' ' H ' ' C' ' 28' ' ' LYS . 94.2 mttt -169.55 30.17 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.736 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -99.32 78.88 0.51 Allowed Glycine 0 CA--C 1.538 1.469 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 178.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.571 ' H ' HD22 ' C' ' 27' ' ' ASN . . . -110.43 112.75 24.89 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 114.512 1.301 . . . . 0.0 114.512 -176.079 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 44.1 pt -140.59 143.78 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.958 176.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -113.56 122.45 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.153 0.502 . . . . 0.0 110.054 178.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 105.39 1.04 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 106.839 -2.504 . . . . 0.0 106.839 177.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.412 ' H ' HD23 ' C' ' 34' ' ' LEU . 56.9 mt -137.19 145.24 43.46 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 122.818 1.294 . . . . 0.0 114.157 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -104.79 108.72 20.36 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 174.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -116.33 102.34 13.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.768 ' N ' HE22 ' D' ' 15' ' ' GLN . . . 111.75 164.19 17.5 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-O 122.015 0.786 . . . . 0.0 111.412 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.516 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 164.82 -55.95 0.27 Allowed Glycine 0 CA--C 1.542 1.741 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -178.208 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 t -119.76 134.4 63.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.43 ' O ' ' CG1' ' B' ' 40' ' ' VAL . 81.3 t . . . . . 0 C--O 1.22 -0.447 0 CA-C-O 118.163 -0.923 . . . . 0.0 110.721 179.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . 0.527 ' O ' ' CE1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -151.1 158.86 44.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.616 0.246 . . . . 0.0 110.628 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -89.64 120.78 31.21 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.598 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.523 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 2.8 p -138.94 138.6 41.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.232 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.523 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 84.3 m-70 -146.65 135.17 22.02 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.777 0.322 . . . . 0.0 111.413 -179.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' D' ' 14' ' ' HIS . 41.8 m-70 -151.26 172.03 16.5 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -126.65 141.81 51.74 Favored 'General case' 0 CA--C 1.522 -0.128 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 174.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -115.76 108.99 17.05 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 118.697 -0.668 . . . . 0.0 111.62 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mp -124.12 115.06 20.53 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 118.804 0.729 . . . . 0.0 109.056 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 81.2 t -109.32 122.16 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -111.56 103.46 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 15.7 t80 -113.67 125.12 53.79 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.226 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.81 133.35 33.9 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.786 0.803 . . . . 0.0 112.866 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -95.8 120.08 35.43 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.58 48.89 1.62 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -176.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.433 ' CG1' ' N ' ' C' ' 25' ' ' GLY . 73.3 t -71.89 161.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.481 ' O ' ' HB3' ' C' ' 26' ' ' SER . . . 109.35 -30.5 8.5 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 108.159 -1.976 . . . . 0.0 108.159 -176.489 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.512 ' OG ' ' CB ' ' D' ' 26' ' ' SER . 25.8 t 99.96 111.75 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.296 1.838 . . . . 0.0 110.657 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.571 HD22 ' H ' ' B' ' 30' ' ' ALA . 30.8 t30 -71.51 162.01 30.12 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.855 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.503 ' H ' ' HB3' ' B' ' 28' ' ' LYS . 28.2 ttpt -48.7 -39.36 24.34 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 176.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.49 69.15 0.04 OUTLIER Glycine 0 CA--C 1.542 1.762 0 CA-C-O 118.669 -1.073 . . . . 0.0 111.488 -173.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 130.17 41.41 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 120.14 1.97 . . . . 0.0 113.938 -173.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.494 ' CD1' ' O ' ' O' ' 38' ' ' GLY . 36.8 mt -139.18 141.24 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 113.738 -1.573 . . . . 0.0 114.284 -176.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.441 HD12 HG23 ' C' ' 32' ' ' ILE . 46.8 mt -117.78 118.52 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 175.096 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.17 113.2 1.88 Allowed Glycine 0 N--CA 1.474 1.185 0 N-CA-C 108.846 -1.701 . . . . 0.0 108.846 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.412 HD23 ' H ' ' B' ' 34' ' ' LEU . 3.1 mt -138.89 151.8 47.26 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-O 123.51 1.624 . . . . 0.0 114.499 -177.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 88.1 mmm -105.31 107.1 17.91 Favored 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 111.073 -2.785 . . . . 0.0 104.359 174.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -111.29 143.06 21.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' OE1' ' E' ' 15' ' ' GLN . . . 166.85 -102.06 0.19 Allowed Glycine 0 C--N 1.302 -1.352 0 C-N-CA 119.507 -1.33 . . . . 0.0 111.007 -177.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.516 ' HA3' ' H ' ' B' ' 38' ' ' GLY . . . 51.31 70.77 0.78 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.308 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.453 HG22 ' H ' ' D' ' 39' ' ' VAL . 22.9 t -72.14 142.08 15.75 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.226 0 CA-C-O 120.801 0.334 . . . . 0.0 111.718 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.334 179.186 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.465 0.277 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.523 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 8.6 t60 -146.44 129.79 16.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.935 0.397 . . . . 0.0 110.728 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 2.9 p80 -152.31 161.58 42.4 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.102 178.312 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.768 HE22 ' N ' ' B' ' 37' ' ' GLY . 24.9 mt-30 -90.09 159.59 16.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.347 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 48.1 mmtt -139.63 98.08 3.41 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.95 131.1 44.22 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.117 0.485 . . . . 0.0 110.059 178.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 62.9 t -121.53 124.85 72.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.52 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.7 m-85 -111.81 102.6 10.86 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 18.1 t80 -112.89 122.14 46.77 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.86 -0.155 . . . . 0.0 110.732 -178.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.28 134.31 30.84 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 122.106 0.955 . . . . 0.0 113.096 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.455 ' OE2' ' OE1' ' E' ' 22' ' ' GLU . 49.5 tp10 -101.2 126.8 47.95 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.594 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 52.5 p-10 -167.25 48.52 0.06 Allowed 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -72.44 160.97 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.11 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -30.06 8.81 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.094 -1.203 . . . . 0.0 110.094 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.512 ' CB ' ' OG ' ' C' ' 26' ' ' SER . 4.7 p -83.04 141.1 32.3 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 115.014 1.487 . . . . 0.0 115.014 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.671 ' O ' ' N ' ' D' ' 29' ' ' GLY . 34.1 p30 -73.21 -155.48 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.474 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -53.84 48.33 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 113.22 0.822 . . . . 0.0 113.22 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.671 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -100.19 56.01 0.84 Allowed Glycine 0 CA--C 1.542 1.75 0 CA-C-O 119.8 -0.445 . . . . 0.0 112.224 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -153.33 109.21 3.29 Favored 'General case' 0 C--O 1.24 0.594 0 CA-C-N 118.244 1.022 . . . . 0.0 110.277 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.405 ' HA ' ' O ' ' E' ' 31' ' ' ILE . 56.2 mt -133.04 130.37 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 119.104 -1.038 . . . . 0.0 113.549 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.448 HD13 HG23 ' D' ' 32' ' ' ILE . 73.9 mt -112.62 108.32 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 176.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.07 111.6 3.79 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.498 ' CD1' ' CE1' ' F' ' 19' ' ' PHE . 92.2 mt -134.36 134.97 42.34 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -111.39 103.96 12.37 Favored 'General case' 0 N--CA 1.439 -1.021 0 CA-C-N 111.506 -2.588 . . . . 0.0 105.957 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 21.2 m -115.53 122.73 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.787 -179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.44 112.77 1.48 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.668 ' N ' HE21 ' F' ' 15' ' ' GLN . . . -120.61 62.4 0.5 Allowed Glycine 0 CA--C 1.539 1.559 0 N-CA-C 116.237 1.255 . . . . 0.0 116.237 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.486 ' CG1' ' H ' ' D' ' 40' ' ' VAL . 31.2 t -76.83 168.81 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 120.892 2.346 . . . . 0.0 108.403 176.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.486 ' H ' ' CG1' ' D' ' 39' ' ' VAL . 3.6 p . . . . . 0 C--O 1.222 -0.39 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.657 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -98.51 134.4 41.53 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -158.55 153.67 25.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.88 0.371 . . . . 0.0 111.497 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.54 112.6 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -127.27 118.67 24.68 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -177.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.458 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 22.9 p-80 -157.57 159.64 37.31 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.531 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.415 ' OE1' ' O ' ' C' ' 37' ' ' GLY . 1.3 mp0 -90.23 159.02 16.92 Favored 'General case' 0 C--O 1.224 -0.242 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 13.0 tttm -140.96 101.13 3.98 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.402 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -130.44 127.89 40.2 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.7 t -117.71 126.21 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' E' ' 19' ' ' PHE . 0.2 OUTLIER -113.72 103.74 11.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 -179.454 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 22.3 t80 -113.21 118.53 34.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 121.443 -0.103 . . . . 0.0 111.138 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.57 138.33 36.13 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 119.668 -0.813 . . . . 0.0 112.256 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE2' ' D' ' 22' ' ' GLU . 88.6 mt-10 -101.51 119.77 39.28 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.37 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.544 ' O ' ' CG1' ' E' ' 24' ' ' VAL . 16.6 t0 -119.24 -49.89 2.37 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -179.373 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' E' ' 23' ' ' ASP . 0.1 OUTLIER 163.81 -166.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 179.367 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.36 -35.6 91.89 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.153 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 22.1 t -155.82 112.63 3.19 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 30' ' ' ALA . 20.0 p30 -53.01 170.22 0.08 Allowed 'General case' 0 N--CA 1.464 0.231 0 C-N-CA 117.114 -1.835 . . . . 0.0 108.626 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -61.24 -39.05 88.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.224 -0.991 . . . . 0.0 112.238 175.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.474 ' N ' ' OD1' ' E' ' 27' ' ' ASN . . . -178.97 74.97 0.07 OUTLIER Glycine 0 CA--C 1.544 1.856 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.076 -177.256 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.527 ' N ' ' OD1' ' E' ' 27' ' ' ASN . . . -80.64 163.65 23.46 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.537 1.668 . . . . 0.0 111.669 -178.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' D' ' 31' ' ' ILE . 79.8 mt -131.16 127.55 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.431 ' O ' ' HA ' ' F' ' 32' ' ' ILE . 3.2 tt -123.14 109.33 23.28 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . 0.524 ' HA2' ' H ' ' F' ' 33' ' ' GLY . . . -80.08 116.46 4.27 Favored Glycine 0 C--O 1.241 0.568 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' F' ' 34' ' ' LEU . 38.8 tp -110.14 104.21 13.03 Favored 'General case' 0 C--O 1.267 1.982 0 CA-C-N 120.096 1.948 . . . . 0.0 110.767 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.661 ' HA ' ' O ' ' F' ' 34' ' ' LEU . 29.0 tpp -115.8 110.48 19.13 Favored 'General case' 0 C--N 1.351 0.648 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.466 ' H ' ' HA ' ' F' ' 35' ' ' MET . 39.5 t -84.89 172.64 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.374 1.655 0 C-N-CA 117.431 -1.708 . . . . 0.0 107.157 177.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -176.75 92.99 0.09 OUTLIER Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.359 -1.877 . . . . 0.0 111.672 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' E' ' 39' ' ' VAL . . . 119.13 85.49 0.98 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-N 119.435 1.618 . . . . 0.0 114.009 178.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' E' ' 38' ' ' GLY . 1.8 p . . . . . 0 N--CA 1.484 1.246 0 N-CA-C 113.87 1.063 . . . . 0.0 113.87 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 . . . . . 0 CA--C 1.521 -0.159 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 27.1 m -138.22 157.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.514 0.673 . . . . 0.0 112.225 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -146.07 98.18 3.06 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.059 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.458 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 97.4 m-70 -151.9 168.08 26.28 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.668 HE21 ' N ' ' D' ' 38' ' ' GLY . 66.0 mt-30 -89.75 158.19 17.64 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -140.23 96.08 2.99 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.122 0.487 . . . . 0.0 109.889 177.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.6 ' N ' ' CD2' ' F' ' 17' ' ' LEU . 0.3 OUTLIER -118.82 112.06 19.23 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.928 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 14.6 t -101.28 110.96 29.46 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.728 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.498 ' CE1' ' CD1' ' D' ' 34' ' ' LEU . 15.6 m-85 -104.3 101.33 11.04 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.401 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 61.4 t80 -126.02 125.55 42.84 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 122.236 1.017 . . . . 0.0 111.762 -178.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.37 132.04 51.65 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' E' ' 24' ' ' VAL . 45.9 tp10 -62.17 103.3 0.37 Allowed 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 118.586 -1.246 . . . . 0.0 108.011 -178.062 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' E' ' 24' ' ' VAL . 8.3 m-20 . . . . . 0 N--CA 1.454 -0.258 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.071 -178.078 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.517 ' CB ' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.222 0.534 . . . . 0.0 111.135 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 5.4 mm -113.53 135.3 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.137 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.431 ' HA ' ' O ' ' E' ' 32' ' ' ILE . 82.9 mt -103.91 117.41 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.95 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . 0.524 ' H ' ' HA2' ' E' ' 33' ' ' GLY . . . -58.4 -154.61 0.01 OUTLIER Glycine 0 C--O 1.209 -1.46 0 CA-C-N 118.65 0.659 . . . . 0.0 113.233 -178.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . 0.661 ' O ' ' HA ' ' E' ' 35' ' ' MET . 74.4 mt -99.47 125.79 45.27 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 178.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.721 ' SD ' ' N ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -103.33 83.53 2.19 Favored 'General case' 0 C--O 1.171 -3.045 0 C-N-CA 130.117 3.367 . . . . 0.0 114.197 179.508 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.461 ' CG2' ' O ' ' F' ' 36' ' ' VAL . 2.7 m -92.77 115.21 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 117.785 -3.072 . . . . 0.0 112.713 175.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -117.19 122.51 5.48 Favored Glycine 0 CA--C 1.516 0.12 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 178.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.36 -61.61 7.27 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.046 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 37.2 t -147.88 137.77 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.171 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 178.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.135 -0.936 . . . . 0.0 110.34 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 4.4 m . . . . . 0 N--CA 1.467 0.384 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -104.74 121.68 44.12 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.821 0.343 . . . . 0.0 110.918 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 31.0 t60 -155.03 165.9 35.29 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.763 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.524 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 14.6 pt20 -157.06 142.22 17.18 Favored 'General case' 0 C--N 1.339 0.111 0 CA-C-O 121.174 0.512 . . . . 0.0 111.144 178.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 51.5 pttt -86.3 122.03 29.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.307 178.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.8 mt -127.41 118.07 23.39 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -133.73 133.44 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-O 120.697 0.284 . . . . 0.0 111.585 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -139.14 142.61 38.02 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.896 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -152.0 151.59 31.36 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 119.726 -0.79 . . . . 0.0 112.781 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.51 129.26 50.95 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.036 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -82.19 -173.58 4.62 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -176.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' N ' ' G' ' 23' ' ' ASP . 0.7 OUTLIER . . . . . 0 N--CA 1.469 0.507 0 CA-C-N 112.877 -1.965 . . . . 0.0 115.771 -178.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 . . . . . 0 N--CA 1.466 0.353 0 N-CA-C 110.501 -0.185 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -78.62 40.53 0.38 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.75 78.57 0.56 Allowed Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.729 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.66 59.97 4.41 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-N 119.814 1.807 . . . . 0.0 113.456 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 4.5 pt -147.99 123.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 177.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 87.8 mt -109.23 113.67 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.222 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.32 99.81 0.98 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 105.688 -2.965 . . . . 0.0 105.688 176.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.434 HD11 ' H ' ' G' ' 35' ' ' MET . 43.0 tp -157.92 154.8 28.44 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 118.007 -1.477 . . . . 0.0 113.468 -175.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.434 ' H ' HD11 ' G' ' 34' ' ' LEU . 55.0 tpp -102.1 119.89 39.54 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 113.007 -1.906 . . . . 0.0 107.07 177.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 47.2 t -124.2 112.17 31.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.221 0.534 . . . . 0.0 110.798 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.06 -131.89 10.19 Favored Glycine 0 C--N 1.316 -0.567 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.5 -61.35 0.38 Allowed Glycine 0 CA--C 1.537 1.445 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -178.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.486 ' CG2' ' N ' ' G' ' 40' ' ' VAL . 2.4 p -127.78 164.76 28.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . 0.486 ' N ' ' CG2' ' G' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.605 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' N ' ' H' ' 11' ' ' GLU . 60.7 t80 -148.73 179.88 7.5 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.284 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . 0.625 ' N ' ' CD2' ' H' ' 10' ' ' TYR . 80.9 mm-40 -66.96 126.93 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.47 126.62 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.621 ' CE1' ' CD2' ' I' ' 13' ' ' HIS . 15.7 p-80 -151.51 139.23 19.77 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.491 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.581 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 22.6 m-70 -145.33 160.7 41.13 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-O 121.046 0.451 . . . . 0.0 110.134 177.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.515 ' CD ' HE22 ' I' ' 15' ' ' GLN . 57.8 tt0 -90.2 160.44 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.139 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -139.84 102.74 4.49 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 7.3 tt -126.35 124.07 39.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.24 0.543 . . . . 0.0 111.191 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -122.0 130.88 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.301 179.1 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -125.95 113.12 16.75 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.058 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -114.47 120.25 39.63 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.68 126.23 41.55 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.811 0.815 . . . . 0.0 113.187 -178.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.416 ' OE2' ' OD2' ' G' ' 23' ' ' ASP . 80.0 tt0 -97.62 113.06 24.71 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 107.07 -1.455 . . . . 0.0 107.07 177.02 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 57.5 t0 -131.12 52.06 2.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.295 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p -74.69 142.97 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 C-N-CA 119.944 -0.703 . . . . 0.0 109.577 -177.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.43 38.37 3.75 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.387 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.401 ' OG ' ' OG ' ' I' ' 26' ' ' SER . 0.9 OUTLIER 73.39 120.04 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.784 -0.208 . . . . 0.0 111.162 179.123 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.439 ' CG ' ' OD2' ' I' ' 23' ' ' ASP . 8.2 m-20 -83.24 162.0 21.32 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.174 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -47.04 -39.53 13.01 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.683 177.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.04 69.15 0.02 OUTLIER Glycine 0 CA--C 1.537 1.448 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.55 -176.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -51.64 100.73 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 118.544 1.172 . . . . 0.0 114.045 -176.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 43.5 pt -137.86 139.27 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.671 178.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 86.9 mt -106.89 109.11 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.17 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.071 179.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.98 96.86 1.13 Allowed Glycine 0 CA--C 1.519 0.313 0 N-CA-C 105.506 -3.037 . . . . 0.0 105.506 176.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 67.4 mt -135.23 149.47 49.87 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-O 123.48 1.609 . . . . 0.0 114.129 -175.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -119.55 106.71 12.47 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 111.795 -2.457 . . . . 0.0 104.447 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 79.3 t -106.52 102.78 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.612 0.72 . . . . 0.0 110.521 -177.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -31.1 152.44 0.01 OUTLIER Glycine 0 N--CA 1.469 0.859 0 CA-C-N 114.56 -1.2 . . . . 0.0 113.723 -178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . -88.44 -57.46 1.86 Allowed Glycine 0 N--CA 1.47 0.965 0 CA-C-N 114.98 -0.61 . . . . 0.0 113.338 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 40' ' ' VAL . 60.7 t -24.28 146.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 39' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.217 -0.622 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.869 -179.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . 0.519 ' O ' ' CD2' ' H' ' 10' ' ' TYR . 90.8 m-85 -97.63 129.81 44.7 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.516 ' O ' ' NE2' ' J' ' 13' ' ' HIS . 95.8 mt-10 -141.13 143.46 34.29 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.763 0.316 . . . . 0.0 111.335 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 18.9 t -143.55 91.55 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.381 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.621 ' CD2' ' CE1' ' H' ' 13' ' ' HIS . 3.9 m170 -132.74 133.63 43.72 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 116.967 -0.106 . . . . 0.0 111.187 -178.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.729 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 11.3 m80 -145.74 160.7 41.35 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 178.383 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.515 HE22 ' CD ' ' H' ' 15' ' ' GLN . 69.1 tp60 -90.17 157.58 17.66 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 174.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -141.91 102.28 4.11 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 119.971 -0.691 . . . . 0.0 110.648 176.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 25.5 mt -120.51 118.41 30.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.652 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -111.8 114.77 48.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 177.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -108.53 105.25 14.81 Favored 'General case' 0 CA--C 1.539 0.533 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -116.17 132.63 56.61 Favored 'General case' 0 N--CA 1.479 1.02 0 O-C-N 122.212 -0.305 . . . . 0.0 111.091 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.22 149.65 32.31 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -178.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -105.59 163.36 12.73 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 113.966 -1.47 . . . . 0.0 108.124 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.446 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 34.6 t0 -174.47 47.08 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 -176.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.416 ' N ' ' OD2' ' J' ' 23' ' ' ASP . 0.1 OUTLIER -91.09 170.56 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 122.381 1.086 . . . . 0.0 110.308 -175.583 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.15 27.43 62.08 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.984 -176.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.401 ' OG ' ' OG ' ' H' ' 26' ' ' SER . 1.7 t 165.78 146.87 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -53.02 138.12 31.38 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 119.126 -1.03 . . . . 0.0 108.844 178.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 31.2 tttm -62.35 -49.77 74.23 Favored 'General case' 0 CA--C 1.53 0.193 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 100.82 57.47 0.87 Allowed Glycine 0 CA--C 1.544 1.854 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.03 115.55 30.79 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 120.12 1.96 . . . . 0.0 116.198 -172.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 97.1 mt -129.89 120.98 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.371 176.302 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 28.9 mt -106.1 114.08 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.36 109.05 1.9 Allowed Glycine 0 C--O 1.236 0.271 0 N-CA-C 106.151 -2.78 . . . . 0.0 106.151 176.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.436 HD12 ' N ' ' I' ' 35' ' ' MET . 0.1 OUTLIER -161.31 150.13 16.11 Favored 'General case' 0 CA--C 1.504 -0.793 0 C-N-CA 117.445 -1.702 . . . . 0.0 112.905 -175.63 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.436 ' N ' HD12 ' I' ' 34' ' ' LEU . 29.9 mtp -116.41 117.49 30.07 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-N 112.714 -2.039 . . . . 0.0 107.716 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' I' ' 37' ' ' GLY . 1.5 t -101.11 102.61 13.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.77 153.49 0.01 OUTLIER Glycine 0 N--CA 1.474 1.168 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.6 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.683 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -117.6 56.16 0.55 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 118.843 2.297 . . . . 0.0 118.843 -175.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.427 ' O ' ' O ' ' I' ' 40' ' ' VAL . 61.5 t -101.83 129.06 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 CA-C-N 119.886 1.843 . . . . 0.0 110.234 177.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.427 ' O ' ' O ' ' I' ' 39' ' ' VAL . 47.3 t . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.489 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -147.8 157.59 43.61 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.796 0.332 . . . . 0.0 110.283 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -151.16 114.92 4.93 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.479 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 79.2 t -128.74 133.33 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.814 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' O ' ' I' ' 11' ' ' GLU . 48.9 m-70 -141.19 100.33 3.78 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.484 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.729 ' H ' ' CD2' ' I' ' 14' ' ' HIS . 45.4 p-80 -149.22 161.08 42.72 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.362 177.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -90.16 159.79 16.58 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -139.78 103.63 4.71 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.629 179.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -128.34 118.42 23.18 Favored 'General case' 0 C--O 1.239 0.544 0 CA-C-O 121.868 0.842 . . . . 0.0 109.391 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 88.1 t -108.93 111.13 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.51 0 CA-C-N 114.141 -1.39 . . . . 0.0 109.17 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.564 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 16.5 m-85 -108.63 103.95 13.16 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.42 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 3.9 m-85 -120.05 130.72 54.82 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -177.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.4 120.07 16.16 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 177.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.51 ' O ' ' OD1' ' J' ' 23' ' ' ASP . 87.3 mt-10 -145.0 141.36 28.87 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -176.268 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.595 ' CG ' ' H ' ' J' ' 24' ' ' VAL . 5.3 p-10 147.17 -69.39 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.938 0 O-C-N 125.076 1.485 . . . . 0.0 110.125 176.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.678 ' CG2' ' H ' ' J' ' 25' ' ' GLY . 7.6 p -54.97 -122.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.499 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.678 ' H ' ' CG2' ' J' ' 24' ' ' VAL . . . 140.31 -35.17 1.92 Allowed Glycine 0 CA--C 1.528 0.866 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.661 177.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 16.1 t -80.45 118.66 22.27 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 121.041 2.42 . . . . 0.0 106.415 171.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.432 ' H ' ' CB ' ' K' ' 26' ' ' SER . 8.0 m-20 -91.44 160.28 15.53 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 121.977 2.171 . . . . 0.0 111.038 176.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -46.31 -39.93 10.93 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-O 122.729 1.252 . . . . 0.0 109.541 173.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.94 68.52 0.02 OUTLIER Glycine 0 CA--C 1.54 1.648 0 CA-C-N 112.401 -2.181 . . . . 0.0 107.954 -176.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.442 ' CB ' ' OD2' ' K' ' 23' ' ' ASP . . . -51.59 138.2 23.13 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 116.331 1.974 . . . . 0.0 116.331 -173.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 82.6 mt -135.14 126.57 46.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 113.327 -1.76 . . . . 0.0 112.228 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -108.95 109.72 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.02 99.73 0.99 Allowed Glycine 0 N--CA 1.462 0.433 0 N-CA-C 106.404 -2.678 . . . . 0.0 106.404 178.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 96.9 mt -134.94 134.63 40.8 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -175.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 45.7 tpp -104.51 107.52 18.49 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 103.936 -2.616 . . . . 0.0 103.936 174.1 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 t -120.21 113.14 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 122.445 1.117 . . . . 0.0 110.745 -178.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -73.04 -122.39 0.08 OUTLIER Glycine 0 C--N 1.313 -0.733 0 CA-C-N 112.876 -1.966 . . . . 0.0 110.732 175.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.683 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . 71.52 60.77 4.18 Favored Glycine 0 C--N 1.318 -0.446 0 CA-C-N 111.628 -2.286 . . . . 0.0 115.791 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 7.3 m -81.75 129.35 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.427 ' CG1' ' HZ2' ' P' ' 28' ' ' LYS . 9.3 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.414 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -111.83 135.18 52.79 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -136.29 144.78 44.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.748 0.308 . . . . 0.0 110.599 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 99.2 t -128.55 130.18 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 39.0 m-70 -136.19 113.73 10.91 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.079 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.497 ' O ' ' CB ' ' J' ' 14' ' ' HIS . 14.8 p-80 -152.84 162.38 41.36 Favored 'General case' 0 C--O 1.217 -0.612 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.904 178.531 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 10.3 tt0 -90.07 158.66 17.21 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.764 -1.939 . . . . 0.0 105.764 175.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -140.7 96.52 3.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 119.21 0.914 . . . . 0.0 110.825 178.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . 0.6 ' N ' ' CD2' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -120.87 110.58 16.49 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.582 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 7.7 p -114.5 114.25 46.08 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.564 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 28.7 m-85 -107.23 104.22 13.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.567 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 25.7 t80 -112.67 123.56 50.58 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.128 -178.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.475 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -151.87 139.12 19.32 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 118.72 -1.192 . . . . 0.0 114.126 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.419 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 94.2 mt-10 -79.59 109.46 14.0 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.523 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . 49.3 t0 -146.31 46.71 1.22 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -177.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' J' ' 25' ' ' GLY . 10.9 p -98.65 161.41 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 175.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.22 27.68 61.48 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.281 176.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.438 ' HG ' ' N ' ' K' ' 27' ' ' ASN . 24.9 t -83.9 -120.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.445 -0.902 . . . . 0.0 113.305 -175.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 26.7 t-20 -93.27 163.01 13.78 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 122.597 1.189 . . . . 0.0 113.493 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 68.7 mttm -41.97 -37.91 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 112.491 -2.14 . . . . 0.0 111.185 176.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.19 71.97 0.22 Allowed Glycine 0 CA--C 1.54 1.646 0 CA-C-N 115.744 -0.662 . . . . 0.0 114.253 -172.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.427 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . -82.02 173.2 12.4 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 18.0 tt -148.23 160.23 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.185 0 N-CA-C 116.17 1.915 . . . . 0.0 116.17 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.77 125.58 61.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 113.572 -1.649 . . . . 0.0 109.711 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.3 123.22 4.3 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.435 ' CD2' ' C ' ' K' ' 34' ' ' LEU . 2.3 tt -130.26 130.57 44.74 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-O 120.97 0.414 . . . . 0.0 110.496 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 5.6 mtp -124.84 130.17 51.86 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.248 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.434 ' CG1' ' N ' ' K' ' 37' ' ' GLY . 50.6 t -124.76 158.69 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.159 0.504 . . . . 0.0 110.667 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.434 ' N ' ' CG1' ' K' ' 36' ' ' VAL . . . -63.65 -103.08 0.01 OUTLIER Glycine 0 CA--C 1.53 0.997 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.32 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -135.89 -74.36 0.07 OUTLIER Glycine 0 CA--C 1.538 1.485 0 C-N-CA 121.472 -0.394 . . . . 0.0 113.249 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 120.715 0.293 . . . . 0.0 111.202 -178.835 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.615 0.245 . . . . 0.0 110.36 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.81 114.68 47.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.895 0.379 . . . . 0.0 110.615 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.576 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -147.16 105.77 3.81 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.211 179.814 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.484 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 79.2 m80 -151.49 166.94 29.56 Favored 'General case' 0 C--O 1.221 -0.429 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 38.6 tt0 -89.78 158.46 17.49 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.02 102.38 4.38 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.247 -0.581 . . . . 0.0 111.822 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . 0.52 ' N ' ' CD2' ' L' ' 17' ' ' LEU . 0.1 OUTLIER -116.61 108.09 15.52 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 176.537 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -106.98 111.14 34.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.57 -179.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -105.56 101.07 10.61 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.567 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 30.9 t80 -125.71 131.67 52.53 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 121.203 0.525 . . . . 0.0 110.756 -178.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -140.29 157.15 46.01 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.147 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.439 ' C ' ' O ' ' L' ' 21' ' ' ALA . 80.2 tt0 -31.1 129.54 0.13 Allowed 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 122.029 0.918 . . . . 0.0 112.48 -174.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' L' ' 23' ' ' ASP . 66.9 t0 -109.84 47.34 0.95 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 113.496 -1.684 . . . . 0.0 112.986 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 3.1 m -63.02 -167.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.349 -178.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.54 27.83 9.13 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.219 -0.446 . . . . 0.0 113.616 -175.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 48.0 t -153.67 120.28 5.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.424 0.63 . . . . 0.0 109.935 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 p30 -40.7 167.0 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.135 0 CA-C-N 114.978 -1.01 . . . . 0.0 112.187 -178.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.523 ' NZ ' ' O ' ' K' ' 23' ' ' ASP . 63.9 tttp -80.22 -50.0 10.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.199 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.85 50.59 3.05 Favored Glycine 0 CA--C 1.543 1.84 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.427 ' CB ' ' O ' ' K' ' 30' ' ' ALA . . . -130.57 -169.15 2.09 Favored 'General case' 0 C--N 1.341 0.224 0 CA-C-O 121.354 0.597 . . . . 0.0 110.597 -178.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.41 HD11 HG23 ' L' ' 31' ' ' ILE . 96.7 mt -118.64 138.55 48.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.786 178.062 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -122.15 128.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.64 122.52 3.42 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 111.635 -0.586 . . . . 0.0 111.635 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 57.6 mt -117.99 125.42 50.36 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -132.81 127.65 35.0 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.485 ' CG2' ' N ' ' L' ' 37' ' ' GLY . 2.6 p -140.46 171.72 12.75 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.485 ' N ' ' CG2' ' L' ' 36' ' ' VAL . . . -168.12 94.49 0.11 Allowed Glycine 0 C--N 1.311 -0.852 0 C-N-CA 118.536 -1.792 . . . . 0.0 112.036 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.5 -81.41 0.11 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.747 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' K' ' 38' ' ' GLY . 38.8 t . . . . . 0 N--CA 1.463 0.217 0 CA-C-O 121.105 0.479 . . . . 0.0 110.359 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.464 0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . 0.459 ' CG1' ' H ' ' N' ' 12' ' ' VAL . 2.4 p -123.0 131.82 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.286 0.565 . . . . 0.0 110.101 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . 0.456 ' CG ' ' N ' ' M' ' 14' ' ' HIS . 76.4 t60 -72.65 164.08 27.05 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.309 -178.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.588 ' N ' ' ND1' ' M' ' 14' ' ' HIS . 1.2 m-70 -99.13 166.17 11.37 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -89.8 159.82 16.82 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.54 107.98 5.85 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.1 mt -129.76 114.92 16.56 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 121.098 0.475 . . . . 0.0 110.227 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 54.3 t -125.23 132.17 71.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.031 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 t80 -136.28 127.41 28.0 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.45 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -131.48 146.32 52.19 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.16 128.29 23.88 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 121.741 0.781 . . . . 0.0 112.743 -178.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -92.17 -149.25 0.24 Allowed 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -46.62 -60.08 2.61 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.613 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . 0.419 ' CG1' ' N ' ' M' ' 25' ' ' GLY . 47.9 t -84.76 171.56 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 175.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . 0.419 ' N ' ' CG1' ' M' ' 24' ' ' VAL . . . 94.03 -29.98 8.1 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 176.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 7.3 p -84.23 139.98 31.99 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.146 -1.527 . . . . 0.0 113.575 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -73.03 179.5 3.74 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 177.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CG ' ' N' ' 28' ' ' LYS . 98.4 mttt -49.77 -37.58 30.4 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 117.943 -1.503 . . . . 0.0 110.548 -175.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.05 -78.38 0.06 OUTLIER Glycine 0 CA--C 1.53 1.023 0 C-N-CA 118.89 -1.624 . . . . 0.0 113.777 174.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' N' ' 30' ' ' ALA . . . -147.35 81.63 1.53 Allowed 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 117.819 0.81 . . . . 0.0 112.942 178.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . 0.407 ' O ' ' CG2' ' M' ' 31' ' ' ILE . 14.3 tt -123.34 105.39 15.69 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 2.4 mt -119.11 111.87 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 C-N-CA 119.659 -0.816 . . . . 0.0 111.452 -178.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.41 105.61 1.16 Allowed Glycine 0 N--CA 1.46 0.258 0 N-CA-C 104.153 -3.579 . . . . 0.0 104.153 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . 0.4 HD12 ' H ' ' M' ' 35' ' ' MET . 45.6 tp -153.71 158.17 40.6 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.579 -173.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 35' ' ' MET . . . . . 0.4 ' H ' HD12 ' M' ' 34' ' ' LEU . 0.7 OUTLIER -104.88 110.18 22.45 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 112.736 -2.029 . . . . 0.0 106.991 177.182 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.62 131.24 70.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.12 -111.17 3.89 Favored Glycine 0 C--N 1.318 -0.466 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.436 ' O ' ' CG2' ' N' ' 39' ' ' VAL . . . 75.12 -73.76 1.5 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.403 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 17.6 m -95.69 -176.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.175 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.403 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 1.3 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.607 178.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . 0.487 ' CD1' ' O ' ' O' ' 9' ' ' GLY . 97.9 m-85 -108.0 139.7 42.25 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.26 124.14 51.8 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.957 0.408 . . . . 0.0 111.023 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . 0.459 ' H ' ' CG1' ' M' ' 12' ' ' VAL . 3.4 t -137.88 97.14 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.745 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.57 ' ND1' ' ND1' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -151.5 151.07 31.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 121.108 -0.237 . . . . 0.0 110.675 179.524 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -124.79 162.58 23.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.047 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -89.88 158.79 17.28 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -140.53 99.94 3.75 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -124.04 119.3 29.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -123.01 128.34 75.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.648 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -123.76 123.95 41.64 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.897 179.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -129.18 123.14 31.31 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.805 0.336 . . . . 0.0 110.283 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 132.22 50.38 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.424 ' O ' ' CB ' ' N' ' 23' ' ' ASP . 83.1 tt0 -157.38 151.46 24.65 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.424 ' CB ' ' O ' ' N' ' 22' ' ' GLU . 9.5 m-20 92.29 46.92 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 113.603 -1.635 . . . . 0.0 115.185 176.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 24.2 m -101.52 158.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 -37.5 94.76 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.582 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.579 ' O ' ' O ' ' N' ' 27' ' ' ASN . 86.4 p -162.47 117.17 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 117.093 -1.432 . . . . 0.0 107.165 177.001 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.579 ' O ' ' O ' ' N' ' 26' ' ' SER . 11.6 t-20 -23.45 151.2 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 120.332 1.424 . . . . 0.0 111.908 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.418 ' CG ' ' O ' ' M' ' 28' ' ' LYS . 73.8 mmtt -107.83 47.87 0.87 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 115.999 -1.953 . . . . 0.0 115.264 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 61.8 0.52 Allowed Glycine 0 N--CA 1.489 2.202 0 CA-C-N 124.083 3.129 . . . . 0.0 114.067 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . 0.459 ' HA ' ' O ' ' M' ' 30' ' ' ALA . . . -88.31 98.95 11.88 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 121.076 2.438 . . . . 0.0 111.476 -174.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 18.9 tt -134.61 129.33 52.12 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-N 110.856 -2.884 . . . . 0.0 110.2 -177.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . 0.406 HD12 HG21 ' N' ' 32' ' ' ILE . 95.8 mt -113.04 110.87 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.78 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.25 93.51 0.72 Allowed Glycine 0 N--CA 1.467 0.722 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -125.12 133.32 52.89 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.018 1.39 . . . . 0.0 112.269 -174.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 2.7 mtp -103.55 106.06 16.47 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 176.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 p -127.9 123.11 60.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.246 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 149.63 -113.2 0.59 Allowed Glycine 0 C--N 1.311 -0.818 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.48 -72.58 0.62 Allowed Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' N' ' 40' ' ' VAL . 45.1 t -123.36 163.96 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 178.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . 0.48 ' C ' ' NE2' ' P' ' 13' ' ' HIS . 18.6 m . . . . . 0 N--CA 1.471 0.579 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.715 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' N' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -114.28 147.19 39.42 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.711 0.291 . . . . 0.0 110.293 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -87.49 109.88 19.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.09 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 51.5 t -129.62 123.86 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.505 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.64 ' CE1' ' HZ1' ' A' ' 28' ' ' LYS . 7.3 m-70 -137.57 150.42 47.46 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.598 ' CD2' ' CE1' ' P' ' 14' ' ' HIS . 4.7 m80 -136.86 157.45 46.73 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.169 178.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -86.3 157.46 19.91 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 175.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -160.25 101.76 1.4 Allowed 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.255 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 3.2 mt -132.47 122.73 25.37 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.335 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 89.2 t -113.56 113.27 43.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.941 178.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -108.4 102.54 11.63 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -113.33 125.03 53.83 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -177.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.15 125.91 40.05 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -124.51 178.93 5.16 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 52.44 58.94 4.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 113.19 -1.823 . . . . 0.0 112.05 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 63.2 t -78.25 123.0 34.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.911 -1.041 . . . . 0.0 109.214 175.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.414 ' H ' ' HA ' ' N' ' 26' ' ' SER . . . -90.49 -38.54 6.21 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.577 -177.472 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' O' ' 27' ' ' ASN . 46.8 t -161.97 116.51 1.91 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 118.454 1.127 . . . . 0.0 111.907 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' O' ' 26' ' ' SER . 57.2 p30 -24.12 163.73 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.358 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -152.16 -22.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.943 178.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.2 97.32 2.43 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.19 140.94 29.12 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-O 121.776 0.798 . . . . 0.0 111.974 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 mt -143.41 135.77 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.19 -0.914 . . . . 0.0 113.064 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 82.3 mt -114.38 112.08 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 176.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.01 109.48 2.34 Favored Glycine 0 C--O 1.24 0.505 0 N-CA-C 105.575 -3.01 . . . . 0.0 105.575 176.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -144.91 142.34 29.79 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 123.019 1.39 . . . . 0.0 114.038 -175.263 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 94.8 mmm -103.75 110.57 22.72 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 112.133 -2.303 . . . . 0.0 105.366 176.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . 0.416 ' CG1' ' NE2' ' Q' ' 15' ' ' GLN . 47.1 t -117.93 123.12 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-O 120.823 0.344 . . . . 0.0 110.087 -177.101 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.38 -113.24 0.63 Allowed Glycine 0 C--N 1.32 -0.339 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.494 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . 87.5 -73.12 2.42 Favored Glycine 0 CA--C 1.541 1.677 0 CA-C-O 119.93 -0.372 . . . . 0.0 112.649 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' O' ' 40' ' ' VAL . 45.2 t -134.51 161.04 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.463 ' N ' ' CG1' ' O' ' 39' ' ' VAL . 6.3 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.315 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.541 ' O ' ' NE2' ' O' ' 14' ' ' HIS . 2.8 m . . . . . 0 N--CA 1.467 0.413 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.48 ' NE2' ' C ' ' N' ' 40' ' ' VAL . 8.2 t60 -90.7 120.79 32.05 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.344 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' CD2' ' O' ' 14' ' ' HIS . 11.6 p-80 -152.97 161.82 42.08 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.659 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -90.23 158.77 17.04 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.646 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -140.94 105.27 4.84 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 31.2 mt -122.7 123.18 40.53 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 120.314 -0.554 . . . . 0.0 110.433 178.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.2 t -114.51 106.51 20.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.47 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 57.3 m-85 -106.76 111.52 24.09 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -133.7 130.39 38.09 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.456 1.28 . . . . 0.0 114.456 -176.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.54 125.16 37.75 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.838 177.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -111.74 150.81 29.72 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 115.764 1.764 . . . . 0.0 115.764 -175.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' OE1' ' Q' ' 22' ' ' GLU . 83.6 m-20 63.38 46.56 4.33 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 117.685 2.476 . . . . 0.0 117.685 173.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.456 ' CG1' ' H ' ' P' ' 25' ' ' GLY . 8.7 t -100.44 -179.44 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 115.556 -2.458 . . . . 0.0 109.523 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.5 ' O ' ' CB ' ' P' ' 26' ' ' SER . . . -72.6 -30.65 63.88 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 121.195 -0.526 . . . . 0.0 113.469 176.073 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.5 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 9.7 t 100.72 111.33 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 -174.217 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.544 ' CG ' ' H ' ' P' ' 28' ' ' LYS . 22.8 t-20 -71.31 173.47 7.75 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 117.459 -1.697 . . . . 0.0 112.724 -176.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.544 ' H ' ' CG ' ' P' ' 27' ' ' ASN . 88.7 tttt -52.45 -36.78 55.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.43 177.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.52 77.18 0.06 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.661 -177.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.83 154.11 2.22 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 118.307 1.053 . . . . 0.0 110.44 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -121.22 131.23 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -177.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . 0.412 HD11 HG22 ' P' ' 32' ' ' ILE . 73.7 mt -114.33 110.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.04 109.21 2.74 Favored Glycine 0 N--CA 1.463 0.497 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . 0.51 ' CD1' ' CE1' ' R' ' 19' ' ' PHE . 95.4 mt -135.0 133.48 39.49 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.445 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 4.0 mtp -107.62 104.02 13.46 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 174.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.76 103.07 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.32 -153.11 24.62 Favored Glycine 0 C--N 1.31 -0.892 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.95 -56.68 0.6 Allowed Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -178.1 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.436 ' O ' ' OXT' ' P' ' 40' ' ' VAL . 11.5 p -124.36 154.99 31.91 Favored 'Isoleucine or valine' 0 C--O 1.231 0.085 0 C-N-CA 122.66 0.384 . . . . 0.0 110.054 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.436 ' OXT' ' O ' ' P' ' 39' ' ' VAL . 1.9 t . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 118.067 -0.968 . . . . 0.0 111.028 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -119.73 120.71 37.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.82 154.01 43.77 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.043 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . 0.472 ' H ' ' CG1' ' P' ' 12' ' ' VAL . 12.7 m -133.0 120.11 39.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 121.625 0.726 . . . . 0.0 111.84 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.4 ' CD2' ' H ' ' Q' ' 13' ' ' HIS . 4.0 m-70 -90.1 110.73 21.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.233 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.527 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 2.3 t-80 -119.37 159.62 23.84 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.424 ' N ' ' ND1' ' Q' ' 14' ' ' HIS . 9.6 tt0 -86.24 157.84 19.85 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 76.5 tttt -160.04 94.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.539 177.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mt -131.56 127.15 36.58 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 28.1 m -117.45 122.11 69.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.47 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 22.0 m-85 -112.63 105.37 13.53 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -127.32 137.02 52.71 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.644 0.735 . . . . 0.0 112.686 -177.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -146.74 145.04 29.82 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 119.78 -0.768 . . . . 0.0 113.03 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.446 ' OE1' ' OD1' ' P' ' 23' ' ' ASP . 82.8 mt-10 -79.27 149.66 31.76 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.443 ' OD1' ' O ' ' R' ' 22' ' ' GLU . 6.9 p-10 -168.14 47.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -176.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 5.7 t -71.58 170.02 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.105 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.75 26.7 53.16 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 104.537 -3.425 . . . . 0.0 104.537 -175.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 24.0 p -80.85 116.5 20.86 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 117.047 2.24 . . . . 0.0 117.047 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -90.22 -152.16 0.26 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 111.286 -2.688 . . . . 0.0 104.947 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -48.56 -41.03 29.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 119.695 1.134 . . . . 0.0 108.333 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.44 -63.95 0.6 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 117.064 1.586 . . . . 0.0 117.064 173.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.16 165.21 32.07 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 120.108 1.954 . . . . 0.0 115.057 -176.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 69.2 mt -125.35 127.55 72.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 CA-C-N 111.321 -2.672 . . . . 0.0 106.786 178.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 tt -134.79 133.33 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 121.781 0.801 . . . . 0.0 112.698 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.4 109.93 2.16 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 107.764 -2.134 . . . . 0.0 107.764 177.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 18.5 tp -116.63 119.04 34.26 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -178.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.22 137.45 52.03 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.934 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 21.4 t -111.19 131.9 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.067 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.29 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . -45.62 -111.7 0.0 OUTLIER Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.322 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . -101.48 -71.5 0.93 Allowed Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 69.3 t -109.08 129.86 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.275 0.538 . . . . 0.0 109.862 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.838 -179.397 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.61 132.53 51.65 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -72.34 142.81 48.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . 0.448 ' H ' ' CG1' ' Q' ' 12' ' ' VAL . 5.4 m -121.13 131.96 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-O 121.901 0.858 . . . . 0.0 112.01 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 4.1 m80 -133.47 124.96 27.97 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 114.448 -1.251 . . . . 0.0 108.92 178.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 99.2 m-70 -149.28 172.04 15.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.809 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.516 ' OE1' ' N ' ' R' ' 15' ' ' GLN . 14.0 mp0 -89.42 150.33 22.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.614 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -150.17 98.78 2.73 Favored 'General case' 0 C--N 1.311 -1.066 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 178.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -127.05 124.58 39.64 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.625 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 66.5 t -106.62 114.66 46.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD1' ' P' ' 34' ' ' LEU . 17.1 m-85 -106.59 105.81 16.02 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' N ' ' R' ' 21' ' ' ALA . 66.2 t80 -146.9 156.76 43.33 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 122.463 1.125 . . . . 0.0 113.261 -177.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . 0.428 ' N ' ' CG ' ' R' ' 20' ' ' PHE . . . -150.02 148.24 28.8 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.878 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.443 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 83.4 tt0 -76.49 112.54 13.13 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.56 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.484 ' N ' ' OD1' ' R' ' 23' ' ' ASP . 19.5 p-10 -177.23 48.92 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.642 -177.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -72.11 160.49 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 118.605 -1.238 . . . . 0.0 108.879 -178.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.35 -34.83 5.18 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 107.286 -2.326 . . . . 0.0 107.286 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.425 ' OG ' ' O ' ' R' ' 23' ' ' ASP . 11.9 p -80.53 119.98 23.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 113.193 -1.504 . . . . 0.0 109.852 179.082 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' R' ' 29' ' ' GLY . 13.6 m120 -87.72 -175.17 5.07 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.091 -178.067 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -49.52 49.64 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.7 51.49 0.92 Allowed Glycine 0 CA--C 1.546 1.972 0 CA-C-N 118.776 0.717 . . . . 0.0 112.333 178.539 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.17 172.94 11.24 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.2 mt -113.35 120.4 63.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -125.01 127.97 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.935 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.19 116.68 3.01 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 178.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 40.4 tp -124.1 122.51 38.04 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.6 mtp -139.72 147.34 40.76 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.173 0.511 . . . . 0.0 112.279 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -130.15 155.27 41.46 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.075 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.5 179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.99 102.75 2.29 Favored Glycine 0 CA--C 1.523 0.582 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.95 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.97 -76.17 0.73 Allowed Glycine 0 CA--C 1.535 1.329 0 N-CA-C 115.241 0.857 . . . . 0.0 115.241 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . 0.485 ' O ' ' O ' ' Q' ' 38' ' ' GLY . 54.0 t -122.7 139.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 117.916 0.858 . . . . 0.0 112.708 -177.033 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.987 179.214 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.473 ' CD ' ' HE2' ' A' ' 13' ' ' HIS . 80.8 tt0 . . . . . 0 N--CA 1.465 0.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 51.8 t -120.16 129.51 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.619 0.723 . . . . 0.0 111.098 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.473 ' HE2' ' CD ' ' A' ' 11' ' ' GLU . 98.2 m-70 -126.04 166.16 17.48 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.713 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 53.0 p-80 -82.92 167.31 18.13 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.238 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -157.87 142.92 16.71 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.611 178.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -81.51 127.98 33.41 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.2 mt -125.48 114.49 18.87 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -127.55 131.49 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.176 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -134.55 130.79 37.1 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.148 0.499 . . . . 0.0 111.702 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -113.9 123.02 48.76 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.034 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.02 129.46 46.74 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.155 0.502 . . . . 0.0 111.656 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -92.99 -176.28 4.14 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 t0 . . . . . 0 C--N 1.324 -0.501 0 CA-C-O 121.402 0.62 . . . . 0.0 109.629 179.296 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.0 m120 . . . . . 0 N--CA 1.471 0.595 0 N-CA-C 115.862 1.801 . . . . 0.0 115.862 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -42.89 -36.25 1.45 Allowed 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 112.369 -2.196 . . . . 0.0 113.261 171.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -102.39 87.75 0.63 Allowed Glycine 0 CA--C 1.526 0.761 0 CA-C-N 113.051 -1.886 . . . . 0.0 117.335 -168.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.52 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -96.27 128.66 43.39 Favored 'General case' 0 CA--C 1.551 1.01 0 CA-C-O 124.975 2.321 . . . . 0.0 110.403 -177.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -145.59 160.23 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 CA-C-N 110.546 -3.024 . . . . 0.0 111.329 -175.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 52.0 mt -104.43 109.46 27.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 175.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.13 94.88 0.69 Allowed Glycine 0 CA--C 1.508 -0.39 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 178.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.4 mt -144.26 154.63 43.28 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 122.881 1.324 . . . . 0.0 113.43 -176.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 6.1 ttm -114.48 114.95 26.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 112.466 -2.152 . . . . 0.0 107.431 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.26 102.84 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.1 -151.75 20.83 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 109.299 -1.521 . . . . 0.0 109.299 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.485 ' O ' ' CD1' ' G' ' 31' ' ' ILE . . . 117.24 -56.33 0.54 Allowed Glycine 0 CA--C 1.543 1.797 0 C-N-CA 121.534 -0.365 . . . . 0.0 112.713 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 40' ' ' VAL . 7.2 p -133.1 177.47 7.09 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.453 ' C ' ' O ' ' A' ' 39' ' ' VAL . 6.0 m . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 117.901 -1.047 . . . . 0.0 111.965 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -84.23 138.02 33.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.76 0.314 . . . . 0.0 110.322 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -106.35 125.77 51.41 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.988 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 54.1 t -122.35 130.03 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.725 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m80 -117.42 157.6 25.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.609 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.605 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 52.9 t60 -80.72 166.86 20.63 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.111 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.559 ' O ' ' CE1' ' B' ' 14' ' ' HIS . 29.6 pt20 -129.29 151.08 50.34 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.15 0.5 . . . . 0.0 110.334 179.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -96.9 120.88 38.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.144 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 tt -116.76 115.56 25.84 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.8 t -121.34 128.68 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.205 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.248 -179.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -129.63 117.48 20.44 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 32.4 t80 -112.57 122.42 47.63 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.04 116.11 26.22 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.929 0.871 . . . . 0.0 112.394 -178.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -95.98 135.35 37.85 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.518 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -150.65 51.27 0.87 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.356 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.23 151.27 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 C-N-CA 118.486 -1.285 . . . . 0.0 110.21 -177.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.52 -32.4 6.64 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 106.166 -2.774 . . . . 0.0 106.166 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.504 ' HB3' ' N ' ' C' ' 26' ' ' SER . 0.5 OUTLIER 71.5 106.09 0.06 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 112.732 -1.734 . . . . 0.0 112.262 176.045 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.598 ' N ' ' OG ' ' C' ' 26' ' ' SER . 43.8 m-80 -101.63 163.36 12.3 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 119.217 -0.993 . . . . 0.0 112.815 177.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.49 ' O ' ' O ' ' C' ' 27' ' ' ASN . 99.7 mttt -41.45 -39.2 1.44 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 119.739 3.237 . . . . 0.0 119.739 178.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -110.72 69.7 0.21 Allowed Glycine 0 N--CA 1.497 2.713 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 -170.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.417 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -97.47 102.33 14.07 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 120.527 2.164 . . . . 0.0 111.978 178.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 7.0 pt -147.49 153.03 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.125 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.431 HD11 HG22 ' B' ' 32' ' ' ILE . 88.9 mt -107.44 114.09 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.53 106.09 1.93 Allowed Glycine 0 N--CA 1.464 0.504 0 N-CA-C 106.256 -2.738 . . . . 0.0 106.256 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -141.76 142.4 33.24 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.653 -1.219 . . . . 0.0 114.249 -175.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -116.67 110.94 19.13 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.359 177.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' C' ' 36' ' ' VAL . 0.4 OUTLIER -132.75 102.94 5.57 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.596 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 -179.299 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.51 -151.85 21.21 Favored Glycine 0 C--N 1.306 -1.088 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.21 -57.05 0.8 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -178.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.411 ' O ' ' C ' ' B' ' 40' ' ' VAL . 12.8 m -123.47 174.14 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 C-N-CA 123.826 0.851 . . . . 0.0 110.073 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.411 ' C ' ' O ' ' B' ' 39' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.572 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -83.23 139.53 33.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.291 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -81.6 118.94 23.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.407 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 53.4 t -130.31 133.75 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.137 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.62 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -139.13 100.8 4.11 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 121.218 -0.193 . . . . 0.0 111.134 179.205 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.605 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 13.6 m170 -117.19 160.5 20.95 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -86.41 155.54 20.54 Favored 'General case' 0 N--CA 1.457 -0.108 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . 0.538 ' CB ' ' HE2' ' B' ' 14' ' ' HIS . 85.4 tttt -161.18 94.66 1.01 Allowed 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.186 176.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 20.8 mt -121.71 117.85 27.65 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.887 178.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 4.8 t -105.69 110.17 30.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -108.92 105.84 15.55 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.57 122.8 47.05 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.459 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.73 146.45 37.78 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -81.04 108.66 14.9 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.693 178.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.416 ' OD2' ' CB ' ' D' ' 21' ' ' ALA . 82.0 m-20 -105.28 51.93 0.75 Allowed 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 113.507 -1.679 . . . . 0.0 110.238 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.0 t -71.34 -133.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 114.933 -1.031 . . . . 0.0 108.455 -174.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.46 38.07 3.38 Favored Glycine 0 N--CA 1.468 0.823 0 CA-C-O 124.111 1.95 . . . . 0.0 109.973 -169.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.598 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 1.2 m -72.29 102.9 3.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 108.651 -3.775 . . . . 0.0 102.243 171.037 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' B' ' 28' ' ' LYS . 88.2 m-20 -108.21 -170.14 1.63 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -171.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.426 ' O ' ' O ' ' N' ' 40' ' ' VAL . 98.6 mttt 32.36 41.27 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 113.668 -1.606 . . . . 0.0 111.12 -172.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . -176.72 61.1 0.1 OUTLIER Glycine 0 CA--C 1.546 1.976 0 CA-C-N 114.809 -1.087 . . . . 0.0 111.715 172.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.28 95.33 5.55 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 118.713 1.256 . . . . 0.0 110.505 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.515 ' CD1' ' O ' ' O' ' 38' ' ' GLY . 2.0 tt -164.41 153.48 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 C-N-CA 115.164 -2.615 . . . . 0.0 116.353 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.432 HD12 HG23 ' C' ' 32' ' ' ILE . 93.0 mt -112.73 112.34 40.01 Favored 'Isoleucine or valine' 0 C--N 1.35 0.601 0 CA-C-N 114.31 -1.314 . . . . 0.0 108.9 177.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.29 112.21 3.66 Favored Glycine 0 N--CA 1.464 0.554 0 N-CA-C 105.013 -3.235 . . . . 0.0 105.013 176.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 tt -148.05 146.3 28.81 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 117.619 -1.633 . . . . 0.0 114.474 -173.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 9.0 mtp -121.94 113.15 19.21 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' B' ' 36' ' ' VAL . 3.1 p -139.88 103.06 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.837 -177.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.06 -155.27 26.43 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 119.848 -1.168 . . . . 0.0 112.282 177.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 61.1 54.73 34.26 Favored Glycine 0 CA--C 1.544 1.862 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.574 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.456 ' O ' ' O ' ' C' ' 40' ' ' VAL . 2.6 m -156.2 -168.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.341 0.23 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.476 ' OXT' ' CG1' ' D' ' 40' ' ' VAL . 88.3 t . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.991 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.469 0.496 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.62 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 17.3 m-70 -134.82 107.43 7.39 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.593 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.593 ' ND1' ' O ' ' E' ' 14' ' ' HIS . 59.9 t60 -132.57 157.86 43.66 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.723 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.558 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 43.2 tt0 -85.82 157.38 20.23 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -160.09 100.15 1.38 Allowed 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.237 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 29.6 mt -123.5 115.02 20.86 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 178.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.9 109.1 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 59.9 m-85 -107.8 104.02 13.42 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.612 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 47.4 t80 -113.47 125.74 54.56 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . 0.416 ' CB ' ' OD2' ' C' ' 23' ' ' ASP . . . -135.94 135.06 39.3 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 122.712 1.244 . . . . 0.0 113.242 -178.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -84.4 113.5 21.22 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.022 -1.444 . . . . 0.0 108.963 179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.521 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 5.7 p-10 -146.44 48.57 1.18 Allowed 'General case' 0 CA--C 1.516 -0.365 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -72.58 160.79 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 177.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.38 -28.4 10.97 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.51 ' OG ' ' O ' ' E' ' 26' ' ' SER . 7.7 t 74.6 119.6 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 114.268 -0.966 . . . . 0.0 110.264 -178.25 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -83.29 163.25 20.81 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 120.078 -0.649 . . . . 0.0 111.278 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -46.98 -37.0 8.39 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 178.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.74 77.55 0.07 OUTLIER Glycine 0 CA--C 1.538 1.501 0 C-N-CA 120.497 -0.859 . . . . 0.0 113.085 -175.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.71 137.64 37.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 118.698 1.249 . . . . 0.0 111.082 -178.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 31.5 mt -127.34 138.65 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 CA-C-N 114.793 -1.094 . . . . 0.0 113.36 -176.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 67.2 mt -115.28 120.7 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 175.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.39 119.51 2.11 Favored Glycine 0 N--CA 1.467 0.731 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.494 ' N ' ' CD2' ' D' ' 34' ' ' LEU . 1.9 pt? -165.62 162.53 18.99 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 117.75 -1.58 . . . . 0.0 114.987 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 50.6 tpp -101.43 111.65 23.94 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 112.163 -2.289 . . . . 0.0 106.907 176.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.418 ' CG1' ' NE2' ' F' ' 15' ' ' GLN . 55.7 t -118.47 102.57 13.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 121.265 -0.174 . . . . 0.0 110.78 -178.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.03 -161.86 16.34 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.69 -55.34 0.5 Allowed Glycine 0 CA--C 1.539 1.578 0 CA-C-O 119.316 -0.713 . . . . 0.0 112.453 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.543 ' CG2' ' CD1' ' J' ' 31' ' ' ILE . 33.8 m -136.61 152.8 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.555 0 CA-C-N 118.776 1.288 . . . . 0.0 110.867 178.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.543 ' H ' ' CD1' ' K' ' 31' ' ' ILE . 60.7 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.485 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -106.97 135.75 48.0 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.839 0.352 . . . . 0.0 110.353 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -76.53 106.37 8.14 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.713 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 m -139.78 156.43 25.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.162 0.506 . . . . 0.0 110.938 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.412 ' C ' ' CD2' ' E' ' 14' ' ' HIS . 21.7 m-70 -148.27 117.57 6.9 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.141 178.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.593 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 13.3 m-70 -141.28 162.41 35.54 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 110.923 179.047 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.421 ' OE1' ' OE1' ' F' ' 15' ' ' GLN . 78.7 mt-30 -85.32 157.27 20.6 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 176.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -159.53 104.3 1.61 Allowed 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.322 0.582 . . . . 0.0 109.461 178.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.3 mt -125.07 116.8 22.67 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.773 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -107.48 101.85 13.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 74.1 m-85 -103.45 101.22 11.11 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 178.002 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.612 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 24.5 t80 -116.2 128.65 55.79 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.474 0.178 . . . . 0.0 111.156 -177.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.31 139.57 33.64 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.52 0.676 . . . . 0.0 112.755 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.519 ' O ' ' CG ' ' D' ' 23' ' ' ASP . 97.7 mt-10 -79.28 155.05 28.69 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' F' ' 23' ' ' ASP . 2.4 t70 -169.62 48.56 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.286 -1.366 . . . . 0.0 113.418 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 1.8 t -72.28 161.61 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 119.179 -1.008 . . . . 0.0 108.598 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.68 -28.65 10.38 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -176.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.526 ' O ' ' CB ' ' E' ' 27' ' ' ASN . 1.6 m 80.56 -114.71 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 113.644 -1.278 . . . . 0.0 112.232 -179.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.526 ' CB ' ' O ' ' E' ' 26' ' ' SER . 4.2 t-20 89.24 179.9 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -48.33 -38.43 19.05 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.85 -68.22 0.55 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-N 114.297 -1.32 . . . . 0.0 114.781 176.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.41 ' O ' ' CB ' ' F' ' 30' ' ' ALA . . . 179.91 171.0 1.13 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 119.044 1.422 . . . . 0.0 112.688 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.405 HD11 HG21 ' E' ' 31' ' ' ILE . 98.6 mt -131.85 128.36 59.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 113.976 -1.465 . . . . 0.0 108.587 177.309 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 52.1 mt -123.93 124.91 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.133 0.492 . . . . 0.0 111.822 -177.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 110.92 2.34 Favored Glycine 0 N--CA 1.47 0.96 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 21.8 mt -118.17 114.31 22.86 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -177.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 78.4 mmm -105.8 116.17 31.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 177.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.508 ' CG1' ' N ' ' E' ' 37' ' ' GLY . 61.7 t -128.44 170.85 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.701 0.762 . . . . 0.0 112.365 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.508 ' N ' ' CG1' ' E' ' 36' ' ' VAL . . . -168.26 94.28 0.11 Allowed Glycine 0 C--N 1.308 -1.021 0 N-CA-C 108.164 -1.975 . . . . 0.0 108.164 176.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.33 -73.15 0.42 Allowed Glycine 0 CA--C 1.54 1.626 0 CA-C-N 117.287 0.543 . . . . 0.0 112.927 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 76.2 t . . . . . 0 N--CA 1.437 -1.081 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.926 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.555 0.217 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.437 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 8.0 p -141.32 138.2 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.403 0.621 . . . . 0.0 110.948 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 4.6 m80 -140.98 133.57 28.61 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.121 -178.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.592 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 45.7 m80 -148.54 164.74 33.32 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.02 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.45 ' NE2' ' H ' ' F' ' 16' ' ' LYS . 70.9 tp60 -89.8 151.46 21.78 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.69 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . 0.45 ' H ' ' NE2' ' F' ' 15' ' ' GLN . 99.1 mttt -152.89 100.08 2.48 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.559 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.449 HD12 ' H ' ' F' ' 17' ' ' LEU . 0.2 OUTLIER -121.6 118.98 30.57 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 177.209 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.69 106.07 19.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.432 ' CE1' ' CD2' ' E' ' 19' ' ' PHE . 55.7 m-85 -104.32 103.59 13.36 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -117.24 109.82 17.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.223 0.535 . . . . 0.0 110.513 -178.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.96 117.98 28.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 177.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -90.33 112.08 23.53 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 119.222 -0.991 . . . . 0.0 113.583 -176.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' E' ' 23' ' ' ASP . 1.1 m-20 . . . . . 0 C--N 1.351 0.648 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.935 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.41 ' CB ' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.54 0.589 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mm -105.05 131.52 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 tt -137.7 129.5 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.979 0.419 . . . . 0.0 111.627 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.66 123.11 5.13 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 mt -116.59 120.31 38.28 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -123.69 130.11 52.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.538 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 29.5 m -115.96 158.38 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.08 -103.03 0.01 OUTLIER Glycine 0 CA--C 1.524 0.616 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.961 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.42 -76.66 0.5 Allowed Glycine 0 CA--C 1.534 1.231 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.425 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.47 ' O ' ' CD1' ' L' ' 31' ' ' ILE . 58.6 t -126.91 131.8 70.63 Favored 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-N 117.338 0.569 . . . . 0.0 110.343 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 10.9 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.861 -179.794 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.465 0.303 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -133.84 112.42 11.3 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.691 0.282 . . . . 0.0 110.913 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.436 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 47.9 p-80 -152.92 168.73 24.81 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.292 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 69.1 tp60 -158.22 142.46 15.88 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.654 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -81.86 126.63 32.12 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.033 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 tt -134.43 119.58 18.73 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 12.6 m -132.82 135.81 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.355 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -127.24 126.46 42.75 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.807 178.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' H' ' 20' ' ' PHE . 43.5 t80 -128.94 127.45 41.77 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.682 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.69 119.67 21.69 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 121.303 0.573 . . . . 0.0 110.977 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -92.57 124.6 36.71 Favored 'General case' 0 C--N 1.342 0.27 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.596 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.43 ' H ' ' HB3' ' H' ' 22' ' ' GLU . 67.0 t0 . . . . . 0 N--CA 1.474 0.748 0 C-N-CA 124.809 1.244 . . . . 0.0 113.086 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 121.526 0.679 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -54.61 -38.51 66.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.59 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.24 70.96 0.2 Allowed Glycine 0 CA--C 1.537 1.423 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.171 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.25 116.94 29.43 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 123.988 1.851 . . . . 0.0 112.69 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.485 ' CD1' ' O ' ' A' ' 38' ' ' GLY . 14.8 pt -146.95 149.21 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 111.993 -2.367 . . . . 0.0 109.904 -179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 55.0 mt -105.05 112.0 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.12 96.05 0.74 Allowed Glycine 0 N--CA 1.467 0.735 0 N-CA-C 107.264 -2.334 . . . . 0.0 107.264 178.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 78.3 mt -144.07 156.27 44.3 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 122.972 1.367 . . . . 0.0 113.848 -177.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' CG ' ' H' ' 35' ' ' MET . 44.1 tpp -103.57 111.16 23.5 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 112.166 -2.288 . . . . 0.0 106.315 176.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 t -131.54 111.78 19.7 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.432 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 127.99 -132.07 7.26 Favored Glycine 0 C--N 1.315 -0.623 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.49 -63.67 3.87 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.093 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 m -102.57 169.15 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-O 120.95 0.405 . . . . 0.0 110.844 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . 0.507 ' OXT' ' NE2' ' J' ' 13' ' ' HIS . 9.7 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.264 179.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -107.86 133.27 52.46 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.814 0.34 . . . . 0.0 110.179 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.62 128.6 22.01 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.225 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -122.99 131.34 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.805 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -132.4 105.77 7.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.811 0.339 . . . . 0.0 111.6 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.692 ' CD2' ' H ' ' H' ' 15' ' ' GLN . 1.1 t-80 -155.6 169.13 25.01 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.702 178.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.692 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 14.1 pt20 -157.45 142.19 16.64 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.985 0.421 . . . . 0.0 110.449 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -84.02 113.38 20.97 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.356 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.9 mt -119.66 113.41 20.63 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 79.7 t -124.38 131.72 72.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 CA-C-O 120.898 0.38 . . . . 0.0 111.636 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -126.7 116.57 21.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.309 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' G' ' 20' ' ' PHE . 30.0 t80 -117.23 123.83 47.59 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.18 138.56 25.29 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-O 122.454 1.121 . . . . 0.0 113.633 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.43 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 80.8 tt0 -90.14 149.5 22.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.152 -1.386 . . . . 0.0 109.402 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.405 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 66.4 t0 -174.32 48.43 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.682 -0.407 . . . . 0.0 112.042 -178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 t -72.67 161.43 4.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.213 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.505 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 108.95 -30.24 8.89 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.505 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 6.2 p 93.06 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.085 0.554 . . . . 0.0 111.015 178.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.625 HD22 ' CB ' ' H' ' 30' ' ' ALA . 17.6 p30 -74.02 175.05 7.77 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 119.889 -0.725 . . . . 0.0 110.448 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.616 ' NZ ' ' CE1' ' C' ' 13' ' ' HIS . 94.0 mttt -51.18 -36.93 43.63 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' H' ' 27' ' ' ASN . . . 179.54 77.22 0.06 OUTLIER Glycine 0 CA--C 1.529 0.961 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.729 -176.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.625 ' CB ' HD22 ' H' ' 27' ' ' ASN . . . -52.06 131.89 32.28 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 118.295 1.047 . . . . 0.0 113.567 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.438 HG22 HD12 ' H' ' 31' ' ' ILE . 51.6 mt -141.38 133.42 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mt -105.55 108.97 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 174.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.44 104.42 1.8 Allowed Glycine 0 N--CA 1.462 0.427 0 N-CA-C 106.948 -2.461 . . . . 0.0 106.948 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 81.0 mt -138.23 136.77 36.88 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 119.013 -1.075 . . . . 0.0 113.774 -176.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.472 ' CG ' ' SD ' ' G' ' 35' ' ' MET . 32.9 tpp -99.84 107.1 19.04 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 173.533 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 24.8 t -130.24 142.3 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -178.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 124.57 -101.95 0.68 Allowed Glycine 0 C--N 1.312 -0.759 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.19 -79.28 0.02 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' H' ' 37' ' ' GLY . 5.5 p -144.04 150.2 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.077 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.545 ' OXT' ' CG2' ' I' ' 40' ' ' VAL . 5.1 p . . . . . 0 C--O 1.217 -0.655 0 CA-C-O 118.14 -0.933 . . . . 0.0 111.117 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -108.44 136.66 47.69 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.842 0.353 . . . . 0.0 110.254 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.491 ' CD ' ' N ' ' I' ' 11' ' ' GLU . 1.8 pm0 -117.91 135.58 54.03 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.525 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.435 HG22 ' H ' ' J' ' 12' ' ' VAL . 70.2 t -124.97 126.51 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.202 -179.141 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -134.85 146.14 48.97 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.805 0.336 . . . . 0.0 111.33 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.459 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 59.4 m80 -147.82 172.69 13.74 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 121.132 0.492 . . . . 0.0 110.502 177.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 40.7 tt0 -137.86 140.89 40.68 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 176.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -130.15 110.06 11.3 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.105 -0.638 . . . . 0.0 112.413 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -121.81 113.12 19.22 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 175.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 8.0 t -105.56 109.43 27.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 80.3 m-85 -104.3 100.71 10.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.115 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -115.2 127.42 55.51 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -168.58 177.46 5.2 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 117.624 -1.63 . . . . 0.0 114.891 -177.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -77.92 156.96 29.98 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 175.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.722 ' O ' ' O ' ' I' ' 24' ' ' VAL . 67.9 t0 -169.84 60.56 0.04 OUTLIER 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 119.291 -0.964 . . . . 0.0 112.483 -175.214 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.722 ' O ' ' O ' ' I' ' 23' ' ' ASP . 3.4 t -44.53 -111.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.448 ' O ' ' N ' ' I' ' 27' ' ' ASN . . . 159.5 -45.37 0.44 Allowed Glycine 0 CA--C 1.502 -0.751 0 C-N-CA 116.091 -2.957 . . . . 0.0 116.561 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.498 ' C ' ' ND2' ' I' ' 27' ' ' ASN . 46.9 t -66.69 103.85 1.18 Allowed 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 113.773 -3.171 . . . . 0.0 106.11 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.53 ' O ' ' N ' ' I' ' 29' ' ' GLY . 1.6 m120 -137.02 170.13 16.61 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 113.963 -1.471 . . . . 0.0 109.132 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.499 ' C ' ' O ' ' I' ' 27' ' ' ASN . 52.7 mttp -25.84 -42.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.535 0 O-C-N 123.882 0.739 . . . . 0.0 111.217 173.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 160.68 67.6 0.02 OUTLIER Glycine 0 CA--C 1.554 2.494 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.677 -178.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -52.14 138.23 26.13 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 118.477 1.138 . . . . 0.0 112.166 -178.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 3.0 tt -144.59 145.93 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.428 HD13 HG22 ' I' ' 32' ' ' ILE . 3.9 mt -105.37 108.58 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 175.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.32 101.45 1.68 Allowed Glycine 0 N--CA 1.47 0.903 0 N-CA-C 106.41 -2.676 . . . . 0.0 106.41 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 3.1 mp -130.71 130.21 43.54 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -174.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 83.5 mmm -101.34 112.44 24.96 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 47.0 t -127.56 142.14 44.43 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.743 -174.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.16 -101.6 0.44 Allowed Glycine 0 C--N 1.318 -0.451 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 178.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.526 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 83.83 -81.02 1.77 Allowed Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 56.1 t -143.2 143.91 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.545 ' CG2' ' OXT' ' H' ' 40' ' ' VAL . 21.5 m . . . . . 0 N--CA 1.473 0.688 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.975 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.88 132.81 53.06 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.884 0.373 . . . . 0.0 110.622 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -75.51 123.43 25.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.435 ' H ' HG22 ' I' ' 12' ' ' VAL . 3.2 m -134.9 155.97 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.285 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.541 ' CG ' ' O ' ' H' ' 40' ' ' VAL . 2.1 t-80 -158.52 103.66 1.77 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.02 178.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.498 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 4.3 m-70 -137.23 159.09 42.93 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.786 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -90.26 159.26 16.78 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 105.67 -1.974 . . . . 0.0 105.67 175.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -140.66 109.73 6.13 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.845 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -130.04 120.02 24.06 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 20.3 m -116.28 117.93 57.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 177.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.407 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 32.2 m-85 -107.92 103.54 12.81 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -118.46 134.63 54.92 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.557 0.218 . . . . 0.0 110.989 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.31 146.24 23.53 Favored 'General case' 0 C--O 1.241 0.606 0 C-N-CA 117.919 -1.512 . . . . 0.0 114.842 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 72.3 mm-40 -86.8 147.47 25.81 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 113.578 -1.646 . . . . 0.0 108.915 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.492 ' OD1' ' N ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -160.18 51.88 0.32 Allowed 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -177.072 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.5 t -75.43 142.41 14.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 116.783 -1.967 . . . . 0.0 108.378 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.26 -37.22 3.84 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.49 119.95 23.84 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 113.663 -1.268 . . . . 0.0 112.697 -178.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.565 ' O ' ' N ' ' J' ' 29' ' ' GLY . 22.1 m-20 -88.38 158.01 18.53 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.039 -0.665 . . . . 0.0 109.437 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -47.91 48.35 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.216 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -101.47 52.55 0.88 Allowed Glycine 0 N--CA 1.481 1.664 0 CA-C-N 119.234 0.925 . . . . 0.0 113.905 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.01 179.44 5.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.4 0.619 . . . . 0.0 110.142 179.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.543 ' CD1' ' CG2' ' D' ' 39' ' ' VAL . 42.2 pt -138.96 145.04 28.27 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -108.67 110.44 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.053 177.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.77 95.88 0.91 Allowed Glycine 0 C--O 1.24 0.488 0 N-CA-C 104.673 -3.371 . . . . 0.0 104.673 176.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tt -133.11 132.27 41.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 123.062 1.41 . . . . 0.0 113.647 -175.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 11.1 mtp -107.89 109.39 20.89 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 112.208 -2.269 . . . . 0.0 107.393 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 12.0 p -104.44 111.51 34.32 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.469 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 178.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.47 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -58.62 131.91 52.29 Favored Glycine 0 N--CA 1.462 0.388 0 CA-C-N 115.146 -0.933 . . . . 0.0 114.403 -175.613 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.511 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . -89.42 63.62 3.32 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.423 ' O ' ' C ' ' J' ' 40' ' ' VAL . 28.7 m -112.86 125.6 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 CA-C-O 121.148 0.499 . . . . 0.0 110.695 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' J' ' 39' ' ' VAL . 3.3 t . . . . . 0 C--O 1.219 -0.535 0 CA-C-N 114.951 -1.022 . . . . 0.0 112.204 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -82.71 139.77 33.46 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.808 0.337 . . . . 0.0 110.51 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.402 ' HB3' ' HE2' ' K' ' 13' ' ' HIS . 95.7 mt-10 -92.24 121.63 33.94 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.276 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.35 132.03 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.969 0.414 . . . . 0.0 111.356 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.446 ' C ' ' ND1' ' K' ' 14' ' ' HIS . 2.6 m-70 -141.79 137.5 31.59 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.311 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.572 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 28.1 m80 -147.57 162.18 39.63 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -90.02 158.27 17.42 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 176.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.27 97.74 3.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 119.608 -0.837 . . . . 0.0 111.228 177.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 19.3 mt -121.49 118.62 29.77 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 176.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.85 111.81 37.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.584 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -105.09 100.92 10.5 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 49.6 t80 -121.78 122.33 39.26 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.732 0.301 . . . . 0.0 111.675 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.48 ' O ' ' CB ' ' L' ' 21' ' ' ALA . . . -154.13 159.0 41.26 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 118.504 -1.278 . . . . 0.0 114.25 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.492 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 96.6 mt-10 -85.71 161.09 19.36 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 177.174 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 22.2 p30 177.65 48.8 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 118.198 0.454 . . . . 0.0 112.167 -178.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -72.43 160.68 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 118.4 -1.32 . . . . 0.0 112.97 -176.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -28.7 10.29 Favored Glycine 0 CA--C 1.535 1.316 0 CA-C-N 113.634 -1.621 . . . . 0.0 112.419 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p 73.76 119.34 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.449 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 29.0 t-20 -83.3 163.49 20.65 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 119.494 -0.882 . . . . 0.0 112.477 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.449 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 99.4 mttt -47.35 -37.22 10.74 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 114.438 -1.255 . . . . 0.0 113.974 176.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.98 77.0 0.06 OUTLIER Glycine 0 CA--C 1.545 1.955 0 C-N-CA 120.059 -1.067 . . . . 0.0 114.42 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.485 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . -80.02 167.95 19.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 119.379 1.59 . . . . 0.0 110.351 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.543 ' CD1' ' H ' ' D' ' 40' ' ' VAL . 43.3 mt -133.24 127.98 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -176.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 pt -125.17 121.69 61.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 121.486 0.66 . . . . 0.0 109.998 176.32 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.26 115.73 2.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.496 ' N ' ' CD1' ' K' ' 34' ' ' LEU . 2.9 mp -122.0 119.89 32.77 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.406 ' SD ' ' CE ' ' L' ' 35' ' ' MET . 27.7 ttp -137.58 147.88 45.43 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 118.441 -1.303 . . . . 0.0 112.913 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -121.38 171.82 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 113.914 -1.493 . . . . 0.0 108.847 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.3 94.18 0.11 Allowed Glycine 0 N--CA 1.437 -1.279 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.999 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.49 ' O ' ' CD1' ' Q' ' 31' ' ' ILE . . . 152.11 -80.97 0.19 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.432 176.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . 0.511 ' N ' ' O ' ' J' ' 38' ' ' GLY . 90.2 t . . . . . 0 N--CA 1.466 0.334 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.743 0.306 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.12 132.88 70.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.271 0.557 . . . . 0.0 111.137 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.491 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.3 p80 -148.18 107.31 3.88 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.741 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.572 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.9 m80 -147.91 164.86 32.43 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 109.909 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.47 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 75.7 mt-30 -89.76 158.85 17.34 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.915 0.388 . . . . 0.0 111.175 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -140.07 102.56 4.42 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -120.37 118.14 29.59 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -105.04 116.43 48.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.487 ' CD1' ' N ' ' L' ' 19' ' ' PHE . 8.6 m-85 -105.16 103.7 13.29 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' O ' ' L' ' 21' ' ' ALA . 75.7 t80 -153.21 158.87 42.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 123.177 1.465 . . . . 0.0 113.807 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.528 ' O ' ' CE2' ' L' ' 20' ' ' PHE . . . -145.81 159.1 43.68 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 113.41 -1.723 . . . . 0.0 107.578 178.574 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.43 ' C ' ' H ' ' L' ' 24' ' ' VAL . 81.3 tt0 -39.95 152.7 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.27 -0.572 . . . . 0.0 111.677 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 p30 -65.45 47.33 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.807 -177.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.476 HG23 ' H ' ' L' ' 26' ' ' SER . 24.1 m -61.04 -179.12 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.483 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.34 29.62 12.11 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.476 ' H ' HG23 ' L' ' 24' ' ' VAL . 34.5 t -80.14 110.81 15.9 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.554 ' O ' ' N ' ' L' ' 29' ' ' GLY . 11.2 m120 -95.06 -166.31 1.44 Allowed 'General case' 0 C--O 1.222 -0.348 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.632 -179.433 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.57 47.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.01 56.59 0.93 Allowed Glycine 0 CA--C 1.538 1.508 0 CA-C-N 119.756 1.162 . . . . 0.0 111.431 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' K' ' 30' ' ' ALA . . . -170.27 177.11 4.27 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.47 ' CD1' ' O ' ' F' ' 39' ' ' VAL . 39.2 mt -106.97 125.59 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.531 ' CD1' ' N ' ' L' ' 32' ' ' ILE . 3.1 mp -110.45 115.89 50.94 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.229 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.1 107.26 1.15 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . 0.417 ' C ' ' CD2' ' L' ' 34' ' ' LEU . 6.3 tt -122.7 120.39 33.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.406 ' CE ' ' SD ' ' K' ' 35' ' ' MET . 28.6 mtm -136.17 144.62 45.09 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.462 0.648 . . . . 0.0 112.546 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.469 ' O ' ' O ' ' L' ' 37' ' ' GLY . 54.0 t -116.18 131.52 68.46 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.686 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -32.92 -111.3 0.0 OUTLIER Glycine 0 CA--C 1.532 1.113 0 CA-C-N 115.058 -0.974 . . . . 0.0 114.315 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.55 -71.64 0.53 Allowed Glycine 0 CA--C 1.536 1.35 0 CA-C-N 115.289 -0.456 . . . . 0.0 112.886 -178.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 121.46 0.647 . . . . 0.0 111.27 -179.061 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 . . . . . 0 N--CA 1.456 -0.128 0 CA-C-O 120.737 0.303 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 52.0 t -116.48 129.58 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.298 0.57 . . . . 0.0 110.116 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -81.4 163.09 23.06 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.372 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 89.5 m-70 -105.09 160.97 14.64 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 121.265 0.555 . . . . 0.0 111.768 -179.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -89.98 160.25 16.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.62 178.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -139.38 110.9 7.08 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.1 mt -135.93 117.44 14.81 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.551 0.691 . . . . 0.0 111.081 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.17 132.95 70.55 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.813 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -128.04 134.21 49.18 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.771 0.32 . . . . 0.0 110.552 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.496 ' O ' ' CD2' ' M' ' 20' ' ' PHE . 53.2 p90 -127.43 126.02 41.63 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 129.25 47.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.225 0.536 . . . . 0.0 111.962 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -155.34 126.7 7.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.007 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.69 46.45 24.66 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.332 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 11.6 m -76.11 179.55 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.0 28.11 6.86 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.813 -179.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' M' ' 27' ' ' ASN . 5.5 t -170.46 -134.11 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.912 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' M' ' 26' ' ' SER . 22.2 t-20 -30.81 143.58 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.847 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -132.9 -26.08 1.78 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.748 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.99 -108.87 0.26 Allowed Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.143 -1.027 . . . . 0.0 111.052 179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.45 96.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.45 -0.5 . . . . 0.0 112.1 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -115.24 105.28 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 55.0 mt -110.73 112.6 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 120.411 -0.516 . . . . 0.0 109.745 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.75 104.45 1.22 Allowed Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 104.977 -3.249 . . . . 0.0 104.977 176.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 30.0 tp -155.2 151.36 28.06 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 117.489 -1.685 . . . . 0.0 114.409 -174.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 93.9 mmm -100.27 111.51 23.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 112.659 -2.064 . . . . 0.0 106.878 177.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 41.9 t -119.66 131.37 72.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.34 -111.28 4.13 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' N' ' 37' ' ' GLY . . . 81.13 -74.03 2.49 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -178.105 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.18 161.37 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.468 ' CB ' ' HE2' ' P' ' 13' ' ' HIS . 10.7 m . . . . . 0 N--CA 1.47 0.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.538 177.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.159 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -105.24 131.51 52.62 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -114.8 115.29 26.77 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.204 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -129.57 123.02 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.174 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -143.58 130.71 20.71 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.196 0.522 . . . . 0.0 110.473 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.637 ' ND1' ' NE2' ' O' ' 14' ' ' HIS . 19.5 t60 -159.75 170.08 22.27 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CD2' ' N' ' 14' ' ' HIS . 75.2 mt-30 -155.14 140.71 17.91 Favored 'General case' 0 CA--C 1.517 -0.32 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.767 177.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 48.0 tttp -93.98 111.04 22.7 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.867 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 13.6 mt -119.91 114.43 22.06 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 177.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 6.3 p -138.6 141.86 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 119.692 -0.803 . . . . 0.0 112.135 -179.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -131.36 122.55 26.55 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.07 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -112.88 123.48 50.4 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.633 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.05 121.06 40.25 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' O' ' 22' ' ' GLU . 82.6 tt0 -136.32 156.38 48.72 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 121.208 0.527 . . . . 0.0 112.31 -177.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 20.0 t0 76.63 54.74 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.364 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 90.8 t -68.05 135.25 28.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.57 -34.26 2.3 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 120.995 -0.621 . . . . 0.0 111.836 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' N' ' 27' ' ' ASN . 29.5 t -162.41 120.3 2.12 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-N 116.847 0.323 . . . . 0.0 110.991 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.516 ' O ' ' O ' ' N' ' 26' ' ' SER . 17.5 p30 -22.26 152.74 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -163.19 24.58 0.09 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.434 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.52 105.29 1.13 Allowed Glycine 0 N--CA 1.466 0.683 0 C-N-CA 119.06 -1.543 . . . . 0.0 113.435 178.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.96 95.63 5.59 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 122.072 0.939 . . . . 0.0 108.777 179.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 79.4 mt -137.44 136.13 46.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 114.826 -1.079 . . . . 0.0 112.225 -177.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . 0.425 HG21 HD11 ' N' ' 32' ' ' ILE . 77.1 mt -106.76 105.64 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 175.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.38 91.98 0.66 Allowed Glycine 0 N--CA 1.467 0.742 0 N-CA-C 106.197 -2.761 . . . . 0.0 106.197 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 mp -132.74 152.55 51.73 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 123.35 1.548 . . . . 0.0 114.452 -175.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -115.65 107.26 14.87 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 175.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' O' ' 37' ' ' GLY . 47.6 t -117.63 123.16 71.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.05 -177.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.702 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 134.75 -113.86 1.2 Allowed Glycine 0 C--N 1.317 -0.515 0 N-CA-C 110.524 -1.03 . . . . 0.0 110.524 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.83 -71.64 0.66 Allowed Glycine 0 CA--C 1.533 1.188 0 N-CA-C 110.618 -0.993 . . . . 0.0 110.618 -178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 83.6 t -126.49 138.58 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 177.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' C' ' 28' ' ' LYS . 66.2 t . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.909 -1.043 . . . . 0.0 110.056 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -107.19 134.31 50.49 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.83 0.348 . . . . 0.0 110.466 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.98 133.61 39.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.827 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.56 140.28 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.085 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.477 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 42.0 t-80 -147.5 95.53 2.54 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.392 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.637 ' NE2' ' ND1' ' N' ' 14' ' ' HIS . 0.3 OUTLIER -161.05 170.9 19.58 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 178.798 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -97.33 143.47 28.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.699 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -124.64 118.98 27.73 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -122.76 128.93 51.14 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.516 0.674 . . . . 0.0 111.337 179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 98.2 t -119.07 111.99 35.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -107.7 108.0 19.04 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 178.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -122.87 126.67 47.77 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.83 117.06 28.26 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' O' ' 24' ' ' VAL . 83.5 tt0 -83.43 153.18 24.63 Favored 'General case' 0 N--CA 1.461 0.083 0 N-CA-C 113.438 0.903 . . . . 0.0 113.438 -176.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' O' ' 24' ' ' VAL . 65.6 t0 8.66 51.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 113.034 -1.894 . . . . 0.0 114.654 -179.155 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.578 ' CG1' ' H ' ' O' ' 25' ' ' GLY . 11.6 t -55.89 -132.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 174.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.578 ' H ' ' CG1' ' O' ' 24' ' ' VAL . . . 144.47 -29.77 1.88 Allowed Glycine 0 C--O 1.226 -0.365 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.337 175.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.461 ' O ' ' CE ' ' P' ' 28' ' ' LYS . 5.8 t -89.92 -132.89 0.1 Allowed 'General case' 0 CA--C 1.55 0.974 0 CA-C-O 122.986 1.374 . . . . 0.0 113.292 179.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 12.2 m120 79.28 138.9 0.07 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 127.669 2.388 . . . . 0.0 111.22 178.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -48.83 -48.45 41.62 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 117.2 2.296 . . . . 0.0 117.2 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.67 62.48 0.06 OUTLIER Glycine 0 CA--C 1.545 1.921 0 CA-C-O 118.084 -1.398 . . . . 0.0 111.498 -171.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -52.71 143.92 15.22 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 120.681 2.241 . . . . 0.0 116.714 -170.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.526 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 70.8 mt -138.79 153.89 25.87 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 CA-C-N 110.942 -2.845 . . . . 0.0 113.871 -175.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . 0.423 HG22 HD12 ' O' ' 32' ' ' ILE . 75.5 mt -117.1 110.53 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 174.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.44 106.96 2.41 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 104.732 -3.347 . . . . 0.0 104.732 176.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 26.7 tp -148.37 139.21 23.01 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 122.747 1.26 . . . . 0.0 113.696 -174.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 24.5 ttm -114.33 110.98 20.76 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 113.648 -1.615 . . . . 0.0 107.428 176.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . 0.437 ' O ' ' HA3' ' P' ' 37' ' ' GLY . 1.7 t -89.91 103.74 14.47 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.784 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . -20.06 144.5 0.01 OUTLIER Glycine 0 N--CA 1.481 1.69 0 C-N-CA 124.136 0.874 . . . . 0.0 115.077 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.515 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . -100.78 59.12 0.68 Allowed Glycine 0 CA--C 1.541 1.673 0 CA-C-N 115.022 -0.589 . . . . 0.0 113.6 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.23 161.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-N 117.423 0.611 . . . . 0.0 110.607 179.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 78.0 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.306 179.584 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 40.3 t . . . . . 0 N--CA 1.467 0.386 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 0.9 OUTLIER -146.05 105.35 3.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.381 -179.307 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 2.1 p-80 -134.1 160.59 37.31 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.449 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.702 HE22 ' N ' ' N' ' 37' ' ' GLY . 3.3 mt-30 -89.99 159.22 17.0 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.133 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -140.07 103.27 4.58 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -128.88 125.68 38.14 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 121.399 0.619 . . . . 0.0 110.657 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 79.6 t -118.38 117.38 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.679 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CE1' ' Q' ' 19' ' ' PHE . 29.4 m-85 -114.01 103.84 11.55 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 27.6 t80 -117.64 126.93 53.4 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.665 0.269 . . . . 0.0 111.059 -178.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.1 115.91 15.66 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 121.062 0.458 . . . . 0.0 111.497 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.545 ' O ' ' N ' ' O' ' 24' ' ' VAL . 80.4 tt0 -92.71 112.81 24.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.576 ' O ' ' NZ ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -139.19 46.76 1.92 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.681 -175.909 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.582 ' CG2' ' H ' ' P' ' 25' ' ' GLY . 7.7 p -73.15 179.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.453 0.644 . . . . 0.0 111.554 -178.133 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.582 ' H ' ' CG2' ' P' ' 24' ' ' VAL . . . 99.66 -34.66 5.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 118.647 -1.085 . . . . 0.0 114.468 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.466 ' O ' ' C ' ' P' ' 27' ' ' ASN . 96.2 p -162.24 120.43 2.2 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.381 2.09 . . . . 0.0 112.791 176.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.466 ' C ' ' O ' ' P' ' 26' ' ' SER . 65.8 t30 -23.56 141.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 123.611 0.569 . . . . 0.0 111.371 177.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.576 ' NZ ' ' O ' ' P' ' 23' ' ' ASP . 64.7 mttp -122.24 -32.93 3.58 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 177.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.33 79.85 0.91 Allowed Glycine 0 CA--C 1.536 1.381 0 N-CA-C 108.343 -1.903 . . . . 0.0 108.343 -176.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.7 144.04 30.9 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-N 118.172 0.986 . . . . 0.0 111.727 -175.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 5.8 mt -125.07 138.64 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 113.815 -1.538 . . . . 0.0 113.563 -177.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 96.4 mt -118.76 112.35 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.98 100.22 1.45 Allowed Glycine 0 CA--C 1.509 -0.302 0 N-CA-C 104.557 -3.417 . . . . 0.0 104.557 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 7.7 tt -137.07 138.22 40.16 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-O 123.014 1.387 . . . . 0.0 114.533 -174.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 5.5 ttm -104.66 111.44 24.14 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.002 -1.908 . . . . 0.0 106.909 176.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -85.24 101.65 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 C-N-CA 118.585 -1.246 . . . . 0.0 108.269 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.561 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . . . -88.89 153.91 24.18 Favored Glycine 0 C--N 1.316 -0.579 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.445 ' N ' ' HA2' ' O' ' 38' ' ' GLY . . . 136.68 58.86 0.06 OUTLIER Glycine 0 N--CA 1.466 0.639 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.609 ' CG2' ' H ' ' Q' ' 38' ' ' GLY . 49.7 t -79.51 133.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.449 ' CG2' ' NE2' ' R' ' 13' ' ' HIS . 9.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.956 -1.021 . . . . 0.0 111.748 -178.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.1 135.37 46.58 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.838 0.351 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -103.02 122.55 44.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.209 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' Q' ' 13' ' ' HIS . 46.8 t -142.37 168.16 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.689 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.418 ' N ' ' CG1' ' Q' ' 12' ' ' VAL . 8.3 p80 -64.1 127.47 31.57 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -177.678 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.505 ' O ' ' CB ' ' P' ' 14' ' ' HIS . 7.0 p80 -157.46 168.46 27.26 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.157 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.561 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 79.1 mt-30 -89.97 151.39 21.72 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.921 -0.487 . . . . 0.0 110.313 178.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -148.76 106.48 3.68 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . 0.412 HD12 ' N ' ' Q' ' 17' ' ' LEU . 4.5 mp -135.68 124.46 23.92 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.264 0.554 . . . . 0.0 111.017 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -108.1 116.29 51.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 178.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CE1' ' P' ' 19' ' ' PHE . 60.3 m-85 -112.42 109.23 18.72 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.226 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 41.4 t80 -125.45 128.17 47.65 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.55 134.3 37.34 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.129 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -114.74 124.29 51.4 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.507 ' N ' ' OD1' ' Q' ' 23' ' ' ASP . 12.6 p-10 -147.28 59.73 1.16 Allowed 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.382 0.611 . . . . 0.0 111.873 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.685 ' CG1' ' H ' ' Q' ' 25' ' ' GLY . 4.8 t 72.07 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.018 176.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.685 ' H ' ' CG1' ' Q' ' 24' ' ' VAL . . . -107.91 29.3 10.46 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.312 177.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 48.7 m -65.1 -113.96 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 118.716 1.258 . . . . 0.0 111.223 -176.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -155.94 169.19 25.01 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 119.631 -0.827 . . . . 0.0 112.362 179.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt 27.36 43.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.224 -1.353 . . . . 0.0 112.723 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.84 60.25 0.74 Allowed Glycine 0 N--CA 1.475 1.24 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.21 177.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.19 118.63 0.57 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 119.229 1.514 . . . . 0.0 113.043 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . 0.49 ' CD1' ' O ' ' K' ' 38' ' ' GLY . 1.7 tt -136.14 125.38 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 175.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 64.5 mt -128.66 133.79 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.198 -176.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.85 112.57 2.36 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 108.164 -1.974 . . . . 0.0 108.164 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 58.4 mt -119.16 120.44 37.1 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.093 0.473 . . . . 0.0 110.935 -177.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 11.0 mtp -124.7 130.92 53.33 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.362 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -105.81 159.86 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 CA-C-O 121.359 0.6 . . . . 0.0 110.75 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.84 -102.77 0.01 OUTLIER Glycine 0 CA--C 1.528 0.854 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.086 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.609 ' H ' ' CG2' ' P' ' 39' ' ' VAL . . . -116.97 -77.17 0.62 Allowed Glycine 0 CA--C 1.534 1.269 0 CA-C-O 119.864 -0.409 . . . . 0.0 113.166 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.433 ' HA ' ' O ' ' R' ' 39' ' ' VAL . 39.3 t -115.01 129.9 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 117.682 0.741 . . . . 0.0 111.861 -178.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.493 ' N ' ' O ' ' R' ' 40' ' ' VAL . 42.6 t . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.694 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -79.54 138.4 37.49 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -111.31 128.58 55.99 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.433 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 30.8 t -110.46 93.17 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.451 0.643 . . . . 0.0 110.609 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.517 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 50.1 p-80 -120.32 105.77 11.24 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.545 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 84.6 t60 -141.11 170.73 15.17 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.752 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.531 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 93.0 mm-40 -89.55 150.62 22.35 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -149.59 99.0 2.84 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -139.02 124.78 19.65 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.529 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -104.96 118.52 52.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -111.92 105.8 14.33 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 t80 -130.14 125.7 35.7 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.61 0.719 . . . . 0.0 112.104 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.59 126.4 38.4 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.269 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 79.1 tt0 -89.21 110.81 21.52 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 119.938 -0.705 . . . . 0.0 110.965 -178.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.448 ' OD2' ' OD2' ' Q' ' 23' ' ' ASP . 54.0 m-20 -163.11 -60.25 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' R' ' 25' ' ' GLY . 98.2 t -55.81 162.49 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.742 -179.435 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . 0.431 ' N ' ' CG1' ' R' ' 24' ' ' VAL . . . -157.3 -27.84 0.03 OUTLIER Glycine 0 CA--C 1.52 0.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 93.1 p -80.74 -130.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.268 -0.466 . . . . 0.0 109.912 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.565 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.0 m-80 -99.18 -164.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.499 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -47.76 49.48 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 125.372 1.469 . . . . 0.0 114.793 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.38 51.76 0.92 Allowed Glycine 0 CA--C 1.55 2.229 0 CA-C-N 119.344 0.974 . . . . 0.0 113.715 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.19 165.61 22.0 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.6 mt -114.31 112.21 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 CA-C-N 119.73 1.15 . . . . 0.0 110.042 178.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -125.73 127.72 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.843 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.66 119.41 3.5 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 48.4 tp -123.25 123.08 39.95 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mtp -138.38 147.42 43.39 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.06 161.51 38.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.123 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.3 -102.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.501 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.34 -78.02 0.87 Allowed Glycine 0 N--CA 1.475 1.289 0 C-N-CA 121.707 -0.283 . . . . 0.0 112.891 -178.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' Q' ' 39' ' ' VAL . 70.1 t -96.1 132.82 39.4 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.865 0 CA-C-N 117.519 0.659 . . . . 0.0 110.855 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' Q' ' 40' ' ' VAL . 10.7 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.444 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.465 0.276 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.8 131.98 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.413 0.625 . . . . 0.0 111.159 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.1 m80 -117.38 156.82 27.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.461 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.512 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -84.21 167.85 16.29 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.918 -179.755 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 69.0 tp60 -159.15 143.26 15.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.632 178.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -80.2 123.5 27.98 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 99.3 mt -125.6 116.28 21.47 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 177.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.54 134.06 56.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.739 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -127.71 131.49 49.73 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.466 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 55.0 p90 -134.95 130.94 36.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.685 0.278 . . . . 0.0 111.374 -178.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.63 120.56 38.4 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -136.98 136.16 38.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.406 0.622 . . . . 0.0 112.081 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.9 t0 . . . . . 0 C--N 1.33 -0.267 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 177.931 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 . . . . . 0 N--CA 1.466 0.351 0 CA-C-O 120.846 0.355 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -79.55 39.64 0.41 Allowed 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.41 79.36 0.94 Allowed Glycine 0 N--CA 1.47 0.939 0 C-N-CA 117.886 -2.102 . . . . 0.0 110.976 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.445 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -81.41 74.81 8.39 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 119.589 1.695 . . . . 0.0 113.955 -175.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 89.7 mt -145.39 122.58 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.408 HD11 HG23 ' A' ' 32' ' ' ILE . 97.1 mt -116.86 122.97 71.19 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-O 121.344 0.592 . . . . 0.0 112.109 -177.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.91 101.2 0.67 Allowed Glycine 0 C--N 1.319 -0.41 0 N-CA-C 105.311 -3.116 . . . . 0.0 105.311 176.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.437 HD13 ' H ' ' A' ' 35' ' ' MET . 49.2 tp -156.71 153.71 28.88 Favored 'General case' 0 C--O 1.241 0.629 0 C-N-CA 118.128 -1.429 . . . . 0.0 113.617 -176.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.437 ' H ' HD13 ' A' ' 34' ' ' LEU . 84.5 mmm -99.31 120.78 40.13 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 112.714 -2.039 . . . . 0.0 108.055 178.217 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 t -111.39 124.6 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.62 -114.22 6.29 Favored Glycine 0 CA--C 1.528 0.889 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.42 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.17 -71.51 0.73 Allowed Glycine 0 CA--C 1.539 1.58 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 40' ' ' VAL . 2.6 t -66.23 159.25 4.53 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.982 -1.009 . . . . 0.0 111.793 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' C' ' 9' ' ' GLY . 92.1 m-85 -98.43 132.32 43.98 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -138.03 139.81 39.78 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.013 0.435 . . . . 0.0 111.304 -179.522 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.446 ' CG1' ' HE2' ' A' ' 14' ' ' HIS . 74.2 t -124.42 130.89 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -117.55 98.05 6.19 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' B' ' 15' ' ' GLN . 11.5 t60 -160.61 164.54 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.542 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 50.9 tt0 -158.1 142.33 15.92 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.319 178.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.52 121.25 27.34 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.022 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 tt -136.22 121.32 18.93 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.706 0.685 . . . . 0.0 110.831 178.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 13.9 m -134.65 141.4 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.937 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -128.32 127.03 41.95 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.184 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -123.24 129.58 51.57 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.743 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.0 119.65 31.02 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -138.84 164.04 30.68 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.001 0.429 . . . . 0.0 111.545 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.58 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 54.2 t0 42.0 47.57 3.83 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -81.58 163.4 3.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 117.786 -1.565 . . . . 0.0 108.567 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.61 -38.16 57.52 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -177.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.62 ' O ' ' O ' ' B' ' 27' ' ' ASN . 45.9 t -162.54 117.24 1.81 Allowed 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.505 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.708 HD22 ' N ' ' C' ' 28' ' ' LYS . 55.2 t-20 -22.02 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.212 0 O-C-N 123.933 0.771 . . . . 0.0 111.713 175.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.545 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 62.7 tttt -163.29 24.56 0.09 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . 89.53 106.64 1.16 Allowed Glycine 0 N--CA 1.468 0.805 0 C-N-CA 118.396 -1.859 . . . . 0.0 113.814 177.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.89 101.83 10.38 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 122.734 1.254 . . . . 0.0 109.881 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -119.61 129.44 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 114.22 -1.355 . . . . 0.0 110.641 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 49.7 mt -109.95 111.24 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.114 0.483 . . . . 0.0 109.82 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 99.21 0.99 Allowed Glycine 0 C--O 1.238 0.396 0 N-CA-C 105.885 -2.886 . . . . 0.0 105.885 177.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 80.0 mt -138.24 145.67 41.65 Favored 'General case' 0 CA--C 1.499 -1.001 0 CA-C-O 122.792 1.282 . . . . 0.0 113.139 -175.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.7 mtp -116.36 109.44 17.35 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 112.837 -1.983 . . . . 0.0 107.473 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.411 ' O ' ' CG2' ' B' ' 36' ' ' VAL . 2.8 m -132.88 123.19 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.696 ' N ' HE22 ' D' ' 15' ' ' GLN . . . 144.85 -113.4 0.72 Allowed Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.427 ' O ' ' CG1' ' B' ' 39' ' ' VAL . . . 76.94 -72.97 2.0 Allowed Glycine 0 CA--C 1.535 1.3 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.427 ' CG1' ' O ' ' B' ' 38' ' ' GLY . 2.9 m -166.67 118.92 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.551 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 17.2 m . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.746 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -122.47 140.38 52.8 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.731 0.3 . . . . 0.0 110.34 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . 0.499 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 57.6 mp0 -76.52 115.82 16.63 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.059 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.414 ' HB ' ' HE2' ' C' ' 14' ' ' HIS . 26.7 m -137.01 159.76 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.473 ' O ' ' CB ' ' D' ' 13' ' ' HIS . 6.3 m80 -145.71 132.27 19.82 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.025 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.489 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.8 m-70 -150.57 170.9 18.03 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.074 177.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.2 tp60 -138.53 140.83 39.25 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 177.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -130.02 106.12 8.42 Favored 'General case' 0 C--N 1.318 -0.764 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.413 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 mt -118.34 113.86 22.06 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.47 116.27 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -109.37 106.16 15.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -120.81 127.97 52.43 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -176.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.62 131.36 35.71 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.124 0.488 . . . . 0.0 111.164 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.489 ' O ' ' CG ' ' C' ' 23' ' ' ASP . 77.4 tt0 -146.46 101.9 3.53 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 113.659 0.985 . . . . 0.0 113.659 -179.067 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.58 ' OD2' ' N ' ' B' ' 23' ' ' ASP . 70.5 m-20 -175.86 -71.83 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 175.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.473 ' O ' ' CG1' ' C' ' 24' ' ' VAL . 11.2 p -78.75 114.78 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.069 -1.423 . . . . 0.0 107.54 175.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.23 -39.26 5.74 Favored Glycine 0 N--CA 1.461 0.336 0 C-N-CA 117.408 -2.33 . . . . 0.0 109.044 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 5.0 t -93.15 111.47 23.12 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 173.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -79.85 171.41 15.15 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 118.017 -1.473 . . . . 0.0 109.996 177.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.708 ' N ' HD22 ' B' ' 27' ' ' ASN . 99.0 mttt -50.37 -36.88 34.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.207 1.003 . . . . 0.0 109.472 174.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.19 76.72 0.06 OUTLIER Glycine 0 CA--C 1.54 1.642 0 CA-C-N 113.372 -1.74 . . . . 0.0 110.175 -178.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.492 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . -80.19 129.79 34.75 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 119.323 1.562 . . . . 0.0 113.104 -176.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 46.8 pt -144.61 146.22 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.983 -177.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 76.9 mt -108.96 116.35 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.689 178.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.8 102.99 1.66 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.247 -3.141 . . . . 0.0 105.247 175.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -134.93 141.02 46.18 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -175.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.65 113.29 26.48 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 175.201 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' D' ' 35' ' ' MET . 3.1 t -129.46 134.42 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.86 -104.29 0.28 Allowed Glycine 0 C--N 1.305 -1.145 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' C' ' 39' ' ' VAL . . . 46.87 70.73 0.63 Allowed Glycine 0 CA--C 1.537 1.423 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.478 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' C' ' 38' ' ' GLY . 6.3 t -6.78 120.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.539 ' OXT' ' CE1' ' E' ' 13' ' ' HIS . 26.8 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.156 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 4.5 m . . . . . 0 N--CA 1.468 0.46 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' O ' ' B' ' 40' ' ' VAL . 2.1 p80 -147.78 138.46 23.21 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.702 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 0.2 OUTLIER -145.91 158.67 43.86 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.052 178.454 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.696 HE22 ' N ' ' B' ' 37' ' ' GLY . 84.8 mt-30 -90.43 158.19 17.2 Favored 'General case' 0 N--CA 1.455 -0.196 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 174.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.37 103.08 4.35 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 176.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . 0.621 ' N ' ' CD2' ' D' ' 17' ' ' LEU . 0.1 OUTLIER -118.69 119.41 34.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.053 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 82.8 t -112.94 112.26 39.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -110.92 103.96 12.5 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -114.29 118.84 35.04 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.831 -0.168 . . . . 0.0 110.926 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.14 118.4 8.95 Favored 'General case' 0 C--O 1.246 0.883 0 CA-C-O 122.147 0.975 . . . . 0.0 111.742 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -178.09 158.96 1.26 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 114.387 -1.279 . . . . 0.0 111.073 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.449 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 35.2 t70 -173.06 -59.91 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 114.167 1.173 . . . . 0.0 114.167 177.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.439 HG21 ' H ' ' D' ' 26' ' ' SER . 3.0 m -77.96 -178.99 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 118.896 -1.121 . . . . 0.0 113.208 -176.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.71 19.82 38.85 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 114.044 -1.435 . . . . 0.0 113.081 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.439 ' H ' HG21 ' D' ' 24' ' ' VAL . 8.9 t -126.65 151.16 48.43 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 118.309 1.055 . . . . 0.0 112.775 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.424 ' ND2' ' O ' ' E' ' 24' ' ' VAL . 57.9 t-20 -52.36 137.27 29.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.276 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.411 ' CB ' ' O ' ' E' ' 22' ' ' GLU . 87.1 tttt -63.5 -50.97 67.53 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.884 -177.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.66 50.35 3.15 Favored Glycine 0 CA--C 1.541 1.673 0 C-N-CA 119.949 -1.12 . . . . 0.0 110.755 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.492 ' CB ' ' O ' ' C' ' 30' ' ' ALA . . . -130.58 -179.9 5.55 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 118.803 1.301 . . . . 0.0 114.033 -174.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.487 ' HA ' ' O ' ' E' ' 31' ' ' ILE . 16.3 tt -136.37 144.74 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 CA-C-N 113.281 -1.781 . . . . 0.0 112.717 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.453 HD12 HG22 ' D' ' 32' ' ' ILE . 4.6 mt -103.92 109.88 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 175.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.6 104.26 0.88 Allowed Glycine 0 N--CA 1.466 0.697 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -157.28 157.71 34.73 Favored 'General case' 0 C--O 1.245 0.835 0 CA-C-O 123.879 1.8 . . . . 0.0 114.019 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.437 ' O ' ' O ' ' C' ' 36' ' ' VAL . 0.9 OUTLIER -97.1 119.5 35.7 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 110.516 -3.038 . . . . 0.0 108.683 178.371 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' E' ' 35' ' ' MET . 38.3 t -121.86 142.41 38.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 178.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.514 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.25 -102.14 0.19 Allowed Glycine 0 C--N 1.296 -1.666 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -176.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' D' ' 39' ' ' VAL . . . 47.56 71.39 0.56 Allowed Glycine 0 CA--C 1.526 0.772 0 C-N-CA 120.048 -1.072 . . . . 0.0 110.643 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.45 ' O ' ' O ' ' D' ' 38' ' ' GLY . 59.4 t -22.53 142.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.642 0.777 . . . . 0.0 112.886 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' D' ' 39' ' ' VAL . 16.6 m . . . . . 0 N--CA 1.471 0.622 0 CA-C-O 117.742 -1.123 . . . . 0.0 111.053 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -72.46 125.7 28.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.733 0.302 . . . . 0.0 110.543 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -148.39 130.87 15.76 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.629 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 8.4 m -134.01 131.11 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.032 0.444 . . . . 0.0 110.79 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.539 ' CE1' ' OXT' ' C' ' 40' ' ' VAL . 3.4 p80 -150.21 146.55 26.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.875 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.457 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 41.5 m-70 -147.52 162.57 38.81 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-O 121.09 0.472 . . . . 0.0 111.49 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.523 ' NE2' ' OE1' ' D' ' 15' ' ' GLN . 56.6 tp60 -85.17 157.26 20.7 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 176.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -159.45 98.41 1.4 Allowed 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 118.473 -1.291 . . . . 0.0 112.378 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.427 ' CD1' ' N ' ' E' ' 17' ' ' LEU . 5.9 mp -122.26 123.13 40.74 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.586 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 p -120.51 118.89 58.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' F' ' 19' ' ' PHE . 17.3 m-85 -108.91 105.71 15.36 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -108.53 114.45 28.29 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.494 ' O ' ' CB ' ' F' ' 21' ' ' ALA . . . -164.48 173.48 12.04 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 117.609 -1.636 . . . . 0.0 114.736 -177.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.411 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 73.4 mt-10 -77.75 141.18 39.43 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.339 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -175.41 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 120.475 0.179 . . . . 0.0 110.616 -177.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.621 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 11.7 t -61.05 -179.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.638 0.732 . . . . 0.0 112.219 -176.299 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.621 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -100.89 28.69 14.82 Favored Glycine 0 N--CA 1.467 0.716 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.366 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 19.6 m -83.56 -119.97 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -177.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' E' ' 29' ' ' GLY . 8.5 m120 -91.35 -151.53 0.26 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.852 -175.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp 44.1 -47.4 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 -176.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 130.98 60.54 0.09 OUTLIER Glycine 0 N--CA 1.49 2.252 0 CA-C-N 122.629 2.468 . . . . 0.0 115.899 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.83 116.92 11.69 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 119.301 1.55 . . . . 0.0 110.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' D' ' 31' ' ' ILE . 77.6 mt -125.26 146.75 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.798 -177.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.416 HG22 HD13 ' E' ' 32' ' ' ILE . 96.6 mt -134.2 113.62 17.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 O-C-N 121.438 -0.789 . . . . 0.0 110.426 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.82 107.53 2.02 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 20.4 tp -128.4 120.5 27.08 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.288 0.566 . . . . 0.0 112.271 -177.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 53.3 tpp -106.69 121.18 43.83 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.154 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.515 ' O ' ' O ' ' E' ' 37' ' ' GLY . 83.7 t -109.42 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.515 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -22.66 152.95 0.0 OUTLIER Glycine 0 N--CA 1.479 1.518 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.296 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . -54.94 -54.41 33.79 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.004 -0.887 . . . . 0.0 114.492 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 70.5 t . . . . . 0 N--CA 1.477 0.896 0 CA-C-N 119.17 1.485 . . . . 0.0 110.395 -179.291 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 . . . . . 0 N--CA 1.469 0.519 0 CA-C-O 120.664 0.269 . . . . 0.0 110.752 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.41 122.84 67.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.167 0.508 . . . . 0.0 110.842 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.66 ' CE1' ' HZ3' ' K' ' 28' ' ' LYS . 0.3 OUTLIER -154.64 121.59 5.55 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.265 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.478 ' ND1' ' C ' ' F' ' 14' ' ' HIS . 0.1 OUTLIER -151.8 166.25 31.95 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.853 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.514 HE22 ' H ' ' D' ' 37' ' ' GLY . 12.3 tt0 -89.82 156.68 18.33 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 76.7 tttt -141.83 101.55 3.98 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 120.729 -0.389 . . . . 0.0 110.862 178.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.614 ' N ' ' CD2' ' F' ' 17' ' ' LEU . 0.2 OUTLIER -118.0 111.68 19.26 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -107.77 110.04 30.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' E' ' 19' ' ' PHE . 29.3 m-85 -106.31 103.29 12.73 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 178.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -123.31 129.48 51.39 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.619 0.723 . . . . 0.0 110.589 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.494 ' CB ' ' O ' ' E' ' 21' ' ' ALA . . . -147.63 149.03 31.74 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 120.042 -0.663 . . . . 0.0 109.372 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.31 121.73 17.47 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.695 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.46 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 67.4 t0 . . . . . 0 CA--C 1.53 0.188 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.514 -0.415 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 10.4 tt -133.13 136.3 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 CA-C-O 122.103 0.954 . . . . 0.0 112.704 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 89.9 mt -122.17 131.9 72.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 111.34 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.76 119.93 3.66 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.9 tp -125.47 126.52 45.04 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mtp -142.53 142.39 32.23 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.504 ' CG2' ' N ' ' F' ' 37' ' ' GLY . 2.3 p -140.78 171.39 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.504 ' N ' ' CG2' ' F' ' 36' ' ' VAL . . . -168.03 94.15 0.11 Allowed Glycine 0 C--N 1.306 -1.086 0 C-N-CA 119.202 -1.475 . . . . 0.0 111.887 179.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.27 -81.44 0.11 Allowed Glycine 0 CA--C 1.529 0.929 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.308 176.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' E' ' 38' ' ' GLY . 40.2 t -156.5 130.99 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-O 121.488 0.661 . . . . 0.0 110.45 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.636 179.765 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 121.042 0.448 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 79.5 m80 -110.0 151.28 27.35 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.152 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.665 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 0.2 OUTLIER -84.33 168.02 16.01 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.175 0.512 . . . . 0.0 110.838 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.665 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 99.6 mm-40 -154.97 142.35 19.57 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -84.7 121.82 28.2 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.745 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 92.5 mt -126.25 127.92 46.38 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -141.4 139.14 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.907 0.384 . . . . 0.0 111.595 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -135.79 137.16 41.32 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.246 0.546 . . . . 0.0 110.747 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.486 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 53.6 p90 -132.9 130.2 39.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.439 -178.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.83 125.86 48.6 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.622 0.725 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -156.5 -121.25 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.151 -0.931 . . . . 0.0 108.961 -178.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 55.5 p30 . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 124.425 1.09 . . . . 0.0 113.688 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.528 ' O ' ' NZ ' ' H' ' 28' ' ' LYS . 71.0 m-20 . . . . . 0 CA--C 1.534 0.346 0 N-CA-C 112.074 0.398 . . . . 0.0 112.074 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -110.59 -39.78 4.79 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 122.437 1.113 . . . . 0.0 108.601 175.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.6 -69.35 3.03 Favored Glycine 0 CA--C 1.536 1.396 0 CA-C-N 113.037 -1.892 . . . . 0.0 113.061 178.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.45 79.98 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 118.162 0.981 . . . . 0.0 113.245 176.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 81.1 mt -122.25 107.07 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.978 1.263 . . . . 0.0 107.612 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.406 HD12 HG22 ' G' ' 32' ' ' ILE . 93.9 mt -122.29 112.08 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.436 0.636 . . . . 0.0 112.393 -177.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.64 103.54 1.46 Allowed Glycine 0 N--CA 1.461 0.328 0 N-CA-C 105.279 -3.128 . . . . 0.0 105.279 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.0 mt -143.29 162.89 34.47 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 123.556 1.646 . . . . 0.0 115.174 -175.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -113.19 107.72 16.3 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 111.367 -2.651 . . . . 0.0 104.087 175.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 27.4 t -122.25 131.61 72.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.73 -111.33 3.27 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.5 -73.92 1.34 Allowed Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.08 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 t -79.62 168.59 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.813 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.09 138.53 43.09 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.836 0.351 . . . . 0.0 110.792 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -126.86 140.73 52.13 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.719 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.95 131.63 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 120.869 0.366 . . . . 0.0 110.133 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -124.75 159.56 30.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.977 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.534 ' CD2' ' H ' ' I' ' 14' ' ' HIS . 83.8 m-70 -119.25 172.98 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -92.53 149.33 21.43 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . 0.472 ' HZ2' ' CE1' ' G' ' 14' ' ' HIS . 64.8 mttp -101.42 128.24 47.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.8 tp -122.84 124.51 43.44 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.04 0.448 . . . . 0.0 111.377 -179.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.93 124.8 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -133.4 126.62 31.66 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -145.33 143.51 30.2 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 119.141 -1.024 . . . . 0.0 112.379 178.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.99 123.83 43.38 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.942 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.73 162.77 35.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 120.126 -0.63 . . . . 0.0 112.509 -178.22 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 59.92 47.2 10.24 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.054 -0.976 . . . . 0.0 112.742 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 2.4 t -83.4 166.96 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 116.515 -2.074 . . . . 0.0 107.26 -179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.502 ' H ' ' ND2' ' G' ' 27' ' ' ASN . . . -72.37 -36.33 59.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 119.628 -1.272 . . . . 0.0 114.723 178.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.768 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.8 t -174.14 126.66 0.35 Allowed 'General case' 0 C--O 1.224 -0.273 0 CA-C-O 117.723 -1.132 . . . . 0.0 112.147 -176.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.768 ' O ' ' O ' ' H' ' 26' ' ' SER . 10.8 t30 -2.44 146.4 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 175.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.528 ' NZ ' ' O ' ' G' ' 27' ' ' ASN . 58.9 tttt -159.31 30.34 0.2 Allowed 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 179.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.72 89.24 0.69 Allowed Glycine 0 C--N 1.345 1.044 0 C-N-CA 117.17 -2.443 . . . . 0.0 114.108 176.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.524 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -110.41 102.65 11.26 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 123.371 1.558 . . . . 0.0 112.045 -178.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 80.7 mt -123.02 131.01 74.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 112.765 -2.016 . . . . 0.0 110.651 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 81.3 mt -113.21 108.75 26.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 175.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.66 121.82 4.5 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -178.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -169.49 163.16 10.36 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 123.904 1.811 . . . . 0.0 113.91 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -100.21 116.55 32.47 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 111.483 -2.598 . . . . 0.0 108.576 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' I' ' 35' ' ' MET . 53.8 t -127.8 123.69 61.53 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.565 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.13 -114.35 2.26 Favored Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.412 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.35 -72.68 2.77 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -152.07 151.23 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 O-C-N 122.7 -0.294 . . . . 0.0 110.47 177.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.421 ' H ' ' HB ' ' I' ' 39' ' ' VAL . 7.2 p . . . . . 0 C--O 1.218 -0.563 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.454 178.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.76 161.4 41.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.74 0.305 . . . . 0.0 110.448 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.41 139.24 51.72 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.578 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 4.7 m -126.89 136.46 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -138.91 93.62 2.72 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.537 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.534 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 52.3 p-80 -157.1 153.47 27.86 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 118.793 -1.163 . . . . 0.0 112.52 176.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -90.81 161.49 15.25 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.748 176.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -139.47 110.98 7.08 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 177.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -129.47 131.63 46.73 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.264 0.554 . . . . 0.0 110.942 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 76.0 t -121.15 120.14 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -118.53 111.16 18.26 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -121.66 135.21 54.98 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 122.311 -0.243 . . . . 0.0 111.358 -178.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . 0.569 ' CB ' ' NZ ' ' I' ' 28' ' ' LYS . . . -139.28 136.05 34.49 Favored 'General case' 0 CA--C 1.555 1.152 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.558 ' C ' ' HZ1' ' I' ' 28' ' ' LYS . 79.7 tt0 -117.29 152.75 34.23 Favored 'General case' 0 N--CA 1.484 1.266 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.259 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.438 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 16.8 t70 -171.49 51.23 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -177.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 16.8 t -63.19 151.04 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.47 -179.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.92 -35.27 4.96 Favored Glycine 0 CA--C 1.539 1.538 0 CA-C-N 116.153 -0.476 . . . . 0.0 113.639 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' I' ' 27' ' ' ASN . 28.9 t -151.68 124.15 8.35 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.639 HD21 ' N ' ' I' ' 27' ' ' ASN . 0.7 OUTLIER -41.19 145.86 0.21 Allowed 'General case' 0 C--N 1.348 0.514 0 C-N-CA 118.396 -1.322 . . . . 0.0 109.774 -175.687 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.569 ' NZ ' ' CB ' ' I' ' 21' ' ' ALA . 18.3 tttt -75.08 -49.65 19.01 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -177.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 109.51 59.43 0.52 Allowed Glycine 0 CA--C 1.545 1.964 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -177.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.1 114.2 26.08 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -172.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 82.8 mt -134.28 127.25 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 113.858 -1.519 . . . . 0.0 109.334 176.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 14.2 tt -121.01 114.96 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.548 177.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.21 108.7 2.62 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 178.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 mp -135.12 148.2 49.71 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.952 1.358 . . . . 0.0 114.116 -177.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.44 ' O ' ' O ' ' H' ' 36' ' ' VAL . 86.4 mmm -107.75 112.72 25.54 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-N 112.686 -2.052 . . . . 0.0 106.809 175.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.472 HG11 HE22 ' L' ' 15' ' ' GLN . 4.8 t -136.51 161.91 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.012 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.628 ' H ' HE22 ' K' ' 15' ' ' GLN . . . 81.1 102.44 0.33 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 119.424 -1.37 . . . . 0.0 112.005 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.44 ' N ' ' CA ' ' J' ' 38' ' ' GLY . . . -154.45 -71.12 0.01 OUTLIER Glycine 0 CA--C 1.544 1.847 0 CA-C-O 118.899 -0.945 . . . . 0.0 111.406 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.43 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 16.0 t -119.3 128.95 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 119.406 1.603 . . . . 0.0 109.137 177.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.43 ' OXT' ' O ' ' I' ' 39' ' ' VAL . 77.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.216 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -107.39 132.39 53.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.808 0.337 . . . . 0.0 110.667 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . 0.534 ' OE1' ' N ' ' J' ' 11' ' ' GLU . 58.1 mp0 -123.96 134.98 53.37 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.333 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -124.52 132.6 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.568 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.538 ' CD2' ' N ' ' J' ' 14' ' ' HIS . 4.2 t-160 -129.01 137.59 51.43 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.163 0.506 . . . . 0.0 110.476 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.538 ' N ' ' CD2' ' J' ' 13' ' ' HIS . 83.1 m-70 -154.85 176.92 11.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 122.103 0.954 . . . . 0.0 111.777 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.425 ' NE2' ' CG1' ' H' ' 36' ' ' VAL . 38.6 tt0 -159.77 137.14 9.68 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.257 -2.127 . . . . 0.0 105.257 177.298 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -134.25 113.8 12.36 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.075 -0.65 . . . . 0.0 112.66 -178.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 7.0 mp -133.87 117.67 17.08 Favored 'General case' 0 CA--C 1.508 -0.64 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -106.8 110.01 30.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.1 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -108.12 104.18 13.54 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 178.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.435 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 5.0 m-85 -123.24 129.91 52.03 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 118.76 20.33 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.476 ' OE2' ' CE1' ' K' ' 20' ' ' PHE . 76.0 mt-10 -145.81 133.41 20.95 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 -176.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.48 ' N ' ' OE1' ' K' ' 22' ' ' GLU . 0.2 OUTLIER 164.69 -70.4 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.404 175.643 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.542 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 22.8 t -58.17 -121.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 113.761 -1.563 . . . . 0.0 110.415 175.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.542 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . 142.08 -35.55 1.75 Allowed Glycine 0 C--O 1.222 -0.64 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.591 -179.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.402 ' O ' ' CG ' ' I' ' 27' ' ' ASN . 10.2 t -80.45 118.55 22.17 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 122.606 3.203 . . . . 0.0 103.119 169.009 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.646 ' CG ' ' H ' ' J' ' 30' ' ' ALA . 21.7 p30 -90.6 158.84 16.75 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 123.413 2.824 . . . . 0.0 110.966 178.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.642 ' CE ' HD22 ' H' ' 27' ' ' ASN . 98.3 mttt -48.12 -40.42 23.53 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 122.823 1.297 . . . . 0.0 110.985 173.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.43 67.85 0.04 OUTLIER Glycine 0 CA--C 1.545 1.911 0 CA-C-N 111.854 -2.43 . . . . 0.0 108.586 -174.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.646 ' H ' ' CG ' ' J' ' 27' ' ' ASN . . . -70.31 138.68 51.7 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-N 120.169 1.984 . . . . 0.0 114.2 -171.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.41 ' HA ' ' O ' ' K' ' 31' ' ' ILE . 86.2 mt -140.22 136.8 37.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-N 112.906 -1.952 . . . . 0.0 114.606 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 4.7 mt -108.74 109.3 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.92 108.66 2.43 Favored Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 12.7 tp -142.49 136.85 29.79 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 118.674 -1.21 . . . . 0.0 113.657 -175.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.433 ' O ' ' O ' ' I' ' 36' ' ' VAL . 0.6 OUTLIER -104.89 120.57 41.75 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.211 -1.813 . . . . 0.0 107.145 177.109 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.427 ' CG1' ' OE1' ' L' ' 15' ' ' GLN . 43.4 t -125.11 167.35 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 121.315 0.578 . . . . 0.0 110.897 -176.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.65 102.49 2.8 Favored Glycine 0 N--CA 1.467 0.752 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.891 178.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.516 ' O ' ' C ' ' J' ' 39' ' ' VAL . . . -121.89 65.61 0.48 Allowed Glycine 0 CA--C 1.539 1.593 0 CA-C-O 117.858 -1.523 . . . . 0.0 113.125 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.516 ' C ' ' O ' ' J' ' 38' ' ' GLY . 71.1 t -12.84 127.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 CA-C-N 119.905 1.852 . . . . 0.0 113.769 -176.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.42 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 10.7 m . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.943 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.462 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -107.1 135.7 48.21 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.862 0.363 . . . . 0.0 110.385 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.512 ' N ' ' OE1' ' K' ' 11' ' ' GLU . 57.6 mp0 -131.82 146.06 51.92 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.954 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.466 ' C ' ' CD2' ' K' ' 13' ' ' HIS . 55.6 t -123.82 128.5 74.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.082 0.468 . . . . 0.0 110.769 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.518 ' CE1' ' NZ ' ' O' ' 28' ' ' LYS . 36.7 m-70 -148.05 100.21 3.15 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.638 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.583 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 4.7 m80 -145.14 157.71 44.02 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.901 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.628 HE22 ' H ' ' I' ' 37' ' ' GLY . 79.3 mt-30 -90.27 159.25 16.78 Favored 'General case' 0 CA--C 1.515 -0.4 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 174.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -140.71 103.62 4.55 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.502 177.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -131.47 119.61 21.82 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.549 0.69 . . . . 0.0 109.456 177.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.1 t -106.05 113.01 41.7 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 114.766 -1.107 . . . . 0.0 108.629 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' K' ' 19' ' ' PHE . 1.8 m-85 -105.95 101.59 11.08 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.584 -1.636 . . . . 0.0 106.584 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.476 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 40.6 t80 -117.95 126.83 53.09 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 120.984 0.421 . . . . 0.0 111.064 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.79 142.33 27.62 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 119.657 -0.817 . . . . 0.0 112.727 -179.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 85.6 mt-10 -82.68 115.56 21.67 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.544 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.501 ' CG ' ' ND2' ' J' ' 27' ' ' ASN . 68.5 t0 -131.85 46.4 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.732 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.427 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 6.4 t -83.48 171.76 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.277 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.755 -177.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.468 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 95.45 -29.43 9.64 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 91.81 115.1 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 -178.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.503 ' ND2' ' H ' ' K' ' 28' ' ' LYS . 9.1 t-20 -73.79 163.13 28.36 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 118.377 -1.329 . . . . 0.0 111.378 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.66 ' HZ3' ' CE1' ' F' ' 13' ' ' HIS . 99.1 mttt -48.12 -37.24 14.95 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.853 175.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.99 76.92 0.06 OUTLIER Glycine 0 CA--C 1.541 1.684 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.755 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.95 139.89 36.88 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 119.133 1.466 . . . . 0.0 110.173 -178.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' J' ' 31' ' ' ILE . 7.1 mt -130.85 133.71 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -175.398 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 33.7 pt -121.0 118.77 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 121.596 0.712 . . . . 0.0 109.323 176.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 118.24 4.22 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -178.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.594 ' CD2' ' CE2' ' L' ' 19' ' ' PHE . 4.2 mp -129.03 118.42 22.52 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.973 0.892 . . . . 0.0 111.716 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -102.74 115.31 30.33 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.193 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.508 ' CG1' ' H ' ' K' ' 37' ' ' GLY . 42.6 t -116.76 174.12 3.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.508 ' H ' ' CG1' ' K' ' 36' ' ' VAL . . . 163.05 -95.41 0.13 Allowed Glycine 0 C--N 1.305 -1.181 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' K' ' 37' ' ' GLY . . . 28.48 78.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.401 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 90.5 t . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -179.032 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.735 0.303 . . . . 0.0 110.387 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.59 122.01 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.17 0.509 . . . . 0.0 110.786 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.489 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -153.12 101.21 2.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.63 179.47 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.583 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.7 m80 -146.28 164.34 32.65 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.532 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 23.8 tt0 -90.02 158.45 17.34 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.636 0.236 . . . . 0.0 111.636 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.53 109.57 6.11 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 121.55 0.69 . . . . 0.0 111.555 178.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 22.4 mt -128.68 117.26 20.88 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -105.14 108.47 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.613 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' K' ' 34' ' ' LEU . 42.8 m-85 -102.45 105.36 15.92 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -129.19 122.01 28.86 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.642 0.734 . . . . 0.0 111.099 -178.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.35 133.0 47.2 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.454 ' O ' ' C ' ' K' ' 23' ' ' ASP . 79.6 mm-40 -77.27 114.76 16.43 Favored 'General case' 0 C--O 1.222 -0.388 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.641 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p30 -168.5 46.46 0.04 OUTLIER 'General case' 0 C--O 1.231 0.099 0 C-N-CA 119.838 -0.745 . . . . 0.0 112.833 -178.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.2 m -83.65 172.68 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 119.225 -0.99 . . . . 0.0 108.941 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.51 -29.82 8.57 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 15.7 p -84.77 139.9 31.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.38 -0.41 . . . . 0.0 110.993 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.509 ' OD1' ' N ' ' L' ' 28' ' ' LYS . 61.6 t-20 -73.15 149.17 43.19 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.509 ' N ' ' OD1' ' L' ' 27' ' ' ASN . 6.3 tmtt? 64.68 -49.71 0.32 Allowed 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' L' ' 27' ' ' ASN . . . 94.83 -54.79 1.92 Allowed Glycine 0 CA--C 1.542 1.745 0 CA-C-N 116.201 -0.454 . . . . 0.0 114.079 177.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.42 -172.75 1.31 Allowed 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 117.666 0.733 . . . . 0.0 109.69 -179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 97.8 mt -98.41 119.09 45.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 176.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 88.9 mt -115.3 122.84 70.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 106.22 0.84 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 178.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 10.0 tt -133.45 131.17 39.59 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 33.4 ttp -151.59 160.3 43.72 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.709 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 27.1 m -109.47 173.96 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.339 0.123 0 CA-C-O 121.152 0.501 . . . . 0.0 111.108 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -166.51 94.64 0.11 Allowed Glycine 0 C--N 1.306 -1.098 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.03 83.4 0.79 Allowed Glycine 0 N--CA 1.473 1.149 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 21.8 m . . . . . 0 CA--C 1.535 0.393 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.877 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 N--CA 1.463 0.198 0 CA-C-O 120.762 0.315 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -126.83 130.17 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 121.198 0.523 . . . . 0.0 110.15 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -124.52 163.06 22.68 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.172 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 41.9 p-80 -87.41 170.76 11.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.217 -179.447 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.14 150.95 50.31 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.017 179.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -96.65 123.77 40.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.214 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -127.8 116.06 19.6 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -126.27 134.51 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.09 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -137.29 141.04 41.93 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 178.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -144.42 146.84 32.71 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.413 -179.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.52 119.71 21.92 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.144 0.497 . . . . 0.0 110.462 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' M' ' 24' ' ' VAL . 97.5 mt-10 -103.59 -162.71 0.93 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.544 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' M' ' 22' ' ' GLU . 96.9 m-20 -23.64 -59.69 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 123.222 0.609 . . . . 0.0 112.345 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . 0.454 ' O ' ' O ' ' M' ' 22' ' ' GLU . 32.6 m -91.3 169.87 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -178.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.37 28.36 57.98 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 26' ' ' SER . . . . . 0.452 ' OG ' ' OD2' ' N' ' 23' ' ' ASP . 11.9 t -97.02 110.7 23.19 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.094 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 p30 -78.14 175.42 10.17 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -176.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -49.75 -36.23 25.07 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 112.507 -2.133 . . . . 0.0 115.074 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.94 78.63 0.06 OUTLIER Glycine 0 N--CA 1.471 1.012 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.643 -172.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.03 108.62 0.26 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-O 124.362 2.029 . . . . 0.0 113.306 -175.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 15.1 tt -128.34 125.71 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 110.537 -3.028 . . . . 0.0 108.388 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 92.8 mt -102.64 108.88 25.12 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.527 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.92 92.82 0.67 Allowed Glycine 0 CA--C 1.508 -0.352 0 N-CA-C 105.44 -3.064 . . . . 0.0 105.44 176.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . 0.467 ' O ' ' CD2' ' N' ' 34' ' ' LEU . 92.8 mt -135.36 156.57 48.71 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 122.81 1.29 . . . . 0.0 113.861 -176.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -108.9 105.27 14.75 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 112.426 -2.17 . . . . 0.0 106.25 176.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 50.4 t -106.12 111.83 36.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.03 -132.12 8.74 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 93.81 -63.19 1.87 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.621 179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 1.2 m -111.14 161.3 9.74 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -178.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.949 -1.025 . . . . 0.0 110.764 -179.987 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -81.71 138.37 35.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.758 0.313 . . . . 0.0 110.27 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -76.45 116.33 17.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.692 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -137.7 157.63 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.112 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 21.8 t-160 -145.46 98.81 3.2 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.871 0.367 . . . . 0.0 111.311 179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.477 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 28.4 p-80 -153.98 168.12 27.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.338 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -129.45 150.35 50.84 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 110.064 178.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -98.15 124.0 42.49 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 7.6 tt -125.84 124.45 40.93 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.483 0.583 . . . . 0.0 109.701 178.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -125.94 134.41 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.603 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.4 t80 -130.63 120.3 23.75 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.811 0.339 . . . . 0.0 111.051 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -112.36 127.77 56.1 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.75 132.91 42.8 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-N 118.584 0.629 . . . . 0.0 111.958 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -170.09 128.44 0.89 Allowed 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.023 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.493 ' CG ' ' H ' ' N' ' 24' ' ' VAL . 16.6 p-10 -155.05 -59.81 0.11 Allowed 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 119.89 -0.724 . . . . 0.0 111.618 177.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.493 ' H ' ' CG ' ' N' ' 23' ' ' ASP . 16.9 m -102.87 -176.83 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.94 -33.69 70.5 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 1.5 m -147.86 118.87 7.66 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -59.9 169.06 1.56 Allowed 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 117.919 -1.512 . . . . 0.0 110.922 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -54.69 -36.96 65.23 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 115.305 1.594 . . . . 0.0 115.305 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.75 77.58 0.07 OUTLIER Glycine 0 CA--C 1.54 1.634 0 C-N-CA 120.123 -1.037 . . . . 0.0 113.429 -174.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.86 116.71 20.17 Favored 'General case' 0 CA--C 1.548 0.894 0 CA-C-N 118.866 1.333 . . . . 0.0 113.638 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . 0.412 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 2.8 tt -146.08 134.09 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.125 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 15.8 mt -109.38 120.55 60.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 CA-C-O 120.971 0.415 . . . . 0.0 110.64 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.03 112.75 2.68 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 105.795 -2.922 . . . . 0.0 105.795 176.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . 0.467 ' CD2' ' O ' ' M' ' 34' ' ' LEU . 0.3 OUTLIER -151.91 144.13 23.97 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 117.773 -1.571 . . . . 0.0 115.074 -175.206 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 89.7 mmm -105.8 108.36 19.84 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 174.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.404 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . 2.0 t -106.9 101.79 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 118.878 0.763 . . . . 0.0 110.884 -177.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.09 -171.14 20.56 Favored Glycine 0 C--N 1.323 -0.173 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.66 -55.04 0.41 Allowed Glycine 0 CA--C 1.547 2.036 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 -178.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -159.49 135.26 1.8 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 CA-C-N 117.628 0.714 . . . . 0.0 109.768 177.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 22.6 m . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.225 179.07 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -82.05 137.84 34.97 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.821 0.343 . . . . 0.0 110.488 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -114.74 134.93 54.7 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.592 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 75.3 t -122.45 130.25 74.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.856 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.456 ' ND1' ' C ' ' O' ' 13' ' ' HIS . 3.5 t-80 -146.58 102.74 3.6 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.574 0.226 . . . . 0.0 111.364 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' P' ' 14' ' ' HIS . 8.0 p-80 -156.34 164.48 38.25 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.919 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -89.84 158.82 17.29 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -140.1 119.23 12.75 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -135.82 130.02 33.33 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 122.321 1.057 . . . . 0.0 111.777 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -112.09 118.23 57.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 177.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -110.32 102.78 11.4 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 14.6 t80 -114.83 127.8 55.93 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.73 115.11 20.86 Favored 'General case' 0 C--O 1.243 0.742 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . 0.448 ' O ' ' C ' ' O' ' 23' ' ' ASP . 83.0 tt0 -86.7 151.28 23.55 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.142 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.448 ' C ' ' O ' ' O' ' 22' ' ' GLU . 49.0 t0 26.83 49.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.904 -176.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' P' ' 22' ' ' GLU . 1.1 p -68.75 154.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.013 -1.449 . . . . 0.0 108.179 175.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.424 ' N ' ' CG2' ' O' ' 24' ' ' VAL . . . -131.51 -28.81 0.61 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.559 ' OG ' ' N ' ' O' ' 27' ' ' ASN . 3.3 t 63.69 -110.14 0.28 Allowed 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.53 178.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.559 ' N ' ' OG ' ' O' ' 26' ' ' SER . 32.9 m-20 150.51 -161.37 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.551 0 O-C-N 124.473 1.108 . . . . 0.0 109.153 -178.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.518 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 98.8 mttt -29.71 -40.4 0.02 OUTLIER 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -179.013 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -170.07 70.05 0.14 Allowed Glycine 0 CA--C 1.541 1.662 0 C-N-CA 118.489 -1.815 . . . . 0.0 115.908 -173.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.75 150.18 43.06 Favored 'General case' 0 C--N 1.363 1.175 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.407 HD12 HG21 ' O' ' 31' ' ' ILE . 20.6 mt -140.69 149.85 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 118.076 2.621 . . . . 0.0 118.076 -171.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . 0.412 HG23 HD12 ' O' ' 32' ' ' ILE . 6.7 mt -111.78 106.76 21.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 N-CA-C 104.871 -2.27 . . . . 0.0 104.871 173.152 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.43 98.5 0.78 Allowed Glycine 0 N--CA 1.473 1.15 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 mp -136.67 151.92 49.82 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 123.698 1.713 . . . . 0.0 114.433 -175.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -113.15 112.04 23.13 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 111.947 -2.388 . . . . 0.0 106.019 176.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.09 147.69 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . 0.861 ' H ' HE22 ' Q' ' 15' ' ' GLN . . . 127.32 103.04 1.22 Allowed Glycine 0 C--N 1.307 -1.057 0 N-CA-C 109.384 -1.487 . . . . 0.0 109.384 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.525 ' O ' ' C ' ' O' ' 39' ' ' VAL . . . -108.47 72.42 0.2 Allowed Glycine 0 CA--C 1.533 1.179 0 CA-C-O 117.612 -1.66 . . . . 0.0 112.074 179.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.591 ' H ' HG22 ' P' ' 39' ' ' VAL . 7.6 p -12.86 130.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 CA-C-N 119.804 1.802 . . . . 0.0 113.325 -175.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.375 179.717 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 19.4 m . . . . . 0 N--CA 1.467 0.412 0 CA-C-O 120.778 0.323 . . . . 0.0 110.545 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.441 ' HB3' ' H ' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -135.44 140.24 44.74 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.449 -179.27 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' O' ' 14' ' ' HIS . 5.5 m-70 -125.42 161.17 27.66 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 178.074 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 27.2 tp60 -89.89 158.15 17.56 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -141.47 100.22 3.73 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.437 178.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 9.0 mp -134.5 122.8 22.95 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 176.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -122.4 127.39 75.08 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -115.87 106.25 13.61 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 30.5 t80 -110.97 125.67 53.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.156 -178.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.41 122.74 18.25 Favored 'General case' 0 CA--C 1.553 1.064 0 CA-C-O 121.751 0.786 . . . . 0.0 112.615 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.495 ' O ' ' O ' ' O' ' 24' ' ' VAL . 83.1 tt0 -87.42 116.66 25.68 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.408 -1.269 . . . . 0.0 110.926 179.018 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.563 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 34.2 m-20 -144.81 46.73 1.35 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.051 0.54 . . . . 0.0 112.053 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.594 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 1.0 OUTLIER -82.14 173.37 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 123.229 1.49 . . . . 0.0 113.237 -175.594 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.42 -33.66 4.84 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-N 111.286 -2.688 . . . . 0.0 113.992 177.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.712 ' O ' ' O ' ' P' ' 27' ' ' ASN . 13.3 t -174.16 126.61 0.35 Allowed 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 118.974 1.387 . . . . 0.0 112.819 175.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.777 HD21 ' H ' ' Q' ' 27' ' ' ASN . 12.6 p30 -2.69 145.94 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 173.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.435 ' CG ' ' O ' ' P' ' 27' ' ' ASN . 93.1 mttt -158.48 30.34 0.23 Allowed 'General case' 0 N--CA 1.475 0.806 0 O-C-N 120.69 -1.256 . . . . 0.0 114.033 176.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.31 88.81 0.9 Allowed Glycine 0 CA--C 1.531 1.065 0 C-N-CA 119.503 -1.332 . . . . 0.0 113.727 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.88 105.54 7.83 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 117.871 0.836 . . . . 0.0 112.047 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 58.4 mt -119.21 124.25 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 CA-C-O 119.27 -0.395 . . . . 0.0 110.056 177.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . 0.432 HD13 HG21 ' P' ' 32' ' ' ILE . 49.9 mt -109.91 110.55 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.56 100.06 1.04 Allowed Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 104.588 -3.405 . . . . 0.0 104.588 175.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 tt -144.63 137.37 26.63 Favored 'General case' 0 C--O 1.241 0.635 0 C-N-CA 118.681 -1.207 . . . . 0.0 112.883 -174.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 22.1 mtp -112.27 127.73 56.06 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 113.837 -1.529 . . . . 0.0 110.512 179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.74 103.18 14.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.22 -153.48 25.09 Favored Glycine 0 C--N 1.308 -0.983 0 C-N-CA 119.276 -1.44 . . . . 0.0 111.191 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.637 ' H ' ' CG1' ' Q' ' 40' ' ' VAL . . . 99.16 -56.45 0.92 Allowed Glycine 0 CA--C 1.543 1.795 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.591 HG22 ' H ' ' O' ' 39' ' ' VAL . 27.7 m -128.88 160.2 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.73 0.812 . . . . 0.0 112.265 -177.602 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 t . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.719 -179.449 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.79 90.13 3.24 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -142.77 147.97 36.42 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.766 0.317 . . . . 0.0 110.596 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -140.87 135.86 33.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.658 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 4.6 m80 -142.63 125.0 15.57 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.651 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.504 ' CE1' ' CE1' ' P' ' 14' ' ' HIS . 15.1 p-80 -152.61 160.42 43.19 Favored 'General case' 0 C--O 1.222 -0.368 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.645 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.861 HE22 ' H ' ' O' ' 37' ' ' GLY . 88.3 mt-30 -90.03 158.92 17.12 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 176.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -140.73 108.35 5.61 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mp -130.97 124.13 30.32 Favored 'General case' 0 CA--C 1.511 -0.52 0 C-N-CA 119.962 -0.695 . . . . 0.0 109.726 177.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -110.1 122.34 64.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.519 ' CE2' ' CE1' ' R' ' 19' ' ' PHE . 24.0 m-85 -112.03 99.9 8.45 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 178.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -108.96 121.2 44.63 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.422 -177.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . 0.543 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -152.76 161.12 42.98 Favored 'General case' 0 C--O 1.217 -0.625 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.628 -179.017 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.594 ' OE1' ' N ' ' P' ' 24' ' ' VAL . 99.6 mt-10 -87.55 114.52 24.23 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.781 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 68.4 t0 -109.23 52.0 0.73 Allowed 'General case' 0 N--CA 1.478 0.949 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.071 -177.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' Q' ' 25' ' ' GLY . 38.5 t -41.43 161.38 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.983 0.897 . . . . 0.0 112.247 -176.15 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.411 ' N ' ' CG1' ' Q' ' 24' ' ' VAL . . . -93.14 32.59 5.58 Favored Glycine 0 N--CA 1.468 0.798 0 CA-C-N 113.848 -1.524 . . . . 0.0 114.273 -174.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.454 ' CB ' HD21 ' P' ' 27' ' ' ASN . 69.5 m -92.62 -112.38 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 117.593 0.696 . . . . 0.0 109.936 -178.233 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.777 ' H ' HD21 ' P' ' 27' ' ' ASN . 9.8 m120 -85.97 179.18 7.05 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 119.853 1.206 . . . . 0.0 112.91 -176.674 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -52.58 48.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -98.56 56.57 1.01 Allowed Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.164 -1.017 . . . . 0.0 112.936 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.63 103.49 0.7 Allowed 'General case' 0 C--O 1.24 0.56 0 CA-C-N 119.013 1.406 . . . . 0.0 112.921 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 pt -142.69 139.82 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 120.099 -0.64 . . . . 0.0 109.601 177.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 4.8 tt -140.23 132.71 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 105.66 1.47 Allowed Glycine 0 C--N 1.337 0.589 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 176.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 53.0 tp -120.47 122.6 41.03 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.642 0.734 . . . . 0.0 112.201 -176.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -111.78 115.67 29.44 Favored 'General case' 0 C--O 1.223 -0.301 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.558 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' N ' ' Q' ' 37' ' ' GLY . 81.9 t -108.17 171.03 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-O 121.414 0.626 . . . . 0.0 111.26 -178.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.526 ' N ' ' CG1' ' Q' ' 36' ' ' VAL . . . 130.34 93.44 0.66 Allowed Glycine 0 C--N 1.311 -0.835 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.29 -74.46 0.26 Allowed Glycine 0 CA--C 1.534 1.235 0 C-N-CA 121.287 -0.483 . . . . 0.0 112.236 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -81.71 118.19 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.341 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 179.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.637 ' CG1' ' H ' ' P' ' 38' ' ' GLY . 3.1 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.414 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -126.78 154.62 44.01 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.915 0.388 . . . . 0.0 110.544 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -68.43 125.42 26.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.583 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 9.2 p -139.97 138.85 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.286 0.565 . . . . 0.0 111.373 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -149.26 105.22 3.47 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.552 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.415 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 93.4 m-70 -145.95 166.47 25.92 Favored 'General case' 0 C--O 1.221 -0.441 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.567 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -89.73 158.68 17.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.134 0.492 . . . . 0.0 110.66 -179.546 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -140.22 103.02 4.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.56 -0.745 . . . . 0.0 109.438 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 10.8 mp -124.99 120.85 32.72 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 95.5 t -105.22 116.62 49.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.519 ' CE1' ' CE2' ' Q' ' 19' ' ' PHE . 78.2 m-85 -111.89 103.7 11.95 Favored 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -140.17 150.65 44.47 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-O 121.804 0.812 . . . . 0.0 111.594 -177.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . 0.543 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -139.31 143.48 37.88 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.067 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -82.7 157.62 23.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.513 -178.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 58.69 50.45 8.87 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 24.9 t -48.9 163.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.134 -178.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.76 24.0 0.06 OUTLIER Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -178.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 4.3 m -64.94 111.68 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.776 0.798 . . . . 0.0 110.566 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.702 ' O ' ' N ' ' R' ' 29' ' ' GLY . 24.7 t-20 -149.09 176.0 10.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.956 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . 0.484 ' H ' ' CG ' ' R' ' 27' ' ' ASN . 65.5 tttm -8.95 -45.91 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.952 0 O-C-N 124.401 1.063 . . . . 0.0 113.559 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.702 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -94.49 58.74 1.92 Allowed Glycine 0 CA--C 1.544 1.847 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.823 179.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 136.91 9.85 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 50.5 mt -124.77 119.5 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 CA-C-O 121.627 0.727 . . . . 0.0 111.644 -178.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 mm -113.36 121.84 66.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.782 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 115.98 2.26 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 7.3 tp -137.03 125.38 23.33 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 9.8 ptm -160.89 172.94 16.07 Favored 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.366 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -124.72 167.33 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-O 121.327 0.584 . . . . 0.0 111.529 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.57 -102.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 114.986 -1.006 . . . . 0.0 111.103 179.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.02 -77.87 1.09 Allowed Glycine 0 CA--C 1.532 1.137 0 N-CA-C 111.559 -0.617 . . . . 0.0 111.559 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 79.3 t -121.3 132.37 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 117.17 0.485 . . . . 0.0 110.401 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 4.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.325 179.757 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 N--CA 1.466 0.354 0 CA-C-O 120.796 0.332 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.557 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 53.0 t -124.89 131.33 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.144 0.497 . . . . 0.0 110.25 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -93.94 163.06 13.65 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.436 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.643 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -86.0 171.94 11.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.708 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 28.5 pt20 -158.09 142.96 16.44 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.571 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -80.24 133.95 36.05 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.895 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.6 mt -129.29 116.31 18.92 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.971 0.415 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -125.43 133.75 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.954 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -134.94 129.0 33.58 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 53.6 p90 -122.62 130.47 53.03 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.408 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.28 114.99 21.57 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.455 0.645 . . . . 0.0 111.339 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.442 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 74.9 mt-10 -154.92 152.73 30.08 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 22' ' ' GLU . 3.9 p-10 . . . . . 0 N--CA 1.465 0.277 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.461 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.599 ' ND2' ' H ' ' A' ' 28' ' ' LYS . 5.1 t-20 . . . . . 0 N--CA 1.468 0.449 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.599 ' H ' ' ND2' ' A' ' 27' ' ' ASN . 98.3 mttt -156.27 -18.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.24 -1.346 . . . . 0.0 107.817 178.032 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.465 ' HA3' ' H ' ' B' ' 28' ' ' LYS . . . 71.83 -98.47 0.78 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.46 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.79 88.54 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.075 179.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.5 mt -138.12 117.24 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' B' ' 33' ' ' GLY . 39.7 mt -108.91 112.49 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 93.93 0.64 Allowed Glycine 0 CA--C 1.507 -0.444 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -140.78 165.0 28.7 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 123.335 1.541 . . . . 0.0 114.289 -175.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 38.5 tpp -120.9 107.81 13.14 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 111.999 -2.364 . . . . 0.0 106.786 177.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.6 t -110.84 124.0 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 179.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.9 -114.46 2.73 Favored Glycine 0 C--N 1.318 -0.461 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 -176.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.34 -71.92 1.48 Allowed Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.153 -1.022 . . . . 0.0 111.353 178.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.433 ' HA ' ' CD1' ' G' ' 31' ' ' ILE . 34.2 m -111.33 -175.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.714 0.769 . . . . 0.0 111.5 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.546 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.6 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-N 114.247 -1.342 . . . . 0.0 110.309 178.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -147.44 158.0 43.8 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.441 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.55 120.7 12.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 121.081 0.467 . . . . 0.0 110.623 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.49 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 16.0 t -130.1 117.39 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.557 ' CE1' ' H ' ' A' ' 12' ' ' VAL . 3.7 m-70 -137.68 112.27 8.79 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.445 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.563 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -151.96 160.13 43.58 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.332 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 78.7 mt-30 -131.95 151.36 51.77 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.983 0.42 . . . . 0.0 111.949 179.069 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -97.76 121.33 39.55 Favored 'General case' 0 C--O 1.238 0.485 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.3 mt -120.93 119.25 32.06 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 118.58 0.627 . . . . 0.0 110.301 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.43 132.43 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.873 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -125.88 124.0 39.89 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.112 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.466 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 34.2 t80 -117.91 126.47 52.42 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.36 141.69 33.81 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -104.36 147.7 27.23 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.14 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 3.4 t70 -171.9 51.89 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.023 -177.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 2.6 t -75.51 143.64 12.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-O 121.726 0.774 . . . . 0.0 111.714 -176.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.06 38.18 3.9 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 114.405 -1.27 . . . . 0.0 112.332 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.09 120.0 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 122.192 0.197 . . . . 0.0 110.904 177.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.527 ' ND2' ' O ' ' B' ' 23' ' ' ASP . 2.1 m120 -83.38 162.6 20.99 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.373 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.465 ' H ' ' HA3' ' A' ' 29' ' ' GLY . 99.1 mttt -47.24 -37.61 10.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.459 0.647 . . . . 0.0 110.782 175.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.68 0.06 OUTLIER Glycine 0 CA--C 1.54 1.596 0 CA-C-N 115.217 -0.902 . . . . 0.0 111.898 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.78 94.87 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 119.634 1.717 . . . . 0.0 112.204 -178.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -144.62 134.77 19.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.432 -177.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.405 HG21 HD11 ' B' ' 32' ' ' ILE . 91.6 mt -105.08 108.3 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.098 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -112.31 102.55 1.36 Allowed Glycine 0 CA--C 1.508 -0.37 0 N-CA-C 105.539 -3.024 . . . . 0.0 105.539 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 tt -150.62 148.38 28.55 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 118.42 -1.312 . . . . 0.0 112.226 -174.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 7.2 mtp -110.05 110.09 20.87 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 113.518 -1.674 . . . . 0.0 107.075 179.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.451 ' O ' ' CG1' ' B' ' 36' ' ' VAL . 4.1 p -119.62 111.51 33.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.35 -131.24 4.28 Favored Glycine 0 C--N 1.308 -1.007 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -178.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.499 ' O ' ' CG2' ' C' ' 39' ' ' VAL . . . 87.27 -63.93 3.89 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 120.508 -0.853 . . . . 0.0 111.542 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 m -136.78 154.17 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.338 -178.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -105.35 133.13 50.62 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.631 0.253 . . . . 0.0 110.384 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -97.65 122.74 41.08 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.651 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 19.4 m -125.4 133.07 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.159 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.546 ' CE1' ' OXT' ' A' ' 40' ' ' VAL . 5.6 t-80 -147.85 96.79 2.71 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.896 179.203 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.563 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 50.1 p-80 -157.24 167.57 29.96 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.738 -0.21 . . . . 0.0 111.265 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -89.99 158.45 17.36 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.437 0.637 . . . . 0.0 110.788 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -140.29 113.51 8.43 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 176.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mt -127.94 123.15 34.18 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 122.071 0.938 . . . . 0.0 111.478 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 67.1 t -111.14 117.03 54.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 177.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.432 ' CD2' ' CE2' ' D' ' 19' ' ' PHE . 56.2 m-85 -107.08 105.85 16.07 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 11.7 t80 -113.84 124.41 52.16 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.7 -0.227 . . . . 0.0 111.152 -178.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.66 122.34 30.6 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.647 0.736 . . . . 0.0 110.396 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -94.31 137.99 32.83 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.217 -178.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.516 ' N ' ' OE1' ' D' ' 22' ' ' GLU . 8.7 m-20 43.17 47.12 5.3 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.41 0.624 . . . . 0.0 109.354 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.438 HG13 ' H ' ' C' ' 25' ' ' GLY . 0.2 OUTLIER -61.43 -169.25 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.799 -177.195 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.495 ' HA3' ' H ' ' B' ' 27' ' ' ASN . . . -111.74 33.34 5.83 Favored Glycine 0 C--N 1.318 -0.427 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.098 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.43 ' O ' ' N ' ' D' ' 26' ' ' SER . 27.3 t -62.63 104.87 0.57 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.497 0.665 . . . . 0.0 109.221 -178.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.857 ' O ' ' N ' ' C' ' 29' ' ' GLY . 7.8 m120 -157.6 179.23 9.42 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.616 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm 1.86 -44.7 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 125.067 1.48 . . . . 0.0 114.212 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.857 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -111.14 58.57 0.39 Allowed Glycine 0 CA--C 1.542 1.764 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 178.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.35 99.75 8.95 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 117.349 0.575 . . . . 0.0 109.973 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.443 HG23 ' H ' ' D' ' 31' ' ' ILE . 29.7 pt -147.93 156.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 117.88 -1.528 . . . . 0.0 114.385 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.436 HG23 HD11 ' C' ' 32' ' ' ILE . 95.9 mt -107.6 112.15 38.84 Favored 'Isoleucine or valine' 0 C--N 1.345 0.376 0 CA-C-N 114.053 -1.431 . . . . 0.0 108.695 176.35 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.91 93.76 0.74 Allowed Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 104.412 -3.475 . . . . 0.0 104.412 175.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -135.0 132.57 38.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 122.365 1.079 . . . . 0.0 113.294 -174.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 6.4 mtp -99.99 111.33 23.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.673 177.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 t -110.8 103.32 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.13 -154.62 22.93 Favored Glycine 0 N--CA 1.46 0.254 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.673 178.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.21 -55.89 0.5 Allowed Glycine 0 CA--C 1.545 1.936 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.499 ' CG2' ' O ' ' B' ' 38' ' ' GLY . 68.6 t -136.04 162.97 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 C-N-CA 123.273 0.629 . . . . 0.0 110.167 178.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.452 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 75.9 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.889 -1.053 . . . . 0.0 111.056 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 1.3 p . . . . . 0 C--O 1.222 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.24 142.65 31.45 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.074 0.464 . . . . 0.0 110.228 179.089 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.554 ' O ' ' CG ' ' C' ' 14' ' ' HIS . 27.7 p-80 -146.12 162.6 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.114 178.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -89.67 158.19 17.68 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.311 179.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 85.6 tttt -140.68 106.28 5.1 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . 0.49 ' N ' ' CD2' ' D' ' 17' ' ' LEU . 1.7 mm? -123.37 124.95 44.08 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.849 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -123.11 112.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.432 ' CE2' ' CD2' ' C' ' 19' ' ' PHE . 27.1 m-85 -108.77 103.79 12.94 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 179.452 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.4 t80 -111.71 124.72 52.91 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.89 141.41 38.56 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.443 1.116 . . . . 0.0 112.923 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' C' ' 23' ' ' ASP . 84.2 mt-10 -75.85 118.32 18.52 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.065 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.42 ' O ' ' O ' ' D' ' 24' ' ' VAL . 13.6 t0 -57.15 59.77 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.591 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.441 ' N ' ' O ' ' D' ' 22' ' ' GLU . 43.3 t -63.05 -113.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' C' ' 26' ' ' SER . . . -104.4 44.37 1.49 Allowed Glycine 0 N--CA 1.478 1.489 0 CA-C-N 121.446 1.93 . . . . 0.0 111.973 -174.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.452 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 1.3 t -70.64 100.51 1.86 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 112.938 -1.631 . . . . 0.0 107.879 175.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -118.62 -153.18 0.53 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.389 0.614 . . . . 0.0 112.564 -174.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -37.58 -41.86 0.5 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.704 -177.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.07 68.39 1.96 Allowed Glycine 0 CA--C 1.537 1.417 0 C-N-CA 120.374 -0.917 . . . . 0.0 111.771 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.85 136.4 32.33 Favored 'General case' 0 C--N 1.349 0.555 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.447 HG22 HD12 ' D' ' 31' ' ' ILE . 39.7 mt -145.53 146.7 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 N-CA-C 115.398 1.629 . . . . 0.0 115.398 -175.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.426 HD12 HG23 ' D' ' 32' ' ' ILE . 0.2 OUTLIER -108.46 111.58 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.494 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.15 102.48 0.8 Allowed Glycine 0 N--CA 1.463 0.497 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.415 ' CD2' ' CZ ' ' E' ' 19' ' ' PHE . 2.9 mp -137.16 135.23 37.17 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 122.424 1.107 . . . . 0.0 113.652 -178.166 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -98.91 113.51 25.69 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.355 177.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' E' ' 35' ' ' MET . 2.9 t -118.92 103.22 14.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -177.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.405 ' CA ' ' H ' ' E' ' 38' ' ' GLY . . . 147.25 -153.62 25.45 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.928 -1.129 . . . . 0.0 110.54 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 104.45 -56.33 0.56 Allowed Glycine 0 CA--C 1.541 1.675 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.43 ' C ' ' O ' ' E' ' 38' ' ' GLY . 7.3 p -119.98 140.9 42.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 CA-C-O 121.361 0.601 . . . . 0.0 111.526 -178.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.614 179.902 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -115.75 136.48 53.01 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 120.627 0.251 . . . . 0.0 110.539 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.19 142.57 45.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.259 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 79.4 t -127.16 133.33 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 CA-C-O 120.785 0.326 . . . . 0.0 111.246 -179.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 m170 -137.81 100.0 4.06 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.422 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.0 OUTLIER -151.56 165.6 33.77 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 121.594 0.711 . . . . 0.0 112.801 -179.593 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -84.35 157.12 21.57 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.324 178.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -159.28 103.1 1.61 Allowed 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.433 ' N ' HD13 ' E' ' 17' ' ' LEU . 3.5 mp -137.43 131.45 31.98 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.387 0.613 . . . . 0.0 111.786 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -117.59 112.28 38.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.415 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 27.4 m-85 -106.07 105.83 16.06 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 178.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -116.68 117.64 30.37 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.25 123.12 31.13 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.441 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 78.0 tt0 -154.11 154.21 33.22 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 117.9 2.555 . . . . 0.0 117.9 -175.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.454 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 52.6 m-20 109.72 46.5 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 111.646 -2.525 . . . . 0.0 116.372 174.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.409 HG11 ' O ' ' D' ' 23' ' ' ASP . 1.8 m -118.15 174.64 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -59.88 -28.25 65.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 107.868 -2.093 . . . . 0.0 107.868 172.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.483 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 3.7 p 143.0 129.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 112.524 -1.838 . . . . 0.0 106.209 -177.087 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.452 ' OD1' ' O ' ' D' ' 26' ' ' SER . 2.6 t30 -53.59 141.57 25.37 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.886 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -58.37 -48.81 79.41 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -179.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.441 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -170.23 59.27 0.19 Allowed Glycine 0 CA--C 1.54 1.629 0 C-N-CA 120.246 -0.978 . . . . 0.0 114.368 -175.615 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.65 169.17 16.54 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 119.124 1.462 . . . . 0.0 113.132 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 77.5 mt -120.97 137.47 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 113.784 -1.553 . . . . 0.0 110.301 -179.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -121.11 121.75 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.79 114.5 2.0 Favored Glycine 0 N--CA 1.471 0.981 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 59.4 mt -127.81 124.28 37.23 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 111.088 -178.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.441 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.0 mtp -108.22 111.77 23.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.245 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.467 ' CG1' ' H ' ' E' ' 37' ' ' GLY . 40.2 t -90.28 173.79 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.467 ' H ' ' CG1' ' E' ' 36' ' ' VAL . . . 162.16 -95.52 0.13 Allowed Glycine 0 C--N 1.305 -1.175 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.096 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.43 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 87.73 -83.69 1.53 Allowed Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t . . . . . 0 N--CA 1.432 -1.336 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 176.56 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . 0.516 ' N ' ' OE1' ' F' ' 11' ' ' GLU . 57.9 mp0 . . . . . 0 N--CA 1.465 0.31 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -128.67 135.05 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.351 0.596 . . . . 0.0 111.409 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.656 ' CE1' ' HZ3' ' J' ' 28' ' ' LYS . 0.0 OUTLIER -142.19 131.98 24.22 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.492 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 83.4 t60 -155.15 167.81 29.12 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 28.5 mp0 -89.51 150.34 22.5 Favored 'General case' 0 CA--C 1.517 -0.298 0 C-N-CA 120.531 -0.468 . . . . 0.0 109.87 179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -151.99 97.26 2.31 Favored 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . 0.413 ' N ' HD11 ' F' ' 17' ' ' LEU . 3.9 mp -133.83 116.25 15.45 Favored 'General case' 0 CA--C 1.506 -0.715 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.705 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -99.99 109.49 24.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -104.89 98.92 8.57 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -112.83 111.43 22.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.338 0.589 . . . . 0.0 109.476 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.43 131.33 38.03 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.454 ' OE1' ' N ' ' E' ' 23' ' ' ASP . 84.6 tt0 -69.52 115.59 8.95 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 118.441 -1.304 . . . . 0.0 109.479 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.443 ' O ' ' OD2' ' F' ' 23' ' ' ASP . 18.9 t70 . . . . . 0 CA--C 1.53 0.196 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.64 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.291 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.442 HG22 ' H ' ' R' ' 40' ' ' VAL . 86.2 mt -132.78 142.84 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 119.786 -0.765 . . . . 0.0 113.002 -177.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -131.57 128.91 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.774 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.14 131.34 5.66 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 7.7 tt -135.89 127.46 28.83 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.8 mtp -140.2 149.7 43.25 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -178.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -92.91 154.77 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.614 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.93 102.59 2.94 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.19 -73.64 0.0 OUTLIER Glycine 0 CA--C 1.537 1.417 0 CA-C-N 115.41 -0.395 . . . . 0.0 113.139 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.548 ' N ' ' O ' ' F' ' 37' ' ' GLY . 90.4 t -151.32 136.55 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 117.848 0.824 . . . . 0.0 110.255 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.565 179.865 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t . . . . . 0 N--CA 1.465 0.3 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.474 ' O ' ' O ' ' H' ' 13' ' ' HIS . 98.3 m-70 -135.14 101.77 4.97 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.864 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' N ' ' G' ' 15' ' ' GLN . 6.6 t-80 -157.2 161.63 39.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.228 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.553 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 13.2 pt20 -174.3 147.86 1.22 Allowed 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.102 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 pttt -79.51 121.8 25.66 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.207 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 96.3 mt -131.75 116.42 17.25 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 177.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -126.69 136.22 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.129 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.538 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 68.1 m-85 -135.1 125.88 27.29 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.357 0.599 . . . . 0.0 111.086 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.493 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -115.11 129.62 56.72 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.43 124.33 39.91 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -177.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -137.21 115.27 11.57 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 63.7 t0 . . . . . 0 N--CA 1.468 0.461 0 CA-C-O 121.666 0.746 . . . . 0.0 109.046 -177.561 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 29.0 m-20 . . . . . 0 N--CA 1.462 0.144 0 CA-C-O 122.08 0.943 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.642 ' O ' ' N ' ' H' ' 28' ' ' LYS . 99.2 mttt -37.68 -40.76 0.44 Allowed 'General case' 0 C--O 1.214 -0.775 0 CA-C-N 113.534 -1.667 . . . . 0.0 111.227 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.78 68.8 0.21 Allowed Glycine 0 CA--C 1.545 1.943 0 O-C-N 121.653 -0.654 . . . . 0.0 112.552 -176.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -96.7 113.24 24.78 Favored 'General case' 0 C--N 1.368 1.376 0 CA-C-O 124.124 1.916 . . . . 0.0 111.287 -179.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 39' ' ' VAL . 38.1 mt -129.16 131.8 67.53 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 110.337 -3.119 . . . . 0.0 108.843 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.424 ' O ' ' O ' ' H' ' 33' ' ' GLY . 31.8 mt -103.32 106.39 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.34 94.95 0.79 Allowed Glycine 0 CA--C 1.504 -0.613 0 N-CA-C 106.185 -2.766 . . . . 0.0 106.185 177.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.405 ' H ' HD21 ' H' ' 34' ' ' LEU . 58.3 mt -144.38 156.1 44.07 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 123.162 1.458 . . . . 0.0 112.813 -177.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.2 mtp -105.22 113.22 26.68 Favored 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 111.983 -2.371 . . . . 0.0 106.001 176.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 48.4 t -109.04 102.33 13.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.63 -162.5 47.7 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.12 -55.67 0.52 Allowed Glycine 0 CA--C 1.532 1.138 0 CA-C-O 118.82 -0.989 . . . . 0.0 111.919 179.114 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.407 ' O ' ' C ' ' G' ' 40' ' ' VAL . 1.6 m -70.48 176.86 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.428 0 CA-C-N 118.27 1.035 . . . . 0.0 109.499 177.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' G' ' 39' ' ' VAL . 7.1 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.879 -1.058 . . . . 0.0 111.587 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.93 133.17 50.18 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.41 141.49 31.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.941 0.4 . . . . 0.0 110.959 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' H' ' 13' ' ' HIS . 71.0 t -143.01 161.75 17.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.474 ' O ' ' O ' ' G' ' 13' ' ' HIS . 44.5 m80 -135.21 159.14 42.49 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 179.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 42.8 p-80 -85.61 166.19 16.42 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.805 -179.099 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -100.39 152.72 20.02 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -109.31 109.95 20.99 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -119.01 122.86 43.14 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.853 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -124.21 126.74 72.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.415 179.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' CD1' ' G' ' 19' ' ' PHE . 34.2 m-85 -133.89 126.14 29.81 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.812 -0.811 . . . . 0.0 108.812 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.457 ' CZ ' ' CB ' ' G' ' 20' ' ' PHE . 24.3 p90 -143.44 151.39 40.29 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 119.31 -0.956 . . . . 0.0 111.676 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.31 130.02 51.16 Favored 'General case' 0 C--O 1.251 1.171 0 CA-C-O 121.926 0.87 . . . . 0.0 111.467 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -60.98 -166.13 0.01 OUTLIER 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.879 -1.51 . . . . 0.0 107.757 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.497 ' O ' ' O ' ' H' ' 24' ' ' VAL . 33.2 t70 -84.22 57.65 4.35 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 116.669 -2.012 . . . . 0.0 115.41 -175.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.613 ' CG2' ' H ' ' H' ' 25' ' ' GLY . 1.3 p -68.64 -112.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.271 1 N-CA-C 100.069 -4.048 . . . . 0.0 100.069 166.451 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.613 ' H ' ' CG2' ' H' ' 24' ' ' VAL . . . 124.41 -39.39 2.14 Favored Glycine 0 C--N 1.331 0.283 0 N-CA-C 117.985 1.954 . . . . 0.0 117.985 167.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.23 110.5 5.25 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 115.632 -2.427 . . . . 0.0 112.968 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 1.093 ' O ' ' N ' ' H' ' 29' ' ' GLY . 0.0 OUTLIER -122.7 156.97 33.29 Favored 'General case' 0 C--O 1.207 -1.145 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 167.314 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.642 ' N ' ' O ' ' G' ' 28' ' ' LYS . 13.1 tttt -34.51 49.15 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 122.721 2.509 . . . . 0.0 111.16 172.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 1.093 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 101.26 -52.22 0.9 Allowed Glycine 0 CA--C 1.563 3.044 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -177.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.474 ' CB ' ' O ' ' H' ' 29' ' ' GLY . . . 129.35 115.38 0.0 OUTLIER 'General case' 0 C--N 1.377 1.799 0 C-N-CA 125.946 1.698 . . . . 0.0 107.977 177.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 72.2 mt -126.54 128.13 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 CA-C-N 122.056 2.207 . . . . 0.0 114.793 -178.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -111.67 110.51 32.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 175.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -116.46 105.4 1.35 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.215 -2.354 . . . . 0.0 107.215 178.269 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.496 ' O ' ' CD2' ' I' ' 34' ' ' LEU . 73.8 mt -140.65 148.86 41.51 Favored 'General case' 0 CA--C 1.508 -0.66 0 CA-C-O 122.832 1.301 . . . . 0.0 113.376 -176.069 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 4.8 ttm -113.86 112.36 23.23 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 175.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.499 ' O ' ' CG1' ' H' ' 36' ' ' VAL . 5.0 p -132.39 102.55 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.714 ' N ' HE22 ' J' ' 15' ' ' GLN . . . 122.52 -163.29 15.97 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' I' ' 37' ' ' GLY . . . 128.28 -54.57 0.78 Allowed Glycine 0 CA--C 1.547 2.06 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.291 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.419 ' CG2' ' CD1' ' N' ' 31' ' ' ILE . 14.6 t -109.7 165.99 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.681 0.793 . . . . 0.0 110.127 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.528 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 2.5 m . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.658 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.36 133.67 52.23 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.772 0.32 . . . . 0.0 110.509 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 54.6 tp10 -75.35 122.57 23.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.245 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -139.51 160.86 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.548 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 21.8 t60 -145.73 100.25 3.39 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 121.253 -0.179 . . . . 0.0 110.724 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' J' ' 14' ' ' HIS . 45.3 p-80 -165.52 169.57 15.34 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -89.84 158.95 17.24 Favored 'General case' 0 C--N 1.341 0.215 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.829 178.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -139.97 111.12 7.0 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -127.95 128.64 45.43 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.247 0.546 . . . . 0.0 110.332 178.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 71.4 t -112.76 120.77 63.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -114.0 106.42 14.4 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.58 ' CD1' ' CD2' ' J' ' 20' ' ' PHE . 1.9 t80 -115.52 129.14 56.43 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 122.342 -0.224 . . . . 0.0 110.451 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . 0.411 ' N ' ' CD1' ' I' ' 20' ' ' PHE . . . -150.18 130.57 13.79 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -178.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -95.65 119.42 34.12 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -118.64 46.3 1.86 Allowed 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -175.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 23.7 m -92.74 173.55 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 175.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.32 27.82 65.12 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 118.244 -1.931 . . . . 0.0 109.908 -177.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p 166.66 146.68 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -53.15 136.93 35.11 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 117.416 2.376 . . . . 0.0 117.416 -173.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.462 ' O ' ' CA ' ' J' ' 29' ' ' GLY . 37.9 mttt -60.84 51.06 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 CA-C-N 110.704 -2.953 . . . . 0.0 114.293 173.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.07 51.94 0.69 Allowed Glycine 0 N--CA 1.495 2.609 0 O-C-N 120.494 -1.379 . . . . 0.0 116.148 -172.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' J' ' 30' ' ' ALA . . . -100.31 147.09 26.17 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-O 123.685 1.707 . . . . 0.0 114.993 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 13.7 tt -132.29 135.88 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.248 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.442 HD11 HG23 ' I' ' 32' ' ' ILE . 89.6 mt -106.28 108.6 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.141 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.01 111.0 3.63 Favored Glycine 0 C--O 1.24 0.496 0 N-CA-C 105.305 -3.118 . . . . 0.0 105.305 176.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.496 ' CD2' ' O ' ' H' ' 34' ' ' LEU . 0.3 OUTLIER -148.32 141.07 24.6 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 117.68 -1.608 . . . . 0.0 115.073 -174.462 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 81.6 mmm -103.13 114.65 29.12 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-N 112.233 -2.258 . . . . 0.0 105.134 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 58.4 t -122.57 131.75 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 CA-C-O 120.809 0.337 . . . . 0.0 111.047 -176.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' H' ' 38' ' ' GLY . . . 80.44 -111.22 3.24 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 120.629 -0.796 . . . . 0.0 114.807 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.55 -70.51 0.22 Allowed Glycine 0 CA--C 1.539 1.583 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.408 ' HB ' ' CD1' ' O' ' 31' ' ' ILE . 2.6 p -134.61 137.07 51.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.558 ' OXT' ' ND1' ' L' ' 13' ' ' HIS . 27.5 m . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.814 -1.088 . . . . 0.0 111.284 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.54 137.67 44.12 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -130.67 139.02 50.32 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.899 0.381 . . . . 0.0 110.843 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 41.8 t -123.24 125.29 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.561 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 3.3 m80 -120.96 121.92 39.05 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.166 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.557 ' O ' ' CG ' ' I' ' 14' ' ' HIS . 0.3 OUTLIER -152.45 156.41 39.4 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.19 176.478 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.714 HE22 ' N ' ' H' ' 37' ' ' GLY . 83.8 mt-30 -90.37 160.22 16.2 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -139.7 97.21 3.22 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.27 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.407 ' HB3' ' CZ ' ' J' ' 19' ' ' PHE . 11.1 mp -122.8 121.49 36.41 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-O 121.703 0.763 . . . . 0.0 109.549 176.406 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 21.9 t -110.67 116.23 51.89 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.564 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.407 ' CZ ' ' HB3' ' J' ' 17' ' ' LEU . 33.9 m-85 -112.58 104.46 12.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CD1' ' I' ' 20' ' ' PHE . 4.5 t80 -115.09 131.02 57.06 Favored 'General case' 0 N--CA 1.478 0.939 0 O-C-N 122.449 -0.157 . . . . 0.0 110.882 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . 0.558 ' O ' ' HA ' ' K' ' 21' ' ' ALA . . . -168.38 171.82 8.85 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 123.631 1.681 . . . . 0.0 115.464 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -111.62 113.84 26.49 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 113.164 -1.834 . . . . 0.0 107.426 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -172.82 49.81 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.589 ' CG2' ' H ' ' J' ' 25' ' ' GLY . 13.2 p -154.81 -179.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.879 -178.636 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.593 ' HA3' ' H ' ' K' ' 25' ' ' GLY . . . 61.59 29.74 72.72 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 116.905 1.522 . . . . 0.0 116.905 178.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.626 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.7 m -145.32 -120.8 0.08 Allowed 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.626 ' O ' ' O ' ' J' ' 26' ' ' SER . 1.3 p-10 -53.51 -156.61 0.0 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 176.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.656 ' HZ3' ' CE1' ' F' ' 13' ' ' HIS . 99.0 mttt -63.36 -39.9 95.79 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 119.573 -1.954 . . . . 0.0 107.084 -173.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' J' ' 27' ' ' ASN . . . 92.5 -65.69 2.09 Favored Glycine 0 N--CA 1.473 1.112 0 C-N-CA 119.732 -1.223 . . . . 0.0 114.966 174.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.424 ' HA ' ' O ' ' I' ' 30' ' ' ALA . . . -169.56 155.36 6.03 Favored 'General case' 0 N--CA 1.44 -0.93 0 C-N-CA 116.759 -1.977 . . . . 0.0 115.346 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.477 ' HA ' ' O ' ' K' ' 31' ' ' ILE . 0.8 OUTLIER -135.3 124.96 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 111.065 -2.788 . . . . 0.0 109.628 177.417 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 mt -108.22 117.12 53.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.93 100.73 1.2 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.785 -2.926 . . . . 0.0 105.785 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -127.86 129.79 47.5 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 114.87 1.433 . . . . 0.0 114.87 -175.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.58 109.92 22.4 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.293 -2.484 . . . . 0.0 104.293 174.185 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.417 ' N ' ' O ' ' K' ' 35' ' ' MET . 2.0 t -125.64 153.19 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.095 0.474 . . . . 0.0 111.497 -175.386 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.47 -101.89 0.2 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.172 178.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.528 ' H ' ' N ' ' K' ' 37' ' ' GLY . . . 99.29 -76.66 0.51 Allowed Glycine 0 CA--C 1.537 1.408 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -177.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.446 ' O ' ' OXT' ' J' ' 40' ' ' VAL . 28.0 m -131.46 161.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 CA-C-N 118.362 1.081 . . . . 0.0 110.482 178.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.446 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 44.8 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.907 -1.044 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.76 131.83 54.7 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.759 0.314 . . . . 0.0 110.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -101.84 107.59 18.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -144.63 149.68 17.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.561 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -143.2 94.8 2.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.049 178.753 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.615 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 46.8 m170 -119.94 167.57 12.01 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.948 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.435 ' O ' ' CB ' ' L' ' 16' ' ' LYS . 34.9 tp60 -89.76 157.74 17.82 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . 0.419 ' N ' ' HG3' ' K' ' 15' ' ' GLN . 16.3 tttt -140.93 95.41 2.84 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.074 -0.651 . . . . 0.0 110.797 178.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 2.5 mt -131.87 129.62 40.6 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 176.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 3.5 p -118.6 119.33 60.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.476 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 29.9 m-85 -106.05 105.73 15.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 6.0 t80 -113.59 120.31 40.51 Favored 'General case' 0 C--O 1.226 -0.177 0 CA-C-O 120.66 0.267 . . . . 0.0 111.679 -177.352 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.558 ' HA ' ' O ' ' J' ' 21' ' ' ALA . . . -150.66 120.49 7.08 Favored 'General case' 0 C--O 1.245 0.858 0 C-N-CA 119.704 -0.798 . . . . 0.0 110.547 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.563 ' CG ' ' N ' ' K' ' 23' ' ' ASP . 54.5 tt0 -178.18 163.54 1.69 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 116.988 2.218 . . . . 0.0 116.988 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.563 ' N ' ' CG ' ' K' ' 22' ' ' GLU . 19.9 t70 174.05 -74.13 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 112.03 -2.35 . . . . 0.0 106.978 172.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.527 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 3.2 p -67.7 -113.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 170.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.593 ' H ' ' HA3' ' J' ' 25' ' ' GLY . . . 134.7 -37.79 1.9 Allowed Glycine 0 CA--C 1.541 1.7 0 N-CA-C 121.421 3.328 . . . . 0.0 121.421 171.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.5 t -71.81 118.09 14.21 Favored 'General case' 0 N--CA 1.482 1.167 1 CA-C-N 125.935 4.867 . . . . 0.0 107.28 177.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.658 ' ND2' ' H ' ' K' ' 30' ' ' ALA . 0.5 OUTLIER -103.77 160.58 14.66 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 120.36 1.436 . . . . 0.0 113.127 179.271 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -44.45 -39.85 5.07 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 67.67 0.04 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-O 118.939 -0.923 . . . . 0.0 113.484 -174.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.658 ' H ' ' ND2' ' K' ' 27' ' ' ASN . . . -71.04 156.18 39.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.82 1.81 . . . . 0.0 113.607 -176.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' J' ' 31' ' ' ILE . 82.2 mt -122.92 126.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.92 -178.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 13.0 tt -130.96 118.0 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 O-C-N 121.245 -0.91 . . . . 0.0 110.51 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.81 111.62 1.87 Allowed Glycine 0 N--CA 1.466 0.699 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 82.1 mt -122.92 117.3 25.23 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.165 0.507 . . . . 0.0 110.728 -178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.417 ' O ' ' N ' ' J' ' 36' ' ' VAL . 8.0 mtp -108.3 114.41 28.25 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.404 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 46.2 t -119.65 144.76 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 107.726 -1.212 . . . . 0.0 107.726 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.528 ' N ' ' H ' ' J' ' 38' ' ' GLY . . . -136.51 102.68 0.41 Allowed Glycine 0 C--N 1.32 -0.31 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.104 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' J' ' 40' ' ' VAL . . . -61.28 -67.13 2.26 Favored Glycine 0 CA--C 1.54 1.652 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 176.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 16.7 m . . . . . 0 N--CA 1.435 -1.2 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 179.375 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 120.505 0.193 . . . . 0.0 110.631 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . 0.41 ' C ' ' HE2' ' K' ' 14' ' ' HIS . 2.3 t -115.94 126.24 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 110.044 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.558 ' ND1' ' OXT' ' I' ' 40' ' ' VAL . 10.8 m-70 -130.86 104.59 7.24 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.214 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.615 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 83.2 t60 -160.61 164.57 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 178.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.501 ' O ' ' CD2' ' L' ' 14' ' ' HIS . 88.0 mm-40 -89.76 158.57 17.46 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . 0.435 ' CB ' ' O ' ' K' ' 15' ' ' GLN . 16.7 tttt -140.4 93.93 2.68 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.72 118.15 27.4 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -102.81 108.06 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.801 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.476 ' CE1' ' CD1' ' K' ' 19' ' ' PHE . 79.7 m-85 -100.32 98.14 8.83 Favored 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 39.7 t80 -108.38 105.15 14.69 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -165.95 171.51 12.53 Favored 'General case' 0 CA--C 1.484 -1.567 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.634 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -75.94 104.71 6.6 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -147.0 48.01 1.15 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.41 -176.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p -65.23 169.75 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -92.2 -42.53 4.6 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 118.709 -1.71 . . . . 0.0 113.819 -176.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.51 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 4.6 m -67.72 109.49 3.35 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 117.861 -1.536 . . . . 0.0 111.906 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.68 ' O ' ' N ' ' L' ' 29' ' ' GLY . 21.4 m120 -145.21 158.68 43.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 173.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.537 ' C ' ' O ' ' L' ' 27' ' ' ASN . 42.0 tttp -18.2 -43.51 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 CA-C-O 121.936 0.874 . . . . 0.0 111.312 175.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.68 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -178.45 63.33 0.08 OUTLIER Glycine 0 CA--C 1.553 2.411 0 CA-C-N 113.885 -1.507 . . . . 0.0 112.381 177.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.94 163.08 15.74 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.13 1.465 . . . . 0.0 110.019 179.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 22.2 pt -141.15 135.49 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 119.252 -0.979 . . . . 0.0 112.027 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.428 HD12 HG21 ' L' ' 32' ' ' ILE . 96.2 mt -118.53 121.09 66.2 Favored 'Isoleucine or valine' 0 C--N 1.34 0.18 0 CA-C-N 114.73 -1.123 . . . . 0.0 111.227 -179.125 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.11 116.3 2.41 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -126.42 125.65 42.51 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.3 ttm -129.3 130.3 45.98 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.099 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' L' ' 37' ' ' GLY . 55.7 t -124.21 131.87 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -42.56 -111.62 0.0 OUTLIER Glycine 0 N--CA 1.468 0.82 0 CA-C-N 115.483 -0.781 . . . . 0.0 112.631 178.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.99 64.93 3.96 Favored Glycine 0 CA--C 1.532 1.116 0 CA-C-N 114.706 -0.747 . . . . 0.0 111.455 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.424 ' O ' ' CD1' ' R' ' 31' ' ' ILE . 41.8 t . . . . . 0 C--N 1.346 0.456 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.463 0.186 0 CA-C-O 120.741 0.305 . . . . 0.0 110.598 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.0 t -113.65 128.61 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.31 162.67 15.77 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.711 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.483 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 3.4 m-70 -83.33 168.71 16.39 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.652 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -129.2 150.86 50.4 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -97.26 111.81 23.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.353 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.69 114.04 18.14 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.88 132.88 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.357 -179.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -133.25 134.83 44.46 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.86 0.362 . . . . 0.0 110.919 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -128.26 131.82 48.74 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.766 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.6 111.14 7.55 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.108 0.48 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -159.1 151.13 20.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.372 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 51.96 46.43 26.61 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.818 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . 0.59 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 39.6 t -80.45 179.89 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . 0.59 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -71.44 -33.75 63.99 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.878 -178.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 26' ' ' SER . . . . . 0.594 ' O ' ' O ' ' M' ' 27' ' ' ASN . 25.5 t -162.51 120.61 2.13 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . 0.594 ' O ' ' O ' ' M' ' 26' ' ' SER . 13.6 t30 -22.03 153.22 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.98 0 O-C-N 124.424 1.078 . . . . 0.0 111.976 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -163.17 24.54 0.09 Allowed 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 114.638 1.347 . . . . 0.0 114.638 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.28 106.15 1.11 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 118.539 -1.791 . . . . 0.0 114.913 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . 0.698 ' H ' ' ND2' ' N' ' 27' ' ' ASN . . . -111.48 80.24 1.29 Allowed 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 124.098 1.904 . . . . 0.0 109.999 178.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 59.6 mt -130.36 130.01 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-N 110.974 -2.83 . . . . 0.0 108.419 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' N' ' 33' ' ' GLY . 47.1 mt -103.94 106.18 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.92 97.43 1.14 Allowed Glycine 0 CA--C 1.506 -0.476 0 N-CA-C 105.055 -3.218 . . . . 0.0 105.055 176.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . 0.402 HD13 ' H ' ' M' ' 35' ' ' MET . 52.2 tp -148.95 152.92 37.2 Favored 'General case' 0 N--CA 1.463 0.213 0 C-N-CA 118.308 -1.357 . . . . 0.0 113.826 -174.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 35' ' ' MET . . . . . 0.402 ' H ' HD13 ' M' ' 34' ' ' LEU . 91.7 mmm -110.21 110.31 21.11 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 112.946 -1.934 . . . . 0.0 107.177 178.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 96.4 t -104.29 122.88 57.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.32 -113.24 0.58 Allowed Glycine 0 C--N 1.309 -0.94 0 N-CA-C 108.419 -1.873 . . . . 0.0 108.419 -178.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.68 -69.57 0.22 Allowed Glycine 0 CA--C 1.533 1.179 0 C-N-CA 121.438 -0.411 . . . . 0.0 112.413 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' M' ' 40' ' ' VAL . 3.1 m -137.57 166.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 122.649 0.38 . . . . 0.0 110.373 -179.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.544 ' OXT' ' N ' ' N' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.888 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.88 135.67 49.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.845 0.355 . . . . 0.0 110.395 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -140.71 146.42 37.76 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.023 0.439 . . . . 0.0 110.721 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 70.2 t -126.98 133.66 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.706 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.553 ' ND1' ' CE1' ' O' ' 13' ' ' HIS . 77.1 m80 -102.97 97.66 7.74 Favored 'General case' 0 N--CA 1.471 0.62 0 O-C-N 122.093 -0.38 . . . . 0.0 110.509 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' N' ' 15' ' ' GLN . 1.7 t-80 -159.95 168.53 25.47 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.941 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.636 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 81.9 mt-30 -156.0 142.27 18.38 Favored 'General case' 0 C--N 1.34 0.166 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 178.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -84.73 120.64 26.64 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.822 179.156 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.11 124.03 33.71 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.755 0.312 . . . . 0.0 110.192 178.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.21 131.58 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -129.37 115.58 17.77 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.147 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 t80 -111.9 126.17 54.83 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.0 147.56 31.79 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -177.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -132.46 133.0 43.31 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.016 178.178 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -158.05 46.62 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . 0.516 ' CG1' ' N ' ' N' ' 25' ' ' GLY . 20.8 t -91.79 169.18 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 178.003 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.516 ' N ' ' CG1' ' N' ' 24' ' ' VAL . . . 77.16 34.8 40.24 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.008 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 169.51 -114.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -176.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.698 ' ND2' ' H ' ' M' ' 30' ' ' ALA . 28.9 t30 -61.89 170.88 1.87 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.358 0.599 . . . . 0.0 111.782 -177.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.492 ' N ' ' CG ' ' N' ' 27' ' ' ASN . 81.7 tttt -54.15 -39.36 66.44 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.474 -176.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.34 -63.51 0.53 Allowed Glycine 0 CA--C 1.531 1.04 0 C-N-CA 119.639 -1.267 . . . . 0.0 114.107 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.86 99.52 3.81 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 120.319 2.059 . . . . 0.0 115.529 -176.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . 0.419 ' CD1' ' CG2' ' H' ' 39' ' ' VAL . 96.3 mt -122.59 118.94 56.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 114.162 -1.381 . . . . 0.0 107.304 173.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . 0.414 HD12 HG21 ' N' ' 32' ' ' ILE . 74.8 mt -107.71 108.32 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 119.041 -1.064 . . . . 0.0 110.28 178.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -109.08 98.66 1.18 Allowed Glycine 0 C--O 1.234 0.138 0 N-CA-C 104.641 -3.384 . . . . 0.0 104.641 175.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . 0.501 ' CD2' ' N ' ' N' ' 35' ' ' MET . 3.0 tt -145.25 147.84 32.84 Favored 'General case' 0 CA--C 1.506 -0.727 0 C-N-CA 118.352 -1.339 . . . . 0.0 113.065 -174.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 35' ' ' MET . . . . . 0.501 ' N ' ' CD2' ' N' ' 34' ' ' LEU . 12.7 mtp -112.0 115.67 29.31 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 113.215 -1.812 . . . . 0.0 108.786 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.507 ' O ' ' N ' ' O' ' 37' ' ' GLY . 51.4 t -114.59 111.63 36.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 179.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.716 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 135.21 -131.75 5.95 Favored Glycine 0 C--N 1.316 -0.562 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.74 -63.69 4.05 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' N' ' 40' ' ' VAL . 11.4 m -104.52 161.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.952 0.501 . . . . 0.0 110.384 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . 0.56 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 47.5 t . . . . . 0 C--O 1.218 -0.602 0 CA-C-O 117.852 -1.071 . . . . 0.0 111.58 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.29 139.43 44.24 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -102.05 124.28 47.39 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.566 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.44 ' HB ' ' HE2' ' O' ' 14' ' ' HIS . 1.4 m -125.49 125.91 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.553 ' CE1' ' ND1' ' N' ' 13' ' ' HIS . 21.0 m-70 -121.48 122.17 39.15 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 121.193 0.521 . . . . 0.0 112.208 -177.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.524 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 0.6 OUTLIER -150.27 175.95 11.32 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.576 178.38 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.448 ' NE2' ' CD1' ' O' ' 17' ' ' LEU . 39.2 tt0 -152.74 139.75 19.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.587 0.708 . . . . 0.0 109.107 175.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . 0.456 ' CG ' ' HE2' ' N' ' 14' ' ' HIS . 61.3 mttt -95.68 108.64 20.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.592 -1.185 . . . . 0.0 111.043 177.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . 0.448 ' CD1' ' NE2' ' O' ' 15' ' ' GLN . 5.0 mt -124.03 109.64 13.77 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 119.293 0.951 . . . . 0.0 108.729 175.678 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -107.39 116.4 50.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.877 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -110.99 103.31 11.77 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.41 ' CD1' ' HB3' ' P' ' 20' ' ' PHE . 2.7 m-85 -110.38 133.92 52.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.354 0.262 . . . . 0.0 110.303 -178.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.77 136.56 29.0 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-O 122.99 1.376 . . . . 0.0 114.128 -179.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 26.5 tp10 -93.12 163.79 13.5 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 113.263 -1.79 . . . . 0.0 106.986 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.437 ' OD1' ' OD2' ' P' ' 23' ' ' ASP . 54.5 p-10 -172.93 52.36 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.106 -0.638 . . . . 0.0 111.091 -176.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 13.5 m -74.5 142.17 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 117.981 -1.488 . . . . 0.0 112.47 -174.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.465 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . 98.97 38.14 3.93 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.233 179.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.591 ' H ' ' CG1' ' P' ' 24' ' ' VAL . 2.7 p 72.74 120.16 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.11 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' O' ' 27' ' ' ASN . 54.7 p30 -83.62 156.24 22.8 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 115.968 -2.293 . . . . 0.0 109.956 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -48.66 -42.53 34.82 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.874 1.435 . . . . 0.0 114.874 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . 0.443 ' O ' ' CE ' ' N' ' 28' ' ' LYS . . . 160.19 67.37 0.02 OUTLIER Glycine 0 CA--C 1.546 1.998 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.117 -176.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.67 132.22 30.65 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 120.305 2.053 . . . . 0.0 114.155 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.408 ' CD1' ' HB ' ' I' ' 39' ' ' VAL . 9.8 tt -137.36 131.88 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 114.57 -1.196 . . . . 0.0 112.18 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . 0.442 HG23 HD13 ' O' ' 32' ' ' ILE . 71.3 mt -108.25 114.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.378 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.97 94.9 0.77 Allowed Glycine 0 N--CA 1.468 0.792 0 N-CA-C 107.236 -2.345 . . . . 0.0 107.236 177.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -121.32 134.6 55.14 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 122.476 1.132 . . . . 0.0 113.264 -176.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -113.0 104.41 12.36 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 173.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . 0.551 ' O ' ' N ' ' P' ' 37' ' ' GLY . 2.5 t -113.6 103.46 15.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . 136.85 -153.53 21.77 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.663 177.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.636 ' H ' ' H ' ' P' ' 38' ' ' GLY . . . 137.79 -56.29 0.67 Allowed Glycine 0 CA--C 1.543 1.796 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -178.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 5.0 p -133.15 154.78 40.05 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.486 ' OXT' ' CG2' ' P' ' 40' ' ' VAL . 17.3 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.999 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 43.9 t . . . . . 0 N--CA 1.467 0.42 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.537 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 12.3 m170 -44.22 110.77 0.24 Allowed 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.946 -178.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' O ' ' Q' ' 14' ' ' HIS . 55.4 t60 -152.62 154.43 35.35 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.716 HE22 ' N ' ' N' ' 37' ' ' GLY . 81.9 mt-30 -98.47 169.81 9.28 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -158.26 103.99 1.84 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.976 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -134.05 133.28 41.0 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.521 0.677 . . . . 0.0 110.861 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 64.1 t -123.55 120.94 61.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.935 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' P' ' 19' ' ' PHE . 5.5 m-85 -112.73 112.3 23.71 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.41 ' HB3' ' CD1' ' O' ' 20' ' ' PHE . 26.4 t80 -125.2 122.47 37.11 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -176.768 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.9 122.09 29.54 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.521 ' CG ' ' N ' ' P' ' 23' ' ' ASP . 69.6 tt0 -167.45 158.97 11.95 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 117.695 2.479 . . . . 0.0 117.695 -176.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.521 ' N ' ' CG ' ' P' ' 22' ' ' GLU . 1.7 p30 150.64 -70.05 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 111.643 -2.526 . . . . 0.0 108.386 175.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.591 ' CG1' ' H ' ' O' ' 26' ' ' SER . 4.4 m -57.05 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 122.099 0.952 . . . . 0.0 109.336 174.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 141.57 -36.25 1.73 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.621 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 m -70.33 114.49 8.51 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 115.916 -2.314 . . . . 0.0 105.18 171.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.718 ' ND2' ' H ' ' P' ' 30' ' ' ALA . 50.3 p-10 -119.98 154.6 34.27 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 121.212 1.824 . . . . 0.0 111.926 176.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -34.52 -39.46 0.09 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 173.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' Q' ' 29' ' ' GLY . . . 140.07 74.52 0.05 OUTLIER Glycine 0 CA--C 1.553 2.447 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -175.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . 0.718 ' H ' ' ND2' ' P' ' 27' ' ' ASN . . . -70.55 170.14 12.74 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 116.099 1.888 . . . . 0.0 116.099 -173.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . 0.419 ' CD1' ' CB ' ' J' ' 39' ' ' VAL . 0.9 OUTLIER -149.14 143.7 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 CA-C-N 112.739 -2.028 . . . . 0.0 114.907 -176.103 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 3.7 mt -113.12 113.06 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 174.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.38 101.8 1.2 Allowed Glycine 0 N--CA 1.462 0.402 0 N-CA-C 105.82 -2.912 . . . . 0.0 105.82 176.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 9.0 tt -144.49 132.08 21.06 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 122.866 1.317 . . . . 0.0 112.397 -175.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 74.0 mtp -120.86 119.59 33.11 Favored 'General case' 0 CA--C 1.495 -1.153 0 CA-C-N 113.163 -1.835 . . . . 0.0 107.512 178.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -95.67 113.85 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.604 -178.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.551 ' N ' ' O ' ' O' ' 36' ' ' VAL . . . -65.64 -123.29 0.01 OUTLIER Glycine 0 CA--C 1.521 0.408 0 CA-C-N 113.871 -1.513 . . . . 0.0 110.799 177.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.636 ' H ' ' H ' ' O' ' 38' ' ' GLY . . . 66.64 60.86 5.79 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-N 114.301 -0.95 . . . . 0.0 113.641 179.261 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -84.71 124.14 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.486 ' CG2' ' OXT' ' O' ' 40' ' ' VAL . 3.1 t . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 118.341 -0.838 . . . . 0.0 112.428 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.29 131.07 55.09 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -141.23 138.23 33.14 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.542 -179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -125.28 129.92 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.435 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.704 ' HE2' ' NE2' ' Q' ' 15' ' ' GLN . 14.2 t60 -136.4 132.98 36.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.912 0.387 . . . . 0.0 110.811 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.583 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 3.7 m80 -145.48 162.58 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.515 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.704 ' NE2' ' HE2' ' Q' ' 13' ' ' HIS . 17.6 mp0 -89.95 157.26 17.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 176.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -141.66 102.34 4.16 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 176.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -131.37 119.47 21.73 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-O 121.389 0.614 . . . . 0.0 111.143 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -107.44 111.8 37.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.429 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 88.3 m-85 -106.63 103.44 12.88 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.015 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.58 ' CE2' ' CD2' ' R' ' 20' ' ' PHE . 26.1 t80 -110.01 119.34 39.01 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.47 128.34 21.91 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.424 0.63 . . . . 0.0 111.349 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 38.9 tt0 -91.29 109.96 21.25 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 99.1 m-20 -141.96 48.27 1.6 Allowed 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.212 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -72.86 160.56 5.27 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.481 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.82 -30.04 8.42 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.7 t 61.46 109.96 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 118.903 -0.57 . . . . 0.0 112.157 177.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.744 ' O ' ' N ' ' Q' ' 29' ' ' GLY . 14.9 t-20 -129.41 159.74 35.27 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -29.53 48.82 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 N-CA-C 117.641 2.46 . . . . 0.0 117.641 -178.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . 0.744 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -171.93 52.61 0.18 Allowed Glycine 0 CA--C 1.536 1.399 0 CA-C-N 120.552 1.524 . . . . 0.0 112.34 171.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.04 95.06 9.57 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.819 1.809 . . . . 0.0 111.295 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 49.4 mt -133.36 123.98 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 CA-C-N 120.66 1.573 . . . . 0.0 112.687 -178.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -126.97 121.97 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.636 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.75 114.05 2.01 Favored Glycine 0 N--CA 1.467 0.76 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 89.8 mt -124.98 119.73 29.57 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.504 0.192 . . . . 0.0 110.576 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 82.1 mtp -127.93 124.4 37.27 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 64.2 t -115.93 146.9 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.503 -0.555 . . . . 0.0 109.503 178.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.91 102.29 0.41 Allowed Glycine 0 C--N 1.315 -0.634 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.99 -71.09 0.65 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-O 121.559 0.533 . . . . 0.0 111.945 178.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' Q' ' 40' ' ' VAL . 2.4 m -126.2 119.01 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.468 ' CB ' ' O ' ' Q' ' 39' ' ' VAL . 61.1 t . . . . . 0 N--CA 1.487 1.403 0 C-N-CA 124.34 1.056 . . . . 0.0 109.882 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -115.22 140.57 48.98 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -73.48 129.99 39.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.458 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 72.0 t -126.07 131.86 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.115 0.483 . . . . 0.0 110.343 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -132.84 95.72 3.64 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.711 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' OE1' ' R' ' 15' ' ' GLN . 84.8 t60 -155.36 161.93 40.93 Favored 'General case' 0 C--O 1.222 -0.349 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.515 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.2 OUTLIER -90.17 159.8 16.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.867 0.365 . . . . 0.0 111.452 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 57.7 tttt -139.96 107.12 5.47 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . 0.64 ' N ' ' CD2' ' R' ' 17' ' ' LEU . 0.0 OUTLIER -126.82 121.3 31.53 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.694 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -104.34 111.31 33.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 177.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -103.44 103.77 13.78 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CE2' ' Q' ' 20' ' ' PHE . 62.3 t80 -114.07 109.2 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.352 0.596 . . . . 0.0 109.58 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.47 125.08 33.49 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -81.98 114.38 20.52 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.719 -178.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.401 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.0 t0 -150.24 46.27 0.9 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.671 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.451 ' CG1' ' H ' ' R' ' 25' ' ' GLY . 24.1 t -96.02 175.93 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . 0.451 ' H ' ' CG1' ' R' ' 24' ' ' VAL . . . 70.96 26.97 72.99 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 26' ' ' SER . . . . . 0.48 ' O ' ' O ' ' R' ' 27' ' ' ASN . 28.5 t -153.37 120.29 5.71 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.101 0.476 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.48 ' O ' ' O ' ' R' ' 26' ' ' SER . 16.3 m120 -42.07 178.78 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.663 -179.198 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -72.58 45.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.923 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' R' ' 27' ' ' ASN . . . -92.08 59.53 2.74 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.525 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.37 165.86 33.69 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 122.545 -0.385 . . . . 0.0 110.33 -178.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . 0.424 ' CD1' ' O ' ' L' ' 39' ' ' VAL . 93.6 mt -109.95 119.01 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.261 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 18.6 tt -130.37 124.07 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.921 0.391 . . . . 0.0 110.223 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.43 120.3 3.66 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 42.9 mt -121.48 121.57 37.81 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -179.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 75.4 mtp -128.95 131.03 47.46 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.45 0.643 . . . . 0.0 112.175 -179.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -134.38 142.67 40.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.935 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.63 -102.31 0.2 Allowed Glycine 0 C--N 1.306 -1.097 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' R' ' 39' ' ' VAL . . . 109.06 -71.85 0.2 Allowed Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.11 -0.828 . . . . 0.0 112.055 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . 0.452 ' C ' ' O ' ' R' ' 38' ' ' GLY . 94.1 t -29.95 123.03 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 118.492 1.146 . . . . 0.0 111.657 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . 0.442 ' H ' HG22 ' F' ' 31' ' ' ILE . 91.7 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.974 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 CA--C 1.527 0.092 0 CA-C-O 120.709 0.29 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 m -123.05 131.41 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.389 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 75.1 t60 -137.67 141.01 41.13 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.257 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 15' ' ' GLN . 0.4 OUTLIER -84.58 166.62 17.02 Favored 'General case' 0 CA--C 1.532 0.267 0 CA-C-O 121.248 0.547 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.625 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 83.0 mt-30 -157.45 143.09 17.36 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.071 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -81.07 134.36 35.65 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.334 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.92 116.56 22.39 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -125.26 133.68 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.054 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -140.33 139.52 35.43 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.016 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.526 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.1 p90 -126.46 127.81 45.97 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.65 116.22 29.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.302 0.572 . . . . 0.0 111.018 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -142.4 120.9 12.46 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 C--N 1.329 -0.323 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.14 -179.445 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.472 0.664 0 CA-C-O 119.304 -0.379 . . . . 0.0 110.662 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' B' ' 22' ' ' GLU . 52.3 mtpt -118.36 -38.34 3.19 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 120.123 -0.631 . . . . 0.0 112.271 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.7 -78.59 0.93 Allowed Glycine 0 N--CA 1.468 0.792 0 C-N-CA 118.951 -1.595 . . . . 0.0 112.919 -177.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.56 93.64 0.2 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.938 -0.705 . . . . 0.0 112.114 178.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 92.7 mt -126.28 104.73 13.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 32' ' ' ILE . 96.5 mt -110.57 112.01 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.099 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.609 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.6 92.66 0.5 Allowed Glycine 0 CA--C 1.508 -0.383 0 N-CA-C 104.356 -3.498 . . . . 0.0 104.356 176.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.5 mt -151.79 177.95 9.88 Favored 'General case' 0 CA--C 1.51 -0.594 0 CA-C-O 122.969 1.366 . . . . 0.0 111.985 -175.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 31.4 mtp -140.38 119.38 12.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 113.096 -1.865 . . . . 0.0 108.902 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -131.97 113.56 22.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 178.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 154.38 -124.64 1.58 Allowed Glycine 0 C--N 1.307 -1.058 0 N-CA-C 109.106 -1.597 . . . . 0.0 109.106 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.62 -67.03 3.6 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.977 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.447 ' CG2' ' N ' ' A' ' 40' ' ' VAL . 2.4 p -115.56 166.49 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.447 ' N ' ' CG2' ' A' ' 39' ' ' VAL . 9.8 m . . . . . 0 N--CA 1.472 0.646 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.58 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -106.27 133.21 51.33 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -93.17 106.02 18.03 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.788 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -128.9 130.81 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 81.3 t60 -134.16 105.76 6.83 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.814 0.34 . . . . 0.0 111.166 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.635 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 4.5 t60 -157.12 167.37 30.59 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.584 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.59 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 84.3 mt-30 -154.75 141.84 19.33 Favored 'General case' 0 C--N 1.339 0.127 0 N-CA-C 109.627 -0.509 . . . . 0.0 109.627 177.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -85.53 131.5 34.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.624 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -122.16 120.97 35.79 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 118.121 0.419 . . . . 0.0 110.117 177.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -124.61 131.97 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -131.14 123.29 28.24 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.616 -179.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -112.79 124.85 53.52 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.15 126.28 45.89 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' A' ' 28' ' ' LYS . 79.0 tt0 -115.07 162.98 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.912 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -178.81 48.71 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 122.337 0.255 . . . . 0.0 110.443 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 2.7 t -72.57 161.05 5.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 122.363 1.077 . . . . 0.0 112.749 -174.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 107.07 -34.71 5.52 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 113.051 -1.886 . . . . 0.0 112.588 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' B' ' 27' ' ' ASN . 89.2 p -162.46 120.07 2.08 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.831 1.315 . . . . 0.0 113.851 177.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.604 ' ND2' ' ND2' ' C' ' 27' ' ' ASN . 18.0 t-20 -22.37 153.41 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.362 0.665 . . . . 0.0 111.644 174.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.461 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 56.3 tttt -165.45 26.5 0.05 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.72 107.93 0.38 Allowed Glycine 0 N--CA 1.47 0.944 0 C-N-CA 118.239 -1.934 . . . . 0.0 115.7 174.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -120.47 105.23 10.66 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-O 122.363 1.078 . . . . 0.0 108.136 177.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.416 ' CD1' ' O ' ' N' ' 38' ' ' GLY . 2.6 mt -133.49 135.63 55.67 Favored 'Isoleucine or valine' 0 C--N 1.346 0.435 0 CA-C-N 114.746 -1.116 . . . . 0.0 113.163 -176.036 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 94.1 mt -113.15 110.78 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.383 176.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.01 102.33 1.07 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 105.327 -3.109 . . . . 0.0 105.327 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 12.2 tp -146.67 144.42 29.46 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 117.828 -1.549 . . . . 0.0 114.765 -174.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.43 114.81 29.06 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 112.277 -2.238 . . . . 0.0 108.299 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 17.0 t -133.21 123.2 46.98 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 119.916 -0.714 . . . . 0.0 110.938 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.7 -113.74 1.02 Allowed Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.7 -72.72 2.58 Favored Glycine 0 CA--C 1.536 1.348 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' B' ' 40' ' ' VAL . 47.6 t -134.31 164.56 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 122.463 -0.434 . . . . 0.0 110.946 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.446 ' CG2' ' O ' ' C' ' 39' ' ' VAL . 53.1 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.886 -1.054 . . . . 0.0 109.961 178.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.142 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -81.93 140.28 34.14 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -139.08 139.36 37.71 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.871 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 130.96 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.602 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 33.2 m80 -145.7 101.43 3.56 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 120.107 -0.637 . . . . 0.0 112.183 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.635 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.0 p-80 -155.89 155.0 32.12 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 118.415 -1.314 . . . . 0.0 111.95 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -90.48 161.19 15.63 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.416 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . 0.417 ' HD2' ' HE2' ' B' ' 14' ' ' HIS . 99.0 mttt -139.32 112.65 8.22 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 175.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 3.6 mt -116.24 111.48 20.22 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.475 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 t -111.08 110.12 31.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -110.32 113.09 25.48 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -112.32 124.88 53.45 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.676 -0.238 . . . . 0.0 110.505 -178.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . 0.57 ' O ' ' NZ ' ' C' ' 28' ' ' LYS . . . -131.78 136.77 47.8 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.508 0.671 . . . . 0.0 112.724 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.442 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 15.5 pt-20 -163.81 133.2 3.98 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.3 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -150.02 -60.3 0.2 Allowed 'General case' 0 C--N 1.353 0.758 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.489 ' CG1' ' N ' ' C' ' 25' ' ' GLY . 35.9 t -94.15 170.55 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 117.378 -1.729 . . . . 0.0 112.579 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.489 ' N ' ' CG1' ' C' ' 24' ' ' VAL . . . -81.51 27.83 3.2 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.404 173.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.626 ' HG ' ' H ' ' C' ' 27' ' ' ASN . 4.8 t -170.56 -138.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 118.947 1.374 . . . . 0.0 112.75 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.626 ' H ' ' HG ' ' C' ' 26' ' ' SER . 66.4 t30 -34.52 127.69 0.46 Allowed 'General case' 0 C--N 1.349 0.547 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.178 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.629 ' NZ ' ' N ' ' D' ' 22' ' ' GLU . 71.2 tttt -104.94 -42.16 5.41 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . 81.18 60.88 2.18 Favored Glycine 0 CA--C 1.543 1.812 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.528 ' N ' ' OG ' ' D' ' 26' ' ' SER . . . -110.21 112.39 24.34 Favored 'General case' 0 C--N 1.361 1.101 0 CA-C-O 123.237 1.494 . . . . 0.0 114.077 -175.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 tt -134.63 127.19 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 112.218 -2.264 . . . . 0.0 109.228 179.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.2 mt -106.56 116.32 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.213 -179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.97 106.36 1.62 Allowed Glycine 0 N--CA 1.466 0.695 0 N-CA-C 106.551 -2.619 . . . . 0.0 106.551 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -133.05 134.63 44.61 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 114.128 1.159 . . . . 0.0 114.128 -174.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -113.02 98.94 7.48 Favored 'General case' 0 N--CA 1.432 -1.338 0 N-CA-C 101.591 -3.485 . . . . 0.0 101.591 173.058 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.02 132.22 65.61 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 N-CA-C 114.76 1.393 . . . . 0.0 114.76 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.09 111.97 1.25 Allowed Glycine 0 CA--C 1.521 0.461 0 CA-C-N 114.267 -1.333 . . . . 0.0 113.194 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -97.9 -60.51 0.92 Allowed Glycine 0 CA--C 1.54 1.609 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 176.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.446 ' O ' ' CG2' ' B' ' 40' ' ' VAL . 10.0 p -145.06 150.5 15.93 Favored 'Isoleucine or valine' 0 C--N 1.342 0.269 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.497 ' OXT' ' ND1' ' E' ' 13' ' ' HIS . 9.8 p . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.534 -179.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 m . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 121.433 0.635 . . . . 0.0 110.594 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.602 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 2.5 t60 -126.83 127.87 45.66 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.694 -178.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.575 ' HE2' ' CE1' ' C' ' 14' ' ' HIS . 1.5 p-80 -134.19 164.39 27.46 Favored 'General case' 0 C--O 1.221 -0.396 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.165 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 44.4 tp60 -90.1 151.51 21.58 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 178.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -150.33 97.13 2.5 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 7.4 mt -123.29 121.56 36.15 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.07 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -114.89 106.54 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -107.78 106.0 16.1 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -116.76 129.38 56.08 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.787 -175.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . 0.573 ' CB ' ' NZ ' ' C' ' 28' ' ' LYS . . . -133.86 128.73 35.26 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-O 121.54 0.686 . . . . 0.0 111.295 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.629 ' N ' ' NZ ' ' C' ' 28' ' ' LYS . 98.9 mt-10 -95.13 139.4 31.51 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.381 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.501 ' O ' ' O ' ' D' ' 24' ' ' VAL . 9.9 m-20 65.36 47.92 2.22 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 177.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.501 ' O ' ' O ' ' D' ' 23' ' ' ASP . 5.2 m -52.45 -175.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 119.215 -0.994 . . . . 0.0 108.433 177.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 165.43 19.46 0.02 OUTLIER Glycine 0 CA--C 1.523 0.548 0 C-N-CA 118.252 -1.928 . . . . 0.0 113.342 -177.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.528 ' OG ' ' N ' ' C' ' 30' ' ' ALA . 5.2 m -80.33 -130.37 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' CG1' ' P' ' 39' ' ' VAL . 9.7 m120 -100.48 149.78 23.33 Favored 'General case' 0 CA--C 1.516 -0.332 0 C-N-CA 119.048 -1.061 . . . . 0.0 109.745 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.477 ' HZ2' ' C ' ' R' ' 40' ' ' VAL . 95.8 mttt 37.78 42.54 0.41 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.346 -1.297 . . . . 0.0 110.887 -177.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.56 -66.42 2.32 Favored Glycine 0 CA--C 1.545 1.947 0 CA-C-N 116.514 -0.312 . . . . 0.0 113.245 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.21 165.41 9.06 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.525 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 11.9 tt -129.59 129.92 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.733 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.4 HD13 HG21 ' D' ' 32' ' ' ILE . 75.1 mt -113.52 112.68 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.761 178.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.64 97.01 1.39 Allowed Glycine 0 C--O 1.239 0.409 0 N-CA-C 104.226 -3.55 . . . . 0.0 104.226 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 64.9 tp -117.09 121.54 41.59 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -173.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -112.03 97.93 7.0 Favored 'General case' 0 N--CA 1.433 -1.3 0 N-CA-C 103.796 -2.668 . . . . 0.0 103.796 173.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.591 ' CG2' HE22 ' E' ' 15' ' ' GLN . 14.3 p -119.09 120.84 65.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.268 0 C-N-CA 119.714 -0.794 . . . . 0.0 110.454 -177.202 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -99.51 121.88 7.37 Favored Glycine 0 C--N 1.332 0.345 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' E' ' 39' ' ' VAL . . . -119.24 62.07 0.47 Allowed Glycine 0 CA--C 1.532 1.149 0 CA-C-O 119.035 -0.869 . . . . 0.0 112.532 178.076 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 49.2 t -84.3 130.04 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 119.324 1.562 . . . . 0.0 109.742 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.284 179.438 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -110.79 134.79 52.2 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.655 0.264 . . . . 0.0 110.302 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -105.54 137.59 43.13 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.994 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.473 HG12 ' H ' ' F' ' 12' ' ' VAL . 4.2 p -139.52 156.39 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.916 0.389 . . . . 0.0 111.42 -178.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.497 ' ND1' ' OXT' ' C' ' 40' ' ' VAL . 7.7 p80 -74.19 125.06 27.55 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.194 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 52.6 p-80 -154.05 166.36 33.28 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.339 178.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.591 HE22 ' CG2' ' D' ' 36' ' ' VAL . 16.8 tt0 -89.84 151.71 21.63 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 178.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -149.57 105.27 3.43 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.858 177.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -117.59 117.06 28.38 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.893 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 103.88 15.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.639 ' CE2' ' CE1' ' F' ' 19' ' ' PHE . 3.7 m-30 -106.54 109.12 20.94 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -129.72 130.9 46.05 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 120.058 -0.657 . . . . 0.0 112.521 -176.24 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' D' ' 21' ' ' ALA . . . -124.47 133.18 53.43 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.936 178.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 92.0 mt-10 -127.18 170.64 12.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 116.982 2.216 . . . . 0.0 116.982 -176.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.454 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 11.4 p30 48.18 46.31 19.77 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 110.722 -2.944 . . . . 0.0 116.167 177.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.41 HG21 ' H ' ' E' ' 26' ' ' SER . 15.7 m -72.12 -168.79 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.247 -0.981 . . . . 0.0 108.947 174.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.42 36.81 3.96 Favored Glycine 0 N--CA 1.467 0.725 0 N-CA-C 105.815 -2.914 . . . . 0.0 105.815 172.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.41 ' H ' HG21 ' E' ' 24' ' ' VAL . 21.3 t 61.63 111.21 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 113.339 -1.43 . . . . 0.0 107.844 -175.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.481 ' O ' ' N ' ' E' ' 29' ' ' GLY . 98.8 m-20 -130.0 161.1 31.7 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . 0.433 ' C ' ' O ' ' E' ' 27' ' ' ASN . 98.3 mttt -28.63 -40.27 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.294 173.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 107.68 -63.45 0.28 Allowed Glycine 0 CA--C 1.54 1.611 0 CA-C-O 117.096 -1.947 . . . . 0.0 115.968 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.426 ' CB ' ' O ' ' E' ' 29' ' ' GLY . . . -179.75 168.89 1.34 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 122.903 3.351 . . . . 0.0 115.915 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 91.2 mt -119.53 125.09 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 111.18 -2.736 . . . . 0.0 106.087 175.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 89.5 mt -130.49 128.76 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.94 106.28 1.01 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.445 ' C ' ' CD2' ' E' ' 34' ' ' LEU . 7.3 tt -115.61 122.75 46.55 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-O 120.926 0.393 . . . . 0.0 111.672 -176.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.2 mtp -118.76 126.07 51.04 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.635 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' F' ' 37' ' ' GLY . 59.1 t -90.68 156.38 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 121.142 0.496 . . . . 0.0 111.052 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.456 ' O ' ' N ' ' E' ' 39' ' ' VAL . . . -102.13 102.5 2.33 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.299 -179.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.56 -73.56 0.0 OUTLIER Glycine 0 CA--C 1.541 1.676 0 N-CA-C 115.567 0.987 . . . . 0.0 115.567 177.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' D' ' 38' ' ' GLY . 6.6 p . . . . . 0 N--CA 1.48 1.074 0 CA-C-N 118.577 1.189 . . . . 0.0 111.64 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 120.678 0.275 . . . . 0.0 110.56 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.473 ' H ' HG12 ' E' ' 12' ' ' VAL . 67.9 t -124.46 127.5 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.952 0.882 . . . . 0.0 111.439 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 5.8 p80 -126.51 103.29 7.52 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.981 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.43 ' CD2' ' N ' ' F' ' 14' ' ' HIS . 0.3 OUTLIER -148.08 169.38 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.423 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -89.58 156.88 18.32 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 119.227 -0.989 . . . . 0.0 110.65 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.21 104.71 4.68 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -124.76 112.31 16.56 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -107.13 107.16 22.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.639 ' CE1' ' CE2' ' E' ' 19' ' ' PHE . 13.1 m-85 -118.89 108.78 15.22 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.525 ' CE2' ' O ' ' F' ' 21' ' ' ALA . 57.7 t80 -148.76 163.32 37.7 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.33 1.062 . . . . 0.0 113.234 -178.428 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.525 ' O ' ' CE2' ' F' ' 20' ' ' PHE . . . -137.62 138.34 39.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.582 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -77.94 112.67 15.07 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 p30 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.244 -176.727 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.516 -0.359 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 97.1 mt -119.73 124.68 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 33.7 pt -135.79 137.18 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 121.215 0.531 . . . . 0.0 111.218 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.96 120.31 2.34 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 6.2 tt -118.54 121.98 41.55 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 4.8 ttm -119.25 120.37 36.81 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.958 0.409 . . . . 0.0 111.101 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.472 ' O ' ' O ' ' F' ' 37' ' ' GLY . 22.4 m -87.12 131.8 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.076 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -46.97 -111.82 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 121.918 0.732 . . . . 0.0 112.103 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.64 -71.36 0.83 Allowed Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -102.5 128.58 55.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-O 121.339 0.59 . . . . 0.0 110.751 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.585 -179.982 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 N--CA 1.466 0.374 0 CA-C-O 120.953 0.406 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 37.8 p-80 -143.69 161.09 39.46 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.509 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.41 ' CE1' ' CD2' ' H' ' 13' ' ' HIS . 72.3 m80 -150.22 173.48 13.89 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.154 -179.607 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 29.7 pt20 -92.33 150.27 20.94 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -101.31 151.16 22.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.131 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 tp -137.45 124.83 21.92 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.561 0.696 . . . . 0.0 111.681 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 65.8 t -124.82 129.97 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 114.99 -1.004 . . . . 0.0 108.819 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -134.27 130.63 37.37 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.198 0.523 . . . . 0.0 111.285 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.6 p90 -135.67 128.37 30.91 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.752 179.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.6 138.37 54.56 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.801 0.334 . . . . 0.0 110.898 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -81.96 -168.78 2.07 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.593 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.406 -179.011 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.552 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 15.4 t-20 . . . . . 0 CA--C 1.534 0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 111.618 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.552 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 77.4 tttt -56.09 -36.55 68.27 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.869 -1.06 . . . . 0.0 111.685 178.799 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.65 82.15 0.45 Allowed Glycine 0 CA--C 1.53 1.018 0 CA-C-N 114.127 -1.397 . . . . 0.0 113.508 -174.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.95 102.98 13.59 Favored 'General case' 0 C--O 1.242 0.698 0 CA-C-O 124.132 1.92 . . . . 0.0 109.775 -178.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 53.1 mt -126.45 132.54 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 CA-C-N 110.506 -3.043 . . . . 0.0 108.868 -177.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 33.5 mt -103.66 110.79 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 176.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.81 104.98 1.44 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 107.524 -2.23 . . . . 0.0 107.524 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.415 HD12 ' H ' ' G' ' 35' ' ' MET . 50.7 tp -163.0 152.79 15.67 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 117.976 -1.49 . . . . 0.0 113.64 -177.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.415 ' H ' HD12 ' G' ' 34' ' ' LEU . 45.4 tpp -100.03 116.87 33.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 112.572 -2.103 . . . . 0.0 107.953 178.036 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -123.09 112.1 32.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.53 -131.88 10.75 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.47 -62.66 0.31 Allowed Glycine 0 CA--C 1.54 1.648 0 C-N-CA 121.436 -0.411 . . . . 0.0 112.442 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.59 ' CG2' ' NZ ' ' N' ' 28' ' ' LYS . 12.6 p -116.22 160.47 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 C-N-CA 122.542 0.337 . . . . 0.0 110.936 -179.554 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . 0.512 ' N ' ' CG1' ' H' ' 39' ' ' VAL . 24.7 t . . . . . 0 N--CA 1.471 0.588 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.401 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -83.21 139.76 32.95 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.727 0.298 . . . . 0.0 110.509 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.34 140.76 39.62 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.5 t -129.96 134.51 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.636 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.41 ' CD2' ' CE1' ' G' ' 14' ' ' HIS . 20.6 t-160 -129.58 100.46 5.54 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.825 0.345 . . . . 0.0 110.843 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 0.1 OUTLIER -159.3 171.98 18.84 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.128 179.851 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.645 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 84.6 mt-30 -152.2 141.31 21.3 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 178.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -88.08 114.53 24.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.79 178.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 70.8 mt -119.55 112.99 20.04 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -120.77 131.12 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 120.792 0.329 . . . . 0.0 111.441 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -133.15 116.15 15.92 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.585 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' CD2' ' I' ' 20' ' ' PHE . 10.4 m-85 -122.65 134.84 54.48 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.11 127.83 23.33 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 80.3 tt0 -95.02 117.38 30.06 Favored 'General case' 0 CA--C 1.522 -0.101 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 176.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.45 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 84.5 m-20 -136.05 46.99 2.26 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -175.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 17.0 t -99.88 162.98 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 C-N-CA 118.013 -1.475 . . . . 0.0 108.386 -179.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.99 28.58 70.27 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -178.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.532 ' OG ' ' N ' ' H' ' 27' ' ' ASN . 20.0 p -170.53 -132.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.801 0.81 . . . . 0.0 112.467 -175.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.532 ' N ' ' OG ' ' H' ' 26' ' ' SER . 1.6 m120 -30.7 143.67 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 114.1 -1.409 . . . . 0.0 113.713 -177.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -132.53 -25.14 1.95 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 113.609 -1.632 . . . . 0.0 111.224 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.83 109.37 2.83 Favored Glycine 0 N--CA 1.47 0.913 0 CA-C-N 116.187 -0.46 . . . . 0.0 113.376 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 111.99 12.61 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 122.385 1.088 . . . . 0.0 112.621 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 tt -140.34 137.99 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 114.515 -1.22 . . . . 0.0 111.124 178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.439 HG21 HD13 ' H' ' 32' ' ' ILE . 95.5 mt -106.19 113.88 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.609 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.74 100.67 1.13 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 106.631 -2.588 . . . . 0.0 106.631 176.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 90.7 mt -141.76 153.45 44.59 Favored 'General case' 0 CA--C 1.51 -0.564 0 CA-C-O 122.844 1.307 . . . . 0.0 113.586 -175.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 4.1 mtp -116.87 117.18 29.02 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 112.498 -2.137 . . . . 0.0 105.939 176.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' K' ' 15' ' ' GLN . 58.9 t -123.56 102.42 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 O-C-N 122.469 -0.144 . . . . 0.0 111.35 -176.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.64 -162.37 23.76 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.437 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 146.71 -55.64 0.52 Allowed Glycine 0 CA--C 1.547 2.093 0 CA-C-O 119.572 -0.571 . . . . 0.0 112.561 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.512 ' CG1' ' N ' ' G' ' 40' ' ' VAL . 3.0 p -142.44 162.51 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-N 118.498 1.149 . . . . 0.0 110.248 178.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.854 178.877 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . 0.514 ' CD1' ' O ' ' J' ' 9' ' ' GLY . 97.7 m-85 -99.28 132.59 44.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.723 0.297 . . . . 0.0 110.572 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.5 ' CD ' ' N ' ' I' ' 11' ' ' GLU . 2.0 pm0 -154.4 141.25 19.14 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.054 0.454 . . . . 0.0 111.446 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -126.81 129.35 71.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.968 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 18.7 m80 -116.25 138.88 50.93 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 110.35 -0.241 . . . . 0.0 110.35 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -149.85 167.85 25.4 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.351 177.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -139.22 141.07 37.91 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -129.8 104.3 7.32 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.394 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -111.9 113.29 25.53 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 t -109.08 107.48 22.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 57.7 m-85 -109.05 108.45 19.16 Favored 'General case' 0 CA--C 1.546 0.821 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.447 ' CD2' ' CE2' ' H' ' 20' ' ' PHE . 5.4 m-85 -117.5 130.42 56.43 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 122.184 -0.322 . . . . 0.0 110.917 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.29 134.22 30.69 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.563 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 85.5 mt-10 -92.4 -161.33 0.82 Allowed 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.217 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.563 ' OD1' ' O ' ' I' ' 22' ' ' GLU . 0.4 OUTLIER 95.12 54.2 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 -177.689 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 1.1 m -81.3 133.49 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 CA-C-O 125.133 2.397 . . . . 0.0 116.264 -169.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.611 ' H ' ' HA ' ' J' ' 23' ' ' ASP . . . 94.5 -41.99 2.5 Favored Glycine 0 N--CA 1.443 -0.869 2 CA-C-N 107.471 -4.422 . . . . 0.0 113.594 172.516 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 94.6 p -68.39 110.85 4.31 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 115.976 -1.964 . . . . 0.0 112.039 174.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.749 ' ND2' ' H ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -147.66 124.47 11.23 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 123.313 2.778 . . . . 0.0 111.566 166.739 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.406 ' C ' ' O ' ' I' ' 27' ' ' ASN . 94.0 mttt -18.11 -52.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 115.638 1.718 . . . . 0.0 115.638 172.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.61 52.77 0.02 OUTLIER Glycine 0 CA--C 1.563 3.08 0 CA-C-N 112.584 -2.098 . . . . 0.0 109.661 -175.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.749 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . -41.98 141.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -171.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 55.0 mt -143.19 147.79 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 112.831 -1.986 . . . . 0.0 113.701 -177.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 mt -110.58 111.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 174.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.09 104.57 1.96 Allowed Glycine 0 N--CA 1.466 0.643 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mt -141.14 144.56 34.91 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -175.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 49.2 tpp -112.85 115.67 28.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 104.644 -2.354 . . . . 0.0 104.644 173.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.443 ' O ' ' N ' ' J' ' 37' ' ' GLY . 47.5 t -123.44 102.62 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 118.055 0.389 . . . . 0.0 111.874 -175.767 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.693 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 107.31 -161.93 13.54 Favored Glycine 0 N--CA 1.467 0.714 0 C-N-CA 120.486 -0.864 . . . . 0.0 112.803 177.557 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.734 ' H ' ' H ' ' J' ' 38' ' ' GLY . . . 148.15 -55.35 0.5 Allowed Glycine 0 CA--C 1.542 1.75 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 18.2 t -114.43 130.46 68.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 C-N-CA 123.409 0.684 . . . . 0.0 109.217 178.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.898 179.247 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . 0.514 ' O ' ' CD1' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -117.13 143.83 45.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.675 0.274 . . . . 0.0 110.434 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -73.68 108.58 6.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.86 0.362 . . . . 0.0 110.677 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.7 136.64 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.31 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -145.87 126.07 13.85 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.948 -0.301 . . . . 0.0 111.159 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 m-70 -140.41 157.57 45.33 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.012 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -90.31 158.85 16.95 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 174.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 44.1 tttp -141.18 113.55 8.09 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.163 177.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.401 HD12 ' N ' ' J' ' 17' ' ' LEU . 2.8 mp -136.61 127.94 28.28 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.755 0.788 . . . . 0.0 110.84 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -112.95 112.23 39.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 CA-C-N 114.464 -1.244 . . . . 0.0 108.76 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' K' ' 19' ' ' PHE . 18.5 m-85 -106.98 106.33 16.8 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.598 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 20.4 t80 -113.79 114.8 26.81 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.53 122.59 22.62 Favored 'General case' 0 C--O 1.246 0.9 0 CA-C-O 122.153 0.977 . . . . 0.0 111.829 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 96.5 mt-10 -83.89 125.46 32.01 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-N 113.824 -1.535 . . . . 0.0 107.861 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.611 ' HA ' ' H ' ' I' ' 25' ' ' GLY . 61.2 m-20 -166.45 47.29 0.07 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 118.158 -0.925 . . . . 0.0 113.393 -174.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.563 ' N ' ' OE1' ' K' ' 22' ' ' GLU . 9.3 p -98.6 161.31 3.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 CA-C-N 121.419 1.918 . . . . 0.0 109.286 -176.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.653 ' H ' ' N ' ' K' ' 25' ' ' GLY . . . 73.23 28.87 65.3 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 106.662 -2.575 . . . . 0.0 106.662 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 8.7 t -104.5 -120.75 0.21 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 -173.255 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.415 ' OD1' ' O ' ' I' ' 27' ' ' ASN . 2.2 m120 -81.8 163.75 22.14 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -175.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -47.47 -36.82 10.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 112.661 -2.063 . . . . 0.0 114.504 178.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.8 77.84 0.06 OUTLIER Glycine 0 CA--C 1.532 1.104 0 C-N-CA 119.147 -1.501 . . . . 0.0 114.859 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.21 169.0 0.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 118.847 1.324 . . . . 0.0 110.555 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -127.39 135.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 115.212 1.56 . . . . 0.0 115.212 -175.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 53.7 mt -106.49 105.75 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 172.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.18 101.17 1.94 Allowed Glycine 0 CA--C 1.508 -0.398 0 N-CA-C 104.849 -3.301 . . . . 0.0 104.849 176.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tt -143.33 125.74 15.7 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-O 123.081 1.419 . . . . 0.0 112.618 -175.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.7 mtp -104.68 118.07 35.66 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 112.582 -2.099 . . . . 0.0 107.875 178.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -105.91 114.09 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' I' ' 36' ' ' VAL . . . -64.78 -123.24 0.01 OUTLIER Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.734 ' H ' ' H ' ' I' ' 38' ' ' GLY . . . 64.99 61.05 6.15 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 114.278 -0.961 . . . . 0.0 114.573 178.357 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -92.52 130.17 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 177.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.495 ' OXT' ' CG1' ' J' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.84 -1.076 . . . . 0.0 111.859 -177.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -104.69 133.41 49.57 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.75 0.309 . . . . 0.0 110.609 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -142.9 133.29 24.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.666 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 95.2 t -124.97 123.8 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.462 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.459 ' C ' ' CD2' ' K' ' 13' ' ' HIS . 6.4 t-160 -145.04 112.98 6.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.044 0.449 . . . . 0.0 111.305 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.638 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 19.0 m-70 -140.41 159.22 42.68 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 177.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.693 HE22 ' N ' ' I' ' 37' ' ' GLY . 77.0 mt-30 -90.18 159.35 16.79 Favored 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 175.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.03 101.0 4.06 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mp -125.89 125.91 43.57 Favored 'General case' 0 CA--C 1.506 -0.73 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.785 178.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 5.2 p -119.49 118.33 56.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' J' ' 19' ' ' PHE . 53.2 m-85 -107.03 105.98 16.28 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.728 -1.123 . . . . 0.0 109.69 -178.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.1 t80 -106.24 108.09 19.43 Favored 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -148.36 155.11 40.86 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.94 1.352 . . . . 0.0 113.38 -177.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.563 ' OE1' ' N ' ' J' ' 24' ' ' VAL . 97.0 mt-10 -93.06 117.58 30.23 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.908 -179.273 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.427 ' OD2' ' OD1' ' L' ' 23' ' ' ASP . 13.6 m-20 -67.4 -51.25 54.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 114.418 -1.265 . . . . 0.0 111.547 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.529 ' CG2' ' N ' ' K' ' 25' ' ' GLY . 2.3 p 158.8 161.84 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -177.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.653 ' N ' ' H ' ' J' ' 25' ' ' GLY . . . -63.29 30.41 0.08 OUTLIER Glycine 0 CA--C 1.532 1.116 0 N-CA-C 118.509 2.164 . . . . 0.0 118.509 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.575 ' OG ' ' O ' ' K' ' 25' ' ' GLY . 5.2 m -169.96 -127.8 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 121.293 2.546 . . . . 0.0 114.104 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.471 ' C ' ' H ' ' K' ' 29' ' ' GLY . 60.2 t30 -48.13 152.29 0.85 Allowed 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 113.577 0.955 . . . . 0.0 113.577 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.444 ' O ' ' CB ' ' L' ' 30' ' ' ALA . 85.0 tttt -70.33 48.84 0.11 Allowed 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.471 ' H ' ' C ' ' K' ' 27' ' ' ASN . . . -82.47 51.1 4.46 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.27 -0.966 . . . . 0.0 112.707 -176.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 173.58 7.13 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 42.2 mt -125.46 127.75 72.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.743 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 33.4 pt -132.63 127.6 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.664 0.745 . . . . 0.0 111.753 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.34 110.93 2.15 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.481 ' N ' ' CD2' ' K' ' 34' ' ' LEU . 1.9 mm? -121.64 116.16 24.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.902 0.382 . . . . 0.0 110.066 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 4.1 ttm -107.81 130.28 54.99 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 54.0 t -125.64 131.84 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 CA-C-O 121.915 0.864 . . . . 0.0 112.352 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.03 -111.41 0.01 OUTLIER Glycine 0 CA--C 1.527 0.827 0 CA-C-N 113.722 -1.581 . . . . 0.0 111.085 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' OXT' ' J' ' 40' ' ' VAL . . . 105.91 -70.55 0.23 Allowed Glycine 0 N--CA 1.473 1.101 0 CA-C-N 114.518 -0.841 . . . . 0.0 111.758 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.435 -1.195 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 . . . . . 0 N--CA 1.463 0.22 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 t -110.79 115.93 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 110.462 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.5 p80 -147.19 101.5 3.4 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.975 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.638 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 97.6 m-70 -156.55 164.92 37.64 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 178.123 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.449 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 96.5 mm-40 -89.97 159.36 16.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.358 . . . . 0.0 111.104 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.78 104.18 4.83 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.605 0.716 . . . . 0.0 109.494 177.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -122.69 115.48 22.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.338 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -101.64 97.76 6.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.472 ' CE1' ' CE2' ' K' ' 19' ' ' PHE . 85.2 m-85 -93.87 98.93 11.39 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.368 -1.715 . . . . 0.0 106.368 178.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -122.38 127.02 49.22 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.746 0.784 . . . . 0.0 109.996 -178.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.11 150.96 36.03 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -64.45 107.79 1.46 Allowed 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 118.549 -1.26 . . . . 0.0 108.758 -178.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.427 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 13.8 m-20 -153.89 50.0 0.66 Allowed 'General case' 0 C--O 1.231 0.122 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 95.8 t -82.8 149.3 4.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 178.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.93 36.25 5.83 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 18.1 t -76.45 102.35 5.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.706 0.765 . . . . 0.0 111.487 -176.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -97.48 -167.61 1.56 Allowed 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.543 -1.208 . . . . 0.0 112.188 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -49.13 -40.55 32.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.042 -1.436 . . . . 0.0 114.38 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.31 68.79 1.86 Allowed Glycine 0 N--CA 1.477 1.432 0 N-CA-C 114.971 0.748 . . . . 0.0 114.971 -175.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.444 ' CB ' ' O ' ' K' ' 28' ' ' LYS . . . -141.74 141.71 33.26 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -120.6 117.69 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.125 0 CA-C-N 120.443 1.474 . . . . 0.0 111.577 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -119.57 122.18 68.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-N 114.812 -1.086 . . . . 0.0 110.205 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.4 106.72 0.91 Allowed Glycine 0 N--CA 1.464 0.547 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.9 tp -125.17 123.9 40.61 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 94.0 mtp -132.77 133.58 43.61 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.436 0.636 . . . . 0.0 112.217 -179.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.5 t -128.87 132.35 67.55 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.135 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 177.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.6 112.19 3.53 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 119.182 -1.485 . . . . 0.0 111.736 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.34 -63.51 4.46 Favored Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 177.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 124.229 1.012 . . . . 0.0 108.355 -179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 42.7 tp10 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 120.89 0.376 . . . . 0.0 110.048 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 70.4 t -125.87 131.6 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.814 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -107.43 107.81 18.86 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.695 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 42.8 p-80 -152.66 165.94 33.68 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-O 121.212 0.53 . . . . 0.0 111.728 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 52.7 tt0 -170.75 147.99 2.87 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.271 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -77.9 120.41 22.74 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -128.31 113.81 16.1 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -130.19 130.07 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.354 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -133.56 141.88 47.91 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.44 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.408 ' O ' ' CD2' ' M' ' 20' ' ' PHE . 50.9 p90 -134.8 129.28 34.31 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.714 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.53 116.59 31.11 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.326 0.584 . . . . 0.0 110.339 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . 0.498 ' O ' ' N ' ' M' ' 24' ' ' VAL . 67.3 mt-10 -150.9 -139.06 0.09 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.329 -0.851 . . . . 0.0 108.918 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 53.7 p30 -53.05 50.99 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.694 1.197 . . . . 0.0 113.226 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . 0.498 ' N ' ' O ' ' M' ' 22' ' ' GLU . 2.7 t -101.02 -141.73 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . 0.461 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -72.59 -36.99 58.29 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 119.161 -1.495 . . . . 0.0 113.273 -175.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 26' ' ' SER . . . . . 0.425 ' O ' ' C ' ' M' ' 27' ' ' ASN . 93.8 p -162.27 117.26 1.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 118.873 1.336 . . . . 0.0 112.134 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . 0.529 ' ND2' ' O ' ' N' ' 25' ' ' GLY . 99.1 m-20 -23.33 144.83 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.769 -1.105 . . . . 0.0 113.194 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -120.24 -36.6 3.21 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 173.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.14 -70.2 2.98 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 112.275 -2.239 . . . . 0.0 112.584 178.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.46 74.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.533 0.666 . . . . 0.0 112.022 176.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . 0.411 ' CG2' ' O ' ' M' ' 31' ' ' ILE . 19.3 tt -128.58 108.94 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 CA-C-N 119.243 0.929 . . . . 0.0 109.313 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . 0.432 HD12 HG21 ' M' ' 32' ' ' ILE . 96.6 mt -114.48 109.55 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.592 -179.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.25 98.36 0.69 Allowed Glycine 0 N--CA 1.461 0.308 0 N-CA-C 106.154 -2.778 . . . . 0.0 106.154 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . 0.42 ' H ' HD22 ' N' ' 34' ' ' LEU . 82.5 mt -145.93 164.6 31.5 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 123.269 1.509 . . . . 0.0 113.888 -176.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.9 mmm -113.77 110.19 19.77 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 111.771 -2.468 . . . . 0.0 106.859 177.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -118.04 111.78 35.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 134.69 -131.52 5.92 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.02 -63.08 0.75 Allowed Glycine 0 CA--C 1.536 1.398 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.449 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 2.1 t -114.04 160.71 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-N 116.992 0.396 . . . . 0.0 110.05 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.449 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 21.8 m . . . . . 0 N--CA 1.469 0.48 0 CA-C-O 117.836 -1.078 . . . . 0.0 111.918 178.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.113 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -85.51 137.9 32.57 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -100.77 141.95 32.92 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.487 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -124.72 132.78 70.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.376 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 51.0 m170 -116.98 99.79 7.31 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' N ' ' N' ' 15' ' ' GLN . 23.1 t60 -154.01 165.82 34.96 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.594 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.665 HE21 ' NE2' ' O' ' 15' ' ' GLN . 13.4 pt20 -160.34 143.52 13.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.217 178.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -80.0 112.2 17.06 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.457 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 tt -120.98 117.92 28.53 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -125.72 131.83 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.09 0.471 . . . . 0.0 111.094 -179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -126.94 119.12 25.95 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 87.5 t80 -118.21 126.32 51.95 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.32 129.49 43.27 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 121.292 0.568 . . . . 0.0 112.355 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -88.65 115.99 26.58 Favored 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -87.04 47.6 1.53 Allowed 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -110.48 151.64 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 176.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . 0.529 ' O ' ' ND2' ' M' ' 27' ' ' ASN . . . 63.39 29.83 75.73 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.496 ' O ' ' O ' ' N' ' 27' ' ' ASN . 4.7 t -155.65 111.24 3.04 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 113.854 1.057 . . . . 0.0 113.854 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' N' ' 26' ' ' SER . 7.1 m120 -49.7 -164.75 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.178 176.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.59 ' NZ ' ' CG2' ' G' ' 39' ' ' VAL . 81.7 mttt 78.38 -41.17 0.3 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.543 1.137 . . . . 0.0 114.012 177.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.96 -68.28 3.45 Favored Glycine 0 CA--C 1.545 1.96 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.731 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.98 107.85 0.03 OUTLIER 'General case' 0 C--N 1.346 0.448 0 CA-C-N 117.576 0.688 . . . . 0.0 111.853 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . 0.437 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 0.2 OUTLIER -123.89 122.09 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 O-C-N 122.208 -0.307 . . . . 0.0 110.489 178.755 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 60.5 mt -114.36 116.15 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 110.39 2.22 Favored Glycine 0 N--CA 1.468 0.775 0 N-CA-C 106.179 -2.769 . . . . 0.0 106.179 177.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . 0.452 ' H ' HD22 ' O' ' 34' ' ' LEU . 76.5 mt -144.67 143.58 30.81 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -174.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 1.7 ttm -110.11 106.66 16.22 Favored 'General case' 0 N--CA 1.441 -0.895 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 173.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.548 ' C ' HE22 ' P' ' 15' ' ' GLN . 29.6 m -126.31 123.33 63.3 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.571 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 138.18 -113.58 0.99 Allowed Glycine 0 C--N 1.308 -1.011 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . 0.416 ' O ' ' CD1' ' B' ' 31' ' ' ILE . . . 73.08 -72.78 1.09 Allowed Glycine 0 CA--C 1.532 1.109 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.052 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 52.0 t -113.34 132.61 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 98.8 t . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.363 179.896 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.119 -1.593 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -112.85 138.4 49.74 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.993 0.425 . . . . 0.0 110.571 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . 0.548 ' O ' ' CE1' ' P' ' 13' ' ' HIS . 98.3 mt-10 -140.92 162.93 34.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.714 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . 0.554 ' CG1' ' H ' ' P' ' 12' ' ' VAL . 5.0 m -118.53 126.87 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.467 ' C ' ' CG ' ' O' ' 14' ' ' HIS . 10.3 m80 -129.92 136.23 49.24 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.329 0.585 . . . . 0.0 112.028 -178.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.691 ' CE1' ' H ' ' P' ' 14' ' ' HIS . 5.1 m-70 -156.97 176.0 13.35 Favored 'General case' 0 C--O 1.223 -0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.294 179.241 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.665 ' NE2' HE21 ' N' ' 15' ' ' GLN . 59.0 tt0 -152.96 140.11 19.38 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.267 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . 0.557 ' N ' ' CE1' ' N' ' 14' ' ' HIS . 88.2 tttt -94.45 110.89 22.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.167 -0.469 . . . . 0.0 112.106 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . 0.549 ' N ' ' CD2' ' O' ' 17' ' ' LEU . 0.7 OUTLIER -117.73 109.8 17.05 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 176.102 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -110.11 113.89 45.49 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -113.36 106.88 15.12 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.77 125.03 53.23 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.789 0.328 . . . . 0.0 110.553 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.58 122.73 28.04 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -149.32 -176.77 5.5 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.492 ' N ' ' OE1' ' P' ' 22' ' ' GLU . 96.7 m-20 66.22 50.32 1.39 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 113.365 -1.743 . . . . 0.0 112.298 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 67.0 t -82.45 146.43 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.91 -39.12 64.65 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 118.682 -1.723 . . . . 0.0 110.57 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.721 ' O ' ' O ' ' O' ' 27' ' ' ASN . 39.4 t -174.15 124.78 0.33 Allowed 'General case' 0 C--O 1.221 -0.436 0 CA-C-O 118.525 -0.75 . . . . 0.0 110.185 178.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.721 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.5 t-20 -2.62 145.99 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 178.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.417 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 93.4 mttt -159.03 30.93 0.21 Allowed 'General case' 0 N--CA 1.468 0.44 0 O-C-N 121.805 -0.56 . . . . 0.0 112.413 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.71 88.28 0.72 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 119.49 -1.338 . . . . 0.0 113.028 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 134.41 52.45 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.949 0.881 . . . . 0.0 109.873 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 4.5 tt -149.23 140.54 17.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.744 -175.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . 0.445 HD11 HG22 ' O' ' 32' ' ' ILE . 73.6 mt -110.57 109.86 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 176.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.54 101.85 0.96 Allowed Glycine 0 N--CA 1.469 0.855 0 N-CA-C 108.489 -1.845 . . . . 0.0 108.489 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . 0.452 HD22 ' H ' ' N' ' 34' ' ' LEU . 0.3 OUTLIER -141.92 158.83 43.32 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 122.962 1.363 . . . . 0.0 114.175 -177.052 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -112.16 112.71 24.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 111.618 -2.537 . . . . 0.0 106.315 175.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 88.6 t -119.68 111.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -177.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . 0.707 ' N ' HE22 ' Q' ' 15' ' ' GLN . . . 136.01 -131.67 5.81 Favored Glycine 0 C--N 1.319 -0.397 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.567 178.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.96 -63.26 0.75 Allowed Glycine 0 CA--C 1.541 1.66 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 55.9 t -126.95 133.34 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 96.6 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.723 179.9 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.554 ' H ' ' CG1' ' O' ' 12' ' ' VAL . 34.7 m . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 121.185 0.517 . . . . 0.0 111.455 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.548 ' CE1' ' O ' ' O' ' 11' ' ' GLU . 80.0 m-70 -147.48 104.62 3.65 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.024 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.691 ' H ' ' CE1' ' O' ' 14' ' ' HIS . 40.0 m-70 -148.74 159.43 44.14 Favored 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.734 178.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.571 HE22 ' N ' ' N' ' 37' ' ' GLY . 7.5 mt-30 -90.31 159.89 16.42 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 114.215 -1.357 . . . . 0.0 107.822 175.111 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.34 99.21 3.6 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.37 122.63 34.18 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.116 0.484 . . . . 0.0 110.525 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.44 114.31 45.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.47 ' CD2' ' CE1' ' Q' ' 19' ' ' PHE . 59.4 m-85 -112.36 108.01 17.03 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -112.78 124.11 51.85 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 137.05 34.74 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 113.837 1.051 . . . . 0.0 113.837 -178.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.492 ' OE1' ' N ' ' O' ' 23' ' ' ASP . 78.9 tt0 -81.6 116.94 21.58 Favored 'General case' 0 N--CA 1.462 0.149 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -138.34 50.28 1.89 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -176.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -81.85 148.4 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.625 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.485 ' O ' ' CB ' ' O' ' 27' ' ' ASN . . . 93.72 36.16 5.92 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 106.412 -2.675 . . . . 0.0 106.412 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.549 ' OG ' ' ND2' ' Q' ' 27' ' ' ASN . 21.9 p -76.05 102.62 5.75 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 122.443 1.116 . . . . 0.0 112.498 -174.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -96.87 -164.47 1.15 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 112.823 -1.99 . . . . 0.0 110.889 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt -48.74 -40.25 27.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.895 -1.048 . . . . 0.0 111.877 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.77 70.08 1.88 Allowed Glycine 0 CA--C 1.543 1.809 0 N-CA-C 114.937 0.735 . . . . 0.0 114.937 -174.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.36 111.04 6.81 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 104.969 -2.234 . . . . 0.0 104.969 176.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 57.6 mt -135.42 136.18 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -172.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . 0.438 HD11 HG23 ' P' ' 32' ' ' ILE . 3.0 mt -106.05 106.07 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.26 99.38 1.18 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 106.482 -2.647 . . . . 0.0 106.482 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 tp -128.43 123.59 34.11 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-O 122.419 1.104 . . . . 0.0 112.821 -176.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -98.47 104.35 16.38 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 175.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . 0.493 ' CG1' ' O ' ' P' ' 36' ' ' VAL . 8.7 p -119.18 113.76 42.43 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -177.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.22 -123.85 1.21 Allowed Glycine 0 C--N 1.309 -0.958 0 C-N-CA 118.95 -1.595 . . . . 0.0 111.79 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.525 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 81.26 -67.72 3.57 Favored Glycine 0 CA--C 1.536 1.354 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -178.087 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.439 ' CG1' ' OD1' ' D' ' 27' ' ' ASN . 67.9 t -136.09 155.61 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.651 179.976 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -108.56 134.77 50.85 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.751 0.31 . . . . 0.0 110.313 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -88.87 117.96 28.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.878 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -127.98 135.51 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 120.949 0.404 . . . . 0.0 110.991 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.488 ' N ' ' CD2' ' Q' ' 13' ' ' HIS . 2.0 m-70 -136.18 118.29 15.44 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.628 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.621 ' CD2' ' H ' ' R' ' 14' ' ' HIS . 22.7 m80 -147.23 159.6 43.45 Favored 'General case' 0 C--O 1.219 -0.534 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.29 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.707 HE22 ' N ' ' O' ' 37' ' ' GLY . 0.7 OUTLIER -90.25 159.59 16.61 Favored 'General case' 0 C--N 1.334 -0.084 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 176.145 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 66.5 tttt -140.2 104.34 4.79 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 120.313 -0.555 . . . . 0.0 109.697 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -128.88 126.23 39.29 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 121.724 0.773 . . . . 0.0 111.006 179.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 84.8 t -114.3 113.63 44.32 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 114.721 -1.127 . . . . 0.0 108.837 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.47 ' CE1' ' CD2' ' P' ' 19' ' ' PHE . 59.5 m-85 -110.76 103.65 12.21 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 178.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -112.45 125.09 53.84 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.888 -178.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.68 143.61 35.2 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -84.64 137.37 33.31 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 120.166 -0.613 . . . . 0.0 109.619 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 35.8 p-10 -177.75 50.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.159 -177.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -81.8 149.27 4.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.904 1.335 . . . . 0.0 113.828 -174.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.43 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 93.09 36.7 5.9 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 111.784 -2.462 . . . . 0.0 112.887 178.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . 0.43 ' OG ' ' O ' ' Q' ' 25' ' ' GLY . 3.2 p 72.65 120.18 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 118.621 -0.704 . . . . 0.0 110.546 175.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.549 ' ND2' ' OG ' ' P' ' 26' ' ' SER . 1.6 m120 -83.11 160.99 21.77 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 116.824 -1.95 . . . . 0.0 108.057 176.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -48.74 -39.79 26.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.573 0.702 . . . . 0.0 111.381 176.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.23 67.46 0.04 OUTLIER Glycine 0 CA--C 1.541 1.711 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.075 -177.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 152.18 43.89 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 118.449 1.125 . . . . 0.0 112.002 -176.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 6.3 mt -113.3 129.19 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.328 -177.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 99.8 mt -124.69 116.06 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.72 117.02 3.16 Favored Glycine 0 N--CA 1.47 0.951 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 29.2 tp -124.55 120.64 32.53 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 93.7 mtp -135.17 144.94 47.3 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -178.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.403 HG11 ' H ' ' Q' ' 37' ' ' GLY . 2.9 t -118.82 164.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.403 ' H ' HG11 ' Q' ' 36' ' ' VAL . . . -168.68 93.68 0.1 Allowed Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.056 -1.068 . . . . 0.0 111.119 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.45 -81.86 0.11 Allowed Glycine 0 CA--C 1.536 1.347 0 C-N-CA 120.473 -0.87 . . . . 0.0 112.465 177.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -157.68 147.57 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.158 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.552 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.95 133.09 51.23 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.876 0.37 . . . . 0.0 110.609 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 21.1 pt-20 -77.99 150.65 33.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.762 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -123.69 131.62 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.105 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.428 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.0 OUTLIER -152.22 112.67 4.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.487 -179.656 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.621 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 75.0 m80 -149.81 164.43 35.35 Favored 'General case' 0 C--O 1.22 -0.472 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.441 ' OE1' ' OE1' ' Q' ' 15' ' ' GLN . 60.0 mt-30 -89.94 159.5 16.88 Favored 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 120.317 -0.553 . . . . 0.0 110.401 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 61.8 tttp -139.55 115.19 10.02 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.456 0.646 . . . . 0.0 110.332 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 1.2 mp -135.46 125.54 26.04 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.796 179.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 3.5 p -112.96 116.48 52.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 176.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.431 ' CE1' ' CD2' ' Q' ' 19' ' ' PHE . 55.3 m-85 -105.17 104.77 14.57 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -123.73 124.37 42.58 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.997 0.903 . . . . 0.0 112.099 -177.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.65 130.2 54.03 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -70.21 110.15 5.04 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 118.813 -1.155 . . . . 0.0 110.377 -177.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 179.57 48.62 0.0 OUTLIER 'General case' 0 C--N 1.342 0.277 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.42 ' CG1' ' N ' ' R' ' 25' ' ' GLY . 69.0 t -72.85 160.34 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 117.324 -1.75 . . . . 0.0 108.644 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . 0.42 ' N ' ' CG1' ' R' ' 24' ' ' VAL . . . 110.35 -33.27 6.06 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.3 m -72.2 129.57 38.77 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 113.028 -1.586 . . . . 0.0 111.806 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . 0.67 ' O ' ' N ' ' R' ' 29' ' ' GLY . 98.6 m-20 -90.86 -161.91 0.86 Allowed 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.22 47.58 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . 0.67 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.28 56.9 0.9 Allowed Glycine 0 CA--C 1.541 1.686 0 CA-C-N 119.301 0.955 . . . . 0.0 111.997 178.184 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.97 168.61 13.73 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 15.9 tt -116.15 110.28 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.439 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.5 mt -117.11 128.63 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.542 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.14 115.07 2.44 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.46 117.4 25.87 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 8.9 ttp -141.19 124.38 16.46 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.364 0.602 . . . . 0.0 111.126 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.32 111.68 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 120.125 -0.63 . . . . 0.0 111.753 -179.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.8 132.17 10.9 Favored Glycine 0 CA--C 1.518 0.273 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 176.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . 0.412 ' O ' ' C ' ' R' ' 39' ' ' VAL . . . 109.49 63.24 0.53 Allowed Glycine 0 N--CA 1.474 1.18 0 CA-C-N 118.201 1.0 . . . . 0.0 112.95 179.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' R' ' 38' ' ' GLY . 41.4 t -32.17 151.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 117.285 0.543 . . . . 0.0 112.287 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . 0.477 ' C ' ' HZ2' ' D' ' 28' ' ' LYS . 28.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.765 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.45 ' O ' ' OE1' ' B' ' 11' ' ' GLU . 95.7 mt-10 . . . . . 0 N--CA 1.464 0.239 0 CA-C-O 121.029 0.443 . . . . 0.0 110.419 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 m -137.27 162.13 33.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.966 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -145.13 135.53 24.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.583 0.23 . . . . 0.0 110.785 179.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.572 ' CD2' ' N ' ' A' ' 15' ' ' GLN . 20.8 t60 -158.06 165.18 35.7 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.972 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 68.2 tp60 -158.97 142.45 14.89 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 121.027 0.442 . . . . 0.0 109.97 177.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -82.51 124.16 29.85 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.473 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.0 mt -127.18 119.52 26.63 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -141.49 146.45 23.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.363 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -147.52 141.2 25.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.11 0.481 . . . . 0.0 111.427 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.476 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 49.6 p90 -115.34 132.64 56.55 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.05 126.93 46.15 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 -177.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -128.14 -140.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 . . . . . 0 CA--C 1.538 0.518 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.659 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.5 p30 . . . . . 0 C--O 1.232 0.18 0 N-CA-C 115.159 1.54 . . . . 0.0 115.159 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.439 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 96.0 mttt -55.86 -37.48 68.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 112.081 -2.327 . . . . 0.0 112.409 -179.055 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.05 77.72 0.4 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 112.079 -0.408 . . . . 0.0 112.079 -175.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.39 141.67 41.43 Favored 'General case' 0 C--O 1.243 0.746 0 CA-C-O 123.736 1.731 . . . . 0.0 113.012 -177.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -126.76 127.63 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.739 -2.482 . . . . 0.0 108.406 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.452 ' O ' ' O ' ' B' ' 33' ' ' GLY . 80.8 mt -100.9 105.66 18.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.07 96.39 1.15 Allowed Glycine 0 CA--C 1.505 -0.589 0 N-CA-C 104.385 -3.486 . . . . 0.0 104.385 176.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 51.6 tp -148.2 159.21 44.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 123.002 1.382 . . . . 0.0 112.969 -174.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.487 ' CE ' ' SD ' ' B' ' 35' ' ' MET . 17.0 mtp -119.52 117.51 28.59 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.482 179.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -119.24 111.85 35.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 177.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.22 -131.99 8.14 Favored Glycine 0 C--N 1.315 -0.602 0 N-CA-C 107.543 -2.223 . . . . 0.0 107.543 -177.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' B' ' 39' ' ' VAL . . . 87.05 -63.72 3.99 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 120.126 -1.035 . . . . 0.0 111.608 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -108.26 179.89 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 120.847 0.356 . . . . 0.0 110.106 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 85.9 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.852 -1.071 . . . . 0.0 110.959 178.97 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.17 132.13 54.41 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.31 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' O ' ' A' ' 11' ' ' GLU . 80.7 mm-40 -124.63 122.77 38.46 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.439 ' CG1' ' C ' ' C' ' 12' ' ' VAL . 3.6 t -112.92 100.27 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.983 0.42 . . . . 0.0 110.52 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 12.2 p-80 -138.82 145.19 39.76 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.747 -178.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.548 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 2.9 p80 -146.33 160.35 42.14 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.482 0.658 . . . . 0.0 111.98 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' OE1' ' C' ' 15' ' ' GLN . 85.9 mt-30 -90.3 159.67 16.53 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.178 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -139.97 108.05 5.75 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.49 130.84 53.48 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 120.875 0.369 . . . . 0.0 111.021 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.84 130.88 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.713 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -127.26 129.64 48.11 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -128.68 124.19 35.05 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.05 134.37 54.78 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.173 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.484 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 81.9 tt0 -161.74 159.8 27.65 Favored 'General case' 0 CA--C 1.55 0.969 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 -178.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' B' ' 24' ' ' VAL . 19.4 t70 112.83 -70.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 127.055 2.142 . . . . 0.0 110.854 177.205 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.524 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.7 t -58.77 -122.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 173.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.427 ' CA ' ' O ' ' C' ' 23' ' ' ASP . . . 139.12 -34.94 2.02 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-O 118.089 -1.395 . . . . 0.0 116.262 172.651 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -80.43 119.52 23.23 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 121.355 2.578 . . . . 0.0 106.59 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 28' ' ' LYS . 3.0 m120 -89.78 157.7 17.83 Favored 'General case' 0 C--N 1.344 0.368 0 C-N-CA 116.11 -2.236 . . . . 0.0 108.181 176.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -48.31 -40.53 25.39 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 122.394 1.092 . . . . 0.0 110.983 174.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 67.64 0.04 OUTLIER Glycine 0 CA--C 1.549 2.21 0 CA-C-N 112.956 -1.929 . . . . 0.0 110.5 -174.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.07 141.89 52.74 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 120.09 1.945 . . . . 0.0 115.168 -172.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 19.8 mt -136.23 134.09 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 113.159 -1.837 . . . . 0.0 113.106 -175.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.92 103.0 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 174.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -103.69 103.88 2.4 Favored Glycine 0 CA--C 1.507 -0.446 0 N-CA-C 104.309 -3.516 . . . . 0.0 104.309 175.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 17.8 tp -146.12 147.66 31.79 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 118.272 -1.371 . . . . 0.0 113.538 -173.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.487 ' SD ' ' CE ' ' A' ' 35' ' ' MET . 3.9 ttm -113.13 116.37 29.74 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-N 112.815 -1.993 . . . . 0.0 107.824 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 37.8 t -118.95 123.73 71.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.76 -114.15 2.03 Favored Glycine 0 C--N 1.315 -0.591 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.535 ' O ' ' CD1' ' H' ' 31' ' ' ILE . . . 81.02 -72.65 2.7 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.486 ' CG2' ' O ' ' A' ' 38' ' ' GLY . 24.8 t -124.54 163.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.532 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 20.7 m . . . . . 0 N--CA 1.473 0.689 0 CA-C-O 117.782 -1.104 . . . . 0.0 111.694 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.97 135.59 50.59 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -138.83 144.9 39.46 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.439 ' C ' ' CG1' ' B' ' 12' ' ' VAL . 27.6 m -138.19 164.43 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-O 120.963 0.411 . . . . 0.0 111.807 -179.029 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.423 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 4.2 p-80 -129.48 132.92 47.04 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.301 0.572 . . . . 0.0 112.131 -178.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.538 ' CG ' ' O ' ' D' ' 14' ' ' HIS . 17.7 p-80 -157.26 169.52 24.56 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.066 178.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' OE1' ' B' ' 15' ' ' GLN . 99.5 mm-40 -89.67 156.61 18.45 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.112 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -141.36 115.41 9.25 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.993 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' D' ' 17' ' ' LEU . 4.6 mp -135.24 118.8 16.96 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 122.018 0.913 . . . . 0.0 111.029 178.153 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -106.76 117.51 52.7 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.402 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 54.9 m-85 -109.93 99.73 8.81 Favored 'General case' 0 N--CA 1.447 -0.582 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -109.79 126.67 54.01 Favored 'General case' 0 C--O 1.241 0.626 0 CA-C-O 121.41 0.624 . . . . 0.0 111.058 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.17 113.26 15.49 Favored 'General case' 0 C--O 1.244 0.778 0 CA-C-O 121.884 0.85 . . . . 0.0 110.806 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.424 ' OE2' ' OD1' ' C' ' 23' ' ' ASP . 0.4 OUTLIER -86.17 103.3 14.68 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.065 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.427 ' O ' ' CA ' ' B' ' 25' ' ' GLY . 35.5 m-20 50.84 50.15 19.61 Favored 'General case' 0 C--O 1.214 -0.793 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.47 -177.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.623 ' CG2' ' H ' ' C' ' 25' ' ' GLY . 9.9 p -160.1 -174.22 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.094 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.623 ' H ' ' CG2' ' C' ' 24' ' ' VAL . . . 59.78 26.82 63.27 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.777 178.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' C' ' 27' ' ' ASN . 62.8 m -166.19 -145.94 0.08 Allowed 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' C' ' 26' ' ' SER . 10.6 m-20 55.48 142.25 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 120.906 0.384 . . . . 0.0 111.797 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.713 ' H ' ' CB ' ' D' ' 26' ' ' SER . 71.1 mmtt 62.47 46.06 5.96 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 61.08 0.79 Allowed Glycine 0 N--CA 1.474 1.204 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.083 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -101.87 119.3 38.56 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-O 121.567 0.698 . . . . 0.0 109.66 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.421 HG23 HD11 ' C' ' 31' ' ' ILE . 3.6 tt -137.07 136.34 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 120.021 -0.672 . . . . 0.0 112.438 -177.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.412 HD13 HG23 ' C' ' 32' ' ' ILE . 63.5 mt -107.09 107.42 22.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 176.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.06 100.95 2.01 Favored Glycine 0 C--O 1.237 0.327 0 N-CA-C 104.89 -3.284 . . . . 0.0 104.89 175.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -133.25 138.08 46.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.99 1.376 . . . . 0.0 114.314 -174.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -109.14 110.75 22.07 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 175.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 25.0 t -122.98 123.16 67.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 118.429 0.559 . . . . 0.0 109.529 -177.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.5 -113.19 0.65 Allowed Glycine 0 C--N 1.315 -0.59 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.964 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 74.05 -72.98 1.32 Allowed Glycine 0 CA--C 1.548 2.122 0 CA-C-N 114.863 -0.669 . . . . 0.0 111.641 -177.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -131.51 136.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.404 ' O ' ' OXT' ' D' ' 40' ' ' VAL . 73.7 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.373 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . 0.462 ' CG1' ' N ' ' D' ' 13' ' ' HIS . 68.4 t . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.532 ' CE1' ' O ' ' B' ' 40' ' ' VAL . 2.3 t-80 -63.35 103.86 0.55 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.604 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 12.6 t60 -146.72 159.76 43.08 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.536 -178.158 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.604 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 36.1 tp60 -84.65 157.97 20.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -178.635 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -159.56 100.23 1.47 Allowed 'General case' 0 C--N 1.315 -0.913 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.39 178.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . 0.409 ' HA ' ' O ' ' C' ' 17' ' ' LEU . 6.2 mt -132.8 136.13 46.1 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -120.59 124.23 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.955 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 37.9 m-85 -117.82 106.18 12.74 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.485 ' CZ ' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -122.17 129.45 52.31 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -176.604 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.19 114.35 9.08 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.952 0.882 . . . . 0.0 110.624 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.401 ' HB2' ' H ' ' C' ' 23' ' ' ASP . 95.5 mt-10 -92.65 -174.74 3.74 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 54.3 t0 31.17 52.23 0.16 Allowed 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.823 1.786 . . . . 0.0 115.823 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.56 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 86.6 t -64.96 145.5 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 118.734 -1.187 . . . . 0.0 108.172 177.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.84 -24.35 0.73 Allowed Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.713 ' CB ' ' H ' ' C' ' 28' ' ' LYS . 4.8 t -72.09 160.17 32.93 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 122.311 1.053 . . . . 0.0 112.785 -177.334 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.711 ' O ' ' N ' ' D' ' 29' ' ' GLY . 97.8 m-20 -91.68 -130.06 0.11 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.384 -1.735 . . . . 0.0 110.159 -178.249 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -48.49 54.94 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.931 1.292 . . . . 0.0 112.317 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . 0.711 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -110.28 -48.79 0.74 Allowed Glycine 0 CA--C 1.546 1.971 0 C-N-CA 124.529 1.062 . . . . 0.0 113.808 -176.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.71 113.61 20.5 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.56 130.0 64.69 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 CA-C-N 112.453 -2.158 . . . . 0.0 111.339 178.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.447 HG21 HD12 ' D' ' 32' ' ' ILE . 47.6 mt -108.22 109.77 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 175.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.54 104.06 2.54 Favored Glycine 0 N--CA 1.462 0.395 0 N-CA-C 104.145 -3.582 . . . . 0.0 104.145 174.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 25.0 tp -133.88 128.18 34.07 Favored 'General case' 0 C--O 1.246 0.881 0 N-CA-C 116.477 2.029 . . . . 0.0 116.477 -172.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -104.38 111.54 24.22 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-N 112.793 -2.003 . . . . 0.0 107.377 174.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' E' ' 36' ' ' VAL . 17.3 t -109.43 143.9 18.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.745 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 168.31 -101.95 0.18 Allowed Glycine 0 C--N 1.294 -1.766 0 C-N-CA 118.818 -1.658 . . . . 0.0 111.462 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.416 ' O ' ' O ' ' D' ' 39' ' ' VAL . . . 42.48 72.16 0.32 Allowed Glycine 0 N--CA 1.466 0.658 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -177.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.536 ' C ' ' HZ2' ' I' ' 28' ' ' LYS . 92.2 t -36.2 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -176.556 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.441 ' N ' ' CG1' ' D' ' 39' ' ' VAL . 19.7 m . . . . . 0 C--O 1.222 -0.386 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.593 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.73 136.59 47.22 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.817 0.341 . . . . 0.0 110.436 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.31 120.88 41.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.792 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.45 ' O ' ' CG1' ' D' ' 12' ' ' VAL . 33.8 t -112.08 95.32 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 121.189 0.518 . . . . 0.0 111.241 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 5.4 t-80 -118.65 109.97 16.76 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.26 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.634 ' CE1' ' N ' ' F' ' 14' ' ' HIS . 43.0 m-70 -138.13 165.04 27.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.213 0.53 . . . . 0.0 110.7 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -90.26 151.62 21.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.401 ' H ' ' HB3' ' D' ' 15' ' ' GLN . 88.8 tttt -149.68 107.46 3.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.526 178.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.7 mp -129.07 120.59 26.22 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.15 121.21 60.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.95 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.503 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 30.5 m-85 -116.34 100.77 8.13 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 177.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.485 ' CD1' ' CZ ' ' D' ' 20' ' ' PHE . 14.3 t80 -121.68 134.9 54.97 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -177.281 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.501 ' O ' ' CB ' ' F' ' 21' ' ' ALA . . . -160.3 -178.36 6.89 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 119.167 -1.013 . . . . 0.0 113.691 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.56 ' OE1' ' N ' ' D' ' 24' ' ' VAL . 34.6 tt0 -68.07 159.98 29.79 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.94 -178.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 t0 175.65 60.26 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.798 0.839 . . . . 0.0 109.472 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 4.7 t -81.44 -113.36 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 116.956 -1.497 . . . . 0.0 111.305 -171.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.73 -42.12 47.69 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 114.839 -3.553 . . . . 0.0 115.4 -171.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' E' ' 27' ' ' ASN . 35.9 t -156.7 110.39 2.67 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 121.376 2.588 . . . . 0.0 114.298 175.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' E' ' 26' ' ' SER . 28.7 t-20 -55.69 162.83 1.55 Allowed 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 172.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -58.53 -42.65 88.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 122.127 2.24 . . . . 0.0 110.265 175.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 64.27 0.04 OUTLIER Glycine 0 CA--C 1.551 2.305 0 CA-C-N 114.104 -1.407 . . . . 0.0 111.856 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.447 ' O ' ' CB ' ' F' ' 30' ' ' ALA . . . -72.25 161.29 31.06 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 119.344 1.572 . . . . 0.0 112.461 -176.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.481 ' CG2' ' OXT' ' Q' ' 40' ' ' VAL . 97.9 mt -134.08 136.63 53.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-O 121.421 0.629 . . . . 0.0 112.472 -177.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 98.0 mt -130.6 129.98 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.929 -0.482 . . . . 0.0 111.702 -179.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.95 114.26 2.47 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 20.4 mt -124.75 124.01 41.22 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 110.183 -0.302 . . . . 0.0 110.183 -177.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 88.5 mtp -130.3 134.34 47.14 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 119.9 -0.72 . . . . 0.0 112.553 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.436 HG23 ' H ' ' F' ' 37' ' ' GLY . 0.8 OUTLIER -91.85 155.35 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 177.468 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.421 ' H ' ' HA2' ' D' ' 37' ' ' GLY . . . -102.96 102.8 2.3 Favored Glycine 0 CA--C 1.529 0.968 0 N-CA-C 112.256 -0.338 . . . . 0.0 112.256 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 52.58 -73.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.639 0 N-CA-C 115.009 0.764 . . . . 0.0 115.009 178.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.416 ' N ' ' O ' ' E' ' 37' ' ' GLY . 40.9 t . . . . . 0 N--CA 1.481 1.1 0 CA-C-N 118.211 1.005 . . . . 0.0 111.222 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 CA--C 1.529 0.136 0 CA-C-O 120.769 0.318 . . . . 0.0 110.334 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.558 ' C ' ' HE2' ' E' ' 14' ' ' HIS . 2.7 t -108.21 111.01 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-O 121.163 0.506 . . . . 0.0 110.503 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' N ' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -145.23 117.72 8.54 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.209 -179.689 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.634 ' N ' ' CE1' ' E' ' 14' ' ' HIS . 79.5 m80 -156.97 169.4 24.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.447 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.745 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.3 tt0 -89.67 155.78 19.0 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -141.39 116.32 9.84 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.557 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.06 121.75 18.56 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 19.7 t -106.11 117.11 51.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.081 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' CD1' ' F' ' 20' ' ' PHE . 11.2 m-85 -116.05 98.2 6.5 Favored 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.539 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 58.1 m-85 -152.08 173.65 14.66 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 122.806 1.288 . . . . 0.0 112.315 -178.235 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' E' ' 21' ' ' ALA . . . -152.11 155.18 37.36 Favored 'General case' 0 N--CA 1.435 -1.189 0 CA-C-N 114.101 -1.408 . . . . 0.0 109.897 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -75.52 137.78 41.1 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -176.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 . . . . . 0 N--CA 1.462 0.146 0 CA-C-N 114.112 -1.404 . . . . 0.0 113.599 177.445 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.447 ' CB ' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 90.6 mt -121.13 131.84 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.601 -178.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -122.61 117.82 53.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.331 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.66 126.81 6.98 Favored Glycine 0 N--CA 1.469 0.851 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 tp -131.83 114.45 14.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 90.6 mtp -122.01 135.49 54.84 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 120.617 -0.433 . . . . 0.0 112.104 -178.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 51.2 t -108.28 132.69 55.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.208 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.803 179.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.6 112.4 4.23 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.533 -0.627 . . . . 0.0 111.533 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.98 -70.41 0.0 OUTLIER Glycine 0 CA--C 1.538 1.484 0 N-CA-C 114.011 0.364 . . . . 0.0 114.011 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.542 ' N ' ' O ' ' F' ' 37' ' ' GLY . 46.3 t -123.97 132.68 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-O 121.586 0.708 . . . . 0.0 111.885 -178.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' F' ' 39' ' ' VAL . 11.6 t . . . . . 0 C--O 1.218 -0.571 0 CA-C-O 117.785 -1.102 . . . . 0.0 110.381 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . 0.476 ' CG1' ' O ' ' H' ' 12' ' ' VAL . 12.3 m . . . . . 0 N--CA 1.469 0.52 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 51.7 m-70 -145.31 130.31 18.34 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.3 0.571 . . . . 0.0 111.965 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 42.2 p-80 -152.74 172.4 16.75 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.478 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -128.97 151.01 50.15 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -95.22 128.7 42.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.688 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -126.96 117.92 23.48 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -133.95 134.27 55.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -144.77 146.9 32.36 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.46 0.648 . . . . 0.0 111.452 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.521 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 54.6 p90 -129.23 129.61 45.22 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.046 179.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.3 120.81 41.67 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.131 0.491 . . . . 0.0 112.085 -178.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -157.98 151.72 23.83 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 . . . . . 0 N--CA 1.467 0.387 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.812 179.481 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 121.526 0.679 . . . . 0.0 112.814 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -110.59 -39.21 4.96 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.96 -69.41 3.09 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 112.415 -2.175 . . . . 0.0 111.702 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.78 87.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 117.59 0.695 . . . . 0.0 111.239 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -133.32 113.71 19.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.541 0 O-C-N 121.765 -0.584 . . . . 0.0 109.702 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 66.8 mt -108.21 110.72 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.13 97.54 0.63 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 105.298 -3.121 . . . . 0.0 105.298 177.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.422 ' O ' ' CD1' ' H' ' 34' ' ' LEU . 56.8 tp -160.63 159.41 30.4 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 118.18 -1.408 . . . . 0.0 111.89 -175.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.417 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 23.8 mtp -122.75 121.91 37.46 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.418 -1.264 . . . . 0.0 109.19 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -118.32 103.1 14.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.69 -153.05 24.57 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . 0.437 ' O ' ' CG2' ' H' ' 39' ' ' VAL . . . 111.82 -56.2 0.48 Allowed Glycine 0 CA--C 1.542 1.779 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.86 160.8 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.756 -1.116 . . . . 0.0 110.395 179.316 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -113.61 135.65 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.739 0.304 . . . . 0.0 110.364 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -109.11 116.02 31.15 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.497 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . 0.476 ' O ' ' CG1' ' G' ' 12' ' ' VAL . 6.6 t -116.14 95.01 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 120.916 0.389 . . . . 0.0 110.092 179.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.538 ' ND1' ' O ' ' G' ' 13' ' ' HIS . 17.9 p-80 -147.84 165.68 29.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.871 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.632 ' HE2' ' CG2' ' I' ' 12' ' ' VAL . 0.1 OUTLIER -107.73 161.61 14.73 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.361 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.87 159.64 16.87 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -140.0 101.27 4.13 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.8 tp -127.97 121.9 31.03 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.115 0.483 . . . . 0.0 110.611 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.32 126.59 72.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.201 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.625 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -131.07 123.0 27.72 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.44 ' CZ ' ' CG ' ' H' ' 22' ' ' GLU . 19.5 t80 -119.5 126.11 50.5 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.34 121.56 38.87 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -177.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.44 ' CG ' ' CZ ' ' H' ' 20' ' ' PHE . 58.0 mt-10 -116.82 98.06 6.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 114.052 -1.431 . . . . 0.0 107.348 176.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.482 ' O ' HG11 ' I' ' 24' ' ' VAL . 96.8 m-20 -112.38 51.5 0.81 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 84.7 t -75.44 144.58 11.87 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 O-C-N 124.118 0.887 . . . . 0.0 110.61 -175.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.61 -38.31 3.37 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-N 113.84 -1.527 . . . . 0.0 110.562 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 26' ' ' SER . . . . . 0.46 ' O ' ' O ' ' H' ' 27' ' ' ASN . 74.8 m -120.48 -112.18 0.33 Allowed 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.466 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 51.1 t-20 52.13 152.9 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.327 1.051 . . . . 0.0 110.908 -176.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.466 ' N ' ' OD1' ' H' ' 27' ' ' ASN . 67.6 mttm -140.48 -28.88 0.7 Allowed 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 115.189 1.552 . . . . 0.0 115.189 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.01 88.08 0.11 Allowed Glycine 0 N--CA 1.474 1.216 0 CA-C-O 119.471 -0.627 . . . . 0.0 113.74 -170.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.421 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -79.07 128.46 33.3 Favored 'General case' 0 CA--C 1.545 0.787 0 CA-C-O 123.308 1.528 . . . . 0.0 112.682 -175.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 30.7 mt -137.32 139.66 43.43 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 112.638 -2.074 . . . . 0.0 113.399 -176.067 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 80.6 mt -109.48 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 175.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.37 99.3 0.82 Allowed Glycine 0 C--O 1.237 0.308 0 N-CA-C 105.573 -3.011 . . . . 0.0 105.573 176.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.43 ' HB3' ' CD2' ' I' ' 34' ' ' LEU . 8.4 tp -142.4 140.89 32.16 Favored 'General case' 0 C--O 1.242 0.669 0 CA-C-O 123.007 1.384 . . . . 0.0 113.251 -174.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.1 mtp -107.47 111.75 24.2 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 112.315 -2.221 . . . . 0.0 108.387 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.585 ' CG1' ' NE2' ' J' ' 15' ' ' GLN . 2.0 t -117.77 122.99 71.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.66 -113.18 0.6 Allowed Glycine 0 C--N 1.313 -0.731 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.67 -73.28 2.66 Favored Glycine 0 CA--C 1.533 1.171 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.479 ' O ' ' C ' ' H' ' 40' ' ' VAL . 34.9 t -133.86 157.1 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.479 ' C ' ' O ' ' H' ' 39' ' ' VAL . 70.1 t . . . . . 0 N--CA 1.471 0.577 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.295 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -112.16 136.04 52.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.858 0.361 . . . . 0.0 110.534 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -99.6 109.19 21.71 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.379 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.632 ' CG2' ' HE2' ' H' ' 14' ' ' HIS . 2.4 m -139.75 162.44 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.905 -178.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.425 ' CD2' ' N ' ' I' ' 13' ' ' HIS . 2.8 m-70 -138.86 97.29 3.29 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 119.264 -0.398 . . . . 0.0 110.432 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.557 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 7.2 m170 -122.36 156.91 32.95 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 119.827 -0.749 . . . . 0.0 112.28 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.537 ' OE1' ' NE2' ' J' ' 15' ' ' GLN . 2.9 tt0 -90.44 159.59 16.47 Favored 'General case' 0 C--N 1.341 0.22 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 175.609 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.66 106.45 5.14 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 176.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 80.0 mt -117.21 114.97 24.41 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.045 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -114.29 103.26 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 14.5 m-30 -114.42 113.87 25.08 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -116.76 131.3 56.99 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -178.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.19 138.76 50.76 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 117.81 0.277 . . . . 0.0 111.184 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -76.67 176.38 8.46 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 119.237 3.051 . . . . 0.0 119.237 -174.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -72.49 50.11 0.23 Allowed 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 128.892 2.877 . . . . 0.0 114.132 -178.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.669 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 1.8 t -74.77 -143.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -175.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.669 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -95.97 36.7 3.72 Favored Glycine 0 N--CA 1.465 0.573 0 C-N-CA 129.274 3.321 . . . . 0.0 107.706 -173.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.421 ' H ' ' C ' ' I' ' 24' ' ' VAL . 11.1 t -74.25 104.62 5.1 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 109.975 -3.113 . . . . 0.0 109.995 -176.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.708 ' O ' ' C ' ' I' ' 28' ' ' LYS . 86.1 m-20 -93.0 -149.23 0.26 Allowed 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 101.107 -3.664 . . . . 0.0 101.107 -176.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.708 ' C ' ' O ' ' I' ' 27' ' ' ASN . 82.3 tttt -32.64 -42.66 0.08 Allowed 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 124.173 3.17 . . . . 0.0 106.235 -170.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 91.29 -61.42 2.9 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 121.583 3.393 . . . . 0.0 121.583 159.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.22 117.11 24.58 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 -171.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.488 ' CD1' ' O ' ' C' ' 38' ' ' GLY . 3.5 mt -127.28 117.12 46.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 174.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 25.2 mt -100.22 112.93 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.03 100.12 1.07 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 106.548 -2.621 . . . . 0.0 106.548 177.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.43 ' CD2' ' HB3' ' H' ' 34' ' ' LEU . 98.0 mt -131.79 145.04 51.36 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.454 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -118.93 102.43 8.77 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 174.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.457 ' CG2' ' NE2' ' K' ' 15' ' ' GLN . 8.0 p -123.07 122.9 66.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.616 0.722 . . . . 0.0 109.88 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.29 -113.59 0.75 Allowed Glycine 0 C--N 1.31 -0.876 0 N-CA-C 107.57 -2.212 . . . . 0.0 107.57 -179.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.77 -72.37 1.05 Allowed Glycine 0 CA--C 1.535 1.303 0 C-N-CA 121.214 -0.517 . . . . 0.0 113.533 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 21.4 t -132.55 160.95 42.24 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 121.01 0.433 . . . . 0.0 111.698 -177.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.528 ' OXT' ' CE1' ' K' ' 13' ' ' HIS . 10.9 p . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.4 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -71.02 127.32 32.16 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -142.97 156.07 44.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.967 0.413 . . . . 0.0 110.608 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.591 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -130.78 134.62 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 97.6 m-70 -120.83 124.85 46.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.46 -178.25 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' CE1' ' K' ' 14' ' ' HIS . 51.3 m-70 -151.58 169.82 21.18 Favored 'General case' 0 C--O 1.222 -0.382 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.585 ' NE2' ' CG1' ' H' ' 36' ' ' VAL . 8.5 tt0 -137.69 150.17 47.11 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -115.7 113.89 24.1 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.692 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 89.5 mt -108.84 107.34 17.71 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 176.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 t -110.96 102.53 14.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.456 ' CD2' ' CE1' ' K' ' 19' ' ' PHE . 12.4 m-85 -113.05 112.0 23.1 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -114.98 125.98 54.23 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 116.636 -0.256 . . . . 0.0 110.873 -178.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.49 129.54 33.28 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.666 0.745 . . . . 0.0 111.862 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -82.32 116.89 22.03 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -124.96 51.78 1.63 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -176.138 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -75.07 143.31 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.82 0 N-CA-C 103.047 -2.946 . . . . 0.0 103.047 175.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.58 37.57 3.7 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 105.768 -2.933 . . . . 0.0 105.768 -172.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.458 ' OG ' ' OD1' ' K' ' 27' ' ' ASN . 5.3 t -69.48 105.11 2.51 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 113.522 -1.339 . . . . 0.0 107.94 -177.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -117.85 -151.88 0.49 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 113.149 -1.841 . . . . 0.0 113.522 -172.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -37.54 -40.81 0.41 Allowed 'General case' 0 CA--C 1.551 0.999 0 N-CA-C 119.736 3.236 . . . . 0.0 119.736 -171.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.421 ' O ' ' CE ' ' I' ' 28' ' ' LYS . . . -171.29 69.47 0.12 Allowed Glycine 0 N--CA 1.484 1.844 0 C-N-CA 115.193 -3.384 . . . . 0.0 119.44 -174.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.39 140.73 46.81 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 120.307 2.053 . . . . 0.0 109.172 177.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.507 HG21 ' H ' ' K' ' 31' ' ' ILE . 10.1 pt -146.62 153.6 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 96.4 mt -114.56 128.47 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.305 176.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.36 112.55 0.97 Allowed Glycine 0 N--CA 1.462 0.42 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.415 ' C ' ' CD1' ' J' ' 34' ' ' LEU . 3.6 pp -164.65 165.63 20.78 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 117.588 -1.645 . . . . 0.0 114.986 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 70.6 mmm -113.87 117.56 31.75 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 112.746 -2.024 . . . . 0.0 110.653 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 15.3 t -111.5 102.51 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 N-CA-C 109.246 -0.649 . . . . 0.0 109.246 178.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.673 ' N ' HE22 ' L' ' 15' ' ' GLN . . . 125.09 -162.31 19.41 Favored Glycine 0 N--CA 1.465 0.585 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.386 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' K' ' 38' ' ' GLY . . . 137.84 -55.38 0.68 Allowed Glycine 0 CA--C 1.542 1.745 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' J' ' 40' ' ' VAL . 43.5 t -125.29 134.04 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.853 0.861 . . . . 0.0 108.798 177.672 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.441 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 74.1 t . . . . . 0 C--O 1.216 -0.685 0 CA-C-O 118.088 -0.958 . . . . 0.0 111.711 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.05 134.54 53.54 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.482 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 97.8 mt-10 -144.56 169.48 17.88 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.859 0.361 . . . . 0.0 111.276 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 19.6 t -104.18 128.26 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' OXT' ' I' ' 40' ' ' VAL . 81.7 t60 -138.93 114.81 10.06 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.636 ' CE1' ' CD2' ' J' ' 14' ' ' HIS . 7.5 p80 -155.22 165.29 37.14 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.182 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.457 ' NE2' ' CG2' ' I' ' 36' ' ' VAL . 58.3 tt0 -129.48 149.95 51.04 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 119.699 -0.8 . . . . 0.0 111.179 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.96 109.15 21.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.004 177.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . 0.568 ' CD1' ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -103.95 105.12 15.2 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 176.557 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.1 103.89 16.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.445 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.456 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 5.1 m-85 -114.39 108.26 16.65 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -106.69 120.8 42.95 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.42 131.36 41.7 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.415 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.533 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 97.4 mt-10 -87.09 104.61 16.5 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.465 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 0.5 OUTLIER -135.13 48.66 2.25 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.733 -177.322 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 55.0 t -71.92 161.38 4.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.553 -178.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.26 -28.35 10.43 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 -177.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.433 ' OG ' ' OG ' ' L' ' 26' ' ' SER . 0.8 OUTLIER 74.57 119.73 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.051 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.458 ' OD1' ' OG ' ' J' ' 26' ' ' SER . 93.3 m-20 -83.24 162.79 21.08 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.832 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -47.19 -37.28 9.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.294 177.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.78 77.35 0.07 OUTLIER Glycine 0 CA--C 1.532 1.147 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.597 -174.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.53 153.7 29.35 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 118.217 1.009 . . . . 0.0 110.01 -178.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.507 ' H ' HG21 ' J' ' 31' ' ' ILE . 57.4 mt -133.78 141.24 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 113.874 1.064 . . . . 0.0 113.874 -175.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -127.02 118.36 50.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.169 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.16 109.56 1.72 Allowed Glycine 0 N--CA 1.471 1.002 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 29.3 mt -127.84 125.27 39.43 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 112.811 0.671 . . . . 0.0 112.811 -175.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.7 mtp -106.94 106.01 16.32 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.26 173.23 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 159.64 -95.39 0.14 Allowed Glycine 0 C--N 1.3 -1.45 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.458 -178.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' J' ' 38' ' ' GLY . . . 98.13 -80.53 0.61 Allowed Glycine 0 N--CA 1.47 0.95 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 -176.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . 0.474 ' C ' ' CD1' ' Q' ' 31' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.439 -1.014 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.931 0.396 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 58.9 t -128.76 134.34 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.376 -178.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.482 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 85.0 m-70 -135.12 84.65 2.11 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.7 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.486 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 85.2 t60 -162.7 168.51 21.48 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.141 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.673 HE22 ' N ' ' J' ' 37' ' ' GLY . 78.8 mt-30 -100.35 151.33 21.63 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.345 0.593 . . . . 0.0 111.788 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -112.63 110.21 20.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.745 177.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -104.77 109.88 22.0 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 42.8 t -117.21 102.38 13.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.424 ' CD1' ' CD2' ' K' ' 19' ' ' PHE . 5.0 m-85 -115.72 107.11 14.66 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -113.96 119.71 38.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.099 0.476 . . . . 0.0 111.515 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.23 127.17 52.17 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -78.04 111.25 13.73 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.329 -177.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 56.9 p30 -178.39 48.66 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.157 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.618 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -72.62 160.32 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 C-N-CA 118.431 -1.308 . . . . 0.0 109.449 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.05 -33.19 6.01 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.433 ' OG ' ' OG ' ' K' ' 26' ' ' SER . 4.7 m -72.09 129.56 38.79 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 113.824 -1.188 . . . . 0.0 111.102 179.08 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.645 ' O ' ' N ' ' L' ' 29' ' ' GLY . 98.7 m-20 -90.98 -162.51 0.92 Allowed 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.46 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.28 47.59 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 115.127 1.529 . . . . 0.0 115.127 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.645 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.17 57.08 0.9 Allowed Glycine 0 CA--C 1.54 1.608 0 CA-C-N 119.483 1.038 . . . . 0.0 112.016 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.07 171.73 10.74 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -121.27 121.73 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 177.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -125.43 133.58 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.864 0.364 . . . . 0.0 111.57 -178.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.99 117.98 2.06 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.4 tp -115.21 123.53 49.1 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mmm -124.83 128.03 48.07 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.659 0.266 . . . . 0.0 111.552 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.2 t -97.4 152.24 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-O 121.353 0.597 . . . . 0.0 111.929 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.527 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . -80.79 102.5 2.13 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' L' ' 37' ' ' GLY . . . 11.46 -73.04 0.0 OUTLIER Glycine 0 CA--C 1.539 1.588 0 C-N-CA 123.459 0.552 . . . . 0.0 113.92 -178.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.527 ' N ' ' O ' ' L' ' 37' ' ' GLY . 74.5 t . . . . . 0 C--N 1.346 0.42 0 CA-C-N 118.221 1.011 . . . . 0.0 110.073 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 C--O 1.233 0.208 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -139.49 139.5 38.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 121.159 0.504 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -89.49 166.73 13.5 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.229 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.594 ' N ' ' ND1' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -82.26 171.42 14.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.0 0.429 . . . . 0.0 111.212 -179.342 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -128.8 151.03 50.04 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -96.3 106.77 19.04 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.704 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 87.2 mt -128.22 114.41 16.92 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 121.005 0.431 . . . . 0.0 110.057 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -126.61 130.8 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.715 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -128.18 131.23 48.9 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.619 ' CZ ' ' CD1' ' N' ' 20' ' ' PHE . 1.6 t80 -134.38 128.84 34.42 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.204 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 118.46 31.86 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.935 0.398 . . . . 0.0 109.949 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . 0.436 ' O ' ' N ' ' M' ' 24' ' ' VAL . 94.5 mt-10 -110.53 -148.59 0.43 Allowed 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.773 -178.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.57 50.13 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.855 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 2.3 t -71.72 -142.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . 0.47 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -111.48 38.75 3.14 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.904 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m 61.76 111.18 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.113 0.482 . . . . 0.0 112.082 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . 0.45 ' O ' ' C ' ' M' ' 28' ' ' LYS . 91.2 m-20 -129.85 -161.55 1.13 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.193 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . 0.45 ' C ' ' O ' ' M' ' 27' ' ' ASN . 73.6 mmtt -30.95 -41.31 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 120.914 0.387 . . . . 0.0 110.996 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' M' ' 27' ' ' ASN . . . 91.35 -64.92 2.54 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.794 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . 0.473 ' O ' ' O ' ' N' ' 29' ' ' GLY . . . -170.37 70.1 0.05 Allowed 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 117.616 0.708 . . . . 0.0 112.483 177.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 82.0 mt -130.89 115.09 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 4.0 mt -112.89 116.16 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 C-N-CA 120.062 -0.655 . . . . 0.0 111.107 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.16 105.0 1.18 Allowed Glycine 0 N--CA 1.461 0.315 0 N-CA-C 105.389 -3.084 . . . . 0.0 105.389 177.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 47.1 tp -161.02 152.34 19.02 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 117.548 -1.661 . . . . 0.0 114.354 -174.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 3.8 ttm -104.26 115.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-N 112.56 -2.109 . . . . 0.0 106.856 176.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . 0.517 ' O ' ' N ' ' N' ' 37' ' ' GLY . 36.5 t -116.91 103.87 15.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.29 -153.22 16.88 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 120.026 -1.083 . . . . 0.0 110.952 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.522 ' H ' ' N ' ' N' ' 38' ' ' GLY . . . 147.65 -54.64 0.52 Allowed Glycine 0 CA--C 1.539 1.551 0 CA-C-O 119.721 -0.488 . . . . 0.0 111.93 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' M' ' 40' ' ' VAL . 10.0 p -114.73 151.89 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.963 0.881 . . . . 0.0 108.787 178.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.54 ' OXT' ' CG1' ' M' ' 40' ' ' VAL . 8.5 p . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 117.854 -1.069 . . . . 0.0 111.151 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.64 134.33 48.93 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -151.38 135.77 16.89 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.999 0.428 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 34.1 m -137.03 162.09 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.624 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . 0.51 ' C ' ' ND1' ' N' ' 14' ' ' HIS . 83.4 m-70 -143.34 104.86 4.31 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.489 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.511 ' HE2' ' CD2' ' O' ' 14' ' ' HIS . 20.0 m80 -152.08 167.05 29.71 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.701 0.286 . . . . 0.0 110.67 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -155.7 141.17 17.76 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -89.82 107.39 19.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 119.215 -0.421 . . . . 0.0 111.666 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -123.78 115.57 21.57 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 177.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -121.49 131.13 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.828 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -129.97 112.35 13.42 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.522 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CZ ' ' M' ' 20' ' ' PHE . 16.5 t80 -113.81 130.37 56.47 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.44 133.14 40.16 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 113.232 0.827 . . . . 0.0 113.232 -178.049 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -92.38 120.83 33.27 Favored 'General case' 0 C--N 1.34 0.168 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.547 177.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.57 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 70.8 m-20 -148.39 50.39 1.02 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.981 -177.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 37.6 t -81.41 148.65 5.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 118.951 -1.1 . . . . 0.0 109.719 -177.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.57 37.04 5.66 Favored Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.9 p 73.18 120.21 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.617 ' ND2' ' N ' ' N' ' 27' ' ' ASN . 0.1 OUTLIER -83.09 162.44 21.34 Favored 'General case' 0 C--N 1.341 0.211 0 C-N-CA 118.262 -1.375 . . . . 0.0 111.499 -179.098 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -47.22 -37.17 9.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.955 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' M' ' 30' ' ' ALA . . . -178.96 77.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.579 0 CA-C-O 118.766 -1.019 . . . . 0.0 112.199 -173.387 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' O' ' 30' ' ' ALA . . . -79.26 107.51 12.07 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-N 119.848 1.824 . . . . 0.0 112.835 -175.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . 0.571 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 18.4 tt -153.32 133.83 4.34 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 CA-C-N 113.627 -1.624 . . . . 0.0 111.336 -177.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . 0.456 HD11 HG23 ' N' ' 32' ' ' ILE . 85.0 mt -106.96 108.26 24.76 Favored 'Isoleucine or valine' 0 C--N 1.341 0.198 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 177.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.67 100.46 1.0 Allowed Glycine 0 N--CA 1.46 0.269 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 mt -146.59 157.91 43.81 Favored 'General case' 0 CA--C 1.5 -0.952 0 CA-C-O 123.665 1.698 . . . . 0.0 112.478 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 8.0 mtp -113.79 108.53 17.22 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 111.156 -2.747 . . . . 0.0 104.604 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -87.25 100.96 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 106.144 -1.798 . . . . 0.0 106.144 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' M' ' 36' ' ' VAL . . . -73.23 163.0 54.86 Favored Glycine 0 CA--C 1.52 0.353 0 CA-C-N 112.724 -2.034 . . . . 0.0 113.383 -178.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . 0.522 ' N ' ' H ' ' M' ' 38' ' ' GLY . . . 114.92 60.72 0.37 Allowed Glycine 0 N--CA 1.471 0.972 0 C-N-CA 121.389 -0.434 . . . . 0.0 113.681 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . 0.582 ' CG1' ' H ' ' O' ' 39' ' ' VAL . 57.3 t -71.09 130.91 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.501 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.999 -1.001 . . . . 0.0 111.3 -179.031 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.48 132.97 52.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.759 0.314 . . . . 0.0 110.364 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -123.58 121.83 36.61 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.131 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 m -131.43 155.27 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.506 ' C ' ' CD2' ' O' ' 14' ' ' HIS . 86.7 m-70 -149.07 102.96 3.3 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.478 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.511 ' CD2' ' HE2' ' N' ' 14' ' ' HIS . 0.1 OUTLIER -149.27 176.44 10.53 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -149.25 140.0 22.7 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 174.616 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -95.05 110.24 22.19 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.227 1.566 . . . . 0.0 115.227 -178.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -124.13 115.09 20.57 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 174.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -112.74 115.82 50.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.643 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 48.4 m-85 -112.22 104.97 13.19 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -111.86 131.75 55.15 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.9 136.61 32.46 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -95.2 113.86 25.58 Favored 'General case' 0 CA--C 1.52 -0.175 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 175.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.413 ' CB ' HD22 ' N' ' 27' ' ' ASN . 18.1 m-20 -133.99 48.62 2.33 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 t -72.88 161.09 5.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 C-N-CA 118.218 -1.393 . . . . 0.0 109.664 -179.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.27 -29.89 9.56 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 -178.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 1.2 m 92.83 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 113.66 -1.27 . . . . 0.0 107.791 -178.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.499 ' OD1' ' N ' ' O' ' 30' ' ' ALA . 2.7 p30 -73.96 164.39 26.68 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.935 0.874 . . . . 0.0 113.071 -178.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.08 -36.28 12.84 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.862 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.38 78.5 0.07 OUTLIER Glycine 0 CA--C 1.532 1.119 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.354 -173.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . 0.499 ' N ' ' OD1' ' O' ' 27' ' ' ASN . . . -79.19 109.73 13.8 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 123.286 1.517 . . . . 0.0 110.955 -176.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 77.8 mt -133.15 142.21 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 113.483 -1.689 . . . . 0.0 112.802 -176.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . 0.421 HD11 HG22 ' O' ' 32' ' ' ILE . 52.9 mt -106.78 107.9 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 175.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.05 104.97 2.23 Favored Glycine 0 C--O 1.239 0.437 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 53.7 mt -140.35 144.0 36.06 Favored 'General case' 0 CA--C 1.504 -0.815 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -175.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 3.0 mtp -116.42 109.22 17.02 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 112.212 -2.267 . . . . 0.0 105.038 175.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -105.86 101.8 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.812 0.815 . . . . 0.0 111.05 -177.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.77 -179.11 0.65 Allowed Glycine 0 CA--C 1.538 1.5 0 CA-C-N 114.112 -1.404 . . . . 0.0 115.303 178.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' P' ' 38' ' ' GLY . . . -116.3 -58.3 0.32 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 114.253 -0.973 . . . . 0.0 111.788 179.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.582 ' H ' ' CG1' ' N' ' 39' ' ' VAL . 45.5 t -115.84 124.92 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.644 ' CG2' HE22 ' R' ' 15' ' ' GLN . 12.3 m . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.451 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.402 HG22 ' HE2' ' P' ' 14' ' ' HIS . 2.2 p . . . . . 0 N--CA 1.463 0.2 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.671 ' HE2' HE22 ' P' ' 15' ' ' GLN . 7.5 t60 -144.98 134.25 22.9 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 -179.116 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.644 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 18.9 m-70 -147.45 156.42 42.85 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 175.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.671 HE22 ' HE2' ' P' ' 13' ' ' HIS . 3.1 mp0 -90.42 160.35 16.1 Favored 'General case' 0 C--O 1.225 -0.237 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -140.09 95.52 2.9 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.725 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -136.22 130.64 33.43 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.142 0.496 . . . . 0.0 111.122 179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 24.1 t -119.94 115.21 46.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.489 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.485 ' CD1' ' CE1' ' Q' ' 19' ' ' PHE . 19.3 m-85 -109.09 111.87 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -127.01 123.45 37.1 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 -176.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.18 121.85 43.31 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 176.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -93.86 152.41 18.91 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 117.843 2.535 . . . . 0.0 117.843 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.409 ' OD1' ' OE1' ' Q' ' 22' ' ' GLU . 93.3 m-20 27.92 51.52 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 111.238 -2.71 . . . . 0.0 117.807 175.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 65.1 t -81.69 141.23 15.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 117.13 -1.828 . . . . 0.0 106.181 175.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' Q' ' 24' ' ' VAL . . . -71.53 -41.54 57.51 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 117.584 -2.246 . . . . 0.0 110.809 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.422 ' O ' ' C ' ' P' ' 27' ' ' ASN . 42.3 t -156.63 112.3 2.93 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 118.355 -0.831 . . . . 0.0 109.452 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.422 ' C ' ' O ' ' P' ' 26' ' ' SER . 7.4 t-20 -48.96 157.78 0.38 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.127 178.375 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.65 -47.88 61.83 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.665 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.82 61.21 0.08 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 114.261 -1.336 . . . . 0.0 109.768 -176.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' O' ' 30' ' ' ALA . . . -85.09 158.43 20.43 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 123.668 1.699 . . . . 0.0 115.377 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . 0.451 HG22 HD13 ' P' ' 31' ' ' ILE . 65.1 mt -145.05 148.3 17.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 112.342 -2.208 . . . . 0.0 113.482 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . 0.458 HG22 HD12 ' P' ' 32' ' ' ILE . 52.9 mt -106.19 107.64 23.17 Favored 'Isoleucine or valine' 0 C--N 1.35 0.625 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.159 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.89 101.38 2.27 Favored Glycine 0 N--CA 1.463 0.462 0 N-CA-C 104.215 -3.554 . . . . 0.0 104.215 175.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 26.4 tp -133.49 130.25 38.3 Favored 'General case' 0 C--O 1.239 0.544 0 N-CA-C 115.979 1.844 . . . . 0.0 115.979 -173.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 40.2 tpp -111.27 109.27 19.22 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 174.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 10.6 t -100.13 102.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.91 0.386 . . . . 0.0 110.573 -177.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.0 163.48 0.06 OUTLIER Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' O' ' 38' ' ' GLY . . . -94.57 -58.03 1.22 Allowed Glycine 0 CA--C 1.536 1.392 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.241 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' P' ' 40' ' ' VAL . 24.0 t -151.28 138.89 13.82 Favored 'Isoleucine or valine' 0 C--N 1.347 0.479 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.574 ' H ' ' C ' ' Q' ' 38' ' ' GLY . 31.1 t . . . . . 0 C--O 1.214 -0.789 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.435 -177.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.471 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -107.08 131.07 54.51 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -149.43 137.58 20.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.978 0.418 . . . . 0.0 110.348 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -127.58 118.44 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.571 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.59 ' HE2' ' C ' ' O' ' 40' ' ' VAL . 12.0 p-80 -158.47 121.05 3.7 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.868 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.644 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 4.1 p-80 -148.8 165.62 30.9 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 176.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.406 ' HA ' ' H ' ' P' ' 15' ' ' GLN . 9.8 pt20 -99.75 149.93 22.84 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.454 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . 0.498 ' CE ' ' HE2' ' Q' ' 14' ' ' HIS . 98.8 mttt -114.74 98.61 6.95 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.951 178.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . 0.404 ' HB3' ' CZ ' ' Q' ' 19' ' ' PHE . 6.0 mp -123.2 116.98 24.3 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 177.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -107.88 111.14 34.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.485 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 37.1 m-85 -107.21 107.34 18.25 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 178.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' R' ' 20' ' ' PHE . 12.9 t80 -122.52 124.92 44.66 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -176.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.36 118.31 27.21 Favored 'General case' 0 C--O 1.243 0.711 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 177.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' P' ' 23' ' ' ASP . 82.7 tt0 -82.77 146.24 29.09 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -176.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.492 ' O ' ' O ' ' R' ' 22' ' ' GLU . 64.2 t0 63.87 -52.13 0.25 Allowed 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 113.878 -1.51 . . . . 0.0 112.089 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' P' ' 25' ' ' GLY . 0.8 OUTLIER 50.51 -153.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.302 177.842 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.403 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 143.39 19.03 0.22 Allowed Glycine 0 N--CA 1.464 0.544 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 -177.026 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.13 129.9 42.3 Favored 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 114.691 -0.754 . . . . 0.0 109.342 -178.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.525 ' CG ' ' H ' ' Q' ' 28' ' ' LYS . 45.3 t-20 -126.98 -130.62 0.23 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.186 -174.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.525 ' H ' ' CG ' ' Q' ' 27' ' ' ASN . 74.1 mmtt -38.79 -46.87 1.32 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.041 -0.982 . . . . 0.0 111.483 -176.591 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.19 52.44 0.9 Allowed Glycine 0 CA--C 1.547 2.058 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.786 -177.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.8 127.43 41.95 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-O 120.915 0.388 . . . . 0.0 110.103 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . 0.474 ' CD1' ' C ' ' K' ' 39' ' ' VAL . 28.9 mt -142.81 153.25 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-O 121.821 0.819 . . . . 0.0 113.064 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 86.5 mt -136.22 123.34 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 O-C-N 121.795 -0.565 . . . . 0.0 110.34 179.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.4 110.66 1.29 Allowed Glycine 0 N--CA 1.468 0.77 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 28.4 mt -119.34 121.2 39.03 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.634 0.255 . . . . 0.0 111.444 -178.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 95.3 mmm -111.33 127.61 55.7 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.405 ' O ' ' N ' ' R' ' 37' ' ' GLY . 53.6 t -122.79 131.73 72.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-N 118.69 0.677 . . . . 0.0 112.103 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -55.82 -111.52 0.01 OUTLIER Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.743 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.574 ' C ' ' H ' ' P' ' 40' ' ' VAL . . . 95.86 -72.92 0.87 Allowed Glycine 0 CA--C 1.537 1.436 0 N-CA-C 111.962 -0.455 . . . . 0.0 111.962 179.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.437 ' CG2' ' O ' ' Q' ' 38' ' ' GLY . 14.2 t -164.1 121.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . 0.481 ' OXT' ' CG2' ' E' ' 31' ' ' ILE . 58.7 t . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.992 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -82.69 131.06 35.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.811 0.339 . . . . 0.0 110.93 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' R' ' 11' ' ' GLU . 56.3 mp0 -118.98 148.43 42.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.815 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 20.1 t -106.97 98.05 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.494 0.664 . . . . 0.0 110.885 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -120.25 93.5 4.07 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.901 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -153.88 164.02 39.08 Favored 'General case' 0 C--O 1.222 -0.392 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.644 HE22 ' CG2' ' O' ' 40' ' ' VAL . 90.4 mm-40 -89.85 158.41 17.47 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.417 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -140.4 90.13 2.33 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -134.37 120.14 19.48 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.2 t -104.89 113.5 42.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -104.9 98.05 7.83 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 106.028 -1.842 . . . . 0.0 106.028 177.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' Q' ' 20' ' ' PHE . 42.0 t80 -115.22 114.28 25.02 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.58 0.705 . . . . 0.0 110.847 -178.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' R' ' 23' ' ' ASP . . . -128.37 125.11 38.0 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.492 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 81.0 tt0 -71.5 85.13 0.84 Allowed 'General case' 0 C--O 1.223 -0.319 0 C-N-CA 117.414 -1.714 . . . . 0.0 106.958 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' R' ' 21' ' ' ALA . 51.2 p30 -132.72 51.89 2.12 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.459 -176.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 69.5 t -74.82 143.29 13.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.19 37.56 3.8 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 42.5 t -75.53 101.93 5.06 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 121.47 0.652 . . . . 0.0 110.201 -179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -96.44 -163.15 1.02 Allowed 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.965 -177.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -47.72 -42.14 24.51 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 114.225 -1.352 . . . . 0.0 113.701 -177.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.99 61.68 1.92 Allowed Glycine 0 CA--C 1.54 1.652 0 C-N-CA 120.301 -0.952 . . . . 0.0 114.187 -175.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.09 135.02 9.89 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 177.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.6 mt -118.01 128.45 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 CA-C-O 121.399 0.619 . . . . 0.0 111.965 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 48.2 mm -120.4 123.34 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.894 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 118.05 2.8 Favored Glycine 0 N--CA 1.468 0.786 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 67.8 mt -116.54 114.9 24.81 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 85.9 mmm -134.27 136.23 43.43 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.042 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.63 155.84 34.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 121.33 0.585 . . . . 0.0 111.006 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -52.93 -102.27 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.149 178.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 49.24 71.06 0.66 Allowed Glycine 0 CA--C 1.529 0.939 0 CA-C-N 115.148 -0.526 . . . . 0.0 111.807 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' R' ' 40' ' ' VAL . 59.9 t -112.29 165.69 7.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . 0.413 ' N ' ' CG1' ' R' ' 39' ' ' VAL . 15.5 m . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.101 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 . . . . . 0 N--CA 1.466 0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.23 140.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.476 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -142.11 158.37 43.82 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.069 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.614 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -89.26 169.56 11.34 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.021 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -129.42 150.71 50.65 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -97.14 118.92 34.63 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.691 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.3 mt -124.77 114.9 19.88 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -132.83 136.4 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.351 -0.386 . . . . 0.0 109.977 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -128.03 130.52 48.42 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.456 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -123.6 120.49 32.97 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.999 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.04 127.43 48.77 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.404 ' CD ' ' OE1' ' B' ' 22' ' ' GLU . 83.2 tt0 -147.95 149.14 31.66 Favored 'General case' 0 CA--C 1.533 0.327 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -178.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.0 t0 . . . . . 0 N--CA 1.466 0.34 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 176.861 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . 0.726 ' H ' ' HZ2' ' B' ' 28' ' ' LYS . 9.9 t-20 . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.591 ' H ' ' ND2' ' A' ' 27' ' ' ASN . 68.1 mttm -78.66 40.42 0.38 Allowed 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.961 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.463 ' C ' ' H ' ' A' ' 31' ' ' ILE . . . 119.57 78.37 0.56 Allowed Glycine 0 CA--C 1.533 1.167 0 CA-C-O 118.362 -1.243 . . . . 0.0 113.938 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.68 43.41 0.75 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-N 121.011 2.405 . . . . 0.0 110.9 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.463 ' H ' ' C ' ' A' ' 29' ' ' GLY . 54.9 mt -150.47 126.94 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 CA-C-N 113.148 -1.842 . . . . 0.0 106.866 178.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.432 ' O ' ' O ' ' B' ' 33' ' ' GLY . 50.7 mt -105.89 110.2 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.987 -0.745 . . . . 0.0 108.987 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.56 93.7 0.57 Allowed Glycine 0 CA--C 1.508 -0.368 0 N-CA-C 105.614 -2.994 . . . . 0.0 105.614 177.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -147.17 168.04 22.67 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 122.998 1.38 . . . . 0.0 114.133 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -120.22 110.64 16.84 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 112.224 -2.262 . . . . 0.0 107.229 178.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -97.92 113.44 32.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.498 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.68 -125.03 1.49 Allowed Glycine 0 C--N 1.315 -0.596 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.24 -62.89 0.37 Allowed Glycine 0 CA--C 1.546 1.987 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.9 m -134.73 159.9 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 116.999 0.399 . . . . 0.0 110.009 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 42.9 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.336 179.222 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.94 146.06 34.42 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.644 0.259 . . . . 0.0 110.358 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.493 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 58.5 mp0 -72.68 119.31 16.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.963 0.411 . . . . 0.0 110.263 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . 0.497 ' CG2' ' HE2' ' A' ' 14' ' ' HIS . 26.0 m -134.89 161.01 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.835 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -131.32 96.15 3.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.075 0.464 . . . . 0.0 111.704 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.61 ' CD2' ' HE2' ' C' ' 14' ' ' HIS . 24.6 p80 -156.89 169.15 25.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 177.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 47.6 tt0 -129.51 150.45 50.85 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.956 0.407 . . . . 0.0 110.128 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -98.37 119.94 37.93 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.722 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 7.0 tt -122.76 122.79 39.55 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 118.194 0.452 . . . . 0.0 110.537 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -126.22 128.76 71.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.239 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 t80 -124.6 114.06 18.88 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.872 0.368 . . . . 0.0 110.022 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.643 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 32.7 t80 -115.34 119.98 38.08 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.647 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.13 128.28 37.76 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.718 0.771 . . . . 0.0 112.219 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.404 ' OE1' ' CD ' ' A' ' 22' ' ' GLU . 87.8 mt-10 -96.73 111.98 23.92 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.055 178.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -104.17 46.42 0.92 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.06 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.496 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 20.7 t -82.33 176.07 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.629 -178.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.496 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . 91.87 -28.27 8.84 Favored Glycine 0 N--CA 1.465 0.622 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -177.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 2.1 p 166.31 131.52 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 60.1 t-20 -45.84 130.84 9.54 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.726 ' HZ2' ' H ' ' A' ' 27' ' ' ASN . 98.7 mttt -89.28 -46.61 8.64 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.36 60.92 0.1 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.588 -1.291 . . . . 0.0 113.28 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.86 113.95 8.44 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.968 1.47 . . . . 0.0 114.968 -176.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 93.0 mt -127.66 130.1 70.28 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 CA-C-N 112.696 -2.047 . . . . 0.0 109.702 178.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.412 ' O ' ' O ' ' C' ' 33' ' ' GLY . 94.3 mt -110.06 116.33 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 O-C-N 121.578 -0.701 . . . . 0.0 110.551 178.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -118.97 96.17 0.65 Allowed Glycine 0 C--O 1.238 0.352 0 N-CA-C 104.924 -3.271 . . . . 0.0 104.924 176.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 20.5 tp -135.9 136.74 40.74 Favored 'General case' 0 CA--C 1.502 -0.889 0 C-N-CA 119.268 -0.973 . . . . 0.0 113.099 -174.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.4 mtp -106.39 108.75 20.42 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -102.1 103.33 14.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.99 -153.61 25.11 Favored Glycine 0 N--CA 1.447 -0.622 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.44 -55.79 0.53 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -178.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.434 ' O ' ' OXT' ' B' ' 40' ' ' VAL . 27.8 m -124.05 137.02 58.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 123.449 0.7 . . . . 0.0 111.279 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.523 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 40.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.651 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.409 -1.477 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -105.35 135.37 46.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.934 0.397 . . . . 0.0 110.468 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -138.24 139.53 39.27 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.384 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 t -106.7 91.22 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -104.39 131.17 52.04 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.2 0.524 . . . . 0.0 111.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.61 ' HE2' ' CD2' ' B' ' 14' ' ' HIS . 1.0 OUTLIER -151.0 165.23 34.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.534 179.285 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 95.8 mm-40 -90.02 151.94 21.42 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -148.4 99.12 2.99 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -131.28 128.99 40.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.447 0.641 . . . . 0.0 111.399 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.99 114.56 45.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.05 107.83 18.32 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.643 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 17.1 t80 -113.77 124.86 53.27 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 122.009 0.123 . . . . 0.0 111.114 -178.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.82 131.83 21.67 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 120.262 -0.575 . . . . 0.0 112.516 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.04 112.43 21.77 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.179 0.514 . . . . 0.0 110.711 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.452 ' OD1' ' OD2' ' D' ' 23' ' ' ASP . 13.6 p-10 -124.86 46.56 2.3 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.559 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . 0.628 ' CG1' ' H ' ' C' ' 25' ' ' GLY . 21.8 t -73.38 179.74 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.774 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.628 ' H ' ' CG1' ' C' ' 24' ' ' VAL . . . 99.26 -35.38 4.73 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-N 114.329 -1.305 . . . . 0.0 113.413 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.489 ' O ' ' O ' ' C' ' 27' ' ' ASN . 28.6 t -162.38 117.53 1.87 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.6 1.7 . . . . 0.0 112.548 175.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' C' ' 26' ' ' SER . 67.2 m-20 -23.23 151.39 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 118.976 -0.535 . . . . 0.0 112.232 175.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 39.5 tttp -167.55 31.36 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 173.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' D' ' 27' ' ' ASN . . . 81.01 80.81 0.85 Allowed Glycine 0 CA--C 1.535 1.328 0 C-N-CA 117.886 -2.102 . . . . 0.0 114.097 175.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.93 119.49 38.88 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.447 1.623 . . . . 0.0 109.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 82.9 mt -123.14 132.53 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -177.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 mt -105.79 108.45 25.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 174.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' B' ' 32' ' ' ILE . . . -123.64 106.76 1.01 Allowed Glycine 0 N--CA 1.465 0.577 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 mp -139.27 143.36 37.91 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 122.702 1.239 . . . . 0.0 113.434 -177.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -113.49 103.66 11.49 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 175.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -111.72 102.91 14.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.09 -151.78 20.89 Favored Glycine 0 C--N 1.31 -0.879 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -178.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.91 -56.81 0.6 Allowed Glycine 0 CA--C 1.54 1.618 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.725 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . 0.415 ' N ' HG23 ' D' ' 39' ' ' VAL . 33.6 m -135.81 163.71 34.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 123.037 0.535 . . . . 0.0 111.095 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.987 -179.434 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 N--CA 1.463 0.186 0 CA-C-O 121.046 0.45 . . . . 0.0 110.237 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.62 ' NE2' ' ND1' ' E' ' 13' ' ' HIS . 5.7 p80 -133.52 119.44 19.53 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -149.07 164.86 33.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.528 0.68 . . . . 0.0 112.144 -178.449 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.531 ' OE1' ' NE2' ' E' ' 15' ' ' GLN . 85.1 mt-30 -84.49 156.59 21.64 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 176.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -159.26 105.87 1.73 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 120.043 -0.663 . . . . 0.0 109.237 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . 0.429 ' N ' HD11 ' D' ' 17' ' ' LEU . 3.4 mp -136.67 127.85 28.01 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.434 0.635 . . . . 0.0 111.695 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -109.72 115.43 49.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.347 178.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' E' ' 19' ' ' PHE . 35.2 m-85 -108.55 106.95 17.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 47.3 t80 -111.87 119.01 37.1 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.851 -179.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.73 138.57 28.93 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 119.569 -0.852 . . . . 0.0 112.968 -179.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.3 mt-10 -120.15 133.45 55.5 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.776 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 0.0 OUTLIER -149.41 59.78 1.02 Allowed 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.652 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 4.4 t 91.3 -169.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 176.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.652 ' H ' ' CG1' ' D' ' 24' ' ' VAL . . . -76.98 -33.82 44.36 Favored Glycine 0 C--O 1.214 -1.146 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 26' ' ' SER . . . . . 0.449 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 5.3 p -147.3 118.4 7.74 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.289 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . 0.412 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 17.7 t-20 -59.93 169.03 1.59 Allowed 'General case' 0 C--N 1.333 -0.113 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.884 -179.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -55.25 -38.06 68.04 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.839 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.58 71.42 0.1 Allowed Glycine 0 CA--C 1.533 1.215 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.829 -174.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.49 135.27 47.05 Favored 'General case' 0 C--O 1.245 0.832 0 CA-C-N 118.785 1.293 . . . . 0.0 112.694 -174.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.565 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 77.9 mt -139.28 134.62 40.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 113.845 -1.525 . . . . 0.0 114.09 -176.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.444 HD11 HG23 ' D' ' 32' ' ' ILE . 3.6 mt -107.48 111.22 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 174.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.55 103.45 0.92 Allowed Glycine 0 N--CA 1.46 0.297 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 177.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 6.1 tt -140.8 146.63 37.87 Favored 'General case' 0 CA--C 1.513 -0.463 0 C-N-CA 119.055 -1.058 . . . . 0.0 113.171 -176.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 17.9 mtp -120.21 115.25 23.25 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.194 178.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.97 102.83 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.27 -151.31 19.53 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 119.66 -1.257 . . . . 0.0 110.561 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.7 -57.4 0.84 Allowed Glycine 0 CA--C 1.544 1.88 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.484 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.461 ' C ' ' O ' ' E' ' 38' ' ' GLY . 27.7 m -134.93 159.92 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 C-N-CA 123.356 0.662 . . . . 0.0 110.773 -178.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.53 -179.603 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.48 134.76 48.06 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.385 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -142.07 146.0 34.96 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.173 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.503 ' CG2' ' CD2' ' E' ' 14' ' ' HIS . 3.3 p -139.83 148.69 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 121.065 0.459 . . . . 0.0 110.716 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.622 ' CD2' ' NE2' ' F' ' 13' ' ' HIS . 0.1 OUTLIER -143.27 119.26 10.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.755 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.534 ' ND1' ' N ' ' F' ' 14' ' ' HIS . 90.1 m-70 -143.9 164.35 30.81 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.014 178.313 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' OE1' ' D' ' 15' ' ' GLN . 64.4 tp60 -89.98 151.93 21.45 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 177.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -148.74 98.8 2.91 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.782 177.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . 0.531 ' CD2' HE21 ' E' ' 15' ' ' GLN . 37.1 mt -122.8 119.33 30.26 Favored 'General case' 0 CA--C 1.509 -0.615 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.081 178.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -107.62 104.32 16.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' D' ' 19' ' ' PHE . 73.9 m-85 -103.67 105.69 15.99 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.49 114.57 28.66 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 -179.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.47 138.43 31.0 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 119.096 -1.042 . . . . 0.0 112.623 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -84.59 141.85 30.39 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.624 -179.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 0.6 OUTLIER 172.64 47.07 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.066 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -179.095 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' D' ' 25' ' ' GLY . 3.5 m -73.43 175.28 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.307 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 100.14 -29.75 11.56 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.165 176.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 92.01 114.67 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 -177.796 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . 0.412 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 78.6 m-20 -73.92 174.53 8.4 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.754 -178.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.11 -36.69 41.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.559 178.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.79 77.08 0.07 OUTLIER Glycine 0 CA--C 1.532 1.094 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -177.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.28 155.4 27.3 Favored 'General case' 0 C--O 1.241 0.64 0 CA-C-O 121.946 0.879 . . . . 0.0 111.673 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.448 HD11 ' H ' ' Q' ' 39' ' ' VAL . 75.0 mt -131.44 133.34 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 114.554 -1.203 . . . . 0.0 112.248 -177.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.43 115.35 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.49 113.42 1.6 Allowed Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 46.8 tp -123.37 121.38 35.64 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-O 120.825 0.345 . . . . 0.0 110.619 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.1 mtp -109.57 105.72 15.14 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.485 ' CG1' ' H ' ' E' ' 37' ' ' GLY . 21.6 t -91.84 174.33 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.373 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.485 ' H ' ' CG1' ' E' ' 36' ' ' VAL . . . 167.99 -95.15 0.11 Allowed Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 92.64 -82.64 1.12 Allowed Glycine 0 N--CA 1.474 1.193 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -178.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.417 ' O ' ' OXT' ' F' ' 40' ' ' VAL . 64.4 t . . . . . 0 N--CA 1.432 -1.329 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.548 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 N--CA 1.465 0.292 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -112.82 100.67 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.165 0.507 . . . . 0.0 109.757 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.622 ' NE2' ' CD2' ' E' ' 13' ' ' HIS . 68.8 m80 -140.16 114.6 9.28 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.954 -178.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.534 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 77.2 m80 -156.21 162.1 40.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 177.31 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -90.06 158.23 17.42 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.678 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 31.9 tttt -141.16 98.28 3.34 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 175.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 7.9 mt -119.06 110.75 17.45 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 83.1 t -101.29 99.26 8.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.4 ' CD1' ' CD2' ' E' ' 19' ' ' PHE . 92.6 m-85 -96.51 95.08 7.76 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 106.768 -1.568 . . . . 0.0 106.768 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.8 t80 -107.4 109.25 20.93 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.548 ' O ' ' N ' ' F' ' 23' ' ' ASP . . . -148.82 135.41 19.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.508 ' O ' ' O ' ' E' ' 23' ' ' ASP . 63.3 mt-10 -74.98 79.53 2.18 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 102.807 -3.035 . . . . 0.0 102.807 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' F' ' 21' ' ' ALA . 53.0 p30 . . . . . 0 CA--C 1.511 -0.527 0 CA-C-N 112.472 -2.149 . . . . 0.0 113.729 -173.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.43 HD12 HG21 ' F' ' 31' ' ' ILE . 96.5 mt -134.97 136.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -128.54 124.7 62.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.82 129.05 4.31 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.663 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.6 125.34 44.66 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 95.6 mmm -131.47 133.28 44.98 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.609 -179.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 14.7 p -141.48 149.77 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 120.815 0.341 . . . . 0.0 110.788 178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.12 102.04 0.42 Allowed Glycine 0 C--N 1.322 -0.216 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.22 -71.95 0.4 Allowed Glycine 0 CA--C 1.539 1.584 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.077 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.455 ' O ' ' OXT' ' F' ' 40' ' ' VAL . 5.6 m -79.31 167.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.523 ' H ' ' CG2' ' L' ' 31' ' ' ILE . 27.2 m . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.502 179.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 65.1 t . . . . . 0 N--CA 1.466 0.362 0 CA-C-O 120.953 0.406 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -82.16 160.77 23.01 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.643 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.421 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 33.9 p-80 -99.5 169.49 9.27 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.083 0.468 . . . . 0.0 111.356 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -129.69 151.38 50.35 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.036 179.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -95.63 130.57 42.47 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.59 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.1 mt -126.19 112.43 15.77 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.218 0.532 . . . . 0.0 109.783 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 m -125.65 132.49 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.179 -179.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -127.0 113.32 16.32 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -111.82 117.51 33.01 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 110.297 -0.261 . . . . 0.0 110.297 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.04 107.39 14.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -151.36 138.96 19.63 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 . . . . . 0 C--N 1.329 -0.315 0 C-N-CA 119.985 -0.686 . . . . 0.0 110.857 178.614 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.482 1.169 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -158.88 17.48 0.19 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 121.942 -0.474 . . . . 0.0 110.326 177.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.33 169.53 0.66 Allowed Glycine 0 CA--C 1.524 0.651 0 CA-C-N 115.892 -0.594 . . . . 0.0 112.898 176.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . 0.422 ' H ' ' HB2' ' H' ' 27' ' ' ASN . . . -130.83 87.31 2.47 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.346 0.593 . . . . 0.0 111.588 178.38 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 42.2 pt -138.83 127.12 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.223 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 177.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.462 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.8 mt -107.73 111.12 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.29 95.14 0.65 Allowed Glycine 0 N--CA 1.463 0.458 0 N-CA-C 105.347 -3.101 . . . . 0.0 105.347 177.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.4 mt -142.71 161.34 38.34 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 122.462 1.125 . . . . 0.0 113.861 -175.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 54.9 tpp -120.67 115.02 22.55 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 113.041 -1.89 . . . . 0.0 107.843 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.57 111.76 19.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.61 -131.49 5.52 Favored Glycine 0 C--N 1.315 -0.585 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.55 -63.18 1.13 Allowed Glycine 0 CA--C 1.535 1.333 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.718 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . 0.404 ' O ' ' C ' ' G' ' 40' ' ' VAL . 11.9 p -120.47 153.34 23.59 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . 0.531 ' OXT' ' CE1' ' J' ' 13' ' ' HIS . 22.7 m . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 118.06 -0.971 . . . . 0.0 111.069 -178.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.62 134.75 52.98 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.727 0.299 . . . . 0.0 110.289 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.73 137.96 37.24 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.4 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 t -123.78 107.63 19.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 81.0 t60 -126.63 120.9 30.66 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.92 0.391 . . . . 0.0 110.579 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' O ' ' I' ' 14' ' ' HIS . 11.7 t60 -155.59 170.28 22.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.094 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.595 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 82.5 mt-30 -156.0 141.95 18.1 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -82.38 120.41 25.4 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.362 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -120.54 114.5 21.84 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 25.6 m -133.98 131.79 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 121.364 0.602 . . . . 0.0 111.195 179.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -122.26 120.14 33.24 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.201 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -117.34 122.17 43.15 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.736 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.61 115.73 22.62 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.551 ' O ' ' N ' ' H' ' 24' ' ' VAL . 95.7 mt-10 -115.8 141.84 47.56 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 112.86 0.689 . . . . 0.0 112.86 -178.025 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 54.38 -59.71 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 114.668 -1.151 . . . . 0.0 113.789 178.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.551 ' N ' ' O ' ' H' ' 22' ' ' GLU . 16.3 m -93.48 172.04 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-O 122.005 0.907 . . . . 0.0 111.616 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.97 27.93 65.65 Favored Glycine 0 CA--C 1.529 0.948 0 CA-C-N 113.841 -1.527 . . . . 0.0 112.762 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 46.6 t -98.38 110.83 23.35 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . 0.426 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 5.4 t-20 -77.19 172.81 12.66 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 118.062 -1.455 . . . . 0.0 110.562 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.543 ' O ' ' N ' ' I' ' 28' ' ' LYS . 68.7 mttm -52.4 -36.46 54.16 Favored 'General case' 0 C--O 1.218 -0.575 0 CA-C-O 121.988 0.899 . . . . 0.0 110.821 176.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -132.12 79.48 0.35 Allowed Glycine 0 N--CA 1.47 0.901 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.466 -175.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.61 132.53 43.87 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 118.829 1.314 . . . . 0.0 111.132 -176.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.417 HD11 HG23 ' H' ' 31' ' ' ILE . 87.5 mt -140.84 147.55 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 113.954 -1.475 . . . . 0.0 113.544 -174.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 65.3 mt -106.86 107.25 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -111.56 98.59 1.03 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.178 -2.369 . . . . 0.0 107.178 178.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 mt -135.18 139.09 44.29 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.584 1.183 . . . . 0.0 113.392 -176.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -106.21 108.66 20.29 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.15 -2.537 . . . . 0.0 104.15 175.287 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 53.1 t -127.94 131.26 69.77 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.247 0 CA-C-O 121.184 0.516 . . . . 0.0 112.159 -175.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.88 -111.11 3.68 Favored Glycine 0 C--N 1.32 -0.339 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.749 178.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.7 -74.22 2.42 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' G' ' 40' ' ' VAL . 18.2 t -110.43 135.93 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 122.902 0.481 . . . . 0.0 110.475 179.08 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 69.9 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.322 178.249 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.423 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -82.89 136.71 34.5 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.869 0.366 . . . . 0.0 110.533 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -78.6 155.39 29.63 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.424 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.494 ' CG1' ' N ' ' I' ' 13' ' ' HIS . 74.0 t -138.4 166.91 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.931 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.551 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 11.0 m-70 -54.99 143.0 27.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.777 0.322 . . . . 0.0 111.46 -178.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 16.7 t-80 -153.9 154.31 33.64 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.601 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 64.2 tp60 -98.76 169.3 9.58 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 118.315 0.507 . . . . 0.0 111.208 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 82.2 tttt -159.73 104.29 1.57 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 176.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 11.7 mt -123.89 123.29 40.1 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 121.236 0.541 . . . . 0.0 111.472 178.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -115.91 112.08 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 177.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -112.54 107.36 16.07 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -114.74 126.93 55.41 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 130.09 25.35 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.817 0.818 . . . . 0.0 113.114 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.453 ' OE1' ' OE1' ' J' ' 22' ' ' GLU . 58.5 mm-40 -95.6 120.23 35.48 Favored 'General case' 0 N--CA 1.461 0.096 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -125.72 48.64 2.04 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.038 0.385 . . . . 0.0 112.038 -177.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' I' ' 25' ' ' GLY . 81.2 t -72.39 161.11 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 C-N-CA 118.447 -1.301 . . . . 0.0 109.896 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.481 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 108.39 -30.05 9.34 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 22.9 p 93.28 113.59 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 112.573 -1.814 . . . . 0.0 109.619 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -74.19 161.95 29.44 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 117.916 -1.514 . . . . 0.0 110.649 178.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.591 ' HZ2' ' CG ' ' D' ' 13' ' ' HIS . 72.7 tttt -48.65 -39.5 24.5 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 174.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.33 68.82 0.04 OUTLIER Glycine 0 CA--C 1.551 2.327 0 CA-C-O 118.826 -0.986 . . . . 0.0 112.421 -174.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.25 150.62 46.22 Favored 'General case' 0 N--CA 1.478 0.938 0 CA-C-N 119.775 1.787 . . . . 0.0 114.587 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.5 mt -141.44 152.32 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 113.517 -1.674 . . . . 0.0 113.996 -176.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.44 HD12 HG22 ' I' ' 32' ' ' ILE . 6.6 mt -106.93 109.08 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 174.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.42 106.03 2.04 Favored Glycine 0 N--CA 1.465 0.617 0 N-CA-C 106.323 -2.711 . . . . 0.0 106.323 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 26.6 tp -147.54 140.25 24.79 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.837 1.303 . . . . 0.0 113.969 -174.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 42.8 tpp -110.04 115.08 29.13 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 113.033 -1.894 . . . . 0.0 106.799 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.79 123.13 51.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.06 -113.55 0.86 Allowed Glycine 0 C--N 1.317 -0.527 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 86.24 -73.01 2.58 Favored Glycine 0 CA--C 1.536 1.405 0 CA-C-N 115.48 -0.36 . . . . 0.0 112.211 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 39.7 t -123.19 146.09 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.437 ' OXT' ' O ' ' I' ' 39' ' ' VAL . 52.9 t . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.651 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.84 134.33 54.41 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . 0.41 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 98.9 mt-10 -74.57 130.79 40.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.483 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 32.9 m -138.38 88.09 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-O 121.601 0.715 . . . . 0.0 110.904 -179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.551 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 6.1 t60 -129.03 128.14 43.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.433 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.569 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -140.67 173.64 11.29 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.426 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 10.2 tt0 -124.64 142.45 51.37 Favored 'General case' 0 C--O 1.224 -0.248 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.465 177.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.82 112.16 23.45 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 119.168 -0.444 . . . . 0.0 111.078 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 24.0 mt -118.43 114.36 22.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.613 0.642 . . . . 0.0 109.984 177.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 t -110.13 105.83 19.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.481 ' CD2' ' CE1' ' K' ' 19' ' ' PHE . 65.5 m-85 -106.36 106.67 17.3 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.454 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.6 t80 -115.24 122.48 46.11 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.77 138.3 32.19 Favored 'General case' 0 C--O 1.253 1.26 0 CA-C-O 123.091 1.424 . . . . 0.0 114.479 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.453 ' OE1' ' OE1' ' I' ' 22' ' ' GLU . 24.0 tt0 -79.89 90.99 5.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 113.526 -1.67 . . . . 0.0 107.614 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.685 ' O ' ' O ' ' K' ' 22' ' ' GLU . 84.3 m-20 -89.98 60.04 4.76 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 111.773 -2.467 . . . . 0.0 110.42 -178.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -62.7 -112.65 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-O 117.109 -1.424 . . . . 0.0 108.282 -174.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.82 44.51 1.47 Allowed Glycine 0 N--CA 1.472 1.081 0 CA-C-N 121.707 2.049 . . . . 0.0 112.078 -172.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 29.0 t -71.82 100.64 2.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -109.67 -150.81 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.176 -175.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 34.96 42.07 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 113.36 0.874 . . . . 0.0 113.36 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.55 71.82 0.63 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 117.297 1.679 . . . . 0.0 117.297 177.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.33 120.27 40.82 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 174.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 42.3 mt -145.12 155.45 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -174.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.448 HD12 HG22 ' J' ' 32' ' ' ILE . 40.7 mt -111.89 111.23 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.27 103.88 1.64 Allowed Glycine 0 N--CA 1.467 0.75 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 177.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 12.2 tp -137.33 137.31 38.79 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 122.205 1.003 . . . . 0.0 113.663 -175.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -111.39 114.22 27.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 113.677 -1.601 . . . . 0.0 107.543 176.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.423 ' O ' ' OE1' ' L' ' 15' ' ' GLN . 1.3 m -121.23 103.21 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 120.399 0.143 . . . . 0.0 111.11 -178.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.39 -153.43 25.33 Favored Glycine 0 C--N 1.318 -0.468 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.016 178.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.479 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 126.15 -56.4 0.71 Allowed Glycine 0 CA--C 1.541 1.71 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' J' ' 40' ' ' VAL . 55.0 t -136.5 137.17 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.437 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 61.2 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.433 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.98 143.81 41.07 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.754 0.311 . . . . 0.0 110.644 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -129.41 149.87 51.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.434 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.534 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 34.2 m -140.37 161.45 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.498 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.505 ' CD2' ' H ' ' J' ' 13' ' ' HIS . 28.1 m80 -70.17 118.15 12.64 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' O ' ' L' ' 14' ' ' HIS . 65.9 t60 -148.23 162.82 38.71 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.107 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 41.3 tt0 -90.2 152.28 21.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.819 179.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -150.39 93.14 1.94 Allowed 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.616 177.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 2.0 mt -120.93 115.31 22.96 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.47 105.41 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.481 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 52.1 m-85 -104.28 103.67 13.45 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.454 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 31.9 t80 -113.07 119.3 37.37 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.524 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -156.74 162.71 39.76 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 122.626 1.203 . . . . 0.0 113.604 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.685 ' O ' ' O ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -82.05 118.81 23.31 Favored 'General case' 0 C--O 1.206 -1.22 0 C-N-CA 118.344 -1.342 . . . . 0.0 111.347 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.54 ' O ' ' CG1' ' K' ' 24' ' ' VAL . 65.2 m-20 -62.09 -50.41 72.04 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 120.251 -1.53 . . . . 0.0 110.016 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.54 ' CG1' ' O ' ' K' ' 23' ' ' ASP . 0.3 OUTLIER 159.6 171.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 178.626 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 -33.27 76.14 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 177.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.3 m -162.68 120.94 2.1 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 114.186 -1.007 . . . . 0.0 109.872 -177.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' K' ' 26' ' ' SER . 39.7 t30 -22.25 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -164.69 29.82 0.07 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.528 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.91 88.04 0.82 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.685 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.36 155.95 45.51 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 6.9 mt -127.1 146.93 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 113.657 0.984 . . . . 0.0 113.657 -176.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.43 HD12 HG22 ' K' ' 32' ' ' ILE . 96.7 mt -128.13 114.88 36.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.318 178.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.75 113.89 3.21 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 20.3 tp -122.84 124.36 43.11 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 17.8 mtp -129.24 131.09 46.98 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.409 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.44 ' CG1' ' N ' ' K' ' 37' ' ' GLY . 57.8 t -100.84 166.28 2.37 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-O 121.003 0.43 . . . . 0.0 110.568 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.44 ' N ' ' CG1' ' K' ' 36' ' ' VAL . . . -75.01 -102.91 0.1 OUTLIER Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.151 179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.55 -77.16 0.59 Allowed Glycine 0 N--CA 1.474 1.217 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 45.5 t . . . . . 0 N--CA 1.469 0.497 0 CA-C-O 121.428 0.632 . . . . 0.0 110.585 -179.352 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.596 0.236 . . . . 0.0 110.529 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 55.1 t -123.84 133.82 68.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.533 0.682 . . . . 0.0 110.942 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.492 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 2.5 m-70 -131.33 127.24 37.24 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.181 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.546 ' O ' ' ND1' ' K' ' 14' ' ' HIS . 94.9 m-70 -155.01 165.46 36.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.423 ' OE1' ' O ' ' J' ' 36' ' ' VAL . 47.5 mt-30 -89.69 156.64 18.42 Favored 'General case' 0 CA--C 1.518 -0.282 0 C-N-CA 119.521 -0.871 . . . . 0.0 109.635 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 52.4 tttp -141.99 95.66 2.84 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.221 177.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.65 108.19 15.14 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -107.11 103.93 16.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -101.23 102.13 12.97 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 178.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.7 t80 -126.52 129.7 49.15 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 121.35 0.595 . . . . 0.0 110.231 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -144.84 149.09 34.8 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 120.059 -0.656 . . . . 0.0 110.66 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -74.24 120.98 20.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.657 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -163.52 51.61 0.16 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 120.372 -0.531 . . . . 0.0 112.067 -178.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -76.15 143.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 118.119 -1.432 . . . . 0.0 108.51 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.52 -37.52 3.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.6 118.26 22.02 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 113.379 -1.411 . . . . 0.0 112.057 -179.267 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' L' ' 29' ' ' GLY . 57.3 p30 -89.01 -177.95 5.58 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -51.98 49.66 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 115.089 1.514 . . . . 0.0 115.089 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -101.58 51.35 0.93 Allowed Glycine 0 CA--C 1.549 2.182 0 CA-C-N 119.698 1.135 . . . . 0.0 113.515 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.38 174.47 9.83 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.523 ' CG2' ' H ' ' F' ' 40' ' ' VAL . 0.6 OUTLIER -106.91 119.91 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 176.214 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.421 HD13 HG23 ' L' ' 32' ' ' ILE . 95.0 mt -123.62 128.66 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 120.876 0.369 . . . . 0.0 111.7 -178.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 116.24 2.22 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 178.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 34.3 mt -119.64 124.59 46.67 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.7 ttm -124.04 123.54 40.57 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.468 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' L' ' 37' ' ' GLY . 72.8 t -98.33 131.52 45.24 Favored 'Isoleucine or valine' 0 C--N 1.34 0.17 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -34.6 -111.51 0.0 OUTLIER Glycine 0 CA--C 1.531 1.089 0 O-C-N 123.543 0.527 . . . . 0.0 113.257 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.68 -71.65 0.62 Allowed Glycine 0 CA--C 1.535 1.298 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t . . . . . 0 N--CA 1.468 0.462 0 CA-C-O 121.165 0.507 . . . . 0.0 110.998 179.949 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 . . . . . 0 N--CA 1.457 -0.085 0 CA-C-O 120.874 0.369 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -125.48 131.93 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.349 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -106.28 160.71 15.15 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.633 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.507 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 8.5 p80 -83.43 166.91 17.96 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 120.392 -0.523 . . . . 0.0 110.617 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -129.95 152.07 49.82 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.927 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -94.38 112.3 24.08 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -116.88 120.61 39.02 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.879 0.371 . . . . 0.0 110.124 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -129.61 132.54 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.049 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -142.25 134.23 27.3 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.989 0.423 . . . . 0.0 110.828 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.448 ' CD1' ' O ' ' M' ' 20' ' ' PHE . 52.8 p90 -123.31 133.11 54.18 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.732 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.91 125.66 41.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 121.145 0.498 . . . . 0.0 111.543 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -156.33 126.34 6.47 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.586 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.24 46.41 25.29 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . 0.617 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 21.6 t -76.7 -179.8 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.349 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . 0.617 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -88.88 28.15 6.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 26' ' ' SER . . . . . 0.443 ' O ' ' C ' ' M' ' 27' ' ' ASN . 4.7 t -169.74 -134.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.865 -0.421 . . . . 0.0 109.865 -178.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . 0.443 ' C ' ' O ' ' M' ' 26' ' ' SER . 3.0 t-20 -32.04 134.19 0.09 Allowed 'General case' 0 N--CA 1.472 0.671 0 O-C-N 122.985 0.178 . . . . 0.0 111.141 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . 0.452 ' O ' ' OD2' ' N' ' 23' ' ' ASP . 68.7 mttm -118.23 -38.5 3.18 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.04 -76.99 1.02 Allowed Glycine 0 CA--C 1.53 0.969 0 C-N-CA 118.794 -1.67 . . . . 0.0 112.178 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . 171.05 99.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.386 0.593 . . . . 0.0 111.31 178.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -127.9 116.63 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . 0.436 ' O ' ' O ' ' N' ' 33' ' ' GLY . 96.5 mt -113.49 108.1 24.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.26 96.87 0.78 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 105.45 -3.06 . . . . 0.0 105.45 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 91.3 mt -142.63 163.5 32.64 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 123.12 1.438 . . . . 0.0 114.163 -175.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -117.62 110.71 18.24 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 111.824 -2.443 . . . . 0.0 105.977 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 74.6 t -117.92 131.61 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 121.334 0.588 . . . . 0.0 110.15 -178.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.54 -111.42 3.36 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.924 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.1 -73.03 0.97 Allowed Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -99.17 158.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.339 0.149 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 11.7 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.567 -179.84 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -83.07 139.41 33.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.614 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -140.63 128.06 21.29 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.765 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -127.46 130.27 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -123.71 104.37 8.95 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.913 0.387 . . . . 0.0 111.667 -179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 1.0 OUTLIER -158.31 170.57 21.94 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.864 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 51.7 tt0 -155.44 141.46 18.28 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.897 0.379 . . . . 0.0 110.355 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -87.04 117.51 25.81 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.801 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -118.69 124.4 47.26 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 179.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.02 126.84 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 120.994 0.426 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -130.85 130.27 43.39 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.861 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -124.29 128.49 49.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 118.6 26.57 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.013 0.435 . . . . 0.0 110.458 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -127.22 128.69 46.48 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.463 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 34.4 m-20 -162.47 51.26 0.19 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.164 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 89.2 t -63.21 150.81 9.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.041 0.448 . . . . 0.0 110.668 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.06 -37.37 3.8 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.508 ' O ' ' O ' ' N' ' 27' ' ' ASN . 51.4 m -120.49 -112.36 0.33 Allowed 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.794 0.33 . . . . 0.0 111.588 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.524 ' ND2' ' OD1' ' O' ' 23' ' ' ASP . 16.3 m-20 52.31 153.08 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.69 -178.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' O' ' 28' ' ' LYS . 68.8 mttm -139.7 -29.57 0.73 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 113.712 1.005 . . . . 0.0 113.712 -179.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.73 85.02 0.11 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 120.421 -0.895 . . . . 0.0 113.935 -174.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.86 123.64 28.44 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 118.824 1.312 . . . . 0.0 110.627 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 70.0 mt -129.98 134.53 62.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.515 -175.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . 0.442 HD11 HG22 ' N' ' 32' ' ' ILE . 68.0 mt -105.0 104.93 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 106.87 -1.529 . . . . 0.0 106.87 174.323 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -110.41 109.44 2.64 Favored Glycine 0 C--O 1.235 0.202 0 N-CA-C 106.274 -2.73 . . . . 0.0 106.274 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -151.55 139.13 19.62 Favored 'General case' 0 CA--C 1.511 -0.535 0 C-N-CA 117.432 -1.707 . . . . 0.0 113.379 -175.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -105.25 108.88 20.63 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 111.756 -2.475 . . . . 0.0 106.424 177.401 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . 0.609 ' CG1' HE22 ' P' ' 15' ' ' GLN . 8.7 p -132.8 142.6 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.141 -177.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.74 -102.02 0.75 Allowed Glycine 0 C--N 1.32 -0.307 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' O' ' 39' ' ' VAL . . . 77.01 -80.76 1.21 Allowed Glycine 0 CA--C 1.531 1.064 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.49 149.51 14.66 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 33.3 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.873 -1.061 . . . . 0.0 110.256 179.452 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -148.93 159.94 43.73 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.729 0.299 . . . . 0.0 110.484 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -134.55 160.22 38.74 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.619 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -118.45 131.04 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.281 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 37.3 m-70 -140.13 123.6 17.08 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' ND1' ' P' ' 14' ' ' HIS . 30.9 m80 -147.58 174.09 12.08 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 121.25 0.548 . . . . 0.0 111.152 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 67.0 tp60 -137.69 140.8 40.98 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . 0.541 ' CG ' ' HE2' ' N' ' 14' ' ' HIS . 98.9 mttt -129.96 104.55 7.42 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 12.7 mt -116.61 116.3 27.32 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.006 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.89 106.34 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 13.6 m-30 -112.02 118.07 34.42 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -119.62 127.24 52.75 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.789 -0.187 . . . . 0.0 110.933 -179.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.39 124.83 26.35 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 121.944 0.878 . . . . 0.0 112.053 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' O' ' 23' ' ' ASP . 80.4 tt0 -96.09 141.79 29.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.316 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.524 ' OD1' ' ND2' ' N' ' 27' ' ' ASN . 65.3 m-20 -162.75 47.22 0.15 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.87 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.558 ' N ' ' OE1' ' P' ' 22' ' ' GLU . 25.0 m -62.77 -179.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 121.716 0.769 . . . . 0.0 111.535 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . 0.475 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 91.25 -29.01 7.42 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 114.22 -1.354 . . . . 0.0 113.358 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 0.9 OUTLIER 167.63 127.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 118.385 1.093 . . . . 0.0 112.798 179.467 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . 0.515 ' ND2' ' O ' ' P' ' 27' ' ' ASN . 39.4 t-20 -36.72 138.48 0.24 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 176.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' N' ' 28' ' ' LYS . 78.1 mttt -150.56 34.82 0.62 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 121.077 0.465 . . . . 0.0 111.684 -176.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.35 80.39 0.95 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 176.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.01 110.99 23.1 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 42.8 mt -121.93 130.72 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -176.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.5 mt -107.44 103.64 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.27 102.41 2.21 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 104.146 -3.582 . . . . 0.0 104.146 176.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 13.0 tp -140.19 135.87 32.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -172.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 35' ' ' MET . . . . . 0.428 ' SD ' ' CG ' ' P' ' 35' ' ' MET . 89.5 mmm -111.64 108.73 18.3 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 112.369 -2.196 . . . . 0.0 106.185 177.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . 0.597 ' CG1' ' NE2' ' Q' ' 15' ' ' GLN . 21.4 t -115.67 131.51 67.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.447 0.641 . . . . 0.0 111.94 -177.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' P' ' 37' ' ' GLY . . . 75.39 111.71 0.1 Allowed Glycine 0 CA--C 1.526 0.737 0 CA-C-N 114.767 -1.106 . . . . 0.0 114.222 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -94.17 -60.1 1.14 Allowed Glycine 0 CA--C 1.542 1.762 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' N' ' 38' ' ' GLY . 5.7 t -122.02 131.12 73.85 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.429 ' H ' ' HB ' ' P' ' 39' ' ' VAL . 91.4 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.922 -1.037 . . . . 0.0 110.476 -178.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . 0.461 ' CG2' ' O ' ' P' ' 12' ' ' VAL . 1.4 m . . . . . 0 N--CA 1.467 0.404 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 9.2 t60 -146.39 134.15 21.17 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 120.511 -0.475 . . . . 0.0 112.115 -177.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' NE2' ' O' ' 14' ' ' HIS . 1.0 OUTLIER -145.96 156.01 43.22 Favored 'General case' 0 C--O 1.23 0.068 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 176.314 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.616 HE21 ' CG ' ' P' ' 17' ' ' LEU . 53.1 tt0 -90.56 159.71 16.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.661 177.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 51.5 tttm -140.91 105.65 4.92 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.115 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . 0.616 ' CG ' HE21 ' P' ' 15' ' ' GLN . 39.6 mt -115.25 119.76 37.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-O 121.202 0.525 . . . . 0.0 111.166 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -116.75 98.29 6.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.436 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 16.9 m-30 -112.86 110.35 20.39 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -112.51 128.7 56.42 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.925 -179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' Q' ' 21' ' ' ALA . . . -153.5 158.13 40.86 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.953 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.558 ' OE1' ' N ' ' O' ' 24' ' ' VAL . 99.1 mt-10 -85.83 112.21 20.9 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.405 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 9.8 p-10 -112.44 52.07 0.79 Allowed 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 113.511 -1.677 . . . . 0.0 108.847 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . 0.489 ' CG1' ' N ' ' P' ' 25' ' ' GLY . 96.4 t -41.35 161.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 122.169 0.985 . . . . 0.0 112.249 -175.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.489 ' N ' ' CG1' ' P' ' 24' ' ' VAL . . . -93.14 32.61 5.57 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-N 113.077 -1.874 . . . . 0.0 114.218 -173.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.411 ' HB3' ' H ' ' O' ' 27' ' ' ASN . 11.9 t -92.57 -112.91 0.1 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.515 ' O ' ' ND2' ' O' ' 27' ' ' ASN . 15.4 m120 -86.27 156.58 20.2 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 118.097 -1.441 . . . . 0.0 110.893 -178.043 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 50.1 pttt -49.16 46.27 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . -99.38 58.17 0.85 Allowed Glycine 0 CA--C 1.545 1.915 0 CA-C-N 118.875 0.761 . . . . 0.0 112.322 179.065 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . 0.445 ' O ' ' CB ' ' Q' ' 30' ' ' ALA . . . -152.72 108.06 3.27 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 117.811 0.805 . . . . 0.0 110.856 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . 0.479 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 14.0 pt -145.04 147.86 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.9 mt -114.4 115.89 50.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.341 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.46 98.31 1.12 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 104.739 -3.344 . . . . 0.0 104.739 174.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 22.6 tp -127.49 132.43 49.98 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -173.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' P' P ' 35' ' ' MET . . . . . 0.428 ' CG ' ' SD ' ' O' ' 35' ' ' MET . 90.6 mmm -111.56 112.83 24.82 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 174.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . 0.422 HG23 HE22 ' R' ' 15' ' ' GLN . 0.0 OUTLIER -121.32 102.35 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -176.001 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' O' ' 37' ' ' GLY . . . 141.55 -161.34 27.0 Favored Glycine 0 CA--C 1.509 -0.339 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.802 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . 0.565 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 148.16 -55.8 0.5 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-O 119.234 -0.759 . . . . 0.0 111.229 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . 0.429 ' HB ' ' H ' ' O' ' 40' ' ' VAL . 73.3 t -144.72 139.85 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 118.355 1.078 . . . . 0.0 108.805 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 86.7 t . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 118.074 -0.965 . . . . 0.0 111.321 178.705 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -81.46 139.37 35.24 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.835 0.35 . . . . 0.0 110.609 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -85.36 110.0 18.8 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . 0.561 ' O ' ' NE2' ' P' ' 14' ' ' HIS . 34.4 m -141.13 165.27 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.434 ' N ' ' CD2' ' Q' ' 13' ' ' HIS . 3.1 m-70 -132.93 121.13 22.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.785 178.326 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.588 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 32.1 m-70 -144.82 161.83 38.29 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.626 178.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . 0.597 ' NE2' ' CG1' ' O' ' 36' ' ' VAL . 58.1 tp60 -90.09 157.81 17.6 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.52 102.34 4.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 176.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 77.7 mt -116.14 117.11 29.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 C-N-CA 120.317 -0.553 . . . . 0.0 111.06 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 41.1 t -118.01 99.28 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 177.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 7.2 m-30 -110.57 107.64 17.32 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -120.49 138.84 53.6 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.989 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . 0.426 ' HA ' ' O ' ' P' ' 21' ' ' ALA . . . -147.62 151.79 36.79 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' P' ' 23' ' ' ASP . 80.5 tt0 -80.27 121.8 26.09 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.217 -179.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.458 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 67.1 t0 -136.22 52.08 1.99 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.7 142.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 25' ' ' GLY . . . 100.4 38.05 3.61 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 106.082 -2.807 . . . . 0.0 106.082 -174.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 37.2 t -69.71 104.03 2.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.003 1.382 . . . . 0.0 114.568 -172.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . 0.505 ' O ' ' C ' ' Q' ' 28' ' ' LYS . 10.8 m120 -118.82 -153.33 0.53 Allowed 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 111.824 -2.444 . . . . 0.0 105.036 178.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . 0.505 ' C ' ' O ' ' Q' ' 27' ' ' ASN . 99.0 mttt -35.42 -41.15 0.17 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 120.354 1.434 . . . . 0.0 109.9 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.02 -65.42 2.59 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.95 1.54 . . . . 0.0 116.95 172.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' P' ' 30' ' ' ALA . . . -171.01 174.95 4.53 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.981 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.6 mt -121.12 118.08 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-N 113.347 -1.751 . . . . 0.0 107.015 176.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -120.38 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.24 0.543 . . . . 0.0 112.282 -178.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.81 114.34 2.07 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 32.0 mt -120.9 128.91 53.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 57.2 mtp -132.47 132.14 42.4 Favored 'General case' 0 CA--C 1.514 -0.405 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.314 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . 0.445 ' O ' ' N ' ' R' ' 37' ' ' GLY . 69.2 t -115.65 135.58 55.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.551 ' O ' ' N ' ' P' ' 38' ' ' GLY . . . -139.44 103.32 0.38 Allowed Glycine 0 C--N 1.306 -1.095 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 148.56 72.5 0.01 OUTLIER Glycine 0 N--CA 1.479 1.524 0 CA-C-N 119.76 1.78 . . . . 0.0 114.635 -178.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . 0.448 ' C ' ' O ' ' Q' ' 38' ' ' GLY . 37.2 t -18.63 125.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.601 0.761 . . . . 0.0 112.699 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.639 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -81.96 140.16 34.17 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.889 0.376 . . . . 0.0 110.589 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -113.53 128.04 56.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.711 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . 0.419 ' H ' HG12 ' Q' ' 12' ' ' VAL . 78.5 t -135.28 156.71 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.125 0.488 . . . . 0.0 110.982 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -144.06 132.42 22.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.252 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . 0.588 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 64.2 m80 -151.73 161.73 42.18 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . 0.422 HE22 HG23 ' P' ' 36' ' ' VAL . 52.3 tt0 -90.13 158.45 17.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.89 0.376 . . . . 0.0 111.486 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.6 100.83 3.95 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . 0.402 ' H ' HD11 ' R' ' 17' ' ' LEU . 0.3 OUTLIER -111.64 112.78 24.73 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.958 0.409 . . . . 0.0 109.948 179.313 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 87.6 t -117.83 101.64 12.18 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . 0.465 ' O ' ' CD1' ' R' ' 20' ' ' PHE . 4.0 m-85 -119.43 116.83 26.96 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' R' ' 19' ' ' PHE . 80.1 m-85 -150.8 160.03 44.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 122.08 0.943 . . . . 0.0 112.384 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.36 145.94 51.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.129 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.77 153.87 40.63 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 122.095 0.95 . . . . 0.0 113.49 -175.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 61.0 t0 61.98 47.93 5.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 113.581 -1.645 . . . . 0.0 111.676 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.453 ' CG1' ' N ' ' R' ' 25' ' ' GLY . 45.4 t -59.68 171.12 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.911 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . 0.453 ' N ' ' CG1' ' R' ' 24' ' ' VAL . . . 161.12 31.41 0.02 OUTLIER Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 3.3 t 72.73 120.75 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 95.7 m-20 -83.04 162.3 21.44 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.428 -0.909 . . . . 0.0 111.508 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -48.08 -39.67 20.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.407 177.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.38 66.89 0.04 OUTLIER Glycine 0 CA--C 1.539 1.557 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.829 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.81 159.32 34.52 Favored 'General case' 0 C--N 1.345 0.409 0 CA-C-N 117.837 0.819 . . . . 0.0 110.117 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -107.42 116.14 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -124.25 125.44 70.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-O 120.803 0.335 . . . . 0.0 110.566 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.15 121.05 3.24 Favored Glycine 0 N--CA 1.463 0.478 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . 0.533 ' CD2' ' H ' ' R' ' 34' ' ' LEU . 1.2 pt? -123.15 128.26 49.81 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 121.433 0.635 . . . . 0.0 110.471 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 91.3 mmm -123.56 120.03 31.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.022 -178.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 96.2 t -100.28 115.42 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.33 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -115.25 122.97 5.78 Favored Glycine 0 CA--C 1.508 -0.384 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 177.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.92 66.48 0.46 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.428 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 26.8 m -53.89 152.59 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 117.43 0.615 . . . . 0.0 110.574 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.756 179.685 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mm-40 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.705 0.288 . . . . 0.0 110.709 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 73.2 t -138.61 87.22 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.563 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -148.54 143.66 26.79 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.592 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 0.5 OUTLIER -111.94 163.14 14.56 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.144 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -89.91 158.74 17.28 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -140.62 106.86 5.24 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 87.9 mt -136.11 120.09 17.54 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.917 0.78 . . . . 0.0 110.772 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.34 136.01 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.703 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -125.46 119.38 28.08 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.907 0.384 . . . . 0.0 111.203 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -108.39 118.73 37.53 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.16 117.5 30.21 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.215 0.531 . . . . 0.0 111.2 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.73 -162.56 0.33 Allowed 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 115.294 -0.867 . . . . 0.0 108.897 179.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 60.8 t0 . . . . . 0 CA--C 1.531 0.234 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.697 -179.352 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.6 m120 . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 122.016 0.912 . . . . 0.0 112.869 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 28' ' ' LYS . 99.3 mttt -46.77 -38.87 10.74 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 113.666 -1.606 . . . . 0.0 112.331 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.09 70.47 0.21 Allowed Glycine 0 CA--C 1.532 1.139 0 CA-C-N 114.575 -1.193 . . . . 0.0 114.335 -173.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' B' ' 30' ' ' ALA . . . -95.21 117.0 29.48 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 123.86 1.79 . . . . 0.0 112.071 -177.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 32.0 pt -149.59 147.78 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 112.457 -2.156 . . . . 0.0 108.589 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.421 HG23 HD12 ' A' ' 32' ' ' ILE . 97.8 mt -105.74 114.03 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.26 95.04 0.72 Allowed Glycine 0 N--CA 1.462 0.376 0 N-CA-C 105.639 -2.984 . . . . 0.0 105.639 177.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -142.95 151.78 41.3 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 122.664 1.221 . . . . 0.0 113.901 -176.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 89.5 mmm -106.99 108.98 20.76 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-N 112.634 -2.075 . . . . 0.0 105.616 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 24.3 t -124.14 112.05 31.1 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -178.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.486 ' CA ' ' NE2' ' C' ' 15' ' ' GLN . . . 115.48 -132.09 10.09 Favored Glycine 0 C--N 1.321 -0.296 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 92.06 -63.34 2.46 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.579 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' VAL . 1.1 m -96.03 177.86 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . 0.466 ' H ' ' HB3' ' H' ' 28' ' ' LYS . 7.3 p . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.746 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -107.06 132.41 53.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.736 0.303 . . . . 0.0 110.243 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.519 ' O ' ' CE1' ' C' ' 13' ' ' HIS . 84.2 tt0 -151.35 128.37 11.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.398 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.05 109.93 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-O 121.438 0.637 . . . . 0.0 110.358 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.424 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 22.6 p-80 -151.21 158.97 44.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.726 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.52 ' CD2' ' ND1' ' A' ' 14' ' ' HIS . 2.8 m-70 -143.04 163.89 31.58 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.63 178.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -89.96 152.01 21.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -149.16 100.98 3.1 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 69.8 mt -122.78 121.91 37.44 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.789 0.328 . . . . 0.0 110.41 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.6 t -125.79 125.88 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.552 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -124.17 120.88 33.57 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.57 0.224 . . . . 0.0 110.695 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -122.58 121.06 35.58 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 116.697 -0.228 . . . . 0.0 110.967 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.98 130.15 55.53 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.655 0.264 . . . . 0.0 110.611 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.452 ' CG ' ' N ' ' B' ' 23' ' ' ASP . 77.0 tt0 -66.73 154.87 39.61 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -175.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.452 ' N ' ' CG ' ' B' ' 22' ' ' GLU . 65.8 t0 -67.15 47.79 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 111.216 -2.72 . . . . 0.0 113.833 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 24' ' ' VAL . . . . . 0.489 HG13 ' H ' ' B' ' 25' ' ' GLY . 1.9 t -60.73 -179.5 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 118.388 -1.325 . . . . 0.0 111.527 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 25' ' ' GLY . . . . . 0.489 ' H ' HG13 ' B' ' 24' ' ' VAL . . . -99.71 28.91 13.33 Favored Glycine 0 N--CA 1.471 0.999 0 CA-C-N 114.809 -1.087 . . . . 0.0 115.681 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' B' ' 27' ' ' ASN . 42.8 t -162.18 116.14 1.83 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 120.089 1.945 . . . . 0.0 113.869 -176.107 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' B' ' 26' ' ' SER . 10.5 m120 -22.71 164.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.848 0 O-C-N 125.311 1.632 . . . . 0.0 112.636 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.8 mttt -155.39 -20.71 0.11 Allowed 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 119.826 -0.75 . . . . 0.0 112.646 -177.192 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.38 97.8 0.06 OUTLIER Glycine 0 C--N 1.334 0.462 0 C-N-CA 117.497 -2.287 . . . . 0.0 109.603 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 30' ' ' ALA . . . -120.05 119.08 32.32 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 122.66 1.219 . . . . 0.0 112.505 -176.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.434 HG22 HD13 ' B' ' 31' ' ' ILE . 97.3 mt -127.45 132.29 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 113.971 -1.468 . . . . 0.0 111.097 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 23.1 mt -102.72 116.63 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -115.63 98.56 0.84 Allowed Glycine 0 C--O 1.237 0.287 0 N-CA-C 105.818 -2.913 . . . . 0.0 105.818 177.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -137.68 135.14 36.2 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 122.495 1.14 . . . . 0.0 112.558 -175.459 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 4.4 mtp -104.05 110.36 22.5 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 113.311 -1.768 . . . . 0.0 106.842 177.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -131.21 123.09 52.69 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.84 -113.4 0.66 Allowed Glycine 0 C--N 1.311 -0.84 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.61 -72.62 0.82 Allowed Glycine 0 CA--C 1.532 1.103 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . 0.455 ' O ' ' C ' ' B' ' 40' ' ' VAL . 3.7 p -144.58 157.48 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' B' ' 39' ' ' VAL . 20.4 m . . . . . 0 N--CA 1.473 0.686 0 CA-C-O 117.965 -1.017 . . . . 0.0 111.921 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -107.94 136.16 48.11 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -122.12 100.99 7.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.862 0.363 . . . . 0.0 110.323 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . 0.506 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 1.5 p -145.1 137.55 21.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.345 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' B' ' 11' ' ' GLU . 2.0 m-70 -147.22 135.31 21.47 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.116 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.653 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 32.8 m-70 -142.23 161.08 38.92 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.243 -0.583 . . . . 0.0 110.977 177.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.486 ' NE2' ' CA ' ' A' ' 37' ' ' GLY . 22.8 mt-30 -85.41 157.16 20.56 Favored 'General case' 0 CA--C 1.523 -0.09 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 176.109 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -159.22 91.94 1.05 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -128.82 122.35 30.26 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.968 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 m -124.48 120.79 59.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -113.47 108.16 16.82 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.317 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -110.59 122.01 46.72 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.41 125.72 33.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.914 0.864 . . . . 0.0 112.406 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 94.9 mt-10 -98.72 110.14 22.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 177.699 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.41 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 99.2 m-20 -140.45 49.26 1.72 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.618 -1.174 . . . . 0.0 111.2 -175.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 53.8 t -71.44 161.39 4.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 C-N-CA 119.339 -0.945 . . . . 0.0 109.901 -175.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 25' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 109.46 -29.87 9.09 Favored Glycine 0 CA--C 1.531 1.031 0 N-CA-C 107.315 -2.314 . . . . 0.0 107.315 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 26' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 1.1 m 93.21 114.58 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 114.194 -1.003 . . . . 0.0 110.583 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -73.58 164.05 27.18 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.551 0.691 . . . . 0.0 112.266 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' D' ' 28' ' ' LYS . 98.9 mttt -48.01 -37.01 13.84 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 114.109 1.151 . . . . 0.0 114.109 178.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.85 77.21 0.06 OUTLIER Glycine 0 CA--C 1.536 1.367 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.971 -175.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.0 138.27 37.01 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 122.547 1.165 . . . . 0.0 113.478 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.421 HD12 HG21 ' C' ' 31' ' ' ILE . 94.1 mt -142.42 144.89 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 114.328 -1.305 . . . . 0.0 112.656 -178.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.47 HG21 HD13 ' C' ' 32' ' ' ILE . 75.6 mt -106.71 111.4 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 174.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.94 101.66 0.89 Allowed Glycine 0 N--CA 1.465 0.592 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 6.6 mp -141.9 148.01 38.02 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.954 1.359 . . . . 0.0 113.329 -178.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -104.4 111.52 24.21 Favored 'General case' 0 N--CA 1.44 -0.925 0 CA-C-N 112.097 -2.319 . . . . 0.0 105.692 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' D' ' 36' ' ' VAL . 55.1 t -124.81 123.22 65.32 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.741 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -178.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.07 -113.31 0.77 Allowed Glycine 0 C--N 1.312 -0.794 0 C-N-CA 119.75 -1.214 . . . . 0.0 111.958 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.78 -73.01 2.68 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 13.6 p -172.79 132.92 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 177.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . 0.555 ' CG2' ' NE2' ' F' ' 13' ' ' HIS . 21.4 m . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.776 -1.107 . . . . 0.0 110.043 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 20.3 m . . . . . 0 N--CA 1.466 0.329 0 CA-C-O 121.231 0.539 . . . . 0.0 111.218 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.498 ' O ' ' CG ' ' E' ' 13' ' ' HIS . 7.6 m80 -140.07 135.6 32.76 Favored 'General case' 0 C--O 1.225 -0.194 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.032 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.653 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 1.3 t-80 -136.88 156.0 49.04 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.649 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.629 HE21 ' CD1' ' D' ' 17' ' ' LEU . 54.8 tt0 -87.55 157.15 19.23 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -162.45 92.93 0.83 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.674 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . 0.629 ' CD1' HE21 ' D' ' 15' ' ' GLN . 23.3 mt -122.39 114.17 20.37 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.9 t -110.64 109.18 27.5 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.534 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -109.62 107.37 17.42 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -122.24 131.58 54.0 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-O 120.737 0.303 . . . . 0.0 111.544 -177.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.06 140.01 32.44 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 122.033 0.921 . . . . 0.0 112.998 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -82.03 113.87 20.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 122.039 0.923 . . . . 0.0 111.372 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.443 ' H ' ' HB3' ' E' ' 22' ' ' GLU . 54.4 m-20 50.17 46.42 24.77 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 113.551 -1.659 . . . . 0.0 112.267 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 24' ' ' VAL . . . . . 0.539 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 96.4 t -111.62 177.64 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 104.719 -2.326 . . . . 0.0 104.719 174.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 25' ' ' GLY . . . . . 0.539 ' H ' ' CG1' ' D' ' 24' ' ' VAL . . . 63.02 28.69 72.49 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 178.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 48.9 m -108.67 -120.01 0.26 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.794 0.807 . . . . 0.0 112.498 -177.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -79.94 174.05 11.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.338 -178.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' C' ' 28' ' ' LYS . 99.1 mttt 58.32 39.91 25.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 113.998 1.11 . . . . 0.0 113.998 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.11 70.99 0.95 Allowed Glycine 0 N--CA 1.477 1.422 0 C-N-CA 119.031 -1.557 . . . . 0.0 116.346 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.0 109.08 15.08 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.365 0.602 . . . . 0.0 109.917 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -133.57 141.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 N-CA-C 114.101 1.148 . . . . 0.0 114.101 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.401 HD11 HG21 ' D' ' 32' ' ' ILE . 6.4 mt -108.69 113.9 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.91 102.97 1.27 Allowed Glycine 0 C--O 1.24 0.511 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 177.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -133.93 134.51 42.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 122.181 0.991 . . . . 0.0 112.877 -176.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -105.17 112.36 25.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 113.445 -1.707 . . . . 0.0 107.304 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' E' ' 37' ' ' GLY . 0.4 OUTLIER -114.17 177.06 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.165 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.53 -96.29 0.33 Allowed Glycine 0 C--N 1.31 -0.877 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . 0.496 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 38.17 75.92 0.08 OUTLIER Glycine 0 CA--C 1.533 1.207 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.056 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.496 ' C ' ' O ' ' D' ' 38' ' ' GLY . 60.4 t -6.35 123.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -178.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.509 ' O ' ' NZ ' ' K' ' 28' ' ' LYS . 55.3 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.455 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -81.81 138.98 35.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -136.28 140.61 43.55 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.029 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 70.4 t -124.35 124.97 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 110.465 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.607 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.5 OUTLIER -156.4 134.75 11.44 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 179.387 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.607 ' N ' ' ND1' ' E' ' 13' ' ' HIS . 34.8 m-70 -143.52 167.38 22.35 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.73 0.3 . . . . 0.0 110.464 179.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -89.64 151.3 21.97 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 14.3 mttt -153.35 98.73 2.29 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.011 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mt -121.84 116.13 23.88 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -111.21 101.54 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -106.75 102.65 12.01 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -122.49 132.99 54.59 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-O 121.229 0.537 . . . . 0.0 112.225 -178.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -138.77 145.34 40.08 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.42 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.443 ' HB3' ' H ' ' D' ' 23' ' ' ASP . 79.5 tt0 -68.73 147.16 52.21 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 117.574 -1.65 . . . . 0.0 108.804 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.534 ' O ' ' O ' ' E' ' 24' ' ' VAL . 21.2 t70 -128.05 61.6 1.44 Allowed 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.083 -174.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' E' ' 23' ' ' ASP . 4.7 t -33.64 -110.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.318 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -113.4 46.49 1.16 Allowed Glycine 0 N--CA 1.485 1.952 0 CA-C-N 120.173 1.351 . . . . 0.0 115.421 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.515 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.8 t 91.56 111.5 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 122.318 0.247 . . . . 0.0 111.378 176.204 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -75.35 163.88 27.0 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.644 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.88 -39.41 25.76 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.13 0.04 OUTLIER Glycine 0 CA--C 1.544 1.849 0 C-N-CA 120.159 -1.02 . . . . 0.0 113.312 -176.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.76 145.17 50.6 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.333 1.566 . . . . 0.0 111.727 -177.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 1.3 tt -131.72 141.75 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 CA-C-O 121.675 0.75 . . . . 0.0 111.968 -177.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 94.5 mt -124.98 131.43 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.78 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.56 117.2 2.72 Favored Glycine 0 CA--C 1.533 1.182 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 36.5 mt -123.55 122.81 39.14 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.236 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.0 mmm -119.73 129.18 54.39 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.468 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 54.2 t -94.15 135.05 29.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.985 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' D' ' 36' ' ' VAL . . . -99.9 -103.42 2.51 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -63.27 75.12 0.04 OUTLIER Glycine 0 CA--C 1.534 1.229 0 CA-C-N 113.891 -1.155 . . . . 0.0 112.48 179.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . 0.431 HG13 ' H ' ' F' ' 39' ' ' VAL . 8.8 m . . . . . 0 CA--C 1.541 0.607 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.736 0.303 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.453 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 2.6 t -108.22 106.02 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.839 0.352 . . . . 0.0 110.471 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.587 ' ND1' ' N ' ' F' ' 14' ' ' HIS . 17.1 t-80 -152.97 139.89 19.12 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.587 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 81.0 t60 -150.52 168.64 23.61 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.833 178.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.49 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 51.1 tt0 -89.56 150.35 22.46 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -151.82 96.35 2.22 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.195 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.84 109.74 17.47 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -108.58 106.27 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.475 ' O ' ' CD1' ' F' ' 20' ' ' PHE . 44.3 m-85 -109.04 107.35 17.66 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.475 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 9.2 m-85 -146.63 140.69 26.21 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 118.29 -1.364 . . . . 0.0 114.063 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.416 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -114.86 119.34 36.26 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.649 -2.723 . . . . 0.0 103.649 174.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -95.09 134.49 37.74 Favored 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 117.533 2.42 . . . . 0.0 117.533 -172.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 24.4 p-10 . . . . . 0 C--N 1.348 0.525 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.598 173.427 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.19 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 14.6 tt -129.61 137.83 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.451 178.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -132.66 140.45 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.57 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.47 124.43 3.68 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 9.3 tt -130.69 127.15 38.27 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.8 mtp -139.33 145.4 39.02 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 6.3 p -144.59 146.07 20.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.11 177.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.45 102.11 0.37 Allowed Glycine 0 C--N 1.319 -0.368 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.172 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.6 -73.56 0.3 Allowed Glycine 0 CA--C 1.536 1.381 0 C-N-CA 120.454 -0.879 . . . . 0.0 113.96 176.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' F' ' 40' ' ' VAL . 99.1 t -146.82 163.31 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.998 0.428 . . . . 0.0 110.443 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . 0.454 ' N ' ' CG1' ' F' ' 39' ' ' VAL . 8.0 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.896 -1.049 . . . . 0.0 110.334 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 12' ' ' VAL . . . . . 0.476 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 99.4 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 121.174 0.511 . . . . 0.0 110.967 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -103.89 158.52 16.35 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.742 -179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.618 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 18.6 t60 -85.62 166.97 15.78 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.718 -179.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.618 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 83.6 mt-30 -155.29 141.81 18.74 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.169 0.509 . . . . 0.0 110.357 178.184 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -88.03 110.16 20.4 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.743 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mp -120.42 112.91 19.58 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 177.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -125.74 131.32 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.155 -178.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.68 128.25 42.17 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.469 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -128.29 126.78 41.49 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.75 122.61 38.52 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.706 0.765 . . . . 0.0 112.012 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -121.56 133.25 55.01 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.536 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.63 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 98.3 m-20 . . . . . 0 C--N 1.32 -0.677 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.181 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.53 ' OD1' ' NZ ' ' H' ' 28' ' ' LYS . 71.6 m-20 . . . . . 0 N--CA 1.466 0.344 0 CA-C-O 121.057 0.456 . . . . 0.0 111.541 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm 51.12 39.22 22.92 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.24 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.25 -66.67 1.59 Allowed Glycine 0 CA--C 1.539 1.565 0 C-N-CA 120.158 -1.02 . . . . 0.0 110.68 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' H' ' 30' ' ' ALA . . . -150.7 62.32 0.93 Allowed 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 119.593 1.696 . . . . 0.0 114.605 177.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 80.6 mt -136.45 113.44 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 176.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.445 ' O ' ' O ' ' H' ' 33' ' ' GLY . 96.4 mt -107.87 106.2 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.606 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.03 97.17 0.94 Allowed Glycine 0 CA--C 1.508 -0.357 0 N-CA-C 104.95 -3.26 . . . . 0.0 104.95 176.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.415 HD12 ' H ' ' G' ' 35' ' ' MET . 52.4 tp -155.63 154.39 31.54 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 118.188 -1.405 . . . . 0.0 113.361 -175.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.415 ' H ' HD12 ' G' ' 34' ' ' LEU . 8.1 mtp -112.11 122.47 47.83 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-N 112.989 -1.914 . . . . 0.0 108.655 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.32 112.07 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.69 -132.07 10.94 Favored Glycine 0 CA--C 1.519 0.303 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.53 -62.64 0.42 Allowed Glycine 0 CA--C 1.536 1.37 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 t -92.78 164.41 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 40' ' ' VAL . . . . . 0.552 ' N ' ' CG2' ' H' ' 39' ' ' VAL . 8.5 p . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.991 -1.005 . . . . 0.0 110.585 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.196 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 44.3 t80 -71.38 133.5 46.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.906 0.384 . . . . 0.0 110.587 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -94.29 115.62 27.89 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.388 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.15 136.09 32.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.338 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.501 ' NE2' ' OE2' ' I' ' 11' ' ' GLU . 81.0 m80 -113.4 149.54 33.98 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 9.6 p-80 -86.82 164.15 16.82 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.983 -179.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -100.81 152.6 20.32 Favored 'General case' 0 CA--C 1.522 -0.098 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.837 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -110.84 107.86 17.49 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 177.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -123.16 117.38 25.24 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 m -132.14 133.76 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.132 0.491 . . . . 0.0 111.033 179.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -129.91 129.65 44.14 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.559 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.408 ' CE2' ' CG ' ' I' ' 20' ' ' PHE . 29.2 m-85 -127.43 131.57 50.22 Favored 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.465 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.19 122.38 31.73 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 82.6 tt0 -147.17 121.67 9.73 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 114.621 1.341 . . . . 0.0 114.621 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.63 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 1.7 p-10 156.24 -74.5 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.379 175.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.667 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 3.6 p -67.53 -112.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.713 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 25' ' ' GLY . . . . . 0.667 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . 126.39 -38.76 2.14 Favored Glycine 0 N--CA 1.454 -0.128 0 CA-C-N 113.866 -1.516 . . . . 0.0 111.133 176.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 16.2 t -70.4 112.7 6.89 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 174.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -113.68 168.54 9.69 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.815 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 28' ' ' LYS . . . . . 0.53 ' NZ ' ' OD1' ' G' ' 27' ' ' ASN . 99.2 mttt -39.39 -38.42 0.55 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.618 -1.173 . . . . 0.0 111.091 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 29' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' H' ' 31' ' ' ILE . . . 179.72 77.08 0.06 OUTLIER Glycine 0 CA--C 1.535 1.314 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.909 -176.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.454 ' O ' ' HA ' ' I' ' 30' ' ' ALA . . . -51.49 91.14 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 119.131 1.466 . . . . 0.0 112.157 -177.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.402 ' N ' ' O ' ' H' ' 29' ' ' GLY . 96.8 mt -134.21 138.63 49.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.135 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.427 HG21 HD11 ' H' ' 32' ' ' ILE . 96.8 mt -108.32 104.95 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 177.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -105.13 97.09 1.29 Allowed Glycine 0 N--CA 1.461 0.3 0 N-CA-C 104.565 -3.414 . . . . 0.0 104.565 176.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 15.2 tp -143.09 136.43 28.29 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 118.731 -1.187 . . . . 0.0 113.044 -174.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.8 mtp -105.18 118.82 37.52 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 113.176 -1.829 . . . . 0.0 106.845 178.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.502 ' O ' ' NE2' ' J' ' 15' ' ' GLN . 10.9 t -130.03 102.62 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -177.346 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.43 -162.49 12.38 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.16 -55.44 0.52 Allowed Glycine 0 CA--C 1.542 1.747 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.552 ' CG2' ' N ' ' G' ' 40' ' ' VAL . 1.8 m -127.99 161.57 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.45 ' OXT' ' O ' ' O' ' 28' ' ' LYS . 46.6 t . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.012 177.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.93 135.45 48.46 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.793 0.33 . . . . 0.0 110.367 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 11' ' ' GLU . . . . . 0.501 ' OE2' ' NE2' ' H' ' 13' ' ' HIS . 97.3 mt-10 -74.35 109.4 7.8 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.475 ' CG2' ' O ' ' J' ' 12' ' ' VAL . 23.2 m -139.27 159.79 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.942 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.477 ' CD2' ' OXT' ' G' ' 40' ' ' VAL . 78.0 m80 -69.78 114.25 7.8 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.611 -178.116 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 13.2 t60 -161.9 169.98 20.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.273 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.645 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 57.9 tt0 -156.27 140.28 16.34 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 120.191 -0.603 . . . . 0.0 110.4 177.053 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -97.92 113.94 25.9 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 178.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 58.8 mt -121.98 114.22 20.66 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.4 t -116.41 109.68 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -108.01 106.44 16.67 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.408 ' CG ' ' CE2' ' H' ' 20' ' ' PHE . 35.3 t80 -120.6 132.97 55.4 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -176.316 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' J' ' 21' ' ' ALA . . . -149.7 146.5 27.27 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-O 121.63 0.729 . . . . 0.0 112.651 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.422 ' OE2' ' OE2' ' H' ' 22' ' ' GLU . 77.9 mt-10 -103.88 151.55 22.99 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.837 178.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.602 ' N ' ' O ' ' J' ' 22' ' ' GLU . 71.4 m-20 57.47 48.79 13.93 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.14 0.495 . . . . 0.0 110.405 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.518 ' O ' ' CG2' ' J' ' 24' ' ' VAL . 0.1 OUTLIER -137.4 -173.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-O 121.66 0.743 . . . . 0.0 110.824 -177.23 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 28.2 67.67 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -177.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 71.3 m -143.56 -128.18 0.09 Allowed 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.58 ' CG ' ' H ' ' I' ' 28' ' ' LYS . 50.5 t30 54.38 -159.48 0.17 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 178.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.58 ' H ' ' CG ' ' I' ' 27' ' ' ASN . 64.1 mttp -64.46 -39.61 94.14 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.46 1.652 . . . . 0.0 115.46 -173.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.31 66.31 0.25 Allowed Glycine 0 N--CA 1.472 1.067 0 C-N-CA 118.52 -1.8 . . . . 0.0 114.616 -175.127 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' H' ' 30' ' ' ALA . . . -82.7 131.95 35.19 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 122.156 0.979 . . . . 0.0 112.111 -178.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 50.5 mt -144.05 143.4 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 114.447 -1.251 . . . . 0.0 113.585 -177.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.431 HD13 HG21 ' I' ' 32' ' ' ILE . 54.1 mt -105.15 101.99 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 173.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -103.62 98.5 1.61 Allowed Glycine 0 CA--C 1.507 -0.452 0 N-CA-C 104.913 -3.275 . . . . 0.0 104.913 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 tp -140.13 135.12 32.17 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 122.287 1.041 . . . . 0.0 113.281 -173.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 5.9 mtp -109.43 117.66 34.61 Favored 'General case' 0 CA--C 1.512 -0.484 0 CA-C-N 113.612 -1.631 . . . . 0.0 107.205 177.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 4.4 t -130.42 111.82 21.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 CA-C-O 120.624 0.25 . . . . 0.0 110.736 -177.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.712 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 138.33 -131.07 5.23 Favored Glycine 0 C--N 1.318 -0.434 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.144 177.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.05 -61.76 0.39 Allowed Glycine 0 CA--C 1.543 1.828 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . 0.422 ' CG1' ' N ' ' H' ' 40' ' ' VAL . 4.0 p -146.21 151.25 14.59 Favored 'Isoleucine or valine' 0 C--N 1.344 0.339 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 175.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . 0.439 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 58.6 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.753 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.62 133.04 51.01 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.928 0.394 . . . . 0.0 110.732 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -85.18 125.29 32.71 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.912 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.54 ' CG1' ' HE2' ' J' ' 14' ' ' HIS . 96.0 t -125.82 108.64 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.621 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -111.78 124.38 52.22 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' K' ' 14' ' ' HIS . 47.1 m-70 -148.67 162.9 38.8 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 120.29 -0.564 . . . . 0.0 109.735 174.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.686 ' NE2' HE21 ' K' ' 15' ' ' GLN . 85.0 mt-30 -100.69 147.17 26.31 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.114 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 13.8 mttt -118.34 92.37 3.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mt -117.24 115.54 25.5 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.693 -178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.7 t -113.5 102.38 13.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -104.05 107.09 17.83 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 178.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.567 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -121.95 124.07 43.17 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.622 -176.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' I' ' 21' ' ' ALA . . . -136.27 115.48 12.52 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' I' ' 23' ' ' ASP . 98.0 mt-10 -120.18 177.74 4.9 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 118.333 2.716 . . . . 0.0 118.333 -174.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 41.5 t0 28.62 46.31 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 119.946 3.313 . . . . 0.0 119.946 175.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.518 ' CG2' ' O ' ' I' ' 24' ' ' VAL . 0.2 OUTLIER -80.57 -179.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 175.105 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.05 -29.23 69.18 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 118.126 -1.988 . . . . 0.0 112.274 -178.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.421 ' O ' ' C ' ' J' ' 27' ' ' ASN . 1.5 t 168.16 127.24 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.813 0.807 . . . . 0.0 112.079 175.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.466 HD22 ' N ' ' J' ' 30' ' ' ALA . 2.0 t-20 -37.21 133.94 0.63 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.733 174.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.417 ' HB2' ' O ' ' I' ' 27' ' ' ASN . 67.6 mttm -109.27 -40.27 4.98 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 118.969 0.804 . . . . 0.0 111.118 177.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.45 64.35 0.24 Allowed Glycine 0 CA--C 1.541 1.718 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.924 -178.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.466 ' N ' HD22 ' J' ' 27' ' ' ASN . . . -83.7 143.26 30.15 Favored 'General case' 0 C--O 1.245 0.855 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -177.612 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 79.9 mt -135.78 131.0 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 114.832 -1.076 . . . . 0.0 111.677 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 3.0 mt -106.22 110.36 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 176.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 99.0 1.06 Allowed Glycine 0 C--O 1.239 0.441 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 177.018 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 24.3 tp -134.93 123.59 23.62 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.414 1.102 . . . . 0.0 113.697 -175.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttm -98.29 116.69 31.05 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 176.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -130.11 103.3 8.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 C-N-CA 121.365 -0.134 . . . . 0.0 111.049 -177.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.22 -153.72 25.23 Favored Glycine 0 CA--C 1.509 -0.283 0 C-N-CA 120.035 -1.079 . . . . 0.0 112.358 178.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.493 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 138.73 -56.31 0.65 Allowed Glycine 0 CA--C 1.544 1.898 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.787 -178.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . 0.41 ' HB ' ' H ' ' I' ' 40' ' ' VAL . 87.8 t -135.93 157.89 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 40' ' ' VAL . . . . . 0.406 ' N ' ' CG1' ' J' ' 39' ' ' VAL . 17.3 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.528 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -108.85 146.54 33.52 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.854 0.359 . . . . 0.0 110.561 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -70.32 128.81 37.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -111.94 121.05 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.785 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.667 ' CG ' ' HZ3' ' O' ' 28' ' ' LYS . 6.6 p80 -151.59 113.72 4.51 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.377 -0.529 . . . . 0.0 112.027 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' J' ' 14' ' ' HIS . 13.4 p-80 -153.34 160.31 42.65 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.389 177.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.712 HE22 ' N ' ' I' ' 37' ' ' GLY . 88.3 mt-30 -90.12 160.08 16.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.213 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -139.42 109.38 6.37 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.457 0.646 . . . . 0.0 109.902 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mt -118.55 122.41 42.58 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.865 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 16.7 t -113.49 101.05 11.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -100.79 102.67 13.8 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 105.232 -2.136 . . . . 0.0 105.232 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CD1' ' L' ' 20' ' ' PHE . 1.4 t80 -113.4 124.96 53.66 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -177.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' K' ' 23' ' ' ASP . . . -160.76 162.78 32.51 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 -177.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -72.36 136.83 46.25 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.669 ' O ' ' O ' ' K' ' 24' ' ' VAL . 6.4 m-20 -152.5 61.03 0.82 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.987 1.477 . . . . 0.0 114.987 -173.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.669 ' O ' ' O ' ' K' ' 23' ' ' ASP . 34.4 t -44.16 -110.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' K' ' 27' ' ' ASN . . . 162.82 -46.51 0.33 Allowed Glycine 0 CA--C 1.506 -0.519 0 C-N-CA 116.707 -2.663 . . . . 0.0 115.781 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m -65.99 101.56 0.69 Allowed 'General case' 0 CA--C 1.519 -0.25 0 CA-C-N 123.605 3.702 . . . . 0.0 104.373 178.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.539 ' N ' ' O ' ' K' ' 25' ' ' GLY . 28.2 m-20 -130.04 161.4 31.08 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 114.847 -1.069 . . . . 0.0 112.455 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.509 ' NZ ' ' O ' ' D' ' 40' ' ' VAL . 61.3 tttt -28.71 -39.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.833 172.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . 141.75 73.81 0.04 OUTLIER Glycine 0 CA--C 1.545 1.914 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.103 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.44 150.03 46.63 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 121.804 0.811 . . . . 0.0 112.681 -177.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mp -136.42 138.26 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 CA-C-N 114.689 -1.141 . . . . 0.0 112.78 -177.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -117.68 119.99 63.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 178.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.46 117.41 3.31 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 67.7 mt -123.47 129.18 50.86 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 73.2 mtp -137.61 136.68 37.75 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.365 -0.934 . . . . 0.0 113.061 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.433 ' O ' ' O ' ' K' ' 37' ' ' GLY . 10.8 t -113.31 155.27 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.149 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -52.25 -102.34 0.01 OUTLIER Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' L' ' 38' ' ' GLY . . . -138.03 -74.6 0.06 OUTLIER Glycine 0 CA--C 1.527 0.792 0 C-N-CA 120.823 -0.704 . . . . 0.0 113.177 178.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 CA--C 1.514 -0.428 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.428 -178.698 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 N--CA 1.465 0.293 0 CA-C-O 120.634 0.254 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 91.1 t -111.91 101.41 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 121.265 0.555 . . . . 0.0 110.877 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.481 ' O ' ' CG ' ' L' ' 14' ' ' HIS . 5.0 p80 -147.2 90.82 1.92 Allowed 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.639 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.481 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 69.3 m80 -158.19 168.31 27.42 Favored 'General case' 0 C--O 1.223 -0.295 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.461 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 94.8 mm-40 -89.84 158.45 17.46 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -139.92 105.27 5.06 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.465 0.65 . . . . 0.0 110.492 178.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . 0.453 HD12 ' H ' ' L' ' 17' ' ' LEU . 0.2 OUTLIER -116.16 113.9 23.73 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.695 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -106.79 103.85 16.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -99.78 101.71 12.94 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.574 ' CD1' ' CZ ' ' K' ' 20' ' ' PHE . 15.1 t80 -110.04 103.13 11.83 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.87 137.31 46.64 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 -178.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.525 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.9 mt-10 -78.62 102.77 8.15 Favored 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 118.879 -1.128 . . . . 0.0 108.636 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 44.2 p-10 -155.77 46.62 0.48 Allowed 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 112.786 0.661 . . . . 0.0 112.786 -177.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 32.9 m -83.22 172.69 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 118.819 -1.152 . . . . 0.0 109.788 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 96.02 -28.68 11.86 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.9 t 91.68 119.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.533 ' O ' ' N ' ' L' ' 29' ' ' GLY . 15.4 m-20 -71.95 150.3 44.24 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.221 -179.013 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -53.17 47.45 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 101.77 63.38 0.75 Allowed Glycine 0 CA--C 1.543 1.799 0 C-N-CA 119.928 -1.129 . . . . 0.0 114.088 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.63 169.46 10.06 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 178.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 12.6 tt -139.8 151.03 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.16 0 C-N-CA 119.008 -1.077 . . . . 0.0 113.626 -177.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 15.0 tt -135.48 134.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.152 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.64 134.22 6.52 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.315 -0.469 . . . . 0.0 111.971 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tt -127.25 124.72 39.51 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mtp -140.86 146.58 37.7 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -177.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 8.8 t -139.33 132.13 37.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.463 177.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -106.97 112.42 3.76 Favored Glycine 0 N--CA 1.468 0.794 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . 112.52 71.25 0.58 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 117.522 0.661 . . . . 0.0 112.477 178.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' L' ' 38' ' ' GLY . 66.2 t . . . . . 0 N--CA 1.478 0.956 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 . . . . . 0 N--CA 1.46 0.046 0 N-CA-C 110.154 -0.314 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 29.0 m -114.9 130.13 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.95 0.405 . . . . 0.0 110.714 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 75.6 m80 -95.06 165.8 12.25 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 14' ' ' HIS . . . . . 0.481 ' CD2' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -86.47 168.0 14.15 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.498 -179.36 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -129.17 150.72 50.44 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -97.62 120.91 38.85 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.595 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.29 115.3 20.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -140.34 140.59 34.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.383 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -143.18 141.32 31.11 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.095 0.474 . . . . 0.0 110.674 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 20' ' ' PHE . . . . . 0.484 ' CD1' ' O ' ' M' ' 20' ' ' PHE . 53.1 p90 -127.4 128.38 45.73 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.66 127.41 46.24 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.329 0.585 . . . . 0.0 111.378 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -138.67 146.34 41.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.94 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 58.47 59.84 2.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.44 . . . . 0.0 112.173 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 24' ' ' VAL . . . . . 0.533 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 4.1 t 70.59 175.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.514 0.673 . . . . 0.0 111.732 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 25' ' ' GLY . . . . . 0.533 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . 100.65 -34.72 5.35 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.948 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 6.1 p -82.92 -121.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 176.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 27' ' ' ASN . . . . . 0.464 ' ND2' ' H ' ' M' ' 31' ' ' ILE . 8.9 p30 -92.42 161.21 14.74 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 176.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 28' ' ' LYS . . . . . 0.413 ' O ' ' CD ' ' N' ' 28' ' ' LYS . 72.8 tttt -45.29 -39.2 6.32 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 119.139 -1.025 . . . . 0.0 110.517 -179.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 29' ' ' GLY . . . . . 0.445 ' O ' ' OD2' ' N' ' 23' ' ' ASP . . . -146.9 -76.18 0.02 OUTLIER Glycine 0 N--CA 1.473 1.11 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.893 177.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.76 87.81 0.82 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-O 121.129 0.49 . . . . 0.0 111.611 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 31' ' ' ILE . . . . . 0.487 ' CG2' ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -138.33 115.56 11.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 32' ' ' ILE . . . . . 0.406 ' O ' ' O ' ' N' ' 33' ' ' GLY . 43.1 mt -107.09 109.37 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.88 92.46 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 105.886 -2.885 . . . . 0.0 105.886 177.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -143.56 167.16 22.87 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 114.927 1.455 . . . . 0.0 114.927 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -123.45 106.58 10.75 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 112.108 -2.315 . . . . 0.0 107.062 177.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 43.9 t -112.46 111.97 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 CA-C-O 121.264 0.554 . . . . 0.0 109.835 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.42 -131.7 7.74 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 38' ' ' GLY . . . . . 0.451 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 94.47 -63.27 1.66 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.786 -1.325 . . . . 0.0 109.786 -178.289 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 4.7 m -96.65 173.51 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' M' M ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' N' ' 40' ' ' VAL . 26.8 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.938 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 9' ' ' GLY . . . . . 0.409 ' H ' ' H ' ' N' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 10' ' ' TYR . . . . . 0.409 ' H ' ' H ' ' N' ' 9' ' ' GLY . 97.4 m-85 -106.42 134.8 49.0 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.764 0.316 . . . . 0.0 110.333 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -114.97 119.71 37.43 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.796 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 58.8 t -126.96 131.4 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -142.32 130.27 21.83 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.443 0.64 . . . . 0.0 112.63 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 14' ' ' HIS . . . . . 0.513 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 33.0 m-70 -153.1 172.39 16.97 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.218 177.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -155.18 141.0 18.15 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.821 -0.751 . . . . 0.0 109.741 177.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -88.53 113.66 24.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.161 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 mp -111.24 113.1 25.36 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.12 132.16 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-O 120.891 0.377 . . . . 0.0 111.35 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -141.23 127.45 19.69 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.956 0.408 . . . . 0.0 111.835 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -117.23 131.58 56.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.29 133.23 34.75 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -122.02 145.31 48.26 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.359 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' M' ' 29' ' ' GLY . 51.6 m-20 -160.94 46.68 0.21 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.918 0.39 . . . . 0.0 111.161 -178.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 m -73.35 -179.79 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.74 0.781 . . . . 0.0 111.99 -178.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.17 -35.33 4.76 Favored Glycine 0 CA--C 1.53 0.99 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.95 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' N' ' 27' ' ' ASN . 84.8 p -162.56 117.04 1.79 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 118.061 0.931 . . . . 0.0 110.874 176.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' N' ' 26' ' ' SER . 55.6 p30 -21.63 161.73 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 28' ' ' LYS . . . . . 0.454 ' CG ' ' O ' ' N' ' 27' ' ' ASN . 60.5 mttm -158.61 -10.3 0.07 Allowed 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 120.389 -0.524 . . . . 0.0 112.405 174.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.36 118.12 0.64 Allowed Glycine 0 CA--C 1.537 1.408 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.631 178.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 30' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' O' ' 29' ' ' GLY . . . -102.91 113.33 26.7 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-O 121.599 0.714 . . . . 0.0 111.98 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 81.4 mt -135.5 131.05 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 32' ' ' ILE . . . . . 0.42 HD11 HG22 ' N' ' 32' ' ' ILE . 92.8 mt -107.08 111.04 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -116.0 105.6 1.42 Allowed Glycine 0 C--N 1.322 -0.234 0 N-CA-C 105.217 -3.153 . . . . 0.0 105.217 176.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 tt -152.77 140.75 20.23 Favored 'General case' 0 CA--C 1.504 -0.8 0 C-N-CA 117.953 -1.499 . . . . 0.0 111.747 -174.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 45.3 mtp -114.29 116.02 28.32 Favored 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.664 -1.607 . . . . 0.0 107.825 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -93.65 102.84 14.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 37' ' ' GLY . . . . . 0.451 ' HA3' ' H ' ' M' ' 38' ' ' GLY . . . -35.38 152.74 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.121 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 38' ' ' GLY . . . . . 0.563 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -85.28 -57.55 2.21 Favored Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.837 -0.697 . . . . 0.0 114.326 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 6.1 m -52.85 140.97 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 119.42 1.61 . . . . 0.0 110.812 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' N' N ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' M' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.552 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -106.53 127.24 53.16 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 11' ' ' GLU . . . . . 0.472 ' O ' ' NE2' ' P' ' 13' ' ' HIS . 97.4 mt-10 -146.7 158.96 44.02 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.809 0.337 . . . . 0.0 111.01 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 55.2 t -129.53 118.3 45.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.659 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -134.36 137.56 44.23 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 14' ' ' HIS . . . . . 0.698 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 66.2 t60 -151.12 153.2 34.57 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 119.027 -1.069 . . . . 0.0 112.278 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 15.2 tp60 -87.83 158.8 18.65 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.263 0.625 . . . . 0.0 110.791 177.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 71.5 tttt -159.09 95.21 1.25 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.252 176.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 17' ' ' LEU . . . . . 0.401 ' CD1' ' N ' ' O' ' 17' ' ' LEU . 8.2 mp -116.45 127.16 54.34 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.283 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -127.23 107.04 16.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.91 113.23 25.43 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 20' ' ' PHE . . . . . 0.481 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 45.8 t80 -111.77 121.53 45.32 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.19 136.91 47.38 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 122.065 0.936 . . . . 0.0 112.492 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 22' ' ' GLU . . . . . 0.481 ' O ' ' CG ' ' O' ' 23' ' ' ASP . 51.6 tt0 -65.85 179.59 0.85 Allowed 'General case' 0 N--CA 1.444 -0.758 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 178.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 23' ' ' ASP . . . . . 0.481 ' CG ' ' O ' ' O' ' 22' ' ' GLU . 1.8 m-20 167.59 58.8 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.978 -174.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 24' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' O' ' 23' ' ' ASP . 18.4 t -62.92 -114.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -177.237 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.01 43.51 1.66 Allowed Glycine 0 N--CA 1.47 0.922 0 CA-C-N 121.71 2.05 . . . . 0.0 109.677 -176.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 26' ' ' SER . . . . . 0.412 ' HG ' ' H ' ' N' ' 28' ' ' LYS . 19.4 t -74.37 99.93 3.64 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 111.479 -2.36 . . . . 0.0 108.724 174.101 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -94.72 -161.73 0.88 Allowed 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.617 0.722 . . . . 0.0 112.045 -177.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 28' ' ' LYS . . . . . 0.667 ' HZ3' ' CG ' ' K' ' 13' ' ' HIS . 70.5 tttt 38.38 40.54 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 29' ' ' GLY . . . . . 0.535 ' O ' ' N ' ' N' ' 30' ' ' ALA . . . -177.72 62.34 0.09 OUTLIER Glycine 0 CA--C 1.541 1.672 0 C-N-CA 118.974 -1.584 . . . . 0.0 115.221 173.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.45 90.4 3.29 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 118.05 0.925 . . . . 0.0 110.883 174.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 71.3 mt -140.96 132.94 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-N 120.869 1.668 . . . . 0.0 113.826 -179.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 32' ' ' ILE . . . . . 0.425 HG22 HD11 ' O' ' 32' ' ' ILE . 78.1 mt -109.88 109.0 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.1 99.28 1.06 Allowed Glycine 0 C--O 1.239 0.414 0 N-CA-C 105.547 -3.021 . . . . 0.0 105.547 177.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 10.3 tp -128.23 130.56 48.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 122.458 1.123 . . . . 0.0 113.507 -174.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.94 104.24 13.95 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 36' ' ' VAL . . . . . 0.495 ' CG2' ' OE1' ' P' ' 15' ' ' GLN . 8.0 p -131.48 142.55 42.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.81 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.97 -102.04 0.82 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.46 -80.17 0.06 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' O' O ' 39' ' ' VAL . . . . . 0.563 ' O ' ' O ' ' N' ' 38' ' ' GLY . 3.4 m -148.44 167.66 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 176.308 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' O' O ' 40' ' ' VAL . . . . . 0.483 ' CG1' ' HE2' ' Q' ' 13' ' ' HIS . 1.4 p . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.377 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 121.044 0.449 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' P' P ' 13' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 86.3 m-70 -142.48 118.81 10.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.437 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 14' ' ' HIS . . . . . 0.698 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 0.0 OUTLIER -146.9 170.74 16.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.472 0.653 . . . . 0.0 111.821 -179.552 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' P' P ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG2' ' O' ' 36' ' ' VAL . 47.7 tt0 -107.45 149.8 27.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.448 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 16' ' ' LYS . . . . . 0.66 ' CG ' ' HE2' ' O' ' 14' ' ' HIS . 71.8 mttt -139.91 110.64 6.78 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 176.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mt -126.88 116.67 21.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -110.11 105.54 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 19' ' ' PHE . . . . . 0.531 ' CD2' ' CE1' ' Q' ' 19' ' ' PHE . 92.5 m-85 -106.59 107.19 18.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 179.192 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 20' ' ' PHE . . . . . 0.596 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 31.3 t80 -116.06 124.29 50.05 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.73 -178.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.41 138.25 30.97 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.75 0.786 . . . . 0.0 112.432 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 22' ' ' GLU . . . . . 0.504 ' O ' ' CB ' ' P' ' 23' ' ' ASP . 20.9 tt0 -76.81 -174.54 3.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 23' ' ' ASP . . . . . 0.504 ' CB ' ' O ' ' P' ' 22' ' ' GLU . 10.3 m-20 142.99 50.02 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 p -82.78 149.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 C-N-CA 119.341 -0.943 . . . . 0.0 111.404 -177.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 25' ' ' GLY . . . . . 0.431 ' O ' ' OG ' ' P' ' 26' ' ' SER . . . 93.23 36.81 5.83 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-N 113.614 -1.63 . . . . 0.0 111.848 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 26' ' ' SER . . . . . 0.59 ' N ' ' O ' ' Q' ' 24' ' ' VAL . 3.4 p 72.65 120.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 27' ' ' ASN . . . . . 0.791 HD21 ' H ' ' P' ' 29' ' ' GLY . 10.4 t30 -83.2 161.75 21.44 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.809 175.24 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 28' ' ' LYS . . . . . 0.628 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 75.4 tttt -48.54 -39.38 23.26 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 113.461 0.912 . . . . 0.0 113.461 177.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 29' ' ' GLY . . . . . 0.791 ' H ' HD21 ' P' ' 27' ' ' ASN . . . 171.59 68.85 0.04 OUTLIER Glycine 0 CA--C 1.544 1.863 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -174.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.22 145.76 51.17 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 119.062 1.431 . . . . 0.0 114.673 -173.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 31' ' ' ILE . . . . . 0.493 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 75.2 mt -136.08 133.94 50.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 CA-C-N 113.46 -1.7 . . . . 0.0 113.651 -177.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 55.0 mt -107.67 117.06 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 175.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.77 102.02 1.06 Allowed Glycine 0 N--CA 1.466 0.657 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 176.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.25 132.36 51.72 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -175.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -109.17 99.71 8.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.2 -2.519 . . . . 0.0 104.2 174.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -114.06 103.15 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.719 -175.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.31 -153.77 25.46 Favored Glycine 0 C--N 1.319 -0.39 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.813 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.43 -56.03 0.57 Allowed Glycine 0 CA--C 1.545 1.946 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -178.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -153.24 157.55 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 177.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' P' P ' 40' ' ' VAL . . . . . 0.44 ' O ' ' CE1' ' R' ' 13' ' ' HIS . 7.0 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.459 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.56 135.1 54.28 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.805 0.336 . . . . 0.0 110.468 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 11' ' ' GLU . . . . . 0.411 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 96.5 mt-10 -87.26 119.61 27.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.984 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -118.32 126.1 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.075 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 13' ' ' HIS . . . . . 0.608 ' ND1' ' N ' ' Q' ' 14' ' ' HIS . 0.1 OUTLIER -152.74 140.55 20.03 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.989 -179.525 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' Q' Q ' 14' ' ' HIS . . . . . 0.608 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 1.1 p80 -159.68 161.7 34.96 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -90.02 158.71 17.22 Favored 'General case' 0 CA--C 1.516 -0.349 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.747 178.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -140.81 101.9 4.17 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 176.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mp -119.06 113.42 20.91 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.92 106.63 21.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 19' ' ' PHE . . . . . 0.531 ' CE1' ' CD2' ' P' ' 19' ' ' PHE . 72.2 m-85 -107.04 103.05 12.37 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 20' ' ' PHE . . . . . 0.596 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 37.3 t80 -108.79 118.32 36.47 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 21' ' ' ALA . . . . . 0.471 ' O ' ' OE1' ' R' ' 22' ' ' GLU . . . -140.79 138.02 33.78 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.85 0.833 . . . . 0.0 112.967 -179.106 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' P' ' 23' ' ' ASP . 94.7 mt-10 -85.03 122.34 29.11 Favored 'General case' 0 C--O 1.22 -0.497 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 177.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 23' ' ' ASP . . . . . 0.417 ' CG ' ' O ' ' Q' ' 22' ' ' GLU . 35.4 m-20 -162.44 52.15 0.2 Allowed 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -176.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 24' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' P' ' 26' ' ' SER . 93.2 t -74.45 142.25 14.98 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 C-N-CA 117.923 -1.511 . . . . 0.0 110.069 -178.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.46 37.49 3.75 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -178.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -64.57 106.44 1.16 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.698 0.761 . . . . 0.0 111.576 -177.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -149.85 -161.25 1.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.429 -1.26 . . . . 0.0 110.173 -179.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 29.5 40.82 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.53 70.91 0.63 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 116.36 1.304 . . . . 0.0 116.36 175.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.53 114.14 27.72 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 175.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 31' ' ' ILE . . . . . 0.431 HD12 HG21 ' Q' ' 31' ' ' ILE . 66.6 mt -130.29 135.33 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 CA-C-N 119.108 0.867 . . . . 0.0 113.238 -178.177 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -121.59 114.71 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.14 114.84 3.29 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 14.3 tp -117.63 117.18 28.69 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 122.251 0.221 . . . . 0.0 110.429 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.2 mtp -121.76 124.28 43.84 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 67.1 t -110.81 131.48 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 121.108 0.48 . . . . 0.0 111.087 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 37' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' Q' ' 38' ' ' GLY . . . -72.81 111.68 3.63 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 38' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' Q' ' 37' ' ' GLY . . . -6.09 -67.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.428 0 C-N-CA 123.608 0.623 . . . . 0.0 114.224 -178.049 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.09 120.63 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 118.351 1.076 . . . . 0.0 109.68 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 29.1 t . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.272 -179.312 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -148.29 160.75 42.65 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 11' ' ' GLU . . . . . 0.411 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 79.2 mm-40 -114.74 151.32 33.92 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.154 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 57.4 t -107.09 105.97 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.043 0.449 . . . . 0.0 110.705 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 13' ' ' HIS . . . . . 0.599 ' ND1' ' O ' ' Q' ' 13' ' ' HIS . 63.0 t60 -148.82 130.14 14.68 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.224 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 42.0 p-80 -154.03 162.8 40.94 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.833 176.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -89.86 158.29 17.52 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 68.9 tttt -140.82 103.15 4.44 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 17' ' ' LEU . . . . . 0.458 ' N ' ' CD2' ' R' ' 17' ' ' LEU . 0.1 OUTLIER -115.51 109.29 17.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.702 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -106.28 104.09 16.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -100.25 100.95 11.84 Favored 'General case' 0 CA--C 1.509 -0.599 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 178.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -110.77 110.33 20.93 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.299 0.571 . . . . 0.0 109.949 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.6 130.29 45.48 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 22' ' ' GLU . . . . . 0.518 ' OE2' ' CZ ' ' Q' ' 20' ' ' PHE . 52.2 mp0 -77.86 108.99 11.5 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 118.597 -1.241 . . . . 0.0 110.686 -177.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 23' ' ' ASP . . . . . 0.613 ' CG ' ' H ' ' R' ' 24' ' ' VAL . 22.8 p-10 -178.83 -69.79 0.01 OUTLIER 'General case' 0 C--N 1.347 0.463 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 178.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 24' ' ' VAL . . . . . 0.613 ' H ' ' CG ' ' R' ' 23' ' ' ASP . 42.9 t -147.28 120.59 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -177.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.75 -43.73 91.09 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 119.546 -1.311 . . . . 0.0 110.659 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 44.1 m -139.56 -111.03 0.15 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 117.231 0.515 . . . . 0.0 111.283 177.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 7.1 m120 55.69 152.67 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.859 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -70.41 48.79 0.11 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.465 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 -52.06 1.38 Allowed Glycine 0 CA--C 1.541 1.664 0 C-N-CA 120.705 -0.76 . . . . 0.0 113.859 -178.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.4 176.44 5.15 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-N 117.454 0.627 . . . . 0.0 109.972 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 85.7 mt -110.45 116.97 53.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -113.63 127.44 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.039 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.85 113.13 1.7 Allowed Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 34' ' ' LEU . . . . . 0.422 ' CD2' ' C ' ' R' ' 34' ' ' LEU . 6.9 tt -118.05 121.43 40.57 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 93.9 mtp -140.01 143.16 36.31 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.567 -0.453 . . . . 0.0 111.075 -179.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' R' ' 37' ' ' GLY . 3.3 p -122.83 131.56 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . -34.05 -111.41 0.0 OUTLIER Glycine 0 CA--C 1.529 0.933 0 CA-C-N 115.102 -0.953 . . . . 0.0 113.591 179.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.52 -71.68 0.63 Allowed Glycine 0 CA--C 1.537 1.42 0 CA-C-N 115.563 -0.319 . . . . 0.0 113.288 -178.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' R' R ' 39' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' Q' ' 38' ' ' GLY . 6.8 p -138.49 142.71 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 117.618 0.709 . . . . 0.0 112.254 -178.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.455 178.629 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -109.02 134.77 51.22 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.892 0.377 . . . . 0.0 110.504 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -145.01 135.18 23.97 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.98 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -126.01 131.52 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.033 0.444 . . . . 0.0 110.467 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.6 p-80 -98.93 162.15 13.24 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.926 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 49.5 p-80 -86.39 169.5 12.85 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.805 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -129.5 151.28 50.29 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.45 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -96.54 124.35 40.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.773 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 91.4 mt -123.94 120.94 33.98 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-O 121.11 0.481 . . . . 0.0 110.76 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -127.41 133.47 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.874 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -133.41 124.43 27.1 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.822 0.344 . . . . 0.0 110.53 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 55.1 p90 -124.21 132.25 53.59 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.91 140.48 32.83 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.036 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 41.3 tp10 -107.07 158.35 17.12 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 114.071 -1.422 . . . . 0.0 107.491 177.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -171.02 46.63 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 119.594 -0.842 . . . . 0.0 112.455 -178.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.476 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 45.3 t -82.74 173.58 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 C-N-CA 119.315 -0.954 . . . . 0.0 108.635 -179.405 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.476 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . 91.11 -33.16 4.82 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.699 -1.76 . . . . 0.0 108.699 -177.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.3 p -151.29 124.23 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.547 HD22 ' C ' ' B' ' 27' ' ' ASN . 13.8 t-20 -41.62 149.9 0.11 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.811 -176.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -73.32 -49.25 28.48 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.96 59.69 0.5 Allowed Glycine 0 CA--C 1.543 1.83 0 C-N-CA 119.976 -1.107 . . . . 0.0 110.372 -175.34 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.57 92.42 9.08 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 123.513 1.625 . . . . 0.0 113.491 -175.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.43 ' CD1' ' O ' ' M' ' 38' ' ' GLY . 1.1 pt -142.3 122.81 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 111.789 -2.46 . . . . 0.0 106.322 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.443 ' O ' ' O ' ' B' ' 33' ' ' GLY . 58.8 mt -104.83 110.12 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.77 92.08 0.58 Allowed Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 104.609 -3.396 . . . . 0.0 104.609 176.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 82.0 mt -146.45 169.62 18.52 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-O 122.954 1.359 . . . . 0.0 112.814 -175.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 53.3 mtp -141.75 119.31 11.66 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.781 -2.009 . . . . 0.0 108.735 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 11.7 m -124.74 113.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.05 -123.95 1.19 Allowed Glycine 0 C--N 1.305 -1.185 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.441 ' O ' ' CG1' ' B' ' 39' ' ' VAL . . . 80.73 -67.39 3.56 Favored Glycine 0 CA--C 1.535 1.318 0 C-N-CA 120.387 -0.911 . . . . 0.0 111.328 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.23 156.11 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.145 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 87.7 t80 -87.5 126.34 34.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.341 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.04 140.78 34.32 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.555 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 62.4 t -127.6 132.78 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.044 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 86.0 m-70 -143.02 94.08 2.58 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.831 0.348 . . . . 0.0 110.695 179.344 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.609 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 6.9 t60 -158.56 170.18 22.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.813 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.609 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 51.3 tt0 -155.42 141.18 18.06 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.898 0.38 . . . . 0.0 110.213 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -89.0 124.42 34.25 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.27 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 tp -120.96 117.52 27.5 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 177.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.5 129.38 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.787 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -128.78 121.75 29.04 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.717 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.611 ' CD2' ' CD1' ' C' ' 20' ' ' PHE . 7.4 m-85 -122.46 129.03 51.6 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.17 137.4 34.36 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.527 0.68 . . . . 0.0 112.793 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' A' ' 22' ' ' GLU . 86.8 mt-10 -96.09 118.82 33.45 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.303 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -143.43 51.71 1.36 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.316 -179.045 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 71.3 t -75.7 143.49 13.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.957 0.884 . . . . 0.0 110.807 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.65 38.23 3.99 Favored Glycine 0 CA--C 1.525 0.656 0 CA-C-N 113.813 -1.539 . . . . 0.0 109.373 -178.698 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.9 t 73.18 120.01 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 115.241 -0.479 . . . . 0.0 110.608 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.748 HD22 ' H ' ' B' ' 30' ' ' ALA . 3.8 p30 -83.07 163.78 20.7 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 119.571 -0.851 . . . . 0.0 108.809 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -46.98 -37.06 8.5 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.249 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' B' ' 31' ' ' ILE . . . 179.53 77.05 0.06 OUTLIER Glycine 0 CA--C 1.531 1.068 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.823 -177.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.748 ' H ' HD22 ' B' ' 27' ' ' ASN . . . -51.77 91.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 119.371 1.586 . . . . 0.0 110.776 -179.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.455 ' N ' ' O ' ' B' ' 29' ' ' GLY . 66.8 mt -132.98 133.51 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.742 -177.697 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -107.96 109.7 29.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -113.29 97.05 0.84 Allowed Glycine 0 CA--C 1.507 -0.465 0 N-CA-C 104.19 -3.564 . . . . 0.0 104.19 176.28 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 40.1 tp -141.71 147.29 37.2 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 122.978 1.371 . . . . 0.0 113.47 -173.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 11.6 mtp -116.6 112.62 21.56 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 112.662 -2.063 . . . . 0.0 108.826 178.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 30.1 m -127.24 123.07 61.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 142.77 -113.52 0.79 Allowed Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.428 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 73.77 -72.74 1.27 Allowed Glycine 0 CA--C 1.535 1.29 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.441 ' CG1' ' O ' ' A' ' 38' ' ' GLY . 14.7 p -158.65 138.58 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 178.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.48 ' CG1' ' CD2' ' D' ' 13' ' ' HIS . 1.9 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.504 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -107.85 131.81 54.1 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.32 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -129.59 125.16 35.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.151 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -130.24 134.45 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.083 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.577 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 3.9 t60 -139.95 139.85 36.22 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.544 ' HE2' ' CB ' ' D' ' 16' ' ' LYS . 52.5 t60 -155.56 168.78 26.04 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.508 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.441 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.1 tt0 -138.74 140.81 38.82 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.582 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -130.4 113.47 14.37 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 35.6 mt -118.79 110.94 17.82 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.745 178.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 23.1 t -109.15 110.88 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -106.53 108.64 20.25 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.611 ' CD1' ' CD2' ' B' ' 20' ' ' PHE . 14.6 t80 -114.91 124.71 52.41 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 122.424 -0.173 . . . . 0.0 111.273 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 139.57 26.98 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.447 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 98.0 mt-10 -89.89 143.2 26.99 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.481 178.58 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.447 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 0.0 OUTLIER -164.66 50.44 0.12 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -177.893 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 37.6 t -80.87 149.37 5.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 122.83 1.3 . . . . 0.0 112.417 -174.431 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.6 36.92 5.69 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 112.052 -2.34 . . . . 0.0 110.28 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' D' ' 24' ' ' VAL . 19.8 t 72.64 120.12 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.789 0.835 . . . . 0.0 110.028 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.664 ' ND2' ' H ' ' B' ' 30' ' ' ALA . 25.9 t30 -83.18 161.99 21.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 116.991 -1.884 . . . . 0.0 110.284 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -47.41 -37.03 10.66 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.421 ' H ' ' ND2' ' C' ' 27' ' ' ASN . . . -178.76 78.16 0.06 OUTLIER Glycine 0 CA--C 1.538 1.508 0 CA-C-O 119.294 -0.726 . . . . 0.0 112.343 -173.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.635 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . -79.18 119.04 21.71 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 123.299 1.524 . . . . 0.0 112.997 -175.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 78.4 mt -139.1 139.89 39.22 Favored 'Isoleucine or valine' 0 C--N 1.353 0.724 0 CA-C-N 112.32 -2.218 . . . . 0.0 113.426 -176.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.405 HD13 HG22 ' C' ' 32' ' ' ILE . 64.1 mt -109.11 112.36 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.31 98.43 0.93 Allowed Glycine 0 C--O 1.238 0.392 0 N-CA-C 106.069 -2.812 . . . . 0.0 106.069 177.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 13.0 tp -133.26 134.59 44.14 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 122.495 1.14 . . . . 0.0 113.931 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.5 mtp -104.88 106.83 17.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 175.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 12.6 p -123.02 122.98 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.97 -113.11 0.55 Allowed Glycine 0 C--N 1.312 -0.801 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -177.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.51 ' O ' ' O ' ' C' ' 39' ' ' VAL . . . 55.73 64.98 3.89 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 119.789 -1.196 . . . . 0.0 112.61 178.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.51 ' O ' ' O ' ' C' ' 38' ' ' GLY . 33.8 m 16.08 114.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 2.6 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.491 179.972 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -83.09 139.37 33.26 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -109.13 118.34 36.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.148 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 t -115.21 91.14 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.154 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 3.5 t60 -143.89 122.72 12.68 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 110.372 -0.233 . . . . 0.0 110.372 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.663 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -118.77 161.53 19.96 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.114 0.483 . . . . 0.0 110.316 178.714 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -85.05 157.04 20.84 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.544 ' CB ' ' HE2' ' C' ' 14' ' ' HIS . 87.0 tttt -160.31 102.21 1.4 Allowed 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.321 177.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 3.1 mt -126.73 121.51 32.22 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -112.4 112.31 39.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -107.64 107.02 17.63 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.545 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 32.5 t80 -110.56 120.56 42.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 -178.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.87 144.99 27.26 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 118.748 -1.181 . . . . 0.0 113.687 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.434 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 98.1 mt-10 -96.05 136.36 36.61 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.99 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' E' ' 22' ' ' GLU . 12.3 m-20 -160.13 49.95 0.29 Allowed 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.647 -178.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' C' ' 26' ' ' SER . 35.7 m -81.67 150.65 4.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 122.601 1.191 . . . . 0.0 113.49 -176.096 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' E' ' 24' ' ' VAL . . . 93.94 36.97 5.59 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-N 112.59 -2.096 . . . . 0.0 111.705 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.461 ' O ' ' OG ' ' C' ' 26' ' ' SER . 0.7 OUTLIER 72.77 120.11 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.333 -0.434 . . . . 0.0 111.544 175.992 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.635 ' ND2' ' H ' ' C' ' 30' ' ' ALA . 13.4 t30 -83.07 162.3 21.4 Favored 'General case' 0 C--O 1.231 0.103 0 C-N-CA 117.94 -1.504 . . . . 0.0 107.997 176.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.614 ' NZ ' ' ND1' ' Q' ' 13' ' ' HIS . 83.1 tttt -47.53 -37.45 12.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.489 177.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.79 0.06 OUTLIER Glycine 0 CA--C 1.539 1.589 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.554 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.77 119.67 4.47 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -125.5 125.17 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.517 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 mt -106.82 112.71 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 173.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.13 114.71 2.01 Favored Glycine 0 N--CA 1.462 0.429 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -160.78 158.16 28.08 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 123.21 1.481 . . . . 0.0 113.595 -178.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mmm -110.72 111.64 22.97 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 111.967 -2.378 . . . . 0.0 108.882 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 9.0 t -106.09 112.74 40.62 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.714 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -179.09 -121.96 0.74 Allowed Glycine 0 C--N 1.304 -1.22 0 C-N-CA 118.331 -1.89 . . . . 0.0 111.643 -179.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 63.63 61.55 6.12 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 119.65 -1.262 . . . . 0.0 111.347 -178.365 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.46 ' CG2' ' O ' ' E' ' 39' ' ' VAL . 5.6 p -18.62 122.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.076 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.992 179.112 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.144 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -83.73 139.8 32.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.799 0.333 . . . . 0.0 110.758 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.467 ' OE2' ' NE2' ' D' ' 14' ' ' HIS . 79.4 tt0 -155.22 151.24 27.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.988 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.565 ' O ' ' CE1' ' D' ' 14' ' ' HIS . 59.0 t -140.51 168.01 17.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.778 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.499 ' CB ' ' O ' ' D' ' 13' ' ' HIS . 20.8 p-80 -64.34 140.85 58.91 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.601 ' HE2' ' CG1' ' F' ' 12' ' ' VAL . 65.0 m80 -150.63 166.43 30.33 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.697 177.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -89.82 150.99 22.0 Favored 'General case' 0 CA--C 1.522 -0.114 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -152.24 99.18 2.49 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 176.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.549 ' CD2' ' N ' ' E' ' 17' ' ' LEU . 1.3 mm? -118.33 114.11 22.46 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -110.18 106.65 21.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.1 m-85 -103.15 103.75 13.84 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 30.3 t80 -110.39 118.52 36.52 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 121.138 -0.225 . . . . 0.0 111.027 -178.455 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.48 137.01 28.24 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 118.907 -1.117 . . . . 0.0 113.155 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' D' ' 23' ' ' ASP . 97.7 mt-10 -88.37 115.57 25.97 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 177.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' F' ' 22' ' ' GLU . 0.0 OUTLIER -148.57 48.85 1.02 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -175.485 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.458 ' O ' ' N ' ' D' ' 25' ' ' GLY . 67.2 t -71.9 160.1 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 118.007 -1.477 . . . . 0.0 108.199 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.08 -36.62 4.12 Favored Glycine 0 N--CA 1.464 0.541 0 N-CA-C 108.097 -2.001 . . . . 0.0 108.097 -178.246 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.469 ' HG ' ' H ' ' D' ' 27' ' ' ASN . 4.2 m -65.79 112.52 3.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 113.22 -1.49 . . . . 0.0 110.622 -179.277 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -148.98 162.33 40.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.758 0.789 . . . . 0.0 110.922 -178.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 29.84 43.11 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.785 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.19 59.69 0.13 Allowed Glycine 0 CA--C 1.543 1.803 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.484 173.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.72 141.26 40.97 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.534 -0.746 . . . . 0.0 110.322 177.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 1.6 tt -132.52 125.33 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 CA-C-N 119.606 1.094 . . . . 0.0 110.232 176.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 87.1 mt -127.45 127.29 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.851 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.96 107.04 0.86 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 7.3 tt -122.9 123.86 41.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 86.1 mtp -134.08 145.57 49.49 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 119.958 -0.697 . . . . 0.0 112.391 -179.407 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -124.23 136.85 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.885 0.85 . . . . 0.0 110.659 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.78 103.28 0.39 Allowed Glycine 0 C--N 1.315 -0.63 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' E' ' 39' ' ' VAL . . . 127.12 75.75 0.21 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.157 -178.627 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.46 ' O ' ' CG2' ' D' ' 39' ' ' VAL . 7.3 t -17.36 120.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 123.628 0.771 . . . . 0.0 112.981 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 N--CA 1.469 0.518 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.355 179.516 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -110.34 133.89 52.82 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.781 0.324 . . . . 0.0 110.503 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.53 151.55 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.601 ' CG1' ' HE2' ' E' ' 14' ' ' HIS . 18.2 t -132.64 133.33 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.505 0.669 . . . . 0.0 111.379 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.511 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 0.3 OUTLIER -146.05 117.26 7.87 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.992 179.417 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 76.9 m80 -156.71 165.52 36.02 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.672 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -84.19 155.28 22.61 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.743 178.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -159.98 100.18 1.4 Allowed 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 121.291 0.567 . . . . 0.0 109.865 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.5 mp -125.62 114.92 19.35 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.331 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 12.4 t -99.83 102.61 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.919 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 178.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -95.16 95.22 8.4 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.413 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 64.8 t80 -111.16 113.52 26.1 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-O 121.548 0.69 . . . . 0.0 109.202 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.74 134.76 17.95 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 120.361 -0.536 . . . . 0.0 109.581 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' E' ' 23' ' ' ASP . 96.3 mt-10 -76.74 85.02 3.36 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 178.466 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.655 ' O ' ' O ' ' F' ' 24' ' ' VAL . 51.1 p30 176.32 52.09 0.0 OUTLIER 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.488 -175.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.655 ' O ' ' O ' ' F' ' 23' ' ' ASP . 3.0 t -52.73 -132.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -177.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.81 -38.63 0.21 Allowed Glycine 0 CA--C 1.509 -0.316 0 C-N-CA 116.127 -2.94 . . . . 0.0 116.263 -177.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 43.0 t -64.64 110.68 2.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 115.164 -2.614 . . . . 0.0 107.932 -176.545 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.728 ' O ' ' N ' ' F' ' 29' ' ' GLY . 16.7 p30 -149.62 174.89 12.05 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 112.548 -2.114 . . . . 0.0 108.031 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.461 ' C ' ' O ' ' F' ' 27' ' ' ASN . 88.4 tttt -8.77 -45.2 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.746 0 O-C-N 124.534 1.146 . . . . 0.0 114.015 177.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -169.61 60.45 0.19 Allowed Glycine 0 CA--C 1.553 2.435 0 C-N-CA 119.943 -1.122 . . . . 0.0 115.368 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.99 172.04 11.63 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 85.9 mt -115.59 112.12 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 120.667 1.576 . . . . 0.0 111.562 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.412 HD11 HG22 ' F' ' 32' ' ' ILE . 90.7 mt -123.97 123.19 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.89 119.55 3.03 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 38.4 mt -122.87 119.7 31.31 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mtp -140.6 151.38 44.62 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 -178.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 m -127.41 164.55 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.421 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.36 -102.82 0.09 OUTLIER Glycine 0 CA--C 1.525 0.664 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.653 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.09 -77.83 1.24 Allowed Glycine 0 CA--C 1.536 1.38 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.473 ' CG2' ' N ' ' F' ' 40' ' ' VAL . 3.4 p -125.78 162.48 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 117.208 0.504 . . . . 0.0 111.266 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.473 ' N ' ' CG2' ' F' ' 39' ' ' VAL . 9.6 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.58 -178.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -111.51 132.84 54.22 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.27 102.33 4.08 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.976 0.417 . . . . 0.0 110.303 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 77.5 t -131.38 130.21 62.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.613 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -145.38 131.6 19.48 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.42 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.6 p-80 -152.02 167.49 28.25 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.805 178.489 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -157.53 142.91 17.13 Favored 'General case' 0 CA--C 1.52 -0.202 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -81.53 126.2 31.41 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.584 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.7 mt -126.52 118.23 24.48 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -141.88 139.79 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 121.026 0.441 . . . . 0.0 110.999 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -134.74 131.84 38.07 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.58 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.498 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 55.1 p90 -131.06 130.34 43.12 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.93 0.395 . . . . 0.0 111.042 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.12 117.37 26.98 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.016 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -143.31 147.44 34.74 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.462 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 53.69 46.43 25.93 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.035 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -80.47 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.804 -178.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.35 -33.49 64.41 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.743 ' O ' ' O ' ' G' ' 27' ' ' ASN . 41.3 p -162.68 120.38 2.04 Favored 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 120.298 -0.561 . . . . 0.0 112.097 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.743 ' O ' ' O ' ' G' ' 26' ' ' SER . 9.1 m120 -21.61 -174.65 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 115.41 1.634 . . . . 0.0 115.41 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -173.86 -21.04 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.419 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.539 ' N ' ' OD2' ' H' ' 23' ' ' ASP . . . 71.66 -97.9 0.73 Allowed Glycine 0 N--CA 1.465 0.624 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.61 97.02 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.112 0.482 . . . . 0.0 111.487 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 91.2 mt -123.03 110.83 27.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.041 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -113.76 107.32 22.63 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.78 100.08 0.92 Allowed Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 104.393 -3.483 . . . . 0.0 104.393 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 48.3 tp -150.36 149.28 29.86 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-O 123.034 1.397 . . . . 0.0 113.954 -174.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 mtp -105.64 106.32 16.76 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 112.183 -2.281 . . . . 0.0 106.015 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.468 ' O ' ' CG1' ' G' ' 36' ' ' VAL . 3.8 p -128.47 113.95 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.43 -124.9 1.95 Allowed Glycine 0 C--N 1.307 -1.061 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.1 -66.89 3.7 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.995 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.495 ' CG2' ' H ' ' G' ' 40' ' ' VAL . 12.6 p -108.08 176.01 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.528 ' O ' ' CE1' ' I' ' 13' ' ' HIS . 2.5 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.116 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.347 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -105.64 132.44 51.78 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -159.48 114.43 2.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.069 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.453 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 79.6 t -126.66 128.9 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.483 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 43.4 m-70 -147.61 114.97 6.28 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.462 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.489 ' CE1' ' H ' ' I' ' 14' ' ' HIS . 12.9 m-70 -149.74 169.07 21.92 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -156.52 141.58 17.24 Favored 'General case' 0 CA--C 1.518 -0.278 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 177.061 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -86.85 120.5 28.2 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.218 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.418 ' C ' ' CD1' ' H' ' 17' ' ' LEU . 0.6 OUTLIER -117.22 113.91 22.89 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.007 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.1 t -122.17 131.03 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 120.867 0.365 . . . . 0.0 111.386 -178.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 37.7 t80 -126.98 116.81 21.33 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.614 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 8.0 t80 -122.63 127.2 49.05 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.95 134.84 32.11 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 112.754 0.649 . . . . 0.0 112.754 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -107.71 121.24 44.31 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.272 178.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.539 ' OD2' ' N ' ' G' ' 29' ' ' GLY . 93.6 m-20 -140.33 46.38 1.82 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.012 -178.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.622 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 20.6 t -81.68 177.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.36 -177.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.622 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . 92.72 -33.92 4.77 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.426 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.55 ' O ' ' O ' ' H' ' 27' ' ' ASN . 37.0 t -162.52 120.31 2.09 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 119.062 1.431 . . . . 0.0 113.502 177.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.55 ' O ' ' O ' ' H' ' 26' ' ' SER . 53.4 p-10 -22.41 153.23 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.946 0 O-C-N 124.266 0.979 . . . . 0.0 112.05 175.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.527 ' HZ1' ' C ' ' G' ' 27' ' ' ASN . 61.7 tttt -165.43 26.42 0.05 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 118.392 -1.323 . . . . 0.0 114.162 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.561 ' H ' ' H ' ' I' ' 28' ' ' LYS . . . 82.03 108.01 0.4 Allowed Glycine 0 CA--C 1.525 0.717 0 C-N-CA 118.987 -1.578 . . . . 0.0 114.448 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.433 ' HB3' HD21 ' I' ' 27' ' ' ASN . . . -120.49 106.49 11.86 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 122.118 0.961 . . . . 0.0 109.273 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 tt -141.45 132.66 27.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 CA-C-N 114.687 -1.142 . . . . 0.0 111.83 -177.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 6.6 mt -108.13 111.69 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.48 103.18 1.42 Allowed Glycine 0 N--CA 1.46 0.248 0 N-CA-C 105.543 -3.023 . . . . 0.0 105.543 177.131 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -146.47 145.12 30.08 Favored 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 117.92 -1.512 . . . . 0.0 114.271 -174.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.4 mtp -111.12 112.34 24.07 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 112.935 -1.938 . . . . 0.0 107.02 176.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -119.69 102.88 13.43 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.88 -151.56 20.16 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.97 -56.55 0.54 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.448 ' CG1' ' C ' ' G' ' 39' ' ' VAL . 6.3 p -153.69 161.12 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 177.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.441 ' N ' ' CG2' ' H' ' 39' ' ' VAL . 14.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.787 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -111.89 133.94 53.76 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.731 0.301 . . . . 0.0 110.557 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -155.39 144.95 21.19 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.895 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -127.37 118.67 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.108 0.48 . . . . 0.0 109.946 179.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' O ' ' G' ' 40' ' ' VAL . 2.9 t-80 -147.83 120.2 8.43 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.588 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.489 ' H ' ' CE1' ' H' ' 14' ' ' HIS . 4.8 m170 -122.48 162.74 21.15 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 120.794 -0.362 . . . . 0.0 110.823 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.03 153.94 20.19 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.728 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -145.47 97.07 2.93 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.646 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -121.14 121.91 38.86 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.347 178.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -117.11 110.16 30.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -107.76 108.97 20.43 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 28.0 t80 -115.68 126.33 53.98 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.91 135.82 34.83 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -94.09 140.6 29.54 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.532 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 7.4 p-10 -176.83 52.14 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.697 0.284 . . . . 0.0 110.442 -175.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 3.3 p -74.52 143.16 13.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 122.653 1.216 . . . . 0.0 112.637 -175.197 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.452 ' O ' ' OG ' ' I' ' 26' ' ' SER . . . 99.53 38.22 3.77 Favored Glycine 0 CA--C 1.529 0.961 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.434 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 7.0 p 73.17 120.2 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.131 -0.535 . . . . 0.0 111.907 176.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.609 ' O ' ' N ' ' I' ' 29' ' ' GLY . 2.4 m-20 -83.93 152.68 24.36 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 118.257 -1.377 . . . . 0.0 108.669 175.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.561 ' H ' ' H ' ' H' ' 29' ' ' GLY . 30.1 mtmt -50.68 43.66 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.862 0 CA-C-O 116.966 -1.492 . . . . 0.0 114.178 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 120.94 77.44 0.47 Allowed Glycine 0 N--CA 1.487 2.04 0 CA-C-N 122.555 2.434 . . . . 0.0 113.013 -178.229 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.22 112.12 18.25 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.316 1.558 . . . . 0.0 111.8 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 12.7 tt -145.74 141.67 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -177.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 38.3 mt -111.16 113.19 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 176.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.01 99.93 0.95 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 177.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 5.9 mp -136.22 148.22 47.98 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 123.411 1.577 . . . . 0.0 114.124 -176.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -116.59 106.31 13.41 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 111.724 -2.489 . . . . 0.0 104.526 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.424 ' O ' ' HA ' ' J' ' 36' ' ' VAL . 38.6 t -126.58 142.75 42.25 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.74 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.152 -175.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.73 -101.99 0.71 Allowed Glycine 0 C--N 1.312 -0.768 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.41 ' O ' ' CG2' ' J' ' 39' ' ' VAL . . . 66.69 -80.09 0.12 Allowed Glycine 0 CA--C 1.533 1.204 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.665 -179.298 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 40' ' ' VAL . 21.9 t -116.28 131.3 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 C-N-CA 123.068 0.547 . . . . 0.0 109.998 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 39' ' ' VAL . 8.8 p . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 118.038 -0.982 . . . . 0.0 111.43 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -108.39 136.28 48.29 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.741 0.305 . . . . 0.0 110.24 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -78.13 108.98 11.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.96 129.72 68.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.757 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' K' ' 14' ' ' HIS . 67.1 m80 -124.88 127.31 46.91 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.823 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.629 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 12.7 t60 -152.09 170.43 19.96 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.228 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.629 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 32.8 tt0 -138.5 140.65 39.25 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -130.57 104.28 7.13 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.464 ' CD1' ' CG ' ' J' ' 15' ' ' GLN . 6.3 mp -122.8 120.2 32.85 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.736 177.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -113.7 112.25 39.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.911 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.441 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 43.7 m-85 -109.4 108.13 18.55 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 37.2 t80 -116.66 125.12 51.29 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.58 0.228 . . . . 0.0 110.955 -179.278 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.94 133.49 33.8 Favored 'General case' 0 C--O 1.241 0.627 0 CA-C-O 121.452 0.644 . . . . 0.0 111.842 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.453 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 80.1 tt0 -90.47 119.75 31.01 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.534 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.537 ' CG ' HD22 ' I' ' 27' ' ' ASN . 0.2 OUTLIER -147.39 52.05 1.06 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.443 -0.799 . . . . 0.0 108.901 -178.14 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.89 143.14 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 122.448 1.118 . . . . 0.0 112.793 -175.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.09 38.16 3.9 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 112.699 -2.046 . . . . 0.0 112.197 178.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 22.0 t 72.68 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.453 0.701 . . . . 0.0 111.11 176.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -83.18 161.75 21.46 Favored 'General case' 0 C--N 1.34 0.194 0 C-N-CA 117.18 -1.808 . . . . 0.0 110.221 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -47.7 -37.28 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 175.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.03 78.06 0.06 OUTLIER Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.741 -1.033 . . . . 0.0 112.236 -172.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.84 116.87 19.45 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 120.076 1.938 . . . . 0.0 111.66 -175.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 5.0 tt -134.01 136.91 53.04 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 CA-C-N 112.253 -2.249 . . . . 0.0 113.134 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.444 HD11 HG21 ' J' ' 32' ' ' ILE . 89.4 mt -113.09 122.66 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 120.999 0.428 . . . . 0.0 110.609 178.106 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.85 104.42 0.97 Allowed Glycine 0 N--CA 1.462 0.396 0 N-CA-C 106.339 -2.704 . . . . 0.0 106.339 176.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.42 ' CD2' ' N ' ' J' ' 35' ' ' MET . 5.0 tt -144.46 142.85 30.57 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-O 122.578 1.18 . . . . 0.0 112.47 -175.707 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.42 ' N ' ' CD2' ' J' ' 34' ' ' LEU . 28.6 mtp -116.32 115.05 25.21 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.145 -1.843 . . . . 0.0 108.779 178.367 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' I' ' 36' ' ' VAL . 0.1 OUTLIER -97.62 111.35 27.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.512 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 178.956 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.52 131.49 42.96 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.331 -177.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.95 63.51 3.16 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 121.279 -0.486 . . . . 0.0 111.938 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.41 ' CG2' ' O ' ' I' ' 38' ' ' GLY . 42.7 t -124.62 126.36 71.54 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 CA-C-O 121.461 0.648 . . . . 0.0 110.029 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.589 -179.208 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.66 135.76 48.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.657 0.265 . . . . 0.0 110.506 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.16 111.65 16.76 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.334 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 4.5 m -130.67 126.56 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.185 0.517 . . . . 0.0 111.03 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.622 ' CE1' ' HZ2' ' P' ' 28' ' ' LYS . 56.7 m170 -110.16 157.58 19.24 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.699 ' CD2' ' H ' ' K' ' 15' ' ' GLN . 29.1 t60 -158.01 178.02 10.68 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 119.434 -0.906 . . . . 0.0 112.826 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.699 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 31.6 tt0 -160.37 140.57 11.48 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 114.197 -1.365 . . . . 0.0 107.54 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -159.48 115.97 2.58 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.947 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -128.07 125.03 38.49 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 114.395 -1.275 . . . . 0.0 109.196 178.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 26.3 m -116.03 121.09 66.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.441 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 24.1 m-85 -109.16 109.85 20.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.695 -178.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -111.92 118.67 36.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 122.357 -0.214 . . . . 0.0 111.04 -179.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.66 126.74 27.94 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 110.315 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' J' ' 23' ' ' ASP . 75.4 mt-10 -87.8 140.58 29.36 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.406 -179.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.522 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 7.0 p-10 178.52 48.87 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 17.8 m -72.16 160.61 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 119.309 -0.956 . . . . 0.0 109.887 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.22 -33.25 5.95 Favored Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.149 177.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 1.7 p -72.23 129.98 39.73 Favored 'General case' 0 N--CA 1.465 0.325 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 46.5 t-20 -90.86 143.65 26.5 Favored 'General case' 0 C--O 1.232 0.154 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 176.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.48 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 51.7 tttp 43.52 42.84 4.22 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' L' ' 23' ' ' ASP . . . -101.69 60.48 0.58 Allowed Glycine 0 N--CA 1.476 1.308 0 CA-C-O 119.269 -0.74 . . . . 0.0 114.111 -178.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.86 119.95 4.94 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 119.204 1.502 . . . . 0.0 111.772 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 74.3 mt -121.6 116.83 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -124.17 128.3 73.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.22 103.18 0.79 Allowed Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.024 -2.03 . . . . 0.0 108.024 177.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 30.2 tp -117.11 121.4 41.17 Favored 'General case' 0 C--O 1.24 0.58 0 CA-C-O 121.265 0.555 . . . . 0.0 110.007 -178.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 18.5 ttm -120.86 129.86 53.69 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.16 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' K' ' 37' ' ' GLY . 54.9 t -115.78 131.93 66.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.886 178.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -45.03 -111.73 0.0 OUTLIER Glycine 0 CA--C 1.529 0.915 0 CA-C-N 115.519 -0.764 . . . . 0.0 112.349 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -107.15 -71.69 0.77 Allowed Glycine 0 CA--C 1.534 1.223 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 54.1 t -125.2 127.19 71.96 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.475 ' N ' ' O ' ' L' ' 40' ' ' VAL . 8.4 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.738 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -109.48 137.14 47.76 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 110.365 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -73.54 147.41 44.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.488 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 m -129.93 135.78 60.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.081 0.467 . . . . 0.0 111.567 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 5.1 p80 -146.85 97.97 2.98 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.275 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -154.69 162.59 41.06 Favored 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -89.95 159.24 17.01 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.203 0.525 . . . . 0.0 111.632 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -140.06 110.6 6.72 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.791 177.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 mt -118.09 112.19 19.89 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.555 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 9.0 t -104.21 100.67 10.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -94.44 99.87 11.97 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -116.24 112.17 21.22 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.466 0.651 . . . . 0.0 110.984 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.1 135.41 32.52 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 107.842 -1.169 . . . . 0.0 107.842 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.447 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 80.3 mm-40 -73.39 108.89 6.51 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 118.627 -1.229 . . . . 0.0 108.401 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' L' ' 24' ' ' VAL . 64.9 m-20 -164.03 61.39 0.16 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.514 -176.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' L' ' 23' ' ' ASP . 8.9 t 55.63 155.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.153 -177.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.24 24.2 0.19 Allowed Glycine 0 CA--C 1.521 0.413 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 40.3 t -81.86 -120.93 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' L' ' 29' ' ' GLY . 99.3 m-20 -93.05 -165.61 1.37 Allowed 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.754 -0.778 . . . . 0.0 109.502 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -47.98 47.68 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 115.732 1.753 . . . . 0.0 115.732 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.64 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.31 56.86 0.89 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-N 119.253 0.933 . . . . 0.0 112.339 177.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.62 169.8 9.97 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 8.3 mm -112.98 111.31 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 176.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -125.75 130.1 72.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.594 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.0 116.48 2.73 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 56.9 tp -118.32 123.08 44.47 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttm -125.66 124.99 42.35 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.24 132.45 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.8 112.13 3.6 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.193 -178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.97 -71.17 0.01 OUTLIER Glycine 0 CA--C 1.538 1.521 0 N-CA-C 115.216 0.847 . . . . 0.0 115.216 177.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' K' ' 38' ' ' GLY . 54.1 t -134.43 137.13 52.02 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 CA-C-N 117.96 0.88 . . . . 0.0 112.007 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' K' ' 40' ' ' VAL . 61.7 t . . . . . 0 C--O 1.213 -0.837 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.091 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -110.04 138.56 46.25 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.911 0.386 . . . . 0.0 110.567 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -71.19 139.88 50.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -122.01 131.29 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.01 0.434 . . . . 0.0 110.07 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -119.27 130.35 55.38 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.273 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.598 ' HE2' ' CG1' ' N' ' 12' ' ' VAL . 13.6 m-70 -83.23 167.09 18.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.138 0.494 . . . . 0.0 111.126 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -93.38 159.98 15.01 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.425 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.145 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 88.7 mt -130.1 130.75 45.24 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.965 0.412 . . . . 0.0 111.465 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 67.3 t -133.75 132.2 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.963 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -138.67 136.71 36.14 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.171 0.51 . . . . 0.0 112.001 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -121.11 125.15 46.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.063 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.62 113.75 25.49 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 121.345 0.593 . . . . 0.0 111.224 -179.503 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . 0.418 ' OE1' ' OE2' ' N' ' 22' ' ' GLU . 12.4 pt-20 -173.16 150.31 1.92 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.724 179.747 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 56.03 46.95 20.77 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.158 178.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -101.03 -170.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.12 -32.43 84.01 Favored Glycine 0 N--CA 1.468 0.822 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.241 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 47.6 t -152.88 125.11 8.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.366 0.583 . . . . 0.0 109.789 177.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.427 ' N ' ' OD1' ' M' ' 27' ' ' ASN . 1.9 m-20 -38.93 134.58 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.956 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.67 -39.54 4.84 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 122.192 0.996 . . . . 0.0 108.39 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.89 -69.29 3.09 Favored Glycine 0 CA--C 1.534 1.261 0 CA-C-N 113.348 -1.751 . . . . 0.0 110.753 -178.662 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.6 82.38 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 117.335 0.568 . . . . 0.0 111.009 176.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 14.6 tt -121.4 104.58 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 119.592 1.087 . . . . 0.0 109.482 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -124.39 116.59 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 CA-C-O 121.402 0.62 . . . . 0.0 111.618 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.83 104.93 0.86 Allowed Glycine 0 N--CA 1.464 0.529 0 N-CA-C 106.086 -2.806 . . . . 0.0 106.086 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 85.7 mt -145.28 159.81 42.46 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 123.3 1.524 . . . . 0.0 114.214 -176.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 35.4 tpp -107.08 108.5 20.01 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.844 -2.435 . . . . 0.0 105.85 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 4.7 m -119.57 123.06 70.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 119.055 0.843 . . . . 0.0 109.68 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.25 -113.7 0.9 Allowed Glycine 0 C--N 1.31 -0.897 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.43 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . 95.48 -72.13 0.95 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 112.318 -0.313 . . . . 0.0 112.318 179.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 40' ' ' VAL . 2.4 t -122.29 159.23 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 O-C-N 122.691 -0.3 . . . . 0.0 110.621 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 39' ' ' VAL . 2.9 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.827 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -108.21 132.48 53.61 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.835 0.35 . . . . 0.0 110.401 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -125.88 126.86 45.11 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.027 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . 0.598 ' CG1' ' HE2' ' M' ' 14' ' ' HIS . 59.2 t -127.73 130.33 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-O 120.871 0.367 . . . . 0.0 110.994 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.497 ' O ' ' CD2' ' M' ' 14' ' ' HIS . 29.8 t-80 -79.66 161.31 25.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.813 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . . . . . . . . . 29.8 p-80 -93.26 163.18 13.71 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.216 0.531 . . . . 0.0 111.322 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -89.88 160.12 16.61 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.61 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.22 131.6 28.48 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -132.59 127.37 34.86 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.348 0.594 . . . . 0.0 111.199 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.5 130.77 72.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.613 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -132.43 122.41 24.93 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.086 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 5.7 t80 -121.15 127.6 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.285 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.49 117.3 25.6 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.418 ' OE2' ' OE1' ' M' ' 22' ' ' GLU . 97.7 mt-10 -81.59 179.63 7.76 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 119.811 -0.755 . . . . 0.0 109.297 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.489 ' O ' ' CB ' ' N' ' 24' ' ' VAL . 62.3 t0 -60.53 -46.91 88.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 119.193 -1.003 . . . . 0.0 108.494 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.727 ' CG1' ' H ' ' N' ' 25' ' ' GLY . 9.4 t 99.81 -161.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.727 ' H ' ' CG1' ' N' ' 24' ' ' VAL . . . -71.32 -33.4 64.53 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' N' ' 27' ' ' ASN . 34.2 t -162.55 120.55 2.1 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.577 ' O ' ' O ' ' N' ' 26' ' ' SER . 41.2 t-20 -22.0 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 114.682 -1.145 . . . . 0.0 112.443 177.177 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.518 ' N ' ' OD1' ' N' ' 27' ' ' ASN . 69.9 tttt -163.03 24.39 0.09 Allowed 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.9 107.68 1.25 Allowed Glycine 0 N--CA 1.476 1.35 0 C-N-CA 117.506 -2.283 . . . . 0.0 113.929 177.629 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.53 102.69 11.52 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 123.637 1.684 . . . . 0.0 109.912 -178.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 20.7 mt -130.19 130.48 65.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 112.388 -2.187 . . . . 0.0 110.824 -176.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 10.1 tt -123.6 116.3 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.805 0.812 . . . . 0.0 109.844 176.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.1 111.58 3.26 Favored Glycine 0 C--N 1.333 0.411 0 N-CA-C 107.02 -2.432 . . . . 0.0 107.02 178.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -137.88 139.22 39.75 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 122.633 1.206 . . . . 0.0 113.636 -176.094 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 95.7 mmm -106.36 111.56 24.19 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.1 t -117.19 123.15 71.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -178.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.38 -113.0 0.55 Allowed Glycine 0 C--N 1.306 -1.12 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.747 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.78 -73.16 2.71 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' M' ' 40' ' ' VAL . 62.8 t -138.17 138.39 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.062 0.545 . . . . 0.0 109.777 179.505 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' O' ' 40' ' ' VAL . 46.5 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.538 -0.744 . . . . 0.0 111.681 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.96 137.4 46.03 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.873 0.368 . . . . 0.0 110.521 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -93.23 113.31 25.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.374 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -125.28 128.72 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 120.781 0.324 . . . . 0.0 110.167 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -131.29 138.27 49.18 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.612 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 83.2 t60 -154.64 153.85 32.02 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 118.346 -1.342 . . . . 0.0 112.836 179.387 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 33.8 tt0 -90.63 164.44 14.18 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.721 177.19 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 102.18 0.33 Allowed 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mt -122.86 119.59 30.98 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.414 179.354 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 15.6 t -106.96 115.32 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.401 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -113.87 105.48 13.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 12.5 t80 -107.2 125.46 51.14 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.377 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.39 135.59 44.77 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -177.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -112.19 139.87 47.37 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.452 177.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -156.41 46.52 0.44 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.814 0.34 . . . . 0.0 110.127 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.503 ' CG1' ' H ' ' O' ' 25' ' ' GLY . 3.0 t -82.64 174.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 122.314 1.054 . . . . 0.0 112.552 -176.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.503 ' H ' ' CG1' ' O' ' 24' ' ' VAL . . . 92.59 -35.91 3.88 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-N 113.228 -1.805 . . . . 0.0 112.661 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.647 ' O ' ' O ' ' O' ' 27' ' ' ASN . 21.6 p -172.28 113.74 0.3 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 118.974 1.387 . . . . 0.0 112.218 175.232 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.647 ' O ' ' O ' ' O' ' 26' ' ' SER . 25.2 p30 -10.59 153.34 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 0 O-C-N 124.55 1.157 . . . . 0.0 113.994 176.428 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.513 ' NZ ' ' O ' ' N' ' 27' ' ' ASN . 32.2 tttt -166.33 26.19 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 118.457 -1.297 . . . . 0.0 113.843 172.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.65 107.33 0.37 Allowed Glycine 0 CA--C 1.53 0.982 0 C-N-CA 119.318 -1.42 . . . . 0.0 112.474 178.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . 0.696 ' H ' HD21 ' P' ' 27' ' ' ASN . . . -120.97 112.48 18.81 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.031 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 83.6 mt -131.68 131.85 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -176.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . 0.421 HG23 HD11 ' O' ' 32' ' ' ILE . 88.6 mt -108.22 106.06 19.96 Favored 'Isoleucine or valine' 0 C--N 1.344 0.351 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 174.025 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.58 101.58 1.23 Allowed Glycine 0 N--CA 1.464 0.541 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 3.5 mp -139.78 146.46 39.49 Favored 'General case' 0 CA--C 1.508 -0.638 0 CA-C-O 123.14 1.447 . . . . 0.0 113.329 -176.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 12.3 mtp -113.24 108.66 17.57 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 111.828 -2.442 . . . . 0.0 106.371 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 m -124.13 102.85 11.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.03 -151.6 21.01 Favored Glycine 0 C--N 1.302 -1.332 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.062 179.643 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.29 -57.1 1.45 Allowed Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' O' ' 40' ' ' VAL . 33.4 m -129.07 159.3 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 123.253 0.621 . . . . 0.0 110.633 -178.342 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.441 ' OXT' ' O ' ' N' ' 40' ' ' VAL . 3.5 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.069 -0.967 . . . . 0.0 111.648 -178.747 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . 0.422 ' H ' ' H ' ' P' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . 0.422 ' H ' ' H ' ' P' ' 9' ' ' GLY . 98.0 m-85 -111.36 133.89 53.34 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.055 0.455 . . . . 0.0 110.583 -179.787 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -138.91 157.48 45.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.28 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 6.7 t -107.0 95.22 3.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.943 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.631 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 18.0 m170 -120.63 110.83 16.89 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.834 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.612 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 0.2 OUTLIER -160.69 166.99 27.86 Favored 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.17 177.771 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.496 ' NE2' HE21 ' Q' ' 15' ' ' GLN . 15.6 pt20 -89.94 151.6 21.63 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.733 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . 0.506 ' CB ' ' HE2' ' O' ' 14' ' ' HIS . 86.7 tttt -149.79 119.26 6.91 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.47 0.653 . . . . 0.0 110.727 177.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mp -138.99 132.37 30.12 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.218 178.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.02 120.98 65.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.515 ' CD1' ' CE1' ' Q' ' 19' ' ' PHE . 13.4 m-85 -110.78 112.19 23.89 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 22.4 t80 -119.84 127.76 53.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -175.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.81 127.25 48.84 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.577 ' CG ' ' H ' ' P' ' 23' ' ' ASP . 19.1 tt0 -72.07 177.06 4.6 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 115.75 1.759 . . . . 0.0 115.75 -173.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.577 ' H ' ' CG ' ' P' ' 22' ' ' GLU . 55.3 t0 -45.31 47.42 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 112.349 -2.205 . . . . 0.0 116.731 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.558 ' CG1' ' H ' ' P' ' 25' ' ' GLY . 49.0 t -60.88 -179.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 117.903 -1.519 . . . . 0.0 107.317 177.385 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.558 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . -102.08 34.97 5.27 Favored Glycine 0 N--CA 1.469 0.898 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 0.8 OUTLIER 74.53 120.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 -177.535 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.696 HD21 ' H ' ' O' ' 30' ' ' ALA . 12.2 p-10 -82.79 172.7 12.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 122.125 0.964 . . . . 0.0 113.312 -177.155 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.622 ' HZ2' ' CE1' ' K' ' 13' ' ' HIS . 87.6 tttt -49.2 -36.25 19.32 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.462 -1.699 . . . . 0.0 111.572 177.389 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.48 ' C ' HD22 ' P' ' 27' ' ' ASN . . . -178.42 78.01 0.07 OUTLIER Glycine 0 CA--C 1.541 1.688 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.336 -174.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . 0.569 ' N ' HD22 ' P' ' 27' ' ' ASN . . . -79.85 139.32 37.21 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 121.752 0.787 . . . . 0.0 111.132 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 9.5 tt -149.98 141.83 17.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 -176.179 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 75.3 mt -105.72 109.55 28.24 Favored 'Isoleucine or valine' 0 C--N 1.349 0.55 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.2 99.58 1.71 Allowed Glycine 0 C--O 1.24 0.492 0 N-CA-C 105.39 -3.084 . . . . 0.0 105.39 176.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 5.4 tp -128.41 134.77 48.86 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 -175.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 35' ' ' MET . . . . . 0.487 ' SD ' ' O ' ' Q' ' 35' ' ' MET . 60.0 tpp -112.69 110.98 21.45 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.006 -1.452 . . . . 0.0 107.62 176.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . 0.473 ' O ' ' CG1' ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -105.09 111.79 36.01 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.228 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.341 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.433 ' O ' ' NE2' ' R' ' 15' ' ' GLN . . . -63.75 131.99 40.53 Favored Glycine 0 N--CA 1.465 0.588 0 CA-C-N 115.868 -0.606 . . . . 0.0 113.204 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.435 ' CA ' ' H ' ' Q' ' 39' ' ' VAL . . . -77.92 64.15 3.41 Favored Glycine 0 CA--C 1.541 1.669 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.42 154.28 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 123.44 0.696 . . . . 0.0 110.266 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 1.4 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.419 -179.762 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -82.02 137.29 35.12 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.814 0.34 . . . . 0.0 110.753 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -74.03 150.1 40.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.664 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . 0.531 ' O ' ' CD2' ' Q' ' 14' ' ' HIS . 27.0 m -128.69 -175.84 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.107 0.479 . . . . 0.0 111.04 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.631 ' CD2' ' H ' ' P' ' 13' ' ' HIS . 2.9 m170 -67.44 105.31 1.77 Allowed 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -176.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.559 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 4.7 m-70 -114.53 160.91 18.7 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 175.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.496 HE21 ' NE2' ' P' ' 15' ' ' GLN . 42.8 tt0 -89.99 157.32 17.88 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.251 178.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -142.19 94.8 2.7 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.606 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -127.76 115.5 18.77 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.923 177.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 t -112.54 110.63 32.91 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.672 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.515 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 57.7 m-85 -107.92 102.1 11.32 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 178.057 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 33.5 t80 -111.25 124.19 51.72 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.345 -0.243 . . . . 0.0 110.345 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.8 128.57 24.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.203 0.525 . . . . 0.0 111.779 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -86.92 104.14 15.97 Favored 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD2' ' R' ' 23' ' ' ASP . 39.5 p-10 -135.05 52.27 2.05 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.562 -1.199 . . . . 0.0 111.517 -175.765 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 86.8 t -73.75 142.57 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.537 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -177.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.88 37.69 3.59 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 106.846 -2.502 . . . . 0.0 106.846 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 11.2 t -70.4 103.65 2.49 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.644 -0.778 . . . . 0.0 111.281 -178.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -117.97 -151.93 0.49 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.905 -178.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -39.8 -42.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.391 -1.277 . . . . 0.0 113.468 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.9 61.74 0.7 Allowed Glycine 0 CA--C 1.545 1.942 0 N-CA-C 115.793 1.077 . . . . 0.0 115.793 -174.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.24 107.85 5.34 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 87.3 mt -132.97 133.45 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -176.168 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.72 123.03 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 177.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.85 119.86 3.29 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 46.3 mt -120.56 119.86 34.15 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 120.692 0.282 . . . . 0.0 110.273 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . 0.487 ' O ' ' SD ' ' P' ' 35' ' ' MET . 94.0 mmm -116.52 123.71 48.09 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.473 ' CG1' ' O ' ' P' ' 36' ' ' VAL . 6.5 t -140.04 163.8 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.18 93.38 0.1 Allowed Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 119.513 -1.327 . . . . 0.0 111.382 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.23 -81.98 0.11 Allowed Glycine 0 CA--C 1.533 1.182 0 C-N-CA 119.709 -1.234 . . . . 0.0 113.41 176.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.435 ' H ' ' CA ' ' P' ' 38' ' ' GLY . 10.6 m -147.0 162.09 8.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 120.858 0.361 . . . . 0.0 110.425 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.984 -1.007 . . . . 0.0 110.481 -179.855 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -108.5 134.71 50.9 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.765 0.316 . . . . 0.0 110.328 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.512 ' N ' ' OE1' ' R' ' 11' ' ' GLU . 57.2 mp0 -77.04 135.7 38.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . 0.559 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 40.7 t -139.0 163.31 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.133 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -89.04 119.6 29.7 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.553 178.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -149.51 171.15 17.07 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.797 0.332 . . . . 0.0 111.675 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.433 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 32.8 mt-30 -83.64 154.65 23.6 Favored 'General case' 0 N--CA 1.456 -0.139 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . 0.417 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 70.4 tttt -159.75 104.6 1.57 Allowed 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.637 0.732 . . . . 0.0 109.573 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 mp -126.14 119.71 28.24 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.325 178.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 26.7 t -101.72 107.9 22.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -103.04 99.51 9.4 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 178.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -118.48 119.58 34.98 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-O 121.731 0.777 . . . . 0.0 111.457 -177.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.99 134.11 52.73 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' R' ' 23' ' ' ASP . 83.0 mt-10 -68.72 103.96 1.88 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.226 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' R' ' 22' ' ' GLU . 5.3 p30 140.46 48.44 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 O-C-N 125.107 1.504 . . . . 0.0 108.519 -178.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 36.0 m -72.32 161.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.341 0.591 . . . . 0.0 111.579 -177.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . 0.405 ' O ' ' OG ' ' R' ' 26' ' ' SER . . . 111.7 -29.79 8.3 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.219 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.42 ' O ' ' OG ' ' R' ' 26' ' ' SER . 6.3 p 61.68 109.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.638 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.732 ' O ' ' N ' ' R' ' 29' ' ' GLY . 66.0 t30 -129.72 -179.93 5.47 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.313 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . 0.534 ' H ' ' CG ' ' R' ' 27' ' ' ASN . 98.9 mttt -29.6 47.81 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 126.325 1.85 . . . . 0.0 115.927 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.732 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -170.05 -59.03 0.04 OUTLIER Glycine 0 CA--C 1.539 1.554 0 C-N-CA 120.045 -1.074 . . . . 0.0 113.686 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.0 153.98 27.16 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 117.644 0.722 . . . . 0.0 112.132 -177.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 97.9 mt -121.93 132.37 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.31 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -123.69 128.41 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.313 -0.403 . . . . 0.0 109.929 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.51 120.29 3.65 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 35.9 mt -110.15 115.3 29.49 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.3 tpp -128.26 122.9 32.8 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 21.8 t -136.35 171.55 16.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -167.93 94.4 0.11 Allowed Glycine 0 C--N 1.309 -0.931 0 C-N-CA 119.598 -1.287 . . . . 0.0 111.439 178.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.0 -81.44 0.14 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 177.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 19.0 m -154.96 151.16 11.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.29 179.812 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.524 ' CE2' ' O ' ' A' ' 11' ' ' GLU . 82.6 t80 -84.08 129.29 34.91 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.751 0.31 . . . . 0.0 110.637 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.524 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 98.7 mt-10 -81.0 155.79 26.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.205 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.2 t -121.79 128.87 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.095 0.474 . . . . 0.0 110.421 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -119.55 163.59 17.09 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.485 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.45 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 3.0 m-70 -83.51 164.71 19.67 Favored 'General case' 0 C--N 1.332 -0.157 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.231 -179.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -130.56 152.51 49.86 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.319 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -94.37 116.6 29.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 30.3 tp -122.28 115.68 22.77 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.195 0.521 . . . . 0.0 110.017 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 79.1 t -128.48 132.03 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.529 -178.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -136.62 139.15 41.88 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.986 0.422 . . . . 0.0 110.305 178.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -139.19 132.83 30.52 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.23 119.18 24.68 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.862 0.839 . . . . 0.0 111.141 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -152.12 142.63 22.66 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.89 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 53.3 t0 64.6 47.58 2.85 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.427 HG12 ' H ' ' A' ' 25' ' ' GLY . 1.3 t -100.17 -161.47 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 177.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.427 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -72.49 -35.78 59.41 Favored Glycine 0 C--N 1.34 0.784 0 C-N-CA 118.218 -1.944 . . . . 0.0 108.784 178.636 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 53.7 m -156.06 112.49 3.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 10.5 m120 -52.61 172.52 0.04 OUTLIER 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.576 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.411 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 98.4 mttt -62.74 -38.94 92.49 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.835 1.302 . . . . 0.0 107.579 174.272 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.91 -69.48 3.3 Favored Glycine 0 CA--C 1.533 1.174 0 CA-C-N 112.021 -2.354 . . . . 0.0 111.641 -177.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.73 61.27 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 118.64 1.22 . . . . 0.0 112.764 175.388 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 83.7 mt -131.99 102.05 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.558 0 CA-C-N 119.904 1.229 . . . . 0.0 108.257 179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 80.8 mt -108.32 113.69 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.749 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.74 94.61 0.55 Allowed Glycine 0 N--CA 1.463 0.439 0 N-CA-C 104.748 -3.341 . . . . 0.0 104.748 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 87.5 mt -143.22 157.75 44.22 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 122.788 1.28 . . . . 0.0 114.055 -175.199 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 4.7 mtp -115.99 106.07 13.37 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 112.435 -2.166 . . . . 0.0 107.154 177.357 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 43.6 t -124.25 112.03 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.31 -131.89 8.57 Favored Glycine 0 C--N 1.322 -0.246 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.83 -62.69 0.4 Allowed Glycine 0 CA--C 1.534 1.259 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.267 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.444 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 26.9 m -108.34 162.78 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.189 0.495 . . . . 0.0 110.261 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 44.6 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.829 -1.081 . . . . 0.0 110.699 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -105.52 130.95 53.48 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 110.403 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -106.89 116.35 31.78 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.999 0.428 . . . . 0.0 110.729 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.31 128.95 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.373 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.614 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 6.2 t-160 -127.78 106.97 9.49 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.964 0.411 . . . . 0.0 110.468 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.588 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 4.3 t60 -152.82 168.68 24.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.99 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.588 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 54.5 tt0 -155.96 141.42 17.7 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt -85.65 123.71 31.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.944 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 tt -126.01 115.85 20.53 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.006 0.431 . . . . 0.0 110.221 178.835 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 m -123.98 131.84 72.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.382 179.297 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 71.9 t80 -125.76 122.32 35.91 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.251 -178.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -115.71 123.68 48.94 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.95 143.33 31.93 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 114.185 1.179 . . . . 0.0 114.185 -178.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.9 mt-10 -91.46 154.75 18.93 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' B' ' 22' ' ' GLU . 70.0 m-20 -139.18 46.5 1.93 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.555 1.317 . . . . 0.0 114.555 -176.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.545 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 60.7 t -111.72 177.03 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 C-N-CA 118.562 -1.255 . . . . 0.0 108.291 177.615 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.545 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . 62.39 28.35 70.91 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.291 -0.727 . . . . 0.0 111.531 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 24.5 p -170.55 -131.55 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.674 0 CA-C-N 118.558 1.179 . . . . 0.0 113.596 -176.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.529 ' N ' ' OG ' ' B' ' 26' ' ' SER . 90.9 m-20 -30.79 173.01 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 112.803 -1.999 . . . . 0.0 115.449 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 53.0 mtmt -161.28 -21.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.451 -178.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.8 110.73 3.1 Favored Glycine 0 CA--C 1.532 1.123 0 CA-C-N 113.85 -1.523 . . . . 0.0 109.722 177.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.409 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -129.86 110.25 11.56 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 123.025 1.393 . . . . 0.0 112.814 -176.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 71.9 mt -142.73 139.85 28.09 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-N 113.824 -1.535 . . . . 0.0 112.134 -178.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 27.0 mt -106.9 114.34 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 107.157 -1.424 . . . . 0.0 107.157 174.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.08 106.32 1.42 Allowed Glycine 0 N--CA 1.461 0.312 0 N-CA-C 106.677 -2.569 . . . . 0.0 106.677 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -143.18 141.81 31.26 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.376 -1.33 . . . . 0.0 113.064 -175.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -108.88 109.31 20.38 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 112.455 -2.157 . . . . 0.0 106.637 177.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 32.8 m -133.7 151.69 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.073 0.463 . . . . 0.0 110.091 -177.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.81 -101.85 2.67 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -178.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.08 -80.74 0.58 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.187 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 38.6 t -111.47 135.15 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.602 ' H ' ' CG2' ' C' ' 39' ' ' VAL . 64.1 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.131 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . 0.467 ' OH ' ' NE2' ' E' ' 13' ' ' HIS . 90.1 t80 -73.55 132.52 42.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.986 0.422 . . . . 0.0 110.691 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.42 ' O ' ' CE2' ' C' ' 10' ' ' TYR . 96.3 mt-10 -75.54 136.85 40.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.24 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.471 ' CG2' ' O ' ' C' ' 12' ' ' VAL . 16.7 m -129.45 108.16 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.828 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' B' ' 13' ' ' HIS . 15.4 m-70 -142.64 135.6 28.28 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -178.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.575 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.6 p-80 -153.6 156.19 37.5 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.24 176.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.5 tp60 -99.44 154.2 18.41 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 174.812 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -121.58 109.68 15.09 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 173.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 34.5 mt -118.45 112.99 20.66 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.112 178.113 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -116.64 111.39 35.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 106.862 -1.532 . . . . 0.0 106.862 175.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 71.8 m-85 -102.79 108.84 20.22 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' C' ' 20' ' ' PHE . 26.0 t80 -110.7 123.94 50.98 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.565 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.22 138.99 35.52 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -90.79 108.31 19.75 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 176.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -100.28 46.7 0.95 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -176.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.433 ' CG1' ' N ' ' C' ' 25' ' ' GLY . 54.3 t -101.12 162.23 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 176.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.433 ' N ' ' CG1' ' C' ' 24' ' ' VAL . . . 69.98 30.64 69.92 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 176.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.77 ' O ' ' O ' ' C' ' 27' ' ' ASN . 20.6 p -173.06 -118.73 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.406 1.103 . . . . 0.0 113.307 -177.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.77 ' O ' ' O ' ' C' ' 26' ' ' SER . 61.4 t30 21.35 172.91 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 126.0 1.72 . . . . 0.0 114.446 -176.589 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -159.97 -29.54 0.06 Allowed 'General case' 0 N--CA 1.466 0.372 0 O-C-N 121.334 -0.853 . . . . 0.0 112.648 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.69 81.59 0.09 OUTLIER Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.294 -173.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -78.42 130.7 36.4 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 122.798 1.285 . . . . 0.0 113.057 -175.07 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 76.6 mt -130.31 134.18 62.86 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 113.022 -1.899 . . . . 0.0 111.581 -178.343 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.446 HG21 HD12 ' C' ' 32' ' ' ILE . 87.7 mt -107.91 121.99 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.3 102.24 0.63 Allowed Glycine 0 N--CA 1.469 0.848 0 N-CA-C 107.845 -2.102 . . . . 0.0 107.845 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 5.9 mp -139.13 146.65 40.91 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 123.219 1.485 . . . . 0.0 113.538 -176.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -106.69 109.64 21.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 112.19 -2.277 . . . . 0.0 106.798 177.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.411 ' CG1' ' OE1' ' E' ' 15' ' ' GLN . 18.5 t -121.33 131.06 73.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 120.957 0.408 . . . . 0.0 111.695 -176.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.03 -110.85 3.1 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.575 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.32 -73.12 0.68 Allowed Glycine 0 CA--C 1.544 1.849 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -177.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.602 ' CG2' ' H ' ' B' ' 40' ' ' VAL . 1.3 m -132.32 179.77 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 176.844 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.434 ' OXT' ' O ' ' I' ' 28' ' ' LYS . 46.8 t . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.696 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.162 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -106.16 135.05 48.32 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.801 0.334 . . . . 0.0 110.56 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -74.15 126.25 30.16 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.471 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.8 m -137.52 132.75 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.14 -178.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.54 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 22.4 t-80 -61.9 121.22 12.39 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.595 -177.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.77 ' CD2' ' H ' ' E' ' 14' ' ' HIS . 35.3 m170 -150.45 162.55 40.37 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 68.2 tp60 -85.99 156.85 20.28 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 175.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -159.78 102.21 1.49 Allowed 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.29 -0.964 . . . . 0.0 109.914 177.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 16.2 mt -132.16 122.35 25.17 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.361 0.601 . . . . 0.0 111.478 -179.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 91.2 t -113.36 107.56 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.449 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 80.8 m-85 -104.22 106.87 17.53 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -126.69 128.59 46.94 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -176.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.82 124.03 41.22 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.345 177.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -89.27 153.35 20.97 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 122.059 0.933 . . . . 0.0 113.262 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 98.2 m-20 40.59 55.25 2.95 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 113.631 -1.622 . . . . 0.0 113.257 177.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 98.4 t -66.06 135.12 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 177.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.32 -32.54 1.79 Allowed Glycine 0 N--CA 1.468 0.798 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.414 ' OG ' ' O ' ' C' ' 27' ' ' ASN . 26.8 m -71.25 120.34 16.69 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.147 0.499 . . . . 0.0 110.231 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.506 ' ND2' ' H ' ' E' ' 25' ' ' GLY . 3.9 m120 -103.41 -151.82 0.44 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.184 -178.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.459 ' N ' ' OD1' ' E' ' 27' ' ' ASN . 26.2 pttm 31.72 41.84 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.432 -1.258 . . . . 0.0 114.074 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -173.36 60.89 0.14 Allowed Glycine 0 CA--C 1.54 1.594 0 C-N-CA 119.672 -1.252 . . . . 0.0 113.63 174.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.661 ' N ' ' ND2' ' E' ' 27' ' ' ASN . . . -107.95 109.88 21.48 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 117.717 0.759 . . . . 0.0 109.508 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -134.09 128.59 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 118.952 -1.099 . . . . 0.0 112.186 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -112.55 119.29 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 177.382 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.43 98.88 0.8 Allowed Glycine 0 C--O 1.239 0.453 0 N-CA-C 105.895 -2.882 . . . . 0.0 105.895 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 11.3 tp -131.47 136.45 47.94 Favored 'General case' 0 C--O 1.244 0.81 0 CA-C-O 122.658 1.218 . . . . 0.0 113.795 -175.779 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -109.54 110.0 20.96 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 113.064 -1.88 . . . . 0.0 108.217 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.5 122.87 67.25 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.5 -113.58 0.71 Allowed Glycine 0 C--N 1.307 -1.031 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 96.11 -71.98 0.86 Allowed Glycine 0 CA--C 1.53 1.022 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.554 ' CG2' ' O ' ' J' ' 29' ' ' GLY . 0.3 OUTLIER -141.4 163.06 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 178.005 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' D' ' 39' ' ' VAL . 21.2 t . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 118.215 -0.897 . . . . 0.0 111.746 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.75 136.07 46.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.953 0.406 . . . . 0.0 110.686 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -113.72 119.75 38.47 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.301 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.55 ' C ' ' HE2' ' D' ' 14' ' ' HIS . 50.9 t -127.17 134.21 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 121.395 0.617 . . . . 0.0 110.025 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.48 ' CA ' ' HE2' ' D' ' 14' ' ' HIS . 38.1 m-70 -129.23 106.4 8.8 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.934 -178.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.77 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 3.3 p80 -151.87 161.35 42.79 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 177.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.411 ' OE1' ' CG1' ' C' ' 36' ' ' VAL . 79.1 mm-40 -90.01 158.12 17.5 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -141.1 100.03 3.72 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -133.38 126.1 30.56 Favored 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.643 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -113.62 106.66 21.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.505 178.22 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.449 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 89.8 m-85 -105.79 106.05 16.38 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.303 -1.739 . . . . 0.0 106.303 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -133.53 135.13 44.18 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.091 1.145 . . . . 0.0 114.091 -176.235 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.32 129.91 46.99 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.988 177.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -91.25 166.26 13.03 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.115 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 25.99 47.27 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 112.293 -2.23 . . . . 0.0 115.835 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.461 ' N ' ' O ' ' F' ' 22' ' ' GLU . 53.4 t -67.43 171.43 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 174.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.506 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . -117.75 37.41 3.3 Favored Glycine 0 N--CA 1.48 1.581 0 C-N-CA 119.433 -1.365 . . . . 0.0 111.264 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 72.52 119.99 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.499 . . . . 0.0 110.236 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.661 ' ND2' ' N ' ' D' ' 30' ' ' ALA . 81.4 m-20 -83.19 163.62 20.68 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.952 176.588 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.402 ' H ' ' HA ' ' D' ' 28' ' ' LYS . 97.4 mttt -46.93 -36.93 8.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 122.022 0.915 . . . . 0.0 108.946 175.206 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 77.42 0.06 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 113.694 -1.594 . . . . 0.0 110.558 -177.593 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.73 149.26 4.8 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.775 0.787 . . . . 0.0 110.648 -178.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.44 137.14 56.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.67 122.11 68.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 114.491 -1.231 . . . . 0.0 109.784 178.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.37 106.76 1.36 Allowed Glycine 0 N--CA 1.465 0.607 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 27.0 tp -126.16 125.52 42.61 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.872 0.367 . . . . 0.0 111.313 -177.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.445 ' CG ' ' N ' ' E' ' 36' ' ' VAL . 27.3 ttp -146.29 158.85 43.92 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.614 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.445 ' N ' ' CG ' ' E' ' 35' ' ' MET . 1.3 m -115.02 162.93 12.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.1 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.77 -102.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.371 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -78.47 1.05 Allowed Glycine 0 CA--C 1.534 1.243 0 C-N-CA 121.659 -0.305 . . . . 0.0 112.781 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 9.3 p -93.01 128.12 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 116.952 0.376 . . . . 0.0 111.107 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 80.5 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.07 -0.967 . . . . 0.0 110.323 -179.702 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -103.4 132.34 49.74 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.734 0.302 . . . . 0.0 110.201 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 pt-20 -143.45 150.68 39.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.813 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -124.32 132.83 70.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.018 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.482 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 8.5 p80 -144.74 114.69 7.37 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 121.206 0.526 . . . . 0.0 112.337 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.437 ' ND1' ' O ' ' F' ' 15' ' ' GLN . 54.8 t-80 -151.35 164.35 36.87 Favored 'General case' 0 C--O 1.217 -0.609 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.437 ' O ' ' ND1' ' F' ' 14' ' ' HIS . 88.7 mt-30 -89.91 158.33 17.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 119.113 0.87 . . . . 0.0 111.383 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.53 95.78 2.92 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -130.4 119.31 22.52 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -107.32 105.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.442 ' CE1' ' CD2' ' E' ' 19' ' ' PHE . 78.9 m-85 -107.59 109.0 20.53 Favored 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 20.3 t80 -147.21 137.62 23.42 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 118.618 -1.233 . . . . 0.0 113.826 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.33 130.48 49.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.08 -1.418 . . . . 0.0 107.468 177.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' E' ' 24' ' ' VAL . 96.9 mt-10 -82.29 115.79 21.52 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.043 -0.663 . . . . 0.0 111.653 -178.223 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 9.6 p-10 177.12 -64.54 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.7 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.48 133.72 29.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.246 -178.126 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.23 -30.8 1.83 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.169 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 91.0 p -80.96 -130.27 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -176.197 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.467 ' O ' ' N ' ' F' ' 29' ' ' GLY . 11.6 m120 -99.24 -164.49 1.13 Allowed 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 114.344 1.239 . . . . 0.0 114.344 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -48.14 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 112.816 -1.993 . . . . 0.0 114.936 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -96.16 56.98 1.49 Allowed Glycine 0 CA--C 1.544 1.887 0 C-N-CA 120.188 -1.006 . . . . 0.0 111.878 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.76 179.56 9.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.402 HD13 HG21 ' F' ' 31' ' ' ILE . 96.3 mt -121.2 127.24 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 118.486 0.585 . . . . 0.0 109.79 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 95.1 mt -128.2 131.7 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-O 120.865 0.364 . . . . 0.0 111.45 -178.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.3 116.86 2.67 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.1 tp -122.75 126.13 46.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 5.0 ttp -140.19 139.81 35.75 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 122.365 1.079 . . . . 0.0 113.845 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.478 ' O ' ' O ' ' F' ' 37' ' ' GLY . 43.8 t -117.31 131.95 68.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 CA-C-N 113.758 -1.565 . . . . 0.0 109.523 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -41.25 -111.62 0.0 OUTLIER Glycine 0 CA--C 1.531 1.046 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.907 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -71.7 0.6 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 111.767 -0.533 . . . . 0.0 111.767 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 94.6 t -76.99 131.53 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 117.3 0.55 . . . . 0.0 110.325 179.117 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 14.9 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.148 -0.929 . . . . 0.0 110.608 -179.754 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -105.06 133.55 49.66 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -141.68 144.45 34.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.268 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.45 160.63 41.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -138.2 117.34 12.61 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 121.006 0.432 . . . . 0.0 111.546 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.505 ' O ' ' NE2' ' G' ' 15' ' ' GLN . 49.1 p-80 -151.74 168.05 26.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.099 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.505 ' NE2' ' O ' ' G' ' 14' ' ' HIS . 97.7 mm-40 -156.98 143.23 18.07 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.046 0.45 . . . . 0.0 110.07 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -81.27 118.23 22.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 178.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.0 tp -136.76 118.92 15.48 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.313 0.577 . . . . 0.0 111.349 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 m -137.0 153.44 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.965 178.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -146.51 130.74 17.48 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-O 120.964 0.411 . . . . 0.0 111.195 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -123.04 132.2 54.02 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 126.94 35.6 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.467 0.651 . . . . 0.0 112.685 -178.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -96.36 145.31 25.73 Favored 'General case' 0 C--N 1.34 0.159 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.406 ' OD2' ' O ' ' G' ' 26' ' ' SER . 10.2 t70 -172.33 46.9 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.717 -176.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.441 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 5.2 t -82.21 172.68 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.307 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.441 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . 90.92 -33.9 4.47 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 -176.639 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.439 ' H ' ' C ' ' G' ' 24' ' ' VAL . 71.1 m -151.98 122.97 7.57 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 114.122 -1.039 . . . . 0.0 108.896 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.594 ' OD1' ' N ' ' G' ' 28' ' ' LYS . 31.7 t-20 -41.82 151.18 0.1 Allowed 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.852 179.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.594 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 88.5 tttt -69.43 -48.36 61.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.28 0.562 . . . . 0.0 110.411 178.073 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.542 ' N ' ' OD1' ' G' ' 27' ' ' ASN . . . 129.81 59.92 0.1 Allowed Glycine 0 CA--C 1.54 1.633 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 -176.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.09 89.28 0.82 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 87.3 mt -137.27 117.84 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-N 113.315 -1.766 . . . . 0.0 106.857 177.035 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.484 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.4 mt -106.17 110.64 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 94.86 0.67 Allowed Glycine 0 CA--C 1.508 -0.399 0 N-CA-C 105.097 -3.201 . . . . 0.0 105.097 177.021 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 79.7 mt -147.49 168.44 21.91 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-O 123.254 1.502 . . . . 0.0 113.766 -175.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 94.5 mmm -120.96 114.39 21.46 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 112.064 -2.335 . . . . 0.0 107.16 178.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 41.4 t -124.6 131.53 72.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.53 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.54 -111.31 3.3 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.719 -0.953 . . . . 0.0 110.719 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.4 -73.79 1.33 Allowed Glycine 0 CA--C 1.536 1.395 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.252 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 22.3 m -87.02 171.55 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 117.401 0.6 . . . . 0.0 110.381 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.243 179.273 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -107.62 129.71 54.97 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.711 0.291 . . . . 0.0 110.346 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -154.85 148.76 25.66 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-O 121.166 0.508 . . . . 0.0 111.552 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.648 ' CG1' ' HE2' ' H' ' 14' ' ' HIS . 55.7 t -124.5 130.03 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.459 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 26.0 p-80 -147.46 142.81 27.37 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 119.48 -0.888 . . . . 0.0 113.131 -179.245 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.648 ' HE2' ' CG1' ' H' ' 12' ' ' VAL . 1.5 m-70 -146.23 170.36 16.91 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 114.512 -1.222 . . . . 0.0 108.217 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -155.83 141.28 17.72 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.366 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -87.94 108.67 19.3 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.973 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -121.13 110.71 16.54 Favored 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.361 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 72.0 t -122.13 130.62 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.192 -178.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -126.52 118.98 26.0 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -122.35 125.93 46.98 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.61 131.26 39.42 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.457 0.646 . . . . 0.0 112.677 -179.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -97.68 127.1 43.38 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.541 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.574 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 97.1 m-20 -139.25 46.55 1.92 Allowed 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.598 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.59 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 21.5 t -82.8 173.34 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-O 122.697 1.237 . . . . 0.0 113.06 -176.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.59 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . 92.74 -35.16 4.17 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 112.596 -2.093 . . . . 0.0 114.26 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' H' ' 27' ' ' ASN . 32.2 t -162.55 117.38 1.82 Allowed 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 120.691 2.246 . . . . 0.0 114.192 175.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' H' ' 26' ' ' SER . 45.0 p-10 -22.55 153.13 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.116 0.566 . . . . 0.0 112.297 173.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 7.7 tttm -165.95 26.38 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 117.948 -1.501 . . . . 0.0 114.887 173.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 107.77 0.38 Allowed Glycine 0 CA--C 1.532 1.11 0 C-N-CA 119.004 -1.57 . . . . 0.0 113.944 177.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.7 111.47 17.65 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 87.4 mt -130.22 133.61 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.445 ' O ' ' O ' ' I' ' 33' ' ' GLY . 93.6 mt -105.71 108.46 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.306 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -109.44 101.92 1.54 Allowed Glycine 0 N--CA 1.465 0.623 0 N-CA-C 105.897 -2.881 . . . . 0.0 105.897 177.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.431 HD11 ' H ' ' H' ' 35' ' ' MET . 47.2 tp -152.53 145.62 24.59 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 117.306 -1.758 . . . . 0.0 114.612 -173.726 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.431 ' H ' HD11 ' H' ' 34' ' ' LEU . 3.8 ttm -106.9 117.02 32.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.71 177.457 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.19 102.49 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.801 -178.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.27 -163.93 26.78 Favored Glycine 0 CA--C 1.524 0.617 0 C-N-CA 120.354 -0.926 . . . . 0.0 112.655 177.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.412 ' HA2' ' H ' ' I' ' 38' ' ' GLY . . . 156.2 -54.55 0.41 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.7 m -141.31 164.21 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 176.072 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.538 ' OXT' ' NZ ' ' N' ' 28' ' ' LYS . 1.3 p . . . . . 0 N--CA 1.467 0.377 0 CA-C-O 117.802 -1.094 . . . . 0.0 111.353 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.25 135.41 46.67 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.691 0.281 . . . . 0.0 110.387 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' NE2' ' I' ' 13' ' ' HIS . 45.7 tp10 -147.11 100.9 3.35 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.908 0.385 . . . . 0.0 110.256 179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.405 ' H ' HG21 ' H' ' 12' ' ' VAL . 4.9 m -141.75 127.41 18.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.986 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' CE1' ' H' ' 13' ' ' HIS . 49.5 m170 -113.59 136.24 53.03 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.829 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.527 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 70.7 m80 -156.64 176.04 13.26 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.29 0.567 . . . . 0.0 110.515 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 40.8 tp60 -159.33 139.09 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 174.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -105.39 113.61 27.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 118.999 -0.524 . . . . 0.0 111.5 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -129.5 112.48 13.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 15.1 m -119.43 124.87 73.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -112.16 116.76 30.98 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 114.752 -1.113 . . . . 0.0 108.673 -178.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -119.08 129.14 54.92 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.767 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.87 138.19 30.08 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.436 -0.506 . . . . 0.0 112.165 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -131.91 130.95 42.23 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 120.458 -0.497 . . . . 0.0 112.261 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.521 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 0.3 OUTLIER -130.98 -49.94 1.03 Allowed 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.188 0.518 . . . . 0.0 110.477 178.644 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.424 ' CG2' ' C ' ' I' ' 23' ' ' ASP . 2.0 t 77.7 143.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.939 176.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.496 ' H ' ' CG2' ' J' ' 24' ' ' VAL . . . 92.08 37.46 5.99 Favored Glycine 0 CA--C 1.525 0.662 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.372 174.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 3.0 p 72.69 120.15 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 117.744 0.772 . . . . 0.0 110.237 177.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.629 ' H ' ' ND2' ' J' ' 27' ' ' ASN . 13.8 p30 -83.03 161.3 21.75 Favored 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 117.598 -1.641 . . . . 0.0 109.192 177.131 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.434 ' O ' ' OXT' ' C' ' 40' ' ' VAL . 95.8 mttt -48.63 -39.54 24.49 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 176.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.45 0.04 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -175.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.61 139.15 51.32 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 119.027 1.413 . . . . 0.0 114.281 -174.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 61.2 mt -141.57 143.78 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 113.529 -1.669 . . . . 0.0 113.026 -178.172 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 9.8 mt -104.31 109.72 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 175.72 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -109.51 100.75 1.38 Allowed Glycine 0 N--CA 1.463 0.454 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -139.14 143.27 38.13 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.928 1.347 . . . . 0.0 113.681 -175.52 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 87.7 mmm -117.12 108.71 16.03 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 111.939 -2.391 . . . . 0.0 104.61 175.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 24.4 m -126.14 130.94 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 118.695 -1.202 . . . . 0.0 112.77 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.88 111.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 113.048 -1.887 . . . . 0.0 113.477 177.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.412 ' H ' ' HA2' ' H' ' 38' ' ' GLY . . . -80.81 -60.53 2.29 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.206 -1.157 . . . . 0.0 110.206 175.404 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.3 p -146.2 150.08 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 121.407 0.622 . . . . 0.0 110.407 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.51 ' OXT' ' NE2' ' L' ' 13' ' ' HIS . 21.3 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.659 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -105.31 133.5 49.98 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.602 ' CG ' ' HE2' ' J' ' 13' ' ' HIS . 80.4 tt0 -153.34 114.81 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.005 0.431 . . . . 0.0 110.645 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.635 ' CG2' ' HE2' ' J' ' 14' ' ' HIS . 2.2 p -138.83 138.34 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.847 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.602 ' HE2' ' CG ' ' J' ' 11' ' ' GLU . 19.7 m-70 -139.19 147.83 42.34 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.814 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.635 ' HE2' ' CG2' ' J' ' 12' ' ' VAL . 56.9 m-70 -151.97 160.92 43.35 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.615 177.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 tp60 -90.46 158.35 17.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 177.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -141.48 90.82 2.32 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.288 176.109 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 9.2 mp -128.54 129.86 46.61 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 118.813 0.733 . . . . 0.0 110.688 177.616 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 18.4 t -125.64 116.83 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.682 179.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 12.6 m-85 -109.31 106.95 16.97 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 6.3 t80 -114.01 121.91 45.32 Favored 'General case' 0 N--CA 1.478 0.973 0 O-C-N 122.263 -0.273 . . . . 0.0 110.337 -178.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.24 138.73 37.07 Favored 'General case' 0 C--O 1.253 1.259 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 52.7 tt0 -66.92 149.6 50.39 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.697 ' O ' ' O ' ' J' ' 24' ' ' VAL . 65.1 t0 -168.38 64.5 0.07 Allowed 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -168.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.697 ' O ' ' O ' ' J' ' 23' ' ' ASP . 58.7 t -43.06 -104.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 CA-C-O 113.942 -2.932 . . . . 0.0 103.809 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 166.75 -48.18 0.26 Allowed Glycine 0 N--CA 1.482 1.754 2 CA-C-N 127.32 4.6 . . . . 0.0 119.696 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 41.0 t -65.8 101.0 0.6 Allowed 'General case' 0 C--N 1.322 -0.596 1 CA-C-N 125.567 4.683 . . . . 0.0 105.867 -179.531 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.629 ' ND2' ' H ' ' I' ' 27' ' ' ASN . 1.1 m-20 -129.48 160.88 31.79 Favored 'General case' 0 C--N 1.348 0.504 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.75 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.407 ' C ' ' O ' ' J' ' 27' ' ' ASN . 70.3 mmtt -29.61 -39.42 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.785 -1.098 . . . . 0.0 113.44 174.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.554 ' O ' ' CG2' ' D' ' 39' ' ' VAL . . . 140.93 74.87 0.04 OUTLIER Glycine 0 CA--C 1.552 2.371 0 C-N-CA 119.668 -1.253 . . . . 0.0 112.341 -175.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.03 155.54 40.44 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 120.631 2.215 . . . . 0.0 113.061 -174.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' D' ' 38' ' ' GLY . 57.6 mt -138.2 148.53 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 3.9 mt -109.84 110.99 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 173.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.4 103.81 1.71 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 33.4 tp -143.44 132.58 23.08 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 115.695 1.739 . . . . 0.0 115.695 -173.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 78.4 mmm -103.75 123.75 47.62 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 112.78 -2.009 . . . . 0.0 106.886 176.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -135.25 155.68 37.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-O 121.549 0.69 . . . . 0.0 112.441 -176.411 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.741 ' H ' HE22 ' L' ' 15' ' ' GLN . . . 79.76 -101.42 1.92 Allowed Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.933 176.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.6 -80.31 1.61 Allowed Glycine 0 CA--C 1.537 1.451 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -176.291 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 59.2 t -124.06 131.57 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-N 117.742 0.771 . . . . 0.0 109.624 177.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.516 ' OXT' ' CD2' ' L' ' 13' ' ' HIS . 27.6 t . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.27 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.442 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . 0.441 ' CD2' ' O ' ' K' ' 11' ' ' GLU . 52.6 t80 -70.69 134.95 47.96 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.883 0.373 . . . . 0.0 110.523 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.441 ' O ' ' CD2' ' K' ' 10' ' ' TYR . 68.8 mm-40 -75.22 154.68 37.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.746 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 27.8 m -122.91 129.59 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.363 0.602 . . . . 0.0 111.847 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.56 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 2.9 t60 -148.99 138.09 21.48 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.129 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.531 ' NE2' ' O ' ' L' ' 12' ' ' VAL . 15.3 m-70 -134.51 158.86 42.85 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -90.17 159.51 16.72 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 57.4 tttt -140.47 95.13 2.82 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 120.041 -0.664 . . . . 0.0 109.758 177.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 37.2 mt -118.47 111.67 18.95 Favored 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 177.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -108.29 107.25 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 84.7 m-85 -104.03 105.68 15.93 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.9 t80 -110.74 114.91 28.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.38 135.93 20.6 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 122.023 0.916 . . . . 0.0 111.867 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.558 ' O ' ' CB ' ' K' ' 23' ' ' ASP . 98.3 mt-10 -69.15 -174.92 0.69 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 118.145 -1.422 . . . . 0.0 107.97 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.564 ' HA ' ' O ' ' J' ' 24' ' ' VAL . 10.5 t0 144.98 46.6 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.474 0.654 . . . . 0.0 109.927 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.526 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 25.4 t -84.03 172.16 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.862 -178.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.526 ' H ' ' CG1' ' K' ' 24' ' ' VAL . . . 95.71 -29.68 9.46 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 178.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.485 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 92.07 114.02 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 114.446 -0.877 . . . . 0.0 109.06 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.518 ' OD1' ' N ' ' K' ' 30' ' ' ALA . 1.4 p30 -74.3 174.48 8.76 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.361 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.28 -36.75 43.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.97 76.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.541 0 CA-C-O 119.679 -0.512 . . . . 0.0 112.67 -177.02 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.518 ' N ' ' OD1' ' K' ' 27' ' ' ASN . . . -80.12 149.7 30.5 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 118.745 1.272 . . . . 0.0 110.527 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 59.1 mt -130.77 135.97 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.547 -0.752 . . . . 0.0 112.14 -177.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.33 119.24 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.09 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.74 109.77 1.53 Allowed Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 70.7 mt -122.78 118.38 27.86 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.248 0.547 . . . . 0.0 110.626 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 95.9 mmm -110.74 122.27 47.4 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.004 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.11 132.37 67.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.318 -179.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.24 112.1 3.45 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 178.625 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -76.65 73.18 1.9 Allowed Glycine 0 CA--C 1.532 1.148 0 C-N-CA 120.243 -0.98 . . . . 0.0 113.498 -178.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 22.1 t -128.43 133.57 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' J' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.836 -1.078 . . . . 0.0 110.766 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.64 136.59 43.89 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.817 0.341 . . . . 0.0 110.597 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.52 148.12 47.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.917 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . 0.61 ' CG2' ' H ' ' L' ' 13' ' ' HIS . 11.3 p -138.98 -179.18 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.911 0.386 . . . . 0.0 111.07 -178.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.61 ' H ' ' CG2' ' L' ' 12' ' ' VAL . 0.3 OUTLIER -122.81 108.52 13.11 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.525 -179.941 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.436 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 40.8 t-80 -150.38 165.52 32.85 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.741 HE22 ' H ' ' J' ' 37' ' ' GLY . 51.3 tt0 -89.74 158.73 17.4 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.643 0.259 . . . . 0.0 110.788 -179.03 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -140.01 107.56 5.59 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.252 0.548 . . . . 0.0 111.256 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mt -115.97 109.15 17.16 Favored 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -105.09 103.55 15.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 65.8 m-85 -100.46 100.54 11.31 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.192 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.603 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 52.2 t80 -106.41 95.95 6.11 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.84 145.07 31.46 Favored 'General case' 0 CA--C 1.495 -1.138 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.655 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' K' ' 23' ' ' ASP . 80.8 mm-40 -82.6 96.04 7.96 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.728 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 91.8 m-20 -132.56 62.63 1.64 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 112.052 -177.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.449 ' CG1' ' H ' ' L' ' 25' ' ' GLY . 1.5 t 60.51 -141.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.207 0.527 . . . . 0.0 110.871 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.449 ' H ' ' CG1' ' L' ' 24' ' ' VAL . . . 156.63 -29.53 0.55 Allowed Glycine 0 CA--C 1.519 0.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.979 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 87.8 p -63.21 -123.66 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.191 -0.505 . . . . 0.0 110.868 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.542 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 5.9 t-20 -156.97 -154.14 0.45 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.856 -178.492 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.542 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 68.6 mttm 28.32 41.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.09 -62.59 0.04 OUTLIER Glycine 0 CA--C 1.537 1.445 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.723 178.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.83 148.08 29.02 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.785 0.792 . . . . 0.0 110.488 178.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 6.7 mm -114.76 125.89 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -120.18 124.6 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.72 115.46 1.7 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.7 tp -126.2 120.73 30.81 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mtp -135.38 147.55 49.09 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -177.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 33.6 m -119.36 159.29 20.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.132 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.643 178.277 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.44 ' HA3' ' H ' ' K' ' 38' ' ' GLY . . . -61.89 -102.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.487 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.96 -75.14 0.11 Allowed Glycine 0 CA--C 1.534 1.237 0 C-N-CA 121.83 -0.224 . . . . 0.0 112.88 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' K' ' 38' ' ' GLY . 3.0 m -106.49 123.76 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.296 0.57 . . . . 0.0 111.399 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.258 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . 0.517 ' CG ' ' O ' ' N' ' 9' ' ' GLY . 94.6 m-85 -111.77 132.86 54.38 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.738 0.304 . . . . 0.0 110.217 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.69 171.37 14.14 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.145 0.498 . . . . 0.0 111.025 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.42 130.66 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.158 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 m80 -128.65 113.18 15.07 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 17.9 p-80 -152.56 168.23 26.25 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.548 178.033 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -129.23 150.65 50.52 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.085 178.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -97.56 116.25 29.4 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.3 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -124.97 114.07 18.65 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 118.154 0.434 . . . . 0.0 110.093 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 19.1 m -131.67 132.52 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.641 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -135.7 133.99 38.67 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-O 121.077 0.465 . . . . 0.0 111.745 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -121.61 129.39 52.8 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.98 131.81 44.62 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.332 0.587 . . . . 0.0 112.164 -178.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -120.23 142.27 49.18 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.557 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 37.42 54.68 1.39 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.306 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 45.6 t -67.79 135.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.76 -33.49 2.04 Favored Glycine 0 N--CA 1.47 0.901 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 62.8 p -82.31 -121.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.131 0.491 . . . . 0.0 111.206 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 10.9 m120 -93.22 -160.5 0.76 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.063 -178.217 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 35.28 40.37 0.06 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.38 -64.37 1.22 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.26 49.74 0.44 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.043 0.922 . . . . 0.0 111.772 175.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 97.0 mt -138.49 106.84 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 CA-C-N 114.157 -1.383 . . . . 0.0 107.474 179.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.2 mt -102.7 104.43 16.53 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.335 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.09 95.71 0.75 Allowed Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 104.071 -3.612 . . . . 0.0 104.071 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . 0.401 ' O ' ' CD2' ' N' ' 34' ' ' LEU . 43.1 tp -146.07 150.4 35.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 122.843 1.306 . . . . 0.0 113.809 -173.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -110.02 106.95 16.66 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 112.65 -2.068 . . . . 0.0 106.228 177.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . 0.476 ' O ' ' CG1' ' M' ' 36' ' ' VAL . 4.0 p -127.35 114.07 34.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.6 -124.61 1.88 Allowed Glycine 0 C--N 1.309 -0.958 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.96 -67.11 3.29 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.043 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 13.0 m -78.4 169.1 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-O 121.041 0.448 . . . . 0.0 110.472 -179.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.458 179.981 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' M' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -115.44 142.01 47.29 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.87 0.367 . . . . 0.0 110.52 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . 0.526 ' O ' ' NE2' ' O' ' 13' ' ' HIS . 82.4 tt0 -69.18 120.64 15.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.095 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.51 120.45 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.618 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.474 ' CE1' ' OE2' ' N' ' 11' ' ' GLU . 60.4 m170 -113.68 150.71 32.85 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.901 -178.98 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.555 ' CE1' ' O ' ' O' ' 12' ' ' VAL . 75.2 m-70 -141.92 172.01 13.28 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 121.19 0.519 . . . . 0.0 110.403 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 68.4 tp60 -138.25 140.87 39.86 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttm -130.17 107.0 8.97 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 5.9 tt -122.6 116.33 23.66 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 80.0 t -121.01 126.22 74.95 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.333 -179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -127.03 122.02 33.25 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -125.32 125.21 43.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.032 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.95 131.4 53.56 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 179.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -81.05 -166.81 1.22 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.325 0.583 . . . . 0.0 112.53 -177.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.518 ' N ' ' OE1' ' O' ' 22' ' ' GLU . 66.2 t0 -61.97 47.51 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 114.765 -1.107 . . . . 0.0 112.394 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.628 ' CG1' ' H ' ' N' ' 25' ' ' GLY . 30.3 t -61.04 -179.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.019 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.628 ' H ' ' CG1' ' N' ' 24' ' ' VAL . . . -100.96 29.31 12.77 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 121.636 -0.316 . . . . 0.0 112.718 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 10.7 t -81.05 112.86 18.82 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.163 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 72.1 m-20 -89.75 -175.06 4.52 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.538 ' NZ ' ' OXT' ' H' ' 40' ' ' VAL . 59.3 mttp 49.29 37.64 11.9 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 111.525 -2.58 . . . . 0.0 114.824 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . 0.495 ' O ' ' CB ' ' N' ' 30' ' ' ALA . . . 92.01 -77.98 1.28 Allowed Glycine 0 N--CA 1.469 0.851 0 N-CA-C 114.517 0.567 . . . . 0.0 114.517 172.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . 0.495 ' CB ' ' O ' ' N' ' 29' ' ' GLY . . . 150.87 162.64 0.0 OUTLIER 'General case' 0 C--O 1.238 0.464 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 28.8 pt -141.32 126.92 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.029 178.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -113.04 114.55 47.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.47 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.95 105.95 1.66 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 104.936 -3.266 . . . . 0.0 104.936 175.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . 0.401 ' CD2' ' O ' ' M' ' 34' ' ' LEU . 0.4 OUTLIER -146.32 144.32 29.73 Favored 'General case' 0 CA--C 1.51 -0.581 0 C-N-CA 117.716 -1.594 . . . . 0.0 114.512 -174.18 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 36.3 tpp -106.97 107.77 18.95 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 174.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -121.52 143.68 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 -178.216 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.452 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 113.26 -102.68 1.29 Allowed Glycine 0 C--N 1.316 -0.55 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 178.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 85.69 -80.3 1.81 Allowed Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -178.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 43.4 t -153.03 123.54 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 177.644 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . 0.408 ' OXT' ' CG2' ' O' ' 40' ' ' VAL . 9.1 m . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.724 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -115.44 141.51 47.95 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.876 0.369 . . . . 0.0 110.687 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -83.11 116.78 22.48 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.233 -0.439 . . . . 0.0 109.933 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.555 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 2.9 m -138.44 160.66 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.823 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 94.3 m-70 -76.74 113.39 14.35 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.529 178.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.572 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 83.6 t60 -148.02 153.23 38.68 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 119.576 -0.849 . . . . 0.0 111.875 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.563 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 42.1 tt0 -98.65 169.61 9.38 Favored 'General case' 0 C--N 1.345 0.396 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -158.57 104.44 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.681 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 31.5 mt -122.29 116.02 23.35 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 177.515 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -125.0 117.59 50.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-O 121.883 0.849 . . . . 0.0 109.576 178.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -112.31 115.08 28.19 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.429 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -114.63 133.93 55.46 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 122.523 0.329 . . . . 0.0 110.524 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.58 142.11 27.64 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 113.68 0.993 . . . . 0.0 113.68 -178.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' N' ' 23' ' ' ASP . 95.9 mt-10 -78.99 104.98 10.0 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 104.481 -2.415 . . . . 0.0 104.481 175.486 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.519 ' N ' ' O ' ' P' ' 22' ' ' GLU . 17.6 p30 -83.27 49.03 1.48 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 117.736 2.495 . . . . 0.0 117.736 -172.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 89.9 t -71.56 160.44 5.24 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 C-N-CA 114.803 -2.759 . . . . 0.0 104.221 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.481 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.92 -30.8 8.31 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 -175.065 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 2.5 m 100.59 111.13 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 112.932 -1.634 . . . . 0.0 112.072 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.563 ' CG ' ' H ' ' O' ' 28' ' ' LYS . 12.7 t-20 -70.48 -179.43 2.09 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.702 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.563 ' H ' ' CG ' ' O' ' 27' ' ' ASN . 51.9 tttt 65.53 -47.29 0.38 Allowed 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' O' ' 27' ' ' ASN . . . -81.95 59.38 4.87 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 107.039 -2.424 . . . . 0.0 107.039 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . 0.443 ' H ' ' C ' ' O' ' 28' ' ' LYS . . . -140.31 -171.02 3.11 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 109.739 -3.231 . . . . 0.0 105.513 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.423 HD13 HG23 ' O' ' 31' ' ' ILE . 81.5 mt -128.81 125.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 119.509 -0.876 . . . . 0.0 113.342 -179.564 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . 0.451 HD13 HG22 ' O' ' 32' ' ' ILE . 88.9 mt -104.33 104.54 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 174.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.05 109.92 2.78 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 105.553 -3.019 . . . . 0.0 105.553 177.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -162.98 150.0 12.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 115.737 -2.385 . . . . 0.0 114.742 -174.991 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.0 mmm -110.08 105.05 14.02 Favored 'General case' 0 CA--C 1.496 -1.102 0 CA-C-N 111.604 -2.544 . . . . 0.0 106.199 179.106 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 11.9 p -118.64 142.12 35.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -178.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.04 -102.08 0.21 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 120.076 -1.059 . . . . 0.0 110.549 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.507 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . 73.99 64.75 2.36 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 120.571 -0.823 . . . . 0.0 113.182 -178.498 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.507 ' O ' ' O ' ' O' ' 38' ' ' GLY . 9.1 p -10.79 140.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.414 ' CG1' ' OXT' ' P' ' 40' ' ' VAL . 7.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.059 177.314 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -107.73 131.46 54.41 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.702 0.287 . . . . 0.0 110.591 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 69.5 mm-40 -136.66 113.83 10.67 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.734 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.413 HG13 ' H ' ' Q' ' 12' ' ' VAL . 6.2 m -126.14 130.71 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.598 ' H ' ' CE1' ' Q' ' 13' ' ' HIS . 0.6 OUTLIER -129.54 115.67 17.79 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.055 0.455 . . . . 0.0 112.008 -178.991 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.572 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 4.5 p80 -156.11 167.16 31.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.359 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.452 HE22 ' N ' ' N' ' 37' ' ' GLY . 53.2 tt0 -89.78 158.48 17.49 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -140.32 115.08 9.54 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.636 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 14.4 mt -119.47 122.28 41.34 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.523 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -119.63 107.56 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 47.8 m-85 -110.03 107.95 18.0 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 178.197 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -116.4 125.56 52.22 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.596 0.236 . . . . 0.0 110.694 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . 0.49 ' CB ' ' ND2' ' O' ' 27' ' ' ASN . . . -129.59 127.78 41.36 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.141 0.496 . . . . 0.0 110.231 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' O' ' 23' ' ' ASP . 16.6 pt-20 -122.03 158.77 28.45 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.433 ' C ' ' OD1' ' O' ' 23' ' ' ASP . 29.8 m-20 76.43 55.98 0.05 OUTLIER 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 113.439 -1.709 . . . . 0.0 112.859 178.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 3.8 m -77.4 129.21 37.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.21 -35.41 4.48 Favored Glycine 0 CA--C 1.536 1.383 0 C-N-CA 118.854 -1.641 . . . . 0.0 112.127 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.652 ' O ' ' O ' ' P' ' 27' ' ' ASN . 16.4 t -173.97 125.82 0.36 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 119.562 1.681 . . . . 0.0 114.179 175.323 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.652 ' O ' ' O ' ' P' ' 26' ' ' SER . 44.6 m-20 -2.86 145.73 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.25 1.42 . . . . 0.0 114.683 173.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -160.31 32.23 0.17 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.73 80.95 0.89 Allowed Glycine 0 N--CA 1.482 1.748 0 C-N-CA 117.768 -2.158 . . . . 0.0 112.939 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' O' ' 28' ' ' LYS . . . -101.94 131.41 48.35 Favored 'General case' 0 CA--C 1.508 -0.651 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -176.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 91.1 mt -133.47 122.49 44.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.164 178.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 43.7 mt -107.17 110.43 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 175.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.03 102.88 0.86 Allowed Glycine 0 N--CA 1.462 0.369 0 N-CA-C 107.788 -2.125 . . . . 0.0 107.788 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 4.0 pp -157.35 162.35 39.09 Favored 'General case' 0 CA--C 1.493 -1.224 0 C-N-CA 117.664 -1.615 . . . . 0.0 113.621 -177.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 23.3 mtp -119.89 123.19 42.98 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 112.215 -2.266 . . . . 0.0 109.628 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . 0.609 ' O ' ' O ' ' P' ' 37' ' ' GLY . 0.1 OUTLIER -98.17 101.95 12.81 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.965 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.609 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 28.42 172.77 0.0 OUTLIER Glycine 0 N--CA 1.468 0.78 0 C-N-CA 126.04 1.781 . . . . 0.0 116.491 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.03 -58.21 0.59 Allowed Glycine 0 CA--C 1.536 1.378 0 CA-C-N 113.45 -1.375 . . . . 0.0 112.678 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' P' ' 40' ' ' VAL . 72.7 t -105.58 131.4 55.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 CA-C-O 121.195 0.521 . . . . 0.0 111.091 -178.307 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' P' ' 39' ' ' VAL . 5.6 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.3 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -106.58 133.83 50.66 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.02 139.25 37.78 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.758 0.313 . . . . 0.0 110.549 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . 0.455 ' C ' ' CD2' ' Q' ' 13' ' ' HIS . 29.0 m -137.13 158.1 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 121.085 0.469 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.598 ' CE1' ' H ' ' P' ' 13' ' ' HIS . 44.8 m-70 -147.5 115.18 6.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.91 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.631 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 83.2 m-70 -131.89 160.38 35.89 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.721 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 48.8 tt0 -90.09 159.18 16.94 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -140.68 92.39 2.51 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.836 178.028 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 3.0 mt -115.01 115.12 26.33 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -119.49 107.77 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.397 -179.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.585 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 35.4 m-85 -110.1 101.95 10.7 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 104.311 -2.477 . . . . 0.0 104.311 175.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -123.45 133.37 54.06 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.139 -0.482 . . . . 0.0 112.286 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.09 154.65 49.23 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.528 ' O ' ' N ' ' Q' ' 24' ' ' VAL . 75.4 tt0 -72.58 163.05 28.66 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 65.7 t0 0.78 54.28 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 116.317 1.969 . . . . 0.0 116.317 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' Q' ' 22' ' ' GLU . 0.3 OUTLIER -66.56 137.17 25.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 176.425 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' Q' ' 26' ' ' SER . . . -118.04 -28.34 2.25 Favored Glycine 0 CA--C 1.542 1.745 0 CA-C-O 118.94 -0.922 . . . . 0.0 110.919 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 0.7 OUTLIER 91.11 116.81 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 118.895 1.348 . . . . 0.0 114.607 173.656 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -72.96 174.81 7.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.232 0.539 . . . . 0.0 111.086 177.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -53.84 -38.88 65.1 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.688 178.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.04 69.21 0.21 Allowed Glycine 0 CA--C 1.537 1.438 0 N-CA-C 115.517 0.967 . . . . 0.0 115.517 -175.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.14 121.45 41.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.837 0.819 . . . . 0.0 109.151 178.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 86.1 mt -125.81 132.52 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 121.101 0.477 . . . . 0.0 111.646 -178.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -122.53 121.93 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.521 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.69 108.16 1.15 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 15.7 mt -117.68 122.4 43.43 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -136.12 144.46 45.09 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.447 ' CG1' ' N ' ' Q' ' 37' ' ' GLY . 63.7 t -117.99 168.28 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.381 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.447 ' N ' ' CG1' ' Q' ' 36' ' ' VAL . . . -169.15 93.81 0.1 Allowed Glycine 0 C--N 1.314 -0.672 0 C-N-CA 118.915 -1.612 . . . . 0.0 112.932 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.0 -81.51 0.1 OUTLIER Glycine 0 CA--C 1.536 1.391 0 CA-C-N 118.74 1.27 . . . . 0.0 113.373 177.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -171.99 136.81 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 118.299 1.05 . . . . 0.0 110.293 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.094 -0.955 . . . . 0.0 110.634 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.06 142.03 38.85 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 110.315 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -131.18 148.71 52.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.946 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . 0.454 ' C ' ' CD2' ' R' ' 13' ' ' HIS . 2.6 p -129.51 135.85 60.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-O 121.434 0.635 . . . . 0.0 110.857 -179.695 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.489 ' N ' ' CD2' ' R' ' 13' ' ' HIS . 1.3 m-70 -139.9 133.13 29.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.631 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 83.7 t60 -153.55 161.56 42.1 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.453 ' O ' ' CD2' ' R' ' 14' ' ' HIS . 18.4 tt0 -90.14 158.87 17.06 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.306 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 37.7 tttp -140.52 104.6 4.79 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 177.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . 0.428 ' HB2' ' CE2' ' R' ' 19' ' ' PHE . 0.1 OUTLIER -118.58 114.05 22.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.477 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -117.36 107.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.028 0.442 . . . . 0.0 110.439 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.546 ' O ' ' CD2' ' R' ' 20' ' ' PHE . 16.2 m-85 -113.4 101.45 9.39 Favored 'General case' 0 N--CA 1.461 0.118 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . 0.546 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 63.0 m-85 -157.59 -177.75 6.82 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.695 1.236 . . . . 0.0 113.801 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.02 154.41 41.17 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.05 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -82.15 148.9 28.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.111 0.482 . . . . 0.0 111.7 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 58.14 48.14 13.37 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.753 179.127 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 15.3 t -66.52 166.56 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.812 179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.76 15.96 0.04 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.5 p -83.11 140.82 32.41 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.607 ' O ' ' N ' ' R' ' 29' ' ' GLY . 71.5 m-80 -73.15 150.99 41.74 Favored 'General case' 0 C--O 1.223 -0.297 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.299 177.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -51.32 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.81 58.33 0.8 Allowed Glycine 0 CA--C 1.541 1.681 0 CA-C-N 118.611 0.641 . . . . 0.0 112.479 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -147.59 170.14 18.12 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 117.454 0.627 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 87.9 mt -119.89 123.95 71.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -121.57 130.22 74.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.665 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.08 111.44 1.16 Allowed Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 8.0 tt -119.27 121.42 39.6 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 87.9 mtp -141.64 145.16 34.63 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.384 0.611 . . . . 0.0 112.117 -178.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.2 p -144.01 143.4 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 119.526 -0.869 . . . . 0.0 111.623 177.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.03 -102.62 1.02 Allowed Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 174.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 23.23 73.5 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 112.758 -1.721 . . . . 0.0 115.48 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 96.8 t -49.39 134.4 7.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 117.008 0.404 . . . . 0.0 110.41 178.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.848 179.818 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -81.08 139.83 35.45 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -100.72 108.66 20.56 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.071 0.462 . . . . 0.0 111.461 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 m -136.22 157.57 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 178.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.427 ' C ' ' CG ' ' A' ' 14' ' ' HIS . 64.8 t-80 -145.32 124.06 12.59 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.712 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.513 ' CE1' ' H ' ' B' ' 14' ' ' HIS . 29.4 m-70 -151.47 165.97 32.55 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.133 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.9 tp60 -159.72 143.36 14.43 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.942 0.401 . . . . 0.0 110.053 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -80.44 120.37 24.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.352 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.8 mt -129.71 112.36 13.57 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.5 t -125.52 131.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.377 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -122.99 124.02 42.21 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.4 p90 -132.48 130.59 40.68 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.765 0.317 . . . . 0.0 110.382 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.19 132.69 40.05 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.068 0.461 . . . . 0.0 110.299 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 23' ' ' ASP . 13.2 pt-20 -83.87 -170.47 3.09 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.989 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 23' ' ' ASP . 21.3 p-10 -33.32 -60.36 0.35 Allowed 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.258 0.349 . . . . 0.0 111.15 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.44 ' CG2' ' N ' ' A' ' 25' ' ' GLY . 3.6 p -72.51 160.9 5.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.44 ' N ' ' CG2' ' A' ' 24' ' ' VAL . . . 110.49 -35.09 5.02 Favored Glycine 0 N--CA 1.467 0.734 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 33.8 p -80.59 119.05 22.73 Favored 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.56 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 14.5 t-20 -88.5 179.36 6.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.749 0.785 . . . . 0.0 112.129 -178.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.64 ' HZ1' ' CE1' ' O' ' 13' ' ' HIS . 71.4 tttt -54.4 -38.23 65.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.491 178.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.52 71.42 0.2 Allowed Glycine 0 CA--C 1.536 1.395 0 CA-C-N 114.937 -1.029 . . . . 0.0 114.137 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.474 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -95.65 98.43 10.48 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-O 124.367 2.032 . . . . 0.0 111.036 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 6.0 pt -134.76 139.56 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 111.538 -2.574 . . . . 0.0 108.685 -179.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 43.4 mt -108.57 112.45 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.5 96.8 0.76 Allowed Glycine 0 N--CA 1.463 0.434 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.403 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 77.2 mt -147.08 169.87 18.35 Favored 'General case' 0 CA--C 1.506 -0.721 0 CA-C-O 122.622 1.201 . . . . 0.0 111.834 -176.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 23.5 mtp -124.68 119.42 28.92 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 113.403 -1.726 . . . . 0.0 108.894 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.551 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 2.5 t -108.95 111.9 38.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.52 -131.72 7.97 Favored Glycine 0 C--N 1.32 -0.356 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.6 -62.51 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.439 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 25.2 m -122.96 163.34 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.439 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 99.0 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . 0.527 ' CE1' ' O ' ' C' ' 9' ' ' GLY . 97.2 m-85 -106.12 132.89 51.65 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.541 ' N ' ' OE1' ' B' ' 11' ' ' GLU . 56.9 mp0 -110.31 124.0 50.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.465 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 53.7 t -124.73 128.15 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.522 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 41.2 t60 -131.44 122.24 25.91 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 120.941 0.4 . . . . 0.0 111.595 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.521 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 74.2 t60 -157.78 168.36 27.43 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.593 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.435 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 83.6 mt-30 -154.77 141.81 19.29 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.277 0.56 . . . . 0.0 110.747 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -87.09 110.9 20.41 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.712 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.0 mp -121.52 112.72 18.85 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.518 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -121.65 131.8 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.718 0.294 . . . . 0.0 110.676 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -122.96 116.27 23.29 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.364 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -119.11 126.07 50.76 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.7 136.65 31.05 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.842 1.052 . . . . 0.0 113.842 -178.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -111.53 117.52 33.23 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 176.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.525 ' OD2' ' ND2' ' B' ' 27' ' ' ASN . 65.5 t0 -107.0 46.31 0.94 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -177.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' B' ' 25' ' ' GLY . 61.8 t -83.57 173.26 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.737 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.454 ' N ' ' CG1' ' B' ' 24' ' ' VAL . . . 93.6 -28.17 10.71 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.905 177.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.812 ' O ' ' O ' ' B' ' 27' ' ' ASN . 78.0 p 178.61 -129.35 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.524 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.825 -178.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.812 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.1 t30 10.16 152.06 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.503 ' HB3' ' H ' ' C' ' 28' ' ' LYS . 94.2 mttt -169.55 30.17 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.736 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -99.32 78.88 0.51 Allowed Glycine 0 CA--C 1.538 1.469 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 178.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.571 ' H ' HD22 ' C' ' 27' ' ' ASN . . . -110.43 112.75 24.89 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 114.512 1.301 . . . . 0.0 114.512 -176.079 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 44.1 pt -140.59 143.78 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.958 176.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -113.56 122.45 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.153 0.502 . . . . 0.0 110.054 178.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 105.39 1.04 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 106.839 -2.504 . . . . 0.0 106.839 177.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.412 ' H ' HD23 ' C' ' 34' ' ' LEU . 56.9 mt -137.19 145.24 43.46 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 122.818 1.294 . . . . 0.0 114.157 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -104.79 108.72 20.36 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 174.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -116.33 102.34 13.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.768 ' N ' HE22 ' D' ' 15' ' ' GLN . . . 111.75 164.19 17.5 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-O 122.015 0.786 . . . . 0.0 111.412 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.516 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 164.82 -55.95 0.27 Allowed Glycine 0 CA--C 1.542 1.741 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -178.208 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 t -119.76 134.4 63.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.43 ' O ' ' CG1' ' B' ' 40' ' ' VAL . 81.3 t . . . . . 0 C--O 1.22 -0.447 0 CA-C-O 118.163 -0.923 . . . . 0.0 110.721 179.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . 0.527 ' O ' ' CE1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -151.1 158.86 44.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.616 0.246 . . . . 0.0 110.628 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -89.64 120.78 31.21 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.598 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.523 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 2.8 p -138.94 138.6 41.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.232 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.523 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 84.3 m-70 -146.65 135.17 22.02 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.777 0.322 . . . . 0.0 111.413 -179.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' D' ' 14' ' ' HIS . 41.8 m-70 -151.26 172.03 16.5 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -126.65 141.81 51.74 Favored 'General case' 0 CA--C 1.522 -0.128 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 174.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -115.76 108.99 17.05 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 118.697 -0.668 . . . . 0.0 111.62 179.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mp -124.12 115.06 20.53 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 118.804 0.729 . . . . 0.0 109.056 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 81.2 t -109.32 122.16 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -111.56 103.46 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 15.7 t80 -113.67 125.12 53.79 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.226 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.81 133.35 33.9 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.786 0.803 . . . . 0.0 112.866 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -95.8 120.08 35.43 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.58 48.89 1.62 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -176.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.433 ' CG1' ' N ' ' C' ' 25' ' ' GLY . 73.3 t -71.89 161.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.481 ' O ' ' HB3' ' C' ' 26' ' ' SER . . . 109.35 -30.5 8.5 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 108.159 -1.976 . . . . 0.0 108.159 -176.489 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.512 ' OG ' ' CB ' ' D' ' 26' ' ' SER . 25.8 t 99.96 111.75 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.296 1.838 . . . . 0.0 110.657 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.571 HD22 ' H ' ' B' ' 30' ' ' ALA . 30.8 t30 -71.51 162.01 30.12 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.855 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.503 ' H ' ' HB3' ' B' ' 28' ' ' LYS . 28.2 ttpt -48.7 -39.36 24.34 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 176.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.49 69.15 0.04 OUTLIER Glycine 0 CA--C 1.542 1.762 0 CA-C-O 118.669 -1.073 . . . . 0.0 111.488 -173.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 130.17 41.41 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 120.14 1.97 . . . . 0.0 113.938 -173.772 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.494 ' CD1' ' O ' ' O' ' 38' ' ' GLY . 36.8 mt -139.18 141.24 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 113.738 -1.573 . . . . 0.0 114.284 -176.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.441 HD12 HG23 ' C' ' 32' ' ' ILE . 46.8 mt -117.78 118.52 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 175.096 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.17 113.2 1.88 Allowed Glycine 0 N--CA 1.474 1.185 0 N-CA-C 108.846 -1.701 . . . . 0.0 108.846 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.412 HD23 ' H ' ' B' ' 34' ' ' LEU . 3.1 mt -138.89 151.8 47.26 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-O 123.51 1.624 . . . . 0.0 114.499 -177.49 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 88.1 mmm -105.31 107.1 17.91 Favored 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 111.073 -2.785 . . . . 0.0 104.359 174.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -111.29 143.06 21.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' OE1' ' E' ' 15' ' ' GLN . . . 166.85 -102.06 0.19 Allowed Glycine 0 C--N 1.302 -1.352 0 C-N-CA 119.507 -1.33 . . . . 0.0 111.007 -177.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.516 ' HA3' ' H ' ' B' ' 38' ' ' GLY . . . 51.31 70.77 0.78 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.308 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.453 HG22 ' H ' ' D' ' 39' ' ' VAL . 22.9 t -72.14 142.08 15.75 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.226 0 CA-C-O 120.801 0.334 . . . . 0.0 111.718 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 14.8 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.334 179.186 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -110.84 137.2 48.78 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -143.54 134.21 25.08 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.782 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -138.8 131.97 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.88 179.312 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.523 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 8.6 t60 -146.44 129.79 16.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.935 0.397 . . . . 0.0 110.728 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 2.9 p80 -152.31 161.58 42.4 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.102 178.312 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.768 HE22 ' N ' ' B' ' 37' ' ' GLY . 24.9 mt-30 -90.09 159.59 16.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.347 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 48.1 mmtt -139.63 98.08 3.41 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -130.95 131.1 44.22 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.117 0.485 . . . . 0.0 110.059 178.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 62.9 t -121.53 124.85 72.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.52 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.7 m-85 -111.81 102.6 10.86 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 18.1 t80 -112.89 122.14 46.77 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.86 -0.155 . . . . 0.0 110.732 -178.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.28 134.31 30.84 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 122.106 0.955 . . . . 0.0 113.096 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.455 ' OE2' ' OE1' ' E' ' 22' ' ' GLU . 49.5 tp10 -101.2 126.8 47.95 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.594 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 52.5 p-10 -167.25 48.52 0.06 Allowed 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -72.44 160.97 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.11 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -30.06 8.81 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.094 -1.203 . . . . 0.0 110.094 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.512 ' CB ' ' OG ' ' C' ' 26' ' ' SER . 4.7 p -83.04 141.1 32.3 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 115.014 1.487 . . . . 0.0 115.014 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.671 ' O ' ' N ' ' D' ' 29' ' ' GLY . 34.1 p30 -73.21 -155.48 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.474 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -53.84 48.33 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 113.22 0.822 . . . . 0.0 113.22 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.671 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -100.19 56.01 0.84 Allowed Glycine 0 CA--C 1.542 1.75 0 CA-C-O 119.8 -0.445 . . . . 0.0 112.224 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -153.33 109.21 3.29 Favored 'General case' 0 C--O 1.24 0.594 0 CA-C-N 118.244 1.022 . . . . 0.0 110.277 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.405 ' HA ' ' O ' ' E' ' 31' ' ' ILE . 56.2 mt -133.04 130.37 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 119.104 -1.038 . . . . 0.0 113.549 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.448 HD13 HG23 ' D' ' 32' ' ' ILE . 73.9 mt -112.62 108.32 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 176.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.07 111.6 3.79 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.498 ' CD1' ' CE1' ' F' ' 19' ' ' PHE . 92.2 mt -134.36 134.97 42.34 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -111.39 103.96 12.37 Favored 'General case' 0 N--CA 1.439 -1.021 0 CA-C-N 111.506 -2.588 . . . . 0.0 105.957 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 21.2 m -115.53 122.73 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.787 -179.632 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.44 112.77 1.48 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.668 ' N ' HE21 ' F' ' 15' ' ' GLN . . . -120.61 62.4 0.5 Allowed Glycine 0 CA--C 1.539 1.559 0 N-CA-C 116.237 1.255 . . . . 0.0 116.237 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.486 ' CG1' ' H ' ' D' ' 40' ' ' VAL . 31.2 t -76.83 168.81 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 120.892 2.346 . . . . 0.0 108.403 176.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.486 ' H ' ' CG1' ' D' ' 39' ' ' VAL . 3.6 p . . . . . 0 C--O 1.222 -0.39 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.657 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -98.51 134.4 41.53 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -158.55 153.67 25.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.88 0.371 . . . . 0.0 111.497 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.54 112.6 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 1.7 t60 -127.27 118.67 24.68 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -177.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.458 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 22.9 p-80 -157.57 159.64 37.31 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.531 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.415 ' OE1' ' O ' ' C' ' 37' ' ' GLY . 1.3 mp0 -90.23 159.02 16.92 Favored 'General case' 0 C--O 1.224 -0.242 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 13.0 tttm -140.96 101.13 3.98 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.402 176.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 mp -130.44 127.89 40.2 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.7 t -117.71 126.21 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.579 ' CD1' ' N ' ' E' ' 19' ' ' PHE . 0.2 OUTLIER -113.72 103.74 11.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 -179.454 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 22.3 t80 -113.21 118.53 34.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 121.443 -0.103 . . . . 0.0 111.138 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.57 138.33 36.13 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 119.668 -0.813 . . . . 0.0 112.256 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE2' ' D' ' 22' ' ' GLU . 88.6 mt-10 -101.51 119.77 39.28 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.37 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.544 ' O ' ' CG1' ' E' ' 24' ' ' VAL . 16.6 t0 -119.24 -49.89 2.37 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -179.373 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.544 ' CG1' ' O ' ' E' ' 23' ' ' ASP . 0.1 OUTLIER 163.81 -166.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 179.367 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.36 -35.6 91.89 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.153 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.455 ' OG ' ' O ' ' F' ' 28' ' ' LYS . 22.1 t -155.82 112.63 3.19 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.83 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 30' ' ' ALA . 20.0 p30 -53.01 170.22 0.08 Allowed 'General case' 0 N--CA 1.464 0.231 0 C-N-CA 117.114 -1.835 . . . . 0.0 108.626 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -61.24 -39.05 88.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.224 -0.991 . . . . 0.0 112.238 175.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.474 ' N ' ' OD1' ' E' ' 27' ' ' ASN . . . -178.97 74.97 0.07 OUTLIER Glycine 0 CA--C 1.544 1.856 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.076 -177.256 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.527 ' N ' ' OD1' ' E' ' 27' ' ' ASN . . . -80.64 163.65 23.46 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.537 1.668 . . . . 0.0 111.669 -178.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' D' ' 31' ' ' ILE . 79.8 mt -131.16 127.55 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.431 ' O ' ' HA ' ' F' ' 32' ' ' ILE . 3.2 tt -123.14 109.33 23.28 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.524 ' HA2' ' H ' ' F' ' 33' ' ' GLY . . . -80.08 116.46 4.27 Favored Glycine 0 C--O 1.241 0.568 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' F' ' 34' ' ' LEU . 38.8 tp -110.14 104.21 13.03 Favored 'General case' 0 C--O 1.267 1.982 0 CA-C-N 120.096 1.948 . . . . 0.0 110.767 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.661 ' HA ' ' O ' ' F' ' 34' ' ' LEU . 29.0 tpp -115.8 110.48 19.13 Favored 'General case' 0 C--N 1.351 0.648 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.466 ' H ' ' HA ' ' F' ' 35' ' ' MET . 39.5 t -84.89 172.64 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.374 1.655 0 C-N-CA 117.431 -1.708 . . . . 0.0 107.157 177.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -176.75 92.99 0.09 OUTLIER Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.359 -1.877 . . . . 0.0 111.672 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.407 ' O ' ' C ' ' E' ' 39' ' ' VAL . . . 119.13 85.49 0.98 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-N 119.435 1.618 . . . . 0.0 114.009 178.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' E' ' 38' ' ' GLY . 1.8 p -24.1 121.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 113.87 1.063 . . . . 0.0 113.87 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.587 178.812 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.505 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -106.2 136.0 46.68 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.837 0.351 . . . . 0.0 110.585 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -82.69 117.4 22.6 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.015 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 27.1 m -138.22 157.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.514 0.673 . . . . 0.0 112.225 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -146.07 98.18 3.06 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.059 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.458 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 97.4 m-70 -151.9 168.08 26.28 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.668 HE21 ' N ' ' D' ' 38' ' ' GLY . 66.0 mt-30 -89.75 158.19 17.64 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -140.23 96.08 2.99 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.122 0.487 . . . . 0.0 109.889 177.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.6 ' N ' ' CD2' ' F' ' 17' ' ' LEU . 0.3 OUTLIER -118.82 112.06 19.23 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.928 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 14.6 t -101.28 110.96 29.46 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.728 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.498 ' CE1' ' CD1' ' D' ' 34' ' ' LEU . 15.6 m-85 -104.3 101.33 11.04 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.401 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 61.4 t80 -126.02 125.55 42.84 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 122.236 1.017 . . . . 0.0 111.762 -178.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.37 132.04 51.65 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' E' ' 24' ' ' VAL . 45.9 tp10 -62.17 103.3 0.37 Allowed 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 118.586 -1.246 . . . . 0.0 108.011 -178.062 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' E' ' 24' ' ' VAL . 8.3 m-20 -163.92 46.22 0.11 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.071 -178.078 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.621 ' CG1' ' H ' ' F' ' 25' ' ' GLY . 40.5 t -89.78 -175.56 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.621 ' H ' ' CG1' ' F' ' 24' ' ' VAL . . . 81.35 -34.0 2.47 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.542 ' H ' ' C ' ' F' ' 24' ' ' VAL . 96.2 p -151.93 123.68 7.96 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 113.92 -1.14 . . . . 0.0 108.987 -177.089 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.52 ' O ' ' O ' ' F' ' 26' ' ' SER . 10.6 m120 -40.75 167.29 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.068 0.461 . . . . 0.0 110.77 -176.962 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.455 ' O ' ' OG ' ' E' ' 26' ' ' SER . 74.1 tttt -79.56 -49.93 11.47 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -175.651 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.41 50.73 3.11 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 118.706 -1.711 . . . . 0.0 111.154 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.517 ' CB ' ' O ' ' E' ' 30' ' ' ALA . . . -130.43 179.62 5.82 Favored 'General case' 0 C--N 1.343 0.289 0 CA-C-N 118.454 1.127 . . . . 0.0 111.135 -175.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 5.4 mm -113.53 135.3 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.137 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.431 ' HA ' ' O ' ' E' ' 32' ' ' ILE . 82.9 mt -103.91 117.41 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.95 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . 0.524 ' H ' ' HA2' ' E' ' 33' ' ' GLY . . . -58.4 -154.61 0.01 OUTLIER Glycine 0 C--O 1.209 -1.46 0 CA-C-N 118.65 0.659 . . . . 0.0 113.233 -178.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . 0.661 ' O ' ' HA ' ' E' ' 35' ' ' MET . 74.4 mt -99.47 125.79 45.27 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 178.785 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.721 ' SD ' ' N ' ' F' ' 35' ' ' MET . 0.0 OUTLIER -103.33 83.53 2.19 Favored 'General case' 0 C--O 1.171 -3.045 0 C-N-CA 130.117 3.367 . . . . 0.0 114.197 179.508 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.461 ' CG2' ' O ' ' F' ' 36' ' ' VAL . 2.7 m -92.77 115.21 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 117.785 -3.072 . . . . 0.0 112.713 175.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -117.19 122.51 5.48 Favored Glycine 0 CA--C 1.516 0.12 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 178.119 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.36 -61.61 7.27 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.046 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 37.2 t -147.88 137.77 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.171 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 178.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.135 -0.936 . . . . 0.0 110.34 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -109.6 135.24 50.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.708 0.289 . . . . 0.0 110.413 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . 0.431 ' O ' ' OE1' ' H' ' 11' ' ' GLU . 82.0 tt0 -95.81 123.28 39.32 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.866 0.365 . . . . 0.0 110.236 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 4.4 m -132.69 132.66 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.942 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -104.74 121.68 44.12 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.821 0.343 . . . . 0.0 110.918 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 31.0 t60 -155.03 165.9 35.29 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.763 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.524 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 14.6 pt20 -157.06 142.22 17.18 Favored 'General case' 0 C--N 1.339 0.111 0 CA-C-O 121.174 0.512 . . . . 0.0 111.144 178.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 51.5 pttt -86.3 122.03 29.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.307 178.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.8 mt -127.41 118.07 23.39 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -133.73 133.44 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-O 120.697 0.284 . . . . 0.0 111.585 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -139.14 142.61 38.02 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.896 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -152.0 151.59 31.36 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 119.726 -0.79 . . . . 0.0 112.781 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.51 129.26 50.95 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.036 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.428 ' O ' ' N ' ' G' ' 24' ' ' VAL . 96.4 mt-10 -82.19 -173.58 4.62 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -176.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' N ' ' G' ' 23' ' ' ASP . 0.7 OUTLIER -51.61 46.41 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 112.877 -1.965 . . . . 0.0 115.771 -178.007 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.428 ' N ' ' O ' ' G' ' 22' ' ' GLU . 34.5 m -80.51 179.86 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 117.969 -1.492 . . . . 0.0 107.63 178.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.43 -33.48 64.17 Favored Glycine 0 CA--C 1.521 0.46 0 C-N-CA 119.598 -1.287 . . . . 0.0 112.842 -178.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.461 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.9 p -152.84 122.43 6.82 Favored 'General case' 0 C--N 1.329 -0.306 0 O-C-N 122.567 -0.372 . . . . 0.0 111.152 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.461 ' O ' ' O ' ' G' ' 26' ' ' SER . 25.1 t-20 -40.92 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.501 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -78.62 40.53 0.38 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.75 78.57 0.56 Allowed Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.729 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.66 59.97 4.41 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-N 119.814 1.807 . . . . 0.0 113.456 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 4.5 pt -147.99 123.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 177.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 87.8 mt -109.23 113.67 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.222 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.32 99.81 0.98 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 105.688 -2.965 . . . . 0.0 105.688 176.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.434 HD11 ' H ' ' G' ' 35' ' ' MET . 43.0 tp -157.92 154.8 28.44 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 118.007 -1.477 . . . . 0.0 113.468 -175.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.434 ' H ' HD11 ' G' ' 34' ' ' LEU . 55.0 tpp -102.1 119.89 39.54 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 113.007 -1.906 . . . . 0.0 107.07 177.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 47.2 t -124.2 112.17 31.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.221 0.534 . . . . 0.0 110.798 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.06 -131.89 10.19 Favored Glycine 0 C--N 1.316 -0.567 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.5 -61.35 0.38 Allowed Glycine 0 CA--C 1.537 1.445 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -178.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.486 ' CG2' ' N ' ' G' ' 40' ' ' VAL . 2.4 p -127.78 164.76 28.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.486 ' N ' ' CG2' ' G' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.605 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' N ' ' H' ' 11' ' ' GLU . 60.7 t80 -148.73 179.88 7.5 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.284 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.625 ' N ' ' CD2' ' H' ' 10' ' ' TYR . 80.9 mm-40 -66.96 126.93 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.47 126.62 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.621 ' CE1' ' CD2' ' I' ' 13' ' ' HIS . 15.7 p-80 -151.51 139.23 19.77 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.491 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.581 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 22.6 m-70 -145.33 160.7 41.13 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-O 121.046 0.451 . . . . 0.0 110.134 177.853 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.515 ' CD ' HE22 ' I' ' 15' ' ' GLN . 57.8 tt0 -90.2 160.44 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.139 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -139.84 102.74 4.49 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 7.3 tt -126.35 124.07 39.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.24 0.543 . . . . 0.0 111.191 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 65.4 t -122.0 130.88 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.301 179.1 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -125.95 113.12 16.75 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.058 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -114.47 120.25 39.63 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.68 126.23 41.55 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.811 0.815 . . . . 0.0 113.187 -178.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.416 ' OE2' ' OD2' ' G' ' 23' ' ' ASP . 80.0 tt0 -97.62 113.06 24.71 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 107.07 -1.455 . . . . 0.0 107.07 177.02 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 57.5 t0 -131.12 52.06 2.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.295 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p -74.69 142.97 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 C-N-CA 119.944 -0.703 . . . . 0.0 109.577 -177.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.43 38.37 3.75 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.387 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.401 ' OG ' ' OG ' ' I' ' 26' ' ' SER . 0.9 OUTLIER 73.39 120.04 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.784 -0.208 . . . . 0.0 111.162 179.123 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.439 ' CG ' ' OD2' ' I' ' 23' ' ' ASP . 8.2 m-20 -83.24 162.0 21.32 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.174 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -47.04 -39.53 13.01 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.683 177.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.04 69.15 0.02 OUTLIER Glycine 0 CA--C 1.537 1.448 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.55 -176.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -51.64 100.73 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 118.544 1.172 . . . . 0.0 114.045 -176.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 43.5 pt -137.86 139.27 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.671 178.463 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 86.9 mt -106.89 109.11 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.17 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.071 179.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.98 96.86 1.13 Allowed Glycine 0 CA--C 1.519 0.313 0 N-CA-C 105.506 -3.037 . . . . 0.0 105.506 176.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 67.4 mt -135.23 149.47 49.87 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-O 123.48 1.609 . . . . 0.0 114.129 -175.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -119.55 106.71 12.47 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 111.795 -2.457 . . . . 0.0 104.447 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 79.3 t -106.52 102.78 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.612 0.72 . . . . 0.0 110.521 -177.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -31.1 152.44 0.01 OUTLIER Glycine 0 N--CA 1.469 0.859 0 CA-C-N 114.56 -1.2 . . . . 0.0 113.723 -178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . -88.44 -57.46 1.86 Allowed Glycine 0 N--CA 1.47 0.965 0 CA-C-N 114.98 -0.61 . . . . 0.0 113.338 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 40' ' ' VAL . 60.7 t -24.28 146.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 39' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.217 -0.622 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.869 -179.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . 0.519 ' O ' ' CD2' ' H' ' 10' ' ' TYR . 90.8 m-85 -97.63 129.81 44.7 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.516 ' O ' ' NE2' ' J' ' 13' ' ' HIS . 95.8 mt-10 -141.13 143.46 34.29 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.763 0.316 . . . . 0.0 111.335 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 18.9 t -143.55 91.55 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.381 179.402 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.621 ' CD2' ' CE1' ' H' ' 13' ' ' HIS . 3.9 m170 -132.74 133.63 43.72 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 116.967 -0.106 . . . . 0.0 111.187 -178.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.729 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 11.3 m80 -145.74 160.7 41.35 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 178.383 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.515 HE22 ' CD ' ' H' ' 15' ' ' GLN . 69.1 tp60 -90.17 157.58 17.66 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 174.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -141.91 102.28 4.11 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 119.971 -0.691 . . . . 0.0 110.648 176.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 25.5 mt -120.51 118.41 30.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.652 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -111.8 114.77 48.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 177.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -108.53 105.25 14.81 Favored 'General case' 0 CA--C 1.539 0.533 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -116.17 132.63 56.61 Favored 'General case' 0 N--CA 1.479 1.02 0 O-C-N 122.212 -0.305 . . . . 0.0 111.091 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.22 149.65 32.31 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -178.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -105.59 163.36 12.73 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 113.966 -1.47 . . . . 0.0 108.124 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.446 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 34.6 t0 -174.47 47.08 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 -176.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.416 ' N ' ' OD2' ' J' ' 23' ' ' ASP . 0.1 OUTLIER -91.09 170.56 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 122.381 1.086 . . . . 0.0 110.308 -175.583 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.15 27.43 62.08 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.984 -176.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.401 ' OG ' ' OG ' ' H' ' 26' ' ' SER . 1.7 t 165.78 146.87 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -53.02 138.12 31.38 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 119.126 -1.03 . . . . 0.0 108.844 178.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 31.2 tttm -62.35 -49.77 74.23 Favored 'General case' 0 CA--C 1.53 0.193 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -179.017 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 100.82 57.47 0.87 Allowed Glycine 0 CA--C 1.544 1.854 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.03 115.55 30.79 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 120.12 1.96 . . . . 0.0 116.198 -172.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 97.1 mt -129.89 120.98 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.371 176.302 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 28.9 mt -106.1 114.08 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.36 109.05 1.9 Allowed Glycine 0 C--O 1.236 0.271 0 N-CA-C 106.151 -2.78 . . . . 0.0 106.151 176.527 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.436 HD12 ' N ' ' I' ' 35' ' ' MET . 0.1 OUTLIER -161.31 150.13 16.11 Favored 'General case' 0 CA--C 1.504 -0.793 0 C-N-CA 117.445 -1.702 . . . . 0.0 112.905 -175.63 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.436 ' N ' HD12 ' I' ' 34' ' ' LEU . 29.9 mtp -116.41 117.49 30.07 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-N 112.714 -2.039 . . . . 0.0 107.716 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' I' ' 37' ' ' GLY . 1.5 t -101.11 102.61 13.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.77 153.49 0.01 OUTLIER Glycine 0 N--CA 1.474 1.168 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.6 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.683 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -117.6 56.16 0.55 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 118.843 2.297 . . . . 0.0 118.843 -175.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.427 ' O ' ' O ' ' I' ' 40' ' ' VAL . 61.5 t -101.83 129.06 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 CA-C-N 119.886 1.843 . . . . 0.0 110.234 177.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.427 ' O ' ' O ' ' I' ' 39' ' ' VAL . 47.3 t . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.489 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -147.8 157.59 43.61 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.796 0.332 . . . . 0.0 110.283 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -151.16 114.92 4.93 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.479 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 79.2 t -128.74 133.33 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.814 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' O ' ' I' ' 11' ' ' GLU . 48.9 m-70 -141.19 100.33 3.78 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.484 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.729 ' H ' ' CD2' ' I' ' 14' ' ' HIS . 45.4 p-80 -149.22 161.08 42.72 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.362 177.738 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -90.16 159.79 16.58 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -139.78 103.63 4.71 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.629 179.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -128.34 118.42 23.18 Favored 'General case' 0 C--O 1.239 0.544 0 CA-C-O 121.868 0.842 . . . . 0.0 109.391 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 88.1 t -108.93 111.13 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.51 0 CA-C-N 114.141 -1.39 . . . . 0.0 109.17 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.564 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 16.5 m-85 -108.63 103.95 13.16 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.42 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 3.9 m-85 -120.05 130.72 54.82 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -177.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.4 120.07 16.16 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 177.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.51 ' O ' ' OD1' ' J' ' 23' ' ' ASP . 87.3 mt-10 -145.0 141.36 28.87 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -176.268 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.595 ' CG ' ' H ' ' J' ' 24' ' ' VAL . 5.3 p-10 147.17 -69.39 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.938 0 O-C-N 125.076 1.485 . . . . 0.0 110.125 176.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.678 ' CG2' ' H ' ' J' ' 25' ' ' GLY . 7.6 p -54.97 -122.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.499 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.678 ' H ' ' CG2' ' J' ' 24' ' ' VAL . . . 140.31 -35.17 1.92 Allowed Glycine 0 CA--C 1.528 0.866 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.661 177.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 16.1 t -80.45 118.66 22.27 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 121.041 2.42 . . . . 0.0 106.415 171.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.432 ' H ' ' CB ' ' K' ' 26' ' ' SER . 8.0 m-20 -91.44 160.28 15.53 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 121.977 2.171 . . . . 0.0 111.038 176.743 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -46.31 -39.93 10.93 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-O 122.729 1.252 . . . . 0.0 109.541 173.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.94 68.52 0.02 OUTLIER Glycine 0 CA--C 1.54 1.648 0 CA-C-N 112.401 -2.181 . . . . 0.0 107.954 -176.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.442 ' CB ' ' OD2' ' K' ' 23' ' ' ASP . . . -51.59 138.2 23.13 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 116.331 1.974 . . . . 0.0 116.331 -173.577 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 82.6 mt -135.14 126.57 46.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 113.327 -1.76 . . . . 0.0 112.228 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -108.95 109.72 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.02 99.73 0.99 Allowed Glycine 0 N--CA 1.462 0.433 0 N-CA-C 106.404 -2.678 . . . . 0.0 106.404 178.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 96.9 mt -134.94 134.63 40.8 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -175.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 45.7 tpp -104.51 107.52 18.49 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 103.936 -2.616 . . . . 0.0 103.936 174.1 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 t -120.21 113.14 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 122.445 1.117 . . . . 0.0 110.745 -178.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -73.04 -122.39 0.08 OUTLIER Glycine 0 C--N 1.313 -0.733 0 CA-C-N 112.876 -1.966 . . . . 0.0 110.732 175.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.683 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . 71.52 60.77 4.18 Favored Glycine 0 C--N 1.318 -0.446 0 CA-C-N 111.628 -2.286 . . . . 0.0 115.791 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 7.3 m -81.75 129.35 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.136 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.427 ' CG1' ' HZ2' ' P' ' 28' ' ' LYS . 9.3 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.414 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -111.83 135.18 52.79 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -136.29 144.78 44.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.748 0.308 . . . . 0.0 110.599 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 99.2 t -128.55 130.18 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 39.0 m-70 -136.19 113.73 10.91 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.079 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.497 ' O ' ' CB ' ' J' ' 14' ' ' HIS . 14.8 p-80 -152.84 162.38 41.36 Favored 'General case' 0 C--O 1.217 -0.612 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.904 178.531 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 10.3 tt0 -90.07 158.66 17.21 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.764 -1.939 . . . . 0.0 105.764 175.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 34.5 tttt -140.7 96.52 3.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 119.21 0.914 . . . . 0.0 110.825 178.623 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . 0.6 ' N ' ' CD2' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -120.87 110.58 16.49 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.582 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 7.7 p -114.5 114.25 46.08 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.12 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.564 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 28.7 m-85 -107.23 104.22 13.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.567 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 25.7 t80 -112.67 123.56 50.58 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.128 -178.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.475 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -151.87 139.12 19.32 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 118.72 -1.192 . . . . 0.0 114.126 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.419 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 94.2 mt-10 -79.59 109.46 14.0 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.523 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . 49.3 t0 -146.31 46.71 1.22 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -177.063 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' J' ' 25' ' ' GLY . 10.9 p -98.65 161.41 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 175.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.22 27.68 61.48 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.281 176.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.438 ' HG ' ' N ' ' K' ' 27' ' ' ASN . 24.9 t -83.9 -120.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.445 -0.902 . . . . 0.0 113.305 -175.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 26.7 t-20 -93.27 163.01 13.78 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 122.597 1.189 . . . . 0.0 113.493 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 68.7 mttm -41.97 -37.91 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 112.491 -2.14 . . . . 0.0 111.185 176.534 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.19 71.97 0.22 Allowed Glycine 0 CA--C 1.54 1.646 0 CA-C-N 115.744 -0.662 . . . . 0.0 114.253 -172.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.427 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . -82.02 173.2 12.4 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 18.0 tt -148.23 160.23 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.185 0 N-CA-C 116.17 1.915 . . . . 0.0 116.17 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.77 125.58 61.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 113.572 -1.649 . . . . 0.0 109.711 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.3 123.22 4.3 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.435 ' CD2' ' C ' ' K' ' 34' ' ' LEU . 2.3 tt -130.26 130.57 44.74 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-O 120.97 0.414 . . . . 0.0 110.496 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 5.6 mtp -124.84 130.17 51.86 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.248 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.434 ' CG1' ' N ' ' K' ' 37' ' ' GLY . 50.6 t -124.76 158.69 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.159 0.504 . . . . 0.0 110.667 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.434 ' N ' ' CG1' ' K' ' 36' ' ' VAL . . . -63.65 -103.08 0.01 OUTLIER Glycine 0 CA--C 1.53 0.997 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.32 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -135.89 -74.36 0.07 OUTLIER Glycine 0 CA--C 1.538 1.485 0 C-N-CA 121.472 -0.394 . . . . 0.0 113.249 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 59.6 t -74.91 133.39 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 120.715 0.293 . . . . 0.0 111.202 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.723 -179.721 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.8 136.07 50.41 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.827 0.346 . . . . 0.0 110.695 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -87.77 148.73 24.58 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.36 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.81 114.68 47.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.895 0.379 . . . . 0.0 110.615 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.576 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -147.16 105.77 3.81 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.211 179.814 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.484 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 79.2 m80 -151.49 166.94 29.56 Favored 'General case' 0 C--O 1.221 -0.429 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 38.6 tt0 -89.78 158.46 17.49 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.02 102.38 4.38 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.247 -0.581 . . . . 0.0 111.822 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . 0.52 ' N ' ' CD2' ' L' ' 17' ' ' LEU . 0.1 OUTLIER -116.61 108.09 15.52 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 176.537 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -106.98 111.14 34.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.57 -179.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -105.56 101.07 10.61 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.567 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 30.9 t80 -125.71 131.67 52.53 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 121.203 0.525 . . . . 0.0 110.756 -178.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.475 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -140.29 157.15 46.01 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.147 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.439 ' C ' ' O ' ' L' ' 21' ' ' ALA . 80.2 tt0 -31.1 129.54 0.13 Allowed 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 122.029 0.918 . . . . 0.0 112.48 -174.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' L' ' 23' ' ' ASP . 66.9 t0 -109.84 47.34 0.95 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 113.496 -1.684 . . . . 0.0 112.986 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 3.1 m -63.02 -167.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.349 -178.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.54 27.83 9.13 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.219 -0.446 . . . . 0.0 113.616 -175.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 48.0 t -153.67 120.28 5.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.424 0.63 . . . . 0.0 109.935 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 p30 -40.7 167.0 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.135 0 CA-C-N 114.978 -1.01 . . . . 0.0 112.187 -178.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.523 ' NZ ' ' O ' ' K' ' 23' ' ' ASP . 63.9 tttp -80.22 -50.0 10.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.199 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.85 50.59 3.05 Favored Glycine 0 CA--C 1.543 1.84 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.427 ' CB ' ' O ' ' K' ' 30' ' ' ALA . . . -130.57 -169.15 2.09 Favored 'General case' 0 C--N 1.341 0.224 0 CA-C-O 121.354 0.597 . . . . 0.0 110.597 -178.201 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.41 HD11 HG23 ' L' ' 31' ' ' ILE . 96.7 mt -118.64 138.55 48.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.786 178.062 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -122.15 128.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.64 122.52 3.42 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 111.635 -0.586 . . . . 0.0 111.635 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 57.6 mt -117.99 125.42 50.36 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -132.81 127.65 35.0 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.485 ' CG2' ' N ' ' L' ' 37' ' ' GLY . 2.6 p -140.46 171.72 12.75 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.485 ' N ' ' CG2' ' L' ' 36' ' ' VAL . . . -168.12 94.49 0.11 Allowed Glycine 0 C--N 1.311 -0.852 0 C-N-CA 118.536 -1.792 . . . . 0.0 112.036 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.5 -81.41 0.11 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.747 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' K' ' 38' ' ' GLY . 38.8 t -150.12 136.71 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.105 0.479 . . . . 0.0 110.359 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 19.1 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.533 179.822 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -112.24 137.83 49.79 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.909 0.385 . . . . 0.0 110.582 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -140.44 164.47 30.05 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.356 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . 0.459 ' CG1' ' H ' ' N' ' 12' ' ' VAL . 2.4 p -123.0 131.82 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.286 0.565 . . . . 0.0 110.101 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . 0.456 ' CG ' ' N ' ' M' ' 14' ' ' HIS . 76.4 t60 -72.65 164.08 27.05 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.309 -178.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.588 ' N ' ' ND1' ' M' ' 14' ' ' HIS . 1.2 m-70 -99.13 166.17 11.37 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -89.8 159.82 16.82 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.54 107.98 5.85 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.1 mt -129.76 114.92 16.56 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 121.098 0.475 . . . . 0.0 110.227 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 54.3 t -125.23 132.17 71.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.031 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 t80 -136.28 127.41 28.0 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.45 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -131.48 146.32 52.19 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.16 128.29 23.88 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 121.741 0.781 . . . . 0.0 112.743 -178.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -92.17 -149.25 0.24 Allowed 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -46.62 -60.08 2.61 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.613 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.419 ' CG1' ' N ' ' M' ' 25' ' ' GLY . 47.9 t -84.76 171.56 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 175.92 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.419 ' N ' ' CG1' ' M' ' 24' ' ' VAL . . . 94.03 -29.98 8.1 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 176.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 7.3 p -84.23 139.98 31.99 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.146 -1.527 . . . . 0.0 113.575 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -73.03 179.5 3.74 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 177.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CG ' ' N' ' 28' ' ' LYS . 98.4 mttt -49.77 -37.58 30.4 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 117.943 -1.503 . . . . 0.0 110.548 -175.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.05 -78.38 0.06 OUTLIER Glycine 0 CA--C 1.53 1.023 0 C-N-CA 118.89 -1.624 . . . . 0.0 113.777 174.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' N' ' 30' ' ' ALA . . . -147.35 81.63 1.53 Allowed 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 117.819 0.81 . . . . 0.0 112.942 178.75 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . 0.407 ' O ' ' CG2' ' M' ' 31' ' ' ILE . 14.3 tt -123.34 105.39 15.69 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.98 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 2.4 mt -119.11 111.87 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 C-N-CA 119.659 -0.816 . . . . 0.0 111.452 -178.8 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.41 105.61 1.16 Allowed Glycine 0 N--CA 1.46 0.258 0 N-CA-C 104.153 -3.579 . . . . 0.0 104.153 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . 0.4 HD12 ' H ' ' M' ' 35' ' ' MET . 45.6 tp -153.71 158.17 40.6 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.579 -173.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 35' ' ' MET . . . . . 0.4 ' H ' HD12 ' M' ' 34' ' ' LEU . 0.7 OUTLIER -104.88 110.18 22.45 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 112.736 -2.029 . . . . 0.0 106.991 177.182 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.62 131.24 70.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.12 -111.17 3.89 Favored Glycine 0 C--N 1.318 -0.466 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.436 ' O ' ' CG2' ' N' ' 39' ' ' VAL . . . 75.12 -73.76 1.5 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.403 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 17.6 m -95.69 -176.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.175 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.403 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 1.3 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.607 178.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . 0.487 ' CD1' ' O ' ' O' ' 9' ' ' GLY . 97.9 m-85 -108.0 139.7 42.25 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.26 124.14 51.8 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.957 0.408 . . . . 0.0 111.023 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . 0.459 ' H ' ' CG1' ' M' ' 12' ' ' VAL . 3.4 t -137.88 97.14 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.745 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.57 ' ND1' ' ND1' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -151.5 151.07 31.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 121.108 -0.237 . . . . 0.0 110.675 179.524 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -124.79 162.58 23.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.047 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -89.88 158.79 17.28 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -140.53 99.94 3.75 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -124.04 119.3 29.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -123.01 128.34 75.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.648 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -123.76 123.95 41.64 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.897 179.149 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -129.18 123.14 31.31 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.805 0.336 . . . . 0.0 110.283 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 132.22 50.38 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.424 ' O ' ' CB ' ' N' ' 23' ' ' ASP . 83.1 tt0 -157.38 151.46 24.65 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.424 ' CB ' ' O ' ' N' ' 22' ' ' GLU . 9.5 m-20 92.29 46.92 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 113.603 -1.635 . . . . 0.0 115.185 176.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 24.2 m -101.52 158.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 -37.5 94.76 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.582 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.579 ' O ' ' O ' ' N' ' 27' ' ' ASN . 86.4 p -162.47 117.17 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 117.093 -1.432 . . . . 0.0 107.165 177.001 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.579 ' O ' ' O ' ' N' ' 26' ' ' SER . 11.6 t-20 -23.45 151.2 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 120.332 1.424 . . . . 0.0 111.908 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.418 ' CG ' ' O ' ' M' ' 28' ' ' LYS . 73.8 mmtt -107.83 47.87 0.87 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 115.999 -1.953 . . . . 0.0 115.264 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 61.8 0.52 Allowed Glycine 0 N--CA 1.489 2.202 0 CA-C-N 124.083 3.129 . . . . 0.0 114.067 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . 0.459 ' HA ' ' O ' ' M' ' 30' ' ' ALA . . . -88.31 98.95 11.88 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 121.076 2.438 . . . . 0.0 111.476 -174.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 18.9 tt -134.61 129.33 52.12 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-N 110.856 -2.884 . . . . 0.0 110.2 -177.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . 0.406 HD12 HG21 ' N' ' 32' ' ' ILE . 95.8 mt -113.04 110.87 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.78 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.25 93.51 0.72 Allowed Glycine 0 N--CA 1.467 0.722 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 175.646 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -125.12 133.32 52.89 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.018 1.39 . . . . 0.0 112.269 -174.41 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 2.7 mtp -103.55 106.06 16.47 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 176.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 p -127.9 123.11 60.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.246 -178.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 149.63 -113.2 0.59 Allowed Glycine 0 C--N 1.311 -0.818 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 70.48 -72.58 0.62 Allowed Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' N' ' 40' ' ' VAL . 45.1 t -123.36 163.96 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 178.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . 0.48 ' C ' ' NE2' ' P' ' 13' ' ' HIS . 18.6 m . . . . . 0 N--CA 1.471 0.579 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.715 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' N' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -114.28 147.19 39.42 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.711 0.291 . . . . 0.0 110.293 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -87.49 109.88 19.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.09 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 51.5 t -129.62 123.86 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.505 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.64 ' CE1' ' HZ1' ' A' ' 28' ' ' LYS . 7.3 m-70 -137.57 150.42 47.46 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.598 ' CD2' ' CE1' ' P' ' 14' ' ' HIS . 4.7 m80 -136.86 157.45 46.73 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.169 178.33 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -86.3 157.46 19.91 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 175.109 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -160.25 101.76 1.4 Allowed 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.255 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 3.2 mt -132.47 122.73 25.37 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.335 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 89.2 t -113.56 113.27 43.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.941 178.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -108.4 102.54 11.63 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.393 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -113.33 125.03 53.83 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -177.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.15 125.91 40.05 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -124.51 178.93 5.16 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 52.44 58.94 4.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 113.19 -1.823 . . . . 0.0 112.05 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 63.2 t -78.25 123.0 34.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.911 -1.041 . . . . 0.0 109.214 175.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.414 ' H ' ' HA ' ' N' ' 26' ' ' SER . . . -90.49 -38.54 6.21 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.577 -177.472 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' O' ' 27' ' ' ASN . 46.8 t -161.97 116.51 1.91 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 118.454 1.127 . . . . 0.0 111.907 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' O' ' 26' ' ' SER . 57.2 p30 -24.12 163.73 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.358 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -152.16 -22.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.943 178.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.2 97.32 2.43 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.19 140.94 29.12 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-O 121.776 0.798 . . . . 0.0 111.974 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 mt -143.41 135.77 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.19 -0.914 . . . . 0.0 113.064 -179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 82.3 mt -114.38 112.08 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 176.076 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.01 109.48 2.34 Favored Glycine 0 C--O 1.24 0.505 0 N-CA-C 105.575 -3.01 . . . . 0.0 105.575 176.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -144.91 142.34 29.79 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 123.019 1.39 . . . . 0.0 114.038 -175.263 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 94.8 mmm -103.75 110.57 22.72 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 112.133 -2.303 . . . . 0.0 105.366 176.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . 0.416 ' CG1' ' NE2' ' Q' ' 15' ' ' GLN . 47.1 t -117.93 123.12 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-O 120.823 0.344 . . . . 0.0 110.087 -177.101 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.38 -113.24 0.63 Allowed Glycine 0 C--N 1.32 -0.339 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.494 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . 87.5 -73.12 2.42 Favored Glycine 0 CA--C 1.541 1.677 0 CA-C-O 119.93 -0.372 . . . . 0.0 112.649 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.463 ' CG1' ' N ' ' O' ' 40' ' ' VAL . 45.2 t -134.51 161.04 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.463 ' N ' ' CG1' ' O' ' 39' ' ' VAL . 6.3 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.315 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -106.44 136.25 46.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.829 0.347 . . . . 0.0 110.284 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -87.94 119.6 28.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.037 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.541 ' O ' ' NE2' ' O' ' 14' ' ' HIS . 2.8 m -136.83 160.71 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.466 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.48 ' NE2' ' C ' ' N' ' 40' ' ' VAL . 8.2 t60 -90.7 120.79 32.05 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.344 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' CD2' ' O' ' 14' ' ' HIS . 11.6 p-80 -152.97 161.82 42.08 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.659 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 95.4 mt-30 -90.23 158.77 17.04 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.646 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -140.94 105.27 4.84 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 31.2 mt -122.7 123.18 40.53 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 120.314 -0.554 . . . . 0.0 110.433 178.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.2 t -114.51 106.51 20.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.47 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 57.3 m-85 -106.76 111.52 24.09 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -133.7 130.39 38.09 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.456 1.28 . . . . 0.0 114.456 -176.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.54 125.16 37.75 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.838 177.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -111.74 150.81 29.72 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 115.764 1.764 . . . . 0.0 115.764 -175.23 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.446 ' OD1' ' OE1' ' Q' ' 22' ' ' GLU . 83.6 m-20 63.38 46.56 4.33 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 117.685 2.476 . . . . 0.0 117.685 173.939 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.456 ' CG1' ' H ' ' P' ' 25' ' ' GLY . 8.7 t -100.44 -179.44 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 115.556 -2.458 . . . . 0.0 109.523 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.5 ' O ' ' CB ' ' P' ' 26' ' ' SER . . . -72.6 -30.65 63.88 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 121.195 -0.526 . . . . 0.0 113.469 176.073 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.5 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 9.7 t 100.72 111.33 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 -174.217 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.544 ' CG ' ' H ' ' P' ' 28' ' ' LYS . 22.8 t-20 -71.31 173.47 7.75 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 117.459 -1.697 . . . . 0.0 112.724 -176.622 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.544 ' H ' ' CG ' ' P' ' 27' ' ' ASN . 88.7 tttt -52.45 -36.78 55.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.43 177.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.52 77.18 0.06 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.661 -177.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.83 154.11 2.22 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 118.307 1.053 . . . . 0.0 110.44 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 69.4 mt -121.22 131.23 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -177.271 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . 0.412 HD11 HG22 ' P' ' 32' ' ' ILE . 73.7 mt -114.33 110.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.584 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.04 109.21 2.74 Favored Glycine 0 N--CA 1.463 0.497 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . 0.51 ' CD1' ' CE1' ' R' ' 19' ' ' PHE . 95.4 mt -135.0 133.48 39.49 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.445 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 4.0 mtp -107.62 104.02 13.46 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 174.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.76 103.07 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.32 -153.11 24.62 Favored Glycine 0 C--N 1.31 -0.892 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.95 -56.68 0.6 Allowed Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -178.1 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.436 ' O ' ' OXT' ' P' ' 40' ' ' VAL . 11.5 p -124.36 154.99 31.91 Favored 'Isoleucine or valine' 0 C--O 1.231 0.085 0 C-N-CA 122.66 0.384 . . . . 0.0 110.054 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.436 ' OXT' ' O ' ' P' ' 39' ' ' VAL . 1.9 t . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 118.067 -0.968 . . . . 0.0 111.028 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -119.73 120.71 37.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.82 154.01 43.77 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.043 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . 0.472 ' H ' ' CG1' ' P' ' 12' ' ' VAL . 12.7 m -133.0 120.11 39.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 121.625 0.726 . . . . 0.0 111.84 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.4 ' CD2' ' H ' ' Q' ' 13' ' ' HIS . 4.0 m-70 -90.1 110.73 21.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.233 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.527 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 2.3 t-80 -119.37 159.62 23.84 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.424 ' N ' ' ND1' ' Q' ' 14' ' ' HIS . 9.6 tt0 -86.24 157.84 19.85 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 76.5 tttt -160.04 94.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.539 177.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mt -131.56 127.15 36.58 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 28.1 m -117.45 122.11 69.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.47 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 22.0 m-85 -112.63 105.37 13.53 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -127.32 137.02 52.71 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.644 0.735 . . . . 0.0 112.686 -177.036 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -146.74 145.04 29.82 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 119.78 -0.768 . . . . 0.0 113.03 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.446 ' OE1' ' OD1' ' P' ' 23' ' ' ASP . 82.8 mt-10 -79.27 149.66 31.76 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.443 ' OD1' ' O ' ' R' ' 22' ' ' GLU . 6.9 p-10 -168.14 47.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -176.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 5.7 t -71.58 170.02 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.105 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.75 26.7 53.16 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 104.537 -3.425 . . . . 0.0 104.537 -175.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 24.0 p -80.85 116.5 20.86 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 117.047 2.24 . . . . 0.0 117.047 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -90.22 -152.16 0.26 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 111.286 -2.688 . . . . 0.0 104.947 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -48.56 -41.03 29.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 119.695 1.134 . . . . 0.0 108.333 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.44 -63.95 0.6 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 117.064 1.586 . . . . 0.0 117.064 173.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.16 165.21 32.07 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 120.108 1.954 . . . . 0.0 115.057 -176.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 69.2 mt -125.35 127.55 72.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 CA-C-N 111.321 -2.672 . . . . 0.0 106.786 178.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 tt -134.79 133.33 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 121.781 0.801 . . . . 0.0 112.698 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.4 109.93 2.16 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 107.764 -2.134 . . . . 0.0 107.764 177.2 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 18.5 tp -116.63 119.04 34.26 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -178.651 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.22 137.45 52.03 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.934 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 21.4 t -111.19 131.9 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.067 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.29 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . -45.62 -111.7 0.0 OUTLIER Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.322 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . -101.48 -71.5 0.93 Allowed Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 69.3 t -109.08 129.86 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.275 0.538 . . . . 0.0 109.862 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.838 -179.397 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.61 132.53 51.65 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -72.34 142.81 48.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . 0.448 ' H ' ' CG1' ' Q' ' 12' ' ' VAL . 5.4 m -121.13 131.96 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-O 121.901 0.858 . . . . 0.0 112.01 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 4.1 m80 -133.47 124.96 27.97 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 114.448 -1.251 . . . . 0.0 108.92 178.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 99.2 m-70 -149.28 172.04 15.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.809 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.516 ' OE1' ' N ' ' R' ' 15' ' ' GLN . 14.0 mp0 -89.42 150.33 22.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.614 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -150.17 98.78 2.73 Favored 'General case' 0 C--N 1.311 -1.066 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 178.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -127.05 124.58 39.64 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.625 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 66.5 t -106.62 114.66 46.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD1' ' P' ' 34' ' ' LEU . 17.1 m-85 -106.59 105.81 16.02 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' N ' ' R' ' 21' ' ' ALA . 66.2 t80 -146.9 156.76 43.33 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 122.463 1.125 . . . . 0.0 113.261 -177.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . 0.428 ' N ' ' CG ' ' R' ' 20' ' ' PHE . . . -150.02 148.24 28.8 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.878 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.443 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 83.4 tt0 -76.49 112.54 13.13 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.56 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.484 ' N ' ' OD1' ' R' ' 23' ' ' ASP . 19.5 p-10 -177.23 48.92 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.642 -177.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -72.11 160.49 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 118.605 -1.238 . . . . 0.0 108.879 -178.592 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.35 -34.83 5.18 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 107.286 -2.326 . . . . 0.0 107.286 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.425 ' OG ' ' O ' ' R' ' 23' ' ' ASP . 11.9 p -80.53 119.98 23.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 113.193 -1.504 . . . . 0.0 109.852 179.082 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' R' ' 29' ' ' GLY . 13.6 m120 -87.72 -175.17 5.07 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.091 -178.067 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -49.52 49.64 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.7 51.49 0.92 Allowed Glycine 0 CA--C 1.546 1.972 0 CA-C-N 118.776 0.717 . . . . 0.0 112.333 178.539 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.17 172.94 11.24 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.2 mt -113.35 120.4 63.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -125.01 127.97 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.935 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.19 116.68 3.01 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 178.426 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 40.4 tp -124.1 122.51 38.04 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.6 mtp -139.72 147.34 40.76 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.173 0.511 . . . . 0.0 112.279 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -130.15 155.27 41.46 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.075 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.5 179.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.99 102.75 2.29 Favored Glycine 0 CA--C 1.523 0.582 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.95 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.97 -76.17 0.73 Allowed Glycine 0 CA--C 1.535 1.329 0 N-CA-C 115.241 0.857 . . . . 0.0 115.241 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . 0.485 ' O ' ' O ' ' Q' ' 38' ' ' GLY . 54.0 t -122.7 139.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 117.916 0.858 . . . . 0.0 112.708 -177.033 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.987 179.214 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -83.82 142.25 30.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.869 0.366 . . . . 0.0 110.814 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.473 ' CD ' ' HE2' ' A' ' 13' ' ' HIS . 80.8 tt0 -138.85 146.48 41.27 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.68 179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 51.8 t -120.16 129.51 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.619 0.723 . . . . 0.0 111.098 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.473 ' HE2' ' CD ' ' A' ' 11' ' ' GLU . 98.2 m-70 -126.04 166.16 17.48 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.713 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 53.0 p-80 -82.92 167.31 18.13 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.238 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -157.87 142.92 16.71 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.611 178.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -81.51 127.98 33.41 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.2 mt -125.48 114.49 18.87 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -127.55 131.49 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.176 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -134.55 130.79 37.1 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.148 0.499 . . . . 0.0 111.702 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -113.9 123.02 48.76 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.034 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.02 129.46 46.74 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.155 0.502 . . . . 0.0 111.656 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -92.99 -176.28 4.14 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.409 ' C ' ' CG2' ' A' ' 24' ' ' VAL . 48.5 t0 -58.6 -48.2 81.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.402 0.62 . . . . 0.0 109.629 179.296 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 25' ' ' GLY . 1.0 OUTLIER 72.4 -162.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.962 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.435 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -109.27 27.17 13.04 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 119.195 -0.78 . . . . 0.0 112.488 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -81.67 -127.09 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 119.424 1.612 . . . . 0.0 111.087 -178.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -100.67 160.91 13.97 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 115.862 1.801 . . . . 0.0 115.862 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -42.89 -36.25 1.45 Allowed 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 112.369 -2.196 . . . . 0.0 113.261 171.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -102.39 87.75 0.63 Allowed Glycine 0 CA--C 1.526 0.761 0 CA-C-N 113.051 -1.886 . . . . 0.0 117.335 -168.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.52 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -96.27 128.66 43.39 Favored 'General case' 0 CA--C 1.551 1.01 0 CA-C-O 124.975 2.321 . . . . 0.0 110.403 -177.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -145.59 160.23 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 CA-C-N 110.546 -3.024 . . . . 0.0 111.329 -175.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 52.0 mt -104.43 109.46 27.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 175.638 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.13 94.88 0.69 Allowed Glycine 0 CA--C 1.508 -0.39 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 178.576 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.4 mt -144.26 154.63 43.28 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 122.881 1.324 . . . . 0.0 113.43 -176.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 6.1 ttm -114.48 114.95 26.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 112.466 -2.152 . . . . 0.0 107.431 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.26 102.84 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.1 -151.75 20.83 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 109.299 -1.521 . . . . 0.0 109.299 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.485 ' O ' ' CD1' ' G' ' 31' ' ' ILE . . . 117.24 -56.33 0.54 Allowed Glycine 0 CA--C 1.543 1.797 0 C-N-CA 121.534 -0.365 . . . . 0.0 112.713 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 40' ' ' VAL . 7.2 p -133.1 177.47 7.09 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.453 ' C ' ' O ' ' A' ' 39' ' ' VAL . 6.0 m . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 117.901 -1.047 . . . . 0.0 111.965 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -84.23 138.02 33.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.76 0.314 . . . . 0.0 110.322 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -106.35 125.77 51.41 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.988 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 54.1 t -122.35 130.03 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.725 -179.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m80 -117.42 157.6 25.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.609 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.605 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 52.9 t60 -80.72 166.86 20.63 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.111 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.559 ' O ' ' CE1' ' B' ' 14' ' ' HIS . 29.6 pt20 -129.29 151.08 50.34 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.15 0.5 . . . . 0.0 110.334 179.454 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -96.9 120.88 38.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.144 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 tt -116.76 115.56 25.84 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.8 t -121.34 128.68 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.205 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.248 -179.435 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -129.63 117.48 20.44 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 32.4 t80 -112.57 122.42 47.63 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.04 116.11 26.22 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.929 0.871 . . . . 0.0 112.394 -178.504 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -95.98 135.35 37.85 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.518 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -150.65 51.27 0.87 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.356 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.23 151.27 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 C-N-CA 118.486 -1.285 . . . . 0.0 110.21 -177.54 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.52 -32.4 6.64 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 106.166 -2.774 . . . . 0.0 106.166 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.504 ' HB3' ' N ' ' C' ' 26' ' ' SER . 0.5 OUTLIER 71.5 106.09 0.06 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 112.732 -1.734 . . . . 0.0 112.262 176.045 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.598 ' N ' ' OG ' ' C' ' 26' ' ' SER . 43.8 m-80 -101.63 163.36 12.3 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 119.217 -0.993 . . . . 0.0 112.815 177.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.49 ' O ' ' O ' ' C' ' 27' ' ' ASN . 99.7 mttt -41.45 -39.2 1.44 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 119.739 3.237 . . . . 0.0 119.739 178.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -110.72 69.7 0.21 Allowed Glycine 0 N--CA 1.497 2.713 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 -170.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.417 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -97.47 102.33 14.07 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 120.527 2.164 . . . . 0.0 111.978 178.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 7.0 pt -147.49 153.03 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.125 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.431 HD11 HG22 ' B' ' 32' ' ' ILE . 88.9 mt -107.44 114.09 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.53 106.09 1.93 Allowed Glycine 0 N--CA 1.464 0.504 0 N-CA-C 106.256 -2.738 . . . . 0.0 106.256 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -141.76 142.4 33.24 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.653 -1.219 . . . . 0.0 114.249 -175.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -116.67 110.94 19.13 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.359 177.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.426 ' O ' ' HA ' ' C' ' 36' ' ' VAL . 0.4 OUTLIER -132.75 102.94 5.57 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.596 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 -179.299 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.51 -151.85 21.21 Favored Glycine 0 C--N 1.306 -1.088 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 100.21 -57.05 0.8 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -178.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.411 ' O ' ' C ' ' B' ' 40' ' ' VAL . 12.8 m -123.47 174.14 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 C-N-CA 123.826 0.851 . . . . 0.0 110.073 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.411 ' C ' ' O ' ' B' ' 39' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.572 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -83.23 139.53 33.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.291 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -81.6 118.94 23.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.407 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 53.4 t -130.31 133.75 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.137 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.62 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -139.13 100.8 4.11 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 121.218 -0.193 . . . . 0.0 111.134 179.205 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.605 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 13.6 m170 -117.19 160.5 20.95 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -86.41 155.54 20.54 Favored 'General case' 0 N--CA 1.457 -0.108 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . 0.538 ' CB ' ' HE2' ' B' ' 14' ' ' HIS . 85.4 tttt -161.18 94.66 1.01 Allowed 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.186 176.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 20.8 mt -121.71 117.85 27.65 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.887 178.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 4.8 t -105.69 110.17 30.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -108.92 105.84 15.55 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.57 122.8 47.05 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.459 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.73 146.45 37.78 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -81.04 108.66 14.9 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.693 178.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.416 ' OD2' ' CB ' ' D' ' 21' ' ' ALA . 82.0 m-20 -105.28 51.93 0.75 Allowed 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 113.507 -1.679 . . . . 0.0 110.238 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.0 t -71.34 -133.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 114.933 -1.031 . . . . 0.0 108.455 -174.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.46 38.07 3.38 Favored Glycine 0 N--CA 1.468 0.823 0 CA-C-O 124.111 1.95 . . . . 0.0 109.973 -169.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.598 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 1.2 m -72.29 102.9 3.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 108.651 -3.775 . . . . 0.0 102.243 171.037 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' B' ' 28' ' ' LYS . 88.2 m-20 -108.21 -170.14 1.63 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -171.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.426 ' O ' ' O ' ' N' ' 40' ' ' VAL . 98.6 mttt 32.36 41.27 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 113.668 -1.606 . . . . 0.0 111.12 -172.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . -176.72 61.1 0.1 OUTLIER Glycine 0 CA--C 1.546 1.976 0 CA-C-N 114.809 -1.087 . . . . 0.0 111.715 172.416 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.28 95.33 5.55 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 118.713 1.256 . . . . 0.0 110.505 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.515 ' CD1' ' O ' ' O' ' 38' ' ' GLY . 2.0 tt -164.41 153.48 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 C-N-CA 115.164 -2.615 . . . . 0.0 116.353 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.432 HD12 HG23 ' C' ' 32' ' ' ILE . 93.0 mt -112.73 112.34 40.01 Favored 'Isoleucine or valine' 0 C--N 1.35 0.601 0 CA-C-N 114.31 -1.314 . . . . 0.0 108.9 177.272 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.29 112.21 3.66 Favored Glycine 0 N--CA 1.464 0.554 0 N-CA-C 105.013 -3.235 . . . . 0.0 105.013 176.147 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 tt -148.05 146.3 28.81 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 117.619 -1.633 . . . . 0.0 114.474 -173.286 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 9.0 mtp -121.94 113.15 19.21 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.426 ' HA ' ' O ' ' B' ' 36' ' ' VAL . 3.1 p -139.88 103.06 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.837 -177.26 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.06 -155.27 26.43 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 119.848 -1.168 . . . . 0.0 112.282 177.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 61.1 54.73 34.26 Favored Glycine 0 CA--C 1.544 1.862 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.574 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.456 ' O ' ' O ' ' C' ' 40' ' ' VAL . 2.6 m -156.2 -168.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.341 0.23 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.476 ' OXT' ' CG1' ' D' ' 40' ' ' VAL . 88.3 t . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.991 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -83.25 137.08 34.15 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.887 0.375 . . . . 0.0 110.716 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -121.9 129.37 52.5 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.071 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -111.05 123.35 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.447 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.62 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 17.3 m-70 -134.82 107.43 7.39 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.593 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.593 ' ND1' ' O ' ' E' ' 14' ' ' HIS . 59.9 t60 -132.57 157.86 43.66 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.723 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.558 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 43.2 tt0 -85.82 157.38 20.23 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -160.09 100.15 1.38 Allowed 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.237 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 29.6 mt -123.5 115.02 20.86 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 178.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.9 109.1 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 59.9 m-85 -107.8 104.02 13.42 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.612 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 47.4 t80 -113.47 125.74 54.56 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . 0.416 ' CB ' ' OD2' ' C' ' 23' ' ' ASP . . . -135.94 135.06 39.3 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 122.712 1.244 . . . . 0.0 113.242 -178.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -84.4 113.5 21.22 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.022 -1.444 . . . . 0.0 108.963 179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.521 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 5.7 p-10 -146.44 48.57 1.18 Allowed 'General case' 0 CA--C 1.516 -0.365 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -72.58 160.79 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 177.486 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.38 -28.4 10.97 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.51 ' OG ' ' O ' ' E' ' 26' ' ' SER . 7.7 t 74.6 119.6 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 114.268 -0.966 . . . . 0.0 110.264 -178.25 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -83.29 163.25 20.81 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 120.078 -0.649 . . . . 0.0 111.278 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -46.98 -37.0 8.39 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 178.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.74 77.55 0.07 OUTLIER Glycine 0 CA--C 1.538 1.501 0 C-N-CA 120.497 -0.859 . . . . 0.0 113.085 -175.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.71 137.64 37.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 118.698 1.249 . . . . 0.0 111.082 -178.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 31.5 mt -127.34 138.65 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 CA-C-N 114.793 -1.094 . . . . 0.0 113.36 -176.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 67.2 mt -115.28 120.7 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 175.005 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.39 119.51 2.11 Favored Glycine 0 N--CA 1.467 0.731 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.494 ' N ' ' CD2' ' D' ' 34' ' ' LEU . 1.9 pt? -165.62 162.53 18.99 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 117.75 -1.58 . . . . 0.0 114.987 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 50.6 tpp -101.43 111.65 23.94 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 112.163 -2.289 . . . . 0.0 106.907 176.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.418 ' CG1' ' NE2' ' F' ' 15' ' ' GLN . 55.7 t -118.47 102.57 13.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 121.265 -0.174 . . . . 0.0 110.78 -178.8 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.03 -161.86 16.34 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.473 ' O ' ' OXT' ' E' ' 40' ' ' VAL . . . 148.69 -55.34 0.5 Allowed Glycine 0 CA--C 1.539 1.578 0 CA-C-O 119.316 -0.713 . . . . 0.0 112.453 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.543 ' CG2' ' CD1' ' J' ' 31' ' ' ILE . 33.8 m -136.61 152.8 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.555 0 CA-C-N 118.776 1.288 . . . . 0.0 110.867 178.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.543 ' H ' ' CD1' ' K' ' 31' ' ' ILE . 60.7 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.485 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -106.97 135.75 48.0 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.839 0.352 . . . . 0.0 110.353 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -76.53 106.37 8.14 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.713 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 m -139.78 156.43 25.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.162 0.506 . . . . 0.0 110.938 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.412 ' C ' ' CD2' ' E' ' 14' ' ' HIS . 21.7 m-70 -148.27 117.57 6.9 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.141 178.963 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.593 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 13.3 m-70 -141.28 162.41 35.54 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 110.923 179.047 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.421 ' OE1' ' OE1' ' F' ' 15' ' ' GLN . 78.7 mt-30 -85.32 157.27 20.6 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 176.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -159.53 104.3 1.61 Allowed 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.322 0.582 . . . . 0.0 109.461 178.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.3 mt -125.07 116.8 22.67 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.773 -179.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -107.48 101.85 13.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 74.1 m-85 -103.45 101.22 11.11 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 178.002 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.612 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 24.5 t80 -116.2 128.65 55.79 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.474 0.178 . . . . 0.0 111.156 -177.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.31 139.57 33.64 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.52 0.676 . . . . 0.0 112.755 -179.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.519 ' O ' ' CG ' ' D' ' 23' ' ' ASP . 97.7 mt-10 -79.28 155.05 28.69 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' F' ' 23' ' ' ASP . 2.4 t70 -169.62 48.56 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.286 -1.366 . . . . 0.0 113.418 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 1.8 t -72.28 161.61 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 119.179 -1.008 . . . . 0.0 108.598 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.68 -28.65 10.38 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -176.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.526 ' O ' ' CB ' ' E' ' 27' ' ' ASN . 1.6 m 80.56 -114.71 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 113.644 -1.278 . . . . 0.0 112.232 -179.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.526 ' CB ' ' O ' ' E' ' 26' ' ' SER . 4.2 t-20 89.24 179.9 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -48.33 -38.43 19.05 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.85 -68.22 0.55 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-N 114.297 -1.32 . . . . 0.0 114.781 176.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.41 ' O ' ' CB ' ' F' ' 30' ' ' ALA . . . 179.91 171.0 1.13 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 119.044 1.422 . . . . 0.0 112.688 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.405 HD11 HG21 ' E' ' 31' ' ' ILE . 98.6 mt -131.85 128.36 59.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 113.976 -1.465 . . . . 0.0 108.587 177.309 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 52.1 mt -123.93 124.91 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.133 0.492 . . . . 0.0 111.822 -177.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 110.92 2.34 Favored Glycine 0 N--CA 1.47 0.96 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 21.8 mt -118.17 114.31 22.86 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -177.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 78.4 mmm -105.8 116.17 31.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 177.095 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.508 ' CG1' ' N ' ' E' ' 37' ' ' GLY . 61.7 t -128.44 170.85 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.701 0.762 . . . . 0.0 112.365 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.508 ' N ' ' CG1' ' E' ' 36' ' ' VAL . . . -168.26 94.28 0.11 Allowed Glycine 0 C--N 1.308 -1.021 0 N-CA-C 108.164 -1.975 . . . . 0.0 108.164 176.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.33 -73.15 0.42 Allowed Glycine 0 CA--C 1.54 1.626 0 CA-C-N 117.287 0.543 . . . . 0.0 112.927 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 76.2 t -123.77 94.32 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.473 ' OXT' ' O ' ' D' ' 38' ' ' GLY . 4.1 p . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.551 -178.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -103.43 122.58 45.18 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.82 0.343 . . . . 0.0 110.263 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -128.42 130.52 47.75 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.633 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.437 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 8.0 p -141.32 138.2 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.403 0.621 . . . . 0.0 110.948 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 4.6 m80 -140.98 133.57 28.61 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.121 -178.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.592 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 45.7 m80 -148.54 164.74 33.32 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.02 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.45 ' NE2' ' H ' ' F' ' 16' ' ' LYS . 70.9 tp60 -89.8 151.46 21.78 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.69 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . 0.45 ' H ' ' NE2' ' F' ' 15' ' ' GLN . 99.1 mttt -152.89 100.08 2.48 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.559 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.449 HD12 ' H ' ' F' ' 17' ' ' LEU . 0.2 OUTLIER -121.6 118.98 30.57 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 177.209 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.69 106.07 19.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.432 ' CE1' ' CD2' ' E' ' 19' ' ' PHE . 55.7 m-85 -104.32 103.59 13.36 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -117.24 109.82 17.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.223 0.535 . . . . 0.0 110.513 -178.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.96 117.98 28.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 177.252 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -90.33 112.08 23.53 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 119.222 -0.991 . . . . 0.0 113.583 -176.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' E' ' 23' ' ' ASP . 1.1 m-20 -127.94 -59.93 1.17 Allowed 'General case' 0 C--N 1.351 0.648 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.935 176.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -102.92 -178.79 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 175.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.6 -35.03 56.08 Favored Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.746 -1.741 . . . . 0.0 108.746 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.4 p -95.03 121.72 36.94 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 112.496 -1.852 . . . . 0.0 113.151 -178.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -74.23 -151.08 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt 53.84 48.31 21.61 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.41 -53.11 0.57 Allowed Glycine 0 CA--C 1.542 1.768 0 CA-C-N 114.756 -1.111 . . . . 0.0 114.168 -177.634 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.41 ' CB ' ' O ' ' E' ' 30' ' ' ALA . . . -84.14 -156.94 0.24 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.589 0.756 . . . . 0.0 112.033 -175.111 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mm -105.05 131.52 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 19.6 tt -137.7 129.5 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.979 0.419 . . . . 0.0 111.627 -179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.66 123.11 5.13 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 mt -116.59 120.31 38.28 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -123.69 130.11 52.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.538 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 29.5 m -115.96 158.38 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.08 -103.03 0.01 OUTLIER Glycine 0 CA--C 1.524 0.616 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.961 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.42 -76.66 0.5 Allowed Glycine 0 CA--C 1.534 1.231 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.425 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.47 ' O ' ' CD1' ' L' ' 31' ' ' ILE . 58.6 t -126.91 131.8 70.63 Favored 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-N 117.338 0.569 . . . . 0.0 110.343 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 10.9 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.861 -179.794 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -111.63 132.89 54.26 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . 0.533 ' N ' ' OE1' ' G' ' 11' ' ' GLU . 57.8 mp0 -120.85 125.21 46.92 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.278 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.85 149.43 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.294 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -133.84 112.42 11.3 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.691 0.282 . . . . 0.0 110.913 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.436 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 47.9 p-80 -152.92 168.73 24.81 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.292 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 69.1 tp60 -158.22 142.46 15.88 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.654 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -81.86 126.63 32.12 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.033 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 6.5 tt -134.43 119.58 18.73 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.658 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 12.6 m -132.82 135.81 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.355 -179.325 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -127.24 126.46 42.75 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.807 178.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' H' ' 20' ' ' PHE . 43.5 t80 -128.94 127.45 41.77 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.682 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.69 119.67 21.69 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 121.303 0.573 . . . . 0.0 110.977 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.632 ' O ' ' N ' ' G' ' 24' ' ' VAL . 79.9 tt0 -92.57 124.6 36.71 Favored 'General case' 0 C--N 1.342 0.27 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.596 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.43 ' H ' ' HB3' ' H' ' 22' ' ' GLU . 67.0 t0 47.76 -60.63 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.809 1.244 . . . . 0.0 113.086 -179.264 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' G' ' 22' ' ' GLU . 5.2 p -72.97 160.72 5.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-O 121.126 0.489 . . . . 0.0 110.973 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.24 -35.23 4.96 Favored Glycine 0 N--CA 1.469 0.852 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.535 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.2 m -80.74 118.81 22.61 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.225 0.512 . . . . 0.0 110.218 178.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -88.82 179.23 6.25 Favored 'General case' 0 C--N 1.333 -0.137 0 C-N-CA 119.648 -0.821 . . . . 0.0 111.143 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -54.61 -38.51 66.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.59 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.24 70.96 0.2 Allowed Glycine 0 CA--C 1.537 1.423 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.171 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.25 116.94 29.43 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 123.988 1.851 . . . . 0.0 112.69 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.485 ' CD1' ' O ' ' A' ' 38' ' ' GLY . 14.8 pt -146.95 149.21 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 111.993 -2.367 . . . . 0.0 109.904 -179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 55.0 mt -105.05 112.0 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.12 96.05 0.74 Allowed Glycine 0 N--CA 1.467 0.735 0 N-CA-C 107.264 -2.334 . . . . 0.0 107.264 178.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 78.3 mt -144.07 156.27 44.3 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 122.972 1.367 . . . . 0.0 113.848 -177.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' CG ' ' H' ' 35' ' ' MET . 44.1 tpp -103.57 111.16 23.5 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 112.166 -2.288 . . . . 0.0 106.315 176.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 3.5 t -131.54 111.78 19.7 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.432 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 127.99 -132.07 7.26 Favored Glycine 0 C--N 1.315 -0.623 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 87.49 -63.67 3.87 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.093 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 m -102.57 169.15 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-O 120.95 0.405 . . . . 0.0 110.844 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.507 ' OXT' ' NE2' ' J' ' 13' ' ' HIS . 9.7 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.264 179.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -107.86 133.27 52.46 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.814 0.34 . . . . 0.0 110.179 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.62 128.6 22.01 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.225 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -122.99 131.34 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.805 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -132.4 105.77 7.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.811 0.339 . . . . 0.0 111.6 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.692 ' CD2' ' H ' ' H' ' 15' ' ' GLN . 1.1 t-80 -155.6 169.13 25.01 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.702 178.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.692 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 14.1 pt20 -157.45 142.19 16.64 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.985 0.421 . . . . 0.0 110.449 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -84.02 113.38 20.97 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.356 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.9 mt -119.66 113.41 20.63 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 79.7 t -124.38 131.72 72.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 CA-C-O 120.898 0.38 . . . . 0.0 111.636 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -126.7 116.57 21.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.309 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' G' ' 20' ' ' PHE . 30.0 t80 -117.23 123.83 47.59 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.18 138.56 25.29 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-O 122.454 1.121 . . . . 0.0 113.633 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.43 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 80.8 tt0 -90.14 149.5 22.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.152 -1.386 . . . . 0.0 109.402 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.405 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 66.4 t0 -174.32 48.43 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.682 -0.407 . . . . 0.0 112.042 -178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 t -72.67 161.43 4.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.213 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.505 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 108.95 -30.24 8.89 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.505 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 6.2 p 93.06 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.085 0.554 . . . . 0.0 111.015 178.52 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.625 HD22 ' CB ' ' H' ' 30' ' ' ALA . 17.6 p30 -74.02 175.05 7.77 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 119.889 -0.725 . . . . 0.0 110.448 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.616 ' NZ ' ' CE1' ' C' ' 13' ' ' HIS . 94.0 mttt -51.18 -36.93 43.63 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' H' ' 27' ' ' ASN . . . 179.54 77.22 0.06 OUTLIER Glycine 0 CA--C 1.529 0.961 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.729 -176.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.625 ' CB ' HD22 ' H' ' 27' ' ' ASN . . . -52.06 131.89 32.28 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 118.295 1.047 . . . . 0.0 113.567 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.438 HG22 HD12 ' H' ' 31' ' ' ILE . 51.6 mt -141.38 133.42 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 31.3 mt -105.55 108.97 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 174.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.44 104.42 1.8 Allowed Glycine 0 N--CA 1.462 0.427 0 N-CA-C 106.948 -2.461 . . . . 0.0 106.948 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 81.0 mt -138.23 136.77 36.88 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 119.013 -1.075 . . . . 0.0 113.774 -176.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.472 ' CG ' ' SD ' ' G' ' 35' ' ' MET . 32.9 tpp -99.84 107.1 19.04 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 173.533 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 24.8 t -130.24 142.3 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -178.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 124.57 -101.95 0.68 Allowed Glycine 0 C--N 1.312 -0.759 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.19 -79.28 0.02 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.497 ' N ' ' O ' ' H' ' 37' ' ' GLY . 5.5 p -144.04 150.2 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.077 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.545 ' OXT' ' CG2' ' I' ' 40' ' ' VAL . 5.1 p . . . . . 0 C--O 1.217 -0.655 0 CA-C-O 118.14 -0.933 . . . . 0.0 111.117 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -108.44 136.66 47.69 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.842 0.353 . . . . 0.0 110.254 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.491 ' CD ' ' N ' ' I' ' 11' ' ' GLU . 1.8 pm0 -117.91 135.58 54.03 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.525 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.435 HG22 ' H ' ' J' ' 12' ' ' VAL . 70.2 t -124.97 126.51 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.202 -179.141 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -134.85 146.14 48.97 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.805 0.336 . . . . 0.0 111.33 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.459 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 59.4 m80 -147.82 172.69 13.74 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 121.132 0.492 . . . . 0.0 110.502 177.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 40.7 tt0 -137.86 140.89 40.68 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 176.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -130.15 110.06 11.3 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.105 -0.638 . . . . 0.0 112.413 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 mp -121.81 113.12 19.22 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 175.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 8.0 t -105.56 109.43 27.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 80.3 m-85 -104.3 100.71 10.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.115 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -115.2 127.42 55.51 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -168.58 177.46 5.2 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 117.624 -1.63 . . . . 0.0 114.891 -177.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 67.8 mm-40 -77.92 156.96 29.98 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 175.327 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.722 ' O ' ' O ' ' I' ' 24' ' ' VAL . 67.9 t0 -169.84 60.56 0.04 OUTLIER 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 119.291 -0.964 . . . . 0.0 112.483 -175.214 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.722 ' O ' ' O ' ' I' ' 23' ' ' ASP . 3.4 t -44.53 -111.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.196 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.448 ' O ' ' N ' ' I' ' 27' ' ' ASN . . . 159.5 -45.37 0.44 Allowed Glycine 0 CA--C 1.502 -0.751 0 C-N-CA 116.091 -2.957 . . . . 0.0 116.561 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.498 ' C ' ' ND2' ' I' ' 27' ' ' ASN . 46.9 t -66.69 103.85 1.18 Allowed 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 113.773 -3.171 . . . . 0.0 106.11 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.53 ' O ' ' N ' ' I' ' 29' ' ' GLY . 1.6 m120 -137.02 170.13 16.61 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 113.963 -1.471 . . . . 0.0 109.132 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.499 ' C ' ' O ' ' I' ' 27' ' ' ASN . 52.7 mttp -25.84 -42.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.535 0 O-C-N 123.882 0.739 . . . . 0.0 111.217 173.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 160.68 67.6 0.02 OUTLIER Glycine 0 CA--C 1.554 2.494 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.677 -178.51 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -52.14 138.23 26.13 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 118.477 1.138 . . . . 0.0 112.166 -178.697 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 3.0 tt -144.59 145.93 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.428 HD13 HG22 ' I' ' 32' ' ' ILE . 3.9 mt -105.37 108.58 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 175.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.32 101.45 1.68 Allowed Glycine 0 N--CA 1.47 0.903 0 N-CA-C 106.41 -2.676 . . . . 0.0 106.41 178.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 3.1 mp -130.71 130.21 43.54 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -174.621 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 83.5 mmm -101.34 112.44 24.96 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 47.0 t -127.56 142.14 44.43 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.743 -174.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.16 -101.6 0.44 Allowed Glycine 0 C--N 1.318 -0.451 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 178.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.526 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 83.83 -81.02 1.77 Allowed Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 56.1 t -143.2 143.91 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.545 ' CG2' ' OXT' ' H' ' 40' ' ' VAL . 21.5 m . . . . . 0 N--CA 1.473 0.688 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.975 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.88 132.81 53.06 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.884 0.373 . . . . 0.0 110.622 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -75.51 123.43 25.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.435 ' H ' HG22 ' I' ' 12' ' ' VAL . 3.2 m -134.9 155.97 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.285 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.541 ' CG ' ' O ' ' H' ' 40' ' ' VAL . 2.1 t-80 -158.52 103.66 1.77 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.02 178.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.498 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 4.3 m-70 -137.23 159.09 42.93 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.786 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 5.8 tt0 -90.26 159.26 16.78 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 105.67 -1.974 . . . . 0.0 105.67 175.091 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 78.9 tttt -140.66 109.73 6.13 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.845 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -130.04 120.02 24.06 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 20.3 m -116.28 117.93 57.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 177.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.407 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 32.2 m-85 -107.92 103.54 12.81 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -118.46 134.63 54.92 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.557 0.218 . . . . 0.0 110.989 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.31 146.24 23.53 Favored 'General case' 0 C--O 1.241 0.606 0 C-N-CA 117.919 -1.512 . . . . 0.0 114.842 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 72.3 mm-40 -86.8 147.47 25.81 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 113.578 -1.646 . . . . 0.0 108.915 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.492 ' OD1' ' N ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -160.18 51.88 0.32 Allowed 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -177.072 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.5 t -75.43 142.41 14.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 116.783 -1.967 . . . . 0.0 108.378 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.26 -37.22 3.84 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.49 119.95 23.84 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 113.663 -1.268 . . . . 0.0 112.697 -178.493 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.565 ' O ' ' N ' ' J' ' 29' ' ' GLY . 22.1 m-20 -88.38 158.01 18.53 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.039 -0.665 . . . . 0.0 109.437 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 75.8 tttt -47.91 48.35 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.216 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -101.47 52.55 0.88 Allowed Glycine 0 N--CA 1.481 1.664 0 CA-C-N 119.234 0.925 . . . . 0.0 113.905 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.01 179.44 5.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.4 0.619 . . . . 0.0 110.142 179.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.543 ' CD1' ' CG2' ' D' ' 39' ' ' VAL . 42.2 pt -138.96 145.04 28.27 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -108.67 110.44 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.053 177.535 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.77 95.88 0.91 Allowed Glycine 0 C--O 1.24 0.488 0 N-CA-C 104.673 -3.371 . . . . 0.0 104.673 176.044 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tt -133.11 132.27 41.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 123.062 1.41 . . . . 0.0 113.647 -175.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 11.1 mtp -107.89 109.39 20.89 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 112.208 -2.269 . . . . 0.0 107.393 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 12.0 p -104.44 111.51 34.32 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.469 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 178.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.47 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -58.62 131.91 52.29 Favored Glycine 0 N--CA 1.462 0.388 0 CA-C-N 115.146 -0.933 . . . . 0.0 114.403 -175.613 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.511 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . -89.42 63.62 3.32 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.423 ' O ' ' C ' ' J' ' 40' ' ' VAL . 28.7 m -112.86 125.6 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 CA-C-O 121.148 0.499 . . . . 0.0 110.695 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.423 ' C ' ' O ' ' J' ' 39' ' ' VAL . 3.3 t . . . . . 0 C--O 1.219 -0.535 0 CA-C-N 114.951 -1.022 . . . . 0.0 112.204 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . 0.477 ' CE1' ' O ' ' L' ' 9' ' ' GLY . 94.4 m-85 -82.71 139.77 33.46 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.808 0.337 . . . . 0.0 110.51 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.402 ' HB3' ' HE2' ' K' ' 13' ' ' HIS . 95.7 mt-10 -92.24 121.63 33.94 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.276 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -130.35 132.03 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.969 0.414 . . . . 0.0 111.356 -179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.446 ' C ' ' ND1' ' K' ' 14' ' ' HIS . 2.6 m-70 -141.79 137.5 31.59 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.311 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.572 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 28.1 m80 -147.57 162.18 39.63 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -90.02 158.27 17.42 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 176.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.27 97.74 3.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 119.608 -0.837 . . . . 0.0 111.228 177.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 19.3 mt -121.49 118.62 29.77 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 176.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.85 111.81 37.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.584 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -105.09 100.92 10.5 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 49.6 t80 -121.78 122.33 39.26 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.732 0.301 . . . . 0.0 111.675 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.48 ' O ' ' CB ' ' L' ' 21' ' ' ALA . . . -154.13 159.0 41.26 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 118.504 -1.278 . . . . 0.0 114.25 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.492 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 96.6 mt-10 -85.71 161.09 19.36 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 177.174 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 22.2 p30 177.65 48.8 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 118.198 0.454 . . . . 0.0 112.167 -178.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -72.43 160.68 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 118.4 -1.32 . . . . 0.0 112.97 -176.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -28.7 10.29 Favored Glycine 0 CA--C 1.535 1.316 0 CA-C-N 113.634 -1.621 . . . . 0.0 112.419 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p 73.76 119.34 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.449 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 29.0 t-20 -83.3 163.49 20.65 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 119.494 -0.882 . . . . 0.0 112.477 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.449 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 99.4 mttt -47.35 -37.22 10.74 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 114.438 -1.255 . . . . 0.0 113.974 176.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.98 77.0 0.06 OUTLIER Glycine 0 CA--C 1.545 1.955 0 C-N-CA 120.059 -1.067 . . . . 0.0 114.42 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.485 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . -80.02 167.95 19.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 119.379 1.59 . . . . 0.0 110.351 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.543 ' CD1' ' H ' ' D' ' 40' ' ' VAL . 43.3 mt -133.24 127.98 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -176.688 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 pt -125.17 121.69 61.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 121.486 0.66 . . . . 0.0 109.998 176.32 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.26 115.73 2.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.496 ' N ' ' CD1' ' K' ' 34' ' ' LEU . 2.9 mp -122.0 119.89 32.77 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.406 ' SD ' ' CE ' ' L' ' 35' ' ' MET . 27.7 ttp -137.58 147.88 45.43 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 118.441 -1.303 . . . . 0.0 112.913 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -121.38 171.82 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 113.914 -1.493 . . . . 0.0 108.847 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.3 94.18 0.11 Allowed Glycine 0 N--CA 1.437 -1.279 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.999 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.49 ' O ' ' CD1' ' Q' ' 31' ' ' ILE . . . 152.11 -80.97 0.19 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.432 176.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . 0.511 ' N ' ' O ' ' J' ' 38' ' ' GLY . 90.2 t -154.75 142.97 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 4.8 p . . . . . 0 C--N 1.325 -0.458 0 CA-C-O 117.844 -1.074 . . . . 0.0 110.769 179.649 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . 0.477 ' O ' ' CE1' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -122.44 152.49 40.19 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.731 0.301 . . . . 0.0 110.398 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -69.68 139.02 53.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.519 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 m -122.12 132.88 70.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.271 0.557 . . . . 0.0 111.137 -179.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.491 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.3 p80 -148.18 107.31 3.88 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.741 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.572 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.9 m80 -147.91 164.86 32.43 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 109.909 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.47 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 75.7 mt-30 -89.76 158.85 17.34 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.915 0.388 . . . . 0.0 111.175 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -140.07 102.56 4.42 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 9.7 mp -120.37 118.14 29.59 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -105.04 116.43 48.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.487 ' CD1' ' N ' ' L' ' 19' ' ' PHE . 8.6 m-85 -105.16 103.7 13.29 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' O ' ' L' ' 21' ' ' ALA . 75.7 t80 -153.21 158.87 42.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 123.177 1.465 . . . . 0.0 113.807 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.528 ' O ' ' CE2' ' L' ' 20' ' ' PHE . . . -145.81 159.1 43.68 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 113.41 -1.723 . . . . 0.0 107.578 178.574 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.43 ' C ' ' H ' ' L' ' 24' ' ' VAL . 81.3 tt0 -39.95 152.7 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.27 -0.572 . . . . 0.0 111.677 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 p30 -65.45 47.33 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.807 -177.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.476 HG23 ' H ' ' L' ' 26' ' ' SER . 24.1 m -61.04 -179.12 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.483 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.34 29.62 12.11 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.476 ' H ' HG23 ' L' ' 24' ' ' VAL . 34.5 t -80.14 110.81 15.9 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.554 ' O ' ' N ' ' L' ' 29' ' ' GLY . 11.2 m120 -95.06 -166.31 1.44 Allowed 'General case' 0 C--O 1.222 -0.348 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.632 -179.433 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.57 47.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.01 56.59 0.93 Allowed Glycine 0 CA--C 1.538 1.508 0 CA-C-N 119.756 1.162 . . . . 0.0 111.431 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' K' ' 30' ' ' ALA . . . -170.27 177.11 4.27 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.47 ' CD1' ' O ' ' F' ' 39' ' ' VAL . 39.2 mt -106.97 125.59 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.531 ' CD1' ' N ' ' L' ' 32' ' ' ILE . 3.1 mp -110.45 115.89 50.94 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.229 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.1 107.26 1.15 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . 0.417 ' C ' ' CD2' ' L' ' 34' ' ' LEU . 6.3 tt -122.7 120.39 33.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.465 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.406 ' CE ' ' SD ' ' K' ' 35' ' ' MET . 28.6 mtm -136.17 144.62 45.09 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.462 0.648 . . . . 0.0 112.546 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.469 ' O ' ' O ' ' L' ' 37' ' ' GLY . 54.0 t -116.18 131.52 68.46 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.686 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -32.92 -111.3 0.0 OUTLIER Glycine 0 CA--C 1.532 1.113 0 CA-C-N 115.058 -0.974 . . . . 0.0 114.315 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.55 -71.64 0.53 Allowed Glycine 0 CA--C 1.536 1.35 0 CA-C-N 115.289 -0.456 . . . . 0.0 112.886 -178.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 53.3 t -106.88 131.85 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-O 121.46 0.647 . . . . 0.0 111.27 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.594 179.765 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -84.32 138.83 32.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.996 0.427 . . . . 0.0 110.838 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -75.49 159.81 30.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 52.0 t -116.48 129.58 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.298 0.57 . . . . 0.0 110.116 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -81.4 163.09 23.06 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.372 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 89.5 m-70 -105.09 160.97 14.64 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 121.265 0.555 . . . . 0.0 111.768 -179.151 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -89.98 160.25 16.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.62 178.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -139.38 110.9 7.08 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.1 mt -135.93 117.44 14.81 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.551 0.691 . . . . 0.0 111.081 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.17 132.95 70.55 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.813 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -128.04 134.21 49.18 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.771 0.32 . . . . 0.0 110.552 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.496 ' O ' ' CD2' ' M' ' 20' ' ' PHE . 53.2 p90 -127.43 126.02 41.63 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.525 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 129.25 47.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.225 0.536 . . . . 0.0 111.962 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -155.34 126.7 7.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.007 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.69 46.45 24.66 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.332 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 11.6 m -76.11 179.55 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.0 28.11 6.86 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.813 -179.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' M' ' 27' ' ' ASN . 5.5 t -170.46 -134.11 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.912 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' M' ' 26' ' ' SER . 22.2 t-20 -30.81 143.58 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.847 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -132.9 -26.08 1.78 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.748 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.99 -108.87 0.26 Allowed Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.143 -1.027 . . . . 0.0 111.052 179.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.45 96.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.45 -0.5 . . . . 0.0 112.1 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -115.24 105.28 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 55.0 mt -110.73 112.6 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 120.411 -0.516 . . . . 0.0 109.745 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.75 104.45 1.22 Allowed Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 104.977 -3.249 . . . . 0.0 104.977 176.874 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 30.0 tp -155.2 151.36 28.06 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 117.489 -1.685 . . . . 0.0 114.409 -174.297 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 93.9 mmm -100.27 111.51 23.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 112.659 -2.064 . . . . 0.0 106.878 177.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 41.9 t -119.66 131.37 72.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.34 -111.28 4.13 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' N' ' 37' ' ' GLY . . . 81.13 -74.03 2.49 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -178.105 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.18 161.37 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.468 ' CB ' ' HE2' ' P' ' 13' ' ' HIS . 10.7 m . . . . . 0 N--CA 1.47 0.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.538 177.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.159 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -105.24 131.51 52.62 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -114.8 115.29 26.77 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.204 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -129.57 123.02 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.174 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -143.58 130.71 20.71 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.196 0.522 . . . . 0.0 110.473 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.637 ' ND1' ' NE2' ' O' ' 14' ' ' HIS . 19.5 t60 -159.75 170.08 22.27 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CD2' ' N' ' 14' ' ' HIS . 75.2 mt-30 -155.14 140.71 17.91 Favored 'General case' 0 CA--C 1.517 -0.32 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.767 177.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 48.0 tttp -93.98 111.04 22.7 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.867 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 13.6 mt -119.91 114.43 22.06 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 177.021 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 6.3 p -138.6 141.86 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 119.692 -0.803 . . . . 0.0 112.135 -179.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -131.36 122.55 26.55 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.07 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 59.8 m-85 -112.88 123.48 50.4 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.633 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.05 121.06 40.25 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' O' ' 22' ' ' GLU . 82.6 tt0 -136.32 156.38 48.72 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 121.208 0.527 . . . . 0.0 112.31 -177.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 20.0 t0 76.63 54.74 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.364 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 90.8 t -68.05 135.25 28.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.57 -34.26 2.3 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 120.995 -0.621 . . . . 0.0 111.836 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' N' ' 27' ' ' ASN . 29.5 t -162.41 120.3 2.12 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-N 116.847 0.323 . . . . 0.0 110.991 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.516 ' O ' ' O ' ' N' ' 26' ' ' SER . 17.5 p30 -22.26 152.74 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -163.19 24.58 0.09 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.434 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.52 105.29 1.13 Allowed Glycine 0 N--CA 1.466 0.683 0 C-N-CA 119.06 -1.543 . . . . 0.0 113.435 178.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.96 95.63 5.59 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 122.072 0.939 . . . . 0.0 108.777 179.052 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 79.4 mt -137.44 136.13 46.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 114.826 -1.079 . . . . 0.0 112.225 -177.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . 0.425 HG21 HD11 ' N' ' 32' ' ' ILE . 77.1 mt -106.76 105.64 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 175.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.38 91.98 0.66 Allowed Glycine 0 N--CA 1.467 0.742 0 N-CA-C 106.197 -2.761 . . . . 0.0 106.197 178.335 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 mp -132.74 152.55 51.73 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 123.35 1.548 . . . . 0.0 114.452 -175.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -115.65 107.26 14.87 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 175.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' O' ' 37' ' ' GLY . 47.6 t -117.63 123.16 71.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.05 -177.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.702 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 134.75 -113.86 1.2 Allowed Glycine 0 C--N 1.317 -0.515 0 N-CA-C 110.524 -1.03 . . . . 0.0 110.524 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.83 -71.64 0.66 Allowed Glycine 0 CA--C 1.533 1.188 0 N-CA-C 110.618 -0.993 . . . . 0.0 110.618 -178.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 83.6 t -126.49 138.58 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 177.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' C' ' 28' ' ' LYS . 66.2 t . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.909 -1.043 . . . . 0.0 110.056 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -107.19 134.31 50.49 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.83 0.348 . . . . 0.0 110.466 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.98 133.61 39.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.827 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.56 140.28 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.085 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.477 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 42.0 t-80 -147.5 95.53 2.54 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.392 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.637 ' NE2' ' ND1' ' N' ' 14' ' ' HIS . 0.3 OUTLIER -161.05 170.9 19.58 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 178.798 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 50.1 tt0 -97.33 143.47 28.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.699 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -124.64 118.98 27.73 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.7 mp -122.76 128.93 51.14 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.516 0.674 . . . . 0.0 111.337 179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 98.2 t -119.07 111.99 35.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.023 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -107.7 108.0 19.04 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 178.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -122.87 126.67 47.77 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.83 117.06 28.26 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' O' ' 24' ' ' VAL . 83.5 tt0 -83.43 153.18 24.63 Favored 'General case' 0 N--CA 1.461 0.083 0 N-CA-C 113.438 0.903 . . . . 0.0 113.438 -176.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' O' ' 24' ' ' VAL . 65.6 t0 8.66 51.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 113.034 -1.894 . . . . 0.0 114.654 -179.155 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.578 ' CG1' ' H ' ' O' ' 25' ' ' GLY . 11.6 t -55.89 -132.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 174.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.578 ' H ' ' CG1' ' O' ' 24' ' ' VAL . . . 144.47 -29.77 1.88 Allowed Glycine 0 C--O 1.226 -0.365 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.337 175.863 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.461 ' O ' ' CE ' ' P' ' 28' ' ' LYS . 5.8 t -89.92 -132.89 0.1 Allowed 'General case' 0 CA--C 1.55 0.974 0 CA-C-O 122.986 1.374 . . . . 0.0 113.292 179.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 12.2 m120 79.28 138.9 0.07 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 127.669 2.388 . . . . 0.0 111.22 178.334 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -48.83 -48.45 41.62 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 117.2 2.296 . . . . 0.0 117.2 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.67 62.48 0.06 OUTLIER Glycine 0 CA--C 1.545 1.921 0 CA-C-O 118.084 -1.398 . . . . 0.0 111.498 -171.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -52.71 143.92 15.22 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 120.681 2.241 . . . . 0.0 116.714 -170.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.526 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 70.8 mt -138.79 153.89 25.87 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 CA-C-N 110.942 -2.845 . . . . 0.0 113.871 -175.01 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . 0.423 HG22 HD12 ' O' ' 32' ' ' ILE . 75.5 mt -117.1 110.53 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 174.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.44 106.96 2.41 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 104.732 -3.347 . . . . 0.0 104.732 176.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 26.7 tp -148.37 139.21 23.01 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 122.747 1.26 . . . . 0.0 113.696 -174.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 24.5 ttm -114.33 110.98 20.76 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 113.648 -1.615 . . . . 0.0 107.428 176.572 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . 0.437 ' O ' ' HA3' ' P' ' 37' ' ' GLY . 1.7 t -89.91 103.74 14.47 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.784 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . -20.06 144.5 0.01 OUTLIER Glycine 0 N--CA 1.481 1.69 0 C-N-CA 124.136 0.874 . . . . 0.0 115.077 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.515 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . -100.78 59.12 0.68 Allowed Glycine 0 CA--C 1.541 1.673 0 CA-C-N 115.022 -0.589 . . . . 0.0 113.6 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 21.5 t -135.23 161.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-N 117.423 0.611 . . . . 0.0 110.607 179.049 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 78.0 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.306 179.584 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.031 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -105.78 135.26 47.53 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.82 0.343 . . . . 0.0 110.309 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . 0.521 ' N ' ' OE1' ' P' ' 11' ' ' GLU . 57.8 mp0 -111.96 125.34 53.95 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.127 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 40.3 t -120.95 127.54 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.974 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 0.9 OUTLIER -146.05 105.35 3.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.381 -179.307 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 2.1 p-80 -134.1 160.59 37.31 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.449 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.702 HE22 ' N ' ' N' ' 37' ' ' GLY . 3.3 mt-30 -89.99 159.22 17.0 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.133 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -140.07 103.27 4.58 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -128.88 125.68 38.14 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 121.399 0.619 . . . . 0.0 110.657 179.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 79.6 t -118.38 117.38 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.679 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CE1' ' Q' ' 19' ' ' PHE . 29.4 m-85 -114.01 103.84 11.55 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 27.6 t80 -117.64 126.93 53.4 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.665 0.269 . . . . 0.0 111.059 -178.053 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.1 115.91 15.66 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 121.062 0.458 . . . . 0.0 111.497 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.545 ' O ' ' N ' ' O' ' 24' ' ' VAL . 80.4 tt0 -92.71 112.81 24.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.576 ' O ' ' NZ ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -139.19 46.76 1.92 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.681 -175.909 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.582 ' CG2' ' H ' ' P' ' 25' ' ' GLY . 7.7 p -73.15 179.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.453 0.644 . . . . 0.0 111.554 -178.133 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.582 ' H ' ' CG2' ' P' ' 24' ' ' VAL . . . 99.66 -34.66 5.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 118.647 -1.085 . . . . 0.0 114.468 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.466 ' O ' ' C ' ' P' ' 27' ' ' ASN . 96.2 p -162.24 120.43 2.2 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.381 2.09 . . . . 0.0 112.791 176.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.466 ' C ' ' O ' ' P' ' 26' ' ' SER . 65.8 t30 -23.56 141.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 123.611 0.569 . . . . 0.0 111.371 177.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.576 ' NZ ' ' O ' ' P' ' 23' ' ' ASP . 64.7 mttp -122.24 -32.93 3.58 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 177.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.33 79.85 0.91 Allowed Glycine 0 CA--C 1.536 1.381 0 N-CA-C 108.343 -1.903 . . . . 0.0 108.343 -176.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.7 144.04 30.9 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-N 118.172 0.986 . . . . 0.0 111.727 -175.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 5.8 mt -125.07 138.64 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 113.815 -1.538 . . . . 0.0 113.563 -177.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 96.4 mt -118.76 112.35 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 176.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.98 100.22 1.45 Allowed Glycine 0 CA--C 1.509 -0.302 0 N-CA-C 104.557 -3.417 . . . . 0.0 104.557 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 7.7 tt -137.07 138.22 40.16 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-O 123.014 1.387 . . . . 0.0 114.533 -174.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 5.5 ttm -104.66 111.44 24.14 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.002 -1.908 . . . . 0.0 106.909 176.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -85.24 101.65 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 C-N-CA 118.585 -1.246 . . . . 0.0 108.269 -179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.561 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . . . -88.89 153.91 24.18 Favored Glycine 0 C--N 1.316 -0.579 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.445 ' N ' ' HA2' ' O' ' 38' ' ' GLY . . . 136.68 58.86 0.06 OUTLIER Glycine 0 N--CA 1.466 0.639 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.609 ' CG2' ' H ' ' Q' ' 38' ' ' GLY . 49.7 t -79.51 133.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.449 ' CG2' ' NE2' ' R' ' 13' ' ' HIS . 9.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.956 -1.021 . . . . 0.0 111.748 -178.788 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.1 135.37 46.58 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.838 0.351 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -103.02 122.55 44.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.209 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' Q' ' 13' ' ' HIS . 46.8 t -142.37 168.16 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.689 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.418 ' N ' ' CG1' ' Q' ' 12' ' ' VAL . 8.3 p80 -64.1 127.47 31.57 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -177.678 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.505 ' O ' ' CB ' ' P' ' 14' ' ' HIS . 7.0 p80 -157.46 168.46 27.26 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.157 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.561 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 79.1 mt-30 -89.97 151.39 21.72 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.921 -0.487 . . . . 0.0 110.313 178.457 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -148.76 106.48 3.68 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . 0.412 HD12 ' N ' ' Q' ' 17' ' ' LEU . 4.5 mp -135.68 124.46 23.92 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.264 0.554 . . . . 0.0 111.017 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -108.1 116.29 51.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 178.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.483 ' CE1' ' CE1' ' P' ' 19' ' ' PHE . 60.3 m-85 -112.42 109.23 18.72 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.226 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 41.4 t80 -125.45 128.17 47.65 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.55 134.3 37.34 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.129 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -114.74 124.29 51.4 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.507 ' N ' ' OD1' ' Q' ' 23' ' ' ASP . 12.6 p-10 -147.28 59.73 1.16 Allowed 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.382 0.611 . . . . 0.0 111.873 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.685 ' CG1' ' H ' ' Q' ' 25' ' ' GLY . 4.8 t 72.07 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.018 176.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.685 ' H ' ' CG1' ' Q' ' 24' ' ' VAL . . . -107.91 29.3 10.46 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.312 177.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 48.7 m -65.1 -113.96 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 118.716 1.258 . . . . 0.0 111.223 -176.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -155.94 169.19 25.01 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 119.631 -0.827 . . . . 0.0 112.362 179.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt 27.36 43.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.224 -1.353 . . . . 0.0 112.723 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.84 60.25 0.74 Allowed Glycine 0 N--CA 1.475 1.24 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.21 177.521 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.19 118.63 0.57 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 119.229 1.514 . . . . 0.0 113.043 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . 0.49 ' CD1' ' O ' ' K' ' 38' ' ' GLY . 1.7 tt -136.14 125.38 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 175.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 64.5 mt -128.66 133.79 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.198 -176.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.85 112.57 2.36 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 108.164 -1.974 . . . . 0.0 108.164 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 58.4 mt -119.16 120.44 37.1 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.093 0.473 . . . . 0.0 110.935 -177.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 11.0 mtp -124.7 130.92 53.33 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.362 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -105.81 159.86 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 CA-C-O 121.359 0.6 . . . . 0.0 110.75 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.84 -102.77 0.01 OUTLIER Glycine 0 CA--C 1.528 0.854 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.086 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.609 ' H ' ' CG2' ' P' ' 39' ' ' VAL . . . -116.97 -77.17 0.62 Allowed Glycine 0 CA--C 1.534 1.269 0 CA-C-O 119.864 -0.409 . . . . 0.0 113.166 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.433 ' HA ' ' O ' ' R' ' 39' ' ' VAL . 39.3 t -115.01 129.9 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 117.682 0.741 . . . . 0.0 111.861 -178.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.493 ' N ' ' O ' ' R' ' 40' ' ' VAL . 42.6 t . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.694 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -79.54 138.4 37.49 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -111.31 128.58 55.99 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.433 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 30.8 t -110.46 93.17 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.451 0.643 . . . . 0.0 110.609 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.517 ' O ' ' CG ' ' R' ' 13' ' ' HIS . 50.1 p-80 -120.32 105.77 11.24 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.545 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 84.6 t60 -141.11 170.73 15.17 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.752 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.531 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 93.0 mm-40 -89.55 150.62 22.35 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -149.59 99.0 2.84 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -139.02 124.78 19.65 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.529 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -104.96 118.52 52.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 55.3 m-85 -111.92 105.8 14.33 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 t80 -130.14 125.7 35.7 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.61 0.719 . . . . 0.0 112.104 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.59 126.4 38.4 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.269 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 79.1 tt0 -89.21 110.81 21.52 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 119.938 -0.705 . . . . 0.0 110.965 -178.686 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.448 ' OD2' ' OD2' ' Q' ' 23' ' ' ASP . 54.0 m-20 -163.11 -60.25 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' R' ' 25' ' ' GLY . 98.2 t -55.81 162.49 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.742 -179.435 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . 0.431 ' N ' ' CG1' ' R' ' 24' ' ' VAL . . . -157.3 -27.84 0.03 OUTLIER Glycine 0 CA--C 1.52 0.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 93.1 p -80.74 -130.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.268 -0.466 . . . . 0.0 109.912 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.565 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.0 m-80 -99.18 -164.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.499 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -47.76 49.48 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 125.372 1.469 . . . . 0.0 114.793 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.565 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.38 51.76 0.92 Allowed Glycine 0 CA--C 1.55 2.229 0 CA-C-N 119.344 0.974 . . . . 0.0 113.715 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.19 165.61 22.0 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.6 mt -114.31 112.21 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 CA-C-N 119.73 1.15 . . . . 0.0 110.042 178.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -125.73 127.72 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.843 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.66 119.41 3.5 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.09 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 48.4 tp -123.25 123.08 39.95 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mtp -138.38 147.42 43.39 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.06 161.51 38.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.123 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.3 -102.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.501 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.34 -78.02 0.87 Allowed Glycine 0 N--CA 1.475 1.289 0 C-N-CA 121.707 -0.283 . . . . 0.0 112.891 -178.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' Q' ' 39' ' ' VAL . 70.1 t -96.1 132.82 39.4 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.865 0 CA-C-N 117.519 0.659 . . . . 0.0 110.855 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' Q' ' 40' ' ' VAL . 10.7 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.444 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.426 ' O ' ' OE2' ' B' ' 11' ' ' GLU . 95.9 m-85 -83.09 139.87 32.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.747 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -130.0 146.2 51.68 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.872 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.8 131.98 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.413 0.625 . . . . 0.0 111.159 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.1 m80 -117.38 156.82 27.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.461 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.512 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -84.21 167.85 16.29 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.918 -179.755 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 69.0 tp60 -159.15 143.26 15.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.632 178.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -80.2 123.5 27.98 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 99.3 mt -125.6 116.28 21.47 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 177.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.54 134.06 56.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.739 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -127.71 131.49 49.73 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.466 ' CD2' ' O ' ' A' ' 20' ' ' PHE . 55.0 p90 -134.95 130.94 36.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.685 0.278 . . . . 0.0 111.374 -178.941 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.63 120.56 38.4 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -136.98 136.16 38.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.406 0.622 . . . . 0.0 112.081 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.9 t0 59.42 47.08 11.58 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -101.33 159.15 4.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.1 -36.56 93.11 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.772 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.494 ' O ' ' O ' ' A' ' 27' ' ' ASN . 28.4 t -152.93 121.87 6.53 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.272 -0.464 . . . . 0.0 109.893 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' A' ' 26' ' ' SER . 26.7 t-20 -40.68 167.47 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.89 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -79.55 39.64 0.41 Allowed 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.41 79.36 0.94 Allowed Glycine 0 N--CA 1.47 0.939 0 C-N-CA 117.886 -2.102 . . . . 0.0 110.976 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.445 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -81.41 74.81 8.39 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 119.589 1.695 . . . . 0.0 113.955 -175.947 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 89.7 mt -145.39 122.58 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 177.107 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.408 HD11 HG23 ' A' ' 32' ' ' ILE . 97.1 mt -116.86 122.97 71.19 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-O 121.344 0.592 . . . . 0.0 112.109 -177.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.91 101.2 0.67 Allowed Glycine 0 C--N 1.319 -0.41 0 N-CA-C 105.311 -3.116 . . . . 0.0 105.311 176.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.437 HD13 ' H ' ' A' ' 35' ' ' MET . 49.2 tp -156.71 153.71 28.88 Favored 'General case' 0 C--O 1.241 0.629 0 C-N-CA 118.128 -1.429 . . . . 0.0 113.617 -176.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.437 ' H ' HD13 ' A' ' 34' ' ' LEU . 84.5 mmm -99.31 120.78 40.13 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 112.714 -2.039 . . . . 0.0 108.055 178.217 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 t -111.39 124.6 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.62 -114.22 6.29 Favored Glycine 0 CA--C 1.528 0.889 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.42 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.17 -71.51 0.73 Allowed Glycine 0 CA--C 1.539 1.58 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 40' ' ' VAL . 2.6 t -66.23 159.25 4.53 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.982 -1.009 . . . . 0.0 111.793 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' C' ' 9' ' ' GLY . 92.1 m-85 -98.43 132.32 43.98 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 10' ' ' TYR . 97.0 mt-10 -138.03 139.81 39.78 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.013 0.435 . . . . 0.0 111.304 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.446 ' CG1' ' HE2' ' A' ' 14' ' ' HIS . 74.2 t -124.42 130.89 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -117.55 98.05 6.19 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' B' ' 15' ' ' GLN . 11.5 t60 -160.61 164.54 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.542 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 50.9 tt0 -158.1 142.33 15.92 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.319 178.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.52 121.25 27.34 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.022 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 tt -136.22 121.32 18.93 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.706 0.685 . . . . 0.0 110.831 178.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 13.9 m -134.65 141.4 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.937 -179.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -128.32 127.03 41.95 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.184 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -123.24 129.58 51.57 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.743 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.0 119.65 31.02 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.456 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -138.84 164.04 30.68 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.001 0.429 . . . . 0.0 111.545 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.58 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 54.2 t0 42.0 47.57 3.83 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -81.58 163.4 3.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 117.786 -1.565 . . . . 0.0 108.567 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.61 -38.16 57.52 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -177.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.62 ' O ' ' O ' ' B' ' 27' ' ' ASN . 45.9 t -162.54 117.24 1.81 Allowed 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.505 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.708 HD22 ' N ' ' C' ' 28' ' ' LYS . 55.2 t-20 -22.02 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.212 0 O-C-N 123.933 0.771 . . . . 0.0 111.713 175.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.545 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 62.7 tttt -163.29 24.56 0.09 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . 89.53 106.64 1.16 Allowed Glycine 0 N--CA 1.468 0.805 0 C-N-CA 118.396 -1.859 . . . . 0.0 113.814 177.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.89 101.83 10.38 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 122.734 1.254 . . . . 0.0 109.881 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -119.61 129.44 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 114.22 -1.355 . . . . 0.0 110.641 -179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 49.7 mt -109.95 111.24 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.114 0.483 . . . . 0.0 109.82 177.577 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 99.21 0.99 Allowed Glycine 0 C--O 1.238 0.396 0 N-CA-C 105.885 -2.886 . . . . 0.0 105.885 177.067 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 80.0 mt -138.24 145.67 41.65 Favored 'General case' 0 CA--C 1.499 -1.001 0 CA-C-O 122.792 1.282 . . . . 0.0 113.139 -175.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.7 mtp -116.36 109.44 17.35 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 112.837 -1.983 . . . . 0.0 107.473 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.411 ' O ' ' CG2' ' B' ' 36' ' ' VAL . 2.8 m -132.88 123.19 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.696 ' N ' HE22 ' D' ' 15' ' ' GLN . . . 144.85 -113.4 0.72 Allowed Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.427 ' O ' ' CG1' ' B' ' 39' ' ' VAL . . . 76.94 -72.97 2.0 Allowed Glycine 0 CA--C 1.535 1.3 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.427 ' CG1' ' O ' ' B' ' 38' ' ' GLY . 2.9 m -166.67 118.92 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.551 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 17.2 m . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.746 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -122.47 140.38 52.8 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.731 0.3 . . . . 0.0 110.34 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.499 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 57.6 mp0 -76.52 115.82 16.63 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.059 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.414 ' HB ' ' HE2' ' C' ' 14' ' ' HIS . 26.7 m -137.01 159.76 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.473 ' O ' ' CB ' ' D' ' 13' ' ' HIS . 6.3 m80 -145.71 132.27 19.82 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.025 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.489 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.8 m-70 -150.57 170.9 18.03 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.074 177.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.2 tp60 -138.53 140.83 39.25 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 177.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -130.02 106.12 8.42 Favored 'General case' 0 C--N 1.318 -0.764 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.413 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 mt -118.34 113.86 22.06 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.47 116.27 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -109.37 106.16 15.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -120.81 127.97 52.43 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -176.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.62 131.36 35.71 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.124 0.488 . . . . 0.0 111.164 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.489 ' O ' ' CG ' ' C' ' 23' ' ' ASP . 77.4 tt0 -146.46 101.9 3.53 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 113.659 0.985 . . . . 0.0 113.659 -179.067 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.58 ' OD2' ' N ' ' B' ' 23' ' ' ASP . 70.5 m-20 -175.86 -71.83 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 175.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.473 ' O ' ' CG1' ' C' ' 24' ' ' VAL . 11.2 p -78.75 114.78 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.069 -1.423 . . . . 0.0 107.54 175.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.23 -39.26 5.74 Favored Glycine 0 N--CA 1.461 0.336 0 C-N-CA 117.408 -2.33 . . . . 0.0 109.044 -179.702 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 5.0 t -93.15 111.47 23.12 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 173.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -79.85 171.41 15.15 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 118.017 -1.473 . . . . 0.0 109.996 177.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.708 ' N ' HD22 ' B' ' 27' ' ' ASN . 99.0 mttt -50.37 -36.88 34.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.207 1.003 . . . . 0.0 109.472 174.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.19 76.72 0.06 OUTLIER Glycine 0 CA--C 1.54 1.642 0 CA-C-N 113.372 -1.74 . . . . 0.0 110.175 -178.119 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.492 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . -80.19 129.79 34.75 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 119.323 1.562 . . . . 0.0 113.104 -176.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 46.8 pt -144.61 146.22 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.983 -177.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 76.9 mt -108.96 116.35 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.689 178.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.8 102.99 1.66 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.247 -3.141 . . . . 0.0 105.247 175.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -134.93 141.02 46.18 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -175.122 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.65 113.29 26.48 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 175.201 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' D' ' 35' ' ' MET . 3.1 t -129.46 134.42 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.86 -104.29 0.28 Allowed Glycine 0 C--N 1.305 -1.145 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' C' ' 39' ' ' VAL . . . 46.87 70.73 0.63 Allowed Glycine 0 CA--C 1.537 1.423 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.478 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' C' ' 38' ' ' GLY . 6.3 t -6.78 120.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.539 ' OXT' ' CE1' ' E' ' 13' ' ' HIS . 26.8 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.156 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.473 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 26.3 p90 -147.66 158.36 43.98 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 120.892 0.377 . . . . 0.0 110.729 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -134.33 121.68 21.56 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.568 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 4.5 m -129.25 132.55 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' O ' ' B' ' 40' ' ' VAL . 2.1 p80 -147.78 138.46 23.21 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.702 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 0.2 OUTLIER -145.91 158.67 43.86 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.052 178.454 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.696 HE22 ' N ' ' B' ' 37' ' ' GLY . 84.8 mt-30 -90.43 158.19 17.2 Favored 'General case' 0 N--CA 1.455 -0.196 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 174.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.37 103.08 4.35 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 176.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . 0.621 ' N ' ' CD2' ' D' ' 17' ' ' LEU . 0.1 OUTLIER -118.69 119.41 34.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.053 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 82.8 t -112.94 112.26 39.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 44.7 m-85 -110.92 103.96 12.5 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -114.29 118.84 35.04 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.831 -0.168 . . . . 0.0 110.926 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.14 118.4 8.95 Favored 'General case' 0 C--O 1.246 0.883 0 CA-C-O 122.147 0.975 . . . . 0.0 111.742 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -178.09 158.96 1.26 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 114.387 -1.279 . . . . 0.0 111.073 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.449 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 35.2 t70 -173.06 -59.91 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 114.167 1.173 . . . . 0.0 114.167 177.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.439 HG21 ' H ' ' D' ' 26' ' ' SER . 3.0 m -77.96 -178.99 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 118.896 -1.121 . . . . 0.0 113.208 -176.609 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.71 19.82 38.85 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 114.044 -1.435 . . . . 0.0 113.081 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.439 ' H ' HG21 ' D' ' 24' ' ' VAL . 8.9 t -126.65 151.16 48.43 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 118.309 1.055 . . . . 0.0 112.775 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.424 ' ND2' ' O ' ' E' ' 24' ' ' VAL . 57.9 t-20 -52.36 137.27 29.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.276 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.411 ' CB ' ' O ' ' E' ' 22' ' ' GLU . 87.1 tttt -63.5 -50.97 67.53 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.884 -177.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.66 50.35 3.15 Favored Glycine 0 CA--C 1.541 1.673 0 C-N-CA 119.949 -1.12 . . . . 0.0 110.755 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.492 ' CB ' ' O ' ' C' ' 30' ' ' ALA . . . -130.58 -179.9 5.55 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 118.803 1.301 . . . . 0.0 114.033 -174.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.487 ' HA ' ' O ' ' E' ' 31' ' ' ILE . 16.3 tt -136.37 144.74 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 CA-C-N 113.281 -1.781 . . . . 0.0 112.717 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.453 HD12 HG22 ' D' ' 32' ' ' ILE . 4.6 mt -103.92 109.88 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 175.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.6 104.26 0.88 Allowed Glycine 0 N--CA 1.466 0.697 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -157.28 157.71 34.73 Favored 'General case' 0 C--O 1.245 0.835 0 CA-C-O 123.879 1.8 . . . . 0.0 114.019 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.437 ' O ' ' O ' ' C' ' 36' ' ' VAL . 0.9 OUTLIER -97.1 119.5 35.7 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 110.516 -3.038 . . . . 0.0 108.683 178.371 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' E' ' 35' ' ' MET . 38.3 t -121.86 142.41 38.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 178.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.514 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.25 -102.14 0.19 Allowed Glycine 0 C--N 1.296 -1.666 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -176.898 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' D' ' 39' ' ' VAL . . . 47.56 71.39 0.56 Allowed Glycine 0 CA--C 1.526 0.772 0 C-N-CA 120.048 -1.072 . . . . 0.0 110.643 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.45 ' O ' ' O ' ' D' ' 38' ' ' GLY . 59.4 t -22.53 142.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.642 0.777 . . . . 0.0 112.886 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' D' ' 39' ' ' VAL . 16.6 m . . . . . 0 N--CA 1.471 0.622 0 CA-C-O 117.742 -1.123 . . . . 0.0 111.053 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -72.46 125.7 28.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.733 0.302 . . . . 0.0 110.543 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -148.39 130.87 15.76 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.629 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 8.4 m -134.01 131.11 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.032 0.444 . . . . 0.0 110.79 179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.539 ' CE1' ' OXT' ' C' ' 40' ' ' VAL . 3.4 p80 -150.21 146.55 26.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.875 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.457 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 41.5 m-70 -147.52 162.57 38.81 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-O 121.09 0.472 . . . . 0.0 111.49 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.523 ' NE2' ' OE1' ' D' ' 15' ' ' GLN . 56.6 tp60 -85.17 157.26 20.7 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 176.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -159.45 98.41 1.4 Allowed 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 118.473 -1.291 . . . . 0.0 112.378 179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.427 ' CD1' ' N ' ' E' ' 17' ' ' LEU . 5.9 mp -122.26 123.13 40.74 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.586 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 p -120.51 118.89 58.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' F' ' 19' ' ' PHE . 17.3 m-85 -108.91 105.71 15.36 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -108.53 114.45 28.29 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.494 ' O ' ' CB ' ' F' ' 21' ' ' ALA . . . -164.48 173.48 12.04 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 117.609 -1.636 . . . . 0.0 114.736 -177.819 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.411 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 73.4 mt-10 -77.75 141.18 39.43 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.339 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -175.41 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 120.475 0.179 . . . . 0.0 110.616 -177.51 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.621 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 11.7 t -61.05 -179.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.638 0.732 . . . . 0.0 112.219 -176.299 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.621 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -100.89 28.69 14.82 Favored Glycine 0 N--CA 1.467 0.716 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.366 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 19.6 m -83.56 -119.97 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -177.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' E' ' 29' ' ' GLY . 8.5 m120 -91.35 -151.53 0.26 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.852 -175.765 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp 44.1 -47.4 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 -176.652 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 130.98 60.54 0.09 OUTLIER Glycine 0 N--CA 1.49 2.252 0 CA-C-N 122.629 2.468 . . . . 0.0 115.899 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.83 116.92 11.69 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 119.301 1.55 . . . . 0.0 110.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.487 ' O ' ' HA ' ' D' ' 31' ' ' ILE . 77.6 mt -125.26 146.75 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.798 -177.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.416 HG22 HD13 ' E' ' 32' ' ' ILE . 96.6 mt -134.2 113.62 17.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 O-C-N 121.438 -0.789 . . . . 0.0 110.426 178.238 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.82 107.53 2.02 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 20.4 tp -128.4 120.5 27.08 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.288 0.566 . . . . 0.0 112.271 -177.234 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 53.3 tpp -106.69 121.18 43.83 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.154 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.515 ' O ' ' O ' ' E' ' 37' ' ' GLY . 83.7 t -109.42 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.515 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -22.66 152.95 0.0 OUTLIER Glycine 0 N--CA 1.479 1.518 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.296 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . -54.94 -54.41 33.79 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.004 -0.887 . . . . 0.0 114.492 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 70.5 t -102.89 130.53 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 119.17 1.485 . . . . 0.0 110.395 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.692 -179.663 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.451 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -148.99 158.39 44.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 120.768 0.318 . . . . 0.0 110.753 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -117.71 131.26 56.64 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.752 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.41 122.84 67.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.167 0.508 . . . . 0.0 110.842 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.66 ' CE1' ' HZ3' ' K' ' 28' ' ' LYS . 0.3 OUTLIER -154.64 121.59 5.55 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.265 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.478 ' ND1' ' C ' ' F' ' 14' ' ' HIS . 0.1 OUTLIER -151.8 166.25 31.95 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.853 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.514 HE22 ' H ' ' D' ' 37' ' ' GLY . 12.3 tt0 -89.82 156.68 18.33 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 76.7 tttt -141.83 101.55 3.98 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 120.729 -0.389 . . . . 0.0 110.862 178.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.614 ' N ' ' CD2' ' F' ' 17' ' ' LEU . 0.2 OUTLIER -118.0 111.68 19.26 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -107.77 110.04 30.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' E' ' 19' ' ' PHE . 29.3 m-85 -106.31 103.29 12.73 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 178.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -123.31 129.48 51.39 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.619 0.723 . . . . 0.0 110.589 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.494 ' CB ' ' O ' ' E' ' 21' ' ' ALA . . . -147.63 149.03 31.74 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 120.042 -0.663 . . . . 0.0 109.372 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.31 121.73 17.47 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.695 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OG ' ' F' ' 26' ' ' SER . 67.4 t0 -154.35 46.59 0.58 Allowed 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' F' ' 25' ' ' GLY . 53.3 t -100.98 163.77 3.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.428 ' N ' ' CG1' ' F' ' 24' ' ' VAL . . . 70.87 29.19 69.54 Favored Glycine 0 CA--C 1.528 0.891 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.87 178.2 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.463 ' OG ' ' OD1' ' F' ' 23' ' ' ASP . 22.3 p -155.73 111.97 3.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.206 0.527 . . . . 0.0 111.377 -177.306 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -49.45 178.85 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.297 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -70.27 46.45 0.08 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.415 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.17 58.62 2.76 Favored Glycine 0 CA--C 1.548 2.12 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.075 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.51 172.03 18.59 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 10.4 tt -133.13 136.3 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 CA-C-O 122.103 0.954 . . . . 0.0 112.704 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 89.9 mt -122.17 131.9 72.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 111.34 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.76 119.93 3.66 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.9 tp -125.47 126.52 45.04 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mtp -142.53 142.39 32.23 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.504 ' CG2' ' N ' ' F' ' 37' ' ' GLY . 2.3 p -140.78 171.39 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.504 ' N ' ' CG2' ' F' ' 36' ' ' VAL . . . -168.03 94.15 0.11 Allowed Glycine 0 C--N 1.306 -1.086 0 C-N-CA 119.202 -1.475 . . . . 0.0 111.887 179.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.27 -81.44 0.11 Allowed Glycine 0 CA--C 1.529 0.929 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.308 176.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.493 ' O ' ' O ' ' E' ' 38' ' ' GLY . 40.2 t -156.5 130.99 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-O 121.488 0.661 . . . . 0.0 110.45 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.636 179.765 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.451 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -112.39 138.12 49.58 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.881 0.372 . . . . 0.0 110.948 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -84.53 147.12 27.21 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.982 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.37 133.19 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.042 0.448 . . . . 0.0 110.486 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 79.5 m80 -110.0 151.28 27.35 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.152 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.665 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 0.2 OUTLIER -84.33 168.02 16.01 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.175 0.512 . . . . 0.0 110.838 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.665 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 99.6 mm-40 -154.97 142.35 19.57 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -84.7 121.82 28.2 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.745 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 92.5 mt -126.25 127.92 46.38 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -141.4 139.14 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.907 0.384 . . . . 0.0 111.595 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -135.79 137.16 41.32 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.246 0.546 . . . . 0.0 110.747 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.486 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 53.6 p90 -132.9 130.2 39.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.439 -178.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.83 125.86 48.6 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.622 0.725 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.557 ' O ' ' N ' ' G' ' 24' ' ' VAL . 13.0 pt-20 -156.5 -121.25 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.151 -0.931 . . . . 0.0 108.961 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 55.5 p30 -52.61 47.76 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.425 1.09 . . . . 0.0 113.688 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.557 ' N ' ' O ' ' G' ' 22' ' ' GLU . 1.7 t -99.72 -161.28 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -178.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.438 ' H ' HG13 ' G' ' 24' ' ' VAL . . . -72.41 -33.29 61.47 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 119.188 -1.482 . . . . 0.0 113.654 -175.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -153.48 123.83 7.07 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.421 1.611 . . . . 0.0 112.175 176.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.528 ' O ' ' NZ ' ' H' ' 28' ' ' LYS . 71.0 m-20 -39.14 135.39 0.97 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.074 175.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -110.59 -39.78 4.79 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 122.437 1.113 . . . . 0.0 108.601 175.367 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.6 -69.35 3.03 Favored Glycine 0 CA--C 1.536 1.396 0 CA-C-N 113.037 -1.892 . . . . 0.0 113.061 178.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.45 79.98 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 118.162 0.981 . . . . 0.0 113.245 176.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 81.1 mt -122.25 107.07 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.978 1.263 . . . . 0.0 107.612 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.406 HD12 HG22 ' G' ' 32' ' ' ILE . 93.9 mt -122.29 112.08 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.436 0.636 . . . . 0.0 112.393 -177.73 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.64 103.54 1.46 Allowed Glycine 0 N--CA 1.461 0.328 0 N-CA-C 105.279 -3.128 . . . . 0.0 105.279 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.0 mt -143.29 162.89 34.47 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 123.556 1.646 . . . . 0.0 115.174 -175.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -113.19 107.72 16.3 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 111.367 -2.651 . . . . 0.0 104.087 175.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 27.4 t -122.25 131.61 72.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.73 -111.33 3.27 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.5 -73.92 1.34 Allowed Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.08 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 t -79.62 168.59 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.813 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.09 138.53 43.09 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.836 0.351 . . . . 0.0 110.792 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -126.86 140.73 52.13 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.719 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.95 131.63 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 120.869 0.366 . . . . 0.0 110.133 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -124.75 159.56 30.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.977 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.534 ' CD2' ' H ' ' I' ' 14' ' ' HIS . 83.8 m-70 -119.25 172.98 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -92.53 149.33 21.43 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . 0.472 ' HZ2' ' CE1' ' G' ' 14' ' ' HIS . 64.8 mttp -101.42 128.24 47.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.8 tp -122.84 124.51 43.44 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.04 0.448 . . . . 0.0 111.377 -179.341 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.93 124.8 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.098 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -133.4 126.62 31.66 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -145.33 143.51 30.2 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 119.141 -1.024 . . . . 0.0 112.379 178.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.99 123.83 43.38 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.942 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.73 162.77 35.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 120.126 -0.63 . . . . 0.0 112.509 -178.22 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 59.92 47.2 10.24 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.054 -0.976 . . . . 0.0 112.742 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 2.4 t -83.4 166.96 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 116.515 -2.074 . . . . 0.0 107.26 -179.263 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.502 ' H ' ' ND2' ' G' ' 27' ' ' ASN . . . -72.37 -36.33 59.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 119.628 -1.272 . . . . 0.0 114.723 178.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.768 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.8 t -174.14 126.66 0.35 Allowed 'General case' 0 C--O 1.224 -0.273 0 CA-C-O 117.723 -1.132 . . . . 0.0 112.147 -176.595 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.768 ' O ' ' O ' ' H' ' 26' ' ' SER . 10.8 t30 -2.44 146.4 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 175.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.528 ' NZ ' ' O ' ' G' ' 27' ' ' ASN . 58.9 tttt -159.31 30.34 0.2 Allowed 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 179.746 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.72 89.24 0.69 Allowed Glycine 0 C--N 1.345 1.044 0 C-N-CA 117.17 -2.443 . . . . 0.0 114.108 176.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.524 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -110.41 102.65 11.26 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 123.371 1.558 . . . . 0.0 112.045 -178.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 80.7 mt -123.02 131.01 74.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 112.765 -2.016 . . . . 0.0 110.651 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 81.3 mt -113.21 108.75 26.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 175.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.66 121.82 4.5 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -178.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -169.49 163.16 10.36 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 123.904 1.811 . . . . 0.0 113.91 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -100.21 116.55 32.47 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 111.483 -2.598 . . . . 0.0 108.576 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' I' ' 35' ' ' MET . 53.8 t -127.8 123.69 61.53 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.565 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.13 -114.35 2.26 Favored Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.412 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.35 -72.68 2.77 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -152.07 151.23 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 O-C-N 122.7 -0.294 . . . . 0.0 110.47 177.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.421 ' H ' ' HB ' ' I' ' 39' ' ' VAL . 7.2 p . . . . . 0 C--O 1.218 -0.563 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.454 178.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.76 161.4 41.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.74 0.305 . . . . 0.0 110.448 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.41 139.24 51.72 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.578 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 4.7 m -126.89 136.46 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -138.91 93.62 2.72 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.537 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.534 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 52.3 p-80 -157.1 153.47 27.86 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 118.793 -1.163 . . . . 0.0 112.52 176.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -90.81 161.49 15.25 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.748 176.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -139.47 110.98 7.08 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 177.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -129.47 131.63 46.73 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.264 0.554 . . . . 0.0 110.942 178.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 76.0 t -121.15 120.14 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -118.53 111.16 18.26 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -121.66 135.21 54.98 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 122.311 -0.243 . . . . 0.0 111.358 -178.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.569 ' CB ' ' NZ ' ' I' ' 28' ' ' LYS . . . -139.28 136.05 34.49 Favored 'General case' 0 CA--C 1.555 1.152 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.338 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.558 ' C ' ' HZ1' ' I' ' 28' ' ' LYS . 79.7 tt0 -117.29 152.75 34.23 Favored 'General case' 0 N--CA 1.484 1.266 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.259 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.438 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 16.8 t70 -171.49 51.23 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -177.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 16.8 t -63.19 151.04 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.47 -179.194 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.92 -35.27 4.96 Favored Glycine 0 CA--C 1.539 1.538 0 CA-C-N 116.153 -0.476 . . . . 0.0 113.639 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' I' ' 27' ' ' ASN . 28.9 t -151.68 124.15 8.35 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.639 HD21 ' N ' ' I' ' 27' ' ' ASN . 0.7 OUTLIER -41.19 145.86 0.21 Allowed 'General case' 0 C--N 1.348 0.514 0 C-N-CA 118.396 -1.322 . . . . 0.0 109.774 -175.687 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.569 ' NZ ' ' CB ' ' I' ' 21' ' ' ALA . 18.3 tttt -75.08 -49.65 19.01 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -177.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 109.51 59.43 0.52 Allowed Glycine 0 CA--C 1.545 1.964 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -177.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.1 114.2 26.08 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -172.565 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 82.8 mt -134.28 127.25 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 113.858 -1.519 . . . . 0.0 109.334 176.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 14.2 tt -121.01 114.96 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.548 177.344 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.21 108.7 2.62 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 178.73 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 mp -135.12 148.2 49.71 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.952 1.358 . . . . 0.0 114.116 -177.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.44 ' O ' ' O ' ' H' ' 36' ' ' VAL . 86.4 mmm -107.75 112.72 25.54 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-N 112.686 -2.052 . . . . 0.0 106.809 175.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.472 HG11 HE22 ' L' ' 15' ' ' GLN . 4.8 t -136.51 161.91 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.012 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.628 ' H ' HE22 ' K' ' 15' ' ' GLN . . . 81.1 102.44 0.33 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 119.424 -1.37 . . . . 0.0 112.005 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.44 ' N ' ' CA ' ' J' ' 38' ' ' GLY . . . -154.45 -71.12 0.01 OUTLIER Glycine 0 CA--C 1.544 1.847 0 CA-C-O 118.899 -0.945 . . . . 0.0 111.406 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.43 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 16.0 t -119.3 128.95 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 119.406 1.603 . . . . 0.0 109.137 177.684 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.43 ' OXT' ' O ' ' I' ' 39' ' ' VAL . 77.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.216 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -107.39 132.39 53.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.808 0.337 . . . . 0.0 110.667 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.534 ' OE1' ' N ' ' J' ' 11' ' ' GLU . 58.1 mp0 -123.96 134.98 53.37 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.333 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -124.52 132.6 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.568 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.538 ' CD2' ' N ' ' J' ' 14' ' ' HIS . 4.2 t-160 -129.01 137.59 51.43 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.163 0.506 . . . . 0.0 110.476 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.538 ' N ' ' CD2' ' J' ' 13' ' ' HIS . 83.1 m-70 -154.85 176.92 11.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 122.103 0.954 . . . . 0.0 111.777 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.425 ' NE2' ' CG1' ' H' ' 36' ' ' VAL . 38.6 tt0 -159.77 137.14 9.68 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.257 -2.127 . . . . 0.0 105.257 177.298 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 84.9 tttt -134.25 113.8 12.36 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.075 -0.65 . . . . 0.0 112.66 -178.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 7.0 mp -133.87 117.67 17.08 Favored 'General case' 0 CA--C 1.508 -0.64 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 176.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -106.8 110.01 30.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.1 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -108.12 104.18 13.54 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 178.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.435 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 5.0 m-85 -123.24 129.91 52.03 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 118.76 20.33 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.476 ' OE2' ' CE1' ' K' ' 20' ' ' PHE . 76.0 mt-10 -145.81 133.41 20.95 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 -176.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.48 ' N ' ' OE1' ' K' ' 22' ' ' GLU . 0.2 OUTLIER 164.69 -70.4 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.404 175.643 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.542 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 22.8 t -58.17 -121.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 113.761 -1.563 . . . . 0.0 110.415 175.231 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.542 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . 142.08 -35.55 1.75 Allowed Glycine 0 C--O 1.222 -0.64 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.591 -179.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.402 ' O ' ' CG ' ' I' ' 27' ' ' ASN . 10.2 t -80.45 118.55 22.17 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 122.606 3.203 . . . . 0.0 103.119 169.009 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.646 ' CG ' ' H ' ' J' ' 30' ' ' ALA . 21.7 p30 -90.6 158.84 16.75 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 123.413 2.824 . . . . 0.0 110.966 178.191 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.642 ' CE ' HD22 ' H' ' 27' ' ' ASN . 98.3 mttt -48.12 -40.42 23.53 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 122.823 1.297 . . . . 0.0 110.985 173.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.43 67.85 0.04 OUTLIER Glycine 0 CA--C 1.545 1.911 0 CA-C-N 111.854 -2.43 . . . . 0.0 108.586 -174.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.646 ' H ' ' CG ' ' J' ' 27' ' ' ASN . . . -70.31 138.68 51.7 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-N 120.169 1.984 . . . . 0.0 114.2 -171.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.41 ' HA ' ' O ' ' K' ' 31' ' ' ILE . 86.2 mt -140.22 136.8 37.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-N 112.906 -1.952 . . . . 0.0 114.606 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 4.7 mt -108.74 109.3 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.92 108.66 2.43 Favored Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 12.7 tp -142.49 136.85 29.79 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 118.674 -1.21 . . . . 0.0 113.657 -175.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.433 ' O ' ' O ' ' I' ' 36' ' ' VAL . 0.6 OUTLIER -104.89 120.57 41.75 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.211 -1.813 . . . . 0.0 107.145 177.109 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.427 ' CG1' ' OE1' ' L' ' 15' ' ' GLN . 43.4 t -125.11 167.35 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 121.315 0.578 . . . . 0.0 110.897 -176.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 106.65 102.49 2.8 Favored Glycine 0 N--CA 1.467 0.752 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.891 178.207 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.516 ' O ' ' C ' ' J' ' 39' ' ' VAL . . . -121.89 65.61 0.48 Allowed Glycine 0 CA--C 1.539 1.593 0 CA-C-O 117.858 -1.523 . . . . 0.0 113.125 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.516 ' C ' ' O ' ' J' ' 38' ' ' GLY . 71.1 t -12.84 127.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 CA-C-N 119.905 1.852 . . . . 0.0 113.769 -176.031 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.42 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 10.7 m . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.943 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.462 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -107.1 135.7 48.21 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.862 0.363 . . . . 0.0 110.385 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.512 ' N ' ' OE1' ' K' ' 11' ' ' GLU . 57.6 mp0 -131.82 146.06 51.92 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.954 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.466 ' C ' ' CD2' ' K' ' 13' ' ' HIS . 55.6 t -123.82 128.5 74.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.082 0.468 . . . . 0.0 110.769 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.518 ' CE1' ' NZ ' ' O' ' 28' ' ' LYS . 36.7 m-70 -148.05 100.21 3.15 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.638 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.583 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 4.7 m80 -145.14 157.71 44.02 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.901 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.628 HE22 ' H ' ' I' ' 37' ' ' GLY . 79.3 mt-30 -90.27 159.25 16.78 Favored 'General case' 0 CA--C 1.515 -0.4 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 174.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -140.71 103.62 4.55 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.502 177.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -131.47 119.61 21.82 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.549 0.69 . . . . 0.0 109.456 177.504 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.1 t -106.05 113.01 41.7 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 114.766 -1.107 . . . . 0.0 108.629 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.505 ' CD1' ' N ' ' K' ' 19' ' ' PHE . 1.8 m-85 -105.95 101.59 11.08 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.584 -1.636 . . . . 0.0 106.584 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.476 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 40.6 t80 -117.95 126.83 53.09 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 120.984 0.421 . . . . 0.0 111.064 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.79 142.33 27.62 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 119.657 -0.817 . . . . 0.0 112.727 -179.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 85.6 mt-10 -82.68 115.56 21.67 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.544 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.501 ' CG ' ' ND2' ' J' ' 27' ' ' ASN . 68.5 t0 -131.85 46.4 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.732 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.427 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 6.4 t -83.48 171.76 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.277 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.755 -177.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.468 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 95.45 -29.43 9.64 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.004 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 91.81 115.1 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 -178.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.503 ' ND2' ' H ' ' K' ' 28' ' ' LYS . 9.1 t-20 -73.79 163.13 28.36 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 118.377 -1.329 . . . . 0.0 111.378 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.66 ' HZ3' ' CE1' ' F' ' 13' ' ' HIS . 99.1 mttt -48.12 -37.24 14.95 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.853 175.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.99 76.92 0.06 OUTLIER Glycine 0 CA--C 1.541 1.684 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.755 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.95 139.89 36.88 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 119.133 1.466 . . . . 0.0 110.173 -178.413 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' J' ' 31' ' ' ILE . 7.1 mt -130.85 133.71 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -175.398 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 33.7 pt -121.0 118.77 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 121.596 0.712 . . . . 0.0 109.323 176.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 118.24 4.22 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -178.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.594 ' CD2' ' CE2' ' L' ' 19' ' ' PHE . 4.2 mp -129.03 118.42 22.52 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.973 0.892 . . . . 0.0 111.716 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -102.74 115.31 30.33 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.193 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.508 ' CG1' ' H ' ' K' ' 37' ' ' GLY . 42.6 t -116.76 174.12 3.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.508 ' H ' ' CG1' ' K' ' 36' ' ' VAL . . . 163.05 -95.41 0.13 Allowed Glycine 0 C--N 1.305 -1.181 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' K' ' 37' ' ' GLY . . . 28.48 78.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.401 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 90.5 t -33.89 118.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 t . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.361 179.373 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.0 m-85 -106.96 135.1 49.09 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.678 0.275 . . . . 0.0 110.637 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -108.22 156.35 19.44 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.387 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.59 122.01 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.17 0.509 . . . . 0.0 110.786 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.489 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -153.12 101.21 2.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.63 179.47 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.583 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.7 m80 -146.28 164.34 32.65 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.532 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 23.8 tt0 -90.02 158.45 17.34 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.636 0.236 . . . . 0.0 111.636 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.53 109.57 6.11 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 121.55 0.69 . . . . 0.0 111.555 178.165 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 22.4 mt -128.68 117.26 20.88 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -105.14 108.47 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.613 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.58 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' K' ' 34' ' ' LEU . 42.8 m-85 -102.45 105.36 15.92 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.52 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -129.19 122.01 28.86 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.642 0.734 . . . . 0.0 111.099 -178.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.35 133.0 47.2 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.998 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.454 ' O ' ' C ' ' K' ' 23' ' ' ASP . 79.6 mm-40 -77.27 114.76 16.43 Favored 'General case' 0 C--O 1.222 -0.388 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.641 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p30 -168.5 46.46 0.04 OUTLIER 'General case' 0 C--O 1.231 0.099 0 C-N-CA 119.838 -0.745 . . . . 0.0 112.833 -178.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.2 m -83.65 172.68 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 119.225 -0.99 . . . . 0.0 108.941 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.51 -29.82 8.57 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 15.7 p -84.77 139.9 31.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.38 -0.41 . . . . 0.0 110.993 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.509 ' OD1' ' N ' ' L' ' 28' ' ' LYS . 61.6 t-20 -73.15 149.17 43.19 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.509 ' N ' ' OD1' ' L' ' 27' ' ' ASN . 6.3 tmtt? 64.68 -49.71 0.32 Allowed 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' L' ' 27' ' ' ASN . . . 94.83 -54.79 1.92 Allowed Glycine 0 CA--C 1.542 1.745 0 CA-C-N 116.201 -0.454 . . . . 0.0 114.079 177.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.42 -172.75 1.31 Allowed 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 117.666 0.733 . . . . 0.0 109.69 -179.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 97.8 mt -98.41 119.09 45.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 176.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 88.9 mt -115.3 122.84 70.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 106.22 0.84 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 178.118 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 10.0 tt -133.45 131.17 39.59 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 33.4 ttp -151.59 160.3 43.72 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.709 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 27.1 m -109.47 173.96 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.339 0.123 0 CA-C-O 121.152 0.501 . . . . 0.0 111.108 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -166.51 94.64 0.11 Allowed Glycine 0 C--N 1.306 -1.098 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.03 83.4 0.79 Allowed Glycine 0 N--CA 1.473 1.149 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 21.8 m -53.29 141.84 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.15 -0.929 . . . . 0.0 110.556 179.171 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -148.48 158.36 44.07 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.879 0.371 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -92.32 126.01 37.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.915 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -126.83 130.17 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 121.198 0.523 . . . . 0.0 110.15 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -124.52 163.06 22.68 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.172 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 41.9 p-80 -87.41 170.76 11.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.217 -179.447 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.14 150.95 50.31 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.017 179.116 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -96.65 123.77 40.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.214 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -127.8 116.06 19.6 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -126.27 134.51 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.09 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -137.29 141.04 41.93 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 178.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -144.42 146.84 32.71 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.413 -179.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.52 119.71 21.92 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.144 0.497 . . . . 0.0 110.462 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' M' ' 24' ' ' VAL . 97.5 mt-10 -103.59 -162.71 0.93 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.544 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' M' ' 22' ' ' GLU . 96.9 m-20 -23.64 -59.69 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 123.222 0.609 . . . . 0.0 112.345 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.454 ' O ' ' O ' ' M' ' 22' ' ' GLU . 32.6 m -91.3 169.87 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -178.636 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.37 28.36 57.98 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.452 ' OG ' ' OD2' ' N' ' 23' ' ' ASP . 11.9 t -97.02 110.7 23.19 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.094 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 p30 -78.14 175.42 10.17 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -176.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -49.75 -36.23 25.07 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 112.507 -2.133 . . . . 0.0 115.074 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.94 78.63 0.06 OUTLIER Glycine 0 N--CA 1.471 1.012 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.643 -172.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.03 108.62 0.26 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-O 124.362 2.029 . . . . 0.0 113.306 -175.542 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 15.1 tt -128.34 125.71 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 110.537 -3.028 . . . . 0.0 108.388 -179.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 92.8 mt -102.64 108.88 25.12 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.527 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.92 92.82 0.67 Allowed Glycine 0 CA--C 1.508 -0.352 0 N-CA-C 105.44 -3.064 . . . . 0.0 105.44 176.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . 0.467 ' O ' ' CD2' ' N' ' 34' ' ' LEU . 92.8 mt -135.36 156.57 48.71 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 122.81 1.29 . . . . 0.0 113.861 -176.408 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -108.9 105.27 14.75 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 112.426 -2.17 . . . . 0.0 106.25 176.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 50.4 t -106.12 111.83 36.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.03 -132.12 8.74 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 93.81 -63.19 1.87 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.621 179.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 1.2 m -111.14 161.3 9.74 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -178.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.949 -1.025 . . . . 0.0 110.764 -179.987 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -81.71 138.37 35.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.758 0.313 . . . . 0.0 110.27 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -76.45 116.33 17.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.692 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -137.7 157.63 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.112 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 21.8 t-160 -145.46 98.81 3.2 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.871 0.367 . . . . 0.0 111.311 179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.477 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 28.4 p-80 -153.98 168.12 27.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.338 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -129.45 150.35 50.84 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 110.064 178.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -98.15 124.0 42.49 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.282 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 7.6 tt -125.84 124.45 40.93 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.483 0.583 . . . . 0.0 109.701 178.563 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -125.94 134.41 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.603 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.4 t80 -130.63 120.3 23.75 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.811 0.339 . . . . 0.0 111.051 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -112.36 127.77 56.1 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.75 132.91 42.8 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-N 118.584 0.629 . . . . 0.0 111.958 -179.567 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -170.09 128.44 0.89 Allowed 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.023 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.493 ' CG ' ' H ' ' N' ' 24' ' ' VAL . 16.6 p-10 -155.05 -59.81 0.11 Allowed 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 119.89 -0.724 . . . . 0.0 111.618 177.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.493 ' H ' ' CG ' ' N' ' 23' ' ' ASP . 16.9 m -102.87 -176.83 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.94 -33.69 70.5 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 1.5 m -147.86 118.87 7.66 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -59.9 169.06 1.56 Allowed 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 117.919 -1.512 . . . . 0.0 110.922 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -54.69 -36.96 65.23 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 115.305 1.594 . . . . 0.0 115.305 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.75 77.58 0.07 OUTLIER Glycine 0 CA--C 1.54 1.634 0 C-N-CA 120.123 -1.037 . . . . 0.0 113.429 -174.448 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.86 116.71 20.17 Favored 'General case' 0 CA--C 1.548 0.894 0 CA-C-N 118.866 1.333 . . . . 0.0 113.638 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . 0.412 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 2.8 tt -146.08 134.09 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.125 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 15.8 mt -109.38 120.55 60.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 CA-C-O 120.971 0.415 . . . . 0.0 110.64 179.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.03 112.75 2.68 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 105.795 -2.922 . . . . 0.0 105.795 176.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . 0.467 ' CD2' ' O ' ' M' ' 34' ' ' LEU . 0.3 OUTLIER -151.91 144.13 23.97 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 117.773 -1.571 . . . . 0.0 115.074 -175.206 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 89.7 mmm -105.8 108.36 19.84 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 174.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.404 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . 2.0 t -106.9 101.79 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 118.878 0.763 . . . . 0.0 110.884 -177.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.09 -171.14 20.56 Favored Glycine 0 C--N 1.323 -0.173 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 155.66 -55.04 0.41 Allowed Glycine 0 CA--C 1.547 2.036 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 -178.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -159.49 135.26 1.8 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 CA-C-N 117.628 0.714 . . . . 0.0 109.768 177.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 22.6 m . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.225 179.07 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -82.05 137.84 34.97 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.821 0.343 . . . . 0.0 110.488 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -114.74 134.93 54.7 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.592 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 75.3 t -122.45 130.25 74.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.856 179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.456 ' ND1' ' C ' ' O' ' 13' ' ' HIS . 3.5 t-80 -146.58 102.74 3.6 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.574 0.226 . . . . 0.0 111.364 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' P' ' 14' ' ' HIS . 8.0 p-80 -156.34 164.48 38.25 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.919 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -89.84 158.82 17.29 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -140.1 119.23 12.75 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -135.82 130.02 33.33 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 122.321 1.057 . . . . 0.0 111.777 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -112.09 118.23 57.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 177.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -110.32 102.78 11.4 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 14.6 t80 -114.83 127.8 55.93 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.73 115.11 20.86 Favored 'General case' 0 C--O 1.243 0.742 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . 0.448 ' O ' ' C ' ' O' ' 23' ' ' ASP . 83.0 tt0 -86.7 151.28 23.55 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.142 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.448 ' C ' ' O ' ' O' ' 22' ' ' GLU . 49.0 t0 26.83 49.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.904 -176.154 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' P' ' 22' ' ' GLU . 1.1 p -68.75 154.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.013 -1.449 . . . . 0.0 108.179 175.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.424 ' N ' ' CG2' ' O' ' 24' ' ' VAL . . . -131.51 -28.81 0.61 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.559 ' OG ' ' N ' ' O' ' 27' ' ' ASN . 3.3 t 63.69 -110.14 0.28 Allowed 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.53 178.66 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.559 ' N ' ' OG ' ' O' ' 26' ' ' SER . 32.9 m-20 150.51 -161.37 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.551 0 O-C-N 124.473 1.108 . . . . 0.0 109.153 -178.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.518 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 98.8 mttt -29.71 -40.4 0.02 OUTLIER 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -179.013 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -170.07 70.05 0.14 Allowed Glycine 0 CA--C 1.541 1.662 0 C-N-CA 118.489 -1.815 . . . . 0.0 115.908 -173.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.75 150.18 43.06 Favored 'General case' 0 C--N 1.363 1.175 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.407 HD12 HG21 ' O' ' 31' ' ' ILE . 20.6 mt -140.69 149.85 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 118.076 2.621 . . . . 0.0 118.076 -171.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . 0.412 HG23 HD12 ' O' ' 32' ' ' ILE . 6.7 mt -111.78 106.76 21.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 N-CA-C 104.871 -2.27 . . . . 0.0 104.871 173.152 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.43 98.5 0.78 Allowed Glycine 0 N--CA 1.473 1.15 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 8.8 mp -136.67 151.92 49.82 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 123.698 1.713 . . . . 0.0 114.433 -175.462 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -113.15 112.04 23.13 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 111.947 -2.388 . . . . 0.0 106.019 176.483 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.09 147.69 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . 0.861 ' H ' HE22 ' Q' ' 15' ' ' GLN . . . 127.32 103.04 1.22 Allowed Glycine 0 C--N 1.307 -1.057 0 N-CA-C 109.384 -1.487 . . . . 0.0 109.384 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.525 ' O ' ' C ' ' O' ' 39' ' ' VAL . . . -108.47 72.42 0.2 Allowed Glycine 0 CA--C 1.533 1.179 0 CA-C-O 117.612 -1.66 . . . . 0.0 112.074 179.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.591 ' H ' HG22 ' P' ' 39' ' ' VAL . 7.6 p -12.86 130.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 CA-C-N 119.804 1.802 . . . . 0.0 113.325 -175.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.375 179.717 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -104.09 132.13 50.66 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . 0.417 ' O ' ' NE2' ' Q' ' 13' ' ' HIS . 96.7 mt-10 -126.57 118.0 23.97 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.676 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 19.4 m -139.64 113.75 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.545 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.441 ' HB3' ' H ' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -135.44 140.24 44.74 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.449 -179.27 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' O' ' 14' ' ' HIS . 5.5 m-70 -125.42 161.17 27.66 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 178.074 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 27.2 tp60 -89.89 158.15 17.56 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -141.47 100.22 3.73 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.437 178.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 9.0 mp -134.5 122.8 22.95 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 176.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -122.4 127.39 75.08 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -115.87 106.25 13.61 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 30.5 t80 -110.97 125.67 53.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.156 -178.527 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.41 122.74 18.25 Favored 'General case' 0 CA--C 1.553 1.064 0 CA-C-O 121.751 0.786 . . . . 0.0 112.615 -179.544 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.495 ' O ' ' O ' ' O' ' 24' ' ' VAL . 83.1 tt0 -87.42 116.66 25.68 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.408 -1.269 . . . . 0.0 110.926 179.018 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.563 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 34.2 m-20 -144.81 46.73 1.35 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.051 0.54 . . . . 0.0 112.053 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.594 ' N ' ' OE1' ' Q' ' 22' ' ' GLU . 1.0 OUTLIER -82.14 173.37 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 123.229 1.49 . . . . 0.0 113.237 -175.594 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.42 -33.66 4.84 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-N 111.286 -2.688 . . . . 0.0 113.992 177.054 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.712 ' O ' ' O ' ' P' ' 27' ' ' ASN . 13.3 t -174.16 126.61 0.35 Allowed 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 118.974 1.387 . . . . 0.0 112.819 175.672 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.777 HD21 ' H ' ' Q' ' 27' ' ' ASN . 12.6 p30 -2.69 145.94 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 173.751 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.435 ' CG ' ' O ' ' P' ' 27' ' ' ASN . 93.1 mttt -158.48 30.34 0.23 Allowed 'General case' 0 N--CA 1.475 0.806 0 O-C-N 120.69 -1.256 . . . . 0.0 114.033 176.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.31 88.81 0.9 Allowed Glycine 0 CA--C 1.531 1.065 0 C-N-CA 119.503 -1.332 . . . . 0.0 113.727 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.88 105.54 7.83 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 117.871 0.836 . . . . 0.0 112.047 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 58.4 mt -119.21 124.25 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 CA-C-O 119.27 -0.395 . . . . 0.0 110.056 177.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . 0.432 HD13 HG21 ' P' ' 32' ' ' ILE . 49.9 mt -109.91 110.55 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.802 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.56 100.06 1.04 Allowed Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 104.588 -3.405 . . . . 0.0 104.588 175.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 tt -144.63 137.37 26.63 Favored 'General case' 0 C--O 1.241 0.635 0 C-N-CA 118.681 -1.207 . . . . 0.0 112.883 -174.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 22.1 mtp -112.27 127.73 56.06 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 113.837 -1.529 . . . . 0.0 110.512 179.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.74 103.18 14.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.369 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.22 -153.48 25.09 Favored Glycine 0 C--N 1.308 -0.983 0 C-N-CA 119.276 -1.44 . . . . 0.0 111.191 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.637 ' H ' ' CG1' ' Q' ' 40' ' ' VAL . . . 99.16 -56.45 0.92 Allowed Glycine 0 CA--C 1.543 1.795 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.591 HG22 ' H ' ' O' ' 39' ' ' VAL . 27.7 m -128.88 160.2 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.73 0.812 . . . . 0.0 112.265 -177.602 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 2.8 t . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.719 -179.449 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.79 90.13 3.24 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -142.77 147.97 36.42 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.766 0.317 . . . . 0.0 110.596 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -140.87 135.86 33.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.658 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.417 ' NE2' ' O ' ' P' ' 11' ' ' GLU . 4.6 m80 -142.63 125.0 15.57 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.651 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.504 ' CE1' ' CE1' ' P' ' 14' ' ' HIS . 15.1 p-80 -152.61 160.42 43.19 Favored 'General case' 0 C--O 1.222 -0.368 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.645 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.861 HE22 ' H ' ' O' ' 37' ' ' GLY . 88.3 mt-30 -90.03 158.92 17.12 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 176.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -140.73 108.35 5.61 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 3.8 mp -130.97 124.13 30.32 Favored 'General case' 0 CA--C 1.511 -0.52 0 C-N-CA 119.962 -0.695 . . . . 0.0 109.726 177.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -110.1 122.34 64.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.519 ' CE2' ' CE1' ' R' ' 19' ' ' PHE . 24.0 m-85 -112.03 99.9 8.45 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 178.647 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -108.96 121.2 44.63 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.422 -177.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . 0.543 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -152.76 161.12 42.98 Favored 'General case' 0 C--O 1.217 -0.625 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.628 -179.017 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.594 ' OE1' ' N ' ' P' ' 24' ' ' VAL . 99.6 mt-10 -87.55 114.52 24.23 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.781 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 68.4 t0 -109.23 52.0 0.73 Allowed 'General case' 0 N--CA 1.478 0.949 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.071 -177.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.411 ' CG1' ' N ' ' Q' ' 25' ' ' GLY . 38.5 t -41.43 161.38 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.983 0.897 . . . . 0.0 112.247 -176.15 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.411 ' N ' ' CG1' ' Q' ' 24' ' ' VAL . . . -93.14 32.59 5.58 Favored Glycine 0 N--CA 1.468 0.798 0 CA-C-N 113.848 -1.524 . . . . 0.0 114.273 -174.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.454 ' CB ' HD21 ' P' ' 27' ' ' ASN . 69.5 m -92.62 -112.38 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 117.593 0.696 . . . . 0.0 109.936 -178.233 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.777 ' H ' HD21 ' P' ' 27' ' ' ASN . 9.8 m120 -85.97 179.18 7.05 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 119.853 1.206 . . . . 0.0 112.91 -176.674 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -52.58 48.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -98.56 56.57 1.01 Allowed Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.164 -1.017 . . . . 0.0 112.936 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.63 103.49 0.7 Allowed 'General case' 0 C--O 1.24 0.56 0 CA-C-N 119.013 1.406 . . . . 0.0 112.921 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 pt -142.69 139.82 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 120.099 -0.64 . . . . 0.0 109.601 177.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 4.8 tt -140.23 132.71 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 105.66 1.47 Allowed Glycine 0 C--N 1.337 0.589 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 176.096 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 53.0 tp -120.47 122.6 41.03 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.642 0.734 . . . . 0.0 112.201 -176.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -111.78 115.67 29.44 Favored 'General case' 0 C--O 1.223 -0.301 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.558 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.526 ' CG1' ' N ' ' Q' ' 37' ' ' GLY . 81.9 t -108.17 171.03 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-O 121.414 0.626 . . . . 0.0 111.26 -178.902 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.526 ' N ' ' CG1' ' Q' ' 36' ' ' VAL . . . 130.34 93.44 0.66 Allowed Glycine 0 C--N 1.311 -0.835 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.29 -74.46 0.26 Allowed Glycine 0 CA--C 1.534 1.235 0 C-N-CA 121.287 -0.483 . . . . 0.0 112.236 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -81.71 118.19 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.341 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 179.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.637 ' CG1' ' H ' ' P' ' 38' ' ' GLY . 3.1 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.414 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -126.78 154.62 44.01 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.915 0.388 . . . . 0.0 110.544 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -68.43 125.42 26.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.583 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 9.2 p -139.97 138.85 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.286 0.565 . . . . 0.0 111.373 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -149.26 105.22 3.47 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.552 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.415 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 93.4 m-70 -145.95 166.47 25.92 Favored 'General case' 0 C--O 1.221 -0.441 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.567 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -89.73 158.68 17.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.134 0.492 . . . . 0.0 110.66 -179.546 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -140.22 103.02 4.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.56 -0.745 . . . . 0.0 109.438 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 10.8 mp -124.99 120.85 32.72 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 95.5 t -105.22 116.62 49.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.519 ' CE1' ' CE2' ' Q' ' 19' ' ' PHE . 78.2 m-85 -111.89 103.7 11.95 Favored 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -140.17 150.65 44.47 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-O 121.804 0.812 . . . . 0.0 111.594 -177.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . 0.543 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -139.31 143.48 37.88 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.067 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -82.7 157.62 23.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.513 -178.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 58.69 50.45 8.87 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.773 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 24.9 t -48.9 163.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.134 -178.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -175.76 24.0 0.06 OUTLIER Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -178.4 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 4.3 m -64.94 111.68 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.776 0.798 . . . . 0.0 110.566 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.702 ' O ' ' N ' ' R' ' 29' ' ' GLY . 24.7 t-20 -149.09 176.0 10.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.956 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . 0.484 ' H ' ' CG ' ' R' ' 27' ' ' ASN . 65.5 tttm -8.95 -45.91 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.952 0 O-C-N 124.401 1.063 . . . . 0.0 113.559 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.702 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -94.49 58.74 1.92 Allowed Glycine 0 CA--C 1.544 1.847 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.823 179.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 136.91 9.85 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 50.5 mt -124.77 119.5 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 CA-C-O 121.627 0.727 . . . . 0.0 111.644 -178.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 mm -113.36 121.84 66.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.782 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 115.98 2.26 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 7.3 tp -137.03 125.38 23.33 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.713 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 9.8 ptm -160.89 172.94 16.07 Favored 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.366 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -124.72 167.33 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-O 121.327 0.584 . . . . 0.0 111.529 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.57 -102.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 114.986 -1.006 . . . . 0.0 111.103 179.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.02 -77.87 1.09 Allowed Glycine 0 CA--C 1.532 1.137 0 N-CA-C 111.559 -0.617 . . . . 0.0 111.559 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 79.3 t -121.3 132.37 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 117.17 0.485 . . . . 0.0 110.401 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 4.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.325 179.757 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 78.3 t80 -80.65 129.97 34.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.738 0.304 . . . . 0.0 110.327 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -132.95 147.89 52.28 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.754 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.557 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 53.0 t -124.89 131.33 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.144 0.497 . . . . 0.0 110.25 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -93.94 163.06 13.65 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.436 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.643 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -86.0 171.94 11.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.708 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 28.5 pt20 -158.09 142.96 16.44 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.571 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -80.24 133.95 36.05 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.895 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.6 mt -129.29 116.31 18.92 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.971 0.415 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -125.43 133.75 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.954 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -134.94 129.0 33.58 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 53.6 p90 -122.62 130.47 53.03 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.408 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.28 114.99 21.57 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.455 0.645 . . . . 0.0 111.339 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.442 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 74.9 mt-10 -154.92 152.73 30.08 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 22' ' ' GLU . 3.9 p-10 45.21 46.46 9.89 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.461 179.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -80.42 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.77 -177.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.3 -33.5 64.54 Favored Glycine 0 CA--C 1.526 0.767 0 CA-C-N 115.287 -0.87 . . . . 0.0 113.143 -177.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.589 ' O ' ' O ' ' A' ' 27' ' ' ASN . 89.6 p -162.38 120.24 2.13 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.98 0.89 . . . . 0.0 111.912 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.599 ' ND2' ' H ' ' A' ' 28' ' ' LYS . 5.1 t-20 -22.51 163.21 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 114.006 -1.452 . . . . 0.0 114.439 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.599 ' H ' ' ND2' ' A' ' 27' ' ' ASN . 98.3 mttt -156.27 -18.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.24 -1.346 . . . . 0.0 107.817 178.032 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.465 ' HA3' ' H ' ' B' ' 28' ' ' LYS . . . 71.83 -98.47 0.78 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.46 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.79 88.54 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.075 179.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.5 mt -138.12 117.24 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' B' ' 33' ' ' GLY . 39.7 mt -108.91 112.49 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 93.93 0.64 Allowed Glycine 0 CA--C 1.507 -0.444 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -140.78 165.0 28.7 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 123.335 1.541 . . . . 0.0 114.289 -175.586 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 38.5 tpp -120.9 107.81 13.14 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 111.999 -2.364 . . . . 0.0 106.786 177.626 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 63.6 t -110.84 124.0 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 179.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.9 -114.46 2.73 Favored Glycine 0 C--N 1.318 -0.461 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 -176.49 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.34 -71.92 1.48 Allowed Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.153 -1.022 . . . . 0.0 111.353 178.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.433 ' HA ' ' CD1' ' G' ' 31' ' ' ILE . 34.2 m -111.33 -175.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.714 0.769 . . . . 0.0 111.5 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.546 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.6 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-N 114.247 -1.342 . . . . 0.0 110.309 178.443 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -147.44 158.0 43.8 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.441 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.55 120.7 12.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 121.081 0.467 . . . . 0.0 110.623 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.49 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 16.0 t -130.1 117.39 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.557 ' CE1' ' H ' ' A' ' 12' ' ' VAL . 3.7 m-70 -137.68 112.27 8.79 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.445 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.563 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -151.96 160.13 43.58 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.332 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 78.7 mt-30 -131.95 151.36 51.77 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.983 0.42 . . . . 0.0 111.949 179.069 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -97.76 121.33 39.55 Favored 'General case' 0 C--O 1.238 0.485 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.3 mt -120.93 119.25 32.06 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 118.58 0.627 . . . . 0.0 110.301 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.43 132.43 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.873 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -125.88 124.0 39.89 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.112 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.466 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 34.2 t80 -117.91 126.47 52.42 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.36 141.69 33.81 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -104.36 147.7 27.23 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.14 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 3.4 t70 -171.9 51.89 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.023 -177.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 2.6 t -75.51 143.64 12.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-O 121.726 0.774 . . . . 0.0 111.714 -176.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.06 38.18 3.9 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 114.405 -1.27 . . . . 0.0 112.332 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.09 120.0 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 122.192 0.197 . . . . 0.0 110.904 177.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.527 ' ND2' ' O ' ' B' ' 23' ' ' ASP . 2.1 m120 -83.38 162.6 20.99 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.373 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.465 ' H ' ' HA3' ' A' ' 29' ' ' GLY . 99.1 mttt -47.24 -37.61 10.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.459 0.647 . . . . 0.0 110.782 175.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.68 0.06 OUTLIER Glycine 0 CA--C 1.54 1.596 0 CA-C-N 115.217 -0.902 . . . . 0.0 111.898 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.78 94.87 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 119.634 1.717 . . . . 0.0 112.204 -178.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 69.3 mt -144.62 134.77 19.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.432 -177.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.405 HG21 HD11 ' B' ' 32' ' ' ILE . 91.6 mt -105.08 108.3 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.098 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -112.31 102.55 1.36 Allowed Glycine 0 CA--C 1.508 -0.37 0 N-CA-C 105.539 -3.024 . . . . 0.0 105.539 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.6 tt -150.62 148.38 28.55 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 118.42 -1.312 . . . . 0.0 112.226 -174.822 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 7.2 mtp -110.05 110.09 20.87 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 113.518 -1.674 . . . . 0.0 107.075 179.07 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.451 ' O ' ' CG1' ' B' ' 36' ' ' VAL . 4.1 p -119.62 111.51 33.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.35 -131.24 4.28 Favored Glycine 0 C--N 1.308 -1.007 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -178.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.499 ' O ' ' CG2' ' C' ' 39' ' ' VAL . . . 87.27 -63.93 3.89 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 120.508 -0.853 . . . . 0.0 111.542 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 m -136.78 154.17 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.338 -178.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -105.35 133.13 50.62 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.631 0.253 . . . . 0.0 110.384 179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -97.65 122.74 41.08 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.651 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 19.4 m -125.4 133.07 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.159 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.546 ' CE1' ' OXT' ' A' ' 40' ' ' VAL . 5.6 t-80 -147.85 96.79 2.71 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.896 179.203 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.563 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 50.1 p-80 -157.24 167.57 29.96 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.738 -0.21 . . . . 0.0 111.265 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -89.99 158.45 17.36 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.437 0.637 . . . . 0.0 110.788 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -140.29 113.51 8.43 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 176.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mt -127.94 123.15 34.18 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 122.071 0.938 . . . . 0.0 111.478 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 67.1 t -111.14 117.03 54.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 177.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.432 ' CD2' ' CE2' ' D' ' 19' ' ' PHE . 56.2 m-85 -107.08 105.85 16.07 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 11.7 t80 -113.84 124.41 52.16 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.7 -0.227 . . . . 0.0 111.152 -178.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.66 122.34 30.6 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.647 0.736 . . . . 0.0 110.396 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -94.31 137.99 32.83 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.217 -178.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.516 ' N ' ' OE1' ' D' ' 22' ' ' GLU . 8.7 m-20 43.17 47.12 5.3 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.41 0.624 . . . . 0.0 109.354 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.438 HG13 ' H ' ' C' ' 25' ' ' GLY . 0.2 OUTLIER -61.43 -169.25 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.799 -177.195 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.495 ' HA3' ' H ' ' B' ' 27' ' ' ASN . . . -111.74 33.34 5.83 Favored Glycine 0 C--N 1.318 -0.427 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.098 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.43 ' O ' ' N ' ' D' ' 26' ' ' SER . 27.3 t -62.63 104.87 0.57 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.497 0.665 . . . . 0.0 109.221 -178.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.857 ' O ' ' N ' ' C' ' 29' ' ' GLY . 7.8 m120 -157.6 179.23 9.42 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.616 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm 1.86 -44.7 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 125.067 1.48 . . . . 0.0 114.212 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.857 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -111.14 58.57 0.39 Allowed Glycine 0 CA--C 1.542 1.764 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 178.578 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.35 99.75 8.95 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 117.349 0.575 . . . . 0.0 109.973 179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.443 HG23 ' H ' ' D' ' 31' ' ' ILE . 29.7 pt -147.93 156.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 117.88 -1.528 . . . . 0.0 114.385 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.436 HG23 HD11 ' C' ' 32' ' ' ILE . 95.9 mt -107.6 112.15 38.84 Favored 'Isoleucine or valine' 0 C--N 1.345 0.376 0 CA-C-N 114.053 -1.431 . . . . 0.0 108.695 176.35 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.91 93.76 0.74 Allowed Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 104.412 -3.475 . . . . 0.0 104.412 175.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 42.3 tp -135.0 132.57 38.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 122.365 1.079 . . . . 0.0 113.294 -174.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 6.4 mtp -99.99 111.33 23.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.673 177.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 t -110.8 103.32 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.13 -154.62 22.93 Favored Glycine 0 N--CA 1.46 0.254 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.673 178.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.21 -55.89 0.5 Allowed Glycine 0 CA--C 1.545 1.936 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.499 ' CG2' ' O ' ' B' ' 38' ' ' GLY . 68.6 t -136.04 162.97 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 C-N-CA 123.273 0.629 . . . . 0.0 110.167 178.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.452 ' N ' ' CG1' ' C' ' 39' ' ' VAL . 75.9 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.889 -1.053 . . . . 0.0 111.056 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.175 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -106.81 134.53 49.81 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -127.6 128.64 45.91 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 121.126 0.489 . . . . 0.0 111.195 -179.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 1.3 p -145.14 112.62 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.684 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.24 142.65 31.45 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.074 0.464 . . . . 0.0 110.228 179.089 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.554 ' O ' ' CG ' ' C' ' 14' ' ' HIS . 27.7 p-80 -146.12 162.6 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.114 178.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -89.67 158.19 17.68 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.311 179.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 85.6 tttt -140.68 106.28 5.1 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . 0.49 ' N ' ' CD2' ' D' ' 17' ' ' LEU . 1.7 mm? -123.37 124.95 44.08 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.849 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -123.11 112.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.432 ' CE2' ' CD2' ' C' ' 19' ' ' PHE . 27.1 m-85 -108.77 103.79 12.94 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 179.452 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.4 t80 -111.71 124.72 52.91 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.89 141.41 38.56 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.443 1.116 . . . . 0.0 112.923 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' C' ' 23' ' ' ASP . 84.2 mt-10 -75.85 118.32 18.52 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.065 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.42 ' O ' ' O ' ' D' ' 24' ' ' VAL . 13.6 t0 -57.15 59.77 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.591 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.441 ' N ' ' O ' ' D' ' 22' ' ' GLU . 43.3 t -63.05 -113.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' C' ' 26' ' ' SER . . . -104.4 44.37 1.49 Allowed Glycine 0 N--CA 1.478 1.489 0 CA-C-N 121.446 1.93 . . . . 0.0 111.973 -174.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.452 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 1.3 t -70.64 100.51 1.86 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 112.938 -1.631 . . . . 0.0 107.879 175.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -118.62 -153.18 0.53 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.389 0.614 . . . . 0.0 112.564 -174.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -37.58 -41.86 0.5 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.704 -177.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.07 68.39 1.96 Allowed Glycine 0 CA--C 1.537 1.417 0 C-N-CA 120.374 -0.917 . . . . 0.0 111.771 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.85 136.4 32.33 Favored 'General case' 0 C--N 1.349 0.555 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.447 HG22 HD12 ' D' ' 31' ' ' ILE . 39.7 mt -145.53 146.7 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 N-CA-C 115.398 1.629 . . . . 0.0 115.398 -175.135 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.426 HD12 HG23 ' D' ' 32' ' ' ILE . 0.2 OUTLIER -108.46 111.58 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.494 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.15 102.48 0.8 Allowed Glycine 0 N--CA 1.463 0.497 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.415 ' CD2' ' CZ ' ' E' ' 19' ' ' PHE . 2.9 mp -137.16 135.23 37.17 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 122.424 1.107 . . . . 0.0 113.652 -178.166 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -98.91 113.51 25.69 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.355 177.412 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' E' ' 35' ' ' MET . 2.9 t -118.92 103.22 14.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -177.785 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.405 ' CA ' ' H ' ' E' ' 38' ' ' GLY . . . 147.25 -153.62 25.45 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.928 -1.129 . . . . 0.0 110.54 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' E' ' 40' ' ' VAL . . . 104.45 -56.33 0.56 Allowed Glycine 0 CA--C 1.541 1.675 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.43 ' C ' ' O ' ' E' ' 38' ' ' GLY . 7.3 p -119.98 140.9 42.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 CA-C-O 121.361 0.601 . . . . 0.0 111.526 -178.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.614 179.902 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -115.75 136.48 53.01 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 120.627 0.251 . . . . 0.0 110.539 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.19 142.57 45.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.259 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 79.4 t -127.16 133.33 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 CA-C-O 120.785 0.326 . . . . 0.0 111.246 -179.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 m170 -137.81 100.0 4.06 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.422 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.0 OUTLIER -151.56 165.6 33.77 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 121.594 0.711 . . . . 0.0 112.801 -179.593 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -84.35 157.12 21.57 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.324 178.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -159.28 103.1 1.61 Allowed 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.433 ' N ' HD13 ' E' ' 17' ' ' LEU . 3.5 mp -137.43 131.45 31.98 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.387 0.613 . . . . 0.0 111.786 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -117.59 112.28 38.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.415 ' CZ ' ' CD2' ' D' ' 34' ' ' LEU . 27.4 m-85 -106.07 105.83 16.06 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 178.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -116.68 117.64 30.37 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.25 123.12 31.13 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.441 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 78.0 tt0 -154.11 154.21 33.22 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 117.9 2.555 . . . . 0.0 117.9 -175.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.454 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 52.6 m-20 109.72 46.5 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 111.646 -2.525 . . . . 0.0 116.372 174.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.409 HG11 ' O ' ' D' ' 23' ' ' ASP . 1.8 m -118.15 174.64 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.788 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -59.88 -28.25 65.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 107.868 -2.093 . . . . 0.0 107.868 172.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.483 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 3.7 p 143.0 129.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 112.524 -1.838 . . . . 0.0 106.209 -177.087 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.452 ' OD1' ' O ' ' D' ' 26' ' ' SER . 2.6 t30 -53.59 141.57 25.37 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.886 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -58.37 -48.81 79.41 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -179.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.441 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -170.23 59.27 0.19 Allowed Glycine 0 CA--C 1.54 1.629 0 C-N-CA 120.246 -0.978 . . . . 0.0 114.368 -175.615 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.65 169.17 16.54 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 119.124 1.462 . . . . 0.0 113.132 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 77.5 mt -120.97 137.47 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 113.784 -1.553 . . . . 0.0 110.301 -179.553 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -121.11 121.75 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.79 114.5 2.0 Favored Glycine 0 N--CA 1.471 0.981 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 59.4 mt -127.81 124.28 37.23 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 111.088 -178.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.441 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.0 mtp -108.22 111.77 23.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.245 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.467 ' CG1' ' H ' ' E' ' 37' ' ' GLY . 40.2 t -90.28 173.79 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.467 ' H ' ' CG1' ' E' ' 36' ' ' VAL . . . 162.16 -95.52 0.13 Allowed Glycine 0 C--N 1.305 -1.175 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.096 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.43 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 87.73 -83.69 1.53 Allowed Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -67.57 97.26 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 176.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' D' ' 38' ' ' GLY . 80.2 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.517 -179.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -114.74 139.57 49.58 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.022 0.439 . . . . 0.0 110.712 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.516 ' N ' ' OE1' ' F' ' 11' ' ' GLU . 57.9 mp0 -126.03 146.56 49.84 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.661 179.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -128.67 135.05 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.351 0.596 . . . . 0.0 111.409 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.656 ' CE1' ' HZ3' ' J' ' 28' ' ' LYS . 0.0 OUTLIER -142.19 131.98 24.22 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.492 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 83.4 t60 -155.15 167.81 29.12 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 28.5 mp0 -89.51 150.34 22.5 Favored 'General case' 0 CA--C 1.517 -0.298 0 C-N-CA 120.531 -0.468 . . . . 0.0 109.87 179.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -151.99 97.26 2.31 Favored 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . 0.413 ' N ' HD11 ' F' ' 17' ' ' LEU . 3.9 mp -133.83 116.25 15.45 Favored 'General case' 0 CA--C 1.506 -0.715 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.705 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -99.99 109.49 24.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 65.1 m-85 -104.89 98.92 8.57 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -112.83 111.43 22.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.338 0.589 . . . . 0.0 109.476 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.43 131.33 38.03 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.454 ' OE1' ' N ' ' E' ' 23' ' ' ASP . 84.6 tt0 -69.52 115.59 8.95 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 118.441 -1.304 . . . . 0.0 109.479 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.443 ' O ' ' OD2' ' F' ' 23' ' ' ASP . 18.9 t70 -167.8 51.79 0.06 Allowed 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.64 -178.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 75.5 t -75.38 142.96 13.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.36 38.03 3.63 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 5.1 m -70.68 102.18 2.23 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.575 0.702 . . . . 0.0 110.871 -178.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 42.4 p30 -119.51 -170.25 1.91 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.995 -178.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -33.89 -41.85 0.11 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.566 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.59 67.22 2.51 Favored Glycine 0 CA--C 1.542 1.746 0 CA-C-N 116.347 -0.388 . . . . 0.0 112.34 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . 171.27 139.01 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.442 HG22 ' H ' ' R' ' 40' ' ' VAL . 86.2 mt -132.78 142.84 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 119.786 -0.765 . . . . 0.0 113.002 -177.946 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -131.57 128.91 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.774 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.14 131.34 5.66 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 7.7 tt -135.89 127.46 28.83 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.8 mtp -140.2 149.7 43.25 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -178.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -92.91 154.77 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.614 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.93 102.59 2.94 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.19 -73.64 0.0 OUTLIER Glycine 0 CA--C 1.537 1.417 0 CA-C-N 115.41 -0.395 . . . . 0.0 113.139 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.548 ' N ' ' O ' ' F' ' 37' ' ' GLY . 90.4 t -151.32 136.55 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 117.848 0.824 . . . . 0.0 110.255 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.565 179.865 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -112.42 134.17 54.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.285 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' H' ' 11' ' ' GLU . 96.3 mt-10 -83.12 123.77 29.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.188 0.518 . . . . 0.0 110.894 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -134.52 137.08 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.869 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.474 ' O ' ' O ' ' H' ' 13' ' ' HIS . 98.3 m-70 -135.14 101.77 4.97 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.864 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' N ' ' G' ' 15' ' ' GLN . 6.6 t-80 -157.2 161.63 39.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.228 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.553 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 13.2 pt20 -174.3 147.86 1.22 Allowed 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.102 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 pttt -79.51 121.8 25.66 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.207 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 96.3 mt -131.75 116.42 17.25 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 177.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -126.69 136.22 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.129 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.538 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 68.1 m-85 -135.1 125.88 27.29 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.357 0.599 . . . . 0.0 111.086 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.493 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -115.11 129.62 56.72 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.43 124.33 39.91 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -177.29 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -137.21 115.27 11.57 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 63.7 t0 50.25 49.91 19.65 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.666 0.746 . . . . 0.0 109.046 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 29.5 m -82.11 -142.47 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.094 179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.522 ' O ' ' ND2' ' G' ' 27' ' ' ASN . . . -91.94 -38.38 5.77 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -178.37 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 2.3 m -69.13 113.89 6.91 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' G' ' 25' ' ' GLY . 29.0 m-20 -117.86 -150.42 0.46 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 112.608 -2.087 . . . . 0.0 112.439 -173.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.642 ' O ' ' N ' ' H' ' 28' ' ' LYS . 99.2 mttt -37.68 -40.76 0.44 Allowed 'General case' 0 C--O 1.214 -0.775 0 CA-C-N 113.534 -1.667 . . . . 0.0 111.227 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.78 68.8 0.21 Allowed Glycine 0 CA--C 1.545 1.943 0 O-C-N 121.653 -0.654 . . . . 0.0 112.552 -176.326 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -96.7 113.24 24.78 Favored 'General case' 0 C--N 1.368 1.376 0 CA-C-O 124.124 1.916 . . . . 0.0 111.287 -179.161 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 39' ' ' VAL . 38.1 mt -129.16 131.8 67.53 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 110.337 -3.119 . . . . 0.0 108.843 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.424 ' O ' ' O ' ' H' ' 33' ' ' GLY . 31.8 mt -103.32 106.39 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.34 94.95 0.79 Allowed Glycine 0 CA--C 1.504 -0.613 0 N-CA-C 106.185 -2.766 . . . . 0.0 106.185 177.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.405 ' H ' HD21 ' H' ' 34' ' ' LEU . 58.3 mt -144.38 156.1 44.07 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 123.162 1.458 . . . . 0.0 112.813 -177.473 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.2 mtp -105.22 113.22 26.68 Favored 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 111.983 -2.371 . . . . 0.0 106.001 176.204 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 48.4 t -109.04 102.33 13.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.63 -162.5 47.7 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.12 -55.67 0.52 Allowed Glycine 0 CA--C 1.532 1.138 0 CA-C-O 118.82 -0.989 . . . . 0.0 111.919 179.114 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.407 ' O ' ' C ' ' G' ' 40' ' ' VAL . 1.6 m -70.48 176.86 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.428 0 CA-C-N 118.27 1.035 . . . . 0.0 109.499 177.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' G' ' 39' ' ' VAL . 7.1 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.879 -1.058 . . . . 0.0 111.587 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.93 133.17 50.18 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' G' ' 11' ' ' GLU . 97.3 mt-10 -83.41 141.49 31.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.941 0.4 . . . . 0.0 110.959 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' N ' ' H' ' 13' ' ' HIS . 71.0 t -143.01 161.75 17.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.474 ' O ' ' O ' ' G' ' 13' ' ' HIS . 44.5 m80 -135.21 159.14 42.49 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 179.317 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 42.8 p-80 -85.61 166.19 16.42 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.805 -179.099 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -100.39 152.72 20.02 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -109.31 109.95 20.99 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -119.01 122.86 43.14 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.853 179.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -124.21 126.74 72.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.415 179.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' CD1' ' G' ' 19' ' ' PHE . 34.2 m-85 -133.89 126.14 29.81 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.812 -0.811 . . . . 0.0 108.812 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.457 ' CZ ' ' CB ' ' G' ' 20' ' ' PHE . 24.3 p90 -143.44 151.39 40.29 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 119.31 -0.956 . . . . 0.0 111.676 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.31 130.02 51.16 Favored 'General case' 0 C--O 1.251 1.171 0 CA-C-O 121.926 0.87 . . . . 0.0 111.467 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -60.98 -166.13 0.01 OUTLIER 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.879 -1.51 . . . . 0.0 107.757 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.497 ' O ' ' O ' ' H' ' 24' ' ' VAL . 33.2 t70 -84.22 57.65 4.35 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 116.669 -2.012 . . . . 0.0 115.41 -175.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.613 ' CG2' ' H ' ' H' ' 25' ' ' GLY . 1.3 p -68.64 -112.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.271 1 N-CA-C 100.069 -4.048 . . . . 0.0 100.069 166.451 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.613 ' H ' ' CG2' ' H' ' 24' ' ' VAL . . . 124.41 -39.39 2.14 Favored Glycine 0 C--N 1.331 0.283 0 N-CA-C 117.985 1.954 . . . . 0.0 117.985 167.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.23 110.5 5.25 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 115.632 -2.427 . . . . 0.0 112.968 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 1.093 ' O ' ' N ' ' H' ' 29' ' ' GLY . 0.0 OUTLIER -122.7 156.97 33.29 Favored 'General case' 0 C--O 1.207 -1.145 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 167.314 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.642 ' N ' ' O ' ' G' ' 28' ' ' LYS . 13.1 tttt -34.51 49.15 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 122.721 2.509 . . . . 0.0 111.16 172.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 1.093 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 101.26 -52.22 0.9 Allowed Glycine 0 CA--C 1.563 3.044 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -177.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.474 ' CB ' ' O ' ' H' ' 29' ' ' GLY . . . 129.35 115.38 0.0 OUTLIER 'General case' 0 C--N 1.377 1.799 0 C-N-CA 125.946 1.698 . . . . 0.0 107.977 177.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 72.2 mt -126.54 128.13 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 CA-C-N 122.056 2.207 . . . . 0.0 114.793 -178.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -111.67 110.51 32.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 175.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -116.46 105.4 1.35 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.215 -2.354 . . . . 0.0 107.215 178.269 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.496 ' O ' ' CD2' ' I' ' 34' ' ' LEU . 73.8 mt -140.65 148.86 41.51 Favored 'General case' 0 CA--C 1.508 -0.66 0 CA-C-O 122.832 1.301 . . . . 0.0 113.376 -176.069 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 4.8 ttm -113.86 112.36 23.23 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 175.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.499 ' O ' ' CG1' ' H' ' 36' ' ' VAL . 5.0 p -132.39 102.55 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.714 ' N ' HE22 ' J' ' 15' ' ' GLN . . . 122.52 -163.29 15.97 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' I' ' 37' ' ' GLY . . . 128.28 -54.57 0.78 Allowed Glycine 0 CA--C 1.547 2.06 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.291 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.419 ' CG2' ' CD1' ' N' ' 31' ' ' ILE . 14.6 t -109.7 165.99 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.681 0.793 . . . . 0.0 110.127 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.528 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 2.5 m . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.658 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.36 133.67 52.23 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.772 0.32 . . . . 0.0 110.509 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 54.6 tp10 -75.35 122.57 23.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.245 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -139.51 160.86 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.548 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 21.8 t60 -145.73 100.25 3.39 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 121.253 -0.179 . . . . 0.0 110.724 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' J' ' 14' ' ' HIS . 45.3 p-80 -165.52 169.57 15.34 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -89.84 158.95 17.24 Favored 'General case' 0 C--N 1.341 0.215 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.829 178.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -139.97 111.12 7.0 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 10.5 mp -127.95 128.64 45.43 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.247 0.546 . . . . 0.0 110.332 178.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 71.4 t -112.76 120.77 63.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -114.0 106.42 14.4 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.58 ' CD1' ' CD2' ' J' ' 20' ' ' PHE . 1.9 t80 -115.52 129.14 56.43 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 122.342 -0.224 . . . . 0.0 110.451 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.411 ' N ' ' CD1' ' I' ' 20' ' ' PHE . . . -150.18 130.57 13.79 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -178.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -95.65 119.42 34.12 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -118.64 46.3 1.86 Allowed 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -175.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 23.7 m -92.74 173.55 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 175.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.32 27.82 65.12 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 118.244 -1.931 . . . . 0.0 109.908 -177.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p 166.66 146.68 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -53.15 136.93 35.11 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 117.416 2.376 . . . . 0.0 117.416 -173.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.462 ' O ' ' CA ' ' J' ' 29' ' ' GLY . 37.9 mttt -60.84 51.06 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 CA-C-N 110.704 -2.953 . . . . 0.0 114.293 173.825 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.07 51.94 0.69 Allowed Glycine 0 N--CA 1.495 2.609 0 O-C-N 120.494 -1.379 . . . . 0.0 116.148 -172.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' J' ' 30' ' ' ALA . . . -100.31 147.09 26.17 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-O 123.685 1.707 . . . . 0.0 114.993 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 13.7 tt -132.29 135.88 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.248 -179.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.442 HD11 HG23 ' I' ' 32' ' ' ILE . 89.6 mt -106.28 108.6 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.141 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.01 111.0 3.63 Favored Glycine 0 C--O 1.24 0.496 0 N-CA-C 105.305 -3.118 . . . . 0.0 105.305 176.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.496 ' CD2' ' O ' ' H' ' 34' ' ' LEU . 0.3 OUTLIER -148.32 141.07 24.6 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 117.68 -1.608 . . . . 0.0 115.073 -174.462 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 81.6 mmm -103.13 114.65 29.12 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-N 112.233 -2.258 . . . . 0.0 105.134 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 58.4 t -122.57 131.75 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 CA-C-O 120.809 0.337 . . . . 0.0 111.047 -176.367 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' H' ' 38' ' ' GLY . . . 80.44 -111.22 3.24 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 120.629 -0.796 . . . . 0.0 114.807 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.55 -70.51 0.22 Allowed Glycine 0 CA--C 1.539 1.583 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.408 ' HB ' ' CD1' ' O' ' 31' ' ' ILE . 2.6 p -134.61 137.07 51.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.558 ' OXT' ' ND1' ' L' ' 13' ' ' HIS . 27.5 m . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.814 -1.088 . . . . 0.0 111.284 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.54 137.67 44.12 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -130.67 139.02 50.32 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.899 0.381 . . . . 0.0 110.843 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 41.8 t -123.24 125.29 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.561 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 3.3 m80 -120.96 121.92 39.05 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.166 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.557 ' O ' ' CG ' ' I' ' 14' ' ' HIS . 0.3 OUTLIER -152.45 156.41 39.4 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.19 176.478 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.714 HE22 ' N ' ' H' ' 37' ' ' GLY . 83.8 mt-30 -90.37 160.22 16.2 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -139.7 97.21 3.22 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.27 179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.407 ' HB3' ' CZ ' ' J' ' 19' ' ' PHE . 11.1 mp -122.8 121.49 36.41 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-O 121.703 0.763 . . . . 0.0 109.549 176.406 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 21.9 t -110.67 116.23 51.89 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.564 179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.407 ' CZ ' ' HB3' ' J' ' 17' ' ' LEU . 33.9 m-85 -112.58 104.46 12.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CD1' ' I' ' 20' ' ' PHE . 4.5 t80 -115.09 131.02 57.06 Favored 'General case' 0 N--CA 1.478 0.939 0 O-C-N 122.449 -0.157 . . . . 0.0 110.882 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . 0.558 ' O ' ' HA ' ' K' ' 21' ' ' ALA . . . -168.38 171.82 8.85 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 123.631 1.681 . . . . 0.0 115.464 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -111.62 113.84 26.49 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 113.164 -1.834 . . . . 0.0 107.426 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -172.82 49.81 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.589 ' CG2' ' H ' ' J' ' 25' ' ' GLY . 13.2 p -154.81 -179.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.879 -178.636 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.593 ' HA3' ' H ' ' K' ' 25' ' ' GLY . . . 61.59 29.74 72.72 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 116.905 1.522 . . . . 0.0 116.905 178.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.626 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.7 m -145.32 -120.8 0.08 Allowed 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.626 ' O ' ' O ' ' J' ' 26' ' ' SER . 1.3 p-10 -53.51 -156.61 0.0 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 176.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.656 ' HZ3' ' CE1' ' F' ' 13' ' ' HIS . 99.0 mttt -63.36 -39.9 95.79 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 119.573 -1.954 . . . . 0.0 107.084 -173.103 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' J' ' 27' ' ' ASN . . . 92.5 -65.69 2.09 Favored Glycine 0 N--CA 1.473 1.112 0 C-N-CA 119.732 -1.223 . . . . 0.0 114.966 174.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.424 ' HA ' ' O ' ' I' ' 30' ' ' ALA . . . -169.56 155.36 6.03 Favored 'General case' 0 N--CA 1.44 -0.93 0 C-N-CA 116.759 -1.977 . . . . 0.0 115.346 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.477 ' HA ' ' O ' ' K' ' 31' ' ' ILE . 0.8 OUTLIER -135.3 124.96 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 111.065 -2.788 . . . . 0.0 109.628 177.417 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 44.8 mt -108.22 117.12 53.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.93 100.73 1.2 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.785 -2.926 . . . . 0.0 105.785 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -127.86 129.79 47.5 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 114.87 1.433 . . . . 0.0 114.87 -175.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.58 109.92 22.4 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.293 -2.484 . . . . 0.0 104.293 174.185 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.417 ' N ' ' O ' ' K' ' 35' ' ' MET . 2.0 t -125.64 153.19 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.095 0.474 . . . . 0.0 111.497 -175.386 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.47 -101.89 0.2 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.172 178.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.528 ' H ' ' N ' ' K' ' 37' ' ' GLY . . . 99.29 -76.66 0.51 Allowed Glycine 0 CA--C 1.537 1.408 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -177.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.446 ' O ' ' OXT' ' J' ' 40' ' ' VAL . 28.0 m -131.46 161.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 CA-C-N 118.362 1.081 . . . . 0.0 110.482 178.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.446 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 44.8 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.907 -1.044 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.76 131.83 54.7 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.759 0.314 . . . . 0.0 110.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -101.84 107.59 18.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -144.63 149.68 17.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.699 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.561 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -143.2 94.8 2.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.049 178.753 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.615 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 46.8 m170 -119.94 167.57 12.01 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.948 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.435 ' O ' ' CB ' ' L' ' 16' ' ' LYS . 34.9 tp60 -89.76 157.74 17.82 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . 0.419 ' N ' ' HG3' ' K' ' 15' ' ' GLN . 16.3 tttt -140.93 95.41 2.84 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.074 -0.651 . . . . 0.0 110.797 178.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 2.5 mt -131.87 129.62 40.6 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 176.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 3.5 p -118.6 119.33 60.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.476 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 29.9 m-85 -106.05 105.73 15.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 6.0 t80 -113.59 120.31 40.51 Favored 'General case' 0 C--O 1.226 -0.177 0 CA-C-O 120.66 0.267 . . . . 0.0 111.679 -177.352 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.558 ' HA ' ' O ' ' J' ' 21' ' ' ALA . . . -150.66 120.49 7.08 Favored 'General case' 0 C--O 1.245 0.858 0 C-N-CA 119.704 -0.798 . . . . 0.0 110.547 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.563 ' CG ' ' N ' ' K' ' 23' ' ' ASP . 54.5 tt0 -178.18 163.54 1.69 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 116.988 2.218 . . . . 0.0 116.988 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.563 ' N ' ' CG ' ' K' ' 22' ' ' GLU . 19.9 t70 174.05 -74.13 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 112.03 -2.35 . . . . 0.0 106.978 172.681 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.527 ' CG1' ' H ' ' K' ' 25' ' ' GLY . 3.2 p -67.7 -113.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 170.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.593 ' H ' ' HA3' ' J' ' 25' ' ' GLY . . . 134.7 -37.79 1.9 Allowed Glycine 0 CA--C 1.541 1.7 0 N-CA-C 121.421 3.328 . . . . 0.0 121.421 171.426 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.5 t -71.81 118.09 14.21 Favored 'General case' 0 N--CA 1.482 1.167 1 CA-C-N 125.935 4.867 . . . . 0.0 107.28 177.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.658 ' ND2' ' H ' ' K' ' 30' ' ' ALA . 0.5 OUTLIER -103.77 160.58 14.66 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 120.36 1.436 . . . . 0.0 113.127 179.271 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -44.45 -39.85 5.07 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 67.67 0.04 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-O 118.939 -0.923 . . . . 0.0 113.484 -174.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.658 ' H ' ' ND2' ' K' ' 27' ' ' ASN . . . -71.04 156.18 39.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.82 1.81 . . . . 0.0 113.607 -176.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.477 ' O ' ' HA ' ' J' ' 31' ' ' ILE . 82.2 mt -122.92 126.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.92 -178.781 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 13.0 tt -130.96 118.0 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 O-C-N 121.245 -0.91 . . . . 0.0 110.51 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.81 111.62 1.87 Allowed Glycine 0 N--CA 1.466 0.699 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 82.1 mt -122.92 117.3 25.23 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.165 0.507 . . . . 0.0 110.728 -178.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.417 ' O ' ' N ' ' J' ' 36' ' ' VAL . 8.0 mtp -108.3 114.41 28.25 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.404 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 46.2 t -119.65 144.76 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 107.726 -1.212 . . . . 0.0 107.726 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.528 ' N ' ' H ' ' J' ' 38' ' ' GLY . . . -136.51 102.68 0.41 Allowed Glycine 0 C--N 1.32 -0.31 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.104 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' J' ' 40' ' ' VAL . . . -61.28 -67.13 2.26 Favored Glycine 0 CA--C 1.54 1.652 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 176.83 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 16.7 m -143.44 112.86 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.88 -1.057 . . . . 0.0 110.882 -179.713 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.74 130.96 55.62 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.743 0.306 . . . . 0.0 110.305 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -93.56 142.05 27.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.631 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . 0.41 ' C ' ' HE2' ' K' ' 14' ' ' HIS . 2.3 t -115.94 126.24 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 110.044 179.724 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.558 ' ND1' ' OXT' ' I' ' 40' ' ' VAL . 10.8 m-70 -130.86 104.59 7.24 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.214 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.615 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 83.2 t60 -160.61 164.57 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 178.187 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.501 ' O ' ' CD2' ' L' ' 14' ' ' HIS . 88.0 mm-40 -89.76 158.57 17.46 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . 0.435 ' CB ' ' O ' ' K' ' 15' ' ' GLN . 16.7 tttt -140.4 93.93 2.68 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mp -122.72 118.15 27.4 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -102.81 108.06 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.801 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.476 ' CE1' ' CD1' ' K' ' 19' ' ' PHE . 79.7 m-85 -100.32 98.14 8.83 Favored 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 39.7 t80 -108.38 105.15 14.69 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -165.95 171.51 12.53 Favored 'General case' 0 CA--C 1.484 -1.567 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.634 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -75.94 104.71 6.6 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.066 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -147.0 48.01 1.15 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.41 -176.242 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 7.5 p -65.23 169.75 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -92.2 -42.53 4.6 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 118.709 -1.71 . . . . 0.0 113.819 -176.689 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.51 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 4.6 m -67.72 109.49 3.35 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 117.861 -1.536 . . . . 0.0 111.906 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.68 ' O ' ' N ' ' L' ' 29' ' ' GLY . 21.4 m120 -145.21 158.68 43.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 173.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.537 ' C ' ' O ' ' L' ' 27' ' ' ASN . 42.0 tttp -18.2 -43.51 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 CA-C-O 121.936 0.874 . . . . 0.0 111.312 175.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.68 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -178.45 63.33 0.08 OUTLIER Glycine 0 CA--C 1.553 2.411 0 CA-C-N 113.885 -1.507 . . . . 0.0 112.381 177.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.94 163.08 15.74 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.13 1.465 . . . . 0.0 110.019 179.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 22.2 pt -141.15 135.49 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 119.252 -0.979 . . . . 0.0 112.027 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.428 HD12 HG21 ' L' ' 32' ' ' ILE . 96.2 mt -118.53 121.09 66.2 Favored 'Isoleucine or valine' 0 C--N 1.34 0.18 0 CA-C-N 114.73 -1.123 . . . . 0.0 111.227 -179.125 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.11 116.3 2.41 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 179.251 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -126.42 125.65 42.51 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.3 ttm -129.3 130.3 45.98 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.099 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' L' ' 37' ' ' GLY . 55.7 t -124.21 131.87 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -42.56 -111.62 0.0 OUTLIER Glycine 0 N--CA 1.468 0.82 0 CA-C-N 115.483 -0.781 . . . . 0.0 112.631 178.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.99 64.93 3.96 Favored Glycine 0 CA--C 1.532 1.116 0 CA-C-N 114.706 -0.747 . . . . 0.0 111.455 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.424 ' O ' ' CD1' ' R' ' 31' ' ' ILE . 41.8 t -115.9 157.91 16.52 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' L' ' 39' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.616 -178.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.407 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -107.42 131.04 54.71 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.758 0.313 . . . . 0.0 110.662 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.07 166.87 15.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.598 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.0 t -113.65 128.61 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.31 162.67 15.77 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.711 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.483 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 3.4 m-70 -83.33 168.71 16.39 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.652 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -129.2 150.86 50.4 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -97.26 111.81 23.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.353 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.69 114.04 18.14 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.88 132.88 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.357 -179.31 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -133.25 134.83 44.46 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.86 0.362 . . . . 0.0 110.919 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -128.26 131.82 48.74 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.766 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.6 111.14 7.55 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.108 0.48 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -159.1 151.13 20.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.372 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 51.96 46.43 26.61 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.818 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.59 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 39.6 t -80.45 179.89 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.59 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -71.44 -33.75 63.99 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.878 -178.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.594 ' O ' ' O ' ' M' ' 27' ' ' ASN . 25.5 t -162.51 120.61 2.13 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.594 ' O ' ' O ' ' M' ' 26' ' ' SER . 13.6 t30 -22.03 153.22 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.98 0 O-C-N 124.424 1.078 . . . . 0.0 111.976 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -163.17 24.54 0.09 Allowed 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 114.638 1.347 . . . . 0.0 114.638 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.28 106.15 1.11 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 118.539 -1.791 . . . . 0.0 114.913 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . 0.698 ' H ' ' ND2' ' N' ' 27' ' ' ASN . . . -111.48 80.24 1.29 Allowed 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 124.098 1.904 . . . . 0.0 109.999 178.334 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 59.6 mt -130.36 130.01 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-N 110.974 -2.83 . . . . 0.0 108.419 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' N' ' 33' ' ' GLY . 47.1 mt -103.94 106.18 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.952 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.92 97.43 1.14 Allowed Glycine 0 CA--C 1.506 -0.476 0 N-CA-C 105.055 -3.218 . . . . 0.0 105.055 176.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . 0.402 HD13 ' H ' ' M' ' 35' ' ' MET . 52.2 tp -148.95 152.92 37.2 Favored 'General case' 0 N--CA 1.463 0.213 0 C-N-CA 118.308 -1.357 . . . . 0.0 113.826 -174.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 35' ' ' MET . . . . . 0.402 ' H ' HD13 ' M' ' 34' ' ' LEU . 91.7 mmm -110.21 110.31 21.11 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 112.946 -1.934 . . . . 0.0 107.177 178.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 96.4 t -104.29 122.88 57.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 178.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.32 -113.24 0.58 Allowed Glycine 0 C--N 1.309 -0.94 0 N-CA-C 108.419 -1.873 . . . . 0.0 108.419 -178.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.68 -69.57 0.22 Allowed Glycine 0 CA--C 1.533 1.179 0 C-N-CA 121.438 -0.411 . . . . 0.0 112.413 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' M' ' 40' ' ' VAL . 3.1 m -137.57 166.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 122.649 0.38 . . . . 0.0 110.373 -179.608 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.544 ' OXT' ' N ' ' N' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.888 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.88 135.67 49.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.845 0.355 . . . . 0.0 110.395 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -140.71 146.42 37.76 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.023 0.439 . . . . 0.0 110.721 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 70.2 t -126.98 133.66 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.706 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.553 ' ND1' ' CE1' ' O' ' 13' ' ' HIS . 77.1 m80 -102.97 97.66 7.74 Favored 'General case' 0 N--CA 1.471 0.62 0 O-C-N 122.093 -0.38 . . . . 0.0 110.509 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' N' ' 15' ' ' GLN . 1.7 t-80 -159.95 168.53 25.47 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.941 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.636 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 81.9 mt-30 -156.0 142.27 18.38 Favored 'General case' 0 C--N 1.34 0.166 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 178.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -84.73 120.64 26.64 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.822 179.156 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.11 124.03 33.71 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.755 0.312 . . . . 0.0 110.192 178.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.21 131.58 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -129.37 115.58 17.77 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.147 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 t80 -111.9 126.17 54.83 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.0 147.56 31.79 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -177.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -132.46 133.0 43.31 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.016 178.178 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -158.05 46.62 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . 0.516 ' CG1' ' N ' ' N' ' 25' ' ' GLY . 20.8 t -91.79 169.18 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 178.003 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.516 ' N ' ' CG1' ' N' ' 24' ' ' VAL . . . 77.16 34.8 40.24 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.008 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 169.51 -114.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -176.461 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.698 ' ND2' ' H ' ' M' ' 30' ' ' ALA . 28.9 t30 -61.89 170.88 1.87 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.358 0.599 . . . . 0.0 111.782 -177.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.492 ' N ' ' CG ' ' N' ' 27' ' ' ASN . 81.7 tttt -54.15 -39.36 66.44 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.474 -176.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.34 -63.51 0.53 Allowed Glycine 0 CA--C 1.531 1.04 0 C-N-CA 119.639 -1.267 . . . . 0.0 114.107 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.86 99.52 3.81 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 120.319 2.059 . . . . 0.0 115.529 -176.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . 0.419 ' CD1' ' CG2' ' H' ' 39' ' ' VAL . 96.3 mt -122.59 118.94 56.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 114.162 -1.381 . . . . 0.0 107.304 173.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . 0.414 HD12 HG21 ' N' ' 32' ' ' ILE . 74.8 mt -107.71 108.32 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 119.041 -1.064 . . . . 0.0 110.28 178.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -109.08 98.66 1.18 Allowed Glycine 0 C--O 1.234 0.138 0 N-CA-C 104.641 -3.384 . . . . 0.0 104.641 175.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . 0.501 ' CD2' ' N ' ' N' ' 35' ' ' MET . 3.0 tt -145.25 147.84 32.84 Favored 'General case' 0 CA--C 1.506 -0.727 0 C-N-CA 118.352 -1.339 . . . . 0.0 113.065 -174.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 35' ' ' MET . . . . . 0.501 ' N ' ' CD2' ' N' ' 34' ' ' LEU . 12.7 mtp -112.0 115.67 29.31 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 113.215 -1.812 . . . . 0.0 108.786 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.507 ' O ' ' N ' ' O' ' 37' ' ' GLY . 51.4 t -114.59 111.63 36.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 179.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.716 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 135.21 -131.75 5.95 Favored Glycine 0 C--N 1.316 -0.562 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.74 -63.69 4.05 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' N' ' 40' ' ' VAL . 11.4 m -104.52 161.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.952 0.501 . . . . 0.0 110.384 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . 0.56 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 47.5 t . . . . . 0 C--O 1.218 -0.602 0 CA-C-O 117.852 -1.071 . . . . 0.0 111.58 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.29 139.43 44.24 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -102.05 124.28 47.39 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.566 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.44 ' HB ' ' HE2' ' O' ' 14' ' ' HIS . 1.4 m -125.49 125.91 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.553 ' CE1' ' ND1' ' N' ' 13' ' ' HIS . 21.0 m-70 -121.48 122.17 39.15 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 121.193 0.521 . . . . 0.0 112.208 -177.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.524 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 0.6 OUTLIER -150.27 175.95 11.32 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.576 178.38 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.448 ' NE2' ' CD1' ' O' ' 17' ' ' LEU . 39.2 tt0 -152.74 139.75 19.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.587 0.708 . . . . 0.0 109.107 175.593 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . 0.456 ' CG ' ' HE2' ' N' ' 14' ' ' HIS . 61.3 mttt -95.68 108.64 20.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.592 -1.185 . . . . 0.0 111.043 177.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . 0.448 ' CD1' ' NE2' ' O' ' 15' ' ' GLN . 5.0 mt -124.03 109.64 13.77 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 119.293 0.951 . . . . 0.0 108.729 175.678 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -107.39 116.4 50.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.877 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -110.99 103.31 11.77 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.41 ' CD1' ' HB3' ' P' ' 20' ' ' PHE . 2.7 m-85 -110.38 133.92 52.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.354 0.262 . . . . 0.0 110.303 -178.726 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.77 136.56 29.0 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-O 122.99 1.376 . . . . 0.0 114.128 -179.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 26.5 tp10 -93.12 163.79 13.5 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 113.263 -1.79 . . . . 0.0 106.986 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.437 ' OD1' ' OD2' ' P' ' 23' ' ' ASP . 54.5 p-10 -172.93 52.36 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.106 -0.638 . . . . 0.0 111.091 -176.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 13.5 m -74.5 142.17 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 117.981 -1.488 . . . . 0.0 112.47 -174.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.465 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . 98.97 38.14 3.93 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.233 179.623 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.591 ' H ' ' CG1' ' P' ' 24' ' ' VAL . 2.7 p 72.74 120.16 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.11 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' O' ' 27' ' ' ASN . 54.7 p30 -83.62 156.24 22.8 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 115.968 -2.293 . . . . 0.0 109.956 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -48.66 -42.53 34.82 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.874 1.435 . . . . 0.0 114.874 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . 0.443 ' O ' ' CE ' ' N' ' 28' ' ' LYS . . . 160.19 67.37 0.02 OUTLIER Glycine 0 CA--C 1.546 1.998 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.117 -176.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.67 132.22 30.65 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 120.305 2.053 . . . . 0.0 114.155 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.408 ' CD1' ' HB ' ' I' ' 39' ' ' VAL . 9.8 tt -137.36 131.88 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 114.57 -1.196 . . . . 0.0 112.18 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . 0.442 HG23 HD13 ' O' ' 32' ' ' ILE . 71.3 mt -108.25 114.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.378 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.97 94.9 0.77 Allowed Glycine 0 N--CA 1.468 0.792 0 N-CA-C 107.236 -2.345 . . . . 0.0 107.236 177.099 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mm? -121.32 134.6 55.14 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 122.476 1.132 . . . . 0.0 113.264 -176.181 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -113.0 104.41 12.36 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 173.809 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . 0.551 ' O ' ' N ' ' P' ' 37' ' ' GLY . 2.5 t -113.6 103.46 15.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . 136.85 -153.53 21.77 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.663 177.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.636 ' H ' ' H ' ' P' ' 38' ' ' GLY . . . 137.79 -56.29 0.67 Allowed Glycine 0 CA--C 1.543 1.796 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -178.011 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 5.0 p -133.15 154.78 40.05 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.486 ' OXT' ' CG2' ' P' ' 40' ' ' VAL . 17.3 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.999 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -109.07 135.54 50.06 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.579 0.228 . . . . 0.0 110.627 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -73.61 133.19 43.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.946 0.403 . . . . 0.0 110.653 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 43.9 t -136.81 166.29 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.635 -179.668 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.537 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 12.3 m170 -44.22 110.77 0.24 Allowed 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.946 -178.324 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' O ' ' Q' ' 14' ' ' HIS . 55.4 t60 -152.62 154.43 35.35 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.716 HE22 ' N ' ' N' ' 37' ' ' GLY . 81.9 mt-30 -98.47 169.81 9.28 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -158.26 103.99 1.84 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.976 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -134.05 133.28 41.0 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.521 0.677 . . . . 0.0 110.861 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 64.1 t -123.55 120.94 61.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.935 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' N ' ' P' ' 19' ' ' PHE . 5.5 m-85 -112.73 112.3 23.71 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.41 ' HB3' ' CD1' ' O' ' 20' ' ' PHE . 26.4 t80 -125.2 122.47 37.11 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -176.768 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.9 122.09 29.54 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.521 ' CG ' ' N ' ' P' ' 23' ' ' ASP . 69.6 tt0 -167.45 158.97 11.95 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 117.695 2.479 . . . . 0.0 117.695 -176.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.521 ' N ' ' CG ' ' P' ' 22' ' ' GLU . 1.7 p30 150.64 -70.05 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 111.643 -2.526 . . . . 0.0 108.386 175.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.591 ' CG1' ' H ' ' O' ' 26' ' ' SER . 4.4 m -57.05 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 122.099 0.952 . . . . 0.0 109.336 174.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 141.57 -36.25 1.73 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.621 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 m -70.33 114.49 8.51 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 115.916 -2.314 . . . . 0.0 105.18 171.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.718 ' ND2' ' H ' ' P' ' 30' ' ' ALA . 50.3 p-10 -119.98 154.6 34.27 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 121.212 1.824 . . . . 0.0 111.926 176.435 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -34.52 -39.46 0.09 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 173.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' Q' ' 29' ' ' GLY . . . 140.07 74.52 0.05 OUTLIER Glycine 0 CA--C 1.553 2.447 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -175.295 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . 0.718 ' H ' ' ND2' ' P' ' 27' ' ' ASN . . . -70.55 170.14 12.74 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 116.099 1.888 . . . . 0.0 116.099 -173.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . 0.419 ' CD1' ' CB ' ' J' ' 39' ' ' VAL . 0.9 OUTLIER -149.14 143.7 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 CA-C-N 112.739 -2.028 . . . . 0.0 114.907 -176.103 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 3.7 mt -113.12 113.06 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 174.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.38 101.8 1.2 Allowed Glycine 0 N--CA 1.462 0.402 0 N-CA-C 105.82 -2.912 . . . . 0.0 105.82 176.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 9.0 tt -144.49 132.08 21.06 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 122.866 1.317 . . . . 0.0 112.397 -175.543 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 74.0 mtp -120.86 119.59 33.11 Favored 'General case' 0 CA--C 1.495 -1.153 0 CA-C-N 113.163 -1.835 . . . . 0.0 107.512 178.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -95.67 113.85 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.604 -178.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.551 ' N ' ' O ' ' O' ' 36' ' ' VAL . . . -65.64 -123.29 0.01 OUTLIER Glycine 0 CA--C 1.521 0.408 0 CA-C-N 113.871 -1.513 . . . . 0.0 110.799 177.205 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.636 ' H ' ' H ' ' O' ' 38' ' ' GLY . . . 66.64 60.86 5.79 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-N 114.301 -0.95 . . . . 0.0 113.641 179.261 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -84.71 124.14 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.082 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.486 ' CG2' ' OXT' ' O' ' 40' ' ' VAL . 3.1 t . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 118.341 -0.838 . . . . 0.0 112.428 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.29 131.07 55.09 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -141.23 138.23 33.14 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.542 -179.482 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 34.5 m -125.28 129.92 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.435 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.704 ' HE2' ' NE2' ' Q' ' 15' ' ' GLN . 14.2 t60 -136.4 132.98 36.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.912 0.387 . . . . 0.0 110.811 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.583 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 3.7 m80 -145.48 162.58 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.515 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.704 ' NE2' ' HE2' ' Q' ' 13' ' ' HIS . 17.6 mp0 -89.95 157.26 17.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 176.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -141.66 102.34 4.16 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 176.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -131.37 119.47 21.73 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-O 121.389 0.614 . . . . 0.0 111.143 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -107.44 111.8 37.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.429 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 88.3 m-85 -106.63 103.44 12.88 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.015 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.58 ' CE2' ' CD2' ' R' ' 20' ' ' PHE . 26.1 t80 -110.01 119.34 39.01 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.47 128.34 21.91 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.424 0.63 . . . . 0.0 111.349 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 38.9 tt0 -91.29 109.96 21.25 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 99.1 m-20 -141.96 48.27 1.6 Allowed 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.212 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -72.86 160.56 5.27 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.481 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.82 -30.04 8.42 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.7 t 61.46 109.96 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 118.903 -0.57 . . . . 0.0 112.157 177.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.744 ' O ' ' N ' ' Q' ' 29' ' ' GLY . 14.9 t-20 -129.41 159.74 35.27 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -29.53 48.82 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 N-CA-C 117.641 2.46 . . . . 0.0 117.641 -178.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . 0.744 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -171.93 52.61 0.18 Allowed Glycine 0 CA--C 1.536 1.399 0 CA-C-N 120.552 1.524 . . . . 0.0 112.34 171.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.04 95.06 9.57 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.819 1.809 . . . . 0.0 111.295 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 49.4 mt -133.36 123.98 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 CA-C-N 120.66 1.573 . . . . 0.0 112.687 -178.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -126.97 121.97 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.636 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.75 114.05 2.01 Favored Glycine 0 N--CA 1.467 0.76 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.387 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 89.8 mt -124.98 119.73 29.57 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.504 0.192 . . . . 0.0 110.576 -178.755 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 82.1 mtp -127.93 124.4 37.27 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 64.2 t -115.93 146.9 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.503 -0.555 . . . . 0.0 109.503 178.48 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.91 102.29 0.41 Allowed Glycine 0 C--N 1.315 -0.634 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.99 -71.09 0.65 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-O 121.559 0.533 . . . . 0.0 111.945 178.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.468 ' O ' ' CB ' ' Q' ' 40' ' ' VAL . 2.4 m -126.2 119.01 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.468 ' CB ' ' O ' ' Q' ' 39' ' ' VAL . 61.1 t . . . . . 0 N--CA 1.487 1.403 0 C-N-CA 124.34 1.056 . . . . 0.0 109.882 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -115.22 140.57 48.98 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -73.48 129.99 39.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.458 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 72.0 t -126.07 131.86 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.115 0.483 . . . . 0.0 110.343 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -132.84 95.72 3.64 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.711 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' OE1' ' R' ' 15' ' ' GLN . 84.8 t60 -155.36 161.93 40.93 Favored 'General case' 0 C--O 1.222 -0.349 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.489 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.515 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.2 OUTLIER -90.17 159.8 16.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.867 0.365 . . . . 0.0 111.452 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 57.7 tttt -139.96 107.12 5.47 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.224 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . 0.64 ' N ' ' CD2' ' R' ' 17' ' ' LEU . 0.0 OUTLIER -126.82 121.3 31.53 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.694 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -104.34 111.31 33.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 177.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -103.44 103.77 13.78 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CE2' ' Q' ' 20' ' ' PHE . 62.3 t80 -114.07 109.2 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.352 0.596 . . . . 0.0 109.58 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.47 125.08 33.49 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -81.98 114.38 20.52 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.719 -178.394 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.401 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.0 t0 -150.24 46.27 0.9 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.671 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.451 ' CG1' ' H ' ' R' ' 25' ' ' GLY . 24.1 t -96.02 175.93 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . 0.451 ' H ' ' CG1' ' R' ' 24' ' ' VAL . . . 70.96 26.97 72.99 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 26' ' ' SER . . . . . 0.48 ' O ' ' O ' ' R' ' 27' ' ' ASN . 28.5 t -153.37 120.29 5.71 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.101 0.476 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.48 ' O ' ' O ' ' R' ' 26' ' ' SER . 16.3 m120 -42.07 178.78 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.663 -179.198 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -72.58 45.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.923 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.446 ' H ' ' C ' ' R' ' 27' ' ' ASN . . . -92.08 59.53 2.74 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.525 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.37 165.86 33.69 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 122.545 -0.385 . . . . 0.0 110.33 -178.38 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . 0.424 ' CD1' ' O ' ' L' ' 39' ' ' VAL . 93.6 mt -109.95 119.01 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.261 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 18.6 tt -130.37 124.07 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.921 0.391 . . . . 0.0 110.223 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.43 120.3 3.66 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 42.9 mt -121.48 121.57 37.81 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -179.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 75.4 mtp -128.95 131.03 47.46 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.45 0.643 . . . . 0.0 112.175 -179.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -134.38 142.67 40.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.935 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.63 -102.31 0.2 Allowed Glycine 0 C--N 1.306 -1.097 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' R' ' 39' ' ' VAL . . . 109.06 -71.85 0.2 Allowed Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.11 -0.828 . . . . 0.0 112.055 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . 0.452 ' C ' ' O ' ' R' ' 38' ' ' GLY . 94.1 t -29.95 123.03 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 118.492 1.146 . . . . 0.0 111.657 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . 0.442 ' H ' HG22 ' F' ' 31' ' ' ILE . 91.7 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.974 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -112.7 137.63 50.7 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.812 0.339 . . . . 0.0 110.444 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.5 134.17 33.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.458 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 m -123.05 131.41 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.389 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 75.1 t60 -137.67 141.01 41.13 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.257 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 15' ' ' GLN . 0.4 OUTLIER -84.58 166.62 17.02 Favored 'General case' 0 CA--C 1.532 0.267 0 CA-C-O 121.248 0.547 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.625 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 83.0 mt-30 -157.45 143.09 17.36 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.071 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -81.07 134.36 35.65 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.334 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.92 116.56 22.39 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -125.26 133.68 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.054 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -140.33 139.52 35.43 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.016 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.526 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.1 p90 -126.46 127.81 45.97 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.65 116.22 29.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.302 0.572 . . . . 0.0 111.018 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -142.4 120.9 12.46 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 58.44 46.43 15.16 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.14 -179.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.573 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 40.1 t -75.96 179.71 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.573 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -88.96 27.71 7.16 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.047 -178.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.438 ' O ' ' C ' ' A' ' 27' ' ' ASN . 7.8 t -170.19 -136.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' SER . 99.5 m-20 -32.48 133.96 0.11 Allowed 'General case' 0 N--CA 1.472 0.664 0 CA-C-O 119.304 -0.379 . . . . 0.0 110.662 177.312 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' B' ' 22' ' ' GLU . 52.3 mtpt -118.36 -38.34 3.19 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 120.123 -0.631 . . . . 0.0 112.271 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.7 -78.59 0.93 Allowed Glycine 0 N--CA 1.468 0.792 0 C-N-CA 118.951 -1.595 . . . . 0.0 112.919 -177.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.56 93.64 0.2 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.938 -0.705 . . . . 0.0 112.114 178.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 92.7 mt -126.28 104.73 13.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.408 HG21 HD13 ' A' ' 32' ' ' ILE . 96.5 mt -110.57 112.01 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.099 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.609 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.6 92.66 0.5 Allowed Glycine 0 CA--C 1.508 -0.383 0 N-CA-C 104.356 -3.498 . . . . 0.0 104.356 176.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 91.5 mt -151.79 177.95 9.88 Favored 'General case' 0 CA--C 1.51 -0.594 0 CA-C-O 122.969 1.366 . . . . 0.0 111.985 -175.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 31.4 mtp -140.38 119.38 12.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 113.096 -1.865 . . . . 0.0 108.902 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 1.7 m -131.97 113.56 22.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 178.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 154.38 -124.64 1.58 Allowed Glycine 0 C--N 1.307 -1.058 0 N-CA-C 109.106 -1.597 . . . . 0.0 109.106 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.62 -67.03 3.6 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.977 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.447 ' CG2' ' N ' ' A' ' 40' ' ' VAL . 2.4 p -115.56 166.49 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.447 ' N ' ' CG2' ' A' ' 39' ' ' VAL . 9.8 m . . . . . 0 N--CA 1.472 0.646 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.58 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -106.27 133.21 51.33 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -93.17 106.02 18.03 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.788 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -128.9 130.81 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 81.3 t60 -134.16 105.76 6.83 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.814 0.34 . . . . 0.0 111.166 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.635 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 4.5 t60 -157.12 167.37 30.59 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.584 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.59 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 84.3 mt-30 -154.75 141.84 19.33 Favored 'General case' 0 C--N 1.339 0.127 0 N-CA-C 109.627 -0.509 . . . . 0.0 109.627 177.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -85.53 131.5 34.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.624 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -122.16 120.97 35.79 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 118.121 0.419 . . . . 0.0 110.117 177.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -124.61 131.97 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -131.14 123.29 28.24 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.616 -179.069 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -112.79 124.85 53.52 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.352 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.15 126.28 45.89 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -178.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' A' ' 28' ' ' LYS . 79.0 tt0 -115.07 162.98 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.912 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -178.81 48.71 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 122.337 0.255 . . . . 0.0 110.443 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 2.7 t -72.57 161.05 5.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 122.363 1.077 . . . . 0.0 112.749 -174.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 107.07 -34.71 5.52 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 113.051 -1.886 . . . . 0.0 112.588 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' B' ' 27' ' ' ASN . 89.2 p -162.46 120.07 2.08 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.831 1.315 . . . . 0.0 113.851 177.811 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.604 ' ND2' ' ND2' ' C' ' 27' ' ' ASN . 18.0 t-20 -22.37 153.41 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.362 0.665 . . . . 0.0 111.644 174.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.461 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 56.3 tttt -165.45 26.5 0.05 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.72 107.93 0.38 Allowed Glycine 0 N--CA 1.47 0.944 0 C-N-CA 118.239 -1.934 . . . . 0.0 115.7 174.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -120.47 105.23 10.66 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-O 122.363 1.078 . . . . 0.0 108.136 177.582 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.416 ' CD1' ' O ' ' N' ' 38' ' ' GLY . 2.6 mt -133.49 135.63 55.67 Favored 'Isoleucine or valine' 0 C--N 1.346 0.435 0 CA-C-N 114.746 -1.116 . . . . 0.0 113.163 -176.036 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 94.1 mt -113.15 110.78 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.383 176.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.01 102.33 1.07 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 105.327 -3.109 . . . . 0.0 105.327 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 12.2 tp -146.67 144.42 29.46 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 117.828 -1.549 . . . . 0.0 114.765 -174.139 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.43 114.81 29.06 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 112.277 -2.238 . . . . 0.0 108.299 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 17.0 t -133.21 123.2 46.98 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 119.916 -0.714 . . . . 0.0 110.938 -179.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.7 -113.74 1.02 Allowed Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.7 -72.72 2.58 Favored Glycine 0 CA--C 1.536 1.348 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.431 ' CG1' ' N ' ' B' ' 40' ' ' VAL . 47.6 t -134.31 164.56 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 122.463 -0.434 . . . . 0.0 110.946 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.446 ' CG2' ' O ' ' C' ' 39' ' ' VAL . 53.1 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.886 -1.054 . . . . 0.0 109.961 178.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.142 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -81.93 140.28 34.14 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -139.08 139.36 37.71 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.871 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 130.96 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.602 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 33.2 m80 -145.7 101.43 3.56 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 120.107 -0.637 . . . . 0.0 112.183 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.635 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.0 p-80 -155.89 155.0 32.12 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 118.415 -1.314 . . . . 0.0 111.95 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -90.48 161.19 15.63 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.416 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . 0.417 ' HD2' ' HE2' ' B' ' 14' ' ' HIS . 99.0 mttt -139.32 112.65 8.22 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 175.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 3.6 mt -116.24 111.48 20.22 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.475 -179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 t -111.08 110.12 31.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 96.0 m-85 -110.32 113.09 25.48 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -112.32 124.88 53.45 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.676 -0.238 . . . . 0.0 110.505 -178.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . 0.57 ' O ' ' NZ ' ' C' ' 28' ' ' LYS . . . -131.78 136.77 47.8 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.508 0.671 . . . . 0.0 112.724 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.442 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 15.5 pt-20 -163.81 133.2 3.98 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.3 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -150.02 -60.3 0.2 Allowed 'General case' 0 C--N 1.353 0.758 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.56 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.489 ' CG1' ' N ' ' C' ' 25' ' ' GLY . 35.9 t -94.15 170.55 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 117.378 -1.729 . . . . 0.0 112.579 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.489 ' N ' ' CG1' ' C' ' 24' ' ' VAL . . . -81.51 27.83 3.2 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.404 173.827 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.626 ' HG ' ' H ' ' C' ' 27' ' ' ASN . 4.8 t -170.56 -138.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 118.947 1.374 . . . . 0.0 112.75 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.626 ' H ' ' HG ' ' C' ' 26' ' ' SER . 66.4 t30 -34.52 127.69 0.46 Allowed 'General case' 0 C--N 1.349 0.547 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.178 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.629 ' NZ ' ' N ' ' D' ' 22' ' ' GLU . 71.2 tttt -104.94 -42.16 5.41 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . 81.18 60.88 2.18 Favored Glycine 0 CA--C 1.543 1.812 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.528 ' N ' ' OG ' ' D' ' 26' ' ' SER . . . -110.21 112.39 24.34 Favored 'General case' 0 C--N 1.361 1.101 0 CA-C-O 123.237 1.494 . . . . 0.0 114.077 -175.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 1.1 tt -134.63 127.19 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 112.218 -2.264 . . . . 0.0 109.228 179.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 29.2 mt -106.56 116.32 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.213 -179.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.97 106.36 1.62 Allowed Glycine 0 N--CA 1.466 0.695 0 N-CA-C 106.551 -2.619 . . . . 0.0 106.551 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -133.05 134.63 44.61 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 114.128 1.159 . . . . 0.0 114.128 -174.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -113.02 98.94 7.48 Favored 'General case' 0 N--CA 1.432 -1.338 0 N-CA-C 101.591 -3.485 . . . . 0.0 101.591 173.058 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.02 132.22 65.61 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 N-CA-C 114.76 1.393 . . . . 0.0 114.76 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.09 111.97 1.25 Allowed Glycine 0 CA--C 1.521 0.461 0 CA-C-N 114.267 -1.333 . . . . 0.0 113.194 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -97.9 -60.51 0.92 Allowed Glycine 0 CA--C 1.54 1.609 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 176.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.446 ' O ' ' CG2' ' B' ' 40' ' ' VAL . 10.0 p -145.06 150.5 15.93 Favored 'Isoleucine or valine' 0 C--N 1.342 0.269 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.497 ' OXT' ' ND1' ' E' ' 13' ' ' HIS . 9.8 p . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.534 -179.232 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -115.59 138.01 51.49 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.014 0.435 . . . . 0.0 110.745 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -71.97 140.61 49.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.136 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 22.0 m -126.23 109.99 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.433 0.635 . . . . 0.0 110.594 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.602 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 2.5 t60 -126.83 127.87 45.66 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.694 -178.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.575 ' HE2' ' CE1' ' C' ' 14' ' ' HIS . 1.5 p-80 -134.19 164.39 27.46 Favored 'General case' 0 C--O 1.221 -0.396 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.165 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 44.4 tp60 -90.1 151.51 21.58 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 178.093 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -150.33 97.13 2.5 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 7.4 mt -123.29 121.56 36.15 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.07 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -114.89 106.54 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -107.78 106.0 16.1 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 177.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -116.76 129.38 56.08 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.787 -175.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . 0.573 ' CB ' ' NZ ' ' C' ' 28' ' ' LYS . . . -133.86 128.73 35.26 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-O 121.54 0.686 . . . . 0.0 111.295 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.629 ' N ' ' NZ ' ' C' ' 28' ' ' LYS . 98.9 mt-10 -95.13 139.4 31.51 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.381 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.501 ' O ' ' O ' ' D' ' 24' ' ' VAL . 9.9 m-20 65.36 47.92 2.22 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 177.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.501 ' O ' ' O ' ' D' ' 23' ' ' ASP . 5.2 m -52.45 -175.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 119.215 -0.994 . . . . 0.0 108.433 177.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 165.43 19.46 0.02 OUTLIER Glycine 0 CA--C 1.523 0.548 0 C-N-CA 118.252 -1.928 . . . . 0.0 113.342 -177.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.528 ' OG ' ' N ' ' C' ' 30' ' ' ALA . 5.2 m -80.33 -130.37 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' CG1' ' P' ' 39' ' ' VAL . 9.7 m120 -100.48 149.78 23.33 Favored 'General case' 0 CA--C 1.516 -0.332 0 C-N-CA 119.048 -1.061 . . . . 0.0 109.745 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.477 ' HZ2' ' C ' ' R' ' 40' ' ' VAL . 95.8 mttt 37.78 42.54 0.41 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.346 -1.297 . . . . 0.0 110.887 -177.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.56 -66.42 2.32 Favored Glycine 0 CA--C 1.545 1.947 0 CA-C-N 116.514 -0.312 . . . . 0.0 113.245 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.21 165.41 9.06 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.525 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 11.9 tt -129.59 129.92 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.733 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.4 HD13 HG21 ' D' ' 32' ' ' ILE . 75.1 mt -113.52 112.68 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.761 178.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.64 97.01 1.39 Allowed Glycine 0 C--O 1.239 0.409 0 N-CA-C 104.226 -3.55 . . . . 0.0 104.226 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 64.9 tp -117.09 121.54 41.59 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -173.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -112.03 97.93 7.0 Favored 'General case' 0 N--CA 1.433 -1.3 0 N-CA-C 103.796 -2.668 . . . . 0.0 103.796 173.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.591 ' CG2' HE22 ' E' ' 15' ' ' GLN . 14.3 p -119.09 120.84 65.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.268 0 C-N-CA 119.714 -0.794 . . . . 0.0 110.454 -177.202 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -99.51 121.88 7.37 Favored Glycine 0 C--N 1.332 0.345 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' E' ' 39' ' ' VAL . . . -119.24 62.07 0.47 Allowed Glycine 0 CA--C 1.532 1.149 0 CA-C-O 119.035 -0.869 . . . . 0.0 112.532 178.076 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 49.2 t -84.3 130.04 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 119.324 1.562 . . . . 0.0 109.742 179.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 16.9 m . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.284 179.438 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -110.79 134.79 52.2 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.655 0.264 . . . . 0.0 110.302 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 73.1 tt0 -105.54 137.59 43.13 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.994 -179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.473 HG12 ' H ' ' F' ' 12' ' ' VAL . 4.2 p -139.52 156.39 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.916 0.389 . . . . 0.0 111.42 -178.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.497 ' ND1' ' OXT' ' C' ' 40' ' ' VAL . 7.7 p80 -74.19 125.06 27.55 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.194 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 52.6 p-80 -154.05 166.36 33.28 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.339 178.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.591 HE22 ' CG2' ' D' ' 36' ' ' VAL . 16.8 tt0 -89.84 151.71 21.63 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 178.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -149.57 105.27 3.43 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.858 177.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -117.59 117.06 28.38 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.893 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 103.88 15.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.639 ' CE2' ' CE1' ' F' ' 19' ' ' PHE . 3.7 m-30 -106.54 109.12 20.94 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.153 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -129.72 130.9 46.05 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 120.058 -0.657 . . . . 0.0 112.521 -176.24 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.409 ' HA ' ' O ' ' D' ' 21' ' ' ALA . . . -124.47 133.18 53.43 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.936 178.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 92.0 mt-10 -127.18 170.64 12.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 116.982 2.216 . . . . 0.0 116.982 -176.007 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.454 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 11.4 p30 48.18 46.31 19.77 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 110.722 -2.944 . . . . 0.0 116.167 177.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.41 HG21 ' H ' ' E' ' 26' ' ' SER . 15.7 m -72.12 -168.79 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.247 -0.981 . . . . 0.0 108.947 174.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.42 36.81 3.96 Favored Glycine 0 N--CA 1.467 0.725 0 N-CA-C 105.815 -2.914 . . . . 0.0 105.815 172.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.41 ' H ' HG21 ' E' ' 24' ' ' VAL . 21.3 t 61.63 111.21 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 113.339 -1.43 . . . . 0.0 107.844 -175.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.481 ' O ' ' N ' ' E' ' 29' ' ' GLY . 98.8 m-20 -130.0 161.1 31.7 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.433 ' C ' ' O ' ' E' ' 27' ' ' ASN . 98.3 mttt -28.63 -40.27 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.294 173.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.481 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 107.68 -63.45 0.28 Allowed Glycine 0 CA--C 1.54 1.611 0 CA-C-O 117.096 -1.947 . . . . 0.0 115.968 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.426 ' CB ' ' O ' ' E' ' 29' ' ' GLY . . . -179.75 168.89 1.34 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 122.903 3.351 . . . . 0.0 115.915 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 91.2 mt -119.53 125.09 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 111.18 -2.736 . . . . 0.0 106.087 175.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 89.5 mt -130.49 128.76 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.94 106.28 1.01 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.445 ' C ' ' CD2' ' E' ' 34' ' ' LEU . 7.3 tt -115.61 122.75 46.55 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-O 120.926 0.393 . . . . 0.0 111.672 -176.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 8.2 mtp -118.76 126.07 51.04 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.635 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.439 ' HB ' ' H ' ' F' ' 37' ' ' GLY . 59.1 t -90.68 156.38 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 121.142 0.496 . . . . 0.0 111.052 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.456 ' O ' ' N ' ' E' ' 39' ' ' VAL . . . -102.13 102.5 2.33 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.299 -179.321 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.56 -73.56 0.0 OUTLIER Glycine 0 CA--C 1.541 1.676 0 N-CA-C 115.567 0.987 . . . . 0.0 115.567 177.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' D' ' 38' ' ' GLY . 6.6 p -129.05 153.85 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-N 118.577 1.189 . . . . 0.0 111.64 -178.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 67.8 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.037 -0.982 . . . . 0.0 110.695 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.6 t80 -72.47 129.52 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.842 0.354 . . . . 0.0 110.611 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -141.43 140.26 33.58 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.56 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.473 ' H ' HG12 ' E' ' 12' ' ' VAL . 67.9 t -124.46 127.5 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.952 0.882 . . . . 0.0 111.439 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 5.8 p80 -126.51 103.29 7.52 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.981 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.43 ' CD2' ' N ' ' F' ' 14' ' ' HIS . 0.3 OUTLIER -148.08 169.38 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.423 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -89.58 156.88 18.32 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 119.227 -0.989 . . . . 0.0 110.65 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.21 104.71 4.68 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -124.76 112.31 16.56 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -107.13 107.16 22.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.639 ' CE1' ' CE2' ' E' ' 19' ' ' PHE . 13.1 m-85 -118.89 108.78 15.22 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.525 ' CE2' ' O ' ' F' ' 21' ' ' ALA . 57.7 t80 -148.76 163.32 37.7 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.33 1.062 . . . . 0.0 113.234 -178.428 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.525 ' O ' ' CE2' ' F' ' 20' ' ' PHE . . . -137.62 138.34 39.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.582 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -77.94 112.67 15.07 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 p30 -174.18 48.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.244 -176.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 35.3 m -71.86 160.57 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.043 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.5 -34.66 5.26 Favored Glycine 0 CA--C 1.521 0.409 0 N-CA-C 105.724 -2.95 . . . . 0.0 105.724 -175.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 40.5 t -80.55 120.12 24.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 112.25 -1.975 . . . . 0.0 109.524 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.567 ' O ' ' N ' ' F' ' 29' ' ' GLY . 64.7 t30 -87.43 -175.8 5.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.59 -177.559 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.521 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 99.0 mttt -49.58 49.59 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 115.44 1.644 . . . . 0.0 115.44 -176.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.567 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -101.75 51.42 0.92 Allowed Glycine 0 CA--C 1.545 1.921 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.222 177.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.2 170.19 14.39 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 97.1 mt -119.73 124.68 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 33.7 pt -135.79 137.18 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 121.215 0.531 . . . . 0.0 111.218 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.96 120.31 2.34 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 6.2 tt -118.54 121.98 41.55 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 4.8 ttm -119.25 120.37 36.81 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.958 0.409 . . . . 0.0 111.101 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.472 ' O ' ' O ' ' F' ' 37' ' ' GLY . 22.4 m -87.12 131.8 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.076 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -46.97 -111.82 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 121.918 0.732 . . . . 0.0 112.103 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.64 -71.36 0.83 Allowed Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.364 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -102.5 128.58 55.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-O 121.339 0.59 . . . . 0.0 110.751 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.585 -179.982 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -80.54 143.16 33.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.832 0.349 . . . . 0.0 110.805 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -122.68 164.56 18.04 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.268 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.08 131.4 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.25 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 37.8 p-80 -143.69 161.09 39.46 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.509 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.41 ' CE1' ' CD2' ' H' ' 13' ' ' HIS . 72.3 m80 -150.22 173.48 13.89 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.154 -179.607 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 29.7 pt20 -92.33 150.27 20.94 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -101.31 151.16 22.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.131 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 tp -137.45 124.83 21.92 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.561 0.696 . . . . 0.0 111.681 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 65.8 t -124.82 129.97 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 114.99 -1.004 . . . . 0.0 108.819 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -134.27 130.63 37.37 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.198 0.523 . . . . 0.0 111.285 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.6 p90 -135.67 128.37 30.91 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.752 179.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.6 138.37 54.56 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.801 0.334 . . . . 0.0 110.898 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -81.96 -168.78 2.07 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.593 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -36.38 -60.46 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.406 -179.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 4.1 t -72.73 160.68 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.499 0.666 . . . . 0.0 111.72 -178.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.29 -35.21 4.97 Favored Glycine 0 N--CA 1.466 0.671 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.077 177.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.438 ' OG ' ' OD1' ' H' ' 23' ' ' ASP . 38.7 m -80.71 119.36 23.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 178.32 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.552 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 15.4 t-20 -88.38 178.91 6.44 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.618 -179.725 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.552 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 77.4 tttt -56.09 -36.55 68.27 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.869 -1.06 . . . . 0.0 111.685 178.799 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.65 82.15 0.45 Allowed Glycine 0 CA--C 1.53 1.018 0 CA-C-N 114.127 -1.397 . . . . 0.0 113.508 -174.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.95 102.98 13.59 Favored 'General case' 0 C--O 1.242 0.698 0 CA-C-O 124.132 1.92 . . . . 0.0 109.775 -178.555 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 53.1 mt -126.45 132.54 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 CA-C-N 110.506 -3.043 . . . . 0.0 108.868 -177.459 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 33.5 mt -103.66 110.79 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 176.359 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.81 104.98 1.44 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 107.524 -2.23 . . . . 0.0 107.524 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.415 HD12 ' H ' ' G' ' 35' ' ' MET . 50.7 tp -163.0 152.79 15.67 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 117.976 -1.49 . . . . 0.0 113.64 -177.274 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.415 ' H ' HD12 ' G' ' 34' ' ' LEU . 45.4 tpp -100.03 116.87 33.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 112.572 -2.103 . . . . 0.0 107.953 178.036 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -123.09 112.1 32.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.53 -131.88 10.75 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.47 -62.66 0.31 Allowed Glycine 0 CA--C 1.54 1.648 0 C-N-CA 121.436 -0.411 . . . . 0.0 112.442 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.59 ' CG2' ' NZ ' ' N' ' 28' ' ' LYS . 12.6 p -116.22 160.47 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 C-N-CA 122.542 0.337 . . . . 0.0 110.936 -179.554 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.512 ' N ' ' CG1' ' H' ' 39' ' ' VAL . 24.7 t . . . . . 0 N--CA 1.471 0.588 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.401 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -83.21 139.76 32.95 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.727 0.298 . . . . 0.0 110.509 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.34 140.76 39.62 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.5 t -129.96 134.51 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.636 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.41 ' CD2' ' CE1' ' G' ' 14' ' ' HIS . 20.6 t-160 -129.58 100.46 5.54 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.825 0.345 . . . . 0.0 110.843 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 0.1 OUTLIER -159.3 171.98 18.84 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.128 179.851 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.645 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 84.6 mt-30 -152.2 141.31 21.3 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 178.092 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -88.08 114.53 24.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.79 178.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 70.8 mt -119.55 112.99 20.04 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -120.77 131.12 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 120.792 0.329 . . . . 0.0 111.441 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -133.15 116.15 15.92 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.585 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' CD2' ' I' ' 20' ' ' PHE . 10.4 m-85 -122.65 134.84 54.48 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.11 127.83 23.33 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 80.3 tt0 -95.02 117.38 30.06 Favored 'General case' 0 CA--C 1.522 -0.101 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 176.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.45 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 84.5 m-20 -136.05 46.99 2.26 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -175.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 17.0 t -99.88 162.98 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 C-N-CA 118.013 -1.475 . . . . 0.0 108.386 -179.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 70.99 28.58 70.27 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -178.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.532 ' OG ' ' N ' ' H' ' 27' ' ' ASN . 20.0 p -170.53 -132.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.801 0.81 . . . . 0.0 112.467 -175.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.532 ' N ' ' OG ' ' H' ' 26' ' ' SER . 1.6 m120 -30.7 143.67 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 114.1 -1.409 . . . . 0.0 113.713 -177.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -132.53 -25.14 1.95 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 113.609 -1.632 . . . . 0.0 111.224 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.83 109.37 2.83 Favored Glycine 0 N--CA 1.47 0.913 0 CA-C-N 116.187 -0.46 . . . . 0.0 113.376 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 111.99 12.61 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 122.385 1.088 . . . . 0.0 112.621 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 14.9 tt -140.34 137.99 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 114.515 -1.22 . . . . 0.0 111.124 178.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.439 HG21 HD13 ' H' ' 32' ' ' ILE . 95.5 mt -106.19 113.88 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.609 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.74 100.67 1.13 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 106.631 -2.588 . . . . 0.0 106.631 176.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 90.7 mt -141.76 153.45 44.59 Favored 'General case' 0 CA--C 1.51 -0.564 0 CA-C-O 122.844 1.307 . . . . 0.0 113.586 -175.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 4.1 mtp -116.87 117.18 29.02 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 112.498 -2.137 . . . . 0.0 105.939 176.002 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' K' ' 15' ' ' GLN . 58.9 t -123.56 102.42 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 O-C-N 122.469 -0.144 . . . . 0.0 111.35 -176.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.64 -162.37 23.76 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.437 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 146.71 -55.64 0.52 Allowed Glycine 0 CA--C 1.547 2.093 0 CA-C-O 119.572 -0.571 . . . . 0.0 112.561 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.512 ' CG1' ' N ' ' G' ' 40' ' ' VAL . 3.0 p -142.44 162.51 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-N 118.498 1.149 . . . . 0.0 110.248 178.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.854 178.877 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . 0.514 ' CD1' ' O ' ' J' ' 9' ' ' GLY . 97.7 m-85 -99.28 132.59 44.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.723 0.297 . . . . 0.0 110.572 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.5 ' CD ' ' N ' ' I' ' 11' ' ' GLU . 2.0 pm0 -154.4 141.25 19.14 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.054 0.454 . . . . 0.0 111.446 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -126.81 129.35 71.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.968 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 18.7 m80 -116.25 138.88 50.93 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 110.35 -0.241 . . . . 0.0 110.35 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -149.85 167.85 25.4 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.351 177.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -139.22 141.07 37.91 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -129.8 104.3 7.32 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.394 179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -111.9 113.29 25.53 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 t -109.08 107.48 22.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 57.7 m-85 -109.05 108.45 19.16 Favored 'General case' 0 CA--C 1.546 0.821 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.447 ' CD2' ' CE2' ' H' ' 20' ' ' PHE . 5.4 m-85 -117.5 130.42 56.43 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 122.184 -0.322 . . . . 0.0 110.917 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.29 134.22 30.69 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.563 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 85.5 mt-10 -92.4 -161.33 0.82 Allowed 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.217 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.563 ' OD1' ' O ' ' I' ' 22' ' ' GLU . 0.4 OUTLIER 95.12 54.2 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 -177.689 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 1.1 m -81.3 133.49 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 CA-C-O 125.133 2.397 . . . . 0.0 116.264 -169.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.611 ' H ' ' HA ' ' J' ' 23' ' ' ASP . . . 94.5 -41.99 2.5 Favored Glycine 0 N--CA 1.443 -0.869 2 CA-C-N 107.471 -4.422 . . . . 0.0 113.594 172.516 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 94.6 p -68.39 110.85 4.31 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 115.976 -1.964 . . . . 0.0 112.039 174.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.749 ' ND2' ' H ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -147.66 124.47 11.23 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 123.313 2.778 . . . . 0.0 111.566 166.739 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.406 ' C ' ' O ' ' I' ' 27' ' ' ASN . 94.0 mttt -18.11 -52.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 115.638 1.718 . . . . 0.0 115.638 172.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.61 52.77 0.02 OUTLIER Glycine 0 CA--C 1.563 3.08 0 CA-C-N 112.584 -2.098 . . . . 0.0 109.661 -175.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.749 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . -41.98 141.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -171.221 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 55.0 mt -143.19 147.79 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 112.831 -1.986 . . . . 0.0 113.701 -177.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 27.3 mt -110.58 111.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 174.546 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.09 104.57 1.96 Allowed Glycine 0 N--CA 1.466 0.643 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mt -141.14 144.56 34.91 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -175.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 49.2 tpp -112.85 115.67 28.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 104.644 -2.354 . . . . 0.0 104.644 173.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.443 ' O ' ' N ' ' J' ' 37' ' ' GLY . 47.5 t -123.44 102.62 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 118.055 0.389 . . . . 0.0 111.874 -175.767 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.693 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 107.31 -161.93 13.54 Favored Glycine 0 N--CA 1.467 0.714 0 C-N-CA 120.486 -0.864 . . . . 0.0 112.803 177.557 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.734 ' H ' ' H ' ' J' ' 38' ' ' GLY . . . 148.15 -55.35 0.5 Allowed Glycine 0 CA--C 1.542 1.75 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 18.2 t -114.43 130.46 68.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 C-N-CA 123.409 0.684 . . . . 0.0 109.217 178.554 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.898 179.247 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . 0.514 ' O ' ' CD1' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -117.13 143.83 45.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.675 0.274 . . . . 0.0 110.434 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -73.68 108.58 6.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.86 0.362 . . . . 0.0 110.677 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.7 136.64 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.31 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -145.87 126.07 13.85 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.948 -0.301 . . . . 0.0 111.159 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 m-70 -140.41 157.57 45.33 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.012 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -90.31 158.85 16.95 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 174.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 44.1 tttp -141.18 113.55 8.09 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.163 177.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.401 HD12 ' N ' ' J' ' 17' ' ' LEU . 2.8 mp -136.61 127.94 28.28 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.755 0.788 . . . . 0.0 110.84 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -112.95 112.23 39.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 CA-C-N 114.464 -1.244 . . . . 0.0 108.76 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' K' ' 19' ' ' PHE . 18.5 m-85 -106.98 106.33 16.8 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.598 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 20.4 t80 -113.79 114.8 26.81 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.53 122.59 22.62 Favored 'General case' 0 C--O 1.246 0.9 0 CA-C-O 122.153 0.977 . . . . 0.0 111.829 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 96.5 mt-10 -83.89 125.46 32.01 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-N 113.824 -1.535 . . . . 0.0 107.861 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.611 ' HA ' ' H ' ' I' ' 25' ' ' GLY . 61.2 m-20 -166.45 47.29 0.07 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 118.158 -0.925 . . . . 0.0 113.393 -174.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.563 ' N ' ' OE1' ' K' ' 22' ' ' GLU . 9.3 p -98.6 161.31 3.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 CA-C-N 121.419 1.918 . . . . 0.0 109.286 -176.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.653 ' H ' ' N ' ' K' ' 25' ' ' GLY . . . 73.23 28.87 65.3 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 106.662 -2.575 . . . . 0.0 106.662 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 8.7 t -104.5 -120.75 0.21 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 -173.255 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.415 ' OD1' ' O ' ' I' ' 27' ' ' ASN . 2.2 m120 -81.8 163.75 22.14 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -175.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -47.47 -36.82 10.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 112.661 -2.063 . . . . 0.0 114.504 178.075 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.8 77.84 0.06 OUTLIER Glycine 0 CA--C 1.532 1.104 0 C-N-CA 119.147 -1.501 . . . . 0.0 114.859 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.21 169.0 0.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 118.847 1.324 . . . . 0.0 110.555 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 68.8 mt -127.39 135.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 115.212 1.56 . . . . 0.0 115.212 -175.02 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 53.7 mt -106.49 105.75 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 172.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.18 101.17 1.94 Allowed Glycine 0 CA--C 1.508 -0.398 0 N-CA-C 104.849 -3.301 . . . . 0.0 104.849 176.354 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tt -143.33 125.74 15.7 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-O 123.081 1.419 . . . . 0.0 112.618 -175.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.7 mtp -104.68 118.07 35.66 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 112.582 -2.099 . . . . 0.0 107.875 178.226 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -105.91 114.09 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' I' ' 36' ' ' VAL . . . -64.78 -123.24 0.01 OUTLIER Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.734 ' H ' ' H ' ' I' ' 38' ' ' GLY . . . 64.99 61.05 6.15 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 114.278 -0.961 . . . . 0.0 114.573 178.357 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -92.52 130.17 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 177.817 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.495 ' OXT' ' CG1' ' J' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.84 -1.076 . . . . 0.0 111.859 -177.604 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -104.69 133.41 49.57 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.75 0.309 . . . . 0.0 110.609 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -142.9 133.29 24.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.666 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 95.2 t -124.97 123.8 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.462 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.459 ' C ' ' CD2' ' K' ' 13' ' ' HIS . 6.4 t-160 -145.04 112.98 6.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.044 0.449 . . . . 0.0 111.305 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.638 ' CE1' ' N ' ' L' ' 14' ' ' HIS . 19.0 m-70 -140.41 159.22 42.68 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 177.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.693 HE22 ' N ' ' I' ' 37' ' ' GLY . 77.0 mt-30 -90.18 159.35 16.79 Favored 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 175.713 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.03 101.0 4.06 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 7.7 mp -125.89 125.91 43.57 Favored 'General case' 0 CA--C 1.506 -0.73 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.785 178.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 5.2 p -119.49 118.33 56.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' J' ' 19' ' ' PHE . 53.2 m-85 -107.03 105.98 16.28 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.728 -1.123 . . . . 0.0 109.69 -178.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.1 t80 -106.24 108.09 19.43 Favored 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -148.36 155.11 40.86 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.94 1.352 . . . . 0.0 113.38 -177.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.563 ' OE1' ' N ' ' J' ' 24' ' ' VAL . 97.0 mt-10 -93.06 117.58 30.23 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.908 -179.273 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.427 ' OD2' ' OD1' ' L' ' 23' ' ' ASP . 13.6 m-20 -67.4 -51.25 54.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 114.418 -1.265 . . . . 0.0 111.547 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.529 ' CG2' ' N ' ' K' ' 25' ' ' GLY . 2.3 p 158.8 161.84 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -177.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.653 ' N ' ' H ' ' J' ' 25' ' ' GLY . . . -63.29 30.41 0.08 OUTLIER Glycine 0 CA--C 1.532 1.116 0 N-CA-C 118.509 2.164 . . . . 0.0 118.509 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.575 ' OG ' ' O ' ' K' ' 25' ' ' GLY . 5.2 m -169.96 -127.8 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 121.293 2.546 . . . . 0.0 114.104 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.471 ' C ' ' H ' ' K' ' 29' ' ' GLY . 60.2 t30 -48.13 152.29 0.85 Allowed 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 113.577 0.955 . . . . 0.0 113.577 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.444 ' O ' ' CB ' ' L' ' 30' ' ' ALA . 85.0 tttt -70.33 48.84 0.11 Allowed 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.471 ' H ' ' C ' ' K' ' 27' ' ' ASN . . . -82.47 51.1 4.46 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.27 -0.966 . . . . 0.0 112.707 -176.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 173.58 7.13 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 42.2 mt -125.46 127.75 72.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.743 -179.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 33.4 pt -132.63 127.6 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.664 0.745 . . . . 0.0 111.753 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.34 110.93 2.15 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.481 ' N ' ' CD2' ' K' ' 34' ' ' LEU . 1.9 mm? -121.64 116.16 24.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.902 0.382 . . . . 0.0 110.066 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 4.1 ttm -107.81 130.28 54.99 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.445 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 54.0 t -125.64 131.84 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 CA-C-O 121.915 0.864 . . . . 0.0 112.352 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.03 -111.41 0.01 OUTLIER Glycine 0 CA--C 1.527 0.827 0 CA-C-N 113.722 -1.581 . . . . 0.0 111.085 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' OXT' ' J' ' 40' ' ' VAL . . . 105.91 -70.55 0.23 Allowed Glycine 0 N--CA 1.473 1.101 0 CA-C-N 114.518 -0.841 . . . . 0.0 111.758 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -155.58 97.21 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 2.3 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.946 179.712 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -108.79 132.64 53.79 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -144.54 142.63 30.35 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.921 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 t -110.79 115.93 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 110.462 -179.335 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.528 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.5 p80 -147.19 101.5 3.4 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.975 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.638 ' N ' ' CE1' ' K' ' 14' ' ' HIS . 97.6 m-70 -156.55 164.92 37.64 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 178.123 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.449 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 96.5 mm-40 -89.97 159.36 16.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.358 . . . . 0.0 111.104 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.78 104.18 4.83 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.605 0.716 . . . . 0.0 109.494 177.701 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 1.8 mt -122.69 115.48 22.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.338 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -101.64 97.76 6.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.327 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.472 ' CE1' ' CE2' ' K' ' 19' ' ' PHE . 85.2 m-85 -93.87 98.93 11.39 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.368 -1.715 . . . . 0.0 106.368 178.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -122.38 127.02 49.22 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.746 0.784 . . . . 0.0 109.996 -178.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.46 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.11 150.96 36.03 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -64.45 107.79 1.46 Allowed 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 118.549 -1.26 . . . . 0.0 108.758 -178.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.427 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 13.8 m-20 -153.89 50.0 0.66 Allowed 'General case' 0 C--O 1.231 0.122 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 95.8 t -82.8 149.3 4.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 178.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.93 36.25 5.83 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 18.1 t -76.45 102.35 5.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.706 0.765 . . . . 0.0 111.487 -176.616 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -97.48 -167.61 1.56 Allowed 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.543 -1.208 . . . . 0.0 112.188 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -49.13 -40.55 32.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.042 -1.436 . . . . 0.0 114.38 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.31 68.79 1.86 Allowed Glycine 0 N--CA 1.477 1.432 0 N-CA-C 114.971 0.748 . . . . 0.0 114.971 -175.09 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.444 ' CB ' ' O ' ' K' ' 28' ' ' LYS . . . -141.74 141.71 33.26 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -120.6 117.69 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.125 0 CA-C-N 120.443 1.474 . . . . 0.0 111.577 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.4 mt -119.57 122.18 68.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-N 114.812 -1.086 . . . . 0.0 110.205 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.4 106.72 0.91 Allowed Glycine 0 N--CA 1.464 0.547 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.9 tp -125.17 123.9 40.61 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 94.0 mtp -132.77 133.58 43.61 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.436 0.636 . . . . 0.0 112.217 -179.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.5 t -128.87 132.35 67.55 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.135 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 177.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.6 112.19 3.53 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 119.182 -1.485 . . . . 0.0 111.736 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.34 -63.51 4.46 Favored Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 177.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' L' ' 40' ' ' VAL . 0.8 OUTLIER -125.65 -169.5 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 C-N-CA 124.229 1.012 . . . . 0.0 108.355 -179.111 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.485 ' H ' ' CD1' ' R' ' 31' ' ' ILE . 0.7 OUTLIER . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.348 -0.834 . . . . 0.0 111.734 179.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . 0.4 ' H ' ' H ' ' M' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . 0.4 ' H ' ' H ' ' M' ' 9' ' ' GLY . 92.8 m-85 -110.2 138.54 46.45 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.728 0.299 . . . . 0.0 110.487 179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 42.7 tp10 -141.67 110.41 6.13 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.89 0.376 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 70.4 t -125.87 131.6 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.814 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -107.43 107.81 18.86 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.695 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 42.8 p-80 -152.66 165.94 33.68 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-O 121.212 0.53 . . . . 0.0 111.728 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 52.7 tt0 -170.75 147.99 2.87 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.271 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -77.9 120.41 22.74 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -128.31 113.81 16.1 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -130.19 130.07 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.354 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -133.56 141.88 47.91 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.44 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.408 ' O ' ' CD2' ' M' ' 20' ' ' PHE . 50.9 p90 -134.8 129.28 34.31 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.714 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.53 116.59 31.11 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.326 0.584 . . . . 0.0 110.339 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . 0.498 ' O ' ' N ' ' M' ' 24' ' ' VAL . 67.3 mt-10 -150.9 -139.06 0.09 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.329 -0.851 . . . . 0.0 108.918 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 53.7 p30 -53.05 50.99 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.694 1.197 . . . . 0.0 113.226 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.498 ' N ' ' O ' ' M' ' 22' ' ' GLU . 2.7 t -101.02 -141.73 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.886 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.461 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -72.59 -36.99 58.29 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 119.161 -1.495 . . . . 0.0 113.273 -175.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.425 ' O ' ' C ' ' M' ' 27' ' ' ASN . 93.8 p -162.27 117.26 1.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 118.873 1.336 . . . . 0.0 112.134 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.529 ' ND2' ' O ' ' N' ' 25' ' ' GLY . 99.1 m-20 -23.33 144.83 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.769 -1.105 . . . . 0.0 113.194 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -120.24 -36.6 3.21 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 173.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.14 -70.2 2.98 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 112.275 -2.239 . . . . 0.0 112.584 178.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.46 74.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.533 0.666 . . . . 0.0 112.022 176.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . 0.411 ' CG2' ' O ' ' M' ' 31' ' ' ILE . 19.3 tt -128.58 108.94 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 CA-C-N 119.243 0.929 . . . . 0.0 109.313 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . 0.432 HD12 HG21 ' M' ' 32' ' ' ILE . 96.6 mt -114.48 109.55 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.592 -179.706 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.25 98.36 0.69 Allowed Glycine 0 N--CA 1.461 0.308 0 N-CA-C 106.154 -2.778 . . . . 0.0 106.154 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . 0.42 ' H ' HD22 ' N' ' 34' ' ' LEU . 82.5 mt -145.93 164.6 31.5 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 123.269 1.509 . . . . 0.0 113.888 -176.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.9 mmm -113.77 110.19 19.77 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 111.771 -2.468 . . . . 0.0 106.859 177.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -118.04 111.78 35.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 134.69 -131.52 5.92 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.02 -63.08 0.75 Allowed Glycine 0 CA--C 1.536 1.398 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.261 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.449 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 2.1 t -114.04 160.71 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-N 116.992 0.396 . . . . 0.0 110.05 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.449 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 21.8 m . . . . . 0 N--CA 1.469 0.48 0 CA-C-O 117.836 -1.078 . . . . 0.0 111.918 178.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.113 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -85.51 137.9 32.57 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -100.77 141.95 32.92 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.487 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -124.72 132.78 70.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.376 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 51.0 m170 -116.98 99.79 7.31 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' N ' ' N' ' 15' ' ' GLN . 23.1 t60 -154.01 165.82 34.96 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.594 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.665 HE21 ' NE2' ' O' ' 15' ' ' GLN . 13.4 pt20 -160.34 143.52 13.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.217 178.721 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -80.0 112.2 17.06 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.457 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 tt -120.98 117.92 28.53 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -125.72 131.83 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.09 0.471 . . . . 0.0 111.094 -179.376 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -126.94 119.12 25.95 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 87.5 t80 -118.21 126.32 51.95 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.32 129.49 43.27 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 121.292 0.568 . . . . 0.0 112.355 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -88.65 115.99 26.58 Favored 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -87.04 47.6 1.53 Allowed 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -110.48 151.64 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 176.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . 0.529 ' O ' ' ND2' ' M' ' 27' ' ' ASN . . . 63.39 29.83 75.73 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.496 ' O ' ' O ' ' N' ' 27' ' ' ASN . 4.7 t -155.65 111.24 3.04 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 113.854 1.057 . . . . 0.0 113.854 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' N' ' 26' ' ' SER . 7.1 m120 -49.7 -164.75 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.178 176.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.59 ' NZ ' ' CG2' ' G' ' 39' ' ' VAL . 81.7 mttt 78.38 -41.17 0.3 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.543 1.137 . . . . 0.0 114.012 177.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.96 -68.28 3.45 Favored Glycine 0 CA--C 1.545 1.96 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.731 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.98 107.85 0.03 OUTLIER 'General case' 0 C--N 1.346 0.448 0 CA-C-N 117.576 0.688 . . . . 0.0 111.853 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . 0.437 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 0.2 OUTLIER -123.89 122.09 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 O-C-N 122.208 -0.307 . . . . 0.0 110.489 178.755 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 60.5 mt -114.36 116.15 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 110.39 2.22 Favored Glycine 0 N--CA 1.468 0.775 0 N-CA-C 106.179 -2.769 . . . . 0.0 106.179 177.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . 0.452 ' H ' HD22 ' O' ' 34' ' ' LEU . 76.5 mt -144.67 143.58 30.81 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -174.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 1.7 ttm -110.11 106.66 16.22 Favored 'General case' 0 N--CA 1.441 -0.895 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 173.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.548 ' C ' HE22 ' P' ' 15' ' ' GLN . 29.6 m -126.31 123.33 63.3 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.571 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 138.18 -113.58 0.99 Allowed Glycine 0 C--N 1.308 -1.011 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . 0.416 ' O ' ' CD1' ' B' ' 31' ' ' ILE . . . 73.08 -72.78 1.09 Allowed Glycine 0 CA--C 1.532 1.109 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.052 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 52.0 t -113.34 132.61 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 98.8 t . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.363 179.896 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.119 -1.593 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -112.85 138.4 49.74 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.993 0.425 . . . . 0.0 110.571 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . 0.548 ' O ' ' CE1' ' P' ' 13' ' ' HIS . 98.3 mt-10 -140.92 162.93 34.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.714 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . 0.554 ' CG1' ' H ' ' P' ' 12' ' ' VAL . 5.0 m -118.53 126.87 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.467 ' C ' ' CG ' ' O' ' 14' ' ' HIS . 10.3 m80 -129.92 136.23 49.24 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.329 0.585 . . . . 0.0 112.028 -178.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.691 ' CE1' ' H ' ' P' ' 14' ' ' HIS . 5.1 m-70 -156.97 176.0 13.35 Favored 'General case' 0 C--O 1.223 -0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.294 179.241 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.665 ' NE2' HE21 ' N' ' 15' ' ' GLN . 59.0 tt0 -152.96 140.11 19.38 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.267 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . 0.557 ' N ' ' CE1' ' N' ' 14' ' ' HIS . 88.2 tttt -94.45 110.89 22.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.167 -0.469 . . . . 0.0 112.106 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . 0.549 ' N ' ' CD2' ' O' ' 17' ' ' LEU . 0.7 OUTLIER -117.73 109.8 17.05 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 176.102 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -110.11 113.89 45.49 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -113.36 106.88 15.12 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.77 125.03 53.23 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.789 0.328 . . . . 0.0 110.553 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.58 122.73 28.04 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -149.32 -176.77 5.5 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.492 ' N ' ' OE1' ' P' ' 22' ' ' GLU . 96.7 m-20 66.22 50.32 1.39 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 113.365 -1.743 . . . . 0.0 112.298 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 67.0 t -82.45 146.43 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.91 -39.12 64.65 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 118.682 -1.723 . . . . 0.0 110.57 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.721 ' O ' ' O ' ' O' ' 27' ' ' ASN . 39.4 t -174.15 124.78 0.33 Allowed 'General case' 0 C--O 1.221 -0.436 0 CA-C-O 118.525 -0.75 . . . . 0.0 110.185 178.411 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.721 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.5 t-20 -2.62 145.99 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 178.422 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.417 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 93.4 mttt -159.03 30.93 0.21 Allowed 'General case' 0 N--CA 1.468 0.44 0 O-C-N 121.805 -0.56 . . . . 0.0 112.413 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.71 88.28 0.72 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 119.49 -1.338 . . . . 0.0 113.028 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 134.41 52.45 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.949 0.881 . . . . 0.0 109.873 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 4.5 tt -149.23 140.54 17.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.744 -175.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . 0.445 HD11 HG22 ' O' ' 32' ' ' ILE . 73.6 mt -110.57 109.86 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 176.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.54 101.85 0.96 Allowed Glycine 0 N--CA 1.469 0.855 0 N-CA-C 108.489 -1.845 . . . . 0.0 108.489 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . 0.452 HD22 ' H ' ' N' ' 34' ' ' LEU . 0.3 OUTLIER -141.92 158.83 43.32 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 122.962 1.363 . . . . 0.0 114.175 -177.052 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -112.16 112.71 24.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 111.618 -2.537 . . . . 0.0 106.315 175.724 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 88.6 t -119.68 111.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -177.788 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . 0.707 ' N ' HE22 ' Q' ' 15' ' ' GLN . . . 136.01 -131.67 5.81 Favored Glycine 0 C--N 1.319 -0.397 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.567 178.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 98.96 -63.26 0.75 Allowed Glycine 0 CA--C 1.541 1.66 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . . . . . . . . . 55.9 t -126.95 133.34 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . . . . . . . . . 96.6 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.723 179.9 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -108.79 135.69 49.6 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.078 0.466 . . . . 0.0 110.793 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -89.7 116.77 28.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.11 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.554 ' H ' ' CG1' ' O' ' 12' ' ' VAL . 34.7 m -136.31 159.86 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.185 0.517 . . . . 0.0 111.455 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.548 ' CE1' ' O ' ' O' ' 11' ' ' GLU . 80.0 m-70 -147.48 104.62 3.65 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.024 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.691 ' H ' ' CE1' ' O' ' 14' ' ' HIS . 40.0 m-70 -148.74 159.43 44.14 Favored 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.734 178.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.571 HE22 ' N ' ' N' ' 37' ' ' GLY . 7.5 mt-30 -90.31 159.89 16.42 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 114.215 -1.357 . . . . 0.0 107.822 175.111 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.34 99.21 3.6 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -127.37 122.63 34.18 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.116 0.484 . . . . 0.0 110.525 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.44 114.31 45.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.47 ' CD2' ' CE1' ' Q' ' 19' ' ' PHE . 59.4 m-85 -112.36 108.01 17.03 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -112.78 124.11 51.85 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.318 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 137.05 34.74 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 113.837 1.051 . . . . 0.0 113.837 -178.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.492 ' OE1' ' N ' ' O' ' 23' ' ' ASP . 78.9 tt0 -81.6 116.94 21.58 Favored 'General case' 0 N--CA 1.462 0.149 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.057 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -138.34 50.28 1.89 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -176.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -81.85 148.4 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.625 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.485 ' O ' ' CB ' ' O' ' 27' ' ' ASN . . . 93.72 36.16 5.92 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 106.412 -2.675 . . . . 0.0 106.412 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.549 ' OG ' ' ND2' ' Q' ' 27' ' ' ASN . 21.9 p -76.05 102.62 5.75 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 122.443 1.116 . . . . 0.0 112.498 -174.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -96.87 -164.47 1.15 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 112.823 -1.99 . . . . 0.0 110.889 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt -48.74 -40.25 27.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.895 -1.048 . . . . 0.0 111.877 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.77 70.08 1.88 Allowed Glycine 0 CA--C 1.543 1.809 0 N-CA-C 114.937 0.735 . . . . 0.0 114.937 -174.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.36 111.04 6.81 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 104.969 -2.234 . . . . 0.0 104.969 176.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . . . . . . . . . 57.6 mt -135.42 136.18 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -172.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . 0.438 HD11 HG23 ' P' ' 32' ' ' ILE . 3.0 mt -106.05 106.07 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.26 99.38 1.18 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 106.482 -2.647 . . . . 0.0 106.482 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 2.8 tp -128.43 123.59 34.11 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-O 122.419 1.104 . . . . 0.0 112.821 -176.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -98.47 104.35 16.38 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 175.422 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . 0.493 ' CG1' ' O ' ' P' ' 36' ' ' VAL . 8.7 p -119.18 113.76 42.43 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -177.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.22 -123.85 1.21 Allowed Glycine 0 C--N 1.309 -0.958 0 C-N-CA 118.95 -1.595 . . . . 0.0 111.79 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.525 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 81.26 -67.72 3.57 Favored Glycine 0 CA--C 1.536 1.354 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -178.087 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.439 ' CG1' ' OD1' ' D' ' 27' ' ' ASN . 67.9 t -136.09 155.61 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.925 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.651 179.976 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -108.56 134.77 50.85 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.751 0.31 . . . . 0.0 110.313 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -88.87 117.96 28.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.878 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -127.98 135.51 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 120.949 0.404 . . . . 0.0 110.991 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.488 ' N ' ' CD2' ' Q' ' 13' ' ' HIS . 2.0 m-70 -136.18 118.29 15.44 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.628 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.621 ' CD2' ' H ' ' R' ' 14' ' ' HIS . 22.7 m80 -147.23 159.6 43.45 Favored 'General case' 0 C--O 1.219 -0.534 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.29 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.707 HE22 ' N ' ' O' ' 37' ' ' GLY . 0.7 OUTLIER -90.25 159.59 16.61 Favored 'General case' 0 C--N 1.334 -0.084 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 176.145 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 66.5 tttt -140.2 104.34 4.79 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 120.313 -0.555 . . . . 0.0 109.697 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 4.3 mp -128.88 126.23 39.29 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 121.724 0.773 . . . . 0.0 111.006 179.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 84.8 t -114.3 113.63 44.32 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 114.721 -1.127 . . . . 0.0 108.837 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.47 ' CE1' ' CD2' ' P' ' 19' ' ' PHE . 59.5 m-85 -110.76 103.65 12.21 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 178.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -112.45 125.09 53.84 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.888 -178.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.68 143.61 35.2 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -84.64 137.37 33.31 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 120.166 -0.613 . . . . 0.0 109.619 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . . . . . . . . . 35.8 p-10 -177.75 50.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.159 -177.542 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -81.8 149.27 4.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.904 1.335 . . . . 0.0 113.828 -174.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.43 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 93.09 36.7 5.9 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 111.784 -2.462 . . . . 0.0 112.887 178.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . 0.43 ' OG ' ' O ' ' Q' ' 25' ' ' GLY . 3.2 p 72.65 120.18 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 118.621 -0.704 . . . . 0.0 110.546 175.994 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.549 ' ND2' ' OG ' ' P' ' 26' ' ' SER . 1.6 m120 -83.11 160.99 21.77 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 116.824 -1.95 . . . . 0.0 108.057 176.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -48.74 -39.79 26.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.573 0.702 . . . . 0.0 111.381 176.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.23 67.46 0.04 OUTLIER Glycine 0 CA--C 1.541 1.711 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.075 -177.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 152.18 43.89 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 118.449 1.125 . . . . 0.0 112.002 -176.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 6.3 mt -113.3 129.19 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.328 -177.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 99.8 mt -124.69 116.06 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.72 117.02 3.16 Favored Glycine 0 N--CA 1.47 0.951 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.244 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 29.2 tp -124.55 120.64 32.53 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 93.7 mtp -135.17 144.94 47.3 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -178.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.403 HG11 ' H ' ' Q' ' 37' ' ' GLY . 2.9 t -118.82 164.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.403 ' H ' HG11 ' Q' ' 36' ' ' VAL . . . -168.68 93.68 0.1 Allowed Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.056 -1.068 . . . . 0.0 111.119 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.45 -81.86 0.11 Allowed Glycine 0 CA--C 1.536 1.347 0 C-N-CA 120.473 -0.87 . . . . 0.0 112.465 177.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -157.68 147.57 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.158 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.552 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.95 133.09 51.23 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.876 0.37 . . . . 0.0 110.609 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 21.1 pt-20 -77.99 150.65 33.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.762 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -123.69 131.62 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.105 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.428 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.0 OUTLIER -152.22 112.67 4.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.487 -179.656 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.621 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 75.0 m80 -149.81 164.43 35.35 Favored 'General case' 0 C--O 1.22 -0.472 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.441 ' OE1' ' OE1' ' Q' ' 15' ' ' GLN . 60.0 mt-30 -89.94 159.5 16.88 Favored 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 120.317 -0.553 . . . . 0.0 110.401 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 61.8 tttp -139.55 115.19 10.02 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.456 0.646 . . . . 0.0 110.332 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 1.2 mp -135.46 125.54 26.04 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.796 179.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 3.5 p -112.96 116.48 52.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 176.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.431 ' CE1' ' CD2' ' Q' ' 19' ' ' PHE . 55.3 m-85 -105.17 104.77 14.57 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -123.73 124.37 42.58 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.997 0.903 . . . . 0.0 112.099 -177.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.65 130.2 54.03 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -70.21 110.15 5.04 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 118.813 -1.155 . . . . 0.0 110.377 -177.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 179.57 48.62 0.0 OUTLIER 'General case' 0 C--N 1.342 0.277 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.42 ' CG1' ' N ' ' R' ' 25' ' ' GLY . 69.0 t -72.85 160.34 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 117.324 -1.75 . . . . 0.0 108.644 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . 0.42 ' N ' ' CG1' ' R' ' 24' ' ' VAL . . . 110.35 -33.27 6.06 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.3 m -72.2 129.57 38.77 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 113.028 -1.586 . . . . 0.0 111.806 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . 0.67 ' O ' ' N ' ' R' ' 29' ' ' GLY . 98.6 m-20 -90.86 -161.91 0.86 Allowed 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.22 47.58 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . 0.67 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.28 56.9 0.9 Allowed Glycine 0 CA--C 1.541 1.686 0 CA-C-N 119.301 0.955 . . . . 0.0 111.997 178.184 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.97 168.61 13.73 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . 0.485 ' CD1' ' H ' ' L' ' 40' ' ' VAL . 15.9 tt -116.15 110.28 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.5 mt -117.11 128.63 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.542 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.14 115.07 2.44 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.46 117.4 25.87 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 8.9 ttp -141.19 124.38 16.46 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.364 0.602 . . . . 0.0 111.126 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.32 111.68 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 120.125 -0.63 . . . . 0.0 111.753 -179.409 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.8 132.17 10.9 Favored Glycine 0 CA--C 1.518 0.273 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 176.845 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . 0.412 ' O ' ' C ' ' R' ' 39' ' ' VAL . . . 109.49 63.24 0.53 Allowed Glycine 0 N--CA 1.474 1.18 0 CA-C-N 118.201 1.0 . . . . 0.0 112.95 179.618 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' R' ' 38' ' ' GLY . 41.4 t -32.17 151.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 117.285 0.543 . . . . 0.0 112.287 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . 0.477 ' C ' ' HZ2' ' D' ' 28' ' ' LYS . 28.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.765 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.097 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -108.23 137.04 46.88 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.706 0.288 . . . . 0.0 110.76 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.45 ' O ' ' OE1' ' B' ' 11' ' ' GLU . 95.7 mt-10 -118.28 140.02 50.45 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.029 0.443 . . . . 0.0 110.419 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 m -137.27 162.13 33.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.966 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 80.2 m80 -145.13 135.53 24.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.583 0.23 . . . . 0.0 110.785 179.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.572 ' CD2' ' N ' ' A' ' 15' ' ' GLN . 20.8 t60 -158.06 165.18 35.7 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.972 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 68.2 tp60 -158.97 142.45 14.89 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 121.027 0.442 . . . . 0.0 109.97 177.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -82.51 124.16 29.85 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.473 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.0 mt -127.18 119.52 26.63 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -141.49 146.45 23.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.363 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -147.52 141.2 25.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.11 0.481 . . . . 0.0 111.427 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.476 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 49.6 p90 -115.34 132.64 56.55 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.05 126.93 46.15 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 -177.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.513 ' C ' ' H ' ' A' ' 24' ' ' VAL . 96.0 mt-10 -128.14 -140.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.767 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -68.49 50.44 0.07 Allowed 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.551 ' CG1' ' N ' ' A' ' 25' ' ' GLY . 3.9 p -93.21 -142.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.748 -1.114 . . . . 0.0 110.761 -177.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.551 ' N ' ' CG1' ' A' ' 24' ' ' VAL . . . -82.78 -36.98 14.28 Favored Glycine 0 CA--C 1.526 0.744 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.037 -177.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 28.9 t -81.28 118.34 22.53 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.5 p30 -88.23 -179.31 6.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 115.159 1.54 . . . . 0.0 115.159 -174.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.439 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 96.0 mttt -55.86 -37.48 68.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 112.081 -2.327 . . . . 0.0 112.409 -179.055 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.05 77.72 0.4 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 112.079 -0.408 . . . . 0.0 112.079 -175.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.39 141.67 41.43 Favored 'General case' 0 C--O 1.243 0.746 0 CA-C-O 123.736 1.731 . . . . 0.0 113.012 -177.132 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -126.76 127.63 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.739 -2.482 . . . . 0.0 108.406 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.452 ' O ' ' O ' ' B' ' 33' ' ' GLY . 80.8 mt -100.9 105.66 18.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.381 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.07 96.39 1.15 Allowed Glycine 0 CA--C 1.505 -0.589 0 N-CA-C 104.385 -3.486 . . . . 0.0 104.385 176.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 51.6 tp -148.2 159.21 44.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 123.002 1.382 . . . . 0.0 112.969 -174.643 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.487 ' CE ' ' SD ' ' B' ' 35' ' ' MET . 17.0 mtp -119.52 117.51 28.59 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.482 179.443 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -119.24 111.85 35.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 177.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.22 -131.99 8.14 Favored Glycine 0 C--N 1.315 -0.602 0 N-CA-C 107.543 -2.223 . . . . 0.0 107.543 -177.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' B' ' 39' ' ' VAL . . . 87.05 -63.72 3.99 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 120.126 -1.035 . . . . 0.0 111.608 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -108.26 179.89 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 120.847 0.356 . . . . 0.0 110.106 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 85.9 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.852 -1.071 . . . . 0.0 110.959 178.97 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.17 132.13 54.41 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.31 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' O ' ' A' ' 11' ' ' GLU . 80.7 mm-40 -124.63 122.77 38.46 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.439 ' CG1' ' C ' ' C' ' 12' ' ' VAL . 3.6 t -112.92 100.27 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.983 0.42 . . . . 0.0 110.52 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 12.2 p-80 -138.82 145.19 39.76 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.747 -178.216 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.548 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 2.9 p80 -146.33 160.35 42.14 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.482 0.658 . . . . 0.0 111.98 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' OE1' ' C' ' 15' ' ' GLN . 85.9 mt-30 -90.3 159.67 16.53 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.178 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -139.97 108.05 5.75 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.49 130.84 53.48 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 120.875 0.369 . . . . 0.0 111.021 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.84 130.88 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.713 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -127.26 129.64 48.11 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -128.68 124.19 35.05 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.05 134.37 54.78 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.173 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.484 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 81.9 tt0 -161.74 159.8 27.65 Favored 'General case' 0 CA--C 1.55 0.969 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 -178.463 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' B' ' 24' ' ' VAL . 19.4 t70 112.83 -70.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 127.055 2.142 . . . . 0.0 110.854 177.205 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.524 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.7 t -58.77 -122.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 173.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.427 ' CA ' ' O ' ' C' ' 23' ' ' ASP . . . 139.12 -34.94 2.02 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-O 118.089 -1.395 . . . . 0.0 116.262 172.651 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -80.43 119.52 23.23 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 121.355 2.578 . . . . 0.0 106.59 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 28' ' ' LYS . 3.0 m120 -89.78 157.7 17.83 Favored 'General case' 0 C--N 1.344 0.368 0 C-N-CA 116.11 -2.236 . . . . 0.0 108.181 176.87 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -48.31 -40.53 25.39 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 122.394 1.092 . . . . 0.0 110.983 174.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 67.64 0.04 OUTLIER Glycine 0 CA--C 1.549 2.21 0 CA-C-N 112.956 -1.929 . . . . 0.0 110.5 -174.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.07 141.89 52.74 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 120.09 1.945 . . . . 0.0 115.168 -172.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 19.8 mt -136.23 134.09 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 113.159 -1.837 . . . . 0.0 113.106 -175.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.92 103.0 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 174.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -103.69 103.88 2.4 Favored Glycine 0 CA--C 1.507 -0.446 0 N-CA-C 104.309 -3.516 . . . . 0.0 104.309 175.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 17.8 tp -146.12 147.66 31.79 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 118.272 -1.371 . . . . 0.0 113.538 -173.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.487 ' SD ' ' CE ' ' A' ' 35' ' ' MET . 3.9 ttm -113.13 116.37 29.74 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-N 112.815 -1.993 . . . . 0.0 107.824 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 37.8 t -118.95 123.73 71.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.129 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.76 -114.15 2.03 Favored Glycine 0 C--N 1.315 -0.591 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.535 ' O ' ' CD1' ' H' ' 31' ' ' ILE . . . 81.02 -72.65 2.7 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.486 ' CG2' ' O ' ' A' ' 38' ' ' GLY . 24.8 t -124.54 163.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.532 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 20.7 m . . . . . 0 N--CA 1.473 0.689 0 CA-C-O 117.782 -1.104 . . . . 0.0 111.694 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.97 135.59 50.59 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -138.83 144.9 39.46 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.439 ' C ' ' CG1' ' B' ' 12' ' ' VAL . 27.6 m -138.19 164.43 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-O 120.963 0.411 . . . . 0.0 111.807 -179.029 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.423 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 4.2 p-80 -129.48 132.92 47.04 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.301 0.572 . . . . 0.0 112.131 -178.552 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.538 ' CG ' ' O ' ' D' ' 14' ' ' HIS . 17.7 p-80 -157.26 169.52 24.56 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.066 178.743 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' OE1' ' B' ' 15' ' ' GLN . 99.5 mm-40 -89.67 156.61 18.45 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.112 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -141.36 115.41 9.25 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.993 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . 0.409 ' O ' ' HA ' ' D' ' 17' ' ' LEU . 4.6 mp -135.24 118.8 16.96 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 122.018 0.913 . . . . 0.0 111.029 178.153 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -106.76 117.51 52.7 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.402 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 54.9 m-85 -109.93 99.73 8.81 Favored 'General case' 0 N--CA 1.447 -0.582 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -109.79 126.67 54.01 Favored 'General case' 0 C--O 1.241 0.626 0 CA-C-O 121.41 0.624 . . . . 0.0 111.058 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.17 113.26 15.49 Favored 'General case' 0 C--O 1.244 0.778 0 CA-C-O 121.884 0.85 . . . . 0.0 110.806 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.424 ' OE2' ' OD1' ' C' ' 23' ' ' ASP . 0.4 OUTLIER -86.17 103.3 14.68 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.065 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.427 ' O ' ' CA ' ' B' ' 25' ' ' GLY . 35.5 m-20 50.84 50.15 19.61 Favored 'General case' 0 C--O 1.214 -0.793 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.47 -177.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.623 ' CG2' ' H ' ' C' ' 25' ' ' GLY . 9.9 p -160.1 -174.22 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.094 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.623 ' H ' ' CG2' ' C' ' 24' ' ' VAL . . . 59.78 26.82 63.27 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.777 178.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' C' ' 27' ' ' ASN . 62.8 m -166.19 -145.94 0.08 Allowed 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' C' ' 26' ' ' SER . 10.6 m-20 55.48 142.25 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 120.906 0.384 . . . . 0.0 111.797 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.713 ' H ' ' CB ' ' D' ' 26' ' ' SER . 71.1 mmtt 62.47 46.06 5.96 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 61.08 0.79 Allowed Glycine 0 N--CA 1.474 1.204 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.083 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -101.87 119.3 38.56 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-O 121.567 0.698 . . . . 0.0 109.66 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.421 HG23 HD11 ' C' ' 31' ' ' ILE . 3.6 tt -137.07 136.34 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 120.021 -0.672 . . . . 0.0 112.438 -177.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.412 HD13 HG23 ' C' ' 32' ' ' ILE . 63.5 mt -107.09 107.42 22.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 176.687 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.06 100.95 2.01 Favored Glycine 0 C--O 1.237 0.327 0 N-CA-C 104.89 -3.284 . . . . 0.0 104.89 175.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -133.25 138.08 46.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.99 1.376 . . . . 0.0 114.314 -174.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -109.14 110.75 22.07 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 175.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 25.0 t -122.98 123.16 67.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 118.429 0.559 . . . . 0.0 109.529 -177.02 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.5 -113.19 0.65 Allowed Glycine 0 C--N 1.315 -0.59 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.964 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 74.05 -72.98 1.32 Allowed Glycine 0 CA--C 1.548 2.122 0 CA-C-N 114.863 -0.669 . . . . 0.0 111.641 -177.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -131.51 136.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.404 ' O ' ' OXT' ' D' ' 40' ' ' VAL . 73.7 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.373 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -107.02 134.03 50.78 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.915 0.388 . . . . 0.0 110.652 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -75.78 146.69 39.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.582 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . 0.462 ' CG1' ' N ' ' D' ' 13' ' ' HIS . 68.4 t -132.94 162.07 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.553 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.532 ' CE1' ' O ' ' B' ' 40' ' ' VAL . 2.3 t-80 -63.35 103.86 0.55 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.604 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 12.6 t60 -146.72 159.76 43.08 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.536 -178.158 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.604 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 36.1 tp60 -84.65 157.97 20.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -178.635 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -159.56 100.23 1.47 Allowed 'General case' 0 C--N 1.315 -0.913 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.39 178.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . 0.409 ' HA ' ' O ' ' C' ' 17' ' ' LEU . 6.2 mt -132.8 136.13 46.1 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -120.59 124.23 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.955 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 37.9 m-85 -117.82 106.18 12.74 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.485 ' CZ ' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -122.17 129.45 52.31 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -176.604 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.19 114.35 9.08 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.952 0.882 . . . . 0.0 110.624 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.401 ' HB2' ' H ' ' C' ' 23' ' ' ASP . 95.5 mt-10 -92.65 -174.74 3.74 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 54.3 t0 31.17 52.23 0.16 Allowed 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.823 1.786 . . . . 0.0 115.823 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.56 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 86.6 t -64.96 145.5 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 118.734 -1.187 . . . . 0.0 108.172 177.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.84 -24.35 0.73 Allowed Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.713 ' CB ' ' H ' ' C' ' 28' ' ' LYS . 4.8 t -72.09 160.17 32.93 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 122.311 1.053 . . . . 0.0 112.785 -177.334 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.711 ' O ' ' N ' ' D' ' 29' ' ' GLY . 97.8 m-20 -91.68 -130.06 0.11 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.384 -1.735 . . . . 0.0 110.159 -178.249 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -48.49 54.94 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.931 1.292 . . . . 0.0 112.317 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.711 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -110.28 -48.79 0.74 Allowed Glycine 0 CA--C 1.546 1.971 0 C-N-CA 124.529 1.062 . . . . 0.0 113.808 -176.53 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.71 113.61 20.5 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 96.1 mt -130.56 130.0 64.69 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 CA-C-N 112.453 -2.158 . . . . 0.0 111.339 178.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.447 HG21 HD12 ' D' ' 32' ' ' ILE . 47.6 mt -108.22 109.77 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 175.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.54 104.06 2.54 Favored Glycine 0 N--CA 1.462 0.395 0 N-CA-C 104.145 -3.582 . . . . 0.0 104.145 174.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 25.0 tp -133.88 128.18 34.07 Favored 'General case' 0 C--O 1.246 0.881 0 N-CA-C 116.477 2.029 . . . . 0.0 116.477 -172.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -104.38 111.54 24.22 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-N 112.793 -2.003 . . . . 0.0 107.377 174.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.408 ' O ' ' HA ' ' E' ' 36' ' ' VAL . 17.3 t -109.43 143.9 18.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.745 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 168.31 -101.95 0.18 Allowed Glycine 0 C--N 1.294 -1.766 0 C-N-CA 118.818 -1.658 . . . . 0.0 111.462 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.416 ' O ' ' O ' ' D' ' 39' ' ' VAL . . . 42.48 72.16 0.32 Allowed Glycine 0 N--CA 1.466 0.658 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -177.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.536 ' C ' ' HZ2' ' I' ' 28' ' ' LYS . 92.2 t -36.2 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -176.556 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.441 ' N ' ' CG1' ' D' ' 39' ' ' VAL . 19.7 m . . . . . 0 C--O 1.222 -0.386 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.593 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.73 136.59 47.22 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.817 0.341 . . . . 0.0 110.436 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.31 120.88 41.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.792 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.45 ' O ' ' CG1' ' D' ' 12' ' ' VAL . 33.8 t -112.08 95.32 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 121.189 0.518 . . . . 0.0 111.241 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 5.4 t-80 -118.65 109.97 16.76 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.26 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.634 ' CE1' ' N ' ' F' ' 14' ' ' HIS . 43.0 m-70 -138.13 165.04 27.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.213 0.53 . . . . 0.0 110.7 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -90.26 151.62 21.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.401 ' H ' ' HB3' ' D' ' 15' ' ' GLN . 88.8 tttt -149.68 107.46 3.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.526 178.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 8.7 mp -129.07 120.59 26.22 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.21 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.15 121.21 60.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.95 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.503 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 30.5 m-85 -116.34 100.77 8.13 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 177.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.485 ' CD1' ' CZ ' ' D' ' 20' ' ' PHE . 14.3 t80 -121.68 134.9 54.97 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -177.281 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.501 ' O ' ' CB ' ' F' ' 21' ' ' ALA . . . -160.3 -178.36 6.89 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 119.167 -1.013 . . . . 0.0 113.691 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.56 ' OE1' ' N ' ' D' ' 24' ' ' VAL . 34.6 tt0 -68.07 159.98 29.79 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.94 -178.658 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 t0 175.65 60.26 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.798 0.839 . . . . 0.0 109.472 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 4.7 t -81.44 -113.36 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 116.956 -1.497 . . . . 0.0 111.305 -171.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.73 -42.12 47.69 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 114.839 -3.553 . . . . 0.0 115.4 -171.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' E' ' 27' ' ' ASN . 35.9 t -156.7 110.39 2.67 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 121.376 2.588 . . . . 0.0 114.298 175.156 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' E' ' 26' ' ' SER . 28.7 t-20 -55.69 162.83 1.55 Allowed 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 172.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -58.53 -42.65 88.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 122.127 2.24 . . . . 0.0 110.265 175.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 64.27 0.04 OUTLIER Glycine 0 CA--C 1.551 2.305 0 CA-C-N 114.104 -1.407 . . . . 0.0 111.856 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.447 ' O ' ' CB ' ' F' ' 30' ' ' ALA . . . -72.25 161.29 31.06 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 119.344 1.572 . . . . 0.0 112.461 -176.759 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.481 ' CG2' ' OXT' ' Q' ' 40' ' ' VAL . 97.9 mt -134.08 136.63 53.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-O 121.421 0.629 . . . . 0.0 112.472 -177.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 98.0 mt -130.6 129.98 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.929 -0.482 . . . . 0.0 111.702 -179.362 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.95 114.26 2.47 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 20.4 mt -124.75 124.01 41.22 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 110.183 -0.302 . . . . 0.0 110.183 -177.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 88.5 mtp -130.3 134.34 47.14 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 119.9 -0.72 . . . . 0.0 112.553 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.436 HG23 ' H ' ' F' ' 37' ' ' GLY . 0.8 OUTLIER -91.85 155.35 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 177.468 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.421 ' H ' ' HA2' ' D' ' 37' ' ' GLY . . . -102.96 102.8 2.3 Favored Glycine 0 CA--C 1.529 0.968 0 N-CA-C 112.256 -0.338 . . . . 0.0 112.256 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 52.58 -73.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.639 0 N-CA-C 115.009 0.764 . . . . 0.0 115.009 178.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.416 ' N ' ' O ' ' E' ' 37' ' ' GLY . 40.9 t -129.89 138.14 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.211 1.005 . . . . 0.0 111.222 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' F' ' 40' ' ' VAL . 77.2 t . . . . . 0 N--CA 1.472 0.638 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.177 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.445 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -109.6 134.19 52.23 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.676 0.274 . . . . 0.0 110.461 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -79.07 154.28 29.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.334 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.558 ' C ' ' HE2' ' E' ' 14' ' ' HIS . 2.7 t -108.21 111.01 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-O 121.163 0.506 . . . . 0.0 110.503 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' N ' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -145.23 117.72 8.54 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.209 -179.689 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.634 ' N ' ' CE1' ' E' ' 14' ' ' HIS . 79.5 m80 -156.97 169.4 24.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.447 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.745 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.3 tt0 -89.67 155.78 19.0 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -141.39 116.32 9.84 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.557 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 1.6 mp -137.06 121.75 18.56 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 19.7 t -106.11 117.11 51.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.081 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' CD1' ' F' ' 20' ' ' PHE . 11.2 m-85 -116.05 98.2 6.5 Favored 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.539 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 58.1 m-85 -152.08 173.65 14.66 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 122.806 1.288 . . . . 0.0 112.315 -178.235 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' E' ' 21' ' ' ALA . . . -152.11 155.18 37.36 Favored 'General case' 0 N--CA 1.435 -1.189 0 CA-C-N 114.101 -1.408 . . . . 0.0 109.897 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -75.52 137.78 41.1 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -176.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 60.15 50.12 6.73 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-N 114.112 -1.404 . . . . 0.0 113.599 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.403 ' CG1' ' N ' ' F' ' 25' ' ' GLY . 82.2 t -54.93 162.92 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 118.832 -1.147 . . . . 0.0 108.734 179.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.403 ' N ' ' CG1' ' F' ' 24' ' ' VAL . . . -156.62 -26.06 0.03 OUTLIER Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.023 -179.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 10.8 m -71.5 130.19 40.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -175.695 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.767 ' O ' ' N ' ' F' ' 29' ' ' GLY . 13.9 m120 -90.9 -156.2 0.43 Allowed 'General case' 0 C--O 1.22 -0.475 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 176.371 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -49.15 50.39 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 112.972 0.73 . . . . 0.0 112.972 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.767 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -100.2 -51.09 1.27 Allowed Glycine 0 CA--C 1.539 1.582 0 C-N-CA 123.762 0.696 . . . . 0.0 111.947 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.447 ' CB ' ' O ' ' E' ' 30' ' ' ALA . . . -101.65 178.22 4.69 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -179.142 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 90.6 mt -121.13 131.84 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.601 -178.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -122.61 117.82 53.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.331 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.66 126.81 6.98 Favored Glycine 0 N--CA 1.469 0.851 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 tp -131.83 114.45 14.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 90.6 mtp -122.01 135.49 54.84 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 120.617 -0.433 . . . . 0.0 112.104 -178.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 51.2 t -108.28 132.69 55.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.208 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.803 179.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.6 112.4 4.23 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.533 -0.627 . . . . 0.0 111.533 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.98 -70.41 0.0 OUTLIER Glycine 0 CA--C 1.538 1.484 0 N-CA-C 114.011 0.364 . . . . 0.0 114.011 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.542 ' N ' ' O ' ' F' ' 37' ' ' GLY . 46.3 t -123.97 132.68 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-O 121.586 0.708 . . . . 0.0 111.885 -178.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' E' ' 40' ' ' VAL . 11.6 t . . . . . 0 C--O 1.218 -0.571 0 CA-C-O 117.785 -1.102 . . . . 0.0 110.381 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -107.58 138.42 43.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -156.99 116.82 3.47 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.89 0.376 . . . . 0.0 110.894 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.476 ' CG1' ' O ' ' H' ' 12' ' ' VAL . 12.3 m -131.52 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.911 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 51.7 m-70 -145.31 130.31 18.34 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.3 0.571 . . . . 0.0 111.965 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 42.2 p-80 -152.74 172.4 16.75 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.478 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -128.97 151.01 50.15 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -95.22 128.7 42.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.688 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -126.96 117.92 23.48 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -133.95 134.27 55.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -144.77 146.9 32.36 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.46 0.648 . . . . 0.0 111.452 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.521 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 54.6 p90 -129.23 129.61 45.22 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.046 179.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.3 120.81 41.67 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.131 0.491 . . . . 0.0 112.085 -178.536 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -157.98 151.72 23.83 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 57.01 46.45 19.35 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.812 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -80.29 -179.8 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.933 0.397 . . . . 0.0 110.338 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.15 -32.39 65.69 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 33.3 t -152.55 125.83 8.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.341 0.591 . . . . 0.0 109.576 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -38.93 134.14 1.04 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.814 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -110.59 -39.21 4.96 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.96 -69.41 3.09 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 112.415 -2.175 . . . . 0.0 111.702 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . 179.78 87.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 117.59 0.695 . . . . 0.0 111.239 176.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -133.32 113.71 19.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.541 0 O-C-N 121.765 -0.584 . . . . 0.0 109.702 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 66.8 mt -108.21 110.72 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.13 97.54 0.63 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 105.298 -3.121 . . . . 0.0 105.298 177.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.422 ' O ' ' CD1' ' H' ' 34' ' ' LEU . 56.8 tp -160.63 159.41 30.4 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 118.18 -1.408 . . . . 0.0 111.89 -175.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.417 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 23.8 mtp -122.75 121.91 37.46 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.418 -1.264 . . . . 0.0 109.19 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 2.0 t -118.32 103.1 14.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.14 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.69 -153.05 24.57 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . 0.437 ' O ' ' CG2' ' H' ' 39' ' ' VAL . . . 111.82 -56.2 0.48 Allowed Glycine 0 CA--C 1.542 1.779 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.86 160.8 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.756 -1.116 . . . . 0.0 110.395 179.316 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -113.61 135.65 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.739 0.304 . . . . 0.0 110.364 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -109.11 116.02 31.15 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.497 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . 0.476 ' O ' ' CG1' ' G' ' 12' ' ' VAL . 6.6 t -116.14 95.01 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 120.916 0.389 . . . . 0.0 110.092 179.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.538 ' ND1' ' O ' ' G' ' 13' ' ' HIS . 17.9 p-80 -147.84 165.68 29.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.871 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.632 ' HE2' ' CG2' ' I' ' 12' ' ' VAL . 0.1 OUTLIER -107.73 161.61 14.73 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.361 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.87 159.64 16.87 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -140.0 101.27 4.13 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.8 tp -127.97 121.9 31.03 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.115 0.483 . . . . 0.0 110.611 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.32 126.59 72.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.201 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.625 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -131.07 123.0 27.72 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.44 ' CZ ' ' CG ' ' H' ' 22' ' ' GLU . 19.5 t80 -119.5 126.11 50.5 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.34 121.56 38.87 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -177.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.44 ' CG ' ' CZ ' ' H' ' 20' ' ' PHE . 58.0 mt-10 -116.82 98.06 6.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 114.052 -1.431 . . . . 0.0 107.348 176.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.482 ' O ' HG11 ' I' ' 24' ' ' VAL . 96.8 m-20 -112.38 51.5 0.81 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 84.7 t -75.44 144.58 11.87 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 O-C-N 124.118 0.887 . . . . 0.0 110.61 -175.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.61 -38.31 3.37 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-N 113.84 -1.527 . . . . 0.0 110.562 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.46 ' O ' ' O ' ' H' ' 27' ' ' ASN . 74.8 m -120.48 -112.18 0.33 Allowed 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.466 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 51.1 t-20 52.13 152.9 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.327 1.051 . . . . 0.0 110.908 -176.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.466 ' N ' ' OD1' ' H' ' 27' ' ' ASN . 67.6 mttm -140.48 -28.88 0.7 Allowed 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 115.189 1.552 . . . . 0.0 115.189 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.01 88.08 0.11 Allowed Glycine 0 N--CA 1.474 1.216 0 CA-C-O 119.471 -0.627 . . . . 0.0 113.74 -170.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.421 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -79.07 128.46 33.3 Favored 'General case' 0 CA--C 1.545 0.787 0 CA-C-O 123.308 1.528 . . . . 0.0 112.682 -175.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 30.7 mt -137.32 139.66 43.43 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 112.638 -2.074 . . . . 0.0 113.399 -176.067 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 80.6 mt -109.48 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 175.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.37 99.3 0.82 Allowed Glycine 0 C--O 1.237 0.308 0 N-CA-C 105.573 -3.011 . . . . 0.0 105.573 176.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.43 ' HB3' ' CD2' ' I' ' 34' ' ' LEU . 8.4 tp -142.4 140.89 32.16 Favored 'General case' 0 C--O 1.242 0.669 0 CA-C-O 123.007 1.384 . . . . 0.0 113.251 -174.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.1 mtp -107.47 111.75 24.2 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 112.315 -2.221 . . . . 0.0 108.387 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.585 ' CG1' ' NE2' ' J' ' 15' ' ' GLN . 2.0 t -117.77 122.99 71.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.66 -113.18 0.6 Allowed Glycine 0 C--N 1.313 -0.731 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.67 -73.28 2.66 Favored Glycine 0 CA--C 1.533 1.171 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.479 ' O ' ' C ' ' H' ' 40' ' ' VAL . 34.9 t -133.86 157.1 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.251 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.479 ' C ' ' O ' ' H' ' 39' ' ' VAL . 70.1 t . . . . . 0 N--CA 1.471 0.577 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.295 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -112.16 136.04 52.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.858 0.361 . . . . 0.0 110.534 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -99.6 109.19 21.71 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.379 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.632 ' CG2' ' HE2' ' H' ' 14' ' ' HIS . 2.4 m -139.75 162.44 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.905 -178.975 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.425 ' CD2' ' N ' ' I' ' 13' ' ' HIS . 2.8 m-70 -138.86 97.29 3.29 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 119.264 -0.398 . . . . 0.0 110.432 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.557 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 7.2 m170 -122.36 156.91 32.95 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 119.827 -0.749 . . . . 0.0 112.28 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.537 ' OE1' ' NE2' ' J' ' 15' ' ' GLN . 2.9 tt0 -90.44 159.59 16.47 Favored 'General case' 0 C--N 1.341 0.22 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 175.609 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.66 106.45 5.14 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 176.393 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 80.0 mt -117.21 114.97 24.41 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.045 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -114.29 103.26 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 14.5 m-30 -114.42 113.87 25.08 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -116.76 131.3 56.99 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -178.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.19 138.76 50.76 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 117.81 0.277 . . . . 0.0 111.184 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -76.67 176.38 8.46 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 119.237 3.051 . . . . 0.0 119.237 -174.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -72.49 50.11 0.23 Allowed 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 128.892 2.877 . . . . 0.0 114.132 -178.096 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.669 ' CG1' ' H ' ' I' ' 25' ' ' GLY . 1.8 t -74.77 -143.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -175.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.669 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . -95.97 36.7 3.72 Favored Glycine 0 N--CA 1.465 0.573 0 C-N-CA 129.274 3.321 . . . . 0.0 107.706 -173.433 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.421 ' H ' ' C ' ' I' ' 24' ' ' VAL . 11.1 t -74.25 104.62 5.1 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 109.975 -3.113 . . . . 0.0 109.995 -176.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.708 ' O ' ' C ' ' I' ' 28' ' ' LYS . 86.1 m-20 -93.0 -149.23 0.26 Allowed 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 101.107 -3.664 . . . . 0.0 101.107 -176.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.708 ' C ' ' O ' ' I' ' 27' ' ' ASN . 82.3 tttt -32.64 -42.66 0.08 Allowed 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 124.173 3.17 . . . . 0.0 106.235 -170.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 91.29 -61.42 2.9 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 121.583 3.393 . . . . 0.0 121.583 159.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.22 117.11 24.58 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 -171.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.488 ' CD1' ' O ' ' C' ' 38' ' ' GLY . 3.5 mt -127.28 117.12 46.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 174.239 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 25.2 mt -100.22 112.93 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.03 100.12 1.07 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 106.548 -2.621 . . . . 0.0 106.548 177.197 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.43 ' CD2' ' HB3' ' H' ' 34' ' ' LEU . 98.0 mt -131.79 145.04 51.36 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.454 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -118.93 102.43 8.77 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 174.248 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.457 ' CG2' ' NE2' ' K' ' 15' ' ' GLN . 8.0 p -123.07 122.9 66.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.616 0.722 . . . . 0.0 109.88 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.29 -113.59 0.75 Allowed Glycine 0 C--N 1.31 -0.876 0 N-CA-C 107.57 -2.212 . . . . 0.0 107.57 -179.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.77 -72.37 1.05 Allowed Glycine 0 CA--C 1.535 1.303 0 C-N-CA 121.214 -0.517 . . . . 0.0 113.533 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 21.4 t -132.55 160.95 42.24 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 121.01 0.433 . . . . 0.0 111.698 -177.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.528 ' OXT' ' CE1' ' K' ' 13' ' ' HIS . 10.9 p . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.4 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -71.02 127.32 32.16 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -142.97 156.07 44.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.967 0.413 . . . . 0.0 110.608 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.591 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -130.78 134.62 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 97.6 m-70 -120.83 124.85 46.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.46 -178.25 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' CE1' ' K' ' 14' ' ' HIS . 51.3 m-70 -151.58 169.82 21.18 Favored 'General case' 0 C--O 1.222 -0.382 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.585 ' NE2' ' CG1' ' H' ' 36' ' ' VAL . 8.5 tt0 -137.69 150.17 47.11 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -115.7 113.89 24.1 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.692 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 89.5 mt -108.84 107.34 17.71 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 176.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 t -110.96 102.53 14.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.456 ' CD2' ' CE1' ' K' ' 19' ' ' PHE . 12.4 m-85 -113.05 112.0 23.1 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -114.98 125.98 54.23 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 116.636 -0.256 . . . . 0.0 110.873 -178.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.49 129.54 33.28 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.666 0.745 . . . . 0.0 111.862 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -82.32 116.89 22.03 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -124.96 51.78 1.63 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -176.138 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -75.07 143.31 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.82 0 N-CA-C 103.047 -2.946 . . . . 0.0 103.047 175.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.58 37.57 3.7 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 105.768 -2.933 . . . . 0.0 105.768 -172.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.458 ' OG ' ' OD1' ' K' ' 27' ' ' ASN . 5.3 t -69.48 105.11 2.51 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 113.522 -1.339 . . . . 0.0 107.94 -177.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -117.85 -151.88 0.49 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 113.149 -1.841 . . . . 0.0 113.522 -172.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -37.54 -40.81 0.41 Allowed 'General case' 0 CA--C 1.551 0.999 0 N-CA-C 119.736 3.236 . . . . 0.0 119.736 -171.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.421 ' O ' ' CE ' ' I' ' 28' ' ' LYS . . . -171.29 69.47 0.12 Allowed Glycine 0 N--CA 1.484 1.844 0 C-N-CA 115.193 -3.384 . . . . 0.0 119.44 -174.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.39 140.73 46.81 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 120.307 2.053 . . . . 0.0 109.172 177.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.507 HG21 ' H ' ' K' ' 31' ' ' ILE . 10.1 pt -146.62 153.6 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 96.4 mt -114.56 128.47 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.305 176.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.36 112.55 0.97 Allowed Glycine 0 N--CA 1.462 0.42 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.415 ' C ' ' CD1' ' J' ' 34' ' ' LEU . 3.6 pp -164.65 165.63 20.78 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 117.588 -1.645 . . . . 0.0 114.986 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 70.6 mmm -113.87 117.56 31.75 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 112.746 -2.024 . . . . 0.0 110.653 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 15.3 t -111.5 102.51 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 N-CA-C 109.246 -0.649 . . . . 0.0 109.246 178.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.673 ' N ' HE22 ' L' ' 15' ' ' GLN . . . 125.09 -162.31 19.41 Favored Glycine 0 N--CA 1.465 0.585 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.386 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' K' ' 38' ' ' GLY . . . 137.84 -55.38 0.68 Allowed Glycine 0 CA--C 1.542 1.745 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' J' ' 40' ' ' VAL . 43.5 t -125.29 134.04 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.853 0.861 . . . . 0.0 108.798 177.672 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.441 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 74.1 t . . . . . 0 C--O 1.216 -0.685 0 CA-C-O 118.088 -0.958 . . . . 0.0 111.711 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.05 134.54 53.54 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.482 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 97.8 mt-10 -144.56 169.48 17.88 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.859 0.361 . . . . 0.0 111.276 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 19.6 t -104.18 128.26 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' OXT' ' I' ' 40' ' ' VAL . 81.7 t60 -138.93 114.81 10.06 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.636 ' CE1' ' CD2' ' J' ' 14' ' ' HIS . 7.5 p80 -155.22 165.29 37.14 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.182 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.457 ' NE2' ' CG2' ' I' ' 36' ' ' VAL . 58.3 tt0 -129.48 149.95 51.04 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 119.699 -0.8 . . . . 0.0 111.179 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.96 109.15 21.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.004 177.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . 0.568 ' CD1' ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -103.95 105.12 15.2 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 176.557 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.1 103.89 16.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.445 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.456 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 5.1 m-85 -114.39 108.26 16.65 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.207 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -106.69 120.8 42.95 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.42 131.36 41.7 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.415 -179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.533 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 97.4 mt-10 -87.09 104.61 16.5 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.465 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 0.5 OUTLIER -135.13 48.66 2.25 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.733 -177.322 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 55.0 t -71.92 161.38 4.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.553 -178.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.26 -28.35 10.43 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 -177.442 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.433 ' OG ' ' OG ' ' L' ' 26' ' ' SER . 0.8 OUTLIER 74.57 119.73 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.051 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.458 ' OD1' ' OG ' ' J' ' 26' ' ' SER . 93.3 m-20 -83.24 162.79 21.08 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.832 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -47.19 -37.28 9.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.294 177.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.78 77.35 0.07 OUTLIER Glycine 0 CA--C 1.532 1.147 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.597 -174.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.53 153.7 29.35 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 118.217 1.009 . . . . 0.0 110.01 -178.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.507 ' H ' HG21 ' J' ' 31' ' ' ILE . 57.4 mt -133.78 141.24 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 113.874 1.064 . . . . 0.0 113.874 -175.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -127.02 118.36 50.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.169 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.16 109.56 1.72 Allowed Glycine 0 N--CA 1.471 1.002 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 29.3 mt -127.84 125.27 39.43 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 112.811 0.671 . . . . 0.0 112.811 -175.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.7 mtp -106.94 106.01 16.32 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 9.9 p -97.26 173.23 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.827 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . 159.64 -95.39 0.14 Allowed Glycine 0 C--N 1.3 -1.45 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.458 -178.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' J' ' 38' ' ' GLY . . . 98.13 -80.53 0.61 Allowed Glycine 0 N--CA 1.47 0.95 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 -176.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . 0.474 ' C ' ' CD1' ' Q' ' 31' ' ' ILE . 0.0 OUTLIER -85.05 94.08 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 176.416 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.578 ' N ' ' CD1' ' Q' ' 31' ' ' ILE . 13.1 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.799 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -106.49 136.2 46.67 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.544 0.211 . . . . 0.0 110.526 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -139.34 155.51 47.64 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.931 0.396 . . . . 0.0 110.503 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 58.9 t -128.76 134.34 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.376 -178.89 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.482 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 85.0 m-70 -135.12 84.65 2.11 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.7 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.486 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 85.2 t60 -162.7 168.51 21.48 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.141 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.673 HE22 ' N ' ' J' ' 37' ' ' GLY . 78.8 mt-30 -100.35 151.33 21.63 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.345 0.593 . . . . 0.0 111.788 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -112.63 110.21 20.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.745 177.341 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -104.77 109.88 22.0 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 42.8 t -117.21 102.38 13.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.424 ' CD1' ' CD2' ' K' ' 19' ' ' PHE . 5.0 m-85 -115.72 107.11 14.66 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -113.96 119.71 38.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.099 0.476 . . . . 0.0 111.515 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.23 127.17 52.17 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.248 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -78.04 111.25 13.73 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.329 -177.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 56.9 p30 -178.39 48.66 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.157 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.618 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -72.62 160.32 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 C-N-CA 118.431 -1.308 . . . . 0.0 109.449 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.05 -33.19 6.01 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.433 ' OG ' ' OG ' ' K' ' 26' ' ' SER . 4.7 m -72.09 129.56 38.79 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 113.824 -1.188 . . . . 0.0 111.102 179.08 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.645 ' O ' ' N ' ' L' ' 29' ' ' GLY . 98.7 m-20 -90.98 -162.51 0.92 Allowed 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.46 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.28 47.59 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 115.127 1.529 . . . . 0.0 115.127 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.645 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.17 57.08 0.9 Allowed Glycine 0 CA--C 1.54 1.608 0 CA-C-N 119.483 1.038 . . . . 0.0 112.016 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.07 171.73 10.74 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 94.5 mt -121.27 121.73 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 177.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -125.43 133.58 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.864 0.364 . . . . 0.0 111.57 -178.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.99 117.98 2.06 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.4 tp -115.21 123.53 49.1 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mmm -124.83 128.03 48.07 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.659 0.266 . . . . 0.0 111.552 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.2 t -97.4 152.24 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-O 121.353 0.597 . . . . 0.0 111.929 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.527 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . -80.79 102.5 2.13 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' L' ' 37' ' ' GLY . . . 11.46 -73.04 0.0 OUTLIER Glycine 0 CA--C 1.539 1.588 0 C-N-CA 123.459 0.552 . . . . 0.0 113.92 -178.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.527 ' N ' ' O ' ' L' ' 37' ' ' GLY . 74.5 t -129.95 136.07 59.7 Favored 'Isoleucine or valine' 0 C--N 1.346 0.42 0 CA-C-N 118.221 1.011 . . . . 0.0 110.073 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 13.8 m . . . . . 0 C--O 1.219 -0.543 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.336 -179.754 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -112.52 133.8 54.39 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 110.344 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -71.71 144.26 49.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.029 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -139.49 139.5 38.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 121.159 0.504 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -89.49 166.73 13.5 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.229 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.594 ' N ' ' ND1' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -82.26 171.42 14.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.0 0.429 . . . . 0.0 111.212 -179.342 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -128.8 151.03 50.04 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -96.3 106.77 19.04 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.704 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 87.2 mt -128.22 114.41 16.92 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 121.005 0.431 . . . . 0.0 110.057 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -126.61 130.8 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.715 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -128.18 131.23 48.9 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.619 ' CZ ' ' CD1' ' N' ' 20' ' ' PHE . 1.6 t80 -134.38 128.84 34.42 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.204 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 118.46 31.86 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.935 0.398 . . . . 0.0 109.949 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . 0.436 ' O ' ' N ' ' M' ' 24' ' ' VAL . 94.5 mt-10 -110.53 -148.59 0.43 Allowed 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.773 -178.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.57 50.13 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.855 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.47 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 2.3 t -71.72 -142.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.47 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -111.48 38.75 3.14 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.904 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m 61.76 111.18 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.113 0.482 . . . . 0.0 112.082 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.45 ' O ' ' C ' ' M' ' 28' ' ' LYS . 91.2 m-20 -129.85 -161.55 1.13 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.193 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . 0.45 ' C ' ' O ' ' M' ' 27' ' ' ASN . 73.6 mmtt -30.95 -41.31 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 120.914 0.387 . . . . 0.0 110.996 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' M' ' 27' ' ' ASN . . . 91.35 -64.92 2.54 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.794 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . 0.473 ' O ' ' O ' ' N' ' 29' ' ' GLY . . . -170.37 70.1 0.05 Allowed 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 117.616 0.708 . . . . 0.0 112.483 177.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 82.0 mt -130.89 115.09 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 4.0 mt -112.89 116.16 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 C-N-CA 120.062 -0.655 . . . . 0.0 111.107 -179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.16 105.0 1.18 Allowed Glycine 0 N--CA 1.461 0.315 0 N-CA-C 105.389 -3.084 . . . . 0.0 105.389 177.108 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 47.1 tp -161.02 152.34 19.02 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 117.548 -1.661 . . . . 0.0 114.354 -174.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 3.8 ttm -104.26 115.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-N 112.56 -2.109 . . . . 0.0 106.856 176.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . 0.517 ' O ' ' N ' ' N' ' 37' ' ' GLY . 36.5 t -116.91 103.87 15.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.29 -153.22 16.88 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 120.026 -1.083 . . . . 0.0 110.952 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.522 ' H ' ' N ' ' N' ' 38' ' ' GLY . . . 147.65 -54.64 0.52 Allowed Glycine 0 CA--C 1.539 1.551 0 CA-C-O 119.721 -0.488 . . . . 0.0 111.93 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' M' ' 40' ' ' VAL . 10.0 p -114.73 151.89 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.963 0.881 . . . . 0.0 108.787 178.411 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.54 ' OXT' ' CG1' ' M' ' 40' ' ' VAL . 8.5 p . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 117.854 -1.069 . . . . 0.0 111.151 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.64 134.33 48.93 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -151.38 135.77 16.89 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.999 0.428 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 34.1 m -137.03 162.09 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.624 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . 0.51 ' C ' ' ND1' ' N' ' 14' ' ' HIS . 83.4 m-70 -143.34 104.86 4.31 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.489 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.511 ' HE2' ' CD2' ' O' ' 14' ' ' HIS . 20.0 m80 -152.08 167.05 29.71 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.701 0.286 . . . . 0.0 110.67 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -155.7 141.17 17.76 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -89.82 107.39 19.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 119.215 -0.421 . . . . 0.0 111.666 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 33.4 tp -123.78 115.57 21.57 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 177.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -121.49 131.13 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.828 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -129.97 112.35 13.42 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.522 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CZ ' ' M' ' 20' ' ' PHE . 16.5 t80 -113.81 130.37 56.47 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.44 133.14 40.16 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 113.232 0.827 . . . . 0.0 113.232 -178.049 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -92.38 120.83 33.27 Favored 'General case' 0 C--N 1.34 0.168 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.547 177.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.57 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 70.8 m-20 -148.39 50.39 1.02 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.981 -177.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 37.6 t -81.41 148.65 5.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 118.951 -1.1 . . . . 0.0 109.719 -177.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.57 37.04 5.66 Favored Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.9 p 73.18 120.21 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.617 ' ND2' ' N ' ' N' ' 27' ' ' ASN . 0.1 OUTLIER -83.09 162.44 21.34 Favored 'General case' 0 C--N 1.341 0.211 0 C-N-CA 118.262 -1.375 . . . . 0.0 111.499 -179.098 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -47.22 -37.17 9.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.955 176.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' M' ' 30' ' ' ALA . . . -178.96 77.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.579 0 CA-C-O 118.766 -1.019 . . . . 0.0 112.199 -173.387 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . 0.493 ' O ' ' HA ' ' O' ' 30' ' ' ALA . . . -79.26 107.51 12.07 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-N 119.848 1.824 . . . . 0.0 112.835 -175.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . 0.571 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 18.4 tt -153.32 133.83 4.34 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 CA-C-N 113.627 -1.624 . . . . 0.0 111.336 -177.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . 0.456 HD11 HG23 ' N' ' 32' ' ' ILE . 85.0 mt -106.96 108.26 24.76 Favored 'Isoleucine or valine' 0 C--N 1.341 0.198 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 177.226 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.67 100.46 1.0 Allowed Glycine 0 N--CA 1.46 0.269 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 1.4 mt -146.59 157.91 43.81 Favored 'General case' 0 CA--C 1.5 -0.952 0 CA-C-O 123.665 1.698 . . . . 0.0 112.478 -178.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 8.0 mtp -113.79 108.53 17.22 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 111.156 -2.747 . . . . 0.0 104.604 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -87.25 100.96 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 106.144 -1.798 . . . . 0.0 106.144 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' M' ' 36' ' ' VAL . . . -73.23 163.0 54.86 Favored Glycine 0 CA--C 1.52 0.353 0 CA-C-N 112.724 -2.034 . . . . 0.0 113.383 -178.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . 0.522 ' N ' ' H ' ' M' ' 38' ' ' GLY . . . 114.92 60.72 0.37 Allowed Glycine 0 N--CA 1.471 0.972 0 C-N-CA 121.389 -0.434 . . . . 0.0 113.681 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . 0.582 ' CG1' ' H ' ' O' ' 39' ' ' VAL . 57.3 t -71.09 130.91 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.501 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 10.8 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.999 -1.001 . . . . 0.0 111.3 -179.031 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.48 132.97 52.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.759 0.314 . . . . 0.0 110.364 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -123.58 121.83 36.61 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.131 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 m -131.43 155.27 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.506 ' C ' ' CD2' ' O' ' 14' ' ' HIS . 86.7 m-70 -149.07 102.96 3.3 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.478 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.511 ' CD2' ' HE2' ' N' ' 14' ' ' HIS . 0.1 OUTLIER -149.27 176.44 10.53 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -149.25 140.0 22.7 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 174.616 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -95.05 110.24 22.19 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.227 1.566 . . . . 0.0 115.227 -178.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 10.9 mp -124.13 115.09 20.57 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 174.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -112.74 115.82 50.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.643 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 48.4 m-85 -112.22 104.97 13.19 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -111.86 131.75 55.15 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.9 136.61 32.46 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -95.2 113.86 25.58 Favored 'General case' 0 CA--C 1.52 -0.175 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 175.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.413 ' CB ' HD22 ' N' ' 27' ' ' ASN . 18.1 m-20 -133.99 48.62 2.33 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . . . . . . . . . 18.6 t -72.88 161.09 5.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 C-N-CA 118.218 -1.393 . . . . 0.0 109.664 -179.406 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.27 -29.89 9.56 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 -178.71 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 1.2 m 92.83 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 113.66 -1.27 . . . . 0.0 107.791 -178.736 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.499 ' OD1' ' N ' ' O' ' 30' ' ' ALA . 2.7 p30 -73.96 164.39 26.68 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.935 0.874 . . . . 0.0 113.071 -178.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.08 -36.28 12.84 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.862 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.38 78.5 0.07 OUTLIER Glycine 0 CA--C 1.532 1.119 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.354 -173.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . 0.499 ' N ' ' OD1' ' O' ' 27' ' ' ASN . . . -79.19 109.73 13.8 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 123.286 1.517 . . . . 0.0 110.955 -176.496 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 77.8 mt -133.15 142.21 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 113.483 -1.689 . . . . 0.0 112.802 -176.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . 0.421 HD11 HG22 ' O' ' 32' ' ' ILE . 52.9 mt -106.78 107.9 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 175.799 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.05 104.97 2.23 Favored Glycine 0 C--O 1.239 0.437 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 53.7 mt -140.35 144.0 36.06 Favored 'General case' 0 CA--C 1.504 -0.815 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -175.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 3.0 mtp -116.42 109.22 17.02 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 112.212 -2.267 . . . . 0.0 105.038 175.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -105.86 101.8 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.812 0.815 . . . . 0.0 111.05 -177.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.77 -179.11 0.65 Allowed Glycine 0 CA--C 1.538 1.5 0 CA-C-N 114.112 -1.404 . . . . 0.0 115.303 178.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' P' ' 38' ' ' GLY . . . -116.3 -58.3 0.32 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 114.253 -0.973 . . . . 0.0 111.788 179.282 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.582 ' H ' ' CG1' ' N' ' 39' ' ' VAL . 45.5 t -115.84 124.92 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.644 ' CG2' HE22 ' R' ' 15' ' ' GLN . 12.3 m . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.451 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 39.9 p90 -148.65 158.73 44.34 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.832 0.348 . . . . 0.0 110.768 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.31 123.8 31.97 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.839 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.402 HG22 ' HE2' ' P' ' 14' ' ' HIS . 2.2 p -130.04 132.3 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.801 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.671 ' HE2' HE22 ' P' ' 15' ' ' GLN . 7.5 t60 -144.98 134.25 22.9 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 -179.116 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.644 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 18.9 m-70 -147.45 156.42 42.85 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 175.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.671 HE22 ' HE2' ' P' ' 13' ' ' HIS . 3.1 mp0 -90.42 160.35 16.1 Favored 'General case' 0 C--O 1.225 -0.237 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.021 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -140.09 95.52 2.9 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.725 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -136.22 130.64 33.43 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.142 0.496 . . . . 0.0 111.122 179.03 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 24.1 t -119.94 115.21 46.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.489 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.485 ' CD1' ' CE1' ' Q' ' 19' ' ' PHE . 19.3 m-85 -109.09 111.87 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -127.01 123.45 37.1 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 -176.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.18 121.85 43.31 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 176.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -93.86 152.41 18.91 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 117.843 2.535 . . . . 0.0 117.843 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.409 ' OD1' ' OE1' ' Q' ' 22' ' ' GLU . 93.3 m-20 27.92 51.52 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 111.238 -2.71 . . . . 0.0 117.807 175.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 65.1 t -81.69 141.23 15.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 117.13 -1.828 . . . . 0.0 106.181 175.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' Q' ' 24' ' ' VAL . . . -71.53 -41.54 57.51 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 117.584 -2.246 . . . . 0.0 110.809 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.422 ' O ' ' C ' ' P' ' 27' ' ' ASN . 42.3 t -156.63 112.3 2.93 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 118.355 -0.831 . . . . 0.0 109.452 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.422 ' C ' ' O ' ' P' ' 26' ' ' SER . 7.4 t-20 -48.96 157.78 0.38 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.127 178.375 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.65 -47.88 61.83 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.665 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.82 61.21 0.08 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 114.261 -1.336 . . . . 0.0 109.768 -176.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' O' ' 30' ' ' ALA . . . -85.09 158.43 20.43 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 123.668 1.699 . . . . 0.0 115.377 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . 0.451 HG22 HD13 ' P' ' 31' ' ' ILE . 65.1 mt -145.05 148.3 17.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 112.342 -2.208 . . . . 0.0 113.482 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . 0.458 HG22 HD12 ' P' ' 32' ' ' ILE . 52.9 mt -106.19 107.64 23.17 Favored 'Isoleucine or valine' 0 C--N 1.35 0.625 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.159 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.89 101.38 2.27 Favored Glycine 0 N--CA 1.463 0.462 0 N-CA-C 104.215 -3.554 . . . . 0.0 104.215 175.292 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 26.4 tp -133.49 130.25 38.3 Favored 'General case' 0 C--O 1.239 0.544 0 N-CA-C 115.979 1.844 . . . . 0.0 115.979 -173.008 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 40.2 tpp -111.27 109.27 19.22 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 174.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 10.6 t -100.13 102.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.91 0.386 . . . . 0.0 110.573 -177.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.0 163.48 0.06 OUTLIER Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' O' ' 38' ' ' GLY . . . -94.57 -58.03 1.22 Allowed Glycine 0 CA--C 1.536 1.392 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.241 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' P' ' 40' ' ' VAL . 24.0 t -151.28 138.89 13.82 Favored 'Isoleucine or valine' 0 C--N 1.347 0.479 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.574 ' H ' ' C ' ' Q' ' 38' ' ' GLY . 31.1 t . . . . . 0 C--O 1.214 -0.789 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.435 -177.299 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.471 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -107.08 131.07 54.51 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -149.43 137.58 20.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.978 0.418 . . . . 0.0 110.348 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -127.58 118.44 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.571 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.59 ' HE2' ' C ' ' O' ' 40' ' ' VAL . 12.0 p-80 -158.47 121.05 3.7 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.868 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.644 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 4.1 p-80 -148.8 165.62 30.9 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 176.113 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.406 ' HA ' ' H ' ' P' ' 15' ' ' GLN . 9.8 pt20 -99.75 149.93 22.84 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.454 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . 0.498 ' CE ' ' HE2' ' Q' ' 14' ' ' HIS . 98.8 mttt -114.74 98.61 6.95 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.951 178.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . 0.404 ' HB3' ' CZ ' ' Q' ' 19' ' ' PHE . 6.0 mp -123.2 116.98 24.3 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 177.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -107.88 111.14 34.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.485 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 37.1 m-85 -107.21 107.34 18.25 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 178.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' R' ' 20' ' ' PHE . 12.9 t80 -122.52 124.92 44.66 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -176.27 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.36 118.31 27.21 Favored 'General case' 0 C--O 1.243 0.711 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 177.44 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' P' ' 23' ' ' ASP . 82.7 tt0 -82.77 146.24 29.09 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -176.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.492 ' O ' ' O ' ' R' ' 22' ' ' GLU . 64.2 t0 63.87 -52.13 0.25 Allowed 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 113.878 -1.51 . . . . 0.0 112.089 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' P' ' 25' ' ' GLY . 0.8 OUTLIER 50.51 -153.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.302 177.842 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.403 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 143.39 19.03 0.22 Allowed Glycine 0 N--CA 1.464 0.544 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 -177.026 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -63.13 129.9 42.3 Favored 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 114.691 -0.754 . . . . 0.0 109.342 -178.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.525 ' CG ' ' H ' ' Q' ' 28' ' ' LYS . 45.3 t-20 -126.98 -130.62 0.23 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.186 -174.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.525 ' H ' ' CG ' ' Q' ' 27' ' ' ASN . 74.1 mmtt -38.79 -46.87 1.32 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.041 -0.982 . . . . 0.0 111.483 -176.591 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.19 52.44 0.9 Allowed Glycine 0 CA--C 1.547 2.058 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.786 -177.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.8 127.43 41.95 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-O 120.915 0.388 . . . . 0.0 110.103 179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . 0.578 ' CD1' ' N ' ' K' ' 40' ' ' VAL . 28.9 mt -142.81 153.25 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-O 121.821 0.819 . . . . 0.0 113.064 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 86.5 mt -136.22 123.34 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 O-C-N 121.795 -0.565 . . . . 0.0 110.34 179.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.4 110.66 1.29 Allowed Glycine 0 N--CA 1.468 0.77 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 28.4 mt -119.34 121.2 39.03 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.634 0.255 . . . . 0.0 111.444 -178.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 95.3 mmm -111.33 127.61 55.7 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.405 ' O ' ' N ' ' R' ' 37' ' ' GLY . 53.6 t -122.79 131.73 72.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-N 118.69 0.677 . . . . 0.0 112.103 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -55.82 -111.52 0.01 OUTLIER Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.743 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.574 ' C ' ' H ' ' P' ' 40' ' ' VAL . . . 95.86 -72.92 0.87 Allowed Glycine 0 CA--C 1.537 1.436 0 N-CA-C 111.962 -0.455 . . . . 0.0 111.962 179.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.437 ' CG2' ' O ' ' Q' ' 38' ' ' GLY . 14.2 t -164.1 121.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . 0.481 ' OXT' ' CG2' ' E' ' 31' ' ' ILE . 58.7 t . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.992 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -82.69 131.06 35.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.811 0.339 . . . . 0.0 110.93 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' R' ' 11' ' ' GLU . 56.3 mp0 -118.98 148.43 42.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.815 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 20.1 t -106.97 98.05 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.494 0.664 . . . . 0.0 110.885 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -120.25 93.5 4.07 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.901 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -153.88 164.02 39.08 Favored 'General case' 0 C--O 1.222 -0.392 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.644 HE22 ' CG2' ' O' ' 40' ' ' VAL . 90.4 mm-40 -89.85 158.41 17.47 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.417 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -140.4 90.13 2.33 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -134.37 120.14 19.48 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.2 t -104.89 113.5 42.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -104.9 98.05 7.83 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 106.028 -1.842 . . . . 0.0 106.028 177.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' Q' ' 20' ' ' PHE . 42.0 t80 -115.22 114.28 25.02 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.58 0.705 . . . . 0.0 110.847 -178.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' R' ' 23' ' ' ASP . . . -128.37 125.11 38.0 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.492 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 81.0 tt0 -71.5 85.13 0.84 Allowed 'General case' 0 C--O 1.223 -0.319 0 C-N-CA 117.414 -1.714 . . . . 0.0 106.958 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' R' ' 21' ' ' ALA . 51.2 p30 -132.72 51.89 2.12 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.459 -176.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 69.5 t -74.82 143.29 13.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.19 37.56 3.8 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.037 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 42.5 t -75.53 101.93 5.06 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 121.47 0.652 . . . . 0.0 110.201 -179.426 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -96.44 -163.15 1.02 Allowed 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.965 -177.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -47.72 -42.14 24.51 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 114.225 -1.352 . . . . 0.0 113.701 -177.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.99 61.68 1.92 Allowed Glycine 0 CA--C 1.54 1.652 0 C-N-CA 120.301 -0.952 . . . . 0.0 114.187 -175.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.09 135.02 9.89 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 177.55 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.6 mt -118.01 128.45 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 CA-C-O 121.399 0.619 . . . . 0.0 111.965 -178.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 48.2 mm -120.4 123.34 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.894 178.634 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 118.05 2.8 Favored Glycine 0 N--CA 1.468 0.786 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 67.8 mt -116.54 114.9 24.81 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 85.9 mmm -134.27 136.23 43.43 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.042 -178.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.63 155.84 34.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 121.33 0.585 . . . . 0.0 111.006 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -52.93 -102.27 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.149 178.312 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 49.24 71.06 0.66 Allowed Glycine 0 CA--C 1.529 0.939 0 CA-C-N 115.148 -0.526 . . . . 0.0 111.807 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . 0.413 ' CG1' ' N ' ' R' ' 40' ' ' VAL . 59.9 t -112.29 165.69 7.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . 0.413 ' N ' ' CG1' ' R' ' 39' ' ' VAL . 15.5 m . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.101 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -112.91 133.69 54.77 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -128.08 132.17 49.04 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.141 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.23 140.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.476 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -142.11 158.37 43.82 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.069 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.614 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -89.26 169.56 11.34 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.021 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -129.42 150.71 50.65 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -97.14 118.92 34.63 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.691 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.3 mt -124.77 114.9 19.88 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -132.83 136.4 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.351 -0.386 . . . . 0.0 109.977 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -128.03 130.52 48.42 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.456 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -123.6 120.49 32.97 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.999 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.04 127.43 48.77 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.404 ' CD ' ' OE1' ' B' ' 22' ' ' GLU . 83.2 tt0 -147.95 149.14 31.66 Favored 'General case' 0 CA--C 1.533 0.327 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -178.327 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.0 t0 51.68 46.38 26.62 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 176.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.498 ' CG1' ' H ' ' A' ' 25' ' ' GLY . 41.2 t -102.45 -177.87 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.147 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.498 ' H ' ' CG1' ' A' ' 24' ' ' VAL . . . -70.41 -32.83 68.06 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 177.733 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 27' ' ' ASN . 46.7 t -152.36 123.27 7.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.013 -1.093 . . . . 0.0 108.25 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.726 ' H ' ' HZ2' ' B' ' 28' ' ' LYS . 9.9 t-20 -40.88 166.61 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.246 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.591 ' H ' ' ND2' ' A' ' 27' ' ' ASN . 68.1 mttm -78.66 40.42 0.38 Allowed 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.961 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.463 ' C ' ' H ' ' A' ' 31' ' ' ILE . . . 119.57 78.37 0.56 Allowed Glycine 0 CA--C 1.533 1.167 0 CA-C-O 118.362 -1.243 . . . . 0.0 113.938 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.68 43.41 0.75 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-N 121.011 2.405 . . . . 0.0 110.9 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.463 ' H ' ' C ' ' A' ' 29' ' ' GLY . 54.9 mt -150.47 126.94 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 CA-C-N 113.148 -1.842 . . . . 0.0 106.866 178.871 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.432 ' O ' ' O ' ' B' ' 33' ' ' GLY . 50.7 mt -105.89 110.2 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.987 -0.745 . . . . 0.0 108.987 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.56 93.7 0.57 Allowed Glycine 0 CA--C 1.508 -0.368 0 N-CA-C 105.614 -2.994 . . . . 0.0 105.614 177.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -147.17 168.04 22.67 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 122.998 1.38 . . . . 0.0 114.133 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -120.22 110.64 16.84 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 112.224 -2.262 . . . . 0.0 107.229 178.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -97.92 113.44 32.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.498 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.68 -125.03 1.49 Allowed Glycine 0 C--N 1.315 -0.596 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.24 -62.89 0.37 Allowed Glycine 0 CA--C 1.546 1.987 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.9 m -134.73 159.9 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 116.999 0.399 . . . . 0.0 110.009 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 42.9 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.336 179.222 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.94 146.06 34.42 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.644 0.259 . . . . 0.0 110.358 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.493 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 58.5 mp0 -72.68 119.31 16.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.963 0.411 . . . . 0.0 110.263 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . 0.497 ' CG2' ' HE2' ' A' ' 14' ' ' HIS . 26.0 m -134.89 161.01 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.835 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -131.32 96.15 3.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.075 0.464 . . . . 0.0 111.704 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.61 ' CD2' ' HE2' ' C' ' 14' ' ' HIS . 24.6 p80 -156.89 169.15 25.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 177.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 47.6 tt0 -129.51 150.45 50.85 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.956 0.407 . . . . 0.0 110.128 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -98.37 119.94 37.93 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.722 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 7.0 tt -122.76 122.79 39.55 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 118.194 0.452 . . . . 0.0 110.537 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -126.22 128.76 71.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.239 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 t80 -124.6 114.06 18.88 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.872 0.368 . . . . 0.0 110.022 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.643 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 32.7 t80 -115.34 119.98 38.08 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.647 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.13 128.28 37.76 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.718 0.771 . . . . 0.0 112.219 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.404 ' OE1' ' CD ' ' A' ' 22' ' ' GLU . 87.8 mt-10 -96.73 111.98 23.92 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.055 178.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -104.17 46.42 0.92 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.06 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.496 ' CG1' ' H ' ' B' ' 25' ' ' GLY . 20.7 t -82.33 176.07 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.629 -178.876 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.496 ' H ' ' CG1' ' B' ' 24' ' ' VAL . . . 91.87 -28.27 8.84 Favored Glycine 0 N--CA 1.465 0.622 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -177.993 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 2.1 p 166.31 131.52 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 60.1 t-20 -45.84 130.84 9.54 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.726 ' HZ2' ' H ' ' A' ' 27' ' ' ASN . 98.7 mttt -89.28 -46.61 8.64 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.36 60.92 0.1 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.588 -1.291 . . . . 0.0 113.28 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.86 113.95 8.44 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.968 1.47 . . . . 0.0 114.968 -176.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 93.0 mt -127.66 130.1 70.28 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 CA-C-N 112.696 -2.047 . . . . 0.0 109.702 178.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.412 ' O ' ' O ' ' C' ' 33' ' ' GLY . 94.3 mt -110.06 116.33 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 O-C-N 121.578 -0.701 . . . . 0.0 110.551 178.443 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -118.97 96.17 0.65 Allowed Glycine 0 C--O 1.238 0.352 0 N-CA-C 104.924 -3.271 . . . . 0.0 104.924 176.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 20.5 tp -135.9 136.74 40.74 Favored 'General case' 0 CA--C 1.502 -0.889 0 C-N-CA 119.268 -0.973 . . . . 0.0 113.099 -174.375 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.4 mtp -106.39 108.75 20.42 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -102.1 103.33 14.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.99 -153.61 25.11 Favored Glycine 0 N--CA 1.447 -0.622 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.44 -55.79 0.53 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -178.193 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.434 ' O ' ' OXT' ' B' ' 40' ' ' VAL . 27.8 m -124.05 137.02 58.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 123.449 0.7 . . . . 0.0 111.279 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.523 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 40.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.651 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.409 -1.477 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -105.35 135.37 46.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.934 0.397 . . . . 0.0 110.468 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.412 ' O ' ' OE2' ' D' ' 11' ' ' GLU . 80.1 mm-40 -138.24 139.53 39.27 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.384 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 t -106.7 91.22 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.826 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -104.39 131.17 52.04 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.2 0.524 . . . . 0.0 111.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.61 ' HE2' ' CD2' ' B' ' 14' ' ' HIS . 1.0 OUTLIER -151.0 165.23 34.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.534 179.285 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 95.8 mm-40 -90.02 151.94 21.42 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -148.4 99.12 2.99 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -131.28 128.99 40.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.447 0.641 . . . . 0.0 111.399 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.99 114.56 45.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.05 107.83 18.32 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.643 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 17.1 t80 -113.77 124.86 53.27 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 122.009 0.123 . . . . 0.0 111.114 -178.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.82 131.83 21.67 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 120.262 -0.575 . . . . 0.0 112.516 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.04 112.43 21.77 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.179 0.514 . . . . 0.0 110.711 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.452 ' OD1' ' OD2' ' D' ' 23' ' ' ASP . 13.6 p-10 -124.86 46.56 2.3 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.559 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.628 ' CG1' ' H ' ' C' ' 25' ' ' GLY . 21.8 t -73.38 179.74 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.774 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.628 ' H ' ' CG1' ' C' ' 24' ' ' VAL . . . 99.26 -35.38 4.73 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-N 114.329 -1.305 . . . . 0.0 113.413 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.489 ' O ' ' O ' ' C' ' 27' ' ' ASN . 28.6 t -162.38 117.53 1.87 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.6 1.7 . . . . 0.0 112.548 175.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.489 ' O ' ' O ' ' C' ' 26' ' ' SER . 67.2 m-20 -23.23 151.39 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 118.976 -0.535 . . . . 0.0 112.232 175.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 39.5 tttp -167.55 31.36 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 173.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' D' ' 27' ' ' ASN . . . 81.01 80.81 0.85 Allowed Glycine 0 CA--C 1.535 1.328 0 C-N-CA 117.886 -2.102 . . . . 0.0 114.097 175.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.93 119.49 38.88 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.447 1.623 . . . . 0.0 109.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 82.9 mt -123.14 132.53 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -177.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 2.8 mt -105.79 108.45 25.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 174.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' B' ' 32' ' ' ILE . . . -123.64 106.76 1.01 Allowed Glycine 0 N--CA 1.465 0.577 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 3.0 mp -139.27 143.36 37.91 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 122.702 1.239 . . . . 0.0 113.434 -177.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -113.49 103.66 11.49 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 175.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 t -111.72 102.91 14.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.09 -151.78 20.89 Favored Glycine 0 C--N 1.31 -0.879 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -178.427 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.91 -56.81 0.6 Allowed Glycine 0 CA--C 1.54 1.618 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.725 -179.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . 0.415 ' N ' HG23 ' D' ' 39' ' ' VAL . 33.6 m -135.81 163.71 34.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 123.037 0.535 . . . . 0.0 111.095 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.987 -179.434 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -149.34 158.15 43.93 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.844 0.354 . . . . 0.0 110.439 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.412 ' OE2' ' O ' ' C' ' 11' ' ' GLU . 83.3 tt0 -154.96 131.5 10.55 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.037 0.446 . . . . 0.0 110.488 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -139.4 137.43 40.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.237 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.62 ' NE2' ' ND1' ' E' ' 13' ' ' HIS . 5.7 p80 -133.52 119.44 19.53 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -149.07 164.86 33.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.528 0.68 . . . . 0.0 112.144 -178.449 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.531 ' OE1' ' NE2' ' E' ' 15' ' ' GLN . 85.1 mt-30 -84.49 156.59 21.64 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 176.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -159.26 105.87 1.73 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 120.043 -0.663 . . . . 0.0 109.237 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . 0.429 ' N ' HD11 ' D' ' 17' ' ' LEU . 3.4 mp -136.67 127.85 28.01 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.434 0.635 . . . . 0.0 111.695 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -109.72 115.43 49.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.347 178.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' E' ' 19' ' ' PHE . 35.2 m-85 -108.55 106.95 17.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 47.3 t80 -111.87 119.01 37.1 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.851 -179.302 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.73 138.57 28.93 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 119.569 -0.852 . . . . 0.0 112.968 -179.24 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.3 mt-10 -120.15 133.45 55.5 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.776 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.506 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 0.0 OUTLIER -149.41 59.78 1.02 Allowed 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.652 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 4.4 t 91.3 -169.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 176.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.652 ' H ' ' CG1' ' D' ' 24' ' ' VAL . . . -76.98 -33.82 44.36 Favored Glycine 0 C--O 1.214 -1.146 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.449 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 5.3 p -147.3 118.4 7.74 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.289 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.412 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 17.7 t-20 -59.93 169.03 1.59 Allowed 'General case' 0 C--N 1.333 -0.113 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.884 -179.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -55.25 -38.06 68.04 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.839 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.58 71.42 0.1 Allowed Glycine 0 CA--C 1.533 1.215 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.829 -174.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.49 135.27 47.05 Favored 'General case' 0 C--O 1.245 0.832 0 CA-C-N 118.785 1.293 . . . . 0.0 112.694 -174.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.565 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 77.9 mt -139.28 134.62 40.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 113.845 -1.525 . . . . 0.0 114.09 -176.29 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.444 HD11 HG23 ' D' ' 32' ' ' ILE . 3.6 mt -107.48 111.22 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 174.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.55 103.45 0.92 Allowed Glycine 0 N--CA 1.46 0.297 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 177.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 6.1 tt -140.8 146.63 37.87 Favored 'General case' 0 CA--C 1.513 -0.463 0 C-N-CA 119.055 -1.058 . . . . 0.0 113.171 -176.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 17.9 mtp -120.21 115.25 23.25 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.194 178.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.97 102.83 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.27 -151.31 19.53 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 119.66 -1.257 . . . . 0.0 110.561 179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.401 ' O ' ' OXT' ' E' ' 40' ' ' VAL . . . 99.7 -57.4 0.84 Allowed Glycine 0 CA--C 1.544 1.88 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.484 -178.382 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.461 ' C ' ' O ' ' E' ' 38' ' ' GLY . 27.7 m -134.93 159.92 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 C-N-CA 123.356 0.662 . . . . 0.0 110.773 -178.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.53 -179.603 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.48 134.76 48.06 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.385 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -142.07 146.0 34.96 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.173 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.503 ' CG2' ' CD2' ' E' ' 14' ' ' HIS . 3.3 p -139.83 148.69 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 121.065 0.459 . . . . 0.0 110.716 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.622 ' CD2' ' NE2' ' F' ' 13' ' ' HIS . 0.1 OUTLIER -143.27 119.26 10.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.755 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.534 ' ND1' ' N ' ' F' ' 14' ' ' HIS . 90.1 m-70 -143.9 164.35 30.81 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.014 178.313 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' OE1' ' D' ' 15' ' ' GLN . 64.4 tp60 -89.98 151.93 21.45 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 177.526 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -148.74 98.8 2.91 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.782 177.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . 0.531 ' CD2' HE21 ' E' ' 15' ' ' GLN . 37.1 mt -122.8 119.33 30.26 Favored 'General case' 0 CA--C 1.509 -0.615 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.081 178.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -107.62 104.32 16.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' D' ' 19' ' ' PHE . 73.9 m-85 -103.67 105.69 15.99 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -107.49 114.57 28.66 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 -179.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.47 138.43 31.0 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 119.096 -1.042 . . . . 0.0 112.623 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -84.59 141.85 30.39 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.624 -179.251 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 0.6 OUTLIER 172.64 47.07 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.066 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -179.095 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' D' ' 25' ' ' GLY . 3.5 m -73.43 175.28 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.307 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 100.14 -29.75 11.56 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.165 176.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 92.01 114.67 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 -177.796 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.468 ' O ' ' ND2' ' F' ' 27' ' ' ASN . 78.6 m-20 -73.92 174.53 8.4 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.754 -178.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.11 -36.69 41.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.559 178.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.79 77.08 0.07 OUTLIER Glycine 0 CA--C 1.532 1.094 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -177.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.28 155.4 27.3 Favored 'General case' 0 C--O 1.241 0.64 0 CA-C-O 121.946 0.879 . . . . 0.0 111.673 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.448 HD11 ' H ' ' Q' ' 39' ' ' VAL . 75.0 mt -131.44 133.34 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 114.554 -1.203 . . . . 0.0 112.248 -177.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.43 115.35 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.289 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.49 113.42 1.6 Allowed Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 46.8 tp -123.37 121.38 35.64 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-O 120.825 0.345 . . . . 0.0 110.619 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.1 mtp -109.57 105.72 15.14 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.485 ' CG1' ' H ' ' E' ' 37' ' ' GLY . 21.6 t -91.84 174.33 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.373 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.485 ' H ' ' CG1' ' E' ' 36' ' ' VAL . . . 167.99 -95.15 0.11 Allowed Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 92.64 -82.64 1.12 Allowed Glycine 0 N--CA 1.474 1.193 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -178.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.417 ' O ' ' OXT' ' F' ' 40' ' ' VAL . 64.4 t -72.17 101.89 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.329 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.401 ' OXT' ' O ' ' D' ' 38' ' ' GLY . 8.8 p . . . . . 0 C--O 1.222 -0.37 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.793 -179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -112.98 138.18 50.26 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.815 0.341 . . . . 0.0 110.792 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -110.01 113.47 26.21 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.895 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -112.82 100.67 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.165 0.507 . . . . 0.0 109.757 179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.622 ' NE2' ' CD2' ' E' ' 13' ' ' HIS . 68.8 m80 -140.16 114.6 9.28 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.954 -178.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.534 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 77.2 m80 -156.21 162.1 40.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 177.31 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -90.06 158.23 17.42 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.678 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 31.9 tttt -141.16 98.28 3.34 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 175.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 7.9 mt -119.06 110.75 17.45 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 83.1 t -101.29 99.26 8.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.4 ' CD1' ' CD2' ' E' ' 19' ' ' PHE . 92.6 m-85 -96.51 95.08 7.76 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 106.768 -1.568 . . . . 0.0 106.768 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 67.8 t80 -107.4 109.25 20.93 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.548 ' O ' ' N ' ' F' ' 23' ' ' ASP . . . -148.82 135.41 19.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.508 ' O ' ' O ' ' E' ' 23' ' ' ASP . 63.3 mt-10 -74.98 79.53 2.18 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 102.807 -3.035 . . . . 0.0 102.807 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.749 ' O ' ' O ' ' F' ' 24' ' ' VAL . 53.0 p30 -120.71 54.34 1.08 Allowed 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 112.472 -2.149 . . . . 0.0 113.729 -173.304 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.749 ' O ' ' O ' ' F' ' 23' ' ' ASP . 13.7 t -52.64 -123.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 177.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.427 ' O ' ' CB ' ' F' ' 30' ' ' ALA . . . 139.76 -35.84 1.89 Allowed Glycine 0 N--CA 1.469 0.837 0 C-N-CA 117.428 -2.32 . . . . 0.0 116.648 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 41.5 t -65.44 111.51 3.11 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 115.142 -2.623 . . . . 0.0 109.372 -174.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.703 ' O ' ' N ' ' F' ' 29' ' ' GLY . 71.5 m-20 -149.45 175.19 11.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 111.235 -2.711 . . . . 0.0 106.97 179.116 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.46 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.9 tttt -8.95 -45.31 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.916 0 N-CA-C 114.55 1.315 . . . . 0.0 114.55 176.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.703 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -170.03 60.66 0.18 Allowed Glycine 0 CA--C 1.551 2.304 0 C-N-CA 120.151 -1.023 . . . . 0.0 115.165 179.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.427 ' CB ' ' O ' ' F' ' 25' ' ' GLY . . . -85.57 160.86 19.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 118.936 1.368 . . . . 0.0 109.965 178.161 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.43 HD12 HG21 ' F' ' 31' ' ' ILE . 96.5 mt -134.97 136.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -128.54 124.7 62.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.82 129.05 4.31 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.663 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.6 125.34 44.66 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 95.6 mmm -131.47 133.28 44.98 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.609 -179.084 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 14.7 p -141.48 149.77 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 120.815 0.341 . . . . 0.0 110.788 178.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.12 102.04 0.42 Allowed Glycine 0 C--N 1.322 -0.216 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.22 -71.95 0.4 Allowed Glycine 0 CA--C 1.539 1.584 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.077 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.455 ' O ' ' OXT' ' F' ' 40' ' ' VAL . 5.6 m -79.31 167.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.523 ' H ' ' CG2' ' L' ' 31' ' ' ILE . 27.2 m . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.502 179.329 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . 0.527 ' CD2' ' O ' ' G' ' 11' ' ' GLU . 86.7 t80 -73.19 139.84 46.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.776 0.322 . . . . 0.0 110.405 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . 0.527 ' O ' ' CD2' ' G' ' 10' ' ' TYR . 79.4 mm-40 -70.73 150.32 46.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.535 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 65.1 t -120.94 130.54 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.953 0.406 . . . . 0.0 110.018 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -82.16 160.77 23.01 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.643 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.421 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 33.9 p-80 -99.5 169.49 9.27 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.083 0.468 . . . . 0.0 111.356 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -129.69 151.38 50.35 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.036 179.038 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -95.63 130.57 42.47 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.59 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.1 mt -126.19 112.43 15.77 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.218 0.532 . . . . 0.0 109.783 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 21.2 m -125.65 132.49 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.179 -179.227 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -127.0 113.32 16.32 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -111.82 117.51 33.01 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 110.297 -0.261 . . . . 0.0 110.297 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.04 107.39 14.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -151.36 138.96 19.63 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 55.18 46.41 23.91 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 119.985 -0.686 . . . . 0.0 110.857 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.54 ' CG1' ' H ' ' G' ' 25' ' ' GLY . 37.0 t -80.42 -179.86 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.54 ' H ' ' CG1' ' G' ' 24' ' ' VAL . . . -71.27 -31.82 65.84 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.371 -177.246 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 15.2 t -173.93 127.53 0.38 Allowed 'General case' 0 C--O 1.224 -0.283 0 CA-C-N 118.35 1.075 . . . . 0.0 113.656 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.6 m-20 -2.56 150.74 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 175.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -158.88 17.48 0.19 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 121.942 -0.474 . . . . 0.0 110.326 177.08 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.33 169.53 0.66 Allowed Glycine 0 CA--C 1.524 0.651 0 CA-C-N 115.892 -0.594 . . . . 0.0 112.898 176.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.422 ' H ' ' HB2' ' H' ' 27' ' ' ASN . . . -130.83 87.31 2.47 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.346 0.593 . . . . 0.0 111.588 178.38 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 42.2 pt -138.83 127.12 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.223 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 177.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.462 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.8 mt -107.73 111.12 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.29 95.14 0.65 Allowed Glycine 0 N--CA 1.463 0.458 0 N-CA-C 105.347 -3.101 . . . . 0.0 105.347 177.056 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.4 mt -142.71 161.34 38.34 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 122.462 1.125 . . . . 0.0 113.861 -175.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 54.9 tpp -120.67 115.02 22.55 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 113.041 -1.89 . . . . 0.0 107.843 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.57 111.76 19.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.61 -131.49 5.52 Favored Glycine 0 C--N 1.315 -0.585 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.55 -63.18 1.13 Allowed Glycine 0 CA--C 1.535 1.333 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.718 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.404 ' O ' ' C ' ' G' ' 40' ' ' VAL . 11.9 p -120.47 153.34 23.59 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.531 ' OXT' ' CE1' ' J' ' 13' ' ' HIS . 22.7 m . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 118.06 -0.971 . . . . 0.0 111.069 -178.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.62 134.75 52.98 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.727 0.299 . . . . 0.0 110.289 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.73 137.96 37.24 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.4 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.0 t -123.78 107.63 19.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 81.0 t60 -126.63 120.9 30.66 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.92 0.391 . . . . 0.0 110.579 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' O ' ' I' ' 14' ' ' HIS . 11.7 t60 -155.59 170.28 22.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.094 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.595 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 82.5 mt-30 -156.0 141.95 18.1 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -82.38 120.41 25.4 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.362 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -120.54 114.5 21.84 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 25.6 m -133.98 131.79 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 121.364 0.602 . . . . 0.0 111.195 179.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -122.26 120.14 33.24 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.201 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -117.34 122.17 43.15 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.736 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.61 115.73 22.62 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.44 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.551 ' O ' ' N ' ' H' ' 24' ' ' VAL . 95.7 mt-10 -115.8 141.84 47.56 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 112.86 0.689 . . . . 0.0 112.86 -178.025 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 54.38 -59.71 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 114.668 -1.151 . . . . 0.0 113.789 178.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.551 ' N ' ' O ' ' H' ' 22' ' ' GLU . 16.3 m -93.48 172.04 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-O 122.005 0.907 . . . . 0.0 111.616 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.97 27.93 65.65 Favored Glycine 0 CA--C 1.529 0.948 0 CA-C-N 113.841 -1.527 . . . . 0.0 112.762 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 46.6 t -98.38 110.83 23.35 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.426 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 5.4 t-20 -77.19 172.81 12.66 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 118.062 -1.455 . . . . 0.0 110.562 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.543 ' O ' ' N ' ' I' ' 28' ' ' LYS . 68.7 mttm -52.4 -36.46 54.16 Favored 'General case' 0 C--O 1.218 -0.575 0 CA-C-O 121.988 0.899 . . . . 0.0 110.821 176.055 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -132.12 79.48 0.35 Allowed Glycine 0 N--CA 1.47 0.901 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.466 -175.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.61 132.53 43.87 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 118.829 1.314 . . . . 0.0 111.132 -176.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.417 HD11 HG23 ' H' ' 31' ' ' ILE . 87.5 mt -140.84 147.55 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 113.954 -1.475 . . . . 0.0 113.544 -174.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 65.3 mt -106.86 107.25 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -111.56 98.59 1.03 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.178 -2.369 . . . . 0.0 107.178 178.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.4 mt -135.18 139.09 44.29 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.584 1.183 . . . . 0.0 113.392 -176.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -106.21 108.66 20.29 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.15 -2.537 . . . . 0.0 104.15 175.287 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 53.1 t -127.94 131.26 69.77 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.247 0 CA-C-O 121.184 0.516 . . . . 0.0 112.159 -175.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.88 -111.11 3.68 Favored Glycine 0 C--N 1.32 -0.339 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.749 178.444 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.7 -74.22 2.42 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.415 ' O ' ' O ' ' G' ' 40' ' ' VAL . 18.2 t -110.43 135.93 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 122.902 0.481 . . . . 0.0 110.475 179.08 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 69.9 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.322 178.249 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.423 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -82.89 136.71 34.5 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.869 0.366 . . . . 0.0 110.533 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -78.6 155.39 29.63 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.424 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.494 ' CG1' ' N ' ' I' ' 13' ' ' HIS . 74.0 t -138.4 166.91 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.931 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.551 ' O ' ' ND1' ' J' ' 13' ' ' HIS . 11.0 m-70 -54.99 143.0 27.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.777 0.322 . . . . 0.0 111.46 -178.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 16.7 t-80 -153.9 154.31 33.64 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.601 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 64.2 tp60 -98.76 169.3 9.58 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 118.315 0.507 . . . . 0.0 111.208 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 82.2 tttt -159.73 104.29 1.57 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 176.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 11.7 mt -123.89 123.29 40.1 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 121.236 0.541 . . . . 0.0 111.472 178.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -115.91 112.08 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 177.593 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -112.54 107.36 16.07 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -114.74 126.93 55.41 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 130.09 25.35 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.817 0.818 . . . . 0.0 113.114 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.453 ' OE1' ' OE1' ' J' ' 22' ' ' GLU . 58.5 mm-40 -95.6 120.23 35.48 Favored 'General case' 0 N--CA 1.461 0.096 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -125.72 48.64 2.04 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.038 0.385 . . . . 0.0 112.038 -177.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.428 ' CG1' ' N ' ' I' ' 25' ' ' GLY . 81.2 t -72.39 161.11 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 C-N-CA 118.447 -1.301 . . . . 0.0 109.896 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.481 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 108.39 -30.05 9.34 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 22.9 p 93.28 113.59 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 112.573 -1.814 . . . . 0.0 109.619 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -74.19 161.95 29.44 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 117.916 -1.514 . . . . 0.0 110.649 178.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.591 ' HZ2' ' CG ' ' D' ' 13' ' ' HIS . 72.7 tttt -48.65 -39.5 24.5 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 174.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.33 68.82 0.04 OUTLIER Glycine 0 CA--C 1.551 2.327 0 CA-C-O 118.826 -0.986 . . . . 0.0 112.421 -174.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.25 150.62 46.22 Favored 'General case' 0 N--CA 1.478 0.938 0 CA-C-N 119.775 1.787 . . . . 0.0 114.587 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 77.5 mt -141.44 152.32 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 113.517 -1.674 . . . . 0.0 113.996 -176.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.44 HD12 HG22 ' I' ' 32' ' ' ILE . 6.6 mt -106.93 109.08 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 174.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.42 106.03 2.04 Favored Glycine 0 N--CA 1.465 0.617 0 N-CA-C 106.323 -2.711 . . . . 0.0 106.323 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 26.6 tp -147.54 140.25 24.79 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.837 1.303 . . . . 0.0 113.969 -174.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 42.8 tpp -110.04 115.08 29.13 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 113.033 -1.894 . . . . 0.0 106.799 177.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.79 123.13 51.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.06 -113.55 0.86 Allowed Glycine 0 C--N 1.317 -0.527 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 86.24 -73.01 2.58 Favored Glycine 0 CA--C 1.536 1.405 0 CA-C-N 115.48 -0.36 . . . . 0.0 112.211 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 39.7 t -123.19 146.09 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.437 ' OXT' ' O ' ' I' ' 39' ' ' VAL . 52.9 t . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.651 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.84 134.33 54.41 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.41 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 98.9 mt-10 -74.57 130.79 40.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.483 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 32.9 m -138.38 88.09 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-O 121.601 0.715 . . . . 0.0 110.904 -179.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.551 ' ND1' ' O ' ' I' ' 13' ' ' HIS . 6.1 t60 -129.03 128.14 43.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.433 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.569 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -140.67 173.64 11.29 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.426 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 10.2 tt0 -124.64 142.45 51.37 Favored 'General case' 0 C--O 1.224 -0.248 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.465 177.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.82 112.16 23.45 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 119.168 -0.444 . . . . 0.0 111.078 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 24.0 mt -118.43 114.36 22.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.613 0.642 . . . . 0.0 109.984 177.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 t -110.13 105.83 19.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.481 ' CD2' ' CE1' ' K' ' 19' ' ' PHE . 65.5 m-85 -106.36 106.67 17.3 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.454 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.6 t80 -115.24 122.48 46.11 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.77 138.3 32.19 Favored 'General case' 0 C--O 1.253 1.26 0 CA-C-O 123.091 1.424 . . . . 0.0 114.479 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.453 ' OE1' ' OE1' ' I' ' 22' ' ' GLU . 24.0 tt0 -79.89 90.99 5.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 113.526 -1.67 . . . . 0.0 107.614 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.685 ' O ' ' O ' ' K' ' 22' ' ' GLU . 84.3 m-20 -89.98 60.04 4.76 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 111.773 -2.467 . . . . 0.0 110.42 -178.944 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -62.7 -112.65 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-O 117.109 -1.424 . . . . 0.0 108.282 -174.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -103.82 44.51 1.47 Allowed Glycine 0 N--CA 1.472 1.081 0 CA-C-N 121.707 2.049 . . . . 0.0 112.078 -172.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 29.0 t -71.82 100.64 2.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -109.67 -150.81 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.176 -175.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 34.96 42.07 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 113.36 0.874 . . . . 0.0 113.36 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.55 71.82 0.63 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 117.297 1.679 . . . . 0.0 117.297 177.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.33 120.27 40.82 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 174.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 42.3 mt -145.12 155.45 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -174.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.448 HD12 HG22 ' J' ' 32' ' ' ILE . 40.7 mt -111.89 111.23 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.811 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.27 103.88 1.64 Allowed Glycine 0 N--CA 1.467 0.75 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 177.261 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 12.2 tp -137.33 137.31 38.79 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 122.205 1.003 . . . . 0.0 113.663 -175.795 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -111.39 114.22 27.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 113.677 -1.601 . . . . 0.0 107.543 176.419 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.423 ' O ' ' OE1' ' L' ' 15' ' ' GLN . 1.3 m -121.23 103.21 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 120.399 0.143 . . . . 0.0 111.11 -178.547 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.39 -153.43 25.33 Favored Glycine 0 C--N 1.318 -0.468 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.016 178.053 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.479 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 126.15 -56.4 0.71 Allowed Glycine 0 CA--C 1.541 1.71 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' J' ' 40' ' ' VAL . 55.0 t -136.5 137.17 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.437 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 61.2 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.433 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.98 143.81 41.07 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.754 0.311 . . . . 0.0 110.644 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -129.41 149.87 51.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.434 179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.534 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 34.2 m -140.37 161.45 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.498 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.505 ' CD2' ' H ' ' J' ' 13' ' ' HIS . 28.1 m80 -70.17 118.15 12.64 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' O ' ' L' ' 14' ' ' HIS . 65.9 t60 -148.23 162.82 38.71 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.107 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 41.3 tt0 -90.2 152.28 21.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.819 179.418 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -150.39 93.14 1.94 Allowed 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.616 177.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 2.0 mt -120.93 115.31 22.96 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.47 105.41 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.481 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 52.1 m-85 -104.28 103.67 13.45 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.454 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 31.9 t80 -113.07 119.3 37.37 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.524 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -156.74 162.71 39.76 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 122.626 1.203 . . . . 0.0 113.604 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.685 ' O ' ' O ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -82.05 118.81 23.31 Favored 'General case' 0 C--O 1.206 -1.22 0 C-N-CA 118.344 -1.342 . . . . 0.0 111.347 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.54 ' O ' ' CG1' ' K' ' 24' ' ' VAL . 65.2 m-20 -62.09 -50.41 72.04 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 120.251 -1.53 . . . . 0.0 110.016 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.54 ' CG1' ' O ' ' K' ' 23' ' ' ASP . 0.3 OUTLIER 159.6 171.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 178.626 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 -33.27 76.14 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 177.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.3 m -162.68 120.94 2.1 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 114.186 -1.007 . . . . 0.0 109.872 -177.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' K' ' 26' ' ' SER . 39.7 t30 -22.25 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -164.69 29.82 0.07 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.528 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.91 88.04 0.82 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.685 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.36 155.95 45.51 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 6.9 mt -127.1 146.93 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 113.657 0.984 . . . . 0.0 113.657 -176.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.43 HD12 HG22 ' K' ' 32' ' ' ILE . 96.7 mt -128.13 114.88 36.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.318 178.307 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.75 113.89 3.21 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 20.3 tp -122.84 124.36 43.11 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.802 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 17.8 mtp -129.24 131.09 46.98 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.409 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.44 ' CG1' ' N ' ' K' ' 37' ' ' GLY . 57.8 t -100.84 166.28 2.37 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-O 121.003 0.43 . . . . 0.0 110.568 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.44 ' N ' ' CG1' ' K' ' 36' ' ' VAL . . . -75.01 -102.91 0.1 OUTLIER Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.151 179.378 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.55 -77.16 0.59 Allowed Glycine 0 N--CA 1.474 1.217 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 45.5 t -115.26 132.05 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 121.428 0.632 . . . . 0.0 110.585 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' L' ' 40' ' ' VAL . 15.1 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.547 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -115.31 140.8 48.8 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.104 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -70.53 137.91 50.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.529 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 55.1 t -123.84 133.82 68.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.533 0.682 . . . . 0.0 110.942 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.492 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 2.5 m-70 -131.33 127.24 37.24 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.181 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.546 ' O ' ' ND1' ' K' ' 14' ' ' HIS . 94.9 m-70 -155.01 165.46 36.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.902 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.423 ' OE1' ' O ' ' J' ' 36' ' ' VAL . 47.5 mt-30 -89.69 156.64 18.42 Favored 'General case' 0 CA--C 1.518 -0.282 0 C-N-CA 119.521 -0.871 . . . . 0.0 109.635 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 52.4 tttp -141.99 95.66 2.84 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.221 177.542 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -117.65 108.19 15.14 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -107.11 103.93 16.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -101.23 102.13 12.97 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 178.13 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.7 t80 -126.52 129.7 49.15 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 121.35 0.595 . . . . 0.0 110.231 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.524 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -144.84 149.09 34.8 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 120.059 -0.656 . . . . 0.0 110.66 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -74.24 120.98 20.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.657 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -163.52 51.61 0.16 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 120.372 -0.531 . . . . 0.0 112.067 -178.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -76.15 143.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 118.119 -1.432 . . . . 0.0 108.51 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.52 -37.52 3.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.6 118.26 22.02 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 113.379 -1.411 . . . . 0.0 112.057 -179.267 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' L' ' 29' ' ' GLY . 57.3 p30 -89.01 -177.95 5.58 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -51.98 49.66 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 115.089 1.514 . . . . 0.0 115.089 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -101.58 51.35 0.93 Allowed Glycine 0 CA--C 1.549 2.182 0 CA-C-N 119.698 1.135 . . . . 0.0 113.515 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.38 174.47 9.83 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.523 ' CG2' ' H ' ' F' ' 40' ' ' VAL . 0.6 OUTLIER -106.91 119.91 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 176.214 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.421 HD13 HG23 ' L' ' 32' ' ' ILE . 95.0 mt -123.62 128.66 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 120.876 0.369 . . . . 0.0 111.7 -178.073 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 116.24 2.22 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 178.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 34.3 mt -119.64 124.59 46.67 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.7 ttm -124.04 123.54 40.57 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.468 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' L' ' 37' ' ' GLY . 72.8 t -98.33 131.52 45.24 Favored 'Isoleucine or valine' 0 C--N 1.34 0.17 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -34.6 -111.51 0.0 OUTLIER Glycine 0 CA--C 1.531 1.089 0 O-C-N 123.543 0.527 . . . . 0.0 113.257 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.68 -71.65 0.62 Allowed Glycine 0 CA--C 1.535 1.298 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.33 129.93 72.97 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.165 0.507 . . . . 0.0 110.998 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' K' ' 40' ' ' VAL . 8.7 p . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 117.899 -1.048 . . . . 0.0 110.724 179.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . 0.415 ' H ' ' H ' ' M' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.327 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . 0.415 ' H ' ' H ' ' M' ' 9' ' ' GLY . 97.3 m-85 -114.09 139.14 49.55 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.711 0.291 . . . . 0.0 110.593 -179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -71.17 127.64 33.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.874 0.369 . . . . 0.0 110.119 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -125.48 131.93 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.349 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -106.28 160.71 15.15 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.633 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.507 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 8.5 p80 -83.43 166.91 17.96 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 120.392 -0.523 . . . . 0.0 110.617 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -129.95 152.07 49.82 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.927 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 63.6 mttp -94.38 112.3 24.08 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.497 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 11.1 mp -116.88 120.61 39.02 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.879 0.371 . . . . 0.0 110.124 179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -129.61 132.54 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.049 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -142.25 134.23 27.3 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.989 0.423 . . . . 0.0 110.828 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.448 ' CD1' ' O ' ' M' ' 20' ' ' PHE . 52.8 p90 -123.31 133.11 54.18 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.732 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.91 125.66 41.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 121.145 0.498 . . . . 0.0 111.543 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -156.33 126.34 6.47 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.586 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.24 46.41 25.29 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.617 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 21.6 t -76.7 -179.8 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.349 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.617 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . -88.88 28.15 6.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 26' ' ' SER . . . . . 0.443 ' O ' ' C ' ' M' ' 27' ' ' ASN . 4.7 t -169.74 -134.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.865 -0.421 . . . . 0.0 109.865 -178.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.443 ' C ' ' O ' ' M' ' 26' ' ' SER . 3.0 t-20 -32.04 134.19 0.09 Allowed 'General case' 0 N--CA 1.472 0.671 0 O-C-N 122.985 0.178 . . . . 0.0 111.141 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . 0.452 ' O ' ' OD2' ' N' ' 23' ' ' ASP . 68.7 mttm -118.23 -38.5 3.18 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.04 -76.99 1.02 Allowed Glycine 0 CA--C 1.53 0.969 0 C-N-CA 118.794 -1.67 . . . . 0.0 112.178 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . 171.05 99.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.386 0.593 . . . . 0.0 111.31 178.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -127.9 116.63 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . 0.436 ' O ' ' O ' ' N' ' 33' ' ' GLY . 96.5 mt -113.49 108.1 24.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.26 96.87 0.78 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 105.45 -3.06 . . . . 0.0 105.45 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 91.3 mt -142.63 163.5 32.64 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 123.12 1.438 . . . . 0.0 114.163 -175.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -117.62 110.71 18.24 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 111.824 -2.443 . . . . 0.0 105.977 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 74.6 t -117.92 131.61 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 121.334 0.588 . . . . 0.0 110.15 -178.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.54 -111.42 3.36 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.924 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.1 -73.03 0.97 Allowed Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -99.17 158.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.339 0.149 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 11.7 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.567 -179.84 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -83.07 139.41 33.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.614 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -140.63 128.06 21.29 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.765 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -127.46 130.27 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -123.71 104.37 8.95 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.913 0.387 . . . . 0.0 111.667 -179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 1.0 OUTLIER -158.31 170.57 21.94 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.864 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 51.7 tt0 -155.44 141.46 18.28 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.897 0.379 . . . . 0.0 110.355 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -87.04 117.51 25.81 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.801 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -118.69 124.4 47.26 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 179.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.02 126.84 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 120.994 0.426 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -130.85 130.27 43.39 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.861 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -124.29 128.49 49.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 118.6 26.57 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.013 0.435 . . . . 0.0 110.458 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -127.22 128.69 46.48 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.463 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 34.4 m-20 -162.47 51.26 0.19 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.164 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 89.2 t -63.21 150.81 9.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.041 0.448 . . . . 0.0 110.668 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.06 -37.37 3.8 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.508 ' O ' ' O ' ' N' ' 27' ' ' ASN . 51.4 m -120.49 -112.36 0.33 Allowed 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.794 0.33 . . . . 0.0 111.588 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.524 ' ND2' ' OD1' ' O' ' 23' ' ' ASP . 16.3 m-20 52.31 153.08 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.69 -178.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' O' ' 28' ' ' LYS . 68.8 mttm -139.7 -29.57 0.73 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 113.712 1.005 . . . . 0.0 113.712 -179.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.73 85.02 0.11 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 120.421 -0.895 . . . . 0.0 113.935 -174.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.86 123.64 28.44 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 118.824 1.312 . . . . 0.0 110.627 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 70.0 mt -129.98 134.53 62.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.515 -175.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . 0.442 HD11 HG22 ' N' ' 32' ' ' ILE . 68.0 mt -105.0 104.93 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 106.87 -1.529 . . . . 0.0 106.87 174.323 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -110.41 109.44 2.64 Favored Glycine 0 C--O 1.235 0.202 0 N-CA-C 106.274 -2.73 . . . . 0.0 106.274 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -151.55 139.13 19.62 Favored 'General case' 0 CA--C 1.511 -0.535 0 C-N-CA 117.432 -1.707 . . . . 0.0 113.379 -175.412 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -105.25 108.88 20.63 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 111.756 -2.475 . . . . 0.0 106.424 177.401 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . 0.609 ' CG1' HE22 ' P' ' 15' ' ' GLN . 8.7 p -132.8 142.6 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.141 -177.687 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.74 -102.02 0.75 Allowed Glycine 0 C--N 1.32 -0.307 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' O' ' 39' ' ' VAL . . . 77.01 -80.76 1.21 Allowed Glycine 0 CA--C 1.531 1.064 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.49 149.51 14.66 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.574 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 33.3 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.873 -1.061 . . . . 0.0 110.256 179.452 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -148.93 159.94 43.73 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.729 0.299 . . . . 0.0 110.484 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -134.55 160.22 38.74 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.619 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -118.45 131.04 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.281 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 37.3 m-70 -140.13 123.6 17.08 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' ND1' ' P' ' 14' ' ' HIS . 30.9 m80 -147.58 174.09 12.08 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 121.25 0.548 . . . . 0.0 111.152 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 67.0 tp60 -137.69 140.8 40.98 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.821 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . 0.541 ' CG ' ' HE2' ' N' ' 14' ' ' HIS . 98.9 mttt -129.96 104.55 7.42 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 12.7 mt -116.61 116.3 27.32 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.006 179.544 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.89 106.34 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.891 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 13.6 m-30 -112.02 118.07 34.42 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -119.62 127.24 52.75 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.789 -0.187 . . . . 0.0 110.933 -179.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.39 124.83 26.35 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 121.944 0.878 . . . . 0.0 112.053 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' O' ' 23' ' ' ASP . 80.4 tt0 -96.09 141.79 29.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.316 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.524 ' OD1' ' ND2' ' N' ' 27' ' ' ASN . 65.3 m-20 -162.75 47.22 0.15 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.87 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.558 ' N ' ' OE1' ' P' ' 22' ' ' GLU . 25.0 m -62.77 -179.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 121.716 0.769 . . . . 0.0 111.535 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . 0.475 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 91.25 -29.01 7.42 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 114.22 -1.354 . . . . 0.0 113.358 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 0.9 OUTLIER 167.63 127.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 118.385 1.093 . . . . 0.0 112.798 179.467 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . 0.515 ' ND2' ' O ' ' P' ' 27' ' ' ASN . 39.4 t-20 -36.72 138.48 0.24 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 176.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' N' ' 28' ' ' LYS . 78.1 mttt -150.56 34.82 0.62 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 121.077 0.465 . . . . 0.0 111.684 -176.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.35 80.39 0.95 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 176.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.01 110.99 23.1 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 42.8 mt -121.93 130.72 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -176.545 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.5 mt -107.44 103.64 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.281 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.27 102.41 2.21 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 104.146 -3.582 . . . . 0.0 104.146 176.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 13.0 tp -140.19 135.87 32.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -172.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 35' ' ' MET . . . . . 0.428 ' SD ' ' CG ' ' P' ' 35' ' ' MET . 89.5 mmm -111.64 108.73 18.3 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 112.369 -2.196 . . . . 0.0 106.185 177.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . 0.597 ' CG1' ' NE2' ' Q' ' 15' ' ' GLN . 21.4 t -115.67 131.51 67.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.447 0.641 . . . . 0.0 111.94 -177.069 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' P' ' 37' ' ' GLY . . . 75.39 111.71 0.1 Allowed Glycine 0 CA--C 1.526 0.737 0 CA-C-N 114.767 -1.106 . . . . 0.0 114.222 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -94.17 -60.1 1.14 Allowed Glycine 0 CA--C 1.542 1.762 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' N' ' 38' ' ' GLY . 5.7 t -122.02 131.12 73.85 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.429 ' H ' ' HB ' ' P' ' 39' ' ' VAL . 91.4 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.922 -1.037 . . . . 0.0 110.476 -178.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . 0.436 ' O ' ' OE1' ' Q' ' 11' ' ' GLU . 93.5 m-85 -106.94 138.71 42.6 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.878 0.37 . . . . 0.0 110.31 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . 0.509 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 96.2 mt-10 -71.8 152.06 42.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.478 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . 0.461 ' CG2' ' O ' ' P' ' 12' ' ' VAL . 1.4 m -110.46 119.94 60.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 9.2 t60 -146.39 134.15 21.17 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 120.511 -0.475 . . . . 0.0 112.115 -177.846 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' NE2' ' O' ' 14' ' ' HIS . 1.0 OUTLIER -145.96 156.01 43.22 Favored 'General case' 0 C--O 1.23 0.068 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 176.314 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.616 HE21 ' CG ' ' P' ' 17' ' ' LEU . 53.1 tt0 -90.56 159.71 16.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.661 177.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 51.5 tttm -140.91 105.65 4.92 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.115 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . 0.616 ' CG ' HE21 ' P' ' 15' ' ' GLN . 39.6 mt -115.25 119.76 37.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-O 121.202 0.525 . . . . 0.0 111.166 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -116.75 98.29 6.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.436 ' CE1' ' CD2' ' O' ' 19' ' ' PHE . 16.9 m-30 -112.86 110.35 20.39 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -112.51 128.7 56.42 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.925 -179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . 0.426 ' O ' ' HA ' ' Q' ' 21' ' ' ALA . . . -153.5 158.13 40.86 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.953 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.558 ' OE1' ' N ' ' O' ' 24' ' ' VAL . 99.1 mt-10 -85.83 112.21 20.9 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.405 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 9.8 p-10 -112.44 52.07 0.79 Allowed 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 113.511 -1.677 . . . . 0.0 108.847 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . 0.489 ' CG1' ' N ' ' P' ' 25' ' ' GLY . 96.4 t -41.35 161.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 122.169 0.985 . . . . 0.0 112.249 -175.087 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.489 ' N ' ' CG1' ' P' ' 24' ' ' VAL . . . -93.14 32.61 5.57 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-N 113.077 -1.874 . . . . 0.0 114.218 -173.509 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.411 ' HB3' ' H ' ' O' ' 27' ' ' ASN . 11.9 t -92.57 -112.91 0.1 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.515 ' O ' ' ND2' ' O' ' 27' ' ' ASN . 15.4 m120 -86.27 156.58 20.2 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 118.097 -1.441 . . . . 0.0 110.893 -178.043 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 50.1 pttt -49.16 46.27 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . -99.38 58.17 0.85 Allowed Glycine 0 CA--C 1.545 1.915 0 CA-C-N 118.875 0.761 . . . . 0.0 112.322 179.065 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . 0.445 ' O ' ' CB ' ' Q' ' 30' ' ' ALA . . . -152.72 108.06 3.27 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 117.811 0.805 . . . . 0.0 110.856 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . 0.479 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 14.0 pt -145.04 147.86 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.9 mt -114.4 115.89 50.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.341 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.46 98.31 1.12 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 104.739 -3.344 . . . . 0.0 104.739 174.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 22.6 tp -127.49 132.43 49.98 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -173.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' P' P ' 35' ' ' MET . . . . . 0.428 ' CG ' ' SD ' ' O' ' 35' ' ' MET . 90.6 mmm -111.56 112.83 24.82 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 174.756 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . 0.422 HG23 HE22 ' R' ' 15' ' ' GLN . 0.0 OUTLIER -121.32 102.35 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -176.001 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' O' ' 37' ' ' GLY . . . 141.55 -161.34 27.0 Favored Glycine 0 CA--C 1.509 -0.339 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.802 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . 0.565 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 148.16 -55.8 0.5 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-O 119.234 -0.759 . . . . 0.0 111.229 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . 0.429 ' HB ' ' H ' ' O' ' 40' ' ' VAL . 73.3 t -144.72 139.85 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 118.355 1.078 . . . . 0.0 108.805 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 86.7 t . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 118.074 -0.965 . . . . 0.0 111.321 178.705 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -81.46 139.37 35.24 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.835 0.35 . . . . 0.0 110.609 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . 0.436 ' OE1' ' O ' ' P' ' 10' ' ' TYR . 95.9 mt-10 -85.36 110.0 18.8 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . 0.561 ' O ' ' NE2' ' P' ' 14' ' ' HIS . 34.4 m -141.13 165.27 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.509 ' CE1' ' O ' ' P' ' 11' ' ' GLU . 3.1 m-70 -132.93 121.13 22.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.785 178.326 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.588 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 32.1 m-70 -144.82 161.83 38.29 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.626 178.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . 0.597 ' NE2' ' CG1' ' O' ' 36' ' ' VAL . 58.1 tp60 -90.09 157.81 17.6 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.52 102.34 4.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 176.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 77.7 mt -116.14 117.11 29.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 C-N-CA 120.317 -0.553 . . . . 0.0 111.06 179.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 41.1 t -118.01 99.28 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 177.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . . . . . . . . . 7.2 m-30 -110.57 107.64 17.32 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -120.49 138.84 53.6 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.989 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . 0.426 ' HA ' ' O ' ' P' ' 21' ' ' ALA . . . -147.62 151.79 36.79 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' P' ' 23' ' ' ASP . 80.5 tt0 -80.27 121.8 26.09 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.217 -179.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.458 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 67.1 t0 -136.22 52.08 1.99 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.7 142.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.435 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 25' ' ' GLY . . . 100.4 38.05 3.61 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 106.082 -2.807 . . . . 0.0 106.082 -174.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 37.2 t -69.71 104.03 2.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.003 1.382 . . . . 0.0 114.568 -172.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . 0.505 ' O ' ' C ' ' Q' ' 28' ' ' LYS . 10.8 m120 -118.82 -153.33 0.53 Allowed 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 111.824 -2.444 . . . . 0.0 105.036 178.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . 0.505 ' C ' ' O ' ' Q' ' 27' ' ' ASN . 99.0 mttt -35.42 -41.15 0.17 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 120.354 1.434 . . . . 0.0 109.9 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.02 -65.42 2.59 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.95 1.54 . . . . 0.0 116.95 172.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . 0.445 ' CB ' ' O ' ' P' ' 30' ' ' ALA . . . -171.01 174.95 4.53 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.981 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.6 mt -121.12 118.08 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-N 113.347 -1.751 . . . . 0.0 107.015 176.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -120.38 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.24 0.543 . . . . 0.0 112.282 -178.04 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.81 114.34 2.07 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 32.0 mt -120.9 128.91 53.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 57.2 mtp -132.47 132.14 42.4 Favored 'General case' 0 CA--C 1.514 -0.405 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.314 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . 0.445 ' O ' ' N ' ' R' ' 37' ' ' GLY . 69.2 t -115.65 135.58 55.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.551 ' O ' ' N ' ' P' ' 38' ' ' GLY . . . -139.44 103.32 0.38 Allowed Glycine 0 C--N 1.306 -1.095 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 148.56 72.5 0.01 OUTLIER Glycine 0 N--CA 1.479 1.524 0 CA-C-N 119.76 1.78 . . . . 0.0 114.635 -178.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . 0.448 ' C ' ' O ' ' Q' ' 38' ' ' GLY . 37.2 t -18.63 125.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.601 0.761 . . . . 0.0 112.699 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.639 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -81.96 140.16 34.17 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.889 0.376 . . . . 0.0 110.589 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -113.53 128.04 56.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.711 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . 0.419 ' H ' HG12 ' Q' ' 12' ' ' VAL . 78.5 t -135.28 156.71 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.125 0.488 . . . . 0.0 110.982 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 3.2 m-70 -144.06 132.42 22.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.252 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . 0.588 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 64.2 m80 -151.73 161.73 42.18 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.016 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . 0.422 HE22 HG23 ' P' ' 36' ' ' VAL . 52.3 tt0 -90.13 158.45 17.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.89 0.376 . . . . 0.0 111.486 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.6 100.83 3.95 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . 0.402 ' H ' HD11 ' R' ' 17' ' ' LEU . 0.3 OUTLIER -111.64 112.78 24.73 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.958 0.409 . . . . 0.0 109.948 179.313 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 87.6 t -117.83 101.64 12.18 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . 0.465 ' O ' ' CD1' ' R' ' 20' ' ' PHE . 4.0 m-85 -119.43 116.83 26.96 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' R' ' 19' ' ' PHE . 80.1 m-85 -150.8 160.03 44.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 122.08 0.943 . . . . 0.0 112.384 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.36 145.94 51.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.129 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.77 153.87 40.63 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 122.095 0.95 . . . . 0.0 113.49 -175.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 61.0 t0 61.98 47.93 5.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 113.581 -1.645 . . . . 0.0 111.676 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.453 ' CG1' ' N ' ' R' ' 25' ' ' GLY . 45.4 t -59.68 171.12 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.911 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . 0.453 ' N ' ' CG1' ' R' ' 24' ' ' VAL . . . 161.12 31.41 0.02 OUTLIER Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 3.3 t 72.73 120.75 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 95.7 m-20 -83.04 162.3 21.44 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.428 -0.909 . . . . 0.0 111.508 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -48.08 -39.67 20.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.407 177.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.38 66.89 0.04 OUTLIER Glycine 0 CA--C 1.539 1.557 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.829 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.81 159.32 34.52 Favored 'General case' 0 C--N 1.345 0.409 0 CA-C-N 117.837 0.819 . . . . 0.0 110.117 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -107.42 116.14 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -124.25 125.44 70.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-O 120.803 0.335 . . . . 0.0 110.566 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.15 121.05 3.24 Favored Glycine 0 N--CA 1.463 0.478 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . 0.533 ' CD2' ' H ' ' R' ' 34' ' ' LEU . 1.2 pt? -123.15 128.26 49.81 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 121.433 0.635 . . . . 0.0 110.471 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 91.3 mmm -123.56 120.03 31.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.022 -178.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 96.2 t -100.28 115.42 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.33 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -115.25 122.97 5.78 Favored Glycine 0 CA--C 1.508 -0.384 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 177.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.92 66.48 0.46 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.428 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 26.8 m -53.89 152.59 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 117.43 0.615 . . . . 0.0 110.574 179.359 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.756 179.685 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.505 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 95.2 m-85 -84.14 140.03 32.03 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.726 0.298 . . . . 0.0 110.792 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' OE2' ' O ' ' A' ' 10' ' ' TYR . 43.9 mm-40 -136.94 114.23 10.83 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.709 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 73.2 t -138.61 87.22 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.563 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -148.54 143.66 26.79 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.592 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 0.5 OUTLIER -111.94 163.14 14.56 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.144 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -89.91 158.74 17.28 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -140.62 106.86 5.24 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 87.9 mt -136.11 120.09 17.54 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.917 0.78 . . . . 0.0 110.772 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.34 136.01 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.703 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -125.46 119.38 28.08 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.907 0.384 . . . . 0.0 111.203 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -108.39 118.73 37.53 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.16 117.5 30.21 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.215 0.531 . . . . 0.0 111.2 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.73 -162.56 0.33 Allowed 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 115.294 -0.867 . . . . 0.0 108.897 179.399 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -39.8 -60.54 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.697 -179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.8 t -73.15 160.77 5.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.26 -34.97 5.11 Favored Glycine 0 N--CA 1.467 0.731 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.203 177.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.433 ' CB ' ' NZ ' ' B' ' 28' ' ' LYS . 5.3 t -80.45 119.5 23.22 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.431 -0.508 . . . . 0.0 109.807 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -90.04 161.23 15.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 122.016 0.912 . . . . 0.0 112.869 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 28' ' ' LYS . 99.3 mttt -46.77 -38.87 10.74 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 113.666 -1.606 . . . . 0.0 112.331 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.09 70.47 0.21 Allowed Glycine 0 CA--C 1.532 1.139 0 CA-C-N 114.575 -1.193 . . . . 0.0 114.335 -173.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.486 ' O ' ' HA ' ' B' ' 30' ' ' ALA . . . -95.21 117.0 29.48 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 123.86 1.79 . . . . 0.0 112.071 -177.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 32.0 pt -149.59 147.78 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 112.457 -2.156 . . . . 0.0 108.589 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.421 HG23 HD12 ' A' ' 32' ' ' ILE . 97.8 mt -105.74 114.03 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.26 95.04 0.72 Allowed Glycine 0 N--CA 1.462 0.376 0 N-CA-C 105.639 -2.984 . . . . 0.0 105.639 177.141 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -142.95 151.78 41.3 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 122.664 1.221 . . . . 0.0 113.901 -176.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 89.5 mmm -106.99 108.98 20.76 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-N 112.634 -2.075 . . . . 0.0 105.616 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 24.3 t -124.14 112.05 31.1 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -178.307 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.486 ' CA ' ' NE2' ' C' ' 15' ' ' GLN . . . 115.48 -132.09 10.09 Favored Glycine 0 C--N 1.321 -0.296 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 92.06 -63.34 2.46 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.579 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' VAL . 1.1 m -96.03 177.86 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . 0.466 ' H ' ' HB3' ' H' ' 28' ' ' LYS . 7.3 p . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.746 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -107.06 132.41 53.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.736 0.303 . . . . 0.0 110.243 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.519 ' O ' ' CE1' ' C' ' 13' ' ' HIS . 84.2 tt0 -151.35 128.37 11.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.398 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.05 109.93 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-O 121.438 0.637 . . . . 0.0 110.358 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.424 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 22.6 p-80 -151.21 158.97 44.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.726 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.52 ' CD2' ' ND1' ' A' ' 14' ' ' HIS . 2.8 m-70 -143.04 163.89 31.58 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.63 178.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -89.96 152.01 21.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -149.16 100.98 3.1 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 69.8 mt -122.78 121.91 37.44 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.789 0.328 . . . . 0.0 110.41 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.6 t -125.79 125.88 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.552 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -124.17 120.88 33.57 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.57 0.224 . . . . 0.0 110.695 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -122.58 121.06 35.58 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 116.697 -0.228 . . . . 0.0 110.967 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.98 130.15 55.53 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.655 0.264 . . . . 0.0 110.611 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.452 ' CG ' ' N ' ' B' ' 23' ' ' ASP . 77.0 tt0 -66.73 154.87 39.61 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -175.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.452 ' N ' ' CG ' ' B' ' 22' ' ' GLU . 65.8 t0 -67.15 47.79 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 111.216 -2.72 . . . . 0.0 113.833 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.489 HG13 ' H ' ' B' ' 25' ' ' GLY . 1.9 t -60.73 -179.5 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 118.388 -1.325 . . . . 0.0 111.527 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.489 ' H ' HG13 ' B' ' 24' ' ' VAL . . . -99.71 28.91 13.33 Favored Glycine 0 N--CA 1.471 0.999 0 CA-C-N 114.809 -1.087 . . . . 0.0 115.681 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' B' ' 27' ' ' ASN . 42.8 t -162.18 116.14 1.83 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 120.089 1.945 . . . . 0.0 113.869 -176.107 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' B' ' 26' ' ' SER . 10.5 m120 -22.71 164.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.848 0 O-C-N 125.311 1.632 . . . . 0.0 112.636 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.8 mttt -155.39 -20.71 0.11 Allowed 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 119.826 -0.75 . . . . 0.0 112.646 -177.192 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.38 97.8 0.06 OUTLIER Glycine 0 C--N 1.334 0.462 0 C-N-CA 117.497 -2.287 . . . . 0.0 109.603 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.486 ' HA ' ' O ' ' A' ' 30' ' ' ALA . . . -120.05 119.08 32.32 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 122.66 1.219 . . . . 0.0 112.505 -176.085 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.434 HG22 HD13 ' B' ' 31' ' ' ILE . 97.3 mt -127.45 132.29 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 113.971 -1.468 . . . . 0.0 111.097 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 23.1 mt -102.72 116.63 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -115.63 98.56 0.84 Allowed Glycine 0 C--O 1.237 0.287 0 N-CA-C 105.818 -2.913 . . . . 0.0 105.818 177.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -137.68 135.14 36.2 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 122.495 1.14 . . . . 0.0 112.558 -175.459 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 4.4 mtp -104.05 110.36 22.5 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 113.311 -1.768 . . . . 0.0 106.842 177.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 m -131.21 123.09 52.69 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.2 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.84 -113.4 0.66 Allowed Glycine 0 C--N 1.311 -0.84 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.61 -72.62 0.82 Allowed Glycine 0 CA--C 1.532 1.103 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . 0.455 ' O ' ' C ' ' B' ' 40' ' ' VAL . 3.7 p -144.58 157.48 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' B' ' 39' ' ' VAL . 20.4 m . . . . . 0 N--CA 1.473 0.686 0 CA-C-O 117.965 -1.017 . . . . 0.0 111.921 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -107.94 136.16 48.11 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -122.12 100.99 7.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.862 0.363 . . . . 0.0 110.323 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . 0.506 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 1.5 p -145.1 137.55 21.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.345 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' B' ' 11' ' ' GLU . 2.0 m-70 -147.22 135.31 21.47 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.116 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.653 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 32.8 m-70 -142.23 161.08 38.92 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.243 -0.583 . . . . 0.0 110.977 177.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.486 ' NE2' ' CA ' ' A' ' 37' ' ' GLY . 22.8 mt-30 -85.41 157.16 20.56 Favored 'General case' 0 CA--C 1.523 -0.09 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 176.109 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -159.22 91.94 1.05 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -128.82 122.35 30.26 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.968 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 m -124.48 120.79 59.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -113.47 108.16 16.82 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.317 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -110.59 122.01 46.72 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.41 125.72 33.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.914 0.864 . . . . 0.0 112.406 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 94.9 mt-10 -98.72 110.14 22.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 177.699 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.41 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 99.2 m-20 -140.45 49.26 1.72 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.618 -1.174 . . . . 0.0 111.2 -175.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 53.8 t -71.44 161.39 4.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 C-N-CA 119.339 -0.945 . . . . 0.0 109.901 -175.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.489 ' O ' ' CB ' ' C' ' 26' ' ' SER . . . 109.46 -29.87 9.09 Favored Glycine 0 CA--C 1.531 1.031 0 N-CA-C 107.315 -2.314 . . . . 0.0 107.315 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 1.1 m 93.21 114.58 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 114.194 -1.003 . . . . 0.0 110.583 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -73.58 164.05 27.18 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.551 0.691 . . . . 0.0 112.266 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' D' ' 28' ' ' LYS . 98.9 mttt -48.01 -37.01 13.84 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 114.109 1.151 . . . . 0.0 114.109 178.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.85 77.21 0.06 OUTLIER Glycine 0 CA--C 1.536 1.367 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.971 -175.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.0 138.27 37.01 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 122.547 1.165 . . . . 0.0 113.478 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.421 HD12 HG21 ' C' ' 31' ' ' ILE . 94.1 mt -142.42 144.89 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 114.328 -1.305 . . . . 0.0 112.656 -178.763 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.47 HG21 HD13 ' C' ' 32' ' ' ILE . 75.6 mt -106.71 111.4 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 174.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.94 101.66 0.89 Allowed Glycine 0 N--CA 1.465 0.592 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 6.6 mp -141.9 148.01 38.02 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.954 1.359 . . . . 0.0 113.329 -178.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -104.4 111.52 24.21 Favored 'General case' 0 N--CA 1.44 -0.925 0 CA-C-N 112.097 -2.319 . . . . 0.0 105.692 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' D' ' 36' ' ' VAL . 55.1 t -124.81 123.22 65.32 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.741 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -178.028 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.07 -113.31 0.77 Allowed Glycine 0 C--N 1.312 -0.794 0 C-N-CA 119.75 -1.214 . . . . 0.0 111.958 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.78 -73.01 2.68 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 13.6 p -172.79 132.92 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 177.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . 0.555 ' CG2' ' NE2' ' F' ' 13' ' ' HIS . 21.4 m . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.776 -1.107 . . . . 0.0 110.043 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -105.87 132.68 51.69 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.774 0.321 . . . . 0.0 110.63 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -97.36 113.77 25.47 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.622 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 20.3 m -133.86 134.68 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.231 0.539 . . . . 0.0 111.218 -179.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.498 ' O ' ' CG ' ' E' ' 13' ' ' HIS . 7.6 m80 -140.07 135.6 32.76 Favored 'General case' 0 C--O 1.225 -0.194 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.032 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.653 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 1.3 t-80 -136.88 156.0 49.04 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.649 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.629 HE21 ' CD1' ' D' ' 17' ' ' LEU . 54.8 tt0 -87.55 157.15 19.23 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -162.45 92.93 0.83 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.674 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . 0.629 ' CD1' HE21 ' D' ' 15' ' ' GLN . 23.3 mt -122.39 114.17 20.37 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.315 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.9 t -110.64 109.18 27.5 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.534 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 66.0 m-85 -109.62 107.37 17.42 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -122.24 131.58 54.0 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-O 120.737 0.303 . . . . 0.0 111.544 -177.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.06 140.01 32.44 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 122.033 0.921 . . . . 0.0 112.998 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -82.03 113.87 20.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 122.039 0.923 . . . . 0.0 111.372 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.443 ' H ' ' HB3' ' E' ' 22' ' ' GLU . 54.4 m-20 50.17 46.42 24.77 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 113.551 -1.659 . . . . 0.0 112.267 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.539 ' CG1' ' H ' ' D' ' 25' ' ' GLY . 96.4 t -111.62 177.64 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 104.719 -2.326 . . . . 0.0 104.719 174.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.539 ' H ' ' CG1' ' D' ' 24' ' ' VAL . . . 63.02 28.69 72.49 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 178.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 48.9 m -108.67 -120.01 0.26 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.794 0.807 . . . . 0.0 112.498 -177.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -79.94 174.05 11.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.338 -178.496 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' C' ' 28' ' ' LYS . 99.1 mttt 58.32 39.91 25.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 113.998 1.11 . . . . 0.0 113.998 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.11 70.99 0.95 Allowed Glycine 0 N--CA 1.477 1.422 0 C-N-CA 119.031 -1.557 . . . . 0.0 116.346 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.0 109.08 15.08 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.365 0.602 . . . . 0.0 109.917 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 2.1 mt -133.57 141.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 N-CA-C 114.101 1.148 . . . . 0.0 114.101 -177.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.401 HD11 HG21 ' D' ' 32' ' ' ILE . 6.4 mt -108.69 113.9 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.91 102.97 1.27 Allowed Glycine 0 C--O 1.24 0.511 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 177.469 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.5 tp -133.93 134.51 42.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 122.181 0.991 . . . . 0.0 112.877 -176.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -105.17 112.36 25.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 113.445 -1.707 . . . . 0.0 107.304 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.542 ' O ' ' N ' ' E' ' 37' ' ' GLY . 0.4 OUTLIER -114.17 177.06 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.165 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.53 -96.29 0.33 Allowed Glycine 0 C--N 1.31 -0.877 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.633 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . 0.496 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 38.17 75.92 0.08 OUTLIER Glycine 0 CA--C 1.533 1.207 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.056 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.496 ' C ' ' O ' ' D' ' 38' ' ' GLY . 60.4 t -6.35 123.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -178.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.509 ' O ' ' NZ ' ' K' ' 28' ' ' LYS . 55.3 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.455 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -81.81 138.98 35.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -136.28 140.61 43.55 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.029 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 70.4 t -124.35 124.97 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 110.465 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.607 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.5 OUTLIER -156.4 134.75 11.44 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 179.387 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.607 ' N ' ' ND1' ' E' ' 13' ' ' HIS . 34.8 m-70 -143.52 167.38 22.35 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.73 0.3 . . . . 0.0 110.464 179.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 34.4 tt0 -89.64 151.3 21.97 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 14.3 mttt -153.35 98.73 2.29 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.011 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 mt -121.84 116.13 23.88 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 178.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -111.21 101.54 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 41.2 m-85 -106.75 102.65 12.01 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -122.49 132.99 54.59 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-O 121.229 0.537 . . . . 0.0 112.225 -178.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -138.77 145.34 40.08 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.42 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.443 ' HB3' ' H ' ' D' ' 23' ' ' ASP . 79.5 tt0 -68.73 147.16 52.21 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 117.574 -1.65 . . . . 0.0 108.804 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.534 ' O ' ' O ' ' E' ' 24' ' ' VAL . 21.2 t70 -128.05 61.6 1.44 Allowed 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.083 -174.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' E' ' 23' ' ' ASP . 4.7 t -33.64 -110.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.318 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -113.4 46.49 1.16 Allowed Glycine 0 N--CA 1.485 1.952 0 CA-C-N 120.173 1.351 . . . . 0.0 115.421 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.515 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.8 t 91.56 111.5 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 122.318 0.247 . . . . 0.0 111.378 176.204 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -75.35 163.88 27.0 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.644 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.88 -39.41 25.76 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.13 0.04 OUTLIER Glycine 0 CA--C 1.544 1.849 0 C-N-CA 120.159 -1.02 . . . . 0.0 113.312 -176.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.76 145.17 50.6 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.333 1.566 . . . . 0.0 111.727 -177.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 1.3 tt -131.72 141.75 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 CA-C-O 121.675 0.75 . . . . 0.0 111.968 -177.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 94.5 mt -124.98 131.43 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.78 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.56 117.2 2.72 Favored Glycine 0 CA--C 1.533 1.182 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 36.5 mt -123.55 122.81 39.14 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.236 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.0 mmm -119.73 129.18 54.39 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.468 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 54.2 t -94.15 135.05 29.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.985 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' D' ' 36' ' ' VAL . . . -99.9 -103.42 2.51 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -63.27 75.12 0.04 OUTLIER Glycine 0 CA--C 1.534 1.229 0 CA-C-N 113.891 -1.155 . . . . 0.0 112.48 179.591 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . 0.431 HG13 ' H ' ' F' ' 39' ' ' VAL . 8.8 m -46.12 159.65 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 39.2 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.822 179.819 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -111.98 136.97 50.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.685 0.279 . . . . 0.0 110.707 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.66 140.79 36.47 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.6 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.453 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 2.6 t -108.22 106.02 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.839 0.352 . . . . 0.0 110.471 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.587 ' ND1' ' N ' ' F' ' 14' ' ' HIS . 17.1 t-80 -152.97 139.89 19.12 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.587 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 81.0 t60 -150.52 168.64 23.61 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.833 178.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.49 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 51.1 tt0 -89.56 150.35 22.46 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -151.82 96.35 2.22 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.195 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -116.84 109.74 17.47 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.273 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -108.58 106.27 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.475 ' O ' ' CD1' ' F' ' 20' ' ' PHE . 44.3 m-85 -109.04 107.35 17.66 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.475 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 9.2 m-85 -146.63 140.69 26.21 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 118.29 -1.364 . . . . 0.0 114.063 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.416 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -114.86 119.34 36.26 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.649 -2.723 . . . . 0.0 103.649 174.836 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -95.09 134.49 37.74 Favored 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 117.533 2.42 . . . . 0.0 117.533 -172.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.471 ' CG ' ' H ' ' F' ' 24' ' ' VAL . 24.4 p-10 174.25 -59.82 0.01 OUTLIER 'General case' 0 C--N 1.348 0.525 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.598 173.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.471 ' H ' ' CG ' ' F' ' 23' ' ' ASP . 31.1 m -117.19 173.09 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.808 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.35 -34.69 86.02 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.872 176.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 88.9 p -156.84 114.31 3.16 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 114.994 -0.603 . . . . 0.0 110.835 -176.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 95.9 m-20 -51.44 171.43 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.648 -178.584 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.69 -39.84 92.88 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.06 67.03 0.13 Allowed Glycine 0 CA--C 1.537 1.461 0 C-N-CA 119.094 -1.527 . . . . 0.0 114.809 -178.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.12 174.95 7.94 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.027 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 14.6 tt -129.61 137.83 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.451 178.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -132.66 140.45 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.57 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.47 124.43 3.68 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 9.3 tt -130.69 127.15 38.27 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.8 mtp -139.33 145.4 39.02 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 6.3 p -144.59 146.07 20.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.11 177.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.45 102.11 0.37 Allowed Glycine 0 C--N 1.319 -0.368 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.172 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.6 -73.56 0.3 Allowed Glycine 0 CA--C 1.536 1.381 0 C-N-CA 120.454 -0.879 . . . . 0.0 113.96 176.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.454 ' CG1' ' N ' ' F' ' 40' ' ' VAL . 99.1 t -146.82 163.31 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.998 0.428 . . . . 0.0 110.443 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . 0.454 ' N ' ' CG1' ' F' ' 39' ' ' VAL . 8.0 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.896 -1.049 . . . . 0.0 110.334 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -113.05 134.05 54.7 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-O 120.807 0.337 . . . . 0.0 110.377 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -150.9 154.0 36.35 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.833 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.476 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 99.4 t -120.96 133.96 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 121.174 0.511 . . . . 0.0 110.967 179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -103.89 158.52 16.35 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.742 -179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.618 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 18.6 t60 -85.62 166.97 15.78 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.718 -179.569 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.618 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 83.6 mt-30 -155.29 141.81 18.74 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.169 0.509 . . . . 0.0 110.357 178.184 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -88.03 110.16 20.4 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.743 178.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mp -120.42 112.91 19.58 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 177.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -125.74 131.32 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.155 -178.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.68 128.25 42.17 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.469 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -128.29 126.78 41.49 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.75 122.61 38.52 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.706 0.765 . . . . 0.0 112.012 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -121.56 133.25 55.01 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.536 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.63 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 98.3 m-20 53.49 55.03 9.17 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.181 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 5.1 m -67.71 134.53 30.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.1 -31.62 2.21 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.357 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 19.1 m -93.24 -130.25 0.13 Allowed 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -177.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.53 ' OD1' ' NZ ' ' H' ' 28' ' ' LYS . 71.6 m-20 -82.91 -167.64 1.74 Allowed 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 114.5 -1.227 . . . . 0.0 111.541 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm 51.12 39.22 22.92 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.24 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.25 -66.67 1.59 Allowed Glycine 0 CA--C 1.539 1.565 0 C-N-CA 120.158 -1.02 . . . . 0.0 110.68 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' H' ' 30' ' ' ALA . . . -150.7 62.32 0.93 Allowed 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 119.593 1.696 . . . . 0.0 114.605 177.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 80.6 mt -136.45 113.44 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 176.246 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.445 ' O ' ' O ' ' H' ' 33' ' ' GLY . 96.4 mt -107.87 106.2 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.606 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.03 97.17 0.94 Allowed Glycine 0 CA--C 1.508 -0.357 0 N-CA-C 104.95 -3.26 . . . . 0.0 104.95 176.393 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.415 HD12 ' H ' ' G' ' 35' ' ' MET . 52.4 tp -155.63 154.39 31.54 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 118.188 -1.405 . . . . 0.0 113.361 -175.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.415 ' H ' HD12 ' G' ' 34' ' ' LEU . 8.1 mtp -112.11 122.47 47.83 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-N 112.989 -1.914 . . . . 0.0 108.655 178.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 35.9 m -131.32 112.07 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.69 -132.07 10.94 Favored Glycine 0 CA--C 1.519 0.303 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.53 -62.64 0.42 Allowed Glycine 0 CA--C 1.536 1.37 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 t -92.78 164.41 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.552 ' N ' ' CG2' ' H' ' 39' ' ' VAL . 8.5 p . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.991 -1.005 . . . . 0.0 110.585 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.196 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 44.3 t80 -71.38 133.5 46.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.906 0.384 . . . . 0.0 110.587 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -94.29 115.62 27.89 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.388 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.15 136.09 32.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.338 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.501 ' NE2' ' OE2' ' I' ' 11' ' ' GLU . 81.0 m80 -113.4 149.54 33.98 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 9.6 p-80 -86.82 164.15 16.82 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.983 -179.376 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -100.81 152.6 20.32 Favored 'General case' 0 CA--C 1.522 -0.098 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.837 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -110.84 107.86 17.49 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 177.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -123.16 117.38 25.24 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 12.9 m -132.14 133.76 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.132 0.491 . . . . 0.0 111.033 179.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -129.91 129.65 44.14 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.559 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.408 ' CE2' ' CG ' ' I' ' 20' ' ' PHE . 29.2 m-85 -127.43 131.57 50.22 Favored 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.465 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.19 122.38 31.73 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 82.6 tt0 -147.17 121.67 9.73 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 114.621 1.341 . . . . 0.0 114.621 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.63 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 1.7 p-10 156.24 -74.5 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.379 175.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.667 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 3.6 p -67.53 -112.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.713 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.667 ' H ' ' CG1' ' H' ' 24' ' ' VAL . . . 126.39 -38.76 2.14 Favored Glycine 0 N--CA 1.454 -0.128 0 CA-C-N 113.866 -1.516 . . . . 0.0 111.133 176.545 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 16.2 t -70.4 112.7 6.89 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 174.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -113.68 168.54 9.69 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.815 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.53 ' NZ ' ' OD1' ' G' ' 27' ' ' ASN . 99.2 mttt -39.39 -38.42 0.55 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.618 -1.173 . . . . 0.0 111.091 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.402 ' O ' ' N ' ' H' ' 31' ' ' ILE . . . 179.72 77.08 0.06 OUTLIER Glycine 0 CA--C 1.535 1.314 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.909 -176.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.454 ' O ' ' HA ' ' I' ' 30' ' ' ALA . . . -51.49 91.14 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 119.131 1.466 . . . . 0.0 112.157 -177.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.402 ' N ' ' O ' ' H' ' 29' ' ' GLY . 96.8 mt -134.21 138.63 49.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.135 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.427 HG21 HD11 ' H' ' 32' ' ' ILE . 96.8 mt -108.32 104.95 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 177.867 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -105.13 97.09 1.29 Allowed Glycine 0 N--CA 1.461 0.3 0 N-CA-C 104.565 -3.414 . . . . 0.0 104.565 176.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 15.2 tp -143.09 136.43 28.29 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 118.731 -1.187 . . . . 0.0 113.044 -174.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.8 mtp -105.18 118.82 37.52 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 113.176 -1.829 . . . . 0.0 106.845 178.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.502 ' O ' ' NE2' ' J' ' 15' ' ' GLN . 10.9 t -130.03 102.62 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -177.346 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.43 -162.49 12.38 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.58 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.16 -55.44 0.52 Allowed Glycine 0 CA--C 1.542 1.747 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.552 ' CG2' ' N ' ' G' ' 40' ' ' VAL . 1.8 m -127.99 161.57 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.45 ' OXT' ' O ' ' O' ' 28' ' ' LYS . 46.6 t . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.012 177.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.93 135.45 48.46 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.793 0.33 . . . . 0.0 110.367 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.501 ' OE2' ' NE2' ' H' ' 13' ' ' HIS . 97.3 mt-10 -74.35 109.4 7.8 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.475 ' CG2' ' O ' ' J' ' 12' ' ' VAL . 23.2 m -139.27 159.79 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.942 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.477 ' CD2' ' OXT' ' G' ' 40' ' ' VAL . 78.0 m80 -69.78 114.25 7.8 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.611 -178.116 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 13.2 t60 -161.9 169.98 20.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.273 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.645 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 57.9 tt0 -156.27 140.28 16.34 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 120.191 -0.603 . . . . 0.0 110.4 177.053 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -97.92 113.94 25.9 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 178.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 58.8 mt -121.98 114.22 20.66 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.4 t -116.41 109.68 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -108.01 106.44 16.67 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.408 ' CG ' ' CE2' ' H' ' 20' ' ' PHE . 35.3 t80 -120.6 132.97 55.4 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -176.316 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' J' ' 21' ' ' ALA . . . -149.7 146.5 27.27 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-O 121.63 0.729 . . . . 0.0 112.651 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.422 ' OE2' ' OE2' ' H' ' 22' ' ' GLU . 77.9 mt-10 -103.88 151.55 22.99 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.837 178.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.602 ' N ' ' O ' ' J' ' 22' ' ' GLU . 71.4 m-20 57.47 48.79 13.93 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.14 0.495 . . . . 0.0 110.405 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.518 ' O ' ' CG2' ' J' ' 24' ' ' VAL . 0.1 OUTLIER -137.4 -173.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-O 121.66 0.743 . . . . 0.0 110.824 -177.23 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 28.2 67.67 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -177.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 71.3 m -143.56 -128.18 0.09 Allowed 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.58 ' CG ' ' H ' ' I' ' 28' ' ' LYS . 50.5 t30 54.38 -159.48 0.17 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 178.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.58 ' H ' ' CG ' ' I' ' 27' ' ' ASN . 64.1 mttp -64.46 -39.61 94.14 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.46 1.652 . . . . 0.0 115.46 -173.309 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.31 66.31 0.25 Allowed Glycine 0 N--CA 1.472 1.067 0 C-N-CA 118.52 -1.8 . . . . 0.0 114.616 -175.127 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' H' ' 30' ' ' ALA . . . -82.7 131.95 35.19 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 122.156 0.979 . . . . 0.0 112.111 -178.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 50.5 mt -144.05 143.4 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 114.447 -1.251 . . . . 0.0 113.585 -177.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.431 HD13 HG21 ' I' ' 32' ' ' ILE . 54.1 mt -105.15 101.99 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 173.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -103.62 98.5 1.61 Allowed Glycine 0 CA--C 1.507 -0.452 0 N-CA-C 104.913 -3.275 . . . . 0.0 104.913 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 23.7 tp -140.13 135.12 32.17 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 122.287 1.041 . . . . 0.0 113.281 -173.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 5.9 mtp -109.43 117.66 34.61 Favored 'General case' 0 CA--C 1.512 -0.484 0 CA-C-N 113.612 -1.631 . . . . 0.0 107.205 177.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 4.4 t -130.42 111.82 21.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 CA-C-O 120.624 0.25 . . . . 0.0 110.736 -177.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.712 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 138.33 -131.07 5.23 Favored Glycine 0 C--N 1.318 -0.434 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.144 177.681 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.05 -61.76 0.39 Allowed Glycine 0 CA--C 1.543 1.828 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . 0.422 ' CG1' ' N ' ' H' ' 40' ' ' VAL . 4.0 p -146.21 151.25 14.59 Favored 'Isoleucine or valine' 0 C--N 1.344 0.339 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 175.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . 0.439 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 58.6 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.753 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.62 133.04 51.01 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.928 0.394 . . . . 0.0 110.732 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -85.18 125.29 32.71 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.912 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.54 ' CG1' ' HE2' ' J' ' 14' ' ' HIS . 96.0 t -125.82 108.64 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.621 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -111.78 124.38 52.22 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' K' ' 14' ' ' HIS . 47.1 m-70 -148.67 162.9 38.8 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 120.29 -0.564 . . . . 0.0 109.735 174.34 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.686 ' NE2' HE21 ' K' ' 15' ' ' GLN . 85.0 mt-30 -100.69 147.17 26.31 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.114 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 13.8 mttt -118.34 92.37 3.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 mt -117.24 115.54 25.5 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.693 -178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.7 t -113.5 102.38 13.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 64.6 m-85 -104.05 107.09 17.83 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 178.222 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.567 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -121.95 124.07 43.17 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.622 -176.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' I' ' 21' ' ' ALA . . . -136.27 115.48 12.52 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' I' ' 23' ' ' ASP . 98.0 mt-10 -120.18 177.74 4.9 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 118.333 2.716 . . . . 0.0 118.333 -174.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 41.5 t0 28.62 46.31 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 119.946 3.313 . . . . 0.0 119.946 175.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.518 ' CG2' ' O ' ' I' ' 24' ' ' VAL . 0.2 OUTLIER -80.57 -179.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 175.105 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.05 -29.23 69.18 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 118.126 -1.988 . . . . 0.0 112.274 -178.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.421 ' O ' ' C ' ' J' ' 27' ' ' ASN . 1.5 t 168.16 127.24 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.813 0.807 . . . . 0.0 112.079 175.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.466 HD22 ' N ' ' J' ' 30' ' ' ALA . 2.0 t-20 -37.21 133.94 0.63 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.733 174.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.417 ' HB2' ' O ' ' I' ' 27' ' ' ASN . 67.6 mttm -109.27 -40.27 4.98 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 118.969 0.804 . . . . 0.0 111.118 177.285 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.45 64.35 0.24 Allowed Glycine 0 CA--C 1.541 1.718 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.924 -178.482 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.466 ' N ' HD22 ' J' ' 27' ' ' ASN . . . -83.7 143.26 30.15 Favored 'General case' 0 C--O 1.245 0.855 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -177.612 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 79.9 mt -135.78 131.0 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 114.832 -1.076 . . . . 0.0 111.677 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 3.0 mt -106.22 110.36 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 176.275 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 99.0 1.06 Allowed Glycine 0 C--O 1.239 0.441 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 177.018 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 24.3 tp -134.93 123.59 23.62 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.414 1.102 . . . . 0.0 113.697 -175.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 2.2 ttm -98.29 116.69 31.05 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 176.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -130.11 103.3 8.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 C-N-CA 121.365 -0.134 . . . . 0.0 111.049 -177.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.22 -153.72 25.23 Favored Glycine 0 CA--C 1.509 -0.283 0 C-N-CA 120.035 -1.079 . . . . 0.0 112.358 178.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.493 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 138.73 -56.31 0.65 Allowed Glycine 0 CA--C 1.544 1.898 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.787 -178.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.41 ' HB ' ' H ' ' I' ' 40' ' ' VAL . 87.8 t -135.93 157.89 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.059 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.406 ' N ' ' CG1' ' J' ' 39' ' ' VAL . 17.3 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.528 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -108.85 146.54 33.52 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.854 0.359 . . . . 0.0 110.561 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -70.32 128.81 37.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -111.94 121.05 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.785 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.667 ' CG ' ' HZ3' ' O' ' 28' ' ' LYS . 6.6 p80 -151.59 113.72 4.51 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.377 -0.529 . . . . 0.0 112.027 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' J' ' 14' ' ' HIS . 13.4 p-80 -153.34 160.31 42.65 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.389 177.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.712 HE22 ' N ' ' I' ' 37' ' ' GLY . 88.3 mt-30 -90.12 160.08 16.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.213 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -139.42 109.38 6.37 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.457 0.646 . . . . 0.0 109.902 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mt -118.55 122.41 42.58 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.865 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 16.7 t -113.49 101.05 11.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -100.79 102.67 13.8 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 105.232 -2.136 . . . . 0.0 105.232 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CD1' ' L' ' 20' ' ' PHE . 1.4 t80 -113.4 124.96 53.66 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -177.483 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' K' ' 23' ' ' ASP . . . -160.76 162.78 32.51 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 -177.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -72.36 136.83 46.25 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.163 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.669 ' O ' ' O ' ' K' ' 24' ' ' VAL . 6.4 m-20 -152.5 61.03 0.82 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.987 1.477 . . . . 0.0 114.987 -173.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.669 ' O ' ' O ' ' K' ' 23' ' ' ASP . 34.4 t -44.16 -110.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' K' ' 27' ' ' ASN . . . 162.82 -46.51 0.33 Allowed Glycine 0 CA--C 1.506 -0.519 0 C-N-CA 116.707 -2.663 . . . . 0.0 115.781 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m -65.99 101.56 0.69 Allowed 'General case' 0 CA--C 1.519 -0.25 0 CA-C-N 123.605 3.702 . . . . 0.0 104.373 178.539 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.539 ' N ' ' O ' ' K' ' 25' ' ' GLY . 28.2 m-20 -130.04 161.4 31.08 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 114.847 -1.069 . . . . 0.0 112.455 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.509 ' NZ ' ' O ' ' D' ' 40' ' ' VAL . 61.3 tttt -28.71 -39.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.833 172.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . 141.75 73.81 0.04 OUTLIER Glycine 0 CA--C 1.545 1.914 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.103 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.44 150.03 46.63 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 121.804 0.811 . . . . 0.0 112.681 -177.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 2.6 mp -136.42 138.26 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 CA-C-N 114.689 -1.141 . . . . 0.0 112.78 -177.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -117.68 119.99 63.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 178.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.46 117.41 3.31 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 67.7 mt -123.47 129.18 50.86 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 73.2 mtp -137.61 136.68 37.75 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.365 -0.934 . . . . 0.0 113.061 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.433 ' O ' ' O ' ' K' ' 37' ' ' GLY . 10.8 t -113.31 155.27 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.149 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -52.25 -102.34 0.01 OUTLIER Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' L' ' 38' ' ' GLY . . . -138.03 -74.6 0.06 OUTLIER Glycine 0 CA--C 1.527 0.792 0 C-N-CA 120.823 -0.704 . . . . 0.0 113.177 178.946 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 6.6 m -73.81 130.78 35.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.428 -178.698 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.29 179.967 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -103.94 133.04 49.58 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.795 0.331 . . . . 0.0 110.583 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -126.88 134.24 50.52 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 91.1 t -111.91 101.41 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 121.265 0.555 . . . . 0.0 110.877 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.481 ' O ' ' CG ' ' L' ' 14' ' ' HIS . 5.0 p80 -147.2 90.82 1.92 Allowed 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.639 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.481 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 69.3 m80 -158.19 168.31 27.42 Favored 'General case' 0 C--O 1.223 -0.295 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.461 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 94.8 mm-40 -89.84 158.45 17.46 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.71 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -139.92 105.27 5.06 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.465 0.65 . . . . 0.0 110.492 178.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . 0.453 HD12 ' H ' ' L' ' 17' ' ' LEU . 0.2 OUTLIER -116.16 113.9 23.73 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.695 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -106.79 103.85 16.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -99.78 101.71 12.94 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.574 ' CD1' ' CZ ' ' K' ' 20' ' ' PHE . 15.1 t80 -110.04 103.13 11.83 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.87 137.31 46.64 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 -178.408 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.525 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.9 mt-10 -78.62 102.77 8.15 Favored 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 118.879 -1.128 . . . . 0.0 108.636 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 44.2 p-10 -155.77 46.62 0.48 Allowed 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 112.786 0.661 . . . . 0.0 112.786 -177.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 32.9 m -83.22 172.69 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 118.819 -1.152 . . . . 0.0 109.788 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 96.02 -28.68 11.86 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.9 t 91.68 119.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.533 ' O ' ' N ' ' L' ' 29' ' ' GLY . 15.4 m-20 -71.95 150.3 44.24 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.221 -179.013 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -53.17 47.45 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.507 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 101.77 63.38 0.75 Allowed Glycine 0 CA--C 1.543 1.799 0 C-N-CA 119.928 -1.129 . . . . 0.0 114.088 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.63 169.46 10.06 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 178.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 12.6 tt -139.8 151.03 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.16 0 C-N-CA 119.008 -1.077 . . . . 0.0 113.626 -177.197 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 15.0 tt -135.48 134.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.152 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.64 134.22 6.52 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.315 -0.469 . . . . 0.0 111.971 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tt -127.25 124.72 39.51 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mtp -140.86 146.58 37.7 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -177.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 8.8 t -139.33 132.13 37.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.463 177.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -106.97 112.42 3.76 Favored Glycine 0 N--CA 1.468 0.794 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . 112.52 71.25 0.58 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 117.522 0.661 . . . . 0.0 112.477 178.804 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' L' ' 38' ' ' GLY . 66.2 t -27.33 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . 0.439 ' N ' ' CG1' ' L' ' 39' ' ' VAL . 92.9 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.788 178.594 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' M' M ' 10' ' ' TYR . . . . . 0.491 ' CE2' ' O ' ' M' ' 11' ' ' GLU . 88.6 t80 -73.06 132.67 43.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.535 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 11' ' ' GLU . . . . . 0.491 ' O ' ' CE2' ' M' ' 10' ' ' TYR . 79.7 tt0 -74.08 152.38 39.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.154 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 29.0 m -114.9 130.13 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.95 0.405 . . . . 0.0 110.714 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 75.6 m80 -95.06 165.8 12.25 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 14' ' ' HIS . . . . . 0.481 ' CD2' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -86.47 168.0 14.15 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.498 -179.36 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -129.17 150.72 50.44 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -97.62 120.91 38.85 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.595 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.29 115.3 20.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -140.34 140.59 34.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.383 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -143.18 141.32 31.11 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.095 0.474 . . . . 0.0 110.674 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 20' ' ' PHE . . . . . 0.484 ' CD1' ' O ' ' M' ' 20' ' ' PHE . 53.1 p90 -127.4 128.38 45.73 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.66 127.41 46.24 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.329 0.585 . . . . 0.0 111.378 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -138.67 146.34 41.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.94 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 58.47 59.84 2.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.44 . . . . 0.0 112.173 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 24' ' ' VAL . . . . . 0.533 ' CG1' ' H ' ' M' ' 25' ' ' GLY . 4.1 t 70.59 175.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.514 0.673 . . . . 0.0 111.732 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 25' ' ' GLY . . . . . 0.533 ' H ' ' CG1' ' M' ' 24' ' ' VAL . . . 100.65 -34.72 5.35 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.948 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 6.1 p -82.92 -121.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 176.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 27' ' ' ASN . . . . . 0.464 ' ND2' ' H ' ' M' ' 31' ' ' ILE . 8.9 p30 -92.42 161.21 14.74 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 176.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 28' ' ' LYS . . . . . 0.413 ' O ' ' CD ' ' N' ' 28' ' ' LYS . 72.8 tttt -45.29 -39.2 6.32 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 119.139 -1.025 . . . . 0.0 110.517 -179.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 29' ' ' GLY . . . . . 0.445 ' O ' ' OD2' ' N' ' 23' ' ' ASP . . . -146.9 -76.18 0.02 OUTLIER Glycine 0 N--CA 1.473 1.11 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.893 177.784 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.76 87.81 0.82 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-O 121.129 0.49 . . . . 0.0 111.611 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 31' ' ' ILE . . . . . 0.487 ' CG2' ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -138.33 115.56 11.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 32' ' ' ILE . . . . . 0.406 ' O ' ' O ' ' N' ' 33' ' ' GLY . 43.1 mt -107.09 109.37 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.88 92.46 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 105.886 -2.885 . . . . 0.0 105.886 177.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -143.56 167.16 22.87 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 114.927 1.455 . . . . 0.0 114.927 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -123.45 106.58 10.75 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 112.108 -2.315 . . . . 0.0 107.062 177.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 43.9 t -112.46 111.97 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 CA-C-O 121.264 0.554 . . . . 0.0 109.835 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.42 -131.7 7.74 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 38' ' ' GLY . . . . . 0.451 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 94.47 -63.27 1.66 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.786 -1.325 . . . . 0.0 109.786 -178.289 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 4.7 m -96.65 173.51 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.882 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' M' M ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' N' ' 40' ' ' VAL . 26.8 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.938 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 9' ' ' GLY . . . . . 0.409 ' H ' ' H ' ' N' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 10' ' ' TYR . . . . . 0.409 ' H ' ' H ' ' N' ' 9' ' ' GLY . 97.4 m-85 -106.42 134.8 49.0 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.764 0.316 . . . . 0.0 110.333 -179.876 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -114.97 119.71 37.43 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.796 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 58.8 t -126.96 131.4 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -142.32 130.27 21.83 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.443 0.64 . . . . 0.0 112.63 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 14' ' ' HIS . . . . . 0.513 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 33.0 m-70 -153.1 172.39 16.97 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.218 177.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -155.18 141.0 18.15 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.821 -0.751 . . . . 0.0 109.741 177.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -88.53 113.66 24.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.161 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 8.3 mp -111.24 113.1 25.36 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.245 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.12 132.16 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-O 120.891 0.377 . . . . 0.0 111.35 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -141.23 127.45 19.69 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.956 0.408 . . . . 0.0 111.835 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -117.23 131.58 56.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.254 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.29 133.23 34.75 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -122.02 145.31 48.26 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.359 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' M' ' 29' ' ' GLY . 51.6 m-20 -160.94 46.68 0.21 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.918 0.39 . . . . 0.0 111.161 -178.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 m -73.35 -179.79 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.74 0.781 . . . . 0.0 111.99 -178.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.17 -35.33 4.76 Favored Glycine 0 CA--C 1.53 0.99 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.95 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' N' ' 27' ' ' ASN . 84.8 p -162.56 117.04 1.79 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 118.061 0.931 . . . . 0.0 110.874 176.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' N' ' 26' ' ' SER . 55.6 p30 -21.63 161.73 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 28' ' ' LYS . . . . . 0.454 ' CG ' ' O ' ' N' ' 27' ' ' ASN . 60.5 mttm -158.61 -10.3 0.07 Allowed 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 120.389 -0.524 . . . . 0.0 112.405 174.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.36 118.12 0.64 Allowed Glycine 0 CA--C 1.537 1.408 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.631 178.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 30' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' O' ' 29' ' ' GLY . . . -102.91 113.33 26.7 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-O 121.599 0.714 . . . . 0.0 111.98 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 31' ' ' ILE . . . . . . . . . . . . . 81.4 mt -135.5 131.05 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 32' ' ' ILE . . . . . 0.42 HD11 HG22 ' N' ' 32' ' ' ILE . 92.8 mt -107.08 111.04 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.01 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -116.0 105.6 1.42 Allowed Glycine 0 C--N 1.322 -0.234 0 N-CA-C 105.217 -3.153 . . . . 0.0 105.217 176.672 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 tt -152.77 140.75 20.23 Favored 'General case' 0 CA--C 1.504 -0.8 0 C-N-CA 117.953 -1.499 . . . . 0.0 111.747 -174.551 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 45.3 mtp -114.29 116.02 28.32 Favored 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.664 -1.607 . . . . 0.0 107.825 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -93.65 102.84 14.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 37' ' ' GLY . . . . . 0.451 ' HA3' ' H ' ' M' ' 38' ' ' GLY . . . -35.38 152.74 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.121 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 38' ' ' GLY . . . . . 0.563 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -85.28 -57.55 2.21 Favored Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.837 -0.697 . . . . 0.0 114.326 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 6.1 m -52.85 140.97 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 119.42 1.61 . . . . 0.0 110.812 -178.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' N' N ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' M' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.552 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -106.53 127.24 53.16 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 11' ' ' GLU . . . . . 0.472 ' O ' ' NE2' ' P' ' 13' ' ' HIS . 97.4 mt-10 -146.7 158.96 44.02 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.809 0.337 . . . . 0.0 111.01 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 55.2 t -129.53 118.3 45.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.659 179.403 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -134.36 137.56 44.23 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 14' ' ' HIS . . . . . 0.698 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 66.2 t60 -151.12 153.2 34.57 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 119.027 -1.069 . . . . 0.0 112.278 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 15.2 tp60 -87.83 158.8 18.65 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.263 0.625 . . . . 0.0 110.791 177.472 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 71.5 tttt -159.09 95.21 1.25 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.252 176.797 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 17' ' ' LEU . . . . . 0.401 ' CD1' ' N ' ' O' ' 17' ' ' LEU . 8.2 mp -116.45 127.16 54.34 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.283 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -127.23 107.04 16.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.91 113.23 25.43 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 20' ' ' PHE . . . . . 0.481 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 45.8 t80 -111.77 121.53 45.32 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.19 136.91 47.38 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 122.065 0.936 . . . . 0.0 112.492 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 22' ' ' GLU . . . . . 0.481 ' O ' ' CG ' ' O' ' 23' ' ' ASP . 51.6 tt0 -65.85 179.59 0.85 Allowed 'General case' 0 N--CA 1.444 -0.758 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 178.989 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 23' ' ' ASP . . . . . 0.481 ' CG ' ' O ' ' O' ' 22' ' ' GLU . 1.8 m-20 167.59 58.8 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.978 -174.68 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 24' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' O' ' 23' ' ' ASP . 18.4 t -62.92 -114.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -177.237 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.01 43.51 1.66 Allowed Glycine 0 N--CA 1.47 0.922 0 CA-C-N 121.71 2.05 . . . . 0.0 109.677 -176.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 26' ' ' SER . . . . . 0.412 ' HG ' ' H ' ' N' ' 28' ' ' LYS . 19.4 t -74.37 99.93 3.64 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 111.479 -2.36 . . . . 0.0 108.724 174.101 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -94.72 -161.73 0.88 Allowed 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.617 0.722 . . . . 0.0 112.045 -177.263 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 28' ' ' LYS . . . . . 0.667 ' HZ3' ' CG ' ' K' ' 13' ' ' HIS . 70.5 tttt 38.38 40.54 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 29' ' ' GLY . . . . . 0.535 ' O ' ' N ' ' N' ' 30' ' ' ALA . . . -177.72 62.34 0.09 OUTLIER Glycine 0 CA--C 1.541 1.672 0 C-N-CA 118.974 -1.584 . . . . 0.0 115.221 173.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.45 90.4 3.29 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 118.05 0.925 . . . . 0.0 110.883 174.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 71.3 mt -140.96 132.94 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-N 120.869 1.668 . . . . 0.0 113.826 -179.125 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 32' ' ' ILE . . . . . 0.425 HG22 HD11 ' O' ' 32' ' ' ILE . 78.1 mt -109.88 109.0 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.1 99.28 1.06 Allowed Glycine 0 C--O 1.239 0.414 0 N-CA-C 105.547 -3.021 . . . . 0.0 105.547 177.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 34' ' ' LEU . . . . . . . . . . . . . 10.3 tp -128.23 130.56 48.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 122.458 1.123 . . . . 0.0 113.507 -174.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.94 104.24 13.95 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 36' ' ' VAL . . . . . 0.495 ' CG2' ' OE1' ' P' ' 15' ' ' GLN . 8.0 p -131.48 142.55 42.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.81 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.97 -102.04 0.82 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.46 -80.17 0.06 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' O' O ' 39' ' ' VAL . . . . . 0.563 ' O ' ' O ' ' N' ' 38' ' ' GLY . 3.4 m -148.44 167.66 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 176.308 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' O' O ' 40' ' ' VAL . . . . . 0.483 ' CG1' ' HE2' ' Q' ' 13' ' ' HIS . 1.4 p . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.377 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -109.35 136.85 48.11 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.74 0.305 . . . . 0.0 110.299 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -103.14 114.93 29.62 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.438 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -141.87 135.64 29.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.495 179.57 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 13' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 86.3 m-70 -142.48 118.81 10.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.437 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 14' ' ' HIS . . . . . 0.698 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 0.0 OUTLIER -146.9 170.74 16.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.472 0.653 . . . . 0.0 111.821 -179.552 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' P' P ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG2' ' O' ' 36' ' ' VAL . 47.7 tt0 -107.45 149.8 27.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.448 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 16' ' ' LYS . . . . . 0.66 ' CG ' ' HE2' ' O' ' 14' ' ' HIS . 71.8 mttt -139.91 110.64 6.78 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 176.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mt -126.88 116.67 21.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -110.11 105.54 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 19' ' ' PHE . . . . . 0.531 ' CD2' ' CE1' ' Q' ' 19' ' ' PHE . 92.5 m-85 -106.59 107.19 18.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 179.192 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 20' ' ' PHE . . . . . 0.596 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 31.3 t80 -116.06 124.29 50.05 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.73 -178.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.41 138.25 30.97 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.75 0.786 . . . . 0.0 112.432 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 22' ' ' GLU . . . . . 0.504 ' O ' ' CB ' ' P' ' 23' ' ' ASP . 20.9 tt0 -76.81 -174.54 3.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 23' ' ' ASP . . . . . 0.504 ' CB ' ' O ' ' P' ' 22' ' ' GLU . 10.3 m-20 142.99 50.02 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 p -82.78 149.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 C-N-CA 119.341 -0.943 . . . . 0.0 111.404 -177.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 25' ' ' GLY . . . . . 0.431 ' O ' ' OG ' ' P' ' 26' ' ' SER . . . 93.23 36.81 5.83 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-N 113.614 -1.63 . . . . 0.0 111.848 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 26' ' ' SER . . . . . 0.59 ' N ' ' O ' ' Q' ' 24' ' ' VAL . 3.4 p 72.65 120.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 27' ' ' ASN . . . . . 0.791 HD21 ' H ' ' P' ' 29' ' ' GLY . 10.4 t30 -83.2 161.75 21.44 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.809 175.24 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 28' ' ' LYS . . . . . 0.628 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 75.4 tttt -48.54 -39.38 23.26 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 113.461 0.912 . . . . 0.0 113.461 177.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 29' ' ' GLY . . . . . 0.791 ' H ' HD21 ' P' ' 27' ' ' ASN . . . 171.59 68.85 0.04 OUTLIER Glycine 0 CA--C 1.544 1.863 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -174.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.22 145.76 51.17 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 119.062 1.431 . . . . 0.0 114.673 -173.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 31' ' ' ILE . . . . . 0.493 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 75.2 mt -136.08 133.94 50.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 CA-C-N 113.46 -1.7 . . . . 0.0 113.651 -177.505 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 55.0 mt -107.67 117.06 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 175.614 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.77 102.02 1.06 Allowed Glycine 0 N--CA 1.466 0.657 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 176.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -126.25 132.36 51.72 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -175.571 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -109.17 99.71 8.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.2 -2.519 . . . . 0.0 104.2 174.306 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -114.06 103.15 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.719 -175.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.31 -153.77 25.46 Favored Glycine 0 C--N 1.319 -0.39 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.813 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.43 -56.03 0.57 Allowed Glycine 0 CA--C 1.545 1.946 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -178.461 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -153.24 157.55 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 177.566 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' P' P ' 40' ' ' VAL . . . . . 0.44 ' O ' ' CE1' ' R' ' 13' ' ' HIS . 7.0 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.459 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.56 135.1 54.28 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.805 0.336 . . . . 0.0 110.468 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 11' ' ' GLU . . . . . 0.411 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 96.5 mt-10 -87.26 119.61 27.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.984 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -118.32 126.1 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.075 179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 13' ' ' HIS . . . . . 0.608 ' ND1' ' N ' ' Q' ' 14' ' ' HIS . 0.1 OUTLIER -152.74 140.55 20.03 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.989 -179.525 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' Q' Q ' 14' ' ' HIS . . . . . 0.608 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 1.1 p80 -159.68 161.7 34.96 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 15' ' ' GLN . . . . . . . . . . . . . 75.5 mt-30 -90.02 158.71 17.22 Favored 'General case' 0 CA--C 1.516 -0.349 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.747 178.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -140.81 101.9 4.17 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 176.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mp -119.06 113.42 20.91 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.92 106.63 21.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 19' ' ' PHE . . . . . 0.531 ' CE1' ' CD2' ' P' ' 19' ' ' PHE . 72.2 m-85 -107.04 103.05 12.37 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.296 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 20' ' ' PHE . . . . . 0.596 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 37.3 t80 -108.79 118.32 36.47 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.747 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 21' ' ' ALA . . . . . 0.471 ' O ' ' OE1' ' R' ' 22' ' ' GLU . . . -140.79 138.02 33.78 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.85 0.833 . . . . 0.0 112.967 -179.106 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' P' ' 23' ' ' ASP . 94.7 mt-10 -85.03 122.34 29.11 Favored 'General case' 0 C--O 1.22 -0.497 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 177.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 23' ' ' ASP . . . . . 0.417 ' CG ' ' O ' ' Q' ' 22' ' ' GLU . 35.4 m-20 -162.44 52.15 0.2 Allowed 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -176.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 24' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' P' ' 26' ' ' SER . 93.2 t -74.45 142.25 14.98 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 C-N-CA 117.923 -1.511 . . . . 0.0 110.069 -178.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.46 37.49 3.75 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -178.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -64.57 106.44 1.16 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.698 0.761 . . . . 0.0 111.576 -177.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -149.85 -161.25 1.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.429 -1.26 . . . . 0.0 110.173 -179.604 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 29.5 40.82 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.53 70.91 0.63 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 116.36 1.304 . . . . 0.0 116.36 175.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.53 114.14 27.72 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 175.632 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 31' ' ' ILE . . . . . 0.431 HD12 HG21 ' Q' ' 31' ' ' ILE . 66.6 mt -130.29 135.33 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 CA-C-N 119.108 0.867 . . . . 0.0 113.238 -178.177 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -121.59 114.71 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.14 114.84 3.29 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 14.3 tp -117.63 117.18 28.69 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 122.251 0.221 . . . . 0.0 110.429 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.2 mtp -121.76 124.28 43.84 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 67.1 t -110.81 131.48 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 121.108 0.48 . . . . 0.0 111.087 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 37' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' Q' ' 38' ' ' GLY . . . -72.81 111.68 3.63 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 38' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' Q' ' 37' ' ' GLY . . . -6.09 -67.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.428 0 C-N-CA 123.608 0.623 . . . . 0.0 114.224 -178.049 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.09 120.63 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 118.351 1.076 . . . . 0.0 109.68 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 29.1 t . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.272 -179.312 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -148.29 160.75 42.65 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 11' ' ' GLU . . . . . 0.411 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 79.2 mm-40 -114.74 151.32 33.92 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.154 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 57.4 t -107.09 105.97 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.043 0.449 . . . . 0.0 110.705 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 13' ' ' HIS . . . . . 0.599 ' ND1' ' O ' ' Q' ' 13' ' ' HIS . 63.0 t60 -148.82 130.14 14.68 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.224 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 42.0 p-80 -154.03 162.8 40.94 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.833 176.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 15' ' ' GLN . . . . . . . . . . . . . 5.5 tt0 -89.86 158.29 17.52 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 68.9 tttt -140.82 103.15 4.44 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 17' ' ' LEU . . . . . 0.458 ' N ' ' CD2' ' R' ' 17' ' ' LEU . 0.1 OUTLIER -115.51 109.29 17.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.702 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -106.28 104.09 16.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 19' ' ' PHE . . . . . . . . . . . . . 51.2 m-85 -100.25 100.95 11.84 Favored 'General case' 0 CA--C 1.509 -0.599 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 178.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -110.77 110.33 20.93 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.299 0.571 . . . . 0.0 109.949 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.6 130.29 45.48 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 22' ' ' GLU . . . . . 0.518 ' OE2' ' CZ ' ' Q' ' 20' ' ' PHE . 52.2 mp0 -77.86 108.99 11.5 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 118.597 -1.241 . . . . 0.0 110.686 -177.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 23' ' ' ASP . . . . . 0.613 ' CG ' ' H ' ' R' ' 24' ' ' VAL . 22.8 p-10 -178.83 -69.79 0.01 OUTLIER 'General case' 0 C--N 1.347 0.463 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 178.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 24' ' ' VAL . . . . . 0.613 ' H ' ' CG ' ' R' ' 23' ' ' ASP . 42.9 t -147.28 120.59 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -177.518 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.75 -43.73 91.09 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 119.546 -1.311 . . . . 0.0 110.659 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 44.1 m -139.56 -111.03 0.15 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 117.231 0.515 . . . . 0.0 111.283 177.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 7.1 m120 55.69 152.67 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.859 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -70.41 48.79 0.11 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.465 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 -52.06 1.38 Allowed Glycine 0 CA--C 1.541 1.664 0 C-N-CA 120.705 -0.76 . . . . 0.0 113.859 -178.424 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.4 176.44 5.15 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-N 117.454 0.627 . . . . 0.0 109.972 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 85.7 mt -110.45 116.97 53.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -113.63 127.44 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.039 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.85 113.13 1.7 Allowed Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 34' ' ' LEU . . . . . 0.422 ' CD2' ' C ' ' R' ' 34' ' ' LEU . 6.9 tt -118.05 121.43 40.57 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 93.9 mtp -140.01 143.16 36.31 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.567 -0.453 . . . . 0.0 111.075 -179.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' R' ' 37' ' ' GLY . 3.3 p -122.83 131.56 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' R' ' 36' ' ' VAL . . . -34.05 -111.41 0.0 OUTLIER Glycine 0 CA--C 1.529 0.933 0 CA-C-N 115.102 -0.953 . . . . 0.0 113.591 179.598 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.52 -71.68 0.63 Allowed Glycine 0 CA--C 1.537 1.42 0 CA-C-N 115.563 -0.319 . . . . 0.0 113.288 -178.292 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' R' R ' 39' ' ' VAL . . . . . 0.43 ' O ' ' O ' ' Q' ' 38' ' ' GLY . 6.8 p -138.49 142.71 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 117.618 0.709 . . . . 0.0 112.254 -178.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.455 178.629 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 . . . . . 0 N--CA 1.463 0.199 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -126.01 131.52 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.033 0.444 . . . . 0.0 110.467 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.6 p-80 -98.93 162.15 13.24 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.926 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 49.5 p-80 -86.39 169.5 12.85 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.805 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -129.5 151.28 50.29 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.45 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -96.54 124.35 40.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.773 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 91.4 mt -123.94 120.94 33.98 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-O 121.11 0.481 . . . . 0.0 110.76 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -127.41 133.47 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.874 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -133.41 124.43 27.1 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.822 0.344 . . . . 0.0 110.53 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 55.1 p90 -124.21 132.25 53.59 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.91 140.48 32.83 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.036 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 41.3 tp10 -107.07 158.35 17.12 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 114.071 -1.422 . . . . 0.0 107.491 177.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 t70 . . . . . 0 C--N 1.33 -0.268 0 C-N-CA 119.594 -0.842 . . . . 0.0 112.455 -178.655 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.581 HD21 ' C ' ' B' ' 27' ' ' ASN . 13.8 t-20 . . . . . 0 CA--C 1.534 0.359 0 CA-C-O 120.409 0.147 . . . . 0.0 110.811 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -73.32 -49.25 28.48 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.96 59.69 0.5 Allowed Glycine 0 CA--C 1.543 1.83 0 C-N-CA 119.976 -1.107 . . . . 0.0 110.372 -175.34 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.57 92.42 9.08 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 123.513 1.625 . . . . 0.0 113.491 -175.215 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.534 HG21 HG21 ' N' ' 39' ' ' VAL . 1.1 pt -142.3 122.81 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 111.789 -2.46 . . . . 0.0 106.322 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.443 ' O ' ' O ' ' B' ' 33' ' ' GLY . 58.8 mt -104.83 110.12 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.77 92.08 0.58 Allowed Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 104.609 -3.396 . . . . 0.0 104.609 176.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.608 ' O ' HD12 ' B' ' 34' ' ' LEU . 82.0 mt -146.45 169.62 18.52 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-O 122.954 1.359 . . . . 0.0 112.814 -175.206 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 53.3 mtp -141.75 119.31 11.66 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.781 -2.009 . . . . 0.0 108.735 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.793 ' CG2' HG12 ' B' ' 36' ' ' VAL . 11.7 m -124.74 113.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.05 -123.95 1.19 Allowed Glycine 0 C--N 1.305 -1.185 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.561 ' O ' HD13 ' G' ' 31' ' ' ILE . . . 80.73 -67.39 3.56 Favored Glycine 0 CA--C 1.535 1.318 0 C-N-CA 120.387 -0.911 . . . . 0.0 111.328 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.23 156.11 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.145 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 10' ' ' TYR . . . . . 0.477 ' CE2' HG23 ' B' ' 12' ' ' VAL . 87.7 t80 -87.5 126.34 34.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.341 179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.04 140.78 34.32 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.555 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.477 HG23 ' CE2' ' B' ' 10' ' ' TYR . 62.4 t -127.6 132.78 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.044 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.548 ' HB2' ' CD2' ' C' ' 13' ' ' HIS . 74.6 m80 -143.02 94.08 2.58 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.831 0.348 . . . . 0.0 110.695 179.344 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.609 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 6.9 t60 -158.56 170.18 22.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.813 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.609 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 17.6 tt0 -155.42 141.18 18.06 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.898 0.38 . . . . 0.0 110.213 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -89.0 124.42 34.25 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.27 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 tp -120.96 117.52 27.5 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 177.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.5 129.38 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.787 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -128.78 121.75 29.04 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.717 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.611 ' CD2' ' CD1' ' C' ' 20' ' ' PHE . 7.4 m-85 -122.46 129.03 51.6 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.17 137.4 34.36 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.527 0.68 . . . . 0.0 112.793 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' A' ' 22' ' ' GLU . 86.8 mt-10 -96.09 118.82 33.45 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.303 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.424 ' H ' ' HB2' ' C' ' 22' ' ' GLU . 0.3 OUTLIER -143.43 51.71 1.36 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.316 -179.045 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 71.3 t -75.7 143.49 13.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.957 0.884 . . . . 0.0 110.807 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.65 38.23 3.99 Favored Glycine 0 CA--C 1.525 0.656 0 CA-C-N 113.813 -1.539 . . . . 0.0 109.373 -178.698 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.9 t 73.18 120.01 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 115.241 -0.479 . . . . 0.0 110.608 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.841 HD21 ' H ' ' B' ' 30' ' ' ALA . 3.8 p30 -83.07 163.78 20.7 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 119.571 -0.851 . . . . 0.0 108.809 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -46.98 -37.06 8.5 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.249 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' B' ' 31' ' ' ILE . . . 179.53 77.05 0.06 OUTLIER Glycine 0 CA--C 1.531 1.068 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.823 -177.498 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.841 ' H ' HD21 ' B' ' 27' ' ' ASN . . . -51.77 91.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 119.371 1.586 . . . . 0.0 110.776 -179.315 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.956 HD12 HG22 ' N' ' 39' ' ' VAL . 66.8 mt -132.98 133.51 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.742 -177.697 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -107.96 109.7 29.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -113.29 97.05 0.84 Allowed Glycine 0 CA--C 1.507 -0.465 0 N-CA-C 104.19 -3.564 . . . . 0.0 104.19 176.28 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.647 HD12 ' H ' ' B' ' 35' ' ' MET . 40.1 tp -141.71 147.29 37.2 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 122.978 1.371 . . . . 0.0 113.47 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.647 ' H ' HD12 ' B' ' 34' ' ' LEU . 11.6 mtp -116.6 112.62 21.56 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 112.662 -2.063 . . . . 0.0 108.826 178.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.793 HG12 ' CG2' ' A' ' 36' ' ' VAL . 30.1 m -127.24 123.07 61.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.043 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 142.77 -113.52 0.79 Allowed Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.489 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 73.77 -72.74 1.27 Allowed Glycine 0 CA--C 1.535 1.29 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.441 ' CG1' ' O ' ' A' ' 38' ' ' GLY . 14.7 p -158.65 138.58 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 178.823 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.48 ' CG1' ' CD2' ' D' ' 13' ' ' HIS . 1.9 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.504 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -107.85 131.81 54.1 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.32 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -129.59 125.16 35.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.151 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -130.24 134.45 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.083 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.577 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 21.0 t-80 -139.95 139.85 36.22 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.532 ' CE1' ' O ' ' D' ' 14' ' ' HIS . 52.5 t60 -155.56 168.78 26.04 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.508 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.441 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.1 tt0 -138.74 140.81 38.82 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.582 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -130.4 113.47 14.37 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.488 HD12 HD22 ' D' ' 17' ' ' LEU . 35.6 mt -118.79 110.94 17.82 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.745 178.624 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 23.1 t -109.15 110.88 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.25 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -106.53 108.64 20.25 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.611 ' CD1' ' CD2' ' B' ' 20' ' ' PHE . 14.6 t80 -114.91 124.71 52.41 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 122.424 -0.173 . . . . 0.0 111.273 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 139.57 26.98 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.447 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 98.0 mt-10 -89.89 143.2 26.99 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.481 178.58 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.447 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 0.0 OUTLIER -164.66 50.44 0.12 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -177.893 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.404 HG13 ' CG2' ' D' ' 24' ' ' VAL . 37.6 t -80.87 149.37 5.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 122.83 1.3 . . . . 0.0 112.417 -174.431 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.6 36.92 5.69 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 112.052 -2.34 . . . . 0.0 110.28 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' D' ' 24' ' ' VAL . 19.8 t 72.64 120.12 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.789 0.835 . . . . 0.0 110.028 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.679 ' ND2' ' ND2' ' B' ' 27' ' ' ASN . 9.7 t-20 -83.18 161.99 21.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 116.991 -1.884 . . . . 0.0 110.284 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.489 ' H ' ' ND2' ' C' ' 27' ' ' ASN . 61.0 mttp -47.41 -37.03 10.66 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 175.811 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.76 78.16 0.06 OUTLIER Glycine 0 CA--C 1.538 1.508 0 CA-C-O 119.294 -0.726 . . . . 0.0 112.343 -173.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.723 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . -79.18 119.04 21.71 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 123.299 1.524 . . . . 0.0 112.997 -175.284 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.675 HD12 HG12 ' O' ' 39' ' ' VAL . 78.4 mt -139.1 139.89 39.22 Favored 'Isoleucine or valine' 0 C--N 1.353 0.724 0 CA-C-N 112.32 -2.218 . . . . 0.0 113.426 -176.703 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.433 HD13 ' CD2' ' E' ' 19' ' ' PHE . 64.1 mt -109.11 112.36 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.31 98.43 0.93 Allowed Glycine 0 C--O 1.238 0.392 0 N-CA-C 106.069 -2.812 . . . . 0.0 106.069 177.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 13.0 tp -133.26 134.59 44.14 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 122.495 1.14 . . . . 0.0 113.931 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.5 mtp -104.88 106.83 17.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 175.053 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.407 HG11 HD21 ' F' ' 17' ' ' LEU . 12.6 p -123.02 122.98 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.97 -113.11 0.55 Allowed Glycine 0 C--N 1.312 -0.801 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -177.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.51 ' O ' ' O ' ' C' ' 39' ' ' VAL . . . 55.73 64.98 3.89 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 119.789 -1.196 . . . . 0.0 112.61 178.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.528 HG23 ' O ' ' C' ' 39' ' ' VAL . 33.8 m 16.08 114.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.05 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.407 ' H ' HG23 ' C' ' 40' ' ' VAL . 2.6 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.491 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 t . . . . . 0 N--CA 1.466 0.338 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 3.5 t60 -143.89 122.72 12.68 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 110.372 -0.233 . . . . 0.0 110.372 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.663 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -118.77 161.53 19.96 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.114 0.483 . . . . 0.0 110.316 178.714 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.461 ' OE1' HD11 ' E' ' 17' ' ' LEU . 43.4 tt0 -85.05 157.04 20.84 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.091 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.637 ' O ' HD23 ' D' ' 17' ' ' LEU . 87.0 tttt -160.31 102.21 1.4 Allowed 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.321 177.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.731 ' CD1' HG11 ' B' ' 36' ' ' VAL . 3.1 mt -126.73 121.51 32.22 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -112.4 112.31 39.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -107.64 107.02 17.63 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.545 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 32.5 t80 -110.56 120.56 42.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 -178.714 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.87 144.99 27.26 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 118.748 -1.181 . . . . 0.0 113.687 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.434 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 98.1 mt-10 -96.05 136.36 36.61 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.99 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -160.13 49.95 0.29 Allowed 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.647 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' C' ' 26' ' ' SER . 35.7 m -81.67 150.65 4.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 122.601 1.191 . . . . 0.0 113.49 -176.096 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' E' ' 24' ' ' VAL . . . 93.94 36.97 5.59 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-N 112.59 -2.096 . . . . 0.0 111.705 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 72.77 120.11 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.333 -0.434 . . . . 0.0 111.544 175.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.723 ' ND2' ' H ' ' C' ' 30' ' ' ALA . 13.4 t30 -83.07 162.3 21.4 Favored 'General case' 0 C--O 1.231 0.103 0 C-N-CA 117.94 -1.504 . . . . 0.0 107.997 176.349 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.614 ' NZ ' ' ND1' ' Q' ' 13' ' ' HIS . 83.1 tttt -47.53 -37.45 12.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.489 177.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.79 0.06 OUTLIER Glycine 0 CA--C 1.539 1.589 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.554 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.77 119.67 4.47 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -125.5 125.17 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.517 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 mt -106.82 112.71 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 173.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.13 114.71 2.01 Favored Glycine 0 N--CA 1.462 0.429 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.429 HD12 ' N ' ' D' ' 34' ' ' LEU . 0.3 OUTLIER -160.78 158.16 28.08 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 123.21 1.481 . . . . 0.0 113.595 -178.826 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mmm -110.72 111.64 22.97 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 111.967 -2.378 . . . . 0.0 108.882 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.613 HG11 HD11 ' F' ' 17' ' ' LEU . 9.0 t -106.09 112.74 40.62 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.714 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.175 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -179.09 -121.96 0.74 Allowed Glycine 0 C--N 1.304 -1.22 0 C-N-CA 118.331 -1.89 . . . . 0.0 111.643 -179.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 63.63 61.55 6.12 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 119.65 -1.262 . . . . 0.0 111.347 -178.365 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.702 HG23 ' O ' ' E' ' 39' ' ' VAL . 5.6 p -18.62 122.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.076 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.992 179.112 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.144 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -83.73 139.8 32.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.799 0.333 . . . . 0.0 110.758 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.467 ' OE2' ' NE2' ' D' ' 14' ' ' HIS . 79.4 tt0 -155.22 151.24 27.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.988 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.645 HG12 ' N ' ' E' ' 13' ' ' HIS . 59.0 t -140.51 168.01 17.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.778 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.645 ' N ' HG12 ' E' ' 12' ' ' VAL . 20.8 p-80 -64.34 140.85 58.91 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' F' ' 12' ' ' VAL . 65.0 m80 -150.63 166.43 30.33 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.697 177.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -89.82 150.99 22.0 Favored 'General case' 0 CA--C 1.522 -0.114 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.565 ' C ' HD22 ' E' ' 17' ' ' LEU . 67.8 mttm -152.24 99.18 2.49 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 176.576 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.804 HD22 ' N ' ' E' ' 17' ' ' LEU . 1.3 mm? -118.33 114.11 22.46 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.857 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -110.18 106.65 21.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.436 ' CZ ' ' HB3' ' E' ' 17' ' ' LEU . 35.1 m-85 -103.15 103.75 13.84 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 30.3 t80 -110.39 118.52 36.52 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 121.138 -0.225 . . . . 0.0 111.027 -178.455 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.48 137.01 28.24 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 118.907 -1.117 . . . . 0.0 113.155 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -88.37 115.57 25.97 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' F' ' 22' ' ' GLU . 0.0 OUTLIER -148.57 48.85 1.02 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -175.485 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.51 HG12 ' N ' ' E' ' 25' ' ' GLY . 67.2 t -71.9 160.1 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 118.007 -1.477 . . . . 0.0 108.199 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.51 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 111.08 -36.62 4.12 Favored Glycine 0 N--CA 1.464 0.541 0 N-CA-C 108.097 -2.001 . . . . 0.0 108.097 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -65.79 112.52 3.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 113.22 -1.49 . . . . 0.0 110.622 -179.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -148.98 162.33 40.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.758 0.789 . . . . 0.0 110.922 -178.213 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 29.84 43.11 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.785 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.19 59.69 0.13 Allowed Glycine 0 CA--C 1.543 1.803 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.484 173.972 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.72 141.26 40.97 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.534 -0.746 . . . . 0.0 110.322 177.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.432 HD12 HG13 ' Q' ' 39' ' ' VAL . 1.6 tt -132.52 125.33 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 CA-C-N 119.606 1.094 . . . . 0.0 110.232 176.514 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 87.1 mt -127.45 127.29 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.851 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.96 107.04 0.86 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.606 HD23 ' C ' ' E' ' 34' ' ' LEU . 7.3 tt -122.9 123.86 41.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.515 ' N ' HD23 ' E' ' 34' ' ' LEU . 86.1 mtp -134.08 145.57 49.49 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 119.958 -0.697 . . . . 0.0 112.391 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -124.23 136.85 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.885 0.85 . . . . 0.0 110.659 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.78 103.28 0.39 Allowed Glycine 0 C--N 1.315 -0.63 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' E' ' 39' ' ' VAL . . . 127.12 75.75 0.21 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.157 -178.627 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.702 ' O ' HG23 ' D' ' 39' ' ' VAL . 7.3 t . . . . . 0 N--CA 1.479 1.012 0 C-N-CA 123.628 0.771 . . . . 0.0 112.981 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 C--O 1.231 0.102 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 18.2 t -132.64 133.33 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.505 0.669 . . . . 0.0 111.379 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.515 ' HD1' ' CE1' ' E' ' 13' ' ' HIS . 0.3 OUTLIER -146.05 117.26 7.87 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.992 179.417 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 76.9 m80 -156.71 165.52 36.02 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.672 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.501 ' CD ' HG12 ' D' ' 36' ' ' VAL . 78.6 mt-30 -84.19 155.28 22.61 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.743 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -159.98 100.18 1.4 Allowed 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 121.291 0.567 . . . . 0.0 109.865 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.613 HD11 HG11 ' D' ' 36' ' ' VAL . 2.5 mp -125.62 114.92 19.35 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.331 178.586 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 12.4 t -99.83 102.61 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.919 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 178.002 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -95.16 95.22 8.4 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.413 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 64.8 t80 -111.16 113.52 26.1 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-O 121.548 0.69 . . . . 0.0 109.202 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.74 134.76 17.95 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 120.361 -0.536 . . . . 0.0 109.581 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' E' ' 23' ' ' ASP . 96.3 mt-10 -76.74 85.02 3.36 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 178.466 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 51.1 p30 . . . . . 0 CA--C 1.517 -0.306 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.488 -175.178 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.912 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 85.9 mt -115.59 112.12 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 120.667 1.576 . . . . 0.0 111.562 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -123.97 123.19 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.89 119.55 3.03 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 38.4 mt -122.87 119.7 31.31 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mtp -140.6 151.38 44.62 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 -178.551 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 m -127.41 164.55 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.421 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.36 -102.82 0.09 OUTLIER Glycine 0 CA--C 1.525 0.664 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.653 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.09 -77.83 1.24 Allowed Glycine 0 CA--C 1.536 1.38 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.526 HG22 ' N ' ' F' ' 40' ' ' VAL . 3.4 p -125.78 162.48 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 117.208 0.504 . . . . 0.0 111.266 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.526 ' N ' HG22 ' F' ' 39' ' ' VAL . 9.6 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.58 -178.348 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 77.5 t . . . . . 0 N--CA 1.463 0.198 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -145.38 131.6 19.48 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.42 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.6 p-80 -152.02 167.49 28.25 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.805 178.489 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -157.53 142.91 17.13 Favored 'General case' 0 CA--C 1.52 -0.202 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -81.53 126.2 31.41 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.584 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.7 mt -126.52 118.23 24.48 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -141.88 139.79 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 121.026 0.441 . . . . 0.0 110.999 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -134.74 131.84 38.07 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.58 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.498 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 55.1 p90 -131.06 130.34 43.12 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.93 0.395 . . . . 0.0 111.042 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.12 117.37 26.98 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.016 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -143.31 147.44 34.74 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.462 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 C--N 1.327 -0.373 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.035 179.776 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.622 ' HB2' ' HZ2' ' H' ' 28' ' ' LYS . 93.7 m-20 . . . . . 0 N--CA 1.483 1.187 0 N-CA-C 115.41 1.634 . . . . 0.0 115.41 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -173.86 -21.04 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.419 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.539 ' N ' ' OD2' ' H' ' 23' ' ' ASP . . . 71.66 -97.9 0.73 Allowed Glycine 0 N--CA 1.465 0.624 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.61 97.02 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.112 0.482 . . . . 0.0 111.487 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.561 HD13 ' O ' ' A' ' 38' ' ' GLY . 91.2 mt -123.03 110.83 27.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.041 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -113.76 107.32 22.63 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.78 100.08 0.92 Allowed Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 104.393 -3.483 . . . . 0.0 104.393 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.468 ' O ' HD23 ' H' ' 34' ' ' LEU . 48.3 tp -150.36 149.28 29.86 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-O 123.034 1.397 . . . . 0.0 113.954 -174.52 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 mtp -105.64 106.32 16.76 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 112.183 -2.281 . . . . 0.0 106.015 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.642 HG21 HD11 ' I' ' 17' ' ' LEU . 3.8 p -128.47 113.95 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.43 -124.9 1.95 Allowed Glycine 0 C--N 1.307 -1.061 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.1 -66.89 3.7 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.995 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.663 HG22 ' N ' ' G' ' 40' ' ' VAL . 12.6 p -108.08 176.01 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.663 ' N ' HG22 ' G' ' 39' ' ' VAL . 2.5 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.116 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.347 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -105.64 132.44 51.78 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -159.48 114.43 2.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.069 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.46 HG22 ' CG1' ' I' ' 12' ' ' VAL . 79.6 t -126.66 128.9 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.483 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 61.5 m80 -147.61 114.97 6.28 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.462 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.504 ' CE1' ' H ' ' I' ' 14' ' ' HIS . 12.9 m-70 -149.74 169.07 21.92 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.442 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -156.52 141.58 17.24 Favored 'General case' 0 CA--C 1.518 -0.278 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 177.061 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -86.85 120.5 28.2 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.218 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.555 HD13 ' N ' ' H' ' 18' ' ' VAL . 0.6 OUTLIER -117.22 113.91 22.89 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.007 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.555 ' N ' HD13 ' H' ' 17' ' ' LEU . 69.1 t -122.17 131.03 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 120.867 0.365 . . . . 0.0 111.386 -178.654 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 37.7 t80 -126.98 116.81 21.33 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.614 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 8.0 t80 -122.63 127.2 49.05 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.95 134.84 32.11 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 112.754 0.649 . . . . 0.0 112.754 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -107.71 121.24 44.31 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.272 178.534 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.539 ' OD2' ' N ' ' G' ' 29' ' ' GLY . 93.6 m-20 -140.33 46.38 1.82 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.012 -178.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.786 HG12 ' H ' ' H' ' 25' ' ' GLY . 20.6 t -81.68 177.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.36 -177.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.786 ' H ' HG12 ' H' ' 24' ' ' VAL . . . 92.72 -33.92 4.77 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.426 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.55 ' O ' ' O ' ' H' ' 27' ' ' ASN . 37.0 t -162.52 120.31 2.09 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 119.062 1.431 . . . . 0.0 113.502 177.539 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.55 ' O ' ' O ' ' H' ' 26' ' ' SER . 53.4 p-10 -22.41 153.23 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.946 0 O-C-N 124.266 0.979 . . . . 0.0 112.05 175.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.622 ' HZ2' ' HB2' ' G' ' 27' ' ' ASN . 61.7 tttt -165.43 26.42 0.05 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 118.392 -1.323 . . . . 0.0 114.162 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.58 ' H ' ' H ' ' I' ' 28' ' ' LYS . . . 82.03 108.01 0.4 Allowed Glycine 0 CA--C 1.525 0.717 0 C-N-CA 118.987 -1.578 . . . . 0.0 114.448 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.49 106.49 11.86 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 122.118 0.961 . . . . 0.0 109.273 178.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.43 HD12 ' O ' ' B' ' 38' ' ' GLY . 1.9 tt -141.45 132.66 27.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 CA-C-N 114.687 -1.142 . . . . 0.0 111.83 -177.658 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.559 HG22 HD11 ' I' ' 34' ' ' LEU . 6.6 mt -108.13 111.69 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.074 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.48 103.18 1.42 Allowed Glycine 0 N--CA 1.46 0.248 0 N-CA-C 105.543 -3.023 . . . . 0.0 105.543 177.131 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.468 HD23 ' O ' ' G' ' 34' ' ' LEU . 0.4 OUTLIER -146.47 145.12 30.08 Favored 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 117.92 -1.512 . . . . 0.0 114.271 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.4 mtp -111.12 112.34 24.07 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 112.935 -1.938 . . . . 0.0 107.02 176.182 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.428 HG12 ' NE2' ' J' ' 15' ' ' GLN . 0.7 OUTLIER -119.69 102.88 13.43 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.812 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.88 -151.56 20.16 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.97 -56.55 0.54 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.559 HG22 ' N ' ' H' ' 40' ' ' VAL . 6.3 p -153.69 161.12 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 177.787 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.559 ' N ' HG22 ' H' ' 39' ' ' VAL . 14.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.787 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -111.89 133.94 53.76 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.731 0.301 . . . . 0.0 110.557 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -155.39 144.95 21.19 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.895 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.46 ' CG1' HG22 ' H' ' 12' ' ' VAL . 2.5 p -127.37 118.67 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.108 0.48 . . . . 0.0 109.946 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' O ' ' G' ' 40' ' ' VAL . 2.9 t-80 -147.83 120.2 8.43 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.588 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.504 ' H ' ' CE1' ' H' ' 14' ' ' HIS . 4.8 m170 -122.48 162.74 21.15 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 120.794 -0.362 . . . . 0.0 110.823 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.03 153.94 20.19 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.728 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -145.47 97.07 2.93 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.646 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.642 HD11 HG21 ' G' ' 36' ' ' VAL . 18.4 mt -121.14 121.91 38.86 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.347 178.272 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -117.11 110.16 30.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -107.76 108.97 20.43 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 28.0 t80 -115.68 126.33 53.98 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.91 135.82 34.83 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -94.09 140.6 29.54 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.142 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 7.4 p-10 -176.83 52.14 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.697 0.284 . . . . 0.0 110.442 -175.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.468 HG12 HG13 ' H' ' 24' ' ' VAL . 3.3 p -74.52 143.16 13.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 122.653 1.216 . . . . 0.0 112.637 -175.197 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.427 ' O ' ' OG ' ' I' ' 26' ' ' SER . . . 99.53 38.22 3.77 Favored Glycine 0 CA--C 1.529 0.961 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.434 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 7.0 p 73.17 120.2 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.131 -0.535 . . . . 0.0 111.907 176.343 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' I' ' 29' ' ' GLY . 1.6 m120 -83.93 152.68 24.36 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 118.257 -1.377 . . . . 0.0 108.669 175.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.58 ' H ' ' H ' ' H' ' 29' ' ' GLY . 30.1 mtmt -50.68 43.66 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.862 0 CA-C-O 116.966 -1.492 . . . . 0.0 114.178 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 120.94 77.44 0.47 Allowed Glycine 0 N--CA 1.487 2.04 0 CA-C-N 122.555 2.434 . . . . 0.0 113.013 -178.229 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.22 112.12 18.25 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.316 1.558 . . . . 0.0 111.8 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.437 HD12 HG13 ' C' ' 39' ' ' VAL . 12.7 tt -145.74 141.67 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -177.21 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.598 HG23 HD13 ' I' ' 34' ' ' LEU . 38.3 mt -111.16 113.19 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 176.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.714 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -115.01 99.93 0.95 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 177.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.714 HD12 ' O ' ' I' ' 33' ' ' GLY . 5.9 mp -136.22 148.22 47.98 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 123.411 1.577 . . . . 0.0 114.124 -176.796 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -116.59 106.31 13.41 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 111.724 -2.489 . . . . 0.0 104.526 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.479 ' HB ' HD21 ' J' ' 34' ' ' LEU . 38.6 t -126.58 142.75 42.25 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.74 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.152 -175.609 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.73 -101.99 0.71 Allowed Glycine 0 C--N 1.312 -0.768 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.676 ' O ' HG21 ' J' ' 39' ' ' VAL . . . 66.69 -80.09 0.12 Allowed Glycine 0 CA--C 1.533 1.204 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.665 -179.298 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.637 HG22 HD12 ' O' ' 31' ' ' ILE . 21.9 t -116.28 131.3 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 C-N-CA 123.068 0.547 . . . . 0.0 109.998 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 39' ' ' VAL . 8.8 p . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 118.038 -0.982 . . . . 0.0 111.43 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -108.39 136.28 48.29 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.741 0.305 . . . . 0.0 110.24 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -78.13 108.98 11.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.96 129.72 68.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.757 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' K' ' 14' ' ' HIS . 67.1 m80 -124.88 127.31 46.91 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.823 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.629 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 12.7 t60 -152.09 170.43 19.96 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.228 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.629 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 6.7 tt0 -138.5 140.65 39.25 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -130.57 104.28 7.13 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.464 ' CD1' ' CG ' ' J' ' 15' ' ' GLN . 6.3 mp -122.8 120.2 32.85 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.736 177.468 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -113.7 112.25 39.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.911 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.441 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 43.7 m-85 -109.4 108.13 18.55 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 37.2 t80 -116.66 125.12 51.29 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.58 0.228 . . . . 0.0 110.955 -179.278 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.94 133.49 33.8 Favored 'General case' 0 C--O 1.241 0.627 0 CA-C-O 121.452 0.644 . . . . 0.0 111.842 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.453 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 80.1 tt0 -90.47 119.75 31.01 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.534 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.432 ' OD1' ' OD2' ' I' ' 23' ' ' ASP . 0.2 OUTLIER -147.39 52.05 1.06 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.443 -0.799 . . . . 0.0 108.901 -178.14 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.89 143.14 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 122.448 1.118 . . . . 0.0 112.793 -175.153 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' J' ' 26' ' ' SER . . . 99.09 38.16 3.9 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 112.699 -2.046 . . . . 0.0 112.197 178.617 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.404 ' HB3' ' O ' ' J' ' 25' ' ' GLY . 22.0 t 72.68 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.453 0.701 . . . . 0.0 111.11 176.638 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -83.18 161.75 21.46 Favored 'General case' 0 C--N 1.34 0.194 0 C-N-CA 117.18 -1.808 . . . . 0.0 110.221 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -47.7 -37.28 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 175.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.03 78.06 0.06 OUTLIER Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.741 -1.033 . . . . 0.0 112.236 -172.242 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.84 116.87 19.45 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 120.076 1.938 . . . . 0.0 111.66 -175.336 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 5.0 tt -134.01 136.91 53.04 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 CA-C-N 112.253 -2.249 . . . . 0.0 113.134 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.09 122.66 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 120.999 0.428 . . . . 0.0 110.609 178.106 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.85 104.42 0.97 Allowed Glycine 0 N--CA 1.462 0.396 0 N-CA-C 106.339 -2.704 . . . . 0.0 106.339 176.467 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.897 HD23 ' N ' ' J' ' 35' ' ' MET . 5.0 tt -144.46 142.85 30.57 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-O 122.578 1.18 . . . . 0.0 112.47 -175.707 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.897 ' N ' HD23 ' J' ' 34' ' ' LEU . 28.6 mtp -116.32 115.05 25.21 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.145 -1.843 . . . . 0.0 108.779 178.367 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.829 HG11 HD11 ' L' ' 17' ' ' LEU . 0.1 OUTLIER -97.62 111.35 27.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.512 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 178.956 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.52 131.49 42.96 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.331 -177.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.95 63.51 3.16 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 121.279 -0.486 . . . . 0.0 111.938 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.676 HG21 ' O ' ' I' ' 38' ' ' GLY . 42.7 t -124.62 126.36 71.54 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 CA-C-O 121.461 0.648 . . . . 0.0 110.029 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.589 -179.208 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.66 135.76 48.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.657 0.265 . . . . 0.0 110.506 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.16 111.65 16.76 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.334 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.501 HG23 ' O ' ' K' ' 12' ' ' VAL . 4.5 m -130.67 126.56 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.185 0.517 . . . . 0.0 111.03 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -110.16 157.58 19.24 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.612 ' CG ' ' H ' ' K' ' 15' ' ' GLN . 22.4 t-80 -158.01 178.02 10.68 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 119.434 -0.906 . . . . 0.0 112.826 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.612 ' H ' ' CG ' ' K' ' 14' ' ' HIS . 31.6 tt0 -160.37 140.57 11.48 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 114.197 -1.365 . . . . 0.0 107.54 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -159.48 115.97 2.58 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.947 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.46 ' N ' HD12 ' K' ' 17' ' ' LEU . 4.6 mp -128.07 125.03 38.49 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 114.395 -1.275 . . . . 0.0 109.196 178.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 26.3 m -116.03 121.09 66.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.441 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 24.1 m-85 -109.16 109.85 20.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.695 -178.771 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -111.92 118.67 36.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 122.357 -0.214 . . . . 0.0 111.04 -179.109 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.66 126.74 27.94 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 110.315 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' J' ' 23' ' ' ASP . 75.4 mt-10 -87.8 140.58 29.36 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.406 -179.464 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 7.0 p-10 178.52 48.87 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 17.8 m -72.16 160.61 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 119.309 -0.956 . . . . 0.0 109.887 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.22 -33.25 5.95 Favored Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.149 177.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 1.7 p -72.23 129.98 39.73 Favored 'General case' 0 N--CA 1.465 0.325 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 46.5 t-20 -90.86 143.65 26.5 Favored 'General case' 0 C--O 1.232 0.154 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 176.269 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.48 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 51.7 tttp 43.52 42.84 4.22 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' L' ' 23' ' ' ASP . . . -101.69 60.48 0.58 Allowed Glycine 0 N--CA 1.476 1.308 0 CA-C-O 119.269 -0.74 . . . . 0.0 114.111 -178.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.86 119.95 4.94 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 119.204 1.502 . . . . 0.0 111.772 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 74.3 mt -121.6 116.83 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -124.17 128.3 73.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.22 103.18 0.79 Allowed Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.024 -2.03 . . . . 0.0 108.024 177.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.638 HD11 ' CG2' ' J' ' 36' ' ' VAL . 30.2 tp -117.11 121.4 41.17 Favored 'General case' 0 C--O 1.24 0.58 0 CA-C-O 121.265 0.555 . . . . 0.0 110.007 -178.42 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 18.5 ttm -120.86 129.86 53.69 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.16 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' K' ' 37' ' ' GLY . 54.9 t -115.78 131.93 66.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.886 178.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -45.03 -111.73 0.0 OUTLIER Glycine 0 CA--C 1.529 0.915 0 CA-C-N 115.519 -0.764 . . . . 0.0 112.349 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -107.15 -71.69 0.77 Allowed Glycine 0 CA--C 1.534 1.223 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.448 HG22 ' O ' ' L' ' 39' ' ' VAL . 54.1 t . . . . . 0 CA--C 1.506 -0.719 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.562 0.22 . . . . 0.0 110.488 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 m -129.93 135.78 60.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.081 0.467 . . . . 0.0 111.567 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 5.1 p80 -146.85 97.97 2.98 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.275 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -154.69 162.59 41.06 Favored 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -89.95 159.24 17.01 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.203 0.525 . . . . 0.0 111.632 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 16' ' ' LYS . . . . . 0.442 ' HD2' ' HE1' ' K' ' 14' ' ' HIS . 92.8 mttt -140.06 110.6 6.72 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.791 177.361 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.829 HD11 HG11 ' J' ' 36' ' ' VAL . 25.9 mt -118.09 112.19 19.89 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.555 178.802 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 9.0 t -104.21 100.67 10.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.871 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -94.44 99.87 11.97 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -116.24 112.17 21.22 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.466 0.651 . . . . 0.0 110.984 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.1 135.41 32.52 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 107.842 -1.169 . . . . 0.0 107.842 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.497 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 80.3 mm-40 -73.39 108.89 6.51 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 118.627 -1.229 . . . . 0.0 108.401 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' L' ' 24' ' ' VAL . 64.9 m-20 -164.03 61.39 0.16 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.514 -176.982 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' L' ' 23' ' ' ASP . 8.9 t 55.63 155.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.153 -177.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.24 24.2 0.19 Allowed Glycine 0 CA--C 1.521 0.413 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 40.3 t -81.86 -120.93 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' L' ' 29' ' ' GLY . 99.3 m-20 -93.05 -165.61 1.37 Allowed 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.754 -0.778 . . . . 0.0 109.502 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -47.98 47.68 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 115.732 1.753 . . . . 0.0 115.732 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.64 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.31 56.86 0.89 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-N 119.253 0.933 . . . . 0.0 112.339 177.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.62 169.8 9.97 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.433 ' CD1' HG12 ' F' ' 39' ' ' VAL . 8.3 mm -112.98 111.31 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 176.781 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -125.75 130.1 72.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.594 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.0 116.48 2.73 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 56.9 tp -118.32 123.08 44.47 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttm -125.66 124.99 42.35 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.24 132.45 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.8 112.13 3.6 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.193 -178.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.97 -71.17 0.01 OUTLIER Glycine 0 CA--C 1.538 1.521 0 N-CA-C 115.216 0.847 . . . . 0.0 115.216 177.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' K' ' 38' ' ' GLY . 54.1 t . . . . . 0 C--O 1.214 -0.765 0 CA-C-N 117.96 0.88 . . . . 0.0 112.007 -178.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.814 0.34 . . . . 0.0 110.784 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -122.01 131.29 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.01 0.434 . . . . 0.0 110.07 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -119.27 130.35 55.38 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.273 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.497 ' CD2' ' O ' ' N' ' 13' ' ' HIS . 13.6 m-70 -83.23 167.09 18.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.138 0.494 . . . . 0.0 111.126 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -93.38 159.98 15.01 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.425 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.145 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 88.7 mt -130.1 130.75 45.24 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.965 0.412 . . . . 0.0 111.465 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 67.3 t -133.75 132.2 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.963 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -138.67 136.71 36.14 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.171 0.51 . . . . 0.0 112.001 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -121.11 125.15 46.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.063 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.62 113.75 25.49 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 121.345 0.593 . . . . 0.0 111.224 -179.503 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 22' ' ' GLU . . . . . 0.418 ' OE1' ' OE2' ' N' ' 22' ' ' GLU . 12.4 pt-20 -173.16 150.31 1.92 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.724 179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 56.03 46.95 20.77 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.158 178.355 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -101.03 -170.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.12 -32.43 84.01 Favored Glycine 0 N--CA 1.468 0.822 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.241 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 47.6 t -152.88 125.11 8.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.366 0.583 . . . . 0.0 109.789 177.801 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 27' ' ' ASN . . . . . 0.641 ' HA ' HG11 ' N' ' 24' ' ' VAL . 1.9 m-20 -38.93 134.58 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.956 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.67 -39.54 4.84 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 122.192 0.996 . . . . 0.0 108.39 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 29' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 79.89 -69.29 3.09 Favored Glycine 0 CA--C 1.534 1.261 0 CA-C-N 113.348 -1.751 . . . . 0.0 110.753 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 30' ' ' ALA . . . . . 0.593 ' HB3' ' HA ' ' N' ' 30' ' ' ALA . . . 179.6 82.38 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 117.335 0.568 . . . . 0.0 111.009 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.608 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.6 tt -121.4 104.58 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 119.592 1.087 . . . . 0.0 109.482 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -124.39 116.59 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 CA-C-O 121.402 0.62 . . . . 0.0 111.618 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.83 104.93 0.86 Allowed Glycine 0 N--CA 1.464 0.529 0 N-CA-C 106.086 -2.806 . . . . 0.0 106.086 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 34' ' ' LEU . . . . . 0.458 ' HB2' HD11 ' N' ' 34' ' ' LEU . 85.7 mt -145.28 159.81 42.46 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 123.3 1.524 . . . . 0.0 114.214 -176.189 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 35.4 tpp -107.08 108.5 20.01 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.844 -2.435 . . . . 0.0 105.85 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 4.7 m -119.57 123.06 70.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 119.055 0.843 . . . . 0.0 109.68 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.25 -113.7 0.9 Allowed Glycine 0 C--N 1.31 -0.897 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.43 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . 95.48 -72.13 0.95 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 112.318 -0.313 . . . . 0.0 112.318 179.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 40' ' ' VAL . 2.4 t -122.29 159.23 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 O-C-N 122.691 -0.3 . . . . 0.0 110.621 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 39' ' ' VAL . 2.9 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.827 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -108.21 132.48 53.61 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.835 0.35 . . . . 0.0 110.401 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -125.88 126.86 45.11 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.027 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.416 ' CG1' ' NE2' ' M' ' 14' ' ' HIS . 59.2 t -127.73 130.33 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-O 120.871 0.367 . . . . 0.0 110.994 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.497 ' O ' ' CD2' ' M' ' 14' ' ' HIS . 29.8 t-80 -79.66 161.31 25.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.813 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 14' ' ' HIS . . . . . . . . . . . . . 29.8 p-80 -93.26 163.18 13.71 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.216 0.531 . . . . 0.0 111.322 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -89.88 160.12 16.61 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.61 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.22 131.6 28.48 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -132.59 127.37 34.86 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.348 0.594 . . . . 0.0 111.199 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.5 130.77 72.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.613 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -132.43 122.41 24.93 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.086 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 5.7 t80 -121.15 127.6 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.285 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.49 117.3 25.6 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.418 ' OE2' ' OE1' ' M' ' 22' ' ' GLU . 97.7 mt-10 -81.59 179.63 7.76 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 119.811 -0.755 . . . . 0.0 109.297 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.633 ' O ' HG23 ' N' ' 24' ' ' VAL . 62.3 t0 -60.53 -46.91 88.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 119.193 -1.003 . . . . 0.0 108.494 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 1.011 HG12 ' H ' ' N' ' 25' ' ' GLY . 9.4 t 99.81 -161.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 1.011 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -71.32 -33.4 64.53 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' N' ' 27' ' ' ASN . 34.2 t -162.55 120.55 2.1 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.577 ' O ' ' O ' ' N' ' 26' ' ' SER . 41.2 t-20 -22.0 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 114.682 -1.145 . . . . 0.0 112.443 177.177 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.669 ' HA ' ' HZ3' ' O' ' 28' ' ' LYS . 69.9 tttt -163.03 24.39 0.09 Allowed 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.9 107.68 1.25 Allowed Glycine 0 N--CA 1.476 1.35 0 C-N-CA 117.506 -2.283 . . . . 0.0 113.929 177.629 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 30' ' ' ALA . . . . . 0.593 ' HA ' ' HB3' ' M' ' 30' ' ' ALA . . . -109.53 102.69 11.52 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 123.637 1.684 . . . . 0.0 109.912 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.483 HD13 HG21 ' I' ' 39' ' ' VAL . 20.7 mt -130.19 130.48 65.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 112.388 -2.187 . . . . 0.0 110.824 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.423 HD13 ' HD2' ' P' ' 19' ' ' PHE . 10.1 tt -123.6 116.3 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.805 0.812 . . . . 0.0 109.844 176.611 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.568 ' O ' HD12 ' N' ' 34' ' ' LEU . . . -109.1 111.58 3.26 Favored Glycine 0 C--N 1.333 0.411 0 N-CA-C 107.02 -2.432 . . . . 0.0 107.02 178.733 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.568 HD12 ' O ' ' N' ' 33' ' ' GLY . 0.8 OUTLIER -137.88 139.22 39.75 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 122.633 1.206 . . . . 0.0 113.636 -176.094 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 95.7 mmm -106.36 111.56 24.19 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.711 HG11 HD11 ' P' ' 17' ' ' LEU . 2.1 t -117.19 123.15 71.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -178.105 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.38 -113.0 0.55 Allowed Glycine 0 C--N 1.306 -1.12 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.747 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.78 -73.16 2.71 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.956 HG22 HD12 ' B' ' 31' ' ' ILE . 62.8 t -138.17 138.39 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.062 0.545 . . . . 0.0 109.777 179.505 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' O' ' 40' ' ' VAL . 46.5 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.538 -0.744 . . . . 0.0 111.681 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.96 137.4 46.03 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.873 0.368 . . . . 0.0 110.521 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -93.23 113.31 25.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.374 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -125.28 128.72 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 120.781 0.324 . . . . 0.0 110.167 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -131.29 138.27 49.18 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.612 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 83.2 t60 -154.64 153.85 32.02 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 118.346 -1.342 . . . . 0.0 112.836 179.387 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 33.8 tt0 -90.63 164.44 14.18 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.721 177.19 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 102.18 0.33 Allowed 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mt -122.86 119.59 30.98 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.414 179.354 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 15.6 t -106.96 115.32 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.401 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -113.87 105.48 13.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 12.5 t80 -107.2 125.46 51.14 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.377 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.39 135.59 44.77 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -177.532 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -112.19 139.87 47.37 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.452 177.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -156.41 46.52 0.44 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.814 0.34 . . . . 0.0 110.127 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.712 HG12 ' H ' ' O' ' 25' ' ' GLY . 3.0 t -82.64 174.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 122.314 1.054 . . . . 0.0 112.552 -176.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.712 ' H ' HG12 ' O' ' 24' ' ' VAL . . . 92.59 -35.91 3.88 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-N 113.228 -1.805 . . . . 0.0 112.661 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.647 ' O ' ' O ' ' O' ' 27' ' ' ASN . 21.6 p -172.28 113.74 0.3 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 118.974 1.387 . . . . 0.0 112.218 175.232 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.647 ' O ' ' O ' ' O' ' 26' ' ' SER . 25.2 p30 -10.59 153.34 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 0 O-C-N 124.55 1.157 . . . . 0.0 113.994 176.428 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.669 ' HZ3' ' HA ' ' N' ' 28' ' ' LYS . 32.2 tttt -166.33 26.19 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 118.457 -1.297 . . . . 0.0 113.843 172.101 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.65 107.33 0.37 Allowed Glycine 0 CA--C 1.53 0.982 0 C-N-CA 119.318 -1.42 . . . . 0.0 112.474 178.459 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.97 112.48 18.81 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.031 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.637 HD12 HG22 ' I' ' 39' ' ' VAL . 83.6 mt -131.68 131.85 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -176.205 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.641 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 88.6 mt -108.22 106.06 19.96 Favored 'Isoleucine or valine' 0 C--N 1.344 0.351 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 174.025 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.47 ' O ' HD12 ' O' ' 34' ' ' LEU . . . -112.58 101.58 1.23 Allowed Glycine 0 N--CA 1.464 0.541 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.512 HD13 HG23 ' O' ' 32' ' ' ILE . 3.5 mp -139.78 146.46 39.49 Favored 'General case' 0 CA--C 1.508 -0.638 0 CA-C-O 123.14 1.447 . . . . 0.0 113.329 -176.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 12.3 mtp -113.24 108.66 17.57 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 111.828 -2.442 . . . . 0.0 106.371 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.654 HG12 ' HB ' ' N' ' 36' ' ' VAL . 1.5 m -124.13 102.85 11.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.03 -151.6 21.01 Favored Glycine 0 C--N 1.302 -1.332 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.062 179.643 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.29 -57.1 1.45 Allowed Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.804 HG11 HD13 ' B' ' 31' ' ' ILE . 33.4 m -129.07 159.3 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 123.253 0.621 . . . . 0.0 110.633 -178.342 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.552 HG22 ' C ' ' P' ' 40' ' ' VAL . 3.5 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.069 -0.967 . . . . 0.0 111.648 -178.747 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.462 0.169 0 CA-C-O 120.951 0.405 . . . . 0.0 109.943 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.695 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 18.0 m170 -120.63 110.83 16.89 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.834 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.612 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 0.2 OUTLIER -160.69 166.99 27.86 Favored 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.17 177.771 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.501 ' OE1' HG12 ' N' ' 36' ' ' VAL . 15.6 pt20 -89.94 151.6 21.63 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.733 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 16' ' ' LYS . . . . . 0.462 ' H ' ' HB3' ' O' ' 15' ' ' GLN . 86.7 tttt -149.79 119.26 6.91 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.47 0.653 . . . . 0.0 110.727 177.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.711 HD11 HG11 ' N' ' 36' ' ' VAL . 3.5 mp -138.99 132.37 30.12 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.218 178.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.02 120.98 65.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.515 ' CD1' ' CE1' ' Q' ' 19' ' ' PHE . 13.4 m-85 -110.78 112.19 23.89 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 22.4 t80 -119.84 127.76 53.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -175.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.81 127.25 48.84 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.221 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.571 ' CG ' ' H ' ' P' ' 23' ' ' ASP . 19.1 tt0 -72.07 177.06 4.6 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 115.75 1.759 . . . . 0.0 115.75 -173.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.571 ' H ' ' CG ' ' P' ' 22' ' ' GLU . 55.3 t0 -45.31 47.42 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 112.349 -2.205 . . . . 0.0 116.731 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.751 HG12 ' H ' ' P' ' 25' ' ' GLY . 49.0 t -60.88 -179.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 117.903 -1.519 . . . . 0.0 107.317 177.385 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.751 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -102.08 34.97 5.27 Favored Glycine 0 N--CA 1.469 0.898 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 0.8 OUTLIER 74.53 120.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 -177.535 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.998 HD22 ' N ' ' P' ' 30' ' ' ALA . 0.1 OUTLIER -82.79 172.7 12.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 122.125 0.964 . . . . 0.0 113.312 -177.155 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.414 ' H ' ' HB2' ' O' ' 27' ' ' ASN . 87.6 tttt -49.2 -36.25 19.32 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.462 -1.699 . . . . 0.0 111.572 177.389 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.42 78.01 0.07 OUTLIER Glycine 0 CA--C 1.541 1.688 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.336 -174.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 30' ' ' ALA . . . . . 0.998 ' N ' HD22 ' P' ' 27' ' ' ASN . . . -79.85 139.32 37.21 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 121.752 0.787 . . . . 0.0 111.132 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.671 HG21 HG13 ' J' ' 39' ' ' VAL . 9.5 tt -149.98 141.83 17.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 -176.179 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.503 HG12 HD12 ' O' ' 32' ' ' ILE . 75.3 mt -105.72 109.55 28.24 Favored 'Isoleucine or valine' 0 C--N 1.349 0.55 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.655 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.2 99.58 1.71 Allowed Glycine 0 C--O 1.24 0.492 0 N-CA-C 105.39 -3.084 . . . . 0.0 105.39 176.176 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.531 HD23 HG22 ' P' ' 36' ' ' VAL . 5.4 tp -128.41 134.77 48.86 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 -175.274 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 35' ' ' MET . . . . . 0.487 ' SD ' ' O ' ' Q' ' 35' ' ' MET . 60.0 tpp -112.69 110.98 21.45 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.006 -1.452 . . . . 0.0 107.62 176.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.9 ' O ' HG13 ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -105.09 111.79 36.01 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.228 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.341 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' P' P ' 37' ' ' GLY . . . . . 0.433 ' O ' ' NE2' ' R' ' 15' ' ' GLN . . . -63.75 131.99 40.53 Favored Glycine 0 N--CA 1.465 0.588 0 CA-C-N 115.868 -0.606 . . . . 0.0 113.204 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.584 ' O ' HG22 ' Q' ' 39' ' ' VAL . . . -77.92 64.15 3.41 Favored Glycine 0 CA--C 1.541 1.669 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.42 154.28 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 123.44 0.696 . . . . 0.0 110.266 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.552 ' C ' HG22 ' O' ' 40' ' ' VAL . 1.4 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.419 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -82.02 137.29 35.12 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.814 0.34 . . . . 0.0 110.753 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -74.03 150.1 40.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.664 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.531 ' O ' ' CD2' ' Q' ' 14' ' ' HIS . 27.0 m -128.69 -175.84 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.107 0.479 . . . . 0.0 111.04 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.695 ' CD2' ' H ' ' P' ' 13' ' ' HIS . 2.9 m170 -67.44 105.31 1.77 Allowed 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -176.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.554 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 4.7 m-70 -114.53 160.91 18.7 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 175.683 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.454 ' HB3' ' H ' ' R' ' 16' ' ' LYS . 15.5 tt0 -89.99 157.32 17.88 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.251 178.536 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -142.19 94.8 2.7 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.606 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -127.76 115.5 18.77 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.923 177.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 t -112.54 110.63 32.91 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.672 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.641 ' CD1' HD13 ' O' ' 32' ' ' ILE . 57.7 m-85 -107.92 102.1 11.32 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 178.057 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 33.5 t80 -111.25 124.19 51.72 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.345 -0.243 . . . . 0.0 110.345 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.8 128.57 24.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.203 0.525 . . . . 0.0 111.779 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -86.92 104.14 15.97 Favored 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD2' ' R' ' 23' ' ' ASP . 39.5 p-10 -135.05 52.27 2.05 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.562 -1.199 . . . . 0.0 111.517 -175.765 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 86.8 t -73.75 142.57 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.537 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -177.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.88 37.69 3.59 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 106.846 -2.502 . . . . 0.0 106.846 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 11.2 t -70.4 103.65 2.49 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.644 -0.778 . . . . 0.0 111.281 -178.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -117.97 -151.93 0.49 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.905 -178.625 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -39.8 -42.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.391 -1.277 . . . . 0.0 113.468 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.9 61.74 0.7 Allowed Glycine 0 CA--C 1.545 1.942 0 N-CA-C 115.793 1.077 . . . . 0.0 115.793 -174.161 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . 0.468 ' HB3' ' HB2' ' R' ' 30' ' ' ALA . . . -141.24 107.85 5.34 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' P' ' 31' ' ' ILE . 87.3 mt -132.97 133.45 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.72 123.03 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 177.422 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.85 119.86 3.29 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 46.3 mt -120.56 119.86 34.15 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 120.692 0.282 . . . . 0.0 110.273 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.487 ' O ' ' SD ' ' P' ' 35' ' ' MET . 94.0 mmm -116.52 123.71 48.09 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.9 HG13 ' O ' ' P' ' 36' ' ' VAL . 6.5 t -140.04 163.8 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.18 93.38 0.1 Allowed Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 119.513 -1.327 . . . . 0.0 111.382 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.23 -81.98 0.11 Allowed Glycine 0 CA--C 1.533 1.182 0 C-N-CA 119.709 -1.234 . . . . 0.0 113.41 176.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.584 HG22 ' O ' ' P' ' 38' ' ' GLY . 10.6 m -147.0 162.09 8.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 120.858 0.361 . . . . 0.0 110.425 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.984 -1.007 . . . . 0.0 110.481 -179.855 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -108.5 134.71 50.9 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.765 0.316 . . . . 0.0 110.328 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 57.2 mp0 -77.04 135.7 38.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.554 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 40.7 t -139.0 163.31 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.133 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.551 ' N ' HG12 ' R' ' 12' ' ' VAL . 0.1 OUTLIER -89.04 119.6 29.7 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.553 178.343 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -149.51 171.15 17.07 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.797 0.332 . . . . 0.0 111.675 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.433 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 32.8 mt-30 -83.64 154.65 23.6 Favored 'General case' 0 N--CA 1.456 -0.139 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.454 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 70.4 tttt -159.75 104.6 1.57 Allowed 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.637 0.732 . . . . 0.0 109.573 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.415 HD11 HG11 ' P' ' 36' ' ' VAL . 2.7 mp -126.14 119.71 28.24 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.325 178.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 26.7 t -101.72 107.9 22.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.405 ' CD1' HD13 ' P' ' 32' ' ' ILE . 74.5 m-85 -103.04 99.51 9.4 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 178.083 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -118.48 119.58 34.98 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-O 121.731 0.777 . . . . 0.0 111.457 -177.873 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.426 ' HB1' ' OD2' ' Q' ' 23' ' ' ASP . . . -124.99 134.11 52.73 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' R' ' 23' ' ' ASP . 83.0 mt-10 -68.72 103.96 1.88 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.226 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' R' ' 22' ' ' GLU . 5.3 p30 140.46 48.44 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 O-C-N 125.107 1.504 . . . . 0.0 108.519 -178.454 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 36.0 m -72.32 161.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.341 0.591 . . . . 0.0 111.579 -177.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.7 -29.79 8.3 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.219 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.42 ' O ' ' OG ' ' R' ' 26' ' ' SER . 6.3 p 61.68 109.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.638 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.732 ' O ' ' N ' ' R' ' 29' ' ' GLY . 66.0 t30 -129.72 -179.93 5.47 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.313 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 28' ' ' LYS . . . . . 0.505 ' H ' ' CG ' ' R' ' 27' ' ' ASN . 98.9 mttt -29.6 47.81 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 126.325 1.85 . . . . 0.0 115.927 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.732 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -170.05 -59.03 0.04 OUTLIER Glycine 0 CA--C 1.539 1.554 0 C-N-CA 120.045 -1.074 . . . . 0.0 113.686 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 30' ' ' ALA . . . . . 0.468 ' HB2' ' HB3' ' Q' ' 30' ' ' ALA . . . -81.0 153.98 27.16 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 117.644 0.722 . . . . 0.0 112.132 -177.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 97.9 mt -121.93 132.37 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.31 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -123.69 128.41 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.313 -0.403 . . . . 0.0 109.929 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.51 120.29 3.65 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 35.9 mt -110.15 115.3 29.49 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.3 tpp -128.26 122.9 32.8 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.564 HG12 ' N ' ' R' ' 37' ' ' GLY . 21.8 t -136.35 171.55 16.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.564 ' N ' HG12 ' R' ' 36' ' ' VAL . . . -167.93 94.4 0.11 Allowed Glycine 0 C--N 1.309 -0.931 0 C-N-CA 119.598 -1.287 . . . . 0.0 111.439 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.0 -81.44 0.14 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 177.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 19.0 m -154.96 151.16 11.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.29 179.812 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.232 0.159 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.2 t -121.79 128.87 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.095 0.474 . . . . 0.0 110.421 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -119.55 163.59 17.09 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.485 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.497 ' CD2' ' H ' ' A' ' 14' ' ' HIS . 3.0 m-70 -83.51 164.71 19.67 Favored 'General case' 0 C--N 1.332 -0.157 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.231 -179.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -130.56 152.51 49.86 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.319 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -94.37 116.6 29.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.451 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 30.3 tp -122.28 115.68 22.77 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.195 0.521 . . . . 0.0 110.017 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . 0.621 HG22 HG22 ' B' ' 18' ' ' VAL . 79.1 t -128.48 132.03 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.529 -178.526 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -136.62 139.15 41.88 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.986 0.422 . . . . 0.0 110.305 178.057 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -139.19 132.83 30.52 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.23 119.18 24.68 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.862 0.839 . . . . 0.0 111.141 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -152.12 142.63 22.66 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.89 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 53.3 t0 . . . . . 0 CA--C 1.534 0.362 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 177.624 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 10.5 m120 . . . . . 0 N--CA 1.454 -0.27 0 CA-C-O 120.667 0.27 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -62.74 -38.94 92.49 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.835 1.302 . . . . 0.0 107.579 174.272 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.442 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 81.91 -69.48 3.3 Favored Glycine 0 CA--C 1.533 1.174 0 CA-C-N 112.021 -2.354 . . . . 0.0 111.641 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.442 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . 179.73 61.27 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 118.64 1.22 . . . . 0.0 112.764 175.388 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.615 ' CD1' HG12 ' M' ' 39' ' ' VAL . 83.7 mt -131.99 102.05 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.558 0 CA-C-N 119.904 1.229 . . . . 0.0 108.257 179.039 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 80.8 mt -108.32 113.69 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.749 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.74 94.61 0.55 Allowed Glycine 0 N--CA 1.463 0.439 0 N-CA-C 104.748 -3.341 . . . . 0.0 104.748 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.569 ' O ' HD23 ' B' ' 34' ' ' LEU . 87.5 mt -143.22 157.75 44.22 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 122.788 1.28 . . . . 0.0 114.055 -175.199 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 4.7 mtp -115.99 106.07 13.37 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 112.435 -2.166 . . . . 0.0 107.154 177.357 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 1.02 HG11 HD11 ' C' ' 17' ' ' LEU . 43.6 t -124.25 112.03 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.31 -131.89 8.57 Favored Glycine 0 C--N 1.322 -0.246 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.83 -62.69 0.4 Allowed Glycine 0 CA--C 1.534 1.259 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.267 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.879 HG12 HD12 ' G' ' 31' ' ' ILE . 26.9 m -108.34 162.78 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.189 0.495 . . . . 0.0 110.261 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 44.6 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.829 -1.081 . . . . 0.0 110.699 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -105.52 130.95 53.48 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 110.403 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -106.89 116.35 31.78 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.999 0.428 . . . . 0.0 110.729 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.31 128.95 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.373 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.614 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 1.3 t-80 -127.78 106.97 9.49 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.964 0.411 . . . . 0.0 110.468 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.588 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 4.3 t60 -152.82 168.68 24.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.99 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.588 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 12.4 tt0 -155.96 141.42 17.7 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt -85.65 123.71 31.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.944 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.538 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.7 tt -126.01 115.85 20.53 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.006 0.431 . . . . 0.0 110.221 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 18' ' ' VAL . 2.6 m -123.98 131.84 72.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.382 179.297 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.437 ' CE2' ' HB2' ' B' ' 21' ' ' ALA . 71.9 t80 -125.76 122.32 35.91 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.251 -178.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -115.71 123.68 48.94 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' ALA . . . . . 0.437 ' HB2' ' CE2' ' B' ' 19' ' ' PHE . . . -142.95 143.33 31.93 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 114.185 1.179 . . . . 0.0 114.185 -178.671 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.9 mt-10 -91.46 154.75 18.93 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.549 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' B' ' 22' ' ' GLU . 70.0 m-20 -139.18 46.5 1.93 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.555 1.317 . . . . 0.0 114.555 -176.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.708 HG12 ' N ' ' B' ' 25' ' ' GLY . 60.7 t -111.72 177.03 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 C-N-CA 118.562 -1.255 . . . . 0.0 108.291 177.615 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.708 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 62.39 28.35 70.91 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.291 -0.727 . . . . 0.0 111.531 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 24.5 p -170.55 -131.55 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.674 0 CA-C-N 118.558 1.179 . . . . 0.0 113.596 -176.823 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.529 ' N ' ' OG ' ' B' ' 26' ' ' SER . 16.2 m120 -30.79 173.01 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 112.803 -1.999 . . . . 0.0 115.449 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.412 ' H ' ' H ' ' B' ' 29' ' ' GLY . 53.0 mtmt -161.28 -21.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.451 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' B' ' 28' ' ' LYS . . . -78.8 110.73 3.1 Favored Glycine 0 CA--C 1.532 1.123 0 CA-C-N 113.85 -1.523 . . . . 0.0 109.722 177.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -129.86 110.25 11.56 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 123.025 1.393 . . . . 0.0 112.814 -176.21 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.552 HD11 HG23 ' N' ' 39' ' ' VAL . 71.9 mt -142.73 139.85 28.09 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-N 113.824 -1.535 . . . . 0.0 112.134 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.789 HG22 HD11 ' C' ' 34' ' ' LEU . 27.0 mt -106.9 114.34 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 107.157 -1.424 . . . . 0.0 107.157 174.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.08 106.32 1.42 Allowed Glycine 0 N--CA 1.461 0.312 0 N-CA-C 106.677 -2.569 . . . . 0.0 106.677 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.569 HD23 ' O ' ' A' ' 34' ' ' LEU . 0.4 OUTLIER -143.18 141.81 31.26 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.376 -1.33 . . . . 0.0 113.064 -175.833 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -108.88 109.31 20.38 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 112.455 -2.157 . . . . 0.0 106.637 177.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.501 ' CG1' HD22 ' B' ' 34' ' ' LEU . 32.8 m -133.7 151.69 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.073 0.463 . . . . 0.0 110.091 -177.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.81 -101.85 2.67 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -178.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.08 -80.74 0.58 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.187 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.6 HG21 HD11 ' G' ' 31' ' ' ILE . 38.6 t -111.47 135.15 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.629 ' H ' ' CG2' ' C' ' 39' ' ' VAL . 64.1 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.131 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 10' ' ' TYR . . . . . 0.42 ' CE2' ' O ' ' C' ' 11' ' ' GLU . 90.1 t80 -73.55 132.52 42.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.986 0.422 . . . . 0.0 110.691 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 11' ' ' GLU . . . . . 0.42 ' O ' ' CE2' ' C' ' 10' ' ' TYR . 96.3 mt-10 -75.54 136.85 40.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.24 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.693 HG23 ' O ' ' C' ' 12' ' ' VAL . 16.7 m -129.45 108.16 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.828 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' B' ' 13' ' ' HIS . 15.4 m-70 -142.64 135.6 28.28 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -178.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.575 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.6 p-80 -153.6 156.19 37.5 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.24 176.335 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.5 tp60 -99.44 154.2 18.41 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 174.812 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -121.58 109.68 15.09 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 173.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 1.02 HD11 HG11 ' A' ' 36' ' ' VAL . 34.5 mt -118.45 112.99 20.66 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.112 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 18' ' ' VAL . . . . . 0.45 ' CG1' HG12 ' B' ' 18' ' ' VAL . 3.0 p -116.64 111.39 35.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 106.862 -1.532 . . . . 0.0 106.862 175.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' C' ' 17' ' ' LEU . 71.8 m-85 -102.79 108.84 20.22 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' C' ' 20' ' ' PHE . 26.0 t80 -110.7 123.94 50.98 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.565 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.22 138.99 35.52 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -90.79 108.31 19.75 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 176.527 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -100.28 46.7 0.95 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -176.061 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.566 ' O ' HG22 ' B' ' 24' ' ' VAL . 54.3 t -101.12 162.23 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 176.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.54 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 69.98 30.64 69.92 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 176.629 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.77 ' O ' ' O ' ' C' ' 27' ' ' ASN . 20.6 p -173.06 -118.73 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.406 1.103 . . . . 0.0 113.307 -177.156 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.77 ' O ' ' O ' ' C' ' 26' ' ' SER . 61.4 t30 21.35 172.91 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 126.0 1.72 . . . . 0.0 114.446 -176.589 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -159.97 -29.54 0.06 Allowed 'General case' 0 N--CA 1.466 0.372 0 O-C-N 121.334 -0.853 . . . . 0.0 112.648 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.69 81.59 0.09 OUTLIER Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.294 -173.72 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -78.42 130.7 36.4 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 122.798 1.285 . . . . 0.0 113.057 -175.07 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.839 HD11 HG12 ' O' ' 39' ' ' VAL . 76.6 mt -130.31 134.18 62.86 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 113.022 -1.899 . . . . 0.0 111.581 -178.343 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.648 HD13 ' CD1' ' E' ' 19' ' ' PHE . 87.7 mt -107.91 121.99 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.71 ' O ' HD12 ' C' ' 34' ' ' LEU . . . -126.3 102.24 0.63 Allowed Glycine 0 N--CA 1.469 0.848 0 N-CA-C 107.845 -2.102 . . . . 0.0 107.845 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.789 HD11 HG22 ' B' ' 32' ' ' ILE . 5.9 mp -139.13 146.65 40.91 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 123.219 1.485 . . . . 0.0 113.538 -176.707 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -106.69 109.64 21.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 112.19 -2.277 . . . . 0.0 106.798 177.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.474 HG21 HD11 ' D' ' 34' ' ' LEU . 18.5 t -121.33 131.06 73.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 120.957 0.408 . . . . 0.0 111.695 -176.049 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.03 -110.85 3.1 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.575 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.32 -73.12 0.68 Allowed Glycine 0 CA--C 1.544 1.849 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -177.515 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.629 ' CG2' ' H ' ' B' ' 40' ' ' VAL . 1.3 m -132.32 179.77 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 176.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.475 ' N ' HG12 ' D' ' 39' ' ' VAL . 46.8 t . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.696 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.472 0.632 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.54 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 22.4 t-80 -61.9 121.22 12.39 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.595 -177.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.798 ' CD2' ' H ' ' E' ' 14' ' ' HIS . 35.3 m170 -150.45 162.55 40.37 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.408 ' HB2' HE22 ' E' ' 15' ' ' GLN . 10.3 tp-100 -85.99 156.85 20.28 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 175.338 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -159.78 102.21 1.49 Allowed 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.29 -0.964 . . . . 0.0 109.914 177.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.456 HD22 HD12 ' C' ' 17' ' ' LEU . 16.2 mt -132.16 122.35 25.17 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.361 0.601 . . . . 0.0 111.478 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 91.2 t -113.36 107.56 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.907 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.449 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 80.8 m-85 -104.22 106.87 17.53 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -126.69 128.59 46.94 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -176.059 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.82 124.03 41.22 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.345 177.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -89.27 153.35 20.97 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 122.059 0.933 . . . . 0.0 113.262 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.451 ' O ' HG22 ' C' ' 24' ' ' VAL . 98.2 m-20 40.59 55.25 2.95 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 113.631 -1.622 . . . . 0.0 113.257 177.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.651 HG21 ' HB1' ' E' ' 21' ' ' ALA . 98.4 t -66.06 135.12 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 177.513 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.32 -32.54 1.79 Allowed Glycine 0 N--CA 1.468 0.798 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.414 ' OG ' ' O ' ' C' ' 27' ' ' ASN . 26.8 m -71.25 120.34 16.69 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.147 0.499 . . . . 0.0 110.231 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 14.4 m-20 -103.41 -151.82 0.44 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.184 -178.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.466 ' H ' ' HA ' ' E' ' 27' ' ' ASN . 26.2 pttm 31.72 41.84 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.432 -1.258 . . . . 0.0 114.074 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.41 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -173.36 60.89 0.14 Allowed Glycine 0 CA--C 1.54 1.594 0 C-N-CA 119.672 -1.252 . . . . 0.0 113.63 174.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.661 ' N ' ' ND2' ' E' ' 27' ' ' ASN . . . -107.95 109.88 21.48 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 117.717 0.759 . . . . 0.0 109.508 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.514 HD11 HG23 ' P' ' 39' ' ' VAL . 69.3 mt -134.09 128.59 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 118.952 -1.099 . . . . 0.0 112.186 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.613 HD13 ' CD1' ' F' ' 19' ' ' PHE . 95.7 mt -112.55 119.29 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 177.382 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.43 98.88 0.8 Allowed Glycine 0 C--O 1.239 0.453 0 N-CA-C 105.895 -2.882 . . . . 0.0 105.895 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.474 HD11 HG21 ' C' ' 36' ' ' VAL . 11.3 tp -131.47 136.45 47.94 Favored 'General case' 0 C--O 1.244 0.81 0 CA-C-O 122.658 1.218 . . . . 0.0 113.795 -175.779 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -109.54 110.0 20.96 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 113.064 -1.88 . . . . 0.0 108.217 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.5 122.87 67.25 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.5 -113.58 0.71 Allowed Glycine 0 C--N 1.307 -1.031 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 96.11 -71.98 0.86 Allowed Glycine 0 CA--C 1.53 1.022 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.554 ' CG2' ' O ' ' J' ' 29' ' ' GLY . 0.3 OUTLIER -141.4 163.06 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 178.005 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' D' ' 39' ' ' VAL . 21.2 t . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 118.215 -0.897 . . . . 0.0 111.746 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.75 136.07 46.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.953 0.406 . . . . 0.0 110.686 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -113.72 119.75 38.47 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.301 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.549 ' O ' ' NE2' ' D' ' 14' ' ' HIS . 50.9 t -127.17 134.21 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 121.395 0.617 . . . . 0.0 110.025 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -129.23 106.4 8.8 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.934 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.798 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 3.3 p80 -151.87 161.35 42.79 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 177.427 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.411 ' OE1' ' CG1' ' C' ' 36' ' ' VAL . 79.1 mm-40 -90.01 158.12 17.5 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -141.1 100.03 3.72 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.405 ' N ' HD12 ' E' ' 17' ' ' LEU . 5.2 mp -133.38 126.1 30.56 Favored 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.643 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -113.62 106.66 21.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.505 178.22 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.648 ' CD1' HD13 ' C' ' 32' ' ' ILE . 89.8 m-85 -105.79 106.05 16.38 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.303 -1.739 . . . . 0.0 106.303 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -133.53 135.13 44.18 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.091 1.145 . . . . 0.0 114.091 -176.235 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.651 ' HB1' HG21 ' D' ' 24' ' ' VAL . . . -128.32 129.91 46.99 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.988 177.505 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.418 ' HB2' ' H ' ' D' ' 23' ' ' ASP . 97.8 mt-10 -91.25 166.26 13.03 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.115 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 25.99 47.27 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 112.293 -2.23 . . . . 0.0 115.835 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.6 HG12 ' N ' ' E' ' 25' ' ' GLY . 53.4 t -67.43 171.43 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 174.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.6 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -117.75 37.41 3.3 Favored Glycine 0 N--CA 1.48 1.581 0 C-N-CA 119.433 -1.365 . . . . 0.0 111.264 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 72.52 119.99 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.499 . . . . 0.0 110.236 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.661 ' ND2' ' N ' ' D' ' 30' ' ' ALA . 81.4 m-20 -83.19 163.62 20.68 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.952 176.588 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -46.93 -36.93 8.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 122.022 0.915 . . . . 0.0 108.946 175.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 77.42 0.06 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 113.694 -1.594 . . . . 0.0 110.558 -177.593 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.73 149.26 4.8 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.775 0.787 . . . . 0.0 110.648 -178.32 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.44 137.14 56.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.176 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.67 122.11 68.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 114.491 -1.231 . . . . 0.0 109.784 178.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.37 106.76 1.36 Allowed Glycine 0 N--CA 1.465 0.607 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 27.0 tp -126.16 125.52 42.61 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.872 0.367 . . . . 0.0 111.313 -177.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.445 ' CG ' ' N ' ' E' ' 36' ' ' VAL . 27.3 ttp -146.29 158.85 43.92 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.614 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.581 HG22 ' HA ' ' F' ' 36' ' ' VAL . 1.3 m -115.02 162.93 12.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.1 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.77 -102.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.371 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -78.47 1.05 Allowed Glycine 0 CA--C 1.534 1.243 0 C-N-CA 121.659 -0.305 . . . . 0.0 112.781 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.446 HG13 ' O ' ' E' ' 39' ' ' VAL . 9.3 p . . . . . 0 N--CA 1.469 0.508 0 CA-C-N 116.952 0.376 . . . . 0.0 111.107 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 pt-20 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 120.74 0.305 . . . . 0.0 110.813 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -124.32 132.83 70.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.018 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.482 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 8.5 p80 -144.74 114.69 7.37 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 121.206 0.526 . . . . 0.0 112.337 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.437 ' ND1' ' O ' ' F' ' 15' ' ' GLN . 54.8 t-80 -151.35 164.35 36.87 Favored 'General case' 0 C--O 1.217 -0.609 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.437 ' O ' ' ND1' ' F' ' 14' ' ' HIS . 88.7 mt-30 -89.91 158.33 17.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 119.113 0.87 . . . . 0.0 111.383 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.53 95.78 2.92 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -130.4 119.31 22.52 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -107.32 105.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.32 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.613 ' CD1' HD13 ' D' ' 32' ' ' ILE . 78.9 m-85 -107.59 109.0 20.53 Favored 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 20.3 t80 -147.21 137.62 23.42 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 118.618 -1.233 . . . . 0.0 113.826 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.33 130.48 49.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.08 -1.418 . . . . 0.0 107.468 177.217 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' E' ' 24' ' ' VAL . 96.9 mt-10 -82.29 115.79 21.52 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.043 -0.663 . . . . 0.0 111.653 -178.223 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 9.6 p-10 . . . . . 0 CA--C 1.529 0.155 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.7 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.3 mt -121.2 127.24 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 118.486 0.585 . . . . 0.0 109.79 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 95.1 mt -128.2 131.7 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-O 120.865 0.364 . . . . 0.0 111.45 -178.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.3 116.86 2.67 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.1 tp -122.75 126.13 46.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 5.0 ttp -140.19 139.81 35.75 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 122.365 1.079 . . . . 0.0 113.845 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.581 ' HA ' HG22 ' E' ' 36' ' ' VAL . 43.8 t -117.31 131.95 68.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 CA-C-N 113.758 -1.565 . . . . 0.0 109.523 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -41.25 -111.62 0.0 OUTLIER Glycine 0 CA--C 1.531 1.046 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.907 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -71.7 0.6 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 111.767 -0.533 . . . . 0.0 111.767 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 94.6 t -76.99 131.53 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 117.3 0.55 . . . . 0.0 110.325 179.117 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.421 HG22 ' O ' ' F' ' 40' ' ' VAL . 14.9 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.148 -0.929 . . . . 0.0 110.608 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.466 0.326 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -138.2 117.34 12.61 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 121.006 0.432 . . . . 0.0 111.546 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.474 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 49.1 p-80 -151.74 168.05 26.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.099 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 29.2 mm100 -156.98 143.23 18.07 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.046 0.45 . . . . 0.0 110.07 179.249 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -81.27 118.23 22.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 178.535 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.0 tp -136.76 118.92 15.48 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.313 0.577 . . . . 0.0 111.349 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 m -137.0 153.44 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.965 178.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -146.51 130.74 17.48 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-O 120.964 0.411 . . . . 0.0 111.195 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -123.04 132.2 54.02 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 126.94 35.6 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.467 0.651 . . . . 0.0 112.685 -178.319 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -96.36 145.31 25.73 Favored 'General case' 0 C--N 1.34 0.159 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 10.2 t70 . . . . . 0 C--N 1.322 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.717 -176.896 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.594 ' OD1' ' N ' ' G' ' 28' ' ' LYS . 31.7 t-20 . . . . . 0 N--CA 1.47 0.535 0 CA-C-O 120.677 0.275 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.617 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 88.5 tttt -69.43 -48.36 61.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.28 0.562 . . . . 0.0 110.411 178.073 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.521 ' N ' ' OD1' ' G' ' 27' ' ' ASN . . . 129.81 59.92 0.1 Allowed Glycine 0 CA--C 1.54 1.633 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 -176.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.09 89.28 0.82 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.879 HD12 HG12 ' A' ' 39' ' ' VAL . 87.3 mt -137.27 117.84 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-N 113.315 -1.766 . . . . 0.0 106.857 177.035 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.484 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.4 mt -106.17 110.64 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 94.86 0.67 Allowed Glycine 0 CA--C 1.508 -0.399 0 N-CA-C 105.097 -3.201 . . . . 0.0 105.097 177.021 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.705 ' O ' HD12 ' H' ' 34' ' ' LEU . 79.7 mt -147.49 168.44 21.91 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-O 123.254 1.502 . . . . 0.0 113.766 -175.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 94.5 mmm -120.96 114.39 21.46 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 112.064 -2.335 . . . . 0.0 107.16 178.464 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.495 HG21 HD22 ' I' ' 17' ' ' LEU . 41.4 t -124.6 131.53 72.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.54 -111.31 3.3 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.719 -0.953 . . . . 0.0 110.719 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.4 -73.79 1.33 Allowed Glycine 0 CA--C 1.536 1.395 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.252 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.627 HG12 HD12 ' M' ' 31' ' ' ILE . 22.3 m -87.02 171.55 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 117.401 0.6 . . . . 0.0 110.381 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.243 179.273 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -107.62 129.71 54.97 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.711 0.291 . . . . 0.0 110.346 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -154.85 148.76 25.66 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-O 121.166 0.508 . . . . 0.0 111.552 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.514 HG13 ' CG2' ' I' ' 12' ' ' VAL . 55.7 t -124.5 130.03 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.459 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 26.2 p80 -147.46 142.81 27.37 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 119.48 -0.888 . . . . 0.0 113.131 -179.245 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.474 ' O ' ' CB ' ' G' ' 14' ' ' HIS . 1.5 m-70 -146.23 170.36 16.91 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 114.512 -1.222 . . . . 0.0 108.217 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -155.83 141.28 17.72 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.366 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -87.94 108.67 19.3 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.973 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -121.13 110.71 16.54 Favored 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.361 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.416 HG22 ' CG2' ' I' ' 18' ' ' VAL . 72.0 t -122.13 130.62 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.192 -178.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -126.52 118.98 26.0 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -122.35 125.93 46.98 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.61 131.26 39.42 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.457 0.646 . . . . 0.0 112.677 -179.073 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -97.68 127.1 43.38 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.541 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.617 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 97.1 m-20 -139.25 46.55 1.92 Allowed 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.598 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.694 HG12 ' N ' ' H' ' 25' ' ' GLY . 21.5 t -82.8 173.34 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-O 122.697 1.237 . . . . 0.0 113.06 -176.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.694 ' N ' HG12 ' H' ' 24' ' ' VAL . . . 92.74 -35.16 4.17 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 112.596 -2.093 . . . . 0.0 114.26 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' H' ' 27' ' ' ASN . 32.2 t -162.55 117.38 1.82 Allowed 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 120.691 2.246 . . . . 0.0 114.192 175.341 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' H' ' 26' ' ' SER . 45.0 p-10 -22.55 153.13 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.116 0.566 . . . . 0.0 112.297 173.584 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 7.7 tttm -165.95 26.38 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 117.948 -1.501 . . . . 0.0 114.887 173.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 107.77 0.38 Allowed Glycine 0 CA--C 1.532 1.11 0 C-N-CA 119.004 -1.57 . . . . 0.0 113.944 177.21 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.7 111.47 17.65 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.466 HD11 HG13 ' C' ' 39' ' ' VAL . 87.4 mt -130.22 133.61 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.775 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.533 HD13 ' CD2' ' J' ' 19' ' ' PHE . 93.6 mt -105.71 108.46 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.306 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -109.44 101.92 1.54 Allowed Glycine 0 N--CA 1.465 0.623 0 N-CA-C 105.897 -2.881 . . . . 0.0 105.897 177.05 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.705 HD12 ' O ' ' G' ' 34' ' ' LEU . 47.2 tp -152.53 145.62 24.59 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 117.306 -1.758 . . . . 0.0 114.612 -173.726 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.583 ' H ' HD12 ' H' ' 34' ' ' LEU . 3.8 ttm -106.9 117.02 32.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.71 177.457 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.473 ' CG2' HG12 ' I' ' 36' ' ' VAL . 2.9 t -118.19 102.49 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.801 -178.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.27 -163.93 26.78 Favored Glycine 0 CA--C 1.524 0.617 0 C-N-CA 120.354 -0.926 . . . . 0.0 112.655 177.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.52 ' HA2' ' H ' ' I' ' 38' ' ' GLY . . . 156.2 -54.55 0.41 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.721 HG13 HD13 ' N' ' 31' ' ' ILE . 3.7 m -141.31 164.21 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 176.072 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.538 ' OXT' ' NZ ' ' N' ' 28' ' ' LYS . 1.3 p . . . . . 0 N--CA 1.467 0.377 0 CA-C-O 117.802 -1.094 . . . . 0.0 111.353 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.25 135.41 46.67 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.691 0.281 . . . . 0.0 110.387 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' NE2' ' I' ' 13' ' ' HIS . 45.7 tp10 -147.11 100.9 3.35 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.908 0.385 . . . . 0.0 110.256 179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.514 ' CG2' HG13 ' H' ' 12' ' ' VAL . 4.9 m -141.75 127.41 18.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.986 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.409 ' NE2' ' OE2' ' I' ' 11' ' ' GLU . 49.5 m170 -113.59 136.24 53.03 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.829 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.527 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 70.7 m80 -156.64 176.04 13.26 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.29 0.567 . . . . 0.0 110.515 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.411 ' CG ' HD11 ' I' ' 17' ' ' LEU . 40.8 tp60 -159.33 139.09 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -105.39 113.61 27.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 118.999 -0.524 . . . . 0.0 111.5 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.495 HD22 HG21 ' G' ' 36' ' ' VAL . 0.7 OUTLIER -129.5 112.48 13.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.557 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.416 ' CG2' HG22 ' H' ' 18' ' ' VAL . 15.1 m -119.43 124.87 73.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -112.16 116.76 30.98 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 114.752 -1.113 . . . . 0.0 108.673 -178.419 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -119.08 129.14 54.92 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.767 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.87 138.19 30.08 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.436 -0.506 . . . . 0.0 112.165 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -131.91 130.95 42.23 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 120.458 -0.497 . . . . 0.0 112.261 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.64 ' C ' HG23 ' I' ' 24' ' ' VAL . 0.3 OUTLIER -130.98 -49.94 1.03 Allowed 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.188 0.518 . . . . 0.0 110.477 178.644 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.699 HG22 ' CD ' ' J' ' 22' ' ' GLU . 2.0 t 77.7 143.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.939 176.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.531 ' H ' ' CG2' ' J' ' 24' ' ' VAL . . . 92.08 37.46 5.99 Favored Glycine 0 CA--C 1.525 0.662 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.372 174.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 3.0 p 72.69 120.15 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 117.744 0.772 . . . . 0.0 110.237 177.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.598 ' H ' ' ND2' ' J' ' 27' ' ' ASN . 13.8 p30 -83.03 161.3 21.75 Favored 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 117.598 -1.641 . . . . 0.0 109.192 177.131 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.434 ' O ' ' OXT' ' C' ' 40' ' ' VAL . 95.8 mttt -48.63 -39.54 24.49 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 176.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.45 0.04 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -175.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.61 139.15 51.32 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 119.027 1.413 . . . . 0.0 114.281 -174.476 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.589 HD12 HG12 ' C' ' 39' ' ' VAL . 61.2 mt -141.57 143.78 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 113.529 -1.669 . . . . 0.0 113.026 -178.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.435 HG23 HD12 ' I' ' 34' ' ' LEU . 9.8 mt -104.31 109.72 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 175.72 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -109.51 100.75 1.38 Allowed Glycine 0 N--CA 1.463 0.454 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.629 ' O ' HD12 ' J' ' 34' ' ' LEU . 0.2 OUTLIER -139.14 143.27 38.13 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.928 1.347 . . . . 0.0 113.681 -175.52 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.407 ' SD ' ' HB2' ' J' ' 35' ' ' MET . 87.7 mmm -117.12 108.71 16.03 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 111.939 -2.391 . . . . 0.0 104.61 175.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.703 ' CG2' HG12 ' J' ' 36' ' ' VAL . 24.4 m -126.14 130.94 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 118.695 -1.202 . . . . 0.0 112.77 -178.149 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.88 111.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 113.048 -1.887 . . . . 0.0 113.477 177.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.52 ' H ' ' HA2' ' H' ' 38' ' ' GLY . . . -80.81 -60.53 2.29 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.206 -1.157 . . . . 0.0 110.206 175.404 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.3 p -146.2 150.08 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 121.407 0.622 . . . . 0.0 110.407 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.815 HG11 ' CD2' ' K' ' 13' ' ' HIS . 21.3 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.659 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -105.31 133.5 49.98 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 11' ' ' GLU . . . . . 0.64 ' CG ' ' HE2' ' J' ' 13' ' ' HIS . 80.4 tt0 -153.34 114.81 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.005 0.431 . . . . 0.0 110.645 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.436 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -138.83 138.34 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.847 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.64 ' HE2' ' CG ' ' J' ' 11' ' ' GLU . 19.7 m-70 -139.19 147.83 42.34 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.814 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.527 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 56.9 m-70 -151.97 160.92 43.35 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.615 177.201 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 tp60 -90.46 158.35 17.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 177.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.743 ' C ' HD12 ' J' ' 17' ' ' LEU . 97.6 mttt -141.48 90.82 2.32 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.288 176.109 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.743 HD12 ' C ' ' J' ' 16' ' ' LYS . 9.2 mp -128.54 129.86 46.61 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 118.813 0.733 . . . . 0.0 110.688 177.616 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 18.4 t -125.64 116.83 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.682 179.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 12.6 m-85 -109.31 106.95 16.97 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 6.3 t80 -114.01 121.91 45.32 Favored 'General case' 0 N--CA 1.478 0.973 0 O-C-N 122.263 -0.273 . . . . 0.0 110.337 -178.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.24 138.73 37.07 Favored 'General case' 0 C--O 1.253 1.259 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.699 ' CD ' HG22 ' I' ' 24' ' ' VAL . 52.7 tt0 -66.92 149.6 50.39 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 176.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.697 ' O ' ' O ' ' J' ' 24' ' ' VAL . 65.1 t0 -168.38 64.5 0.07 Allowed 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -168.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.697 ' O ' ' O ' ' J' ' 23' ' ' ASP . 58.7 t -43.06 -104.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 CA-C-O 113.942 -2.932 . . . . 0.0 103.809 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 166.75 -48.18 0.26 Allowed Glycine 0 N--CA 1.482 1.754 2 CA-C-N 127.32 4.6 . . . . 0.0 119.696 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 41.0 t -65.8 101.0 0.6 Allowed 'General case' 0 C--N 1.322 -0.596 1 CA-C-N 125.567 4.683 . . . . 0.0 105.867 -179.531 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.598 ' ND2' ' H ' ' I' ' 27' ' ' ASN . 1.1 m-20 -129.48 160.88 31.79 Favored 'General case' 0 C--N 1.348 0.504 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.75 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.407 ' C ' ' O ' ' J' ' 27' ' ' ASN . 70.3 mmtt -29.61 -39.42 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.785 -1.098 . . . . 0.0 113.44 174.424 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.554 ' O ' ' CG2' ' D' ' 39' ' ' VAL . . . 140.93 74.87 0.04 OUTLIER Glycine 0 CA--C 1.552 2.371 0 C-N-CA 119.668 -1.253 . . . . 0.0 112.341 -175.561 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.03 155.54 40.44 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 120.631 2.215 . . . . 0.0 113.061 -174.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' D' ' 38' ' ' GLY . 57.6 mt -138.2 148.53 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 3.9 mt -109.84 110.99 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 173.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.4 103.81 1.71 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.629 HD12 ' O ' ' I' ' 34' ' ' LEU . 33.4 tp -143.44 132.58 23.08 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 115.695 1.739 . . . . 0.0 115.695 -173.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.445 ' N ' HD12 ' J' ' 34' ' ' LEU . 78.4 mmm -103.75 123.75 47.62 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 112.78 -2.009 . . . . 0.0 106.886 176.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.703 HG12 ' CG2' ' I' ' 36' ' ' VAL . 2.8 m -135.25 155.68 37.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-O 121.549 0.69 . . . . 0.0 112.441 -176.411 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 79.76 -101.42 1.92 Allowed Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.933 176.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.6 -80.31 1.61 Allowed Glycine 0 CA--C 1.537 1.451 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -176.291 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.468 HG23 HD12 ' P' ' 31' ' ' ILE . 59.2 t -124.06 131.57 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-N 117.742 0.771 . . . . 0.0 109.624 177.786 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.516 ' OXT' ' CD2' ' L' ' 13' ' ' HIS . 27.6 t . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.27 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.442 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' K' K ' 10' ' ' TYR . . . . . 0.441 ' CD2' ' O ' ' K' ' 11' ' ' GLU . 52.6 t80 -70.69 134.95 47.96 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.883 0.373 . . . . 0.0 110.523 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.441 ' O ' ' CD2' ' K' ' 10' ' ' TYR . 68.8 mm-40 -75.22 154.68 37.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.746 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 27.8 m -122.91 129.59 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.363 0.602 . . . . 0.0 111.847 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.815 ' CD2' HG11 ' I' ' 40' ' ' VAL . 2.9 t60 -148.99 138.09 21.48 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.129 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.531 ' NE2' ' O ' ' L' ' 12' ' ' VAL . 15.3 m-70 -134.51 158.86 42.85 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.516 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -90.17 159.51 16.72 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 57.4 tttt -140.47 95.13 2.82 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 120.041 -0.664 . . . . 0.0 109.758 177.002 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.602 ' CD1' HG21 ' I' ' 36' ' ' VAL . 37.2 mt -118.47 111.67 18.95 Favored 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 177.798 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -108.29 107.25 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 84.7 m-85 -104.03 105.68 15.93 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.9 t80 -110.74 114.91 28.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.38 135.93 20.6 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 122.023 0.916 . . . . 0.0 111.867 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.558 ' O ' ' CB ' ' K' ' 23' ' ' ASP . 98.3 mt-10 -69.15 -174.92 0.69 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 118.145 -1.422 . . . . 0.0 107.97 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' J' ' 24' ' ' VAL . 10.5 t0 144.98 46.6 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.474 0.654 . . . . 0.0 109.927 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.687 HG12 ' N ' ' K' ' 25' ' ' GLY . 25.4 t -84.03 172.16 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.862 -178.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.687 ' N ' HG12 ' K' ' 24' ' ' VAL . . . 95.71 -29.68 9.46 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 178.363 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.485 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 92.07 114.02 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 114.446 -0.877 . . . . 0.0 109.06 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.614 ' OD1' ' HB2' ' K' ' 30' ' ' ALA . 1.4 p30 -74.3 174.48 8.76 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.361 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.28 -36.75 43.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.97 76.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.541 0 CA-C-O 119.679 -0.512 . . . . 0.0 112.67 -177.02 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.614 ' HB2' ' OD1' ' K' ' 27' ' ' ASN . . . -80.12 149.7 30.5 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 118.745 1.272 . . . . 0.0 110.527 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.532 HG23 ' HB ' ' L' ' 31' ' ' ILE . 59.1 mt -130.77 135.97 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.547 -0.752 . . . . 0.0 112.14 -177.31 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.33 119.24 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.09 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.74 109.77 1.53 Allowed Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 70.7 mt -122.78 118.38 27.86 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.248 0.547 . . . . 0.0 110.626 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 95.9 mmm -110.74 122.27 47.4 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.004 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.11 132.37 67.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.318 -179.608 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.24 112.1 3.45 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 178.625 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.533 ' H ' ' HA3' ' L' ' 37' ' ' GLY . . . -76.65 73.18 1.9 Allowed Glycine 0 CA--C 1.532 1.148 0 C-N-CA 120.243 -0.98 . . . . 0.0 113.498 -178.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.663 HG23 HD12 ' Q' ' 31' ' ' ILE . 22.1 t . . . . . 0 N--CA 1.467 0.425 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 C--O 1.232 0.147 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.832 HG22 ' H ' ' L' ' 13' ' ' HIS . 11.3 p -138.98 -179.18 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.911 0.386 . . . . 0.0 111.07 -178.181 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.832 ' H ' HG22 ' L' ' 12' ' ' VAL . 0.3 OUTLIER -122.81 108.52 13.11 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.525 -179.941 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.436 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 40.8 t-80 -150.38 165.52 32.85 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.436 HE22 ' HB ' ' J' ' 36' ' ' VAL . 8.9 tt0 -89.74 158.73 17.4 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.643 0.259 . . . . 0.0 110.788 -179.03 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -140.01 107.56 5.59 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.252 0.548 . . . . 0.0 111.256 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.412 ' HB3' ' CZ ' ' L' ' 19' ' ' PHE . 4.4 mt -115.97 109.15 17.16 Favored 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.883 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -105.09 103.55 15.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.412 ' CZ ' ' HB3' ' L' ' 17' ' ' LEU . 65.8 m-85 -100.46 100.54 11.31 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.603 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 52.2 t80 -106.41 95.95 6.11 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.84 145.07 31.46 Favored 'General case' 0 CA--C 1.495 -1.138 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.655 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' K' ' 23' ' ' ASP . 80.8 mm-40 -82.6 96.04 7.96 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.728 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 91.8 m-20 -132.56 62.63 1.64 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 112.052 -177.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.479 HG12 ' H ' ' L' ' 25' ' ' GLY . 1.5 t 60.51 -141.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.207 0.527 . . . . 0.0 110.871 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.479 ' H ' HG12 ' L' ' 24' ' ' VAL . . . 156.63 -29.53 0.55 Allowed Glycine 0 CA--C 1.519 0.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.979 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 87.8 p -63.21 -123.66 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.191 -0.505 . . . . 0.0 110.868 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.509 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 5.9 t-20 -156.97 -154.14 0.45 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.856 -178.492 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.509 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 68.6 mttm 28.32 41.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.09 -62.59 0.04 OUTLIER Glycine 0 CA--C 1.537 1.445 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.723 178.122 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.83 148.08 29.02 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.785 0.792 . . . . 0.0 110.488 178.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.532 ' HB ' HG23 ' K' ' 31' ' ' ILE . 6.7 mm -114.76 125.89 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.432 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -120.18 124.6 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.72 115.46 1.7 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.7 tp -126.2 120.73 30.81 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mtp -135.38 147.55 49.09 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -177.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 33.6 m -119.36 159.29 20.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.132 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.643 178.277 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.533 ' HA3' ' H ' ' K' ' 38' ' ' GLY . . . -61.89 -102.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.487 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.96 -75.14 0.11 Allowed Glycine 0 CA--C 1.534 1.237 0 C-N-CA 121.83 -0.224 . . . . 0.0 112.88 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' K' ' 38' ' ' GLY . 3.0 m . . . . . 0 N--CA 1.466 0.373 0 CA-C-O 121.296 0.57 . . . . 0.0 111.399 -178.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 N--CA 1.466 0.344 0 CA-C-O 121.145 0.498 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.42 130.66 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.158 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 m80 -128.65 113.18 15.07 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 17.9 p-80 -152.56 168.23 26.25 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.548 178.033 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -129.23 150.65 50.52 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.085 178.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -97.56 116.25 29.4 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.3 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -124.97 114.07 18.65 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 118.154 0.434 . . . . 0.0 110.093 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 18' ' ' VAL . . . . . 0.431 ' O ' HG23 ' M' ' 18' ' ' VAL . 19.1 m -131.67 132.52 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.641 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -135.7 133.99 38.67 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-O 121.077 0.465 . . . . 0.0 111.745 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -121.61 129.39 52.8 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 21' ' ' ALA . . . . . 0.498 ' HB1' ' CG2' ' M' ' 24' ' ' VAL . . . -130.98 131.81 44.62 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.332 0.587 . . . . 0.0 112.164 -178.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -120.23 142.27 49.18 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.557 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 37.42 54.68 1.39 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.306 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.498 ' CG2' ' HB1' ' M' ' 21' ' ' ALA . 45.6 t -67.79 135.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.439 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.76 -33.49 2.04 Favored Glycine 0 N--CA 1.47 0.901 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 62.8 p -82.31 -121.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.131 0.491 . . . . 0.0 111.206 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 27' ' ' ASN . . . . . 0.49 ' O ' HG11 ' M' ' 24' ' ' VAL . 77.7 m-20 -93.22 -160.5 0.76 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.063 -178.217 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 35.28 40.37 0.06 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.38 -64.37 1.22 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 30' ' ' ALA . . . . . 0.556 ' HB3' ' OG ' ' N' ' 26' ' ' SER . . . -157.26 49.74 0.44 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.043 0.922 . . . . 0.0 111.772 175.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.627 HD12 HG12 ' G' ' 39' ' ' VAL . 97.0 mt -138.49 106.84 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 CA-C-N 114.157 -1.383 . . . . 0.0 107.474 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.2 mt -102.7 104.43 16.53 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.335 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.09 95.71 0.75 Allowed Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 104.071 -3.612 . . . . 0.0 104.071 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 34' ' ' LEU . . . . . 0.68 ' O ' HD23 ' N' ' 34' ' ' LEU . 43.1 tp -146.07 150.4 35.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 122.843 1.306 . . . . 0.0 113.809 -173.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -110.02 106.95 16.66 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 112.65 -2.068 . . . . 0.0 106.228 177.174 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.563 HG13 ' O ' ' M' ' 36' ' ' VAL . 4.0 p -127.35 114.07 34.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.6 -124.61 1.88 Allowed Glycine 0 C--N 1.309 -0.958 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.96 -67.11 3.29 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.043 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.615 HG12 ' CD1' ' A' ' 31' ' ' ILE . 13.0 m -78.4 169.1 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-O 121.041 0.448 . . . . 0.0 110.472 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.406 HG22 ' OXT' ' M' ' 40' ' ' VAL . 3.5 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.458 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -115.44 142.01 47.29 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.87 0.367 . . . . 0.0 110.52 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 11' ' ' GLU . . . . . 0.526 ' O ' ' NE2' ' O' ' 13' ' ' HIS . 82.4 tt0 -69.18 120.64 15.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.095 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.51 120.45 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.618 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.474 ' CE1' ' OE2' ' N' ' 11' ' ' GLU . 60.4 m170 -113.68 150.71 32.85 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.901 -178.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.555 ' CE1' ' O ' ' O' ' 12' ' ' VAL . 75.2 m-70 -141.92 172.01 13.28 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 121.19 0.519 . . . . 0.0 110.403 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 68.4 tp60 -138.25 140.87 39.86 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttm -130.17 107.0 8.97 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.535 HD23 ' C ' ' N' ' 17' ' ' LEU . 5.9 tt -122.6 116.33 23.66 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 18' ' ' VAL . . . . . 0.437 HG22 ' CG1' ' O' ' 18' ' ' VAL . 80.0 t -121.01 126.22 74.95 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.333 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -127.03 122.02 33.25 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -125.32 125.21 43.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.032 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.95 131.4 53.56 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 179.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.425 ' O ' ' N ' ' N' ' 24' ' ' VAL . 95.1 mt-10 -81.05 -166.81 1.22 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.325 0.583 . . . . 0.0 112.53 -177.748 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.518 ' N ' ' OE1' ' O' ' 22' ' ' GLU . 66.2 t0 -61.97 47.51 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 114.765 -1.107 . . . . 0.0 112.394 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.855 HG12 ' H ' ' N' ' 25' ' ' GLY . 30.3 t -61.04 -179.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.019 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 0.855 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -100.96 29.31 12.77 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 121.636 -0.316 . . . . 0.0 112.718 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.556 ' OG ' ' HB3' ' M' ' 30' ' ' ALA . 10.7 t -81.05 112.86 18.82 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 72.1 m-20 -89.75 -175.06 4.52 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.538 ' NZ ' ' OXT' ' H' ' 40' ' ' VAL . 59.3 mttp 49.29 37.64 11.9 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 111.525 -2.58 . . . . 0.0 114.824 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 29' ' ' GLY . . . . . 0.61 ' O ' ' HB2' ' N' ' 30' ' ' ALA . . . 92.01 -77.98 1.28 Allowed Glycine 0 N--CA 1.469 0.851 0 N-CA-C 114.517 0.567 . . . . 0.0 114.517 172.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 30' ' ' ALA . . . . . 0.898 ' O ' ' HB1' ' O' ' 30' ' ' ALA . . . 150.87 162.64 0.0 OUTLIER 'General case' 0 C--O 1.238 0.464 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.721 HD13 HG13 ' H' ' 39' ' ' VAL . 28.8 pt -141.32 126.92 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.029 178.566 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -113.04 114.55 47.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.47 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.95 105.95 1.66 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 104.936 -3.266 . . . . 0.0 104.936 175.725 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.68 HD23 ' O ' ' M' ' 34' ' ' LEU . 0.4 OUTLIER -146.32 144.32 29.73 Favored 'General case' 0 CA--C 1.51 -0.581 0 C-N-CA 117.716 -1.594 . . . . 0.0 114.512 -174.18 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 36.3 tpp -106.97 107.77 18.95 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 174.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.429 HG13 HD22 ' N' ' 34' ' ' LEU . 0.0 OUTLIER -121.52 143.68 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 -178.216 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.26 -102.68 1.29 Allowed Glycine 0 C--N 1.316 -0.55 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.427 ' C ' HD11 ' B' ' 31' ' ' ILE . . . 85.69 -80.3 1.81 Allowed Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -178.542 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.552 HG23 HD11 ' B' ' 31' ' ' ILE . 43.4 t -153.03 123.54 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 177.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.524 HG22 ' O ' ' O' ' 38' ' ' GLY . 9.1 m . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.724 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -115.44 141.51 47.95 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.876 0.369 . . . . 0.0 110.687 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -83.11 116.78 22.48 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.233 -0.439 . . . . 0.0 109.933 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.555 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 2.9 m -138.44 160.66 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.823 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 94.3 m-70 -76.74 113.39 14.35 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.529 178.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.572 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 83.6 t60 -148.02 153.23 38.68 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 119.576 -0.849 . . . . 0.0 111.875 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.563 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 42.1 tt0 -98.65 169.61 9.38 Favored 'General case' 0 C--N 1.345 0.396 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.338 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -158.57 104.44 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.681 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.521 ' CD1' HG11 ' M' ' 36' ' ' VAL . 31.5 mt -122.29 116.02 23.35 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 177.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 18' ' ' VAL . . . . . 0.437 ' CG1' HG22 ' N' ' 18' ' ' VAL . 3.3 p -125.0 117.59 50.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-O 121.883 0.849 . . . . 0.0 109.576 178.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -112.31 115.08 28.19 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.429 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -114.63 133.93 55.46 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 122.523 0.329 . . . . 0.0 110.524 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.58 142.11 27.64 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 113.68 0.993 . . . . 0.0 113.68 -178.937 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 22' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' N' ' 23' ' ' ASP . 95.9 mt-10 -78.99 104.98 10.0 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 104.481 -2.415 . . . . 0.0 104.481 175.486 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.814 ' HB3' ' HB1' ' P' ' 21' ' ' ALA . 17.6 p30 -83.27 49.03 1.48 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 117.736 2.495 . . . . 0.0 117.736 -172.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.471 HG12 ' N ' ' O' ' 25' ' ' GLY . 89.9 t -71.56 160.44 5.24 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 C-N-CA 114.803 -2.759 . . . . 0.0 104.221 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.481 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.92 -30.8 8.31 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 -175.065 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 2.5 m 100.59 111.13 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 112.932 -1.634 . . . . 0.0 112.072 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.555 ' O ' ' N ' ' O' ' 29' ' ' GLY . 12.7 t-20 -70.48 -179.43 2.09 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.702 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.537 ' H ' ' CG ' ' O' ' 27' ' ' ASN . 51.9 tttt 65.53 -47.29 0.38 Allowed 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' O' ' 27' ' ' ASN . . . -81.95 59.38 4.87 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 107.039 -2.424 . . . . 0.0 107.039 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 30' ' ' ALA . . . . . 0.898 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -140.31 -171.02 3.11 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 109.739 -3.231 . . . . 0.0 105.513 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 81.5 mt -128.81 125.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 119.509 -0.876 . . . . 0.0 113.342 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.464 HD13 ' CD2' ' Q' ' 19' ' ' PHE . 88.9 mt -104.33 104.54 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 174.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.05 109.92 2.78 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 105.553 -3.019 . . . . 0.0 105.553 177.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.602 ' O ' HD23 ' O' ' 34' ' ' LEU . 0.0 OUTLIER -162.98 150.0 12.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 115.737 -2.385 . . . . 0.0 114.742 -174.991 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.0 mmm -110.08 105.05 14.02 Favored 'General case' 0 CA--C 1.496 -1.102 0 CA-C-N 111.604 -2.544 . . . . 0.0 106.199 179.106 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.5 ' HB ' HD21 ' O' ' 34' ' ' LEU . 11.9 p -118.64 142.12 35.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -178.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.04 -102.08 0.21 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 120.076 -1.059 . . . . 0.0 110.549 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.524 ' O ' HG22 ' N' ' 40' ' ' VAL . . . 73.99 64.75 2.36 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 120.571 -0.823 . . . . 0.0 113.182 -178.498 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.839 HG12 HD11 ' C' ' 31' ' ' ILE . 9.1 p -10.79 140.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.414 ' CG1' ' OXT' ' P' ' 40' ' ' VAL . 7.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.059 177.314 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.499 HG12 ' H ' ' Q' ' 12' ' ' VAL . 6.2 m . . . . . 0 N--CA 1.463 0.223 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.627 ' H ' ' CE1' ' Q' ' 13' ' ' HIS . 0.6 OUTLIER -129.54 115.67 17.79 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.055 0.455 . . . . 0.0 112.008 -178.991 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.572 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 4.5 p80 -156.11 167.16 31.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.359 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.423 ' NE2' ' HB ' ' N' ' 36' ' ' VAL . 13.6 tt0 -89.78 158.48 17.49 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -140.32 115.08 9.54 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.636 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.424 ' HB3' ' CE2' ' P' ' 19' ' ' PHE . 14.4 mt -119.47 122.28 41.34 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.523 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -119.63 107.56 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 47.8 m-85 -110.03 107.95 18.0 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 178.197 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -116.4 125.56 52.22 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.596 0.236 . . . . 0.0 110.694 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 21' ' ' ALA . . . . . 0.814 ' HB1' ' HB3' ' O' ' 23' ' ' ASP . . . -129.59 127.78 41.36 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.141 0.496 . . . . 0.0 110.231 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' O' ' 23' ' ' ASP . 16.6 pt-20 -122.03 158.77 28.45 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.433 ' C ' ' OD1' ' O' ' 23' ' ' ASP . 29.8 m-20 76.43 55.98 0.05 OUTLIER 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 113.439 -1.709 . . . . 0.0 112.859 178.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.412 HG12 ' H ' ' O' ' 27' ' ' ASN . 3.8 m -77.4 129.21 37.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.21 -35.41 4.48 Favored Glycine 0 CA--C 1.536 1.383 0 C-N-CA 118.854 -1.641 . . . . 0.0 112.127 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.652 ' O ' ' O ' ' P' ' 27' ' ' ASN . 16.4 t -173.97 125.82 0.36 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 119.562 1.681 . . . . 0.0 114.179 175.323 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.652 ' O ' ' O ' ' P' ' 26' ' ' SER . 44.6 m-20 -2.86 145.73 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.25 1.42 . . . . 0.0 114.683 173.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -160.31 32.23 0.17 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.73 80.95 0.89 Allowed Glycine 0 N--CA 1.482 1.748 0 C-N-CA 117.768 -2.158 . . . . 0.0 112.939 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 30' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' O' ' 28' ' ' LYS . . . -101.94 131.41 48.35 Favored 'General case' 0 CA--C 1.508 -0.651 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -176.551 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.506 HD11 HG21 ' K' ' 39' ' ' VAL . 91.1 mt -133.47 122.49 44.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.164 178.601 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.441 HD13 HG21 ' P' ' 32' ' ' ILE . 43.7 mt -107.17 110.43 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.03 102.88 0.86 Allowed Glycine 0 N--CA 1.462 0.369 0 N-CA-C 107.788 -2.125 . . . . 0.0 107.788 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.452 ' HB2' HD23 ' O' ' 34' ' ' LEU . 4.0 pp -157.35 162.35 39.09 Favored 'General case' 0 CA--C 1.493 -1.224 0 C-N-CA 117.664 -1.615 . . . . 0.0 113.621 -177.584 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 23.3 mtp -119.89 123.19 42.98 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 112.215 -2.266 . . . . 0.0 109.628 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.609 ' O ' ' O ' ' P' ' 37' ' ' GLY . 0.1 OUTLIER -98.17 101.95 12.81 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.965 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' P' P ' 37' ' ' GLY . . . . . 0.609 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 28.42 172.77 0.0 OUTLIER Glycine 0 N--CA 1.468 0.78 0 C-N-CA 126.04 1.781 . . . . 0.0 116.491 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.03 -58.21 0.59 Allowed Glycine 0 CA--C 1.536 1.378 0 CA-C-N 113.45 -1.375 . . . . 0.0 112.678 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.514 HG23 HD11 ' D' ' 31' ' ' ILE . 72.7 t -105.58 131.4 55.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 CA-C-O 121.195 0.521 . . . . 0.0 111.091 -178.307 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' P' ' 39' ' ' VAL . 5.6 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.3 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -106.58 133.83 50.66 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.02 139.25 37.78 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.758 0.313 . . . . 0.0 110.549 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.499 ' H ' HG12 ' P' ' 12' ' ' VAL . 29.0 m -137.13 158.1 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 121.085 0.469 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.627 ' CE1' ' H ' ' P' ' 13' ' ' HIS . 44.8 m-70 -147.5 115.18 6.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.91 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.631 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 83.2 m-70 -131.89 160.38 35.89 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.721 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.5 ' OE1' HD11 ' Q' ' 17' ' ' LEU . 48.8 tt0 -90.09 159.18 16.94 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -140.68 92.39 2.51 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.836 178.028 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.5 HD11 ' OE1' ' Q' ' 15' ' ' GLN . 3.0 mt -115.01 115.12 26.33 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -119.49 107.77 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.397 -179.344 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.585 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 35.4 m-85 -110.1 101.95 10.7 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 104.311 -2.477 . . . . 0.0 104.311 175.607 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -123.45 133.37 54.06 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.139 -0.482 . . . . 0.0 112.286 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.518 ' HB2' ' OD1' ' O' ' 27' ' ' ASN . . . -138.09 154.65 49.23 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.528 ' O ' ' N ' ' Q' ' 24' ' ' VAL . 75.4 tt0 -72.58 163.05 28.66 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.473 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 65.7 t0 0.78 54.28 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 116.317 1.969 . . . . 0.0 116.317 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' Q' ' 22' ' ' GLU . 0.3 OUTLIER -66.56 137.17 25.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 176.425 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' Q' ' 26' ' ' SER . . . -118.04 -28.34 2.25 Favored Glycine 0 CA--C 1.542 1.745 0 CA-C-O 118.94 -0.922 . . . . 0.0 110.919 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 0.7 OUTLIER 91.11 116.81 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 118.895 1.348 . . . . 0.0 114.607 173.656 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -72.96 174.81 7.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.232 0.539 . . . . 0.0 111.086 177.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -53.84 -38.88 65.1 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.688 178.186 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.46 ' O ' HG13 ' K' ' 39' ' ' VAL . . . -109.04 69.21 0.21 Allowed Glycine 0 CA--C 1.537 1.438 0 N-CA-C 115.517 0.967 . . . . 0.0 115.517 -175.501 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.14 121.45 41.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.837 0.819 . . . . 0.0 109.151 178.205 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.663 HD12 HG23 ' K' ' 39' ' ' VAL . 86.1 mt -125.81 132.52 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 121.101 0.477 . . . . 0.0 111.646 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -122.53 121.93 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.521 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.69 108.16 1.15 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 15.7 mt -117.68 122.4 43.43 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -136.12 144.46 45.09 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.568 HG12 ' N ' ' Q' ' 37' ' ' GLY . 63.7 t -117.99 168.28 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.381 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.568 ' N ' HG12 ' Q' ' 36' ' ' VAL . . . -169.15 93.81 0.1 Allowed Glycine 0 C--N 1.314 -0.672 0 C-N-CA 118.915 -1.612 . . . . 0.0 112.932 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.0 -81.51 0.1 OUTLIER Glycine 0 CA--C 1.536 1.391 0 CA-C-N 118.74 1.27 . . . . 0.0 113.373 177.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -171.99 136.81 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 118.299 1.05 . . . . 0.0 110.293 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.094 -0.955 . . . . 0.0 110.634 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.06 142.03 38.85 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 110.315 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -131.18 148.71 52.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.946 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.481 ' H ' HG12 ' Q' ' 12' ' ' VAL . 2.6 p -129.51 135.85 60.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-O 121.434 0.635 . . . . 0.0 110.857 -179.695 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.605 ' HD1' ' HB2' ' Q' ' 13' ' ' HIS . 1.3 m-70 -139.9 133.13 29.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.631 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 31.4 t-80 -153.55 161.56 42.1 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.42 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 18.4 tt0 -90.14 158.87 17.06 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.306 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.426 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 37.7 tttp -140.52 104.6 4.79 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.463 ' N ' HD23 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -118.58 114.05 22.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.477 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -117.36 107.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.028 0.442 . . . . 0.0 110.439 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.546 ' O ' ' CD2' ' R' ' 20' ' ' PHE . 16.2 m-85 -113.4 101.45 9.39 Favored 'General case' 0 N--CA 1.461 0.118 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 20' ' ' PHE . . . . . 0.546 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 63.0 m-85 -157.59 -177.75 6.82 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.695 1.236 . . . . 0.0 113.801 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.02 154.41 41.17 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.05 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -82.15 148.9 28.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.111 0.482 . . . . 0.0 111.7 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 58.14 48.14 13.37 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.753 179.127 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.501 HG12 ' N ' ' R' ' 25' ' ' GLY . 15.3 t -66.52 166.56 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.812 179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.501 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -175.76 15.96 0.04 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.5 p -83.11 140.82 32.41 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.652 ' O ' ' N ' ' R' ' 29' ' ' GLY . 71.5 m-80 -73.15 150.99 41.74 Favored 'General case' 0 C--O 1.223 -0.297 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.299 177.863 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -51.32 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.652 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.81 58.33 0.8 Allowed Glycine 0 CA--C 1.541 1.681 0 CA-C-N 118.611 0.641 . . . . 0.0 112.479 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -147.59 170.14 18.12 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 117.454 0.627 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 87.9 mt -119.89 123.95 71.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -121.57 130.22 74.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.665 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.08 111.44 1.16 Allowed Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.53 ' C ' HD23 ' R' ' 34' ' ' LEU . 8.0 tt -119.27 121.42 39.6 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 87.9 mtp -141.64 145.16 34.63 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.384 0.611 . . . . 0.0 112.117 -178.559 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.477 HG23 ' HB ' ' Q' ' 36' ' ' VAL . 2.2 p -144.01 143.4 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 119.526 -0.869 . . . . 0.0 111.623 177.487 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.03 -102.62 1.02 Allowed Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 174.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 23.23 73.5 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 112.758 -1.721 . . . . 0.0 115.48 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 96.8 t -49.39 134.4 7.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 117.008 0.404 . . . . 0.0 110.41 178.476 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.848 179.818 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 . . . . . 0 N--CA 1.466 0.34 0 CA-C-O 121.071 0.462 . . . . 0.0 111.461 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 m -136.22 157.57 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 178.578 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.427 ' C ' ' CG ' ' A' ' 14' ' ' HIS . 64.8 t-80 -145.32 124.06 12.59 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.712 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.529 ' CE1' ' H ' ' B' ' 14' ' ' HIS . 29.4 m-70 -151.47 165.97 32.55 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.133 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.9 tp60 -159.72 143.36 14.43 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.942 0.401 . . . . 0.0 110.053 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -80.44 120.37 24.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.352 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.8 mt -129.71 112.36 13.57 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.5 t -125.52 131.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.377 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -122.99 124.02 42.21 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.4 p90 -132.48 130.59 40.68 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.765 0.317 . . . . 0.0 110.382 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.19 132.69 40.05 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.068 0.461 . . . . 0.0 110.299 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 23' ' ' ASP . 13.2 pt-20 -83.87 -170.47 3.09 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.989 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 23' ' ' ASP . 21.3 p-10 . . . . . 0 N--CA 1.466 0.366 0 O-C-N 123.258 0.349 . . . . 0.0 111.15 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 0.529 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 14.5 t-20 . . . . . 0 CA--C 1.529 0.151 0 CA-C-O 121.749 0.785 . . . . 0.0 112.129 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.598 ' NZ ' ' CE1' ' O' ' 13' ' ' HIS . 71.4 tttt -54.4 -38.23 65.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.491 178.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.52 71.42 0.2 Allowed Glycine 0 CA--C 1.536 1.395 0 CA-C-N 114.937 -1.029 . . . . 0.0 114.137 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.474 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -95.65 98.43 10.48 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-O 124.367 2.032 . . . . 0.0 111.036 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.437 HG22 HG12 ' B' ' 31' ' ' ILE . 6.0 pt -134.76 139.56 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 111.538 -2.574 . . . . 0.0 108.685 -179.424 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.425 HG21 HD13 ' A' ' 32' ' ' ILE . 43.4 mt -108.57 112.45 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.5 96.8 0.76 Allowed Glycine 0 N--CA 1.463 0.434 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.424 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 77.2 mt -147.08 169.87 18.35 Favored 'General case' 0 CA--C 1.506 -0.721 0 CA-C-O 122.622 1.201 . . . . 0.0 111.834 -176.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 23.5 mtp -124.68 119.42 28.92 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 113.403 -1.726 . . . . 0.0 108.894 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.551 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 2.5 t -108.95 111.9 38.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.52 -131.72 7.97 Favored Glycine 0 C--N 1.32 -0.356 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.6 -62.51 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.439 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 25.2 m -122.96 163.34 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.445 HG12 ' O ' ' A' ' 40' ' ' VAL . 99.0 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 10' ' ' TYR . . . . . 0.527 ' CE1' ' O ' ' C' ' 9' ' ' GLY . 97.2 m-85 -106.12 132.89 51.65 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.541 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.9 mp0 -110.31 124.0 50.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.465 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.452 HG22 HG12 ' C' ' 12' ' ' VAL . 53.7 t -124.73 128.15 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 41.2 t60 -131.44 122.24 25.91 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 120.941 0.4 . . . . 0.0 111.595 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.529 ' H ' ' CE1' ' A' ' 14' ' ' HIS . 74.2 t60 -157.78 168.36 27.43 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.593 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.435 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 83.6 mt-30 -154.77 141.81 19.29 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.277 0.56 . . . . 0.0 110.747 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -87.09 110.9 20.41 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.712 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.403 HD12 ' N ' ' B' ' 17' ' ' LEU . 6.0 mp -121.52 112.72 18.85 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.518 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -121.65 131.8 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.718 0.294 . . . . 0.0 110.676 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -122.96 116.27 23.29 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.364 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -119.11 126.07 50.76 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.7 136.65 31.05 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.842 1.052 . . . . 0.0 113.842 -178.036 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -111.53 117.52 33.23 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 176.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.525 ' OD2' ' ND2' ' B' ' 27' ' ' ASN . 65.5 t0 -107.0 46.31 0.94 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -177.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.648 HG12 ' N ' ' B' ' 25' ' ' GLY . 61.8 t -83.57 173.26 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.737 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.648 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 93.6 -28.17 10.71 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.905 177.674 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.812 ' O ' ' O ' ' B' ' 27' ' ' ASN . 78.0 p 178.61 -129.35 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.524 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.825 -178.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.812 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.1 t30 10.16 152.06 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.578 ' HB3' ' H ' ' C' ' 28' ' ' LYS . 94.2 mttt -169.55 30.17 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.736 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -99.32 78.88 0.51 Allowed Glycine 0 CA--C 1.538 1.469 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 178.357 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.616 ' H ' HD21 ' C' ' 27' ' ' ASN . . . -110.43 112.75 24.89 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 114.512 1.301 . . . . 0.0 114.512 -176.079 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.437 HG12 HG22 ' A' ' 31' ' ' ILE . 44.1 pt -140.59 143.78 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.958 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -113.56 122.45 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.153 0.502 . . . . 0.0 110.054 178.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 105.39 1.04 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 106.839 -2.504 . . . . 0.0 106.839 177.249 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.738 ' HB2' HD22 ' C' ' 34' ' ' LEU . 56.9 mt -137.19 145.24 43.46 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 122.818 1.294 . . . . 0.0 114.157 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -104.79 108.72 20.36 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 174.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -116.33 102.34 13.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.817 ' N ' HE22 ' D' ' 15' ' ' GLN . . . 111.75 164.19 17.5 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-O 122.015 0.786 . . . . 0.0 111.412 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.584 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 164.82 -55.95 0.27 Allowed Glycine 0 CA--C 1.542 1.741 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -178.208 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 t -119.76 134.4 63.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.63 HG11 ' ND1' ' E' ' 13' ' ' HIS . 81.3 t . . . . . 0 C--O 1.22 -0.447 0 CA-C-O 118.163 -0.923 . . . . 0.0 110.721 179.245 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 9' ' ' GLY . . . . . 0.527 ' O ' ' CE1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -151.1 158.86 44.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.616 0.246 . . . . 0.0 110.628 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -89.64 120.78 31.21 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.598 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.544 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 2.8 p -138.94 138.6 41.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.232 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.523 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 84.3 m-70 -146.65 135.17 22.02 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.777 0.322 . . . . 0.0 111.413 -179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' D' ' 14' ' ' HIS . 41.8 m-70 -151.26 172.03 16.5 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -126.65 141.81 51.74 Favored 'General case' 0 CA--C 1.522 -0.128 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 174.471 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.418 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.5 tttt -115.76 108.99 17.05 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 118.697 -0.668 . . . . 0.0 111.62 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.418 HD12 ' C ' ' C' ' 16' ' ' LYS . 8.4 mp -124.12 115.06 20.53 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 118.804 0.729 . . . . 0.0 109.056 175.646 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 81.2 t -109.32 122.16 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.326 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -111.56 103.46 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 15.7 t80 -113.67 125.12 53.79 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.226 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.81 133.35 33.9 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.786 0.803 . . . . 0.0 112.866 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -95.8 120.08 35.43 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.58 48.89 1.62 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -176.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.526 HG12 ' N ' ' C' ' 25' ' ' GLY . 73.3 t -71.89 161.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.526 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 109.35 -30.5 8.5 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 108.159 -1.976 . . . . 0.0 108.159 -176.489 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.518 ' HB3' ' O ' ' C' ' 25' ' ' GLY . 25.8 t 99.96 111.75 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.296 1.838 . . . . 0.0 110.657 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.616 HD21 ' H ' ' B' ' 30' ' ' ALA . 30.8 t30 -71.51 162.01 30.12 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.855 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.578 ' H ' ' HB3' ' B' ' 28' ' ' LYS . 28.2 ttpt -48.7 -39.36 24.34 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 176.147 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.49 69.15 0.04 OUTLIER Glycine 0 CA--C 1.542 1.762 0 CA-C-O 118.669 -1.073 . . . . 0.0 111.488 -173.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 130.17 41.41 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 120.14 1.97 . . . . 0.0 113.938 -173.772 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.494 ' CD1' ' O ' ' O' ' 38' ' ' GLY . 36.8 mt -139.18 141.24 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 113.738 -1.573 . . . . 0.0 114.284 -176.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.8 mt -117.78 118.52 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 175.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.953 ' O ' HD23 ' C' ' 34' ' ' LEU . . . -125.17 113.2 1.88 Allowed Glycine 0 N--CA 1.474 1.185 0 N-CA-C 108.846 -1.701 . . . . 0.0 108.846 178.885 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.953 HD23 ' O ' ' C' ' 33' ' ' GLY . 3.1 mt -138.89 151.8 47.26 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-O 123.51 1.624 . . . . 0.0 114.499 -177.49 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 88.1 mmm -105.31 107.1 17.91 Favored 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 111.073 -2.785 . . . . 0.0 104.359 174.762 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.72 ' HB ' HG12 ' D' ' 36' ' ' VAL . 2.9 t -111.29 143.06 21.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' OE1' ' E' ' 15' ' ' GLN . . . 166.85 -102.06 0.19 Allowed Glycine 0 C--N 1.302 -1.352 0 C-N-CA 119.507 -1.33 . . . . 0.0 111.007 -177.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.584 ' HA3' ' H ' ' B' ' 38' ' ' GLY . . . 51.31 70.77 0.78 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.308 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.742 HG13 ' O ' ' D' ' 39' ' ' VAL . 22.9 t -72.14 142.08 15.75 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.226 0 CA-C-O 120.801 0.334 . . . . 0.0 111.718 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.429 HG12 ' CD2' ' E' ' 13' ' ' HIS . 14.8 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.334 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.465 0.277 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.523 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 8.6 t60 -146.44 129.79 16.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.935 0.397 . . . . 0.0 110.728 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 2.9 p80 -152.31 161.58 42.4 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.102 178.312 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.817 HE22 ' N ' ' B' ' 37' ' ' GLY . 24.9 mt-30 -90.09 159.59 16.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.347 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.718 ' C ' HD12 ' D' ' 17' ' ' LEU . 48.1 mmtt -139.63 98.08 3.41 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.718 HD12 ' C ' ' D' ' 16' ' ' LYS . 5.4 mp -130.95 131.1 44.22 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.117 0.485 . . . . 0.0 110.059 178.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 62.9 t -121.53 124.85 72.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.52 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.7 m-85 -111.81 102.6 10.86 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 18.1 t80 -112.89 122.14 46.77 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.86 -0.155 . . . . 0.0 110.732 -178.55 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.28 134.31 30.84 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 122.106 0.955 . . . . 0.0 113.096 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.455 ' OE2' ' OE1' ' E' ' 22' ' ' GLU . 49.5 tp10 -101.2 126.8 47.95 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.594 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 52.5 p-10 -167.25 48.52 0.06 Allowed 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -72.44 160.97 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.11 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -30.06 8.81 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.094 -1.203 . . . . 0.0 110.094 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.512 ' CB ' ' OG ' ' C' ' 26' ' ' SER . 4.7 p -83.04 141.1 32.3 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 115.014 1.487 . . . . 0.0 115.014 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.671 ' O ' ' N ' ' D' ' 29' ' ' GLY . 34.1 p30 -73.21 -155.48 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.474 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -53.84 48.33 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 113.22 0.822 . . . . 0.0 113.22 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.671 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -100.19 56.01 0.84 Allowed Glycine 0 CA--C 1.542 1.75 0 CA-C-O 119.8 -0.445 . . . . 0.0 112.224 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -153.33 109.21 3.29 Favored 'General case' 0 C--O 1.24 0.594 0 CA-C-N 118.244 1.022 . . . . 0.0 110.277 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 56.2 mt -133.04 130.37 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 119.104 -1.038 . . . . 0.0 113.549 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.407 ' O ' ' N ' ' E' ' 33' ' ' GLY . 73.9 mt -112.62 108.32 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 176.142 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.07 111.6 3.79 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.498 ' CD1' ' CE1' ' F' ' 19' ' ' PHE . 92.2 mt -134.36 134.97 42.34 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -111.39 103.96 12.37 Favored 'General case' 0 N--CA 1.439 -1.021 0 CA-C-N 111.506 -2.588 . . . . 0.0 105.957 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.72 HG12 ' HB ' ' C' ' 36' ' ' VAL . 21.2 m -115.53 122.73 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.787 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.44 112.77 1.48 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.488 ' N ' ' OE1' ' F' ' 15' ' ' GLN . . . -120.61 62.4 0.5 Allowed Glycine 0 CA--C 1.539 1.559 0 N-CA-C 116.237 1.255 . . . . 0.0 116.237 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.742 ' O ' HG13 ' C' ' 39' ' ' VAL . 31.2 t -76.83 168.81 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 120.892 2.346 . . . . 0.0 108.403 176.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.65 ' N ' HG12 ' D' ' 39' ' ' VAL . 3.6 p . . . . . 0 C--O 1.222 -0.39 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.657 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -98.51 134.4 41.53 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -158.55 153.67 25.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.88 0.371 . . . . 0.0 111.497 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.54 112.6 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.63 ' ND1' HG11 ' B' ' 40' ' ' VAL . 1.7 t60 -127.27 118.67 24.68 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -177.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.458 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 22.9 p-80 -157.57 159.64 37.31 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.531 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.415 ' OE1' ' O ' ' C' ' 37' ' ' GLY . 1.3 mp0 -90.23 159.02 16.92 Favored 'General case' 0 C--O 1.224 -0.242 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.764 ' C ' HD12 ' E' ' 17' ' ' LEU . 13.0 tttm -140.96 101.13 3.98 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.402 176.446 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.764 HD12 ' C ' ' E' ' 16' ' ' LYS . 6.7 mp -130.44 127.89 40.2 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.7 t -117.71 126.21 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.579 ' N ' ' CD1' ' E' ' 19' ' ' PHE . 0.2 OUTLIER -113.72 103.74 11.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 -179.454 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 22.3 t80 -113.21 118.53 34.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 121.443 -0.103 . . . . 0.0 111.138 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.57 138.33 36.13 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 119.668 -0.813 . . . . 0.0 112.256 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE2' ' D' ' 22' ' ' GLU . 88.6 mt-10 -101.51 119.77 39.28 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.37 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.875 ' O ' HG13 ' E' ' 24' ' ' VAL . 16.6 t0 -119.24 -49.89 2.37 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -179.373 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.875 HG13 ' O ' ' E' ' 23' ' ' ASP . 0.1 OUTLIER 163.81 -166.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 179.367 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.36 -35.6 91.89 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.153 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 22.1 t -155.82 112.63 3.19 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 30' ' ' ALA . 20.0 p30 -53.01 170.22 0.08 Allowed 'General case' 0 N--CA 1.464 0.231 0 C-N-CA 117.114 -1.835 . . . . 0.0 108.626 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -61.24 -39.05 88.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.224 -0.991 . . . . 0.0 112.238 175.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.474 ' N ' ' OD1' ' E' ' 27' ' ' ASN . . . -178.97 74.97 0.07 OUTLIER Glycine 0 CA--C 1.544 1.856 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.076 -177.256 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.658 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -80.64 163.65 23.46 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.537 1.668 . . . . 0.0 111.669 -178.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.413 HD11 ' HB ' ' Q' ' 39' ' ' VAL . 79.8 mt -131.16 127.55 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.537 HD11 ' CD2' ' F' ' 19' ' ' PHE . 3.2 tt -123.14 109.33 23.28 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.562 ' HA2' ' H ' ' F' ' 33' ' ' GLY . . . -80.08 116.46 4.27 Favored Glycine 0 C--O 1.241 0.568 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' F' ' 34' ' ' LEU . 38.8 tp -110.14 104.21 13.03 Favored 'General case' 0 C--O 1.267 1.982 0 CA-C-N 120.096 1.948 . . . . 0.0 110.767 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.762 ' HA ' ' HA ' ' F' ' 35' ' ' MET . 29.0 tpp -115.8 110.48 19.13 Favored 'General case' 0 C--N 1.351 0.648 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.558 HG12 ' N ' ' E' ' 37' ' ' GLY . 39.5 t -84.89 172.64 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.374 1.655 0 C-N-CA 117.431 -1.708 . . . . 0.0 107.157 177.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.558 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -176.75 92.99 0.09 OUTLIER Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.359 -1.877 . . . . 0.0 111.672 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.463 ' C ' HG22 ' D' ' 39' ' ' VAL . . . 119.13 85.49 0.98 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-N 119.435 1.618 . . . . 0.0 114.009 178.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' E' ' 38' ' ' GLY . 1.8 p . . . . . 0 N--CA 1.484 1.246 0 N-CA-C 113.87 1.063 . . . . 0.0 113.87 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 . . . . . 0 CA--C 1.521 -0.159 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 27.1 m -138.22 157.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.514 0.673 . . . . 0.0 112.225 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -146.07 98.18 3.06 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.059 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.458 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 97.4 m-70 -151.9 168.08 26.28 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.498 ' HB3' HD21 ' F' ' 17' ' ' LEU . 17.2 mt-30 -89.75 158.19 17.64 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 16' ' ' LYS . . . . . 0.491 ' C ' HD22 ' F' ' 17' ' ' LEU . 64.5 mttp -140.23 96.08 2.99 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.122 0.487 . . . . 0.0 109.889 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.877 HD22 ' N ' ' F' ' 17' ' ' LEU . 0.3 OUTLIER -118.82 112.06 19.23 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.928 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 14.6 t -101.28 110.96 29.46 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.728 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.537 ' CD2' HD11 ' E' ' 32' ' ' ILE . 15.6 m-85 -104.3 101.33 11.04 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.401 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 61.4 t80 -126.02 125.55 42.84 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 122.236 1.017 . . . . 0.0 111.762 -178.038 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.37 132.04 51.65 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' E' ' 24' ' ' VAL . 45.9 tp10 -62.17 103.3 0.37 Allowed 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 118.586 -1.246 . . . . 0.0 108.011 -178.062 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' E' ' 24' ' ' VAL . 8.3 m-20 . . . . . 0 N--CA 1.454 -0.258 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.071 -178.078 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.658 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.222 0.534 . . . . 0.0 111.135 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 5.4 mm -113.53 135.3 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.137 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' E' ' 32' ' ' ILE . 82.9 mt -103.91 117.41 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.95 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 33' ' ' GLY . . . . . 0.562 ' H ' ' HA2' ' E' ' 33' ' ' GLY . . . -58.4 -154.61 0.01 OUTLIER Glycine 0 C--O 1.209 -1.46 0 CA-C-N 118.65 0.659 . . . . 0.0 113.233 -178.33 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.633 ' O ' ' HA ' ' E' ' 35' ' ' MET . 74.4 mt -99.47 125.79 45.27 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 178.785 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.762 ' HA ' ' HA ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -103.33 83.53 2.19 Favored 'General case' 0 C--O 1.171 -3.045 0 C-N-CA 130.117 3.367 . . . . 0.0 114.197 179.508 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.575 HG23 ' O ' ' F' ' 36' ' ' VAL . 2.7 m -92.77 115.21 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 117.785 -3.072 . . . . 0.0 112.713 175.534 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -117.19 122.51 5.48 Favored Glycine 0 CA--C 1.516 0.12 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 178.119 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.36 -61.61 7.27 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.046 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 37.2 t -147.88 137.77 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.171 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 178.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.135 -0.936 . . . . 0.0 110.34 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.417 ' O ' HG23 ' G' ' 12' ' ' VAL . 4.4 m . . . . . 0 N--CA 1.467 0.384 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -104.74 121.68 44.12 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.821 0.343 . . . . 0.0 110.918 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 31.0 t60 -155.03 165.9 35.29 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.763 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.524 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 14.6 pt20 -157.06 142.22 17.18 Favored 'General case' 0 C--N 1.339 0.111 0 CA-C-O 121.174 0.512 . . . . 0.0 111.144 178.195 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.413 ' H ' ' HG2' ' G' ' 16' ' ' LYS . 51.5 pttt -86.3 122.03 29.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.307 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.8 mt -127.41 118.07 23.39 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -133.73 133.44 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-O 120.697 0.284 . . . . 0.0 111.585 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -139.14 142.61 38.02 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.896 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -152.0 151.59 31.36 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 119.726 -0.79 . . . . 0.0 112.781 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.51 129.26 50.95 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.036 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -82.19 -173.58 4.62 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -176.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.416 ' OD2' ' OE2' ' H' ' 22' ' ' GLU . 0.7 OUTLIER . . . . . 0 N--CA 1.469 0.507 0 CA-C-N 112.877 -1.965 . . . . 0.0 115.771 -178.007 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 . . . . . 0 N--CA 1.466 0.353 0 N-CA-C 110.501 -0.185 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -78.62 40.53 0.38 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.75 78.57 0.56 Allowed Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.729 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.66 59.97 4.41 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-N 119.814 1.807 . . . . 0.0 113.456 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 4.5 pt -147.99 123.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 177.162 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 87.8 mt -109.23 113.67 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.222 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.32 99.81 0.98 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 105.688 -2.965 . . . . 0.0 105.688 176.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.445 ' O ' HD23 ' H' ' 34' ' ' LEU . 43.0 tp -157.92 154.8 28.44 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 118.007 -1.477 . . . . 0.0 113.468 -175.625 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 55.0 tpp -102.1 119.89 39.54 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 113.007 -1.906 . . . . 0.0 107.07 177.509 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 47.2 t -124.2 112.17 31.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.221 0.534 . . . . 0.0 110.798 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.06 -131.89 10.19 Favored Glycine 0 C--N 1.316 -0.567 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . 115.5 -61.35 0.38 Allowed Glycine 0 CA--C 1.537 1.445 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.55 HG22 ' N ' ' G' ' 40' ' ' VAL . 2.4 p -127.78 164.76 28.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.55 ' N ' HG22 ' G' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.605 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' N ' ' H' ' 11' ' ' GLU . 60.7 t80 -148.73 179.88 7.5 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.284 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 11' ' ' GLU . . . . . 0.625 ' N ' ' CD2' ' H' ' 10' ' ' TYR . 80.9 mm-40 -66.96 126.93 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.47 126.62 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.465 ' NE2' ' CE1' ' I' ' 13' ' ' HIS . 10.8 p80 -151.51 139.23 19.77 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.491 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.581 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 22.6 m-70 -145.33 160.7 41.13 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-O 121.046 0.451 . . . . 0.0 110.134 177.853 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -90.2 160.44 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.139 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -139.84 102.74 4.49 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.561 ' C ' HD23 ' H' ' 17' ' ' LEU . 7.3 tt -126.35 124.07 39.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.24 0.543 . . . . 0.0 111.191 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.478 ' N ' HD23 ' H' ' 17' ' ' LEU . 65.4 t -122.0 130.88 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.301 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -125.95 113.12 16.75 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.058 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -114.47 120.25 39.63 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.68 126.23 41.55 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.811 0.815 . . . . 0.0 113.187 -178.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.416 ' OE2' ' OD2' ' G' ' 23' ' ' ASP . 80.0 tt0 -97.62 113.06 24.71 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 107.07 -1.455 . . . . 0.0 107.07 177.02 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 57.5 t0 -131.12 52.06 2.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.295 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p -74.69 142.97 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 C-N-CA 119.944 -0.703 . . . . 0.0 109.577 -177.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.43 38.37 3.75 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.387 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 73.39 120.04 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.784 -0.208 . . . . 0.0 111.162 179.123 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.439 ' CG ' ' OD2' ' I' ' 23' ' ' ASP . 8.2 m-20 -83.24 162.0 21.32 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.174 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -47.04 -39.53 13.01 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.683 177.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.04 69.15 0.02 OUTLIER Glycine 0 CA--C 1.537 1.448 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.55 -176.245 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -51.64 100.73 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 118.544 1.172 . . . . 0.0 114.045 -176.469 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.523 HG22 ' HB ' ' I' ' 31' ' ' ILE . 43.5 pt -137.86 139.27 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.671 178.463 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.486 ' CG2' HD12 ' H' ' 34' ' ' LEU . 86.9 mt -106.89 109.11 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.17 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.071 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.98 96.86 1.13 Allowed Glycine 0 CA--C 1.519 0.313 0 N-CA-C 105.506 -3.037 . . . . 0.0 105.506 176.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.486 HD12 ' CG2' ' H' ' 32' ' ' ILE . 67.4 mt -135.23 149.47 49.87 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-O 123.48 1.609 . . . . 0.0 114.129 -175.418 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -119.55 106.71 12.47 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 111.795 -2.457 . . . . 0.0 104.447 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 79.3 t -106.52 102.78 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.612 0.72 . . . . 0.0 110.521 -177.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.462 ' HA3' ' H ' ' G' ' 38' ' ' GLY . . . -31.1 152.44 0.01 OUTLIER Glycine 0 N--CA 1.469 0.859 0 CA-C-N 114.56 -1.2 . . . . 0.0 113.723 -178.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . -88.44 -57.46 1.86 Allowed Glycine 0 N--CA 1.47 0.965 0 CA-C-N 114.98 -0.61 . . . . 0.0 113.338 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 40' ' ' VAL . 60.7 t -24.28 146.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 39' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.217 -0.622 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.869 -179.564 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' I' I ' 10' ' ' TYR . . . . . 0.519 ' O ' ' CD2' ' H' ' 10' ' ' TYR . 90.8 m-85 -97.63 129.81 44.7 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.516 ' O ' ' NE2' ' J' ' 13' ' ' HIS . 95.8 mt-10 -141.13 143.46 34.29 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.763 0.316 . . . . 0.0 111.335 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.518 HG22 ' H ' ' J' ' 12' ' ' VAL . 18.9 t -143.55 91.55 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.381 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.51 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 5.4 m-70 -132.74 133.63 43.72 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 116.967 -0.106 . . . . 0.0 111.187 -178.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.757 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 11.3 m80 -145.74 160.7 41.35 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 178.383 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 10.2 tp-100 -90.17 157.58 17.66 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 174.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -141.91 102.28 4.11 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 119.971 -0.691 . . . . 0.0 110.648 176.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 25.5 mt -120.51 118.41 30.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.652 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -111.8 114.77 48.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 177.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -108.53 105.25 14.81 Favored 'General case' 0 CA--C 1.539 0.533 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -116.17 132.63 56.61 Favored 'General case' 0 N--CA 1.479 1.02 0 O-C-N 122.212 -0.305 . . . . 0.0 111.091 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.22 149.65 32.31 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -178.407 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -105.59 163.36 12.73 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 113.966 -1.47 . . . . 0.0 108.124 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.474 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 34.6 t0 -174.47 47.08 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 -176.563 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.416 ' N ' ' OD2' ' J' ' 23' ' ' ASP . 0.1 OUTLIER -91.09 170.56 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 122.381 1.086 . . . . 0.0 110.308 -175.583 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.15 27.43 62.08 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.984 -176.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 1.7 t 165.78 146.87 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -53.02 138.12 31.38 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 119.126 -1.03 . . . . 0.0 108.844 178.621 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.6 ' HB2' HG11 ' J' ' 24' ' ' VAL . 31.2 tttm -62.35 -49.77 74.23 Favored 'General case' 0 CA--C 1.53 0.193 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 100.82 57.47 0.87 Allowed Glycine 0 CA--C 1.544 1.854 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.434 ' HB3' ' OD1' ' J' ' 27' ' ' ASN . . . -102.03 115.55 30.79 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 120.12 1.96 . . . . 0.0 116.198 -172.705 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.523 ' HB ' HG22 ' H' ' 31' ' ' ILE . 97.1 mt -129.89 120.98 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.371 176.302 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.627 HG22 HD21 ' J' ' 34' ' ' LEU . 28.9 mt -106.1 114.08 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.337 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.36 109.05 1.9 Allowed Glycine 0 C--O 1.236 0.271 0 N-CA-C 106.151 -2.78 . . . . 0.0 106.151 176.527 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.483 HD12 ' O ' ' H' ' 34' ' ' LEU . 0.1 OUTLIER -161.31 150.13 16.11 Favored 'General case' 0 CA--C 1.504 -0.793 0 C-N-CA 117.445 -1.702 . . . . 0.0 112.905 -175.63 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.443 ' N ' HD12 ' I' ' 34' ' ' LEU . 29.9 mtp -116.41 117.49 30.07 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-N 112.714 -2.039 . . . . 0.0 107.716 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.551 HG12 ' NE2' ' K' ' 15' ' ' GLN . 1.5 t -101.11 102.61 13.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.77 153.49 0.01 OUTLIER Glycine 0 N--CA 1.474 1.168 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.6 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.752 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -117.6 56.16 0.55 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 118.843 2.297 . . . . 0.0 118.843 -175.631 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.463 HG12 HG23 ' I' ' 40' ' ' VAL . 61.5 t -101.83 129.06 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 CA-C-N 119.886 1.843 . . . . 0.0 110.234 177.213 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.463 HG23 HG12 ' I' ' 39' ' ' VAL . 47.3 t . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.489 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -147.8 157.59 43.61 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.796 0.332 . . . . 0.0 110.283 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -151.16 114.92 4.93 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.479 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.518 ' H ' HG22 ' I' ' 12' ' ' VAL . 79.2 t -128.74 133.33 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.814 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' O ' ' I' ' 11' ' ' GLU . 48.9 m-70 -141.19 100.33 3.78 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.484 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.757 ' H ' ' CD2' ' I' ' 14' ' ' HIS . 45.4 p-80 -149.22 161.08 42.72 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.362 177.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -90.16 159.79 16.58 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -139.78 103.63 4.71 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.629 179.357 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -128.34 118.42 23.18 Favored 'General case' 0 C--O 1.239 0.544 0 CA-C-O 121.868 0.842 . . . . 0.0 109.391 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 88.1 t -108.93 111.13 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.51 0 CA-C-N 114.141 -1.39 . . . . 0.0 109.17 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.564 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 16.5 m-85 -108.63 103.95 13.16 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.42 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 3.9 m-85 -120.05 130.72 54.82 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -177.039 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.4 120.07 16.16 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 177.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.51 ' O ' ' OD1' ' J' ' 23' ' ' ASP . 87.3 mt-10 -145.0 141.36 28.87 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -176.268 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.575 ' CG ' ' H ' ' J' ' 24' ' ' VAL . 5.3 p-10 147.17 -69.39 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.938 0 O-C-N 125.076 1.485 . . . . 0.0 110.125 176.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.831 HG22 ' H ' ' J' ' 25' ' ' GLY . 7.6 p -54.97 -122.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.499 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.831 ' H ' HG22 ' J' ' 24' ' ' VAL . . . 140.31 -35.17 1.92 Allowed Glycine 0 CA--C 1.528 0.866 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.661 177.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 16.1 t -80.45 118.66 22.27 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 121.041 2.42 . . . . 0.0 106.415 171.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.473 HD21 ' N ' ' J' ' 27' ' ' ASN . 1.0 OUTLIER -91.44 160.28 15.53 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 121.977 2.171 . . . . 0.0 111.038 176.743 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -46.31 -39.93 10.93 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-O 122.729 1.252 . . . . 0.0 109.541 173.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.94 68.52 0.02 OUTLIER Glycine 0 CA--C 1.54 1.648 0 CA-C-N 112.401 -2.181 . . . . 0.0 107.954 -176.156 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.716 ' O ' ' HB1' ' K' ' 30' ' ' ALA . . . -51.59 138.2 23.13 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 116.331 1.974 . . . . 0.0 116.331 -173.577 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.734 HD11 ' HB ' ' D' ' 39' ' ' VAL . 82.6 mt -135.14 126.57 46.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 113.327 -1.76 . . . . 0.0 112.228 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -108.95 109.72 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.02 99.73 0.99 Allowed Glycine 0 N--CA 1.462 0.433 0 N-CA-C 106.404 -2.678 . . . . 0.0 106.404 178.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.627 HD21 HG22 ' I' ' 32' ' ' ILE . 96.9 mt -134.94 134.63 40.8 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -175.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 45.7 tpp -104.51 107.52 18.49 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 103.936 -2.616 . . . . 0.0 103.936 174.1 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.59 ' O ' HG22 ' K' ' 36' ' ' VAL . 4.2 t -120.21 113.14 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 122.445 1.117 . . . . 0.0 110.745 -178.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -73.04 -122.39 0.08 OUTLIER Glycine 0 C--N 1.313 -0.733 0 CA-C-N 112.876 -1.966 . . . . 0.0 110.732 175.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.752 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . 71.52 60.77 4.18 Favored Glycine 0 C--N 1.318 -0.446 0 CA-C-N 111.628 -2.286 . . . . 0.0 115.791 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.961 HG22 HD11 ' P' ' 31' ' ' ILE . 7.3 m -81.75 129.35 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.136 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 9.3 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.414 179.976 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -111.83 135.18 52.79 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -136.29 144.78 44.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.748 0.308 . . . . 0.0 110.599 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 99.2 t -128.55 130.18 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 39.0 m-70 -136.19 113.73 10.91 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.079 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.497 ' O ' ' CB ' ' J' ' 14' ' ' HIS . 14.8 p-80 -152.84 162.38 41.36 Favored 'General case' 0 C--O 1.217 -0.612 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.904 178.531 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.551 ' NE2' HG12 ' I' ' 36' ' ' VAL . 10.3 tt0 -90.07 158.66 17.21 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.764 -1.939 . . . . 0.0 105.764 175.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.482 ' C ' HD13 ' K' ' 17' ' ' LEU . 34.5 tttt -140.7 96.52 3.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 119.21 0.914 . . . . 0.0 110.825 178.623 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.885 HD22 ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -120.87 110.58 16.49 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.582 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.431 HG13 ' O ' ' K' ' 18' ' ' VAL . 7.7 p -114.5 114.25 46.08 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.12 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.564 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 28.7 m-85 -107.23 104.22 13.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.567 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 25.7 t80 -112.67 123.56 50.58 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.128 -178.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -151.87 139.12 19.32 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 118.72 -1.192 . . . . 0.0 114.126 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.419 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 94.2 mt-10 -79.59 109.46 14.0 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.523 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . 49.3 t0 -146.31 46.71 1.22 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -177.063 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.502 HG22 ' N ' ' K' ' 25' ' ' GLY . 10.9 p -98.65 161.41 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 175.692 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.502 ' N ' HG22 ' K' ' 24' ' ' VAL . . . 76.22 27.68 61.48 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.281 176.25 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.469 ' CB ' ' H ' ' J' ' 27' ' ' ASN . 24.9 t -83.9 -120.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.445 -0.902 . . . . 0.0 113.305 -175.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 26.7 t-20 -93.27 163.01 13.78 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 122.597 1.189 . . . . 0.0 113.493 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 68.7 mttm -41.97 -37.91 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 112.491 -2.14 . . . . 0.0 111.185 176.534 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.19 71.97 0.22 Allowed Glycine 0 CA--C 1.54 1.646 0 CA-C-N 115.744 -0.662 . . . . 0.0 114.253 -172.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.716 ' HB1' ' O ' ' J' ' 30' ' ' ALA . . . -82.02 173.2 12.4 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 18.0 tt -148.23 160.23 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.185 0 N-CA-C 116.17 1.915 . . . . 0.0 116.17 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.77 125.58 61.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 113.572 -1.649 . . . . 0.0 109.711 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.3 123.22 4.3 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.661 HD23 ' C ' ' K' ' 34' ' ' LEU . 2.3 tt -130.26 130.57 44.74 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-O 120.97 0.414 . . . . 0.0 110.496 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 5.6 mtp -124.84 130.17 51.86 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.248 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.59 HG22 ' O ' ' J' ' 36' ' ' VAL . 50.6 t -124.76 158.69 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.159 0.504 . . . . 0.0 110.667 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.442 ' N ' HG12 ' K' ' 36' ' ' VAL . . . -63.65 -103.08 0.01 OUTLIER Glycine 0 CA--C 1.53 0.997 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.32 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -135.89 -74.36 0.07 OUTLIER Glycine 0 CA--C 1.538 1.485 0 C-N-CA 121.472 -0.394 . . . . 0.0 113.249 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 120.715 0.293 . . . . 0.0 111.202 -178.835 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.615 0.245 . . . . 0.0 110.36 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.81 114.68 47.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.895 0.379 . . . . 0.0 110.615 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.576 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -147.16 105.77 3.81 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.211 179.814 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.484 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 79.2 m80 -151.49 166.94 29.56 Favored 'General case' 0 C--O 1.221 -0.429 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 38.6 tt0 -89.78 158.46 17.49 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.02 102.38 4.38 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.247 -0.581 . . . . 0.0 111.822 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.707 ' N ' HD23 ' L' ' 17' ' ' LEU . 0.1 OUTLIER -116.61 108.09 15.52 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 176.537 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -106.98 111.14 34.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.57 -179.2 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -105.56 101.07 10.61 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.567 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 30.9 t80 -125.71 131.67 52.53 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 121.203 0.525 . . . . 0.0 110.756 -178.357 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -140.29 157.15 46.01 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.147 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.439 ' C ' ' O ' ' L' ' 21' ' ' ALA . 80.2 tt0 -31.1 129.54 0.13 Allowed 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 122.029 0.918 . . . . 0.0 112.48 -174.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.434 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 66.9 t0 -109.84 47.34 0.95 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 113.496 -1.684 . . . . 0.0 112.986 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.48 ' CG2' HG21 ' K' ' 24' ' ' VAL . 3.1 m -63.02 -167.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.349 -178.465 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.54 27.83 9.13 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.219 -0.446 . . . . 0.0 113.616 -175.163 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 48.0 t -153.67 120.28 5.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.424 0.63 . . . . 0.0 109.935 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 p30 -40.7 167.0 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.135 0 CA-C-N 114.978 -1.01 . . . . 0.0 112.187 -178.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.523 ' NZ ' ' O ' ' K' ' 23' ' ' ASP . 63.9 tttp -80.22 -50.0 10.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.199 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.85 50.59 3.05 Favored Glycine 0 CA--C 1.543 1.84 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.707 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -130.57 -169.15 2.09 Favored 'General case' 0 C--N 1.341 0.224 0 CA-C-O 121.354 0.597 . . . . 0.0 110.597 -178.201 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -118.64 138.55 48.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.786 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -122.15 128.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.64 122.52 3.42 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 111.635 -0.586 . . . . 0.0 111.635 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 57.6 mt -117.99 125.42 50.36 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -132.81 127.65 35.0 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.619 HG22 ' N ' ' L' ' 37' ' ' GLY . 2.6 p -140.46 171.72 12.75 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.111 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.619 ' N ' HG22 ' L' ' 36' ' ' VAL . . . -168.12 94.49 0.11 Allowed Glycine 0 C--N 1.311 -0.852 0 C-N-CA 118.536 -1.792 . . . . 0.0 112.036 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.5 -81.41 0.11 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.747 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' K' ' 38' ' ' GLY . 38.8 t . . . . . 0 N--CA 1.463 0.217 0 CA-C-O 121.105 0.479 . . . . 0.0 110.359 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.464 0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' M' M ' 12' ' ' VAL . . . . . 0.485 ' CG1' ' H ' ' N' ' 12' ' ' VAL . 2.4 p -123.0 131.82 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.286 0.565 . . . . 0.0 110.101 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 13' ' ' HIS . . . . . 0.456 ' CG ' ' N ' ' M' ' 14' ' ' HIS . 76.4 t60 -72.65 164.08 27.05 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.309 -178.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.588 ' ND1' ' N ' ' M' ' 14' ' ' HIS . 1.2 m-70 -99.13 166.17 11.37 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -89.8 159.82 16.82 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.54 107.98 5.85 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.1 mt -129.76 114.92 16.56 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 121.098 0.475 . . . . 0.0 110.227 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 54.3 t -125.23 132.17 71.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.031 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 t80 -136.28 127.41 28.0 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.45 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -131.48 146.32 52.19 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.16 128.29 23.88 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 121.741 0.781 . . . . 0.0 112.743 -178.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -92.17 -149.25 0.24 Allowed 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -46.62 -60.08 2.61 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.613 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.618 HG12 ' N ' ' M' ' 25' ' ' GLY . 47.9 t -84.76 171.56 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 175.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 25' ' ' GLY . . . . . 0.618 ' N ' HG12 ' M' ' 24' ' ' VAL . . . 94.03 -29.98 8.1 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 176.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 7.3 p -84.23 139.98 31.99 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.146 -1.527 . . . . 0.0 113.575 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 -73.03 179.5 3.74 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 177.226 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CG ' ' N' ' 28' ' ' LYS . 98.4 mttt -49.77 -37.58 30.4 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 117.943 -1.503 . . . . 0.0 110.548 -175.601 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.05 -78.38 0.06 OUTLIER Glycine 0 CA--C 1.53 1.023 0 C-N-CA 118.89 -1.624 . . . . 0.0 113.777 174.64 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 30' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' N' ' 30' ' ' ALA . . . -147.35 81.63 1.53 Allowed 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 117.819 0.81 . . . . 0.0 112.942 178.75 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.639 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -123.34 105.39 15.69 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 32' ' ' ILE . . . . . 0.437 HG22 HD21 ' N' ' 34' ' ' LEU . 2.4 mt -119.11 111.87 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 C-N-CA 119.659 -0.816 . . . . 0.0 111.452 -178.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.41 105.61 1.16 Allowed Glycine 0 N--CA 1.46 0.258 0 N-CA-C 104.153 -3.579 . . . . 0.0 104.153 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 34' ' ' LEU . . . . . 0.412 ' HG ' ' N ' ' M' ' 35' ' ' MET . 45.6 tp -153.71 158.17 40.6 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.579 -173.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 35' ' ' MET . . . . . 0.412 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 0.7 OUTLIER -104.88 110.18 22.45 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 112.736 -2.029 . . . . 0.0 106.991 177.182 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.62 131.24 70.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.12 -111.17 3.89 Favored Glycine 0 C--N 1.318 -0.466 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.498 ' O ' HG23 ' N' ' 39' ' ' VAL . . . 75.12 -73.76 1.5 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.403 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 17.6 m -95.69 -176.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.175 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.463 HG12 ' NZ ' ' C' ' 28' ' ' LYS . 1.3 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.607 178.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' N' N ' 10' ' ' TYR . . . . . 0.487 ' CD1' ' O ' ' O' ' 9' ' ' GLY . 97.9 m-85 -108.0 139.7 42.25 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.26 124.14 51.8 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.957 0.408 . . . . 0.0 111.023 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.485 ' H ' ' CG1' ' M' ' 12' ' ' VAL . 3.4 t -137.88 97.14 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.745 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.519 ' ND1' ' ND1' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -151.5 151.07 31.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 121.108 -0.237 . . . . 0.0 110.675 179.524 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -124.79 162.58 23.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.047 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -89.88 158.79 17.28 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 16' ' ' LYS . . . . . 0.748 ' C ' HD12 ' N' ' 17' ' ' LEU . 98.8 mttt -140.53 99.94 3.75 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.748 HD12 ' C ' ' N' ' 16' ' ' LYS . 10.9 mp -124.04 119.3 29.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -123.01 128.34 75.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.648 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -123.76 123.95 41.64 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.897 179.149 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -129.18 123.14 31.31 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.805 0.336 . . . . 0.0 110.283 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 132.22 50.38 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.424 ' O ' ' CB ' ' N' ' 23' ' ' ASP . 83.1 tt0 -157.38 151.46 24.65 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.424 ' CB ' ' O ' ' N' ' 22' ' ' GLU . 9.5 m-20 92.29 46.92 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 113.603 -1.635 . . . . 0.0 115.185 176.452 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 24.2 m -101.52 158.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 -37.5 94.76 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.582 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.579 ' O ' ' O ' ' N' ' 27' ' ' ASN . 86.4 p -162.47 117.17 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 117.093 -1.432 . . . . 0.0 107.165 177.001 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.579 ' O ' ' O ' ' N' ' 26' ' ' SER . 11.6 t-20 -23.45 151.2 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 120.332 1.424 . . . . 0.0 111.908 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.491 ' O ' HG23 ' G' ' 39' ' ' VAL . 73.8 mmtt -107.83 47.87 0.87 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 115.999 -1.953 . . . . 0.0 115.264 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 61.8 0.52 Allowed Glycine 0 N--CA 1.489 2.202 0 CA-C-N 124.083 3.129 . . . . 0.0 114.067 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 30' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' M' ' 30' ' ' ALA . . . -88.31 98.95 11.88 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 121.076 2.438 . . . . 0.0 111.476 -174.38 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.455 HG23 ' O ' ' N' ' 31' ' ' ILE . 18.9 tt -134.61 129.33 52.12 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-N 110.856 -2.884 . . . . 0.0 110.2 -177.558 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.57 HD13 ' CD1' ' P' ' 19' ' ' PHE . 95.8 mt -113.04 110.87 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.78 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.544 ' O ' HD22 ' N' ' 34' ' ' LEU . . . -111.25 93.51 0.72 Allowed Glycine 0 N--CA 1.467 0.722 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 175.646 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.544 HD22 ' O ' ' N' ' 33' ' ' GLY . 1.3 mm? -125.12 133.32 52.89 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.018 1.39 . . . . 0.0 112.269 -174.41 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 2.7 mtp -103.55 106.06 16.47 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 176.624 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 1.008 HG21 HD11 ' P' ' 17' ' ' LEU . 2.5 p -127.9 123.11 60.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.246 -178.219 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 149.63 -113.2 0.59 Allowed Glycine 0 C--N 1.311 -0.818 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.473 ' O ' HG23 ' O' ' 39' ' ' VAL . . . 70.48 -72.58 0.62 Allowed Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.505 HG12 ' N ' ' N' ' 40' ' ' VAL . 45.1 t -123.36 163.96 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 178.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.505 ' N ' HG12 ' N' ' 39' ' ' VAL . 18.6 m . . . . . 0 N--CA 1.471 0.579 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.715 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 9' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' N' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -114.28 147.19 39.42 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.711 0.291 . . . . 0.0 110.293 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -87.49 109.88 19.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.09 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.479 HG13 ' C ' ' P' ' 12' ' ' VAL . 51.5 t -129.62 123.86 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.505 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.598 ' CE1' ' NZ ' ' A' ' 28' ' ' LYS . 7.3 m-70 -137.57 150.42 47.46 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.598 ' CD2' ' CE1' ' P' ' 14' ' ' HIS . 4.7 m80 -136.86 157.45 46.73 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.169 178.33 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -86.3 157.46 19.91 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 175.109 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -160.25 101.76 1.4 Allowed 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.255 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 3.2 mt -132.47 122.73 25.37 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.335 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 89.2 t -113.56 113.27 43.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.941 178.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -108.4 102.54 11.63 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.393 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -113.33 125.03 53.83 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -177.637 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.15 125.91 40.05 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -124.51 178.93 5.16 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 52.44 58.94 4.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 113.19 -1.823 . . . . 0.0 112.05 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.684 HG11 HG13 ' P' ' 24' ' ' VAL . 63.2 t -78.25 123.0 34.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.911 -1.041 . . . . 0.0 109.214 175.48 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.512 ' H ' ' HA ' ' N' ' 26' ' ' SER . . . -90.49 -38.54 6.21 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.577 -177.472 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' O' ' 27' ' ' ASN . 46.8 t -161.97 116.51 1.91 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 118.454 1.127 . . . . 0.0 111.907 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' O' ' 26' ' ' SER . 57.2 p30 -24.12 163.73 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.358 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -152.16 -22.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.943 178.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.2 97.32 2.43 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.19 140.94 29.12 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-O 121.776 0.798 . . . . 0.0 111.974 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.43 HD12 HG22 ' I' ' 39' ' ' VAL . 14.9 mt -143.41 135.77 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.19 -0.914 . . . . 0.0 113.064 -179.242 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.594 HD13 ' CD2' ' Q' ' 19' ' ' PHE . 82.3 mt -114.38 112.08 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 176.076 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.01 109.48 2.34 Favored Glycine 0 C--O 1.24 0.505 0 N-CA-C 105.575 -3.01 . . . . 0.0 105.575 176.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.437 ' CD2' HG12 ' N' ' 36' ' ' VAL . 0.2 OUTLIER -144.91 142.34 29.79 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 123.019 1.39 . . . . 0.0 114.038 -175.263 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 94.8 mmm -103.75 110.57 22.72 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 112.133 -2.303 . . . . 0.0 105.366 176.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.497 HG12 ' NE2' ' Q' ' 15' ' ' GLN . 47.1 t -117.93 123.12 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-O 120.823 0.344 . . . . 0.0 110.087 -177.101 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.38 -113.24 0.63 Allowed Glycine 0 C--N 1.32 -0.339 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.494 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . 87.5 -73.12 2.42 Favored Glycine 0 CA--C 1.541 1.677 0 CA-C-O 119.93 -0.372 . . . . 0.0 112.649 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.708 ' C ' HG11 ' P' ' 39' ' ' VAL . 45.2 t -134.51 161.04 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.539 ' N ' HG21 ' P' ' 39' ' ' VAL . 6.3 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.315 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.541 ' O ' ' NE2' ' O' ' 14' ' ' HIS . 2.8 m . . . . . 0 N--CA 1.467 0.413 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.48 ' NE2' ' C ' ' N' ' 40' ' ' VAL . 8.2 t60 -90.7 120.79 32.05 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.344 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' CD2' ' O' ' 14' ' ' HIS . 11.6 p-80 -152.97 161.82 42.08 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.659 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -90.23 158.77 17.04 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.646 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -140.94 105.27 4.84 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 1.008 HD11 HG21 ' N' ' 36' ' ' VAL . 31.2 mt -122.7 123.18 40.53 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 120.314 -0.554 . . . . 0.0 110.433 178.856 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 18' ' ' VAL . . . . . 0.413 HG13 ' CG2' ' Q' ' 18' ' ' VAL . 2.2 t -114.51 106.51 20.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.63 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' N' ' 32' ' ' ILE . 57.3 m-85 -106.76 111.52 24.09 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -133.7 130.39 38.09 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.456 1.28 . . . . 0.0 114.456 -176.262 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.54 125.16 37.75 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.838 177.395 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -111.74 150.81 29.72 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 115.764 1.764 . . . . 0.0 115.764 -175.23 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.536 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 83.6 m-20 63.38 46.56 4.33 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 117.685 2.476 . . . . 0.0 117.685 173.939 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.691 HG12 ' H ' ' P' ' 25' ' ' GLY . 8.7 t -100.44 -179.44 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 115.556 -2.458 . . . . 0.0 109.523 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.691 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -72.6 -30.65 63.88 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 121.195 -0.526 . . . . 0.0 113.469 176.073 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.5 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 9.7 t 100.72 111.33 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 -174.217 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.503 ' CG ' ' N ' ' P' ' 28' ' ' LYS . 22.8 t-20 -71.31 173.47 7.75 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 117.459 -1.697 . . . . 0.0 112.724 -176.622 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.503 ' N ' ' CG ' ' P' ' 27' ' ' ASN . 88.7 tttt -52.45 -36.78 55.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.43 177.363 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.52 77.18 0.06 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.661 -177.095 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.83 154.11 2.22 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 118.307 1.053 . . . . 0.0 110.44 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.961 HD11 HG22 ' J' ' 39' ' ' VAL . 69.4 mt -121.22 131.23 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 73.7 mt -114.33 110.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.04 109.21 2.74 Favored Glycine 0 N--CA 1.463 0.497 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.51 ' CD1' ' CE1' ' R' ' 19' ' ' PHE . 95.4 mt -135.0 133.48 39.49 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.445 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 4.0 mtp -107.62 104.02 13.46 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 174.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.76 103.07 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.32 -153.11 24.62 Favored Glycine 0 C--N 1.31 -0.892 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.95 -56.68 0.6 Allowed Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -178.1 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.708 HG11 ' C ' ' O' ' 39' ' ' VAL . 11.5 p -124.36 154.99 31.91 Favored 'Isoleucine or valine' 0 C--O 1.231 0.085 0 C-N-CA 122.66 0.384 . . . . 0.0 110.054 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.461 HG23 ' H ' ' P' ' 40' ' ' VAL . 1.9 t . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 118.067 -0.968 . . . . 0.0 111.028 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -119.73 120.71 37.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.82 154.01 43.77 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.043 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.566 HG12 ' H ' ' R' ' 12' ' ' VAL . 12.7 m -133.0 120.11 39.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 121.625 0.726 . . . . 0.0 111.84 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.444 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 4.0 m-70 -90.1 110.73 21.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.233 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.527 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 2.3 t-80 -119.37 159.62 23.84 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.497 ' NE2' HG12 ' O' ' 36' ' ' VAL . 9.6 tt0 -86.24 157.84 19.85 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . 0.766 ' O ' HD23 ' Q' ' 17' ' ' LEU . 76.5 tttt -160.04 94.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.539 177.882 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.766 HD23 ' O ' ' Q' ' 16' ' ' LYS . 1.7 mt -131.56 127.15 36.58 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . 0.413 ' CG2' HG13 ' P' ' 18' ' ' VAL . 28.1 m -117.45 122.11 69.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 178.499 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.594 ' CD2' HD13 ' O' ' 32' ' ' ILE . 22.0 m-85 -112.63 105.37 13.53 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -127.32 137.02 52.71 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.644 0.735 . . . . 0.0 112.686 -177.036 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -146.74 145.04 29.82 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 119.78 -0.768 . . . . 0.0 113.03 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.536 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 82.8 mt-10 -79.27 149.66 31.76 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.528 ' OD1' ' HB1' ' R' ' 21' ' ' ALA . 6.9 p-10 -168.14 47.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -176.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.45 HG12 ' H ' ' Q' ' 25' ' ' GLY . 5.7 t -71.58 170.02 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.105 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.239 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.45 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 80.75 26.7 53.16 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 104.537 -3.425 . . . . 0.0 104.537 -175.71 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 24.0 p -80.85 116.5 20.86 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 117.047 2.24 . . . . 0.0 117.047 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -90.22 -152.16 0.26 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 111.286 -2.688 . . . . 0.0 104.947 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -48.56 -41.03 29.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 119.695 1.134 . . . . 0.0 108.333 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.44 -63.95 0.6 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 117.064 1.586 . . . . 0.0 117.064 173.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.16 165.21 32.07 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 120.108 1.954 . . . . 0.0 115.057 -176.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 69.2 mt -125.35 127.55 72.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 CA-C-N 111.321 -2.672 . . . . 0.0 106.786 178.099 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 tt -134.79 133.33 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 121.781 0.801 . . . . 0.0 112.698 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.4 109.93 2.16 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 107.764 -2.134 . . . . 0.0 107.764 177.2 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.414 HD23 HD13 ' R' ' 34' ' ' LEU . 18.5 tp -116.63 119.04 34.26 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.22 137.45 52.03 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.934 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 21.4 t -111.19 131.9 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.067 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.29 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . -45.62 -111.7 0.0 OUTLIER Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.322 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . -101.48 -71.5 0.93 Allowed Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.413 ' HB ' HD11 ' E' ' 31' ' ' ILE . 69.3 t -109.08 129.86 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.275 0.538 . . . . 0.0 109.862 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.838 -179.397 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.61 132.53 51.65 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -72.34 142.81 48.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.566 ' H ' HG12 ' Q' ' 12' ' ' VAL . 5.4 m -121.13 131.96 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-O 121.901 0.858 . . . . 0.0 112.01 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 4.1 m80 -133.47 124.96 27.97 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 114.448 -1.251 . . . . 0.0 108.92 178.435 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 99.2 m-70 -149.28 172.04 15.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.809 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.516 ' OE1' ' N ' ' R' ' 15' ' ' GLN . 14.0 mp0 -89.42 150.33 22.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.614 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.767 ' C ' HD12 ' R' ' 17' ' ' LEU . 74.1 tttt -150.17 98.78 2.73 Favored 'General case' 0 C--N 1.311 -1.066 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 178.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.767 HD12 ' C ' ' R' ' 16' ' ' LYS . 9.7 mp -127.05 124.58 39.64 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.625 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 66.5 t -106.62 114.66 46.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD1' ' P' ' 34' ' ' LEU . 17.1 m-85 -106.59 105.81 16.02 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' N ' ' R' ' 21' ' ' ALA . 66.2 t80 -146.9 156.76 43.33 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 122.463 1.125 . . . . 0.0 113.261 -177.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.528 ' HB1' ' OD1' ' Q' ' 23' ' ' ASP . . . -150.02 148.24 28.8 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.878 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.443 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 83.4 tt0 -76.49 112.54 13.13 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.56 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.484 ' OD1' ' N ' ' R' ' 23' ' ' ASP . 19.5 p-10 -177.23 48.92 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.642 -177.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -72.11 160.49 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 118.605 -1.238 . . . . 0.0 108.879 -178.592 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.35 -34.83 5.18 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 107.286 -2.326 . . . . 0.0 107.286 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.425 ' OG ' ' O ' ' R' ' 23' ' ' ASP . 11.9 p -80.53 119.98 23.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 113.193 -1.504 . . . . 0.0 109.852 179.082 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' R' ' 29' ' ' GLY . 89.9 m-20 -87.72 -175.17 5.07 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.091 -178.067 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -49.52 49.64 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.7 51.49 0.92 Allowed Glycine 0 CA--C 1.546 1.972 0 CA-C-N 118.776 0.717 . . . . 0.0 112.333 178.539 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.17 172.94 11.24 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.2 mt -113.35 120.4 63.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -125.01 127.97 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.935 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.19 116.68 3.01 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 178.426 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.414 HD13 HD23 ' Q' ' 34' ' ' LEU . 40.4 tp -124.1 122.51 38.04 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.6 mtp -139.72 147.34 40.76 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.173 0.511 . . . . 0.0 112.279 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.401 HG22 ' N ' ' R' ' 37' ' ' GLY . 2.9 p -130.15 155.27 41.46 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.075 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.5 179.177 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.401 ' N ' HG22 ' R' ' 36' ' ' VAL . . . -102.99 102.75 2.29 Favored Glycine 0 CA--C 1.523 0.582 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.95 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.97 -76.17 0.73 Allowed Glycine 0 CA--C 1.535 1.329 0 N-CA-C 115.241 0.857 . . . . 0.0 115.241 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.485 ' O ' ' O ' ' Q' ' 38' ' ' GLY . 54.0 t -122.7 139.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 117.916 0.858 . . . . 0.0 112.708 -177.033 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.987 179.214 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.439 ' CD ' ' NE2' ' A' ' 13' ' ' HIS . 80.8 tt0 . . . . . 0 N--CA 1.465 0.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 51.8 t -120.16 129.51 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.619 0.723 . . . . 0.0 111.098 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.439 ' NE2' ' CD ' ' A' ' 11' ' ' GLU . 98.2 m-70 -126.04 166.16 17.48 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.713 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 53.0 p-80 -82.92 167.31 18.13 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.238 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -157.87 142.92 16.71 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.611 178.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -81.51 127.98 33.41 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.116 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.2 mt -125.48 114.49 18.87 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -127.55 131.49 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.176 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -134.55 130.79 37.1 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.148 0.499 . . . . 0.0 111.702 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -113.9 123.02 48.76 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.034 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.02 129.46 46.74 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.155 0.502 . . . . 0.0 111.656 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -92.99 -176.28 4.14 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 t0 . . . . . 0 C--N 1.324 -0.501 0 CA-C-O 121.402 0.62 . . . . 0.0 109.629 179.296 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 . . . . . 0 N--CA 1.471 0.595 0 N-CA-C 115.862 1.801 . . . . 0.0 115.862 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -42.89 -36.25 1.45 Allowed 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 112.369 -2.196 . . . . 0.0 113.261 171.574 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -102.39 87.75 0.63 Allowed Glycine 0 CA--C 1.526 0.761 0 CA-C-N 113.051 -1.886 . . . . 0.0 117.335 -168.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.52 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -96.27 128.66 43.39 Favored 'General case' 0 CA--C 1.551 1.01 0 CA-C-O 124.975 2.321 . . . . 0.0 110.403 -177.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -145.59 160.23 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 CA-C-N 110.546 -3.024 . . . . 0.0 111.329 -175.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 52.0 mt -104.43 109.46 27.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 175.638 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.13 94.88 0.69 Allowed Glycine 0 CA--C 1.508 -0.39 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 178.576 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.489 ' O ' HD12 ' B' ' 34' ' ' LEU . 89.4 mt -144.26 154.63 43.28 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 122.881 1.324 . . . . 0.0 113.43 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 6.1 ttm -114.48 114.95 26.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 112.466 -2.152 . . . . 0.0 107.431 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.4 HG11 HD11 ' C' ' 17' ' ' LEU . 0.0 OUTLIER -129.26 102.84 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.807 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.1 -151.75 20.83 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 109.299 -1.521 . . . . 0.0 109.299 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.61 ' O ' HG11 ' B' ' 39' ' ' VAL . . . 117.24 -56.33 0.54 Allowed Glycine 0 CA--C 1.543 1.797 0 C-N-CA 121.534 -0.365 . . . . 0.0 112.713 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.764 ' C ' HG21 ' B' ' 39' ' ' VAL . 7.2 p -133.1 177.47 7.09 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.672 ' H ' HG22 ' A' ' 39' ' ' VAL . 6.0 m . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 117.901 -1.047 . . . . 0.0 111.965 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -84.23 138.02 33.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.76 0.314 . . . . 0.0 110.322 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -106.35 125.77 51.41 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.988 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.52 HG11 ' CE1' ' C' ' 13' ' ' HIS . 54.1 t -122.35 130.03 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.725 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m80 -117.42 157.6 25.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.609 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.605 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 52.9 t60 -80.72 166.86 20.63 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.111 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.559 ' O ' ' CE1' ' B' ' 14' ' ' HIS . 29.6 pt20 -129.29 151.08 50.34 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.15 0.5 . . . . 0.0 110.334 179.454 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -96.9 120.88 38.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.144 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.434 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.3 tt -116.76 115.56 25.84 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.8 t -121.34 128.68 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.205 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.248 -179.435 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -129.63 117.48 20.44 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.662 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 32.4 t80 -112.57 122.42 47.63 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.04 116.11 26.22 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.929 0.871 . . . . 0.0 112.394 -178.504 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -95.98 135.35 37.85 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.518 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -150.65 51.27 0.87 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.356 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.23 151.27 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 C-N-CA 118.486 -1.285 . . . . 0.0 110.21 -177.54 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.52 -32.4 6.64 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 106.166 -2.774 . . . . 0.0 106.166 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.539 ' HB3' ' N ' ' C' ' 26' ' ' SER . 0.5 OUTLIER 71.5 106.09 0.06 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 112.732 -1.734 . . . . 0.0 112.262 176.045 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.598 ' N ' ' OG ' ' C' ' 26' ' ' SER . 43.8 m-80 -101.63 163.36 12.3 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 119.217 -0.993 . . . . 0.0 112.815 177.318 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.49 ' O ' ' O ' ' C' ' 27' ' ' ASN . 99.7 mttt -41.45 -39.2 1.44 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 119.739 3.237 . . . . 0.0 119.739 178.652 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -110.72 69.7 0.21 Allowed Glycine 0 N--CA 1.497 2.713 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 -170.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.417 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -97.47 102.33 14.07 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 120.527 2.164 . . . . 0.0 111.978 178.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 7.0 pt -147.49 153.03 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.125 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' D' ' 19' ' ' PHE . 88.9 mt -107.44 114.09 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.53 106.09 1.93 Allowed Glycine 0 N--CA 1.464 0.504 0 N-CA-C 106.256 -2.738 . . . . 0.0 106.256 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.489 HD12 ' O ' ' A' ' 34' ' ' LEU . 10.5 tp -141.76 142.4 33.24 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.653 -1.219 . . . . 0.0 114.249 -175.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -116.67 110.94 19.13 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.359 177.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' C' ' 36' ' ' VAL . 0.4 OUTLIER -132.75 102.94 5.57 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.596 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 -179.299 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.51 -151.85 21.21 Favored Glycine 0 C--N 1.306 -1.088 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.407 ' C ' HG12 ' C' ' 39' ' ' VAL . . . 100.21 -57.05 0.8 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -178.718 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.764 HG21 ' C ' ' A' ' 39' ' ' VAL . 12.8 m -123.47 174.14 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 C-N-CA 123.826 0.851 . . . . 0.0 110.073 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.411 ' C ' ' O ' ' B' ' 39' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.572 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -83.23 139.53 33.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.291 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -81.6 118.94 23.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.407 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 53.4 t -130.31 133.75 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.137 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.618 ' CE1' ' HZ3' ' H' ' 28' ' ' LYS . 0.2 OUTLIER -139.13 100.8 4.11 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 121.218 -0.193 . . . . 0.0 111.134 179.205 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.605 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 13.6 m170 -117.19 160.5 20.95 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -86.41 155.54 20.54 Favored 'General case' 0 N--CA 1.457 -0.108 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.413 ' CB ' ' NE2' ' B' ' 14' ' ' HIS . 85.4 tttt -161.18 94.66 1.01 Allowed 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.186 176.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.4 HD11 HG11 ' A' ' 36' ' ' VAL . 20.8 mt -121.71 117.85 27.65 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.887 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 4.8 t -105.69 110.17 30.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -108.92 105.84 15.55 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.57 122.8 47.05 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.459 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.73 146.45 37.78 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -81.04 108.66 14.9 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.693 178.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.565 ' CG ' ' HB1' ' D' ' 21' ' ' ALA . 82.0 m-20 -105.28 51.93 0.75 Allowed 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 113.507 -1.679 . . . . 0.0 110.238 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.0 t -71.34 -133.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 114.933 -1.031 . . . . 0.0 108.455 -174.689 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.46 38.07 3.38 Favored Glycine 0 N--CA 1.468 0.823 0 CA-C-O 124.111 1.95 . . . . 0.0 109.973 -169.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.598 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 1.2 m -72.29 102.9 3.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 108.651 -3.775 . . . . 0.0 102.243 171.037 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' B' ' 28' ' ' LYS . 88.2 m-20 -108.21 -170.14 1.63 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -171.08 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.426 ' O ' ' O ' ' N' ' 40' ' ' VAL . 98.6 mttt 32.36 41.27 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 113.668 -1.606 . . . . 0.0 111.12 -172.234 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . -176.72 61.1 0.1 OUTLIER Glycine 0 CA--C 1.546 1.976 0 CA-C-N 114.809 -1.087 . . . . 0.0 111.715 172.416 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.28 95.33 5.55 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 118.713 1.256 . . . . 0.0 110.505 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.705 HD13 HG22 ' O' ' 39' ' ' VAL . 2.0 tt -164.41 153.48 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 C-N-CA 115.164 -2.615 . . . . 0.0 116.353 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.422 HD13 ' CD1' ' E' ' 19' ' ' PHE . 93.0 mt -112.73 112.34 40.01 Favored 'Isoleucine or valine' 0 C--N 1.35 0.601 0 CA-C-N 114.31 -1.314 . . . . 0.0 108.9 177.272 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.29 112.21 3.66 Favored Glycine 0 N--CA 1.464 0.554 0 N-CA-C 105.013 -3.235 . . . . 0.0 105.013 176.147 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 tt -148.05 146.3 28.81 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 117.619 -1.633 . . . . 0.0 114.474 -173.286 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 9.0 mtp -121.94 113.15 19.21 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.709 HG21 HD21 ' E' ' 17' ' ' LEU . 3.1 p -139.88 103.06 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.837 -177.26 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.06 -155.27 26.43 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 119.848 -1.168 . . . . 0.0 112.282 177.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 61.1 54.73 34.26 Favored Glycine 0 CA--C 1.544 1.862 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.574 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.456 ' O ' ' O ' ' C' ' 40' ' ' VAL . 2.6 m -156.2 -168.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.341 0.23 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.519 HG13 ' O ' ' I' ' 28' ' ' LYS . 88.3 t . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.991 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.469 0.496 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.527 ' CD2' ' HB2' ' C' ' 13' ' ' HIS . 19.9 m80 -134.82 107.43 7.39 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.593 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.593 ' ND1' ' O ' ' E' ' 14' ' ' HIS . 59.9 t60 -132.57 157.86 43.66 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.723 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.558 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 43.2 tt0 -85.82 157.38 20.23 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -160.09 100.15 1.38 Allowed 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.237 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 29.6 mt -123.5 115.02 20.86 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 178.122 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.9 109.1 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 59.9 m-85 -107.8 104.02 13.42 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.612 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 47.4 t80 -113.47 125.74 54.56 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.565 ' HB1' ' CG ' ' C' ' 23' ' ' ASP . . . -135.94 135.06 39.3 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 122.712 1.244 . . . . 0.0 113.242 -178.251 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -84.4 113.5 21.22 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.022 -1.444 . . . . 0.0 108.963 179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.635 ' OD2' ' HB1' ' E' ' 21' ' ' ALA . 5.7 p-10 -146.44 48.57 1.18 Allowed 'General case' 0 CA--C 1.516 -0.365 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.457 ' H ' HG12 ' D' ' 24' ' ' VAL . 0.6 OUTLIER -72.58 160.79 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 177.486 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.38 -28.4 10.97 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' E' ' 26' ' ' SER . 7.7 t 74.6 119.6 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 114.268 -0.966 . . . . 0.0 110.264 -178.25 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -83.29 163.25 20.81 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 120.078 -0.649 . . . . 0.0 111.278 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -46.98 -37.0 8.39 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 178.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.74 77.55 0.07 OUTLIER Glycine 0 CA--C 1.538 1.501 0 C-N-CA 120.497 -0.859 . . . . 0.0 113.085 -175.003 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.71 137.64 37.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 118.698 1.249 . . . . 0.0 111.082 -178.126 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.532 HD13 ' HB ' ' P' ' 39' ' ' VAL . 31.5 mt -127.34 138.65 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 CA-C-N 114.793 -1.094 . . . . 0.0 113.36 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' F' ' 19' ' ' PHE . 67.2 mt -115.28 120.7 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 175.005 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.39 119.51 2.11 Favored Glycine 0 N--CA 1.467 0.731 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.705 ' N ' HD23 ' D' ' 34' ' ' LEU . 1.9 pt? -165.62 162.53 18.99 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 117.75 -1.58 . . . . 0.0 114.987 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 50.6 tpp -101.43 111.65 23.94 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 112.163 -2.289 . . . . 0.0 106.907 176.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.759 HG11 HD23 ' F' ' 17' ' ' LEU . 55.7 t -118.47 102.57 13.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 121.265 -0.174 . . . . 0.0 110.78 -178.8 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.03 -161.86 16.34 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.69 -55.34 0.5 Allowed Glycine 0 CA--C 1.539 1.578 0 CA-C-O 119.316 -0.713 . . . . 0.0 112.453 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.65 HG21 ' CD1' ' J' ' 31' ' ' ILE . 33.8 m -136.61 152.8 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.555 0 CA-C-N 118.776 1.288 . . . . 0.0 110.867 178.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.593 ' H ' ' CD1' ' K' ' 31' ' ' ILE . 60.7 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.485 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -106.97 135.75 48.0 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.839 0.352 . . . . 0.0 110.353 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -76.53 106.37 8.14 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.713 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 m -139.78 156.43 25.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.162 0.506 . . . . 0.0 110.938 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.412 ' C ' ' CD2' ' E' ' 14' ' ' HIS . 21.7 m-70 -148.27 117.57 6.9 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.141 178.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.593 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 13.3 m-70 -141.28 162.41 35.54 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 110.923 179.047 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.421 ' OE1' ' OE1' ' F' ' 15' ' ' GLN . 78.7 mt-30 -85.32 157.27 20.6 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 176.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -159.53 104.3 1.61 Allowed 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.322 0.582 . . . . 0.0 109.461 178.178 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.709 HD21 HG21 ' C' ' 36' ' ' VAL . 2.3 mt -125.07 116.8 22.67 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.773 -179.51 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -107.48 101.85 13.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 74.1 m-85 -103.45 101.22 11.11 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 178.002 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.612 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 24.5 t80 -116.2 128.65 55.79 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.474 0.178 . . . . 0.0 111.156 -177.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.635 ' HB1' ' OD2' ' D' ' 23' ' ' ASP . . . -141.31 139.57 33.64 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.52 0.676 . . . . 0.0 112.755 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.567 ' HB2' ' H ' ' D' ' 23' ' ' ASP . 97.7 mt-10 -79.28 155.05 28.69 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.341 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' F' ' 23' ' ' ASP . 2.4 t70 -169.62 48.56 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.286 -1.366 . . . . 0.0 113.418 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 1.8 t -72.28 161.61 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 119.179 -1.008 . . . . 0.0 108.598 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.68 -28.65 10.38 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -176.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.526 ' O ' ' CB ' ' E' ' 27' ' ' ASN . 1.6 m 80.56 -114.71 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 113.644 -1.278 . . . . 0.0 112.232 -179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.526 ' CB ' ' O ' ' E' ' 26' ' ' SER . 4.2 t-20 89.24 179.9 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -48.33 -38.43 19.05 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' E' ' 30' ' ' ALA . . . 99.85 -68.22 0.55 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-N 114.297 -1.32 . . . . 0.0 114.781 176.456 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.963 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . 179.91 171.0 1.13 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 119.044 1.422 . . . . 0.0 112.688 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 98.6 mt -131.85 128.36 59.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 113.976 -1.465 . . . . 0.0 108.587 177.309 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.472 ' CG2' HD21 ' E' ' 34' ' ' LEU . 52.1 mt -123.93 124.91 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.133 0.492 . . . . 0.0 111.822 -177.439 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 110.92 2.34 Favored Glycine 0 N--CA 1.47 0.96 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.472 HD21 ' CG2' ' E' ' 32' ' ' ILE . 21.8 mt -118.17 114.31 22.86 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -177.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 78.4 mmm -105.8 116.17 31.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 177.095 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.67 HG12 ' N ' ' E' ' 37' ' ' GLY . 61.7 t -128.44 170.85 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.701 0.762 . . . . 0.0 112.365 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.67 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -168.26 94.28 0.11 Allowed Glycine 0 C--N 1.308 -1.021 0 N-CA-C 108.164 -1.975 . . . . 0.0 108.164 176.488 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.33 -73.15 0.42 Allowed Glycine 0 CA--C 1.54 1.626 0 CA-C-N 117.287 0.543 . . . . 0.0 112.927 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.773 HG13 HD11 ' K' ' 31' ' ' ILE . 76.2 t . . . . . 0 N--CA 1.437 -1.081 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.555 0.217 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.516 HG13 ' NE2' ' E' ' 14' ' ' HIS . 8.0 p -141.32 138.2 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.403 0.621 . . . . 0.0 110.948 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.406 ' HA ' ' CE1' ' E' ' 14' ' ' HIS . 4.6 m80 -140.98 133.57 28.61 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.121 -178.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.583 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 45.7 m80 -148.54 164.74 33.32 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.02 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.448 ' NE2' ' H ' ' F' ' 16' ' ' LYS . 70.9 tp60 -89.8 151.46 21.78 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.69 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 16' ' ' LYS . . . . . 0.448 ' H ' ' NE2' ' F' ' 15' ' ' GLN . 99.1 mttt -152.89 100.08 2.48 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.559 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.759 HD23 HG11 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -121.6 118.98 30.57 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 177.209 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.69 106.07 19.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.719 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.572 ' CD1' HD13 ' D' ' 32' ' ' ILE . 55.7 m-85 -104.32 103.59 13.36 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -117.24 109.82 17.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.223 0.535 . . . . 0.0 110.513 -178.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.96 117.98 28.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 177.252 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -90.33 112.08 23.53 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 119.222 -0.991 . . . . 0.0 113.583 -176.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' E' ' 23' ' ' ASP . 1.1 m-20 . . . . . 0 C--N 1.351 0.648 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.935 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.963 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.54 0.589 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mm -105.05 131.52 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.44 HG23 ' O ' ' F' ' 32' ' ' ILE . 19.6 tt -137.7 129.5 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.979 0.419 . . . . 0.0 111.627 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.66 123.11 5.13 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 mt -116.59 120.31 38.28 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -123.69 130.11 52.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.538 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 29.5 m -115.96 158.38 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.08 -103.03 0.01 OUTLIER Glycine 0 CA--C 1.524 0.616 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.961 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.42 -76.66 0.5 Allowed Glycine 0 CA--C 1.534 1.231 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.425 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.47 ' O ' ' CD1' ' L' ' 31' ' ' ILE . 58.6 t -126.91 131.8 70.63 Favored 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-N 117.338 0.569 . . . . 0.0 110.343 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.449 HG22 ' H ' ' F' ' 40' ' ' VAL . 10.9 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.861 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.465 0.303 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -133.84 112.42 11.3 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.691 0.282 . . . . 0.0 110.913 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.436 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 47.9 p-80 -152.92 168.73 24.81 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.292 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 69.1 tp60 -158.22 142.46 15.88 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.654 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -81.86 126.63 32.12 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.033 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.58 ' C ' HD23 ' G' ' 17' ' ' LEU . 6.5 tt -134.43 119.58 18.73 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.658 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.505 ' N ' HD23 ' G' ' 17' ' ' LEU . 12.6 m -132.82 135.81 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.355 -179.325 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -127.24 126.46 42.75 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.807 178.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' H' ' 20' ' ' PHE . 43.5 t80 -128.94 127.45 41.77 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.682 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.69 119.67 21.69 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 121.303 0.573 . . . . 0.0 110.977 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -92.57 124.6 36.71 Favored 'General case' 0 C--N 1.342 0.27 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.596 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.528 ' H ' ' HB3' ' H' ' 22' ' ' GLU . 67.0 t0 . . . . . 0 N--CA 1.474 0.748 0 C-N-CA 124.809 1.244 . . . . 0.0 113.086 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 121.526 0.679 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -54.61 -38.51 66.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.59 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.24 70.96 0.2 Allowed Glycine 0 CA--C 1.537 1.423 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.171 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.25 116.94 29.43 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 123.988 1.851 . . . . 0.0 112.69 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.485 ' CD1' ' O ' ' A' ' 38' ' ' GLY . 14.8 pt -146.95 149.21 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 111.993 -2.367 . . . . 0.0 109.904 -179.28 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.418 HD13 HG21 ' G' ' 32' ' ' ILE . 55.0 mt -105.05 112.0 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.587 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.12 96.05 0.74 Allowed Glycine 0 N--CA 1.467 0.735 0 N-CA-C 107.264 -2.334 . . . . 0.0 107.264 178.362 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 78.3 mt -144.07 156.27 44.3 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 122.972 1.367 . . . . 0.0 113.848 -177.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' CG ' ' H' ' 35' ' ' MET . 44.1 tpp -103.57 111.16 23.5 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 112.166 -2.288 . . . . 0.0 106.315 176.318 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.444 HG12 HE21 ' J' ' 15' ' ' GLN . 3.5 t -131.54 111.78 19.7 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.432 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 127.99 -132.07 7.26 Favored Glycine 0 C--N 1.315 -0.623 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.418 ' O ' HG12 ' H' ' 39' ' ' VAL . . . 87.49 -63.67 3.87 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.093 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 m -102.57 169.15 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-O 120.95 0.405 . . . . 0.0 110.844 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.507 ' OXT' ' NE2' ' J' ' 13' ' ' HIS . 9.7 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.264 179.184 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -107.86 133.27 52.46 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.814 0.34 . . . . 0.0 110.179 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.62 128.6 22.01 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.225 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -122.99 131.34 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.805 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -132.4 105.77 7.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.811 0.339 . . . . 0.0 111.6 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.673 ' CD2' ' H ' ' H' ' 15' ' ' GLN . 1.1 t-80 -155.6 169.13 25.01 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.702 178.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.673 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 14.1 pt20 -157.45 142.19 16.64 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.985 0.421 . . . . 0.0 110.449 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -84.02 113.38 20.97 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.356 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.9 mt -119.66 113.41 20.63 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.132 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 79.7 t -124.38 131.72 72.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 CA-C-O 120.898 0.38 . . . . 0.0 111.636 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -126.7 116.57 21.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.309 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' G' ' 20' ' ' PHE . 30.0 t80 -117.23 123.83 47.59 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.18 138.56 25.29 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-O 122.454 1.121 . . . . 0.0 113.633 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.528 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 80.8 tt0 -90.14 149.5 22.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.152 -1.386 . . . . 0.0 109.402 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.411 ' N ' ' HB2' ' I' ' 22' ' ' GLU . 66.4 t0 -174.32 48.43 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.682 -0.407 . . . . 0.0 112.042 -178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.426 HG12 ' N ' ' H' ' 25' ' ' GLY . 4.1 t -72.67 161.43 4.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.213 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.505 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 108.95 -30.24 8.89 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.505 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 6.2 p 93.06 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.085 0.554 . . . . 0.0 111.015 178.52 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 1.07 HD21 ' HB2' ' H' ' 30' ' ' ALA . 17.6 p30 -74.02 175.05 7.77 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 119.889 -0.725 . . . . 0.0 110.448 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.618 ' HZ3' ' CE1' ' C' ' 13' ' ' HIS . 94.0 mttt -51.18 -36.93 43.63 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' H' ' 27' ' ' ASN . . . 179.54 77.22 0.06 OUTLIER Glycine 0 CA--C 1.529 0.961 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.729 -176.262 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 1.07 ' HB2' HD21 ' H' ' 27' ' ' ASN . . . -52.06 131.89 32.28 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 118.295 1.047 . . . . 0.0 113.567 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.578 HD12 HG12 ' B' ' 39' ' ' VAL . 51.6 mt -141.38 133.42 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.454 HD13 HG21 ' H' ' 32' ' ' ILE . 31.3 mt -105.55 108.97 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 174.159 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.44 104.42 1.8 Allowed Glycine 0 N--CA 1.462 0.427 0 N-CA-C 106.948 -2.461 . . . . 0.0 106.948 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.415 HD21 HG22 ' G' ' 32' ' ' ILE . 81.0 mt -138.23 136.77 36.88 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 119.013 -1.075 . . . . 0.0 113.774 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.472 ' CG ' ' SD ' ' G' ' 35' ' ' MET . 32.9 tpp -99.84 107.1 19.04 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 173.533 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' I' ' 36' ' ' VAL . 24.8 t -130.24 142.3 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -178.47 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 124.57 -101.95 0.68 Allowed Glycine 0 C--N 1.312 -0.759 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.19 -79.28 0.02 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.529 HG21 ' CA ' ' N' ' 29' ' ' GLY . 5.5 p -144.04 150.2 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.077 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.545 ' OXT' ' CG2' ' I' ' 40' ' ' VAL . 5.1 p . . . . . 0 C--O 1.217 -0.655 0 CA-C-O 118.14 -0.933 . . . . 0.0 111.117 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -108.44 136.66 47.69 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.842 0.353 . . . . 0.0 110.254 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.491 ' N ' ' CD ' ' I' ' 11' ' ' GLU . 1.8 pm0 -117.91 135.58 54.03 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.525 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.507 HG22 ' H ' ' J' ' 12' ' ' VAL . 70.2 t -124.97 126.51 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.202 -179.141 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -134.85 146.14 48.97 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.805 0.336 . . . . 0.0 111.33 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.403 ' CE1' HG23 ' J' ' 12' ' ' VAL . 96.6 m-70 -147.82 172.69 13.74 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 121.132 0.492 . . . . 0.0 110.502 177.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 40.7 tt0 -137.86 140.89 40.68 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 176.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -130.15 110.06 11.3 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.105 -0.638 . . . . 0.0 112.413 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.43 ' CD2' HG21 ' G' ' 36' ' ' VAL . 5.6 mp -121.81 113.12 19.22 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 175.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.502 HG13 ' CG2' ' J' ' 18' ' ' VAL . 8.0 t -105.56 109.43 27.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.043 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 80.3 m-85 -104.3 100.71 10.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.115 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -115.2 127.42 55.51 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -168.58 177.46 5.2 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 117.624 -1.63 . . . . 0.0 114.891 -177.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.411 ' HB2' ' N ' ' H' ' 23' ' ' ASP . 67.8 mm-40 -77.92 156.96 29.98 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 175.327 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.722 ' O ' ' O ' ' I' ' 24' ' ' VAL . 67.9 t0 -169.84 60.56 0.04 OUTLIER 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 119.291 -0.964 . . . . 0.0 112.483 -175.214 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.722 ' O ' ' O ' ' I' ' 23' ' ' ASP . 3.4 t -44.53 -111.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.196 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.448 ' O ' ' N ' ' I' ' 27' ' ' ASN . . . 159.5 -45.37 0.44 Allowed Glycine 0 CA--C 1.502 -0.751 0 C-N-CA 116.091 -2.957 . . . . 0.0 116.561 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 46.9 t -66.69 103.85 1.18 Allowed 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 113.773 -3.171 . . . . 0.0 106.11 -179.198 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.53 ' O ' ' N ' ' I' ' 29' ' ' GLY . 2.4 m-20 -137.02 170.13 16.61 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 113.963 -1.471 . . . . 0.0 109.132 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.519 ' O ' HG13 ' C' ' 40' ' ' VAL . 52.7 mttp -25.84 -42.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.535 0 O-C-N 123.882 0.739 . . . . 0.0 111.217 173.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 160.68 67.6 0.02 OUTLIER Glycine 0 CA--C 1.554 2.494 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.677 -178.51 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' I' ' 27' ' ' ASN . . . -52.14 138.23 26.13 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 118.477 1.138 . . . . 0.0 112.166 -178.697 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.68 HD12 HD11 ' J' ' 31' ' ' ILE . 3.0 tt -144.59 145.93 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.23 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.498 HG23 HD13 ' I' ' 34' ' ' LEU . 3.9 mt -105.37 108.58 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 175.162 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.727 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -107.32 101.45 1.68 Allowed Glycine 0 N--CA 1.47 0.903 0 N-CA-C 106.41 -2.676 . . . . 0.0 106.41 178.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.727 HD12 ' O ' ' I' ' 33' ' ' GLY . 3.1 mp -130.71 130.21 43.54 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -174.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 83.5 mmm -101.34 112.44 24.96 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' H' ' 36' ' ' VAL . 47.0 t -127.56 142.14 44.43 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.743 -174.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.16 -101.6 0.44 Allowed Glycine 0 C--N 1.318 -0.451 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 178.288 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.526 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 83.83 -81.02 1.77 Allowed Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.517 HG22 HD12 ' O' ' 31' ' ' ILE . 56.1 t -143.2 143.91 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.545 ' CG2' ' OXT' ' H' ' 40' ' ' VAL . 21.5 m . . . . . 0 N--CA 1.473 0.688 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.975 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.88 132.81 53.06 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.884 0.373 . . . . 0.0 110.622 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -75.51 123.43 25.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.507 ' H ' HG22 ' I' ' 12' ' ' VAL . 3.2 m -134.9 155.97 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.285 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.541 ' CG ' ' O ' ' H' ' 40' ' ' VAL . 2.1 t-80 -158.52 103.66 1.77 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.02 178.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.498 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 4.3 m-70 -137.23 159.09 42.93 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.786 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.444 HE21 HG12 ' G' ' 36' ' ' VAL . 5.8 tt0 -90.26 159.26 16.78 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 105.67 -1.974 . . . . 0.0 105.67 175.091 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.664 ' C ' HD12 ' J' ' 17' ' ' LEU . 78.9 tttt -140.66 109.73 6.13 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.845 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.664 HD12 ' C ' ' J' ' 16' ' ' LYS . 4.5 mp -130.04 120.02 24.06 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.293 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 18' ' ' VAL . . . . . 0.502 ' CG2' HG13 ' I' ' 18' ' ' VAL . 20.3 m -116.28 117.93 57.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 177.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.407 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 32.2 m-85 -107.92 103.54 12.81 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -118.46 134.63 54.92 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.557 0.218 . . . . 0.0 110.989 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.31 146.24 23.53 Favored 'General case' 0 C--O 1.241 0.606 0 C-N-CA 117.919 -1.512 . . . . 0.0 114.842 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 72.3 mm-40 -86.8 147.47 25.81 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 113.578 -1.646 . . . . 0.0 108.915 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.492 ' OD2' ' O ' ' I' ' 23' ' ' ASP . 0.0 OUTLIER -160.18 51.88 0.32 Allowed 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -177.072 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.5 t -75.43 142.41 14.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 116.783 -1.967 . . . . 0.0 108.378 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.26 -37.22 3.84 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.49 119.95 23.84 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 113.663 -1.268 . . . . 0.0 112.697 -178.493 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.623 ' O ' ' N ' ' J' ' 29' ' ' GLY . 22.1 m-20 -88.38 158.01 18.53 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.039 -0.665 . . . . 0.0 109.437 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.782 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 75.8 tttt -47.91 48.35 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.216 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.623 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -101.47 52.55 0.88 Allowed Glycine 0 N--CA 1.481 1.664 0 CA-C-N 119.234 0.925 . . . . 0.0 113.905 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.555 ' O ' ' HB1' ' K' ' 30' ' ' ALA . . . -130.01 179.44 5.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.4 0.619 . . . . 0.0 110.142 179.179 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.68 HD11 HD12 ' I' ' 31' ' ' ILE . 42.2 pt -138.96 145.04 28.27 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.488 HG22 ' O ' ' J' ' 32' ' ' ILE . 0.6 OUTLIER -108.67 110.44 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.053 177.535 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.77 95.88 0.91 Allowed Glycine 0 C--O 1.24 0.488 0 N-CA-C 104.673 -3.371 . . . . 0.0 104.673 176.044 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.412 HD21 ' CD2' ' L' ' 17' ' ' LEU . 6.3 tt -133.11 132.27 41.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 123.062 1.41 . . . . 0.0 113.647 -175.131 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 11.1 mtp -107.89 109.39 20.89 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 112.208 -2.269 . . . . 0.0 107.393 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.689 ' O ' HG13 ' K' ' 36' ' ' VAL . 12.0 p -104.44 111.51 34.32 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.469 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 178.839 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.621 ' O ' ' NE2' ' L' ' 15' ' ' GLN . . . -58.62 131.91 52.29 Favored Glycine 0 N--CA 1.462 0.388 0 CA-C-N 115.146 -0.933 . . . . 0.0 114.403 -175.613 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . -89.42 63.62 3.32 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.455 HG23 ' O ' ' J' ' 39' ' ' VAL . 28.7 m -112.86 125.6 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 CA-C-O 121.148 0.499 . . . . 0.0 110.695 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.474 ' HB ' HG12 ' I' ' 40' ' ' VAL . 3.3 t . . . . . 0 C--O 1.219 -0.535 0 CA-C-N 114.951 -1.022 . . . . 0.0 112.204 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -82.71 139.77 33.46 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.808 0.337 . . . . 0.0 110.51 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.459 ' HB3' ' HE2' ' K' ' 13' ' ' HIS . 95.7 mt-10 -92.24 121.63 33.94 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.276 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.428 HG12 ' H ' ' L' ' 12' ' ' VAL . 34.0 m -130.35 132.03 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.969 0.414 . . . . 0.0 111.356 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.459 ' HE2' ' HB3' ' K' ' 11' ' ' GLU . 2.6 m-70 -141.79 137.5 31.59 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.311 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.647 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 28.1 m80 -147.57 162.18 39.63 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -90.02 158.27 17.42 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 176.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.27 97.74 3.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 119.608 -0.837 . . . . 0.0 111.228 177.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 19.3 mt -121.49 118.62 29.77 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 176.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.85 111.81 37.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.584 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -105.09 100.92 10.5 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 49.6 t80 -121.78 122.33 39.26 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.732 0.301 . . . . 0.0 111.675 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.581 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -154.13 159.0 41.26 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 118.504 -1.278 . . . . 0.0 114.25 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.469 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 96.6 mt-10 -85.71 161.09 19.36 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 177.174 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 22.2 p30 177.65 48.8 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 118.198 0.454 . . . . 0.0 112.167 -178.403 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.442 ' H ' HG23 ' K' ' 24' ' ' VAL . 0.2 OUTLIER -72.43 160.68 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 118.4 -1.32 . . . . 0.0 112.97 -176.136 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -28.7 10.29 Favored Glycine 0 CA--C 1.535 1.316 0 CA-C-N 113.634 -1.621 . . . . 0.0 112.419 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p 73.76 119.34 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.449 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 29.0 t-20 -83.3 163.49 20.65 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 119.494 -0.882 . . . . 0.0 112.477 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.449 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 99.4 mttt -47.35 -37.22 10.74 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 114.438 -1.255 . . . . 0.0 113.974 176.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.98 77.0 0.06 OUTLIER Glycine 0 CA--C 1.545 1.955 0 C-N-CA 120.059 -1.067 . . . . 0.0 114.42 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.782 ' HB2' ' O ' ' J' ' 28' ' ' LYS . . . -80.02 167.95 19.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 119.379 1.59 . . . . 0.0 110.351 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.773 HD11 HG13 ' E' ' 39' ' ' VAL . 43.3 mt -133.24 127.98 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -176.688 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.403 HD13 HG21 ' K' ' 32' ' ' ILE . 14.7 pt -125.17 121.69 61.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 121.486 0.66 . . . . 0.0 109.998 176.32 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.608 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -126.26 115.73 2.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.746 HD12 ' N ' ' K' ' 34' ' ' LEU . 2.9 mp -122.0 119.89 32.77 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.406 ' SD ' ' CE ' ' L' ' 35' ' ' MET . 27.7 ttp -137.58 147.88 45.43 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 118.441 -1.303 . . . . 0.0 112.913 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.689 HG13 ' O ' ' J' ' 36' ' ' VAL . 1.4 t -121.38 171.82 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 113.914 -1.493 . . . . 0.0 108.847 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.3 94.18 0.11 Allowed Glycine 0 N--CA 1.437 -1.279 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.999 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.525 ' HA2' HD11 ' Q' ' 31' ' ' ILE . . . 152.11 -80.97 0.19 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.432 176.302 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.61 HG23 HD13 ' Q' ' 31' ' ' ILE . 90.2 t . . . . . 0 N--CA 1.466 0.334 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.743 0.306 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.428 ' H ' HG12 ' K' ' 12' ' ' VAL . 6.2 m -122.12 132.88 70.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.271 0.557 . . . . 0.0 111.137 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.447 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.3 p80 -148.18 107.31 3.88 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.741 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.647 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.9 m80 -147.91 164.86 32.43 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 109.909 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.621 ' NE2' ' O ' ' J' ' 37' ' ' GLY . 32.7 mt-30 -89.76 158.85 17.34 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.915 0.388 . . . . 0.0 111.175 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 16' ' ' LYS . . . . . 0.686 ' C ' HD12 ' L' ' 17' ' ' LEU . 68.5 mttm -140.07 102.56 4.42 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.686 HD12 ' C ' ' L' ' 16' ' ' LYS . 9.7 mp -120.37 118.14 29.59 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -105.04 116.43 48.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.517 ' CZ ' HD23 ' K' ' 34' ' ' LEU . 8.6 m-85 -105.16 103.7 13.29 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.87 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' O ' ' L' ' 21' ' ' ALA . 75.7 t80 -153.21 158.87 42.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 123.177 1.465 . . . . 0.0 113.807 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.581 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -145.81 159.1 43.68 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 113.41 -1.723 . . . . 0.0 107.578 178.574 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.404 ' C ' ' O ' ' L' ' 21' ' ' ALA . 81.3 tt0 -39.95 152.7 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.27 -0.572 . . . . 0.0 111.677 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 p30 -65.45 47.33 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.807 -177.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.546 HG23 ' H ' ' L' ' 26' ' ' SER . 24.1 m -61.04 -179.12 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.483 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.34 29.62 12.11 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.546 ' H ' HG23 ' L' ' 24' ' ' VAL . 34.5 t -80.14 110.81 15.9 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.607 ' O ' ' N ' ' L' ' 29' ' ' GLY . 80.6 m-20 -95.06 -166.31 1.44 Allowed 'General case' 0 C--O 1.222 -0.348 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.632 -179.433 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.57 47.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.01 56.59 0.93 Allowed Glycine 0 CA--C 1.538 1.508 0 CA-C-N 119.756 1.162 . . . . 0.0 111.431 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.658 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -170.27 177.11 4.27 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.555 HD12 HG12 ' E' ' 39' ' ' VAL . 39.2 mt -106.97 125.59 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.478 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.765 HD12 ' N ' ' L' ' 32' ' ' ILE . 3.1 mp -110.45 115.89 50.94 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.229 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.1 107.26 1.15 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.622 HD23 ' C ' ' L' ' 34' ' ' LEU . 6.3 tt -122.7 120.39 33.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.582 ' N ' HD23 ' L' ' 34' ' ' LEU . 28.6 mtm -136.17 144.62 45.09 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.462 0.648 . . . . 0.0 112.546 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.469 ' O ' ' O ' ' L' ' 37' ' ' GLY . 54.0 t -116.18 131.52 68.46 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.686 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -32.92 -111.3 0.0 OUTLIER Glycine 0 CA--C 1.532 1.113 0 CA-C-N 115.058 -0.974 . . . . 0.0 114.315 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.55 -71.64 0.53 Allowed Glycine 0 CA--C 1.536 1.35 0 CA-C-N 115.289 -0.456 . . . . 0.0 112.886 -178.501 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.404 ' CG2' HD11 ' R' ' 31' ' ' ILE . 53.3 t . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 121.46 0.647 . . . . 0.0 111.27 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 . . . . . 0 N--CA 1.456 -0.128 0 CA-C-O 120.737 0.303 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 52.0 t -116.48 129.58 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.298 0.57 . . . . 0.0 110.116 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -81.4 163.09 23.06 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.372 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 89.5 m-70 -105.09 160.97 14.64 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 121.265 0.555 . . . . 0.0 111.768 -179.151 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 15' ' ' GLN . . . . . 0.427 ' H ' ' HG2' ' N' ' 15' ' ' GLN . 87.9 mt-30 -89.98 160.25 16.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.62 178.145 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -139.38 110.9 7.08 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.1 mt -135.93 117.44 14.81 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.551 0.691 . . . . 0.0 111.081 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.17 132.95 70.55 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.813 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -128.04 134.21 49.18 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.771 0.32 . . . . 0.0 110.552 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.496 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 53.2 p90 -127.43 126.02 41.63 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.525 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 129.25 47.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.225 0.536 . . . . 0.0 111.962 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -155.34 126.7 7.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.007 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.69 46.45 24.66 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.332 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.446 HG22 ' H ' ' M' ' 24' ' ' VAL . 11.6 m -76.11 179.55 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.0 28.11 6.86 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.813 -179.363 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' M' ' 27' ' ' ASN . 5.5 t -170.46 -134.11 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.912 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 27' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' M' ' 26' ' ' SER . 22.2 t-20 -30.81 143.58 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.847 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -132.9 -26.08 1.78 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.748 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.99 -108.87 0.26 Allowed Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.143 -1.027 . . . . 0.0 111.052 179.645 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.45 96.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.45 -0.5 . . . . 0.0 112.1 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -115.24 105.28 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 32' ' ' ILE . . . . . 0.747 HG22 HD11 ' N' ' 34' ' ' LEU . 55.0 mt -110.73 112.6 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 120.411 -0.516 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.75 104.45 1.22 Allowed Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 104.977 -3.249 . . . . 0.0 104.977 176.874 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 30.0 tp -155.2 151.36 28.06 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 117.489 -1.685 . . . . 0.0 114.409 -174.297 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 93.9 mmm -100.27 111.51 23.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 112.659 -2.064 . . . . 0.0 106.878 177.18 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' N' ' 36' ' ' VAL . 41.9 t -119.66 131.37 72.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.582 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.34 -111.28 4.13 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' N' ' 37' ' ' GLY . . . 81.13 -74.03 2.49 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -178.105 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.18 161.37 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.402 HG22 ' CG1' ' N' ' 39' ' ' VAL . 10.7 m . . . . . 0 N--CA 1.47 0.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.538 177.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.159 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -105.24 131.51 52.62 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -114.8 115.29 26.77 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.204 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -129.57 123.02 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.174 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -143.58 130.71 20.71 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.196 0.522 . . . . 0.0 110.473 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.637 ' ND1' ' NE2' ' O' ' 14' ' ' HIS . 19.5 t60 -159.75 170.08 22.27 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CD2' ' N' ' 14' ' ' HIS . 75.2 mt-30 -155.14 140.71 17.91 Favored 'General case' 0 CA--C 1.517 -0.32 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.767 177.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 48.0 tttp -93.98 111.04 22.7 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.867 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 13.6 mt -119.91 114.43 22.06 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 177.021 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 18' ' ' VAL . . . . . 0.478 HG21 ' CE2' ' N' ' 20' ' ' PHE . 6.3 p -138.6 141.86 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 119.692 -0.803 . . . . 0.0 112.135 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -131.36 122.55 26.55 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.07 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.478 ' CE2' HG21 ' N' ' 18' ' ' VAL . 59.8 m-85 -112.88 123.48 50.4 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.633 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.05 121.06 40.25 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' O' ' 22' ' ' GLU . 82.6 tt0 -136.32 156.38 48.72 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 121.208 0.527 . . . . 0.0 112.31 -177.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 20.0 t0 76.63 54.74 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.364 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.631 HG21 HG13 ' O' ' 24' ' ' VAL . 90.8 t -68.05 135.25 28.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.511 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.57 -34.26 2.3 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 120.995 -0.621 . . . . 0.0 111.836 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' N' ' 27' ' ' ASN . 29.5 t -162.41 120.3 2.12 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-N 116.847 0.323 . . . . 0.0 110.991 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.516 ' O ' ' O ' ' N' ' 26' ' ' SER . 17.5 p30 -22.26 152.74 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -163.19 24.58 0.09 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.434 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 29' ' ' GLY . . . . . 0.529 ' CA ' HG21 ' H' ' 39' ' ' VAL . . . 89.52 105.29 1.13 Allowed Glycine 0 N--CA 1.466 0.683 0 C-N-CA 119.06 -1.543 . . . . 0.0 113.435 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 30' ' ' ALA . . . . . 0.531 ' HB3' ' HB2' ' O' ' 30' ' ' ALA . . . -111.96 95.63 5.59 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 122.072 0.939 . . . . 0.0 108.777 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.45 HD11 HG23 ' I' ' 39' ' ' VAL . 79.4 mt -137.44 136.13 46.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 114.826 -1.079 . . . . 0.0 112.225 -177.182 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.704 HG23 HD13 ' N' ' 34' ' ' LEU . 77.1 mt -106.76 105.64 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 175.233 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.667 ' O ' HD12 ' N' ' 34' ' ' LEU . . . -110.38 91.98 0.66 Allowed Glycine 0 N--CA 1.467 0.742 0 N-CA-C 106.197 -2.761 . . . . 0.0 106.197 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.747 HD11 HG22 ' M' ' 32' ' ' ILE . 8.8 mp -132.74 152.55 51.73 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 123.35 1.548 . . . . 0.0 114.452 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -115.65 107.26 14.87 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 175.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' O' ' 37' ' ' GLY . 47.6 t -117.63 123.16 71.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.05 -177.302 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' M' ' 38' ' ' GLY . . . 134.75 -113.86 1.2 Allowed Glycine 0 C--N 1.317 -0.515 0 N-CA-C 110.524 -1.03 . . . . 0.0 110.524 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.805 ' O ' HG21 ' O' ' 39' ' ' VAL . . . 97.83 -71.64 0.66 Allowed Glycine 0 CA--C 1.533 1.188 0 N-CA-C 110.618 -0.993 . . . . 0.0 110.618 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.402 ' CG1' HG22 ' M' ' 40' ' ' VAL . 83.6 t -126.49 138.58 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 177.072 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' C' ' 28' ' ' LYS . 66.2 t . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.909 -1.043 . . . . 0.0 110.056 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -107.19 134.31 50.49 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.83 0.348 . . . . 0.0 110.466 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.98 133.61 39.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.827 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.56 140.28 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.085 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.477 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 42.0 t-80 -147.5 95.53 2.54 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.392 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.637 ' NE2' ' ND1' ' N' ' 14' ' ' HIS . 0.3 OUTLIER -161.05 170.9 19.58 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 178.798 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -97.33 143.47 28.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.699 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -124.64 118.98 27.73 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.492 ' N ' HD12 ' O' ' 17' ' ' LEU . 4.7 mp -122.76 128.93 51.14 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.516 0.674 . . . . 0.0 111.337 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 98.2 t -119.07 111.99 35.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.023 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' M' ' 32' ' ' ILE . 91.4 m-85 -107.7 108.0 19.04 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -122.87 126.67 47.77 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.83 117.06 28.26 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 22' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' O' ' 24' ' ' VAL . 83.5 tt0 -83.43 153.18 24.63 Favored 'General case' 0 N--CA 1.461 0.083 0 N-CA-C 113.438 0.903 . . . . 0.0 113.438 -176.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' O' ' 24' ' ' VAL . 65.6 t0 8.66 51.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 113.034 -1.894 . . . . 0.0 114.654 -179.155 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.709 HG12 ' H ' ' O' ' 25' ' ' GLY . 11.6 t -55.89 -132.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 174.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.709 ' H ' HG12 ' O' ' 24' ' ' VAL . . . 144.47 -29.77 1.88 Allowed Glycine 0 C--O 1.226 -0.365 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.337 175.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.461 ' O ' ' CE ' ' P' ' 28' ' ' LYS . 5.8 t -89.92 -132.89 0.1 Allowed 'General case' 0 CA--C 1.55 0.974 0 CA-C-O 122.986 1.374 . . . . 0.0 113.292 179.162 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.466 ' H ' ' HB3' ' N' ' 27' ' ' ASN . 12.2 m120 79.28 138.9 0.07 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 127.669 2.388 . . . . 0.0 111.22 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -48.83 -48.45 41.62 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 117.2 2.296 . . . . 0.0 117.2 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.67 62.48 0.06 OUTLIER Glycine 0 CA--C 1.545 1.921 0 CA-C-O 118.084 -1.398 . . . . 0.0 111.498 -171.36 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 30' ' ' ALA . . . . . 0.531 ' HB2' ' HB3' ' N' ' 30' ' ' ALA . . . -52.71 143.92 15.22 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 120.681 2.241 . . . . 0.0 116.714 -170.349 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.526 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 70.8 mt -138.79 153.89 25.87 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 CA-C-N 110.942 -2.845 . . . . 0.0 113.871 -175.01 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.556 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 75.5 mt -117.1 110.53 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 174.699 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.44 106.96 2.41 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 104.732 -3.347 . . . . 0.0 104.732 176.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.669 HD12 ' O ' ' N' ' 34' ' ' LEU . 26.7 tp -148.37 139.21 23.01 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 122.747 1.26 . . . . 0.0 113.696 -174.129 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.458 ' H ' HD12 ' O' ' 34' ' ' LEU . 24.5 ttm -114.33 110.98 20.76 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 113.648 -1.615 . . . . 0.0 107.428 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.458 ' O ' ' HA3' ' P' ' 37' ' ' GLY . 1.7 t -89.91 103.74 14.47 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.784 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 37' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . -20.06 144.5 0.01 OUTLIER Glycine 0 N--CA 1.481 1.69 0 C-N-CA 124.136 0.874 . . . . 0.0 115.077 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.515 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . -100.78 59.12 0.68 Allowed Glycine 0 CA--C 1.541 1.673 0 CA-C-N 115.022 -0.589 . . . . 0.0 113.6 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.805 HG21 ' O ' ' N' ' 38' ' ' GLY . 21.5 t -135.23 161.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-N 117.423 0.611 . . . . 0.0 110.607 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.499 ' N ' HG12 ' O' ' 39' ' ' VAL . 78.0 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.306 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.419 HG22 ' O ' ' Q' ' 11' ' ' GLU . 40.3 t . . . . . 0 N--CA 1.467 0.386 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 0.9 OUTLIER -146.05 105.35 3.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.381 -179.307 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.535 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 4.9 p80 -134.1 160.59 37.31 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.449 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.404 ' HB2' HE21 ' P' ' 15' ' ' GLN . 0.1 OUTLIER -89.99 159.22 17.0 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.133 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -140.07 103.27 4.58 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.412 HD22 HG21 ' N' ' 36' ' ' VAL . 5.0 mp -128.88 125.68 38.14 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 121.399 0.619 . . . . 0.0 110.657 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 79.6 t -118.38 117.38 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.679 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' HD13 ' N' ' 32' ' ' ILE . 29.4 m-85 -114.01 103.84 11.55 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 27.6 t80 -117.64 126.93 53.4 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.665 0.269 . . . . 0.0 111.059 -178.053 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.1 115.91 15.66 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 121.062 0.458 . . . . 0.0 111.497 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.545 ' O ' ' N ' ' O' ' 24' ' ' VAL . 80.4 tt0 -92.71 112.81 24.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.612 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.563 ' O ' ' NZ ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -139.19 46.76 1.92 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.681 -175.909 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.78 HG22 ' H ' ' P' ' 25' ' ' GLY . 7.7 p -73.15 179.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.453 0.644 . . . . 0.0 111.554 -178.133 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.78 ' H ' HG22 ' P' ' 24' ' ' VAL . . . 99.66 -34.66 5.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 118.647 -1.085 . . . . 0.0 114.468 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.466 ' O ' ' C ' ' P' ' 27' ' ' ASN . 96.2 p -162.24 120.43 2.2 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.381 2.09 . . . . 0.0 112.791 176.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.466 ' C ' ' O ' ' P' ' 26' ' ' SER . 65.8 t30 -23.56 141.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 123.611 0.569 . . . . 0.0 111.371 177.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' P' ' 23' ' ' ASP . 64.7 mttp -122.24 -32.93 3.58 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 177.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.33 79.85 0.91 Allowed Glycine 0 CA--C 1.536 1.381 0 N-CA-C 108.343 -1.903 . . . . 0.0 108.343 -176.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.7 144.04 30.9 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-N 118.172 0.986 . . . . 0.0 111.727 -175.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.458 HG23 HG23 ' Q' ' 31' ' ' ILE . 5.8 mt -125.07 138.64 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 113.815 -1.538 . . . . 0.0 113.563 -177.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.524 HD13 ' CD1' ' R' ' 19' ' ' PHE . 96.4 mt -118.76 112.35 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 176.566 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.98 100.22 1.45 Allowed Glycine 0 CA--C 1.509 -0.302 0 N-CA-C 104.557 -3.417 . . . . 0.0 104.557 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.523 ' CD2' HG22 ' P' ' 36' ' ' VAL . 7.7 tt -137.07 138.22 40.16 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-O 123.014 1.387 . . . . 0.0 114.533 -174.588 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 5.5 ttm -104.66 111.44 24.14 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.002 -1.908 . . . . 0.0 106.909 176.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.523 HG22 ' CD2' ' P' ' 34' ' ' LEU . 3.4 t -85.24 101.65 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 C-N-CA 118.585 -1.246 . . . . 0.0 108.269 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 37' ' ' GLY . . . . . 0.561 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . . . -88.89 153.91 24.18 Favored Glycine 0 C--N 1.316 -0.579 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.467 ' N ' ' HA2' ' O' ' 38' ' ' GLY . . . 136.68 58.86 0.06 OUTLIER Glycine 0 N--CA 1.466 0.639 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.662 ' CG2' ' H ' ' Q' ' 38' ' ' GLY . 49.7 t -79.51 133.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.463 HG23 ' NE2' ' R' ' 13' ' ' HIS . 9.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.956 -1.021 . . . . 0.0 111.748 -178.788 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.1 135.37 46.58 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.838 0.351 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . 0.419 ' O ' HG22 ' P' ' 12' ' ' VAL . 96.8 mt-10 -103.02 122.55 44.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.209 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.588 HG12 ' N ' ' Q' ' 13' ' ' HIS . 46.8 t -142.37 168.16 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.689 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.588 ' N ' HG12 ' Q' ' 12' ' ' VAL . 8.3 p80 -64.1 127.47 31.57 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -177.678 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.505 ' O ' ' CB ' ' P' ' 14' ' ' HIS . 7.0 p80 -157.46 168.46 27.26 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.157 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.561 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 79.1 mt-30 -89.97 151.39 21.72 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.921 -0.487 . . . . 0.0 110.313 178.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -148.76 106.48 3.68 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.42 ' N ' HD12 ' Q' ' 17' ' ' LEU . 4.5 mp -135.68 124.46 23.92 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.264 0.554 . . . . 0.0 111.017 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -108.1 116.29 51.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 178.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.556 ' CD1' HD13 ' O' ' 32' ' ' ILE . 60.3 m-85 -112.42 109.23 18.72 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.226 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 41.4 t80 -125.45 128.17 47.65 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.55 134.3 37.34 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.129 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -114.74 124.29 51.4 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' Q' ' 23' ' ' ASP . 12.6 p-10 -147.28 59.73 1.16 Allowed 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.382 0.611 . . . . 0.0 111.873 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.961 HG12 ' H ' ' Q' ' 25' ' ' GLY . 4.8 t 72.07 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.018 176.692 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.961 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -107.91 29.3 10.46 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.312 177.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 48.7 m -65.1 -113.96 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 118.716 1.258 . . . . 0.0 111.223 -176.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -155.94 169.19 25.01 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 119.631 -0.827 . . . . 0.0 112.362 179.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt 27.36 43.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.224 -1.353 . . . . 0.0 112.723 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.84 60.25 0.74 Allowed Glycine 0 N--CA 1.475 1.24 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.21 177.521 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.19 118.63 0.57 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 119.229 1.514 . . . . 0.0 113.043 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.61 HD13 HG23 ' K' ' 39' ' ' VAL . 1.7 tt -136.14 125.38 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 175.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . 0.477 HG22 ' HG ' ' Q' ' 34' ' ' LEU . 64.5 mt -128.66 133.79 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.198 -176.641 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.85 112.57 2.36 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 108.164 -1.974 . . . . 0.0 108.164 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.477 ' HG ' HG22 ' Q' ' 32' ' ' ILE . 58.4 mt -119.16 120.44 37.1 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.093 0.473 . . . . 0.0 110.935 -177.47 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 11.0 mtp -124.7 130.92 53.33 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.362 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -105.81 159.86 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 CA-C-O 121.359 0.6 . . . . 0.0 110.75 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.84 -102.77 0.01 OUTLIER Glycine 0 CA--C 1.528 0.854 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.086 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.662 ' H ' ' CG2' ' P' ' 39' ' ' VAL . . . -116.97 -77.17 0.62 Allowed Glycine 0 CA--C 1.534 1.269 0 CA-C-O 119.864 -0.409 . . . . 0.0 113.166 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' R' ' 39' ' ' VAL . 39.3 t -115.01 129.9 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 117.682 0.741 . . . . 0.0 111.861 -178.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.493 ' N ' ' O ' ' R' ' 40' ' ' VAL . 42.6 t . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.694 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -79.54 138.4 37.49 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -111.31 128.58 55.99 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.433 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.477 ' H ' HG21 ' Q' ' 12' ' ' VAL . 30.8 t -110.46 93.17 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.451 0.643 . . . . 0.0 110.609 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.517 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 50.1 p-80 -120.32 105.77 11.24 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.545 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 84.6 t60 -141.11 170.73 15.17 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.752 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.531 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 93.0 mm-40 -89.55 150.62 22.35 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -149.59 99.0 2.84 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -139.02 124.78 19.65 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.529 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -104.96 118.52 52.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.524 ' CD1' HD13 ' P' ' 32' ' ' ILE . 55.3 m-85 -111.92 105.8 14.33 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 t80 -130.14 125.7 35.7 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.61 0.719 . . . . 0.0 112.104 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.59 126.4 38.4 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.269 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 79.1 tt0 -89.21 110.81 21.52 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 119.938 -0.705 . . . . 0.0 110.965 -178.686 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.448 ' OD2' ' OD2' ' Q' ' 23' ' ' ASP . 54.0 m-20 -163.11 -60.25 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.561 HG12 ' N ' ' R' ' 25' ' ' GLY . 98.2 t -55.81 162.49 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.742 -179.435 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.561 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -157.3 -27.84 0.03 OUTLIER Glycine 0 CA--C 1.52 0.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 93.1 p -80.74 -130.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.268 -0.466 . . . . 0.0 109.912 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.0 m-80 -99.18 -164.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.499 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -47.76 49.48 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 125.372 1.469 . . . . 0.0 114.793 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.38 51.76 0.92 Allowed Glycine 0 CA--C 1.55 2.229 0 CA-C-N 119.344 0.974 . . . . 0.0 113.715 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.19 165.61 22.0 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.404 HD11 ' CG2' ' L' ' 39' ' ' VAL . 96.6 mt -114.31 112.21 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 CA-C-N 119.73 1.15 . . . . 0.0 110.042 178.111 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -125.73 127.72 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.843 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.66 119.41 3.5 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.09 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 48.4 tp -123.25 123.08 39.95 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mtp -138.38 147.42 43.39 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.06 161.51 38.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.123 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.3 -102.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.501 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.34 -78.02 0.87 Allowed Glycine 0 N--CA 1.475 1.289 0 C-N-CA 121.707 -0.283 . . . . 0.0 112.891 -178.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' Q' ' 39' ' ' VAL . 70.1 t -96.1 132.82 39.4 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.865 0 CA-C-N 117.519 0.659 . . . . 0.0 110.855 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' Q' ' 40' ' ' VAL . 10.7 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.444 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.465 0.276 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.8 131.98 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.413 0.625 . . . . 0.0 111.159 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.1 m80 -117.38 156.82 27.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.461 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.512 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -84.21 167.85 16.29 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.918 -179.755 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 69.0 tp60 -159.15 143.26 15.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.632 178.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -80.2 123.5 27.98 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.455 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 99.3 mt -125.6 116.28 21.47 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 177.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.54 134.06 56.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.739 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -127.71 131.49 49.73 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.466 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.0 p90 -134.95 130.94 36.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.685 0.278 . . . . 0.0 111.374 -178.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.63 120.56 38.4 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.777 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -136.98 136.16 38.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.406 0.622 . . . . 0.0 112.081 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.9 t0 . . . . . 0 C--N 1.33 -0.267 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 177.931 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 . . . . . 0 N--CA 1.466 0.351 0 CA-C-O 120.846 0.355 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -79.55 39.64 0.41 Allowed 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.41 79.36 0.94 Allowed Glycine 0 N--CA 1.47 0.939 0 C-N-CA 117.886 -2.102 . . . . 0.0 110.976 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.445 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -81.41 74.81 8.39 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 119.589 1.695 . . . . 0.0 113.955 -175.947 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.67 ' CD1' HG12 ' M' ' 39' ' ' VAL . 89.7 mt -145.39 122.58 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 177.107 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -116.86 122.97 71.19 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-O 121.344 0.592 . . . . 0.0 112.109 -177.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.91 101.2 0.67 Allowed Glycine 0 C--N 1.319 -0.41 0 N-CA-C 105.311 -3.116 . . . . 0.0 105.311 176.377 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -156.71 153.71 28.88 Favored 'General case' 0 C--O 1.241 0.629 0 C-N-CA 118.128 -1.429 . . . . 0.0 113.617 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mmm -99.31 120.78 40.13 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 112.714 -2.039 . . . . 0.0 108.055 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.601 ' HB ' HG12 ' B' ' 36' ' ' VAL . 2.8 t -111.39 124.6 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.62 -114.22 6.29 Favored Glycine 0 CA--C 1.528 0.889 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.42 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.17 -71.51 0.73 Allowed Glycine 0 CA--C 1.539 1.58 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.455 ' H ' HG23 ' A' ' 39' ' ' VAL . 2.6 t -66.23 159.25 4.53 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.982 -1.009 . . . . 0.0 111.793 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 10' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' C' ' 9' ' ' GLY . 92.1 m-85 -98.43 132.32 43.98 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.412 ' H ' ' HG3' ' C' ' 11' ' ' GLU . 97.0 mt-10 -138.03 139.81 39.78 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.013 0.435 . . . . 0.0 111.304 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.47 ' CG1' ' HE2' ' A' ' 14' ' ' HIS . 74.2 t -124.42 130.89 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -117.55 98.05 6.19 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' B' ' 15' ' ' GLN . 11.5 t60 -160.61 164.54 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.542 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 19.8 tt0 -158.1 142.33 15.92 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.319 178.033 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.52 121.25 27.34 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.022 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.604 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.4 tt -136.22 121.32 18.93 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.706 0.685 . . . . 0.0 110.831 178.673 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.548 ' N ' HD23 ' B' ' 17' ' ' LEU . 13.9 m -134.65 141.4 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.937 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -128.32 127.03 41.95 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.184 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -123.24 129.58 51.57 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.743 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.0 119.65 31.02 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.456 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -138.84 164.04 30.68 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.001 0.429 . . . . 0.0 111.545 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.58 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 54.2 t0 42.0 47.57 3.83 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -81.58 163.4 3.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 117.786 -1.565 . . . . 0.0 108.567 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.61 -38.16 57.52 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -177.3 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.62 ' O ' ' O ' ' B' ' 27' ' ' ASN . 45.9 t -162.54 117.24 1.81 Allowed 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.505 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.746 HD21 ' N ' ' C' ' 28' ' ' LYS . 55.2 t-20 -22.02 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.212 0 O-C-N 123.933 0.771 . . . . 0.0 111.713 175.557 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.545 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 62.7 tttt -163.29 24.56 0.09 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . 89.53 106.64 1.16 Allowed Glycine 0 N--CA 1.468 0.805 0 C-N-CA 118.396 -1.859 . . . . 0.0 113.814 177.431 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.89 101.83 10.38 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 122.734 1.254 . . . . 0.0 109.881 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.7 HD11 ' HB ' ' N' ' 39' ' ' VAL . 91.8 mt -119.61 129.44 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 114.22 -1.355 . . . . 0.0 110.641 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.43 ' CG2' HD12 ' B' ' 34' ' ' LEU . 49.7 mt -109.95 111.24 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.114 0.483 . . . . 0.0 109.82 177.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 99.21 0.99 Allowed Glycine 0 C--O 1.238 0.396 0 N-CA-C 105.885 -2.886 . . . . 0.0 105.885 177.067 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.629 ' O ' HD23 ' C' ' 34' ' ' LEU . 80.0 mt -138.24 145.67 41.65 Favored 'General case' 0 CA--C 1.499 -1.001 0 CA-C-O 122.792 1.282 . . . . 0.0 113.139 -175.242 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.7 mtp -116.36 109.44 17.35 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 112.837 -1.983 . . . . 0.0 107.473 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.601 HG12 ' HB ' ' A' ' 36' ' ' VAL . 2.8 m -132.88 123.19 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.742 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 144.85 -113.4 0.72 Allowed Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.684 ' O ' HG13 ' B' ' 39' ' ' VAL . . . 76.94 -72.97 2.0 Allowed Glycine 0 CA--C 1.535 1.3 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.684 HG13 ' O ' ' B' ' 38' ' ' GLY . 2.9 m -166.67 118.92 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.551 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 17.2 m . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.746 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 9' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -122.47 140.38 52.8 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.731 0.3 . . . . 0.0 110.34 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 11' ' ' GLU . . . . . 0.499 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 57.6 mp0 -76.52 115.82 16.63 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.059 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 26.7 m -137.01 159.76 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.473 ' O ' ' CB ' ' D' ' 13' ' ' HIS . 16.3 m-70 -145.71 132.27 19.82 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.025 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.489 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.8 m-70 -150.57 170.9 18.03 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.074 177.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.2 tp60 -138.53 140.83 39.25 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 177.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -130.02 106.12 8.42 Favored 'General case' 0 C--N 1.318 -0.764 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.413 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 mt -118.34 113.86 22.06 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.47 116.27 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -109.37 106.16 15.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.557 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -120.81 127.97 52.43 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -176.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.62 131.36 35.71 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.124 0.488 . . . . 0.0 111.164 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.489 ' O ' ' CG ' ' C' ' 23' ' ' ASP . 77.4 tt0 -146.46 101.9 3.53 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 113.659 0.985 . . . . 0.0 113.659 -179.067 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.58 ' OD2' ' N ' ' B' ' 23' ' ' ASP . 70.5 m-20 -175.86 -71.83 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 175.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.622 HG13 ' O ' ' C' ' 24' ' ' VAL . 11.2 p -78.75 114.78 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.069 -1.423 . . . . 0.0 107.54 175.203 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.421 ' HA3' HG22 ' D' ' 24' ' ' VAL . . . -91.23 -39.26 5.74 Favored Glycine 0 N--CA 1.461 0.336 0 C-N-CA 117.408 -2.33 . . . . 0.0 109.044 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 5.0 t -93.15 111.47 23.12 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 173.342 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -79.85 171.41 15.15 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 118.017 -1.473 . . . . 0.0 109.996 177.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.746 ' N ' HD21 ' B' ' 27' ' ' ASN . 99.0 mttt -50.37 -36.88 34.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.207 1.003 . . . . 0.0 109.472 174.746 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.19 76.72 0.06 OUTLIER Glycine 0 CA--C 1.54 1.642 0 CA-C-N 113.372 -1.74 . . . . 0.0 110.175 -178.119 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.498 ' O ' ' HB1' ' D' ' 30' ' ' ALA . . . -80.19 129.79 34.75 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 119.323 1.562 . . . . 0.0 113.104 -176.259 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.924 HG22 HG22 ' D' ' 31' ' ' ILE . 46.8 pt -144.61 146.22 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.983 -177.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 76.9 mt -108.96 116.35 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.689 178.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.8 102.99 1.66 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.247 -3.141 . . . . 0.0 105.247 175.599 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.629 HD23 ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -134.93 141.02 46.18 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -175.122 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.65 113.29 26.48 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 175.201 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.491 HG22 HD22 ' C' ' 34' ' ' LEU . 3.1 t -129.46 134.42 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.86 -104.29 0.28 Allowed Glycine 0 C--N 1.305 -1.145 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' C' ' 39' ' ' VAL . . . 46.87 70.73 0.63 Allowed Glycine 0 CA--C 1.537 1.423 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.478 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.882 HG13 ' O ' ' D' ' 39' ' ' VAL . 6.3 t -6.78 120.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.539 ' OXT' ' CE1' ' E' ' 13' ' ' HIS . 26.8 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.156 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.436 HG12 ' H ' ' E' ' 12' ' ' VAL . 4.5 m . . . . . 0 N--CA 1.468 0.46 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' O ' ' B' ' 40' ' ' VAL . 2.1 p80 -147.78 138.46 23.21 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.702 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.546 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.2 OUTLIER -145.91 158.67 43.86 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.052 178.454 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.742 HE22 ' H ' ' B' ' 37' ' ' GLY . 84.8 mt-30 -90.43 158.19 17.2 Favored 'General case' 0 N--CA 1.455 -0.196 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 174.068 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.481 ' C ' HD22 ' D' ' 17' ' ' LEU . 98.7 mttt -141.37 103.08 4.35 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 176.66 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.907 HD22 ' N ' ' D' ' 17' ' ' LEU . 0.1 OUTLIER -118.69 119.41 34.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.053 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 82.8 t -112.94 112.26 39.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.384 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 44.7 m-85 -110.92 103.96 12.5 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -114.29 118.84 35.04 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.831 -0.168 . . . . 0.0 110.926 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.14 118.4 8.95 Favored 'General case' 0 C--O 1.246 0.883 0 CA-C-O 122.147 0.975 . . . . 0.0 111.742 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -178.09 158.96 1.26 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 114.387 -1.279 . . . . 0.0 111.073 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.449 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 35.2 t70 -173.06 -59.91 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 114.167 1.173 . . . . 0.0 114.167 177.538 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.843 HG23 ' H ' ' D' ' 26' ' ' SER . 3.0 m -77.96 -178.99 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 118.896 -1.121 . . . . 0.0 113.208 -176.609 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.71 19.82 38.85 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 114.044 -1.435 . . . . 0.0 113.081 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.843 ' H ' HG23 ' D' ' 24' ' ' VAL . 8.9 t -126.65 151.16 48.43 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 118.309 1.055 . . . . 0.0 112.775 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.489 HD22 ' H ' ' E' ' 26' ' ' SER . 57.9 t-20 -52.36 137.27 29.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.276 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.411 ' CB ' ' O ' ' E' ' 22' ' ' GLU . 87.1 tttt -63.5 -50.97 67.53 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.884 -177.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.66 50.35 3.15 Favored Glycine 0 CA--C 1.541 1.673 0 C-N-CA 119.949 -1.12 . . . . 0.0 110.755 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.498 ' HB1' ' O ' ' C' ' 30' ' ' ALA . . . -130.58 -179.9 5.55 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 118.803 1.301 . . . . 0.0 114.033 -174.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.924 HG22 HG22 ' C' ' 31' ' ' ILE . 16.3 tt -136.37 144.74 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 CA-C-N 113.281 -1.781 . . . . 0.0 112.717 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.442 HD13 ' CD1' ' F' ' 19' ' ' PHE . 4.6 mt -103.92 109.88 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 175.6 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.6 104.26 0.88 Allowed Glycine 0 N--CA 1.466 0.697 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -157.28 157.71 34.73 Favored 'General case' 0 C--O 1.245 0.835 0 CA-C-O 123.879 1.8 . . . . 0.0 114.019 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.437 ' O ' ' O ' ' C' ' 36' ' ' VAL . 0.9 OUTLIER -97.1 119.5 35.7 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 110.516 -3.038 . . . . 0.0 108.683 178.371 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' E' ' 35' ' ' MET . 38.3 t -121.86 142.41 38.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 178.649 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.563 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.25 -102.14 0.19 Allowed Glycine 0 C--N 1.296 -1.666 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -176.898 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' D' ' 39' ' ' VAL . . . 47.56 71.39 0.56 Allowed Glycine 0 CA--C 1.526 0.772 0 C-N-CA 120.048 -1.072 . . . . 0.0 110.643 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.882 ' O ' HG13 ' C' ' 39' ' ' VAL . 59.4 t -22.53 142.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.642 0.777 . . . . 0.0 112.886 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.477 HG13 HG12 ' D' ' 39' ' ' VAL . 16.6 m . . . . . 0 N--CA 1.471 0.622 0 CA-C-O 117.742 -1.123 . . . . 0.0 111.053 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -72.46 125.7 28.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.733 0.302 . . . . 0.0 110.543 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -148.39 130.87 15.76 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.629 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.436 ' H ' HG12 ' D' ' 12' ' ' VAL . 8.4 m -134.01 131.11 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.032 0.444 . . . . 0.0 110.79 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.539 ' CE1' ' OXT' ' C' ' 40' ' ' VAL . 3.4 p80 -150.21 146.55 26.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.875 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.472 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 41.5 m-70 -147.52 162.57 38.81 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-O 121.09 0.472 . . . . 0.0 111.49 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.523 ' NE2' ' OE1' ' D' ' 15' ' ' GLN . 56.6 tp60 -85.17 157.26 20.7 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 176.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.684 ' C ' HD12 ' E' ' 17' ' ' LEU . 86.7 tttt -159.45 98.41 1.4 Allowed 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 118.473 -1.291 . . . . 0.0 112.378 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.684 HD12 ' C ' ' E' ' 16' ' ' LYS . 5.9 mp -122.26 123.13 40.74 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.586 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 p -120.51 118.89 58.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' F' ' 19' ' ' PHE . 17.3 m-85 -108.91 105.71 15.36 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -108.53 114.45 28.29 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.539 ' O ' ' HB1' ' F' ' 21' ' ' ALA . . . -164.48 173.48 12.04 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 117.609 -1.636 . . . . 0.0 114.736 -177.819 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.411 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 73.4 mt-10 -77.75 141.18 39.43 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.339 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -175.41 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 120.475 0.179 . . . . 0.0 110.616 -177.51 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.858 HG12 ' H ' ' E' ' 25' ' ' GLY . 11.7 t -61.05 -179.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.638 0.732 . . . . 0.0 112.219 -176.299 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.858 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -100.89 28.69 14.82 Favored Glycine 0 N--CA 1.467 0.716 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.366 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.489 ' H ' HD22 ' D' ' 27' ' ' ASN . 19.6 m -83.56 -119.97 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -177.31 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' E' ' 29' ' ' GLY . 8.5 m120 -91.35 -151.53 0.26 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.852 -175.765 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp 44.1 -47.4 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 -176.652 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 130.98 60.54 0.09 OUTLIER Glycine 0 N--CA 1.49 2.252 0 CA-C-N 122.629 2.468 . . . . 0.0 115.899 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.83 116.92 11.69 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 119.301 1.55 . . . . 0.0 110.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.499 HD11 ' HB ' ' Q' ' 39' ' ' VAL . 77.6 mt -125.26 146.75 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.798 -177.264 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -134.2 113.62 17.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 O-C-N 121.438 -0.789 . . . . 0.0 110.426 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.82 107.53 2.02 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 20.4 tp -128.4 120.5 27.08 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.288 0.566 . . . . 0.0 112.271 -177.234 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 53.3 tpp -106.69 121.18 43.83 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.154 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.515 ' O ' ' O ' ' E' ' 37' ' ' GLY . 83.7 t -109.42 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.515 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -22.66 152.95 0.0 OUTLIER Glycine 0 N--CA 1.479 1.518 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.296 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . -54.94 -54.41 33.79 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.004 -0.887 . . . . 0.0 114.492 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.6 HG23 HD11 ' K' ' 31' ' ' ILE . 70.5 t . . . . . 0 N--CA 1.477 0.896 0 CA-C-N 119.17 1.485 . . . . 0.0 110.395 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 . . . . . 0 N--CA 1.469 0.519 0 CA-C-O 120.664 0.269 . . . . 0.0 110.752 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.41 122.84 67.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.167 0.508 . . . . 0.0 110.842 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.709 ' N ' ' HD1' ' F' ' 13' ' ' HIS . 0.3 OUTLIER -154.64 121.59 5.55 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.265 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.627 ' C ' ' HD1' ' F' ' 14' ' ' HIS . 0.1 OUTLIER -151.8 166.25 31.95 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.853 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.563 HE22 ' H ' ' D' ' 37' ' ' GLY . 12.3 tt0 -89.82 156.68 18.33 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 16' ' ' LYS . . . . . 0.465 ' C ' HD22 ' F' ' 17' ' ' LEU . 76.7 tttt -141.83 101.55 3.98 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 120.729 -0.389 . . . . 0.0 110.862 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.909 HD22 ' N ' ' F' ' 17' ' ' LEU . 0.2 OUTLIER -118.0 111.68 19.26 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -107.77 110.04 30.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.442 ' CD1' HD13 ' D' ' 32' ' ' ILE . 29.3 m-85 -106.31 103.29 12.73 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 178.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -123.31 129.48 51.39 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.619 0.723 . . . . 0.0 110.589 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.539 ' HB1' ' O ' ' E' ' 21' ' ' ALA . . . -147.63 149.03 31.74 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 120.042 -0.663 . . . . 0.0 109.372 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.31 121.73 17.47 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.695 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.46 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 67.4 t0 . . . . . 0 CA--C 1.53 0.188 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.514 -0.415 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 10.4 tt -133.13 136.3 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 CA-C-O 122.103 0.954 . . . . 0.0 112.704 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 89.9 mt -122.17 131.9 72.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 111.34 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.76 119.93 3.66 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.9 tp -125.47 126.52 45.04 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mtp -142.53 142.39 32.23 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.598 HG22 ' N ' ' F' ' 37' ' ' GLY . 2.3 p -140.78 171.39 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.529 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.598 ' N ' HG22 ' F' ' 36' ' ' VAL . . . -168.03 94.15 0.11 Allowed Glycine 0 C--N 1.306 -1.086 0 C-N-CA 119.202 -1.475 . . . . 0.0 111.887 179.023 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 38' ' ' GLY . . . . . 0.503 ' O ' HG23 ' F' ' 39' ' ' VAL . . . 165.27 -81.44 0.11 Allowed Glycine 0 CA--C 1.529 0.929 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.308 176.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.503 HG23 ' O ' ' F' ' 38' ' ' GLY . 40.2 t -156.5 130.99 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-O 121.488 0.661 . . . . 0.0 110.45 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.636 179.765 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 121.042 0.448 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 79.5 m80 -110.0 151.28 27.35 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.152 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.539 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 0.5 OUTLIER -84.33 168.02 16.01 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.175 0.512 . . . . 0.0 110.838 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.539 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 99.6 mm-40 -154.97 142.35 19.57 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -84.7 121.82 28.2 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.745 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 92.5 mt -126.25 127.92 46.38 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -141.4 139.14 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.907 0.384 . . . . 0.0 111.595 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -135.79 137.16 41.32 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.246 0.546 . . . . 0.0 110.747 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.486 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 53.6 p90 -132.9 130.2 39.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.439 -178.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.83 125.86 48.6 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.622 0.725 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -156.5 -121.25 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.151 -0.931 . . . . 0.0 108.961 -178.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 55.5 p30 . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 124.425 1.09 . . . . 0.0 113.688 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 11.3 m120 . . . . . 0 CA--C 1.534 0.346 0 N-CA-C 112.074 0.398 . . . . 0.0 112.074 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -110.59 -39.78 4.79 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 122.437 1.113 . . . . 0.0 108.601 175.367 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 79.6 -69.35 3.03 Favored Glycine 0 CA--C 1.536 1.396 0 CA-C-N 113.037 -1.892 . . . . 0.0 113.061 178.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.483 ' HB2' ' O ' ' G' ' 29' ' ' GLY . . . 179.45 79.98 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 118.162 0.981 . . . . 0.0 113.245 176.673 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 81.1 mt -122.25 107.07 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.978 1.263 . . . . 0.0 107.612 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.41 HD13 ' CD1' ' I' ' 19' ' ' PHE . 93.9 mt -122.29 112.08 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.436 0.636 . . . . 0.0 112.393 -177.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.64 103.54 1.46 Allowed Glycine 0 N--CA 1.461 0.328 0 N-CA-C 105.279 -3.128 . . . . 0.0 105.279 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.0 mt -143.29 162.89 34.47 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 123.556 1.646 . . . . 0.0 115.174 -175.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -113.19 107.72 16.3 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 111.367 -2.651 . . . . 0.0 104.087 175.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 27.4 t -122.25 131.61 72.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.73 -111.33 3.27 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.447 ' O ' HG12 ' H' ' 39' ' ' VAL . . . 74.5 -73.92 1.34 Allowed Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.08 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 t -79.62 168.59 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.813 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.09 138.53 43.09 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.836 0.351 . . . . 0.0 110.792 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -126.86 140.73 52.13 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.719 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.95 131.63 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 120.869 0.366 . . . . 0.0 110.133 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -124.75 159.56 30.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.977 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -119.25 172.98 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -92.53 149.33 21.43 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.41 ' HD2' ' CE1' ' G' ' 14' ' ' HIS . 64.8 mttp -101.42 128.24 47.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.8 tp -122.84 124.51 43.44 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.04 0.448 . . . . 0.0 111.377 -179.341 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.93 124.8 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.098 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -133.4 126.62 31.66 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.402 ' CZ ' ' HB3' ' G' ' 20' ' ' PHE . 37.4 p90 -145.33 143.51 30.2 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 119.141 -1.024 . . . . 0.0 112.379 178.773 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.99 123.83 43.38 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.942 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.73 162.77 35.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 120.126 -0.63 . . . . 0.0 112.509 -178.22 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 59.92 47.2 10.24 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.054 -0.976 . . . . 0.0 112.742 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.609 HG12 ' H ' ' H' ' 26' ' ' SER . 2.4 t -83.4 166.96 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 116.515 -2.074 . . . . 0.0 107.26 -179.263 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.37 -36.33 59.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 119.628 -1.272 . . . . 0.0 114.723 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.768 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.8 t -174.14 126.66 0.35 Allowed 'General case' 0 C--O 1.224 -0.273 0 CA-C-O 117.723 -1.132 . . . . 0.0 112.147 -176.595 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.768 ' O ' ' O ' ' H' ' 26' ' ' SER . 8.8 t-20 -2.44 146.4 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 175.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 58.9 tttt -159.31 30.34 0.2 Allowed 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.486 ' HA3' HG21 ' B' ' 39' ' ' VAL . . . 82.72 89.24 0.69 Allowed Glycine 0 C--N 1.345 1.044 0 C-N-CA 117.17 -2.443 . . . . 0.0 114.108 176.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.524 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -110.41 102.65 11.26 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 123.371 1.558 . . . . 0.0 112.045 -178.231 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.574 HD11 HG13 ' B' ' 39' ' ' VAL . 80.7 mt -123.02 131.01 74.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 112.765 -2.016 . . . . 0.0 110.651 -179.691 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.584 HD13 ' CD1' ' J' ' 19' ' ' PHE . 81.3 mt -113.21 108.75 26.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 175.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.66 121.82 4.5 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -178.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.643 ' CD2' HD11 ' I' ' 34' ' ' LEU . 0.8 OUTLIER -169.49 163.16 10.36 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 123.904 1.811 . . . . 0.0 113.91 -179.925 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -100.21 116.55 32.47 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 111.483 -2.598 . . . . 0.0 108.576 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' I' ' 35' ' ' MET . 53.8 t -127.8 123.69 61.53 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.565 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.13 -114.35 2.26 Favored Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.412 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.35 -72.68 2.77 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.54 ' HB ' HG21 ' N' ' 31' ' ' ILE . 2.5 p -152.07 151.23 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 O-C-N 122.7 -0.294 . . . . 0.0 110.47 177.631 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.621 HG21 ' CD2' ' J' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.218 -0.563 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.454 178.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.76 161.4 41.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.74 0.305 . . . . 0.0 110.448 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.41 139.24 51.72 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.578 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 4.7 m -126.89 136.46 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -138.91 93.62 2.72 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.537 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.456 ' CB ' ' O ' ' J' ' 14' ' ' HIS . 52.3 p-80 -157.1 153.47 27.86 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 118.793 -1.163 . . . . 0.0 112.52 176.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -90.81 161.49 15.25 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.748 176.366 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -139.47 110.98 7.08 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 177.557 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' I' ' 17' ' ' LEU . 4.3 mp -129.47 131.63 46.73 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.264 0.554 . . . . 0.0 110.942 178.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 76.0 t -121.15 120.14 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.41 ' CD1' HD13 ' G' ' 32' ' ' ILE . 61.3 m-85 -118.53 111.16 18.26 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -121.66 135.21 54.98 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 122.311 -0.243 . . . . 0.0 111.358 -178.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 1.113 ' HB1' ' HZ1' ' I' ' 28' ' ' LYS . . . -139.28 136.05 34.49 Favored 'General case' 0 CA--C 1.555 1.152 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.338 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.489 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 79.7 tt0 -117.29 152.75 34.23 Favored 'General case' 0 N--CA 1.484 1.266 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.259 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.466 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 16.8 t70 -171.49 51.23 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -177.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.437 HG22 ' HB2' ' J' ' 23' ' ' ASP . 16.8 t -63.19 151.04 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.47 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.92 -35.27 4.96 Favored Glycine 0 CA--C 1.539 1.538 0 CA-C-N 116.153 -0.476 . . . . 0.0 113.639 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' I' ' 27' ' ' ASN . 28.9 t -151.68 124.15 8.35 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.643 ' HA ' HG11 ' J' ' 24' ' ' VAL . 1.7 m-20 -41.19 145.86 0.21 Allowed 'General case' 0 C--N 1.348 0.514 0 C-N-CA 118.396 -1.322 . . . . 0.0 109.774 -175.687 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 1.113 ' HZ1' ' HB1' ' I' ' 21' ' ' ALA . 18.3 tttt -75.08 -49.65 19.01 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -177.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 109.51 59.43 0.52 Allowed Glycine 0 CA--C 1.545 1.964 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -177.293 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.1 114.2 26.08 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -172.565 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 82.8 mt -134.28 127.25 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 113.858 -1.519 . . . . 0.0 109.334 176.489 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.538 HD13 ' HD2' ' K' ' 19' ' ' PHE . 14.2 tt -121.01 114.96 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.548 177.344 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.739 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -109.21 108.7 2.62 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.739 HD12 ' O ' ' I' ' 33' ' ' GLY . 2.4 mp -135.12 148.2 49.71 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.952 1.358 . . . . 0.0 114.116 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.44 ' O ' ' O ' ' H' ' 36' ' ' VAL . 86.4 mmm -107.75 112.72 25.54 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-N 112.686 -2.052 . . . . 0.0 106.809 175.332 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.433 ' O ' ' O ' ' J' ' 35' ' ' MET . 4.8 t -136.51 161.91 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.012 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.71 ' H ' HE22 ' K' ' 15' ' ' GLN . . . 81.1 102.44 0.33 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 119.424 -1.37 . . . . 0.0 112.005 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.44 ' N ' ' CA ' ' J' ' 38' ' ' GLY . . . -154.45 -71.12 0.01 OUTLIER Glycine 0 CA--C 1.544 1.847 0 CA-C-O 118.899 -0.945 . . . . 0.0 111.406 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.489 HG13 ' O ' ' O' ' 29' ' ' GLY . 16.0 t -119.3 128.95 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 119.406 1.603 . . . . 0.0 109.137 177.684 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.43 ' OXT' ' O ' ' I' ' 39' ' ' VAL . 77.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.216 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -107.39 132.39 53.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.808 0.337 . . . . 0.0 110.667 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 11' ' ' GLU . . . . . 0.534 ' OE1' ' N ' ' J' ' 11' ' ' GLU . 58.1 mp0 -123.96 134.98 53.37 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.333 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -124.52 132.6 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.568 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.621 ' CD2' HG21 ' H' ' 40' ' ' VAL . 4.2 t-160 -129.01 137.59 51.43 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.163 0.506 . . . . 0.0 110.476 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.538 ' N ' ' CD2' ' J' ' 13' ' ' HIS . 83.1 m-70 -154.85 176.92 11.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 122.103 0.954 . . . . 0.0 111.777 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -159.77 137.14 9.68 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.257 -2.127 . . . . 0.0 105.257 177.298 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.839 ' C ' HD12 ' J' ' 17' ' ' LEU . 84.9 tttt -134.25 113.8 12.36 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.075 -0.65 . . . . 0.0 112.66 -178.669 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.839 HD12 ' C ' ' J' ' 16' ' ' LYS . 7.0 mp -133.87 117.67 17.08 Favored 'General case' 0 CA--C 1.508 -0.64 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 176.824 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -106.8 110.01 30.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.1 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.584 ' CD1' HD13 ' H' ' 32' ' ' ILE . 62.6 m-85 -108.12 104.18 13.54 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 178.759 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.435 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 5.0 m-85 -123.24 129.91 52.03 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 118.76 20.33 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.476 ' OE2' ' CE1' ' K' ' 20' ' ' PHE . 76.0 mt-10 -145.81 133.41 20.95 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 -176.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.796 ' OD1' HG23 ' J' ' 24' ' ' VAL . 0.2 OUTLIER 164.69 -70.4 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.404 175.643 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.796 HG23 ' OD1' ' J' ' 23' ' ' ASP . 22.8 t -58.17 -121.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 113.761 -1.563 . . . . 0.0 110.415 175.231 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.661 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 142.08 -35.55 1.75 Allowed Glycine 0 C--O 1.222 -0.64 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.591 -179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.402 ' O ' ' CG ' ' I' ' 27' ' ' ASN . 10.2 t -80.45 118.55 22.17 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 122.606 3.203 . . . . 0.0 103.119 169.009 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.667 ' CG ' ' H ' ' J' ' 30' ' ' ALA . 21.7 p30 -90.6 158.84 16.75 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 123.413 2.824 . . . . 0.0 110.966 178.191 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -48.12 -40.42 23.53 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 122.823 1.297 . . . . 0.0 110.985 173.386 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.43 67.85 0.04 OUTLIER Glycine 0 CA--C 1.545 1.911 0 CA-C-N 111.854 -2.43 . . . . 0.0 108.586 -174.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.667 ' H ' ' CG ' ' J' ' 27' ' ' ASN . . . -70.31 138.68 51.7 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-N 120.169 1.984 . . . . 0.0 114.2 -171.808 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.673 HD11 ' CG2' ' D' ' 39' ' ' VAL . 86.2 mt -140.22 136.8 37.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-N 112.906 -1.952 . . . . 0.0 114.606 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.422 ' O ' HG22 ' J' ' 32' ' ' ILE . 4.7 mt -108.74 109.3 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.92 108.66 2.43 Favored Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.417 HD12 ' O ' ' I' ' 34' ' ' LEU . 12.7 tp -142.49 136.85 29.79 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 118.674 -1.21 . . . . 0.0 113.657 -175.041 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.433 ' O ' ' O ' ' I' ' 36' ' ' VAL . 0.6 OUTLIER -104.89 120.57 41.75 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.211 -1.813 . . . . 0.0 107.145 177.109 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.572 ' CG1' ' NE2' ' L' ' 15' ' ' GLN . 43.4 t -125.11 167.35 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 121.315 0.578 . . . . 0.0 110.897 -176.1 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.483 ' N ' HG12 ' J' ' 36' ' ' VAL . . . 106.65 102.49 2.8 Favored Glycine 0 N--CA 1.467 0.752 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.891 178.207 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.516 ' O ' ' C ' ' J' ' 39' ' ' VAL . . . -121.89 65.61 0.48 Allowed Glycine 0 CA--C 1.539 1.593 0 CA-C-O 117.858 -1.523 . . . . 0.0 113.125 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.643 ' HB ' HD11 ' P' ' 31' ' ' ILE . 71.1 t -12.84 127.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 CA-C-N 119.905 1.852 . . . . 0.0 113.769 -176.031 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.42 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 10.7 m . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.943 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.462 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -107.1 135.7 48.21 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.862 0.363 . . . . 0.0 110.385 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 57.6 mp0 -131.82 146.06 51.92 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.954 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 55.6 t -123.82 128.5 74.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.082 0.468 . . . . 0.0 110.769 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.561 ' CD2' ' HB3' ' J' ' 13' ' ' HIS . 48.6 m80 -148.05 100.21 3.15 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.638 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.66 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 4.7 m80 -145.14 157.71 44.02 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.901 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.71 HE22 ' H ' ' I' ' 37' ' ' GLY . 79.3 mt-30 -90.27 159.25 16.78 Favored 'General case' 0 CA--C 1.515 -0.4 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 174.54 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -140.71 103.62 4.55 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.502 177.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.42 HD22 HG21 ' I' ' 36' ' ' VAL . 5.1 mp -131.47 119.61 21.82 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.549 0.69 . . . . 0.0 109.456 177.504 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.1 t -106.05 113.01 41.7 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 114.766 -1.107 . . . . 0.0 108.629 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.538 ' HD2' HD13 ' I' ' 32' ' ' ILE . 1.8 m-85 -105.95 101.59 11.08 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.584 -1.636 . . . . 0.0 106.584 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.476 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 40.6 t80 -117.95 126.83 53.09 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 120.984 0.421 . . . . 0.0 111.064 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -146.79 142.33 27.62 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 119.657 -0.817 . . . . 0.0 112.727 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 85.6 mt-10 -82.68 115.56 21.67 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.544 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.516 ' CG ' HD22 ' J' ' 27' ' ' ASN . 68.5 t0 -131.85 46.4 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.732 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.584 HG12 ' H ' ' K' ' 25' ' ' GLY . 6.4 t -83.48 171.76 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.277 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.755 -177.064 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.584 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 95.45 -29.43 9.64 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.004 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 91.81 115.1 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 -178.658 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.452 ' ND2' ' H ' ' K' ' 28' ' ' LYS . 9.1 t-20 -73.79 163.13 28.36 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 118.377 -1.329 . . . . 0.0 111.378 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.578 ' NZ ' ' NE2' ' F' ' 13' ' ' HIS . 99.1 mttt -48.12 -37.24 14.95 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.853 175.393 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.99 76.92 0.06 OUTLIER Glycine 0 CA--C 1.541 1.684 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.755 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.416 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -79.95 139.89 36.88 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 119.133 1.466 . . . . 0.0 110.173 -178.413 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.6 HD11 HG23 ' E' ' 39' ' ' VAL . 7.1 mt -130.85 133.71 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -175.398 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.459 HD11 HG12 ' L' ' 32' ' ' ILE . 33.7 pt -121.0 118.77 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 121.596 0.712 . . . . 0.0 109.323 176.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 118.24 4.22 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -178.998 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.594 ' CD2' ' CE2' ' L' ' 19' ' ' PHE . 4.2 mp -129.03 118.42 22.52 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.973 0.892 . . . . 0.0 111.716 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -102.74 115.31 30.33 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.193 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.675 HG12 ' N ' ' K' ' 37' ' ' GLY . 42.6 t -116.76 174.12 3.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.675 ' N ' HG12 ' K' ' 36' ' ' VAL . . . 163.05 -95.41 0.13 Allowed Glycine 0 C--N 1.305 -1.181 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' K' ' 37' ' ' GLY . . . 28.48 78.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.401 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.56 HG13 ' O ' ' L' ' 39' ' ' VAL . 90.5 t . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.735 0.303 . . . . 0.0 110.387 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.59 122.01 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.17 0.509 . . . . 0.0 110.786 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.489 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -153.12 101.21 2.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.63 179.47 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.66 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.7 m80 -146.28 164.34 32.65 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.572 ' NE2' ' CG1' ' J' ' 36' ' ' VAL . 5.2 tt0 -90.02 158.45 17.34 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.636 0.236 . . . . 0.0 111.636 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.53 109.57 6.11 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 121.55 0.69 . . . . 0.0 111.555 178.165 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 22.4 mt -128.68 117.26 20.88 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -105.14 108.47 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.613 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.58 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' K' ' 34' ' ' LEU . 42.8 m-85 -102.45 105.36 15.92 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.52 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -129.19 122.01 28.86 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.642 0.734 . . . . 0.0 111.099 -178.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -129.35 133.0 47.2 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.454 ' O ' ' C ' ' K' ' 23' ' ' ASP . 79.6 mm-40 -77.27 114.76 16.43 Favored 'General case' 0 C--O 1.222 -0.388 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.641 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p30 -168.5 46.46 0.04 OUTLIER 'General case' 0 C--O 1.231 0.099 0 C-N-CA 119.838 -0.745 . . . . 0.0 112.833 -178.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.2 m -83.65 172.68 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 119.225 -0.99 . . . . 0.0 108.941 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.51 -29.82 8.57 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 15.7 p -84.77 139.9 31.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.38 -0.41 . . . . 0.0 110.993 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' N ' ' L' ' 29' ' ' GLY . 61.6 t-20 -73.15 149.17 43.19 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.509 ' N ' ' OD1' ' L' ' 27' ' ' ASN . 6.3 tmtt? 64.68 -49.71 0.32 Allowed 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 94.83 -54.79 1.92 Allowed Glycine 0 CA--C 1.542 1.745 0 CA-C-N 116.201 -0.454 . . . . 0.0 114.079 177.436 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.416 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -170.42 -172.75 1.31 Allowed 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 117.666 0.733 . . . . 0.0 109.69 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 97.8 mt -98.41 119.09 45.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 176.33 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.459 HG12 HD11 ' K' ' 32' ' ' ILE . 88.9 mt -115.3 122.84 70.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -177.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 106.22 0.84 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 178.118 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 10.0 tt -133.45 131.17 39.59 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 33.4 ttp -151.59 160.3 43.72 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.709 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 27.1 m -109.47 173.96 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.339 0.123 0 CA-C-O 121.152 0.501 . . . . 0.0 111.108 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.451 ' H ' ' HA2' ' K' ' 37' ' ' GLY . . . -166.51 94.64 0.11 Allowed Glycine 0 C--N 1.306 -1.098 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.03 83.4 0.79 Allowed Glycine 0 N--CA 1.473 1.149 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.56 ' O ' HG13 ' K' ' 39' ' ' VAL . 21.8 m . . . . . 0 CA--C 1.535 0.393 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 N--CA 1.463 0.198 0 CA-C-O 120.762 0.315 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -126.83 130.17 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 121.198 0.523 . . . . 0.0 110.15 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -124.52 163.06 22.68 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.172 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 41.9 p-80 -87.41 170.76 11.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.217 -179.447 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.14 150.95 50.31 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.017 179.116 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -96.65 123.77 40.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.214 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -127.8 116.06 19.6 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -126.27 134.51 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.09 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -137.29 141.04 41.93 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 178.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -144.42 146.84 32.71 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.413 -179.649 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.52 119.71 21.92 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.144 0.497 . . . . 0.0 110.462 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 22' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' M' ' 24' ' ' VAL . 97.5 mt-10 -103.59 -162.71 0.93 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.544 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 23' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' M' ' 22' ' ' GLU . 96.9 m-20 -23.64 -59.69 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 123.222 0.609 . . . . 0.0 112.345 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.454 ' O ' ' O ' ' M' ' 22' ' ' GLU . 32.6 m -91.3 169.87 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -178.636 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.37 28.36 57.98 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 11.9 t -97.02 110.7 23.19 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 p30 -78.14 175.42 10.17 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -176.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -49.75 -36.23 25.07 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 112.507 -2.133 . . . . 0.0 115.074 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.94 78.63 0.06 OUTLIER Glycine 0 N--CA 1.471 1.012 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.643 -172.425 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.03 108.62 0.26 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-O 124.362 2.029 . . . . 0.0 113.306 -175.542 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.552 HG23 ' O ' ' M' ' 31' ' ' ILE . 15.1 tt -128.34 125.71 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 110.537 -3.028 . . . . 0.0 108.388 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 92.8 mt -102.64 108.88 25.12 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.527 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.92 92.82 0.67 Allowed Glycine 0 CA--C 1.508 -0.352 0 N-CA-C 105.44 -3.064 . . . . 0.0 105.44 176.827 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 34' ' ' LEU . . . . . 0.632 ' O ' HD23 ' N' ' 34' ' ' LEU . 92.8 mt -135.36 156.57 48.71 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 122.81 1.29 . . . . 0.0 113.861 -176.408 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -108.9 105.27 14.75 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 112.426 -2.17 . . . . 0.0 106.25 176.539 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.583 HG23 HD21 ' N' ' 34' ' ' LEU . 50.4 t -106.12 111.83 36.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.03 -132.12 8.74 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.418 ' O ' HG12 ' N' ' 39' ' ' VAL . . . 93.81 -63.19 1.87 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.621 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.67 HG12 ' CD1' ' A' ' 31' ' ' ILE . 1.2 m -111.14 161.3 9.74 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -178.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.949 -1.025 . . . . 0.0 110.764 -179.987 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -81.71 138.37 35.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.758 0.313 . . . . 0.0 110.27 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -76.45 116.33 17.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.692 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.438 HG12 ' H ' ' O' ' 12' ' ' VAL . 34.5 m -137.7 157.63 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.112 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -145.46 98.81 3.2 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.871 0.367 . . . . 0.0 111.311 179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.477 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 28.4 p-80 -153.98 168.12 27.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.338 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -129.45 150.35 50.84 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 110.064 178.105 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -98.15 124.0 42.49 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.282 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.4 ' C ' HD23 ' N' ' 17' ' ' LEU . 7.6 tt -125.84 124.45 40.93 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.483 0.583 . . . . 0.0 109.701 178.563 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -125.94 134.41 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.603 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 19' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' N' ' 21' ' ' ALA . 74.4 t80 -130.63 120.3 23.75 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.811 0.339 . . . . 0.0 111.051 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -112.36 127.77 56.1 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 21' ' ' ALA . . . . . 0.438 ' HB2' ' CE2' ' N' ' 19' ' ' PHE . . . -132.75 132.91 42.8 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-N 118.584 0.629 . . . . 0.0 111.958 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -170.09 128.44 0.89 Allowed 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.023 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.465 ' CG ' ' H ' ' N' ' 24' ' ' VAL . 16.6 p-10 -155.05 -59.81 0.11 Allowed 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 119.89 -0.724 . . . . 0.0 111.618 177.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.465 ' H ' ' CG ' ' N' ' 23' ' ' ASP . 16.9 m -102.87 -176.83 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.94 -33.69 70.5 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 1.5 m -147.86 118.87 7.66 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -59.9 169.06 1.56 Allowed 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 117.919 -1.512 . . . . 0.0 110.922 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -54.69 -36.96 65.23 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 115.305 1.594 . . . . 0.0 115.305 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.75 77.58 0.07 OUTLIER Glycine 0 CA--C 1.54 1.634 0 C-N-CA 120.123 -1.037 . . . . 0.0 113.429 -174.448 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.86 116.71 20.17 Favored 'General case' 0 CA--C 1.548 0.894 0 CA-C-N 118.866 1.333 . . . . 0.0 113.638 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.54 HG21 ' HB ' ' H' ' 39' ' ' VAL . 2.8 tt -146.08 134.09 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.125 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.51 HG22 HD11 ' O' ' 34' ' ' LEU . 15.8 mt -109.38 120.55 60.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 CA-C-O 120.971 0.415 . . . . 0.0 110.64 179.427 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.03 112.75 2.68 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 105.795 -2.922 . . . . 0.0 105.795 176.389 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.632 HD23 ' O ' ' M' ' 34' ' ' LEU . 0.3 OUTLIER -151.91 144.13 23.97 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 117.773 -1.571 . . . . 0.0 115.074 -175.206 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.406 ' SD ' ' HB2' ' O' ' 35' ' ' MET . 89.7 mmm -105.8 108.36 19.84 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.404 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . 2.0 t -106.9 101.79 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 118.878 0.763 . . . . 0.0 110.884 -177.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.09 -171.14 20.56 Favored Glycine 0 C--N 1.323 -0.173 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.488 ' O ' HG12 ' O' ' 39' ' ' VAL . . . 155.66 -55.04 0.41 Allowed Glycine 0 CA--C 1.547 2.036 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 -178.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.7 ' HB ' HD11 ' B' ' 31' ' ' ILE . 10.6 p -159.49 135.26 1.8 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 CA-C-N 117.628 0.714 . . . . 0.0 109.768 177.924 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.462 HG13 ' O ' ' N' ' 39' ' ' VAL . 22.6 m . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.225 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -82.05 137.84 34.97 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.821 0.343 . . . . 0.0 110.488 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -114.74 134.93 54.7 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.592 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.438 ' H ' HG12 ' N' ' 12' ' ' VAL . 75.3 t -122.45 130.25 74.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.856 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.503 ' H ' ' HB3' ' P' ' 13' ' ' HIS . 3.5 t-80 -146.58 102.74 3.6 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.574 0.226 . . . . 0.0 111.364 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' P' ' 14' ' ' HIS . 22.2 p80 -156.34 164.48 38.25 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.919 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -89.84 158.82 17.29 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -140.1 119.23 12.75 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -135.82 130.02 33.33 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 122.321 1.057 . . . . 0.0 111.777 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 18' ' ' VAL . . . . . 0.599 HG13 HG13 ' P' ' 18' ' ' VAL . 48.1 t -112.09 118.23 57.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 177.637 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -110.32 102.78 11.4 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 14.6 t80 -114.83 127.8 55.93 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.73 115.11 20.86 Favored 'General case' 0 C--O 1.243 0.742 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.457 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 22' ' ' GLU . . . . . 0.448 ' O ' ' C ' ' O' ' 23' ' ' ASP . 83.0 tt0 -86.7 151.28 23.55 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.142 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.448 ' C ' ' O ' ' O' ' 22' ' ' GLU . 49.0 t0 26.83 49.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.904 -176.154 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.656 HG11 ' HB1' ' P' ' 21' ' ' ALA . 1.1 p -68.75 154.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.013 -1.449 . . . . 0.0 108.179 175.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.424 ' N ' ' CG2' ' O' ' 24' ' ' VAL . . . -131.51 -28.81 0.61 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.667 ' OG ' ' HB2' ' O' ' 30' ' ' ALA . 3.3 t 63.69 -110.14 0.28 Allowed 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.53 178.66 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.559 ' N ' ' OG ' ' O' ' 26' ' ' SER . 32.9 m-20 150.51 -161.37 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.551 0 O-C-N 124.473 1.108 . . . . 0.0 109.153 -178.259 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.444 ' H ' ' HB3' ' O' ' 27' ' ' ASN . 98.8 mttt -29.71 -40.4 0.02 OUTLIER 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -179.013 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.489 ' O ' HG13 ' I' ' 39' ' ' VAL . . . -170.07 70.05 0.14 Allowed Glycine 0 CA--C 1.541 1.662 0 C-N-CA 118.489 -1.815 . . . . 0.0 115.908 -173.074 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 30' ' ' ALA . . . . . 0.667 ' HB2' ' OG ' ' O' ' 26' ' ' SER . . . -72.75 150.18 43.06 Favored 'General case' 0 C--N 1.363 1.175 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.423 HG22 ' N ' ' O' ' 32' ' ' ILE . 20.6 mt -140.69 149.85 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 118.076 2.621 . . . . 0.0 118.076 -171.525 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.722 HG23 HD13 ' O' ' 34' ' ' LEU . 6.7 mt -111.78 106.76 21.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 N-CA-C 104.871 -2.27 . . . . 0.0 104.871 173.152 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.799 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -117.43 98.5 0.78 Allowed Glycine 0 N--CA 1.473 1.15 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.799 HD12 ' C ' ' O' ' 33' ' ' GLY . 8.8 mp -136.67 151.92 49.82 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 123.698 1.713 . . . . 0.0 114.433 -175.462 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.406 ' HB2' ' SD ' ' N' ' 35' ' ' MET . 0.8 OUTLIER -113.15 112.04 23.13 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 111.947 -2.388 . . . . 0.0 106.019 176.483 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.09 147.69 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.229 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' O' O ' 37' ' ' GLY . . . . . 0.921 ' H ' HE22 ' Q' ' 15' ' ' GLN . . . 127.32 103.04 1.22 Allowed Glycine 0 C--N 1.307 -1.057 0 N-CA-C 109.384 -1.487 . . . . 0.0 109.384 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.525 ' O ' ' C ' ' O' ' 39' ' ' VAL . . . -108.47 72.42 0.2 Allowed Glycine 0 CA--C 1.533 1.179 0 CA-C-O 117.612 -1.66 . . . . 0.0 112.074 179.34 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.822 ' H ' HG21 ' P' ' 39' ' ' VAL . 7.6 p -12.86 130.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 CA-C-N 119.804 1.802 . . . . 0.0 113.325 -175.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.426 ' O ' HG23 ' O' ' 40' ' ' VAL . 5.6 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.375 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.613 HG12 ' H ' ' Q' ' 12' ' ' VAL . 19.4 m . . . . . 0 N--CA 1.467 0.412 0 CA-C-O 120.778 0.323 . . . . 0.0 110.545 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.503 ' HB3' ' H ' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -135.44 140.24 44.74 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.449 -179.27 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' O' ' 14' ' ' HIS . 5.5 m-70 -125.42 161.17 27.66 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 178.074 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 27.2 tp60 -89.89 158.15 17.56 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 16' ' ' LYS . . . . . 0.781 ' C ' HD12 ' P' ' 17' ' ' LEU . 68.2 mttm -141.47 100.22 3.73 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.437 178.599 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.781 HD12 ' C ' ' P' ' 16' ' ' LYS . 9.0 mp -134.5 122.8 22.95 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 176.394 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 18' ' ' VAL . . . . . 0.599 HG13 HG13 ' O' ' 18' ' ' VAL . 3.8 p -122.4 127.39 75.08 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -115.87 106.25 13.61 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 30.5 t80 -110.97 125.67 53.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.156 -178.527 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 21' ' ' ALA . . . . . 0.656 ' HB1' HG11 ' O' ' 24' ' ' VAL . . . -138.41 122.74 18.25 Favored 'General case' 0 CA--C 1.553 1.064 0 CA-C-O 121.751 0.786 . . . . 0.0 112.615 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.578 ' O ' HG13 ' O' ' 24' ' ' VAL . 83.1 tt0 -87.42 116.66 25.68 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.408 -1.269 . . . . 0.0 110.926 179.018 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.565 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 34.2 m-20 -144.81 46.73 1.35 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.051 0.54 . . . . 0.0 112.053 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.85 HG13 ' CD ' ' Q' ' 22' ' ' GLU . 1.0 OUTLIER -82.14 173.37 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 123.229 1.49 . . . . 0.0 113.237 -175.594 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.42 -33.66 4.84 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-N 111.286 -2.688 . . . . 0.0 113.992 177.054 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.712 ' O ' ' O ' ' P' ' 27' ' ' ASN . 13.3 t -174.16 126.61 0.35 Allowed 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 118.974 1.387 . . . . 0.0 112.819 175.672 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.712 ' O ' ' O ' ' P' ' 26' ' ' SER . 1.0 OUTLIER -2.69 145.94 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 173.751 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.435 ' CG ' ' O ' ' P' ' 27' ' ' ASN . 93.1 mttt -158.48 30.34 0.23 Allowed 'General case' 0 N--CA 1.475 0.806 0 O-C-N 120.69 -1.256 . . . . 0.0 114.033 176.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.31 88.81 0.9 Allowed Glycine 0 CA--C 1.531 1.065 0 C-N-CA 119.503 -1.332 . . . . 0.0 113.727 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.88 105.54 7.83 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 117.871 0.836 . . . . 0.0 112.047 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.643 HD11 ' HB ' ' J' ' 39' ' ' VAL . 58.4 mt -119.21 124.25 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 CA-C-O 119.27 -0.395 . . . . 0.0 110.056 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.468 HD13 ' CD1' ' R' ' 19' ' ' PHE . 49.9 mt -109.91 110.55 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.802 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.56 100.06 1.04 Allowed Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 104.588 -3.405 . . . . 0.0 104.588 175.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 tt -144.63 137.37 26.63 Favored 'General case' 0 C--O 1.241 0.635 0 C-N-CA 118.681 -1.207 . . . . 0.0 112.883 -174.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 22.1 mtp -112.27 127.73 56.06 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 113.837 -1.529 . . . . 0.0 110.512 179.172 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.505 HG11 HD13 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -117.74 103.18 14.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.22 -153.48 25.09 Favored Glycine 0 C--N 1.308 -0.983 0 C-N-CA 119.276 -1.44 . . . . 0.0 111.191 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.702 ' H ' ' CG1' ' Q' ' 40' ' ' VAL . . . 99.16 -56.45 0.92 Allowed Glycine 0 CA--C 1.543 1.795 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.902 HG12 HG21 ' D' ' 31' ' ' ILE . 27.7 m -128.88 160.2 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.73 0.812 . . . . 0.0 112.265 -177.602 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.415 ' H ' HG23 ' P' ' 40' ' ' VAL . 2.8 t . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.719 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.79 90.13 3.24 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -142.77 147.97 36.42 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.766 0.317 . . . . 0.0 110.596 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.613 ' H ' HG12 ' P' ' 12' ' ' VAL . 2.2 p -140.87 135.86 33.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.658 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 4.6 m80 -142.63 125.0 15.57 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.651 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.415 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 10.2 p80 -152.61 160.42 43.19 Favored 'General case' 0 C--O 1.222 -0.368 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.645 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.921 HE22 ' H ' ' O' ' 37' ' ' GLY . 88.3 mt-30 -90.03 158.92 17.12 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 176.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -140.73 108.35 5.61 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.074 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.424 ' N ' HD12 ' Q' ' 17' ' ' LEU . 3.8 mp -130.97 124.13 30.32 Favored 'General case' 0 CA--C 1.511 -0.52 0 C-N-CA 119.962 -0.695 . . . . 0.0 109.726 177.083 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -110.1 122.34 64.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.519 ' CE2' ' CE1' ' R' ' 19' ' ' PHE . 24.0 m-85 -112.03 99.9 8.45 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 178.647 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -108.96 121.2 44.63 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.422 -177.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.568 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -152.76 161.12 42.98 Favored 'General case' 0 C--O 1.217 -0.625 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.628 -179.017 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.85 ' CD ' HG13 ' P' ' 24' ' ' VAL . 99.6 mt-10 -87.55 114.52 24.23 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.781 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 68.4 t0 -109.23 52.0 0.73 Allowed 'General case' 0 N--CA 1.478 0.949 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.071 -177.528 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.559 HG12 ' N ' ' Q' ' 25' ' ' GLY . 38.5 t -41.43 161.38 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.983 0.897 . . . . 0.0 112.247 -176.15 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.559 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . -93.14 32.59 5.58 Favored Glycine 0 N--CA 1.468 0.798 0 CA-C-N 113.848 -1.524 . . . . 0.0 114.273 -174.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 69.5 m -92.62 -112.38 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 117.593 0.696 . . . . 0.0 109.936 -178.233 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.502 ' O ' ' N ' ' Q' ' 29' ' ' GLY . 84.1 m-20 -85.97 179.18 7.05 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 119.853 1.206 . . . . 0.0 112.91 -176.674 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -52.58 48.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -98.56 56.57 1.01 Allowed Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.164 -1.017 . . . . 0.0 112.936 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.63 103.49 0.7 Allowed 'General case' 0 C--O 1.24 0.56 0 CA-C-N 119.013 1.406 . . . . 0.0 112.921 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.418 HD13 HG21 ' Q' ' 31' ' ' ILE . 1.1 pt -142.69 139.82 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 120.099 -0.64 . . . . 0.0 109.601 177.242 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 4.8 tt -140.23 132.71 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 105.66 1.47 Allowed Glycine 0 C--N 1.337 0.589 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 176.096 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.506 HD23 HD13 ' R' ' 34' ' ' LEU . 53.0 tp -120.47 122.6 41.03 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.642 0.734 . . . . 0.0 112.201 -176.257 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -111.78 115.67 29.44 Favored 'General case' 0 C--O 1.223 -0.301 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.558 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.619 HG12 ' N ' ' Q' ' 37' ' ' GLY . 81.9 t -108.17 171.03 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-O 121.414 0.626 . . . . 0.0 111.26 -178.902 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.619 ' N ' HG12 ' Q' ' 36' ' ' VAL . . . 130.34 93.44 0.66 Allowed Glycine 0 C--N 1.311 -0.835 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.29 -74.46 0.26 Allowed Glycine 0 CA--C 1.534 1.235 0 C-N-CA 121.287 -0.483 . . . . 0.0 112.236 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.586 ' O ' HG23 ' Q' ' 39' ' ' VAL . 34.6 m -81.71 118.19 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.341 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.702 ' CG1' ' H ' ' P' ' 38' ' ' GLY . 3.1 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.414 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -126.78 154.62 44.01 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.915 0.388 . . . . 0.0 110.544 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -68.43 125.42 26.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.583 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 9.2 p -139.97 138.85 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.286 0.565 . . . . 0.0 111.373 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -149.26 105.22 3.47 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.552 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.415 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 93.4 m-70 -145.95 166.47 25.92 Favored 'General case' 0 C--O 1.221 -0.441 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.19 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.608 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -89.73 158.68 17.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.134 0.492 . . . . 0.0 110.66 -179.546 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.778 ' C ' HD12 ' R' ' 17' ' ' LEU . 98.6 mttt -140.22 103.02 4.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.56 -0.745 . . . . 0.0 109.438 178.483 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.778 HD12 ' C ' ' R' ' 16' ' ' LYS . 10.8 mp -124.99 120.85 32.72 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 95.5 t -105.22 116.62 49.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.519 ' CE1' ' CE2' ' Q' ' 19' ' ' PHE . 78.2 m-85 -111.89 103.7 11.95 Favored 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.279 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -140.17 150.65 44.47 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-O 121.804 0.812 . . . . 0.0 111.594 -177.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -139.31 143.48 37.88 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.067 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -82.7 157.62 23.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.513 -178.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 58.69 50.45 8.87 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.773 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.525 HG12 ' N ' ' R' ' 25' ' ' GLY . 24.9 t -48.9 163.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.134 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.525 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -175.76 24.0 0.06 OUTLIER Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -178.4 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 4.3 m -64.94 111.68 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.776 0.798 . . . . 0.0 110.566 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.702 ' O ' ' N ' ' R' ' 29' ' ' GLY . 24.7 t-20 -149.09 176.0 10.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.956 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 28' ' ' LYS . . . . . 0.455 ' C ' ' O ' ' R' ' 27' ' ' ASN . 65.5 tttm -8.95 -45.91 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.952 0 O-C-N 124.401 1.063 . . . . 0.0 113.559 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.702 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -94.49 58.74 1.92 Allowed Glycine 0 CA--C 1.544 1.847 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.823 179.468 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 136.91 9.85 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.433 HD12 HG21 ' K' ' 39' ' ' VAL . 50.5 mt -124.77 119.5 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 CA-C-O 121.627 0.727 . . . . 0.0 111.644 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 mm -113.36 121.84 66.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.782 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 115.98 2.26 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.54 HD12 ' N ' ' R' ' 35' ' ' MET . 7.3 tp -137.03 125.38 23.33 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 35' ' ' MET . . . . . 0.54 ' N ' HD12 ' R' ' 34' ' ' LEU . 9.8 ptm -160.89 172.94 16.07 Favored 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.366 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -124.72 167.33 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-O 121.327 0.584 . . . . 0.0 111.529 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.57 -102.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 114.986 -1.006 . . . . 0.0 111.103 179.068 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.02 -77.87 1.09 Allowed Glycine 0 CA--C 1.532 1.137 0 N-CA-C 111.559 -0.617 . . . . 0.0 111.559 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 79.3 t -121.3 132.37 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 117.17 0.485 . . . . 0.0 110.401 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.467 HG22 ' OXT' ' R' ' 40' ' ' VAL . 4.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.325 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 N--CA 1.466 0.354 0 CA-C-O 120.796 0.332 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.607 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 53.0 t -124.89 131.33 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.144 0.497 . . . . 0.0 110.25 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -93.94 163.06 13.65 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.436 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.643 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -86.0 171.94 11.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.708 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 28.5 pt20 -158.09 142.96 16.44 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.571 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -80.24 133.95 36.05 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.895 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.6 mt -129.29 116.31 18.92 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.971 0.415 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -125.43 133.75 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.954 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -134.94 129.0 33.58 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 53.6 p90 -122.62 130.47 53.03 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.408 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.28 114.99 21.57 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.455 0.645 . . . . 0.0 111.339 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.442 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 74.9 mt-10 -154.92 152.73 30.08 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 22' ' ' GLU . 3.9 p-10 . . . . . 0 N--CA 1.465 0.277 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.461 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 65.4 t30 . . . . . 0 N--CA 1.468 0.449 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.403 ' H ' ' H ' ' A' ' 29' ' ' GLY . 98.3 mttt -156.27 -18.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.24 -1.346 . . . . 0.0 107.817 178.032 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.504 ' HA3' ' H ' ' B' ' 28' ' ' LYS . . . 71.83 -98.47 0.78 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.46 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.79 88.54 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.075 179.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.5 mt -138.12 117.24 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.493 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' B' ' 33' ' ' GLY . 39.7 mt -108.91 112.49 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 93.93 0.64 Allowed Glycine 0 CA--C 1.507 -0.444 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.417 HD12 ' CG2' ' A' ' 32' ' ' ILE . 91.8 mt -140.78 165.0 28.7 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 123.335 1.541 . . . . 0.0 114.289 -175.586 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 38.5 tpp -120.9 107.81 13.14 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 111.999 -2.364 . . . . 0.0 106.786 177.626 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.413 ' HB ' HD21 ' B' ' 34' ' ' LEU . 63.6 t -110.84 124.0 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.9 -114.46 2.73 Favored Glycine 0 C--N 1.318 -0.461 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 -176.49 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.34 -71.92 1.48 Allowed Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.153 -1.022 . . . . 0.0 111.353 178.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.464 ' HA ' ' CD1' ' G' ' 31' ' ' ILE . 34.2 m -111.33 -175.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.714 0.769 . . . . 0.0 111.5 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.546 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.6 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-N 114.247 -1.342 . . . . 0.0 110.309 178.443 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -147.44 158.0 43.8 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.441 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.55 120.7 12.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 121.081 0.467 . . . . 0.0 110.623 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.49 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 16.0 t -130.1 117.39 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.607 ' CE1' ' H ' ' A' ' 12' ' ' VAL . 3.7 m-70 -137.68 112.27 8.79 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.445 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.563 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -151.96 160.13 43.58 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.332 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 78.7 mt-30 -131.95 151.36 51.77 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.983 0.42 . . . . 0.0 111.949 179.069 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -97.76 121.33 39.55 Favored 'General case' 0 C--O 1.238 0.485 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.3 mt -120.93 119.25 32.06 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 118.58 0.627 . . . . 0.0 110.301 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.43 132.43 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.873 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -125.88 124.0 39.89 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.112 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.466 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 34.2 t80 -117.91 126.47 52.42 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.36 141.69 33.81 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -104.36 147.7 27.23 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.14 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 3.4 t70 -171.9 51.89 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.023 -177.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.483 HG22 ' CB ' ' C' ' 23' ' ' ASP . 2.6 t -75.51 143.64 12.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-O 121.726 0.774 . . . . 0.0 111.714 -176.783 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.06 38.18 3.9 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 114.405 -1.27 . . . . 0.0 112.332 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.09 120.0 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 122.192 0.197 . . . . 0.0 110.904 177.541 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.554 ' H ' ' HA3' ' C' ' 25' ' ' GLY . 2.1 m120 -83.38 162.6 20.99 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.373 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.504 ' H ' ' HA3' ' A' ' 29' ' ' GLY . 99.1 mttt -47.24 -37.61 10.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.459 0.647 . . . . 0.0 110.782 175.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.68 0.06 OUTLIER Glycine 0 CA--C 1.54 1.596 0 CA-C-N 115.217 -0.902 . . . . 0.0 111.898 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -51.78 94.87 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 119.634 1.717 . . . . 0.0 112.204 -178.141 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.52 HD12 HG12 ' N' ' 39' ' ' VAL . 69.3 mt -144.62 134.77 19.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.432 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' D' ' 19' ' ' PHE . 91.6 mt -105.08 108.3 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.098 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -112.31 102.55 1.36 Allowed Glycine 0 CA--C 1.508 -0.37 0 N-CA-C 105.539 -3.024 . . . . 0.0 105.539 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.651 ' O ' HD12 ' C' ' 34' ' ' LEU . 7.6 tt -150.62 148.38 28.55 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 118.42 -1.312 . . . . 0.0 112.226 -174.822 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.623 ' N ' HD23 ' B' ' 34' ' ' LEU . 7.2 mtp -110.05 110.09 20.87 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 113.518 -1.674 . . . . 0.0 107.075 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.53 ' O ' HG13 ' B' ' 36' ' ' VAL . 4.1 p -119.62 111.51 33.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.35 -131.24 4.28 Favored Glycine 0 C--N 1.308 -1.007 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -178.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.499 ' O ' ' CG2' ' C' ' 39' ' ' VAL . . . 87.27 -63.93 3.89 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 120.508 -0.853 . . . . 0.0 111.542 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.545 HG11 HD13 ' G' ' 31' ' ' ILE . 3.1 m -136.78 154.17 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.429 ' H ' HG23 ' B' ' 40' ' ' VAL . 0.5 OUTLIER . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.338 -178.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 10' ' ' TYR . . . . . 0.723 ' HH ' ' N ' ' E' ' 9' ' ' GLY . 92.9 m-85 -105.35 133.13 50.62 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.631 0.253 . . . . 0.0 110.384 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -97.65 122.74 41.08 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.651 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.431 ' H ' HG13 ' B' ' 12' ' ' VAL . 19.4 m -125.4 133.07 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.159 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.546 ' CE1' ' OXT' ' A' ' 40' ' ' VAL . 5.6 t-80 -147.85 96.79 2.71 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.896 179.203 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.563 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 50.1 p-80 -157.24 167.57 29.96 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.738 -0.21 . . . . 0.0 111.265 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -89.99 158.45 17.36 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.437 0.637 . . . . 0.0 110.788 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -140.29 113.51 8.43 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 176.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mt -127.94 123.15 34.18 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 122.071 0.938 . . . . 0.0 111.478 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 67.1 t -111.14 117.03 54.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 177.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.432 ' CD2' ' CE2' ' D' ' 19' ' ' PHE . 56.2 m-85 -107.08 105.85 16.07 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 11.7 t80 -113.84 124.41 52.16 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.7 -0.227 . . . . 0.0 111.152 -178.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.66 122.34 30.6 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.647 0.736 . . . . 0.0 110.396 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -94.31 137.99 32.83 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.217 -178.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.516 ' N ' ' OE1' ' D' ' 22' ' ' GLU . 8.7 m-20 43.17 47.12 5.3 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.41 0.624 . . . . 0.0 109.354 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.648 ' O ' HG21 ' D' ' 24' ' ' VAL . 0.2 OUTLIER -61.43 -169.25 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.799 -177.195 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.579 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -111.74 33.34 5.83 Favored Glycine 0 C--N 1.318 -0.427 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.098 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.43 ' O ' ' N ' ' D' ' 26' ' ' SER . 27.3 t -62.63 104.87 0.57 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.497 0.665 . . . . 0.0 109.221 -178.775 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.857 ' O ' ' N ' ' C' ' 29' ' ' GLY . 7.8 m120 -157.6 179.23 9.42 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.616 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm 1.86 -44.7 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 125.067 1.48 . . . . 0.0 114.212 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.857 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -111.14 58.57 0.39 Allowed Glycine 0 CA--C 1.542 1.764 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 178.578 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.423 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -109.35 99.75 8.95 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 117.349 0.575 . . . . 0.0 109.973 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.426 HG22 ' N ' ' D' ' 31' ' ' ILE . 29.7 pt -147.93 156.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 117.88 -1.528 . . . . 0.0 114.385 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' E' ' 19' ' ' PHE . 95.9 mt -107.6 112.15 38.84 Favored 'Isoleucine or valine' 0 C--N 1.345 0.376 0 CA-C-N 114.053 -1.431 . . . . 0.0 108.695 176.35 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.91 93.76 0.74 Allowed Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 104.412 -3.475 . . . . 0.0 104.412 175.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.651 HD12 ' O ' ' B' ' 34' ' ' LEU . 42.3 tp -135.0 132.57 38.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 122.365 1.079 . . . . 0.0 113.294 -174.913 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.417 ' H ' HD12 ' C' ' 34' ' ' LEU . 6.4 mtp -99.99 111.33 23.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.673 177.919 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.532 HG12 ' CD ' ' E' ' 15' ' ' GLN . 3.1 t -110.8 103.32 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.13 -154.62 22.93 Favored Glycine 0 N--CA 1.46 0.254 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.673 178.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.21 -55.89 0.5 Allowed Glycine 0 CA--C 1.545 1.936 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.882 ' C ' HG11 ' D' ' 39' ' ' VAL . 68.6 t -136.04 162.97 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 C-N-CA 123.273 0.629 . . . . 0.0 110.167 178.23 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.676 ' N ' HG21 ' D' ' 39' ' ' VAL . 75.9 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.889 -1.053 . . . . 0.0 111.056 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 1.3 p . . . . . 0 C--O 1.222 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.24 142.65 31.45 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.074 0.464 . . . . 0.0 110.228 179.089 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.554 ' O ' ' CG ' ' C' ' 14' ' ' HIS . 27.7 p-80 -146.12 162.6 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.114 178.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -89.67 158.19 17.68 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.311 179.423 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.675 ' C ' HD22 ' D' ' 17' ' ' LEU . 85.6 tttt -140.68 106.28 5.1 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.719 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.7 mm? -123.37 124.95 44.08 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.849 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -123.11 112.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' B' ' 32' ' ' ILE . 27.1 m-85 -108.77 103.79 12.94 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 179.452 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.4 t80 -111.71 124.72 52.91 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.89 141.41 38.56 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.443 1.116 . . . . 0.0 112.923 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.536 ' O ' HG23 ' D' ' 24' ' ' VAL . 84.2 mt-10 -75.85 118.32 18.52 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.065 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' HG13 ' E' ' 24' ' ' VAL . 13.6 t0 -57.15 59.77 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.591 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.648 HG21 ' O ' ' C' ' 24' ' ' VAL . 43.3 t -63.05 -113.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.419 ' N ' HG12 ' D' ' 24' ' ' VAL . . . -104.4 44.37 1.49 Allowed Glycine 0 N--CA 1.478 1.489 0 CA-C-N 121.446 1.93 . . . . 0.0 111.973 -174.887 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.608 ' O ' ' ND2' ' E' ' 27' ' ' ASN . 1.3 t -70.64 100.51 1.86 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 112.938 -1.631 . . . . 0.0 107.879 175.323 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -118.62 -153.18 0.53 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.389 0.614 . . . . 0.0 112.564 -174.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -37.58 -41.86 0.5 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.704 -177.302 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.07 68.39 1.96 Allowed Glycine 0 CA--C 1.537 1.417 0 C-N-CA 120.374 -0.917 . . . . 0.0 111.771 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.85 136.4 32.33 Favored 'General case' 0 C--N 1.349 0.555 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.598 HD11 ' O ' ' P' ' 39' ' ' VAL . 39.7 mt -145.53 146.7 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 N-CA-C 115.398 1.629 . . . . 0.0 115.398 -175.135 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.463 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -108.46 111.58 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.494 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.15 102.48 0.8 Allowed Glycine 0 N--CA 1.463 0.497 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.415 ' CD2' ' CZ ' ' E' ' 19' ' ' PHE . 2.9 mp -137.16 135.23 37.17 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 122.424 1.107 . . . . 0.0 113.652 -178.166 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -98.91 113.51 25.69 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.355 177.412 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' E' ' 35' ' ' MET . 2.9 t -118.92 103.22 14.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -177.785 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.481 ' CA ' ' H ' ' E' ' 38' ' ' GLY . . . 147.25 -153.62 25.45 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.928 -1.129 . . . . 0.0 110.54 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 104.45 -56.33 0.56 Allowed Glycine 0 CA--C 1.541 1.675 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.882 HG11 ' C ' ' C' ' 39' ' ' VAL . 7.3 p -119.98 140.9 42.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 CA-C-O 121.361 0.601 . . . . 0.0 111.526 -178.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.454 ' O ' HG13 ' D' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.614 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 9' ' ' GLY . . . . . 0.723 ' N ' ' HH ' ' C' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -115.75 136.48 53.01 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 120.627 0.251 . . . . 0.0 110.539 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.19 142.57 45.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.259 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 79.4 t -127.16 133.33 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 CA-C-O 120.785 0.326 . . . . 0.0 111.246 -179.123 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 m170 -137.81 100.0 4.06 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.422 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.0 OUTLIER -151.56 165.6 33.77 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 121.594 0.711 . . . . 0.0 112.801 -179.593 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.532 ' CD ' HG12 ' C' ' 36' ' ' VAL . 87.2 mt-30 -84.35 157.12 21.57 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.324 178.829 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -159.28 103.1 1.61 Allowed 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.451 HD12 ' N ' ' E' ' 17' ' ' LEU . 3.5 mp -137.43 131.45 31.98 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.387 0.613 . . . . 0.0 111.786 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -117.59 112.28 38.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.534 ' CD2' HD13 ' C' ' 32' ' ' ILE . 27.4 m-85 -106.07 105.83 16.06 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 178.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -116.68 117.64 30.37 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.25 123.12 31.13 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.441 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 78.0 tt0 -154.11 154.21 33.22 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 117.9 2.555 . . . . 0.0 117.9 -175.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.454 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 52.6 m-20 109.72 46.5 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 111.646 -2.525 . . . . 0.0 116.372 174.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.459 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 1.8 m -118.15 174.64 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.788 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -59.88 -28.25 65.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 107.868 -2.093 . . . . 0.0 107.868 172.463 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.483 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 3.7 p 143.0 129.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 112.524 -1.838 . . . . 0.0 106.209 -177.087 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.608 ' ND2' ' O ' ' D' ' 26' ' ' SER . 18.0 t-20 -53.59 141.57 25.37 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.886 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -58.37 -48.81 79.41 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -179.248 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -170.23 59.27 0.19 Allowed Glycine 0 CA--C 1.54 1.629 0 C-N-CA 120.246 -0.978 . . . . 0.0 114.368 -175.615 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.65 169.17 16.54 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 119.124 1.462 . . . . 0.0 113.132 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.507 HD11 HG12 ' Q' ' 39' ' ' VAL . 77.5 mt -120.97 137.47 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 113.784 -1.553 . . . . 0.0 110.301 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -121.11 121.75 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.79 114.5 2.0 Favored Glycine 0 N--CA 1.471 0.981 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.623 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 59.4 mt -127.81 124.28 37.23 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 111.088 -178.583 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.441 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.0 mtp -108.22 111.77 23.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.245 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.636 HG12 ' N ' ' E' ' 37' ' ' GLY . 40.2 t -90.28 173.79 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.594 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.636 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 162.16 -95.52 0.13 Allowed Glycine 0 C--N 1.305 -1.175 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.096 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.481 ' H ' ' CA ' ' D' ' 37' ' ' GLY . . . 87.73 -83.69 1.53 Allowed Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.629 HG13 HD11 ' K' ' 31' ' ' ILE . 55.3 t . . . . . 0 N--CA 1.432 -1.336 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 176.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' F' ' 11' ' ' GLU . 57.9 mp0 . . . . . 0 N--CA 1.465 0.31 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.575 ' C ' ' CD2' ' F' ' 13' ' ' HIS . 3.7 p -128.67 135.05 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.351 0.596 . . . . 0.0 111.409 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.793 ' CD2' ' N ' ' F' ' 13' ' ' HIS . 0.1 OUTLIER -142.19 131.98 24.22 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.492 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 32.1 t-80 -155.15 167.81 29.12 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 28.5 mp0 -89.51 150.34 22.5 Favored 'General case' 0 CA--C 1.517 -0.298 0 C-N-CA 120.531 -0.468 . . . . 0.0 109.87 179.088 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -151.99 97.26 2.31 Favored 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.431 ' CD1' HG11 ' D' ' 36' ' ' VAL . 3.9 mp -133.83 116.25 15.45 Favored 'General case' 0 CA--C 1.506 -0.715 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.705 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -99.99 109.49 24.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.623 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 65.1 m-85 -104.89 98.92 8.57 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -112.83 111.43 22.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.338 0.589 . . . . 0.0 109.476 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.43 131.33 38.03 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.842 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' N ' ' E' ' 24' ' ' VAL . 84.6 tt0 -69.52 115.59 8.95 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 118.441 -1.304 . . . . 0.0 109.479 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.443 ' OD2' ' O ' ' F' ' 23' ' ' ASP . 18.9 t70 . . . . . 0 CA--C 1.53 0.196 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.64 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.291 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.508 HD13 ' HA ' ' R' ' 39' ' ' VAL . 86.2 mt -132.78 142.84 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 119.786 -0.765 . . . . 0.0 113.002 -177.946 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -131.57 128.91 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.774 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.14 131.34 5.66 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.486 HD23 ' C ' ' F' ' 34' ' ' LEU . 7.7 tt -135.89 127.46 28.83 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.454 ' N ' HD23 ' F' ' 34' ' ' LEU . 92.8 mtp -140.2 149.7 43.25 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -178.305 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -92.91 154.77 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.614 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.93 102.59 2.94 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.19 -73.64 0.0 OUTLIER Glycine 0 CA--C 1.537 1.417 0 CA-C-N 115.41 -0.395 . . . . 0.0 113.139 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.548 ' N ' ' O ' ' F' ' 37' ' ' GLY . 90.4 t -151.32 136.55 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 117.848 0.824 . . . . 0.0 110.255 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.422 HG12 ' H ' ' F' ' 40' ' ' VAL . 5.8 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.565 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.406 HG22 ' CE1' ' H' ' 13' ' ' HIS . 62.0 t . . . . . 0 N--CA 1.465 0.3 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.474 ' O ' ' O ' ' H' ' 13' ' ' HIS . 98.3 m-70 -135.14 101.77 4.97 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.864 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' N ' ' G' ' 15' ' ' GLN . 6.6 t-80 -157.2 161.63 39.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.228 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.553 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 13.2 pt20 -174.3 147.86 1.22 Allowed 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.102 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 pttt -79.51 121.8 25.66 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.207 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.498 HD11 ' NE2' ' G' ' 15' ' ' GLN . 96.3 mt -131.75 116.42 17.25 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -126.69 136.22 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.129 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.538 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 68.1 m-85 -135.1 125.88 27.29 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.357 0.599 . . . . 0.0 111.086 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.493 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -115.11 129.62 56.72 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.43 124.33 39.91 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -177.29 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -137.21 115.27 11.57 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.532 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 63.7 t0 . . . . . 0 N--CA 1.468 0.461 0 CA-C-O 121.666 0.746 . . . . 0.0 109.046 -177.561 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 29.0 m-20 . . . . . 0 N--CA 1.462 0.144 0 CA-C-O 122.08 0.943 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.642 ' O ' ' N ' ' H' ' 28' ' ' LYS . 99.2 mttt -37.68 -40.76 0.44 Allowed 'General case' 0 C--O 1.214 -0.775 0 CA-C-N 113.534 -1.667 . . . . 0.0 111.227 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.78 68.8 0.21 Allowed Glycine 0 CA--C 1.545 1.943 0 O-C-N 121.653 -0.654 . . . . 0.0 112.552 -176.326 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.595 ' HB3' ' HB3' ' H' ' 27' ' ' ASN . . . -96.7 113.24 24.78 Favored 'General case' 0 C--N 1.368 1.376 0 CA-C-O 124.124 1.916 . . . . 0.0 111.287 -179.161 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.545 HD13 HG11 ' B' ' 39' ' ' VAL . 38.1 mt -129.16 131.8 67.53 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 110.337 -3.119 . . . . 0.0 108.843 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.514 HG22 HD21 ' H' ' 34' ' ' LEU . 31.8 mt -103.32 106.39 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.538 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.34 94.95 0.79 Allowed Glycine 0 CA--C 1.504 -0.613 0 N-CA-C 106.185 -2.766 . . . . 0.0 106.185 177.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.421 ' H ' HD23 ' H' ' 34' ' ' LEU . 58.3 mt -144.38 156.1 44.07 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 123.162 1.458 . . . . 0.0 112.813 -177.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.2 mtp -105.22 113.22 26.68 Favored 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 111.983 -2.371 . . . . 0.0 106.001 176.204 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.481 HG11 HD11 ' J' ' 17' ' ' LEU . 48.4 t -109.04 102.33 13.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.63 -162.5 47.7 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.12 -55.67 0.52 Allowed Glycine 0 CA--C 1.532 1.138 0 CA-C-O 118.82 -0.989 . . . . 0.0 111.919 179.114 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.505 HG12 ' CD1' ' M' ' 31' ' ' ILE . 1.6 m -70.48 176.86 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.428 0 CA-C-N 118.27 1.035 . . . . 0.0 109.499 177.017 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' G' ' 39' ' ' VAL . 7.1 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.879 -1.058 . . . . 0.0 111.587 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.93 133.17 50.18 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.41 141.49 31.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.941 0.4 . . . . 0.0 110.959 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.609 HG11 ' ND1' ' I' ' 13' ' ' HIS . 71.0 t -143.01 161.75 17.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.526 ' N ' HG12 ' H' ' 12' ' ' VAL . 44.5 m80 -135.21 159.14 42.49 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 179.317 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 42.8 p-80 -85.61 166.19 16.42 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.805 -179.099 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -100.39 152.72 20.02 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.618 ' C ' HD12 ' H' ' 17' ' ' LEU . 88.6 tttt -109.31 109.95 20.99 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.618 HD12 ' C ' ' H' ' 16' ' ' LYS . 11.1 mp -119.01 122.86 43.14 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.853 179.535 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -124.21 126.74 72.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.415 179.116 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' CD1' ' G' ' 19' ' ' PHE . 34.2 m-85 -133.89 126.14 29.81 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.812 -0.811 . . . . 0.0 108.812 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.457 ' CZ ' ' CB ' ' G' ' 20' ' ' PHE . 24.3 p90 -143.44 151.39 40.29 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 119.31 -0.956 . . . . 0.0 111.676 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.31 130.02 51.16 Favored 'General case' 0 C--O 1.251 1.171 0 CA-C-O 121.926 0.87 . . . . 0.0 111.467 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -60.98 -166.13 0.01 OUTLIER 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.879 -1.51 . . . . 0.0 107.757 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.572 ' OD1' HG22 ' I' ' 24' ' ' VAL . 33.2 t70 -84.22 57.65 4.35 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 116.669 -2.012 . . . . 0.0 115.41 -175.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.961 HG22 ' H ' ' H' ' 25' ' ' GLY . 1.3 p -68.64 -112.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.271 1 N-CA-C 100.069 -4.048 . . . . 0.0 100.069 166.451 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.961 ' H ' HG22 ' H' ' 24' ' ' VAL . . . 124.41 -39.39 2.14 Favored Glycine 0 C--N 1.331 0.283 0 N-CA-C 117.985 1.954 . . . . 0.0 117.985 167.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.23 110.5 5.25 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 115.632 -2.427 . . . . 0.0 112.968 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 1.093 ' O ' ' N ' ' H' ' 29' ' ' GLY . 0.0 OUTLIER -122.7 156.97 33.29 Favored 'General case' 0 C--O 1.207 -1.145 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 167.314 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.642 ' N ' ' O ' ' G' ' 28' ' ' LYS . 13.1 tttt -34.51 49.15 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 122.721 2.509 . . . . 0.0 111.16 172.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 1.093 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 101.26 -52.22 0.9 Allowed Glycine 0 CA--C 1.563 3.044 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -177.393 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' I' ' 30' ' ' ALA . . . 129.35 115.38 0.0 OUTLIER 'General case' 0 C--N 1.377 1.799 0 C-N-CA 125.946 1.698 . . . . 0.0 107.977 177.885 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.46 HD13 HG12 ' B' ' 39' ' ' VAL . 72.2 mt -126.54 128.13 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 CA-C-N 122.056 2.207 . . . . 0.0 114.793 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -111.67 110.51 32.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 175.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -116.46 105.4 1.35 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.215 -2.354 . . . . 0.0 107.215 178.269 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.583 ' O ' HD23 ' I' ' 34' ' ' LEU . 73.8 mt -140.65 148.86 41.51 Favored 'General case' 0 CA--C 1.508 -0.66 0 CA-C-O 122.832 1.301 . . . . 0.0 113.376 -176.069 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 4.8 ttm -113.86 112.36 23.23 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 175.8 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.644 ' O ' HG13 ' H' ' 36' ' ' VAL . 5.0 p -132.39 102.55 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.752 ' N ' HE22 ' J' ' 15' ' ' GLN . . . 122.52 -163.29 15.97 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' I' ' 37' ' ' GLY . . . 128.28 -54.57 0.78 Allowed Glycine 0 CA--C 1.547 2.06 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.291 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.842 HG22 ' CD1' ' N' ' 31' ' ' ILE . 14.6 t -109.7 165.99 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.681 0.793 . . . . 0.0 110.127 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.528 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 2.5 m . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.658 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.36 133.67 52.23 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.772 0.32 . . . . 0.0 110.509 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 54.6 tp10 -75.35 122.57 23.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.245 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -139.51 160.86 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.548 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.609 ' ND1' HG11 ' H' ' 12' ' ' VAL . 21.8 t60 -145.73 100.25 3.39 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 121.253 -0.179 . . . . 0.0 110.724 179.073 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' J' ' 14' ' ' HIS . 45.3 p-80 -165.52 169.57 15.34 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -89.84 158.95 17.24 Favored 'General case' 0 C--N 1.341 0.215 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.829 178.118 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.765 ' C ' HD12 ' I' ' 17' ' ' LEU . 83.7 tttt -139.97 111.12 7.0 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.581 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.765 HD12 ' C ' ' I' ' 16' ' ' LYS . 10.5 mp -127.95 128.64 45.43 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.247 0.546 . . . . 0.0 110.332 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 71.4 t -112.76 120.77 63.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -114.0 106.42 14.4 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.58 ' CD1' ' CD2' ' J' ' 20' ' ' PHE . 1.9 t80 -115.52 129.14 56.43 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 122.342 -0.224 . . . . 0.0 110.451 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.411 ' N ' ' CD1' ' I' ' 20' ' ' PHE . . . -150.18 130.57 13.79 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -178.771 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -95.65 119.42 34.12 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.365 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -118.64 46.3 1.86 Allowed 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -175.589 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.572 HG22 ' OD1' ' H' ' 23' ' ' ASP . 23.7 m -92.74 173.55 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 175.691 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.32 27.82 65.12 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 118.244 -1.931 . . . . 0.0 109.908 -177.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p 166.66 146.68 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -53.15 136.93 35.11 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 117.416 2.376 . . . . 0.0 117.416 -173.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.469 ' O ' ' HA2' ' J' ' 29' ' ' GLY . 37.9 mttt -60.84 51.06 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 CA-C-N 110.704 -2.953 . . . . 0.0 114.293 173.825 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.07 51.94 0.69 Allowed Glycine 0 N--CA 1.495 2.609 0 O-C-N 120.494 -1.379 . . . . 0.0 116.148 -172.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.526 ' HB2' ' HB3' ' H' ' 30' ' ' ALA . . . -100.31 147.09 26.17 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-O 123.685 1.707 . . . . 0.0 114.993 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.751 HD13 HG22 ' C' ' 39' ' ' VAL . 13.7 tt -132.29 135.88 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.248 -179.203 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 89.6 mt -106.28 108.6 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.01 111.0 3.63 Favored Glycine 0 C--O 1.24 0.496 0 N-CA-C 105.305 -3.118 . . . . 0.0 105.305 176.155 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.583 HD23 ' O ' ' H' ' 34' ' ' LEU . 0.3 OUTLIER -148.32 141.07 24.6 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 117.68 -1.608 . . . . 0.0 115.073 -174.462 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 81.6 mmm -103.13 114.65 29.12 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-N 112.233 -2.258 . . . . 0.0 105.134 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.413 HG22 HD22 ' I' ' 34' ' ' LEU . 58.4 t -122.57 131.75 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 CA-C-O 120.809 0.337 . . . . 0.0 111.047 -176.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' H' ' 38' ' ' GLY . . . 80.44 -111.22 3.24 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 120.629 -0.796 . . . . 0.0 114.807 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.55 -70.51 0.22 Allowed Glycine 0 CA--C 1.539 1.583 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.456 ' HB ' ' CD1' ' O' ' 31' ' ' ILE . 2.6 p -134.61 137.07 51.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.558 ' OXT' ' ND1' ' L' ' 13' ' ' HIS . 27.5 m . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.814 -1.088 . . . . 0.0 111.284 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.54 137.67 44.12 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -130.67 139.02 50.32 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.899 0.381 . . . . 0.0 110.843 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 41.8 t -123.24 125.29 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.56 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 3.3 m80 -120.96 121.92 39.05 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.166 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.557 ' O ' ' CG ' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -152.45 156.41 39.4 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.19 176.478 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.752 HE22 ' N ' ' H' ' 37' ' ' GLY . 83.8 mt-30 -90.37 160.22 16.2 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.617 ' C ' HD12 ' J' ' 17' ' ' LEU . 68.5 mttm -139.7 97.21 3.22 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.27 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.617 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.1 mp -122.8 121.49 36.41 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-O 121.703 0.763 . . . . 0.0 109.549 176.406 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 18' ' ' VAL . . . . . 0.506 HG13 HG13 ' K' ' 18' ' ' VAL . 21.9 t -110.67 116.23 51.89 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.564 179.716 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.432 ' CZ ' ' HB3' ' J' ' 17' ' ' LEU . 33.9 m-85 -112.58 104.46 12.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CD1' ' I' ' 20' ' ' PHE . 4.5 t80 -115.09 131.02 57.06 Favored 'General case' 0 N--CA 1.478 0.939 0 O-C-N 122.449 -0.157 . . . . 0.0 110.882 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 21' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' K' ' 21' ' ' ALA . . . -168.38 171.82 8.85 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 123.631 1.681 . . . . 0.0 115.464 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -111.62 113.84 26.49 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 113.164 -1.834 . . . . 0.0 107.426 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -172.82 49.81 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.754 HG22 ' H ' ' J' ' 25' ' ' GLY . 13.2 p -154.81 -179.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.879 -178.636 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.754 ' H ' HG22 ' J' ' 24' ' ' VAL . . . 61.59 29.74 72.72 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 116.905 1.522 . . . . 0.0 116.905 178.428 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.626 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.7 m -145.32 -120.8 0.08 Allowed 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.626 ' O ' ' O ' ' J' ' 26' ' ' SER . 1.3 p-10 -53.51 -156.61 0.0 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 176.638 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.468 ' N ' ' OD1' ' J' ' 27' ' ' ASN . 99.0 mttt -63.36 -39.9 95.79 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 119.573 -1.954 . . . . 0.0 107.084 -173.103 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' J' ' 27' ' ' ASN . . . 92.5 -65.69 2.09 Favored Glycine 0 N--CA 1.473 1.112 0 C-N-CA 119.732 -1.223 . . . . 0.0 114.966 174.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' I' ' 30' ' ' ALA . . . -169.56 155.36 6.03 Favored 'General case' 0 N--CA 1.44 -0.93 0 C-N-CA 116.759 -1.977 . . . . 0.0 115.346 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.509 ' HA ' ' O ' ' K' ' 31' ' ' ILE . 0.8 OUTLIER -135.3 124.96 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 111.065 -2.788 . . . . 0.0 109.628 177.417 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.425 HD13 HG21 ' J' ' 32' ' ' ILE . 44.8 mt -108.22 117.12 53.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.635 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.93 100.73 1.2 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.785 -2.926 . . . . 0.0 105.785 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -127.86 129.79 47.5 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 114.87 1.433 . . . . 0.0 114.87 -175.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.58 109.92 22.4 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.293 -2.484 . . . . 0.0 104.293 174.185 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.417 ' N ' ' O ' ' K' ' 35' ' ' MET . 2.0 t -125.64 153.19 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.095 0.474 . . . . 0.0 111.497 -175.386 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.47 -101.89 0.2 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.172 178.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.561 ' H ' ' N ' ' K' ' 37' ' ' GLY . . . 99.29 -76.66 0.51 Allowed Glycine 0 CA--C 1.537 1.408 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -177.777 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.852 HG11 HD11 ' P' ' 31' ' ' ILE . 28.0 m -131.46 161.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 CA-C-N 118.362 1.081 . . . . 0.0 110.482 178.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.446 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 44.8 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.907 -1.044 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.76 131.83 54.7 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.759 0.314 . . . . 0.0 110.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -101.84 107.59 18.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.42 HG23 ' NE2' ' K' ' 14' ' ' HIS . 2.5 p -144.63 149.68 17.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.56 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -143.2 94.8 2.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.049 178.753 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.667 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 46.8 m170 -119.94 167.57 12.01 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.948 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.808 HE21 HD21 ' K' ' 17' ' ' LEU . 34.9 tp60 -89.76 157.74 17.82 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.804 ' O ' HD23 ' K' ' 17' ' ' LEU . 16.3 tttt -140.93 95.41 2.84 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.074 -0.651 . . . . 0.0 110.797 178.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.808 HD21 HE21 ' K' ' 15' ' ' GLN . 2.5 mt -131.87 129.62 40.6 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 176.378 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.506 HG13 HG13 ' J' ' 18' ' ' VAL . 3.5 p -118.6 119.33 60.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.186 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.476 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 29.9 m-85 -106.05 105.73 15.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 6.0 t80 -113.59 120.31 40.51 Favored 'General case' 0 C--O 1.226 -0.177 0 CA-C-O 120.66 0.267 . . . . 0.0 111.679 -177.352 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.597 ' HA ' ' O ' ' J' ' 21' ' ' ALA . . . -150.66 120.49 7.08 Favored 'General case' 0 C--O 1.245 0.858 0 C-N-CA 119.704 -0.798 . . . . 0.0 110.547 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.563 ' CG ' ' N ' ' K' ' 23' ' ' ASP . 54.5 tt0 -178.18 163.54 1.69 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 116.988 2.218 . . . . 0.0 116.988 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.563 ' N ' ' CG ' ' K' ' 22' ' ' GLU . 19.9 t70 174.05 -74.13 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 112.03 -2.35 . . . . 0.0 106.978 172.681 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.611 HG22 ' H ' ' K' ' 25' ' ' GLY . 3.2 p -67.7 -113.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 170.481 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.673 ' H ' ' HA3' ' J' ' 25' ' ' GLY . . . 134.7 -37.79 1.9 Allowed Glycine 0 CA--C 1.541 1.7 0 N-CA-C 121.421 3.328 . . . . 0.0 121.421 171.426 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.5 t -71.81 118.09 14.21 Favored 'General case' 0 N--CA 1.482 1.167 1 CA-C-N 125.935 4.867 . . . . 0.0 107.28 177.515 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -103.77 160.58 14.66 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 120.36 1.436 . . . . 0.0 113.127 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -44.45 -39.85 5.07 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 67.67 0.04 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-O 118.939 -0.923 . . . . 0.0 113.484 -174.745 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.463 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -71.04 156.18 39.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.82 1.81 . . . . 0.0 113.607 -176.772 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.629 HD11 HG13 ' E' ' 39' ' ' VAL . 82.2 mt -122.92 126.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.92 -178.781 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 13.0 tt -130.96 118.0 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 O-C-N 121.245 -0.91 . . . . 0.0 110.51 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.81 111.62 1.87 Allowed Glycine 0 N--CA 1.466 0.699 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.62 HD13 ' CE2' ' L' ' 19' ' ' PHE . 82.1 mt -122.92 117.3 25.23 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.165 0.507 . . . . 0.0 110.728 -178.962 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.417 ' O ' ' N ' ' J' ' 36' ' ' VAL . 8.0 mtp -108.3 114.41 28.25 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.404 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 46.2 t -119.65 144.76 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 107.726 -1.212 . . . . 0.0 107.726 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.561 ' N ' ' H ' ' J' ' 38' ' ' GLY . . . -136.51 102.68 0.41 Allowed Glycine 0 C--N 1.32 -0.31 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.104 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' J' ' 40' ' ' VAL . . . -61.28 -67.13 2.26 Favored Glycine 0 CA--C 1.54 1.652 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 176.83 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.485 ' HB ' HD11 ' Q' ' 31' ' ' ILE . 16.7 m . . . . . 0 N--CA 1.435 -1.2 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 120.505 0.193 . . . . 0.0 110.631 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 t -115.94 126.24 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 110.044 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.558 ' ND1' ' OXT' ' I' ' 40' ' ' VAL . 10.8 m-70 -130.86 104.59 7.24 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.214 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.667 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 30.3 t-80 -160.61 164.57 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 178.187 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.438 ' N ' ' CG ' ' L' ' 14' ' ' HIS . 88.0 mm-40 -89.76 158.57 17.46 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.843 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 16' ' ' LYS . . . . . 0.728 ' C ' HD12 ' L' ' 17' ' ' LEU . 16.7 tttt -140.4 93.93 2.68 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.728 HD12 ' C ' ' L' ' 16' ' ' LYS . 10.0 mp -122.72 118.15 27.4 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -102.81 108.06 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.801 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.62 ' CE2' HD13 ' K' ' 34' ' ' LEU . 79.7 m-85 -100.32 98.14 8.83 Favored 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 39.7 t80 -108.38 105.15 14.69 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -165.95 171.51 12.53 Favored 'General case' 0 CA--C 1.484 -1.567 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.634 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -75.94 104.71 6.6 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.066 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -147.0 48.01 1.15 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.41 -176.242 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.563 HG22 ' N ' ' L' ' 25' ' ' GLY . 7.5 p -65.23 169.75 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.563 ' N ' HG22 ' L' ' 24' ' ' VAL . . . -92.2 -42.53 4.6 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 118.709 -1.71 . . . . 0.0 113.819 -176.689 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.51 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 4.6 m -67.72 109.49 3.35 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 117.861 -1.536 . . . . 0.0 111.906 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.68 ' O ' ' N ' ' L' ' 29' ' ' GLY . 21.4 m120 -145.21 158.68 43.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 173.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.537 ' C ' ' O ' ' L' ' 27' ' ' ASN . 42.0 tttp -18.2 -43.51 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 CA-C-O 121.936 0.874 . . . . 0.0 111.312 175.709 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.68 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -178.45 63.33 0.08 OUTLIER Glycine 0 CA--C 1.553 2.411 0 CA-C-N 113.885 -1.507 . . . . 0.0 112.381 177.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -88.94 163.08 15.74 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.13 1.465 . . . . 0.0 110.019 179.418 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 22.2 pt -141.15 135.49 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 119.252 -0.979 . . . . 0.0 112.027 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -118.53 121.09 66.2 Favored 'Isoleucine or valine' 0 C--N 1.34 0.18 0 CA-C-N 114.73 -1.123 . . . . 0.0 111.227 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.11 116.3 2.41 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -126.42 125.65 42.51 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.3 ttm -129.3 130.3 45.98 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.099 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' L' ' 37' ' ' GLY . 55.7 t -124.21 131.87 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -42.56 -111.62 0.0 OUTLIER Glycine 0 N--CA 1.468 0.82 0 CA-C-N 115.483 -0.781 . . . . 0.0 112.631 178.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.99 64.93 3.96 Favored Glycine 0 CA--C 1.532 1.116 0 CA-C-N 114.706 -0.747 . . . . 0.0 111.455 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.649 ' O ' HD11 ' R' ' 31' ' ' ILE . 41.8 t . . . . . 0 C--N 1.346 0.456 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.463 0.186 0 CA-C-O 120.741 0.305 . . . . 0.0 110.598 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.0 t -113.65 128.61 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.31 162.67 15.77 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.711 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.519 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 3.4 m-70 -83.33 168.71 16.39 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.652 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -129.2 150.86 50.4 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.477 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -97.26 111.81 23.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.353 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.69 114.04 18.14 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.88 132.88 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.357 -179.31 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -133.25 134.83 44.46 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.86 0.362 . . . . 0.0 110.919 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -128.26 131.82 48.74 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.766 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.6 111.14 7.55 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.108 0.48 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -159.1 151.13 20.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.372 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 51.96 46.43 26.61 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.818 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.809 HG12 ' H ' ' M' ' 25' ' ' GLY . 39.6 t -80.45 179.89 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 25' ' ' GLY . . . . . 0.809 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -71.44 -33.75 63.99 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.878 -178.667 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 26' ' ' SER . . . . . 0.594 ' O ' ' O ' ' M' ' 27' ' ' ASN . 25.5 t -162.51 120.61 2.13 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 27' ' ' ASN . . . . . 0.594 ' O ' ' O ' ' M' ' 26' ' ' SER . 13.6 t30 -22.03 153.22 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.98 0 O-C-N 124.424 1.078 . . . . 0.0 111.976 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -163.17 24.54 0.09 Allowed 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 114.638 1.347 . . . . 0.0 114.638 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.28 106.15 1.11 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 118.539 -1.791 . . . . 0.0 114.913 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 30' ' ' ALA . . . . . 0.727 ' H ' ' ND2' ' N' ' 27' ' ' ASN . . . -111.48 80.24 1.29 Allowed 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 124.098 1.904 . . . . 0.0 109.999 178.334 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.599 HD11 HG21 ' H' ' 39' ' ' VAL . 59.6 mt -130.36 130.01 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-N 110.974 -2.83 . . . . 0.0 108.419 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 32' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' N' ' 33' ' ' GLY . 47.1 mt -103.94 106.18 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.92 97.43 1.14 Allowed Glycine 0 CA--C 1.506 -0.476 0 N-CA-C 105.055 -3.218 . . . . 0.0 105.055 176.772 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -148.95 152.92 37.2 Favored 'General case' 0 N--CA 1.463 0.213 0 C-N-CA 118.308 -1.357 . . . . 0.0 113.826 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 91.7 mmm -110.21 110.31 21.11 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 112.946 -1.934 . . . . 0.0 107.177 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.63 HG23 HD21 ' N' ' 34' ' ' LEU . 96.4 t -104.29 122.88 57.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.32 -113.24 0.58 Allowed Glycine 0 C--N 1.309 -0.94 0 N-CA-C 108.419 -1.873 . . . . 0.0 108.419 -178.041 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.68 -69.57 0.22 Allowed Glycine 0 CA--C 1.533 1.179 0 C-N-CA 121.438 -0.411 . . . . 0.0 112.413 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' M' ' 40' ' ' VAL . 3.1 m -137.57 166.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 122.649 0.38 . . . . 0.0 110.373 -179.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.544 ' OXT' ' N ' ' N' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.888 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.88 135.67 49.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.845 0.355 . . . . 0.0 110.395 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -140.71 146.42 37.76 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.023 0.439 . . . . 0.0 110.721 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.458 HG22 HG22 ' O' ' 12' ' ' VAL . 70.2 t -126.98 133.66 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.706 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.511 ' HB2' ' CD2' ' O' ' 13' ' ' HIS . 77.1 m80 -102.97 97.66 7.74 Favored 'General case' 0 N--CA 1.471 0.62 0 O-C-N 122.093 -0.38 . . . . 0.0 110.509 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' N' ' 15' ' ' GLN . 1.7 t-80 -159.95 168.53 25.47 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.941 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.636 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 81.9 mt-30 -156.0 142.27 18.38 Favored 'General case' 0 C--N 1.34 0.166 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 178.161 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -84.73 120.64 26.64 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.822 179.156 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.484 HD12 ' O ' ' N' ' 15' ' ' GLN . 4.8 mp -129.11 124.03 33.71 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.755 0.312 . . . . 0.0 110.192 178.274 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.21 131.58 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -129.37 115.58 17.77 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.147 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 t80 -111.9 126.17 54.83 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.0 147.56 31.79 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -177.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -132.46 133.0 43.31 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.016 178.178 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -158.05 46.62 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 24' ' ' VAL . . . . . 0.54 HG12 ' N ' ' N' ' 25' ' ' GLY . 20.8 t -91.79 169.18 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 178.003 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 0.54 ' N ' HG12 ' N' ' 24' ' ' VAL . . . 77.16 34.8 40.24 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.008 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 169.51 -114.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -176.461 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.727 ' ND2' ' H ' ' M' ' 30' ' ' ALA . 28.9 t30 -61.89 170.88 1.87 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.358 0.599 . . . . 0.0 111.782 -177.336 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.561 ' HD3' HD11 ' N' ' 31' ' ' ILE . 81.7 tttt -54.15 -39.36 66.44 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.474 -176.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.34 -63.51 0.53 Allowed Glycine 0 CA--C 1.531 1.04 0 C-N-CA 119.639 -1.267 . . . . 0.0 114.107 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.86 99.52 3.81 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 120.319 2.059 . . . . 0.0 115.529 -176.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.842 ' CD1' HG22 ' H' ' 39' ' ' VAL . 96.3 mt -122.59 118.94 56.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 114.162 -1.381 . . . . 0.0 107.304 173.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' P' ' 19' ' ' PHE . 74.8 mt -107.71 108.32 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 119.041 -1.064 . . . . 0.0 110.28 178.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -109.08 98.66 1.18 Allowed Glycine 0 C--O 1.234 0.138 0 N-CA-C 104.641 -3.384 . . . . 0.0 104.641 175.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.963 HD23 ' N ' ' N' ' 35' ' ' MET . 3.0 tt -145.25 147.84 32.84 Favored 'General case' 0 CA--C 1.506 -0.727 0 C-N-CA 118.352 -1.339 . . . . 0.0 113.065 -174.218 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.963 ' N ' HD23 ' N' ' 34' ' ' LEU . 12.7 mtp -112.0 115.67 29.31 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 113.215 -1.812 . . . . 0.0 108.786 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.675 HG23 HD22 ' N' ' 34' ' ' LEU . 51.4 t -114.59 111.63 36.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 179.44 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.21 -131.75 5.95 Favored Glycine 0 C--N 1.316 -0.562 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.74 -63.69 4.05 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.52 HG12 HD12 ' B' ' 31' ' ' ILE . 11.4 m -104.52 161.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.952 0.501 . . . . 0.0 110.384 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.56 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 47.5 t . . . . . 0 C--O 1.218 -0.602 0 CA-C-O 117.852 -1.071 . . . . 0.0 111.58 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.29 139.43 44.24 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -102.05 124.28 47.39 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.566 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.458 HG22 HG22 ' N' ' 12' ' ' VAL . 1.4 m -125.49 125.91 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.511 ' CD2' ' HB2' ' N' ' 13' ' ' HIS . 23.2 m80 -121.48 122.17 39.15 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 121.193 0.521 . . . . 0.0 112.208 -177.49 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.524 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 0.6 OUTLIER -150.27 175.95 11.32 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.576 178.38 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.481 ' OE1' HD11 ' O' ' 17' ' ' LEU . 5.0 tt0 -152.74 139.75 19.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.587 0.708 . . . . 0.0 109.107 175.593 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 61.3 mttt -95.68 108.64 20.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.592 -1.185 . . . . 0.0 111.043 177.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.481 HD11 ' OE1' ' O' ' 15' ' ' GLN . 5.0 mt -124.03 109.64 13.77 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 119.293 0.951 . . . . 0.0 108.729 175.678 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -107.39 116.4 50.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.877 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -110.99 103.31 11.77 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' P' ' 20' ' ' PHE . 2.7 m-85 -110.38 133.92 52.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.354 0.262 . . . . 0.0 110.303 -178.726 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.77 136.56 29.0 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-O 122.99 1.376 . . . . 0.0 114.128 -179.336 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 26.5 tp10 -93.12 163.79 13.5 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 113.263 -1.79 . . . . 0.0 106.986 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.437 ' OD1' ' OD2' ' P' ' 23' ' ' ASP . 54.5 p-10 -172.93 52.36 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.106 -0.638 . . . . 0.0 111.091 -176.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.605 ' HA ' HG13 ' P' ' 24' ' ' VAL . 13.5 m -74.5 142.17 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 117.981 -1.488 . . . . 0.0 112.47 -174.796 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.501 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . 98.97 38.14 3.93 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.233 179.623 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.993 ' H ' HG11 ' P' ' 24' ' ' VAL . 2.7 p 72.74 120.16 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.11 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' O' ' 27' ' ' ASN . 54.7 p30 -83.62 156.24 22.8 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 115.968 -2.293 . . . . 0.0 109.956 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -48.66 -42.53 34.82 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.874 1.435 . . . . 0.0 114.874 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.443 ' O ' ' CE ' ' N' ' 28' ' ' LYS . . . 160.19 67.37 0.02 OUTLIER Glycine 0 CA--C 1.546 1.998 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.117 -176.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.67 132.22 30.65 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 120.305 2.053 . . . . 0.0 114.155 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.456 ' CD1' ' HB ' ' I' ' 39' ' ' VAL . 9.8 tt -137.36 131.88 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 114.57 -1.196 . . . . 0.0 112.18 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.569 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 71.3 mt -108.25 114.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.378 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.445 ' O ' HD22 ' O' ' 34' ' ' LEU . . . -111.97 94.9 0.77 Allowed Glycine 0 N--CA 1.468 0.792 0 N-CA-C 107.236 -2.345 . . . . 0.0 107.236 177.099 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.461 ' HB2' HD12 ' P' ' 34' ' ' LEU . 1.3 mm? -121.32 134.6 55.14 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 122.476 1.132 . . . . 0.0 113.264 -176.181 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -113.0 104.41 12.36 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 173.809 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.576 HG11 HD13 ' Q' ' 17' ' ' LEU . 2.5 t -113.6 103.46 15.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . 136.85 -153.53 21.77 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.663 177.712 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.724 ' H ' ' H ' ' P' ' 38' ' ' GLY . . . 137.79 -56.29 0.67 Allowed Glycine 0 CA--C 1.543 1.796 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -178.011 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.433 HG22 HG23 ' O' ' 40' ' ' VAL . 5.0 p -133.15 154.78 40.05 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.525 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.486 ' OXT' ' CG2' ' P' ' 40' ' ' VAL . 17.3 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.999 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 43.9 t . . . . . 0 N--CA 1.467 0.42 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.537 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 12.3 m170 -44.22 110.77 0.24 Allowed 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.946 -178.324 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' O ' ' Q' ' 14' ' ' HIS . 55.4 t60 -152.62 154.43 35.35 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.555 ' O ' ' CD2' ' P' ' 14' ' ' HIS . 30.7 mt-30 -98.47 169.81 9.28 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -158.26 103.99 1.84 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.976 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -134.05 133.28 41.0 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.521 0.677 . . . . 0.0 110.861 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 64.1 t -123.55 120.94 61.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.935 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' N' ' 32' ' ' ILE . 5.5 m-85 -112.73 112.3 23.71 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.441 ' HB3' ' CD1' ' O' ' 20' ' ' PHE . 26.4 t80 -125.2 122.47 37.11 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -176.768 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.9 122.09 29.54 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.747 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.521 ' CG ' ' N ' ' P' ' 23' ' ' ASP . 69.6 tt0 -167.45 158.97 11.95 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 117.695 2.479 . . . . 0.0 117.695 -176.925 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.521 ' N ' ' CG ' ' P' ' 22' ' ' GLU . 1.7 p30 150.64 -70.05 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 111.643 -2.526 . . . . 0.0 108.386 175.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.993 HG11 ' H ' ' O' ' 26' ' ' SER . 4.4 m -57.05 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 122.099 0.952 . . . . 0.0 109.336 174.758 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.4 ' H ' ' HB ' ' P' ' 24' ' ' VAL . . . 141.57 -36.25 1.73 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.621 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 m -70.33 114.49 8.51 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 115.916 -2.314 . . . . 0.0 105.18 171.554 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.693 HD21 ' H ' ' P' ' 27' ' ' ASN . 0.0 OUTLIER -119.98 154.6 34.27 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 121.212 1.824 . . . . 0.0 111.926 176.435 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -34.52 -39.46 0.09 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 173.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 29' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' Q' ' 29' ' ' GLY . . . 140.07 74.52 0.05 OUTLIER Glycine 0 CA--C 1.553 2.447 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -175.295 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 30' ' ' ALA . . . . . 0.445 ' O ' ' O ' ' Q' ' 29' ' ' GLY . . . -70.55 170.14 12.74 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 116.099 1.888 . . . . 0.0 116.099 -173.609 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.852 HD11 HG11 ' J' ' 39' ' ' VAL . 0.9 OUTLIER -149.14 143.7 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 CA-C-N 112.739 -2.028 . . . . 0.0 114.907 -176.103 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.461 HG12 HD12 ' O' ' 32' ' ' ILE . 3.7 mt -113.12 113.06 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.38 101.8 1.2 Allowed Glycine 0 N--CA 1.462 0.402 0 N-CA-C 105.82 -2.912 . . . . 0.0 105.82 176.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.54 ' C ' HD23 ' P' ' 34' ' ' LEU . 9.0 tt -144.49 132.08 21.06 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 122.866 1.317 . . . . 0.0 112.397 -175.543 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 35' ' ' MET . . . . . 0.485 ' N ' HD23 ' P' ' 34' ' ' LEU . 74.0 mtp -120.86 119.59 33.11 Favored 'General case' 0 CA--C 1.495 -1.153 0 CA-C-N 113.163 -1.835 . . . . 0.0 107.512 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.437 ' CG2' HG22 ' Q' ' 36' ' ' VAL . 0.0 OUTLIER -95.67 113.85 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.604 -178.521 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' P' P ' 37' ' ' GLY . . . . . 0.551 ' N ' ' O ' ' O' ' 36' ' ' VAL . . . -65.64 -123.29 0.01 OUTLIER Glycine 0 CA--C 1.521 0.408 0 CA-C-N 113.871 -1.513 . . . . 0.0 110.799 177.205 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.724 ' H ' ' H ' ' O' ' 38' ' ' GLY . . . 66.64 60.86 5.79 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-N 114.301 -0.95 . . . . 0.0 113.641 179.261 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.598 ' O ' HD11 ' D' ' 31' ' ' ILE . 0.7 OUTLIER -84.71 124.14 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.082 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.505 ' C ' HG12 ' Q' ' 39' ' ' VAL . 3.1 t . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 118.341 -0.838 . . . . 0.0 112.428 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.29 131.07 55.09 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . 0.434 ' H ' ' HG2' ' R' ' 11' ' ' GLU . 96.4 mt-10 -141.23 138.23 33.14 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.542 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.448 HG12 ' H ' ' R' ' 12' ' ' VAL . 34.5 m -125.28 129.92 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.435 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.56 ' CE1' ' O ' ' N' ' 40' ' ' VAL . 14.2 t60 -136.4 132.98 36.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.912 0.387 . . . . 0.0 110.811 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.583 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 3.7 m80 -145.48 162.58 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.515 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.496 ' HG2' HG12 ' O' ' 36' ' ' VAL . 1.9 mp0 -89.95 157.26 17.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 176.619 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . 0.42 ' HB2' ' NE2' ' P' ' 14' ' ' HIS . 87.9 tttt -141.66 102.34 4.16 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 176.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.576 HD13 HG11 ' O' ' 36' ' ' VAL . 5.2 mp -131.37 119.47 21.73 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-O 121.389 0.614 . . . . 0.0 111.143 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -107.44 111.8 37.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.569 ' CD1' HD13 ' O' ' 32' ' ' ILE . 88.3 m-85 -106.63 103.44 12.88 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.015 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.58 ' CE2' ' CD2' ' R' ' 20' ' ' PHE . 26.1 t80 -110.01 119.34 39.01 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.47 128.34 21.91 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.424 0.63 . . . . 0.0 111.349 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 38.9 tt0 -91.29 109.96 21.25 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 99.1 m-20 -141.96 48.27 1.6 Allowed 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.212 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -72.86 160.56 5.27 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.481 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.82 -30.04 8.42 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.573 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.7 t 61.46 109.96 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 118.903 -0.57 . . . . 0.0 112.157 177.297 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.744 ' O ' ' N ' ' Q' ' 29' ' ' GLY . 13.9 t30 -129.41 159.74 35.27 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -29.53 48.82 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 N-CA-C 117.641 2.46 . . . . 0.0 117.641 -178.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.744 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -171.93 52.61 0.18 Allowed Glycine 0 CA--C 1.536 1.399 0 CA-C-N 120.552 1.524 . . . . 0.0 112.34 171.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.04 95.06 9.57 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.819 1.809 . . . . 0.0 111.295 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.485 HD11 ' HB ' ' K' ' 39' ' ' VAL . 49.4 mt -133.36 123.98 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 CA-C-N 120.66 1.573 . . . . 0.0 112.687 -178.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -126.97 121.97 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.636 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.75 114.05 2.01 Favored Glycine 0 N--CA 1.467 0.76 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.387 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.688 HD22 ' CZ ' ' R' ' 19' ' ' PHE . 89.8 mt -124.98 119.73 29.57 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.504 0.192 . . . . 0.0 110.576 -178.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.421 ' O ' HG23 ' P' ' 36' ' ' VAL . 82.1 mtp -127.93 124.4 37.27 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.437 HG22 ' CG2' ' P' ' 36' ' ' VAL . 64.2 t -115.93 146.9 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.503 -0.555 . . . . 0.0 109.503 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.91 102.29 0.41 Allowed Glycine 0 C--N 1.315 -0.634 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.99 -71.09 0.65 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-O 121.559 0.533 . . . . 0.0 111.945 178.452 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.507 HG12 HD11 ' E' ' 31' ' ' ILE . 2.4 m -126.2 119.01 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.468 ' CB ' ' O ' ' Q' ' 39' ' ' VAL . 61.1 t . . . . . 0 N--CA 1.487 1.403 0 C-N-CA 124.34 1.056 . . . . 0.0 109.882 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -115.22 140.57 48.98 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.434 ' HG2' ' H ' ' Q' ' 11' ' ' GLU . 97.1 mt-10 -73.48 129.99 39.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.448 ' H ' HG12 ' Q' ' 12' ' ' VAL . 72.0 t -126.07 131.86 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.115 0.483 . . . . 0.0 110.343 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -132.84 95.72 3.64 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.711 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' OE1' ' R' ' 15' ' ' GLN . 84.8 t60 -155.36 161.93 40.93 Favored 'General case' 0 C--O 1.222 -0.349 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.489 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.57 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.2 OUTLIER -90.17 159.8 16.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.867 0.365 . . . . 0.0 111.452 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.694 ' C ' HD13 ' R' ' 17' ' ' LEU . 57.7 tttt -139.96 107.12 5.47 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.902 HD22 ' N ' ' R' ' 17' ' ' LEU . 0.0 OUTLIER -126.82 121.3 31.53 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.694 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -104.34 111.31 33.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 177.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.688 ' CZ ' HD22 ' Q' ' 34' ' ' LEU . 80.1 m-85 -103.44 103.77 13.78 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CE2' ' Q' ' 20' ' ' PHE . 62.3 t80 -114.07 109.2 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.352 0.596 . . . . 0.0 109.58 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.47 125.08 33.49 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -81.98 114.38 20.52 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.719 -178.394 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.401 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.0 t0 -150.24 46.27 0.9 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.671 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.658 HG12 ' H ' ' R' ' 25' ' ' GLY . 24.1 t -96.02 175.93 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.658 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 70.96 26.97 72.99 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 26' ' ' SER . . . . . 0.48 ' O ' ' O ' ' R' ' 27' ' ' ASN . 28.5 t -153.37 120.29 5.71 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.101 0.476 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.48 ' O ' ' O ' ' R' ' 26' ' ' SER . 78.6 m-20 -42.07 178.78 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.663 -179.198 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -72.58 45.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.923 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' R' ' 27' ' ' ASN . . . -92.08 59.53 2.74 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.525 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.37 165.86 33.69 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 122.545 -0.385 . . . . 0.0 110.33 -178.38 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.649 HD11 ' O ' ' L' ' 39' ' ' VAL . 93.6 mt -109.95 119.01 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.261 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 32' ' ' ILE . . . . . 0.5 HG23 ' O ' ' R' ' 32' ' ' ILE . 18.6 tt -130.37 124.07 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.921 0.391 . . . . 0.0 110.223 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.43 120.3 3.66 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 42.9 mt -121.48 121.57 37.81 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -179.371 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 75.4 mtp -128.95 131.03 47.46 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.45 0.643 . . . . 0.0 112.175 -179.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -134.38 142.67 40.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.935 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.63 -102.31 0.2 Allowed Glycine 0 C--N 1.306 -1.097 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' R' R ' 38' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' R' ' 39' ' ' VAL . . . 109.06 -71.85 0.2 Allowed Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.11 -0.828 . . . . 0.0 112.055 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.508 ' HA ' HD13 ' F' ' 31' ' ' ILE . 94.1 t -29.95 123.03 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 118.492 1.146 . . . . 0.0 111.657 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.446 ' H ' HG21 ' F' ' 31' ' ' ILE . 91.7 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.974 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 CA--C 1.527 0.092 0 CA-C-O 120.709 0.29 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 m -123.05 131.41 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.389 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 37.5 t-80 -137.67 141.01 41.13 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.257 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 15' ' ' GLN . 0.4 OUTLIER -84.58 166.62 17.02 Favored 'General case' 0 CA--C 1.532 0.267 0 CA-C-O 121.248 0.547 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.625 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 83.0 mt-30 -157.45 143.09 17.36 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.071 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -81.07 134.36 35.65 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.334 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.92 116.56 22.39 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -125.26 133.68 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.054 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -140.33 139.52 35.43 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.016 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.526 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.1 p90 -126.46 127.81 45.97 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.65 116.22 29.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.302 0.572 . . . . 0.0 111.018 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -142.4 120.9 12.46 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 C--N 1.329 -0.323 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.14 -179.445 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.472 0.664 0 CA-C-O 119.304 -0.379 . . . . 0.0 110.662 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' B' ' 22' ' ' GLU . 52.3 mtpt -118.36 -38.34 3.19 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 120.123 -0.631 . . . . 0.0 112.271 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.432 ' O ' ' HB1' ' B' ' 21' ' ' ALA . . . -80.7 -78.59 0.93 Allowed Glycine 0 N--CA 1.468 0.792 0 C-N-CA 118.951 -1.595 . . . . 0.0 112.919 -177.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.56 93.64 0.2 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.938 -0.705 . . . . 0.0 112.114 178.788 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 92.7 mt -126.28 104.73 13.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.413 HD13 ' CD1' ' C' ' 19' ' ' PHE . 96.5 mt -110.57 112.01 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.099 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.609 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.6 92.66 0.5 Allowed Glycine 0 CA--C 1.508 -0.383 0 N-CA-C 104.356 -3.498 . . . . 0.0 104.356 176.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.686 ' O ' HD12 ' B' ' 34' ' ' LEU . 91.5 mt -151.79 177.95 9.88 Favored 'General case' 0 CA--C 1.51 -0.594 0 CA-C-O 122.969 1.366 . . . . 0.0 111.985 -175.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 31.4 mtp -140.38 119.38 12.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 113.096 -1.865 . . . . 0.0 108.902 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.483 HG21 HD13 ' C' ' 17' ' ' LEU . 1.7 m -131.97 113.56 22.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 154.38 -124.64 1.58 Allowed Glycine 0 C--N 1.307 -1.058 0 N-CA-C 109.106 -1.597 . . . . 0.0 109.106 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.62 -67.03 3.6 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.977 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 40' ' ' VAL . 2.4 p -115.56 166.49 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.521 ' N ' HG22 ' A' ' 39' ' ' VAL . 9.8 m . . . . . 0 N--CA 1.472 0.646 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.58 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -106.27 133.21 51.33 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -93.17 106.02 18.03 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.788 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -128.9 130.81 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 81.3 t60 -134.16 105.76 6.83 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.814 0.34 . . . . 0.0 111.166 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.635 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 4.5 t60 -157.12 167.37 30.59 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.584 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.591 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 33.9 mt-30 -154.75 141.84 19.33 Favored 'General case' 0 C--N 1.339 0.127 0 N-CA-C 109.627 -0.509 . . . . 0.0 109.627 177.706 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -85.53 131.5 34.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.624 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.467 HD23 HD23 ' C' ' 17' ' ' LEU . 33.4 tp -122.16 120.97 35.79 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 118.121 0.419 . . . . 0.0 110.117 177.786 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -124.61 131.97 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -131.14 123.29 28.24 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.616 -179.069 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -112.79 124.85 53.52 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.352 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 21' ' ' ALA . . . . . 0.432 ' HB1' ' O ' ' A' ' 29' ' ' GLY . . . -124.15 126.28 45.89 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -178.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' A' ' 28' ' ' LYS . 79.0 tt0 -115.07 162.98 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.912 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -178.81 48.71 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 122.337 0.255 . . . . 0.0 110.443 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.522 HG22 ' O ' ' C' ' 23' ' ' ASP . 2.7 t -72.57 161.05 5.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 122.363 1.077 . . . . 0.0 112.749 -174.248 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.402 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 107.07 -34.71 5.52 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 113.051 -1.886 . . . . 0.0 112.588 178.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' B' ' 27' ' ' ASN . 89.2 p -162.46 120.07 2.08 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.831 1.315 . . . . 0.0 113.851 177.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.611 ' ND2' ' N ' ' B' ' 28' ' ' LYS . 0.5 OUTLIER -22.37 153.41 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.362 0.665 . . . . 0.0 111.644 174.68 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.611 ' N ' ' ND2' ' B' ' 27' ' ' ASN . 56.3 tttt -165.45 26.5 0.05 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.72 107.93 0.38 Allowed Glycine 0 N--CA 1.47 0.944 0 C-N-CA 118.239 -1.934 . . . . 0.0 115.7 174.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -120.47 105.23 10.66 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-O 122.363 1.078 . . . . 0.0 108.136 177.582 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.47 HD11 ' O ' ' N' ' 38' ' ' GLY . 2.6 mt -133.49 135.63 55.67 Favored 'Isoleucine or valine' 0 C--N 1.346 0.435 0 CA-C-N 114.746 -1.116 . . . . 0.0 113.163 -176.036 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.654 HD13 ' CD1' ' D' ' 19' ' ' PHE . 94.1 mt -113.15 110.78 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.383 176.46 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.01 102.33 1.07 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 105.327 -3.109 . . . . 0.0 105.327 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.686 HD12 ' O ' ' A' ' 34' ' ' LEU . 12.2 tp -146.67 144.42 29.46 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 117.828 -1.549 . . . . 0.0 114.765 -174.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.43 114.81 29.06 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 112.277 -2.238 . . . . 0.0 108.299 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.732 HG11 HD21 ' D' ' 17' ' ' LEU . 17.0 t -133.21 123.2 46.98 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 119.916 -0.714 . . . . 0.0 110.938 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.7 -113.74 1.02 Allowed Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.719 ' O ' HD12 ' I' ' 31' ' ' ILE . . . 86.7 -72.72 2.58 Favored Glycine 0 CA--C 1.536 1.348 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.633 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.585 HG12 ' N ' ' B' ' 40' ' ' VAL . 47.6 t -134.31 164.56 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 122.463 -0.434 . . . . 0.0 110.946 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.585 ' N ' HG12 ' B' ' 39' ' ' VAL . 53.1 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.886 -1.054 . . . . 0.0 109.961 178.466 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.142 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -81.93 140.28 34.14 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -139.08 139.36 37.71 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.871 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 130.96 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.602 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 88.9 m-70 -145.7 101.43 3.56 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 120.107 -0.637 . . . . 0.0 112.183 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.635 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.0 p-80 -155.89 155.0 32.12 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 118.415 -1.314 . . . . 0.0 111.95 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -90.48 161.19 15.63 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.416 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -139.32 112.65 8.22 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 175.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.49 HD12 ' CD2' ' D' ' 17' ' ' LEU . 3.6 mt -116.24 111.48 20.22 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.475 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 t -111.08 110.12 31.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.413 ' CD1' HD13 ' A' ' 32' ' ' ILE . 96.0 m-85 -110.32 113.09 25.48 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -112.32 124.88 53.45 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.676 -0.238 . . . . 0.0 110.505 -178.586 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 21' ' ' ALA . . . . . 0.554 ' O ' ' NZ ' ' C' ' 28' ' ' LYS . . . -131.78 136.77 47.8 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.508 0.671 . . . . 0.0 112.724 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.442 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 15.5 pt-20 -163.81 133.2 3.98 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.3 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.522 ' O ' HG22 ' B' ' 24' ' ' VAL . 0.2 OUTLIER -150.02 -60.3 0.2 Allowed 'General case' 0 C--N 1.353 0.758 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.669 HG12 ' N ' ' C' ' 25' ' ' GLY . 35.9 t -94.15 170.55 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 117.378 -1.729 . . . . 0.0 112.579 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.669 ' N ' HG12 ' C' ' 24' ' ' VAL . . . -81.51 27.83 3.2 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.404 173.827 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' C' ' 27' ' ' ASN . 4.8 t -170.56 -138.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 118.947 1.374 . . . . 0.0 112.75 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.543 ' ND2' ' O ' ' D' ' 25' ' ' GLY . 4.3 t-20 -34.52 127.69 0.46 Allowed 'General case' 0 C--N 1.349 0.547 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.178 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.943 ' HZ3' ' HB1' ' D' ' 21' ' ' ALA . 71.2 tttt -104.94 -42.16 5.41 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . 81.18 60.88 2.18 Favored Glycine 0 CA--C 1.543 1.812 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.622 ' H ' ' HG ' ' D' ' 26' ' ' SER . . . -110.21 112.39 24.34 Favored 'General case' 0 C--N 1.361 1.101 0 CA-C-O 123.237 1.494 . . . . 0.0 114.077 -175.047 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.556 HG21 ' CG2' ' O' ' 39' ' ' VAL . 1.1 tt -134.63 127.19 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 112.218 -2.264 . . . . 0.0 109.228 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.417 HD13 HG21 ' C' ' 32' ' ' ILE . 29.2 mt -106.56 116.32 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.213 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.97 106.36 1.62 Allowed Glycine 0 N--CA 1.466 0.695 0 N-CA-C 106.551 -2.619 . . . . 0.0 106.551 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -133.05 134.63 44.61 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 114.128 1.159 . . . . 0.0 114.128 -174.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -113.02 98.94 7.48 Favored 'General case' 0 N--CA 1.432 -1.338 0 N-CA-C 101.591 -3.485 . . . . 0.0 101.591 173.058 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.02 132.22 65.61 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 N-CA-C 114.76 1.393 . . . . 0.0 114.76 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.09 111.97 1.25 Allowed Glycine 0 CA--C 1.521 0.461 0 CA-C-N 114.267 -1.333 . . . . 0.0 113.194 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -97.9 -60.51 0.92 Allowed Glycine 0 CA--C 1.54 1.609 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 176.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.662 ' HB ' HD11 ' I' ' 31' ' ' ILE . 10.0 p -145.06 150.5 15.93 Favored 'Isoleucine or valine' 0 C--N 1.342 0.269 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.497 ' OXT' ' ND1' ' E' ' 13' ' ' HIS . 9.8 p . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.534 -179.232 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.583 HG23 ' O ' ' D' ' 12' ' ' VAL . 22.0 m . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 121.433 0.635 . . . . 0.0 110.594 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.602 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 2.5 t60 -126.83 127.87 45.66 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.694 -178.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.461 ' HB3' ' H ' ' E' ' 14' ' ' HIS . 1.5 p-80 -134.19 164.39 27.46 Favored 'General case' 0 C--O 1.221 -0.396 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.165 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -90.1 151.51 21.58 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 178.093 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -150.33 97.13 2.5 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.732 HD21 HG11 ' B' ' 36' ' ' VAL . 7.4 mt -123.29 121.56 36.15 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.07 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -114.89 106.54 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.654 ' CD1' HD13 ' B' ' 32' ' ' ILE . 91.4 m-85 -107.78 106.0 16.1 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 177.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -116.76 129.38 56.08 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.787 -175.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.943 ' HB1' ' HZ3' ' C' ' 28' ' ' LYS . . . -133.86 128.73 35.26 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-O 121.54 0.686 . . . . 0.0 111.295 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.629 ' N ' ' NZ ' ' C' ' 28' ' ' LYS . 98.9 mt-10 -95.13 139.4 31.51 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.381 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.501 ' O ' ' O ' ' D' ' 24' ' ' VAL . 9.9 m-20 65.36 47.92 2.22 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 177.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.501 ' O ' ' O ' ' D' ' 23' ' ' ASP . 5.2 m -52.45 -175.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 119.215 -0.994 . . . . 0.0 108.433 177.511 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.543 ' O ' ' ND2' ' C' ' 27' ' ' ASN . . . 165.43 19.46 0.02 OUTLIER Glycine 0 CA--C 1.523 0.548 0 C-N-CA 118.252 -1.928 . . . . 0.0 113.342 -177.47 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.622 ' HG ' ' H ' ' C' ' 30' ' ' ALA . 5.2 m -80.33 -130.37 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' CG1' ' P' ' 39' ' ' VAL . 9.7 m120 -100.48 149.78 23.33 Favored 'General case' 0 CA--C 1.516 -0.332 0 C-N-CA 119.048 -1.061 . . . . 0.0 109.745 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.498 ' NZ ' HD11 ' F' ' 31' ' ' ILE . 95.8 mttt 37.78 42.54 0.41 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.346 -1.297 . . . . 0.0 110.887 -177.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.56 -66.42 2.32 Favored Glycine 0 CA--C 1.545 1.947 0 CA-C-N 116.514 -0.312 . . . . 0.0 113.245 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.21 165.41 9.06 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.525 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 11.9 tt -129.59 129.92 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.733 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -113.52 112.68 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.761 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.64 97.01 1.39 Allowed Glycine 0 C--O 1.239 0.409 0 N-CA-C 104.226 -3.55 . . . . 0.0 104.226 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.427 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 64.9 tp -117.09 121.54 41.59 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -173.603 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -112.03 97.93 7.0 Favored 'General case' 0 N--CA 1.433 -1.3 0 N-CA-C 103.796 -2.668 . . . . 0.0 103.796 173.22 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.628 ' CG2' HE22 ' E' ' 15' ' ' GLN . 14.3 p -119.09 120.84 65.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.268 0 C-N-CA 119.714 -0.794 . . . . 0.0 110.454 -177.202 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -99.51 121.88 7.37 Favored Glycine 0 C--N 1.332 0.345 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' E' ' 39' ' ' VAL . . . -119.24 62.07 0.47 Allowed Glycine 0 CA--C 1.532 1.149 0 CA-C-O 119.035 -0.869 . . . . 0.0 112.532 178.076 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.63 ' HB ' HD11 ' J' ' 31' ' ' ILE . 49.2 t -84.3 130.04 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 119.324 1.562 . . . . 0.0 109.742 179.179 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.431 ' O ' HG12 ' D' ' 39' ' ' VAL . 16.9 m . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.284 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -110.79 134.79 52.2 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.655 0.264 . . . . 0.0 110.302 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.433 ' O ' HG11 ' D' ' 12' ' ' VAL . 73.1 tt0 -105.54 137.59 43.13 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.994 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.553 HG11 ' H ' ' F' ' 12' ' ' VAL . 4.2 p -139.52 156.39 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.916 0.389 . . . . 0.0 111.42 -178.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.497 ' ND1' ' OXT' ' C' ' 40' ' ' VAL . 7.7 p80 -74.19 125.06 27.55 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.194 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.461 ' H ' ' HB3' ' D' ' 14' ' ' HIS . 52.6 p-80 -154.05 166.36 33.28 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.339 178.229 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.628 HE22 ' CG2' ' D' ' 36' ' ' VAL . 16.8 tt0 -89.84 151.71 21.63 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 178.857 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -149.57 105.27 3.43 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.858 177.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -117.59 117.06 28.38 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.893 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 103.88 15.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.639 ' CE2' ' CE1' ' F' ' 19' ' ' PHE . 3.7 m-30 -106.54 109.12 20.94 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.153 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -129.72 130.9 46.05 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 120.058 -0.657 . . . . 0.0 112.521 -176.24 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.441 ' HB1' HG13 ' D' ' 24' ' ' VAL . . . -124.47 133.18 53.43 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.936 178.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 92.0 mt-10 -127.18 170.64 12.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 116.982 2.216 . . . . 0.0 116.982 -176.007 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.454 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 11.4 p30 48.18 46.31 19.77 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 110.722 -2.944 . . . . 0.0 116.167 177.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.677 HG23 ' H ' ' E' ' 26' ' ' SER . 15.7 m -72.12 -168.79 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.247 -0.981 . . . . 0.0 108.947 174.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.42 36.81 3.96 Favored Glycine 0 N--CA 1.467 0.725 0 N-CA-C 105.815 -2.914 . . . . 0.0 105.815 172.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.677 ' H ' HG23 ' E' ' 24' ' ' VAL . 21.3 t 61.63 111.21 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 113.339 -1.43 . . . . 0.0 107.844 -175.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.481 ' O ' ' N ' ' E' ' 29' ' ' GLY . 98.8 m-20 -130.0 161.1 31.7 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 28' ' ' LYS . . . . . 0.433 ' C ' ' O ' ' E' ' 27' ' ' ASN . 98.3 mttt -28.63 -40.27 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.294 173.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 29' ' ' GLY . . . . . 0.612 ' O ' ' HB2' ' E' ' 30' ' ' ALA . . . 107.68 -63.45 0.28 Allowed Glycine 0 CA--C 1.54 1.611 0 CA-C-O 117.096 -1.947 . . . . 0.0 115.968 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.612 ' HB2' ' O ' ' E' ' 29' ' ' GLY . . . -179.75 168.89 1.34 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 122.903 3.351 . . . . 0.0 115.915 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 91.2 mt -119.53 125.09 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 111.18 -2.736 . . . . 0.0 106.087 175.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 89.5 mt -130.49 128.76 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.94 106.28 1.01 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.675 HD23 ' C ' ' E' ' 34' ' ' LEU . 7.3 tt -115.61 122.75 46.55 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-O 120.926 0.393 . . . . 0.0 111.672 -176.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.457 ' N ' HD23 ' E' ' 34' ' ' LEU . 8.2 mtp -118.76 126.07 51.04 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.635 178.482 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.474 HG12 ' N ' ' E' ' 37' ' ' GLY . 59.1 t -90.68 156.38 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 121.142 0.496 . . . . 0.0 111.052 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.474 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -102.13 102.5 2.33 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.299 -179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.56 -73.56 0.0 OUTLIER Glycine 0 CA--C 1.541 1.676 0 N-CA-C 115.567 0.987 . . . . 0.0 115.567 177.685 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' D' ' 38' ' ' GLY . 6.6 p . . . . . 0 N--CA 1.48 1.074 0 CA-C-N 118.577 1.189 . . . . 0.0 111.64 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 120.678 0.275 . . . . 0.0 110.56 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.553 ' H ' HG11 ' E' ' 12' ' ' VAL . 67.9 t -124.46 127.5 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.952 0.882 . . . . 0.0 111.439 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 5.8 p80 -126.51 103.29 7.52 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.981 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.528 ' CE1' ' HE3' ' F' ' 16' ' ' LYS . 0.0 OUTLIER -148.08 169.38 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.423 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 31.5 mt-30 -89.58 156.88 18.32 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 119.227 -0.989 . . . . 0.0 110.65 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 16' ' ' LYS . . . . . 0.528 ' HE3' ' CE1' ' F' ' 14' ' ' HIS . 98.9 mttt -141.21 104.71 4.68 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.104 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.585 ' H ' HD12 ' F' ' 17' ' ' LEU . 0.0 OUTLIER -124.76 112.31 16.56 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -107.13 107.16 22.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.639 ' CE1' ' CE2' ' E' ' 19' ' ' PHE . 13.1 m-85 -118.89 108.78 15.22 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.525 ' CE2' ' O ' ' F' ' 21' ' ' ALA . 57.7 t80 -148.76 163.32 37.7 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.33 1.062 . . . . 0.0 113.234 -178.428 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.525 ' O ' ' CE2' ' F' ' 20' ' ' PHE . . . -137.62 138.34 39.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.582 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -77.94 112.67 15.07 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 p30 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.244 -176.727 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.523 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.516 -0.359 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.498 HD11 ' NZ ' ' D' ' 28' ' ' LYS . 97.1 mt -119.73 124.68 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.294 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 33.7 pt -135.79 137.18 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 121.215 0.531 . . . . 0.0 111.218 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.96 120.31 2.34 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.584 HD23 ' C ' ' F' ' 34' ' ' LEU . 6.2 tt -118.54 121.98 41.55 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.576 ' N ' HD23 ' F' ' 34' ' ' LEU . 4.8 ttm -119.25 120.37 36.81 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.958 0.409 . . . . 0.0 111.101 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.472 ' O ' ' O ' ' F' ' 37' ' ' GLY . 22.4 m -87.12 131.8 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.076 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -46.97 -111.82 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 121.918 0.732 . . . . 0.0 112.103 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.64 -71.36 0.83 Allowed Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.364 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -102.5 128.58 55.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-O 121.339 0.59 . . . . 0.0 110.751 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.585 -179.982 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 N--CA 1.466 0.374 0 CA-C-O 120.953 0.406 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 37.8 p-80 -143.69 161.09 39.46 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.509 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -150.22 173.48 13.89 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.154 -179.607 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 29.7 pt20 -92.33 150.27 20.94 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -101.31 151.16 22.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.131 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 tp -137.45 124.83 21.92 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.561 0.696 . . . . 0.0 111.681 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 65.8 t -124.82 129.97 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 114.99 -1.004 . . . . 0.0 108.819 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -134.27 130.63 37.37 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.198 0.523 . . . . 0.0 111.285 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.6 p90 -135.67 128.37 30.91 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.752 179.498 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.6 138.37 54.56 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.801 0.334 . . . . 0.0 110.898 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -81.96 -168.78 2.07 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.593 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.406 -179.011 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.506 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 15.4 t-20 . . . . . 0 CA--C 1.534 0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 111.618 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.506 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 77.4 tttt -56.09 -36.55 68.27 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.869 -1.06 . . . . 0.0 111.685 178.799 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.65 82.15 0.45 Allowed Glycine 0 CA--C 1.53 1.018 0 CA-C-N 114.127 -1.397 . . . . 0.0 113.508 -174.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . -101.95 102.98 13.59 Favored 'General case' 0 C--O 1.242 0.698 0 CA-C-O 124.132 1.92 . . . . 0.0 109.775 -178.555 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.506 HG23 HG23 ' H' ' 31' ' ' ILE . 53.1 mt -126.45 132.54 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 CA-C-N 110.506 -3.043 . . . . 0.0 108.868 -177.459 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.505 HG22 HD21 ' H' ' 34' ' ' LEU . 33.5 mt -103.66 110.79 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 176.359 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.81 104.98 1.44 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 107.524 -2.23 . . . . 0.0 107.524 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.7 tp -163.0 152.79 15.67 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 117.976 -1.49 . . . . 0.0 113.64 -177.274 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.43 ' SD ' ' HB2' ' H' ' 35' ' ' MET . 45.4 tpp -100.03 116.87 33.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 112.572 -2.103 . . . . 0.0 107.953 178.036 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -123.09 112.1 32.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.53 -131.88 10.75 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.47 -62.66 0.31 Allowed Glycine 0 CA--C 1.54 1.648 0 C-N-CA 121.436 -0.411 . . . . 0.0 112.442 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.674 ' O ' HG23 ' G' ' 40' ' ' VAL . 12.6 p -116.22 160.47 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 C-N-CA 122.542 0.337 . . . . 0.0 110.936 -179.554 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.674 HG23 ' O ' ' G' ' 39' ' ' VAL . 24.7 t . . . . . 0 N--CA 1.471 0.588 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.401 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -83.21 139.76 32.95 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.727 0.298 . . . . 0.0 110.509 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.34 140.76 39.62 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.5 t -129.96 134.51 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.636 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 20.6 t-160 -129.58 100.46 5.54 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.825 0.345 . . . . 0.0 110.843 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 0.1 OUTLIER -159.3 171.98 18.84 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.128 179.851 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.645 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 26.3 mt-30 -152.2 141.31 21.3 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 178.092 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -88.08 114.53 24.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.79 178.006 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 70.8 mt -119.55 112.99 20.04 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -120.77 131.12 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 120.792 0.329 . . . . 0.0 111.441 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -133.15 116.15 15.92 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.585 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' CD2' ' I' ' 20' ' ' PHE . 10.4 m-85 -122.65 134.84 54.48 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.142 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.11 127.83 23.33 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 80.3 tt0 -95.02 117.38 30.06 Favored 'General case' 0 CA--C 1.522 -0.101 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 176.303 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.45 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 84.5 m-20 -136.05 46.99 2.26 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -175.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.66 HG22 ' HA ' ' I' ' 23' ' ' ASP . 17.0 t -99.88 162.98 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 C-N-CA 118.013 -1.475 . . . . 0.0 108.386 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.459 ' N ' HG12 ' H' ' 24' ' ' VAL . . . 70.99 28.58 70.27 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -178.286 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.532 ' OG ' ' N ' ' H' ' 27' ' ' ASN . 20.0 p -170.53 -132.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.801 0.81 . . . . 0.0 112.467 -175.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.532 ' N ' ' OG ' ' H' ' 26' ' ' SER . 3.0 m-20 -30.7 143.67 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 114.1 -1.409 . . . . 0.0 113.713 -177.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -132.53 -25.14 1.95 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 113.609 -1.632 . . . . 0.0 111.224 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . -78.83 109.37 2.83 Favored Glycine 0 N--CA 1.47 0.913 0 CA-C-N 116.187 -0.46 . . . . 0.0 113.376 -176.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 111.99 12.61 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 122.385 1.088 . . . . 0.0 112.621 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.506 HG23 HG23 ' G' ' 31' ' ' ILE . 14.9 tt -140.34 137.99 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 114.515 -1.22 . . . . 0.0 111.124 178.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.439 ' CG2' HD12 ' H' ' 34' ' ' LEU . 95.5 mt -106.19 113.88 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.609 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.74 100.67 1.13 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 106.631 -2.588 . . . . 0.0 106.631 176.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.505 HD21 HG22 ' G' ' 32' ' ' ILE . 90.7 mt -141.76 153.45 44.59 Favored 'General case' 0 CA--C 1.51 -0.564 0 CA-C-O 122.844 1.307 . . . . 0.0 113.586 -175.467 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.43 ' HB2' ' SD ' ' G' ' 35' ' ' MET . 4.1 mtp -116.87 117.18 29.02 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 112.498 -2.137 . . . . 0.0 105.939 176.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' K' ' 15' ' ' GLN . 58.9 t -123.56 102.42 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 O-C-N 122.469 -0.144 . . . . 0.0 111.35 -176.404 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.64 -162.37 23.76 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.437 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 146.71 -55.64 0.52 Allowed Glycine 0 CA--C 1.547 2.093 0 CA-C-O 119.572 -0.571 . . . . 0.0 112.561 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.613 ' CG2' HG21 ' N' ' 31' ' ' ILE . 3.0 p -142.44 162.51 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-N 118.498 1.149 . . . . 0.0 110.248 178.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.432 HG23 ' ND1' ' K' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' I' I ' 10' ' ' TYR . . . . . 0.514 ' CD1' ' O ' ' J' ' 9' ' ' GLY . 97.7 m-85 -99.28 132.59 44.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.723 0.297 . . . . 0.0 110.572 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' I' ' 11' ' ' GLU . 2.0 pm0 -154.4 141.25 19.14 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.054 0.454 . . . . 0.0 111.446 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -126.81 129.35 71.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.968 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 18.7 m80 -116.25 138.88 50.93 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 110.35 -0.241 . . . . 0.0 110.35 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -149.85 167.85 25.4 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.351 177.231 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -139.22 141.07 37.91 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.456 ' C ' HD22 ' I' ' 17' ' ' LEU . 99.5 mttt -129.8 104.3 7.32 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.394 179.167 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.463 HD12 ' CZ ' ' I' ' 19' ' ' PHE . 3.6 mm? -111.9 113.29 25.53 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 t -109.08 107.48 22.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.463 ' CZ ' HD12 ' I' ' 17' ' ' LEU . 57.7 m-85 -109.05 108.45 19.16 Favored 'General case' 0 CA--C 1.546 0.821 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.447 ' CD2' ' CE2' ' H' ' 20' ' ' PHE . 5.4 m-85 -117.5 130.42 56.43 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 122.184 -0.322 . . . . 0.0 110.917 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.29 134.22 30.69 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.563 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 85.5 mt-10 -92.4 -161.33 0.82 Allowed 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.217 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.66 ' HA ' HG22 ' H' ' 24' ' ' VAL . 0.4 OUTLIER 95.12 54.2 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 -177.689 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.458 HG13 ' H ' ' I' ' 24' ' ' VAL . 1.1 m -81.3 133.49 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 CA-C-O 125.133 2.397 . . . . 0.0 116.264 -169.817 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.707 ' H ' ' HA ' ' J' ' 23' ' ' ASP . . . 94.5 -41.99 2.5 Favored Glycine 0 N--CA 1.443 -0.869 2 CA-C-N 107.471 -4.422 . . . . 0.0 113.594 172.516 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 94.6 p -68.39 110.85 4.31 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 115.976 -1.964 . . . . 0.0 112.039 174.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.888 ' ND2' ' H ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -147.66 124.47 11.23 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 123.313 2.778 . . . . 0.0 111.566 166.739 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.408 ' HZ2' HG23 ' A' ' 39' ' ' VAL . 94.0 mttt -18.11 -52.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 115.638 1.718 . . . . 0.0 115.638 172.142 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.61 52.77 0.02 OUTLIER Glycine 0 CA--C 1.563 3.08 0 CA-C-N 112.584 -2.098 . . . . 0.0 109.661 -175.25 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.888 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . -41.98 141.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -171.221 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.719 HD12 ' O ' ' B' ' 38' ' ' GLY . 55.0 mt -143.19 147.79 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 112.831 -1.986 . . . . 0.0 113.701 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.429 HD13 HG21 ' I' ' 32' ' ' ILE . 27.3 mt -110.58 111.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 174.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.09 104.57 1.96 Allowed Glycine 0 N--CA 1.466 0.643 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mt -141.14 144.56 34.91 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -175.762 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 49.2 tpp -112.85 115.67 28.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 104.644 -2.354 . . . . 0.0 104.644 173.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.51 HG12 ' OE1' ' K' ' 15' ' ' GLN . 47.5 t -123.44 102.62 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 118.055 0.389 . . . . 0.0 111.874 -175.767 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.737 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 107.31 -161.93 13.54 Favored Glycine 0 N--CA 1.467 0.714 0 C-N-CA 120.486 -0.864 . . . . 0.0 112.803 177.557 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.822 ' H ' ' H ' ' J' ' 38' ' ' GLY . . . 148.15 -55.35 0.5 Allowed Glycine 0 CA--C 1.542 1.75 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.746 HG21 HD12 ' N' ' 31' ' ' ILE . 18.2 t -114.43 130.46 68.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 C-N-CA 123.409 0.684 . . . . 0.0 109.217 178.554 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.492 HG23 ' ND1' ' K' ' 13' ' ' HIS . 2.4 p . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.898 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 9' ' ' GLY . . . . . 0.514 ' O ' ' CD1' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -117.13 143.83 45.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.675 0.274 . . . . 0.0 110.434 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -73.68 108.58 6.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.86 0.362 . . . . 0.0 110.677 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.7 136.64 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.31 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 -145.87 126.07 13.85 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.948 -0.301 . . . . 0.0 111.159 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 m-70 -140.41 157.57 45.33 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.012 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -90.31 158.85 16.95 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 174.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 44.1 tttp -141.18 113.55 8.09 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.163 177.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.429 ' N ' HD12 ' J' ' 17' ' ' LEU . 2.8 mp -136.61 127.94 28.28 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.755 0.788 . . . . 0.0 110.84 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -112.95 112.23 39.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 CA-C-N 114.464 -1.244 . . . . 0.0 108.76 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' K' ' 19' ' ' PHE . 18.5 m-85 -106.98 106.33 16.8 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.598 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 20.4 t80 -113.79 114.8 26.81 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.53 122.59 22.62 Favored 'General case' 0 C--O 1.246 0.9 0 CA-C-O 122.153 0.977 . . . . 0.0 111.829 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 96.5 mt-10 -83.89 125.46 32.01 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-N 113.824 -1.535 . . . . 0.0 107.861 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.707 ' HA ' ' H ' ' I' ' 25' ' ' GLY . 61.2 m-20 -166.45 47.29 0.07 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 118.158 -0.925 . . . . 0.0 113.393 -174.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.563 ' N ' ' OE1' ' K' ' 22' ' ' GLU . 9.3 p -98.6 161.31 3.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 CA-C-N 121.419 1.918 . . . . 0.0 109.286 -176.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.741 ' H ' ' N ' ' K' ' 25' ' ' GLY . . . 73.23 28.87 65.3 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 106.662 -2.575 . . . . 0.0 106.662 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 8.7 t -104.5 -120.75 0.21 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 -173.255 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.676 HD21 ' N ' ' J' ' 27' ' ' ASN . 0.7 OUTLIER -81.8 163.75 22.14 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -175.287 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -47.47 -36.82 10.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 112.661 -2.063 . . . . 0.0 114.504 178.075 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.8 77.84 0.06 OUTLIER Glycine 0 CA--C 1.532 1.104 0 C-N-CA 119.147 -1.501 . . . . 0.0 114.859 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.21 169.0 0.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 118.847 1.324 . . . . 0.0 110.555 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.63 HD11 ' HB ' ' D' ' 39' ' ' VAL . 68.8 mt -127.39 135.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 115.212 1.56 . . . . 0.0 115.212 -175.02 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 53.7 mt -106.49 105.75 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 172.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.18 101.17 1.94 Allowed Glycine 0 CA--C 1.508 -0.398 0 N-CA-C 104.849 -3.301 . . . . 0.0 104.849 176.354 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.752 ' CD2' HG22 ' J' ' 36' ' ' VAL . 6.5 tt -143.33 125.74 15.7 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-O 123.081 1.419 . . . . 0.0 112.618 -175.083 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.7 mtp -104.68 118.07 35.66 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 112.582 -2.099 . . . . 0.0 107.875 178.226 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.752 HG22 ' CD2' ' J' ' 34' ' ' LEU . 1.8 t -105.91 114.09 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' I' ' 36' ' ' VAL . . . -64.78 -123.24 0.01 OUTLIER Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.822 ' H ' ' H ' ' I' ' 38' ' ' GLY . . . 64.99 61.05 6.15 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 114.278 -0.961 . . . . 0.0 114.573 178.357 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.466 ' HB ' HD13 ' P' ' 31' ' ' ILE . 1.0 OUTLIER -92.52 130.17 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 177.817 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.652 ' OXT' HG13 ' J' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.84 -1.076 . . . . 0.0 111.859 -177.604 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -104.69 133.41 49.57 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.75 0.309 . . . . 0.0 110.609 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -142.9 133.29 24.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.666 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 95.2 t -124.97 123.8 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.462 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.492 ' ND1' HG23 ' I' ' 40' ' ' VAL . 6.4 t-160 -145.04 112.98 6.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.044 0.449 . . . . 0.0 111.305 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.673 ' CE1' ' H ' ' L' ' 14' ' ' HIS . 19.0 m-70 -140.41 159.22 42.68 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 177.316 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.737 HE22 ' N ' ' I' ' 37' ' ' GLY . 77.0 mt-30 -90.18 159.35 16.79 Favored 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 175.713 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.711 ' C ' HD12 ' K' ' 17' ' ' LEU . 99.2 mttt -140.03 101.0 4.06 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.711 HD12 ' C ' ' K' ' 16' ' ' LYS . 7.7 mp -125.89 125.91 43.57 Favored 'General case' 0 CA--C 1.506 -0.73 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.785 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.405 HG13 ' O ' ' K' ' 18' ' ' VAL . 5.2 p -119.49 118.33 56.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' J' ' 19' ' ' PHE . 53.2 m-85 -107.03 105.98 16.28 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.728 -1.123 . . . . 0.0 109.69 -178.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.1 t80 -106.24 108.09 19.43 Favored 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.051 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -148.36 155.11 40.86 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.94 1.352 . . . . 0.0 113.38 -177.649 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.568 ' HB2' ' H ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -93.06 117.58 30.23 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.908 -179.273 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.427 ' OD2' ' OD1' ' L' ' 23' ' ' ASP . 13.6 m-20 -67.4 -51.25 54.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 114.418 -1.265 . . . . 0.0 111.547 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.568 HG22 ' N ' ' K' ' 25' ' ' GLY . 2.3 p 158.8 161.84 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -177.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.741 ' N ' ' H ' ' J' ' 25' ' ' GLY . . . -63.29 30.41 0.08 OUTLIER Glycine 0 CA--C 1.532 1.116 0 N-CA-C 118.509 2.164 . . . . 0.0 118.509 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.575 ' OG ' ' O ' ' K' ' 25' ' ' GLY . 5.2 m -169.96 -127.8 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 121.293 2.546 . . . . 0.0 114.104 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.437 ' O ' ' N ' ' K' ' 29' ' ' GLY . 60.2 t30 -48.13 152.29 0.85 Allowed 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 113.577 0.955 . . . . 0.0 113.577 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.449 ' NZ ' HD11 ' L' ' 32' ' ' ILE . 85.0 tttt -70.33 48.84 0.11 Allowed 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . -82.47 51.1 4.46 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.27 -0.966 . . . . 0.0 112.707 -176.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 173.58 7.13 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.529 HD12 HG13 ' D' ' 39' ' ' VAL . 42.2 mt -125.46 127.75 72.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.743 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.424 HD13 HG21 ' K' ' 32' ' ' ILE . 33.4 pt -132.63 127.6 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.664 0.745 . . . . 0.0 111.753 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.608 ' C ' HD22 ' K' ' 34' ' ' LEU . . . -117.34 110.93 2.15 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.709 HD22 ' N ' ' K' ' 34' ' ' LEU . 1.9 mm? -121.64 116.16 24.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.902 0.382 . . . . 0.0 110.066 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 4.1 ttm -107.81 130.28 54.99 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.445 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 54.0 t -125.64 131.84 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 CA-C-O 121.915 0.864 . . . . 0.0 112.352 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.03 -111.41 0.01 OUTLIER Glycine 0 CA--C 1.527 0.827 0 CA-C-N 113.722 -1.581 . . . . 0.0 111.085 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' OXT' ' J' ' 40' ' ' VAL . . . 105.91 -70.55 0.23 Allowed Glycine 0 N--CA 1.473 1.101 0 CA-C-N 114.518 -0.841 . . . . 0.0 111.758 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.435 -1.195 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 . . . . . 0 N--CA 1.463 0.22 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.533 HG12 ' NE2' ' K' ' 14' ' ' HIS . 2.1 t -110.79 115.93 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 110.462 -179.335 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.5 p80 -147.19 101.5 3.4 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.975 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.673 ' H ' ' CE1' ' K' ' 14' ' ' HIS . 97.6 m-70 -156.55 164.92 37.64 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 178.123 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.449 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 96.5 mm-40 -89.97 159.36 16.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.358 . . . . 0.0 111.104 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.78 104.18 4.83 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.605 0.716 . . . . 0.0 109.494 177.701 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.663 ' CD1' HG21 ' J' ' 36' ' ' VAL . 1.8 mt -122.69 115.48 22.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -101.64 97.76 6.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.327 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.565 ' CZ ' HD12 ' K' ' 34' ' ' LEU . 85.2 m-85 -93.87 98.93 11.39 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.368 -1.715 . . . . 0.0 106.368 178.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -122.38 127.02 49.22 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.746 0.784 . . . . 0.0 109.996 -178.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.11 150.96 36.03 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -64.45 107.79 1.46 Allowed 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 118.549 -1.26 . . . . 0.0 108.758 -178.026 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.427 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 13.8 m-20 -153.89 50.0 0.66 Allowed 'General case' 0 C--O 1.231 0.122 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.454 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 95.8 t -82.8 149.3 4.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 178.095 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.93 36.25 5.83 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 18.1 t -76.45 102.35 5.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.706 0.765 . . . . 0.0 111.487 -176.616 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -97.48 -167.61 1.56 Allowed 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.543 -1.208 . . . . 0.0 112.188 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -49.13 -40.55 32.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.042 -1.436 . . . . 0.0 114.38 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.31 68.79 1.86 Allowed Glycine 0 N--CA 1.477 1.432 0 N-CA-C 114.971 0.748 . . . . 0.0 114.971 -175.09 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.444 ' CB ' ' O ' ' K' ' 28' ' ' LYS . . . -141.74 141.71 33.26 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -120.6 117.69 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.125 0 CA-C-N 120.443 1.474 . . . . 0.0 111.577 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.449 HD11 ' NZ ' ' K' ' 28' ' ' LYS . 95.4 mt -119.57 122.18 68.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-N 114.812 -1.086 . . . . 0.0 110.205 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.4 106.72 0.91 Allowed Glycine 0 N--CA 1.464 0.547 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.9 tp -125.17 123.9 40.61 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 94.0 mtp -132.77 133.58 43.61 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.436 0.636 . . . . 0.0 112.217 -179.06 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.5 t -128.87 132.35 67.55 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.135 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 177.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.6 112.19 3.53 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 119.182 -1.485 . . . . 0.0 111.736 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.34 -63.51 4.46 Favored Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 177.158 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.506 ' CA ' HD11 ' R' ' 31' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 124.229 1.012 . . . . 0.0 108.355 -179.111 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 42.7 tp10 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 120.89 0.376 . . . . 0.0 110.048 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 70.4 t -125.87 131.6 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.814 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -107.43 107.81 18.86 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.695 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 42.8 p-80 -152.66 165.94 33.68 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-O 121.212 0.53 . . . . 0.0 111.728 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 52.7 tt0 -170.75 147.99 2.87 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.271 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -77.9 120.41 22.74 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -128.31 113.81 16.1 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -130.19 130.07 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.354 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -133.56 141.88 47.91 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.44 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.408 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 50.9 p90 -134.8 129.28 34.31 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.714 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.53 116.59 31.11 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.326 0.584 . . . . 0.0 110.339 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 22' ' ' GLU . . . . . 0.581 ' O ' ' N ' ' M' ' 24' ' ' VAL . 67.3 mt-10 -150.9 -139.06 0.09 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.329 -0.851 . . . . 0.0 108.918 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 53.7 p30 -53.05 50.99 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.694 1.197 . . . . 0.0 113.226 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.587 HG12 ' H ' ' M' ' 25' ' ' GLY . 2.7 t -101.02 -141.73 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.886 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 25' ' ' GLY . . . . . 0.587 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -72.59 -36.99 58.29 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 119.161 -1.495 . . . . 0.0 113.273 -175.309 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 26' ' ' SER . . . . . 0.425 ' O ' ' C ' ' M' ' 27' ' ' ASN . 93.8 p -162.27 117.26 1.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 118.873 1.336 . . . . 0.0 112.134 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 27' ' ' ASN . . . . . 0.529 ' ND2' ' O ' ' N' ' 25' ' ' GLY . 99.1 m-20 -23.33 144.83 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.769 -1.105 . . . . 0.0 113.194 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -120.24 -36.6 3.21 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 173.796 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 29' ' ' GLY . . . . . 0.437 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 80.14 -70.2 2.98 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 112.275 -2.239 . . . . 0.0 112.584 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 30' ' ' ALA . . . . . 0.437 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 179.46 74.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.533 0.666 . . . . 0.0 112.022 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.6 HG23 ' O ' ' M' ' 31' ' ' ILE . 19.3 tt -128.58 108.94 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 CA-C-N 119.243 0.929 . . . . 0.0 109.313 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 32' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' O' ' 19' ' ' PHE . 96.6 mt -114.48 109.55 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.592 -179.706 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.25 98.36 0.69 Allowed Glycine 0 N--CA 1.461 0.308 0 N-CA-C 106.154 -2.778 . . . . 0.0 106.154 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 82.5 mt -145.93 164.6 31.5 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 123.269 1.509 . . . . 0.0 113.888 -176.65 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.9 mmm -113.77 110.19 19.77 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 111.771 -2.468 . . . . 0.0 106.859 177.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -118.04 111.78 35.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 134.69 -131.52 5.92 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.02 -63.08 0.75 Allowed Glycine 0 CA--C 1.536 1.398 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.261 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.449 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 2.1 t -114.04 160.71 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-N 116.992 0.396 . . . . 0.0 110.05 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.449 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 21.8 m . . . . . 0 N--CA 1.469 0.48 0 CA-C-O 117.836 -1.078 . . . . 0.0 111.918 178.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.113 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -85.51 137.9 32.57 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -100.77 141.95 32.92 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.487 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -124.72 132.78 70.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.376 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 51.0 m170 -116.98 99.79 7.31 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' N ' ' N' ' 15' ' ' GLN . 23.1 t60 -154.01 165.82 34.96 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.594 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.636 ' N ' ' CD2' ' N' ' 14' ' ' HIS . 13.4 pt20 -160.34 143.52 13.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.217 178.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -80.0 112.2 17.06 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.457 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 tt -120.98 117.92 28.53 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -125.72 131.83 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.09 0.471 . . . . 0.0 111.094 -179.376 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -126.94 119.12 25.95 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 87.5 t80 -118.21 126.32 51.95 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.32 129.49 43.27 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 121.292 0.568 . . . . 0.0 112.355 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -88.65 115.99 26.58 Favored 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -87.04 47.6 1.53 Allowed 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -110.48 151.64 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 176.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 25' ' ' GLY . . . . . 0.529 ' O ' ' ND2' ' M' ' 27' ' ' ASN . . . 63.39 29.83 75.73 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.496 ' O ' ' O ' ' N' ' 27' ' ' ASN . 4.7 t -155.65 111.24 3.04 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 113.854 1.057 . . . . 0.0 113.854 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' N' ' 26' ' ' SER . 60.8 m-20 -49.7 -164.75 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.178 176.565 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.59 ' NZ ' ' CG2' ' G' ' 39' ' ' VAL . 81.7 mttt 78.38 -41.17 0.3 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.543 1.137 . . . . 0.0 114.012 177.331 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.96 -68.28 3.45 Favored Glycine 0 CA--C 1.545 1.96 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.731 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.98 107.85 0.03 OUTLIER 'General case' 0 C--N 1.346 0.448 0 CA-C-N 117.576 0.688 . . . . 0.0 111.853 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.746 HD12 HG21 ' I' ' 39' ' ' VAL . 0.2 OUTLIER -123.89 122.09 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 O-C-N 122.208 -0.307 . . . . 0.0 110.489 178.755 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.595 HD13 ' CD1' ' P' ' 19' ' ' PHE . 60.5 mt -114.36 116.15 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 110.39 2.22 Favored Glycine 0 N--CA 1.468 0.775 0 N-CA-C 106.179 -2.769 . . . . 0.0 106.179 177.488 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.639 ' HB2' HD22 ' O' ' 34' ' ' LEU . 76.5 mt -144.67 143.58 30.81 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -174.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 1.7 ttm -110.11 106.66 16.22 Favored 'General case' 0 N--CA 1.441 -0.895 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 173.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.542 HG11 ' CD2' ' P' ' 17' ' ' LEU . 29.6 m -126.31 123.33 63.3 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.18 -113.58 0.99 Allowed Glycine 0 C--N 1.308 -1.011 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.47 ' O ' HD11 ' B' ' 31' ' ' ILE . . . 73.08 -72.78 1.09 Allowed Glycine 0 CA--C 1.532 1.109 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.052 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 52.0 t -113.34 132.61 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 98.8 t . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.363 179.896 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.119 -1.593 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -112.85 138.4 49.74 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.993 0.425 . . . . 0.0 110.571 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 11' ' ' GLU . . . . . 0.548 ' O ' ' CE1' ' P' ' 13' ' ' HIS . 98.3 mt-10 -140.92 162.93 34.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.714 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.462 HG23 ' O ' ' O' ' 12' ' ' VAL . 5.0 m -118.53 126.87 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.467 ' C ' ' CG ' ' O' ' 14' ' ' HIS . 10.3 m80 -129.92 136.23 49.24 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.329 0.585 . . . . 0.0 112.028 -178.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.708 ' CE1' ' H ' ' P' ' 14' ' ' HIS . 5.1 m-70 -156.97 176.0 13.35 Favored 'General case' 0 C--O 1.223 -0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.294 179.241 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -152.96 140.11 19.38 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 16' ' ' LYS . . . . . 0.557 ' N ' ' CE1' ' N' ' 14' ' ' HIS . 88.2 tttt -94.45 110.89 22.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.167 -0.469 . . . . 0.0 112.106 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.82 HD22 ' N ' ' O' ' 17' ' ' LEU . 0.7 OUTLIER -117.73 109.8 17.05 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 176.102 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -110.11 113.89 45.49 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.572 ' CD1' HD13 ' M' ' 32' ' ' ILE . 77.9 m-85 -113.36 106.88 15.12 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.77 125.03 53.23 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.789 0.328 . . . . 0.0 110.553 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.58 122.73 28.04 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -149.32 -176.77 5.5 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.431 ' N ' ' OE1' ' P' ' 22' ' ' GLU . 96.7 m-20 66.22 50.32 1.39 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 113.365 -1.743 . . . . 0.0 112.298 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.447 HG12 ' H ' ' O' ' 26' ' ' SER . 67.0 t -82.45 146.43 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.91 -39.12 64.65 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 118.682 -1.723 . . . . 0.0 110.57 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.721 ' O ' ' O ' ' O' ' 27' ' ' ASN . 39.4 t -174.15 124.78 0.33 Allowed 'General case' 0 C--O 1.221 -0.436 0 CA-C-O 118.525 -0.75 . . . . 0.0 110.185 178.411 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.721 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.5 t-20 -2.62 145.99 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 178.422 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.417 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 93.4 mttt -159.03 30.93 0.21 Allowed 'General case' 0 N--CA 1.468 0.44 0 O-C-N 121.805 -0.56 . . . . 0.0 112.413 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.71 88.28 0.72 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 119.49 -1.338 . . . . 0.0 113.028 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 134.41 52.45 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.949 0.881 . . . . 0.0 109.873 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.715 HD13 HG22 ' I' ' 39' ' ' VAL . 4.5 tt -149.23 140.54 17.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.744 -175.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.56 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 73.6 mt -110.57 109.86 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 176.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 33' ' ' GLY . . . . . 0.817 ' O ' HD23 ' O' ' 34' ' ' LEU . . . -117.54 101.85 0.96 Allowed Glycine 0 N--CA 1.469 0.855 0 N-CA-C 108.489 -1.845 . . . . 0.0 108.489 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.817 HD23 ' O ' ' O' ' 33' ' ' GLY . 0.3 OUTLIER -141.92 158.83 43.32 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 122.962 1.363 . . . . 0.0 114.175 -177.052 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -112.16 112.71 24.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 111.618 -2.537 . . . . 0.0 106.315 175.724 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.449 HG22 ' CG2' ' N' ' 36' ' ' VAL . 88.6 t -119.68 111.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -177.788 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.01 -131.67 5.81 Favored Glycine 0 C--N 1.319 -0.397 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.567 178.697 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.431 ' O ' HG23 ' P' ' 39' ' ' VAL . . . 98.96 -63.26 0.75 Allowed Glycine 0 CA--C 1.541 1.66 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.42 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.556 ' CG2' HG21 ' C' ' 31' ' ' ILE . 55.9 t -126.95 133.34 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.407 ' H ' HG11 ' P' ' 39' ' ' VAL . 96.6 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.723 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 121.185 0.517 . . . . 0.0 111.455 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.548 ' CE1' ' O ' ' O' ' 11' ' ' GLU . 80.0 m-70 -147.48 104.62 3.65 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.024 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.708 ' H ' ' CE1' ' O' ' 14' ' ' HIS . 40.0 m-70 -148.74 159.43 44.14 Favored 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.734 178.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.432 HE21 ' HG2' ' Q' ' 15' ' ' GLN . 2.3 mt-30 -90.31 159.89 16.42 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 114.215 -1.357 . . . . 0.0 107.822 175.111 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.34 99.21 3.6 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.542 ' CD2' HG11 ' N' ' 36' ' ' VAL . 4.6 mp -127.37 122.63 34.18 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.116 0.484 . . . . 0.0 110.525 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.44 114.31 45.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.595 ' CD1' HD13 ' N' ' 32' ' ' ILE . 59.4 m-85 -112.36 108.01 17.03 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -112.78 124.11 51.85 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.318 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 137.05 34.74 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 113.837 1.051 . . . . 0.0 113.837 -178.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.431 ' OE1' ' N ' ' O' ' 23' ' ' ASP . 78.9 tt0 -81.6 116.94 21.58 Favored 'General case' 0 N--CA 1.462 0.149 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.057 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.404 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 99.7 m-20 -138.34 50.28 1.89 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -176.66 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -81.85 148.4 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.625 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.485 ' O ' ' CB ' ' O' ' 27' ' ' ASN . . . 93.72 36.16 5.92 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 106.412 -2.675 . . . . 0.0 106.412 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 21.9 p -76.05 102.62 5.75 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 122.443 1.116 . . . . 0.0 112.498 -174.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -96.87 -164.47 1.15 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 112.823 -1.99 . . . . 0.0 110.889 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt -48.74 -40.25 27.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.895 -1.048 . . . . 0.0 111.877 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.77 70.08 1.88 Allowed Glycine 0 CA--C 1.543 1.809 0 N-CA-C 114.937 0.735 . . . . 0.0 114.937 -174.351 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.36 111.04 6.81 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 104.969 -2.234 . . . . 0.0 104.969 176.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.466 HD13 ' HB ' ' J' ' 39' ' ' VAL . 57.6 mt -135.42 136.18 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -172.371 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.471 HD13 ' CD1' ' R' ' 19' ' ' PHE . 3.0 mt -106.05 106.07 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.26 99.38 1.18 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 106.482 -2.647 . . . . 0.0 106.482 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.502 ' CD1' HD12 ' O' ' 34' ' ' LEU . 2.8 tp -128.43 123.59 34.11 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-O 122.419 1.104 . . . . 0.0 112.821 -176.277 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -98.47 104.35 16.38 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 175.422 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.623 HG13 ' O ' ' P' ' 36' ' ' VAL . 8.7 p -119.18 113.76 42.43 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -177.57 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.22 -123.85 1.21 Allowed Glycine 0 C--N 1.309 -0.958 0 C-N-CA 118.95 -1.595 . . . . 0.0 111.79 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.525 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 81.26 -67.72 3.57 Favored Glycine 0 CA--C 1.536 1.354 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -178.087 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.439 ' CG1' ' OD1' ' D' ' 27' ' ' ASN . 67.9 t -136.09 155.61 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.419 ' N ' HG12 ' P' ' 39' ' ' VAL . 11.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.651 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -108.56 134.77 50.85 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.751 0.31 . . . . 0.0 110.313 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -88.87 117.96 28.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.878 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -127.98 135.51 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 120.949 0.404 . . . . 0.0 110.991 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.488 ' CD2' ' N ' ' Q' ' 13' ' ' HIS . 2.0 m-70 -136.18 118.29 15.44 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.628 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.692 ' CD2' ' H ' ' R' ' 14' ' ' HIS . 22.7 m80 -147.23 159.6 43.45 Favored 'General case' 0 C--O 1.219 -0.534 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.29 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.598 ' NE2' ' OE1' ' R' ' 15' ' ' GLN . 0.0 OUTLIER -90.25 159.59 16.61 Favored 'General case' 0 C--N 1.334 -0.084 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 176.145 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 66.5 tttt -140.2 104.34 4.79 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 120.313 -0.555 . . . . 0.0 109.697 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' Q' ' 17' ' ' LEU . 4.3 mp -128.88 126.23 39.29 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 121.724 0.773 . . . . 0.0 111.006 179.153 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 84.8 t -114.3 113.63 44.32 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 114.721 -1.127 . . . . 0.0 108.837 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.56 ' CD1' HD13 ' O' ' 32' ' ' ILE . 59.5 m-85 -110.76 103.65 12.21 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 178.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -112.45 125.09 53.84 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.888 -178.22 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.68 143.61 35.2 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.404 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 93.7 mt-10 -84.64 137.37 33.31 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 120.166 -0.613 . . . . 0.0 109.619 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.531 ' OD2' ' HB1' ' R' ' 21' ' ' ALA . 35.8 p-10 -177.75 50.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.159 -177.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.473 HG22 ' O ' ' R' ' 22' ' ' GLU . 61.5 t -81.8 149.27 4.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.904 1.335 . . . . 0.0 113.828 -174.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.415 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 93.09 36.7 5.9 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 111.784 -2.462 . . . . 0.0 112.887 178.128 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' Q' ' 25' ' ' GLY . 3.2 p 72.65 120.18 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 118.621 -0.704 . . . . 0.0 110.546 175.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.611 HD21 ' HB2' ' Q' ' 30' ' ' ALA . 6.9 m-20 -83.11 160.99 21.77 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 116.824 -1.95 . . . . 0.0 108.057 176.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -48.74 -39.79 26.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.573 0.702 . . . . 0.0 111.381 176.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.23 67.46 0.04 OUTLIER Glycine 0 CA--C 1.541 1.711 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.075 -177.063 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . 0.611 ' HB2' HD21 ' Q' ' 27' ' ' ASN . . . -70.96 152.18 43.89 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 118.449 1.125 . . . . 0.0 112.002 -176.69 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.443 HG23 HG23 ' R' ' 31' ' ' ILE . 6.3 mt -113.3 129.19 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.328 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 99.8 mt -124.69 116.06 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.72 117.02 3.16 Favored Glycine 0 N--CA 1.47 0.951 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.244 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 29.2 tp -124.55 120.64 32.53 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 93.7 mtp -135.17 144.94 47.3 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -178.091 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.82 164.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.68 93.68 0.1 Allowed Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.056 -1.068 . . . . 0.0 111.119 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' H ' ' HA3' ' R' ' 38' ' ' GLY . . . 164.45 -81.86 0.11 Allowed Glycine 0 CA--C 1.536 1.347 0 C-N-CA 120.473 -0.87 . . . . 0.0 112.465 177.674 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -157.68 147.57 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.158 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.392 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.552 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.95 133.09 51.23 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.876 0.37 . . . . 0.0 110.609 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 21.1 pt-20 -77.99 150.65 33.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.762 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.4 HG12 ' HE2' ' Q' ' 14' ' ' HIS . 52.9 t -123.69 131.62 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.105 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.428 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.0 OUTLIER -152.22 112.67 4.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.487 -179.656 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.692 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 75.0 m80 -149.81 164.43 35.35 Favored 'General case' 0 C--O 1.22 -0.472 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.598 ' OE1' ' NE2' ' Q' ' 15' ' ' GLN . 60.0 mt-30 -89.94 159.5 16.88 Favored 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 120.317 -0.553 . . . . 0.0 110.401 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 61.8 tttp -139.55 115.19 10.02 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.456 0.646 . . . . 0.0 110.332 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.448 ' N ' HD12 ' R' ' 17' ' ' LEU . 1.2 mp -135.46 125.54 26.04 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.796 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 3.5 p -112.96 116.48 52.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 176.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.471 ' CD1' HD13 ' P' ' 32' ' ' ILE . 55.3 m-85 -105.17 104.77 14.57 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -123.73 124.37 42.58 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.997 0.903 . . . . 0.0 112.099 -177.696 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.531 ' HB1' ' OD2' ' Q' ' 23' ' ' ASP . . . -120.65 130.2 54.03 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.023 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.473 ' O ' HG22 ' Q' ' 24' ' ' VAL . 97.8 mt-10 -70.21 110.15 5.04 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 118.813 -1.155 . . . . 0.0 110.377 -177.421 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 179.57 48.62 0.0 OUTLIER 'General case' 0 C--N 1.342 0.277 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.519 HG12 ' N ' ' R' ' 25' ' ' GLY . 69.0 t -72.85 160.34 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 117.324 -1.75 . . . . 0.0 108.644 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.519 ' N ' HG12 ' R' ' 24' ' ' VAL . . . 110.35 -33.27 6.06 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.3 m -72.2 129.57 38.77 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 113.028 -1.586 . . . . 0.0 111.806 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 27' ' ' ASN . . . . . 0.67 ' O ' ' N ' ' R' ' 29' ' ' GLY . 98.6 m-20 -90.86 -161.91 0.86 Allowed 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.22 47.58 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 29' ' ' GLY . . . . . 0.67 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.28 56.9 0.9 Allowed Glycine 0 CA--C 1.541 1.686 0 CA-C-N 119.301 0.955 . . . . 0.0 111.997 178.184 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.97 168.61 13.73 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.506 HD11 ' CA ' ' L' ' 39' ' ' VAL . 15.9 tt -116.15 110.28 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.439 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.5 mt -117.11 128.63 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.542 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.14 115.07 2.44 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.46 117.4 25.87 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 8.9 ttp -141.19 124.38 16.46 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.364 0.602 . . . . 0.0 111.126 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.32 111.68 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 120.125 -0.63 . . . . 0.0 111.753 -179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.8 132.17 10.9 Favored Glycine 0 CA--C 1.518 0.273 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 176.845 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' R' R ' 38' ' ' GLY . . . . . 0.417 ' HA3' ' H ' ' Q' ' 38' ' ' GLY . . . 109.49 63.24 0.53 Allowed Glycine 0 N--CA 1.474 1.18 0 CA-C-N 118.201 1.0 . . . . 0.0 112.95 179.618 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' R' ' 38' ' ' GLY . 41.4 t -32.17 151.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 117.285 0.543 . . . . 0.0 112.287 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.765 179.682 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.45 ' O ' ' OE1' ' B' ' 11' ' ' GLU . 95.7 mt-10 . . . . . 0 N--CA 1.464 0.239 0 CA-C-O 121.029 0.443 . . . . 0.0 110.419 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 m -137.27 162.13 33.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.966 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.461 ' H ' ' HB3' ' B' ' 13' ' ' HIS . 80.2 m80 -145.13 135.53 24.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.583 0.23 . . . . 0.0 110.785 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.572 ' CD2' ' N ' ' A' ' 15' ' ' GLN . 20.8 t60 -158.06 165.18 35.7 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.972 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 68.2 tp60 -158.97 142.45 14.89 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 121.027 0.442 . . . . 0.0 109.97 177.552 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -82.51 124.16 29.85 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.473 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.0 mt -127.18 119.52 26.63 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -141.49 146.45 23.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.363 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -147.52 141.2 25.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.11 0.481 . . . . 0.0 111.427 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.476 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 49.6 p90 -115.34 132.64 56.55 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.229 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.05 126.93 46.15 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 -177.205 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -128.14 -140.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 . . . . . 0 CA--C 1.538 0.518 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.659 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.5 p30 . . . . . 0 C--O 1.232 0.18 0 N-CA-C 115.159 1.54 . . . . 0.0 115.159 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.439 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 96.0 mttt -55.86 -37.48 68.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 112.081 -2.327 . . . . 0.0 112.409 -179.055 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.05 77.72 0.4 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 112.079 -0.408 . . . . 0.0 112.079 -175.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.39 141.67 41.43 Favored 'General case' 0 C--O 1.243 0.746 0 CA-C-O 123.736 1.731 . . . . 0.0 113.012 -177.132 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -126.76 127.63 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.739 -2.482 . . . . 0.0 108.406 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.452 ' O ' ' O ' ' B' ' 33' ' ' GLY . 80.8 mt -100.9 105.66 18.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.381 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.07 96.39 1.15 Allowed Glycine 0 CA--C 1.505 -0.589 0 N-CA-C 104.385 -3.486 . . . . 0.0 104.385 176.422 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.932 ' O ' HD12 ' B' ' 34' ' ' LEU . 51.6 tp -148.2 159.21 44.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 123.002 1.382 . . . . 0.0 112.969 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.487 ' CE ' ' SD ' ' B' ' 35' ' ' MET . 17.0 mtp -119.52 117.51 28.59 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.482 179.443 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 36' ' ' VAL . 27.3 m -119.24 111.85 35.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 177.844 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.22 -131.99 8.14 Favored Glycine 0 C--N 1.315 -0.602 0 N-CA-C 107.543 -2.223 . . . . 0.0 107.543 -177.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' B' ' 39' ' ' VAL . . . 87.05 -63.72 3.99 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 120.126 -1.035 . . . . 0.0 111.608 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -108.26 179.89 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 120.847 0.356 . . . . 0.0 110.106 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.455 HG12 ' CD2' ' C' ' 13' ' ' HIS . 85.9 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.852 -1.071 . . . . 0.0 110.959 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.17 132.13 54.41 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.31 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' O ' ' A' ' 11' ' ' GLU . 80.7 mm-40 -124.63 122.77 38.46 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.439 ' CG1' ' C ' ' C' ' 12' ' ' VAL . 3.6 t -112.92 100.27 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.983 0.42 . . . . 0.0 110.52 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.461 ' HB3' ' H ' ' A' ' 13' ' ' HIS . 12.2 p-80 -138.82 145.19 39.76 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.747 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.548 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 2.9 p80 -146.33 160.35 42.14 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.482 0.658 . . . . 0.0 111.98 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.546 ' NE2' ' OE1' ' C' ' 15' ' ' GLN . 34.4 mt-30 -90.3 159.67 16.53 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.178 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -139.97 108.05 5.75 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.49 130.84 53.48 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 120.875 0.369 . . . . 0.0 111.021 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.84 130.88 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.713 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -127.26 129.64 48.11 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -128.68 124.19 35.05 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.05 134.37 54.78 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.173 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.484 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 81.9 tt0 -161.74 159.8 27.65 Favored 'General case' 0 CA--C 1.55 0.969 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 -178.463 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' B' ' 24' ' ' VAL . 19.4 t70 112.83 -70.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 127.055 2.142 . . . . 0.0 110.854 177.205 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.524 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.7 t -58.77 -122.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 173.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.46 ' H ' HG12 ' B' ' 24' ' ' VAL . . . 139.12 -34.94 2.02 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-O 118.089 -1.395 . . . . 0.0 116.262 172.651 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -80.43 119.52 23.23 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 121.355 2.578 . . . . 0.0 106.59 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 28' ' ' LYS . 3.0 m120 -89.78 157.7 17.83 Favored 'General case' 0 C--N 1.344 0.368 0 C-N-CA 116.11 -2.236 . . . . 0.0 108.181 176.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -48.31 -40.53 25.39 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 122.394 1.092 . . . . 0.0 110.983 174.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 67.64 0.04 OUTLIER Glycine 0 CA--C 1.549 2.21 0 CA-C-N 112.956 -1.929 . . . . 0.0 110.5 -174.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.07 141.89 52.74 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 120.09 1.945 . . . . 0.0 115.168 -172.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.895 HG23 HG23 ' C' ' 31' ' ' ILE . 19.8 mt -136.23 134.09 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 113.159 -1.837 . . . . 0.0 113.106 -175.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.92 103.0 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 174.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -103.69 103.88 2.4 Favored Glycine 0 CA--C 1.507 -0.446 0 N-CA-C 104.309 -3.516 . . . . 0.0 104.309 175.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.932 HD12 ' O ' ' A' ' 34' ' ' LEU . 17.8 tp -146.12 147.66 31.79 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 118.272 -1.371 . . . . 0.0 113.538 -173.021 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.487 ' SD ' ' CE ' ' A' ' 35' ' ' MET . 3.9 ttm -113.13 116.37 29.74 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-N 112.815 -1.993 . . . . 0.0 107.824 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.406 HG23 HD21 ' C' ' 34' ' ' LEU . 37.8 t -118.95 123.73 71.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.76 -114.15 2.03 Favored Glycine 0 C--N 1.315 -0.591 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.535 ' O ' ' CD1' ' H' ' 31' ' ' ILE . . . 81.02 -72.65 2.7 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.486 ' CG2' ' O ' ' A' ' 38' ' ' GLY . 24.8 t -124.54 163.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.532 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 20.7 m . . . . . 0 N--CA 1.473 0.689 0 CA-C-O 117.782 -1.104 . . . . 0.0 111.694 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.97 135.59 50.59 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -138.83 144.9 39.46 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.801 HG21 ' C ' ' D' ' 12' ' ' VAL . 27.6 m -138.19 164.43 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-O 120.963 0.411 . . . . 0.0 111.807 -179.029 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.455 ' CD2' HG12 ' A' ' 40' ' ' VAL . 4.2 p-80 -129.48 132.92 47.04 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.301 0.572 . . . . 0.0 112.131 -178.552 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.538 ' CG ' ' O ' ' D' ' 14' ' ' HIS . 17.7 p-80 -157.26 169.52 24.56 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.066 178.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.546 ' OE1' ' NE2' ' B' ' 15' ' ' GLN . 99.5 mm-40 -89.67 156.61 18.45 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.112 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -141.36 115.41 9.25 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.993 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.453 ' HB2' HD22 ' D' ' 17' ' ' LEU . 4.6 mp -135.24 118.8 16.96 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 122.018 0.913 . . . . 0.0 111.029 178.153 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -106.76 117.51 52.7 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.402 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 54.9 m-85 -109.93 99.73 8.81 Favored 'General case' 0 N--CA 1.447 -0.582 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -109.79 126.67 54.01 Favored 'General case' 0 C--O 1.241 0.626 0 CA-C-O 121.41 0.624 . . . . 0.0 111.058 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 21' ' ' ALA . . . . . 0.638 ' HB1' HG13 ' C' ' 24' ' ' VAL . . . -128.17 113.26 15.49 Favored 'General case' 0 C--O 1.244 0.778 0 CA-C-O 121.884 0.85 . . . . 0.0 110.806 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.424 ' OE2' ' OD1' ' C' ' 23' ' ' ASP . 0.4 OUTLIER -86.17 103.3 14.68 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.065 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.474 ' H ' ' HB2' ' D' ' 22' ' ' GLU . 35.5 m-20 50.84 50.15 19.61 Favored 'General case' 0 C--O 1.214 -0.793 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.47 -177.417 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.939 HG22 ' H ' ' C' ' 25' ' ' GLY . 9.9 p -160.1 -174.22 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.094 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.939 ' H ' HG22 ' C' ' 24' ' ' VAL . . . 59.78 26.82 63.27 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.777 178.288 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' C' ' 27' ' ' ASN . 62.8 m -166.19 -145.94 0.08 Allowed 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' C' ' 26' ' ' SER . 10.6 m-20 55.48 142.25 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 120.906 0.384 . . . . 0.0 111.797 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.745 ' H ' ' CB ' ' D' ' 26' ' ' SER . 71.1 mmtt 62.47 46.06 5.96 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 61.08 0.79 Allowed Glycine 0 N--CA 1.474 1.204 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.083 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -101.87 119.3 38.56 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-O 121.567 0.698 . . . . 0.0 109.66 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.895 HG23 HG23 ' B' ' 31' ' ' ILE . 3.6 tt -137.07 136.34 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 120.021 -0.672 . . . . 0.0 112.438 -177.615 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.414 HD13 ' CD1' ' E' ' 19' ' ' PHE . 63.5 mt -107.09 107.42 22.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 176.687 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.06 100.95 2.01 Favored Glycine 0 C--O 1.237 0.327 0 N-CA-C 104.89 -3.284 . . . . 0.0 104.89 175.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.756 HD23 ' O ' ' B' ' 34' ' ' LEU . 0.8 OUTLIER -133.25 138.08 46.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.99 1.376 . . . . 0.0 114.314 -174.75 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -109.14 110.75 22.07 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 175.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.417 HG22 HD22 ' C' ' 34' ' ' LEU . 25.0 t -122.98 123.16 67.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 118.429 0.559 . . . . 0.0 109.529 -177.02 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.5 -113.19 0.65 Allowed Glycine 0 C--N 1.315 -0.59 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.964 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 74.05 -72.98 1.32 Allowed Glycine 0 CA--C 1.548 2.122 0 CA-C-N 114.863 -0.669 . . . . 0.0 111.641 -177.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -131.51 136.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.405 ' OXT' HG12 ' C' ' 40' ' ' VAL . 73.7 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.373 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.801 ' C ' HG21 ' C' ' 12' ' ' VAL . 68.4 t . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.566 ' N ' HG12 ' D' ' 12' ' ' VAL . 2.3 t-80 -63.35 103.86 0.55 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.604 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 12.6 t60 -146.72 159.76 43.08 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.536 -178.158 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.604 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 36.1 tp60 -84.65 157.97 20.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -178.635 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.84 ' O ' HD23 ' D' ' 17' ' ' LEU . 88.1 tttt -159.56 100.23 1.47 Allowed 'General case' 0 C--N 1.315 -0.913 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.39 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.84 HD23 ' O ' ' D' ' 16' ' ' LYS . 6.2 mt -132.8 136.13 46.1 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -120.59 124.23 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.955 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 37.9 m-85 -117.82 106.18 12.74 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.485 ' CZ ' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -122.17 129.45 52.31 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -176.604 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.19 114.35 9.08 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.952 0.882 . . . . 0.0 110.624 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.474 ' HB2' ' H ' ' C' ' 23' ' ' ASP . 95.5 mt-10 -92.65 -174.74 3.74 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 54.3 t0 31.17 52.23 0.16 Allowed 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.823 1.786 . . . . 0.0 115.823 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.56 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 86.6 t -64.96 145.5 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 118.734 -1.187 . . . . 0.0 108.172 177.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.84 -24.35 0.73 Allowed Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.745 ' CB ' ' H ' ' C' ' 28' ' ' LYS . 4.8 t -72.09 160.17 32.93 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 122.311 1.053 . . . . 0.0 112.785 -177.334 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.711 ' O ' ' N ' ' D' ' 29' ' ' GLY . 97.8 m-20 -91.68 -130.06 0.11 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.384 -1.735 . . . . 0.0 110.159 -178.249 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -48.49 54.94 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.931 1.292 . . . . 0.0 112.317 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 29' ' ' GLY . . . . . 0.711 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -110.28 -48.79 0.74 Allowed Glycine 0 CA--C 1.546 1.971 0 C-N-CA 124.529 1.062 . . . . 0.0 113.808 -176.53 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.411 ' HA ' ' O ' ' C' ' 30' ' ' ALA . . . -82.71 113.61 20.5 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.73 HD12 HG22 ' O' ' 39' ' ' VAL . 96.1 mt -130.56 130.0 64.69 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 CA-C-N 112.453 -2.158 . . . . 0.0 111.339 178.459 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.483 ' HB ' HG23 ' E' ' 32' ' ' ILE . 47.6 mt -108.22 109.77 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 175.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.54 104.06 2.54 Favored Glycine 0 N--CA 1.462 0.395 0 N-CA-C 104.145 -3.582 . . . . 0.0 104.145 174.998 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.57 HD12 ' O ' ' C' ' 34' ' ' LEU . 25.0 tp -133.88 128.18 34.07 Favored 'General case' 0 C--O 1.246 0.881 0 N-CA-C 116.477 2.029 . . . . 0.0 116.477 -172.573 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -104.38 111.54 24.22 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-N 112.793 -2.003 . . . . 0.0 107.377 174.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 17.3 t -109.43 143.9 18.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.792 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 168.31 -101.95 0.18 Allowed Glycine 0 C--N 1.294 -1.766 0 C-N-CA 118.818 -1.658 . . . . 0.0 111.462 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.445 ' HA3' ' N ' ' C' ' 38' ' ' GLY . . . 42.48 72.16 0.32 Allowed Glycine 0 N--CA 1.466 0.658 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -177.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.831 HG21 HD12 ' K' ' 31' ' ' ILE . 92.2 t -36.2 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -176.556 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.534 ' N ' HG12 ' D' ' 39' ' ' VAL . 19.7 m . . . . . 0 C--O 1.222 -0.386 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.593 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.73 136.59 47.22 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.817 0.341 . . . . 0.0 110.436 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.31 120.88 41.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.792 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.507 ' H ' HG21 ' D' ' 12' ' ' VAL . 33.8 t -112.08 95.32 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 121.189 0.518 . . . . 0.0 111.241 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 5.4 t-80 -118.65 109.97 16.76 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.26 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.634 ' CE1' ' N ' ' F' ' 14' ' ' HIS . 43.0 m-70 -138.13 165.04 27.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.213 0.53 . . . . 0.0 110.7 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -90.26 151.62 21.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.819 ' C ' HD12 ' E' ' 17' ' ' LEU . 88.8 tttt -149.68 107.46 3.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.526 178.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.819 HD12 ' C ' ' E' ' 16' ' ' LYS . 8.7 mp -129.07 120.59 26.22 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.21 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.15 121.21 60.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.95 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.503 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 30.5 m-85 -116.34 100.77 8.13 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 177.654 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.485 ' CD1' ' CZ ' ' D' ' 20' ' ' PHE . 14.3 t80 -121.68 134.9 54.97 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -177.281 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.599 ' O ' ' HB1' ' F' ' 21' ' ' ALA . . . -160.3 -178.36 6.89 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 119.167 -1.013 . . . . 0.0 113.691 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.56 ' OE1' ' N ' ' D' ' 24' ' ' VAL . 34.6 tt0 -68.07 159.98 29.79 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.94 -178.658 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 t0 175.65 60.26 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.798 0.839 . . . . 0.0 109.472 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 4.7 t -81.44 -113.36 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 116.956 -1.497 . . . . 0.0 111.305 -171.225 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.73 -42.12 47.69 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 114.839 -3.553 . . . . 0.0 115.4 -171.554 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' E' ' 27' ' ' ASN . 35.9 t -156.7 110.39 2.67 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 121.376 2.588 . . . . 0.0 114.298 175.156 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' E' ' 26' ' ' SER . 28.7 t-20 -55.69 162.83 1.55 Allowed 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 172.345 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -58.53 -42.65 88.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 122.127 2.24 . . . . 0.0 110.265 175.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 64.27 0.04 OUTLIER Glycine 0 CA--C 1.551 2.305 0 CA-C-N 114.104 -1.407 . . . . 0.0 111.856 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.876 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -72.25 161.29 31.06 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 119.344 1.572 . . . . 0.0 112.461 -176.759 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.481 ' CG2' ' OXT' ' Q' ' 40' ' ' VAL . 97.9 mt -134.08 136.63 53.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-O 121.421 0.629 . . . . 0.0 112.472 -177.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.483 HG23 ' HB ' ' D' ' 32' ' ' ILE . 98.0 mt -130.6 129.98 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.929 -0.482 . . . . 0.0 111.702 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.95 114.26 2.47 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.452 HD13 ' CE2' ' F' ' 19' ' ' PHE . 20.4 mt -124.75 124.01 41.22 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 110.183 -0.302 . . . . 0.0 110.183 -177.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 88.5 mtp -130.3 134.34 47.14 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 119.9 -0.72 . . . . 0.0 112.553 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.469 HG22 ' HA ' ' F' ' 36' ' ' VAL . 0.8 OUTLIER -91.85 155.35 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 177.468 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.502 ' H ' ' HA2' ' D' ' 37' ' ' GLY . . . -102.96 102.8 2.3 Favored Glycine 0 CA--C 1.529 0.968 0 N-CA-C 112.256 -0.338 . . . . 0.0 112.256 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 52.58 -73.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.639 0 N-CA-C 115.009 0.764 . . . . 0.0 115.009 178.063 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.416 ' N ' ' O ' ' E' ' 37' ' ' GLY . 40.9 t . . . . . 0 N--CA 1.481 1.1 0 CA-C-N 118.211 1.005 . . . . 0.0 111.222 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 CA--C 1.529 0.136 0 CA-C-O 120.769 0.318 . . . . 0.0 110.334 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.482 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 2.7 t -108.21 111.01 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-O 121.163 0.506 . . . . 0.0 110.503 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.545 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -145.23 117.72 8.54 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.209 -179.689 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.634 ' N ' ' CE1' ' E' ' 14' ' ' HIS . 79.5 m80 -156.97 169.4 24.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.447 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.792 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.3 tt0 -89.67 155.78 19.0 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -141.39 116.32 9.84 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.557 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.448 HD12 ' N ' ' F' ' 17' ' ' LEU . 1.6 mp -137.06 121.75 18.56 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 19.7 t -106.11 117.11 51.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.081 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' CD1' ' F' ' 20' ' ' PHE . 11.2 m-85 -116.05 98.2 6.5 Favored 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.539 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 58.1 m-85 -152.08 173.65 14.66 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 122.806 1.288 . . . . 0.0 112.315 -178.235 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.599 ' HB1' ' O ' ' E' ' 21' ' ' ALA . . . -152.11 155.18 37.36 Favored 'General case' 0 N--CA 1.435 -1.189 0 CA-C-N 114.101 -1.408 . . . . 0.0 109.897 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -75.52 137.78 41.1 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -176.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 . . . . . 0 N--CA 1.462 0.146 0 CA-C-N 114.112 -1.404 . . . . 0.0 113.599 177.445 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.876 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.55 HD11 ' O ' ' R' ' 39' ' ' VAL . 90.6 mt -121.13 131.84 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.601 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -122.61 117.82 53.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.331 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.66 126.81 6.98 Favored Glycine 0 N--CA 1.469 0.851 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 tp -131.83 114.45 14.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 90.6 mtp -122.01 135.49 54.84 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 120.617 -0.433 . . . . 0.0 112.104 -178.223 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.469 ' HA ' HG22 ' E' ' 36' ' ' VAL . 51.2 t -108.28 132.69 55.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.208 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.803 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.6 112.4 4.23 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.533 -0.627 . . . . 0.0 111.533 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.98 -70.41 0.0 OUTLIER Glycine 0 CA--C 1.538 1.484 0 N-CA-C 114.011 0.364 . . . . 0.0 114.011 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.542 ' N ' ' O ' ' F' ' 37' ' ' GLY . 46.3 t -123.97 132.68 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-O 121.586 0.708 . . . . 0.0 111.885 -178.413 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' F' ' 39' ' ' VAL . 11.6 t . . . . . 0 C--O 1.218 -0.571 0 CA-C-O 117.785 -1.102 . . . . 0.0 110.381 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.552 HG12 ' O ' ' H' ' 12' ' ' VAL . 12.3 m . . . . . 0 N--CA 1.469 0.52 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 51.7 m-70 -145.31 130.31 18.34 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.3 0.571 . . . . 0.0 111.965 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 42.2 p-80 -152.74 172.4 16.75 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.478 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -128.97 151.01 50.15 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -95.22 128.7 42.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.688 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -126.96 117.92 23.48 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -133.95 134.27 55.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -144.77 146.9 32.36 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.46 0.648 . . . . 0.0 111.452 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 54.6 p90 -129.23 129.61 45.22 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.046 179.059 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.3 120.81 41.67 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.131 0.491 . . . . 0.0 112.085 -178.536 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -157.98 151.72 23.83 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 . . . . . 0 N--CA 1.467 0.387 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.812 179.481 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 121.526 0.679 . . . . 0.0 112.814 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -110.59 -39.21 4.96 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 79.96 -69.41 3.09 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 112.415 -2.175 . . . . 0.0 111.702 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.435 ' HB3' ' CB ' ' H' ' 30' ' ' ALA . . . 179.78 87.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 117.59 0.695 . . . . 0.0 111.239 176.731 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -133.32 113.71 19.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.541 0 O-C-N 121.765 -0.584 . . . . 0.0 109.702 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' I' ' 19' ' ' PHE . 66.8 mt -108.21 110.72 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.308 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.13 97.54 0.63 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 105.298 -3.121 . . . . 0.0 105.298 177.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.752 ' O ' HD12 ' H' ' 34' ' ' LEU . 56.8 tp -160.63 159.41 30.4 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 118.18 -1.408 . . . . 0.0 111.89 -175.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.448 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 23.8 mtp -122.75 121.91 37.46 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.418 -1.264 . . . . 0.0 109.19 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.599 HG12 ' CD ' ' I' ' 15' ' ' GLN . 2.0 t -118.32 103.1 14.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.14 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.69 -153.05 24.57 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 38' ' ' GLY . . . . . 0.445 ' O ' HG23 ' H' ' 39' ' ' VAL . . . 111.82 -56.2 0.48 Allowed Glycine 0 CA--C 1.542 1.779 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.86 160.8 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.756 -1.116 . . . . 0.0 110.395 179.316 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -113.61 135.65 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.739 0.304 . . . . 0.0 110.364 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -109.11 116.02 31.15 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.497 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.718 HG13 ' CE1' ' I' ' 13' ' ' HIS . 6.6 t -116.14 95.01 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 120.916 0.389 . . . . 0.0 110.092 179.218 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.538 ' ND1' ' O ' ' G' ' 13' ' ' HIS . 17.9 p-80 -147.84 165.68 29.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.871 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.653 ' HE2' ' CG2' ' I' ' 12' ' ' VAL . 0.1 OUTLIER -107.73 161.61 14.73 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.361 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.87 159.64 16.87 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -140.0 101.27 4.13 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.8 tp -127.97 121.9 31.03 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.115 0.483 . . . . 0.0 110.611 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.32 126.59 72.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.201 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.625 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -131.07 123.0 27.72 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.44 ' CZ ' ' CG ' ' H' ' 22' ' ' GLU . 19.5 t80 -119.5 126.11 50.5 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.34 121.56 38.87 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -177.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.44 ' CG ' ' CZ ' ' H' ' 20' ' ' PHE . 58.0 mt-10 -116.82 98.06 6.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 114.052 -1.431 . . . . 0.0 107.348 176.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -112.38 51.5 0.81 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.549 ' HA ' HG13 ' I' ' 24' ' ' VAL . 84.7 t -75.44 144.58 11.87 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 O-C-N 124.118 0.887 . . . . 0.0 110.61 -175.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.61 -38.31 3.37 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-N 113.84 -1.527 . . . . 0.0 110.562 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 26' ' ' SER . . . . . 0.46 ' O ' ' O ' ' H' ' 27' ' ' ASN . 74.8 m -120.48 -112.18 0.33 Allowed 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.466 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 51.1 t-20 52.13 152.9 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.327 1.051 . . . . 0.0 110.908 -176.618 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.466 ' N ' ' OD1' ' H' ' 27' ' ' ASN . 67.6 mttm -140.48 -28.88 0.7 Allowed 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 115.189 1.552 . . . . 0.0 115.189 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.01 88.08 0.11 Allowed Glycine 0 N--CA 1.474 1.216 0 CA-C-O 119.471 -0.627 . . . . 0.0 113.74 -170.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.435 ' CB ' ' HB3' ' G' ' 30' ' ' ALA . . . -79.07 128.46 33.3 Favored 'General case' 0 CA--C 1.545 0.787 0 CA-C-O 123.308 1.528 . . . . 0.0 112.682 -175.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 30.7 mt -137.32 139.66 43.43 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 112.638 -2.074 . . . . 0.0 113.399 -176.067 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.413 HG22 HD21 ' I' ' 34' ' ' LEU . 80.6 mt -109.48 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 175.833 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.37 99.3 0.82 Allowed Glycine 0 C--O 1.237 0.308 0 N-CA-C 105.573 -3.011 . . . . 0.0 105.573 176.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.752 HD12 ' O ' ' G' ' 34' ' ' LEU . 8.4 tp -142.4 140.89 32.16 Favored 'General case' 0 C--O 1.242 0.669 0 CA-C-O 123.007 1.384 . . . . 0.0 113.251 -174.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.1 mtp -107.47 111.75 24.2 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 112.315 -2.221 . . . . 0.0 108.387 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.534 HG11 HD21 ' J' ' 17' ' ' LEU . 2.0 t -117.77 122.99 71.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.66 -113.18 0.6 Allowed Glycine 0 C--N 1.313 -0.731 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.67 -73.28 2.66 Favored Glycine 0 CA--C 1.533 1.171 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.563 ' HA ' HG21 ' I' ' 39' ' ' VAL . 34.9 t -133.86 157.1 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.251 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.479 ' C ' ' O ' ' H' ' 39' ' ' VAL . 70.1 t . . . . . 0 N--CA 1.471 0.577 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.295 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -112.16 136.04 52.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.858 0.361 . . . . 0.0 110.534 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -99.6 109.19 21.71 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.379 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.653 ' CG2' ' HE2' ' H' ' 14' ' ' HIS . 2.4 m -139.75 162.44 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.905 -178.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.718 ' CE1' HG13 ' H' ' 12' ' ' VAL . 2.0 m80 -138.86 97.29 3.29 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 119.264 -0.398 . . . . 0.0 110.432 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.527 ' CE1' ' HB ' ' I' ' 12' ' ' VAL . 5.5 m-70 -122.36 156.91 32.95 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 119.827 -0.749 . . . . 0.0 112.28 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.599 ' CD ' HG12 ' G' ' 36' ' ' VAL . 3.2 tt0 -90.44 159.59 16.47 Favored 'General case' 0 C--N 1.341 0.22 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 175.609 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.66 106.45 5.14 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 176.393 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.458 HD21 HG11 ' G' ' 36' ' ' VAL . 80.0 mt -117.21 114.97 24.41 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.045 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -114.29 103.26 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.534 ' CD2' HD13 ' G' ' 32' ' ' ILE . 14.5 m-30 -114.42 113.87 25.08 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -116.76 131.3 56.99 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -178.076 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.19 138.76 50.76 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 117.81 0.277 . . . . 0.0 111.184 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -76.67 176.38 8.46 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 119.237 3.051 . . . . 0.0 119.237 -174.157 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -72.49 50.11 0.23 Allowed 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 128.892 2.877 . . . . 0.0 114.132 -178.096 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.662 HG12 ' H ' ' I' ' 25' ' ' GLY . 1.8 t -74.77 -143.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -175.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.662 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -95.97 36.7 3.72 Favored Glycine 0 N--CA 1.465 0.573 0 C-N-CA 129.274 3.321 . . . . 0.0 107.706 -173.433 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.1 t -74.25 104.62 5.1 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 109.975 -3.113 . . . . 0.0 109.995 -176.854 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.708 ' O ' ' C ' ' I' ' 28' ' ' LYS . 86.1 m-20 -93.0 -149.23 0.26 Allowed 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 101.107 -3.664 . . . . 0.0 101.107 -176.436 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.708 ' C ' ' O ' ' I' ' 27' ' ' ASN . 82.3 tttt -32.64 -42.66 0.08 Allowed 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 124.173 3.17 . . . . 0.0 106.235 -170.22 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 91.29 -61.42 2.9 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 121.583 3.393 . . . . 0.0 121.583 159.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.22 117.11 24.58 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 -171.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.488 ' CD1' ' O ' ' C' ' 38' ' ' GLY . 3.5 mt -127.28 117.12 46.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 174.239 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.421 HD13 HG21 ' I' ' 32' ' ' ILE . 25.2 mt -100.22 112.93 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.03 100.12 1.07 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 106.548 -2.621 . . . . 0.0 106.548 177.197 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.462 ' CD2' ' HB3' ' H' ' 34' ' ' LEU . 98.0 mt -131.79 145.04 51.36 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.454 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -118.93 102.43 8.77 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 174.248 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.519 HG22 ' NE2' ' K' ' 15' ' ' GLN . 8.0 p -123.07 122.9 66.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.616 0.722 . . . . 0.0 109.88 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.29 -113.59 0.75 Allowed Glycine 0 C--N 1.31 -0.876 0 N-CA-C 107.57 -2.212 . . . . 0.0 107.57 -179.499 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.77 -72.37 1.05 Allowed Glycine 0 CA--C 1.535 1.303 0 C-N-CA 121.214 -0.517 . . . . 0.0 113.533 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.715 HG22 HD12 ' O' ' 31' ' ' ILE . 21.4 t -132.55 160.95 42.24 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 121.01 0.433 . . . . 0.0 111.698 -177.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.587 HG22 ' O ' ' I' ' 40' ' ' VAL . 10.9 p . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.4 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -71.02 127.32 32.16 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -142.97 156.07 44.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.967 0.413 . . . . 0.0 110.608 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.591 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -130.78 134.62 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 97.6 m-70 -120.83 124.85 46.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.46 -178.25 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' CE1' ' K' ' 14' ' ' HIS . 51.3 m-70 -151.58 169.82 21.18 Favored 'General case' 0 C--O 1.222 -0.382 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.535 ' OE1' ' NE2' ' I' ' 15' ' ' GLN . 2.3 tt0 -137.69 150.17 47.11 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -115.7 113.89 24.1 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.692 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.534 HD21 HG11 ' H' ' 36' ' ' VAL . 89.5 mt -108.84 107.34 17.71 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 176.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 t -110.96 102.53 14.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.456 ' CD2' ' CE1' ' K' ' 19' ' ' PHE . 12.4 m-85 -113.05 112.0 23.1 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -114.98 125.98 54.23 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 116.636 -0.256 . . . . 0.0 110.873 -178.189 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.49 129.54 33.28 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.666 0.745 . . . . 0.0 111.862 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -82.32 116.89 22.03 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -124.96 51.78 1.63 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -176.138 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -75.07 143.31 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.82 0 N-CA-C 103.047 -2.946 . . . . 0.0 103.047 175.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.58 37.57 3.7 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 105.768 -2.933 . . . . 0.0 105.768 -172.717 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.434 ' HG ' ' CG ' ' K' ' 27' ' ' ASN . 5.3 t -69.48 105.11 2.51 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 113.522 -1.339 . . . . 0.0 107.94 -177.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -117.85 -151.88 0.49 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 113.149 -1.841 . . . . 0.0 113.522 -172.302 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -37.54 -40.81 0.41 Allowed 'General case' 0 CA--C 1.551 0.999 0 N-CA-C 119.736 3.236 . . . . 0.0 119.736 -171.489 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.421 ' O ' ' CE ' ' I' ' 28' ' ' LYS . . . -171.29 69.47 0.12 Allowed Glycine 0 N--CA 1.484 1.844 0 C-N-CA 115.193 -3.384 . . . . 0.0 119.44 -174.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.39 140.73 46.81 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 120.307 2.053 . . . . 0.0 109.172 177.056 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.506 HG22 ' H ' ' K' ' 31' ' ' ILE . 10.1 pt -146.62 153.6 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 96.4 mt -114.56 128.47 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.305 176.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.36 112.55 0.97 Allowed Glycine 0 N--CA 1.462 0.42 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.651 HD12 ' C ' ' J' ' 34' ' ' LEU . 3.6 pp -164.65 165.63 20.78 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 117.588 -1.645 . . . . 0.0 114.986 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 70.6 mmm -113.87 117.56 31.75 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 112.746 -2.024 . . . . 0.0 110.653 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.601 HG12 ' CD ' ' L' ' 15' ' ' GLN . 15.3 t -111.5 102.51 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 N-CA-C 109.246 -0.649 . . . . 0.0 109.246 178.744 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.7 ' N ' HE22 ' L' ' 15' ' ' GLN . . . 125.09 -162.31 19.41 Favored Glycine 0 N--CA 1.465 0.585 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.386 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' K' ' 38' ' ' GLY . . . 137.84 -55.38 0.68 Allowed Glycine 0 CA--C 1.542 1.745 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.504 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.908 HG22 HD12 ' P' ' 31' ' ' ILE . 43.5 t -125.29 134.04 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.853 0.861 . . . . 0.0 108.798 177.672 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.695 ' HA ' HG13 ' K' ' 39' ' ' VAL . 74.1 t . . . . . 0 C--O 1.216 -0.685 0 CA-C-O 118.088 -0.958 . . . . 0.0 111.711 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.05 134.54 53.54 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.482 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 97.8 mt-10 -144.56 169.48 17.88 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.859 0.361 . . . . 0.0 111.276 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.471 HG13 ' H ' ' L' ' 12' ' ' VAL . 19.6 t -104.18 128.26 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.076 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' OXT' ' I' ' 40' ' ' VAL . 81.7 t60 -138.93 114.81 10.06 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.636 ' CE1' ' CD2' ' J' ' 14' ' ' HIS . 7.5 p80 -155.22 165.29 37.14 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.182 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.519 ' NE2' HG22 ' I' ' 36' ' ' VAL . 7.1 tt0 -129.48 149.95 51.04 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 119.699 -0.8 . . . . 0.0 111.179 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.96 109.15 21.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.004 177.266 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.568 ' CD1' ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -103.95 105.12 15.2 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 176.557 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.1 103.89 16.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.445 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.456 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 5.1 m-85 -114.39 108.26 16.65 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.207 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -106.69 120.8 42.95 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.461 ' HB1' ' OD1' ' J' ' 23' ' ' ASP . . . -132.42 131.36 41.7 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.415 -179.261 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.533 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 97.4 mt-10 -87.09 104.61 16.5 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.771 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 0.5 OUTLIER -135.13 48.66 2.25 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.733 -177.322 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.546 HG12 ' N ' ' K' ' 25' ' ' GLY . 55.0 t -71.92 161.38 4.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.553 -178.614 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.546 ' N ' HG12 ' K' ' 24' ' ' VAL . . . 110.26 -28.35 10.43 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 -177.442 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 74.57 119.73 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.051 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.434 ' CG ' ' HG ' ' J' ' 26' ' ' SER . 93.3 m-20 -83.24 162.79 21.08 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.832 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -47.19 -37.28 9.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.294 177.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.78 77.35 0.07 OUTLIER Glycine 0 CA--C 1.532 1.147 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.597 -174.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.53 153.7 29.35 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 118.217 1.009 . . . . 0.0 110.01 -178.299 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.831 HD12 HG21 ' D' ' 39' ' ' VAL . 57.4 mt -133.78 141.24 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 113.874 1.064 . . . . 0.0 113.874 -175.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -127.02 118.36 50.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.169 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.16 109.56 1.72 Allowed Glycine 0 N--CA 1.471 1.002 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.418 HD22 HD11 ' J' ' 34' ' ' LEU . 29.3 mt -127.84 125.27 39.43 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 112.811 0.671 . . . . 0.0 112.811 -175.7 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.7 mtp -106.94 106.01 16.32 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.623 HG22 ' H ' ' K' ' 37' ' ' GLY . 9.9 p -97.26 173.23 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.623 ' H ' HG22 ' K' ' 36' ' ' VAL . . . 159.64 -95.39 0.14 Allowed Glycine 0 C--N 1.3 -1.45 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.458 -178.107 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' J' ' 38' ' ' GLY . . . 98.13 -80.53 0.61 Allowed Glycine 0 N--CA 1.47 0.95 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 -176.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.695 HG13 ' HA ' ' J' ' 40' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.439 -1.014 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.931 0.396 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.471 ' H ' HG13 ' K' ' 12' ' ' VAL . 58.9 t -128.76 134.34 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.376 -178.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.482 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 85.0 m-70 -135.12 84.65 2.11 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.7 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.486 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 40.4 t-80 -162.7 168.51 21.48 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.141 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.7 HE22 ' N ' ' J' ' 37' ' ' GLY . 78.8 mt-30 -100.35 151.33 21.63 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.345 0.593 . . . . 0.0 111.788 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -112.63 110.21 20.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.745 177.341 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.467 HD22 HG11 ' J' ' 36' ' ' VAL . 0.1 OUTLIER -104.77 109.88 22.0 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.863 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 42.8 t -117.21 102.38 13.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.424 ' CD1' ' CD2' ' K' ' 19' ' ' PHE . 5.0 m-85 -115.72 107.11 14.66 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -113.96 119.71 38.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.099 0.476 . . . . 0.0 111.515 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.23 127.17 52.17 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.248 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -78.04 111.25 13.73 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.329 -177.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 56.9 p30 -178.39 48.66 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.157 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.618 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -72.62 160.32 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 C-N-CA 118.431 -1.308 . . . . 0.0 109.449 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.05 -33.19 6.01 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.7 m -72.09 129.56 38.79 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 113.824 -1.188 . . . . 0.0 111.102 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.645 ' O ' ' N ' ' L' ' 29' ' ' GLY . 98.7 m-20 -90.98 -162.51 0.92 Allowed 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.46 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.28 47.59 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 115.127 1.529 . . . . 0.0 115.127 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.645 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.17 57.08 0.9 Allowed Glycine 0 CA--C 1.54 1.608 0 CA-C-N 119.483 1.038 . . . . 0.0 112.016 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.07 171.73 10.74 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.416 HD11 ' CG2' ' F' ' 39' ' ' VAL . 94.5 mt -121.27 121.73 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 177.108 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -125.43 133.58 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.864 0.364 . . . . 0.0 111.57 -178.721 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.99 117.98 2.06 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.4 tp -115.21 123.53 49.1 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mmm -124.83 128.03 48.07 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.659 0.266 . . . . 0.0 111.552 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.2 t -97.4 152.24 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-O 121.353 0.597 . . . . 0.0 111.929 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.527 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . -80.79 102.5 2.13 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 38' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' L' ' 37' ' ' GLY . . . 11.46 -73.04 0.0 OUTLIER Glycine 0 CA--C 1.539 1.588 0 C-N-CA 123.459 0.552 . . . . 0.0 113.92 -178.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.527 ' N ' ' O ' ' L' ' 37' ' ' GLY . 74.5 t . . . . . 0 C--N 1.346 0.42 0 CA-C-N 118.221 1.011 . . . . 0.0 110.073 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 C--O 1.233 0.208 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -139.49 139.5 38.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 121.159 0.504 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -89.49 166.73 13.5 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.229 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.594 ' ND1' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -82.26 171.42 14.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.0 0.429 . . . . 0.0 111.212 -179.342 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -128.8 151.03 50.04 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -96.3 106.77 19.04 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.704 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 87.2 mt -128.22 114.41 16.92 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 121.005 0.431 . . . . 0.0 110.057 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -126.61 130.8 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.715 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -128.18 131.23 48.9 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.619 ' CZ ' ' CD1' ' N' ' 20' ' ' PHE . 1.6 t80 -134.38 128.84 34.42 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.204 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 118.46 31.86 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.935 0.398 . . . . 0.0 109.949 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 22' ' ' GLU . . . . . 0.566 ' O ' HG23 ' M' ' 24' ' ' VAL . 94.5 mt-10 -110.53 -148.59 0.43 Allowed 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.773 -178.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.57 50.13 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.855 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.59 HG12 ' H ' ' M' ' 25' ' ' GLY . 2.3 t -71.72 -142.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 25' ' ' GLY . . . . . 0.59 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -111.48 38.75 3.14 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.904 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m 61.76 111.18 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.113 0.482 . . . . 0.0 112.082 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 27' ' ' ASN . . . . . 0.45 ' O ' ' C ' ' M' ' 28' ' ' LYS . 91.2 m-20 -129.85 -161.55 1.13 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.193 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 28' ' ' LYS . . . . . 0.45 ' C ' ' O ' ' M' ' 27' ' ' ASN . 73.6 mmtt -30.95 -41.31 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 120.914 0.387 . . . . 0.0 110.996 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 29' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' M' ' 27' ' ' ASN . . . 91.35 -64.92 2.54 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.794 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 30' ' ' ALA . . . . . 0.473 ' O ' ' O ' ' N' ' 29' ' ' GLY . . . -170.37 70.1 0.05 Allowed 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 117.616 0.708 . . . . 0.0 112.483 177.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 82.0 mt -130.89 115.09 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 32' ' ' ILE . . . . . 0.52 HG22 HD21 ' N' ' 34' ' ' LEU . 4.0 mt -112.89 116.16 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 C-N-CA 120.062 -0.655 . . . . 0.0 111.107 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.16 105.0 1.18 Allowed Glycine 0 N--CA 1.461 0.315 0 N-CA-C 105.389 -3.084 . . . . 0.0 105.389 177.108 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 34' ' ' LEU . . . . . 0.578 ' HB3' HD22 ' N' ' 34' ' ' LEU . 47.1 tp -161.02 152.34 19.02 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 117.548 -1.661 . . . . 0.0 114.354 -174.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 3.8 ttm -104.26 115.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-N 112.56 -2.109 . . . . 0.0 106.856 176.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.517 ' O ' ' N ' ' N' ' 37' ' ' GLY . 36.5 t -116.91 103.87 15.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.29 -153.22 16.88 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 120.026 -1.083 . . . . 0.0 110.952 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.586 ' H ' ' N ' ' N' ' 38' ' ' GLY . . . 147.65 -54.64 0.52 Allowed Glycine 0 CA--C 1.539 1.551 0 CA-C-O 119.721 -0.488 . . . . 0.0 111.93 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' M' ' 40' ' ' VAL . 10.0 p -114.73 151.89 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.963 0.881 . . . . 0.0 108.787 178.411 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.779 ' OXT' HG13 ' M' ' 40' ' ' VAL . 8.5 p . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 117.854 -1.069 . . . . 0.0 111.151 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.64 134.33 48.93 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -151.38 135.77 16.89 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.999 0.428 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.412 HG12 ' CG2' ' O' ' 12' ' ' VAL . 34.1 m -137.03 162.09 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.624 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 13' ' ' HIS . . . . . 0.51 ' C ' ' ND1' ' N' ' 14' ' ' HIS . 83.4 m-70 -143.34 104.86 4.31 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.489 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.51 ' ND1' ' C ' ' N' ' 13' ' ' HIS . 20.0 m80 -152.08 167.05 29.71 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.701 0.286 . . . . 0.0 110.67 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -155.7 141.17 17.76 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.032 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -89.82 107.39 19.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 119.215 -0.421 . . . . 0.0 111.666 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.432 HD23 ' HG ' ' O' ' 17' ' ' LEU . 33.4 tp -123.78 115.57 21.57 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 177.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -121.49 131.13 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.828 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -129.97 112.35 13.42 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.522 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CZ ' ' M' ' 20' ' ' PHE . 16.5 t80 -113.81 130.37 56.47 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.44 133.14 40.16 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 113.232 0.827 . . . . 0.0 113.232 -178.049 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -92.38 120.83 33.27 Favored 'General case' 0 C--N 1.34 0.168 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.547 177.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.57 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 70.8 m-20 -148.39 50.39 1.02 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.981 -177.337 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 37.6 t -81.41 148.65 5.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 118.951 -1.1 . . . . 0.0 109.719 -177.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.57 37.04 5.66 Favored Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.9 p 73.18 120.21 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.617 ' ND2' ' N ' ' N' ' 27' ' ' ASN . 0.1 OUTLIER -83.09 162.44 21.34 Favored 'General case' 0 C--N 1.341 0.211 0 C-N-CA 118.262 -1.375 . . . . 0.0 111.499 -179.098 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.418 ' H ' ' HG2' ' N' ' 28' ' ' LYS . 72.5 mmtt -47.22 -37.17 9.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.955 176.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 29' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' M' ' 30' ' ' ALA . . . -178.96 77.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.579 0 CA-C-O 118.766 -1.019 . . . . 0.0 112.199 -173.387 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 30' ' ' ALA . . . . . 0.525 ' O ' ' HA ' ' O' ' 30' ' ' ALA . . . -79.26 107.51 12.07 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-N 119.848 1.824 . . . . 0.0 112.835 -175.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.571 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 18.4 tt -153.32 133.83 4.34 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 CA-C-N 113.627 -1.624 . . . . 0.0 111.336 -177.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.553 HD13 ' CD2' ' P' ' 19' ' ' PHE . 85.0 mt -106.96 108.26 24.76 Favored 'Isoleucine or valine' 0 C--N 1.341 0.198 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 177.226 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.807 ' O ' HD23 ' N' ' 34' ' ' LEU . . . -114.67 100.46 1.0 Allowed Glycine 0 N--CA 1.46 0.269 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 178.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.807 HD23 ' O ' ' N' ' 33' ' ' GLY . 1.4 mt -146.59 157.91 43.81 Favored 'General case' 0 CA--C 1.5 -0.952 0 CA-C-O 123.665 1.698 . . . . 0.0 112.478 -178.047 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 8.0 mtp -113.79 108.53 17.22 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 111.156 -2.747 . . . . 0.0 104.604 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -87.25 100.96 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 106.144 -1.798 . . . . 0.0 106.144 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' M' ' 36' ' ' VAL . . . -73.23 163.0 54.86 Favored Glycine 0 CA--C 1.52 0.353 0 CA-C-N 112.724 -2.034 . . . . 0.0 113.383 -178.715 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.586 ' N ' ' H ' ' M' ' 38' ' ' GLY . . . 114.92 60.72 0.37 Allowed Glycine 0 N--CA 1.471 0.972 0 C-N-CA 121.389 -0.434 . . . . 0.0 113.681 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 1.038 HG13 ' H ' ' O' ' 39' ' ' VAL . 57.3 t -71.09 130.91 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.501 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.519 HG22 ' CD2' ' P' ' 13' ' ' HIS . 10.8 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.999 -1.001 . . . . 0.0 111.3 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.48 132.97 52.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.759 0.314 . . . . 0.0 110.364 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -123.58 121.83 36.61 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.131 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.486 ' HB ' ' CE1' ' O' ' 14' ' ' HIS . 2.3 m -131.43 155.27 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.594 ' HB2' ' HD1' ' P' ' 13' ' ' HIS . 80.0 m80 -149.07 102.96 3.3 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.478 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.565 ' CD2' ' O ' ' P' ' 14' ' ' HIS . 0.0 OUTLIER -149.27 176.44 10.53 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.412 ' CG ' HD13 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -149.25 140.0 22.7 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 174.616 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' O' O ' 16' ' ' LYS . . . . . 0.654 ' C ' HD12 ' O' ' 17' ' ' LEU . 54.1 mtmt -95.05 110.24 22.19 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.227 1.566 . . . . 0.0 115.227 -178.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.654 HD12 ' C ' ' O' ' 16' ' ' LYS . 10.9 mp -124.13 115.09 20.57 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 174.69 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -112.74 115.82 50.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.643 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.429 ' HZ ' HD23 ' O' ' 17' ' ' LEU . 48.4 m-85 -112.22 104.97 13.19 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -111.86 131.75 55.15 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.9 136.61 32.46 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -95.2 113.86 25.58 Favored 'General case' 0 CA--C 1.52 -0.175 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 175.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.446 ' CB ' HD21 ' N' ' 27' ' ' ASN . 18.1 m-20 -133.99 48.62 2.33 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.542 HG22 ' O ' ' P' ' 23' ' ' ASP . 18.6 t -72.88 161.09 5.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 C-N-CA 118.218 -1.393 . . . . 0.0 109.664 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.27 -29.89 9.56 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 -178.71 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 1.2 m 92.83 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 113.66 -1.27 . . . . 0.0 107.791 -178.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.697 ' OD1' ' HB2' ' O' ' 30' ' ' ALA . 2.7 p30 -73.96 164.39 26.68 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.935 0.874 . . . . 0.0 113.071 -178.241 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.08 -36.28 12.84 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.862 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.38 78.5 0.07 OUTLIER Glycine 0 CA--C 1.532 1.119 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.354 -173.11 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 30' ' ' ALA . . . . . 0.697 ' HB2' ' OD1' ' O' ' 27' ' ' ASN . . . -79.19 109.73 13.8 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 123.286 1.517 . . . . 0.0 110.955 -176.496 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.715 HD12 HG22 ' I' ' 39' ' ' VAL . 77.8 mt -133.15 142.21 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 113.483 -1.689 . . . . 0.0 112.802 -176.859 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.499 ' CG2' HD12 ' O' ' 34' ' ' LEU . 52.9 mt -106.78 107.9 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 175.799 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.05 104.97 2.23 Favored Glycine 0 C--O 1.239 0.437 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.499 HD12 ' CG2' ' O' ' 32' ' ' ILE . 53.7 mt -140.35 144.0 36.06 Favored 'General case' 0 CA--C 1.504 -0.815 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -175.48 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 3.0 mtp -116.42 109.22 17.02 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 112.212 -2.267 . . . . 0.0 105.038 175.028 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -105.86 101.8 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.812 0.815 . . . . 0.0 111.05 -177.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.77 -179.11 0.65 Allowed Glycine 0 CA--C 1.538 1.5 0 CA-C-N 114.112 -1.404 . . . . 0.0 115.303 178.394 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' O' O ' 38' ' ' GLY . . . . . 0.69 ' H ' HG22 ' N' ' 39' ' ' VAL . . . -116.3 -58.3 0.32 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 114.253 -0.973 . . . . 0.0 111.788 179.282 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 1.038 ' H ' HG13 ' N' ' 39' ' ' VAL . 45.5 t -115.84 124.92 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.664 ' CG2' HE22 ' R' ' 15' ' ' GLN . 12.3 m . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.451 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p . . . . . 0 N--CA 1.463 0.2 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.594 ' HD1' ' HB2' ' O' ' 13' ' ' HIS . 7.5 t60 -144.98 134.25 22.9 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 -179.116 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.688 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 18.9 m-70 -147.45 156.42 42.85 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 175.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.426 ' H ' ' HA ' ' Q' ' 15' ' ' GLN . 0.8 OUTLIER -90.42 160.35 16.1 Favored 'General case' 0 C--O 1.225 -0.237 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.021 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' P' P ' 16' ' ' LYS . . . . . 0.502 ' HE2' ' CD2' ' O' ' 14' ' ' HIS . 67.9 mttm -140.09 95.52 2.9 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.725 177.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -136.22 130.64 33.43 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.142 0.496 . . . . 0.0 111.122 179.03 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 24.1 t -119.94 115.21 46.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.489 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.553 ' CD2' HD13 ' N' ' 32' ' ' ILE . 19.3 m-85 -109.09 111.87 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -127.01 123.45 37.1 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 -176.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.18 121.85 43.31 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 176.412 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -93.86 152.41 18.91 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 117.843 2.535 . . . . 0.0 117.843 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.542 ' O ' HG22 ' O' ' 24' ' ' VAL . 93.3 m-20 27.92 51.52 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 111.238 -2.71 . . . . 0.0 117.807 175.566 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 65.1 t -81.69 141.23 15.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 117.13 -1.828 . . . . 0.0 106.181 175.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' Q' ' 24' ' ' VAL . . . -71.53 -41.54 57.51 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 117.584 -2.246 . . . . 0.0 110.809 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.422 ' O ' ' C ' ' P' ' 27' ' ' ASN . 42.3 t -156.63 112.3 2.93 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 118.355 -0.831 . . . . 0.0 109.452 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.642 HD21 ' HB3' ' O' ' 30' ' ' ALA . 7.4 t-20 -48.96 157.78 0.38 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.127 178.375 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.65 -47.88 61.83 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.665 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.82 61.21 0.08 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 114.261 -1.336 . . . . 0.0 109.768 -176.444 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 30' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' O' ' 30' ' ' ALA . . . -85.09 158.43 20.43 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 123.668 1.699 . . . . 0.0 115.377 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.908 HD12 HG22 ' J' ' 39' ' ' VAL . 65.1 mt -145.05 148.3 17.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 112.342 -2.208 . . . . 0.0 113.482 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 52.9 mt -106.19 107.64 23.17 Favored 'Isoleucine or valine' 0 C--N 1.35 0.625 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.89 101.38 2.27 Favored Glycine 0 N--CA 1.463 0.462 0 N-CA-C 104.215 -3.554 . . . . 0.0 104.215 175.292 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.419 HD23 HD22 ' Q' ' 34' ' ' LEU . 26.4 tp -133.49 130.25 38.3 Favored 'General case' 0 C--O 1.239 0.544 0 N-CA-C 115.979 1.844 . . . . 0.0 115.979 -173.008 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 40.2 tpp -111.27 109.27 19.22 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 174.344 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.494 HG13 ' OE1' ' Q' ' 15' ' ' GLN . 10.6 t -100.13 102.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.91 0.386 . . . . 0.0 110.573 -177.84 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.0 163.48 0.06 OUTLIER Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' O' ' 38' ' ' GLY . . . -94.57 -58.03 1.22 Allowed Glycine 0 CA--C 1.536 1.392 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.241 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.674 ' HB ' HD13 ' D' ' 31' ' ' ILE . 24.0 t -151.28 138.89 13.82 Favored 'Isoleucine or valine' 0 C--N 1.347 0.479 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.666 ' H ' ' C ' ' Q' ' 38' ' ' GLY . 31.1 t . . . . . 0 C--O 1.214 -0.789 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.435 -177.299 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.471 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -107.08 131.07 54.51 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -149.43 137.58 20.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.978 0.418 . . . . 0.0 110.348 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -127.58 118.44 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.571 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.522 ' NE2' ' C ' ' O' ' 40' ' ' VAL . 12.0 p-80 -158.47 121.05 3.7 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.868 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.688 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 9.4 p80 -148.8 165.62 30.9 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 176.113 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.494 ' OE1' HG13 ' P' ' 36' ' ' VAL . 1.6 pt20 -99.75 149.93 22.84 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.454 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . 0.594 ' CE ' ' HE1' ' Q' ' 14' ' ' HIS . 98.8 mttt -114.74 98.61 6.95 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.951 178.253 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.447 ' HB3' ' CZ ' ' Q' ' 19' ' ' PHE . 6.0 mp -123.2 116.98 24.3 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 177.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -107.88 111.14 34.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.485 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 37.1 m-85 -107.21 107.34 18.25 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 178.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' R' ' 20' ' ' PHE . 12.9 t80 -122.52 124.92 44.66 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -176.27 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.36 118.31 27.21 Favored 'General case' 0 C--O 1.243 0.711 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 177.44 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' P' ' 23' ' ' ASP . 82.7 tt0 -82.77 146.24 29.09 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -176.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.492 ' O ' ' O ' ' R' ' 22' ' ' GLU . 64.2 t0 63.87 -52.13 0.25 Allowed 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 113.878 -1.51 . . . . 0.0 112.089 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.54 HG12 ' H ' ' Q' ' 25' ' ' GLY . 0.8 OUTLIER 50.51 -153.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.302 177.842 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.54 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 143.39 19.03 0.22 Allowed Glycine 0 N--CA 1.464 0.544 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 -177.026 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . 0.568 ' OG ' ' HB2' ' Q' ' 30' ' ' ALA . 0.3 OUTLIER -63.13 129.9 42.3 Favored 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 114.691 -0.754 . . . . 0.0 109.342 -178.22 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.477 ' CG ' ' H ' ' Q' ' 28' ' ' LYS . 45.3 t-20 -126.98 -130.62 0.23 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.186 -174.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.477 ' H ' ' CG ' ' Q' ' 27' ' ' ASN . 74.1 mmtt -38.79 -46.87 1.32 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.041 -0.982 . . . . 0.0 111.483 -176.591 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.19 52.44 0.9 Allowed Glycine 0 CA--C 1.547 2.058 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.786 -177.597 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . 0.568 ' HB2' ' OG ' ' Q' ' 26' ' ' SER . . . -128.8 127.43 41.95 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-O 120.915 0.388 . . . . 0.0 110.103 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.699 HG23 ' HB ' ' R' ' 31' ' ' ILE . 28.9 mt -142.81 153.25 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-O 121.821 0.819 . . . . 0.0 113.064 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . 0.491 HD12 ' CD1' ' R' ' 32' ' ' ILE . 86.5 mt -136.22 123.34 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 O-C-N 121.795 -0.565 . . . . 0.0 110.34 179.113 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.4 110.66 1.29 Allowed Glycine 0 N--CA 1.468 0.77 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . 0.419 HD22 HD23 ' P' ' 34' ' ' LEU . 28.4 mt -119.34 121.2 39.03 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.634 0.255 . . . . 0.0 111.444 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . 0.4 ' SD ' ' HB2' ' R' ' 35' ' ' MET . 95.3 mmm -111.33 127.61 55.7 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.77 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.425 HG13 ' HG3' ' R' ' 15' ' ' GLN . 53.6 t -122.79 131.73 72.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-N 118.69 0.677 . . . . 0.0 112.103 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -55.82 -111.52 0.01 OUTLIER Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.743 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.688 ' O ' HG23 ' Q' ' 39' ' ' VAL . . . 95.86 -72.92 0.87 Allowed Glycine 0 CA--C 1.537 1.436 0 N-CA-C 111.962 -0.455 . . . . 0.0 111.962 179.536 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.688 HG23 ' O ' ' Q' ' 38' ' ' GLY . 14.2 t -164.1 121.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . 0.52 ' O ' HG21 ' F' ' 31' ' ' ILE . 58.7 t . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.992 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -82.69 131.06 35.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.811 0.339 . . . . 0.0 110.93 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' R' ' 11' ' ' GLU . 56.3 mp0 -118.98 148.43 42.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.815 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 20.1 t -106.97 98.05 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.494 0.664 . . . . 0.0 110.885 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -120.25 93.5 4.07 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.901 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -153.88 164.02 39.08 Favored 'General case' 0 C--O 1.222 -0.392 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.664 HE22 ' CG2' ' O' ' 40' ' ' VAL . 90.4 mm-40 -89.85 158.41 17.47 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.417 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.448 ' HD2' ' CE1' ' Q' ' 14' ' ' HIS . 13.5 tttt -140.4 90.13 2.33 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.316 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -134.37 120.14 19.48 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.2 t -104.89 113.5 42.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.408 ' CE1' HD22 ' P' ' 34' ' ' LEU . 25.1 m-85 -104.9 98.05 7.83 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 106.028 -1.842 . . . . 0.0 106.028 177.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' Q' ' 20' ' ' PHE . 42.0 t80 -115.22 114.28 25.02 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.58 0.705 . . . . 0.0 110.847 -178.47 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' R' ' 23' ' ' ASP . . . -128.37 125.11 38.0 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.342 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.492 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 81.0 tt0 -71.5 85.13 0.84 Allowed 'General case' 0 C--O 1.223 -0.319 0 C-N-CA 117.414 -1.714 . . . . 0.0 106.958 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' R' ' 21' ' ' ALA . 51.2 p30 -132.72 51.89 2.12 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.459 -176.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 69.5 t -74.82 143.29 13.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.19 37.56 3.8 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.037 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 42.5 t -75.53 101.93 5.06 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 121.47 0.652 . . . . 0.0 110.201 -179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -96.44 -163.15 1.02 Allowed 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.965 -177.325 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -47.72 -42.14 24.51 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 114.225 -1.352 . . . . 0.0 113.701 -177.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.99 61.68 1.92 Allowed Glycine 0 CA--C 1.54 1.652 0 C-N-CA 120.301 -0.952 . . . . 0.0 114.187 -175.487 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.09 135.02 9.89 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 177.55 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 31' ' ' ILE . . . . . 0.699 ' HB ' HG23 ' Q' ' 31' ' ' ILE . 96.6 mt -118.01 128.45 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 CA-C-O 121.399 0.619 . . . . 0.0 111.965 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 32' ' ' ILE . . . . . 0.491 ' CD1' HD12 ' Q' ' 32' ' ' ILE . 48.2 mm -120.4 123.34 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.894 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 118.05 2.8 Favored Glycine 0 N--CA 1.468 0.786 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.401 ' CD2' HD12 ' Q' ' 34' ' ' LEU . 67.8 mt -116.54 114.9 24.81 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 35' ' ' MET . . . . . 0.4 ' HB2' ' SD ' ' Q' ' 35' ' ' MET . 85.9 mmm -134.27 136.23 43.43 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.042 -178.455 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.63 155.84 34.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 121.33 0.585 . . . . 0.0 111.006 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -52.93 -102.27 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.149 178.312 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 49.24 71.06 0.66 Allowed Glycine 0 CA--C 1.529 0.939 0 CA-C-N 115.148 -0.526 . . . . 0.0 111.807 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.572 HG12 ' N ' ' R' ' 40' ' ' VAL . 59.9 t -112.29 165.69 7.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' R' R ' 40' ' ' VAL . . . . . 0.572 ' N ' HG12 ' R' ' 39' ' ' VAL . 15.5 m . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.101 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 . . . . . 0 N--CA 1.466 0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.23 140.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.476 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -142.11 158.37 43.82 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.069 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.614 ' CD2' ' N ' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -89.26 169.56 11.34 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.021 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -129.42 150.71 50.65 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -97.14 118.92 34.63 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.691 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.3 mt -124.77 114.9 19.88 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -132.83 136.4 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.351 -0.386 . . . . 0.0 109.977 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -128.03 130.52 48.42 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.456 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -123.6 120.49 32.97 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.999 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.04 127.43 48.77 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.404 ' CD ' ' OE1' ' B' ' 22' ' ' GLU . 83.2 tt0 -147.95 149.14 31.66 Favored 'General case' 0 CA--C 1.533 0.327 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -178.327 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.0 t0 . . . . . 0 N--CA 1.466 0.34 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 176.861 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASN . . . . . 1.048 ' N ' ' HZ3' ' B' ' 28' ' ' LYS . 33.0 t30 . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.421 ' N ' ' CG ' ' A' ' 27' ' ' ASN . 68.1 mttm -78.66 40.42 0.38 Allowed 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.961 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.422 ' C ' ' H ' ' A' ' 31' ' ' ILE . . . 119.57 78.37 0.56 Allowed Glycine 0 CA--C 1.533 1.167 0 CA-C-O 118.362 -1.243 . . . . 0.0 113.938 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.68 43.41 0.75 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-N 121.011 2.405 . . . . 0.0 110.9 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.422 ' H ' ' C ' ' A' ' 29' ' ' GLY . 54.9 mt -150.47 126.94 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 CA-C-N 113.148 -1.842 . . . . 0.0 106.866 178.871 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.432 ' O ' ' O ' ' B' ' 33' ' ' GLY . 50.7 mt -105.89 110.2 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.987 -0.745 . . . . 0.0 108.987 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.56 93.7 0.57 Allowed Glycine 0 CA--C 1.508 -0.368 0 N-CA-C 105.614 -2.994 . . . . 0.0 105.614 177.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -147.17 168.04 22.67 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 122.998 1.38 . . . . 0.0 114.133 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -120.22 110.64 16.84 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 112.224 -2.262 . . . . 0.0 107.229 178.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG2' HD11 ' B' ' 34' ' ' LEU . 2.9 t -97.92 113.44 32.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.498 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.68 -125.03 1.49 Allowed Glycine 0 C--N 1.315 -0.596 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.24 -62.89 0.37 Allowed Glycine 0 CA--C 1.546 1.987 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.552 ' O ' HG21 ' B' ' 39' ' ' VAL . 2.9 m -134.73 159.9 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 116.999 0.399 . . . . 0.0 110.009 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.473 HG21 ' CA ' ' H' ' 29' ' ' GLY . 42.9 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.336 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.94 146.06 34.42 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.644 0.259 . . . . 0.0 110.358 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 58.5 mp0 -72.68 119.31 16.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.963 0.411 . . . . 0.0 110.263 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.457 ' CG2' ' NE2' ' A' ' 14' ' ' HIS . 26.0 m -134.89 161.01 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.835 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -131.32 96.15 3.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.075 0.464 . . . . 0.0 111.704 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.479 ' C ' ' CD2' ' B' ' 14' ' ' HIS . 8.5 p-80 -156.89 169.15 25.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 177.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 21.3 tt0 -129.51 150.45 50.85 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.956 0.407 . . . . 0.0 110.128 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -98.37 119.94 37.93 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.722 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.606 ' C ' HD23 ' B' ' 17' ' ' LEU . 7.0 tt -122.76 122.79 39.55 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 118.194 0.452 . . . . 0.0 110.537 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.53 ' N ' HD23 ' B' ' 17' ' ' LEU . 69.3 t -126.22 128.76 71.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.239 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 t80 -124.6 114.06 18.88 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.872 0.368 . . . . 0.0 110.022 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.643 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 32.7 t80 -115.34 119.98 38.08 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.647 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.13 128.28 37.76 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.718 0.771 . . . . 0.0 112.219 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.404 ' OE1' ' CD ' ' A' ' 22' ' ' GLU . 87.8 mt-10 -96.73 111.98 23.92 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.055 178.26 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -104.17 46.42 0.92 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.06 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.726 HG12 ' H ' ' B' ' 25' ' ' GLY . 20.7 t -82.33 176.07 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.629 -178.876 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.726 ' H ' HG12 ' B' ' 24' ' ' VAL . . . 91.87 -28.27 8.84 Favored Glycine 0 N--CA 1.465 0.622 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -177.993 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 2.1 p 166.31 131.52 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 60.1 t-20 -45.84 130.84 9.54 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 1.048 ' HZ3' ' N ' ' A' ' 27' ' ' ASN . 98.7 mttt -89.28 -46.61 8.64 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.36 60.92 0.1 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.588 -1.291 . . . . 0.0 113.28 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.86 113.95 8.44 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.968 1.47 . . . . 0.0 114.968 -176.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 93.0 mt -127.66 130.1 70.28 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 CA-C-N 112.696 -2.047 . . . . 0.0 109.702 178.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.515 HD13 ' CD2' ' D' ' 19' ' ' PHE . 94.3 mt -110.06 116.33 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 O-C-N 121.578 -0.701 . . . . 0.0 110.551 178.443 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -118.97 96.17 0.65 Allowed Glycine 0 C--O 1.238 0.352 0 N-CA-C 104.924 -3.271 . . . . 0.0 104.924 176.184 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.483 HD11 ' CG2' ' A' ' 36' ' ' VAL . 20.5 tp -135.9 136.74 40.74 Favored 'General case' 0 CA--C 1.502 -0.889 0 C-N-CA 119.268 -0.973 . . . . 0.0 113.099 -174.375 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.4 mtp -106.39 108.75 20.42 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.445 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.59 ' HB ' HG13 ' C' ' 36' ' ' VAL . 2.5 t -102.1 103.33 14.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.99 -153.61 25.11 Favored Glycine 0 N--CA 1.447 -0.622 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.501 ' O ' HG11 ' C' ' 39' ' ' VAL . . . 115.44 -55.79 0.53 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -178.193 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.818 ' C ' HG21 ' C' ' 39' ' ' VAL . 27.8 m -124.05 137.02 58.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 123.449 0.7 . . . . 0.0 111.279 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.523 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 40.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.651 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.409 -1.477 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -105.35 135.37 46.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.934 0.397 . . . . 0.0 110.468 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -138.24 139.53 39.27 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.384 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.405 HG13 ' O ' ' D' ' 12' ' ' VAL . 3.4 t -106.7 91.22 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -104.39 131.17 52.04 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.2 0.524 . . . . 0.0 111.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -151.0 165.23 34.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.534 179.285 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 95.8 mm-40 -90.02 151.94 21.42 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.139 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -148.4 99.12 2.99 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -131.28 128.99 40.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.447 0.641 . . . . 0.0 111.399 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.99 114.56 45.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.05 107.83 18.32 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.643 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 17.1 t80 -113.77 124.86 53.27 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 122.009 0.123 . . . . 0.0 111.114 -178.34 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.82 131.83 21.67 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 120.262 -0.575 . . . . 0.0 112.516 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.04 112.43 21.77 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.179 0.514 . . . . 0.0 110.711 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.452 ' OD1' ' OD2' ' D' ' 23' ' ' ASP . 13.6 p-10 -124.86 46.56 2.3 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.559 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.765 HG12 ' H ' ' C' ' 25' ' ' GLY . 21.8 t -73.38 179.74 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.774 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.765 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 99.26 -35.38 4.73 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-N 114.329 -1.305 . . . . 0.0 113.413 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.489 ' O ' ' O ' ' C' ' 27' ' ' ASN . 28.6 t -162.38 117.53 1.87 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.6 1.7 . . . . 0.0 112.548 175.545 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 27' ' ' ASN . . . . . 0.794 ' N ' HG21 ' D' ' 24' ' ' VAL . 67.2 m-20 -23.23 151.39 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 118.976 -0.535 . . . . 0.0 112.232 175.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 39.5 tttp -167.55 31.36 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 173.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' D' ' 27' ' ' ASN . . . 81.01 80.81 0.85 Allowed Glycine 0 CA--C 1.535 1.328 0 C-N-CA 117.886 -2.102 . . . . 0.0 114.097 175.586 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.93 119.49 38.88 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.447 1.623 . . . . 0.0 109.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.607 HD11 HG23 ' P' ' 39' ' ' VAL . 82.9 mt -123.14 132.53 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -177.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.423 HG23 ' CD1' ' C' ' 34' ' ' LEU . 2.8 mt -105.79 108.45 25.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' B' ' 32' ' ' ILE . . . -123.64 106.76 1.01 Allowed Glycine 0 N--CA 1.465 0.577 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.423 ' CD1' HG23 ' C' ' 32' ' ' ILE . 3.0 mp -139.27 143.36 37.91 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 122.702 1.239 . . . . 0.0 113.434 -177.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -113.49 103.66 11.49 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 175.141 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.951 HG11 HD11 ' E' ' 17' ' ' LEU . 2.4 t -111.72 102.91 14.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.09 -151.78 20.89 Favored Glycine 0 C--N 1.31 -0.879 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -178.427 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 38' ' ' GLY . . . . . 0.687 ' O ' HG11 ' D' ' 39' ' ' VAL . . . 102.91 -56.81 0.6 Allowed Glycine 0 CA--C 1.54 1.618 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.725 -179.183 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.818 HG21 ' C ' ' B' ' 39' ' ' VAL . 33.6 m -135.81 163.71 34.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 123.037 0.535 . . . . 0.0 111.095 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.987 -179.434 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.405 ' O ' HG13 ' C' ' 12' ' ' VAL . 2.4 p . . . . . 0 N--CA 1.463 0.186 0 CA-C-O 121.046 0.45 . . . . 0.0 110.237 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.811 ' CD2' ' HD1' ' E' ' 13' ' ' HIS . 5.7 p80 -133.52 119.44 19.53 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.687 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -149.07 164.86 33.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.528 0.68 . . . . 0.0 112.144 -178.449 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.568 ' CD ' HG12 ' B' ' 36' ' ' VAL . 85.1 mt-30 -84.49 156.59 21.64 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 176.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -159.26 105.87 1.73 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 120.043 -0.663 . . . . 0.0 109.237 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.453 ' CD1' HG11 ' B' ' 36' ' ' VAL . 3.4 mp -136.67 127.85 28.01 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.434 0.635 . . . . 0.0 111.695 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -109.72 115.43 49.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.347 178.46 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' E' ' 19' ' ' PHE . 35.2 m-85 -108.55 106.95 17.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 47.3 t80 -111.87 119.01 37.1 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.851 -179.302 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.73 138.57 28.93 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 119.569 -0.852 . . . . 0.0 112.968 -179.24 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.3 mt-10 -120.15 133.45 55.5 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.776 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.616 ' C ' HG23 ' D' ' 24' ' ' VAL . 0.0 OUTLIER -149.41 59.78 1.02 Allowed 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.999 HG12 ' H ' ' D' ' 25' ' ' GLY . 4.4 t 91.3 -169.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 176.494 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.999 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -76.98 -33.82 44.36 Favored Glycine 0 C--O 1.214 -1.146 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 26' ' ' SER . . . . . 0.449 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 5.3 p -147.3 118.4 7.74 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.289 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 27' ' ' ASN . . . . . 0.412 ' OD1' ' N ' ' C' ' 29' ' ' GLY . 17.7 t-20 -59.93 169.03 1.59 Allowed 'General case' 0 C--N 1.333 -0.113 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.884 -179.126 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -55.25 -38.06 68.04 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.839 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.58 71.42 0.1 Allowed Glycine 0 CA--C 1.533 1.215 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.829 -174.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.49 135.27 47.05 Favored 'General case' 0 C--O 1.245 0.832 0 CA-C-N 118.785 1.293 . . . . 0.0 112.694 -174.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.565 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 77.9 mt -139.28 134.62 40.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 113.845 -1.525 . . . . 0.0 114.09 -176.29 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 mt -107.48 111.22 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 174.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.55 103.45 0.92 Allowed Glycine 0 N--CA 1.46 0.297 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 177.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.504 HD23 ' N ' ' D' ' 35' ' ' MET . 6.1 tt -140.8 146.63 37.87 Favored 'General case' 0 CA--C 1.513 -0.463 0 C-N-CA 119.055 -1.058 . . . . 0.0 113.171 -176.051 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.504 ' N ' HD23 ' D' ' 34' ' ' LEU . 17.9 mtp -120.21 115.25 23.25 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.194 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.784 HG11 HD11 ' F' ' 17' ' ' LEU . 0.0 OUTLIER -115.97 102.83 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.675 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.45 ' HA2' ' H ' ' E' ' 38' ' ' GLY . . . 166.27 -151.31 19.53 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 119.66 -1.257 . . . . 0.0 110.561 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.7 -57.4 0.84 Allowed Glycine 0 CA--C 1.544 1.88 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.484 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.751 HG21 ' C ' ' C' ' 39' ' ' VAL . 27.7 m -134.93 159.92 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 C-N-CA 123.356 0.662 . . . . 0.0 110.773 -178.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.53 -179.603 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.48 134.76 48.06 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.385 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -142.07 146.0 34.96 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.173 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.503 ' CG2' ' CD2' ' E' ' 14' ' ' HIS . 3.3 p -139.83 148.69 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 121.065 0.459 . . . . 0.0 110.716 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.811 ' HD1' ' CD2' ' D' ' 13' ' ' HIS . 0.1 OUTLIER -143.27 119.26 10.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.755 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.591 ' HE2' HG12 ' F' ' 12' ' ' VAL . 90.1 m-70 -143.9 164.35 30.81 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.014 178.313 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.619 HE21 HD21 ' E' ' 17' ' ' LEU . 64.4 tp60 -89.98 151.93 21.45 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 177.526 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -148.74 98.8 2.91 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.782 177.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.951 HD11 HG11 ' C' ' 36' ' ' VAL . 37.1 mt -122.8 119.33 30.26 Favored 'General case' 0 CA--C 1.509 -0.615 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.081 178.133 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -107.62 104.32 16.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' D' ' 19' ' ' PHE . 73.9 m-85 -103.67 105.69 15.99 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 2.7 m-85 -107.49 114.57 28.66 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.47 138.43 31.0 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 119.096 -1.042 . . . . 0.0 112.623 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -84.59 141.85 30.39 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.624 -179.251 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 0.6 OUTLIER 172.64 47.07 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.066 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -179.095 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' D' ' 25' ' ' GLY . 3.5 m -73.43 175.28 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.307 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 100.14 -29.75 11.56 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.165 176.731 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 92.01 114.67 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 -177.796 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' E' E ' 27' ' ' ASN . . . . . 0.412 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 78.6 m-20 -73.92 174.53 8.4 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.754 -178.181 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.11 -36.69 41.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.559 178.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.79 77.08 0.07 OUTLIER Glycine 0 CA--C 1.532 1.094 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -177.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.28 155.4 27.3 Favored 'General case' 0 C--O 1.241 0.64 0 CA-C-O 121.946 0.879 . . . . 0.0 111.673 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.879 HD11 ' H ' ' Q' ' 39' ' ' VAL . 75.0 mt -131.44 133.34 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 114.554 -1.203 . . . . 0.0 112.248 -177.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.43 115.35 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.289 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.49 113.42 1.6 Allowed Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 46.8 tp -123.37 121.38 35.64 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-O 120.825 0.345 . . . . 0.0 110.619 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.1 mtp -109.57 105.72 15.14 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.65 HG12 ' H ' ' E' ' 37' ' ' GLY . 21.6 t -91.84 174.33 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.373 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.65 ' H ' HG12 ' E' ' 36' ' ' VAL . . . 167.99 -95.15 0.11 Allowed Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 92.64 -82.64 1.12 Allowed Glycine 0 N--CA 1.474 1.193 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -178.044 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.442 HG13 HD11 ' K' ' 31' ' ' ILE . 64.4 t . . . . . 0 N--CA 1.432 -1.329 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.548 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 N--CA 1.465 0.292 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.591 HG12 ' HE2' ' E' ' 14' ' ' HIS . 2.5 t -112.82 100.67 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.165 0.507 . . . . 0.0 109.757 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.622 ' NE2' ' CD2' ' E' ' 13' ' ' HIS . 68.8 m80 -140.16 114.6 9.28 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.954 -178.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.534 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 77.2 m80 -156.21 162.1 40.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 177.31 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -90.06 158.23 17.42 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.678 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 31.9 tttt -141.16 98.28 3.34 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 175.83 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.784 HD11 HG11 ' D' ' 36' ' ' VAL . 7.9 mt -119.06 110.75 17.45 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 83.1 t -101.29 99.26 8.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.4 ' CD1' ' CD2' ' E' ' 19' ' ' PHE . 92.6 m-85 -96.51 95.08 7.76 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 106.768 -1.568 . . . . 0.0 106.768 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.421 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 67.8 t80 -107.4 109.25 20.93 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.585 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.548 ' O ' ' N ' ' F' ' 23' ' ' ASP . . . -148.82 135.41 19.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.584 ' HB3' HG12 ' E' ' 24' ' ' VAL . 63.3 mt-10 -74.98 79.53 2.18 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 102.807 -3.035 . . . . 0.0 102.807 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' F' ' 21' ' ' ALA . 53.0 p30 . . . . . 0 CA--C 1.511 -0.527 0 CA-C-N 112.472 -2.149 . . . . 0.0 113.729 -173.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.691 HD11 HG22 ' R' ' 39' ' ' VAL . 96.5 mt -134.97 136.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -128.54 124.7 62.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.82 129.05 4.31 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.663 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.6 125.34 44.66 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 95.6 mmm -131.47 133.28 44.98 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.609 -179.084 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 14.7 p -141.48 149.77 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 120.815 0.341 . . . . 0.0 110.788 178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.12 102.04 0.42 Allowed Glycine 0 C--N 1.322 -0.216 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.22 -71.95 0.4 Allowed Glycine 0 CA--C 1.539 1.584 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.077 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.455 ' O ' ' OXT' ' F' ' 40' ' ' VAL . 5.6 m -79.31 167.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.609 ' H ' ' CG2' ' L' ' 31' ' ' ILE . 27.2 m . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.502 179.329 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 12' ' ' VAL . . . . . 0.403 HG11 ' ND1' ' H' ' 13' ' ' HIS . 65.1 t . . . . . 0 N--CA 1.466 0.362 0 CA-C-O 120.953 0.406 . . . . 0.0 110.018 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -82.16 160.77 23.01 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.643 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.421 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 33.9 p-80 -99.5 169.49 9.27 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.083 0.468 . . . . 0.0 111.356 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.442 ' H ' ' HG2' ' H' ' 15' ' ' GLN . 67.1 tp60 -129.69 151.38 50.35 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.036 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -95.63 130.57 42.47 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.59 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.1 mt -126.19 112.43 15.77 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.218 0.532 . . . . 0.0 109.783 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.456 HG23 ' O ' ' G' ' 18' ' ' VAL . 21.2 m -125.65 132.49 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.179 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -127.0 113.32 16.32 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -111.82 117.51 33.01 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 110.297 -0.261 . . . . 0.0 110.297 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.04 107.39 14.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -151.36 138.96 19.63 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 . . . . . 0 C--N 1.329 -0.315 0 C-N-CA 119.985 -0.686 . . . . 0.0 110.857 178.614 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.482 1.169 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -158.88 17.48 0.19 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 121.942 -0.474 . . . . 0.0 110.326 177.08 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.33 169.53 0.66 Allowed Glycine 0 CA--C 1.524 0.651 0 CA-C-N 115.892 -0.594 . . . . 0.0 112.898 176.268 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.414 ' H ' ' HB2' ' H' ' 27' ' ' ASN . . . -130.83 87.31 2.47 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.346 0.593 . . . . 0.0 111.588 178.38 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.463 HD11 HG12 ' A' ' 39' ' ' VAL . 42.2 pt -138.83 127.12 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.223 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 177.423 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.462 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.8 mt -107.73 111.12 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.29 95.14 0.65 Allowed Glycine 0 N--CA 1.463 0.458 0 N-CA-C 105.347 -3.101 . . . . 0.0 105.347 177.056 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.4 mt -142.71 161.34 38.34 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 122.462 1.125 . . . . 0.0 113.861 -175.933 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 54.9 tpp -120.67 115.02 22.55 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 113.041 -1.89 . . . . 0.0 107.843 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.61 HG23 HG22 ' H' ' 36' ' ' VAL . 0.0 OUTLIER -131.57 111.76 19.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 179.728 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.61 -131.49 5.52 Favored Glycine 0 C--N 1.315 -0.585 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.55 -63.18 1.13 Allowed Glycine 0 CA--C 1.535 1.333 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.718 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 39' ' ' VAL . . . . . 0.404 ' O ' ' C ' ' G' ' 40' ' ' VAL . 11.9 p -120.47 153.34 23.59 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.531 ' OXT' ' CE1' ' J' ' 13' ' ' HIS . 22.7 m . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 118.06 -0.971 . . . . 0.0 111.069 -178.431 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.62 134.75 52.98 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.727 0.299 . . . . 0.0 110.289 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.73 137.96 37.24 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.4 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.479 HG22 ' O ' ' I' ' 11' ' ' GLU . 2.0 t -123.78 107.63 19.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 81.0 t60 -126.63 120.9 30.66 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.92 0.391 . . . . 0.0 110.579 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' O ' ' I' ' 14' ' ' HIS . 11.7 t60 -155.59 170.28 22.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.094 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.595 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 82.5 mt-30 -156.0 141.95 18.1 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.276 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -82.38 120.41 25.4 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.362 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.4 ' HB2' HD23 ' I' ' 17' ' ' LEU . 5.7 mp -120.54 114.5 21.84 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.978 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.42 HG12 ' HB ' ' I' ' 18' ' ' VAL . 25.6 m -133.98 131.79 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 121.364 0.602 . . . . 0.0 111.195 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -122.26 120.14 33.24 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.201 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -117.34 122.17 43.15 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.736 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.61 115.73 22.62 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.44 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.551 ' O ' ' N ' ' H' ' 24' ' ' VAL . 95.7 mt-10 -115.8 141.84 47.56 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 112.86 0.689 . . . . 0.0 112.86 -178.025 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.432 ' H ' ' HB2' ' I' ' 22' ' ' GLU . 88.5 m-20 54.38 -59.71 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 114.668 -1.151 . . . . 0.0 113.789 178.138 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.551 ' N ' ' O ' ' H' ' 22' ' ' GLU . 16.3 m -93.48 172.04 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-O 122.005 0.907 . . . . 0.0 111.616 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.97 27.93 65.65 Favored Glycine 0 CA--C 1.529 0.948 0 CA-C-N 113.841 -1.527 . . . . 0.0 112.762 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 46.6 t -98.38 110.83 23.35 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 27' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 5.4 t-20 -77.19 172.81 12.66 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 118.062 -1.455 . . . . 0.0 110.562 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.583 ' O ' ' N ' ' I' ' 28' ' ' LYS . 68.7 mttm -52.4 -36.46 54.16 Favored 'General case' 0 C--O 1.218 -0.575 0 CA-C-O 121.988 0.899 . . . . 0.0 110.821 176.055 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.473 ' CA ' HG21 ' A' ' 40' ' ' VAL . . . -132.12 79.48 0.35 Allowed Glycine 0 N--CA 1.47 0.901 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.466 -175.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.61 132.53 43.87 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 118.829 1.314 . . . . 0.0 111.132 -176.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.421 ' CD1' ' HA ' ' B' ' 39' ' ' VAL . 87.5 mt -140.84 147.55 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 113.954 -1.475 . . . . 0.0 113.544 -174.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.588 HD13 ' CD1' ' J' ' 19' ' ' PHE . 65.3 mt -106.86 107.25 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -111.56 98.59 1.03 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.178 -2.369 . . . . 0.0 107.178 178.2 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.647 ' O ' HD12 ' I' ' 34' ' ' LEU . 2.4 mt -135.18 139.09 44.29 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.584 1.183 . . . . 0.0 113.392 -176.201 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -106.21 108.66 20.29 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.15 -2.537 . . . . 0.0 104.15 175.287 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 1.001 HG11 HD11 ' J' ' 17' ' ' LEU . 53.1 t -127.94 131.26 69.77 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.247 0 CA-C-O 121.184 0.516 . . . . 0.0 112.159 -175.198 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.88 -111.11 3.68 Favored Glycine 0 C--N 1.32 -0.339 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.749 178.444 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.7 -74.22 2.42 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.429 HG22 ' O ' ' N' ' 29' ' ' GLY . 18.2 t -110.43 135.93 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 122.902 0.481 . . . . 0.0 110.475 179.08 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.472 HG12 ' O ' ' H' ' 40' ' ' VAL . 69.9 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.322 178.249 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.423 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -82.89 136.71 34.5 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.869 0.366 . . . . 0.0 110.533 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.479 ' O ' HG22 ' H' ' 12' ' ' VAL . 80.2 mm-40 -78.6 155.39 29.63 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.424 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' I' ' 13' ' ' HIS . 74.0 t -138.4 166.91 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.931 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.587 ' N ' HG12 ' I' ' 12' ' ' VAL . 11.0 m-70 -54.99 143.0 27.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.777 0.322 . . . . 0.0 111.46 -178.397 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 16.7 t-80 -153.9 154.31 33.64 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.601 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 64.2 tp60 -98.76 169.3 9.58 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 118.315 0.507 . . . . 0.0 111.208 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 82.2 tttt -159.73 104.29 1.57 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 176.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.4 HD23 ' HB2' ' H' ' 17' ' ' LEU . 11.7 mt -123.89 123.29 40.1 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 121.236 0.541 . . . . 0.0 111.472 178.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.42 ' HB ' HG12 ' H' ' 18' ' ' VAL . 60.3 t -115.91 112.08 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 177.593 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -112.54 107.36 16.07 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -114.74 126.93 55.41 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 130.09 25.35 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.817 0.818 . . . . 0.0 113.114 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.453 ' OE1' ' OE1' ' J' ' 22' ' ' GLU . 58.5 mm-40 -95.6 120.23 35.48 Favored 'General case' 0 N--CA 1.461 0.096 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.892 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.455 ' H ' ' HB3' ' J' ' 22' ' ' GLU . 90.6 m-20 -125.72 48.64 2.04 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.038 0.385 . . . . 0.0 112.038 -177.508 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.565 HG12 ' N ' ' I' ' 25' ' ' GLY . 81.2 t -72.39 161.11 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 C-N-CA 118.447 -1.301 . . . . 0.0 109.896 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.565 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 108.39 -30.05 9.34 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 22.9 p 93.28 113.59 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 112.573 -1.814 . . . . 0.0 109.619 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.411 ' HA ' HD21 ' I' ' 27' ' ' ASN . 8.6 m120 -74.19 161.95 29.44 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 117.916 -1.514 . . . . 0.0 110.649 178.232 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.583 ' N ' ' O ' ' H' ' 28' ' ' LYS . 72.7 tttt -48.65 -39.5 24.5 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 174.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.33 68.82 0.04 OUTLIER Glycine 0 CA--C 1.551 2.327 0 CA-C-O 118.826 -0.986 . . . . 0.0 112.421 -174.395 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.25 150.62 46.22 Favored 'General case' 0 N--CA 1.478 0.938 0 CA-C-N 119.775 1.787 . . . . 0.0 114.587 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.55 HD12 HG12 ' C' ' 39' ' ' VAL . 77.5 mt -141.44 152.32 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 113.517 -1.674 . . . . 0.0 113.996 -176.237 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.454 HD13 ' CD1' ' K' ' 19' ' ' PHE . 6.6 mt -106.93 109.08 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 174.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.42 106.03 2.04 Favored Glycine 0 N--CA 1.465 0.617 0 N-CA-C 106.323 -2.711 . . . . 0.0 106.323 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.647 HD12 ' O ' ' H' ' 34' ' ' LEU . 26.6 tp -147.54 140.25 24.79 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.837 1.303 . . . . 0.0 113.969 -174.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.548 ' H ' HD12 ' I' ' 34' ' ' LEU . 42.8 tpp -110.04 115.08 29.13 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 113.033 -1.894 . . . . 0.0 106.799 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.79 123.13 51.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.06 -113.55 0.86 Allowed Glycine 0 C--N 1.317 -0.527 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 86.24 -73.01 2.58 Favored Glycine 0 CA--C 1.536 1.405 0 CA-C-N 115.48 -0.36 . . . . 0.0 112.211 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 39.7 t -123.19 146.09 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.472 HG13 ' ND1' ' L' ' 13' ' ' HIS . 52.9 t . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.651 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.84 134.33 54.41 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 11' ' ' GLU . . . . . 0.41 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 98.9 mt-10 -74.57 130.79 40.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.483 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.589 HG23 ' O ' ' J' ' 12' ' ' VAL . 32.9 m -138.38 88.09 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-O 121.601 0.715 . . . . 0.0 110.904 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.562 ' H ' ' CD2' ' K' ' 13' ' ' HIS . 6.1 t60 -129.03 128.14 43.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.433 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.569 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -140.67 173.64 11.29 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.426 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -124.64 142.45 51.37 Favored 'General case' 0 C--O 1.224 -0.248 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.465 177.542 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.82 112.16 23.45 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 119.168 -0.444 . . . . 0.0 111.078 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 1.001 HD11 HG11 ' H' ' 36' ' ' VAL . 24.0 mt -118.43 114.36 22.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.613 0.642 . . . . 0.0 109.984 177.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 t -110.13 105.83 19.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.588 ' CD1' HD13 ' H' ' 32' ' ' ILE . 65.5 m-85 -106.36 106.67 17.3 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.454 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.6 t80 -115.24 122.48 46.11 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.77 138.3 32.19 Favored 'General case' 0 C--O 1.253 1.26 0 CA-C-O 123.091 1.424 . . . . 0.0 114.479 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.455 ' HB3' ' H ' ' I' ' 23' ' ' ASP . 24.0 tt0 -79.89 90.99 5.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 113.526 -1.67 . . . . 0.0 107.614 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.685 ' O ' ' O ' ' K' ' 22' ' ' GLU . 84.3 m-20 -89.98 60.04 4.76 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 111.773 -2.467 . . . . 0.0 110.42 -178.944 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -62.7 -112.65 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-O 117.109 -1.424 . . . . 0.0 108.282 -174.209 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.608 ' HA2' HG12 ' K' ' 24' ' ' VAL . . . -103.82 44.51 1.47 Allowed Glycine 0 N--CA 1.472 1.081 0 CA-C-N 121.707 2.049 . . . . 0.0 112.078 -172.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 29.0 t -71.82 100.64 2.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -109.67 -150.81 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.176 -175.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 34.96 42.07 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 113.36 0.874 . . . . 0.0 113.36 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.55 71.82 0.63 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 117.297 1.679 . . . . 0.0 117.297 177.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.33 120.27 40.82 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 174.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.471 HG22 ' N ' ' J' ' 32' ' ' ILE . 42.3 mt -145.12 155.45 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -174.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.471 ' N ' HG22 ' J' ' 31' ' ' ILE . 40.7 mt -111.89 111.23 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.811 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.27 103.88 1.64 Allowed Glycine 0 N--CA 1.467 0.75 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 177.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.432 ' CD2' HG13 ' J' ' 36' ' ' VAL . 12.2 tp -137.33 137.31 38.79 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 122.205 1.003 . . . . 0.0 113.663 -175.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -111.39 114.22 27.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 113.677 -1.601 . . . . 0.0 107.543 176.419 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.432 HG13 ' CD2' ' J' ' 34' ' ' LEU . 1.3 m -121.23 103.21 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 120.399 0.143 . . . . 0.0 111.11 -178.547 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.39 -153.43 25.33 Favored Glycine 0 C--N 1.318 -0.468 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.016 178.053 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.479 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 126.15 -56.4 0.71 Allowed Glycine 0 CA--C 1.541 1.71 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.657 HG12 HG23 ' J' ' 40' ' ' VAL . 55.0 t -136.5 137.17 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.657 HG23 HG12 ' J' ' 39' ' ' VAL . 61.2 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.433 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.98 143.81 41.07 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.754 0.311 . . . . 0.0 110.644 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.489 ' O ' HG12 ' J' ' 12' ' ' VAL . 97.0 mt-10 -129.41 149.87 51.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.434 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.534 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 34.2 m -140.37 161.45 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.498 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.562 ' CD2' ' H ' ' J' ' 13' ' ' HIS . 28.1 m80 -70.17 118.15 12.64 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.005 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' O ' ' L' ' 14' ' ' HIS . 65.9 t60 -148.23 162.82 38.71 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.107 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.435 ' HB3' ' H ' ' L' ' 16' ' ' LYS . 41.3 tt0 -90.2 152.28 21.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.819 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -150.39 93.14 1.94 Allowed 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.616 177.358 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.438 HD22 HD12 ' J' ' 17' ' ' LEU . 2.0 mt -120.93 115.31 22.96 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.47 105.41 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.112 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.481 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 52.1 m-85 -104.28 103.67 13.45 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.454 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 31.9 t80 -113.07 119.3 37.37 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.016 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.546 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -156.74 162.71 39.76 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 122.626 1.203 . . . . 0.0 113.604 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.685 ' O ' ' O ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -82.05 118.81 23.31 Favored 'General case' 0 C--O 1.206 -1.22 0 C-N-CA 118.344 -1.342 . . . . 0.0 111.347 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.908 ' O ' HG13 ' K' ' 24' ' ' VAL . 65.2 m-20 -62.09 -50.41 72.04 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 120.251 -1.53 . . . . 0.0 110.016 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.908 HG13 ' O ' ' K' ' 23' ' ' ASP . 0.3 OUTLIER 159.6 171.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 178.626 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 -33.27 76.14 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 177.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.3 m -162.68 120.94 2.1 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 114.186 -1.007 . . . . 0.0 109.872 -177.879 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' K' ' 26' ' ' SER . 39.7 t30 -22.25 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -164.69 29.82 0.07 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.528 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.91 88.04 0.82 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.685 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.36 155.95 45.51 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.442 HD11 HG13 ' E' ' 39' ' ' VAL . 6.9 mt -127.1 146.93 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 113.657 0.984 . . . . 0.0 113.657 -176.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -128.13 114.88 36.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.318 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.75 113.89 3.21 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.409 HD21 HD13 ' L' ' 17' ' ' LEU . 20.3 tp -122.84 124.36 43.11 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 17.8 mtp -129.24 131.09 46.98 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.409 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.593 HG12 ' N ' ' K' ' 37' ' ' GLY . 57.8 t -100.84 166.28 2.37 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-O 121.003 0.43 . . . . 0.0 110.568 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.593 ' N ' HG12 ' K' ' 36' ' ' VAL . . . -75.01 -102.91 0.1 OUTLIER Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.151 179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.55 -77.16 0.59 Allowed Glycine 0 N--CA 1.474 1.217 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.422 HG22 ' O ' ' L' ' 39' ' ' VAL . 45.5 t . . . . . 0 N--CA 1.469 0.497 0 CA-C-O 121.428 0.632 . . . . 0.0 110.585 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.596 0.236 . . . . 0.0 110.529 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 55.1 t -123.84 133.82 68.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.533 0.682 . . . . 0.0 110.942 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.492 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 2.5 m-70 -131.33 127.24 37.24 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.181 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.546 ' O ' ' ND1' ' K' ' 14' ' ' HIS . 94.9 m-70 -155.01 165.46 36.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.423 ' OE1' ' O ' ' J' ' 36' ' ' VAL . 47.5 mt-30 -89.69 156.64 18.42 Favored 'General case' 0 CA--C 1.518 -0.282 0 C-N-CA 119.521 -0.871 . . . . 0.0 109.635 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 16' ' ' LYS . . . . . 0.435 ' H ' ' HB3' ' K' ' 15' ' ' GLN . 52.4 tttp -141.99 95.66 2.84 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.221 177.542 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.409 HD13 HD21 ' K' ' 34' ' ' LEU . 0.1 OUTLIER -117.65 108.19 15.14 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.299 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -107.11 103.93 16.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.058 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -101.23 102.13 12.97 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 178.13 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.7 t80 -126.52 129.7 49.15 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 121.35 0.595 . . . . 0.0 110.231 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -144.84 149.09 34.8 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 120.059 -0.656 . . . . 0.0 110.66 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -74.24 120.98 20.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.657 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -163.52 51.61 0.16 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 120.372 -0.531 . . . . 0.0 112.067 -178.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -76.15 143.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 118.119 -1.432 . . . . 0.0 108.51 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.52 -37.52 3.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.42 ' HB2' ' H ' ' K' ' 27' ' ' ASN . 0.3 OUTLIER -80.6 118.26 22.02 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 113.379 -1.411 . . . . 0.0 112.057 -179.267 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' L' ' 29' ' ' GLY . 57.3 p30 -89.01 -177.95 5.58 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -51.98 49.66 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 115.089 1.514 . . . . 0.0 115.089 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -101.58 51.35 0.93 Allowed Glycine 0 CA--C 1.549 2.182 0 CA-C-N 119.698 1.135 . . . . 0.0 113.515 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.38 174.47 9.83 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.609 ' CG2' ' H ' ' F' ' 40' ' ' VAL . 0.6 OUTLIER -106.91 119.91 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 176.214 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.0 mt -123.62 128.66 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 120.876 0.369 . . . . 0.0 111.7 -178.073 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 116.24 2.22 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 178.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 34.3 mt -119.64 124.59 46.67 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.7 ttm -124.04 123.54 40.57 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.468 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' L' ' 37' ' ' GLY . 72.8 t -98.33 131.52 45.24 Favored 'Isoleucine or valine' 0 C--N 1.34 0.17 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -34.6 -111.51 0.0 OUTLIER Glycine 0 CA--C 1.531 1.089 0 O-C-N 123.543 0.527 . . . . 0.0 113.257 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.68 -71.65 0.62 Allowed Glycine 0 CA--C 1.535 1.298 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.422 ' O ' HG22 ' K' ' 39' ' ' VAL . 53.2 t . . . . . 0 N--CA 1.468 0.462 0 CA-C-O 121.165 0.507 . . . . 0.0 110.998 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 . . . . . 0 N--CA 1.457 -0.085 0 CA-C-O 120.874 0.369 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -125.48 131.93 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.349 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -106.28 160.71 15.15 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.633 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 35.1 p-80 -83.43 166.91 17.96 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 120.392 -0.523 . . . . 0.0 110.617 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -129.95 152.07 49.82 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.927 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 16' ' ' LYS . . . . . 0.59 ' C ' HD12 ' M' ' 17' ' ' LEU . 63.6 mttp -94.38 112.3 24.08 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 17' ' ' LEU . . . . . 0.59 HD12 ' C ' ' M' ' 16' ' ' LYS . 11.1 mp -116.88 120.61 39.02 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.879 0.371 . . . . 0.0 110.124 179.454 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -129.61 132.54 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.049 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -142.25 134.23 27.3 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.989 0.423 . . . . 0.0 110.828 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.448 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 52.8 p90 -123.31 133.11 54.18 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.732 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.91 125.66 41.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 121.145 0.498 . . . . 0.0 111.543 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -156.33 126.34 6.47 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.586 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.24 46.41 25.29 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.831 HG12 ' H ' ' M' ' 25' ' ' GLY . 21.6 t -76.7 -179.8 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.349 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 25' ' ' GLY . . . . . 0.831 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -88.88 28.15 6.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 26' ' ' SER . . . . . 0.443 ' O ' ' C ' ' M' ' 27' ' ' ASN . 4.7 t -169.74 -134.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.865 -0.421 . . . . 0.0 109.865 -178.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 27' ' ' ASN . . . . . 0.443 ' C ' ' O ' ' M' ' 26' ' ' SER . 24.8 t30 -32.04 134.19 0.09 Allowed 'General case' 0 N--CA 1.472 0.671 0 O-C-N 122.985 0.178 . . . . 0.0 111.141 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 28' ' ' LYS . . . . . 0.452 ' O ' ' OD2' ' N' ' 23' ' ' ASP . 68.7 mttm -118.23 -38.5 3.18 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 29' ' ' GLY . . . . . 0.587 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . -81.04 -76.99 1.02 Allowed Glycine 0 CA--C 1.53 0.969 0 C-N-CA 118.794 -1.67 . . . . 0.0 112.178 -179.363 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 30' ' ' ALA . . . . . 0.587 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 171.05 99.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.386 0.593 . . . . 0.0 111.31 178.284 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -127.9 116.63 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 32' ' ' ILE . . . . . 0.436 ' O ' ' O ' ' N' ' 33' ' ' GLY . 96.5 mt -113.49 108.1 24.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.26 96.87 0.78 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 105.45 -3.06 . . . . 0.0 105.45 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 34' ' ' LEU . . . . . 0.623 ' O ' HD12 ' N' ' 34' ' ' LEU . 91.3 mt -142.63 163.5 32.64 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 123.12 1.438 . . . . 0.0 114.163 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -117.62 110.71 18.24 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 111.824 -2.443 . . . . 0.0 105.977 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.895 HG11 HD11 ' O' ' 17' ' ' LEU . 74.6 t -117.92 131.61 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 121.334 0.588 . . . . 0.0 110.15 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.54 -111.42 3.36 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.924 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.1 -73.03 0.97 Allowed Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.424 HG12 ' N ' ' M' ' 40' ' ' VAL . 56.0 t -99.17 158.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.339 0.149 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.424 ' N ' HG12 ' M' ' 39' ' ' VAL . 11.7 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.567 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -83.07 139.41 33.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.614 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -140.63 128.06 21.29 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.765 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -127.46 130.27 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -123.71 104.37 8.95 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.913 0.387 . . . . 0.0 111.667 -179.27 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 1.0 OUTLIER -158.31 170.57 21.94 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.864 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' N' N ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 19.5 tt0 -155.44 141.46 18.28 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.897 0.379 . . . . 0.0 110.355 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -87.04 117.51 25.81 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.801 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -118.69 124.4 47.26 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 179.055 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.02 126.84 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 120.994 0.426 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -130.85 130.27 43.39 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.861 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -124.29 128.49 49.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 118.6 26.57 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.013 0.435 . . . . 0.0 110.458 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -127.22 128.69 46.48 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.463 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 34.4 m-20 -162.47 51.26 0.19 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.164 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 89.2 t -63.21 150.81 9.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.041 0.448 . . . . 0.0 110.668 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.06 -37.37 3.8 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.508 ' O ' ' O ' ' N' ' 27' ' ' ASN . 51.4 m -120.49 -112.36 0.33 Allowed 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.794 0.33 . . . . 0.0 111.588 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.524 ' ND2' ' OD1' ' O' ' 23' ' ' ASP . 16.3 m-20 52.31 153.08 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.69 -178.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' O' ' 28' ' ' LYS . 68.8 mttm -139.7 -29.57 0.73 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 113.712 1.005 . . . . 0.0 113.712 -179.017 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 29' ' ' GLY . . . . . 0.429 ' O ' HG22 ' H' ' 39' ' ' VAL . . . -161.73 85.02 0.11 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 120.421 -0.895 . . . . 0.0 113.935 -174.547 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.86 123.64 28.44 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 118.824 1.312 . . . . 0.0 110.627 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 0.432 HD11 HG23 ' I' ' 39' ' ' VAL . 70.0 mt -129.98 134.53 62.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.515 -175.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -105.0 104.93 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 106.87 -1.529 . . . . 0.0 106.87 174.323 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -110.41 109.44 2.64 Favored Glycine 0 C--O 1.235 0.202 0 N-CA-C 106.274 -2.73 . . . . 0.0 106.274 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.623 HD12 ' O ' ' M' ' 34' ' ' LEU . 15.8 tp -151.55 139.13 19.62 Favored 'General case' 0 CA--C 1.511 -0.535 0 C-N-CA 117.432 -1.707 . . . . 0.0 113.379 -175.412 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 35' ' ' MET . . . . . 0.528 ' H ' HD12 ' N' ' 34' ' ' LEU . 0.8 OUTLIER -105.25 108.88 20.63 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 111.756 -2.475 . . . . 0.0 106.424 177.401 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' N' N ' 36' ' ' VAL . . . . . 0.644 HG11 HD11 ' P' ' 17' ' ' LEU . 8.7 p -132.8 142.6 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.141 -177.687 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.74 -102.02 0.75 Allowed Glycine 0 C--N 1.32 -0.307 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' O' ' 39' ' ' VAL . . . 77.01 -80.76 1.21 Allowed Glycine 0 CA--C 1.531 1.064 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.49 149.51 14.66 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.574 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.411 HG12 ' CD2' ' P' ' 13' ' ' HIS . 33.3 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.873 -1.061 . . . . 0.0 110.256 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -148.93 159.94 43.73 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.729 0.299 . . . . 0.0 110.484 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -134.55 160.22 38.74 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.619 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -118.45 131.04 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.281 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 37.3 m-70 -140.13 123.6 17.08 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.715 ' CE1' ' HD1' ' P' ' 14' ' ' HIS . 30.9 m80 -147.58 174.09 12.08 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 121.25 0.548 . . . . 0.0 111.152 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 10.0 tp-100 -137.69 140.8 40.98 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.821 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -129.96 104.55 7.42 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.895 HD11 HG11 ' M' ' 36' ' ' VAL . 12.7 mt -116.61 116.3 27.32 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.006 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.89 106.34 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.891 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 13.6 m-30 -112.02 118.07 34.42 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -119.62 127.24 52.75 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.789 -0.187 . . . . 0.0 110.933 -179.184 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.39 124.83 26.35 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 121.944 0.878 . . . . 0.0 112.053 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 22' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' O' ' 23' ' ' ASP . 80.4 tt0 -96.09 141.79 29.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.316 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.524 ' OD1' ' ND2' ' N' ' 27' ' ' ASN . 65.3 m-20 -162.75 47.22 0.15 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.87 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.621 HG13 ' OE1' ' P' ' 22' ' ' GLU . 25.0 m -62.77 -179.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 121.716 0.769 . . . . 0.0 111.535 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 25' ' ' GLY . . . . . 0.475 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 91.25 -29.01 7.42 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 114.22 -1.354 . . . . 0.0 113.358 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 0.9 OUTLIER 167.63 127.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 118.385 1.093 . . . . 0.0 112.798 179.467 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' O' O ' 27' ' ' ASN . . . . . 0.515 ' ND2' ' O ' ' P' ' 27' ' ' ASN . 39.4 t-20 -36.72 138.48 0.24 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 176.137 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' N' ' 28' ' ' LYS . 78.1 mttt -150.56 34.82 0.62 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 121.077 0.465 . . . . 0.0 111.684 -176.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.35 80.39 0.95 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 176.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.01 110.99 23.1 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 42.8 mt -121.93 130.72 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -176.545 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.5 mt -107.44 103.64 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.281 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.27 102.41 2.21 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 104.146 -3.582 . . . . 0.0 104.146 176.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.557 HD12 ' O ' ' N' ' 34' ' ' LEU . 13.0 tp -140.19 135.87 32.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -172.67 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 35' ' ' MET . . . . . 0.428 ' SD ' ' CG ' ' P' ' 35' ' ' MET . 89.5 mmm -111.64 108.73 18.3 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 112.369 -2.196 . . . . 0.0 106.185 177.922 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.495 HG11 HD21 ' Q' ' 17' ' ' LEU . 21.4 t -115.67 131.51 67.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.447 0.641 . . . . 0.0 111.94 -177.069 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' P' ' 37' ' ' GLY . . . 75.39 111.71 0.1 Allowed Glycine 0 CA--C 1.526 0.737 0 CA-C-N 114.767 -1.106 . . . . 0.0 114.222 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -94.17 -60.1 1.14 Allowed Glycine 0 CA--C 1.542 1.762 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' N' ' 38' ' ' GLY . 5.7 t -122.02 131.12 73.85 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.442 ' H ' ' HB ' ' P' ' 39' ' ' VAL . 91.4 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.922 -1.037 . . . . 0.0 110.476 -178.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 12' ' ' VAL . . . . . 0.461 ' O ' ' CG2' ' P' ' 12' ' ' VAL . 1.4 m . . . . . 0 N--CA 1.467 0.404 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 9.2 t60 -146.39 134.15 21.17 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 120.511 -0.475 . . . . 0.0 112.115 -177.846 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.715 ' HD1' ' CE1' ' O' ' 14' ' ' HIS . 1.0 OUTLIER -145.96 156.01 43.22 Favored 'General case' 0 C--O 1.23 0.068 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 176.314 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.429 ' OE1' HD11 ' P' ' 17' ' ' LEU . 7.4 tt0 -90.56 159.71 16.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.661 177.26 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 51.5 tttm -140.91 105.65 4.92 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.115 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 17' ' ' LEU . . . . . 0.644 HD11 HG11 ' N' ' 36' ' ' VAL . 39.6 mt -115.25 119.76 37.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-O 121.202 0.525 . . . . 0.0 111.166 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -116.75 98.29 6.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.489 ' CE2' HD13 ' P' ' 17' ' ' LEU . 16.9 m-30 -112.86 110.35 20.39 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -112.51 128.7 56.42 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.925 -179.455 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.5 158.13 40.86 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.953 -178.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.621 ' OE1' HG13 ' O' ' 24' ' ' VAL . 99.1 mt-10 -85.83 112.21 20.9 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.405 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 9.8 p-10 -112.44 52.07 0.79 Allowed 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 113.511 -1.677 . . . . 0.0 108.847 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 24' ' ' VAL . . . . . 0.565 HG12 ' N ' ' P' ' 25' ' ' GLY . 96.4 t -41.35 161.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 122.169 0.985 . . . . 0.0 112.249 -175.087 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.565 ' N ' HG12 ' P' ' 24' ' ' VAL . . . -93.14 32.61 5.57 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-N 113.077 -1.874 . . . . 0.0 114.218 -173.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.429 ' HB3' ' H ' ' O' ' 27' ' ' ASN . 11.9 t -92.57 -112.91 0.1 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.575 ' O ' ' N ' ' P' ' 29' ' ' GLY . 83.7 m-20 -86.27 156.58 20.2 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 118.097 -1.441 . . . . 0.0 110.893 -178.043 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 50.1 pttt -49.16 46.27 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . -99.38 58.17 0.85 Allowed Glycine 0 CA--C 1.545 1.915 0 CA-C-N 118.875 0.761 . . . . 0.0 112.322 179.065 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 30' ' ' ALA . . . . . 0.576 ' O ' ' HB1' ' Q' ' 30' ' ' ALA . . . -152.72 108.06 3.27 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 117.811 0.805 . . . . 0.0 110.856 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.479 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 14.0 pt -145.04 147.86 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.9 mt -114.4 115.89 50.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.341 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.46 98.31 1.12 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 104.739 -3.344 . . . . 0.0 104.739 174.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 22.6 tp -127.49 132.43 49.98 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -173.89 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' P' P ' 35' ' ' MET . . . . . 0.428 ' CG ' ' SD ' ' O' ' 35' ' ' MET . 90.6 mmm -111.56 112.83 24.82 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 174.756 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.494 HG21 HE22 ' R' ' 15' ' ' GLN . 0.0 OUTLIER -121.32 102.35 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -176.001 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' P' P ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' O' ' 37' ' ' GLY . . . 141.55 -161.34 27.0 Favored Glycine 0 CA--C 1.509 -0.339 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.802 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 38' ' ' GLY . . . . . 0.565 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 148.16 -55.8 0.5 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-O 119.234 -0.759 . . . . 0.0 111.229 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.607 HG23 HD11 ' C' ' 31' ' ' ILE . 73.3 t -144.72 139.85 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 118.355 1.078 . . . . 0.0 108.805 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 86.7 t . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 118.074 -0.965 . . . . 0.0 111.321 178.705 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -81.46 139.37 35.24 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.835 0.35 . . . . 0.0 110.609 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -85.36 110.0 18.8 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.632 HG12 ' H ' ' R' ' 12' ' ' VAL . 34.4 m -141.13 165.27 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.424 ' C ' ' CD2' ' Q' ' 14' ' ' HIS . 1.6 m80 -132.93 121.13 22.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.785 178.326 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.588 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 32.1 m-70 -144.82 161.83 38.29 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.626 178.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.437 ' OE1' ' CG1' ' O' ' 36' ' ' VAL . 8.4 tp-100 -90.09 157.81 17.6 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.52 102.34 4.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 176.013 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.594 HD22 HD12 ' P' ' 17' ' ' LEU . 77.7 mt -116.14 117.11 29.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 C-N-CA 120.317 -0.553 . . . . 0.0 111.06 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 41.1 t -118.01 99.28 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 177.698 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.403 ' CZ ' ' HB3' ' Q' ' 17' ' ' LEU . 7.2 m-30 -110.57 107.64 17.32 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.17 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -120.49 138.84 53.6 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.989 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -147.62 151.79 36.79 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' P' ' 23' ' ' ASP . 80.5 tt0 -80.27 121.8 26.09 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.217 -179.244 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 67.1 t0 -136.22 52.08 1.99 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.7 142.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.435 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 25' ' ' GLY . . . 100.4 38.05 3.61 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 106.082 -2.807 . . . . 0.0 106.082 -174.773 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 37.2 t -69.71 104.03 2.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.003 1.382 . . . . 0.0 114.568 -172.453 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . 0.505 ' O ' ' C ' ' Q' ' 28' ' ' LYS . 97.5 m-20 -118.82 -153.33 0.53 Allowed 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 111.824 -2.444 . . . . 0.0 105.036 178.63 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' O ' ' HB2' ' R' ' 30' ' ' ALA . 99.0 mttt -35.42 -41.15 0.17 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 120.354 1.434 . . . . 0.0 109.9 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.02 -65.42 2.59 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.95 1.54 . . . . 0.0 116.95 172.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . 0.576 ' HB1' ' O ' ' P' ' 30' ' ' ALA . . . -171.01 174.95 4.53 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.981 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.6 mt -121.12 118.08 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-N 113.347 -1.751 . . . . 0.0 107.015 176.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -120.38 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.24 0.543 . . . . 0.0 112.282 -178.04 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.81 114.34 2.07 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 32.0 mt -120.9 128.91 53.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 57.2 mtp -132.47 132.14 42.4 Favored 'General case' 0 CA--C 1.514 -0.405 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.314 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . 0.445 ' O ' ' N ' ' R' ' 37' ' ' GLY . 69.2 t -115.65 135.58 55.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.551 ' O ' ' N ' ' P' ' 38' ' ' GLY . . . -139.44 103.32 0.38 Allowed Glycine 0 C--N 1.306 -1.095 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 148.56 72.5 0.01 OUTLIER Glycine 0 N--CA 1.479 1.524 0 CA-C-N 119.76 1.78 . . . . 0.0 114.635 -178.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . 0.879 ' H ' HD11 ' E' ' 31' ' ' ILE . 37.2 t -18.63 125.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.601 0.761 . . . . 0.0 112.699 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.639 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -81.96 140.16 34.17 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.889 0.376 . . . . 0.0 110.589 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -113.53 128.04 56.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.711 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 12' ' ' VAL . . . . . 0.632 ' H ' HG12 ' Q' ' 12' ' ' VAL . 78.5 t -135.28 156.71 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.125 0.488 . . . . 0.0 110.982 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.437 ' N ' HG12 ' R' ' 12' ' ' VAL . 3.2 m-70 -144.06 132.42 22.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.252 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 14' ' ' HIS . . . . . 0.588 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 64.2 m80 -151.73 161.73 42.18 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.016 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.597 ' NE2' HD23 ' R' ' 17' ' ' LEU . 52.3 tt0 -90.13 158.45 17.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.89 0.376 . . . . 0.0 111.486 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.6 100.83 3.95 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.597 HD23 ' NE2' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -111.64 112.78 24.73 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.958 0.409 . . . . 0.0 109.948 179.313 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 87.6 t -117.83 101.64 12.18 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.465 ' O ' ' CD1' ' R' ' 20' ' ' PHE . 4.0 m-85 -119.43 116.83 26.96 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 20' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' R' ' 19' ' ' PHE . 80.1 m-85 -150.8 160.03 44.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 122.08 0.943 . . . . 0.0 112.384 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 21' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -129.36 145.94 51.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.129 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.77 153.87 40.63 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 122.095 0.95 . . . . 0.0 113.49 -175.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 61.0 t0 61.98 47.93 5.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 113.581 -1.645 . . . . 0.0 111.676 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.638 HG12 ' N ' ' R' ' 25' ' ' GLY . 45.4 t -59.68 171.12 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.911 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 25' ' ' GLY . . . . . 0.638 ' N ' HG12 ' R' ' 24' ' ' VAL . . . 161.12 31.41 0.02 OUTLIER Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 3.3 t 72.73 120.75 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 95.7 m-20 -83.04 162.3 21.44 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.428 -0.909 . . . . 0.0 111.508 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -48.08 -39.67 20.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.407 177.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.38 66.89 0.04 OUTLIER Glycine 0 CA--C 1.539 1.557 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.829 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 30' ' ' ALA . . . . . 0.55 ' HB2' ' O ' ' Q' ' 28' ' ' LYS . . . -71.81 159.32 34.52 Favored 'General case' 0 C--N 1.345 0.409 0 CA-C-N 117.837 0.819 . . . . 0.0 110.117 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -107.42 116.14 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -124.25 125.44 70.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-O 120.803 0.335 . . . . 0.0 110.566 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.15 121.05 3.24 Favored Glycine 0 N--CA 1.463 0.478 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.905 ' H ' HD23 ' R' ' 34' ' ' LEU . 1.2 pt? -123.15 128.26 49.81 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 121.433 0.635 . . . . 0.0 110.471 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 91.3 mmm -123.56 120.03 31.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.022 -178.777 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 96.2 t -100.28 115.42 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.33 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -115.25 122.97 5.78 Favored Glycine 0 CA--C 1.508 -0.384 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 177.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.92 66.48 0.46 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.428 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.691 HG22 HD11 ' F' ' 31' ' ' ILE . 26.8 m -53.89 152.59 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 117.43 0.615 . . . . 0.0 110.574 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.756 179.685 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mm-40 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.705 0.288 . . . . 0.0 110.709 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.774 HG13 HG13 ' B' ' 12' ' ' VAL . 73.2 t -138.61 87.22 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.563 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -148.54 143.66 26.79 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.592 ' CD2' ' N ' ' A' ' 14' ' ' HIS . 0.5 OUTLIER -111.94 163.14 14.56 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.144 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -89.91 158.74 17.28 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -140.62 106.86 5.24 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 87.9 mt -136.11 120.09 17.54 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.917 0.78 . . . . 0.0 110.772 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.34 136.01 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.703 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -125.46 119.38 28.08 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.907 0.384 . . . . 0.0 111.203 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -108.39 118.73 37.53 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.16 117.5 30.21 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.215 0.531 . . . . 0.0 111.2 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.73 -162.56 0.33 Allowed 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 115.294 -0.867 . . . . 0.0 108.897 179.399 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 60.8 t0 . . . . . 0 CA--C 1.531 0.234 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.697 -179.352 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 122.016 0.912 . . . . 0.0 112.869 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 28' ' ' LYS . 99.3 mttt -46.77 -38.87 10.74 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 113.666 -1.606 . . . . 0.0 112.331 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.09 70.47 0.21 Allowed Glycine 0 CA--C 1.532 1.139 0 CA-C-N 114.575 -1.193 . . . . 0.0 114.335 -173.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' B' ' 30' ' ' ALA . . . -95.21 117.0 29.48 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 123.86 1.79 . . . . 0.0 112.071 -177.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 32.0 pt -149.59 147.78 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 112.457 -2.156 . . . . 0.0 108.589 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.406 ' O ' ' O ' ' B' ' 33' ' ' GLY . 97.8 mt -105.74 114.03 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.26 95.04 0.72 Allowed Glycine 0 N--CA 1.462 0.376 0 N-CA-C 105.639 -2.984 . . . . 0.0 105.639 177.141 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -142.95 151.78 41.3 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 122.664 1.221 . . . . 0.0 113.901 -176.328 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 89.5 mmm -106.99 108.98 20.76 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-N 112.634 -2.075 . . . . 0.0 105.616 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' B' ' 36' ' ' VAL . 24.3 t -124.14 112.05 31.1 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -178.307 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.48 -132.09 10.09 Favored Glycine 0 C--N 1.321 -0.296 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 -178.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.436 ' O ' HG12 ' B' ' 39' ' ' VAL . . . 92.06 -63.34 2.46 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.579 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' VAL . 1.1 m -96.03 177.86 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.537 ' H ' ' HB3' ' H' ' 28' ' ' LYS . 7.3 p . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.746 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -107.06 132.41 53.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.736 0.303 . . . . 0.0 110.243 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.519 ' O ' ' CE1' ' C' ' 13' ' ' HIS . 84.2 tt0 -151.35 128.37 11.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.398 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.774 HG13 HG13 ' A' ' 12' ' ' VAL . 0.2 OUTLIER -127.05 109.93 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-O 121.438 0.637 . . . . 0.0 110.358 179.703 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.444 ' CE1' ' HD1' ' C' ' 13' ' ' HIS . 22.6 p-80 -151.21 158.97 44.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.726 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.52 ' CD2' ' ND1' ' A' ' 14' ' ' HIS . 2.8 m-70 -143.04 163.89 31.58 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.63 178.588 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -89.96 152.01 21.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -149.16 100.98 3.1 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 69.8 mt -122.78 121.91 37.44 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.789 0.328 . . . . 0.0 110.41 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 18' ' ' VAL . . . . . 0.722 HG22 HG22 ' C' ' 18' ' ' VAL . 60.6 t -125.79 125.88 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.552 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -124.17 120.88 33.57 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.57 0.224 . . . . 0.0 110.695 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -122.58 121.06 35.58 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 116.697 -0.228 . . . . 0.0 110.967 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.98 130.15 55.53 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.655 0.264 . . . . 0.0 110.611 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.452 ' CG ' ' N ' ' B' ' 23' ' ' ASP . 77.0 tt0 -66.73 154.87 39.61 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -175.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.452 ' N ' ' CG ' ' B' ' 22' ' ' GLU . 65.8 t0 -67.15 47.79 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 111.216 -2.72 . . . . 0.0 113.833 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 24' ' ' VAL . . . . . 0.739 HG12 ' H ' ' B' ' 25' ' ' GLY . 1.9 t -60.73 -179.5 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 118.388 -1.325 . . . . 0.0 111.527 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 25' ' ' GLY . . . . . 0.739 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -99.71 28.91 13.33 Favored Glycine 0 N--CA 1.471 0.999 0 CA-C-N 114.809 -1.087 . . . . 0.0 115.681 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' B' ' 27' ' ' ASN . 42.8 t -162.18 116.14 1.83 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 120.089 1.945 . . . . 0.0 113.869 -176.107 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' B' ' 26' ' ' SER . 92.7 m-20 -22.71 164.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.848 0 O-C-N 125.311 1.632 . . . . 0.0 112.636 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.8 mttt -155.39 -20.71 0.11 Allowed 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 119.826 -0.75 . . . . 0.0 112.646 -177.192 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.38 97.8 0.06 OUTLIER Glycine 0 C--N 1.334 0.462 0 C-N-CA 117.497 -2.287 . . . . 0.0 109.603 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.517 ' HA ' ' O ' ' A' ' 30' ' ' ALA . . . -120.05 119.08 32.32 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 122.66 1.219 . . . . 0.0 112.505 -176.085 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.655 HD11 HG13 ' N' ' 39' ' ' VAL . 97.3 mt -127.45 132.29 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 113.971 -1.468 . . . . 0.0 111.097 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.602 HG22 HD11 ' C' ' 34' ' ' LEU . 23.1 mt -102.72 116.63 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -115.63 98.56 0.84 Allowed Glycine 0 C--O 1.237 0.287 0 N-CA-C 105.818 -2.913 . . . . 0.0 105.818 177.171 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -137.68 135.14 36.2 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 122.495 1.14 . . . . 0.0 112.558 -175.459 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 4.4 mtp -104.05 110.36 22.5 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 113.311 -1.768 . . . . 0.0 106.842 177.221 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.566 HG23 HG22 ' C' ' 36' ' ' VAL . 1.4 m -131.21 123.09 52.69 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.84 -113.4 0.66 Allowed Glycine 0 C--N 1.311 -0.84 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.61 -72.62 0.82 Allowed Glycine 0 CA--C 1.532 1.103 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' VAL . . . . . 0.564 HG21 ' CA ' ' H' ' 29' ' ' GLY . 3.7 p -144.58 157.48 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' B' ' 39' ' ' VAL . 20.4 m . . . . . 0 N--CA 1.473 0.686 0 CA-C-O 117.965 -1.017 . . . . 0.0 111.921 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -107.94 136.16 48.11 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -122.12 100.99 7.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.862 0.363 . . . . 0.0 110.323 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 12' ' ' VAL . . . . . 0.529 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 1.5 p -145.1 137.55 21.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.345 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' B' ' 11' ' ' GLU . 2.0 m-70 -147.22 135.31 21.47 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.116 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.653 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 32.8 m-70 -142.23 161.08 38.92 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.243 -0.583 . . . . 0.0 110.977 177.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -85.41 157.16 20.56 Favored 'General case' 0 CA--C 1.523 -0.09 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 176.109 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -159.22 91.94 1.05 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.387 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 17' ' ' LEU . . . . . 0.421 HD12 ' N ' ' C' ' 17' ' ' LEU . 5.2 mp -128.82 122.35 30.26 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.968 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 18' ' ' VAL . . . . . 0.722 HG22 HG22 ' B' ' 18' ' ' VAL . 3.9 m -124.48 120.79 59.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -113.47 108.16 16.82 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.317 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -110.59 122.01 46.72 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.41 125.72 33.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.914 0.864 . . . . 0.0 112.406 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 94.9 mt-10 -98.72 110.14 22.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 177.699 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.41 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 99.2 m-20 -140.45 49.26 1.72 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.618 -1.174 . . . . 0.0 111.2 -175.451 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 24' ' ' VAL . . . . . 0.556 HG12 ' N ' ' C' ' 25' ' ' GLY . 53.8 t -71.44 161.39 4.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 C-N-CA 119.339 -0.945 . . . . 0.0 109.901 -175.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 25' ' ' GLY . . . . . 0.556 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 109.46 -29.87 9.09 Favored Glycine 0 CA--C 1.531 1.031 0 N-CA-C 107.315 -2.314 . . . . 0.0 107.315 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 26' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 1.1 m 93.21 114.58 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 114.194 -1.003 . . . . 0.0 110.583 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -73.58 164.05 27.18 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.551 0.691 . . . . 0.0 112.266 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' D' ' 28' ' ' LYS . 98.9 mttt -48.01 -37.01 13.84 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 114.109 1.151 . . . . 0.0 114.109 178.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.85 77.21 0.06 OUTLIER Glycine 0 CA--C 1.536 1.367 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.971 -175.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.0 138.27 37.01 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 122.547 1.165 . . . . 0.0 113.478 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.574 HD11 HG22 ' O' ' 39' ' ' VAL . 94.1 mt -142.42 144.89 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 114.328 -1.305 . . . . 0.0 112.656 -178.763 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.551 HD13 ' CD1' ' E' ' 19' ' ' PHE . 75.6 mt -106.71 111.4 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 174.099 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.72 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -118.94 101.66 0.89 Allowed Glycine 0 N--CA 1.465 0.592 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 179.213 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.72 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.6 mp -141.9 148.01 38.02 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.954 1.359 . . . . 0.0 113.329 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -104.4 111.52 24.21 Favored 'General case' 0 N--CA 1.44 -0.925 0 CA-C-N 112.097 -2.319 . . . . 0.0 105.692 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.98 HG11 HD11 ' E' ' 17' ' ' LEU . 55.1 t -124.81 123.22 65.32 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.741 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -178.028 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.07 -113.31 0.77 Allowed Glycine 0 C--N 1.312 -0.794 0 C-N-CA 119.75 -1.214 . . . . 0.0 111.958 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.78 -73.01 2.68 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 39' ' ' VAL . . . . . 0.652 ' HB ' HD11 ' I' ' 31' ' ' ILE . 13.6 p -172.79 132.92 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.555 ' CG2' ' NE2' ' F' ' 13' ' ' HIS . 21.4 m . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.776 -1.107 . . . . 0.0 110.043 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.482 HG23 HG23 ' C' ' 12' ' ' VAL . 20.3 m . . . . . 0 N--CA 1.466 0.329 0 CA-C-O 121.231 0.539 . . . . 0.0 111.218 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.498 ' O ' ' CG ' ' E' ' 13' ' ' HIS . 19.1 m-70 -140.07 135.6 32.76 Favored 'General case' 0 C--O 1.225 -0.194 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.032 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.653 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 1.3 t-80 -136.88 156.0 49.04 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.649 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.568 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 6.9 tt0 -87.55 157.15 19.23 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -162.45 92.93 0.83 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.674 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.407 ' HB3' ' CZ ' ' D' ' 19' ' ' PHE . 23.3 mt -122.39 114.17 20.37 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.315 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.9 t -110.64 109.18 27.5 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.534 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.407 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 66.0 m-85 -109.62 107.37 17.42 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -122.24 131.58 54.0 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-O 120.737 0.303 . . . . 0.0 111.544 -177.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.06 140.01 32.44 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 122.033 0.921 . . . . 0.0 112.998 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -82.03 113.87 20.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 122.039 0.923 . . . . 0.0 111.372 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.546 ' H ' ' HB3' ' E' ' 22' ' ' GLU . 54.4 m-20 50.17 46.42 24.77 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 113.551 -1.659 . . . . 0.0 112.267 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 24' ' ' VAL . . . . . 0.707 HG12 ' N ' ' D' ' 25' ' ' GLY . 96.4 t -111.62 177.64 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 104.719 -2.326 . . . . 0.0 104.719 174.437 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 25' ' ' GLY . . . . . 0.707 ' N ' HG12 ' D' ' 24' ' ' VAL . . . 63.02 28.69 72.49 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 178.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 48.9 m -108.67 -120.01 0.26 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.794 0.807 . . . . 0.0 112.498 -177.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -79.94 174.05 11.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.338 -178.496 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' C' ' 28' ' ' LYS . 99.1 mttt 58.32 39.91 25.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 113.998 1.11 . . . . 0.0 113.998 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.11 70.99 0.95 Allowed Glycine 0 N--CA 1.477 1.422 0 C-N-CA 119.031 -1.557 . . . . 0.0 116.346 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.0 109.08 15.08 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.365 0.602 . . . . 0.0 109.917 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.565 HD11 HG23 ' P' ' 39' ' ' VAL . 2.1 mt -133.57 141.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 N-CA-C 114.101 1.148 . . . . 0.0 114.101 -177.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.578 HD13 ' CD1' ' F' ' 19' ' ' PHE . 6.4 mt -108.69 113.9 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.481 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.91 102.97 1.27 Allowed Glycine 0 C--O 1.24 0.511 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 177.469 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.459 HD23 HG13 ' D' ' 36' ' ' VAL . 10.5 tp -133.93 134.51 42.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 122.181 0.991 . . . . 0.0 112.877 -176.725 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -105.17 112.36 25.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 113.445 -1.707 . . . . 0.0 107.304 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' E' ' 37' ' ' GLY . 0.4 OUTLIER -114.17 177.06 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.165 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.414 ' HA3' ' H ' ' E' ' 37' ' ' GLY . . . 131.53 -96.29 0.33 Allowed Glycine 0 C--N 1.31 -0.877 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 38' ' ' GLY . . . . . 0.496 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 38.17 75.92 0.08 OUTLIER Glycine 0 CA--C 1.533 1.207 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.056 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.563 ' CG2' HD11 ' J' ' 31' ' ' ILE . 60.4 t -6.35 123.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -178.01 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.509 ' O ' ' NZ ' ' K' ' 28' ' ' LYS . 55.3 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.455 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -81.81 138.98 35.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -136.28 140.61 43.55 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.029 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.434 ' H ' HG12 ' D' ' 12' ' ' VAL . 70.4 t -124.35 124.97 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 110.465 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.607 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.5 OUTLIER -156.4 134.75 11.44 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 179.387 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.607 ' N ' ' ND1' ' E' ' 13' ' ' HIS . 34.8 m-70 -143.52 167.38 22.35 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.73 0.3 . . . . 0.0 110.464 179.256 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.63 ' NE2' HG12 ' C' ' 36' ' ' VAL . 34.4 tt0 -89.64 151.3 21.97 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 177.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 14.3 mttt -153.35 98.73 2.29 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.011 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.98 HD11 HG11 ' C' ' 36' ' ' VAL . 2.9 mt -121.84 116.13 23.88 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 178.39 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -111.21 101.54 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.551 ' CD1' HD13 ' C' ' 32' ' ' ILE . 41.2 m-85 -106.75 102.65 12.01 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.171 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -122.49 132.99 54.59 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-O 121.229 0.537 . . . . 0.0 112.225 -178.357 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -138.77 145.34 40.08 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.42 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.546 ' HB3' ' H ' ' D' ' 23' ' ' ASP . 79.5 tt0 -68.73 147.16 52.21 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 117.574 -1.65 . . . . 0.0 108.804 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.534 ' O ' ' O ' ' E' ' 24' ' ' VAL . 21.2 t70 -128.05 61.6 1.44 Allowed 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.083 -174.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' E' ' 23' ' ' ASP . 4.7 t -33.64 -110.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.318 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -113.4 46.49 1.16 Allowed Glycine 0 N--CA 1.485 1.952 0 CA-C-N 120.173 1.351 . . . . 0.0 115.421 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.515 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.8 t 91.56 111.5 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 122.318 0.247 . . . . 0.0 111.378 176.204 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -75.35 163.88 27.0 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.644 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.88 -39.41 25.76 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.13 0.04 OUTLIER Glycine 0 CA--C 1.544 1.849 0 C-N-CA 120.159 -1.02 . . . . 0.0 113.312 -176.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.76 145.17 50.6 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.333 1.566 . . . . 0.0 111.727 -177.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.499 HG23 HG23 ' D' ' 31' ' ' ILE . 1.3 tt -131.72 141.75 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 CA-C-O 121.675 0.75 . . . . 0.0 111.968 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 94.5 mt -124.98 131.43 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.78 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.56 117.2 2.72 Favored Glycine 0 CA--C 1.533 1.182 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 36.5 mt -123.55 122.81 39.14 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.236 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.0 mmm -119.73 129.18 54.39 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.468 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 54.2 t -94.15 135.05 29.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.985 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' D' ' 36' ' ' VAL . . . -99.9 -103.42 2.51 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -63.27 75.12 0.04 OUTLIER Glycine 0 CA--C 1.534 1.229 0 CA-C-N 113.891 -1.155 . . . . 0.0 112.48 179.591 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.505 HG11 ' H ' ' F' ' 39' ' ' VAL . 8.8 m . . . . . 0 CA--C 1.541 0.607 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.736 0.303 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.481 HG12 ' NE2' ' E' ' 14' ' ' HIS . 2.6 t -108.22 106.02 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.839 0.352 . . . . 0.0 110.471 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.587 ' ND1' ' N ' ' F' ' 14' ' ' HIS . 17.1 t-80 -152.97 139.89 19.12 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.587 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 81.0 t60 -150.52 168.64 23.61 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.833 178.18 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.49 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 18.1 tt0 -89.56 150.35 22.46 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -151.82 96.35 2.22 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.195 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.431 HD22 HG11 ' D' ' 36' ' ' VAL . 0.3 OUTLIER -116.84 109.74 17.47 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.273 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -108.58 106.27 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.578 ' CD1' HD13 ' D' ' 32' ' ' ILE . 44.3 m-85 -109.04 107.35 17.66 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.475 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 9.2 m-85 -146.63 140.69 26.21 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 118.29 -1.364 . . . . 0.0 114.063 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.517 ' HB1' ' HB2' ' E' ' 23' ' ' ASP . . . -114.86 119.34 36.26 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.649 -2.723 . . . . 0.0 103.649 174.836 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -95.09 134.49 37.74 Favored 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 117.533 2.42 . . . . 0.0 117.533 -172.614 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 24.4 p-10 . . . . . 0 C--N 1.348 0.525 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.598 173.427 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.19 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.525 HD12 HG12 ' R' ' 39' ' ' VAL . 14.6 tt -129.61 137.83 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.451 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -132.66 140.45 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.57 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.47 124.43 3.68 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 34' ' ' LEU . . . . . 0.432 HD23 ' C ' ' F' ' 34' ' ' LEU . 9.3 tt -130.69 127.15 38.27 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.8 mtp -139.33 145.4 39.02 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.437 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 6.3 p -144.59 146.07 20.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.11 177.436 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.45 102.11 0.37 Allowed Glycine 0 C--N 1.319 -0.368 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.172 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.6 -73.56 0.3 Allowed Glycine 0 CA--C 1.536 1.381 0 C-N-CA 120.454 -0.879 . . . . 0.0 113.96 176.553 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.598 HG12 ' N ' ' F' ' 40' ' ' VAL . 99.1 t -146.82 163.31 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.998 0.428 . . . . 0.0 110.443 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 40' ' ' VAL . . . . . 0.598 ' N ' HG12 ' F' ' 39' ' ' VAL . 8.0 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.896 -1.049 . . . . 0.0 110.334 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 99.4 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 121.174 0.511 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -103.89 158.52 16.35 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.742 -179.596 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.618 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 18.6 t60 -85.62 166.97 15.78 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.718 -179.569 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.618 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 83.6 mt-30 -155.29 141.81 18.74 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.169 0.509 . . . . 0.0 110.357 178.184 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.629 ' C ' HD12 ' G' ' 17' ' ' LEU . 99.0 mttt -88.03 110.16 20.4 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.743 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.629 HD12 ' C ' ' G' ' 16' ' ' LYS . 11.3 mp -120.42 112.91 19.58 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.404 HG22 ' CG2' ' H' ' 18' ' ' VAL . 61.8 t -125.74 131.32 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.155 -178.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.68 128.25 42.17 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.469 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -128.29 126.78 41.49 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.402 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.75 122.61 38.52 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.706 0.765 . . . . 0.0 112.012 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -121.56 133.25 55.01 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.536 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.718 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 98.3 m-20 . . . . . 0 C--N 1.32 -0.677 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.181 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.522 ' OD1' ' NZ ' ' H' ' 28' ' ' LYS . 71.6 m-20 . . . . . 0 N--CA 1.466 0.344 0 CA-C-O 121.057 0.456 . . . . 0.0 111.541 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm 51.12 39.22 22.92 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.24 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.25 -66.67 1.59 Allowed Glycine 0 CA--C 1.539 1.565 0 C-N-CA 120.158 -1.02 . . . . 0.0 110.68 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' H' ' 30' ' ' ALA . . . -150.7 62.32 0.93 Allowed 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 119.593 1.696 . . . . 0.0 114.605 177.232 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 80.6 mt -136.45 113.44 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 176.246 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.445 ' O ' ' O ' ' H' ' 33' ' ' GLY . 96.4 mt -107.87 106.2 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.606 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.03 97.17 0.94 Allowed Glycine 0 CA--C 1.508 -0.357 0 N-CA-C 104.95 -3.26 . . . . 0.0 104.95 176.393 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.833 ' O ' HD12 ' H' ' 34' ' ' LEU . 52.4 tp -155.63 154.39 31.54 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 118.188 -1.405 . . . . 0.0 113.361 -175.152 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 8.1 mtp -112.11 122.47 47.83 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-N 112.989 -1.914 . . . . 0.0 108.655 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.704 HG21 ' CD1' ' I' ' 17' ' ' LEU . 35.9 m -131.32 112.07 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.025 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.69 -132.07 10.94 Favored Glycine 0 CA--C 1.519 0.303 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.53 -62.64 0.42 Allowed Glycine 0 CA--C 1.536 1.37 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 t -92.78 164.41 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 40' ' ' VAL . . . . . 0.552 ' N ' ' CG2' ' H' ' 39' ' ' VAL . 8.5 p . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.991 -1.005 . . . . 0.0 110.585 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.196 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 44.3 t80 -71.38 133.5 46.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.906 0.384 . . . . 0.0 110.587 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -94.29 115.62 27.89 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.388 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.15 136.09 32.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.338 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.501 ' NE2' ' OE2' ' I' ' 11' ' ' GLU . 81.0 m80 -113.4 149.54 33.98 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 9.6 p-80 -86.82 164.15 16.82 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.983 -179.376 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -100.81 152.6 20.32 Favored 'General case' 0 CA--C 1.522 -0.098 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.837 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -110.84 107.86 17.49 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 177.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -123.16 117.38 25.24 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.404 ' CG2' HG22 ' G' ' 18' ' ' VAL . 12.9 m -132.14 133.76 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.132 0.491 . . . . 0.0 111.033 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -129.91 129.65 44.14 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.559 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.408 ' CE2' ' CG ' ' I' ' 20' ' ' PHE . 29.2 m-85 -127.43 131.57 50.22 Favored 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.465 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.19 122.38 31.73 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 82.6 tt0 -147.17 121.67 9.73 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 114.621 1.341 . . . . 0.0 114.621 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.718 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 1.7 p-10 156.24 -74.5 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.379 175.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.741 HG22 ' N ' ' H' ' 25' ' ' GLY . 3.6 p -67.53 -112.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.713 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 25' ' ' GLY . . . . . 0.741 ' N ' HG22 ' H' ' 24' ' ' VAL . . . 126.39 -38.76 2.14 Favored Glycine 0 N--CA 1.454 -0.128 0 CA-C-N 113.866 -1.516 . . . . 0.0 111.133 176.545 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 16.2 t -70.4 112.7 6.89 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 174.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -113.68 168.54 9.69 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.815 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 28' ' ' LYS . . . . . 0.537 ' HB3' ' H ' ' A' ' 40' ' ' VAL . 99.2 mttt -39.39 -38.42 0.55 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.618 -1.173 . . . . 0.0 111.091 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 29' ' ' GLY . . . . . 0.564 ' CA ' HG21 ' B' ' 39' ' ' VAL . . . 179.72 77.08 0.06 OUTLIER Glycine 0 CA--C 1.535 1.314 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.909 -176.711 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' I' ' 30' ' ' ALA . . . -51.49 91.14 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 119.131 1.466 . . . . 0.0 112.157 -177.182 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.402 ' N ' ' O ' ' H' ' 29' ' ' GLY . 96.8 mt -134.21 138.63 49.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.135 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.571 HD13 ' CD1' ' J' ' 19' ' ' PHE . 96.8 mt -108.32 104.95 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 177.867 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -105.13 97.09 1.29 Allowed Glycine 0 N--CA 1.461 0.3 0 N-CA-C 104.565 -3.414 . . . . 0.0 104.565 176.015 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.833 HD12 ' O ' ' G' ' 34' ' ' LEU . 15.2 tp -143.09 136.43 28.29 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 118.731 -1.187 . . . . 0.0 113.044 -174.081 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.8 mtp -105.18 118.82 37.52 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 113.176 -1.829 . . . . 0.0 106.845 178.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.576 HG12 ' CD ' ' J' ' 15' ' ' GLN . 10.9 t -130.03 102.62 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -177.346 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.43 -162.49 12.38 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.16 -55.44 0.52 Allowed Glycine 0 CA--C 1.542 1.747 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 1.085 HG12 HD12 ' N' ' 31' ' ' ILE . 1.8 m -127.99 161.57 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.45 ' OXT' ' O ' ' O' ' 28' ' ' LYS . 46.6 t . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.012 177.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.93 135.45 48.46 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.793 0.33 . . . . 0.0 110.367 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 11' ' ' GLU . . . . . 0.501 ' OE2' ' NE2' ' H' ' 13' ' ' HIS . 97.3 mt-10 -74.35 109.4 7.8 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.475 ' CG2' ' O ' ' J' ' 12' ' ' VAL . 23.2 m -139.27 159.79 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.942 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.477 ' CD2' ' OXT' ' G' ' 40' ' ' VAL . 78.0 m80 -69.78 114.25 7.8 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.611 -178.116 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 13.2 t60 -161.9 169.98 20.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.273 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.645 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 7.0 tt0 -156.27 140.28 16.34 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 120.191 -0.603 . . . . 0.0 110.4 177.053 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -97.92 113.94 25.9 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 178.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.704 ' CD1' HG21 ' G' ' 36' ' ' VAL . 58.8 mt -121.98 114.22 20.66 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.4 t -116.41 109.68 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.444 ' CD1' HD13 ' G' ' 32' ' ' ILE . 74.1 m-85 -108.01 106.44 16.67 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.408 ' CG ' ' CE2' ' H' ' 20' ' ' PHE . 35.3 t80 -120.6 132.97 55.4 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -176.316 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 21' ' ' ALA . . . . . 0.66 ' HB3' HG21 ' I' ' 24' ' ' VAL . . . -149.7 146.5 27.27 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-O 121.63 0.729 . . . . 0.0 112.651 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.422 ' OE2' ' OE2' ' H' ' 22' ' ' GLU . 77.9 mt-10 -103.88 151.55 22.99 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.837 178.891 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.602 ' N ' ' O ' ' J' ' 22' ' ' GLU . 71.4 m-20 57.47 48.79 13.93 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.14 0.495 . . . . 0.0 110.405 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.662 HG23 ' HB1' ' J' ' 21' ' ' ALA . 0.1 OUTLIER -137.4 -173.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-O 121.66 0.743 . . . . 0.0 110.824 -177.23 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 28.2 67.67 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -177.529 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.538 ' HB2' HG21 ' J' ' 24' ' ' VAL . 71.3 m -143.56 -128.18 0.09 Allowed 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.548 ' CG ' ' H ' ' I' ' 28' ' ' LYS . 50.5 t30 54.38 -159.48 0.17 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 178.704 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.548 ' H ' ' CG ' ' I' ' 27' ' ' ASN . 64.1 mttp -64.46 -39.61 94.14 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.46 1.652 . . . . 0.0 115.46 -173.309 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.31 66.31 0.25 Allowed Glycine 0 N--CA 1.472 1.067 0 C-N-CA 118.52 -1.8 . . . . 0.0 114.616 -175.127 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' H' ' 30' ' ' ALA . . . -82.7 131.95 35.19 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 122.156 0.979 . . . . 0.0 112.111 -178.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.652 HD11 ' HB ' ' C' ' 39' ' ' VAL . 50.5 mt -144.05 143.4 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 114.447 -1.251 . . . . 0.0 113.585 -177.036 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.421 HD12 HG12 ' J' ' 32' ' ' ILE . 54.1 mt -105.15 101.99 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 173.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -103.62 98.5 1.61 Allowed Glycine 0 CA--C 1.507 -0.452 0 N-CA-C 104.913 -3.275 . . . . 0.0 104.913 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.596 HD12 ' O ' ' H' ' 34' ' ' LEU . 23.7 tp -140.13 135.12 32.17 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 122.287 1.041 . . . . 0.0 113.281 -173.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.408 ' N ' HD12 ' I' ' 34' ' ' LEU . 5.9 mtp -109.43 117.66 34.61 Favored 'General case' 0 CA--C 1.512 -0.484 0 CA-C-N 113.612 -1.631 . . . . 0.0 107.205 177.533 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.565 HG11 HD11 ' K' ' 17' ' ' LEU . 4.4 t -130.42 111.82 21.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 CA-C-O 120.624 0.25 . . . . 0.0 110.736 -177.429 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.33 -131.07 5.23 Favored Glycine 0 C--N 1.318 -0.434 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.144 177.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.05 -61.76 0.39 Allowed Glycine 0 CA--C 1.543 1.828 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 39' ' ' VAL . . . . . 0.746 HG21 ' HA2' ' O' ' 29' ' ' GLY . 4.0 p -146.21 151.25 14.59 Favored 'Isoleucine or valine' 0 C--N 1.344 0.339 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 175.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.506 HG23 ' O ' ' I' ' 39' ' ' VAL . 58.6 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.753 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.62 133.04 51.01 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.928 0.394 . . . . 0.0 110.732 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -85.18 125.29 32.71 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.912 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.483 ' CG1' ' NE2' ' J' ' 14' ' ' HIS . 96.0 t -125.82 108.64 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.621 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -111.78 124.38 52.22 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.257 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.883 ' HD1' ' H ' ' K' ' 14' ' ' HIS . 47.1 m-70 -148.67 162.9 38.8 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 120.29 -0.564 . . . . 0.0 109.735 174.34 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.576 ' CD ' HG12 ' H' ' 36' ' ' VAL . 85.0 mt-30 -100.69 147.17 26.31 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.114 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 13.8 mttt -118.34 92.37 3.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.589 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.895 HD12 HD22 ' K' ' 17' ' ' LEU . 6.9 mt -117.24 115.54 25.5 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.693 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.7 t -113.5 102.38 13.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.571 ' CD1' HD13 ' H' ' 32' ' ' ILE . 64.6 m-85 -104.05 107.09 17.83 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 178.222 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.567 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -121.95 124.07 43.17 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.622 -176.321 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 21' ' ' ALA . . . . . 0.662 ' HB1' HG23 ' I' ' 24' ' ' VAL . . . -136.27 115.48 12.52 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' I' ' 23' ' ' ASP . 98.0 mt-10 -120.18 177.74 4.9 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 118.333 2.716 . . . . 0.0 118.333 -174.85 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 41.5 t0 28.62 46.31 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 119.946 3.313 . . . . 0.0 119.946 175.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.656 HG22 ' N ' ' I' ' 24' ' ' VAL . 0.2 OUTLIER -80.57 -179.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 175.105 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.05 -29.23 69.18 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 118.126 -1.988 . . . . 0.0 112.274 -178.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.421 ' O ' ' C ' ' J' ' 27' ' ' ASN . 1.5 t 168.16 127.24 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.813 0.807 . . . . 0.0 112.079 175.473 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.59 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 50.7 t30 -37.21 133.94 0.63 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.733 174.851 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' I' ' 27' ' ' ASN . 67.6 mttm -109.27 -40.27 4.98 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 118.969 0.804 . . . . 0.0 111.118 177.285 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.45 64.35 0.24 Allowed Glycine 0 CA--C 1.541 1.718 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.924 -178.482 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.7 143.26 30.15 Favored 'General case' 0 C--O 1.245 0.855 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -177.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.563 HD11 ' CG2' ' D' ' 39' ' ' VAL . 79.9 mt -135.78 131.0 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 114.832 -1.076 . . . . 0.0 111.677 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.425 ' O ' HG22 ' J' ' 32' ' ' ILE . 3.0 mt -106.22 110.36 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 176.275 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 99.0 1.06 Allowed Glycine 0 C--O 1.239 0.441 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 177.018 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.546 HD12 ' O ' ' I' ' 34' ' ' LEU . 24.3 tp -134.93 123.59 23.62 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.414 1.102 . . . . 0.0 113.697 -175.612 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.43 ' N ' HD12 ' J' ' 34' ' ' LEU . 2.2 ttm -98.29 116.69 31.05 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 176.367 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.518 HG21 HD23 ' L' ' 17' ' ' LEU . 0.5 OUTLIER -130.11 103.3 8.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 C-N-CA 121.365 -0.134 . . . . 0.0 111.049 -177.434 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.22 -153.72 25.23 Favored Glycine 0 CA--C 1.509 -0.283 0 C-N-CA 120.035 -1.079 . . . . 0.0 112.358 178.18 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.493 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 138.73 -56.31 0.65 Allowed Glycine 0 CA--C 1.544 1.898 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.787 -178.555 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 39' ' ' VAL . . . . . 0.53 HG12 ' N ' ' J' ' 40' ' ' VAL . 87.8 t -135.93 157.89 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.059 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 40' ' ' VAL . . . . . 0.53 ' N ' HG12 ' J' ' 39' ' ' VAL . 17.3 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.528 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -108.85 146.54 33.52 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.854 0.359 . . . . 0.0 110.561 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -70.32 128.81 37.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -111.94 121.05 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.785 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.628 ' CE1' ' NZ ' ' P' ' 28' ' ' LYS . 6.6 p80 -151.59 113.72 4.51 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.377 -0.529 . . . . 0.0 112.027 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.883 ' H ' ' HD1' ' J' ' 14' ' ' HIS . 21.0 p80 -153.34 160.31 42.65 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.389 177.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.55 ' NE2' ' OE1' ' L' ' 15' ' ' GLN . 33.3 mt-30 -90.12 160.08 16.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.213 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -139.42 109.38 6.37 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.457 0.646 . . . . 0.0 109.902 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.895 HD22 HD12 ' J' ' 17' ' ' LEU . 1.1 mt -118.55 122.41 42.58 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.865 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 16.7 t -113.49 101.05 11.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -100.79 102.67 13.8 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 105.232 -2.136 . . . . 0.0 105.232 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CD1' ' L' ' 20' ' ' PHE . 1.4 t80 -113.4 124.96 53.66 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -177.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' K' ' 23' ' ' ASP . . . -160.76 162.78 32.51 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 -177.642 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -72.36 136.83 46.25 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.163 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.729 ' CG ' ' HB1' ' L' ' 21' ' ' ALA . 6.4 m-20 -152.5 61.03 0.82 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.987 1.477 . . . . 0.0 114.987 -173.403 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.669 ' O ' ' O ' ' K' ' 23' ' ' ASP . 34.4 t -44.16 -110.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' K' ' 27' ' ' ASN . . . 162.82 -46.51 0.33 Allowed Glycine 0 CA--C 1.506 -0.519 0 C-N-CA 116.707 -2.663 . . . . 0.0 115.781 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m -65.99 101.56 0.69 Allowed 'General case' 0 CA--C 1.519 -0.25 0 CA-C-N 123.605 3.702 . . . . 0.0 104.373 178.539 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.59 ' ND2' ' O ' ' J' ' 27' ' ' ASN . 7.4 m120 -130.04 161.4 31.08 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 114.847 -1.069 . . . . 0.0 112.455 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.509 ' NZ ' ' O ' ' D' ' 40' ' ' VAL . 61.3 tttt -28.71 -39.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.833 172.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . 141.75 73.81 0.04 OUTLIER Glycine 0 CA--C 1.545 1.914 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.103 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.44 150.03 46.63 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 121.804 0.811 . . . . 0.0 112.681 -177.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.418 ' CG1' HG22 ' L' ' 31' ' ' ILE . 2.6 mp -136.42 138.26 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 CA-C-N 114.689 -1.141 . . . . 0.0 112.78 -177.783 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -117.68 119.99 63.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 178.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.46 117.41 3.31 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 67.7 mt -123.47 129.18 50.86 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 73.2 mtp -137.61 136.68 37.75 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.365 -0.934 . . . . 0.0 113.061 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.495 ' HB ' HG13 ' L' ' 36' ' ' VAL . 10.8 t -113.31 155.27 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.149 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -52.25 -102.34 0.01 OUTLIER Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' L' ' 38' ' ' GLY . . . -138.03 -74.6 0.06 OUTLIER Glycine 0 CA--C 1.527 0.792 0 C-N-CA 120.823 -0.704 . . . . 0.0 113.177 178.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 39' ' ' VAL . . . . . 0.74 HG13 HD11 ' Q' ' 31' ' ' ILE . 6.6 m . . . . . 0 CA--C 1.514 -0.428 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.428 -178.698 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 N--CA 1.465 0.293 0 CA-C-O 120.634 0.254 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 91.1 t -111.91 101.41 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 121.265 0.555 . . . . 0.0 110.877 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.481 ' O ' ' CG ' ' L' ' 14' ' ' HIS . 5.0 p80 -147.2 90.82 1.92 Allowed 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.639 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.481 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 69.3 m80 -158.19 168.31 27.42 Favored 'General case' 0 C--O 1.223 -0.295 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.55 ' OE1' ' NE2' ' K' ' 15' ' ' GLN . 94.8 mm-40 -89.84 158.45 17.46 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.71 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -139.92 105.27 5.06 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.465 0.65 . . . . 0.0 110.492 178.583 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.518 HD23 HG21 ' J' ' 36' ' ' VAL . 0.2 OUTLIER -116.16 113.9 23.73 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.695 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -106.79 103.85 16.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -99.78 101.71 12.94 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.574 ' CD1' ' CZ ' ' K' ' 20' ' ' PHE . 15.1 t80 -110.04 103.13 11.83 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.729 ' HB1' ' CG ' ' K' ' 23' ' ' ASP . . . -132.87 137.31 46.64 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 -178.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.525 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.9 mt-10 -78.62 102.77 8.15 Favored 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 118.879 -1.128 . . . . 0.0 108.636 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 44.2 p-10 -155.77 46.62 0.48 Allowed 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 112.786 0.661 . . . . 0.0 112.786 -177.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 32.9 m -83.22 172.69 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 118.819 -1.152 . . . . 0.0 109.788 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 96.02 -28.68 11.86 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.9 t 91.68 119.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.533 ' O ' ' N ' ' L' ' 29' ' ' GLY . 15.4 m-20 -71.95 150.3 44.24 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.221 -179.013 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -53.17 47.45 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 101.77 63.38 0.75 Allowed Glycine 0 CA--C 1.543 1.799 0 C-N-CA 119.928 -1.129 . . . . 0.0 114.088 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.63 169.46 10.06 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 178.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.418 HG22 ' CG1' ' K' ' 31' ' ' ILE . 12.6 tt -139.8 151.03 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.16 0 C-N-CA 119.008 -1.077 . . . . 0.0 113.626 -177.197 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 15.0 tt -135.48 134.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.152 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.64 134.22 6.52 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.315 -0.469 . . . . 0.0 111.971 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tt -127.25 124.72 39.51 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mtp -140.86 146.58 37.7 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -177.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.495 HG13 ' HB ' ' K' ' 36' ' ' VAL . 8.8 t -139.33 132.13 37.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.463 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -106.97 112.42 3.76 Favored Glycine 0 N--CA 1.468 0.794 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.023 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 38' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . 112.52 71.25 0.58 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 117.522 0.661 . . . . 0.0 112.477 178.804 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 39' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' L' ' 38' ' ' GLY . 66.2 t . . . . . 0 N--CA 1.478 0.956 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 . . . . . 0 N--CA 1.46 0.046 0 N-CA-C 110.154 -0.314 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' M' M ' 12' ' ' VAL . . . . . 0.42 HG23 ' O ' ' M' ' 12' ' ' VAL . 29.0 m -114.9 130.13 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.95 0.405 . . . . 0.0 110.714 -179.6 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 75.6 m80 -95.06 165.8 12.25 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 14' ' ' HIS . . . . . 0.481 ' CD2' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -86.47 168.0 14.15 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.498 -179.36 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -129.17 150.72 50.44 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.108 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -97.62 120.91 38.85 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.595 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.29 115.3 20.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -140.34 140.59 34.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.383 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -143.18 141.32 31.11 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.095 0.474 . . . . 0.0 110.674 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 20' ' ' PHE . . . . . 0.484 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 53.1 p90 -127.4 128.38 45.73 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.66 127.41 46.24 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.329 0.585 . . . . 0.0 111.378 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -138.67 146.34 41.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.94 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 58.47 59.84 2.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.44 . . . . 0.0 112.173 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 24' ' ' VAL . . . . . 0.765 HG12 ' H ' ' M' ' 25' ' ' GLY . 4.1 t 70.59 175.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.514 0.673 . . . . 0.0 111.732 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 25' ' ' GLY . . . . . 0.765 ' H ' HG12 ' M' ' 24' ' ' VAL . . . 100.65 -34.72 5.35 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.948 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 6.1 p -82.92 -121.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 176.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 27' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' M' ' 31' ' ' ILE . 8.9 p30 -92.42 161.21 14.74 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 176.403 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 28' ' ' LYS . . . . . 0.413 ' O ' ' CD ' ' N' ' 28' ' ' LYS . 72.8 tttt -45.29 -39.2 6.32 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 119.139 -1.025 . . . . 0.0 110.517 -179.403 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 29' ' ' GLY . . . . . 0.445 ' O ' ' OD2' ' N' ' 23' ' ' ASP . . . -146.9 -76.18 0.02 OUTLIER Glycine 0 N--CA 1.473 1.11 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.893 177.784 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.76 87.81 0.82 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-O 121.129 0.49 . . . . 0.0 111.611 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 31' ' ' ILE . . . . . 0.658 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -138.33 115.56 11.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 32' ' ' ILE . . . . . 0.42 HD13 HG21 ' M' ' 32' ' ' ILE . 43.1 mt -107.09 109.37 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.88 92.46 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 105.886 -2.885 . . . . 0.0 105.886 177.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -143.56 167.16 22.87 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 114.927 1.455 . . . . 0.0 114.927 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -123.45 106.58 10.75 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 112.108 -2.315 . . . . 0.0 107.062 177.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 36' ' ' VAL . . . . . 0.551 HG21 HD21 ' O' ' 17' ' ' LEU . 43.9 t -112.46 111.97 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 CA-C-O 121.264 0.554 . . . . 0.0 109.835 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.42 -131.7 7.74 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' M' M ' 38' ' ' GLY . . . . . 0.492 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 94.47 -63.27 1.66 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.786 -1.325 . . . . 0.0 109.786 -178.289 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 39' ' ' VAL . . . . . 0.436 HG22 ' H ' ' M' ' 39' ' ' VAL . 4.7 m -96.65 173.51 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' M' M ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' N' ' 40' ' ' VAL . 26.8 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.938 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -106.42 134.8 49.0 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.764 0.316 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -114.97 119.71 37.43 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.796 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 12' ' ' VAL . . . . . 0.415 ' CG1' ' HE2' ' N' ' 14' ' ' HIS . 58.8 t -126.96 131.4 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -142.32 130.27 21.83 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.443 0.64 . . . . 0.0 112.63 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 14' ' ' HIS . . . . . 0.513 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 33.0 m-70 -153.1 172.39 16.97 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.218 177.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -155.18 141.0 18.15 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.821 -0.751 . . . . 0.0 109.741 177.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -88.53 113.66 24.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.161 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 17' ' ' LEU . . . . . 0.418 ' N ' HD12 ' N' ' 17' ' ' LEU . 8.3 mp -111.24 113.1 25.36 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.245 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.12 132.16 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-O 120.891 0.377 . . . . 0.0 111.35 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -141.23 127.45 19.69 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.956 0.408 . . . . 0.0 111.835 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -117.23 131.58 56.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.254 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.29 133.23 34.75 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -122.02 145.31 48.26 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.359 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' M' ' 29' ' ' GLY . 51.6 m-20 -160.94 46.68 0.21 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.918 0.39 . . . . 0.0 111.161 -178.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 m -73.35 -179.79 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.74 0.781 . . . . 0.0 111.99 -178.232 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.17 -35.33 4.76 Favored Glycine 0 CA--C 1.53 0.99 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.95 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' N' ' 27' ' ' ASN . 84.8 p -162.56 117.04 1.79 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 118.061 0.931 . . . . 0.0 110.874 176.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' N' ' 26' ' ' SER . 55.6 p30 -21.63 161.73 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 28' ' ' LYS . . . . . 0.454 ' CG ' ' O ' ' N' ' 27' ' ' ASN . 60.5 mttm -158.61 -10.3 0.07 Allowed 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 120.389 -0.524 . . . . 0.0 112.405 174.861 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.36 118.12 0.64 Allowed Glycine 0 CA--C 1.537 1.408 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.631 178.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 30' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' O' ' 29' ' ' GLY . . . -102.91 113.33 26.7 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-O 121.599 0.714 . . . . 0.0 111.98 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 31' ' ' ILE . . . . . 1.085 HD12 HG12 ' H' ' 39' ' ' VAL . 81.4 mt -135.5 131.05 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 32' ' ' ILE . . . . . 0.608 HD13 ' CD1' ' P' ' 19' ' ' PHE . 92.8 mt -107.08 111.04 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.01 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -116.0 105.6 1.42 Allowed Glycine 0 C--N 1.322 -0.234 0 N-CA-C 105.217 -3.153 . . . . 0.0 105.217 176.672 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 34' ' ' LEU . . . . . 0.633 ' O ' HD12 ' O' ' 34' ' ' LEU . 7.0 tt -152.77 140.75 20.23 Favored 'General case' 0 CA--C 1.504 -0.8 0 C-N-CA 117.953 -1.499 . . . . 0.0 111.747 -174.551 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 45.3 mtp -114.29 116.02 28.32 Favored 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.664 -1.607 . . . . 0.0 107.825 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -93.65 102.84 14.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 37' ' ' GLY . . . . . 0.492 ' HA3' ' H ' ' M' ' 38' ' ' GLY . . . -35.38 152.74 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.121 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 38' ' ' GLY . . . . . 0.563 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -85.28 -57.55 2.21 Favored Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.837 -0.697 . . . . 0.0 114.326 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 39' ' ' VAL . . . . . 0.655 HG13 HD11 ' B' ' 31' ' ' ILE . 6.1 m -52.85 140.97 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 119.42 1.61 . . . . 0.0 110.812 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' N' N ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' M' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.552 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -106.53 127.24 53.16 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 11' ' ' GLU . . . . . 0.472 ' O ' ' NE2' ' P' ' 13' ' ' HIS . 97.4 mt-10 -146.7 158.96 44.02 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.809 0.337 . . . . 0.0 111.01 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 12' ' ' VAL . . . . . 0.418 HG12 ' CE1' ' N' ' 14' ' ' HIS . 55.2 t -129.53 118.3 45.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.659 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 27.8 m80 -134.36 137.56 44.23 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 14' ' ' HIS . . . . . 0.698 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 66.2 t60 -151.12 153.2 34.57 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 119.027 -1.069 . . . . 0.0 112.278 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 15.2 tp60 -87.83 158.8 18.65 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.263 0.625 . . . . 0.0 110.791 177.472 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 16' ' ' LYS . . . . . 0.602 ' C ' HD12 ' O' ' 17' ' ' LEU . 71.5 tttt -159.09 95.21 1.25 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.252 176.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 17' ' ' LEU . . . . . 0.602 HD12 ' C ' ' O' ' 16' ' ' LYS . 8.2 mp -116.45 127.16 54.34 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.283 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -127.23 107.04 16.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.91 113.23 25.43 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 20' ' ' PHE . . . . . 0.481 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 45.8 t80 -111.77 121.53 45.32 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.19 136.91 47.38 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 122.065 0.936 . . . . 0.0 112.492 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 22' ' ' GLU . . . . . 0.498 ' HG2' ' H ' ' O' ' 23' ' ' ASP . 51.6 tt0 -65.85 179.59 0.85 Allowed 'General case' 0 N--CA 1.444 -0.758 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 178.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 23' ' ' ASP . . . . . 0.498 ' H ' ' HG2' ' O' ' 22' ' ' GLU . 1.8 m-20 167.59 58.8 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.978 -174.68 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 24' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' O' ' 23' ' ' ASP . 18.4 t -62.92 -114.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -177.237 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.01 43.51 1.66 Allowed Glycine 0 N--CA 1.47 0.922 0 CA-C-N 121.71 2.05 . . . . 0.0 109.677 -176.003 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 19.4 t -74.37 99.93 3.64 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 111.479 -2.36 . . . . 0.0 108.724 174.101 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -94.72 -161.73 0.88 Allowed 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.617 0.722 . . . . 0.0 112.045 -177.263 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 28' ' ' LYS . . . . . 0.587 ' NZ ' ' CB ' ' K' ' 13' ' ' HIS . 70.5 tttt 38.38 40.54 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 29' ' ' GLY . . . . . 0.746 ' HA2' HG21 ' I' ' 39' ' ' VAL . . . -177.72 62.34 0.09 OUTLIER Glycine 0 CA--C 1.541 1.672 0 C-N-CA 118.974 -1.584 . . . . 0.0 115.221 173.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 30' ' ' ALA . . . . . 0.449 ' HB2' ' ND2' ' P' ' 27' ' ' ASN . . . -109.45 90.4 3.29 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 118.05 0.925 . . . . 0.0 110.883 174.951 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 71.3 mt -140.96 132.94 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-N 120.869 1.668 . . . . 0.0 113.826 -179.125 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 32' ' ' ILE . . . . . 0.6 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 78.1 mt -109.88 109.0 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.702 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.1 99.28 1.06 Allowed Glycine 0 C--O 1.239 0.414 0 N-CA-C 105.547 -3.021 . . . . 0.0 105.547 177.028 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 34' ' ' LEU . . . . . 0.633 HD12 ' O ' ' N' ' 34' ' ' LEU . 10.3 tp -128.23 130.56 48.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 122.458 1.123 . . . . 0.0 113.507 -174.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.94 104.24 13.95 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 36' ' ' VAL . . . . . 0.559 HG11 ' CD2' ' Q' ' 17' ' ' LEU . 8.0 p -131.48 142.55 42.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.81 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.97 -102.04 0.82 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.46 -80.17 0.06 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' O' O ' 39' ' ' VAL . . . . . 0.574 HG22 HD11 ' C' ' 31' ' ' ILE . 3.4 m -148.44 167.66 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 176.308 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' O' O ' 40' ' ' VAL . . . . . 0.774 HG13 ' HE2' ' Q' ' 13' ' ' HIS . 1.4 p . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.377 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 121.044 0.449 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' P' P ' 13' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 86.3 m-70 -142.48 118.81 10.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.437 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 14' ' ' HIS . . . . . 0.698 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 0.0 OUTLIER -146.9 170.74 16.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.472 0.653 . . . . 0.0 111.821 -179.552 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' P' P ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG2' ' O' ' 36' ' ' VAL . 47.7 tt0 -107.45 149.8 27.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.448 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -139.91 110.64 6.78 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 176.146 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mt -126.88 116.67 21.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -110.11 105.54 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 19' ' ' PHE . . . . . 0.608 ' CD1' HD13 ' N' ' 32' ' ' ILE . 92.5 m-85 -106.59 107.19 18.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 179.192 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 20' ' ' PHE . . . . . 0.596 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 31.3 t80 -116.06 124.29 50.05 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.73 -178.598 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.41 138.25 30.97 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.75 0.786 . . . . 0.0 112.432 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 22' ' ' GLU . . . . . 0.504 ' O ' ' CB ' ' P' ' 23' ' ' ASP . 20.9 tt0 -76.81 -174.54 3.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 23' ' ' ASP . . . . . 0.504 ' CB ' ' O ' ' P' ' 22' ' ' GLU . 10.3 m-20 142.99 50.02 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 p -82.78 149.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 C-N-CA 119.341 -0.943 . . . . 0.0 111.404 -177.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 25' ' ' GLY . . . . . 0.406 ' O ' ' OG ' ' P' ' 26' ' ' SER . . . 93.23 36.81 5.83 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-N 113.614 -1.63 . . . . 0.0 111.848 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 26' ' ' SER . . . . . 0.59 ' N ' ' O ' ' Q' ' 24' ' ' VAL . 3.4 p 72.65 120.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 27' ' ' ASN . . . . . 0.449 ' ND2' ' HB2' ' O' ' 30' ' ' ALA . 28.9 t-20 -83.2 161.75 21.44 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.809 175.24 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 28' ' ' LYS . . . . . 0.628 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 75.4 tttt -48.54 -39.38 23.26 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 113.461 0.912 . . . . 0.0 113.461 177.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.59 68.85 0.04 OUTLIER Glycine 0 CA--C 1.544 1.863 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -174.451 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.22 145.76 51.17 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 119.062 1.431 . . . . 0.0 114.673 -173.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 31' ' ' ILE . . . . . 0.507 HD12 HG22 ' J' ' 39' ' ' VAL . 75.2 mt -136.08 133.94 50.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 CA-C-N 113.46 -1.7 . . . . 0.0 113.651 -177.505 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 32' ' ' ILE . . . . . 0.423 HD13 HG21 ' P' ' 32' ' ' ILE . 55.0 mt -107.67 117.06 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 175.614 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.77 102.02 1.06 Allowed Glycine 0 N--CA 1.466 0.657 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 176.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 34' ' ' LEU . . . . . 0.612 HD23 HG22 ' P' ' 36' ' ' VAL . 0.3 OUTLIER -126.25 132.36 51.72 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -175.571 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -109.17 99.71 8.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.2 -2.519 . . . . 0.0 104.2 174.306 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 36' ' ' VAL . . . . . 0.612 HG22 HD23 ' P' ' 34' ' ' LEU . 1.4 t -114.06 103.15 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.719 -175.32 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.31 -153.77 25.46 Favored Glycine 0 C--N 1.319 -0.39 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.813 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.43 -56.03 0.57 Allowed Glycine 0 CA--C 1.545 1.946 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -178.461 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' P' P ' 39' ' ' VAL . . . . . 0.565 HG23 HD11 ' D' ' 31' ' ' ILE . 0.9 OUTLIER -153.24 157.55 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 177.566 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' P' P ' 40' ' ' VAL . . . . . 0.602 HG13 ' CD2' ' R' ' 13' ' ' HIS . 7.0 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.459 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.56 135.1 54.28 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.805 0.336 . . . . 0.0 110.468 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 11' ' ' GLU . . . . . 0.411 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 96.5 mt-10 -87.26 119.61 27.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.984 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 12' ' ' VAL . . . . . 0.482 ' O ' HG23 ' Q' ' 12' ' ' VAL . 33.3 m -118.32 126.1 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.075 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 13' ' ' HIS . . . . . 0.774 ' HE2' HG13 ' O' ' 40' ' ' VAL . 0.1 OUTLIER -152.74 140.55 20.03 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.989 -179.525 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' Q' Q ' 14' ' ' HIS . . . . . 0.608 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 1.1 p80 -159.68 161.7 34.96 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 15' ' ' GLN . . . . . 0.431 ' HB3' HD11 ' Q' ' 17' ' ' LEU . 75.5 mt-30 -90.02 158.71 17.22 Favored 'General case' 0 CA--C 1.516 -0.349 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.747 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -140.81 101.9 4.17 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 176.452 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 17' ' ' LEU . . . . . 0.56 ' N ' HD12 ' Q' ' 17' ' ' LEU . 1.1 mp -119.06 113.42 20.91 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.33 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.92 106.63 21.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 19' ' ' PHE . . . . . 0.6 ' CD1' HD13 ' O' ' 32' ' ' ILE . 72.2 m-85 -107.04 103.05 12.37 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.296 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 20' ' ' PHE . . . . . 0.596 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 37.3 t80 -108.79 118.32 36.47 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.747 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 21' ' ' ALA . . . . . 0.471 ' O ' ' OE1' ' R' ' 22' ' ' GLU . . . -140.79 138.02 33.78 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.85 0.833 . . . . 0.0 112.967 -179.106 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' P' ' 23' ' ' ASP . 94.7 mt-10 -85.03 122.34 29.11 Favored 'General case' 0 C--O 1.22 -0.497 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 177.637 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 23' ' ' ASP . . . . . 0.417 ' CG ' ' O ' ' Q' ' 22' ' ' GLU . 35.4 m-20 -162.44 52.15 0.2 Allowed 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -176.686 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 24' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' P' ' 26' ' ' SER . 93.2 t -74.45 142.25 14.98 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 C-N-CA 117.923 -1.511 . . . . 0.0 110.069 -178.268 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.46 37.49 3.75 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -178.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -64.57 106.44 1.16 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.698 0.761 . . . . 0.0 111.576 -177.312 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -149.85 -161.25 1.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.429 -1.26 . . . . 0.0 110.173 -179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 29.5 40.82 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 29' ' ' GLY . . . . . 0.682 ' HA2' HG11 ' K' ' 39' ' ' VAL . . . 110.53 70.91 0.63 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 116.36 1.304 . . . . 0.0 116.36 175.543 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.53 114.14 27.72 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 175.632 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 31' ' ' ILE . . . . . 0.74 HD11 HG13 ' K' ' 39' ' ' VAL . 66.6 mt -130.29 135.33 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 CA-C-N 119.108 0.867 . . . . 0.0 113.238 -178.177 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -121.59 114.71 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.14 114.84 3.29 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 14.3 tp -117.63 117.18 28.69 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 122.251 0.221 . . . . 0.0 110.429 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.2 mtp -121.76 124.28 43.84 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 67.1 t -110.81 131.48 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 121.108 0.48 . . . . 0.0 111.087 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 37' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' Q' ' 38' ' ' GLY . . . -72.81 111.68 3.63 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 38' ' ' GLY . . . . . 0.5 ' H ' ' HA3' ' R' ' 37' ' ' GLY . . . -6.09 -67.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.428 0 C-N-CA 123.608 0.623 . . . . 0.0 114.224 -178.049 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.09 120.63 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 118.351 1.076 . . . . 0.0 109.68 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 29.1 t . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.272 -179.312 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -148.29 160.75 42.65 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 11' ' ' GLU . . . . . 0.411 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 79.2 mm-40 -114.74 151.32 33.92 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.154 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 57.4 t -107.09 105.97 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.043 0.449 . . . . 0.0 110.705 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 13' ' ' HIS . . . . . 0.602 ' CD2' HG13 ' P' ' 40' ' ' VAL . 63.0 t60 -148.82 130.14 14.68 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.224 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 42.0 p-80 -154.03 162.8 40.94 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.833 176.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 15' ' ' GLN . . . . . 0.592 ' CD ' HG12 ' P' ' 36' ' ' VAL . 5.5 tt0 -89.86 158.29 17.52 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 16' ' ' LYS . . . . . 0.545 ' O ' HD12 ' Q' ' 17' ' ' LEU . 68.9 tttt -140.82 103.15 4.44 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 17' ' ' LEU . . . . . 0.612 ' N ' HD23 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -115.51 109.29 17.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.702 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -106.28 104.09 16.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 19' ' ' PHE . . . . . 0.431 ' HE1' HD22 ' P' ' 34' ' ' LEU . 51.2 m-85 -100.25 100.95 11.84 Favored 'General case' 0 CA--C 1.509 -0.599 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 178.252 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -110.77 110.33 20.93 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.299 0.571 . . . . 0.0 109.949 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.6 130.29 45.48 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 22' ' ' GLU . . . . . 0.518 ' OE2' ' CZ ' ' Q' ' 20' ' ' PHE . 52.2 mp0 -77.86 108.99 11.5 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 118.597 -1.241 . . . . 0.0 110.686 -177.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 23' ' ' ASP . . . . . 0.573 ' CG ' ' H ' ' R' ' 24' ' ' VAL . 22.8 p-10 -178.83 -69.79 0.01 OUTLIER 'General case' 0 C--N 1.347 0.463 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 178.364 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 24' ' ' VAL . . . . . 0.573 ' H ' ' CG ' ' R' ' 23' ' ' ASP . 42.9 t -147.28 120.59 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -177.518 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.75 -43.73 91.09 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 119.546 -1.311 . . . . 0.0 110.659 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 44.1 m -139.56 -111.03 0.15 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 117.231 0.515 . . . . 0.0 111.283 177.753 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 7.1 m120 55.69 152.67 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.859 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -70.41 48.79 0.11 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.465 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 -52.06 1.38 Allowed Glycine 0 CA--C 1.541 1.664 0 C-N-CA 120.705 -0.76 . . . . 0.0 113.859 -178.424 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.4 176.44 5.15 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-N 117.454 0.627 . . . . 0.0 109.972 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 85.7 mt -110.45 116.97 53.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -113.63 127.44 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.039 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.85 113.13 1.7 Allowed Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' R' R ' 34' ' ' LEU . . . . . 0.646 ' C ' HD23 ' R' ' 34' ' ' LEU . 6.9 tt -118.05 121.43 40.57 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 35' ' ' MET . . . . . 0.549 ' N ' HD23 ' R' ' 34' ' ' LEU . 93.9 mtp -140.01 143.16 36.31 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.567 -0.453 . . . . 0.0 111.075 -179.134 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' R' ' 37' ' ' GLY . 3.3 p -122.83 131.56 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 37' ' ' GLY . . . . . 0.5 ' HA3' ' H ' ' Q' ' 38' ' ' GLY . . . -34.05 -111.41 0.0 OUTLIER Glycine 0 CA--C 1.529 0.933 0 CA-C-N 115.102 -0.953 . . . . 0.0 113.591 179.598 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 38' ' ' GLY . . . . . 0.41 ' H ' ' CA ' ' Q' ' 38' ' ' GLY . . . -111.52 -71.68 0.63 Allowed Glycine 0 CA--C 1.537 1.42 0 CA-C-N 115.563 -0.319 . . . . 0.0 113.288 -178.292 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 39' ' ' VAL . . . . . 0.525 HG12 HD12 ' F' ' 31' ' ' ILE . 6.8 p -138.49 142.71 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 117.618 0.709 . . . . 0.0 112.254 -178.124 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.455 178.629 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -109.02 134.77 51.22 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.892 0.377 . . . . 0.0 110.504 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -145.01 135.18 23.97 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.98 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -126.01 131.52 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.033 0.444 . . . . 0.0 110.467 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.6 p-80 -98.93 162.15 13.24 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.926 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 49.5 p-80 -86.39 169.5 12.85 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.805 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -129.5 151.28 50.29 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.45 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -96.54 124.35 40.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.773 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 91.4 mt -123.94 120.94 33.98 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-O 121.11 0.481 . . . . 0.0 110.76 179.356 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -127.41 133.47 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.874 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -133.41 124.43 27.1 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.822 0.344 . . . . 0.0 110.53 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 55.1 p90 -124.21 132.25 53.59 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.91 140.48 32.83 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.036 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 41.3 tp10 -107.07 158.35 17.12 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 114.071 -1.422 . . . . 0.0 107.491 177.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -171.02 46.63 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 119.594 -0.842 . . . . 0.0 112.455 -178.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.65 HG12 ' N ' ' A' ' 25' ' ' GLY . 45.3 t -82.74 173.58 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 C-N-CA 119.315 -0.954 . . . . 0.0 108.635 -179.405 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.65 ' N ' HG12 ' A' ' 24' ' ' VAL . . . 91.11 -33.16 4.82 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.699 -1.76 . . . . 0.0 108.699 -177.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.3 p -151.29 124.23 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.581 HD21 ' C ' ' B' ' 27' ' ' ASN . 13.8 t-20 -41.62 149.9 0.11 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.811 -176.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -73.32 -49.25 28.48 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.96 59.69 0.5 Allowed Glycine 0 CA--C 1.543 1.83 0 C-N-CA 119.976 -1.107 . . . . 0.0 110.372 -175.34 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.57 92.42 9.08 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 123.513 1.625 . . . . 0.0 113.491 -175.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.534 HG21 HG21 ' N' ' 39' ' ' VAL . 1.1 pt -142.3 122.81 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 111.789 -2.46 . . . . 0.0 106.322 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.443 ' O ' ' O ' ' B' ' 33' ' ' GLY . 58.8 mt -104.83 110.12 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.77 92.08 0.58 Allowed Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 104.609 -3.396 . . . . 0.0 104.609 176.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.608 ' O ' HD12 ' B' ' 34' ' ' LEU . 82.0 mt -146.45 169.62 18.52 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-O 122.954 1.359 . . . . 0.0 112.814 -175.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 53.3 mtp -141.75 119.31 11.66 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.781 -2.009 . . . . 0.0 108.735 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.793 ' CG2' HG12 ' B' ' 36' ' ' VAL . 11.7 m -124.74 113.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.05 -123.95 1.19 Allowed Glycine 0 C--N 1.305 -1.185 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.561 ' O ' HD13 ' G' ' 31' ' ' ILE . . . 80.73 -67.39 3.56 Favored Glycine 0 CA--C 1.535 1.318 0 C-N-CA 120.387 -0.911 . . . . 0.0 111.328 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.23 156.11 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.145 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 10' ' ' TYR . . . . . 0.477 ' CE2' HG23 ' B' ' 12' ' ' VAL . 87.7 t80 -87.5 126.34 34.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.341 179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.04 140.78 34.32 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.555 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.477 HG23 ' CE2' ' B' ' 10' ' ' TYR . 62.4 t -127.6 132.78 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.044 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.548 ' HB2' ' CD2' ' C' ' 13' ' ' HIS . 74.6 m80 -143.02 94.08 2.58 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.831 0.348 . . . . 0.0 110.695 179.344 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.609 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 6.9 t60 -158.56 170.18 22.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.813 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.609 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 17.6 tt0 -155.42 141.18 18.06 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.898 0.38 . . . . 0.0 110.213 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -89.0 124.42 34.25 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.27 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 tp -120.96 117.52 27.5 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 177.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.5 129.38 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.787 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -128.78 121.75 29.04 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.717 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.611 ' CD2' ' CD1' ' C' ' 20' ' ' PHE . 7.4 m-85 -122.46 129.03 51.6 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.17 137.4 34.36 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.527 0.68 . . . . 0.0 112.793 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' A' ' 22' ' ' GLU . 86.8 mt-10 -96.09 118.82 33.45 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.303 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.424 ' H ' ' HB2' ' C' ' 22' ' ' GLU . 0.3 OUTLIER -143.43 51.71 1.36 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.316 -179.045 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 71.3 t -75.7 143.49 13.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.957 0.884 . . . . 0.0 110.807 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.65 38.23 3.99 Favored Glycine 0 CA--C 1.525 0.656 0 CA-C-N 113.813 -1.539 . . . . 0.0 109.373 -178.698 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.9 t 73.18 120.01 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 115.241 -0.479 . . . . 0.0 110.608 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.841 HD21 ' H ' ' B' ' 30' ' ' ALA . 3.8 p30 -83.07 163.78 20.7 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 119.571 -0.851 . . . . 0.0 108.809 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -46.98 -37.06 8.5 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.249 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' B' ' 31' ' ' ILE . . . 179.53 77.05 0.06 OUTLIER Glycine 0 CA--C 1.531 1.068 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.823 -177.498 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.841 ' H ' HD21 ' B' ' 27' ' ' ASN . . . -51.77 91.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 119.371 1.586 . . . . 0.0 110.776 -179.315 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.956 HD12 HG22 ' N' ' 39' ' ' VAL . 66.8 mt -132.98 133.51 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.742 -177.697 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -107.96 109.7 29.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -113.29 97.05 0.84 Allowed Glycine 0 CA--C 1.507 -0.465 0 N-CA-C 104.19 -3.564 . . . . 0.0 104.19 176.28 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.647 HD12 ' H ' ' B' ' 35' ' ' MET . 40.1 tp -141.71 147.29 37.2 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 122.978 1.371 . . . . 0.0 113.47 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.647 ' H ' HD12 ' B' ' 34' ' ' LEU . 11.6 mtp -116.6 112.62 21.56 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 112.662 -2.063 . . . . 0.0 108.826 178.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.793 HG12 ' CG2' ' A' ' 36' ' ' VAL . 30.1 m -127.24 123.07 61.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.043 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 142.77 -113.52 0.79 Allowed Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.489 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 73.77 -72.74 1.27 Allowed Glycine 0 CA--C 1.535 1.29 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.441 ' CG1' ' O ' ' A' ' 38' ' ' GLY . 14.7 p -158.65 138.58 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 178.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.48 ' CG1' ' CD2' ' D' ' 13' ' ' HIS . 1.9 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.504 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -107.85 131.81 54.1 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.32 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -129.59 125.16 35.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.151 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -130.24 134.45 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.083 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.577 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 21.0 t-80 -139.95 139.85 36.22 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.532 ' CE1' ' O ' ' D' ' 14' ' ' HIS . 52.5 t60 -155.56 168.78 26.04 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.508 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.441 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.1 tt0 -138.74 140.81 38.82 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.582 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -130.4 113.47 14.37 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.488 HD12 HD22 ' D' ' 17' ' ' LEU . 35.6 mt -118.79 110.94 17.82 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.745 178.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 23.1 t -109.15 110.88 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -106.53 108.64 20.25 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.611 ' CD1' ' CD2' ' B' ' 20' ' ' PHE . 14.6 t80 -114.91 124.71 52.41 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 122.424 -0.173 . . . . 0.0 111.273 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 139.57 26.98 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.447 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 98.0 mt-10 -89.89 143.2 26.99 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.481 178.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.447 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 0.0 OUTLIER -164.66 50.44 0.12 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -177.893 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.404 HG13 ' CG2' ' D' ' 24' ' ' VAL . 37.6 t -80.87 149.37 5.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 122.83 1.3 . . . . 0.0 112.417 -174.431 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.6 36.92 5.69 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 112.052 -2.34 . . . . 0.0 110.28 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' D' ' 24' ' ' VAL . 19.8 t 72.64 120.12 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.789 0.835 . . . . 0.0 110.028 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.679 ' ND2' ' ND2' ' B' ' 27' ' ' ASN . 9.7 t-20 -83.18 161.99 21.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 116.991 -1.884 . . . . 0.0 110.284 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.489 ' H ' ' ND2' ' C' ' 27' ' ' ASN . 61.0 mttp -47.41 -37.03 10.66 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 175.811 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.76 78.16 0.06 OUTLIER Glycine 0 CA--C 1.538 1.508 0 CA-C-O 119.294 -0.726 . . . . 0.0 112.343 -173.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.723 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . -79.18 119.04 21.71 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 123.299 1.524 . . . . 0.0 112.997 -175.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.675 HD12 HG12 ' O' ' 39' ' ' VAL . 78.4 mt -139.1 139.89 39.22 Favored 'Isoleucine or valine' 0 C--N 1.353 0.724 0 CA-C-N 112.32 -2.218 . . . . 0.0 113.426 -176.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.433 HD13 ' CD2' ' E' ' 19' ' ' PHE . 64.1 mt -109.11 112.36 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.31 98.43 0.93 Allowed Glycine 0 C--O 1.238 0.392 0 N-CA-C 106.069 -2.812 . . . . 0.0 106.069 177.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 13.0 tp -133.26 134.59 44.14 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 122.495 1.14 . . . . 0.0 113.931 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.5 mtp -104.88 106.83 17.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 175.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.407 HG11 HD21 ' F' ' 17' ' ' LEU . 12.6 p -123.02 122.98 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.97 -113.11 0.55 Allowed Glycine 0 C--N 1.312 -0.801 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -177.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.51 ' O ' ' O ' ' C' ' 39' ' ' VAL . . . 55.73 64.98 3.89 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 119.789 -1.196 . . . . 0.0 112.61 178.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.528 HG23 ' O ' ' C' ' 39' ' ' VAL . 33.8 m 16.08 114.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.05 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.407 ' H ' HG23 ' C' ' 40' ' ' VAL . 2.6 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.491 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -83.09 139.37 33.26 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -109.13 118.34 36.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.148 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 t -115.21 91.14 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.154 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 3.5 t60 -143.89 122.72 12.68 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 110.372 -0.233 . . . . 0.0 110.372 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.663 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -118.77 161.53 19.96 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.114 0.483 . . . . 0.0 110.316 178.714 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.461 ' OE1' HD11 ' E' ' 17' ' ' LEU . 43.4 tt0 -85.05 157.04 20.84 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.091 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.637 ' O ' HD23 ' D' ' 17' ' ' LEU . 87.0 tttt -160.31 102.21 1.4 Allowed 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.321 177.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.731 ' CD1' HG11 ' B' ' 36' ' ' VAL . 3.1 mt -126.73 121.51 32.22 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -112.4 112.31 39.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -107.64 107.02 17.63 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.545 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 32.5 t80 -110.56 120.56 42.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 -178.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.87 144.99 27.26 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 118.748 -1.181 . . . . 0.0 113.687 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.434 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 98.1 mt-10 -96.05 136.36 36.61 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.99 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -160.13 49.95 0.29 Allowed 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.647 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' C' ' 26' ' ' SER . 35.7 m -81.67 150.65 4.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 122.601 1.191 . . . . 0.0 113.49 -176.096 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' E' ' 24' ' ' VAL . . . 93.94 36.97 5.59 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-N 112.59 -2.096 . . . . 0.0 111.705 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 72.77 120.11 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.333 -0.434 . . . . 0.0 111.544 175.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.723 ' ND2' ' H ' ' C' ' 30' ' ' ALA . 13.4 t30 -83.07 162.3 21.4 Favored 'General case' 0 C--O 1.231 0.103 0 C-N-CA 117.94 -1.504 . . . . 0.0 107.997 176.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.614 ' NZ ' ' ND1' ' Q' ' 13' ' ' HIS . 83.1 tttt -47.53 -37.45 12.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.489 177.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.79 0.06 OUTLIER Glycine 0 CA--C 1.539 1.589 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.554 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.77 119.67 4.47 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -125.5 125.17 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.517 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 mt -106.82 112.71 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 173.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.13 114.71 2.01 Favored Glycine 0 N--CA 1.462 0.429 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.429 HD12 ' N ' ' D' ' 34' ' ' LEU . 0.3 OUTLIER -160.78 158.16 28.08 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 123.21 1.481 . . . . 0.0 113.595 -178.826 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mmm -110.72 111.64 22.97 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 111.967 -2.378 . . . . 0.0 108.882 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.613 HG11 HD11 ' F' ' 17' ' ' LEU . 9.0 t -106.09 112.74 40.62 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.714 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.175 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -179.09 -121.96 0.74 Allowed Glycine 0 C--N 1.304 -1.22 0 C-N-CA 118.331 -1.89 . . . . 0.0 111.643 -179.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 63.63 61.55 6.12 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 119.65 -1.262 . . . . 0.0 111.347 -178.365 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.702 HG23 ' O ' ' E' ' 39' ' ' VAL . 5.6 p -18.62 122.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.076 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.992 179.112 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.144 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -83.73 139.8 32.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.799 0.333 . . . . 0.0 110.758 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.467 ' OE2' ' NE2' ' D' ' 14' ' ' HIS . 79.4 tt0 -155.22 151.24 27.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.988 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.645 HG12 ' N ' ' E' ' 13' ' ' HIS . 59.0 t -140.51 168.01 17.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.778 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.645 ' N ' HG12 ' E' ' 12' ' ' VAL . 20.8 p-80 -64.34 140.85 58.91 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' F' ' 12' ' ' VAL . 65.0 m80 -150.63 166.43 30.33 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.697 177.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -89.82 150.99 22.0 Favored 'General case' 0 CA--C 1.522 -0.114 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.565 ' C ' HD22 ' E' ' 17' ' ' LEU . 67.8 mttm -152.24 99.18 2.49 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 176.576 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.804 HD22 ' N ' ' E' ' 17' ' ' LEU . 1.3 mm? -118.33 114.11 22.46 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -110.18 106.65 21.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.436 ' CZ ' ' HB3' ' E' ' 17' ' ' LEU . 35.1 m-85 -103.15 103.75 13.84 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 30.3 t80 -110.39 118.52 36.52 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 121.138 -0.225 . . . . 0.0 111.027 -178.455 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.48 137.01 28.24 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 118.907 -1.117 . . . . 0.0 113.155 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -88.37 115.57 25.97 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 177.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' F' ' 22' ' ' GLU . 0.0 OUTLIER -148.57 48.85 1.02 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -175.485 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.51 HG12 ' N ' ' E' ' 25' ' ' GLY . 67.2 t -71.9 160.1 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 118.007 -1.477 . . . . 0.0 108.199 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.51 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 111.08 -36.62 4.12 Favored Glycine 0 N--CA 1.464 0.541 0 N-CA-C 108.097 -2.001 . . . . 0.0 108.097 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -65.79 112.52 3.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 113.22 -1.49 . . . . 0.0 110.622 -179.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -148.98 162.33 40.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.758 0.789 . . . . 0.0 110.922 -178.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 29.84 43.11 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.785 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.19 59.69 0.13 Allowed Glycine 0 CA--C 1.543 1.803 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.484 173.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.72 141.26 40.97 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.534 -0.746 . . . . 0.0 110.322 177.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.432 HD12 HG13 ' Q' ' 39' ' ' VAL . 1.6 tt -132.52 125.33 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 CA-C-N 119.606 1.094 . . . . 0.0 110.232 176.514 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 87.1 mt -127.45 127.29 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.851 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.96 107.04 0.86 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.606 HD23 ' C ' ' E' ' 34' ' ' LEU . 7.3 tt -122.9 123.86 41.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.515 ' N ' HD23 ' E' ' 34' ' ' LEU . 86.1 mtp -134.08 145.57 49.49 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 119.958 -0.697 . . . . 0.0 112.391 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -124.23 136.85 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.885 0.85 . . . . 0.0 110.659 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.78 103.28 0.39 Allowed Glycine 0 C--N 1.315 -0.63 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' E' ' 39' ' ' VAL . . . 127.12 75.75 0.21 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.157 -178.627 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.702 ' O ' HG23 ' D' ' 39' ' ' VAL . 7.3 t -17.36 120.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 123.628 0.771 . . . . 0.0 112.981 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 N--CA 1.469 0.518 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.355 179.516 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -110.34 133.89 52.82 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.781 0.324 . . . . 0.0 110.503 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.53 151.55 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 18.2 t -132.64 133.33 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.505 0.669 . . . . 0.0 111.379 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.515 ' HD1' ' CE1' ' E' ' 13' ' ' HIS . 0.3 OUTLIER -146.05 117.26 7.87 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.992 179.417 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 76.9 m80 -156.71 165.52 36.02 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.672 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.501 ' CD ' HG12 ' D' ' 36' ' ' VAL . 21.5 mt-30 -84.19 155.28 22.61 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.743 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -159.98 100.18 1.4 Allowed 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 121.291 0.567 . . . . 0.0 109.865 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.613 HD11 HG11 ' D' ' 36' ' ' VAL . 2.5 mp -125.62 114.92 19.35 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.331 178.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 12.4 t -99.83 102.61 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.919 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 178.002 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -95.16 95.22 8.4 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.413 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 64.8 t80 -111.16 113.52 26.1 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-O 121.548 0.69 . . . . 0.0 109.202 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.74 134.76 17.95 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 120.361 -0.536 . . . . 0.0 109.581 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' E' ' 23' ' ' ASP . 96.3 mt-10 -76.74 85.02 3.36 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 178.466 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.655 ' O ' ' O ' ' F' ' 24' ' ' VAL . 51.1 p30 176.32 52.09 0.0 OUTLIER 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.488 -175.178 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.655 ' O ' ' O ' ' F' ' 23' ' ' ASP . 3.0 t -52.73 -132.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -177.101 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' F' ' 30' ' ' ALA . . . 168.81 -38.63 0.21 Allowed Glycine 0 CA--C 1.509 -0.316 0 C-N-CA 116.127 -2.94 . . . . 0.0 116.263 -177.816 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 43.0 t -64.64 110.68 2.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 115.164 -2.614 . . . . 0.0 107.932 -176.545 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.728 ' O ' ' N ' ' F' ' 29' ' ' GLY . 16.7 p30 -149.62 174.89 12.05 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 112.548 -2.114 . . . . 0.0 108.031 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.461 ' C ' ' O ' ' F' ' 27' ' ' ASN . 88.4 tttt -8.77 -45.2 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.746 0 O-C-N 124.534 1.146 . . . . 0.0 114.015 177.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -169.61 60.45 0.19 Allowed Glycine 0 CA--C 1.553 2.435 0 C-N-CA 119.943 -1.122 . . . . 0.0 115.368 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.43 ' HB2' ' O ' ' F' ' 25' ' ' GLY . . . -84.99 172.04 11.63 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 85.9 mt -115.59 112.12 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 120.667 1.576 . . . . 0.0 111.562 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -123.97 123.19 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.89 119.55 3.03 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 38.4 mt -122.87 119.7 31.31 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mtp -140.6 151.38 44.62 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 -178.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 m -127.41 164.55 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.421 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.36 -102.82 0.09 OUTLIER Glycine 0 CA--C 1.525 0.664 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.653 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.09 -77.83 1.24 Allowed Glycine 0 CA--C 1.536 1.38 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.526 HG22 ' N ' ' F' ' 40' ' ' VAL . 3.4 p -125.78 162.48 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 117.208 0.504 . . . . 0.0 111.266 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.526 ' N ' HG22 ' F' ' 39' ' ' VAL . 9.6 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.58 -178.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -111.51 132.84 54.22 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.27 102.33 4.08 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.976 0.417 . . . . 0.0 110.303 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 77.5 t -131.38 130.21 62.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.613 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -145.38 131.6 19.48 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.42 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.6 p-80 -152.02 167.49 28.25 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.805 178.489 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 79.5 mt-30 -157.53 142.91 17.13 Favored 'General case' 0 CA--C 1.52 -0.202 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -81.53 126.2 31.41 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.584 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.7 mt -126.52 118.23 24.48 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -141.88 139.79 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 121.026 0.441 . . . . 0.0 110.999 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -134.74 131.84 38.07 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.58 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.498 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 55.1 p90 -131.06 130.34 43.12 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.93 0.395 . . . . 0.0 111.042 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.12 117.37 26.98 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.016 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -143.31 147.44 34.74 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.462 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 53.69 46.43 25.93 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.035 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -80.47 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.804 -178.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.35 -33.49 64.41 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.743 ' O ' ' O ' ' G' ' 27' ' ' ASN . 41.3 p -162.68 120.38 2.04 Favored 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 120.298 -0.561 . . . . 0.0 112.097 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.743 ' O ' ' O ' ' G' ' 26' ' ' SER . 93.7 m-20 -21.61 -174.65 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 115.41 1.634 . . . . 0.0 115.41 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -173.86 -21.04 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.419 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.539 ' N ' ' OD2' ' H' ' 23' ' ' ASP . . . 71.66 -97.9 0.73 Allowed Glycine 0 N--CA 1.465 0.624 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.61 97.02 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.112 0.482 . . . . 0.0 111.487 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.561 HD13 ' O ' ' A' ' 38' ' ' GLY . 91.2 mt -123.03 110.83 27.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.041 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -113.76 107.32 22.63 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.78 100.08 0.92 Allowed Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 104.393 -3.483 . . . . 0.0 104.393 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.468 ' O ' HD23 ' H' ' 34' ' ' LEU . 48.3 tp -150.36 149.28 29.86 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-O 123.034 1.397 . . . . 0.0 113.954 -174.52 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 mtp -105.64 106.32 16.76 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 112.183 -2.281 . . . . 0.0 106.015 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.642 HG21 HD11 ' I' ' 17' ' ' LEU . 3.8 p -128.47 113.95 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.43 -124.9 1.95 Allowed Glycine 0 C--N 1.307 -1.061 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.1 -66.89 3.7 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.995 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.663 HG22 ' N ' ' G' ' 40' ' ' VAL . 12.6 p -108.08 176.01 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.663 ' N ' HG22 ' G' ' 39' ' ' VAL . 2.5 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.116 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.347 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -105.64 132.44 51.78 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -159.48 114.43 2.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.069 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.46 HG22 ' CG1' ' I' ' 12' ' ' VAL . 79.6 t -126.66 128.9 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.483 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 61.5 m80 -147.61 114.97 6.28 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.462 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.504 ' CE1' ' H ' ' I' ' 14' ' ' HIS . 12.9 m-70 -149.74 169.07 21.92 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.442 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -156.52 141.58 17.24 Favored 'General case' 0 CA--C 1.518 -0.278 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 177.061 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -86.85 120.5 28.2 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.218 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.555 HD13 ' N ' ' H' ' 18' ' ' VAL . 0.6 OUTLIER -117.22 113.91 22.89 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.007 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.555 ' N ' HD13 ' H' ' 17' ' ' LEU . 69.1 t -122.17 131.03 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 120.867 0.365 . . . . 0.0 111.386 -178.654 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 37.7 t80 -126.98 116.81 21.33 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.614 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 8.0 t80 -122.63 127.2 49.05 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.95 134.84 32.11 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 112.754 0.649 . . . . 0.0 112.754 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -107.71 121.24 44.31 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.272 178.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.539 ' OD2' ' N ' ' G' ' 29' ' ' GLY . 93.6 m-20 -140.33 46.38 1.82 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.012 -178.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.786 HG12 ' H ' ' H' ' 25' ' ' GLY . 20.6 t -81.68 177.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.36 -177.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.786 ' H ' HG12 ' H' ' 24' ' ' VAL . . . 92.72 -33.92 4.77 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.426 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.55 ' O ' ' O ' ' H' ' 27' ' ' ASN . 37.0 t -162.52 120.31 2.09 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 119.062 1.431 . . . . 0.0 113.502 177.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.55 ' O ' ' O ' ' H' ' 26' ' ' SER . 53.4 p-10 -22.41 153.23 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.946 0 O-C-N 124.266 0.979 . . . . 0.0 112.05 175.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.622 ' HZ2' ' HB2' ' G' ' 27' ' ' ASN . 61.7 tttt -165.43 26.42 0.05 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 118.392 -1.323 . . . . 0.0 114.162 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.58 ' H ' ' H ' ' I' ' 28' ' ' LYS . . . 82.03 108.01 0.4 Allowed Glycine 0 CA--C 1.525 0.717 0 C-N-CA 118.987 -1.578 . . . . 0.0 114.448 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.49 106.49 11.86 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 122.118 0.961 . . . . 0.0 109.273 178.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.43 HD12 ' O ' ' B' ' 38' ' ' GLY . 1.9 tt -141.45 132.66 27.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 CA-C-N 114.687 -1.142 . . . . 0.0 111.83 -177.658 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.559 HG22 HD11 ' I' ' 34' ' ' LEU . 6.6 mt -108.13 111.69 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.074 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.48 103.18 1.42 Allowed Glycine 0 N--CA 1.46 0.248 0 N-CA-C 105.543 -3.023 . . . . 0.0 105.543 177.131 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.468 HD23 ' O ' ' G' ' 34' ' ' LEU . 0.4 OUTLIER -146.47 145.12 30.08 Favored 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 117.92 -1.512 . . . . 0.0 114.271 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.4 mtp -111.12 112.34 24.07 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 112.935 -1.938 . . . . 0.0 107.02 176.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.428 HG12 ' NE2' ' J' ' 15' ' ' GLN . 0.7 OUTLIER -119.69 102.88 13.43 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.812 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.88 -151.56 20.16 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.97 -56.55 0.54 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.559 HG22 ' N ' ' H' ' 40' ' ' VAL . 6.3 p -153.69 161.12 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 177.787 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.559 ' N ' HG22 ' H' ' 39' ' ' VAL . 14.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.787 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -111.89 133.94 53.76 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.731 0.301 . . . . 0.0 110.557 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -155.39 144.95 21.19 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.895 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.46 ' CG1' HG22 ' H' ' 12' ' ' VAL . 2.5 p -127.37 118.67 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.108 0.48 . . . . 0.0 109.946 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' O ' ' G' ' 40' ' ' VAL . 2.9 t-80 -147.83 120.2 8.43 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.588 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.504 ' H ' ' CE1' ' H' ' 14' ' ' HIS . 4.8 m170 -122.48 162.74 21.15 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 120.794 -0.362 . . . . 0.0 110.823 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.03 153.94 20.19 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.728 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -145.47 97.07 2.93 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.646 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.642 HD11 HG21 ' G' ' 36' ' ' VAL . 18.4 mt -121.14 121.91 38.86 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.347 178.272 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -117.11 110.16 30.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -107.76 108.97 20.43 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 28.0 t80 -115.68 126.33 53.98 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.91 135.82 34.83 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -94.09 140.6 29.54 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.142 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 7.4 p-10 -176.83 52.14 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.697 0.284 . . . . 0.0 110.442 -175.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.468 HG12 HG13 ' H' ' 24' ' ' VAL . 3.3 p -74.52 143.16 13.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 122.653 1.216 . . . . 0.0 112.637 -175.197 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.427 ' O ' ' OG ' ' I' ' 26' ' ' SER . . . 99.53 38.22 3.77 Favored Glycine 0 CA--C 1.529 0.961 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.434 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 7.0 p 73.17 120.2 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.131 -0.535 . . . . 0.0 111.907 176.343 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' I' ' 29' ' ' GLY . 1.6 m120 -83.93 152.68 24.36 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 118.257 -1.377 . . . . 0.0 108.669 175.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.58 ' H ' ' H ' ' H' ' 29' ' ' GLY . 30.1 mtmt -50.68 43.66 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.862 0 CA-C-O 116.966 -1.492 . . . . 0.0 114.178 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 120.94 77.44 0.47 Allowed Glycine 0 N--CA 1.487 2.04 0 CA-C-N 122.555 2.434 . . . . 0.0 113.013 -178.229 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.22 112.12 18.25 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.316 1.558 . . . . 0.0 111.8 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.437 HD12 HG13 ' C' ' 39' ' ' VAL . 12.7 tt -145.74 141.67 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -177.21 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.598 HG23 HD13 ' I' ' 34' ' ' LEU . 38.3 mt -111.16 113.19 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 176.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.714 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -115.01 99.93 0.95 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 177.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.714 HD12 ' O ' ' I' ' 33' ' ' GLY . 5.9 mp -136.22 148.22 47.98 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 123.411 1.577 . . . . 0.0 114.124 -176.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -116.59 106.31 13.41 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 111.724 -2.489 . . . . 0.0 104.526 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.479 ' HB ' HD21 ' J' ' 34' ' ' LEU . 38.6 t -126.58 142.75 42.25 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.74 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.152 -175.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.73 -101.99 0.71 Allowed Glycine 0 C--N 1.312 -0.768 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.676 ' O ' HG21 ' J' ' 39' ' ' VAL . . . 66.69 -80.09 0.12 Allowed Glycine 0 CA--C 1.533 1.204 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.665 -179.298 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.637 HG22 HD12 ' O' ' 31' ' ' ILE . 21.9 t -116.28 131.3 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 C-N-CA 123.068 0.547 . . . . 0.0 109.998 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 39' ' ' VAL . 8.8 p . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 118.038 -0.982 . . . . 0.0 111.43 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -108.39 136.28 48.29 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.741 0.305 . . . . 0.0 110.24 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -78.13 108.98 11.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.96 129.72 68.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.757 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' K' ' 14' ' ' HIS . 67.1 m80 -124.88 127.31 46.91 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.823 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.629 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 12.7 t60 -152.09 170.43 19.96 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.228 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.629 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 6.7 tt0 -138.5 140.65 39.25 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -130.57 104.28 7.13 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.464 ' CD1' ' CG ' ' J' ' 15' ' ' GLN . 6.3 mp -122.8 120.2 32.85 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.736 177.468 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -113.7 112.25 39.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.911 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.441 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 43.7 m-85 -109.4 108.13 18.55 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 37.2 t80 -116.66 125.12 51.29 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.58 0.228 . . . . 0.0 110.955 -179.278 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.94 133.49 33.8 Favored 'General case' 0 C--O 1.241 0.627 0 CA-C-O 121.452 0.644 . . . . 0.0 111.842 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.453 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 80.1 tt0 -90.47 119.75 31.01 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.534 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.432 ' OD1' ' OD2' ' I' ' 23' ' ' ASP . 0.2 OUTLIER -147.39 52.05 1.06 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.443 -0.799 . . . . 0.0 108.901 -178.14 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.89 143.14 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 122.448 1.118 . . . . 0.0 112.793 -175.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' J' ' 26' ' ' SER . . . 99.09 38.16 3.9 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 112.699 -2.046 . . . . 0.0 112.197 178.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.404 ' HB3' ' O ' ' J' ' 25' ' ' GLY . 22.0 t 72.68 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.453 0.701 . . . . 0.0 111.11 176.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -83.18 161.75 21.46 Favored 'General case' 0 C--N 1.34 0.194 0 C-N-CA 117.18 -1.808 . . . . 0.0 110.221 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -47.7 -37.28 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 175.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.03 78.06 0.06 OUTLIER Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.741 -1.033 . . . . 0.0 112.236 -172.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.84 116.87 19.45 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 120.076 1.938 . . . . 0.0 111.66 -175.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 5.0 tt -134.01 136.91 53.04 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 CA-C-N 112.253 -2.249 . . . . 0.0 113.134 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.09 122.66 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 120.999 0.428 . . . . 0.0 110.609 178.106 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.85 104.42 0.97 Allowed Glycine 0 N--CA 1.462 0.396 0 N-CA-C 106.339 -2.704 . . . . 0.0 106.339 176.467 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.897 HD23 ' N ' ' J' ' 35' ' ' MET . 5.0 tt -144.46 142.85 30.57 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-O 122.578 1.18 . . . . 0.0 112.47 -175.707 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.897 ' N ' HD23 ' J' ' 34' ' ' LEU . 28.6 mtp -116.32 115.05 25.21 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.145 -1.843 . . . . 0.0 108.779 178.367 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.829 HG11 HD11 ' L' ' 17' ' ' LEU . 0.1 OUTLIER -97.62 111.35 27.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.512 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 178.956 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.52 131.49 42.96 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.331 -177.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.95 63.51 3.16 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 121.279 -0.486 . . . . 0.0 111.938 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.676 HG21 ' O ' ' I' ' 38' ' ' GLY . 42.7 t -124.62 126.36 71.54 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 CA-C-O 121.461 0.648 . . . . 0.0 110.029 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.589 -179.208 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.66 135.76 48.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.657 0.265 . . . . 0.0 110.506 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.16 111.65 16.76 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.334 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.501 HG23 ' O ' ' K' ' 12' ' ' VAL . 4.5 m -130.67 126.56 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.185 0.517 . . . . 0.0 111.03 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -110.16 157.58 19.24 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.612 ' CG ' ' H ' ' K' ' 15' ' ' GLN . 22.4 t-80 -158.01 178.02 10.68 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 119.434 -0.906 . . . . 0.0 112.826 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.612 ' H ' ' CG ' ' K' ' 14' ' ' HIS . 31.6 tt0 -160.37 140.57 11.48 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 114.197 -1.365 . . . . 0.0 107.54 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -159.48 115.97 2.58 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.947 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.46 ' N ' HD12 ' K' ' 17' ' ' LEU . 4.6 mp -128.07 125.03 38.49 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 114.395 -1.275 . . . . 0.0 109.196 178.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 26.3 m -116.03 121.09 66.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.441 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 24.1 m-85 -109.16 109.85 20.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.695 -178.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -111.92 118.67 36.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 122.357 -0.214 . . . . 0.0 111.04 -179.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.66 126.74 27.94 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 110.315 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' J' ' 23' ' ' ASP . 75.4 mt-10 -87.8 140.58 29.36 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.406 -179.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 7.0 p-10 178.52 48.87 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 17.8 m -72.16 160.61 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 119.309 -0.956 . . . . 0.0 109.887 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.22 -33.25 5.95 Favored Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.149 177.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 1.7 p -72.23 129.98 39.73 Favored 'General case' 0 N--CA 1.465 0.325 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 46.5 t-20 -90.86 143.65 26.5 Favored 'General case' 0 C--O 1.232 0.154 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 176.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.48 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 51.7 tttp 43.52 42.84 4.22 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' L' ' 23' ' ' ASP . . . -101.69 60.48 0.58 Allowed Glycine 0 N--CA 1.476 1.308 0 CA-C-O 119.269 -0.74 . . . . 0.0 114.111 -178.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.86 119.95 4.94 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 119.204 1.502 . . . . 0.0 111.772 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 74.3 mt -121.6 116.83 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -124.17 128.3 73.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.22 103.18 0.79 Allowed Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.024 -2.03 . . . . 0.0 108.024 177.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.638 HD11 ' CG2' ' J' ' 36' ' ' VAL . 30.2 tp -117.11 121.4 41.17 Favored 'General case' 0 C--O 1.24 0.58 0 CA-C-O 121.265 0.555 . . . . 0.0 110.007 -178.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 18.5 ttm -120.86 129.86 53.69 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.16 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' K' ' 37' ' ' GLY . 54.9 t -115.78 131.93 66.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.886 178.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -45.03 -111.73 0.0 OUTLIER Glycine 0 CA--C 1.529 0.915 0 CA-C-N 115.519 -0.764 . . . . 0.0 112.349 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -107.15 -71.69 0.77 Allowed Glycine 0 CA--C 1.534 1.223 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.448 HG22 ' O ' ' L' ' 39' ' ' VAL . 54.1 t -125.2 127.19 71.96 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.521 HG23 ' OXT' ' K' ' 40' ' ' VAL . 8.4 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.738 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -109.48 137.14 47.76 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 110.365 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -73.54 147.41 44.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.488 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 m -129.93 135.78 60.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.081 0.467 . . . . 0.0 111.567 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 5.1 p80 -146.85 97.97 2.98 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.275 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -154.69 162.59 41.06 Favored 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -89.95 159.24 17.01 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.203 0.525 . . . . 0.0 111.632 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 16' ' ' LYS . . . . . 0.442 ' HD2' ' HE1' ' K' ' 14' ' ' HIS . 92.8 mttt -140.06 110.6 6.72 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.791 177.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.829 HD11 HG11 ' J' ' 36' ' ' VAL . 25.9 mt -118.09 112.19 19.89 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.555 178.802 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 9.0 t -104.21 100.67 10.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -94.44 99.87 11.97 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -116.24 112.17 21.22 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.466 0.651 . . . . 0.0 110.984 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.1 135.41 32.52 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 107.842 -1.169 . . . . 0.0 107.842 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.497 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 80.3 mm-40 -73.39 108.89 6.51 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 118.627 -1.229 . . . . 0.0 108.401 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' L' ' 24' ' ' VAL . 64.9 m-20 -164.03 61.39 0.16 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.514 -176.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' L' ' 23' ' ' ASP . 8.9 t 55.63 155.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.153 -177.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.24 24.2 0.19 Allowed Glycine 0 CA--C 1.521 0.413 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 40.3 t -81.86 -120.93 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' L' ' 29' ' ' GLY . 99.3 m-20 -93.05 -165.61 1.37 Allowed 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.754 -0.778 . . . . 0.0 109.502 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -47.98 47.68 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 115.732 1.753 . . . . 0.0 115.732 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.64 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.31 56.86 0.89 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-N 119.253 0.933 . . . . 0.0 112.339 177.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.62 169.8 9.97 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.433 ' CD1' HG12 ' F' ' 39' ' ' VAL . 8.3 mm -112.98 111.31 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 176.781 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -125.75 130.1 72.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.594 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.0 116.48 2.73 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 56.9 tp -118.32 123.08 44.47 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttm -125.66 124.99 42.35 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.24 132.45 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.8 112.13 3.6 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.193 -178.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.97 -71.17 0.01 OUTLIER Glycine 0 CA--C 1.538 1.521 0 N-CA-C 115.216 0.847 . . . . 0.0 115.216 177.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' K' ' 38' ' ' GLY . 54.1 t -134.43 137.13 52.02 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 CA-C-N 117.96 0.88 . . . . 0.0 112.007 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' K' ' 40' ' ' VAL . 61.7 t . . . . . 0 C--O 1.213 -0.837 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.091 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -110.04 138.56 46.25 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.911 0.386 . . . . 0.0 110.567 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -71.19 139.88 50.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -122.01 131.29 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.01 0.434 . . . . 0.0 110.07 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -119.27 130.35 55.38 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.273 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.497 ' CD2' ' O ' ' N' ' 13' ' ' HIS . 13.6 m-70 -83.23 167.09 18.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.138 0.494 . . . . 0.0 111.126 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -93.38 159.98 15.01 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.425 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.145 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 88.7 mt -130.1 130.75 45.24 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.965 0.412 . . . . 0.0 111.465 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 67.3 t -133.75 132.2 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.963 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -138.67 136.71 36.14 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.171 0.51 . . . . 0.0 112.001 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -121.11 125.15 46.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.063 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.62 113.75 25.49 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 121.345 0.593 . . . . 0.0 111.224 -179.503 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 22' ' ' GLU . . . . . 0.418 ' OE1' ' OE2' ' N' ' 22' ' ' GLU . 12.4 pt-20 -173.16 150.31 1.92 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.724 179.747 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 56.03 46.95 20.77 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.158 178.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -101.03 -170.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.12 -32.43 84.01 Favored Glycine 0 N--CA 1.468 0.822 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.241 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 47.6 t -152.88 125.11 8.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.366 0.583 . . . . 0.0 109.789 177.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.641 ' HA ' HG11 ' N' ' 24' ' ' VAL . 1.9 m-20 -38.93 134.58 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.956 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.67 -39.54 4.84 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 122.192 0.996 . . . . 0.0 108.39 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 29' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 79.89 -69.29 3.09 Favored Glycine 0 CA--C 1.534 1.261 0 CA-C-N 113.348 -1.751 . . . . 0.0 110.753 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.593 ' HB3' ' HA ' ' N' ' 30' ' ' ALA . . . 179.6 82.38 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 117.335 0.568 . . . . 0.0 111.009 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.608 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.6 tt -121.4 104.58 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 119.592 1.087 . . . . 0.0 109.482 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -124.39 116.59 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 CA-C-O 121.402 0.62 . . . . 0.0 111.618 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.83 104.93 0.86 Allowed Glycine 0 N--CA 1.464 0.529 0 N-CA-C 106.086 -2.806 . . . . 0.0 106.086 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 34' ' ' LEU . . . . . 0.458 ' HB2' HD11 ' N' ' 34' ' ' LEU . 85.7 mt -145.28 159.81 42.46 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 123.3 1.524 . . . . 0.0 114.214 -176.189 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 35.4 tpp -107.08 108.5 20.01 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.844 -2.435 . . . . 0.0 105.85 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 4.7 m -119.57 123.06 70.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 119.055 0.843 . . . . 0.0 109.68 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.25 -113.7 0.9 Allowed Glycine 0 C--N 1.31 -0.897 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.43 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . 95.48 -72.13 0.95 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 112.318 -0.313 . . . . 0.0 112.318 179.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 40' ' ' VAL . 2.4 t -122.29 159.23 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 O-C-N 122.691 -0.3 . . . . 0.0 110.621 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 39' ' ' VAL . 2.9 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.827 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -108.21 132.48 53.61 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.835 0.35 . . . . 0.0 110.401 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -125.88 126.86 45.11 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.027 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.416 ' CG1' ' NE2' ' M' ' 14' ' ' HIS . 59.2 t -127.73 130.33 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-O 120.871 0.367 . . . . 0.0 110.994 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.497 ' O ' ' CD2' ' M' ' 14' ' ' HIS . 29.8 t-80 -79.66 161.31 25.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.813 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 14' ' ' HIS . . . . . . . . . . . . . 29.8 p-80 -93.26 163.18 13.71 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.216 0.531 . . . . 0.0 111.322 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -89.88 160.12 16.61 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.61 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.22 131.6 28.48 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -132.59 127.37 34.86 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.348 0.594 . . . . 0.0 111.199 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.5 130.77 72.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.613 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -132.43 122.41 24.93 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.086 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 5.7 t80 -121.15 127.6 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.285 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.49 117.3 25.6 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.418 ' OE2' ' OE1' ' M' ' 22' ' ' GLU . 97.7 mt-10 -81.59 179.63 7.76 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 119.811 -0.755 . . . . 0.0 109.297 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.633 ' O ' HG23 ' N' ' 24' ' ' VAL . 62.3 t0 -60.53 -46.91 88.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 119.193 -1.003 . . . . 0.0 108.494 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 1.011 HG12 ' H ' ' N' ' 25' ' ' GLY . 9.4 t 99.81 -161.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 1.011 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -71.32 -33.4 64.53 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' N' ' 27' ' ' ASN . 34.2 t -162.55 120.55 2.1 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.577 ' O ' ' O ' ' N' ' 26' ' ' SER . 41.2 t-20 -22.0 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 114.682 -1.145 . . . . 0.0 112.443 177.177 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.669 ' HA ' ' HZ3' ' O' ' 28' ' ' LYS . 69.9 tttt -163.03 24.39 0.09 Allowed 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.9 107.68 1.25 Allowed Glycine 0 N--CA 1.476 1.35 0 C-N-CA 117.506 -2.283 . . . . 0.0 113.929 177.629 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 30' ' ' ALA . . . . . 0.593 ' HA ' ' HB3' ' M' ' 30' ' ' ALA . . . -109.53 102.69 11.52 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 123.637 1.684 . . . . 0.0 109.912 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.483 HD13 HG21 ' I' ' 39' ' ' VAL . 20.7 mt -130.19 130.48 65.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 112.388 -2.187 . . . . 0.0 110.824 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.423 HD13 ' HD2' ' P' ' 19' ' ' PHE . 10.1 tt -123.6 116.3 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.805 0.812 . . . . 0.0 109.844 176.611 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.568 ' O ' HD12 ' N' ' 34' ' ' LEU . . . -109.1 111.58 3.26 Favored Glycine 0 C--N 1.333 0.411 0 N-CA-C 107.02 -2.432 . . . . 0.0 107.02 178.733 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.568 HD12 ' O ' ' N' ' 33' ' ' GLY . 0.8 OUTLIER -137.88 139.22 39.75 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 122.633 1.206 . . . . 0.0 113.636 -176.094 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 95.7 mmm -106.36 111.56 24.19 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.711 HG11 HD11 ' P' ' 17' ' ' LEU . 2.1 t -117.19 123.15 71.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -178.105 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.38 -113.0 0.55 Allowed Glycine 0 C--N 1.306 -1.12 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.747 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.78 -73.16 2.71 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.956 HG22 HD12 ' B' ' 31' ' ' ILE . 62.8 t -138.17 138.39 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.062 0.545 . . . . 0.0 109.777 179.505 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' O' ' 40' ' ' VAL . 46.5 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.538 -0.744 . . . . 0.0 111.681 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.96 137.4 46.03 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.873 0.368 . . . . 0.0 110.521 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -93.23 113.31 25.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.374 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -125.28 128.72 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 120.781 0.324 . . . . 0.0 110.167 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -131.29 138.27 49.18 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.612 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 83.2 t60 -154.64 153.85 32.02 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 118.346 -1.342 . . . . 0.0 112.836 179.387 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 33.8 tt0 -90.63 164.44 14.18 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.721 177.19 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 102.18 0.33 Allowed 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mt -122.86 119.59 30.98 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.414 179.354 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 15.6 t -106.96 115.32 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.401 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -113.87 105.48 13.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 12.5 t80 -107.2 125.46 51.14 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.377 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.39 135.59 44.77 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -177.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -112.19 139.87 47.37 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.452 177.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -156.41 46.52 0.44 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.814 0.34 . . . . 0.0 110.127 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.712 HG12 ' H ' ' O' ' 25' ' ' GLY . 3.0 t -82.64 174.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 122.314 1.054 . . . . 0.0 112.552 -176.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.712 ' H ' HG12 ' O' ' 24' ' ' VAL . . . 92.59 -35.91 3.88 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-N 113.228 -1.805 . . . . 0.0 112.661 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.647 ' O ' ' O ' ' O' ' 27' ' ' ASN . 21.6 p -172.28 113.74 0.3 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 118.974 1.387 . . . . 0.0 112.218 175.232 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.647 ' O ' ' O ' ' O' ' 26' ' ' SER . 25.2 p30 -10.59 153.34 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 0 O-C-N 124.55 1.157 . . . . 0.0 113.994 176.428 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.669 ' HZ3' ' HA ' ' N' ' 28' ' ' LYS . 32.2 tttt -166.33 26.19 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 118.457 -1.297 . . . . 0.0 113.843 172.101 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.65 107.33 0.37 Allowed Glycine 0 CA--C 1.53 0.982 0 C-N-CA 119.318 -1.42 . . . . 0.0 112.474 178.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.97 112.48 18.81 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.031 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.637 HD12 HG22 ' I' ' 39' ' ' VAL . 83.6 mt -131.68 131.85 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -176.205 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.641 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 88.6 mt -108.22 106.06 19.96 Favored 'Isoleucine or valine' 0 C--N 1.344 0.351 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 174.025 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.47 ' O ' HD12 ' O' ' 34' ' ' LEU . . . -112.58 101.58 1.23 Allowed Glycine 0 N--CA 1.464 0.541 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.512 HD13 HG23 ' O' ' 32' ' ' ILE . 3.5 mp -139.78 146.46 39.49 Favored 'General case' 0 CA--C 1.508 -0.638 0 CA-C-O 123.14 1.447 . . . . 0.0 113.329 -176.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 12.3 mtp -113.24 108.66 17.57 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 111.828 -2.442 . . . . 0.0 106.371 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.654 HG12 ' HB ' ' N' ' 36' ' ' VAL . 1.5 m -124.13 102.85 11.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.03 -151.6 21.01 Favored Glycine 0 C--N 1.302 -1.332 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.062 179.643 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.29 -57.1 1.45 Allowed Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.804 HG11 HD13 ' B' ' 31' ' ' ILE . 33.4 m -129.07 159.3 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 123.253 0.621 . . . . 0.0 110.633 -178.342 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.552 HG22 ' C ' ' P' ' 40' ' ' VAL . 3.5 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.069 -0.967 . . . . 0.0 111.648 -178.747 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -111.36 133.89 53.34 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.055 0.455 . . . . 0.0 110.583 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -138.91 157.48 45.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.28 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 6.7 t -107.0 95.22 3.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.943 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.695 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 18.0 m170 -120.63 110.83 16.89 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.834 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.612 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 0.2 OUTLIER -160.69 166.99 27.86 Favored 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.17 177.771 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.501 ' OE1' HG12 ' N' ' 36' ' ' VAL . 15.6 pt20 -89.94 151.6 21.63 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.733 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 16' ' ' LYS . . . . . 0.462 ' H ' ' HB3' ' O' ' 15' ' ' GLN . 86.7 tttt -149.79 119.26 6.91 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.47 0.653 . . . . 0.0 110.727 177.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.711 HD11 HG11 ' N' ' 36' ' ' VAL . 3.5 mp -138.99 132.37 30.12 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.218 178.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.02 120.98 65.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.515 ' CD1' ' CE1' ' Q' ' 19' ' ' PHE . 13.4 m-85 -110.78 112.19 23.89 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 22.4 t80 -119.84 127.76 53.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -175.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.81 127.25 48.84 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.571 ' CG ' ' H ' ' P' ' 23' ' ' ASP . 19.1 tt0 -72.07 177.06 4.6 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 115.75 1.759 . . . . 0.0 115.75 -173.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.571 ' H ' ' CG ' ' P' ' 22' ' ' GLU . 55.3 t0 -45.31 47.42 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 112.349 -2.205 . . . . 0.0 116.731 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.751 HG12 ' H ' ' P' ' 25' ' ' GLY . 49.0 t -60.88 -179.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 117.903 -1.519 . . . . 0.0 107.317 177.385 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.751 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -102.08 34.97 5.27 Favored Glycine 0 N--CA 1.469 0.898 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 0.8 OUTLIER 74.53 120.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 -177.535 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.998 HD22 ' N ' ' P' ' 30' ' ' ALA . 0.1 OUTLIER -82.79 172.7 12.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 122.125 0.964 . . . . 0.0 113.312 -177.155 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.414 ' H ' ' HB2' ' O' ' 27' ' ' ASN . 87.6 tttt -49.2 -36.25 19.32 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.462 -1.699 . . . . 0.0 111.572 177.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.42 78.01 0.07 OUTLIER Glycine 0 CA--C 1.541 1.688 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.336 -174.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 30' ' ' ALA . . . . . 0.998 ' N ' HD22 ' P' ' 27' ' ' ASN . . . -79.85 139.32 37.21 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 121.752 0.787 . . . . 0.0 111.132 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.671 HG21 HG13 ' J' ' 39' ' ' VAL . 9.5 tt -149.98 141.83 17.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 -176.179 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.503 HG12 HD12 ' O' ' 32' ' ' ILE . 75.3 mt -105.72 109.55 28.24 Favored 'Isoleucine or valine' 0 C--N 1.349 0.55 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.2 99.58 1.71 Allowed Glycine 0 C--O 1.24 0.492 0 N-CA-C 105.39 -3.084 . . . . 0.0 105.39 176.176 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.531 HD23 HG22 ' P' ' 36' ' ' VAL . 5.4 tp -128.41 134.77 48.86 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 -175.274 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 35' ' ' MET . . . . . 0.487 ' SD ' ' O ' ' Q' ' 35' ' ' MET . 60.0 tpp -112.69 110.98 21.45 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.006 -1.452 . . . . 0.0 107.62 176.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.9 ' O ' HG13 ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -105.09 111.79 36.01 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.228 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.341 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' P' P ' 37' ' ' GLY . . . . . 0.433 ' O ' ' NE2' ' R' ' 15' ' ' GLN . . . -63.75 131.99 40.53 Favored Glycine 0 N--CA 1.465 0.588 0 CA-C-N 115.868 -0.606 . . . . 0.0 113.204 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.584 ' O ' HG22 ' Q' ' 39' ' ' VAL . . . -77.92 64.15 3.41 Favored Glycine 0 CA--C 1.541 1.669 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.42 154.28 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 123.44 0.696 . . . . 0.0 110.266 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.552 ' C ' HG22 ' O' ' 40' ' ' VAL . 1.4 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.419 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -82.02 137.29 35.12 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.814 0.34 . . . . 0.0 110.753 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -74.03 150.1 40.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.664 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.531 ' O ' ' CD2' ' Q' ' 14' ' ' HIS . 27.0 m -128.69 -175.84 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.107 0.479 . . . . 0.0 111.04 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.695 ' CD2' ' H ' ' P' ' 13' ' ' HIS . 2.9 m170 -67.44 105.31 1.77 Allowed 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -176.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.554 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 4.7 m-70 -114.53 160.91 18.7 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 175.683 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.454 ' HB3' ' H ' ' R' ' 16' ' ' LYS . 15.5 tt0 -89.99 157.32 17.88 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.251 178.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -142.19 94.8 2.7 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.606 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -127.76 115.5 18.77 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.923 177.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 t -112.54 110.63 32.91 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.672 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.641 ' CD1' HD13 ' O' ' 32' ' ' ILE . 57.7 m-85 -107.92 102.1 11.32 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 178.057 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 33.5 t80 -111.25 124.19 51.72 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.345 -0.243 . . . . 0.0 110.345 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.8 128.57 24.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.203 0.525 . . . . 0.0 111.779 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -86.92 104.14 15.97 Favored 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD2' ' R' ' 23' ' ' ASP . 39.5 p-10 -135.05 52.27 2.05 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.562 -1.199 . . . . 0.0 111.517 -175.765 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 86.8 t -73.75 142.57 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.537 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -177.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.88 37.69 3.59 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 106.846 -2.502 . . . . 0.0 106.846 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 11.2 t -70.4 103.65 2.49 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.644 -0.778 . . . . 0.0 111.281 -178.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -117.97 -151.93 0.49 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.905 -178.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -39.8 -42.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.391 -1.277 . . . . 0.0 113.468 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.9 61.74 0.7 Allowed Glycine 0 CA--C 1.545 1.942 0 N-CA-C 115.793 1.077 . . . . 0.0 115.793 -174.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . 0.468 ' HB3' ' HB2' ' R' ' 30' ' ' ALA . . . -141.24 107.85 5.34 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' P' ' 31' ' ' ILE . 87.3 mt -132.97 133.45 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.72 123.03 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 177.422 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.85 119.86 3.29 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 46.3 mt -120.56 119.86 34.15 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 120.692 0.282 . . . . 0.0 110.273 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.487 ' O ' ' SD ' ' P' ' 35' ' ' MET . 94.0 mmm -116.52 123.71 48.09 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.9 HG13 ' O ' ' P' ' 36' ' ' VAL . 6.5 t -140.04 163.8 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.18 93.38 0.1 Allowed Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 119.513 -1.327 . . . . 0.0 111.382 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.23 -81.98 0.11 Allowed Glycine 0 CA--C 1.533 1.182 0 C-N-CA 119.709 -1.234 . . . . 0.0 113.41 176.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.584 HG22 ' O ' ' P' ' 38' ' ' GLY . 10.6 m -147.0 162.09 8.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 120.858 0.361 . . . . 0.0 110.425 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.984 -1.007 . . . . 0.0 110.481 -179.855 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -108.5 134.71 50.9 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.765 0.316 . . . . 0.0 110.328 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 57.2 mp0 -77.04 135.7 38.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.554 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 40.7 t -139.0 163.31 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.133 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.551 ' N ' HG12 ' R' ' 12' ' ' VAL . 0.1 OUTLIER -89.04 119.6 29.7 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.553 178.343 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -149.51 171.15 17.07 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.797 0.332 . . . . 0.0 111.675 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.433 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 32.8 mt-30 -83.64 154.65 23.6 Favored 'General case' 0 N--CA 1.456 -0.139 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.454 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 70.4 tttt -159.75 104.6 1.57 Allowed 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.637 0.732 . . . . 0.0 109.573 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.415 HD11 HG11 ' P' ' 36' ' ' VAL . 2.7 mp -126.14 119.71 28.24 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.325 178.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 26.7 t -101.72 107.9 22.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.405 ' CD1' HD13 ' P' ' 32' ' ' ILE . 74.5 m-85 -103.04 99.51 9.4 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 178.083 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -118.48 119.58 34.98 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-O 121.731 0.777 . . . . 0.0 111.457 -177.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.426 ' HB1' ' OD2' ' Q' ' 23' ' ' ASP . . . -124.99 134.11 52.73 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' R' ' 23' ' ' ASP . 83.0 mt-10 -68.72 103.96 1.88 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.226 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' R' ' 22' ' ' GLU . 5.3 p30 140.46 48.44 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 O-C-N 125.107 1.504 . . . . 0.0 108.519 -178.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 36.0 m -72.32 161.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.341 0.591 . . . . 0.0 111.579 -177.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.7 -29.79 8.3 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.219 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.42 ' O ' ' OG ' ' R' ' 26' ' ' SER . 6.3 p 61.68 109.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.638 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.732 ' O ' ' N ' ' R' ' 29' ' ' GLY . 66.0 t30 -129.72 -179.93 5.47 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.313 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 28' ' ' LYS . . . . . 0.505 ' H ' ' CG ' ' R' ' 27' ' ' ASN . 98.9 mttt -29.6 47.81 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 126.325 1.85 . . . . 0.0 115.927 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.732 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -170.05 -59.03 0.04 OUTLIER Glycine 0 CA--C 1.539 1.554 0 C-N-CA 120.045 -1.074 . . . . 0.0 113.686 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 30' ' ' ALA . . . . . 0.468 ' HB2' ' HB3' ' Q' ' 30' ' ' ALA . . . -81.0 153.98 27.16 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 117.644 0.722 . . . . 0.0 112.132 -177.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 97.9 mt -121.93 132.37 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.31 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -123.69 128.41 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.313 -0.403 . . . . 0.0 109.929 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.51 120.29 3.65 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 35.9 mt -110.15 115.3 29.49 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.3 tpp -128.26 122.9 32.8 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.564 HG12 ' N ' ' R' ' 37' ' ' GLY . 21.8 t -136.35 171.55 16.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.564 ' N ' HG12 ' R' ' 36' ' ' VAL . . . -167.93 94.4 0.11 Allowed Glycine 0 C--N 1.309 -0.931 0 C-N-CA 119.598 -1.287 . . . . 0.0 111.439 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.0 -81.44 0.14 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 177.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 19.0 m -154.96 151.16 11.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.29 179.812 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.524 ' CE2' ' O ' ' A' ' 11' ' ' GLU . 82.6 t80 -84.08 129.29 34.91 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.751 0.31 . . . . 0.0 110.637 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.524 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 98.7 mt-10 -81.0 155.79 26.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.205 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.2 t -121.79 128.87 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.095 0.474 . . . . 0.0 110.421 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -119.55 163.59 17.09 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.485 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.497 ' CD2' ' H ' ' A' ' 14' ' ' HIS . 3.0 m-70 -83.51 164.71 19.67 Favored 'General case' 0 C--N 1.332 -0.157 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.231 -179.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -130.56 152.51 49.86 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.319 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -94.37 116.6 29.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.451 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 30.3 tp -122.28 115.68 22.77 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.195 0.521 . . . . 0.0 110.017 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . 0.621 HG22 HG22 ' B' ' 18' ' ' VAL . 79.1 t -128.48 132.03 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.529 -178.526 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -136.62 139.15 41.88 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.986 0.422 . . . . 0.0 110.305 178.057 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -139.19 132.83 30.52 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.23 119.18 24.68 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.862 0.839 . . . . 0.0 111.141 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -152.12 142.63 22.66 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.89 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 53.3 t0 64.6 47.58 2.85 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.419 HG12 ' H ' ' A' ' 25' ' ' GLY . 1.3 t -100.17 -161.47 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 177.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.419 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -72.49 -35.78 59.41 Favored Glycine 0 C--N 1.34 0.784 0 C-N-CA 118.218 -1.944 . . . . 0.0 108.784 178.636 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 53.7 m -156.06 112.49 3.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 10.5 m120 -52.61 172.52 0.04 OUTLIER 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.576 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -62.74 -38.94 92.49 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.835 1.302 . . . . 0.0 107.579 174.272 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.442 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 81.91 -69.48 3.3 Favored Glycine 0 CA--C 1.533 1.174 0 CA-C-N 112.021 -2.354 . . . . 0.0 111.641 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.442 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . 179.73 61.27 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 118.64 1.22 . . . . 0.0 112.764 175.388 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.615 ' CD1' HG12 ' M' ' 39' ' ' VAL . 83.7 mt -131.99 102.05 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.558 0 CA-C-N 119.904 1.229 . . . . 0.0 108.257 179.039 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 80.8 mt -108.32 113.69 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.749 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.74 94.61 0.55 Allowed Glycine 0 N--CA 1.463 0.439 0 N-CA-C 104.748 -3.341 . . . . 0.0 104.748 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.569 ' O ' HD23 ' B' ' 34' ' ' LEU . 87.5 mt -143.22 157.75 44.22 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 122.788 1.28 . . . . 0.0 114.055 -175.199 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 4.7 mtp -115.99 106.07 13.37 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 112.435 -2.166 . . . . 0.0 107.154 177.357 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 1.02 HG11 HD11 ' C' ' 17' ' ' LEU . 43.6 t -124.25 112.03 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.31 -131.89 8.57 Favored Glycine 0 C--N 1.322 -0.246 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.83 -62.69 0.4 Allowed Glycine 0 CA--C 1.534 1.259 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.267 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.879 HG12 HD12 ' G' ' 31' ' ' ILE . 26.9 m -108.34 162.78 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.189 0.495 . . . . 0.0 110.261 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 44.6 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.829 -1.081 . . . . 0.0 110.699 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -105.52 130.95 53.48 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 110.403 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -106.89 116.35 31.78 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.999 0.428 . . . . 0.0 110.729 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.31 128.95 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.373 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.614 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 1.3 t-80 -127.78 106.97 9.49 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.964 0.411 . . . . 0.0 110.468 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.588 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 4.3 t60 -152.82 168.68 24.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.99 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.588 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 12.4 tt0 -155.96 141.42 17.7 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt -85.65 123.71 31.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.944 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.538 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.7 tt -126.01 115.85 20.53 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.006 0.431 . . . . 0.0 110.221 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 18' ' ' VAL . 2.6 m -123.98 131.84 72.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.382 179.297 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.437 ' CE2' ' HB2' ' B' ' 21' ' ' ALA . 71.9 t80 -125.76 122.32 35.91 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.251 -178.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -115.71 123.68 48.94 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' ALA . . . . . 0.437 ' HB2' ' CE2' ' B' ' 19' ' ' PHE . . . -142.95 143.33 31.93 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 114.185 1.179 . . . . 0.0 114.185 -178.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.9 mt-10 -91.46 154.75 18.93 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' B' ' 22' ' ' GLU . 70.0 m-20 -139.18 46.5 1.93 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.555 1.317 . . . . 0.0 114.555 -176.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.708 HG12 ' N ' ' B' ' 25' ' ' GLY . 60.7 t -111.72 177.03 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 C-N-CA 118.562 -1.255 . . . . 0.0 108.291 177.615 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.708 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 62.39 28.35 70.91 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.291 -0.727 . . . . 0.0 111.531 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 24.5 p -170.55 -131.55 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.674 0 CA-C-N 118.558 1.179 . . . . 0.0 113.596 -176.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.529 ' N ' ' OG ' ' B' ' 26' ' ' SER . 16.2 m120 -30.79 173.01 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 112.803 -1.999 . . . . 0.0 115.449 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.412 ' H ' ' H ' ' B' ' 29' ' ' GLY . 53.0 mtmt -161.28 -21.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.451 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' B' ' 28' ' ' LYS . . . -78.8 110.73 3.1 Favored Glycine 0 CA--C 1.532 1.123 0 CA-C-N 113.85 -1.523 . . . . 0.0 109.722 177.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -129.86 110.25 11.56 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 123.025 1.393 . . . . 0.0 112.814 -176.21 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.552 HD11 HG23 ' N' ' 39' ' ' VAL . 71.9 mt -142.73 139.85 28.09 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-N 113.824 -1.535 . . . . 0.0 112.134 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.789 HG22 HD11 ' C' ' 34' ' ' LEU . 27.0 mt -106.9 114.34 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 107.157 -1.424 . . . . 0.0 107.157 174.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.08 106.32 1.42 Allowed Glycine 0 N--CA 1.461 0.312 0 N-CA-C 106.677 -2.569 . . . . 0.0 106.677 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.569 HD23 ' O ' ' A' ' 34' ' ' LEU . 0.4 OUTLIER -143.18 141.81 31.26 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.376 -1.33 . . . . 0.0 113.064 -175.833 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -108.88 109.31 20.38 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 112.455 -2.157 . . . . 0.0 106.637 177.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.501 ' CG1' HD22 ' B' ' 34' ' ' LEU . 32.8 m -133.7 151.69 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.073 0.463 . . . . 0.0 110.091 -177.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.81 -101.85 2.67 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -178.674 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.08 -80.74 0.58 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.187 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.6 HG21 HD11 ' G' ' 31' ' ' ILE . 38.6 t -111.47 135.15 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.629 ' H ' ' CG2' ' C' ' 39' ' ' VAL . 64.1 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.131 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 10' ' ' TYR . . . . . 0.42 ' CE2' ' O ' ' C' ' 11' ' ' GLU . 90.1 t80 -73.55 132.52 42.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.986 0.422 . . . . 0.0 110.691 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.42 ' O ' ' CE2' ' C' ' 10' ' ' TYR . 96.3 mt-10 -75.54 136.85 40.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.24 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.693 HG23 ' O ' ' C' ' 12' ' ' VAL . 16.7 m -129.45 108.16 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.828 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' B' ' 13' ' ' HIS . 15.4 m-70 -142.64 135.6 28.28 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -178.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.575 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.6 p-80 -153.6 156.19 37.5 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.24 176.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.5 tp60 -99.44 154.2 18.41 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 174.812 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -121.58 109.68 15.09 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 173.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 1.02 HD11 HG11 ' A' ' 36' ' ' VAL . 34.5 mt -118.45 112.99 20.66 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.112 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 18' ' ' VAL . . . . . 0.45 ' CG1' HG12 ' B' ' 18' ' ' VAL . 3.0 p -116.64 111.39 35.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 106.862 -1.532 . . . . 0.0 106.862 175.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' C' ' 17' ' ' LEU . 71.8 m-85 -102.79 108.84 20.22 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' C' ' 20' ' ' PHE . 26.0 t80 -110.7 123.94 50.98 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.565 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.22 138.99 35.52 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -90.79 108.31 19.75 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 176.527 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -100.28 46.7 0.95 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -176.061 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.566 ' O ' HG22 ' B' ' 24' ' ' VAL . 54.3 t -101.12 162.23 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 176.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.54 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 69.98 30.64 69.92 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 176.629 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.77 ' O ' ' O ' ' C' ' 27' ' ' ASN . 20.6 p -173.06 -118.73 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.406 1.103 . . . . 0.0 113.307 -177.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.77 ' O ' ' O ' ' C' ' 26' ' ' SER . 61.4 t30 21.35 172.91 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 126.0 1.72 . . . . 0.0 114.446 -176.589 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -159.97 -29.54 0.06 Allowed 'General case' 0 N--CA 1.466 0.372 0 O-C-N 121.334 -0.853 . . . . 0.0 112.648 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.69 81.59 0.09 OUTLIER Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.294 -173.72 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -78.42 130.7 36.4 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 122.798 1.285 . . . . 0.0 113.057 -175.07 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.839 HD11 HG12 ' O' ' 39' ' ' VAL . 76.6 mt -130.31 134.18 62.86 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 113.022 -1.899 . . . . 0.0 111.581 -178.343 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.648 HD13 ' CD1' ' E' ' 19' ' ' PHE . 87.7 mt -107.91 121.99 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.71 ' O ' HD12 ' C' ' 34' ' ' LEU . . . -126.3 102.24 0.63 Allowed Glycine 0 N--CA 1.469 0.848 0 N-CA-C 107.845 -2.102 . . . . 0.0 107.845 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.789 HD11 HG22 ' B' ' 32' ' ' ILE . 5.9 mp -139.13 146.65 40.91 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 123.219 1.485 . . . . 0.0 113.538 -176.707 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -106.69 109.64 21.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 112.19 -2.277 . . . . 0.0 106.798 177.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.474 HG21 HD11 ' D' ' 34' ' ' LEU . 18.5 t -121.33 131.06 73.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 120.957 0.408 . . . . 0.0 111.695 -176.049 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.03 -110.85 3.1 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.575 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.32 -73.12 0.68 Allowed Glycine 0 CA--C 1.544 1.849 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -177.515 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.629 ' CG2' ' H ' ' B' ' 40' ' ' VAL . 1.3 m -132.32 179.77 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 176.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.475 ' N ' HG12 ' D' ' 39' ' ' VAL . 46.8 t . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.696 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.162 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -106.16 135.05 48.32 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.801 0.334 . . . . 0.0 110.56 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.447 ' O ' HG11 ' C' ' 12' ' ' VAL . 97.4 mt-10 -74.15 126.25 30.16 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.471 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.8 m -137.52 132.75 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.14 -178.395 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.54 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 22.4 t-80 -61.9 121.22 12.39 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.595 -177.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.798 ' CD2' ' H ' ' E' ' 14' ' ' HIS . 35.3 m170 -150.45 162.55 40.37 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.408 ' HB2' HE22 ' E' ' 15' ' ' GLN . 10.3 tp-100 -85.99 156.85 20.28 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 175.338 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -159.78 102.21 1.49 Allowed 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.29 -0.964 . . . . 0.0 109.914 177.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.456 HD22 HD12 ' C' ' 17' ' ' LEU . 16.2 mt -132.16 122.35 25.17 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.361 0.601 . . . . 0.0 111.478 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 91.2 t -113.36 107.56 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.449 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 80.8 m-85 -104.22 106.87 17.53 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -126.69 128.59 46.94 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -176.059 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.82 124.03 41.22 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.345 177.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -89.27 153.35 20.97 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 122.059 0.933 . . . . 0.0 113.262 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.451 ' O ' HG22 ' C' ' 24' ' ' VAL . 98.2 m-20 40.59 55.25 2.95 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 113.631 -1.622 . . . . 0.0 113.257 177.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.651 HG21 ' HB1' ' E' ' 21' ' ' ALA . 98.4 t -66.06 135.12 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 177.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.32 -32.54 1.79 Allowed Glycine 0 N--CA 1.468 0.798 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.414 ' OG ' ' O ' ' C' ' 27' ' ' ASN . 26.8 m -71.25 120.34 16.69 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.147 0.499 . . . . 0.0 110.231 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 14.4 m-20 -103.41 -151.82 0.44 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.184 -178.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.466 ' H ' ' HA ' ' E' ' 27' ' ' ASN . 26.2 pttm 31.72 41.84 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.432 -1.258 . . . . 0.0 114.074 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.41 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -173.36 60.89 0.14 Allowed Glycine 0 CA--C 1.54 1.594 0 C-N-CA 119.672 -1.252 . . . . 0.0 113.63 174.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.661 ' N ' ' ND2' ' E' ' 27' ' ' ASN . . . -107.95 109.88 21.48 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 117.717 0.759 . . . . 0.0 109.508 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.514 HD11 HG23 ' P' ' 39' ' ' VAL . 69.3 mt -134.09 128.59 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 118.952 -1.099 . . . . 0.0 112.186 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.613 HD13 ' CD1' ' F' ' 19' ' ' PHE . 95.7 mt -112.55 119.29 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 177.382 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.43 98.88 0.8 Allowed Glycine 0 C--O 1.239 0.453 0 N-CA-C 105.895 -2.882 . . . . 0.0 105.895 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.474 HD11 HG21 ' C' ' 36' ' ' VAL . 11.3 tp -131.47 136.45 47.94 Favored 'General case' 0 C--O 1.244 0.81 0 CA-C-O 122.658 1.218 . . . . 0.0 113.795 -175.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -109.54 110.0 20.96 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 113.064 -1.88 . . . . 0.0 108.217 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.5 122.87 67.25 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.5 -113.58 0.71 Allowed Glycine 0 C--N 1.307 -1.031 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 96.11 -71.98 0.86 Allowed Glycine 0 CA--C 1.53 1.022 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.554 ' CG2' ' O ' ' J' ' 29' ' ' GLY . 0.3 OUTLIER -141.4 163.06 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 178.005 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' D' ' 39' ' ' VAL . 21.2 t . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 118.215 -0.897 . . . . 0.0 111.746 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.75 136.07 46.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.953 0.406 . . . . 0.0 110.686 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -113.72 119.75 38.47 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.301 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.549 ' O ' ' NE2' ' D' ' 14' ' ' HIS . 50.9 t -127.17 134.21 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 121.395 0.617 . . . . 0.0 110.025 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -129.23 106.4 8.8 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.934 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.798 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 3.3 p80 -151.87 161.35 42.79 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 177.427 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.411 ' OE1' ' CG1' ' C' ' 36' ' ' VAL . 79.1 mm-40 -90.01 158.12 17.5 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -141.1 100.03 3.72 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.405 ' N ' HD12 ' E' ' 17' ' ' LEU . 5.2 mp -133.38 126.1 30.56 Favored 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.643 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -113.62 106.66 21.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.505 178.22 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.648 ' CD1' HD13 ' C' ' 32' ' ' ILE . 89.8 m-85 -105.79 106.05 16.38 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.303 -1.739 . . . . 0.0 106.303 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -133.53 135.13 44.18 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.091 1.145 . . . . 0.0 114.091 -176.235 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.651 ' HB1' HG21 ' D' ' 24' ' ' VAL . . . -128.32 129.91 46.99 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.988 177.505 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.418 ' HB2' ' H ' ' D' ' 23' ' ' ASP . 97.8 mt-10 -91.25 166.26 13.03 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.115 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 25.99 47.27 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 112.293 -2.23 . . . . 0.0 115.835 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.6 HG12 ' N ' ' E' ' 25' ' ' GLY . 53.4 t -67.43 171.43 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 174.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.6 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -117.75 37.41 3.3 Favored Glycine 0 N--CA 1.48 1.581 0 C-N-CA 119.433 -1.365 . . . . 0.0 111.264 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 72.52 119.99 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.499 . . . . 0.0 110.236 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.661 ' ND2' ' N ' ' D' ' 30' ' ' ALA . 81.4 m-20 -83.19 163.62 20.68 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.952 176.588 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -46.93 -36.93 8.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 122.022 0.915 . . . . 0.0 108.946 175.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 77.42 0.06 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 113.694 -1.594 . . . . 0.0 110.558 -177.593 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.73 149.26 4.8 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.775 0.787 . . . . 0.0 110.648 -178.32 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.44 137.14 56.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.67 122.11 68.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 114.491 -1.231 . . . . 0.0 109.784 178.027 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.37 106.76 1.36 Allowed Glycine 0 N--CA 1.465 0.607 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 27.0 tp -126.16 125.52 42.61 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.872 0.367 . . . . 0.0 111.313 -177.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.445 ' CG ' ' N ' ' E' ' 36' ' ' VAL . 27.3 ttp -146.29 158.85 43.92 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.614 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.581 HG22 ' HA ' ' F' ' 36' ' ' VAL . 1.3 m -115.02 162.93 12.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.1 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.77 -102.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.371 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -78.47 1.05 Allowed Glycine 0 CA--C 1.534 1.243 0 C-N-CA 121.659 -0.305 . . . . 0.0 112.781 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.446 HG13 ' O ' ' E' ' 39' ' ' VAL . 9.3 p -93.01 128.12 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 116.952 0.376 . . . . 0.0 111.107 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.472 ' OXT' HG21 ' E' ' 36' ' ' VAL . 80.5 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.07 -0.967 . . . . 0.0 110.323 -179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -103.4 132.34 49.74 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.734 0.302 . . . . 0.0 110.201 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 pt-20 -143.45 150.68 39.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.813 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -124.32 132.83 70.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.018 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.482 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 8.5 p80 -144.74 114.69 7.37 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 121.206 0.526 . . . . 0.0 112.337 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.437 ' ND1' ' O ' ' F' ' 15' ' ' GLN . 54.8 t-80 -151.35 164.35 36.87 Favored 'General case' 0 C--O 1.217 -0.609 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.437 ' O ' ' ND1' ' F' ' 14' ' ' HIS . 88.7 mt-30 -89.91 158.33 17.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 119.113 0.87 . . . . 0.0 111.383 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.53 95.78 2.92 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -130.4 119.31 22.52 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -107.32 105.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.32 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.613 ' CD1' HD13 ' D' ' 32' ' ' ILE . 78.9 m-85 -107.59 109.0 20.53 Favored 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 20.3 t80 -147.21 137.62 23.42 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 118.618 -1.233 . . . . 0.0 113.826 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.33 130.48 49.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.08 -1.418 . . . . 0.0 107.468 177.217 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' E' ' 24' ' ' VAL . 96.9 mt-10 -82.29 115.79 21.52 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.043 -0.663 . . . . 0.0 111.653 -178.223 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 9.6 p-10 177.12 -64.54 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.7 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.48 133.72 29.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.246 -178.126 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.23 -30.8 1.83 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.169 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 91.0 p -80.96 -130.27 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -176.197 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.541 ' O ' ' N ' ' F' ' 29' ' ' GLY . 11.6 m120 -99.24 -164.49 1.13 Allowed 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 114.344 1.239 . . . . 0.0 114.344 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -48.14 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 112.816 -1.993 . . . . 0.0 114.936 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -96.16 56.98 1.49 Allowed Glycine 0 CA--C 1.544 1.887 0 C-N-CA 120.188 -1.006 . . . . 0.0 111.878 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.76 179.56 9.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.3 mt -121.2 127.24 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 118.486 0.585 . . . . 0.0 109.79 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 95.1 mt -128.2 131.7 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-O 120.865 0.364 . . . . 0.0 111.45 -178.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.3 116.86 2.67 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.1 tp -122.75 126.13 46.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 5.0 ttp -140.19 139.81 35.75 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 122.365 1.079 . . . . 0.0 113.845 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.581 ' HA ' HG22 ' E' ' 36' ' ' VAL . 43.8 t -117.31 131.95 68.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 CA-C-N 113.758 -1.565 . . . . 0.0 109.523 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -41.25 -111.62 0.0 OUTLIER Glycine 0 CA--C 1.531 1.046 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.907 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -71.7 0.6 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 111.767 -0.533 . . . . 0.0 111.767 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 94.6 t -76.99 131.53 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 117.3 0.55 . . . . 0.0 110.325 179.117 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.421 HG22 ' O ' ' F' ' 40' ' ' VAL . 14.9 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.148 -0.929 . . . . 0.0 110.608 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 10' ' ' TYR . . . . . 0.561 ' HH ' ' N ' ' I' ' 9' ' ' GLY . 94.1 m-85 -105.06 133.55 49.66 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -141.68 144.45 34.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.268 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.45 160.63 41.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -138.2 117.34 12.61 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 121.006 0.432 . . . . 0.0 111.546 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.474 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 49.1 p-80 -151.74 168.05 26.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.099 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 29.2 mm100 -156.98 143.23 18.07 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.046 0.45 . . . . 0.0 110.07 179.249 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -81.27 118.23 22.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 178.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.0 tp -136.76 118.92 15.48 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.313 0.577 . . . . 0.0 111.349 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 m -137.0 153.44 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.965 178.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -146.51 130.74 17.48 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-O 120.964 0.411 . . . . 0.0 111.195 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -123.04 132.2 54.02 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 126.94 35.6 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.467 0.651 . . . . 0.0 112.685 -178.319 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -96.36 145.31 25.73 Favored 'General case' 0 C--N 1.34 0.159 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.406 ' OD2' ' O ' ' G' ' 26' ' ' SER . 10.2 t70 -172.33 46.9 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.717 -176.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.672 HG12 ' H ' ' G' ' 25' ' ' GLY . 5.2 t -82.21 172.68 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.307 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.672 ' H ' HG12 ' G' ' 24' ' ' VAL . . . 90.92 -33.9 4.47 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 -176.639 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.406 ' H ' ' C ' ' G' ' 24' ' ' VAL . 71.1 m -151.98 122.97 7.57 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 114.122 -1.039 . . . . 0.0 108.896 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.594 ' OD1' ' N ' ' G' ' 28' ' ' LYS . 31.7 t-20 -41.82 151.18 0.1 Allowed 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.852 179.051 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.617 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 88.5 tttt -69.43 -48.36 61.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.28 0.562 . . . . 0.0 110.411 178.073 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.521 ' N ' ' OD1' ' G' ' 27' ' ' ASN . . . 129.81 59.92 0.1 Allowed Glycine 0 CA--C 1.54 1.633 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 -176.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.09 89.28 0.82 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.879 HD12 HG12 ' A' ' 39' ' ' VAL . 87.3 mt -137.27 117.84 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-N 113.315 -1.766 . . . . 0.0 106.857 177.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.484 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.4 mt -106.17 110.64 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 94.86 0.67 Allowed Glycine 0 CA--C 1.508 -0.399 0 N-CA-C 105.097 -3.201 . . . . 0.0 105.097 177.021 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.705 ' O ' HD12 ' H' ' 34' ' ' LEU . 79.7 mt -147.49 168.44 21.91 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-O 123.254 1.502 . . . . 0.0 113.766 -175.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 94.5 mmm -120.96 114.39 21.46 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 112.064 -2.335 . . . . 0.0 107.16 178.464 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.495 HG21 HD22 ' I' ' 17' ' ' LEU . 41.4 t -124.6 131.53 72.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.54 -111.31 3.3 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.719 -0.953 . . . . 0.0 110.719 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.4 -73.79 1.33 Allowed Glycine 0 CA--C 1.536 1.395 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.252 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.627 HG12 HD12 ' M' ' 31' ' ' ILE . 22.3 m -87.02 171.55 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 117.401 0.6 . . . . 0.0 110.381 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.243 179.273 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -107.62 129.71 54.97 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.711 0.291 . . . . 0.0 110.346 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -154.85 148.76 25.66 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-O 121.166 0.508 . . . . 0.0 111.552 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.514 HG13 ' CG2' ' I' ' 12' ' ' VAL . 55.7 t -124.5 130.03 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.459 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 26.2 p80 -147.46 142.81 27.37 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 119.48 -0.888 . . . . 0.0 113.131 -179.245 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.474 ' O ' ' CB ' ' G' ' 14' ' ' HIS . 1.5 m-70 -146.23 170.36 16.91 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 114.512 -1.222 . . . . 0.0 108.217 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -155.83 141.28 17.72 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.366 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -87.94 108.67 19.3 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.973 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -121.13 110.71 16.54 Favored 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.361 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.416 HG22 ' CG2' ' I' ' 18' ' ' VAL . 72.0 t -122.13 130.62 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.192 -178.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -126.52 118.98 26.0 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -122.35 125.93 46.98 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.61 131.26 39.42 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.457 0.646 . . . . 0.0 112.677 -179.073 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -97.68 127.1 43.38 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.541 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.617 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 97.1 m-20 -139.25 46.55 1.92 Allowed 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.598 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.694 HG12 ' N ' ' H' ' 25' ' ' GLY . 21.5 t -82.8 173.34 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-O 122.697 1.237 . . . . 0.0 113.06 -176.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.694 ' N ' HG12 ' H' ' 24' ' ' VAL . . . 92.74 -35.16 4.17 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 112.596 -2.093 . . . . 0.0 114.26 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' H' ' 27' ' ' ASN . 32.2 t -162.55 117.38 1.82 Allowed 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 120.691 2.246 . . . . 0.0 114.192 175.341 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' H' ' 26' ' ' SER . 45.0 p-10 -22.55 153.13 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.116 0.566 . . . . 0.0 112.297 173.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 7.7 tttm -165.95 26.38 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 117.948 -1.501 . . . . 0.0 114.887 173.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 107.77 0.38 Allowed Glycine 0 CA--C 1.532 1.11 0 C-N-CA 119.004 -1.57 . . . . 0.0 113.944 177.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.7 111.47 17.65 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.466 HD11 HG13 ' C' ' 39' ' ' VAL . 87.4 mt -130.22 133.61 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.533 HD13 ' CD2' ' J' ' 19' ' ' PHE . 93.6 mt -105.71 108.46 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.306 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -109.44 101.92 1.54 Allowed Glycine 0 N--CA 1.465 0.623 0 N-CA-C 105.897 -2.881 . . . . 0.0 105.897 177.05 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.705 HD12 ' O ' ' G' ' 34' ' ' LEU . 47.2 tp -152.53 145.62 24.59 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 117.306 -1.758 . . . . 0.0 114.612 -173.726 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.583 ' H ' HD12 ' H' ' 34' ' ' LEU . 3.8 ttm -106.9 117.02 32.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.71 177.457 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.473 ' CG2' HG12 ' I' ' 36' ' ' VAL . 2.9 t -118.19 102.49 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.801 -178.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.27 -163.93 26.78 Favored Glycine 0 CA--C 1.524 0.617 0 C-N-CA 120.354 -0.926 . . . . 0.0 112.655 177.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.52 ' HA2' ' H ' ' I' ' 38' ' ' GLY . . . 156.2 -54.55 0.41 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.721 HG13 HD13 ' N' ' 31' ' ' ILE . 3.7 m -141.31 164.21 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 176.072 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.538 ' OXT' ' NZ ' ' N' ' 28' ' ' LYS . 1.3 p . . . . . 0 N--CA 1.467 0.377 0 CA-C-O 117.802 -1.094 . . . . 0.0 111.353 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 9' ' ' GLY . . . . . 0.561 ' N ' ' HH ' ' G' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.25 135.41 46.67 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.691 0.281 . . . . 0.0 110.387 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' NE2' ' I' ' 13' ' ' HIS . 45.7 tp10 -147.11 100.9 3.35 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.908 0.385 . . . . 0.0 110.256 179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.514 ' CG2' HG13 ' H' ' 12' ' ' VAL . 4.9 m -141.75 127.41 18.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.986 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.409 ' NE2' ' OE2' ' I' ' 11' ' ' GLU . 49.5 m170 -113.59 136.24 53.03 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.829 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.527 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 70.7 m80 -156.64 176.04 13.26 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.29 0.567 . . . . 0.0 110.515 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.411 ' CG ' HD11 ' I' ' 17' ' ' LEU . 40.8 tp60 -159.33 139.09 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -105.39 113.61 27.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 118.999 -0.524 . . . . 0.0 111.5 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.495 HD22 HG21 ' G' ' 36' ' ' VAL . 0.7 OUTLIER -129.5 112.48 13.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.557 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.416 ' CG2' HG22 ' H' ' 18' ' ' VAL . 15.1 m -119.43 124.87 73.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -112.16 116.76 30.98 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 114.752 -1.113 . . . . 0.0 108.673 -178.419 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -119.08 129.14 54.92 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.767 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.87 138.19 30.08 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.436 -0.506 . . . . 0.0 112.165 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -131.91 130.95 42.23 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 120.458 -0.497 . . . . 0.0 112.261 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.64 ' C ' HG23 ' I' ' 24' ' ' VAL . 0.3 OUTLIER -130.98 -49.94 1.03 Allowed 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.188 0.518 . . . . 0.0 110.477 178.644 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.699 HG22 ' CD ' ' J' ' 22' ' ' GLU . 2.0 t 77.7 143.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.939 176.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.531 ' H ' ' CG2' ' J' ' 24' ' ' VAL . . . 92.08 37.46 5.99 Favored Glycine 0 CA--C 1.525 0.662 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.372 174.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 3.0 p 72.69 120.15 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 117.744 0.772 . . . . 0.0 110.237 177.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.598 ' H ' ' ND2' ' J' ' 27' ' ' ASN . 13.8 p30 -83.03 161.3 21.75 Favored 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 117.598 -1.641 . . . . 0.0 109.192 177.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.434 ' O ' ' OXT' ' C' ' 40' ' ' VAL . 95.8 mttt -48.63 -39.54 24.49 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 176.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.45 0.04 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -175.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.61 139.15 51.32 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 119.027 1.413 . . . . 0.0 114.281 -174.476 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.589 HD12 HG12 ' C' ' 39' ' ' VAL . 61.2 mt -141.57 143.78 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 113.529 -1.669 . . . . 0.0 113.026 -178.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.435 HG23 HD12 ' I' ' 34' ' ' LEU . 9.8 mt -104.31 109.72 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 175.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -109.51 100.75 1.38 Allowed Glycine 0 N--CA 1.463 0.454 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.629 ' O ' HD12 ' J' ' 34' ' ' LEU . 0.2 OUTLIER -139.14 143.27 38.13 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.928 1.347 . . . . 0.0 113.681 -175.52 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.407 ' SD ' ' HB2' ' J' ' 35' ' ' MET . 87.7 mmm -117.12 108.71 16.03 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 111.939 -2.391 . . . . 0.0 104.61 175.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.703 ' CG2' HG12 ' J' ' 36' ' ' VAL . 24.4 m -126.14 130.94 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 118.695 -1.202 . . . . 0.0 112.77 -178.149 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.88 111.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 113.048 -1.887 . . . . 0.0 113.477 177.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.52 ' H ' ' HA2' ' H' ' 38' ' ' GLY . . . -80.81 -60.53 2.29 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.206 -1.157 . . . . 0.0 110.206 175.404 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.3 p -146.2 150.08 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 121.407 0.622 . . . . 0.0 110.407 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.815 HG11 ' CD2' ' K' ' 13' ' ' HIS . 21.3 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.659 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -105.31 133.5 49.98 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.64 ' CG ' ' HE2' ' J' ' 13' ' ' HIS . 80.4 tt0 -153.34 114.81 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.005 0.431 . . . . 0.0 110.645 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.436 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -138.83 138.34 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.847 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.64 ' HE2' ' CG ' ' J' ' 11' ' ' GLU . 19.7 m-70 -139.19 147.83 42.34 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.814 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.527 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 56.9 m-70 -151.97 160.92 43.35 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.615 177.201 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 tp60 -90.46 158.35 17.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 177.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.743 ' C ' HD12 ' J' ' 17' ' ' LEU . 97.6 mttt -141.48 90.82 2.32 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.288 176.109 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.743 HD12 ' C ' ' J' ' 16' ' ' LYS . 9.2 mp -128.54 129.86 46.61 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 118.813 0.733 . . . . 0.0 110.688 177.616 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 18.4 t -125.64 116.83 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.682 179.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 12.6 m-85 -109.31 106.95 16.97 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 6.3 t80 -114.01 121.91 45.32 Favored 'General case' 0 N--CA 1.478 0.973 0 O-C-N 122.263 -0.273 . . . . 0.0 110.337 -178.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.24 138.73 37.07 Favored 'General case' 0 C--O 1.253 1.259 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.699 ' CD ' HG22 ' I' ' 24' ' ' VAL . 52.7 tt0 -66.92 149.6 50.39 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 176.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.697 ' O ' ' O ' ' J' ' 24' ' ' VAL . 65.1 t0 -168.38 64.5 0.07 Allowed 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -168.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.697 ' O ' ' O ' ' J' ' 23' ' ' ASP . 58.7 t -43.06 -104.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 CA-C-O 113.942 -2.932 . . . . 0.0 103.809 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 166.75 -48.18 0.26 Allowed Glycine 0 N--CA 1.482 1.754 2 CA-C-N 127.32 4.6 . . . . 0.0 119.696 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 41.0 t -65.8 101.0 0.6 Allowed 'General case' 0 C--N 1.322 -0.596 1 CA-C-N 125.567 4.683 . . . . 0.0 105.867 -179.531 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.598 ' ND2' ' H ' ' I' ' 27' ' ' ASN . 1.1 m-20 -129.48 160.88 31.79 Favored 'General case' 0 C--N 1.348 0.504 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.75 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.407 ' C ' ' O ' ' J' ' 27' ' ' ASN . 70.3 mmtt -29.61 -39.42 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.785 -1.098 . . . . 0.0 113.44 174.424 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.554 ' O ' ' CG2' ' D' ' 39' ' ' VAL . . . 140.93 74.87 0.04 OUTLIER Glycine 0 CA--C 1.552 2.371 0 C-N-CA 119.668 -1.253 . . . . 0.0 112.341 -175.561 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.03 155.54 40.44 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 120.631 2.215 . . . . 0.0 113.061 -174.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' D' ' 38' ' ' GLY . 57.6 mt -138.2 148.53 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 3.9 mt -109.84 110.99 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 173.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.4 103.81 1.71 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.629 HD12 ' O ' ' I' ' 34' ' ' LEU . 33.4 tp -143.44 132.58 23.08 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 115.695 1.739 . . . . 0.0 115.695 -173.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.445 ' N ' HD12 ' J' ' 34' ' ' LEU . 78.4 mmm -103.75 123.75 47.62 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 112.78 -2.009 . . . . 0.0 106.886 176.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.703 HG12 ' CG2' ' I' ' 36' ' ' VAL . 2.8 m -135.25 155.68 37.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-O 121.549 0.69 . . . . 0.0 112.441 -176.411 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 79.76 -101.42 1.92 Allowed Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.933 176.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.6 -80.31 1.61 Allowed Glycine 0 CA--C 1.537 1.451 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -176.291 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.468 HG23 HD12 ' P' ' 31' ' ' ILE . 59.2 t -124.06 131.57 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-N 117.742 0.771 . . . . 0.0 109.624 177.786 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.516 ' OXT' ' CD2' ' L' ' 13' ' ' HIS . 27.6 t . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.27 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.442 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' K' K ' 10' ' ' TYR . . . . . 0.441 ' CD2' ' O ' ' K' ' 11' ' ' GLU . 52.6 t80 -70.69 134.95 47.96 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.883 0.373 . . . . 0.0 110.523 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.441 ' O ' ' CD2' ' K' ' 10' ' ' TYR . 68.8 mm-40 -75.22 154.68 37.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.746 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 27.8 m -122.91 129.59 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.363 0.602 . . . . 0.0 111.847 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.815 ' CD2' HG11 ' I' ' 40' ' ' VAL . 2.9 t60 -148.99 138.09 21.48 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.129 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.531 ' NE2' ' O ' ' L' ' 12' ' ' VAL . 15.3 m-70 -134.51 158.86 42.85 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 11.5 tt0 -90.17 159.51 16.72 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 57.4 tttt -140.47 95.13 2.82 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 120.041 -0.664 . . . . 0.0 109.758 177.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.602 ' CD1' HG21 ' I' ' 36' ' ' VAL . 37.2 mt -118.47 111.67 18.95 Favored 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 177.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -108.29 107.25 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 84.7 m-85 -104.03 105.68 15.93 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.9 t80 -110.74 114.91 28.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.38 135.93 20.6 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 122.023 0.916 . . . . 0.0 111.867 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.558 ' O ' ' CB ' ' K' ' 23' ' ' ASP . 98.3 mt-10 -69.15 -174.92 0.69 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 118.145 -1.422 . . . . 0.0 107.97 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' J' ' 24' ' ' VAL . 10.5 t0 144.98 46.6 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.474 0.654 . . . . 0.0 109.927 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.687 HG12 ' N ' ' K' ' 25' ' ' GLY . 25.4 t -84.03 172.16 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.862 -178.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.687 ' N ' HG12 ' K' ' 24' ' ' VAL . . . 95.71 -29.68 9.46 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 178.363 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.485 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 92.07 114.02 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 114.446 -0.877 . . . . 0.0 109.06 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.614 ' OD1' ' HB2' ' K' ' 30' ' ' ALA . 1.4 p30 -74.3 174.48 8.76 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.361 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.28 -36.75 43.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.97 76.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.541 0 CA-C-O 119.679 -0.512 . . . . 0.0 112.67 -177.02 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.614 ' HB2' ' OD1' ' K' ' 27' ' ' ASN . . . -80.12 149.7 30.5 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 118.745 1.272 . . . . 0.0 110.527 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.532 HG23 ' HB ' ' L' ' 31' ' ' ILE . 59.1 mt -130.77 135.97 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.547 -0.752 . . . . 0.0 112.14 -177.31 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.33 119.24 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.09 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.74 109.77 1.53 Allowed Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 70.7 mt -122.78 118.38 27.86 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.248 0.547 . . . . 0.0 110.626 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 95.9 mmm -110.74 122.27 47.4 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.004 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.11 132.37 67.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.318 -179.608 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.24 112.1 3.45 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 178.625 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.533 ' H ' ' HA3' ' L' ' 37' ' ' GLY . . . -76.65 73.18 1.9 Allowed Glycine 0 CA--C 1.532 1.148 0 C-N-CA 120.243 -0.98 . . . . 0.0 113.498 -178.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.663 HG23 HD12 ' Q' ' 31' ' ' ILE . 22.1 t -128.43 133.57 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.499 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' J' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.836 -1.078 . . . . 0.0 110.766 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.64 136.59 43.89 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.817 0.341 . . . . 0.0 110.597 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.52 148.12 47.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.917 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.832 HG22 ' H ' ' L' ' 13' ' ' HIS . 11.3 p -138.98 -179.18 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.911 0.386 . . . . 0.0 111.07 -178.181 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.832 ' H ' HG22 ' L' ' 12' ' ' VAL . 0.3 OUTLIER -122.81 108.52 13.11 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.525 -179.941 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.436 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 40.8 t-80 -150.38 165.52 32.85 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.436 HE22 ' HB ' ' J' ' 36' ' ' VAL . 8.9 tt0 -89.74 158.73 17.4 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.643 0.259 . . . . 0.0 110.788 -179.03 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -140.01 107.56 5.59 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.252 0.548 . . . . 0.0 111.256 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.412 ' HB3' ' CZ ' ' L' ' 19' ' ' PHE . 4.4 mt -115.97 109.15 17.16 Favored 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.883 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -105.09 103.55 15.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.412 ' CZ ' ' HB3' ' L' ' 17' ' ' LEU . 65.8 m-85 -100.46 100.54 11.31 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.603 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 52.2 t80 -106.41 95.95 6.11 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.84 145.07 31.46 Favored 'General case' 0 CA--C 1.495 -1.138 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.655 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' K' ' 23' ' ' ASP . 80.8 mm-40 -82.6 96.04 7.96 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.728 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 91.8 m-20 -132.56 62.63 1.64 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 112.052 -177.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.479 HG12 ' H ' ' L' ' 25' ' ' GLY . 1.5 t 60.51 -141.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.207 0.527 . . . . 0.0 110.871 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.479 ' H ' HG12 ' L' ' 24' ' ' VAL . . . 156.63 -29.53 0.55 Allowed Glycine 0 CA--C 1.519 0.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 87.8 p -63.21 -123.66 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.191 -0.505 . . . . 0.0 110.868 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.509 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 5.9 t-20 -156.97 -154.14 0.45 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.856 -178.492 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.509 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 68.6 mttm 28.32 41.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.09 -62.59 0.04 OUTLIER Glycine 0 CA--C 1.537 1.445 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.723 178.122 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.83 148.08 29.02 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.785 0.792 . . . . 0.0 110.488 178.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.532 ' HB ' HG23 ' K' ' 31' ' ' ILE . 6.7 mm -114.76 125.89 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.432 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -120.18 124.6 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.72 115.46 1.7 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.7 tp -126.2 120.73 30.81 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mtp -135.38 147.55 49.09 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -177.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 33.6 m -119.36 159.29 20.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.132 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.643 178.277 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.533 ' HA3' ' H ' ' K' ' 38' ' ' GLY . . . -61.89 -102.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.487 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.96 -75.14 0.11 Allowed Glycine 0 CA--C 1.534 1.237 0 C-N-CA 121.83 -0.224 . . . . 0.0 112.88 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' K' ' 38' ' ' GLY . 3.0 m -106.49 123.76 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.296 0.57 . . . . 0.0 111.399 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.258 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' M' M ' 10' ' ' TYR . . . . . 0.517 ' CG ' ' O ' ' N' ' 9' ' ' GLY . 94.6 m-85 -111.77 132.86 54.38 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.738 0.304 . . . . 0.0 110.217 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.69 171.37 14.14 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.145 0.498 . . . . 0.0 111.025 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.42 130.66 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.158 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 m80 -128.65 113.18 15.07 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 17.9 p-80 -152.56 168.23 26.25 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.548 178.033 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -129.23 150.65 50.52 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.085 178.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -97.56 116.25 29.4 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.3 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -124.97 114.07 18.65 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 118.154 0.434 . . . . 0.0 110.093 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 18' ' ' VAL . . . . . 0.431 ' O ' HG23 ' M' ' 18' ' ' VAL . 19.1 m -131.67 132.52 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.641 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -135.7 133.99 38.67 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-O 121.077 0.465 . . . . 0.0 111.745 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -121.61 129.39 52.8 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 21' ' ' ALA . . . . . 0.498 ' HB1' ' CG2' ' M' ' 24' ' ' VAL . . . -130.98 131.81 44.62 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.332 0.587 . . . . 0.0 112.164 -178.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -120.23 142.27 49.18 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.557 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 37.42 54.68 1.39 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.306 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.498 ' CG2' ' HB1' ' M' ' 21' ' ' ALA . 45.6 t -67.79 135.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.439 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.76 -33.49 2.04 Favored Glycine 0 N--CA 1.47 0.901 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 62.8 p -82.31 -121.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.131 0.491 . . . . 0.0 111.206 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.49 ' O ' HG11 ' M' ' 24' ' ' VAL . 77.7 m-20 -93.22 -160.5 0.76 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.063 -178.217 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 35.28 40.37 0.06 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.38 -64.37 1.22 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.556 ' HB3' ' OG ' ' N' ' 26' ' ' SER . . . -157.26 49.74 0.44 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.043 0.922 . . . . 0.0 111.772 175.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.627 HD12 HG12 ' G' ' 39' ' ' VAL . 97.0 mt -138.49 106.84 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 CA-C-N 114.157 -1.383 . . . . 0.0 107.474 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.2 mt -102.7 104.43 16.53 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.335 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.09 95.71 0.75 Allowed Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 104.071 -3.612 . . . . 0.0 104.071 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 34' ' ' LEU . . . . . 0.68 ' O ' HD23 ' N' ' 34' ' ' LEU . 43.1 tp -146.07 150.4 35.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 122.843 1.306 . . . . 0.0 113.809 -173.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -110.02 106.95 16.66 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 112.65 -2.068 . . . . 0.0 106.228 177.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.563 HG13 ' O ' ' M' ' 36' ' ' VAL . 4.0 p -127.35 114.07 34.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.6 -124.61 1.88 Allowed Glycine 0 C--N 1.309 -0.958 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.96 -67.11 3.29 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.043 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.615 HG12 ' CD1' ' A' ' 31' ' ' ILE . 13.0 m -78.4 169.1 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-O 121.041 0.448 . . . . 0.0 110.472 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.406 HG22 ' OXT' ' M' ' 40' ' ' VAL . 3.5 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.458 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 9' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' M' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -115.44 142.01 47.29 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.87 0.367 . . . . 0.0 110.52 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 11' ' ' GLU . . . . . 0.526 ' O ' ' NE2' ' O' ' 13' ' ' HIS . 82.4 tt0 -69.18 120.64 15.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.095 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.51 120.45 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.618 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.474 ' CE1' ' OE2' ' N' ' 11' ' ' GLU . 60.4 m170 -113.68 150.71 32.85 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.901 -178.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.555 ' CE1' ' O ' ' O' ' 12' ' ' VAL . 75.2 m-70 -141.92 172.01 13.28 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 121.19 0.519 . . . . 0.0 110.403 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 68.4 tp60 -138.25 140.87 39.86 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttm -130.17 107.0 8.97 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.535 HD23 ' C ' ' N' ' 17' ' ' LEU . 5.9 tt -122.6 116.33 23.66 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 18' ' ' VAL . . . . . 0.437 HG22 ' CG1' ' O' ' 18' ' ' VAL . 80.0 t -121.01 126.22 74.95 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.333 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -127.03 122.02 33.25 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -125.32 125.21 43.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.032 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.95 131.4 53.56 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 179.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.425 ' O ' ' N ' ' N' ' 24' ' ' VAL . 95.1 mt-10 -81.05 -166.81 1.22 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.325 0.583 . . . . 0.0 112.53 -177.748 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.518 ' N ' ' OE1' ' O' ' 22' ' ' GLU . 66.2 t0 -61.97 47.51 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 114.765 -1.107 . . . . 0.0 112.394 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.855 HG12 ' H ' ' N' ' 25' ' ' GLY . 30.3 t -61.04 -179.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.019 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 0.855 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -100.96 29.31 12.77 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 121.636 -0.316 . . . . 0.0 112.718 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.556 ' OG ' ' HB3' ' M' ' 30' ' ' ALA . 10.7 t -81.05 112.86 18.82 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 72.1 m-20 -89.75 -175.06 4.52 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.538 ' NZ ' ' OXT' ' H' ' 40' ' ' VAL . 59.3 mttp 49.29 37.64 11.9 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 111.525 -2.58 . . . . 0.0 114.824 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 29' ' ' GLY . . . . . 0.61 ' O ' ' HB2' ' N' ' 30' ' ' ALA . . . 92.01 -77.98 1.28 Allowed Glycine 0 N--CA 1.469 0.851 0 N-CA-C 114.517 0.567 . . . . 0.0 114.517 172.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 30' ' ' ALA . . . . . 0.898 ' O ' ' HB1' ' O' ' 30' ' ' ALA . . . 150.87 162.64 0.0 OUTLIER 'General case' 0 C--O 1.238 0.464 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.721 HD13 HG13 ' H' ' 39' ' ' VAL . 28.8 pt -141.32 126.92 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.029 178.566 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -113.04 114.55 47.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.47 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.95 105.95 1.66 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 104.936 -3.266 . . . . 0.0 104.936 175.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.68 HD23 ' O ' ' M' ' 34' ' ' LEU . 0.4 OUTLIER -146.32 144.32 29.73 Favored 'General case' 0 CA--C 1.51 -0.581 0 C-N-CA 117.716 -1.594 . . . . 0.0 114.512 -174.18 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 36.3 tpp -106.97 107.77 18.95 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 174.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.429 HG13 HD22 ' N' ' 34' ' ' LEU . 0.0 OUTLIER -121.52 143.68 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 -178.216 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 113.26 -102.68 1.29 Allowed Glycine 0 C--N 1.316 -0.55 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 178.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.427 ' C ' HD11 ' B' ' 31' ' ' ILE . . . 85.69 -80.3 1.81 Allowed Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -178.542 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.552 HG23 HD11 ' B' ' 31' ' ' ILE . 43.4 t -153.03 123.54 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 177.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.524 HG22 ' O ' ' O' ' 38' ' ' GLY . 9.1 m . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.724 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -115.44 141.51 47.95 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.876 0.369 . . . . 0.0 110.687 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -83.11 116.78 22.48 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.233 -0.439 . . . . 0.0 109.933 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.555 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 2.9 m -138.44 160.66 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.823 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 94.3 m-70 -76.74 113.39 14.35 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.529 178.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.572 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 83.6 t60 -148.02 153.23 38.68 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 119.576 -0.849 . . . . 0.0 111.875 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.563 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 42.1 tt0 -98.65 169.61 9.38 Favored 'General case' 0 C--N 1.345 0.396 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.338 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -158.57 104.44 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.681 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.521 ' CD1' HG11 ' M' ' 36' ' ' VAL . 31.5 mt -122.29 116.02 23.35 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 177.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 18' ' ' VAL . . . . . 0.437 ' CG1' HG22 ' N' ' 18' ' ' VAL . 3.3 p -125.0 117.59 50.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-O 121.883 0.849 . . . . 0.0 109.576 178.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -112.31 115.08 28.19 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.429 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -114.63 133.93 55.46 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 122.523 0.329 . . . . 0.0 110.524 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.58 142.11 27.64 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 113.68 0.993 . . . . 0.0 113.68 -178.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 22' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' N' ' 23' ' ' ASP . 95.9 mt-10 -78.99 104.98 10.0 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 104.481 -2.415 . . . . 0.0 104.481 175.486 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.814 ' HB3' ' HB1' ' P' ' 21' ' ' ALA . 17.6 p30 -83.27 49.03 1.48 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 117.736 2.495 . . . . 0.0 117.736 -172.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.471 HG12 ' N ' ' O' ' 25' ' ' GLY . 89.9 t -71.56 160.44 5.24 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 C-N-CA 114.803 -2.759 . . . . 0.0 104.221 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.481 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.92 -30.8 8.31 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 -175.065 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 2.5 m 100.59 111.13 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 112.932 -1.634 . . . . 0.0 112.072 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.555 ' O ' ' N ' ' O' ' 29' ' ' GLY . 12.7 t-20 -70.48 -179.43 2.09 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.702 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.537 ' H ' ' CG ' ' O' ' 27' ' ' ASN . 51.9 tttt 65.53 -47.29 0.38 Allowed 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' O' ' 27' ' ' ASN . . . -81.95 59.38 4.87 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 107.039 -2.424 . . . . 0.0 107.039 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 30' ' ' ALA . . . . . 0.898 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -140.31 -171.02 3.11 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 109.739 -3.231 . . . . 0.0 105.513 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 81.5 mt -128.81 125.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 119.509 -0.876 . . . . 0.0 113.342 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.464 HD13 ' CD2' ' Q' ' 19' ' ' PHE . 88.9 mt -104.33 104.54 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 174.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.05 109.92 2.78 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 105.553 -3.019 . . . . 0.0 105.553 177.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.602 ' O ' HD23 ' O' ' 34' ' ' LEU . 0.0 OUTLIER -162.98 150.0 12.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 115.737 -2.385 . . . . 0.0 114.742 -174.991 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.0 mmm -110.08 105.05 14.02 Favored 'General case' 0 CA--C 1.496 -1.102 0 CA-C-N 111.604 -2.544 . . . . 0.0 106.199 179.106 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.5 ' HB ' HD21 ' O' ' 34' ' ' LEU . 11.9 p -118.64 142.12 35.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -178.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.04 -102.08 0.21 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 120.076 -1.059 . . . . 0.0 110.549 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.524 ' O ' HG22 ' N' ' 40' ' ' VAL . . . 73.99 64.75 2.36 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 120.571 -0.823 . . . . 0.0 113.182 -178.498 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.839 HG12 HD11 ' C' ' 31' ' ' ILE . 9.1 p -10.79 140.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.414 ' CG1' ' OXT' ' P' ' 40' ' ' VAL . 7.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.059 177.314 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -107.73 131.46 54.41 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.702 0.287 . . . . 0.0 110.591 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 11' ' ' GLU . . . . . 0.408 ' H ' ' HG2' ' Q' ' 11' ' ' GLU . 69.5 mm-40 -136.66 113.83 10.67 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.734 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.499 HG12 ' H ' ' Q' ' 12' ' ' VAL . 6.2 m -126.14 130.71 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.627 ' H ' ' CE1' ' Q' ' 13' ' ' HIS . 0.6 OUTLIER -129.54 115.67 17.79 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.055 0.455 . . . . 0.0 112.008 -178.991 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.572 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 4.5 p80 -156.11 167.16 31.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.359 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.423 ' NE2' ' HB ' ' N' ' 36' ' ' VAL . 13.6 tt0 -89.78 158.48 17.49 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -140.32 115.08 9.54 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.636 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.424 ' HB3' ' CE2' ' P' ' 19' ' ' PHE . 14.4 mt -119.47 122.28 41.34 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -119.63 107.56 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 47.8 m-85 -110.03 107.95 18.0 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 178.197 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -116.4 125.56 52.22 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.596 0.236 . . . . 0.0 110.694 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 21' ' ' ALA . . . . . 0.814 ' HB1' ' HB3' ' O' ' 23' ' ' ASP . . . -129.59 127.78 41.36 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.141 0.496 . . . . 0.0 110.231 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' O' ' 23' ' ' ASP . 16.6 pt-20 -122.03 158.77 28.45 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.433 ' C ' ' OD1' ' O' ' 23' ' ' ASP . 29.8 m-20 76.43 55.98 0.05 OUTLIER 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 113.439 -1.709 . . . . 0.0 112.859 178.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.412 HG12 ' H ' ' O' ' 27' ' ' ASN . 3.8 m -77.4 129.21 37.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.21 -35.41 4.48 Favored Glycine 0 CA--C 1.536 1.383 0 C-N-CA 118.854 -1.641 . . . . 0.0 112.127 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.652 ' O ' ' O ' ' P' ' 27' ' ' ASN . 16.4 t -173.97 125.82 0.36 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 119.562 1.681 . . . . 0.0 114.179 175.323 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.652 ' O ' ' O ' ' P' ' 26' ' ' SER . 44.6 m-20 -2.86 145.73 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.25 1.42 . . . . 0.0 114.683 173.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -160.31 32.23 0.17 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.73 80.95 0.89 Allowed Glycine 0 N--CA 1.482 1.748 0 C-N-CA 117.768 -2.158 . . . . 0.0 112.939 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 30' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' O' ' 28' ' ' LYS . . . -101.94 131.41 48.35 Favored 'General case' 0 CA--C 1.508 -0.651 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -176.551 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.506 HD11 HG21 ' K' ' 39' ' ' VAL . 91.1 mt -133.47 122.49 44.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.164 178.601 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.441 HD13 HG21 ' P' ' 32' ' ' ILE . 43.7 mt -107.17 110.43 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.03 102.88 0.86 Allowed Glycine 0 N--CA 1.462 0.369 0 N-CA-C 107.788 -2.125 . . . . 0.0 107.788 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.452 ' HB2' HD23 ' O' ' 34' ' ' LEU . 4.0 pp -157.35 162.35 39.09 Favored 'General case' 0 CA--C 1.493 -1.224 0 C-N-CA 117.664 -1.615 . . . . 0.0 113.621 -177.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 23.3 mtp -119.89 123.19 42.98 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 112.215 -2.266 . . . . 0.0 109.628 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.609 ' O ' ' O ' ' P' ' 37' ' ' GLY . 0.1 OUTLIER -98.17 101.95 12.81 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.965 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' P' P ' 37' ' ' GLY . . . . . 0.609 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 28.42 172.77 0.0 OUTLIER Glycine 0 N--CA 1.468 0.78 0 C-N-CA 126.04 1.781 . . . . 0.0 116.491 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.03 -58.21 0.59 Allowed Glycine 0 CA--C 1.536 1.378 0 CA-C-N 113.45 -1.375 . . . . 0.0 112.678 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.514 HG23 HD11 ' D' ' 31' ' ' ILE . 72.7 t -105.58 131.4 55.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 CA-C-O 121.195 0.521 . . . . 0.0 111.091 -178.307 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' P' ' 39' ' ' VAL . 5.6 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.3 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -106.58 133.83 50.66 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.408 ' HG2' ' H ' ' P' ' 11' ' ' GLU . 96.5 mt-10 -139.02 139.25 37.78 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.758 0.313 . . . . 0.0 110.549 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.499 ' H ' HG12 ' P' ' 12' ' ' VAL . 29.0 m -137.13 158.1 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 121.085 0.469 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.627 ' CE1' ' H ' ' P' ' 13' ' ' HIS . 44.8 m-70 -147.5 115.18 6.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.91 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.631 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 83.2 m-70 -131.89 160.38 35.89 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.721 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.5 ' OE1' HD11 ' Q' ' 17' ' ' LEU . 48.8 tt0 -90.09 159.18 16.94 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -140.68 92.39 2.51 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.836 178.028 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.5 HD11 ' OE1' ' Q' ' 15' ' ' GLN . 3.0 mt -115.01 115.12 26.33 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -119.49 107.77 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.397 -179.344 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.585 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 35.4 m-85 -110.1 101.95 10.7 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 104.311 -2.477 . . . . 0.0 104.311 175.607 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -123.45 133.37 54.06 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.139 -0.482 . . . . 0.0 112.286 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.518 ' HB2' ' OD1' ' O' ' 27' ' ' ASN . . . -138.09 154.65 49.23 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.528 ' O ' ' N ' ' Q' ' 24' ' ' VAL . 75.4 tt0 -72.58 163.05 28.66 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.473 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 65.7 t0 0.78 54.28 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 116.317 1.969 . . . . 0.0 116.317 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' Q' ' 22' ' ' GLU . 0.3 OUTLIER -66.56 137.17 25.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 176.425 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' Q' ' 26' ' ' SER . . . -118.04 -28.34 2.25 Favored Glycine 0 CA--C 1.542 1.745 0 CA-C-O 118.94 -0.922 . . . . 0.0 110.919 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 0.7 OUTLIER 91.11 116.81 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 118.895 1.348 . . . . 0.0 114.607 173.656 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -72.96 174.81 7.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.232 0.539 . . . . 0.0 111.086 177.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -53.84 -38.88 65.1 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.688 178.186 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.46 ' O ' HG13 ' K' ' 39' ' ' VAL . . . -109.04 69.21 0.21 Allowed Glycine 0 CA--C 1.537 1.438 0 N-CA-C 115.517 0.967 . . . . 0.0 115.517 -175.501 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.14 121.45 41.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.837 0.819 . . . . 0.0 109.151 178.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.663 HD12 HG23 ' K' ' 39' ' ' VAL . 86.1 mt -125.81 132.52 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 121.101 0.477 . . . . 0.0 111.646 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -122.53 121.93 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.521 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.69 108.16 1.15 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 15.7 mt -117.68 122.4 43.43 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -136.12 144.46 45.09 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.568 HG12 ' N ' ' Q' ' 37' ' ' GLY . 63.7 t -117.99 168.28 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.381 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.568 ' N ' HG12 ' Q' ' 36' ' ' VAL . . . -169.15 93.81 0.1 Allowed Glycine 0 C--N 1.314 -0.672 0 C-N-CA 118.915 -1.612 . . . . 0.0 112.932 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.0 -81.51 0.1 OUTLIER Glycine 0 CA--C 1.536 1.391 0 CA-C-N 118.74 1.27 . . . . 0.0 113.373 177.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -171.99 136.81 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 118.299 1.05 . . . . 0.0 110.293 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.094 -0.955 . . . . 0.0 110.634 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.06 142.03 38.85 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 110.315 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -131.18 148.71 52.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.946 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.481 ' H ' HG12 ' Q' ' 12' ' ' VAL . 2.6 p -129.51 135.85 60.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-O 121.434 0.635 . . . . 0.0 110.857 -179.695 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.605 ' HD1' ' HB2' ' Q' ' 13' ' ' HIS . 1.3 m-70 -139.9 133.13 29.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.631 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 31.4 t-80 -153.55 161.56 42.1 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.42 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 18.4 tt0 -90.14 158.87 17.06 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.306 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.426 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 37.7 tttp -140.52 104.6 4.79 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.463 ' N ' HD23 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -118.58 114.05 22.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.477 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -117.36 107.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.028 0.442 . . . . 0.0 110.439 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.546 ' O ' ' CD2' ' R' ' 20' ' ' PHE . 16.2 m-85 -113.4 101.45 9.39 Favored 'General case' 0 N--CA 1.461 0.118 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 20' ' ' PHE . . . . . 0.546 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 63.0 m-85 -157.59 -177.75 6.82 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.695 1.236 . . . . 0.0 113.801 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.02 154.41 41.17 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.05 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -82.15 148.9 28.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.111 0.482 . . . . 0.0 111.7 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 58.14 48.14 13.37 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.753 179.127 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.501 HG12 ' N ' ' R' ' 25' ' ' GLY . 15.3 t -66.52 166.56 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.812 179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.501 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -175.76 15.96 0.04 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.5 p -83.11 140.82 32.41 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.652 ' O ' ' N ' ' R' ' 29' ' ' GLY . 71.5 m-80 -73.15 150.99 41.74 Favored 'General case' 0 C--O 1.223 -0.297 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.299 177.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -51.32 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.652 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.81 58.33 0.8 Allowed Glycine 0 CA--C 1.541 1.681 0 CA-C-N 118.611 0.641 . . . . 0.0 112.479 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -147.59 170.14 18.12 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 117.454 0.627 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 87.9 mt -119.89 123.95 71.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -121.57 130.22 74.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.665 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.08 111.44 1.16 Allowed Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.53 ' C ' HD23 ' R' ' 34' ' ' LEU . 8.0 tt -119.27 121.42 39.6 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 87.9 mtp -141.64 145.16 34.63 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.384 0.611 . . . . 0.0 112.117 -178.559 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.477 HG23 ' HB ' ' Q' ' 36' ' ' VAL . 2.2 p -144.01 143.4 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 119.526 -0.869 . . . . 0.0 111.623 177.487 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.03 -102.62 1.02 Allowed Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 174.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 23.23 73.5 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 112.758 -1.721 . . . . 0.0 115.48 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 96.8 t -49.39 134.4 7.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 117.008 0.404 . . . . 0.0 110.41 178.476 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.848 179.818 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -81.08 139.83 35.45 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -100.72 108.66 20.56 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.071 0.462 . . . . 0.0 111.461 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 m -136.22 157.57 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 178.578 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.427 ' C ' ' CG ' ' A' ' 14' ' ' HIS . 64.8 t-80 -145.32 124.06 12.59 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.712 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.529 ' CE1' ' H ' ' B' ' 14' ' ' HIS . 29.4 m-70 -151.47 165.97 32.55 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.133 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.9 tp60 -159.72 143.36 14.43 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.942 0.401 . . . . 0.0 110.053 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -80.44 120.37 24.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.352 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.8 mt -129.71 112.36 13.57 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.5 t -125.52 131.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.377 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -122.99 124.02 42.21 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.4 p90 -132.48 130.59 40.68 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.765 0.317 . . . . 0.0 110.382 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.19 132.69 40.05 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.068 0.461 . . . . 0.0 110.299 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 23' ' ' ASP . 13.2 pt-20 -83.87 -170.47 3.09 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.989 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 23' ' ' ASP . 21.3 p-10 -33.32 -60.36 0.35 Allowed 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.258 0.349 . . . . 0.0 111.15 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.523 HG22 ' N ' ' A' ' 25' ' ' GLY . 3.6 p -72.51 160.9 5.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' N ' HG22 ' A' ' 24' ' ' VAL . . . 110.49 -35.09 5.02 Favored Glycine 0 N--CA 1.467 0.734 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 33.8 p -80.59 119.05 22.73 Favored 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.529 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 14.5 t-20 -88.5 179.36 6.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.749 0.785 . . . . 0.0 112.129 -178.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.598 ' NZ ' ' CE1' ' O' ' 13' ' ' HIS . 71.4 tttt -54.4 -38.23 65.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.491 178.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.52 71.42 0.2 Allowed Glycine 0 CA--C 1.536 1.395 0 CA-C-N 114.937 -1.029 . . . . 0.0 114.137 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.474 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -95.65 98.43 10.48 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-O 124.367 2.032 . . . . 0.0 111.036 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.437 HG22 HG12 ' B' ' 31' ' ' ILE . 6.0 pt -134.76 139.56 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 111.538 -2.574 . . . . 0.0 108.685 -179.424 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.425 HG21 HD13 ' A' ' 32' ' ' ILE . 43.4 mt -108.57 112.45 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.5 96.8 0.76 Allowed Glycine 0 N--CA 1.463 0.434 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.424 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 77.2 mt -147.08 169.87 18.35 Favored 'General case' 0 CA--C 1.506 -0.721 0 CA-C-O 122.622 1.201 . . . . 0.0 111.834 -176.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 23.5 mtp -124.68 119.42 28.92 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 113.403 -1.726 . . . . 0.0 108.894 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.551 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 2.5 t -108.95 111.9 38.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.52 -131.72 7.97 Favored Glycine 0 C--N 1.32 -0.356 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.6 -62.51 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.439 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 25.2 m -122.96 163.34 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.445 HG12 ' O ' ' A' ' 40' ' ' VAL . 99.0 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 10' ' ' TYR . . . . . 0.527 ' CE1' ' O ' ' C' ' 9' ' ' GLY . 97.2 m-85 -106.12 132.89 51.65 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.541 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.9 mp0 -110.31 124.0 50.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.465 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.452 HG22 HG12 ' C' ' 12' ' ' VAL . 53.7 t -124.73 128.15 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 41.2 t60 -131.44 122.24 25.91 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 120.941 0.4 . . . . 0.0 111.595 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.529 ' H ' ' CE1' ' A' ' 14' ' ' HIS . 74.2 t60 -157.78 168.36 27.43 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.593 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.435 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 83.6 mt-30 -154.77 141.81 19.29 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.277 0.56 . . . . 0.0 110.747 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -87.09 110.9 20.41 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.712 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.403 HD12 ' N ' ' B' ' 17' ' ' LEU . 6.0 mp -121.52 112.72 18.85 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.518 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -121.65 131.8 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.718 0.294 . . . . 0.0 110.676 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -122.96 116.27 23.29 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.364 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -119.11 126.07 50.76 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.7 136.65 31.05 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.842 1.052 . . . . 0.0 113.842 -178.036 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -111.53 117.52 33.23 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 176.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.525 ' OD2' ' ND2' ' B' ' 27' ' ' ASN . 65.5 t0 -107.0 46.31 0.94 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -177.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.648 HG12 ' N ' ' B' ' 25' ' ' GLY . 61.8 t -83.57 173.26 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.737 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.648 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 93.6 -28.17 10.71 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.905 177.674 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.812 ' O ' ' O ' ' B' ' 27' ' ' ASN . 78.0 p 178.61 -129.35 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.524 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.825 -178.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.812 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.1 t30 10.16 152.06 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.578 ' HB3' ' H ' ' C' ' 28' ' ' LYS . 94.2 mttt -169.55 30.17 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.736 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -99.32 78.88 0.51 Allowed Glycine 0 CA--C 1.538 1.469 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 178.357 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.616 ' H ' HD21 ' C' ' 27' ' ' ASN . . . -110.43 112.75 24.89 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 114.512 1.301 . . . . 0.0 114.512 -176.079 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.437 HG12 HG22 ' A' ' 31' ' ' ILE . 44.1 pt -140.59 143.78 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.958 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -113.56 122.45 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.153 0.502 . . . . 0.0 110.054 178.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 105.39 1.04 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 106.839 -2.504 . . . . 0.0 106.839 177.249 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.738 ' HB2' HD22 ' C' ' 34' ' ' LEU . 56.9 mt -137.19 145.24 43.46 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 122.818 1.294 . . . . 0.0 114.157 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -104.79 108.72 20.36 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 174.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -116.33 102.34 13.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.817 ' N ' HE22 ' D' ' 15' ' ' GLN . . . 111.75 164.19 17.5 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-O 122.015 0.786 . . . . 0.0 111.412 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.584 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 164.82 -55.95 0.27 Allowed Glycine 0 CA--C 1.542 1.741 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -178.208 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 t -119.76 134.4 63.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.63 HG11 ' ND1' ' E' ' 13' ' ' HIS . 81.3 t . . . . . 0 C--O 1.22 -0.447 0 CA-C-O 118.163 -0.923 . . . . 0.0 110.721 179.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 9' ' ' GLY . . . . . 0.527 ' O ' ' CE1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -151.1 158.86 44.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.616 0.246 . . . . 0.0 110.628 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -89.64 120.78 31.21 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.598 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.544 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 2.8 p -138.94 138.6 41.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.232 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.523 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 84.3 m-70 -146.65 135.17 22.02 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.777 0.322 . . . . 0.0 111.413 -179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' D' ' 14' ' ' HIS . 41.8 m-70 -151.26 172.03 16.5 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -126.65 141.81 51.74 Favored 'General case' 0 CA--C 1.522 -0.128 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 174.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.418 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.5 tttt -115.76 108.99 17.05 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 118.697 -0.668 . . . . 0.0 111.62 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.418 HD12 ' C ' ' C' ' 16' ' ' LYS . 8.4 mp -124.12 115.06 20.53 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 118.804 0.729 . . . . 0.0 109.056 175.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 81.2 t -109.32 122.16 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.326 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -111.56 103.46 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 15.7 t80 -113.67 125.12 53.79 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.226 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.81 133.35 33.9 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.786 0.803 . . . . 0.0 112.866 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -95.8 120.08 35.43 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.58 48.89 1.62 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -176.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.526 HG12 ' N ' ' C' ' 25' ' ' GLY . 73.3 t -71.89 161.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.526 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 109.35 -30.5 8.5 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 108.159 -1.976 . . . . 0.0 108.159 -176.489 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.518 ' HB3' ' O ' ' C' ' 25' ' ' GLY . 25.8 t 99.96 111.75 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.296 1.838 . . . . 0.0 110.657 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.616 HD21 ' H ' ' B' ' 30' ' ' ALA . 30.8 t30 -71.51 162.01 30.12 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.855 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.578 ' H ' ' HB3' ' B' ' 28' ' ' LYS . 28.2 ttpt -48.7 -39.36 24.34 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 176.147 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.49 69.15 0.04 OUTLIER Glycine 0 CA--C 1.542 1.762 0 CA-C-O 118.669 -1.073 . . . . 0.0 111.488 -173.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 130.17 41.41 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 120.14 1.97 . . . . 0.0 113.938 -173.772 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.494 ' CD1' ' O ' ' O' ' 38' ' ' GLY . 36.8 mt -139.18 141.24 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 113.738 -1.573 . . . . 0.0 114.284 -176.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.8 mt -117.78 118.52 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 175.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.953 ' O ' HD23 ' C' ' 34' ' ' LEU . . . -125.17 113.2 1.88 Allowed Glycine 0 N--CA 1.474 1.185 0 N-CA-C 108.846 -1.701 . . . . 0.0 108.846 178.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.953 HD23 ' O ' ' C' ' 33' ' ' GLY . 3.1 mt -138.89 151.8 47.26 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-O 123.51 1.624 . . . . 0.0 114.499 -177.49 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 88.1 mmm -105.31 107.1 17.91 Favored 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 111.073 -2.785 . . . . 0.0 104.359 174.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.72 ' HB ' HG12 ' D' ' 36' ' ' VAL . 2.9 t -111.29 143.06 21.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' OE1' ' E' ' 15' ' ' GLN . . . 166.85 -102.06 0.19 Allowed Glycine 0 C--N 1.302 -1.352 0 C-N-CA 119.507 -1.33 . . . . 0.0 111.007 -177.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.584 ' HA3' ' H ' ' B' ' 38' ' ' GLY . . . 51.31 70.77 0.78 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.308 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.742 HG13 ' O ' ' D' ' 39' ' ' VAL . 22.9 t -72.14 142.08 15.75 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.226 0 CA-C-O 120.801 0.334 . . . . 0.0 111.718 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.429 HG12 ' CD2' ' E' ' 13' ' ' HIS . 14.8 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.334 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -110.84 137.2 48.78 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -143.54 134.21 25.08 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.782 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -138.8 131.97 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.88 179.312 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.523 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 8.6 t60 -146.44 129.79 16.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.935 0.397 . . . . 0.0 110.728 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 2.9 p80 -152.31 161.58 42.4 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.102 178.312 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.817 HE22 ' N ' ' B' ' 37' ' ' GLY . 24.9 mt-30 -90.09 159.59 16.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.347 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.718 ' C ' HD12 ' D' ' 17' ' ' LEU . 48.1 mmtt -139.63 98.08 3.41 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.718 HD12 ' C ' ' D' ' 16' ' ' LYS . 5.4 mp -130.95 131.1 44.22 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.117 0.485 . . . . 0.0 110.059 178.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 62.9 t -121.53 124.85 72.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.52 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.7 m-85 -111.81 102.6 10.86 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 18.1 t80 -112.89 122.14 46.77 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.86 -0.155 . . . . 0.0 110.732 -178.55 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.28 134.31 30.84 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 122.106 0.955 . . . . 0.0 113.096 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.455 ' OE2' ' OE1' ' E' ' 22' ' ' GLU . 49.5 tp10 -101.2 126.8 47.95 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.594 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 52.5 p-10 -167.25 48.52 0.06 Allowed 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -72.44 160.97 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.11 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -30.06 8.81 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.094 -1.203 . . . . 0.0 110.094 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.512 ' CB ' ' OG ' ' C' ' 26' ' ' SER . 4.7 p -83.04 141.1 32.3 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 115.014 1.487 . . . . 0.0 115.014 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.671 ' O ' ' N ' ' D' ' 29' ' ' GLY . 34.1 p30 -73.21 -155.48 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.474 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -53.84 48.33 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 113.22 0.822 . . . . 0.0 113.22 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.671 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -100.19 56.01 0.84 Allowed Glycine 0 CA--C 1.542 1.75 0 CA-C-O 119.8 -0.445 . . . . 0.0 112.224 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -153.33 109.21 3.29 Favored 'General case' 0 C--O 1.24 0.594 0 CA-C-N 118.244 1.022 . . . . 0.0 110.277 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 56.2 mt -133.04 130.37 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 119.104 -1.038 . . . . 0.0 113.549 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.407 ' O ' ' N ' ' E' ' 33' ' ' GLY . 73.9 mt -112.62 108.32 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 176.142 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.07 111.6 3.79 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.498 ' CD1' ' CE1' ' F' ' 19' ' ' PHE . 92.2 mt -134.36 134.97 42.34 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -111.39 103.96 12.37 Favored 'General case' 0 N--CA 1.439 -1.021 0 CA-C-N 111.506 -2.588 . . . . 0.0 105.957 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.72 HG12 ' HB ' ' C' ' 36' ' ' VAL . 21.2 m -115.53 122.73 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.787 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.44 112.77 1.48 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.488 ' N ' ' OE1' ' F' ' 15' ' ' GLN . . . -120.61 62.4 0.5 Allowed Glycine 0 CA--C 1.539 1.559 0 N-CA-C 116.237 1.255 . . . . 0.0 116.237 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.742 ' O ' HG13 ' C' ' 39' ' ' VAL . 31.2 t -76.83 168.81 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 120.892 2.346 . . . . 0.0 108.403 176.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.65 ' N ' HG12 ' D' ' 39' ' ' VAL . 3.6 p . . . . . 0 C--O 1.222 -0.39 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.657 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -98.51 134.4 41.53 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -158.55 153.67 25.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.88 0.371 . . . . 0.0 111.497 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.54 112.6 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.63 ' ND1' HG11 ' B' ' 40' ' ' VAL . 1.7 t60 -127.27 118.67 24.68 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -177.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.458 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 22.9 p-80 -157.57 159.64 37.31 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.531 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.415 ' OE1' ' O ' ' C' ' 37' ' ' GLY . 1.3 mp0 -90.23 159.02 16.92 Favored 'General case' 0 C--O 1.224 -0.242 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.764 ' C ' HD12 ' E' ' 17' ' ' LEU . 13.0 tttm -140.96 101.13 3.98 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.402 176.446 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.764 HD12 ' C ' ' E' ' 16' ' ' LYS . 6.7 mp -130.44 127.89 40.2 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.7 t -117.71 126.21 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.579 ' N ' ' CD1' ' E' ' 19' ' ' PHE . 0.2 OUTLIER -113.72 103.74 11.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 -179.454 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 22.3 t80 -113.21 118.53 34.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 121.443 -0.103 . . . . 0.0 111.138 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.57 138.33 36.13 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 119.668 -0.813 . . . . 0.0 112.256 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE2' ' D' ' 22' ' ' GLU . 88.6 mt-10 -101.51 119.77 39.28 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.37 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.875 ' O ' HG13 ' E' ' 24' ' ' VAL . 16.6 t0 -119.24 -49.89 2.37 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -179.373 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.875 HG13 ' O ' ' E' ' 23' ' ' ASP . 0.1 OUTLIER 163.81 -166.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 179.367 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.36 -35.6 91.89 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.153 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' F' ' 28' ' ' LYS . 22.1 t -155.82 112.63 3.19 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.83 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 30' ' ' ALA . 20.0 p30 -53.01 170.22 0.08 Allowed 'General case' 0 N--CA 1.464 0.231 0 C-N-CA 117.114 -1.835 . . . . 0.0 108.626 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -61.24 -39.05 88.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.224 -0.991 . . . . 0.0 112.238 175.83 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.474 ' N ' ' OD1' ' E' ' 27' ' ' ASN . . . -178.97 74.97 0.07 OUTLIER Glycine 0 CA--C 1.544 1.856 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.076 -177.256 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.658 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -80.64 163.65 23.46 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.537 1.668 . . . . 0.0 111.669 -178.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.413 HD11 ' HB ' ' Q' ' 39' ' ' VAL . 79.8 mt -131.16 127.55 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.537 HD11 ' CD2' ' F' ' 19' ' ' PHE . 3.2 tt -123.14 109.33 23.28 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.562 ' HA2' ' H ' ' F' ' 33' ' ' GLY . . . -80.08 116.46 4.27 Favored Glycine 0 C--O 1.241 0.568 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' F' ' 34' ' ' LEU . 38.8 tp -110.14 104.21 13.03 Favored 'General case' 0 C--O 1.267 1.982 0 CA-C-N 120.096 1.948 . . . . 0.0 110.767 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.762 ' HA ' ' HA ' ' F' ' 35' ' ' MET . 29.0 tpp -115.8 110.48 19.13 Favored 'General case' 0 C--N 1.351 0.648 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.558 HG12 ' N ' ' E' ' 37' ' ' GLY . 39.5 t -84.89 172.64 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.374 1.655 0 C-N-CA 117.431 -1.708 . . . . 0.0 107.157 177.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.558 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -176.75 92.99 0.09 OUTLIER Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.359 -1.877 . . . . 0.0 111.672 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.463 ' C ' HG22 ' D' ' 39' ' ' VAL . . . 119.13 85.49 0.98 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-N 119.435 1.618 . . . . 0.0 114.009 178.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' E' ' 38' ' ' GLY . 1.8 p -24.1 121.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 113.87 1.063 . . . . 0.0 113.87 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.587 178.812 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.505 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -106.2 136.0 46.68 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.837 0.351 . . . . 0.0 110.585 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -82.69 117.4 22.6 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.015 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 27.1 m -138.22 157.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.514 0.673 . . . . 0.0 112.225 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 2.1 p80 -146.07 98.18 3.06 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.059 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.458 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 97.4 m-70 -151.9 168.08 26.28 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.498 ' HB3' HD21 ' F' ' 17' ' ' LEU . 17.2 mt-30 -89.75 158.19 17.64 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 16' ' ' LYS . . . . . 0.491 ' C ' HD22 ' F' ' 17' ' ' LEU . 64.5 mttp -140.23 96.08 2.99 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.122 0.487 . . . . 0.0 109.889 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.877 HD22 ' N ' ' F' ' 17' ' ' LEU . 0.3 OUTLIER -118.82 112.06 19.23 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.928 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 14.6 t -101.28 110.96 29.46 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.728 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.537 ' CD2' HD11 ' E' ' 32' ' ' ILE . 15.6 m-85 -104.3 101.33 11.04 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.401 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 61.4 t80 -126.02 125.55 42.84 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 122.236 1.017 . . . . 0.0 111.762 -178.038 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.37 132.04 51.65 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' E' ' 24' ' ' VAL . 45.9 tp10 -62.17 103.3 0.37 Allowed 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 118.586 -1.246 . . . . 0.0 108.011 -178.062 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' E' ' 24' ' ' VAL . 8.3 m-20 -163.92 46.22 0.11 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.071 -178.078 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.846 HG12 ' H ' ' F' ' 25' ' ' GLY . 40.5 t -89.78 -175.56 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.846 ' H ' HG12 ' F' ' 24' ' ' VAL . . . 81.35 -34.0 2.47 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.52 ' O ' ' O ' ' F' ' 27' ' ' ASN . 96.2 p -151.93 123.68 7.96 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 113.92 -1.14 . . . . 0.0 108.987 -177.089 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.52 ' O ' ' O ' ' F' ' 26' ' ' SER . 89.3 m-20 -40.75 167.29 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.068 0.461 . . . . 0.0 110.77 -176.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.454 ' O ' ' OG ' ' E' ' 26' ' ' SER . 74.1 tttt -79.56 -49.93 11.47 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -175.651 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.41 50.73 3.11 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 118.706 -1.711 . . . . 0.0 111.154 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.658 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -130.43 179.62 5.82 Favored 'General case' 0 C--N 1.343 0.289 0 CA-C-N 118.454 1.127 . . . . 0.0 111.135 -175.774 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 5.4 mm -113.53 135.3 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.137 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' E' ' 32' ' ' ILE . 82.9 mt -103.91 117.41 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.95 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 33' ' ' GLY . . . . . 0.562 ' H ' ' HA2' ' E' ' 33' ' ' GLY . . . -58.4 -154.61 0.01 OUTLIER Glycine 0 C--O 1.209 -1.46 0 CA-C-N 118.65 0.659 . . . . 0.0 113.233 -178.33 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.633 ' O ' ' HA ' ' E' ' 35' ' ' MET . 74.4 mt -99.47 125.79 45.27 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 178.785 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.762 ' HA ' ' HA ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -103.33 83.53 2.19 Favored 'General case' 0 C--O 1.171 -3.045 0 C-N-CA 130.117 3.367 . . . . 0.0 114.197 179.508 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.575 HG23 ' O ' ' F' ' 36' ' ' VAL . 2.7 m -92.77 115.21 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 117.785 -3.072 . . . . 0.0 112.713 175.534 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -117.19 122.51 5.48 Favored Glycine 0 CA--C 1.516 0.12 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 178.119 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.36 -61.61 7.27 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.046 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 37.2 t -147.88 137.77 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.171 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 178.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.135 -0.936 . . . . 0.0 110.34 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -109.6 135.24 50.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.708 0.289 . . . . 0.0 110.413 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 11' ' ' GLU . . . . . 0.431 ' O ' ' OE1' ' H' ' 11' ' ' GLU . 82.0 tt0 -95.81 123.28 39.32 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.866 0.365 . . . . 0.0 110.236 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.417 ' O ' HG23 ' G' ' 12' ' ' VAL . 4.4 m -132.69 132.66 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.942 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -104.74 121.68 44.12 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.821 0.343 . . . . 0.0 110.918 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 31.0 t60 -155.03 165.9 35.29 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.763 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.524 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 14.6 pt20 -157.06 142.22 17.18 Favored 'General case' 0 C--N 1.339 0.111 0 CA-C-O 121.174 0.512 . . . . 0.0 111.144 178.195 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.413 ' H ' ' HG2' ' G' ' 16' ' ' LYS . 51.5 pttt -86.3 122.03 29.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.307 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.8 mt -127.41 118.07 23.39 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -133.73 133.44 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-O 120.697 0.284 . . . . 0.0 111.585 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -139.14 142.61 38.02 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.896 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -152.0 151.59 31.36 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 119.726 -0.79 . . . . 0.0 112.781 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.51 129.26 50.95 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.036 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.428 ' O ' ' N ' ' G' ' 24' ' ' VAL . 96.4 mt-10 -82.19 -173.58 4.62 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -176.37 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.416 ' OD2' ' OE2' ' H' ' 22' ' ' GLU . 0.7 OUTLIER -51.61 46.41 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 112.877 -1.965 . . . . 0.0 115.771 -178.007 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.428 ' N ' ' O ' ' G' ' 22' ' ' GLU . 34.5 m -80.51 179.86 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 117.969 -1.492 . . . . 0.0 107.63 178.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.43 -33.48 64.17 Favored Glycine 0 CA--C 1.521 0.46 0 C-N-CA 119.598 -1.287 . . . . 0.0 112.842 -178.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.461 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.9 p -152.84 122.43 6.82 Favored 'General case' 0 C--N 1.329 -0.306 0 O-C-N 122.567 -0.372 . . . . 0.0 111.152 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.461 ' O ' ' O ' ' G' ' 26' ' ' SER . 25.1 t-20 -40.92 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.501 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -78.62 40.53 0.38 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.75 78.57 0.56 Allowed Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.729 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.66 59.97 4.41 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-N 119.814 1.807 . . . . 0.0 113.456 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 4.5 pt -147.99 123.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 177.162 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 87.8 mt -109.23 113.67 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.222 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.32 99.81 0.98 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 105.688 -2.965 . . . . 0.0 105.688 176.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.445 ' O ' HD23 ' H' ' 34' ' ' LEU . 43.0 tp -157.92 154.8 28.44 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 118.007 -1.477 . . . . 0.0 113.468 -175.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 55.0 tpp -102.1 119.89 39.54 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 113.007 -1.906 . . . . 0.0 107.07 177.509 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 47.2 t -124.2 112.17 31.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.221 0.534 . . . . 0.0 110.798 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.06 -131.89 10.19 Favored Glycine 0 C--N 1.316 -0.567 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . 115.5 -61.35 0.38 Allowed Glycine 0 CA--C 1.537 1.445 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.55 HG22 ' N ' ' G' ' 40' ' ' VAL . 2.4 p -127.78 164.76 28.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.55 ' N ' HG22 ' G' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.605 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' N ' ' H' ' 11' ' ' GLU . 60.7 t80 -148.73 179.88 7.5 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.284 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.625 ' N ' ' CD2' ' H' ' 10' ' ' TYR . 80.9 mm-40 -66.96 126.93 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.47 126.62 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.465 ' NE2' ' CE1' ' I' ' 13' ' ' HIS . 10.8 p80 -151.51 139.23 19.77 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.491 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.581 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 22.6 m-70 -145.33 160.7 41.13 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-O 121.046 0.451 . . . . 0.0 110.134 177.853 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -90.2 160.44 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -139.84 102.74 4.49 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.561 ' C ' HD23 ' H' ' 17' ' ' LEU . 7.3 tt -126.35 124.07 39.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.24 0.543 . . . . 0.0 111.191 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.478 ' N ' HD23 ' H' ' 17' ' ' LEU . 65.4 t -122.0 130.88 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.301 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -125.95 113.12 16.75 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.058 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -114.47 120.25 39.63 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.68 126.23 41.55 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.811 0.815 . . . . 0.0 113.187 -178.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.416 ' OE2' ' OD2' ' G' ' 23' ' ' ASP . 80.0 tt0 -97.62 113.06 24.71 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 107.07 -1.455 . . . . 0.0 107.07 177.02 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 57.5 t0 -131.12 52.06 2.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.295 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p -74.69 142.97 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 C-N-CA 119.944 -0.703 . . . . 0.0 109.577 -177.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.43 38.37 3.75 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.387 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 73.39 120.04 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.784 -0.208 . . . . 0.0 111.162 179.123 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.439 ' CG ' ' OD2' ' I' ' 23' ' ' ASP . 8.2 m-20 -83.24 162.0 21.32 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.174 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -47.04 -39.53 13.01 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.683 177.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.04 69.15 0.02 OUTLIER Glycine 0 CA--C 1.537 1.448 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.55 -176.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -51.64 100.73 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 118.544 1.172 . . . . 0.0 114.045 -176.469 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.523 HG22 ' HB ' ' I' ' 31' ' ' ILE . 43.5 pt -137.86 139.27 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.671 178.463 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.486 ' CG2' HD12 ' H' ' 34' ' ' LEU . 86.9 mt -106.89 109.11 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.17 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.071 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.98 96.86 1.13 Allowed Glycine 0 CA--C 1.519 0.313 0 N-CA-C 105.506 -3.037 . . . . 0.0 105.506 176.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.486 HD12 ' CG2' ' H' ' 32' ' ' ILE . 67.4 mt -135.23 149.47 49.87 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-O 123.48 1.609 . . . . 0.0 114.129 -175.418 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -119.55 106.71 12.47 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 111.795 -2.457 . . . . 0.0 104.447 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 79.3 t -106.52 102.78 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.612 0.72 . . . . 0.0 110.521 -177.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.462 ' HA3' ' H ' ' G' ' 38' ' ' GLY . . . -31.1 152.44 0.01 OUTLIER Glycine 0 N--CA 1.469 0.859 0 CA-C-N 114.56 -1.2 . . . . 0.0 113.723 -178.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . -88.44 -57.46 1.86 Allowed Glycine 0 N--CA 1.47 0.965 0 CA-C-N 114.98 -0.61 . . . . 0.0 113.338 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 40' ' ' VAL . 60.7 t -24.28 146.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 39' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.217 -0.622 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.869 -179.564 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' I' I ' 10' ' ' TYR . . . . . 0.519 ' O ' ' CD2' ' H' ' 10' ' ' TYR . 90.8 m-85 -97.63 129.81 44.7 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.516 ' O ' ' NE2' ' J' ' 13' ' ' HIS . 95.8 mt-10 -141.13 143.46 34.29 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.763 0.316 . . . . 0.0 111.335 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.518 HG22 ' H ' ' J' ' 12' ' ' VAL . 18.9 t -143.55 91.55 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.381 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.51 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 5.4 m-70 -132.74 133.63 43.72 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 116.967 -0.106 . . . . 0.0 111.187 -178.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.757 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 11.3 m80 -145.74 160.7 41.35 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 178.383 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 10.2 tp-100 -90.17 157.58 17.66 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 174.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -141.91 102.28 4.11 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 119.971 -0.691 . . . . 0.0 110.648 176.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 25.5 mt -120.51 118.41 30.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.652 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -111.8 114.77 48.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 177.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -108.53 105.25 14.81 Favored 'General case' 0 CA--C 1.539 0.533 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -116.17 132.63 56.61 Favored 'General case' 0 N--CA 1.479 1.02 0 O-C-N 122.212 -0.305 . . . . 0.0 111.091 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.22 149.65 32.31 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -178.407 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -105.59 163.36 12.73 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 113.966 -1.47 . . . . 0.0 108.124 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.474 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 34.6 t0 -174.47 47.08 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 -176.563 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.416 ' N ' ' OD2' ' J' ' 23' ' ' ASP . 0.1 OUTLIER -91.09 170.56 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 122.381 1.086 . . . . 0.0 110.308 -175.583 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.15 27.43 62.08 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.984 -176.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 1.7 t 165.78 146.87 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -53.02 138.12 31.38 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 119.126 -1.03 . . . . 0.0 108.844 178.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.6 ' HB2' HG11 ' J' ' 24' ' ' VAL . 31.2 tttm -62.35 -49.77 74.23 Favored 'General case' 0 CA--C 1.53 0.193 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 100.82 57.47 0.87 Allowed Glycine 0 CA--C 1.544 1.854 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.434 ' HB3' ' OD1' ' J' ' 27' ' ' ASN . . . -102.03 115.55 30.79 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 120.12 1.96 . . . . 0.0 116.198 -172.705 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.523 ' HB ' HG22 ' H' ' 31' ' ' ILE . 97.1 mt -129.89 120.98 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.371 176.302 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.627 HG22 HD21 ' J' ' 34' ' ' LEU . 28.9 mt -106.1 114.08 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.337 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.36 109.05 1.9 Allowed Glycine 0 C--O 1.236 0.271 0 N-CA-C 106.151 -2.78 . . . . 0.0 106.151 176.527 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.483 HD12 ' O ' ' H' ' 34' ' ' LEU . 0.1 OUTLIER -161.31 150.13 16.11 Favored 'General case' 0 CA--C 1.504 -0.793 0 C-N-CA 117.445 -1.702 . . . . 0.0 112.905 -175.63 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.443 ' N ' HD12 ' I' ' 34' ' ' LEU . 29.9 mtp -116.41 117.49 30.07 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-N 112.714 -2.039 . . . . 0.0 107.716 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.551 HG12 ' NE2' ' K' ' 15' ' ' GLN . 1.5 t -101.11 102.61 13.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.77 153.49 0.01 OUTLIER Glycine 0 N--CA 1.474 1.168 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.6 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.752 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -117.6 56.16 0.55 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 118.843 2.297 . . . . 0.0 118.843 -175.631 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.463 HG12 HG23 ' I' ' 40' ' ' VAL . 61.5 t -101.83 129.06 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 CA-C-N 119.886 1.843 . . . . 0.0 110.234 177.213 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.463 HG23 HG12 ' I' ' 39' ' ' VAL . 47.3 t . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.489 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -147.8 157.59 43.61 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.796 0.332 . . . . 0.0 110.283 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -151.16 114.92 4.93 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.479 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.518 ' H ' HG22 ' I' ' 12' ' ' VAL . 79.2 t -128.74 133.33 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.814 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' O ' ' I' ' 11' ' ' GLU . 48.9 m-70 -141.19 100.33 3.78 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.484 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.757 ' H ' ' CD2' ' I' ' 14' ' ' HIS . 45.4 p-80 -149.22 161.08 42.72 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.362 177.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -90.16 159.79 16.58 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -139.78 103.63 4.71 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.629 179.357 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -128.34 118.42 23.18 Favored 'General case' 0 C--O 1.239 0.544 0 CA-C-O 121.868 0.842 . . . . 0.0 109.391 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 88.1 t -108.93 111.13 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.51 0 CA-C-N 114.141 -1.39 . . . . 0.0 109.17 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.564 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 16.5 m-85 -108.63 103.95 13.16 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.42 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 3.9 m-85 -120.05 130.72 54.82 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -177.039 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.4 120.07 16.16 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 177.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.51 ' O ' ' OD1' ' J' ' 23' ' ' ASP . 87.3 mt-10 -145.0 141.36 28.87 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -176.268 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.575 ' CG ' ' H ' ' J' ' 24' ' ' VAL . 5.3 p-10 147.17 -69.39 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.938 0 O-C-N 125.076 1.485 . . . . 0.0 110.125 176.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.831 HG22 ' H ' ' J' ' 25' ' ' GLY . 7.6 p -54.97 -122.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.499 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.831 ' H ' HG22 ' J' ' 24' ' ' VAL . . . 140.31 -35.17 1.92 Allowed Glycine 0 CA--C 1.528 0.866 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.661 177.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 16.1 t -80.45 118.66 22.27 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 121.041 2.42 . . . . 0.0 106.415 171.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.473 HD21 ' N ' ' J' ' 27' ' ' ASN . 1.0 OUTLIER -91.44 160.28 15.53 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 121.977 2.171 . . . . 0.0 111.038 176.743 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -46.31 -39.93 10.93 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-O 122.729 1.252 . . . . 0.0 109.541 173.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.94 68.52 0.02 OUTLIER Glycine 0 CA--C 1.54 1.648 0 CA-C-N 112.401 -2.181 . . . . 0.0 107.954 -176.156 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.716 ' O ' ' HB1' ' K' ' 30' ' ' ALA . . . -51.59 138.2 23.13 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 116.331 1.974 . . . . 0.0 116.331 -173.577 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.734 HD11 ' HB ' ' D' ' 39' ' ' VAL . 82.6 mt -135.14 126.57 46.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 113.327 -1.76 . . . . 0.0 112.228 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -108.95 109.72 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.02 99.73 0.99 Allowed Glycine 0 N--CA 1.462 0.433 0 N-CA-C 106.404 -2.678 . . . . 0.0 106.404 178.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.627 HD21 HG22 ' I' ' 32' ' ' ILE . 96.9 mt -134.94 134.63 40.8 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -175.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 45.7 tpp -104.51 107.52 18.49 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 103.936 -2.616 . . . . 0.0 103.936 174.1 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.59 ' O ' HG22 ' K' ' 36' ' ' VAL . 4.2 t -120.21 113.14 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 122.445 1.117 . . . . 0.0 110.745 -178.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -73.04 -122.39 0.08 OUTLIER Glycine 0 C--N 1.313 -0.733 0 CA-C-N 112.876 -1.966 . . . . 0.0 110.732 175.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.752 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . 71.52 60.77 4.18 Favored Glycine 0 C--N 1.318 -0.446 0 CA-C-N 111.628 -2.286 . . . . 0.0 115.791 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.961 HG22 HD11 ' P' ' 31' ' ' ILE . 7.3 m -81.75 129.35 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.136 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 9.3 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.414 179.976 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -111.83 135.18 52.79 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -136.29 144.78 44.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.748 0.308 . . . . 0.0 110.599 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 99.2 t -128.55 130.18 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 39.0 m-70 -136.19 113.73 10.91 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.079 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.497 ' O ' ' CB ' ' J' ' 14' ' ' HIS . 14.8 p-80 -152.84 162.38 41.36 Favored 'General case' 0 C--O 1.217 -0.612 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.904 178.531 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.551 ' NE2' HG12 ' I' ' 36' ' ' VAL . 10.3 tt0 -90.07 158.66 17.21 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.764 -1.939 . . . . 0.0 105.764 175.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.482 ' C ' HD13 ' K' ' 17' ' ' LEU . 34.5 tttt -140.7 96.52 3.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 119.21 0.914 . . . . 0.0 110.825 178.623 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.885 HD22 ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -120.87 110.58 16.49 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.582 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.431 HG13 ' O ' ' K' ' 18' ' ' VAL . 7.7 p -114.5 114.25 46.08 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.12 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.564 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 28.7 m-85 -107.23 104.22 13.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.567 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 25.7 t80 -112.67 123.56 50.58 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.128 -178.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -151.87 139.12 19.32 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 118.72 -1.192 . . . . 0.0 114.126 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.419 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 94.2 mt-10 -79.59 109.46 14.0 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.523 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . 49.3 t0 -146.31 46.71 1.22 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -177.063 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.502 HG22 ' N ' ' K' ' 25' ' ' GLY . 10.9 p -98.65 161.41 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 175.692 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.502 ' N ' HG22 ' K' ' 24' ' ' VAL . . . 76.22 27.68 61.48 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.281 176.25 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.469 ' CB ' ' H ' ' J' ' 27' ' ' ASN . 24.9 t -83.9 -120.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.445 -0.902 . . . . 0.0 113.305 -175.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 26.7 t-20 -93.27 163.01 13.78 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 122.597 1.189 . . . . 0.0 113.493 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 68.7 mttm -41.97 -37.91 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 112.491 -2.14 . . . . 0.0 111.185 176.534 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.19 71.97 0.22 Allowed Glycine 0 CA--C 1.54 1.646 0 CA-C-N 115.744 -0.662 . . . . 0.0 114.253 -172.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.716 ' HB1' ' O ' ' J' ' 30' ' ' ALA . . . -82.02 173.2 12.4 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 18.0 tt -148.23 160.23 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.185 0 N-CA-C 116.17 1.915 . . . . 0.0 116.17 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.77 125.58 61.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 113.572 -1.649 . . . . 0.0 109.711 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.3 123.22 4.3 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.661 HD23 ' C ' ' K' ' 34' ' ' LEU . 2.3 tt -130.26 130.57 44.74 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-O 120.97 0.414 . . . . 0.0 110.496 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 5.6 mtp -124.84 130.17 51.86 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.248 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.59 HG22 ' O ' ' J' ' 36' ' ' VAL . 50.6 t -124.76 158.69 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.159 0.504 . . . . 0.0 110.667 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.442 ' N ' HG12 ' K' ' 36' ' ' VAL . . . -63.65 -103.08 0.01 OUTLIER Glycine 0 CA--C 1.53 0.997 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.32 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -135.89 -74.36 0.07 OUTLIER Glycine 0 CA--C 1.538 1.485 0 C-N-CA 121.472 -0.394 . . . . 0.0 113.249 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 59.6 t -74.91 133.39 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 120.715 0.293 . . . . 0.0 111.202 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.723 -179.721 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.8 136.07 50.41 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.827 0.346 . . . . 0.0 110.695 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -87.77 148.73 24.58 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.36 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.81 114.68 47.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.895 0.379 . . . . 0.0 110.615 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.576 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -147.16 105.77 3.81 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.211 179.814 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.484 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 79.2 m80 -151.49 166.94 29.56 Favored 'General case' 0 C--O 1.221 -0.429 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 38.6 tt0 -89.78 158.46 17.49 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.02 102.38 4.38 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.247 -0.581 . . . . 0.0 111.822 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.707 ' N ' HD23 ' L' ' 17' ' ' LEU . 0.1 OUTLIER -116.61 108.09 15.52 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 176.537 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -106.98 111.14 34.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.57 -179.2 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -105.56 101.07 10.61 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.567 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 30.9 t80 -125.71 131.67 52.53 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 121.203 0.525 . . . . 0.0 110.756 -178.357 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -140.29 157.15 46.01 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.147 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.439 ' C ' ' O ' ' L' ' 21' ' ' ALA . 80.2 tt0 -31.1 129.54 0.13 Allowed 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 122.029 0.918 . . . . 0.0 112.48 -174.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.434 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 66.9 t0 -109.84 47.34 0.95 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 113.496 -1.684 . . . . 0.0 112.986 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.48 ' CG2' HG21 ' K' ' 24' ' ' VAL . 3.1 m -63.02 -167.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.349 -178.465 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.54 27.83 9.13 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.219 -0.446 . . . . 0.0 113.616 -175.163 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 48.0 t -153.67 120.28 5.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.424 0.63 . . . . 0.0 109.935 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 p30 -40.7 167.0 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.135 0 CA-C-N 114.978 -1.01 . . . . 0.0 112.187 -178.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.523 ' NZ ' ' O ' ' K' ' 23' ' ' ASP . 63.9 tttp -80.22 -50.0 10.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.199 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.85 50.59 3.05 Favored Glycine 0 CA--C 1.543 1.84 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.707 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -130.57 -169.15 2.09 Favored 'General case' 0 C--N 1.341 0.224 0 CA-C-O 121.354 0.597 . . . . 0.0 110.597 -178.201 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -118.64 138.55 48.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.786 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -122.15 128.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.64 122.52 3.42 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 111.635 -0.586 . . . . 0.0 111.635 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 57.6 mt -117.99 125.42 50.36 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -132.81 127.65 35.0 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.619 HG22 ' N ' ' L' ' 37' ' ' GLY . 2.6 p -140.46 171.72 12.75 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.111 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.619 ' N ' HG22 ' L' ' 36' ' ' VAL . . . -168.12 94.49 0.11 Allowed Glycine 0 C--N 1.311 -0.852 0 C-N-CA 118.536 -1.792 . . . . 0.0 112.036 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.5 -81.41 0.11 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.747 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' K' ' 38' ' ' GLY . 38.8 t -150.12 136.71 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.105 0.479 . . . . 0.0 110.359 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.402 HG22 ' H ' ' L' ' 40' ' ' VAL . 19.1 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.533 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -112.24 137.83 49.79 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.909 0.385 . . . . 0.0 110.582 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -140.44 164.47 30.05 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.356 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 12' ' ' VAL . . . . . 0.485 ' CG1' ' H ' ' N' ' 12' ' ' VAL . 2.4 p -123.0 131.82 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.286 0.565 . . . . 0.0 110.101 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 13' ' ' HIS . . . . . 0.456 ' CG ' ' N ' ' M' ' 14' ' ' HIS . 76.4 t60 -72.65 164.08 27.05 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.309 -178.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.588 ' ND1' ' N ' ' M' ' 14' ' ' HIS . 1.2 m-70 -99.13 166.17 11.37 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -89.8 159.82 16.82 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.54 107.98 5.85 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.1 mt -129.76 114.92 16.56 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 121.098 0.475 . . . . 0.0 110.227 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 54.3 t -125.23 132.17 71.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.031 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 t80 -136.28 127.41 28.0 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.45 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -131.48 146.32 52.19 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.16 128.29 23.88 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 121.741 0.781 . . . . 0.0 112.743 -178.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -92.17 -149.25 0.24 Allowed 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -46.62 -60.08 2.61 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.613 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.618 HG12 ' N ' ' M' ' 25' ' ' GLY . 47.9 t -84.76 171.56 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 175.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.618 ' N ' HG12 ' M' ' 24' ' ' VAL . . . 94.03 -29.98 8.1 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 176.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 7.3 p -84.23 139.98 31.99 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.146 -1.527 . . . . 0.0 113.575 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 92.6 m-20 -73.03 179.5 3.74 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 177.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CG ' ' N' ' 28' ' ' LYS . 98.4 mttt -49.77 -37.58 30.4 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 117.943 -1.503 . . . . 0.0 110.548 -175.601 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.05 -78.38 0.06 OUTLIER Glycine 0 CA--C 1.53 1.023 0 C-N-CA 118.89 -1.624 . . . . 0.0 113.777 174.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' N' ' 30' ' ' ALA . . . -147.35 81.63 1.53 Allowed 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 117.819 0.81 . . . . 0.0 112.942 178.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.639 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -123.34 105.39 15.69 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 32' ' ' ILE . . . . . 0.437 HG22 HD21 ' N' ' 34' ' ' LEU . 2.4 mt -119.11 111.87 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 C-N-CA 119.659 -0.816 . . . . 0.0 111.452 -178.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.41 105.61 1.16 Allowed Glycine 0 N--CA 1.46 0.258 0 N-CA-C 104.153 -3.579 . . . . 0.0 104.153 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 34' ' ' LEU . . . . . 0.412 ' HG ' ' N ' ' M' ' 35' ' ' MET . 45.6 tp -153.71 158.17 40.6 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.579 -173.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 35' ' ' MET . . . . . 0.412 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 0.7 OUTLIER -104.88 110.18 22.45 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 112.736 -2.029 . . . . 0.0 106.991 177.182 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.62 131.24 70.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.12 -111.17 3.89 Favored Glycine 0 C--N 1.318 -0.466 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.498 ' O ' HG23 ' N' ' 39' ' ' VAL . . . 75.12 -73.76 1.5 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.403 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 17.6 m -95.69 -176.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.175 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.463 HG12 ' NZ ' ' C' ' 28' ' ' LYS . 1.3 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.607 178.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' N' N ' 10' ' ' TYR . . . . . 0.487 ' CD1' ' O ' ' O' ' 9' ' ' GLY . 97.9 m-85 -108.0 139.7 42.25 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.26 124.14 51.8 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.957 0.408 . . . . 0.0 111.023 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.485 ' H ' ' CG1' ' M' ' 12' ' ' VAL . 3.4 t -137.88 97.14 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.745 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.519 ' ND1' ' ND1' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -151.5 151.07 31.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 121.108 -0.237 . . . . 0.0 110.675 179.524 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -124.79 162.58 23.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.047 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -89.88 158.79 17.28 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 16' ' ' LYS . . . . . 0.748 ' C ' HD12 ' N' ' 17' ' ' LEU . 98.8 mttt -140.53 99.94 3.75 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.748 HD12 ' C ' ' N' ' 16' ' ' LYS . 10.9 mp -124.04 119.3 29.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -123.01 128.34 75.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.648 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -123.76 123.95 41.64 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.897 179.149 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -129.18 123.14 31.31 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.805 0.336 . . . . 0.0 110.283 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 132.22 50.38 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.424 ' O ' ' CB ' ' N' ' 23' ' ' ASP . 83.1 tt0 -157.38 151.46 24.65 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.424 ' CB ' ' O ' ' N' ' 22' ' ' GLU . 9.5 m-20 92.29 46.92 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 113.603 -1.635 . . . . 0.0 115.185 176.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 24.2 m -101.52 158.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 -37.5 94.76 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.582 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.579 ' O ' ' O ' ' N' ' 27' ' ' ASN . 86.4 p -162.47 117.17 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 117.093 -1.432 . . . . 0.0 107.165 177.001 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.579 ' O ' ' O ' ' N' ' 26' ' ' SER . 11.6 t-20 -23.45 151.2 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 120.332 1.424 . . . . 0.0 111.908 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.491 ' O ' HG23 ' G' ' 39' ' ' VAL . 73.8 mmtt -107.83 47.87 0.87 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 115.999 -1.953 . . . . 0.0 115.264 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 61.8 0.52 Allowed Glycine 0 N--CA 1.489 2.202 0 CA-C-N 124.083 3.129 . . . . 0.0 114.067 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 30' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' M' ' 30' ' ' ALA . . . -88.31 98.95 11.88 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 121.076 2.438 . . . . 0.0 111.476 -174.38 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.455 HG23 ' O ' ' N' ' 31' ' ' ILE . 18.9 tt -134.61 129.33 52.12 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-N 110.856 -2.884 . . . . 0.0 110.2 -177.558 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.57 HD13 ' CD1' ' P' ' 19' ' ' PHE . 95.8 mt -113.04 110.87 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.78 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.544 ' O ' HD22 ' N' ' 34' ' ' LEU . . . -111.25 93.51 0.72 Allowed Glycine 0 N--CA 1.467 0.722 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 175.646 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.544 HD22 ' O ' ' N' ' 33' ' ' GLY . 1.3 mm? -125.12 133.32 52.89 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.018 1.39 . . . . 0.0 112.269 -174.41 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 2.7 mtp -103.55 106.06 16.47 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 176.624 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 1.008 HG21 HD11 ' P' ' 17' ' ' LEU . 2.5 p -127.9 123.11 60.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.246 -178.219 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 149.63 -113.2 0.59 Allowed Glycine 0 C--N 1.311 -0.818 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.473 ' O ' HG23 ' O' ' 39' ' ' VAL . . . 70.48 -72.58 0.62 Allowed Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.505 HG12 ' N ' ' N' ' 40' ' ' VAL . 45.1 t -123.36 163.96 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 178.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.505 ' N ' HG12 ' N' ' 39' ' ' VAL . 18.6 m . . . . . 0 N--CA 1.471 0.579 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.715 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 9' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' N' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -114.28 147.19 39.42 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.711 0.291 . . . . 0.0 110.293 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -87.49 109.88 19.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.09 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.479 HG13 ' C ' ' P' ' 12' ' ' VAL . 51.5 t -129.62 123.86 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.505 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.598 ' CE1' ' NZ ' ' A' ' 28' ' ' LYS . 7.3 m-70 -137.57 150.42 47.46 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.598 ' CD2' ' CE1' ' P' ' 14' ' ' HIS . 4.7 m80 -136.86 157.45 46.73 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.169 178.33 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -86.3 157.46 19.91 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 175.109 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -160.25 101.76 1.4 Allowed 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.255 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 3.2 mt -132.47 122.73 25.37 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.335 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 89.2 t -113.56 113.27 43.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.941 178.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -108.4 102.54 11.63 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.393 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -113.33 125.03 53.83 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -177.637 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.15 125.91 40.05 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -124.51 178.93 5.16 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 52.44 58.94 4.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 113.19 -1.823 . . . . 0.0 112.05 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.684 HG11 HG13 ' P' ' 24' ' ' VAL . 63.2 t -78.25 123.0 34.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.911 -1.041 . . . . 0.0 109.214 175.48 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.512 ' H ' ' HA ' ' N' ' 26' ' ' SER . . . -90.49 -38.54 6.21 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.577 -177.472 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' O' ' 27' ' ' ASN . 46.8 t -161.97 116.51 1.91 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 118.454 1.127 . . . . 0.0 111.907 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' O' ' 26' ' ' SER . 57.2 p30 -24.12 163.73 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.358 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -152.16 -22.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.943 178.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.2 97.32 2.43 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.19 140.94 29.12 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-O 121.776 0.798 . . . . 0.0 111.974 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.43 HD12 HG22 ' I' ' 39' ' ' VAL . 14.9 mt -143.41 135.77 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.19 -0.914 . . . . 0.0 113.064 -179.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.594 HD13 ' CD2' ' Q' ' 19' ' ' PHE . 82.3 mt -114.38 112.08 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 176.076 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.01 109.48 2.34 Favored Glycine 0 C--O 1.24 0.505 0 N-CA-C 105.575 -3.01 . . . . 0.0 105.575 176.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.437 ' CD2' HG12 ' N' ' 36' ' ' VAL . 0.2 OUTLIER -144.91 142.34 29.79 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 123.019 1.39 . . . . 0.0 114.038 -175.263 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 94.8 mmm -103.75 110.57 22.72 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 112.133 -2.303 . . . . 0.0 105.366 176.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.497 HG12 ' NE2' ' Q' ' 15' ' ' GLN . 47.1 t -117.93 123.12 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-O 120.823 0.344 . . . . 0.0 110.087 -177.101 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.38 -113.24 0.63 Allowed Glycine 0 C--N 1.32 -0.339 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.494 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . 87.5 -73.12 2.42 Favored Glycine 0 CA--C 1.541 1.677 0 CA-C-O 119.93 -0.372 . . . . 0.0 112.649 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.708 ' C ' HG11 ' P' ' 39' ' ' VAL . 45.2 t -134.51 161.04 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.539 ' N ' HG21 ' P' ' 39' ' ' VAL . 6.3 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.315 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -106.44 136.25 46.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.829 0.347 . . . . 0.0 110.284 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -87.94 119.6 28.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.037 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.541 ' O ' ' NE2' ' O' ' 14' ' ' HIS . 2.8 m -136.83 160.71 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.466 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.48 ' NE2' ' C ' ' N' ' 40' ' ' VAL . 8.2 t60 -90.7 120.79 32.05 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.344 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' CD2' ' O' ' 14' ' ' HIS . 11.6 p-80 -152.97 161.82 42.08 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.659 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -90.23 158.77 17.04 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.646 178.467 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -140.94 105.27 4.84 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 1.008 HD11 HG21 ' N' ' 36' ' ' VAL . 31.2 mt -122.7 123.18 40.53 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 120.314 -0.554 . . . . 0.0 110.433 178.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 18' ' ' VAL . . . . . 0.413 HG13 ' CG2' ' Q' ' 18' ' ' VAL . 2.2 t -114.51 106.51 20.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.63 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' N' ' 32' ' ' ILE . 57.3 m-85 -106.76 111.52 24.09 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -133.7 130.39 38.09 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.456 1.28 . . . . 0.0 114.456 -176.262 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.54 125.16 37.75 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.838 177.395 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -111.74 150.81 29.72 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 115.764 1.764 . . . . 0.0 115.764 -175.23 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.536 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 83.6 m-20 63.38 46.56 4.33 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 117.685 2.476 . . . . 0.0 117.685 173.939 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.691 HG12 ' H ' ' P' ' 25' ' ' GLY . 8.7 t -100.44 -179.44 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 115.556 -2.458 . . . . 0.0 109.523 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.691 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -72.6 -30.65 63.88 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 121.195 -0.526 . . . . 0.0 113.469 176.073 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.5 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 9.7 t 100.72 111.33 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 -174.217 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.503 ' CG ' ' N ' ' P' ' 28' ' ' LYS . 22.8 t-20 -71.31 173.47 7.75 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 117.459 -1.697 . . . . 0.0 112.724 -176.622 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.503 ' N ' ' CG ' ' P' ' 27' ' ' ASN . 88.7 tttt -52.45 -36.78 55.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.43 177.363 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.52 77.18 0.06 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.661 -177.095 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.83 154.11 2.22 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 118.307 1.053 . . . . 0.0 110.44 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.961 HD11 HG22 ' J' ' 39' ' ' VAL . 69.4 mt -121.22 131.23 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 73.7 mt -114.33 110.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.04 109.21 2.74 Favored Glycine 0 N--CA 1.463 0.497 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.51 ' CD1' ' CE1' ' R' ' 19' ' ' PHE . 95.4 mt -135.0 133.48 39.49 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.445 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 4.0 mtp -107.62 104.02 13.46 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 174.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.76 103.07 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.32 -153.11 24.62 Favored Glycine 0 C--N 1.31 -0.892 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.95 -56.68 0.6 Allowed Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -178.1 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.708 HG11 ' C ' ' O' ' 39' ' ' VAL . 11.5 p -124.36 154.99 31.91 Favored 'Isoleucine or valine' 0 C--O 1.231 0.085 0 C-N-CA 122.66 0.384 . . . . 0.0 110.054 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.461 HG23 ' H ' ' P' ' 40' ' ' VAL . 1.9 t . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 118.067 -0.968 . . . . 0.0 111.028 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -119.73 120.71 37.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.82 154.01 43.77 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.043 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.566 HG12 ' H ' ' R' ' 12' ' ' VAL . 12.7 m -133.0 120.11 39.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 121.625 0.726 . . . . 0.0 111.84 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.444 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 4.0 m-70 -90.1 110.73 21.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.233 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.527 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 2.3 t-80 -119.37 159.62 23.84 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.497 ' NE2' HG12 ' O' ' 36' ' ' VAL . 9.6 tt0 -86.24 157.84 19.85 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . 0.766 ' O ' HD23 ' Q' ' 17' ' ' LEU . 76.5 tttt -160.04 94.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.539 177.882 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.766 HD23 ' O ' ' Q' ' 16' ' ' LYS . 1.7 mt -131.56 127.15 36.58 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . 0.413 ' CG2' HG13 ' P' ' 18' ' ' VAL . 28.1 m -117.45 122.11 69.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 178.499 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.594 ' CD2' HD13 ' O' ' 32' ' ' ILE . 22.0 m-85 -112.63 105.37 13.53 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -127.32 137.02 52.71 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.644 0.735 . . . . 0.0 112.686 -177.036 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -146.74 145.04 29.82 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 119.78 -0.768 . . . . 0.0 113.03 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.536 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 82.8 mt-10 -79.27 149.66 31.76 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.528 ' OD1' ' HB1' ' R' ' 21' ' ' ALA . 6.9 p-10 -168.14 47.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -176.797 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.45 HG12 ' H ' ' Q' ' 25' ' ' GLY . 5.7 t -71.58 170.02 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.105 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.239 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.45 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 80.75 26.7 53.16 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 104.537 -3.425 . . . . 0.0 104.537 -175.71 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 24.0 p -80.85 116.5 20.86 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 117.047 2.24 . . . . 0.0 117.047 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -90.22 -152.16 0.26 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 111.286 -2.688 . . . . 0.0 104.947 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -48.56 -41.03 29.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 119.695 1.134 . . . . 0.0 108.333 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.44 -63.95 0.6 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 117.064 1.586 . . . . 0.0 117.064 173.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.16 165.21 32.07 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 120.108 1.954 . . . . 0.0 115.057 -176.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 69.2 mt -125.35 127.55 72.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 CA-C-N 111.321 -2.672 . . . . 0.0 106.786 178.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 tt -134.79 133.33 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 121.781 0.801 . . . . 0.0 112.698 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.4 109.93 2.16 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 107.764 -2.134 . . . . 0.0 107.764 177.2 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.414 HD23 HD13 ' R' ' 34' ' ' LEU . 18.5 tp -116.63 119.04 34.26 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.22 137.45 52.03 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.934 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 21.4 t -111.19 131.9 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.067 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.29 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . -45.62 -111.7 0.0 OUTLIER Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.322 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . -101.48 -71.5 0.93 Allowed Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.413 ' HB ' HD11 ' E' ' 31' ' ' ILE . 69.3 t -109.08 129.86 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.275 0.538 . . . . 0.0 109.862 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.838 -179.397 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.61 132.53 51.65 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -72.34 142.81 48.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.566 ' H ' HG12 ' Q' ' 12' ' ' VAL . 5.4 m -121.13 131.96 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-O 121.901 0.858 . . . . 0.0 112.01 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 4.1 m80 -133.47 124.96 27.97 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 114.448 -1.251 . . . . 0.0 108.92 178.435 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 99.2 m-70 -149.28 172.04 15.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.809 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.516 ' OE1' ' N ' ' R' ' 15' ' ' GLN . 14.0 mp0 -89.42 150.33 22.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.614 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.767 ' C ' HD12 ' R' ' 17' ' ' LEU . 74.1 tttt -150.17 98.78 2.73 Favored 'General case' 0 C--N 1.311 -1.066 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 178.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.767 HD12 ' C ' ' R' ' 16' ' ' LYS . 9.7 mp -127.05 124.58 39.64 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.625 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 66.5 t -106.62 114.66 46.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD1' ' P' ' 34' ' ' LEU . 17.1 m-85 -106.59 105.81 16.02 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' N ' ' R' ' 21' ' ' ALA . 66.2 t80 -146.9 156.76 43.33 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 122.463 1.125 . . . . 0.0 113.261 -177.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.528 ' HB1' ' OD1' ' Q' ' 23' ' ' ASP . . . -150.02 148.24 28.8 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.878 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.443 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 83.4 tt0 -76.49 112.54 13.13 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.56 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.484 ' OD1' ' N ' ' R' ' 23' ' ' ASP . 19.5 p-10 -177.23 48.92 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.642 -177.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -72.11 160.49 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 118.605 -1.238 . . . . 0.0 108.879 -178.592 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.35 -34.83 5.18 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 107.286 -2.326 . . . . 0.0 107.286 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.425 ' OG ' ' O ' ' R' ' 23' ' ' ASP . 11.9 p -80.53 119.98 23.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 113.193 -1.504 . . . . 0.0 109.852 179.082 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' R' ' 29' ' ' GLY . 89.9 m-20 -87.72 -175.17 5.07 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.091 -178.067 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -49.52 49.64 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.7 51.49 0.92 Allowed Glycine 0 CA--C 1.546 1.972 0 CA-C-N 118.776 0.717 . . . . 0.0 112.333 178.539 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.17 172.94 11.24 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.2 mt -113.35 120.4 63.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -125.01 127.97 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.935 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.19 116.68 3.01 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 178.426 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.414 HD13 HD23 ' Q' ' 34' ' ' LEU . 40.4 tp -124.1 122.51 38.04 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.6 mtp -139.72 147.34 40.76 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.173 0.511 . . . . 0.0 112.279 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.401 HG22 ' N ' ' R' ' 37' ' ' GLY . 2.9 p -130.15 155.27 41.46 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.075 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.5 179.177 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.401 ' N ' HG22 ' R' ' 36' ' ' VAL . . . -102.99 102.75 2.29 Favored Glycine 0 CA--C 1.523 0.582 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.95 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.97 -76.17 0.73 Allowed Glycine 0 CA--C 1.535 1.329 0 N-CA-C 115.241 0.857 . . . . 0.0 115.241 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.485 ' O ' ' O ' ' Q' ' 38' ' ' GLY . 54.0 t -122.7 139.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 117.916 0.858 . . . . 0.0 112.708 -177.033 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.987 179.214 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -83.82 142.25 30.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.869 0.366 . . . . 0.0 110.814 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.439 ' CD ' ' NE2' ' A' ' 13' ' ' HIS . 80.8 tt0 -138.85 146.48 41.27 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.68 179.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 51.8 t -120.16 129.51 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.619 0.723 . . . . 0.0 111.098 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.439 ' NE2' ' CD ' ' A' ' 11' ' ' GLU . 98.2 m-70 -126.04 166.16 17.48 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.713 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 53.0 p-80 -82.92 167.31 18.13 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.238 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -157.87 142.92 16.71 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.611 178.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -81.51 127.98 33.41 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.116 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.2 mt -125.48 114.49 18.87 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -127.55 131.49 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.176 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -134.55 130.79 37.1 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.148 0.499 . . . . 0.0 111.702 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -113.9 123.02 48.76 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.034 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.02 129.46 46.74 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.155 0.502 . . . . 0.0 111.656 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 24' ' ' VAL . 98.0 mt-10 -92.99 -176.28 4.14 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 178.766 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.63 ' C ' HG23 ' A' ' 24' ' ' VAL . 48.5 t0 -58.6 -48.2 81.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.402 0.62 . . . . 0.0 109.629 179.296 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.63 HG23 ' C ' ' A' ' 23' ' ' ASP . 1.0 OUTLIER 72.4 -162.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.962 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.596 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -109.27 27.17 13.04 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 119.195 -0.78 . . . . 0.0 112.488 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -81.67 -127.09 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 119.424 1.612 . . . . 0.0 111.087 -178.526 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 81.7 m-20 -100.67 160.91 13.97 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 115.862 1.801 . . . . 0.0 115.862 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -42.89 -36.25 1.45 Allowed 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 112.369 -2.196 . . . . 0.0 113.261 171.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -102.39 87.75 0.63 Allowed Glycine 0 CA--C 1.526 0.761 0 CA-C-N 113.051 -1.886 . . . . 0.0 117.335 -168.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.52 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -96.27 128.66 43.39 Favored 'General case' 0 CA--C 1.551 1.01 0 CA-C-O 124.975 2.321 . . . . 0.0 110.403 -177.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -145.59 160.23 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 CA-C-N 110.546 -3.024 . . . . 0.0 111.329 -175.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 52.0 mt -104.43 109.46 27.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 175.638 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.13 94.88 0.69 Allowed Glycine 0 CA--C 1.508 -0.39 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 178.576 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.489 ' O ' HD12 ' B' ' 34' ' ' LEU . 89.4 mt -144.26 154.63 43.28 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 122.881 1.324 . . . . 0.0 113.43 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 6.1 ttm -114.48 114.95 26.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 112.466 -2.152 . . . . 0.0 107.431 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.4 HG11 HD11 ' C' ' 17' ' ' LEU . 0.0 OUTLIER -129.26 102.84 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.807 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.1 -151.75 20.83 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 109.299 -1.521 . . . . 0.0 109.299 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.61 ' O ' HG11 ' B' ' 39' ' ' VAL . . . 117.24 -56.33 0.54 Allowed Glycine 0 CA--C 1.543 1.797 0 C-N-CA 121.534 -0.365 . . . . 0.0 112.713 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.764 ' C ' HG21 ' B' ' 39' ' ' VAL . 7.2 p -133.1 177.47 7.09 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.672 ' H ' HG22 ' A' ' 39' ' ' VAL . 6.0 m . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 117.901 -1.047 . . . . 0.0 111.965 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -84.23 138.02 33.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.76 0.314 . . . . 0.0 110.322 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -106.35 125.77 51.41 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.988 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.52 HG11 ' CE1' ' C' ' 13' ' ' HIS . 54.1 t -122.35 130.03 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.725 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m80 -117.42 157.6 25.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.609 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.605 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 52.9 t60 -80.72 166.86 20.63 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.111 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.559 ' O ' ' CE1' ' B' ' 14' ' ' HIS . 29.6 pt20 -129.29 151.08 50.34 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.15 0.5 . . . . 0.0 110.334 179.454 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -96.9 120.88 38.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.144 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.434 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.3 tt -116.76 115.56 25.84 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.8 t -121.34 128.68 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.205 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.248 -179.435 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -129.63 117.48 20.44 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 32.4 t80 -112.57 122.42 47.63 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.04 116.11 26.22 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.929 0.871 . . . . 0.0 112.394 -178.504 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -95.98 135.35 37.85 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.518 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -150.65 51.27 0.87 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.356 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.23 151.27 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 C-N-CA 118.486 -1.285 . . . . 0.0 110.21 -177.54 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.52 -32.4 6.64 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 106.166 -2.774 . . . . 0.0 106.166 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.539 ' HB3' ' N ' ' C' ' 26' ' ' SER . 0.5 OUTLIER 71.5 106.09 0.06 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 112.732 -1.734 . . . . 0.0 112.262 176.045 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.598 ' N ' ' OG ' ' C' ' 26' ' ' SER . 43.8 m-80 -101.63 163.36 12.3 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 119.217 -0.993 . . . . 0.0 112.815 177.318 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.49 ' O ' ' O ' ' C' ' 27' ' ' ASN . 99.7 mttt -41.45 -39.2 1.44 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 119.739 3.237 . . . . 0.0 119.739 178.652 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -110.72 69.7 0.21 Allowed Glycine 0 N--CA 1.497 2.713 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 -170.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.417 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -97.47 102.33 14.07 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 120.527 2.164 . . . . 0.0 111.978 178.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 7.0 pt -147.49 153.03 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.125 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' D' ' 19' ' ' PHE . 88.9 mt -107.44 114.09 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.53 106.09 1.93 Allowed Glycine 0 N--CA 1.464 0.504 0 N-CA-C 106.256 -2.738 . . . . 0.0 106.256 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.489 HD12 ' O ' ' A' ' 34' ' ' LEU . 10.5 tp -141.76 142.4 33.24 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.653 -1.219 . . . . 0.0 114.249 -175.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -116.67 110.94 19.13 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.359 177.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' C' ' 36' ' ' VAL . 0.4 OUTLIER -132.75 102.94 5.57 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.596 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 -179.299 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.51 -151.85 21.21 Favored Glycine 0 C--N 1.306 -1.088 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.407 ' C ' HG12 ' C' ' 39' ' ' VAL . . . 100.21 -57.05 0.8 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -178.718 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.764 HG21 ' C ' ' A' ' 39' ' ' VAL . 12.8 m -123.47 174.14 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 C-N-CA 123.826 0.851 . . . . 0.0 110.073 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.411 ' C ' ' O ' ' B' ' 39' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.572 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -83.23 139.53 33.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.291 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -81.6 118.94 23.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.407 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 53.4 t -130.31 133.75 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.137 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.618 ' CE1' ' HZ3' ' H' ' 28' ' ' LYS . 0.2 OUTLIER -139.13 100.8 4.11 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 121.218 -0.193 . . . . 0.0 111.134 179.205 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.605 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 13.6 m170 -117.19 160.5 20.95 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -86.41 155.54 20.54 Favored 'General case' 0 N--CA 1.457 -0.108 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.413 ' CB ' ' NE2' ' B' ' 14' ' ' HIS . 85.4 tttt -161.18 94.66 1.01 Allowed 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.186 176.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.4 HD11 HG11 ' A' ' 36' ' ' VAL . 20.8 mt -121.71 117.85 27.65 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.887 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 4.8 t -105.69 110.17 30.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -108.92 105.84 15.55 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.57 122.8 47.05 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.459 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.73 146.45 37.78 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -81.04 108.66 14.9 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.693 178.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.565 ' CG ' ' HB1' ' D' ' 21' ' ' ALA . 82.0 m-20 -105.28 51.93 0.75 Allowed 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 113.507 -1.679 . . . . 0.0 110.238 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.0 t -71.34 -133.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 114.933 -1.031 . . . . 0.0 108.455 -174.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.46 38.07 3.38 Favored Glycine 0 N--CA 1.468 0.823 0 CA-C-O 124.111 1.95 . . . . 0.0 109.973 -169.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.598 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 1.2 m -72.29 102.9 3.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 108.651 -3.775 . . . . 0.0 102.243 171.037 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' B' ' 28' ' ' LYS . 88.2 m-20 -108.21 -170.14 1.63 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -171.08 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.426 ' O ' ' O ' ' N' ' 40' ' ' VAL . 98.6 mttt 32.36 41.27 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 113.668 -1.606 . . . . 0.0 111.12 -172.234 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . -176.72 61.1 0.1 OUTLIER Glycine 0 CA--C 1.546 1.976 0 CA-C-N 114.809 -1.087 . . . . 0.0 111.715 172.416 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.28 95.33 5.55 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 118.713 1.256 . . . . 0.0 110.505 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.705 HD13 HG22 ' O' ' 39' ' ' VAL . 2.0 tt -164.41 153.48 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 C-N-CA 115.164 -2.615 . . . . 0.0 116.353 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.422 HD13 ' CD1' ' E' ' 19' ' ' PHE . 93.0 mt -112.73 112.34 40.01 Favored 'Isoleucine or valine' 0 C--N 1.35 0.601 0 CA-C-N 114.31 -1.314 . . . . 0.0 108.9 177.272 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.29 112.21 3.66 Favored Glycine 0 N--CA 1.464 0.554 0 N-CA-C 105.013 -3.235 . . . . 0.0 105.013 176.147 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 tt -148.05 146.3 28.81 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 117.619 -1.633 . . . . 0.0 114.474 -173.286 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 9.0 mtp -121.94 113.15 19.21 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.709 HG21 HD21 ' E' ' 17' ' ' LEU . 3.1 p -139.88 103.06 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.837 -177.26 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.06 -155.27 26.43 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 119.848 -1.168 . . . . 0.0 112.282 177.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 61.1 54.73 34.26 Favored Glycine 0 CA--C 1.544 1.862 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.574 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.456 ' O ' ' O ' ' C' ' 40' ' ' VAL . 2.6 m -156.2 -168.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.341 0.23 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.519 HG13 ' O ' ' I' ' 28' ' ' LYS . 88.3 t . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.991 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -83.25 137.08 34.15 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.887 0.375 . . . . 0.0 110.716 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -121.9 129.37 52.5 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.071 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -111.05 123.35 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.447 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.527 ' CD2' ' HB2' ' C' ' 13' ' ' HIS . 19.9 m80 -134.82 107.43 7.39 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.593 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.593 ' ND1' ' O ' ' E' ' 14' ' ' HIS . 59.9 t60 -132.57 157.86 43.66 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.723 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.558 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 43.2 tt0 -85.82 157.38 20.23 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -160.09 100.15 1.38 Allowed 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.237 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 29.6 mt -123.5 115.02 20.86 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 178.122 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.9 109.1 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 59.9 m-85 -107.8 104.02 13.42 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.612 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 47.4 t80 -113.47 125.74 54.56 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.565 ' HB1' ' CG ' ' C' ' 23' ' ' ASP . . . -135.94 135.06 39.3 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 122.712 1.244 . . . . 0.0 113.242 -178.251 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -84.4 113.5 21.22 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.022 -1.444 . . . . 0.0 108.963 179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.635 ' OD2' ' HB1' ' E' ' 21' ' ' ALA . 5.7 p-10 -146.44 48.57 1.18 Allowed 'General case' 0 CA--C 1.516 -0.365 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.457 ' H ' HG12 ' D' ' 24' ' ' VAL . 0.6 OUTLIER -72.58 160.79 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 177.486 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.38 -28.4 10.97 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' E' ' 26' ' ' SER . 7.7 t 74.6 119.6 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 114.268 -0.966 . . . . 0.0 110.264 -178.25 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -83.29 163.25 20.81 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 120.078 -0.649 . . . . 0.0 111.278 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -46.98 -37.0 8.39 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 178.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.74 77.55 0.07 OUTLIER Glycine 0 CA--C 1.538 1.501 0 C-N-CA 120.497 -0.859 . . . . 0.0 113.085 -175.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.71 137.64 37.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 118.698 1.249 . . . . 0.0 111.082 -178.126 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.532 HD13 ' HB ' ' P' ' 39' ' ' VAL . 31.5 mt -127.34 138.65 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 CA-C-N 114.793 -1.094 . . . . 0.0 113.36 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' F' ' 19' ' ' PHE . 67.2 mt -115.28 120.7 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 175.005 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.39 119.51 2.11 Favored Glycine 0 N--CA 1.467 0.731 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.705 ' N ' HD23 ' D' ' 34' ' ' LEU . 1.9 pt? -165.62 162.53 18.99 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 117.75 -1.58 . . . . 0.0 114.987 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 50.6 tpp -101.43 111.65 23.94 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 112.163 -2.289 . . . . 0.0 106.907 176.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.759 HG11 HD23 ' F' ' 17' ' ' LEU . 55.7 t -118.47 102.57 13.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 121.265 -0.174 . . . . 0.0 110.78 -178.8 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.03 -161.86 16.34 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.473 ' O ' ' OXT' ' E' ' 40' ' ' VAL . . . 148.69 -55.34 0.5 Allowed Glycine 0 CA--C 1.539 1.578 0 CA-C-O 119.316 -0.713 . . . . 0.0 112.453 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.65 HG21 ' CD1' ' J' ' 31' ' ' ILE . 33.8 m -136.61 152.8 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.555 0 CA-C-N 118.776 1.288 . . . . 0.0 110.867 178.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.593 ' H ' ' CD1' ' K' ' 31' ' ' ILE . 60.7 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.485 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -106.97 135.75 48.0 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.839 0.352 . . . . 0.0 110.353 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -76.53 106.37 8.14 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.713 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 m -139.78 156.43 25.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.162 0.506 . . . . 0.0 110.938 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.412 ' C ' ' CD2' ' E' ' 14' ' ' HIS . 21.7 m-70 -148.27 117.57 6.9 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.141 178.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.593 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 13.3 m-70 -141.28 162.41 35.54 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 110.923 179.047 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.421 ' OE1' ' OE1' ' F' ' 15' ' ' GLN . 78.7 mt-30 -85.32 157.27 20.6 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 176.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -159.53 104.3 1.61 Allowed 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.322 0.582 . . . . 0.0 109.461 178.178 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.709 HD21 HG21 ' C' ' 36' ' ' VAL . 2.3 mt -125.07 116.8 22.67 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.773 -179.51 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -107.48 101.85 13.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 74.1 m-85 -103.45 101.22 11.11 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 178.002 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.612 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 24.5 t80 -116.2 128.65 55.79 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.474 0.178 . . . . 0.0 111.156 -177.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.635 ' HB1' ' OD2' ' D' ' 23' ' ' ASP . . . -141.31 139.57 33.64 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.52 0.676 . . . . 0.0 112.755 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.567 ' HB2' ' H ' ' D' ' 23' ' ' ASP . 97.7 mt-10 -79.28 155.05 28.69 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.341 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' F' ' 23' ' ' ASP . 2.4 t70 -169.62 48.56 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.286 -1.366 . . . . 0.0 113.418 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 1.8 t -72.28 161.61 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 119.179 -1.008 . . . . 0.0 108.598 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.68 -28.65 10.38 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -176.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.526 ' O ' ' CB ' ' E' ' 27' ' ' ASN . 1.6 m 80.56 -114.71 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 113.644 -1.278 . . . . 0.0 112.232 -179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.526 ' CB ' ' O ' ' E' ' 26' ' ' SER . 4.2 t-20 89.24 179.9 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -48.33 -38.43 19.05 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' E' ' 30' ' ' ALA . . . 99.85 -68.22 0.55 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-N 114.297 -1.32 . . . . 0.0 114.781 176.456 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.963 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . 179.91 171.0 1.13 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 119.044 1.422 . . . . 0.0 112.688 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 98.6 mt -131.85 128.36 59.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 113.976 -1.465 . . . . 0.0 108.587 177.309 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.472 ' CG2' HD21 ' E' ' 34' ' ' LEU . 52.1 mt -123.93 124.91 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.133 0.492 . . . . 0.0 111.822 -177.439 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 110.92 2.34 Favored Glycine 0 N--CA 1.47 0.96 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.472 HD21 ' CG2' ' E' ' 32' ' ' ILE . 21.8 mt -118.17 114.31 22.86 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -177.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 78.4 mmm -105.8 116.17 31.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 177.095 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.67 HG12 ' N ' ' E' ' 37' ' ' GLY . 61.7 t -128.44 170.85 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.701 0.762 . . . . 0.0 112.365 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.67 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -168.26 94.28 0.11 Allowed Glycine 0 C--N 1.308 -1.021 0 N-CA-C 108.164 -1.975 . . . . 0.0 108.164 176.488 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.33 -73.15 0.42 Allowed Glycine 0 CA--C 1.54 1.626 0 CA-C-N 117.287 0.543 . . . . 0.0 112.927 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.773 HG13 HD11 ' K' ' 31' ' ' ILE . 76.2 t -123.77 94.32 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.617 HG11 ' HA3' ' F' ' 37' ' ' GLY . 4.1 p . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.551 -178.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -103.43 122.58 45.18 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.82 0.343 . . . . 0.0 110.263 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -128.42 130.52 47.75 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.633 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.516 HG13 ' NE2' ' E' ' 14' ' ' HIS . 8.0 p -141.32 138.2 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.403 0.621 . . . . 0.0 110.948 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.406 ' HA ' ' CE1' ' E' ' 14' ' ' HIS . 4.6 m80 -140.98 133.57 28.61 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.121 -178.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.583 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 45.7 m80 -148.54 164.74 33.32 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.02 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.448 ' NE2' ' H ' ' F' ' 16' ' ' LYS . 70.9 tp60 -89.8 151.46 21.78 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.69 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 16' ' ' LYS . . . . . 0.448 ' H ' ' NE2' ' F' ' 15' ' ' GLN . 99.1 mttt -152.89 100.08 2.48 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.559 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.759 HD23 HG11 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -121.6 118.98 30.57 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 177.209 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.69 106.07 19.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.572 ' CD1' HD13 ' D' ' 32' ' ' ILE . 55.7 m-85 -104.32 103.59 13.36 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -117.24 109.82 17.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.223 0.535 . . . . 0.0 110.513 -178.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.96 117.98 28.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 177.252 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -90.33 112.08 23.53 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 119.222 -0.991 . . . . 0.0 113.583 -176.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' E' ' 23' ' ' ASP . 1.1 m-20 -127.94 -59.93 1.17 Allowed 'General case' 0 C--N 1.351 0.648 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.935 176.595 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.49 HG23 ' O ' ' F' ' 26' ' ' SER . 0.0 OUTLIER -102.92 -178.79 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 175.378 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.6 -35.03 56.08 Favored Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.746 -1.741 . . . . 0.0 108.746 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.49 ' O ' HG23 ' F' ' 24' ' ' VAL . 4.4 p -95.03 121.72 36.94 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 112.496 -1.852 . . . . 0.0 113.151 -178.09 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -74.23 -151.08 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt 53.84 48.31 21.61 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.049 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.41 -53.11 0.57 Allowed Glycine 0 CA--C 1.542 1.768 0 CA-C-N 114.756 -1.111 . . . . 0.0 114.168 -177.634 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.963 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -84.14 -156.94 0.24 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.589 0.756 . . . . 0.0 112.033 -175.111 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mm -105.05 131.52 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.44 HG23 ' O ' ' F' ' 32' ' ' ILE . 19.6 tt -137.7 129.5 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.979 0.419 . . . . 0.0 111.627 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.66 123.11 5.13 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 mt -116.59 120.31 38.28 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -123.69 130.11 52.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.538 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 29.5 m -115.96 158.38 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.617 ' HA3' HG11 ' E' ' 40' ' ' VAL . . . -63.08 -103.03 0.01 OUTLIER Glycine 0 CA--C 1.524 0.616 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.961 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.42 -76.66 0.5 Allowed Glycine 0 CA--C 1.534 1.231 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.425 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.47 ' O ' ' CD1' ' L' ' 31' ' ' ILE . 58.6 t -126.91 131.8 70.63 Favored 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-N 117.338 0.569 . . . . 0.0 110.343 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.449 HG22 ' H ' ' F' ' 40' ' ' VAL . 10.9 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.861 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -111.63 132.89 54.26 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 11' ' ' GLU . . . . . 0.533 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 57.8 mp0 -120.85 125.21 46.92 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.278 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.85 149.43 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.294 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -133.84 112.42 11.3 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.691 0.282 . . . . 0.0 110.913 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.436 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 47.9 p-80 -152.92 168.73 24.81 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.292 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 69.1 tp60 -158.22 142.46 15.88 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.654 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -81.86 126.63 32.12 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.033 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.58 ' C ' HD23 ' G' ' 17' ' ' LEU . 6.5 tt -134.43 119.58 18.73 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.658 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.505 ' N ' HD23 ' G' ' 17' ' ' LEU . 12.6 m -132.82 135.81 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.355 -179.325 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -127.24 126.46 42.75 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.807 178.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' H' ' 20' ' ' PHE . 43.5 t80 -128.94 127.45 41.77 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.682 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.69 119.67 21.69 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 121.303 0.573 . . . . 0.0 110.977 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.632 ' O ' ' N ' ' G' ' 24' ' ' VAL . 79.9 tt0 -92.57 124.6 36.71 Favored 'General case' 0 C--N 1.342 0.27 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.596 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.528 ' H ' ' HB3' ' H' ' 22' ' ' GLU . 67.0 t0 47.76 -60.63 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.809 1.244 . . . . 0.0 113.086 -179.264 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' G' ' 22' ' ' GLU . 5.2 p -72.97 160.72 5.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-O 121.126 0.489 . . . . 0.0 110.973 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.24 -35.23 4.96 Favored Glycine 0 N--CA 1.469 0.852 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.535 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.2 m -80.74 118.81 22.61 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.225 0.512 . . . . 0.0 110.218 178.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -88.82 179.23 6.25 Favored 'General case' 0 C--N 1.333 -0.137 0 C-N-CA 119.648 -0.821 . . . . 0.0 111.143 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -54.61 -38.51 66.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.59 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.24 70.96 0.2 Allowed Glycine 0 CA--C 1.537 1.423 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.171 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.25 116.94 29.43 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 123.988 1.851 . . . . 0.0 112.69 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.485 ' CD1' ' O ' ' A' ' 38' ' ' GLY . 14.8 pt -146.95 149.21 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 111.993 -2.367 . . . . 0.0 109.904 -179.28 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.418 HD13 HG21 ' G' ' 32' ' ' ILE . 55.0 mt -105.05 112.0 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.587 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.12 96.05 0.74 Allowed Glycine 0 N--CA 1.467 0.735 0 N-CA-C 107.264 -2.334 . . . . 0.0 107.264 178.362 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 78.3 mt -144.07 156.27 44.3 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 122.972 1.367 . . . . 0.0 113.848 -177.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' CG ' ' H' ' 35' ' ' MET . 44.1 tpp -103.57 111.16 23.5 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 112.166 -2.288 . . . . 0.0 106.315 176.318 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.444 HG12 HE21 ' J' ' 15' ' ' GLN . 3.5 t -131.54 111.78 19.7 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.432 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 127.99 -132.07 7.26 Favored Glycine 0 C--N 1.315 -0.623 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.418 ' O ' HG12 ' H' ' 39' ' ' VAL . . . 87.49 -63.67 3.87 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.093 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 m -102.57 169.15 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-O 120.95 0.405 . . . . 0.0 110.844 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.507 ' OXT' ' NE2' ' J' ' 13' ' ' HIS . 9.7 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.264 179.184 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -107.86 133.27 52.46 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.814 0.34 . . . . 0.0 110.179 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.62 128.6 22.01 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.225 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -122.99 131.34 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.805 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -132.4 105.77 7.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.811 0.339 . . . . 0.0 111.6 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.673 ' CD2' ' H ' ' H' ' 15' ' ' GLN . 1.1 t-80 -155.6 169.13 25.01 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.702 178.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.673 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 14.1 pt20 -157.45 142.19 16.64 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.985 0.421 . . . . 0.0 110.449 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -84.02 113.38 20.97 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.356 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.9 mt -119.66 113.41 20.63 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.132 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 79.7 t -124.38 131.72 72.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 CA-C-O 120.898 0.38 . . . . 0.0 111.636 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -126.7 116.57 21.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.309 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' G' ' 20' ' ' PHE . 30.0 t80 -117.23 123.83 47.59 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.18 138.56 25.29 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-O 122.454 1.121 . . . . 0.0 113.633 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.528 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 80.8 tt0 -90.14 149.5 22.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.152 -1.386 . . . . 0.0 109.402 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.411 ' N ' ' HB2' ' I' ' 22' ' ' GLU . 66.4 t0 -174.32 48.43 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.682 -0.407 . . . . 0.0 112.042 -178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.426 HG12 ' N ' ' H' ' 25' ' ' GLY . 4.1 t -72.67 161.43 4.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.213 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.505 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 108.95 -30.24 8.89 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.505 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 6.2 p 93.06 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.085 0.554 . . . . 0.0 111.015 178.52 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 1.07 HD21 ' HB2' ' H' ' 30' ' ' ALA . 17.6 p30 -74.02 175.05 7.77 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 119.889 -0.725 . . . . 0.0 110.448 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.618 ' HZ3' ' CE1' ' C' ' 13' ' ' HIS . 94.0 mttt -51.18 -36.93 43.63 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' H' ' 27' ' ' ASN . . . 179.54 77.22 0.06 OUTLIER Glycine 0 CA--C 1.529 0.961 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.729 -176.262 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 1.07 ' HB2' HD21 ' H' ' 27' ' ' ASN . . . -52.06 131.89 32.28 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 118.295 1.047 . . . . 0.0 113.567 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.578 HD12 HG12 ' B' ' 39' ' ' VAL . 51.6 mt -141.38 133.42 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.454 HD13 HG21 ' H' ' 32' ' ' ILE . 31.3 mt -105.55 108.97 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 174.159 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.44 104.42 1.8 Allowed Glycine 0 N--CA 1.462 0.427 0 N-CA-C 106.948 -2.461 . . . . 0.0 106.948 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.415 HD21 HG22 ' G' ' 32' ' ' ILE . 81.0 mt -138.23 136.77 36.88 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 119.013 -1.075 . . . . 0.0 113.774 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.472 ' CG ' ' SD ' ' G' ' 35' ' ' MET . 32.9 tpp -99.84 107.1 19.04 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 173.533 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' I' ' 36' ' ' VAL . 24.8 t -130.24 142.3 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -178.47 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 124.57 -101.95 0.68 Allowed Glycine 0 C--N 1.312 -0.759 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.19 -79.28 0.02 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.529 HG21 ' CA ' ' N' ' 29' ' ' GLY . 5.5 p -144.04 150.2 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.077 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.545 ' OXT' ' CG2' ' I' ' 40' ' ' VAL . 5.1 p . . . . . 0 C--O 1.217 -0.655 0 CA-C-O 118.14 -0.933 . . . . 0.0 111.117 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -108.44 136.66 47.69 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.842 0.353 . . . . 0.0 110.254 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.491 ' N ' ' CD ' ' I' ' 11' ' ' GLU . 1.8 pm0 -117.91 135.58 54.03 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.525 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.507 HG22 ' H ' ' J' ' 12' ' ' VAL . 70.2 t -124.97 126.51 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.202 -179.141 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -134.85 146.14 48.97 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.805 0.336 . . . . 0.0 111.33 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.403 ' CE1' HG23 ' J' ' 12' ' ' VAL . 96.6 m-70 -147.82 172.69 13.74 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 121.132 0.492 . . . . 0.0 110.502 177.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 40.7 tt0 -137.86 140.89 40.68 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 176.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -130.15 110.06 11.3 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.105 -0.638 . . . . 0.0 112.413 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.43 ' CD2' HG21 ' G' ' 36' ' ' VAL . 5.6 mp -121.81 113.12 19.22 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 175.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.502 HG13 ' CG2' ' J' ' 18' ' ' VAL . 8.0 t -105.56 109.43 27.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.043 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 80.3 m-85 -104.3 100.71 10.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.115 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -115.2 127.42 55.51 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -168.58 177.46 5.2 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 117.624 -1.63 . . . . 0.0 114.891 -177.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.411 ' HB2' ' N ' ' H' ' 23' ' ' ASP . 67.8 mm-40 -77.92 156.96 29.98 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 175.327 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.722 ' O ' ' O ' ' I' ' 24' ' ' VAL . 67.9 t0 -169.84 60.56 0.04 OUTLIER 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 119.291 -0.964 . . . . 0.0 112.483 -175.214 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.722 ' O ' ' O ' ' I' ' 23' ' ' ASP . 3.4 t -44.53 -111.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.196 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.448 ' O ' ' N ' ' I' ' 27' ' ' ASN . . . 159.5 -45.37 0.44 Allowed Glycine 0 CA--C 1.502 -0.751 0 C-N-CA 116.091 -2.957 . . . . 0.0 116.561 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 46.9 t -66.69 103.85 1.18 Allowed 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 113.773 -3.171 . . . . 0.0 106.11 -179.198 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.53 ' O ' ' N ' ' I' ' 29' ' ' GLY . 2.4 m-20 -137.02 170.13 16.61 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 113.963 -1.471 . . . . 0.0 109.132 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.519 ' O ' HG13 ' C' ' 40' ' ' VAL . 52.7 mttp -25.84 -42.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.535 0 O-C-N 123.882 0.739 . . . . 0.0 111.217 173.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 160.68 67.6 0.02 OUTLIER Glycine 0 CA--C 1.554 2.494 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.677 -178.51 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.418 ' HB2' HD21 ' I' ' 27' ' ' ASN . . . -52.14 138.23 26.13 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 118.477 1.138 . . . . 0.0 112.166 -178.697 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.68 HD12 HD11 ' J' ' 31' ' ' ILE . 3.0 tt -144.59 145.93 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.23 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.498 HG23 HD13 ' I' ' 34' ' ' LEU . 3.9 mt -105.37 108.58 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 175.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.727 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -107.32 101.45 1.68 Allowed Glycine 0 N--CA 1.47 0.903 0 N-CA-C 106.41 -2.676 . . . . 0.0 106.41 178.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.727 HD12 ' O ' ' I' ' 33' ' ' GLY . 3.1 mp -130.71 130.21 43.54 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -174.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 83.5 mmm -101.34 112.44 24.96 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' H' ' 36' ' ' VAL . 47.0 t -127.56 142.14 44.43 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.743 -174.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 133.16 -101.6 0.44 Allowed Glycine 0 C--N 1.318 -0.451 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 178.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.526 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 83.83 -81.02 1.77 Allowed Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.517 HG22 HD12 ' O' ' 31' ' ' ILE . 56.1 t -143.2 143.91 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.545 ' CG2' ' OXT' ' H' ' 40' ' ' VAL . 21.5 m . . . . . 0 N--CA 1.473 0.688 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.975 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.88 132.81 53.06 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.884 0.373 . . . . 0.0 110.622 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -75.51 123.43 25.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.507 ' H ' HG22 ' I' ' 12' ' ' VAL . 3.2 m -134.9 155.97 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.285 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.541 ' CG ' ' O ' ' H' ' 40' ' ' VAL . 2.1 t-80 -158.52 103.66 1.77 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.02 178.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.498 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 4.3 m-70 -137.23 159.09 42.93 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.786 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.444 HE21 HG12 ' G' ' 36' ' ' VAL . 5.8 tt0 -90.26 159.26 16.78 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 105.67 -1.974 . . . . 0.0 105.67 175.091 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.664 ' C ' HD12 ' J' ' 17' ' ' LEU . 78.9 tttt -140.66 109.73 6.13 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.845 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.664 HD12 ' C ' ' J' ' 16' ' ' LYS . 4.5 mp -130.04 120.02 24.06 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.293 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 18' ' ' VAL . . . . . 0.502 ' CG2' HG13 ' I' ' 18' ' ' VAL . 20.3 m -116.28 117.93 57.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 177.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.407 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 32.2 m-85 -107.92 103.54 12.81 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -118.46 134.63 54.92 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.557 0.218 . . . . 0.0 110.989 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.31 146.24 23.53 Favored 'General case' 0 C--O 1.241 0.606 0 C-N-CA 117.919 -1.512 . . . . 0.0 114.842 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 72.3 mm-40 -86.8 147.47 25.81 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 113.578 -1.646 . . . . 0.0 108.915 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.492 ' OD2' ' O ' ' I' ' 23' ' ' ASP . 0.0 OUTLIER -160.18 51.88 0.32 Allowed 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -177.072 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.5 t -75.43 142.41 14.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 116.783 -1.967 . . . . 0.0 108.378 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.26 -37.22 3.84 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.49 119.95 23.84 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 113.663 -1.268 . . . . 0.0 112.697 -178.493 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.623 ' O ' ' N ' ' J' ' 29' ' ' GLY . 22.1 m-20 -88.38 158.01 18.53 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.039 -0.665 . . . . 0.0 109.437 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.782 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 75.8 tttt -47.91 48.35 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.216 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.623 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -101.47 52.55 0.88 Allowed Glycine 0 N--CA 1.481 1.664 0 CA-C-N 119.234 0.925 . . . . 0.0 113.905 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.555 ' O ' ' HB1' ' K' ' 30' ' ' ALA . . . -130.01 179.44 5.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.4 0.619 . . . . 0.0 110.142 179.179 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.68 HD11 HD12 ' I' ' 31' ' ' ILE . 42.2 pt -138.96 145.04 28.27 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.488 HG22 ' O ' ' J' ' 32' ' ' ILE . 0.6 OUTLIER -108.67 110.44 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.053 177.535 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.77 95.88 0.91 Allowed Glycine 0 C--O 1.24 0.488 0 N-CA-C 104.673 -3.371 . . . . 0.0 104.673 176.044 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.412 HD21 ' CD2' ' L' ' 17' ' ' LEU . 6.3 tt -133.11 132.27 41.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 123.062 1.41 . . . . 0.0 113.647 -175.131 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 11.1 mtp -107.89 109.39 20.89 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 112.208 -2.269 . . . . 0.0 107.393 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.689 ' O ' HG13 ' K' ' 36' ' ' VAL . 12.0 p -104.44 111.51 34.32 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.469 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 178.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.621 ' O ' ' NE2' ' L' ' 15' ' ' GLN . . . -58.62 131.91 52.29 Favored Glycine 0 N--CA 1.462 0.388 0 CA-C-N 115.146 -0.933 . . . . 0.0 114.403 -175.613 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . -89.42 63.62 3.32 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.455 HG23 ' O ' ' J' ' 39' ' ' VAL . 28.7 m -112.86 125.6 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 CA-C-O 121.148 0.499 . . . . 0.0 110.695 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.474 ' HB ' HG12 ' I' ' 40' ' ' VAL . 3.3 t . . . . . 0 C--O 1.219 -0.535 0 CA-C-N 114.951 -1.022 . . . . 0.0 112.204 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' K' K ' 10' ' ' TYR . . . . . 0.477 ' CE1' ' O ' ' L' ' 9' ' ' GLY . 94.4 m-85 -82.71 139.77 33.46 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.808 0.337 . . . . 0.0 110.51 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.459 ' HB3' ' HE2' ' K' ' 13' ' ' HIS . 95.7 mt-10 -92.24 121.63 33.94 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.276 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.428 HG12 ' H ' ' L' ' 12' ' ' VAL . 34.0 m -130.35 132.03 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.969 0.414 . . . . 0.0 111.356 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.459 ' HE2' ' HB3' ' K' ' 11' ' ' GLU . 2.6 m-70 -141.79 137.5 31.59 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.311 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.647 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 28.1 m80 -147.57 162.18 39.63 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -90.02 158.27 17.42 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 176.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.27 97.74 3.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 119.608 -0.837 . . . . 0.0 111.228 177.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 19.3 mt -121.49 118.62 29.77 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 176.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.85 111.81 37.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.584 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -105.09 100.92 10.5 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 49.6 t80 -121.78 122.33 39.26 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.732 0.301 . . . . 0.0 111.675 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.581 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -154.13 159.0 41.26 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 118.504 -1.278 . . . . 0.0 114.25 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.469 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 96.6 mt-10 -85.71 161.09 19.36 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 177.174 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 22.2 p30 177.65 48.8 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 118.198 0.454 . . . . 0.0 112.167 -178.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.442 ' H ' HG23 ' K' ' 24' ' ' VAL . 0.2 OUTLIER -72.43 160.68 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 118.4 -1.32 . . . . 0.0 112.97 -176.136 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -28.7 10.29 Favored Glycine 0 CA--C 1.535 1.316 0 CA-C-N 113.634 -1.621 . . . . 0.0 112.419 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p 73.76 119.34 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.449 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 29.0 t-20 -83.3 163.49 20.65 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 119.494 -0.882 . . . . 0.0 112.477 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.449 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 99.4 mttt -47.35 -37.22 10.74 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 114.438 -1.255 . . . . 0.0 113.974 176.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.98 77.0 0.06 OUTLIER Glycine 0 CA--C 1.545 1.955 0 C-N-CA 120.059 -1.067 . . . . 0.0 114.42 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.782 ' HB2' ' O ' ' J' ' 28' ' ' LYS . . . -80.02 167.95 19.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 119.379 1.59 . . . . 0.0 110.351 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.773 HD11 HG13 ' E' ' 39' ' ' VAL . 43.3 mt -133.24 127.98 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -176.688 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.403 HD13 HG21 ' K' ' 32' ' ' ILE . 14.7 pt -125.17 121.69 61.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 121.486 0.66 . . . . 0.0 109.998 176.32 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.608 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -126.26 115.73 2.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.746 HD12 ' N ' ' K' ' 34' ' ' LEU . 2.9 mp -122.0 119.89 32.77 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.406 ' SD ' ' CE ' ' L' ' 35' ' ' MET . 27.7 ttp -137.58 147.88 45.43 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 118.441 -1.303 . . . . 0.0 112.913 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.689 HG13 ' O ' ' J' ' 36' ' ' VAL . 1.4 t -121.38 171.82 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 113.914 -1.493 . . . . 0.0 108.847 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.3 94.18 0.11 Allowed Glycine 0 N--CA 1.437 -1.279 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.999 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.525 ' HA2' HD11 ' Q' ' 31' ' ' ILE . . . 152.11 -80.97 0.19 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.432 176.302 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.61 HG23 HD13 ' Q' ' 31' ' ' ILE . 90.2 t -154.75 142.97 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.542 ' OXT' HG13 ' K' ' 40' ' ' VAL . 4.8 p . . . . . 0 C--N 1.325 -0.458 0 CA-C-O 117.844 -1.074 . . . . 0.0 110.769 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 9' ' ' GLY . . . . . 0.477 ' O ' ' CE1' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -122.44 152.49 40.19 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.731 0.301 . . . . 0.0 110.398 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -69.68 139.02 53.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.519 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.428 ' H ' HG12 ' K' ' 12' ' ' VAL . 6.2 m -122.12 132.88 70.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.271 0.557 . . . . 0.0 111.137 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.447 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.3 p80 -148.18 107.31 3.88 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.741 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.647 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.9 m80 -147.91 164.86 32.43 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 109.909 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.621 ' NE2' ' O ' ' J' ' 37' ' ' GLY . 32.7 mt-30 -89.76 158.85 17.34 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.915 0.388 . . . . 0.0 111.175 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 16' ' ' LYS . . . . . 0.686 ' C ' HD12 ' L' ' 17' ' ' LEU . 68.5 mttm -140.07 102.56 4.42 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.686 HD12 ' C ' ' L' ' 16' ' ' LYS . 9.7 mp -120.37 118.14 29.59 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -105.04 116.43 48.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.517 ' CZ ' HD23 ' K' ' 34' ' ' LEU . 8.6 m-85 -105.16 103.7 13.29 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' O ' ' L' ' 21' ' ' ALA . 75.7 t80 -153.21 158.87 42.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 123.177 1.465 . . . . 0.0 113.807 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.581 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -145.81 159.1 43.68 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 113.41 -1.723 . . . . 0.0 107.578 178.574 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.404 ' C ' ' O ' ' L' ' 21' ' ' ALA . 81.3 tt0 -39.95 152.7 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.27 -0.572 . . . . 0.0 111.677 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 p30 -65.45 47.33 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.807 -177.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.546 HG23 ' H ' ' L' ' 26' ' ' SER . 24.1 m -61.04 -179.12 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.483 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.34 29.62 12.11 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.546 ' H ' HG23 ' L' ' 24' ' ' VAL . 34.5 t -80.14 110.81 15.9 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.607 ' O ' ' N ' ' L' ' 29' ' ' GLY . 80.6 m-20 -95.06 -166.31 1.44 Allowed 'General case' 0 C--O 1.222 -0.348 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.632 -179.433 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.57 47.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.01 56.59 0.93 Allowed Glycine 0 CA--C 1.538 1.508 0 CA-C-N 119.756 1.162 . . . . 0.0 111.431 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.658 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -170.27 177.11 4.27 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.555 HD12 HG12 ' E' ' 39' ' ' VAL . 39.2 mt -106.97 125.59 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.478 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.765 HD12 ' N ' ' L' ' 32' ' ' ILE . 3.1 mp -110.45 115.89 50.94 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.229 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.1 107.26 1.15 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.622 HD23 ' C ' ' L' ' 34' ' ' LEU . 6.3 tt -122.7 120.39 33.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.465 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.582 ' N ' HD23 ' L' ' 34' ' ' LEU . 28.6 mtm -136.17 144.62 45.09 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.462 0.648 . . . . 0.0 112.546 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.469 ' O ' ' O ' ' L' ' 37' ' ' GLY . 54.0 t -116.18 131.52 68.46 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.686 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -32.92 -111.3 0.0 OUTLIER Glycine 0 CA--C 1.532 1.113 0 CA-C-N 115.058 -0.974 . . . . 0.0 114.315 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.55 -71.64 0.53 Allowed Glycine 0 CA--C 1.536 1.35 0 CA-C-N 115.289 -0.456 . . . . 0.0 112.886 -178.501 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.404 ' CG2' HD11 ' R' ' 31' ' ' ILE . 53.3 t -106.88 131.85 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-O 121.46 0.647 . . . . 0.0 111.27 -179.061 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.594 179.765 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -84.32 138.83 32.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.996 0.427 . . . . 0.0 110.838 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -75.49 159.81 30.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 52.0 t -116.48 129.58 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.298 0.57 . . . . 0.0 110.116 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -81.4 163.09 23.06 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.372 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 89.5 m-70 -105.09 160.97 14.64 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 121.265 0.555 . . . . 0.0 111.768 -179.151 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 15' ' ' GLN . . . . . 0.427 ' H ' ' HG2' ' N' ' 15' ' ' GLN . 87.9 mt-30 -89.98 160.25 16.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.62 178.145 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -139.38 110.9 7.08 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.1 mt -135.93 117.44 14.81 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.551 0.691 . . . . 0.0 111.081 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.17 132.95 70.55 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.813 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -128.04 134.21 49.18 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.771 0.32 . . . . 0.0 110.552 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.496 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 53.2 p90 -127.43 126.02 41.63 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.525 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 129.25 47.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.225 0.536 . . . . 0.0 111.962 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -155.34 126.7 7.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.007 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.69 46.45 24.66 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.332 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.446 HG22 ' H ' ' M' ' 24' ' ' VAL . 11.6 m -76.11 179.55 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.0 28.11 6.86 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.813 -179.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' M' ' 27' ' ' ASN . 5.5 t -170.46 -134.11 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.912 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' M' ' 26' ' ' SER . 22.2 t-20 -30.81 143.58 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.847 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -132.9 -26.08 1.78 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.748 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.99 -108.87 0.26 Allowed Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.143 -1.027 . . . . 0.0 111.052 179.645 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.45 96.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.45 -0.5 . . . . 0.0 112.1 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -115.24 105.28 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 32' ' ' ILE . . . . . 0.747 HG22 HD11 ' N' ' 34' ' ' LEU . 55.0 mt -110.73 112.6 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 120.411 -0.516 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.75 104.45 1.22 Allowed Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 104.977 -3.249 . . . . 0.0 104.977 176.874 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 30.0 tp -155.2 151.36 28.06 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 117.489 -1.685 . . . . 0.0 114.409 -174.297 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 93.9 mmm -100.27 111.51 23.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 112.659 -2.064 . . . . 0.0 106.878 177.18 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' N' ' 36' ' ' VAL . 41.9 t -119.66 131.37 72.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.582 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.34 -111.28 4.13 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' N' ' 37' ' ' GLY . . . 81.13 -74.03 2.49 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -178.105 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.18 161.37 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.402 HG22 ' CG1' ' N' ' 39' ' ' VAL . 10.7 m . . . . . 0 N--CA 1.47 0.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.538 177.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.159 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -105.24 131.51 52.62 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -114.8 115.29 26.77 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.204 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -129.57 123.02 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.174 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -143.58 130.71 20.71 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.196 0.522 . . . . 0.0 110.473 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.637 ' ND1' ' NE2' ' O' ' 14' ' ' HIS . 19.5 t60 -159.75 170.08 22.27 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CD2' ' N' ' 14' ' ' HIS . 75.2 mt-30 -155.14 140.71 17.91 Favored 'General case' 0 CA--C 1.517 -0.32 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.767 177.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 48.0 tttp -93.98 111.04 22.7 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.867 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 13.6 mt -119.91 114.43 22.06 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 177.021 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 18' ' ' VAL . . . . . 0.478 HG21 ' CE2' ' N' ' 20' ' ' PHE . 6.3 p -138.6 141.86 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 119.692 -0.803 . . . . 0.0 112.135 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -131.36 122.55 26.55 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.07 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.478 ' CE2' HG21 ' N' ' 18' ' ' VAL . 59.8 m-85 -112.88 123.48 50.4 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.633 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.05 121.06 40.25 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' O' ' 22' ' ' GLU . 82.6 tt0 -136.32 156.38 48.72 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 121.208 0.527 . . . . 0.0 112.31 -177.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 20.0 t0 76.63 54.74 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.364 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.631 HG21 HG13 ' O' ' 24' ' ' VAL . 90.8 t -68.05 135.25 28.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.511 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.57 -34.26 2.3 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 120.995 -0.621 . . . . 0.0 111.836 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' N' ' 27' ' ' ASN . 29.5 t -162.41 120.3 2.12 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-N 116.847 0.323 . . . . 0.0 110.991 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.516 ' O ' ' O ' ' N' ' 26' ' ' SER . 17.5 p30 -22.26 152.74 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -163.19 24.58 0.09 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.434 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 29' ' ' GLY . . . . . 0.529 ' CA ' HG21 ' H' ' 39' ' ' VAL . . . 89.52 105.29 1.13 Allowed Glycine 0 N--CA 1.466 0.683 0 C-N-CA 119.06 -1.543 . . . . 0.0 113.435 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 30' ' ' ALA . . . . . 0.531 ' HB3' ' HB2' ' O' ' 30' ' ' ALA . . . -111.96 95.63 5.59 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 122.072 0.939 . . . . 0.0 108.777 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.45 HD11 HG23 ' I' ' 39' ' ' VAL . 79.4 mt -137.44 136.13 46.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 114.826 -1.079 . . . . 0.0 112.225 -177.182 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.704 HG23 HD13 ' N' ' 34' ' ' LEU . 77.1 mt -106.76 105.64 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 175.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.667 ' O ' HD12 ' N' ' 34' ' ' LEU . . . -110.38 91.98 0.66 Allowed Glycine 0 N--CA 1.467 0.742 0 N-CA-C 106.197 -2.761 . . . . 0.0 106.197 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.747 HD11 HG22 ' M' ' 32' ' ' ILE . 8.8 mp -132.74 152.55 51.73 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 123.35 1.548 . . . . 0.0 114.452 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -115.65 107.26 14.87 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 175.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' O' ' 37' ' ' GLY . 47.6 t -117.63 123.16 71.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.05 -177.302 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' M' ' 38' ' ' GLY . . . 134.75 -113.86 1.2 Allowed Glycine 0 C--N 1.317 -0.515 0 N-CA-C 110.524 -1.03 . . . . 0.0 110.524 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.805 ' O ' HG21 ' O' ' 39' ' ' VAL . . . 97.83 -71.64 0.66 Allowed Glycine 0 CA--C 1.533 1.188 0 N-CA-C 110.618 -0.993 . . . . 0.0 110.618 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.402 ' CG1' HG22 ' M' ' 40' ' ' VAL . 83.6 t -126.49 138.58 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 177.072 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' C' ' 28' ' ' LYS . 66.2 t . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.909 -1.043 . . . . 0.0 110.056 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -107.19 134.31 50.49 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.83 0.348 . . . . 0.0 110.466 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.98 133.61 39.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.827 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.56 140.28 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.085 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.477 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 42.0 t-80 -147.5 95.53 2.54 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.392 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.637 ' NE2' ' ND1' ' N' ' 14' ' ' HIS . 0.3 OUTLIER -161.05 170.9 19.58 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 178.798 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 6.6 tt0 -97.33 143.47 28.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.699 177.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -124.64 118.98 27.73 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.492 ' N ' HD12 ' O' ' 17' ' ' LEU . 4.7 mp -122.76 128.93 51.14 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.516 0.674 . . . . 0.0 111.337 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 98.2 t -119.07 111.99 35.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.023 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' M' ' 32' ' ' ILE . 91.4 m-85 -107.7 108.0 19.04 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -122.87 126.67 47.77 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.83 117.06 28.26 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 22' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' O' ' 24' ' ' VAL . 83.5 tt0 -83.43 153.18 24.63 Favored 'General case' 0 N--CA 1.461 0.083 0 N-CA-C 113.438 0.903 . . . . 0.0 113.438 -176.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' O' ' 24' ' ' VAL . 65.6 t0 8.66 51.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 113.034 -1.894 . . . . 0.0 114.654 -179.155 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.709 HG12 ' H ' ' O' ' 25' ' ' GLY . 11.6 t -55.89 -132.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 174.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.709 ' H ' HG12 ' O' ' 24' ' ' VAL . . . 144.47 -29.77 1.88 Allowed Glycine 0 C--O 1.226 -0.365 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.337 175.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.461 ' O ' ' CE ' ' P' ' 28' ' ' LYS . 5.8 t -89.92 -132.89 0.1 Allowed 'General case' 0 CA--C 1.55 0.974 0 CA-C-O 122.986 1.374 . . . . 0.0 113.292 179.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.466 ' H ' ' HB3' ' N' ' 27' ' ' ASN . 12.2 m120 79.28 138.9 0.07 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 127.669 2.388 . . . . 0.0 111.22 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -48.83 -48.45 41.62 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 117.2 2.296 . . . . 0.0 117.2 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.67 62.48 0.06 OUTLIER Glycine 0 CA--C 1.545 1.921 0 CA-C-O 118.084 -1.398 . . . . 0.0 111.498 -171.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 30' ' ' ALA . . . . . 0.531 ' HB2' ' HB3' ' N' ' 30' ' ' ALA . . . -52.71 143.92 15.22 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 120.681 2.241 . . . . 0.0 116.714 -170.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.526 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 70.8 mt -138.79 153.89 25.87 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 CA-C-N 110.942 -2.845 . . . . 0.0 113.871 -175.01 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.556 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 75.5 mt -117.1 110.53 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 174.699 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.44 106.96 2.41 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 104.732 -3.347 . . . . 0.0 104.732 176.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.669 HD12 ' O ' ' N' ' 34' ' ' LEU . 26.7 tp -148.37 139.21 23.01 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 122.747 1.26 . . . . 0.0 113.696 -174.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.458 ' H ' HD12 ' O' ' 34' ' ' LEU . 24.5 ttm -114.33 110.98 20.76 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 113.648 -1.615 . . . . 0.0 107.428 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.458 ' O ' ' HA3' ' P' ' 37' ' ' GLY . 1.7 t -89.91 103.74 14.47 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.784 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 37' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . -20.06 144.5 0.01 OUTLIER Glycine 0 N--CA 1.481 1.69 0 C-N-CA 124.136 0.874 . . . . 0.0 115.077 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.515 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . -100.78 59.12 0.68 Allowed Glycine 0 CA--C 1.541 1.673 0 CA-C-N 115.022 -0.589 . . . . 0.0 113.6 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.805 HG21 ' O ' ' N' ' 38' ' ' GLY . 21.5 t -135.23 161.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-N 117.423 0.611 . . . . 0.0 110.607 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.499 ' N ' HG12 ' O' ' 39' ' ' VAL . 78.0 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.306 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.031 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -105.78 135.26 47.53 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.82 0.343 . . . . 0.0 110.309 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 11' ' ' GLU . . . . . 0.521 ' N ' ' OE1' ' P' ' 11' ' ' GLU . 57.8 mp0 -111.96 125.34 53.95 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.127 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.419 HG22 ' O ' ' Q' ' 11' ' ' GLU . 40.3 t -120.95 127.54 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 0.9 OUTLIER -146.05 105.35 3.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.381 -179.307 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.535 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 4.9 p80 -134.1 160.59 37.31 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.449 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.404 ' HB2' HE21 ' P' ' 15' ' ' GLN . 0.1 OUTLIER -89.99 159.22 17.0 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.133 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -140.07 103.27 4.58 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.412 HD22 HG21 ' N' ' 36' ' ' VAL . 5.0 mp -128.88 125.68 38.14 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 121.399 0.619 . . . . 0.0 110.657 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 79.6 t -118.38 117.38 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.679 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' HD13 ' N' ' 32' ' ' ILE . 29.4 m-85 -114.01 103.84 11.55 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 27.6 t80 -117.64 126.93 53.4 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.665 0.269 . . . . 0.0 111.059 -178.053 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.1 115.91 15.66 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 121.062 0.458 . . . . 0.0 111.497 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.545 ' O ' ' N ' ' O' ' 24' ' ' VAL . 80.4 tt0 -92.71 112.81 24.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.612 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.563 ' O ' ' NZ ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -139.19 46.76 1.92 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.681 -175.909 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.78 HG22 ' H ' ' P' ' 25' ' ' GLY . 7.7 p -73.15 179.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.453 0.644 . . . . 0.0 111.554 -178.133 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.78 ' H ' HG22 ' P' ' 24' ' ' VAL . . . 99.66 -34.66 5.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 118.647 -1.085 . . . . 0.0 114.468 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.466 ' O ' ' C ' ' P' ' 27' ' ' ASN . 96.2 p -162.24 120.43 2.2 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.381 2.09 . . . . 0.0 112.791 176.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.466 ' C ' ' O ' ' P' ' 26' ' ' SER . 65.8 t30 -23.56 141.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 123.611 0.569 . . . . 0.0 111.371 177.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' P' ' 23' ' ' ASP . 64.7 mttp -122.24 -32.93 3.58 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 177.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.33 79.85 0.91 Allowed Glycine 0 CA--C 1.536 1.381 0 N-CA-C 108.343 -1.903 . . . . 0.0 108.343 -176.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.7 144.04 30.9 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-N 118.172 0.986 . . . . 0.0 111.727 -175.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.458 HG23 HG23 ' Q' ' 31' ' ' ILE . 5.8 mt -125.07 138.64 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 113.815 -1.538 . . . . 0.0 113.563 -177.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.524 HD13 ' CD1' ' R' ' 19' ' ' PHE . 96.4 mt -118.76 112.35 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 176.566 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.98 100.22 1.45 Allowed Glycine 0 CA--C 1.509 -0.302 0 N-CA-C 104.557 -3.417 . . . . 0.0 104.557 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.523 ' CD2' HG22 ' P' ' 36' ' ' VAL . 7.7 tt -137.07 138.22 40.16 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-O 123.014 1.387 . . . . 0.0 114.533 -174.588 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 5.5 ttm -104.66 111.44 24.14 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.002 -1.908 . . . . 0.0 106.909 176.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.523 HG22 ' CD2' ' P' ' 34' ' ' LEU . 3.4 t -85.24 101.65 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 C-N-CA 118.585 -1.246 . . . . 0.0 108.269 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 37' ' ' GLY . . . . . 0.561 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . . . -88.89 153.91 24.18 Favored Glycine 0 C--N 1.316 -0.579 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.467 ' N ' ' HA2' ' O' ' 38' ' ' GLY . . . 136.68 58.86 0.06 OUTLIER Glycine 0 N--CA 1.466 0.639 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.662 ' CG2' ' H ' ' Q' ' 38' ' ' GLY . 49.7 t -79.51 133.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.463 HG23 ' NE2' ' R' ' 13' ' ' HIS . 9.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.956 -1.021 . . . . 0.0 111.748 -178.788 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.1 135.37 46.58 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.838 0.351 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.419 ' O ' HG22 ' P' ' 12' ' ' VAL . 96.8 mt-10 -103.02 122.55 44.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.209 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.588 HG12 ' N ' ' Q' ' 13' ' ' HIS . 46.8 t -142.37 168.16 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.689 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.588 ' N ' HG12 ' Q' ' 12' ' ' VAL . 8.3 p80 -64.1 127.47 31.57 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -177.678 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.505 ' O ' ' CB ' ' P' ' 14' ' ' HIS . 7.0 p80 -157.46 168.46 27.26 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.157 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.561 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 79.1 mt-30 -89.97 151.39 21.72 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.921 -0.487 . . . . 0.0 110.313 178.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -148.76 106.48 3.68 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.42 ' N ' HD12 ' Q' ' 17' ' ' LEU . 4.5 mp -135.68 124.46 23.92 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.264 0.554 . . . . 0.0 111.017 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -108.1 116.29 51.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 178.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.556 ' CD1' HD13 ' O' ' 32' ' ' ILE . 60.3 m-85 -112.42 109.23 18.72 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.226 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 41.4 t80 -125.45 128.17 47.65 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.55 134.3 37.34 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.129 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -114.74 124.29 51.4 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' Q' ' 23' ' ' ASP . 12.6 p-10 -147.28 59.73 1.16 Allowed 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.382 0.611 . . . . 0.0 111.873 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.961 HG12 ' H ' ' Q' ' 25' ' ' GLY . 4.8 t 72.07 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.018 176.692 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.961 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -107.91 29.3 10.46 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.312 177.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 48.7 m -65.1 -113.96 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 118.716 1.258 . . . . 0.0 111.223 -176.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -155.94 169.19 25.01 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 119.631 -0.827 . . . . 0.0 112.362 179.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt 27.36 43.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.224 -1.353 . . . . 0.0 112.723 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.84 60.25 0.74 Allowed Glycine 0 N--CA 1.475 1.24 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.21 177.521 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.19 118.63 0.57 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 119.229 1.514 . . . . 0.0 113.043 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.61 HD13 HG23 ' K' ' 39' ' ' VAL . 1.7 tt -136.14 125.38 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 175.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . 0.477 HG22 ' HG ' ' Q' ' 34' ' ' LEU . 64.5 mt -128.66 133.79 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.198 -176.641 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.85 112.57 2.36 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 108.164 -1.974 . . . . 0.0 108.164 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.477 ' HG ' HG22 ' Q' ' 32' ' ' ILE . 58.4 mt -119.16 120.44 37.1 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.093 0.473 . . . . 0.0 110.935 -177.47 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 11.0 mtp -124.7 130.92 53.33 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.362 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -105.81 159.86 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 CA-C-O 121.359 0.6 . . . . 0.0 110.75 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.84 -102.77 0.01 OUTLIER Glycine 0 CA--C 1.528 0.854 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.086 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.662 ' H ' ' CG2' ' P' ' 39' ' ' VAL . . . -116.97 -77.17 0.62 Allowed Glycine 0 CA--C 1.534 1.269 0 CA-C-O 119.864 -0.409 . . . . 0.0 113.166 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' R' ' 39' ' ' VAL . 39.3 t -115.01 129.9 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 117.682 0.741 . . . . 0.0 111.861 -178.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.493 ' N ' ' O ' ' R' ' 40' ' ' VAL . 42.6 t . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.694 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -79.54 138.4 37.49 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -111.31 128.58 55.99 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.433 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.477 ' H ' HG21 ' Q' ' 12' ' ' VAL . 30.8 t -110.46 93.17 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.451 0.643 . . . . 0.0 110.609 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.517 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 50.1 p-80 -120.32 105.77 11.24 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.545 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 84.6 t60 -141.11 170.73 15.17 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.752 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.531 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 93.0 mm-40 -89.55 150.62 22.35 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -149.59 99.0 2.84 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -139.02 124.78 19.65 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.529 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -104.96 118.52 52.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.524 ' CD1' HD13 ' P' ' 32' ' ' ILE . 55.3 m-85 -111.92 105.8 14.33 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 t80 -130.14 125.7 35.7 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.61 0.719 . . . . 0.0 112.104 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.59 126.4 38.4 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.269 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 79.1 tt0 -89.21 110.81 21.52 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 119.938 -0.705 . . . . 0.0 110.965 -178.686 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.448 ' OD2' ' OD2' ' Q' ' 23' ' ' ASP . 54.0 m-20 -163.11 -60.25 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.561 HG12 ' N ' ' R' ' 25' ' ' GLY . 98.2 t -55.81 162.49 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.742 -179.435 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.561 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -157.3 -27.84 0.03 OUTLIER Glycine 0 CA--C 1.52 0.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 93.1 p -80.74 -130.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.268 -0.466 . . . . 0.0 109.912 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.0 m-80 -99.18 -164.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.499 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -47.76 49.48 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 125.372 1.469 . . . . 0.0 114.793 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.38 51.76 0.92 Allowed Glycine 0 CA--C 1.55 2.229 0 CA-C-N 119.344 0.974 . . . . 0.0 113.715 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.19 165.61 22.0 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.404 HD11 ' CG2' ' L' ' 39' ' ' VAL . 96.6 mt -114.31 112.21 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 CA-C-N 119.73 1.15 . . . . 0.0 110.042 178.111 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -125.73 127.72 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.843 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.66 119.41 3.5 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.09 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 48.4 tp -123.25 123.08 39.95 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mtp -138.38 147.42 43.39 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.06 161.51 38.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.123 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.3 -102.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.501 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.34 -78.02 0.87 Allowed Glycine 0 N--CA 1.475 1.289 0 C-N-CA 121.707 -0.283 . . . . 0.0 112.891 -178.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' Q' ' 39' ' ' VAL . 70.1 t -96.1 132.82 39.4 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.865 0 CA-C-N 117.519 0.659 . . . . 0.0 110.855 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' Q' ' 40' ' ' VAL . 10.7 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.444 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.426 ' O ' ' OE2' ' B' ' 11' ' ' GLU . 95.9 m-85 -83.09 139.87 32.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.747 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -130.0 146.2 51.68 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.872 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.8 131.98 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.413 0.625 . . . . 0.0 111.159 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.1 m80 -117.38 156.82 27.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.461 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.512 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -84.21 167.85 16.29 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.918 -179.755 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 69.0 tp60 -159.15 143.26 15.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.632 178.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -80.2 123.5 27.98 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.455 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 99.3 mt -125.6 116.28 21.47 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 177.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.54 134.06 56.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.739 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -127.71 131.49 49.73 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.466 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.0 p90 -134.95 130.94 36.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.685 0.278 . . . . 0.0 111.374 -178.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.63 120.56 38.4 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -136.98 136.16 38.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.406 0.622 . . . . 0.0 112.081 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.9 t0 59.42 47.08 11.58 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -101.33 159.15 4.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.1 -36.56 93.11 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.772 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.494 ' O ' ' O ' ' A' ' 27' ' ' ASN . 28.4 t -152.93 121.87 6.53 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.272 -0.464 . . . . 0.0 109.893 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' A' ' 26' ' ' SER . 26.7 t-20 -40.68 167.47 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.89 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -79.55 39.64 0.41 Allowed 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.41 79.36 0.94 Allowed Glycine 0 N--CA 1.47 0.939 0 C-N-CA 117.886 -2.102 . . . . 0.0 110.976 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.445 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -81.41 74.81 8.39 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 119.589 1.695 . . . . 0.0 113.955 -175.947 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.67 ' CD1' HG12 ' M' ' 39' ' ' VAL . 89.7 mt -145.39 122.58 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 177.107 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -116.86 122.97 71.19 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-O 121.344 0.592 . . . . 0.0 112.109 -177.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.91 101.2 0.67 Allowed Glycine 0 C--N 1.319 -0.41 0 N-CA-C 105.311 -3.116 . . . . 0.0 105.311 176.377 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -156.71 153.71 28.88 Favored 'General case' 0 C--O 1.241 0.629 0 C-N-CA 118.128 -1.429 . . . . 0.0 113.617 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mmm -99.31 120.78 40.13 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 112.714 -2.039 . . . . 0.0 108.055 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.601 ' HB ' HG12 ' B' ' 36' ' ' VAL . 2.8 t -111.39 124.6 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.62 -114.22 6.29 Favored Glycine 0 CA--C 1.528 0.889 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.42 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.17 -71.51 0.73 Allowed Glycine 0 CA--C 1.539 1.58 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.455 ' H ' HG23 ' A' ' 39' ' ' VAL . 2.6 t -66.23 159.25 4.53 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.982 -1.009 . . . . 0.0 111.793 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 10' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' C' ' 9' ' ' GLY . 92.1 m-85 -98.43 132.32 43.98 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 10' ' ' TYR . 97.0 mt-10 -138.03 139.81 39.78 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.013 0.435 . . . . 0.0 111.304 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.47 ' CG1' ' HE2' ' A' ' 14' ' ' HIS . 74.2 t -124.42 130.89 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -117.55 98.05 6.19 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' B' ' 15' ' ' GLN . 11.5 t60 -160.61 164.54 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.542 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 19.8 tt0 -158.1 142.33 15.92 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.319 178.033 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.52 121.25 27.34 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.022 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.604 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.4 tt -136.22 121.32 18.93 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.706 0.685 . . . . 0.0 110.831 178.673 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.548 ' N ' HD23 ' B' ' 17' ' ' LEU . 13.9 m -134.65 141.4 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.937 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -128.32 127.03 41.95 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.184 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -123.24 129.58 51.57 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.743 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.0 119.65 31.02 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.456 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -138.84 164.04 30.68 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.001 0.429 . . . . 0.0 111.545 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.58 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 54.2 t0 42.0 47.57 3.83 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -81.58 163.4 3.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 117.786 -1.565 . . . . 0.0 108.567 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.61 -38.16 57.52 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -177.3 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.62 ' O ' ' O ' ' B' ' 27' ' ' ASN . 45.9 t -162.54 117.24 1.81 Allowed 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.505 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.746 HD21 ' N ' ' C' ' 28' ' ' LYS . 55.2 t-20 -22.02 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.212 0 O-C-N 123.933 0.771 . . . . 0.0 111.713 175.557 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.545 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 62.7 tttt -163.29 24.56 0.09 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . 89.53 106.64 1.16 Allowed Glycine 0 N--CA 1.468 0.805 0 C-N-CA 118.396 -1.859 . . . . 0.0 113.814 177.431 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.89 101.83 10.38 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 122.734 1.254 . . . . 0.0 109.881 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.7 HD11 ' HB ' ' N' ' 39' ' ' VAL . 91.8 mt -119.61 129.44 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 114.22 -1.355 . . . . 0.0 110.641 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.43 ' CG2' HD12 ' B' ' 34' ' ' LEU . 49.7 mt -109.95 111.24 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.114 0.483 . . . . 0.0 109.82 177.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 99.21 0.99 Allowed Glycine 0 C--O 1.238 0.396 0 N-CA-C 105.885 -2.886 . . . . 0.0 105.885 177.067 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.629 ' O ' HD23 ' C' ' 34' ' ' LEU . 80.0 mt -138.24 145.67 41.65 Favored 'General case' 0 CA--C 1.499 -1.001 0 CA-C-O 122.792 1.282 . . . . 0.0 113.139 -175.242 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.7 mtp -116.36 109.44 17.35 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 112.837 -1.983 . . . . 0.0 107.473 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.601 HG12 ' HB ' ' A' ' 36' ' ' VAL . 2.8 m -132.88 123.19 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.742 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 144.85 -113.4 0.72 Allowed Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.684 ' O ' HG13 ' B' ' 39' ' ' VAL . . . 76.94 -72.97 2.0 Allowed Glycine 0 CA--C 1.535 1.3 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.684 HG13 ' O ' ' B' ' 38' ' ' GLY . 2.9 m -166.67 118.92 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.551 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 17.2 m . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.746 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 9' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -122.47 140.38 52.8 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.731 0.3 . . . . 0.0 110.34 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.499 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 57.6 mp0 -76.52 115.82 16.63 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.059 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 26.7 m -137.01 159.76 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.473 ' O ' ' CB ' ' D' ' 13' ' ' HIS . 16.3 m-70 -145.71 132.27 19.82 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.025 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.489 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.8 m-70 -150.57 170.9 18.03 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.074 177.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.2 tp60 -138.53 140.83 39.25 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 177.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -130.02 106.12 8.42 Favored 'General case' 0 C--N 1.318 -0.764 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.413 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 mt -118.34 113.86 22.06 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.47 116.27 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -109.37 106.16 15.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -120.81 127.97 52.43 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -176.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.62 131.36 35.71 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.124 0.488 . . . . 0.0 111.164 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.489 ' O ' ' CG ' ' C' ' 23' ' ' ASP . 77.4 tt0 -146.46 101.9 3.53 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 113.659 0.985 . . . . 0.0 113.659 -179.067 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.58 ' OD2' ' N ' ' B' ' 23' ' ' ASP . 70.5 m-20 -175.86 -71.83 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 175.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.622 HG13 ' O ' ' C' ' 24' ' ' VAL . 11.2 p -78.75 114.78 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.069 -1.423 . . . . 0.0 107.54 175.203 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.421 ' HA3' HG22 ' D' ' 24' ' ' VAL . . . -91.23 -39.26 5.74 Favored Glycine 0 N--CA 1.461 0.336 0 C-N-CA 117.408 -2.33 . . . . 0.0 109.044 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 5.0 t -93.15 111.47 23.12 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 173.342 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -79.85 171.41 15.15 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 118.017 -1.473 . . . . 0.0 109.996 177.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.746 ' N ' HD21 ' B' ' 27' ' ' ASN . 99.0 mttt -50.37 -36.88 34.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.207 1.003 . . . . 0.0 109.472 174.746 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.19 76.72 0.06 OUTLIER Glycine 0 CA--C 1.54 1.642 0 CA-C-N 113.372 -1.74 . . . . 0.0 110.175 -178.119 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.498 ' O ' ' HB1' ' D' ' 30' ' ' ALA . . . -80.19 129.79 34.75 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 119.323 1.562 . . . . 0.0 113.104 -176.259 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.924 HG22 HG22 ' D' ' 31' ' ' ILE . 46.8 pt -144.61 146.22 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.983 -177.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 76.9 mt -108.96 116.35 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.689 178.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.8 102.99 1.66 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.247 -3.141 . . . . 0.0 105.247 175.599 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.629 HD23 ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -134.93 141.02 46.18 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -175.122 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.65 113.29 26.48 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 175.201 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.491 HG22 HD22 ' C' ' 34' ' ' LEU . 3.1 t -129.46 134.42 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.86 -104.29 0.28 Allowed Glycine 0 C--N 1.305 -1.145 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' C' ' 39' ' ' VAL . . . 46.87 70.73 0.63 Allowed Glycine 0 CA--C 1.537 1.423 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.478 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.882 HG13 ' O ' ' D' ' 39' ' ' VAL . 6.3 t -6.78 120.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.539 ' OXT' ' CE1' ' E' ' 13' ' ' HIS . 26.8 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.156 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.473 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 26.3 p90 -147.66 158.36 43.98 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 120.892 0.377 . . . . 0.0 110.729 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.407 ' H ' ' HG2' ' E' ' 11' ' ' GLU . 97.5 mt-10 -134.33 121.68 21.56 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.568 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.436 HG12 ' H ' ' E' ' 12' ' ' VAL . 4.5 m -129.25 132.55 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 179.498 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' O ' ' B' ' 40' ' ' VAL . 2.1 p80 -147.78 138.46 23.21 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.702 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.546 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.2 OUTLIER -145.91 158.67 43.86 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.052 178.454 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.742 HE22 ' H ' ' B' ' 37' ' ' GLY . 84.8 mt-30 -90.43 158.19 17.2 Favored 'General case' 0 N--CA 1.455 -0.196 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 174.068 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.481 ' C ' HD22 ' D' ' 17' ' ' LEU . 98.7 mttt -141.37 103.08 4.35 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 176.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.907 HD22 ' N ' ' D' ' 17' ' ' LEU . 0.1 OUTLIER -118.69 119.41 34.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.053 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 82.8 t -112.94 112.26 39.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.384 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 44.7 m-85 -110.92 103.96 12.5 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -114.29 118.84 35.04 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.831 -0.168 . . . . 0.0 110.926 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.14 118.4 8.95 Favored 'General case' 0 C--O 1.246 0.883 0 CA-C-O 122.147 0.975 . . . . 0.0 111.742 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -178.09 158.96 1.26 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 114.387 -1.279 . . . . 0.0 111.073 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.449 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 35.2 t70 -173.06 -59.91 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 114.167 1.173 . . . . 0.0 114.167 177.538 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.843 HG23 ' H ' ' D' ' 26' ' ' SER . 3.0 m -77.96 -178.99 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 118.896 -1.121 . . . . 0.0 113.208 -176.609 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.71 19.82 38.85 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 114.044 -1.435 . . . . 0.0 113.081 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.843 ' H ' HG23 ' D' ' 24' ' ' VAL . 8.9 t -126.65 151.16 48.43 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 118.309 1.055 . . . . 0.0 112.775 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.489 HD22 ' H ' ' E' ' 26' ' ' SER . 57.9 t-20 -52.36 137.27 29.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.276 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.411 ' CB ' ' O ' ' E' ' 22' ' ' GLU . 87.1 tttt -63.5 -50.97 67.53 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.884 -177.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.66 50.35 3.15 Favored Glycine 0 CA--C 1.541 1.673 0 C-N-CA 119.949 -1.12 . . . . 0.0 110.755 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.498 ' HB1' ' O ' ' C' ' 30' ' ' ALA . . . -130.58 -179.9 5.55 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 118.803 1.301 . . . . 0.0 114.033 -174.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.924 HG22 HG22 ' C' ' 31' ' ' ILE . 16.3 tt -136.37 144.74 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 CA-C-N 113.281 -1.781 . . . . 0.0 112.717 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.442 HD13 ' CD1' ' F' ' 19' ' ' PHE . 4.6 mt -103.92 109.88 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 175.6 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.6 104.26 0.88 Allowed Glycine 0 N--CA 1.466 0.697 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -157.28 157.71 34.73 Favored 'General case' 0 C--O 1.245 0.835 0 CA-C-O 123.879 1.8 . . . . 0.0 114.019 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.437 ' O ' ' O ' ' C' ' 36' ' ' VAL . 0.9 OUTLIER -97.1 119.5 35.7 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 110.516 -3.038 . . . . 0.0 108.683 178.371 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' E' ' 35' ' ' MET . 38.3 t -121.86 142.41 38.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 178.649 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.563 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.25 -102.14 0.19 Allowed Glycine 0 C--N 1.296 -1.666 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -176.898 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' D' ' 39' ' ' VAL . . . 47.56 71.39 0.56 Allowed Glycine 0 CA--C 1.526 0.772 0 C-N-CA 120.048 -1.072 . . . . 0.0 110.643 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.882 ' O ' HG13 ' C' ' 39' ' ' VAL . 59.4 t -22.53 142.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.642 0.777 . . . . 0.0 112.886 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.477 HG13 HG12 ' D' ' 39' ' ' VAL . 16.6 m . . . . . 0 N--CA 1.471 0.622 0 CA-C-O 117.742 -1.123 . . . . 0.0 111.053 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -72.46 125.7 28.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.733 0.302 . . . . 0.0 110.543 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.407 ' HG2' ' H ' ' D' ' 11' ' ' GLU . 96.3 mt-10 -148.39 130.87 15.76 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.629 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.436 ' H ' HG12 ' D' ' 12' ' ' VAL . 8.4 m -134.01 131.11 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.032 0.444 . . . . 0.0 110.79 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.539 ' CE1' ' OXT' ' C' ' 40' ' ' VAL . 3.4 p80 -150.21 146.55 26.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.875 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.472 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 41.5 m-70 -147.52 162.57 38.81 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-O 121.09 0.472 . . . . 0.0 111.49 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.523 ' NE2' ' OE1' ' D' ' 15' ' ' GLN . 56.6 tp60 -85.17 157.26 20.7 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 176.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.684 ' C ' HD12 ' E' ' 17' ' ' LEU . 86.7 tttt -159.45 98.41 1.4 Allowed 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 118.473 -1.291 . . . . 0.0 112.378 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.684 HD12 ' C ' ' E' ' 16' ' ' LYS . 5.9 mp -122.26 123.13 40.74 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.586 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 p -120.51 118.89 58.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' F' ' 19' ' ' PHE . 17.3 m-85 -108.91 105.71 15.36 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -108.53 114.45 28.29 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.539 ' O ' ' HB1' ' F' ' 21' ' ' ALA . . . -164.48 173.48 12.04 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 117.609 -1.636 . . . . 0.0 114.736 -177.819 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.411 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 73.4 mt-10 -77.75 141.18 39.43 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.339 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -175.41 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 120.475 0.179 . . . . 0.0 110.616 -177.51 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.858 HG12 ' H ' ' E' ' 25' ' ' GLY . 11.7 t -61.05 -179.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.638 0.732 . . . . 0.0 112.219 -176.299 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.858 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -100.89 28.69 14.82 Favored Glycine 0 N--CA 1.467 0.716 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.366 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.489 ' H ' HD22 ' D' ' 27' ' ' ASN . 19.6 m -83.56 -119.97 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -177.31 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' E' ' 29' ' ' GLY . 8.5 m120 -91.35 -151.53 0.26 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.852 -175.765 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp 44.1 -47.4 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 -176.652 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 130.98 60.54 0.09 OUTLIER Glycine 0 N--CA 1.49 2.252 0 CA-C-N 122.629 2.468 . . . . 0.0 115.899 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.83 116.92 11.69 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 119.301 1.55 . . . . 0.0 110.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.499 HD11 ' HB ' ' Q' ' 39' ' ' VAL . 77.6 mt -125.26 146.75 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.798 -177.264 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -134.2 113.62 17.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 O-C-N 121.438 -0.789 . . . . 0.0 110.426 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.82 107.53 2.02 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 20.4 tp -128.4 120.5 27.08 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.288 0.566 . . . . 0.0 112.271 -177.234 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 53.3 tpp -106.69 121.18 43.83 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.154 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.515 ' O ' ' O ' ' E' ' 37' ' ' GLY . 83.7 t -109.42 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.515 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -22.66 152.95 0.0 OUTLIER Glycine 0 N--CA 1.479 1.518 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.296 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . -54.94 -54.41 33.79 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.004 -0.887 . . . . 0.0 114.492 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.6 HG23 HD11 ' K' ' 31' ' ' ILE . 70.5 t -102.89 130.53 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 119.17 1.485 . . . . 0.0 110.395 -179.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.692 -179.663 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.451 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -148.99 158.39 44.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 120.768 0.318 . . . . 0.0 110.753 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -117.71 131.26 56.64 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.752 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.41 122.84 67.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.167 0.508 . . . . 0.0 110.842 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.709 ' N ' ' HD1' ' F' ' 13' ' ' HIS . 0.3 OUTLIER -154.64 121.59 5.55 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.265 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.627 ' C ' ' HD1' ' F' ' 14' ' ' HIS . 0.1 OUTLIER -151.8 166.25 31.95 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.853 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.563 HE22 ' H ' ' D' ' 37' ' ' GLY . 12.3 tt0 -89.82 156.68 18.33 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 16' ' ' LYS . . . . . 0.465 ' C ' HD22 ' F' ' 17' ' ' LEU . 76.7 tttt -141.83 101.55 3.98 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 120.729 -0.389 . . . . 0.0 110.862 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.909 HD22 ' N ' ' F' ' 17' ' ' LEU . 0.2 OUTLIER -118.0 111.68 19.26 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -107.77 110.04 30.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.442 ' CD1' HD13 ' D' ' 32' ' ' ILE . 29.3 m-85 -106.31 103.29 12.73 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 178.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -123.31 129.48 51.39 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.619 0.723 . . . . 0.0 110.589 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.539 ' HB1' ' O ' ' E' ' 21' ' ' ALA . . . -147.63 149.03 31.74 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 120.042 -0.663 . . . . 0.0 109.372 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.31 121.73 17.47 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.695 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OG ' ' F' ' 26' ' ' SER . 67.4 t0 -154.35 46.59 0.58 Allowed 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.53 HG12 ' N ' ' F' ' 25' ' ' GLY . 53.3 t -100.98 163.77 3.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.53 ' N ' HG12 ' F' ' 24' ' ' VAL . . . 70.87 29.19 69.54 Favored Glycine 0 CA--C 1.528 0.891 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.87 178.2 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.463 ' OG ' ' OD1' ' F' ' 23' ' ' ASP . 22.3 p -155.73 111.97 3.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.206 0.527 . . . . 0.0 111.377 -177.306 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -49.45 178.85 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.297 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -70.27 46.45 0.08 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.415 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.17 58.62 2.76 Favored Glycine 0 CA--C 1.548 2.12 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.075 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.51 172.03 18.59 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 10.4 tt -133.13 136.3 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 CA-C-O 122.103 0.954 . . . . 0.0 112.704 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 89.9 mt -122.17 131.9 72.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 111.34 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.76 119.93 3.66 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.9 tp -125.47 126.52 45.04 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mtp -142.53 142.39 32.23 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.598 HG22 ' N ' ' F' ' 37' ' ' GLY . 2.3 p -140.78 171.39 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.598 ' N ' HG22 ' F' ' 36' ' ' VAL . . . -168.03 94.15 0.11 Allowed Glycine 0 C--N 1.306 -1.086 0 C-N-CA 119.202 -1.475 . . . . 0.0 111.887 179.023 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 38' ' ' GLY . . . . . 0.503 ' O ' HG23 ' F' ' 39' ' ' VAL . . . 165.27 -81.44 0.11 Allowed Glycine 0 CA--C 1.529 0.929 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.308 176.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.503 HG23 ' O ' ' F' ' 38' ' ' GLY . 40.2 t -156.5 130.99 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-O 121.488 0.661 . . . . 0.0 110.45 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.636 179.765 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.451 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -112.39 138.12 49.58 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.881 0.372 . . . . 0.0 110.948 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -84.53 147.12 27.21 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.982 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.37 133.19 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.042 0.448 . . . . 0.0 110.486 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 79.5 m80 -110.0 151.28 27.35 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.152 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.539 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 0.5 OUTLIER -84.33 168.02 16.01 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.175 0.512 . . . . 0.0 110.838 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.539 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 99.6 mm-40 -154.97 142.35 19.57 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -84.7 121.82 28.2 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.745 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 92.5 mt -126.25 127.92 46.38 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -141.4 139.14 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.907 0.384 . . . . 0.0 111.595 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -135.79 137.16 41.32 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.246 0.546 . . . . 0.0 110.747 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.486 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 53.6 p90 -132.9 130.2 39.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.439 -178.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.83 125.86 48.6 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.622 0.725 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.557 ' O ' ' N ' ' G' ' 24' ' ' VAL . 13.0 pt-20 -156.5 -121.25 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.151 -0.931 . . . . 0.0 108.961 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 55.5 p30 -52.61 47.76 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.425 1.09 . . . . 0.0 113.688 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.598 HG12 ' H ' ' G' ' 25' ' ' GLY . 1.7 t -99.72 -161.28 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -178.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.598 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -72.41 -33.29 61.47 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 119.188 -1.482 . . . . 0.0 113.654 -175.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -153.48 123.83 7.07 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.421 1.611 . . . . 0.0 112.175 176.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 11.3 m120 -39.14 135.39 0.97 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.074 175.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -110.59 -39.78 4.79 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 122.437 1.113 . . . . 0.0 108.601 175.367 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 79.6 -69.35 3.03 Favored Glycine 0 CA--C 1.536 1.396 0 CA-C-N 113.037 -1.892 . . . . 0.0 113.061 178.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.483 ' HB2' ' O ' ' G' ' 29' ' ' GLY . . . 179.45 79.98 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 118.162 0.981 . . . . 0.0 113.245 176.673 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 81.1 mt -122.25 107.07 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.978 1.263 . . . . 0.0 107.612 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.41 HD13 ' CD1' ' I' ' 19' ' ' PHE . 93.9 mt -122.29 112.08 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.436 0.636 . . . . 0.0 112.393 -177.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.64 103.54 1.46 Allowed Glycine 0 N--CA 1.461 0.328 0 N-CA-C 105.279 -3.128 . . . . 0.0 105.279 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.0 mt -143.29 162.89 34.47 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 123.556 1.646 . . . . 0.0 115.174 -175.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -113.19 107.72 16.3 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 111.367 -2.651 . . . . 0.0 104.087 175.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 27.4 t -122.25 131.61 72.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.73 -111.33 3.27 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.447 ' O ' HG12 ' H' ' 39' ' ' VAL . . . 74.5 -73.92 1.34 Allowed Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.08 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 t -79.62 168.59 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.813 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.09 138.53 43.09 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.836 0.351 . . . . 0.0 110.792 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -126.86 140.73 52.13 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.719 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.95 131.63 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 120.869 0.366 . . . . 0.0 110.133 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -124.75 159.56 30.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.977 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 80.1 m80 -119.25 172.98 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -92.53 149.33 21.43 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.41 ' HD2' ' CE1' ' G' ' 14' ' ' HIS . 64.8 mttp -101.42 128.24 47.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.8 tp -122.84 124.51 43.44 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.04 0.448 . . . . 0.0 111.377 -179.341 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.93 124.8 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.098 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -133.4 126.62 31.66 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.402 ' CZ ' ' HB3' ' G' ' 20' ' ' PHE . 37.4 p90 -145.33 143.51 30.2 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 119.141 -1.024 . . . . 0.0 112.379 178.773 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.99 123.83 43.38 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.942 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.73 162.77 35.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 120.126 -0.63 . . . . 0.0 112.509 -178.22 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 59.92 47.2 10.24 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.054 -0.976 . . . . 0.0 112.742 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.609 HG12 ' H ' ' H' ' 26' ' ' SER . 2.4 t -83.4 166.96 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 116.515 -2.074 . . . . 0.0 107.26 -179.263 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.37 -36.33 59.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 119.628 -1.272 . . . . 0.0 114.723 178.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.768 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.8 t -174.14 126.66 0.35 Allowed 'General case' 0 C--O 1.224 -0.273 0 CA-C-O 117.723 -1.132 . . . . 0.0 112.147 -176.595 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.768 ' O ' ' O ' ' H' ' 26' ' ' SER . 8.8 t-20 -2.44 146.4 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 175.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 58.9 tttt -159.31 30.34 0.2 Allowed 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.486 ' HA3' HG21 ' B' ' 39' ' ' VAL . . . 82.72 89.24 0.69 Allowed Glycine 0 C--N 1.345 1.044 0 C-N-CA 117.17 -2.443 . . . . 0.0 114.108 176.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.524 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -110.41 102.65 11.26 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 123.371 1.558 . . . . 0.0 112.045 -178.231 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.574 HD11 HG13 ' B' ' 39' ' ' VAL . 80.7 mt -123.02 131.01 74.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 112.765 -2.016 . . . . 0.0 110.651 -179.691 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.584 HD13 ' CD1' ' J' ' 19' ' ' PHE . 81.3 mt -113.21 108.75 26.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 175.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.66 121.82 4.5 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -178.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.643 ' CD2' HD11 ' I' ' 34' ' ' LEU . 0.8 OUTLIER -169.49 163.16 10.36 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 123.904 1.811 . . . . 0.0 113.91 -179.925 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -100.21 116.55 32.47 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 111.483 -2.598 . . . . 0.0 108.576 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.44 ' O ' ' O ' ' I' ' 35' ' ' MET . 53.8 t -127.8 123.69 61.53 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.565 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.13 -114.35 2.26 Favored Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.412 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.35 -72.68 2.77 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.54 ' HB ' HG21 ' N' ' 31' ' ' ILE . 2.5 p -152.07 151.23 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 O-C-N 122.7 -0.294 . . . . 0.0 110.47 177.631 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.621 HG21 ' CD2' ' J' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.218 -0.563 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.454 178.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.76 161.4 41.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.74 0.305 . . . . 0.0 110.448 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.41 139.24 51.72 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.578 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 4.7 m -126.89 136.46 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -138.91 93.62 2.72 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.537 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.456 ' CB ' ' O ' ' J' ' 14' ' ' HIS . 52.3 p-80 -157.1 153.47 27.86 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 118.793 -1.163 . . . . 0.0 112.52 176.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -90.81 161.49 15.25 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.748 176.366 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -139.47 110.98 7.08 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 177.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' I' ' 17' ' ' LEU . 4.3 mp -129.47 131.63 46.73 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.264 0.554 . . . . 0.0 110.942 178.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 76.0 t -121.15 120.14 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.41 ' CD1' HD13 ' G' ' 32' ' ' ILE . 61.3 m-85 -118.53 111.16 18.26 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -121.66 135.21 54.98 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 122.311 -0.243 . . . . 0.0 111.358 -178.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 1.113 ' HB1' ' HZ1' ' I' ' 28' ' ' LYS . . . -139.28 136.05 34.49 Favored 'General case' 0 CA--C 1.555 1.152 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.338 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.489 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 79.7 tt0 -117.29 152.75 34.23 Favored 'General case' 0 N--CA 1.484 1.266 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.259 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.466 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 16.8 t70 -171.49 51.23 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -177.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.437 HG22 ' HB2' ' J' ' 23' ' ' ASP . 16.8 t -63.19 151.04 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.47 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.92 -35.27 4.96 Favored Glycine 0 CA--C 1.539 1.538 0 CA-C-N 116.153 -0.476 . . . . 0.0 113.639 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' I' ' 27' ' ' ASN . 28.9 t -151.68 124.15 8.35 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.643 ' HA ' HG11 ' J' ' 24' ' ' VAL . 1.7 m-20 -41.19 145.86 0.21 Allowed 'General case' 0 C--N 1.348 0.514 0 C-N-CA 118.396 -1.322 . . . . 0.0 109.774 -175.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 1.113 ' HZ1' ' HB1' ' I' ' 21' ' ' ALA . 18.3 tttt -75.08 -49.65 19.01 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -177.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 109.51 59.43 0.52 Allowed Glycine 0 CA--C 1.545 1.964 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -177.293 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.1 114.2 26.08 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -172.565 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 82.8 mt -134.28 127.25 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 113.858 -1.519 . . . . 0.0 109.334 176.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.538 HD13 ' HD2' ' K' ' 19' ' ' PHE . 14.2 tt -121.01 114.96 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.548 177.344 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.739 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -109.21 108.7 2.62 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.739 HD12 ' O ' ' I' ' 33' ' ' GLY . 2.4 mp -135.12 148.2 49.71 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.952 1.358 . . . . 0.0 114.116 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.44 ' O ' ' O ' ' H' ' 36' ' ' VAL . 86.4 mmm -107.75 112.72 25.54 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-N 112.686 -2.052 . . . . 0.0 106.809 175.332 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.433 ' O ' ' O ' ' J' ' 35' ' ' MET . 4.8 t -136.51 161.91 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.012 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.71 ' H ' HE22 ' K' ' 15' ' ' GLN . . . 81.1 102.44 0.33 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 119.424 -1.37 . . . . 0.0 112.005 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.44 ' N ' ' CA ' ' J' ' 38' ' ' GLY . . . -154.45 -71.12 0.01 OUTLIER Glycine 0 CA--C 1.544 1.847 0 CA-C-O 118.899 -0.945 . . . . 0.0 111.406 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.489 HG13 ' O ' ' O' ' 29' ' ' GLY . 16.0 t -119.3 128.95 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 119.406 1.603 . . . . 0.0 109.137 177.684 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.43 ' OXT' ' O ' ' I' ' 39' ' ' VAL . 77.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.216 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -107.39 132.39 53.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.808 0.337 . . . . 0.0 110.667 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.534 ' OE1' ' N ' ' J' ' 11' ' ' GLU . 58.1 mp0 -123.96 134.98 53.37 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.333 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -124.52 132.6 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.568 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.621 ' CD2' HG21 ' H' ' 40' ' ' VAL . 4.2 t-160 -129.01 137.59 51.43 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.163 0.506 . . . . 0.0 110.476 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.538 ' N ' ' CD2' ' J' ' 13' ' ' HIS . 83.1 m-70 -154.85 176.92 11.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 122.103 0.954 . . . . 0.0 111.777 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -159.77 137.14 9.68 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.257 -2.127 . . . . 0.0 105.257 177.298 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.839 ' C ' HD12 ' J' ' 17' ' ' LEU . 84.9 tttt -134.25 113.8 12.36 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.075 -0.65 . . . . 0.0 112.66 -178.669 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.839 HD12 ' C ' ' J' ' 16' ' ' LYS . 7.0 mp -133.87 117.67 17.08 Favored 'General case' 0 CA--C 1.508 -0.64 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 176.824 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -106.8 110.01 30.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.1 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.584 ' CD1' HD13 ' H' ' 32' ' ' ILE . 62.6 m-85 -108.12 104.18 13.54 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 178.759 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.435 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 5.0 m-85 -123.24 129.91 52.03 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 118.76 20.33 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.476 ' OE2' ' CE1' ' K' ' 20' ' ' PHE . 76.0 mt-10 -145.81 133.41 20.95 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 -176.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.796 ' OD1' HG23 ' J' ' 24' ' ' VAL . 0.2 OUTLIER 164.69 -70.4 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.404 175.643 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.796 HG23 ' OD1' ' J' ' 23' ' ' ASP . 22.8 t -58.17 -121.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 113.761 -1.563 . . . . 0.0 110.415 175.231 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.661 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 142.08 -35.55 1.75 Allowed Glycine 0 C--O 1.222 -0.64 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.591 -179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.402 ' O ' ' CG ' ' I' ' 27' ' ' ASN . 10.2 t -80.45 118.55 22.17 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 122.606 3.203 . . . . 0.0 103.119 169.009 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.667 ' CG ' ' H ' ' J' ' 30' ' ' ALA . 21.7 p30 -90.6 158.84 16.75 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 123.413 2.824 . . . . 0.0 110.966 178.191 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -48.12 -40.42 23.53 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 122.823 1.297 . . . . 0.0 110.985 173.386 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.43 67.85 0.04 OUTLIER Glycine 0 CA--C 1.545 1.911 0 CA-C-N 111.854 -2.43 . . . . 0.0 108.586 -174.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.667 ' H ' ' CG ' ' J' ' 27' ' ' ASN . . . -70.31 138.68 51.7 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-N 120.169 1.984 . . . . 0.0 114.2 -171.808 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.673 HD11 ' CG2' ' D' ' 39' ' ' VAL . 86.2 mt -140.22 136.8 37.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-N 112.906 -1.952 . . . . 0.0 114.606 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.422 ' O ' HG22 ' J' ' 32' ' ' ILE . 4.7 mt -108.74 109.3 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.92 108.66 2.43 Favored Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.417 HD12 ' O ' ' I' ' 34' ' ' LEU . 12.7 tp -142.49 136.85 29.79 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 118.674 -1.21 . . . . 0.0 113.657 -175.041 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.433 ' O ' ' O ' ' I' ' 36' ' ' VAL . 0.6 OUTLIER -104.89 120.57 41.75 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.211 -1.813 . . . . 0.0 107.145 177.109 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.572 ' CG1' ' NE2' ' L' ' 15' ' ' GLN . 43.4 t -125.11 167.35 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 121.315 0.578 . . . . 0.0 110.897 -176.1 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.483 ' N ' HG12 ' J' ' 36' ' ' VAL . . . 106.65 102.49 2.8 Favored Glycine 0 N--CA 1.467 0.752 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.891 178.207 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.516 ' O ' ' C ' ' J' ' 39' ' ' VAL . . . -121.89 65.61 0.48 Allowed Glycine 0 CA--C 1.539 1.593 0 CA-C-O 117.858 -1.523 . . . . 0.0 113.125 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.643 ' HB ' HD11 ' P' ' 31' ' ' ILE . 71.1 t -12.84 127.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 CA-C-N 119.905 1.852 . . . . 0.0 113.769 -176.031 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.42 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 10.7 m . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.943 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.462 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -107.1 135.7 48.21 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.862 0.363 . . . . 0.0 110.385 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 57.6 mp0 -131.82 146.06 51.92 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.954 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 55.6 t -123.82 128.5 74.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.082 0.468 . . . . 0.0 110.769 -179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.561 ' CD2' ' HB3' ' J' ' 13' ' ' HIS . 48.6 m80 -148.05 100.21 3.15 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.638 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.66 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 4.7 m80 -145.14 157.71 44.02 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.901 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.71 HE22 ' H ' ' I' ' 37' ' ' GLY . 79.3 mt-30 -90.27 159.25 16.78 Favored 'General case' 0 CA--C 1.515 -0.4 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 174.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -140.71 103.62 4.55 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.502 177.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.42 HD22 HG21 ' I' ' 36' ' ' VAL . 5.1 mp -131.47 119.61 21.82 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.549 0.69 . . . . 0.0 109.456 177.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.1 t -106.05 113.01 41.7 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 114.766 -1.107 . . . . 0.0 108.629 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.538 ' HD2' HD13 ' I' ' 32' ' ' ILE . 1.8 m-85 -105.95 101.59 11.08 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.584 -1.636 . . . . 0.0 106.584 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.476 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 40.6 t80 -117.95 126.83 53.09 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 120.984 0.421 . . . . 0.0 111.064 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -146.79 142.33 27.62 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 119.657 -0.817 . . . . 0.0 112.727 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 85.6 mt-10 -82.68 115.56 21.67 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.544 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.516 ' CG ' HD22 ' J' ' 27' ' ' ASN . 68.5 t0 -131.85 46.4 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.732 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.584 HG12 ' H ' ' K' ' 25' ' ' GLY . 6.4 t -83.48 171.76 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.277 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.755 -177.064 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.584 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 95.45 -29.43 9.64 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.004 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 91.81 115.1 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 -178.658 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.452 ' ND2' ' H ' ' K' ' 28' ' ' LYS . 9.1 t-20 -73.79 163.13 28.36 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 118.377 -1.329 . . . . 0.0 111.378 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.578 ' NZ ' ' NE2' ' F' ' 13' ' ' HIS . 99.1 mttt -48.12 -37.24 14.95 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.853 175.393 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.99 76.92 0.06 OUTLIER Glycine 0 CA--C 1.541 1.684 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.755 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.416 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -79.95 139.89 36.88 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 119.133 1.466 . . . . 0.0 110.173 -178.413 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.6 HD11 HG23 ' E' ' 39' ' ' VAL . 7.1 mt -130.85 133.71 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -175.398 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.459 HD11 HG12 ' L' ' 32' ' ' ILE . 33.7 pt -121.0 118.77 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 121.596 0.712 . . . . 0.0 109.323 176.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 118.24 4.22 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -178.998 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.594 ' CD2' ' CE2' ' L' ' 19' ' ' PHE . 4.2 mp -129.03 118.42 22.52 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.973 0.892 . . . . 0.0 111.716 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -102.74 115.31 30.33 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.193 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.675 HG12 ' N ' ' K' ' 37' ' ' GLY . 42.6 t -116.76 174.12 3.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.675 ' N ' HG12 ' K' ' 36' ' ' VAL . . . 163.05 -95.41 0.13 Allowed Glycine 0 C--N 1.305 -1.181 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' K' ' 37' ' ' GLY . . . 28.48 78.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.401 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.56 HG13 ' O ' ' L' ' 39' ' ' VAL . 90.5 t -33.89 118.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -179.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 t . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.361 179.373 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.0 m-85 -106.96 135.1 49.09 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.678 0.275 . . . . 0.0 110.637 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -108.22 156.35 19.44 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.387 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.59 122.01 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.17 0.509 . . . . 0.0 110.786 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.489 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -153.12 101.21 2.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.63 179.47 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.66 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.7 m80 -146.28 164.34 32.65 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.572 ' NE2' ' CG1' ' J' ' 36' ' ' VAL . 5.2 tt0 -90.02 158.45 17.34 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.636 0.236 . . . . 0.0 111.636 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.53 109.57 6.11 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 121.55 0.69 . . . . 0.0 111.555 178.165 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 22.4 mt -128.68 117.26 20.88 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -105.14 108.47 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.613 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.58 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' K' ' 34' ' ' LEU . 42.8 m-85 -102.45 105.36 15.92 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.52 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -129.19 122.01 28.86 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.642 0.734 . . . . 0.0 111.099 -178.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -129.35 133.0 47.2 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.454 ' O ' ' C ' ' K' ' 23' ' ' ASP . 79.6 mm-40 -77.27 114.76 16.43 Favored 'General case' 0 C--O 1.222 -0.388 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.641 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p30 -168.5 46.46 0.04 OUTLIER 'General case' 0 C--O 1.231 0.099 0 C-N-CA 119.838 -0.745 . . . . 0.0 112.833 -178.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.2 m -83.65 172.68 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 119.225 -0.99 . . . . 0.0 108.941 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.51 -29.82 8.57 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 15.7 p -84.77 139.9 31.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.38 -0.41 . . . . 0.0 110.993 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' N ' ' L' ' 29' ' ' GLY . 61.6 t-20 -73.15 149.17 43.19 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.509 ' N ' ' OD1' ' L' ' 27' ' ' ASN . 6.3 tmtt? 64.68 -49.71 0.32 Allowed 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 94.83 -54.79 1.92 Allowed Glycine 0 CA--C 1.542 1.745 0 CA-C-N 116.201 -0.454 . . . . 0.0 114.079 177.436 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.416 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -170.42 -172.75 1.31 Allowed 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 117.666 0.733 . . . . 0.0 109.69 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 97.8 mt -98.41 119.09 45.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 176.33 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.459 HG12 HD11 ' K' ' 32' ' ' ILE . 88.9 mt -115.3 122.84 70.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -177.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 106.22 0.84 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 178.118 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 10.0 tt -133.45 131.17 39.59 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 33.4 ttp -151.59 160.3 43.72 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.709 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 27.1 m -109.47 173.96 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.339 0.123 0 CA-C-O 121.152 0.501 . . . . 0.0 111.108 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.451 ' H ' ' HA2' ' K' ' 37' ' ' GLY . . . -166.51 94.64 0.11 Allowed Glycine 0 C--N 1.306 -1.098 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.03 83.4 0.79 Allowed Glycine 0 N--CA 1.473 1.149 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.56 ' O ' HG13 ' K' ' 39' ' ' VAL . 21.8 m -53.29 141.84 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.877 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.15 -0.929 . . . . 0.0 110.556 179.171 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -148.48 158.36 44.07 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.879 0.371 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -92.32 126.01 37.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.915 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -126.83 130.17 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 121.198 0.523 . . . . 0.0 110.15 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -124.52 163.06 22.68 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.172 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 41.9 p-80 -87.41 170.76 11.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.217 -179.447 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.14 150.95 50.31 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.017 179.116 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -96.65 123.77 40.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.214 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -127.8 116.06 19.6 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -126.27 134.51 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.09 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -137.29 141.04 41.93 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 178.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -144.42 146.84 32.71 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.413 -179.649 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.52 119.71 21.92 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.144 0.497 . . . . 0.0 110.462 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 22' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' M' ' 24' ' ' VAL . 97.5 mt-10 -103.59 -162.71 0.93 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.544 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 23' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' M' ' 22' ' ' GLU . 96.9 m-20 -23.64 -59.69 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 123.222 0.609 . . . . 0.0 112.345 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.454 ' O ' ' O ' ' M' ' 22' ' ' GLU . 32.6 m -91.3 169.87 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -178.636 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.37 28.36 57.98 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 11.9 t -97.02 110.7 23.19 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 p30 -78.14 175.42 10.17 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -176.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -49.75 -36.23 25.07 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 112.507 -2.133 . . . . 0.0 115.074 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.94 78.63 0.06 OUTLIER Glycine 0 N--CA 1.471 1.012 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.643 -172.425 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.03 108.62 0.26 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-O 124.362 2.029 . . . . 0.0 113.306 -175.542 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.552 HG23 ' O ' ' M' ' 31' ' ' ILE . 15.1 tt -128.34 125.71 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 110.537 -3.028 . . . . 0.0 108.388 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 92.8 mt -102.64 108.88 25.12 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.527 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.92 92.82 0.67 Allowed Glycine 0 CA--C 1.508 -0.352 0 N-CA-C 105.44 -3.064 . . . . 0.0 105.44 176.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 34' ' ' LEU . . . . . 0.632 ' O ' HD23 ' N' ' 34' ' ' LEU . 92.8 mt -135.36 156.57 48.71 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 122.81 1.29 . . . . 0.0 113.861 -176.408 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -108.9 105.27 14.75 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 112.426 -2.17 . . . . 0.0 106.25 176.539 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.583 HG23 HD21 ' N' ' 34' ' ' LEU . 50.4 t -106.12 111.83 36.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.03 -132.12 8.74 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.418 ' O ' HG12 ' N' ' 39' ' ' VAL . . . 93.81 -63.19 1.87 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.621 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.67 HG12 ' CD1' ' A' ' 31' ' ' ILE . 1.2 m -111.14 161.3 9.74 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -178.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.949 -1.025 . . . . 0.0 110.764 -179.987 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -81.71 138.37 35.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.758 0.313 . . . . 0.0 110.27 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -76.45 116.33 17.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.692 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.438 HG12 ' H ' ' O' ' 12' ' ' VAL . 34.5 m -137.7 157.63 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.112 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 1.8 t60 -145.46 98.81 3.2 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.871 0.367 . . . . 0.0 111.311 179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.477 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 28.4 p-80 -153.98 168.12 27.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.338 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -129.45 150.35 50.84 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 110.064 178.105 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -98.15 124.0 42.49 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.282 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.4 ' C ' HD23 ' N' ' 17' ' ' LEU . 7.6 tt -125.84 124.45 40.93 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.483 0.583 . . . . 0.0 109.701 178.563 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -125.94 134.41 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.603 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 19' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' N' ' 21' ' ' ALA . 74.4 t80 -130.63 120.3 23.75 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.811 0.339 . . . . 0.0 111.051 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -112.36 127.77 56.1 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 21' ' ' ALA . . . . . 0.438 ' HB2' ' CE2' ' N' ' 19' ' ' PHE . . . -132.75 132.91 42.8 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-N 118.584 0.629 . . . . 0.0 111.958 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -170.09 128.44 0.89 Allowed 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.023 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.465 ' CG ' ' H ' ' N' ' 24' ' ' VAL . 16.6 p-10 -155.05 -59.81 0.11 Allowed 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 119.89 -0.724 . . . . 0.0 111.618 177.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.465 ' H ' ' CG ' ' N' ' 23' ' ' ASP . 16.9 m -102.87 -176.83 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.94 -33.69 70.5 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 1.5 m -147.86 118.87 7.66 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -59.9 169.06 1.56 Allowed 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 117.919 -1.512 . . . . 0.0 110.922 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -54.69 -36.96 65.23 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 115.305 1.594 . . . . 0.0 115.305 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.75 77.58 0.07 OUTLIER Glycine 0 CA--C 1.54 1.634 0 C-N-CA 120.123 -1.037 . . . . 0.0 113.429 -174.448 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.86 116.71 20.17 Favored 'General case' 0 CA--C 1.548 0.894 0 CA-C-N 118.866 1.333 . . . . 0.0 113.638 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.54 HG21 ' HB ' ' H' ' 39' ' ' VAL . 2.8 tt -146.08 134.09 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.125 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.51 HG22 HD11 ' O' ' 34' ' ' LEU . 15.8 mt -109.38 120.55 60.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 CA-C-O 120.971 0.415 . . . . 0.0 110.64 179.427 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.03 112.75 2.68 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 105.795 -2.922 . . . . 0.0 105.795 176.389 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.632 HD23 ' O ' ' M' ' 34' ' ' LEU . 0.3 OUTLIER -151.91 144.13 23.97 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 117.773 -1.571 . . . . 0.0 115.074 -175.206 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.406 ' SD ' ' HB2' ' O' ' 35' ' ' MET . 89.7 mmm -105.8 108.36 19.84 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.404 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . 2.0 t -106.9 101.79 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 118.878 0.763 . . . . 0.0 110.884 -177.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.09 -171.14 20.56 Favored Glycine 0 C--N 1.323 -0.173 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.488 ' O ' HG12 ' O' ' 39' ' ' VAL . . . 155.66 -55.04 0.41 Allowed Glycine 0 CA--C 1.547 2.036 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 -178.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.7 ' HB ' HD11 ' B' ' 31' ' ' ILE . 10.6 p -159.49 135.26 1.8 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 CA-C-N 117.628 0.714 . . . . 0.0 109.768 177.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.462 HG13 ' O ' ' N' ' 39' ' ' VAL . 22.6 m . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.225 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -82.05 137.84 34.97 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.821 0.343 . . . . 0.0 110.488 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -114.74 134.93 54.7 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.592 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.438 ' H ' HG12 ' N' ' 12' ' ' VAL . 75.3 t -122.45 130.25 74.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.856 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.503 ' H ' ' HB3' ' P' ' 13' ' ' HIS . 3.5 t-80 -146.58 102.74 3.6 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.574 0.226 . . . . 0.0 111.364 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' P' ' 14' ' ' HIS . 22.2 p80 -156.34 164.48 38.25 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.919 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -89.84 158.82 17.29 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -140.1 119.23 12.75 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -135.82 130.02 33.33 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 122.321 1.057 . . . . 0.0 111.777 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 18' ' ' VAL . . . . . 0.599 HG13 HG13 ' P' ' 18' ' ' VAL . 48.1 t -112.09 118.23 57.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 177.637 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -110.32 102.78 11.4 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 14.6 t80 -114.83 127.8 55.93 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.73 115.11 20.86 Favored 'General case' 0 C--O 1.243 0.742 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.457 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 22' ' ' GLU . . . . . 0.448 ' O ' ' C ' ' O' ' 23' ' ' ASP . 83.0 tt0 -86.7 151.28 23.55 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.142 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.448 ' C ' ' O ' ' O' ' 22' ' ' GLU . 49.0 t0 26.83 49.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.904 -176.154 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.656 HG11 ' HB1' ' P' ' 21' ' ' ALA . 1.1 p -68.75 154.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.013 -1.449 . . . . 0.0 108.179 175.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.424 ' N ' ' CG2' ' O' ' 24' ' ' VAL . . . -131.51 -28.81 0.61 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.667 ' OG ' ' HB2' ' O' ' 30' ' ' ALA . 3.3 t 63.69 -110.14 0.28 Allowed 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.53 178.66 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.559 ' N ' ' OG ' ' O' ' 26' ' ' SER . 32.9 m-20 150.51 -161.37 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.551 0 O-C-N 124.473 1.108 . . . . 0.0 109.153 -178.259 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.444 ' H ' ' HB3' ' O' ' 27' ' ' ASN . 98.8 mttt -29.71 -40.4 0.02 OUTLIER 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -179.013 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.489 ' O ' HG13 ' I' ' 39' ' ' VAL . . . -170.07 70.05 0.14 Allowed Glycine 0 CA--C 1.541 1.662 0 C-N-CA 118.489 -1.815 . . . . 0.0 115.908 -173.074 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 30' ' ' ALA . . . . . 0.667 ' HB2' ' OG ' ' O' ' 26' ' ' SER . . . -72.75 150.18 43.06 Favored 'General case' 0 C--N 1.363 1.175 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.423 HG22 ' N ' ' O' ' 32' ' ' ILE . 20.6 mt -140.69 149.85 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 118.076 2.621 . . . . 0.0 118.076 -171.525 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.722 HG23 HD13 ' O' ' 34' ' ' LEU . 6.7 mt -111.78 106.76 21.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 N-CA-C 104.871 -2.27 . . . . 0.0 104.871 173.152 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.799 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -117.43 98.5 0.78 Allowed Glycine 0 N--CA 1.473 1.15 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.799 HD12 ' C ' ' O' ' 33' ' ' GLY . 8.8 mp -136.67 151.92 49.82 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 123.698 1.713 . . . . 0.0 114.433 -175.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.406 ' HB2' ' SD ' ' N' ' 35' ' ' MET . 0.8 OUTLIER -113.15 112.04 23.13 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 111.947 -2.388 . . . . 0.0 106.019 176.483 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.09 147.69 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.229 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' O' O ' 37' ' ' GLY . . . . . 0.921 ' H ' HE22 ' Q' ' 15' ' ' GLN . . . 127.32 103.04 1.22 Allowed Glycine 0 C--N 1.307 -1.057 0 N-CA-C 109.384 -1.487 . . . . 0.0 109.384 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.525 ' O ' ' C ' ' O' ' 39' ' ' VAL . . . -108.47 72.42 0.2 Allowed Glycine 0 CA--C 1.533 1.179 0 CA-C-O 117.612 -1.66 . . . . 0.0 112.074 179.34 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.822 ' H ' HG21 ' P' ' 39' ' ' VAL . 7.6 p -12.86 130.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 CA-C-N 119.804 1.802 . . . . 0.0 113.325 -175.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.426 ' O ' HG23 ' O' ' 40' ' ' VAL . 5.6 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.375 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -104.09 132.13 50.66 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 11' ' ' GLU . . . . . 0.417 ' O ' ' NE2' ' Q' ' 13' ' ' HIS . 96.7 mt-10 -126.57 118.0 23.97 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.676 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.613 HG12 ' H ' ' Q' ' 12' ' ' VAL . 19.4 m -139.64 113.75 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.545 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.503 ' HB3' ' H ' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -135.44 140.24 44.74 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.449 -179.27 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' O' ' 14' ' ' HIS . 5.5 m-70 -125.42 161.17 27.66 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 178.074 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 27.2 tp60 -89.89 158.15 17.56 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 16' ' ' LYS . . . . . 0.781 ' C ' HD12 ' P' ' 17' ' ' LEU . 68.2 mttm -141.47 100.22 3.73 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.437 178.599 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.781 HD12 ' C ' ' P' ' 16' ' ' LYS . 9.0 mp -134.5 122.8 22.95 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 176.394 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 18' ' ' VAL . . . . . 0.599 HG13 HG13 ' O' ' 18' ' ' VAL . 3.8 p -122.4 127.39 75.08 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -115.87 106.25 13.61 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 30.5 t80 -110.97 125.67 53.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.156 -178.527 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 21' ' ' ALA . . . . . 0.656 ' HB1' HG11 ' O' ' 24' ' ' VAL . . . -138.41 122.74 18.25 Favored 'General case' 0 CA--C 1.553 1.064 0 CA-C-O 121.751 0.786 . . . . 0.0 112.615 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.578 ' O ' HG13 ' O' ' 24' ' ' VAL . 83.1 tt0 -87.42 116.66 25.68 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.408 -1.269 . . . . 0.0 110.926 179.018 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.565 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 34.2 m-20 -144.81 46.73 1.35 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.051 0.54 . . . . 0.0 112.053 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.85 HG13 ' CD ' ' Q' ' 22' ' ' GLU . 1.0 OUTLIER -82.14 173.37 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 123.229 1.49 . . . . 0.0 113.237 -175.594 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.42 -33.66 4.84 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-N 111.286 -2.688 . . . . 0.0 113.992 177.054 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.712 ' O ' ' O ' ' P' ' 27' ' ' ASN . 13.3 t -174.16 126.61 0.35 Allowed 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 118.974 1.387 . . . . 0.0 112.819 175.672 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.712 ' O ' ' O ' ' P' ' 26' ' ' SER . 1.0 OUTLIER -2.69 145.94 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 173.751 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.435 ' CG ' ' O ' ' P' ' 27' ' ' ASN . 93.1 mttt -158.48 30.34 0.23 Allowed 'General case' 0 N--CA 1.475 0.806 0 O-C-N 120.69 -1.256 . . . . 0.0 114.033 176.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.31 88.81 0.9 Allowed Glycine 0 CA--C 1.531 1.065 0 C-N-CA 119.503 -1.332 . . . . 0.0 113.727 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.88 105.54 7.83 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 117.871 0.836 . . . . 0.0 112.047 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.643 HD11 ' HB ' ' J' ' 39' ' ' VAL . 58.4 mt -119.21 124.25 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 CA-C-O 119.27 -0.395 . . . . 0.0 110.056 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.468 HD13 ' CD1' ' R' ' 19' ' ' PHE . 49.9 mt -109.91 110.55 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.802 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.56 100.06 1.04 Allowed Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 104.588 -3.405 . . . . 0.0 104.588 175.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 tt -144.63 137.37 26.63 Favored 'General case' 0 C--O 1.241 0.635 0 C-N-CA 118.681 -1.207 . . . . 0.0 112.883 -174.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 22.1 mtp -112.27 127.73 56.06 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 113.837 -1.529 . . . . 0.0 110.512 179.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.505 HG11 HD13 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -117.74 103.18 14.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.22 -153.48 25.09 Favored Glycine 0 C--N 1.308 -0.983 0 C-N-CA 119.276 -1.44 . . . . 0.0 111.191 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.702 ' H ' ' CG1' ' Q' ' 40' ' ' VAL . . . 99.16 -56.45 0.92 Allowed Glycine 0 CA--C 1.543 1.795 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.902 HG12 HG21 ' D' ' 31' ' ' ILE . 27.7 m -128.88 160.2 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.73 0.812 . . . . 0.0 112.265 -177.602 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.415 ' H ' HG23 ' P' ' 40' ' ' VAL . 2.8 t . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.719 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.79 90.13 3.24 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -142.77 147.97 36.42 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.766 0.317 . . . . 0.0 110.596 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.613 ' H ' HG12 ' P' ' 12' ' ' VAL . 2.2 p -140.87 135.86 33.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.658 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.417 ' NE2' ' O ' ' P' ' 11' ' ' GLU . 4.6 m80 -142.63 125.0 15.57 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.651 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.415 ' CB ' ' O ' ' R' ' 14' ' ' HIS . 10.2 p80 -152.61 160.42 43.19 Favored 'General case' 0 C--O 1.222 -0.368 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.645 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.921 HE22 ' H ' ' O' ' 37' ' ' GLY . 88.3 mt-30 -90.03 158.92 17.12 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 176.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -140.73 108.35 5.61 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.074 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.424 ' N ' HD12 ' Q' ' 17' ' ' LEU . 3.8 mp -130.97 124.13 30.32 Favored 'General case' 0 CA--C 1.511 -0.52 0 C-N-CA 119.962 -0.695 . . . . 0.0 109.726 177.083 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -110.1 122.34 64.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.519 ' CE2' ' CE1' ' R' ' 19' ' ' PHE . 24.0 m-85 -112.03 99.9 8.45 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 178.647 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -108.96 121.2 44.63 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.422 -177.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.568 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -152.76 161.12 42.98 Favored 'General case' 0 C--O 1.217 -0.625 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.628 -179.017 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.85 ' CD ' HG13 ' P' ' 24' ' ' VAL . 99.6 mt-10 -87.55 114.52 24.23 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.781 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 68.4 t0 -109.23 52.0 0.73 Allowed 'General case' 0 N--CA 1.478 0.949 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.071 -177.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.559 HG12 ' N ' ' Q' ' 25' ' ' GLY . 38.5 t -41.43 161.38 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.983 0.897 . . . . 0.0 112.247 -176.15 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.559 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . -93.14 32.59 5.58 Favored Glycine 0 N--CA 1.468 0.798 0 CA-C-N 113.848 -1.524 . . . . 0.0 114.273 -174.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 69.5 m -92.62 -112.38 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 117.593 0.696 . . . . 0.0 109.936 -178.233 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.502 ' O ' ' N ' ' Q' ' 29' ' ' GLY . 84.1 m-20 -85.97 179.18 7.05 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 119.853 1.206 . . . . 0.0 112.91 -176.674 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -52.58 48.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -98.56 56.57 1.01 Allowed Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.164 -1.017 . . . . 0.0 112.936 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.63 103.49 0.7 Allowed 'General case' 0 C--O 1.24 0.56 0 CA-C-N 119.013 1.406 . . . . 0.0 112.921 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.418 HD13 HG21 ' Q' ' 31' ' ' ILE . 1.1 pt -142.69 139.82 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 120.099 -0.64 . . . . 0.0 109.601 177.242 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 4.8 tt -140.23 132.71 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 105.66 1.47 Allowed Glycine 0 C--N 1.337 0.589 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 176.096 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.506 HD23 HD13 ' R' ' 34' ' ' LEU . 53.0 tp -120.47 122.6 41.03 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.642 0.734 . . . . 0.0 112.201 -176.257 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -111.78 115.67 29.44 Favored 'General case' 0 C--O 1.223 -0.301 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.558 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.619 HG12 ' N ' ' Q' ' 37' ' ' GLY . 81.9 t -108.17 171.03 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-O 121.414 0.626 . . . . 0.0 111.26 -178.902 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.619 ' N ' HG12 ' Q' ' 36' ' ' VAL . . . 130.34 93.44 0.66 Allowed Glycine 0 C--N 1.311 -0.835 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.29 -74.46 0.26 Allowed Glycine 0 CA--C 1.534 1.235 0 C-N-CA 121.287 -0.483 . . . . 0.0 112.236 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.586 ' O ' HG23 ' Q' ' 39' ' ' VAL . 34.6 m -81.71 118.19 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.341 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.702 ' CG1' ' H ' ' P' ' 38' ' ' GLY . 3.1 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.414 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -126.78 154.62 44.01 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.915 0.388 . . . . 0.0 110.544 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -68.43 125.42 26.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.583 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 9.2 p -139.97 138.85 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.286 0.565 . . . . 0.0 111.373 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -149.26 105.22 3.47 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.552 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.415 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 93.4 m-70 -145.95 166.47 25.92 Favored 'General case' 0 C--O 1.221 -0.441 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.19 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.608 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -89.73 158.68 17.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.134 0.492 . . . . 0.0 110.66 -179.546 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.778 ' C ' HD12 ' R' ' 17' ' ' LEU . 98.6 mttt -140.22 103.02 4.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.56 -0.745 . . . . 0.0 109.438 178.483 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.778 HD12 ' C ' ' R' ' 16' ' ' LYS . 10.8 mp -124.99 120.85 32.72 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 95.5 t -105.22 116.62 49.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.519 ' CE1' ' CE2' ' Q' ' 19' ' ' PHE . 78.2 m-85 -111.89 103.7 11.95 Favored 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.279 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -140.17 150.65 44.47 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-O 121.804 0.812 . . . . 0.0 111.594 -177.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -139.31 143.48 37.88 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.067 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -82.7 157.62 23.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.513 -178.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 58.69 50.45 8.87 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.773 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.525 HG12 ' N ' ' R' ' 25' ' ' GLY . 24.9 t -48.9 163.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.134 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.525 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -175.76 24.0 0.06 OUTLIER Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -178.4 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 4.3 m -64.94 111.68 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.776 0.798 . . . . 0.0 110.566 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.702 ' O ' ' N ' ' R' ' 29' ' ' GLY . 24.7 t-20 -149.09 176.0 10.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.956 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 28' ' ' LYS . . . . . 0.455 ' C ' ' O ' ' R' ' 27' ' ' ASN . 65.5 tttm -8.95 -45.91 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.952 0 O-C-N 124.401 1.063 . . . . 0.0 113.559 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.702 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -94.49 58.74 1.92 Allowed Glycine 0 CA--C 1.544 1.847 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.823 179.468 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 136.91 9.85 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.433 HD12 HG21 ' K' ' 39' ' ' VAL . 50.5 mt -124.77 119.5 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 CA-C-O 121.627 0.727 . . . . 0.0 111.644 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 mm -113.36 121.84 66.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.782 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 115.98 2.26 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.54 HD12 ' N ' ' R' ' 35' ' ' MET . 7.3 tp -137.03 125.38 23.33 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 35' ' ' MET . . . . . 0.54 ' N ' HD12 ' R' ' 34' ' ' LEU . 9.8 ptm -160.89 172.94 16.07 Favored 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.366 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -124.72 167.33 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-O 121.327 0.584 . . . . 0.0 111.529 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.57 -102.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 114.986 -1.006 . . . . 0.0 111.103 179.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.02 -77.87 1.09 Allowed Glycine 0 CA--C 1.532 1.137 0 N-CA-C 111.559 -0.617 . . . . 0.0 111.559 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 79.3 t -121.3 132.37 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 117.17 0.485 . . . . 0.0 110.401 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.467 HG22 ' OXT' ' R' ' 40' ' ' VAL . 4.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.325 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 78.3 t80 -80.65 129.97 34.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.738 0.304 . . . . 0.0 110.327 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -132.95 147.89 52.28 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.754 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.607 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 53.0 t -124.89 131.33 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.144 0.497 . . . . 0.0 110.25 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -93.94 163.06 13.65 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.436 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.643 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -86.0 171.94 11.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.708 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 28.5 pt20 -158.09 142.96 16.44 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.571 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -80.24 133.95 36.05 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.895 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.6 mt -129.29 116.31 18.92 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.971 0.415 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -125.43 133.75 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.954 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -134.94 129.0 33.58 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 53.6 p90 -122.62 130.47 53.03 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.408 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.28 114.99 21.57 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.455 0.645 . . . . 0.0 111.339 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.442 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 74.9 mt-10 -154.92 152.73 30.08 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 22' ' ' GLU . 3.9 p-10 45.21 46.46 9.89 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.461 179.238 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -80.42 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.77 -177.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.3 -33.5 64.54 Favored Glycine 0 CA--C 1.526 0.767 0 CA-C-N 115.287 -0.87 . . . . 0.0 113.143 -177.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.589 ' O ' ' O ' ' A' ' 27' ' ' ASN . 89.6 p -162.38 120.24 2.13 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.98 0.89 . . . . 0.0 111.912 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.589 ' O ' ' O ' ' A' ' 26' ' ' SER . 65.4 t30 -22.51 163.21 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 114.006 -1.452 . . . . 0.0 114.439 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.403 ' H ' ' H ' ' A' ' 29' ' ' GLY . 98.3 mttt -156.27 -18.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.24 -1.346 . . . . 0.0 107.817 178.032 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.504 ' HA3' ' H ' ' B' ' 28' ' ' LYS . . . 71.83 -98.47 0.78 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.46 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.79 88.54 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.075 179.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.5 mt -138.12 117.24 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.493 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' B' ' 33' ' ' GLY . 39.7 mt -108.91 112.49 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 93.93 0.64 Allowed Glycine 0 CA--C 1.507 -0.444 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.417 HD12 ' CG2' ' A' ' 32' ' ' ILE . 91.8 mt -140.78 165.0 28.7 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 123.335 1.541 . . . . 0.0 114.289 -175.586 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 38.5 tpp -120.9 107.81 13.14 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 111.999 -2.364 . . . . 0.0 106.786 177.626 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.413 ' HB ' HD21 ' B' ' 34' ' ' LEU . 63.6 t -110.84 124.0 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.9 -114.46 2.73 Favored Glycine 0 C--N 1.318 -0.461 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 -176.49 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.34 -71.92 1.48 Allowed Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.153 -1.022 . . . . 0.0 111.353 178.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.464 ' HA ' ' CD1' ' G' ' 31' ' ' ILE . 34.2 m -111.33 -175.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.714 0.769 . . . . 0.0 111.5 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.546 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.6 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-N 114.247 -1.342 . . . . 0.0 110.309 178.443 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -147.44 158.0 43.8 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.441 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.55 120.7 12.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 121.081 0.467 . . . . 0.0 110.623 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.49 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 16.0 t -130.1 117.39 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.607 ' CE1' ' H ' ' A' ' 12' ' ' VAL . 3.7 m-70 -137.68 112.27 8.79 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.445 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.563 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -151.96 160.13 43.58 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.332 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 78.7 mt-30 -131.95 151.36 51.77 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.983 0.42 . . . . 0.0 111.949 179.069 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -97.76 121.33 39.55 Favored 'General case' 0 C--O 1.238 0.485 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.3 mt -120.93 119.25 32.06 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 118.58 0.627 . . . . 0.0 110.301 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.43 132.43 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.873 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -125.88 124.0 39.89 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.112 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.466 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 34.2 t80 -117.91 126.47 52.42 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.36 141.69 33.81 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -104.36 147.7 27.23 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.14 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 3.4 t70 -171.9 51.89 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.023 -177.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.483 HG22 ' CB ' ' C' ' 23' ' ' ASP . 2.6 t -75.51 143.64 12.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-O 121.726 0.774 . . . . 0.0 111.714 -176.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.06 38.18 3.9 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 114.405 -1.27 . . . . 0.0 112.332 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.09 120.0 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 122.192 0.197 . . . . 0.0 110.904 177.541 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.554 ' H ' ' HA3' ' C' ' 25' ' ' GLY . 2.1 m120 -83.38 162.6 20.99 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.373 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.504 ' H ' ' HA3' ' A' ' 29' ' ' GLY . 99.1 mttt -47.24 -37.61 10.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.459 0.647 . . . . 0.0 110.782 175.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.68 0.06 OUTLIER Glycine 0 CA--C 1.54 1.596 0 CA-C-N 115.217 -0.902 . . . . 0.0 111.898 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -51.78 94.87 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 119.634 1.717 . . . . 0.0 112.204 -178.141 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.52 HD12 HG12 ' N' ' 39' ' ' VAL . 69.3 mt -144.62 134.77 19.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.432 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' D' ' 19' ' ' PHE . 91.6 mt -105.08 108.3 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.098 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -112.31 102.55 1.36 Allowed Glycine 0 CA--C 1.508 -0.37 0 N-CA-C 105.539 -3.024 . . . . 0.0 105.539 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.651 ' O ' HD12 ' C' ' 34' ' ' LEU . 7.6 tt -150.62 148.38 28.55 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 118.42 -1.312 . . . . 0.0 112.226 -174.822 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.623 ' N ' HD23 ' B' ' 34' ' ' LEU . 7.2 mtp -110.05 110.09 20.87 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 113.518 -1.674 . . . . 0.0 107.075 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.53 ' O ' HG13 ' B' ' 36' ' ' VAL . 4.1 p -119.62 111.51 33.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.35 -131.24 4.28 Favored Glycine 0 C--N 1.308 -1.007 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -178.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.499 ' O ' ' CG2' ' C' ' 39' ' ' VAL . . . 87.27 -63.93 3.89 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 120.508 -0.853 . . . . 0.0 111.542 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.545 HG11 HD13 ' G' ' 31' ' ' ILE . 3.1 m -136.78 154.17 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.429 ' H ' HG23 ' B' ' 40' ' ' VAL . 0.5 OUTLIER . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.338 -178.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 10' ' ' TYR . . . . . 0.723 ' HH ' ' N ' ' E' ' 9' ' ' GLY . 92.9 m-85 -105.35 133.13 50.62 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.631 0.253 . . . . 0.0 110.384 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -97.65 122.74 41.08 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.651 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.431 ' H ' HG13 ' B' ' 12' ' ' VAL . 19.4 m -125.4 133.07 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.159 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.546 ' CE1' ' OXT' ' A' ' 40' ' ' VAL . 5.6 t-80 -147.85 96.79 2.71 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.896 179.203 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.563 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 50.1 p-80 -157.24 167.57 29.96 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.738 -0.21 . . . . 0.0 111.265 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -89.99 158.45 17.36 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.437 0.637 . . . . 0.0 110.788 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -140.29 113.51 8.43 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 176.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mt -127.94 123.15 34.18 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 122.071 0.938 . . . . 0.0 111.478 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 67.1 t -111.14 117.03 54.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 177.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.432 ' CD2' ' CE2' ' D' ' 19' ' ' PHE . 56.2 m-85 -107.08 105.85 16.07 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 11.7 t80 -113.84 124.41 52.16 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.7 -0.227 . . . . 0.0 111.152 -178.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.66 122.34 30.6 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.647 0.736 . . . . 0.0 110.396 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -94.31 137.99 32.83 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.217 -178.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.516 ' N ' ' OE1' ' D' ' 22' ' ' GLU . 8.7 m-20 43.17 47.12 5.3 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.41 0.624 . . . . 0.0 109.354 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.648 ' O ' HG21 ' D' ' 24' ' ' VAL . 0.2 OUTLIER -61.43 -169.25 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.799 -177.195 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.579 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -111.74 33.34 5.83 Favored Glycine 0 C--N 1.318 -0.427 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.098 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.43 ' O ' ' N ' ' D' ' 26' ' ' SER . 27.3 t -62.63 104.87 0.57 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.497 0.665 . . . . 0.0 109.221 -178.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.857 ' O ' ' N ' ' C' ' 29' ' ' GLY . 7.8 m120 -157.6 179.23 9.42 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.616 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm 1.86 -44.7 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 125.067 1.48 . . . . 0.0 114.212 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.857 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -111.14 58.57 0.39 Allowed Glycine 0 CA--C 1.542 1.764 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 178.578 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.423 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -109.35 99.75 8.95 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 117.349 0.575 . . . . 0.0 109.973 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.426 HG22 ' N ' ' D' ' 31' ' ' ILE . 29.7 pt -147.93 156.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 117.88 -1.528 . . . . 0.0 114.385 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' E' ' 19' ' ' PHE . 95.9 mt -107.6 112.15 38.84 Favored 'Isoleucine or valine' 0 C--N 1.345 0.376 0 CA-C-N 114.053 -1.431 . . . . 0.0 108.695 176.35 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.91 93.76 0.74 Allowed Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 104.412 -3.475 . . . . 0.0 104.412 175.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.651 HD12 ' O ' ' B' ' 34' ' ' LEU . 42.3 tp -135.0 132.57 38.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 122.365 1.079 . . . . 0.0 113.294 -174.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.417 ' H ' HD12 ' C' ' 34' ' ' LEU . 6.4 mtp -99.99 111.33 23.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.673 177.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.532 HG12 ' CD ' ' E' ' 15' ' ' GLN . 3.1 t -110.8 103.32 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.13 -154.62 22.93 Favored Glycine 0 N--CA 1.46 0.254 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.673 178.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.21 -55.89 0.5 Allowed Glycine 0 CA--C 1.545 1.936 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.882 ' C ' HG11 ' D' ' 39' ' ' VAL . 68.6 t -136.04 162.97 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 C-N-CA 123.273 0.629 . . . . 0.0 110.167 178.23 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.676 ' N ' HG21 ' D' ' 39' ' ' VAL . 75.9 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.889 -1.053 . . . . 0.0 111.056 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.175 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -106.81 134.53 49.81 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -127.6 128.64 45.91 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 121.126 0.489 . . . . 0.0 111.195 -179.406 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 1.3 p -145.14 112.62 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.684 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.24 142.65 31.45 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.074 0.464 . . . . 0.0 110.228 179.089 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.554 ' O ' ' CG ' ' C' ' 14' ' ' HIS . 27.7 p-80 -146.12 162.6 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.114 178.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -89.67 158.19 17.68 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.311 179.423 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.675 ' C ' HD22 ' D' ' 17' ' ' LEU . 85.6 tttt -140.68 106.28 5.1 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.719 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.7 mm? -123.37 124.95 44.08 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.849 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -123.11 112.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' B' ' 32' ' ' ILE . 27.1 m-85 -108.77 103.79 12.94 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 179.452 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.4 t80 -111.71 124.72 52.91 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.89 141.41 38.56 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.443 1.116 . . . . 0.0 112.923 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.536 ' O ' HG23 ' D' ' 24' ' ' VAL . 84.2 mt-10 -75.85 118.32 18.52 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.065 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' HG13 ' E' ' 24' ' ' VAL . 13.6 t0 -57.15 59.77 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.591 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.648 HG21 ' O ' ' C' ' 24' ' ' VAL . 43.3 t -63.05 -113.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.419 ' N ' HG12 ' D' ' 24' ' ' VAL . . . -104.4 44.37 1.49 Allowed Glycine 0 N--CA 1.478 1.489 0 CA-C-N 121.446 1.93 . . . . 0.0 111.973 -174.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.608 ' O ' ' ND2' ' E' ' 27' ' ' ASN . 1.3 t -70.64 100.51 1.86 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 112.938 -1.631 . . . . 0.0 107.879 175.323 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -118.62 -153.18 0.53 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.389 0.614 . . . . 0.0 112.564 -174.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -37.58 -41.86 0.5 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.704 -177.302 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.07 68.39 1.96 Allowed Glycine 0 CA--C 1.537 1.417 0 C-N-CA 120.374 -0.917 . . . . 0.0 111.771 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.85 136.4 32.33 Favored 'General case' 0 C--N 1.349 0.555 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.598 HD11 ' O ' ' P' ' 39' ' ' VAL . 39.7 mt -145.53 146.7 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 N-CA-C 115.398 1.629 . . . . 0.0 115.398 -175.135 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.463 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -108.46 111.58 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.494 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.15 102.48 0.8 Allowed Glycine 0 N--CA 1.463 0.497 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.415 ' CD2' ' CZ ' ' E' ' 19' ' ' PHE . 2.9 mp -137.16 135.23 37.17 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 122.424 1.107 . . . . 0.0 113.652 -178.166 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -98.91 113.51 25.69 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.355 177.412 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' E' ' 35' ' ' MET . 2.9 t -118.92 103.22 14.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -177.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.481 ' CA ' ' H ' ' E' ' 38' ' ' GLY . . . 147.25 -153.62 25.45 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.928 -1.129 . . . . 0.0 110.54 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' E' ' 40' ' ' VAL . . . 104.45 -56.33 0.56 Allowed Glycine 0 CA--C 1.541 1.675 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.882 HG11 ' C ' ' C' ' 39' ' ' VAL . 7.3 p -119.98 140.9 42.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 CA-C-O 121.361 0.601 . . . . 0.0 111.526 -178.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.454 ' O ' HG13 ' D' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.614 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 9' ' ' GLY . . . . . 0.723 ' N ' ' HH ' ' C' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -115.75 136.48 53.01 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 120.627 0.251 . . . . 0.0 110.539 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.19 142.57 45.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.259 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 79.4 t -127.16 133.33 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 CA-C-O 120.785 0.326 . . . . 0.0 111.246 -179.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 m170 -137.81 100.0 4.06 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.422 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.0 OUTLIER -151.56 165.6 33.77 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 121.594 0.711 . . . . 0.0 112.801 -179.593 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.532 ' CD ' HG12 ' C' ' 36' ' ' VAL . 87.2 mt-30 -84.35 157.12 21.57 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.324 178.829 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -159.28 103.1 1.61 Allowed 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.451 HD12 ' N ' ' E' ' 17' ' ' LEU . 3.5 mp -137.43 131.45 31.98 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.387 0.613 . . . . 0.0 111.786 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -117.59 112.28 38.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.534 ' CD2' HD13 ' C' ' 32' ' ' ILE . 27.4 m-85 -106.07 105.83 16.06 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 178.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -116.68 117.64 30.37 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.25 123.12 31.13 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.441 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 78.0 tt0 -154.11 154.21 33.22 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 117.9 2.555 . . . . 0.0 117.9 -175.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.454 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 52.6 m-20 109.72 46.5 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 111.646 -2.525 . . . . 0.0 116.372 174.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.459 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 1.8 m -118.15 174.64 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.788 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -59.88 -28.25 65.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 107.868 -2.093 . . . . 0.0 107.868 172.463 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.483 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 3.7 p 143.0 129.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 112.524 -1.838 . . . . 0.0 106.209 -177.087 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.608 ' ND2' ' O ' ' D' ' 26' ' ' SER . 18.0 t-20 -53.59 141.57 25.37 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.886 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -58.37 -48.81 79.41 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -179.248 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -170.23 59.27 0.19 Allowed Glycine 0 CA--C 1.54 1.629 0 C-N-CA 120.246 -0.978 . . . . 0.0 114.368 -175.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.65 169.17 16.54 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 119.124 1.462 . . . . 0.0 113.132 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.507 HD11 HG12 ' Q' ' 39' ' ' VAL . 77.5 mt -120.97 137.47 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 113.784 -1.553 . . . . 0.0 110.301 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -121.11 121.75 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.79 114.5 2.0 Favored Glycine 0 N--CA 1.471 0.981 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.623 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 59.4 mt -127.81 124.28 37.23 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 111.088 -178.583 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.441 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.0 mtp -108.22 111.77 23.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.245 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.636 HG12 ' N ' ' E' ' 37' ' ' GLY . 40.2 t -90.28 173.79 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.636 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 162.16 -95.52 0.13 Allowed Glycine 0 C--N 1.305 -1.175 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.096 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.481 ' H ' ' CA ' ' D' ' 37' ' ' GLY . . . 87.73 -83.69 1.53 Allowed Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.629 HG13 HD11 ' K' ' 31' ' ' ILE . 55.3 t -67.57 97.26 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 176.56 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.494 ' C ' HG21 ' K' ' 31' ' ' ILE . 80.2 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.517 -179.093 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -114.74 139.57 49.58 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.022 0.439 . . . . 0.0 110.712 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' F' ' 11' ' ' GLU . 57.9 mp0 -126.03 146.56 49.84 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.661 179.709 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.575 ' C ' ' CD2' ' F' ' 13' ' ' HIS . 3.7 p -128.67 135.05 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.351 0.596 . . . . 0.0 111.409 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.793 ' CD2' ' N ' ' F' ' 13' ' ' HIS . 0.1 OUTLIER -142.19 131.98 24.22 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.492 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 32.1 t-80 -155.15 167.81 29.12 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 28.5 mp0 -89.51 150.34 22.5 Favored 'General case' 0 CA--C 1.517 -0.298 0 C-N-CA 120.531 -0.468 . . . . 0.0 109.87 179.088 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -151.99 97.26 2.31 Favored 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.431 ' CD1' HG11 ' D' ' 36' ' ' VAL . 3.9 mp -133.83 116.25 15.45 Favored 'General case' 0 CA--C 1.506 -0.715 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.705 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -99.99 109.49 24.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.623 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 65.1 m-85 -104.89 98.92 8.57 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -112.83 111.43 22.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.338 0.589 . . . . 0.0 109.476 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.43 131.33 38.03 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' N ' ' E' ' 24' ' ' VAL . 84.6 tt0 -69.52 115.59 8.95 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 118.441 -1.304 . . . . 0.0 109.479 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.443 ' OD2' ' O ' ' F' ' 23' ' ' ASP . 18.9 t70 -167.8 51.79 0.06 Allowed 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.64 -178.202 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 75.5 t -75.38 142.96 13.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.36 38.03 3.63 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 5.1 m -70.68 102.18 2.23 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.575 0.702 . . . . 0.0 110.871 -178.325 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 42.4 p30 -119.51 -170.25 1.91 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.995 -178.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -33.89 -41.85 0.11 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.566 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.59 67.22 2.51 Favored Glycine 0 CA--C 1.542 1.746 0 CA-C-N 116.347 -0.388 . . . . 0.0 112.34 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . 171.27 139.01 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.508 HD13 ' HA ' ' R' ' 39' ' ' VAL . 86.2 mt -132.78 142.84 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 119.786 -0.765 . . . . 0.0 113.002 -177.946 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -131.57 128.91 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.774 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.14 131.34 5.66 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.486 HD23 ' C ' ' F' ' 34' ' ' LEU . 7.7 tt -135.89 127.46 28.83 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.454 ' N ' HD23 ' F' ' 34' ' ' LEU . 92.8 mtp -140.2 149.7 43.25 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -178.305 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -92.91 154.77 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.614 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.93 102.59 2.94 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.19 -73.64 0.0 OUTLIER Glycine 0 CA--C 1.537 1.417 0 CA-C-N 115.41 -0.395 . . . . 0.0 113.139 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.548 ' N ' ' O ' ' F' ' 37' ' ' GLY . 90.4 t -151.32 136.55 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 117.848 0.824 . . . . 0.0 110.255 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.422 HG12 ' H ' ' F' ' 40' ' ' VAL . 5.8 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.565 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -112.42 134.17 54.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.285 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 11' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' H' ' 11' ' ' GLU . 96.3 mt-10 -83.12 123.77 29.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.188 0.518 . . . . 0.0 110.894 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.406 HG22 ' CE1' ' H' ' 13' ' ' HIS . 62.0 t -134.52 137.08 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.869 -179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.474 ' O ' ' O ' ' H' ' 13' ' ' HIS . 98.3 m-70 -135.14 101.77 4.97 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.864 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' N ' ' G' ' 15' ' ' GLN . 6.6 t-80 -157.2 161.63 39.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.228 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.553 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 13.2 pt20 -174.3 147.86 1.22 Allowed 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.102 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 pttt -79.51 121.8 25.66 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.207 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.498 HD11 ' NE2' ' G' ' 15' ' ' GLN . 96.3 mt -131.75 116.42 17.25 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -126.69 136.22 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.129 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.538 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 68.1 m-85 -135.1 125.88 27.29 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.357 0.599 . . . . 0.0 111.086 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.493 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -115.11 129.62 56.72 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.466 ' CB ' HG11 ' G' ' 24' ' ' VAL . . . -126.43 124.33 39.91 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -177.29 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -137.21 115.27 11.57 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.532 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 63.7 t0 50.25 49.91 19.65 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.666 0.746 . . . . 0.0 109.046 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.466 HG11 ' CB ' ' G' ' 21' ' ' ALA . 29.5 m -82.11 -142.47 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.094 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.411 ' H ' ' HB ' ' G' ' 24' ' ' VAL . . . -91.94 -38.38 5.77 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -178.37 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 2.3 m -69.13 113.89 6.91 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -117.86 -150.42 0.46 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 112.608 -2.087 . . . . 0.0 112.439 -173.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.642 ' O ' ' N ' ' H' ' 28' ' ' LYS . 99.2 mttt -37.68 -40.76 0.44 Allowed 'General case' 0 C--O 1.214 -0.775 0 CA-C-N 113.534 -1.667 . . . . 0.0 111.227 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.78 68.8 0.21 Allowed Glycine 0 CA--C 1.545 1.943 0 O-C-N 121.653 -0.654 . . . . 0.0 112.552 -176.326 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.595 ' HB3' ' HB3' ' H' ' 27' ' ' ASN . . . -96.7 113.24 24.78 Favored 'General case' 0 C--N 1.368 1.376 0 CA-C-O 124.124 1.916 . . . . 0.0 111.287 -179.161 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.545 HD13 HG11 ' B' ' 39' ' ' VAL . 38.1 mt -129.16 131.8 67.53 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 110.337 -3.119 . . . . 0.0 108.843 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.514 HG22 HD21 ' H' ' 34' ' ' LEU . 31.8 mt -103.32 106.39 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.538 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.34 94.95 0.79 Allowed Glycine 0 CA--C 1.504 -0.613 0 N-CA-C 106.185 -2.766 . . . . 0.0 106.185 177.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.421 ' H ' HD23 ' H' ' 34' ' ' LEU . 58.3 mt -144.38 156.1 44.07 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 123.162 1.458 . . . . 0.0 112.813 -177.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.2 mtp -105.22 113.22 26.68 Favored 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 111.983 -2.371 . . . . 0.0 106.001 176.204 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.481 HG11 HD11 ' J' ' 17' ' ' LEU . 48.4 t -109.04 102.33 13.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.63 -162.5 47.7 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.12 -55.67 0.52 Allowed Glycine 0 CA--C 1.532 1.138 0 CA-C-O 118.82 -0.989 . . . . 0.0 111.919 179.114 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.505 HG12 ' CD1' ' M' ' 31' ' ' ILE . 1.6 m -70.48 176.86 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.428 0 CA-C-N 118.27 1.035 . . . . 0.0 109.499 177.017 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' G' ' 39' ' ' VAL . 7.1 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.879 -1.058 . . . . 0.0 111.587 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.93 133.17 50.18 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' G' ' 11' ' ' GLU . 97.3 mt-10 -83.41 141.49 31.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.941 0.4 . . . . 0.0 110.959 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.609 HG11 ' ND1' ' I' ' 13' ' ' HIS . 71.0 t -143.01 161.75 17.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.526 ' N ' HG12 ' H' ' 12' ' ' VAL . 44.5 m80 -135.21 159.14 42.49 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 179.317 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 42.8 p-80 -85.61 166.19 16.42 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.805 -179.099 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -100.39 152.72 20.02 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.618 ' C ' HD12 ' H' ' 17' ' ' LEU . 88.6 tttt -109.31 109.95 20.99 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.618 HD12 ' C ' ' H' ' 16' ' ' LYS . 11.1 mp -119.01 122.86 43.14 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.853 179.535 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -124.21 126.74 72.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.415 179.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' CD1' ' G' ' 19' ' ' PHE . 34.2 m-85 -133.89 126.14 29.81 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.812 -0.811 . . . . 0.0 108.812 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.457 ' CZ ' ' CB ' ' G' ' 20' ' ' PHE . 24.3 p90 -143.44 151.39 40.29 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 119.31 -0.956 . . . . 0.0 111.676 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.31 130.02 51.16 Favored 'General case' 0 C--O 1.251 1.171 0 CA-C-O 121.926 0.87 . . . . 0.0 111.467 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -60.98 -166.13 0.01 OUTLIER 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.879 -1.51 . . . . 0.0 107.757 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.572 ' OD1' HG22 ' I' ' 24' ' ' VAL . 33.2 t70 -84.22 57.65 4.35 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 116.669 -2.012 . . . . 0.0 115.41 -175.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.961 HG22 ' H ' ' H' ' 25' ' ' GLY . 1.3 p -68.64 -112.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.271 1 N-CA-C 100.069 -4.048 . . . . 0.0 100.069 166.451 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.961 ' H ' HG22 ' H' ' 24' ' ' VAL . . . 124.41 -39.39 2.14 Favored Glycine 0 C--N 1.331 0.283 0 N-CA-C 117.985 1.954 . . . . 0.0 117.985 167.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.23 110.5 5.25 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 115.632 -2.427 . . . . 0.0 112.968 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 1.093 ' O ' ' N ' ' H' ' 29' ' ' GLY . 0.0 OUTLIER -122.7 156.97 33.29 Favored 'General case' 0 C--O 1.207 -1.145 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 167.314 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.642 ' N ' ' O ' ' G' ' 28' ' ' LYS . 13.1 tttt -34.51 49.15 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 122.721 2.509 . . . . 0.0 111.16 172.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 1.093 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 101.26 -52.22 0.9 Allowed Glycine 0 CA--C 1.563 3.044 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -177.393 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' I' ' 30' ' ' ALA . . . 129.35 115.38 0.0 OUTLIER 'General case' 0 C--N 1.377 1.799 0 C-N-CA 125.946 1.698 . . . . 0.0 107.977 177.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.46 HD13 HG12 ' B' ' 39' ' ' VAL . 72.2 mt -126.54 128.13 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 CA-C-N 122.056 2.207 . . . . 0.0 114.793 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -111.67 110.51 32.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 175.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -116.46 105.4 1.35 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.215 -2.354 . . . . 0.0 107.215 178.269 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.583 ' O ' HD23 ' I' ' 34' ' ' LEU . 73.8 mt -140.65 148.86 41.51 Favored 'General case' 0 CA--C 1.508 -0.66 0 CA-C-O 122.832 1.301 . . . . 0.0 113.376 -176.069 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 4.8 ttm -113.86 112.36 23.23 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 175.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.644 ' O ' HG13 ' H' ' 36' ' ' VAL . 5.0 p -132.39 102.55 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.752 ' N ' HE22 ' J' ' 15' ' ' GLN . . . 122.52 -163.29 15.97 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' I' ' 37' ' ' GLY . . . 128.28 -54.57 0.78 Allowed Glycine 0 CA--C 1.547 2.06 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.291 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.842 HG22 ' CD1' ' N' ' 31' ' ' ILE . 14.6 t -109.7 165.99 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.681 0.793 . . . . 0.0 110.127 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.528 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 2.5 m . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.658 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.36 133.67 52.23 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.772 0.32 . . . . 0.0 110.509 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 54.6 tp10 -75.35 122.57 23.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.245 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -139.51 160.86 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.548 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.609 ' ND1' HG11 ' H' ' 12' ' ' VAL . 21.8 t60 -145.73 100.25 3.39 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 121.253 -0.179 . . . . 0.0 110.724 179.073 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' J' ' 14' ' ' HIS . 45.3 p-80 -165.52 169.57 15.34 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -89.84 158.95 17.24 Favored 'General case' 0 C--N 1.341 0.215 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.829 178.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.765 ' C ' HD12 ' I' ' 17' ' ' LEU . 83.7 tttt -139.97 111.12 7.0 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.765 HD12 ' C ' ' I' ' 16' ' ' LYS . 10.5 mp -127.95 128.64 45.43 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.247 0.546 . . . . 0.0 110.332 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 71.4 t -112.76 120.77 63.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -114.0 106.42 14.4 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.58 ' CD1' ' CD2' ' J' ' 20' ' ' PHE . 1.9 t80 -115.52 129.14 56.43 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 122.342 -0.224 . . . . 0.0 110.451 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.411 ' N ' ' CD1' ' I' ' 20' ' ' PHE . . . -150.18 130.57 13.79 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -178.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -95.65 119.42 34.12 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -118.64 46.3 1.86 Allowed 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -175.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.572 HG22 ' OD1' ' H' ' 23' ' ' ASP . 23.7 m -92.74 173.55 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 175.691 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.32 27.82 65.12 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 118.244 -1.931 . . . . 0.0 109.908 -177.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p 166.66 146.68 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -53.15 136.93 35.11 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 117.416 2.376 . . . . 0.0 117.416 -173.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.469 ' O ' ' HA2' ' J' ' 29' ' ' GLY . 37.9 mttt -60.84 51.06 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 CA-C-N 110.704 -2.953 . . . . 0.0 114.293 173.825 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.07 51.94 0.69 Allowed Glycine 0 N--CA 1.495 2.609 0 O-C-N 120.494 -1.379 . . . . 0.0 116.148 -172.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.526 ' HB2' ' HB3' ' H' ' 30' ' ' ALA . . . -100.31 147.09 26.17 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-O 123.685 1.707 . . . . 0.0 114.993 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.751 HD13 HG22 ' C' ' 39' ' ' VAL . 13.7 tt -132.29 135.88 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.248 -179.203 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 89.6 mt -106.28 108.6 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.01 111.0 3.63 Favored Glycine 0 C--O 1.24 0.496 0 N-CA-C 105.305 -3.118 . . . . 0.0 105.305 176.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.583 HD23 ' O ' ' H' ' 34' ' ' LEU . 0.3 OUTLIER -148.32 141.07 24.6 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 117.68 -1.608 . . . . 0.0 115.073 -174.462 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 81.6 mmm -103.13 114.65 29.12 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-N 112.233 -2.258 . . . . 0.0 105.134 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.413 HG22 HD22 ' I' ' 34' ' ' LEU . 58.4 t -122.57 131.75 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 CA-C-O 120.809 0.337 . . . . 0.0 111.047 -176.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' H' ' 38' ' ' GLY . . . 80.44 -111.22 3.24 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 120.629 -0.796 . . . . 0.0 114.807 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.55 -70.51 0.22 Allowed Glycine 0 CA--C 1.539 1.583 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.456 ' HB ' ' CD1' ' O' ' 31' ' ' ILE . 2.6 p -134.61 137.07 51.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.558 ' OXT' ' ND1' ' L' ' 13' ' ' HIS . 27.5 m . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.814 -1.088 . . . . 0.0 111.284 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.54 137.67 44.12 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -130.67 139.02 50.32 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.899 0.381 . . . . 0.0 110.843 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 41.8 t -123.24 125.29 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.56 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 3.3 m80 -120.96 121.92 39.05 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.166 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.557 ' O ' ' CG ' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -152.45 156.41 39.4 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.19 176.478 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.752 HE22 ' N ' ' H' ' 37' ' ' GLY . 83.8 mt-30 -90.37 160.22 16.2 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.617 ' C ' HD12 ' J' ' 17' ' ' LEU . 68.5 mttm -139.7 97.21 3.22 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.27 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.617 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.1 mp -122.8 121.49 36.41 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-O 121.703 0.763 . . . . 0.0 109.549 176.406 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 18' ' ' VAL . . . . . 0.506 HG13 HG13 ' K' ' 18' ' ' VAL . 21.9 t -110.67 116.23 51.89 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.564 179.716 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.432 ' CZ ' ' HB3' ' J' ' 17' ' ' LEU . 33.9 m-85 -112.58 104.46 12.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CD1' ' I' ' 20' ' ' PHE . 4.5 t80 -115.09 131.02 57.06 Favored 'General case' 0 N--CA 1.478 0.939 0 O-C-N 122.449 -0.157 . . . . 0.0 110.882 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 21' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' K' ' 21' ' ' ALA . . . -168.38 171.82 8.85 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 123.631 1.681 . . . . 0.0 115.464 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -111.62 113.84 26.49 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 113.164 -1.834 . . . . 0.0 107.426 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -172.82 49.81 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.754 HG22 ' H ' ' J' ' 25' ' ' GLY . 13.2 p -154.81 -179.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.879 -178.636 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.754 ' H ' HG22 ' J' ' 24' ' ' VAL . . . 61.59 29.74 72.72 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 116.905 1.522 . . . . 0.0 116.905 178.428 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.626 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.7 m -145.32 -120.8 0.08 Allowed 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.626 ' O ' ' O ' ' J' ' 26' ' ' SER . 1.3 p-10 -53.51 -156.61 0.0 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 176.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.468 ' N ' ' OD1' ' J' ' 27' ' ' ASN . 99.0 mttt -63.36 -39.9 95.79 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 119.573 -1.954 . . . . 0.0 107.084 -173.103 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' J' ' 27' ' ' ASN . . . 92.5 -65.69 2.09 Favored Glycine 0 N--CA 1.473 1.112 0 C-N-CA 119.732 -1.223 . . . . 0.0 114.966 174.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' I' ' 30' ' ' ALA . . . -169.56 155.36 6.03 Favored 'General case' 0 N--CA 1.44 -0.93 0 C-N-CA 116.759 -1.977 . . . . 0.0 115.346 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.509 ' HA ' ' O ' ' K' ' 31' ' ' ILE . 0.8 OUTLIER -135.3 124.96 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 111.065 -2.788 . . . . 0.0 109.628 177.417 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.425 HD13 HG21 ' J' ' 32' ' ' ILE . 44.8 mt -108.22 117.12 53.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.635 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.93 100.73 1.2 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.785 -2.926 . . . . 0.0 105.785 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -127.86 129.79 47.5 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 114.87 1.433 . . . . 0.0 114.87 -175.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.58 109.92 22.4 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.293 -2.484 . . . . 0.0 104.293 174.185 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.417 ' N ' ' O ' ' K' ' 35' ' ' MET . 2.0 t -125.64 153.19 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.095 0.474 . . . . 0.0 111.497 -175.386 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.47 -101.89 0.2 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.172 178.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.561 ' H ' ' N ' ' K' ' 37' ' ' GLY . . . 99.29 -76.66 0.51 Allowed Glycine 0 CA--C 1.537 1.408 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -177.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.852 HG11 HD11 ' P' ' 31' ' ' ILE . 28.0 m -131.46 161.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 CA-C-N 118.362 1.081 . . . . 0.0 110.482 178.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.446 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 44.8 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.907 -1.044 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.76 131.83 54.7 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.759 0.314 . . . . 0.0 110.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -101.84 107.59 18.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.42 HG23 ' NE2' ' K' ' 14' ' ' HIS . 2.5 p -144.63 149.68 17.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.56 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -143.2 94.8 2.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.049 178.753 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.667 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 46.8 m170 -119.94 167.57 12.01 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.948 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.808 HE21 HD21 ' K' ' 17' ' ' LEU . 34.9 tp60 -89.76 157.74 17.82 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.804 ' O ' HD23 ' K' ' 17' ' ' LEU . 16.3 tttt -140.93 95.41 2.84 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.074 -0.651 . . . . 0.0 110.797 178.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.808 HD21 HE21 ' K' ' 15' ' ' GLN . 2.5 mt -131.87 129.62 40.6 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 176.378 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.506 HG13 HG13 ' J' ' 18' ' ' VAL . 3.5 p -118.6 119.33 60.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.186 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.476 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 29.9 m-85 -106.05 105.73 15.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 6.0 t80 -113.59 120.31 40.51 Favored 'General case' 0 C--O 1.226 -0.177 0 CA-C-O 120.66 0.267 . . . . 0.0 111.679 -177.352 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.597 ' HA ' ' O ' ' J' ' 21' ' ' ALA . . . -150.66 120.49 7.08 Favored 'General case' 0 C--O 1.245 0.858 0 C-N-CA 119.704 -0.798 . . . . 0.0 110.547 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.563 ' CG ' ' N ' ' K' ' 23' ' ' ASP . 54.5 tt0 -178.18 163.54 1.69 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 116.988 2.218 . . . . 0.0 116.988 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.563 ' N ' ' CG ' ' K' ' 22' ' ' GLU . 19.9 t70 174.05 -74.13 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 112.03 -2.35 . . . . 0.0 106.978 172.681 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.611 HG22 ' H ' ' K' ' 25' ' ' GLY . 3.2 p -67.7 -113.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 170.481 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.673 ' H ' ' HA3' ' J' ' 25' ' ' GLY . . . 134.7 -37.79 1.9 Allowed Glycine 0 CA--C 1.541 1.7 0 N-CA-C 121.421 3.328 . . . . 0.0 121.421 171.426 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.5 t -71.81 118.09 14.21 Favored 'General case' 0 N--CA 1.482 1.167 1 CA-C-N 125.935 4.867 . . . . 0.0 107.28 177.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 1.7 p30 -103.77 160.58 14.66 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 120.36 1.436 . . . . 0.0 113.127 179.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -44.45 -39.85 5.07 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 67.67 0.04 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-O 118.939 -0.923 . . . . 0.0 113.484 -174.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.463 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -71.04 156.18 39.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.82 1.81 . . . . 0.0 113.607 -176.772 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.629 HD11 HG13 ' E' ' 39' ' ' VAL . 82.2 mt -122.92 126.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.92 -178.781 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 13.0 tt -130.96 118.0 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 O-C-N 121.245 -0.91 . . . . 0.0 110.51 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.81 111.62 1.87 Allowed Glycine 0 N--CA 1.466 0.699 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.62 HD13 ' CE2' ' L' ' 19' ' ' PHE . 82.1 mt -122.92 117.3 25.23 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.165 0.507 . . . . 0.0 110.728 -178.962 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.417 ' O ' ' N ' ' J' ' 36' ' ' VAL . 8.0 mtp -108.3 114.41 28.25 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.404 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 46.2 t -119.65 144.76 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 107.726 -1.212 . . . . 0.0 107.726 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.561 ' N ' ' H ' ' J' ' 38' ' ' GLY . . . -136.51 102.68 0.41 Allowed Glycine 0 C--N 1.32 -0.31 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.104 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' J' ' 40' ' ' VAL . . . -61.28 -67.13 2.26 Favored Glycine 0 CA--C 1.54 1.652 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 176.83 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.485 ' HB ' HD11 ' Q' ' 31' ' ' ILE . 16.7 m -143.44 112.86 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.752 ' OXT' HG12 ' J' ' 39' ' ' VAL . 2.5 p . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.88 -1.057 . . . . 0.0 110.882 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.74 130.96 55.62 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.743 0.306 . . . . 0.0 110.305 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -93.56 142.05 27.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.631 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 t -115.94 126.24 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 110.044 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.558 ' ND1' ' OXT' ' I' ' 40' ' ' VAL . 10.8 m-70 -130.86 104.59 7.24 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.214 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.667 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 30.3 t-80 -160.61 164.57 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 178.187 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.438 ' N ' ' CG ' ' L' ' 14' ' ' HIS . 88.0 mm-40 -89.76 158.57 17.46 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 16' ' ' LYS . . . . . 0.728 ' C ' HD12 ' L' ' 17' ' ' LEU . 16.7 tttt -140.4 93.93 2.68 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.728 HD12 ' C ' ' L' ' 16' ' ' LYS . 10.0 mp -122.72 118.15 27.4 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -102.81 108.06 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.801 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.62 ' CE2' HD13 ' K' ' 34' ' ' LEU . 79.7 m-85 -100.32 98.14 8.83 Favored 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 39.7 t80 -108.38 105.15 14.69 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -165.95 171.51 12.53 Favored 'General case' 0 CA--C 1.484 -1.567 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.634 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -75.94 104.71 6.6 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.066 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -147.0 48.01 1.15 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.41 -176.242 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.563 HG22 ' N ' ' L' ' 25' ' ' GLY . 7.5 p -65.23 169.75 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.563 ' N ' HG22 ' L' ' 24' ' ' VAL . . . -92.2 -42.53 4.6 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 118.709 -1.71 . . . . 0.0 113.819 -176.689 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.51 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 4.6 m -67.72 109.49 3.35 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 117.861 -1.536 . . . . 0.0 111.906 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.68 ' O ' ' N ' ' L' ' 29' ' ' GLY . 21.4 m120 -145.21 158.68 43.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 173.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.537 ' C ' ' O ' ' L' ' 27' ' ' ASN . 42.0 tttp -18.2 -43.51 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 CA-C-O 121.936 0.874 . . . . 0.0 111.312 175.709 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.68 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -178.45 63.33 0.08 OUTLIER Glycine 0 CA--C 1.553 2.411 0 CA-C-N 113.885 -1.507 . . . . 0.0 112.381 177.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -88.94 163.08 15.74 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.13 1.465 . . . . 0.0 110.019 179.418 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 22.2 pt -141.15 135.49 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 119.252 -0.979 . . . . 0.0 112.027 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -118.53 121.09 66.2 Favored 'Isoleucine or valine' 0 C--N 1.34 0.18 0 CA-C-N 114.73 -1.123 . . . . 0.0 111.227 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.11 116.3 2.41 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 179.251 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -126.42 125.65 42.51 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.3 ttm -129.3 130.3 45.98 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.099 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' L' ' 37' ' ' GLY . 55.7 t -124.21 131.87 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -42.56 -111.62 0.0 OUTLIER Glycine 0 N--CA 1.468 0.82 0 CA-C-N 115.483 -0.781 . . . . 0.0 112.631 178.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.99 64.93 3.96 Favored Glycine 0 CA--C 1.532 1.116 0 CA-C-N 114.706 -0.747 . . . . 0.0 111.455 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.649 ' O ' HD11 ' R' ' 31' ' ' ILE . 41.8 t -115.9 157.91 16.52 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' L' ' 39' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.616 -178.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.407 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -107.42 131.04 54.71 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.758 0.313 . . . . 0.0 110.662 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.07 166.87 15.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.598 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.0 t -113.65 128.61 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.31 162.67 15.77 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.711 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.519 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 3.4 m-70 -83.33 168.71 16.39 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.652 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -129.2 150.86 50.4 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.477 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -97.26 111.81 23.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.353 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.69 114.04 18.14 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.88 132.88 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.357 -179.31 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -133.25 134.83 44.46 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.86 0.362 . . . . 0.0 110.919 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -128.26 131.82 48.74 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.766 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.6 111.14 7.55 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.108 0.48 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -159.1 151.13 20.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.372 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 51.96 46.43 26.61 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.818 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.809 HG12 ' H ' ' M' ' 25' ' ' GLY . 39.6 t -80.45 179.89 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.809 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -71.44 -33.75 63.99 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.878 -178.667 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 26' ' ' SER . . . . . 0.594 ' O ' ' O ' ' M' ' 27' ' ' ASN . 25.5 t -162.51 120.61 2.13 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.594 ' O ' ' O ' ' M' ' 26' ' ' SER . 13.6 t30 -22.03 153.22 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.98 0 O-C-N 124.424 1.078 . . . . 0.0 111.976 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -163.17 24.54 0.09 Allowed 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 114.638 1.347 . . . . 0.0 114.638 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.28 106.15 1.11 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 118.539 -1.791 . . . . 0.0 114.913 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.727 ' H ' ' ND2' ' N' ' 27' ' ' ASN . . . -111.48 80.24 1.29 Allowed 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 124.098 1.904 . . . . 0.0 109.999 178.334 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.599 HD11 HG21 ' H' ' 39' ' ' VAL . 59.6 mt -130.36 130.01 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-N 110.974 -2.83 . . . . 0.0 108.419 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 32' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' N' ' 33' ' ' GLY . 47.1 mt -103.94 106.18 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.92 97.43 1.14 Allowed Glycine 0 CA--C 1.506 -0.476 0 N-CA-C 105.055 -3.218 . . . . 0.0 105.055 176.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -148.95 152.92 37.2 Favored 'General case' 0 N--CA 1.463 0.213 0 C-N-CA 118.308 -1.357 . . . . 0.0 113.826 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 91.7 mmm -110.21 110.31 21.11 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 112.946 -1.934 . . . . 0.0 107.177 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.63 HG23 HD21 ' N' ' 34' ' ' LEU . 96.4 t -104.29 122.88 57.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.32 -113.24 0.58 Allowed Glycine 0 C--N 1.309 -0.94 0 N-CA-C 108.419 -1.873 . . . . 0.0 108.419 -178.041 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.68 -69.57 0.22 Allowed Glycine 0 CA--C 1.533 1.179 0 C-N-CA 121.438 -0.411 . . . . 0.0 112.413 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' M' ' 40' ' ' VAL . 3.1 m -137.57 166.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 122.649 0.38 . . . . 0.0 110.373 -179.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.544 ' OXT' ' N ' ' N' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.888 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.88 135.67 49.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.845 0.355 . . . . 0.0 110.395 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -140.71 146.42 37.76 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.023 0.439 . . . . 0.0 110.721 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.458 HG22 HG22 ' O' ' 12' ' ' VAL . 70.2 t -126.98 133.66 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.706 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.511 ' HB2' ' CD2' ' O' ' 13' ' ' HIS . 77.1 m80 -102.97 97.66 7.74 Favored 'General case' 0 N--CA 1.471 0.62 0 O-C-N 122.093 -0.38 . . . . 0.0 110.509 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' N' ' 15' ' ' GLN . 1.7 t-80 -159.95 168.53 25.47 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.941 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.636 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 81.9 mt-30 -156.0 142.27 18.38 Favored 'General case' 0 C--N 1.34 0.166 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 178.161 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -84.73 120.64 26.64 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.822 179.156 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.484 HD12 ' O ' ' N' ' 15' ' ' GLN . 4.8 mp -129.11 124.03 33.71 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.755 0.312 . . . . 0.0 110.192 178.274 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.21 131.58 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -129.37 115.58 17.77 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.147 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 t80 -111.9 126.17 54.83 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.0 147.56 31.79 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -177.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -132.46 133.0 43.31 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.016 178.178 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -158.05 46.62 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 24' ' ' VAL . . . . . 0.54 HG12 ' N ' ' N' ' 25' ' ' GLY . 20.8 t -91.79 169.18 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 178.003 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 0.54 ' N ' HG12 ' N' ' 24' ' ' VAL . . . 77.16 34.8 40.24 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.008 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 169.51 -114.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -176.461 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.727 ' ND2' ' H ' ' M' ' 30' ' ' ALA . 28.9 t30 -61.89 170.88 1.87 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.358 0.599 . . . . 0.0 111.782 -177.336 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.561 ' HD3' HD11 ' N' ' 31' ' ' ILE . 81.7 tttt -54.15 -39.36 66.44 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.474 -176.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.34 -63.51 0.53 Allowed Glycine 0 CA--C 1.531 1.04 0 C-N-CA 119.639 -1.267 . . . . 0.0 114.107 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.86 99.52 3.81 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 120.319 2.059 . . . . 0.0 115.529 -176.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.842 ' CD1' HG22 ' H' ' 39' ' ' VAL . 96.3 mt -122.59 118.94 56.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 114.162 -1.381 . . . . 0.0 107.304 173.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' P' ' 19' ' ' PHE . 74.8 mt -107.71 108.32 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 119.041 -1.064 . . . . 0.0 110.28 178.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -109.08 98.66 1.18 Allowed Glycine 0 C--O 1.234 0.138 0 N-CA-C 104.641 -3.384 . . . . 0.0 104.641 175.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.963 HD23 ' N ' ' N' ' 35' ' ' MET . 3.0 tt -145.25 147.84 32.84 Favored 'General case' 0 CA--C 1.506 -0.727 0 C-N-CA 118.352 -1.339 . . . . 0.0 113.065 -174.218 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.963 ' N ' HD23 ' N' ' 34' ' ' LEU . 12.7 mtp -112.0 115.67 29.31 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 113.215 -1.812 . . . . 0.0 108.786 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.675 HG23 HD22 ' N' ' 34' ' ' LEU . 51.4 t -114.59 111.63 36.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 179.44 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 135.21 -131.75 5.95 Favored Glycine 0 C--N 1.316 -0.562 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.74 -63.69 4.05 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.52 HG12 HD12 ' B' ' 31' ' ' ILE . 11.4 m -104.52 161.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.952 0.501 . . . . 0.0 110.384 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.56 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 47.5 t . . . . . 0 C--O 1.218 -0.602 0 CA-C-O 117.852 -1.071 . . . . 0.0 111.58 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.29 139.43 44.24 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -102.05 124.28 47.39 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.566 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.458 HG22 HG22 ' N' ' 12' ' ' VAL . 1.4 m -125.49 125.91 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.511 ' CD2' ' HB2' ' N' ' 13' ' ' HIS . 23.2 m80 -121.48 122.17 39.15 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 121.193 0.521 . . . . 0.0 112.208 -177.49 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.524 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 0.6 OUTLIER -150.27 175.95 11.32 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.576 178.38 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.481 ' OE1' HD11 ' O' ' 17' ' ' LEU . 5.0 tt0 -152.74 139.75 19.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.587 0.708 . . . . 0.0 109.107 175.593 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 61.3 mttt -95.68 108.64 20.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.592 -1.185 . . . . 0.0 111.043 177.948 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.481 HD11 ' OE1' ' O' ' 15' ' ' GLN . 5.0 mt -124.03 109.64 13.77 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 119.293 0.951 . . . . 0.0 108.729 175.678 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -107.39 116.4 50.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.877 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -110.99 103.31 11.77 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' P' ' 20' ' ' PHE . 2.7 m-85 -110.38 133.92 52.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.354 0.262 . . . . 0.0 110.303 -178.726 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.77 136.56 29.0 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-O 122.99 1.376 . . . . 0.0 114.128 -179.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 26.5 tp10 -93.12 163.79 13.5 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 113.263 -1.79 . . . . 0.0 106.986 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.437 ' OD1' ' OD2' ' P' ' 23' ' ' ASP . 54.5 p-10 -172.93 52.36 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.106 -0.638 . . . . 0.0 111.091 -176.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.605 ' HA ' HG13 ' P' ' 24' ' ' VAL . 13.5 m -74.5 142.17 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 117.981 -1.488 . . . . 0.0 112.47 -174.796 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.501 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . 98.97 38.14 3.93 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.233 179.623 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.993 ' H ' HG11 ' P' ' 24' ' ' VAL . 2.7 p 72.74 120.16 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.11 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' O' ' 27' ' ' ASN . 54.7 p30 -83.62 156.24 22.8 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 115.968 -2.293 . . . . 0.0 109.956 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -48.66 -42.53 34.82 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.874 1.435 . . . . 0.0 114.874 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.443 ' O ' ' CE ' ' N' ' 28' ' ' LYS . . . 160.19 67.37 0.02 OUTLIER Glycine 0 CA--C 1.546 1.998 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.117 -176.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.67 132.22 30.65 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 120.305 2.053 . . . . 0.0 114.155 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.456 ' CD1' ' HB ' ' I' ' 39' ' ' VAL . 9.8 tt -137.36 131.88 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 114.57 -1.196 . . . . 0.0 112.18 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.569 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 71.3 mt -108.25 114.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.378 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.445 ' O ' HD22 ' O' ' 34' ' ' LEU . . . -111.97 94.9 0.77 Allowed Glycine 0 N--CA 1.468 0.792 0 N-CA-C 107.236 -2.345 . . . . 0.0 107.236 177.099 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.461 ' HB2' HD12 ' P' ' 34' ' ' LEU . 1.3 mm? -121.32 134.6 55.14 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 122.476 1.132 . . . . 0.0 113.264 -176.181 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -113.0 104.41 12.36 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 173.809 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.576 HG11 HD13 ' Q' ' 17' ' ' LEU . 2.5 t -113.6 103.46 15.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . 136.85 -153.53 21.77 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.663 177.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.724 ' H ' ' H ' ' P' ' 38' ' ' GLY . . . 137.79 -56.29 0.67 Allowed Glycine 0 CA--C 1.543 1.796 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -178.011 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.433 HG22 HG23 ' O' ' 40' ' ' VAL . 5.0 p -133.15 154.78 40.05 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.525 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.486 ' OXT' ' CG2' ' P' ' 40' ' ' VAL . 17.3 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.999 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -109.07 135.54 50.06 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.579 0.228 . . . . 0.0 110.627 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -73.61 133.19 43.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.946 0.403 . . . . 0.0 110.653 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 43.9 t -136.81 166.29 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.635 -179.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.537 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 12.3 m170 -44.22 110.77 0.24 Allowed 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.946 -178.324 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' O ' ' Q' ' 14' ' ' HIS . 55.4 t60 -152.62 154.43 35.35 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.555 ' O ' ' CD2' ' P' ' 14' ' ' HIS . 30.7 mt-30 -98.47 169.81 9.28 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -158.26 103.99 1.84 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.976 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -134.05 133.28 41.0 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.521 0.677 . . . . 0.0 110.861 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 64.1 t -123.55 120.94 61.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.935 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' N' ' 32' ' ' ILE . 5.5 m-85 -112.73 112.3 23.71 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.441 ' HB3' ' CD1' ' O' ' 20' ' ' PHE . 26.4 t80 -125.2 122.47 37.11 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -176.768 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.9 122.09 29.54 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.747 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.521 ' CG ' ' N ' ' P' ' 23' ' ' ASP . 69.6 tt0 -167.45 158.97 11.95 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 117.695 2.479 . . . . 0.0 117.695 -176.925 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.521 ' N ' ' CG ' ' P' ' 22' ' ' GLU . 1.7 p30 150.64 -70.05 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 111.643 -2.526 . . . . 0.0 108.386 175.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.993 HG11 ' H ' ' O' ' 26' ' ' SER . 4.4 m -57.05 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 122.099 0.952 . . . . 0.0 109.336 174.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.4 ' H ' ' HB ' ' P' ' 24' ' ' VAL . . . 141.57 -36.25 1.73 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.621 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 m -70.33 114.49 8.51 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 115.916 -2.314 . . . . 0.0 105.18 171.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.693 HD21 ' H ' ' P' ' 27' ' ' ASN . 0.0 OUTLIER -119.98 154.6 34.27 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 121.212 1.824 . . . . 0.0 111.926 176.435 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -34.52 -39.46 0.09 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 173.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 29' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' Q' ' 29' ' ' GLY . . . 140.07 74.52 0.05 OUTLIER Glycine 0 CA--C 1.553 2.447 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -175.295 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 30' ' ' ALA . . . . . 0.445 ' O ' ' O ' ' Q' ' 29' ' ' GLY . . . -70.55 170.14 12.74 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 116.099 1.888 . . . . 0.0 116.099 -173.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.852 HD11 HG11 ' J' ' 39' ' ' VAL . 0.9 OUTLIER -149.14 143.7 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 CA-C-N 112.739 -2.028 . . . . 0.0 114.907 -176.103 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.461 HG12 HD12 ' O' ' 32' ' ' ILE . 3.7 mt -113.12 113.06 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.38 101.8 1.2 Allowed Glycine 0 N--CA 1.462 0.402 0 N-CA-C 105.82 -2.912 . . . . 0.0 105.82 176.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.54 ' C ' HD23 ' P' ' 34' ' ' LEU . 9.0 tt -144.49 132.08 21.06 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 122.866 1.317 . . . . 0.0 112.397 -175.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 35' ' ' MET . . . . . 0.485 ' N ' HD23 ' P' ' 34' ' ' LEU . 74.0 mtp -120.86 119.59 33.11 Favored 'General case' 0 CA--C 1.495 -1.153 0 CA-C-N 113.163 -1.835 . . . . 0.0 107.512 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.437 ' CG2' HG22 ' Q' ' 36' ' ' VAL . 0.0 OUTLIER -95.67 113.85 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.604 -178.521 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' P' P ' 37' ' ' GLY . . . . . 0.551 ' N ' ' O ' ' O' ' 36' ' ' VAL . . . -65.64 -123.29 0.01 OUTLIER Glycine 0 CA--C 1.521 0.408 0 CA-C-N 113.871 -1.513 . . . . 0.0 110.799 177.205 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.724 ' H ' ' H ' ' O' ' 38' ' ' GLY . . . 66.64 60.86 5.79 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-N 114.301 -0.95 . . . . 0.0 113.641 179.261 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.598 ' O ' HD11 ' D' ' 31' ' ' ILE . 0.7 OUTLIER -84.71 124.14 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.082 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.505 ' C ' HG12 ' Q' ' 39' ' ' VAL . 3.1 t . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 118.341 -0.838 . . . . 0.0 112.428 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.29 131.07 55.09 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.434 ' H ' ' HG2' ' R' ' 11' ' ' GLU . 96.4 mt-10 -141.23 138.23 33.14 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.542 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.448 HG12 ' H ' ' R' ' 12' ' ' VAL . 34.5 m -125.28 129.92 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.435 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.56 ' CE1' ' O ' ' N' ' 40' ' ' VAL . 14.2 t60 -136.4 132.98 36.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.912 0.387 . . . . 0.0 110.811 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.583 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 3.7 m80 -145.48 162.58 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.515 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.496 ' HG2' HG12 ' O' ' 36' ' ' VAL . 1.9 mp0 -89.95 157.26 17.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 176.619 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . 0.42 ' HB2' ' NE2' ' P' ' 14' ' ' HIS . 87.9 tttt -141.66 102.34 4.16 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 176.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.576 HD13 HG11 ' O' ' 36' ' ' VAL . 5.2 mp -131.37 119.47 21.73 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-O 121.389 0.614 . . . . 0.0 111.143 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -107.44 111.8 37.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.569 ' CD1' HD13 ' O' ' 32' ' ' ILE . 88.3 m-85 -106.63 103.44 12.88 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.015 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.58 ' CE2' ' CD2' ' R' ' 20' ' ' PHE . 26.1 t80 -110.01 119.34 39.01 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.47 128.34 21.91 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.424 0.63 . . . . 0.0 111.349 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 38.9 tt0 -91.29 109.96 21.25 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 99.1 m-20 -141.96 48.27 1.6 Allowed 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.212 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -72.86 160.56 5.27 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.481 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.82 -30.04 8.42 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.7 t 61.46 109.96 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 118.903 -0.57 . . . . 0.0 112.157 177.297 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.744 ' O ' ' N ' ' Q' ' 29' ' ' GLY . 13.9 t30 -129.41 159.74 35.27 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -29.53 48.82 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 N-CA-C 117.641 2.46 . . . . 0.0 117.641 -178.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.744 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -171.93 52.61 0.18 Allowed Glycine 0 CA--C 1.536 1.399 0 CA-C-N 120.552 1.524 . . . . 0.0 112.34 171.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.04 95.06 9.57 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.819 1.809 . . . . 0.0 111.295 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.485 HD11 ' HB ' ' K' ' 39' ' ' VAL . 49.4 mt -133.36 123.98 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 CA-C-N 120.66 1.573 . . . . 0.0 112.687 -178.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -126.97 121.97 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.636 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.75 114.05 2.01 Favored Glycine 0 N--CA 1.467 0.76 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.387 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.688 HD22 ' CZ ' ' R' ' 19' ' ' PHE . 89.8 mt -124.98 119.73 29.57 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.504 0.192 . . . . 0.0 110.576 -178.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.421 ' O ' HG23 ' P' ' 36' ' ' VAL . 82.1 mtp -127.93 124.4 37.27 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.437 HG22 ' CG2' ' P' ' 36' ' ' VAL . 64.2 t -115.93 146.9 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.503 -0.555 . . . . 0.0 109.503 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.91 102.29 0.41 Allowed Glycine 0 C--N 1.315 -0.634 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.99 -71.09 0.65 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-O 121.559 0.533 . . . . 0.0 111.945 178.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.507 HG12 HD11 ' E' ' 31' ' ' ILE . 2.4 m -126.2 119.01 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.468 ' CB ' ' O ' ' Q' ' 39' ' ' VAL . 61.1 t . . . . . 0 N--CA 1.487 1.403 0 C-N-CA 124.34 1.056 . . . . 0.0 109.882 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -115.22 140.57 48.98 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.434 ' HG2' ' H ' ' Q' ' 11' ' ' GLU . 97.1 mt-10 -73.48 129.99 39.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.448 ' H ' HG12 ' Q' ' 12' ' ' VAL . 72.0 t -126.07 131.86 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.115 0.483 . . . . 0.0 110.343 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -132.84 95.72 3.64 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.711 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' OE1' ' R' ' 15' ' ' GLN . 84.8 t60 -155.36 161.93 40.93 Favored 'General case' 0 C--O 1.222 -0.349 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.489 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.57 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.2 OUTLIER -90.17 159.8 16.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.867 0.365 . . . . 0.0 111.452 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.694 ' C ' HD13 ' R' ' 17' ' ' LEU . 57.7 tttt -139.96 107.12 5.47 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.902 HD22 ' N ' ' R' ' 17' ' ' LEU . 0.0 OUTLIER -126.82 121.3 31.53 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.694 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -104.34 111.31 33.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 177.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.688 ' CZ ' HD22 ' Q' ' 34' ' ' LEU . 80.1 m-85 -103.44 103.77 13.78 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CE2' ' Q' ' 20' ' ' PHE . 62.3 t80 -114.07 109.2 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.352 0.596 . . . . 0.0 109.58 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.47 125.08 33.49 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -81.98 114.38 20.52 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.719 -178.394 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.401 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.0 t0 -150.24 46.27 0.9 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.671 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.658 HG12 ' H ' ' R' ' 25' ' ' GLY . 24.1 t -96.02 175.93 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.658 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 70.96 26.97 72.99 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 26' ' ' SER . . . . . 0.48 ' O ' ' O ' ' R' ' 27' ' ' ASN . 28.5 t -153.37 120.29 5.71 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.101 0.476 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.48 ' O ' ' O ' ' R' ' 26' ' ' SER . 78.6 m-20 -42.07 178.78 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.663 -179.198 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -72.58 45.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.923 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' R' ' 27' ' ' ASN . . . -92.08 59.53 2.74 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.525 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.37 165.86 33.69 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 122.545 -0.385 . . . . 0.0 110.33 -178.38 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.649 HD11 ' O ' ' L' ' 39' ' ' VAL . 93.6 mt -109.95 119.01 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.261 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 32' ' ' ILE . . . . . 0.5 HG23 ' O ' ' R' ' 32' ' ' ILE . 18.6 tt -130.37 124.07 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.921 0.391 . . . . 0.0 110.223 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.43 120.3 3.66 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 42.9 mt -121.48 121.57 37.81 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -179.371 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 75.4 mtp -128.95 131.03 47.46 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.45 0.643 . . . . 0.0 112.175 -179.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -134.38 142.67 40.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.935 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.63 -102.31 0.2 Allowed Glycine 0 C--N 1.306 -1.097 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' R' R ' 38' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' R' ' 39' ' ' VAL . . . 109.06 -71.85 0.2 Allowed Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.11 -0.828 . . . . 0.0 112.055 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.508 ' HA ' HD13 ' F' ' 31' ' ' ILE . 94.1 t -29.95 123.03 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 118.492 1.146 . . . . 0.0 111.657 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.446 ' H ' HG21 ' F' ' 31' ' ' ILE . 91.7 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.974 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -112.7 137.63 50.7 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.812 0.339 . . . . 0.0 110.444 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.5 134.17 33.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.458 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 m -123.05 131.41 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.389 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 37.5 t-80 -137.67 141.01 41.13 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.257 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 15' ' ' GLN . 0.4 OUTLIER -84.58 166.62 17.02 Favored 'General case' 0 CA--C 1.532 0.267 0 CA-C-O 121.248 0.547 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.625 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 83.0 mt-30 -157.45 143.09 17.36 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.071 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -81.07 134.36 35.65 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.334 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.92 116.56 22.39 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -125.26 133.68 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.054 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -140.33 139.52 35.43 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.016 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.526 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.1 p90 -126.46 127.81 45.97 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.65 116.22 29.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.302 0.572 . . . . 0.0 111.018 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -142.4 120.9 12.46 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 58.44 46.43 15.16 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.14 -179.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.789 HG12 ' H ' ' A' ' 25' ' ' GLY . 40.1 t -75.96 179.71 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.789 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -88.96 27.71 7.16 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.047 -178.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.438 ' O ' ' C ' ' A' ' 27' ' ' ASN . 7.8 t -170.19 -136.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' SER . 99.5 m-20 -32.48 133.96 0.11 Allowed 'General case' 0 N--CA 1.472 0.664 0 CA-C-O 119.304 -0.379 . . . . 0.0 110.662 177.312 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' B' ' 22' ' ' GLU . 52.3 mtpt -118.36 -38.34 3.19 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 120.123 -0.631 . . . . 0.0 112.271 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.432 ' O ' ' HB1' ' B' ' 21' ' ' ALA . . . -80.7 -78.59 0.93 Allowed Glycine 0 N--CA 1.468 0.792 0 C-N-CA 118.951 -1.595 . . . . 0.0 112.919 -177.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.56 93.64 0.2 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.938 -0.705 . . . . 0.0 112.114 178.788 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 92.7 mt -126.28 104.73 13.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.413 HD13 ' CD1' ' C' ' 19' ' ' PHE . 96.5 mt -110.57 112.01 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.099 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.609 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.6 92.66 0.5 Allowed Glycine 0 CA--C 1.508 -0.383 0 N-CA-C 104.356 -3.498 . . . . 0.0 104.356 176.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.686 ' O ' HD12 ' B' ' 34' ' ' LEU . 91.5 mt -151.79 177.95 9.88 Favored 'General case' 0 CA--C 1.51 -0.594 0 CA-C-O 122.969 1.366 . . . . 0.0 111.985 -175.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 31.4 mtp -140.38 119.38 12.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 113.096 -1.865 . . . . 0.0 108.902 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.483 HG21 HD13 ' C' ' 17' ' ' LEU . 1.7 m -131.97 113.56 22.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 154.38 -124.64 1.58 Allowed Glycine 0 C--N 1.307 -1.058 0 N-CA-C 109.106 -1.597 . . . . 0.0 109.106 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.62 -67.03 3.6 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.977 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 40' ' ' VAL . 2.4 p -115.56 166.49 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.521 ' N ' HG22 ' A' ' 39' ' ' VAL . 9.8 m . . . . . 0 N--CA 1.472 0.646 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.58 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -106.27 133.21 51.33 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -93.17 106.02 18.03 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.788 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -128.9 130.81 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 81.3 t60 -134.16 105.76 6.83 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.814 0.34 . . . . 0.0 111.166 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.635 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 4.5 t60 -157.12 167.37 30.59 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.584 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.591 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 33.9 mt-30 -154.75 141.84 19.33 Favored 'General case' 0 C--N 1.339 0.127 0 N-CA-C 109.627 -0.509 . . . . 0.0 109.627 177.706 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -85.53 131.5 34.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.624 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.467 HD23 HD23 ' C' ' 17' ' ' LEU . 33.4 tp -122.16 120.97 35.79 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 118.121 0.419 . . . . 0.0 110.117 177.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -124.61 131.97 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -131.14 123.29 28.24 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.616 -179.069 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -112.79 124.85 53.52 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.352 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 21' ' ' ALA . . . . . 0.432 ' HB1' ' O ' ' A' ' 29' ' ' GLY . . . -124.15 126.28 45.89 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -178.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' A' ' 28' ' ' LYS . 79.0 tt0 -115.07 162.98 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.912 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -178.81 48.71 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 122.337 0.255 . . . . 0.0 110.443 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.522 HG22 ' O ' ' C' ' 23' ' ' ASP . 2.7 t -72.57 161.05 5.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 122.363 1.077 . . . . 0.0 112.749 -174.248 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.402 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 107.07 -34.71 5.52 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 113.051 -1.886 . . . . 0.0 112.588 178.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' B' ' 27' ' ' ASN . 89.2 p -162.46 120.07 2.08 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.831 1.315 . . . . 0.0 113.851 177.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.611 ' ND2' ' N ' ' B' ' 28' ' ' LYS . 0.5 OUTLIER -22.37 153.41 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.362 0.665 . . . . 0.0 111.644 174.68 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.611 ' N ' ' ND2' ' B' ' 27' ' ' ASN . 56.3 tttt -165.45 26.5 0.05 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.72 107.93 0.38 Allowed Glycine 0 N--CA 1.47 0.944 0 C-N-CA 118.239 -1.934 . . . . 0.0 115.7 174.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -120.47 105.23 10.66 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-O 122.363 1.078 . . . . 0.0 108.136 177.582 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.47 HD11 ' O ' ' N' ' 38' ' ' GLY . 2.6 mt -133.49 135.63 55.67 Favored 'Isoleucine or valine' 0 C--N 1.346 0.435 0 CA-C-N 114.746 -1.116 . . . . 0.0 113.163 -176.036 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.654 HD13 ' CD1' ' D' ' 19' ' ' PHE . 94.1 mt -113.15 110.78 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.383 176.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.01 102.33 1.07 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 105.327 -3.109 . . . . 0.0 105.327 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.686 HD12 ' O ' ' A' ' 34' ' ' LEU . 12.2 tp -146.67 144.42 29.46 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 117.828 -1.549 . . . . 0.0 114.765 -174.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.43 114.81 29.06 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 112.277 -2.238 . . . . 0.0 108.299 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.732 HG11 HD21 ' D' ' 17' ' ' LEU . 17.0 t -133.21 123.2 46.98 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 119.916 -0.714 . . . . 0.0 110.938 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.7 -113.74 1.02 Allowed Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.719 ' O ' HD12 ' I' ' 31' ' ' ILE . . . 86.7 -72.72 2.58 Favored Glycine 0 CA--C 1.536 1.348 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.585 HG12 ' N ' ' B' ' 40' ' ' VAL . 47.6 t -134.31 164.56 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 122.463 -0.434 . . . . 0.0 110.946 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.585 ' N ' HG12 ' B' ' 39' ' ' VAL . 53.1 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.886 -1.054 . . . . 0.0 109.961 178.466 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.142 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -81.93 140.28 34.14 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -139.08 139.36 37.71 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.871 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 130.96 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.602 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 33.2 m80 -145.7 101.43 3.56 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 120.107 -0.637 . . . . 0.0 112.183 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.635 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.0 p-80 -155.89 155.0 32.12 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 118.415 -1.314 . . . . 0.0 111.95 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -90.48 161.19 15.63 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.416 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -139.32 112.65 8.22 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 175.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.49 HD12 ' CD2' ' D' ' 17' ' ' LEU . 3.6 mt -116.24 111.48 20.22 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.475 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 t -111.08 110.12 31.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.413 ' CD1' HD13 ' A' ' 32' ' ' ILE . 96.0 m-85 -110.32 113.09 25.48 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -112.32 124.88 53.45 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.676 -0.238 . . . . 0.0 110.505 -178.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 21' ' ' ALA . . . . . 0.554 ' O ' ' NZ ' ' C' ' 28' ' ' LYS . . . -131.78 136.77 47.8 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.508 0.671 . . . . 0.0 112.724 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.442 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 15.5 pt-20 -163.81 133.2 3.98 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.3 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.522 ' O ' HG22 ' B' ' 24' ' ' VAL . 0.2 OUTLIER -150.02 -60.3 0.2 Allowed 'General case' 0 C--N 1.353 0.758 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.669 HG12 ' N ' ' C' ' 25' ' ' GLY . 35.9 t -94.15 170.55 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 117.378 -1.729 . . . . 0.0 112.579 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.669 ' N ' HG12 ' C' ' 24' ' ' VAL . . . -81.51 27.83 3.2 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.404 173.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' C' ' 27' ' ' ASN . 4.8 t -170.56 -138.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 118.947 1.374 . . . . 0.0 112.75 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.543 ' ND2' ' O ' ' D' ' 25' ' ' GLY . 4.3 t-20 -34.52 127.69 0.46 Allowed 'General case' 0 C--N 1.349 0.547 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.178 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.943 ' HZ3' ' HB1' ' D' ' 21' ' ' ALA . 71.2 tttt -104.94 -42.16 5.41 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . 81.18 60.88 2.18 Favored Glycine 0 CA--C 1.543 1.812 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.622 ' H ' ' HG ' ' D' ' 26' ' ' SER . . . -110.21 112.39 24.34 Favored 'General case' 0 C--N 1.361 1.101 0 CA-C-O 123.237 1.494 . . . . 0.0 114.077 -175.047 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.556 HG21 ' CG2' ' O' ' 39' ' ' VAL . 1.1 tt -134.63 127.19 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 112.218 -2.264 . . . . 0.0 109.228 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.417 HD13 HG21 ' C' ' 32' ' ' ILE . 29.2 mt -106.56 116.32 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.213 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.97 106.36 1.62 Allowed Glycine 0 N--CA 1.466 0.695 0 N-CA-C 106.551 -2.619 . . . . 0.0 106.551 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -133.05 134.63 44.61 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 114.128 1.159 . . . . 0.0 114.128 -174.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -113.02 98.94 7.48 Favored 'General case' 0 N--CA 1.432 -1.338 0 N-CA-C 101.591 -3.485 . . . . 0.0 101.591 173.058 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.02 132.22 65.61 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 N-CA-C 114.76 1.393 . . . . 0.0 114.76 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.09 111.97 1.25 Allowed Glycine 0 CA--C 1.521 0.461 0 CA-C-N 114.267 -1.333 . . . . 0.0 113.194 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -97.9 -60.51 0.92 Allowed Glycine 0 CA--C 1.54 1.609 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 176.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.662 ' HB ' HD11 ' I' ' 31' ' ' ILE . 10.0 p -145.06 150.5 15.93 Favored 'Isoleucine or valine' 0 C--N 1.342 0.269 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.497 ' OXT' ' ND1' ' E' ' 13' ' ' HIS . 9.8 p . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.534 -179.232 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -115.59 138.01 51.49 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.014 0.435 . . . . 0.0 110.745 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -71.97 140.61 49.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.136 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.583 HG23 ' O ' ' D' ' 12' ' ' VAL . 22.0 m -126.23 109.99 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.433 0.635 . . . . 0.0 110.594 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.602 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 2.5 t60 -126.83 127.87 45.66 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.694 -178.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.461 ' HB3' ' H ' ' E' ' 14' ' ' HIS . 1.5 p-80 -134.19 164.39 27.46 Favored 'General case' 0 C--O 1.221 -0.396 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.165 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 7.4 tp-100 -90.1 151.51 21.58 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 178.093 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -150.33 97.13 2.5 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.732 HD21 HG11 ' B' ' 36' ' ' VAL . 7.4 mt -123.29 121.56 36.15 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.07 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -114.89 106.54 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.654 ' CD1' HD13 ' B' ' 32' ' ' ILE . 91.4 m-85 -107.78 106.0 16.1 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 177.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -116.76 129.38 56.08 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.787 -175.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.943 ' HB1' ' HZ3' ' C' ' 28' ' ' LYS . . . -133.86 128.73 35.26 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-O 121.54 0.686 . . . . 0.0 111.295 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.629 ' N ' ' NZ ' ' C' ' 28' ' ' LYS . 98.9 mt-10 -95.13 139.4 31.51 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.381 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.501 ' O ' ' O ' ' D' ' 24' ' ' VAL . 9.9 m-20 65.36 47.92 2.22 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 177.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.501 ' O ' ' O ' ' D' ' 23' ' ' ASP . 5.2 m -52.45 -175.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 119.215 -0.994 . . . . 0.0 108.433 177.511 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.543 ' O ' ' ND2' ' C' ' 27' ' ' ASN . . . 165.43 19.46 0.02 OUTLIER Glycine 0 CA--C 1.523 0.548 0 C-N-CA 118.252 -1.928 . . . . 0.0 113.342 -177.47 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.622 ' HG ' ' H ' ' C' ' 30' ' ' ALA . 5.2 m -80.33 -130.37 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' CG1' ' P' ' 39' ' ' VAL . 9.7 m120 -100.48 149.78 23.33 Favored 'General case' 0 CA--C 1.516 -0.332 0 C-N-CA 119.048 -1.061 . . . . 0.0 109.745 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.498 ' NZ ' HD11 ' F' ' 31' ' ' ILE . 95.8 mttt 37.78 42.54 0.41 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.346 -1.297 . . . . 0.0 110.887 -177.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.56 -66.42 2.32 Favored Glycine 0 CA--C 1.545 1.947 0 CA-C-N 116.514 -0.312 . . . . 0.0 113.245 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.21 165.41 9.06 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.525 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 11.9 tt -129.59 129.92 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.733 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -113.52 112.68 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.761 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.64 97.01 1.39 Allowed Glycine 0 C--O 1.239 0.409 0 N-CA-C 104.226 -3.55 . . . . 0.0 104.226 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.427 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 64.9 tp -117.09 121.54 41.59 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -173.603 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -112.03 97.93 7.0 Favored 'General case' 0 N--CA 1.433 -1.3 0 N-CA-C 103.796 -2.668 . . . . 0.0 103.796 173.22 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.628 ' CG2' HE22 ' E' ' 15' ' ' GLN . 14.3 p -119.09 120.84 65.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.268 0 C-N-CA 119.714 -0.794 . . . . 0.0 110.454 -177.202 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -99.51 121.88 7.37 Favored Glycine 0 C--N 1.332 0.345 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' E' ' 39' ' ' VAL . . . -119.24 62.07 0.47 Allowed Glycine 0 CA--C 1.532 1.149 0 CA-C-O 119.035 -0.869 . . . . 0.0 112.532 178.076 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.63 ' HB ' HD11 ' J' ' 31' ' ' ILE . 49.2 t -84.3 130.04 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 119.324 1.562 . . . . 0.0 109.742 179.179 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.431 ' O ' HG12 ' D' ' 39' ' ' VAL . 16.9 m . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.284 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -110.79 134.79 52.2 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.655 0.264 . . . . 0.0 110.302 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.433 ' O ' HG11 ' D' ' 12' ' ' VAL . 73.1 tt0 -105.54 137.59 43.13 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.994 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.553 HG11 ' H ' ' F' ' 12' ' ' VAL . 4.2 p -139.52 156.39 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.916 0.389 . . . . 0.0 111.42 -178.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.497 ' ND1' ' OXT' ' C' ' 40' ' ' VAL . 7.7 p80 -74.19 125.06 27.55 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.194 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.461 ' H ' ' HB3' ' D' ' 14' ' ' HIS . 52.6 p-80 -154.05 166.36 33.28 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.339 178.229 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.628 HE22 ' CG2' ' D' ' 36' ' ' VAL . 16.8 tt0 -89.84 151.71 21.63 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 178.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -149.57 105.27 3.43 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.858 177.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -117.59 117.06 28.38 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.893 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 103.88 15.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.639 ' CE2' ' CE1' ' F' ' 19' ' ' PHE . 3.7 m-30 -106.54 109.12 20.94 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.153 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -129.72 130.9 46.05 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 120.058 -0.657 . . . . 0.0 112.521 -176.24 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.441 ' HB1' HG13 ' D' ' 24' ' ' VAL . . . -124.47 133.18 53.43 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.936 178.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 92.0 mt-10 -127.18 170.64 12.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 116.982 2.216 . . . . 0.0 116.982 -176.007 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.454 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 11.4 p30 48.18 46.31 19.77 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 110.722 -2.944 . . . . 0.0 116.167 177.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.677 HG23 ' H ' ' E' ' 26' ' ' SER . 15.7 m -72.12 -168.79 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.247 -0.981 . . . . 0.0 108.947 174.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.42 36.81 3.96 Favored Glycine 0 N--CA 1.467 0.725 0 N-CA-C 105.815 -2.914 . . . . 0.0 105.815 172.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.677 ' H ' HG23 ' E' ' 24' ' ' VAL . 21.3 t 61.63 111.21 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 113.339 -1.43 . . . . 0.0 107.844 -175.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.481 ' O ' ' N ' ' E' ' 29' ' ' GLY . 98.8 m-20 -130.0 161.1 31.7 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.433 ' C ' ' O ' ' E' ' 27' ' ' ASN . 98.3 mttt -28.63 -40.27 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.294 173.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.612 ' O ' ' HB2' ' E' ' 30' ' ' ALA . . . 107.68 -63.45 0.28 Allowed Glycine 0 CA--C 1.54 1.611 0 CA-C-O 117.096 -1.947 . . . . 0.0 115.968 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.612 ' HB2' ' O ' ' E' ' 29' ' ' GLY . . . -179.75 168.89 1.34 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 122.903 3.351 . . . . 0.0 115.915 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 91.2 mt -119.53 125.09 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 111.18 -2.736 . . . . 0.0 106.087 175.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 89.5 mt -130.49 128.76 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.94 106.28 1.01 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.675 HD23 ' C ' ' E' ' 34' ' ' LEU . 7.3 tt -115.61 122.75 46.55 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-O 120.926 0.393 . . . . 0.0 111.672 -176.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.457 ' N ' HD23 ' E' ' 34' ' ' LEU . 8.2 mtp -118.76 126.07 51.04 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.635 178.482 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.474 HG12 ' N ' ' E' ' 37' ' ' GLY . 59.1 t -90.68 156.38 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 121.142 0.496 . . . . 0.0 111.052 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.474 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -102.13 102.5 2.33 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.299 -179.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.56 -73.56 0.0 OUTLIER Glycine 0 CA--C 1.541 1.676 0 N-CA-C 115.567 0.987 . . . . 0.0 115.567 177.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' D' ' 38' ' ' GLY . 6.6 p -129.05 153.85 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-N 118.577 1.189 . . . . 0.0 111.64 -178.221 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 67.8 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.037 -0.982 . . . . 0.0 110.695 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.6 t80 -72.47 129.52 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.842 0.354 . . . . 0.0 110.611 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -141.43 140.26 33.58 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.56 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.553 ' H ' HG11 ' E' ' 12' ' ' VAL . 67.9 t -124.46 127.5 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.952 0.882 . . . . 0.0 111.439 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 5.8 p80 -126.51 103.29 7.52 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.981 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.528 ' CE1' ' HE3' ' F' ' 16' ' ' LYS . 0.0 OUTLIER -148.08 169.38 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.423 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 31.5 mt-30 -89.58 156.88 18.32 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 119.227 -0.989 . . . . 0.0 110.65 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 16' ' ' LYS . . . . . 0.528 ' HE3' ' CE1' ' F' ' 14' ' ' HIS . 98.9 mttt -141.21 104.71 4.68 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.104 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.585 ' H ' HD12 ' F' ' 17' ' ' LEU . 0.0 OUTLIER -124.76 112.31 16.56 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -107.13 107.16 22.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.639 ' CE1' ' CE2' ' E' ' 19' ' ' PHE . 13.1 m-85 -118.89 108.78 15.22 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.525 ' CE2' ' O ' ' F' ' 21' ' ' ALA . 57.7 t80 -148.76 163.32 37.7 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.33 1.062 . . . . 0.0 113.234 -178.428 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.525 ' O ' ' CE2' ' F' ' 20' ' ' PHE . . . -137.62 138.34 39.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.582 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -77.94 112.67 15.07 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 p30 -174.18 48.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.244 -176.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 35.3 m -71.86 160.57 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.043 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.5 -34.66 5.26 Favored Glycine 0 CA--C 1.521 0.409 0 N-CA-C 105.724 -2.95 . . . . 0.0 105.724 -175.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 40.5 t -80.55 120.12 24.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 112.25 -1.975 . . . . 0.0 109.524 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.618 ' O ' ' N ' ' F' ' 29' ' ' GLY . 64.7 t30 -87.43 -175.8 5.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.59 -177.559 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.505 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 99.0 mttt -49.58 49.59 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 115.44 1.644 . . . . 0.0 115.44 -176.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.618 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -101.75 51.42 0.92 Allowed Glycine 0 CA--C 1.545 1.921 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.222 177.314 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.523 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -130.2 170.19 14.39 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.498 HD11 ' NZ ' ' D' ' 28' ' ' LYS . 97.1 mt -119.73 124.68 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.294 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 33.7 pt -135.79 137.18 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 121.215 0.531 . . . . 0.0 111.218 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.96 120.31 2.34 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.584 HD23 ' C ' ' F' ' 34' ' ' LEU . 6.2 tt -118.54 121.98 41.55 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.576 ' N ' HD23 ' F' ' 34' ' ' LEU . 4.8 ttm -119.25 120.37 36.81 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.958 0.409 . . . . 0.0 111.101 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.472 ' O ' ' O ' ' F' ' 37' ' ' GLY . 22.4 m -87.12 131.8 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.076 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -46.97 -111.82 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 121.918 0.732 . . . . 0.0 112.103 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.64 -71.36 0.83 Allowed Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.364 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -102.5 128.58 55.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-O 121.339 0.59 . . . . 0.0 110.751 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.585 -179.982 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -80.54 143.16 33.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.832 0.349 . . . . 0.0 110.805 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -122.68 164.56 18.04 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.268 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.08 131.4 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.25 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 37.8 p-80 -143.69 161.09 39.46 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.509 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 95.4 m-70 -150.22 173.48 13.89 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.154 -179.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 29.7 pt20 -92.33 150.27 20.94 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -101.31 151.16 22.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.131 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 tp -137.45 124.83 21.92 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.561 0.696 . . . . 0.0 111.681 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 65.8 t -124.82 129.97 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 114.99 -1.004 . . . . 0.0 108.819 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -134.27 130.63 37.37 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.198 0.523 . . . . 0.0 111.285 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.6 p90 -135.67 128.37 30.91 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.752 179.498 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.6 138.37 54.56 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.801 0.334 . . . . 0.0 110.898 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -81.96 -168.78 2.07 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.593 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -36.38 -60.46 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.406 -179.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.437 HG12 ' N ' ' G' ' 25' ' ' GLY . 4.1 t -72.73 160.68 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.499 0.666 . . . . 0.0 111.72 -178.367 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.437 ' N ' HG12 ' G' ' 24' ' ' VAL . . . 110.29 -35.21 4.97 Favored Glycine 0 N--CA 1.466 0.671 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.077 177.535 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.438 ' OG ' ' OD1' ' H' ' 23' ' ' ASP . 38.7 m -80.71 119.36 23.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 178.32 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.506 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 15.4 t-20 -88.38 178.91 6.44 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.618 -179.725 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.506 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 77.4 tttt -56.09 -36.55 68.27 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.869 -1.06 . . . . 0.0 111.685 178.799 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.65 82.15 0.45 Allowed Glycine 0 CA--C 1.53 1.018 0 CA-C-N 114.127 -1.397 . . . . 0.0 113.508 -174.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . -101.95 102.98 13.59 Favored 'General case' 0 C--O 1.242 0.698 0 CA-C-O 124.132 1.92 . . . . 0.0 109.775 -178.555 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.506 HG23 HG23 ' H' ' 31' ' ' ILE . 53.1 mt -126.45 132.54 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 CA-C-N 110.506 -3.043 . . . . 0.0 108.868 -177.459 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.505 HG22 HD21 ' H' ' 34' ' ' LEU . 33.5 mt -103.66 110.79 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 176.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.81 104.98 1.44 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 107.524 -2.23 . . . . 0.0 107.524 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.7 tp -163.0 152.79 15.67 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 117.976 -1.49 . . . . 0.0 113.64 -177.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.43 ' SD ' ' HB2' ' H' ' 35' ' ' MET . 45.4 tpp -100.03 116.87 33.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 112.572 -2.103 . . . . 0.0 107.953 178.036 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -123.09 112.1 32.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.53 -131.88 10.75 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.47 -62.66 0.31 Allowed Glycine 0 CA--C 1.54 1.648 0 C-N-CA 121.436 -0.411 . . . . 0.0 112.442 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.674 ' O ' HG23 ' G' ' 40' ' ' VAL . 12.6 p -116.22 160.47 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 C-N-CA 122.542 0.337 . . . . 0.0 110.936 -179.554 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.674 HG23 ' O ' ' G' ' 39' ' ' VAL . 24.7 t . . . . . 0 N--CA 1.471 0.588 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.401 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -83.21 139.76 32.95 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.727 0.298 . . . . 0.0 110.509 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.34 140.76 39.62 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.5 t -129.96 134.51 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.636 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 20.6 t-160 -129.58 100.46 5.54 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.825 0.345 . . . . 0.0 110.843 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 0.1 OUTLIER -159.3 171.98 18.84 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.128 179.851 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.645 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 26.3 mt-30 -152.2 141.31 21.3 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 178.092 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -88.08 114.53 24.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.79 178.006 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 70.8 mt -119.55 112.99 20.04 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -120.77 131.12 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 120.792 0.329 . . . . 0.0 111.441 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -133.15 116.15 15.92 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.585 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' CD2' ' I' ' 20' ' ' PHE . 10.4 m-85 -122.65 134.84 54.48 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.11 127.83 23.33 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 80.3 tt0 -95.02 117.38 30.06 Favored 'General case' 0 CA--C 1.522 -0.101 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 176.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.45 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 84.5 m-20 -136.05 46.99 2.26 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -175.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.66 HG22 ' HA ' ' I' ' 23' ' ' ASP . 17.0 t -99.88 162.98 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 C-N-CA 118.013 -1.475 . . . . 0.0 108.386 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.459 ' N ' HG12 ' H' ' 24' ' ' VAL . . . 70.99 28.58 70.27 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -178.286 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.532 ' OG ' ' N ' ' H' ' 27' ' ' ASN . 20.0 p -170.53 -132.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.801 0.81 . . . . 0.0 112.467 -175.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.532 ' N ' ' OG ' ' H' ' 26' ' ' SER . 1.6 m120 -30.7 143.67 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 114.1 -1.409 . . . . 0.0 113.713 -177.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -132.53 -25.14 1.95 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 113.609 -1.632 . . . . 0.0 111.224 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . -78.83 109.37 2.83 Favored Glycine 0 N--CA 1.47 0.913 0 CA-C-N 116.187 -0.46 . . . . 0.0 113.376 -176.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 111.99 12.61 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 122.385 1.088 . . . . 0.0 112.621 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.506 HG23 HG23 ' G' ' 31' ' ' ILE . 14.9 tt -140.34 137.99 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 114.515 -1.22 . . . . 0.0 111.124 178.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.439 ' CG2' HD12 ' H' ' 34' ' ' LEU . 95.5 mt -106.19 113.88 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.609 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.74 100.67 1.13 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 106.631 -2.588 . . . . 0.0 106.631 176.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.505 HD21 HG22 ' G' ' 32' ' ' ILE . 90.7 mt -141.76 153.45 44.59 Favored 'General case' 0 CA--C 1.51 -0.564 0 CA-C-O 122.844 1.307 . . . . 0.0 113.586 -175.467 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.43 ' HB2' ' SD ' ' G' ' 35' ' ' MET . 4.1 mtp -116.87 117.18 29.02 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 112.498 -2.137 . . . . 0.0 105.939 176.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' K' ' 15' ' ' GLN . 58.9 t -123.56 102.42 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 O-C-N 122.469 -0.144 . . . . 0.0 111.35 -176.404 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.64 -162.37 23.76 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.437 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 146.71 -55.64 0.52 Allowed Glycine 0 CA--C 1.547 2.093 0 CA-C-O 119.572 -0.571 . . . . 0.0 112.561 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.613 ' CG2' HG21 ' N' ' 31' ' ' ILE . 3.0 p -142.44 162.51 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-N 118.498 1.149 . . . . 0.0 110.248 178.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.432 HG23 ' ND1' ' K' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 10' ' ' TYR . . . . . 0.514 ' CD1' ' O ' ' J' ' 9' ' ' GLY . 97.7 m-85 -99.28 132.59 44.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.723 0.297 . . . . 0.0 110.572 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' I' ' 11' ' ' GLU . 2.0 pm0 -154.4 141.25 19.14 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.054 0.454 . . . . 0.0 111.446 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -126.81 129.35 71.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.968 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 18.7 m80 -116.25 138.88 50.93 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 110.35 -0.241 . . . . 0.0 110.35 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -149.85 167.85 25.4 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.351 177.231 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 44.2 tp60 -139.22 141.07 37.91 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.382 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.456 ' C ' HD22 ' I' ' 17' ' ' LEU . 99.5 mttt -129.8 104.3 7.32 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.394 179.167 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.463 HD12 ' CZ ' ' I' ' 19' ' ' PHE . 3.6 mm? -111.9 113.29 25.53 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 t -109.08 107.48 22.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.463 ' CZ ' HD12 ' I' ' 17' ' ' LEU . 57.7 m-85 -109.05 108.45 19.16 Favored 'General case' 0 CA--C 1.546 0.821 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.447 ' CD2' ' CE2' ' H' ' 20' ' ' PHE . 5.4 m-85 -117.5 130.42 56.43 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 122.184 -0.322 . . . . 0.0 110.917 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.29 134.22 30.69 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.563 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 85.5 mt-10 -92.4 -161.33 0.82 Allowed 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.217 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.66 ' HA ' HG22 ' H' ' 24' ' ' VAL . 0.4 OUTLIER 95.12 54.2 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 -177.689 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.458 HG13 ' H ' ' I' ' 24' ' ' VAL . 1.1 m -81.3 133.49 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 CA-C-O 125.133 2.397 . . . . 0.0 116.264 -169.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.707 ' H ' ' HA ' ' J' ' 23' ' ' ASP . . . 94.5 -41.99 2.5 Favored Glycine 0 N--CA 1.443 -0.869 2 CA-C-N 107.471 -4.422 . . . . 0.0 113.594 172.516 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 94.6 p -68.39 110.85 4.31 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 115.976 -1.964 . . . . 0.0 112.039 174.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.888 ' ND2' ' H ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -147.66 124.47 11.23 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 123.313 2.778 . . . . 0.0 111.566 166.739 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.408 ' HZ2' HG23 ' A' ' 39' ' ' VAL . 94.0 mttt -18.11 -52.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 115.638 1.718 . . . . 0.0 115.638 172.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.61 52.77 0.02 OUTLIER Glycine 0 CA--C 1.563 3.08 0 CA-C-N 112.584 -2.098 . . . . 0.0 109.661 -175.25 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.888 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . -41.98 141.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -171.221 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.719 HD12 ' O ' ' B' ' 38' ' ' GLY . 55.0 mt -143.19 147.79 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 112.831 -1.986 . . . . 0.0 113.701 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.429 HD13 HG21 ' I' ' 32' ' ' ILE . 27.3 mt -110.58 111.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 174.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.09 104.57 1.96 Allowed Glycine 0 N--CA 1.466 0.643 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mt -141.14 144.56 34.91 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -175.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 49.2 tpp -112.85 115.67 28.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 104.644 -2.354 . . . . 0.0 104.644 173.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.51 HG12 ' OE1' ' K' ' 15' ' ' GLN . 47.5 t -123.44 102.62 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 118.055 0.389 . . . . 0.0 111.874 -175.767 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.737 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 107.31 -161.93 13.54 Favored Glycine 0 N--CA 1.467 0.714 0 C-N-CA 120.486 -0.864 . . . . 0.0 112.803 177.557 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.822 ' H ' ' H ' ' J' ' 38' ' ' GLY . . . 148.15 -55.35 0.5 Allowed Glycine 0 CA--C 1.542 1.75 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.746 HG21 HD12 ' N' ' 31' ' ' ILE . 18.2 t -114.43 130.46 68.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 C-N-CA 123.409 0.684 . . . . 0.0 109.217 178.554 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.492 HG23 ' ND1' ' K' ' 13' ' ' HIS . 2.4 p . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.898 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 9' ' ' GLY . . . . . 0.514 ' O ' ' CD1' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -117.13 143.83 45.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.675 0.274 . . . . 0.0 110.434 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -73.68 108.58 6.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.86 0.362 . . . . 0.0 110.677 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.7 136.64 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.31 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 1.4 m-70 -145.87 126.07 13.85 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.948 -0.301 . . . . 0.0 111.159 -179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 m-70 -140.41 157.57 45.33 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.012 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -90.31 158.85 16.95 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 174.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 44.1 tttp -141.18 113.55 8.09 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.163 177.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.429 ' N ' HD12 ' J' ' 17' ' ' LEU . 2.8 mp -136.61 127.94 28.28 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.755 0.788 . . . . 0.0 110.84 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -112.95 112.23 39.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 CA-C-N 114.464 -1.244 . . . . 0.0 108.76 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' K' ' 19' ' ' PHE . 18.5 m-85 -106.98 106.33 16.8 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.598 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 20.4 t80 -113.79 114.8 26.81 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.53 122.59 22.62 Favored 'General case' 0 C--O 1.246 0.9 0 CA-C-O 122.153 0.977 . . . . 0.0 111.829 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 96.5 mt-10 -83.89 125.46 32.01 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-N 113.824 -1.535 . . . . 0.0 107.861 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.707 ' HA ' ' H ' ' I' ' 25' ' ' GLY . 61.2 m-20 -166.45 47.29 0.07 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 118.158 -0.925 . . . . 0.0 113.393 -174.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.563 ' N ' ' OE1' ' K' ' 22' ' ' GLU . 9.3 p -98.6 161.31 3.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 CA-C-N 121.419 1.918 . . . . 0.0 109.286 -176.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.741 ' H ' ' N ' ' K' ' 25' ' ' GLY . . . 73.23 28.87 65.3 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 106.662 -2.575 . . . . 0.0 106.662 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 8.7 t -104.5 -120.75 0.21 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 -173.255 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.676 HD21 ' N ' ' J' ' 27' ' ' ASN . 0.7 OUTLIER -81.8 163.75 22.14 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -175.287 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -47.47 -36.82 10.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 112.661 -2.063 . . . . 0.0 114.504 178.075 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.8 77.84 0.06 OUTLIER Glycine 0 CA--C 1.532 1.104 0 C-N-CA 119.147 -1.501 . . . . 0.0 114.859 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.21 169.0 0.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 118.847 1.324 . . . . 0.0 110.555 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.63 HD11 ' HB ' ' D' ' 39' ' ' VAL . 68.8 mt -127.39 135.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 115.212 1.56 . . . . 0.0 115.212 -175.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 53.7 mt -106.49 105.75 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 172.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.18 101.17 1.94 Allowed Glycine 0 CA--C 1.508 -0.398 0 N-CA-C 104.849 -3.301 . . . . 0.0 104.849 176.354 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.752 ' CD2' HG22 ' J' ' 36' ' ' VAL . 6.5 tt -143.33 125.74 15.7 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-O 123.081 1.419 . . . . 0.0 112.618 -175.083 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.7 mtp -104.68 118.07 35.66 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 112.582 -2.099 . . . . 0.0 107.875 178.226 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.752 HG22 ' CD2' ' J' ' 34' ' ' LEU . 1.8 t -105.91 114.09 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' I' ' 36' ' ' VAL . . . -64.78 -123.24 0.01 OUTLIER Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.822 ' H ' ' H ' ' I' ' 38' ' ' GLY . . . 64.99 61.05 6.15 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 114.278 -0.961 . . . . 0.0 114.573 178.357 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.466 ' HB ' HD13 ' P' ' 31' ' ' ILE . 1.0 OUTLIER -92.52 130.17 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 177.817 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.652 ' OXT' HG13 ' J' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.84 -1.076 . . . . 0.0 111.859 -177.604 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -104.69 133.41 49.57 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.75 0.309 . . . . 0.0 110.609 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -142.9 133.29 24.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.666 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 95.2 t -124.97 123.8 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.462 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.492 ' ND1' HG23 ' I' ' 40' ' ' VAL . 6.4 t-160 -145.04 112.98 6.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.044 0.449 . . . . 0.0 111.305 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.673 ' CE1' ' H ' ' L' ' 14' ' ' HIS . 19.0 m-70 -140.41 159.22 42.68 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 177.316 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.737 HE22 ' N ' ' I' ' 37' ' ' GLY . 77.0 mt-30 -90.18 159.35 16.79 Favored 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 175.713 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.711 ' C ' HD12 ' K' ' 17' ' ' LEU . 99.2 mttt -140.03 101.0 4.06 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.711 HD12 ' C ' ' K' ' 16' ' ' LYS . 7.7 mp -125.89 125.91 43.57 Favored 'General case' 0 CA--C 1.506 -0.73 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.785 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.405 HG13 ' O ' ' K' ' 18' ' ' VAL . 5.2 p -119.49 118.33 56.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' J' ' 19' ' ' PHE . 53.2 m-85 -107.03 105.98 16.28 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.728 -1.123 . . . . 0.0 109.69 -178.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.1 t80 -106.24 108.09 19.43 Favored 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -148.36 155.11 40.86 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.94 1.352 . . . . 0.0 113.38 -177.649 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.568 ' HB2' ' H ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -93.06 117.58 30.23 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.908 -179.273 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.427 ' OD2' ' OD1' ' L' ' 23' ' ' ASP . 13.6 m-20 -67.4 -51.25 54.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 114.418 -1.265 . . . . 0.0 111.547 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.568 HG22 ' N ' ' K' ' 25' ' ' GLY . 2.3 p 158.8 161.84 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -177.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.741 ' N ' ' H ' ' J' ' 25' ' ' GLY . . . -63.29 30.41 0.08 OUTLIER Glycine 0 CA--C 1.532 1.116 0 N-CA-C 118.509 2.164 . . . . 0.0 118.509 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.575 ' OG ' ' O ' ' K' ' 25' ' ' GLY . 5.2 m -169.96 -127.8 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 121.293 2.546 . . . . 0.0 114.104 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.437 ' O ' ' N ' ' K' ' 29' ' ' GLY . 60.2 t30 -48.13 152.29 0.85 Allowed 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 113.577 0.955 . . . . 0.0 113.577 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.449 ' NZ ' HD11 ' L' ' 32' ' ' ILE . 85.0 tttt -70.33 48.84 0.11 Allowed 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . -82.47 51.1 4.46 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.27 -0.966 . . . . 0.0 112.707 -176.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 173.58 7.13 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.529 HD12 HG13 ' D' ' 39' ' ' VAL . 42.2 mt -125.46 127.75 72.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.743 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.424 HD13 HG21 ' K' ' 32' ' ' ILE . 33.4 pt -132.63 127.6 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.664 0.745 . . . . 0.0 111.753 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.608 ' C ' HD22 ' K' ' 34' ' ' LEU . . . -117.34 110.93 2.15 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.709 HD22 ' N ' ' K' ' 34' ' ' LEU . 1.9 mm? -121.64 116.16 24.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.902 0.382 . . . . 0.0 110.066 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 4.1 ttm -107.81 130.28 54.99 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.445 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 54.0 t -125.64 131.84 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 CA-C-O 121.915 0.864 . . . . 0.0 112.352 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.03 -111.41 0.01 OUTLIER Glycine 0 CA--C 1.527 0.827 0 CA-C-N 113.722 -1.581 . . . . 0.0 111.085 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' OXT' ' J' ' 40' ' ' VAL . . . 105.91 -70.55 0.23 Allowed Glycine 0 N--CA 1.473 1.101 0 CA-C-N 114.518 -0.841 . . . . 0.0 111.758 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -155.58 97.21 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.403 ' CA ' HG21 ' Q' ' 31' ' ' ILE . 2.3 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.946 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -108.79 132.64 53.79 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -144.54 142.63 30.35 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.921 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.533 HG12 ' NE2' ' K' ' 14' ' ' HIS . 2.1 t -110.79 115.93 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 110.462 -179.335 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.5 p80 -147.19 101.5 3.4 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.975 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.673 ' H ' ' CE1' ' K' ' 14' ' ' HIS . 97.6 m-70 -156.55 164.92 37.64 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 178.123 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.449 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 96.5 mm-40 -89.97 159.36 16.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.358 . . . . 0.0 111.104 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.78 104.18 4.83 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.605 0.716 . . . . 0.0 109.494 177.701 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.663 ' CD1' HG21 ' J' ' 36' ' ' VAL . 1.8 mt -122.69 115.48 22.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -101.64 97.76 6.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.327 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.565 ' CZ ' HD12 ' K' ' 34' ' ' LEU . 85.2 m-85 -93.87 98.93 11.39 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.368 -1.715 . . . . 0.0 106.368 178.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -122.38 127.02 49.22 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.746 0.784 . . . . 0.0 109.996 -178.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.11 150.96 36.03 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -64.45 107.79 1.46 Allowed 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 118.549 -1.26 . . . . 0.0 108.758 -178.026 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.427 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 13.8 m-20 -153.89 50.0 0.66 Allowed 'General case' 0 C--O 1.231 0.122 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.454 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 95.8 t -82.8 149.3 4.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 178.095 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.93 36.25 5.83 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 18.1 t -76.45 102.35 5.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.706 0.765 . . . . 0.0 111.487 -176.616 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -97.48 -167.61 1.56 Allowed 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.543 -1.208 . . . . 0.0 112.188 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -49.13 -40.55 32.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.042 -1.436 . . . . 0.0 114.38 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.31 68.79 1.86 Allowed Glycine 0 N--CA 1.477 1.432 0 N-CA-C 114.971 0.748 . . . . 0.0 114.971 -175.09 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.444 ' CB ' ' O ' ' K' ' 28' ' ' LYS . . . -141.74 141.71 33.26 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -120.6 117.69 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.125 0 CA-C-N 120.443 1.474 . . . . 0.0 111.577 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.449 HD11 ' NZ ' ' K' ' 28' ' ' LYS . 95.4 mt -119.57 122.18 68.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-N 114.812 -1.086 . . . . 0.0 110.205 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.4 106.72 0.91 Allowed Glycine 0 N--CA 1.464 0.547 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.9 tp -125.17 123.9 40.61 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 94.0 mtp -132.77 133.58 43.61 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.436 0.636 . . . . 0.0 112.217 -179.06 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.5 t -128.87 132.35 67.55 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.135 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 177.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.6 112.19 3.53 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 119.182 -1.485 . . . . 0.0 111.736 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.34 -63.51 4.46 Favored Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 177.158 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.506 ' CA ' HD11 ' R' ' 31' ' ' ILE . 0.8 OUTLIER -125.65 -169.5 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 C-N-CA 124.229 1.012 . . . . 0.0 108.355 -179.111 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.909 ' N ' HD11 ' R' ' 31' ' ' ILE . 0.7 OUTLIER . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.348 -0.834 . . . . 0.0 111.734 179.05 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -110.2 138.54 46.45 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.728 0.299 . . . . 0.0 110.487 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 42.7 tp10 -141.67 110.41 6.13 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.89 0.376 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 70.4 t -125.87 131.6 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.814 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -107.43 107.81 18.86 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.695 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 42.8 p-80 -152.66 165.94 33.68 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-O 121.212 0.53 . . . . 0.0 111.728 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 52.7 tt0 -170.75 147.99 2.87 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.271 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -77.9 120.41 22.74 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -128.31 113.81 16.1 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -130.19 130.07 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.354 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -133.56 141.88 47.91 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.44 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.408 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 50.9 p90 -134.8 129.28 34.31 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.714 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.53 116.59 31.11 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.326 0.584 . . . . 0.0 110.339 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 22' ' ' GLU . . . . . 0.581 ' O ' ' N ' ' M' ' 24' ' ' VAL . 67.3 mt-10 -150.9 -139.06 0.09 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.329 -0.851 . . . . 0.0 108.918 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 53.7 p30 -53.05 50.99 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.694 1.197 . . . . 0.0 113.226 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.587 HG12 ' H ' ' M' ' 25' ' ' GLY . 2.7 t -101.02 -141.73 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.886 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.587 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -72.59 -36.99 58.29 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 119.161 -1.495 . . . . 0.0 113.273 -175.309 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 26' ' ' SER . . . . . 0.425 ' O ' ' C ' ' M' ' 27' ' ' ASN . 93.8 p -162.27 117.26 1.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 118.873 1.336 . . . . 0.0 112.134 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.529 ' ND2' ' O ' ' N' ' 25' ' ' GLY . 99.1 m-20 -23.33 144.83 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.769 -1.105 . . . . 0.0 113.194 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -120.24 -36.6 3.21 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 173.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 29' ' ' GLY . . . . . 0.437 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 80.14 -70.2 2.98 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 112.275 -2.239 . . . . 0.0 112.584 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.437 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 179.46 74.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.533 0.666 . . . . 0.0 112.022 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.6 HG23 ' O ' ' M' ' 31' ' ' ILE . 19.3 tt -128.58 108.94 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 CA-C-N 119.243 0.929 . . . . 0.0 109.313 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 32' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' O' ' 19' ' ' PHE . 96.6 mt -114.48 109.55 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.592 -179.706 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.25 98.36 0.69 Allowed Glycine 0 N--CA 1.461 0.308 0 N-CA-C 106.154 -2.778 . . . . 0.0 106.154 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 82.5 mt -145.93 164.6 31.5 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 123.269 1.509 . . . . 0.0 113.888 -176.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.9 mmm -113.77 110.19 19.77 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 111.771 -2.468 . . . . 0.0 106.859 177.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -118.04 111.78 35.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 134.69 -131.52 5.92 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.02 -63.08 0.75 Allowed Glycine 0 CA--C 1.536 1.398 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.261 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.449 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 2.1 t -114.04 160.71 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-N 116.992 0.396 . . . . 0.0 110.05 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.449 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 21.8 m . . . . . 0 N--CA 1.469 0.48 0 CA-C-O 117.836 -1.078 . . . . 0.0 111.918 178.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.113 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -85.51 137.9 32.57 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -100.77 141.95 32.92 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.487 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -124.72 132.78 70.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.376 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 51.0 m170 -116.98 99.79 7.31 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' N ' ' N' ' 15' ' ' GLN . 23.1 t60 -154.01 165.82 34.96 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.594 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.636 ' N ' ' CD2' ' N' ' 14' ' ' HIS . 13.4 pt20 -160.34 143.52 13.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.217 178.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -80.0 112.2 17.06 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.457 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 tt -120.98 117.92 28.53 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -125.72 131.83 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.09 0.471 . . . . 0.0 111.094 -179.376 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -126.94 119.12 25.95 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 87.5 t80 -118.21 126.32 51.95 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.32 129.49 43.27 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 121.292 0.568 . . . . 0.0 112.355 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -88.65 115.99 26.58 Favored 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -87.04 47.6 1.53 Allowed 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -110.48 151.64 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 176.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 25' ' ' GLY . . . . . 0.529 ' O ' ' ND2' ' M' ' 27' ' ' ASN . . . 63.39 29.83 75.73 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.496 ' O ' ' O ' ' N' ' 27' ' ' ASN . 4.7 t -155.65 111.24 3.04 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 113.854 1.057 . . . . 0.0 113.854 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' N' ' 26' ' ' SER . 60.8 m-20 -49.7 -164.75 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.178 176.565 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.59 ' NZ ' ' CG2' ' G' ' 39' ' ' VAL . 81.7 mttt 78.38 -41.17 0.3 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.543 1.137 . . . . 0.0 114.012 177.331 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.96 -68.28 3.45 Favored Glycine 0 CA--C 1.545 1.96 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.731 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.98 107.85 0.03 OUTLIER 'General case' 0 C--N 1.346 0.448 0 CA-C-N 117.576 0.688 . . . . 0.0 111.853 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.746 HD12 HG21 ' I' ' 39' ' ' VAL . 0.2 OUTLIER -123.89 122.09 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 O-C-N 122.208 -0.307 . . . . 0.0 110.489 178.755 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.595 HD13 ' CD1' ' P' ' 19' ' ' PHE . 60.5 mt -114.36 116.15 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 110.39 2.22 Favored Glycine 0 N--CA 1.468 0.775 0 N-CA-C 106.179 -2.769 . . . . 0.0 106.179 177.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.639 ' HB2' HD22 ' O' ' 34' ' ' LEU . 76.5 mt -144.67 143.58 30.81 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -174.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 1.7 ttm -110.11 106.66 16.22 Favored 'General case' 0 N--CA 1.441 -0.895 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 173.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.542 HG11 ' CD2' ' P' ' 17' ' ' LEU . 29.6 m -126.31 123.33 63.3 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.18 -113.58 0.99 Allowed Glycine 0 C--N 1.308 -1.011 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.47 ' O ' HD11 ' B' ' 31' ' ' ILE . . . 73.08 -72.78 1.09 Allowed Glycine 0 CA--C 1.532 1.109 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.052 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 52.0 t -113.34 132.61 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 98.8 t . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.363 179.896 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.119 -1.593 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -112.85 138.4 49.74 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.993 0.425 . . . . 0.0 110.571 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 11' ' ' GLU . . . . . 0.548 ' O ' ' CE1' ' P' ' 13' ' ' HIS . 98.3 mt-10 -140.92 162.93 34.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.714 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.675 HG12 ' H ' ' P' ' 12' ' ' VAL . 5.0 m -118.53 126.87 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.467 ' C ' ' CG ' ' O' ' 14' ' ' HIS . 10.3 m80 -129.92 136.23 49.24 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.329 0.585 . . . . 0.0 112.028 -178.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.708 ' CE1' ' H ' ' P' ' 14' ' ' HIS . 5.1 m-70 -156.97 176.0 13.35 Favored 'General case' 0 C--O 1.223 -0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.294 179.241 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 7.6 tt0 -152.96 140.11 19.38 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 16' ' ' LYS . . . . . 0.557 ' N ' ' CE1' ' N' ' 14' ' ' HIS . 88.2 tttt -94.45 110.89 22.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.167 -0.469 . . . . 0.0 112.106 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.82 HD22 ' N ' ' O' ' 17' ' ' LEU . 0.7 OUTLIER -117.73 109.8 17.05 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 176.102 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -110.11 113.89 45.49 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.572 ' CD1' HD13 ' M' ' 32' ' ' ILE . 77.9 m-85 -113.36 106.88 15.12 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.77 125.03 53.23 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.789 0.328 . . . . 0.0 110.553 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.58 122.73 28.04 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -149.32 -176.77 5.5 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.431 ' N ' ' OE1' ' P' ' 22' ' ' GLU . 96.7 m-20 66.22 50.32 1.39 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 113.365 -1.743 . . . . 0.0 112.298 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.447 HG12 ' H ' ' O' ' 26' ' ' SER . 67.0 t -82.45 146.43 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.91 -39.12 64.65 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 118.682 -1.723 . . . . 0.0 110.57 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.721 ' O ' ' O ' ' O' ' 27' ' ' ASN . 39.4 t -174.15 124.78 0.33 Allowed 'General case' 0 C--O 1.221 -0.436 0 CA-C-O 118.525 -0.75 . . . . 0.0 110.185 178.411 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.721 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.5 t-20 -2.62 145.99 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 178.422 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.417 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 93.4 mttt -159.03 30.93 0.21 Allowed 'General case' 0 N--CA 1.468 0.44 0 O-C-N 121.805 -0.56 . . . . 0.0 112.413 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.71 88.28 0.72 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 119.49 -1.338 . . . . 0.0 113.028 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 134.41 52.45 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.949 0.881 . . . . 0.0 109.873 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.715 HD13 HG22 ' I' ' 39' ' ' VAL . 4.5 tt -149.23 140.54 17.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.744 -175.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.56 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 73.6 mt -110.57 109.86 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 176.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 33' ' ' GLY . . . . . 0.817 ' O ' HD23 ' O' ' 34' ' ' LEU . . . -117.54 101.85 0.96 Allowed Glycine 0 N--CA 1.469 0.855 0 N-CA-C 108.489 -1.845 . . . . 0.0 108.489 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.817 HD23 ' O ' ' O' ' 33' ' ' GLY . 0.3 OUTLIER -141.92 158.83 43.32 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 122.962 1.363 . . . . 0.0 114.175 -177.052 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -112.16 112.71 24.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 111.618 -2.537 . . . . 0.0 106.315 175.724 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.449 HG22 ' CG2' ' N' ' 36' ' ' VAL . 88.6 t -119.68 111.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -177.788 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 136.01 -131.67 5.81 Favored Glycine 0 C--N 1.319 -0.397 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.567 178.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.431 ' O ' HG23 ' P' ' 39' ' ' VAL . . . 98.96 -63.26 0.75 Allowed Glycine 0 CA--C 1.541 1.66 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.42 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.556 ' CG2' HG21 ' C' ' 31' ' ' ILE . 55.9 t -126.95 133.34 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.407 ' H ' HG11 ' P' ' 39' ' ' VAL . 96.6 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.723 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -108.79 135.69 49.6 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.078 0.466 . . . . 0.0 110.793 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -89.7 116.77 28.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.11 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.675 ' H ' HG12 ' O' ' 12' ' ' VAL . 34.7 m -136.31 159.86 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.185 0.517 . . . . 0.0 111.455 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.548 ' CE1' ' O ' ' O' ' 11' ' ' GLU . 80.0 m-70 -147.48 104.62 3.65 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.024 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.708 ' H ' ' CE1' ' O' ' 14' ' ' HIS . 40.0 m-70 -148.74 159.43 44.14 Favored 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.734 178.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.432 HE21 ' HG2' ' Q' ' 15' ' ' GLN . 2.3 mt-30 -90.31 159.89 16.42 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 114.215 -1.357 . . . . 0.0 107.822 175.111 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.34 99.21 3.6 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.542 ' CD2' HG11 ' N' ' 36' ' ' VAL . 4.6 mp -127.37 122.63 34.18 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.116 0.484 . . . . 0.0 110.525 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.44 114.31 45.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.595 ' CD1' HD13 ' N' ' 32' ' ' ILE . 59.4 m-85 -112.36 108.01 17.03 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -112.78 124.11 51.85 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.318 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 137.05 34.74 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 113.837 1.051 . . . . 0.0 113.837 -178.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.431 ' OE1' ' N ' ' O' ' 23' ' ' ASP . 78.9 tt0 -81.6 116.94 21.58 Favored 'General case' 0 N--CA 1.462 0.149 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.057 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.404 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 99.7 m-20 -138.34 50.28 1.89 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -176.66 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -81.85 148.4 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.625 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.485 ' O ' ' CB ' ' O' ' 27' ' ' ASN . . . 93.72 36.16 5.92 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 106.412 -2.675 . . . . 0.0 106.412 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 21.9 p -76.05 102.62 5.75 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 122.443 1.116 . . . . 0.0 112.498 -174.379 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -96.87 -164.47 1.15 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 112.823 -1.99 . . . . 0.0 110.889 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt -48.74 -40.25 27.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.895 -1.048 . . . . 0.0 111.877 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.77 70.08 1.88 Allowed Glycine 0 CA--C 1.543 1.809 0 N-CA-C 114.937 0.735 . . . . 0.0 114.937 -174.351 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.36 111.04 6.81 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 104.969 -2.234 . . . . 0.0 104.969 176.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.466 HD13 ' HB ' ' J' ' 39' ' ' VAL . 57.6 mt -135.42 136.18 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -172.371 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.471 HD13 ' CD1' ' R' ' 19' ' ' PHE . 3.0 mt -106.05 106.07 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.26 99.38 1.18 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 106.482 -2.647 . . . . 0.0 106.482 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.502 ' CD1' HD12 ' O' ' 34' ' ' LEU . 2.8 tp -128.43 123.59 34.11 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-O 122.419 1.104 . . . . 0.0 112.821 -176.277 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -98.47 104.35 16.38 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 175.422 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.623 HG13 ' O ' ' P' ' 36' ' ' VAL . 8.7 p -119.18 113.76 42.43 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -177.57 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.22 -123.85 1.21 Allowed Glycine 0 C--N 1.309 -0.958 0 C-N-CA 118.95 -1.595 . . . . 0.0 111.79 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.525 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 81.26 -67.72 3.57 Favored Glycine 0 CA--C 1.536 1.354 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -178.087 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.439 ' CG1' ' OD1' ' D' ' 27' ' ' ASN . 67.9 t -136.09 155.61 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.419 ' N ' HG12 ' P' ' 39' ' ' VAL . 11.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.651 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -108.56 134.77 50.85 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.751 0.31 . . . . 0.0 110.313 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -88.87 117.96 28.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.878 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -127.98 135.51 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 120.949 0.404 . . . . 0.0 110.991 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.488 ' CD2' ' N ' ' Q' ' 13' ' ' HIS . 2.0 m-70 -136.18 118.29 15.44 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.628 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.692 ' CD2' ' H ' ' R' ' 14' ' ' HIS . 22.7 m80 -147.23 159.6 43.45 Favored 'General case' 0 C--O 1.219 -0.534 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.29 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.598 ' NE2' ' OE1' ' R' ' 15' ' ' GLN . 0.0 OUTLIER -90.25 159.59 16.61 Favored 'General case' 0 C--N 1.334 -0.084 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 176.145 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 66.5 tttt -140.2 104.34 4.79 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 120.313 -0.555 . . . . 0.0 109.697 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' Q' ' 17' ' ' LEU . 4.3 mp -128.88 126.23 39.29 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 121.724 0.773 . . . . 0.0 111.006 179.153 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 84.8 t -114.3 113.63 44.32 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 114.721 -1.127 . . . . 0.0 108.837 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.56 ' CD1' HD13 ' O' ' 32' ' ' ILE . 59.5 m-85 -110.76 103.65 12.21 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 178.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -112.45 125.09 53.84 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.888 -178.22 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.68 143.61 35.2 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.404 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 93.7 mt-10 -84.64 137.37 33.31 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 120.166 -0.613 . . . . 0.0 109.619 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.531 ' OD2' ' HB1' ' R' ' 21' ' ' ALA . 35.8 p-10 -177.75 50.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.159 -177.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.473 HG22 ' O ' ' R' ' 22' ' ' GLU . 61.5 t -81.8 149.27 4.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.904 1.335 . . . . 0.0 113.828 -174.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.415 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 93.09 36.7 5.9 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 111.784 -2.462 . . . . 0.0 112.887 178.128 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' Q' ' 25' ' ' GLY . 3.2 p 72.65 120.18 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 118.621 -0.704 . . . . 0.0 110.546 175.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.611 HD21 ' HB2' ' Q' ' 30' ' ' ALA . 6.9 m-20 -83.11 160.99 21.77 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 116.824 -1.95 . . . . 0.0 108.057 176.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -48.74 -39.79 26.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.573 0.702 . . . . 0.0 111.381 176.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.23 67.46 0.04 OUTLIER Glycine 0 CA--C 1.541 1.711 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.075 -177.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . 0.611 ' HB2' HD21 ' Q' ' 27' ' ' ASN . . . -70.96 152.18 43.89 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 118.449 1.125 . . . . 0.0 112.002 -176.69 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.443 HG23 HG23 ' R' ' 31' ' ' ILE . 6.3 mt -113.3 129.19 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.328 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 99.8 mt -124.69 116.06 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.72 117.02 3.16 Favored Glycine 0 N--CA 1.47 0.951 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.244 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 29.2 tp -124.55 120.64 32.53 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 93.7 mtp -135.17 144.94 47.3 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -178.091 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.82 164.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.68 93.68 0.1 Allowed Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.056 -1.068 . . . . 0.0 111.119 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' H ' ' HA3' ' R' ' 38' ' ' GLY . . . 164.45 -81.86 0.11 Allowed Glycine 0 CA--C 1.536 1.347 0 C-N-CA 120.473 -0.87 . . . . 0.0 112.465 177.674 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -157.68 147.57 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.158 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.392 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.552 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.95 133.09 51.23 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.876 0.37 . . . . 0.0 110.609 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 21.1 pt-20 -77.99 150.65 33.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.762 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.4 HG12 ' HE2' ' Q' ' 14' ' ' HIS . 52.9 t -123.69 131.62 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.105 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.428 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.0 OUTLIER -152.22 112.67 4.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.487 -179.656 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.692 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 75.0 m80 -149.81 164.43 35.35 Favored 'General case' 0 C--O 1.22 -0.472 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.598 ' OE1' ' NE2' ' Q' ' 15' ' ' GLN . 60.0 mt-30 -89.94 159.5 16.88 Favored 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 120.317 -0.553 . . . . 0.0 110.401 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 61.8 tttp -139.55 115.19 10.02 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.456 0.646 . . . . 0.0 110.332 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.448 ' N ' HD12 ' R' ' 17' ' ' LEU . 1.2 mp -135.46 125.54 26.04 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.796 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 3.5 p -112.96 116.48 52.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 176.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.471 ' CD1' HD13 ' P' ' 32' ' ' ILE . 55.3 m-85 -105.17 104.77 14.57 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -123.73 124.37 42.58 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.997 0.903 . . . . 0.0 112.099 -177.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.531 ' HB1' ' OD2' ' Q' ' 23' ' ' ASP . . . -120.65 130.2 54.03 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.473 ' O ' HG22 ' Q' ' 24' ' ' VAL . 97.8 mt-10 -70.21 110.15 5.04 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 118.813 -1.155 . . . . 0.0 110.377 -177.421 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 179.57 48.62 0.0 OUTLIER 'General case' 0 C--N 1.342 0.277 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.519 HG12 ' N ' ' R' ' 25' ' ' GLY . 69.0 t -72.85 160.34 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 117.324 -1.75 . . . . 0.0 108.644 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.519 ' N ' HG12 ' R' ' 24' ' ' VAL . . . 110.35 -33.27 6.06 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.3 m -72.2 129.57 38.77 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 113.028 -1.586 . . . . 0.0 111.806 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 27' ' ' ASN . . . . . 0.67 ' O ' ' N ' ' R' ' 29' ' ' GLY . 98.6 m-20 -90.86 -161.91 0.86 Allowed 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.22 47.58 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 29' ' ' GLY . . . . . 0.67 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.28 56.9 0.9 Allowed Glycine 0 CA--C 1.541 1.686 0 CA-C-N 119.301 0.955 . . . . 0.0 111.997 178.184 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.97 168.61 13.73 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.909 HD11 ' N ' ' L' ' 40' ' ' VAL . 15.9 tt -116.15 110.28 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.439 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.5 mt -117.11 128.63 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.542 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.14 115.07 2.44 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.46 117.4 25.87 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 8.9 ttp -141.19 124.38 16.46 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.364 0.602 . . . . 0.0 111.126 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.32 111.68 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 120.125 -0.63 . . . . 0.0 111.753 -179.409 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.8 132.17 10.9 Favored Glycine 0 CA--C 1.518 0.273 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 176.845 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' R' R ' 38' ' ' GLY . . . . . 0.417 ' HA3' ' H ' ' Q' ' 38' ' ' GLY . . . 109.49 63.24 0.53 Allowed Glycine 0 N--CA 1.474 1.18 0 CA-C-N 118.201 1.0 . . . . 0.0 112.95 179.618 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' R' ' 38' ' ' GLY . 41.4 t -32.17 151.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 117.285 0.543 . . . . 0.0 112.287 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.765 179.682 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.097 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -108.23 137.04 46.88 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.706 0.288 . . . . 0.0 110.76 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.45 ' O ' ' OE1' ' B' ' 11' ' ' GLU . 95.7 mt-10 -118.28 140.02 50.45 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.029 0.443 . . . . 0.0 110.419 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 m -137.27 162.13 33.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.966 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.461 ' H ' ' HB3' ' B' ' 13' ' ' HIS . 80.2 m80 -145.13 135.53 24.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.583 0.23 . . . . 0.0 110.785 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.572 ' CD2' ' N ' ' A' ' 15' ' ' GLN . 20.8 t60 -158.06 165.18 35.7 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.972 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 68.2 tp60 -158.97 142.45 14.89 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 121.027 0.442 . . . . 0.0 109.97 177.552 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -82.51 124.16 29.85 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.473 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.0 mt -127.18 119.52 26.63 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -141.49 146.45 23.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.363 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -147.52 141.2 25.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.11 0.481 . . . . 0.0 111.427 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.476 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 49.6 p90 -115.34 132.64 56.55 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.229 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.05 126.93 46.15 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 -177.205 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.472 ' C ' ' H ' ' A' ' 24' ' ' VAL . 96.0 mt-10 -128.14 -140.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -68.49 50.44 0.07 Allowed 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.791 HG13 ' N ' ' A' ' 25' ' ' GLY . 3.9 p -93.21 -142.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.748 -1.114 . . . . 0.0 110.761 -177.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.791 ' N ' HG13 ' A' ' 24' ' ' VAL . . . -82.78 -36.98 14.28 Favored Glycine 0 CA--C 1.526 0.744 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.037 -177.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.663 ' H ' HG13 ' A' ' 24' ' ' VAL . 28.9 t -81.28 118.34 22.53 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.5 p30 -88.23 -179.31 6.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 115.159 1.54 . . . . 0.0 115.159 -174.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.439 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 96.0 mttt -55.86 -37.48 68.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 112.081 -2.327 . . . . 0.0 112.409 -179.055 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.05 77.72 0.4 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 112.079 -0.408 . . . . 0.0 112.079 -175.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.39 141.67 41.43 Favored 'General case' 0 C--O 1.243 0.746 0 CA-C-O 123.736 1.731 . . . . 0.0 113.012 -177.132 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -126.76 127.63 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.739 -2.482 . . . . 0.0 108.406 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.452 ' O ' ' O ' ' B' ' 33' ' ' GLY . 80.8 mt -100.9 105.66 18.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.381 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.07 96.39 1.15 Allowed Glycine 0 CA--C 1.505 -0.589 0 N-CA-C 104.385 -3.486 . . . . 0.0 104.385 176.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.932 ' O ' HD12 ' B' ' 34' ' ' LEU . 51.6 tp -148.2 159.21 44.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 123.002 1.382 . . . . 0.0 112.969 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.487 ' CE ' ' SD ' ' B' ' 35' ' ' MET . 17.0 mtp -119.52 117.51 28.59 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.482 179.443 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 36' ' ' VAL . 27.3 m -119.24 111.85 35.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 177.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.22 -131.99 8.14 Favored Glycine 0 C--N 1.315 -0.602 0 N-CA-C 107.543 -2.223 . . . . 0.0 107.543 -177.22 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' B' ' 39' ' ' VAL . . . 87.05 -63.72 3.99 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 120.126 -1.035 . . . . 0.0 111.608 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -108.26 179.89 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 120.847 0.356 . . . . 0.0 110.106 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.455 HG12 ' CD2' ' C' ' 13' ' ' HIS . 85.9 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.852 -1.071 . . . . 0.0 110.959 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.17 132.13 54.41 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.31 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' O ' ' A' ' 11' ' ' GLU . 80.7 mm-40 -124.63 122.77 38.46 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.439 ' CG1' ' C ' ' C' ' 12' ' ' VAL . 3.6 t -112.92 100.27 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.983 0.42 . . . . 0.0 110.52 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.461 ' HB3' ' H ' ' A' ' 13' ' ' HIS . 12.2 p-80 -138.82 145.19 39.76 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.747 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.548 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 2.9 p80 -146.33 160.35 42.14 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.482 0.658 . . . . 0.0 111.98 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.546 ' NE2' ' OE1' ' C' ' 15' ' ' GLN . 34.4 mt-30 -90.3 159.67 16.53 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.178 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -139.97 108.05 5.75 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.49 130.84 53.48 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 120.875 0.369 . . . . 0.0 111.021 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.84 130.88 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.713 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -127.26 129.64 48.11 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -128.68 124.19 35.05 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.05 134.37 54.78 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.173 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.484 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 81.9 tt0 -161.74 159.8 27.65 Favored 'General case' 0 CA--C 1.55 0.969 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 -178.463 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' B' ' 24' ' ' VAL . 19.4 t70 112.83 -70.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 127.055 2.142 . . . . 0.0 110.854 177.205 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.524 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.7 t -58.77 -122.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 173.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.46 ' H ' HG12 ' B' ' 24' ' ' VAL . . . 139.12 -34.94 2.02 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-O 118.089 -1.395 . . . . 0.0 116.262 172.651 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -80.43 119.52 23.23 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 121.355 2.578 . . . . 0.0 106.59 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 28' ' ' LYS . 3.0 m120 -89.78 157.7 17.83 Favored 'General case' 0 C--N 1.344 0.368 0 C-N-CA 116.11 -2.236 . . . . 0.0 108.181 176.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -48.31 -40.53 25.39 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 122.394 1.092 . . . . 0.0 110.983 174.07 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 67.64 0.04 OUTLIER Glycine 0 CA--C 1.549 2.21 0 CA-C-N 112.956 -1.929 . . . . 0.0 110.5 -174.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.07 141.89 52.74 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 120.09 1.945 . . . . 0.0 115.168 -172.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.895 HG23 HG23 ' C' ' 31' ' ' ILE . 19.8 mt -136.23 134.09 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 113.159 -1.837 . . . . 0.0 113.106 -175.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.92 103.0 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 174.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -103.69 103.88 2.4 Favored Glycine 0 CA--C 1.507 -0.446 0 N-CA-C 104.309 -3.516 . . . . 0.0 104.309 175.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.932 HD12 ' O ' ' A' ' 34' ' ' LEU . 17.8 tp -146.12 147.66 31.79 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 118.272 -1.371 . . . . 0.0 113.538 -173.021 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.487 ' SD ' ' CE ' ' A' ' 35' ' ' MET . 3.9 ttm -113.13 116.37 29.74 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-N 112.815 -1.993 . . . . 0.0 107.824 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.406 HG23 HD21 ' C' ' 34' ' ' LEU . 37.8 t -118.95 123.73 71.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.76 -114.15 2.03 Favored Glycine 0 C--N 1.315 -0.591 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.535 ' O ' ' CD1' ' H' ' 31' ' ' ILE . . . 81.02 -72.65 2.7 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.486 ' CG2' ' O ' ' A' ' 38' ' ' GLY . 24.8 t -124.54 163.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.532 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 20.7 m . . . . . 0 N--CA 1.473 0.689 0 CA-C-O 117.782 -1.104 . . . . 0.0 111.694 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.97 135.59 50.59 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -138.83 144.9 39.46 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.801 HG21 ' C ' ' D' ' 12' ' ' VAL . 27.6 m -138.19 164.43 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-O 120.963 0.411 . . . . 0.0 111.807 -179.029 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.455 ' CD2' HG12 ' A' ' 40' ' ' VAL . 4.2 p-80 -129.48 132.92 47.04 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.301 0.572 . . . . 0.0 112.131 -178.552 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.538 ' CG ' ' O ' ' D' ' 14' ' ' HIS . 17.7 p-80 -157.26 169.52 24.56 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.066 178.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.546 ' OE1' ' NE2' ' B' ' 15' ' ' GLN . 99.5 mm-40 -89.67 156.61 18.45 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.112 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -141.36 115.41 9.25 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.993 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.453 ' HB2' HD22 ' D' ' 17' ' ' LEU . 4.6 mp -135.24 118.8 16.96 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 122.018 0.913 . . . . 0.0 111.029 178.153 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -106.76 117.51 52.7 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.402 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 54.9 m-85 -109.93 99.73 8.81 Favored 'General case' 0 N--CA 1.447 -0.582 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -109.79 126.67 54.01 Favored 'General case' 0 C--O 1.241 0.626 0 CA-C-O 121.41 0.624 . . . . 0.0 111.058 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 21' ' ' ALA . . . . . 0.638 ' HB1' HG13 ' C' ' 24' ' ' VAL . . . -128.17 113.26 15.49 Favored 'General case' 0 C--O 1.244 0.778 0 CA-C-O 121.884 0.85 . . . . 0.0 110.806 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.424 ' OE2' ' OD1' ' C' ' 23' ' ' ASP . 0.4 OUTLIER -86.17 103.3 14.68 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.065 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.474 ' H ' ' HB2' ' D' ' 22' ' ' GLU . 35.5 m-20 50.84 50.15 19.61 Favored 'General case' 0 C--O 1.214 -0.793 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.47 -177.417 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.939 HG22 ' H ' ' C' ' 25' ' ' GLY . 9.9 p -160.1 -174.22 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.094 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.939 ' H ' HG22 ' C' ' 24' ' ' VAL . . . 59.78 26.82 63.27 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.777 178.288 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' C' ' 27' ' ' ASN . 62.8 m -166.19 -145.94 0.08 Allowed 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' C' ' 26' ' ' SER . 10.6 m-20 55.48 142.25 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 120.906 0.384 . . . . 0.0 111.797 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.745 ' H ' ' CB ' ' D' ' 26' ' ' SER . 71.1 mmtt 62.47 46.06 5.96 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 61.08 0.79 Allowed Glycine 0 N--CA 1.474 1.204 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.083 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -101.87 119.3 38.56 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-O 121.567 0.698 . . . . 0.0 109.66 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.895 HG23 HG23 ' B' ' 31' ' ' ILE . 3.6 tt -137.07 136.34 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 120.021 -0.672 . . . . 0.0 112.438 -177.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.414 HD13 ' CD1' ' E' ' 19' ' ' PHE . 63.5 mt -107.09 107.42 22.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 176.687 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.06 100.95 2.01 Favored Glycine 0 C--O 1.237 0.327 0 N-CA-C 104.89 -3.284 . . . . 0.0 104.89 175.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.756 HD23 ' O ' ' B' ' 34' ' ' LEU . 0.8 OUTLIER -133.25 138.08 46.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.99 1.376 . . . . 0.0 114.314 -174.75 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -109.14 110.75 22.07 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 175.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.417 HG22 HD22 ' C' ' 34' ' ' LEU . 25.0 t -122.98 123.16 67.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 118.429 0.559 . . . . 0.0 109.529 -177.02 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.5 -113.19 0.65 Allowed Glycine 0 C--N 1.315 -0.59 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.964 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 74.05 -72.98 1.32 Allowed Glycine 0 CA--C 1.548 2.122 0 CA-C-N 114.863 -0.669 . . . . 0.0 111.641 -177.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -131.51 136.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.405 ' OXT' HG12 ' C' ' 40' ' ' VAL . 73.7 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.373 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -107.02 134.03 50.78 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.915 0.388 . . . . 0.0 110.652 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -75.78 146.69 39.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.582 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.801 ' C ' HG21 ' C' ' 12' ' ' VAL . 68.4 t -132.94 162.07 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.553 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.566 ' N ' HG12 ' D' ' 12' ' ' VAL . 2.3 t-80 -63.35 103.86 0.55 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.604 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 12.6 t60 -146.72 159.76 43.08 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.536 -178.158 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.604 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 36.1 tp60 -84.65 157.97 20.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -178.635 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.84 ' O ' HD23 ' D' ' 17' ' ' LEU . 88.1 tttt -159.56 100.23 1.47 Allowed 'General case' 0 C--N 1.315 -0.913 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.39 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.84 HD23 ' O ' ' D' ' 16' ' ' LYS . 6.2 mt -132.8 136.13 46.1 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -120.59 124.23 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.955 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 37.9 m-85 -117.82 106.18 12.74 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.485 ' CZ ' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -122.17 129.45 52.31 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -176.604 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.19 114.35 9.08 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.952 0.882 . . . . 0.0 110.624 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.474 ' HB2' ' H ' ' C' ' 23' ' ' ASP . 95.5 mt-10 -92.65 -174.74 3.74 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 54.3 t0 31.17 52.23 0.16 Allowed 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.823 1.786 . . . . 0.0 115.823 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.56 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 86.6 t -64.96 145.5 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 118.734 -1.187 . . . . 0.0 108.172 177.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.84 -24.35 0.73 Allowed Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.745 ' CB ' ' H ' ' C' ' 28' ' ' LYS . 4.8 t -72.09 160.17 32.93 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 122.311 1.053 . . . . 0.0 112.785 -177.334 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.711 ' O ' ' N ' ' D' ' 29' ' ' GLY . 97.8 m-20 -91.68 -130.06 0.11 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.384 -1.735 . . . . 0.0 110.159 -178.249 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -48.49 54.94 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.931 1.292 . . . . 0.0 112.317 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.711 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -110.28 -48.79 0.74 Allowed Glycine 0 CA--C 1.546 1.971 0 C-N-CA 124.529 1.062 . . . . 0.0 113.808 -176.53 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.411 ' HA ' ' O ' ' C' ' 30' ' ' ALA . . . -82.71 113.61 20.5 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.73 HD12 HG22 ' O' ' 39' ' ' VAL . 96.1 mt -130.56 130.0 64.69 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 CA-C-N 112.453 -2.158 . . . . 0.0 111.339 178.459 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.483 ' HB ' HG23 ' E' ' 32' ' ' ILE . 47.6 mt -108.22 109.77 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 175.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.54 104.06 2.54 Favored Glycine 0 N--CA 1.462 0.395 0 N-CA-C 104.145 -3.582 . . . . 0.0 104.145 174.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.57 HD12 ' O ' ' C' ' 34' ' ' LEU . 25.0 tp -133.88 128.18 34.07 Favored 'General case' 0 C--O 1.246 0.881 0 N-CA-C 116.477 2.029 . . . . 0.0 116.477 -172.573 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -104.38 111.54 24.22 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-N 112.793 -2.003 . . . . 0.0 107.377 174.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 17.3 t -109.43 143.9 18.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.792 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 168.31 -101.95 0.18 Allowed Glycine 0 C--N 1.294 -1.766 0 C-N-CA 118.818 -1.658 . . . . 0.0 111.462 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.445 ' HA3' ' N ' ' C' ' 38' ' ' GLY . . . 42.48 72.16 0.32 Allowed Glycine 0 N--CA 1.466 0.658 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -177.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.831 HG21 HD12 ' K' ' 31' ' ' ILE . 92.2 t -36.2 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -176.556 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.534 ' N ' HG12 ' D' ' 39' ' ' VAL . 19.7 m . . . . . 0 C--O 1.222 -0.386 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.593 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.73 136.59 47.22 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.817 0.341 . . . . 0.0 110.436 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.31 120.88 41.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.792 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.507 ' H ' HG21 ' D' ' 12' ' ' VAL . 33.8 t -112.08 95.32 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 121.189 0.518 . . . . 0.0 111.241 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 5.4 t-80 -118.65 109.97 16.76 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.26 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.634 ' CE1' ' N ' ' F' ' 14' ' ' HIS . 43.0 m-70 -138.13 165.04 27.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.213 0.53 . . . . 0.0 110.7 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -90.26 151.62 21.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.819 ' C ' HD12 ' E' ' 17' ' ' LEU . 88.8 tttt -149.68 107.46 3.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.526 178.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.819 HD12 ' C ' ' E' ' 16' ' ' LYS . 8.7 mp -129.07 120.59 26.22 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.21 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.15 121.21 60.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.95 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.503 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 30.5 m-85 -116.34 100.77 8.13 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 177.654 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.485 ' CD1' ' CZ ' ' D' ' 20' ' ' PHE . 14.3 t80 -121.68 134.9 54.97 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -177.281 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.599 ' O ' ' HB1' ' F' ' 21' ' ' ALA . . . -160.3 -178.36 6.89 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 119.167 -1.013 . . . . 0.0 113.691 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.56 ' OE1' ' N ' ' D' ' 24' ' ' VAL . 34.6 tt0 -68.07 159.98 29.79 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.94 -178.658 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 t0 175.65 60.26 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.798 0.839 . . . . 0.0 109.472 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 4.7 t -81.44 -113.36 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 116.956 -1.497 . . . . 0.0 111.305 -171.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.73 -42.12 47.69 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 114.839 -3.553 . . . . 0.0 115.4 -171.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' E' ' 27' ' ' ASN . 35.9 t -156.7 110.39 2.67 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 121.376 2.588 . . . . 0.0 114.298 175.156 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' E' ' 26' ' ' SER . 28.7 t-20 -55.69 162.83 1.55 Allowed 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 172.345 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -58.53 -42.65 88.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 122.127 2.24 . . . . 0.0 110.265 175.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 64.27 0.04 OUTLIER Glycine 0 CA--C 1.551 2.305 0 CA-C-N 114.104 -1.407 . . . . 0.0 111.856 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.876 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -72.25 161.29 31.06 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 119.344 1.572 . . . . 0.0 112.461 -176.759 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.481 ' CG2' ' OXT' ' Q' ' 40' ' ' VAL . 97.9 mt -134.08 136.63 53.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-O 121.421 0.629 . . . . 0.0 112.472 -177.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.483 HG23 ' HB ' ' D' ' 32' ' ' ILE . 98.0 mt -130.6 129.98 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.929 -0.482 . . . . 0.0 111.702 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.95 114.26 2.47 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.452 HD13 ' CE2' ' F' ' 19' ' ' PHE . 20.4 mt -124.75 124.01 41.22 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 110.183 -0.302 . . . . 0.0 110.183 -177.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 88.5 mtp -130.3 134.34 47.14 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 119.9 -0.72 . . . . 0.0 112.553 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.469 HG22 ' HA ' ' F' ' 36' ' ' VAL . 0.8 OUTLIER -91.85 155.35 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 177.468 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.502 ' H ' ' HA2' ' D' ' 37' ' ' GLY . . . -102.96 102.8 2.3 Favored Glycine 0 CA--C 1.529 0.968 0 N-CA-C 112.256 -0.338 . . . . 0.0 112.256 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 52.58 -73.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.639 0 N-CA-C 115.009 0.764 . . . . 0.0 115.009 178.063 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.416 ' N ' ' O ' ' E' ' 37' ' ' GLY . 40.9 t -129.89 138.14 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.211 1.005 . . . . 0.0 111.222 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' F' ' 40' ' ' VAL . 77.2 t . . . . . 0 N--CA 1.472 0.638 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.177 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.445 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -109.6 134.19 52.23 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.676 0.274 . . . . 0.0 110.461 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -79.07 154.28 29.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.334 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.482 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 2.7 t -108.21 111.01 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-O 121.163 0.506 . . . . 0.0 110.503 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.545 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -145.23 117.72 8.54 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.209 -179.689 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.634 ' N ' ' CE1' ' E' ' 14' ' ' HIS . 79.5 m80 -156.97 169.4 24.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.447 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.792 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.3 tt0 -89.67 155.78 19.0 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -141.39 116.32 9.84 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.557 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.448 HD12 ' N ' ' F' ' 17' ' ' LEU . 1.6 mp -137.06 121.75 18.56 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 19.7 t -106.11 117.11 51.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.081 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' CD1' ' F' ' 20' ' ' PHE . 11.2 m-85 -116.05 98.2 6.5 Favored 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.539 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 58.1 m-85 -152.08 173.65 14.66 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 122.806 1.288 . . . . 0.0 112.315 -178.235 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.599 ' HB1' ' O ' ' E' ' 21' ' ' ALA . . . -152.11 155.18 37.36 Favored 'General case' 0 N--CA 1.435 -1.189 0 CA-C-N 114.101 -1.408 . . . . 0.0 109.897 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -75.52 137.78 41.1 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -176.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 60.15 50.12 6.73 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-N 114.112 -1.404 . . . . 0.0 113.599 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.562 HG12 ' N ' ' F' ' 25' ' ' GLY . 82.2 t -54.93 162.92 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 118.832 -1.147 . . . . 0.0 108.734 179.095 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.562 ' N ' HG12 ' F' ' 24' ' ' VAL . . . -156.62 -26.06 0.03 OUTLIER Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.023 -179.059 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 10.8 m -71.5 130.19 40.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -175.695 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.767 ' O ' ' N ' ' F' ' 29' ' ' GLY . 80.4 m-20 -90.9 -156.2 0.43 Allowed 'General case' 0 C--O 1.22 -0.475 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 176.371 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -49.15 50.39 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 112.972 0.73 . . . . 0.0 112.972 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.767 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -100.2 -51.09 1.27 Allowed Glycine 0 CA--C 1.539 1.582 0 C-N-CA 123.762 0.696 . . . . 0.0 111.947 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.876 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -101.65 178.22 4.69 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -179.142 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.55 HD11 ' O ' ' R' ' 39' ' ' VAL . 90.6 mt -121.13 131.84 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.601 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -122.61 117.82 53.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.331 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.66 126.81 6.98 Favored Glycine 0 N--CA 1.469 0.851 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 tp -131.83 114.45 14.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 90.6 mtp -122.01 135.49 54.84 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 120.617 -0.433 . . . . 0.0 112.104 -178.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.469 ' HA ' HG22 ' E' ' 36' ' ' VAL . 51.2 t -108.28 132.69 55.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.208 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.803 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.6 112.4 4.23 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.533 -0.627 . . . . 0.0 111.533 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.98 -70.41 0.0 OUTLIER Glycine 0 CA--C 1.538 1.484 0 N-CA-C 114.011 0.364 . . . . 0.0 114.011 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.542 ' N ' ' O ' ' F' ' 37' ' ' GLY . 46.3 t -123.97 132.68 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-O 121.586 0.708 . . . . 0.0 111.885 -178.413 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' E' ' 40' ' ' VAL . 11.6 t . . . . . 0 C--O 1.218 -0.571 0 CA-C-O 117.785 -1.102 . . . . 0.0 110.381 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -107.58 138.42 43.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -156.99 116.82 3.47 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.89 0.376 . . . . 0.0 110.894 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.552 HG12 ' O ' ' H' ' 12' ' ' VAL . 12.3 m -131.52 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.911 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 51.7 m-70 -145.31 130.31 18.34 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.3 0.571 . . . . 0.0 111.965 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 42.2 p-80 -152.74 172.4 16.75 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.478 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -128.97 151.01 50.15 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -95.22 128.7 42.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.688 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -126.96 117.92 23.48 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -133.95 134.27 55.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -144.77 146.9 32.36 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.46 0.648 . . . . 0.0 111.452 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 54.6 p90 -129.23 129.61 45.22 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.046 179.059 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.3 120.81 41.67 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.131 0.491 . . . . 0.0 112.085 -178.536 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -157.98 151.72 23.83 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 57.01 46.45 19.35 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.812 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -80.29 -179.8 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.933 0.397 . . . . 0.0 110.338 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.15 -32.39 65.69 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.556 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 33.3 t -152.55 125.83 8.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.341 0.591 . . . . 0.0 109.576 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -38.93 134.14 1.04 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.814 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -110.59 -39.21 4.96 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 79.96 -69.41 3.09 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 112.415 -2.175 . . . . 0.0 111.702 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.435 ' HB3' ' CB ' ' H' ' 30' ' ' ALA . . . 179.78 87.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 117.59 0.695 . . . . 0.0 111.239 176.731 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -133.32 113.71 19.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.541 0 O-C-N 121.765 -0.584 . . . . 0.0 109.702 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' I' ' 19' ' ' PHE . 66.8 mt -108.21 110.72 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.308 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.13 97.54 0.63 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 105.298 -3.121 . . . . 0.0 105.298 177.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.752 ' O ' HD12 ' H' ' 34' ' ' LEU . 56.8 tp -160.63 159.41 30.4 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 118.18 -1.408 . . . . 0.0 111.89 -175.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.448 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 23.8 mtp -122.75 121.91 37.46 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.418 -1.264 . . . . 0.0 109.19 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.599 HG12 ' CD ' ' I' ' 15' ' ' GLN . 2.0 t -118.32 103.1 14.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.14 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.69 -153.05 24.57 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 38' ' ' GLY . . . . . 0.445 ' O ' HG23 ' H' ' 39' ' ' VAL . . . 111.82 -56.2 0.48 Allowed Glycine 0 CA--C 1.542 1.779 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.86 160.8 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.756 -1.116 . . . . 0.0 110.395 179.316 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -113.61 135.65 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.739 0.304 . . . . 0.0 110.364 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -109.11 116.02 31.15 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.497 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.718 HG13 ' CE1' ' I' ' 13' ' ' HIS . 6.6 t -116.14 95.01 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 120.916 0.389 . . . . 0.0 110.092 179.218 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.538 ' ND1' ' O ' ' G' ' 13' ' ' HIS . 17.9 p-80 -147.84 165.68 29.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.871 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.653 ' HE2' ' CG2' ' I' ' 12' ' ' VAL . 0.1 OUTLIER -107.73 161.61 14.73 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.361 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.87 159.64 16.87 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -140.0 101.27 4.13 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.8 tp -127.97 121.9 31.03 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.115 0.483 . . . . 0.0 110.611 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.32 126.59 72.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.201 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.625 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -131.07 123.0 27.72 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.44 ' CZ ' ' CG ' ' H' ' 22' ' ' GLU . 19.5 t80 -119.5 126.11 50.5 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.34 121.56 38.87 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -177.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.44 ' CG ' ' CZ ' ' H' ' 20' ' ' PHE . 58.0 mt-10 -116.82 98.06 6.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 114.052 -1.431 . . . . 0.0 107.348 176.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -112.38 51.5 0.81 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.549 ' HA ' HG13 ' I' ' 24' ' ' VAL . 84.7 t -75.44 144.58 11.87 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 O-C-N 124.118 0.887 . . . . 0.0 110.61 -175.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.61 -38.31 3.37 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-N 113.84 -1.527 . . . . 0.0 110.562 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.46 ' O ' ' O ' ' H' ' 27' ' ' ASN . 74.8 m -120.48 -112.18 0.33 Allowed 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.466 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 51.1 t-20 52.13 152.9 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.327 1.051 . . . . 0.0 110.908 -176.618 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.466 ' N ' ' OD1' ' H' ' 27' ' ' ASN . 67.6 mttm -140.48 -28.88 0.7 Allowed 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 115.189 1.552 . . . . 0.0 115.189 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.01 88.08 0.11 Allowed Glycine 0 N--CA 1.474 1.216 0 CA-C-O 119.471 -0.627 . . . . 0.0 113.74 -170.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.435 ' CB ' ' HB3' ' G' ' 30' ' ' ALA . . . -79.07 128.46 33.3 Favored 'General case' 0 CA--C 1.545 0.787 0 CA-C-O 123.308 1.528 . . . . 0.0 112.682 -175.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 30.7 mt -137.32 139.66 43.43 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 112.638 -2.074 . . . . 0.0 113.399 -176.067 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.413 HG22 HD21 ' I' ' 34' ' ' LEU . 80.6 mt -109.48 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 175.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.37 99.3 0.82 Allowed Glycine 0 C--O 1.237 0.308 0 N-CA-C 105.573 -3.011 . . . . 0.0 105.573 176.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.752 HD12 ' O ' ' G' ' 34' ' ' LEU . 8.4 tp -142.4 140.89 32.16 Favored 'General case' 0 C--O 1.242 0.669 0 CA-C-O 123.007 1.384 . . . . 0.0 113.251 -174.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.1 mtp -107.47 111.75 24.2 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 112.315 -2.221 . . . . 0.0 108.387 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.534 HG11 HD21 ' J' ' 17' ' ' LEU . 2.0 t -117.77 122.99 71.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.66 -113.18 0.6 Allowed Glycine 0 C--N 1.313 -0.731 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.67 -73.28 2.66 Favored Glycine 0 CA--C 1.533 1.171 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.563 ' HA ' HG21 ' I' ' 39' ' ' VAL . 34.9 t -133.86 157.1 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.251 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.479 ' C ' ' O ' ' H' ' 39' ' ' VAL . 70.1 t . . . . . 0 N--CA 1.471 0.577 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.295 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -112.16 136.04 52.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.858 0.361 . . . . 0.0 110.534 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -99.6 109.19 21.71 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.379 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.653 ' CG2' ' HE2' ' H' ' 14' ' ' HIS . 2.4 m -139.75 162.44 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.905 -178.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.718 ' CE1' HG13 ' H' ' 12' ' ' VAL . 2.0 m80 -138.86 97.29 3.29 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 119.264 -0.398 . . . . 0.0 110.432 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.527 ' CE1' ' HB ' ' I' ' 12' ' ' VAL . 5.5 m-70 -122.36 156.91 32.95 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 119.827 -0.749 . . . . 0.0 112.28 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.599 ' CD ' HG12 ' G' ' 36' ' ' VAL . 3.2 tt0 -90.44 159.59 16.47 Favored 'General case' 0 C--N 1.341 0.22 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 175.609 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.66 106.45 5.14 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 176.393 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.458 HD21 HG11 ' G' ' 36' ' ' VAL . 80.0 mt -117.21 114.97 24.41 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.045 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -114.29 103.26 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.534 ' CD2' HD13 ' G' ' 32' ' ' ILE . 14.5 m-30 -114.42 113.87 25.08 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -116.76 131.3 56.99 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -178.076 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.19 138.76 50.76 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 117.81 0.277 . . . . 0.0 111.184 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -76.67 176.38 8.46 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 119.237 3.051 . . . . 0.0 119.237 -174.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -72.49 50.11 0.23 Allowed 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 128.892 2.877 . . . . 0.0 114.132 -178.096 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.662 HG12 ' H ' ' I' ' 25' ' ' GLY . 1.8 t -74.77 -143.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -175.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.662 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -95.97 36.7 3.72 Favored Glycine 0 N--CA 1.465 0.573 0 C-N-CA 129.274 3.321 . . . . 0.0 107.706 -173.433 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.1 t -74.25 104.62 5.1 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 109.975 -3.113 . . . . 0.0 109.995 -176.854 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.708 ' O ' ' C ' ' I' ' 28' ' ' LYS . 86.1 m-20 -93.0 -149.23 0.26 Allowed 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 101.107 -3.664 . . . . 0.0 101.107 -176.436 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.708 ' C ' ' O ' ' I' ' 27' ' ' ASN . 82.3 tttt -32.64 -42.66 0.08 Allowed 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 124.173 3.17 . . . . 0.0 106.235 -170.22 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 91.29 -61.42 2.9 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 121.583 3.393 . . . . 0.0 121.583 159.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.22 117.11 24.58 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 -171.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.488 ' CD1' ' O ' ' C' ' 38' ' ' GLY . 3.5 mt -127.28 117.12 46.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 174.239 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.421 HD13 HG21 ' I' ' 32' ' ' ILE . 25.2 mt -100.22 112.93 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.03 100.12 1.07 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 106.548 -2.621 . . . . 0.0 106.548 177.197 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.462 ' CD2' ' HB3' ' H' ' 34' ' ' LEU . 98.0 mt -131.79 145.04 51.36 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.454 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -118.93 102.43 8.77 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 174.248 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.519 HG22 ' NE2' ' K' ' 15' ' ' GLN . 8.0 p -123.07 122.9 66.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.616 0.722 . . . . 0.0 109.88 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.29 -113.59 0.75 Allowed Glycine 0 C--N 1.31 -0.876 0 N-CA-C 107.57 -2.212 . . . . 0.0 107.57 -179.499 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.77 -72.37 1.05 Allowed Glycine 0 CA--C 1.535 1.303 0 C-N-CA 121.214 -0.517 . . . . 0.0 113.533 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.715 HG22 HD12 ' O' ' 31' ' ' ILE . 21.4 t -132.55 160.95 42.24 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 121.01 0.433 . . . . 0.0 111.698 -177.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.587 HG22 ' O ' ' I' ' 40' ' ' VAL . 10.9 p . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.4 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -71.02 127.32 32.16 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -142.97 156.07 44.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.967 0.413 . . . . 0.0 110.608 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.591 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -130.78 134.62 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 97.6 m-70 -120.83 124.85 46.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.46 -178.25 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' CE1' ' K' ' 14' ' ' HIS . 51.3 m-70 -151.58 169.82 21.18 Favored 'General case' 0 C--O 1.222 -0.382 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.535 ' OE1' ' NE2' ' I' ' 15' ' ' GLN . 2.3 tt0 -137.69 150.17 47.11 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -115.7 113.89 24.1 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.692 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.534 HD21 HG11 ' H' ' 36' ' ' VAL . 89.5 mt -108.84 107.34 17.71 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 176.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 t -110.96 102.53 14.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.456 ' CD2' ' CE1' ' K' ' 19' ' ' PHE . 12.4 m-85 -113.05 112.0 23.1 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -114.98 125.98 54.23 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 116.636 -0.256 . . . . 0.0 110.873 -178.189 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.49 129.54 33.28 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.666 0.745 . . . . 0.0 111.862 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -82.32 116.89 22.03 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -124.96 51.78 1.63 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -176.138 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -75.07 143.31 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.82 0 N-CA-C 103.047 -2.946 . . . . 0.0 103.047 175.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.58 37.57 3.7 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 105.768 -2.933 . . . . 0.0 105.768 -172.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.434 ' HG ' ' CG ' ' K' ' 27' ' ' ASN . 5.3 t -69.48 105.11 2.51 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 113.522 -1.339 . . . . 0.0 107.94 -177.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -117.85 -151.88 0.49 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 113.149 -1.841 . . . . 0.0 113.522 -172.302 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -37.54 -40.81 0.41 Allowed 'General case' 0 CA--C 1.551 0.999 0 N-CA-C 119.736 3.236 . . . . 0.0 119.736 -171.489 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.421 ' O ' ' CE ' ' I' ' 28' ' ' LYS . . . -171.29 69.47 0.12 Allowed Glycine 0 N--CA 1.484 1.844 0 C-N-CA 115.193 -3.384 . . . . 0.0 119.44 -174.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.39 140.73 46.81 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 120.307 2.053 . . . . 0.0 109.172 177.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.506 HG22 ' H ' ' K' ' 31' ' ' ILE . 10.1 pt -146.62 153.6 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 96.4 mt -114.56 128.47 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.305 176.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.36 112.55 0.97 Allowed Glycine 0 N--CA 1.462 0.42 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.651 HD12 ' C ' ' J' ' 34' ' ' LEU . 3.6 pp -164.65 165.63 20.78 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 117.588 -1.645 . . . . 0.0 114.986 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 70.6 mmm -113.87 117.56 31.75 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 112.746 -2.024 . . . . 0.0 110.653 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.601 HG12 ' CD ' ' L' ' 15' ' ' GLN . 15.3 t -111.5 102.51 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 N-CA-C 109.246 -0.649 . . . . 0.0 109.246 178.744 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.7 ' N ' HE22 ' L' ' 15' ' ' GLN . . . 125.09 -162.31 19.41 Favored Glycine 0 N--CA 1.465 0.585 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.386 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' K' ' 38' ' ' GLY . . . 137.84 -55.38 0.68 Allowed Glycine 0 CA--C 1.542 1.745 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.504 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.908 HG22 HD12 ' P' ' 31' ' ' ILE . 43.5 t -125.29 134.04 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.853 0.861 . . . . 0.0 108.798 177.672 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.695 ' HA ' HG13 ' K' ' 39' ' ' VAL . 74.1 t . . . . . 0 C--O 1.216 -0.685 0 CA-C-O 118.088 -0.958 . . . . 0.0 111.711 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.05 134.54 53.54 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.482 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 97.8 mt-10 -144.56 169.48 17.88 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.859 0.361 . . . . 0.0 111.276 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.471 HG13 ' H ' ' L' ' 12' ' ' VAL . 19.6 t -104.18 128.26 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' OXT' ' I' ' 40' ' ' VAL . 81.7 t60 -138.93 114.81 10.06 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.636 ' CE1' ' CD2' ' J' ' 14' ' ' HIS . 7.5 p80 -155.22 165.29 37.14 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.182 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.519 ' NE2' HG22 ' I' ' 36' ' ' VAL . 7.1 tt0 -129.48 149.95 51.04 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 119.699 -0.8 . . . . 0.0 111.179 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.96 109.15 21.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.004 177.266 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.568 ' CD1' ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -103.95 105.12 15.2 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 176.557 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.1 103.89 16.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.445 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.456 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 5.1 m-85 -114.39 108.26 16.65 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.207 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -106.69 120.8 42.95 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.461 ' HB1' ' OD1' ' J' ' 23' ' ' ASP . . . -132.42 131.36 41.7 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.415 -179.261 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.533 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 97.4 mt-10 -87.09 104.61 16.5 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.771 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 0.5 OUTLIER -135.13 48.66 2.25 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.733 -177.322 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.546 HG12 ' N ' ' K' ' 25' ' ' GLY . 55.0 t -71.92 161.38 4.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.553 -178.614 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.546 ' N ' HG12 ' K' ' 24' ' ' VAL . . . 110.26 -28.35 10.43 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 -177.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 74.57 119.73 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.051 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.434 ' CG ' ' HG ' ' J' ' 26' ' ' SER . 93.3 m-20 -83.24 162.79 21.08 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.832 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -47.19 -37.28 9.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.294 177.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.78 77.35 0.07 OUTLIER Glycine 0 CA--C 1.532 1.147 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.597 -174.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.53 153.7 29.35 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 118.217 1.009 . . . . 0.0 110.01 -178.299 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.831 HD12 HG21 ' D' ' 39' ' ' VAL . 57.4 mt -133.78 141.24 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 113.874 1.064 . . . . 0.0 113.874 -175.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -127.02 118.36 50.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.169 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.16 109.56 1.72 Allowed Glycine 0 N--CA 1.471 1.002 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.418 HD22 HD11 ' J' ' 34' ' ' LEU . 29.3 mt -127.84 125.27 39.43 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 112.811 0.671 . . . . 0.0 112.811 -175.7 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.7 mtp -106.94 106.01 16.32 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.623 HG22 ' H ' ' K' ' 37' ' ' GLY . 9.9 p -97.26 173.23 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.623 ' H ' HG22 ' K' ' 36' ' ' VAL . . . 159.64 -95.39 0.14 Allowed Glycine 0 C--N 1.3 -1.45 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.458 -178.107 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' J' ' 38' ' ' GLY . . . 98.13 -80.53 0.61 Allowed Glycine 0 N--CA 1.47 0.95 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 -176.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.695 HG13 ' HA ' ' J' ' 40' ' ' VAL . 0.0 OUTLIER -85.05 94.08 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 176.416 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.635 ' C ' HG21 ' Q' ' 31' ' ' ILE . 13.1 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.799 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -106.49 136.2 46.67 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.544 0.211 . . . . 0.0 110.526 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -139.34 155.51 47.64 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.931 0.396 . . . . 0.0 110.503 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.471 ' H ' HG13 ' K' ' 12' ' ' VAL . 58.9 t -128.76 134.34 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.376 -178.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.482 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 85.0 m-70 -135.12 84.65 2.11 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.7 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.486 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 40.4 t-80 -162.7 168.51 21.48 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.141 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.7 HE22 ' N ' ' J' ' 37' ' ' GLY . 78.8 mt-30 -100.35 151.33 21.63 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.345 0.593 . . . . 0.0 111.788 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -112.63 110.21 20.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.745 177.341 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.467 HD22 HG11 ' J' ' 36' ' ' VAL . 0.1 OUTLIER -104.77 109.88 22.0 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.863 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 42.8 t -117.21 102.38 13.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.424 ' CD1' ' CD2' ' K' ' 19' ' ' PHE . 5.0 m-85 -115.72 107.11 14.66 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -113.96 119.71 38.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.099 0.476 . . . . 0.0 111.515 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.23 127.17 52.17 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.248 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -78.04 111.25 13.73 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.329 -177.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 56.9 p30 -178.39 48.66 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.157 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.618 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -72.62 160.32 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 C-N-CA 118.431 -1.308 . . . . 0.0 109.449 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.05 -33.19 6.01 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.7 m -72.09 129.56 38.79 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 113.824 -1.188 . . . . 0.0 111.102 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.645 ' O ' ' N ' ' L' ' 29' ' ' GLY . 98.7 m-20 -90.98 -162.51 0.92 Allowed 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.46 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.28 47.59 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 115.127 1.529 . . . . 0.0 115.127 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.645 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.17 57.08 0.9 Allowed Glycine 0 CA--C 1.54 1.608 0 CA-C-N 119.483 1.038 . . . . 0.0 112.016 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.07 171.73 10.74 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.416 HD11 ' CG2' ' F' ' 39' ' ' VAL . 94.5 mt -121.27 121.73 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 177.108 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -125.43 133.58 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.864 0.364 . . . . 0.0 111.57 -178.721 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.99 117.98 2.06 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.4 tp -115.21 123.53 49.1 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mmm -124.83 128.03 48.07 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.659 0.266 . . . . 0.0 111.552 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.2 t -97.4 152.24 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-O 121.353 0.597 . . . . 0.0 111.929 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.527 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . -80.79 102.5 2.13 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 38' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' L' ' 37' ' ' GLY . . . 11.46 -73.04 0.0 OUTLIER Glycine 0 CA--C 1.539 1.588 0 C-N-CA 123.459 0.552 . . . . 0.0 113.92 -178.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.527 ' N ' ' O ' ' L' ' 37' ' ' GLY . 74.5 t -129.95 136.07 59.7 Favored 'Isoleucine or valine' 0 C--N 1.346 0.42 0 CA-C-N 118.221 1.011 . . . . 0.0 110.073 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.446 ' H ' HG22 ' L' ' 40' ' ' VAL . 13.8 m . . . . . 0 C--O 1.219 -0.543 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.336 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -112.52 133.8 54.39 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 110.344 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -71.71 144.26 49.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.029 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -139.49 139.5 38.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 121.159 0.504 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -89.49 166.73 13.5 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.229 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.594 ' ND1' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -82.26 171.42 14.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.0 0.429 . . . . 0.0 111.212 -179.342 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -128.8 151.03 50.04 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -96.3 106.77 19.04 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.704 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 87.2 mt -128.22 114.41 16.92 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 121.005 0.431 . . . . 0.0 110.057 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -126.61 130.8 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.715 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -128.18 131.23 48.9 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.619 ' CZ ' ' CD1' ' N' ' 20' ' ' PHE . 1.6 t80 -134.38 128.84 34.42 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.204 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 118.46 31.86 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.935 0.398 . . . . 0.0 109.949 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 22' ' ' GLU . . . . . 0.566 ' O ' HG23 ' M' ' 24' ' ' VAL . 94.5 mt-10 -110.53 -148.59 0.43 Allowed 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.773 -178.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.57 50.13 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.855 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.59 HG12 ' H ' ' M' ' 25' ' ' GLY . 2.3 t -71.72 -142.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.59 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -111.48 38.75 3.14 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.904 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m 61.76 111.18 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.113 0.482 . . . . 0.0 112.082 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.45 ' O ' ' C ' ' M' ' 28' ' ' LYS . 91.2 m-20 -129.85 -161.55 1.13 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.193 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 28' ' ' LYS . . . . . 0.45 ' C ' ' O ' ' M' ' 27' ' ' ASN . 73.6 mmtt -30.95 -41.31 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 120.914 0.387 . . . . 0.0 110.996 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 29' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' M' ' 27' ' ' ASN . . . 91.35 -64.92 2.54 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.794 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.473 ' O ' ' O ' ' N' ' 29' ' ' GLY . . . -170.37 70.1 0.05 Allowed 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 117.616 0.708 . . . . 0.0 112.483 177.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 82.0 mt -130.89 115.09 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 32' ' ' ILE . . . . . 0.52 HG22 HD21 ' N' ' 34' ' ' LEU . 4.0 mt -112.89 116.16 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 C-N-CA 120.062 -0.655 . . . . 0.0 111.107 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.16 105.0 1.18 Allowed Glycine 0 N--CA 1.461 0.315 0 N-CA-C 105.389 -3.084 . . . . 0.0 105.389 177.108 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 34' ' ' LEU . . . . . 0.578 ' HB3' HD22 ' N' ' 34' ' ' LEU . 47.1 tp -161.02 152.34 19.02 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 117.548 -1.661 . . . . 0.0 114.354 -174.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 3.8 ttm -104.26 115.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-N 112.56 -2.109 . . . . 0.0 106.856 176.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.517 ' O ' ' N ' ' N' ' 37' ' ' GLY . 36.5 t -116.91 103.87 15.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.29 -153.22 16.88 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 120.026 -1.083 . . . . 0.0 110.952 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.586 ' H ' ' N ' ' N' ' 38' ' ' GLY . . . 147.65 -54.64 0.52 Allowed Glycine 0 CA--C 1.539 1.551 0 CA-C-O 119.721 -0.488 . . . . 0.0 111.93 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' M' ' 40' ' ' VAL . 10.0 p -114.73 151.89 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.963 0.881 . . . . 0.0 108.787 178.411 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.779 ' OXT' HG13 ' M' ' 40' ' ' VAL . 8.5 p . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 117.854 -1.069 . . . . 0.0 111.151 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.64 134.33 48.93 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -151.38 135.77 16.89 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.999 0.428 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.412 HG12 ' CG2' ' O' ' 12' ' ' VAL . 34.1 m -137.03 162.09 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.624 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 13' ' ' HIS . . . . . 0.51 ' C ' ' ND1' ' N' ' 14' ' ' HIS . 83.4 m-70 -143.34 104.86 4.31 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.489 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.51 ' ND1' ' C ' ' N' ' 13' ' ' HIS . 20.0 m80 -152.08 167.05 29.71 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.701 0.286 . . . . 0.0 110.67 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -155.7 141.17 17.76 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.032 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -89.82 107.39 19.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 119.215 -0.421 . . . . 0.0 111.666 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.432 HD23 ' HG ' ' O' ' 17' ' ' LEU . 33.4 tp -123.78 115.57 21.57 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 177.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -121.49 131.13 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.828 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -129.97 112.35 13.42 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.522 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CZ ' ' M' ' 20' ' ' PHE . 16.5 t80 -113.81 130.37 56.47 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.44 133.14 40.16 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 113.232 0.827 . . . . 0.0 113.232 -178.049 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -92.38 120.83 33.27 Favored 'General case' 0 C--N 1.34 0.168 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.547 177.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.57 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 70.8 m-20 -148.39 50.39 1.02 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.981 -177.337 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 37.6 t -81.41 148.65 5.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 118.951 -1.1 . . . . 0.0 109.719 -177.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.57 37.04 5.66 Favored Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.9 p 73.18 120.21 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.617 ' ND2' ' N ' ' N' ' 27' ' ' ASN . 0.1 OUTLIER -83.09 162.44 21.34 Favored 'General case' 0 C--N 1.341 0.211 0 C-N-CA 118.262 -1.375 . . . . 0.0 111.499 -179.098 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.418 ' H ' ' HG2' ' N' ' 28' ' ' LYS . 72.5 mmtt -47.22 -37.17 9.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.955 176.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 29' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' M' ' 30' ' ' ALA . . . -178.96 77.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.579 0 CA-C-O 118.766 -1.019 . . . . 0.0 112.199 -173.387 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 30' ' ' ALA . . . . . 0.525 ' O ' ' HA ' ' O' ' 30' ' ' ALA . . . -79.26 107.51 12.07 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-N 119.848 1.824 . . . . 0.0 112.835 -175.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.571 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 18.4 tt -153.32 133.83 4.34 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 CA-C-N 113.627 -1.624 . . . . 0.0 111.336 -177.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.553 HD13 ' CD2' ' P' ' 19' ' ' PHE . 85.0 mt -106.96 108.26 24.76 Favored 'Isoleucine or valine' 0 C--N 1.341 0.198 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 177.226 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.807 ' O ' HD23 ' N' ' 34' ' ' LEU . . . -114.67 100.46 1.0 Allowed Glycine 0 N--CA 1.46 0.269 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 178.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.807 HD23 ' O ' ' N' ' 33' ' ' GLY . 1.4 mt -146.59 157.91 43.81 Favored 'General case' 0 CA--C 1.5 -0.952 0 CA-C-O 123.665 1.698 . . . . 0.0 112.478 -178.047 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 8.0 mtp -113.79 108.53 17.22 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 111.156 -2.747 . . . . 0.0 104.604 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -87.25 100.96 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 106.144 -1.798 . . . . 0.0 106.144 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' M' ' 36' ' ' VAL . . . -73.23 163.0 54.86 Favored Glycine 0 CA--C 1.52 0.353 0 CA-C-N 112.724 -2.034 . . . . 0.0 113.383 -178.715 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.586 ' N ' ' H ' ' M' ' 38' ' ' GLY . . . 114.92 60.72 0.37 Allowed Glycine 0 N--CA 1.471 0.972 0 C-N-CA 121.389 -0.434 . . . . 0.0 113.681 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 1.038 HG13 ' H ' ' O' ' 39' ' ' VAL . 57.3 t -71.09 130.91 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.501 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.519 HG22 ' CD2' ' P' ' 13' ' ' HIS . 10.8 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.999 -1.001 . . . . 0.0 111.3 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.48 132.97 52.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.759 0.314 . . . . 0.0 110.364 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -123.58 121.83 36.61 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.131 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.486 ' HB ' ' CE1' ' O' ' 14' ' ' HIS . 2.3 m -131.43 155.27 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.594 ' HB2' ' HD1' ' P' ' 13' ' ' HIS . 80.0 m80 -149.07 102.96 3.3 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.478 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.565 ' CD2' ' O ' ' P' ' 14' ' ' HIS . 0.0 OUTLIER -149.27 176.44 10.53 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.412 ' CG ' HD13 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -149.25 140.0 22.7 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 174.616 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' O' O ' 16' ' ' LYS . . . . . 0.654 ' C ' HD12 ' O' ' 17' ' ' LEU . 54.1 mtmt -95.05 110.24 22.19 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.227 1.566 . . . . 0.0 115.227 -178.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.654 HD12 ' C ' ' O' ' 16' ' ' LYS . 10.9 mp -124.13 115.09 20.57 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 174.69 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -112.74 115.82 50.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.643 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.429 ' HZ ' HD23 ' O' ' 17' ' ' LEU . 48.4 m-85 -112.22 104.97 13.19 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -111.86 131.75 55.15 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.9 136.61 32.46 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -95.2 113.86 25.58 Favored 'General case' 0 CA--C 1.52 -0.175 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 175.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.446 ' CB ' HD21 ' N' ' 27' ' ' ASN . 18.1 m-20 -133.99 48.62 2.33 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.542 HG22 ' O ' ' P' ' 23' ' ' ASP . 18.6 t -72.88 161.09 5.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 C-N-CA 118.218 -1.393 . . . . 0.0 109.664 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.27 -29.89 9.56 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 -178.71 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 1.2 m 92.83 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 113.66 -1.27 . . . . 0.0 107.791 -178.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.697 ' OD1' ' HB2' ' O' ' 30' ' ' ALA . 2.7 p30 -73.96 164.39 26.68 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.935 0.874 . . . . 0.0 113.071 -178.241 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.08 -36.28 12.84 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.862 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.38 78.5 0.07 OUTLIER Glycine 0 CA--C 1.532 1.119 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.354 -173.11 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 30' ' ' ALA . . . . . 0.697 ' HB2' ' OD1' ' O' ' 27' ' ' ASN . . . -79.19 109.73 13.8 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 123.286 1.517 . . . . 0.0 110.955 -176.496 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.715 HD12 HG22 ' I' ' 39' ' ' VAL . 77.8 mt -133.15 142.21 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 113.483 -1.689 . . . . 0.0 112.802 -176.859 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.499 ' CG2' HD12 ' O' ' 34' ' ' LEU . 52.9 mt -106.78 107.9 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 175.799 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.05 104.97 2.23 Favored Glycine 0 C--O 1.239 0.437 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.499 HD12 ' CG2' ' O' ' 32' ' ' ILE . 53.7 mt -140.35 144.0 36.06 Favored 'General case' 0 CA--C 1.504 -0.815 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -175.48 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 3.0 mtp -116.42 109.22 17.02 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 112.212 -2.267 . . . . 0.0 105.038 175.028 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 1.8 t -105.86 101.8 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.812 0.815 . . . . 0.0 111.05 -177.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.77 -179.11 0.65 Allowed Glycine 0 CA--C 1.538 1.5 0 CA-C-N 114.112 -1.404 . . . . 0.0 115.303 178.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' O' O ' 38' ' ' GLY . . . . . 0.69 ' H ' HG22 ' N' ' 39' ' ' VAL . . . -116.3 -58.3 0.32 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 114.253 -0.973 . . . . 0.0 111.788 179.282 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 1.038 ' H ' HG13 ' N' ' 39' ' ' VAL . 45.5 t -115.84 124.92 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.664 ' CG2' HE22 ' R' ' 15' ' ' GLN . 12.3 m . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.451 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 39.9 p90 -148.65 158.73 44.34 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.832 0.348 . . . . 0.0 110.768 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.31 123.8 31.97 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.839 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 p -130.04 132.3 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.801 179.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.594 ' HD1' ' HB2' ' O' ' 13' ' ' HIS . 7.5 t60 -144.98 134.25 22.9 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 -179.116 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.688 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 18.9 m-70 -147.45 156.42 42.85 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 175.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.426 ' H ' ' HA ' ' Q' ' 15' ' ' GLN . 0.8 OUTLIER -90.42 160.35 16.1 Favored 'General case' 0 C--O 1.225 -0.237 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.021 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' P' P ' 16' ' ' LYS . . . . . 0.502 ' HE2' ' CD2' ' O' ' 14' ' ' HIS . 67.9 mttm -140.09 95.52 2.9 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.725 177.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -136.22 130.64 33.43 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.142 0.496 . . . . 0.0 111.122 179.03 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 24.1 t -119.94 115.21 46.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.489 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.553 ' CD2' HD13 ' N' ' 32' ' ' ILE . 19.3 m-85 -109.09 111.87 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -127.01 123.45 37.1 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 -176.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.18 121.85 43.31 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 176.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -93.86 152.41 18.91 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 117.843 2.535 . . . . 0.0 117.843 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.542 ' O ' HG22 ' O' ' 24' ' ' VAL . 93.3 m-20 27.92 51.52 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 111.238 -2.71 . . . . 0.0 117.807 175.566 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 65.1 t -81.69 141.23 15.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 117.13 -1.828 . . . . 0.0 106.181 175.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' Q' ' 24' ' ' VAL . . . -71.53 -41.54 57.51 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 117.584 -2.246 . . . . 0.0 110.809 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.422 ' O ' ' C ' ' P' ' 27' ' ' ASN . 42.3 t -156.63 112.3 2.93 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 118.355 -0.831 . . . . 0.0 109.452 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.642 HD21 ' HB3' ' O' ' 30' ' ' ALA . 7.4 t-20 -48.96 157.78 0.38 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.127 178.375 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.65 -47.88 61.83 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.665 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.82 61.21 0.08 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 114.261 -1.336 . . . . 0.0 109.768 -176.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 30' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' O' ' 30' ' ' ALA . . . -85.09 158.43 20.43 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 123.668 1.699 . . . . 0.0 115.377 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.908 HD12 HG22 ' J' ' 39' ' ' VAL . 65.1 mt -145.05 148.3 17.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 112.342 -2.208 . . . . 0.0 113.482 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 52.9 mt -106.19 107.64 23.17 Favored 'Isoleucine or valine' 0 C--N 1.35 0.625 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.89 101.38 2.27 Favored Glycine 0 N--CA 1.463 0.462 0 N-CA-C 104.215 -3.554 . . . . 0.0 104.215 175.292 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.419 HD23 HD22 ' Q' ' 34' ' ' LEU . 26.4 tp -133.49 130.25 38.3 Favored 'General case' 0 C--O 1.239 0.544 0 N-CA-C 115.979 1.844 . . . . 0.0 115.979 -173.008 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 40.2 tpp -111.27 109.27 19.22 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 174.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.494 HG13 ' OE1' ' Q' ' 15' ' ' GLN . 10.6 t -100.13 102.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.91 0.386 . . . . 0.0 110.573 -177.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.0 163.48 0.06 OUTLIER Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' O' ' 38' ' ' GLY . . . -94.57 -58.03 1.22 Allowed Glycine 0 CA--C 1.536 1.392 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.241 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.674 ' HB ' HD13 ' D' ' 31' ' ' ILE . 24.0 t -151.28 138.89 13.82 Favored 'Isoleucine or valine' 0 C--N 1.347 0.479 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.666 ' H ' ' C ' ' Q' ' 38' ' ' GLY . 31.1 t . . . . . 0 C--O 1.214 -0.789 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.435 -177.299 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.471 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -107.08 131.07 54.51 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -149.43 137.58 20.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.978 0.418 . . . . 0.0 110.348 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -127.58 118.44 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.571 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.522 ' NE2' ' C ' ' O' ' 40' ' ' VAL . 12.0 p-80 -158.47 121.05 3.7 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.868 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.688 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 9.4 p80 -148.8 165.62 30.9 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 176.113 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.494 ' OE1' HG13 ' P' ' 36' ' ' VAL . 1.6 pt20 -99.75 149.93 22.84 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.454 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . 0.594 ' CE ' ' HE1' ' Q' ' 14' ' ' HIS . 98.8 mttt -114.74 98.61 6.95 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.951 178.253 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.447 ' HB3' ' CZ ' ' Q' ' 19' ' ' PHE . 6.0 mp -123.2 116.98 24.3 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 177.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -107.88 111.14 34.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.485 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 37.1 m-85 -107.21 107.34 18.25 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 178.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' R' ' 20' ' ' PHE . 12.9 t80 -122.52 124.92 44.66 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -176.27 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.36 118.31 27.21 Favored 'General case' 0 C--O 1.243 0.711 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 177.44 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' P' ' 23' ' ' ASP . 82.7 tt0 -82.77 146.24 29.09 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -176.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.492 ' O ' ' O ' ' R' ' 22' ' ' GLU . 64.2 t0 63.87 -52.13 0.25 Allowed 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 113.878 -1.51 . . . . 0.0 112.089 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.54 HG12 ' H ' ' Q' ' 25' ' ' GLY . 0.8 OUTLIER 50.51 -153.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.302 177.842 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.54 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 143.39 19.03 0.22 Allowed Glycine 0 N--CA 1.464 0.544 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 -177.026 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . 0.568 ' OG ' ' HB2' ' Q' ' 30' ' ' ALA . 0.3 OUTLIER -63.13 129.9 42.3 Favored 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 114.691 -0.754 . . . . 0.0 109.342 -178.22 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.477 ' CG ' ' H ' ' Q' ' 28' ' ' LYS . 45.3 t-20 -126.98 -130.62 0.23 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.186 -174.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.477 ' H ' ' CG ' ' Q' ' 27' ' ' ASN . 74.1 mmtt -38.79 -46.87 1.32 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.041 -0.982 . . . . 0.0 111.483 -176.591 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.19 52.44 0.9 Allowed Glycine 0 CA--C 1.547 2.058 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.786 -177.597 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . 0.568 ' HB2' ' OG ' ' Q' ' 26' ' ' SER . . . -128.8 127.43 41.95 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-O 120.915 0.388 . . . . 0.0 110.103 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.699 HG23 ' HB ' ' R' ' 31' ' ' ILE . 28.9 mt -142.81 153.25 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-O 121.821 0.819 . . . . 0.0 113.064 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . 0.491 HD12 ' CD1' ' R' ' 32' ' ' ILE . 86.5 mt -136.22 123.34 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 O-C-N 121.795 -0.565 . . . . 0.0 110.34 179.113 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.4 110.66 1.29 Allowed Glycine 0 N--CA 1.468 0.77 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . 0.419 HD22 HD23 ' P' ' 34' ' ' LEU . 28.4 mt -119.34 121.2 39.03 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.634 0.255 . . . . 0.0 111.444 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . 0.4 ' SD ' ' HB2' ' R' ' 35' ' ' MET . 95.3 mmm -111.33 127.61 55.7 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.425 HG13 ' HG3' ' R' ' 15' ' ' GLN . 53.6 t -122.79 131.73 72.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-N 118.69 0.677 . . . . 0.0 112.103 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -55.82 -111.52 0.01 OUTLIER Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.743 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.688 ' O ' HG23 ' Q' ' 39' ' ' VAL . . . 95.86 -72.92 0.87 Allowed Glycine 0 CA--C 1.537 1.436 0 N-CA-C 111.962 -0.455 . . . . 0.0 111.962 179.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.688 HG23 ' O ' ' Q' ' 38' ' ' GLY . 14.2 t -164.1 121.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . 0.52 ' O ' HG21 ' F' ' 31' ' ' ILE . 58.7 t . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.992 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -82.69 131.06 35.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.811 0.339 . . . . 0.0 110.93 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' R' ' 11' ' ' GLU . 56.3 mp0 -118.98 148.43 42.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.815 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 20.1 t -106.97 98.05 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.494 0.664 . . . . 0.0 110.885 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -120.25 93.5 4.07 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.901 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -153.88 164.02 39.08 Favored 'General case' 0 C--O 1.222 -0.392 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.664 HE22 ' CG2' ' O' ' 40' ' ' VAL . 90.4 mm-40 -89.85 158.41 17.47 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.417 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.448 ' HD2' ' CE1' ' Q' ' 14' ' ' HIS . 13.5 tttt -140.4 90.13 2.33 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.316 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -134.37 120.14 19.48 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.2 t -104.89 113.5 42.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.408 ' CE1' HD22 ' P' ' 34' ' ' LEU . 25.1 m-85 -104.9 98.05 7.83 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 106.028 -1.842 . . . . 0.0 106.028 177.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' Q' ' 20' ' ' PHE . 42.0 t80 -115.22 114.28 25.02 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.58 0.705 . . . . 0.0 110.847 -178.47 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' R' ' 23' ' ' ASP . . . -128.37 125.11 38.0 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.342 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.492 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 81.0 tt0 -71.5 85.13 0.84 Allowed 'General case' 0 C--O 1.223 -0.319 0 C-N-CA 117.414 -1.714 . . . . 0.0 106.958 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' R' ' 21' ' ' ALA . 51.2 p30 -132.72 51.89 2.12 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.459 -176.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 69.5 t -74.82 143.29 13.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.19 37.56 3.8 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.037 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 42.5 t -75.53 101.93 5.06 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 121.47 0.652 . . . . 0.0 110.201 -179.426 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -96.44 -163.15 1.02 Allowed 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.965 -177.325 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -47.72 -42.14 24.51 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 114.225 -1.352 . . . . 0.0 113.701 -177.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.99 61.68 1.92 Allowed Glycine 0 CA--C 1.54 1.652 0 C-N-CA 120.301 -0.952 . . . . 0.0 114.187 -175.487 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.09 135.02 9.89 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 177.55 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 31' ' ' ILE . . . . . 0.699 ' HB ' HG23 ' Q' ' 31' ' ' ILE . 96.6 mt -118.01 128.45 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 CA-C-O 121.399 0.619 . . . . 0.0 111.965 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 32' ' ' ILE . . . . . 0.491 ' CD1' HD12 ' Q' ' 32' ' ' ILE . 48.2 mm -120.4 123.34 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.894 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 118.05 2.8 Favored Glycine 0 N--CA 1.468 0.786 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.401 ' CD2' HD12 ' Q' ' 34' ' ' LEU . 67.8 mt -116.54 114.9 24.81 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 35' ' ' MET . . . . . 0.4 ' HB2' ' SD ' ' Q' ' 35' ' ' MET . 85.9 mmm -134.27 136.23 43.43 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.042 -178.455 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.63 155.84 34.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 121.33 0.585 . . . . 0.0 111.006 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -52.93 -102.27 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.149 178.312 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 49.24 71.06 0.66 Allowed Glycine 0 CA--C 1.529 0.939 0 CA-C-N 115.148 -0.526 . . . . 0.0 111.807 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.572 HG12 ' N ' ' R' ' 40' ' ' VAL . 59.9 t -112.29 165.69 7.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' R' R ' 40' ' ' VAL . . . . . 0.572 ' N ' HG12 ' R' ' 39' ' ' VAL . 15.5 m . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.101 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -112.91 133.69 54.77 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -128.08 132.17 49.04 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.141 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.23 140.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.476 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -142.11 158.37 43.82 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.069 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.614 ' CD2' ' N ' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -89.26 169.56 11.34 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.021 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -129.42 150.71 50.65 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -97.14 118.92 34.63 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.691 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.3 mt -124.77 114.9 19.88 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -132.83 136.4 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.351 -0.386 . . . . 0.0 109.977 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -128.03 130.52 48.42 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.456 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -123.6 120.49 32.97 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.999 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.04 127.43 48.77 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.404 ' CD ' ' OE1' ' B' ' 22' ' ' GLU . 83.2 tt0 -147.95 149.14 31.66 Favored 'General case' 0 CA--C 1.533 0.327 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -178.327 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.0 t0 51.68 46.38 26.62 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 176.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.734 HG12 ' H ' ' A' ' 25' ' ' GLY . 41.2 t -102.45 -177.87 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.147 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.734 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -70.41 -32.83 68.06 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 177.733 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 27' ' ' ASN . 46.7 t -152.36 123.27 7.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.013 -1.093 . . . . 0.0 108.25 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.732 ' H ' ' NZ ' ' B' ' 28' ' ' LYS . 33.0 t30 -40.88 166.61 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.246 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.421 ' N ' ' CG ' ' A' ' 27' ' ' ASN . 68.1 mttm -78.66 40.42 0.38 Allowed 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.961 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.422 ' C ' ' H ' ' A' ' 31' ' ' ILE . . . 119.57 78.37 0.56 Allowed Glycine 0 CA--C 1.533 1.167 0 CA-C-O 118.362 -1.243 . . . . 0.0 113.938 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.68 43.41 0.75 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-N 121.011 2.405 . . . . 0.0 110.9 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.422 ' H ' ' C ' ' A' ' 29' ' ' GLY . 54.9 mt -150.47 126.94 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 CA-C-N 113.148 -1.842 . . . . 0.0 106.866 178.871 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.432 ' O ' ' O ' ' B' ' 33' ' ' GLY . 50.7 mt -105.89 110.2 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.987 -0.745 . . . . 0.0 108.987 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.56 93.7 0.57 Allowed Glycine 0 CA--C 1.508 -0.368 0 N-CA-C 105.614 -2.994 . . . . 0.0 105.614 177.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -147.17 168.04 22.67 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 122.998 1.38 . . . . 0.0 114.133 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -120.22 110.64 16.84 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 112.224 -2.262 . . . . 0.0 107.229 178.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG2' HD11 ' B' ' 34' ' ' LEU . 2.9 t -97.92 113.44 32.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.498 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.68 -125.03 1.49 Allowed Glycine 0 C--N 1.315 -0.596 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.24 -62.89 0.37 Allowed Glycine 0 CA--C 1.546 1.987 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.552 ' O ' HG21 ' B' ' 39' ' ' VAL . 2.9 m -134.73 159.9 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 116.999 0.399 . . . . 0.0 110.009 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.473 HG21 ' CA ' ' H' ' 29' ' ' GLY . 42.9 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.336 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.94 146.06 34.42 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.644 0.259 . . . . 0.0 110.358 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 58.5 mp0 -72.68 119.31 16.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.963 0.411 . . . . 0.0 110.263 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.457 ' CG2' ' NE2' ' A' ' 14' ' ' HIS . 26.0 m -134.89 161.01 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.835 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -131.32 96.15 3.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.075 0.464 . . . . 0.0 111.704 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.479 ' C ' ' CD2' ' B' ' 14' ' ' HIS . 8.5 p-80 -156.89 169.15 25.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 177.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 21.3 tt0 -129.51 150.45 50.85 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.956 0.407 . . . . 0.0 110.128 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -98.37 119.94 37.93 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.722 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.606 ' C ' HD23 ' B' ' 17' ' ' LEU . 7.0 tt -122.76 122.79 39.55 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 118.194 0.452 . . . . 0.0 110.537 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.53 ' N ' HD23 ' B' ' 17' ' ' LEU . 69.3 t -126.22 128.76 71.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.239 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 t80 -124.6 114.06 18.88 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.872 0.368 . . . . 0.0 110.022 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.643 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 32.7 t80 -115.34 119.98 38.08 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.647 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.13 128.28 37.76 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.718 0.771 . . . . 0.0 112.219 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.404 ' OE1' ' CD ' ' A' ' 22' ' ' GLU . 87.8 mt-10 -96.73 111.98 23.92 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.055 178.26 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -104.17 46.42 0.92 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.06 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.726 HG12 ' H ' ' B' ' 25' ' ' GLY . 20.7 t -82.33 176.07 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.629 -178.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.726 ' H ' HG12 ' B' ' 24' ' ' VAL . . . 91.87 -28.27 8.84 Favored Glycine 0 N--CA 1.465 0.622 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -177.993 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 2.1 p 166.31 131.52 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 60.1 t-20 -45.84 130.84 9.54 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.732 ' NZ ' ' H ' ' A' ' 27' ' ' ASN . 98.7 mttt -89.28 -46.61 8.64 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.36 60.92 0.1 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.588 -1.291 . . . . 0.0 113.28 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.86 113.95 8.44 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.968 1.47 . . . . 0.0 114.968 -176.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 93.0 mt -127.66 130.1 70.28 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 CA-C-N 112.696 -2.047 . . . . 0.0 109.702 178.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.515 HD13 ' CD2' ' D' ' 19' ' ' PHE . 94.3 mt -110.06 116.33 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 O-C-N 121.578 -0.701 . . . . 0.0 110.551 178.443 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -118.97 96.17 0.65 Allowed Glycine 0 C--O 1.238 0.352 0 N-CA-C 104.924 -3.271 . . . . 0.0 104.924 176.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.483 HD11 ' CG2' ' A' ' 36' ' ' VAL . 20.5 tp -135.9 136.74 40.74 Favored 'General case' 0 CA--C 1.502 -0.889 0 C-N-CA 119.268 -0.973 . . . . 0.0 113.099 -174.375 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.4 mtp -106.39 108.75 20.42 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.59 ' HB ' HG13 ' C' ' 36' ' ' VAL . 2.5 t -102.1 103.33 14.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.99 -153.61 25.11 Favored Glycine 0 N--CA 1.447 -0.622 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.501 ' O ' HG11 ' C' ' 39' ' ' VAL . . . 115.44 -55.79 0.53 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -178.193 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.818 ' C ' HG21 ' C' ' 39' ' ' VAL . 27.8 m -124.05 137.02 58.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 123.449 0.7 . . . . 0.0 111.279 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.523 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 40.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.651 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.409 -1.477 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -105.35 135.37 46.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.934 0.397 . . . . 0.0 110.468 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.412 ' O ' ' OE2' ' D' ' 11' ' ' GLU . 80.1 mm-40 -138.24 139.53 39.27 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.384 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.432 HG13 ' H ' ' D' ' 12' ' ' VAL . 3.4 t -106.7 91.22 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -104.39 131.17 52.04 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.2 0.524 . . . . 0.0 111.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -151.0 165.23 34.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.534 179.285 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 95.8 mm-40 -90.02 151.94 21.42 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.139 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -148.4 99.12 2.99 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -131.28 128.99 40.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.447 0.641 . . . . 0.0 111.399 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.99 114.56 45.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.05 107.83 18.32 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.643 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 17.1 t80 -113.77 124.86 53.27 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 122.009 0.123 . . . . 0.0 111.114 -178.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.82 131.83 21.67 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 120.262 -0.575 . . . . 0.0 112.516 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.04 112.43 21.77 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.179 0.514 . . . . 0.0 110.711 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.452 ' OD1' ' OD2' ' D' ' 23' ' ' ASP . 13.6 p-10 -124.86 46.56 2.3 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.559 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.765 HG12 ' H ' ' C' ' 25' ' ' GLY . 21.8 t -73.38 179.74 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.774 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.765 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 99.26 -35.38 4.73 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-N 114.329 -1.305 . . . . 0.0 113.413 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.489 ' O ' ' O ' ' C' ' 27' ' ' ASN . 28.6 t -162.38 117.53 1.87 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.6 1.7 . . . . 0.0 112.548 175.545 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.794 ' N ' HG21 ' D' ' 24' ' ' VAL . 67.2 m-20 -23.23 151.39 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 118.976 -0.535 . . . . 0.0 112.232 175.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 39.5 tttp -167.55 31.36 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 173.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' D' ' 27' ' ' ASN . . . 81.01 80.81 0.85 Allowed Glycine 0 CA--C 1.535 1.328 0 C-N-CA 117.886 -2.102 . . . . 0.0 114.097 175.586 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.93 119.49 38.88 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.447 1.623 . . . . 0.0 109.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.607 HD11 HG23 ' P' ' 39' ' ' VAL . 82.9 mt -123.14 132.53 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -177.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.423 HG23 ' CD1' ' C' ' 34' ' ' LEU . 2.8 mt -105.79 108.45 25.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' B' ' 32' ' ' ILE . . . -123.64 106.76 1.01 Allowed Glycine 0 N--CA 1.465 0.577 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.423 ' CD1' HG23 ' C' ' 32' ' ' ILE . 3.0 mp -139.27 143.36 37.91 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 122.702 1.239 . . . . 0.0 113.434 -177.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -113.49 103.66 11.49 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 175.141 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.951 HG11 HD11 ' E' ' 17' ' ' LEU . 2.4 t -111.72 102.91 14.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.09 -151.78 20.89 Favored Glycine 0 C--N 1.31 -0.879 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -178.427 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 38' ' ' GLY . . . . . 0.687 ' O ' HG11 ' D' ' 39' ' ' VAL . . . 102.91 -56.81 0.6 Allowed Glycine 0 CA--C 1.54 1.618 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.725 -179.183 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.818 HG21 ' C ' ' B' ' 39' ' ' VAL . 33.6 m -135.81 163.71 34.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 123.037 0.535 . . . . 0.0 111.095 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.987 -179.434 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -149.34 158.15 43.93 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.844 0.354 . . . . 0.0 110.439 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.412 ' OE2' ' O ' ' C' ' 11' ' ' GLU . 83.3 tt0 -154.96 131.5 10.55 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.037 0.446 . . . . 0.0 110.488 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.432 ' H ' HG13 ' C' ' 12' ' ' VAL . 2.4 p -139.4 137.43 40.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.237 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.811 ' CD2' ' HD1' ' E' ' 13' ' ' HIS . 5.7 p80 -133.52 119.44 19.53 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.687 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -149.07 164.86 33.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.528 0.68 . . . . 0.0 112.144 -178.449 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.568 ' CD ' HG12 ' B' ' 36' ' ' VAL . 85.1 mt-30 -84.49 156.59 21.64 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 176.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -159.26 105.87 1.73 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 120.043 -0.663 . . . . 0.0 109.237 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.453 ' CD1' HG11 ' B' ' 36' ' ' VAL . 3.4 mp -136.67 127.85 28.01 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.434 0.635 . . . . 0.0 111.695 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -109.72 115.43 49.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.347 178.46 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' E' ' 19' ' ' PHE . 35.2 m-85 -108.55 106.95 17.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 47.3 t80 -111.87 119.01 37.1 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.851 -179.302 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.73 138.57 28.93 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 119.569 -0.852 . . . . 0.0 112.968 -179.24 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.3 mt-10 -120.15 133.45 55.5 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.776 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.616 ' C ' HG23 ' D' ' 24' ' ' VAL . 0.0 OUTLIER -149.41 59.78 1.02 Allowed 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.999 HG12 ' H ' ' D' ' 25' ' ' GLY . 4.4 t 91.3 -169.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 176.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.999 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -76.98 -33.82 44.36 Favored Glycine 0 C--O 1.214 -1.146 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.449 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 5.3 p -147.3 118.4 7.74 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.289 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.412 ' OD1' ' N ' ' C' ' 29' ' ' GLY . 17.7 t-20 -59.93 169.03 1.59 Allowed 'General case' 0 C--N 1.333 -0.113 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.884 -179.126 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -55.25 -38.06 68.04 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.839 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.58 71.42 0.1 Allowed Glycine 0 CA--C 1.533 1.215 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.829 -174.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.49 135.27 47.05 Favored 'General case' 0 C--O 1.245 0.832 0 CA-C-N 118.785 1.293 . . . . 0.0 112.694 -174.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.565 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 77.9 mt -139.28 134.62 40.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 113.845 -1.525 . . . . 0.0 114.09 -176.29 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 mt -107.48 111.22 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 174.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.55 103.45 0.92 Allowed Glycine 0 N--CA 1.46 0.297 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 177.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.504 HD23 ' N ' ' D' ' 35' ' ' MET . 6.1 tt -140.8 146.63 37.87 Favored 'General case' 0 CA--C 1.513 -0.463 0 C-N-CA 119.055 -1.058 . . . . 0.0 113.171 -176.051 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.504 ' N ' HD23 ' D' ' 34' ' ' LEU . 17.9 mtp -120.21 115.25 23.25 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.194 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.784 HG11 HD11 ' F' ' 17' ' ' LEU . 0.0 OUTLIER -115.97 102.83 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.675 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.45 ' HA2' ' H ' ' E' ' 38' ' ' GLY . . . 166.27 -151.31 19.53 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 119.66 -1.257 . . . . 0.0 110.561 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.426 ' H ' ' CG1' ' E' ' 40' ' ' VAL . . . 99.7 -57.4 0.84 Allowed Glycine 0 CA--C 1.544 1.88 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.484 -178.382 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.751 HG21 ' C ' ' C' ' 39' ' ' VAL . 27.7 m -134.93 159.92 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 C-N-CA 123.356 0.662 . . . . 0.0 110.773 -178.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.53 -179.603 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.48 134.76 48.06 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.385 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -142.07 146.0 34.96 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.173 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.503 ' CG2' ' CD2' ' E' ' 14' ' ' HIS . 3.3 p -139.83 148.69 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 121.065 0.459 . . . . 0.0 110.716 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.811 ' HD1' ' CD2' ' D' ' 13' ' ' HIS . 0.1 OUTLIER -143.27 119.26 10.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.755 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.591 ' HE2' HG12 ' F' ' 12' ' ' VAL . 90.1 m-70 -143.9 164.35 30.81 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.014 178.313 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.619 HE21 HD21 ' E' ' 17' ' ' LEU . 64.4 tp60 -89.98 151.93 21.45 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 177.526 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -148.74 98.8 2.91 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.782 177.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.951 HD11 HG11 ' C' ' 36' ' ' VAL . 37.1 mt -122.8 119.33 30.26 Favored 'General case' 0 CA--C 1.509 -0.615 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.081 178.133 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -107.62 104.32 16.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' D' ' 19' ' ' PHE . 73.9 m-85 -103.67 105.69 15.99 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 2.7 m-85 -107.49 114.57 28.66 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.47 138.43 31.0 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 119.096 -1.042 . . . . 0.0 112.623 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -84.59 141.85 30.39 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.624 -179.251 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 0.6 OUTLIER 172.64 47.07 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.066 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -179.095 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' D' ' 25' ' ' GLY . 3.5 m -73.43 175.28 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.307 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 100.14 -29.75 11.56 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.165 176.731 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 92.01 114.67 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 -177.796 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.412 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 78.6 m-20 -73.92 174.53 8.4 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.754 -178.181 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.11 -36.69 41.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.559 178.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.79 77.08 0.07 OUTLIER Glycine 0 CA--C 1.532 1.094 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -177.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.28 155.4 27.3 Favored 'General case' 0 C--O 1.241 0.64 0 CA-C-O 121.946 0.879 . . . . 0.0 111.673 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.879 HD11 ' H ' ' Q' ' 39' ' ' VAL . 75.0 mt -131.44 133.34 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 114.554 -1.203 . . . . 0.0 112.248 -177.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.43 115.35 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.289 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.49 113.42 1.6 Allowed Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 46.8 tp -123.37 121.38 35.64 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-O 120.825 0.345 . . . . 0.0 110.619 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.1 mtp -109.57 105.72 15.14 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.65 HG12 ' H ' ' E' ' 37' ' ' GLY . 21.6 t -91.84 174.33 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.373 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.65 ' H ' HG12 ' E' ' 36' ' ' VAL . . . 167.99 -95.15 0.11 Allowed Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 92.64 -82.64 1.12 Allowed Glycine 0 N--CA 1.474 1.193 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -178.044 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.442 HG13 HD11 ' K' ' 31' ' ' ILE . 64.4 t -72.17 101.89 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.329 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.548 ' N ' HD13 ' K' ' 31' ' ' ILE . 8.8 p . . . . . 0 C--O 1.222 -0.37 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.793 -179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -112.98 138.18 50.26 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.815 0.341 . . . . 0.0 110.792 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -110.01 113.47 26.21 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.895 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.591 HG12 ' HE2' ' E' ' 14' ' ' HIS . 2.5 t -112.82 100.67 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.165 0.507 . . . . 0.0 109.757 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.622 ' NE2' ' CD2' ' E' ' 13' ' ' HIS . 68.8 m80 -140.16 114.6 9.28 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.954 -178.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.534 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 77.2 m80 -156.21 162.1 40.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 177.31 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -90.06 158.23 17.42 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.678 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 31.9 tttt -141.16 98.28 3.34 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 175.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.784 HD11 HG11 ' D' ' 36' ' ' VAL . 7.9 mt -119.06 110.75 17.45 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 83.1 t -101.29 99.26 8.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.4 ' CD1' ' CD2' ' E' ' 19' ' ' PHE . 92.6 m-85 -96.51 95.08 7.76 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 106.768 -1.568 . . . . 0.0 106.768 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.421 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 67.8 t80 -107.4 109.25 20.93 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.585 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.548 ' O ' ' N ' ' F' ' 23' ' ' ASP . . . -148.82 135.41 19.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.584 ' HB3' HG12 ' E' ' 24' ' ' VAL . 63.3 mt-10 -74.98 79.53 2.18 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 102.807 -3.035 . . . . 0.0 102.807 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.749 ' O ' ' O ' ' F' ' 24' ' ' VAL . 53.0 p30 -120.71 54.34 1.08 Allowed 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 112.472 -2.149 . . . . 0.0 113.729 -173.304 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.749 ' O ' ' O ' ' F' ' 23' ' ' ASP . 13.7 t -52.64 -123.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 177.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' F' ' 30' ' ' ALA . . . 139.76 -35.84 1.89 Allowed Glycine 0 N--CA 1.469 0.837 0 C-N-CA 117.428 -2.32 . . . . 0.0 116.648 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.45 ' O ' ' ND2' ' F' ' 27' ' ' ASN . 41.5 t -65.44 111.51 3.11 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 115.142 -2.623 . . . . 0.0 109.372 -174.451 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.703 ' O ' ' N ' ' F' ' 29' ' ' GLY . 22.5 m120 -149.45 175.19 11.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 111.235 -2.711 . . . . 0.0 106.97 179.116 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.46 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.9 tttt -8.95 -45.31 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.916 0 N-CA-C 114.55 1.315 . . . . 0.0 114.55 176.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.703 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -170.03 60.66 0.18 Allowed Glycine 0 CA--C 1.551 2.304 0 C-N-CA 120.151 -1.023 . . . . 0.0 115.165 179.432 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.447 ' HB2' ' O ' ' F' ' 25' ' ' GLY . . . -85.57 160.86 19.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 118.936 1.368 . . . . 0.0 109.965 178.161 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.691 HD11 HG22 ' R' ' 39' ' ' VAL . 96.5 mt -134.97 136.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -128.54 124.7 62.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.82 129.05 4.31 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.663 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.6 125.34 44.66 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 95.6 mmm -131.47 133.28 44.98 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.609 -179.084 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 14.7 p -141.48 149.77 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 120.815 0.341 . . . . 0.0 110.788 178.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.12 102.04 0.42 Allowed Glycine 0 C--N 1.322 -0.216 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.22 -71.95 0.4 Allowed Glycine 0 CA--C 1.539 1.584 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.077 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.455 ' O ' ' OXT' ' F' ' 40' ' ' VAL . 5.6 m -79.31 167.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.609 ' H ' ' CG2' ' L' ' 31' ' ' ILE . 27.2 m . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.502 179.329 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 10' ' ' TYR . . . . . 0.527 ' CD2' ' O ' ' G' ' 11' ' ' GLU . 86.7 t80 -73.19 139.84 46.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.776 0.322 . . . . 0.0 110.405 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 11' ' ' GLU . . . . . 0.527 ' O ' ' CD2' ' G' ' 10' ' ' TYR . 79.4 mm-40 -70.73 150.32 46.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.535 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.403 HG11 ' ND1' ' H' ' 13' ' ' HIS . 65.1 t -120.94 130.54 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.953 0.406 . . . . 0.0 110.018 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -82.16 160.77 23.01 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.643 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.421 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 33.9 p-80 -99.5 169.49 9.27 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.083 0.468 . . . . 0.0 111.356 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.442 ' H ' ' HG2' ' H' ' 15' ' ' GLN . 67.1 tp60 -129.69 151.38 50.35 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.036 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -95.63 130.57 42.47 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.59 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.1 mt -126.19 112.43 15.77 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.218 0.532 . . . . 0.0 109.783 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.456 HG23 ' O ' ' G' ' 18' ' ' VAL . 21.2 m -125.65 132.49 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.179 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -127.0 113.32 16.32 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -111.82 117.51 33.01 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 110.297 -0.261 . . . . 0.0 110.297 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.04 107.39 14.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -151.36 138.96 19.63 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 55.18 46.41 23.91 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 119.985 -0.686 . . . . 0.0 110.857 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.784 HG12 ' H ' ' G' ' 25' ' ' GLY . 37.0 t -80.42 -179.86 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.784 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -71.27 -31.82 65.84 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.371 -177.246 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 15.2 t -173.93 127.53 0.38 Allowed 'General case' 0 C--O 1.224 -0.283 0 CA-C-N 118.35 1.075 . . . . 0.0 113.656 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.6 m-20 -2.56 150.74 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 175.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -158.88 17.48 0.19 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 121.942 -0.474 . . . . 0.0 110.326 177.08 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.33 169.53 0.66 Allowed Glycine 0 CA--C 1.524 0.651 0 CA-C-N 115.892 -0.594 . . . . 0.0 112.898 176.268 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.414 ' H ' ' HB2' ' H' ' 27' ' ' ASN . . . -130.83 87.31 2.47 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.346 0.593 . . . . 0.0 111.588 178.38 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.463 HD11 HG12 ' A' ' 39' ' ' VAL . 42.2 pt -138.83 127.12 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.223 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 177.423 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.462 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.8 mt -107.73 111.12 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.29 95.14 0.65 Allowed Glycine 0 N--CA 1.463 0.458 0 N-CA-C 105.347 -3.101 . . . . 0.0 105.347 177.056 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.4 mt -142.71 161.34 38.34 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 122.462 1.125 . . . . 0.0 113.861 -175.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 54.9 tpp -120.67 115.02 22.55 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 113.041 -1.89 . . . . 0.0 107.843 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.61 HG23 HG22 ' H' ' 36' ' ' VAL . 0.0 OUTLIER -131.57 111.76 19.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 179.728 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.61 -131.49 5.52 Favored Glycine 0 C--N 1.315 -0.585 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.55 -63.18 1.13 Allowed Glycine 0 CA--C 1.535 1.333 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.718 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.404 ' O ' ' C ' ' G' ' 40' ' ' VAL . 11.9 p -120.47 153.34 23.59 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.531 ' OXT' ' CE1' ' J' ' 13' ' ' HIS . 22.7 m . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 118.06 -0.971 . . . . 0.0 111.069 -178.431 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.62 134.75 52.98 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.727 0.299 . . . . 0.0 110.289 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.73 137.96 37.24 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.4 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.479 HG22 ' O ' ' I' ' 11' ' ' GLU . 2.0 t -123.78 107.63 19.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 81.0 t60 -126.63 120.9 30.66 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.92 0.391 . . . . 0.0 110.579 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' O ' ' I' ' 14' ' ' HIS . 11.7 t60 -155.59 170.28 22.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.094 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.595 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 82.5 mt-30 -156.0 141.95 18.1 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.276 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -82.38 120.41 25.4 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.362 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.4 ' HB2' HD23 ' I' ' 17' ' ' LEU . 5.7 mp -120.54 114.5 21.84 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.978 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.42 HG12 ' HB ' ' I' ' 18' ' ' VAL . 25.6 m -133.98 131.79 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 121.364 0.602 . . . . 0.0 111.195 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -122.26 120.14 33.24 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.201 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -117.34 122.17 43.15 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.736 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.61 115.73 22.62 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.44 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.551 ' O ' ' N ' ' H' ' 24' ' ' VAL . 95.7 mt-10 -115.8 141.84 47.56 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 112.86 0.689 . . . . 0.0 112.86 -178.025 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.432 ' H ' ' HB2' ' I' ' 22' ' ' GLU . 88.5 m-20 54.38 -59.71 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 114.668 -1.151 . . . . 0.0 113.789 178.138 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.551 ' N ' ' O ' ' H' ' 22' ' ' GLU . 16.3 m -93.48 172.04 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-O 122.005 0.907 . . . . 0.0 111.616 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.97 27.93 65.65 Favored Glycine 0 CA--C 1.529 0.948 0 CA-C-N 113.841 -1.527 . . . . 0.0 112.762 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 46.6 t -98.38 110.83 23.35 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 5.4 t-20 -77.19 172.81 12.66 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 118.062 -1.455 . . . . 0.0 110.562 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.583 ' O ' ' N ' ' I' ' 28' ' ' LYS . 68.7 mttm -52.4 -36.46 54.16 Favored 'General case' 0 C--O 1.218 -0.575 0 CA-C-O 121.988 0.899 . . . . 0.0 110.821 176.055 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.473 ' CA ' HG21 ' A' ' 40' ' ' VAL . . . -132.12 79.48 0.35 Allowed Glycine 0 N--CA 1.47 0.901 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.466 -175.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.61 132.53 43.87 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 118.829 1.314 . . . . 0.0 111.132 -176.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.421 ' CD1' ' HA ' ' B' ' 39' ' ' VAL . 87.5 mt -140.84 147.55 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 113.954 -1.475 . . . . 0.0 113.544 -174.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.588 HD13 ' CD1' ' J' ' 19' ' ' PHE . 65.3 mt -106.86 107.25 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -111.56 98.59 1.03 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.178 -2.369 . . . . 0.0 107.178 178.2 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.647 ' O ' HD12 ' I' ' 34' ' ' LEU . 2.4 mt -135.18 139.09 44.29 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.584 1.183 . . . . 0.0 113.392 -176.201 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -106.21 108.66 20.29 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.15 -2.537 . . . . 0.0 104.15 175.287 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 1.001 HG11 HD11 ' J' ' 17' ' ' LEU . 53.1 t -127.94 131.26 69.77 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.247 0 CA-C-O 121.184 0.516 . . . . 0.0 112.159 -175.198 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.88 -111.11 3.68 Favored Glycine 0 C--N 1.32 -0.339 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.749 178.444 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.7 -74.22 2.42 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -177.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.429 HG22 ' O ' ' N' ' 29' ' ' GLY . 18.2 t -110.43 135.93 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 122.902 0.481 . . . . 0.0 110.475 179.08 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.472 HG12 ' O ' ' H' ' 40' ' ' VAL . 69.9 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.322 178.249 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.423 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -82.89 136.71 34.5 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.869 0.366 . . . . 0.0 110.533 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.479 ' O ' HG22 ' H' ' 12' ' ' VAL . 80.2 mm-40 -78.6 155.39 29.63 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.424 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' I' ' 13' ' ' HIS . 74.0 t -138.4 166.91 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.931 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.587 ' N ' HG12 ' I' ' 12' ' ' VAL . 11.0 m-70 -54.99 143.0 27.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.777 0.322 . . . . 0.0 111.46 -178.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 16.7 t-80 -153.9 154.31 33.64 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.601 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 64.2 tp60 -98.76 169.3 9.58 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 118.315 0.507 . . . . 0.0 111.208 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 82.2 tttt -159.73 104.29 1.57 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 176.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.4 HD23 ' HB2' ' H' ' 17' ' ' LEU . 11.7 mt -123.89 123.29 40.1 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 121.236 0.541 . . . . 0.0 111.472 178.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.42 ' HB ' HG12 ' H' ' 18' ' ' VAL . 60.3 t -115.91 112.08 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 177.593 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -112.54 107.36 16.07 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -114.74 126.93 55.41 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 130.09 25.35 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.817 0.818 . . . . 0.0 113.114 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.453 ' OE1' ' OE1' ' J' ' 22' ' ' GLU . 58.5 mm-40 -95.6 120.23 35.48 Favored 'General case' 0 N--CA 1.461 0.096 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.892 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.455 ' H ' ' HB3' ' J' ' 22' ' ' GLU . 90.6 m-20 -125.72 48.64 2.04 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.038 0.385 . . . . 0.0 112.038 -177.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.565 HG12 ' N ' ' I' ' 25' ' ' GLY . 81.2 t -72.39 161.11 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 C-N-CA 118.447 -1.301 . . . . 0.0 109.896 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.565 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 108.39 -30.05 9.34 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 22.9 p 93.28 113.59 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 112.573 -1.814 . . . . 0.0 109.619 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.411 ' HA ' HD21 ' I' ' 27' ' ' ASN . 8.6 m120 -74.19 161.95 29.44 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 117.916 -1.514 . . . . 0.0 110.649 178.232 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.583 ' N ' ' O ' ' H' ' 28' ' ' LYS . 72.7 tttt -48.65 -39.5 24.5 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 174.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.33 68.82 0.04 OUTLIER Glycine 0 CA--C 1.551 2.327 0 CA-C-O 118.826 -0.986 . . . . 0.0 112.421 -174.395 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.25 150.62 46.22 Favored 'General case' 0 N--CA 1.478 0.938 0 CA-C-N 119.775 1.787 . . . . 0.0 114.587 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.55 HD12 HG12 ' C' ' 39' ' ' VAL . 77.5 mt -141.44 152.32 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 113.517 -1.674 . . . . 0.0 113.996 -176.237 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.454 HD13 ' CD1' ' K' ' 19' ' ' PHE . 6.6 mt -106.93 109.08 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 174.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.42 106.03 2.04 Favored Glycine 0 N--CA 1.465 0.617 0 N-CA-C 106.323 -2.711 . . . . 0.0 106.323 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.647 HD12 ' O ' ' H' ' 34' ' ' LEU . 26.6 tp -147.54 140.25 24.79 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.837 1.303 . . . . 0.0 113.969 -174.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.548 ' H ' HD12 ' I' ' 34' ' ' LEU . 42.8 tpp -110.04 115.08 29.13 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 113.033 -1.894 . . . . 0.0 106.799 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.79 123.13 51.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.06 -113.55 0.86 Allowed Glycine 0 C--N 1.317 -0.527 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 86.24 -73.01 2.58 Favored Glycine 0 CA--C 1.536 1.405 0 CA-C-N 115.48 -0.36 . . . . 0.0 112.211 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 39.7 t -123.19 146.09 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.472 HG13 ' ND1' ' L' ' 13' ' ' HIS . 52.9 t . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.651 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.84 134.33 54.41 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.41 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 98.9 mt-10 -74.57 130.79 40.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.483 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.589 HG23 ' O ' ' J' ' 12' ' ' VAL . 32.9 m -138.38 88.09 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-O 121.601 0.715 . . . . 0.0 110.904 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.562 ' H ' ' CD2' ' K' ' 13' ' ' HIS . 6.1 t60 -129.03 128.14 43.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.433 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.569 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -140.67 173.64 11.29 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.426 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 2.6 tt0 -124.64 142.45 51.37 Favored 'General case' 0 C--O 1.224 -0.248 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.465 177.542 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.82 112.16 23.45 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 119.168 -0.444 . . . . 0.0 111.078 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 1.001 HD11 HG11 ' H' ' 36' ' ' VAL . 24.0 mt -118.43 114.36 22.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.613 0.642 . . . . 0.0 109.984 177.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 t -110.13 105.83 19.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.588 ' CD1' HD13 ' H' ' 32' ' ' ILE . 65.5 m-85 -106.36 106.67 17.3 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.454 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.6 t80 -115.24 122.48 46.11 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.77 138.3 32.19 Favored 'General case' 0 C--O 1.253 1.26 0 CA-C-O 123.091 1.424 . . . . 0.0 114.479 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.455 ' HB3' ' H ' ' I' ' 23' ' ' ASP . 24.0 tt0 -79.89 90.99 5.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 113.526 -1.67 . . . . 0.0 107.614 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.685 ' O ' ' O ' ' K' ' 22' ' ' GLU . 84.3 m-20 -89.98 60.04 4.76 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 111.773 -2.467 . . . . 0.0 110.42 -178.944 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -62.7 -112.65 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-O 117.109 -1.424 . . . . 0.0 108.282 -174.209 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.608 ' HA2' HG12 ' K' ' 24' ' ' VAL . . . -103.82 44.51 1.47 Allowed Glycine 0 N--CA 1.472 1.081 0 CA-C-N 121.707 2.049 . . . . 0.0 112.078 -172.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 29.0 t -71.82 100.64 2.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -109.67 -150.81 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.176 -175.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 34.96 42.07 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 113.36 0.874 . . . . 0.0 113.36 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.55 71.82 0.63 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 117.297 1.679 . . . . 0.0 117.297 177.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.33 120.27 40.82 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 174.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.471 HG22 ' N ' ' J' ' 32' ' ' ILE . 42.3 mt -145.12 155.45 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -174.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.471 ' N ' HG22 ' J' ' 31' ' ' ILE . 40.7 mt -111.89 111.23 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.27 103.88 1.64 Allowed Glycine 0 N--CA 1.467 0.75 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 177.261 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.432 ' CD2' HG13 ' J' ' 36' ' ' VAL . 12.2 tp -137.33 137.31 38.79 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 122.205 1.003 . . . . 0.0 113.663 -175.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -111.39 114.22 27.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 113.677 -1.601 . . . . 0.0 107.543 176.419 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.573 ' O ' ' NE2' ' L' ' 15' ' ' GLN . 1.3 m -121.23 103.21 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 120.399 0.143 . . . . 0.0 111.11 -178.547 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.39 -153.43 25.33 Favored Glycine 0 C--N 1.318 -0.468 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.016 178.053 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.479 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 126.15 -56.4 0.71 Allowed Glycine 0 CA--C 1.541 1.71 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.657 HG12 HG23 ' J' ' 40' ' ' VAL . 55.0 t -136.5 137.17 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.657 HG23 HG12 ' J' ' 39' ' ' VAL . 61.2 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.433 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.98 143.81 41.07 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.754 0.311 . . . . 0.0 110.644 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.489 ' O ' HG12 ' J' ' 12' ' ' VAL . 97.0 mt-10 -129.41 149.87 51.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.434 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.534 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 34.2 m -140.37 161.45 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.498 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.562 ' CD2' ' H ' ' J' ' 13' ' ' HIS . 28.1 m80 -70.17 118.15 12.64 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' O ' ' L' ' 14' ' ' HIS . 65.9 t60 -148.23 162.82 38.71 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.107 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.435 ' HB3' ' H ' ' L' ' 16' ' ' LYS . 41.3 tt0 -90.2 152.28 21.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.819 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -150.39 93.14 1.94 Allowed 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.616 177.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.438 HD22 HD12 ' J' ' 17' ' ' LEU . 2.0 mt -120.93 115.31 22.96 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.47 105.41 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.481 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 52.1 m-85 -104.28 103.67 13.45 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.454 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 31.9 t80 -113.07 119.3 37.37 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.016 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.546 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -156.74 162.71 39.76 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 122.626 1.203 . . . . 0.0 113.604 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.685 ' O ' ' O ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -82.05 118.81 23.31 Favored 'General case' 0 C--O 1.206 -1.22 0 C-N-CA 118.344 -1.342 . . . . 0.0 111.347 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.908 ' O ' HG13 ' K' ' 24' ' ' VAL . 65.2 m-20 -62.09 -50.41 72.04 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 120.251 -1.53 . . . . 0.0 110.016 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.908 HG13 ' O ' ' K' ' 23' ' ' ASP . 0.3 OUTLIER 159.6 171.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 178.626 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 -33.27 76.14 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 177.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.3 m -162.68 120.94 2.1 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 114.186 -1.007 . . . . 0.0 109.872 -177.879 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' K' ' 26' ' ' SER . 39.7 t30 -22.25 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -164.69 29.82 0.07 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.528 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.91 88.04 0.82 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.685 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.36 155.95 45.51 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.548 HD13 ' N ' ' E' ' 40' ' ' VAL . 6.9 mt -127.1 146.93 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 113.657 0.984 . . . . 0.0 113.657 -176.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -128.13 114.88 36.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.318 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.75 113.89 3.21 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.409 HD21 HD13 ' L' ' 17' ' ' LEU . 20.3 tp -122.84 124.36 43.11 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 17.8 mtp -129.24 131.09 46.98 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.409 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.593 HG12 ' N ' ' K' ' 37' ' ' GLY . 57.8 t -100.84 166.28 2.37 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-O 121.003 0.43 . . . . 0.0 110.568 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.593 ' N ' HG12 ' K' ' 36' ' ' VAL . . . -75.01 -102.91 0.1 OUTLIER Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.151 179.378 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.55 -77.16 0.59 Allowed Glycine 0 N--CA 1.474 1.217 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.422 HG22 ' O ' ' L' ' 39' ' ' VAL . 45.5 t -115.26 132.05 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 121.428 0.632 . . . . 0.0 110.585 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' L' ' 40' ' ' VAL . 15.1 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.547 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -115.31 140.8 48.8 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.104 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -70.53 137.91 50.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.529 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 55.1 t -123.84 133.82 68.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.533 0.682 . . . . 0.0 110.942 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.492 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 2.5 m-70 -131.33 127.24 37.24 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.181 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.546 ' O ' ' ND1' ' K' ' 14' ' ' HIS . 94.9 m-70 -155.01 165.46 36.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.573 ' NE2' ' O ' ' J' ' 36' ' ' VAL . 58.1 mt-30 -89.69 156.64 18.42 Favored 'General case' 0 CA--C 1.518 -0.282 0 C-N-CA 119.521 -0.871 . . . . 0.0 109.635 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 16' ' ' LYS . . . . . 0.435 ' H ' ' HB3' ' K' ' 15' ' ' GLN . 52.4 tttp -141.99 95.66 2.84 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.221 177.542 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.409 HD13 HD21 ' K' ' 34' ' ' LEU . 0.1 OUTLIER -117.65 108.19 15.14 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.299 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -107.11 103.93 16.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.058 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -101.23 102.13 12.97 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 178.13 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.7 t80 -126.52 129.7 49.15 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 121.35 0.595 . . . . 0.0 110.231 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -144.84 149.09 34.8 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 120.059 -0.656 . . . . 0.0 110.66 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -74.24 120.98 20.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.657 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -163.52 51.61 0.16 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 120.372 -0.531 . . . . 0.0 112.067 -178.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -76.15 143.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 118.119 -1.432 . . . . 0.0 108.51 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.52 -37.52 3.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.42 ' HB2' ' H ' ' K' ' 27' ' ' ASN . 0.3 OUTLIER -80.6 118.26 22.02 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 113.379 -1.411 . . . . 0.0 112.057 -179.267 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' L' ' 29' ' ' GLY . 57.3 p30 -89.01 -177.95 5.58 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -51.98 49.66 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 115.089 1.514 . . . . 0.0 115.089 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -101.58 51.35 0.93 Allowed Glycine 0 CA--C 1.549 2.182 0 CA-C-N 119.698 1.135 . . . . 0.0 113.515 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.38 174.47 9.83 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.609 ' CG2' ' H ' ' F' ' 40' ' ' VAL . 0.6 OUTLIER -106.91 119.91 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 176.214 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.0 mt -123.62 128.66 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 120.876 0.369 . . . . 0.0 111.7 -178.073 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 116.24 2.22 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 178.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 34.3 mt -119.64 124.59 46.67 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.7 ttm -124.04 123.54 40.57 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.468 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' L' ' 37' ' ' GLY . 72.8 t -98.33 131.52 45.24 Favored 'Isoleucine or valine' 0 C--N 1.34 0.17 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -34.6 -111.51 0.0 OUTLIER Glycine 0 CA--C 1.531 1.089 0 O-C-N 123.543 0.527 . . . . 0.0 113.257 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.68 -71.65 0.62 Allowed Glycine 0 CA--C 1.535 1.298 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.422 ' O ' HG22 ' K' ' 39' ' ' VAL . 53.2 t -125.33 129.93 72.97 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.165 0.507 . . . . 0.0 110.998 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' K' ' 40' ' ' VAL . 8.7 p . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 117.899 -1.048 . . . . 0.0 110.724 179.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.327 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -114.09 139.14 49.55 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.711 0.291 . . . . 0.0 110.593 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -71.17 127.64 33.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.874 0.369 . . . . 0.0 110.119 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -125.48 131.93 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.349 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -106.28 160.71 15.15 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.633 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 35.1 p-80 -83.43 166.91 17.96 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 120.392 -0.523 . . . . 0.0 110.617 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -129.95 152.07 49.82 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.927 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 16' ' ' LYS . . . . . 0.59 ' C ' HD12 ' M' ' 17' ' ' LEU . 63.6 mttp -94.38 112.3 24.08 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 17' ' ' LEU . . . . . 0.59 HD12 ' C ' ' M' ' 16' ' ' LYS . 11.1 mp -116.88 120.61 39.02 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.879 0.371 . . . . 0.0 110.124 179.454 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -129.61 132.54 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.049 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -142.25 134.23 27.3 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.989 0.423 . . . . 0.0 110.828 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.448 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 52.8 p90 -123.31 133.11 54.18 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.732 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.91 125.66 41.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 121.145 0.498 . . . . 0.0 111.543 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -156.33 126.34 6.47 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.586 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.24 46.41 25.29 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.831 HG12 ' H ' ' M' ' 25' ' ' GLY . 21.6 t -76.7 -179.8 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.349 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.831 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -88.88 28.15 6.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 26' ' ' SER . . . . . 0.443 ' O ' ' C ' ' M' ' 27' ' ' ASN . 4.7 t -169.74 -134.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.865 -0.421 . . . . 0.0 109.865 -178.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.443 ' C ' ' O ' ' M' ' 26' ' ' SER . 24.8 t30 -32.04 134.19 0.09 Allowed 'General case' 0 N--CA 1.472 0.671 0 O-C-N 122.985 0.178 . . . . 0.0 111.141 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 28' ' ' LYS . . . . . 0.452 ' O ' ' OD2' ' N' ' 23' ' ' ASP . 68.7 mttm -118.23 -38.5 3.18 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 29' ' ' GLY . . . . . 0.587 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . -81.04 -76.99 1.02 Allowed Glycine 0 CA--C 1.53 0.969 0 C-N-CA 118.794 -1.67 . . . . 0.0 112.178 -179.363 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 30' ' ' ALA . . . . . 0.587 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 171.05 99.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.386 0.593 . . . . 0.0 111.31 178.284 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -127.9 116.63 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 32' ' ' ILE . . . . . 0.436 ' O ' ' O ' ' N' ' 33' ' ' GLY . 96.5 mt -113.49 108.1 24.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.26 96.87 0.78 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 105.45 -3.06 . . . . 0.0 105.45 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 34' ' ' LEU . . . . . 0.623 ' O ' HD12 ' N' ' 34' ' ' LEU . 91.3 mt -142.63 163.5 32.64 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 123.12 1.438 . . . . 0.0 114.163 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -117.62 110.71 18.24 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 111.824 -2.443 . . . . 0.0 105.977 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.895 HG11 HD11 ' O' ' 17' ' ' LEU . 74.6 t -117.92 131.61 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 121.334 0.588 . . . . 0.0 110.15 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.54 -111.42 3.36 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.924 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.1 -73.03 0.97 Allowed Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.424 HG12 ' N ' ' M' ' 40' ' ' VAL . 56.0 t -99.17 158.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.339 0.149 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.424 ' N ' HG12 ' M' ' 39' ' ' VAL . 11.7 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.567 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -83.07 139.41 33.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.614 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -140.63 128.06 21.29 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.765 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -127.46 130.27 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -123.71 104.37 8.95 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.913 0.387 . . . . 0.0 111.667 -179.27 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 1.0 OUTLIER -158.31 170.57 21.94 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.864 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' N' N ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 19.5 tt0 -155.44 141.46 18.28 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.897 0.379 . . . . 0.0 110.355 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -87.04 117.51 25.81 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.801 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -118.69 124.4 47.26 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 179.055 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.02 126.84 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 120.994 0.426 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -130.85 130.27 43.39 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.861 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -124.29 128.49 49.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 118.6 26.57 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.013 0.435 . . . . 0.0 110.458 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -127.22 128.69 46.48 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.463 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 34.4 m-20 -162.47 51.26 0.19 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.164 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 89.2 t -63.21 150.81 9.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.041 0.448 . . . . 0.0 110.668 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.06 -37.37 3.8 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.508 ' O ' ' O ' ' N' ' 27' ' ' ASN . 51.4 m -120.49 -112.36 0.33 Allowed 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.794 0.33 . . . . 0.0 111.588 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.524 ' ND2' ' OD1' ' O' ' 23' ' ' ASP . 16.3 m-20 52.31 153.08 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.69 -178.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' O' ' 28' ' ' LYS . 68.8 mttm -139.7 -29.57 0.73 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 113.712 1.005 . . . . 0.0 113.712 -179.017 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 29' ' ' GLY . . . . . 0.429 ' O ' HG22 ' H' ' 39' ' ' VAL . . . -161.73 85.02 0.11 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 120.421 -0.895 . . . . 0.0 113.935 -174.547 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.86 123.64 28.44 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 118.824 1.312 . . . . 0.0 110.627 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 0.432 HD11 HG23 ' I' ' 39' ' ' VAL . 70.0 mt -129.98 134.53 62.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.515 -175.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -105.0 104.93 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 106.87 -1.529 . . . . 0.0 106.87 174.323 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -110.41 109.44 2.64 Favored Glycine 0 C--O 1.235 0.202 0 N-CA-C 106.274 -2.73 . . . . 0.0 106.274 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.623 HD12 ' O ' ' M' ' 34' ' ' LEU . 15.8 tp -151.55 139.13 19.62 Favored 'General case' 0 CA--C 1.511 -0.535 0 C-N-CA 117.432 -1.707 . . . . 0.0 113.379 -175.412 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 35' ' ' MET . . . . . 0.528 ' H ' HD12 ' N' ' 34' ' ' LEU . 0.8 OUTLIER -105.25 108.88 20.63 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 111.756 -2.475 . . . . 0.0 106.424 177.401 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' N' N ' 36' ' ' VAL . . . . . 0.644 HG11 HD11 ' P' ' 17' ' ' LEU . 8.7 p -132.8 142.6 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.141 -177.687 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.74 -102.02 0.75 Allowed Glycine 0 C--N 1.32 -0.307 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' O' ' 39' ' ' VAL . . . 77.01 -80.76 1.21 Allowed Glycine 0 CA--C 1.531 1.064 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.49 149.51 14.66 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.574 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.411 HG12 ' CD2' ' P' ' 13' ' ' HIS . 33.3 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.873 -1.061 . . . . 0.0 110.256 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -148.93 159.94 43.73 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.729 0.299 . . . . 0.0 110.484 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -134.55 160.22 38.74 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.619 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -118.45 131.04 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.281 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 37.3 m-70 -140.13 123.6 17.08 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.715 ' CE1' ' HD1' ' P' ' 14' ' ' HIS . 30.9 m80 -147.58 174.09 12.08 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 121.25 0.548 . . . . 0.0 111.152 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 10.0 tp-100 -137.69 140.8 40.98 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -129.96 104.55 7.42 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.895 HD11 HG11 ' M' ' 36' ' ' VAL . 12.7 mt -116.61 116.3 27.32 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.006 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.89 106.34 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.891 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 13.6 m-30 -112.02 118.07 34.42 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -119.62 127.24 52.75 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.789 -0.187 . . . . 0.0 110.933 -179.184 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.39 124.83 26.35 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 121.944 0.878 . . . . 0.0 112.053 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 22' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' O' ' 23' ' ' ASP . 80.4 tt0 -96.09 141.79 29.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.316 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.524 ' OD1' ' ND2' ' N' ' 27' ' ' ASN . 65.3 m-20 -162.75 47.22 0.15 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.87 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.621 HG13 ' OE1' ' P' ' 22' ' ' GLU . 25.0 m -62.77 -179.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 121.716 0.769 . . . . 0.0 111.535 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 25' ' ' GLY . . . . . 0.475 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 91.25 -29.01 7.42 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 114.22 -1.354 . . . . 0.0 113.358 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 0.9 OUTLIER 167.63 127.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 118.385 1.093 . . . . 0.0 112.798 179.467 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' O' O ' 27' ' ' ASN . . . . . 0.515 ' ND2' ' O ' ' P' ' 27' ' ' ASN . 39.4 t-20 -36.72 138.48 0.24 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 176.137 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' N' ' 28' ' ' LYS . 78.1 mttt -150.56 34.82 0.62 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 121.077 0.465 . . . . 0.0 111.684 -176.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.35 80.39 0.95 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 176.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.01 110.99 23.1 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 42.8 mt -121.93 130.72 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -176.545 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.5 mt -107.44 103.64 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.281 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.27 102.41 2.21 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 104.146 -3.582 . . . . 0.0 104.146 176.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.557 HD12 ' O ' ' N' ' 34' ' ' LEU . 13.0 tp -140.19 135.87 32.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -172.67 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 35' ' ' MET . . . . . 0.428 ' SD ' ' CG ' ' P' ' 35' ' ' MET . 89.5 mmm -111.64 108.73 18.3 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 112.369 -2.196 . . . . 0.0 106.185 177.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.495 HG11 HD21 ' Q' ' 17' ' ' LEU . 21.4 t -115.67 131.51 67.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.447 0.641 . . . . 0.0 111.94 -177.069 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' P' ' 37' ' ' GLY . . . 75.39 111.71 0.1 Allowed Glycine 0 CA--C 1.526 0.737 0 CA-C-N 114.767 -1.106 . . . . 0.0 114.222 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -94.17 -60.1 1.14 Allowed Glycine 0 CA--C 1.542 1.762 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' N' ' 38' ' ' GLY . 5.7 t -122.02 131.12 73.85 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.442 ' H ' ' HB ' ' P' ' 39' ' ' VAL . 91.4 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.922 -1.037 . . . . 0.0 110.476 -178.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' P' P ' 10' ' ' TYR . . . . . 0.436 ' O ' ' OE1' ' Q' ' 11' ' ' GLU . 93.5 m-85 -106.94 138.71 42.6 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.878 0.37 . . . . 0.0 110.31 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 11' ' ' GLU . . . . . 0.666 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 96.2 mt-10 -71.8 152.06 42.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.478 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.461 ' O ' ' CG2' ' P' ' 12' ' ' VAL . 1.4 m -110.46 119.94 60.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 9.2 t60 -146.39 134.15 21.17 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 120.511 -0.475 . . . . 0.0 112.115 -177.846 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.715 ' HD1' ' CE1' ' O' ' 14' ' ' HIS . 1.0 OUTLIER -145.96 156.01 43.22 Favored 'General case' 0 C--O 1.23 0.068 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 176.314 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.429 ' OE1' HD11 ' P' ' 17' ' ' LEU . 7.4 tt0 -90.56 159.71 16.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.661 177.26 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 51.5 tttm -140.91 105.65 4.92 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.115 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 17' ' ' LEU . . . . . 0.644 HD11 HG11 ' N' ' 36' ' ' VAL . 39.6 mt -115.25 119.76 37.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-O 121.202 0.525 . . . . 0.0 111.166 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -116.75 98.29 6.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.489 ' CE2' HD13 ' P' ' 17' ' ' LEU . 16.9 m-30 -112.86 110.35 20.39 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -112.51 128.7 56.42 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.925 -179.455 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.5 158.13 40.86 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.953 -178.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.621 ' OE1' HG13 ' O' ' 24' ' ' VAL . 99.1 mt-10 -85.83 112.21 20.9 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.405 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 9.8 p-10 -112.44 52.07 0.79 Allowed 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 113.511 -1.677 . . . . 0.0 108.847 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 24' ' ' VAL . . . . . 0.565 HG12 ' N ' ' P' ' 25' ' ' GLY . 96.4 t -41.35 161.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 122.169 0.985 . . . . 0.0 112.249 -175.087 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.565 ' N ' HG12 ' P' ' 24' ' ' VAL . . . -93.14 32.61 5.57 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-N 113.077 -1.874 . . . . 0.0 114.218 -173.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.429 ' HB3' ' H ' ' O' ' 27' ' ' ASN . 11.9 t -92.57 -112.91 0.1 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.575 ' O ' ' N ' ' P' ' 29' ' ' GLY . 83.7 m-20 -86.27 156.58 20.2 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 118.097 -1.441 . . . . 0.0 110.893 -178.043 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 50.1 pttt -49.16 46.27 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . -99.38 58.17 0.85 Allowed Glycine 0 CA--C 1.545 1.915 0 CA-C-N 118.875 0.761 . . . . 0.0 112.322 179.065 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 30' ' ' ALA . . . . . 0.576 ' O ' ' HB1' ' Q' ' 30' ' ' ALA . . . -152.72 108.06 3.27 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 117.811 0.805 . . . . 0.0 110.856 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.479 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 14.0 pt -145.04 147.86 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.9 mt -114.4 115.89 50.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.341 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.46 98.31 1.12 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 104.739 -3.344 . . . . 0.0 104.739 174.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 22.6 tp -127.49 132.43 49.98 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -173.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' P' P ' 35' ' ' MET . . . . . 0.428 ' CG ' ' SD ' ' O' ' 35' ' ' MET . 90.6 mmm -111.56 112.83 24.82 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 174.756 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.494 HG21 HE22 ' R' ' 15' ' ' GLN . 0.0 OUTLIER -121.32 102.35 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -176.001 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' P' P ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' O' ' 37' ' ' GLY . . . 141.55 -161.34 27.0 Favored Glycine 0 CA--C 1.509 -0.339 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.802 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 38' ' ' GLY . . . . . 0.565 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 148.16 -55.8 0.5 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-O 119.234 -0.759 . . . . 0.0 111.229 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.607 HG23 HD11 ' C' ' 31' ' ' ILE . 73.3 t -144.72 139.85 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 118.355 1.078 . . . . 0.0 108.805 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 86.7 t . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 118.074 -0.965 . . . . 0.0 111.321 178.705 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -81.46 139.37 35.24 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.835 0.35 . . . . 0.0 110.609 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.436 ' OE1' ' O ' ' P' ' 10' ' ' TYR . 95.9 mt-10 -85.36 110.0 18.8 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.632 HG12 ' H ' ' R' ' 12' ' ' VAL . 34.4 m -141.13 165.27 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.666 ' CE1' ' O ' ' P' ' 11' ' ' GLU . 1.6 m80 -132.93 121.13 22.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.785 178.326 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.588 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 32.1 m-70 -144.82 161.83 38.29 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.626 178.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.437 ' OE1' ' CG1' ' O' ' 36' ' ' VAL . 8.4 tp-100 -90.09 157.81 17.6 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.52 102.34 4.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 176.013 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.594 HD22 HD12 ' P' ' 17' ' ' LEU . 77.7 mt -116.14 117.11 29.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 C-N-CA 120.317 -0.553 . . . . 0.0 111.06 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 41.1 t -118.01 99.28 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 177.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.403 ' CZ ' ' HB3' ' Q' ' 17' ' ' LEU . 7.2 m-30 -110.57 107.64 17.32 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.17 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -120.49 138.84 53.6 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.989 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -147.62 151.79 36.79 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' P' ' 23' ' ' ASP . 80.5 tt0 -80.27 121.8 26.09 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.217 -179.244 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 67.1 t0 -136.22 52.08 1.99 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.7 142.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.435 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 25' ' ' GLY . . . 100.4 38.05 3.61 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 106.082 -2.807 . . . . 0.0 106.082 -174.773 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 37.2 t -69.71 104.03 2.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.003 1.382 . . . . 0.0 114.568 -172.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . 0.505 ' O ' ' C ' ' Q' ' 28' ' ' LYS . 97.5 m-20 -118.82 -153.33 0.53 Allowed 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 111.824 -2.444 . . . . 0.0 105.036 178.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' O ' ' HB2' ' R' ' 30' ' ' ALA . 99.0 mttt -35.42 -41.15 0.17 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 120.354 1.434 . . . . 0.0 109.9 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.02 -65.42 2.59 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.95 1.54 . . . . 0.0 116.95 172.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . 0.576 ' HB1' ' O ' ' P' ' 30' ' ' ALA . . . -171.01 174.95 4.53 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.981 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.6 mt -121.12 118.08 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-N 113.347 -1.751 . . . . 0.0 107.015 176.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -120.38 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.24 0.543 . . . . 0.0 112.282 -178.04 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.81 114.34 2.07 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 32.0 mt -120.9 128.91 53.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 57.2 mtp -132.47 132.14 42.4 Favored 'General case' 0 CA--C 1.514 -0.405 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.314 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . 0.445 ' O ' ' N ' ' R' ' 37' ' ' GLY . 69.2 t -115.65 135.58 55.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.551 ' O ' ' N ' ' P' ' 38' ' ' GLY . . . -139.44 103.32 0.38 Allowed Glycine 0 C--N 1.306 -1.095 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 148.56 72.5 0.01 OUTLIER Glycine 0 N--CA 1.479 1.524 0 CA-C-N 119.76 1.78 . . . . 0.0 114.635 -178.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . 0.879 ' H ' HD11 ' E' ' 31' ' ' ILE . 37.2 t -18.63 125.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.601 0.761 . . . . 0.0 112.699 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.639 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -81.96 140.16 34.17 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.889 0.376 . . . . 0.0 110.589 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -113.53 128.04 56.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.711 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 12' ' ' VAL . . . . . 0.632 ' H ' HG12 ' Q' ' 12' ' ' VAL . 78.5 t -135.28 156.71 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.125 0.488 . . . . 0.0 110.982 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.437 ' N ' HG12 ' R' ' 12' ' ' VAL . 3.2 m-70 -144.06 132.42 22.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.252 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 14' ' ' HIS . . . . . 0.588 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 64.2 m80 -151.73 161.73 42.18 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.016 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.597 ' NE2' HD23 ' R' ' 17' ' ' LEU . 52.3 tt0 -90.13 158.45 17.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.89 0.376 . . . . 0.0 111.486 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.6 100.83 3.95 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.597 HD23 ' NE2' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -111.64 112.78 24.73 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.958 0.409 . . . . 0.0 109.948 179.313 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 87.6 t -117.83 101.64 12.18 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.465 ' O ' ' CD1' ' R' ' 20' ' ' PHE . 4.0 m-85 -119.43 116.83 26.96 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 20' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' R' ' 19' ' ' PHE . 80.1 m-85 -150.8 160.03 44.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 122.08 0.943 . . . . 0.0 112.384 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 21' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -129.36 145.94 51.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.129 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.77 153.87 40.63 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 122.095 0.95 . . . . 0.0 113.49 -175.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 61.0 t0 61.98 47.93 5.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 113.581 -1.645 . . . . 0.0 111.676 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.638 HG12 ' N ' ' R' ' 25' ' ' GLY . 45.4 t -59.68 171.12 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.911 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 25' ' ' GLY . . . . . 0.638 ' N ' HG12 ' R' ' 24' ' ' VAL . . . 161.12 31.41 0.02 OUTLIER Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 3.3 t 72.73 120.75 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 95.7 m-20 -83.04 162.3 21.44 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.428 -0.909 . . . . 0.0 111.508 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -48.08 -39.67 20.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.407 177.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.38 66.89 0.04 OUTLIER Glycine 0 CA--C 1.539 1.557 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.829 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 30' ' ' ALA . . . . . 0.55 ' HB2' ' O ' ' Q' ' 28' ' ' LYS . . . -71.81 159.32 34.52 Favored 'General case' 0 C--N 1.345 0.409 0 CA-C-N 117.837 0.819 . . . . 0.0 110.117 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -107.42 116.14 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -124.25 125.44 70.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-O 120.803 0.335 . . . . 0.0 110.566 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.15 121.05 3.24 Favored Glycine 0 N--CA 1.463 0.478 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.905 ' H ' HD23 ' R' ' 34' ' ' LEU . 1.2 pt? -123.15 128.26 49.81 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 121.433 0.635 . . . . 0.0 110.471 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 91.3 mmm -123.56 120.03 31.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.022 -178.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 96.2 t -100.28 115.42 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.33 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -115.25 122.97 5.78 Favored Glycine 0 CA--C 1.508 -0.384 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 177.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.92 66.48 0.46 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.428 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.691 HG22 HD11 ' F' ' 31' ' ' ILE . 26.8 m -53.89 152.59 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 117.43 0.615 . . . . 0.0 110.574 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.756 179.685 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.505 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 95.2 m-85 -84.14 140.03 32.03 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.726 0.298 . . . . 0.0 110.792 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' OE2' ' O ' ' A' ' 10' ' ' TYR . 43.9 mm-40 -136.94 114.23 10.83 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.709 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.774 HG13 HG13 ' B' ' 12' ' ' VAL . 73.2 t -138.61 87.22 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.563 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -148.54 143.66 26.79 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.592 ' CD2' ' N ' ' A' ' 14' ' ' HIS . 0.5 OUTLIER -111.94 163.14 14.56 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.144 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -89.91 158.74 17.28 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -140.62 106.86 5.24 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 87.9 mt -136.11 120.09 17.54 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.917 0.78 . . . . 0.0 110.772 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.34 136.01 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.703 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -125.46 119.38 28.08 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.907 0.384 . . . . 0.0 111.203 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -108.39 118.73 37.53 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.16 117.5 30.21 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.215 0.531 . . . . 0.0 111.2 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.73 -162.56 0.33 Allowed 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 115.294 -0.867 . . . . 0.0 108.897 179.399 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -39.8 -60.54 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.697 -179.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.442 HG12 ' N ' ' A' ' 25' ' ' GLY . 16.8 t -73.15 160.77 5.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.764 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.442 ' N ' HG12 ' A' ' 24' ' ' VAL . . . 110.26 -34.97 5.11 Favored Glycine 0 N--CA 1.467 0.731 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.203 177.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.452 ' CB ' ' HZ3' ' B' ' 28' ' ' LYS . 5.3 t -80.45 119.5 23.22 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.431 -0.508 . . . . 0.0 109.807 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 88.3 m-20 -90.04 161.23 15.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 122.016 0.912 . . . . 0.0 112.869 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 28' ' ' LYS . 99.3 mttt -46.77 -38.87 10.74 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 113.666 -1.606 . . . . 0.0 112.331 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.09 70.47 0.21 Allowed Glycine 0 CA--C 1.532 1.139 0 CA-C-N 114.575 -1.193 . . . . 0.0 114.335 -173.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' B' ' 30' ' ' ALA . . . -95.21 117.0 29.48 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 123.86 1.79 . . . . 0.0 112.071 -177.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 32.0 pt -149.59 147.78 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 112.457 -2.156 . . . . 0.0 108.589 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.406 ' O ' ' O ' ' B' ' 33' ' ' GLY . 97.8 mt -105.74 114.03 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.26 95.04 0.72 Allowed Glycine 0 N--CA 1.462 0.376 0 N-CA-C 105.639 -2.984 . . . . 0.0 105.639 177.141 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -142.95 151.78 41.3 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 122.664 1.221 . . . . 0.0 113.901 -176.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 89.5 mmm -106.99 108.98 20.76 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-N 112.634 -2.075 . . . . 0.0 105.616 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' B' ' 36' ' ' VAL . 24.3 t -124.14 112.05 31.1 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -178.307 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 115.48 -132.09 10.09 Favored Glycine 0 C--N 1.321 -0.296 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 -178.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.436 ' O ' HG12 ' B' ' 39' ' ' VAL . . . 92.06 -63.34 2.46 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.579 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' VAL . 1.1 m -96.03 177.86 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.537 ' H ' ' HB3' ' H' ' 28' ' ' LYS . 7.3 p . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.746 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -107.06 132.41 53.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.736 0.303 . . . . 0.0 110.243 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.519 ' O ' ' CE1' ' C' ' 13' ' ' HIS . 84.2 tt0 -151.35 128.37 11.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.398 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.774 HG13 HG13 ' A' ' 12' ' ' VAL . 0.2 OUTLIER -127.05 109.93 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-O 121.438 0.637 . . . . 0.0 110.358 179.703 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.444 ' CE1' ' HD1' ' C' ' 13' ' ' HIS . 22.6 p-80 -151.21 158.97 44.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.726 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.52 ' CD2' ' ND1' ' A' ' 14' ' ' HIS . 2.8 m-70 -143.04 163.89 31.58 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.63 178.588 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -89.96 152.01 21.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -149.16 100.98 3.1 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 69.8 mt -122.78 121.91 37.44 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.789 0.328 . . . . 0.0 110.41 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 18' ' ' VAL . . . . . 0.722 HG22 HG22 ' C' ' 18' ' ' VAL . 60.6 t -125.79 125.88 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.552 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -124.17 120.88 33.57 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.57 0.224 . . . . 0.0 110.695 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -122.58 121.06 35.58 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 116.697 -0.228 . . . . 0.0 110.967 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.98 130.15 55.53 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.655 0.264 . . . . 0.0 110.611 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.452 ' CG ' ' N ' ' B' ' 23' ' ' ASP . 77.0 tt0 -66.73 154.87 39.61 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -175.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.452 ' N ' ' CG ' ' B' ' 22' ' ' GLU . 65.8 t0 -67.15 47.79 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 111.216 -2.72 . . . . 0.0 113.833 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.739 HG12 ' H ' ' B' ' 25' ' ' GLY . 1.9 t -60.73 -179.5 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 118.388 -1.325 . . . . 0.0 111.527 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.739 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -99.71 28.91 13.33 Favored Glycine 0 N--CA 1.471 0.999 0 CA-C-N 114.809 -1.087 . . . . 0.0 115.681 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' B' ' 27' ' ' ASN . 42.8 t -162.18 116.14 1.83 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 120.089 1.945 . . . . 0.0 113.869 -176.107 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' B' ' 26' ' ' SER . 92.7 m-20 -22.71 164.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.848 0 O-C-N 125.311 1.632 . . . . 0.0 112.636 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.452 ' HZ3' ' CB ' ' A' ' 26' ' ' SER . 98.8 mttt -155.39 -20.71 0.11 Allowed 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 119.826 -0.75 . . . . 0.0 112.646 -177.192 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.38 97.8 0.06 OUTLIER Glycine 0 C--N 1.334 0.462 0 C-N-CA 117.497 -2.287 . . . . 0.0 109.603 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.517 ' HA ' ' O ' ' A' ' 30' ' ' ALA . . . -120.05 119.08 32.32 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 122.66 1.219 . . . . 0.0 112.505 -176.085 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.655 HD11 HG13 ' N' ' 39' ' ' VAL . 97.3 mt -127.45 132.29 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 113.971 -1.468 . . . . 0.0 111.097 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.602 HG22 HD11 ' C' ' 34' ' ' LEU . 23.1 mt -102.72 116.63 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -115.63 98.56 0.84 Allowed Glycine 0 C--O 1.237 0.287 0 N-CA-C 105.818 -2.913 . . . . 0.0 105.818 177.171 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -137.68 135.14 36.2 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 122.495 1.14 . . . . 0.0 112.558 -175.459 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 4.4 mtp -104.05 110.36 22.5 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 113.311 -1.768 . . . . 0.0 106.842 177.221 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.566 HG23 HG22 ' C' ' 36' ' ' VAL . 1.4 m -131.21 123.09 52.69 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.84 -113.4 0.66 Allowed Glycine 0 C--N 1.311 -0.84 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.61 -72.62 0.82 Allowed Glycine 0 CA--C 1.532 1.103 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' VAL . . . . . 0.564 HG21 ' CA ' ' H' ' 29' ' ' GLY . 3.7 p -144.58 157.48 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' B' ' 39' ' ' VAL . 20.4 m . . . . . 0 N--CA 1.473 0.686 0 CA-C-O 117.965 -1.017 . . . . 0.0 111.921 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -107.94 136.16 48.11 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -122.12 100.99 7.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.862 0.363 . . . . 0.0 110.323 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.529 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 1.5 p -145.1 137.55 21.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.345 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' B' ' 11' ' ' GLU . 2.0 m-70 -147.22 135.31 21.47 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.116 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.653 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 32.8 m-70 -142.23 161.08 38.92 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.243 -0.583 . . . . 0.0 110.977 177.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 5.2 mt-30 -85.41 157.16 20.56 Favored 'General case' 0 CA--C 1.523 -0.09 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 176.109 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -159.22 91.94 1.05 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.387 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 17' ' ' LEU . . . . . 0.421 HD12 ' N ' ' C' ' 17' ' ' LEU . 5.2 mp -128.82 122.35 30.26 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.968 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 18' ' ' VAL . . . . . 0.722 HG22 HG22 ' B' ' 18' ' ' VAL . 3.9 m -124.48 120.79 59.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -113.47 108.16 16.82 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.317 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -110.59 122.01 46.72 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.41 125.72 33.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.914 0.864 . . . . 0.0 112.406 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 94.9 mt-10 -98.72 110.14 22.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 177.699 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.41 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 99.2 m-20 -140.45 49.26 1.72 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.618 -1.174 . . . . 0.0 111.2 -175.451 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.556 HG12 ' N ' ' C' ' 25' ' ' GLY . 53.8 t -71.44 161.39 4.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 C-N-CA 119.339 -0.945 . . . . 0.0 109.901 -175.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.556 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 109.46 -29.87 9.09 Favored Glycine 0 CA--C 1.531 1.031 0 N-CA-C 107.315 -2.314 . . . . 0.0 107.315 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 1.1 m 93.21 114.58 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 114.194 -1.003 . . . . 0.0 110.583 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -73.58 164.05 27.18 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.551 0.691 . . . . 0.0 112.266 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' D' ' 28' ' ' LYS . 98.9 mttt -48.01 -37.01 13.84 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 114.109 1.151 . . . . 0.0 114.109 178.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.85 77.21 0.06 OUTLIER Glycine 0 CA--C 1.536 1.367 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.971 -175.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.0 138.27 37.01 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 122.547 1.165 . . . . 0.0 113.478 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.574 HD11 HG22 ' O' ' 39' ' ' VAL . 94.1 mt -142.42 144.89 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 114.328 -1.305 . . . . 0.0 112.656 -178.763 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.551 HD13 ' CD1' ' E' ' 19' ' ' PHE . 75.6 mt -106.71 111.4 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 174.099 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.72 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -118.94 101.66 0.89 Allowed Glycine 0 N--CA 1.465 0.592 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 179.213 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.72 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.6 mp -141.9 148.01 38.02 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.954 1.359 . . . . 0.0 113.329 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -104.4 111.52 24.21 Favored 'General case' 0 N--CA 1.44 -0.925 0 CA-C-N 112.097 -2.319 . . . . 0.0 105.692 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.98 HG11 HD11 ' E' ' 17' ' ' LEU . 55.1 t -124.81 123.22 65.32 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.741 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -178.028 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.07 -113.31 0.77 Allowed Glycine 0 C--N 1.312 -0.794 0 C-N-CA 119.75 -1.214 . . . . 0.0 111.958 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.78 -73.01 2.68 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 39' ' ' VAL . . . . . 0.652 ' HB ' HD11 ' I' ' 31' ' ' ILE . 13.6 p -172.79 132.92 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.555 ' CG2' ' NE2' ' F' ' 13' ' ' HIS . 21.4 m . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.776 -1.107 . . . . 0.0 110.043 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -105.87 132.68 51.69 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.774 0.321 . . . . 0.0 110.63 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -97.36 113.77 25.47 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.622 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.482 HG23 HG23 ' C' ' 12' ' ' VAL . 20.3 m -133.86 134.68 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.231 0.539 . . . . 0.0 111.218 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.498 ' O ' ' CG ' ' E' ' 13' ' ' HIS . 19.1 m-70 -140.07 135.6 32.76 Favored 'General case' 0 C--O 1.225 -0.194 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.032 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.653 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 1.3 t-80 -136.88 156.0 49.04 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.649 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.568 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 6.9 tt0 -87.55 157.15 19.23 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -162.45 92.93 0.83 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.674 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.407 ' HB3' ' CZ ' ' D' ' 19' ' ' PHE . 23.3 mt -122.39 114.17 20.37 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.315 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.9 t -110.64 109.18 27.5 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.534 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.407 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 66.0 m-85 -109.62 107.37 17.42 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -122.24 131.58 54.0 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-O 120.737 0.303 . . . . 0.0 111.544 -177.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.06 140.01 32.44 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 122.033 0.921 . . . . 0.0 112.998 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -82.03 113.87 20.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 122.039 0.923 . . . . 0.0 111.372 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.546 ' H ' ' HB3' ' E' ' 22' ' ' GLU . 54.4 m-20 50.17 46.42 24.77 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 113.551 -1.659 . . . . 0.0 112.267 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.707 HG12 ' N ' ' D' ' 25' ' ' GLY . 96.4 t -111.62 177.64 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 104.719 -2.326 . . . . 0.0 104.719 174.437 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.707 ' N ' HG12 ' D' ' 24' ' ' VAL . . . 63.02 28.69 72.49 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 178.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 48.9 m -108.67 -120.01 0.26 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.794 0.807 . . . . 0.0 112.498 -177.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -79.94 174.05 11.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.338 -178.496 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' C' ' 28' ' ' LYS . 99.1 mttt 58.32 39.91 25.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 113.998 1.11 . . . . 0.0 113.998 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.11 70.99 0.95 Allowed Glycine 0 N--CA 1.477 1.422 0 C-N-CA 119.031 -1.557 . . . . 0.0 116.346 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.0 109.08 15.08 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.365 0.602 . . . . 0.0 109.917 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.565 HD11 HG23 ' P' ' 39' ' ' VAL . 2.1 mt -133.57 141.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 N-CA-C 114.101 1.148 . . . . 0.0 114.101 -177.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.578 HD13 ' CD1' ' F' ' 19' ' ' PHE . 6.4 mt -108.69 113.9 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.481 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.91 102.97 1.27 Allowed Glycine 0 C--O 1.24 0.511 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 177.469 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.459 HD23 HG13 ' D' ' 36' ' ' VAL . 10.5 tp -133.93 134.51 42.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 122.181 0.991 . . . . 0.0 112.877 -176.725 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -105.17 112.36 25.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 113.445 -1.707 . . . . 0.0 107.304 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' E' ' 37' ' ' GLY . 0.4 OUTLIER -114.17 177.06 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.165 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.414 ' HA3' ' H ' ' E' ' 37' ' ' GLY . . . 131.53 -96.29 0.33 Allowed Glycine 0 C--N 1.31 -0.877 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 38' ' ' GLY . . . . . 0.496 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 38.17 75.92 0.08 OUTLIER Glycine 0 CA--C 1.533 1.207 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.056 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.563 ' CG2' HD11 ' J' ' 31' ' ' ILE . 60.4 t -6.35 123.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -178.01 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.509 ' O ' ' NZ ' ' K' ' 28' ' ' LYS . 55.3 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.455 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -81.81 138.98 35.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -136.28 140.61 43.55 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.029 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.434 ' H ' HG12 ' D' ' 12' ' ' VAL . 70.4 t -124.35 124.97 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 110.465 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.607 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.5 OUTLIER -156.4 134.75 11.44 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 179.387 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.607 ' N ' ' ND1' ' E' ' 13' ' ' HIS . 34.8 m-70 -143.52 167.38 22.35 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.73 0.3 . . . . 0.0 110.464 179.256 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.63 ' NE2' HG12 ' C' ' 36' ' ' VAL . 34.4 tt0 -89.64 151.3 21.97 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 177.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 14.3 mttt -153.35 98.73 2.29 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.011 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.98 HD11 HG11 ' C' ' 36' ' ' VAL . 2.9 mt -121.84 116.13 23.88 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 178.39 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -111.21 101.54 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.551 ' CD1' HD13 ' C' ' 32' ' ' ILE . 41.2 m-85 -106.75 102.65 12.01 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.171 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -122.49 132.99 54.59 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-O 121.229 0.537 . . . . 0.0 112.225 -178.357 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -138.77 145.34 40.08 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.42 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.546 ' HB3' ' H ' ' D' ' 23' ' ' ASP . 79.5 tt0 -68.73 147.16 52.21 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 117.574 -1.65 . . . . 0.0 108.804 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.534 ' O ' ' O ' ' E' ' 24' ' ' VAL . 21.2 t70 -128.05 61.6 1.44 Allowed 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.083 -174.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' E' ' 23' ' ' ASP . 4.7 t -33.64 -110.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.318 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -113.4 46.49 1.16 Allowed Glycine 0 N--CA 1.485 1.952 0 CA-C-N 120.173 1.351 . . . . 0.0 115.421 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.515 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.8 t 91.56 111.5 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 122.318 0.247 . . . . 0.0 111.378 176.204 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 8.1 m-20 -75.35 163.88 27.0 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.644 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.88 -39.41 25.76 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.13 0.04 OUTLIER Glycine 0 CA--C 1.544 1.849 0 C-N-CA 120.159 -1.02 . . . . 0.0 113.312 -176.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.76 145.17 50.6 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.333 1.566 . . . . 0.0 111.727 -177.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.499 HG23 HG23 ' D' ' 31' ' ' ILE . 1.3 tt -131.72 141.75 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 CA-C-O 121.675 0.75 . . . . 0.0 111.968 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 94.5 mt -124.98 131.43 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.78 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.56 117.2 2.72 Favored Glycine 0 CA--C 1.533 1.182 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 36.5 mt -123.55 122.81 39.14 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.236 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.0 mmm -119.73 129.18 54.39 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.468 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 54.2 t -94.15 135.05 29.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.985 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' D' ' 36' ' ' VAL . . . -99.9 -103.42 2.51 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -63.27 75.12 0.04 OUTLIER Glycine 0 CA--C 1.534 1.229 0 CA-C-N 113.891 -1.155 . . . . 0.0 112.48 179.591 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.505 HG11 ' H ' ' F' ' 39' ' ' VAL . 8.8 m -46.12 159.65 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 39.2 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.822 179.819 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -111.98 136.97 50.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.685 0.279 . . . . 0.0 110.707 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.66 140.79 36.47 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.6 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.481 HG12 ' NE2' ' E' ' 14' ' ' HIS . 2.6 t -108.22 106.02 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.839 0.352 . . . . 0.0 110.471 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.587 ' ND1' ' N ' ' F' ' 14' ' ' HIS . 17.1 t-80 -152.97 139.89 19.12 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.587 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 81.0 t60 -150.52 168.64 23.61 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.833 178.18 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.49 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 18.1 tt0 -89.56 150.35 22.46 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -151.82 96.35 2.22 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.195 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.431 HD22 HG11 ' D' ' 36' ' ' VAL . 0.3 OUTLIER -116.84 109.74 17.47 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.273 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -108.58 106.27 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.578 ' CD1' HD13 ' D' ' 32' ' ' ILE . 44.3 m-85 -109.04 107.35 17.66 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.475 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 9.2 m-85 -146.63 140.69 26.21 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 118.29 -1.364 . . . . 0.0 114.063 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.517 ' HB1' ' HB2' ' E' ' 23' ' ' ASP . . . -114.86 119.34 36.26 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.649 -2.723 . . . . 0.0 103.649 174.836 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -95.09 134.49 37.74 Favored 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 117.533 2.42 . . . . 0.0 117.533 -172.614 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.472 ' CG ' ' H ' ' F' ' 24' ' ' VAL . 24.4 p-10 174.25 -59.82 0.01 OUTLIER 'General case' 0 C--N 1.348 0.525 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.598 173.427 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.472 ' H ' ' CG ' ' F' ' 23' ' ' ASP . 31.1 m -117.19 173.09 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.808 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.35 -34.69 86.02 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.872 176.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 88.9 p -156.84 114.31 3.16 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 114.994 -0.603 . . . . 0.0 110.835 -176.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 95.9 m-20 -51.44 171.43 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.648 -178.584 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.69 -39.84 92.88 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.06 67.03 0.13 Allowed Glycine 0 CA--C 1.537 1.461 0 C-N-CA 119.094 -1.527 . . . . 0.0 114.809 -178.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.12 174.95 7.94 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.027 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.525 HD12 HG12 ' R' ' 39' ' ' VAL . 14.6 tt -129.61 137.83 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.451 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -132.66 140.45 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.57 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.47 124.43 3.68 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 34' ' ' LEU . . . . . 0.432 HD23 ' C ' ' F' ' 34' ' ' LEU . 9.3 tt -130.69 127.15 38.27 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.8 mtp -139.33 145.4 39.02 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.437 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 6.3 p -144.59 146.07 20.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.11 177.436 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.45 102.11 0.37 Allowed Glycine 0 C--N 1.319 -0.368 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.172 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.6 -73.56 0.3 Allowed Glycine 0 CA--C 1.536 1.381 0 C-N-CA 120.454 -0.879 . . . . 0.0 113.96 176.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.598 HG12 ' N ' ' F' ' 40' ' ' VAL . 99.1 t -146.82 163.31 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.998 0.428 . . . . 0.0 110.443 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 40' ' ' VAL . . . . . 0.598 ' N ' HG12 ' F' ' 39' ' ' VAL . 8.0 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.896 -1.049 . . . . 0.0 110.334 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -113.05 134.05 54.7 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-O 120.807 0.337 . . . . 0.0 110.377 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -150.9 154.0 36.35 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.833 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 99.4 t -120.96 133.96 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 121.174 0.511 . . . . 0.0 110.967 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -103.89 158.52 16.35 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.742 -179.596 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.618 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 18.6 t60 -85.62 166.97 15.78 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.718 -179.569 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.618 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 83.6 mt-30 -155.29 141.81 18.74 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.169 0.509 . . . . 0.0 110.357 178.184 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.629 ' C ' HD12 ' G' ' 17' ' ' LEU . 99.0 mttt -88.03 110.16 20.4 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.743 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.629 HD12 ' C ' ' G' ' 16' ' ' LYS . 11.3 mp -120.42 112.91 19.58 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.404 HG22 ' CG2' ' H' ' 18' ' ' VAL . 61.8 t -125.74 131.32 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.155 -178.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.68 128.25 42.17 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.469 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -128.29 126.78 41.49 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.402 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.75 122.61 38.52 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.706 0.765 . . . . 0.0 112.012 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -121.56 133.25 55.01 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.536 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.718 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 98.3 m-20 53.49 55.03 9.17 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.181 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 5.1 m -67.71 134.53 30.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.1 -31.62 2.21 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.357 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 19.1 m -93.24 -130.25 0.13 Allowed 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -177.882 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.522 ' OD1' ' NZ ' ' H' ' 28' ' ' LYS . 71.6 m-20 -82.91 -167.64 1.74 Allowed 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 114.5 -1.227 . . . . 0.0 111.541 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm 51.12 39.22 22.92 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.24 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.25 -66.67 1.59 Allowed Glycine 0 CA--C 1.539 1.565 0 C-N-CA 120.158 -1.02 . . . . 0.0 110.68 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' H' ' 30' ' ' ALA . . . -150.7 62.32 0.93 Allowed 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 119.593 1.696 . . . . 0.0 114.605 177.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 80.6 mt -136.45 113.44 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 176.246 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.445 ' O ' ' O ' ' H' ' 33' ' ' GLY . 96.4 mt -107.87 106.2 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.606 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.03 97.17 0.94 Allowed Glycine 0 CA--C 1.508 -0.357 0 N-CA-C 104.95 -3.26 . . . . 0.0 104.95 176.393 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.833 ' O ' HD12 ' H' ' 34' ' ' LEU . 52.4 tp -155.63 154.39 31.54 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 118.188 -1.405 . . . . 0.0 113.361 -175.152 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 8.1 mtp -112.11 122.47 47.83 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-N 112.989 -1.914 . . . . 0.0 108.655 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.704 HG21 ' CD1' ' I' ' 17' ' ' LEU . 35.9 m -131.32 112.07 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.69 -132.07 10.94 Favored Glycine 0 CA--C 1.519 0.303 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.53 -62.64 0.42 Allowed Glycine 0 CA--C 1.536 1.37 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 t -92.78 164.41 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.552 ' N ' ' CG2' ' H' ' 39' ' ' VAL . 8.5 p . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.991 -1.005 . . . . 0.0 110.585 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.196 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 44.3 t80 -71.38 133.5 46.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.906 0.384 . . . . 0.0 110.587 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -94.29 115.62 27.89 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.388 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.15 136.09 32.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.338 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.501 ' NE2' ' OE2' ' I' ' 11' ' ' GLU . 81.0 m80 -113.4 149.54 33.98 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 9.6 p-80 -86.82 164.15 16.82 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.983 -179.376 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -100.81 152.6 20.32 Favored 'General case' 0 CA--C 1.522 -0.098 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.837 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -110.84 107.86 17.49 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 177.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -123.16 117.38 25.24 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.404 ' CG2' HG22 ' G' ' 18' ' ' VAL . 12.9 m -132.14 133.76 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.132 0.491 . . . . 0.0 111.033 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -129.91 129.65 44.14 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.559 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.408 ' CE2' ' CG ' ' I' ' 20' ' ' PHE . 29.2 m-85 -127.43 131.57 50.22 Favored 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.465 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.19 122.38 31.73 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 82.6 tt0 -147.17 121.67 9.73 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 114.621 1.341 . . . . 0.0 114.621 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.718 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 1.7 p-10 156.24 -74.5 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.379 175.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.741 HG22 ' N ' ' H' ' 25' ' ' GLY . 3.6 p -67.53 -112.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.713 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.741 ' N ' HG22 ' H' ' 24' ' ' VAL . . . 126.39 -38.76 2.14 Favored Glycine 0 N--CA 1.454 -0.128 0 CA-C-N 113.866 -1.516 . . . . 0.0 111.133 176.545 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 16.2 t -70.4 112.7 6.89 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 174.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -113.68 168.54 9.69 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.815 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.537 ' HB3' ' H ' ' A' ' 40' ' ' VAL . 99.2 mttt -39.39 -38.42 0.55 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.618 -1.173 . . . . 0.0 111.091 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.564 ' CA ' HG21 ' B' ' 39' ' ' VAL . . . 179.72 77.08 0.06 OUTLIER Glycine 0 CA--C 1.535 1.314 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.909 -176.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' I' ' 30' ' ' ALA . . . -51.49 91.14 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 119.131 1.466 . . . . 0.0 112.157 -177.182 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.402 ' N ' ' O ' ' H' ' 29' ' ' GLY . 96.8 mt -134.21 138.63 49.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.135 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.571 HD13 ' CD1' ' J' ' 19' ' ' PHE . 96.8 mt -108.32 104.95 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 177.867 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -105.13 97.09 1.29 Allowed Glycine 0 N--CA 1.461 0.3 0 N-CA-C 104.565 -3.414 . . . . 0.0 104.565 176.015 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.833 HD12 ' O ' ' G' ' 34' ' ' LEU . 15.2 tp -143.09 136.43 28.29 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 118.731 -1.187 . . . . 0.0 113.044 -174.081 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.8 mtp -105.18 118.82 37.52 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 113.176 -1.829 . . . . 0.0 106.845 178.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.576 HG12 ' CD ' ' J' ' 15' ' ' GLN . 10.9 t -130.03 102.62 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -177.346 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.43 -162.49 12.38 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.58 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.16 -55.44 0.52 Allowed Glycine 0 CA--C 1.542 1.747 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 1.085 HG12 HD12 ' N' ' 31' ' ' ILE . 1.8 m -127.99 161.57 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.45 ' OXT' ' O ' ' O' ' 28' ' ' LYS . 46.6 t . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.012 177.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.93 135.45 48.46 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.793 0.33 . . . . 0.0 110.367 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.501 ' OE2' ' NE2' ' H' ' 13' ' ' HIS . 97.3 mt-10 -74.35 109.4 7.8 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.475 ' CG2' ' O ' ' J' ' 12' ' ' VAL . 23.2 m -139.27 159.79 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.942 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.477 ' CD2' ' OXT' ' G' ' 40' ' ' VAL . 78.0 m80 -69.78 114.25 7.8 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.611 -178.116 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 13.2 t60 -161.9 169.98 20.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.273 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.645 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 7.0 tt0 -156.27 140.28 16.34 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 120.191 -0.603 . . . . 0.0 110.4 177.053 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -97.92 113.94 25.9 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 178.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.704 ' CD1' HG21 ' G' ' 36' ' ' VAL . 58.8 mt -121.98 114.22 20.66 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.4 t -116.41 109.68 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.444 ' CD1' HD13 ' G' ' 32' ' ' ILE . 74.1 m-85 -108.01 106.44 16.67 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.408 ' CG ' ' CE2' ' H' ' 20' ' ' PHE . 35.3 t80 -120.6 132.97 55.4 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -176.316 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.66 ' HB3' HG21 ' I' ' 24' ' ' VAL . . . -149.7 146.5 27.27 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-O 121.63 0.729 . . . . 0.0 112.651 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.422 ' OE2' ' OE2' ' H' ' 22' ' ' GLU . 77.9 mt-10 -103.88 151.55 22.99 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.837 178.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.602 ' N ' ' O ' ' J' ' 22' ' ' GLU . 71.4 m-20 57.47 48.79 13.93 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.14 0.495 . . . . 0.0 110.405 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.662 HG23 ' HB1' ' J' ' 21' ' ' ALA . 0.1 OUTLIER -137.4 -173.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-O 121.66 0.743 . . . . 0.0 110.824 -177.23 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 28.2 67.67 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -177.529 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.538 ' HB2' HG21 ' J' ' 24' ' ' VAL . 71.3 m -143.56 -128.18 0.09 Allowed 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.548 ' CG ' ' H ' ' I' ' 28' ' ' LYS . 50.5 t30 54.38 -159.48 0.17 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 178.704 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.548 ' H ' ' CG ' ' I' ' 27' ' ' ASN . 64.1 mttp -64.46 -39.61 94.14 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.46 1.652 . . . . 0.0 115.46 -173.309 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.31 66.31 0.25 Allowed Glycine 0 N--CA 1.472 1.067 0 C-N-CA 118.52 -1.8 . . . . 0.0 114.616 -175.127 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' H' ' 30' ' ' ALA . . . -82.7 131.95 35.19 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 122.156 0.979 . . . . 0.0 112.111 -178.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.652 HD11 ' HB ' ' C' ' 39' ' ' VAL . 50.5 mt -144.05 143.4 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 114.447 -1.251 . . . . 0.0 113.585 -177.036 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.421 HD12 HG12 ' J' ' 32' ' ' ILE . 54.1 mt -105.15 101.99 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 173.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -103.62 98.5 1.61 Allowed Glycine 0 CA--C 1.507 -0.452 0 N-CA-C 104.913 -3.275 . . . . 0.0 104.913 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.596 HD12 ' O ' ' H' ' 34' ' ' LEU . 23.7 tp -140.13 135.12 32.17 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 122.287 1.041 . . . . 0.0 113.281 -173.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.408 ' N ' HD12 ' I' ' 34' ' ' LEU . 5.9 mtp -109.43 117.66 34.61 Favored 'General case' 0 CA--C 1.512 -0.484 0 CA-C-N 113.612 -1.631 . . . . 0.0 107.205 177.533 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.565 HG11 HD11 ' K' ' 17' ' ' LEU . 4.4 t -130.42 111.82 21.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 CA-C-O 120.624 0.25 . . . . 0.0 110.736 -177.429 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.33 -131.07 5.23 Favored Glycine 0 C--N 1.318 -0.434 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.144 177.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.05 -61.76 0.39 Allowed Glycine 0 CA--C 1.543 1.828 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 39' ' ' VAL . . . . . 0.746 HG21 ' HA2' ' O' ' 29' ' ' GLY . 4.0 p -146.21 151.25 14.59 Favored 'Isoleucine or valine' 0 C--N 1.344 0.339 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 175.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.506 HG23 ' O ' ' I' ' 39' ' ' VAL . 58.6 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.753 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.62 133.04 51.01 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.928 0.394 . . . . 0.0 110.732 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -85.18 125.29 32.71 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.912 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.483 ' CG1' ' NE2' ' J' ' 14' ' ' HIS . 96.0 t -125.82 108.64 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.621 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -111.78 124.38 52.22 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.257 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.883 ' HD1' ' H ' ' K' ' 14' ' ' HIS . 47.1 m-70 -148.67 162.9 38.8 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 120.29 -0.564 . . . . 0.0 109.735 174.34 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.576 ' CD ' HG12 ' H' ' 36' ' ' VAL . 85.0 mt-30 -100.69 147.17 26.31 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.114 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 13.8 mttt -118.34 92.37 3.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.589 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.895 HD12 HD22 ' K' ' 17' ' ' LEU . 6.9 mt -117.24 115.54 25.5 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.693 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.7 t -113.5 102.38 13.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.571 ' CD1' HD13 ' H' ' 32' ' ' ILE . 64.6 m-85 -104.05 107.09 17.83 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 178.222 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.567 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -121.95 124.07 43.17 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.622 -176.321 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 21' ' ' ALA . . . . . 0.662 ' HB1' HG23 ' I' ' 24' ' ' VAL . . . -136.27 115.48 12.52 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' I' ' 23' ' ' ASP . 98.0 mt-10 -120.18 177.74 4.9 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 118.333 2.716 . . . . 0.0 118.333 -174.85 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 41.5 t0 28.62 46.31 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 119.946 3.313 . . . . 0.0 119.946 175.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.656 HG22 ' N ' ' I' ' 24' ' ' VAL . 0.2 OUTLIER -80.57 -179.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 175.105 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.05 -29.23 69.18 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 118.126 -1.988 . . . . 0.0 112.274 -178.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.421 ' O ' ' C ' ' J' ' 27' ' ' ASN . 1.5 t 168.16 127.24 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.813 0.807 . . . . 0.0 112.079 175.473 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.59 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 50.7 t30 -37.21 133.94 0.63 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.733 174.851 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' I' ' 27' ' ' ASN . 67.6 mttm -109.27 -40.27 4.98 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 118.969 0.804 . . . . 0.0 111.118 177.285 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.45 64.35 0.24 Allowed Glycine 0 CA--C 1.541 1.718 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.924 -178.482 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.7 143.26 30.15 Favored 'General case' 0 C--O 1.245 0.855 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -177.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.563 HD11 ' CG2' ' D' ' 39' ' ' VAL . 79.9 mt -135.78 131.0 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 114.832 -1.076 . . . . 0.0 111.677 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.425 ' O ' HG22 ' J' ' 32' ' ' ILE . 3.0 mt -106.22 110.36 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 176.275 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 99.0 1.06 Allowed Glycine 0 C--O 1.239 0.441 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 177.018 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.546 HD12 ' O ' ' I' ' 34' ' ' LEU . 24.3 tp -134.93 123.59 23.62 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.414 1.102 . . . . 0.0 113.697 -175.612 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.43 ' N ' HD12 ' J' ' 34' ' ' LEU . 2.2 ttm -98.29 116.69 31.05 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 176.367 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.518 HG21 HD23 ' L' ' 17' ' ' LEU . 0.5 OUTLIER -130.11 103.3 8.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 C-N-CA 121.365 -0.134 . . . . 0.0 111.049 -177.434 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.22 -153.72 25.23 Favored Glycine 0 CA--C 1.509 -0.283 0 C-N-CA 120.035 -1.079 . . . . 0.0 112.358 178.18 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.493 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 138.73 -56.31 0.65 Allowed Glycine 0 CA--C 1.544 1.898 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.787 -178.555 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.53 HG12 ' N ' ' J' ' 40' ' ' VAL . 87.8 t -135.93 157.89 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.059 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.53 ' N ' HG12 ' J' ' 39' ' ' VAL . 17.3 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.528 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -108.85 146.54 33.52 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.854 0.359 . . . . 0.0 110.561 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -70.32 128.81 37.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -111.94 121.05 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.785 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.628 ' CE1' ' NZ ' ' P' ' 28' ' ' LYS . 6.6 p80 -151.59 113.72 4.51 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.377 -0.529 . . . . 0.0 112.027 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.883 ' H ' ' HD1' ' J' ' 14' ' ' HIS . 21.0 p80 -153.34 160.31 42.65 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.389 177.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.55 ' NE2' ' OE1' ' L' ' 15' ' ' GLN . 33.3 mt-30 -90.12 160.08 16.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.213 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -139.42 109.38 6.37 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.457 0.646 . . . . 0.0 109.902 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.895 HD22 HD12 ' J' ' 17' ' ' LEU . 1.1 mt -118.55 122.41 42.58 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.865 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 16.7 t -113.49 101.05 11.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -100.79 102.67 13.8 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 105.232 -2.136 . . . . 0.0 105.232 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CD1' ' L' ' 20' ' ' PHE . 1.4 t80 -113.4 124.96 53.66 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -177.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' K' ' 23' ' ' ASP . . . -160.76 162.78 32.51 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 -177.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -72.36 136.83 46.25 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.163 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.729 ' CG ' ' HB1' ' L' ' 21' ' ' ALA . 6.4 m-20 -152.5 61.03 0.82 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.987 1.477 . . . . 0.0 114.987 -173.403 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.669 ' O ' ' O ' ' K' ' 23' ' ' ASP . 34.4 t -44.16 -110.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' K' ' 27' ' ' ASN . . . 162.82 -46.51 0.33 Allowed Glycine 0 CA--C 1.506 -0.519 0 C-N-CA 116.707 -2.663 . . . . 0.0 115.781 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m -65.99 101.56 0.69 Allowed 'General case' 0 CA--C 1.519 -0.25 0 CA-C-N 123.605 3.702 . . . . 0.0 104.373 178.539 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.59 ' ND2' ' O ' ' J' ' 27' ' ' ASN . 7.4 m120 -130.04 161.4 31.08 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 114.847 -1.069 . . . . 0.0 112.455 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.509 ' NZ ' ' O ' ' D' ' 40' ' ' VAL . 61.3 tttt -28.71 -39.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.833 172.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . 141.75 73.81 0.04 OUTLIER Glycine 0 CA--C 1.545 1.914 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.103 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.44 150.03 46.63 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 121.804 0.811 . . . . 0.0 112.681 -177.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.418 ' CG1' HG22 ' L' ' 31' ' ' ILE . 2.6 mp -136.42 138.26 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 CA-C-N 114.689 -1.141 . . . . 0.0 112.78 -177.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -117.68 119.99 63.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 178.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.46 117.41 3.31 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 67.7 mt -123.47 129.18 50.86 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 73.2 mtp -137.61 136.68 37.75 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.365 -0.934 . . . . 0.0 113.061 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.495 ' HB ' HG13 ' L' ' 36' ' ' VAL . 10.8 t -113.31 155.27 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.149 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -52.25 -102.34 0.01 OUTLIER Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' L' ' 38' ' ' GLY . . . -138.03 -74.6 0.06 OUTLIER Glycine 0 CA--C 1.527 0.792 0 C-N-CA 120.823 -0.704 . . . . 0.0 113.177 178.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 39' ' ' VAL . . . . . 0.74 HG13 HD11 ' Q' ' 31' ' ' ILE . 6.6 m -73.81 130.78 35.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.428 -178.698 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.29 179.967 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -103.94 133.04 49.58 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.795 0.331 . . . . 0.0 110.583 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -126.88 134.24 50.52 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 91.1 t -111.91 101.41 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 121.265 0.555 . . . . 0.0 110.877 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.481 ' O ' ' CG ' ' L' ' 14' ' ' HIS . 5.0 p80 -147.2 90.82 1.92 Allowed 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.639 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.481 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 69.3 m80 -158.19 168.31 27.42 Favored 'General case' 0 C--O 1.223 -0.295 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.55 ' OE1' ' NE2' ' K' ' 15' ' ' GLN . 94.8 mm-40 -89.84 158.45 17.46 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.71 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -139.92 105.27 5.06 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.465 0.65 . . . . 0.0 110.492 178.583 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.518 HD23 HG21 ' J' ' 36' ' ' VAL . 0.2 OUTLIER -116.16 113.9 23.73 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.695 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -106.79 103.85 16.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -99.78 101.71 12.94 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.574 ' CD1' ' CZ ' ' K' ' 20' ' ' PHE . 15.1 t80 -110.04 103.13 11.83 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.729 ' HB1' ' CG ' ' K' ' 23' ' ' ASP . . . -132.87 137.31 46.64 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 -178.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.525 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.9 mt-10 -78.62 102.77 8.15 Favored 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 118.879 -1.128 . . . . 0.0 108.636 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 44.2 p-10 -155.77 46.62 0.48 Allowed 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 112.786 0.661 . . . . 0.0 112.786 -177.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 32.9 m -83.22 172.69 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 118.819 -1.152 . . . . 0.0 109.788 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 96.02 -28.68 11.86 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.9 t 91.68 119.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.533 ' O ' ' N ' ' L' ' 29' ' ' GLY . 15.4 m-20 -71.95 150.3 44.24 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.221 -179.013 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -53.17 47.45 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 101.77 63.38 0.75 Allowed Glycine 0 CA--C 1.543 1.799 0 C-N-CA 119.928 -1.129 . . . . 0.0 114.088 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.63 169.46 10.06 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 178.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.418 HG22 ' CG1' ' K' ' 31' ' ' ILE . 12.6 tt -139.8 151.03 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.16 0 C-N-CA 119.008 -1.077 . . . . 0.0 113.626 -177.197 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 15.0 tt -135.48 134.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.152 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.64 134.22 6.52 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.315 -0.469 . . . . 0.0 111.971 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tt -127.25 124.72 39.51 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mtp -140.86 146.58 37.7 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -177.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.495 HG13 ' HB ' ' K' ' 36' ' ' VAL . 8.8 t -139.33 132.13 37.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.463 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -106.97 112.42 3.76 Favored Glycine 0 N--CA 1.468 0.794 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.023 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 38' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . 112.52 71.25 0.58 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 117.522 0.661 . . . . 0.0 112.477 178.804 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 39' ' ' VAL . . . . . 0.547 HG12 ' N ' ' L' ' 40' ' ' VAL . 66.2 t -27.33 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 40' ' ' VAL . . . . . 0.547 ' N ' HG12 ' L' ' 39' ' ' VAL . 92.9 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.788 178.594 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' M' M ' 10' ' ' TYR . . . . . 0.491 ' CE2' ' O ' ' M' ' 11' ' ' GLU . 88.6 t80 -73.06 132.67 43.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.535 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 11' ' ' GLU . . . . . 0.491 ' O ' ' CE2' ' M' ' 10' ' ' TYR . 79.7 tt0 -74.08 152.38 39.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.154 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 12' ' ' VAL . . . . . 0.42 HG23 ' O ' ' M' ' 12' ' ' VAL . 29.0 m -114.9 130.13 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.95 0.405 . . . . 0.0 110.714 -179.6 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 75.6 m80 -95.06 165.8 12.25 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 14' ' ' HIS . . . . . 0.481 ' CD2' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -86.47 168.0 14.15 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.498 -179.36 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -129.17 150.72 50.44 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -97.62 120.91 38.85 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.595 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.29 115.3 20.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -140.34 140.59 34.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.383 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -143.18 141.32 31.11 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.095 0.474 . . . . 0.0 110.674 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 20' ' ' PHE . . . . . 0.484 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 53.1 p90 -127.4 128.38 45.73 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.66 127.41 46.24 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.329 0.585 . . . . 0.0 111.378 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -138.67 146.34 41.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.94 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 58.47 59.84 2.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.44 . . . . 0.0 112.173 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 24' ' ' VAL . . . . . 0.765 HG12 ' H ' ' M' ' 25' ' ' GLY . 4.1 t 70.59 175.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.514 0.673 . . . . 0.0 111.732 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 25' ' ' GLY . . . . . 0.765 ' H ' HG12 ' M' ' 24' ' ' VAL . . . 100.65 -34.72 5.35 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.948 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 6.1 p -82.92 -121.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 176.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 27' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' M' ' 31' ' ' ILE . 8.9 p30 -92.42 161.21 14.74 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 176.403 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 28' ' ' LYS . . . . . 0.413 ' O ' ' CD ' ' N' ' 28' ' ' LYS . 72.8 tttt -45.29 -39.2 6.32 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 119.139 -1.025 . . . . 0.0 110.517 -179.403 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 29' ' ' GLY . . . . . 0.445 ' O ' ' OD2' ' N' ' 23' ' ' ASP . . . -146.9 -76.18 0.02 OUTLIER Glycine 0 N--CA 1.473 1.11 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.893 177.784 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.76 87.81 0.82 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-O 121.129 0.49 . . . . 0.0 111.611 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 31' ' ' ILE . . . . . 0.658 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -138.33 115.56 11.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 32' ' ' ILE . . . . . 0.42 HD13 HG21 ' M' ' 32' ' ' ILE . 43.1 mt -107.09 109.37 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.88 92.46 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 105.886 -2.885 . . . . 0.0 105.886 177.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -143.56 167.16 22.87 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 114.927 1.455 . . . . 0.0 114.927 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -123.45 106.58 10.75 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 112.108 -2.315 . . . . 0.0 107.062 177.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 36' ' ' VAL . . . . . 0.551 HG21 HD21 ' O' ' 17' ' ' LEU . 43.9 t -112.46 111.97 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 CA-C-O 121.264 0.554 . . . . 0.0 109.835 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.42 -131.7 7.74 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' M' M ' 38' ' ' GLY . . . . . 0.492 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 94.47 -63.27 1.66 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.786 -1.325 . . . . 0.0 109.786 -178.289 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 39' ' ' VAL . . . . . 0.436 HG22 ' H ' ' M' ' 39' ' ' VAL . 4.7 m -96.65 173.51 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' M' M ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' N' ' 40' ' ' VAL . 26.8 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.938 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -106.42 134.8 49.0 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.764 0.316 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -114.97 119.71 37.43 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.796 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 12' ' ' VAL . . . . . 0.415 ' CG1' ' HE2' ' N' ' 14' ' ' HIS . 58.8 t -126.96 131.4 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -142.32 130.27 21.83 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.443 0.64 . . . . 0.0 112.63 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 14' ' ' HIS . . . . . 0.513 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 33.0 m-70 -153.1 172.39 16.97 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.218 177.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -155.18 141.0 18.15 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.821 -0.751 . . . . 0.0 109.741 177.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -88.53 113.66 24.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.161 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 17' ' ' LEU . . . . . 0.418 ' N ' HD12 ' N' ' 17' ' ' LEU . 8.3 mp -111.24 113.1 25.36 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.245 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.12 132.16 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-O 120.891 0.377 . . . . 0.0 111.35 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -141.23 127.45 19.69 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.956 0.408 . . . . 0.0 111.835 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -117.23 131.58 56.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.254 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.29 133.23 34.75 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -122.02 145.31 48.26 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.359 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' M' ' 29' ' ' GLY . 51.6 m-20 -160.94 46.68 0.21 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.918 0.39 . . . . 0.0 111.161 -178.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 m -73.35 -179.79 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.74 0.781 . . . . 0.0 111.99 -178.232 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.17 -35.33 4.76 Favored Glycine 0 CA--C 1.53 0.99 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.95 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' N' ' 27' ' ' ASN . 84.8 p -162.56 117.04 1.79 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 118.061 0.931 . . . . 0.0 110.874 176.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' N' ' 26' ' ' SER . 55.6 p30 -21.63 161.73 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 28' ' ' LYS . . . . . 0.454 ' CG ' ' O ' ' N' ' 27' ' ' ASN . 60.5 mttm -158.61 -10.3 0.07 Allowed 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 120.389 -0.524 . . . . 0.0 112.405 174.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.36 118.12 0.64 Allowed Glycine 0 CA--C 1.537 1.408 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.631 178.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 30' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' O' ' 29' ' ' GLY . . . -102.91 113.33 26.7 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-O 121.599 0.714 . . . . 0.0 111.98 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 31' ' ' ILE . . . . . 1.085 HD12 HG12 ' H' ' 39' ' ' VAL . 81.4 mt -135.5 131.05 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 32' ' ' ILE . . . . . 0.608 HD13 ' CD1' ' P' ' 19' ' ' PHE . 92.8 mt -107.08 111.04 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.01 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -116.0 105.6 1.42 Allowed Glycine 0 C--N 1.322 -0.234 0 N-CA-C 105.217 -3.153 . . . . 0.0 105.217 176.672 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 34' ' ' LEU . . . . . 0.633 ' O ' HD12 ' O' ' 34' ' ' LEU . 7.0 tt -152.77 140.75 20.23 Favored 'General case' 0 CA--C 1.504 -0.8 0 C-N-CA 117.953 -1.499 . . . . 0.0 111.747 -174.551 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 45.3 mtp -114.29 116.02 28.32 Favored 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.664 -1.607 . . . . 0.0 107.825 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -93.65 102.84 14.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 37' ' ' GLY . . . . . 0.492 ' HA3' ' H ' ' M' ' 38' ' ' GLY . . . -35.38 152.74 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.121 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 38' ' ' GLY . . . . . 0.563 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -85.28 -57.55 2.21 Favored Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.837 -0.697 . . . . 0.0 114.326 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 39' ' ' VAL . . . . . 0.655 HG13 HD11 ' B' ' 31' ' ' ILE . 6.1 m -52.85 140.97 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 119.42 1.61 . . . . 0.0 110.812 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' N' N ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' M' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.552 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -106.53 127.24 53.16 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 11' ' ' GLU . . . . . 0.472 ' O ' ' NE2' ' P' ' 13' ' ' HIS . 97.4 mt-10 -146.7 158.96 44.02 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.809 0.337 . . . . 0.0 111.01 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 12' ' ' VAL . . . . . 0.473 HG22 ' H ' ' P' ' 12' ' ' VAL . 55.2 t -129.53 118.3 45.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.659 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 27.8 m80 -134.36 137.56 44.23 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 14' ' ' HIS . . . . . 0.698 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 66.2 t60 -151.12 153.2 34.57 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 119.027 -1.069 . . . . 0.0 112.278 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 15.2 tp60 -87.83 158.8 18.65 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.263 0.625 . . . . 0.0 110.791 177.472 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 16' ' ' LYS . . . . . 0.602 ' C ' HD12 ' O' ' 17' ' ' LEU . 71.5 tttt -159.09 95.21 1.25 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.252 176.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 17' ' ' LEU . . . . . 0.602 HD12 ' C ' ' O' ' 16' ' ' LYS . 8.2 mp -116.45 127.16 54.34 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.283 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -127.23 107.04 16.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.91 113.23 25.43 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 20' ' ' PHE . . . . . 0.481 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 45.8 t80 -111.77 121.53 45.32 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.19 136.91 47.38 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 122.065 0.936 . . . . 0.0 112.492 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 22' ' ' GLU . . . . . 0.498 ' HG2' ' H ' ' O' ' 23' ' ' ASP . 51.6 tt0 -65.85 179.59 0.85 Allowed 'General case' 0 N--CA 1.444 -0.758 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 178.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 23' ' ' ASP . . . . . 0.498 ' H ' ' HG2' ' O' ' 22' ' ' GLU . 1.8 m-20 167.59 58.8 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.978 -174.68 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 24' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' O' ' 23' ' ' ASP . 18.4 t -62.92 -114.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -177.237 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.01 43.51 1.66 Allowed Glycine 0 N--CA 1.47 0.922 0 CA-C-N 121.71 2.05 . . . . 0.0 109.677 -176.003 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 19.4 t -74.37 99.93 3.64 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 111.479 -2.36 . . . . 0.0 108.724 174.101 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -94.72 -161.73 0.88 Allowed 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.617 0.722 . . . . 0.0 112.045 -177.263 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 28' ' ' LYS . . . . . 0.587 ' NZ ' ' CB ' ' K' ' 13' ' ' HIS . 70.5 tttt 38.38 40.54 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 29' ' ' GLY . . . . . 0.746 ' HA2' HG21 ' I' ' 39' ' ' VAL . . . -177.72 62.34 0.09 OUTLIER Glycine 0 CA--C 1.541 1.672 0 C-N-CA 118.974 -1.584 . . . . 0.0 115.221 173.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 30' ' ' ALA . . . . . 0.449 ' HB2' ' ND2' ' P' ' 27' ' ' ASN . . . -109.45 90.4 3.29 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 118.05 0.925 . . . . 0.0 110.883 174.951 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 71.3 mt -140.96 132.94 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-N 120.869 1.668 . . . . 0.0 113.826 -179.125 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 32' ' ' ILE . . . . . 0.6 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 78.1 mt -109.88 109.0 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.702 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.1 99.28 1.06 Allowed Glycine 0 C--O 1.239 0.414 0 N-CA-C 105.547 -3.021 . . . . 0.0 105.547 177.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 34' ' ' LEU . . . . . 0.633 HD12 ' O ' ' N' ' 34' ' ' LEU . 10.3 tp -128.23 130.56 48.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 122.458 1.123 . . . . 0.0 113.507 -174.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.94 104.24 13.95 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 36' ' ' VAL . . . . . 0.559 HG11 ' CD2' ' Q' ' 17' ' ' LEU . 8.0 p -131.48 142.55 42.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.81 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.97 -102.04 0.82 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.46 -80.17 0.06 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' O' O ' 39' ' ' VAL . . . . . 0.574 HG22 HD11 ' C' ' 31' ' ' ILE . 3.4 m -148.44 167.66 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 176.308 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' O' O ' 40' ' ' VAL . . . . . 0.774 HG13 ' HE2' ' Q' ' 13' ' ' HIS . 1.4 p . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.377 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -109.35 136.85 48.11 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.74 0.305 . . . . 0.0 110.299 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -103.14 114.93 29.62 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.438 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 12' ' ' VAL . . . . . 0.473 ' H ' HG22 ' O' ' 12' ' ' VAL . 2.4 p -141.87 135.64 29.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.495 179.57 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 13' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 86.3 m-70 -142.48 118.81 10.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.437 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 14' ' ' HIS . . . . . 0.698 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 0.0 OUTLIER -146.9 170.74 16.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.472 0.653 . . . . 0.0 111.821 -179.552 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' P' P ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG2' ' O' ' 36' ' ' VAL . 47.7 tt0 -107.45 149.8 27.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.448 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -139.91 110.64 6.78 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 176.146 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mt -126.88 116.67 21.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -110.11 105.54 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 19' ' ' PHE . . . . . 0.608 ' CD1' HD13 ' N' ' 32' ' ' ILE . 92.5 m-85 -106.59 107.19 18.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 179.192 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 20' ' ' PHE . . . . . 0.596 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 31.3 t80 -116.06 124.29 50.05 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.73 -178.598 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.41 138.25 30.97 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.75 0.786 . . . . 0.0 112.432 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 22' ' ' GLU . . . . . 0.504 ' O ' ' CB ' ' P' ' 23' ' ' ASP . 20.9 tt0 -76.81 -174.54 3.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 23' ' ' ASP . . . . . 0.504 ' CB ' ' O ' ' P' ' 22' ' ' GLU . 10.3 m-20 142.99 50.02 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 p -82.78 149.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 C-N-CA 119.341 -0.943 . . . . 0.0 111.404 -177.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 25' ' ' GLY . . . . . 0.406 ' O ' ' OG ' ' P' ' 26' ' ' SER . . . 93.23 36.81 5.83 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-N 113.614 -1.63 . . . . 0.0 111.848 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 26' ' ' SER . . . . . 0.59 ' N ' ' O ' ' Q' ' 24' ' ' VAL . 3.4 p 72.65 120.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 27' ' ' ASN . . . . . 0.449 ' ND2' ' HB2' ' O' ' 30' ' ' ALA . 28.9 t-20 -83.2 161.75 21.44 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.809 175.24 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 28' ' ' LYS . . . . . 0.628 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 75.4 tttt -48.54 -39.38 23.26 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 113.461 0.912 . . . . 0.0 113.461 177.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.59 68.85 0.04 OUTLIER Glycine 0 CA--C 1.544 1.863 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -174.451 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.22 145.76 51.17 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 119.062 1.431 . . . . 0.0 114.673 -173.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 31' ' ' ILE . . . . . 0.507 HD12 HG22 ' J' ' 39' ' ' VAL . 75.2 mt -136.08 133.94 50.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 CA-C-N 113.46 -1.7 . . . . 0.0 113.651 -177.505 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 32' ' ' ILE . . . . . 0.423 HD13 HG21 ' P' ' 32' ' ' ILE . 55.0 mt -107.67 117.06 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 175.614 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.77 102.02 1.06 Allowed Glycine 0 N--CA 1.466 0.657 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 176.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 34' ' ' LEU . . . . . 0.612 HD23 HG22 ' P' ' 36' ' ' VAL . 0.3 OUTLIER -126.25 132.36 51.72 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -175.571 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -109.17 99.71 8.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.2 -2.519 . . . . 0.0 104.2 174.306 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 36' ' ' VAL . . . . . 0.612 HG22 HD23 ' P' ' 34' ' ' LEU . 1.4 t -114.06 103.15 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.719 -175.32 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.31 -153.77 25.46 Favored Glycine 0 C--N 1.319 -0.39 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.813 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.43 -56.03 0.57 Allowed Glycine 0 CA--C 1.545 1.946 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -178.461 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' P' P ' 39' ' ' VAL . . . . . 0.565 HG23 HD11 ' D' ' 31' ' ' ILE . 0.9 OUTLIER -153.24 157.55 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 177.566 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' P' P ' 40' ' ' VAL . . . . . 0.602 HG13 ' CD2' ' R' ' 13' ' ' HIS . 7.0 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.459 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.56 135.1 54.28 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.805 0.336 . . . . 0.0 110.468 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 11' ' ' GLU . . . . . 0.411 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 96.5 mt-10 -87.26 119.61 27.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.984 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 12' ' ' VAL . . . . . 0.482 ' O ' HG23 ' Q' ' 12' ' ' VAL . 33.3 m -118.32 126.1 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.075 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 13' ' ' HIS . . . . . 0.774 ' HE2' HG13 ' O' ' 40' ' ' VAL . 0.1 OUTLIER -152.74 140.55 20.03 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.989 -179.525 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' Q' Q ' 14' ' ' HIS . . . . . 0.608 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 1.1 p80 -159.68 161.7 34.96 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 15' ' ' GLN . . . . . 0.431 ' HB3' HD11 ' Q' ' 17' ' ' LEU . 75.5 mt-30 -90.02 158.71 17.22 Favored 'General case' 0 CA--C 1.516 -0.349 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.747 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -140.81 101.9 4.17 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 176.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 17' ' ' LEU . . . . . 0.56 ' N ' HD12 ' Q' ' 17' ' ' LEU . 1.1 mp -119.06 113.42 20.91 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.33 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.92 106.63 21.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 19' ' ' PHE . . . . . 0.6 ' CD1' HD13 ' O' ' 32' ' ' ILE . 72.2 m-85 -107.04 103.05 12.37 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.296 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 20' ' ' PHE . . . . . 0.596 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 37.3 t80 -108.79 118.32 36.47 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.747 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 21' ' ' ALA . . . . . 0.471 ' O ' ' OE1' ' R' ' 22' ' ' GLU . . . -140.79 138.02 33.78 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.85 0.833 . . . . 0.0 112.967 -179.106 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' P' ' 23' ' ' ASP . 94.7 mt-10 -85.03 122.34 29.11 Favored 'General case' 0 C--O 1.22 -0.497 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 177.637 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 23' ' ' ASP . . . . . 0.417 ' CG ' ' O ' ' Q' ' 22' ' ' GLU . 35.4 m-20 -162.44 52.15 0.2 Allowed 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -176.686 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 24' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' P' ' 26' ' ' SER . 93.2 t -74.45 142.25 14.98 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 C-N-CA 117.923 -1.511 . . . . 0.0 110.069 -178.268 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.46 37.49 3.75 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -178.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -64.57 106.44 1.16 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.698 0.761 . . . . 0.0 111.576 -177.312 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -149.85 -161.25 1.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.429 -1.26 . . . . 0.0 110.173 -179.604 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 29.5 40.82 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 29' ' ' GLY . . . . . 0.682 ' HA2' HG11 ' K' ' 39' ' ' VAL . . . 110.53 70.91 0.63 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 116.36 1.304 . . . . 0.0 116.36 175.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.53 114.14 27.72 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 175.632 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 31' ' ' ILE . . . . . 0.74 HD11 HG13 ' K' ' 39' ' ' VAL . 66.6 mt -130.29 135.33 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 CA-C-N 119.108 0.867 . . . . 0.0 113.238 -178.177 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -121.59 114.71 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.14 114.84 3.29 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 14.3 tp -117.63 117.18 28.69 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 122.251 0.221 . . . . 0.0 110.429 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.2 mtp -121.76 124.28 43.84 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 67.1 t -110.81 131.48 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 121.108 0.48 . . . . 0.0 111.087 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 37' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' Q' ' 38' ' ' GLY . . . -72.81 111.68 3.63 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 38' ' ' GLY . . . . . 0.5 ' H ' ' HA3' ' R' ' 37' ' ' GLY . . . -6.09 -67.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.428 0 C-N-CA 123.608 0.623 . . . . 0.0 114.224 -178.049 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.09 120.63 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 118.351 1.076 . . . . 0.0 109.68 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 29.1 t . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.272 -179.312 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -148.29 160.75 42.65 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 11' ' ' GLU . . . . . 0.411 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 79.2 mm-40 -114.74 151.32 33.92 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.154 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 57.4 t -107.09 105.97 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.043 0.449 . . . . 0.0 110.705 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 13' ' ' HIS . . . . . 0.602 ' CD2' HG13 ' P' ' 40' ' ' VAL . 63.0 t60 -148.82 130.14 14.68 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.224 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 42.0 p-80 -154.03 162.8 40.94 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.833 176.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 15' ' ' GLN . . . . . 0.592 ' CD ' HG12 ' P' ' 36' ' ' VAL . 5.5 tt0 -89.86 158.29 17.52 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 16' ' ' LYS . . . . . 0.545 ' O ' HD12 ' Q' ' 17' ' ' LEU . 68.9 tttt -140.82 103.15 4.44 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 17' ' ' LEU . . . . . 0.612 ' N ' HD23 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -115.51 109.29 17.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.702 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -106.28 104.09 16.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 19' ' ' PHE . . . . . 0.431 ' HE1' HD22 ' P' ' 34' ' ' LEU . 51.2 m-85 -100.25 100.95 11.84 Favored 'General case' 0 CA--C 1.509 -0.599 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 178.252 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -110.77 110.33 20.93 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.299 0.571 . . . . 0.0 109.949 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.6 130.29 45.48 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 22' ' ' GLU . . . . . 0.518 ' OE2' ' CZ ' ' Q' ' 20' ' ' PHE . 52.2 mp0 -77.86 108.99 11.5 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 118.597 -1.241 . . . . 0.0 110.686 -177.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 23' ' ' ASP . . . . . 0.573 ' CG ' ' H ' ' R' ' 24' ' ' VAL . 22.8 p-10 -178.83 -69.79 0.01 OUTLIER 'General case' 0 C--N 1.347 0.463 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 178.364 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 24' ' ' VAL . . . . . 0.573 ' H ' ' CG ' ' R' ' 23' ' ' ASP . 42.9 t -147.28 120.59 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -177.518 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.75 -43.73 91.09 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 119.546 -1.311 . . . . 0.0 110.659 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 44.1 m -139.56 -111.03 0.15 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 117.231 0.515 . . . . 0.0 111.283 177.753 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 7.1 m120 55.69 152.67 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.859 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -70.41 48.79 0.11 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.465 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 -52.06 1.38 Allowed Glycine 0 CA--C 1.541 1.664 0 C-N-CA 120.705 -0.76 . . . . 0.0 113.859 -178.424 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.4 176.44 5.15 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-N 117.454 0.627 . . . . 0.0 109.972 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 85.7 mt -110.45 116.97 53.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -113.63 127.44 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.039 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.85 113.13 1.7 Allowed Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' R' R ' 34' ' ' LEU . . . . . 0.646 ' C ' HD23 ' R' ' 34' ' ' LEU . 6.9 tt -118.05 121.43 40.57 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 35' ' ' MET . . . . . 0.549 ' N ' HD23 ' R' ' 34' ' ' LEU . 93.9 mtp -140.01 143.16 36.31 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.567 -0.453 . . . . 0.0 111.075 -179.134 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' R' ' 37' ' ' GLY . 3.3 p -122.83 131.56 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 37' ' ' GLY . . . . . 0.5 ' HA3' ' H ' ' Q' ' 38' ' ' GLY . . . -34.05 -111.41 0.0 OUTLIER Glycine 0 CA--C 1.529 0.933 0 CA-C-N 115.102 -0.953 . . . . 0.0 113.591 179.598 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 38' ' ' GLY . . . . . 0.41 ' H ' ' CA ' ' Q' ' 38' ' ' GLY . . . -111.52 -71.68 0.63 Allowed Glycine 0 CA--C 1.537 1.42 0 CA-C-N 115.563 -0.319 . . . . 0.0 113.288 -178.292 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 39' ' ' VAL . . . . . 0.525 HG12 HD12 ' F' ' 31' ' ' ILE . 6.8 p -138.49 142.71 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 117.618 0.709 . . . . 0.0 112.254 -178.124 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.455 178.629 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 . . . . . 0 N--CA 1.463 0.199 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -126.01 131.52 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.033 0.444 . . . . 0.0 110.467 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.6 p-80 -98.93 162.15 13.24 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.926 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 49.5 p-80 -86.39 169.5 12.85 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.805 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.404 ' HB2' HE21 ' B' ' 15' ' ' GLN . 86.2 mt-30 -129.5 151.28 50.29 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.45 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -96.54 124.35 40.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.773 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . 0.405 HD11 ' NE2' ' B' ' 15' ' ' GLN . 91.4 mt -123.94 120.94 33.98 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-O 121.11 0.481 . . . . 0.0 110.76 179.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -127.41 133.47 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.874 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -133.41 124.43 27.1 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.822 0.344 . . . . 0.0 110.53 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 55.1 p90 -124.21 132.25 53.59 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.91 140.48 32.83 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 41.3 tp10 -107.07 158.35 17.12 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 114.071 -1.422 . . . . 0.0 107.491 177.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 t70 . . . . . 0 C--N 1.33 -0.268 0 C-N-CA 119.594 -0.842 . . . . 0.0 112.455 -178.655 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.581 HD21 ' C ' ' B' ' 27' ' ' ASN . 13.8 t-20 . . . . . 0 CA--C 1.534 0.359 0 CA-C-O 120.409 0.147 . . . . 0.0 110.811 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -73.32 -49.25 28.48 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.96 59.69 0.5 Allowed Glycine 0 CA--C 1.543 1.83 0 C-N-CA 119.976 -1.107 . . . . 0.0 110.372 -175.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.57 92.42 9.08 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 123.513 1.625 . . . . 0.0 113.491 -175.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.534 HG21 HG21 ' N' ' 39' ' ' VAL . 1.1 pt -142.3 122.81 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 111.789 -2.46 . . . . 0.0 106.322 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.443 ' O ' ' O ' ' B' ' 33' ' ' GLY . 58.8 mt -104.83 110.12 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.77 92.08 0.58 Allowed Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 104.609 -3.396 . . . . 0.0 104.609 176.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.608 ' O ' HD12 ' B' ' 34' ' ' LEU . 82.0 mt -146.45 169.62 18.52 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-O 122.954 1.359 . . . . 0.0 112.814 -175.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 53.3 mtp -141.75 119.31 11.66 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.781 -2.009 . . . . 0.0 108.735 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.793 ' CG2' HG12 ' B' ' 36' ' ' VAL . 11.7 m -124.74 113.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.05 -123.95 1.19 Allowed Glycine 0 C--N 1.305 -1.185 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.561 ' O ' HD13 ' G' ' 31' ' ' ILE . . . 80.73 -67.39 3.56 Favored Glycine 0 CA--C 1.535 1.318 0 C-N-CA 120.387 -0.911 . . . . 0.0 111.328 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.23 156.11 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.145 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . 0.477 ' CE2' HG23 ' B' ' 12' ' ' VAL . 87.7 t80 -87.5 126.34 34.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.341 179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.04 140.78 34.32 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.555 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.477 HG23 ' CE2' ' B' ' 10' ' ' TYR . 62.4 t -127.6 132.78 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.044 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 86.0 m-70 -143.02 94.08 2.58 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.831 0.348 . . . . 0.0 110.695 179.344 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.609 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 6.9 t60 -158.56 170.18 22.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.813 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.609 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 51.3 tt0 -155.42 141.18 18.06 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.898 0.38 . . . . 0.0 110.213 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -89.0 124.42 34.25 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.27 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 tp -120.96 117.52 27.5 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 177.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.5 129.38 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.787 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -128.78 121.75 29.04 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.717 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.611 ' CD2' ' CD1' ' C' ' 20' ' ' PHE . 7.4 m-85 -122.46 129.03 51.6 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.17 137.4 34.36 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.527 0.68 . . . . 0.0 112.793 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' A' ' 22' ' ' GLU . 86.8 mt-10 -96.09 118.82 33.45 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.303 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.424 ' H ' ' HB2' ' C' ' 22' ' ' GLU . 0.3 OUTLIER -143.43 51.71 1.36 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.316 -179.045 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 71.3 t -75.7 143.49 13.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.957 0.884 . . . . 0.0 110.807 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.65 38.23 3.99 Favored Glycine 0 CA--C 1.525 0.656 0 CA-C-N 113.813 -1.539 . . . . 0.0 109.373 -178.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.9 t 73.18 120.01 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 115.241 -0.479 . . . . 0.0 110.608 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.841 HD21 ' H ' ' B' ' 30' ' ' ALA . 3.8 p30 -83.07 163.78 20.7 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 119.571 -0.851 . . . . 0.0 108.809 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -46.98 -37.06 8.5 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.249 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' B' ' 31' ' ' ILE . . . 179.53 77.05 0.06 OUTLIER Glycine 0 CA--C 1.531 1.068 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.823 -177.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.841 ' H ' HD21 ' B' ' 27' ' ' ASN . . . -51.77 91.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 119.371 1.586 . . . . 0.0 110.776 -179.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.956 HD12 HG22 ' N' ' 39' ' ' VAL . 66.8 mt -132.98 133.51 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.742 -177.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -107.96 109.7 29.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -113.29 97.05 0.84 Allowed Glycine 0 CA--C 1.507 -0.465 0 N-CA-C 104.19 -3.564 . . . . 0.0 104.19 176.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.647 HD12 ' H ' ' B' ' 35' ' ' MET . 40.1 tp -141.71 147.29 37.2 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 122.978 1.371 . . . . 0.0 113.47 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.647 ' H ' HD12 ' B' ' 34' ' ' LEU . 11.6 mtp -116.6 112.62 21.56 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 112.662 -2.063 . . . . 0.0 108.826 178.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.793 HG12 ' CG2' ' A' ' 36' ' ' VAL . 30.1 m -127.24 123.07 61.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 142.77 -113.52 0.79 Allowed Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.489 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 73.77 -72.74 1.27 Allowed Glycine 0 CA--C 1.535 1.29 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.441 ' CG1' ' O ' ' A' ' 38' ' ' GLY . 14.7 p -158.65 138.58 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 178.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.48 ' CG1' ' CD2' ' D' ' 13' ' ' HIS . 1.9 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.504 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -107.85 131.81 54.1 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.32 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -129.59 125.16 35.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.151 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -130.24 134.45 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.083 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.577 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 3.9 t60 -139.95 139.85 36.22 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.532 ' CE1' ' O ' ' D' ' 14' ' ' HIS . 52.5 t60 -155.56 168.78 26.04 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.508 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.441 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.1 tt0 -138.74 140.81 38.82 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -130.4 113.47 14.37 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.488 HD12 HD22 ' D' ' 17' ' ' LEU . 35.6 mt -118.79 110.94 17.82 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.745 178.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 23.1 t -109.15 110.88 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -106.53 108.64 20.25 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.611 ' CD1' ' CD2' ' B' ' 20' ' ' PHE . 14.6 t80 -114.91 124.71 52.41 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 122.424 -0.173 . . . . 0.0 111.273 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 139.57 26.98 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.447 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 98.0 mt-10 -89.89 143.2 26.99 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.481 178.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.447 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 0.0 OUTLIER -164.66 50.44 0.12 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -177.893 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.404 HG13 ' CG2' ' D' ' 24' ' ' VAL . 37.6 t -80.87 149.37 5.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 122.83 1.3 . . . . 0.0 112.417 -174.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.6 36.92 5.69 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 112.052 -2.34 . . . . 0.0 110.28 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' D' ' 24' ' ' VAL . 19.8 t 72.64 120.12 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.789 0.835 . . . . 0.0 110.028 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.694 ' ND2' ' H ' ' B' ' 30' ' ' ALA . 25.9 t30 -83.18 161.99 21.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 116.991 -1.884 . . . . 0.0 110.284 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -47.41 -37.03 10.66 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.482 ' H ' ' ND2' ' C' ' 27' ' ' ASN . . . -178.76 78.16 0.06 OUTLIER Glycine 0 CA--C 1.538 1.508 0 CA-C-O 119.294 -0.726 . . . . 0.0 112.343 -173.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.723 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . -79.18 119.04 21.71 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 123.299 1.524 . . . . 0.0 112.997 -175.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.675 HD12 HG12 ' O' ' 39' ' ' VAL . 78.4 mt -139.1 139.89 39.22 Favored 'Isoleucine or valine' 0 C--N 1.353 0.724 0 CA-C-N 112.32 -2.218 . . . . 0.0 113.426 -176.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.433 HD13 ' CD2' ' E' ' 19' ' ' PHE . 64.1 mt -109.11 112.36 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.31 98.43 0.93 Allowed Glycine 0 C--O 1.238 0.392 0 N-CA-C 106.069 -2.812 . . . . 0.0 106.069 177.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 13.0 tp -133.26 134.59 44.14 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 122.495 1.14 . . . . 0.0 113.931 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.5 mtp -104.88 106.83 17.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 175.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.407 HG11 HD21 ' F' ' 17' ' ' LEU . 12.6 p -123.02 122.98 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.97 -113.11 0.55 Allowed Glycine 0 C--N 1.312 -0.801 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -177.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.51 ' O ' ' O ' ' C' ' 39' ' ' VAL . . . 55.73 64.98 3.89 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 119.789 -1.196 . . . . 0.0 112.61 178.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.528 HG23 ' O ' ' C' ' 39' ' ' VAL . 33.8 m 16.08 114.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.407 ' H ' HG23 ' C' ' 40' ' ' VAL . 2.6 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.491 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 t . . . . . 0 N--CA 1.466 0.338 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 3.5 t60 -143.89 122.72 12.68 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 110.372 -0.233 . . . . 0.0 110.372 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.663 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -118.77 161.53 19.96 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.114 0.483 . . . . 0.0 110.316 178.714 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.461 ' OE1' HD11 ' E' ' 17' ' ' LEU . 43.4 tt0 -85.05 157.04 20.84 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.637 ' O ' HD23 ' D' ' 17' ' ' LEU . 87.0 tttt -160.31 102.21 1.4 Allowed 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.321 177.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.731 ' CD1' HG11 ' B' ' 36' ' ' VAL . 3.1 mt -126.73 121.51 32.22 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -112.4 112.31 39.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -107.64 107.02 17.63 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.545 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 32.5 t80 -110.56 120.56 42.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 -178.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.87 144.99 27.26 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 118.748 -1.181 . . . . 0.0 113.687 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.434 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 98.1 mt-10 -96.05 136.36 36.61 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.99 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -160.13 49.95 0.29 Allowed 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.647 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' C' ' 26' ' ' SER . 35.7 m -81.67 150.65 4.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 122.601 1.191 . . . . 0.0 113.49 -176.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' E' ' 24' ' ' VAL . . . 93.94 36.97 5.59 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-N 112.59 -2.096 . . . . 0.0 111.705 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 72.77 120.11 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.333 -0.434 . . . . 0.0 111.544 175.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.723 ' ND2' ' H ' ' C' ' 30' ' ' ALA . 13.4 t30 -83.07 162.3 21.4 Favored 'General case' 0 C--O 1.231 0.103 0 C-N-CA 117.94 -1.504 . . . . 0.0 107.997 176.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.614 ' NZ ' ' ND1' ' Q' ' 13' ' ' HIS . 83.1 tttt -47.53 -37.45 12.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.489 177.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.79 0.06 OUTLIER Glycine 0 CA--C 1.539 1.589 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.554 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.77 119.67 4.47 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -125.5 125.17 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.517 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 mt -106.82 112.71 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 173.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.13 114.71 2.01 Favored Glycine 0 N--CA 1.462 0.429 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.429 HD12 ' N ' ' D' ' 34' ' ' LEU . 0.3 OUTLIER -160.78 158.16 28.08 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 123.21 1.481 . . . . 0.0 113.595 -178.826 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mmm -110.72 111.64 22.97 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 111.967 -2.378 . . . . 0.0 108.882 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.613 HG11 HD11 ' F' ' 17' ' ' LEU . 9.0 t -106.09 112.74 40.62 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.714 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -179.09 -121.96 0.74 Allowed Glycine 0 C--N 1.304 -1.22 0 C-N-CA 118.331 -1.89 . . . . 0.0 111.643 -179.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 63.63 61.55 6.12 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 119.65 -1.262 . . . . 0.0 111.347 -178.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.702 HG23 ' O ' ' E' ' 39' ' ' VAL . 5.6 p -18.62 122.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.992 179.112 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.144 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -83.73 139.8 32.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.799 0.333 . . . . 0.0 110.758 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.467 ' OE2' ' NE2' ' D' ' 14' ' ' HIS . 79.4 tt0 -155.22 151.24 27.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.988 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.645 HG12 ' N ' ' E' ' 13' ' ' HIS . 59.0 t -140.51 168.01 17.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.778 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.645 ' N ' HG12 ' E' ' 12' ' ' VAL . 20.8 p-80 -64.34 140.85 58.91 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' F' ' 12' ' ' VAL . 65.0 m80 -150.63 166.43 30.33 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.697 177.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -89.82 150.99 22.0 Favored 'General case' 0 CA--C 1.522 -0.114 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.565 ' C ' HD22 ' E' ' 17' ' ' LEU . 67.8 mttm -152.24 99.18 2.49 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 176.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.804 HD22 ' N ' ' E' ' 17' ' ' LEU . 1.3 mm? -118.33 114.11 22.46 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -110.18 106.65 21.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.436 ' CZ ' ' HB3' ' E' ' 17' ' ' LEU . 35.1 m-85 -103.15 103.75 13.84 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 30.3 t80 -110.39 118.52 36.52 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 121.138 -0.225 . . . . 0.0 111.027 -178.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.48 137.01 28.24 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 118.907 -1.117 . . . . 0.0 113.155 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -88.37 115.57 25.97 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' F' ' 22' ' ' GLU . 0.0 OUTLIER -148.57 48.85 1.02 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -175.485 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.51 HG12 ' N ' ' E' ' 25' ' ' GLY . 67.2 t -71.9 160.1 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 118.007 -1.477 . . . . 0.0 108.199 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.51 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 111.08 -36.62 4.12 Favored Glycine 0 N--CA 1.464 0.541 0 N-CA-C 108.097 -2.001 . . . . 0.0 108.097 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -65.79 112.52 3.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 113.22 -1.49 . . . . 0.0 110.622 -179.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -148.98 162.33 40.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.758 0.789 . . . . 0.0 110.922 -178.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 29.84 43.11 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.785 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.19 59.69 0.13 Allowed Glycine 0 CA--C 1.543 1.803 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.484 173.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.72 141.26 40.97 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.534 -0.746 . . . . 0.0 110.322 177.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.432 HD12 HG13 ' Q' ' 39' ' ' VAL . 1.6 tt -132.52 125.33 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 CA-C-N 119.606 1.094 . . . . 0.0 110.232 176.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 87.1 mt -127.45 127.29 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.851 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.96 107.04 0.86 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.606 HD23 ' C ' ' E' ' 34' ' ' LEU . 7.3 tt -122.9 123.86 41.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.515 ' N ' HD23 ' E' ' 34' ' ' LEU . 86.1 mtp -134.08 145.57 49.49 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 119.958 -0.697 . . . . 0.0 112.391 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -124.23 136.85 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.885 0.85 . . . . 0.0 110.659 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.78 103.28 0.39 Allowed Glycine 0 C--N 1.315 -0.63 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' E' ' 39' ' ' VAL . . . 127.12 75.75 0.21 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.157 -178.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.702 ' O ' HG23 ' D' ' 39' ' ' VAL . 7.3 t . . . . . 0 N--CA 1.479 1.012 0 C-N-CA 123.628 0.771 . . . . 0.0 112.981 -179.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 C--O 1.231 0.102 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 18.2 t -132.64 133.33 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.505 0.669 . . . . 0.0 111.379 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.515 ' HD1' ' CE1' ' E' ' 13' ' ' HIS . 0.3 OUTLIER -146.05 117.26 7.87 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.992 179.417 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 76.9 m80 -156.71 165.52 36.02 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.672 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.501 ' CD ' HG12 ' D' ' 36' ' ' VAL . 78.6 mt-30 -84.19 155.28 22.61 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.743 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -159.98 100.18 1.4 Allowed 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 121.291 0.567 . . . . 0.0 109.865 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.613 HD11 HG11 ' D' ' 36' ' ' VAL . 2.5 mp -125.62 114.92 19.35 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.331 178.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 12.4 t -99.83 102.61 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.919 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 178.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -95.16 95.22 8.4 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.413 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 64.8 t80 -111.16 113.52 26.1 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-O 121.548 0.69 . . . . 0.0 109.202 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.74 134.76 17.95 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 120.361 -0.536 . . . . 0.0 109.581 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' E' ' 23' ' ' ASP . 96.3 mt-10 -76.74 85.02 3.36 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 178.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.415 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 51.1 p30 . . . . . 0 CA--C 1.517 -0.306 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.488 -175.178 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.912 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 85.9 mt -115.59 112.12 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 120.667 1.576 . . . . 0.0 111.562 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -123.97 123.19 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.89 119.55 3.03 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 38.4 mt -122.87 119.7 31.31 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mtp -140.6 151.38 44.62 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 -178.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 m -127.41 164.55 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.421 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.36 -102.82 0.09 OUTLIER Glycine 0 CA--C 1.525 0.664 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.653 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.09 -77.83 1.24 Allowed Glycine 0 CA--C 1.536 1.38 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.526 HG22 ' N ' ' F' ' 40' ' ' VAL . 3.4 p -125.78 162.48 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 117.208 0.504 . . . . 0.0 111.266 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.526 ' N ' HG22 ' F' ' 39' ' ' VAL . 9.6 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.58 -178.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 77.5 t . . . . . 0 N--CA 1.463 0.198 0 N-CA-C 109.613 -0.514 . . . . 0.0 109.613 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -145.38 131.6 19.48 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.42 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.6 p-80 -152.02 167.49 28.25 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.805 178.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -157.53 142.91 17.13 Favored 'General case' 0 CA--C 1.52 -0.202 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -81.53 126.2 31.41 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.584 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.7 mt -126.52 118.23 24.48 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -141.88 139.79 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 121.026 0.441 . . . . 0.0 110.999 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -134.74 131.84 38.07 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.58 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.498 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 55.1 p90 -131.06 130.34 43.12 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.93 0.395 . . . . 0.0 111.042 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.12 117.37 26.98 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.016 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -143.31 147.44 34.74 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.462 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 . . . . . 0 C--N 1.327 -0.373 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.035 179.776 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.622 ' HB2' ' HZ2' ' H' ' 28' ' ' LYS . 9.1 m120 . . . . . 0 N--CA 1.483 1.187 0 N-CA-C 115.41 1.634 . . . . 0.0 115.41 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -173.86 -21.04 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.419 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.539 ' N ' ' OD2' ' H' ' 23' ' ' ASP . . . 71.66 -97.9 0.73 Allowed Glycine 0 N--CA 1.465 0.624 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.61 97.02 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.112 0.482 . . . . 0.0 111.487 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.561 HD13 ' O ' ' A' ' 38' ' ' GLY . 91.2 mt -123.03 110.83 27.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -113.76 107.32 22.63 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.78 100.08 0.92 Allowed Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 104.393 -3.483 . . . . 0.0 104.393 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.468 ' O ' HD23 ' H' ' 34' ' ' LEU . 48.3 tp -150.36 149.28 29.86 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-O 123.034 1.397 . . . . 0.0 113.954 -174.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 mtp -105.64 106.32 16.76 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 112.183 -2.281 . . . . 0.0 106.015 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.642 HG21 HD11 ' I' ' 17' ' ' LEU . 3.8 p -128.47 113.95 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.43 -124.9 1.95 Allowed Glycine 0 C--N 1.307 -1.061 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.1 -66.89 3.7 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.995 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.663 HG22 ' N ' ' G' ' 40' ' ' VAL . 12.6 p -108.08 176.01 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.663 ' N ' HG22 ' G' ' 39' ' ' VAL . 2.5 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.116 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.347 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -105.64 132.44 51.78 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -159.48 114.43 2.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.069 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.46 HG22 ' CG1' ' I' ' 12' ' ' VAL . 79.6 t -126.66 128.9 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.483 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 43.4 m-70 -147.61 114.97 6.28 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.462 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.504 ' CE1' ' H ' ' I' ' 14' ' ' HIS . 12.9 m-70 -149.74 169.07 21.92 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -156.52 141.58 17.24 Favored 'General case' 0 CA--C 1.518 -0.278 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 177.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -86.85 120.5 28.2 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.218 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.555 HD13 ' N ' ' H' ' 18' ' ' VAL . 0.6 OUTLIER -117.22 113.91 22.89 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.007 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.555 ' N ' HD13 ' H' ' 17' ' ' LEU . 69.1 t -122.17 131.03 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 120.867 0.365 . . . . 0.0 111.386 -178.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 37.7 t80 -126.98 116.81 21.33 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.614 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 8.0 t80 -122.63 127.2 49.05 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.95 134.84 32.11 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 112.754 0.649 . . . . 0.0 112.754 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -107.71 121.24 44.31 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.272 178.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.539 ' OD2' ' N ' ' G' ' 29' ' ' GLY . 93.6 m-20 -140.33 46.38 1.82 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.012 -178.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.786 HG12 ' H ' ' H' ' 25' ' ' GLY . 20.6 t -81.68 177.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.36 -177.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.786 ' H ' HG12 ' H' ' 24' ' ' VAL . . . 92.72 -33.92 4.77 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.426 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.55 ' O ' ' O ' ' H' ' 27' ' ' ASN . 37.0 t -162.52 120.31 2.09 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 119.062 1.431 . . . . 0.0 113.502 177.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.55 ' O ' ' O ' ' H' ' 26' ' ' SER . 53.4 p-10 -22.41 153.23 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.946 0 O-C-N 124.266 0.979 . . . . 0.0 112.05 175.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.622 ' HZ2' ' HB2' ' G' ' 27' ' ' ASN . 61.7 tttt -165.43 26.42 0.05 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 118.392 -1.323 . . . . 0.0 114.162 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.58 ' H ' ' H ' ' I' ' 28' ' ' LYS . . . 82.03 108.01 0.4 Allowed Glycine 0 CA--C 1.525 0.717 0 C-N-CA 118.987 -1.578 . . . . 0.0 114.448 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.529 ' HB3' HD22 ' I' ' 27' ' ' ASN . . . -120.49 106.49 11.86 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 122.118 0.961 . . . . 0.0 109.273 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.43 HD12 ' O ' ' B' ' 38' ' ' GLY . 1.9 tt -141.45 132.66 27.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 CA-C-N 114.687 -1.142 . . . . 0.0 111.83 -177.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.559 HG22 HD11 ' I' ' 34' ' ' LEU . 6.6 mt -108.13 111.69 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.48 103.18 1.42 Allowed Glycine 0 N--CA 1.46 0.248 0 N-CA-C 105.543 -3.023 . . . . 0.0 105.543 177.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.468 HD23 ' O ' ' G' ' 34' ' ' LEU . 0.4 OUTLIER -146.47 145.12 30.08 Favored 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 117.92 -1.512 . . . . 0.0 114.271 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.4 mtp -111.12 112.34 24.07 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 112.935 -1.938 . . . . 0.0 107.02 176.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -119.69 102.88 13.43 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.88 -151.56 20.16 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.97 -56.55 0.54 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.559 HG22 ' N ' ' H' ' 40' ' ' VAL . 6.3 p -153.69 161.12 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 177.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.559 ' N ' HG22 ' H' ' 39' ' ' VAL . 14.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.787 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -111.89 133.94 53.76 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.731 0.301 . . . . 0.0 110.557 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -155.39 144.95 21.19 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.895 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.46 ' CG1' HG22 ' H' ' 12' ' ' VAL . 2.5 p -127.37 118.67 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.108 0.48 . . . . 0.0 109.946 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' O ' ' G' ' 40' ' ' VAL . 2.9 t-80 -147.83 120.2 8.43 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.588 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.504 ' H ' ' CE1' ' H' ' 14' ' ' HIS . 4.8 m170 -122.48 162.74 21.15 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 120.794 -0.362 . . . . 0.0 110.823 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.03 153.94 20.19 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.728 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -145.47 97.07 2.93 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.646 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.642 HD11 HG21 ' G' ' 36' ' ' VAL . 18.4 mt -121.14 121.91 38.86 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.347 178.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -117.11 110.16 30.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -107.76 108.97 20.43 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 28.0 t80 -115.68 126.33 53.98 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.91 135.82 34.83 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -94.09 140.6 29.54 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 7.4 p-10 -176.83 52.14 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.697 0.284 . . . . 0.0 110.442 -175.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.468 HG12 HG13 ' H' ' 24' ' ' VAL . 3.3 p -74.52 143.16 13.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 122.653 1.216 . . . . 0.0 112.637 -175.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.427 ' O ' ' OG ' ' I' ' 26' ' ' SER . . . 99.53 38.22 3.77 Favored Glycine 0 CA--C 1.529 0.961 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.434 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 7.0 p 73.17 120.2 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.131 -0.535 . . . . 0.0 111.907 176.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' I' ' 29' ' ' GLY . 2.4 m-20 -83.93 152.68 24.36 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 118.257 -1.377 . . . . 0.0 108.669 175.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.58 ' H ' ' H ' ' H' ' 29' ' ' GLY . 30.1 mtmt -50.68 43.66 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.862 0 CA-C-O 116.966 -1.492 . . . . 0.0 114.178 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 120.94 77.44 0.47 Allowed Glycine 0 N--CA 1.487 2.04 0 CA-C-N 122.555 2.434 . . . . 0.0 113.013 -178.229 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.22 112.12 18.25 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.316 1.558 . . . . 0.0 111.8 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.437 HD12 HG13 ' C' ' 39' ' ' VAL . 12.7 tt -145.74 141.67 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -177.21 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.598 HG23 HD13 ' I' ' 34' ' ' LEU . 38.3 mt -111.16 113.19 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 176.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.714 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -115.01 99.93 0.95 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 177.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.714 HD12 ' O ' ' I' ' 33' ' ' GLY . 5.9 mp -136.22 148.22 47.98 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 123.411 1.577 . . . . 0.0 114.124 -176.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -116.59 106.31 13.41 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 111.724 -2.489 . . . . 0.0 104.526 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.479 ' HB ' HD21 ' J' ' 34' ' ' LEU . 38.6 t -126.58 142.75 42.25 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.74 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.152 -175.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.73 -101.99 0.71 Allowed Glycine 0 C--N 1.312 -0.768 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.676 ' O ' HG21 ' J' ' 39' ' ' VAL . . . 66.69 -80.09 0.12 Allowed Glycine 0 CA--C 1.533 1.204 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.665 -179.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.637 HG22 HD12 ' O' ' 31' ' ' ILE . 21.9 t -116.28 131.3 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 C-N-CA 123.068 0.547 . . . . 0.0 109.998 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 39' ' ' VAL . 8.8 p . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 118.038 -0.982 . . . . 0.0 111.43 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -108.39 136.28 48.29 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.741 0.305 . . . . 0.0 110.24 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -78.13 108.98 11.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.96 129.72 68.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.757 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' K' ' 14' ' ' HIS . 67.1 m80 -124.88 127.31 46.91 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.823 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.629 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 12.7 t60 -152.09 170.43 19.96 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.228 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.629 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 32.8 tt0 -138.5 140.65 39.25 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -130.57 104.28 7.13 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.464 ' CD1' ' CG ' ' J' ' 15' ' ' GLN . 6.3 mp -122.8 120.2 32.85 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.736 177.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -113.7 112.25 39.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.911 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.441 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 43.7 m-85 -109.4 108.13 18.55 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 37.2 t80 -116.66 125.12 51.29 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.58 0.228 . . . . 0.0 110.955 -179.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.94 133.49 33.8 Favored 'General case' 0 C--O 1.241 0.627 0 CA-C-O 121.452 0.644 . . . . 0.0 111.842 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.453 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 80.1 tt0 -90.47 119.75 31.01 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.534 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.587 ' CG ' HD21 ' I' ' 27' ' ' ASN . 0.2 OUTLIER -147.39 52.05 1.06 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.443 -0.799 . . . . 0.0 108.901 -178.14 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.89 143.14 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 122.448 1.118 . . . . 0.0 112.793 -175.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' J' ' 26' ' ' SER . . . 99.09 38.16 3.9 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 112.699 -2.046 . . . . 0.0 112.197 178.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.404 ' HB3' ' O ' ' J' ' 25' ' ' GLY . 22.0 t 72.68 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.453 0.701 . . . . 0.0 111.11 176.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -83.18 161.75 21.46 Favored 'General case' 0 C--N 1.34 0.194 0 C-N-CA 117.18 -1.808 . . . . 0.0 110.221 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -47.7 -37.28 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 175.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.03 78.06 0.06 OUTLIER Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.741 -1.033 . . . . 0.0 112.236 -172.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.84 116.87 19.45 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 120.076 1.938 . . . . 0.0 111.66 -175.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 5.0 tt -134.01 136.91 53.04 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 CA-C-N 112.253 -2.249 . . . . 0.0 113.134 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.09 122.66 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 120.999 0.428 . . . . 0.0 110.609 178.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.85 104.42 0.97 Allowed Glycine 0 N--CA 1.462 0.396 0 N-CA-C 106.339 -2.704 . . . . 0.0 106.339 176.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.897 HD23 ' N ' ' J' ' 35' ' ' MET . 5.0 tt -144.46 142.85 30.57 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-O 122.578 1.18 . . . . 0.0 112.47 -175.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.897 ' N ' HD23 ' J' ' 34' ' ' LEU . 28.6 mtp -116.32 115.05 25.21 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.145 -1.843 . . . . 0.0 108.779 178.367 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.829 HG11 HD11 ' L' ' 17' ' ' LEU . 0.1 OUTLIER -97.62 111.35 27.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.512 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 178.956 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.52 131.49 42.96 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.331 -177.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.95 63.51 3.16 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 121.279 -0.486 . . . . 0.0 111.938 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.676 HG21 ' O ' ' I' ' 38' ' ' GLY . 42.7 t -124.62 126.36 71.54 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 CA-C-O 121.461 0.648 . . . . 0.0 110.029 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.589 -179.208 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.66 135.76 48.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.657 0.265 . . . . 0.0 110.506 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.16 111.65 16.76 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.334 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.501 HG23 ' O ' ' K' ' 12' ' ' VAL . 4.5 m -130.67 126.56 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.185 0.517 . . . . 0.0 111.03 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -110.16 157.58 19.24 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.712 ' CD2' ' H ' ' K' ' 15' ' ' GLN . 29.1 t60 -158.01 178.02 10.68 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 119.434 -0.906 . . . . 0.0 112.826 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.712 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 31.6 tt0 -160.37 140.57 11.48 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 114.197 -1.365 . . . . 0.0 107.54 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -159.48 115.97 2.58 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.947 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.46 ' N ' HD12 ' K' ' 17' ' ' LEU . 4.6 mp -128.07 125.03 38.49 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 114.395 -1.275 . . . . 0.0 109.196 178.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 26.3 m -116.03 121.09 66.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.441 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 24.1 m-85 -109.16 109.85 20.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.695 -178.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -111.92 118.67 36.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 122.357 -0.214 . . . . 0.0 111.04 -179.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.66 126.74 27.94 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 110.315 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' J' ' 23' ' ' ASP . 75.4 mt-10 -87.8 140.58 29.36 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.406 -179.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 7.0 p-10 178.52 48.87 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 17.8 m -72.16 160.61 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 119.309 -0.956 . . . . 0.0 109.887 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.22 -33.25 5.95 Favored Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.149 177.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 1.7 p -72.23 129.98 39.73 Favored 'General case' 0 N--CA 1.465 0.325 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 46.5 t-20 -90.86 143.65 26.5 Favored 'General case' 0 C--O 1.232 0.154 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 176.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.48 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 51.7 tttp 43.52 42.84 4.22 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' L' ' 23' ' ' ASP . . . -101.69 60.48 0.58 Allowed Glycine 0 N--CA 1.476 1.308 0 CA-C-O 119.269 -0.74 . . . . 0.0 114.111 -178.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.86 119.95 4.94 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 119.204 1.502 . . . . 0.0 111.772 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 74.3 mt -121.6 116.83 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -124.17 128.3 73.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.22 103.18 0.79 Allowed Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.024 -2.03 . . . . 0.0 108.024 177.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.638 HD11 ' CG2' ' J' ' 36' ' ' VAL . 30.2 tp -117.11 121.4 41.17 Favored 'General case' 0 C--O 1.24 0.58 0 CA-C-O 121.265 0.555 . . . . 0.0 110.007 -178.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 18.5 ttm -120.86 129.86 53.69 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.16 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' K' ' 37' ' ' GLY . 54.9 t -115.78 131.93 66.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.886 178.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -45.03 -111.73 0.0 OUTLIER Glycine 0 CA--C 1.529 0.915 0 CA-C-N 115.519 -0.764 . . . . 0.0 112.349 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -107.15 -71.69 0.77 Allowed Glycine 0 CA--C 1.534 1.223 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.448 HG22 ' O ' ' L' ' 39' ' ' VAL . 54.1 t . . . . . 0 CA--C 1.506 -0.719 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.562 0.22 . . . . 0.0 110.488 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 m -129.93 135.78 60.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.081 0.467 . . . . 0.0 111.567 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 5.1 p80 -146.85 97.97 2.98 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.275 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -154.69 162.59 41.06 Favored 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -89.95 159.24 17.01 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.203 0.525 . . . . 0.0 111.632 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -140.06 110.6 6.72 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.791 177.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.829 HD11 HG11 ' J' ' 36' ' ' VAL . 25.9 mt -118.09 112.19 19.89 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.555 178.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 9.0 t -104.21 100.67 10.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -94.44 99.87 11.97 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -116.24 112.17 21.22 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.466 0.651 . . . . 0.0 110.984 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.1 135.41 32.52 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 107.842 -1.169 . . . . 0.0 107.842 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.497 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 80.3 mm-40 -73.39 108.89 6.51 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 118.627 -1.229 . . . . 0.0 108.401 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' L' ' 24' ' ' VAL . 64.9 m-20 -164.03 61.39 0.16 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.514 -176.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' L' ' 23' ' ' ASP . 8.9 t 55.63 155.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.153 -177.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.24 24.2 0.19 Allowed Glycine 0 CA--C 1.521 0.413 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 40.3 t -81.86 -120.93 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' L' ' 29' ' ' GLY . 99.3 m-20 -93.05 -165.61 1.37 Allowed 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.754 -0.778 . . . . 0.0 109.502 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -47.98 47.68 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 115.732 1.753 . . . . 0.0 115.732 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.64 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.31 56.86 0.89 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-N 119.253 0.933 . . . . 0.0 112.339 177.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.62 169.8 9.97 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.433 ' CD1' HG12 ' F' ' 39' ' ' VAL . 8.3 mm -112.98 111.31 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 176.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -125.75 130.1 72.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.594 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.0 116.48 2.73 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 56.9 tp -118.32 123.08 44.47 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttm -125.66 124.99 42.35 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.24 132.45 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.8 112.13 3.6 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.193 -178.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.97 -71.17 0.01 OUTLIER Glycine 0 CA--C 1.538 1.521 0 N-CA-C 115.216 0.847 . . . . 0.0 115.216 177.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' K' ' 38' ' ' GLY . 54.1 t . . . . . 0 C--O 1.214 -0.765 0 CA-C-N 117.96 0.88 . . . . 0.0 112.007 -178.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.814 0.34 . . . . 0.0 110.784 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -122.01 131.29 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.01 0.434 . . . . 0.0 110.07 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -119.27 130.35 55.38 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.273 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.497 ' CD2' ' O ' ' N' ' 13' ' ' HIS . 13.6 m-70 -83.23 167.09 18.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.138 0.494 . . . . 0.0 111.126 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -93.38 159.98 15.01 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.425 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.145 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 88.7 mt -130.1 130.75 45.24 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.965 0.412 . . . . 0.0 111.465 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 67.3 t -133.75 132.2 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.963 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -138.67 136.71 36.14 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.171 0.51 . . . . 0.0 112.001 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -121.11 125.15 46.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.063 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.62 113.75 25.49 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 121.345 0.593 . . . . 0.0 111.224 -179.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . 0.418 ' OE1' ' OE2' ' N' ' 22' ' ' GLU . 12.4 pt-20 -173.16 150.31 1.92 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.724 179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 56.03 46.95 20.77 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.158 178.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -101.03 -170.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.12 -32.43 84.01 Favored Glycine 0 N--CA 1.468 0.822 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.241 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 47.6 t -152.88 125.11 8.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.366 0.583 . . . . 0.0 109.789 177.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . 0.641 ' HA ' HG11 ' N' ' 24' ' ' VAL . 1.9 m-20 -38.93 134.58 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.956 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.67 -39.54 4.84 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 122.192 0.996 . . . . 0.0 108.39 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 79.89 -69.29 3.09 Favored Glycine 0 CA--C 1.534 1.261 0 CA-C-N 113.348 -1.751 . . . . 0.0 110.753 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . 0.593 ' HB3' ' HA ' ' N' ' 30' ' ' ALA . . . 179.6 82.38 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 117.335 0.568 . . . . 0.0 111.009 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.608 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.6 tt -121.4 104.58 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 119.592 1.087 . . . . 0.0 109.482 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -124.39 116.59 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 CA-C-O 121.402 0.62 . . . . 0.0 111.618 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.83 104.93 0.86 Allowed Glycine 0 N--CA 1.464 0.529 0 N-CA-C 106.086 -2.806 . . . . 0.0 106.086 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . 0.458 ' HB2' HD11 ' N' ' 34' ' ' LEU . 85.7 mt -145.28 159.81 42.46 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 123.3 1.524 . . . . 0.0 114.214 -176.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 35.4 tpp -107.08 108.5 20.01 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.844 -2.435 . . . . 0.0 105.85 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 4.7 m -119.57 123.06 70.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 119.055 0.843 . . . . 0.0 109.68 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.25 -113.7 0.9 Allowed Glycine 0 C--N 1.31 -0.897 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.43 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . 95.48 -72.13 0.95 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 112.318 -0.313 . . . . 0.0 112.318 179.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 40' ' ' VAL . 2.4 t -122.29 159.23 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 O-C-N 122.691 -0.3 . . . . 0.0 110.621 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 39' ' ' VAL . 2.9 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.827 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -108.21 132.48 53.61 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.835 0.35 . . . . 0.0 110.401 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -125.88 126.86 45.11 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.027 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.416 ' CG1' ' NE2' ' M' ' 14' ' ' HIS . 59.2 t -127.73 130.33 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-O 120.871 0.367 . . . . 0.0 110.994 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.497 ' O ' ' CD2' ' M' ' 14' ' ' HIS . 29.8 t-80 -79.66 161.31 25.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.813 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . . . . . . . . . 29.8 p-80 -93.26 163.18 13.71 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.216 0.531 . . . . 0.0 111.322 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -89.88 160.12 16.61 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.61 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.22 131.6 28.48 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -132.59 127.37 34.86 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.348 0.594 . . . . 0.0 111.199 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.5 130.77 72.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.613 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -132.43 122.41 24.93 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.086 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 5.7 t80 -121.15 127.6 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.285 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.49 117.3 25.6 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.418 ' OE2' ' OE1' ' M' ' 22' ' ' GLU . 97.7 mt-10 -81.59 179.63 7.76 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 119.811 -0.755 . . . . 0.0 109.297 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.633 ' O ' HG23 ' N' ' 24' ' ' VAL . 62.3 t0 -60.53 -46.91 88.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 119.193 -1.003 . . . . 0.0 108.494 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 1.011 HG12 ' H ' ' N' ' 25' ' ' GLY . 9.4 t 99.81 -161.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 1.011 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -71.32 -33.4 64.53 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' N' ' 27' ' ' ASN . 34.2 t -162.55 120.55 2.1 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.577 ' O ' ' O ' ' N' ' 26' ' ' SER . 41.2 t-20 -22.0 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 114.682 -1.145 . . . . 0.0 112.443 177.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.669 ' HA ' ' HZ3' ' O' ' 28' ' ' LYS . 69.9 tttt -163.03 24.39 0.09 Allowed 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.9 107.68 1.25 Allowed Glycine 0 N--CA 1.476 1.35 0 C-N-CA 117.506 -2.283 . . . . 0.0 113.929 177.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . 0.593 ' HA ' ' HB3' ' M' ' 30' ' ' ALA . . . -109.53 102.69 11.52 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 123.637 1.684 . . . . 0.0 109.912 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.483 HD13 HG21 ' I' ' 39' ' ' VAL . 20.7 mt -130.19 130.48 65.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 112.388 -2.187 . . . . 0.0 110.824 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.423 HD13 ' HD2' ' P' ' 19' ' ' PHE . 10.1 tt -123.6 116.3 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.805 0.812 . . . . 0.0 109.844 176.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.568 ' O ' HD12 ' N' ' 34' ' ' LEU . . . -109.1 111.58 3.26 Favored Glycine 0 C--N 1.333 0.411 0 N-CA-C 107.02 -2.432 . . . . 0.0 107.02 178.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.568 HD12 ' O ' ' N' ' 33' ' ' GLY . 0.8 OUTLIER -137.88 139.22 39.75 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 122.633 1.206 . . . . 0.0 113.636 -176.094 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 95.7 mmm -106.36 111.56 24.19 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.711 HG11 HD11 ' P' ' 17' ' ' LEU . 2.1 t -117.19 123.15 71.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -178.105 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.38 -113.0 0.55 Allowed Glycine 0 C--N 1.306 -1.12 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.747 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.78 -73.16 2.71 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.956 HG22 HD12 ' B' ' 31' ' ' ILE . 62.8 t -138.17 138.39 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.062 0.545 . . . . 0.0 109.777 179.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' O' ' 40' ' ' VAL . 46.5 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.538 -0.744 . . . . 0.0 111.681 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.96 137.4 46.03 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.873 0.368 . . . . 0.0 110.521 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -93.23 113.31 25.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.374 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -125.28 128.72 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 120.781 0.324 . . . . 0.0 110.167 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -131.29 138.27 49.18 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.612 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 83.2 t60 -154.64 153.85 32.02 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 118.346 -1.342 . . . . 0.0 112.836 179.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 33.8 tt0 -90.63 164.44 14.18 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.721 177.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 102.18 0.33 Allowed 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mt -122.86 119.59 30.98 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.414 179.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 15.6 t -106.96 115.32 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.401 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -113.87 105.48 13.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 12.5 t80 -107.2 125.46 51.14 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.39 135.59 44.77 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -177.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -112.19 139.87 47.37 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.452 177.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -156.41 46.52 0.44 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.814 0.34 . . . . 0.0 110.127 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.712 HG12 ' H ' ' O' ' 25' ' ' GLY . 3.0 t -82.64 174.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 122.314 1.054 . . . . 0.0 112.552 -176.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.712 ' H ' HG12 ' O' ' 24' ' ' VAL . . . 92.59 -35.91 3.88 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-N 113.228 -1.805 . . . . 0.0 112.661 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.647 ' O ' ' O ' ' O' ' 27' ' ' ASN . 21.6 p -172.28 113.74 0.3 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 118.974 1.387 . . . . 0.0 112.218 175.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.647 ' O ' ' O ' ' O' ' 26' ' ' SER . 25.2 p30 -10.59 153.34 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 0 O-C-N 124.55 1.157 . . . . 0.0 113.994 176.428 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.669 ' HZ3' ' HA ' ' N' ' 28' ' ' LYS . 32.2 tttt -166.33 26.19 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 118.457 -1.297 . . . . 0.0 113.843 172.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.65 107.33 0.37 Allowed Glycine 0 CA--C 1.53 0.982 0 C-N-CA 119.318 -1.42 . . . . 0.0 112.474 178.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . 0.718 ' H ' ' ND2' ' P' ' 27' ' ' ASN . . . -120.97 112.48 18.81 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.637 HD12 HG22 ' I' ' 39' ' ' VAL . 83.6 mt -131.68 131.85 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -176.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.641 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 88.6 mt -108.22 106.06 19.96 Favored 'Isoleucine or valine' 0 C--N 1.344 0.351 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 174.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.47 ' O ' HD12 ' O' ' 34' ' ' LEU . . . -112.58 101.58 1.23 Allowed Glycine 0 N--CA 1.464 0.541 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.512 HD13 HG23 ' O' ' 32' ' ' ILE . 3.5 mp -139.78 146.46 39.49 Favored 'General case' 0 CA--C 1.508 -0.638 0 CA-C-O 123.14 1.447 . . . . 0.0 113.329 -176.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 12.3 mtp -113.24 108.66 17.57 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 111.828 -2.442 . . . . 0.0 106.371 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.654 HG12 ' HB ' ' N' ' 36' ' ' VAL . 1.5 m -124.13 102.85 11.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.03 -151.6 21.01 Favored Glycine 0 C--N 1.302 -1.332 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.062 179.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.29 -57.1 1.45 Allowed Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.804 HG11 HD13 ' B' ' 31' ' ' ILE . 33.4 m -129.07 159.3 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 123.253 0.621 . . . . 0.0 110.633 -178.342 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.552 HG22 ' C ' ' P' ' 40' ' ' VAL . 3.5 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.069 -0.967 . . . . 0.0 111.648 -178.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 N--CA 1.462 0.169 0 CA-C-O 120.951 0.405 . . . . 0.0 109.943 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.695 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 18.0 m170 -120.63 110.83 16.89 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.834 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.612 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 0.2 OUTLIER -160.69 166.99 27.86 Favored 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.17 177.771 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.53 ' NE2' HE21 ' Q' ' 15' ' ' GLN . 15.6 pt20 -89.94 151.6 21.63 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.733 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . 0.462 ' H ' ' HB3' ' O' ' 15' ' ' GLN . 86.7 tttt -149.79 119.26 6.91 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.47 0.653 . . . . 0.0 110.727 177.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.711 HD11 HG11 ' N' ' 36' ' ' VAL . 3.5 mp -138.99 132.37 30.12 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.218 178.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.02 120.98 65.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.515 ' CD1' ' CE1' ' Q' ' 19' ' ' PHE . 13.4 m-85 -110.78 112.19 23.89 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 22.4 t80 -119.84 127.76 53.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -175.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.81 127.25 48.84 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.571 ' CG ' ' H ' ' P' ' 23' ' ' ASP . 19.1 tt0 -72.07 177.06 4.6 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 115.75 1.759 . . . . 0.0 115.75 -173.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.571 ' H ' ' CG ' ' P' ' 22' ' ' GLU . 55.3 t0 -45.31 47.42 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 112.349 -2.205 . . . . 0.0 116.731 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.751 HG12 ' H ' ' P' ' 25' ' ' GLY . 49.0 t -60.88 -179.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 117.903 -1.519 . . . . 0.0 107.317 177.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.751 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -102.08 34.97 5.27 Favored Glycine 0 N--CA 1.469 0.898 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 0.8 OUTLIER 74.53 120.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 -177.535 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.718 ' ND2' ' H ' ' O' ' 30' ' ' ALA . 12.2 p-10 -82.79 172.7 12.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 122.125 0.964 . . . . 0.0 113.312 -177.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.414 ' H ' ' HB2' ' O' ' 27' ' ' ASN . 87.6 tttt -49.2 -36.25 19.32 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.462 -1.699 . . . . 0.0 111.572 177.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.503 ' C ' HD21 ' P' ' 27' ' ' ASN . . . -178.42 78.01 0.07 OUTLIER Glycine 0 CA--C 1.541 1.688 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.336 -174.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . 0.589 ' N ' HD21 ' P' ' 27' ' ' ASN . . . -79.85 139.32 37.21 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 121.752 0.787 . . . . 0.0 111.132 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.671 HG21 HG13 ' J' ' 39' ' ' VAL . 9.5 tt -149.98 141.83 17.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 -176.179 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.503 HG12 HD12 ' O' ' 32' ' ' ILE . 75.3 mt -105.72 109.55 28.24 Favored 'Isoleucine or valine' 0 C--N 1.349 0.55 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.2 99.58 1.71 Allowed Glycine 0 C--O 1.24 0.492 0 N-CA-C 105.39 -3.084 . . . . 0.0 105.39 176.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.531 HD23 HG22 ' P' ' 36' ' ' VAL . 5.4 tp -128.41 134.77 48.86 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 -175.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . 0.487 ' SD ' ' O ' ' Q' ' 35' ' ' MET . 60.0 tpp -112.69 110.98 21.45 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.006 -1.452 . . . . 0.0 107.62 176.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.9 ' O ' HG13 ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -105.09 111.79 36.01 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.228 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.341 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.433 ' O ' ' NE2' ' R' ' 15' ' ' GLN . . . -63.75 131.99 40.53 Favored Glycine 0 N--CA 1.465 0.588 0 CA-C-N 115.868 -0.606 . . . . 0.0 113.204 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.584 ' O ' HG22 ' Q' ' 39' ' ' VAL . . . -77.92 64.15 3.41 Favored Glycine 0 CA--C 1.541 1.669 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.42 154.28 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 123.44 0.696 . . . . 0.0 110.266 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.552 ' C ' HG22 ' O' ' 40' ' ' VAL . 1.4 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.419 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -82.02 137.29 35.12 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.814 0.34 . . . . 0.0 110.753 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -74.03 150.1 40.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.664 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.531 ' O ' ' CD2' ' Q' ' 14' ' ' HIS . 27.0 m -128.69 -175.84 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.107 0.479 . . . . 0.0 111.04 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.695 ' CD2' ' H ' ' P' ' 13' ' ' HIS . 2.9 m170 -67.44 105.31 1.77 Allowed 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -176.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.554 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 4.7 m-70 -114.53 160.91 18.7 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 175.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.53 HE21 ' NE2' ' P' ' 15' ' ' GLN . 42.8 tt0 -89.99 157.32 17.88 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.251 178.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -142.19 94.8 2.7 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.606 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -127.76 115.5 18.77 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.923 177.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 t -112.54 110.63 32.91 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.672 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.641 ' CD1' HD13 ' O' ' 32' ' ' ILE . 57.7 m-85 -107.92 102.1 11.32 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 178.057 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 33.5 t80 -111.25 124.19 51.72 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.345 -0.243 . . . . 0.0 110.345 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.8 128.57 24.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.203 0.525 . . . . 0.0 111.779 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -86.92 104.14 15.97 Favored 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD2' ' R' ' 23' ' ' ASP . 39.5 p-10 -135.05 52.27 2.05 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.562 -1.199 . . . . 0.0 111.517 -175.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 86.8 t -73.75 142.57 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.537 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -177.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.88 37.69 3.59 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 106.846 -2.502 . . . . 0.0 106.846 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 11.2 t -70.4 103.65 2.49 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.644 -0.778 . . . . 0.0 111.281 -178.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -117.97 -151.93 0.49 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.905 -178.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -39.8 -42.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.391 -1.277 . . . . 0.0 113.468 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.9 61.74 0.7 Allowed Glycine 0 CA--C 1.545 1.942 0 N-CA-C 115.793 1.077 . . . . 0.0 115.793 -174.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . 0.468 ' HB3' ' HB2' ' R' ' 30' ' ' ALA . . . -141.24 107.85 5.34 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' P' ' 31' ' ' ILE . 87.3 mt -132.97 133.45 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.72 123.03 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 177.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.85 119.86 3.29 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 46.3 mt -120.56 119.86 34.15 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 120.692 0.282 . . . . 0.0 110.273 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.487 ' O ' ' SD ' ' P' ' 35' ' ' MET . 94.0 mmm -116.52 123.71 48.09 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.9 HG13 ' O ' ' P' ' 36' ' ' VAL . 6.5 t -140.04 163.8 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.18 93.38 0.1 Allowed Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 119.513 -1.327 . . . . 0.0 111.382 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.23 -81.98 0.11 Allowed Glycine 0 CA--C 1.533 1.182 0 C-N-CA 119.709 -1.234 . . . . 0.0 113.41 176.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.584 HG22 ' O ' ' P' ' 38' ' ' GLY . 10.6 m -147.0 162.09 8.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 120.858 0.361 . . . . 0.0 110.425 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.984 -1.007 . . . . 0.0 110.481 -179.855 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -108.5 134.71 50.9 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.765 0.316 . . . . 0.0 110.328 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 57.2 mp0 -77.04 135.7 38.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.554 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 40.7 t -139.0 163.31 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.133 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.551 ' N ' HG12 ' R' ' 12' ' ' VAL . 0.1 OUTLIER -89.04 119.6 29.7 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.553 178.343 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -149.51 171.15 17.07 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.797 0.332 . . . . 0.0 111.675 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.433 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 32.8 mt-30 -83.64 154.65 23.6 Favored 'General case' 0 N--CA 1.456 -0.139 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . 0.454 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 70.4 tttt -159.75 104.6 1.57 Allowed 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.637 0.732 . . . . 0.0 109.573 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.415 HD11 HG11 ' P' ' 36' ' ' VAL . 2.7 mp -126.14 119.71 28.24 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.325 178.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 26.7 t -101.72 107.9 22.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.405 ' CD1' HD13 ' P' ' 32' ' ' ILE . 74.5 m-85 -103.04 99.51 9.4 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 178.083 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -118.48 119.58 34.98 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-O 121.731 0.777 . . . . 0.0 111.457 -177.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.426 ' HB1' ' OD2' ' Q' ' 23' ' ' ASP . . . -124.99 134.11 52.73 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' R' ' 23' ' ' ASP . 83.0 mt-10 -68.72 103.96 1.88 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.226 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' R' ' 22' ' ' GLU . 5.3 p30 140.46 48.44 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 O-C-N 125.107 1.504 . . . . 0.0 108.519 -178.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 36.0 m -72.32 161.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.341 0.591 . . . . 0.0 111.579 -177.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.7 -29.79 8.3 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.219 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.42 ' O ' ' OG ' ' R' ' 26' ' ' SER . 6.3 p 61.68 109.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.638 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.732 ' O ' ' N ' ' R' ' 29' ' ' GLY . 66.0 t30 -129.72 -179.93 5.47 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.313 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . 0.505 ' H ' ' CG ' ' R' ' 27' ' ' ASN . 98.9 mttt -29.6 47.81 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 126.325 1.85 . . . . 0.0 115.927 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.732 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -170.05 -59.03 0.04 OUTLIER Glycine 0 CA--C 1.539 1.554 0 C-N-CA 120.045 -1.074 . . . . 0.0 113.686 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . 0.468 ' HB2' ' HB3' ' Q' ' 30' ' ' ALA . . . -81.0 153.98 27.16 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 117.644 0.722 . . . . 0.0 112.132 -177.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 97.9 mt -121.93 132.37 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.31 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -123.69 128.41 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.313 -0.403 . . . . 0.0 109.929 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.51 120.29 3.65 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 35.9 mt -110.15 115.3 29.49 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.3 tpp -128.26 122.9 32.8 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.564 HG12 ' N ' ' R' ' 37' ' ' GLY . 21.8 t -136.35 171.55 16.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.564 ' N ' HG12 ' R' ' 36' ' ' VAL . . . -167.93 94.4 0.11 Allowed Glycine 0 C--N 1.309 -0.931 0 C-N-CA 119.598 -1.287 . . . . 0.0 111.439 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.0 -81.44 0.14 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 177.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 19.0 m -154.96 151.16 11.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.29 179.812 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.7 mt-10 . . . . . 0 C--O 1.232 0.159 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.2 t -121.79 128.87 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.095 0.474 . . . . 0.0 110.421 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -119.55 163.59 17.09 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.485 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.497 ' CD2' ' H ' ' A' ' 14' ' ' HIS . 3.0 m-70 -83.51 164.71 19.67 Favored 'General case' 0 C--N 1.332 -0.157 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.231 -179.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -130.56 152.51 49.86 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.319 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -94.37 116.6 29.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 30.3 tp -122.28 115.68 22.77 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.195 0.521 . . . . 0.0 110.017 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . 0.621 HG22 HG22 ' B' ' 18' ' ' VAL . 79.1 t -128.48 132.03 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.529 -178.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -136.62 139.15 41.88 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.986 0.422 . . . . 0.0 110.305 178.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -139.19 132.83 30.52 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.23 119.18 24.68 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.862 0.839 . . . . 0.0 111.141 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -152.12 142.63 22.66 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.89 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 53.3 t0 . . . . . 0 CA--C 1.534 0.362 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 177.624 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 10.5 m120 . . . . . 0 N--CA 1.454 -0.27 0 CA-C-O 120.667 0.27 . . . . 0.0 110.576 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.411 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 98.4 mttt -62.74 -38.94 92.49 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.835 1.302 . . . . 0.0 107.579 174.272 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.442 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 81.91 -69.48 3.3 Favored Glycine 0 CA--C 1.533 1.174 0 CA-C-N 112.021 -2.354 . . . . 0.0 111.641 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.442 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . 179.73 61.27 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 118.64 1.22 . . . . 0.0 112.764 175.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.615 ' CD1' HG12 ' M' ' 39' ' ' VAL . 83.7 mt -131.99 102.05 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.558 0 CA-C-N 119.904 1.229 . . . . 0.0 108.257 179.039 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 80.8 mt -108.32 113.69 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.749 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.74 94.61 0.55 Allowed Glycine 0 N--CA 1.463 0.439 0 N-CA-C 104.748 -3.341 . . . . 0.0 104.748 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.569 ' O ' HD23 ' B' ' 34' ' ' LEU . 87.5 mt -143.22 157.75 44.22 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 122.788 1.28 . . . . 0.0 114.055 -175.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 4.7 mtp -115.99 106.07 13.37 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 112.435 -2.166 . . . . 0.0 107.154 177.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 1.02 HG11 HD11 ' C' ' 17' ' ' LEU . 43.6 t -124.25 112.03 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.31 -131.89 8.57 Favored Glycine 0 C--N 1.322 -0.246 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.83 -62.69 0.4 Allowed Glycine 0 CA--C 1.534 1.259 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.267 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.879 HG12 HD12 ' G' ' 31' ' ' ILE . 26.9 m -108.34 162.78 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.189 0.495 . . . . 0.0 110.261 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 44.6 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.829 -1.081 . . . . 0.0 110.699 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -105.52 130.95 53.48 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 110.403 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -106.89 116.35 31.78 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.999 0.428 . . . . 0.0 110.729 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.31 128.95 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.373 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.614 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 6.2 t-160 -127.78 106.97 9.49 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.964 0.411 . . . . 0.0 110.468 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.588 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 4.3 t60 -152.82 168.68 24.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.99 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.588 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 54.5 tt0 -155.96 141.42 17.7 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt -85.65 123.71 31.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.944 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.538 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.7 tt -126.01 115.85 20.53 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.006 0.431 . . . . 0.0 110.221 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 18' ' ' VAL . 2.6 m -123.98 131.84 72.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.382 179.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.437 ' CE2' ' HB2' ' B' ' 21' ' ' ALA . 71.9 t80 -125.76 122.32 35.91 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.251 -178.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -115.71 123.68 48.94 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.437 ' HB2' ' CE2' ' B' ' 19' ' ' PHE . . . -142.95 143.33 31.93 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 114.185 1.179 . . . . 0.0 114.185 -178.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.9 mt-10 -91.46 154.75 18.93 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' B' ' 22' ' ' GLU . 70.0 m-20 -139.18 46.5 1.93 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.555 1.317 . . . . 0.0 114.555 -176.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.708 HG12 ' N ' ' B' ' 25' ' ' GLY . 60.7 t -111.72 177.03 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 C-N-CA 118.562 -1.255 . . . . 0.0 108.291 177.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.708 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 62.39 28.35 70.91 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.291 -0.727 . . . . 0.0 111.531 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 24.5 p -170.55 -131.55 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.674 0 CA-C-N 118.558 1.179 . . . . 0.0 113.596 -176.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.529 ' N ' ' OG ' ' B' ' 26' ' ' SER . 90.9 m-20 -30.79 173.01 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 112.803 -1.999 . . . . 0.0 115.449 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.412 ' H ' ' H ' ' B' ' 29' ' ' GLY . 53.0 mtmt -161.28 -21.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.451 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' B' ' 28' ' ' LYS . . . -78.8 110.73 3.1 Favored Glycine 0 CA--C 1.532 1.123 0 CA-C-N 113.85 -1.523 . . . . 0.0 109.722 177.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -129.86 110.25 11.56 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 123.025 1.393 . . . . 0.0 112.814 -176.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.552 HD11 HG23 ' N' ' 39' ' ' VAL . 71.9 mt -142.73 139.85 28.09 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-N 113.824 -1.535 . . . . 0.0 112.134 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.789 HG22 HD11 ' C' ' 34' ' ' LEU . 27.0 mt -106.9 114.34 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 107.157 -1.424 . . . . 0.0 107.157 174.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.08 106.32 1.42 Allowed Glycine 0 N--CA 1.461 0.312 0 N-CA-C 106.677 -2.569 . . . . 0.0 106.677 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.569 HD23 ' O ' ' A' ' 34' ' ' LEU . 0.4 OUTLIER -143.18 141.81 31.26 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.376 -1.33 . . . . 0.0 113.064 -175.833 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -108.88 109.31 20.38 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 112.455 -2.157 . . . . 0.0 106.637 177.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.501 ' CG1' HD22 ' B' ' 34' ' ' LEU . 32.8 m -133.7 151.69 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.073 0.463 . . . . 0.0 110.091 -177.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.81 -101.85 2.67 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -178.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.08 -80.74 0.58 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.187 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.6 HG21 HD11 ' G' ' 31' ' ' ILE . 38.6 t -111.47 135.15 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.629 ' H ' ' CG2' ' C' ' 39' ' ' VAL . 64.1 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.131 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . 0.42 ' CE2' ' O ' ' C' ' 11' ' ' GLU . 90.1 t80 -73.55 132.52 42.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.986 0.422 . . . . 0.0 110.691 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.42 ' O ' ' CE2' ' C' ' 10' ' ' TYR . 96.3 mt-10 -75.54 136.85 40.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.24 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.693 HG23 ' O ' ' C' ' 12' ' ' VAL . 16.7 m -129.45 108.16 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.828 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' B' ' 13' ' ' HIS . 15.4 m-70 -142.64 135.6 28.28 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -178.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.575 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.6 p-80 -153.6 156.19 37.5 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.24 176.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.5 tp60 -99.44 154.2 18.41 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 174.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -121.58 109.68 15.09 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 173.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 1.02 HD11 HG11 ' A' ' 36' ' ' VAL . 34.5 mt -118.45 112.99 20.66 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.112 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . 0.45 ' CG1' HG12 ' B' ' 18' ' ' VAL . 3.0 p -116.64 111.39 35.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 106.862 -1.532 . . . . 0.0 106.862 175.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' C' ' 17' ' ' LEU . 71.8 m-85 -102.79 108.84 20.22 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' C' ' 20' ' ' PHE . 26.0 t80 -110.7 123.94 50.98 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.565 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.22 138.99 35.52 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -90.79 108.31 19.75 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 176.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -100.28 46.7 0.95 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -176.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.566 ' O ' HG22 ' B' ' 24' ' ' VAL . 54.3 t -101.12 162.23 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 176.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.54 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 69.98 30.64 69.92 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 176.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.77 ' O ' ' O ' ' C' ' 27' ' ' ASN . 20.6 p -173.06 -118.73 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.406 1.103 . . . . 0.0 113.307 -177.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.77 ' O ' ' O ' ' C' ' 26' ' ' SER . 61.4 t30 21.35 172.91 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 126.0 1.72 . . . . 0.0 114.446 -176.589 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -159.97 -29.54 0.06 Allowed 'General case' 0 N--CA 1.466 0.372 0 O-C-N 121.334 -0.853 . . . . 0.0 112.648 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.69 81.59 0.09 OUTLIER Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.294 -173.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -78.42 130.7 36.4 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 122.798 1.285 . . . . 0.0 113.057 -175.07 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.839 HD11 HG12 ' O' ' 39' ' ' VAL . 76.6 mt -130.31 134.18 62.86 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 113.022 -1.899 . . . . 0.0 111.581 -178.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.648 HD13 ' CD1' ' E' ' 19' ' ' PHE . 87.7 mt -107.91 121.99 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.71 ' O ' HD12 ' C' ' 34' ' ' LEU . . . -126.3 102.24 0.63 Allowed Glycine 0 N--CA 1.469 0.848 0 N-CA-C 107.845 -2.102 . . . . 0.0 107.845 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.789 HD11 HG22 ' B' ' 32' ' ' ILE . 5.9 mp -139.13 146.65 40.91 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 123.219 1.485 . . . . 0.0 113.538 -176.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -106.69 109.64 21.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 112.19 -2.277 . . . . 0.0 106.798 177.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.474 HG21 HD11 ' D' ' 34' ' ' LEU . 18.5 t -121.33 131.06 73.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 120.957 0.408 . . . . 0.0 111.695 -176.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.03 -110.85 3.1 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.575 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.32 -73.12 0.68 Allowed Glycine 0 CA--C 1.544 1.849 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -177.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.629 ' CG2' ' H ' ' B' ' 40' ' ' VAL . 1.3 m -132.32 179.77 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 176.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.475 ' N ' HG12 ' D' ' 39' ' ' VAL . 46.8 t . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.696 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.8 m . . . . . 0 N--CA 1.472 0.632 0 N-CA-C 110.14 -0.318 . . . . 0.0 110.14 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.54 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 22.4 t-80 -61.9 121.22 12.39 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.595 -177.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.798 ' CD2' ' H ' ' E' ' 14' ' ' HIS . 35.3 m170 -150.45 162.55 40.37 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.408 ' HB2' HE22 ' E' ' 15' ' ' GLN . 68.2 tp60 -85.99 156.85 20.28 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 175.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -159.78 102.21 1.49 Allowed 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.29 -0.964 . . . . 0.0 109.914 177.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.456 HD22 HD12 ' C' ' 17' ' ' LEU . 16.2 mt -132.16 122.35 25.17 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.361 0.601 . . . . 0.0 111.478 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 91.2 t -113.36 107.56 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.449 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 80.8 m-85 -104.22 106.87 17.53 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -126.69 128.59 46.94 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -176.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.82 124.03 41.22 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.345 177.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -89.27 153.35 20.97 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 122.059 0.933 . . . . 0.0 113.262 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.451 ' O ' HG22 ' C' ' 24' ' ' VAL . 98.2 m-20 40.59 55.25 2.95 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 113.631 -1.622 . . . . 0.0 113.257 177.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.651 HG21 ' HB1' ' E' ' 21' ' ' ALA . 98.4 t -66.06 135.12 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 177.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.32 -32.54 1.79 Allowed Glycine 0 N--CA 1.468 0.798 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.414 ' OG ' ' O ' ' C' ' 27' ' ' ASN . 26.8 m -71.25 120.34 16.69 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.147 0.499 . . . . 0.0 110.231 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.568 ' ND2' ' H ' ' E' ' 25' ' ' GLY . 3.9 m120 -103.41 -151.82 0.44 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.184 -178.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.466 ' H ' ' HA ' ' E' ' 27' ' ' ASN . 26.2 pttm 31.72 41.84 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.432 -1.258 . . . . 0.0 114.074 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.41 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -173.36 60.89 0.14 Allowed Glycine 0 CA--C 1.54 1.594 0 C-N-CA 119.672 -1.252 . . . . 0.0 113.63 174.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.661 ' N ' ' ND2' ' E' ' 27' ' ' ASN . . . -107.95 109.88 21.48 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 117.717 0.759 . . . . 0.0 109.508 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.514 HD11 HG23 ' P' ' 39' ' ' VAL . 69.3 mt -134.09 128.59 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 118.952 -1.099 . . . . 0.0 112.186 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.613 HD13 ' CD1' ' F' ' 19' ' ' PHE . 95.7 mt -112.55 119.29 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 177.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.43 98.88 0.8 Allowed Glycine 0 C--O 1.239 0.453 0 N-CA-C 105.895 -2.882 . . . . 0.0 105.895 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.474 HD11 HG21 ' C' ' 36' ' ' VAL . 11.3 tp -131.47 136.45 47.94 Favored 'General case' 0 C--O 1.244 0.81 0 CA-C-O 122.658 1.218 . . . . 0.0 113.795 -175.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -109.54 110.0 20.96 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 113.064 -1.88 . . . . 0.0 108.217 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.5 122.87 67.25 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.5 -113.58 0.71 Allowed Glycine 0 C--N 1.307 -1.031 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 96.11 -71.98 0.86 Allowed Glycine 0 CA--C 1.53 1.022 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.554 ' CG2' ' O ' ' J' ' 29' ' ' GLY . 0.3 OUTLIER -141.4 163.06 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 178.005 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' D' ' 39' ' ' VAL . 21.2 t . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 118.215 -0.897 . . . . 0.0 111.746 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.75 136.07 46.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.953 0.406 . . . . 0.0 110.686 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -113.72 119.75 38.47 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.301 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.549 ' O ' ' NE2' ' D' ' 14' ' ' HIS . 50.9 t -127.17 134.21 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 121.395 0.617 . . . . 0.0 110.025 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -129.23 106.4 8.8 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.934 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.798 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 3.3 p80 -151.87 161.35 42.79 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 177.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.411 ' OE1' ' CG1' ' C' ' 36' ' ' VAL . 79.1 mm-40 -90.01 158.12 17.5 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -141.1 100.03 3.72 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.405 ' N ' HD12 ' E' ' 17' ' ' LEU . 5.2 mp -133.38 126.1 30.56 Favored 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.643 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -113.62 106.66 21.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.505 178.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.648 ' CD1' HD13 ' C' ' 32' ' ' ILE . 89.8 m-85 -105.79 106.05 16.38 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.303 -1.739 . . . . 0.0 106.303 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -133.53 135.13 44.18 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.091 1.145 . . . . 0.0 114.091 -176.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.651 ' HB1' HG21 ' D' ' 24' ' ' VAL . . . -128.32 129.91 46.99 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.988 177.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.418 ' HB2' ' H ' ' D' ' 23' ' ' ASP . 97.8 mt-10 -91.25 166.26 13.03 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.115 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 25.99 47.27 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 112.293 -2.23 . . . . 0.0 115.835 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.6 HG12 ' N ' ' E' ' 25' ' ' GLY . 53.4 t -67.43 171.43 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 174.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.6 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -117.75 37.41 3.3 Favored Glycine 0 N--CA 1.48 1.581 0 C-N-CA 119.433 -1.365 . . . . 0.0 111.264 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 72.52 119.99 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.499 . . . . 0.0 110.236 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.661 ' ND2' ' N ' ' D' ' 30' ' ' ALA . 81.4 m-20 -83.19 163.62 20.68 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.952 176.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -46.93 -36.93 8.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 122.022 0.915 . . . . 0.0 108.946 175.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 77.42 0.06 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 113.694 -1.594 . . . . 0.0 110.558 -177.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.73 149.26 4.8 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.775 0.787 . . . . 0.0 110.648 -178.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.44 137.14 56.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.67 122.11 68.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 114.491 -1.231 . . . . 0.0 109.784 178.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.37 106.76 1.36 Allowed Glycine 0 N--CA 1.465 0.607 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 27.0 tp -126.16 125.52 42.61 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.872 0.367 . . . . 0.0 111.313 -177.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.445 ' CG ' ' N ' ' E' ' 36' ' ' VAL . 27.3 ttp -146.29 158.85 43.92 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.614 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.581 HG22 ' HA ' ' F' ' 36' ' ' VAL . 1.3 m -115.02 162.93 12.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.1 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.77 -102.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.371 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -78.47 1.05 Allowed Glycine 0 CA--C 1.534 1.243 0 C-N-CA 121.659 -0.305 . . . . 0.0 112.781 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.446 HG13 ' O ' ' E' ' 39' ' ' VAL . 9.3 p . . . . . 0 N--CA 1.469 0.508 0 CA-C-N 116.952 0.376 . . . . 0.0 111.107 -179.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 pt-20 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 120.74 0.305 . . . . 0.0 110.813 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -124.32 132.83 70.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.018 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.482 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 8.5 p80 -144.74 114.69 7.37 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 121.206 0.526 . . . . 0.0 112.337 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.437 ' ND1' ' O ' ' F' ' 15' ' ' GLN . 54.8 t-80 -151.35 164.35 36.87 Favored 'General case' 0 C--O 1.217 -0.609 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.437 ' O ' ' ND1' ' F' ' 14' ' ' HIS . 88.7 mt-30 -89.91 158.33 17.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 119.113 0.87 . . . . 0.0 111.383 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.53 95.78 2.92 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -130.4 119.31 22.52 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -107.32 105.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.613 ' CD1' HD13 ' D' ' 32' ' ' ILE . 78.9 m-85 -107.59 109.0 20.53 Favored 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 20.3 t80 -147.21 137.62 23.42 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 118.618 -1.233 . . . . 0.0 113.826 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.33 130.48 49.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.08 -1.418 . . . . 0.0 107.468 177.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' E' ' 24' ' ' VAL . 96.9 mt-10 -82.29 115.79 21.52 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.043 -0.663 . . . . 0.0 111.653 -178.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 9.6 p-10 . . . . . 0 CA--C 1.529 0.155 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.7 179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.286 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.3 mt -121.2 127.24 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 118.486 0.585 . . . . 0.0 109.79 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 95.1 mt -128.2 131.7 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-O 120.865 0.364 . . . . 0.0 111.45 -178.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.3 116.86 2.67 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.1 tp -122.75 126.13 46.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 5.0 ttp -140.19 139.81 35.75 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 122.365 1.079 . . . . 0.0 113.845 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.581 ' HA ' HG22 ' E' ' 36' ' ' VAL . 43.8 t -117.31 131.95 68.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 CA-C-N 113.758 -1.565 . . . . 0.0 109.523 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -41.25 -111.62 0.0 OUTLIER Glycine 0 CA--C 1.531 1.046 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.907 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -71.7 0.6 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 111.767 -0.533 . . . . 0.0 111.767 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 94.6 t -76.99 131.53 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 117.3 0.55 . . . . 0.0 110.325 179.117 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.421 HG22 ' O ' ' F' ' 40' ' ' VAL . 14.9 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.148 -0.929 . . . . 0.0 110.608 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 m . . . . . 0 N--CA 1.466 0.326 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -138.2 117.34 12.61 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 121.006 0.432 . . . . 0.0 111.546 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.505 ' O ' ' NE2' ' G' ' 15' ' ' GLN . 49.1 p-80 -151.74 168.05 26.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.099 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.505 ' NE2' ' O ' ' G' ' 14' ' ' HIS . 97.7 mm-40 -156.98 143.23 18.07 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.046 0.45 . . . . 0.0 110.07 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -81.27 118.23 22.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 178.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.0 tp -136.76 118.92 15.48 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.313 0.577 . . . . 0.0 111.349 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 m -137.0 153.44 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.965 178.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -146.51 130.74 17.48 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-O 120.964 0.411 . . . . 0.0 111.195 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -123.04 132.2 54.02 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 126.94 35.6 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.467 0.651 . . . . 0.0 112.685 -178.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -96.36 145.31 25.73 Favored 'General case' 0 C--N 1.34 0.159 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 10.2 t70 . . . . . 0 C--N 1.322 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.717 -176.896 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.594 ' OD1' ' N ' ' G' ' 28' ' ' LYS . 31.7 t-20 . . . . . 0 N--CA 1.47 0.535 0 CA-C-O 120.677 0.275 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.617 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 88.5 tttt -69.43 -48.36 61.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.28 0.562 . . . . 0.0 110.411 178.073 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.521 ' N ' ' OD1' ' G' ' 27' ' ' ASN . . . 129.81 59.92 0.1 Allowed Glycine 0 CA--C 1.54 1.633 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 -176.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.09 89.28 0.82 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.879 HD12 HG12 ' A' ' 39' ' ' VAL . 87.3 mt -137.27 117.84 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-N 113.315 -1.766 . . . . 0.0 106.857 177.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.484 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.4 mt -106.17 110.64 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 94.86 0.67 Allowed Glycine 0 CA--C 1.508 -0.399 0 N-CA-C 105.097 -3.201 . . . . 0.0 105.097 177.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.705 ' O ' HD12 ' H' ' 34' ' ' LEU . 79.7 mt -147.49 168.44 21.91 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-O 123.254 1.502 . . . . 0.0 113.766 -175.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 94.5 mmm -120.96 114.39 21.46 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 112.064 -2.335 . . . . 0.0 107.16 178.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.495 HG21 HD22 ' I' ' 17' ' ' LEU . 41.4 t -124.6 131.53 72.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.54 -111.31 3.3 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.719 -0.953 . . . . 0.0 110.719 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.4 -73.79 1.33 Allowed Glycine 0 CA--C 1.536 1.395 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.252 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.627 HG12 HD12 ' M' ' 31' ' ' ILE . 22.3 m -87.02 171.55 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 117.401 0.6 . . . . 0.0 110.381 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.243 179.273 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -107.62 129.71 54.97 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.711 0.291 . . . . 0.0 110.346 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -154.85 148.76 25.66 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-O 121.166 0.508 . . . . 0.0 111.552 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.514 HG13 ' CG2' ' I' ' 12' ' ' VAL . 55.7 t -124.5 130.03 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.459 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 26.0 p-80 -147.46 142.81 27.37 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 119.48 -0.888 . . . . 0.0 113.131 -179.245 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.474 ' O ' ' CB ' ' G' ' 14' ' ' HIS . 1.5 m-70 -146.23 170.36 16.91 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 114.512 -1.222 . . . . 0.0 108.217 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -155.83 141.28 17.72 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.366 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -87.94 108.67 19.3 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.973 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -121.13 110.71 16.54 Favored 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.416 HG22 ' CG2' ' I' ' 18' ' ' VAL . 72.0 t -122.13 130.62 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.192 -178.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -126.52 118.98 26.0 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -122.35 125.93 46.98 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.61 131.26 39.42 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.457 0.646 . . . . 0.0 112.677 -179.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -97.68 127.1 43.38 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.541 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.617 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 97.1 m-20 -139.25 46.55 1.92 Allowed 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.598 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.694 HG12 ' N ' ' H' ' 25' ' ' GLY . 21.5 t -82.8 173.34 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-O 122.697 1.237 . . . . 0.0 113.06 -176.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.694 ' N ' HG12 ' H' ' 24' ' ' VAL . . . 92.74 -35.16 4.17 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 112.596 -2.093 . . . . 0.0 114.26 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' H' ' 27' ' ' ASN . 32.2 t -162.55 117.38 1.82 Allowed 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 120.691 2.246 . . . . 0.0 114.192 175.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' H' ' 26' ' ' SER . 45.0 p-10 -22.55 153.13 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.116 0.566 . . . . 0.0 112.297 173.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 7.7 tttm -165.95 26.38 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 117.948 -1.501 . . . . 0.0 114.887 173.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 107.77 0.38 Allowed Glycine 0 CA--C 1.532 1.11 0 C-N-CA 119.004 -1.57 . . . . 0.0 113.944 177.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.7 111.47 17.65 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.466 HD11 HG13 ' C' ' 39' ' ' VAL . 87.4 mt -130.22 133.61 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.533 HD13 ' CD2' ' J' ' 19' ' ' PHE . 93.6 mt -105.71 108.46 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -109.44 101.92 1.54 Allowed Glycine 0 N--CA 1.465 0.623 0 N-CA-C 105.897 -2.881 . . . . 0.0 105.897 177.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.705 HD12 ' O ' ' G' ' 34' ' ' LEU . 47.2 tp -152.53 145.62 24.59 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 117.306 -1.758 . . . . 0.0 114.612 -173.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.583 ' H ' HD12 ' H' ' 34' ' ' LEU . 3.8 ttm -106.9 117.02 32.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.71 177.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.473 ' CG2' HG12 ' I' ' 36' ' ' VAL . 2.9 t -118.19 102.49 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.801 -178.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.27 -163.93 26.78 Favored Glycine 0 CA--C 1.524 0.617 0 C-N-CA 120.354 -0.926 . . . . 0.0 112.655 177.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.52 ' HA2' ' H ' ' I' ' 38' ' ' GLY . . . 156.2 -54.55 0.41 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.721 HG13 HD13 ' N' ' 31' ' ' ILE . 3.7 m -141.31 164.21 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 176.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.538 ' OXT' ' NZ ' ' N' ' 28' ' ' LYS . 1.3 p . . . . . 0 N--CA 1.467 0.377 0 CA-C-O 117.802 -1.094 . . . . 0.0 111.353 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.25 135.41 46.67 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.691 0.281 . . . . 0.0 110.387 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' NE2' ' I' ' 13' ' ' HIS . 45.7 tp10 -147.11 100.9 3.35 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.908 0.385 . . . . 0.0 110.256 179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.514 ' CG2' HG13 ' H' ' 12' ' ' VAL . 4.9 m -141.75 127.41 18.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.986 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' CE1' ' H' ' 13' ' ' HIS . 49.5 m170 -113.59 136.24 53.03 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.829 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.527 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 70.7 m80 -156.64 176.04 13.26 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.29 0.567 . . . . 0.0 110.515 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.411 ' CG ' HD11 ' I' ' 17' ' ' LEU . 40.8 tp60 -159.33 139.09 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -105.39 113.61 27.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 118.999 -0.524 . . . . 0.0 111.5 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.495 HD22 HG21 ' G' ' 36' ' ' VAL . 0.7 OUTLIER -129.5 112.48 13.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.557 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.416 ' CG2' HG22 ' H' ' 18' ' ' VAL . 15.1 m -119.43 124.87 73.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -112.16 116.76 30.98 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 114.752 -1.113 . . . . 0.0 108.673 -178.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -119.08 129.14 54.92 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.767 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.87 138.19 30.08 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.436 -0.506 . . . . 0.0 112.165 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -131.91 130.95 42.23 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 120.458 -0.497 . . . . 0.0 112.261 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.64 ' C ' HG23 ' I' ' 24' ' ' VAL . 0.3 OUTLIER -130.98 -49.94 1.03 Allowed 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.188 0.518 . . . . 0.0 110.477 178.644 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.699 HG22 ' CD ' ' J' ' 22' ' ' GLU . 2.0 t 77.7 143.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.939 176.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.531 ' H ' ' CG2' ' J' ' 24' ' ' VAL . . . 92.08 37.46 5.99 Favored Glycine 0 CA--C 1.525 0.662 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.372 174.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 3.0 p 72.69 120.15 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 117.744 0.772 . . . . 0.0 110.237 177.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.598 ' H ' ' ND2' ' J' ' 27' ' ' ASN . 13.8 p30 -83.03 161.3 21.75 Favored 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 117.598 -1.641 . . . . 0.0 109.192 177.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.434 ' O ' ' OXT' ' C' ' 40' ' ' VAL . 95.8 mttt -48.63 -39.54 24.49 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 176.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.45 0.04 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -175.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.61 139.15 51.32 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 119.027 1.413 . . . . 0.0 114.281 -174.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.589 HD12 HG12 ' C' ' 39' ' ' VAL . 61.2 mt -141.57 143.78 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 113.529 -1.669 . . . . 0.0 113.026 -178.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.435 HG23 HD12 ' I' ' 34' ' ' LEU . 9.8 mt -104.31 109.72 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 175.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -109.51 100.75 1.38 Allowed Glycine 0 N--CA 1.463 0.454 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.629 ' O ' HD12 ' J' ' 34' ' ' LEU . 0.2 OUTLIER -139.14 143.27 38.13 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.928 1.347 . . . . 0.0 113.681 -175.52 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.407 ' SD ' ' HB2' ' J' ' 35' ' ' MET . 87.7 mmm -117.12 108.71 16.03 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 111.939 -2.391 . . . . 0.0 104.61 175.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.703 ' CG2' HG12 ' J' ' 36' ' ' VAL . 24.4 m -126.14 130.94 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 118.695 -1.202 . . . . 0.0 112.77 -178.149 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.88 111.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 113.048 -1.887 . . . . 0.0 113.477 177.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.52 ' H ' ' HA2' ' H' ' 38' ' ' GLY . . . -80.81 -60.53 2.29 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.206 -1.157 . . . . 0.0 110.206 175.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.3 p -146.2 150.08 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 121.407 0.622 . . . . 0.0 110.407 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.815 HG11 ' CD2' ' K' ' 13' ' ' HIS . 21.3 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.659 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -105.31 133.5 49.98 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . 0.64 ' CG ' ' HE2' ' J' ' 13' ' ' HIS . 80.4 tt0 -153.34 114.81 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.005 0.431 . . . . 0.0 110.645 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.436 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -138.83 138.34 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.847 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.64 ' HE2' ' CG ' ' J' ' 11' ' ' GLU . 19.7 m-70 -139.19 147.83 42.34 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.814 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.527 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 56.9 m-70 -151.97 160.92 43.35 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.615 177.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 tp60 -90.46 158.35 17.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 177.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.743 ' C ' HD12 ' J' ' 17' ' ' LEU . 97.6 mttt -141.48 90.82 2.32 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.288 176.109 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.743 HD12 ' C ' ' J' ' 16' ' ' LYS . 9.2 mp -128.54 129.86 46.61 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 118.813 0.733 . . . . 0.0 110.688 177.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 18.4 t -125.64 116.83 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.682 179.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 12.6 m-85 -109.31 106.95 16.97 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 6.3 t80 -114.01 121.91 45.32 Favored 'General case' 0 N--CA 1.478 0.973 0 O-C-N 122.263 -0.273 . . . . 0.0 110.337 -178.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.24 138.73 37.07 Favored 'General case' 0 C--O 1.253 1.259 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.699 ' CD ' HG22 ' I' ' 24' ' ' VAL . 52.7 tt0 -66.92 149.6 50.39 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 176.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.697 ' O ' ' O ' ' J' ' 24' ' ' VAL . 65.1 t0 -168.38 64.5 0.07 Allowed 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -168.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.697 ' O ' ' O ' ' J' ' 23' ' ' ASP . 58.7 t -43.06 -104.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 CA-C-O 113.942 -2.932 . . . . 0.0 103.809 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 166.75 -48.18 0.26 Allowed Glycine 0 N--CA 1.482 1.754 2 CA-C-N 127.32 4.6 . . . . 0.0 119.696 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 41.0 t -65.8 101.0 0.6 Allowed 'General case' 0 C--N 1.322 -0.596 1 CA-C-N 125.567 4.683 . . . . 0.0 105.867 -179.531 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.598 ' ND2' ' H ' ' I' ' 27' ' ' ASN . 1.1 m-20 -129.48 160.88 31.79 Favored 'General case' 0 C--N 1.348 0.504 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.75 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.407 ' C ' ' O ' ' J' ' 27' ' ' ASN . 70.3 mmtt -29.61 -39.42 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.785 -1.098 . . . . 0.0 113.44 174.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.554 ' O ' ' CG2' ' D' ' 39' ' ' VAL . . . 140.93 74.87 0.04 OUTLIER Glycine 0 CA--C 1.552 2.371 0 C-N-CA 119.668 -1.253 . . . . 0.0 112.341 -175.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.03 155.54 40.44 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 120.631 2.215 . . . . 0.0 113.061 -174.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' D' ' 38' ' ' GLY . 57.6 mt -138.2 148.53 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 3.9 mt -109.84 110.99 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 173.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.4 103.81 1.71 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.629 HD12 ' O ' ' I' ' 34' ' ' LEU . 33.4 tp -143.44 132.58 23.08 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 115.695 1.739 . . . . 0.0 115.695 -173.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.445 ' N ' HD12 ' J' ' 34' ' ' LEU . 78.4 mmm -103.75 123.75 47.62 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 112.78 -2.009 . . . . 0.0 106.886 176.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.703 HG12 ' CG2' ' I' ' 36' ' ' VAL . 2.8 m -135.25 155.68 37.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-O 121.549 0.69 . . . . 0.0 112.441 -176.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.688 ' H ' HE22 ' L' ' 15' ' ' GLN . . . 79.76 -101.42 1.92 Allowed Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.933 176.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.6 -80.31 1.61 Allowed Glycine 0 CA--C 1.537 1.451 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -176.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.468 HG23 HD12 ' P' ' 31' ' ' ILE . 59.2 t -124.06 131.57 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-N 117.742 0.771 . . . . 0.0 109.624 177.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.516 ' OXT' ' CD2' ' L' ' 13' ' ' HIS . 27.6 t . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.27 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.442 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . 0.441 ' CD2' ' O ' ' K' ' 11' ' ' GLU . 52.6 t80 -70.69 134.95 47.96 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.883 0.373 . . . . 0.0 110.523 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.441 ' O ' ' CD2' ' K' ' 10' ' ' TYR . 68.8 mm-40 -75.22 154.68 37.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.746 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 27.8 m -122.91 129.59 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.363 0.602 . . . . 0.0 111.847 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.815 ' CD2' HG11 ' I' ' 40' ' ' VAL . 2.9 t60 -148.99 138.09 21.48 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.129 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.531 ' NE2' ' O ' ' L' ' 12' ' ' VAL . 15.3 m-70 -134.51 158.86 42.85 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -90.17 159.51 16.72 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 57.4 tttt -140.47 95.13 2.82 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 120.041 -0.664 . . . . 0.0 109.758 177.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.602 ' CD1' HG21 ' I' ' 36' ' ' VAL . 37.2 mt -118.47 111.67 18.95 Favored 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 177.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -108.29 107.25 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 84.7 m-85 -104.03 105.68 15.93 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.9 t80 -110.74 114.91 28.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.38 135.93 20.6 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 122.023 0.916 . . . . 0.0 111.867 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.558 ' O ' ' CB ' ' K' ' 23' ' ' ASP . 98.3 mt-10 -69.15 -174.92 0.69 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 118.145 -1.422 . . . . 0.0 107.97 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' J' ' 24' ' ' VAL . 10.5 t0 144.98 46.6 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.474 0.654 . . . . 0.0 109.927 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.687 HG12 ' N ' ' K' ' 25' ' ' GLY . 25.4 t -84.03 172.16 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.862 -178.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.687 ' N ' HG12 ' K' ' 24' ' ' VAL . . . 95.71 -29.68 9.46 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 178.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.485 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 92.07 114.02 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 114.446 -0.877 . . . . 0.0 109.06 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.614 ' OD1' ' HB2' ' K' ' 30' ' ' ALA . 1.4 p30 -74.3 174.48 8.76 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.361 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.28 -36.75 43.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.97 76.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.541 0 CA-C-O 119.679 -0.512 . . . . 0.0 112.67 -177.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.614 ' HB2' ' OD1' ' K' ' 27' ' ' ASN . . . -80.12 149.7 30.5 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 118.745 1.272 . . . . 0.0 110.527 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.532 HG23 ' HB ' ' L' ' 31' ' ' ILE . 59.1 mt -130.77 135.97 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.547 -0.752 . . . . 0.0 112.14 -177.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.33 119.24 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.74 109.77 1.53 Allowed Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 70.7 mt -122.78 118.38 27.86 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.248 0.547 . . . . 0.0 110.626 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 95.9 mmm -110.74 122.27 47.4 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.004 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.11 132.37 67.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.318 -179.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.24 112.1 3.45 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 178.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.533 ' H ' ' HA3' ' L' ' 37' ' ' GLY . . . -76.65 73.18 1.9 Allowed Glycine 0 CA--C 1.532 1.148 0 C-N-CA 120.243 -0.98 . . . . 0.0 113.498 -178.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.663 HG23 HD12 ' Q' ' 31' ' ' ILE . 22.1 t . . . . . 0 N--CA 1.467 0.425 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 . . . . . 0 C--O 1.232 0.147 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.832 HG22 ' H ' ' L' ' 13' ' ' HIS . 11.3 p -138.98 -179.18 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.911 0.386 . . . . 0.0 111.07 -178.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.832 ' H ' HG22 ' L' ' 12' ' ' VAL . 0.3 OUTLIER -122.81 108.52 13.11 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.525 -179.941 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.436 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 40.8 t-80 -150.38 165.52 32.85 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.688 HE22 ' H ' ' J' ' 37' ' ' GLY . 51.3 tt0 -89.74 158.73 17.4 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.643 0.259 . . . . 0.0 110.788 -179.03 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -140.01 107.56 5.59 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.252 0.548 . . . . 0.0 111.256 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.412 ' HB3' ' CZ ' ' L' ' 19' ' ' PHE . 4.4 mt -115.97 109.15 17.16 Favored 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -105.09 103.55 15.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.412 ' CZ ' ' HB3' ' L' ' 17' ' ' LEU . 65.8 m-85 -100.46 100.54 11.31 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.603 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 52.2 t80 -106.41 95.95 6.11 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.84 145.07 31.46 Favored 'General case' 0 CA--C 1.495 -1.138 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.655 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' K' ' 23' ' ' ASP . 80.8 mm-40 -82.6 96.04 7.96 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.728 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 91.8 m-20 -132.56 62.63 1.64 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 112.052 -177.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.479 HG12 ' H ' ' L' ' 25' ' ' GLY . 1.5 t 60.51 -141.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.207 0.527 . . . . 0.0 110.871 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.479 ' H ' HG12 ' L' ' 24' ' ' VAL . . . 156.63 -29.53 0.55 Allowed Glycine 0 CA--C 1.519 0.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 87.8 p -63.21 -123.66 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.191 -0.505 . . . . 0.0 110.868 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.509 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 5.9 t-20 -156.97 -154.14 0.45 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.856 -178.492 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.509 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 68.6 mttm 28.32 41.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.09 -62.59 0.04 OUTLIER Glycine 0 CA--C 1.537 1.445 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.723 178.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.83 148.08 29.02 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.785 0.792 . . . . 0.0 110.488 178.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.532 ' HB ' HG23 ' K' ' 31' ' ' ILE . 6.7 mm -114.76 125.89 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -120.18 124.6 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.72 115.46 1.7 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.7 tp -126.2 120.73 30.81 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mtp -135.38 147.55 49.09 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -177.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 33.6 m -119.36 159.29 20.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.132 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.643 178.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.533 ' HA3' ' H ' ' K' ' 38' ' ' GLY . . . -61.89 -102.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.487 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.96 -75.14 0.11 Allowed Glycine 0 CA--C 1.534 1.237 0 C-N-CA 121.83 -0.224 . . . . 0.0 112.88 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' K' ' 38' ' ' GLY . 3.0 m . . . . . 0 N--CA 1.466 0.373 0 CA-C-O 121.296 0.57 . . . . 0.0 111.399 -178.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 . . . . . 0 N--CA 1.466 0.344 0 CA-C-O 121.145 0.498 . . . . 0.0 111.025 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.42 130.66 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.158 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 m80 -128.65 113.18 15.07 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 17.9 p-80 -152.56 168.23 26.25 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.548 178.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -129.23 150.65 50.52 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.085 178.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -97.56 116.25 29.4 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.3 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -124.97 114.07 18.65 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 118.154 0.434 . . . . 0.0 110.093 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . 0.431 ' O ' HG23 ' M' ' 18' ' ' VAL . 19.1 m -131.67 132.52 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.641 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -135.7 133.99 38.67 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-O 121.077 0.465 . . . . 0.0 111.745 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -121.61 129.39 52.8 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . 0.498 ' HB1' ' CG2' ' M' ' 24' ' ' VAL . . . -130.98 131.81 44.62 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.332 0.587 . . . . 0.0 112.164 -178.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -120.23 142.27 49.18 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.557 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 37.42 54.68 1.39 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.306 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.498 ' CG2' ' HB1' ' M' ' 21' ' ' ALA . 45.6 t -67.79 135.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.76 -33.49 2.04 Favored Glycine 0 N--CA 1.47 0.901 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 62.8 p -82.31 -121.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.131 0.491 . . . . 0.0 111.206 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . 0.49 ' O ' HG11 ' M' ' 24' ' ' VAL . 10.9 m120 -93.22 -160.5 0.76 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.063 -178.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 35.28 40.37 0.06 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.38 -64.37 1.22 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . 0.556 ' HB3' ' OG ' ' N' ' 26' ' ' SER . . . -157.26 49.74 0.44 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.043 0.922 . . . . 0.0 111.772 175.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.627 HD12 HG12 ' G' ' 39' ' ' VAL . 97.0 mt -138.49 106.84 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 CA-C-N 114.157 -1.383 . . . . 0.0 107.474 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.2 mt -102.7 104.43 16.53 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.335 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.09 95.71 0.75 Allowed Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 104.071 -3.612 . . . . 0.0 104.071 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . 0.68 ' O ' HD23 ' N' ' 34' ' ' LEU . 43.1 tp -146.07 150.4 35.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 122.843 1.306 . . . . 0.0 113.809 -173.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -110.02 106.95 16.66 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 112.65 -2.068 . . . . 0.0 106.228 177.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.563 HG13 ' O ' ' M' ' 36' ' ' VAL . 4.0 p -127.35 114.07 34.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.6 -124.61 1.88 Allowed Glycine 0 C--N 1.309 -0.958 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.96 -67.11 3.29 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.043 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.615 HG12 ' CD1' ' A' ' 31' ' ' ILE . 13.0 m -78.4 169.1 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-O 121.041 0.448 . . . . 0.0 110.472 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.406 HG22 ' OXT' ' M' ' 40' ' ' VAL . 3.5 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.458 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -115.44 142.01 47.29 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.87 0.367 . . . . 0.0 110.52 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . 0.526 ' O ' ' NE2' ' O' ' 13' ' ' HIS . 82.4 tt0 -69.18 120.64 15.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.095 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.51 120.45 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.618 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.474 ' CE1' ' OE2' ' N' ' 11' ' ' GLU . 60.4 m170 -113.68 150.71 32.85 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.901 -178.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.555 ' CE1' ' O ' ' O' ' 12' ' ' VAL . 75.2 m-70 -141.92 172.01 13.28 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 121.19 0.519 . . . . 0.0 110.403 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 68.4 tp60 -138.25 140.87 39.86 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttm -130.17 107.0 8.97 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.535 HD23 ' C ' ' N' ' 17' ' ' LEU . 5.9 tt -122.6 116.33 23.66 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . 0.437 HG22 ' CG1' ' O' ' 18' ' ' VAL . 80.0 t -121.01 126.22 74.95 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.333 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -127.03 122.02 33.25 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -125.32 125.21 43.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.032 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.95 131.4 53.56 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 179.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.425 ' O ' ' N ' ' N' ' 24' ' ' VAL . 95.1 mt-10 -81.05 -166.81 1.22 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.325 0.583 . . . . 0.0 112.53 -177.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.518 ' N ' ' OE1' ' O' ' 22' ' ' GLU . 66.2 t0 -61.97 47.51 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 114.765 -1.107 . . . . 0.0 112.394 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.855 HG12 ' H ' ' N' ' 25' ' ' GLY . 30.3 t -61.04 -179.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.019 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 0.855 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -100.96 29.31 12.77 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 121.636 -0.316 . . . . 0.0 112.718 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.556 ' OG ' ' HB3' ' M' ' 30' ' ' ALA . 10.7 t -81.05 112.86 18.82 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 72.1 m-20 -89.75 -175.06 4.52 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.538 ' NZ ' ' OXT' ' H' ' 40' ' ' VAL . 59.3 mttp 49.29 37.64 11.9 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 111.525 -2.58 . . . . 0.0 114.824 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . 0.61 ' O ' ' HB2' ' N' ' 30' ' ' ALA . . . 92.01 -77.98 1.28 Allowed Glycine 0 N--CA 1.469 0.851 0 N-CA-C 114.517 0.567 . . . . 0.0 114.517 172.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . 0.898 ' O ' ' HB1' ' O' ' 30' ' ' ALA . . . 150.87 162.64 0.0 OUTLIER 'General case' 0 C--O 1.238 0.464 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.721 HD13 HG13 ' H' ' 39' ' ' VAL . 28.8 pt -141.32 126.92 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.029 178.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -113.04 114.55 47.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.47 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.95 105.95 1.66 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 104.936 -3.266 . . . . 0.0 104.936 175.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.68 HD23 ' O ' ' M' ' 34' ' ' LEU . 0.4 OUTLIER -146.32 144.32 29.73 Favored 'General case' 0 CA--C 1.51 -0.581 0 C-N-CA 117.716 -1.594 . . . . 0.0 114.512 -174.18 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 36.3 tpp -106.97 107.77 18.95 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 174.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.429 HG13 HD22 ' N' ' 34' ' ' LEU . 0.0 OUTLIER -121.52 143.68 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 -178.216 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.477 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 113.26 -102.68 1.29 Allowed Glycine 0 C--N 1.316 -0.55 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 178.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.427 ' C ' HD11 ' B' ' 31' ' ' ILE . . . 85.69 -80.3 1.81 Allowed Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -178.542 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.552 HG23 HD11 ' B' ' 31' ' ' ILE . 43.4 t -153.03 123.54 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 177.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.524 HG22 ' O ' ' O' ' 38' ' ' GLY . 9.1 m . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.724 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -115.44 141.51 47.95 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.876 0.369 . . . . 0.0 110.687 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -83.11 116.78 22.48 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.233 -0.439 . . . . 0.0 109.933 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.555 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 2.9 m -138.44 160.66 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.823 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 94.3 m-70 -76.74 113.39 14.35 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.529 178.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.572 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 83.6 t60 -148.02 153.23 38.68 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 119.576 -0.849 . . . . 0.0 111.875 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.563 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 42.1 tt0 -98.65 169.61 9.38 Favored 'General case' 0 C--N 1.345 0.396 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -158.57 104.44 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.681 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.521 ' CD1' HG11 ' M' ' 36' ' ' VAL . 31.5 mt -122.29 116.02 23.35 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 177.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . 0.437 ' CG1' HG22 ' N' ' 18' ' ' VAL . 3.3 p -125.0 117.59 50.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-O 121.883 0.849 . . . . 0.0 109.576 178.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -112.31 115.08 28.19 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.429 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -114.63 133.93 55.46 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 122.523 0.329 . . . . 0.0 110.524 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.58 142.11 27.64 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 113.68 0.993 . . . . 0.0 113.68 -178.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' N' ' 23' ' ' ASP . 95.9 mt-10 -78.99 104.98 10.0 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 104.481 -2.415 . . . . 0.0 104.481 175.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.814 ' HB3' ' HB1' ' P' ' 21' ' ' ALA . 17.6 p30 -83.27 49.03 1.48 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 117.736 2.495 . . . . 0.0 117.736 -172.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.471 HG12 ' N ' ' O' ' 25' ' ' GLY . 89.9 t -71.56 160.44 5.24 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 C-N-CA 114.803 -2.759 . . . . 0.0 104.221 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.481 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.92 -30.8 8.31 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 -175.065 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 2.5 m 100.59 111.13 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 112.932 -1.634 . . . . 0.0 112.072 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.555 ' O ' ' N ' ' O' ' 29' ' ' GLY . 12.7 t-20 -70.48 -179.43 2.09 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.702 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.537 ' H ' ' CG ' ' O' ' 27' ' ' ASN . 51.9 tttt 65.53 -47.29 0.38 Allowed 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' O' ' 27' ' ' ASN . . . -81.95 59.38 4.87 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 107.039 -2.424 . . . . 0.0 107.039 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . 0.898 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -140.31 -171.02 3.11 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 109.739 -3.231 . . . . 0.0 105.513 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 81.5 mt -128.81 125.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 119.509 -0.876 . . . . 0.0 113.342 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.464 HD13 ' CD2' ' Q' ' 19' ' ' PHE . 88.9 mt -104.33 104.54 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 174.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.05 109.92 2.78 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 105.553 -3.019 . . . . 0.0 105.553 177.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.602 ' O ' HD23 ' O' ' 34' ' ' LEU . 0.0 OUTLIER -162.98 150.0 12.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 115.737 -2.385 . . . . 0.0 114.742 -174.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.0 mmm -110.08 105.05 14.02 Favored 'General case' 0 CA--C 1.496 -1.102 0 CA-C-N 111.604 -2.544 . . . . 0.0 106.199 179.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.5 ' HB ' HD21 ' O' ' 34' ' ' LEU . 11.9 p -118.64 142.12 35.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -178.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.04 -102.08 0.21 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 120.076 -1.059 . . . . 0.0 110.549 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.524 ' O ' HG22 ' N' ' 40' ' ' VAL . . . 73.99 64.75 2.36 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 120.571 -0.823 . . . . 0.0 113.182 -178.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.839 HG12 HD11 ' C' ' 31' ' ' ILE . 9.1 p -10.79 140.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.414 ' CG1' ' OXT' ' P' ' 40' ' ' VAL . 7.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.059 177.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.499 HG12 ' H ' ' Q' ' 12' ' ' VAL . 6.2 m . . . . . 0 N--CA 1.463 0.223 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.627 ' H ' ' CE1' ' Q' ' 13' ' ' HIS . 0.6 OUTLIER -129.54 115.67 17.79 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.055 0.455 . . . . 0.0 112.008 -178.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.572 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 4.5 p80 -156.11 167.16 31.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.359 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.477 HE22 ' N ' ' N' ' 37' ' ' GLY . 53.2 tt0 -89.78 158.48 17.49 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -140.32 115.08 9.54 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.636 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.424 ' HB3' ' CE2' ' P' ' 19' ' ' PHE . 14.4 mt -119.47 122.28 41.34 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -119.63 107.56 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 47.8 m-85 -110.03 107.95 18.0 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 178.197 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -116.4 125.56 52.22 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.596 0.236 . . . . 0.0 110.694 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . 0.814 ' HB1' ' HB3' ' O' ' 23' ' ' ASP . . . -129.59 127.78 41.36 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.141 0.496 . . . . 0.0 110.231 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' O' ' 23' ' ' ASP . 16.6 pt-20 -122.03 158.77 28.45 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.433 ' C ' ' OD1' ' O' ' 23' ' ' ASP . 29.8 m-20 76.43 55.98 0.05 OUTLIER 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 113.439 -1.709 . . . . 0.0 112.859 178.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.412 HG12 ' H ' ' O' ' 27' ' ' ASN . 3.8 m -77.4 129.21 37.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.21 -35.41 4.48 Favored Glycine 0 CA--C 1.536 1.383 0 C-N-CA 118.854 -1.641 . . . . 0.0 112.127 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.652 ' O ' ' O ' ' P' ' 27' ' ' ASN . 16.4 t -173.97 125.82 0.36 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 119.562 1.681 . . . . 0.0 114.179 175.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.652 ' O ' ' O ' ' P' ' 26' ' ' SER . 44.6 m-20 -2.86 145.73 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.25 1.42 . . . . 0.0 114.683 173.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -160.31 32.23 0.17 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.73 80.95 0.89 Allowed Glycine 0 N--CA 1.482 1.748 0 C-N-CA 117.768 -2.158 . . . . 0.0 112.939 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' O' ' 28' ' ' LYS . . . -101.94 131.41 48.35 Favored 'General case' 0 CA--C 1.508 -0.651 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -176.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.506 HD11 HG21 ' K' ' 39' ' ' VAL . 91.1 mt -133.47 122.49 44.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.164 178.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.441 HD13 HG21 ' P' ' 32' ' ' ILE . 43.7 mt -107.17 110.43 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.03 102.88 0.86 Allowed Glycine 0 N--CA 1.462 0.369 0 N-CA-C 107.788 -2.125 . . . . 0.0 107.788 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.452 ' HB2' HD23 ' O' ' 34' ' ' LEU . 4.0 pp -157.35 162.35 39.09 Favored 'General case' 0 CA--C 1.493 -1.224 0 C-N-CA 117.664 -1.615 . . . . 0.0 113.621 -177.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 23.3 mtp -119.89 123.19 42.98 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 112.215 -2.266 . . . . 0.0 109.628 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.609 ' O ' ' O ' ' P' ' 37' ' ' GLY . 0.1 OUTLIER -98.17 101.95 12.81 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.965 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.609 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 28.42 172.77 0.0 OUTLIER Glycine 0 N--CA 1.468 0.78 0 C-N-CA 126.04 1.781 . . . . 0.0 116.491 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.03 -58.21 0.59 Allowed Glycine 0 CA--C 1.536 1.378 0 CA-C-N 113.45 -1.375 . . . . 0.0 112.678 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.514 HG23 HD11 ' D' ' 31' ' ' ILE . 72.7 t -105.58 131.4 55.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 CA-C-O 121.195 0.521 . . . . 0.0 111.091 -178.307 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' P' ' 39' ' ' VAL . 5.6 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.3 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -106.58 133.83 50.66 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -139.02 139.25 37.78 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.758 0.313 . . . . 0.0 110.549 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.499 ' H ' HG12 ' P' ' 12' ' ' VAL . 29.0 m -137.13 158.1 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 121.085 0.469 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.627 ' CE1' ' H ' ' P' ' 13' ' ' HIS . 44.8 m-70 -147.5 115.18 6.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.91 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.631 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 83.2 m-70 -131.89 160.38 35.89 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.5 ' OE1' HD11 ' Q' ' 17' ' ' LEU . 48.8 tt0 -90.09 159.18 16.94 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -140.68 92.39 2.51 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.836 178.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.5 HD11 ' OE1' ' Q' ' 15' ' ' GLN . 3.0 mt -115.01 115.12 26.33 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -119.49 107.77 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.397 -179.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.585 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 35.4 m-85 -110.1 101.95 10.7 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 104.311 -2.477 . . . . 0.0 104.311 175.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -123.45 133.37 54.06 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.139 -0.482 . . . . 0.0 112.286 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.518 ' HB2' ' OD1' ' O' ' 27' ' ' ASN . . . -138.09 154.65 49.23 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.528 ' O ' ' N ' ' Q' ' 24' ' ' VAL . 75.4 tt0 -72.58 163.05 28.66 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 65.7 t0 0.78 54.28 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 116.317 1.969 . . . . 0.0 116.317 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' Q' ' 22' ' ' GLU . 0.3 OUTLIER -66.56 137.17 25.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 176.425 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' Q' ' 26' ' ' SER . . . -118.04 -28.34 2.25 Favored Glycine 0 CA--C 1.542 1.745 0 CA-C-O 118.94 -0.922 . . . . 0.0 110.919 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 0.7 OUTLIER 91.11 116.81 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 118.895 1.348 . . . . 0.0 114.607 173.656 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -72.96 174.81 7.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.232 0.539 . . . . 0.0 111.086 177.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -53.84 -38.88 65.1 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.688 178.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.46 ' O ' HG13 ' K' ' 39' ' ' VAL . . . -109.04 69.21 0.21 Allowed Glycine 0 CA--C 1.537 1.438 0 N-CA-C 115.517 0.967 . . . . 0.0 115.517 -175.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.14 121.45 41.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.837 0.819 . . . . 0.0 109.151 178.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.663 HD12 HG23 ' K' ' 39' ' ' VAL . 86.1 mt -125.81 132.52 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 121.101 0.477 . . . . 0.0 111.646 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -122.53 121.93 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.521 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.69 108.16 1.15 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 15.7 mt -117.68 122.4 43.43 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -136.12 144.46 45.09 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.568 HG12 ' N ' ' Q' ' 37' ' ' GLY . 63.7 t -117.99 168.28 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.568 ' N ' HG12 ' Q' ' 36' ' ' VAL . . . -169.15 93.81 0.1 Allowed Glycine 0 C--N 1.314 -0.672 0 C-N-CA 118.915 -1.612 . . . . 0.0 112.932 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.0 -81.51 0.1 OUTLIER Glycine 0 CA--C 1.536 1.391 0 CA-C-N 118.74 1.27 . . . . 0.0 113.373 177.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -171.99 136.81 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 118.299 1.05 . . . . 0.0 110.293 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.094 -0.955 . . . . 0.0 110.634 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.06 142.03 38.85 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 110.315 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -131.18 148.71 52.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.946 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.481 ' H ' HG12 ' Q' ' 12' ' ' VAL . 2.6 p -129.51 135.85 60.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-O 121.434 0.635 . . . . 0.0 110.857 -179.695 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.605 ' HD1' ' HB2' ' Q' ' 13' ' ' HIS . 1.3 m-70 -139.9 133.13 29.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.631 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 83.7 t60 -153.55 161.56 42.1 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.453 ' O ' ' CD2' ' R' ' 14' ' ' HIS . 18.4 tt0 -90.14 158.87 17.06 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.306 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . 0.426 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 37.7 tttp -140.52 104.6 4.79 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.463 ' N ' HD23 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -118.58 114.05 22.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.477 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -117.36 107.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.028 0.442 . . . . 0.0 110.439 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.546 ' O ' ' CD2' ' R' ' 20' ' ' PHE . 16.2 m-85 -113.4 101.45 9.39 Favored 'General case' 0 N--CA 1.461 0.118 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . 0.546 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 63.0 m-85 -157.59 -177.75 6.82 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.695 1.236 . . . . 0.0 113.801 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.02 154.41 41.17 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.05 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -82.15 148.9 28.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.111 0.482 . . . . 0.0 111.7 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 58.14 48.14 13.37 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.753 179.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.501 HG12 ' N ' ' R' ' 25' ' ' GLY . 15.3 t -66.52 166.56 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.812 179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.501 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -175.76 15.96 0.04 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.5 p -83.11 140.82 32.41 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.652 ' O ' ' N ' ' R' ' 29' ' ' GLY . 71.5 m-80 -73.15 150.99 41.74 Favored 'General case' 0 C--O 1.223 -0.297 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.299 177.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -51.32 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.652 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.81 58.33 0.8 Allowed Glycine 0 CA--C 1.541 1.681 0 CA-C-N 118.611 0.641 . . . . 0.0 112.479 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -147.59 170.14 18.12 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 117.454 0.627 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 87.9 mt -119.89 123.95 71.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -121.57 130.22 74.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.665 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.08 111.44 1.16 Allowed Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.53 ' C ' HD23 ' R' ' 34' ' ' LEU . 8.0 tt -119.27 121.42 39.6 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 87.9 mtp -141.64 145.16 34.63 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.384 0.611 . . . . 0.0 112.117 -178.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.477 HG23 ' HB ' ' Q' ' 36' ' ' VAL . 2.2 p -144.01 143.4 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 119.526 -0.869 . . . . 0.0 111.623 177.487 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.03 -102.62 1.02 Allowed Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 174.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 23.23 73.5 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 112.758 -1.721 . . . . 0.0 115.48 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 96.8 t -49.39 134.4 7.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 117.008 0.404 . . . . 0.0 110.41 178.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.848 179.818 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 . . . . . 0 N--CA 1.466 0.34 0 CA-C-O 121.071 0.462 . . . . 0.0 111.461 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 m -136.22 157.57 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 178.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.427 ' C ' ' CG ' ' A' ' 14' ' ' HIS . 64.8 t-80 -145.32 124.06 12.59 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.712 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.529 ' CE1' ' H ' ' B' ' 14' ' ' HIS . 29.4 m-70 -151.47 165.97 32.55 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.133 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.9 tp60 -159.72 143.36 14.43 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.942 0.401 . . . . 0.0 110.053 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -80.44 120.37 24.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.352 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.8 mt -129.71 112.36 13.57 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.5 t -125.52 131.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.377 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -122.99 124.02 42.21 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.4 p90 -132.48 130.59 40.68 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.765 0.317 . . . . 0.0 110.382 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.19 132.69 40.05 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.068 0.461 . . . . 0.0 110.299 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 23' ' ' ASP . 13.2 pt-20 -83.87 -170.47 3.09 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.989 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 23' ' ' ASP . 21.3 p-10 . . . . . 0 N--CA 1.466 0.366 0 O-C-N 123.258 0.349 . . . . 0.0 111.15 -179.731 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.529 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 14.5 t-20 . . . . . 0 CA--C 1.529 0.151 0 CA-C-O 121.749 0.785 . . . . 0.0 112.129 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.598 ' NZ ' ' CE1' ' O' ' 13' ' ' HIS . 71.4 tttt -54.4 -38.23 65.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.491 178.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.52 71.42 0.2 Allowed Glycine 0 CA--C 1.536 1.395 0 CA-C-N 114.937 -1.029 . . . . 0.0 114.137 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.474 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -95.65 98.43 10.48 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-O 124.367 2.032 . . . . 0.0 111.036 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.437 HG22 HG12 ' B' ' 31' ' ' ILE . 6.0 pt -134.76 139.56 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 111.538 -2.574 . . . . 0.0 108.685 -179.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.425 HG21 HD13 ' A' ' 32' ' ' ILE . 43.4 mt -108.57 112.45 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.5 96.8 0.76 Allowed Glycine 0 N--CA 1.463 0.434 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.424 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 77.2 mt -147.08 169.87 18.35 Favored 'General case' 0 CA--C 1.506 -0.721 0 CA-C-O 122.622 1.201 . . . . 0.0 111.834 -176.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 23.5 mtp -124.68 119.42 28.92 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 113.403 -1.726 . . . . 0.0 108.894 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.551 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 2.5 t -108.95 111.9 38.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.52 -131.72 7.97 Favored Glycine 0 C--N 1.32 -0.356 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.6 -62.51 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.439 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 25.2 m -122.96 163.34 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.445 HG12 ' O ' ' A' ' 40' ' ' VAL . 99.0 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . 0.527 ' CE1' ' O ' ' C' ' 9' ' ' GLY . 97.2 m-85 -106.12 132.89 51.65 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.541 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.9 mp0 -110.31 124.0 50.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.465 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.452 HG22 HG12 ' C' ' 12' ' ' VAL . 53.7 t -124.73 128.15 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 41.2 t60 -131.44 122.24 25.91 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 120.941 0.4 . . . . 0.0 111.595 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.529 ' H ' ' CE1' ' A' ' 14' ' ' HIS . 74.2 t60 -157.78 168.36 27.43 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.593 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.435 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 83.6 mt-30 -154.77 141.81 19.29 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.277 0.56 . . . . 0.0 110.747 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -87.09 110.9 20.41 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.712 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.403 HD12 ' N ' ' B' ' 17' ' ' LEU . 6.0 mp -121.52 112.72 18.85 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -121.65 131.8 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.718 0.294 . . . . 0.0 110.676 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -122.96 116.27 23.29 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.364 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -119.11 126.07 50.76 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.7 136.65 31.05 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.842 1.052 . . . . 0.0 113.842 -178.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -111.53 117.52 33.23 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 176.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.525 ' OD2' ' ND2' ' B' ' 27' ' ' ASN . 65.5 t0 -107.0 46.31 0.94 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -177.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.648 HG12 ' N ' ' B' ' 25' ' ' GLY . 61.8 t -83.57 173.26 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.648 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 93.6 -28.17 10.71 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.905 177.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.812 ' O ' ' O ' ' B' ' 27' ' ' ASN . 78.0 p 178.61 -129.35 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.524 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.825 -178.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.812 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.1 t30 10.16 152.06 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.578 ' HB3' ' H ' ' C' ' 28' ' ' LYS . 94.2 mttt -169.55 30.17 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.736 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -99.32 78.88 0.51 Allowed Glycine 0 CA--C 1.538 1.469 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 178.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.616 ' H ' HD21 ' C' ' 27' ' ' ASN . . . -110.43 112.75 24.89 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 114.512 1.301 . . . . 0.0 114.512 -176.079 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.437 HG12 HG22 ' A' ' 31' ' ' ILE . 44.1 pt -140.59 143.78 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.958 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -113.56 122.45 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.153 0.502 . . . . 0.0 110.054 178.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 105.39 1.04 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 106.839 -2.504 . . . . 0.0 106.839 177.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.738 ' HB2' HD22 ' C' ' 34' ' ' LEU . 56.9 mt -137.19 145.24 43.46 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 122.818 1.294 . . . . 0.0 114.157 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -104.79 108.72 20.36 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 174.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -116.33 102.34 13.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.817 ' N ' HE22 ' D' ' 15' ' ' GLN . . . 111.75 164.19 17.5 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-O 122.015 0.786 . . . . 0.0 111.412 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.584 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 164.82 -55.95 0.27 Allowed Glycine 0 CA--C 1.542 1.741 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -178.208 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 t -119.76 134.4 63.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.63 HG11 ' ND1' ' E' ' 13' ' ' HIS . 81.3 t . . . . . 0 C--O 1.22 -0.447 0 CA-C-O 118.163 -0.923 . . . . 0.0 110.721 179.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . 0.527 ' O ' ' CE1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -151.1 158.86 44.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.616 0.246 . . . . 0.0 110.628 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -89.64 120.78 31.21 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.598 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.544 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 2.8 p -138.94 138.6 41.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.232 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.523 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 84.3 m-70 -146.65 135.17 22.02 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.777 0.322 . . . . 0.0 111.413 -179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' D' ' 14' ' ' HIS . 41.8 m-70 -151.26 172.03 16.5 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -126.65 141.81 51.74 Favored 'General case' 0 CA--C 1.522 -0.128 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 174.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.418 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.5 tttt -115.76 108.99 17.05 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 118.697 -0.668 . . . . 0.0 111.62 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.418 HD12 ' C ' ' C' ' 16' ' ' LYS . 8.4 mp -124.12 115.06 20.53 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 118.804 0.729 . . . . 0.0 109.056 175.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 81.2 t -109.32 122.16 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -111.56 103.46 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 15.7 t80 -113.67 125.12 53.79 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.226 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.81 133.35 33.9 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.786 0.803 . . . . 0.0 112.866 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -95.8 120.08 35.43 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.58 48.89 1.62 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -176.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.526 HG12 ' N ' ' C' ' 25' ' ' GLY . 73.3 t -71.89 161.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.526 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 109.35 -30.5 8.5 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 108.159 -1.976 . . . . 0.0 108.159 -176.489 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.518 ' HB3' ' O ' ' C' ' 25' ' ' GLY . 25.8 t 99.96 111.75 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.296 1.838 . . . . 0.0 110.657 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.616 HD21 ' H ' ' B' ' 30' ' ' ALA . 30.8 t30 -71.51 162.01 30.12 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.855 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.578 ' H ' ' HB3' ' B' ' 28' ' ' LYS . 28.2 ttpt -48.7 -39.36 24.34 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 176.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.49 69.15 0.04 OUTLIER Glycine 0 CA--C 1.542 1.762 0 CA-C-O 118.669 -1.073 . . . . 0.0 111.488 -173.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 130.17 41.41 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 120.14 1.97 . . . . 0.0 113.938 -173.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.494 ' CD1' ' O ' ' O' ' 38' ' ' GLY . 36.8 mt -139.18 141.24 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 113.738 -1.573 . . . . 0.0 114.284 -176.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.8 mt -117.78 118.52 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 175.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.953 ' O ' HD23 ' C' ' 34' ' ' LEU . . . -125.17 113.2 1.88 Allowed Glycine 0 N--CA 1.474 1.185 0 N-CA-C 108.846 -1.701 . . . . 0.0 108.846 178.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.953 HD23 ' O ' ' C' ' 33' ' ' GLY . 3.1 mt -138.89 151.8 47.26 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-O 123.51 1.624 . . . . 0.0 114.499 -177.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 88.1 mmm -105.31 107.1 17.91 Favored 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 111.073 -2.785 . . . . 0.0 104.359 174.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.72 ' HB ' HG12 ' D' ' 36' ' ' VAL . 2.9 t -111.29 143.06 21.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' OE1' ' E' ' 15' ' ' GLN . . . 166.85 -102.06 0.19 Allowed Glycine 0 C--N 1.302 -1.352 0 C-N-CA 119.507 -1.33 . . . . 0.0 111.007 -177.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.584 ' HA3' ' H ' ' B' ' 38' ' ' GLY . . . 51.31 70.77 0.78 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.308 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.742 HG13 ' O ' ' D' ' 39' ' ' VAL . 22.9 t -72.14 142.08 15.75 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.226 0 CA-C-O 120.801 0.334 . . . . 0.0 111.718 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.429 HG12 ' CD2' ' E' ' 13' ' ' HIS . 14.8 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.334 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.465 0.277 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.523 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 8.6 t60 -146.44 129.79 16.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.935 0.397 . . . . 0.0 110.728 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 2.9 p80 -152.31 161.58 42.4 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.102 178.312 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.817 HE22 ' N ' ' B' ' 37' ' ' GLY . 24.9 mt-30 -90.09 159.59 16.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.347 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.718 ' C ' HD12 ' D' ' 17' ' ' LEU . 48.1 mmtt -139.63 98.08 3.41 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.718 HD12 ' C ' ' D' ' 16' ' ' LYS . 5.4 mp -130.95 131.1 44.22 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.117 0.485 . . . . 0.0 110.059 178.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 62.9 t -121.53 124.85 72.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.52 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.7 m-85 -111.81 102.6 10.86 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 18.1 t80 -112.89 122.14 46.77 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.86 -0.155 . . . . 0.0 110.732 -178.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.28 134.31 30.84 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 122.106 0.955 . . . . 0.0 113.096 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.455 ' OE2' ' OE1' ' E' ' 22' ' ' GLU . 49.5 tp10 -101.2 126.8 47.95 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.594 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 52.5 p-10 -167.25 48.52 0.06 Allowed 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -72.44 160.97 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.11 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -30.06 8.81 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.094 -1.203 . . . . 0.0 110.094 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.512 ' CB ' ' OG ' ' C' ' 26' ' ' SER . 4.7 p -83.04 141.1 32.3 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 115.014 1.487 . . . . 0.0 115.014 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.671 ' O ' ' N ' ' D' ' 29' ' ' GLY . 34.1 p30 -73.21 -155.48 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.474 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -53.84 48.33 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 113.22 0.822 . . . . 0.0 113.22 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.671 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -100.19 56.01 0.84 Allowed Glycine 0 CA--C 1.542 1.75 0 CA-C-O 119.8 -0.445 . . . . 0.0 112.224 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -153.33 109.21 3.29 Favored 'General case' 0 C--O 1.24 0.594 0 CA-C-N 118.244 1.022 . . . . 0.0 110.277 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 56.2 mt -133.04 130.37 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 119.104 -1.038 . . . . 0.0 113.549 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.407 ' O ' ' N ' ' E' ' 33' ' ' GLY . 73.9 mt -112.62 108.32 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 176.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.07 111.6 3.79 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.498 ' CD1' ' CE1' ' F' ' 19' ' ' PHE . 92.2 mt -134.36 134.97 42.34 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -111.39 103.96 12.37 Favored 'General case' 0 N--CA 1.439 -1.021 0 CA-C-N 111.506 -2.588 . . . . 0.0 105.957 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.72 HG12 ' HB ' ' C' ' 36' ' ' VAL . 21.2 m -115.53 122.73 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.787 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.44 112.77 1.48 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.693 ' N ' HE21 ' F' ' 15' ' ' GLN . . . -120.61 62.4 0.5 Allowed Glycine 0 CA--C 1.539 1.559 0 N-CA-C 116.237 1.255 . . . . 0.0 116.237 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.742 ' O ' HG13 ' C' ' 39' ' ' VAL . 31.2 t -76.83 168.81 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 120.892 2.346 . . . . 0.0 108.403 176.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.65 ' N ' HG12 ' D' ' 39' ' ' VAL . 3.6 p . . . . . 0 C--O 1.222 -0.39 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.657 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -98.51 134.4 41.53 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -158.55 153.67 25.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.88 0.371 . . . . 0.0 111.497 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.54 112.6 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.63 ' ND1' HG11 ' B' ' 40' ' ' VAL . 1.7 t60 -127.27 118.67 24.68 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -177.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.458 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 22.9 p-80 -157.57 159.64 37.31 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.531 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.415 ' OE1' ' O ' ' C' ' 37' ' ' GLY . 1.3 mp0 -90.23 159.02 16.92 Favored 'General case' 0 C--O 1.224 -0.242 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.764 ' C ' HD12 ' E' ' 17' ' ' LEU . 13.0 tttm -140.96 101.13 3.98 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.402 176.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.764 HD12 ' C ' ' E' ' 16' ' ' LYS . 6.7 mp -130.44 127.89 40.2 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.7 t -117.71 126.21 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.579 ' N ' ' CD1' ' E' ' 19' ' ' PHE . 0.2 OUTLIER -113.72 103.74 11.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 -179.454 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 22.3 t80 -113.21 118.53 34.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 121.443 -0.103 . . . . 0.0 111.138 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.57 138.33 36.13 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 119.668 -0.813 . . . . 0.0 112.256 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE2' ' D' ' 22' ' ' GLU . 88.6 mt-10 -101.51 119.77 39.28 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.37 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.875 ' O ' HG13 ' E' ' 24' ' ' VAL . 16.6 t0 -119.24 -49.89 2.37 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -179.373 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.875 HG13 ' O ' ' E' ' 23' ' ' ASP . 0.1 OUTLIER 163.81 -166.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 179.367 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.36 -35.6 91.89 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.153 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 22.1 t -155.82 112.63 3.19 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 30' ' ' ALA . 20.0 p30 -53.01 170.22 0.08 Allowed 'General case' 0 N--CA 1.464 0.231 0 C-N-CA 117.114 -1.835 . . . . 0.0 108.626 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -61.24 -39.05 88.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.224 -0.991 . . . . 0.0 112.238 175.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.474 ' N ' ' OD1' ' E' ' 27' ' ' ASN . . . -178.97 74.97 0.07 OUTLIER Glycine 0 CA--C 1.544 1.856 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.076 -177.256 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.658 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -80.64 163.65 23.46 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.537 1.668 . . . . 0.0 111.669 -178.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.413 HD11 ' HB ' ' Q' ' 39' ' ' VAL . 79.8 mt -131.16 127.55 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.537 HD11 ' CD2' ' F' ' 19' ' ' PHE . 3.2 tt -123.14 109.33 23.28 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.562 ' HA2' ' H ' ' F' ' 33' ' ' GLY . . . -80.08 116.46 4.27 Favored Glycine 0 C--O 1.241 0.568 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' F' ' 34' ' ' LEU . 38.8 tp -110.14 104.21 13.03 Favored 'General case' 0 C--O 1.267 1.982 0 CA-C-N 120.096 1.948 . . . . 0.0 110.767 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.762 ' HA ' ' HA ' ' F' ' 35' ' ' MET . 29.0 tpp -115.8 110.48 19.13 Favored 'General case' 0 C--N 1.351 0.648 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.558 HG12 ' N ' ' E' ' 37' ' ' GLY . 39.5 t -84.89 172.64 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.374 1.655 0 C-N-CA 117.431 -1.708 . . . . 0.0 107.157 177.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.558 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -176.75 92.99 0.09 OUTLIER Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.359 -1.877 . . . . 0.0 111.672 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.463 ' C ' HG22 ' D' ' 39' ' ' VAL . . . 119.13 85.49 0.98 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-N 119.435 1.618 . . . . 0.0 114.009 178.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' E' ' 38' ' ' GLY . 1.8 p . . . . . 0 N--CA 1.484 1.246 0 N-CA-C 113.87 1.063 . . . . 0.0 113.87 179.537 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 . . . . . 0 CA--C 1.521 -0.159 0 N-CA-C 110.015 -0.365 . . . . 0.0 110.015 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 27.1 m -138.22 157.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.514 0.673 . . . . 0.0 112.225 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -146.07 98.18 3.06 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.059 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.458 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 97.4 m-70 -151.9 168.08 26.28 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.693 HE21 ' N ' ' D' ' 38' ' ' GLY . 66.0 mt-30 -89.75 158.19 17.64 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . 0.491 ' C ' HD22 ' F' ' 17' ' ' LEU . 64.5 mttp -140.23 96.08 2.99 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.122 0.487 . . . . 0.0 109.889 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.877 HD22 ' N ' ' F' ' 17' ' ' LEU . 0.3 OUTLIER -118.82 112.06 19.23 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.928 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 14.6 t -101.28 110.96 29.46 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.728 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.537 ' CD2' HD11 ' E' ' 32' ' ' ILE . 15.6 m-85 -104.3 101.33 11.04 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.401 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 61.4 t80 -126.02 125.55 42.84 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 122.236 1.017 . . . . 0.0 111.762 -178.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.37 132.04 51.65 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' E' ' 24' ' ' VAL . 45.9 tp10 -62.17 103.3 0.37 Allowed 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 118.586 -1.246 . . . . 0.0 108.011 -178.062 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' E' ' 24' ' ' VAL . 8.3 m-20 . . . . . 0 N--CA 1.454 -0.258 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.071 -178.078 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.658 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.462 0.174 0 CA-C-O 121.222 0.534 . . . . 0.0 111.135 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 5.4 mm -113.53 135.3 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.137 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' E' ' 32' ' ' ILE . 82.9 mt -103.91 117.41 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.95 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . 0.562 ' H ' ' HA2' ' E' ' 33' ' ' GLY . . . -58.4 -154.61 0.01 OUTLIER Glycine 0 C--O 1.209 -1.46 0 CA-C-N 118.65 0.659 . . . . 0.0 113.233 -178.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.633 ' O ' ' HA ' ' E' ' 35' ' ' MET . 74.4 mt -99.47 125.79 45.27 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 178.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.762 ' HA ' ' HA ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -103.33 83.53 2.19 Favored 'General case' 0 C--O 1.171 -3.045 0 C-N-CA 130.117 3.367 . . . . 0.0 114.197 179.508 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.575 HG23 ' O ' ' F' ' 36' ' ' VAL . 2.7 m -92.77 115.21 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 117.785 -3.072 . . . . 0.0 112.713 175.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -117.19 122.51 5.48 Favored Glycine 0 CA--C 1.516 0.12 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 178.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.36 -61.61 7.27 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.046 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 37.2 t -147.88 137.77 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.171 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 178.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.135 -0.936 . . . . 0.0 110.34 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.417 ' O ' HG23 ' G' ' 12' ' ' VAL . 4.4 m . . . . . 0 N--CA 1.467 0.384 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -104.74 121.68 44.12 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.821 0.343 . . . . 0.0 110.918 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 31.0 t60 -155.03 165.9 35.29 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.763 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.524 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 14.6 pt20 -157.06 142.22 17.18 Favored 'General case' 0 C--N 1.339 0.111 0 CA-C-O 121.174 0.512 . . . . 0.0 111.144 178.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.413 ' H ' ' HG2' ' G' ' 16' ' ' LYS . 51.5 pttt -86.3 122.03 29.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.307 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.8 mt -127.41 118.07 23.39 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -133.73 133.44 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-O 120.697 0.284 . . . . 0.0 111.585 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -139.14 142.61 38.02 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.896 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -152.0 151.59 31.36 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 119.726 -0.79 . . . . 0.0 112.781 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.51 129.26 50.95 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.036 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -82.19 -173.58 4.62 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -176.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.416 ' OD2' ' OE2' ' H' ' 22' ' ' GLU . 0.7 OUTLIER . . . . . 0 N--CA 1.469 0.507 0 CA-C-N 112.877 -1.965 . . . . 0.0 115.771 -178.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 . . . . . 0 N--CA 1.466 0.353 0 N-CA-C 110.501 -0.185 . . . . 0.0 110.501 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -78.62 40.53 0.38 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.75 78.57 0.56 Allowed Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.729 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.66 59.97 4.41 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-N 119.814 1.807 . . . . 0.0 113.456 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 4.5 pt -147.99 123.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 177.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 87.8 mt -109.23 113.67 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.222 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.32 99.81 0.98 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 105.688 -2.965 . . . . 0.0 105.688 176.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.445 ' O ' HD23 ' H' ' 34' ' ' LEU . 43.0 tp -157.92 154.8 28.44 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 118.007 -1.477 . . . . 0.0 113.468 -175.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 55.0 tpp -102.1 119.89 39.54 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 113.007 -1.906 . . . . 0.0 107.07 177.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 47.2 t -124.2 112.17 31.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.221 0.534 . . . . 0.0 110.798 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.06 -131.89 10.19 Favored Glycine 0 C--N 1.316 -0.567 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . 115.5 -61.35 0.38 Allowed Glycine 0 CA--C 1.537 1.445 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.55 HG22 ' N ' ' G' ' 40' ' ' VAL . 2.4 p -127.78 164.76 28.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.55 ' N ' HG22 ' G' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.605 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' N ' ' H' ' 11' ' ' GLU . 60.7 t80 -148.73 179.88 7.5 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.284 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . 0.625 ' N ' ' CD2' ' H' ' 10' ' ' TYR . 80.9 mm-40 -66.96 126.93 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.47 126.62 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.621 ' CE1' ' CD2' ' I' ' 13' ' ' HIS . 15.7 p-80 -151.51 139.23 19.77 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.491 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.581 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 22.6 m-70 -145.33 160.7 41.13 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-O 121.046 0.451 . . . . 0.0 110.134 177.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.548 ' CD ' HE22 ' I' ' 15' ' ' GLN . 57.8 tt0 -90.2 160.44 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -139.84 102.74 4.49 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.561 ' C ' HD23 ' H' ' 17' ' ' LEU . 7.3 tt -126.35 124.07 39.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.24 0.543 . . . . 0.0 111.191 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.478 ' N ' HD23 ' H' ' 17' ' ' LEU . 65.4 t -122.0 130.88 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.301 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -125.95 113.12 16.75 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.058 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -114.47 120.25 39.63 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.68 126.23 41.55 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.811 0.815 . . . . 0.0 113.187 -178.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.416 ' OE2' ' OD2' ' G' ' 23' ' ' ASP . 80.0 tt0 -97.62 113.06 24.71 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 107.07 -1.455 . . . . 0.0 107.07 177.02 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 57.5 t0 -131.12 52.06 2.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.295 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p -74.69 142.97 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 C-N-CA 119.944 -0.703 . . . . 0.0 109.577 -177.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.43 38.37 3.75 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.387 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 73.39 120.04 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.784 -0.208 . . . . 0.0 111.162 179.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.439 ' CG ' ' OD2' ' I' ' 23' ' ' ASP . 8.2 m-20 -83.24 162.0 21.32 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.174 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -47.04 -39.53 13.01 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.683 177.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.04 69.15 0.02 OUTLIER Glycine 0 CA--C 1.537 1.448 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.55 -176.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -51.64 100.73 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 118.544 1.172 . . . . 0.0 114.045 -176.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.523 HG22 ' HB ' ' I' ' 31' ' ' ILE . 43.5 pt -137.86 139.27 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.671 178.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.486 ' CG2' HD12 ' H' ' 34' ' ' LEU . 86.9 mt -106.89 109.11 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.17 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.071 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.98 96.86 1.13 Allowed Glycine 0 CA--C 1.519 0.313 0 N-CA-C 105.506 -3.037 . . . . 0.0 105.506 176.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.486 HD12 ' CG2' ' H' ' 32' ' ' ILE . 67.4 mt -135.23 149.47 49.87 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-O 123.48 1.609 . . . . 0.0 114.129 -175.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -119.55 106.71 12.47 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 111.795 -2.457 . . . . 0.0 104.447 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 79.3 t -106.52 102.78 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.612 0.72 . . . . 0.0 110.521 -177.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.462 ' HA3' ' H ' ' G' ' 38' ' ' GLY . . . -31.1 152.44 0.01 OUTLIER Glycine 0 N--CA 1.469 0.859 0 CA-C-N 114.56 -1.2 . . . . 0.0 113.723 -178.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . -88.44 -57.46 1.86 Allowed Glycine 0 N--CA 1.47 0.965 0 CA-C-N 114.98 -0.61 . . . . 0.0 113.338 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 40' ' ' VAL . 60.7 t -24.28 146.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 39' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.217 -0.622 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.869 -179.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . 0.519 ' O ' ' CD2' ' H' ' 10' ' ' TYR . 90.8 m-85 -97.63 129.81 44.7 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.516 ' O ' ' NE2' ' J' ' 13' ' ' HIS . 95.8 mt-10 -141.13 143.46 34.29 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.763 0.316 . . . . 0.0 111.335 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.518 HG22 ' H ' ' J' ' 12' ' ' VAL . 18.9 t -143.55 91.55 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.381 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.621 ' CD2' ' CE1' ' H' ' 13' ' ' HIS . 3.9 m170 -132.74 133.63 43.72 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 116.967 -0.106 . . . . 0.0 111.187 -178.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.757 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 11.3 m80 -145.74 160.7 41.35 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 178.383 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.548 HE22 ' CD ' ' H' ' 15' ' ' GLN . 69.1 tp60 -90.17 157.58 17.66 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 174.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -141.91 102.28 4.11 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 119.971 -0.691 . . . . 0.0 110.648 176.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 25.5 mt -120.51 118.41 30.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.652 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -111.8 114.77 48.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 177.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -108.53 105.25 14.81 Favored 'General case' 0 CA--C 1.539 0.533 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -116.17 132.63 56.61 Favored 'General case' 0 N--CA 1.479 1.02 0 O-C-N 122.212 -0.305 . . . . 0.0 111.091 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.22 149.65 32.31 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -178.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -105.59 163.36 12.73 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 113.966 -1.47 . . . . 0.0 108.124 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.474 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 34.6 t0 -174.47 47.08 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 -176.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.416 ' N ' ' OD2' ' J' ' 23' ' ' ASP . 0.1 OUTLIER -91.09 170.56 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 122.381 1.086 . . . . 0.0 110.308 -175.583 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.15 27.43 62.08 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.984 -176.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 1.7 t 165.78 146.87 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -53.02 138.12 31.38 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 119.126 -1.03 . . . . 0.0 108.844 178.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.6 ' HB2' HG11 ' J' ' 24' ' ' VAL . 31.2 tttm -62.35 -49.77 74.23 Favored 'General case' 0 CA--C 1.53 0.193 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 100.82 57.47 0.87 Allowed Glycine 0 CA--C 1.544 1.854 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.584 ' HB3' ' ND2' ' J' ' 27' ' ' ASN . . . -102.03 115.55 30.79 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 120.12 1.96 . . . . 0.0 116.198 -172.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.523 ' HB ' HG22 ' H' ' 31' ' ' ILE . 97.1 mt -129.89 120.98 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.371 176.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.627 HG22 HD21 ' J' ' 34' ' ' LEU . 28.9 mt -106.1 114.08 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.337 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.36 109.05 1.9 Allowed Glycine 0 C--O 1.236 0.271 0 N-CA-C 106.151 -2.78 . . . . 0.0 106.151 176.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.483 HD12 ' O ' ' H' ' 34' ' ' LEU . 0.1 OUTLIER -161.31 150.13 16.11 Favored 'General case' 0 CA--C 1.504 -0.793 0 C-N-CA 117.445 -1.702 . . . . 0.0 112.905 -175.63 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.443 ' N ' HD12 ' I' ' 34' ' ' LEU . 29.9 mtp -116.41 117.49 30.07 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-N 112.714 -2.039 . . . . 0.0 107.716 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.551 HG12 ' NE2' ' K' ' 15' ' ' GLN . 1.5 t -101.11 102.61 13.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.77 153.49 0.01 OUTLIER Glycine 0 N--CA 1.474 1.168 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.6 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.752 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -117.6 56.16 0.55 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 118.843 2.297 . . . . 0.0 118.843 -175.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.463 HG12 HG23 ' I' ' 40' ' ' VAL . 61.5 t -101.83 129.06 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 CA-C-N 119.886 1.843 . . . . 0.0 110.234 177.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.463 HG23 HG12 ' I' ' 39' ' ' VAL . 47.3 t . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.489 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -147.8 157.59 43.61 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.796 0.332 . . . . 0.0 110.283 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -151.16 114.92 4.93 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.479 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.518 ' H ' HG22 ' I' ' 12' ' ' VAL . 79.2 t -128.74 133.33 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.814 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' O ' ' I' ' 11' ' ' GLU . 48.9 m-70 -141.19 100.33 3.78 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.484 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.757 ' H ' ' CD2' ' I' ' 14' ' ' HIS . 45.4 p-80 -149.22 161.08 42.72 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.362 177.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -90.16 159.79 16.58 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -139.78 103.63 4.71 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.629 179.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -128.34 118.42 23.18 Favored 'General case' 0 C--O 1.239 0.544 0 CA-C-O 121.868 0.842 . . . . 0.0 109.391 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 88.1 t -108.93 111.13 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.51 0 CA-C-N 114.141 -1.39 . . . . 0.0 109.17 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.564 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 16.5 m-85 -108.63 103.95 13.16 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.42 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 3.9 m-85 -120.05 130.72 54.82 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -177.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.4 120.07 16.16 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 177.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.51 ' O ' ' OD1' ' J' ' 23' ' ' ASP . 87.3 mt-10 -145.0 141.36 28.87 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -176.268 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.575 ' CG ' ' H ' ' J' ' 24' ' ' VAL . 5.3 p-10 147.17 -69.39 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.938 0 O-C-N 125.076 1.485 . . . . 0.0 110.125 176.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.831 HG22 ' H ' ' J' ' 25' ' ' GLY . 7.6 p -54.97 -122.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.499 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.831 ' H ' HG22 ' J' ' 24' ' ' VAL . . . 140.31 -35.17 1.92 Allowed Glycine 0 CA--C 1.528 0.866 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.661 177.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 16.1 t -80.45 118.66 22.27 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 121.041 2.42 . . . . 0.0 106.415 171.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.584 ' ND2' ' HB3' ' I' ' 30' ' ' ALA . 8.0 m-20 -91.44 160.28 15.53 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 121.977 2.171 . . . . 0.0 111.038 176.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -46.31 -39.93 10.93 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-O 122.729 1.252 . . . . 0.0 109.541 173.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.94 68.52 0.02 OUTLIER Glycine 0 CA--C 1.54 1.648 0 CA-C-N 112.401 -2.181 . . . . 0.0 107.954 -176.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.716 ' O ' ' HB1' ' K' ' 30' ' ' ALA . . . -51.59 138.2 23.13 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 116.331 1.974 . . . . 0.0 116.331 -173.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.734 HD11 ' HB ' ' D' ' 39' ' ' VAL . 82.6 mt -135.14 126.57 46.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 113.327 -1.76 . . . . 0.0 112.228 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -108.95 109.72 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.02 99.73 0.99 Allowed Glycine 0 N--CA 1.462 0.433 0 N-CA-C 106.404 -2.678 . . . . 0.0 106.404 178.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.627 HD21 HG22 ' I' ' 32' ' ' ILE . 96.9 mt -134.94 134.63 40.8 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -175.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 45.7 tpp -104.51 107.52 18.49 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 103.936 -2.616 . . . . 0.0 103.936 174.1 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.59 ' O ' HG22 ' K' ' 36' ' ' VAL . 4.2 t -120.21 113.14 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 122.445 1.117 . . . . 0.0 110.745 -178.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -73.04 -122.39 0.08 OUTLIER Glycine 0 C--N 1.313 -0.733 0 CA-C-N 112.876 -1.966 . . . . 0.0 110.732 175.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.752 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . 71.52 60.77 4.18 Favored Glycine 0 C--N 1.318 -0.446 0 CA-C-N 111.628 -2.286 . . . . 0.0 115.791 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.961 HG22 HD11 ' P' ' 31' ' ' ILE . 7.3 m -81.75 129.35 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 9.3 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.414 179.976 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -111.83 135.18 52.79 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -136.29 144.78 44.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.748 0.308 . . . . 0.0 110.599 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 99.2 t -128.55 130.18 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 39.0 m-70 -136.19 113.73 10.91 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.079 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.497 ' O ' ' CB ' ' J' ' 14' ' ' HIS . 14.8 p-80 -152.84 162.38 41.36 Favored 'General case' 0 C--O 1.217 -0.612 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.904 178.531 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.551 ' NE2' HG12 ' I' ' 36' ' ' VAL . 10.3 tt0 -90.07 158.66 17.21 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.764 -1.939 . . . . 0.0 105.764 175.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.482 ' C ' HD13 ' K' ' 17' ' ' LEU . 34.5 tttt -140.7 96.52 3.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 119.21 0.914 . . . . 0.0 110.825 178.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.885 HD22 ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -120.87 110.58 16.49 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.582 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.431 HG13 ' O ' ' K' ' 18' ' ' VAL . 7.7 p -114.5 114.25 46.08 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.12 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.564 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 28.7 m-85 -107.23 104.22 13.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.567 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 25.7 t80 -112.67 123.56 50.58 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.128 -178.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -151.87 139.12 19.32 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 118.72 -1.192 . . . . 0.0 114.126 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.419 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 94.2 mt-10 -79.59 109.46 14.0 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.523 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . 49.3 t0 -146.31 46.71 1.22 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -177.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.502 HG22 ' N ' ' K' ' 25' ' ' GLY . 10.9 p -98.65 161.41 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 175.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.502 ' N ' HG22 ' K' ' 24' ' ' VAL . . . 76.22 27.68 61.48 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.281 176.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.469 ' CB ' ' H ' ' J' ' 27' ' ' ASN . 24.9 t -83.9 -120.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.445 -0.902 . . . . 0.0 113.305 -175.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 26.7 t-20 -93.27 163.01 13.78 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 122.597 1.189 . . . . 0.0 113.493 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 68.7 mttm -41.97 -37.91 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 112.491 -2.14 . . . . 0.0 111.185 176.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.19 71.97 0.22 Allowed Glycine 0 CA--C 1.54 1.646 0 CA-C-N 115.744 -0.662 . . . . 0.0 114.253 -172.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.716 ' HB1' ' O ' ' J' ' 30' ' ' ALA . . . -82.02 173.2 12.4 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 18.0 tt -148.23 160.23 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.185 0 N-CA-C 116.17 1.915 . . . . 0.0 116.17 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.77 125.58 61.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 113.572 -1.649 . . . . 0.0 109.711 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.3 123.22 4.3 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.661 HD23 ' C ' ' K' ' 34' ' ' LEU . 2.3 tt -130.26 130.57 44.74 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-O 120.97 0.414 . . . . 0.0 110.496 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 5.6 mtp -124.84 130.17 51.86 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.248 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.59 HG22 ' O ' ' J' ' 36' ' ' VAL . 50.6 t -124.76 158.69 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.159 0.504 . . . . 0.0 110.667 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.442 ' N ' HG12 ' K' ' 36' ' ' VAL . . . -63.65 -103.08 0.01 OUTLIER Glycine 0 CA--C 1.53 0.997 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.32 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -135.89 -74.36 0.07 OUTLIER Glycine 0 CA--C 1.538 1.485 0 C-N-CA 121.472 -0.394 . . . . 0.0 113.249 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 59.6 t . . . . . 0 N--CA 1.466 0.332 0 CA-C-O 120.715 0.293 . . . . 0.0 111.202 -178.835 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.615 0.245 . . . . 0.0 110.36 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.81 114.68 47.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.895 0.379 . . . . 0.0 110.615 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.576 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -147.16 105.77 3.81 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.211 179.814 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.484 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 79.2 m80 -151.49 166.94 29.56 Favored 'General case' 0 C--O 1.221 -0.429 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 38.6 tt0 -89.78 158.46 17.49 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.02 102.38 4.38 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.247 -0.581 . . . . 0.0 111.822 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.707 ' N ' HD23 ' L' ' 17' ' ' LEU . 0.1 OUTLIER -116.61 108.09 15.52 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 176.537 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -106.98 111.14 34.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.57 -179.2 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -105.56 101.07 10.61 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.567 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 30.9 t80 -125.71 131.67 52.53 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 121.203 0.525 . . . . 0.0 110.756 -178.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -140.29 157.15 46.01 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.147 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.439 ' C ' ' O ' ' L' ' 21' ' ' ALA . 80.2 tt0 -31.1 129.54 0.13 Allowed 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 122.029 0.918 . . . . 0.0 112.48 -174.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.434 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 66.9 t0 -109.84 47.34 0.95 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 113.496 -1.684 . . . . 0.0 112.986 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.48 ' CG2' HG21 ' K' ' 24' ' ' VAL . 3.1 m -63.02 -167.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.349 -178.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.54 27.83 9.13 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.219 -0.446 . . . . 0.0 113.616 -175.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 48.0 t -153.67 120.28 5.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.424 0.63 . . . . 0.0 109.935 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 p30 -40.7 167.0 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.135 0 CA-C-N 114.978 -1.01 . . . . 0.0 112.187 -178.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.523 ' NZ ' ' O ' ' K' ' 23' ' ' ASP . 63.9 tttp -80.22 -50.0 10.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.199 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.85 50.59 3.05 Favored Glycine 0 CA--C 1.543 1.84 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.707 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -130.57 -169.15 2.09 Favored 'General case' 0 C--N 1.341 0.224 0 CA-C-O 121.354 0.597 . . . . 0.0 110.597 -178.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -118.64 138.55 48.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.786 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -122.15 128.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.64 122.52 3.42 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 111.635 -0.586 . . . . 0.0 111.635 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 57.6 mt -117.99 125.42 50.36 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -132.81 127.65 35.0 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.619 HG22 ' N ' ' L' ' 37' ' ' GLY . 2.6 p -140.46 171.72 12.75 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.619 ' N ' HG22 ' L' ' 36' ' ' VAL . . . -168.12 94.49 0.11 Allowed Glycine 0 C--N 1.311 -0.852 0 C-N-CA 118.536 -1.792 . . . . 0.0 112.036 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.5 -81.41 0.11 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.747 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' K' ' 38' ' ' GLY . 38.8 t . . . . . 0 N--CA 1.463 0.217 0 CA-C-O 121.105 0.479 . . . . 0.0 110.359 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.464 0.258 0 CA-C-O 120.818 0.342 . . . . 0.0 110.356 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . 0.485 ' CG1' ' H ' ' N' ' 12' ' ' VAL . 2.4 p -123.0 131.82 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.286 0.565 . . . . 0.0 110.101 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . 0.456 ' CG ' ' N ' ' M' ' 14' ' ' HIS . 76.4 t60 -72.65 164.08 27.05 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.309 -178.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.588 ' ND1' ' N ' ' M' ' 14' ' ' HIS . 1.2 m-70 -99.13 166.17 11.37 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -89.8 159.82 16.82 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.54 107.98 5.85 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.1 mt -129.76 114.92 16.56 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 121.098 0.475 . . . . 0.0 110.227 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 54.3 t -125.23 132.17 71.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.031 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 t80 -136.28 127.41 28.0 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.45 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -131.48 146.32 52.19 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.16 128.29 23.88 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 121.741 0.781 . . . . 0.0 112.743 -178.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -92.17 -149.25 0.24 Allowed 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -46.62 -60.08 2.61 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.613 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.618 HG12 ' N ' ' M' ' 25' ' ' GLY . 47.9 t -84.76 171.56 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 175.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . 0.618 ' N ' HG12 ' M' ' 24' ' ' VAL . . . 94.03 -29.98 8.1 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 176.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 7.3 p -84.23 139.98 31.99 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.146 -1.527 . . . . 0.0 113.575 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -73.03 179.5 3.74 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 177.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CG ' ' N' ' 28' ' ' LYS . 98.4 mttt -49.77 -37.58 30.4 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 117.943 -1.503 . . . . 0.0 110.548 -175.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.05 -78.38 0.06 OUTLIER Glycine 0 CA--C 1.53 1.023 0 C-N-CA 118.89 -1.624 . . . . 0.0 113.777 174.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' N' ' 30' ' ' ALA . . . -147.35 81.63 1.53 Allowed 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 117.819 0.81 . . . . 0.0 112.942 178.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.639 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -123.34 105.39 15.69 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . 0.437 HG22 HD21 ' N' ' 34' ' ' LEU . 2.4 mt -119.11 111.87 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 C-N-CA 119.659 -0.816 . . . . 0.0 111.452 -178.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.41 105.61 1.16 Allowed Glycine 0 N--CA 1.46 0.258 0 N-CA-C 104.153 -3.579 . . . . 0.0 104.153 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . 0.412 ' HG ' ' N ' ' M' ' 35' ' ' MET . 45.6 tp -153.71 158.17 40.6 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.579 -173.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . 0.412 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 0.7 OUTLIER -104.88 110.18 22.45 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 112.736 -2.029 . . . . 0.0 106.991 177.182 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.62 131.24 70.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.12 -111.17 3.89 Favored Glycine 0 C--N 1.318 -0.466 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.498 ' O ' HG23 ' N' ' 39' ' ' VAL . . . 75.12 -73.76 1.5 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.403 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 17.6 m -95.69 -176.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.175 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.463 HG12 ' NZ ' ' C' ' 28' ' ' LYS . 1.3 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.607 178.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . 0.487 ' CD1' ' O ' ' O' ' 9' ' ' GLY . 97.9 m-85 -108.0 139.7 42.25 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.26 124.14 51.8 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.957 0.408 . . . . 0.0 111.023 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.485 ' H ' ' CG1' ' M' ' 12' ' ' VAL . 3.4 t -137.88 97.14 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.745 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.519 ' ND1' ' ND1' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -151.5 151.07 31.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 121.108 -0.237 . . . . 0.0 110.675 179.524 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -124.79 162.58 23.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.047 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -89.88 158.79 17.28 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . 0.748 ' C ' HD12 ' N' ' 17' ' ' LEU . 98.8 mttt -140.53 99.94 3.75 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.748 HD12 ' C ' ' N' ' 16' ' ' LYS . 10.9 mp -124.04 119.3 29.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -123.01 128.34 75.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.648 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -123.76 123.95 41.64 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.897 179.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -129.18 123.14 31.31 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.805 0.336 . . . . 0.0 110.283 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 132.22 50.38 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.424 ' O ' ' CB ' ' N' ' 23' ' ' ASP . 83.1 tt0 -157.38 151.46 24.65 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.424 ' CB ' ' O ' ' N' ' 22' ' ' GLU . 9.5 m-20 92.29 46.92 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 113.603 -1.635 . . . . 0.0 115.185 176.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 24.2 m -101.52 158.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 -37.5 94.76 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.582 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.579 ' O ' ' O ' ' N' ' 27' ' ' ASN . 86.4 p -162.47 117.17 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 117.093 -1.432 . . . . 0.0 107.165 177.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.579 ' O ' ' O ' ' N' ' 26' ' ' SER . 11.6 t-20 -23.45 151.2 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 120.332 1.424 . . . . 0.0 111.908 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.491 ' O ' HG23 ' G' ' 39' ' ' VAL . 73.8 mmtt -107.83 47.87 0.87 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 115.999 -1.953 . . . . 0.0 115.264 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 61.8 0.52 Allowed Glycine 0 N--CA 1.489 2.202 0 CA-C-N 124.083 3.129 . . . . 0.0 114.067 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' M' ' 30' ' ' ALA . . . -88.31 98.95 11.88 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 121.076 2.438 . . . . 0.0 111.476 -174.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.455 HG23 ' O ' ' N' ' 31' ' ' ILE . 18.9 tt -134.61 129.33 52.12 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-N 110.856 -2.884 . . . . 0.0 110.2 -177.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.57 HD13 ' CD1' ' P' ' 19' ' ' PHE . 95.8 mt -113.04 110.87 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.78 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.544 ' O ' HD22 ' N' ' 34' ' ' LEU . . . -111.25 93.51 0.72 Allowed Glycine 0 N--CA 1.467 0.722 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 175.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.544 HD22 ' O ' ' N' ' 33' ' ' GLY . 1.3 mm? -125.12 133.32 52.89 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.018 1.39 . . . . 0.0 112.269 -174.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 2.7 mtp -103.55 106.06 16.47 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 176.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 1.008 HG21 HD11 ' P' ' 17' ' ' LEU . 2.5 p -127.9 123.11 60.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.246 -178.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 149.63 -113.2 0.59 Allowed Glycine 0 C--N 1.311 -0.818 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.473 ' O ' HG23 ' O' ' 39' ' ' VAL . . . 70.48 -72.58 0.62 Allowed Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.505 HG12 ' N ' ' N' ' 40' ' ' VAL . 45.1 t -123.36 163.96 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 178.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.505 ' N ' HG12 ' N' ' 39' ' ' VAL . 18.6 m . . . . . 0 N--CA 1.471 0.579 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.715 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' N' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -114.28 147.19 39.42 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.711 0.291 . . . . 0.0 110.293 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -87.49 109.88 19.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.09 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.479 HG13 ' C ' ' P' ' 12' ' ' VAL . 51.5 t -129.62 123.86 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.505 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.598 ' CE1' ' NZ ' ' A' ' 28' ' ' LYS . 7.3 m-70 -137.57 150.42 47.46 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.598 ' CD2' ' CE1' ' P' ' 14' ' ' HIS . 4.7 m80 -136.86 157.45 46.73 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.169 178.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -86.3 157.46 19.91 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 175.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -160.25 101.76 1.4 Allowed 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.255 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 3.2 mt -132.47 122.73 25.37 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.335 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 89.2 t -113.56 113.27 43.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.941 178.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -108.4 102.54 11.63 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -113.33 125.03 53.83 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -177.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.15 125.91 40.05 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -124.51 178.93 5.16 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 52.44 58.94 4.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 113.19 -1.823 . . . . 0.0 112.05 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.684 HG11 HG13 ' P' ' 24' ' ' VAL . 63.2 t -78.25 123.0 34.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.911 -1.041 . . . . 0.0 109.214 175.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.512 ' H ' ' HA ' ' N' ' 26' ' ' SER . . . -90.49 -38.54 6.21 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.577 -177.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' O' ' 27' ' ' ASN . 46.8 t -161.97 116.51 1.91 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 118.454 1.127 . . . . 0.0 111.907 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' O' ' 26' ' ' SER . 57.2 p30 -24.12 163.73 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.358 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -152.16 -22.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.943 178.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.2 97.32 2.43 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.19 140.94 29.12 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-O 121.776 0.798 . . . . 0.0 111.974 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.43 HD12 HG22 ' I' ' 39' ' ' VAL . 14.9 mt -143.41 135.77 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.19 -0.914 . . . . 0.0 113.064 -179.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.594 HD13 ' CD2' ' Q' ' 19' ' ' PHE . 82.3 mt -114.38 112.08 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 176.076 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.01 109.48 2.34 Favored Glycine 0 C--O 1.24 0.505 0 N-CA-C 105.575 -3.01 . . . . 0.0 105.575 176.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.437 ' CD2' HG12 ' N' ' 36' ' ' VAL . 0.2 OUTLIER -144.91 142.34 29.79 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 123.019 1.39 . . . . 0.0 114.038 -175.263 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 94.8 mmm -103.75 110.57 22.72 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 112.133 -2.303 . . . . 0.0 105.366 176.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.497 HG12 ' NE2' ' Q' ' 15' ' ' GLN . 47.1 t -117.93 123.12 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-O 120.823 0.344 . . . . 0.0 110.087 -177.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.38 -113.24 0.63 Allowed Glycine 0 C--N 1.32 -0.339 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.494 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . 87.5 -73.12 2.42 Favored Glycine 0 CA--C 1.541 1.677 0 CA-C-O 119.93 -0.372 . . . . 0.0 112.649 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.708 ' C ' HG11 ' P' ' 39' ' ' VAL . 45.2 t -134.51 161.04 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.539 ' N ' HG21 ' P' ' 39' ' ' VAL . 6.3 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.315 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.541 ' O ' ' NE2' ' O' ' 14' ' ' HIS . 2.8 m . . . . . 0 N--CA 1.467 0.413 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.48 ' NE2' ' C ' ' N' ' 40' ' ' VAL . 8.2 t60 -90.7 120.79 32.05 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.344 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' CD2' ' O' ' 14' ' ' HIS . 11.6 p-80 -152.97 161.82 42.08 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.659 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.475 ' NE2' HG22 ' N' ' 36' ' ' VAL . 95.4 mt-30 -90.23 158.77 17.04 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.646 178.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -140.94 105.27 4.84 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 1.008 HD11 HG21 ' N' ' 36' ' ' VAL . 31.2 mt -122.7 123.18 40.53 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 120.314 -0.554 . . . . 0.0 110.433 178.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . 0.413 HG13 ' CG2' ' Q' ' 18' ' ' VAL . 2.2 t -114.51 106.51 20.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' N' ' 32' ' ' ILE . 57.3 m-85 -106.76 111.52 24.09 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -133.7 130.39 38.09 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.456 1.28 . . . . 0.0 114.456 -176.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.54 125.16 37.75 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.838 177.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -111.74 150.81 29.72 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 115.764 1.764 . . . . 0.0 115.764 -175.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.536 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 83.6 m-20 63.38 46.56 4.33 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 117.685 2.476 . . . . 0.0 117.685 173.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.691 HG12 ' H ' ' P' ' 25' ' ' GLY . 8.7 t -100.44 -179.44 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 115.556 -2.458 . . . . 0.0 109.523 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.691 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -72.6 -30.65 63.88 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 121.195 -0.526 . . . . 0.0 113.469 176.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.5 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 9.7 t 100.72 111.33 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 -174.217 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.503 ' CG ' ' N ' ' P' ' 28' ' ' LYS . 22.8 t-20 -71.31 173.47 7.75 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 117.459 -1.697 . . . . 0.0 112.724 -176.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.503 ' N ' ' CG ' ' P' ' 27' ' ' ASN . 88.7 tttt -52.45 -36.78 55.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.43 177.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.52 77.18 0.06 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.661 -177.095 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.83 154.11 2.22 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 118.307 1.053 . . . . 0.0 110.44 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.961 HD11 HG22 ' J' ' 39' ' ' VAL . 69.4 mt -121.22 131.23 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 73.7 mt -114.33 110.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.04 109.21 2.74 Favored Glycine 0 N--CA 1.463 0.497 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.51 ' CD1' ' CE1' ' R' ' 19' ' ' PHE . 95.4 mt -135.0 133.48 39.49 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.445 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 4.0 mtp -107.62 104.02 13.46 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 174.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.76 103.07 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.32 -153.11 24.62 Favored Glycine 0 C--N 1.31 -0.892 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.95 -56.68 0.6 Allowed Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -178.1 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.708 HG11 ' C ' ' O' ' 39' ' ' VAL . 11.5 p -124.36 154.99 31.91 Favored 'Isoleucine or valine' 0 C--O 1.231 0.085 0 C-N-CA 122.66 0.384 . . . . 0.0 110.054 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.461 HG23 ' H ' ' P' ' 40' ' ' VAL . 1.9 t . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 118.067 -0.968 . . . . 0.0 111.028 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -119.73 120.71 37.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.82 154.01 43.77 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.043 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.566 HG12 ' H ' ' R' ' 12' ' ' VAL . 12.7 m -133.0 120.11 39.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 121.625 0.726 . . . . 0.0 111.84 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.444 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 4.0 m-70 -90.1 110.73 21.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.233 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.527 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 2.3 t-80 -119.37 159.62 23.84 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.497 ' NE2' HG12 ' O' ' 36' ' ' VAL . 9.6 tt0 -86.24 157.84 19.85 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . 0.766 ' O ' HD23 ' Q' ' 17' ' ' LEU . 76.5 tttt -160.04 94.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.539 177.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.766 HD23 ' O ' ' Q' ' 16' ' ' LYS . 1.7 mt -131.56 127.15 36.58 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . 0.413 ' CG2' HG13 ' P' ' 18' ' ' VAL . 28.1 m -117.45 122.11 69.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 178.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.594 ' CD2' HD13 ' O' ' 32' ' ' ILE . 22.0 m-85 -112.63 105.37 13.53 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -127.32 137.02 52.71 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.644 0.735 . . . . 0.0 112.686 -177.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -146.74 145.04 29.82 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 119.78 -0.768 . . . . 0.0 113.03 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.536 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 82.8 mt-10 -79.27 149.66 31.76 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.528 ' OD1' ' HB1' ' R' ' 21' ' ' ALA . 6.9 p-10 -168.14 47.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -176.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.45 HG12 ' H ' ' Q' ' 25' ' ' GLY . 5.7 t -71.58 170.02 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.105 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.45 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 80.75 26.7 53.16 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 104.537 -3.425 . . . . 0.0 104.537 -175.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 24.0 p -80.85 116.5 20.86 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 117.047 2.24 . . . . 0.0 117.047 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -90.22 -152.16 0.26 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 111.286 -2.688 . . . . 0.0 104.947 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -48.56 -41.03 29.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 119.695 1.134 . . . . 0.0 108.333 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.44 -63.95 0.6 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 117.064 1.586 . . . . 0.0 117.064 173.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.16 165.21 32.07 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 120.108 1.954 . . . . 0.0 115.057 -176.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 69.2 mt -125.35 127.55 72.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 CA-C-N 111.321 -2.672 . . . . 0.0 106.786 178.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 tt -134.79 133.33 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 121.781 0.801 . . . . 0.0 112.698 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.4 109.93 2.16 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 107.764 -2.134 . . . . 0.0 107.764 177.2 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.414 HD23 HD13 ' R' ' 34' ' ' LEU . 18.5 tp -116.63 119.04 34.26 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.22 137.45 52.03 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.934 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 21.4 t -111.19 131.9 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.067 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . -45.62 -111.7 0.0 OUTLIER Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.322 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . -101.48 -71.5 0.93 Allowed Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.413 ' HB ' HD11 ' E' ' 31' ' ' ILE . 69.3 t -109.08 129.86 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.275 0.538 . . . . 0.0 109.862 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.838 -179.397 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.61 132.53 51.65 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -72.34 142.81 48.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.566 ' H ' HG12 ' Q' ' 12' ' ' VAL . 5.4 m -121.13 131.96 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-O 121.901 0.858 . . . . 0.0 112.01 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 4.1 m80 -133.47 124.96 27.97 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 114.448 -1.251 . . . . 0.0 108.92 178.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 99.2 m-70 -149.28 172.04 15.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.809 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.516 ' OE1' ' N ' ' R' ' 15' ' ' GLN . 14.0 mp0 -89.42 150.33 22.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.614 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . 0.767 ' C ' HD12 ' R' ' 17' ' ' LEU . 74.1 tttt -150.17 98.78 2.73 Favored 'General case' 0 C--N 1.311 -1.066 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 178.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.767 HD12 ' C ' ' R' ' 16' ' ' LYS . 9.7 mp -127.05 124.58 39.64 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.625 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 66.5 t -106.62 114.66 46.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD1' ' P' ' 34' ' ' LEU . 17.1 m-85 -106.59 105.81 16.02 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' N ' ' R' ' 21' ' ' ALA . 66.2 t80 -146.9 156.76 43.33 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 122.463 1.125 . . . . 0.0 113.261 -177.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.528 ' HB1' ' OD1' ' Q' ' 23' ' ' ASP . . . -150.02 148.24 28.8 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.878 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.443 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 83.4 tt0 -76.49 112.54 13.13 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.56 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.484 ' OD1' ' N ' ' R' ' 23' ' ' ASP . 19.5 p-10 -177.23 48.92 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.642 -177.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -72.11 160.49 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 118.605 -1.238 . . . . 0.0 108.879 -178.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.35 -34.83 5.18 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 107.286 -2.326 . . . . 0.0 107.286 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.425 ' OG ' ' O ' ' R' ' 23' ' ' ASP . 11.9 p -80.53 119.98 23.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 113.193 -1.504 . . . . 0.0 109.852 179.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' R' ' 29' ' ' GLY . 13.6 m120 -87.72 -175.17 5.07 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.091 -178.067 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -49.52 49.64 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.7 51.49 0.92 Allowed Glycine 0 CA--C 1.546 1.972 0 CA-C-N 118.776 0.717 . . . . 0.0 112.333 178.539 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.17 172.94 11.24 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.2 mt -113.35 120.4 63.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -125.01 127.97 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.935 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.19 116.68 3.01 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 178.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.414 HD13 HD23 ' Q' ' 34' ' ' LEU . 40.4 tp -124.1 122.51 38.04 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.6 mtp -139.72 147.34 40.76 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.173 0.511 . . . . 0.0 112.279 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.401 HG22 ' N ' ' R' ' 37' ' ' GLY . 2.9 p -130.15 155.27 41.46 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.075 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.5 179.177 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.401 ' N ' HG22 ' R' ' 36' ' ' VAL . . . -102.99 102.75 2.29 Favored Glycine 0 CA--C 1.523 0.582 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.95 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.97 -76.17 0.73 Allowed Glycine 0 CA--C 1.535 1.329 0 N-CA-C 115.241 0.857 . . . . 0.0 115.241 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.485 ' O ' ' O ' ' Q' ' 38' ' ' GLY . 54.0 t -122.7 139.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 117.916 0.858 . . . . 0.0 112.708 -177.033 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.987 179.214 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.439 ' CD ' ' NE2' ' A' ' 13' ' ' HIS . 80.8 tt0 . . . . . 0 N--CA 1.465 0.3 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 51.8 t -120.16 129.51 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.619 0.723 . . . . 0.0 111.098 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.439 ' NE2' ' CD ' ' A' ' 11' ' ' GLU . 98.2 m-70 -126.04 166.16 17.48 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.713 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 53.0 p-80 -82.92 167.31 18.13 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.238 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -157.87 142.92 16.71 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.611 178.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -81.51 127.98 33.41 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.2 mt -125.48 114.49 18.87 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -127.55 131.49 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.176 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -134.55 130.79 37.1 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.148 0.499 . . . . 0.0 111.702 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -113.9 123.02 48.76 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.034 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.02 129.46 46.74 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.155 0.502 . . . . 0.0 111.656 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -92.99 -176.28 4.14 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 178.766 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 t0 . . . . . 0 C--N 1.324 -0.501 0 CA-C-O 121.402 0.62 . . . . 0.0 109.629 179.296 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.0 m120 . . . . . 0 N--CA 1.471 0.595 0 N-CA-C 115.862 1.801 . . . . 0.0 115.862 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -42.89 -36.25 1.45 Allowed 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 112.369 -2.196 . . . . 0.0 113.261 171.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -102.39 87.75 0.63 Allowed Glycine 0 CA--C 1.526 0.761 0 CA-C-N 113.051 -1.886 . . . . 0.0 117.335 -168.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.52 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -96.27 128.66 43.39 Favored 'General case' 0 CA--C 1.551 1.01 0 CA-C-O 124.975 2.321 . . . . 0.0 110.403 -177.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -145.59 160.23 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 CA-C-N 110.546 -3.024 . . . . 0.0 111.329 -175.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 52.0 mt -104.43 109.46 27.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 175.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.13 94.88 0.69 Allowed Glycine 0 CA--C 1.508 -0.39 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 178.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.489 ' O ' HD12 ' B' ' 34' ' ' LEU . 89.4 mt -144.26 154.63 43.28 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 122.881 1.324 . . . . 0.0 113.43 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 6.1 ttm -114.48 114.95 26.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 112.466 -2.152 . . . . 0.0 107.431 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.4 HG11 HD11 ' C' ' 17' ' ' LEU . 0.0 OUTLIER -129.26 102.84 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.807 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.1 -151.75 20.83 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 109.299 -1.521 . . . . 0.0 109.299 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.61 ' O ' HG11 ' B' ' 39' ' ' VAL . . . 117.24 -56.33 0.54 Allowed Glycine 0 CA--C 1.543 1.797 0 C-N-CA 121.534 -0.365 . . . . 0.0 112.713 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.764 ' C ' HG21 ' B' ' 39' ' ' VAL . 7.2 p -133.1 177.47 7.09 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.672 ' H ' HG22 ' A' ' 39' ' ' VAL . 6.0 m . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 117.901 -1.047 . . . . 0.0 111.965 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -84.23 138.02 33.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.76 0.314 . . . . 0.0 110.322 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -106.35 125.77 51.41 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.988 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.52 HG11 ' CE1' ' C' ' 13' ' ' HIS . 54.1 t -122.35 130.03 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.725 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m80 -117.42 157.6 25.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.609 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.605 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 52.9 t60 -80.72 166.86 20.63 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.111 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.559 ' O ' ' CE1' ' B' ' 14' ' ' HIS . 29.6 pt20 -129.29 151.08 50.34 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.15 0.5 . . . . 0.0 110.334 179.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -96.9 120.88 38.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.144 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.434 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.3 tt -116.76 115.56 25.84 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.8 t -121.34 128.68 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.205 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.248 -179.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -129.63 117.48 20.44 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 32.4 t80 -112.57 122.42 47.63 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.04 116.11 26.22 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.929 0.871 . . . . 0.0 112.394 -178.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -95.98 135.35 37.85 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.518 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -150.65 51.27 0.87 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.356 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.23 151.27 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 C-N-CA 118.486 -1.285 . . . . 0.0 110.21 -177.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.52 -32.4 6.64 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 106.166 -2.774 . . . . 0.0 106.166 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.539 ' HB3' ' N ' ' C' ' 26' ' ' SER . 0.5 OUTLIER 71.5 106.09 0.06 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 112.732 -1.734 . . . . 0.0 112.262 176.045 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.598 ' N ' ' OG ' ' C' ' 26' ' ' SER . 43.8 m-80 -101.63 163.36 12.3 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 119.217 -0.993 . . . . 0.0 112.815 177.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.49 ' O ' ' O ' ' C' ' 27' ' ' ASN . 99.7 mttt -41.45 -39.2 1.44 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 119.739 3.237 . . . . 0.0 119.739 178.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -110.72 69.7 0.21 Allowed Glycine 0 N--CA 1.497 2.713 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 -170.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.417 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -97.47 102.33 14.07 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 120.527 2.164 . . . . 0.0 111.978 178.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 7.0 pt -147.49 153.03 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.125 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' D' ' 19' ' ' PHE . 88.9 mt -107.44 114.09 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.53 106.09 1.93 Allowed Glycine 0 N--CA 1.464 0.504 0 N-CA-C 106.256 -2.738 . . . . 0.0 106.256 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.489 HD12 ' O ' ' A' ' 34' ' ' LEU . 10.5 tp -141.76 142.4 33.24 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.653 -1.219 . . . . 0.0 114.249 -175.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -116.67 110.94 19.13 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.359 177.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' C' ' 36' ' ' VAL . 0.4 OUTLIER -132.75 102.94 5.57 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.596 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 -179.299 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.51 -151.85 21.21 Favored Glycine 0 C--N 1.306 -1.088 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.407 ' C ' HG12 ' C' ' 39' ' ' VAL . . . 100.21 -57.05 0.8 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -178.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.764 HG21 ' C ' ' A' ' 39' ' ' VAL . 12.8 m -123.47 174.14 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 C-N-CA 123.826 0.851 . . . . 0.0 110.073 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.411 ' C ' ' O ' ' B' ' 39' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.572 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -83.23 139.53 33.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.291 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -81.6 118.94 23.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.407 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 53.4 t -130.31 133.75 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.137 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.62 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -139.13 100.8 4.11 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 121.218 -0.193 . . . . 0.0 111.134 179.205 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.605 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 13.6 m170 -117.19 160.5 20.95 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -86.41 155.54 20.54 Favored 'General case' 0 N--CA 1.457 -0.108 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.413 ' CB ' ' NE2' ' B' ' 14' ' ' HIS . 85.4 tttt -161.18 94.66 1.01 Allowed 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.186 176.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.4 HD11 HG11 ' A' ' 36' ' ' VAL . 20.8 mt -121.71 117.85 27.65 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.887 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 4.8 t -105.69 110.17 30.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -108.92 105.84 15.55 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.57 122.8 47.05 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.459 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.73 146.45 37.78 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -81.04 108.66 14.9 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.693 178.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.565 ' CG ' ' HB1' ' D' ' 21' ' ' ALA . 82.0 m-20 -105.28 51.93 0.75 Allowed 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 113.507 -1.679 . . . . 0.0 110.238 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.0 t -71.34 -133.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 114.933 -1.031 . . . . 0.0 108.455 -174.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.46 38.07 3.38 Favored Glycine 0 N--CA 1.468 0.823 0 CA-C-O 124.111 1.95 . . . . 0.0 109.973 -169.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.598 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 1.2 m -72.29 102.9 3.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 108.651 -3.775 . . . . 0.0 102.243 171.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' B' ' 28' ' ' LYS . 88.2 m-20 -108.21 -170.14 1.63 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -171.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.426 ' O ' ' O ' ' N' ' 40' ' ' VAL . 98.6 mttt 32.36 41.27 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 113.668 -1.606 . . . . 0.0 111.12 -172.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . -176.72 61.1 0.1 OUTLIER Glycine 0 CA--C 1.546 1.976 0 CA-C-N 114.809 -1.087 . . . . 0.0 111.715 172.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.28 95.33 5.55 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 118.713 1.256 . . . . 0.0 110.505 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.705 HD13 HG22 ' O' ' 39' ' ' VAL . 2.0 tt -164.41 153.48 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 C-N-CA 115.164 -2.615 . . . . 0.0 116.353 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.422 HD13 ' CD1' ' E' ' 19' ' ' PHE . 93.0 mt -112.73 112.34 40.01 Favored 'Isoleucine or valine' 0 C--N 1.35 0.601 0 CA-C-N 114.31 -1.314 . . . . 0.0 108.9 177.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.29 112.21 3.66 Favored Glycine 0 N--CA 1.464 0.554 0 N-CA-C 105.013 -3.235 . . . . 0.0 105.013 176.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 tt -148.05 146.3 28.81 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 117.619 -1.633 . . . . 0.0 114.474 -173.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 9.0 mtp -121.94 113.15 19.21 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.709 HG21 HD21 ' E' ' 17' ' ' LEU . 3.1 p -139.88 103.06 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.837 -177.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.06 -155.27 26.43 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 119.848 -1.168 . . . . 0.0 112.282 177.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 61.1 54.73 34.26 Favored Glycine 0 CA--C 1.544 1.862 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.574 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.456 ' O ' ' O ' ' C' ' 40' ' ' VAL . 2.6 m -156.2 -168.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.341 0.23 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.519 HG13 ' O ' ' I' ' 28' ' ' LYS . 88.3 t . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.991 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 N--CA 1.469 0.496 0 N-CA-C 110.447 -0.205 . . . . 0.0 110.447 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.62 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 17.3 m-70 -134.82 107.43 7.39 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.593 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.593 ' ND1' ' O ' ' E' ' 14' ' ' HIS . 59.9 t60 -132.57 157.86 43.66 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.723 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.558 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 43.2 tt0 -85.82 157.38 20.23 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -160.09 100.15 1.38 Allowed 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.237 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 29.6 mt -123.5 115.02 20.86 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 178.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.9 109.1 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 59.9 m-85 -107.8 104.02 13.42 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.612 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 47.4 t80 -113.47 125.74 54.56 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.565 ' HB1' ' CG ' ' C' ' 23' ' ' ASP . . . -135.94 135.06 39.3 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 122.712 1.244 . . . . 0.0 113.242 -178.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -84.4 113.5 21.22 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.022 -1.444 . . . . 0.0 108.963 179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.635 ' OD2' ' HB1' ' E' ' 21' ' ' ALA . 5.7 p-10 -146.44 48.57 1.18 Allowed 'General case' 0 CA--C 1.516 -0.365 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.457 ' H ' HG12 ' D' ' 24' ' ' VAL . 0.6 OUTLIER -72.58 160.79 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 177.486 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.38 -28.4 10.97 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' E' ' 26' ' ' SER . 7.7 t 74.6 119.6 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 114.268 -0.966 . . . . 0.0 110.264 -178.25 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -83.29 163.25 20.81 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 120.078 -0.649 . . . . 0.0 111.278 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -46.98 -37.0 8.39 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 178.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.74 77.55 0.07 OUTLIER Glycine 0 CA--C 1.538 1.501 0 C-N-CA 120.497 -0.859 . . . . 0.0 113.085 -175.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.71 137.64 37.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 118.698 1.249 . . . . 0.0 111.082 -178.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.532 HD13 ' HB ' ' P' ' 39' ' ' VAL . 31.5 mt -127.34 138.65 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 CA-C-N 114.793 -1.094 . . . . 0.0 113.36 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' F' ' 19' ' ' PHE . 67.2 mt -115.28 120.7 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 175.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.39 119.51 2.11 Favored Glycine 0 N--CA 1.467 0.731 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.705 ' N ' HD23 ' D' ' 34' ' ' LEU . 1.9 pt? -165.62 162.53 18.99 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 117.75 -1.58 . . . . 0.0 114.987 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 50.6 tpp -101.43 111.65 23.94 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 112.163 -2.289 . . . . 0.0 106.907 176.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.759 HG11 HD23 ' F' ' 17' ' ' LEU . 55.7 t -118.47 102.57 13.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 121.265 -0.174 . . . . 0.0 110.78 -178.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.03 -161.86 16.34 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 148.69 -55.34 0.5 Allowed Glycine 0 CA--C 1.539 1.578 0 CA-C-O 119.316 -0.713 . . . . 0.0 112.453 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.65 HG21 ' CD1' ' J' ' 31' ' ' ILE . 33.8 m -136.61 152.8 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.555 0 CA-C-N 118.776 1.288 . . . . 0.0 110.867 178.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.593 ' H ' ' CD1' ' K' ' 31' ' ' ILE . 60.7 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.485 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -106.97 135.75 48.0 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.839 0.352 . . . . 0.0 110.353 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -76.53 106.37 8.14 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.713 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 m -139.78 156.43 25.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.162 0.506 . . . . 0.0 110.938 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.412 ' C ' ' CD2' ' E' ' 14' ' ' HIS . 21.7 m-70 -148.27 117.57 6.9 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.141 178.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.593 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 13.3 m-70 -141.28 162.41 35.54 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 110.923 179.047 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.421 ' OE1' ' OE1' ' F' ' 15' ' ' GLN . 78.7 mt-30 -85.32 157.27 20.6 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 176.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -159.53 104.3 1.61 Allowed 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.322 0.582 . . . . 0.0 109.461 178.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.709 HD21 HG21 ' C' ' 36' ' ' VAL . 2.3 mt -125.07 116.8 22.67 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.773 -179.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -107.48 101.85 13.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 74.1 m-85 -103.45 101.22 11.11 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 178.002 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.612 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 24.5 t80 -116.2 128.65 55.79 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.474 0.178 . . . . 0.0 111.156 -177.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.635 ' HB1' ' OD2' ' D' ' 23' ' ' ASP . . . -141.31 139.57 33.64 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.52 0.676 . . . . 0.0 112.755 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.567 ' HB2' ' H ' ' D' ' 23' ' ' ASP . 97.7 mt-10 -79.28 155.05 28.69 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' F' ' 23' ' ' ASP . 2.4 t70 -169.62 48.56 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.286 -1.366 . . . . 0.0 113.418 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 1.8 t -72.28 161.61 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 119.179 -1.008 . . . . 0.0 108.598 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.68 -28.65 10.38 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -176.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.526 ' O ' ' CB ' ' E' ' 27' ' ' ASN . 1.6 m 80.56 -114.71 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 113.644 -1.278 . . . . 0.0 112.232 -179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.526 ' CB ' ' O ' ' E' ' 26' ' ' SER . 4.2 t-20 89.24 179.9 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -48.33 -38.43 19.05 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' E' ' 30' ' ' ALA . . . 99.85 -68.22 0.55 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-N 114.297 -1.32 . . . . 0.0 114.781 176.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.963 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . 179.91 171.0 1.13 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 119.044 1.422 . . . . 0.0 112.688 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 98.6 mt -131.85 128.36 59.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 113.976 -1.465 . . . . 0.0 108.587 177.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.472 ' CG2' HD21 ' E' ' 34' ' ' LEU . 52.1 mt -123.93 124.91 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.133 0.492 . . . . 0.0 111.822 -177.439 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 110.92 2.34 Favored Glycine 0 N--CA 1.47 0.96 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.472 HD21 ' CG2' ' E' ' 32' ' ' ILE . 21.8 mt -118.17 114.31 22.86 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -177.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 78.4 mmm -105.8 116.17 31.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 177.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.67 HG12 ' N ' ' E' ' 37' ' ' GLY . 61.7 t -128.44 170.85 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.701 0.762 . . . . 0.0 112.365 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.67 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -168.26 94.28 0.11 Allowed Glycine 0 C--N 1.308 -1.021 0 N-CA-C 108.164 -1.975 . . . . 0.0 108.164 176.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.33 -73.15 0.42 Allowed Glycine 0 CA--C 1.54 1.626 0 CA-C-N 117.287 0.543 . . . . 0.0 112.927 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.773 HG13 HD11 ' K' ' 31' ' ' ILE . 76.2 t . . . . . 0 N--CA 1.437 -1.081 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 . . . . . 0 N--CA 1.465 0.319 0 CA-C-O 120.555 0.217 . . . . 0.0 110.633 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.516 HG13 ' NE2' ' E' ' 14' ' ' HIS . 8.0 p -141.32 138.2 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.403 0.621 . . . . 0.0 110.948 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.406 ' HA ' ' CE1' ' E' ' 14' ' ' HIS . 4.6 m80 -140.98 133.57 28.61 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.121 -178.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.583 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 45.7 m80 -148.54 164.74 33.32 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.02 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.448 ' NE2' ' H ' ' F' ' 16' ' ' LYS . 70.9 tp60 -89.8 151.46 21.78 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.69 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . 0.448 ' H ' ' NE2' ' F' ' 15' ' ' GLN . 99.1 mttt -152.89 100.08 2.48 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.559 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.759 HD23 HG11 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -121.6 118.98 30.57 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 177.209 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.69 106.07 19.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.572 ' CD1' HD13 ' D' ' 32' ' ' ILE . 55.7 m-85 -104.32 103.59 13.36 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -117.24 109.82 17.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.223 0.535 . . . . 0.0 110.513 -178.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.96 117.98 28.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 177.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -90.33 112.08 23.53 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 119.222 -0.991 . . . . 0.0 113.583 -176.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' E' ' 23' ' ' ASP . 1.1 m-20 . . . . . 0 C--N 1.351 0.648 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.935 176.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.963 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.54 0.589 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mm -105.05 131.52 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.44 HG23 ' O ' ' F' ' 32' ' ' ILE . 19.6 tt -137.7 129.5 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.979 0.419 . . . . 0.0 111.627 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.66 123.11 5.13 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 mt -116.59 120.31 38.28 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -123.69 130.11 52.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.538 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 29.5 m -115.96 158.38 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.08 -103.03 0.01 OUTLIER Glycine 0 CA--C 1.524 0.616 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.961 -179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.42 -76.66 0.5 Allowed Glycine 0 CA--C 1.534 1.231 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.425 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.47 ' O ' ' CD1' ' L' ' 31' ' ' ILE . 58.6 t -126.91 131.8 70.63 Favored 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-N 117.338 0.569 . . . . 0.0 110.343 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.449 HG22 ' H ' ' F' ' 40' ' ' VAL . 10.9 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.861 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.465 0.303 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -133.84 112.42 11.3 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.691 0.282 . . . . 0.0 110.913 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.436 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 47.9 p-80 -152.92 168.73 24.81 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.292 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 69.1 tp60 -158.22 142.46 15.88 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.654 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -81.86 126.63 32.12 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.033 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.58 ' C ' HD23 ' G' ' 17' ' ' LEU . 6.5 tt -134.43 119.58 18.73 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.658 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.505 ' N ' HD23 ' G' ' 17' ' ' LEU . 12.6 m -132.82 135.81 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.355 -179.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -127.24 126.46 42.75 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.807 178.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' H' ' 20' ' ' PHE . 43.5 t80 -128.94 127.45 41.77 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.682 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.69 119.67 21.69 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 121.303 0.573 . . . . 0.0 110.977 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -92.57 124.6 36.71 Favored 'General case' 0 C--N 1.342 0.27 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.596 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.528 ' H ' ' HB3' ' H' ' 22' ' ' GLU . 67.0 t0 . . . . . 0 N--CA 1.474 0.748 0 C-N-CA 124.809 1.244 . . . . 0.0 113.086 -179.264 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 121.526 0.679 . . . . 0.0 111.143 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -54.61 -38.51 66.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.59 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.24 70.96 0.2 Allowed Glycine 0 CA--C 1.537 1.423 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.171 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.25 116.94 29.43 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 123.988 1.851 . . . . 0.0 112.69 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.485 ' CD1' ' O ' ' A' ' 38' ' ' GLY . 14.8 pt -146.95 149.21 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 111.993 -2.367 . . . . 0.0 109.904 -179.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.418 HD13 HG21 ' G' ' 32' ' ' ILE . 55.0 mt -105.05 112.0 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.12 96.05 0.74 Allowed Glycine 0 N--CA 1.467 0.735 0 N-CA-C 107.264 -2.334 . . . . 0.0 107.264 178.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 78.3 mt -144.07 156.27 44.3 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 122.972 1.367 . . . . 0.0 113.848 -177.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' CG ' ' H' ' 35' ' ' MET . 44.1 tpp -103.57 111.16 23.5 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 112.166 -2.288 . . . . 0.0 106.315 176.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.444 HG12 HE21 ' J' ' 15' ' ' GLN . 3.5 t -131.54 111.78 19.7 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.432 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 127.99 -132.07 7.26 Favored Glycine 0 C--N 1.315 -0.623 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.418 ' O ' HG12 ' H' ' 39' ' ' VAL . . . 87.49 -63.67 3.87 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.093 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 m -102.57 169.15 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-O 120.95 0.405 . . . . 0.0 110.844 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.507 ' OXT' ' NE2' ' J' ' 13' ' ' HIS . 9.7 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.264 179.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -107.86 133.27 52.46 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.814 0.34 . . . . 0.0 110.179 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.62 128.6 22.01 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.225 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -122.99 131.34 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.805 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -132.4 105.77 7.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.811 0.339 . . . . 0.0 111.6 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.673 ' CD2' ' H ' ' H' ' 15' ' ' GLN . 1.1 t-80 -155.6 169.13 25.01 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.702 178.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.673 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 14.1 pt20 -157.45 142.19 16.64 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.985 0.421 . . . . 0.0 110.449 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -84.02 113.38 20.97 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.356 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.9 mt -119.66 113.41 20.63 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 79.7 t -124.38 131.72 72.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 CA-C-O 120.898 0.38 . . . . 0.0 111.636 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -126.7 116.57 21.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.309 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' G' ' 20' ' ' PHE . 30.0 t80 -117.23 123.83 47.59 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.18 138.56 25.29 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-O 122.454 1.121 . . . . 0.0 113.633 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.528 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 80.8 tt0 -90.14 149.5 22.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.152 -1.386 . . . . 0.0 109.402 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.411 ' N ' ' HB2' ' I' ' 22' ' ' GLU . 66.4 t0 -174.32 48.43 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.682 -0.407 . . . . 0.0 112.042 -178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.426 HG12 ' N ' ' H' ' 25' ' ' GLY . 4.1 t -72.67 161.43 4.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.213 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.505 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 108.95 -30.24 8.89 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.505 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 6.2 p 93.06 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.085 0.554 . . . . 0.0 111.015 178.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 1.07 HD21 ' HB2' ' H' ' 30' ' ' ALA . 17.6 p30 -74.02 175.05 7.77 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 119.889 -0.725 . . . . 0.0 110.448 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.618 ' HZ3' ' CE1' ' C' ' 13' ' ' HIS . 94.0 mttt -51.18 -36.93 43.63 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' H' ' 27' ' ' ASN . . . 179.54 77.22 0.06 OUTLIER Glycine 0 CA--C 1.529 0.961 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.729 -176.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 1.07 ' HB2' HD21 ' H' ' 27' ' ' ASN . . . -52.06 131.89 32.28 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 118.295 1.047 . . . . 0.0 113.567 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.578 HD12 HG12 ' B' ' 39' ' ' VAL . 51.6 mt -141.38 133.42 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.454 HD13 HG21 ' H' ' 32' ' ' ILE . 31.3 mt -105.55 108.97 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 174.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.44 104.42 1.8 Allowed Glycine 0 N--CA 1.462 0.427 0 N-CA-C 106.948 -2.461 . . . . 0.0 106.948 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.415 HD21 HG22 ' G' ' 32' ' ' ILE . 81.0 mt -138.23 136.77 36.88 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 119.013 -1.075 . . . . 0.0 113.774 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.472 ' CG ' ' SD ' ' G' ' 35' ' ' MET . 32.9 tpp -99.84 107.1 19.04 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 173.533 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' I' ' 36' ' ' VAL . 24.8 t -130.24 142.3 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -178.47 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 124.57 -101.95 0.68 Allowed Glycine 0 C--N 1.312 -0.759 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.19 -79.28 0.02 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.529 HG21 ' CA ' ' N' ' 29' ' ' GLY . 5.5 p -144.04 150.2 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.077 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.545 ' OXT' ' CG2' ' I' ' 40' ' ' VAL . 5.1 p . . . . . 0 C--O 1.217 -0.655 0 CA-C-O 118.14 -0.933 . . . . 0.0 111.117 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -108.44 136.66 47.69 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.842 0.353 . . . . 0.0 110.254 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.491 ' N ' ' CD ' ' I' ' 11' ' ' GLU . 1.8 pm0 -117.91 135.58 54.03 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.525 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.507 HG22 ' H ' ' J' ' 12' ' ' VAL . 70.2 t -124.97 126.51 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.202 -179.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -134.85 146.14 48.97 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.805 0.336 . . . . 0.0 111.33 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.516 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 59.4 m80 -147.82 172.69 13.74 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 121.132 0.492 . . . . 0.0 110.502 177.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 40.7 tt0 -137.86 140.89 40.68 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 176.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -130.15 110.06 11.3 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.105 -0.638 . . . . 0.0 112.413 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.43 ' CD2' HG21 ' G' ' 36' ' ' VAL . 5.6 mp -121.81 113.12 19.22 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 175.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.502 HG13 ' CG2' ' J' ' 18' ' ' VAL . 8.0 t -105.56 109.43 27.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 80.3 m-85 -104.3 100.71 10.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.115 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -115.2 127.42 55.51 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -168.58 177.46 5.2 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 117.624 -1.63 . . . . 0.0 114.891 -177.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.411 ' HB2' ' N ' ' H' ' 23' ' ' ASP . 67.8 mm-40 -77.92 156.96 29.98 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 175.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.722 ' O ' ' O ' ' I' ' 24' ' ' VAL . 67.9 t0 -169.84 60.56 0.04 OUTLIER 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 119.291 -0.964 . . . . 0.0 112.483 -175.214 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.722 ' O ' ' O ' ' I' ' 23' ' ' ASP . 3.4 t -44.53 -111.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.196 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.448 ' O ' ' N ' ' I' ' 27' ' ' ASN . . . 159.5 -45.37 0.44 Allowed Glycine 0 CA--C 1.502 -0.751 0 C-N-CA 116.091 -2.957 . . . . 0.0 116.561 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.498 ' C ' ' ND2' ' I' ' 27' ' ' ASN . 46.9 t -66.69 103.85 1.18 Allowed 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 113.773 -3.171 . . . . 0.0 106.11 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.53 ' O ' ' N ' ' I' ' 29' ' ' GLY . 1.6 m120 -137.02 170.13 16.61 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 113.963 -1.471 . . . . 0.0 109.132 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.519 ' O ' HG13 ' C' ' 40' ' ' VAL . 52.7 mttp -25.84 -42.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.535 0 O-C-N 123.882 0.739 . . . . 0.0 111.217 173.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 160.68 67.6 0.02 OUTLIER Glycine 0 CA--C 1.554 2.494 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.677 -178.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -52.14 138.23 26.13 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 118.477 1.138 . . . . 0.0 112.166 -178.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.68 HD12 HD11 ' J' ' 31' ' ' ILE . 3.0 tt -144.59 145.93 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.498 HG23 HD13 ' I' ' 34' ' ' LEU . 3.9 mt -105.37 108.58 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 175.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.727 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -107.32 101.45 1.68 Allowed Glycine 0 N--CA 1.47 0.903 0 N-CA-C 106.41 -2.676 . . . . 0.0 106.41 178.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.727 HD12 ' O ' ' I' ' 33' ' ' GLY . 3.1 mp -130.71 130.21 43.54 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -174.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 83.5 mmm -101.34 112.44 24.96 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' H' ' 36' ' ' VAL . 47.0 t -127.56 142.14 44.43 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.743 -174.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.434 ' HA2' HE21 ' L' ' 15' ' ' GLN . . . 133.16 -101.6 0.44 Allowed Glycine 0 C--N 1.318 -0.451 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.526 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 83.83 -81.02 1.77 Allowed Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.517 HG22 HD12 ' O' ' 31' ' ' ILE . 56.1 t -143.2 143.91 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.545 ' CG2' ' OXT' ' H' ' 40' ' ' VAL . 21.5 m . . . . . 0 N--CA 1.473 0.688 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.975 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.88 132.81 53.06 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.884 0.373 . . . . 0.0 110.622 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -75.51 123.43 25.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.507 ' H ' HG22 ' I' ' 12' ' ' VAL . 3.2 m -134.9 155.97 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.285 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.541 ' CG ' ' O ' ' H' ' 40' ' ' VAL . 2.1 t-80 -158.52 103.66 1.77 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.02 178.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.516 ' H ' ' CD2' ' I' ' 14' ' ' HIS . 4.3 m-70 -137.23 159.09 42.93 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.786 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.444 HE21 HG12 ' G' ' 36' ' ' VAL . 5.8 tt0 -90.26 159.26 16.78 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 105.67 -1.974 . . . . 0.0 105.67 175.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.664 ' C ' HD12 ' J' ' 17' ' ' LEU . 78.9 tttt -140.66 109.73 6.13 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.845 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.664 HD12 ' C ' ' J' ' 16' ' ' LYS . 4.5 mp -130.04 120.02 24.06 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.293 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . 0.502 ' CG2' HG13 ' I' ' 18' ' ' VAL . 20.3 m -116.28 117.93 57.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 177.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.407 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 32.2 m-85 -107.92 103.54 12.81 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -118.46 134.63 54.92 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.557 0.218 . . . . 0.0 110.989 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.31 146.24 23.53 Favored 'General case' 0 C--O 1.241 0.606 0 C-N-CA 117.919 -1.512 . . . . 0.0 114.842 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 72.3 mm-40 -86.8 147.47 25.81 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 113.578 -1.646 . . . . 0.0 108.915 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.492 ' OD2' ' O ' ' I' ' 23' ' ' ASP . 0.0 OUTLIER -160.18 51.88 0.32 Allowed 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -177.072 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.5 t -75.43 142.41 14.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 116.783 -1.967 . . . . 0.0 108.378 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.26 -37.22 3.84 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.49 119.95 23.84 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 113.663 -1.268 . . . . 0.0 112.697 -178.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.623 ' O ' ' N ' ' J' ' 29' ' ' GLY . 22.1 m-20 -88.38 158.01 18.53 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.039 -0.665 . . . . 0.0 109.437 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.782 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 75.8 tttt -47.91 48.35 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.216 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.623 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -101.47 52.55 0.88 Allowed Glycine 0 N--CA 1.481 1.664 0 CA-C-N 119.234 0.925 . . . . 0.0 113.905 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.555 ' O ' ' HB1' ' K' ' 30' ' ' ALA . . . -130.01 179.44 5.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.4 0.619 . . . . 0.0 110.142 179.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.68 HD11 HD12 ' I' ' 31' ' ' ILE . 42.2 pt -138.96 145.04 28.27 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.488 HG22 ' O ' ' J' ' 32' ' ' ILE . 0.6 OUTLIER -108.67 110.44 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.053 177.535 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.77 95.88 0.91 Allowed Glycine 0 C--O 1.24 0.488 0 N-CA-C 104.673 -3.371 . . . . 0.0 104.673 176.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.412 HD21 ' CD2' ' L' ' 17' ' ' LEU . 6.3 tt -133.11 132.27 41.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 123.062 1.41 . . . . 0.0 113.647 -175.131 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 11.1 mtp -107.89 109.39 20.89 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 112.208 -2.269 . . . . 0.0 107.393 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.689 ' O ' HG13 ' K' ' 36' ' ' VAL . 12.0 p -104.44 111.51 34.32 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.469 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 178.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.47 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -58.62 131.91 52.29 Favored Glycine 0 N--CA 1.462 0.388 0 CA-C-N 115.146 -0.933 . . . . 0.0 114.403 -175.613 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . -89.42 63.62 3.32 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.455 HG23 ' O ' ' J' ' 39' ' ' VAL . 28.7 m -112.86 125.6 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 CA-C-O 121.148 0.499 . . . . 0.0 110.695 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.474 ' HB ' HG12 ' I' ' 40' ' ' VAL . 3.3 t . . . . . 0 C--O 1.219 -0.535 0 CA-C-N 114.951 -1.022 . . . . 0.0 112.204 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -82.71 139.77 33.46 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.808 0.337 . . . . 0.0 110.51 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.459 ' HB3' ' HE2' ' K' ' 13' ' ' HIS . 95.7 mt-10 -92.24 121.63 33.94 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.276 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.428 HG12 ' H ' ' L' ' 12' ' ' VAL . 34.0 m -130.35 132.03 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.969 0.414 . . . . 0.0 111.356 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.459 ' HE2' ' HB3' ' K' ' 11' ' ' GLU . 2.6 m-70 -141.79 137.5 31.59 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.311 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.647 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 28.1 m80 -147.57 162.18 39.63 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -90.02 158.27 17.42 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 176.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.27 97.74 3.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 119.608 -0.837 . . . . 0.0 111.228 177.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 19.3 mt -121.49 118.62 29.77 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 176.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.85 111.81 37.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.584 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -105.09 100.92 10.5 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 49.6 t80 -121.78 122.33 39.26 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.732 0.301 . . . . 0.0 111.675 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.581 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -154.13 159.0 41.26 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 118.504 -1.278 . . . . 0.0 114.25 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.469 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 96.6 mt-10 -85.71 161.09 19.36 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 177.174 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 22.2 p30 177.65 48.8 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 118.198 0.454 . . . . 0.0 112.167 -178.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.442 ' H ' HG23 ' K' ' 24' ' ' VAL . 0.2 OUTLIER -72.43 160.68 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 118.4 -1.32 . . . . 0.0 112.97 -176.136 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -28.7 10.29 Favored Glycine 0 CA--C 1.535 1.316 0 CA-C-N 113.634 -1.621 . . . . 0.0 112.419 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p 73.76 119.34 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.449 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 29.0 t-20 -83.3 163.49 20.65 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 119.494 -0.882 . . . . 0.0 112.477 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.449 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 99.4 mttt -47.35 -37.22 10.74 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 114.438 -1.255 . . . . 0.0 113.974 176.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.98 77.0 0.06 OUTLIER Glycine 0 CA--C 1.545 1.955 0 C-N-CA 120.059 -1.067 . . . . 0.0 114.42 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.782 ' HB2' ' O ' ' J' ' 28' ' ' LYS . . . -80.02 167.95 19.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 119.379 1.59 . . . . 0.0 110.351 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.773 HD11 HG13 ' E' ' 39' ' ' VAL . 43.3 mt -133.24 127.98 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -176.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.403 HD13 HG21 ' K' ' 32' ' ' ILE . 14.7 pt -125.17 121.69 61.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 121.486 0.66 . . . . 0.0 109.998 176.32 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.608 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -126.26 115.73 2.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.746 HD12 ' N ' ' K' ' 34' ' ' LEU . 2.9 mp -122.0 119.89 32.77 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.406 ' SD ' ' CE ' ' L' ' 35' ' ' MET . 27.7 ttp -137.58 147.88 45.43 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 118.441 -1.303 . . . . 0.0 112.913 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.689 HG13 ' O ' ' J' ' 36' ' ' VAL . 1.4 t -121.38 171.82 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 113.914 -1.493 . . . . 0.0 108.847 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.3 94.18 0.11 Allowed Glycine 0 N--CA 1.437 -1.279 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.999 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.525 ' HA2' HD11 ' Q' ' 31' ' ' ILE . . . 152.11 -80.97 0.19 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.432 176.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.61 HG23 HD13 ' Q' ' 31' ' ' ILE . 90.2 t . . . . . 0 N--CA 1.466 0.334 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.743 0.306 . . . . 0.0 110.519 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.428 ' H ' HG12 ' K' ' 12' ' ' VAL . 6.2 m -122.12 132.88 70.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.271 0.557 . . . . 0.0 111.137 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.447 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.3 p80 -148.18 107.31 3.88 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.741 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.647 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.9 m80 -147.91 164.86 32.43 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 109.909 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.47 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 75.7 mt-30 -89.76 158.85 17.34 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.915 0.388 . . . . 0.0 111.175 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . 0.686 ' C ' HD12 ' L' ' 17' ' ' LEU . 68.5 mttm -140.07 102.56 4.42 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.686 HD12 ' C ' ' L' ' 16' ' ' LYS . 9.7 mp -120.37 118.14 29.59 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -105.04 116.43 48.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.517 ' CZ ' HD23 ' K' ' 34' ' ' LEU . 8.6 m-85 -105.16 103.7 13.29 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' O ' ' L' ' 21' ' ' ALA . 75.7 t80 -153.21 158.87 42.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 123.177 1.465 . . . . 0.0 113.807 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.581 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -145.81 159.1 43.68 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 113.41 -1.723 . . . . 0.0 107.578 178.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.404 ' C ' ' O ' ' L' ' 21' ' ' ALA . 81.3 tt0 -39.95 152.7 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.27 -0.572 . . . . 0.0 111.677 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 p30 -65.45 47.33 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.807 -177.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.546 HG23 ' H ' ' L' ' 26' ' ' SER . 24.1 m -61.04 -179.12 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.483 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.34 29.62 12.11 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.546 ' H ' HG23 ' L' ' 24' ' ' VAL . 34.5 t -80.14 110.81 15.9 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.607 ' O ' ' N ' ' L' ' 29' ' ' GLY . 11.2 m120 -95.06 -166.31 1.44 Allowed 'General case' 0 C--O 1.222 -0.348 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.632 -179.433 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.57 47.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.01 56.59 0.93 Allowed Glycine 0 CA--C 1.538 1.508 0 CA-C-N 119.756 1.162 . . . . 0.0 111.431 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.658 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -170.27 177.11 4.27 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.555 HD12 HG12 ' E' ' 39' ' ' VAL . 39.2 mt -106.97 125.59 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.765 HD12 ' N ' ' L' ' 32' ' ' ILE . 3.1 mp -110.45 115.89 50.94 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.229 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.1 107.26 1.15 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.622 HD23 ' C ' ' L' ' 34' ' ' LEU . 6.3 tt -122.7 120.39 33.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.582 ' N ' HD23 ' L' ' 34' ' ' LEU . 28.6 mtm -136.17 144.62 45.09 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.462 0.648 . . . . 0.0 112.546 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.469 ' O ' ' O ' ' L' ' 37' ' ' GLY . 54.0 t -116.18 131.52 68.46 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.686 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -32.92 -111.3 0.0 OUTLIER Glycine 0 CA--C 1.532 1.113 0 CA-C-N 115.058 -0.974 . . . . 0.0 114.315 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.55 -71.64 0.53 Allowed Glycine 0 CA--C 1.536 1.35 0 CA-C-N 115.289 -0.456 . . . . 0.0 112.886 -178.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.404 ' CG2' HD11 ' R' ' 31' ' ' ILE . 53.3 t . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 121.46 0.647 . . . . 0.0 111.27 -179.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 . . . . . 0 N--CA 1.456 -0.128 0 CA-C-O 120.737 0.303 . . . . 0.0 110.307 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 52.0 t -116.48 129.58 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.298 0.57 . . . . 0.0 110.116 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -81.4 163.09 23.06 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.372 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 89.5 m-70 -105.09 160.97 14.64 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 121.265 0.555 . . . . 0.0 111.768 -179.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.427 ' H ' ' HG2' ' N' ' 15' ' ' GLN . 87.9 mt-30 -89.98 160.25 16.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.62 178.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -139.38 110.9 7.08 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.1 mt -135.93 117.44 14.81 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.551 0.691 . . . . 0.0 111.081 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.17 132.95 70.55 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.813 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -128.04 134.21 49.18 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.771 0.32 . . . . 0.0 110.552 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.496 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 53.2 p90 -127.43 126.02 41.63 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 129.25 47.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.225 0.536 . . . . 0.0 111.962 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -155.34 126.7 7.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.007 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.69 46.45 24.66 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.332 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.446 HG22 ' H ' ' M' ' 24' ' ' VAL . 11.6 m -76.11 179.55 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.0 28.11 6.86 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.813 -179.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' M' ' 27' ' ' ASN . 5.5 t -170.46 -134.11 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.912 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' M' ' 26' ' ' SER . 22.2 t-20 -30.81 143.58 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.847 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -132.9 -26.08 1.78 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.748 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.99 -108.87 0.26 Allowed Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.143 -1.027 . . . . 0.0 111.052 179.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.45 96.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.45 -0.5 . . . . 0.0 112.1 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -115.24 105.28 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . 0.747 HG22 HD11 ' N' ' 34' ' ' LEU . 55.0 mt -110.73 112.6 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 120.411 -0.516 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.75 104.45 1.22 Allowed Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 104.977 -3.249 . . . . 0.0 104.977 176.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 30.0 tp -155.2 151.36 28.06 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 117.489 -1.685 . . . . 0.0 114.409 -174.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 93.9 mmm -100.27 111.51 23.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 112.659 -2.064 . . . . 0.0 106.878 177.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' N' ' 36' ' ' VAL . 41.9 t -119.66 131.37 72.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.34 -111.28 4.13 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' N' ' 37' ' ' GLY . . . 81.13 -74.03 2.49 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -178.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.18 161.37 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.402 HG22 ' CG1' ' N' ' 39' ' ' VAL . 10.7 m . . . . . 0 N--CA 1.47 0.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.538 177.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.159 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -105.24 131.51 52.62 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -114.8 115.29 26.77 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.204 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -129.57 123.02 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.174 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -143.58 130.71 20.71 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.196 0.522 . . . . 0.0 110.473 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.637 ' ND1' ' NE2' ' O' ' 14' ' ' HIS . 19.5 t60 -159.75 170.08 22.27 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CD2' ' N' ' 14' ' ' HIS . 75.2 mt-30 -155.14 140.71 17.91 Favored 'General case' 0 CA--C 1.517 -0.32 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.767 177.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 48.0 tttp -93.98 111.04 22.7 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.867 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.427 ' CD1' HE21 ' O' ' 15' ' ' GLN . 13.6 mt -119.91 114.43 22.06 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 177.021 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . 0.478 HG21 ' CE2' ' N' ' 20' ' ' PHE . 6.3 p -138.6 141.86 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 119.692 -0.803 . . . . 0.0 112.135 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -131.36 122.55 26.55 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.07 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.478 ' CE2' HG21 ' N' ' 18' ' ' VAL . 59.8 m-85 -112.88 123.48 50.4 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.633 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.05 121.06 40.25 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' O' ' 22' ' ' GLU . 82.6 tt0 -136.32 156.38 48.72 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 121.208 0.527 . . . . 0.0 112.31 -177.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 20.0 t0 76.63 54.74 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.364 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.631 HG21 HG13 ' O' ' 24' ' ' VAL . 90.8 t -68.05 135.25 28.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.57 -34.26 2.3 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 120.995 -0.621 . . . . 0.0 111.836 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' N' ' 27' ' ' ASN . 29.5 t -162.41 120.3 2.12 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-N 116.847 0.323 . . . . 0.0 110.991 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.516 ' O ' ' O ' ' N' ' 26' ' ' SER . 17.5 p30 -22.26 152.74 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -163.19 24.58 0.09 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.434 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . 0.529 ' CA ' HG21 ' H' ' 39' ' ' VAL . . . 89.52 105.29 1.13 Allowed Glycine 0 N--CA 1.466 0.683 0 C-N-CA 119.06 -1.543 . . . . 0.0 113.435 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . 0.531 ' HB3' ' HB2' ' O' ' 30' ' ' ALA . . . -111.96 95.63 5.59 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 122.072 0.939 . . . . 0.0 108.777 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.45 HD11 HG23 ' I' ' 39' ' ' VAL . 79.4 mt -137.44 136.13 46.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 114.826 -1.079 . . . . 0.0 112.225 -177.182 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.704 HG23 HD13 ' N' ' 34' ' ' LEU . 77.1 mt -106.76 105.64 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 175.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.667 ' O ' HD12 ' N' ' 34' ' ' LEU . . . -110.38 91.98 0.66 Allowed Glycine 0 N--CA 1.467 0.742 0 N-CA-C 106.197 -2.761 . . . . 0.0 106.197 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.747 HD11 HG22 ' M' ' 32' ' ' ILE . 8.8 mp -132.74 152.55 51.73 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 123.35 1.548 . . . . 0.0 114.452 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -115.65 107.26 14.87 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 175.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' O' ' 37' ' ' GLY . 47.6 t -117.63 123.16 71.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.05 -177.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.742 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 134.75 -113.86 1.2 Allowed Glycine 0 C--N 1.317 -0.515 0 N-CA-C 110.524 -1.03 . . . . 0.0 110.524 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.805 ' O ' HG21 ' O' ' 39' ' ' VAL . . . 97.83 -71.64 0.66 Allowed Glycine 0 CA--C 1.533 1.188 0 N-CA-C 110.618 -0.993 . . . . 0.0 110.618 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.402 ' CG1' HG22 ' M' ' 40' ' ' VAL . 83.6 t -126.49 138.58 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 177.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' C' ' 28' ' ' LYS . 66.2 t . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.909 -1.043 . . . . 0.0 110.056 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -107.19 134.31 50.49 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.83 0.348 . . . . 0.0 110.466 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.98 133.61 39.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.827 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.56 140.28 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.085 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.477 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 42.0 t-80 -147.5 95.53 2.54 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.392 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.637 ' NE2' ' ND1' ' N' ' 14' ' ' HIS . 0.3 OUTLIER -161.05 170.9 19.58 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 178.798 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.427 HE21 ' CD1' ' N' ' 17' ' ' LEU . 50.1 tt0 -97.33 143.47 28.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.699 177.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -124.64 118.98 27.73 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.492 ' N ' HD12 ' O' ' 17' ' ' LEU . 4.7 mp -122.76 128.93 51.14 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.516 0.674 . . . . 0.0 111.337 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 98.2 t -119.07 111.99 35.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' M' ' 32' ' ' ILE . 91.4 m-85 -107.7 108.0 19.04 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -122.87 126.67 47.77 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.83 117.06 28.26 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' O' ' 24' ' ' VAL . 83.5 tt0 -83.43 153.18 24.63 Favored 'General case' 0 N--CA 1.461 0.083 0 N-CA-C 113.438 0.903 . . . . 0.0 113.438 -176.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' O' ' 24' ' ' VAL . 65.6 t0 8.66 51.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 113.034 -1.894 . . . . 0.0 114.654 -179.155 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.709 HG12 ' H ' ' O' ' 25' ' ' GLY . 11.6 t -55.89 -132.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 174.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.709 ' H ' HG12 ' O' ' 24' ' ' VAL . . . 144.47 -29.77 1.88 Allowed Glycine 0 C--O 1.226 -0.365 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.337 175.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.461 ' O ' ' CE ' ' P' ' 28' ' ' LYS . 5.8 t -89.92 -132.89 0.1 Allowed 'General case' 0 CA--C 1.55 0.974 0 CA-C-O 122.986 1.374 . . . . 0.0 113.292 179.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.466 ' H ' ' HB3' ' N' ' 27' ' ' ASN . 12.2 m120 79.28 138.9 0.07 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 127.669 2.388 . . . . 0.0 111.22 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -48.83 -48.45 41.62 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 117.2 2.296 . . . . 0.0 117.2 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.67 62.48 0.06 OUTLIER Glycine 0 CA--C 1.545 1.921 0 CA-C-O 118.084 -1.398 . . . . 0.0 111.498 -171.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . 0.531 ' HB2' ' HB3' ' N' ' 30' ' ' ALA . . . -52.71 143.92 15.22 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 120.681 2.241 . . . . 0.0 116.714 -170.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.526 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 70.8 mt -138.79 153.89 25.87 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 CA-C-N 110.942 -2.845 . . . . 0.0 113.871 -175.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.556 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 75.5 mt -117.1 110.53 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 174.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.44 106.96 2.41 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 104.732 -3.347 . . . . 0.0 104.732 176.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.669 HD12 ' O ' ' N' ' 34' ' ' LEU . 26.7 tp -148.37 139.21 23.01 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 122.747 1.26 . . . . 0.0 113.696 -174.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.458 ' H ' HD12 ' O' ' 34' ' ' LEU . 24.5 ttm -114.33 110.98 20.76 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 113.648 -1.615 . . . . 0.0 107.428 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.458 ' O ' ' HA3' ' P' ' 37' ' ' GLY . 1.7 t -89.91 103.74 14.47 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.784 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . -20.06 144.5 0.01 OUTLIER Glycine 0 N--CA 1.481 1.69 0 C-N-CA 124.136 0.874 . . . . 0.0 115.077 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.515 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . -100.78 59.12 0.68 Allowed Glycine 0 CA--C 1.541 1.673 0 CA-C-N 115.022 -0.589 . . . . 0.0 113.6 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.805 HG21 ' O ' ' N' ' 38' ' ' GLY . 21.5 t -135.23 161.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-N 117.423 0.611 . . . . 0.0 110.607 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.499 ' N ' HG12 ' O' ' 39' ' ' VAL . 78.0 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.306 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.419 HG22 ' O ' ' Q' ' 11' ' ' GLU . 40.3 t . . . . . 0 N--CA 1.467 0.386 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 0.9 OUTLIER -146.05 105.35 3.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.381 -179.307 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 2.1 p-80 -134.1 160.59 37.31 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.449 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.742 HE22 ' N ' ' N' ' 37' ' ' GLY . 3.3 mt-30 -89.99 159.22 17.0 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -140.07 103.27 4.58 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.412 HD22 HG21 ' N' ' 36' ' ' VAL . 5.0 mp -128.88 125.68 38.14 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 121.399 0.619 . . . . 0.0 110.657 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 79.6 t -118.38 117.38 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.679 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' HD13 ' N' ' 32' ' ' ILE . 29.4 m-85 -114.01 103.84 11.55 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 27.6 t80 -117.64 126.93 53.4 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.665 0.269 . . . . 0.0 111.059 -178.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.1 115.91 15.66 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 121.062 0.458 . . . . 0.0 111.497 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.545 ' O ' ' N ' ' O' ' 24' ' ' VAL . 80.4 tt0 -92.71 112.81 24.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.563 ' O ' ' NZ ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -139.19 46.76 1.92 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.681 -175.909 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.78 HG22 ' H ' ' P' ' 25' ' ' GLY . 7.7 p -73.15 179.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.453 0.644 . . . . 0.0 111.554 -178.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.78 ' H ' HG22 ' P' ' 24' ' ' VAL . . . 99.66 -34.66 5.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 118.647 -1.085 . . . . 0.0 114.468 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.466 ' O ' ' C ' ' P' ' 27' ' ' ASN . 96.2 p -162.24 120.43 2.2 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.381 2.09 . . . . 0.0 112.791 176.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.466 ' C ' ' O ' ' P' ' 26' ' ' SER . 65.8 t30 -23.56 141.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 123.611 0.569 . . . . 0.0 111.371 177.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' P' ' 23' ' ' ASP . 64.7 mttp -122.24 -32.93 3.58 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 177.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.33 79.85 0.91 Allowed Glycine 0 CA--C 1.536 1.381 0 N-CA-C 108.343 -1.903 . . . . 0.0 108.343 -176.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.7 144.04 30.9 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-N 118.172 0.986 . . . . 0.0 111.727 -175.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.458 HG23 HG23 ' Q' ' 31' ' ' ILE . 5.8 mt -125.07 138.64 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 113.815 -1.538 . . . . 0.0 113.563 -177.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.524 HD13 ' CD1' ' R' ' 19' ' ' PHE . 96.4 mt -118.76 112.35 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 176.566 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.98 100.22 1.45 Allowed Glycine 0 CA--C 1.509 -0.302 0 N-CA-C 104.557 -3.417 . . . . 0.0 104.557 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.523 ' CD2' HG22 ' P' ' 36' ' ' VAL . 7.7 tt -137.07 138.22 40.16 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-O 123.014 1.387 . . . . 0.0 114.533 -174.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 5.5 ttm -104.66 111.44 24.14 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.002 -1.908 . . . . 0.0 106.909 176.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.523 HG22 ' CD2' ' P' ' 34' ' ' LEU . 3.4 t -85.24 101.65 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 C-N-CA 118.585 -1.246 . . . . 0.0 108.269 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.561 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . . . -88.89 153.91 24.18 Favored Glycine 0 C--N 1.316 -0.579 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.467 ' N ' ' HA2' ' O' ' 38' ' ' GLY . . . 136.68 58.86 0.06 OUTLIER Glycine 0 N--CA 1.466 0.639 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.662 ' CG2' ' H ' ' Q' ' 38' ' ' GLY . 49.7 t -79.51 133.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.463 HG23 ' NE2' ' R' ' 13' ' ' HIS . 9.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.956 -1.021 . . . . 0.0 111.748 -178.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.1 135.37 46.58 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.838 0.351 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . 0.419 ' O ' HG22 ' P' ' 12' ' ' VAL . 96.8 mt-10 -103.02 122.55 44.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.209 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.588 HG12 ' N ' ' Q' ' 13' ' ' HIS . 46.8 t -142.37 168.16 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.689 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.588 ' N ' HG12 ' Q' ' 12' ' ' VAL . 8.3 p80 -64.1 127.47 31.57 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -177.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.505 ' O ' ' CB ' ' P' ' 14' ' ' HIS . 7.0 p80 -157.46 168.46 27.26 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.157 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.561 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 79.1 mt-30 -89.97 151.39 21.72 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.921 -0.487 . . . . 0.0 110.313 178.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -148.76 106.48 3.68 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.42 ' N ' HD12 ' Q' ' 17' ' ' LEU . 4.5 mp -135.68 124.46 23.92 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.264 0.554 . . . . 0.0 111.017 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -108.1 116.29 51.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 178.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.556 ' CD1' HD13 ' O' ' 32' ' ' ILE . 60.3 m-85 -112.42 109.23 18.72 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.226 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 41.4 t80 -125.45 128.17 47.65 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.55 134.3 37.34 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.129 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -114.74 124.29 51.4 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' Q' ' 23' ' ' ASP . 12.6 p-10 -147.28 59.73 1.16 Allowed 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.382 0.611 . . . . 0.0 111.873 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.961 HG12 ' H ' ' Q' ' 25' ' ' GLY . 4.8 t 72.07 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.018 176.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.961 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -107.91 29.3 10.46 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.312 177.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 48.7 m -65.1 -113.96 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 118.716 1.258 . . . . 0.0 111.223 -176.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -155.94 169.19 25.01 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 119.631 -0.827 . . . . 0.0 112.362 179.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt 27.36 43.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.224 -1.353 . . . . 0.0 112.723 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.84 60.25 0.74 Allowed Glycine 0 N--CA 1.475 1.24 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.21 177.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.19 118.63 0.57 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 119.229 1.514 . . . . 0.0 113.043 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.61 HD13 HG23 ' K' ' 39' ' ' VAL . 1.7 tt -136.14 125.38 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 175.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . 0.477 HG22 ' HG ' ' Q' ' 34' ' ' LEU . 64.5 mt -128.66 133.79 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.198 -176.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.85 112.57 2.36 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 108.164 -1.974 . . . . 0.0 108.164 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.477 ' HG ' HG22 ' Q' ' 32' ' ' ILE . 58.4 mt -119.16 120.44 37.1 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.093 0.473 . . . . 0.0 110.935 -177.47 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 11.0 mtp -124.7 130.92 53.33 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.362 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -105.81 159.86 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 CA-C-O 121.359 0.6 . . . . 0.0 110.75 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.84 -102.77 0.01 OUTLIER Glycine 0 CA--C 1.528 0.854 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.086 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.662 ' H ' ' CG2' ' P' ' 39' ' ' VAL . . . -116.97 -77.17 0.62 Allowed Glycine 0 CA--C 1.534 1.269 0 CA-C-O 119.864 -0.409 . . . . 0.0 113.166 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' R' ' 39' ' ' VAL . 39.3 t -115.01 129.9 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 117.682 0.741 . . . . 0.0 111.861 -178.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.493 ' N ' ' O ' ' R' ' 40' ' ' VAL . 42.6 t . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.694 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -79.54 138.4 37.49 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -111.31 128.58 55.99 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.433 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.477 ' H ' HG21 ' Q' ' 12' ' ' VAL . 30.8 t -110.46 93.17 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.451 0.643 . . . . 0.0 110.609 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.517 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 50.1 p-80 -120.32 105.77 11.24 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.545 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 84.6 t60 -141.11 170.73 15.17 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.752 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.531 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 93.0 mm-40 -89.55 150.62 22.35 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -149.59 99.0 2.84 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -139.02 124.78 19.65 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.529 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -104.96 118.52 52.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.524 ' CD1' HD13 ' P' ' 32' ' ' ILE . 55.3 m-85 -111.92 105.8 14.33 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 t80 -130.14 125.7 35.7 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.61 0.719 . . . . 0.0 112.104 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.59 126.4 38.4 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.269 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 79.1 tt0 -89.21 110.81 21.52 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 119.938 -0.705 . . . . 0.0 110.965 -178.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.448 ' OD2' ' OD2' ' Q' ' 23' ' ' ASP . 54.0 m-20 -163.11 -60.25 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.561 HG12 ' N ' ' R' ' 25' ' ' GLY . 98.2 t -55.81 162.49 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.742 -179.435 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.561 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -157.3 -27.84 0.03 OUTLIER Glycine 0 CA--C 1.52 0.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 93.1 p -80.74 -130.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.268 -0.466 . . . . 0.0 109.912 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.0 m-80 -99.18 -164.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.499 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -47.76 49.48 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 125.372 1.469 . . . . 0.0 114.793 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.38 51.76 0.92 Allowed Glycine 0 CA--C 1.55 2.229 0 CA-C-N 119.344 0.974 . . . . 0.0 113.715 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.19 165.61 22.0 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.404 HD11 ' CG2' ' L' ' 39' ' ' VAL . 96.6 mt -114.31 112.21 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 CA-C-N 119.73 1.15 . . . . 0.0 110.042 178.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -125.73 127.72 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.843 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.66 119.41 3.5 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.09 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 48.4 tp -123.25 123.08 39.95 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mtp -138.38 147.42 43.39 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.06 161.51 38.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.123 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.3 -102.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.501 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.34 -78.02 0.87 Allowed Glycine 0 N--CA 1.475 1.289 0 C-N-CA 121.707 -0.283 . . . . 0.0 112.891 -178.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' Q' ' 39' ' ' VAL . 70.1 t -96.1 132.82 39.4 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.865 0 CA-C-N 117.519 0.659 . . . . 0.0 110.855 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' Q' ' 40' ' ' VAL . 10.7 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.444 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 . . . . . 0 N--CA 1.465 0.276 0 N-CA-C 109.872 -0.418 . . . . 0.0 109.872 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.8 131.98 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.413 0.625 . . . . 0.0 111.159 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.1 m80 -117.38 156.82 27.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.461 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.512 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -84.21 167.85 16.29 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.918 -179.755 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.426 ' HB3' HE21 ' B' ' 15' ' ' GLN . 69.0 tp60 -159.15 143.26 15.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.632 178.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -80.2 123.5 27.98 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 99.3 mt -125.6 116.28 21.47 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 177.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.54 134.06 56.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.739 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -127.71 131.49 49.73 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.466 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.0 p90 -134.95 130.94 36.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.685 0.278 . . . . 0.0 111.374 -178.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.63 120.56 38.4 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -136.98 136.16 38.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.406 0.622 . . . . 0.0 112.081 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.9 t0 . . . . . 0 C--N 1.33 -0.267 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 177.931 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 26.7 t-20 . . . . . 0 N--CA 1.466 0.351 0 CA-C-O 120.846 0.355 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -79.55 39.64 0.41 Allowed 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.41 79.36 0.94 Allowed Glycine 0 N--CA 1.47 0.939 0 C-N-CA 117.886 -2.102 . . . . 0.0 110.976 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.445 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -81.41 74.81 8.39 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 119.589 1.695 . . . . 0.0 113.955 -175.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.67 ' CD1' HG12 ' M' ' 39' ' ' VAL . 89.7 mt -145.39 122.58 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 177.107 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -116.86 122.97 71.19 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-O 121.344 0.592 . . . . 0.0 112.109 -177.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.91 101.2 0.67 Allowed Glycine 0 C--N 1.319 -0.41 0 N-CA-C 105.311 -3.116 . . . . 0.0 105.311 176.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -156.71 153.71 28.88 Favored 'General case' 0 C--O 1.241 0.629 0 C-N-CA 118.128 -1.429 . . . . 0.0 113.617 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mmm -99.31 120.78 40.13 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 112.714 -2.039 . . . . 0.0 108.055 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.601 ' HB ' HG12 ' B' ' 36' ' ' VAL . 2.8 t -111.39 124.6 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.62 -114.22 6.29 Favored Glycine 0 CA--C 1.528 0.889 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.42 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.17 -71.51 0.73 Allowed Glycine 0 CA--C 1.539 1.58 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.455 ' H ' HG23 ' A' ' 39' ' ' VAL . 2.6 t -66.23 159.25 4.53 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.982 -1.009 . . . . 0.0 111.793 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' C' ' 9' ' ' GLY . 92.1 m-85 -98.43 132.32 43.98 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.412 ' H ' ' HG3' ' C' ' 11' ' ' GLU . 97.0 mt-10 -138.03 139.81 39.78 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.013 0.435 . . . . 0.0 111.304 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.47 ' CG1' ' HE2' ' A' ' 14' ' ' HIS . 74.2 t -124.42 130.89 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -117.55 98.05 6.19 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' B' ' 15' ' ' GLN . 11.5 t60 -160.61 164.54 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.542 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 50.9 tt0 -158.1 142.33 15.92 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.319 178.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.52 121.25 27.34 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.022 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.604 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.4 tt -136.22 121.32 18.93 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.706 0.685 . . . . 0.0 110.831 178.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.548 ' N ' HD23 ' B' ' 17' ' ' LEU . 13.9 m -134.65 141.4 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.937 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -128.32 127.03 41.95 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.184 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -123.24 129.58 51.57 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.743 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.0 119.65 31.02 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -138.84 164.04 30.68 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.001 0.429 . . . . 0.0 111.545 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.58 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 54.2 t0 42.0 47.57 3.83 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -81.58 163.4 3.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 117.786 -1.565 . . . . 0.0 108.567 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.61 -38.16 57.52 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -177.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.62 ' O ' ' O ' ' B' ' 27' ' ' ASN . 45.9 t -162.54 117.24 1.81 Allowed 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.746 HD21 ' N ' ' C' ' 28' ' ' LYS . 55.2 t-20 -22.02 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.212 0 O-C-N 123.933 0.771 . . . . 0.0 111.713 175.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.545 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 62.7 tttt -163.29 24.56 0.09 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . 89.53 106.64 1.16 Allowed Glycine 0 N--CA 1.468 0.805 0 C-N-CA 118.396 -1.859 . . . . 0.0 113.814 177.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.89 101.83 10.38 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 122.734 1.254 . . . . 0.0 109.881 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.7 HD11 ' HB ' ' N' ' 39' ' ' VAL . 91.8 mt -119.61 129.44 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 114.22 -1.355 . . . . 0.0 110.641 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.43 ' CG2' HD12 ' B' ' 34' ' ' LEU . 49.7 mt -109.95 111.24 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.114 0.483 . . . . 0.0 109.82 177.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 99.21 0.99 Allowed Glycine 0 C--O 1.238 0.396 0 N-CA-C 105.885 -2.886 . . . . 0.0 105.885 177.067 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.629 ' O ' HD23 ' C' ' 34' ' ' LEU . 80.0 mt -138.24 145.67 41.65 Favored 'General case' 0 CA--C 1.499 -1.001 0 CA-C-O 122.792 1.282 . . . . 0.0 113.139 -175.242 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.7 mtp -116.36 109.44 17.35 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 112.837 -1.983 . . . . 0.0 107.473 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.601 HG12 ' HB ' ' A' ' 36' ' ' VAL . 2.8 m -132.88 123.19 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.742 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 144.85 -113.4 0.72 Allowed Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.684 ' O ' HG13 ' B' ' 39' ' ' VAL . . . 76.94 -72.97 2.0 Allowed Glycine 0 CA--C 1.535 1.3 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.684 HG13 ' O ' ' B' ' 38' ' ' GLY . 2.9 m -166.67 118.92 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.551 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 17.2 m . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.746 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -122.47 140.38 52.8 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.731 0.3 . . . . 0.0 110.34 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . 0.499 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 57.6 mp0 -76.52 115.82 16.63 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.059 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.411 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 26.7 m -137.01 159.76 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.473 ' O ' ' CB ' ' D' ' 13' ' ' HIS . 6.3 m80 -145.71 132.27 19.82 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.025 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.489 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.8 m-70 -150.57 170.9 18.03 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.074 177.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.2 tp60 -138.53 140.83 39.25 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 177.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -130.02 106.12 8.42 Favored 'General case' 0 C--N 1.318 -0.764 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.413 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 mt -118.34 113.86 22.06 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.47 116.27 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -109.37 106.16 15.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -120.81 127.97 52.43 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -176.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.62 131.36 35.71 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.124 0.488 . . . . 0.0 111.164 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.489 ' O ' ' CG ' ' C' ' 23' ' ' ASP . 77.4 tt0 -146.46 101.9 3.53 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 113.659 0.985 . . . . 0.0 113.659 -179.067 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.58 ' OD2' ' N ' ' B' ' 23' ' ' ASP . 70.5 m-20 -175.86 -71.83 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 175.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.622 HG13 ' O ' ' C' ' 24' ' ' VAL . 11.2 p -78.75 114.78 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.069 -1.423 . . . . 0.0 107.54 175.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.421 ' HA3' HG22 ' D' ' 24' ' ' VAL . . . -91.23 -39.26 5.74 Favored Glycine 0 N--CA 1.461 0.336 0 C-N-CA 117.408 -2.33 . . . . 0.0 109.044 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 5.0 t -93.15 111.47 23.12 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 173.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -79.85 171.41 15.15 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 118.017 -1.473 . . . . 0.0 109.996 177.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.746 ' N ' HD21 ' B' ' 27' ' ' ASN . 99.0 mttt -50.37 -36.88 34.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.207 1.003 . . . . 0.0 109.472 174.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.19 76.72 0.06 OUTLIER Glycine 0 CA--C 1.54 1.642 0 CA-C-N 113.372 -1.74 . . . . 0.0 110.175 -178.119 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.498 ' O ' ' HB1' ' D' ' 30' ' ' ALA . . . -80.19 129.79 34.75 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 119.323 1.562 . . . . 0.0 113.104 -176.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.924 HG22 HG22 ' D' ' 31' ' ' ILE . 46.8 pt -144.61 146.22 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.983 -177.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 76.9 mt -108.96 116.35 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.689 178.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.8 102.99 1.66 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.247 -3.141 . . . . 0.0 105.247 175.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.629 HD23 ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -134.93 141.02 46.18 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -175.122 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.65 113.29 26.48 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 175.201 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.491 HG22 HD22 ' C' ' 34' ' ' LEU . 3.1 t -129.46 134.42 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.86 -104.29 0.28 Allowed Glycine 0 C--N 1.305 -1.145 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' C' ' 39' ' ' VAL . . . 46.87 70.73 0.63 Allowed Glycine 0 CA--C 1.537 1.423 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.478 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.882 HG13 ' O ' ' D' ' 39' ' ' VAL . 6.3 t -6.78 120.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.539 ' OXT' ' CE1' ' E' ' 13' ' ' HIS . 26.8 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.156 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.436 HG12 ' H ' ' E' ' 12' ' ' VAL . 4.5 m . . . . . 0 N--CA 1.468 0.46 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' O ' ' B' ' 40' ' ' VAL . 2.1 p80 -147.78 138.46 23.21 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.702 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.546 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.2 OUTLIER -145.91 158.67 43.86 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.052 178.454 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.742 HE22 ' H ' ' B' ' 37' ' ' GLY . 84.8 mt-30 -90.43 158.19 17.2 Favored 'General case' 0 N--CA 1.455 -0.196 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 174.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.481 ' C ' HD22 ' D' ' 17' ' ' LEU . 98.7 mttt -141.37 103.08 4.35 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 176.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.907 HD22 ' N ' ' D' ' 17' ' ' LEU . 0.1 OUTLIER -118.69 119.41 34.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.053 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 82.8 t -112.94 112.26 39.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 44.7 m-85 -110.92 103.96 12.5 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -114.29 118.84 35.04 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.831 -0.168 . . . . 0.0 110.926 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.14 118.4 8.95 Favored 'General case' 0 C--O 1.246 0.883 0 CA-C-O 122.147 0.975 . . . . 0.0 111.742 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -178.09 158.96 1.26 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 114.387 -1.279 . . . . 0.0 111.073 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.449 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 35.2 t70 -173.06 -59.91 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 114.167 1.173 . . . . 0.0 114.167 177.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.843 HG23 ' H ' ' D' ' 26' ' ' SER . 3.0 m -77.96 -178.99 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 118.896 -1.121 . . . . 0.0 113.208 -176.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.71 19.82 38.85 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 114.044 -1.435 . . . . 0.0 113.081 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.843 ' H ' HG23 ' D' ' 24' ' ' VAL . 8.9 t -126.65 151.16 48.43 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 118.309 1.055 . . . . 0.0 112.775 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.489 HD22 ' H ' ' E' ' 26' ' ' SER . 57.9 t-20 -52.36 137.27 29.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.276 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.411 ' CB ' ' O ' ' E' ' 22' ' ' GLU . 87.1 tttt -63.5 -50.97 67.53 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.884 -177.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.66 50.35 3.15 Favored Glycine 0 CA--C 1.541 1.673 0 C-N-CA 119.949 -1.12 . . . . 0.0 110.755 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.498 ' HB1' ' O ' ' C' ' 30' ' ' ALA . . . -130.58 -179.9 5.55 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 118.803 1.301 . . . . 0.0 114.033 -174.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.924 HG22 HG22 ' C' ' 31' ' ' ILE . 16.3 tt -136.37 144.74 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 CA-C-N 113.281 -1.781 . . . . 0.0 112.717 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.442 HD13 ' CD1' ' F' ' 19' ' ' PHE . 4.6 mt -103.92 109.88 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 175.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.6 104.26 0.88 Allowed Glycine 0 N--CA 1.466 0.697 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -157.28 157.71 34.73 Favored 'General case' 0 C--O 1.245 0.835 0 CA-C-O 123.879 1.8 . . . . 0.0 114.019 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.437 ' O ' ' O ' ' C' ' 36' ' ' VAL . 0.9 OUTLIER -97.1 119.5 35.7 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 110.516 -3.038 . . . . 0.0 108.683 178.371 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' E' ' 35' ' ' MET . 38.3 t -121.86 142.41 38.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 178.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.563 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.25 -102.14 0.19 Allowed Glycine 0 C--N 1.296 -1.666 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -176.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' D' ' 39' ' ' VAL . . . 47.56 71.39 0.56 Allowed Glycine 0 CA--C 1.526 0.772 0 C-N-CA 120.048 -1.072 . . . . 0.0 110.643 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.882 ' O ' HG13 ' C' ' 39' ' ' VAL . 59.4 t -22.53 142.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.642 0.777 . . . . 0.0 112.886 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.477 HG13 HG12 ' D' ' 39' ' ' VAL . 16.6 m . . . . . 0 N--CA 1.471 0.622 0 CA-C-O 117.742 -1.123 . . . . 0.0 111.053 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -72.46 125.7 28.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.733 0.302 . . . . 0.0 110.543 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -148.39 130.87 15.76 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.629 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.436 ' H ' HG12 ' D' ' 12' ' ' VAL . 8.4 m -134.01 131.11 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.032 0.444 . . . . 0.0 110.79 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.539 ' CE1' ' OXT' ' C' ' 40' ' ' VAL . 3.4 p80 -150.21 146.55 26.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.875 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.472 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 41.5 m-70 -147.52 162.57 38.81 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-O 121.09 0.472 . . . . 0.0 111.49 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.523 ' NE2' ' OE1' ' D' ' 15' ' ' GLN . 56.6 tp60 -85.17 157.26 20.7 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 176.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.684 ' C ' HD12 ' E' ' 17' ' ' LEU . 86.7 tttt -159.45 98.41 1.4 Allowed 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 118.473 -1.291 . . . . 0.0 112.378 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.684 HD12 ' C ' ' E' ' 16' ' ' LYS . 5.9 mp -122.26 123.13 40.74 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 p -120.51 118.89 58.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' F' ' 19' ' ' PHE . 17.3 m-85 -108.91 105.71 15.36 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -108.53 114.45 28.29 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.539 ' O ' ' HB1' ' F' ' 21' ' ' ALA . . . -164.48 173.48 12.04 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 117.609 -1.636 . . . . 0.0 114.736 -177.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.411 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 73.4 mt-10 -77.75 141.18 39.43 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.339 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -175.41 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 120.475 0.179 . . . . 0.0 110.616 -177.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.858 HG12 ' H ' ' E' ' 25' ' ' GLY . 11.7 t -61.05 -179.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.638 0.732 . . . . 0.0 112.219 -176.299 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.858 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -100.89 28.69 14.82 Favored Glycine 0 N--CA 1.467 0.716 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.366 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.489 ' H ' HD22 ' D' ' 27' ' ' ASN . 19.6 m -83.56 -119.97 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -177.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' E' ' 29' ' ' GLY . 8.5 m120 -91.35 -151.53 0.26 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.852 -175.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp 44.1 -47.4 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 -176.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 130.98 60.54 0.09 OUTLIER Glycine 0 N--CA 1.49 2.252 0 CA-C-N 122.629 2.468 . . . . 0.0 115.899 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.83 116.92 11.69 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 119.301 1.55 . . . . 0.0 110.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.499 HD11 ' HB ' ' Q' ' 39' ' ' VAL . 77.6 mt -125.26 146.75 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.798 -177.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -134.2 113.62 17.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 O-C-N 121.438 -0.789 . . . . 0.0 110.426 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.82 107.53 2.02 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 20.4 tp -128.4 120.5 27.08 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.288 0.566 . . . . 0.0 112.271 -177.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 53.3 tpp -106.69 121.18 43.83 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.154 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.515 ' O ' ' O ' ' E' ' 37' ' ' GLY . 83.7 t -109.42 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.515 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -22.66 152.95 0.0 OUTLIER Glycine 0 N--CA 1.479 1.518 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.296 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . -54.94 -54.41 33.79 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.004 -0.887 . . . . 0.0 114.492 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.6 HG23 HD11 ' K' ' 31' ' ' ILE . 70.5 t . . . . . 0 N--CA 1.477 0.896 0 CA-C-N 119.17 1.485 . . . . 0.0 110.395 -179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 . . . . . 0 N--CA 1.469 0.519 0 CA-C-O 120.664 0.269 . . . . 0.0 110.752 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.41 122.84 67.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.167 0.508 . . . . 0.0 110.842 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.709 ' N ' ' HD1' ' F' ' 13' ' ' HIS . 0.3 OUTLIER -154.64 121.59 5.55 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.265 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.627 ' C ' ' HD1' ' F' ' 14' ' ' HIS . 0.1 OUTLIER -151.8 166.25 31.95 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.853 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.563 HE22 ' H ' ' D' ' 37' ' ' GLY . 12.3 tt0 -89.82 156.68 18.33 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . 0.465 ' C ' HD22 ' F' ' 17' ' ' LEU . 76.7 tttt -141.83 101.55 3.98 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 120.729 -0.389 . . . . 0.0 110.862 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.909 HD22 ' N ' ' F' ' 17' ' ' LEU . 0.2 OUTLIER -118.0 111.68 19.26 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -107.77 110.04 30.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.442 ' CD1' HD13 ' D' ' 32' ' ' ILE . 29.3 m-85 -106.31 103.29 12.73 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 178.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -123.31 129.48 51.39 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.619 0.723 . . . . 0.0 110.589 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.539 ' HB1' ' O ' ' E' ' 21' ' ' ALA . . . -147.63 149.03 31.74 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 120.042 -0.663 . . . . 0.0 109.372 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.31 121.73 17.47 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.695 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.46 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 67.4 t0 . . . . . 0 CA--C 1.53 0.188 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.514 -0.415 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 10.4 tt -133.13 136.3 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 CA-C-O 122.103 0.954 . . . . 0.0 112.704 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 89.9 mt -122.17 131.9 72.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 111.34 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.76 119.93 3.66 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.9 tp -125.47 126.52 45.04 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mtp -142.53 142.39 32.23 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.598 HG22 ' N ' ' F' ' 37' ' ' GLY . 2.3 p -140.78 171.39 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.598 ' N ' HG22 ' F' ' 36' ' ' VAL . . . -168.03 94.15 0.11 Allowed Glycine 0 C--N 1.306 -1.086 0 C-N-CA 119.202 -1.475 . . . . 0.0 111.887 179.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . 0.503 ' O ' HG23 ' F' ' 39' ' ' VAL . . . 165.27 -81.44 0.11 Allowed Glycine 0 CA--C 1.529 0.929 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.308 176.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.503 HG23 ' O ' ' F' ' 38' ' ' GLY . 40.2 t -156.5 130.99 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-O 121.488 0.661 . . . . 0.0 110.45 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.636 179.765 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 46.4 t . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 121.042 0.448 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 79.5 m80 -110.0 151.28 27.35 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.152 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.665 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 0.2 OUTLIER -84.33 168.02 16.01 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.175 0.512 . . . . 0.0 110.838 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.665 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 99.6 mm-40 -154.97 142.35 19.57 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -84.7 121.82 28.2 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.745 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 92.5 mt -126.25 127.92 46.38 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -141.4 139.14 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.907 0.384 . . . . 0.0 111.595 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -135.79 137.16 41.32 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.246 0.546 . . . . 0.0 110.747 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.486 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 53.6 p90 -132.9 130.2 39.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.439 -178.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.83 125.86 48.6 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.622 0.725 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -156.5 -121.25 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.151 -0.931 . . . . 0.0 108.961 -178.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 55.5 p30 . . . . . 0 CA--C 1.545 0.779 0 C-N-CA 124.425 1.09 . . . . 0.0 113.688 179.632 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.57 ' ND2' ' H ' ' H' ' 25' ' ' GLY . 71.0 m-20 . . . . . 0 CA--C 1.534 0.346 0 N-CA-C 112.074 0.398 . . . . 0.0 112.074 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -110.59 -39.78 4.79 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 122.437 1.113 . . . . 0.0 108.601 175.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 79.6 -69.35 3.03 Favored Glycine 0 CA--C 1.536 1.396 0 CA-C-N 113.037 -1.892 . . . . 0.0 113.061 178.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.483 ' HB2' ' O ' ' G' ' 29' ' ' GLY . . . 179.45 79.98 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 118.162 0.981 . . . . 0.0 113.245 176.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 81.1 mt -122.25 107.07 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.978 1.263 . . . . 0.0 107.612 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.41 HD13 ' CD1' ' I' ' 19' ' ' PHE . 93.9 mt -122.29 112.08 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.436 0.636 . . . . 0.0 112.393 -177.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.64 103.54 1.46 Allowed Glycine 0 N--CA 1.461 0.328 0 N-CA-C 105.279 -3.128 . . . . 0.0 105.279 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.0 mt -143.29 162.89 34.47 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 123.556 1.646 . . . . 0.0 115.174 -175.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -113.19 107.72 16.3 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 111.367 -2.651 . . . . 0.0 104.087 175.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 27.4 t -122.25 131.61 72.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.73 -111.33 3.27 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.447 ' O ' HG12 ' H' ' 39' ' ' VAL . . . 74.5 -73.92 1.34 Allowed Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 t -79.62 168.59 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.813 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.09 138.53 43.09 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.836 0.351 . . . . 0.0 110.792 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -126.86 140.73 52.13 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.719 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.95 131.63 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 120.869 0.366 . . . . 0.0 110.133 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -124.75 159.56 30.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.977 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.523 ' CD2' ' H ' ' I' ' 14' ' ' HIS . 83.8 m-70 -119.25 172.98 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -92.53 149.33 21.43 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -101.42 128.24 47.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.8 tp -122.84 124.51 43.44 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.04 0.448 . . . . 0.0 111.377 -179.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.93 124.8 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -133.4 126.62 31.66 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.402 ' CZ ' ' HB3' ' G' ' 20' ' ' PHE . 37.4 p90 -145.33 143.51 30.2 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 119.141 -1.024 . . . . 0.0 112.379 178.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.99 123.83 43.38 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.942 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.73 162.77 35.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 120.126 -0.63 . . . . 0.0 112.509 -178.22 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 59.92 47.2 10.24 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.054 -0.976 . . . . 0.0 112.742 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.609 HG12 ' H ' ' H' ' 26' ' ' SER . 2.4 t -83.4 166.96 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 116.515 -2.074 . . . . 0.0 107.26 -179.263 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.57 ' H ' ' ND2' ' G' ' 27' ' ' ASN . . . -72.37 -36.33 59.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 119.628 -1.272 . . . . 0.0 114.723 178.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.768 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.8 t -174.14 126.66 0.35 Allowed 'General case' 0 C--O 1.224 -0.273 0 CA-C-O 117.723 -1.132 . . . . 0.0 112.147 -176.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.768 ' O ' ' O ' ' H' ' 26' ' ' SER . 10.8 t30 -2.44 146.4 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 175.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 58.9 tttt -159.31 30.34 0.2 Allowed 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.486 ' HA3' HG21 ' B' ' 39' ' ' VAL . . . 82.72 89.24 0.69 Allowed Glycine 0 C--N 1.345 1.044 0 C-N-CA 117.17 -2.443 . . . . 0.0 114.108 176.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.524 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -110.41 102.65 11.26 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 123.371 1.558 . . . . 0.0 112.045 -178.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.574 HD11 HG13 ' B' ' 39' ' ' VAL . 80.7 mt -123.02 131.01 74.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 112.765 -2.016 . . . . 0.0 110.651 -179.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.584 HD13 ' CD1' ' J' ' 19' ' ' PHE . 81.3 mt -113.21 108.75 26.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 175.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.66 121.82 4.5 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -178.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.643 ' CD2' HD11 ' I' ' 34' ' ' LEU . 0.8 OUTLIER -169.49 163.16 10.36 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 123.904 1.811 . . . . 0.0 113.91 -179.925 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -100.21 116.55 32.47 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 111.483 -2.598 . . . . 0.0 108.576 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.532 HG12 ' NE2' ' J' ' 15' ' ' GLN . 53.8 t -127.8 123.69 61.53 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.565 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.13 -114.35 2.26 Favored Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.412 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.35 -72.68 2.77 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.54 ' HB ' HG21 ' N' ' 31' ' ' ILE . 2.5 p -152.07 151.23 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 O-C-N 122.7 -0.294 . . . . 0.0 110.47 177.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.621 HG21 ' CD2' ' J' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.218 -0.563 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.454 178.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.76 161.4 41.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.74 0.305 . . . . 0.0 110.448 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.41 139.24 51.72 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.578 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 4.7 m -126.89 136.46 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -138.91 93.62 2.72 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.537 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.523 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 52.3 p-80 -157.1 153.47 27.86 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 118.793 -1.163 . . . . 0.0 112.52 176.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -90.81 161.49 15.25 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.748 176.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -139.47 110.98 7.08 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 177.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' I' ' 17' ' ' LEU . 4.3 mp -129.47 131.63 46.73 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.264 0.554 . . . . 0.0 110.942 178.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 76.0 t -121.15 120.14 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.41 ' CD1' HD13 ' G' ' 32' ' ' ILE . 61.3 m-85 -118.53 111.16 18.26 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -121.66 135.21 54.98 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 122.311 -0.243 . . . . 0.0 111.358 -178.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 1.113 ' HB1' ' HZ1' ' I' ' 28' ' ' LYS . . . -139.28 136.05 34.49 Favored 'General case' 0 CA--C 1.555 1.152 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.489 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 79.7 tt0 -117.29 152.75 34.23 Favored 'General case' 0 N--CA 1.484 1.266 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.259 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.466 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 16.8 t70 -171.49 51.23 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -177.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.437 HG22 ' HB2' ' J' ' 23' ' ' ASP . 16.8 t -63.19 151.04 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.47 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.92 -35.27 4.96 Favored Glycine 0 CA--C 1.539 1.538 0 CA-C-N 116.153 -0.476 . . . . 0.0 113.639 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' I' ' 27' ' ' ASN . 28.9 t -151.68 124.15 8.35 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.672 ' ND2' ' H ' ' I' ' 27' ' ' ASN . 0.7 OUTLIER -41.19 145.86 0.21 Allowed 'General case' 0 C--N 1.348 0.514 0 C-N-CA 118.396 -1.322 . . . . 0.0 109.774 -175.687 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 1.113 ' HZ1' ' HB1' ' I' ' 21' ' ' ALA . 18.3 tttt -75.08 -49.65 19.01 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -177.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 109.51 59.43 0.52 Allowed Glycine 0 CA--C 1.545 1.964 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -177.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.1 114.2 26.08 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -172.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 82.8 mt -134.28 127.25 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 113.858 -1.519 . . . . 0.0 109.334 176.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.538 HD13 ' HD2' ' K' ' 19' ' ' PHE . 14.2 tt -121.01 114.96 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.548 177.344 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.739 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -109.21 108.7 2.62 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.739 HD12 ' O ' ' I' ' 33' ' ' GLY . 2.4 mp -135.12 148.2 49.71 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.952 1.358 . . . . 0.0 114.116 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.44 ' O ' ' O ' ' H' ' 36' ' ' VAL . 86.4 mmm -107.75 112.72 25.54 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-N 112.686 -2.052 . . . . 0.0 106.809 175.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.492 HG12 HE22 ' L' ' 15' ' ' GLN . 4.8 t -136.51 161.91 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.012 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.71 ' H ' HE22 ' K' ' 15' ' ' GLN . . . 81.1 102.44 0.33 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 119.424 -1.37 . . . . 0.0 112.005 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.44 ' N ' ' CA ' ' J' ' 38' ' ' GLY . . . -154.45 -71.12 0.01 OUTLIER Glycine 0 CA--C 1.544 1.847 0 CA-C-O 118.899 -0.945 . . . . 0.0 111.406 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.489 HG13 ' O ' ' O' ' 29' ' ' GLY . 16.0 t -119.3 128.95 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 119.406 1.603 . . . . 0.0 109.137 177.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.43 ' OXT' ' O ' ' I' ' 39' ' ' VAL . 77.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.216 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -107.39 132.39 53.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.808 0.337 . . . . 0.0 110.667 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . 0.534 ' OE1' ' N ' ' J' ' 11' ' ' GLU . 58.1 mp0 -123.96 134.98 53.37 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.333 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -124.52 132.6 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.568 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.621 ' CD2' HG21 ' H' ' 40' ' ' VAL . 4.2 t-160 -129.01 137.59 51.43 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.163 0.506 . . . . 0.0 110.476 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.538 ' N ' ' CD2' ' J' ' 13' ' ' HIS . 83.1 m-70 -154.85 176.92 11.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 122.103 0.954 . . . . 0.0 111.777 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.532 ' NE2' HG12 ' H' ' 36' ' ' VAL . 38.6 tt0 -159.77 137.14 9.68 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.257 -2.127 . . . . 0.0 105.257 177.298 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.839 ' C ' HD12 ' J' ' 17' ' ' LEU . 84.9 tttt -134.25 113.8 12.36 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.075 -0.65 . . . . 0.0 112.66 -178.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.839 HD12 ' C ' ' J' ' 16' ' ' LYS . 7.0 mp -133.87 117.67 17.08 Favored 'General case' 0 CA--C 1.508 -0.64 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 176.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -106.8 110.01 30.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.1 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.584 ' CD1' HD13 ' H' ' 32' ' ' ILE . 62.6 m-85 -108.12 104.18 13.54 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 178.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.435 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 5.0 m-85 -123.24 129.91 52.03 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 118.76 20.33 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.476 ' OE2' ' CE1' ' K' ' 20' ' ' PHE . 76.0 mt-10 -145.81 133.41 20.95 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 -176.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.796 ' OD1' HG23 ' J' ' 24' ' ' VAL . 0.2 OUTLIER 164.69 -70.4 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.404 175.643 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.796 HG23 ' OD1' ' J' ' 23' ' ' ASP . 22.8 t -58.17 -121.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 113.761 -1.563 . . . . 0.0 110.415 175.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.661 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 142.08 -35.55 1.75 Allowed Glycine 0 C--O 1.222 -0.64 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.591 -179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.402 ' O ' ' CG ' ' I' ' 27' ' ' ASN . 10.2 t -80.45 118.55 22.17 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 122.606 3.203 . . . . 0.0 103.119 169.009 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.667 ' CG ' ' H ' ' J' ' 30' ' ' ALA . 21.7 p30 -90.6 158.84 16.75 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 123.413 2.824 . . . . 0.0 110.966 178.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.68 ' NZ ' HD21 ' H' ' 27' ' ' ASN . 98.3 mttt -48.12 -40.42 23.53 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 122.823 1.297 . . . . 0.0 110.985 173.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.43 67.85 0.04 OUTLIER Glycine 0 CA--C 1.545 1.911 0 CA-C-N 111.854 -2.43 . . . . 0.0 108.586 -174.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.667 ' H ' ' CG ' ' J' ' 27' ' ' ASN . . . -70.31 138.68 51.7 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-N 120.169 1.984 . . . . 0.0 114.2 -171.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.673 HD11 ' CG2' ' D' ' 39' ' ' VAL . 86.2 mt -140.22 136.8 37.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-N 112.906 -1.952 . . . . 0.0 114.606 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.422 ' O ' HG22 ' J' ' 32' ' ' ILE . 4.7 mt -108.74 109.3 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.92 108.66 2.43 Favored Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.417 HD12 ' O ' ' I' ' 34' ' ' LEU . 12.7 tp -142.49 136.85 29.79 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 118.674 -1.21 . . . . 0.0 113.657 -175.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.433 ' O ' ' O ' ' I' ' 36' ' ' VAL . 0.6 OUTLIER -104.89 120.57 41.75 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.211 -1.813 . . . . 0.0 107.145 177.109 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.483 HG12 ' N ' ' J' ' 37' ' ' GLY . 43.4 t -125.11 167.35 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 121.315 0.578 . . . . 0.0 110.897 -176.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.483 ' N ' HG12 ' J' ' 36' ' ' VAL . . . 106.65 102.49 2.8 Favored Glycine 0 N--CA 1.467 0.752 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.891 178.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.516 ' O ' ' C ' ' J' ' 39' ' ' VAL . . . -121.89 65.61 0.48 Allowed Glycine 0 CA--C 1.539 1.593 0 CA-C-O 117.858 -1.523 . . . . 0.0 113.125 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.643 ' HB ' HD11 ' P' ' 31' ' ' ILE . 71.1 t -12.84 127.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 CA-C-N 119.905 1.852 . . . . 0.0 113.769 -176.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.42 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 10.7 m . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.943 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.462 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -107.1 135.7 48.21 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.862 0.363 . . . . 0.0 110.385 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 57.6 mp0 -131.82 146.06 51.92 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.954 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.466 ' C ' ' CD2' ' K' ' 13' ' ' HIS . 55.6 t -123.82 128.5 74.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.082 0.468 . . . . 0.0 110.769 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.518 ' CE1' ' NZ ' ' O' ' 28' ' ' LYS . 36.7 m-70 -148.05 100.21 3.15 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.638 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.66 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 4.7 m80 -145.14 157.71 44.02 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.901 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.71 HE22 ' H ' ' I' ' 37' ' ' GLY . 79.3 mt-30 -90.27 159.25 16.78 Favored 'General case' 0 CA--C 1.515 -0.4 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 174.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -140.71 103.62 4.55 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.502 177.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.455 HD11 ' NE2' ' J' ' 15' ' ' GLN . 5.1 mp -131.47 119.61 21.82 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.549 0.69 . . . . 0.0 109.456 177.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.1 t -106.05 113.01 41.7 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 114.766 -1.107 . . . . 0.0 108.629 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.538 ' HD2' HD13 ' I' ' 32' ' ' ILE . 1.8 m-85 -105.95 101.59 11.08 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.584 -1.636 . . . . 0.0 106.584 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.476 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 40.6 t80 -117.95 126.83 53.09 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 120.984 0.421 . . . . 0.0 111.064 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -146.79 142.33 27.62 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 119.657 -0.817 . . . . 0.0 112.727 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 85.6 mt-10 -82.68 115.56 21.67 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.516 ' CG ' HD22 ' J' ' 27' ' ' ASN . 68.5 t0 -131.85 46.4 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.732 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.584 HG12 ' H ' ' K' ' 25' ' ' GLY . 6.4 t -83.48 171.76 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.277 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.755 -177.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.584 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 95.45 -29.43 9.64 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 91.81 115.1 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 -178.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.452 ' ND2' ' H ' ' K' ' 28' ' ' LYS . 9.1 t-20 -73.79 163.13 28.36 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 118.377 -1.329 . . . . 0.0 111.378 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.578 ' NZ ' ' NE2' ' F' ' 13' ' ' HIS . 99.1 mttt -48.12 -37.24 14.95 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.853 175.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.99 76.92 0.06 OUTLIER Glycine 0 CA--C 1.541 1.684 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.755 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.416 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -79.95 139.89 36.88 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 119.133 1.466 . . . . 0.0 110.173 -178.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.6 HD11 HG23 ' E' ' 39' ' ' VAL . 7.1 mt -130.85 133.71 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -175.398 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.459 HD11 HG12 ' L' ' 32' ' ' ILE . 33.7 pt -121.0 118.77 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 121.596 0.712 . . . . 0.0 109.323 176.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 118.24 4.22 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -178.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.594 ' CD2' ' CE2' ' L' ' 19' ' ' PHE . 4.2 mp -129.03 118.42 22.52 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.973 0.892 . . . . 0.0 111.716 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -102.74 115.31 30.33 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.193 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.675 HG12 ' N ' ' K' ' 37' ' ' GLY . 42.6 t -116.76 174.12 3.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.675 ' N ' HG12 ' K' ' 36' ' ' VAL . . . 163.05 -95.41 0.13 Allowed Glycine 0 C--N 1.305 -1.181 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' K' ' 37' ' ' GLY . . . 28.48 78.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.401 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.56 HG13 ' O ' ' L' ' 39' ' ' VAL . 90.5 t . . . . . 0 N--CA 1.474 0.772 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -179.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.735 0.303 . . . . 0.0 110.387 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.59 122.01 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.17 0.509 . . . . 0.0 110.786 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.489 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -153.12 101.21 2.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.63 179.47 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.66 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.7 m80 -146.28 164.34 32.65 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.532 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 23.8 tt0 -90.02 158.45 17.34 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.636 0.236 . . . . 0.0 111.636 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.53 109.57 6.11 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 121.55 0.69 . . . . 0.0 111.555 178.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 22.4 mt -128.68 117.26 20.88 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -105.14 108.47 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.613 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' K' ' 34' ' ' LEU . 42.8 m-85 -102.45 105.36 15.92 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -129.19 122.01 28.86 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.642 0.734 . . . . 0.0 111.099 -178.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -129.35 133.0 47.2 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.454 ' O ' ' C ' ' K' ' 23' ' ' ASP . 79.6 mm-40 -77.27 114.76 16.43 Favored 'General case' 0 C--O 1.222 -0.388 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.641 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p30 -168.5 46.46 0.04 OUTLIER 'General case' 0 C--O 1.231 0.099 0 C-N-CA 119.838 -0.745 . . . . 0.0 112.833 -178.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.2 m -83.65 172.68 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 119.225 -0.99 . . . . 0.0 108.941 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.51 -29.82 8.57 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 15.7 p -84.77 139.9 31.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.38 -0.41 . . . . 0.0 110.993 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' N ' ' L' ' 29' ' ' GLY . 61.6 t-20 -73.15 149.17 43.19 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.509 ' N ' ' OD1' ' L' ' 27' ' ' ASN . 6.3 tmtt? 64.68 -49.71 0.32 Allowed 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 94.83 -54.79 1.92 Allowed Glycine 0 CA--C 1.542 1.745 0 CA-C-N 116.201 -0.454 . . . . 0.0 114.079 177.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.416 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -170.42 -172.75 1.31 Allowed 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 117.666 0.733 . . . . 0.0 109.69 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 97.8 mt -98.41 119.09 45.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 176.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.459 HG12 HD11 ' K' ' 32' ' ' ILE . 88.9 mt -115.3 122.84 70.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -177.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 106.22 0.84 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 178.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 10.0 tt -133.45 131.17 39.59 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 33.4 ttp -151.59 160.3 43.72 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.709 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 27.1 m -109.47 173.96 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.339 0.123 0 CA-C-O 121.152 0.501 . . . . 0.0 111.108 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.451 ' H ' ' HA2' ' K' ' 37' ' ' GLY . . . -166.51 94.64 0.11 Allowed Glycine 0 C--N 1.306 -1.098 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.03 83.4 0.79 Allowed Glycine 0 N--CA 1.473 1.149 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.56 ' O ' HG13 ' K' ' 39' ' ' VAL . 21.8 m . . . . . 0 CA--C 1.535 0.393 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 . . . . . 0 N--CA 1.463 0.198 0 CA-C-O 120.762 0.315 . . . . 0.0 110.915 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -126.83 130.17 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 121.198 0.523 . . . . 0.0 110.15 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -124.52 163.06 22.68 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.172 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 41.9 p-80 -87.41 170.76 11.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.217 -179.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.14 150.95 50.31 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.017 179.116 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -96.65 123.77 40.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.214 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -127.8 116.06 19.6 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -126.27 134.51 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.09 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -137.29 141.04 41.93 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 178.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -144.42 146.84 32.71 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.413 -179.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.52 119.71 21.92 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.144 0.497 . . . . 0.0 110.462 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' M' ' 24' ' ' VAL . 97.5 mt-10 -103.59 -162.71 0.93 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.544 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' M' ' 22' ' ' GLU . 96.9 m-20 -23.64 -59.69 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 123.222 0.609 . . . . 0.0 112.345 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.454 ' O ' ' O ' ' M' ' 22' ' ' GLU . 32.6 m -91.3 169.87 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -178.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.37 28.36 57.98 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 11.9 t -97.02 110.7 23.19 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 p30 -78.14 175.42 10.17 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -176.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -49.75 -36.23 25.07 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 112.507 -2.133 . . . . 0.0 115.074 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.94 78.63 0.06 OUTLIER Glycine 0 N--CA 1.471 1.012 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.643 -172.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.03 108.62 0.26 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-O 124.362 2.029 . . . . 0.0 113.306 -175.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.552 HG23 ' O ' ' M' ' 31' ' ' ILE . 15.1 tt -128.34 125.71 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 110.537 -3.028 . . . . 0.0 108.388 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 92.8 mt -102.64 108.88 25.12 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.527 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.92 92.82 0.67 Allowed Glycine 0 CA--C 1.508 -0.352 0 N-CA-C 105.44 -3.064 . . . . 0.0 105.44 176.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . 0.632 ' O ' HD23 ' N' ' 34' ' ' LEU . 92.8 mt -135.36 156.57 48.71 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 122.81 1.29 . . . . 0.0 113.861 -176.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -108.9 105.27 14.75 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 112.426 -2.17 . . . . 0.0 106.25 176.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.583 HG23 HD21 ' N' ' 34' ' ' LEU . 50.4 t -106.12 111.83 36.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.03 -132.12 8.74 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.418 ' O ' HG12 ' N' ' 39' ' ' VAL . . . 93.81 -63.19 1.87 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.621 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.67 HG12 ' CD1' ' A' ' 31' ' ' ILE . 1.2 m -111.14 161.3 9.74 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -178.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.949 -1.025 . . . . 0.0 110.764 -179.987 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -81.71 138.37 35.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.758 0.313 . . . . 0.0 110.27 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -76.45 116.33 17.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.692 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.438 HG12 ' H ' ' O' ' 12' ' ' VAL . 34.5 m -137.7 157.63 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.112 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 21.8 t-160 -145.46 98.81 3.2 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.871 0.367 . . . . 0.0 111.311 179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.477 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 28.4 p-80 -153.98 168.12 27.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.338 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -129.45 150.35 50.84 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 110.064 178.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -98.15 124.0 42.49 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.4 ' C ' HD23 ' N' ' 17' ' ' LEU . 7.6 tt -125.84 124.45 40.93 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.483 0.583 . . . . 0.0 109.701 178.563 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -125.94 134.41 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.603 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' N' ' 21' ' ' ALA . 74.4 t80 -130.63 120.3 23.75 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.811 0.339 . . . . 0.0 111.051 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -112.36 127.77 56.1 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . 0.438 ' HB2' ' CE2' ' N' ' 19' ' ' PHE . . . -132.75 132.91 42.8 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-N 118.584 0.629 . . . . 0.0 111.958 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -170.09 128.44 0.89 Allowed 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.023 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.465 ' CG ' ' H ' ' N' ' 24' ' ' VAL . 16.6 p-10 -155.05 -59.81 0.11 Allowed 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 119.89 -0.724 . . . . 0.0 111.618 177.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.465 ' H ' ' CG ' ' N' ' 23' ' ' ASP . 16.9 m -102.87 -176.83 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.94 -33.69 70.5 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 1.5 m -147.86 118.87 7.66 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -59.9 169.06 1.56 Allowed 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 117.919 -1.512 . . . . 0.0 110.922 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -54.69 -36.96 65.23 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 115.305 1.594 . . . . 0.0 115.305 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.75 77.58 0.07 OUTLIER Glycine 0 CA--C 1.54 1.634 0 C-N-CA 120.123 -1.037 . . . . 0.0 113.429 -174.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.86 116.71 20.17 Favored 'General case' 0 CA--C 1.548 0.894 0 CA-C-N 118.866 1.333 . . . . 0.0 113.638 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.54 HG21 ' HB ' ' H' ' 39' ' ' VAL . 2.8 tt -146.08 134.09 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.125 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.51 HG22 HD11 ' O' ' 34' ' ' LEU . 15.8 mt -109.38 120.55 60.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 CA-C-O 120.971 0.415 . . . . 0.0 110.64 179.427 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.03 112.75 2.68 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 105.795 -2.922 . . . . 0.0 105.795 176.389 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.632 HD23 ' O ' ' M' ' 34' ' ' LEU . 0.3 OUTLIER -151.91 144.13 23.97 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 117.773 -1.571 . . . . 0.0 115.074 -175.206 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.406 ' SD ' ' HB2' ' O' ' 35' ' ' MET . 89.7 mmm -105.8 108.36 19.84 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.404 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . 2.0 t -106.9 101.79 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 118.878 0.763 . . . . 0.0 110.884 -177.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.09 -171.14 20.56 Favored Glycine 0 C--N 1.323 -0.173 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.488 ' O ' HG12 ' O' ' 39' ' ' VAL . . . 155.66 -55.04 0.41 Allowed Glycine 0 CA--C 1.547 2.036 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 -178.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.7 ' HB ' HD11 ' B' ' 31' ' ' ILE . 10.6 p -159.49 135.26 1.8 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 CA-C-N 117.628 0.714 . . . . 0.0 109.768 177.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.462 HG13 ' O ' ' N' ' 39' ' ' VAL . 22.6 m . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.225 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -82.05 137.84 34.97 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.821 0.343 . . . . 0.0 110.488 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -114.74 134.93 54.7 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.592 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.438 ' H ' HG12 ' N' ' 12' ' ' VAL . 75.3 t -122.45 130.25 74.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.856 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.503 ' H ' ' HB3' ' P' ' 13' ' ' HIS . 3.5 t-80 -146.58 102.74 3.6 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.574 0.226 . . . . 0.0 111.364 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' P' ' 14' ' ' HIS . 8.0 p-80 -156.34 164.48 38.25 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.919 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -89.84 158.82 17.29 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -140.1 119.23 12.75 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -135.82 130.02 33.33 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 122.321 1.057 . . . . 0.0 111.777 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . 0.599 HG13 HG13 ' P' ' 18' ' ' VAL . 48.1 t -112.09 118.23 57.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 177.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -110.32 102.78 11.4 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 14.6 t80 -114.83 127.8 55.93 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.73 115.11 20.86 Favored 'General case' 0 C--O 1.243 0.742 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . 0.448 ' O ' ' C ' ' O' ' 23' ' ' ASP . 83.0 tt0 -86.7 151.28 23.55 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.142 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.448 ' C ' ' O ' ' O' ' 22' ' ' GLU . 49.0 t0 26.83 49.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.904 -176.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.656 HG11 ' HB1' ' P' ' 21' ' ' ALA . 1.1 p -68.75 154.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.013 -1.449 . . . . 0.0 108.179 175.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.424 ' N ' ' CG2' ' O' ' 24' ' ' VAL . . . -131.51 -28.81 0.61 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.667 ' OG ' ' HB2' ' O' ' 30' ' ' ALA . 3.3 t 63.69 -110.14 0.28 Allowed 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.53 178.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.559 ' N ' ' OG ' ' O' ' 26' ' ' SER . 32.9 m-20 150.51 -161.37 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.551 0 O-C-N 124.473 1.108 . . . . 0.0 109.153 -178.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.518 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 98.8 mttt -29.71 -40.4 0.02 OUTLIER 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -179.013 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.489 ' O ' HG13 ' I' ' 39' ' ' VAL . . . -170.07 70.05 0.14 Allowed Glycine 0 CA--C 1.541 1.662 0 C-N-CA 118.489 -1.815 . . . . 0.0 115.908 -173.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . 0.667 ' HB2' ' OG ' ' O' ' 26' ' ' SER . . . -72.75 150.18 43.06 Favored 'General case' 0 C--N 1.363 1.175 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.423 HG22 ' N ' ' O' ' 32' ' ' ILE . 20.6 mt -140.69 149.85 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 118.076 2.621 . . . . 0.0 118.076 -171.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.722 HG23 HD13 ' O' ' 34' ' ' LEU . 6.7 mt -111.78 106.76 21.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 N-CA-C 104.871 -2.27 . . . . 0.0 104.871 173.152 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.799 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -117.43 98.5 0.78 Allowed Glycine 0 N--CA 1.473 1.15 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.799 HD12 ' C ' ' O' ' 33' ' ' GLY . 8.8 mp -136.67 151.92 49.82 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 123.698 1.713 . . . . 0.0 114.433 -175.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.406 ' HB2' ' SD ' ' N' ' 35' ' ' MET . 0.8 OUTLIER -113.15 112.04 23.13 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 111.947 -2.388 . . . . 0.0 106.019 176.483 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.09 147.69 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.921 ' H ' HE22 ' Q' ' 15' ' ' GLN . . . 127.32 103.04 1.22 Allowed Glycine 0 C--N 1.307 -1.057 0 N-CA-C 109.384 -1.487 . . . . 0.0 109.384 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.525 ' O ' ' C ' ' O' ' 39' ' ' VAL . . . -108.47 72.42 0.2 Allowed Glycine 0 CA--C 1.533 1.179 0 CA-C-O 117.612 -1.66 . . . . 0.0 112.074 179.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.822 ' H ' HG21 ' P' ' 39' ' ' VAL . 7.6 p -12.86 130.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 CA-C-N 119.804 1.802 . . . . 0.0 113.325 -175.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.426 ' O ' HG23 ' O' ' 40' ' ' VAL . 5.6 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.375 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.613 HG12 ' H ' ' Q' ' 12' ' ' VAL . 19.4 m . . . . . 0 N--CA 1.467 0.412 0 CA-C-O 120.778 0.323 . . . . 0.0 110.545 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.503 ' HB3' ' H ' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -135.44 140.24 44.74 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.449 -179.27 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' O' ' 14' ' ' HIS . 5.5 m-70 -125.42 161.17 27.66 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 178.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 27.2 tp60 -89.89 158.15 17.56 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . 0.781 ' C ' HD12 ' P' ' 17' ' ' LEU . 68.2 mttm -141.47 100.22 3.73 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.437 178.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.781 HD12 ' C ' ' P' ' 16' ' ' LYS . 9.0 mp -134.5 122.8 22.95 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 176.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . 0.599 HG13 HG13 ' O' ' 18' ' ' VAL . 3.8 p -122.4 127.39 75.08 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -115.87 106.25 13.61 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 30.5 t80 -110.97 125.67 53.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.156 -178.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . 0.656 ' HB1' HG11 ' O' ' 24' ' ' VAL . . . -138.41 122.74 18.25 Favored 'General case' 0 CA--C 1.553 1.064 0 CA-C-O 121.751 0.786 . . . . 0.0 112.615 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.578 ' O ' HG13 ' O' ' 24' ' ' VAL . 83.1 tt0 -87.42 116.66 25.68 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.408 -1.269 . . . . 0.0 110.926 179.018 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.565 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 34.2 m-20 -144.81 46.73 1.35 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.051 0.54 . . . . 0.0 112.053 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.85 HG13 ' CD ' ' Q' ' 22' ' ' GLU . 1.0 OUTLIER -82.14 173.37 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 123.229 1.49 . . . . 0.0 113.237 -175.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.42 -33.66 4.84 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-N 111.286 -2.688 . . . . 0.0 113.992 177.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.712 ' O ' ' O ' ' P' ' 27' ' ' ASN . 13.3 t -174.16 126.61 0.35 Allowed 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 118.974 1.387 . . . . 0.0 112.819 175.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.825 HD22 ' H ' ' Q' ' 27' ' ' ASN . 12.6 p30 -2.69 145.94 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 173.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.435 ' CG ' ' O ' ' P' ' 27' ' ' ASN . 93.1 mttt -158.48 30.34 0.23 Allowed 'General case' 0 N--CA 1.475 0.806 0 O-C-N 120.69 -1.256 . . . . 0.0 114.033 176.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.31 88.81 0.9 Allowed Glycine 0 CA--C 1.531 1.065 0 C-N-CA 119.503 -1.332 . . . . 0.0 113.727 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.88 105.54 7.83 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 117.871 0.836 . . . . 0.0 112.047 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.643 HD11 ' HB ' ' J' ' 39' ' ' VAL . 58.4 mt -119.21 124.25 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 CA-C-O 119.27 -0.395 . . . . 0.0 110.056 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.468 HD13 ' CD1' ' R' ' 19' ' ' PHE . 49.9 mt -109.91 110.55 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.56 100.06 1.04 Allowed Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 104.588 -3.405 . . . . 0.0 104.588 175.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 tt -144.63 137.37 26.63 Favored 'General case' 0 C--O 1.241 0.635 0 C-N-CA 118.681 -1.207 . . . . 0.0 112.883 -174.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 22.1 mtp -112.27 127.73 56.06 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 113.837 -1.529 . . . . 0.0 110.512 179.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.505 HG11 HD13 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -117.74 103.18 14.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.22 -153.48 25.09 Favored Glycine 0 C--N 1.308 -0.983 0 C-N-CA 119.276 -1.44 . . . . 0.0 111.191 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.702 ' H ' ' CG1' ' Q' ' 40' ' ' VAL . . . 99.16 -56.45 0.92 Allowed Glycine 0 CA--C 1.543 1.795 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.902 HG12 HG21 ' D' ' 31' ' ' ILE . 27.7 m -128.88 160.2 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.73 0.812 . . . . 0.0 112.265 -177.602 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.415 ' H ' HG23 ' P' ' 40' ' ' VAL . 2.8 t . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.719 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.79 90.13 3.24 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -142.77 147.97 36.42 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.766 0.317 . . . . 0.0 110.596 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.613 ' H ' HG12 ' P' ' 12' ' ' VAL . 2.2 p -140.87 135.86 33.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.658 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . . . . . . . . . 4.6 m80 -142.63 125.0 15.57 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.651 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.504 ' CE1' ' CE1' ' P' ' 14' ' ' HIS . 15.1 p-80 -152.61 160.42 43.19 Favored 'General case' 0 C--O 1.222 -0.368 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.645 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.921 HE22 ' H ' ' O' ' 37' ' ' GLY . 88.3 mt-30 -90.03 158.92 17.12 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 176.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -140.73 108.35 5.61 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.424 ' N ' HD12 ' Q' ' 17' ' ' LEU . 3.8 mp -130.97 124.13 30.32 Favored 'General case' 0 CA--C 1.511 -0.52 0 C-N-CA 119.962 -0.695 . . . . 0.0 109.726 177.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -110.1 122.34 64.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.519 ' CE2' ' CE1' ' R' ' 19' ' ' PHE . 24.0 m-85 -112.03 99.9 8.45 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 178.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -108.96 121.2 44.63 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.422 -177.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.568 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -152.76 161.12 42.98 Favored 'General case' 0 C--O 1.217 -0.625 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.628 -179.017 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.85 ' CD ' HG13 ' P' ' 24' ' ' VAL . 99.6 mt-10 -87.55 114.52 24.23 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.781 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 68.4 t0 -109.23 52.0 0.73 Allowed 'General case' 0 N--CA 1.478 0.949 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.071 -177.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.559 HG12 ' N ' ' Q' ' 25' ' ' GLY . 38.5 t -41.43 161.38 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.983 0.897 . . . . 0.0 112.247 -176.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.559 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . -93.14 32.59 5.58 Favored Glycine 0 N--CA 1.468 0.798 0 CA-C-N 113.848 -1.524 . . . . 0.0 114.273 -174.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.488 ' CB ' HD22 ' P' ' 27' ' ' ASN . 69.5 m -92.62 -112.38 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 117.593 0.696 . . . . 0.0 109.936 -178.233 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.825 ' H ' HD22 ' P' ' 27' ' ' ASN . 9.8 m120 -85.97 179.18 7.05 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 119.853 1.206 . . . . 0.0 112.91 -176.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -52.58 48.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -98.56 56.57 1.01 Allowed Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.164 -1.017 . . . . 0.0 112.936 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.63 103.49 0.7 Allowed 'General case' 0 C--O 1.24 0.56 0 CA-C-N 119.013 1.406 . . . . 0.0 112.921 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.418 HD13 HG21 ' Q' ' 31' ' ' ILE . 1.1 pt -142.69 139.82 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 120.099 -0.64 . . . . 0.0 109.601 177.242 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 4.8 tt -140.23 132.71 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 105.66 1.47 Allowed Glycine 0 C--N 1.337 0.589 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 176.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.506 HD23 HD13 ' R' ' 34' ' ' LEU . 53.0 tp -120.47 122.6 41.03 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.642 0.734 . . . . 0.0 112.201 -176.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -111.78 115.67 29.44 Favored 'General case' 0 C--O 1.223 -0.301 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.558 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.619 HG12 ' N ' ' Q' ' 37' ' ' GLY . 81.9 t -108.17 171.03 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-O 121.414 0.626 . . . . 0.0 111.26 -178.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.619 ' N ' HG12 ' Q' ' 36' ' ' VAL . . . 130.34 93.44 0.66 Allowed Glycine 0 C--N 1.311 -0.835 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.29 -74.46 0.26 Allowed Glycine 0 CA--C 1.534 1.235 0 C-N-CA 121.287 -0.483 . . . . 0.0 112.236 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.586 ' O ' HG23 ' Q' ' 39' ' ' VAL . 34.6 m -81.71 118.19 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.341 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.702 ' CG1' ' H ' ' P' ' 38' ' ' GLY . 3.1 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.414 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -126.78 154.62 44.01 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.915 0.388 . . . . 0.0 110.544 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -68.43 125.42 26.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.583 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 9.2 p -139.97 138.85 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.286 0.565 . . . . 0.0 111.373 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -149.26 105.22 3.47 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.552 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.415 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 93.4 m-70 -145.95 166.47 25.92 Favored 'General case' 0 C--O 1.221 -0.441 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.608 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -89.73 158.68 17.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.134 0.492 . . . . 0.0 110.66 -179.546 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . 0.778 ' C ' HD12 ' R' ' 17' ' ' LEU . 98.6 mttt -140.22 103.02 4.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.56 -0.745 . . . . 0.0 109.438 178.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.778 HD12 ' C ' ' R' ' 16' ' ' LYS . 10.8 mp -124.99 120.85 32.72 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 95.5 t -105.22 116.62 49.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.519 ' CE1' ' CE2' ' Q' ' 19' ' ' PHE . 78.2 m-85 -111.89 103.7 11.95 Favored 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -140.17 150.65 44.47 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-O 121.804 0.812 . . . . 0.0 111.594 -177.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -139.31 143.48 37.88 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.067 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -82.7 157.62 23.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.513 -178.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 58.69 50.45 8.87 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.525 HG12 ' N ' ' R' ' 25' ' ' GLY . 24.9 t -48.9 163.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.134 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.525 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -175.76 24.0 0.06 OUTLIER Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -178.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 4.3 m -64.94 111.68 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.776 0.798 . . . . 0.0 110.566 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.702 ' O ' ' N ' ' R' ' 29' ' ' GLY . 24.7 t-20 -149.09 176.0 10.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.956 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . 0.455 ' C ' ' O ' ' R' ' 27' ' ' ASN . 65.5 tttm -8.95 -45.91 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.952 0 O-C-N 124.401 1.063 . . . . 0.0 113.559 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.702 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -94.49 58.74 1.92 Allowed Glycine 0 CA--C 1.544 1.847 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.823 179.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 136.91 9.85 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.433 HD12 HG21 ' K' ' 39' ' ' VAL . 50.5 mt -124.77 119.5 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 CA-C-O 121.627 0.727 . . . . 0.0 111.644 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 mm -113.36 121.84 66.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.782 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 115.98 2.26 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.54 HD12 ' N ' ' R' ' 35' ' ' MET . 7.3 tp -137.03 125.38 23.33 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . 0.54 ' N ' HD12 ' R' ' 34' ' ' LEU . 9.8 ptm -160.89 172.94 16.07 Favored 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.366 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -124.72 167.33 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-O 121.327 0.584 . . . . 0.0 111.529 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.57 -102.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 114.986 -1.006 . . . . 0.0 111.103 179.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.02 -77.87 1.09 Allowed Glycine 0 CA--C 1.532 1.137 0 N-CA-C 111.559 -0.617 . . . . 0.0 111.559 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 79.3 t -121.3 132.37 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 117.17 0.485 . . . . 0.0 110.401 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.467 HG22 ' OXT' ' R' ' 40' ' ' VAL . 4.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.325 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 N--CA 1.466 0.354 0 CA-C-O 120.796 0.332 . . . . 0.0 110.754 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.607 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 53.0 t -124.89 131.33 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.144 0.497 . . . . 0.0 110.25 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -93.94 163.06 13.65 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.436 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.643 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -86.0 171.94 11.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.708 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 28.5 pt20 -158.09 142.96 16.44 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.571 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -80.24 133.95 36.05 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.895 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.6 mt -129.29 116.31 18.92 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.971 0.415 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -125.43 133.75 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.954 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -134.94 129.0 33.58 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 53.6 p90 -122.62 130.47 53.03 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.408 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.28 114.99 21.57 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.455 0.645 . . . . 0.0 111.339 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.442 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 74.9 mt-10 -154.92 152.73 30.08 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 22' ' ' GLU . 3.9 p-10 . . . . . 0 N--CA 1.465 0.277 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.461 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 0.582 ' ND2' ' H ' ' A' ' 28' ' ' LYS . 5.1 t-20 . . . . . 0 N--CA 1.468 0.449 0 N-CA-C 114.439 1.274 . . . . 0.0 114.439 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.582 ' H ' ' ND2' ' A' ' 27' ' ' ASN . 98.3 mttt -156.27 -18.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.24 -1.346 . . . . 0.0 107.817 178.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.504 ' HA3' ' H ' ' B' ' 28' ' ' LYS . . . 71.83 -98.47 0.78 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.46 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.79 88.54 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.075 179.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.5 mt -138.12 117.24 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' B' ' 33' ' ' GLY . 39.7 mt -108.91 112.49 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 93.93 0.64 Allowed Glycine 0 CA--C 1.507 -0.444 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.417 HD12 ' CG2' ' A' ' 32' ' ' ILE . 91.8 mt -140.78 165.0 28.7 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 123.335 1.541 . . . . 0.0 114.289 -175.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 38.5 tpp -120.9 107.81 13.14 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 111.999 -2.364 . . . . 0.0 106.786 177.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.413 ' HB ' HD21 ' B' ' 34' ' ' LEU . 63.6 t -110.84 124.0 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.9 -114.46 2.73 Favored Glycine 0 C--N 1.318 -0.461 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 -176.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.34 -71.92 1.48 Allowed Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.153 -1.022 . . . . 0.0 111.353 178.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.464 ' HA ' ' CD1' ' G' ' 31' ' ' ILE . 34.2 m -111.33 -175.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.714 0.769 . . . . 0.0 111.5 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.546 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.6 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-N 114.247 -1.342 . . . . 0.0 110.309 178.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -147.44 158.0 43.8 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.441 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.55 120.7 12.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 121.081 0.467 . . . . 0.0 110.623 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.49 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 16.0 t -130.1 117.39 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.607 ' CE1' ' H ' ' A' ' 12' ' ' VAL . 3.7 m-70 -137.68 112.27 8.79 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.445 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.563 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -151.96 160.13 43.58 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.332 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 78.7 mt-30 -131.95 151.36 51.77 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.983 0.42 . . . . 0.0 111.949 179.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -97.76 121.33 39.55 Favored 'General case' 0 C--O 1.238 0.485 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.3 mt -120.93 119.25 32.06 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 118.58 0.627 . . . . 0.0 110.301 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.43 132.43 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.873 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -125.88 124.0 39.89 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.112 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.466 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 34.2 t80 -117.91 126.47 52.42 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.36 141.69 33.81 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -104.36 147.7 27.23 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.14 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 3.4 t70 -171.9 51.89 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.023 -177.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.483 HG22 ' CB ' ' C' ' 23' ' ' ASP . 2.6 t -75.51 143.64 12.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-O 121.726 0.774 . . . . 0.0 111.714 -176.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.06 38.18 3.9 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 114.405 -1.27 . . . . 0.0 112.332 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.09 120.0 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 122.192 0.197 . . . . 0.0 110.904 177.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.554 ' H ' ' HA3' ' C' ' 25' ' ' GLY . 2.1 m120 -83.38 162.6 20.99 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.373 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.504 ' H ' ' HA3' ' A' ' 29' ' ' GLY . 99.1 mttt -47.24 -37.61 10.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.459 0.647 . . . . 0.0 110.782 175.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.68 0.06 OUTLIER Glycine 0 CA--C 1.54 1.596 0 CA-C-N 115.217 -0.902 . . . . 0.0 111.898 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -51.78 94.87 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 119.634 1.717 . . . . 0.0 112.204 -178.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.52 HD12 HG12 ' N' ' 39' ' ' VAL . 69.3 mt -144.62 134.77 19.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.432 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' D' ' 19' ' ' PHE . 91.6 mt -105.08 108.3 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.098 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -112.31 102.55 1.36 Allowed Glycine 0 CA--C 1.508 -0.37 0 N-CA-C 105.539 -3.024 . . . . 0.0 105.539 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.651 ' O ' HD12 ' C' ' 34' ' ' LEU . 7.6 tt -150.62 148.38 28.55 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 118.42 -1.312 . . . . 0.0 112.226 -174.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.623 ' N ' HD23 ' B' ' 34' ' ' LEU . 7.2 mtp -110.05 110.09 20.87 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 113.518 -1.674 . . . . 0.0 107.075 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.53 ' O ' HG13 ' B' ' 36' ' ' VAL . 4.1 p -119.62 111.51 33.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.35 -131.24 4.28 Favored Glycine 0 C--N 1.308 -1.007 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -178.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.499 ' O ' ' CG2' ' C' ' 39' ' ' VAL . . . 87.27 -63.93 3.89 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 120.508 -0.853 . . . . 0.0 111.542 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.545 HG11 HD13 ' G' ' 31' ' ' ILE . 3.1 m -136.78 154.17 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.429 ' H ' HG23 ' B' ' 40' ' ' VAL . 0.5 OUTLIER . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.338 -178.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . 0.723 ' HH ' ' N ' ' E' ' 9' ' ' GLY . 92.9 m-85 -105.35 133.13 50.62 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.631 0.253 . . . . 0.0 110.384 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -97.65 122.74 41.08 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.651 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.431 ' H ' HG13 ' B' ' 12' ' ' VAL . 19.4 m -125.4 133.07 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.159 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.546 ' CE1' ' OXT' ' A' ' 40' ' ' VAL . 5.6 t-80 -147.85 96.79 2.71 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.896 179.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.563 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 50.1 p-80 -157.24 167.57 29.96 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.738 -0.21 . . . . 0.0 111.265 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -89.99 158.45 17.36 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.437 0.637 . . . . 0.0 110.788 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -140.29 113.51 8.43 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 176.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mt -127.94 123.15 34.18 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 122.071 0.938 . . . . 0.0 111.478 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 67.1 t -111.14 117.03 54.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 177.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.432 ' CD2' ' CE2' ' D' ' 19' ' ' PHE . 56.2 m-85 -107.08 105.85 16.07 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 11.7 t80 -113.84 124.41 52.16 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.7 -0.227 . . . . 0.0 111.152 -178.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.66 122.34 30.6 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.647 0.736 . . . . 0.0 110.396 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -94.31 137.99 32.83 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.217 -178.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.516 ' N ' ' OE1' ' D' ' 22' ' ' GLU . 8.7 m-20 43.17 47.12 5.3 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.41 0.624 . . . . 0.0 109.354 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.648 ' O ' HG21 ' D' ' 24' ' ' VAL . 0.2 OUTLIER -61.43 -169.25 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.799 -177.195 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.579 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -111.74 33.34 5.83 Favored Glycine 0 C--N 1.318 -0.427 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.098 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.43 ' O ' ' N ' ' D' ' 26' ' ' SER . 27.3 t -62.63 104.87 0.57 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.497 0.665 . . . . 0.0 109.221 -178.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.857 ' O ' ' N ' ' C' ' 29' ' ' GLY . 7.8 m120 -157.6 179.23 9.42 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.616 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm 1.86 -44.7 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 125.067 1.48 . . . . 0.0 114.212 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.857 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -111.14 58.57 0.39 Allowed Glycine 0 CA--C 1.542 1.764 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 178.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.423 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -109.35 99.75 8.95 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 117.349 0.575 . . . . 0.0 109.973 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.426 HG22 ' N ' ' D' ' 31' ' ' ILE . 29.7 pt -147.93 156.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 117.88 -1.528 . . . . 0.0 114.385 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' E' ' 19' ' ' PHE . 95.9 mt -107.6 112.15 38.84 Favored 'Isoleucine or valine' 0 C--N 1.345 0.376 0 CA-C-N 114.053 -1.431 . . . . 0.0 108.695 176.35 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.91 93.76 0.74 Allowed Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 104.412 -3.475 . . . . 0.0 104.412 175.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.651 HD12 ' O ' ' B' ' 34' ' ' LEU . 42.3 tp -135.0 132.57 38.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 122.365 1.079 . . . . 0.0 113.294 -174.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.417 ' H ' HD12 ' C' ' 34' ' ' LEU . 6.4 mtp -99.99 111.33 23.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.673 177.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.532 HG12 ' CD ' ' E' ' 15' ' ' GLN . 3.1 t -110.8 103.32 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.13 -154.62 22.93 Favored Glycine 0 N--CA 1.46 0.254 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.673 178.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.21 -55.89 0.5 Allowed Glycine 0 CA--C 1.545 1.936 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.882 ' C ' HG11 ' D' ' 39' ' ' VAL . 68.6 t -136.04 162.97 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 C-N-CA 123.273 0.629 . . . . 0.0 110.167 178.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.676 ' N ' HG21 ' D' ' 39' ' ' VAL . 75.9 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.889 -1.053 . . . . 0.0 111.056 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 1.3 p . . . . . 0 C--O 1.222 -0.389 0 CA-C-O 120.764 0.316 . . . . 0.0 110.684 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.24 142.65 31.45 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.074 0.464 . . . . 0.0 110.228 179.089 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.554 ' O ' ' CG ' ' C' ' 14' ' ' HIS . 27.7 p-80 -146.12 162.6 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.114 178.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -89.67 158.19 17.68 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.311 179.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.675 ' C ' HD22 ' D' ' 17' ' ' LEU . 85.6 tttt -140.68 106.28 5.1 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.719 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.7 mm? -123.37 124.95 44.08 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.849 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -123.11 112.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' B' ' 32' ' ' ILE . 27.1 m-85 -108.77 103.79 12.94 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 179.452 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.4 t80 -111.71 124.72 52.91 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.89 141.41 38.56 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.443 1.116 . . . . 0.0 112.923 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.536 ' O ' HG23 ' D' ' 24' ' ' VAL . 84.2 mt-10 -75.85 118.32 18.52 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.065 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' HG13 ' E' ' 24' ' ' VAL . 13.6 t0 -57.15 59.77 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.591 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.648 HG21 ' O ' ' C' ' 24' ' ' VAL . 43.3 t -63.05 -113.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.419 ' N ' HG12 ' D' ' 24' ' ' VAL . . . -104.4 44.37 1.49 Allowed Glycine 0 N--CA 1.478 1.489 0 CA-C-N 121.446 1.93 . . . . 0.0 111.973 -174.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.452 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 1.3 t -70.64 100.51 1.86 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 112.938 -1.631 . . . . 0.0 107.879 175.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -118.62 -153.18 0.53 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.389 0.614 . . . . 0.0 112.564 -174.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -37.58 -41.86 0.5 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.704 -177.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.07 68.39 1.96 Allowed Glycine 0 CA--C 1.537 1.417 0 C-N-CA 120.374 -0.917 . . . . 0.0 111.771 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.85 136.4 32.33 Favored 'General case' 0 C--N 1.349 0.555 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.598 HD11 ' O ' ' P' ' 39' ' ' VAL . 39.7 mt -145.53 146.7 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 N-CA-C 115.398 1.629 . . . . 0.0 115.398 -175.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.463 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -108.46 111.58 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.494 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.15 102.48 0.8 Allowed Glycine 0 N--CA 1.463 0.497 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.415 ' CD2' ' CZ ' ' E' ' 19' ' ' PHE . 2.9 mp -137.16 135.23 37.17 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 122.424 1.107 . . . . 0.0 113.652 -178.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -98.91 113.51 25.69 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.355 177.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' E' ' 35' ' ' MET . 2.9 t -118.92 103.22 14.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -177.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.481 ' CA ' ' H ' ' E' ' 38' ' ' GLY . . . 147.25 -153.62 25.45 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.928 -1.129 . . . . 0.0 110.54 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 104.45 -56.33 0.56 Allowed Glycine 0 CA--C 1.541 1.675 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.882 HG11 ' C ' ' C' ' 39' ' ' VAL . 7.3 p -119.98 140.9 42.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 CA-C-O 121.361 0.601 . . . . 0.0 111.526 -178.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.454 ' O ' HG13 ' D' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.614 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . 0.723 ' N ' ' HH ' ' C' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -115.75 136.48 53.01 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 120.627 0.251 . . . . 0.0 110.539 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.19 142.57 45.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.259 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 79.4 t -127.16 133.33 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 CA-C-O 120.785 0.326 . . . . 0.0 111.246 -179.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 m170 -137.81 100.0 4.06 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.422 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.0 OUTLIER -151.56 165.6 33.77 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 121.594 0.711 . . . . 0.0 112.801 -179.593 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.532 ' CD ' HG12 ' C' ' 36' ' ' VAL . 87.2 mt-30 -84.35 157.12 21.57 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.324 178.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -159.28 103.1 1.61 Allowed 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.451 HD12 ' N ' ' E' ' 17' ' ' LEU . 3.5 mp -137.43 131.45 31.98 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.387 0.613 . . . . 0.0 111.786 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -117.59 112.28 38.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.534 ' CD2' HD13 ' C' ' 32' ' ' ILE . 27.4 m-85 -106.07 105.83 16.06 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 178.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -116.68 117.64 30.37 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.25 123.12 31.13 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.441 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 78.0 tt0 -154.11 154.21 33.22 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 117.9 2.555 . . . . 0.0 117.9 -175.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.454 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 52.6 m-20 109.72 46.5 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 111.646 -2.525 . . . . 0.0 116.372 174.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.459 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 1.8 m -118.15 174.64 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -59.88 -28.25 65.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 107.868 -2.093 . . . . 0.0 107.868 172.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.483 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 3.7 p 143.0 129.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 112.524 -1.838 . . . . 0.0 106.209 -177.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.511 ' ND2' ' H ' ' E' ' 29' ' ' GLY . 2.6 t30 -53.59 141.57 25.37 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.886 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -58.37 -48.81 79.41 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -179.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.511 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -170.23 59.27 0.19 Allowed Glycine 0 CA--C 1.54 1.629 0 C-N-CA 120.246 -0.978 . . . . 0.0 114.368 -175.615 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.65 169.17 16.54 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 119.124 1.462 . . . . 0.0 113.132 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.507 HD11 HG12 ' Q' ' 39' ' ' VAL . 77.5 mt -120.97 137.47 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 113.784 -1.553 . . . . 0.0 110.301 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -121.11 121.75 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.79 114.5 2.0 Favored Glycine 0 N--CA 1.471 0.981 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.623 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 59.4 mt -127.81 124.28 37.23 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 111.088 -178.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.441 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.0 mtp -108.22 111.77 23.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.245 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.636 HG12 ' N ' ' E' ' 37' ' ' GLY . 40.2 t -90.28 173.79 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.636 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 162.16 -95.52 0.13 Allowed Glycine 0 C--N 1.305 -1.175 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.096 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.481 ' H ' ' CA ' ' D' ' 37' ' ' GLY . . . 87.73 -83.69 1.53 Allowed Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.629 HG13 HD11 ' K' ' 31' ' ' ILE . 55.3 t . . . . . 0 N--CA 1.432 -1.336 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 176.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' F' ' 11' ' ' GLU . 57.9 mp0 . . . . . 0 N--CA 1.465 0.31 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -128.67 135.05 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.351 0.596 . . . . 0.0 111.409 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -142.19 131.98 24.22 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.492 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 83.4 t60 -155.15 167.81 29.12 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 28.5 mp0 -89.51 150.34 22.5 Favored 'General case' 0 CA--C 1.517 -0.298 0 C-N-CA 120.531 -0.468 . . . . 0.0 109.87 179.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -151.99 97.26 2.31 Favored 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.431 ' CD1' HG11 ' D' ' 36' ' ' VAL . 3.9 mp -133.83 116.25 15.45 Favored 'General case' 0 CA--C 1.506 -0.715 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.705 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -99.99 109.49 24.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.623 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 65.1 m-85 -104.89 98.92 8.57 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -112.83 111.43 22.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.338 0.589 . . . . 0.0 109.476 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.43 131.33 38.03 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' N ' ' E' ' 24' ' ' VAL . 84.6 tt0 -69.52 115.59 8.95 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 118.441 -1.304 . . . . 0.0 109.479 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.443 ' OD2' ' O ' ' F' ' 23' ' ' ASP . 18.9 t70 . . . . . 0 CA--C 1.53 0.196 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.64 -178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.291 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.508 HD13 ' HA ' ' R' ' 39' ' ' VAL . 86.2 mt -132.78 142.84 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 119.786 -0.765 . . . . 0.0 113.002 -177.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -131.57 128.91 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.774 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.14 131.34 5.66 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.486 HD23 ' C ' ' F' ' 34' ' ' LEU . 7.7 tt -135.89 127.46 28.83 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.454 ' N ' HD23 ' F' ' 34' ' ' LEU . 92.8 mtp -140.2 149.7 43.25 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -178.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -92.91 154.77 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.614 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.93 102.59 2.94 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.19 -73.64 0.0 OUTLIER Glycine 0 CA--C 1.537 1.417 0 CA-C-N 115.41 -0.395 . . . . 0.0 113.139 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.548 ' N ' ' O ' ' F' ' 37' ' ' GLY . 90.4 t -151.32 136.55 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 117.848 0.824 . . . . 0.0 110.255 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.422 HG12 ' H ' ' F' ' 40' ' ' VAL . 5.8 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.565 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.406 HG22 ' CE1' ' H' ' 13' ' ' HIS . 62.0 t . . . . . 0 N--CA 1.465 0.3 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.474 ' O ' ' O ' ' H' ' 13' ' ' HIS . 98.3 m-70 -135.14 101.77 4.97 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.864 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' N ' ' G' ' 15' ' ' GLN . 6.6 t-80 -157.2 161.63 39.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.228 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.553 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 13.2 pt20 -174.3 147.86 1.22 Allowed 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.102 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 pttt -79.51 121.8 25.66 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.207 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.498 HD11 ' NE2' ' G' ' 15' ' ' GLN . 96.3 mt -131.75 116.42 17.25 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -126.69 136.22 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.129 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.538 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 68.1 m-85 -135.1 125.88 27.29 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.357 0.599 . . . . 0.0 111.086 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.493 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -115.11 129.62 56.72 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.43 124.33 39.91 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -177.29 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -137.21 115.27 11.57 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 63.7 t0 . . . . . 0 N--CA 1.468 0.461 0 CA-C-O 121.666 0.746 . . . . 0.0 109.046 -177.561 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 29.0 m-20 . . . . . 0 N--CA 1.462 0.144 0 CA-C-O 122.08 0.943 . . . . 0.0 112.439 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.642 ' O ' ' N ' ' H' ' 28' ' ' LYS . 99.2 mttt -37.68 -40.76 0.44 Allowed 'General case' 0 C--O 1.214 -0.775 0 CA-C-N 113.534 -1.667 . . . . 0.0 111.227 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.78 68.8 0.21 Allowed Glycine 0 CA--C 1.545 1.943 0 O-C-N 121.653 -0.654 . . . . 0.0 112.552 -176.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.595 ' HB3' ' HB3' ' H' ' 27' ' ' ASN . . . -96.7 113.24 24.78 Favored 'General case' 0 C--N 1.368 1.376 0 CA-C-O 124.124 1.916 . . . . 0.0 111.287 -179.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.545 HD13 HG11 ' B' ' 39' ' ' VAL . 38.1 mt -129.16 131.8 67.53 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 110.337 -3.119 . . . . 0.0 108.843 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.514 HG22 HD21 ' H' ' 34' ' ' LEU . 31.8 mt -103.32 106.39 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.34 94.95 0.79 Allowed Glycine 0 CA--C 1.504 -0.613 0 N-CA-C 106.185 -2.766 . . . . 0.0 106.185 177.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.421 ' H ' HD23 ' H' ' 34' ' ' LEU . 58.3 mt -144.38 156.1 44.07 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 123.162 1.458 . . . . 0.0 112.813 -177.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.2 mtp -105.22 113.22 26.68 Favored 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 111.983 -2.371 . . . . 0.0 106.001 176.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.481 HG11 HD11 ' J' ' 17' ' ' LEU . 48.4 t -109.04 102.33 13.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.63 -162.5 47.7 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.12 -55.67 0.52 Allowed Glycine 0 CA--C 1.532 1.138 0 CA-C-O 118.82 -0.989 . . . . 0.0 111.919 179.114 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.505 HG12 ' CD1' ' M' ' 31' ' ' ILE . 1.6 m -70.48 176.86 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.428 0 CA-C-N 118.27 1.035 . . . . 0.0 109.499 177.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' G' ' 39' ' ' VAL . 7.1 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.879 -1.058 . . . . 0.0 111.587 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.93 133.17 50.18 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -83.41 141.49 31.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.941 0.4 . . . . 0.0 110.959 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.609 HG11 ' ND1' ' I' ' 13' ' ' HIS . 71.0 t -143.01 161.75 17.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.526 ' N ' HG12 ' H' ' 12' ' ' VAL . 44.5 m80 -135.21 159.14 42.49 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 179.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 42.8 p-80 -85.61 166.19 16.42 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.805 -179.099 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -100.39 152.72 20.02 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.618 ' C ' HD12 ' H' ' 17' ' ' LEU . 88.6 tttt -109.31 109.95 20.99 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.618 HD12 ' C ' ' H' ' 16' ' ' LYS . 11.1 mp -119.01 122.86 43.14 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.853 179.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -124.21 126.74 72.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.415 179.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' CD1' ' G' ' 19' ' ' PHE . 34.2 m-85 -133.89 126.14 29.81 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.812 -0.811 . . . . 0.0 108.812 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.457 ' CZ ' ' CB ' ' G' ' 20' ' ' PHE . 24.3 p90 -143.44 151.39 40.29 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 119.31 -0.956 . . . . 0.0 111.676 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.31 130.02 51.16 Favored 'General case' 0 C--O 1.251 1.171 0 CA-C-O 121.926 0.87 . . . . 0.0 111.467 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -60.98 -166.13 0.01 OUTLIER 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.879 -1.51 . . . . 0.0 107.757 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.572 ' OD1' HG22 ' I' ' 24' ' ' VAL . 33.2 t70 -84.22 57.65 4.35 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 116.669 -2.012 . . . . 0.0 115.41 -175.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.961 HG22 ' H ' ' H' ' 25' ' ' GLY . 1.3 p -68.64 -112.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.271 1 N-CA-C 100.069 -4.048 . . . . 0.0 100.069 166.451 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.961 ' H ' HG22 ' H' ' 24' ' ' VAL . . . 124.41 -39.39 2.14 Favored Glycine 0 C--N 1.331 0.283 0 N-CA-C 117.985 1.954 . . . . 0.0 117.985 167.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.23 110.5 5.25 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 115.632 -2.427 . . . . 0.0 112.968 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 1.093 ' O ' ' N ' ' H' ' 29' ' ' GLY . 0.0 OUTLIER -122.7 156.97 33.29 Favored 'General case' 0 C--O 1.207 -1.145 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 167.314 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.642 ' N ' ' O ' ' G' ' 28' ' ' LYS . 13.1 tttt -34.51 49.15 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 122.721 2.509 . . . . 0.0 111.16 172.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 1.093 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 101.26 -52.22 0.9 Allowed Glycine 0 CA--C 1.563 3.044 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -177.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' I' ' 30' ' ' ALA . . . 129.35 115.38 0.0 OUTLIER 'General case' 0 C--N 1.377 1.799 0 C-N-CA 125.946 1.698 . . . . 0.0 107.977 177.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.46 HD13 HG12 ' B' ' 39' ' ' VAL . 72.2 mt -126.54 128.13 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 CA-C-N 122.056 2.207 . . . . 0.0 114.793 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -111.67 110.51 32.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 175.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -116.46 105.4 1.35 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.215 -2.354 . . . . 0.0 107.215 178.269 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.583 ' O ' HD23 ' I' ' 34' ' ' LEU . 73.8 mt -140.65 148.86 41.51 Favored 'General case' 0 CA--C 1.508 -0.66 0 CA-C-O 122.832 1.301 . . . . 0.0 113.376 -176.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 4.8 ttm -113.86 112.36 23.23 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 175.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.644 ' O ' HG13 ' H' ' 36' ' ' VAL . 5.0 p -132.39 102.55 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.752 ' N ' HE22 ' J' ' 15' ' ' GLN . . . 122.52 -163.29 15.97 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' I' ' 37' ' ' GLY . . . 128.28 -54.57 0.78 Allowed Glycine 0 CA--C 1.547 2.06 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.842 HG22 ' CD1' ' N' ' 31' ' ' ILE . 14.6 t -109.7 165.99 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.681 0.793 . . . . 0.0 110.127 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.528 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 2.5 m . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.658 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.36 133.67 52.23 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.772 0.32 . . . . 0.0 110.509 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 54.6 tp10 -75.35 122.57 23.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.245 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -139.51 160.86 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.548 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.609 ' ND1' HG11 ' H' ' 12' ' ' VAL . 21.8 t60 -145.73 100.25 3.39 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 121.253 -0.179 . . . . 0.0 110.724 179.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' J' ' 14' ' ' HIS . 45.3 p-80 -165.52 169.57 15.34 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -89.84 158.95 17.24 Favored 'General case' 0 C--N 1.341 0.215 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.829 178.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.765 ' C ' HD12 ' I' ' 17' ' ' LEU . 83.7 tttt -139.97 111.12 7.0 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.765 HD12 ' C ' ' I' ' 16' ' ' LYS . 10.5 mp -127.95 128.64 45.43 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.247 0.546 . . . . 0.0 110.332 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 71.4 t -112.76 120.77 63.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -114.0 106.42 14.4 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.58 ' CD1' ' CD2' ' J' ' 20' ' ' PHE . 1.9 t80 -115.52 129.14 56.43 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 122.342 -0.224 . . . . 0.0 110.451 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.411 ' N ' ' CD1' ' I' ' 20' ' ' PHE . . . -150.18 130.57 13.79 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -178.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -95.65 119.42 34.12 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -118.64 46.3 1.86 Allowed 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -175.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.572 HG22 ' OD1' ' H' ' 23' ' ' ASP . 23.7 m -92.74 173.55 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 175.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.32 27.82 65.12 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 118.244 -1.931 . . . . 0.0 109.908 -177.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p 166.66 146.68 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -53.15 136.93 35.11 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 117.416 2.376 . . . . 0.0 117.416 -173.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.469 ' O ' ' HA2' ' J' ' 29' ' ' GLY . 37.9 mttt -60.84 51.06 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 CA-C-N 110.704 -2.953 . . . . 0.0 114.293 173.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.07 51.94 0.69 Allowed Glycine 0 N--CA 1.495 2.609 0 O-C-N 120.494 -1.379 . . . . 0.0 116.148 -172.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.526 ' HB2' ' HB3' ' H' ' 30' ' ' ALA . . . -100.31 147.09 26.17 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-O 123.685 1.707 . . . . 0.0 114.993 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.751 HD13 HG22 ' C' ' 39' ' ' VAL . 13.7 tt -132.29 135.88 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.248 -179.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 89.6 mt -106.28 108.6 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.01 111.0 3.63 Favored Glycine 0 C--O 1.24 0.496 0 N-CA-C 105.305 -3.118 . . . . 0.0 105.305 176.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.583 HD23 ' O ' ' H' ' 34' ' ' LEU . 0.3 OUTLIER -148.32 141.07 24.6 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 117.68 -1.608 . . . . 0.0 115.073 -174.462 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 81.6 mmm -103.13 114.65 29.12 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-N 112.233 -2.258 . . . . 0.0 105.134 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.413 HG22 HD22 ' I' ' 34' ' ' LEU . 58.4 t -122.57 131.75 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 CA-C-O 120.809 0.337 . . . . 0.0 111.047 -176.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' H' ' 38' ' ' GLY . . . 80.44 -111.22 3.24 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 120.629 -0.796 . . . . 0.0 114.807 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.55 -70.51 0.22 Allowed Glycine 0 CA--C 1.539 1.583 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.456 ' HB ' ' CD1' ' O' ' 31' ' ' ILE . 2.6 p -134.61 137.07 51.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.558 ' OXT' ' ND1' ' L' ' 13' ' ' HIS . 27.5 m . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.814 -1.088 . . . . 0.0 111.284 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.54 137.67 44.12 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -130.67 139.02 50.32 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.899 0.381 . . . . 0.0 110.843 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 41.8 t -123.24 125.29 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.56 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 3.3 m80 -120.96 121.92 39.05 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.166 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.557 ' O ' ' CG ' ' I' ' 14' ' ' HIS . 0.3 OUTLIER -152.45 156.41 39.4 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.19 176.478 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.752 HE22 ' N ' ' H' ' 37' ' ' GLY . 83.8 mt-30 -90.37 160.22 16.2 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.617 ' C ' HD12 ' J' ' 17' ' ' LEU . 68.5 mttm -139.7 97.21 3.22 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.27 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.617 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.1 mp -122.8 121.49 36.41 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-O 121.703 0.763 . . . . 0.0 109.549 176.406 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . 0.506 HG13 HG13 ' K' ' 18' ' ' VAL . 21.9 t -110.67 116.23 51.89 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.564 179.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.432 ' CZ ' ' HB3' ' J' ' 17' ' ' LEU . 33.9 m-85 -112.58 104.46 12.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CD1' ' I' ' 20' ' ' PHE . 4.5 t80 -115.09 131.02 57.06 Favored 'General case' 0 N--CA 1.478 0.939 0 O-C-N 122.449 -0.157 . . . . 0.0 110.882 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' K' ' 21' ' ' ALA . . . -168.38 171.82 8.85 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 123.631 1.681 . . . . 0.0 115.464 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -111.62 113.84 26.49 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 113.164 -1.834 . . . . 0.0 107.426 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -172.82 49.81 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.754 HG22 ' H ' ' J' ' 25' ' ' GLY . 13.2 p -154.81 -179.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.879 -178.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.754 ' H ' HG22 ' J' ' 24' ' ' VAL . . . 61.59 29.74 72.72 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 116.905 1.522 . . . . 0.0 116.905 178.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.626 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.7 m -145.32 -120.8 0.08 Allowed 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.626 ' O ' ' O ' ' J' ' 26' ' ' SER . 1.3 p-10 -53.51 -156.61 0.0 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 176.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.486 ' HZ2' ' CE1' ' F' ' 13' ' ' HIS . 99.0 mttt -63.36 -39.9 95.79 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 119.573 -1.954 . . . . 0.0 107.084 -173.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' J' ' 27' ' ' ASN . . . 92.5 -65.69 2.09 Favored Glycine 0 N--CA 1.473 1.112 0 C-N-CA 119.732 -1.223 . . . . 0.0 114.966 174.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' I' ' 30' ' ' ALA . . . -169.56 155.36 6.03 Favored 'General case' 0 N--CA 1.44 -0.93 0 C-N-CA 116.759 -1.977 . . . . 0.0 115.346 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.509 ' HA ' ' O ' ' K' ' 31' ' ' ILE . 0.8 OUTLIER -135.3 124.96 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 111.065 -2.788 . . . . 0.0 109.628 177.417 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.425 HD13 HG21 ' J' ' 32' ' ' ILE . 44.8 mt -108.22 117.12 53.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.93 100.73 1.2 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.785 -2.926 . . . . 0.0 105.785 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -127.86 129.79 47.5 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 114.87 1.433 . . . . 0.0 114.87 -175.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.58 109.92 22.4 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.293 -2.484 . . . . 0.0 104.293 174.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.417 ' N ' ' O ' ' K' ' 35' ' ' MET . 2.0 t -125.64 153.19 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.095 0.474 . . . . 0.0 111.497 -175.386 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.47 -101.89 0.2 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.172 178.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.561 ' H ' ' N ' ' K' ' 37' ' ' GLY . . . 99.29 -76.66 0.51 Allowed Glycine 0 CA--C 1.537 1.408 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -177.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.852 HG11 HD11 ' P' ' 31' ' ' ILE . 28.0 m -131.46 161.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 CA-C-N 118.362 1.081 . . . . 0.0 110.482 178.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.446 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 44.8 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.907 -1.044 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.76 131.83 54.7 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.759 0.314 . . . . 0.0 110.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -101.84 107.59 18.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.42 HG23 ' NE2' ' K' ' 14' ' ' HIS . 2.5 p -144.63 149.68 17.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.56 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -143.2 94.8 2.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.049 178.753 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.667 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 46.8 m170 -119.94 167.57 12.01 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.948 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.808 HE21 HD21 ' K' ' 17' ' ' LEU . 34.9 tp60 -89.76 157.74 17.82 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.804 ' O ' HD23 ' K' ' 17' ' ' LEU . 16.3 tttt -140.93 95.41 2.84 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.074 -0.651 . . . . 0.0 110.797 178.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.808 HD21 HE21 ' K' ' 15' ' ' GLN . 2.5 mt -131.87 129.62 40.6 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 176.378 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.506 HG13 HG13 ' J' ' 18' ' ' VAL . 3.5 p -118.6 119.33 60.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.476 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 29.9 m-85 -106.05 105.73 15.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 6.0 t80 -113.59 120.31 40.51 Favored 'General case' 0 C--O 1.226 -0.177 0 CA-C-O 120.66 0.267 . . . . 0.0 111.679 -177.352 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.597 ' HA ' ' O ' ' J' ' 21' ' ' ALA . . . -150.66 120.49 7.08 Favored 'General case' 0 C--O 1.245 0.858 0 C-N-CA 119.704 -0.798 . . . . 0.0 110.547 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.563 ' CG ' ' N ' ' K' ' 23' ' ' ASP . 54.5 tt0 -178.18 163.54 1.69 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 116.988 2.218 . . . . 0.0 116.988 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.563 ' N ' ' CG ' ' K' ' 22' ' ' GLU . 19.9 t70 174.05 -74.13 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 112.03 -2.35 . . . . 0.0 106.978 172.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.611 HG22 ' H ' ' K' ' 25' ' ' GLY . 3.2 p -67.7 -113.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 170.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.673 ' H ' ' HA3' ' J' ' 25' ' ' GLY . . . 134.7 -37.79 1.9 Allowed Glycine 0 CA--C 1.541 1.7 0 N-CA-C 121.421 3.328 . . . . 0.0 121.421 171.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.5 t -71.81 118.09 14.21 Favored 'General case' 0 N--CA 1.482 1.167 1 CA-C-N 125.935 4.867 . . . . 0.0 107.28 177.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.689 ' ND2' ' H ' ' K' ' 30' ' ' ALA . 0.5 OUTLIER -103.77 160.58 14.66 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 120.36 1.436 . . . . 0.0 113.127 179.271 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -44.45 -39.85 5.07 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 67.67 0.04 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-O 118.939 -0.923 . . . . 0.0 113.484 -174.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.689 ' H ' ' ND2' ' K' ' 27' ' ' ASN . . . -71.04 156.18 39.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.82 1.81 . . . . 0.0 113.607 -176.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.629 HD11 HG13 ' E' ' 39' ' ' VAL . 82.2 mt -122.92 126.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.92 -178.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 13.0 tt -130.96 118.0 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 O-C-N 121.245 -0.91 . . . . 0.0 110.51 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.81 111.62 1.87 Allowed Glycine 0 N--CA 1.466 0.699 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.62 HD13 ' CE2' ' L' ' 19' ' ' PHE . 82.1 mt -122.92 117.3 25.23 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.165 0.507 . . . . 0.0 110.728 -178.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.417 ' O ' ' N ' ' J' ' 36' ' ' VAL . 8.0 mtp -108.3 114.41 28.25 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.404 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 46.2 t -119.65 144.76 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 107.726 -1.212 . . . . 0.0 107.726 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.561 ' N ' ' H ' ' J' ' 38' ' ' GLY . . . -136.51 102.68 0.41 Allowed Glycine 0 C--N 1.32 -0.31 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.104 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' J' ' 40' ' ' VAL . . . -61.28 -67.13 2.26 Favored Glycine 0 CA--C 1.54 1.652 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 176.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.485 ' HB ' HD11 ' Q' ' 31' ' ' ILE . 16.7 m . . . . . 0 N--CA 1.435 -1.2 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 N--CA 1.463 0.202 0 CA-C-O 120.505 0.193 . . . . 0.0 110.631 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 t -115.94 126.24 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 110.044 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.558 ' ND1' ' OXT' ' I' ' 40' ' ' VAL . 10.8 m-70 -130.86 104.59 7.24 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.214 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.667 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 83.2 t60 -160.61 164.57 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 178.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.501 ' O ' ' CD2' ' L' ' 14' ' ' HIS . 88.0 mm-40 -89.76 158.57 17.46 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . 0.728 ' C ' HD12 ' L' ' 17' ' ' LEU . 16.7 tttt -140.4 93.93 2.68 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.728 HD12 ' C ' ' L' ' 16' ' ' LYS . 10.0 mp -122.72 118.15 27.4 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -102.81 108.06 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.801 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.62 ' CE2' HD13 ' K' ' 34' ' ' LEU . 79.7 m-85 -100.32 98.14 8.83 Favored 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 39.7 t80 -108.38 105.15 14.69 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -165.95 171.51 12.53 Favored 'General case' 0 CA--C 1.484 -1.567 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.634 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -75.94 104.71 6.6 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -147.0 48.01 1.15 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.41 -176.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.563 HG22 ' N ' ' L' ' 25' ' ' GLY . 7.5 p -65.23 169.75 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.563 ' N ' HG22 ' L' ' 24' ' ' VAL . . . -92.2 -42.53 4.6 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 118.709 -1.71 . . . . 0.0 113.819 -176.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.51 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 4.6 m -67.72 109.49 3.35 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 117.861 -1.536 . . . . 0.0 111.906 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.68 ' O ' ' N ' ' L' ' 29' ' ' GLY . 21.4 m120 -145.21 158.68 43.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 173.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.537 ' C ' ' O ' ' L' ' 27' ' ' ASN . 42.0 tttp -18.2 -43.51 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 CA-C-O 121.936 0.874 . . . . 0.0 111.312 175.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.68 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -178.45 63.33 0.08 OUTLIER Glycine 0 CA--C 1.553 2.411 0 CA-C-N 113.885 -1.507 . . . . 0.0 112.381 177.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -88.94 163.08 15.74 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.13 1.465 . . . . 0.0 110.019 179.418 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 22.2 pt -141.15 135.49 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 119.252 -0.979 . . . . 0.0 112.027 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -118.53 121.09 66.2 Favored 'Isoleucine or valine' 0 C--N 1.34 0.18 0 CA-C-N 114.73 -1.123 . . . . 0.0 111.227 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.11 116.3 2.41 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -126.42 125.65 42.51 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.3 ttm -129.3 130.3 45.98 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.099 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' L' ' 37' ' ' GLY . 55.7 t -124.21 131.87 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -42.56 -111.62 0.0 OUTLIER Glycine 0 N--CA 1.468 0.82 0 CA-C-N 115.483 -0.781 . . . . 0.0 112.631 178.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.99 64.93 3.96 Favored Glycine 0 CA--C 1.532 1.116 0 CA-C-N 114.706 -0.747 . . . . 0.0 111.455 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.649 ' O ' HD11 ' R' ' 31' ' ' ILE . 41.8 t . . . . . 0 C--N 1.346 0.456 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.787 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 N--CA 1.463 0.186 0 CA-C-O 120.741 0.305 . . . . 0.0 110.598 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.0 t -113.65 128.61 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.31 162.67 15.77 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.711 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.519 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 3.4 m-70 -83.33 168.71 16.39 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.652 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -129.2 150.86 50.4 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -97.26 111.81 23.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.353 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.69 114.04 18.14 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.88 132.88 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.357 -179.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -133.25 134.83 44.46 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.86 0.362 . . . . 0.0 110.919 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -128.26 131.82 48.74 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.766 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.6 111.14 7.55 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.108 0.48 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -159.1 151.13 20.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.372 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 51.96 46.43 26.61 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.818 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.809 HG12 ' H ' ' M' ' 25' ' ' GLY . 39.6 t -80.45 179.89 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . 0.809 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -71.44 -33.75 63.99 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.878 -178.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . 0.594 ' O ' ' O ' ' M' ' 27' ' ' ASN . 25.5 t -162.51 120.61 2.13 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . 0.594 ' O ' ' O ' ' M' ' 26' ' ' SER . 13.6 t30 -22.03 153.22 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.98 0 O-C-N 124.424 1.078 . . . . 0.0 111.976 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -163.17 24.54 0.09 Allowed 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 114.638 1.347 . . . . 0.0 114.638 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.28 106.15 1.11 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 118.539 -1.791 . . . . 0.0 114.913 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . 0.727 ' H ' ' ND2' ' N' ' 27' ' ' ASN . . . -111.48 80.24 1.29 Allowed 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 124.098 1.904 . . . . 0.0 109.999 178.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.599 HD11 HG21 ' H' ' 39' ' ' VAL . 59.6 mt -130.36 130.01 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-N 110.974 -2.83 . . . . 0.0 108.419 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' N' ' 33' ' ' GLY . 47.1 mt -103.94 106.18 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.92 97.43 1.14 Allowed Glycine 0 CA--C 1.506 -0.476 0 N-CA-C 105.055 -3.218 . . . . 0.0 105.055 176.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -148.95 152.92 37.2 Favored 'General case' 0 N--CA 1.463 0.213 0 C-N-CA 118.308 -1.357 . . . . 0.0 113.826 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 91.7 mmm -110.21 110.31 21.11 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 112.946 -1.934 . . . . 0.0 107.177 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.63 HG23 HD21 ' N' ' 34' ' ' LEU . 96.4 t -104.29 122.88 57.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.32 -113.24 0.58 Allowed Glycine 0 C--N 1.309 -0.94 0 N-CA-C 108.419 -1.873 . . . . 0.0 108.419 -178.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.68 -69.57 0.22 Allowed Glycine 0 CA--C 1.533 1.179 0 C-N-CA 121.438 -0.411 . . . . 0.0 112.413 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' M' ' 40' ' ' VAL . 3.1 m -137.57 166.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 122.649 0.38 . . . . 0.0 110.373 -179.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.544 ' OXT' ' N ' ' N' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.888 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.88 135.67 49.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.845 0.355 . . . . 0.0 110.395 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -140.71 146.42 37.76 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.023 0.439 . . . . 0.0 110.721 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.458 HG22 HG22 ' O' ' 12' ' ' VAL . 70.2 t -126.98 133.66 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.706 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.553 ' ND1' ' CE1' ' O' ' 13' ' ' HIS . 77.1 m80 -102.97 97.66 7.74 Favored 'General case' 0 N--CA 1.471 0.62 0 O-C-N 122.093 -0.38 . . . . 0.0 110.509 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' N' ' 15' ' ' GLN . 1.7 t-80 -159.95 168.53 25.47 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.941 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.636 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 81.9 mt-30 -156.0 142.27 18.38 Favored 'General case' 0 C--N 1.34 0.166 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 178.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -84.73 120.64 26.64 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.822 179.156 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.484 HD12 ' O ' ' N' ' 15' ' ' GLN . 4.8 mp -129.11 124.03 33.71 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.755 0.312 . . . . 0.0 110.192 178.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.21 131.58 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -129.37 115.58 17.77 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.147 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 t80 -111.9 126.17 54.83 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.0 147.56 31.79 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -177.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -132.46 133.0 43.31 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.016 178.178 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -158.05 46.62 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . 0.54 HG12 ' N ' ' N' ' 25' ' ' GLY . 20.8 t -91.79 169.18 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 178.003 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 0.54 ' N ' HG12 ' N' ' 24' ' ' VAL . . . 77.16 34.8 40.24 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.008 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 169.51 -114.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -176.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.727 ' ND2' ' H ' ' M' ' 30' ' ' ALA . 28.9 t30 -61.89 170.88 1.87 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.358 0.599 . . . . 0.0 111.782 -177.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.561 ' HD3' HD11 ' N' ' 31' ' ' ILE . 81.7 tttt -54.15 -39.36 66.44 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.474 -176.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.34 -63.51 0.53 Allowed Glycine 0 CA--C 1.531 1.04 0 C-N-CA 119.639 -1.267 . . . . 0.0 114.107 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.86 99.52 3.81 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 120.319 2.059 . . . . 0.0 115.529 -176.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.842 ' CD1' HG22 ' H' ' 39' ' ' VAL . 96.3 mt -122.59 118.94 56.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 114.162 -1.381 . . . . 0.0 107.304 173.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' P' ' 19' ' ' PHE . 74.8 mt -107.71 108.32 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 119.041 -1.064 . . . . 0.0 110.28 178.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -109.08 98.66 1.18 Allowed Glycine 0 C--O 1.234 0.138 0 N-CA-C 104.641 -3.384 . . . . 0.0 104.641 175.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.963 HD23 ' N ' ' N' ' 35' ' ' MET . 3.0 tt -145.25 147.84 32.84 Favored 'General case' 0 CA--C 1.506 -0.727 0 C-N-CA 118.352 -1.339 . . . . 0.0 113.065 -174.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.963 ' N ' HD23 ' N' ' 34' ' ' LEU . 12.7 mtp -112.0 115.67 29.31 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 113.215 -1.812 . . . . 0.0 108.786 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.675 HG23 HD22 ' N' ' 34' ' ' LEU . 51.4 t -114.59 111.63 36.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 179.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.768 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 135.21 -131.75 5.95 Favored Glycine 0 C--N 1.316 -0.562 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.74 -63.69 4.05 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.52 HG12 HD12 ' B' ' 31' ' ' ILE . 11.4 m -104.52 161.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.952 0.501 . . . . 0.0 110.384 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.56 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 47.5 t . . . . . 0 C--O 1.218 -0.602 0 CA-C-O 117.852 -1.071 . . . . 0.0 111.58 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.29 139.43 44.24 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -102.05 124.28 47.39 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.566 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.458 HG22 HG22 ' N' ' 12' ' ' VAL . 1.4 m -125.49 125.91 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.553 ' CE1' ' ND1' ' N' ' 13' ' ' HIS . 21.0 m-70 -121.48 122.17 39.15 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 121.193 0.521 . . . . 0.0 112.208 -177.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.524 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 0.6 OUTLIER -150.27 175.95 11.32 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.576 178.38 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.628 ' NE2' HD11 ' O' ' 17' ' ' LEU . 39.2 tt0 -152.74 139.75 19.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.587 0.708 . . . . 0.0 109.107 175.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 61.3 mttt -95.68 108.64 20.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.592 -1.185 . . . . 0.0 111.043 177.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.628 HD11 ' NE2' ' O' ' 15' ' ' GLN . 5.0 mt -124.03 109.64 13.77 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 119.293 0.951 . . . . 0.0 108.729 175.678 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -107.39 116.4 50.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.877 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -110.99 103.31 11.77 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' P' ' 20' ' ' PHE . 2.7 m-85 -110.38 133.92 52.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.354 0.262 . . . . 0.0 110.303 -178.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.77 136.56 29.0 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-O 122.99 1.376 . . . . 0.0 114.128 -179.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 26.5 tp10 -93.12 163.79 13.5 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 113.263 -1.79 . . . . 0.0 106.986 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.437 ' OD1' ' OD2' ' P' ' 23' ' ' ASP . 54.5 p-10 -172.93 52.36 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.106 -0.638 . . . . 0.0 111.091 -176.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.605 ' HA ' HG13 ' P' ' 24' ' ' VAL . 13.5 m -74.5 142.17 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 117.981 -1.488 . . . . 0.0 112.47 -174.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.501 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . 98.97 38.14 3.93 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.233 179.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.993 ' H ' HG11 ' P' ' 24' ' ' VAL . 2.7 p 72.74 120.16 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.11 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' O' ' 27' ' ' ASN . 54.7 p30 -83.62 156.24 22.8 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 115.968 -2.293 . . . . 0.0 109.956 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -48.66 -42.53 34.82 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.874 1.435 . . . . 0.0 114.874 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.443 ' O ' ' CE ' ' N' ' 28' ' ' LYS . . . 160.19 67.37 0.02 OUTLIER Glycine 0 CA--C 1.546 1.998 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.117 -176.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.67 132.22 30.65 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 120.305 2.053 . . . . 0.0 114.155 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.456 ' CD1' ' HB ' ' I' ' 39' ' ' VAL . 9.8 tt -137.36 131.88 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 114.57 -1.196 . . . . 0.0 112.18 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.569 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 71.3 mt -108.25 114.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.378 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.445 ' O ' HD22 ' O' ' 34' ' ' LEU . . . -111.97 94.9 0.77 Allowed Glycine 0 N--CA 1.468 0.792 0 N-CA-C 107.236 -2.345 . . . . 0.0 107.236 177.099 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.461 ' HB2' HD12 ' P' ' 34' ' ' LEU . 1.3 mm? -121.32 134.6 55.14 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 122.476 1.132 . . . . 0.0 113.264 -176.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -113.0 104.41 12.36 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 173.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.576 HG11 HD13 ' Q' ' 17' ' ' LEU . 2.5 t -113.6 103.46 15.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . 136.85 -153.53 21.77 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.663 177.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.724 ' H ' ' H ' ' P' ' 38' ' ' GLY . . . 137.79 -56.29 0.67 Allowed Glycine 0 CA--C 1.543 1.796 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -178.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.433 HG22 HG23 ' O' ' 40' ' ' VAL . 5.0 p -133.15 154.78 40.05 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.486 ' OXT' ' CG2' ' P' ' 40' ' ' VAL . 17.3 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.999 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 43.9 t . . . . . 0 N--CA 1.467 0.42 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.537 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 12.3 m170 -44.22 110.77 0.24 Allowed 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.946 -178.324 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' O ' ' Q' ' 14' ' ' HIS . 55.4 t60 -152.62 154.43 35.35 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.768 HE22 ' N ' ' N' ' 37' ' ' GLY . 81.9 mt-30 -98.47 169.81 9.28 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -158.26 103.99 1.84 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.976 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -134.05 133.28 41.0 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.521 0.677 . . . . 0.0 110.861 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 64.1 t -123.55 120.94 61.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.935 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' N' ' 32' ' ' ILE . 5.5 m-85 -112.73 112.3 23.71 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.441 ' HB3' ' CD1' ' O' ' 20' ' ' PHE . 26.4 t80 -125.2 122.47 37.11 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -176.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.9 122.09 29.54 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.521 ' CG ' ' N ' ' P' ' 23' ' ' ASP . 69.6 tt0 -167.45 158.97 11.95 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 117.695 2.479 . . . . 0.0 117.695 -176.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.521 ' N ' ' CG ' ' P' ' 22' ' ' GLU . 1.7 p30 150.64 -70.05 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 111.643 -2.526 . . . . 0.0 108.386 175.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.993 HG11 ' H ' ' O' ' 26' ' ' SER . 4.4 m -57.05 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 122.099 0.952 . . . . 0.0 109.336 174.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.4 ' H ' ' HB ' ' P' ' 24' ' ' VAL . . . 141.57 -36.25 1.73 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.621 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 m -70.33 114.49 8.51 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 115.916 -2.314 . . . . 0.0 105.18 171.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.75 ' ND2' ' H ' ' P' ' 30' ' ' ALA . 50.3 p-10 -119.98 154.6 34.27 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 121.212 1.824 . . . . 0.0 111.926 176.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -34.52 -39.46 0.09 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 173.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' Q' ' 29' ' ' GLY . . . 140.07 74.52 0.05 OUTLIER Glycine 0 CA--C 1.553 2.447 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -175.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . 0.75 ' H ' ' ND2' ' P' ' 27' ' ' ASN . . . -70.55 170.14 12.74 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 116.099 1.888 . . . . 0.0 116.099 -173.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.852 HD11 HG11 ' J' ' 39' ' ' VAL . 0.9 OUTLIER -149.14 143.7 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 CA-C-N 112.739 -2.028 . . . . 0.0 114.907 -176.103 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.461 HG12 HD12 ' O' ' 32' ' ' ILE . 3.7 mt -113.12 113.06 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.38 101.8 1.2 Allowed Glycine 0 N--CA 1.462 0.402 0 N-CA-C 105.82 -2.912 . . . . 0.0 105.82 176.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.54 ' C ' HD23 ' P' ' 34' ' ' LEU . 9.0 tt -144.49 132.08 21.06 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 122.866 1.317 . . . . 0.0 112.397 -175.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . 0.485 ' N ' HD23 ' P' ' 34' ' ' LEU . 74.0 mtp -120.86 119.59 33.11 Favored 'General case' 0 CA--C 1.495 -1.153 0 CA-C-N 113.163 -1.835 . . . . 0.0 107.512 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.437 ' CG2' HG22 ' Q' ' 36' ' ' VAL . 0.0 OUTLIER -95.67 113.85 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.604 -178.521 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.551 ' N ' ' O ' ' O' ' 36' ' ' VAL . . . -65.64 -123.29 0.01 OUTLIER Glycine 0 CA--C 1.521 0.408 0 CA-C-N 113.871 -1.513 . . . . 0.0 110.799 177.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.724 ' H ' ' H ' ' O' ' 38' ' ' GLY . . . 66.64 60.86 5.79 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-N 114.301 -0.95 . . . . 0.0 113.641 179.261 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.598 ' O ' HD11 ' D' ' 31' ' ' ILE . 0.7 OUTLIER -84.71 124.14 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.082 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.505 ' C ' HG12 ' Q' ' 39' ' ' VAL . 3.1 t . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 118.341 -0.838 . . . . 0.0 112.428 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.29 131.07 55.09 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . 0.434 ' H ' ' HG2' ' R' ' 11' ' ' GLU . 96.4 mt-10 -141.23 138.23 33.14 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.542 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.448 HG12 ' H ' ' R' ' 12' ' ' VAL . 34.5 m -125.28 129.92 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.435 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.56 ' CE1' ' O ' ' N' ' 40' ' ' VAL . 14.2 t60 -136.4 132.98 36.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.912 0.387 . . . . 0.0 110.811 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.583 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 3.7 m80 -145.48 162.58 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.515 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.496 ' HG2' HG12 ' O' ' 36' ' ' VAL . 17.6 mp0 -89.95 157.26 17.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 176.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . 0.42 ' HB2' ' NE2' ' P' ' 14' ' ' HIS . 87.9 tttt -141.66 102.34 4.16 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 176.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.576 HD13 HG11 ' O' ' 36' ' ' VAL . 5.2 mp -131.37 119.47 21.73 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-O 121.389 0.614 . . . . 0.0 111.143 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -107.44 111.8 37.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.569 ' CD1' HD13 ' O' ' 32' ' ' ILE . 88.3 m-85 -106.63 103.44 12.88 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.015 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.58 ' CE2' ' CD2' ' R' ' 20' ' ' PHE . 26.1 t80 -110.01 119.34 39.01 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.47 128.34 21.91 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.424 0.63 . . . . 0.0 111.349 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 38.9 tt0 -91.29 109.96 21.25 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 99.1 m-20 -141.96 48.27 1.6 Allowed 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.212 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -72.86 160.56 5.27 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.481 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.82 -30.04 8.42 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.7 t 61.46 109.96 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 118.903 -0.57 . . . . 0.0 112.157 177.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.744 ' O ' ' N ' ' Q' ' 29' ' ' GLY . 14.9 t-20 -129.41 159.74 35.27 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -29.53 48.82 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 N-CA-C 117.641 2.46 . . . . 0.0 117.641 -178.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.744 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -171.93 52.61 0.18 Allowed Glycine 0 CA--C 1.536 1.399 0 CA-C-N 120.552 1.524 . . . . 0.0 112.34 171.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.04 95.06 9.57 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.819 1.809 . . . . 0.0 111.295 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.485 HD11 ' HB ' ' K' ' 39' ' ' VAL . 49.4 mt -133.36 123.98 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 CA-C-N 120.66 1.573 . . . . 0.0 112.687 -178.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -126.97 121.97 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.636 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.75 114.05 2.01 Favored Glycine 0 N--CA 1.467 0.76 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.688 HD22 ' CZ ' ' R' ' 19' ' ' PHE . 89.8 mt -124.98 119.73 29.57 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.504 0.192 . . . . 0.0 110.576 -178.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.421 ' O ' HG23 ' P' ' 36' ' ' VAL . 82.1 mtp -127.93 124.4 37.27 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.437 HG22 ' CG2' ' P' ' 36' ' ' VAL . 64.2 t -115.93 146.9 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.503 -0.555 . . . . 0.0 109.503 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.91 102.29 0.41 Allowed Glycine 0 C--N 1.315 -0.634 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.99 -71.09 0.65 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-O 121.559 0.533 . . . . 0.0 111.945 178.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.507 HG12 HD11 ' E' ' 31' ' ' ILE . 2.4 m -126.2 119.01 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.468 ' CB ' ' O ' ' Q' ' 39' ' ' VAL . 61.1 t . . . . . 0 N--CA 1.487 1.403 0 C-N-CA 124.34 1.056 . . . . 0.0 109.882 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -115.22 140.57 48.98 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.434 ' HG2' ' H ' ' Q' ' 11' ' ' GLU . 97.1 mt-10 -73.48 129.99 39.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.448 ' H ' HG12 ' Q' ' 12' ' ' VAL . 72.0 t -126.07 131.86 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.115 0.483 . . . . 0.0 110.343 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -132.84 95.72 3.64 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.711 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' OE1' ' R' ' 15' ' ' GLN . 84.8 t60 -155.36 161.93 40.93 Favored 'General case' 0 C--O 1.222 -0.349 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.57 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.2 OUTLIER -90.17 159.8 16.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.867 0.365 . . . . 0.0 111.452 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . 0.694 ' C ' HD13 ' R' ' 17' ' ' LEU . 57.7 tttt -139.96 107.12 5.47 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.902 HD22 ' N ' ' R' ' 17' ' ' LEU . 0.0 OUTLIER -126.82 121.3 31.53 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.694 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -104.34 111.31 33.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 177.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.688 ' CZ ' HD22 ' Q' ' 34' ' ' LEU . 80.1 m-85 -103.44 103.77 13.78 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CE2' ' Q' ' 20' ' ' PHE . 62.3 t80 -114.07 109.2 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.352 0.596 . . . . 0.0 109.58 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.47 125.08 33.49 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -81.98 114.38 20.52 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.719 -178.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.401 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.0 t0 -150.24 46.27 0.9 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.671 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.658 HG12 ' H ' ' R' ' 25' ' ' GLY . 24.1 t -96.02 175.93 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.658 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 70.96 26.97 72.99 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . 0.48 ' O ' ' O ' ' R' ' 27' ' ' ASN . 28.5 t -153.37 120.29 5.71 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.101 0.476 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.48 ' O ' ' O ' ' R' ' 26' ' ' SER . 16.3 m120 -42.07 178.78 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.663 -179.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -72.58 45.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.923 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' R' ' 27' ' ' ASN . . . -92.08 59.53 2.74 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.525 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.37 165.86 33.69 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 122.545 -0.385 . . . . 0.0 110.33 -178.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.649 HD11 ' O ' ' L' ' 39' ' ' VAL . 93.6 mt -109.95 119.01 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.261 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . 0.5 HG23 ' O ' ' R' ' 32' ' ' ILE . 18.6 tt -130.37 124.07 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.921 0.391 . . . . 0.0 110.223 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.43 120.3 3.66 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 42.9 mt -121.48 121.57 37.81 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -179.371 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 75.4 mtp -128.95 131.03 47.46 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.45 0.643 . . . . 0.0 112.175 -179.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -134.38 142.67 40.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.935 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.63 -102.31 0.2 Allowed Glycine 0 C--N 1.306 -1.097 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' R' ' 39' ' ' VAL . . . 109.06 -71.85 0.2 Allowed Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.11 -0.828 . . . . 0.0 112.055 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.508 ' HA ' HD13 ' F' ' 31' ' ' ILE . 94.1 t -29.95 123.03 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 118.492 1.146 . . . . 0.0 111.657 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.446 ' H ' HG21 ' F' ' 31' ' ' ILE . 91.7 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.974 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 CA--C 1.527 0.092 0 CA-C-O 120.709 0.29 . . . . 0.0 110.458 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 m -123.05 131.41 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.389 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 75.1 t60 -137.67 141.01 41.13 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.257 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 15' ' ' GLN . 0.4 OUTLIER -84.58 166.62 17.02 Favored 'General case' 0 CA--C 1.532 0.267 0 CA-C-O 121.248 0.547 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.625 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 83.0 mt-30 -157.45 143.09 17.36 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.071 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -81.07 134.36 35.65 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.334 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.92 116.56 22.39 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -125.26 133.68 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.054 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -140.33 139.52 35.43 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.016 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.526 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.1 p90 -126.46 127.81 45.97 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.65 116.22 29.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.302 0.572 . . . . 0.0 111.018 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -142.4 120.9 12.46 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 . . . . . 0 C--N 1.329 -0.323 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.14 -179.445 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 99.5 m-20 . . . . . 0 N--CA 1.472 0.664 0 CA-C-O 119.304 -0.379 . . . . 0.0 110.662 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' B' ' 22' ' ' GLU . 52.3 mtpt -118.36 -38.34 3.19 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 120.123 -0.631 . . . . 0.0 112.271 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.432 ' O ' ' HB1' ' B' ' 21' ' ' ALA . . . -80.7 -78.59 0.93 Allowed Glycine 0 N--CA 1.468 0.792 0 C-N-CA 118.951 -1.595 . . . . 0.0 112.919 -177.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.56 93.64 0.2 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.938 -0.705 . . . . 0.0 112.114 178.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 92.7 mt -126.28 104.73 13.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.413 HD13 ' CD1' ' C' ' 19' ' ' PHE . 96.5 mt -110.57 112.01 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.099 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.609 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.6 92.66 0.5 Allowed Glycine 0 CA--C 1.508 -0.383 0 N-CA-C 104.356 -3.498 . . . . 0.0 104.356 176.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.686 ' O ' HD12 ' B' ' 34' ' ' LEU . 91.5 mt -151.79 177.95 9.88 Favored 'General case' 0 CA--C 1.51 -0.594 0 CA-C-O 122.969 1.366 . . . . 0.0 111.985 -175.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 31.4 mtp -140.38 119.38 12.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 113.096 -1.865 . . . . 0.0 108.902 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.483 HG21 HD13 ' C' ' 17' ' ' LEU . 1.7 m -131.97 113.56 22.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 154.38 -124.64 1.58 Allowed Glycine 0 C--N 1.307 -1.058 0 N-CA-C 109.106 -1.597 . . . . 0.0 109.106 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.62 -67.03 3.6 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.977 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 40' ' ' VAL . 2.4 p -115.56 166.49 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.521 ' N ' HG22 ' A' ' 39' ' ' VAL . 9.8 m . . . . . 0 N--CA 1.472 0.646 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.58 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -106.27 133.21 51.33 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -93.17 106.02 18.03 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.788 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -128.9 130.81 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 81.3 t60 -134.16 105.76 6.83 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.814 0.34 . . . . 0.0 111.166 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.635 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 4.5 t60 -157.12 167.37 30.59 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.584 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.591 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 84.3 mt-30 -154.75 141.84 19.33 Favored 'General case' 0 C--N 1.339 0.127 0 N-CA-C 109.627 -0.509 . . . . 0.0 109.627 177.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -85.53 131.5 34.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.624 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.467 HD23 HD23 ' C' ' 17' ' ' LEU . 33.4 tp -122.16 120.97 35.79 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 118.121 0.419 . . . . 0.0 110.117 177.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -124.61 131.97 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -131.14 123.29 28.24 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.616 -179.069 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -112.79 124.85 53.52 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.432 ' HB1' ' O ' ' A' ' 29' ' ' GLY . . . -124.15 126.28 45.89 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -178.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' A' ' 28' ' ' LYS . 79.0 tt0 -115.07 162.98 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.912 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -178.81 48.71 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 122.337 0.255 . . . . 0.0 110.443 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.522 HG22 ' O ' ' C' ' 23' ' ' ASP . 2.7 t -72.57 161.05 5.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 122.363 1.077 . . . . 0.0 112.749 -174.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.402 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 107.07 -34.71 5.52 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 113.051 -1.886 . . . . 0.0 112.588 178.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' B' ' 27' ' ' ASN . 89.2 p -162.46 120.07 2.08 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.831 1.315 . . . . 0.0 113.851 177.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.604 ' ND2' ' ND2' ' C' ' 27' ' ' ASN . 18.0 t-20 -22.37 153.41 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.362 0.665 . . . . 0.0 111.644 174.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.461 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 56.3 tttt -165.45 26.5 0.05 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.72 107.93 0.38 Allowed Glycine 0 N--CA 1.47 0.944 0 C-N-CA 118.239 -1.934 . . . . 0.0 115.7 174.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -120.47 105.23 10.66 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-O 122.363 1.078 . . . . 0.0 108.136 177.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.47 HD11 ' O ' ' N' ' 38' ' ' GLY . 2.6 mt -133.49 135.63 55.67 Favored 'Isoleucine or valine' 0 C--N 1.346 0.435 0 CA-C-N 114.746 -1.116 . . . . 0.0 113.163 -176.036 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.654 HD13 ' CD1' ' D' ' 19' ' ' PHE . 94.1 mt -113.15 110.78 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.383 176.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.01 102.33 1.07 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 105.327 -3.109 . . . . 0.0 105.327 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.686 HD12 ' O ' ' A' ' 34' ' ' LEU . 12.2 tp -146.67 144.42 29.46 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 117.828 -1.549 . . . . 0.0 114.765 -174.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.43 114.81 29.06 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 112.277 -2.238 . . . . 0.0 108.299 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.732 HG11 HD21 ' D' ' 17' ' ' LEU . 17.0 t -133.21 123.2 46.98 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 119.916 -0.714 . . . . 0.0 110.938 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.7 -113.74 1.02 Allowed Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.719 ' O ' HD12 ' I' ' 31' ' ' ILE . . . 86.7 -72.72 2.58 Favored Glycine 0 CA--C 1.536 1.348 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.585 HG12 ' N ' ' B' ' 40' ' ' VAL . 47.6 t -134.31 164.56 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 122.463 -0.434 . . . . 0.0 110.946 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.585 ' N ' HG12 ' B' ' 39' ' ' VAL . 53.1 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.886 -1.054 . . . . 0.0 109.961 178.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.142 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -81.93 140.28 34.14 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -139.08 139.36 37.71 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.871 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 130.96 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.602 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 33.2 m80 -145.7 101.43 3.56 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 120.107 -0.637 . . . . 0.0 112.183 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.635 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.0 p-80 -155.89 155.0 32.12 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 118.415 -1.314 . . . . 0.0 111.95 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -90.48 161.19 15.63 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.416 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -139.32 112.65 8.22 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 175.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.49 HD12 ' CD2' ' D' ' 17' ' ' LEU . 3.6 mt -116.24 111.48 20.22 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.475 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 t -111.08 110.12 31.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.413 ' CD1' HD13 ' A' ' 32' ' ' ILE . 96.0 m-85 -110.32 113.09 25.48 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -112.32 124.88 53.45 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.676 -0.238 . . . . 0.0 110.505 -178.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . 0.554 ' O ' ' NZ ' ' C' ' 28' ' ' LYS . . . -131.78 136.77 47.8 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.508 0.671 . . . . 0.0 112.724 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.442 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 15.5 pt-20 -163.81 133.2 3.98 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.3 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.522 ' O ' HG22 ' B' ' 24' ' ' VAL . 0.2 OUTLIER -150.02 -60.3 0.2 Allowed 'General case' 0 C--N 1.353 0.758 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.669 HG12 ' N ' ' C' ' 25' ' ' GLY . 35.9 t -94.15 170.55 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 117.378 -1.729 . . . . 0.0 112.579 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.669 ' N ' HG12 ' C' ' 24' ' ' VAL . . . -81.51 27.83 3.2 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.404 173.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' C' ' 27' ' ' ASN . 4.8 t -170.56 -138.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 118.947 1.374 . . . . 0.0 112.75 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.604 ' ND2' ' ND2' ' B' ' 27' ' ' ASN . 66.4 t30 -34.52 127.69 0.46 Allowed 'General case' 0 C--N 1.349 0.547 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.178 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.943 ' HZ3' ' HB1' ' D' ' 21' ' ' ALA . 71.2 tttt -104.94 -42.16 5.41 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . 81.18 60.88 2.18 Favored Glycine 0 CA--C 1.543 1.812 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.622 ' H ' ' HG ' ' D' ' 26' ' ' SER . . . -110.21 112.39 24.34 Favored 'General case' 0 C--N 1.361 1.101 0 CA-C-O 123.237 1.494 . . . . 0.0 114.077 -175.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.556 HG21 ' CG2' ' O' ' 39' ' ' VAL . 1.1 tt -134.63 127.19 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 112.218 -2.264 . . . . 0.0 109.228 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.417 HD13 HG21 ' C' ' 32' ' ' ILE . 29.2 mt -106.56 116.32 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.213 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.97 106.36 1.62 Allowed Glycine 0 N--CA 1.466 0.695 0 N-CA-C 106.551 -2.619 . . . . 0.0 106.551 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -133.05 134.63 44.61 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 114.128 1.159 . . . . 0.0 114.128 -174.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -113.02 98.94 7.48 Favored 'General case' 0 N--CA 1.432 -1.338 0 N-CA-C 101.591 -3.485 . . . . 0.0 101.591 173.058 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.02 132.22 65.61 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 N-CA-C 114.76 1.393 . . . . 0.0 114.76 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.09 111.97 1.25 Allowed Glycine 0 CA--C 1.521 0.461 0 CA-C-N 114.267 -1.333 . . . . 0.0 113.194 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -97.9 -60.51 0.92 Allowed Glycine 0 CA--C 1.54 1.609 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 176.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.662 ' HB ' HD11 ' I' ' 31' ' ' ILE . 10.0 p -145.06 150.5 15.93 Favored 'Isoleucine or valine' 0 C--N 1.342 0.269 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.497 ' OXT' ' ND1' ' E' ' 13' ' ' HIS . 9.8 p . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.534 -179.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.583 HG23 ' O ' ' D' ' 12' ' ' VAL . 22.0 m . . . . . 0 N--CA 1.468 0.475 0 CA-C-O 121.433 0.635 . . . . 0.0 110.594 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.602 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 2.5 t60 -126.83 127.87 45.66 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.694 -178.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.461 ' HB3' ' H ' ' E' ' 14' ' ' HIS . 1.5 p-80 -134.19 164.39 27.46 Favored 'General case' 0 C--O 1.221 -0.396 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.165 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.415 ' NE2' HG12 ' B' ' 36' ' ' VAL . 44.4 tp60 -90.1 151.51 21.58 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 178.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -150.33 97.13 2.5 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.732 HD21 HG11 ' B' ' 36' ' ' VAL . 7.4 mt -123.29 121.56 36.15 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.07 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -114.89 106.54 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.654 ' CD1' HD13 ' B' ' 32' ' ' ILE . 91.4 m-85 -107.78 106.0 16.1 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 177.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -116.76 129.38 56.08 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.787 -175.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.943 ' HB1' ' HZ3' ' C' ' 28' ' ' LYS . . . -133.86 128.73 35.26 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-O 121.54 0.686 . . . . 0.0 111.295 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.629 ' N ' ' NZ ' ' C' ' 28' ' ' LYS . 98.9 mt-10 -95.13 139.4 31.51 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.381 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.501 ' O ' ' O ' ' D' ' 24' ' ' VAL . 9.9 m-20 65.36 47.92 2.22 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 177.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.501 ' O ' ' O ' ' D' ' 23' ' ' ASP . 5.2 m -52.45 -175.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 119.215 -0.994 . . . . 0.0 108.433 177.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 165.43 19.46 0.02 OUTLIER Glycine 0 CA--C 1.523 0.548 0 C-N-CA 118.252 -1.928 . . . . 0.0 113.342 -177.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.622 ' HG ' ' H ' ' C' ' 30' ' ' ALA . 5.2 m -80.33 -130.37 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' CG1' ' P' ' 39' ' ' VAL . 9.7 m120 -100.48 149.78 23.33 Favored 'General case' 0 CA--C 1.516 -0.332 0 C-N-CA 119.048 -1.061 . . . . 0.0 109.745 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.498 ' NZ ' HD11 ' F' ' 31' ' ' ILE . 95.8 mttt 37.78 42.54 0.41 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.346 -1.297 . . . . 0.0 110.887 -177.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.56 -66.42 2.32 Favored Glycine 0 CA--C 1.545 1.947 0 CA-C-N 116.514 -0.312 . . . . 0.0 113.245 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.21 165.41 9.06 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.525 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 11.9 tt -129.59 129.92 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.733 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -113.52 112.68 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.761 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.64 97.01 1.39 Allowed Glycine 0 C--O 1.239 0.409 0 N-CA-C 104.226 -3.55 . . . . 0.0 104.226 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.427 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 64.9 tp -117.09 121.54 41.59 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -173.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -112.03 97.93 7.0 Favored 'General case' 0 N--CA 1.433 -1.3 0 N-CA-C 103.796 -2.668 . . . . 0.0 103.796 173.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.628 ' CG2' HE22 ' E' ' 15' ' ' GLN . 14.3 p -119.09 120.84 65.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.268 0 C-N-CA 119.714 -0.794 . . . . 0.0 110.454 -177.202 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -99.51 121.88 7.37 Favored Glycine 0 C--N 1.332 0.345 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' E' ' 39' ' ' VAL . . . -119.24 62.07 0.47 Allowed Glycine 0 CA--C 1.532 1.149 0 CA-C-O 119.035 -0.869 . . . . 0.0 112.532 178.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.63 ' HB ' HD11 ' J' ' 31' ' ' ILE . 49.2 t -84.3 130.04 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 119.324 1.562 . . . . 0.0 109.742 179.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.431 ' O ' HG12 ' D' ' 39' ' ' VAL . 16.9 m . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.284 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -110.79 134.79 52.2 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.655 0.264 . . . . 0.0 110.302 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.433 ' O ' HG11 ' D' ' 12' ' ' VAL . 73.1 tt0 -105.54 137.59 43.13 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.994 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.553 HG11 ' H ' ' F' ' 12' ' ' VAL . 4.2 p -139.52 156.39 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.916 0.389 . . . . 0.0 111.42 -178.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.497 ' ND1' ' OXT' ' C' ' 40' ' ' VAL . 7.7 p80 -74.19 125.06 27.55 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.194 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.461 ' H ' ' HB3' ' D' ' 14' ' ' HIS . 52.6 p-80 -154.05 166.36 33.28 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.339 178.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.628 HE22 ' CG2' ' D' ' 36' ' ' VAL . 16.8 tt0 -89.84 151.71 21.63 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 178.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -149.57 105.27 3.43 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.858 177.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -117.59 117.06 28.38 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.893 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 103.88 15.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.639 ' CE2' ' CE1' ' F' ' 19' ' ' PHE . 3.7 m-30 -106.54 109.12 20.94 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -129.72 130.9 46.05 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 120.058 -0.657 . . . . 0.0 112.521 -176.24 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.441 ' HB1' HG13 ' D' ' 24' ' ' VAL . . . -124.47 133.18 53.43 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.936 178.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 92.0 mt-10 -127.18 170.64 12.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 116.982 2.216 . . . . 0.0 116.982 -176.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.454 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 11.4 p30 48.18 46.31 19.77 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 110.722 -2.944 . . . . 0.0 116.167 177.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.677 HG23 ' H ' ' E' ' 26' ' ' SER . 15.7 m -72.12 -168.79 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.247 -0.981 . . . . 0.0 108.947 174.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.42 36.81 3.96 Favored Glycine 0 N--CA 1.467 0.725 0 N-CA-C 105.815 -2.914 . . . . 0.0 105.815 172.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.677 ' H ' HG23 ' E' ' 24' ' ' VAL . 21.3 t 61.63 111.21 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 113.339 -1.43 . . . . 0.0 107.844 -175.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.481 ' O ' ' N ' ' E' ' 29' ' ' GLY . 98.8 m-20 -130.0 161.1 31.7 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . 0.433 ' C ' ' O ' ' E' ' 27' ' ' ASN . 98.3 mttt -28.63 -40.27 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.294 173.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . 0.612 ' O ' ' HB2' ' E' ' 30' ' ' ALA . . . 107.68 -63.45 0.28 Allowed Glycine 0 CA--C 1.54 1.611 0 CA-C-O 117.096 -1.947 . . . . 0.0 115.968 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.612 ' HB2' ' O ' ' E' ' 29' ' ' GLY . . . -179.75 168.89 1.34 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 122.903 3.351 . . . . 0.0 115.915 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 91.2 mt -119.53 125.09 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 111.18 -2.736 . . . . 0.0 106.087 175.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 89.5 mt -130.49 128.76 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.94 106.28 1.01 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.675 HD23 ' C ' ' E' ' 34' ' ' LEU . 7.3 tt -115.61 122.75 46.55 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-O 120.926 0.393 . . . . 0.0 111.672 -176.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.457 ' N ' HD23 ' E' ' 34' ' ' LEU . 8.2 mtp -118.76 126.07 51.04 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.635 178.482 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.474 HG12 ' N ' ' E' ' 37' ' ' GLY . 59.1 t -90.68 156.38 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 121.142 0.496 . . . . 0.0 111.052 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.474 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -102.13 102.5 2.33 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.299 -179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.56 -73.56 0.0 OUTLIER Glycine 0 CA--C 1.541 1.676 0 N-CA-C 115.567 0.987 . . . . 0.0 115.567 177.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' D' ' 38' ' ' GLY . 6.6 p . . . . . 0 N--CA 1.48 1.074 0 CA-C-N 118.577 1.189 . . . . 0.0 111.64 -178.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 120.678 0.275 . . . . 0.0 110.56 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.553 ' H ' HG11 ' E' ' 12' ' ' VAL . 67.9 t -124.46 127.5 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.952 0.882 . . . . 0.0 111.439 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 5.8 p80 -126.51 103.29 7.52 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.981 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.444 ' CE1' HG11 ' F' ' 12' ' ' VAL . 0.3 OUTLIER -148.08 169.38 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.423 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -89.58 156.88 18.32 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 119.227 -0.989 . . . . 0.0 110.65 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.21 104.71 4.68 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.585 ' H ' HD12 ' F' ' 17' ' ' LEU . 0.0 OUTLIER -124.76 112.31 16.56 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -107.13 107.16 22.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.639 ' CE1' ' CE2' ' E' ' 19' ' ' PHE . 13.1 m-85 -118.89 108.78 15.22 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.525 ' CE2' ' O ' ' F' ' 21' ' ' ALA . 57.7 t80 -148.76 163.32 37.7 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.33 1.062 . . . . 0.0 113.234 -178.428 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.525 ' O ' ' CE2' ' F' ' 20' ' ' PHE . . . -137.62 138.34 39.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.582 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -77.94 112.67 15.07 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 p30 . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.244 -176.727 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.523 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.516 -0.359 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.498 HD11 ' NZ ' ' D' ' 28' ' ' LYS . 97.1 mt -119.73 124.68 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 33.7 pt -135.79 137.18 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 121.215 0.531 . . . . 0.0 111.218 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.96 120.31 2.34 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.584 HD23 ' C ' ' F' ' 34' ' ' LEU . 6.2 tt -118.54 121.98 41.55 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.576 ' N ' HD23 ' F' ' 34' ' ' LEU . 4.8 ttm -119.25 120.37 36.81 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.958 0.409 . . . . 0.0 111.101 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.472 ' O ' ' O ' ' F' ' 37' ' ' GLY . 22.4 m -87.12 131.8 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.076 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -46.97 -111.82 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 121.918 0.732 . . . . 0.0 112.103 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.64 -71.36 0.83 Allowed Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.364 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -102.5 128.58 55.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-O 121.339 0.59 . . . . 0.0 110.751 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.585 -179.982 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 N--CA 1.466 0.374 0 CA-C-O 120.953 0.406 . . . . 0.0 110.25 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 37.8 p-80 -143.69 161.09 39.46 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.509 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.41 ' CE1' ' CD2' ' H' ' 13' ' ' HIS . 72.3 m80 -150.22 173.48 13.89 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.154 -179.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 29.7 pt20 -92.33 150.27 20.94 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -101.31 151.16 22.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.131 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 tp -137.45 124.83 21.92 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.561 0.696 . . . . 0.0 111.681 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 65.8 t -124.82 129.97 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 114.99 -1.004 . . . . 0.0 108.819 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -134.27 130.63 37.37 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.198 0.523 . . . . 0.0 111.285 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.6 p90 -135.67 128.37 30.91 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.752 179.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.6 138.37 54.56 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.801 0.334 . . . . 0.0 110.898 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -81.96 -168.78 2.07 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.593 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.406 -179.011 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.506 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 15.4 t-20 . . . . . 0 CA--C 1.534 0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 111.618 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.506 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 77.4 tttt -56.09 -36.55 68.27 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.869 -1.06 . . . . 0.0 111.685 178.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.65 82.15 0.45 Allowed Glycine 0 CA--C 1.53 1.018 0 CA-C-N 114.127 -1.397 . . . . 0.0 113.508 -174.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . -101.95 102.98 13.59 Favored 'General case' 0 C--O 1.242 0.698 0 CA-C-O 124.132 1.92 . . . . 0.0 109.775 -178.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.506 HG23 HG23 ' H' ' 31' ' ' ILE . 53.1 mt -126.45 132.54 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 CA-C-N 110.506 -3.043 . . . . 0.0 108.868 -177.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.505 HG22 HD21 ' H' ' 34' ' ' LEU . 33.5 mt -103.66 110.79 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 176.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.81 104.98 1.44 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 107.524 -2.23 . . . . 0.0 107.524 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.7 tp -163.0 152.79 15.67 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 117.976 -1.49 . . . . 0.0 113.64 -177.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.43 ' SD ' ' HB2' ' H' ' 35' ' ' MET . 45.4 tpp -100.03 116.87 33.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 112.572 -2.103 . . . . 0.0 107.953 178.036 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -123.09 112.1 32.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.53 -131.88 10.75 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.47 -62.66 0.31 Allowed Glycine 0 CA--C 1.54 1.648 0 C-N-CA 121.436 -0.411 . . . . 0.0 112.442 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.674 ' O ' HG23 ' G' ' 40' ' ' VAL . 12.6 p -116.22 160.47 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 C-N-CA 122.542 0.337 . . . . 0.0 110.936 -179.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.674 HG23 ' O ' ' G' ' 39' ' ' VAL . 24.7 t . . . . . 0 N--CA 1.471 0.588 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.401 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -83.21 139.76 32.95 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.727 0.298 . . . . 0.0 110.509 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.34 140.76 39.62 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.5 t -129.96 134.51 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.636 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.41 ' CD2' ' CE1' ' G' ' 14' ' ' HIS . 20.6 t-160 -129.58 100.46 5.54 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.825 0.345 . . . . 0.0 110.843 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 0.1 OUTLIER -159.3 171.98 18.84 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.128 179.851 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.645 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 84.6 mt-30 -152.2 141.31 21.3 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 178.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -88.08 114.53 24.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.79 178.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 70.8 mt -119.55 112.99 20.04 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -120.77 131.12 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 120.792 0.329 . . . . 0.0 111.441 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -133.15 116.15 15.92 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.585 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' CD2' ' I' ' 20' ' ' PHE . 10.4 m-85 -122.65 134.84 54.48 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.11 127.83 23.33 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 80.3 tt0 -95.02 117.38 30.06 Favored 'General case' 0 CA--C 1.522 -0.101 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 176.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.45 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 84.5 m-20 -136.05 46.99 2.26 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -175.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.66 HG22 ' HA ' ' I' ' 23' ' ' ASP . 17.0 t -99.88 162.98 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 C-N-CA 118.013 -1.475 . . . . 0.0 108.386 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.459 ' N ' HG12 ' H' ' 24' ' ' VAL . . . 70.99 28.58 70.27 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -178.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.532 ' OG ' ' N ' ' H' ' 27' ' ' ASN . 20.0 p -170.53 -132.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.801 0.81 . . . . 0.0 112.467 -175.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.532 ' N ' ' OG ' ' H' ' 26' ' ' SER . 1.6 m120 -30.7 143.67 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 114.1 -1.409 . . . . 0.0 113.713 -177.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -132.53 -25.14 1.95 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 113.609 -1.632 . . . . 0.0 111.224 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . -78.83 109.37 2.83 Favored Glycine 0 N--CA 1.47 0.913 0 CA-C-N 116.187 -0.46 . . . . 0.0 113.376 -176.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 111.99 12.61 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 122.385 1.088 . . . . 0.0 112.621 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.506 HG23 HG23 ' G' ' 31' ' ' ILE . 14.9 tt -140.34 137.99 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 114.515 -1.22 . . . . 0.0 111.124 178.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.439 ' CG2' HD12 ' H' ' 34' ' ' LEU . 95.5 mt -106.19 113.88 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.609 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.74 100.67 1.13 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 106.631 -2.588 . . . . 0.0 106.631 176.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.505 HD21 HG22 ' G' ' 32' ' ' ILE . 90.7 mt -141.76 153.45 44.59 Favored 'General case' 0 CA--C 1.51 -0.564 0 CA-C-O 122.844 1.307 . . . . 0.0 113.586 -175.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.43 ' HB2' ' SD ' ' G' ' 35' ' ' MET . 4.1 mtp -116.87 117.18 29.02 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 112.498 -2.137 . . . . 0.0 105.939 176.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' K' ' 15' ' ' GLN . 58.9 t -123.56 102.42 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 O-C-N 122.469 -0.144 . . . . 0.0 111.35 -176.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.64 -162.37 23.76 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.437 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 146.71 -55.64 0.52 Allowed Glycine 0 CA--C 1.547 2.093 0 CA-C-O 119.572 -0.571 . . . . 0.0 112.561 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.613 ' CG2' HG21 ' N' ' 31' ' ' ILE . 3.0 p -142.44 162.51 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-N 118.498 1.149 . . . . 0.0 110.248 178.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.432 HG23 ' ND1' ' K' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . 0.514 ' CD1' ' O ' ' J' ' 9' ' ' GLY . 97.7 m-85 -99.28 132.59 44.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.723 0.297 . . . . 0.0 110.572 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' I' ' 11' ' ' GLU . 2.0 pm0 -154.4 141.25 19.14 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.054 0.454 . . . . 0.0 111.446 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -126.81 129.35 71.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.968 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 18.7 m80 -116.25 138.88 50.93 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 110.35 -0.241 . . . . 0.0 110.35 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -149.85 167.85 25.4 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.351 177.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.413 ' CB ' HE21 ' J' ' 15' ' ' GLN . 44.2 tp60 -139.22 141.07 37.91 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.456 ' C ' HD22 ' I' ' 17' ' ' LEU . 99.5 mttt -129.8 104.3 7.32 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.394 179.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.463 HD12 ' CZ ' ' I' ' 19' ' ' PHE . 3.6 mm? -111.9 113.29 25.53 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 t -109.08 107.48 22.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.463 ' CZ ' HD12 ' I' ' 17' ' ' LEU . 57.7 m-85 -109.05 108.45 19.16 Favored 'General case' 0 CA--C 1.546 0.821 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.447 ' CD2' ' CE2' ' H' ' 20' ' ' PHE . 5.4 m-85 -117.5 130.42 56.43 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 122.184 -0.322 . . . . 0.0 110.917 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.29 134.22 30.69 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.563 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 85.5 mt-10 -92.4 -161.33 0.82 Allowed 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.217 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.66 ' HA ' HG22 ' H' ' 24' ' ' VAL . 0.4 OUTLIER 95.12 54.2 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 -177.689 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.458 HG13 ' H ' ' I' ' 24' ' ' VAL . 1.1 m -81.3 133.49 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 CA-C-O 125.133 2.397 . . . . 0.0 116.264 -169.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.707 ' H ' ' HA ' ' J' ' 23' ' ' ASP . . . 94.5 -41.99 2.5 Favored Glycine 0 N--CA 1.443 -0.869 2 CA-C-N 107.471 -4.422 . . . . 0.0 113.594 172.516 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 94.6 p -68.39 110.85 4.31 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 115.976 -1.964 . . . . 0.0 112.039 174.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.888 ' ND2' ' H ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -147.66 124.47 11.23 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 123.313 2.778 . . . . 0.0 111.566 166.739 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.408 ' HZ2' HG23 ' A' ' 39' ' ' VAL . 94.0 mttt -18.11 -52.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 115.638 1.718 . . . . 0.0 115.638 172.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.61 52.77 0.02 OUTLIER Glycine 0 CA--C 1.563 3.08 0 CA-C-N 112.584 -2.098 . . . . 0.0 109.661 -175.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.888 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . -41.98 141.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -171.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.719 HD12 ' O ' ' B' ' 38' ' ' GLY . 55.0 mt -143.19 147.79 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 112.831 -1.986 . . . . 0.0 113.701 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.429 HD13 HG21 ' I' ' 32' ' ' ILE . 27.3 mt -110.58 111.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 174.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.09 104.57 1.96 Allowed Glycine 0 N--CA 1.466 0.643 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mt -141.14 144.56 34.91 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -175.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 49.2 tpp -112.85 115.67 28.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 104.644 -2.354 . . . . 0.0 104.644 173.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.51 HG12 ' OE1' ' K' ' 15' ' ' GLN . 47.5 t -123.44 102.62 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 118.055 0.389 . . . . 0.0 111.874 -175.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.737 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 107.31 -161.93 13.54 Favored Glycine 0 N--CA 1.467 0.714 0 C-N-CA 120.486 -0.864 . . . . 0.0 112.803 177.557 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.822 ' H ' ' H ' ' J' ' 38' ' ' GLY . . . 148.15 -55.35 0.5 Allowed Glycine 0 CA--C 1.542 1.75 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.746 HG21 HD12 ' N' ' 31' ' ' ILE . 18.2 t -114.43 130.46 68.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 C-N-CA 123.409 0.684 . . . . 0.0 109.217 178.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.492 HG23 ' ND1' ' K' ' 13' ' ' HIS . 2.4 p . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.898 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . 0.514 ' O ' ' CD1' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -117.13 143.83 45.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.675 0.274 . . . . 0.0 110.434 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -73.68 108.58 6.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.86 0.362 . . . . 0.0 110.677 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.7 136.64 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.31 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -145.87 126.07 13.85 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.948 -0.301 . . . . 0.0 111.159 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 m-70 -140.41 157.57 45.33 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.012 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.413 HE21 ' CB ' ' I' ' 15' ' ' GLN . 3.4 tp60 -90.31 158.85 16.95 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 174.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 44.1 tttp -141.18 113.55 8.09 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.163 177.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.429 ' N ' HD12 ' J' ' 17' ' ' LEU . 2.8 mp -136.61 127.94 28.28 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.755 0.788 . . . . 0.0 110.84 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -112.95 112.23 39.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 CA-C-N 114.464 -1.244 . . . . 0.0 108.76 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' K' ' 19' ' ' PHE . 18.5 m-85 -106.98 106.33 16.8 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.598 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 20.4 t80 -113.79 114.8 26.81 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.53 122.59 22.62 Favored 'General case' 0 C--O 1.246 0.9 0 CA-C-O 122.153 0.977 . . . . 0.0 111.829 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 96.5 mt-10 -83.89 125.46 32.01 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-N 113.824 -1.535 . . . . 0.0 107.861 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.707 ' HA ' ' H ' ' I' ' 25' ' ' GLY . 61.2 m-20 -166.45 47.29 0.07 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 118.158 -0.925 . . . . 0.0 113.393 -174.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.563 ' N ' ' OE1' ' K' ' 22' ' ' GLU . 9.3 p -98.6 161.31 3.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 CA-C-N 121.419 1.918 . . . . 0.0 109.286 -176.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.741 ' H ' ' N ' ' K' ' 25' ' ' GLY . . . 73.23 28.87 65.3 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 106.662 -2.575 . . . . 0.0 106.662 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 8.7 t -104.5 -120.75 0.21 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 -173.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.415 ' OD1' ' O ' ' I' ' 27' ' ' ASN . 2.2 m120 -81.8 163.75 22.14 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -175.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -47.47 -36.82 10.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 112.661 -2.063 . . . . 0.0 114.504 178.075 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.8 77.84 0.06 OUTLIER Glycine 0 CA--C 1.532 1.104 0 C-N-CA 119.147 -1.501 . . . . 0.0 114.859 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.21 169.0 0.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 118.847 1.324 . . . . 0.0 110.555 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.63 HD11 ' HB ' ' D' ' 39' ' ' VAL . 68.8 mt -127.39 135.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 115.212 1.56 . . . . 0.0 115.212 -175.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 53.7 mt -106.49 105.75 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 172.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.18 101.17 1.94 Allowed Glycine 0 CA--C 1.508 -0.398 0 N-CA-C 104.849 -3.301 . . . . 0.0 104.849 176.354 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.752 ' CD2' HG22 ' J' ' 36' ' ' VAL . 6.5 tt -143.33 125.74 15.7 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-O 123.081 1.419 . . . . 0.0 112.618 -175.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.7 mtp -104.68 118.07 35.66 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 112.582 -2.099 . . . . 0.0 107.875 178.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.752 HG22 ' CD2' ' J' ' 34' ' ' LEU . 1.8 t -105.91 114.09 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' I' ' 36' ' ' VAL . . . -64.78 -123.24 0.01 OUTLIER Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.822 ' H ' ' H ' ' I' ' 38' ' ' GLY . . . 64.99 61.05 6.15 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 114.278 -0.961 . . . . 0.0 114.573 178.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.466 ' HB ' HD13 ' P' ' 31' ' ' ILE . 1.0 OUTLIER -92.52 130.17 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 177.817 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.652 ' OXT' HG13 ' J' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.84 -1.076 . . . . 0.0 111.859 -177.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -104.69 133.41 49.57 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.75 0.309 . . . . 0.0 110.609 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -142.9 133.29 24.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.666 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 95.2 t -124.97 123.8 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.462 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.492 ' ND1' HG23 ' I' ' 40' ' ' VAL . 6.4 t-160 -145.04 112.98 6.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.044 0.449 . . . . 0.0 111.305 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.673 ' CE1' ' H ' ' L' ' 14' ' ' HIS . 19.0 m-70 -140.41 159.22 42.68 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 177.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.737 HE22 ' N ' ' I' ' 37' ' ' GLY . 77.0 mt-30 -90.18 159.35 16.79 Favored 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 175.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.711 ' C ' HD12 ' K' ' 17' ' ' LEU . 99.2 mttt -140.03 101.0 4.06 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.711 HD12 ' C ' ' K' ' 16' ' ' LYS . 7.7 mp -125.89 125.91 43.57 Favored 'General case' 0 CA--C 1.506 -0.73 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.785 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.405 HG13 ' O ' ' K' ' 18' ' ' VAL . 5.2 p -119.49 118.33 56.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' J' ' 19' ' ' PHE . 53.2 m-85 -107.03 105.98 16.28 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.728 -1.123 . . . . 0.0 109.69 -178.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.1 t80 -106.24 108.09 19.43 Favored 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -148.36 155.11 40.86 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.94 1.352 . . . . 0.0 113.38 -177.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.568 ' HB2' ' H ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -93.06 117.58 30.23 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.908 -179.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.427 ' OD2' ' OD1' ' L' ' 23' ' ' ASP . 13.6 m-20 -67.4 -51.25 54.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 114.418 -1.265 . . . . 0.0 111.547 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.568 HG22 ' N ' ' K' ' 25' ' ' GLY . 2.3 p 158.8 161.84 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -177.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.741 ' N ' ' H ' ' J' ' 25' ' ' GLY . . . -63.29 30.41 0.08 OUTLIER Glycine 0 CA--C 1.532 1.116 0 N-CA-C 118.509 2.164 . . . . 0.0 118.509 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.575 ' OG ' ' O ' ' K' ' 25' ' ' GLY . 5.2 m -169.96 -127.8 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 121.293 2.546 . . . . 0.0 114.104 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.437 ' O ' ' N ' ' K' ' 29' ' ' GLY . 60.2 t30 -48.13 152.29 0.85 Allowed 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 113.577 0.955 . . . . 0.0 113.577 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.449 ' NZ ' HD11 ' L' ' 32' ' ' ILE . 85.0 tttt -70.33 48.84 0.11 Allowed 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . -82.47 51.1 4.46 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.27 -0.966 . . . . 0.0 112.707 -176.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 173.58 7.13 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.529 HD12 HG13 ' D' ' 39' ' ' VAL . 42.2 mt -125.46 127.75 72.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.743 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.424 HD13 HG21 ' K' ' 32' ' ' ILE . 33.4 pt -132.63 127.6 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.664 0.745 . . . . 0.0 111.753 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.608 ' C ' HD22 ' K' ' 34' ' ' LEU . . . -117.34 110.93 2.15 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.709 HD22 ' N ' ' K' ' 34' ' ' LEU . 1.9 mm? -121.64 116.16 24.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.902 0.382 . . . . 0.0 110.066 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 4.1 ttm -107.81 130.28 54.99 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 54.0 t -125.64 131.84 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 CA-C-O 121.915 0.864 . . . . 0.0 112.352 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.03 -111.41 0.01 OUTLIER Glycine 0 CA--C 1.527 0.827 0 CA-C-N 113.722 -1.581 . . . . 0.0 111.085 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' OXT' ' J' ' 40' ' ' VAL . . . 105.91 -70.55 0.23 Allowed Glycine 0 N--CA 1.473 1.101 0 CA-C-N 114.518 -0.841 . . . . 0.0 111.758 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.435 -1.195 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 . . . . . 0 N--CA 1.463 0.22 0 N-CA-C 109.921 -0.4 . . . . 0.0 109.921 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.533 HG12 ' NE2' ' K' ' 14' ' ' HIS . 2.1 t -110.79 115.93 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 110.462 -179.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.5 p80 -147.19 101.5 3.4 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.975 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.673 ' H ' ' CE1' ' K' ' 14' ' ' HIS . 97.6 m-70 -156.55 164.92 37.64 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 178.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.449 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 96.5 mm-40 -89.97 159.36 16.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.358 . . . . 0.0 111.104 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.78 104.18 4.83 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.605 0.716 . . . . 0.0 109.494 177.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.663 ' CD1' HG21 ' J' ' 36' ' ' VAL . 1.8 mt -122.69 115.48 22.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -101.64 97.76 6.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.565 ' CZ ' HD12 ' K' ' 34' ' ' LEU . 85.2 m-85 -93.87 98.93 11.39 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.368 -1.715 . . . . 0.0 106.368 178.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -122.38 127.02 49.22 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.746 0.784 . . . . 0.0 109.996 -178.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.11 150.96 36.03 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -64.45 107.79 1.46 Allowed 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 118.549 -1.26 . . . . 0.0 108.758 -178.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.427 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 13.8 m-20 -153.89 50.0 0.66 Allowed 'General case' 0 C--O 1.231 0.122 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 95.8 t -82.8 149.3 4.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 178.095 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.93 36.25 5.83 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 18.1 t -76.45 102.35 5.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.706 0.765 . . . . 0.0 111.487 -176.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -97.48 -167.61 1.56 Allowed 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.543 -1.208 . . . . 0.0 112.188 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -49.13 -40.55 32.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.042 -1.436 . . . . 0.0 114.38 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.31 68.79 1.86 Allowed Glycine 0 N--CA 1.477 1.432 0 N-CA-C 114.971 0.748 . . . . 0.0 114.971 -175.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.444 ' CB ' ' O ' ' K' ' 28' ' ' LYS . . . -141.74 141.71 33.26 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -120.6 117.69 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.125 0 CA-C-N 120.443 1.474 . . . . 0.0 111.577 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.449 HD11 ' NZ ' ' K' ' 28' ' ' LYS . 95.4 mt -119.57 122.18 68.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-N 114.812 -1.086 . . . . 0.0 110.205 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.4 106.72 0.91 Allowed Glycine 0 N--CA 1.464 0.547 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.9 tp -125.17 123.9 40.61 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 94.0 mtp -132.77 133.58 43.61 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.436 0.636 . . . . 0.0 112.217 -179.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.5 t -128.87 132.35 67.55 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.135 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 177.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.6 112.19 3.53 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 119.182 -1.485 . . . . 0.0 111.736 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.34 -63.51 4.46 Favored Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 177.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.506 ' CA ' HD11 ' R' ' 31' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 124.229 1.012 . . . . 0.0 108.355 -179.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 42.7 tp10 . . . . . 0 N--CA 1.463 0.221 0 CA-C-O 120.89 0.376 . . . . 0.0 110.048 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 70.4 t -125.87 131.6 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.814 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -107.43 107.81 18.86 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.695 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 42.8 p-80 -152.66 165.94 33.68 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-O 121.212 0.53 . . . . 0.0 111.728 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 52.7 tt0 -170.75 147.99 2.87 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.271 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -77.9 120.41 22.74 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -128.31 113.81 16.1 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -130.19 130.07 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.354 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -133.56 141.88 47.91 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.44 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.408 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 50.9 p90 -134.8 129.28 34.31 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.714 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.53 116.59 31.11 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.326 0.584 . . . . 0.0 110.339 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . 0.581 ' O ' ' N ' ' M' ' 24' ' ' VAL . 67.3 mt-10 -150.9 -139.06 0.09 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.329 -0.851 . . . . 0.0 108.918 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 53.7 p30 -53.05 50.99 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.694 1.197 . . . . 0.0 113.226 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.587 HG12 ' H ' ' M' ' 25' ' ' GLY . 2.7 t -101.02 -141.73 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . 0.587 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -72.59 -36.99 58.29 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 119.161 -1.495 . . . . 0.0 113.273 -175.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . 0.425 ' O ' ' C ' ' M' ' 27' ' ' ASN . 93.8 p -162.27 117.26 1.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 118.873 1.336 . . . . 0.0 112.134 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . 0.529 ' ND2' ' O ' ' N' ' 25' ' ' GLY . 99.1 m-20 -23.33 144.83 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.769 -1.105 . . . . 0.0 113.194 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -120.24 -36.6 3.21 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 173.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . 0.437 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 80.14 -70.2 2.98 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 112.275 -2.239 . . . . 0.0 112.584 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . 0.437 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 179.46 74.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.533 0.666 . . . . 0.0 112.022 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.6 HG23 ' O ' ' M' ' 31' ' ' ILE . 19.3 tt -128.58 108.94 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 CA-C-N 119.243 0.929 . . . . 0.0 109.313 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' O' ' 19' ' ' PHE . 96.6 mt -114.48 109.55 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.592 -179.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.25 98.36 0.69 Allowed Glycine 0 N--CA 1.461 0.308 0 N-CA-C 106.154 -2.778 . . . . 0.0 106.154 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 82.5 mt -145.93 164.6 31.5 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 123.269 1.509 . . . . 0.0 113.888 -176.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.9 mmm -113.77 110.19 19.77 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 111.771 -2.468 . . . . 0.0 106.859 177.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -118.04 111.78 35.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 134.69 -131.52 5.92 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.02 -63.08 0.75 Allowed Glycine 0 CA--C 1.536 1.398 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.449 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 2.1 t -114.04 160.71 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-N 116.992 0.396 . . . . 0.0 110.05 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.449 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 21.8 m . . . . . 0 N--CA 1.469 0.48 0 CA-C-O 117.836 -1.078 . . . . 0.0 111.918 178.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.113 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -85.51 137.9 32.57 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -100.77 141.95 32.92 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.487 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -124.72 132.78 70.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.376 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 51.0 m170 -116.98 99.79 7.31 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' N ' ' N' ' 15' ' ' GLN . 23.1 t60 -154.01 165.82 34.96 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.594 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.705 HE21 ' NE2' ' O' ' 15' ' ' GLN . 13.4 pt20 -160.34 143.52 13.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.217 178.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -80.0 112.2 17.06 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.457 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 tt -120.98 117.92 28.53 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -125.72 131.83 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.09 0.471 . . . . 0.0 111.094 -179.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -126.94 119.12 25.95 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 87.5 t80 -118.21 126.32 51.95 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.32 129.49 43.27 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 121.292 0.568 . . . . 0.0 112.355 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -88.65 115.99 26.58 Favored 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -87.04 47.6 1.53 Allowed 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -110.48 151.64 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 176.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . 0.529 ' O ' ' ND2' ' M' ' 27' ' ' ASN . . . 63.39 29.83 75.73 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.496 ' O ' ' O ' ' N' ' 27' ' ' ASN . 4.7 t -155.65 111.24 3.04 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 113.854 1.057 . . . . 0.0 113.854 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' N' ' 26' ' ' SER . 7.1 m120 -49.7 -164.75 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.178 176.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.59 ' NZ ' ' CG2' ' G' ' 39' ' ' VAL . 81.7 mttt 78.38 -41.17 0.3 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.543 1.137 . . . . 0.0 114.012 177.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.96 -68.28 3.45 Favored Glycine 0 CA--C 1.545 1.96 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.731 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.98 107.85 0.03 OUTLIER 'General case' 0 C--N 1.346 0.448 0 CA-C-N 117.576 0.688 . . . . 0.0 111.853 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.746 HD12 HG21 ' I' ' 39' ' ' VAL . 0.2 OUTLIER -123.89 122.09 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 O-C-N 122.208 -0.307 . . . . 0.0 110.489 178.755 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.595 HD13 ' CD1' ' P' ' 19' ' ' PHE . 60.5 mt -114.36 116.15 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 110.39 2.22 Favored Glycine 0 N--CA 1.468 0.775 0 N-CA-C 106.179 -2.769 . . . . 0.0 106.179 177.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.639 ' HB2' HD22 ' O' ' 34' ' ' LEU . 76.5 mt -144.67 143.58 30.81 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -174.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 1.7 ttm -110.11 106.66 16.22 Favored 'General case' 0 N--CA 1.441 -0.895 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 173.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.585 ' C ' HE22 ' P' ' 15' ' ' GLN . 29.6 m -126.31 123.33 63.3 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.595 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 138.18 -113.58 0.99 Allowed Glycine 0 C--N 1.308 -1.011 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.47 ' O ' HD11 ' B' ' 31' ' ' ILE . . . 73.08 -72.78 1.09 Allowed Glycine 0 CA--C 1.532 1.109 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.052 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 52.0 t -113.34 132.61 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 98.8 t . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.363 179.896 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.119 -1.593 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -112.85 138.4 49.74 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.993 0.425 . . . . 0.0 110.571 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . 0.548 ' O ' ' CE1' ' P' ' 13' ' ' HIS . 98.3 mt-10 -140.92 162.93 34.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.714 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.462 HG23 ' O ' ' O' ' 12' ' ' VAL . 5.0 m -118.53 126.87 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.467 ' C ' ' CG ' ' O' ' 14' ' ' HIS . 10.3 m80 -129.92 136.23 49.24 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.329 0.585 . . . . 0.0 112.028 -178.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.708 ' CE1' ' H ' ' P' ' 14' ' ' HIS . 5.1 m-70 -156.97 176.0 13.35 Favored 'General case' 0 C--O 1.223 -0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.294 179.241 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.705 ' NE2' HE21 ' N' ' 15' ' ' GLN . 59.0 tt0 -152.96 140.11 19.38 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.267 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . 0.557 ' N ' ' CE1' ' N' ' 14' ' ' HIS . 88.2 tttt -94.45 110.89 22.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.167 -0.469 . . . . 0.0 112.106 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.82 HD22 ' N ' ' O' ' 17' ' ' LEU . 0.7 OUTLIER -117.73 109.8 17.05 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 176.102 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -110.11 113.89 45.49 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.572 ' CD1' HD13 ' M' ' 32' ' ' ILE . 77.9 m-85 -113.36 106.88 15.12 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.77 125.03 53.23 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.789 0.328 . . . . 0.0 110.553 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.58 122.73 28.04 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -149.32 -176.77 5.5 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.431 ' N ' ' OE1' ' P' ' 22' ' ' GLU . 96.7 m-20 66.22 50.32 1.39 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 113.365 -1.743 . . . . 0.0 112.298 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.447 HG12 ' H ' ' O' ' 26' ' ' SER . 67.0 t -82.45 146.43 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.91 -39.12 64.65 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 118.682 -1.723 . . . . 0.0 110.57 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.721 ' O ' ' O ' ' O' ' 27' ' ' ASN . 39.4 t -174.15 124.78 0.33 Allowed 'General case' 0 C--O 1.221 -0.436 0 CA-C-O 118.525 -0.75 . . . . 0.0 110.185 178.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.721 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.5 t-20 -2.62 145.99 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 178.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.417 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 93.4 mttt -159.03 30.93 0.21 Allowed 'General case' 0 N--CA 1.468 0.44 0 O-C-N 121.805 -0.56 . . . . 0.0 112.413 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.71 88.28 0.72 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 119.49 -1.338 . . . . 0.0 113.028 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 134.41 52.45 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.949 0.881 . . . . 0.0 109.873 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.715 HD13 HG22 ' I' ' 39' ' ' VAL . 4.5 tt -149.23 140.54 17.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.744 -175.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.56 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 73.6 mt -110.57 109.86 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 176.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . 0.817 ' O ' HD23 ' O' ' 34' ' ' LEU . . . -117.54 101.85 0.96 Allowed Glycine 0 N--CA 1.469 0.855 0 N-CA-C 108.489 -1.845 . . . . 0.0 108.489 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.817 HD23 ' O ' ' O' ' 33' ' ' GLY . 0.3 OUTLIER -141.92 158.83 43.32 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 122.962 1.363 . . . . 0.0 114.175 -177.052 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -112.16 112.71 24.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 111.618 -2.537 . . . . 0.0 106.315 175.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.449 HG22 ' CG2' ' N' ' 36' ' ' VAL . 88.6 t -119.68 111.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -177.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.745 ' N ' HE22 ' Q' ' 15' ' ' GLN . . . 136.01 -131.67 5.81 Favored Glycine 0 C--N 1.319 -0.397 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.567 178.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.431 ' O ' HG23 ' P' ' 39' ' ' VAL . . . 98.96 -63.26 0.75 Allowed Glycine 0 CA--C 1.541 1.66 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.556 ' CG2' HG21 ' C' ' 31' ' ' ILE . 55.9 t -126.95 133.34 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.407 ' H ' HG11 ' P' ' 39' ' ' VAL . 96.6 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.723 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 N--CA 1.467 0.405 0 CA-C-O 121.185 0.517 . . . . 0.0 111.455 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.548 ' CE1' ' O ' ' O' ' 11' ' ' GLU . 80.0 m-70 -147.48 104.62 3.65 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.024 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.708 ' H ' ' CE1' ' O' ' 14' ' ' HIS . 40.0 m-70 -148.74 159.43 44.14 Favored 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.734 178.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.595 HE22 ' N ' ' N' ' 37' ' ' GLY . 7.5 mt-30 -90.31 159.89 16.42 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 114.215 -1.357 . . . . 0.0 107.822 175.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.34 99.21 3.6 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.542 ' CD2' HG11 ' N' ' 36' ' ' VAL . 4.6 mp -127.37 122.63 34.18 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.116 0.484 . . . . 0.0 110.525 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.44 114.31 45.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.595 ' CD1' HD13 ' N' ' 32' ' ' ILE . 59.4 m-85 -112.36 108.01 17.03 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -112.78 124.11 51.85 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 137.05 34.74 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 113.837 1.051 . . . . 0.0 113.837 -178.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.431 ' OE1' ' N ' ' O' ' 23' ' ' ASP . 78.9 tt0 -81.6 116.94 21.58 Favored 'General case' 0 N--CA 1.462 0.149 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.404 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 99.7 m-20 -138.34 50.28 1.89 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -176.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -81.85 148.4 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.625 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.485 ' O ' ' CB ' ' O' ' 27' ' ' ASN . . . 93.72 36.16 5.92 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 106.412 -2.675 . . . . 0.0 106.412 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.549 ' OG ' ' ND2' ' Q' ' 27' ' ' ASN . 21.9 p -76.05 102.62 5.75 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 122.443 1.116 . . . . 0.0 112.498 -174.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -96.87 -164.47 1.15 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 112.823 -1.99 . . . . 0.0 110.889 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt -48.74 -40.25 27.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.895 -1.048 . . . . 0.0 111.877 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.77 70.08 1.88 Allowed Glycine 0 CA--C 1.543 1.809 0 N-CA-C 114.937 0.735 . . . . 0.0 114.937 -174.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.36 111.04 6.81 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 104.969 -2.234 . . . . 0.0 104.969 176.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.466 HD13 ' HB ' ' J' ' 39' ' ' VAL . 57.6 mt -135.42 136.18 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -172.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.471 HD13 ' CD1' ' R' ' 19' ' ' PHE . 3.0 mt -106.05 106.07 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.26 99.38 1.18 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 106.482 -2.647 . . . . 0.0 106.482 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.502 ' CD1' HD12 ' O' ' 34' ' ' LEU . 2.8 tp -128.43 123.59 34.11 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-O 122.419 1.104 . . . . 0.0 112.821 -176.277 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -98.47 104.35 16.38 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 175.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.623 HG13 ' O ' ' P' ' 36' ' ' VAL . 8.7 p -119.18 113.76 42.43 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -177.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.22 -123.85 1.21 Allowed Glycine 0 C--N 1.309 -0.958 0 C-N-CA 118.95 -1.595 . . . . 0.0 111.79 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.525 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 81.26 -67.72 3.57 Favored Glycine 0 CA--C 1.536 1.354 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -178.087 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.439 ' CG1' ' OD1' ' D' ' 27' ' ' ASN . 67.9 t -136.09 155.61 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.419 ' N ' HG12 ' P' ' 39' ' ' VAL . 11.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.651 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -108.56 134.77 50.85 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.751 0.31 . . . . 0.0 110.313 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -88.87 117.96 28.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.878 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -127.98 135.51 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 120.949 0.404 . . . . 0.0 110.991 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.488 ' CD2' ' N ' ' Q' ' 13' ' ' HIS . 2.0 m-70 -136.18 118.29 15.44 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.628 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.692 ' CD2' ' H ' ' R' ' 14' ' ' HIS . 22.7 m80 -147.23 159.6 43.45 Favored 'General case' 0 C--O 1.219 -0.534 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.29 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.745 HE22 ' N ' ' O' ' 37' ' ' GLY . 0.7 OUTLIER -90.25 159.59 16.61 Favored 'General case' 0 C--N 1.334 -0.084 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 176.145 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 66.5 tttt -140.2 104.34 4.79 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 120.313 -0.555 . . . . 0.0 109.697 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' Q' ' 17' ' ' LEU . 4.3 mp -128.88 126.23 39.29 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 121.724 0.773 . . . . 0.0 111.006 179.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 84.8 t -114.3 113.63 44.32 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 114.721 -1.127 . . . . 0.0 108.837 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.56 ' CD1' HD13 ' O' ' 32' ' ' ILE . 59.5 m-85 -110.76 103.65 12.21 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 178.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -112.45 125.09 53.84 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.888 -178.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.68 143.61 35.2 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.404 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 93.7 mt-10 -84.64 137.37 33.31 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 120.166 -0.613 . . . . 0.0 109.619 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.531 ' OD2' ' HB1' ' R' ' 21' ' ' ALA . 35.8 p-10 -177.75 50.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.159 -177.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.473 HG22 ' O ' ' R' ' 22' ' ' GLU . 61.5 t -81.8 149.27 4.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.904 1.335 . . . . 0.0 113.828 -174.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.415 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 93.09 36.7 5.9 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 111.784 -2.462 . . . . 0.0 112.887 178.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' Q' ' 25' ' ' GLY . 3.2 p 72.65 120.18 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 118.621 -0.704 . . . . 0.0 110.546 175.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.549 ' ND2' ' OG ' ' P' ' 26' ' ' SER . 1.6 m120 -83.11 160.99 21.77 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 116.824 -1.95 . . . . 0.0 108.057 176.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -48.74 -39.79 26.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.573 0.702 . . . . 0.0 111.381 176.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.23 67.46 0.04 OUTLIER Glycine 0 CA--C 1.541 1.711 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.075 -177.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 152.18 43.89 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 118.449 1.125 . . . . 0.0 112.002 -176.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.443 HG23 HG23 ' R' ' 31' ' ' ILE . 6.3 mt -113.3 129.19 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.328 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 99.8 mt -124.69 116.06 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.72 117.02 3.16 Favored Glycine 0 N--CA 1.47 0.951 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 29.2 tp -124.55 120.64 32.53 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 93.7 mtp -135.17 144.94 47.3 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -178.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.82 164.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.68 93.68 0.1 Allowed Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.056 -1.068 . . . . 0.0 111.119 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' H ' ' HA3' ' R' ' 38' ' ' GLY . . . 164.45 -81.86 0.11 Allowed Glycine 0 CA--C 1.536 1.347 0 C-N-CA 120.473 -0.87 . . . . 0.0 112.465 177.674 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -157.68 147.57 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.158 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.552 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.95 133.09 51.23 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.876 0.37 . . . . 0.0 110.609 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 21.1 pt-20 -77.99 150.65 33.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.762 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.4 HG12 ' HE2' ' Q' ' 14' ' ' HIS . 52.9 t -123.69 131.62 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.105 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.428 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.0 OUTLIER -152.22 112.67 4.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.487 -179.656 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.692 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 75.0 m80 -149.81 164.43 35.35 Favored 'General case' 0 C--O 1.22 -0.472 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.441 ' OE1' ' OE1' ' Q' ' 15' ' ' GLN . 60.0 mt-30 -89.94 159.5 16.88 Favored 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 120.317 -0.553 . . . . 0.0 110.401 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 61.8 tttp -139.55 115.19 10.02 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.456 0.646 . . . . 0.0 110.332 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.448 ' N ' HD12 ' R' ' 17' ' ' LEU . 1.2 mp -135.46 125.54 26.04 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.796 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 3.5 p -112.96 116.48 52.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 176.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.471 ' CD1' HD13 ' P' ' 32' ' ' ILE . 55.3 m-85 -105.17 104.77 14.57 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -123.73 124.37 42.58 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.997 0.903 . . . . 0.0 112.099 -177.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.531 ' HB1' ' OD2' ' Q' ' 23' ' ' ASP . . . -120.65 130.2 54.03 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.473 ' O ' HG22 ' Q' ' 24' ' ' VAL . 97.8 mt-10 -70.21 110.15 5.04 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 118.813 -1.155 . . . . 0.0 110.377 -177.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 179.57 48.62 0.0 OUTLIER 'General case' 0 C--N 1.342 0.277 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.519 HG12 ' N ' ' R' ' 25' ' ' GLY . 69.0 t -72.85 160.34 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 117.324 -1.75 . . . . 0.0 108.644 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.519 ' N ' HG12 ' R' ' 24' ' ' VAL . . . 110.35 -33.27 6.06 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.3 m -72.2 129.57 38.77 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 113.028 -1.586 . . . . 0.0 111.806 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . 0.67 ' O ' ' N ' ' R' ' 29' ' ' GLY . 98.6 m-20 -90.86 -161.91 0.86 Allowed 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.22 47.58 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . 0.67 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.28 56.9 0.9 Allowed Glycine 0 CA--C 1.541 1.686 0 CA-C-N 119.301 0.955 . . . . 0.0 111.997 178.184 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.97 168.61 13.73 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.506 HD11 ' CA ' ' L' ' 39' ' ' VAL . 15.9 tt -116.15 110.28 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.5 mt -117.11 128.63 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.542 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.14 115.07 2.44 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.46 117.4 25.87 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 8.9 ttp -141.19 124.38 16.46 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.364 0.602 . . . . 0.0 111.126 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.32 111.68 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 120.125 -0.63 . . . . 0.0 111.753 -179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.8 132.17 10.9 Favored Glycine 0 CA--C 1.518 0.273 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 176.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . 0.417 ' HA3' ' H ' ' Q' ' 38' ' ' GLY . . . 109.49 63.24 0.53 Allowed Glycine 0 N--CA 1.474 1.18 0 CA-C-N 118.201 1.0 . . . . 0.0 112.95 179.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' R' ' 38' ' ' GLY . 41.4 t -32.17 151.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 117.285 0.543 . . . . 0.0 112.287 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.765 179.682 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.45 ' O ' ' OE1' ' B' ' 11' ' ' GLU . 95.7 mt-10 . . . . . 0 N--CA 1.464 0.239 0 CA-C-O 121.029 0.443 . . . . 0.0 110.419 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 m -137.27 162.13 33.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.966 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.461 ' H ' ' HB3' ' B' ' 13' ' ' HIS . 80.2 m80 -145.13 135.53 24.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.583 0.23 . . . . 0.0 110.785 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.572 ' CD2' ' N ' ' A' ' 15' ' ' GLN . 20.8 t60 -158.06 165.18 35.7 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.972 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 68.2 tp60 -158.97 142.45 14.89 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 121.027 0.442 . . . . 0.0 109.97 177.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -82.51 124.16 29.85 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.473 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.0 mt -127.18 119.52 26.63 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -141.49 146.45 23.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.363 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -147.52 141.2 25.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.11 0.481 . . . . 0.0 111.427 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.476 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 49.6 p90 -115.34 132.64 56.55 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.05 126.93 46.15 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 -177.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -128.14 -140.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 . . . . . 0 CA--C 1.538 0.518 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.659 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.5 p30 . . . . . 0 C--O 1.232 0.18 0 N-CA-C 115.159 1.54 . . . . 0.0 115.159 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.439 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 96.0 mttt -55.86 -37.48 68.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 112.081 -2.327 . . . . 0.0 112.409 -179.055 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.05 77.72 0.4 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 112.079 -0.408 . . . . 0.0 112.079 -175.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.39 141.67 41.43 Favored 'General case' 0 C--O 1.243 0.746 0 CA-C-O 123.736 1.731 . . . . 0.0 113.012 -177.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -126.76 127.63 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.739 -2.482 . . . . 0.0 108.406 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.452 ' O ' ' O ' ' B' ' 33' ' ' GLY . 80.8 mt -100.9 105.66 18.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.07 96.39 1.15 Allowed Glycine 0 CA--C 1.505 -0.589 0 N-CA-C 104.385 -3.486 . . . . 0.0 104.385 176.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.932 ' O ' HD12 ' B' ' 34' ' ' LEU . 51.6 tp -148.2 159.21 44.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 123.002 1.382 . . . . 0.0 112.969 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.487 ' CE ' ' SD ' ' B' ' 35' ' ' MET . 17.0 mtp -119.52 117.51 28.59 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.482 179.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 36' ' ' VAL . 27.3 m -119.24 111.85 35.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 177.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.22 -131.99 8.14 Favored Glycine 0 C--N 1.315 -0.602 0 N-CA-C 107.543 -2.223 . . . . 0.0 107.543 -177.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' B' ' 39' ' ' VAL . . . 87.05 -63.72 3.99 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 120.126 -1.035 . . . . 0.0 111.608 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -108.26 179.89 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 120.847 0.356 . . . . 0.0 110.106 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.455 HG12 ' CD2' ' C' ' 13' ' ' HIS . 85.9 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.852 -1.071 . . . . 0.0 110.959 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.17 132.13 54.41 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.31 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' O ' ' A' ' 11' ' ' GLU . 80.7 mm-40 -124.63 122.77 38.46 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.439 ' CG1' ' C ' ' C' ' 12' ' ' VAL . 3.6 t -112.92 100.27 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.983 0.42 . . . . 0.0 110.52 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.461 ' HB3' ' H ' ' A' ' 13' ' ' HIS . 12.2 p-80 -138.82 145.19 39.76 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.747 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.548 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 2.9 p80 -146.33 160.35 42.14 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.482 0.658 . . . . 0.0 111.98 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' OE1' ' C' ' 15' ' ' GLN . 85.9 mt-30 -90.3 159.67 16.53 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.178 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -139.97 108.05 5.75 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.49 130.84 53.48 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 120.875 0.369 . . . . 0.0 111.021 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.84 130.88 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.713 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -127.26 129.64 48.11 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -128.68 124.19 35.05 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.05 134.37 54.78 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.173 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.484 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 81.9 tt0 -161.74 159.8 27.65 Favored 'General case' 0 CA--C 1.55 0.969 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 -178.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' B' ' 24' ' ' VAL . 19.4 t70 112.83 -70.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 127.055 2.142 . . . . 0.0 110.854 177.205 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.524 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.7 t -58.77 -122.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 173.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.46 ' H ' HG12 ' B' ' 24' ' ' VAL . . . 139.12 -34.94 2.02 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-O 118.089 -1.395 . . . . 0.0 116.262 172.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -80.43 119.52 23.23 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 121.355 2.578 . . . . 0.0 106.59 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 28' ' ' LYS . 3.0 m120 -89.78 157.7 17.83 Favored 'General case' 0 C--N 1.344 0.368 0 C-N-CA 116.11 -2.236 . . . . 0.0 108.181 176.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -48.31 -40.53 25.39 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 122.394 1.092 . . . . 0.0 110.983 174.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 67.64 0.04 OUTLIER Glycine 0 CA--C 1.549 2.21 0 CA-C-N 112.956 -1.929 . . . . 0.0 110.5 -174.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.07 141.89 52.74 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 120.09 1.945 . . . . 0.0 115.168 -172.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.895 HG23 HG23 ' C' ' 31' ' ' ILE . 19.8 mt -136.23 134.09 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 113.159 -1.837 . . . . 0.0 113.106 -175.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.92 103.0 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 174.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -103.69 103.88 2.4 Favored Glycine 0 CA--C 1.507 -0.446 0 N-CA-C 104.309 -3.516 . . . . 0.0 104.309 175.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.932 HD12 ' O ' ' A' ' 34' ' ' LEU . 17.8 tp -146.12 147.66 31.79 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 118.272 -1.371 . . . . 0.0 113.538 -173.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.487 ' SD ' ' CE ' ' A' ' 35' ' ' MET . 3.9 ttm -113.13 116.37 29.74 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-N 112.815 -1.993 . . . . 0.0 107.824 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.406 HG23 HD21 ' C' ' 34' ' ' LEU . 37.8 t -118.95 123.73 71.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.76 -114.15 2.03 Favored Glycine 0 C--N 1.315 -0.591 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.535 ' O ' ' CD1' ' H' ' 31' ' ' ILE . . . 81.02 -72.65 2.7 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.486 ' CG2' ' O ' ' A' ' 38' ' ' GLY . 24.8 t -124.54 163.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.532 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 20.7 m . . . . . 0 N--CA 1.473 0.689 0 CA-C-O 117.782 -1.104 . . . . 0.0 111.694 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.97 135.59 50.59 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -138.83 144.9 39.46 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.801 HG21 ' C ' ' D' ' 12' ' ' VAL . 27.6 m -138.19 164.43 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-O 120.963 0.411 . . . . 0.0 111.807 -179.029 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.455 ' CD2' HG12 ' A' ' 40' ' ' VAL . 4.2 p-80 -129.48 132.92 47.04 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.301 0.572 . . . . 0.0 112.131 -178.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.538 ' CG ' ' O ' ' D' ' 14' ' ' HIS . 17.7 p-80 -157.26 169.52 24.56 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.066 178.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' OE1' ' B' ' 15' ' ' GLN . 99.5 mm-40 -89.67 156.61 18.45 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.112 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -141.36 115.41 9.25 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.993 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.453 ' HB2' HD22 ' D' ' 17' ' ' LEU . 4.6 mp -135.24 118.8 16.96 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 122.018 0.913 . . . . 0.0 111.029 178.153 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -106.76 117.51 52.7 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.402 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 54.9 m-85 -109.93 99.73 8.81 Favored 'General case' 0 N--CA 1.447 -0.582 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -109.79 126.67 54.01 Favored 'General case' 0 C--O 1.241 0.626 0 CA-C-O 121.41 0.624 . . . . 0.0 111.058 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . 0.638 ' HB1' HG13 ' C' ' 24' ' ' VAL . . . -128.17 113.26 15.49 Favored 'General case' 0 C--O 1.244 0.778 0 CA-C-O 121.884 0.85 . . . . 0.0 110.806 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.424 ' OE2' ' OD1' ' C' ' 23' ' ' ASP . 0.4 OUTLIER -86.17 103.3 14.68 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.065 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.474 ' H ' ' HB2' ' D' ' 22' ' ' GLU . 35.5 m-20 50.84 50.15 19.61 Favored 'General case' 0 C--O 1.214 -0.793 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.47 -177.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.939 HG22 ' H ' ' C' ' 25' ' ' GLY . 9.9 p -160.1 -174.22 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.094 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.939 ' H ' HG22 ' C' ' 24' ' ' VAL . . . 59.78 26.82 63.27 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.777 178.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' C' ' 27' ' ' ASN . 62.8 m -166.19 -145.94 0.08 Allowed 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' C' ' 26' ' ' SER . 10.6 m-20 55.48 142.25 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 120.906 0.384 . . . . 0.0 111.797 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.745 ' H ' ' CB ' ' D' ' 26' ' ' SER . 71.1 mmtt 62.47 46.06 5.96 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 61.08 0.79 Allowed Glycine 0 N--CA 1.474 1.204 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.083 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -101.87 119.3 38.56 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-O 121.567 0.698 . . . . 0.0 109.66 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.895 HG23 HG23 ' B' ' 31' ' ' ILE . 3.6 tt -137.07 136.34 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 120.021 -0.672 . . . . 0.0 112.438 -177.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.414 HD13 ' CD1' ' E' ' 19' ' ' PHE . 63.5 mt -107.09 107.42 22.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 176.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.06 100.95 2.01 Favored Glycine 0 C--O 1.237 0.327 0 N-CA-C 104.89 -3.284 . . . . 0.0 104.89 175.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.756 HD23 ' O ' ' B' ' 34' ' ' LEU . 0.8 OUTLIER -133.25 138.08 46.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.99 1.376 . . . . 0.0 114.314 -174.75 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -109.14 110.75 22.07 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 175.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.417 HG22 HD22 ' C' ' 34' ' ' LEU . 25.0 t -122.98 123.16 67.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 118.429 0.559 . . . . 0.0 109.529 -177.02 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.5 -113.19 0.65 Allowed Glycine 0 C--N 1.315 -0.59 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.964 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 74.05 -72.98 1.32 Allowed Glycine 0 CA--C 1.548 2.122 0 CA-C-N 114.863 -0.669 . . . . 0.0 111.641 -177.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -131.51 136.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.405 ' OXT' HG12 ' C' ' 40' ' ' VAL . 73.7 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.373 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.801 ' C ' HG21 ' C' ' 12' ' ' VAL . 68.4 t . . . . . 0 CA--C 1.532 0.266 0 N-CA-C 109.553 -0.536 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.566 ' N ' HG12 ' D' ' 12' ' ' VAL . 2.3 t-80 -63.35 103.86 0.55 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.604 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 12.6 t60 -146.72 159.76 43.08 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.536 -178.158 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.604 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 36.1 tp60 -84.65 157.97 20.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -178.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.84 ' O ' HD23 ' D' ' 17' ' ' LEU . 88.1 tttt -159.56 100.23 1.47 Allowed 'General case' 0 C--N 1.315 -0.913 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.39 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.84 HD23 ' O ' ' D' ' 16' ' ' LYS . 6.2 mt -132.8 136.13 46.1 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -120.59 124.23 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.955 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 37.9 m-85 -117.82 106.18 12.74 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.485 ' CZ ' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -122.17 129.45 52.31 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -176.604 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.19 114.35 9.08 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.952 0.882 . . . . 0.0 110.624 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.474 ' HB2' ' H ' ' C' ' 23' ' ' ASP . 95.5 mt-10 -92.65 -174.74 3.74 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 54.3 t0 31.17 52.23 0.16 Allowed 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.823 1.786 . . . . 0.0 115.823 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.56 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 86.6 t -64.96 145.5 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 118.734 -1.187 . . . . 0.0 108.172 177.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.84 -24.35 0.73 Allowed Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.745 ' CB ' ' H ' ' C' ' 28' ' ' LYS . 4.8 t -72.09 160.17 32.93 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 122.311 1.053 . . . . 0.0 112.785 -177.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.711 ' O ' ' N ' ' D' ' 29' ' ' GLY . 97.8 m-20 -91.68 -130.06 0.11 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.384 -1.735 . . . . 0.0 110.159 -178.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -48.49 54.94 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.931 1.292 . . . . 0.0 112.317 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . 0.711 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -110.28 -48.79 0.74 Allowed Glycine 0 CA--C 1.546 1.971 0 C-N-CA 124.529 1.062 . . . . 0.0 113.808 -176.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.411 ' HA ' ' O ' ' C' ' 30' ' ' ALA . . . -82.71 113.61 20.5 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.73 HD12 HG22 ' O' ' 39' ' ' VAL . 96.1 mt -130.56 130.0 64.69 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 CA-C-N 112.453 -2.158 . . . . 0.0 111.339 178.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.483 ' HB ' HG23 ' E' ' 32' ' ' ILE . 47.6 mt -108.22 109.77 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 175.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.54 104.06 2.54 Favored Glycine 0 N--CA 1.462 0.395 0 N-CA-C 104.145 -3.582 . . . . 0.0 104.145 174.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.57 HD12 ' O ' ' C' ' 34' ' ' LEU . 25.0 tp -133.88 128.18 34.07 Favored 'General case' 0 C--O 1.246 0.881 0 N-CA-C 116.477 2.029 . . . . 0.0 116.477 -172.573 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -104.38 111.54 24.22 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-N 112.793 -2.003 . . . . 0.0 107.377 174.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 17.3 t -109.43 143.9 18.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.792 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 168.31 -101.95 0.18 Allowed Glycine 0 C--N 1.294 -1.766 0 C-N-CA 118.818 -1.658 . . . . 0.0 111.462 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.445 ' HA3' ' N ' ' C' ' 38' ' ' GLY . . . 42.48 72.16 0.32 Allowed Glycine 0 N--CA 1.466 0.658 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -177.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.831 HG21 HD12 ' K' ' 31' ' ' ILE . 92.2 t -36.2 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -176.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.534 ' N ' HG12 ' D' ' 39' ' ' VAL . 19.7 m . . . . . 0 C--O 1.222 -0.386 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.593 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.73 136.59 47.22 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.817 0.341 . . . . 0.0 110.436 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.31 120.88 41.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.792 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.507 ' H ' HG21 ' D' ' 12' ' ' VAL . 33.8 t -112.08 95.32 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 121.189 0.518 . . . . 0.0 111.241 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 5.4 t-80 -118.65 109.97 16.76 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.26 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.634 ' CE1' ' N ' ' F' ' 14' ' ' HIS . 43.0 m-70 -138.13 165.04 27.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.213 0.53 . . . . 0.0 110.7 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -90.26 151.62 21.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.819 ' C ' HD12 ' E' ' 17' ' ' LEU . 88.8 tttt -149.68 107.46 3.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.526 178.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.819 HD12 ' C ' ' E' ' 16' ' ' LYS . 8.7 mp -129.07 120.59 26.22 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.15 121.21 60.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.95 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.503 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 30.5 m-85 -116.34 100.77 8.13 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 177.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.485 ' CD1' ' CZ ' ' D' ' 20' ' ' PHE . 14.3 t80 -121.68 134.9 54.97 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -177.281 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.599 ' O ' ' HB1' ' F' ' 21' ' ' ALA . . . -160.3 -178.36 6.89 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 119.167 -1.013 . . . . 0.0 113.691 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.56 ' OE1' ' N ' ' D' ' 24' ' ' VAL . 34.6 tt0 -68.07 159.98 29.79 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.94 -178.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 t0 175.65 60.26 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.798 0.839 . . . . 0.0 109.472 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 4.7 t -81.44 -113.36 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 116.956 -1.497 . . . . 0.0 111.305 -171.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.73 -42.12 47.69 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 114.839 -3.553 . . . . 0.0 115.4 -171.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' E' ' 27' ' ' ASN . 35.9 t -156.7 110.39 2.67 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 121.376 2.588 . . . . 0.0 114.298 175.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' E' ' 26' ' ' SER . 28.7 t-20 -55.69 162.83 1.55 Allowed 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 172.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -58.53 -42.65 88.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 122.127 2.24 . . . . 0.0 110.265 175.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 64.27 0.04 OUTLIER Glycine 0 CA--C 1.551 2.305 0 CA-C-N 114.104 -1.407 . . . . 0.0 111.856 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.876 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -72.25 161.29 31.06 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 119.344 1.572 . . . . 0.0 112.461 -176.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.481 ' CG2' ' OXT' ' Q' ' 40' ' ' VAL . 97.9 mt -134.08 136.63 53.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-O 121.421 0.629 . . . . 0.0 112.472 -177.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.483 HG23 ' HB ' ' D' ' 32' ' ' ILE . 98.0 mt -130.6 129.98 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.929 -0.482 . . . . 0.0 111.702 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.95 114.26 2.47 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.452 HD13 ' CE2' ' F' ' 19' ' ' PHE . 20.4 mt -124.75 124.01 41.22 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 110.183 -0.302 . . . . 0.0 110.183 -177.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 88.5 mtp -130.3 134.34 47.14 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 119.9 -0.72 . . . . 0.0 112.553 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.469 HG22 ' HA ' ' F' ' 36' ' ' VAL . 0.8 OUTLIER -91.85 155.35 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 177.468 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.502 ' H ' ' HA2' ' D' ' 37' ' ' GLY . . . -102.96 102.8 2.3 Favored Glycine 0 CA--C 1.529 0.968 0 N-CA-C 112.256 -0.338 . . . . 0.0 112.256 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 52.58 -73.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.639 0 N-CA-C 115.009 0.764 . . . . 0.0 115.009 178.063 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.416 ' N ' ' O ' ' E' ' 37' ' ' GLY . 40.9 t . . . . . 0 N--CA 1.481 1.1 0 CA-C-N 118.211 1.005 . . . . 0.0 111.222 -178.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 . . . . . 0 CA--C 1.529 0.136 0 CA-C-O 120.769 0.318 . . . . 0.0 110.334 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.482 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 2.7 t -108.21 111.01 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-O 121.163 0.506 . . . . 0.0 110.503 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.545 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -145.23 117.72 8.54 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.209 -179.689 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.634 ' N ' ' CE1' ' E' ' 14' ' ' HIS . 79.5 m80 -156.97 169.4 24.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.447 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.792 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.3 tt0 -89.67 155.78 19.0 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -141.39 116.32 9.84 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.557 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.448 HD12 ' N ' ' F' ' 17' ' ' LEU . 1.6 mp -137.06 121.75 18.56 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 19.7 t -106.11 117.11 51.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.081 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' CD1' ' F' ' 20' ' ' PHE . 11.2 m-85 -116.05 98.2 6.5 Favored 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.539 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 58.1 m-85 -152.08 173.65 14.66 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 122.806 1.288 . . . . 0.0 112.315 -178.235 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.599 ' HB1' ' O ' ' E' ' 21' ' ' ALA . . . -152.11 155.18 37.36 Favored 'General case' 0 N--CA 1.435 -1.189 0 CA-C-N 114.101 -1.408 . . . . 0.0 109.897 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -75.52 137.78 41.1 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -176.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 . . . . . 0 N--CA 1.462 0.146 0 CA-C-N 114.112 -1.404 . . . . 0.0 113.599 177.445 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.876 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.454 -0.259 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.55 HD11 ' O ' ' R' ' 39' ' ' VAL . 90.6 mt -121.13 131.84 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.601 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -122.61 117.82 53.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.331 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.66 126.81 6.98 Favored Glycine 0 N--CA 1.469 0.851 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 tp -131.83 114.45 14.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 90.6 mtp -122.01 135.49 54.84 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 120.617 -0.433 . . . . 0.0 112.104 -178.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.469 ' HA ' HG22 ' E' ' 36' ' ' VAL . 51.2 t -108.28 132.69 55.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.208 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.803 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.6 112.4 4.23 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.533 -0.627 . . . . 0.0 111.533 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.98 -70.41 0.0 OUTLIER Glycine 0 CA--C 1.538 1.484 0 N-CA-C 114.011 0.364 . . . . 0.0 114.011 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.542 ' N ' ' O ' ' F' ' 37' ' ' GLY . 46.3 t -123.97 132.68 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-O 121.586 0.708 . . . . 0.0 111.885 -178.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' F' ' 39' ' ' VAL . 11.6 t . . . . . 0 C--O 1.218 -0.571 0 CA-C-O 117.785 -1.102 . . . . 0.0 110.381 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.552 HG12 ' O ' ' H' ' 12' ' ' VAL . 12.3 m . . . . . 0 N--CA 1.469 0.52 0 N-CA-C 109.911 -0.403 . . . . 0.0 109.911 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 51.7 m-70 -145.31 130.31 18.34 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.3 0.571 . . . . 0.0 111.965 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 42.2 p-80 -152.74 172.4 16.75 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.478 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -128.97 151.01 50.15 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -95.22 128.7 42.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.688 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -126.96 117.92 23.48 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -133.95 134.27 55.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -144.77 146.9 32.36 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.46 0.648 . . . . 0.0 111.452 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 54.6 p90 -129.23 129.61 45.22 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.046 179.059 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.3 120.81 41.67 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.131 0.491 . . . . 0.0 112.085 -178.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -157.98 151.72 23.83 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 . . . . . 0 N--CA 1.467 0.387 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.812 179.481 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 . . . . . 0 N--CA 1.454 -0.263 0 CA-C-O 121.526 0.679 . . . . 0.0 112.814 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -110.59 -39.21 4.96 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 79.96 -69.41 3.09 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 112.415 -2.175 . . . . 0.0 111.702 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.435 ' HB3' ' CB ' ' H' ' 30' ' ' ALA . . . 179.78 87.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 117.59 0.695 . . . . 0.0 111.239 176.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -133.32 113.71 19.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.541 0 O-C-N 121.765 -0.584 . . . . 0.0 109.702 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' I' ' 19' ' ' PHE . 66.8 mt -108.21 110.72 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.13 97.54 0.63 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 105.298 -3.121 . . . . 0.0 105.298 177.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.752 ' O ' HD12 ' H' ' 34' ' ' LEU . 56.8 tp -160.63 159.41 30.4 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 118.18 -1.408 . . . . 0.0 111.89 -175.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.448 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 23.8 mtp -122.75 121.91 37.46 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.418 -1.264 . . . . 0.0 109.19 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.599 HG12 ' CD ' ' I' ' 15' ' ' GLN . 2.0 t -118.32 103.1 14.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.69 -153.05 24.57 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . 0.445 ' O ' HG23 ' H' ' 39' ' ' VAL . . . 111.82 -56.2 0.48 Allowed Glycine 0 CA--C 1.542 1.779 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.86 160.8 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.756 -1.116 . . . . 0.0 110.395 179.316 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -113.61 135.65 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.739 0.304 . . . . 0.0 110.364 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -109.11 116.02 31.15 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.497 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.552 ' O ' HG12 ' G' ' 12' ' ' VAL . 6.6 t -116.14 95.01 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 120.916 0.389 . . . . 0.0 110.092 179.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.538 ' ND1' ' O ' ' G' ' 13' ' ' HIS . 17.9 p-80 -147.84 165.68 29.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.871 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.653 ' HE2' ' CG2' ' I' ' 12' ' ' VAL . 0.1 OUTLIER -107.73 161.61 14.73 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.361 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.87 159.64 16.87 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -140.0 101.27 4.13 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.8 tp -127.97 121.9 31.03 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.115 0.483 . . . . 0.0 110.611 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.32 126.59 72.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.201 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.625 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -131.07 123.0 27.72 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.44 ' CZ ' ' CG ' ' H' ' 22' ' ' GLU . 19.5 t80 -119.5 126.11 50.5 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.34 121.56 38.87 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -177.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.44 ' CG ' ' CZ ' ' H' ' 20' ' ' PHE . 58.0 mt-10 -116.82 98.06 6.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 114.052 -1.431 . . . . 0.0 107.348 176.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -112.38 51.5 0.81 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.549 ' HA ' HG13 ' I' ' 24' ' ' VAL . 84.7 t -75.44 144.58 11.87 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 O-C-N 124.118 0.887 . . . . 0.0 110.61 -175.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.61 -38.31 3.37 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-N 113.84 -1.527 . . . . 0.0 110.562 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . 0.46 ' O ' ' O ' ' H' ' 27' ' ' ASN . 74.8 m -120.48 -112.18 0.33 Allowed 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.466 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 51.1 t-20 52.13 152.9 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.327 1.051 . . . . 0.0 110.908 -176.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.466 ' N ' ' OD1' ' H' ' 27' ' ' ASN . 67.6 mttm -140.48 -28.88 0.7 Allowed 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 115.189 1.552 . . . . 0.0 115.189 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.01 88.08 0.11 Allowed Glycine 0 N--CA 1.474 1.216 0 CA-C-O 119.471 -0.627 . . . . 0.0 113.74 -170.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.435 ' CB ' ' HB3' ' G' ' 30' ' ' ALA . . . -79.07 128.46 33.3 Favored 'General case' 0 CA--C 1.545 0.787 0 CA-C-O 123.308 1.528 . . . . 0.0 112.682 -175.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 30.7 mt -137.32 139.66 43.43 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 112.638 -2.074 . . . . 0.0 113.399 -176.067 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.413 HG22 HD21 ' I' ' 34' ' ' LEU . 80.6 mt -109.48 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 175.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.37 99.3 0.82 Allowed Glycine 0 C--O 1.237 0.308 0 N-CA-C 105.573 -3.011 . . . . 0.0 105.573 176.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.752 HD12 ' O ' ' G' ' 34' ' ' LEU . 8.4 tp -142.4 140.89 32.16 Favored 'General case' 0 C--O 1.242 0.669 0 CA-C-O 123.007 1.384 . . . . 0.0 113.251 -174.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.1 mtp -107.47 111.75 24.2 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 112.315 -2.221 . . . . 0.0 108.387 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.585 ' CG1' ' NE2' ' J' ' 15' ' ' GLN . 2.0 t -117.77 122.99 71.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.66 -113.18 0.6 Allowed Glycine 0 C--N 1.313 -0.731 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.67 -73.28 2.66 Favored Glycine 0 CA--C 1.533 1.171 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.563 ' HA ' HG21 ' I' ' 39' ' ' VAL . 34.9 t -133.86 157.1 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.479 ' C ' ' O ' ' H' ' 39' ' ' VAL . 70.1 t . . . . . 0 N--CA 1.471 0.577 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.295 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -112.16 136.04 52.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.858 0.361 . . . . 0.0 110.534 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -99.6 109.19 21.71 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.379 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.653 ' CG2' ' HE2' ' H' ' 14' ' ' HIS . 2.4 m -139.75 162.44 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.905 -178.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.518 ' NE2' HG13 ' H' ' 12' ' ' VAL . 2.8 m-70 -138.86 97.29 3.29 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 119.264 -0.398 . . . . 0.0 110.432 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.61 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 7.2 m170 -122.36 156.91 32.95 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 119.827 -0.749 . . . . 0.0 112.28 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.599 ' CD ' HG12 ' G' ' 36' ' ' VAL . 2.9 tt0 -90.44 159.59 16.47 Favored 'General case' 0 C--N 1.341 0.22 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 175.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.66 106.45 5.14 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 176.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.458 HD21 HG11 ' G' ' 36' ' ' VAL . 80.0 mt -117.21 114.97 24.41 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.045 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -114.29 103.26 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.534 ' CD2' HD13 ' G' ' 32' ' ' ILE . 14.5 m-30 -114.42 113.87 25.08 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -116.76 131.3 56.99 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -178.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.19 138.76 50.76 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 117.81 0.277 . . . . 0.0 111.184 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -76.67 176.38 8.46 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 119.237 3.051 . . . . 0.0 119.237 -174.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -72.49 50.11 0.23 Allowed 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 128.892 2.877 . . . . 0.0 114.132 -178.096 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.662 HG12 ' H ' ' I' ' 25' ' ' GLY . 1.8 t -74.77 -143.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -175.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.662 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -95.97 36.7 3.72 Favored Glycine 0 N--CA 1.465 0.573 0 C-N-CA 129.274 3.321 . . . . 0.0 107.706 -173.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.1 t -74.25 104.62 5.1 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 109.975 -3.113 . . . . 0.0 109.995 -176.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.708 ' O ' ' C ' ' I' ' 28' ' ' LYS . 86.1 m-20 -93.0 -149.23 0.26 Allowed 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 101.107 -3.664 . . . . 0.0 101.107 -176.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.708 ' C ' ' O ' ' I' ' 27' ' ' ASN . 82.3 tttt -32.64 -42.66 0.08 Allowed 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 124.173 3.17 . . . . 0.0 106.235 -170.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 91.29 -61.42 2.9 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 121.583 3.393 . . . . 0.0 121.583 159.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.22 117.11 24.58 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 -171.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.488 ' CD1' ' O ' ' C' ' 38' ' ' GLY . 3.5 mt -127.28 117.12 46.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 174.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.421 HD13 HG21 ' I' ' 32' ' ' ILE . 25.2 mt -100.22 112.93 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.03 100.12 1.07 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 106.548 -2.621 . . . . 0.0 106.548 177.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.462 ' CD2' ' HB3' ' H' ' 34' ' ' LEU . 98.0 mt -131.79 145.04 51.36 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.454 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -118.93 102.43 8.77 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 174.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.498 HG23 HE22 ' K' ' 15' ' ' GLN . 8.0 p -123.07 122.9 66.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.616 0.722 . . . . 0.0 109.88 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.29 -113.59 0.75 Allowed Glycine 0 C--N 1.31 -0.876 0 N-CA-C 107.57 -2.212 . . . . 0.0 107.57 -179.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.77 -72.37 1.05 Allowed Glycine 0 CA--C 1.535 1.303 0 C-N-CA 121.214 -0.517 . . . . 0.0 113.533 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.715 HG22 HD12 ' O' ' 31' ' ' ILE . 21.4 t -132.55 160.95 42.24 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 121.01 0.433 . . . . 0.0 111.698 -177.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.587 HG22 ' O ' ' I' ' 40' ' ' VAL . 10.9 p . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.4 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -71.02 127.32 32.16 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -142.97 156.07 44.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.967 0.413 . . . . 0.0 110.608 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.591 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -130.78 134.62 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 97.6 m-70 -120.83 124.85 46.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.46 -178.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' CE1' ' K' ' 14' ' ' HIS . 51.3 m-70 -151.58 169.82 21.18 Favored 'General case' 0 C--O 1.222 -0.382 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.585 ' NE2' ' CG1' ' H' ' 36' ' ' VAL . 8.5 tt0 -137.69 150.17 47.11 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -115.7 113.89 24.1 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.692 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.534 HD21 HG11 ' H' ' 36' ' ' VAL . 89.5 mt -108.84 107.34 17.71 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 176.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 t -110.96 102.53 14.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.456 ' CD2' ' CE1' ' K' ' 19' ' ' PHE . 12.4 m-85 -113.05 112.0 23.1 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -114.98 125.98 54.23 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 116.636 -0.256 . . . . 0.0 110.873 -178.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.49 129.54 33.28 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.666 0.745 . . . . 0.0 111.862 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -82.32 116.89 22.03 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -124.96 51.78 1.63 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -176.138 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -75.07 143.31 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.82 0 N-CA-C 103.047 -2.946 . . . . 0.0 103.047 175.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.58 37.57 3.7 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 105.768 -2.933 . . . . 0.0 105.768 -172.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.434 ' HG ' ' CG ' ' K' ' 27' ' ' ASN . 5.3 t -69.48 105.11 2.51 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 113.522 -1.339 . . . . 0.0 107.94 -177.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -117.85 -151.88 0.49 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 113.149 -1.841 . . . . 0.0 113.522 -172.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -37.54 -40.81 0.41 Allowed 'General case' 0 CA--C 1.551 0.999 0 N-CA-C 119.736 3.236 . . . . 0.0 119.736 -171.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.421 ' O ' ' CE ' ' I' ' 28' ' ' LYS . . . -171.29 69.47 0.12 Allowed Glycine 0 N--CA 1.484 1.844 0 C-N-CA 115.193 -3.384 . . . . 0.0 119.44 -174.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.39 140.73 46.81 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 120.307 2.053 . . . . 0.0 109.172 177.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.506 HG22 ' H ' ' K' ' 31' ' ' ILE . 10.1 pt -146.62 153.6 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 96.4 mt -114.56 128.47 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.305 176.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.36 112.55 0.97 Allowed Glycine 0 N--CA 1.462 0.42 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.651 HD12 ' C ' ' J' ' 34' ' ' LEU . 3.6 pp -164.65 165.63 20.78 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 117.588 -1.645 . . . . 0.0 114.986 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 70.6 mmm -113.87 117.56 31.75 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 112.746 -2.024 . . . . 0.0 110.653 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.601 HG12 ' CD ' ' L' ' 15' ' ' GLN . 15.3 t -111.5 102.51 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 N-CA-C 109.246 -0.649 . . . . 0.0 109.246 178.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.7 ' N ' HE22 ' L' ' 15' ' ' GLN . . . 125.09 -162.31 19.41 Favored Glycine 0 N--CA 1.465 0.585 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.386 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' K' ' 38' ' ' GLY . . . 137.84 -55.38 0.68 Allowed Glycine 0 CA--C 1.542 1.745 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.908 HG22 HD12 ' P' ' 31' ' ' ILE . 43.5 t -125.29 134.04 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.853 0.861 . . . . 0.0 108.798 177.672 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.695 ' HA ' HG13 ' K' ' 39' ' ' VAL . 74.1 t . . . . . 0 C--O 1.216 -0.685 0 CA-C-O 118.088 -0.958 . . . . 0.0 111.711 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.05 134.54 53.54 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.482 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 97.8 mt-10 -144.56 169.48 17.88 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.859 0.361 . . . . 0.0 111.276 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.471 HG13 ' H ' ' L' ' 12' ' ' VAL . 19.6 t -104.18 128.26 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' OXT' ' I' ' 40' ' ' VAL . 81.7 t60 -138.93 114.81 10.06 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.636 ' CE1' ' CD2' ' J' ' 14' ' ' HIS . 7.5 p80 -155.22 165.29 37.14 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.498 HE22 HG23 ' I' ' 36' ' ' VAL . 58.3 tt0 -129.48 149.95 51.04 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 119.699 -0.8 . . . . 0.0 111.179 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.96 109.15 21.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.004 177.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.568 ' CD1' ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -103.95 105.12 15.2 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 176.557 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.1 103.89 16.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.445 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.456 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 5.1 m-85 -114.39 108.26 16.65 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -106.69 120.8 42.95 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.461 ' HB1' ' OD1' ' J' ' 23' ' ' ASP . . . -132.42 131.36 41.7 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.415 -179.261 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.533 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 97.4 mt-10 -87.09 104.61 16.5 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 0.5 OUTLIER -135.13 48.66 2.25 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.733 -177.322 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.546 HG12 ' N ' ' K' ' 25' ' ' GLY . 55.0 t -71.92 161.38 4.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.553 -178.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.546 ' N ' HG12 ' K' ' 24' ' ' VAL . . . 110.26 -28.35 10.43 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 -177.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 74.57 119.73 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.051 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.434 ' CG ' ' HG ' ' J' ' 26' ' ' SER . 93.3 m-20 -83.24 162.79 21.08 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.832 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -47.19 -37.28 9.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.294 177.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.78 77.35 0.07 OUTLIER Glycine 0 CA--C 1.532 1.147 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.597 -174.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.53 153.7 29.35 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 118.217 1.009 . . . . 0.0 110.01 -178.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.831 HD12 HG21 ' D' ' 39' ' ' VAL . 57.4 mt -133.78 141.24 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 113.874 1.064 . . . . 0.0 113.874 -175.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -127.02 118.36 50.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.169 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.16 109.56 1.72 Allowed Glycine 0 N--CA 1.471 1.002 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.418 HD22 HD11 ' J' ' 34' ' ' LEU . 29.3 mt -127.84 125.27 39.43 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 112.811 0.671 . . . . 0.0 112.811 -175.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.7 mtp -106.94 106.01 16.32 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.623 HG22 ' H ' ' K' ' 37' ' ' GLY . 9.9 p -97.26 173.23 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.623 ' H ' HG22 ' K' ' 36' ' ' VAL . . . 159.64 -95.39 0.14 Allowed Glycine 0 C--N 1.3 -1.45 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.458 -178.107 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' J' ' 38' ' ' GLY . . . 98.13 -80.53 0.61 Allowed Glycine 0 N--CA 1.47 0.95 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 -176.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.695 HG13 ' HA ' ' J' ' 40' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.439 -1.014 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 176.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 . . . . . 0 N--CA 1.468 0.442 0 CA-C-O 120.931 0.396 . . . . 0.0 110.503 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.471 ' H ' HG13 ' K' ' 12' ' ' VAL . 58.9 t -128.76 134.34 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.376 -178.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.482 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 85.0 m-70 -135.12 84.65 2.11 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.7 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.486 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 85.2 t60 -162.7 168.51 21.48 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.141 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.7 HE22 ' N ' ' J' ' 37' ' ' GLY . 78.8 mt-30 -100.35 151.33 21.63 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.345 0.593 . . . . 0.0 111.788 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -112.63 110.21 20.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.745 177.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.467 HD22 HG11 ' J' ' 36' ' ' VAL . 0.1 OUTLIER -104.77 109.88 22.0 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.863 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 42.8 t -117.21 102.38 13.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.424 ' CD1' ' CD2' ' K' ' 19' ' ' PHE . 5.0 m-85 -115.72 107.11 14.66 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -113.96 119.71 38.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.099 0.476 . . . . 0.0 111.515 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.23 127.17 52.17 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -78.04 111.25 13.73 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.329 -177.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 56.9 p30 -178.39 48.66 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.157 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.618 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -72.62 160.32 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 C-N-CA 118.431 -1.308 . . . . 0.0 109.449 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.05 -33.19 6.01 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.7 m -72.09 129.56 38.79 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 113.824 -1.188 . . . . 0.0 111.102 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.645 ' O ' ' N ' ' L' ' 29' ' ' GLY . 98.7 m-20 -90.98 -162.51 0.92 Allowed 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.28 47.59 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 115.127 1.529 . . . . 0.0 115.127 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.645 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.17 57.08 0.9 Allowed Glycine 0 CA--C 1.54 1.608 0 CA-C-N 119.483 1.038 . . . . 0.0 112.016 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.07 171.73 10.74 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.416 HD11 ' CG2' ' F' ' 39' ' ' VAL . 94.5 mt -121.27 121.73 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 177.108 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -125.43 133.58 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.864 0.364 . . . . 0.0 111.57 -178.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.99 117.98 2.06 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.4 tp -115.21 123.53 49.1 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mmm -124.83 128.03 48.07 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.659 0.266 . . . . 0.0 111.552 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.2 t -97.4 152.24 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-O 121.353 0.597 . . . . 0.0 111.929 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.527 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . -80.79 102.5 2.13 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' L' ' 37' ' ' GLY . . . 11.46 -73.04 0.0 OUTLIER Glycine 0 CA--C 1.539 1.588 0 C-N-CA 123.459 0.552 . . . . 0.0 113.92 -178.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.527 ' N ' ' O ' ' L' ' 37' ' ' GLY . 74.5 t . . . . . 0 C--N 1.346 0.42 0 CA-C-N 118.221 1.011 . . . . 0.0 110.073 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 C--O 1.233 0.208 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -139.49 139.5 38.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 121.159 0.504 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -89.49 166.73 13.5 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.229 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.594 ' ND1' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -82.26 171.42 14.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.0 0.429 . . . . 0.0 111.212 -179.342 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -128.8 151.03 50.04 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -96.3 106.77 19.04 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.704 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 87.2 mt -128.22 114.41 16.92 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 121.005 0.431 . . . . 0.0 110.057 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -126.61 130.8 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.715 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -128.18 131.23 48.9 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.619 ' CZ ' ' CD1' ' N' ' 20' ' ' PHE . 1.6 t80 -134.38 128.84 34.42 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.204 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 118.46 31.86 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.935 0.398 . . . . 0.0 109.949 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . 0.566 ' O ' HG23 ' M' ' 24' ' ' VAL . 94.5 mt-10 -110.53 -148.59 0.43 Allowed 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.773 -178.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.57 50.13 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.855 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.59 HG12 ' H ' ' M' ' 25' ' ' GLY . 2.3 t -71.72 -142.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . 0.59 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -111.48 38.75 3.14 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.904 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m 61.76 111.18 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.113 0.482 . . . . 0.0 112.082 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . 0.45 ' O ' ' C ' ' M' ' 28' ' ' LYS . 91.2 m-20 -129.85 -161.55 1.13 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.193 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . 0.45 ' C ' ' O ' ' M' ' 27' ' ' ASN . 73.6 mmtt -30.95 -41.31 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 120.914 0.387 . . . . 0.0 110.996 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' M' ' 27' ' ' ASN . . . 91.35 -64.92 2.54 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.794 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . 0.473 ' O ' ' O ' ' N' ' 29' ' ' GLY . . . -170.37 70.1 0.05 Allowed 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 117.616 0.708 . . . . 0.0 112.483 177.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 82.0 mt -130.89 115.09 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . 0.52 HG22 HD21 ' N' ' 34' ' ' LEU . 4.0 mt -112.89 116.16 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 C-N-CA 120.062 -0.655 . . . . 0.0 111.107 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.16 105.0 1.18 Allowed Glycine 0 N--CA 1.461 0.315 0 N-CA-C 105.389 -3.084 . . . . 0.0 105.389 177.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . 0.578 ' HB3' HD22 ' N' ' 34' ' ' LEU . 47.1 tp -161.02 152.34 19.02 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 117.548 -1.661 . . . . 0.0 114.354 -174.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 3.8 ttm -104.26 115.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-N 112.56 -2.109 . . . . 0.0 106.856 176.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.517 ' O ' ' N ' ' N' ' 37' ' ' GLY . 36.5 t -116.91 103.87 15.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.29 -153.22 16.88 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 120.026 -1.083 . . . . 0.0 110.952 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.586 ' H ' ' N ' ' N' ' 38' ' ' GLY . . . 147.65 -54.64 0.52 Allowed Glycine 0 CA--C 1.539 1.551 0 CA-C-O 119.721 -0.488 . . . . 0.0 111.93 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' M' ' 40' ' ' VAL . 10.0 p -114.73 151.89 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.963 0.881 . . . . 0.0 108.787 178.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.779 ' OXT' HG13 ' M' ' 40' ' ' VAL . 8.5 p . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 117.854 -1.069 . . . . 0.0 111.151 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.64 134.33 48.93 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -151.38 135.77 16.89 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.999 0.428 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.412 HG12 ' CG2' ' O' ' 12' ' ' VAL . 34.1 m -137.03 162.09 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.624 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . 0.51 ' C ' ' ND1' ' N' ' 14' ' ' HIS . 83.4 m-70 -143.34 104.86 4.31 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.489 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.51 ' ND1' ' C ' ' N' ' 13' ' ' HIS . 20.0 m80 -152.08 167.05 29.71 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.701 0.286 . . . . 0.0 110.67 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -155.7 141.17 17.76 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.032 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -89.82 107.39 19.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 119.215 -0.421 . . . . 0.0 111.666 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.432 HD23 ' HG ' ' O' ' 17' ' ' LEU . 33.4 tp -123.78 115.57 21.57 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 177.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -121.49 131.13 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.828 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -129.97 112.35 13.42 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.522 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CZ ' ' M' ' 20' ' ' PHE . 16.5 t80 -113.81 130.37 56.47 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.44 133.14 40.16 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 113.232 0.827 . . . . 0.0 113.232 -178.049 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -92.38 120.83 33.27 Favored 'General case' 0 C--N 1.34 0.168 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.547 177.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.57 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 70.8 m-20 -148.39 50.39 1.02 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.981 -177.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 37.6 t -81.41 148.65 5.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 118.951 -1.1 . . . . 0.0 109.719 -177.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.57 37.04 5.66 Favored Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.9 p 73.18 120.21 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.617 ' ND2' ' N ' ' N' ' 27' ' ' ASN . 0.1 OUTLIER -83.09 162.44 21.34 Favored 'General case' 0 C--N 1.341 0.211 0 C-N-CA 118.262 -1.375 . . . . 0.0 111.499 -179.098 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.418 ' H ' ' HG2' ' N' ' 28' ' ' LYS . 72.5 mmtt -47.22 -37.17 9.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.955 176.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' M' ' 30' ' ' ALA . . . -178.96 77.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.579 0 CA-C-O 118.766 -1.019 . . . . 0.0 112.199 -173.387 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . 0.525 ' O ' ' HA ' ' O' ' 30' ' ' ALA . . . -79.26 107.51 12.07 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-N 119.848 1.824 . . . . 0.0 112.835 -175.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.571 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 18.4 tt -153.32 133.83 4.34 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 CA-C-N 113.627 -1.624 . . . . 0.0 111.336 -177.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.553 HD13 ' CD2' ' P' ' 19' ' ' PHE . 85.0 mt -106.96 108.26 24.76 Favored 'Isoleucine or valine' 0 C--N 1.341 0.198 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 177.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.807 ' O ' HD23 ' N' ' 34' ' ' LEU . . . -114.67 100.46 1.0 Allowed Glycine 0 N--CA 1.46 0.269 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 178.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.807 HD23 ' O ' ' N' ' 33' ' ' GLY . 1.4 mt -146.59 157.91 43.81 Favored 'General case' 0 CA--C 1.5 -0.952 0 CA-C-O 123.665 1.698 . . . . 0.0 112.478 -178.047 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 8.0 mtp -113.79 108.53 17.22 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 111.156 -2.747 . . . . 0.0 104.604 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -87.25 100.96 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 106.144 -1.798 . . . . 0.0 106.144 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' M' ' 36' ' ' VAL . . . -73.23 163.0 54.86 Favored Glycine 0 CA--C 1.52 0.353 0 CA-C-N 112.724 -2.034 . . . . 0.0 113.383 -178.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.586 ' N ' ' H ' ' M' ' 38' ' ' GLY . . . 114.92 60.72 0.37 Allowed Glycine 0 N--CA 1.471 0.972 0 C-N-CA 121.389 -0.434 . . . . 0.0 113.681 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 1.038 HG13 ' H ' ' O' ' 39' ' ' VAL . 57.3 t -71.09 130.91 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.501 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.519 HG22 ' CD2' ' P' ' 13' ' ' HIS . 10.8 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.999 -1.001 . . . . 0.0 111.3 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.48 132.97 52.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.759 0.314 . . . . 0.0 110.364 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -123.58 121.83 36.61 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.131 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.412 ' CG2' HG12 ' N' ' 12' ' ' VAL . 2.3 m -131.43 155.27 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.594 ' HB2' ' HD1' ' P' ' 13' ' ' HIS . 86.7 m-70 -149.07 102.96 3.3 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.478 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.507 ' N ' ' CD2' ' O' ' 14' ' ' HIS . 0.1 OUTLIER -149.27 176.44 10.53 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.412 ' CG ' HD13 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -149.25 140.0 22.7 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 174.616 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . 0.654 ' C ' HD12 ' O' ' 17' ' ' LEU . 54.1 mtmt -95.05 110.24 22.19 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.227 1.566 . . . . 0.0 115.227 -178.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.654 HD12 ' C ' ' O' ' 16' ' ' LYS . 10.9 mp -124.13 115.09 20.57 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 174.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -112.74 115.82 50.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.643 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.429 ' HZ ' HD23 ' O' ' 17' ' ' LEU . 48.4 m-85 -112.22 104.97 13.19 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -111.86 131.75 55.15 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.9 136.61 32.46 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -95.2 113.86 25.58 Favored 'General case' 0 CA--C 1.52 -0.175 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 175.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.446 ' CB ' HD21 ' N' ' 27' ' ' ASN . 18.1 m-20 -133.99 48.62 2.33 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.542 HG22 ' O ' ' P' ' 23' ' ' ASP . 18.6 t -72.88 161.09 5.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 C-N-CA 118.218 -1.393 . . . . 0.0 109.664 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.27 -29.89 9.56 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 -178.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 1.2 m 92.83 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 113.66 -1.27 . . . . 0.0 107.791 -178.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.697 ' OD1' ' HB2' ' O' ' 30' ' ' ALA . 2.7 p30 -73.96 164.39 26.68 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.935 0.874 . . . . 0.0 113.071 -178.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.08 -36.28 12.84 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.862 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.38 78.5 0.07 OUTLIER Glycine 0 CA--C 1.532 1.119 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.354 -173.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . 0.697 ' HB2' ' OD1' ' O' ' 27' ' ' ASN . . . -79.19 109.73 13.8 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 123.286 1.517 . . . . 0.0 110.955 -176.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.715 HD12 HG22 ' I' ' 39' ' ' VAL . 77.8 mt -133.15 142.21 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 113.483 -1.689 . . . . 0.0 112.802 -176.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.499 ' CG2' HD12 ' O' ' 34' ' ' LEU . 52.9 mt -106.78 107.9 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 175.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.05 104.97 2.23 Favored Glycine 0 C--O 1.239 0.437 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.499 HD12 ' CG2' ' O' ' 32' ' ' ILE . 53.7 mt -140.35 144.0 36.06 Favored 'General case' 0 CA--C 1.504 -0.815 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -175.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 3.0 mtp -116.42 109.22 17.02 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 112.212 -2.267 . . . . 0.0 105.038 175.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.426 ' HB ' HE22 ' Q' ' 15' ' ' GLN . 1.8 t -105.86 101.8 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.812 0.815 . . . . 0.0 111.05 -177.119 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.77 -179.11 0.65 Allowed Glycine 0 CA--C 1.538 1.5 0 CA-C-N 114.112 -1.404 . . . . 0.0 115.303 178.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . 0.69 ' H ' HG22 ' N' ' 39' ' ' VAL . . . -116.3 -58.3 0.32 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 114.253 -0.973 . . . . 0.0 111.788 179.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 1.038 ' H ' HG13 ' N' ' 39' ' ' VAL . 45.5 t -115.84 124.92 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.664 ' CG2' HE22 ' R' ' 15' ' ' GLN . 12.3 m . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.451 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.533 HG23 ' HE2' ' P' ' 14' ' ' HIS . 2.2 p . . . . . 0 N--CA 1.463 0.2 0 N-CA-C 109.801 -0.444 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.594 ' HD1' ' HB2' ' O' ' 13' ' ' HIS . 7.5 t60 -144.98 134.25 22.9 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 -179.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.688 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 18.9 m-70 -147.45 156.42 42.85 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 175.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.515 HE22 ' CE1' ' P' ' 13' ' ' HIS . 3.1 mp0 -90.42 160.35 16.1 Favored 'General case' 0 C--O 1.225 -0.237 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -140.09 95.52 2.9 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.725 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -136.22 130.64 33.43 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.142 0.496 . . . . 0.0 111.122 179.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 24.1 t -119.94 115.21 46.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.489 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.553 ' CD2' HD13 ' N' ' 32' ' ' ILE . 19.3 m-85 -109.09 111.87 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -127.01 123.45 37.1 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 -176.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.18 121.85 43.31 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 176.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -93.86 152.41 18.91 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 117.843 2.535 . . . . 0.0 117.843 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.542 ' O ' HG22 ' O' ' 24' ' ' VAL . 93.3 m-20 27.92 51.52 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 111.238 -2.71 . . . . 0.0 117.807 175.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 65.1 t -81.69 141.23 15.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 117.13 -1.828 . . . . 0.0 106.181 175.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' Q' ' 24' ' ' VAL . . . -71.53 -41.54 57.51 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 117.584 -2.246 . . . . 0.0 110.809 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.422 ' O ' ' C ' ' P' ' 27' ' ' ASN . 42.3 t -156.63 112.3 2.93 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 118.355 -0.831 . . . . 0.0 109.452 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.642 HD21 ' HB3' ' O' ' 30' ' ' ALA . 7.4 t-20 -48.96 157.78 0.38 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.127 178.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.65 -47.88 61.83 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.665 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.82 61.21 0.08 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 114.261 -1.336 . . . . 0.0 109.768 -176.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' O' ' 30' ' ' ALA . . . -85.09 158.43 20.43 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 123.668 1.699 . . . . 0.0 115.377 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.908 HD12 HG22 ' J' ' 39' ' ' VAL . 65.1 mt -145.05 148.3 17.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 112.342 -2.208 . . . . 0.0 113.482 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 52.9 mt -106.19 107.64 23.17 Favored 'Isoleucine or valine' 0 C--N 1.35 0.625 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.89 101.38 2.27 Favored Glycine 0 N--CA 1.463 0.462 0 N-CA-C 104.215 -3.554 . . . . 0.0 104.215 175.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.419 HD23 HD22 ' Q' ' 34' ' ' LEU . 26.4 tp -133.49 130.25 38.3 Favored 'General case' 0 C--O 1.239 0.544 0 N-CA-C 115.979 1.844 . . . . 0.0 115.979 -173.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 40.2 tpp -111.27 109.27 19.22 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 174.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.644 HG13 ' NE2' ' Q' ' 15' ' ' GLN . 10.6 t -100.13 102.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.91 0.386 . . . . 0.0 110.573 -177.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.0 163.48 0.06 OUTLIER Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' O' ' 38' ' ' GLY . . . -94.57 -58.03 1.22 Allowed Glycine 0 CA--C 1.536 1.392 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.241 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.674 ' HB ' HD13 ' D' ' 31' ' ' ILE . 24.0 t -151.28 138.89 13.82 Favored 'Isoleucine or valine' 0 C--N 1.347 0.479 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.666 ' H ' ' C ' ' Q' ' 38' ' ' GLY . 31.1 t . . . . . 0 C--O 1.214 -0.789 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.435 -177.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.471 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -107.08 131.07 54.51 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -149.43 137.58 20.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.978 0.418 . . . . 0.0 110.348 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -127.58 118.44 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.571 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.522 ' NE2' ' C ' ' O' ' 40' ' ' VAL . 12.0 p-80 -158.47 121.05 3.7 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.868 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.688 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 4.1 p-80 -148.8 165.62 30.9 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 176.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.644 ' NE2' HG13 ' P' ' 36' ' ' VAL . 9.8 pt20 -99.75 149.93 22.84 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.454 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -114.74 98.61 6.95 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.951 178.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.447 ' HB3' ' CZ ' ' Q' ' 19' ' ' PHE . 6.0 mp -123.2 116.98 24.3 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 177.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -107.88 111.14 34.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.485 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 37.1 m-85 -107.21 107.34 18.25 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 178.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' R' ' 20' ' ' PHE . 12.9 t80 -122.52 124.92 44.66 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -176.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.36 118.31 27.21 Favored 'General case' 0 C--O 1.243 0.711 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 177.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' P' ' 23' ' ' ASP . 82.7 tt0 -82.77 146.24 29.09 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -176.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.492 ' O ' ' O ' ' R' ' 22' ' ' GLU . 64.2 t0 63.87 -52.13 0.25 Allowed 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 113.878 -1.51 . . . . 0.0 112.089 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.54 HG12 ' H ' ' Q' ' 25' ' ' GLY . 0.8 OUTLIER 50.51 -153.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.302 177.842 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.54 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 143.39 19.03 0.22 Allowed Glycine 0 N--CA 1.464 0.544 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 -177.026 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . 0.568 ' OG ' ' HB2' ' Q' ' 30' ' ' ALA . 0.3 OUTLIER -63.13 129.9 42.3 Favored 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 114.691 -0.754 . . . . 0.0 109.342 -178.22 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.477 ' CG ' ' H ' ' Q' ' 28' ' ' LYS . 45.3 t-20 -126.98 -130.62 0.23 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.186 -174.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.477 ' H ' ' CG ' ' Q' ' 27' ' ' ASN . 74.1 mmtt -38.79 -46.87 1.32 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.041 -0.982 . . . . 0.0 111.483 -176.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.19 52.44 0.9 Allowed Glycine 0 CA--C 1.547 2.058 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.786 -177.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . 0.568 ' HB2' ' OG ' ' Q' ' 26' ' ' SER . . . -128.8 127.43 41.95 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-O 120.915 0.388 . . . . 0.0 110.103 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.699 HG23 ' HB ' ' R' ' 31' ' ' ILE . 28.9 mt -142.81 153.25 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-O 121.821 0.819 . . . . 0.0 113.064 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . 0.491 HD12 ' CD1' ' R' ' 32' ' ' ILE . 86.5 mt -136.22 123.34 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 O-C-N 121.795 -0.565 . . . . 0.0 110.34 179.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.4 110.66 1.29 Allowed Glycine 0 N--CA 1.468 0.77 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . 0.419 HD22 HD23 ' P' ' 34' ' ' LEU . 28.4 mt -119.34 121.2 39.03 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.634 0.255 . . . . 0.0 111.444 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . 0.4 ' SD ' ' HB2' ' R' ' 35' ' ' MET . 95.3 mmm -111.33 127.61 55.7 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.425 HG13 ' HG3' ' R' ' 15' ' ' GLN . 53.6 t -122.79 131.73 72.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-N 118.69 0.677 . . . . 0.0 112.103 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -55.82 -111.52 0.01 OUTLIER Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.743 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.688 ' O ' HG23 ' Q' ' 39' ' ' VAL . . . 95.86 -72.92 0.87 Allowed Glycine 0 CA--C 1.537 1.436 0 N-CA-C 111.962 -0.455 . . . . 0.0 111.962 179.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.688 HG23 ' O ' ' Q' ' 38' ' ' GLY . 14.2 t -164.1 121.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . 0.52 ' O ' HG21 ' F' ' 31' ' ' ILE . 58.7 t . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.992 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -82.69 131.06 35.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.811 0.339 . . . . 0.0 110.93 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' R' ' 11' ' ' GLU . 56.3 mp0 -118.98 148.43 42.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.815 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 20.1 t -106.97 98.05 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.494 0.664 . . . . 0.0 110.885 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -120.25 93.5 4.07 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.901 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -153.88 164.02 39.08 Favored 'General case' 0 C--O 1.222 -0.392 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.664 HE22 ' CG2' ' O' ' 40' ' ' VAL . 90.4 mm-40 -89.85 158.41 17.47 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.417 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -140.4 90.13 2.33 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.464 HD21 HE21 ' Q' ' 15' ' ' GLN . 4.8 mp -134.37 120.14 19.48 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.2 t -104.89 113.5 42.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.408 ' CE1' HD22 ' P' ' 34' ' ' LEU . 25.1 m-85 -104.9 98.05 7.83 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 106.028 -1.842 . . . . 0.0 106.028 177.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' Q' ' 20' ' ' PHE . 42.0 t80 -115.22 114.28 25.02 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.58 0.705 . . . . 0.0 110.847 -178.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' R' ' 23' ' ' ASP . . . -128.37 125.11 38.0 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.492 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 81.0 tt0 -71.5 85.13 0.84 Allowed 'General case' 0 C--O 1.223 -0.319 0 C-N-CA 117.414 -1.714 . . . . 0.0 106.958 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' R' ' 21' ' ' ALA . 51.2 p30 -132.72 51.89 2.12 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.459 -176.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 69.5 t -74.82 143.29 13.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.19 37.56 3.8 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 42.5 t -75.53 101.93 5.06 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 121.47 0.652 . . . . 0.0 110.201 -179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -96.44 -163.15 1.02 Allowed 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.965 -177.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -47.72 -42.14 24.51 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 114.225 -1.352 . . . . 0.0 113.701 -177.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.99 61.68 1.92 Allowed Glycine 0 CA--C 1.54 1.652 0 C-N-CA 120.301 -0.952 . . . . 0.0 114.187 -175.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.09 135.02 9.89 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 177.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . 0.699 ' HB ' HG23 ' Q' ' 31' ' ' ILE . 96.6 mt -118.01 128.45 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 CA-C-O 121.399 0.619 . . . . 0.0 111.965 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . 0.491 ' CD1' HD12 ' Q' ' 32' ' ' ILE . 48.2 mm -120.4 123.34 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.894 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 118.05 2.8 Favored Glycine 0 N--CA 1.468 0.786 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.401 ' CD2' HD12 ' Q' ' 34' ' ' LEU . 67.8 mt -116.54 114.9 24.81 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . 0.4 ' HB2' ' SD ' ' Q' ' 35' ' ' MET . 85.9 mmm -134.27 136.23 43.43 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.042 -178.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.63 155.84 34.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 121.33 0.585 . . . . 0.0 111.006 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -52.93 -102.27 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.149 178.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 49.24 71.06 0.66 Allowed Glycine 0 CA--C 1.529 0.939 0 CA-C-N 115.148 -0.526 . . . . 0.0 111.807 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.572 HG12 ' N ' ' R' ' 40' ' ' VAL . 59.9 t -112.29 165.69 7.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . 0.572 ' N ' HG12 ' R' ' 39' ' ' VAL . 15.5 m . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.101 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 . . . . . 0 N--CA 1.466 0.339 0 CA-C-O 120.801 0.334 . . . . 0.0 110.141 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.23 140.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.476 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -142.11 158.37 43.82 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.069 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.614 ' CD2' ' N ' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -89.26 169.56 11.34 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.021 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -129.42 150.71 50.65 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -97.14 118.92 34.63 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.691 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.3 mt -124.77 114.9 19.88 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -132.83 136.4 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.351 -0.386 . . . . 0.0 109.977 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -128.03 130.52 48.42 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.456 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -123.6 120.49 32.97 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.999 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.04 127.43 48.77 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.404 ' CD ' ' OE1' ' B' ' 22' ' ' GLU . 83.2 tt0 -147.95 149.14 31.66 Favored 'General case' 0 CA--C 1.533 0.327 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -178.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.0 t0 . . . . . 0 N--CA 1.466 0.34 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 176.861 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . 1.048 ' N ' ' HZ3' ' B' ' 28' ' ' LYS . 9.9 t-20 . . . . . 0 N--CA 1.469 0.482 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.581 ' H ' ' ND2' ' A' ' 27' ' ' ASN . 68.1 mttm -78.66 40.42 0.38 Allowed 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.961 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.422 ' C ' ' H ' ' A' ' 31' ' ' ILE . . . 119.57 78.37 0.56 Allowed Glycine 0 CA--C 1.533 1.167 0 CA-C-O 118.362 -1.243 . . . . 0.0 113.938 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.68 43.41 0.75 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-N 121.011 2.405 . . . . 0.0 110.9 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.422 ' H ' ' C ' ' A' ' 29' ' ' GLY . 54.9 mt -150.47 126.94 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 CA-C-N 113.148 -1.842 . . . . 0.0 106.866 178.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.432 ' O ' ' O ' ' B' ' 33' ' ' GLY . 50.7 mt -105.89 110.2 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.987 -0.745 . . . . 0.0 108.987 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.56 93.7 0.57 Allowed Glycine 0 CA--C 1.508 -0.368 0 N-CA-C 105.614 -2.994 . . . . 0.0 105.614 177.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -147.17 168.04 22.67 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 122.998 1.38 . . . . 0.0 114.133 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -120.22 110.64 16.84 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 112.224 -2.262 . . . . 0.0 107.229 178.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG2' HD11 ' B' ' 34' ' ' LEU . 2.9 t -97.92 113.44 32.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.498 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.68 -125.03 1.49 Allowed Glycine 0 C--N 1.315 -0.596 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.24 -62.89 0.37 Allowed Glycine 0 CA--C 1.546 1.987 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.552 ' O ' HG21 ' B' ' 39' ' ' VAL . 2.9 m -134.73 159.9 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 116.999 0.399 . . . . 0.0 110.009 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.473 HG21 ' CA ' ' H' ' 29' ' ' GLY . 42.9 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.336 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.94 146.06 34.42 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.644 0.259 . . . . 0.0 110.358 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 58.5 mp0 -72.68 119.31 16.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.963 0.411 . . . . 0.0 110.263 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.457 ' CG2' ' NE2' ' A' ' 14' ' ' HIS . 26.0 m -134.89 161.01 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.835 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -131.32 96.15 3.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.075 0.464 . . . . 0.0 111.704 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.561 ' CD2' ' NE2' ' C' ' 14' ' ' HIS . 24.6 p80 -156.89 169.15 25.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 177.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 47.6 tt0 -129.51 150.45 50.85 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.956 0.407 . . . . 0.0 110.128 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -98.37 119.94 37.93 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.722 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.606 ' C ' HD23 ' B' ' 17' ' ' LEU . 7.0 tt -122.76 122.79 39.55 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 118.194 0.452 . . . . 0.0 110.537 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.53 ' N ' HD23 ' B' ' 17' ' ' LEU . 69.3 t -126.22 128.76 71.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.239 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 t80 -124.6 114.06 18.88 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.872 0.368 . . . . 0.0 110.022 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.643 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 32.7 t80 -115.34 119.98 38.08 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.647 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.452 ' HB1' ' ND2' ' A' ' 27' ' ' ASN . . . -132.13 128.28 37.76 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.718 0.771 . . . . 0.0 112.219 -178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.404 ' OE1' ' CD ' ' A' ' 22' ' ' GLU . 87.8 mt-10 -96.73 111.98 23.92 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.055 178.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -104.17 46.42 0.92 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.06 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.726 HG12 ' H ' ' B' ' 25' ' ' GLY . 20.7 t -82.33 176.07 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.629 -178.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.726 ' H ' HG12 ' B' ' 24' ' ' VAL . . . 91.87 -28.27 8.84 Favored Glycine 0 N--CA 1.465 0.622 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -177.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 2.1 p 166.31 131.52 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 60.1 t-20 -45.84 130.84 9.54 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 1.048 ' HZ3' ' N ' ' A' ' 27' ' ' ASN . 98.7 mttt -89.28 -46.61 8.64 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.36 60.92 0.1 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.588 -1.291 . . . . 0.0 113.28 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.86 113.95 8.44 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.968 1.47 . . . . 0.0 114.968 -176.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 93.0 mt -127.66 130.1 70.28 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 CA-C-N 112.696 -2.047 . . . . 0.0 109.702 178.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.515 HD13 ' CD2' ' D' ' 19' ' ' PHE . 94.3 mt -110.06 116.33 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 O-C-N 121.578 -0.701 . . . . 0.0 110.551 178.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -118.97 96.17 0.65 Allowed Glycine 0 C--O 1.238 0.352 0 N-CA-C 104.924 -3.271 . . . . 0.0 104.924 176.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.483 HD11 ' CG2' ' A' ' 36' ' ' VAL . 20.5 tp -135.9 136.74 40.74 Favored 'General case' 0 CA--C 1.502 -0.889 0 C-N-CA 119.268 -0.973 . . . . 0.0 113.099 -174.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.4 mtp -106.39 108.75 20.42 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.59 ' HB ' HG13 ' C' ' 36' ' ' VAL . 2.5 t -102.1 103.33 14.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.99 -153.61 25.11 Favored Glycine 0 N--CA 1.447 -0.622 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.501 ' O ' HG11 ' C' ' 39' ' ' VAL . . . 115.44 -55.79 0.53 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -178.193 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.818 ' C ' HG21 ' C' ' 39' ' ' VAL . 27.8 m -124.05 137.02 58.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 123.449 0.7 . . . . 0.0 111.279 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.523 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 40.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.651 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.409 -1.477 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -105.35 135.37 46.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.934 0.397 . . . . 0.0 110.468 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -138.24 139.53 39.27 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.384 -179.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.405 HG13 ' O ' ' D' ' 12' ' ' VAL . 3.4 t -106.7 91.22 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -104.39 131.17 52.04 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.2 0.524 . . . . 0.0 111.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.561 ' NE2' ' CD2' ' B' ' 14' ' ' HIS . 1.0 OUTLIER -151.0 165.23 34.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.534 179.285 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 95.8 mm-40 -90.02 151.94 21.42 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -148.4 99.12 2.99 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -131.28 128.99 40.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.447 0.641 . . . . 0.0 111.399 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.99 114.56 45.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.05 107.83 18.32 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.643 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 17.1 t80 -113.77 124.86 53.27 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 122.009 0.123 . . . . 0.0 111.114 -178.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.82 131.83 21.67 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 120.262 -0.575 . . . . 0.0 112.516 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.04 112.43 21.77 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.179 0.514 . . . . 0.0 110.711 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.452 ' OD1' ' OD2' ' D' ' 23' ' ' ASP . 13.6 p-10 -124.86 46.56 2.3 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.559 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.765 HG12 ' H ' ' C' ' 25' ' ' GLY . 21.8 t -73.38 179.74 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.774 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.765 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 99.26 -35.38 4.73 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-N 114.329 -1.305 . . . . 0.0 113.413 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.489 ' O ' ' O ' ' C' ' 27' ' ' ASN . 28.6 t -162.38 117.53 1.87 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.6 1.7 . . . . 0.0 112.548 175.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . 0.794 ' N ' HG21 ' D' ' 24' ' ' VAL . 67.2 m-20 -23.23 151.39 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 118.976 -0.535 . . . . 0.0 112.232 175.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 39.5 tttp -167.55 31.36 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 173.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' D' ' 27' ' ' ASN . . . 81.01 80.81 0.85 Allowed Glycine 0 CA--C 1.535 1.328 0 C-N-CA 117.886 -2.102 . . . . 0.0 114.097 175.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.93 119.49 38.88 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.447 1.623 . . . . 0.0 109.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.607 HD11 HG23 ' P' ' 39' ' ' VAL . 82.9 mt -123.14 132.53 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -177.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.423 HG23 ' CD1' ' C' ' 34' ' ' LEU . 2.8 mt -105.79 108.45 25.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' B' ' 32' ' ' ILE . . . -123.64 106.76 1.01 Allowed Glycine 0 N--CA 1.465 0.577 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.423 ' CD1' HG23 ' C' ' 32' ' ' ILE . 3.0 mp -139.27 143.36 37.91 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 122.702 1.239 . . . . 0.0 113.434 -177.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -113.49 103.66 11.49 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 175.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.951 HG11 HD11 ' E' ' 17' ' ' LEU . 2.4 t -111.72 102.91 14.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.09 -151.78 20.89 Favored Glycine 0 C--N 1.31 -0.879 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -178.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . 0.687 ' O ' HG11 ' D' ' 39' ' ' VAL . . . 102.91 -56.81 0.6 Allowed Glycine 0 CA--C 1.54 1.618 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.725 -179.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.818 HG21 ' C ' ' B' ' 39' ' ' VAL . 33.6 m -135.81 163.71 34.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 123.037 0.535 . . . . 0.0 111.095 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.987 -179.434 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.405 ' O ' HG13 ' C' ' 12' ' ' VAL . 2.4 p . . . . . 0 N--CA 1.463 0.186 0 CA-C-O 121.046 0.45 . . . . 0.0 110.237 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.811 ' CD2' ' HD1' ' E' ' 13' ' ' HIS . 5.7 p80 -133.52 119.44 19.53 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -149.07 164.86 33.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.528 0.68 . . . . 0.0 112.144 -178.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.568 ' CD ' HG12 ' B' ' 36' ' ' VAL . 85.1 mt-30 -84.49 156.59 21.64 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 176.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -159.26 105.87 1.73 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 120.043 -0.663 . . . . 0.0 109.237 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.453 ' CD1' HG11 ' B' ' 36' ' ' VAL . 3.4 mp -136.67 127.85 28.01 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.434 0.635 . . . . 0.0 111.695 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -109.72 115.43 49.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.347 178.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' E' ' 19' ' ' PHE . 35.2 m-85 -108.55 106.95 17.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 47.3 t80 -111.87 119.01 37.1 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.851 -179.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.73 138.57 28.93 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 119.569 -0.852 . . . . 0.0 112.968 -179.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.3 mt-10 -120.15 133.45 55.5 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.776 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.616 ' C ' HG23 ' D' ' 24' ' ' VAL . 0.0 OUTLIER -149.41 59.78 1.02 Allowed 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.999 HG12 ' H ' ' D' ' 25' ' ' GLY . 4.4 t 91.3 -169.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 176.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.999 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -76.98 -33.82 44.36 Favored Glycine 0 C--O 1.214 -1.146 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . 0.449 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 5.3 p -147.3 118.4 7.74 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.289 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . 0.412 ' OD1' ' N ' ' C' ' 29' ' ' GLY . 17.7 t-20 -59.93 169.03 1.59 Allowed 'General case' 0 C--N 1.333 -0.113 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.884 -179.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -55.25 -38.06 68.04 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.839 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.58 71.42 0.1 Allowed Glycine 0 CA--C 1.533 1.215 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.829 -174.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.49 135.27 47.05 Favored 'General case' 0 C--O 1.245 0.832 0 CA-C-N 118.785 1.293 . . . . 0.0 112.694 -174.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.565 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 77.9 mt -139.28 134.62 40.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 113.845 -1.525 . . . . 0.0 114.09 -176.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 mt -107.48 111.22 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 174.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.55 103.45 0.92 Allowed Glycine 0 N--CA 1.46 0.297 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 177.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.504 HD23 ' N ' ' D' ' 35' ' ' MET . 6.1 tt -140.8 146.63 37.87 Favored 'General case' 0 CA--C 1.513 -0.463 0 C-N-CA 119.055 -1.058 . . . . 0.0 113.171 -176.051 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.504 ' N ' HD23 ' D' ' 34' ' ' LEU . 17.9 mtp -120.21 115.25 23.25 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.194 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.784 HG11 HD11 ' F' ' 17' ' ' LEU . 0.0 OUTLIER -115.97 102.83 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.675 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.45 ' HA2' ' H ' ' E' ' 38' ' ' GLY . . . 166.27 -151.31 19.53 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 119.66 -1.257 . . . . 0.0 110.561 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.7 -57.4 0.84 Allowed Glycine 0 CA--C 1.544 1.88 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.484 -178.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.751 HG21 ' C ' ' C' ' 39' ' ' VAL . 27.7 m -134.93 159.92 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 C-N-CA 123.356 0.662 . . . . 0.0 110.773 -178.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.53 -179.603 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.48 134.76 48.06 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.385 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -142.07 146.0 34.96 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.173 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.503 ' CG2' ' CD2' ' E' ' 14' ' ' HIS . 3.3 p -139.83 148.69 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 121.065 0.459 . . . . 0.0 110.716 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.811 ' HD1' ' CD2' ' D' ' 13' ' ' HIS . 0.1 OUTLIER -143.27 119.26 10.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.755 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.591 ' HE2' HG12 ' F' ' 12' ' ' VAL . 90.1 m-70 -143.9 164.35 30.81 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.014 178.313 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.619 HE21 HD21 ' E' ' 17' ' ' LEU . 64.4 tp60 -89.98 151.93 21.45 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 177.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -148.74 98.8 2.91 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.782 177.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.951 HD11 HG11 ' C' ' 36' ' ' VAL . 37.1 mt -122.8 119.33 30.26 Favored 'General case' 0 CA--C 1.509 -0.615 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.081 178.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -107.62 104.32 16.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' D' ' 19' ' ' PHE . 73.9 m-85 -103.67 105.69 15.99 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 2.7 m-85 -107.49 114.57 28.66 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.47 138.43 31.0 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 119.096 -1.042 . . . . 0.0 112.623 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -84.59 141.85 30.39 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.624 -179.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 0.6 OUTLIER 172.64 47.07 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.066 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -179.095 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' D' ' 25' ' ' GLY . 3.5 m -73.43 175.28 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.307 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 100.14 -29.75 11.56 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.165 176.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 92.01 114.67 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 -177.796 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . 0.412 ' OD1' ' O ' ' D' ' 27' ' ' ASN . 78.6 m-20 -73.92 174.53 8.4 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.754 -178.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.11 -36.69 41.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.559 178.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.79 77.08 0.07 OUTLIER Glycine 0 CA--C 1.532 1.094 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -177.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.28 155.4 27.3 Favored 'General case' 0 C--O 1.241 0.64 0 CA-C-O 121.946 0.879 . . . . 0.0 111.673 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.879 HD11 ' H ' ' Q' ' 39' ' ' VAL . 75.0 mt -131.44 133.34 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 114.554 -1.203 . . . . 0.0 112.248 -177.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.43 115.35 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.49 113.42 1.6 Allowed Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 46.8 tp -123.37 121.38 35.64 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-O 120.825 0.345 . . . . 0.0 110.619 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.1 mtp -109.57 105.72 15.14 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.65 HG12 ' H ' ' E' ' 37' ' ' GLY . 21.6 t -91.84 174.33 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.373 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.65 ' H ' HG12 ' E' ' 36' ' ' VAL . . . 167.99 -95.15 0.11 Allowed Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 92.64 -82.64 1.12 Allowed Glycine 0 N--CA 1.474 1.193 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -178.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.442 HG13 HD11 ' K' ' 31' ' ' ILE . 64.4 t . . . . . 0 N--CA 1.432 -1.329 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.548 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 N--CA 1.465 0.292 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.591 HG12 ' HE2' ' E' ' 14' ' ' HIS . 2.5 t -112.82 100.67 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.165 0.507 . . . . 0.0 109.757 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.622 ' NE2' ' CD2' ' E' ' 13' ' ' HIS . 68.8 m80 -140.16 114.6 9.28 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.954 -178.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.534 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 77.2 m80 -156.21 162.1 40.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 177.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -90.06 158.23 17.42 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.678 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 31.9 tttt -141.16 98.28 3.34 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 175.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.784 HD11 HG11 ' D' ' 36' ' ' VAL . 7.9 mt -119.06 110.75 17.45 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 83.1 t -101.29 99.26 8.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.4 ' CD1' ' CD2' ' E' ' 19' ' ' PHE . 92.6 m-85 -96.51 95.08 7.76 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 106.768 -1.568 . . . . 0.0 106.768 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.421 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 67.8 t80 -107.4 109.25 20.93 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.585 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.548 ' O ' ' N ' ' F' ' 23' ' ' ASP . . . -148.82 135.41 19.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.584 ' HB3' HG12 ' E' ' 24' ' ' VAL . 63.3 mt-10 -74.98 79.53 2.18 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 102.807 -3.035 . . . . 0.0 102.807 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.548 ' N ' ' O ' ' F' ' 21' ' ' ALA . 53.0 p30 . . . . . 0 CA--C 1.511 -0.527 0 CA-C-N 112.472 -2.149 . . . . 0.0 113.729 -173.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.766 0 N-CA-C 109.965 -0.383 . . . . 0.0 109.965 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.691 HD11 HG22 ' R' ' 39' ' ' VAL . 96.5 mt -134.97 136.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -128.54 124.7 62.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.82 129.05 4.31 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.663 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.6 125.34 44.66 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 95.6 mmm -131.47 133.28 44.98 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.609 -179.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 14.7 p -141.48 149.77 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 120.815 0.341 . . . . 0.0 110.788 178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.12 102.04 0.42 Allowed Glycine 0 C--N 1.322 -0.216 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.22 -71.95 0.4 Allowed Glycine 0 CA--C 1.539 1.584 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.077 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.455 ' O ' ' OXT' ' F' ' 40' ' ' VAL . 5.6 m -79.31 167.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.609 ' H ' ' CG2' ' L' ' 31' ' ' ILE . 27.2 m . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.502 179.329 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . 0.403 HG11 ' ND1' ' H' ' 13' ' ' HIS . 65.1 t . . . . . 0 N--CA 1.466 0.362 0 CA-C-O 120.953 0.406 . . . . 0.0 110.018 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -82.16 160.77 23.01 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.643 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.421 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 33.9 p-80 -99.5 169.49 9.27 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.083 0.468 . . . . 0.0 111.356 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.442 ' H ' ' HG2' ' H' ' 15' ' ' GLN . 67.1 tp60 -129.69 151.38 50.35 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.036 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -95.63 130.57 42.47 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.59 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.1 mt -126.19 112.43 15.77 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.218 0.532 . . . . 0.0 109.783 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.456 HG23 ' O ' ' G' ' 18' ' ' VAL . 21.2 m -125.65 132.49 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.179 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -127.0 113.32 16.32 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -111.82 117.51 33.01 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 110.297 -0.261 . . . . 0.0 110.297 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.04 107.39 14.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -151.36 138.96 19.63 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 . . . . . 0 C--N 1.329 -0.315 0 C-N-CA 119.985 -0.686 . . . . 0.0 110.857 178.614 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 . . . . . 0 N--CA 1.482 1.169 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -158.88 17.48 0.19 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 121.942 -0.474 . . . . 0.0 110.326 177.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.33 169.53 0.66 Allowed Glycine 0 CA--C 1.524 0.651 0 CA-C-N 115.892 -0.594 . . . . 0.0 112.898 176.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.414 ' H ' ' HB2' ' H' ' 27' ' ' ASN . . . -130.83 87.31 2.47 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.346 0.593 . . . . 0.0 111.588 178.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.463 HD11 HG12 ' A' ' 39' ' ' VAL . 42.2 pt -138.83 127.12 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.223 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 177.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.462 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.8 mt -107.73 111.12 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.29 95.14 0.65 Allowed Glycine 0 N--CA 1.463 0.458 0 N-CA-C 105.347 -3.101 . . . . 0.0 105.347 177.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.4 mt -142.71 161.34 38.34 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 122.462 1.125 . . . . 0.0 113.861 -175.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 54.9 tpp -120.67 115.02 22.55 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 113.041 -1.89 . . . . 0.0 107.843 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.61 HG23 HG22 ' H' ' 36' ' ' VAL . 0.0 OUTLIER -131.57 111.76 19.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 179.728 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.61 -131.49 5.52 Favored Glycine 0 C--N 1.315 -0.585 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.55 -63.18 1.13 Allowed Glycine 0 CA--C 1.535 1.333 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.718 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . 0.404 ' O ' ' C ' ' G' ' 40' ' ' VAL . 11.9 p -120.47 153.34 23.59 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.531 ' OXT' ' CE1' ' J' ' 13' ' ' HIS . 22.7 m . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 118.06 -0.971 . . . . 0.0 111.069 -178.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.62 134.75 52.98 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.727 0.299 . . . . 0.0 110.289 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.73 137.96 37.24 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.4 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.479 HG22 ' O ' ' I' ' 11' ' ' GLU . 2.0 t -123.78 107.63 19.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 81.0 t60 -126.63 120.9 30.66 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.92 0.391 . . . . 0.0 110.579 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' O ' ' I' ' 14' ' ' HIS . 11.7 t60 -155.59 170.28 22.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.094 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.595 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 82.5 mt-30 -156.0 141.95 18.1 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -82.38 120.41 25.4 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.362 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.4 ' HB2' HD23 ' I' ' 17' ' ' LEU . 5.7 mp -120.54 114.5 21.84 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.42 HG12 ' HB ' ' I' ' 18' ' ' VAL . 25.6 m -133.98 131.79 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 121.364 0.602 . . . . 0.0 111.195 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -122.26 120.14 33.24 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.201 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -117.34 122.17 43.15 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.736 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.61 115.73 22.62 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.551 ' O ' ' N ' ' H' ' 24' ' ' VAL . 95.7 mt-10 -115.8 141.84 47.56 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 112.86 0.689 . . . . 0.0 112.86 -178.025 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.432 ' H ' ' HB2' ' I' ' 22' ' ' GLU . 88.5 m-20 54.38 -59.71 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 114.668 -1.151 . . . . 0.0 113.789 178.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.551 ' N ' ' O ' ' H' ' 22' ' ' GLU . 16.3 m -93.48 172.04 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-O 122.005 0.907 . . . . 0.0 111.616 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.97 27.93 65.65 Favored Glycine 0 CA--C 1.529 0.948 0 CA-C-N 113.841 -1.527 . . . . 0.0 112.762 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 46.6 t -98.38 110.83 23.35 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 5.4 t-20 -77.19 172.81 12.66 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 118.062 -1.455 . . . . 0.0 110.562 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.583 ' O ' ' N ' ' I' ' 28' ' ' LYS . 68.7 mttm -52.4 -36.46 54.16 Favored 'General case' 0 C--O 1.218 -0.575 0 CA-C-O 121.988 0.899 . . . . 0.0 110.821 176.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.473 ' CA ' HG21 ' A' ' 40' ' ' VAL . . . -132.12 79.48 0.35 Allowed Glycine 0 N--CA 1.47 0.901 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.466 -175.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.61 132.53 43.87 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 118.829 1.314 . . . . 0.0 111.132 -176.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.421 ' CD1' ' HA ' ' B' ' 39' ' ' VAL . 87.5 mt -140.84 147.55 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 113.954 -1.475 . . . . 0.0 113.544 -174.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.588 HD13 ' CD1' ' J' ' 19' ' ' PHE . 65.3 mt -106.86 107.25 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -111.56 98.59 1.03 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.178 -2.369 . . . . 0.0 107.178 178.2 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.647 ' O ' HD12 ' I' ' 34' ' ' LEU . 2.4 mt -135.18 139.09 44.29 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.584 1.183 . . . . 0.0 113.392 -176.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -106.21 108.66 20.29 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.15 -2.537 . . . . 0.0 104.15 175.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 1.001 HG11 HD11 ' J' ' 17' ' ' LEU . 53.1 t -127.94 131.26 69.77 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.247 0 CA-C-O 121.184 0.516 . . . . 0.0 112.159 -175.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.88 -111.11 3.68 Favored Glycine 0 C--N 1.32 -0.339 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.749 178.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.7 -74.22 2.42 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.429 HG22 ' O ' ' N' ' 29' ' ' GLY . 18.2 t -110.43 135.93 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 122.902 0.481 . . . . 0.0 110.475 179.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.472 HG12 ' O ' ' H' ' 40' ' ' VAL . 69.9 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.322 178.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.423 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -82.89 136.71 34.5 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.869 0.366 . . . . 0.0 110.533 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.479 ' O ' HG22 ' H' ' 12' ' ' VAL . 80.2 mm-40 -78.6 155.39 29.63 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.424 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' I' ' 13' ' ' HIS . 74.0 t -138.4 166.91 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.931 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.587 ' N ' HG12 ' I' ' 12' ' ' VAL . 11.0 m-70 -54.99 143.0 27.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.777 0.322 . . . . 0.0 111.46 -178.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 16.7 t-80 -153.9 154.31 33.64 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.601 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 64.2 tp60 -98.76 169.3 9.58 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 118.315 0.507 . . . . 0.0 111.208 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 82.2 tttt -159.73 104.29 1.57 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 176.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.4 HD23 ' HB2' ' H' ' 17' ' ' LEU . 11.7 mt -123.89 123.29 40.1 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 121.236 0.541 . . . . 0.0 111.472 178.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.42 ' HB ' HG12 ' H' ' 18' ' ' VAL . 60.3 t -115.91 112.08 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 177.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -112.54 107.36 16.07 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -114.74 126.93 55.41 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 130.09 25.35 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.817 0.818 . . . . 0.0 113.114 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.453 ' OE1' ' OE1' ' J' ' 22' ' ' GLU . 58.5 mm-40 -95.6 120.23 35.48 Favored 'General case' 0 N--CA 1.461 0.096 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.455 ' H ' ' HB3' ' J' ' 22' ' ' GLU . 90.6 m-20 -125.72 48.64 2.04 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.038 0.385 . . . . 0.0 112.038 -177.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.565 HG12 ' N ' ' I' ' 25' ' ' GLY . 81.2 t -72.39 161.11 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 C-N-CA 118.447 -1.301 . . . . 0.0 109.896 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.565 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 108.39 -30.05 9.34 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 22.9 p 93.28 113.59 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 112.573 -1.814 . . . . 0.0 109.619 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -74.19 161.95 29.44 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 117.916 -1.514 . . . . 0.0 110.649 178.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.583 ' N ' ' O ' ' H' ' 28' ' ' LYS . 72.7 tttt -48.65 -39.5 24.5 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 174.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.33 68.82 0.04 OUTLIER Glycine 0 CA--C 1.551 2.327 0 CA-C-O 118.826 -0.986 . . . . 0.0 112.421 -174.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.25 150.62 46.22 Favored 'General case' 0 N--CA 1.478 0.938 0 CA-C-N 119.775 1.787 . . . . 0.0 114.587 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.55 HD12 HG12 ' C' ' 39' ' ' VAL . 77.5 mt -141.44 152.32 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 113.517 -1.674 . . . . 0.0 113.996 -176.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.454 HD13 ' CD1' ' K' ' 19' ' ' PHE . 6.6 mt -106.93 109.08 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 174.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.42 106.03 2.04 Favored Glycine 0 N--CA 1.465 0.617 0 N-CA-C 106.323 -2.711 . . . . 0.0 106.323 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.647 HD12 ' O ' ' H' ' 34' ' ' LEU . 26.6 tp -147.54 140.25 24.79 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.837 1.303 . . . . 0.0 113.969 -174.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.548 ' H ' HD12 ' I' ' 34' ' ' LEU . 42.8 tpp -110.04 115.08 29.13 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 113.033 -1.894 . . . . 0.0 106.799 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.79 123.13 51.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.06 -113.55 0.86 Allowed Glycine 0 C--N 1.317 -0.527 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 86.24 -73.01 2.58 Favored Glycine 0 CA--C 1.536 1.405 0 CA-C-N 115.48 -0.36 . . . . 0.0 112.211 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 39.7 t -123.19 146.09 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.472 HG13 ' ND1' ' L' ' 13' ' ' HIS . 52.9 t . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.651 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.84 134.33 54.41 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . 0.41 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 98.9 mt-10 -74.57 130.79 40.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.483 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.589 HG23 ' O ' ' J' ' 12' ' ' VAL . 32.9 m -138.38 88.09 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-O 121.601 0.715 . . . . 0.0 110.904 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.562 ' H ' ' CD2' ' K' ' 13' ' ' HIS . 6.1 t60 -129.03 128.14 43.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.433 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.569 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -140.67 173.64 11.29 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.426 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.489 ' NE2' HG13 ' H' ' 36' ' ' VAL . 10.2 tt0 -124.64 142.45 51.37 Favored 'General case' 0 C--O 1.224 -0.248 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.465 177.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.82 112.16 23.45 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 119.168 -0.444 . . . . 0.0 111.078 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 1.001 HD11 HG11 ' H' ' 36' ' ' VAL . 24.0 mt -118.43 114.36 22.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.613 0.642 . . . . 0.0 109.984 177.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 t -110.13 105.83 19.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.588 ' CD1' HD13 ' H' ' 32' ' ' ILE . 65.5 m-85 -106.36 106.67 17.3 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.454 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.6 t80 -115.24 122.48 46.11 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.77 138.3 32.19 Favored 'General case' 0 C--O 1.253 1.26 0 CA-C-O 123.091 1.424 . . . . 0.0 114.479 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.455 ' HB3' ' H ' ' I' ' 23' ' ' ASP . 24.0 tt0 -79.89 90.99 5.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 113.526 -1.67 . . . . 0.0 107.614 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.685 ' O ' ' O ' ' K' ' 22' ' ' GLU . 84.3 m-20 -89.98 60.04 4.76 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 111.773 -2.467 . . . . 0.0 110.42 -178.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -62.7 -112.65 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-O 117.109 -1.424 . . . . 0.0 108.282 -174.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.608 ' HA2' HG12 ' K' ' 24' ' ' VAL . . . -103.82 44.51 1.47 Allowed Glycine 0 N--CA 1.472 1.081 0 CA-C-N 121.707 2.049 . . . . 0.0 112.078 -172.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 29.0 t -71.82 100.64 2.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -109.67 -150.81 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.176 -175.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 34.96 42.07 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 113.36 0.874 . . . . 0.0 113.36 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.55 71.82 0.63 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 117.297 1.679 . . . . 0.0 117.297 177.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.33 120.27 40.82 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 174.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.471 HG22 ' N ' ' J' ' 32' ' ' ILE . 42.3 mt -145.12 155.45 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -174.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.471 ' N ' HG22 ' J' ' 31' ' ' ILE . 40.7 mt -111.89 111.23 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.27 103.88 1.64 Allowed Glycine 0 N--CA 1.467 0.75 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 177.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.432 ' CD2' HG13 ' J' ' 36' ' ' VAL . 12.2 tp -137.33 137.31 38.79 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 122.205 1.003 . . . . 0.0 113.663 -175.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -111.39 114.22 27.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 113.677 -1.601 . . . . 0.0 107.543 176.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.432 HG13 ' CD2' ' J' ' 34' ' ' LEU . 1.3 m -121.23 103.21 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 120.399 0.143 . . . . 0.0 111.11 -178.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.39 -153.43 25.33 Favored Glycine 0 C--N 1.318 -0.468 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.016 178.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.479 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 126.15 -56.4 0.71 Allowed Glycine 0 CA--C 1.541 1.71 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.657 HG12 HG23 ' J' ' 40' ' ' VAL . 55.0 t -136.5 137.17 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.657 HG23 HG12 ' J' ' 39' ' ' VAL . 61.2 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.433 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.98 143.81 41.07 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.754 0.311 . . . . 0.0 110.644 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.489 ' O ' HG12 ' J' ' 12' ' ' VAL . 97.0 mt-10 -129.41 149.87 51.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.434 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.534 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 34.2 m -140.37 161.45 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.498 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.562 ' CD2' ' H ' ' J' ' 13' ' ' HIS . 28.1 m80 -70.17 118.15 12.64 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' O ' ' L' ' 14' ' ' HIS . 65.9 t60 -148.23 162.82 38.71 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.107 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.435 ' HB3' ' H ' ' L' ' 16' ' ' LYS . 41.3 tt0 -90.2 152.28 21.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.819 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -150.39 93.14 1.94 Allowed 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.616 177.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.438 HD22 HD12 ' J' ' 17' ' ' LEU . 2.0 mt -120.93 115.31 22.96 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.47 105.41 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.481 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 52.1 m-85 -104.28 103.67 13.45 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.454 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 31.9 t80 -113.07 119.3 37.37 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.546 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -156.74 162.71 39.76 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 122.626 1.203 . . . . 0.0 113.604 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.685 ' O ' ' O ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -82.05 118.81 23.31 Favored 'General case' 0 C--O 1.206 -1.22 0 C-N-CA 118.344 -1.342 . . . . 0.0 111.347 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.908 ' O ' HG13 ' K' ' 24' ' ' VAL . 65.2 m-20 -62.09 -50.41 72.04 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 120.251 -1.53 . . . . 0.0 110.016 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.908 HG13 ' O ' ' K' ' 23' ' ' ASP . 0.3 OUTLIER 159.6 171.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 178.626 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 -33.27 76.14 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 177.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.3 m -162.68 120.94 2.1 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 114.186 -1.007 . . . . 0.0 109.872 -177.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' K' ' 26' ' ' SER . 39.7 t30 -22.25 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -164.69 29.82 0.07 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.528 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.91 88.04 0.82 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.685 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.36 155.95 45.51 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.442 HD11 HG13 ' E' ' 39' ' ' VAL . 6.9 mt -127.1 146.93 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 113.657 0.984 . . . . 0.0 113.657 -176.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -128.13 114.88 36.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.318 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.75 113.89 3.21 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.409 HD21 HD13 ' L' ' 17' ' ' LEU . 20.3 tp -122.84 124.36 43.11 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 17.8 mtp -129.24 131.09 46.98 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.409 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.593 HG12 ' N ' ' K' ' 37' ' ' GLY . 57.8 t -100.84 166.28 2.37 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-O 121.003 0.43 . . . . 0.0 110.568 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.593 ' N ' HG12 ' K' ' 36' ' ' VAL . . . -75.01 -102.91 0.1 OUTLIER Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.151 179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.55 -77.16 0.59 Allowed Glycine 0 N--CA 1.474 1.217 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.422 HG22 ' O ' ' L' ' 39' ' ' VAL . 45.5 t . . . . . 0 N--CA 1.469 0.497 0 CA-C-O 121.428 0.632 . . . . 0.0 110.585 -179.352 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.596 0.236 . . . . 0.0 110.529 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 55.1 t -123.84 133.82 68.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.533 0.682 . . . . 0.0 110.942 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.492 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 2.5 m-70 -131.33 127.24 37.24 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.181 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.546 ' O ' ' ND1' ' K' ' 14' ' ' HIS . 94.9 m-70 -155.01 165.46 36.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.423 ' OE1' ' O ' ' J' ' 36' ' ' VAL . 47.5 mt-30 -89.69 156.64 18.42 Favored 'General case' 0 CA--C 1.518 -0.282 0 C-N-CA 119.521 -0.871 . . . . 0.0 109.635 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . 0.435 ' H ' ' HB3' ' K' ' 15' ' ' GLN . 52.4 tttp -141.99 95.66 2.84 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.221 177.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.409 HD13 HD21 ' K' ' 34' ' ' LEU . 0.1 OUTLIER -117.65 108.19 15.14 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.299 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -107.11 103.93 16.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.058 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -101.23 102.13 12.97 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 178.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.7 t80 -126.52 129.7 49.15 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 121.35 0.595 . . . . 0.0 110.231 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -144.84 149.09 34.8 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 120.059 -0.656 . . . . 0.0 110.66 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -74.24 120.98 20.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.657 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -163.52 51.61 0.16 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 120.372 -0.531 . . . . 0.0 112.067 -178.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -76.15 143.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 118.119 -1.432 . . . . 0.0 108.51 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.52 -37.52 3.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.42 ' HB2' ' H ' ' K' ' 27' ' ' ASN . 0.3 OUTLIER -80.6 118.26 22.02 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 113.379 -1.411 . . . . 0.0 112.057 -179.267 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' L' ' 29' ' ' GLY . 57.3 p30 -89.01 -177.95 5.58 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -51.98 49.66 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 115.089 1.514 . . . . 0.0 115.089 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -101.58 51.35 0.93 Allowed Glycine 0 CA--C 1.549 2.182 0 CA-C-N 119.698 1.135 . . . . 0.0 113.515 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.38 174.47 9.83 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.609 ' CG2' ' H ' ' F' ' 40' ' ' VAL . 0.6 OUTLIER -106.91 119.91 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 176.214 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.0 mt -123.62 128.66 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 120.876 0.369 . . . . 0.0 111.7 -178.073 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 116.24 2.22 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 178.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 34.3 mt -119.64 124.59 46.67 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.7 ttm -124.04 123.54 40.57 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.468 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' L' ' 37' ' ' GLY . 72.8 t -98.33 131.52 45.24 Favored 'Isoleucine or valine' 0 C--N 1.34 0.17 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -34.6 -111.51 0.0 OUTLIER Glycine 0 CA--C 1.531 1.089 0 O-C-N 123.543 0.527 . . . . 0.0 113.257 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.68 -71.65 0.62 Allowed Glycine 0 CA--C 1.535 1.298 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.422 ' O ' HG22 ' K' ' 39' ' ' VAL . 53.2 t . . . . . 0 N--CA 1.468 0.462 0 CA-C-O 121.165 0.507 . . . . 0.0 110.998 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 . . . . . 0 N--CA 1.457 -0.085 0 CA-C-O 120.874 0.369 . . . . 0.0 110.119 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -125.48 131.93 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.349 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -106.28 160.71 15.15 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.633 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.592 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 8.5 p80 -83.43 166.91 17.96 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 120.392 -0.523 . . . . 0.0 110.617 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . 0.423 ' HB2' HE21 ' N' ' 15' ' ' GLN . 86.2 mt-30 -129.95 152.07 49.82 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.927 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . 0.59 ' C ' HD12 ' M' ' 17' ' ' LEU . 63.6 mttp -94.38 112.3 24.08 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . 0.59 HD12 ' C ' ' M' ' 16' ' ' LYS . 11.1 mp -116.88 120.61 39.02 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.879 0.371 . . . . 0.0 110.124 179.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -129.61 132.54 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.049 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -142.25 134.23 27.3 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.989 0.423 . . . . 0.0 110.828 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.448 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 52.8 p90 -123.31 133.11 54.18 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.732 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.91 125.66 41.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 121.145 0.498 . . . . 0.0 111.543 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -156.33 126.34 6.47 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.586 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.24 46.41 25.29 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.831 HG12 ' H ' ' M' ' 25' ' ' GLY . 21.6 t -76.7 -179.8 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.349 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . 0.831 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -88.88 28.15 6.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . 0.443 ' O ' ' C ' ' M' ' 27' ' ' ASN . 4.7 t -169.74 -134.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.865 -0.421 . . . . 0.0 109.865 -178.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . 0.443 ' C ' ' O ' ' M' ' 26' ' ' SER . 3.0 t-20 -32.04 134.19 0.09 Allowed 'General case' 0 N--CA 1.472 0.671 0 O-C-N 122.985 0.178 . . . . 0.0 111.141 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . 0.452 ' O ' ' OD2' ' N' ' 23' ' ' ASP . 68.7 mttm -118.23 -38.5 3.18 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . 0.587 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . -81.04 -76.99 1.02 Allowed Glycine 0 CA--C 1.53 0.969 0 C-N-CA 118.794 -1.67 . . . . 0.0 112.178 -179.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . 0.587 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 171.05 99.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.386 0.593 . . . . 0.0 111.31 178.284 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -127.9 116.63 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . 0.436 ' O ' ' O ' ' N' ' 33' ' ' GLY . 96.5 mt -113.49 108.1 24.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.26 96.87 0.78 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 105.45 -3.06 . . . . 0.0 105.45 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . 0.623 ' O ' HD12 ' N' ' 34' ' ' LEU . 91.3 mt -142.63 163.5 32.64 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 123.12 1.438 . . . . 0.0 114.163 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -117.62 110.71 18.24 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 111.824 -2.443 . . . . 0.0 105.977 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.895 HG11 HD11 ' O' ' 17' ' ' LEU . 74.6 t -117.92 131.61 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 121.334 0.588 . . . . 0.0 110.15 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.54 -111.42 3.36 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.924 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.1 -73.03 0.97 Allowed Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.424 HG12 ' N ' ' M' ' 40' ' ' VAL . 56.0 t -99.17 158.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.339 0.149 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.424 ' N ' HG12 ' M' ' 39' ' ' VAL . 11.7 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.567 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -83.07 139.41 33.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.614 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -140.63 128.06 21.29 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.765 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -127.46 130.27 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -123.71 104.37 8.95 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.913 0.387 . . . . 0.0 111.667 -179.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 1.0 OUTLIER -158.31 170.57 21.94 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.864 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 51.7 tt0 -155.44 141.46 18.28 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.897 0.379 . . . . 0.0 110.355 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -87.04 117.51 25.81 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.801 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -118.69 124.4 47.26 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 179.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.02 126.84 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 120.994 0.426 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -130.85 130.27 43.39 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.861 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -124.29 128.49 49.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 118.6 26.57 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.013 0.435 . . . . 0.0 110.458 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -127.22 128.69 46.48 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.463 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 34.4 m-20 -162.47 51.26 0.19 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.164 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 89.2 t -63.21 150.81 9.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.041 0.448 . . . . 0.0 110.668 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.06 -37.37 3.8 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.508 ' O ' ' O ' ' N' ' 27' ' ' ASN . 51.4 m -120.49 -112.36 0.33 Allowed 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.794 0.33 . . . . 0.0 111.588 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.524 ' ND2' ' OD1' ' O' ' 23' ' ' ASP . 16.3 m-20 52.31 153.08 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.69 -178.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' O' ' 28' ' ' LYS . 68.8 mttm -139.7 -29.57 0.73 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 113.712 1.005 . . . . 0.0 113.712 -179.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . 0.429 ' O ' HG22 ' H' ' 39' ' ' VAL . . . -161.73 85.02 0.11 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 120.421 -0.895 . . . . 0.0 113.935 -174.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.86 123.64 28.44 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 118.824 1.312 . . . . 0.0 110.627 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 0.432 HD11 HG23 ' I' ' 39' ' ' VAL . 70.0 mt -129.98 134.53 62.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.515 -175.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -105.0 104.93 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 106.87 -1.529 . . . . 0.0 106.87 174.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -110.41 109.44 2.64 Favored Glycine 0 C--O 1.235 0.202 0 N-CA-C 106.274 -2.73 . . . . 0.0 106.274 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.623 HD12 ' O ' ' M' ' 34' ' ' LEU . 15.8 tp -151.55 139.13 19.62 Favored 'General case' 0 CA--C 1.511 -0.535 0 C-N-CA 117.432 -1.707 . . . . 0.0 113.379 -175.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . 0.528 ' H ' HD12 ' N' ' 34' ' ' LEU . 0.8 OUTLIER -105.25 108.88 20.63 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 111.756 -2.475 . . . . 0.0 106.424 177.401 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . 0.653 ' CG1' HE22 ' P' ' 15' ' ' GLN . 8.7 p -132.8 142.6 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.141 -177.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.74 -102.02 0.75 Allowed Glycine 0 C--N 1.32 -0.307 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' O' ' 39' ' ' VAL . . . 77.01 -80.76 1.21 Allowed Glycine 0 CA--C 1.531 1.064 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.49 149.51 14.66 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.411 HG12 ' CD2' ' P' ' 13' ' ' HIS . 33.3 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.873 -1.061 . . . . 0.0 110.256 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -148.93 159.94 43.73 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.729 0.299 . . . . 0.0 110.484 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -134.55 160.22 38.74 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.619 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -118.45 131.04 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.281 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 37.3 m-70 -140.13 123.6 17.08 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.715 ' CE1' ' HD1' ' P' ' 14' ' ' HIS . 30.9 m80 -147.58 174.09 12.08 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 121.25 0.548 . . . . 0.0 111.152 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.4 HE21 HD21 ' O' ' 17' ' ' LEU . 67.0 tp60 -137.69 140.8 40.98 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -129.96 104.55 7.42 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.895 HD11 HG11 ' M' ' 36' ' ' VAL . 12.7 mt -116.61 116.3 27.32 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.006 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.89 106.34 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 13.6 m-30 -112.02 118.07 34.42 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -119.62 127.24 52.75 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.789 -0.187 . . . . 0.0 110.933 -179.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.39 124.83 26.35 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 121.944 0.878 . . . . 0.0 112.053 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' O' ' 23' ' ' ASP . 80.4 tt0 -96.09 141.79 29.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.316 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.524 ' OD1' ' ND2' ' N' ' 27' ' ' ASN . 65.3 m-20 -162.75 47.22 0.15 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.87 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.621 HG13 ' OE1' ' P' ' 22' ' ' GLU . 25.0 m -62.77 -179.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 121.716 0.769 . . . . 0.0 111.535 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . 0.475 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 91.25 -29.01 7.42 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 114.22 -1.354 . . . . 0.0 113.358 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 0.9 OUTLIER 167.63 127.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 118.385 1.093 . . . . 0.0 112.798 179.467 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . 0.515 ' ND2' ' O ' ' P' ' 27' ' ' ASN . 39.4 t-20 -36.72 138.48 0.24 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 176.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' N' ' 28' ' ' LYS . 78.1 mttt -150.56 34.82 0.62 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 121.077 0.465 . . . . 0.0 111.684 -176.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.35 80.39 0.95 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 176.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.01 110.99 23.1 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 42.8 mt -121.93 130.72 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -176.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.5 mt -107.44 103.64 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.27 102.41 2.21 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 104.146 -3.582 . . . . 0.0 104.146 176.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.557 HD12 ' O ' ' N' ' 34' ' ' LEU . 13.0 tp -140.19 135.87 32.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -172.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . 0.428 ' SD ' ' CG ' ' P' ' 35' ' ' MET . 89.5 mmm -111.64 108.73 18.3 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 112.369 -2.196 . . . . 0.0 106.185 177.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.597 ' CG1' ' NE2' ' Q' ' 15' ' ' GLN . 21.4 t -115.67 131.51 67.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.447 0.641 . . . . 0.0 111.94 -177.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' P' ' 37' ' ' GLY . . . 75.39 111.71 0.1 Allowed Glycine 0 CA--C 1.526 0.737 0 CA-C-N 114.767 -1.106 . . . . 0.0 114.222 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -94.17 -60.1 1.14 Allowed Glycine 0 CA--C 1.542 1.762 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' N' ' 38' ' ' GLY . 5.7 t -122.02 131.12 73.85 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.442 ' H ' ' HB ' ' P' ' 39' ' ' VAL . 91.4 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.922 -1.037 . . . . 0.0 110.476 -178.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . 0.461 ' O ' ' CG2' ' P' ' 12' ' ' VAL . 1.4 m . . . . . 0 N--CA 1.467 0.404 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 9.2 t60 -146.39 134.15 21.17 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 120.511 -0.475 . . . . 0.0 112.115 -177.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.715 ' HD1' ' CE1' ' O' ' 14' ' ' HIS . 1.0 OUTLIER -145.96 156.01 43.22 Favored 'General case' 0 C--O 1.23 0.068 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 176.314 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.653 HE22 ' CG1' ' N' ' 36' ' ' VAL . 53.1 tt0 -90.56 159.71 16.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.661 177.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 51.5 tttm -140.91 105.65 4.92 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.115 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . 0.647 ' CG ' HE21 ' P' ' 15' ' ' GLN . 39.6 mt -115.25 119.76 37.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-O 121.202 0.525 . . . . 0.0 111.166 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -116.75 98.29 6.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.489 ' CE2' HD13 ' P' ' 17' ' ' LEU . 16.9 m-30 -112.86 110.35 20.39 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -112.51 128.7 56.42 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.925 -179.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.5 158.13 40.86 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.953 -178.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.621 ' OE1' HG13 ' O' ' 24' ' ' VAL . 99.1 mt-10 -85.83 112.21 20.9 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.405 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 9.8 p-10 -112.44 52.07 0.79 Allowed 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 113.511 -1.677 . . . . 0.0 108.847 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . 0.565 HG12 ' N ' ' P' ' 25' ' ' GLY . 96.4 t -41.35 161.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 122.169 0.985 . . . . 0.0 112.249 -175.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.565 ' N ' HG12 ' P' ' 24' ' ' VAL . . . -93.14 32.61 5.57 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-N 113.077 -1.874 . . . . 0.0 114.218 -173.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.429 ' HB3' ' H ' ' O' ' 27' ' ' ASN . 11.9 t -92.57 -112.91 0.1 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.575 ' O ' ' N ' ' P' ' 29' ' ' GLY . 15.4 m120 -86.27 156.58 20.2 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 118.097 -1.441 . . . . 0.0 110.893 -178.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 50.1 pttt -49.16 46.27 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . -99.38 58.17 0.85 Allowed Glycine 0 CA--C 1.545 1.915 0 CA-C-N 118.875 0.761 . . . . 0.0 112.322 179.065 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . 0.576 ' O ' ' HB1' ' Q' ' 30' ' ' ALA . . . -152.72 108.06 3.27 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 117.811 0.805 . . . . 0.0 110.856 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.479 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 14.0 pt -145.04 147.86 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.9 mt -114.4 115.89 50.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.341 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.46 98.31 1.12 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 104.739 -3.344 . . . . 0.0 104.739 174.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 22.6 tp -127.49 132.43 49.98 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -173.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . 0.428 ' CG ' ' SD ' ' O' ' 35' ' ' MET . 90.6 mmm -111.56 112.83 24.82 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 174.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.494 HG21 HE22 ' R' ' 15' ' ' GLN . 0.0 OUTLIER -121.32 102.35 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -176.001 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' O' ' 37' ' ' GLY . . . 141.55 -161.34 27.0 Favored Glycine 0 CA--C 1.509 -0.339 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.802 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . 0.565 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 148.16 -55.8 0.5 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-O 119.234 -0.759 . . . . 0.0 111.229 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.607 HG23 HD11 ' C' ' 31' ' ' ILE . 73.3 t -144.72 139.85 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 118.355 1.078 . . . . 0.0 108.805 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 86.7 t . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 118.074 -0.965 . . . . 0.0 111.321 178.705 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -81.46 139.37 35.24 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.835 0.35 . . . . 0.0 110.609 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -85.36 110.0 18.8 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.632 HG12 ' H ' ' R' ' 12' ' ' VAL . 34.4 m -141.13 165.27 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.434 ' CD2' ' N ' ' Q' ' 13' ' ' HIS . 3.1 m-70 -132.93 121.13 22.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.785 178.326 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.588 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 32.1 m-70 -144.82 161.83 38.29 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.626 178.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.597 ' NE2' ' CG1' ' O' ' 36' ' ' VAL . 58.1 tp60 -90.09 157.81 17.6 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.52 102.34 4.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 176.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.594 HD22 HD12 ' P' ' 17' ' ' LEU . 77.7 mt -116.14 117.11 29.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 C-N-CA 120.317 -0.553 . . . . 0.0 111.06 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 41.1 t -118.01 99.28 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 177.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.403 ' CZ ' ' HB3' ' Q' ' 17' ' ' LEU . 7.2 m-30 -110.57 107.64 17.32 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.17 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -120.49 138.84 53.6 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.989 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -147.62 151.79 36.79 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' P' ' 23' ' ' ASP . 80.5 tt0 -80.27 121.8 26.09 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.217 -179.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 67.1 t0 -136.22 52.08 1.99 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.7 142.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 25' ' ' GLY . . . 100.4 38.05 3.61 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 106.082 -2.807 . . . . 0.0 106.082 -174.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 37.2 t -69.71 104.03 2.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.003 1.382 . . . . 0.0 114.568 -172.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . 0.505 ' O ' ' C ' ' Q' ' 28' ' ' LYS . 10.8 m120 -118.82 -153.33 0.53 Allowed 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 111.824 -2.444 . . . . 0.0 105.036 178.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' O ' ' HB2' ' R' ' 30' ' ' ALA . 99.0 mttt -35.42 -41.15 0.17 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 120.354 1.434 . . . . 0.0 109.9 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.02 -65.42 2.59 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.95 1.54 . . . . 0.0 116.95 172.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . 0.576 ' HB1' ' O ' ' P' ' 30' ' ' ALA . . . -171.01 174.95 4.53 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.981 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.6 mt -121.12 118.08 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-N 113.347 -1.751 . . . . 0.0 107.015 176.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -120.38 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.24 0.543 . . . . 0.0 112.282 -178.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.81 114.34 2.07 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 32.0 mt -120.9 128.91 53.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 57.2 mtp -132.47 132.14 42.4 Favored 'General case' 0 CA--C 1.514 -0.405 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.314 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . 0.445 ' O ' ' N ' ' R' ' 37' ' ' GLY . 69.2 t -115.65 135.58 55.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.551 ' O ' ' N ' ' P' ' 38' ' ' GLY . . . -139.44 103.32 0.38 Allowed Glycine 0 C--N 1.306 -1.095 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 148.56 72.5 0.01 OUTLIER Glycine 0 N--CA 1.479 1.524 0 CA-C-N 119.76 1.78 . . . . 0.0 114.635 -178.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . 0.879 ' H ' HD11 ' E' ' 31' ' ' ILE . 37.2 t -18.63 125.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.601 0.761 . . . . 0.0 112.699 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.639 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -81.96 140.16 34.17 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.889 0.376 . . . . 0.0 110.589 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -113.53 128.04 56.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.711 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . 0.632 ' H ' HG12 ' Q' ' 12' ' ' VAL . 78.5 t -135.28 156.71 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.125 0.488 . . . . 0.0 110.982 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.437 ' N ' HG12 ' R' ' 12' ' ' VAL . 3.2 m-70 -144.06 132.42 22.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.252 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . 0.588 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 64.2 m80 -151.73 161.73 42.18 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.597 ' NE2' HD23 ' R' ' 17' ' ' LEU . 52.3 tt0 -90.13 158.45 17.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.89 0.376 . . . . 0.0 111.486 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.6 100.83 3.95 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.597 HD23 ' NE2' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -111.64 112.78 24.73 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.958 0.409 . . . . 0.0 109.948 179.313 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 87.6 t -117.83 101.64 12.18 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.465 ' O ' ' CD1' ' R' ' 20' ' ' PHE . 4.0 m-85 -119.43 116.83 26.96 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' R' ' 19' ' ' PHE . 80.1 m-85 -150.8 160.03 44.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 122.08 0.943 . . . . 0.0 112.384 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -129.36 145.94 51.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.129 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.77 153.87 40.63 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 122.095 0.95 . . . . 0.0 113.49 -175.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 61.0 t0 61.98 47.93 5.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 113.581 -1.645 . . . . 0.0 111.676 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.638 HG12 ' N ' ' R' ' 25' ' ' GLY . 45.4 t -59.68 171.12 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.911 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . 0.638 ' N ' HG12 ' R' ' 24' ' ' VAL . . . 161.12 31.41 0.02 OUTLIER Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 3.3 t 72.73 120.75 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 95.7 m-20 -83.04 162.3 21.44 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.428 -0.909 . . . . 0.0 111.508 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -48.08 -39.67 20.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.407 177.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.38 66.89 0.04 OUTLIER Glycine 0 CA--C 1.539 1.557 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.829 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . 0.55 ' HB2' ' O ' ' Q' ' 28' ' ' LYS . . . -71.81 159.32 34.52 Favored 'General case' 0 C--N 1.345 0.409 0 CA-C-N 117.837 0.819 . . . . 0.0 110.117 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -107.42 116.14 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -124.25 125.44 70.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-O 120.803 0.335 . . . . 0.0 110.566 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.15 121.05 3.24 Favored Glycine 0 N--CA 1.463 0.478 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.905 ' H ' HD23 ' R' ' 34' ' ' LEU . 1.2 pt? -123.15 128.26 49.81 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 121.433 0.635 . . . . 0.0 110.471 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 91.3 mmm -123.56 120.03 31.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.022 -178.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 96.2 t -100.28 115.42 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.33 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -115.25 122.97 5.78 Favored Glycine 0 CA--C 1.508 -0.384 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 177.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.92 66.48 0.46 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.428 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.691 HG22 HD11 ' F' ' 31' ' ' ILE . 26.8 m -53.89 152.59 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 117.43 0.615 . . . . 0.0 110.574 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.756 179.685 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.9 mm-40 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.705 0.288 . . . . 0.0 110.709 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.774 HG13 HG13 ' B' ' 12' ' ' VAL . 73.2 t -138.61 87.22 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.563 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -148.54 143.66 26.79 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.592 ' CD2' ' N ' ' A' ' 14' ' ' HIS . 0.5 OUTLIER -111.94 163.14 14.56 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.144 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -89.91 158.74 17.28 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -140.62 106.86 5.24 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 87.9 mt -136.11 120.09 17.54 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.917 0.78 . . . . 0.0 110.772 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.34 136.01 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.703 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -125.46 119.38 28.08 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.907 0.384 . . . . 0.0 111.203 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -108.39 118.73 37.53 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.16 117.5 30.21 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.215 0.531 . . . . 0.0 111.2 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.73 -162.56 0.33 Allowed 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 115.294 -0.867 . . . . 0.0 108.897 179.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 60.8 t0 . . . . . 0 CA--C 1.531 0.234 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.697 -179.352 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.6 m120 . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 122.016 0.912 . . . . 0.0 112.869 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 28' ' ' LYS . 99.3 mttt -46.77 -38.87 10.74 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 113.666 -1.606 . . . . 0.0 112.331 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.09 70.47 0.21 Allowed Glycine 0 CA--C 1.532 1.139 0 CA-C-N 114.575 -1.193 . . . . 0.0 114.335 -173.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' B' ' 30' ' ' ALA . . . -95.21 117.0 29.48 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 123.86 1.79 . . . . 0.0 112.071 -177.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 32.0 pt -149.59 147.78 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 112.457 -2.156 . . . . 0.0 108.589 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.406 ' O ' ' O ' ' B' ' 33' ' ' GLY . 97.8 mt -105.74 114.03 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.26 95.04 0.72 Allowed Glycine 0 N--CA 1.462 0.376 0 N-CA-C 105.639 -2.984 . . . . 0.0 105.639 177.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -142.95 151.78 41.3 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 122.664 1.221 . . . . 0.0 113.901 -176.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 89.5 mmm -106.99 108.98 20.76 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-N 112.634 -2.075 . . . . 0.0 105.616 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' B' ' 36' ' ' VAL . 24.3 t -124.14 112.05 31.1 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -178.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.486 ' CA ' ' NE2' ' C' ' 15' ' ' GLN . . . 115.48 -132.09 10.09 Favored Glycine 0 C--N 1.321 -0.296 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.436 ' O ' HG12 ' B' ' 39' ' ' VAL . . . 92.06 -63.34 2.46 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.579 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' VAL . 1.1 m -96.03 177.86 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.537 ' H ' ' HB3' ' H' ' 28' ' ' LYS . 7.3 p . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.746 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -107.06 132.41 53.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.736 0.303 . . . . 0.0 110.243 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.519 ' O ' ' CE1' ' C' ' 13' ' ' HIS . 84.2 tt0 -151.35 128.37 11.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.398 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.774 HG13 HG13 ' A' ' 12' ' ' VAL . 0.2 OUTLIER -127.05 109.93 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-O 121.438 0.637 . . . . 0.0 110.358 179.703 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.444 ' CE1' ' HD1' ' C' ' 13' ' ' HIS . 22.6 p-80 -151.21 158.97 44.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.726 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.52 ' CD2' ' ND1' ' A' ' 14' ' ' HIS . 2.8 m-70 -143.04 163.89 31.58 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.63 178.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -89.96 152.01 21.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -149.16 100.98 3.1 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 69.8 mt -122.78 121.91 37.44 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.789 0.328 . . . . 0.0 110.41 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . 0.722 HG22 HG22 ' C' ' 18' ' ' VAL . 60.6 t -125.79 125.88 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.552 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -124.17 120.88 33.57 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.57 0.224 . . . . 0.0 110.695 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -122.58 121.06 35.58 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 116.697 -0.228 . . . . 0.0 110.967 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.98 130.15 55.53 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.655 0.264 . . . . 0.0 110.611 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.452 ' CG ' ' N ' ' B' ' 23' ' ' ASP . 77.0 tt0 -66.73 154.87 39.61 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -175.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.452 ' N ' ' CG ' ' B' ' 22' ' ' GLU . 65.8 t0 -67.15 47.79 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 111.216 -2.72 . . . . 0.0 113.833 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 24' ' ' VAL . . . . . 0.739 HG12 ' H ' ' B' ' 25' ' ' GLY . 1.9 t -60.73 -179.5 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 118.388 -1.325 . . . . 0.0 111.527 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 25' ' ' GLY . . . . . 0.739 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -99.71 28.91 13.33 Favored Glycine 0 N--CA 1.471 0.999 0 CA-C-N 114.809 -1.087 . . . . 0.0 115.681 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' B' ' 27' ' ' ASN . 42.8 t -162.18 116.14 1.83 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 120.089 1.945 . . . . 0.0 113.869 -176.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' B' ' 26' ' ' SER . 10.5 m120 -22.71 164.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.848 0 O-C-N 125.311 1.632 . . . . 0.0 112.636 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' A' ' 28' ' ' LYS . 98.8 mttt -155.39 -20.71 0.11 Allowed 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 119.826 -0.75 . . . . 0.0 112.646 -177.192 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.38 97.8 0.06 OUTLIER Glycine 0 C--N 1.334 0.462 0 C-N-CA 117.497 -2.287 . . . . 0.0 109.603 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.517 ' HA ' ' O ' ' A' ' 30' ' ' ALA . . . -120.05 119.08 32.32 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 122.66 1.219 . . . . 0.0 112.505 -176.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.655 HD11 HG13 ' N' ' 39' ' ' VAL . 97.3 mt -127.45 132.29 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 113.971 -1.468 . . . . 0.0 111.097 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.602 HG22 HD11 ' C' ' 34' ' ' LEU . 23.1 mt -102.72 116.63 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -115.63 98.56 0.84 Allowed Glycine 0 C--O 1.237 0.287 0 N-CA-C 105.818 -2.913 . . . . 0.0 105.818 177.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -137.68 135.14 36.2 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 122.495 1.14 . . . . 0.0 112.558 -175.459 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 4.4 mtp -104.05 110.36 22.5 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 113.311 -1.768 . . . . 0.0 106.842 177.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.566 HG23 HG22 ' C' ' 36' ' ' VAL . 1.4 m -131.21 123.09 52.69 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.84 -113.4 0.66 Allowed Glycine 0 C--N 1.311 -0.84 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.61 -72.62 0.82 Allowed Glycine 0 CA--C 1.532 1.103 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . 0.564 HG21 ' CA ' ' H' ' 29' ' ' GLY . 3.7 p -144.58 157.48 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' B' ' 39' ' ' VAL . 20.4 m . . . . . 0 N--CA 1.473 0.686 0 CA-C-O 117.965 -1.017 . . . . 0.0 111.921 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -107.94 136.16 48.11 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -122.12 100.99 7.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.862 0.363 . . . . 0.0 110.323 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . 0.529 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 1.5 p -145.1 137.55 21.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.345 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' B' ' 11' ' ' GLU . 2.0 m-70 -147.22 135.31 21.47 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.116 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.653 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 32.8 m-70 -142.23 161.08 38.92 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.243 -0.583 . . . . 0.0 110.977 177.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.486 ' NE2' ' CA ' ' A' ' 37' ' ' GLY . 22.8 mt-30 -85.41 157.16 20.56 Favored 'General case' 0 CA--C 1.523 -0.09 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 176.109 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -159.22 91.94 1.05 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . 0.421 HD12 ' N ' ' C' ' 17' ' ' LEU . 5.2 mp -128.82 122.35 30.26 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.968 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . 0.722 HG22 HG22 ' B' ' 18' ' ' VAL . 3.9 m -124.48 120.79 59.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -113.47 108.16 16.82 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.317 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -110.59 122.01 46.72 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.41 125.72 33.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.914 0.864 . . . . 0.0 112.406 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 94.9 mt-10 -98.72 110.14 22.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 177.699 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.41 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 99.2 m-20 -140.45 49.26 1.72 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.618 -1.174 . . . . 0.0 111.2 -175.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 24' ' ' VAL . . . . . 0.556 HG12 ' N ' ' C' ' 25' ' ' GLY . 53.8 t -71.44 161.39 4.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 C-N-CA 119.339 -0.945 . . . . 0.0 109.901 -175.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 25' ' ' GLY . . . . . 0.556 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 109.46 -29.87 9.09 Favored Glycine 0 CA--C 1.531 1.031 0 N-CA-C 107.315 -2.314 . . . . 0.0 107.315 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 26' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 1.1 m 93.21 114.58 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 114.194 -1.003 . . . . 0.0 110.583 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -73.58 164.05 27.18 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.551 0.691 . . . . 0.0 112.266 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' D' ' 28' ' ' LYS . 98.9 mttt -48.01 -37.01 13.84 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 114.109 1.151 . . . . 0.0 114.109 178.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.85 77.21 0.06 OUTLIER Glycine 0 CA--C 1.536 1.367 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.971 -175.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.0 138.27 37.01 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 122.547 1.165 . . . . 0.0 113.478 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.574 HD11 HG22 ' O' ' 39' ' ' VAL . 94.1 mt -142.42 144.89 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 114.328 -1.305 . . . . 0.0 112.656 -178.763 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.551 HD13 ' CD1' ' E' ' 19' ' ' PHE . 75.6 mt -106.71 111.4 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 174.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.72 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -118.94 101.66 0.89 Allowed Glycine 0 N--CA 1.465 0.592 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 179.213 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.72 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.6 mp -141.9 148.01 38.02 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.954 1.359 . . . . 0.0 113.329 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -104.4 111.52 24.21 Favored 'General case' 0 N--CA 1.44 -0.925 0 CA-C-N 112.097 -2.319 . . . . 0.0 105.692 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.98 HG11 HD11 ' E' ' 17' ' ' LEU . 55.1 t -124.81 123.22 65.32 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.741 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -178.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.07 -113.31 0.77 Allowed Glycine 0 C--N 1.312 -0.794 0 C-N-CA 119.75 -1.214 . . . . 0.0 111.958 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.78 -73.01 2.68 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . 0.652 ' HB ' HD11 ' I' ' 31' ' ' ILE . 13.6 p -172.79 132.92 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.555 ' CG2' ' NE2' ' F' ' 13' ' ' HIS . 21.4 m . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.776 -1.107 . . . . 0.0 110.043 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.482 HG23 HG23 ' C' ' 12' ' ' VAL . 20.3 m . . . . . 0 N--CA 1.466 0.329 0 CA-C-O 121.231 0.539 . . . . 0.0 111.218 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.498 ' O ' ' CG ' ' E' ' 13' ' ' HIS . 7.6 m80 -140.07 135.6 32.76 Favored 'General case' 0 C--O 1.225 -0.194 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.032 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.653 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 1.3 t-80 -136.88 156.0 49.04 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.649 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.665 HE21 ' CD1' ' D' ' 17' ' ' LEU . 54.8 tt0 -87.55 157.15 19.23 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -162.45 92.93 0.83 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.674 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.665 ' CD1' HE21 ' D' ' 15' ' ' GLN . 23.3 mt -122.39 114.17 20.37 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.9 t -110.64 109.18 27.5 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.534 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.407 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 66.0 m-85 -109.62 107.37 17.42 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -122.24 131.58 54.0 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-O 120.737 0.303 . . . . 0.0 111.544 -177.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.06 140.01 32.44 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 122.033 0.921 . . . . 0.0 112.998 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -82.03 113.87 20.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 122.039 0.923 . . . . 0.0 111.372 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.546 ' H ' ' HB3' ' E' ' 22' ' ' GLU . 54.4 m-20 50.17 46.42 24.77 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 113.551 -1.659 . . . . 0.0 112.267 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 24' ' ' VAL . . . . . 0.707 HG12 ' N ' ' D' ' 25' ' ' GLY . 96.4 t -111.62 177.64 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 104.719 -2.326 . . . . 0.0 104.719 174.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 25' ' ' GLY . . . . . 0.707 ' N ' HG12 ' D' ' 24' ' ' VAL . . . 63.02 28.69 72.49 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 178.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 48.9 m -108.67 -120.01 0.26 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.794 0.807 . . . . 0.0 112.498 -177.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -79.94 174.05 11.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.338 -178.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' C' ' 28' ' ' LYS . 99.1 mttt 58.32 39.91 25.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 113.998 1.11 . . . . 0.0 113.998 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.11 70.99 0.95 Allowed Glycine 0 N--CA 1.477 1.422 0 C-N-CA 119.031 -1.557 . . . . 0.0 116.346 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.0 109.08 15.08 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.365 0.602 . . . . 0.0 109.917 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.565 HD11 HG23 ' P' ' 39' ' ' VAL . 2.1 mt -133.57 141.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 N-CA-C 114.101 1.148 . . . . 0.0 114.101 -177.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.578 HD13 ' CD1' ' F' ' 19' ' ' PHE . 6.4 mt -108.69 113.9 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.91 102.97 1.27 Allowed Glycine 0 C--O 1.24 0.511 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 177.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.459 HD23 HG13 ' D' ' 36' ' ' VAL . 10.5 tp -133.93 134.51 42.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 122.181 0.991 . . . . 0.0 112.877 -176.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -105.17 112.36 25.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 113.445 -1.707 . . . . 0.0 107.304 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' E' ' 37' ' ' GLY . 0.4 OUTLIER -114.17 177.06 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.165 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.414 ' HA3' ' H ' ' E' ' 37' ' ' GLY . . . 131.53 -96.29 0.33 Allowed Glycine 0 C--N 1.31 -0.877 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . 0.496 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 38.17 75.92 0.08 OUTLIER Glycine 0 CA--C 1.533 1.207 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.056 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.563 ' CG2' HD11 ' J' ' 31' ' ' ILE . 60.4 t -6.35 123.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -178.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.509 ' O ' ' NZ ' ' K' ' 28' ' ' LYS . 55.3 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.455 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -81.81 138.98 35.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -136.28 140.61 43.55 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.029 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.434 ' H ' HG12 ' D' ' 12' ' ' VAL . 70.4 t -124.35 124.97 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 110.465 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.607 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.5 OUTLIER -156.4 134.75 11.44 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 179.387 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.607 ' N ' ' ND1' ' E' ' 13' ' ' HIS . 34.8 m-70 -143.52 167.38 22.35 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.73 0.3 . . . . 0.0 110.464 179.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.63 ' NE2' HG12 ' C' ' 36' ' ' VAL . 34.4 tt0 -89.64 151.3 21.97 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 177.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 14.3 mttt -153.35 98.73 2.29 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.011 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.98 HD11 HG11 ' C' ' 36' ' ' VAL . 2.9 mt -121.84 116.13 23.88 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 178.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -111.21 101.54 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.551 ' CD1' HD13 ' C' ' 32' ' ' ILE . 41.2 m-85 -106.75 102.65 12.01 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -122.49 132.99 54.59 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-O 121.229 0.537 . . . . 0.0 112.225 -178.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -138.77 145.34 40.08 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.42 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.546 ' HB3' ' H ' ' D' ' 23' ' ' ASP . 79.5 tt0 -68.73 147.16 52.21 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 117.574 -1.65 . . . . 0.0 108.804 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.534 ' O ' ' O ' ' E' ' 24' ' ' VAL . 21.2 t70 -128.05 61.6 1.44 Allowed 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.083 -174.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' E' ' 23' ' ' ASP . 4.7 t -33.64 -110.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.318 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -113.4 46.49 1.16 Allowed Glycine 0 N--CA 1.485 1.952 0 CA-C-N 120.173 1.351 . . . . 0.0 115.421 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.515 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.8 t 91.56 111.5 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 122.318 0.247 . . . . 0.0 111.378 176.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -75.35 163.88 27.0 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.644 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.88 -39.41 25.76 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.13 0.04 OUTLIER Glycine 0 CA--C 1.544 1.849 0 C-N-CA 120.159 -1.02 . . . . 0.0 113.312 -176.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.76 145.17 50.6 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.333 1.566 . . . . 0.0 111.727 -177.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.499 HG23 HG23 ' D' ' 31' ' ' ILE . 1.3 tt -131.72 141.75 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 CA-C-O 121.675 0.75 . . . . 0.0 111.968 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 94.5 mt -124.98 131.43 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.78 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.56 117.2 2.72 Favored Glycine 0 CA--C 1.533 1.182 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 36.5 mt -123.55 122.81 39.14 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.236 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.0 mmm -119.73 129.18 54.39 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.468 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 54.2 t -94.15 135.05 29.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.985 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' D' ' 36' ' ' VAL . . . -99.9 -103.42 2.51 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -63.27 75.12 0.04 OUTLIER Glycine 0 CA--C 1.534 1.229 0 CA-C-N 113.891 -1.155 . . . . 0.0 112.48 179.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.505 HG11 ' H ' ' F' ' 39' ' ' VAL . 8.8 m . . . . . 0 CA--C 1.541 0.607 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.736 0.303 . . . . 0.0 110.6 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.481 HG12 ' NE2' ' E' ' 14' ' ' HIS . 2.6 t -108.22 106.02 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.839 0.352 . . . . 0.0 110.471 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.587 ' ND1' ' N ' ' F' ' 14' ' ' HIS . 17.1 t-80 -152.97 139.89 19.12 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.587 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 81.0 t60 -150.52 168.64 23.61 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.833 178.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.49 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 51.1 tt0 -89.56 150.35 22.46 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -151.82 96.35 2.22 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.195 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.431 HD22 HG11 ' D' ' 36' ' ' VAL . 0.3 OUTLIER -116.84 109.74 17.47 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.273 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -108.58 106.27 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.578 ' CD1' HD13 ' D' ' 32' ' ' ILE . 44.3 m-85 -109.04 107.35 17.66 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.475 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 9.2 m-85 -146.63 140.69 26.21 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 118.29 -1.364 . . . . 0.0 114.063 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.517 ' HB1' ' HB2' ' E' ' 23' ' ' ASP . . . -114.86 119.34 36.26 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.649 -2.723 . . . . 0.0 103.649 174.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -95.09 134.49 37.74 Favored 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 117.533 2.42 . . . . 0.0 117.533 -172.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 24.4 p-10 . . . . . 0 C--N 1.348 0.525 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.598 173.427 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.19 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.525 HD12 HG12 ' R' ' 39' ' ' VAL . 14.6 tt -129.61 137.83 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.451 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -132.66 140.45 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.57 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.47 124.43 3.68 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . 0.432 HD23 ' C ' ' F' ' 34' ' ' LEU . 9.3 tt -130.69 127.15 38.27 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.8 mtp -139.33 145.4 39.02 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 6.3 p -144.59 146.07 20.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.11 177.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.45 102.11 0.37 Allowed Glycine 0 C--N 1.319 -0.368 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.172 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.6 -73.56 0.3 Allowed Glycine 0 CA--C 1.536 1.381 0 C-N-CA 120.454 -0.879 . . . . 0.0 113.96 176.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.598 HG12 ' N ' ' F' ' 40' ' ' VAL . 99.1 t -146.82 163.31 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.998 0.428 . . . . 0.0 110.443 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . 0.598 ' N ' HG12 ' F' ' 39' ' ' VAL . 8.0 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.896 -1.049 . . . . 0.0 110.334 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 99.4 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 121.174 0.511 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -103.89 158.52 16.35 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.742 -179.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.618 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 18.6 t60 -85.62 166.97 15.78 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.718 -179.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.618 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 83.6 mt-30 -155.29 141.81 18.74 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.169 0.509 . . . . 0.0 110.357 178.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.629 ' C ' HD12 ' G' ' 17' ' ' LEU . 99.0 mttt -88.03 110.16 20.4 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.743 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.629 HD12 ' C ' ' G' ' 16' ' ' LYS . 11.3 mp -120.42 112.91 19.58 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.404 HG22 ' CG2' ' H' ' 18' ' ' VAL . 61.8 t -125.74 131.32 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.155 -178.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.68 128.25 42.17 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.469 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -128.29 126.78 41.49 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.75 122.61 38.52 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.706 0.765 . . . . 0.0 112.012 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -121.56 133.25 55.01 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.536 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.718 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 98.3 m-20 . . . . . 0 C--N 1.32 -0.677 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.181 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.522 ' OD1' ' NZ ' ' H' ' 28' ' ' LYS . 71.6 m-20 . . . . . 0 N--CA 1.466 0.344 0 CA-C-O 121.057 0.456 . . . . 0.0 111.541 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm 51.12 39.22 22.92 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.24 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.25 -66.67 1.59 Allowed Glycine 0 CA--C 1.539 1.565 0 C-N-CA 120.158 -1.02 . . . . 0.0 110.68 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' H' ' 30' ' ' ALA . . . -150.7 62.32 0.93 Allowed 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 119.593 1.696 . . . . 0.0 114.605 177.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 80.6 mt -136.45 113.44 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 176.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.445 ' O ' ' O ' ' H' ' 33' ' ' GLY . 96.4 mt -107.87 106.2 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.606 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.03 97.17 0.94 Allowed Glycine 0 CA--C 1.508 -0.357 0 N-CA-C 104.95 -3.26 . . . . 0.0 104.95 176.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.833 ' O ' HD12 ' H' ' 34' ' ' LEU . 52.4 tp -155.63 154.39 31.54 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 118.188 -1.405 . . . . 0.0 113.361 -175.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 8.1 mtp -112.11 122.47 47.83 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-N 112.989 -1.914 . . . . 0.0 108.655 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.704 HG21 ' CD1' ' I' ' 17' ' ' LEU . 35.9 m -131.32 112.07 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.69 -132.07 10.94 Favored Glycine 0 CA--C 1.519 0.303 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.53 -62.64 0.42 Allowed Glycine 0 CA--C 1.536 1.37 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 t -92.78 164.41 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 40' ' ' VAL . . . . . 0.552 ' N ' ' CG2' ' H' ' 39' ' ' VAL . 8.5 p . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.991 -1.005 . . . . 0.0 110.585 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.196 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 44.3 t80 -71.38 133.5 46.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.906 0.384 . . . . 0.0 110.587 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -94.29 115.62 27.89 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.388 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.15 136.09 32.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.338 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.501 ' NE2' ' OE2' ' I' ' 11' ' ' GLU . 81.0 m80 -113.4 149.54 33.98 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 9.6 p-80 -86.82 164.15 16.82 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.983 -179.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -100.81 152.6 20.32 Favored 'General case' 0 CA--C 1.522 -0.098 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.837 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -110.84 107.86 17.49 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 177.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -123.16 117.38 25.24 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.404 ' CG2' HG22 ' G' ' 18' ' ' VAL . 12.9 m -132.14 133.76 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.132 0.491 . . . . 0.0 111.033 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -129.91 129.65 44.14 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.559 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.408 ' CE2' ' CG ' ' I' ' 20' ' ' PHE . 29.2 m-85 -127.43 131.57 50.22 Favored 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.465 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.19 122.38 31.73 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 82.6 tt0 -147.17 121.67 9.73 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 114.621 1.341 . . . . 0.0 114.621 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.718 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 1.7 p-10 156.24 -74.5 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.379 175.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.741 HG22 ' N ' ' H' ' 25' ' ' GLY . 3.6 p -67.53 -112.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.713 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 25' ' ' GLY . . . . . 0.741 ' N ' HG22 ' H' ' 24' ' ' VAL . . . 126.39 -38.76 2.14 Favored Glycine 0 N--CA 1.454 -0.128 0 CA-C-N 113.866 -1.516 . . . . 0.0 111.133 176.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 16.2 t -70.4 112.7 6.89 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 174.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -113.68 168.54 9.69 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.815 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 28' ' ' LYS . . . . . 0.537 ' HB3' ' H ' ' A' ' 40' ' ' VAL . 99.2 mttt -39.39 -38.42 0.55 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.618 -1.173 . . . . 0.0 111.091 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 29' ' ' GLY . . . . . 0.564 ' CA ' HG21 ' B' ' 39' ' ' VAL . . . 179.72 77.08 0.06 OUTLIER Glycine 0 CA--C 1.535 1.314 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.909 -176.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' I' ' 30' ' ' ALA . . . -51.49 91.14 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 119.131 1.466 . . . . 0.0 112.157 -177.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.402 ' N ' ' O ' ' H' ' 29' ' ' GLY . 96.8 mt -134.21 138.63 49.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.135 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.571 HD13 ' CD1' ' J' ' 19' ' ' PHE . 96.8 mt -108.32 104.95 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 177.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -105.13 97.09 1.29 Allowed Glycine 0 N--CA 1.461 0.3 0 N-CA-C 104.565 -3.414 . . . . 0.0 104.565 176.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.833 HD12 ' O ' ' G' ' 34' ' ' LEU . 15.2 tp -143.09 136.43 28.29 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 118.731 -1.187 . . . . 0.0 113.044 -174.081 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.8 mtp -105.18 118.82 37.52 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 113.176 -1.829 . . . . 0.0 106.845 178.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.576 HG12 ' CD ' ' J' ' 15' ' ' GLN . 10.9 t -130.03 102.62 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -177.346 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.43 -162.49 12.38 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.16 -55.44 0.52 Allowed Glycine 0 CA--C 1.542 1.747 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 1.085 HG12 HD12 ' N' ' 31' ' ' ILE . 1.8 m -127.99 161.57 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.45 ' OXT' ' O ' ' O' ' 28' ' ' LYS . 46.6 t . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.012 177.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.93 135.45 48.46 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.793 0.33 . . . . 0.0 110.367 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 11' ' ' GLU . . . . . 0.501 ' OE2' ' NE2' ' H' ' 13' ' ' HIS . 97.3 mt-10 -74.35 109.4 7.8 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.475 ' CG2' ' O ' ' J' ' 12' ' ' VAL . 23.2 m -139.27 159.79 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.942 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.477 ' CD2' ' OXT' ' G' ' 40' ' ' VAL . 78.0 m80 -69.78 114.25 7.8 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.611 -178.116 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.645 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 13.2 t60 -161.9 169.98 20.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.273 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.645 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 57.9 tt0 -156.27 140.28 16.34 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 120.191 -0.603 . . . . 0.0 110.4 177.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -97.92 113.94 25.9 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 178.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.704 ' CD1' HG21 ' G' ' 36' ' ' VAL . 58.8 mt -121.98 114.22 20.66 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.4 t -116.41 109.68 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.444 ' CD1' HD13 ' G' ' 32' ' ' ILE . 74.1 m-85 -108.01 106.44 16.67 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.408 ' CG ' ' CE2' ' H' ' 20' ' ' PHE . 35.3 t80 -120.6 132.97 55.4 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -176.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . 0.66 ' HB3' HG21 ' I' ' 24' ' ' VAL . . . -149.7 146.5 27.27 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-O 121.63 0.729 . . . . 0.0 112.651 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.422 ' OE2' ' OE2' ' H' ' 22' ' ' GLU . 77.9 mt-10 -103.88 151.55 22.99 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.837 178.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.602 ' N ' ' O ' ' J' ' 22' ' ' GLU . 71.4 m-20 57.47 48.79 13.93 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.14 0.495 . . . . 0.0 110.405 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.662 HG23 ' HB1' ' J' ' 21' ' ' ALA . 0.1 OUTLIER -137.4 -173.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-O 121.66 0.743 . . . . 0.0 110.824 -177.23 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 28.2 67.67 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -177.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.538 ' HB2' HG21 ' J' ' 24' ' ' VAL . 71.3 m -143.56 -128.18 0.09 Allowed 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.548 ' CG ' ' H ' ' I' ' 28' ' ' LYS . 50.5 t30 54.38 -159.48 0.17 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 178.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.548 ' H ' ' CG ' ' I' ' 27' ' ' ASN . 64.1 mttp -64.46 -39.61 94.14 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.46 1.652 . . . . 0.0 115.46 -173.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.31 66.31 0.25 Allowed Glycine 0 N--CA 1.472 1.067 0 C-N-CA 118.52 -1.8 . . . . 0.0 114.616 -175.127 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' H' ' 30' ' ' ALA . . . -82.7 131.95 35.19 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 122.156 0.979 . . . . 0.0 112.111 -178.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.652 HD11 ' HB ' ' C' ' 39' ' ' VAL . 50.5 mt -144.05 143.4 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 114.447 -1.251 . . . . 0.0 113.585 -177.036 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.421 HD12 HG12 ' J' ' 32' ' ' ILE . 54.1 mt -105.15 101.99 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 173.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -103.62 98.5 1.61 Allowed Glycine 0 CA--C 1.507 -0.452 0 N-CA-C 104.913 -3.275 . . . . 0.0 104.913 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.596 HD12 ' O ' ' H' ' 34' ' ' LEU . 23.7 tp -140.13 135.12 32.17 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 122.287 1.041 . . . . 0.0 113.281 -173.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.408 ' N ' HD12 ' I' ' 34' ' ' LEU . 5.9 mtp -109.43 117.66 34.61 Favored 'General case' 0 CA--C 1.512 -0.484 0 CA-C-N 113.612 -1.631 . . . . 0.0 107.205 177.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.565 HG11 HD11 ' K' ' 17' ' ' LEU . 4.4 t -130.42 111.82 21.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 CA-C-O 120.624 0.25 . . . . 0.0 110.736 -177.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.759 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 138.33 -131.07 5.23 Favored Glycine 0 C--N 1.318 -0.434 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.144 177.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.05 -61.76 0.39 Allowed Glycine 0 CA--C 1.543 1.828 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . 0.746 HG21 ' HA2' ' O' ' 29' ' ' GLY . 4.0 p -146.21 151.25 14.59 Favored 'Isoleucine or valine' 0 C--N 1.344 0.339 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 175.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.506 HG23 ' O ' ' I' ' 39' ' ' VAL . 58.6 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.753 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.62 133.04 51.01 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.928 0.394 . . . . 0.0 110.732 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -85.18 125.29 32.71 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.912 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.483 ' CG1' ' NE2' ' J' ' 14' ' ' HIS . 96.0 t -125.82 108.64 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.621 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -111.78 124.38 52.22 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.883 ' HD1' ' H ' ' K' ' 14' ' ' HIS . 47.1 m-70 -148.67 162.9 38.8 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 120.29 -0.564 . . . . 0.0 109.735 174.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.719 ' NE2' HE21 ' K' ' 15' ' ' GLN . 85.0 mt-30 -100.69 147.17 26.31 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.114 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 13.8 mttt -118.34 92.37 3.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.895 HD12 HD22 ' K' ' 17' ' ' LEU . 6.9 mt -117.24 115.54 25.5 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.693 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.7 t -113.5 102.38 13.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.571 ' CD1' HD13 ' H' ' 32' ' ' ILE . 64.6 m-85 -104.05 107.09 17.83 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 178.222 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.567 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -121.95 124.07 43.17 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.622 -176.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . 0.662 ' HB1' HG23 ' I' ' 24' ' ' VAL . . . -136.27 115.48 12.52 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' I' ' 23' ' ' ASP . 98.0 mt-10 -120.18 177.74 4.9 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 118.333 2.716 . . . . 0.0 118.333 -174.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 41.5 t0 28.62 46.31 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 119.946 3.313 . . . . 0.0 119.946 175.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.656 HG22 ' N ' ' I' ' 24' ' ' VAL . 0.2 OUTLIER -80.57 -179.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 175.105 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.05 -29.23 69.18 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 118.126 -1.988 . . . . 0.0 112.274 -178.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.421 ' O ' ' C ' ' J' ' 27' ' ' ASN . 1.5 t 168.16 127.24 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.813 0.807 . . . . 0.0 112.079 175.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.506 HD21 ' N ' ' J' ' 30' ' ' ALA . 2.0 t-20 -37.21 133.94 0.63 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.733 174.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' I' ' 27' ' ' ASN . 67.6 mttm -109.27 -40.27 4.98 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 118.969 0.804 . . . . 0.0 111.118 177.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.45 64.35 0.24 Allowed Glycine 0 CA--C 1.541 1.718 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.924 -178.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.506 ' N ' HD21 ' J' ' 27' ' ' ASN . . . -83.7 143.26 30.15 Favored 'General case' 0 C--O 1.245 0.855 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -177.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.563 HD11 ' CG2' ' D' ' 39' ' ' VAL . 79.9 mt -135.78 131.0 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 114.832 -1.076 . . . . 0.0 111.677 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.425 ' O ' HG22 ' J' ' 32' ' ' ILE . 3.0 mt -106.22 110.36 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 176.275 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 99.0 1.06 Allowed Glycine 0 C--O 1.239 0.441 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 177.018 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.546 HD12 ' O ' ' I' ' 34' ' ' LEU . 24.3 tp -134.93 123.59 23.62 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.414 1.102 . . . . 0.0 113.697 -175.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.43 ' N ' HD12 ' J' ' 34' ' ' LEU . 2.2 ttm -98.29 116.69 31.05 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 176.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.518 HG21 HD23 ' L' ' 17' ' ' LEU . 0.5 OUTLIER -130.11 103.3 8.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 C-N-CA 121.365 -0.134 . . . . 0.0 111.049 -177.434 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.22 -153.72 25.23 Favored Glycine 0 CA--C 1.509 -0.283 0 C-N-CA 120.035 -1.079 . . . . 0.0 112.358 178.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.493 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 138.73 -56.31 0.65 Allowed Glycine 0 CA--C 1.544 1.898 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.787 -178.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . 0.53 HG12 ' N ' ' J' ' 40' ' ' VAL . 87.8 t -135.93 157.89 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 40' ' ' VAL . . . . . 0.53 ' N ' HG12 ' J' ' 39' ' ' VAL . 17.3 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.528 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -108.85 146.54 33.52 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.854 0.359 . . . . 0.0 110.561 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -70.32 128.81 37.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -111.94 121.05 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.785 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.628 ' CE1' ' NZ ' ' P' ' 28' ' ' LYS . 6.6 p80 -151.59 113.72 4.51 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.377 -0.529 . . . . 0.0 112.027 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.883 ' H ' ' HD1' ' J' ' 14' ' ' HIS . 13.4 p-80 -153.34 160.31 42.65 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.389 177.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.759 HE22 ' N ' ' I' ' 37' ' ' GLY . 88.3 mt-30 -90.12 160.08 16.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.213 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -139.42 109.38 6.37 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.457 0.646 . . . . 0.0 109.902 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.895 HD22 HD12 ' J' ' 17' ' ' LEU . 1.1 mt -118.55 122.41 42.58 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.865 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 16.7 t -113.49 101.05 11.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -100.79 102.67 13.8 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 105.232 -2.136 . . . . 0.0 105.232 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CD1' ' L' ' 20' ' ' PHE . 1.4 t80 -113.4 124.96 53.66 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -177.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' K' ' 23' ' ' ASP . . . -160.76 162.78 32.51 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 -177.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -72.36 136.83 46.25 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.729 ' CG ' ' HB1' ' L' ' 21' ' ' ALA . 6.4 m-20 -152.5 61.03 0.82 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.987 1.477 . . . . 0.0 114.987 -173.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.669 ' O ' ' O ' ' K' ' 23' ' ' ASP . 34.4 t -44.16 -110.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' K' ' 27' ' ' ASN . . . 162.82 -46.51 0.33 Allowed Glycine 0 CA--C 1.506 -0.519 0 C-N-CA 116.707 -2.663 . . . . 0.0 115.781 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m -65.99 101.56 0.69 Allowed 'General case' 0 CA--C 1.519 -0.25 0 CA-C-N 123.605 3.702 . . . . 0.0 104.373 178.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.539 ' N ' ' O ' ' K' ' 25' ' ' GLY . 28.2 m-20 -130.04 161.4 31.08 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 114.847 -1.069 . . . . 0.0 112.455 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.509 ' NZ ' ' O ' ' D' ' 40' ' ' VAL . 61.3 tttt -28.71 -39.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.833 172.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . 141.75 73.81 0.04 OUTLIER Glycine 0 CA--C 1.545 1.914 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.103 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.44 150.03 46.63 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 121.804 0.811 . . . . 0.0 112.681 -177.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.418 ' CG1' HG22 ' L' ' 31' ' ' ILE . 2.6 mp -136.42 138.26 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 CA-C-N 114.689 -1.141 . . . . 0.0 112.78 -177.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -117.68 119.99 63.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 178.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.46 117.41 3.31 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 67.7 mt -123.47 129.18 50.86 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 73.2 mtp -137.61 136.68 37.75 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.365 -0.934 . . . . 0.0 113.061 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.495 ' HB ' HG13 ' L' ' 36' ' ' VAL . 10.8 t -113.31 155.27 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.149 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -52.25 -102.34 0.01 OUTLIER Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' L' ' 38' ' ' GLY . . . -138.03 -74.6 0.06 OUTLIER Glycine 0 CA--C 1.527 0.792 0 C-N-CA 120.823 -0.704 . . . . 0.0 113.177 178.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . 0.74 HG13 HD11 ' Q' ' 31' ' ' ILE . 6.6 m . . . . . 0 CA--C 1.514 -0.428 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.428 -178.698 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 . . . . . 0 N--CA 1.465 0.293 0 CA-C-O 120.634 0.254 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 91.1 t -111.91 101.41 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 121.265 0.555 . . . . 0.0 110.877 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.481 ' O ' ' CG ' ' L' ' 14' ' ' HIS . 5.0 p80 -147.2 90.82 1.92 Allowed 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.639 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.481 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 69.3 m80 -158.19 168.31 27.42 Favored 'General case' 0 C--O 1.223 -0.295 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.461 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 94.8 mm-40 -89.84 158.45 17.46 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -139.92 105.27 5.06 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.465 0.65 . . . . 0.0 110.492 178.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.518 HD23 HG21 ' J' ' 36' ' ' VAL . 0.2 OUTLIER -116.16 113.9 23.73 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.695 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -106.79 103.85 16.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -99.78 101.71 12.94 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.574 ' CD1' ' CZ ' ' K' ' 20' ' ' PHE . 15.1 t80 -110.04 103.13 11.83 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.729 ' HB1' ' CG ' ' K' ' 23' ' ' ASP . . . -132.87 137.31 46.64 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 -178.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.525 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.9 mt-10 -78.62 102.77 8.15 Favored 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 118.879 -1.128 . . . . 0.0 108.636 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 44.2 p-10 -155.77 46.62 0.48 Allowed 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 112.786 0.661 . . . . 0.0 112.786 -177.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 32.9 m -83.22 172.69 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 118.819 -1.152 . . . . 0.0 109.788 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 96.02 -28.68 11.86 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.9 t 91.68 119.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.533 ' O ' ' N ' ' L' ' 29' ' ' GLY . 15.4 m-20 -71.95 150.3 44.24 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.221 -179.013 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -53.17 47.45 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 101.77 63.38 0.75 Allowed Glycine 0 CA--C 1.543 1.799 0 C-N-CA 119.928 -1.129 . . . . 0.0 114.088 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.63 169.46 10.06 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 178.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.418 HG22 ' CG1' ' K' ' 31' ' ' ILE . 12.6 tt -139.8 151.03 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.16 0 C-N-CA 119.008 -1.077 . . . . 0.0 113.626 -177.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 15.0 tt -135.48 134.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.152 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.64 134.22 6.52 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.315 -0.469 . . . . 0.0 111.971 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tt -127.25 124.72 39.51 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mtp -140.86 146.58 37.7 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -177.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.495 HG13 ' HB ' ' K' ' 36' ' ' VAL . 8.8 t -139.33 132.13 37.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.463 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -106.97 112.42 3.76 Favored Glycine 0 N--CA 1.468 0.794 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.023 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . 112.52 71.25 0.58 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 117.522 0.661 . . . . 0.0 112.477 178.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' L' ' 38' ' ' GLY . 66.2 t . . . . . 0 N--CA 1.478 0.956 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 . . . . . 0 N--CA 1.46 0.046 0 N-CA-C 110.154 -0.314 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' M' M ' 12' ' ' VAL . . . . . 0.42 HG23 ' O ' ' M' ' 12' ' ' VAL . 29.0 m -114.9 130.13 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.95 0.405 . . . . 0.0 110.714 -179.6 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 75.6 m80 -95.06 165.8 12.25 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 14' ' ' HIS . . . . . 0.481 ' CD2' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -86.47 168.0 14.15 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.498 -179.36 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -129.17 150.72 50.44 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -97.62 120.91 38.85 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.595 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.29 115.3 20.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -140.34 140.59 34.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.383 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -143.18 141.32 31.11 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.095 0.474 . . . . 0.0 110.674 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 20' ' ' PHE . . . . . 0.484 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 53.1 p90 -127.4 128.38 45.73 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.66 127.41 46.24 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.329 0.585 . . . . 0.0 111.378 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -138.67 146.34 41.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.94 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 58.47 59.84 2.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.44 . . . . 0.0 112.173 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 24' ' ' VAL . . . . . 0.765 HG12 ' H ' ' M' ' 25' ' ' GLY . 4.1 t 70.59 175.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.514 0.673 . . . . 0.0 111.732 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 25' ' ' GLY . . . . . 0.765 ' H ' HG12 ' M' ' 24' ' ' VAL . . . 100.65 -34.72 5.35 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.948 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 6.1 p -82.92 -121.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 176.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 27' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' M' ' 31' ' ' ILE . 8.9 p30 -92.42 161.21 14.74 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 176.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 28' ' ' LYS . . . . . 0.413 ' O ' ' CD ' ' N' ' 28' ' ' LYS . 72.8 tttt -45.29 -39.2 6.32 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 119.139 -1.025 . . . . 0.0 110.517 -179.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 29' ' ' GLY . . . . . 0.445 ' O ' ' OD2' ' N' ' 23' ' ' ASP . . . -146.9 -76.18 0.02 OUTLIER Glycine 0 N--CA 1.473 1.11 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.893 177.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.76 87.81 0.82 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-O 121.129 0.49 . . . . 0.0 111.611 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 31' ' ' ILE . . . . . 0.658 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -138.33 115.56 11.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 32' ' ' ILE . . . . . 0.42 HD13 HG21 ' M' ' 32' ' ' ILE . 43.1 mt -107.09 109.37 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.88 92.46 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 105.886 -2.885 . . . . 0.0 105.886 177.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -143.56 167.16 22.87 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 114.927 1.455 . . . . 0.0 114.927 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -123.45 106.58 10.75 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 112.108 -2.315 . . . . 0.0 107.062 177.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 36' ' ' VAL . . . . . 0.551 HG21 HD21 ' O' ' 17' ' ' LEU . 43.9 t -112.46 111.97 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 CA-C-O 121.264 0.554 . . . . 0.0 109.835 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.42 -131.7 7.74 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' M' M ' 38' ' ' GLY . . . . . 0.492 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 94.47 -63.27 1.66 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.786 -1.325 . . . . 0.0 109.786 -178.289 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 39' ' ' VAL . . . . . 0.436 HG22 ' H ' ' M' ' 39' ' ' VAL . 4.7 m -96.65 173.51 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' M' M ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' N' ' 40' ' ' VAL . 26.8 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.938 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -106.42 134.8 49.0 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.764 0.316 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -114.97 119.71 37.43 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.796 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 12' ' ' VAL . . . . . 0.415 ' CG1' ' HE2' ' N' ' 14' ' ' HIS . 58.8 t -126.96 131.4 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -142.32 130.27 21.83 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.443 0.64 . . . . 0.0 112.63 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 14' ' ' HIS . . . . . 0.513 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 33.0 m-70 -153.1 172.39 16.97 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.218 177.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -155.18 141.0 18.15 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.821 -0.751 . . . . 0.0 109.741 177.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -88.53 113.66 24.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.161 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 17' ' ' LEU . . . . . 0.418 ' N ' HD12 ' N' ' 17' ' ' LEU . 8.3 mp -111.24 113.1 25.36 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.245 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.12 132.16 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-O 120.891 0.377 . . . . 0.0 111.35 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -141.23 127.45 19.69 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.956 0.408 . . . . 0.0 111.835 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -117.23 131.58 56.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.29 133.23 34.75 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -122.02 145.31 48.26 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.359 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' M' ' 29' ' ' GLY . 51.6 m-20 -160.94 46.68 0.21 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.918 0.39 . . . . 0.0 111.161 -178.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 m -73.35 -179.79 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.74 0.781 . . . . 0.0 111.99 -178.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.17 -35.33 4.76 Favored Glycine 0 CA--C 1.53 0.99 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.95 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' N' ' 27' ' ' ASN . 84.8 p -162.56 117.04 1.79 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 118.061 0.931 . . . . 0.0 110.874 176.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' N' ' 26' ' ' SER . 55.6 p30 -21.63 161.73 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 28' ' ' LYS . . . . . 0.454 ' CG ' ' O ' ' N' ' 27' ' ' ASN . 60.5 mttm -158.61 -10.3 0.07 Allowed 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 120.389 -0.524 . . . . 0.0 112.405 174.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.36 118.12 0.64 Allowed Glycine 0 CA--C 1.537 1.408 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.631 178.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 30' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' O' ' 29' ' ' GLY . . . -102.91 113.33 26.7 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-O 121.599 0.714 . . . . 0.0 111.98 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 31' ' ' ILE . . . . . 1.085 HD12 HG12 ' H' ' 39' ' ' VAL . 81.4 mt -135.5 131.05 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 32' ' ' ILE . . . . . 0.608 HD13 ' CD1' ' P' ' 19' ' ' PHE . 92.8 mt -107.08 111.04 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -116.0 105.6 1.42 Allowed Glycine 0 C--N 1.322 -0.234 0 N-CA-C 105.217 -3.153 . . . . 0.0 105.217 176.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 34' ' ' LEU . . . . . 0.633 ' O ' HD12 ' O' ' 34' ' ' LEU . 7.0 tt -152.77 140.75 20.23 Favored 'General case' 0 CA--C 1.504 -0.8 0 C-N-CA 117.953 -1.499 . . . . 0.0 111.747 -174.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 45.3 mtp -114.29 116.02 28.32 Favored 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.664 -1.607 . . . . 0.0 107.825 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -93.65 102.84 14.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 37' ' ' GLY . . . . . 0.492 ' HA3' ' H ' ' M' ' 38' ' ' GLY . . . -35.38 152.74 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.121 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 38' ' ' GLY . . . . . 0.563 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -85.28 -57.55 2.21 Favored Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.837 -0.697 . . . . 0.0 114.326 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 39' ' ' VAL . . . . . 0.655 HG13 HD11 ' B' ' 31' ' ' ILE . 6.1 m -52.85 140.97 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 119.42 1.61 . . . . 0.0 110.812 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' N' N ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' M' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.552 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -106.53 127.24 53.16 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 11' ' ' GLU . . . . . 0.472 ' O ' ' NE2' ' P' ' 13' ' ' HIS . 97.4 mt-10 -146.7 158.96 44.02 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.809 0.337 . . . . 0.0 111.01 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 12' ' ' VAL . . . . . 0.418 HG12 ' CE1' ' N' ' 14' ' ' HIS . 55.2 t -129.53 118.3 45.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.659 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -134.36 137.56 44.23 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 14' ' ' HIS . . . . . 0.698 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 66.2 t60 -151.12 153.2 34.57 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 119.027 -1.069 . . . . 0.0 112.278 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 15.2 tp60 -87.83 158.8 18.65 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.263 0.625 . . . . 0.0 110.791 177.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 16' ' ' LYS . . . . . 0.602 ' C ' HD12 ' O' ' 17' ' ' LEU . 71.5 tttt -159.09 95.21 1.25 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.252 176.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 17' ' ' LEU . . . . . 0.602 HD12 ' C ' ' O' ' 16' ' ' LYS . 8.2 mp -116.45 127.16 54.34 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.283 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -127.23 107.04 16.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.91 113.23 25.43 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 20' ' ' PHE . . . . . 0.481 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 45.8 t80 -111.77 121.53 45.32 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.19 136.91 47.38 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 122.065 0.936 . . . . 0.0 112.492 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 22' ' ' GLU . . . . . 0.498 ' HG2' ' H ' ' O' ' 23' ' ' ASP . 51.6 tt0 -65.85 179.59 0.85 Allowed 'General case' 0 N--CA 1.444 -0.758 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 178.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 23' ' ' ASP . . . . . 0.498 ' H ' ' HG2' ' O' ' 22' ' ' GLU . 1.8 m-20 167.59 58.8 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.978 -174.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 24' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' O' ' 23' ' ' ASP . 18.4 t -62.92 -114.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -177.237 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.01 43.51 1.66 Allowed Glycine 0 N--CA 1.47 0.922 0 CA-C-N 121.71 2.05 . . . . 0.0 109.677 -176.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 19.4 t -74.37 99.93 3.64 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 111.479 -2.36 . . . . 0.0 108.724 174.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -94.72 -161.73 0.88 Allowed 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.617 0.722 . . . . 0.0 112.045 -177.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 28' ' ' LYS . . . . . 0.587 ' NZ ' ' CB ' ' K' ' 13' ' ' HIS . 70.5 tttt 38.38 40.54 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 29' ' ' GLY . . . . . 0.746 ' HA2' HG21 ' I' ' 39' ' ' VAL . . . -177.72 62.34 0.09 OUTLIER Glycine 0 CA--C 1.541 1.672 0 C-N-CA 118.974 -1.584 . . . . 0.0 115.221 173.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.45 90.4 3.29 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 118.05 0.925 . . . . 0.0 110.883 174.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 71.3 mt -140.96 132.94 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-N 120.869 1.668 . . . . 0.0 113.826 -179.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 32' ' ' ILE . . . . . 0.6 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 78.1 mt -109.88 109.0 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.1 99.28 1.06 Allowed Glycine 0 C--O 1.239 0.414 0 N-CA-C 105.547 -3.021 . . . . 0.0 105.547 177.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 34' ' ' LEU . . . . . 0.633 HD12 ' O ' ' N' ' 34' ' ' LEU . 10.3 tp -128.23 130.56 48.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 122.458 1.123 . . . . 0.0 113.507 -174.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.94 104.24 13.95 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 36' ' ' VAL . . . . . 0.559 HG11 ' CD2' ' Q' ' 17' ' ' LEU . 8.0 p -131.48 142.55 42.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.81 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.97 -102.04 0.82 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.46 -80.17 0.06 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' O' O ' 39' ' ' VAL . . . . . 0.574 HG22 HD11 ' C' ' 31' ' ' ILE . 3.4 m -148.44 167.66 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 176.308 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' O' O ' 40' ' ' VAL . . . . . 0.774 HG13 ' HE2' ' Q' ' 13' ' ' HIS . 1.4 p . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.377 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 121.044 0.449 . . . . 0.0 110.495 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' P' P ' 13' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 86.3 m-70 -142.48 118.81 10.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.437 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 14' ' ' HIS . . . . . 0.698 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 0.0 OUTLIER -146.9 170.74 16.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.472 0.653 . . . . 0.0 111.821 -179.552 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' P' P ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG2' ' O' ' 36' ' ' VAL . 47.7 tt0 -107.45 149.8 27.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.448 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -139.91 110.64 6.78 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 176.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mt -126.88 116.67 21.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -110.11 105.54 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 19' ' ' PHE . . . . . 0.608 ' CD1' HD13 ' N' ' 32' ' ' ILE . 92.5 m-85 -106.59 107.19 18.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 179.192 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 20' ' ' PHE . . . . . 0.596 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 31.3 t80 -116.06 124.29 50.05 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.73 -178.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.41 138.25 30.97 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.75 0.786 . . . . 0.0 112.432 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 22' ' ' GLU . . . . . 0.504 ' O ' ' CB ' ' P' ' 23' ' ' ASP . 20.9 tt0 -76.81 -174.54 3.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 23' ' ' ASP . . . . . 0.504 ' CB ' ' O ' ' P' ' 22' ' ' GLU . 10.3 m-20 142.99 50.02 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 p -82.78 149.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 C-N-CA 119.341 -0.943 . . . . 0.0 111.404 -177.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 25' ' ' GLY . . . . . 0.406 ' O ' ' OG ' ' P' ' 26' ' ' SER . . . 93.23 36.81 5.83 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-N 113.614 -1.63 . . . . 0.0 111.848 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 26' ' ' SER . . . . . 0.59 ' N ' ' O ' ' Q' ' 24' ' ' VAL . 3.4 p 72.65 120.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 27' ' ' ASN . . . . . 0.868 HD22 ' H ' ' P' ' 29' ' ' GLY . 10.4 t30 -83.2 161.75 21.44 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.809 175.24 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 28' ' ' LYS . . . . . 0.628 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 75.4 tttt -48.54 -39.38 23.26 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 113.461 0.912 . . . . 0.0 113.461 177.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 29' ' ' GLY . . . . . 0.868 ' H ' HD22 ' P' ' 27' ' ' ASN . . . 171.59 68.85 0.04 OUTLIER Glycine 0 CA--C 1.544 1.863 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -174.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.22 145.76 51.17 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 119.062 1.431 . . . . 0.0 114.673 -173.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 31' ' ' ILE . . . . . 0.507 HD12 HG22 ' J' ' 39' ' ' VAL . 75.2 mt -136.08 133.94 50.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 CA-C-N 113.46 -1.7 . . . . 0.0 113.651 -177.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 32' ' ' ILE . . . . . 0.423 HD13 HG21 ' P' ' 32' ' ' ILE . 55.0 mt -107.67 117.06 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 175.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.77 102.02 1.06 Allowed Glycine 0 N--CA 1.466 0.657 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 176.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 34' ' ' LEU . . . . . 0.612 HD23 HG22 ' P' ' 36' ' ' VAL . 0.3 OUTLIER -126.25 132.36 51.72 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -175.571 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -109.17 99.71 8.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.2 -2.519 . . . . 0.0 104.2 174.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 36' ' ' VAL . . . . . 0.612 HG22 HD23 ' P' ' 34' ' ' LEU . 1.4 t -114.06 103.15 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.719 -175.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.31 -153.77 25.46 Favored Glycine 0 C--N 1.319 -0.39 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.813 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.43 -56.03 0.57 Allowed Glycine 0 CA--C 1.545 1.946 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -178.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' P' P ' 39' ' ' VAL . . . . . 0.565 HG23 HD11 ' D' ' 31' ' ' ILE . 0.9 OUTLIER -153.24 157.55 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 177.566 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' P' P ' 40' ' ' VAL . . . . . 0.602 HG13 ' CD2' ' R' ' 13' ' ' HIS . 7.0 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.459 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.56 135.1 54.28 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.805 0.336 . . . . 0.0 110.468 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 11' ' ' GLU . . . . . 0.411 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 96.5 mt-10 -87.26 119.61 27.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.984 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 12' ' ' VAL . . . . . 0.482 ' O ' HG23 ' Q' ' 12' ' ' VAL . 33.3 m -118.32 126.1 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.075 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 13' ' ' HIS . . . . . 0.774 ' HE2' HG13 ' O' ' 40' ' ' VAL . 0.1 OUTLIER -152.74 140.55 20.03 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.989 -179.525 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' Q' Q ' 14' ' ' HIS . . . . . 0.608 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 1.1 p80 -159.68 161.7 34.96 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 15' ' ' GLN . . . . . 0.431 ' HB3' HD11 ' Q' ' 17' ' ' LEU . 75.5 mt-30 -90.02 158.71 17.22 Favored 'General case' 0 CA--C 1.516 -0.349 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.747 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -140.81 101.9 4.17 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 176.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 17' ' ' LEU . . . . . 0.56 ' N ' HD12 ' Q' ' 17' ' ' LEU . 1.1 mp -119.06 113.42 20.91 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.92 106.63 21.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 19' ' ' PHE . . . . . 0.6 ' CD1' HD13 ' O' ' 32' ' ' ILE . 72.2 m-85 -107.04 103.05 12.37 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 20' ' ' PHE . . . . . 0.596 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 37.3 t80 -108.79 118.32 36.47 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 21' ' ' ALA . . . . . 0.471 ' O ' ' OE1' ' R' ' 22' ' ' GLU . . . -140.79 138.02 33.78 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.85 0.833 . . . . 0.0 112.967 -179.106 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' P' ' 23' ' ' ASP . 94.7 mt-10 -85.03 122.34 29.11 Favored 'General case' 0 C--O 1.22 -0.497 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 177.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 23' ' ' ASP . . . . . 0.417 ' CG ' ' O ' ' Q' ' 22' ' ' GLU . 35.4 m-20 -162.44 52.15 0.2 Allowed 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -176.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 24' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' P' ' 26' ' ' SER . 93.2 t -74.45 142.25 14.98 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 C-N-CA 117.923 -1.511 . . . . 0.0 110.069 -178.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.46 37.49 3.75 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -178.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -64.57 106.44 1.16 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.698 0.761 . . . . 0.0 111.576 -177.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -149.85 -161.25 1.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.429 -1.26 . . . . 0.0 110.173 -179.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 29.5 40.82 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 29' ' ' GLY . . . . . 0.682 ' HA2' HG11 ' K' ' 39' ' ' VAL . . . 110.53 70.91 0.63 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 116.36 1.304 . . . . 0.0 116.36 175.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.53 114.14 27.72 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 175.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 31' ' ' ILE . . . . . 0.74 HD11 HG13 ' K' ' 39' ' ' VAL . 66.6 mt -130.29 135.33 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 CA-C-N 119.108 0.867 . . . . 0.0 113.238 -178.177 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -121.59 114.71 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.14 114.84 3.29 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 14.3 tp -117.63 117.18 28.69 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 122.251 0.221 . . . . 0.0 110.429 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.2 mtp -121.76 124.28 43.84 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 67.1 t -110.81 131.48 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 121.108 0.48 . . . . 0.0 111.087 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 37' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' Q' ' 38' ' ' GLY . . . -72.81 111.68 3.63 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 38' ' ' GLY . . . . . 0.5 ' H ' ' HA3' ' R' ' 37' ' ' GLY . . . -6.09 -67.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.428 0 C-N-CA 123.608 0.623 . . . . 0.0 114.224 -178.049 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.09 120.63 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 118.351 1.076 . . . . 0.0 109.68 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 29.1 t . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.272 -179.312 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -148.29 160.75 42.65 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 11' ' ' GLU . . . . . 0.411 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 79.2 mm-40 -114.74 151.32 33.92 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.154 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 57.4 t -107.09 105.97 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.043 0.449 . . . . 0.0 110.705 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 13' ' ' HIS . . . . . 0.602 ' CD2' HG13 ' P' ' 40' ' ' VAL . 63.0 t60 -148.82 130.14 14.68 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.224 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 42.0 p-80 -154.03 162.8 40.94 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.833 176.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 15' ' ' GLN . . . . . 0.592 ' CD ' HG12 ' P' ' 36' ' ' VAL . 5.5 tt0 -89.86 158.29 17.52 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 16' ' ' LYS . . . . . 0.545 ' O ' HD12 ' Q' ' 17' ' ' LEU . 68.9 tttt -140.82 103.15 4.44 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 17' ' ' LEU . . . . . 0.612 ' N ' HD23 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -115.51 109.29 17.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.702 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -106.28 104.09 16.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 19' ' ' PHE . . . . . 0.431 ' HE1' HD22 ' P' ' 34' ' ' LEU . 51.2 m-85 -100.25 100.95 11.84 Favored 'General case' 0 CA--C 1.509 -0.599 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 178.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -110.77 110.33 20.93 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.299 0.571 . . . . 0.0 109.949 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.6 130.29 45.48 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 22' ' ' GLU . . . . . 0.518 ' OE2' ' CZ ' ' Q' ' 20' ' ' PHE . 52.2 mp0 -77.86 108.99 11.5 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 118.597 -1.241 . . . . 0.0 110.686 -177.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 23' ' ' ASP . . . . . 0.573 ' CG ' ' H ' ' R' ' 24' ' ' VAL . 22.8 p-10 -178.83 -69.79 0.01 OUTLIER 'General case' 0 C--N 1.347 0.463 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 178.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 24' ' ' VAL . . . . . 0.573 ' H ' ' CG ' ' R' ' 23' ' ' ASP . 42.9 t -147.28 120.59 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -177.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.75 -43.73 91.09 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 119.546 -1.311 . . . . 0.0 110.659 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 44.1 m -139.56 -111.03 0.15 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 117.231 0.515 . . . . 0.0 111.283 177.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 7.1 m120 55.69 152.67 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.859 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -70.41 48.79 0.11 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.465 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 -52.06 1.38 Allowed Glycine 0 CA--C 1.541 1.664 0 C-N-CA 120.705 -0.76 . . . . 0.0 113.859 -178.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.4 176.44 5.15 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-N 117.454 0.627 . . . . 0.0 109.972 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 85.7 mt -110.45 116.97 53.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -113.63 127.44 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.039 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.85 113.13 1.7 Allowed Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' R' R ' 34' ' ' LEU . . . . . 0.646 ' C ' HD23 ' R' ' 34' ' ' LEU . 6.9 tt -118.05 121.43 40.57 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 35' ' ' MET . . . . . 0.549 ' N ' HD23 ' R' ' 34' ' ' LEU . 93.9 mtp -140.01 143.16 36.31 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.567 -0.453 . . . . 0.0 111.075 -179.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' R' ' 37' ' ' GLY . 3.3 p -122.83 131.56 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 37' ' ' GLY . . . . . 0.5 ' HA3' ' H ' ' Q' ' 38' ' ' GLY . . . -34.05 -111.41 0.0 OUTLIER Glycine 0 CA--C 1.529 0.933 0 CA-C-N 115.102 -0.953 . . . . 0.0 113.591 179.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 38' ' ' GLY . . . . . 0.41 ' H ' ' CA ' ' Q' ' 38' ' ' GLY . . . -111.52 -71.68 0.63 Allowed Glycine 0 CA--C 1.537 1.42 0 CA-C-N 115.563 -0.319 . . . . 0.0 113.288 -178.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 39' ' ' VAL . . . . . 0.525 HG12 HD12 ' F' ' 31' ' ' ILE . 6.8 p -138.49 142.71 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 117.618 0.709 . . . . 0.0 112.254 -178.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.455 178.629 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.194 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -109.02 134.77 51.22 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.892 0.377 . . . . 0.0 110.504 -179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -145.01 135.18 23.97 Favored 'General case' 0 N--CA 1.463 0.199 0 CA-C-N 116.055 -0.52 . . . . 0.0 109.98 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -126.01 131.52 71.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 121.033 0.444 . . . . 0.0 110.467 -179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 47.6 p-80 -98.93 162.15 13.24 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.808 -0.633 . . . . 0.0 109.926 179.683 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 49.5 p-80 -86.39 169.5 12.85 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.585 -0.446 . . . . 0.0 110.805 -179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.404 ' HB2' HE21 ' B' ' 15' ' ' GLN . 86.2 mt-30 -129.5 151.28 50.29 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.45 179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -96.54 124.35 40.5 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.773 178.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . 0.405 HD11 ' NE2' ' B' ' 15' ' ' GLN . 91.4 mt -123.94 120.94 33.98 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-O 121.11 0.481 . . . . 0.0 110.76 179.356 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 56.0 t -127.41 133.47 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.874 179.595 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.8 t80 -133.41 124.43 27.1 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 120.822 0.344 . . . . 0.0 110.53 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.424 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 55.1 p90 -124.21 132.25 53.59 Favored 'General case' 0 N--CA 1.469 0.519 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.91 140.48 32.83 Favored 'General case' 0 N--CA 1.471 0.625 0 N-CA-C 113.956 1.095 . . . . 0.0 113.956 -178.036 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 41.3 tp10 -107.07 158.35 17.12 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 114.071 -1.422 . . . . 0.0 107.491 177.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 t70 -171.02 46.63 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 119.594 -0.842 . . . . 0.0 112.455 -178.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.65 HG12 ' N ' ' A' ' 25' ' ' GLY . 45.3 t -82.74 173.58 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 C-N-CA 119.315 -0.954 . . . . 0.0 108.635 -179.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.65 ' N ' HG12 ' A' ' 24' ' ' VAL . . . 91.11 -33.16 4.82 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 108.699 -1.76 . . . . 0.0 108.699 -177.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 88.3 p -151.29 124.23 8.64 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 107.717 -1.216 . . . . 0.0 107.717 179.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.581 HD21 ' C ' ' B' ' 27' ' ' ASN . 13.8 t-20 -41.62 149.9 0.11 Allowed 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 120.365 -0.534 . . . . 0.0 110.811 -176.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.0 tttm -73.32 -49.25 28.48 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 114.944 1.461 . . . . 0.0 114.944 -179.122 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.96 59.69 0.5 Allowed Glycine 0 CA--C 1.543 1.83 0 C-N-CA 119.976 -1.107 . . . . 0.0 110.372 -175.34 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -89.57 92.42 9.08 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 123.513 1.625 . . . . 0.0 113.491 -175.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.534 HG21 HG21 ' N' ' 39' ' ' VAL . 1.1 pt -142.3 122.81 11.13 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-N 111.789 -2.46 . . . . 0.0 106.322 178.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.443 ' O ' ' O ' ' B' ' 33' ' ' GLY . 58.8 mt -104.83 110.12 29.78 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.77 92.08 0.58 Allowed Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 104.609 -3.396 . . . . 0.0 104.609 176.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.608 ' O ' HD12 ' B' ' 34' ' ' LEU . 82.0 mt -146.45 169.62 18.52 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-O 122.954 1.359 . . . . 0.0 112.814 -175.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 53.3 mtp -141.75 119.31 11.66 Favored 'General case' 0 N--CA 1.433 -1.277 0 CA-C-N 112.781 -2.009 . . . . 0.0 108.735 179.465 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.793 ' CG2' HG12 ' B' ' 36' ' ' VAL . 11.7 m -124.74 113.65 37.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 166.05 -123.95 1.19 Allowed Glycine 0 C--N 1.305 -1.185 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 -178.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.561 ' O ' HD13 ' G' ' 31' ' ' ILE . . . 80.73 -67.39 3.56 Favored Glycine 0 CA--C 1.535 1.318 0 C-N-CA 120.387 -0.911 . . . . 0.0 111.328 -179.374 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.23 156.11 41.59 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 117.977 -1.011 . . . . 0.0 111.145 -179.728 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.355 -1.498 . . . . 0.0 109.355 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . 0.477 ' CE2' HG23 ' B' ' 12' ' ' VAL . 87.7 t80 -87.5 126.34 34.85 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.688 0.28 . . . . 0.0 110.341 179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -141.04 140.78 34.32 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.555 179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.477 HG23 ' CE2' ' B' ' 10' ' ' TYR . 62.4 t -127.6 132.78 68.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.044 179.793 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.541 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 86.0 m-70 -143.02 94.08 2.58 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.831 0.348 . . . . 0.0 110.695 179.344 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.609 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 6.9 t60 -158.56 170.18 22.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.197 -0.456 . . . . 0.0 109.813 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.609 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 51.3 tt0 -155.42 141.18 18.06 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.898 0.38 . . . . 0.0 110.213 178.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -89.0 124.42 34.25 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.27 178.281 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 tp -120.96 117.52 27.5 Favored 'General case' 0 N--CA 1.472 0.628 0 N-CA-C 109.797 -0.445 . . . . 0.0 109.797 177.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.5 129.38 73.83 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.787 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 65.9 t80 -128.78 121.75 29.04 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.717 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.611 ' CD2' ' CD1' ' C' ' 20' ' ' PHE . 7.4 m-85 -122.46 129.03 51.6 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 109.724 -0.472 . . . . 0.0 109.724 179.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.17 137.4 34.36 Favored 'General case' 0 C--O 1.237 0.434 0 CA-C-O 121.527 0.68 . . . . 0.0 112.793 -179.319 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.461 ' OE1' ' OE1' ' A' ' 22' ' ' GLU . 86.8 mt-10 -96.09 118.82 33.45 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.303 179.009 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.424 ' H ' ' HB2' ' C' ' 22' ' ' GLU . 0.3 OUTLIER -143.43 51.71 1.36 Allowed 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.316 -179.045 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 71.3 t -75.7 143.49 13.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.957 0.884 . . . . 0.0 110.807 -176.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 98.65 38.23 3.99 Favored Glycine 0 CA--C 1.525 0.656 0 CA-C-N 113.813 -1.539 . . . . 0.0 109.373 -178.698 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 3.9 t 73.18 120.01 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.169 0 CA-C-N 115.241 -0.479 . . . . 0.0 110.608 179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.841 HD21 ' H ' ' B' ' 30' ' ' ALA . 3.8 p30 -83.07 163.78 20.7 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 119.571 -0.851 . . . . 0.0 108.809 177.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 95.4 mttt -46.98 -37.06 8.5 Favored 'General case' 0 C--N 1.33 -0.245 0 C-N-CA 119.883 -0.727 . . . . 0.0 111.249 179.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.455 ' O ' ' N ' ' B' ' 31' ' ' ILE . . . 179.53 77.05 0.06 OUTLIER Glycine 0 CA--C 1.531 1.068 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.823 -177.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.841 ' H ' HD21 ' B' ' 27' ' ' ASN . . . -51.77 91.44 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.434 0 CA-C-N 119.371 1.586 . . . . 0.0 110.776 -179.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.956 HD12 HG22 ' N' ' 39' ' ' VAL . 66.8 mt -132.98 133.51 58.71 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 CA-C-N 115.306 -0.861 . . . . 0.0 111.742 -177.697 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -107.96 109.7 29.22 Favored 'Isoleucine or valine' 0 C--O 1.231 0.126 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 177.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -113.29 97.05 0.84 Allowed Glycine 0 CA--C 1.507 -0.465 0 N-CA-C 104.19 -3.564 . . . . 0.0 104.19 176.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.647 HD12 ' H ' ' B' ' 35' ' ' MET . 40.1 tp -141.71 147.29 37.2 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-O 122.978 1.371 . . . . 0.0 113.47 -173.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.647 ' H ' HD12 ' B' ' 34' ' ' LEU . 11.6 mtp -116.6 112.62 21.56 Favored 'General case' 0 N--CA 1.442 -0.861 0 CA-C-N 112.662 -2.063 . . . . 0.0 108.826 178.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.793 HG12 ' CG2' ' A' ' 36' ' ' VAL . 30.1 m -127.24 123.07 61.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.043 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 142.77 -113.52 0.79 Allowed Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.637 -0.985 . . . . 0.0 110.637 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.489 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 73.77 -72.74 1.27 Allowed Glycine 0 CA--C 1.535 1.29 0 N-CA-C 111.369 -0.692 . . . . 0.0 111.369 -178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.441 ' CG1' ' O ' ' A' ' 38' ' ' GLY . 14.7 p -158.65 138.58 3.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 178.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.48 ' CG1' ' CD2' ' D' ' 13' ' ' HIS . 1.9 t . . . . . 0 C--O 1.221 -0.407 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.504 -179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.437 -1.465 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -107.85 131.81 54.1 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.734 0.302 . . . . 0.0 110.32 -179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -129.59 125.16 35.54 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.151 179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -130.24 134.45 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.083 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.577 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 3.9 t60 -139.95 139.85 36.22 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.532 ' CE1' ' O ' ' D' ' 14' ' ' HIS . 52.5 t60 -155.56 168.78 26.04 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 119.358 -0.937 . . . . 0.0 111.508 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.441 ' N ' ' CD2' ' C' ' 14' ' ' HIS . 53.1 tt0 -138.74 140.81 38.82 Favored 'General case' 0 CA--C 1.52 -0.174 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 177.582 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -130.4 113.47 14.37 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.488 HD12 HD22 ' D' ' 17' ' ' LEU . 35.6 mt -118.79 110.94 17.82 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 120.437 -0.505 . . . . 0.0 109.745 178.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 23.1 t -109.15 110.88 33.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -106.53 108.64 20.25 Favored 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 107.856 -1.164 . . . . 0.0 107.856 178.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.611 ' CD1' ' CD2' ' B' ' 20' ' ' PHE . 14.6 t80 -114.91 124.71 52.41 Favored 'General case' 0 N--CA 1.478 0.947 0 O-C-N 122.424 -0.173 . . . . 0.0 111.273 -178.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.44 139.57 26.98 Favored 'General case' 0 N--CA 1.478 0.933 0 N-CA-C 113.56 0.948 . . . . 0.0 113.56 -179.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.447 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 98.0 mt-10 -89.89 143.2 26.99 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.481 178.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.447 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 0.0 OUTLIER -164.66 50.44 0.12 Allowed 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 -177.893 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.404 HG13 ' CG2' ' D' ' 24' ' ' VAL . 37.6 t -80.87 149.37 5.05 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 CA-C-O 122.83 1.3 . . . . 0.0 112.417 -174.431 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.6 36.92 5.69 Favored Glycine 0 CA--C 1.528 0.856 0 CA-C-N 112.052 -2.34 . . . . 0.0 110.28 -179.25 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.544 ' N ' ' O ' ' D' ' 24' ' ' VAL . 19.8 t 72.64 120.12 0.04 OUTLIER 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 123.789 0.835 . . . . 0.0 110.028 177.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.694 ' ND2' ' H ' ' B' ' 30' ' ' ALA . 25.9 t30 -83.18 161.99 21.39 Favored 'General case' 0 CA--C 1.528 0.132 0 C-N-CA 116.991 -1.884 . . . . 0.0 110.284 177.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 61.0 mttp -47.41 -37.03 10.66 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.482 ' H ' ' ND2' ' C' ' 27' ' ' ASN . . . -178.76 78.16 0.06 OUTLIER Glycine 0 CA--C 1.538 1.508 0 CA-C-O 119.294 -0.726 . . . . 0.0 112.343 -173.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.723 ' H ' ' ND2' ' D' ' 27' ' ' ASN . . . -79.18 119.04 21.71 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 123.299 1.524 . . . . 0.0 112.997 -175.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.675 HD12 HG12 ' O' ' 39' ' ' VAL . 78.4 mt -139.1 139.89 39.22 Favored 'Isoleucine or valine' 0 C--N 1.353 0.724 0 CA-C-N 112.32 -2.218 . . . . 0.0 113.426 -176.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.433 HD13 ' CD2' ' E' ' 19' ' ' PHE . 64.1 mt -109.11 112.36 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.31 98.43 0.93 Allowed Glycine 0 C--O 1.238 0.392 0 N-CA-C 106.069 -2.812 . . . . 0.0 106.069 177.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 13.0 tp -133.26 134.59 44.14 Favored 'General case' 0 C--O 1.241 0.607 0 CA-C-O 122.495 1.14 . . . . 0.0 113.931 -175.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 2.5 mtp -104.88 106.83 17.49 Favored 'General case' 0 N--CA 1.446 -0.628 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 175.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.407 HG11 HD21 ' F' ' 17' ' ' LEU . 12.6 p -123.02 122.98 66.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.492 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 156.97 -113.11 0.55 Allowed Glycine 0 C--N 1.312 -0.801 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -177.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.51 ' O ' ' O ' ' C' ' 39' ' ' VAL . . . 55.73 64.98 3.89 Favored Glycine 0 CA--C 1.536 1.366 0 C-N-CA 119.789 -1.196 . . . . 0.0 112.61 178.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.528 HG23 ' O ' ' C' ' 39' ' ' VAL . 33.8 m 16.08 114.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.403 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.407 ' H ' HG23 ' C' ' 40' ' ' VAL . 2.6 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.997 -1.001 . . . . 0.0 110.491 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.491 -1.443 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -83.09 139.37 33.26 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -109.13 118.34 36.5 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.148 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 17.9 t -115.21 91.14 1.68 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.154 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.577 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 3.5 t60 -143.89 122.72 12.68 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 110.372 -0.233 . . . . 0.0 110.372 -179.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.663 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.0 OUTLIER -118.77 161.53 19.96 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 121.114 0.483 . . . . 0.0 110.316 178.714 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.461 ' OE1' HD11 ' E' ' 17' ' ' LEU . 43.4 tt0 -85.05 157.04 20.84 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 178.091 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.637 ' O ' HD23 ' D' ' 17' ' ' LEU . 87.0 tttt -160.31 102.21 1.4 Allowed 'General case' 0 C--N 1.308 -1.233 0 C-N-CA 119.369 -0.932 . . . . 0.0 110.321 177.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.731 ' CD1' HG11 ' B' ' 36' ' ' VAL . 3.1 mt -126.73 121.51 32.22 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 178.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -112.4 112.31 39.9 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 108.833 -0.802 . . . . 0.0 108.833 178.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.4 m-85 -107.64 107.02 17.63 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 179.689 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.545 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 32.5 t80 -110.56 120.56 42.82 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 111.316 0.117 . . . . 0.0 111.316 -178.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.87 144.99 27.26 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 118.748 -1.181 . . . . 0.0 113.687 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.434 ' O ' ' OD2' ' C' ' 23' ' ' ASP . 98.1 mt-10 -96.05 136.36 36.61 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.311 -0.858 . . . . 0.0 110.99 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -160.13 49.95 0.29 Allowed 'General case' 0 N--CA 1.475 0.82 0 CA-C-N 116.678 -0.237 . . . . 0.0 110.647 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.544 ' O ' ' N ' ' C' ' 26' ' ' SER . 35.7 m -81.67 150.65 4.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-O 122.601 1.191 . . . . 0.0 113.49 -176.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' E' ' 24' ' ' VAL . . . 93.94 36.97 5.59 Favored Glycine 0 CA--C 1.53 0.998 0 CA-C-N 112.59 -2.096 . . . . 0.0 111.705 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 72.77 120.11 0.04 OUTLIER 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.333 -0.434 . . . . 0.0 111.544 175.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.723 ' ND2' ' H ' ' C' ' 30' ' ' ALA . 13.4 t30 -83.07 162.3 21.4 Favored 'General case' 0 C--O 1.231 0.103 0 C-N-CA 117.94 -1.504 . . . . 0.0 107.997 176.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.614 ' NZ ' ' ND1' ' Q' ' 13' ' ' HIS . 83.1 tttt -47.53 -37.45 12.14 Favored 'General case' 0 C--N 1.325 -0.459 0 C-N-CA 120.105 -0.638 . . . . 0.0 111.489 177.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.79 0.06 OUTLIER Glycine 0 CA--C 1.539 1.589 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.554 -177.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.77 119.67 4.47 Favored 'General case' 0 N--CA 1.483 1.211 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 -177.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 1.9 mt -125.5 125.17 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.187 0 CA-C-N 114.432 -1.258 . . . . 0.0 113.517 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.2 mt -106.82 112.71 40.98 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.155 0 N-CA-C 105.943 -1.873 . . . . 0.0 105.943 173.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.13 114.71 2.01 Favored Glycine 0 N--CA 1.462 0.429 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.429 HD12 ' N ' ' D' ' 34' ' ' LEU . 0.3 OUTLIER -160.78 158.16 28.08 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 123.21 1.481 . . . . 0.0 113.595 -178.826 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 82.5 mmm -110.72 111.64 22.97 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-N 111.967 -2.378 . . . . 0.0 108.882 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.613 HG11 HD11 ' F' ' 17' ' ' LEU . 9.0 t -106.09 112.74 40.62 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.714 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 179.175 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -179.09 -121.96 0.74 Allowed Glycine 0 C--N 1.304 -1.22 0 C-N-CA 118.331 -1.89 . . . . 0.0 111.643 -179.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.443 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 63.63 61.55 6.12 Favored Glycine 0 CA--C 1.535 1.293 0 C-N-CA 119.65 -1.262 . . . . 0.0 111.347 -178.365 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.702 HG23 ' O ' ' E' ' 39' ' ' VAL . 5.6 p -18.62 122.99 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.25 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -177.076 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 30.2 m . . . . . 0 C--N 1.324 -0.512 0 CA-C-O 117.948 -1.025 . . . . 0.0 110.992 179.112 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.144 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -83.73 139.8 32.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.799 0.333 . . . . 0.0 110.758 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.467 ' OE2' ' NE2' ' D' ' 14' ' ' HIS . 79.4 tt0 -155.22 151.24 27.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.988 179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.645 HG12 ' N ' ' E' ' 13' ' ' HIS . 59.0 t -140.51 168.01 17.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.292 0 CA-C-N 116.536 -0.302 . . . . 0.0 110.778 -179.62 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.645 ' N ' HG12 ' E' ' 12' ' ' VAL . 20.8 p-80 -64.34 140.85 58.91 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 113.943 1.09 . . . . 0.0 113.943 -178.16 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' O ' ' F' ' 12' ' ' VAL . 65.0 m80 -150.63 166.43 30.33 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.697 177.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 85.6 mt-30 -89.82 150.99 22.0 Favored 'General case' 0 CA--C 1.522 -0.114 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 177.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.565 ' C ' HD22 ' E' ' 17' ' ' LEU . 67.8 mttm -152.24 99.18 2.49 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 176.576 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.804 HD22 ' N ' ' E' ' 17' ' ' LEU . 1.3 mm? -118.33 114.11 22.46 Favored 'General case' 0 CA--C 1.509 -0.631 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 88.5 t -110.18 106.65 21.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.436 ' CZ ' ' HB3' ' E' ' 17' ' ' LEU . 35.1 m-85 -103.15 103.75 13.84 Favored 'General case' 0 C--O 1.232 0.175 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 30.3 t80 -110.39 118.52 36.52 Favored 'General case' 0 N--CA 1.468 0.467 0 C-N-CA 121.138 -0.225 . . . . 0.0 111.027 -178.455 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.48 137.01 28.24 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 118.907 -1.117 . . . . 0.0 113.155 -179.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -88.37 115.57 25.97 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 106.581 -1.637 . . . . 0.0 106.581 177.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.456 ' C ' ' O ' ' F' ' 22' ' ' GLU . 0.0 OUTLIER -148.57 48.85 1.02 Allowed 'General case' 0 CA--C 1.536 0.421 0 N-CA-C 113.355 0.872 . . . . 0.0 113.355 -175.485 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.51 HG12 ' N ' ' E' ' 25' ' ' GLY . 67.2 t -71.9 160.1 5.42 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.253 0 C-N-CA 118.007 -1.477 . . . . 0.0 108.199 -179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.51 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 111.08 -36.62 4.12 Favored Glycine 0 N--CA 1.464 0.541 0 N-CA-C 108.097 -2.001 . . . . 0.0 108.097 -178.246 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 m -65.79 112.52 3.77 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 113.22 -1.49 . . . . 0.0 110.622 -179.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 34.3 p-10 -148.98 162.33 40.12 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 121.758 0.789 . . . . 0.0 110.922 -178.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 29.84 43.11 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 114.123 -1.399 . . . . 0.0 112.785 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -174.19 59.69 0.13 Allowed Glycine 0 CA--C 1.543 1.803 0 C-N-CA 121.012 -0.613 . . . . 0.0 112.484 173.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.72 141.26 40.97 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-O 118.534 -0.746 . . . . 0.0 110.322 177.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.432 HD12 HG13 ' Q' ' 39' ' ' VAL . 1.6 tt -132.52 125.33 53.16 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.9 0 CA-C-N 119.606 1.094 . . . . 0.0 110.232 176.514 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 87.1 mt -127.45 127.29 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.851 -179.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.96 107.04 0.86 Allowed Glycine 0 CA--C 1.527 0.839 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 179.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.606 HD23 ' C ' ' E' ' 34' ' ' LEU . 7.3 tt -122.9 123.86 41.91 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.515 ' N ' HD23 ' E' ' 34' ' ' LEU . 86.1 mtp -134.08 145.57 49.49 Favored 'General case' 0 CA--C 1.514 -0.417 0 C-N-CA 119.958 -0.697 . . . . 0.0 112.391 -179.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -124.23 136.85 59.12 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.885 0.85 . . . . 0.0 110.659 178.409 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -138.78 103.28 0.39 Allowed Glycine 0 C--N 1.315 -0.63 0 N-CA-C 108.715 -1.754 . . . . 0.0 108.715 -179.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' E' ' 39' ' ' VAL . . . 127.12 75.75 0.21 Allowed Glycine 0 N--CA 1.474 1.205 0 C-N-CA 120.49 -0.862 . . . . 0.0 112.157 -178.627 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.702 ' O ' HG23 ' D' ' 39' ' ' VAL . 7.3 t -17.36 120.29 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.012 0 C-N-CA 123.628 0.771 . . . . 0.0 112.981 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 N--CA 1.469 0.518 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.355 179.516 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -110.34 133.89 52.82 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-O 120.781 0.324 . . . . 0.0 110.503 -179.922 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.53 151.55 39.47 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 179.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 18.2 t -132.64 133.33 59.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.505 0.669 . . . . 0.0 111.379 -179.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.515 ' HD1' ' CE1' ' E' ' 13' ' ' HIS . 0.3 OUTLIER -146.05 117.26 7.87 Favored 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.992 179.417 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.511 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 76.9 m80 -156.71 165.52 36.02 Favored 'General case' 0 C--N 1.331 -0.207 0 C-N-CA 120.407 -0.517 . . . . 0.0 111.672 179.512 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.501 ' CD ' HG12 ' D' ' 36' ' ' VAL . 78.6 mt-30 -84.19 155.28 22.61 Favored 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 115.673 -0.694 . . . . 0.0 109.743 178.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 69.2 tttt -159.98 100.18 1.4 Allowed 'General case' 0 C--N 1.309 -1.191 0 CA-C-O 121.291 0.567 . . . . 0.0 109.865 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.613 HD11 HG11 ' D' ' 36' ' ' VAL . 2.5 mp -125.62 114.92 19.35 Favored 'General case' 0 CA--C 1.499 -1.011 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.331 178.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 12.4 t -99.83 102.61 13.65 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.919 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 178.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.7 m-85 -95.16 95.22 8.4 Favored 'General case' 0 N--CA 1.444 -0.73 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 178.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.413 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 64.8 t80 -111.16 113.52 26.1 Favored 'General case' 0 CA--C 1.508 -0.652 0 CA-C-O 121.548 0.69 . . . . 0.0 109.202 -179.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.74 134.76 17.95 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 120.361 -0.536 . . . . 0.0 109.581 -179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.456 ' O ' ' C ' ' E' ' 23' ' ' ASP . 96.3 mt-10 -76.74 85.02 3.36 Favored 'General case' 0 C--N 1.324 -0.52 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 178.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.655 ' O ' ' O ' ' F' ' 24' ' ' VAL . 51.1 p30 176.32 52.09 0.0 OUTLIER 'General case' 0 CA--C 1.517 -0.306 0 CA-C-N 114.416 -1.266 . . . . 0.0 109.488 -175.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.655 ' O ' ' O ' ' F' ' 23' ' ' ASP . 3.0 t -52.73 -132.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.463 0.201 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 -177.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.43 ' O ' ' HB2' ' F' ' 30' ' ' ALA . . . 168.81 -38.63 0.21 Allowed Glycine 0 CA--C 1.509 -0.316 0 C-N-CA 116.127 -2.94 . . . . 0.0 116.263 -177.816 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 43.0 t -64.64 110.68 2.43 Favored 'General case' 0 N--CA 1.446 -0.627 0 C-N-CA 115.164 -2.614 . . . . 0.0 107.932 -176.545 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.728 ' O ' ' N ' ' F' ' 29' ' ' GLY . 16.7 p30 -149.62 174.89 12.05 Favored 'General case' 0 N--CA 1.446 -0.647 0 CA-C-N 112.548 -2.114 . . . . 0.0 108.031 179.728 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.461 ' C ' ' O ' ' F' ' 27' ' ' ASN . 88.4 tttt -8.77 -45.2 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.746 0 O-C-N 124.534 1.146 . . . . 0.0 114.015 177.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.728 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -169.61 60.45 0.19 Allowed Glycine 0 CA--C 1.553 2.435 0 C-N-CA 119.943 -1.122 . . . . 0.0 115.368 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.43 ' HB2' ' O ' ' F' ' 25' ' ' GLY . . . -84.99 172.04 11.63 Favored 'General case' 0 N--CA 1.477 0.912 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 85.9 mt -115.59 112.12 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.107 0 CA-C-N 120.667 1.576 . . . . 0.0 111.562 -179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -123.97 123.19 66.28 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 179.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.89 119.55 3.03 Favored Glycine 0 CA--C 1.527 0.812 0 N-CA-C 111.777 -0.529 . . . . 0.0 111.777 -179.234 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 38.4 mt -122.87 119.7 31.31 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 179.043 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mtp -140.6 151.38 44.62 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 113.331 0.863 . . . . 0.0 113.331 -178.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 m -127.41 164.55 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.265 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.421 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.36 -102.82 0.09 OUTLIER Glycine 0 CA--C 1.525 0.664 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.653 178.213 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -103.09 -77.83 1.24 Allowed Glycine 0 CA--C 1.536 1.38 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.526 HG22 ' N ' ' F' ' 40' ' ' VAL . 3.4 p -125.78 162.48 28.94 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 117.208 0.504 . . . . 0.0 111.266 -179.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.526 ' N ' HG22 ' F' ' 39' ' ' VAL . 9.6 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.924 -1.036 . . . . 0.0 110.58 -178.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -111.51 132.84 54.22 Favored 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 110.336 -0.246 . . . . 0.0 110.336 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.27 102.33 4.08 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.976 0.417 . . . . 0.0 110.303 179.41 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 77.5 t -131.38 130.21 62.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.936 -0.575 . . . . 0.0 109.613 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -145.38 131.6 19.48 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 120.112 -0.635 . . . . 0.0 112.42 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 45.6 p-80 -152.02 167.49 28.25 Favored 'General case' 0 C--N 1.334 -0.108 0 CA-C-N 115.245 -0.889 . . . . 0.0 109.805 178.489 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -157.53 142.91 17.13 Favored 'General case' 0 CA--C 1.52 -0.202 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 179.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -81.53 126.2 31.41 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.584 179.006 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.7 mt -126.52 118.23 24.48 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 178.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -141.88 139.79 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 121.026 0.441 . . . . 0.0 110.999 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 87.7 t80 -134.74 131.84 38.07 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 115.715 -0.675 . . . . 0.0 109.58 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.498 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 55.1 p90 -131.06 130.34 43.12 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.93 0.395 . . . . 0.0 111.042 -179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -121.12 117.37 26.98 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.016 179.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -143.31 147.44 34.74 Favored 'General case' 0 N--CA 1.461 0.106 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.462 179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 53.69 46.43 25.93 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.288 -0.565 . . . . 0.0 110.035 179.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 35.9 m -80.47 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.804 -178.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.35 -33.49 64.41 Favored Glycine 0 CA--C 1.522 0.514 0 N-CA-C 111.505 -0.638 . . . . 0.0 111.505 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.743 ' O ' ' O ' ' G' ' 27' ' ' ASN . 41.3 p -162.68 120.38 2.04 Favored 'General case' 0 C--O 1.223 -0.318 0 C-N-CA 120.298 -0.561 . . . . 0.0 112.097 -179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.743 ' O ' ' O ' ' G' ' 26' ' ' SER . 9.1 m120 -21.61 -174.65 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.187 0 N-CA-C 115.41 1.634 . . . . 0.0 115.41 178.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -173.86 -21.04 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.327 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.419 179.44 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.539 ' N ' ' OD2' ' H' ' 23' ' ' ASP . . . 71.66 -97.9 0.73 Allowed Glycine 0 N--CA 1.465 0.624 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.6 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.61 97.02 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.112 0.482 . . . . 0.0 111.487 179.071 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.561 HD13 ' O ' ' A' ' 38' ' ' GLY . 91.2 mt -123.03 110.83 27.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 178.041 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 92.0 mt -113.76 107.32 22.63 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.78 100.08 0.92 Allowed Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 104.393 -3.483 . . . . 0.0 104.393 176.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.468 ' O ' HD23 ' H' ' 34' ' ' LEU . 48.3 tp -150.36 149.28 29.86 Favored 'General case' 0 CA--C 1.511 -0.538 0 CA-C-O 123.034 1.397 . . . . 0.0 113.954 -174.52 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.8 mtp -105.64 106.32 16.76 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-N 112.183 -2.281 . . . . 0.0 106.015 176.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.642 HG21 HD11 ' I' ' 17' ' ' LEU . 3.8 p -128.47 113.95 31.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.43 -124.9 1.95 Allowed Glycine 0 C--N 1.307 -1.061 0 N-CA-C 109.227 -1.549 . . . . 0.0 109.227 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.1 -66.89 3.7 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 120.951 -0.642 . . . . 0.0 111.995 179.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.663 HG22 ' N ' ' G' ' 40' ' ' VAL . 12.6 p -108.08 176.01 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.465 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -179.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.663 ' N ' HG22 ' G' ' 39' ' ' VAL . 2.5 m . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.133 -0.937 . . . . 0.0 110.116 178.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.347 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -105.64 132.44 51.78 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -159.48 114.43 2.41 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.069 -179.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.46 HG22 ' CG1' ' I' ' 12' ' ' VAL . 79.6 t -126.66 128.9 71.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 179.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.483 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 43.4 m-70 -147.61 114.97 6.28 Favored 'General case' 0 N--CA 1.465 0.32 0 C-N-CA 120.589 -0.444 . . . . 0.0 111.462 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.504 ' CE1' ' H ' ' I' ' 14' ' ' HIS . 12.9 m-70 -149.74 169.07 21.92 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 pt20 -156.52 141.58 17.24 Favored 'General case' 0 CA--C 1.518 -0.278 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 177.061 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -86.85 120.5 28.2 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.218 178.388 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.555 HD13 ' N ' ' H' ' 18' ' ' VAL . 0.6 OUTLIER -117.22 113.91 22.89 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 177.007 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.555 ' N ' HD13 ' H' ' 17' ' ' LEU . 69.1 t -122.17 131.03 74.03 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 CA-C-O 120.867 0.365 . . . . 0.0 111.386 -178.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 37.7 t80 -126.98 116.81 21.33 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.614 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 8.0 t80 -122.63 127.2 49.05 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.95 134.84 32.11 Favored 'General case' 0 N--CA 1.472 0.659 0 N-CA-C 112.754 0.649 . . . . 0.0 112.754 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -107.71 121.24 44.31 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.272 178.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.539 ' OD2' ' N ' ' G' ' 29' ' ' GLY . 93.6 m-20 -140.33 46.38 1.82 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.012 -178.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.786 HG12 ' H ' ' H' ' 25' ' ' GLY . 20.6 t -81.68 177.47 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.152 -0.931 . . . . 0.0 111.36 -177.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.786 ' H ' HG12 ' H' ' 24' ' ' VAL . . . 92.72 -33.92 4.77 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.377 -1.283 . . . . 0.0 112.426 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.55 ' O ' ' O ' ' H' ' 27' ' ' ASN . 37.0 t -162.52 120.31 2.09 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 119.062 1.431 . . . . 0.0 113.502 177.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.55 ' O ' ' O ' ' H' ' 26' ' ' SER . 53.4 p-10 -22.41 153.23 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.946 0 O-C-N 124.266 0.979 . . . . 0.0 112.05 175.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.622 ' HZ2' ' HB2' ' G' ' 27' ' ' ASN . 61.7 tttt -165.43 26.42 0.05 Allowed 'General case' 0 CA--C 1.532 0.274 0 C-N-CA 118.392 -1.323 . . . . 0.0 114.162 176.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.58 ' H ' ' H ' ' I' ' 28' ' ' LYS . . . 82.03 108.01 0.4 Allowed Glycine 0 CA--C 1.525 0.717 0 C-N-CA 118.987 -1.578 . . . . 0.0 114.448 176.552 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.529 ' HB3' HD22 ' I' ' 27' ' ' ASN . . . -120.49 106.49 11.86 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-O 122.118 0.961 . . . . 0.0 109.273 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.43 HD12 ' O ' ' B' ' 38' ' ' GLY . 1.9 tt -141.45 132.66 27.31 Favored 'Isoleucine or valine' 0 C--O 1.237 0.413 0 CA-C-N 114.687 -1.142 . . . . 0.0 111.83 -177.658 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.559 HG22 HD11 ' I' ' 34' ' ' LEU . 6.6 mt -108.13 111.69 37.0 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 177.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.48 103.18 1.42 Allowed Glycine 0 N--CA 1.46 0.248 0 N-CA-C 105.543 -3.023 . . . . 0.0 105.543 177.131 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.468 HD23 ' O ' ' G' ' 34' ' ' LEU . 0.4 OUTLIER -146.47 145.12 30.08 Favored 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 117.92 -1.512 . . . . 0.0 114.271 -174.483 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 10.4 mtp -111.12 112.34 24.07 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 112.935 -1.938 . . . . 0.0 107.02 176.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -119.69 102.88 13.43 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 N-CA-C 109.023 -0.732 . . . . 0.0 109.023 -178.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.88 -151.56 20.16 Favored Glycine 0 C--N 1.313 -0.739 0 N-CA-C 110.311 -1.116 . . . . 0.0 110.311 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.97 -56.55 0.54 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 111.541 -0.624 . . . . 0.0 111.541 -178.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.559 HG22 ' N ' ' H' ' 40' ' ' VAL . 6.3 p -153.69 161.12 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 177.787 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.559 ' N ' HG22 ' H' ' 39' ' ' VAL . 14.2 m . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.787 -179.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.207 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -111.89 133.94 53.76 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 120.731 0.301 . . . . 0.0 110.557 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -155.39 144.95 21.19 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.895 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.46 ' CG1' HG22 ' H' ' 12' ' ' VAL . 2.5 p -127.37 118.67 50.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.409 0 CA-C-O 121.108 0.48 . . . . 0.0 109.946 179.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' O ' ' G' ' 40' ' ' VAL . 2.9 t-80 -147.83 120.2 8.43 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.588 -179.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.504 ' H ' ' CE1' ' H' ' 14' ' ' HIS . 4.8 m170 -122.48 162.74 21.15 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 120.794 -0.362 . . . . 0.0 110.823 178.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 29.5 tt0 -90.03 153.94 20.19 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 116.057 -0.519 . . . . 0.0 109.728 178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -145.47 97.07 2.93 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 120.42 -0.512 . . . . 0.0 110.646 177.387 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.642 HD11 HG21 ' G' ' 36' ' ' VAL . 18.4 mt -121.14 121.91 38.86 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.347 178.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -117.11 110.16 30.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 86.3 m-85 -107.76 108.97 20.43 Favored 'General case' 0 C--N 1.331 -0.228 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 179.61 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.614 ' CD1' ' CE2' ' H' ' 20' ' ' PHE . 28.0 t80 -115.68 126.33 53.98 Favored 'General case' 0 N--CA 1.472 0.669 0 N-CA-C 110.319 -0.252 . . . . 0.0 110.319 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.91 135.82 34.83 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.5 tt0 -94.09 140.6 29.54 Favored 'General case' 0 CA--C 1.532 0.255 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 178.142 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.532 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 7.4 p-10 -176.83 52.14 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.697 0.284 . . . . 0.0 110.442 -175.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.468 HG12 HG13 ' H' ' 24' ' ' VAL . 3.3 p -74.52 143.16 13.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 122.653 1.216 . . . . 0.0 112.637 -175.197 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.427 ' O ' ' OG ' ' I' ' 26' ' ' SER . . . 99.53 38.22 3.77 Favored Glycine 0 CA--C 1.529 0.961 0 CA-C-N 112.664 -2.062 . . . . 0.0 111.434 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 7.0 p 73.17 120.2 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 115.131 -0.535 . . . . 0.0 111.907 176.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' I' ' 29' ' ' GLY . 2.4 m-20 -83.93 152.68 24.36 Favored 'General case' 0 C--O 1.225 -0.22 0 C-N-CA 118.257 -1.377 . . . . 0.0 108.669 175.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.58 ' H ' ' H ' ' H' ' 29' ' ' GLY . 30.1 mtmt -50.68 43.66 0.0 OUTLIER 'General case' 0 CA--C 1.547 0.862 0 CA-C-O 116.966 -1.492 . . . . 0.0 114.178 175.571 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.625 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 120.94 77.44 0.47 Allowed Glycine 0 N--CA 1.487 2.04 0 CA-C-N 122.555 2.434 . . . . 0.0 113.013 -178.229 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.22 112.12 18.25 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-N 119.316 1.558 . . . . 0.0 111.8 -177.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.437 HD12 HG13 ' C' ' 39' ' ' VAL . 12.7 tt -145.74 141.67 21.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 N-CA-C 114.203 1.186 . . . . 0.0 114.203 -177.21 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.598 HG23 HD13 ' I' ' 34' ' ' LEU . 38.3 mt -111.16 113.19 43.56 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 176.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.714 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -115.01 99.93 0.95 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 107.465 -2.254 . . . . 0.0 107.465 177.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.714 HD12 ' O ' ' I' ' 33' ' ' GLY . 5.9 mp -136.22 148.22 47.98 Favored 'General case' 0 CA--C 1.513 -0.47 0 CA-C-O 123.411 1.577 . . . . 0.0 114.124 -176.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -116.59 106.31 13.41 Favored 'General case' 0 N--CA 1.436 -1.146 0 CA-C-N 111.724 -2.489 . . . . 0.0 104.526 175.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.479 ' HB ' HD21 ' J' ' 34' ' ' LEU . 38.6 t -126.58 142.75 42.25 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.74 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.152 -175.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 123.73 -101.99 0.71 Allowed Glycine 0 C--N 1.312 -0.768 0 N-CA-C 111.339 -0.704 . . . . 0.0 111.339 177.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.676 ' O ' HG21 ' J' ' 39' ' ' VAL . . . 66.69 -80.09 0.12 Allowed Glycine 0 CA--C 1.533 1.204 0 C-N-CA 120.206 -0.997 . . . . 0.0 110.665 -179.298 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.637 HG22 HD12 ' O' ' 31' ' ' ILE . 21.9 t -116.28 131.3 69.23 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.134 0 C-N-CA 123.068 0.547 . . . . 0.0 109.998 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.449 ' O ' ' O ' ' I' ' 39' ' ' VAL . 8.8 p . . . . . 0 C--O 1.218 -0.569 0 CA-C-O 118.038 -0.982 . . . . 0.0 111.43 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.481 -1.448 . . . . 0.0 109.481 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -108.39 136.28 48.29 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.741 0.305 . . . . 0.0 110.24 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -78.13 108.98 11.83 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.327 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.96 129.72 68.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.757 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.44 ' O ' ' N ' ' K' ' 14' ' ' HIS . 67.1 m80 -124.88 127.31 46.91 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.823 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.629 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 12.7 t60 -152.09 170.43 19.96 Favored 'General case' 0 N--CA 1.464 0.274 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.228 179.446 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.629 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 32.8 tt0 -138.5 140.65 39.25 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 177.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttm -130.57 104.28 7.13 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.464 ' CD1' ' CG ' ' J' ' 15' ' ' GLN . 6.3 mp -122.8 120.2 32.85 Favored 'General case' 0 N--CA 1.482 1.133 0 C-N-CA 120.223 -0.591 . . . . 0.0 109.736 177.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 41.0 t -113.7 112.25 39.46 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.911 179.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.441 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 43.7 m-85 -109.4 108.13 18.55 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 108.16 -1.052 . . . . 0.0 108.16 178.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.608 ' CD1' ' CE2' ' I' ' 20' ' ' PHE . 37.2 t80 -116.66 125.12 51.29 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-O 120.58 0.228 . . . . 0.0 110.955 -179.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.94 133.49 33.8 Favored 'General case' 0 C--O 1.241 0.627 0 CA-C-O 121.452 0.644 . . . . 0.0 111.842 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.453 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 80.1 tt0 -90.47 119.75 31.01 Favored 'General case' 0 C--N 1.339 0.143 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.534 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.587 ' CG ' HD21 ' I' ' 27' ' ' ASN . 0.2 OUTLIER -147.39 52.05 1.06 Allowed 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.443 -0.799 . . . . 0.0 108.901 -178.14 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.6 t -74.89 143.14 13.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 122.448 1.118 . . . . 0.0 112.793 -175.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.404 ' O ' ' HB3' ' J' ' 26' ' ' SER . . . 99.09 38.16 3.9 Favored Glycine 0 CA--C 1.531 1.037 0 CA-C-N 112.699 -2.046 . . . . 0.0 112.197 178.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.404 ' HB3' ' O ' ' J' ' 25' ' ' GLY . 22.0 t 72.68 120.02 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.845 0 C-N-CA 123.453 0.701 . . . . 0.0 111.11 176.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -83.18 161.75 21.46 Favored 'General case' 0 C--N 1.34 0.194 0 C-N-CA 117.18 -1.808 . . . . 0.0 110.221 177.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -47.7 -37.28 12.75 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 175.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.03 78.06 0.06 OUTLIER Glycine 0 CA--C 1.534 1.26 0 CA-C-O 118.741 -1.033 . . . . 0.0 112.236 -172.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -78.84 116.87 19.45 Favored 'General case' 0 N--CA 1.475 0.787 0 CA-C-N 120.076 1.938 . . . . 0.0 111.66 -175.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 5.0 tt -134.01 136.91 53.04 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.836 0 CA-C-N 112.253 -2.249 . . . . 0.0 113.134 -175.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 89.4 mt -113.09 122.66 67.65 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 120.999 0.428 . . . . 0.0 110.609 178.106 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.85 104.42 0.97 Allowed Glycine 0 N--CA 1.462 0.396 0 N-CA-C 106.339 -2.704 . . . . 0.0 106.339 176.467 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.897 HD23 ' N ' ' J' ' 35' ' ' MET . 5.0 tt -144.46 142.85 30.57 Favored 'General case' 0 C--O 1.239 0.529 0 CA-C-O 122.578 1.18 . . . . 0.0 112.47 -175.707 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.897 ' N ' HD23 ' J' ' 34' ' ' LEU . 28.6 mtp -116.32 115.05 25.21 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-N 113.145 -1.843 . . . . 0.0 108.779 178.367 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.829 HG11 HD11 ' L' ' 17' ' ' LEU . 0.1 OUTLIER -97.62 111.35 27.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.512 0 N-CA-C 106.811 -1.551 . . . . 0.0 106.811 178.956 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -53.52 131.49 42.96 Favored Glycine 0 CA--C 1.526 0.775 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.331 -177.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -89.95 63.51 3.16 Favored Glycine 0 CA--C 1.537 1.452 0 C-N-CA 121.279 -0.486 . . . . 0.0 111.938 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.676 HG21 ' O ' ' I' ' 38' ' ' GLY . 42.7 t -124.62 126.36 71.54 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.115 0 CA-C-O 121.461 0.648 . . . . 0.0 110.029 179.116 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.589 -179.208 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.66 135.76 48.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-O 120.657 0.265 . . . . 0.0 110.506 -179.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -123.16 111.65 16.76 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.334 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.501 HG23 ' O ' ' K' ' 12' ' ' VAL . 4.5 m -130.67 126.56 60.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.185 0.517 . . . . 0.0 111.03 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 56.7 m170 -110.16 157.58 19.24 Favored 'General case' 0 C--N 1.33 -0.263 0 N-CA-C 108.598 -0.89 . . . . 0.0 108.598 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.712 ' CD2' ' H ' ' K' ' 15' ' ' GLN . 29.1 t60 -158.01 178.02 10.68 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 119.434 -0.906 . . . . 0.0 112.826 -179.304 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.712 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 31.6 tt0 -160.37 140.57 11.48 Favored 'General case' 0 N--CA 1.451 -0.42 0 CA-C-N 114.197 -1.365 . . . . 0.0 107.54 179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -159.48 115.97 2.58 Favored 'General case' 0 C--N 1.315 -0.895 0 C-N-CA 119.178 -1.009 . . . . 0.0 111.947 -178.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.46 ' N ' HD12 ' K' ' 17' ' ' LEU . 4.6 mp -128.07 125.03 38.49 Favored 'General case' 0 CA--C 1.506 -0.728 0 CA-C-N 114.395 -1.275 . . . . 0.0 109.196 178.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 26.3 m -116.03 121.09 66.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.441 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 24.1 m-85 -109.16 109.85 20.93 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.695 -178.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -111.92 118.67 36.14 Favored 'General case' 0 N--CA 1.469 0.49 0 O-C-N 122.357 -0.214 . . . . 0.0 111.04 -179.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.66 126.74 27.94 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 121.141 0.496 . . . . 0.0 110.315 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.416 ' O ' ' O ' ' J' ' 23' ' ' ASP . 75.4 mt-10 -87.8 140.58 29.36 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.204 -0.598 . . . . 0.0 110.406 -179.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 7.0 p-10 178.52 48.87 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 112.641 0.608 . . . . 0.0 112.641 -177.708 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 17.8 m -72.16 160.61 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 C-N-CA 119.309 -0.956 . . . . 0.0 109.887 -179.728 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.22 -33.25 5.95 Favored Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.848 -0.615 . . . . 0.0 112.149 177.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 1.7 p -72.23 129.98 39.73 Favored 'General case' 0 N--CA 1.465 0.325 0 N-CA-C 111.98 0.363 . . . . 0.0 111.98 -179.32 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.48 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 46.5 t-20 -90.86 143.65 26.5 Favored 'General case' 0 C--O 1.232 0.154 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 176.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.48 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 51.7 tttp 43.52 42.84 4.22 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 179.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.414 ' O ' ' CG ' ' L' ' 23' ' ' ASP . . . -101.69 60.48 0.58 Allowed Glycine 0 N--CA 1.476 1.308 0 CA-C-O 119.269 -0.74 . . . . 0.0 114.111 -178.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.86 119.95 4.94 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 119.204 1.502 . . . . 0.0 111.772 179.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 74.3 mt -121.6 116.83 50.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 108.442 -0.947 . . . . 0.0 108.442 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -124.17 128.3 73.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 N-CA-C 112.771 0.656 . . . . 0.0 112.771 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.22 103.18 0.79 Allowed Glycine 0 CA--C 1.523 0.535 0 N-CA-C 108.024 -2.03 . . . . 0.0 108.024 177.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.638 HD11 ' CG2' ' J' ' 36' ' ' VAL . 30.2 tp -117.11 121.4 41.17 Favored 'General case' 0 C--O 1.24 0.58 0 CA-C-O 121.265 0.555 . . . . 0.0 110.007 -178.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 18.5 ttm -120.86 129.86 53.69 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.16 -178.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' K' ' 37' ' ' GLY . 54.9 t -115.78 131.93 66.75 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.886 178.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -45.03 -111.73 0.0 OUTLIER Glycine 0 CA--C 1.529 0.915 0 CA-C-N 115.519 -0.764 . . . . 0.0 112.349 178.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.476 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -107.15 -71.69 0.77 Allowed Glycine 0 CA--C 1.534 1.223 0 N-CA-C 111.883 -0.487 . . . . 0.0 111.883 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.448 HG22 ' O ' ' L' ' 39' ' ' VAL . 54.1 t -125.2 127.19 71.96 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.719 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.521 HG23 ' OXT' ' K' ' 40' ' ' VAL . 8.4 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.738 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -109.48 137.14 47.76 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.723 0.297 . . . . 0.0 110.365 179.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -73.54 147.41 44.01 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.488 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 m -129.93 135.78 60.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.081 0.467 . . . . 0.0 111.567 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 5.1 p80 -146.85 97.97 2.98 Favored 'General case' 0 CA--C 1.53 0.197 0 CA-C-N 115.661 -0.699 . . . . 0.0 111.275 179.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 29.4 p-80 -154.69 162.59 41.06 Favored 'General case' 0 N--CA 1.463 0.206 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.826 178.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 5.6 pt20 -89.95 159.24 17.01 Favored 'General case' 0 CA--C 1.521 -0.158 0 CA-C-O 121.203 0.525 . . . . 0.0 111.632 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 92.8 mttt -140.06 110.6 6.72 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.457 -0.792 . . . . 0.0 109.791 177.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.829 HD11 HG11 ' J' ' 36' ' ' VAL . 25.9 mt -118.09 112.19 19.89 Favored 'General case' 0 CA--C 1.504 -0.793 0 CA-C-N 115.942 -0.572 . . . . 0.0 109.555 178.802 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 9.0 t -104.21 100.67 10.96 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 176.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 64.3 m-85 -94.44 99.87 11.97 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 106.487 -1.671 . . . . 0.0 106.487 178.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 49.5 t80 -116.24 112.17 21.22 Favored 'General case' 0 CA--C 1.517 -0.297 0 CA-C-O 121.466 0.651 . . . . 0.0 110.984 -178.478 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.1 135.41 32.52 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 107.842 -1.169 . . . . 0.0 107.842 178.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.497 ' HB2' ' H ' ' K' ' 23' ' ' ASP . 80.3 mm-40 -73.39 108.89 6.51 Favored 'General case' 0 C--N 1.323 -0.55 0 C-N-CA 118.627 -1.229 . . . . 0.0 108.401 -179.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.471 ' O ' ' O ' ' L' ' 24' ' ' VAL . 64.9 m-20 -164.03 61.39 0.16 Allowed 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.514 -176.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.471 ' O ' ' O ' ' L' ' 23' ' ' ASP . 8.9 t 55.63 155.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.332 -0.195 0 C-N-CA 119.665 -0.814 . . . . 0.0 110.153 -177.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -163.24 24.2 0.19 Allowed Glycine 0 CA--C 1.521 0.413 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -175.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 40.3 t -81.86 -120.93 0.02 OUTLIER 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 107.677 -1.231 . . . . 0.0 107.677 178.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.64 ' O ' ' N ' ' L' ' 29' ' ' GLY . 99.3 m-20 -93.05 -165.61 1.37 Allowed 'General case' 0 C--N 1.325 -0.471 0 C-N-CA 119.754 -0.778 . . . . 0.0 109.502 -179.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -47.98 47.68 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 115.732 1.753 . . . . 0.0 115.732 -176.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.64 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.31 56.86 0.89 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-N 119.253 0.933 . . . . 0.0 112.339 177.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -168.62 169.8 9.97 Favored 'General case' 0 CA--C 1.513 -0.475 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 179.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.433 ' CD1' HG12 ' F' ' 39' ' ' VAL . 8.3 mm -112.98 111.31 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 176.781 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -125.75 130.1 72.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.594 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.0 116.48 2.73 Favored Glycine 0 CA--C 1.528 0.87 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 178.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 56.9 tp -118.32 123.08 44.47 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.901 -0.407 . . . . 0.0 109.901 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 13.4 ttm -125.66 124.99 42.35 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.101 0.408 . . . . 0.0 112.101 -179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 53.2 t -124.24 132.45 71.32 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 109.345 -0.613 . . . . 0.0 109.345 178.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.8 112.13 3.6 Favored Glycine 0 CA--C 1.531 1.087 0 CA-C-N 115.907 -0.588 . . . . 0.0 113.193 -178.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.97 -71.17 0.01 OUTLIER Glycine 0 CA--C 1.538 1.521 0 N-CA-C 115.216 0.847 . . . . 0.0 115.216 177.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.476 ' O ' ' O ' ' K' ' 38' ' ' GLY . 54.1 t -134.43 137.13 52.02 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.765 0 CA-C-N 117.96 0.88 . . . . 0.0 112.007 -178.302 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.475 ' O ' ' N ' ' K' ' 40' ' ' VAL . 61.7 t . . . . . 0 C--O 1.213 -0.837 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.091 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -110.04 138.56 46.25 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.911 0.386 . . . . 0.0 110.567 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -71.19 139.88 50.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.784 -179.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.6 t -122.01 131.29 73.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.01 0.434 . . . . 0.0 110.07 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 85.6 t60 -119.27 130.35 55.38 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.273 -179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.497 ' CD2' ' O ' ' N' ' 13' ' ' HIS . 13.6 m-70 -83.23 167.09 18.02 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.138 0.494 . . . . 0.0 111.126 -179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -93.38 159.98 15.01 Favored 'General case' 0 CA--C 1.518 -0.279 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.425 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -111.32 145.96 37.9 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.456 -0.793 . . . . 0.0 109.145 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 88.7 mt -130.1 130.75 45.24 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 120.965 0.412 . . . . 0.0 111.465 -179.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 67.3 t -133.75 132.2 56.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.375 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.963 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -138.67 136.71 36.14 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 121.171 0.51 . . . . 0.0 112.001 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -121.11 125.15 46.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 115.432 -0.804 . . . . 0.0 109.063 178.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.62 113.75 25.49 Favored 'General case' 0 C--O 1.239 0.534 0 CA-C-O 121.345 0.593 . . . . 0.0 111.224 -179.503 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . 0.418 ' OE1' ' OE2' ' N' ' 22' ' ' GLU . 12.4 pt-20 -173.16 150.31 1.92 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 115.271 -0.877 . . . . 0.0 108.724 179.747 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 96.7 m-20 56.03 46.95 20.77 Favored 'General case' 0 CA--C 1.535 0.391 0 C-N-CA 120.1 -0.64 . . . . 0.0 112.158 178.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . . . . . . . . . 34.5 m -101.03 -170.5 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 -178.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -65.12 -32.43 84.01 Favored Glycine 0 N--CA 1.468 0.822 0 C-N-CA 120.961 -0.638 . . . . 0.0 112.241 -177.184 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 47.6 t -152.88 125.11 8.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.366 0.583 . . . . 0.0 109.789 177.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.641 ' HA ' HG11 ' N' ' 24' ' ' VAL . 1.9 m-20 -38.93 134.58 0.99 Allowed 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.956 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.67 -39.54 4.84 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 122.192 0.996 . . . . 0.0 108.39 176.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . 0.454 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 79.89 -69.29 3.09 Favored Glycine 0 CA--C 1.534 1.261 0 CA-C-N 113.348 -1.751 . . . . 0.0 110.753 -178.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.593 ' HB3' ' HA ' ' N' ' 30' ' ' ALA . . . 179.6 82.38 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 117.335 0.568 . . . . 0.0 111.009 176.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.608 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.6 tt -121.4 104.58 15.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 119.592 1.087 . . . . 0.0 109.482 179.709 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.6 mt -124.39 116.59 48.09 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 CA-C-O 121.402 0.62 . . . . 0.0 111.618 -179.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.83 104.93 0.86 Allowed Glycine 0 N--CA 1.464 0.529 0 N-CA-C 106.086 -2.806 . . . . 0.0 106.086 176.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . 0.458 ' HB2' HD11 ' N' ' 34' ' ' LEU . 85.7 mt -145.28 159.81 42.46 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 123.3 1.524 . . . . 0.0 114.214 -176.189 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 35.4 tpp -107.08 108.5 20.01 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.844 -2.435 . . . . 0.0 105.85 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 4.7 m -119.57 123.06 70.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-N 119.055 0.843 . . . . 0.0 109.68 -179.272 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 140.25 -113.7 0.9 Allowed Glycine 0 C--N 1.31 -0.897 0 N-CA-C 109.026 -1.63 . . . . 0.0 109.026 179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.43 ' O ' ' CD1' ' A' ' 31' ' ' ILE . . . 95.48 -72.13 0.95 Allowed Glycine 0 CA--C 1.532 1.11 0 N-CA-C 112.318 -0.313 . . . . 0.0 112.318 179.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 40' ' ' VAL . 2.4 t -122.29 159.23 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.318 0 O-C-N 122.691 -0.3 . . . . 0.0 110.621 -179.721 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' M' ' 39' ' ' VAL . 2.9 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.14 -0.933 . . . . 0.0 110.827 179.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.408 -1.477 . . . . 0.0 109.408 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -108.21 132.48 53.61 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.835 0.35 . . . . 0.0 110.401 179.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -125.88 126.86 45.11 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.027 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.416 ' CG1' ' NE2' ' M' ' 14' ' ' HIS . 59.2 t -127.73 130.33 70.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-O 120.871 0.367 . . . . 0.0 110.994 -179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.497 ' O ' ' CD2' ' M' ' 14' ' ' HIS . 29.8 t-80 -79.66 161.31 25.92 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.813 179.675 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . . . . . . . . . 29.8 p-80 -93.26 163.18 13.71 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-O 121.216 0.531 . . . . 0.0 111.322 -179.565 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -89.88 160.12 16.61 Favored 'General case' 0 CA--C 1.519 -0.213 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.61 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.22 131.6 28.48 Favored 'General case' 0 C--N 1.314 -0.95 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 4.6 mp -132.59 127.37 34.86 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 121.348 0.594 . . . . 0.0 111.199 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.5 130.77 72.71 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.613 179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -132.43 122.41 24.93 Favored 'General case' 0 C--O 1.234 0.256 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.086 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.549 ' CZ ' ' CD1' ' O' ' 20' ' ' PHE . 5.7 t80 -121.15 127.6 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.285 -179.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.49 117.3 25.6 Favored 'General case' 0 C--O 1.237 0.419 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.418 ' OE2' ' OE1' ' M' ' 22' ' ' GLU . 97.7 mt-10 -81.59 179.63 7.76 Favored 'General case' 0 N--CA 1.466 0.354 0 C-N-CA 119.811 -0.755 . . . . 0.0 109.297 180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.633 ' O ' HG23 ' N' ' 24' ' ' VAL . 62.3 t0 -60.53 -46.91 88.42 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 119.193 -1.003 . . . . 0.0 108.494 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 1.011 HG12 ' H ' ' N' ' 25' ' ' GLY . 9.4 t 99.81 -161.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 1.011 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -71.32 -33.4 64.53 Favored Glycine 0 N--CA 1.444 -0.78 0 N-CA-C 109.02 -1.632 . . . . 0.0 109.02 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' N' ' 27' ' ' ASN . 34.2 t -162.55 120.55 2.1 Favored 'General case' 0 CA--C 1.536 0.429 0 N-CA-C 112.541 0.571 . . . . 0.0 112.541 179.473 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.577 ' O ' ' O ' ' N' ' 26' ' ' SER . 41.2 t-20 -22.0 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 CA-C-N 114.682 -1.145 . . . . 0.0 112.443 177.177 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.669 ' HA ' ' HZ3' ' O' ' 28' ' ' LYS . 69.9 tttt -163.03 24.39 0.09 Allowed 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 115.163 1.542 . . . . 0.0 115.163 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.9 107.68 1.25 Allowed Glycine 0 N--CA 1.476 1.35 0 C-N-CA 117.506 -2.283 . . . . 0.0 113.929 177.629 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . 0.593 ' HA ' ' HB3' ' M' ' 30' ' ' ALA . . . -109.53 102.69 11.52 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-O 123.637 1.684 . . . . 0.0 109.912 -178.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.483 HD13 HG21 ' I' ' 39' ' ' VAL . 20.7 mt -130.19 130.48 65.75 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 112.388 -2.187 . . . . 0.0 110.824 -176.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.423 HD13 ' HD2' ' P' ' 19' ' ' PHE . 10.1 tt -123.6 116.3 47.84 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.805 0.812 . . . . 0.0 109.844 176.611 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.568 ' O ' HD12 ' N' ' 34' ' ' LEU . . . -109.1 111.58 3.26 Favored Glycine 0 C--N 1.333 0.411 0 N-CA-C 107.02 -2.432 . . . . 0.0 107.02 178.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.568 HD12 ' O ' ' N' ' 33' ' ' GLY . 0.8 OUTLIER -137.88 139.22 39.75 Favored 'General case' 0 C--O 1.235 0.331 0 CA-C-O 122.633 1.206 . . . . 0.0 113.636 -176.094 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 95.7 mmm -106.36 111.56 24.19 Favored 'General case' 0 C--N 1.319 -0.723 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 175.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.711 HG11 HD11 ' P' ' 17' ' ' LEU . 2.1 t -117.19 123.15 71.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 109.564 -0.532 . . . . 0.0 109.564 -178.105 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 155.38 -113.0 0.55 Allowed Glycine 0 C--N 1.306 -1.12 0 C-N-CA 119.793 -1.194 . . . . 0.0 110.747 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 82.78 -73.16 2.71 Favored Glycine 0 CA--C 1.533 1.195 0 N-CA-C 110.927 -0.869 . . . . 0.0 110.927 -178.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.956 HG22 HD12 ' B' ' 31' ' ' ILE . 62.8 t -138.17 138.39 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 C-N-CA 123.062 0.545 . . . . 0.0 109.777 179.505 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.441 ' O ' ' OXT' ' O' ' 40' ' ' VAL . 46.5 t . . . . . 0 C--O 1.218 -0.562 0 CA-C-O 118.538 -0.744 . . . . 0.0 111.681 179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -107.96 137.4 46.03 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.873 0.368 . . . . 0.0 110.521 179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -93.23 113.31 25.49 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.374 -179.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -125.28 128.72 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 CA-C-O 120.781 0.324 . . . . 0.0 110.167 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 49.7 m80 -131.29 138.27 49.18 Favored 'General case' 0 N--CA 1.466 0.348 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.612 ' ND1' ' CE1' ' P' ' 14' ' ' HIS . 83.2 t60 -154.64 153.85 32.02 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 118.346 -1.342 . . . . 0.0 112.836 179.387 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.529 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 33.8 tt0 -90.63 164.44 14.18 Favored 'General case' 0 CA--C 1.519 -0.234 0 CA-C-N 114.646 -1.161 . . . . 0.0 109.721 177.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -169.54 102.18 0.33 Allowed 'General case' 0 C--N 1.296 -1.722 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mt -122.86 119.59 30.98 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.414 179.354 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 15.6 t -106.96 115.32 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.429 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.401 178.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 79.4 m-85 -113.87 105.48 13.32 Favored 'General case' 0 CA--C 1.529 0.165 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.617 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 12.5 t80 -107.2 125.46 51.14 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.377 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.39 135.59 44.77 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -177.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -112.19 139.87 47.37 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 115.112 -0.949 . . . . 0.0 109.452 177.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 11.2 m-20 -156.41 46.52 0.44 Allowed 'General case' 0 N--CA 1.468 0.447 0 CA-C-O 120.814 0.34 . . . . 0.0 110.127 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.712 HG12 ' H ' ' O' ' 25' ' ' GLY . 3.0 t -82.64 174.35 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 122.314 1.054 . . . . 0.0 112.552 -176.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.712 ' H ' HG12 ' O' ' 24' ' ' VAL . . . 92.59 -35.91 3.88 Favored Glycine 0 CA--C 1.533 1.197 0 CA-C-N 113.228 -1.805 . . . . 0.0 112.661 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.647 ' O ' ' O ' ' O' ' 27' ' ' ASN . 21.6 p -172.28 113.74 0.3 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 118.974 1.387 . . . . 0.0 112.218 175.232 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.647 ' O ' ' O ' ' O' ' 26' ' ' SER . 25.2 p30 -10.59 153.34 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.878 0 O-C-N 124.55 1.157 . . . . 0.0 113.994 176.428 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.669 ' HZ3' ' HA ' ' N' ' 28' ' ' LYS . 32.2 tttt -166.33 26.19 0.04 OUTLIER 'General case' 0 N--CA 1.463 0.194 0 C-N-CA 118.457 -1.297 . . . . 0.0 113.843 172.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.65 107.33 0.37 Allowed Glycine 0 CA--C 1.53 0.982 0 C-N-CA 119.318 -1.42 . . . . 0.0 112.474 178.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . 0.718 ' H ' ' ND2' ' P' ' 27' ' ' ASN . . . -120.97 112.48 18.81 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.031 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.637 HD12 HG22 ' I' ' 39' ' ' VAL . 83.6 mt -131.68 131.85 62.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -176.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.641 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 88.6 mt -108.22 106.06 19.96 Favored 'Isoleucine or valine' 0 C--N 1.344 0.351 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 174.025 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.47 ' O ' HD12 ' O' ' 34' ' ' LEU . . . -112.58 101.58 1.23 Allowed Glycine 0 N--CA 1.464 0.541 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.512 HD13 HG23 ' O' ' 32' ' ' ILE . 3.5 mp -139.78 146.46 39.49 Favored 'General case' 0 CA--C 1.508 -0.638 0 CA-C-O 123.14 1.447 . . . . 0.0 113.329 -176.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 12.3 mtp -113.24 108.66 17.57 Favored 'General case' 0 N--CA 1.435 -1.197 0 CA-C-N 111.828 -2.442 . . . . 0.0 106.371 177.17 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.654 HG12 ' HB ' ' N' ' 36' ' ' VAL . 1.5 m -124.13 102.85 11.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.03 -151.6 21.01 Favored Glycine 0 C--N 1.302 -1.332 0 C-N-CA 119.505 -1.331 . . . . 0.0 110.062 179.643 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.29 -57.1 1.45 Allowed Glycine 0 CA--C 1.533 1.203 0 N-CA-C 110.525 -1.03 . . . . 0.0 110.525 -178.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.804 HG11 HD13 ' B' ' 31' ' ' ILE . 33.4 m -129.07 159.3 41.26 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.318 0 C-N-CA 123.253 0.621 . . . . 0.0 110.633 -178.342 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.552 HG22 ' C ' ' P' ' 40' ' ' VAL . 3.5 t . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.069 -0.967 . . . . 0.0 111.648 -178.747 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.337 -1.505 . . . . 0.0 109.337 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -111.36 133.89 53.34 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.055 0.455 . . . . 0.0 110.583 -179.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -138.91 157.48 45.96 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.28 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . . . . . . . . . 6.7 t -107.0 95.22 3.62 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.191 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.943 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.695 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 18.0 m170 -120.63 110.83 16.89 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.834 -179.601 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.612 ' CE1' ' ND1' ' O' ' 14' ' ' HIS . 0.2 OUTLIER -160.69 166.99 27.86 Favored 'General case' 0 N--CA 1.466 0.325 0 C-N-CA 119.403 -0.919 . . . . 0.0 113.17 177.771 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.53 ' NE2' HE21 ' Q' ' 15' ' ' GLN . 15.6 pt20 -89.94 151.6 21.63 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.733 178.771 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . 0.462 ' H ' ' HB3' ' O' ' 15' ' ' GLN . 86.7 tttt -149.79 119.26 6.91 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.47 0.653 . . . . 0.0 110.727 177.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.711 HD11 HG11 ' N' ' 36' ' ' VAL . 3.5 mp -138.99 132.37 30.12 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.218 178.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 28.3 m -119.02 120.98 65.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 N-CA-C 106.869 -1.53 . . . . 0.0 106.869 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.515 ' CD1' ' CE1' ' Q' ' 19' ' ' PHE . 13.4 m-85 -110.78 112.19 23.89 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 -178.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.617 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 22.4 t80 -119.84 127.76 53.05 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 113.019 0.748 . . . . 0.0 113.019 -175.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.81 127.25 48.84 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.571 ' CG ' ' H ' ' P' ' 23' ' ' ASP . 19.1 tt0 -72.07 177.06 4.6 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 115.75 1.759 . . . . 0.0 115.75 -173.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.571 ' H ' ' CG ' ' P' ' 22' ' ' GLU . 55.3 t0 -45.31 47.42 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 112.349 -2.205 . . . . 0.0 116.731 -177.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.751 HG12 ' H ' ' P' ' 25' ' ' GLY . 49.0 t -60.88 -179.84 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 C-N-CA 117.903 -1.519 . . . . 0.0 107.317 177.385 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.751 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -102.08 34.97 5.27 Favored Glycine 0 N--CA 1.469 0.898 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.415 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 0.8 OUTLIER 74.53 120.35 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 106.443 -1.688 . . . . 0.0 106.443 -177.535 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.718 ' ND2' ' H ' ' O' ' 30' ' ' ALA . 12.2 p-10 -82.79 172.7 12.58 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 122.125 0.964 . . . . 0.0 113.312 -177.155 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.414 ' H ' ' HB2' ' O' ' 27' ' ' ASN . 87.6 tttt -49.2 -36.25 19.32 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.462 -1.699 . . . . 0.0 111.572 177.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.503 ' C ' HD21 ' P' ' 27' ' ' ASN . . . -178.42 78.01 0.07 OUTLIER Glycine 0 CA--C 1.541 1.688 0 CA-C-N 115.58 -0.736 . . . . 0.0 112.336 -174.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . 0.589 ' N ' HD21 ' P' ' 27' ' ' ASN . . . -79.85 139.32 37.21 Favored 'General case' 0 C--N 1.353 0.758 0 CA-C-O 121.752 0.787 . . . . 0.0 111.132 -177.755 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.671 HG21 HG13 ' J' ' 39' ' ' VAL . 9.5 tt -149.98 141.83 17.19 Favored 'Isoleucine or valine' 0 C--O 1.239 0.52 0 N-CA-C 114.028 1.122 . . . . 0.0 114.028 -176.179 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.503 HG12 HD12 ' O' ' 32' ' ' ILE . 75.3 mt -105.72 109.55 28.24 Favored 'Isoleucine or valine' 0 C--N 1.349 0.55 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 176.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.2 99.58 1.71 Allowed Glycine 0 C--O 1.24 0.492 0 N-CA-C 105.39 -3.084 . . . . 0.0 105.39 176.176 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.531 HD23 HG22 ' P' ' 36' ' ' VAL . 5.4 tp -128.41 134.77 48.86 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 113.955 1.094 . . . . 0.0 113.955 -175.274 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . 0.487 ' SD ' ' O ' ' Q' ' 35' ' ' MET . 60.0 tpp -112.69 110.98 21.45 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 114.006 -1.452 . . . . 0.0 107.62 176.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.9 ' O ' HG13 ' Q' ' 36' ' ' VAL . 0.2 OUTLIER -105.09 111.79 36.01 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.228 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 179.341 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.433 ' O ' ' NE2' ' R' ' 15' ' ' GLN . . . -63.75 131.99 40.53 Favored Glycine 0 N--CA 1.465 0.588 0 CA-C-N 115.868 -0.606 . . . . 0.0 113.204 -177.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.584 ' O ' HG22 ' Q' ' 39' ' ' VAL . . . -77.92 64.15 3.41 Favored Glycine 0 CA--C 1.541 1.669 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 m -127.42 154.28 37.59 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.465 0 C-N-CA 123.44 0.696 . . . . 0.0 110.266 -178.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.552 ' C ' HG22 ' O' ' 40' ' ' VAL . 1.4 p . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.183 -0.913 . . . . 0.0 110.419 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -82.02 137.29 35.12 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.814 0.34 . . . . 0.0 110.753 -179.931 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -74.03 150.1 40.85 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.664 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.531 ' O ' ' CD2' ' Q' ' 14' ' ' HIS . 27.0 m -128.69 -175.84 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 121.107 0.479 . . . . 0.0 111.04 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.695 ' CD2' ' H ' ' P' ' 13' ' ' HIS . 2.9 m170 -67.44 105.31 1.77 Allowed 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -176.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.554 ' ND1' ' O ' ' R' ' 12' ' ' VAL . 4.7 m-70 -114.53 160.91 18.7 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 175.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.53 HE21 ' NE2' ' P' ' 15' ' ' GLN . 42.8 tt0 -89.99 157.32 17.88 Favored 'General case' 0 CA--C 1.516 -0.343 0 C-N-CA 119.016 -1.074 . . . . 0.0 109.251 178.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -142.19 94.8 2.7 Favored 'General case' 0 C--N 1.314 -0.939 0 C-N-CA 120.21 -0.596 . . . . 0.0 111.606 177.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . . . . . . . . . 11.8 mt -127.76 115.5 18.77 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 119.869 -0.732 . . . . 0.0 109.923 177.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 t -112.54 110.63 32.91 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.672 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.746 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.641 ' CD1' HD13 ' O' ' 32' ' ' ILE . 57.7 m-85 -107.92 102.1 11.32 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 178.057 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.418 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 33.5 t80 -111.25 124.19 51.72 Favored 'General case' 0 C--N 1.329 -0.298 0 N-CA-C 110.345 -0.243 . . . . 0.0 110.345 -178.414 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.8 128.57 24.94 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.203 0.525 . . . . 0.0 111.779 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 70.6 tt0 -86.92 104.14 15.97 Favored 'General case' 0 CA--C 1.516 -0.344 0 N-CA-C 106.493 -1.669 . . . . 0.0 106.493 176.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD2' ' R' ' 23' ' ' ASP . 39.5 p-10 -135.05 52.27 2.05 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 114.562 -1.199 . . . . 0.0 111.517 -175.765 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 86.8 t -73.75 142.57 14.71 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.537 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 -177.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.88 37.69 3.59 Favored Glycine 0 CA--C 1.529 0.924 0 N-CA-C 106.846 -2.502 . . . . 0.0 106.846 -174.204 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 11.2 t -70.4 103.65 2.49 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.644 -0.778 . . . . 0.0 111.281 -178.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 53.0 p-10 -117.97 -151.93 0.49 Allowed 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 114.541 -1.209 . . . . 0.0 110.905 -178.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -39.8 -42.43 1.28 Allowed 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 114.391 -1.277 . . . . 0.0 113.468 -178.591 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.9 61.74 0.7 Allowed Glycine 0 CA--C 1.545 1.942 0 N-CA-C 115.793 1.077 . . . . 0.0 115.793 -174.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . 0.468 ' HB3' ' HB2' ' R' ' 30' ' ' ALA . . . -141.24 107.85 5.34 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 107.694 -1.225 . . . . 0.0 107.694 176.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.407 ' O ' ' HA ' ' P' ' 31' ' ' ILE . 87.3 mt -132.97 133.45 58.78 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.132 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -176.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.72 123.03 69.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 177.422 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.85 119.86 3.29 Favored Glycine 0 CA--C 1.531 1.085 0 N-CA-C 111.258 -0.737 . . . . 0.0 111.258 -179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 46.3 mt -120.56 119.86 34.15 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 120.692 0.282 . . . . 0.0 110.273 -179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.487 ' O ' ' SD ' ' P' ' 35' ' ' MET . 94.0 mmm -116.52 123.71 48.09 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 112.257 0.466 . . . . 0.0 112.257 -179.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.9 HG13 ' O ' ' P' ' 36' ' ' VAL . 6.5 t -140.04 163.8 23.72 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 178.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -169.18 93.38 0.1 Allowed Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 119.513 -1.327 . . . . 0.0 111.382 177.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.23 -81.98 0.11 Allowed Glycine 0 CA--C 1.533 1.182 0 C-N-CA 119.709 -1.234 . . . . 0.0 113.41 176.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.584 HG22 ' O ' ' P' ' 38' ' ' GLY . 10.6 m -147.0 162.09 8.45 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.394 0 CA-C-O 120.858 0.361 . . . . 0.0 110.425 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 66.6 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.984 -1.007 . . . . 0.0 110.481 -179.855 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -108.5 134.71 50.9 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.765 0.316 . . . . 0.0 110.328 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' R' ' 11' ' ' GLU . 57.2 mp0 -77.04 135.7 38.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.669 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.554 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 40.7 t -139.0 163.31 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.133 -179.863 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.551 ' N ' HG12 ' R' ' 12' ' ' VAL . 0.1 OUTLIER -89.04 119.6 29.7 Favored 'General case' 0 CA--C 1.536 0.41 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.553 178.343 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 80.2 m-70 -149.51 171.15 17.07 Favored 'General case' 0 N--CA 1.47 0.538 0 CA-C-O 120.797 0.332 . . . . 0.0 111.675 -179.279 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.433 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 32.8 mt-30 -83.64 154.65 23.6 Favored 'General case' 0 N--CA 1.456 -0.139 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 179.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . 0.454 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 70.4 tttt -159.75 104.6 1.57 Allowed 'General case' 0 C--N 1.311 -1.096 0 CA-C-O 121.637 0.732 . . . . 0.0 109.573 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.415 HD11 HG11 ' P' ' 36' ' ' VAL . 2.7 mp -126.14 119.71 28.24 Favored 'General case' 0 CA--C 1.505 -0.758 0 CA-C-N 114.926 -1.034 . . . . 0.0 109.325 178.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 26.7 t -101.72 107.9 22.53 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 107.334 -1.358 . . . . 0.0 107.334 177.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.405 ' CD1' HD13 ' P' ' 32' ' ' ILE . 74.5 m-85 -103.04 99.51 9.4 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 105.816 -1.92 . . . . 0.0 105.816 178.083 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -118.48 119.58 34.98 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-O 121.731 0.777 . . . . 0.0 111.457 -177.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.426 ' HB1' ' OD2' ' Q' ' 23' ' ' ASP . . . -124.99 134.11 52.73 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 106.912 -1.514 . . . . 0.0 106.912 178.059 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.485 ' O ' ' CB ' ' R' ' 23' ' ' ASP . 83.0 mt-10 -68.72 103.96 1.88 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.226 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.485 ' CB ' ' O ' ' R' ' 22' ' ' GLU . 5.3 p30 140.46 48.44 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.733 0 O-C-N 125.107 1.504 . . . . 0.0 108.519 -178.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 36.0 m -72.32 161.27 4.91 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-O 121.341 0.591 . . . . 0.0 111.579 -177.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.7 -29.79 8.3 Favored Glycine 0 CA--C 1.529 0.96 0 CA-C-N 114.888 -1.051 . . . . 0.0 111.219 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.42 ' O ' ' OG ' ' R' ' 26' ' ' SER . 6.3 p 61.68 109.86 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 120.645 -0.422 . . . . 0.0 110.638 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.732 ' O ' ' N ' ' R' ' 29' ' ' GLY . 66.0 t30 -129.72 -179.93 5.47 Favored 'General case' 0 N--CA 1.469 0.517 0 C-N-CA 120.865 -0.334 . . . . 0.0 111.313 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . 0.505 ' H ' ' CG ' ' R' ' 27' ' ' ASN . 98.9 mttt -29.6 47.81 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 C-N-CA 126.325 1.85 . . . . 0.0 115.927 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.732 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -170.05 -59.03 0.04 OUTLIER Glycine 0 CA--C 1.539 1.554 0 C-N-CA 120.045 -1.074 . . . . 0.0 113.686 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . 0.468 ' HB2' ' HB3' ' Q' ' 30' ' ' ALA . . . -81.0 153.98 27.16 Favored 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 117.644 0.722 . . . . 0.0 112.132 -177.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 97.9 mt -121.93 132.37 71.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.891 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.31 179.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.6 mt -123.69 128.41 74.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 116.313 -0.403 . . . . 0.0 109.929 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.51 120.29 3.65 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 111.836 -0.505 . . . . 0.0 111.836 -179.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 35.9 mt -110.15 115.3 29.49 Favored 'General case' 0 CA--C 1.515 -0.383 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 33.3 tpp -128.26 122.9 32.8 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 -177.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.564 HG12 ' N ' ' R' ' 37' ' ' GLY . 21.8 t -136.35 171.55 16.71 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 177.684 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.564 ' N ' HG12 ' R' ' 36' ' ' VAL . . . -167.93 94.4 0.11 Allowed Glycine 0 C--N 1.309 -0.931 0 C-N-CA 119.598 -1.287 . . . . 0.0 111.439 178.832 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 161.0 -81.44 0.14 Allowed Glycine 0 CA--C 1.532 1.109 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 177.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 19.0 m -154.96 151.16 11.01 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.141 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 177.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 5.6 t . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.29 179.812 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.524 ' CE2' ' O ' ' A' ' 11' ' ' GLU . 82.6 t80 -84.08 129.29 34.91 Favored 'General case' 0 C--O 1.232 0.174 0 CA-C-O 120.751 0.31 . . . . 0.0 110.637 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.524 ' O ' ' CE2' ' A' ' 10' ' ' TYR . 98.7 mt-10 -81.0 155.79 26.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.205 179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 70.2 t -121.79 128.87 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.095 0.474 . . . . 0.0 110.421 -179.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 92.0 m-70 -119.55 163.59 17.09 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.485 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.497 ' CD2' ' H ' ' A' ' 14' ' ' HIS . 3.0 m-70 -83.51 164.71 19.67 Favored 'General case' 0 C--N 1.332 -0.157 0 C-N-CA 120.153 -0.619 . . . . 0.0 111.231 -179.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.2 mt-30 -130.56 152.51 49.86 Favored 'General case' 0 N--CA 1.456 -0.145 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.319 179.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -94.37 116.6 29.0 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 178.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 30.3 tp -122.28 115.68 22.77 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.195 0.521 . . . . 0.0 110.017 -179.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . 0.621 HG22 HG22 ' B' ' 18' ' ' VAL . 79.1 t -128.48 132.03 68.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.69 -0.686 . . . . 0.0 111.529 -178.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -136.62 139.15 41.88 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.986 0.422 . . . . 0.0 110.305 178.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 p90 -139.19 132.83 30.52 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 120.749 -0.38 . . . . 0.0 110.942 179.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.23 119.18 24.68 Favored 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.862 0.839 . . . . 0.0 111.141 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -152.12 142.63 22.66 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.89 -179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 53.3 t0 64.6 47.58 2.85 Favored 'General case' 0 CA--C 1.534 0.362 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 177.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.419 HG12 ' H ' ' A' ' 25' ' ' GLY . 1.3 t -100.17 -161.47 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 177.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.419 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -72.49 -35.78 59.41 Favored Glycine 0 C--N 1.34 0.784 0 C-N-CA 118.218 -1.944 . . . . 0.0 108.784 178.636 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 53.7 m -156.06 112.49 3.11 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 107.999 -1.112 . . . . 0.0 107.999 174.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 10.5 m120 -52.61 172.52 0.04 OUTLIER 'General case' 0 C--N 1.321 -0.632 0 C-N-CA 119.039 -1.064 . . . . 0.0 110.576 178.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.411 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 98.4 mttt -62.74 -38.94 92.49 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 122.835 1.302 . . . . 0.0 107.579 174.272 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.442 ' O ' ' HB2' ' A' ' 30' ' ' ALA . . . 81.91 -69.48 3.3 Favored Glycine 0 CA--C 1.533 1.174 0 CA-C-N 112.021 -2.354 . . . . 0.0 111.641 -177.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.442 ' HB2' ' O ' ' A' ' 29' ' ' GLY . . . 179.73 61.27 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 118.64 1.22 . . . . 0.0 112.764 175.388 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.615 ' CD1' HG12 ' M' ' 39' ' ' VAL . 83.7 mt -131.99 102.05 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.558 0 CA-C-N 119.904 1.229 . . . . 0.0 108.257 179.039 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 80.8 mt -108.32 113.69 44.6 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 C-N-CA 120.615 -0.434 . . . . 0.0 110.749 -179.188 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.74 94.61 0.55 Allowed Glycine 0 N--CA 1.463 0.439 0 N-CA-C 104.748 -3.341 . . . . 0.0 104.748 176.524 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.569 ' O ' HD23 ' B' ' 34' ' ' LEU . 87.5 mt -143.22 157.75 44.22 Favored 'General case' 0 CA--C 1.513 -0.464 0 CA-C-O 122.788 1.28 . . . . 0.0 114.055 -175.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 4.7 mtp -115.99 106.07 13.37 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 112.435 -2.166 . . . . 0.0 107.154 177.357 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 1.02 HG11 HD11 ' C' ' 17' ' ' LEU . 43.6 t -124.25 112.03 30.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 -179.728 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.31 -131.89 8.57 Favored Glycine 0 C--N 1.322 -0.246 0 N-CA-C 108.678 -1.769 . . . . 0.0 108.678 -179.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.83 -62.69 0.4 Allowed Glycine 0 CA--C 1.534 1.259 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.267 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.879 HG12 HD12 ' G' ' 31' ' ' ILE . 26.9 m -108.34 162.78 6.19 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.189 0.495 . . . . 0.0 110.261 -179.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.444 ' OXT' ' O ' ' A' ' 39' ' ' VAL . 44.6 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.829 -1.081 . . . . 0.0 110.699 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -105.52 130.95 53.48 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.674 0.273 . . . . 0.0 110.403 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -106.89 116.35 31.78 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.999 0.428 . . . . 0.0 110.729 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -132.31 128.95 59.21 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.373 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.614 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 6.2 t-160 -127.78 106.97 9.49 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-O 120.964 0.411 . . . . 0.0 110.468 -179.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.588 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 4.3 t60 -152.82 168.68 24.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.326 -0.397 . . . . 0.0 109.99 -179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.588 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 54.5 tt0 -155.96 141.42 17.7 Favored 'General case' 0 N--CA 1.45 -0.433 0 N-CA-C 109.504 -0.554 . . . . 0.0 109.504 178.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 51.8 mtmt -85.65 123.71 31.36 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.944 178.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.538 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.7 tt -126.01 115.85 20.53 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.006 0.431 . . . . 0.0 110.221 178.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 18' ' ' VAL . 2.6 m -123.98 131.84 72.29 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.382 179.297 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.437 ' CE2' ' HB2' ' B' ' 21' ' ' ALA . 71.9 t80 -125.76 122.32 35.91 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.251 -178.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 m-85 -115.71 123.68 48.94 Favored 'General case' 0 N--CA 1.476 0.842 0 N-CA-C 109.621 -0.511 . . . . 0.0 109.621 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.437 ' HB2' ' CE2' ' B' ' 19' ' ' PHE . . . -142.95 143.33 31.93 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 114.185 1.179 . . . . 0.0 114.185 -178.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.9 mt-10 -91.46 154.75 18.93 Favored 'General case' 0 N--CA 1.472 0.675 0 N-CA-C 107.527 -1.286 . . . . 0.0 107.527 176.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' B' ' 22' ' ' GLU . 70.0 m-20 -139.18 46.5 1.93 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.555 1.317 . . . . 0.0 114.555 -176.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.708 HG12 ' N ' ' B' ' 25' ' ' GLY . 60.7 t -111.72 177.03 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.451 0 C-N-CA 118.562 -1.255 . . . . 0.0 108.291 177.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.708 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 62.39 28.35 70.91 Favored Glycine 0 CA--C 1.529 0.917 0 CA-C-O 119.291 -0.727 . . . . 0.0 111.531 176.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.529 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 24.5 p -170.55 -131.55 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.674 0 CA-C-N 118.558 1.179 . . . . 0.0 113.596 -176.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.529 ' N ' ' OG ' ' B' ' 26' ' ' SER . 90.9 m-20 -30.79 173.01 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.409 0 CA-C-N 112.803 -1.999 . . . . 0.0 115.449 -179.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.412 ' H ' ' H ' ' B' ' 29' ' ' GLY . 53.0 mtmt -161.28 -21.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.451 -178.34 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.412 ' H ' ' H ' ' B' ' 28' ' ' LYS . . . -78.8 110.73 3.1 Favored Glycine 0 CA--C 1.532 1.123 0 CA-C-N 113.85 -1.523 . . . . 0.0 109.722 177.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -129.86 110.25 11.56 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 123.025 1.393 . . . . 0.0 112.814 -176.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.552 HD11 HG23 ' N' ' 39' ' ' VAL . 71.9 mt -142.73 139.85 28.09 Favored 'Isoleucine or valine' 0 C--O 1.24 0.56 0 CA-C-N 113.824 -1.535 . . . . 0.0 112.134 -178.26 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.789 HG22 HD11 ' C' ' 34' ' ' LEU . 27.0 mt -106.9 114.34 45.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 107.157 -1.424 . . . . 0.0 107.157 174.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.08 106.32 1.42 Allowed Glycine 0 N--CA 1.461 0.312 0 N-CA-C 106.677 -2.569 . . . . 0.0 106.677 178.226 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.569 HD23 ' O ' ' A' ' 34' ' ' LEU . 0.4 OUTLIER -143.18 141.81 31.26 Favored 'General case' 0 CA--C 1.511 -0.521 0 C-N-CA 118.376 -1.33 . . . . 0.0 113.064 -175.833 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -108.88 109.31 20.38 Favored 'General case' 0 N--CA 1.436 -1.174 0 CA-C-N 112.455 -2.157 . . . . 0.0 106.637 177.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.501 ' CG1' HD22 ' B' ' 34' ' ' LEU . 32.8 m -133.7 151.69 33.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.073 0.463 . . . . 0.0 110.091 -177.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.81 -101.85 2.67 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.228 -1.149 . . . . 0.0 110.228 -178.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 72.08 -80.74 0.58 Allowed Glycine 0 CA--C 1.534 1.248 0 C-N-CA 120.573 -0.822 . . . . 0.0 111.187 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.6 HG21 HD11 ' G' ' 31' ' ' ILE . 38.6 t -111.47 135.15 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.444 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.629 ' H ' ' CG2' ' C' ' 39' ' ' VAL . 64.1 t . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.131 179.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.454 -1.459 . . . . 0.0 109.454 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . 0.42 ' CE2' ' O ' ' C' ' 11' ' ' GLU . 90.1 t80 -73.55 132.52 42.93 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.986 0.422 . . . . 0.0 110.691 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.42 ' O ' ' CE2' ' C' ' 10' ' ' TYR . 96.3 mt-10 -75.54 136.85 40.56 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.24 -179.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.693 HG23 ' O ' ' C' ' 12' ' ' VAL . 16.7 m -129.45 108.16 16.25 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.828 -179.611 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.614 ' ND1' ' N ' ' B' ' 13' ' ' HIS . 15.4 m-70 -142.64 135.6 28.28 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 112.163 0.431 . . . . 0.0 112.163 -178.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.575 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.6 p-80 -153.6 156.19 37.5 Favored 'General case' 0 C--O 1.224 -0.251 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.24 176.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.5 tp60 -99.44 154.2 18.41 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 174.812 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -121.58 109.68 15.09 Favored 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 107.348 -1.353 . . . . 0.0 107.348 173.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 1.02 HD11 HG11 ' A' ' 36' ' ' VAL . 34.5 mt -118.45 112.99 20.66 Favored 'General case' 0 CA--C 1.504 -0.825 0 C-N-CA 119.766 -0.774 . . . . 0.0 110.112 178.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . 0.45 ' CG1' HG12 ' B' ' 18' ' ' VAL . 3.0 p -116.64 111.39 35.01 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.673 0 N-CA-C 106.862 -1.532 . . . . 0.0 106.862 175.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.422 ' CE2' ' HB3' ' C' ' 17' ' ' LEU . 71.8 m-85 -102.79 108.84 20.22 Favored 'General case' 0 N--CA 1.451 -0.421 0 N-CA-C 106.876 -1.528 . . . . 0.0 106.876 179.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' C' ' 20' ' ' PHE . 26.0 t80 -110.7 123.94 50.98 Favored 'General case' 0 C--O 1.236 0.383 0 CA-C-N 116.401 -0.363 . . . . 0.0 110.565 -177.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.22 138.99 35.52 Favored 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 113.195 0.813 . . . . 0.0 113.195 -178.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -90.79 108.31 19.75 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 106.251 -1.759 . . . . 0.0 106.251 176.527 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 95.3 m-20 -100.28 46.7 0.95 Allowed 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 113.934 1.087 . . . . 0.0 113.934 -176.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.566 ' O ' HG22 ' B' ' 24' ' ' VAL . 54.3 t -101.12 162.23 3.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.608 0 N-CA-C 107.021 -1.474 . . . . 0.0 107.021 176.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.54 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 69.98 30.64 69.92 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 176.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.77 ' O ' ' O ' ' C' ' 27' ' ' ASN . 20.6 p -173.06 -118.73 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.433 0 CA-C-N 118.406 1.103 . . . . 0.0 113.307 -177.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.77 ' O ' ' O ' ' C' ' 26' ' ' SER . 61.4 t30 21.35 172.91 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 C-N-CA 126.0 1.72 . . . . 0.0 114.446 -176.589 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 63.7 tttm -159.97 -29.54 0.06 Allowed 'General case' 0 N--CA 1.466 0.372 0 O-C-N 121.334 -0.853 . . . . 0.0 112.648 -178.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -169.69 81.59 0.09 OUTLIER Glycine 0 CA--C 1.528 0.877 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.294 -173.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -78.42 130.7 36.4 Favored 'General case' 0 C--O 1.24 0.604 0 CA-C-O 122.798 1.285 . . . . 0.0 113.057 -175.07 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.839 HD11 HG12 ' O' ' 39' ' ' VAL . 76.6 mt -130.31 134.18 62.86 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 113.022 -1.899 . . . . 0.0 111.581 -178.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.648 HD13 ' CD1' ' E' ' 19' ' ' PHE . 87.7 mt -107.91 121.99 61.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.824 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 177.227 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.71 ' O ' HD12 ' C' ' 34' ' ' LEU . . . -126.3 102.24 0.63 Allowed Glycine 0 N--CA 1.469 0.848 0 N-CA-C 107.845 -2.102 . . . . 0.0 107.845 178.507 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.789 HD11 HG22 ' B' ' 32' ' ' ILE . 5.9 mp -139.13 146.65 40.91 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-O 123.219 1.485 . . . . 0.0 113.538 -176.707 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -106.69 109.64 21.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-N 112.19 -2.277 . . . . 0.0 106.798 177.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.474 HG21 HD11 ' D' ' 34' ' ' LEU . 18.5 t -121.33 131.06 73.96 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.364 0 CA-C-O 120.957 0.408 . . . . 0.0 111.695 -176.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.03 -110.85 3.1 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 112.575 178.536 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.32 -73.12 0.68 Allowed Glycine 0 CA--C 1.544 1.849 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 -177.515 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.629 ' CG2' ' H ' ' B' ' 40' ' ' VAL . 1.3 m -132.32 179.77 4.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 N-CA-C 108.844 -0.799 . . . . 0.0 108.844 176.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.475 ' N ' HG12 ' D' ' 39' ' ' VAL . 46.8 t . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.098 -0.953 . . . . 0.0 109.696 178.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.162 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -106.16 135.05 48.32 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.801 0.334 . . . . 0.0 110.56 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.447 ' O ' HG11 ' C' ' 12' ' ' VAL . 97.4 mt-10 -74.15 126.25 30.16 Favored 'General case' 0 CA--C 1.534 0.335 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.471 -179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 5.8 m -137.52 132.75 45.5 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.14 -178.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.54 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 22.4 t-80 -61.9 121.22 12.39 Favored 'General case' 0 C--N 1.326 -0.418 0 C-N-CA 120.377 -0.529 . . . . 0.0 111.595 -177.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.798 ' CD2' ' H ' ' E' ' 14' ' ' HIS . 35.3 m170 -150.45 162.55 40.37 Favored 'General case' 0 N--CA 1.472 0.666 0 N-CA-C 113.111 0.782 . . . . 0.0 113.111 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.408 ' HB2' HE22 ' E' ' 15' ' ' GLN . 68.2 tp60 -85.99 156.85 20.28 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 107.347 -1.353 . . . . 0.0 107.347 175.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -159.78 102.21 1.49 Allowed 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.29 -0.964 . . . . 0.0 109.914 177.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.456 HD22 HD12 ' C' ' 17' ' ' LEU . 16.2 mt -132.16 122.35 25.17 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.361 0.601 . . . . 0.0 111.478 -179.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 91.2 t -113.36 107.56 23.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 177.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.449 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 80.8 m-85 -104.22 106.87 17.53 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 178.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 t80 -126.69 128.59 46.94 Favored 'General case' 0 N--CA 1.47 0.546 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 -176.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.82 124.03 41.22 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.345 177.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 81.9 mt-10 -89.27 153.35 20.97 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 122.059 0.933 . . . . 0.0 113.262 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.451 ' O ' HG22 ' C' ' 24' ' ' VAL . 98.2 m-20 40.59 55.25 2.95 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 113.631 -1.622 . . . . 0.0 113.257 177.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.651 HG21 ' HB1' ' E' ' 21' ' ' ALA . 98.4 t -66.06 135.12 28.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 177.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -115.32 -32.54 1.79 Allowed Glycine 0 N--CA 1.468 0.798 0 N-CA-C 111.295 -0.722 . . . . 0.0 111.295 -178.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.414 ' OG ' ' O ' ' C' ' 27' ' ' ASN . 26.8 m -71.25 120.34 16.69 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.147 0.499 . . . . 0.0 110.231 179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.568 ' ND2' ' H ' ' E' ' 25' ' ' GLY . 3.9 m120 -103.41 -151.82 0.44 Allowed 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.184 -178.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.466 ' H ' ' HA ' ' E' ' 27' ' ' ASN . 26.2 pttm 31.72 41.84 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.68 0 CA-C-N 114.432 -1.258 . . . . 0.0 114.074 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.41 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -173.36 60.89 0.14 Allowed Glycine 0 CA--C 1.54 1.594 0 C-N-CA 119.672 -1.252 . . . . 0.0 113.63 174.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.661 ' N ' ' ND2' ' E' ' 27' ' ' ASN . . . -107.95 109.88 21.48 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-N 117.717 0.759 . . . . 0.0 109.508 176.819 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.514 HD11 HG23 ' P' ' 39' ' ' VAL . 69.3 mt -134.09 128.59 52.99 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.134 0 C-N-CA 118.952 -1.099 . . . . 0.0 112.186 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.613 HD13 ' CD1' ' F' ' 19' ' ' PHE . 95.7 mt -112.55 119.29 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 N-CA-C 109.822 -0.436 . . . . 0.0 109.822 177.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.43 98.88 0.8 Allowed Glycine 0 C--O 1.239 0.453 0 N-CA-C 105.895 -2.882 . . . . 0.0 105.895 176.92 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.474 HD11 HG21 ' C' ' 36' ' ' VAL . 11.3 tp -131.47 136.45 47.94 Favored 'General case' 0 C--O 1.244 0.81 0 CA-C-O 122.658 1.218 . . . . 0.0 113.795 -175.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -109.54 110.0 20.96 Favored 'General case' 0 N--CA 1.448 -0.551 0 CA-C-N 113.064 -1.88 . . . . 0.0 108.217 176.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -122.5 122.87 67.25 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.303 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 179.097 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 145.5 -113.58 0.71 Allowed Glycine 0 C--N 1.307 -1.031 0 N-CA-C 110.613 -0.995 . . . . 0.0 110.613 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' J' ' 31' ' ' ILE . . . 96.11 -71.98 0.86 Allowed Glycine 0 CA--C 1.53 1.022 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.554 ' CG2' ' O ' ' J' ' 29' ' ' GLY . 0.3 OUTLIER -141.4 163.06 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.296 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 178.005 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.429 ' O ' ' O ' ' D' ' 39' ' ' VAL . 21.2 t . . . . . 0 N--CA 1.469 0.505 0 CA-C-O 118.215 -0.897 . . . . 0.0 111.746 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 80.6 m-85 -105.75 136.07 46.03 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.953 0.406 . . . . 0.0 110.686 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -113.72 119.75 38.47 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.301 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.549 ' O ' ' NE2' ' D' ' 14' ' ' HIS . 50.9 t -127.17 134.21 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.397 0 CA-C-O 121.395 0.617 . . . . 0.0 110.025 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 38.1 m-70 -129.23 106.4 8.8 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.934 -178.72 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.798 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 3.3 p80 -151.87 161.35 42.79 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 120.728 0.299 . . . . 0.0 110.396 177.427 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.411 ' OE1' ' CG1' ' C' ' 36' ' ' VAL . 79.1 mm-40 -90.01 158.12 17.5 Favored 'General case' 0 N--CA 1.45 -0.435 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 176.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 59.2 mttt -141.1 100.03 3.72 Favored 'General case' 0 C--N 1.314 -0.972 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 176.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.405 ' N ' HD12 ' E' ' 17' ' ' LEU . 5.2 mp -133.38 126.1 30.56 Favored 'General case' 0 CA--C 1.508 -0.672 0 C-N-CA 120.065 -0.654 . . . . 0.0 111.643 179.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -113.62 106.66 21.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.505 178.22 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.648 ' CD1' HD13 ' C' ' 32' ' ' ILE . 89.8 m-85 -105.79 106.05 16.38 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 106.303 -1.739 . . . . 0.0 106.303 178.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 t80 -133.53 135.13 44.18 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.091 1.145 . . . . 0.0 114.091 -176.235 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.651 ' HB1' HG21 ' D' ' 24' ' ' VAL . . . -128.32 129.91 46.99 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.988 177.505 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.418 ' HB2' ' H ' ' D' ' 23' ' ' ASP . 97.8 mt-10 -91.25 166.26 13.03 Favored 'General case' 0 N--CA 1.476 0.862 0 N-CA-C 114.927 1.454 . . . . 0.0 114.927 -177.115 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 25.99 47.27 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 112.293 -2.23 . . . . 0.0 115.835 178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.6 HG12 ' N ' ' E' ' 25' ' ' GLY . 53.4 t -67.43 171.43 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 174.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.6 ' N ' HG12 ' E' ' 24' ' ' VAL . . . -117.75 37.41 3.3 Favored Glycine 0 N--CA 1.48 1.581 0 C-N-CA 119.433 -1.365 . . . . 0.0 111.264 178.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 72.52 119.99 0.04 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 115.202 -0.499 . . . . 0.0 110.236 177.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.661 ' ND2' ' N ' ' D' ' 30' ' ' ALA . 81.4 m-20 -83.19 163.62 20.68 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.639 -0.825 . . . . 0.0 109.952 176.588 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -46.93 -36.93 8.19 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 122.022 0.915 . . . . 0.0 108.946 175.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.66 77.42 0.06 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 113.694 -1.594 . . . . 0.0 110.558 -177.593 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.73 149.26 4.8 Favored 'General case' 0 N--CA 1.478 0.941 0 CA-C-N 117.775 0.787 . . . . 0.0 110.648 -178.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 2.8 mp -131.44 137.14 56.07 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -177.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -118.67 122.11 68.63 Favored 'Isoleucine or valine' 0 C--O 1.232 0.178 0 CA-C-N 114.491 -1.231 . . . . 0.0 109.784 178.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.37 106.76 1.36 Allowed Glycine 0 N--CA 1.465 0.607 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 178.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 27.0 tp -126.16 125.52 42.61 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-O 120.872 0.367 . . . . 0.0 111.313 -177.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.445 ' CG ' ' N ' ' E' ' 36' ' ' VAL . 27.3 ttp -146.29 158.85 43.92 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 119.494 -0.882 . . . . 0.0 111.614 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.581 HG22 ' HA ' ' F' ' 36' ' ' VAL . 1.3 m -115.02 162.93 12.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.804 -0.634 . . . . 0.0 111.1 -179.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.77 -102.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.55 0 CA-C-N 115.452 -0.795 . . . . 0.0 111.371 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -109.04 -78.47 1.05 Allowed Glycine 0 CA--C 1.534 1.243 0 C-N-CA 121.659 -0.305 . . . . 0.0 112.781 -179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.446 HG13 ' O ' ' E' ' 39' ' ' VAL . 9.3 p -93.01 128.12 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 116.952 0.376 . . . . 0.0 111.107 -179.086 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.472 ' OXT' HG21 ' E' ' 36' ' ' VAL . 80.5 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.07 -0.967 . . . . 0.0 110.323 -179.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -103.4 132.34 49.74 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.734 0.302 . . . . 0.0 110.201 -179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 20.6 pt-20 -143.45 150.68 39.36 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.813 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -124.32 132.83 70.77 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.018 179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.482 ' O ' ' CG ' ' F' ' 13' ' ' HIS . 8.5 p80 -144.74 114.69 7.37 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-O 121.206 0.526 . . . . 0.0 112.337 -179.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.437 ' ND1' ' O ' ' F' ' 15' ' ' GLN . 54.8 t-80 -151.35 164.35 36.87 Favored 'General case' 0 C--O 1.217 -0.609 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.437 ' O ' ' ND1' ' F' ' 14' ' ' HIS . 88.7 mt-30 -89.91 158.33 17.47 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 119.113 0.87 . . . . 0.0 111.383 -179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -140.53 95.78 2.92 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 107.817 -1.179 . . . . 0.0 107.817 176.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -130.4 119.31 22.52 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 110.062 -0.347 . . . . 0.0 110.062 -178.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 94.0 t -107.32 105.83 19.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 178.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.613 ' CD1' HD13 ' D' ' 32' ' ' ILE . 78.9 m-85 -107.59 109.0 20.53 Favored 'General case' 0 CA--C 1.517 -0.307 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 178.995 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 20.3 t80 -147.21 137.62 23.42 Favored 'General case' 0 N--CA 1.47 0.545 0 C-N-CA 118.618 -1.233 . . . . 0.0 113.826 -178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.33 130.48 49.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.08 -1.418 . . . . 0.0 107.468 177.217 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.461 ' O ' ' N ' ' E' ' 24' ' ' VAL . 96.9 mt-10 -82.29 115.79 21.52 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 120.043 -0.663 . . . . 0.0 111.653 -178.223 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.52 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 9.6 p-10 177.12 -64.54 0.01 OUTLIER 'General case' 0 CA--C 1.529 0.155 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.7 179.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 91.4 t -64.48 133.72 29.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 C-N-CA 119.852 -0.739 . . . . 0.0 110.246 -178.126 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.23 -30.8 1.83 Allowed Glycine 0 CA--C 1.528 0.846 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.169 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 91.0 p -80.96 -130.27 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 -176.197 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.541 ' O ' ' N ' ' F' ' 29' ' ' GLY . 11.6 m120 -99.24 -164.49 1.13 Allowed 'General case' 0 N--CA 1.468 0.448 0 N-CA-C 114.344 1.239 . . . . 0.0 114.344 -176.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -48.14 48.19 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.746 0 CA-C-N 112.816 -1.993 . . . . 0.0 114.936 179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.541 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -96.16 56.98 1.49 Allowed Glycine 0 CA--C 1.544 1.887 0 C-N-CA 120.188 -1.006 . . . . 0.0 111.878 -178.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.76 179.56 9.1 Favored 'General case' 0 N--CA 1.453 -0.286 0 N-CA-C 106.98 -1.489 . . . . 0.0 106.98 179.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 96.3 mt -121.2 127.24 75.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 118.486 0.585 . . . . 0.0 109.79 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 95.1 mt -128.2 131.7 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-O 120.865 0.364 . . . . 0.0 111.45 -178.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.3 116.86 2.67 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.1 tp -122.75 126.13 46.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 -179.222 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 5.0 ttp -140.19 139.81 35.75 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 122.365 1.079 . . . . 0.0 113.845 -179.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.581 ' HA ' HG22 ' E' ' 36' ' ' VAL . 43.8 t -117.31 131.95 68.53 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.395 0 CA-C-N 113.758 -1.565 . . . . 0.0 109.523 179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.478 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -41.25 -111.62 0.0 OUTLIER Glycine 0 CA--C 1.531 1.046 0 CA-C-N 116.051 -0.522 . . . . 0.0 112.907 179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.43 -71.7 0.6 Allowed Glycine 0 CA--C 1.535 1.291 0 N-CA-C 111.767 -0.533 . . . . 0.0 111.767 -179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 94.6 t -76.99 131.53 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 117.3 0.55 . . . . 0.0 110.325 179.117 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.421 HG22 ' O ' ' F' ' 40' ' ' VAL . 14.9 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.148 -0.929 . . . . 0.0 110.608 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . 0.561 ' HH ' ' N ' ' I' ' 9' ' ' GLY . 94.1 m-85 -105.06 133.55 49.66 Favored 'General case' 0 N--CA 1.467 0.391 0 N-CA-C 110.049 -0.352 . . . . 0.0 110.049 179.648 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -141.68 144.45 34.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.268 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 18.5 m -134.45 160.63 41.42 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 80.4 m80 -138.2 117.34 12.61 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 121.006 0.432 . . . . 0.0 111.546 -179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.505 ' O ' ' NE2' ' G' ' 15' ' ' GLN . 49.1 p-80 -151.74 168.05 26.26 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.099 178.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.505 ' NE2' ' O ' ' G' ' 14' ' ' HIS . 97.7 mm-40 -156.98 143.23 18.07 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 121.046 0.45 . . . . 0.0 110.07 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -81.27 118.23 22.44 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.106 -0.497 . . . . 0.0 109.863 178.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 45.0 tp -136.76 118.92 15.48 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 121.313 0.577 . . . . 0.0 111.349 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 m -137.0 153.44 29.63 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.965 178.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 32.2 t80 -146.51 130.74 17.48 Favored 'General case' 0 N--CA 1.461 0.112 0 CA-C-O 120.964 0.411 . . . . 0.0 111.195 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.5 p90 -123.04 132.2 54.02 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 126.94 35.6 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.467 0.651 . . . . 0.0 112.685 -178.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -96.36 145.31 25.73 Favored 'General case' 0 C--N 1.34 0.159 0 N-CA-C 107.471 -1.307 . . . . 0.0 107.471 177.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.406 ' OD2' ' O ' ' G' ' 26' ' ' SER . 10.2 t70 -172.33 46.9 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.616 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.717 -176.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.672 HG12 ' H ' ' G' ' 25' ' ' GLY . 5.2 t -82.21 172.68 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.307 -176.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.672 ' H ' HG12 ' G' ' 24' ' ' VAL . . . 90.92 -33.9 4.47 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 106.734 -2.546 . . . . 0.0 106.734 -176.639 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.406 ' H ' ' C ' ' G' ' 24' ' ' VAL . 71.1 m -151.98 122.97 7.57 Favored 'General case' 0 CA--C 1.534 0.362 0 CA-C-N 114.122 -1.039 . . . . 0.0 108.896 176.361 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.594 ' OD1' ' N ' ' G' ' 28' ' ' LYS . 31.7 t-20 -41.82 151.18 0.1 Allowed 'General case' 0 N--CA 1.47 0.535 0 C-N-CA 120.627 -0.429 . . . . 0.0 110.852 179.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.617 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 88.5 tttt -69.43 -48.36 61.2 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.28 0.562 . . . . 0.0 110.411 178.073 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.521 ' N ' ' OD1' ' G' ' 27' ' ' ASN . . . 129.81 59.92 0.1 Allowed Glycine 0 CA--C 1.54 1.633 0 N-CA-C 110.052 -1.219 . . . . 0.0 110.052 -176.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.09 89.28 0.82 Allowed 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.879 HD12 HG12 ' A' ' 39' ' ' VAL . 87.3 mt -137.27 117.84 16.96 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.546 0 CA-C-N 113.315 -1.766 . . . . 0.0 106.857 177.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.484 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.4 mt -106.17 110.64 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.445 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 94.86 0.67 Allowed Glycine 0 CA--C 1.508 -0.399 0 N-CA-C 105.097 -3.201 . . . . 0.0 105.097 177.021 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.705 ' O ' HD12 ' H' ' 34' ' ' LEU . 79.7 mt -147.49 168.44 21.91 Favored 'General case' 0 C--O 1.24 0.596 0 CA-C-O 123.254 1.502 . . . . 0.0 113.766 -175.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 94.5 mmm -120.96 114.39 21.46 Favored 'General case' 0 N--CA 1.442 -0.863 0 CA-C-N 112.064 -2.335 . . . . 0.0 107.16 178.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.495 HG21 HD22 ' I' ' 17' ' ' LEU . 41.4 t -124.6 131.53 72.58 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 81.54 -111.31 3.3 Favored Glycine 0 CA--C 1.529 0.956 0 N-CA-C 110.719 -0.953 . . . . 0.0 110.719 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.4 -73.79 1.33 Allowed Glycine 0 CA--C 1.536 1.395 0 C-N-CA 121.041 -0.6 . . . . 0.0 112.252 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.627 HG12 HD12 ' M' ' 31' ' ' ILE . 22.3 m -87.02 171.55 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.22 0 CA-C-N 117.401 0.6 . . . . 0.0 110.381 179.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 53.3 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.243 179.273 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.336 0 N-CA-C 109.574 -1.411 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -107.62 129.71 54.97 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.711 0.291 . . . . 0.0 110.346 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -154.85 148.76 25.66 Favored 'General case' 0 C--N 1.333 -0.13 0 CA-C-O 121.166 0.508 . . . . 0.0 111.552 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.514 HG13 ' CG2' ' I' ' 12' ' ' VAL . 55.7 t -124.5 130.03 73.64 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.459 ' C ' ' CD2' ' H' ' 14' ' ' HIS . 26.0 p-80 -147.46 142.81 27.37 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 119.48 -0.888 . . . . 0.0 113.131 -179.245 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.474 ' O ' ' CB ' ' G' ' 14' ' ' HIS . 1.5 m-70 -146.23 170.36 16.91 Favored 'General case' 0 C--N 1.333 -0.148 0 CA-C-N 114.512 -1.222 . . . . 0.0 108.217 177.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -155.83 141.28 17.72 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 120.068 -0.653 . . . . 0.0 110.366 178.196 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 59.4 tttt -87.94 108.67 19.3 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.973 178.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 8.5 tt -121.13 110.71 16.54 Favored 'General case' 0 N--CA 1.469 0.525 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 177.361 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.416 HG22 ' CG2' ' I' ' 18' ' ' VAL . 72.0 t -122.13 130.62 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.192 -178.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.9 t80 -126.52 118.98 26.0 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.043 -0.354 . . . . 0.0 110.043 179.032 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.8 t80 -122.35 125.93 46.98 Favored 'General case' 0 N--CA 1.469 0.484 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.61 131.26 39.42 Favored 'General case' 0 C--O 1.24 0.602 0 CA-C-O 121.457 0.646 . . . . 0.0 112.677 -179.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 76.1 tt0 -97.68 127.1 43.38 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-N 114.996 -1.002 . . . . 0.0 108.541 178.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.617 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 97.1 m-20 -139.25 46.55 1.92 Allowed 'General case' 0 N--CA 1.469 0.517 0 CA-C-N 116.679 -0.237 . . . . 0.0 111.598 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.694 HG12 ' N ' ' H' ' 25' ' ' GLY . 21.5 t -82.8 173.34 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.002 0 CA-C-O 122.697 1.237 . . . . 0.0 113.06 -176.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.694 ' N ' HG12 ' H' ' 24' ' ' VAL . . . 92.74 -35.16 4.17 Favored Glycine 0 CA--C 1.538 1.473 0 CA-C-N 112.596 -2.093 . . . . 0.0 114.26 178.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' H' ' 27' ' ' ASN . 32.2 t -162.55 117.38 1.82 Allowed 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 120.691 2.246 . . . . 0.0 114.192 175.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' H' ' 26' ' ' SER . 45.0 p-10 -22.55 153.13 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.298 0 C-N-CA 123.116 0.566 . . . . 0.0 112.297 173.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 7.7 tttm -165.95 26.38 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 117.948 -1.501 . . . . 0.0 114.887 173.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.8 107.77 0.38 Allowed Glycine 0 CA--C 1.532 1.11 0 C-N-CA 119.004 -1.57 . . . . 0.0 113.944 177.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.7 111.47 17.65 Favored 'General case' 0 N--CA 1.473 0.699 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 179.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.466 HD11 HG13 ' C' ' 39' ' ' VAL . 87.4 mt -130.22 133.61 63.86 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.979 0 N-CA-C 112.809 0.67 . . . . 0.0 112.809 -177.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.533 HD13 ' CD2' ' J' ' 19' ' ' PHE . 93.6 mt -105.71 108.46 25.09 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 175.306 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -109.44 101.92 1.54 Allowed Glycine 0 N--CA 1.465 0.623 0 N-CA-C 105.897 -2.881 . . . . 0.0 105.897 177.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.705 HD12 ' O ' ' G' ' 34' ' ' LEU . 47.2 tp -152.53 145.62 24.59 Favored 'General case' 0 C--N 1.327 -0.397 0 C-N-CA 117.306 -1.758 . . . . 0.0 114.612 -173.726 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.583 ' H ' HD12 ' H' ' 34' ' ' LEU . 3.8 ttm -106.9 117.02 32.97 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 112.93 -1.941 . . . . 0.0 107.71 177.457 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.473 ' CG2' HG12 ' I' ' 36' ' ' VAL . 2.9 t -118.19 102.49 13.31 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.147 0 C-N-CA 121.167 -0.213 . . . . 0.0 110.801 -178.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.27 -163.93 26.78 Favored Glycine 0 CA--C 1.524 0.617 0 C-N-CA 120.354 -0.926 . . . . 0.0 112.655 177.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.52 ' HA2' ' H ' ' I' ' 38' ' ' GLY . . . 156.2 -54.55 0.41 Allowed Glycine 0 CA--C 1.545 1.915 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -178.621 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.721 HG13 HD13 ' N' ' 31' ' ' ILE . 3.7 m -141.31 164.21 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 176.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.538 ' OXT' ' NZ ' ' N' ' 28' ' ' LYS . 1.3 p . . . . . 0 N--CA 1.467 0.377 0 CA-C-O 117.802 -1.094 . . . . 0.0 111.353 178.206 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . 0.561 ' N ' ' HH ' ' G' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.411 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.25 135.41 46.67 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 120.691 0.281 . . . . 0.0 110.387 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.409 ' OE2' ' NE2' ' I' ' 13' ' ' HIS . 45.7 tp10 -147.11 100.9 3.35 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.908 0.385 . . . . 0.0 110.256 179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.514 ' CG2' HG13 ' H' ' 12' ' ' VAL . 4.9 m -141.75 127.41 18.4 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.303 -0.408 . . . . 0.0 109.986 179.074 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' CE1' ' H' ' 13' ' ' HIS . 49.5 m170 -113.59 136.24 53.03 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.829 -178.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.527 ' CD2' ' O ' ' J' ' 14' ' ' HIS . 70.7 m80 -156.64 176.04 13.26 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.29 0.567 . . . . 0.0 110.515 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.411 ' CG ' HD11 ' I' ' 17' ' ' LEU . 40.8 tp60 -159.33 139.09 11.67 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 105.872 -1.899 . . . . 0.0 105.872 174.066 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -105.39 113.61 27.3 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-O 118.999 -0.524 . . . . 0.0 111.5 179.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.495 HD22 HG21 ' G' ' 36' ' ' VAL . 0.7 OUTLIER -129.5 112.48 13.8 Favored 'General case' 0 CA--C 1.508 -0.637 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 176.557 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.416 ' CG2' HG22 ' H' ' 18' ' ' VAL . 15.1 m -119.43 124.87 73.76 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -112.16 116.76 30.98 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 114.752 -1.113 . . . . 0.0 108.673 -178.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 11.8 m-85 -119.08 129.14 54.92 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 116.717 -0.219 . . . . 0.0 110.767 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.87 138.19 30.08 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 120.436 -0.506 . . . . 0.0 112.165 -179.639 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -131.91 130.95 42.23 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 120.458 -0.497 . . . . 0.0 112.261 -179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.64 ' C ' HG23 ' I' ' 24' ' ' VAL . 0.3 OUTLIER -130.98 -49.94 1.03 Allowed 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.188 0.518 . . . . 0.0 110.477 178.644 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.699 HG22 ' CD ' ' J' ' 22' ' ' GLU . 2.0 t 77.7 143.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.912 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.939 176.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.531 ' H ' ' CG2' ' J' ' 24' ' ' VAL . . . 92.08 37.46 5.99 Favored Glycine 0 CA--C 1.525 0.662 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.372 174.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.458 ' OG ' ' O ' ' I' ' 25' ' ' GLY . 3.0 p 72.69 120.15 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 117.744 0.772 . . . . 0.0 110.237 177.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.598 ' H ' ' ND2' ' J' ' 27' ' ' ASN . 13.8 p30 -83.03 161.3 21.75 Favored 'General case' 0 N--CA 1.463 0.181 0 C-N-CA 117.598 -1.641 . . . . 0.0 109.192 177.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.434 ' O ' ' OXT' ' C' ' 40' ' ' VAL . 95.8 mttt -48.63 -39.54 24.49 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 176.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.45 0.04 OUTLIER Glycine 0 CA--C 1.539 1.589 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -175.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.61 139.15 51.32 Favored 'General case' 0 C--O 1.241 0.655 0 CA-C-N 119.027 1.413 . . . . 0.0 114.281 -174.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.589 HD12 HG12 ' C' ' 39' ' ' VAL . 61.2 mt -141.57 143.78 26.9 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.594 0 CA-C-N 113.529 -1.669 . . . . 0.0 113.026 -178.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.435 HG23 HD12 ' I' ' 34' ' ' LEU . 9.8 mt -104.31 109.72 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 N-CA-C 107.339 -1.356 . . . . 0.0 107.339 175.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -109.51 100.75 1.38 Allowed Glycine 0 N--CA 1.463 0.454 0 N-CA-C 106.36 -2.696 . . . . 0.0 106.36 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.629 ' O ' HD12 ' J' ' 34' ' ' LEU . 0.2 OUTLIER -139.14 143.27 38.13 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.928 1.347 . . . . 0.0 113.681 -175.52 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.407 ' SD ' ' HB2' ' J' ' 35' ' ' MET . 87.7 mmm -117.12 108.71 16.03 Favored 'General case' 0 N--CA 1.44 -0.969 0 CA-C-N 111.939 -2.391 . . . . 0.0 104.61 175.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.703 ' CG2' HG12 ' J' ' 36' ' ' VAL . 24.4 m -126.14 130.94 72.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 C-N-CA 118.695 -1.202 . . . . 0.0 112.77 -178.149 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 62.88 111.17 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 113.048 -1.887 . . . . 0.0 113.477 177.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.52 ' H ' ' HA2' ' H' ' 38' ' ' GLY . . . -80.81 -60.53 2.29 Favored Glycine 0 CA--C 1.53 1.003 0 N-CA-C 110.206 -1.157 . . . . 0.0 110.206 175.404 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.3 p -146.2 150.08 15.59 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.353 0 CA-C-O 121.407 0.622 . . . . 0.0 110.407 179.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.815 HG11 ' CD2' ' K' ' 13' ' ' HIS . 21.3 t . . . . . 0 C--O 1.219 -0.513 0 CA-C-N 114.838 -1.074 . . . . 0.0 109.659 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -105.31 133.5 49.98 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.64 ' CG ' ' HE2' ' J' ' 13' ' ' HIS . 80.4 tt0 -153.34 114.81 4.21 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 121.005 0.431 . . . . 0.0 110.645 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.436 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -138.83 138.34 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.847 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.64 ' HE2' ' CG ' ' J' ' 11' ' ' GLU . 19.7 m-70 -139.19 147.83 42.34 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.732 -0.213 . . . . 0.0 110.814 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.527 ' O ' ' CD2' ' I' ' 14' ' ' HIS . 56.9 m-70 -151.97 160.92 43.35 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.615 177.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 17.3 tp60 -90.46 158.35 17.1 Favored 'General case' 0 N--CA 1.453 -0.281 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 177.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.743 ' C ' HD12 ' J' ' 17' ' ' LEU . 97.6 mttt -141.48 90.82 2.32 Favored 'General case' 0 C--N 1.317 -0.814 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.288 176.109 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.743 HD12 ' C ' ' J' ' 16' ' ' LYS . 9.2 mp -128.54 129.86 46.61 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 118.813 0.733 . . . . 0.0 110.688 177.616 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 18.4 t -125.64 116.83 47.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 CA-C-N 115.349 -0.841 . . . . 0.0 109.682 179.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' K' ' 19' ' ' PHE . 12.6 m-85 -109.31 106.95 16.97 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.169 -1.048 . . . . 0.0 108.169 179.444 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 6.3 t80 -114.01 121.91 45.32 Favored 'General case' 0 N--CA 1.478 0.973 0 O-C-N 122.263 -0.273 . . . . 0.0 110.337 -178.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.24 138.73 37.07 Favored 'General case' 0 C--O 1.253 1.259 0 N-CA-C 114.146 1.165 . . . . 0.0 114.146 -179.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.699 ' CD ' HG22 ' I' ' 24' ' ' VAL . 52.7 tt0 -66.92 149.6 50.39 Favored 'General case' 0 CA--C 1.502 -0.881 0 N-CA-C 103.022 -2.955 . . . . 0.0 103.022 176.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.697 ' O ' ' O ' ' J' ' 24' ' ' VAL . 65.1 t0 -168.38 64.5 0.07 Allowed 'General case' 0 C--N 1.309 -1.164 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -168.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.697 ' O ' ' O ' ' J' ' 23' ' ' ASP . 58.7 t -43.06 -104.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.422 0 CA-C-O 113.942 -2.932 . . . . 0.0 103.809 -177.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 166.75 -48.18 0.26 Allowed Glycine 0 N--CA 1.482 1.754 2 CA-C-N 127.32 4.6 . . . . 0.0 119.696 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 41.0 t -65.8 101.0 0.6 Allowed 'General case' 0 C--N 1.322 -0.596 1 CA-C-N 125.567 4.683 . . . . 0.0 105.867 -179.531 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.598 ' ND2' ' H ' ' I' ' 27' ' ' ASN . 1.1 m-20 -129.48 160.88 31.79 Favored 'General case' 0 C--N 1.348 0.504 0 CA-C-N 114.974 -1.012 . . . . 0.0 111.75 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.407 ' C ' ' O ' ' J' ' 27' ' ' ASN . 70.3 mmtt -29.61 -39.42 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 114.785 -1.098 . . . . 0.0 113.44 174.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.554 ' O ' ' CG2' ' D' ' 39' ' ' VAL . . . 140.93 74.87 0.04 OUTLIER Glycine 0 CA--C 1.552 2.371 0 C-N-CA 119.668 -1.253 . . . . 0.0 112.341 -175.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.03 155.54 40.44 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-N 120.631 2.215 . . . . 0.0 113.061 -174.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' D' ' 38' ' ' GLY . 57.6 mt -138.2 148.53 24.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 N-CA-C 115.555 1.687 . . . . 0.0 115.555 -173.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 3.9 mt -109.84 110.99 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.244 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 173.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.4 103.81 1.71 Allowed Glycine 0 N--CA 1.467 0.757 0 N-CA-C 105.772 -2.931 . . . . 0.0 105.772 177.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.629 HD12 ' O ' ' I' ' 34' ' ' LEU . 33.4 tp -143.44 132.58 23.08 Favored 'General case' 0 C--O 1.238 0.462 0 N-CA-C 115.695 1.739 . . . . 0.0 115.695 -173.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.445 ' N ' HD12 ' J' ' 34' ' ' LEU . 78.4 mmm -103.75 123.75 47.62 Favored 'General case' 0 C--O 1.234 0.287 0 CA-C-N 112.78 -2.009 . . . . 0.0 106.886 176.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.703 HG12 ' CG2' ' I' ' 36' ' ' VAL . 2.8 m -135.25 155.68 37.83 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-O 121.549 0.69 . . . . 0.0 112.441 -176.411 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.688 ' H ' HE22 ' L' ' 15' ' ' GLN . . . 79.76 -101.42 1.92 Allowed Glycine 0 CA--C 1.527 0.839 0 CA-C-N 115.013 -0.994 . . . . 0.0 114.933 176.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 88.6 -80.31 1.61 Allowed Glycine 0 CA--C 1.537 1.451 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 -176.291 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.468 HG23 HD12 ' P' ' 31' ' ' ILE . 59.2 t -124.06 131.57 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.829 0 CA-C-N 117.742 0.771 . . . . 0.0 109.624 177.786 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.516 ' OXT' ' CD2' ' L' ' 13' ' ' HIS . 27.6 t . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.928 -1.034 . . . . 0.0 110.27 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.442 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . 0.441 ' CD2' ' O ' ' K' ' 11' ' ' GLU . 52.6 t80 -70.69 134.95 47.96 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 120.883 0.373 . . . . 0.0 110.523 -179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.441 ' O ' ' CD2' ' K' ' 10' ' ' TYR . 68.8 mm-40 -75.22 154.68 37.44 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.746 -179.469 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 27.8 m -122.91 129.59 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.363 0.602 . . . . 0.0 111.847 -179.111 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.815 ' CD2' HG11 ' I' ' 40' ' ' VAL . 2.9 t60 -148.99 138.09 21.48 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.129 -179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.531 ' NE2' ' O ' ' L' ' 12' ' ' VAL . 15.3 m-70 -134.51 158.86 42.85 Favored 'General case' 0 N--CA 1.463 0.222 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 176.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 35.3 tt0 -90.17 159.51 16.72 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 176.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 57.4 tttt -140.47 95.13 2.82 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 120.041 -0.664 . . . . 0.0 109.758 177.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.602 ' CD1' HG21 ' I' ' 36' ' ' VAL . 37.2 mt -118.47 111.67 18.95 Favored 'General case' 0 N--CA 1.477 0.886 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 177.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 96.9 t -108.29 107.25 22.36 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.668 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.565 ' CE1' ' CE1' ' J' ' 19' ' ' PHE . 84.7 m-85 -104.03 105.68 15.93 Favored 'General case' 0 C--N 1.327 -0.409 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.9 t80 -110.74 114.91 28.64 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.38 135.93 20.6 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 122.023 0.916 . . . . 0.0 111.867 -179.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.558 ' O ' ' CB ' ' K' ' 23' ' ' ASP . 98.3 mt-10 -69.15 -174.92 0.69 Allowed 'General case' 0 N--CA 1.472 0.659 0 C-N-CA 118.145 -1.422 . . . . 0.0 107.97 178.21 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' J' ' 24' ' ' VAL . 10.5 t0 144.98 46.6 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-O 121.474 0.654 . . . . 0.0 109.927 -179.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.687 HG12 ' N ' ' K' ' 25' ' ' GLY . 25.4 t -84.03 172.16 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 C-N-CA 119.675 -0.81 . . . . 0.0 110.862 -178.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.687 ' N ' HG12 ' K' ' 24' ' ' VAL . . . 95.71 -29.68 9.46 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 109.929 -1.269 . . . . 0.0 109.929 178.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.485 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 92.07 114.02 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 114.446 -0.877 . . . . 0.0 109.06 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.614 ' OD1' ' HB2' ' K' ' 30' ' ' ALA . 1.4 p30 -74.3 174.48 8.76 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 119.348 -0.941 . . . . 0.0 110.361 179.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.28 -36.75 43.73 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.019 -0.537 . . . . 0.0 112.358 178.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.97 76.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.541 0 CA-C-O 119.679 -0.512 . . . . 0.0 112.67 -177.02 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.614 ' HB2' ' OD1' ' K' ' 27' ' ' ASN . . . -80.12 149.7 30.5 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 118.745 1.272 . . . . 0.0 110.527 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.532 HG23 ' HB ' ' L' ' 31' ' ' ILE . 59.1 mt -130.77 135.97 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 CA-C-N 115.547 -0.752 . . . . 0.0 112.14 -177.31 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 40.2 mm -115.33 119.24 61.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 179.09 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.74 109.77 1.53 Allowed Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.384 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 70.7 mt -122.78 118.38 27.86 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.248 0.547 . . . . 0.0 110.626 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 95.9 mmm -110.74 122.27 47.4 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.004 179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.11 132.37 67.07 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.164 0 CA-C-N 116.579 -0.282 . . . . 0.0 110.318 -179.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.24 112.1 3.45 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 178.625 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.533 ' H ' ' HA3' ' L' ' 37' ' ' GLY . . . -76.65 73.18 1.9 Allowed Glycine 0 CA--C 1.532 1.148 0 C-N-CA 120.243 -0.98 . . . . 0.0 113.498 -178.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.663 HG23 HD12 ' Q' ' 31' ' ' ILE . 22.1 t -128.43 133.57 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 176.499 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' J' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.836 -1.078 . . . . 0.0 110.766 179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.64 136.59 43.89 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.817 0.341 . . . . 0.0 110.597 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.52 148.12 47.05 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.917 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.832 HG22 ' H ' ' L' ' 13' ' ' HIS . 11.3 p -138.98 -179.18 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.911 0.386 . . . . 0.0 111.07 -178.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.832 ' H ' HG22 ' L' ' 12' ' ' VAL . 0.3 OUTLIER -122.81 108.52 13.11 Favored 'General case' 0 CA--C 1.537 0.445 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.525 -179.941 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.436 ' O ' ' CG ' ' K' ' 14' ' ' HIS . 40.8 t-80 -150.38 165.52 32.85 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.688 HE22 ' H ' ' J' ' 37' ' ' GLY . 51.3 tt0 -89.74 158.73 17.4 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.643 0.259 . . . . 0.0 110.788 -179.03 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 69.1 tttt -140.01 107.56 5.59 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.252 0.548 . . . . 0.0 111.256 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.412 ' HB3' ' CZ ' ' L' ' 19' ' ' PHE . 4.4 mt -115.97 109.15 17.16 Favored 'General case' 0 CA--C 1.513 -0.458 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 177.883 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -105.09 103.55 15.51 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 N-CA-C 107.836 -1.172 . . . . 0.0 107.836 178.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.412 ' CZ ' ' HB3' ' L' ' 17' ' ' LEU . 65.8 m-85 -100.46 100.54 11.31 Favored 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 179.192 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.603 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 52.2 t80 -106.41 95.95 6.11 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 105.95 -1.87 . . . . 0.0 105.95 177.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.84 145.07 31.46 Favored 'General case' 0 CA--C 1.495 -1.138 0 C-N-CA 120.216 -0.594 . . . . 0.0 109.655 -178.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.426 ' O ' ' O ' ' K' ' 23' ' ' ASP . 80.8 mm-40 -82.6 96.04 7.96 Favored 'General case' 0 C--N 1.313 -1.01 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.728 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 91.8 m-20 -132.56 62.63 1.64 Allowed 'General case' 0 N--CA 1.468 0.47 0 CA-C-N 116.171 -0.468 . . . . 0.0 112.052 -177.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.479 HG12 ' H ' ' L' ' 25' ' ' GLY . 1.5 t 60.51 -141.63 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.207 0.527 . . . . 0.0 110.871 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.479 ' H ' HG12 ' L' ' 24' ' ' VAL . . . 156.63 -29.53 0.55 Allowed Glycine 0 CA--C 1.519 0.323 0 N-CA-C 109.182 -1.567 . . . . 0.0 109.182 -178.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 87.8 p -63.21 -123.66 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.191 -0.505 . . . . 0.0 110.868 179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.509 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 5.9 t-20 -156.97 -154.14 0.45 Allowed 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.856 -178.492 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.509 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 68.6 mttm 28.32 41.63 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 113.234 0.827 . . . . 0.0 113.234 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -171.09 -62.59 0.04 OUTLIER Glycine 0 CA--C 1.537 1.445 0 C-N-CA 120.678 -0.773 . . . . 0.0 112.723 178.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.83 148.08 29.02 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 117.785 0.792 . . . . 0.0 110.488 178.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.532 ' HB ' HG23 ' K' ' 31' ' ' ILE . 6.7 mm -114.76 125.89 72.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 178.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -120.18 124.6 72.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 179.216 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.72 115.46 1.7 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 111.056 -0.818 . . . . 0.0 111.056 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.7 tp -126.2 120.73 30.81 Favored 'General case' 0 CA--C 1.515 -0.384 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 179.029 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 93.8 mtp -135.38 147.55 49.09 Favored 'General case' 0 N--CA 1.468 0.465 0 N-CA-C 113.271 0.841 . . . . 0.0 113.271 -177.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 33.6 m -119.36 159.29 20.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.132 0 CA-C-N 114.719 -1.128 . . . . 0.0 108.643 178.277 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.533 ' HA3' ' H ' ' K' ' 38' ' ' GLY . . . -61.89 -102.79 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 C-N-CA 120.672 -0.775 . . . . 0.0 111.487 -179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.96 -75.14 0.11 Allowed Glycine 0 CA--C 1.534 1.237 0 C-N-CA 121.83 -0.224 . . . . 0.0 112.88 -179.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' K' ' 38' ' ' GLY . 3.0 m -106.49 123.76 61.53 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-O 121.296 0.57 . . . . 0.0 111.399 -178.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 2.2 t . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 117.932 -1.032 . . . . 0.0 110.258 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . 0.517 ' CG ' ' O ' ' N' ' 9' ' ' GLY . 94.6 m-85 -111.77 132.86 54.38 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.738 0.304 . . . . 0.0 110.217 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -142.69 171.37 14.14 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 121.145 0.498 . . . . 0.0 111.025 -179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -111.42 130.66 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 115.429 -0.805 . . . . 0.0 109.158 179.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 m80 -128.65 113.18 15.07 Favored 'General case' 0 N--CA 1.47 0.564 0 N-CA-C 112.224 0.453 . . . . 0.0 112.224 -179.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 17.9 p-80 -152.56 168.23 26.25 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.548 178.033 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -129.23 150.65 50.52 Favored 'General case' 0 CA--C 1.518 -0.258 0 CA-C-O 121.016 0.436 . . . . 0.0 110.085 178.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -97.56 116.25 29.4 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.3 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -124.97 114.07 18.65 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 118.154 0.434 . . . . 0.0 110.093 179.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . 0.431 ' O ' HG23 ' M' ' 18' ' ' VAL . 19.1 m -131.67 132.52 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.641 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -135.7 133.99 38.67 Favored 'General case' 0 N--CA 1.471 0.625 0 CA-C-O 121.077 0.465 . . . . 0.0 111.745 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -121.61 129.39 52.8 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 178.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . 0.498 ' HB1' ' CG2' ' M' ' 24' ' ' VAL . . . -130.98 131.81 44.62 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.332 0.587 . . . . 0.0 112.164 -178.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -120.23 142.27 49.18 Favored 'General case' 0 CA--C 1.527 0.087 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.557 179.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 66.1 t0 37.42 54.68 1.39 Allowed 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.179 -0.919 . . . . 0.0 112.306 -179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.498 ' CG2' ' HB1' ' M' ' 21' ' ' ALA . 45.6 t -67.79 135.61 28.15 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 177.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -112.76 -33.49 2.04 Favored Glycine 0 N--CA 1.47 0.901 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -178.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 62.8 p -82.31 -121.73 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.131 0.491 . . . . 0.0 111.206 -179.103 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.49 ' O ' HG11 ' M' ' 24' ' ' VAL . 10.9 m120 -93.22 -160.5 0.76 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.063 -178.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm 35.28 40.37 0.06 Allowed 'General case' 0 CA--C 1.535 0.384 0 N-CA-C 112.639 0.607 . . . . 0.0 112.639 -178.048 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.38 -64.37 1.22 Allowed Glycine 0 CA--C 1.538 1.518 0 N-CA-C 109.334 -1.507 . . . . 0.0 109.334 177.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.556 ' HB3' ' OG ' ' N' ' 26' ' ' SER . . . -157.26 49.74 0.44 Allowed 'General case' 0 CA--C 1.545 0.776 0 CA-C-N 118.043 0.922 . . . . 0.0 111.772 175.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.627 HD12 HG12 ' G' ' 39' ' ' VAL . 97.0 mt -138.49 106.84 3.59 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 CA-C-N 114.157 -1.383 . . . . 0.0 107.474 179.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 74.2 mt -102.7 104.43 16.53 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.335 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.09 95.71 0.75 Allowed Glycine 0 CA--C 1.505 -0.58 0 N-CA-C 104.071 -3.612 . . . . 0.0 104.071 176.854 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . 0.68 ' O ' HD23 ' N' ' 34' ' ' LEU . 43.1 tp -146.07 150.4 35.89 Favored 'General case' 0 C--O 1.235 0.324 0 CA-C-O 122.843 1.306 . . . . 0.0 113.809 -173.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -110.02 106.95 16.66 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-N 112.65 -2.068 . . . . 0.0 106.228 177.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.563 HG13 ' O ' ' M' ' 36' ' ' VAL . 4.0 p -127.35 114.07 34.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.6 -124.61 1.88 Allowed Glycine 0 C--N 1.309 -0.958 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.204 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 78.96 -67.11 3.29 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 121.283 -0.484 . . . . 0.0 112.043 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.615 HG12 ' CD1' ' A' ' 31' ' ' ILE . 13.0 m -78.4 169.1 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.253 0 CA-C-O 121.041 0.448 . . . . 0.0 110.472 -179.73 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.406 HG22 ' OXT' ' M' ' 40' ' ' VAL . 3.5 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.11 -0.947 . . . . 0.0 110.458 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . 0.517 ' O ' ' CG ' ' M' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 93.8 m-85 -115.44 142.01 47.29 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.87 0.367 . . . . 0.0 110.52 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . 0.526 ' O ' ' NE2' ' O' ' 13' ' ' HIS . 82.4 tt0 -69.18 120.64 15.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.095 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 t -128.51 120.45 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 CA-C-N 116.517 -0.31 . . . . 0.0 110.618 -179.682 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.474 ' CE1' ' OE2' ' N' ' 11' ' ' GLU . 60.4 m170 -113.68 150.71 32.85 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.901 -178.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.555 ' CE1' ' O ' ' O' ' 12' ' ' VAL . 75.2 m-70 -141.92 172.01 13.28 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 121.19 0.519 . . . . 0.0 110.403 178.472 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 68.4 tp60 -138.25 140.87 39.86 Favored 'General case' 0 CA--C 1.516 -0.329 0 N-CA-C 107.884 -1.154 . . . . 0.0 107.884 177.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 60.6 tttm -130.17 107.0 8.97 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.535 HD23 ' C ' ' N' ' 17' ' ' LEU . 5.9 tt -122.6 116.33 23.66 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . 0.437 HG22 ' CG1' ' O' ' 18' ' ' VAL . 80.0 t -121.01 126.22 74.95 Favored 'Isoleucine or valine' 0 C--O 1.233 0.226 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.333 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 92.6 t80 -127.03 122.02 33.25 Favored 'General case' 0 N--CA 1.469 0.49 0 N-CA-C 109.715 -0.476 . . . . 0.0 109.715 179.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -125.32 125.21 43.14 Favored 'General case' 0 N--CA 1.469 0.498 0 CA-C-N 116.821 -0.172 . . . . 0.0 111.032 -179.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.95 131.4 53.56 Favored 'General case' 0 N--CA 1.471 0.586 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 179.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.425 ' O ' ' N ' ' N' ' 24' ' ' VAL . 95.1 mt-10 -81.05 -166.81 1.22 Allowed 'General case' 0 N--CA 1.468 0.435 0 CA-C-O 121.325 0.583 . . . . 0.0 112.53 -177.748 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.518 ' N ' ' OE1' ' O' ' 22' ' ' GLU . 66.2 t0 -61.97 47.51 0.01 OUTLIER 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 114.765 -1.107 . . . . 0.0 112.394 -178.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.855 HG12 ' H ' ' N' ' 25' ' ' GLY . 30.3 t -61.04 -179.02 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 C-N-CA 120.547 -0.461 . . . . 0.0 110.019 -179.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 0.855 ' H ' HG12 ' N' ' 24' ' ' VAL . . . -100.96 29.31 12.77 Favored Glycine 0 CA--C 1.531 1.048 0 C-N-CA 121.636 -0.316 . . . . 0.0 112.718 -177.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.556 ' OG ' ' HB3' ' M' ' 30' ' ' ALA . 10.7 t -81.05 112.86 18.82 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 178.163 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 72.1 m-20 -89.75 -175.06 4.52 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 115.18 1.548 . . . . 0.0 115.18 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.538 ' NZ ' ' OXT' ' H' ' 40' ' ' VAL . 59.3 mttp 49.29 37.64 11.9 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 111.525 -2.58 . . . . 0.0 114.824 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . 0.61 ' O ' ' HB2' ' N' ' 30' ' ' ALA . . . 92.01 -77.98 1.28 Allowed Glycine 0 N--CA 1.469 0.851 0 N-CA-C 114.517 0.567 . . . . 0.0 114.517 172.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . 0.898 ' O ' ' HB1' ' O' ' 30' ' ' ALA . . . 150.87 162.64 0.0 OUTLIER 'General case' 0 C--O 1.238 0.464 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 -178.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.721 HD13 HG13 ' H' ' 39' ' ' VAL . 28.8 pt -141.32 126.92 18.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 C-N-CA 119.8 -0.76 . . . . 0.0 112.029 178.566 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 97.4 mt -113.04 114.55 47.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.47 -179.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.95 105.95 1.66 Allowed Glycine 0 N--CA 1.462 0.38 0 N-CA-C 104.936 -3.266 . . . . 0.0 104.936 175.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.68 HD23 ' O ' ' M' ' 34' ' ' LEU . 0.4 OUTLIER -146.32 144.32 29.73 Favored 'General case' 0 CA--C 1.51 -0.581 0 C-N-CA 117.716 -1.594 . . . . 0.0 114.512 -174.18 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 36.3 tpp -106.97 107.77 18.95 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 105.208 -2.145 . . . . 0.0 105.208 174.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.429 HG13 HD22 ' N' ' 34' ' ' LEU . 0.0 OUTLIER -121.52 143.68 33.14 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 N-CA-C 108.709 -0.849 . . . . 0.0 108.709 -178.216 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.477 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 113.26 -102.68 1.29 Allowed Glycine 0 C--N 1.316 -0.55 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 178.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.427 ' C ' HD11 ' B' ' 31' ' ' ILE . . . 85.69 -80.3 1.81 Allowed Glycine 0 CA--C 1.534 1.245 0 N-CA-C 110.264 -1.135 . . . . 0.0 110.264 -178.542 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.552 HG23 HD11 ' B' ' 31' ' ' ILE . 43.4 t -153.03 123.54 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.462 0.136 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 177.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.524 HG22 ' O ' ' O' ' 38' ' ' GLY . 9.1 m . . . . . 0 C--O 1.22 -0.498 0 CA-C-O 117.884 -1.055 . . . . 0.0 110.724 -179.675 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.42 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -115.44 141.51 47.95 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.876 0.369 . . . . 0.0 110.687 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -83.11 116.78 22.48 Favored 'General case' 0 CA--C 1.531 0.221 0 CA-C-N 116.233 -0.439 . . . . 0.0 109.933 179.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.555 ' O ' ' CE1' ' N' ' 14' ' ' HIS . 2.9 m -138.44 160.66 31.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.823 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 94.3 m-70 -76.74 113.39 14.35 Favored 'General case' 0 C--N 1.327 -0.413 0 C-N-CA 120.114 -0.634 . . . . 0.0 109.529 178.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.572 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 83.6 t60 -148.02 153.23 38.68 Favored 'General case' 0 N--CA 1.47 0.547 0 C-N-CA 119.576 -0.849 . . . . 0.0 111.875 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.563 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 42.1 tt0 -98.65 169.61 9.38 Favored 'General case' 0 C--N 1.345 0.396 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -158.57 104.44 1.8 Allowed 'General case' 0 C--N 1.309 -1.182 0 C-N-CA 120.11 -0.636 . . . . 0.0 110.681 176.669 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.521 ' CD1' HG11 ' M' ' 36' ' ' VAL . 31.5 mt -122.29 116.02 23.35 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 177.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . 0.437 ' CG1' HG22 ' N' ' 18' ' ' VAL . 3.3 p -125.0 117.59 50.56 Favored 'Isoleucine or valine' 0 C--O 1.237 0.425 0 CA-C-O 121.883 0.849 . . . . 0.0 109.576 178.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -112.31 115.08 28.19 Favored 'General case' 0 CA--C 1.546 0.809 0 CA-C-N 114.314 -1.312 . . . . 0.0 108.429 179.973 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -114.63 133.93 55.46 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 122.523 0.329 . . . . 0.0 110.524 -179.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.58 142.11 27.64 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 113.68 0.993 . . . . 0.0 113.68 -178.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . 0.518 ' OE1' ' N ' ' N' ' 23' ' ' ASP . 95.9 mt-10 -78.99 104.98 10.0 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 104.481 -2.415 . . . . 0.0 104.481 175.486 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.814 ' HB3' ' HB1' ' P' ' 21' ' ' ALA . 17.6 p30 -83.27 49.03 1.48 Allowed 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 117.736 2.495 . . . . 0.0 117.736 -172.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.471 HG12 ' N ' ' O' ' 25' ' ' GLY . 89.9 t -71.56 160.44 5.24 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.443 0 C-N-CA 114.803 -2.759 . . . . 0.0 104.221 178.645 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.481 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.92 -30.8 8.31 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 106.015 -2.834 . . . . 0.0 106.015 -175.065 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 2.5 m 100.59 111.13 0.01 OUTLIER 'General case' 0 N--CA 1.475 0.804 0 CA-C-N 112.932 -1.634 . . . . 0.0 112.072 -179.128 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.555 ' O ' ' N ' ' O' ' 29' ' ' GLY . 12.7 t-20 -70.48 -179.43 2.09 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.702 179.569 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.537 ' H ' ' CG ' ' O' ' 27' ' ' ASN . 51.9 tttt 65.53 -47.29 0.38 Allowed 'General case' 0 CA--C 1.511 -0.524 0 N-CA-C 108.621 -0.881 . . . . 0.0 108.621 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.555 ' N ' ' O ' ' O' ' 27' ' ' ASN . . . -81.95 59.38 4.87 Favored Glycine 0 CA--C 1.526 0.723 0 N-CA-C 107.039 -2.424 . . . . 0.0 107.039 -179.787 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . 0.898 ' HB1' ' O ' ' N' ' 30' ' ' ALA . . . -140.31 -171.02 3.11 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 109.739 -3.231 . . . . 0.0 105.513 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 81.5 mt -128.81 125.97 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.85 0 C-N-CA 119.509 -0.876 . . . . 0.0 113.342 -179.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.464 HD13 ' CD2' ' Q' ' 19' ' ' PHE . 88.9 mt -104.33 104.54 16.97 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.679 0 N-CA-C 106.734 -1.58 . . . . 0.0 106.734 174.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.05 109.92 2.78 Favored Glycine 0 CA--C 1.505 -0.568 0 N-CA-C 105.553 -3.019 . . . . 0.0 105.553 177.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.602 ' O ' HD23 ' O' ' 34' ' ' LEU . 0.0 OUTLIER -162.98 150.0 12.91 Favored 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 115.737 -2.385 . . . . 0.0 114.742 -174.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 93.0 mmm -110.08 105.05 14.02 Favored 'General case' 0 CA--C 1.496 -1.102 0 CA-C-N 111.604 -2.544 . . . . 0.0 106.199 179.106 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.5 ' HB ' HD21 ' O' ' 34' ' ' LEU . 11.9 p -118.64 142.12 35.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.872 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -178.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 158.04 -102.08 0.21 Allowed Glycine 0 C--N 1.313 -0.696 0 C-N-CA 120.076 -1.059 . . . . 0.0 110.549 -176.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.524 ' O ' HG22 ' N' ' 40' ' ' VAL . . . 73.99 64.75 2.36 Favored Glycine 0 CA--C 1.54 1.648 0 C-N-CA 120.571 -0.823 . . . . 0.0 113.182 -178.498 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.839 HG12 HD11 ' C' ' 31' ' ' ILE . 9.1 p -10.79 140.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -179.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.414 ' CG1' ' OXT' ' P' ' 40' ' ' VAL . 7.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.059 177.314 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.179 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 64.3 m-85 -107.73 131.46 54.41 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.702 0.287 . . . . 0.0 110.591 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . 0.408 ' H ' ' HG2' ' Q' ' 11' ' ' GLU . 69.5 mm-40 -136.66 113.83 10.67 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.734 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.499 HG12 ' H ' ' Q' ' 12' ' ' VAL . 6.2 m -126.14 130.71 72.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.301 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.627 ' H ' ' CE1' ' Q' ' 13' ' ' HIS . 0.6 OUTLIER -129.54 115.67 17.79 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 121.055 0.455 . . . . 0.0 112.008 -178.991 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.572 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 4.5 p80 -156.11 167.16 31.29 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.359 179.113 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.477 HE22 ' N ' ' N' ' 37' ' ' GLY . 53.2 tt0 -89.78 158.48 17.49 Favored 'General case' 0 N--CA 1.452 -0.342 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -140.32 115.08 9.54 Favored 'General case' 0 C--N 1.316 -0.864 0 C-N-CA 120.995 -0.282 . . . . 0.0 110.636 179.56 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.424 ' HB3' ' CE2' ' P' ' 19' ' ' PHE . 14.4 mt -119.47 122.28 41.34 Favored 'General case' 0 N--CA 1.471 0.607 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 46.4 t -119.63 107.56 21.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 178.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' ' CE2' ' Q' ' 19' ' ' PHE . 47.8 m-85 -110.03 107.95 18.0 Favored 'General case' 0 C--O 1.234 0.251 0 N-CA-C 107.424 -1.324 . . . . 0.0 107.424 178.197 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 88.2 t80 -116.4 125.56 52.22 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 120.596 0.236 . . . . 0.0 110.694 -178.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . 0.814 ' HB1' ' HB3' ' O' ' 23' ' ' ASP . . . -129.59 127.78 41.36 Favored 'General case' 0 CA--C 1.54 0.576 0 CA-C-O 121.141 0.496 . . . . 0.0 110.231 -179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.519 ' O ' ' N ' ' O' ' 23' ' ' ASP . 16.6 pt-20 -122.03 158.77 28.45 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -177.417 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.433 ' C ' ' OD1' ' O' ' 23' ' ' ASP . 29.8 m-20 76.43 55.98 0.05 OUTLIER 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 113.439 -1.709 . . . . 0.0 112.859 178.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.412 HG12 ' H ' ' O' ' 27' ' ' ASN . 3.8 m -77.4 129.21 37.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 176.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . -100.21 -35.41 4.48 Favored Glycine 0 CA--C 1.536 1.383 0 C-N-CA 118.854 -1.641 . . . . 0.0 112.127 -178.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.652 ' O ' ' O ' ' P' ' 27' ' ' ASN . 16.4 t -173.97 125.82 0.36 Allowed 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 119.562 1.681 . . . . 0.0 114.179 175.323 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.652 ' O ' ' O ' ' P' ' 26' ' ' SER . 44.6 m-20 -2.86 145.73 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.282 0 C-N-CA 125.25 1.42 . . . . 0.0 114.683 173.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 34.1 tttt -160.31 32.23 0.17 Allowed 'General case' 0 N--CA 1.475 0.807 0 N-CA-C 117.307 2.336 . . . . 0.0 117.307 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.73 80.95 0.89 Allowed Glycine 0 N--CA 1.482 1.748 0 C-N-CA 117.768 -2.158 . . . . 0.0 112.939 178.159 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . 0.514 ' CB ' ' O ' ' O' ' 28' ' ' LYS . . . -101.94 131.41 48.35 Favored 'General case' 0 CA--C 1.508 -0.651 0 N-CA-C 113.217 0.821 . . . . 0.0 113.217 -176.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.506 HD11 HG21 ' K' ' 39' ' ' VAL . 91.1 mt -133.47 122.49 44.23 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 115.757 -0.656 . . . . 0.0 112.164 178.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.441 HD13 HG21 ' P' ' 32' ' ' ILE . 43.7 mt -107.17 110.43 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 106.658 -1.608 . . . . 0.0 106.658 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.03 102.88 0.86 Allowed Glycine 0 N--CA 1.462 0.369 0 N-CA-C 107.788 -2.125 . . . . 0.0 107.788 178.718 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.452 ' HB2' HD23 ' O' ' 34' ' ' LEU . 4.0 pp -157.35 162.35 39.09 Favored 'General case' 0 CA--C 1.493 -1.224 0 C-N-CA 117.664 -1.615 . . . . 0.0 113.621 -177.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 23.3 mtp -119.89 123.19 42.98 Favored 'General case' 0 N--CA 1.436 -1.129 0 CA-C-N 112.215 -2.266 . . . . 0.0 109.628 179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.609 ' O ' ' O ' ' P' ' 37' ' ' GLY . 0.1 OUTLIER -98.17 101.95 12.81 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 179.965 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.609 ' O ' ' O ' ' P' ' 36' ' ' VAL . . . 28.42 172.77 0.0 OUTLIER Glycine 0 N--CA 1.468 0.78 0 C-N-CA 126.04 1.781 . . . . 0.0 116.491 179.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.03 -58.21 0.59 Allowed Glycine 0 CA--C 1.536 1.378 0 CA-C-N 113.45 -1.375 . . . . 0.0 112.678 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.514 HG23 HD11 ' D' ' 31' ' ' ILE . 72.7 t -105.58 131.4 55.08 Favored 'Isoleucine or valine' 0 C--N 1.345 0.383 0 CA-C-O 121.195 0.521 . . . . 0.0 111.091 -178.307 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' P' ' 39' ' ' VAL . 5.6 p . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 118.271 -0.871 . . . . 0.0 111.3 -179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -106.58 133.83 50.66 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.114 -0.328 . . . . 0.0 110.114 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . 0.408 ' HG2' ' H ' ' P' ' 11' ' ' GLU . 96.5 mt-10 -139.02 139.25 37.78 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.758 0.313 . . . . 0.0 110.549 -179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.499 ' H ' HG12 ' P' ' 12' ' ' VAL . 29.0 m -137.13 158.1 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.339 0 CA-C-O 121.085 0.469 . . . . 0.0 110.839 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.627 ' CE1' ' H ' ' P' ' 13' ' ' HIS . 44.8 m-70 -147.5 115.18 6.39 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.91 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.631 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 83.2 m-70 -131.89 160.38 35.89 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.228 -0.656 . . . . 0.0 109.228 177.721 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.5 ' OE1' HD11 ' Q' ' 17' ' ' LEU . 48.8 tt0 -90.09 159.18 16.94 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.207 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 53.8 mtpt -140.68 92.39 2.51 Favored 'General case' 0 C--N 1.316 -0.885 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.836 178.028 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.5 HD11 ' OE1' ' Q' ' 15' ' ' GLN . 3.0 mt -115.01 115.12 26.33 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.078 -1.082 . . . . 0.0 108.078 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -119.49 107.77 22.07 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.397 -179.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.585 ' CE2' ' CD2' ' P' ' 19' ' ' PHE . 35.4 m-85 -110.1 101.95 10.7 Favored 'General case' 0 C--O 1.237 0.433 0 N-CA-C 104.311 -2.477 . . . . 0.0 104.311 175.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 10.0 t80 -123.45 133.37 54.06 Favored 'General case' 0 C--O 1.239 0.52 0 CA-C-N 116.139 -0.482 . . . . 0.0 112.286 -175.703 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.518 ' HB2' ' OD1' ' O' ' 27' ' ' ASN . . . -138.09 154.65 49.23 Favored 'General case' 0 N--CA 1.471 0.601 0 N-CA-C 113.256 0.836 . . . . 0.0 113.256 -179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.528 ' O ' ' N ' ' Q' ' 24' ' ' VAL . 75.4 tt0 -72.58 163.05 28.66 Favored 'General case' 0 CA--C 1.549 0.915 0 N-CA-C 113.632 0.975 . . . . 0.0 113.632 -177.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 65.7 t0 0.78 54.28 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 116.317 1.969 . . . . 0.0 116.317 -178.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.528 ' N ' ' O ' ' Q' ' 22' ' ' GLU . 0.3 OUTLIER -66.56 137.17 25.39 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 112.3 0.481 . . . . 0.0 112.3 176.425 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.537 ' O ' ' CB ' ' Q' ' 26' ' ' SER . . . -118.04 -28.34 2.25 Favored Glycine 0 CA--C 1.542 1.745 0 CA-C-O 118.94 -0.922 . . . . 0.0 110.919 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.537 ' CB ' ' O ' ' Q' ' 25' ' ' GLY . 0.7 OUTLIER 91.11 116.81 0.03 OUTLIER 'General case' 0 N--CA 1.488 1.454 0 CA-C-N 118.895 1.348 . . . . 0.0 114.607 173.656 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 64.0 t30 -72.96 174.81 7.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 121.232 0.539 . . . . 0.0 111.086 177.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -53.84 -38.88 65.1 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.335 -0.848 . . . . 0.0 112.688 178.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.46 ' O ' HG13 ' K' ' 39' ' ' VAL . . . -109.04 69.21 0.21 Allowed Glycine 0 CA--C 1.537 1.438 0 N-CA-C 115.517 0.967 . . . . 0.0 115.517 -175.501 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.14 121.45 41.45 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 117.837 0.819 . . . . 0.0 109.151 178.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.663 HD12 HG23 ' K' ' 39' ' ' VAL . 86.1 mt -125.81 132.52 70.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 121.101 0.477 . . . . 0.0 111.646 -178.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 90.3 mt -122.53 121.93 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.521 178.979 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.69 108.16 1.15 Allowed Glycine 0 C--N 1.34 0.796 0 N-CA-C 110.062 -1.215 . . . . 0.0 110.062 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 15.7 mt -117.68 122.4 43.43 Favored 'General case' 0 C--O 1.236 0.382 0 N-CA-C 108.925 -0.768 . . . . 0.0 108.925 -178.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 87.6 mtp -136.12 144.46 45.09 Favored 'General case' 0 N--CA 1.47 0.572 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -178.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.568 HG12 ' N ' ' Q' ' 37' ' ' GLY . 63.7 t -117.99 168.28 10.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 178.381 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.568 ' N ' HG12 ' Q' ' 36' ' ' VAL . . . -169.15 93.81 0.1 Allowed Glycine 0 C--N 1.314 -0.672 0 C-N-CA 118.915 -1.612 . . . . 0.0 112.932 -179.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.0 -81.51 0.1 OUTLIER Glycine 0 CA--C 1.536 1.391 0 CA-C-N 118.74 1.27 . . . . 0.0 113.373 177.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -171.99 136.81 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 118.299 1.05 . . . . 0.0 110.293 178.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 47.7 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 118.094 -0.955 . . . . 0.0 110.634 -179.965 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -108.06 142.03 38.85 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.848 0.356 . . . . 0.0 110.315 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 20.1 pt-20 -131.18 148.71 52.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.946 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.481 ' H ' HG12 ' Q' ' 12' ' ' VAL . 2.6 p -129.51 135.85 60.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-O 121.434 0.635 . . . . 0.0 110.857 -179.695 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.605 ' HD1' ' HB2' ' Q' ' 13' ' ' HIS . 1.3 m-70 -139.9 133.13 29.79 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.856 -179.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.631 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 83.7 t60 -153.55 161.56 42.1 Favored 'General case' 0 C--N 1.33 -0.275 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 176.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.453 ' O ' ' CD2' ' R' ' 14' ' ' HIS . 18.4 tt0 -90.14 158.87 17.06 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.595 -0.442 . . . . 0.0 110.306 -179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . 0.426 ' H ' ' HB3' ' Q' ' 15' ' ' GLN . 37.7 tttp -140.52 104.6 4.79 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 177.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.463 ' N ' HD23 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -118.58 114.05 22.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 178.477 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 39.3 t -117.36 107.12 21.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-O 121.028 0.442 . . . . 0.0 110.439 -179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.546 ' O ' ' CD2' ' R' ' 20' ' ' PHE . 16.2 m-85 -113.4 101.45 9.39 Favored 'General case' 0 N--CA 1.461 0.118 0 N-CA-C 106.302 -1.74 . . . . 0.0 106.302 177.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . 0.546 ' CD2' ' O ' ' R' ' 19' ' ' PHE . 63.0 m-85 -157.59 -177.75 6.82 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.695 1.236 . . . . 0.0 113.801 -177.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -147.02 154.41 41.17 Favored 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 114.027 -1.442 . . . . 0.0 110.05 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 80.2 tt0 -82.15 148.9 28.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.111 0.482 . . . . 0.0 111.7 -178.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 58.14 48.14 13.37 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.178 -0.919 . . . . 0.0 111.753 179.127 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.501 HG12 ' N ' ' R' ' 25' ' ' GLY . 15.3 t -66.52 166.56 1.56 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 120.095 -0.642 . . . . 0.0 109.812 179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.501 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -175.76 15.96 0.04 OUTLIER Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.5 p -83.11 140.82 32.41 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.73 0.641 . . . . 0.0 112.73 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.652 ' O ' ' N ' ' R' ' 29' ' ' GLY . 71.5 m-80 -73.15 150.99 41.74 Favored 'General case' 0 C--O 1.223 -0.297 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.299 177.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -51.32 45.8 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.652 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.81 58.33 0.8 Allowed Glycine 0 CA--C 1.541 1.681 0 CA-C-N 118.611 0.641 . . . . 0.0 112.479 179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -147.59 170.14 18.12 Favored 'General case' 0 CA--C 1.515 -0.389 0 CA-C-N 117.454 0.627 . . . . 0.0 109.529 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 87.9 mt -119.89 123.95 71.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 92.3 mt -121.57 130.22 74.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.665 -179.015 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.08 111.44 1.16 Allowed Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.112 -1.195 . . . . 0.0 110.112 179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.53 ' C ' HD23 ' R' ' 34' ' ' LEU . 8.0 tt -119.27 121.42 39.6 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.245 -1.02 . . . . 0.0 108.245 179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 87.9 mtp -141.64 145.16 34.63 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.384 0.611 . . . . 0.0 112.117 -178.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.477 HG23 ' HB ' ' Q' ' 36' ' ' VAL . 2.2 p -144.01 143.4 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 119.526 -0.869 . . . . 0.0 111.623 177.487 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.03 -102.62 1.02 Allowed Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 106.457 -2.657 . . . . 0.0 106.457 174.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 23.23 73.5 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.296 0 CA-C-N 112.758 -1.721 . . . . 0.0 115.48 175.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 96.8 t -49.39 134.4 7.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 CA-C-N 117.008 0.404 . . . . 0.0 110.41 178.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.848 179.818 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.696 -1.361 . . . . 0.0 109.696 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -81.08 139.83 35.45 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 109.728 -0.471 . . . . 0.0 109.728 179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -100.72 108.66 20.56 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 121.071 0.462 . . . . 0.0 111.461 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 m -136.22 157.57 37.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 178.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.427 ' C ' ' CG ' ' A' ' 14' ' ' HIS . 64.8 t-80 -145.32 124.06 12.59 Favored 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 120.34 -0.544 . . . . 0.0 111.712 -179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.529 ' CE1' ' H ' ' B' ' 14' ' ' HIS . 29.4 m-70 -151.47 165.97 32.55 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.133 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 66.9 tp60 -159.72 143.36 14.43 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.942 0.401 . . . . 0.0 110.053 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -80.44 120.37 24.36 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.352 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.8 mt -129.71 112.36 13.57 Favored 'General case' 0 C--O 1.236 0.361 0 N-CA-C 109.758 -0.46 . . . . 0.0 109.758 178.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 53.5 t -125.52 131.53 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.377 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -122.99 124.02 42.21 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.4 p90 -132.48 130.59 40.68 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-O 120.765 0.317 . . . . 0.0 110.382 -179.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.19 132.69 40.05 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-O 121.068 0.461 . . . . 0.0 110.299 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.435 ' O ' ' C ' ' A' ' 23' ' ' ASP . 13.2 pt-20 -83.87 -170.47 3.09 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.989 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 23' ' ' ASP . 21.3 p-10 -33.32 -60.36 0.35 Allowed 'General case' 0 N--CA 1.466 0.366 0 O-C-N 123.258 0.349 . . . . 0.0 111.15 -179.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.523 HG22 ' N ' ' A' ' 25' ' ' GLY . 3.6 p -72.51 160.9 5.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.523 ' N ' HG22 ' A' ' 24' ' ' VAL . . . 110.49 -35.09 5.02 Favored Glycine 0 N--CA 1.467 0.734 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 179.573 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 33.8 p -80.59 119.05 22.73 Favored 'General case' 0 CA--C 1.52 -0.186 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 178.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.529 ' CG ' ' H ' ' A' ' 28' ' ' LYS . 14.5 t-20 -88.5 179.36 6.31 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 121.749 0.785 . . . . 0.0 112.129 -178.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.598 ' NZ ' ' CE1' ' O' ' 13' ' ' HIS . 71.4 tttt -54.4 -38.23 65.95 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 113.884 -1.507 . . . . 0.0 112.491 178.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.52 71.42 0.2 Allowed Glycine 0 CA--C 1.536 1.395 0 CA-C-N 114.937 -1.029 . . . . 0.0 114.137 -174.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.474 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -95.65 98.43 10.48 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-O 124.367 2.032 . . . . 0.0 111.036 -178.374 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.437 HG22 HG12 ' B' ' 31' ' ' ILE . 6.0 pt -134.76 139.56 47.3 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 111.538 -2.574 . . . . 0.0 108.685 -179.424 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.425 HG21 HD13 ' A' ' 32' ' ' ILE . 43.4 mt -108.57 112.45 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.5 96.8 0.76 Allowed Glycine 0 N--CA 1.463 0.434 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 176.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.424 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 77.2 mt -147.08 169.87 18.35 Favored 'General case' 0 CA--C 1.506 -0.721 0 CA-C-O 122.622 1.201 . . . . 0.0 111.834 -176.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 23.5 mtp -124.68 119.42 28.92 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 113.403 -1.726 . . . . 0.0 108.894 178.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.551 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 2.5 t -108.95 111.9 38.13 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 106.431 -1.692 . . . . 0.0 106.431 177.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.52 -131.72 7.97 Favored Glycine 0 C--N 1.32 -0.356 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.6 -62.51 0.31 Allowed Glycine 0 CA--C 1.54 1.652 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 -179.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.439 ' O ' ' OXT' ' A' ' 40' ' ' VAL . 25.2 m -122.96 163.34 21.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 N-CA-C 109.826 -0.435 . . . . 0.0 109.826 179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.445 HG12 ' O ' ' A' ' 40' ' ' VAL . 99.0 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.938 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . 0.527 ' CE1' ' O ' ' C' ' 9' ' ' GLY . 97.2 m-85 -106.12 132.89 51.65 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.541 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 56.9 mp0 -110.31 124.0 50.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.465 -179.666 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.452 HG22 HG12 ' C' ' 12' ' ' VAL . 53.7 t -124.73 128.15 73.17 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.52 ' N ' ' ND1' ' C' ' 13' ' ' HIS . 41.2 t60 -131.44 122.24 25.91 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 120.941 0.4 . . . . 0.0 111.595 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.529 ' H ' ' CE1' ' A' ' 14' ' ' HIS . 74.2 t60 -157.78 168.36 27.43 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.593 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.435 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 83.6 mt-30 -154.77 141.81 19.29 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.277 0.56 . . . . 0.0 110.747 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -87.09 110.9 20.41 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.305 -0.862 . . . . 0.0 110.712 177.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.403 HD12 ' N ' ' B' ' 17' ' ' LEU . 6.0 mp -121.52 112.72 18.85 Favored 'General case' 0 N--CA 1.473 0.685 0 N-CA-C 108.517 -0.92 . . . . 0.0 108.517 177.518 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.0 t -121.65 131.8 72.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.619 0 CA-C-O 120.718 0.294 . . . . 0.0 110.676 -179.216 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 78.6 m-85 -122.96 116.27 23.29 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.364 179.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -119.11 126.07 50.76 Favored 'General case' 0 N--CA 1.468 0.455 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 178.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.7 136.65 31.05 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 113.842 1.052 . . . . 0.0 113.842 -178.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -111.53 117.52 33.23 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 176.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.525 ' OD2' ' ND2' ' B' ' 27' ' ' ASN . 65.5 t0 -107.0 46.31 0.94 Allowed 'General case' 0 N--CA 1.468 0.474 0 N-CA-C 113.516 0.932 . . . . 0.0 113.516 -177.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.648 HG12 ' N ' ' B' ' 25' ' ' GLY . 61.8 t -83.57 173.26 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.597 0 N-CA-C 108.47 -0.937 . . . . 0.0 108.47 177.737 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.648 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 93.6 -28.17 10.71 Favored Glycine 0 CA--C 1.528 0.904 0 C-N-CA 121.268 -0.491 . . . . 0.0 112.905 177.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.812 ' O ' ' O ' ' B' ' 27' ' ' ASN . 78.0 p 178.61 -129.35 0.0 OUTLIER 'General case' 0 C--O 1.219 -0.524 0 CA-C-O 119.123 -0.465 . . . . 0.0 109.825 -178.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.812 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.1 t30 10.16 152.06 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 N-CA-C 115.524 1.676 . . . . 0.0 115.524 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.578 ' HB3' ' H ' ' C' ' 28' ' ' LYS . 94.2 mttt -169.55 30.17 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.569 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.736 -179.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -99.32 78.88 0.51 Allowed Glycine 0 CA--C 1.538 1.469 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 178.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.616 ' H ' HD21 ' C' ' 27' ' ' ASN . . . -110.43 112.75 24.89 Favored 'General case' 0 N--CA 1.477 0.89 0 N-CA-C 114.512 1.301 . . . . 0.0 114.512 -176.079 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.437 HG12 HG22 ' A' ' 31' ' ' ILE . 44.1 pt -140.59 143.78 28.43 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 CA-C-N 114.97 -1.014 . . . . 0.0 110.958 176.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 67.8 mt -113.56 122.45 67.72 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.153 0.502 . . . . 0.0 110.054 178.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.93 105.39 1.04 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 106.839 -2.504 . . . . 0.0 106.839 177.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.738 ' HB2' HD22 ' C' ' 34' ' ' LEU . 56.9 mt -137.19 145.24 43.46 Favored 'General case' 0 CA--C 1.504 -0.804 0 CA-C-O 122.818 1.294 . . . . 0.0 114.157 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -104.79 108.72 20.36 Favored 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 104.487 -2.412 . . . . 0.0 104.487 174.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 39.2 t -116.33 102.34 13.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -176.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.817 ' N ' HE22 ' D' ' 15' ' ' GLN . . . 111.75 164.19 17.5 Favored Glycine 0 CA--C 1.519 0.336 0 CA-C-O 122.015 0.786 . . . . 0.0 111.412 -179.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.584 ' H ' ' HA3' ' C' ' 38' ' ' GLY . . . 164.82 -55.95 0.27 Allowed Glycine 0 CA--C 1.542 1.741 0 N-CA-C 108.949 -1.66 . . . . 0.0 108.949 -178.208 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 24.5 t -119.76 134.4 63.41 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.151 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.63 HG11 ' ND1' ' E' ' 13' ' ' HIS . 81.3 t . . . . . 0 C--O 1.22 -0.447 0 CA-C-O 118.163 -0.923 . . . . 0.0 110.721 179.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . 0.527 ' O ' ' CE1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -151.1 158.86 44.57 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.616 0.246 . . . . 0.0 110.628 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -89.64 120.78 31.21 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.598 179.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.544 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 2.8 p -138.94 138.6 41.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.232 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.523 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 84.3 m-70 -146.65 135.17 22.02 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.777 0.322 . . . . 0.0 111.413 -179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' D' ' 14' ' ' HIS . 41.8 m-70 -151.26 172.03 16.5 Favored 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 177.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 45.8 tt0 -126.65 141.81 51.74 Favored 'General case' 0 CA--C 1.522 -0.128 0 N-CA-C 106.437 -1.69 . . . . 0.0 106.437 174.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.418 ' C ' HD12 ' C' ' 17' ' ' LEU . 88.5 tttt -115.76 108.99 17.05 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 118.697 -0.668 . . . . 0.0 111.62 179.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.418 HD12 ' C ' ' C' ' 16' ' ' LYS . 8.4 mp -124.12 115.06 20.53 Favored 'General case' 0 N--CA 1.48 1.052 0 CA-C-N 118.804 0.729 . . . . 0.0 109.056 175.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 81.2 t -109.32 122.16 63.52 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.416 0 N-CA-C 108.026 -1.101 . . . . 0.0 108.026 178.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -111.56 103.46 11.79 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.601 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 15.7 t80 -113.67 125.12 53.79 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 109.856 -0.424 . . . . 0.0 109.856 -179.226 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.81 133.35 33.9 Favored 'General case' 0 C--O 1.239 0.526 0 CA-C-O 121.786 0.803 . . . . 0.0 112.866 -179.187 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 94.5 mt-10 -95.8 120.08 35.43 Favored 'General case' 0 CA--C 1.52 -0.192 0 N-CA-C 107.951 -1.129 . . . . 0.0 107.951 177.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 29.0 t0 -141.58 48.89 1.62 Allowed 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -176.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.526 HG12 ' N ' ' C' ' 25' ' ' GLY . 73.3 t -71.89 161.34 4.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 -179.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.526 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 109.35 -30.5 8.5 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 108.159 -1.976 . . . . 0.0 108.159 -176.489 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.518 ' HB3' ' O ' ' C' ' 25' ' ' GLY . 25.8 t 99.96 111.75 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 C-N-CA 126.296 1.838 . . . . 0.0 110.657 -178.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.616 HD21 ' H ' ' B' ' 30' ' ' ALA . 30.8 t30 -71.51 162.01 30.12 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 119.171 -1.011 . . . . 0.0 111.855 -179.332 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.578 ' H ' ' HB3' ' B' ' 28' ' ' LYS . 28.2 ttpt -48.7 -39.36 24.34 Favored 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 114.645 1.35 . . . . 0.0 114.645 176.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.49 69.15 0.04 OUTLIER Glycine 0 CA--C 1.542 1.762 0 CA-C-O 118.669 -1.073 . . . . 0.0 111.488 -173.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.05 130.17 41.41 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 120.14 1.97 . . . . 0.0 113.938 -173.772 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.494 ' CD1' ' O ' ' O' ' 38' ' ' GLY . 36.8 mt -139.18 141.24 36.45 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.868 0 CA-C-N 113.738 -1.573 . . . . 0.0 114.284 -176.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.8 mt -117.78 118.52 58.64 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.734 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 175.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.953 ' O ' HD23 ' C' ' 34' ' ' LEU . . . -125.17 113.2 1.88 Allowed Glycine 0 N--CA 1.474 1.185 0 N-CA-C 108.846 -1.701 . . . . 0.0 108.846 178.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.953 HD23 ' O ' ' C' ' 33' ' ' GLY . 3.1 mt -138.89 151.8 47.26 Favored 'General case' 0 C--O 1.243 0.762 0 CA-C-O 123.51 1.624 . . . . 0.0 114.499 -177.49 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 88.1 mmm -105.31 107.1 17.91 Favored 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 111.073 -2.785 . . . . 0.0 104.359 174.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.72 ' HB ' HG12 ' D' ' 36' ' ' VAL . 2.9 t -111.29 143.06 21.89 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 N-CA-C 108.157 -1.053 . . . . 0.0 108.157 -177.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.415 ' O ' ' OE1' ' E' ' 15' ' ' GLN . . . 166.85 -102.06 0.19 Allowed Glycine 0 C--N 1.302 -1.352 0 C-N-CA 119.507 -1.33 . . . . 0.0 111.007 -177.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.584 ' HA3' ' H ' ' B' ' 38' ' ' GLY . . . 51.31 70.77 0.78 Allowed Glycine 0 CA--C 1.533 1.166 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.308 -177.819 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.742 HG13 ' O ' ' D' ' 39' ' ' VAL . 22.9 t -72.14 142.08 15.75 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.226 0 CA-C-O 120.801 0.334 . . . . 0.0 111.718 -179.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.429 HG12 ' CD2' ' E' ' 13' ' ' HIS . 14.8 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.004 -0.998 . . . . 0.0 110.334 179.186 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -110.84 137.2 48.78 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 110.059 -0.348 . . . . 0.0 110.059 179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -143.54 134.21 25.08 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.782 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -138.8 131.97 39.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.88 179.312 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.523 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 8.6 t60 -146.44 129.79 16.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.935 0.397 . . . . 0.0 110.728 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CE1' ' C' ' 14' ' ' HIS . 2.9 p80 -152.31 161.58 42.4 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.102 178.312 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.817 HE22 ' N ' ' B' ' 37' ' ' GLY . 24.9 mt-30 -90.09 159.59 16.73 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 178.347 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.718 ' C ' HD12 ' D' ' 17' ' ' LEU . 48.1 mmtt -139.63 98.08 3.41 Favored 'General case' 0 C--N 1.31 -1.125 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.718 HD12 ' C ' ' D' ' 16' ' ' LYS . 5.4 mp -130.95 131.1 44.22 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-O 121.117 0.485 . . . . 0.0 110.059 178.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 62.9 t -121.53 124.85 72.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.52 179.003 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 33.7 m-85 -111.81 102.6 10.86 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 107.782 -1.192 . . . . 0.0 107.782 178.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 18.1 t80 -112.89 122.14 46.77 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.86 -0.155 . . . . 0.0 110.732 -178.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.28 134.31 30.84 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 122.106 0.955 . . . . 0.0 113.096 -179.474 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.455 ' OE2' ' OE1' ' E' ' 22' ' ' GLU . 49.5 tp10 -101.2 126.8 47.95 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 114.573 -1.194 . . . . 0.0 108.594 178.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 52.5 p-10 -167.25 48.52 0.06 Allowed 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -178.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 17.1 m -72.44 160.97 5.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 C-N-CA 118.573 -1.251 . . . . 0.0 108.11 178.863 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -30.06 8.81 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.094 -1.203 . . . . 0.0 110.094 -178.947 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.512 ' CB ' ' OG ' ' C' ' 26' ' ' SER . 4.7 p -83.04 141.1 32.3 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 115.014 1.487 . . . . 0.0 115.014 -174.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.671 ' O ' ' N ' ' D' ' 29' ' ' GLY . 34.1 p30 -73.21 -155.48 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.562 0 CA-C-N 113.248 -1.796 . . . . 0.0 107.474 177.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 91.3 mttt -53.84 48.33 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.75 0 N-CA-C 113.22 0.822 . . . . 0.0 113.22 -178.342 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.671 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -100.19 56.01 0.84 Allowed Glycine 0 CA--C 1.542 1.75 0 CA-C-O 119.8 -0.445 . . . . 0.0 112.224 177.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -153.33 109.21 3.29 Favored 'General case' 0 C--O 1.24 0.594 0 CA-C-N 118.244 1.022 . . . . 0.0 110.277 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 56.2 mt -133.04 130.37 58.23 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.93 0 C-N-CA 119.104 -1.038 . . . . 0.0 113.549 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.407 ' O ' ' N ' ' E' ' 33' ' ' GLY . 73.9 mt -112.62 108.32 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.778 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 176.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.07 111.6 3.79 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 106.928 -2.469 . . . . 0.0 106.928 177.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.498 ' CD1' ' CE1' ' F' ' 19' ' ' PHE . 92.2 mt -134.36 134.97 42.34 Favored 'General case' 0 CA--C 1.504 -0.824 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -175.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -111.39 103.96 12.37 Favored 'General case' 0 N--CA 1.439 -1.021 0 CA-C-N 111.506 -2.588 . . . . 0.0 105.957 175.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.72 HG12 ' HB ' ' C' ' 36' ' ' VAL . 21.2 m -115.53 122.73 69.97 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.37 0 C-N-CA 119.644 -0.822 . . . . 0.0 109.787 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.44 112.77 1.48 Allowed Glycine 0 N--CA 1.463 0.444 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.693 ' N ' HE21 ' F' ' 15' ' ' GLN . . . -120.61 62.4 0.5 Allowed Glycine 0 CA--C 1.539 1.559 0 N-CA-C 116.237 1.255 . . . . 0.0 116.237 -178.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.742 ' O ' HG13 ' C' ' 39' ' ' VAL . 31.2 t -76.83 168.81 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 120.892 2.346 . . . . 0.0 108.403 176.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.65 ' N ' HG12 ' D' ' 39' ' ' VAL . 3.6 p . . . . . 0 C--O 1.222 -0.39 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.657 -178.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -98.51 134.4 41.53 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 110.063 -0.347 . . . . 0.0 110.063 179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 20.5 pt-20 -158.55 153.67 25.38 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.88 0.371 . . . . 0.0 111.497 -179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -107.54 112.6 40.76 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.343 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.023 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.63 ' ND1' HG11 ' B' ' 40' ' ' VAL . 1.7 t60 -127.27 118.67 24.68 Favored 'General case' 0 N--CA 1.469 0.504 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -177.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.458 ' CB ' ' O ' ' F' ' 14' ' ' HIS . 22.9 p-80 -157.57 159.64 37.31 Favored 'General case' 0 C--O 1.225 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.531 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.415 ' OE1' ' O ' ' C' ' 37' ' ' GLY . 1.3 mp0 -90.23 159.02 16.92 Favored 'General case' 0 C--O 1.224 -0.242 0 N-CA-C 106.827 -1.546 . . . . 0.0 106.827 176.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.764 ' C ' HD12 ' E' ' 17' ' ' LEU . 13.0 tttm -140.96 101.13 3.98 Favored 'General case' 0 C--N 1.314 -0.935 0 C-N-CA 119.887 -0.725 . . . . 0.0 109.402 176.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.764 HD12 ' C ' ' E' ' 16' ' ' LYS . 6.7 mp -130.44 127.89 40.2 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 62.7 t -117.71 126.21 74.61 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.221 0 N-CA-C 109.136 -0.691 . . . . 0.0 109.136 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.579 ' N ' ' CD1' ' E' ' 19' ' ' PHE . 0.2 OUTLIER -113.72 103.74 11.52 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 107.744 -1.206 . . . . 0.0 107.744 -179.454 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 22.3 t80 -113.21 118.53 34.92 Favored 'General case' 0 N--CA 1.469 0.518 0 C-N-CA 121.443 -0.103 . . . . 0.0 111.138 -178.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.57 138.33 36.13 Favored 'General case' 0 N--CA 1.473 0.702 0 C-N-CA 119.668 -0.813 . . . . 0.0 112.256 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.455 ' OE1' ' OE2' ' D' ' 22' ' ' GLU . 88.6 mt-10 -101.51 119.77 39.28 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 120.315 -0.554 . . . . 0.0 110.37 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.875 ' O ' HG13 ' E' ' 24' ' ' VAL . 16.6 t0 -119.24 -49.89 2.37 Favored 'General case' 0 N--CA 1.475 0.809 0 N-CA-C 111.916 0.339 . . . . 0.0 111.916 -179.373 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.875 HG13 ' O ' ' E' ' 23' ' ' ASP . 0.1 OUTLIER 163.81 -166.93 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 N-CA-C 105.649 -1.982 . . . . 0.0 105.649 179.367 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.36 -35.6 91.89 Favored Glycine 0 CA--C 1.527 0.793 0 C-N-CA 119.417 -1.373 . . . . 0.0 110.153 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.454 ' OG ' ' O ' ' F' ' 28' ' ' LYS . 22.1 t -155.82 112.63 3.19 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 176.83 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' E' ' 30' ' ' ALA . 20.0 p30 -53.01 170.22 0.08 Allowed 'General case' 0 N--CA 1.464 0.231 0 C-N-CA 117.114 -1.835 . . . . 0.0 108.626 179.407 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 62.8 mttp -61.24 -39.05 88.86 Favored 'General case' 0 C--N 1.328 -0.34 0 C-N-CA 119.224 -0.991 . . . . 0.0 112.238 175.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.474 ' N ' ' OD1' ' E' ' 27' ' ' ASN . . . -178.97 74.97 0.07 OUTLIER Glycine 0 CA--C 1.544 1.856 0 CA-C-O 119.215 -0.769 . . . . 0.0 113.076 -177.256 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.658 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -80.64 163.65 23.46 Favored 'General case' 0 N--CA 1.471 0.578 0 CA-C-N 119.537 1.668 . . . . 0.0 111.669 -178.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.413 HD11 ' HB ' ' Q' ' 39' ' ' VAL . 79.8 mt -131.16 127.55 60.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 C-N-CA 120.515 -0.474 . . . . 0.0 111.709 -177.841 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.537 HD11 ' CD2' ' F' ' 19' ' ' PHE . 3.2 tt -123.14 109.33 23.28 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.665 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.562 ' HA2' ' H ' ' F' ' 33' ' ' GLY . . . -80.08 116.46 4.27 Favored Glycine 0 C--O 1.241 0.568 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.557 ' O ' ' C ' ' F' ' 34' ' ' LEU . 38.8 tp -110.14 104.21 13.03 Favored 'General case' 0 C--O 1.267 1.982 0 CA-C-N 120.096 1.948 . . . . 0.0 110.767 -177.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.762 ' HA ' ' HA ' ' F' ' 35' ' ' MET . 29.0 tpp -115.8 110.48 19.13 Favored 'General case' 0 C--N 1.351 0.648 0 N-CA-C 113.182 0.808 . . . . 0.0 113.182 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.558 HG12 ' N ' ' E' ' 37' ' ' GLY . 39.5 t -84.89 172.64 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.374 1.655 0 C-N-CA 117.431 -1.708 . . . . 0.0 107.157 177.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.558 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -176.75 92.99 0.09 OUTLIER Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.359 -1.877 . . . . 0.0 111.672 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.463 ' C ' HG22 ' D' ' 39' ' ' VAL . . . 119.13 85.49 0.98 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-N 119.435 1.618 . . . . 0.0 114.009 178.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' E' ' 38' ' ' GLY . 1.8 p -24.1 121.06 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 N-CA-C 113.87 1.063 . . . . 0.0 113.87 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 7.5 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.587 178.812 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.505 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -106.2 136.0 46.68 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.837 0.351 . . . . 0.0 110.585 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -82.69 117.4 22.6 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.015 179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 27.1 m -138.22 157.65 31.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 CA-C-O 121.514 0.673 . . . . 0.0 112.225 -179.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 -146.07 98.18 3.06 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.059 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.458 ' O ' ' CB ' ' E' ' 14' ' ' HIS . 97.4 m-70 -151.9 168.08 26.28 Favored 'General case' 0 C--O 1.221 -0.402 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.693 HE21 ' N ' ' D' ' 38' ' ' GLY . 66.0 mt-30 -89.75 158.19 17.64 Favored 'General case' 0 C--N 1.33 -0.265 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . 0.491 ' C ' HD22 ' F' ' 17' ' ' LEU . 64.5 mttp -140.23 96.08 2.99 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-O 121.122 0.487 . . . . 0.0 109.889 177.775 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.877 HD22 ' N ' ' F' ' 17' ' ' LEU . 0.3 OUTLIER -118.82 112.06 19.23 Favored 'General case' 0 CA--C 1.514 -0.432 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 177.928 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 14.6 t -101.28 110.96 29.46 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.728 0 N-CA-C 108.469 -0.937 . . . . 0.0 108.469 179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.537 ' CD2' HD11 ' E' ' 32' ' ' ILE . 15.6 m-85 -104.3 101.33 11.04 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 106.898 -1.519 . . . . 0.0 106.898 178.449 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.401 ' CD1' ' CE2' ' E' ' 20' ' ' PHE . 61.4 t80 -126.02 125.55 42.84 Favored 'General case' 0 CA--C 1.515 -0.399 0 CA-C-O 122.236 1.017 . . . . 0.0 111.762 -178.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.37 132.04 51.65 Favored 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 177.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.497 ' O ' ' O ' ' E' ' 24' ' ' VAL . 45.9 tp10 -62.17 103.3 0.37 Allowed 'General case' 0 CA--C 1.512 -0.503 0 C-N-CA 118.586 -1.246 . . . . 0.0 108.011 -178.062 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' O ' ' E' ' 24' ' ' VAL . 8.3 m-20 -163.92 46.22 0.11 Allowed 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.071 -178.078 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.846 HG12 ' H ' ' F' ' 25' ' ' GLY . 40.5 t -89.78 -175.56 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.846 ' H ' HG12 ' F' ' 24' ' ' VAL . . . 81.35 -34.0 2.47 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.52 ' O ' ' O ' ' F' ' 27' ' ' ASN . 96.2 p -151.93 123.68 7.96 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 113.92 -1.14 . . . . 0.0 108.987 -177.089 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.52 ' O ' ' O ' ' F' ' 26' ' ' SER . 10.6 m120 -40.75 167.29 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.068 0.461 . . . . 0.0 110.77 -176.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.454 ' O ' ' OG ' ' E' ' 26' ' ' SER . 74.1 tttt -79.56 -49.93 11.47 Favored 'General case' 0 C--N 1.332 -0.179 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 -175.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.41 50.73 3.11 Favored Glycine 0 CA--C 1.539 1.594 0 C-N-CA 118.706 -1.711 . . . . 0.0 111.154 -179.455 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.658 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -130.43 179.62 5.82 Favored 'General case' 0 C--N 1.343 0.289 0 CA-C-N 118.454 1.127 . . . . 0.0 111.135 -175.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 5.4 mm -113.53 135.3 53.55 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.06 0 CA-C-N 115.401 -0.818 . . . . 0.0 111.137 -179.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' E' ' 32' ' ' ILE . 82.9 mt -103.91 117.41 49.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.95 179.857 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . 0.562 ' H ' ' HA2' ' E' ' 33' ' ' GLY . . . -58.4 -154.61 0.01 OUTLIER Glycine 0 C--O 1.209 -1.46 0 CA-C-N 118.65 0.659 . . . . 0.0 113.233 -178.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.633 ' O ' ' HA ' ' E' ' 35' ' ' MET . 74.4 mt -99.47 125.79 45.27 Favored 'General case' 0 C--O 1.213 -0.82 0 N-CA-C 113.702 1.001 . . . . 0.0 113.702 178.785 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.762 ' HA ' ' HA ' ' E' ' 35' ' ' MET . 0.0 OUTLIER -103.33 83.53 2.19 Favored 'General case' 0 C--O 1.171 -3.045 0 C-N-CA 130.117 3.367 . . . . 0.0 114.197 179.508 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.575 HG23 ' O ' ' F' ' 36' ' ' VAL . 2.7 m -92.77 115.21 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.965 0 O-C-N 117.785 -3.072 . . . . 0.0 112.713 175.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -117.19 122.51 5.48 Favored Glycine 0 CA--C 1.516 0.12 0 N-CA-C 109.32 -1.512 . . . . 0.0 109.32 178.119 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -56.36 -61.61 7.27 Favored Glycine 0 CA--C 1.536 1.392 0 C-N-CA 119.662 -1.256 . . . . 0.0 111.046 179.277 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 37.2 t -147.88 137.77 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.171 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 178.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 118.135 -0.936 . . . . 0.0 110.34 -179.756 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -109.6 135.24 50.89 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.708 0.289 . . . . 0.0 110.413 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.431 ' O ' ' OE1' ' H' ' 11' ' ' GLU . 82.0 tt0 -95.81 123.28 39.32 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.866 0.365 . . . . 0.0 110.236 179.837 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.417 ' O ' HG23 ' G' ' 12' ' ' VAL . 4.4 m -132.69 132.66 59.73 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-N 115.953 -0.567 . . . . 0.0 109.942 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 -104.74 121.68 44.12 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 120.821 0.343 . . . . 0.0 110.918 -179.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.544 ' ND1' ' O ' ' H' ' 14' ' ' HIS . 31.0 t60 -155.03 165.9 35.29 Favored 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.686 -0.405 . . . . 0.0 110.763 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.524 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 14.6 pt20 -157.06 142.22 17.18 Favored 'General case' 0 C--N 1.339 0.111 0 CA-C-O 121.174 0.512 . . . . 0.0 111.144 178.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.413 ' H ' ' HG2' ' G' ' 16' ' ' LYS . 51.5 pttt -86.3 122.03 29.71 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.382 -0.826 . . . . 0.0 112.307 178.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 65.8 mt -127.41 118.07 23.39 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 177.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -133.73 133.44 56.85 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 CA-C-O 120.697 0.284 . . . . 0.0 111.585 -179.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -139.14 142.61 38.02 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 116.133 -0.485 . . . . 0.0 109.896 178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -152.0 151.59 31.36 Favored 'General case' 0 C--N 1.332 -0.161 0 C-N-CA 119.726 -0.79 . . . . 0.0 112.781 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.51 129.26 50.95 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.036 178.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.428 ' O ' ' N ' ' G' ' 24' ' ' VAL . 96.4 mt-10 -82.19 -173.58 4.62 Favored 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 114.605 1.335 . . . . 0.0 114.605 -176.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.416 ' OD2' ' OE2' ' H' ' 22' ' ' GLU . 0.7 OUTLIER -51.61 46.41 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 112.877 -1.965 . . . . 0.0 115.771 -178.007 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.428 ' N ' ' O ' ' G' ' 22' ' ' GLU . 34.5 m -80.51 179.86 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 C-N-CA 117.969 -1.492 . . . . 0.0 107.63 178.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.43 -33.48 64.17 Favored Glycine 0 CA--C 1.521 0.46 0 C-N-CA 119.598 -1.287 . . . . 0.0 112.842 -178.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.461 ' O ' ' O ' ' G' ' 27' ' ' ASN . 98.9 p -152.84 122.43 6.82 Favored 'General case' 0 C--N 1.329 -0.306 0 O-C-N 122.567 -0.372 . . . . 0.0 111.152 179.786 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.461 ' O ' ' O ' ' G' ' 26' ' ' SER . 25.1 t-20 -40.92 166.46 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.353 0 C-N-CA 120.193 -0.603 . . . . 0.0 110.501 178.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -78.62 40.53 0.38 Allowed 'General case' 0 C--N 1.326 -0.43 0 N-CA-C 112.371 0.508 . . . . 0.0 112.371 179.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 119.75 78.57 0.56 Allowed Glycine 0 N--CA 1.482 1.712 0 C-N-CA 119.94 -1.124 . . . . 0.0 112.729 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.66 59.97 4.41 Favored 'General case' 0 N--CA 1.485 1.322 0 CA-C-N 119.814 1.807 . . . . 0.0 113.456 -178.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 4.5 pt -147.99 123.12 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 N-CA-C 105.682 -1.97 . . . . 0.0 105.682 177.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 87.8 mt -109.23 113.67 44.8 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.647 -0.421 . . . . 0.0 111.222 -178.049 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.32 99.81 0.98 Allowed Glycine 0 N--CA 1.461 0.344 0 N-CA-C 105.688 -2.965 . . . . 0.0 105.688 176.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.445 ' O ' HD23 ' H' ' 34' ' ' LEU . 43.0 tp -157.92 154.8 28.44 Favored 'General case' 0 C--O 1.239 0.529 0 C-N-CA 118.007 -1.477 . . . . 0.0 113.468 -175.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 55.0 tpp -102.1 119.89 39.54 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 113.007 -1.906 . . . . 0.0 107.07 177.509 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 47.2 t -124.2 112.17 31.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 121.221 0.534 . . . . 0.0 110.798 -179.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 114.06 -131.89 10.19 Favored Glycine 0 C--N 1.316 -0.567 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.462 ' H ' ' HA3' ' H' ' 37' ' ' GLY . . . 115.5 -61.35 0.38 Allowed Glycine 0 CA--C 1.537 1.445 0 N-CA-C 111.576 -0.61 . . . . 0.0 111.576 -178.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.55 HG22 ' N ' ' G' ' 40' ' ' VAL . 2.4 p -127.78 164.76 28.33 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -179.525 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.55 ' N ' HG22 ' G' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.605 179.192 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.436 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . 0.625 ' CD2' ' N ' ' H' ' 11' ' ' GLU . 60.7 t80 -148.73 179.88 7.5 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.827 0.346 . . . . 0.0 110.284 -179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.625 ' N ' ' CD2' ' H' ' 10' ' ' TYR . 80.9 mm-40 -66.96 126.93 30.67 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.632 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -127.47 126.62 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 179.065 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.621 ' CE1' ' CD2' ' I' ' 13' ' ' HIS . 15.7 p-80 -151.51 139.23 19.77 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.726 -0.39 . . . . 0.0 111.491 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.581 ' ND1' ' N ' ' I' ' 14' ' ' HIS . 22.6 m-70 -145.33 160.7 41.13 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-O 121.046 0.451 . . . . 0.0 110.134 177.853 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.548 ' CD ' HE22 ' I' ' 15' ' ' GLN . 57.8 tt0 -90.2 160.44 16.21 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.185 -1.043 . . . . 0.0 108.185 177.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -139.84 102.74 4.49 Favored 'General case' 0 C--N 1.311 -1.067 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 178.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.561 ' C ' HD23 ' H' ' 17' ' ' LEU . 7.3 tt -126.35 124.07 39.43 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 121.24 0.543 . . . . 0.0 111.191 -179.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.478 ' N ' HD23 ' H' ' 17' ' ' LEU . 65.4 t -122.0 130.88 74.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 115.503 -0.771 . . . . 0.0 110.301 179.1 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 79.5 t80 -125.95 113.12 16.75 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.058 179.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -114.47 120.25 39.63 Favored 'General case' 0 N--CA 1.473 0.712 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.68 126.23 41.55 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 121.811 0.815 . . . . 0.0 113.187 -178.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.416 ' OE2' ' OD2' ' G' ' 23' ' ' ASP . 80.0 tt0 -97.62 113.06 24.71 Favored 'General case' 0 N--CA 1.456 -0.173 0 N-CA-C 107.07 -1.455 . . . . 0.0 107.07 177.02 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.432 ' O ' ' OD1' ' H' ' 27' ' ' ASN . 57.5 t0 -131.12 52.06 2.09 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.749 -0.66 . . . . 0.0 111.295 -176.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 15.0 p -74.69 142.97 13.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 C-N-CA 119.944 -0.703 . . . . 0.0 109.577 -177.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.43 38.37 3.75 Favored Glycine 0 CA--C 1.532 1.107 0 CA-C-N 114.786 -1.097 . . . . 0.0 110.387 -178.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 73.39 120.04 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.784 -0.208 . . . . 0.0 111.162 179.123 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.439 ' CG ' ' OD2' ' I' ' 23' ' ' ASP . 8.2 m-20 -83.24 162.0 21.32 Favored 'General case' 0 C--N 1.34 0.166 0 C-N-CA 119.445 -0.902 . . . . 0.0 110.174 178.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -47.04 -39.53 13.01 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.683 177.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.04 69.15 0.02 OUTLIER Glycine 0 CA--C 1.537 1.448 0 CA-C-N 115.265 -0.88 . . . . 0.0 111.55 -176.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -51.64 100.73 0.03 OUTLIER 'General case' 0 N--CA 1.48 1.05 0 CA-C-N 118.544 1.172 . . . . 0.0 114.045 -176.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.523 HG22 ' HB ' ' I' ' 31' ' ' ILE . 43.5 pt -137.86 139.27 43.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.671 178.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.486 ' CG2' HD12 ' H' ' 34' ' ' LEU . 86.9 mt -106.89 109.11 26.94 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.17 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.071 179.331 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.98 96.86 1.13 Allowed Glycine 0 CA--C 1.519 0.313 0 N-CA-C 105.506 -3.037 . . . . 0.0 105.506 176.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.486 HD12 ' CG2' ' H' ' 32' ' ' ILE . 67.4 mt -135.23 149.47 49.87 Favored 'General case' 0 CA--C 1.508 -0.659 0 CA-C-O 123.48 1.609 . . . . 0.0 114.129 -175.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -119.55 106.71 12.47 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 111.795 -2.457 . . . . 0.0 104.447 176.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 79.3 t -106.52 102.78 14.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 CA-C-O 121.612 0.72 . . . . 0.0 110.521 -177.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.462 ' HA3' ' H ' ' G' ' 38' ' ' GLY . . . -31.1 152.44 0.01 OUTLIER Glycine 0 N--CA 1.469 0.859 0 CA-C-N 114.56 -1.2 . . . . 0.0 113.723 -178.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' H' ' 39' ' ' VAL . . . -88.44 -57.46 1.86 Allowed Glycine 0 N--CA 1.47 0.965 0 CA-C-N 114.98 -0.61 . . . . 0.0 113.338 179.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 40' ' ' VAL . 60.7 t -24.28 146.07 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 N-CA-C 112.833 0.679 . . . . 0.0 112.833 -178.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' H' ' 39' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--O 1.217 -0.622 0 CA-C-O 118.18 -0.914 . . . . 0.0 110.869 -179.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.389 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . 0.519 ' O ' ' CD2' ' H' ' 10' ' ' TYR . 90.8 m-85 -97.63 129.81 44.7 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.896 -0.409 . . . . 0.0 109.896 179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.516 ' O ' ' NE2' ' J' ' 13' ' ' HIS . 95.8 mt-10 -141.13 143.46 34.29 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 120.763 0.316 . . . . 0.0 111.335 -179.455 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.518 HG22 ' H ' ' J' ' 12' ' ' VAL . 18.9 t -143.55 91.55 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.381 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.621 ' CD2' ' CE1' ' H' ' 13' ' ' HIS . 3.9 m170 -132.74 133.63 43.72 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 116.967 -0.106 . . . . 0.0 111.187 -178.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.757 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 11.3 m80 -145.74 160.7 41.35 Favored 'General case' 0 N--CA 1.474 0.737 0 N-CA-C 112.351 0.5 . . . . 0.0 112.351 178.383 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.548 HE22 ' CD ' ' H' ' 15' ' ' GLN . 69.1 tp60 -90.17 157.58 17.66 Favored 'General case' 0 N--CA 1.455 -0.221 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 174.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -141.91 102.28 4.11 Favored 'General case' 0 C--N 1.314 -0.95 0 C-N-CA 119.971 -0.691 . . . . 0.0 110.648 176.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 25.5 mt -120.51 118.41 30.17 Favored 'General case' 0 N--CA 1.479 0.988 0 C-N-CA 120.333 -0.547 . . . . 0.0 109.652 176.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 45.0 t -111.8 114.77 48.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 177.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -108.53 105.25 14.81 Favored 'General case' 0 CA--C 1.539 0.533 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 178.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -116.17 132.63 56.61 Favored 'General case' 0 N--CA 1.479 1.02 0 O-C-N 122.212 -0.305 . . . . 0.0 111.091 -178.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.22 149.65 32.31 Favored 'General case' 0 N--CA 1.474 0.753 0 N-CA-C 115.393 1.627 . . . . 0.0 115.393 -178.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -105.59 163.36 12.73 Favored 'General case' 0 N--CA 1.475 0.785 0 CA-C-N 113.966 -1.47 . . . . 0.0 108.124 177.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.474 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 34.6 t0 -174.47 47.08 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 113.903 1.075 . . . . 0.0 113.903 -176.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.416 ' N ' ' OD2' ' J' ' 23' ' ' ASP . 0.1 OUTLIER -91.09 170.56 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 122.381 1.086 . . . . 0.0 110.308 -175.583 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 76.15 27.43 62.08 Favored Glycine 0 CA--C 1.53 1.001 0 CA-C-N 113.577 -1.647 . . . . 0.0 109.984 -176.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 1.7 t 165.78 146.87 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.711 -0.478 . . . . 0.0 109.711 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -53.02 138.12 31.38 Favored 'General case' 0 N--CA 1.466 0.328 0 C-N-CA 119.126 -1.03 . . . . 0.0 108.844 178.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.6 ' HB2' HG11 ' J' ' 24' ' ' VAL . 31.2 tttm -62.35 -49.77 74.23 Favored 'General case' 0 CA--C 1.53 0.193 0 N-CA-C 114.974 1.472 . . . . 0.0 114.974 -179.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.511 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 100.82 57.47 0.87 Allowed Glycine 0 CA--C 1.544 1.854 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -178.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.584 ' HB3' ' ND2' ' J' ' 27' ' ' ASN . . . -102.03 115.55 30.79 Favored 'General case' 0 N--CA 1.48 1.058 0 CA-C-N 120.12 1.96 . . . . 0.0 116.198 -172.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.523 ' HB ' HG22 ' H' ' 31' ' ' ILE . 97.1 mt -129.89 120.98 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 CA-C-N 114.051 -1.431 . . . . 0.0 109.371 176.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.627 HG22 HD21 ' J' ' 34' ' ' LEU . 28.9 mt -106.1 114.08 44.5 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.337 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.36 109.05 1.9 Allowed Glycine 0 C--O 1.236 0.271 0 N-CA-C 106.151 -2.78 . . . . 0.0 106.151 176.527 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.483 HD12 ' O ' ' H' ' 34' ' ' LEU . 0.1 OUTLIER -161.31 150.13 16.11 Favored 'General case' 0 CA--C 1.504 -0.793 0 C-N-CA 117.445 -1.702 . . . . 0.0 112.905 -175.63 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.443 ' N ' HD12 ' I' ' 34' ' ' LEU . 29.9 mtp -116.41 117.49 30.07 Favored 'General case' 0 C--N 1.313 -1.022 0 CA-C-N 112.714 -2.039 . . . . 0.0 107.716 177.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.551 HG12 ' NE2' ' K' ' 15' ' ' GLN . 1.5 t -101.11 102.61 13.7 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 N-CA-C 108.461 -0.941 . . . . 0.0 108.461 179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -32.77 153.49 0.01 OUTLIER Glycine 0 N--CA 1.474 1.168 0 CA-C-N 115.293 -0.867 . . . . 0.0 111.6 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.752 ' CA ' ' H ' ' J' ' 38' ' ' GLY . . . -117.6 56.16 0.55 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 118.843 2.297 . . . . 0.0 118.843 -175.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.463 HG12 HG23 ' I' ' 40' ' ' VAL . 61.5 t -101.83 129.06 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.855 0 CA-C-N 119.886 1.843 . . . . 0.0 110.234 177.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.463 HG23 HG12 ' I' ' 39' ' ' VAL . 47.3 t . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 117.936 -1.03 . . . . 0.0 110.489 -179.35 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.307 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.8 p90 -147.8 157.59 43.61 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.796 0.332 . . . . 0.0 110.283 179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -151.16 114.92 4.93 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.479 -179.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.518 ' H ' HG22 ' I' ' 12' ' ' VAL . 79.2 t -128.74 133.33 66.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-O 121.163 0.506 . . . . 0.0 110.814 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.516 ' NE2' ' O ' ' I' ' 11' ' ' GLU . 48.9 m-70 -141.19 100.33 3.78 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.484 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.757 ' H ' ' CD2' ' I' ' 14' ' ' HIS . 45.4 p-80 -149.22 161.08 42.72 Favored 'General case' 0 C--O 1.223 -0.295 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.362 177.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 19.7 tt0 -90.16 159.79 16.58 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 176.593 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 84.0 tttt -139.78 103.63 4.71 Favored 'General case' 0 C--N 1.315 -0.91 0 C-N-CA 119.645 -0.822 . . . . 0.0 111.629 179.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -128.34 118.42 23.18 Favored 'General case' 0 C--O 1.239 0.544 0 CA-C-O 121.868 0.842 . . . . 0.0 109.391 177.26 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 88.1 t -108.93 111.13 34.74 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.51 0 CA-C-N 114.141 -1.39 . . . . 0.0 109.17 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.564 ' CD2' ' CD1' ' K' ' 19' ' ' PHE . 16.5 m-85 -108.63 103.95 13.16 Favored 'General case' 0 CA--C 1.532 0.273 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.42 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 3.9 m-85 -120.05 130.72 54.82 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -177.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.4 120.07 16.16 Favored 'General case' 0 N--CA 1.474 0.759 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 177.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.51 ' O ' ' OD1' ' J' ' 23' ' ' ASP . 87.3 mt-10 -145.0 141.36 28.87 Favored 'General case' 0 N--CA 1.485 1.302 0 N-CA-C 115.191 1.552 . . . . 0.0 115.191 -176.268 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.575 ' CG ' ' H ' ' J' ' 24' ' ' VAL . 5.3 p-10 147.17 -69.39 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.938 0 O-C-N 125.076 1.485 . . . . 0.0 110.125 176.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.831 HG22 ' H ' ' J' ' 25' ' ' GLY . 7.6 p -54.97 -122.91 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.617 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.499 178.106 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.831 ' H ' HG22 ' J' ' 24' ' ' VAL . . . 140.31 -35.17 1.92 Allowed Glycine 0 CA--C 1.528 0.866 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.661 177.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 16.1 t -80.45 118.66 22.27 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 121.041 2.42 . . . . 0.0 106.415 171.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.584 ' ND2' ' HB3' ' I' ' 30' ' ' ALA . 8.0 m-20 -91.44 160.28 15.53 Favored 'General case' 0 N--CA 1.477 0.902 0 CA-C-N 121.977 2.171 . . . . 0.0 111.038 176.743 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 72.1 mmtt -46.31 -39.93 10.93 Favored 'General case' 0 N--CA 1.462 0.145 0 CA-C-O 122.729 1.252 . . . . 0.0 109.541 173.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 160.94 68.52 0.02 OUTLIER Glycine 0 CA--C 1.54 1.648 0 CA-C-N 112.401 -2.181 . . . . 0.0 107.954 -176.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.716 ' O ' ' HB1' ' K' ' 30' ' ' ALA . . . -51.59 138.2 23.13 Favored 'General case' 0 N--CA 1.473 0.678 0 N-CA-C 116.331 1.974 . . . . 0.0 116.331 -173.577 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.734 HD11 ' HB ' ' D' ' 39' ' ' VAL . 82.6 mt -135.14 126.57 46.38 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-N 113.327 -1.76 . . . . 0.0 112.228 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 1.8 mt -108.95 109.72 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 174.569 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.02 99.73 0.99 Allowed Glycine 0 N--CA 1.462 0.433 0 N-CA-C 106.404 -2.678 . . . . 0.0 106.404 178.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.627 HD21 HG22 ' I' ' 32' ' ' ILE . 96.9 mt -134.94 134.63 40.8 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 114.736 1.384 . . . . 0.0 114.736 -175.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 45.7 tpp -104.51 107.52 18.49 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 103.936 -2.616 . . . . 0.0 103.936 174.1 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.59 ' O ' HG22 ' K' ' 36' ' ' VAL . 4.2 t -120.21 113.14 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 122.445 1.117 . . . . 0.0 110.745 -178.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.418 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -73.04 -122.39 0.08 OUTLIER Glycine 0 C--N 1.313 -0.733 0 CA-C-N 112.876 -1.966 . . . . 0.0 110.732 175.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.752 ' H ' ' CA ' ' I' ' 38' ' ' GLY . . . 71.52 60.77 4.18 Favored Glycine 0 C--N 1.318 -0.446 0 CA-C-N 111.628 -2.286 . . . . 0.0 115.791 178.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.961 HG22 HD11 ' P' ' 31' ' ' ILE . 7.3 m -81.75 129.35 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.489 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 175.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 9.3 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.073 -0.965 . . . . 0.0 110.414 179.976 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -111.83 135.18 52.79 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -136.29 144.78 44.93 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.748 0.308 . . . . 0.0 110.599 -179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 99.2 t -128.55 130.18 68.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.547 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 39.0 m-70 -136.19 113.73 10.91 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 116.744 -0.207 . . . . 0.0 111.079 179.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.497 ' O ' ' CB ' ' J' ' 14' ' ' HIS . 14.8 p-80 -152.84 162.38 41.36 Favored 'General case' 0 C--O 1.217 -0.612 0 C-N-CA 120.957 -0.297 . . . . 0.0 110.904 178.531 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.551 ' NE2' HG12 ' I' ' 36' ' ' VAL . 10.3 tt0 -90.07 158.66 17.21 Favored 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.764 -1.939 . . . . 0.0 105.764 175.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.482 ' C ' HD13 ' K' ' 17' ' ' LEU . 34.5 tttt -140.7 96.52 3.03 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 119.21 0.914 . . . . 0.0 110.825 178.623 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.885 HD22 ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -120.87 110.58 16.49 Favored 'General case' 0 CA--C 1.51 -0.563 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 177.582 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.431 HG13 ' O ' ' K' ' 18' ' ' VAL . 7.7 p -114.5 114.25 46.08 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.601 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 179.12 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.564 ' CD1' ' CD2' ' J' ' 19' ' ' PHE . 28.7 m-85 -107.23 104.22 13.78 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 179.642 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.567 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 25.7 t80 -112.67 123.56 50.58 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.128 -178.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -151.87 139.12 19.32 Favored 'General case' 0 C--N 1.33 -0.268 0 C-N-CA 118.72 -1.192 . . . . 0.0 114.126 -178.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.419 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 94.2 mt-10 -79.59 109.46 14.0 Favored 'General case' 0 C--N 1.319 -0.725 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 174.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.523 ' O ' ' NZ ' ' L' ' 28' ' ' LYS . 49.3 t0 -146.31 46.71 1.22 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 113.529 0.937 . . . . 0.0 113.529 -177.063 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.502 HG22 ' N ' ' K' ' 25' ' ' GLY . 10.9 p -98.65 161.41 3.03 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.469 0 N-CA-C 107.546 -1.279 . . . . 0.0 107.546 175.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.502 ' N ' HG22 ' K' ' 24' ' ' VAL . . . 76.22 27.68 61.48 Favored Glycine 0 CA--C 1.52 0.351 0 C-N-CA 119.564 -1.303 . . . . 0.0 110.281 176.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.469 ' CB ' ' H ' ' J' ' 27' ' ' ASN . 24.9 t -83.9 -120.3 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 119.445 -0.902 . . . . 0.0 113.305 -175.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.459 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 26.7 t-20 -93.27 163.01 13.78 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 122.597 1.189 . . . . 0.0 113.493 -177.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.459 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 68.7 mttm -41.97 -37.91 1.46 Allowed 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 112.491 -2.14 . . . . 0.0 111.185 176.534 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.19 71.97 0.22 Allowed Glycine 0 CA--C 1.54 1.646 0 CA-C-N 115.744 -0.662 . . . . 0.0 114.253 -172.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.716 ' HB1' ' O ' ' J' ' 30' ' ' ALA . . . -82.02 173.2 12.4 Favored 'General case' 0 C--N 1.354 0.787 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 18.0 tt -148.23 160.23 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.185 0 N-CA-C 116.17 1.915 . . . . 0.0 116.17 -172.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.77 125.58 61.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.373 0 CA-C-N 113.572 -1.649 . . . . 0.0 109.711 178.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.3 123.22 4.3 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 179.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.661 HD23 ' C ' ' K' ' 34' ' ' LEU . 2.3 tt -130.26 130.57 44.74 Favored 'General case' 0 CA--C 1.518 -0.267 0 CA-C-O 120.97 0.414 . . . . 0.0 110.496 -178.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 5.6 mtp -124.84 130.17 51.86 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.248 -179.876 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.59 HG22 ' O ' ' J' ' 36' ' ' VAL . 50.6 t -124.76 158.69 31.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 121.159 0.504 . . . . 0.0 110.667 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.442 ' N ' HG12 ' K' ' 36' ' ' VAL . . . -63.65 -103.08 0.01 OUTLIER Glycine 0 CA--C 1.53 0.997 0 CA-C-N 115.622 -0.717 . . . . 0.0 112.32 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . -135.89 -74.36 0.07 OUTLIER Glycine 0 CA--C 1.538 1.485 0 C-N-CA 121.472 -0.394 . . . . 0.0 113.249 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 59.6 t -74.91 133.39 31.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 CA-C-O 120.715 0.293 . . . . 0.0 111.202 -178.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 11.9 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.952 -1.023 . . . . 0.0 110.723 -179.721 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.8 136.07 50.41 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.827 0.346 . . . . 0.0 110.695 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -87.77 148.73 24.58 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.36 179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 86.5 t -109.81 114.68 47.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.895 0.379 . . . . 0.0 110.615 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.576 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -147.16 105.77 3.81 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.211 179.814 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.484 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 79.2 m80 -151.49 166.94 29.56 Favored 'General case' 0 C--O 1.221 -0.429 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 38.6 tt0 -89.78 158.46 17.49 Favored 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -140.02 102.38 4.38 Favored 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 120.247 -0.581 . . . . 0.0 111.822 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.707 ' N ' HD23 ' L' ' 17' ' ' LEU . 0.1 OUTLIER -116.61 108.09 15.52 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 176.537 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -106.98 111.14 34.39 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.49 0 C-N-CA 120.65 -0.42 . . . . 0.0 110.57 -179.2 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 32.9 m-85 -105.56 101.07 10.61 Favored 'General case' 0 N--CA 1.451 -0.406 0 N-CA-C 106.161 -1.792 . . . . 0.0 106.161 177.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.567 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 30.9 t80 -125.71 131.67 52.53 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 121.203 0.525 . . . . 0.0 110.756 -178.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -140.29 157.15 46.01 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.147 179.047 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.439 ' C ' ' O ' ' L' ' 21' ' ' ALA . 80.2 tt0 -31.1 129.54 0.13 Allowed 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 122.029 0.918 . . . . 0.0 112.48 -174.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.434 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 66.9 t0 -109.84 47.34 0.95 Allowed 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 113.496 -1.684 . . . . 0.0 112.986 -176.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.48 ' CG2' HG21 ' K' ' 24' ' ' VAL . 3.1 m -63.02 -167.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 C-N-CA 120.614 -0.434 . . . . 0.0 110.349 -178.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -91.54 27.83 9.13 Favored Glycine 0 CA--C 1.528 0.878 0 CA-C-N 116.219 -0.446 . . . . 0.0 113.616 -175.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 48.0 t -153.67 120.28 5.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.424 0.63 . . . . 0.0 109.935 179.311 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 48.7 p30 -40.7 167.0 0.0 OUTLIER 'General case' 0 CA--C 1.521 -0.135 0 CA-C-N 114.978 -1.01 . . . . 0.0 112.187 -178.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.523 ' NZ ' ' O ' ' K' ' 23' ' ' ASP . 63.9 tttp -80.22 -50.0 10.84 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.044 -0.98 . . . . 0.0 111.199 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.85 50.59 3.05 Favored Glycine 0 CA--C 1.543 1.84 0 N-CA-C 111.328 -0.709 . . . . 0.0 111.328 -178.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.707 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -130.57 -169.15 2.09 Favored 'General case' 0 C--N 1.341 0.224 0 CA-C-O 121.354 0.597 . . . . 0.0 110.597 -178.201 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -118.64 138.55 48.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.786 178.062 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.7 mt -122.15 128.58 75.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 -179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.64 122.52 3.42 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 111.635 -0.586 . . . . 0.0 111.635 -179.692 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 57.6 mt -117.99 125.42 50.36 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 178.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -132.81 127.65 35.0 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.619 HG22 ' N ' ' L' ' 37' ' ' GLY . 2.6 p -140.46 171.72 12.75 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.107 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 178.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.619 ' N ' HG22 ' L' ' 36' ' ' VAL . . . -168.12 94.49 0.11 Allowed Glycine 0 C--N 1.311 -0.852 0 C-N-CA 118.536 -1.792 . . . . 0.0 112.036 -179.964 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.5 -81.41 0.11 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.747 177.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.466 ' O ' ' O ' ' K' ' 38' ' ' GLY . 38.8 t -150.12 136.71 12.64 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-O 121.105 0.479 . . . . 0.0 110.359 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.402 HG22 ' H ' ' L' ' 40' ' ' VAL . 19.1 m . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.533 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.44 -1.464 . . . . 0.0 109.44 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -112.24 137.83 49.79 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 120.909 0.385 . . . . 0.0 110.582 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -140.44 164.47 30.05 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.356 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . 0.485 ' CG1' ' H ' ' N' ' 12' ' ' VAL . 2.4 p -123.0 131.82 72.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 121.286 0.565 . . . . 0.0 110.101 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . 0.456 ' CG ' ' N ' ' M' ' 14' ' ' HIS . 76.4 t60 -72.65 164.08 27.05 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.335 -0.848 . . . . 0.0 111.309 -178.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.588 ' ND1' ' N ' ' M' ' 14' ' ' HIS . 1.2 m-70 -99.13 166.17 11.37 Favored 'General case' 0 CA--C 1.529 0.15 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.646 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -89.8 159.82 16.82 Favored 'General case' 0 CA--C 1.517 -0.292 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -139.54 107.98 5.85 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 109.959 -0.386 . . . . 0.0 109.959 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 94.1 mt -129.76 114.92 16.56 Favored 'General case' 0 C--O 1.237 0.4 0 CA-C-O 121.098 0.475 . . . . 0.0 110.227 179.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 54.3 t -125.23 132.17 71.48 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.031 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 76.1 t80 -136.28 127.41 28.0 Favored 'General case' 0 C--O 1.234 0.243 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.45 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -131.48 146.32 52.19 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.16 128.29 23.88 Favored 'General case' 0 C--O 1.239 0.513 0 CA-C-O 121.741 0.781 . . . . 0.0 112.743 -178.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 71.5 mm-40 -92.17 -149.25 0.24 Allowed 'General case' 0 CA--C 1.52 -0.204 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -46.62 -60.08 2.61 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.613 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.618 HG12 ' N ' ' M' ' 25' ' ' GLY . 47.9 t -84.76 171.56 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.519 -0.216 0 N-CA-C 107.756 -1.202 . . . . 0.0 107.756 175.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.618 ' N ' HG12 ' M' ' 24' ' ' VAL . . . 94.03 -29.98 8.1 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 176.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 7.3 p -84.23 139.98 31.99 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 113.146 -1.527 . . . . 0.0 113.575 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 10.6 m120 -73.03 179.5 3.74 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 105.382 -2.081 . . . . 0.0 105.382 177.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CG ' ' N' ' 28' ' ' LYS . 98.4 mttt -49.77 -37.58 30.4 Favored 'General case' 0 C--N 1.324 -0.507 0 C-N-CA 117.943 -1.503 . . . . 0.0 110.548 -175.601 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.05 -78.38 0.06 OUTLIER Glycine 0 CA--C 1.53 1.023 0 C-N-CA 118.89 -1.624 . . . . 0.0 113.777 174.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' N' ' 30' ' ' ALA . . . -147.35 81.63 1.53 Allowed 'General case' 0 CA--C 1.541 0.602 0 CA-C-N 117.819 0.81 . . . . 0.0 112.942 178.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.639 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -123.34 105.39 15.69 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.69 0 N-CA-C 107.706 -1.22 . . . . 0.0 107.706 177.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . 0.437 HG22 HD21 ' N' ' 34' ' ' LEU . 2.4 mt -119.11 111.87 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 C-N-CA 119.659 -0.816 . . . . 0.0 111.452 -178.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.41 105.61 1.16 Allowed Glycine 0 N--CA 1.46 0.258 0 N-CA-C 104.153 -3.579 . . . . 0.0 104.153 176.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . 0.412 ' HG ' ' N ' ' M' ' 35' ' ' MET . 45.6 tp -153.71 158.17 40.6 Favored 'General case' 0 C--O 1.237 0.433 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.579 -173.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . 0.412 ' N ' ' HG ' ' M' ' 34' ' ' LEU . 0.7 OUTLIER -104.88 110.18 22.45 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 112.736 -2.029 . . . . 0.0 106.991 177.182 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 76.9 t -117.62 131.24 70.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.12 -111.17 3.89 Favored Glycine 0 C--N 1.318 -0.466 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.498 ' O ' HG23 ' N' ' 39' ' ' VAL . . . 75.12 -73.76 1.5 Allowed Glycine 0 CA--C 1.53 0.985 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 -178.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.403 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 17.6 m -95.69 -176.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.25 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.175 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.463 HG12 ' NZ ' ' C' ' 28' ' ' LYS . 1.3 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.607 178.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . 0.487 ' CD1' ' O ' ' O' ' 9' ' ' GLY . 97.9 m-85 -108.0 139.7 42.25 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -113.26 124.14 51.8 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-O 120.957 0.408 . . . . 0.0 111.023 -179.495 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.485 ' H ' ' CG1' ' M' ' 12' ' ' VAL . 3.4 t -137.88 97.14 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.745 179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.519 ' ND1' ' ND1' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -151.5 151.07 31.12 Favored 'General case' 0 N--CA 1.467 0.416 0 C-N-CA 121.108 -0.237 . . . . 0.0 110.675 179.524 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 0.4 OUTLIER -124.79 162.58 23.98 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.047 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -89.88 158.79 17.28 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 178.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . 0.748 ' C ' HD12 ' N' ' 17' ' ' LEU . 98.8 mttt -140.53 99.94 3.75 Favored 'General case' 0 C--N 1.311 -1.108 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.748 HD12 ' C ' ' N' ' 16' ' ' LYS . 10.9 mp -124.04 119.3 29.12 Favored 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 109.979 -0.378 . . . . 0.0 109.979 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 71.2 t -123.01 128.34 75.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.648 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -123.76 123.95 41.64 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.897 179.149 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -129.18 123.14 31.31 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.805 0.336 . . . . 0.0 110.283 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 132.22 50.38 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 110.137 -0.32 . . . . 0.0 110.137 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.424 ' O ' ' CB ' ' N' ' 23' ' ' ASP . 83.1 tt0 -157.38 151.46 24.65 Favored 'General case' 0 CA--C 1.534 0.331 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -179.353 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.424 ' CB ' ' O ' ' N' ' 22' ' ' GLU . 9.5 m-20 92.29 46.92 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.65 0 CA-C-N 113.603 -1.635 . . . . 0.0 115.185 176.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 24.2 m -101.52 158.72 4.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 106.422 -1.696 . . . . 0.0 106.422 174.567 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.43 -37.5 94.76 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 118.23 -1.938 . . . . 0.0 111.582 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.579 ' O ' ' O ' ' N' ' 27' ' ' ASN . 86.4 p -162.47 117.17 1.82 Allowed 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 117.093 -1.432 . . . . 0.0 107.165 177.001 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.579 ' O ' ' O ' ' N' ' 26' ' ' SER . 11.6 t-20 -23.45 151.2 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.513 0 CA-C-N 120.332 1.424 . . . . 0.0 111.908 -178.173 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.491 ' O ' HG23 ' G' ' 39' ' ' VAL . 73.8 mmtt -107.83 47.87 0.87 Allowed 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 115.999 -1.953 . . . . 0.0 115.264 177.094 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.51 61.8 0.52 Allowed Glycine 0 N--CA 1.489 2.202 0 CA-C-N 124.083 3.129 . . . . 0.0 114.067 -179.081 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' M' ' 30' ' ' ALA . . . -88.31 98.95 11.88 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 121.076 2.438 . . . . 0.0 111.476 -174.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.455 HG23 ' O ' ' N' ' 31' ' ' ILE . 18.9 tt -134.61 129.33 52.12 Favored 'Isoleucine or valine' 0 C--O 1.241 0.645 0 CA-C-N 110.856 -2.884 . . . . 0.0 110.2 -177.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.57 HD13 ' CD1' ' P' ' 19' ' ' PHE . 95.8 mt -113.04 110.87 33.77 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 115.861 -0.608 . . . . 0.0 110.78 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.544 ' O ' HD22 ' N' ' 34' ' ' LEU . . . -111.25 93.51 0.72 Allowed Glycine 0 N--CA 1.467 0.722 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 175.646 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.544 HD22 ' O ' ' N' ' 33' ' ' GLY . 1.3 mm? -125.12 133.32 52.89 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 123.018 1.39 . . . . 0.0 112.269 -174.41 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 2.7 mtp -103.55 106.06 16.47 Favored 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 105.164 -2.161 . . . . 0.0 105.164 176.624 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 1.008 HG21 HD11 ' P' ' 17' ' ' LEU . 2.5 p -127.9 123.11 60.12 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.128 0 C-N-CA 120.229 -0.589 . . . . 0.0 110.246 -178.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 149.63 -113.2 0.59 Allowed Glycine 0 C--N 1.311 -0.818 0 N-CA-C 108.926 -1.67 . . . . 0.0 108.926 -179.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.473 ' O ' HG23 ' O' ' 39' ' ' VAL . . . 70.48 -72.58 0.62 Allowed Glycine 0 CA--C 1.532 1.095 0 N-CA-C 111.142 -0.783 . . . . 0.0 111.142 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.505 HG12 ' N ' ' N' ' 40' ' ' VAL . 45.1 t -123.36 163.96 21.72 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.4 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 178.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.505 ' N ' HG12 ' N' ' 39' ' ' VAL . 18.6 m . . . . . 0 N--CA 1.471 0.579 0 CA-C-O 118.204 -0.903 . . . . 0.0 111.715 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . 0.487 ' O ' ' CD1' ' N' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.492 2.387 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -114.28 147.19 39.42 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.711 0.291 . . . . 0.0 110.293 -179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -87.49 109.88 19.92 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.09 -179.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.479 HG13 ' C ' ' P' ' 12' ' ' VAL . 51.5 t -129.62 123.86 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.505 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.598 ' CE1' ' NZ ' ' A' ' 28' ' ' LYS . 7.3 m-70 -137.57 150.42 47.46 Favored 'General case' 0 N--CA 1.465 0.319 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.598 ' CD2' ' CE1' ' P' ' 14' ' ' HIS . 4.7 m80 -136.86 157.45 46.73 Favored 'General case' 0 CA--C 1.532 0.252 0 C-N-CA 119.636 -0.826 . . . . 0.0 111.169 178.33 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 62.0 tp60 -86.3 157.46 19.91 Favored 'General case' 0 CA--C 1.512 -0.494 0 N-CA-C 106.78 -1.563 . . . . 0.0 106.78 175.109 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -160.25 101.76 1.4 Allowed 'General case' 0 C--N 1.301 -1.511 0 C-N-CA 119.067 -1.053 . . . . 0.0 110.255 177.306 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 3.2 mt -132.47 122.73 25.37 Favored 'General case' 0 CA--C 1.516 -0.338 0 CA-C-N 115.681 -0.69 . . . . 0.0 110.335 178.812 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 89.2 t -113.56 113.27 43.46 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 115.133 -0.939 . . . . 0.0 108.941 178.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 60.1 m-85 -108.4 102.54 11.63 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 178.393 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -113.33 125.03 53.83 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 112.235 0.457 . . . . 0.0 112.235 -177.637 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.15 125.91 40.05 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.179 -0.675 . . . . 0.0 109.179 177.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -124.51 178.93 5.16 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.988 1.107 . . . . 0.0 113.988 -177.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 52.44 58.94 4.87 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 113.19 -1.823 . . . . 0.0 112.05 -178.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.684 HG11 HG13 ' P' ' 24' ' ' VAL . 63.2 t -78.25 123.0 34.39 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 CA-C-N 114.911 -1.041 . . . . 0.0 109.214 175.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.512 ' H ' ' HA ' ' N' ' 26' ' ' SER . . . -90.49 -38.54 6.21 Favored Glycine 0 CA--C 1.531 1.087 0 C-N-CA 121.055 -0.593 . . . . 0.0 112.577 -177.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.583 ' O ' ' O ' ' O' ' 27' ' ' ASN . 46.8 t -161.97 116.51 1.91 Allowed 'General case' 0 N--CA 1.468 0.452 0 CA-C-N 118.454 1.127 . . . . 0.0 111.907 -179.79 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.583 ' O ' ' O ' ' O' ' 26' ' ' SER . 57.2 p30 -24.12 163.73 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 114.262 -1.335 . . . . 0.0 114.358 -179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 22.3 tttp -152.16 -22.09 0.18 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.551 -1.204 . . . . 0.0 109.943 178.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.2 97.32 2.43 Favored Glycine 0 N--CA 1.468 0.774 0 N-CA-C 110.387 -1.085 . . . . 0.0 110.387 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.19 140.94 29.12 Favored 'General case' 0 C--O 1.242 0.692 0 CA-C-O 121.776 0.798 . . . . 0.0 111.974 -177.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.43 HD12 HG22 ' I' ' 39' ' ' VAL . 14.9 mt -143.41 135.77 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.19 -0.914 . . . . 0.0 113.064 -179.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.594 HD13 ' CD2' ' Q' ' 19' ' ' PHE . 82.3 mt -114.38 112.08 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 176.076 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.01 109.48 2.34 Favored Glycine 0 C--O 1.24 0.505 0 N-CA-C 105.575 -3.01 . . . . 0.0 105.575 176.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.437 ' CD2' HG12 ' N' ' 36' ' ' VAL . 0.2 OUTLIER -144.91 142.34 29.79 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 123.019 1.39 . . . . 0.0 114.038 -175.263 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 94.8 mmm -103.75 110.57 22.72 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-N 112.133 -2.303 . . . . 0.0 105.366 176.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.497 HG12 ' NE2' ' Q' ' 15' ' ' GLN . 47.1 t -117.93 123.12 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-O 120.823 0.344 . . . . 0.0 110.087 -177.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.38 -113.24 0.63 Allowed Glycine 0 C--N 1.32 -0.339 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.242 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.494 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . 87.5 -73.12 2.42 Favored Glycine 0 CA--C 1.541 1.677 0 CA-C-O 119.93 -0.372 . . . . 0.0 112.649 -179.779 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.708 ' C ' HG11 ' P' ' 39' ' ' VAL . 45.2 t -134.51 161.04 41.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.682 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.539 ' N ' HG21 ' P' ' 39' ' ' VAL . 6.3 p . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 118.076 -0.964 . . . . 0.0 110.315 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -106.44 136.25 46.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.829 0.347 . . . . 0.0 110.284 -179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -87.94 119.6 28.46 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.945 -0.571 . . . . 0.0 110.037 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.541 ' O ' ' NE2' ' O' ' 14' ' ' HIS . 2.8 m -136.83 160.71 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.466 -178.948 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.48 ' NE2' ' C ' ' N' ' 40' ' ' VAL . 8.2 t60 -90.7 120.79 32.05 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.344 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.598 ' CE1' ' CD2' ' O' ' 14' ' ' HIS . 11.6 p-80 -152.97 161.82 42.08 Favored 'General case' 0 N--CA 1.469 0.497 0 CA-C-N 116.563 -0.29 . . . . 0.0 110.659 178.754 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.475 ' NE2' HG22 ' N' ' 36' ' ' VAL . 95.4 mt-30 -90.23 158.77 17.04 Favored 'General case' 0 C--N 1.34 0.153 0 C-N-CA 120.844 -0.342 . . . . 0.0 110.646 178.467 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -140.94 105.27 4.84 Favored 'General case' 0 C--N 1.317 -0.824 0 N-CA-C 109.467 -0.568 . . . . 0.0 109.467 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 1.008 HD11 HG21 ' N' ' 36' ' ' VAL . 31.2 mt -122.7 123.18 40.53 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 120.314 -0.554 . . . . 0.0 110.433 178.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . 0.413 HG13 ' CG2' ' Q' ' 18' ' ' VAL . 2.2 t -114.51 106.51 20.78 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.63 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' N' ' 32' ' ' ILE . 57.3 m-85 -106.76 111.52 24.09 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -133.7 130.39 38.09 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 114.456 1.28 . . . . 0.0 114.456 -176.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.54 125.16 37.75 Favored 'General case' 0 N--CA 1.483 1.206 0 CA-C-N 115.382 -0.826 . . . . 0.0 108.838 177.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 55.6 tt0 -111.74 150.81 29.72 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 115.764 1.764 . . . . 0.0 115.764 -175.23 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.536 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 83.6 m-20 63.38 46.56 4.33 Favored 'General case' 0 CA--C 1.539 0.529 0 N-CA-C 117.685 2.476 . . . . 0.0 117.685 173.939 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.691 HG12 ' H ' ' P' ' 25' ' ' GLY . 8.7 t -100.44 -179.44 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.588 0 C-N-CA 115.556 -2.458 . . . . 0.0 109.523 178.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.691 ' H ' HG12 ' P' ' 24' ' ' VAL . . . -72.6 -30.65 63.88 Favored Glycine 0 CA--C 1.528 0.873 0 C-N-CA 121.195 -0.526 . . . . 0.0 113.469 176.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.5 ' CB ' ' O ' ' P' ' 25' ' ' GLY . 9.7 t 100.72 111.33 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.58 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 -174.217 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.503 ' CG ' ' N ' ' P' ' 28' ' ' LYS . 22.8 t-20 -71.31 173.47 7.75 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 117.459 -1.697 . . . . 0.0 112.724 -176.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.503 ' N ' ' CG ' ' P' ' 27' ' ' ASN . 88.7 tttt -52.45 -36.78 55.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.071 -0.968 . . . . 0.0 111.43 177.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.52 77.18 0.06 OUTLIER Glycine 0 CA--C 1.537 1.422 0 CA-C-N 115.724 -0.671 . . . . 0.0 112.661 -177.095 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.83 154.11 2.22 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-N 118.307 1.053 . . . . 0.0 110.44 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.961 HD11 HG22 ' J' ' 39' ' ' VAL . 69.4 mt -121.22 131.23 73.55 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.145 0 N-CA-C 113.064 0.764 . . . . 0.0 113.064 -177.271 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 73.7 mt -114.33 110.27 31.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 N-CA-C 108.115 -1.069 . . . . 0.0 108.115 175.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.04 109.21 2.74 Favored Glycine 0 N--CA 1.463 0.497 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 177.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.51 ' CD1' ' CE1' ' R' ' 19' ' ' PHE . 95.4 mt -135.0 133.48 39.49 Favored 'General case' 0 CA--C 1.509 -0.623 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -175.445 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 4.0 mtp -107.62 104.02 13.46 Favored 'General case' 0 N--CA 1.437 -1.094 0 N-CA-C 104.419 -2.437 . . . . 0.0 104.419 174.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.76 103.07 12.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 -176.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.32 -153.11 24.62 Favored Glycine 0 C--N 1.31 -0.892 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 179.728 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 102.95 -56.68 0.6 Allowed Glycine 0 CA--C 1.537 1.42 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -178.1 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.708 HG11 ' C ' ' O' ' 39' ' ' VAL . 11.5 p -124.36 154.99 31.91 Favored 'Isoleucine or valine' 0 C--O 1.231 0.085 0 C-N-CA 122.66 0.384 . . . . 0.0 110.054 -179.909 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.461 HG23 ' H ' ' P' ' 40' ' ' VAL . 1.9 t . . . . . 0 C--O 1.221 -0.409 0 CA-C-O 118.067 -0.968 . . . . 0.0 111.028 -179.355 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -119.73 120.71 37.36 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.782 0.325 . . . . 0.0 110.79 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -142.82 154.01 43.77 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.043 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.566 HG12 ' H ' ' R' ' 12' ' ' VAL . 12.7 m -133.0 120.11 39.53 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 121.625 0.726 . . . . 0.0 111.84 -179.31 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.444 ' H ' ' CD2' ' Q' ' 13' ' ' HIS . 4.0 m-70 -90.1 110.73 21.73 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.233 179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.527 ' ND1' ' O ' ' R' ' 14' ' ' HIS . 2.3 t-80 -119.37 159.62 23.84 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 179.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.497 ' NE2' HG12 ' O' ' 36' ' ' VAL . 9.6 tt0 -86.24 157.84 19.85 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 110.032 -0.358 . . . . 0.0 110.032 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . 0.766 ' O ' HD23 ' Q' ' 17' ' ' LEU . 76.5 tttt -160.04 94.96 1.14 Allowed 'General case' 0 C--N 1.31 -1.128 0 C-N-CA 119.395 -0.922 . . . . 0.0 111.539 177.882 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.766 HD23 ' O ' ' Q' ' 16' ' ' LYS . 1.7 mt -131.56 127.15 36.58 Favored 'General case' 0 N--CA 1.475 0.787 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . 0.413 ' CG2' HG13 ' P' ' 18' ' ' VAL . 28.1 m -117.45 122.11 69.13 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.576 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 178.499 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.594 ' CD2' HD13 ' O' ' 32' ' ' ILE . 22.0 m-85 -112.63 105.37 13.53 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 179.299 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 35.6 t80 -127.32 137.02 52.71 Favored 'General case' 0 N--CA 1.477 0.922 0 CA-C-O 121.644 0.735 . . . . 0.0 112.686 -177.036 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -146.74 145.04 29.82 Favored 'General case' 0 N--CA 1.467 0.375 0 C-N-CA 119.78 -0.768 . . . . 0.0 113.03 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.536 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 82.8 mt-10 -79.27 149.66 31.76 Favored 'General case' 0 CA--C 1.515 -0.394 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 177.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.528 ' OD1' ' HB1' ' R' ' 21' ' ' ALA . 6.9 p-10 -168.14 47.59 0.05 OUTLIER 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -176.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.45 HG12 ' H ' ' Q' ' 25' ' ' GLY . 5.7 t -71.58 170.02 1.41 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.105 0 N-CA-C 106.467 -1.679 . . . . 0.0 106.467 179.239 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.45 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 80.75 26.7 53.16 Favored Glycine 0 C--N 1.336 0.566 0 N-CA-C 104.537 -3.425 . . . . 0.0 104.537 -175.71 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 24.0 p -80.85 116.5 20.86 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 117.047 2.24 . . . . 0.0 117.047 -171.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.9 m-20 -90.22 -152.16 0.26 Allowed 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 111.286 -2.688 . . . . 0.0 104.947 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -48.56 -41.03 29.26 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 119.695 1.134 . . . . 0.0 108.333 -177.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.44 -63.95 0.6 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 117.064 1.586 . . . . 0.0 117.064 173.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -160.16 165.21 32.07 Favored 'General case' 0 C--O 1.236 0.372 0 CA-C-N 120.108 1.954 . . . . 0.0 115.057 -176.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 69.2 mt -125.35 127.55 72.01 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 CA-C-N 111.321 -2.672 . . . . 0.0 106.786 178.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 11.5 tt -134.79 133.33 54.13 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-O 121.781 0.801 . . . . 0.0 112.698 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.4 109.93 2.16 Favored Glycine 0 CA--C 1.521 0.445 0 N-CA-C 107.764 -2.134 . . . . 0.0 107.764 177.2 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.414 HD23 HD13 ' R' ' 34' ' ' LEU . 18.5 tp -116.63 119.04 34.26 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 -178.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 88.6 mtp -128.22 137.45 52.03 Favored 'General case' 0 CA--C 1.518 -0.257 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.934 -178.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' Q' ' 37' ' ' GLY . 21.4 t -111.19 131.9 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.067 0 N-CA-C 109.554 -0.536 . . . . 0.0 109.554 179.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' Q' ' 36' ' ' VAL . . . -45.62 -111.7 0.0 OUTLIER Glycine 0 CA--C 1.525 0.67 0 CA-C-N 115.503 -0.771 . . . . 0.0 112.322 179.479 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.485 ' O ' ' O ' ' R' ' 39' ' ' VAL . . . -101.48 -71.5 0.93 Allowed Glycine 0 CA--C 1.535 1.339 0 N-CA-C 111.753 -0.539 . . . . 0.0 111.753 -179.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.413 ' HB ' HD11 ' E' ' 31' ' ' ILE . 69.3 t -109.08 129.86 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 CA-C-N 117.275 0.538 . . . . 0.0 109.862 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 4.6 p . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.838 -179.397 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -105.61 132.53 51.65 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -72.34 142.81 48.8 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.996 -0.282 . . . . 0.0 110.89 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.566 ' H ' HG12 ' Q' ' 12' ' ' VAL . 5.4 m -121.13 131.96 71.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 CA-C-O 121.901 0.858 . . . . 0.0 112.01 -179.66 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 4.1 m80 -133.47 124.96 27.97 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 114.448 -1.251 . . . . 0.0 108.92 178.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.527 ' O ' ' ND1' ' Q' ' 14' ' ' HIS . 99.2 m-70 -149.28 172.04 15.52 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.862 0.363 . . . . 0.0 110.809 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.516 ' OE1' ' N ' ' R' ' 15' ' ' GLN . 14.0 mp0 -89.42 150.33 22.56 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.934 -0.575 . . . . 0.0 109.614 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . 0.767 ' C ' HD12 ' R' ' 17' ' ' LEU . 74.1 tttt -150.17 98.78 2.73 Favored 'General case' 0 C--N 1.311 -1.066 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 178.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.767 HD12 ' C ' ' R' ' 16' ' ' LYS . 9.7 mp -127.05 124.58 39.64 Favored 'General case' 0 CA--C 1.513 -0.458 0 CA-C-N 115.509 -0.769 . . . . 0.0 109.625 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 66.5 t -106.62 114.66 46.36 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 178.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.51 ' CE1' ' CD1' ' P' ' 34' ' ' LEU . 17.1 m-85 -106.59 105.81 16.02 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 106.374 -1.713 . . . . 0.0 106.374 177.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . 0.428 ' CG ' ' N ' ' R' ' 21' ' ' ALA . 66.2 t80 -146.9 156.76 43.33 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 122.463 1.125 . . . . 0.0 113.261 -177.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.528 ' HB1' ' OD1' ' Q' ' 23' ' ' ASP . . . -150.02 148.24 28.8 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.878 179.792 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.443 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 83.4 tt0 -76.49 112.54 13.13 Favored 'General case' 0 N--CA 1.466 0.334 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.56 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.484 ' OD1' ' N ' ' R' ' 23' ' ' ASP . 19.5 p-10 -177.23 48.92 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.015 -0.539 . . . . 0.0 111.642 -177.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 30.6 m -72.11 160.49 5.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 118.605 -1.238 . . . . 0.0 108.879 -178.592 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.35 -34.83 5.18 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 107.286 -2.326 . . . . 0.0 107.286 -177.39 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.425 ' OG ' ' O ' ' R' ' 23' ' ' ASP . 11.9 p -80.53 119.98 23.9 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 113.193 -1.504 . . . . 0.0 109.852 179.082 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.63 ' O ' ' N ' ' R' ' 29' ' ' GLY . 13.6 m120 -87.72 -175.17 5.07 Favored 'General case' 0 C--N 1.325 -0.47 0 C-N-CA 120.609 -0.437 . . . . 0.0 110.091 -178.067 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 74.8 tttt -49.52 49.64 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 114.797 1.406 . . . . 0.0 114.797 -177.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.63 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.7 51.49 0.92 Allowed Glycine 0 CA--C 1.546 1.972 0 CA-C-N 118.776 0.717 . . . . 0.0 112.333 178.539 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.17 172.94 11.24 Favored 'General case' 0 CA--C 1.518 -0.262 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 178.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 96.2 mt -113.35 120.4 63.19 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 109.047 -0.723 . . . . 0.0 109.047 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -125.01 127.97 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-N 116.02 -0.536 . . . . 0.0 111.935 -178.183 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.19 116.68 3.01 Favored Glycine 0 N--CA 1.466 0.679 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 178.426 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.414 HD13 HD23 ' Q' ' 34' ' ' LEU . 40.4 tp -124.1 122.51 38.04 Favored 'General case' 0 CA--C 1.516 -0.351 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.6 mtp -139.72 147.34 40.76 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.173 0.511 . . . . 0.0 112.279 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.401 HG22 ' N ' ' R' ' 37' ' ' GLY . 2.9 p -130.15 155.27 41.46 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.075 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.5 179.177 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.401 ' N ' HG22 ' R' ' 36' ' ' VAL . . . -102.99 102.75 2.29 Favored Glycine 0 CA--C 1.523 0.582 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.95 -179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.97 -76.17 0.73 Allowed Glycine 0 CA--C 1.535 1.329 0 N-CA-C 115.241 0.857 . . . . 0.0 115.241 177.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.485 ' O ' ' O ' ' Q' ' 38' ' ' GLY . 54.0 t -122.7 139.46 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 CA-C-N 117.916 0.858 . . . . 0.0 112.708 -177.033 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 t . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.987 179.214 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.663 -1.375 . . . . 0.0 109.663 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.9 m-85 -83.82 142.25 30.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.869 0.366 . . . . 0.0 110.814 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.439 ' CD ' ' NE2' ' A' ' 13' ' ' HIS . 80.8 tt0 -138.85 146.48 41.27 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.68 179.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 51.8 t -120.16 129.51 75.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-O 121.619 0.723 . . . . 0.0 111.098 -179.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.439 ' NE2' ' CD ' ' A' ' 11' ' ' GLU . 98.2 m-70 -126.04 166.16 17.48 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 114.628 -1.169 . . . . 0.0 109.713 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 53.0 p-80 -82.92 167.31 18.13 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 120.557 -0.457 . . . . 0.0 111.238 -179.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 79.6 mt-30 -157.87 142.92 16.71 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.611 178.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.9 mttm -81.51 127.98 33.41 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 178.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.2 mt -125.48 114.49 18.87 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 178.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 59.5 t -127.55 131.49 70.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.176 -179.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -134.55 130.79 37.1 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.148 0.499 . . . . 0.0 111.702 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -113.9 123.02 48.76 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.034 178.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.02 129.46 46.74 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 121.155 0.502 . . . . 0.0 111.656 -179.104 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.625 ' O ' HG23 ' A' ' 24' ' ' VAL . 98.0 mt-10 -92.99 -176.28 4.14 Favored 'General case' 0 C--N 1.326 -0.413 0 N-CA-C 109.2 -0.667 . . . . 0.0 109.2 178.766 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.63 ' C ' HG23 ' A' ' 24' ' ' VAL . 48.5 t0 -58.6 -48.2 81.77 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-O 121.402 0.62 . . . . 0.0 109.629 179.296 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.63 HG23 ' C ' ' A' ' 23' ' ' ASP . 1.0 OUTLIER 72.4 -162.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 -178.962 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.596 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -109.27 27.17 13.04 Favored Glycine 0 CA--C 1.524 0.626 0 CA-C-O 119.195 -0.78 . . . . 0.0 112.488 -179.709 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 26.5 m -81.67 -127.09 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 119.424 1.612 . . . . 0.0 111.087 -178.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -100.67 160.91 13.97 Favored 'General case' 0 N--CA 1.471 0.595 0 N-CA-C 115.862 1.801 . . . . 0.0 115.862 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -42.89 -36.25 1.45 Allowed 'General case' 0 C--O 1.221 -0.439 0 CA-C-N 112.369 -2.196 . . . . 0.0 113.261 171.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -102.39 87.75 0.63 Allowed Glycine 0 CA--C 1.526 0.761 0 CA-C-N 113.051 -1.886 . . . . 0.0 117.335 -168.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.52 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -96.27 128.66 43.39 Favored 'General case' 0 CA--C 1.551 1.01 0 CA-C-O 124.975 2.321 . . . . 0.0 110.403 -177.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -145.59 160.23 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.748 0 CA-C-N 110.546 -3.024 . . . . 0.0 111.329 -175.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 52.0 mt -104.43 109.46 27.5 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 N-CA-C 106.616 -1.624 . . . . 0.0 106.616 175.638 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.13 94.88 0.69 Allowed Glycine 0 CA--C 1.508 -0.39 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 178.576 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.489 ' O ' HD12 ' B' ' 34' ' ' LEU . 89.4 mt -144.26 154.63 43.28 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 122.881 1.324 . . . . 0.0 113.43 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 6.1 ttm -114.48 114.95 26.48 Favored 'General case' 0 N--CA 1.447 -0.577 0 CA-C-N 112.466 -2.152 . . . . 0.0 107.431 178.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.4 HG11 HD11 ' C' ' 17' ' ' LEU . 0.0 OUTLIER -129.26 102.84 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 N-CA-C 108.622 -0.881 . . . . 0.0 108.622 -179.807 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.1 -151.75 20.83 Favored Glycine 0 N--CA 1.442 -0.932 0 N-CA-C 109.299 -1.521 . . . . 0.0 109.299 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.61 ' O ' HG11 ' B' ' 39' ' ' VAL . . . 117.24 -56.33 0.54 Allowed Glycine 0 CA--C 1.543 1.797 0 C-N-CA 121.534 -0.365 . . . . 0.0 112.713 -179.713 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.764 ' C ' HG21 ' B' ' 39' ' ' VAL . 7.2 p -133.1 177.47 7.09 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.655 0 N-CA-C 109.293 -0.632 . . . . 0.0 109.293 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.672 ' H ' HG22 ' A' ' 39' ' ' VAL . 6.0 m . . . . . 0 N--CA 1.477 0.921 0 CA-C-O 117.901 -1.047 . . . . 0.0 111.965 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.654 -1.378 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -84.23 138.02 33.18 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.76 0.314 . . . . 0.0 110.322 -179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -106.35 125.77 51.41 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.302 -0.408 . . . . 0.0 109.988 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.52 HG11 ' CE1' ' C' ' 13' ' ' HIS . 54.1 t -122.35 130.03 74.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.833 0.349 . . . . 0.0 110.725 -179.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 60.3 m80 -117.42 157.6 25.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.004 -0.543 . . . . 0.0 109.609 179.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.605 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 52.9 t60 -80.72 166.86 20.63 Favored 'General case' 0 C--N 1.327 -0.403 0 C-N-CA 120.849 -0.34 . . . . 0.0 110.111 -179.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.559 ' O ' ' CE1' ' B' ' 14' ' ' HIS . 29.6 pt20 -129.29 151.08 50.34 Favored 'General case' 0 CA--C 1.519 -0.242 0 CA-C-O 121.15 0.5 . . . . 0.0 110.334 179.454 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 67.6 mttm -96.9 120.88 38.06 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.144 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.434 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.3 tt -116.76 115.56 25.84 Favored 'General case' 0 C--N 1.351 0.633 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 177.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 75.8 t -121.34 128.68 75.97 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.205 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.248 -179.435 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 20.9 t80 -129.63 117.48 20.44 Favored 'General case' 0 C--N 1.332 -0.191 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 32.4 t80 -112.57 122.42 47.63 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.04 116.11 26.22 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.929 0.871 . . . . 0.0 112.394 -178.504 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 78.0 tt0 -95.98 135.35 37.85 Favored 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.41 -1.268 . . . . 0.0 108.518 178.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.8 t0 -150.65 51.27 0.87 Allowed 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.356 -178.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 87.7 t -63.23 151.27 8.6 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.627 0 C-N-CA 118.486 -1.285 . . . . 0.0 110.21 -177.54 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.52 -32.4 6.64 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 106.166 -2.774 . . . . 0.0 106.166 -179.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.539 ' HB3' ' N ' ' C' ' 26' ' ' SER . 0.5 OUTLIER 71.5 106.09 0.06 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 112.732 -1.734 . . . . 0.0 112.262 176.045 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.598 ' N ' ' OG ' ' C' ' 26' ' ' SER . 43.8 m-80 -101.63 163.36 12.3 Favored 'General case' 0 CA--C 1.553 1.06 0 C-N-CA 119.217 -0.993 . . . . 0.0 112.815 177.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.49 ' O ' ' O ' ' C' ' 27' ' ' ASN . 99.7 mttt -41.45 -39.2 1.44 Allowed 'General case' 0 N--CA 1.487 1.403 0 N-CA-C 119.739 3.237 . . . . 0.0 119.739 178.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.52 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . -110.72 69.7 0.21 Allowed Glycine 0 N--CA 1.497 2.713 0 N-CA-C 119.318 2.487 . . . . 0.0 119.318 -170.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.417 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -97.47 102.33 14.07 Favored 'General case' 0 N--CA 1.485 1.276 0 CA-C-N 120.527 2.164 . . . . 0.0 111.978 178.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 7.0 pt -147.49 153.03 12.42 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.125 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 179.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.54 HD13 ' CD1' ' D' ' 19' ' ' PHE . 88.9 mt -107.44 114.09 45.33 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 N-CA-C 109.427 -0.583 . . . . 0.0 109.427 176.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.53 106.09 1.93 Allowed Glycine 0 N--CA 1.464 0.504 0 N-CA-C 106.256 -2.738 . . . . 0.0 106.256 176.589 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.489 HD12 ' O ' ' A' ' 34' ' ' LEU . 10.5 tp -141.76 142.4 33.24 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.653 -1.219 . . . . 0.0 114.249 -175.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 94.7 mmm -116.67 110.94 19.13 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 113.657 -1.611 . . . . 0.0 107.359 177.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' C' ' 36' ' ' VAL . 0.4 OUTLIER -132.75 102.94 5.57 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.596 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 -179.299 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.51 -151.85 21.21 Favored Glycine 0 C--N 1.306 -1.088 0 C-N-CA 119.31 -1.424 . . . . 0.0 110.482 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.407 ' C ' HG12 ' C' ' 39' ' ' VAL . . . 100.21 -57.05 0.8 Allowed Glycine 0 CA--C 1.539 1.543 0 N-CA-C 111.062 -0.815 . . . . 0.0 111.062 -178.718 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.764 HG21 ' C ' ' A' ' 39' ' ' VAL . 12.8 m -123.47 174.14 8.17 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.632 0 C-N-CA 123.826 0.851 . . . . 0.0 110.073 -179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.411 ' C ' ' O ' ' B' ' 39' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.47 0.527 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.572 179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -83.23 139.53 33.06 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.864 0.364 . . . . 0.0 110.291 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -81.6 118.94 23.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.155 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.407 ' C ' ' CD2' ' C' ' 13' ' ' HIS . 53.4 t -130.31 133.75 63.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.137 -179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.62 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 0.2 OUTLIER -139.13 100.8 4.11 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 121.218 -0.193 . . . . 0.0 111.134 179.205 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.605 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 13.6 m170 -117.19 160.5 20.95 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -86.41 155.54 20.54 Favored 'General case' 0 N--CA 1.457 -0.108 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 175.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.413 ' CB ' ' NE2' ' B' ' 14' ' ' HIS . 85.4 tttt -161.18 94.66 1.01 Allowed 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 118.998 -1.081 . . . . 0.0 111.186 176.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.4 HD11 HG11 ' A' ' 36' ' ' VAL . 20.8 mt -121.71 117.85 27.65 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.232 -0.894 . . . . 0.0 109.887 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 4.8 t -105.69 110.17 30.29 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.54 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 177.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 91.3 m-85 -108.92 105.84 15.55 Favored 'General case' 0 C--O 1.233 0.229 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 -179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -106.57 122.8 47.05 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.459 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.73 146.45 37.78 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -176.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -81.04 108.66 14.9 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.693 178.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.565 ' CG ' ' HB1' ' D' ' 21' ' ' ALA . 82.0 m-20 -105.28 51.93 0.75 Allowed 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 113.507 -1.679 . . . . 0.0 110.238 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.0 t -71.34 -133.21 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 CA-C-N 114.933 -1.031 . . . . 0.0 108.455 -174.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -102.46 38.07 3.38 Favored Glycine 0 N--CA 1.468 0.823 0 CA-C-O 124.111 1.95 . . . . 0.0 109.973 -169.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.598 ' OG ' ' N ' ' B' ' 27' ' ' ASN . 1.2 m -72.29 102.9 3.23 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-N 108.651 -3.775 . . . . 0.0 102.243 171.037 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.49 ' O ' ' O ' ' B' ' 28' ' ' LYS . 88.2 m-20 -108.21 -170.14 1.63 Allowed 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 -171.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.426 ' O ' ' O ' ' N' ' 40' ' ' VAL . 98.6 mttt 32.36 41.27 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 113.668 -1.606 . . . . 0.0 111.12 -172.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . -176.72 61.1 0.1 OUTLIER Glycine 0 CA--C 1.546 1.976 0 CA-C-N 114.809 -1.087 . . . . 0.0 111.715 172.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.28 95.33 5.55 Favored 'General case' 0 N--CA 1.476 0.826 0 CA-C-N 118.713 1.256 . . . . 0.0 110.505 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.705 HD13 HG22 ' O' ' 39' ' ' VAL . 2.0 tt -164.41 153.48 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 C-N-CA 115.164 -2.615 . . . . 0.0 116.353 -179.154 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.422 HD13 ' CD1' ' E' ' 19' ' ' PHE . 93.0 mt -112.73 112.34 40.01 Favored 'Isoleucine or valine' 0 C--N 1.35 0.601 0 CA-C-N 114.31 -1.314 . . . . 0.0 108.9 177.272 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.29 112.21 3.66 Favored Glycine 0 N--CA 1.464 0.554 0 N-CA-C 105.013 -3.235 . . . . 0.0 105.013 176.147 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 1.2 tt -148.05 146.3 28.81 Favored 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 117.619 -1.633 . . . . 0.0 114.474 -173.286 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 9.0 mtp -121.94 113.15 19.21 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 107.009 -1.478 . . . . 0.0 107.009 177.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.709 HG21 HD21 ' E' ' 17' ' ' LEU . 3.1 p -139.88 103.06 1.62 Allowed 'Isoleucine or valine' 0 C--O 1.22 -0.48 0 C-N-CA 120.76 -0.376 . . . . 0.0 111.837 -177.26 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.06 -155.27 26.43 Favored Glycine 0 C--N 1.318 -0.42 0 C-N-CA 119.848 -1.168 . . . . 0.0 112.282 177.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 61.1 54.73 34.26 Favored Glycine 0 CA--C 1.544 1.862 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.574 -177.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.456 ' O ' ' O ' ' C' ' 40' ' ' VAL . 2.6 m -156.2 -168.37 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.341 0.23 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 -179.745 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.519 HG13 ' O ' ' I' ' 28' ' ' LYS . 88.3 t . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.991 179.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.37 -1.492 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -83.25 137.08 34.15 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.887 0.375 . . . . 0.0 110.716 -179.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -121.9 129.37 52.5 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.071 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 t -111.05 123.35 66.87 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.447 -179.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.62 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 17.3 m-70 -134.82 107.43 7.39 Favored 'General case' 0 N--CA 1.47 0.551 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 179.593 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.593 ' ND1' ' O ' ' E' ' 14' ' ' HIS . 59.9 t60 -132.57 157.86 43.66 Favored 'General case' 0 N--CA 1.468 0.462 0 C-N-CA 120.164 -0.614 . . . . 0.0 110.723 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.558 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 43.2 tt0 -85.82 157.38 20.23 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.463 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -160.09 100.15 1.38 Allowed 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 120.019 -0.672 . . . . 0.0 110.237 176.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 29.6 mt -123.5 115.02 20.86 Favored 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 108.848 -0.797 . . . . 0.0 108.848 178.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 40.9 t -108.9 109.1 27.07 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.503 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 59.9 m-85 -107.8 104.02 13.42 Favored 'General case' 0 C--N 1.328 -0.351 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 178.482 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.612 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 47.4 t80 -113.47 125.74 54.56 Favored 'General case' 0 N--CA 1.468 0.45 0 N-CA-C 109.499 -0.556 . . . . 0.0 109.499 -179.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.565 ' HB1' ' CG ' ' C' ' 23' ' ' ASP . . . -135.94 135.06 39.3 Favored 'General case' 0 C--O 1.242 0.665 0 CA-C-O 122.712 1.244 . . . . 0.0 113.242 -178.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 98.8 mt-10 -84.4 113.5 21.22 Favored 'General case' 0 CA--C 1.519 -0.216 0 CA-C-N 114.022 -1.444 . . . . 0.0 108.963 179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.635 ' OD2' ' HB1' ' E' ' 21' ' ' ALA . 5.7 p-10 -146.44 48.57 1.18 Allowed 'General case' 0 CA--C 1.516 -0.365 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.457 ' H ' HG12 ' D' ' 24' ' ' VAL . 0.6 OUTLIER -72.58 160.79 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 N-CA-C 106.2 -1.778 . . . . 0.0 106.2 177.486 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.38 -28.4 10.97 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.445 ' OG ' ' O ' ' E' ' 26' ' ' SER . 7.7 t 74.6 119.6 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 114.268 -0.966 . . . . 0.0 110.264 -178.25 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 28.3 m120 -83.29 163.25 20.81 Favored 'General case' 0 C--N 1.341 0.225 0 C-N-CA 120.078 -0.649 . . . . 0.0 111.278 -179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -46.98 -37.0 8.39 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 113.703 1.001 . . . . 0.0 113.703 178.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.74 77.55 0.07 OUTLIER Glycine 0 CA--C 1.538 1.501 0 C-N-CA 120.497 -0.859 . . . . 0.0 113.085 -175.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.71 137.64 37.1 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 118.698 1.249 . . . . 0.0 111.082 -178.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.532 HD13 ' HB ' ' P' ' 39' ' ' VAL . 31.5 mt -127.34 138.65 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 CA-C-N 114.793 -1.094 . . . . 0.0 113.36 -176.365 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' F' ' 19' ' ' PHE . 67.2 mt -115.28 120.7 65.4 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 N-CA-C 106.852 -1.536 . . . . 0.0 106.852 175.005 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.39 119.51 2.11 Favored Glycine 0 N--CA 1.467 0.731 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.705 ' N ' HD23 ' D' ' 34' ' ' LEU . 1.9 pt? -165.62 162.53 18.99 Favored 'General case' 0 C--O 1.242 0.703 0 C-N-CA 117.75 -1.58 . . . . 0.0 114.987 -178.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 50.6 tpp -101.43 111.65 23.94 Favored 'General case' 0 CA--C 1.505 -0.759 0 CA-C-N 112.163 -2.289 . . . . 0.0 106.907 176.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.759 HG11 HD23 ' F' ' 17' ' ' LEU . 55.7 t -118.47 102.57 13.36 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 121.265 -0.174 . . . . 0.0 110.78 -178.8 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . 103.03 -161.86 16.34 Favored Glycine 0 N--CA 1.462 0.394 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 179.421 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.473 ' O ' ' OXT' ' E' ' 40' ' ' VAL . . . 148.69 -55.34 0.5 Allowed Glycine 0 CA--C 1.539 1.578 0 CA-C-O 119.316 -0.713 . . . . 0.0 112.453 -179.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.65 HG21 ' CD1' ' J' ' 31' ' ' ILE . 33.8 m -136.61 152.8 29.65 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.555 0 CA-C-N 118.776 1.288 . . . . 0.0 110.867 178.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.593 ' H ' ' CD1' ' K' ' 31' ' ' ILE . 60.7 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.485 -179.143 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.615 -1.394 . . . . 0.0 109.615 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -106.97 135.75 48.0 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.839 0.352 . . . . 0.0 110.353 179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -76.53 106.37 8.14 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.713 -179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 m -139.78 156.43 25.73 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.238 0 CA-C-O 121.162 0.506 . . . . 0.0 110.938 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.412 ' C ' ' CD2' ' E' ' 14' ' ' HIS . 21.7 m-70 -148.27 117.57 6.9 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.141 178.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.593 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 13.3 m-70 -141.28 162.41 35.54 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 110.923 179.047 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.421 ' OE1' ' OE1' ' F' ' 15' ' ' GLN . 78.7 mt-30 -85.32 157.27 20.6 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 176.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -159.53 104.3 1.61 Allowed 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.322 0.582 . . . . 0.0 109.461 178.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.709 HD21 HG21 ' C' ' 36' ' ' VAL . 2.3 mt -125.07 116.8 22.67 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.773 -179.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -107.48 101.85 13.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 N-CA-C 107.49 -1.3 . . . . 0.0 107.49 176.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 74.1 m-85 -103.45 101.22 11.11 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 178.002 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.612 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 24.5 t80 -116.2 128.65 55.79 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 120.474 0.178 . . . . 0.0 111.156 -177.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.635 ' HB1' ' OD2' ' D' ' 23' ' ' ASP . . . -141.31 139.57 33.64 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.52 0.676 . . . . 0.0 112.755 -179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.567 ' HB2' ' H ' ' D' ' 23' ' ' ASP . 97.7 mt-10 -79.28 155.05 28.69 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' F' ' 23' ' ' ASP . 2.4 t70 -169.62 48.56 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 118.286 -1.366 . . . . 0.0 113.418 -177.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 1.8 t -72.28 161.61 4.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 C-N-CA 119.179 -1.008 . . . . 0.0 108.598 179.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.68 -28.65 10.38 Favored Glycine 0 N--CA 1.47 0.904 0 N-CA-C 108.315 -1.914 . . . . 0.0 108.315 -176.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.526 ' O ' ' CB ' ' E' ' 27' ' ' ASN . 1.6 m 80.56 -114.71 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 113.644 -1.278 . . . . 0.0 112.232 -179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.526 ' CB ' ' O ' ' E' ' 26' ' ' SER . 4.2 t-20 89.24 179.9 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.563 0 N-CA-C 108.304 -0.998 . . . . 0.0 108.304 -179.289 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt -48.33 -38.43 19.05 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 177.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.472 ' O ' ' HB2' ' E' ' 30' ' ' ALA . . . 99.85 -68.22 0.55 Allowed Glycine 0 CA--C 1.534 1.251 0 CA-C-N 114.297 -1.32 . . . . 0.0 114.781 176.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.963 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . 179.91 171.0 1.13 Allowed 'General case' 0 N--CA 1.452 -0.348 0 CA-C-N 119.044 1.422 . . . . 0.0 112.688 -179.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 98.6 mt -131.85 128.36 59.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 113.976 -1.465 . . . . 0.0 108.587 177.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.472 ' CG2' HD21 ' E' ' 34' ' ' LEU . 52.1 mt -123.93 124.91 70.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 CA-C-O 121.133 0.492 . . . . 0.0 111.822 -177.439 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 110.92 2.34 Favored Glycine 0 N--CA 1.47 0.96 0 N-CA-C 108.816 -1.714 . . . . 0.0 108.816 177.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.472 HD21 ' CG2' ' E' ' 32' ' ' ILE . 21.8 mt -118.17 114.31 22.86 Favored 'General case' 0 C--O 1.24 0.595 0 N-CA-C 111.974 0.361 . . . . 0.0 111.974 -177.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 78.4 mmm -105.8 116.17 31.48 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 177.095 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.67 HG12 ' N ' ' E' ' 37' ' ' GLY . 61.7 t -128.44 170.85 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.471 0 CA-C-O 121.701 0.762 . . . . 0.0 112.365 -177.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.67 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -168.26 94.28 0.11 Allowed Glycine 0 C--N 1.308 -1.021 0 N-CA-C 108.164 -1.975 . . . . 0.0 108.164 176.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.33 -73.15 0.42 Allowed Glycine 0 CA--C 1.54 1.626 0 CA-C-N 117.287 0.543 . . . . 0.0 112.927 179.457 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.773 HG13 HD11 ' K' ' 31' ' ' ILE . 76.2 t -123.77 94.32 2.8 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.081 0 N-CA-C 106.283 -1.747 . . . . 0.0 106.283 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.617 HG11 ' HA3' ' F' ' 37' ' ' GLY . 4.1 p . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 118.192 -0.909 . . . . 0.0 111.551 -178.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.394 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.1 t80 -103.43 122.58 45.18 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.82 0.343 . . . . 0.0 110.263 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -128.42 130.52 47.75 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.633 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.516 HG13 ' NE2' ' E' ' 14' ' ' HIS . 8.0 p -141.32 138.2 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-O 121.403 0.621 . . . . 0.0 110.948 179.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.406 ' HA ' ' CE1' ' E' ' 14' ' ' HIS . 4.6 m80 -140.98 133.57 28.61 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 114.995 -1.002 . . . . 0.0 111.121 -178.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.583 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 45.7 m80 -148.54 164.74 33.32 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.583 -0.447 . . . . 0.0 111.02 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.448 ' NE2' ' H ' ' F' ' 16' ' ' LYS . 70.9 tp60 -89.8 151.46 21.78 Favored 'General case' 0 C--O 1.23 0.074 0 CA-C-N 116.068 -0.515 . . . . 0.0 111.69 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . 0.448 ' H ' ' NE2' ' F' ' 15' ' ' GLN . 99.1 mttt -152.89 100.08 2.48 Favored 'General case' 0 C--N 1.319 -0.751 0 C-N-CA 120.712 -0.395 . . . . 0.0 110.559 176.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.759 HD23 HG11 ' D' ' 36' ' ' VAL . 0.2 OUTLIER -121.6 118.98 30.57 Favored 'General case' 0 N--CA 1.475 0.782 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 177.209 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.3 t -113.69 106.07 19.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.572 ' CD1' HD13 ' D' ' 32' ' ' ILE . 55.7 m-85 -104.32 103.59 13.36 Favored 'General case' 0 CA--C 1.512 -0.516 0 N-CA-C 106.856 -1.535 . . . . 0.0 106.856 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -117.24 109.82 17.35 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.223 0.535 . . . . 0.0 110.513 -178.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.96 117.98 28.7 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 177.252 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -90.33 112.08 23.53 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 119.222 -0.991 . . . . 0.0 113.583 -176.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OD1' ' E' ' 23' ' ' ASP . 1.1 m-20 -127.94 -59.93 1.17 Allowed 'General case' 0 C--N 1.351 0.648 0 C-N-CA 119.846 -0.742 . . . . 0.0 110.935 176.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.49 HG23 ' O ' ' F' ' 26' ' ' SER . 0.0 OUTLIER -102.92 -178.79 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.51 -0.576 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 175.378 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -73.6 -35.03 56.08 Favored Glycine 0 CA--C 1.53 1.031 0 N-CA-C 108.746 -1.741 . . . . 0.0 108.746 172.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.49 ' O ' HG23 ' F' ' 24' ' ' VAL . 4.4 p -95.03 121.72 36.94 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 112.496 -1.852 . . . . 0.0 113.151 -178.09 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 92.9 m-20 -74.23 -151.08 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt 53.84 48.31 21.61 Favored 'General case' 0 CA--C 1.531 0.224 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 -179.049 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.41 -53.11 0.57 Allowed Glycine 0 CA--C 1.542 1.768 0 CA-C-N 114.756 -1.111 . . . . 0.0 114.168 -177.634 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.963 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -84.14 -156.94 0.24 Allowed 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.589 0.756 . . . . 0.0 112.033 -175.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 2.3 mm -105.05 131.52 54.06 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.03 0 N-CA-C 109.512 -0.551 . . . . 0.0 109.512 179.212 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.44 HG23 ' O ' ' F' ' 32' ' ' ILE . 19.6 tt -137.7 129.5 40.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-O 120.979 0.419 . . . . 0.0 111.627 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.66 123.11 5.13 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 14.6 mt -116.59 120.31 38.28 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 96.2 mmm -123.69 130.11 52.15 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 120.878 -0.329 . . . . 0.0 111.538 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 29.5 m -115.96 158.38 16.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 N-CA-C 109.401 -0.592 . . . . 0.0 109.401 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.617 ' HA3' HG11 ' E' ' 40' ' ' VAL . . . -63.08 -103.03 0.01 OUTLIER Glycine 0 CA--C 1.524 0.616 0 C-N-CA 121.214 -0.517 . . . . 0.0 112.961 -179.361 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -119.42 -76.66 0.5 Allowed Glycine 0 CA--C 1.534 1.231 0 CA-C-N 115.58 -0.31 . . . . 0.0 112.425 -179.347 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.47 ' O ' ' CD1' ' L' ' 31' ' ' ILE . 58.6 t -126.91 131.8 70.63 Favored 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-N 117.338 0.569 . . . . 0.0 110.343 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.449 HG22 ' H ' ' F' ' 40' ' ' VAL . 10.9 m . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.861 -179.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -111.63 132.89 54.26 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.77 0.319 . . . . 0.0 110.472 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.533 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 57.8 mp0 -120.85 125.21 46.92 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.278 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.85 149.43 22.32 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.294 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -133.84 112.42 11.3 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.691 0.282 . . . . 0.0 110.913 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.436 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 47.9 p-80 -152.92 168.73 24.81 Favored 'General case' 0 CA--C 1.531 0.244 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.292 179.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 69.1 tp60 -158.22 142.46 15.88 Favored 'General case' 0 N--CA 1.455 -0.212 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.654 178.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -81.86 126.63 32.12 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.18 -0.463 . . . . 0.0 111.033 179.082 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.58 ' C ' HD23 ' G' ' 17' ' ' LEU . 6.5 tt -134.43 119.58 18.73 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 178.658 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.505 ' N ' HD23 ' G' ' 17' ' ' LEU . 12.6 m -132.82 135.81 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.355 -179.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 92.2 t80 -127.24 126.46 42.75 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.807 178.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' H' ' 20' ' ' PHE . 43.5 t80 -128.94 127.45 41.77 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.585 -0.28 . . . . 0.0 110.682 -179.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.69 119.67 21.69 Favored 'General case' 0 N--CA 1.472 0.647 0 CA-C-O 121.303 0.573 . . . . 0.0 110.977 179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.632 ' O ' ' N ' ' G' ' 24' ' ' VAL . 79.9 tt0 -92.57 124.6 36.71 Favored 'General case' 0 C--N 1.342 0.27 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.596 -179.91 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.528 ' H ' ' HB3' ' H' ' 22' ' ' GLU . 67.0 t0 47.76 -60.63 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.809 1.244 . . . . 0.0 113.086 -179.264 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' G' ' 22' ' ' GLU . 5.2 p -72.97 160.72 5.22 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-O 121.126 0.489 . . . . 0.0 110.973 179.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.24 -35.23 4.96 Favored Glycine 0 N--CA 1.469 0.852 0 CA-C-N 115.34 -0.845 . . . . 0.0 112.535 176.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 18.2 m -80.74 118.81 22.61 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 117.225 0.512 . . . . 0.0 110.218 178.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 51.1 p-10 -88.82 179.23 6.25 Favored 'General case' 0 C--N 1.333 -0.137 0 C-N-CA 119.648 -0.821 . . . . 0.0 111.143 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -54.61 -38.51 66.88 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.772 -1.104 . . . . 0.0 111.59 177.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.24 70.96 0.2 Allowed Glycine 0 CA--C 1.537 1.423 0 CA-C-N 114.247 -1.342 . . . . 0.0 113.171 -175.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -95.25 116.94 29.43 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 123.988 1.851 . . . . 0.0 112.69 -176.449 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.485 ' CD1' ' O ' ' A' ' 38' ' ' GLY . 14.8 pt -146.95 149.21 15.95 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.757 0 CA-C-N 111.993 -2.367 . . . . 0.0 109.904 -179.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.418 HD13 HG21 ' G' ' 32' ' ' ILE . 55.0 mt -105.05 112.0 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 N-CA-C 107.87 -1.159 . . . . 0.0 107.87 177.587 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.12 96.05 0.74 Allowed Glycine 0 N--CA 1.467 0.735 0 N-CA-C 107.264 -2.334 . . . . 0.0 107.264 178.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 78.3 mt -144.07 156.27 44.3 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-O 122.972 1.367 . . . . 0.0 113.848 -177.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' CG ' ' H' ' 35' ' ' MET . 44.1 tpp -103.57 111.16 23.5 Favored 'General case' 0 N--CA 1.447 -0.619 0 CA-C-N 112.166 -2.288 . . . . 0.0 106.315 176.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.444 HG12 HE21 ' J' ' 15' ' ' GLN . 3.5 t -131.54 111.78 19.7 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.432 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 127.99 -132.07 7.26 Favored Glycine 0 C--N 1.315 -0.623 0 N-CA-C 108.936 -1.666 . . . . 0.0 108.936 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.418 ' O ' HG12 ' H' ' 39' ' ' VAL . . . 87.49 -63.67 3.87 Favored Glycine 0 CA--C 1.539 1.566 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.093 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 m -102.57 169.15 1.96 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.252 0 CA-C-O 120.95 0.405 . . . . 0.0 110.844 -179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.507 ' OXT' ' NE2' ' J' ' 13' ' ' HIS . 9.7 p . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.9 -1.048 . . . . 0.0 110.264 179.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.195 0 N-CA-C 109.344 -1.502 . . . . 0.0 109.344 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -107.86 133.27 52.46 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-O 120.814 0.34 . . . . 0.0 110.179 179.927 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -140.62 128.6 22.01 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.225 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.1 t -122.99 131.34 73.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.805 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 86.4 t60 -132.4 105.77 7.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-O 120.811 0.339 . . . . 0.0 111.6 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.673 ' CD2' ' H ' ' H' ' 15' ' ' GLN . 1.1 t-80 -155.6 169.13 25.01 Favored 'General case' 0 CA--C 1.533 0.327 0 CA-C-N 116.034 -0.53 . . . . 0.0 109.702 178.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.673 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 14.1 pt20 -157.45 142.19 16.64 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-O 120.985 0.421 . . . . 0.0 110.449 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -84.02 113.38 20.97 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.356 179.02 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.9 mt -119.66 113.41 20.63 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 178.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 79.7 t -124.38 131.72 72.39 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.732 0 CA-C-O 120.898 0.38 . . . . 0.0 111.636 -178.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -126.7 116.57 21.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.309 179.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.425 ' CD1' ' CD1' ' G' ' 20' ' ' PHE . 30.0 t80 -117.23 123.83 47.59 Favored 'General case' 0 N--CA 1.47 0.528 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.18 138.56 25.29 Favored 'General case' 0 N--CA 1.473 0.683 0 CA-C-O 122.454 1.121 . . . . 0.0 113.633 -178.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.528 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 80.8 tt0 -90.14 149.5 22.42 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.152 -1.386 . . . . 0.0 109.402 178.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.411 ' N ' ' HB2' ' I' ' 22' ' ' GLU . 66.4 t0 -174.32 48.43 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.223 0 C-N-CA 120.682 -0.407 . . . . 0.0 112.042 -178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.426 HG12 ' N ' ' H' ' 25' ' ' GLY . 4.1 t -72.67 161.43 4.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 C-N-CA 119.63 -0.828 . . . . 0.0 110.213 -179.342 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.505 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 108.95 -30.24 8.89 Favored Glycine 0 N--CA 1.466 0.688 0 N-CA-C 110.569 -1.012 . . . . 0.0 110.569 179.504 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.505 ' CB ' ' O ' ' H' ' 25' ' ' GLY . 6.2 p 93.06 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 123.085 0.554 . . . . 0.0 111.015 178.52 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 1.07 HD21 ' HB2' ' H' ' 30' ' ' ALA . 17.6 p30 -74.02 175.05 7.77 Favored 'General case' 0 C--N 1.331 -0.234 0 C-N-CA 119.889 -0.725 . . . . 0.0 110.448 178.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.618 ' HZ3' ' CE1' ' C' ' 13' ' ' HIS . 94.0 mttt -51.18 -36.93 43.63 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 113.378 0.881 . . . . 0.0 113.378 178.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.512 ' N ' ' OD1' ' H' ' 27' ' ' ASN . . . 179.54 77.22 0.06 OUTLIER Glycine 0 CA--C 1.529 0.961 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.729 -176.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 1.07 ' HB2' HD21 ' H' ' 27' ' ' ASN . . . -52.06 131.89 32.28 Favored 'General case' 0 CA--C 1.553 1.069 0 CA-C-N 118.295 1.047 . . . . 0.0 113.567 -178.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.578 HD12 HG12 ' B' ' 39' ' ' VAL . 51.6 mt -141.38 133.42 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.454 HD13 HG21 ' H' ' 32' ' ' ILE . 31.3 mt -105.55 108.97 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 174.159 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.44 104.42 1.8 Allowed Glycine 0 N--CA 1.462 0.427 0 N-CA-C 106.948 -2.461 . . . . 0.0 106.948 177.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.415 HD21 HG22 ' G' ' 32' ' ' ILE . 81.0 mt -138.23 136.77 36.88 Favored 'General case' 0 CA--C 1.504 -0.82 0 C-N-CA 119.013 -1.075 . . . . 0.0 113.774 -176.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.472 ' CG ' ' SD ' ' G' ' 35' ' ' MET . 32.9 tpp -99.84 107.1 19.04 Favored 'General case' 0 N--CA 1.436 -1.15 0 N-CA-C 103.735 -2.691 . . . . 0.0 103.735 173.533 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.441 ' O ' ' HA ' ' I' ' 36' ' ' VAL . 24.8 t -130.24 142.3 44.13 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.778 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -178.47 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' H' ' 39' ' ' VAL . . . 124.57 -101.95 0.68 Allowed Glycine 0 C--N 1.312 -0.759 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 62.19 -79.28 0.02 OUTLIER Glycine 0 CA--C 1.525 0.694 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.118 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.529 HG21 ' CA ' ' N' ' 29' ' ' GLY . 5.5 p -144.04 150.2 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.413 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 177.077 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.545 ' OXT' ' CG2' ' I' ' 40' ' ' VAL . 5.1 p . . . . . 0 C--O 1.217 -0.655 0 CA-C-O 118.14 -0.933 . . . . 0.0 111.117 179.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -108.44 136.66 47.69 Favored 'General case' 0 N--CA 1.464 0.229 0 CA-C-O 120.842 0.353 . . . . 0.0 110.254 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.491 ' N ' ' CD ' ' I' ' 11' ' ' GLU . 1.8 pm0 -117.91 135.58 54.03 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.525 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.507 HG22 ' H ' ' J' ' 12' ' ' VAL . 70.2 t -124.97 126.51 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.202 -179.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 5.6 m80 -134.85 146.14 48.97 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 120.805 0.336 . . . . 0.0 111.33 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.516 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 59.4 m80 -147.82 172.69 13.74 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 121.132 0.492 . . . . 0.0 110.502 177.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 40.7 tt0 -137.86 140.89 40.68 Favored 'General case' 0 C--N 1.33 -0.255 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 176.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -130.15 110.06 11.3 Favored 'General case' 0 C--N 1.322 -0.606 0 C-N-CA 120.105 -0.638 . . . . 0.0 112.413 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.43 ' CD2' HG21 ' G' ' 36' ' ' VAL . 5.6 mp -121.81 113.12 19.22 Favored 'General case' 0 C--O 1.24 0.559 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 175.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.502 HG13 ' CG2' ' J' ' 18' ' ' VAL . 8.0 t -105.56 109.43 27.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.407 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 80.3 m-85 -104.3 100.71 10.43 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.115 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 33.8 t80 -115.2 127.42 55.51 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.881 -0.415 . . . . 0.0 109.881 -179.014 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -168.58 177.46 5.2 Favored 'General case' 0 CA--C 1.512 -0.49 0 C-N-CA 117.624 -1.63 . . . . 0.0 114.891 -177.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.411 ' HB2' ' N ' ' H' ' 23' ' ' ASP . 67.8 mm-40 -77.92 156.96 29.98 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 104.974 -2.232 . . . . 0.0 104.974 175.327 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.722 ' O ' ' O ' ' I' ' 24' ' ' VAL . 67.9 t0 -169.84 60.56 0.04 OUTLIER 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 119.291 -0.964 . . . . 0.0 112.483 -175.214 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.722 ' O ' ' O ' ' I' ' 23' ' ' ASP . 3.4 t -44.53 -111.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -178.196 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.448 ' O ' ' N ' ' I' ' 27' ' ' ASN . . . 159.5 -45.37 0.44 Allowed Glycine 0 CA--C 1.502 -0.751 0 C-N-CA 116.091 -2.957 . . . . 0.0 116.561 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.498 ' C ' ' ND2' ' I' ' 27' ' ' ASN . 46.9 t -66.69 103.85 1.18 Allowed 'General case' 0 N--CA 1.447 -0.578 0 C-N-CA 113.773 -3.171 . . . . 0.0 106.11 -179.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.53 ' O ' ' N ' ' I' ' 29' ' ' GLY . 1.6 m120 -137.02 170.13 16.61 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 113.963 -1.471 . . . . 0.0 109.132 178.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.519 ' O ' HG13 ' C' ' 40' ' ' VAL . 52.7 mttp -25.84 -42.04 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.535 0 O-C-N 123.882 0.739 . . . . 0.0 111.217 173.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 160.68 67.6 0.02 OUTLIER Glycine 0 CA--C 1.554 2.494 0 CA-C-N 114.981 -1.009 . . . . 0.0 112.677 -178.51 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -52.14 138.23 26.13 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-N 118.477 1.138 . . . . 0.0 112.166 -178.697 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.68 HD12 HD11 ' J' ' 31' ' ' ILE . 3.0 tt -144.59 145.93 20.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.498 HG23 HD13 ' I' ' 34' ' ' LEU . 3.9 mt -105.37 108.58 25.32 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 105.43 -2.063 . . . . 0.0 105.43 175.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.727 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -107.32 101.45 1.68 Allowed Glycine 0 N--CA 1.47 0.903 0 N-CA-C 106.41 -2.676 . . . . 0.0 106.41 178.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.727 HD12 ' O ' ' I' ' 33' ' ' GLY . 3.1 mp -130.71 130.21 43.54 Favored 'General case' 0 C--O 1.235 0.31 0 N-CA-C 114.033 1.123 . . . . 0.0 114.033 -174.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 83.5 mmm -101.34 112.44 24.96 Favored 'General case' 0 CA--C 1.508 -0.655 0 N-CA-C 104.442 -2.429 . . . . 0.0 104.442 174.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.441 ' HA ' ' O ' ' H' ' 36' ' ' VAL . 47.0 t -127.56 142.14 44.43 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.371 0 C-N-CA 120.953 -0.299 . . . . 0.0 111.743 -174.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.434 ' HA2' HE21 ' L' ' 15' ' ' GLN . . . 133.16 -101.6 0.44 Allowed Glycine 0 C--N 1.318 -0.451 0 N-CA-C 111.356 -0.697 . . . . 0.0 111.356 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.526 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 83.83 -81.02 1.77 Allowed Glycine 0 CA--C 1.539 1.537 0 N-CA-C 111.322 -0.711 . . . . 0.0 111.322 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.517 HG22 HD12 ' O' ' 31' ' ' ILE . 56.1 t -143.2 143.91 24.32 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 177.381 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.545 ' CG2' ' OXT' ' H' ' 40' ' ' VAL . 21.5 m . . . . . 0 N--CA 1.473 0.688 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.975 -178.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.372 0 N-CA-C 109.536 -1.426 . . . . 0.0 109.536 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -107.88 132.81 53.06 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.884 0.373 . . . . 0.0 110.622 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -75.51 123.43 25.44 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.906 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.507 ' H ' HG22 ' I' ' 12' ' ' VAL . 3.2 m -134.9 155.97 39.08 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.285 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.541 ' CG ' ' O ' ' H' ' 40' ' ' VAL . 2.1 t-80 -158.52 103.66 1.77 Allowed 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.02 178.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.516 ' H ' ' CD2' ' I' ' 14' ' ' HIS . 4.3 m-70 -137.23 159.09 42.93 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.786 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.444 HE21 HG12 ' G' ' 36' ' ' VAL . 5.8 tt0 -90.26 159.26 16.78 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 105.67 -1.974 . . . . 0.0 105.67 175.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.664 ' C ' HD12 ' J' ' 17' ' ' LEU . 78.9 tttt -140.66 109.73 6.13 Favored 'General case' 0 C--N 1.313 -1.002 0 C-N-CA 119.835 -0.746 . . . . 0.0 110.845 178.363 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.664 HD12 ' C ' ' J' ' 16' ' ' LYS . 4.5 mp -130.04 120.02 24.06 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.293 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . 0.502 ' CG2' HG13 ' I' ' 18' ' ' VAL . 20.3 m -116.28 117.93 57.13 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 177.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.407 ' CE1' ' CD2' ' I' ' 19' ' ' PHE . 32.2 m-85 -107.92 103.54 12.81 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 179.369 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -118.46 134.63 54.92 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-O 120.557 0.218 . . . . 0.0 110.989 -178.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.31 146.24 23.53 Favored 'General case' 0 C--O 1.241 0.606 0 C-N-CA 117.919 -1.512 . . . . 0.0 114.842 179.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 72.3 mm-40 -86.8 147.47 25.81 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 113.578 -1.646 . . . . 0.0 108.915 179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.492 ' OD2' ' O ' ' I' ' 23' ' ' ASP . 0.0 OUTLIER -160.18 51.88 0.32 Allowed 'General case' 0 CA--C 1.542 0.639 0 N-CA-C 113.679 0.992 . . . . 0.0 113.679 -177.072 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 99.5 t -75.43 142.41 14.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 C-N-CA 116.783 -1.967 . . . . 0.0 108.378 179.331 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.26 -37.22 3.84 Favored Glycine 0 CA--C 1.529 0.935 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -80.49 119.95 23.84 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 113.663 -1.268 . . . . 0.0 112.697 -178.493 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.623 ' O ' ' N ' ' J' ' 29' ' ' GLY . 22.1 m-20 -88.38 158.01 18.53 Favored 'General case' 0 C--N 1.323 -0.548 0 C-N-CA 120.039 -0.665 . . . . 0.0 109.437 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.782 ' O ' ' HB2' ' K' ' 30' ' ' ALA . 75.8 tttt -47.91 48.35 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.216 0 N-CA-C 114.531 1.308 . . . . 0.0 114.531 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.623 ' N ' ' O ' ' J' ' 27' ' ' ASN . . . -101.47 52.55 0.88 Allowed Glycine 0 N--CA 1.481 1.664 0 CA-C-N 119.234 0.925 . . . . 0.0 113.905 -177.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.555 ' O ' ' HB1' ' K' ' 30' ' ' ALA . . . -130.01 179.44 5.87 Favored 'General case' 0 C--O 1.243 0.752 0 CA-C-O 121.4 0.619 . . . . 0.0 110.142 179.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.68 HD11 HD12 ' I' ' 31' ' ' ILE . 42.2 pt -138.96 145.04 28.27 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 N-CA-C 113.411 0.893 . . . . 0.0 113.411 178.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.488 HG22 ' O ' ' J' ' 32' ' ' ILE . 0.6 OUTLIER -108.67 110.44 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.053 177.535 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.77 95.88 0.91 Allowed Glycine 0 C--O 1.24 0.488 0 N-CA-C 104.673 -3.371 . . . . 0.0 104.673 176.044 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.412 HD21 ' CD2' ' L' ' 17' ' ' LEU . 6.3 tt -133.11 132.27 41.51 Favored 'General case' 0 C--O 1.245 0.841 0 CA-C-O 123.062 1.41 . . . . 0.0 113.647 -175.131 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 11.1 mtp -107.89 109.39 20.89 Favored 'General case' 0 N--CA 1.435 -1.193 0 CA-C-N 112.208 -2.269 . . . . 0.0 107.393 176.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.689 ' O ' HG13 ' K' ' 36' ' ' VAL . 12.0 p -104.44 111.51 34.32 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.469 0 N-CA-C 106.016 -1.846 . . . . 0.0 106.016 178.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.47 ' O ' ' OE1' ' L' ' 15' ' ' GLN . . . -58.62 131.91 52.29 Favored Glycine 0 N--CA 1.462 0.388 0 CA-C-N 115.146 -0.933 . . . . 0.0 114.403 -175.613 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.525 ' O ' ' N ' ' K' ' 39' ' ' VAL . . . -89.42 63.62 3.32 Favored Glycine 0 CA--C 1.532 1.101 0 N-CA-C 110.194 -1.163 . . . . 0.0 110.194 177.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.455 HG23 ' O ' ' J' ' 39' ' ' VAL . 28.7 m -112.86 125.6 70.14 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.053 0 CA-C-O 121.148 0.499 . . . . 0.0 110.695 -178.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.474 ' HB ' HG12 ' I' ' 40' ' ' VAL . 3.3 t . . . . . 0 C--O 1.219 -0.535 0 CA-C-N 114.951 -1.022 . . . . 0.0 112.204 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . 0.477 ' CE1' ' O ' ' L' ' 9' ' ' GLY . 94.4 m-85 -82.71 139.77 33.46 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.808 0.337 . . . . 0.0 110.51 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.459 ' HB3' ' HE2' ' K' ' 13' ' ' HIS . 95.7 mt-10 -92.24 121.63 33.94 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.276 -179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.428 HG12 ' H ' ' L' ' 12' ' ' VAL . 34.0 m -130.35 132.03 65.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-O 120.969 0.414 . . . . 0.0 111.356 -179.416 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.459 ' HE2' ' HB3' ' K' ' 11' ' ' GLU . 2.6 m-70 -141.79 137.5 31.59 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.311 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.647 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 28.1 m80 -147.57 162.18 39.63 Favored 'General case' 0 N--CA 1.467 0.418 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 177.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 43.0 tp60 -90.02 158.27 17.42 Favored 'General case' 0 N--CA 1.452 -0.333 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 176.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.27 97.74 3.23 Favored 'General case' 0 C--N 1.316 -0.859 0 C-N-CA 119.608 -0.837 . . . . 0.0 111.228 177.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 19.3 mt -121.49 118.62 29.77 Favored 'General case' 0 N--CA 1.48 1.057 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 176.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 t -107.85 111.81 37.47 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.768 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.584 178.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 27.0 m-85 -105.09 100.92 10.5 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 177.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 49.6 t80 -121.78 122.33 39.26 Favored 'General case' 0 N--CA 1.471 0.612 0 CA-C-O 120.732 0.301 . . . . 0.0 111.675 -177.656 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.581 ' O ' ' HB1' ' L' ' 21' ' ' ALA . . . -154.13 159.0 41.26 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 118.504 -1.278 . . . . 0.0 114.25 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.469 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 96.6 mt-10 -85.71 161.09 19.36 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 107.624 -1.25 . . . . 0.0 107.624 177.174 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 22.2 p30 177.65 48.8 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 CA-C-N 118.198 0.454 . . . . 0.0 112.167 -178.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.442 ' H ' HG23 ' K' ' 24' ' ' VAL . 0.2 OUTLIER -72.43 160.68 5.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 C-N-CA 118.4 -1.32 . . . . 0.0 112.97 -176.136 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.71 -28.7 10.29 Favored Glycine 0 CA--C 1.535 1.316 0 CA-C-N 113.634 -1.621 . . . . 0.0 112.419 175.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p 73.76 119.34 0.05 OUTLIER 'General case' 0 N--CA 1.469 0.478 0 N-CA-C 109.804 -0.443 . . . . 0.0 109.804 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.449 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 29.0 t-20 -83.3 163.49 20.65 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 119.494 -0.882 . . . . 0.0 112.477 178.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.449 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 99.4 mttt -47.35 -37.22 10.74 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 114.438 -1.255 . . . . 0.0 113.974 176.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.98 77.0 0.06 OUTLIER Glycine 0 CA--C 1.545 1.955 0 C-N-CA 120.059 -1.067 . . . . 0.0 114.42 -175.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.782 ' HB2' ' O ' ' J' ' 28' ' ' LYS . . . -80.02 167.95 19.8 Favored 'General case' 0 N--CA 1.474 0.773 0 CA-C-N 119.379 1.59 . . . . 0.0 110.351 -179.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.773 HD11 HG13 ' E' ' 39' ' ' VAL . 43.3 mt -133.24 127.98 55.03 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 N-CA-C 113.072 0.767 . . . . 0.0 113.072 -176.688 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.403 HD13 HG21 ' K' ' 32' ' ' ILE . 14.7 pt -125.17 121.69 61.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.578 0 CA-C-O 121.486 0.66 . . . . 0.0 109.998 176.32 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.608 ' C ' HD12 ' K' ' 34' ' ' LEU . . . -126.26 115.73 2.37 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.746 HD12 ' N ' ' K' ' 34' ' ' LEU . 2.9 mp -122.0 119.89 32.77 Favored 'General case' 0 CA--C 1.516 -0.36 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.406 ' SD ' ' CE ' ' L' ' 35' ' ' MET . 27.7 ttp -137.58 147.88 45.43 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 118.441 -1.303 . . . . 0.0 112.913 179.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.689 HG13 ' O ' ' J' ' 36' ' ' VAL . 1.4 t -121.38 171.82 9.46 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.268 0 CA-C-N 113.914 -1.493 . . . . 0.0 108.847 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.3 94.18 0.11 Allowed Glycine 0 N--CA 1.437 -1.279 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.999 178.622 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.525 ' HA2' HD11 ' Q' ' 31' ' ' ILE . . . 152.11 -80.97 0.19 Allowed Glycine 0 CA--C 1.541 1.681 0 C-N-CA 121.0 -0.619 . . . . 0.0 113.432 176.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.61 HG23 HD13 ' Q' ' 31' ' ' ILE . 90.2 t -154.75 142.97 13.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 N-CA-C 109.408 -0.59 . . . . 0.0 109.408 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.542 ' OXT' HG13 ' K' ' 40' ' ' VAL . 4.8 p . . . . . 0 C--N 1.325 -0.458 0 CA-C-O 117.844 -1.074 . . . . 0.0 110.769 179.649 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . 0.477 ' O ' ' CE1' ' K' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -122.44 152.49 40.19 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.731 0.301 . . . . 0.0 110.398 -179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -69.68 139.02 53.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.519 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.428 ' H ' HG12 ' K' ' 12' ' ' VAL . 6.2 m -122.12 132.88 70.05 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 121.271 0.557 . . . . 0.0 111.137 -179.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.447 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.3 p80 -148.18 107.31 3.88 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 115.47 -0.787 . . . . 0.0 110.741 179.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.647 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.9 m80 -147.91 164.86 32.43 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.238 -0.437 . . . . 0.0 109.909 179.215 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.47 ' OE1' ' O ' ' J' ' 37' ' ' GLY . 75.7 mt-30 -89.76 158.85 17.34 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 120.915 0.388 . . . . 0.0 111.175 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . 0.686 ' C ' HD12 ' L' ' 17' ' ' LEU . 68.5 mttm -140.07 102.56 4.42 Favored 'General case' 0 C--N 1.319 -0.76 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.686 HD12 ' C ' ' L' ' 16' ' ' LYS . 9.7 mp -120.37 118.14 29.59 Favored 'General case' 0 CA--C 1.516 -0.336 0 N-CA-C 107.765 -1.198 . . . . 0.0 107.765 178.113 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 66.1 t -105.04 116.43 48.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.517 ' CZ ' HD23 ' K' ' 34' ' ' LEU . 8.6 m-85 -105.16 103.7 13.29 Favored 'General case' 0 N--CA 1.452 -0.371 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 178.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.528 ' CE2' ' O ' ' L' ' 21' ' ' ALA . 75.7 t80 -153.21 158.87 42.39 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-O 123.177 1.465 . . . . 0.0 113.807 -177.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.581 ' HB1' ' O ' ' K' ' 21' ' ' ALA . . . -145.81 159.1 43.68 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 113.41 -1.723 . . . . 0.0 107.578 178.574 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.404 ' C ' ' O ' ' L' ' 21' ' ' ALA . 81.3 tt0 -39.95 152.7 0.03 OUTLIER 'General case' 0 C--N 1.324 -0.503 0 C-N-CA 120.27 -0.572 . . . . 0.0 111.677 -175.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 48.5 p30 -65.45 47.33 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.807 -177.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.546 HG23 ' H ' ' L' ' 26' ' ' SER . 24.1 m -61.04 -179.12 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.483 -179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.34 29.62 12.11 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.546 ' H ' HG23 ' L' ' 24' ' ' VAL . 34.5 t -80.14 110.81 15.9 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 179.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.607 ' O ' ' N ' ' L' ' 29' ' ' GLY . 11.2 m120 -95.06 -166.31 1.44 Allowed 'General case' 0 C--O 1.222 -0.348 0 C-N-CA 120.16 -0.616 . . . . 0.0 110.632 -179.433 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -48.57 47.87 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.725 0 N-CA-C 115.635 1.717 . . . . 0.0 115.635 -178.744 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.607 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.01 56.59 0.93 Allowed Glycine 0 CA--C 1.538 1.508 0 CA-C-N 119.756 1.162 . . . . 0.0 111.431 177.84 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.658 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -170.27 177.11 4.27 Favored 'General case' 0 N--CA 1.445 -0.678 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -179.231 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.555 HD12 HG12 ' E' ' 39' ' ' VAL . 39.2 mt -106.97 125.59 63.03 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 175.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.765 HD12 ' N ' ' L' ' 32' ' ' ILE . 3.1 mp -110.45 115.89 50.94 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.284 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.229 -179.771 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.1 107.26 1.15 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.622 HD23 ' C ' ' L' ' 34' ' ' LEU . 6.3 tt -122.7 120.39 33.52 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.446 -0.575 . . . . 0.0 109.446 179.465 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.582 ' N ' HD23 ' L' ' 34' ' ' LEU . 28.6 mtm -136.17 144.62 45.09 Favored 'General case' 0 N--CA 1.481 1.099 0 CA-C-O 121.462 0.648 . . . . 0.0 112.546 179.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.469 ' O ' ' O ' ' L' ' 37' ' ' GLY . 54.0 t -116.18 131.52 68.46 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.251 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.686 179.661 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -32.92 -111.3 0.0 OUTLIER Glycine 0 CA--C 1.532 1.113 0 CA-C-N 115.058 -0.974 . . . . 0.0 114.315 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.55 -71.64 0.53 Allowed Glycine 0 CA--C 1.536 1.35 0 CA-C-N 115.289 -0.456 . . . . 0.0 112.886 -178.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.404 ' CG2' HD11 ' R' ' 31' ' ' ILE . 53.3 t -106.88 131.85 55.73 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.613 0 CA-C-O 121.46 0.647 . . . . 0.0 111.27 -179.061 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.594 179.765 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.221 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -84.32 138.83 32.69 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.996 0.427 . . . . 0.0 110.838 -179.897 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -75.49 159.81 30.9 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.307 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 52.0 t -116.48 129.58 72.7 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.298 0.57 . . . . 0.0 110.116 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 37.4 m80 -81.4 163.09 23.06 Favored 'General case' 0 C--O 1.233 0.187 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.372 -179.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' N' ' 14' ' ' HIS . 89.5 m-70 -105.09 160.97 14.64 Favored 'General case' 0 N--CA 1.462 0.152 0 CA-C-O 121.265 0.555 . . . . 0.0 111.768 -179.151 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.427 ' H ' ' HG2' ' N' ' 15' ' ' GLN . 87.9 mt-30 -89.98 160.25 16.47 Favored 'General case' 0 N--CA 1.451 -0.388 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.62 178.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -139.38 110.9 7.08 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.1 mt -135.93 117.44 14.81 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.551 0.691 . . . . 0.0 111.081 -179.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -125.17 132.95 70.55 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 114.862 -1.063 . . . . 0.0 109.813 179.514 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 83.5 m-85 -128.04 134.21 49.18 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.771 0.32 . . . . 0.0 110.552 179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.496 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 53.2 p90 -127.43 126.02 41.63 Favored 'General case' 0 N--CA 1.466 0.369 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 179.525 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.27 129.25 47.37 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.225 0.536 . . . . 0.0 111.962 -178.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -155.34 126.7 7.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.698 -0.683 . . . . 0.0 110.007 179.062 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 54.69 46.45 24.66 Favored 'General case' 0 C--N 1.329 -0.305 0 C-N-CA 120.696 -0.402 . . . . 0.0 110.332 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.446 HG22 ' H ' ' M' ' 24' ' ' VAL . 11.6 m -76.11 179.55 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.0 28.11 6.86 Favored Glycine 0 CA--C 1.525 0.699 0 C-N-CA 121.051 -0.595 . . . . 0.0 111.813 -179.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' M' ' 27' ' ' ASN . 5.5 t -170.46 -134.11 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.331 0 C-N-CA 120.663 -0.415 . . . . 0.0 110.912 178.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.405 ' C ' ' O ' ' M' ' 26' ' ' SER . 22.2 t-20 -30.81 143.58 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 116.047 -0.524 . . . . 0.0 111.847 179.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -132.9 -26.08 1.78 Allowed 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.667 -0.242 . . . . 0.0 110.748 178.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . -79.99 -108.87 0.26 Allowed Glycine 0 CA--C 1.525 0.665 0 C-N-CA 120.143 -1.027 . . . . 0.0 111.052 179.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.45 96.94 0.25 Allowed 'General case' 0 C--N 1.329 -0.312 0 C-N-CA 120.45 -0.5 . . . . 0.0 112.1 178.313 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 91.8 mt -115.24 105.28 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . 0.747 HG22 HD11 ' N' ' 34' ' ' LEU . 55.0 mt -110.73 112.6 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 C-N-CA 120.411 -0.516 . . . . 0.0 109.745 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.75 104.45 1.22 Allowed Glycine 0 CA--C 1.509 -0.29 0 N-CA-C 104.977 -3.249 . . . . 0.0 104.977 176.874 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 30.0 tp -155.2 151.36 28.06 Favored 'General case' 0 C--O 1.24 0.557 0 C-N-CA 117.489 -1.685 . . . . 0.0 114.409 -174.297 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 93.9 mmm -100.27 111.51 23.79 Favored 'General case' 0 N--CA 1.442 -0.826 0 CA-C-N 112.659 -2.064 . . . . 0.0 106.878 177.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' N' ' 36' ' ' VAL . 41.9 t -119.66 131.37 72.38 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 -178.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.34 -111.28 4.13 Favored Glycine 0 C--N 1.318 -0.471 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -178.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' N' ' 37' ' ' GLY . . . 81.13 -74.03 2.49 Favored Glycine 0 CA--C 1.531 1.055 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -178.105 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.18 161.37 17.15 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.431 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.402 HG22 ' CG1' ' N' ' 39' ' ' VAL . 10.7 m . . . . . 0 N--CA 1.47 0.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.538 177.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.159 0 N-CA-C 109.18 -1.568 . . . . 0.0 109.18 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -105.24 131.51 52.62 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 49.3 tp10 -114.8 115.29 26.77 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.204 -179.724 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -129.57 123.02 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 116.387 -0.369 . . . . 0.0 110.174 179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 82.6 t60 -143.58 130.71 20.71 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.196 0.522 . . . . 0.0 110.473 179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.637 ' ND1' ' NE2' ' O' ' 14' ' ' HIS . 19.5 t60 -159.75 170.08 22.27 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.187 -0.671 . . . . 0.0 109.187 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.554 ' N ' ' CD2' ' N' ' 14' ' ' HIS . 75.2 mt-30 -155.14 140.71 17.91 Favored 'General case' 0 CA--C 1.517 -0.32 0 C-N-CA 120.236 -0.586 . . . . 0.0 109.767 177.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 48.0 tttp -93.98 111.04 22.7 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.638 -0.71 . . . . 0.0 110.867 177.615 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.427 ' CD1' HE21 ' O' ' 15' ' ' GLN . 13.6 mt -119.91 114.43 22.06 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 177.021 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . 0.478 HG21 ' CE2' ' N' ' 20' ' ' PHE . 6.3 p -138.6 141.86 36.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 119.692 -0.803 . . . . 0.0 112.135 -179.31 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -131.36 122.55 26.55 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.07 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.478 ' CE2' HG21 ' N' ' 18' ' ' VAL . 59.8 m-85 -112.88 123.48 50.4 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.633 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.05 121.06 40.25 Favored 'General case' 0 N--CA 1.473 0.696 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.354 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' OE1' ' O' ' 22' ' ' GLU . 82.6 tt0 -136.32 156.38 48.72 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 121.208 0.527 . . . . 0.0 112.31 -177.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 20.0 t0 76.63 54.74 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.364 178.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.631 HG21 HG13 ' O' ' 24' ' ' VAL . 90.8 t -68.05 135.25 28.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -110.57 -34.26 2.3 Favored Glycine 0 CA--C 1.53 0.997 0 C-N-CA 120.995 -0.621 . . . . 0.0 111.836 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.516 ' O ' ' O ' ' N' ' 27' ' ' ASN . 29.5 t -162.41 120.3 2.12 Favored 'General case' 0 C--O 1.224 -0.281 0 CA-C-N 116.847 0.323 . . . . 0.0 110.991 179.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.516 ' O ' ' O ' ' N' ' 26' ' ' SER . 17.5 p30 -22.26 152.74 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 N-CA-C 113.168 0.803 . . . . 0.0 113.168 179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 89.9 mttt -163.19 24.58 0.09 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.434 177.464 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . 0.529 ' CA ' HG21 ' H' ' 39' ' ' VAL . . . 89.52 105.29 1.13 Allowed Glycine 0 N--CA 1.466 0.683 0 C-N-CA 119.06 -1.543 . . . . 0.0 113.435 178.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . 0.531 ' HB3' ' HB2' ' O' ' 30' ' ' ALA . . . -111.96 95.63 5.59 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 122.072 0.939 . . . . 0.0 108.777 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.45 HD11 HG23 ' I' ' 39' ' ' VAL . 79.4 mt -137.44 136.13 46.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.346 0 CA-C-N 114.826 -1.079 . . . . 0.0 112.225 -177.182 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.704 HG23 HD13 ' N' ' 34' ' ' LEU . 77.1 mt -106.76 105.64 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 107.051 -1.463 . . . . 0.0 107.051 175.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.667 ' O ' HD12 ' N' ' 34' ' ' LEU . . . -110.38 91.98 0.66 Allowed Glycine 0 N--CA 1.467 0.742 0 N-CA-C 106.197 -2.761 . . . . 0.0 106.197 178.335 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.747 HD11 HG22 ' M' ' 32' ' ' ILE . 8.8 mp -132.74 152.55 51.73 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 123.35 1.548 . . . . 0.0 114.452 -175.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -115.65 107.26 14.87 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 104.488 -2.412 . . . . 0.0 104.488 175.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.528 ' O ' ' N ' ' O' ' 37' ' ' GLY . 47.6 t -117.63 123.16 71.36 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.368 0 C-N-CA 120.199 -0.6 . . . . 0.0 111.05 -177.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.742 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 134.75 -113.86 1.2 Allowed Glycine 0 C--N 1.317 -0.515 0 N-CA-C 110.524 -1.03 . . . . 0.0 110.524 178.352 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.805 ' O ' HG21 ' O' ' 39' ' ' VAL . . . 97.83 -71.64 0.66 Allowed Glycine 0 CA--C 1.533 1.188 0 N-CA-C 110.618 -0.993 . . . . 0.0 110.618 -178.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.402 ' CG1' HG22 ' M' ' 40' ' ' VAL . 83.6 t -126.49 138.58 54.26 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 N-CA-C 107.028 -1.471 . . . . 0.0 107.028 177.072 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.426 ' O ' ' O ' ' C' ' 28' ' ' LYS . 66.2 t . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 117.909 -1.043 . . . . 0.0 110.056 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -107.19 134.31 50.49 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.83 0.348 . . . . 0.0 110.466 -179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -95.98 133.61 39.99 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.827 -179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.56 140.28 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.085 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.477 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 42.0 t-80 -147.5 95.53 2.54 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 121.043 -0.263 . . . . 0.0 111.392 179.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.637 ' NE2' ' ND1' ' N' ' 14' ' ' HIS . 0.3 OUTLIER -161.05 170.9 19.58 Favored 'General case' 0 N--CA 1.469 0.493 0 N-CA-C 113.605 0.965 . . . . 0.0 113.605 178.798 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.427 HE21 ' CD1' ' N' ' 17' ' ' LEU . 50.1 tt0 -97.33 143.47 28.05 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.699 177.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -124.64 118.98 27.73 Favored 'General case' 0 N--CA 1.473 0.723 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.492 ' N ' HD12 ' O' ' 17' ' ' LEU . 4.7 mp -122.76 128.93 51.14 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-O 121.516 0.674 . . . . 0.0 111.337 179.736 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 98.2 t -119.07 111.99 35.78 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.023 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.57 ' CD1' HD13 ' M' ' 32' ' ' ILE . 91.4 m-85 -107.7 108.0 19.04 Favored 'General case' 0 C--O 1.236 0.351 0 N-CA-C 106.18 -1.785 . . . . 0.0 106.18 178.279 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 21.1 t80 -122.87 126.67 47.77 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 113.274 0.842 . . . . 0.0 113.274 -175.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.83 117.06 28.26 Favored 'General case' 0 C--O 1.237 0.422 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . 0.558 ' O ' ' N ' ' O' ' 24' ' ' VAL . 83.5 tt0 -83.43 153.18 24.63 Favored 'General case' 0 N--CA 1.461 0.083 0 N-CA-C 113.438 0.903 . . . . 0.0 113.438 -176.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.562 ' O ' ' O ' ' O' ' 24' ' ' VAL . 65.6 t0 8.66 51.56 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 113.034 -1.894 . . . . 0.0 114.654 -179.155 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.709 HG12 ' H ' ' O' ' 25' ' ' GLY . 11.6 t -55.89 -132.17 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 174.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.709 ' H ' HG12 ' O' ' 24' ' ' VAL . . . 144.47 -29.77 1.88 Allowed Glycine 0 C--O 1.226 -0.365 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.337 175.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.461 ' O ' ' CE ' ' P' ' 28' ' ' LYS . 5.8 t -89.92 -132.89 0.1 Allowed 'General case' 0 CA--C 1.55 0.974 0 CA-C-O 122.986 1.374 . . . . 0.0 113.292 179.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.466 ' H ' ' HB3' ' N' ' 27' ' ' ASN . 12.2 m120 79.28 138.9 0.07 Allowed 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 127.669 2.388 . . . . 0.0 111.22 178.334 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -48.83 -48.45 41.62 Favored 'General case' 0 CA--C 1.541 0.629 0 N-CA-C 117.2 2.296 . . . . 0.0 117.2 176.309 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 176.67 62.48 0.06 OUTLIER Glycine 0 CA--C 1.545 1.921 0 CA-C-O 118.084 -1.398 . . . . 0.0 111.498 -171.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . 0.531 ' HB2' ' HB3' ' N' ' 30' ' ' ALA . . . -52.71 143.92 15.22 Favored 'General case' 0 N--CA 1.483 1.2 0 CA-C-N 120.681 2.241 . . . . 0.0 116.714 -170.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.526 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 70.8 mt -138.79 153.89 25.87 Favored 'Isoleucine or valine' 0 C--N 1.355 0.834 0 CA-C-N 110.942 -2.845 . . . . 0.0 113.871 -175.01 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.556 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 75.5 mt -117.1 110.53 31.57 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 174.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.44 106.96 2.41 Favored Glycine 0 CA--C 1.508 -0.397 0 N-CA-C 104.732 -3.347 . . . . 0.0 104.732 176.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.669 HD12 ' O ' ' N' ' 34' ' ' LEU . 26.7 tp -148.37 139.21 23.01 Favored 'General case' 0 CA--C 1.507 -0.711 0 CA-C-O 122.747 1.26 . . . . 0.0 113.696 -174.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.458 ' H ' HD12 ' O' ' 34' ' ' LEU . 24.5 ttm -114.33 110.98 20.76 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 113.648 -1.615 . . . . 0.0 107.428 176.572 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.458 ' O ' ' HA3' ' P' ' 37' ' ' GLY . 1.7 t -89.91 103.74 14.47 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.784 0 N-CA-C 105.47 -2.048 . . . . 0.0 105.47 178.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . -20.06 144.5 0.01 OUTLIER Glycine 0 N--CA 1.481 1.69 0 C-N-CA 124.136 0.874 . . . . 0.0 115.077 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.515 ' O ' ' CD1' ' C' ' 31' ' ' ILE . . . -100.78 59.12 0.68 Allowed Glycine 0 CA--C 1.541 1.673 0 CA-C-N 115.022 -0.589 . . . . 0.0 113.6 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.805 HG21 ' O ' ' N' ' 38' ' ' GLY . 21.5 t -135.23 161.42 39.68 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-N 117.423 0.611 . . . . 0.0 110.607 179.049 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.499 ' N ' HG12 ' O' ' 39' ' ' VAL . 78.0 t . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.306 179.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.486 2.031 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -105.78 135.26 47.53 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.82 0.343 . . . . 0.0 110.309 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . 0.521 ' N ' ' OE1' ' P' ' 11' ' ' GLU . 57.8 mp0 -111.96 125.34 53.95 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.127 179.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.419 HG22 ' O ' ' Q' ' 11' ' ' GLU . 40.3 t -120.95 127.54 75.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.477 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 0.9 OUTLIER -146.05 105.35 3.92 Favored 'General case' 0 C--N 1.328 -0.354 0 C-N-CA 120.442 -0.503 . . . . 0.0 111.381 -179.307 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 2.1 p-80 -134.1 160.59 37.31 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 178.449 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.742 HE22 ' N ' ' N' ' 37' ' ' GLY . 3.3 mt-30 -89.99 159.22 17.0 Favored 'General case' 0 C--N 1.33 -0.264 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 178.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 65.5 mttm -140.07 103.27 4.58 Favored 'General case' 0 C--N 1.31 -1.135 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 177.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.412 HD22 HG21 ' N' ' 36' ' ' VAL . 5.0 mp -128.88 125.68 38.14 Favored 'General case' 0 CA--C 1.51 -0.574 0 CA-C-O 121.399 0.619 . . . . 0.0 110.657 179.229 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 79.6 t -118.38 117.38 54.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.168 -0.924 . . . . 0.0 108.679 179.211 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.585 ' CD2' HD13 ' N' ' 32' ' ' ILE . 29.4 m-85 -114.01 103.84 11.55 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 106.805 -1.554 . . . . 0.0 106.805 178.668 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.622 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 27.6 t80 -117.64 126.93 53.4 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 120.665 0.269 . . . . 0.0 111.059 -178.053 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.1 115.91 15.66 Favored 'General case' 0 C--O 1.237 0.412 0 CA-C-O 121.062 0.458 . . . . 0.0 111.497 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.545 ' O ' ' N ' ' O' ' 24' ' ' VAL . 80.4 tt0 -92.71 112.81 24.89 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 177.612 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.563 ' O ' ' NZ ' ' P' ' 28' ' ' LYS . 0.0 OUTLIER -139.19 46.76 1.92 Allowed 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.681 -175.909 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.78 HG22 ' H ' ' P' ' 25' ' ' GLY . 7.7 p -73.15 179.92 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.873 0 CA-C-O 121.453 0.644 . . . . 0.0 111.554 -178.133 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.78 ' H ' HG22 ' P' ' 24' ' ' VAL . . . 99.66 -34.66 5.28 Favored Glycine 0 CA--C 1.541 1.692 0 CA-C-O 118.647 -1.085 . . . . 0.0 114.468 179.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.466 ' O ' ' C ' ' P' ' 27' ' ' ASN . 96.2 p -162.24 120.43 2.2 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 120.381 2.09 . . . . 0.0 112.791 176.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.466 ' C ' ' O ' ' P' ' 26' ' ' SER . 65.8 t30 -23.56 141.49 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 123.611 0.569 . . . . 0.0 111.371 177.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' P' ' 23' ' ' ASP . 64.7 mttp -122.24 -32.93 3.58 Favored 'General case' 0 N--CA 1.473 0.714 0 N-CA-C 115.228 1.566 . . . . 0.0 115.228 177.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.33 79.85 0.91 Allowed Glycine 0 CA--C 1.536 1.381 0 N-CA-C 108.343 -1.903 . . . . 0.0 108.343 -176.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.7 144.04 30.9 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-N 118.172 0.986 . . . . 0.0 111.727 -175.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.458 HG23 HG23 ' Q' ' 31' ' ' ILE . 5.8 mt -125.07 138.64 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.675 0 CA-C-N 113.815 -1.538 . . . . 0.0 113.563 -177.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.524 HD13 ' CD1' ' R' ' 19' ' ' PHE . 96.4 mt -118.76 112.35 37.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 176.566 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.98 100.22 1.45 Allowed Glycine 0 CA--C 1.509 -0.302 0 N-CA-C 104.557 -3.417 . . . . 0.0 104.557 175.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.523 ' CD2' HG22 ' P' ' 36' ' ' VAL . 7.7 tt -137.07 138.22 40.16 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-O 123.014 1.387 . . . . 0.0 114.533 -174.588 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 5.5 ttm -104.66 111.44 24.14 Favored 'General case' 0 N--CA 1.444 -0.749 0 CA-C-N 113.002 -1.908 . . . . 0.0 106.909 176.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.523 HG22 ' CD2' ' P' ' 34' ' ' LEU . 3.4 t -85.24 101.65 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.647 0 C-N-CA 118.585 -1.246 . . . . 0.0 108.269 -179.535 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.561 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . . . -88.89 153.91 24.18 Favored Glycine 0 C--N 1.316 -0.579 0 N-CA-C 110.256 -1.137 . . . . 0.0 110.256 177.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.467 ' N ' ' HA2' ' O' ' 38' ' ' GLY . . . 136.68 58.86 0.06 OUTLIER Glycine 0 N--CA 1.466 0.639 0 N-CA-C 112.01 -0.436 . . . . 0.0 112.01 178.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.662 ' CG2' ' H ' ' Q' ' 38' ' ' GLY . 49.7 t -79.51 133.35 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.385 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.463 HG23 ' NE2' ' R' ' 13' ' ' HIS . 9.6 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 117.956 -1.021 . . . . 0.0 111.748 -178.788 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.226 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -105.1 135.37 46.58 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.838 0.351 . . . . 0.0 110.513 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . 0.419 ' O ' HG22 ' P' ' 12' ' ' VAL . 96.8 mt-10 -103.02 122.55 44.85 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.209 179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.588 HG12 ' N ' ' Q' ' 13' ' ' HIS . 46.8 t -142.37 168.16 14.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.07 -0.513 . . . . 0.0 110.689 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.588 ' N ' HG12 ' Q' ' 12' ' ' VAL . 8.3 p80 -64.1 127.47 31.57 Favored 'General case' 0 CA--C 1.536 0.433 0 N-CA-C 113.212 0.819 . . . . 0.0 113.212 -177.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.505 ' O ' ' CB ' ' P' ' 14' ' ' HIS . 7.0 p80 -157.46 168.46 27.26 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.157 178.83 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.561 ' NE2' ' O ' ' P' ' 37' ' ' GLY . 79.1 mt-30 -89.97 151.39 21.72 Favored 'General case' 0 N--CA 1.465 0.276 0 O-C-N 121.921 -0.487 . . . . 0.0 110.313 178.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 74.3 tttt -148.76 106.48 3.68 Favored 'General case' 0 C--N 1.318 -0.779 0 N-CA-C 109.712 -0.477 . . . . 0.0 109.712 178.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.42 ' N ' HD12 ' Q' ' 17' ' ' LEU . 4.5 mp -135.68 124.46 23.92 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 121.264 0.554 . . . . 0.0 111.017 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 92.5 t -108.1 116.29 51.08 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 178.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.556 ' CD1' HD13 ' O' ' 32' ' ' ILE . 60.3 m-85 -112.42 109.23 18.72 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 108.204 -1.036 . . . . 0.0 108.204 179.226 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.622 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 41.4 t80 -125.45 128.17 47.65 Favored 'General case' 0 N--CA 1.473 0.716 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -178.275 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.55 134.3 37.34 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.129 179.227 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . . . . . . . . . 80.4 tt0 -114.74 124.29 51.4 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.337 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.507 ' OD1' ' N ' ' Q' ' 23' ' ' ASP . 12.6 p-10 -147.28 59.73 1.16 Allowed 'General case' 0 N--CA 1.47 0.537 0 CA-C-O 121.382 0.611 . . . . 0.0 111.873 178.253 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.961 HG12 ' H ' ' Q' ' 25' ' ' GLY . 4.8 t 72.07 -174.83 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.018 176.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.961 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . -107.91 29.3 10.46 Favored Glycine 0 CA--C 1.529 0.956 0 CA-C-N 114.217 -1.356 . . . . 0.0 111.312 177.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 48.7 m -65.1 -113.96 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 118.716 1.258 . . . . 0.0 111.223 -176.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 61.4 t30 -155.94 169.19 25.01 Favored 'General case' 0 C--O 1.232 0.136 0 C-N-CA 119.631 -0.827 . . . . 0.0 112.362 179.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt 27.36 43.39 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.224 -1.353 . . . . 0.0 112.723 179.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -99.84 60.25 0.74 Allowed Glycine 0 N--CA 1.475 1.24 0 C-N-CA 120.028 -1.082 . . . . 0.0 112.21 177.521 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.19 118.63 0.57 Allowed 'General case' 0 C--O 1.237 0.419 0 CA-C-N 119.229 1.514 . . . . 0.0 113.043 179.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.61 HD13 HG23 ' K' ' 39' ' ' VAL . 1.7 tt -136.14 125.38 38.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 175.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . 0.477 HG22 ' HG ' ' Q' ' 34' ' ' LEU . 64.5 mt -128.66 133.79 65.77 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.198 -176.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.85 112.57 2.36 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 108.164 -1.974 . . . . 0.0 108.164 177.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.477 ' HG ' HG22 ' Q' ' 32' ' ' ILE . 58.4 mt -119.16 120.44 37.1 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.093 0.473 . . . . 0.0 110.935 -177.47 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 11.0 mtp -124.7 130.92 53.33 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.362 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 3.0 t -105.81 159.86 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.525 0 CA-C-O 121.359 0.6 . . . . 0.0 110.75 -179.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -62.84 -102.77 0.01 OUTLIER Glycine 0 CA--C 1.528 0.854 0 CA-C-N 115.117 -0.947 . . . . 0.0 113.086 -179.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.662 ' H ' ' CG2' ' P' ' 39' ' ' VAL . . . -116.97 -77.17 0.62 Allowed Glycine 0 CA--C 1.534 1.269 0 CA-C-O 119.864 -0.409 . . . . 0.0 113.166 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' R' ' 39' ' ' VAL . 39.3 t -115.01 129.9 70.41 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 117.682 0.741 . . . . 0.0 111.861 -178.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.493 ' N ' ' O ' ' R' ' 40' ' ' VAL . 42.6 t . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.694 179.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.822 -1.311 . . . . 0.0 109.822 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -79.54 138.4 37.49 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 110.045 -0.354 . . . . 0.0 110.045 179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 72.7 mm-40 -111.31 128.58 55.99 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.433 -179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.477 ' H ' HG21 ' Q' ' 12' ' ' VAL . 30.8 t -110.46 93.17 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 CA-C-O 121.451 0.643 . . . . 0.0 110.609 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.517 ' CG ' ' O ' ' R' ' 13' ' ' HIS . 50.1 p-80 -120.32 105.77 11.24 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.545 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.531 ' CG ' ' N ' ' R' ' 15' ' ' GLN . 84.6 t60 -141.11 170.73 15.17 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.752 179.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.531 ' N ' ' CG ' ' R' ' 14' ' ' HIS . 93.0 mm-40 -89.55 150.62 22.35 Favored 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 120.612 -0.435 . . . . 0.0 110.261 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 72.2 tttt -149.59 99.0 2.84 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -139.02 124.78 19.65 Favored 'General case' 0 CA--C 1.514 -0.442 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.529 179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 72.1 t -104.96 118.52 52.48 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.524 ' CD1' HD13 ' P' ' 32' ' ' ILE . 55.3 m-85 -111.92 105.8 14.33 Favored 'General case' 0 C--N 1.332 -0.181 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 179.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 58.5 t80 -130.14 125.7 35.7 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-O 121.61 0.719 . . . . 0.0 112.104 -178.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.59 126.4 38.4 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.269 178.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.428 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 79.1 tt0 -89.21 110.81 21.52 Favored 'General case' 0 N--CA 1.469 0.522 0 C-N-CA 119.938 -0.705 . . . . 0.0 110.965 -178.686 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.448 ' OD2' ' OD2' ' Q' ' 23' ' ' ASP . 54.0 m-20 -163.11 -60.25 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.41 179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.561 HG12 ' N ' ' R' ' 25' ' ' GLY . 98.2 t -55.81 162.49 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.378 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.742 -179.435 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.561 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -157.3 -27.84 0.03 OUTLIER Glycine 0 CA--C 1.52 0.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 93.1 p -80.74 -130.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.268 -0.466 . . . . 0.0 109.912 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.597 ' O ' ' N ' ' R' ' 29' ' ' GLY . 69.0 m-80 -99.18 -164.77 1.16 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.499 -179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -47.76 49.48 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 C-N-CA 125.372 1.469 . . . . 0.0 114.793 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.597 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -101.38 51.76 0.92 Allowed Glycine 0 CA--C 1.55 2.229 0 CA-C-N 119.344 0.974 . . . . 0.0 113.715 -178.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.19 165.61 22.0 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 106.303 -1.74 . . . . 0.0 106.303 176.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.404 HD11 ' CG2' ' L' ' 39' ' ' VAL . 96.6 mt -114.31 112.21 39.19 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.032 0 CA-C-N 119.73 1.15 . . . . 0.0 110.042 178.111 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 95.3 mt -125.73 127.72 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.504 -0.316 . . . . 0.0 110.843 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.66 119.41 3.5 Favored Glycine 0 N--CA 1.468 0.773 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.09 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 48.4 tp -123.25 123.08 39.95 Favored 'General case' 0 CA--C 1.511 -0.529 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 -179.492 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 92.7 mtp -138.38 147.42 43.39 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 112.887 0.699 . . . . 0.0 112.887 -179.177 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 33.2 m -129.06 161.51 38.27 Favored 'Isoleucine or valine' 0 C--O 1.233 0.197 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.123 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.3 -102.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.063 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.501 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.34 -78.02 0.87 Allowed Glycine 0 N--CA 1.475 1.289 0 C-N-CA 121.707 -0.283 . . . . 0.0 112.891 -178.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' Q' ' 39' ' ' VAL . 70.1 t -96.1 132.82 39.4 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.865 0 CA-C-N 117.519 0.659 . . . . 0.0 110.855 -179.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.493 ' O ' ' N ' ' Q' ' 40' ' ' VAL . 10.7 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.444 179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.426 ' O ' ' OE2' ' B' ' 11' ' ' GLU . 95.9 m-85 -83.09 139.87 32.97 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.921 0.391 . . . . 0.0 110.747 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -130.0 146.2 51.68 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.872 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 55.0 t -121.8 131.98 71.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.413 0.625 . . . . 0.0 111.159 -179.439 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 73.1 m80 -117.38 156.82 27.24 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.461 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.512 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.0 OUTLIER -84.21 167.85 16.29 Favored 'General case' 0 C--N 1.33 -0.279 0 C-N-CA 120.342 -0.543 . . . . 0.0 110.918 -179.755 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.426 ' HB3' HE21 ' B' ' 15' ' ' GLN . 69.0 tp60 -159.15 143.26 15.25 Favored 'General case' 0 N--CA 1.452 -0.375 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.632 178.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -80.2 123.5 27.98 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.093 179.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 99.3 mt -125.6 116.28 21.47 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 177.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 p -133.54 134.06 56.97 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.739 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -127.71 131.49 49.73 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 178.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.466 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 55.0 p90 -134.95 130.94 36.61 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.685 0.278 . . . . 0.0 111.374 -178.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.63 120.56 38.4 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 tt0 -136.98 136.16 38.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.406 0.622 . . . . 0.0 112.081 -178.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.9 t0 59.42 47.08 11.58 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 113.715 1.006 . . . . 0.0 113.715 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -101.33 159.15 4.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 N-CA-C 108.301 -1.0 . . . . 0.0 108.301 177.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -62.1 -36.56 93.11 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 120.992 -0.623 . . . . 0.0 111.772 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.494 ' O ' ' O ' ' A' ' 27' ' ' ASN . 28.4 t -152.93 121.87 6.53 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.272 -0.464 . . . . 0.0 109.893 -178.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.494 ' O ' ' O ' ' A' ' 26' ' ' SER . 26.7 t-20 -40.68 167.47 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.351 0 C-N-CA 120.217 -0.593 . . . . 0.0 110.89 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -79.55 39.64 0.41 Allowed 'General case' 0 CA--C 1.535 0.39 0 N-CA-C 113.608 0.966 . . . . 0.0 113.608 -178.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.41 79.36 0.94 Allowed Glycine 0 N--CA 1.47 0.939 0 C-N-CA 117.886 -2.102 . . . . 0.0 110.976 178.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.445 ' O ' ' O ' ' B' ' 29' ' ' GLY . . . -81.41 74.81 8.39 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-N 119.589 1.695 . . . . 0.0 113.955 -175.947 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.67 ' CD1' HG12 ' M' ' 39' ' ' VAL . 89.7 mt -145.39 122.58 4.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 N-CA-C 105.972 -1.862 . . . . 0.0 105.972 177.107 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 97.1 mt -116.86 122.97 71.19 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 CA-C-O 121.344 0.592 . . . . 0.0 112.109 -177.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.91 101.2 0.67 Allowed Glycine 0 C--N 1.319 -0.41 0 N-CA-C 105.311 -3.116 . . . . 0.0 105.311 176.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -156.71 153.71 28.88 Favored 'General case' 0 C--O 1.241 0.629 0 C-N-CA 118.128 -1.429 . . . . 0.0 113.617 -176.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 84.5 mmm -99.31 120.78 40.13 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 112.714 -2.039 . . . . 0.0 108.055 178.217 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.601 ' HB ' HG12 ' B' ' 36' ' ' VAL . 2.8 t -111.39 124.6 68.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 66.62 -114.22 6.29 Favored Glycine 0 CA--C 1.528 0.889 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.42 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 97.17 -71.51 0.73 Allowed Glycine 0 CA--C 1.539 1.58 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -178.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.455 ' H ' HG23 ' A' ' 39' ' ' VAL . 2.6 t -66.23 159.25 4.53 Favored 'Isoleucine or valine' 0 C--N 1.34 0.189 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 178.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.444 ' C ' ' O ' ' A' ' 39' ' ' VAL . 7.7 p . . . . . 0 C--O 1.22 -0.493 0 CA-C-O 117.982 -1.009 . . . . 0.0 111.793 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.23 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . 0.49 ' CD2' ' O ' ' C' ' 9' ' ' GLY . 92.1 m-85 -98.43 132.32 43.98 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 110.188 -0.301 . . . . 0.0 110.188 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' A' ' 10' ' ' TYR . 97.0 mt-10 -138.03 139.81 39.78 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 121.013 0.435 . . . . 0.0 111.304 -179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.47 ' CG1' ' HE2' ' A' ' 14' ' ' HIS . 74.2 t -124.42 130.89 73.44 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 N-CA-C 108.329 -0.989 . . . . 0.0 108.329 179.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -117.55 98.05 6.19 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 111.965 0.357 . . . . 0.0 111.965 -178.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' N ' ' B' ' 15' ' ' GLN . 11.5 t60 -160.61 164.54 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.375 177.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.542 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 50.9 tt0 -158.1 142.33 15.92 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 120.748 -0.381 . . . . 0.0 110.319 178.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -84.52 121.25 27.34 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.022 178.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.604 ' C ' HD23 ' B' ' 17' ' ' LEU . 6.4 tt -136.22 121.32 18.93 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-N 118.706 0.685 . . . . 0.0 110.831 178.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.548 ' N ' HD23 ' B' ' 17' ' ' LEU . 13.9 m -134.65 141.4 43.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.937 -179.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -128.32 127.03 41.95 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.184 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 31.1 m-85 -123.24 129.58 51.57 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.743 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.0 119.65 31.02 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 178.456 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -138.84 164.04 30.68 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-O 121.001 0.429 . . . . 0.0 111.545 -178.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.58 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 54.2 t0 42.0 47.57 3.83 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.082 0.771 . . . . 0.0 113.082 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -81.58 163.4 3.24 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 C-N-CA 117.786 -1.565 . . . . 0.0 108.567 -179.518 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.61 -38.16 57.52 Favored Glycine 0 CA--C 1.533 1.18 0 N-CA-C 116.197 1.239 . . . . 0.0 116.197 -177.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.62 ' O ' ' O ' ' B' ' 27' ' ' ASN . 45.9 t -162.54 117.24 1.81 Allowed 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 114.933 1.457 . . . . 0.0 114.933 -176.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.746 HD21 ' N ' ' C' ' 28' ' ' LYS . 55.2 t-20 -22.02 153.29 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.212 0 O-C-N 123.933 0.771 . . . . 0.0 111.713 175.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.545 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 62.7 tttt -163.29 24.56 0.09 Allowed 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' A' ' 30' ' ' ALA . . . 89.53 106.64 1.16 Allowed Glycine 0 N--CA 1.468 0.805 0 C-N-CA 118.396 -1.859 . . . . 0.0 113.814 177.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.89 101.83 10.38 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-O 122.734 1.254 . . . . 0.0 109.881 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.7 HD11 ' HB ' ' N' ' 39' ' ' VAL . 91.8 mt -119.61 129.44 75.34 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 CA-C-N 114.22 -1.355 . . . . 0.0 110.641 -179.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.43 ' CG2' HD12 ' B' ' 34' ' ' LEU . 49.7 mt -109.95 111.24 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.114 0.483 . . . . 0.0 109.82 177.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.21 99.21 0.99 Allowed Glycine 0 C--O 1.238 0.396 0 N-CA-C 105.885 -2.886 . . . . 0.0 105.885 177.067 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.629 ' O ' HD23 ' C' ' 34' ' ' LEU . 80.0 mt -138.24 145.67 41.65 Favored 'General case' 0 CA--C 1.499 -1.001 0 CA-C-O 122.792 1.282 . . . . 0.0 113.139 -175.242 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 10.7 mtp -116.36 109.44 17.35 Favored 'General case' 0 C--N 1.311 -1.1 0 CA-C-N 112.837 -1.983 . . . . 0.0 107.473 177.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.601 HG12 ' HB ' ' A' ' 36' ' ' VAL . 2.8 m -132.88 123.19 48.12 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.282 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 179.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.742 ' H ' HE22 ' D' ' 15' ' ' GLN . . . 144.85 -113.4 0.72 Allowed Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.204 -1.158 . . . . 0.0 110.204 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.684 ' O ' HG13 ' B' ' 39' ' ' VAL . . . 76.94 -72.97 2.0 Allowed Glycine 0 CA--C 1.535 1.3 0 N-CA-C 111.084 -0.806 . . . . 0.0 111.084 -178.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.684 HG13 ' O ' ' B' ' 38' ' ' GLY . 2.9 m -166.67 118.92 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.173 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.551 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 17.2 m . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 117.995 -1.003 . . . . 0.0 110.746 179.738 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . 0.49 ' O ' ' CD2' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.606 -1.398 . . . . 0.0 109.606 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -122.47 140.38 52.8 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.731 0.3 . . . . 0.0 110.34 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.499 ' OE1' ' N ' ' C' ' 11' ' ' GLU . 57.6 mp0 -76.52 115.82 16.63 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.059 -179.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.411 ' O ' ' CD2' ' C' ' 13' ' ' HIS . 26.7 m -137.01 159.76 36.65 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.242 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.473 ' O ' ' CB ' ' D' ' 13' ' ' HIS . 6.3 m80 -145.71 132.27 19.82 Favored 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.025 -179.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.489 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 6.8 m-70 -150.57 170.9 18.03 Favored 'General case' 0 C--N 1.328 -0.345 0 C-N-CA 120.501 -0.48 . . . . 0.0 110.074 177.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 67.2 tp60 -138.53 140.83 39.25 Favored 'General case' 0 CA--C 1.519 -0.235 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 177.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -130.02 106.12 8.42 Favored 'General case' 0 C--N 1.318 -0.764 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.413 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 13.0 mt -118.34 113.86 22.06 Favored 'General case' 0 N--CA 1.468 0.44 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 176.803 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 50.0 t -108.47 116.27 51.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 N-CA-C 109.102 -0.703 . . . . 0.0 109.102 179.016 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -109.37 106.16 15.84 Favored 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 106.963 -1.495 . . . . 0.0 106.963 178.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -120.81 127.97 52.43 Favored 'General case' 0 N--CA 1.479 0.99 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -176.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.62 131.36 35.71 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 121.124 0.488 . . . . 0.0 111.164 179.607 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.489 ' O ' ' CG ' ' C' ' 23' ' ' ASP . 77.4 tt0 -146.46 101.9 3.53 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 113.659 0.985 . . . . 0.0 113.659 -179.067 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.58 ' OD2' ' N ' ' B' ' 23' ' ' ASP . 70.5 m-20 -175.86 -71.83 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 175.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.622 HG13 ' O ' ' C' ' 24' ' ' VAL . 11.2 p -78.75 114.78 19.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.069 -1.423 . . . . 0.0 107.54 175.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.421 ' HA3' HG22 ' D' ' 24' ' ' VAL . . . -91.23 -39.26 5.74 Favored Glycine 0 N--CA 1.461 0.336 0 C-N-CA 117.408 -2.33 . . . . 0.0 109.044 -179.702 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 5.0 t -93.15 111.47 23.12 Favored 'General case' 0 N--CA 1.461 0.117 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 173.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 19.4 m120 -79.85 171.41 15.15 Favored 'General case' 0 C--N 1.33 -0.261 0 C-N-CA 118.017 -1.473 . . . . 0.0 109.996 177.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.746 ' N ' HD21 ' B' ' 27' ' ' ASN . 99.0 mttt -50.37 -36.88 34.41 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 122.207 1.003 . . . . 0.0 109.472 174.746 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -179.19 76.72 0.06 OUTLIER Glycine 0 CA--C 1.54 1.642 0 CA-C-N 113.372 -1.74 . . . . 0.0 110.175 -178.119 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.498 ' O ' ' HB1' ' D' ' 30' ' ' ALA . . . -80.19 129.79 34.75 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 119.323 1.562 . . . . 0.0 113.104 -176.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.924 HG22 HG22 ' D' ' 31' ' ' ILE . 46.8 pt -144.61 146.22 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.983 -177.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 76.9 mt -108.96 116.35 51.79 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.621 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.689 178.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.8 102.99 1.66 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.247 -3.141 . . . . 0.0 105.247 175.599 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.629 HD23 ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -134.93 141.02 46.18 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 114.21 1.189 . . . . 0.0 114.21 -175.122 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.65 113.29 26.48 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 175.201 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.491 HG22 HD22 ' C' ' 34' ' ' LEU . 3.1 t -129.46 134.42 63.61 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 -177.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.86 -104.29 0.28 Allowed Glycine 0 C--N 1.305 -1.145 0 N-CA-C 110.319 -1.112 . . . . 0.0 110.319 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' C' ' 39' ' ' VAL . . . 46.87 70.73 0.63 Allowed Glycine 0 CA--C 1.537 1.423 0 C-N-CA 120.363 -0.922 . . . . 0.0 112.478 -179.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.882 HG13 ' O ' ' D' ' 39' ' ' VAL . 6.3 t -6.78 120.24 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.484 1.233 0 N-CA-C 113.647 0.98 . . . . 0.0 113.647 -178.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.539 ' OXT' ' CE1' ' E' ' 13' ' ' HIS . 26.8 m . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.156 179.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.473 0 N-CA-C 109.946 -1.262 . . . . 0.0 109.946 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 26.3 p90 -147.66 158.36 43.98 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-O 120.892 0.377 . . . . 0.0 110.729 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.407 ' H ' ' HG2' ' E' ' 11' ' ' GLU . 97.5 mt-10 -134.33 121.68 21.56 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.568 179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.436 HG12 ' H ' ' E' ' 12' ' ' VAL . 4.5 m -129.25 132.55 66.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.678 -0.489 . . . . 0.0 109.678 179.498 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.551 ' CE1' ' O ' ' B' ' 40' ' ' VAL . 2.1 p80 -147.78 138.46 23.21 Favored 'General case' 0 N--CA 1.468 0.466 0 C-N-CA 120.894 -0.322 . . . . 0.0 111.702 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.546 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 0.2 OUTLIER -145.91 158.67 43.86 Favored 'General case' 0 N--CA 1.465 0.299 0 C-N-CA 120.695 -0.402 . . . . 0.0 111.052 178.454 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.742 HE22 ' H ' ' B' ' 37' ' ' GLY . 84.8 mt-30 -90.43 158.19 17.2 Favored 'General case' 0 N--CA 1.455 -0.196 0 N-CA-C 107.554 -1.276 . . . . 0.0 107.554 174.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.481 ' C ' HD22 ' D' ' 17' ' ' LEU . 98.7 mttt -141.37 103.08 4.35 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 176.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.907 HD22 ' N ' ' D' ' 17' ' ' LEU . 0.1 OUTLIER -118.69 119.41 34.37 Favored 'General case' 0 N--CA 1.47 0.549 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 179.053 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 82.8 t -112.94 112.26 39.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 179.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 44.7 m-85 -110.92 103.96 12.5 Favored 'General case' 0 C--O 1.232 0.181 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -114.29 118.84 35.04 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.831 -0.168 . . . . 0.0 110.926 -178.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.14 118.4 8.95 Favored 'General case' 0 C--O 1.246 0.883 0 CA-C-O 122.147 0.975 . . . . 0.0 111.742 179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -178.09 158.96 1.26 Allowed 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 114.387 -1.279 . . . . 0.0 111.073 -179.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.449 ' OD2' ' O ' ' C' ' 23' ' ' ASP . 35.2 t70 -173.06 -59.91 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.338 0 N-CA-C 114.167 1.173 . . . . 0.0 114.167 177.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.843 HG23 ' H ' ' D' ' 26' ' ' SER . 3.0 m -77.96 -178.99 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 C-N-CA 118.896 -1.121 . . . . 0.0 113.208 -176.609 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -89.71 19.82 38.85 Favored Glycine 0 CA--C 1.532 1.134 0 CA-C-N 114.044 -1.435 . . . . 0.0 113.081 179.435 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.843 ' H ' HG23 ' D' ' 24' ' ' VAL . 8.9 t -126.65 151.16 48.43 Favored 'General case' 0 N--CA 1.477 0.913 0 CA-C-N 118.309 1.055 . . . . 0.0 112.775 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.489 HD22 ' H ' ' E' ' 26' ' ' SER . 57.9 t-20 -52.36 137.27 29.55 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.276 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.411 ' CB ' ' O ' ' E' ' 22' ' ' GLU . 87.1 tttt -63.5 -50.97 67.53 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.568 -0.742 . . . . 0.0 112.884 -177.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.66 50.35 3.15 Favored Glycine 0 CA--C 1.541 1.673 0 C-N-CA 119.949 -1.12 . . . . 0.0 110.755 179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.498 ' HB1' ' O ' ' C' ' 30' ' ' ALA . . . -130.58 -179.9 5.55 Favored 'General case' 0 C--N 1.348 0.537 0 CA-C-N 118.803 1.301 . . . . 0.0 114.033 -174.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.924 HG22 HG22 ' C' ' 31' ' ' ILE . 16.3 tt -136.37 144.74 32.08 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.04 0 CA-C-N 113.281 -1.781 . . . . 0.0 112.717 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.442 HD13 ' CD1' ' F' ' 19' ' ' PHE . 4.6 mt -103.92 109.88 28.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 N-CA-C 106.084 -1.821 . . . . 0.0 106.084 175.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.6 104.26 0.88 Allowed Glycine 0 N--CA 1.466 0.697 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -157.28 157.71 34.73 Favored 'General case' 0 C--O 1.245 0.835 0 CA-C-O 123.879 1.8 . . . . 0.0 114.019 -178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.437 ' O ' ' O ' ' C' ' 36' ' ' VAL . 0.9 OUTLIER -97.1 119.5 35.7 Favored 'General case' 0 N--CA 1.435 -1.207 0 CA-C-N 110.516 -3.038 . . . . 0.0 108.683 178.371 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' E' ' 35' ' ' MET . 38.3 t -121.86 142.41 38.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.893 0 N-CA-C 105.683 -1.969 . . . . 0.0 105.683 178.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.563 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 165.25 -102.14 0.19 Allowed Glycine 0 C--N 1.296 -1.666 0 N-CA-C 109.682 -1.367 . . . . 0.0 109.682 -176.898 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' D' ' 39' ' ' VAL . . . 47.56 71.39 0.56 Allowed Glycine 0 CA--C 1.526 0.772 0 C-N-CA 120.048 -1.072 . . . . 0.0 110.643 -178.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.882 ' O ' HG13 ' C' ' 39' ' ' VAL . 59.4 t -22.53 142.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 123.642 0.777 . . . . 0.0 112.886 -178.359 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.477 HG13 HG12 ' D' ' 39' ' ' VAL . 16.6 m . . . . . 0 N--CA 1.471 0.622 0 CA-C-O 117.742 -1.123 . . . . 0.0 111.053 -178.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -72.46 125.7 28.05 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.733 0.302 . . . . 0.0 110.543 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.407 ' HG2' ' H ' ' D' ' 11' ' ' GLU . 96.3 mt-10 -148.39 130.87 15.76 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.629 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.436 ' H ' HG12 ' D' ' 12' ' ' VAL . 8.4 m -134.01 131.11 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 CA-C-O 121.032 0.444 . . . . 0.0 110.79 179.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.539 ' CE1' ' OXT' ' C' ' 40' ' ' VAL . 3.4 p80 -150.21 146.55 26.9 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.875 179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.472 ' H ' ' CD2' ' D' ' 14' ' ' HIS . 41.5 m-70 -147.52 162.57 38.81 Favored 'General case' 0 C--O 1.223 -0.339 0 CA-C-O 121.09 0.472 . . . . 0.0 111.49 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.523 ' NE2' ' OE1' ' D' ' 15' ' ' GLN . 56.6 tp60 -85.17 157.26 20.7 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.28 -1.378 . . . . 0.0 107.28 176.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.684 ' C ' HD12 ' E' ' 17' ' ' LEU . 86.7 tttt -159.45 98.41 1.4 Allowed 'General case' 0 C--N 1.312 -1.046 0 C-N-CA 118.473 -1.291 . . . . 0.0 112.378 179.524 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.684 HD12 ' C ' ' E' ' 16' ' ' LYS . 5.9 mp -122.26 123.13 40.74 Favored 'General case' 0 CA--C 1.512 -0.518 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 176.586 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 3.9 p -120.51 118.89 58.1 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.521 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.415 ' CE1' ' CE1' ' F' ' 19' ' ' PHE . 17.3 m-85 -108.91 105.71 15.36 Favored 'General case' 0 N--CA 1.452 -0.329 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 24.0 t80 -108.53 114.45 28.29 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.539 ' O ' ' HB1' ' F' ' 21' ' ' ALA . . . -164.48 173.48 12.04 Favored 'General case' 0 N--CA 1.466 0.366 0 C-N-CA 117.609 -1.636 . . . . 0.0 114.736 -177.819 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.411 ' O ' ' CB ' ' D' ' 28' ' ' LYS . 73.4 mt-10 -77.75 141.18 39.43 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 177.339 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 15.0 t0 -175.41 47.63 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.907 0 CA-C-O 120.475 0.179 . . . . 0.0 110.616 -177.51 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.858 HG12 ' H ' ' E' ' 25' ' ' GLY . 11.7 t -61.05 -179.09 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-O 121.638 0.732 . . . . 0.0 112.219 -176.299 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.858 ' H ' HG12 ' E' ' 24' ' ' VAL . . . -100.89 28.69 14.82 Favored Glycine 0 N--CA 1.467 0.716 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.366 -178.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.489 ' H ' HD22 ' D' ' 27' ' ' ASN . 19.6 m -83.56 -119.97 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 112.479 0.548 . . . . 0.0 112.479 -177.31 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.558 ' O ' ' N ' ' E' ' 29' ' ' GLY . 8.5 m120 -91.35 -151.53 0.26 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.852 -175.765 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 64.7 mttp 44.1 -47.4 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.681 0 N-CA-C 116.161 1.911 . . . . 0.0 116.161 -176.652 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.558 ' N ' ' O ' ' E' ' 27' ' ' ASN . . . 130.98 60.54 0.09 OUTLIER Glycine 0 N--CA 1.49 2.252 0 CA-C-N 122.629 2.468 . . . . 0.0 115.899 179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.83 116.92 11.69 Favored 'General case' 0 CA--C 1.55 0.945 0 CA-C-N 119.301 1.55 . . . . 0.0 110.771 179.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.499 HD11 ' HB ' ' Q' ' 39' ' ' VAL . 77.6 mt -125.26 146.75 30.42 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.641 -1.163 . . . . 0.0 111.798 -177.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -134.2 113.62 17.81 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 O-C-N 121.438 -0.789 . . . . 0.0 110.426 178.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.82 107.53 2.02 Favored Glycine 0 N--CA 1.47 0.923 0 N-CA-C 108.738 -1.745 . . . . 0.0 108.738 178.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 20.4 tp -128.4 120.5 27.08 Favored 'General case' 0 C--O 1.238 0.482 0 CA-C-O 121.288 0.566 . . . . 0.0 112.271 -177.234 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.434 ' O ' ' O ' ' D' ' 36' ' ' VAL . 53.3 tpp -106.69 121.18 43.83 Favored 'General case' 0 N--CA 1.474 0.774 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.154 177.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.515 ' O ' ' O ' ' E' ' 37' ' ' GLY . 83.7 t -109.42 102.49 14.08 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 N-CA-C 112.239 0.459 . . . . 0.0 112.239 -179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.515 ' O ' ' O ' ' E' ' 36' ' ' VAL . . . -22.66 152.95 0.0 OUTLIER Glycine 0 N--CA 1.479 1.518 0 CA-C-N 115.673 -0.694 . . . . 0.0 114.296 179.39 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . -54.94 -54.41 33.79 Favored Glycine 0 CA--C 1.542 1.732 0 CA-C-O 119.004 -0.887 . . . . 0.0 114.492 -179.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.6 HG23 HD11 ' K' ' 31' ' ' ILE . 70.5 t -102.89 130.53 52.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 119.17 1.485 . . . . 0.0 110.395 -179.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 6.3 t . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.908 -1.044 . . . . 0.0 110.692 -179.663 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.451 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -148.99 158.39 44.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-O 120.768 0.318 . . . . 0.0 110.753 -179.928 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -117.71 131.26 56.64 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.752 -179.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 2.2 t -122.41 122.84 67.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-O 121.167 0.508 . . . . 0.0 110.842 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.709 ' N ' ' HD1' ' F' ' 13' ' ' HIS . 0.3 OUTLIER -154.64 121.59 5.55 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 115.462 -0.79 . . . . 0.0 111.265 179.753 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.627 ' C ' ' HD1' ' F' ' 14' ' ' HIS . 0.1 OUTLIER -151.8 166.25 31.95 Favored 'General case' 0 N--CA 1.469 0.481 0 N-CA-C 109.781 -0.452 . . . . 0.0 109.781 178.853 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.563 HE22 ' H ' ' D' ' 37' ' ' GLY . 12.3 tt0 -89.82 156.68 18.33 Favored 'General case' 0 CA--C 1.531 0.221 0 N-CA-C 109.392 -0.596 . . . . 0.0 109.392 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . 0.465 ' C ' HD22 ' F' ' 17' ' ' LEU . 76.7 tttt -141.83 101.55 3.98 Favored 'General case' 0 C--N 1.318 -0.761 0 C-N-CA 120.729 -0.389 . . . . 0.0 110.862 178.379 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.909 HD22 ' N ' ' F' ' 17' ' ' LEU . 0.2 OUTLIER -118.0 111.68 19.26 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 178.24 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 93.8 t -107.77 110.04 30.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.442 ' CD1' HD13 ' D' ' 32' ' ' ILE . 29.3 m-85 -106.31 103.29 12.73 Favored 'General case' 0 CA--C 1.514 -0.407 0 N-CA-C 107.613 -1.255 . . . . 0.0 107.613 178.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -123.31 129.48 51.39 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.619 0.723 . . . . 0.0 110.589 -178.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.539 ' HB1' ' O ' ' E' ' 21' ' ' ALA . . . -147.63 149.03 31.74 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 120.042 -0.663 . . . . 0.0 109.372 179.458 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -69.31 121.73 17.47 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 119.752 -0.779 . . . . 0.0 109.695 -178.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.463 ' OD1' ' OG ' ' F' ' 26' ' ' SER . 67.4 t0 -154.35 46.59 0.58 Allowed 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 112.657 0.614 . . . . 0.0 112.657 -178.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.53 HG12 ' N ' ' F' ' 25' ' ' GLY . 53.3 t -100.98 163.77 3.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 N-CA-C 106.797 -1.557 . . . . 0.0 106.797 176.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.53 ' N ' HG12 ' F' ' 24' ' ' VAL . . . 70.87 29.19 69.54 Favored Glycine 0 CA--C 1.528 0.891 0 C-N-CA 119.717 -1.23 . . . . 0.0 110.87 178.2 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.463 ' OG ' ' OD1' ' F' ' 23' ' ' ASP . 22.3 p -155.73 111.97 3.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.206 0.527 . . . . 0.0 111.377 -177.306 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -49.45 178.85 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.297 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -70.27 46.45 0.08 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.415 -177.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.17 58.62 2.76 Favored Glycine 0 CA--C 1.548 2.12 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.075 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.51 172.03 18.59 Favored 'General case' 0 CA--C 1.514 -0.415 0 N-CA-C 107.03 -1.47 . . . . 0.0 107.03 179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 10.4 tt -133.13 136.3 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.236 0 CA-C-O 122.103 0.954 . . . . 0.0 112.704 -179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 89.9 mt -122.17 131.9 72.16 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 CA-C-N 114.221 -1.354 . . . . 0.0 111.34 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.76 119.93 3.66 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 109.823 -1.311 . . . . 0.0 109.823 178.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 50.9 tp -125.47 126.52 45.04 Favored 'General case' 0 CA--C 1.515 -0.378 0 N-CA-C 109.005 -0.739 . . . . 0.0 109.005 -179.221 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mtp -142.53 142.39 32.23 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 113.808 1.04 . . . . 0.0 113.808 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.598 HG22 ' N ' ' F' ' 37' ' ' GLY . 2.3 p -140.78 171.39 12.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 177.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.598 ' N ' HG22 ' F' ' 36' ' ' VAL . . . -168.03 94.15 0.11 Allowed Glycine 0 C--N 1.306 -1.086 0 C-N-CA 119.202 -1.475 . . . . 0.0 111.887 179.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . 0.503 ' O ' HG23 ' F' ' 39' ' ' VAL . . . 165.27 -81.44 0.11 Allowed Glycine 0 CA--C 1.529 0.929 0 C-N-CA 120.601 -0.809 . . . . 0.0 112.308 176.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.503 HG23 ' O ' ' F' ' 38' ' ' GLY . 40.2 t -156.5 130.99 1.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 CA-C-O 121.488 0.661 . . . . 0.0 110.45 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 26.0 m . . . . . 0 C--O 1.221 -0.44 0 CA-C-O 117.858 -1.068 . . . . 0.0 110.636 179.765 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.451 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -112.39 138.12 49.58 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.881 0.372 . . . . 0.0 110.948 -179.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -84.53 147.12 27.21 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.982 179.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 46.4 t -123.37 133.19 69.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 121.042 0.448 . . . . 0.0 110.486 -179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 79.5 m80 -110.0 151.28 27.35 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.152 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.665 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 0.2 OUTLIER -84.33 168.02 16.01 Favored 'General case' 0 CA--C 1.534 0.357 0 CA-C-O 121.175 0.512 . . . . 0.0 110.838 -179.371 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.665 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 99.6 mm-40 -154.97 142.35 19.57 Favored 'General case' 0 C--O 1.231 0.121 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 178.318 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -84.7 121.82 28.2 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.745 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 92.5 mt -126.25 127.92 46.38 Favored 'General case' 0 N--CA 1.472 0.661 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 177.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -141.4 139.14 32.73 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.907 0.384 . . . . 0.0 111.595 -179.137 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -135.79 137.16 41.32 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.246 0.546 . . . . 0.0 110.747 179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.486 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 53.6 p90 -132.9 130.2 39.36 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 116.014 -0.539 . . . . 0.0 111.439 -178.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.83 125.86 48.6 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.622 0.725 . . . . 0.0 111.298 179.741 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.557 ' O ' ' N ' ' G' ' 24' ' ' VAL . 13.0 pt-20 -156.5 -121.25 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.151 -0.931 . . . . 0.0 108.961 -178.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 55.5 p30 -52.61 47.76 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.779 0 C-N-CA 124.425 1.09 . . . . 0.0 113.688 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.598 HG12 ' H ' ' G' ' 25' ' ' GLY . 1.7 t -99.72 -161.28 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 -178.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.598 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -72.41 -33.29 61.47 Favored Glycine 0 CA--C 1.527 0.816 0 C-N-CA 119.188 -1.482 . . . . 0.0 113.654 -175.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 89.5 p -153.48 123.83 7.07 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 119.421 1.611 . . . . 0.0 112.175 176.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.57 ' ND2' ' H ' ' H' ' 25' ' ' GLY . 71.0 m-20 -39.14 135.39 0.97 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.074 175.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -110.59 -39.78 4.79 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-O 122.437 1.113 . . . . 0.0 108.601 175.367 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.483 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 79.6 -69.35 3.03 Favored Glycine 0 CA--C 1.536 1.396 0 CA-C-N 113.037 -1.892 . . . . 0.0 113.061 178.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.483 ' HB2' ' O ' ' G' ' 29' ' ' GLY . . . 179.45 79.98 0.01 OUTLIER 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 118.162 0.981 . . . . 0.0 113.245 176.673 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 81.1 mt -122.25 107.07 18.92 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 119.978 1.263 . . . . 0.0 107.612 176.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.41 HD13 ' CD1' ' I' ' 19' ' ' PHE . 93.9 mt -122.29 112.08 33.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 121.436 0.636 . . . . 0.0 112.393 -177.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.64 103.54 1.46 Allowed Glycine 0 N--CA 1.461 0.328 0 N-CA-C 105.279 -3.128 . . . . 0.0 105.279 175.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 90.0 mt -143.29 162.89 34.47 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 123.556 1.646 . . . . 0.0 115.174 -175.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 24.8 tpp -113.19 107.72 16.3 Favored 'General case' 0 N--CA 1.442 -0.842 0 CA-C-N 111.367 -2.651 . . . . 0.0 104.087 175.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 27.4 t -122.25 131.61 72.82 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.396 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -177.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 80.73 -111.33 3.27 Favored Glycine 0 CA--C 1.521 0.415 0 N-CA-C 110.381 -1.088 . . . . 0.0 110.381 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.447 ' O ' HG12 ' H' ' 39' ' ' VAL . . . 74.5 -73.92 1.34 Allowed Glycine 0 CA--C 1.53 1.001 0 N-CA-C 110.358 -1.097 . . . . 0.0 110.358 -179.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 1.3 t -79.62 168.59 1.89 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 N-CA-C 108.706 -0.849 . . . . 0.0 108.706 177.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 67.5 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.813 179.888 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -107.09 138.53 43.09 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.836 0.351 . . . . 0.0 110.792 -179.87 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -126.86 140.73 52.13 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.024 -0.534 . . . . 0.0 109.719 179.544 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 56.0 t -122.95 131.63 72.91 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-O 120.869 0.366 . . . . 0.0 110.133 -179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 98.4 m-70 -124.75 159.56 30.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.053 -0.521 . . . . 0.0 109.977 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.523 ' CD2' ' H ' ' I' ' 14' ' ' HIS . 83.8 m-70 -119.25 172.98 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.6 -0.518 . . . . 0.0 109.6 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -92.53 149.33 21.43 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -101.42 128.24 47.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 178.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 42.8 tp -122.84 124.51 43.44 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 121.04 0.448 . . . . 0.0 111.377 -179.341 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 63.3 t -118.93 124.8 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 N-CA-C 108.61 -0.885 . . . . 0.0 108.61 178.098 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 t80 -133.4 126.62 31.66 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -179.224 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.402 ' CZ ' ' HB3' ' G' ' 20' ' ' PHE . 37.4 p90 -145.33 143.51 30.2 Favored 'General case' 0 N--CA 1.465 0.303 0 C-N-CA 119.141 -1.024 . . . . 0.0 112.379 178.773 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.99 123.83 43.38 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 114.811 -1.086 . . . . 0.0 108.942 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -143.73 162.77 35.15 Favored 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 120.126 -0.63 . . . . 0.0 112.509 -178.22 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 59.92 47.2 10.24 Favored 'General case' 0 C--O 1.234 0.254 0 CA-C-N 115.054 -0.976 . . . . 0.0 112.742 177.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.609 HG12 ' H ' ' H' ' 26' ' ' SER . 2.4 t -83.4 166.96 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 C-N-CA 116.515 -2.074 . . . . 0.0 107.26 -179.263 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.57 ' H ' ' ND2' ' G' ' 27' ' ' ASN . . . -72.37 -36.33 59.5 Favored Glycine 0 C--N 1.339 0.741 0 C-N-CA 119.628 -1.272 . . . . 0.0 114.723 178.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.768 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.8 t -174.14 126.66 0.35 Allowed 'General case' 0 C--O 1.224 -0.273 0 CA-C-O 117.723 -1.132 . . . . 0.0 112.147 -176.595 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.768 ' O ' ' O ' ' H' ' 26' ' ' SER . 10.8 t30 -2.44 146.4 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.644 0 N-CA-C 114.068 1.136 . . . . 0.0 114.068 175.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 58.9 tttt -159.31 30.34 0.2 Allowed 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.486 ' HA3' HG21 ' B' ' 39' ' ' VAL . . . 82.72 89.24 0.69 Allowed Glycine 0 C--N 1.345 1.044 0 C-N-CA 117.17 -2.443 . . . . 0.0 114.108 176.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.524 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -110.41 102.65 11.26 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 123.371 1.558 . . . . 0.0 112.045 -178.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.574 HD11 HG13 ' B' ' 39' ' ' VAL . 80.7 mt -123.02 131.01 74.07 Favored 'Isoleucine or valine' 0 C--O 1.237 0.404 0 CA-C-N 112.765 -2.016 . . . . 0.0 110.651 -179.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.584 HD13 ' CD1' ' J' ' 19' ' ' PHE . 81.3 mt -113.21 108.75 26.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 N-CA-C 106.841 -1.54 . . . . 0.0 106.841 175.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.66 121.82 4.5 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.561 -1.015 . . . . 0.0 110.561 -178.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.643 ' CD2' HD11 ' I' ' 34' ' ' LEU . 0.8 OUTLIER -169.49 163.16 10.36 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-O 123.904 1.811 . . . . 0.0 113.91 -179.925 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 3.4 mtp -100.21 116.55 32.47 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-N 111.483 -2.598 . . . . 0.0 108.576 179.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.532 HG12 ' NE2' ' J' ' 15' ' ' GLN . 53.8 t -127.8 123.69 61.53 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.565 0 N-CA-C 107.372 -1.344 . . . . 0.0 107.372 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.13 -114.35 2.26 Favored Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.325 -1.11 . . . . 0.0 110.325 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.412 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.35 -72.68 2.77 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 -178.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.54 ' HB ' HG21 ' N' ' 31' ' ' ILE . 2.5 p -152.07 151.23 12.29 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.208 0 O-C-N 122.7 -0.294 . . . . 0.0 110.47 177.631 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.621 HG21 ' CD2' ' J' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.218 -0.563 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.454 178.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.76 161.4 41.29 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.74 0.305 . . . . 0.0 110.448 -179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -129.41 139.24 51.72 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.578 -179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 4.7 m -126.89 136.46 60.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.225 179.923 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.0 m-70 -138.91 93.62 2.72 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.644 -0.253 . . . . 0.0 111.537 -179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.523 ' H ' ' CD2' ' H' ' 14' ' ' HIS . 52.3 p-80 -157.1 153.47 27.86 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 118.793 -1.163 . . . . 0.0 112.52 176.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 20.2 tt0 -90.81 161.49 15.25 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.748 176.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -139.47 110.98 7.08 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 177.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' I' ' 17' ' ' LEU . 4.3 mp -129.47 131.63 46.73 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 121.264 0.554 . . . . 0.0 110.942 178.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 76.0 t -121.15 120.14 61.27 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.304 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.41 ' CD1' HD13 ' G' ' 32' ' ' ILE . 61.3 m-85 -118.53 111.16 18.26 Favored 'General case' 0 CA--C 1.54 0.58 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 62.1 t80 -121.66 135.21 54.98 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 122.311 -0.243 . . . . 0.0 111.358 -178.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 1.113 ' HB1' ' HZ1' ' I' ' 28' ' ' LYS . . . -139.28 136.05 34.49 Favored 'General case' 0 CA--C 1.555 1.152 0 N-CA-C 113.549 0.944 . . . . 0.0 113.549 -178.338 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.489 ' N ' ' NZ ' ' I' ' 28' ' ' LYS . 79.7 tt0 -117.29 152.75 34.23 Favored 'General case' 0 N--CA 1.484 1.266 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.259 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.466 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 16.8 t70 -171.49 51.23 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.045 0 N-CA-C 114.451 1.278 . . . . 0.0 114.451 -177.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.437 HG22 ' HB2' ' J' ' 23' ' ' ASP . 16.8 t -63.19 151.04 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 119.811 -0.756 . . . . 0.0 111.47 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 109.92 -35.27 4.96 Favored Glycine 0 CA--C 1.539 1.538 0 CA-C-N 116.153 -0.476 . . . . 0.0 113.639 176.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.436 ' O ' ' C ' ' I' ' 27' ' ' ASN . 28.9 t -151.68 124.15 8.35 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 -178.443 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.672 ' ND2' ' H ' ' I' ' 27' ' ' ASN . 0.7 OUTLIER -41.19 145.86 0.21 Allowed 'General case' 0 C--N 1.348 0.514 0 C-N-CA 118.396 -1.322 . . . . 0.0 109.774 -175.687 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 1.113 ' HZ1' ' HB1' ' I' ' 21' ' ' ALA . 18.3 tttt -75.08 -49.65 19.01 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 115.828 1.788 . . . . 0.0 115.828 -177.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.524 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 109.51 59.43 0.52 Allowed Glycine 0 CA--C 1.545 1.964 0 N-CA-C 108.956 -1.658 . . . . 0.0 108.956 -177.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.1 114.2 26.08 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 116.656 2.095 . . . . 0.0 116.656 -172.565 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 82.8 mt -134.28 127.25 50.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 113.858 -1.519 . . . . 0.0 109.334 176.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.538 HD13 ' HD2' ' K' ' 19' ' ' PHE . 14.2 tt -121.01 114.96 45.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 C-N-CA 119.636 -0.826 . . . . 0.0 110.548 177.344 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.739 ' O ' HD12 ' I' ' 34' ' ' LEU . . . -109.21 108.7 2.62 Favored Glycine 0 C--N 1.338 0.691 0 N-CA-C 108.187 -1.965 . . . . 0.0 108.187 178.73 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.739 HD12 ' O ' ' I' ' 33' ' ' GLY . 2.4 mp -135.12 148.2 49.71 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.952 1.358 . . . . 0.0 114.116 -177.157 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.44 ' O ' ' O ' ' H' ' 36' ' ' VAL . 86.4 mmm -107.75 112.72 25.54 Favored 'General case' 0 CA--C 1.507 -0.699 0 CA-C-N 112.686 -2.052 . . . . 0.0 106.809 175.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.492 HG12 HE22 ' L' ' 15' ' ' GLN . 4.8 t -136.51 161.91 36.1 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 -179.012 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.71 ' H ' HE22 ' K' ' 15' ' ' GLN . . . 81.1 102.44 0.33 Allowed Glycine 0 CA--C 1.528 0.869 0 C-N-CA 119.424 -1.37 . . . . 0.0 112.005 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.44 ' N ' ' CA ' ' J' ' 38' ' ' GLY . . . -154.45 -71.12 0.01 OUTLIER Glycine 0 CA--C 1.544 1.847 0 CA-C-O 118.899 -0.945 . . . . 0.0 111.406 179.282 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.489 HG13 ' O ' ' O' ' 29' ' ' GLY . 16.0 t -119.3 128.95 75.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.957 0 CA-C-N 119.406 1.603 . . . . 0.0 109.137 177.684 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.43 ' OXT' ' O ' ' I' ' 39' ' ' VAL . 77.8 t . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.216 -179.13 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.275 0 N-CA-C 109.85 -1.3 . . . . 0.0 109.85 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -107.39 132.39 53.22 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 120.808 0.337 . . . . 0.0 110.667 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.534 ' OE1' ' N ' ' J' ' 11' ' ' GLU . 58.1 mp0 -123.96 134.98 53.37 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.333 179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.5 t -124.52 132.6 71.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.206 0 CA-C-N 115.937 -0.574 . . . . 0.0 109.568 179.682 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.621 ' CD2' HG21 ' H' ' 40' ' ' VAL . 4.2 t-160 -129.01 137.59 51.43 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-O 121.163 0.506 . . . . 0.0 110.476 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.538 ' N ' ' CD2' ' J' ' 13' ' ' HIS . 83.1 m-70 -154.85 176.92 11.87 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 122.103 0.954 . . . . 0.0 111.777 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.532 ' NE2' HG12 ' H' ' 36' ' ' VAL . 38.6 tt0 -159.77 137.14 9.68 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.257 -2.127 . . . . 0.0 105.257 177.298 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.839 ' C ' HD12 ' J' ' 17' ' ' LEU . 84.9 tttt -134.25 113.8 12.36 Favored 'General case' 0 C--N 1.32 -0.706 0 C-N-CA 120.075 -0.65 . . . . 0.0 112.66 -178.669 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.839 HD12 ' C ' ' J' ' 16' ' ' LYS . 7.0 mp -133.87 117.67 17.08 Favored 'General case' 0 CA--C 1.508 -0.64 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 176.824 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 59.3 t -106.8 110.01 30.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.1 -179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.584 ' CD1' HD13 ' H' ' 32' ' ' ILE . 62.6 m-85 -108.12 104.18 13.54 Favored 'General case' 0 C--O 1.234 0.268 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 178.759 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.435 ' CZ ' ' CB ' ' K' ' 20' ' ' PHE . 5.0 m-85 -123.24 129.91 52.03 Favored 'General case' 0 N--CA 1.475 0.802 0 N-CA-C 112.978 0.733 . . . . 0.0 112.978 -177.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.8 118.76 20.33 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.476 ' OE2' ' CE1' ' K' ' 20' ' ' PHE . 76.0 mt-10 -145.81 133.41 20.95 Favored 'General case' 0 N--CA 1.476 0.875 0 N-CA-C 115.053 1.501 . . . . 0.0 115.053 -176.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.796 ' OD1' HG23 ' J' ' 24' ' ' VAL . 0.2 OUTLIER 164.69 -70.4 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.404 175.643 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.796 HG23 ' OD1' ' J' ' 23' ' ' ASP . 22.8 t -58.17 -121.98 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 113.761 -1.563 . . . . 0.0 110.415 175.231 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.661 ' N ' HG12 ' J' ' 24' ' ' VAL . . . 142.08 -35.55 1.75 Allowed Glycine 0 C--O 1.222 -0.64 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.591 -179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.402 ' O ' ' CG ' ' I' ' 27' ' ' ASN . 10.2 t -80.45 118.55 22.17 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 122.606 3.203 . . . . 0.0 103.119 169.009 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.667 ' CG ' ' H ' ' J' ' 30' ' ' ALA . 21.7 p30 -90.6 158.84 16.75 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 123.413 2.824 . . . . 0.0 110.966 178.191 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.68 ' NZ ' HD21 ' H' ' 27' ' ' ASN . 98.3 mttt -48.12 -40.42 23.53 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 122.823 1.297 . . . . 0.0 110.985 173.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.43 67.85 0.04 OUTLIER Glycine 0 CA--C 1.545 1.911 0 CA-C-N 111.854 -2.43 . . . . 0.0 108.586 -174.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.667 ' H ' ' CG ' ' J' ' 27' ' ' ASN . . . -70.31 138.68 51.7 Favored 'General case' 0 C--O 1.242 0.703 0 CA-C-N 120.169 1.984 . . . . 0.0 114.2 -171.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.673 HD11 ' CG2' ' D' ' 39' ' ' VAL . 86.2 mt -140.22 136.8 37.5 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.734 0 CA-C-N 112.906 -1.952 . . . . 0.0 114.606 -175.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.422 ' O ' HG22 ' J' ' 32' ' ' ILE . 4.7 mt -108.74 109.3 27.81 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.117 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 174.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.92 108.66 2.43 Favored Glycine 0 N--CA 1.465 0.625 0 N-CA-C 106.12 -2.792 . . . . 0.0 106.12 177.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.417 HD12 ' O ' ' I' ' 34' ' ' LEU . 12.7 tp -142.49 136.85 29.79 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 118.674 -1.21 . . . . 0.0 113.657 -175.041 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.433 ' O ' ' O ' ' I' ' 36' ' ' VAL . 0.6 OUTLIER -104.89 120.57 41.75 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-N 113.211 -1.813 . . . . 0.0 107.145 177.109 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.483 HG12 ' N ' ' J' ' 37' ' ' GLY . 43.4 t -125.11 167.35 19.39 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 CA-C-O 121.315 0.578 . . . . 0.0 110.897 -176.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.483 ' N ' HG12 ' J' ' 36' ' ' VAL . . . 106.65 102.49 2.8 Favored Glycine 0 N--CA 1.467 0.752 0 CA-C-N 115.074 -0.966 . . . . 0.0 111.891 178.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.516 ' O ' ' C ' ' J' ' 39' ' ' VAL . . . -121.89 65.61 0.48 Allowed Glycine 0 CA--C 1.539 1.593 0 CA-C-O 117.858 -1.523 . . . . 0.0 113.125 178.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.643 ' HB ' HD11 ' P' ' 31' ' ' ILE . 71.1 t -12.84 127.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 CA-C-N 119.905 1.852 . . . . 0.0 113.769 -176.031 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.42 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 10.7 m . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.943 179.786 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.462 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -107.1 135.7 48.21 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-O 120.862 0.363 . . . . 0.0 110.385 179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 57.6 mp0 -131.82 146.06 51.92 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.05 -0.523 . . . . 0.0 109.954 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.466 ' C ' ' CD2' ' K' ' 13' ' ' HIS . 55.6 t -123.82 128.5 74.33 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 121.082 0.468 . . . . 0.0 110.769 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.518 ' CE1' ' NZ ' ' O' ' 28' ' ' LYS . 36.7 m-70 -148.05 100.21 3.15 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.638 179.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.66 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 4.7 m80 -145.14 157.71 44.02 Favored 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 120.08 -0.648 . . . . 0.0 110.901 178.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.71 HE22 ' H ' ' I' ' 37' ' ' GLY . 79.3 mt-30 -90.27 159.25 16.78 Favored 'General case' 0 CA--C 1.515 -0.4 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 174.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 45.5 tttt -140.71 103.62 4.55 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 119.816 -0.753 . . . . 0.0 110.502 177.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.455 HD11 ' NE2' ' J' ' 15' ' ' GLN . 5.1 mp -131.47 119.61 21.82 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-O 121.549 0.69 . . . . 0.0 109.456 177.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 12.1 t -106.05 113.01 41.7 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.47 0 CA-C-N 114.766 -1.107 . . . . 0.0 108.629 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.538 ' HD2' HD13 ' I' ' 32' ' ' ILE . 1.8 m-85 -105.95 101.59 11.08 Favored 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 106.584 -1.636 . . . . 0.0 106.584 178.755 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.476 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 40.6 t80 -117.95 126.83 53.09 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 120.984 0.421 . . . . 0.0 111.064 -177.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.413 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -146.79 142.33 27.62 Favored 'General case' 0 C--N 1.332 -0.193 0 C-N-CA 119.657 -0.817 . . . . 0.0 112.727 -179.07 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.48 ' OE1' ' N ' ' J' ' 23' ' ' ASP . 85.6 mt-10 -82.68 115.56 21.67 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 107.099 -1.445 . . . . 0.0 107.099 176.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.516 ' CG ' HD22 ' J' ' 27' ' ' ASN . 68.5 t0 -131.85 46.4 2.65 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.732 -178.516 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.584 HG12 ' H ' ' K' ' 25' ' ' GLY . 6.4 t -83.48 171.76 1.16 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.277 0 C-N-CA 119.198 -1.001 . . . . 0.0 111.755 -177.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.584 ' H ' HG12 ' K' ' 24' ' ' VAL . . . 95.45 -29.43 9.64 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 109.284 -1.526 . . . . 0.0 109.284 179.004 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' K' ' 25' ' ' GLY . 1.2 m 91.81 115.1 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 -178.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.452 ' ND2' ' H ' ' K' ' 28' ' ' LYS . 9.1 t-20 -73.79 163.13 28.36 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 118.377 -1.329 . . . . 0.0 111.378 -178.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.578 ' NZ ' ' NE2' ' F' ' 13' ' ' HIS . 99.1 mttt -48.12 -37.24 14.95 Favored 'General case' 0 N--CA 1.451 -0.401 0 CA-C-N 115.28 -0.873 . . . . 0.0 109.853 175.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.99 76.92 0.06 OUTLIER Glycine 0 CA--C 1.541 1.684 0 CA-C-N 114.281 -1.327 . . . . 0.0 111.755 -176.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.416 ' O ' ' HB1' ' L' ' 30' ' ' ALA . . . -79.95 139.89 36.88 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-N 119.133 1.466 . . . . 0.0 110.173 -178.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.6 HD11 HG23 ' E' ' 39' ' ' VAL . 7.1 mt -130.85 133.71 62.76 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 N-CA-C 113.443 0.905 . . . . 0.0 113.443 -175.398 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.459 HD11 HG12 ' L' ' 32' ' ' ILE . 33.7 pt -121.0 118.77 57.34 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 CA-C-O 121.596 0.712 . . . . 0.0 109.323 176.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.42 118.24 4.22 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -178.998 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.594 ' CD2' ' CE2' ' L' ' 19' ' ' PHE . 4.2 mp -129.03 118.42 22.52 Favored 'General case' 0 C--O 1.238 0.449 0 CA-C-O 121.973 0.892 . . . . 0.0 111.716 -178.203 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 0.6 OUTLIER -102.74 115.31 30.33 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 114.397 -1.274 . . . . 0.0 108.193 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.675 HG12 ' N ' ' K' ' 37' ' ' GLY . 42.6 t -116.76 174.12 3.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 N-CA-C 109.716 -0.476 . . . . 0.0 109.716 -178.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.675 ' N ' HG12 ' K' ' 36' ' ' VAL . . . 163.05 -95.41 0.13 Allowed Glycine 0 C--N 1.305 -1.181 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.448 ' C ' ' O ' ' K' ' 37' ' ' GLY . . . 28.48 78.63 0.01 OUTLIER Glycine 0 CA--C 1.536 1.401 0 N-CA-C 112.46 -0.256 . . . . 0.0 112.46 179.874 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.56 HG13 ' O ' ' L' ' 39' ' ' VAL . 90.5 t -33.89 118.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.474 0.772 0 N-CA-C 112.582 0.586 . . . . 0.0 112.582 -179.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 t . . . . . 0 C--O 1.219 -0.546 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.361 179.373 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.335 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 99.0 m-85 -106.96 135.1 49.09 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.678 0.275 . . . . 0.0 110.637 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 22.3 pt-20 -108.22 156.35 19.44 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.387 179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.59 122.01 65.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-O 121.17 0.509 . . . . 0.0 110.786 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.489 ' N ' ' ND1' ' L' ' 13' ' ' HIS . 0.0 OUTLIER -153.12 101.21 2.54 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.63 179.47 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.66 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 78.7 m80 -146.28 164.34 32.65 Favored 'General case' 0 C--O 1.222 -0.386 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 179.211 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.532 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 23.8 tt0 -90.02 158.45 17.34 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 111.636 0.236 . . . . 0.0 111.636 -179.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -140.53 109.57 6.11 Favored 'General case' 0 C--O 1.242 0.708 0 CA-C-O 121.55 0.69 . . . . 0.0 111.555 178.165 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 22.4 mt -128.68 117.26 20.88 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -105.14 108.47 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.613 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.58 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.594 ' CE2' ' CD2' ' K' ' 34' ' ' LEU . 42.8 m-85 -102.45 105.36 15.92 Favored 'General case' 0 CA--C 1.515 -0.372 0 N-CA-C 107.627 -1.249 . . . . 0.0 107.627 178.52 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -129.19 122.01 28.86 Favored 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.642 0.734 . . . . 0.0 111.099 -178.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -129.35 133.0 47.2 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 108.193 -1.04 . . . . 0.0 108.193 177.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.454 ' O ' ' C ' ' K' ' 23' ' ' ASP . 79.6 mm-40 -77.27 114.76 16.43 Favored 'General case' 0 C--O 1.222 -0.388 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.641 -178.632 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p30 -168.5 46.46 0.04 OUTLIER 'General case' 0 C--O 1.231 0.099 0 C-N-CA 119.838 -0.745 . . . . 0.0 112.833 -178.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.2 m -83.65 172.68 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 C-N-CA 119.225 -0.99 . . . . 0.0 108.941 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 94.51 -29.82 8.57 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.806 -0.917 . . . . 0.0 110.806 178.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 15.7 p -84.77 139.9 31.62 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.38 -0.41 . . . . 0.0 110.993 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' N ' ' L' ' 29' ' ' GLY . 61.6 t-20 -73.15 149.17 43.19 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 178.868 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.509 ' N ' ' OD1' ' L' ' 27' ' ' ASN . 6.3 tmtt? 64.68 -49.71 0.32 Allowed 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 94.83 -54.79 1.92 Allowed Glycine 0 CA--C 1.542 1.745 0 CA-C-N 116.201 -0.454 . . . . 0.0 114.079 177.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.416 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -170.42 -172.75 1.31 Allowed 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 117.666 0.733 . . . . 0.0 109.69 -179.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 97.8 mt -98.41 119.09 45.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 176.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.459 HG12 HD11 ' K' ' 32' ' ' ILE . 88.9 mt -115.3 122.84 70.08 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 112.373 0.509 . . . . 0.0 112.373 -177.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.32 106.22 0.84 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 108.846 -1.702 . . . . 0.0 108.846 178.118 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 10.0 tt -133.45 131.17 39.59 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 -179.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 33.4 ttp -151.59 160.3 43.72 Favored 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 119.792 -0.763 . . . . 0.0 111.709 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 27.1 m -109.47 173.96 1.9 Allowed 'Isoleucine or valine' 0 C--N 1.339 0.123 0 CA-C-O 121.152 0.501 . . . . 0.0 111.108 -179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.451 ' H ' ' HA2' ' K' ' 37' ' ' GLY . . . -166.51 94.64 0.11 Allowed Glycine 0 C--N 1.306 -1.098 0 N-CA-C 109.212 -1.555 . . . . 0.0 109.212 179.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 120.03 83.4 0.79 Allowed Glycine 0 N--CA 1.473 1.149 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -179.328 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.56 ' O ' HG13 ' K' ' 39' ' ' VAL . 21.8 m -53.29 141.84 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.393 0 N-CA-C 112.587 0.588 . . . . 0.0 112.587 -178.877 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 11.2 m . . . . . 0 C--O 1.219 -0.521 0 CA-C-O 118.15 -0.929 . . . . 0.0 110.556 179.171 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 43.9 p90 -148.48 158.36 44.07 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.879 0.371 . . . . 0.0 110.445 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -92.32 126.01 37.22 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.915 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 p -126.83 130.17 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 121.198 0.523 . . . . 0.0 110.15 179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -124.52 163.06 22.68 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.172 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.477 ' CB ' ' O ' ' N' ' 14' ' ' HIS . 41.9 p-80 -87.41 170.76 11.1 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 120.965 0.412 . . . . 0.0 111.217 -179.447 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -129.14 150.95 50.31 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.017 179.116 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -96.65 123.77 40.43 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.214 178.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -127.8 116.06 19.6 Favored 'General case' 0 N--CA 1.47 0.555 0 N-CA-C 109.865 -0.42 . . . . 0.0 109.865 178.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.3 t -126.27 134.51 66.27 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.09 -179.085 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 m-85 -137.29 141.04 41.93 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.879 -0.415 . . . . 0.0 109.879 178.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 53.5 p90 -144.42 146.84 32.71 Favored 'General case' 0 N--CA 1.464 0.272 0 C-N-CA 120.619 -0.432 . . . . 0.0 111.413 -179.649 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.52 119.71 21.92 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 121.144 0.497 . . . . 0.0 110.462 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . 0.454 ' O ' ' O ' ' M' ' 24' ' ' VAL . 97.5 mt-10 -103.59 -162.71 0.93 Allowed 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.544 -179.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' M' ' 22' ' ' GLU . 96.9 m-20 -23.64 -59.69 0.04 OUTLIER 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 123.222 0.609 . . . . 0.0 112.345 179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.454 ' O ' ' O ' ' M' ' 22' ' ' GLU . 32.6 m -91.3 169.87 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 -178.636 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.37 28.36 57.98 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -178.546 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 11.9 t -97.02 110.7 23.19 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 178.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . . . . . . . . . 57.3 p30 -78.14 175.42 10.17 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 114.356 1.243 . . . . 0.0 114.356 -176.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -49.75 -36.23 25.07 Favored 'General case' 0 CA--C 1.536 0.439 0 CA-C-N 112.507 -2.133 . . . . 0.0 115.074 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.94 78.63 0.06 OUTLIER Glycine 0 N--CA 1.471 1.012 0 C-N-CA 120.587 -0.816 . . . . 0.0 111.643 -172.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.03 108.62 0.26 Allowed 'General case' 0 CA--C 1.542 0.663 0 CA-C-O 124.362 2.029 . . . . 0.0 113.306 -175.542 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.552 HG23 ' O ' ' M' ' 31' ' ' ILE . 15.1 tt -128.34 125.71 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.046 0 CA-C-N 110.537 -3.028 . . . . 0.0 108.388 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . . . . . . . . . 92.8 mt -102.64 108.88 25.12 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.367 0 C-N-CA 120.146 -0.622 . . . . 0.0 109.527 179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.92 92.82 0.67 Allowed Glycine 0 CA--C 1.508 -0.352 0 N-CA-C 105.44 -3.064 . . . . 0.0 105.44 176.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . 0.632 ' O ' HD23 ' N' ' 34' ' ' LEU . 92.8 mt -135.36 156.57 48.71 Favored 'General case' 0 N--CA 1.472 0.675 0 CA-C-O 122.81 1.29 . . . . 0.0 113.861 -176.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -108.9 105.27 14.75 Favored 'General case' 0 N--CA 1.443 -0.806 0 CA-C-N 112.426 -2.17 . . . . 0.0 106.25 176.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.583 HG23 HD21 ' N' ' 34' ' ' LEU . 50.4 t -106.12 111.83 36.8 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 N-CA-C 106.803 -1.555 . . . . 0.0 106.803 178.539 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.03 -132.12 8.74 Favored Glycine 0 C--N 1.315 -0.608 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 -177.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.418 ' O ' HG12 ' N' ' 39' ' ' VAL . . . 93.81 -63.19 1.87 Allowed Glycine 0 CA--C 1.534 1.28 0 C-N-CA 120.373 -0.917 . . . . 0.0 112.621 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.67 HG12 ' CD1' ' A' ' 31' ' ' ILE . 1.2 m -111.14 161.3 9.74 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.261 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 -178.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . . . . . . . . . 6.0 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.949 -1.025 . . . . 0.0 110.764 -179.987 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.369 0 N-CA-C 109.233 -1.547 . . . . 0.0 109.233 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -81.71 138.37 35.24 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.758 0.313 . . . . 0.0 110.27 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 79.7 mm-40 -76.45 116.33 17.03 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.692 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.438 HG12 ' H ' ' O' ' 12' ' ' VAL . 34.5 m -137.7 157.63 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.112 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 21.8 t-160 -145.46 98.81 3.2 Favored 'General case' 0 N--CA 1.462 0.147 0 CA-C-O 120.871 0.367 . . . . 0.0 111.311 179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.477 ' O ' ' CB ' ' M' ' 14' ' ' HIS . 28.4 p-80 -153.98 168.12 27.48 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.338 178.714 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -129.45 150.35 50.84 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 110.064 178.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -98.15 124.0 42.49 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 177.282 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.4 ' C ' HD23 ' N' ' 17' ' ' LEU . 7.6 tt -125.84 124.45 40.93 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-N 118.483 0.583 . . . . 0.0 109.701 178.563 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -125.94 134.41 66.64 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.603 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . 0.438 ' CE2' ' HB2' ' N' ' 21' ' ' ALA . 74.4 t80 -130.63 120.3 23.75 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.811 0.339 . . . . 0.0 111.051 -179.799 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 55.8 m-85 -112.36 127.77 56.1 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . 0.438 ' HB2' ' CE2' ' N' ' 19' ' ' PHE . . . -132.75 132.91 42.8 Favored 'General case' 0 C--O 1.241 0.617 0 CA-C-N 118.584 0.629 . . . . 0.0 111.958 -179.567 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 81.7 tt0 -170.09 128.44 0.89 Allowed 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.023 179.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.465 ' CG ' ' H ' ' N' ' 24' ' ' VAL . 16.6 p-10 -155.05 -59.81 0.11 Allowed 'General case' 0 N--CA 1.462 0.13 0 C-N-CA 119.89 -0.724 . . . . 0.0 111.618 177.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.465 ' H ' ' CG ' ' N' ' 23' ' ' ASP . 16.9 m -102.87 -176.83 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.506 -0.734 0 N-CA-C 109.096 -0.705 . . . . 0.0 109.096 179.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . -69.94 -33.69 70.5 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 109.809 -1.317 . . . . 0.0 109.809 178.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 1.5 m -147.86 118.87 7.66 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 -59.9 169.06 1.56 Allowed 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 117.919 -1.512 . . . . 0.0 110.922 -179.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -54.69 -36.96 65.23 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 115.305 1.594 . . . . 0.0 115.305 178.11 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.75 77.58 0.07 OUTLIER Glycine 0 CA--C 1.54 1.634 0 C-N-CA 120.123 -1.037 . . . . 0.0 113.429 -174.448 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.86 116.71 20.17 Favored 'General case' 0 CA--C 1.548 0.894 0 CA-C-N 118.866 1.333 . . . . 0.0 113.638 -176.674 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.54 HG21 ' HB ' ' H' ' 39' ' ' VAL . 2.8 tt -146.08 134.09 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.125 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.51 HG22 HD11 ' O' ' 34' ' ' LEU . 15.8 mt -109.38 120.55 60.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 CA-C-O 120.971 0.415 . . . . 0.0 110.64 179.427 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.03 112.75 2.68 Favored Glycine 0 CA--C 1.52 0.367 0 N-CA-C 105.795 -2.922 . . . . 0.0 105.795 176.389 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.632 HD23 ' O ' ' M' ' 34' ' ' LEU . 0.3 OUTLIER -151.91 144.13 23.97 Favored 'General case' 0 CA--C 1.519 -0.242 0 C-N-CA 117.773 -1.571 . . . . 0.0 115.074 -175.206 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.406 ' SD ' ' HB2' ' O' ' 35' ' ' MET . 89.7 mmm -105.8 108.36 19.84 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 104.861 -2.274 . . . . 0.0 104.861 174.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.404 ' O ' ' NE2' ' Q' ' 15' ' ' GLN . 2.0 t -106.9 101.79 13.01 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 118.878 0.763 . . . . 0.0 110.884 -177.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 130.09 -171.14 20.56 Favored Glycine 0 C--N 1.323 -0.173 0 N-CA-C 111.018 -0.833 . . . . 0.0 111.018 179.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.488 ' O ' HG12 ' O' ' 39' ' ' VAL . . . 155.66 -55.04 0.41 Allowed Glycine 0 CA--C 1.547 2.036 0 N-CA-C 111.429 -0.668 . . . . 0.0 111.429 -178.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.7 ' HB ' HD11 ' B' ' 31' ' ' ILE . 10.6 p -159.49 135.26 1.8 Allowed 'Isoleucine or valine' 0 CA--C 1.516 -0.338 0 CA-C-N 117.628 0.714 . . . . 0.0 109.768 177.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.462 HG13 ' O ' ' N' ' 39' ' ' VAL . 22.6 m . . . . . 0 C--O 1.218 -0.556 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.225 179.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 92.7 m-85 -82.05 137.84 34.97 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.821 0.343 . . . . 0.0 110.488 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -114.74 134.93 54.7 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.592 -179.784 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.438 ' H ' HG12 ' N' ' 12' ' ' VAL . 75.3 t -122.45 130.25 74.66 Favored 'Isoleucine or valine' 0 C--O 1.233 0.211 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.856 179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.503 ' H ' ' HB3' ' P' ' 13' ' ' HIS . 3.5 t-80 -146.58 102.74 3.6 Favored 'General case' 0 N--CA 1.468 0.468 0 CA-C-O 120.574 0.226 . . . . 0.0 111.364 179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' P' ' 14' ' ' HIS . 8.0 p-80 -156.34 164.48 38.25 Favored 'General case' 0 N--CA 1.466 0.34 0 C-N-CA 121.045 -0.262 . . . . 0.0 110.919 179.178 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -89.84 158.82 17.29 Favored 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 178.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -140.1 119.23 12.75 Favored 'General case' 0 C--N 1.313 -0.982 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -135.82 130.02 33.33 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-O 122.321 1.057 . . . . 0.0 111.777 178.352 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . 0.599 HG13 HG13 ' P' ' 18' ' ' VAL . 48.1 t -112.09 118.23 57.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 177.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 34.6 m-85 -110.32 102.78 11.4 Favored 'General case' 0 C--O 1.235 0.296 0 N-CA-C 106.424 -1.695 . . . . 0.0 106.424 178.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.616 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 14.6 t80 -114.83 127.8 55.93 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 112.255 0.465 . . . . 0.0 112.255 -176.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.73 115.11 20.86 Favored 'General case' 0 C--O 1.243 0.742 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . 0.448 ' O ' ' C ' ' O' ' 23' ' ' ASP . 83.0 tt0 -86.7 151.28 23.55 Favored 'General case' 0 CA--C 1.518 -0.259 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.142 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.448 ' C ' ' O ' ' O' ' 22' ' ' GLU . 49.0 t0 26.83 49.52 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.904 -176.154 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.656 HG11 ' HB1' ' P' ' 21' ' ' ALA . 1.1 p -68.75 154.76 8.12 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.013 -1.449 . . . . 0.0 108.179 175.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.424 ' N ' ' CG2' ' O' ' 24' ' ' VAL . . . -131.51 -28.81 0.61 Allowed Glycine 0 C--N 1.31 -0.862 0 N-CA-C 108.875 -1.69 . . . . 0.0 108.875 -178.667 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.667 ' OG ' ' HB2' ' O' ' 30' ' ' ALA . 3.3 t 63.69 -110.14 0.28 Allowed 'General case' 0 CA--C 1.511 -0.55 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.53 178.66 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.559 ' N ' ' OG ' ' O' ' 26' ' ' SER . 32.9 m-20 150.51 -161.37 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.551 0 O-C-N 124.473 1.108 . . . . 0.0 109.153 -178.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.518 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 98.8 mttt -29.71 -40.4 0.02 OUTLIER 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -179.013 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.489 ' O ' HG13 ' I' ' 39' ' ' VAL . . . -170.07 70.05 0.14 Allowed Glycine 0 CA--C 1.541 1.662 0 C-N-CA 118.489 -1.815 . . . . 0.0 115.908 -173.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . 0.667 ' HB2' ' OG ' ' O' ' 26' ' ' SER . . . -72.75 150.18 43.06 Favored 'General case' 0 C--N 1.363 1.175 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.423 HG22 ' N ' ' O' ' 32' ' ' ILE . 20.6 mt -140.69 149.85 21.03 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 N-CA-C 118.076 2.621 . . . . 0.0 118.076 -171.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.722 HG23 HD13 ' O' ' 34' ' ' LEU . 6.7 mt -111.78 106.76 21.38 Favored 'Isoleucine or valine' 0 C--N 1.348 0.528 0 N-CA-C 104.871 -2.27 . . . . 0.0 104.871 173.152 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.799 ' C ' HD12 ' O' ' 34' ' ' LEU . . . -117.43 98.5 0.78 Allowed Glycine 0 N--CA 1.473 1.15 0 N-CA-C 107.616 -2.194 . . . . 0.0 107.616 179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.799 HD12 ' C ' ' O' ' 33' ' ' GLY . 8.8 mp -136.67 151.92 49.82 Favored 'General case' 0 CA--C 1.514 -0.439 0 CA-C-O 123.698 1.713 . . . . 0.0 114.433 -175.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.406 ' HB2' ' SD ' ' N' ' 35' ' ' MET . 0.8 OUTLIER -113.15 112.04 23.13 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 111.947 -2.388 . . . . 0.0 106.019 176.483 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . . . . . . . . . 46.9 t -112.09 147.69 15.74 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -178.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.921 ' H ' HE22 ' Q' ' 15' ' ' GLN . . . 127.32 103.04 1.22 Allowed Glycine 0 C--N 1.307 -1.057 0 N-CA-C 109.384 -1.487 . . . . 0.0 109.384 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.525 ' O ' ' C ' ' O' ' 39' ' ' VAL . . . -108.47 72.42 0.2 Allowed Glycine 0 CA--C 1.533 1.179 0 CA-C-O 117.612 -1.66 . . . . 0.0 112.074 179.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.822 ' H ' HG21 ' P' ' 39' ' ' VAL . 7.6 p -12.86 130.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 CA-C-N 119.804 1.802 . . . . 0.0 113.325 -175.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.426 ' O ' HG23 ' O' ' 40' ' ' VAL . 5.6 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.375 179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.765 -1.334 . . . . 0.0 109.765 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -104.09 132.13 50.66 Favored 'General case' 0 N--CA 1.463 0.218 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . 0.417 ' O ' ' NE2' ' Q' ' 13' ' ' HIS . 96.7 mt-10 -126.57 118.0 23.97 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 116.348 -0.387 . . . . 0.0 110.676 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.613 HG12 ' H ' ' Q' ' 12' ' ' VAL . 19.4 m -139.64 113.75 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-N 116.47 -0.332 . . . . 0.0 110.545 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.503 ' HB3' ' H ' ' O' ' 13' ' ' HIS . 0.0 OUTLIER -135.44 140.24 44.74 Favored 'General case' 0 N--CA 1.47 0.526 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.449 -179.27 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' O' ' 14' ' ' HIS . 5.5 m-70 -125.42 161.17 27.66 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 108.954 -0.758 . . . . 0.0 108.954 178.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . . . . . . . . . 27.2 tp60 -89.89 158.15 17.56 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . 0.781 ' C ' HD12 ' P' ' 17' ' ' LEU . 68.2 mttm -141.47 100.22 3.73 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 120.535 -0.466 . . . . 0.0 111.437 178.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.781 HD12 ' C ' ' P' ' 16' ' ' LYS . 9.0 mp -134.5 122.8 22.95 Favored 'General case' 0 N--CA 1.48 1.031 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 176.394 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . 0.599 HG13 HG13 ' O' ' 18' ' ' VAL . 3.8 p -122.4 127.39 75.08 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.506 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 178.33 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -115.87 106.25 13.61 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 107.964 -1.125 . . . . 0.0 107.964 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.616 ' CD1' ' CE2' ' O' ' 20' ' ' PHE . 30.5 t80 -110.97 125.67 53.96 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-N 116.798 -0.183 . . . . 0.0 111.156 -178.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . 0.656 ' HB1' HG11 ' O' ' 24' ' ' VAL . . . -138.41 122.74 18.25 Favored 'General case' 0 CA--C 1.553 1.064 0 CA-C-O 121.751 0.786 . . . . 0.0 112.615 -179.544 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.578 ' O ' HG13 ' O' ' 24' ' ' VAL . 83.1 tt0 -87.42 116.66 25.68 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.408 -1.269 . . . . 0.0 110.926 179.018 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.565 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 34.2 m-20 -144.81 46.73 1.35 Allowed 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.051 0.54 . . . . 0.0 112.053 -178.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.85 HG13 ' CD ' ' Q' ' 22' ' ' GLU . 1.0 OUTLIER -82.14 173.37 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 123.229 1.49 . . . . 0.0 113.237 -175.594 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . . . . . . . . . . . 92.42 -33.66 4.84 Favored Glycine 0 CA--C 1.535 1.293 0 CA-C-N 111.286 -2.688 . . . . 0.0 113.992 177.054 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.712 ' O ' ' O ' ' P' ' 27' ' ' ASN . 13.3 t -174.16 126.61 0.35 Allowed 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 118.974 1.387 . . . . 0.0 112.819 175.672 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.825 HD22 ' H ' ' Q' ' 27' ' ' ASN . 12.6 p30 -2.69 145.94 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.035 0 N-CA-C 113.952 1.093 . . . . 0.0 113.952 173.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.435 ' CG ' ' O ' ' P' ' 27' ' ' ASN . 93.1 mttt -158.48 30.34 0.23 Allowed 'General case' 0 N--CA 1.475 0.806 0 O-C-N 120.69 -1.256 . . . . 0.0 114.033 176.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 85.31 88.81 0.9 Allowed Glycine 0 CA--C 1.531 1.065 0 C-N-CA 119.503 -1.332 . . . . 0.0 113.727 175.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.88 105.54 7.83 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-N 117.871 0.836 . . . . 0.0 112.047 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.643 HD11 ' HB ' ' J' ' 39' ' ' VAL . 58.4 mt -119.21 124.25 72.76 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.95 0 CA-C-O 119.27 -0.395 . . . . 0.0 110.056 177.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.468 HD13 ' CD1' ' R' ' 19' ' ' PHE . 49.9 mt -109.91 110.55 32.54 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.252 0 N-CA-C 108.435 -0.95 . . . . 0.0 108.435 175.802 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.56 100.06 1.04 Allowed Glycine 0 CA--C 1.504 -0.625 0 N-CA-C 104.588 -3.405 . . . . 0.0 104.588 175.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 5.0 tt -144.63 137.37 26.63 Favored 'General case' 0 C--O 1.241 0.635 0 C-N-CA 118.681 -1.207 . . . . 0.0 112.883 -174.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 22.1 mtp -112.27 127.73 56.06 Favored 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 113.837 -1.529 . . . . 0.0 110.512 179.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.505 HG11 HD13 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -117.74 103.18 14.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 179.369 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.22 -153.48 25.09 Favored Glycine 0 C--N 1.308 -0.983 0 C-N-CA 119.276 -1.44 . . . . 0.0 111.191 -179.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.702 ' H ' ' CG1' ' Q' ' 40' ' ' VAL . . . 99.16 -56.45 0.92 Allowed Glycine 0 CA--C 1.543 1.795 0 N-CA-C 111.222 -0.751 . . . . 0.0 111.222 -178.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.902 HG12 HG21 ' D' ' 31' ' ' ILE . 27.7 m -128.88 160.2 39.89 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.73 0.812 . . . . 0.0 112.265 -177.602 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.415 ' H ' HG23 ' P' ' 40' ' ' VAL . 2.8 t . . . . . 0 C--O 1.219 -0.531 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.719 -179.449 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -110.79 90.13 3.24 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 110.287 -0.264 . . . . 0.0 110.287 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -142.77 147.97 36.42 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.766 0.317 . . . . 0.0 110.596 -179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.613 ' H ' HG12 ' P' ' 12' ' ' VAL . 2.2 p -140.87 135.86 33.94 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.309 0 CA-C-O 120.848 0.356 . . . . 0.0 110.658 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.417 ' NE2' ' O ' ' P' ' 11' ' ' GLU . 4.6 m80 -142.63 125.0 15.57 Favored 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.651 179.679 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.504 ' CE1' ' CE1' ' P' ' 14' ' ' HIS . 15.1 p-80 -152.61 160.42 43.19 Favored 'General case' 0 C--O 1.222 -0.368 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.645 178.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.921 HE22 ' H ' ' O' ' 37' ' ' GLY . 88.3 mt-30 -90.03 158.92 17.12 Favored 'General case' 0 CA--C 1.51 -0.588 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 176.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 73.0 tttt -140.73 108.35 5.61 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 177.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.424 ' N ' HD12 ' Q' ' 17' ' ' LEU . 3.8 mp -130.97 124.13 30.32 Favored 'General case' 0 CA--C 1.511 -0.52 0 C-N-CA 119.962 -0.695 . . . . 0.0 109.726 177.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 53.9 t -110.1 122.34 64.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.66 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.519 ' CE2' ' CE1' ' R' ' 19' ' ' PHE . 24.0 m-85 -112.03 99.9 8.45 Favored 'General case' 0 N--CA 1.451 -0.42 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 178.647 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 47.8 t80 -108.96 121.2 44.63 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.422 -177.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.568 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -152.76 161.12 42.98 Favored 'General case' 0 C--O 1.217 -0.625 0 C-N-CA 118.963 -1.095 . . . . 0.0 112.628 -179.017 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.85 ' CD ' HG13 ' P' ' 24' ' ' VAL . 99.6 mt-10 -87.55 114.52 24.23 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 119.072 -1.051 . . . . 0.0 110.781 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.4 ' O ' ' O ' ' Q' ' 24' ' ' VAL . 68.4 t0 -109.23 52.0 0.73 Allowed 'General case' 0 N--CA 1.478 0.949 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.071 -177.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.559 HG12 ' N ' ' Q' ' 25' ' ' GLY . 38.5 t -41.43 161.38 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 121.983 0.897 . . . . 0.0 112.247 -176.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.559 ' N ' HG12 ' Q' ' 24' ' ' VAL . . . -93.14 32.59 5.58 Favored Glycine 0 N--CA 1.468 0.798 0 CA-C-N 113.848 -1.524 . . . . 0.0 114.273 -174.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.488 ' CB ' HD22 ' P' ' 27' ' ' ASN . 69.5 m -92.62 -112.38 0.1 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 117.593 0.696 . . . . 0.0 109.936 -178.233 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.825 ' H ' HD22 ' P' ' 27' ' ' ASN . 9.8 m120 -85.97 179.18 7.05 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-N 119.853 1.206 . . . . 0.0 112.91 -176.674 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -52.58 48.11 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.028 1.492 . . . . 0.0 115.028 -178.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.502 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -98.56 56.57 1.01 Allowed Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.164 -1.017 . . . . 0.0 112.936 179.006 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -165.63 103.49 0.7 Allowed 'General case' 0 C--O 1.24 0.56 0 CA-C-N 119.013 1.406 . . . . 0.0 112.921 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.418 HD13 HG21 ' Q' ' 31' ' ' ILE . 1.1 pt -142.69 139.82 28.23 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 C-N-CA 120.099 -0.64 . . . . 0.0 109.601 177.242 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 4.8 tt -140.23 132.71 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.7 0 N-CA-C 113.076 0.769 . . . . 0.0 113.076 -178.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.49 105.66 1.47 Allowed Glycine 0 C--N 1.337 0.589 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 176.096 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.506 HD23 HD13 ' R' ' 34' ' ' LEU . 53.0 tp -120.47 122.6 41.03 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.642 0.734 . . . . 0.0 112.201 -176.257 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -111.78 115.67 29.44 Favored 'General case' 0 C--O 1.223 -0.301 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.558 178.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.619 HG12 ' N ' ' Q' ' 37' ' ' GLY . 81.9 t -108.17 171.03 2.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.304 0 CA-C-O 121.414 0.626 . . . . 0.0 111.26 -178.902 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.619 ' N ' HG12 ' Q' ' 36' ' ' VAL . . . 130.34 93.44 0.66 Allowed Glycine 0 C--N 1.311 -0.835 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 178.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.29 -74.46 0.26 Allowed Glycine 0 CA--C 1.534 1.235 0 C-N-CA 121.287 -0.483 . . . . 0.0 112.236 179.285 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.586 ' O ' HG23 ' Q' ' 39' ' ' VAL . 34.6 m -81.71 118.19 29.03 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.341 0 N-CA-C 108.596 -0.891 . . . . 0.0 108.596 179.069 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.702 ' CG1' ' H ' ' P' ' 38' ' ' GLY . 3.1 p . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 117.913 -1.041 . . . . 0.0 110.414 179.161 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.418 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -126.78 154.62 44.01 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.915 0.388 . . . . 0.0 110.544 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 80.8 tt0 -68.43 125.42 26.41 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.583 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 9.2 p -139.97 138.85 37.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 121.286 0.565 . . . . 0.0 111.373 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -149.26 105.22 3.47 Favored 'General case' 0 C--O 1.232 0.148 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.552 179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.415 ' O ' ' CB ' ' Q' ' 14' ' ' HIS . 93.4 m-70 -145.95 166.47 25.92 Favored 'General case' 0 C--O 1.221 -0.441 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.608 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -89.73 158.68 17.43 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.134 0.492 . . . . 0.0 110.66 -179.546 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . 0.778 ' C ' HD12 ' R' ' 17' ' ' LEU . 98.6 mttt -140.22 103.02 4.5 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.56 -0.745 . . . . 0.0 109.438 178.483 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.778 HD12 ' C ' ' R' ' 16' ' ' LYS . 10.8 mp -124.99 120.85 32.72 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 178.473 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 95.5 t -105.22 116.62 49.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.755 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.519 ' CE1' ' CE2' ' Q' ' 19' ' ' PHE . 78.2 m-85 -111.89 103.7 11.95 Favored 'General case' 0 CA--C 1.508 -0.669 0 N-CA-C 106.11 -1.811 . . . . 0.0 106.11 178.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 85.9 t80 -140.17 150.65 44.47 Favored 'General case' 0 CA--C 1.509 -0.633 0 CA-C-O 121.804 0.812 . . . . 0.0 111.594 -177.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.568 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -139.31 143.48 37.88 Favored 'General case' 0 N--CA 1.444 -0.773 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.067 179.422 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -82.7 157.62 23.24 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.513 -178.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 93.8 m-20 58.69 50.45 8.87 Favored 'General case' 0 CA--C 1.517 -0.312 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -178.773 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.525 HG12 ' N ' ' R' ' 25' ' ' GLY . 24.9 t -48.9 163.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.134 -178.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.525 ' N ' HG12 ' R' ' 24' ' ' VAL . . . -175.76 24.0 0.06 OUTLIER Glycine 0 CA--C 1.521 0.464 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -178.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 4.3 m -64.94 111.68 2.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.776 0.798 . . . . 0.0 110.566 -178.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.702 ' O ' ' N ' ' R' ' 29' ' ' GLY . 24.7 t-20 -149.09 176.0 10.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.345 -1.298 . . . . 0.0 108.956 -179.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . 0.455 ' C ' ' O ' ' R' ' 27' ' ' ASN . 65.5 tttm -8.95 -45.91 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.952 0 O-C-N 124.401 1.063 . . . . 0.0 113.559 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.702 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -94.49 58.74 1.92 Allowed Glycine 0 CA--C 1.544 1.847 0 C-N-CA 121.074 -0.584 . . . . 0.0 112.823 179.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.47 136.91 9.85 Favored 'General case' 0 CA--C 1.517 -0.324 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.433 HD12 HG21 ' K' ' 39' ' ' VAL . 50.5 mt -124.77 119.5 56.26 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 CA-C-O 121.627 0.727 . . . . 0.0 111.644 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 29.3 mm -113.36 121.84 66.33 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.294 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.782 -179.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 115.98 2.26 Favored Glycine 0 CA--C 1.531 1.044 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 178.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.54 HD12 ' N ' ' R' ' 35' ' ' MET . 7.3 tp -137.03 125.38 23.33 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 -178.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . 0.54 ' N ' HD12 ' R' ' 34' ' ' LEU . 9.8 ptm -160.89 172.94 16.07 Favored 'General case' 0 N--CA 1.464 0.269 0 C-N-CA 119.625 -0.83 . . . . 0.0 111.366 179.845 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 27.3 m -124.72 167.33 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-O 121.327 0.584 . . . . 0.0 111.529 -179.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.57 -102.64 0.08 OUTLIER Glycine 0 CA--C 1.525 0.697 0 CA-C-N 114.986 -1.006 . . . . 0.0 111.103 179.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.02 -77.87 1.09 Allowed Glycine 0 CA--C 1.532 1.137 0 N-CA-C 111.559 -0.617 . . . . 0.0 111.559 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . . . . . . . . . 79.3 t -121.3 132.37 70.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 117.17 0.485 . . . . 0.0 110.401 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.467 HG22 ' OXT' ' R' ' 40' ' ' VAL . 4.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.325 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 78.3 t80 -80.65 129.97 34.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.738 0.304 . . . . 0.0 110.327 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -132.95 147.89 52.28 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-N 116.339 -0.392 . . . . 0.0 110.754 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.607 ' H ' ' CE1' ' B' ' 13' ' ' HIS . 53.0 t -124.89 131.33 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.144 0.497 . . . . 0.0 110.25 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 80.8 m80 -93.94 163.06 13.65 Favored 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 115.596 -0.729 . . . . 0.0 110.436 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.643 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 0.2 OUTLIER -86.0 171.94 11.04 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.708 -179.749 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 28.5 pt20 -158.09 142.96 16.44 Favored 'General case' 0 N--CA 1.453 -0.322 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.571 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 64.6 pttt -80.24 133.95 36.05 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.895 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 90.6 mt -129.29 116.31 18.92 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.971 0.415 . . . . 0.0 109.964 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.3 t -125.43 133.75 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.954 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -134.94 129.0 33.58 Favored 'General case' 0 N--CA 1.467 0.411 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.509 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 53.6 p90 -122.62 130.47 53.03 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.494 -0.321 . . . . 0.0 110.408 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.28 114.99 21.57 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.455 0.645 . . . . 0.0 111.339 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.442 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 74.9 mt-10 -154.92 152.73 30.08 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.404 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 22' ' ' GLU . 3.9 p-10 45.21 46.46 9.89 Favored 'General case' 0 N--CA 1.465 0.277 0 C-N-CA 120.113 -0.635 . . . . 0.0 110.461 179.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 26.3 m -80.42 -179.92 0.46 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.77 -177.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.3 -33.5 64.54 Favored Glycine 0 CA--C 1.526 0.767 0 CA-C-N 115.287 -0.87 . . . . 0.0 113.143 -177.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.589 ' O ' ' O ' ' A' ' 27' ' ' ASN . 89.6 p -162.38 120.24 2.13 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.98 0.89 . . . . 0.0 111.912 -179.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.589 ' O ' ' O ' ' A' ' 26' ' ' SER . 5.1 t-20 -22.51 163.21 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 114.006 -1.452 . . . . 0.0 114.439 179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.582 ' H ' ' ND2' ' A' ' 27' ' ' ASN . 98.3 mttt -156.27 -18.64 0.1 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 114.24 -1.346 . . . . 0.0 107.817 178.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.504 ' HA3' ' H ' ' B' ' 28' ' ' LYS . . . 71.83 -98.47 0.78 Allowed Glycine 0 CA--C 1.523 0.544 0 CA-C-N 114.321 -1.309 . . . . 0.0 111.46 179.891 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.79 88.54 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.906 -0.318 . . . . 0.0 111.075 179.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 97.5 mt -138.12 117.24 14.4 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 178.493 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.426 ' O ' ' O ' ' B' ' 33' ' ' GLY . 39.7 mt -108.91 112.49 40.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.41 93.93 0.64 Allowed Glycine 0 CA--C 1.507 -0.444 0 N-CA-C 105.128 -3.189 . . . . 0.0 105.128 177.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.417 HD12 ' CG2' ' A' ' 32' ' ' ILE . 91.8 mt -140.78 165.0 28.7 Favored 'General case' 0 CA--C 1.513 -0.467 0 CA-C-O 123.335 1.541 . . . . 0.0 114.289 -175.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 38.5 tpp -120.9 107.81 13.14 Favored 'General case' 0 N--CA 1.44 -0.927 0 CA-C-N 111.999 -2.364 . . . . 0.0 106.786 177.626 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.413 ' HB ' HD21 ' B' ' 34' ' ' LEU . 63.6 t -110.84 124.0 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 179.19 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 119.9 -114.46 2.73 Favored Glycine 0 C--N 1.318 -0.461 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 -176.49 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 74.34 -71.92 1.48 Allowed Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.153 -1.022 . . . . 0.0 111.353 178.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.464 ' HA ' ' CD1' ' G' ' 31' ' ' ILE . 34.2 m -111.33 -175.79 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.426 0 CA-C-O 121.714 0.769 . . . . 0.0 111.5 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.546 ' OXT' ' CE1' ' C' ' 13' ' ' HIS . 1.6 p . . . . . 0 C--O 1.22 -0.455 0 CA-C-N 114.247 -1.342 . . . . 0.0 110.309 178.443 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 47.0 p90 -147.44 158.0 43.8 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.763 0.316 . . . . 0.0 110.441 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -141.55 120.7 12.95 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 121.081 0.467 . . . . 0.0 110.623 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.49 ' C ' ' ND1' ' B' ' 13' ' ' HIS . 16.0 t -130.1 117.39 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.122 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.607 ' CE1' ' H ' ' A' ' 12' ' ' VAL . 3.7 m-70 -137.68 112.27 8.79 Favored 'General case' 0 N--CA 1.469 0.509 0 C-N-CA 120.361 -0.536 . . . . 0.0 111.445 -179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.563 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 0.2 OUTLIER -151.96 160.13 43.58 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 178.332 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CD2' ' B' ' 14' ' ' HIS . 78.7 mt-30 -131.95 151.36 51.77 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 120.983 0.42 . . . . 0.0 111.949 179.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 64.1 mttp -97.76 121.33 39.55 Favored 'General case' 0 C--O 1.238 0.485 0 N-CA-C 107.885 -1.154 . . . . 0.0 107.885 175.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 10.3 mt -120.93 119.25 32.06 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 118.58 0.627 . . . . 0.0 110.301 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 79.3 t -124.43 132.43 71.35 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.509 0 CA-C-N 116.606 -0.27 . . . . 0.0 110.873 -179.785 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 m-85 -125.88 124.0 39.89 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.455 -0.339 . . . . 0.0 111.112 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.466 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 34.2 t80 -117.91 126.47 52.42 Favored 'General case' 0 N--CA 1.468 0.452 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.36 141.69 33.81 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -177.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -104.36 147.7 27.23 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 114.442 -1.254 . . . . 0.0 108.14 177.322 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.527 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 3.4 t70 -171.9 51.89 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.317 0 C-N-CA 120.641 -0.424 . . . . 0.0 111.023 -177.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.483 HG22 ' CB ' ' C' ' 23' ' ' ASP . 2.6 t -75.51 143.64 12.99 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.761 0 CA-C-O 121.726 0.774 . . . . 0.0 111.714 -176.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.06 38.18 3.9 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 114.405 -1.27 . . . . 0.0 112.332 179.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 73.09 120.0 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 122.192 0.197 . . . . 0.0 110.904 177.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.554 ' H ' ' HA3' ' C' ' 25' ' ' GLY . 2.1 m120 -83.38 162.6 20.99 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.373 178.146 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.504 ' H ' ' HA3' ' A' ' 29' ' ' GLY . 99.1 mttt -47.24 -37.61 10.79 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.459 0.647 . . . . 0.0 110.782 175.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.37 76.68 0.06 OUTLIER Glycine 0 CA--C 1.54 1.596 0 CA-C-N 115.217 -0.902 . . . . 0.0 111.898 -177.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.423 ' O ' ' HA ' ' C' ' 30' ' ' ALA . . . -51.78 94.87 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.459 0 CA-C-N 119.634 1.717 . . . . 0.0 112.204 -178.141 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.52 HD12 HG12 ' N' ' 39' ' ' VAL . 69.3 mt -144.62 134.77 19.74 Favored 'Isoleucine or valine' 0 C--O 1.236 0.393 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.432 -177.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' D' ' 19' ' ' PHE . 91.6 mt -105.08 108.3 24.62 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.098 0 N-CA-C 107.779 -1.193 . . . . 0.0 107.779 175.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.426 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -112.31 102.55 1.36 Allowed Glycine 0 CA--C 1.508 -0.37 0 N-CA-C 105.539 -3.024 . . . . 0.0 105.539 177.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.651 ' O ' HD12 ' C' ' 34' ' ' LEU . 7.6 tt -150.62 148.38 28.55 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 118.42 -1.312 . . . . 0.0 112.226 -174.822 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.623 ' N ' HD23 ' B' ' 34' ' ' LEU . 7.2 mtp -110.05 110.09 20.87 Favored 'General case' 0 C--N 1.313 -1.005 0 CA-C-N 113.518 -1.674 . . . . 0.0 107.075 179.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.53 ' O ' HG13 ' B' ' 36' ' ' VAL . 4.1 p -119.62 111.51 33.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 179.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.35 -131.24 4.28 Favored Glycine 0 C--N 1.308 -1.007 0 N-CA-C 108.044 -2.023 . . . . 0.0 108.044 -178.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.499 ' O ' ' CG2' ' C' ' 39' ' ' VAL . . . 87.27 -63.93 3.89 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 120.508 -0.853 . . . . 0.0 111.542 -179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.545 HG11 HD13 ' G' ' 31' ' ' ILE . 3.1 m -136.78 154.17 31.34 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.531 0 N-CA-C 109.71 -0.478 . . . . 0.0 109.71 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.429 ' H ' HG23 ' B' ' 40' ' ' VAL . 0.5 OUTLIER . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.972 -1.013 . . . . 0.0 110.338 -178.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.433 0 N-CA-C 109.686 -1.366 . . . . 0.0 109.686 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . 0.723 ' HH ' ' N ' ' E' ' 9' ' ' GLY . 92.9 m-85 -105.35 133.13 50.62 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 120.631 0.253 . . . . 0.0 110.384 179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -97.65 122.74 41.08 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.4 -0.364 . . . . 0.0 110.651 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.431 ' H ' HG13 ' B' ' 12' ' ' VAL . 19.4 m -125.4 133.07 70.18 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.159 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.546 ' CE1' ' OXT' ' A' ' 40' ' ' VAL . 5.6 t-80 -147.85 96.79 2.71 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.578 -0.283 . . . . 0.0 110.896 179.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.563 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 50.1 p-80 -157.24 167.57 29.96 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 116.738 -0.21 . . . . 0.0 111.265 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mm-40 -89.99 158.45 17.36 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 121.437 0.637 . . . . 0.0 110.788 179.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -140.29 113.51 8.43 Favored 'General case' 0 C--N 1.311 -1.068 0 N-CA-C 107.509 -1.293 . . . . 0.0 107.509 176.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 8.4 mt -127.94 123.15 34.18 Favored 'General case' 0 N--CA 1.472 0.663 0 CA-C-O 122.071 0.938 . . . . 0.0 111.478 179.002 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 67.1 t -111.14 117.03 54.07 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 N-CA-C 107.505 -1.294 . . . . 0.0 107.505 177.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.432 ' CD2' ' CE2' ' D' ' 19' ' ' PHE . 56.2 m-85 -107.08 105.85 16.07 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.613 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 11.7 t80 -113.84 124.41 52.16 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.7 -0.227 . . . . 0.0 111.152 -178.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.66 122.34 30.6 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.647 0.736 . . . . 0.0 110.396 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 82.0 tt0 -94.31 137.99 32.83 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.217 -178.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.516 ' N ' ' OE1' ' D' ' 22' ' ' GLU . 8.7 m-20 43.17 47.12 5.3 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.41 0.624 . . . . 0.0 109.354 179.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.648 ' O ' HG21 ' D' ' 24' ' ' VAL . 0.2 OUTLIER -61.43 -169.25 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.799 -177.195 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.579 ' H ' HG12 ' C' ' 24' ' ' VAL . . . -111.74 33.34 5.83 Favored Glycine 0 C--N 1.318 -0.427 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.098 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.43 ' O ' ' N ' ' D' ' 26' ' ' SER . 27.3 t -62.63 104.87 0.57 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.497 0.665 . . . . 0.0 109.221 -178.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.857 ' O ' ' N ' ' C' ' 29' ' ' GLY . 7.8 m120 -157.6 179.23 9.42 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 114.685 -1.143 . . . . 0.0 108.616 -178.347 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm 1.86 -44.7 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.051 0 O-C-N 125.067 1.48 . . . . 0.0 114.212 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.857 ' N ' ' O ' ' C' ' 27' ' ' ASN . . . -111.14 58.57 0.39 Allowed Glycine 0 CA--C 1.542 1.764 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 178.578 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.423 ' HA ' ' O ' ' B' ' 30' ' ' ALA . . . -109.35 99.75 8.95 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 117.349 0.575 . . . . 0.0 109.973 179.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.426 HG22 ' N ' ' D' ' 31' ' ' ILE . 29.7 pt -147.93 156.97 9.01 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.371 0 C-N-CA 117.88 -1.528 . . . . 0.0 114.385 179.714 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' E' ' 19' ' ' PHE . 95.9 mt -107.6 112.15 38.84 Favored 'Isoleucine or valine' 0 C--N 1.345 0.376 0 CA-C-N 114.053 -1.431 . . . . 0.0 108.695 176.35 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.91 93.76 0.74 Allowed Glycine 0 CA--C 1.507 -0.451 0 N-CA-C 104.412 -3.475 . . . . 0.0 104.412 175.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.651 HD12 ' O ' ' B' ' 34' ' ' LEU . 42.3 tp -135.0 132.57 38.48 Favored 'General case' 0 CA--C 1.515 -0.39 0 CA-C-O 122.365 1.079 . . . . 0.0 113.294 -174.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.417 ' H ' HD12 ' C' ' 34' ' ' LEU . 6.4 mtp -99.99 111.33 23.63 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 113.916 -1.493 . . . . 0.0 108.673 177.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.532 HG12 ' CD ' ' E' ' 15' ' ' GLN . 3.1 t -110.8 103.32 15.29 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 109.568 -0.53 . . . . 0.0 109.568 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 138.13 -154.62 22.93 Favored Glycine 0 N--CA 1.46 0.254 0 C-N-CA 120.585 -0.817 . . . . 0.0 111.673 178.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.21 -55.89 0.5 Allowed Glycine 0 CA--C 1.545 1.936 0 N-CA-C 111.428 -0.669 . . . . 0.0 111.428 -178.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.882 ' C ' HG11 ' D' ' 39' ' ' VAL . 68.6 t -136.04 162.97 35.49 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 C-N-CA 123.273 0.629 . . . . 0.0 110.167 178.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.676 ' N ' HG21 ' D' ' 39' ' ' VAL . 75.9 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.889 -1.053 . . . . 0.0 111.056 -179.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.175 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -106.81 134.53 49.81 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.924 -0.398 . . . . 0.0 109.924 179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -127.6 128.64 45.91 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-O 121.126 0.489 . . . . 0.0 111.195 -179.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 1.3 p -145.14 112.62 1.34 Allowed 'Isoleucine or valine' 0 C--O 1.222 -0.389 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.684 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -143.24 142.65 31.45 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.074 0.464 . . . . 0.0 110.228 179.089 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.554 ' O ' ' CG ' ' C' ' 14' ' ' HIS . 27.7 p-80 -146.12 162.6 37.6 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.592 -0.731 . . . . 0.0 109.114 178.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -89.67 158.19 17.68 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 119.735 -0.786 . . . . 0.0 109.311 179.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.675 ' C ' HD22 ' D' ' 17' ' ' LEU . 85.6 tttt -140.68 106.28 5.1 Favored 'General case' 0 C--N 1.31 -1.137 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.719 HD22 ' N ' ' D' ' 17' ' ' LEU . 1.7 mm? -123.37 124.95 44.08 Favored 'General case' 0 N--CA 1.471 0.608 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.849 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -123.11 112.2 32.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.767 -0.827 . . . . 0.0 108.767 177.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' B' ' 32' ' ' ILE . 27.1 m-85 -108.77 103.79 12.94 Favored 'General case' 0 CA--C 1.532 0.279 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 179.452 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.613 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.4 t80 -111.71 124.72 52.91 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 110.474 -0.195 . . . . 0.0 110.474 -179.004 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.89 141.41 38.56 Favored 'General case' 0 C--O 1.242 0.699 0 CA-C-O 122.443 1.116 . . . . 0.0 112.923 -178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.536 ' O ' HG23 ' D' ' 24' ' ' VAL . 84.2 mt-10 -75.85 118.32 18.52 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.065 179.193 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.425 ' O ' HG13 ' E' ' 24' ' ' VAL . 13.6 t0 -57.15 59.77 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.882 0 CA-C-N 113.231 -1.804 . . . . 0.0 113.591 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.648 HG21 ' O ' ' C' ' 24' ' ' VAL . 43.3 t -63.05 -113.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 N-CA-C 107.06 -1.459 . . . . 0.0 107.06 -177.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.419 ' N ' HG12 ' D' ' 24' ' ' VAL . . . -104.4 44.37 1.49 Allowed Glycine 0 N--CA 1.478 1.489 0 CA-C-N 121.446 1.93 . . . . 0.0 111.973 -174.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.452 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 1.3 t -70.64 100.51 1.86 Allowed 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 112.938 -1.631 . . . . 0.0 107.879 175.323 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -118.62 -153.18 0.53 Allowed 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.389 0.614 . . . . 0.0 112.564 -174.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -37.58 -41.86 0.5 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 114.88 -1.054 . . . . 0.0 111.704 -177.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.07 68.39 1.96 Allowed Glycine 0 CA--C 1.537 1.417 0 C-N-CA 120.374 -0.917 . . . . 0.0 111.771 -177.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.85 136.4 32.33 Favored 'General case' 0 C--N 1.349 0.555 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 179.05 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.598 HD11 ' O ' ' P' ' 39' ' ' VAL . 39.7 mt -145.53 146.7 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.736 0 N-CA-C 115.398 1.629 . . . . 0.0 115.398 -175.135 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.463 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -108.46 111.58 36.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.666 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.494 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.15 102.48 0.8 Allowed Glycine 0 N--CA 1.463 0.497 0 N-CA-C 108.4 -1.88 . . . . 0.0 108.4 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.415 ' CD2' ' CZ ' ' E' ' 19' ' ' PHE . 2.9 mp -137.16 135.23 37.17 Favored 'General case' 0 C--O 1.242 0.658 0 CA-C-O 122.424 1.107 . . . . 0.0 113.652 -178.166 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -98.91 113.51 25.69 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-N 113.299 -1.773 . . . . 0.0 107.355 177.412 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.441 ' O ' ' O ' ' E' ' 35' ' ' MET . 2.9 t -118.92 103.22 14.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 -177.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.481 ' CA ' ' H ' ' E' ' 38' ' ' GLY . . . 147.25 -153.62 25.45 Favored Glycine 0 C--N 1.31 -0.877 0 C-N-CA 119.928 -1.129 . . . . 0.0 110.54 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.431 ' O ' ' O ' ' E' ' 40' ' ' VAL . . . 104.45 -56.33 0.56 Allowed Glycine 0 CA--C 1.541 1.675 0 N-CA-C 111.573 -0.611 . . . . 0.0 111.573 -178.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.882 HG11 ' C ' ' C' ' 39' ' ' VAL . 7.3 p -119.98 140.9 42.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.352 0 CA-C-O 121.361 0.601 . . . . 0.0 111.526 -178.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.454 ' O ' HG13 ' D' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.614 179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . 0.723 ' N ' ' HH ' ' C' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -115.75 136.48 53.01 Favored 'General case' 0 N--CA 1.467 0.375 0 CA-C-O 120.627 0.251 . . . . 0.0 110.539 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -74.19 142.57 45.41 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.259 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 79.4 t -127.16 133.33 68.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.475 0 CA-C-O 120.785 0.326 . . . . 0.0 111.246 -179.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 48.1 m170 -137.81 100.0 4.06 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 178.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.422 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.0 OUTLIER -151.56 165.6 33.77 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 121.594 0.711 . . . . 0.0 112.801 -179.593 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.532 ' CD ' HG12 ' C' ' 36' ' ' VAL . 87.2 mt-30 -84.35 157.12 21.57 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 114.798 -1.092 . . . . 0.0 109.324 178.829 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -159.28 103.1 1.61 Allowed 'General case' 0 C--N 1.311 -1.104 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 179.172 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.451 HD12 ' N ' ' E' ' 17' ' ' LEU . 3.5 mp -137.43 131.45 31.98 Favored 'General case' 0 CA--C 1.514 -0.423 0 CA-C-O 121.387 0.613 . . . . 0.0 111.786 -179.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -117.59 112.28 38.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.534 ' CD2' HD13 ' C' ' 32' ' ' ILE . 27.4 m-85 -106.07 105.83 16.06 Favored 'General case' 0 C--O 1.233 0.211 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 178.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -116.68 117.64 30.37 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.75 0.648 . . . . 0.0 112.75 -176.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.25 123.12 31.13 Favored 'General case' 0 N--CA 1.469 0.511 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 177.341 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.441 ' O ' ' CB ' ' E' ' 23' ' ' ASP . 78.0 tt0 -154.11 154.21 33.22 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 117.9 2.555 . . . . 0.0 117.9 -175.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.454 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 52.6 m-20 109.72 46.5 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 111.646 -2.525 . . . . 0.0 116.372 174.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.459 ' N ' ' OE1' ' F' ' 22' ' ' GLU . 1.8 m -118.15 174.64 4.0 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.789 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 172.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.483 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -59.88 -28.25 65.65 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 107.868 -2.093 . . . . 0.0 107.868 172.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.483 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 3.7 p 143.0 129.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 112.524 -1.838 . . . . 0.0 106.209 -177.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.511 ' ND2' ' H ' ' E' ' 29' ' ' GLY . 2.6 t30 -53.59 141.57 25.37 Favored 'General case' 0 N--CA 1.468 0.465 0 C-N-CA 118.694 -1.202 . . . . 0.0 110.886 -176.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -58.37 -48.81 79.41 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -179.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.511 ' H ' ' ND2' ' E' ' 27' ' ' ASN . . . -170.23 59.27 0.19 Allowed Glycine 0 CA--C 1.54 1.629 0 C-N-CA 120.246 -0.978 . . . . 0.0 114.368 -175.615 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.65 169.17 16.54 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-N 119.124 1.462 . . . . 0.0 113.132 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.507 HD11 HG12 ' Q' ' 39' ' ' VAL . 77.5 mt -120.97 137.47 54.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.461 0 CA-C-N 113.784 -1.553 . . . . 0.0 110.301 -179.553 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 55.5 mt -121.11 121.75 65.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 N-CA-C 109.298 -0.63 . . . . 0.0 109.298 178.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.79 114.5 2.0 Favored Glycine 0 N--CA 1.471 0.981 0 N-CA-C 110.46 -1.056 . . . . 0.0 110.46 -179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.623 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 59.4 mt -127.81 124.28 37.23 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-O 120.978 0.418 . . . . 0.0 111.088 -178.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.441 ' O ' ' O ' ' D' ' 36' ' ' VAL . 4.0 mtp -108.22 111.77 23.92 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.541 -0.464 . . . . 0.0 110.245 178.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.636 HG12 ' N ' ' E' ' 37' ' ' GLY . 40.2 t -90.28 173.79 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.636 ' N ' HG12 ' E' ' 36' ' ' VAL . . . 162.16 -95.52 0.13 Allowed Glycine 0 C--N 1.305 -1.175 0 C-N-CA 120.321 -0.943 . . . . 0.0 111.096 -179.643 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.481 ' H ' ' CA ' ' D' ' 37' ' ' GLY . . . 87.73 -83.69 1.53 Allowed Glycine 0 N--CA 1.473 1.108 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.629 HG13 HD11 ' K' ' 31' ' ' ILE . 55.3 t -67.57 97.26 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.336 0 N-CA-C 106.49 -1.671 . . . . 0.0 106.49 176.56 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.494 ' C ' HG21 ' K' ' 31' ' ' ILE . 80.2 t . . . . . 0 C--O 1.22 -0.454 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.517 -179.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.422 -1.471 . . . . 0.0 109.422 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -114.74 139.57 49.58 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 121.022 0.439 . . . . 0.0 110.712 -179.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.516 ' OE1' ' N ' ' F' ' 11' ' ' GLU . 57.9 mp0 -126.03 146.56 49.84 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.661 179.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.7 p -128.67 135.05 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.351 0.596 . . . . 0.0 111.409 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -142.19 131.98 24.22 Favored 'General case' 0 CA--C 1.535 0.397 0 CA-C-N 115.067 -0.97 . . . . 0.0 110.492 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' F' ' 15' ' ' GLN . 83.4 t60 -155.15 167.81 29.12 Favored 'General case' 0 C--N 1.33 -0.276 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 177.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 28.5 mp0 -89.51 150.34 22.5 Favored 'General case' 0 CA--C 1.517 -0.298 0 C-N-CA 120.531 -0.468 . . . . 0.0 109.87 179.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -151.99 97.26 2.31 Favored 'General case' 0 C--N 1.309 -1.181 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.431 ' CD1' HG11 ' D' ' 36' ' ' VAL . 3.9 mp -133.83 116.25 15.45 Favored 'General case' 0 CA--C 1.506 -0.715 0 CA-C-N 115.978 -0.555 . . . . 0.0 109.705 179.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 98.5 t -99.99 109.49 24.97 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.623 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 65.1 m-85 -104.89 98.92 8.57 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -112.83 111.43 22.2 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 121.338 0.589 . . . . 0.0 109.476 179.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.43 131.33 38.03 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 107.503 -1.295 . . . . 0.0 107.503 178.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' N ' ' E' ' 24' ' ' VAL . 84.6 tt0 -69.52 115.59 8.95 Favored 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 118.441 -1.304 . . . . 0.0 109.479 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.443 ' OD2' ' O ' ' F' ' 23' ' ' ASP . 18.9 t70 -167.8 51.79 0.06 Allowed 'General case' 0 CA--C 1.53 0.196 0 CA-C-N 115.141 -0.936 . . . . 0.0 110.64 -178.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 75.5 t -75.38 142.96 13.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.36 38.03 3.63 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -178.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 5.1 m -70.68 102.18 2.23 Favored 'General case' 0 N--CA 1.462 0.153 0 CA-C-O 121.575 0.702 . . . . 0.0 110.871 -178.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 42.4 p30 -119.51 -170.25 1.91 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.995 -178.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.3 mttm -33.89 -41.85 0.11 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.566 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -90.59 67.22 2.51 Favored Glycine 0 CA--C 1.542 1.746 0 CA-C-N 116.347 -0.388 . . . . 0.0 112.34 -178.667 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . 171.27 139.01 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.291 0 N-CA-C 106.857 -1.535 . . . . 0.0 106.857 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.508 HD13 ' HA ' ' R' ' 39' ' ' VAL . 86.2 mt -132.78 142.84 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 C-N-CA 119.786 -0.765 . . . . 0.0 113.002 -177.946 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 90.7 mt -131.57 128.91 61.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.774 178.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.14 131.34 5.66 Favored Glycine 0 CA--C 1.53 1.007 0 N-CA-C 111.66 -0.576 . . . . 0.0 111.66 -179.523 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.486 HD23 ' C ' ' F' ' 34' ' ' LEU . 7.7 tt -135.89 127.46 28.83 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.454 ' N ' HD23 ' F' ' 34' ' ' LEU . 92.8 mtp -140.2 149.7 43.25 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 113.171 0.804 . . . . 0.0 113.171 -178.305 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -92.91 154.77 3.18 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.614 179.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.548 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.93 102.59 2.94 Favored Glycine 0 CA--C 1.528 0.902 0 N-CA-C 111.581 -0.608 . . . . 0.0 111.581 -179.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.19 -73.64 0.0 OUTLIER Glycine 0 CA--C 1.537 1.417 0 CA-C-N 115.41 -0.395 . . . . 0.0 113.139 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.548 ' N ' ' O ' ' F' ' 37' ' ' GLY . 90.4 t -151.32 136.55 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 117.848 0.824 . . . . 0.0 110.255 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.422 HG12 ' H ' ' F' ' 40' ' ' VAL . 5.8 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.565 179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -112.42 134.17 54.1 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.846 0.355 . . . . 0.0 110.285 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' H' ' 11' ' ' GLU . 96.3 mt-10 -83.12 123.77 29.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.188 0.518 . . . . 0.0 110.894 -179.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.406 HG22 ' CE1' ' H' ' 13' ' ' HIS . 62.0 t -134.52 137.08 51.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.77 -0.65 . . . . 0.0 109.869 -179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.474 ' O ' ' O ' ' H' ' 13' ' ' HIS . 98.3 m-70 -135.14 101.77 4.97 Favored 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 120.637 -0.425 . . . . 0.0 111.864 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.553 ' ND1' ' N ' ' G' ' 15' ' ' GLN . 6.6 t-80 -157.2 161.63 39.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.228 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.553 ' N ' ' ND1' ' G' ' 14' ' ' HIS . 13.2 pt20 -174.3 147.86 1.22 Allowed 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.102 177.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 57.3 pttt -79.51 121.8 25.66 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.91 -0.586 . . . . 0.0 112.207 178.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.498 HD11 ' NE2' ' G' ' 15' ' ' GLN . 96.3 mt -131.75 116.42 17.25 Favored 'General case' 0 N--CA 1.47 0.532 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 55.5 t -126.69 136.22 61.45 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 116.004 -0.544 . . . . 0.0 111.129 -178.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.538 ' CD1' ' CZ ' ' H' ' 19' ' ' PHE . 68.1 m-85 -135.1 125.88 27.29 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.357 0.599 . . . . 0.0 111.086 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.493 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -115.11 129.62 56.72 Favored 'General case' 0 N--CA 1.466 0.335 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.466 ' CB ' HG11 ' G' ' 24' ' ' VAL . . . -126.43 124.33 39.91 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -177.29 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.2 tt0 -137.21 115.27 11.57 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 107.472 -1.307 . . . . 0.0 107.472 177.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 63.7 t0 50.25 49.91 19.65 Favored 'General case' 0 N--CA 1.468 0.461 0 CA-C-O 121.666 0.746 . . . . 0.0 109.046 -177.561 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.466 HG11 ' CB ' ' G' ' 21' ' ' ALA . 29.5 m -82.11 -142.47 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.316 -0.863 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.094 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.522 ' O ' ' ND2' ' G' ' 27' ' ' ASN . . . -91.94 -38.38 5.77 Favored Glycine 0 CA--C 1.521 0.438 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -178.37 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 2.3 m -69.13 113.89 6.91 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' G' ' 25' ' ' GLY . 29.0 m-20 -117.86 -150.42 0.46 Allowed 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 112.608 -2.087 . . . . 0.0 112.439 -173.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.642 ' O ' ' N ' ' H' ' 28' ' ' LYS . 99.2 mttt -37.68 -40.76 0.44 Allowed 'General case' 0 C--O 1.214 -0.775 0 CA-C-N 113.534 -1.667 . . . . 0.0 111.227 -178.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -109.78 68.8 0.21 Allowed Glycine 0 CA--C 1.545 1.943 0 O-C-N 121.653 -0.654 . . . . 0.0 112.552 -176.326 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.595 ' HB3' ' HB3' ' H' ' 27' ' ' ASN . . . -96.7 113.24 24.78 Favored 'General case' 0 C--N 1.368 1.376 0 CA-C-O 124.124 1.916 . . . . 0.0 111.287 -179.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.545 HD13 HG11 ' B' ' 39' ' ' VAL . 38.1 mt -129.16 131.8 67.53 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.889 0 CA-C-N 110.337 -3.119 . . . . 0.0 108.843 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.514 HG22 HD21 ' H' ' 34' ' ' LEU . 31.8 mt -103.32 106.39 20.05 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 106.921 -1.511 . . . . 0.0 106.921 176.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.34 94.95 0.79 Allowed Glycine 0 CA--C 1.504 -0.613 0 N-CA-C 106.185 -2.766 . . . . 0.0 106.185 177.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.421 ' H ' HD23 ' H' ' 34' ' ' LEU . 58.3 mt -144.38 156.1 44.07 Favored 'General case' 0 C--O 1.239 0.523 0 CA-C-O 123.162 1.458 . . . . 0.0 112.813 -177.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 4.2 mtp -105.22 113.22 26.68 Favored 'General case' 0 N--CA 1.437 -1.099 0 CA-C-N 111.983 -2.371 . . . . 0.0 106.001 176.204 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.481 HG11 HD11 ' J' ' 17' ' ' LEU . 48.4 t -109.04 102.33 13.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.508 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 67.63 -162.5 47.7 Favored Glycine 0 CA--C 1.521 0.462 0 N-CA-C 110.088 -1.205 . . . . 0.0 110.088 -179.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.12 -55.67 0.52 Allowed Glycine 0 CA--C 1.532 1.138 0 CA-C-O 118.82 -0.989 . . . . 0.0 111.919 179.114 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.505 HG12 ' CD1' ' M' ' 31' ' ' ILE . 1.6 m -70.48 176.86 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.346 0.428 0 CA-C-N 118.27 1.035 . . . . 0.0 109.499 177.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' G' ' 39' ' ' VAL . 7.1 p . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 117.879 -1.058 . . . . 0.0 111.587 179.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -104.93 133.17 50.18 Favored 'General case' 0 N--CA 1.466 0.327 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' G' ' 11' ' ' GLU . 97.3 mt-10 -83.41 141.49 31.68 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.941 0.4 . . . . 0.0 110.959 -179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.609 HG11 ' ND1' ' I' ' 13' ' ' HIS . 71.0 t -143.01 161.75 17.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 179.531 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.526 ' N ' HG12 ' H' ' 12' ' ' VAL . 44.5 m80 -135.21 159.14 42.49 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 109.433 -0.581 . . . . 0.0 109.433 179.317 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.439 ' CB ' ' O ' ' I' ' 14' ' ' HIS . 42.8 p-80 -85.61 166.19 16.42 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.805 -179.099 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 -100.39 152.72 20.02 Favored 'General case' 0 CA--C 1.51 -0.594 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.618 ' C ' HD12 ' H' ' 17' ' ' LEU . 88.6 tttt -109.31 109.95 20.99 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.618 HD12 ' C ' ' H' ' 16' ' ' LYS . 11.1 mp -119.01 122.86 43.14 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.853 179.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -124.21 126.74 72.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-N 115.86 -0.609 . . . . 0.0 109.415 179.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.538 ' CZ ' ' CD1' ' G' ' 19' ' ' PHE . 34.2 m-85 -133.89 126.14 29.81 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.812 -0.811 . . . . 0.0 108.812 179.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.457 ' CZ ' ' CB ' ' G' ' 20' ' ' PHE . 24.3 p90 -143.44 151.39 40.29 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 119.31 -0.956 . . . . 0.0 111.676 179.283 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.31 130.02 51.16 Favored 'General case' 0 C--O 1.251 1.171 0 CA-C-O 121.926 0.87 . . . . 0.0 111.467 -179.3 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 92.2 mt-10 -60.98 -166.13 0.01 OUTLIER 'General case' 0 CA--C 1.501 -0.931 0 CA-C-N 113.879 -1.51 . . . . 0.0 107.757 179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.572 ' OD1' HG22 ' I' ' 24' ' ' VAL . 33.2 t70 -84.22 57.65 4.35 Favored 'General case' 0 N--CA 1.444 -0.726 0 C-N-CA 116.669 -2.012 . . . . 0.0 115.41 -175.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.961 HG22 ' H ' ' H' ' 25' ' ' GLY . 1.3 p -68.64 -112.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.454 -0.271 1 N-CA-C 100.069 -4.048 . . . . 0.0 100.069 166.451 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.961 ' H ' HG22 ' H' ' 24' ' ' VAL . . . 124.41 -39.39 2.14 Favored Glycine 0 C--N 1.331 0.283 0 N-CA-C 117.985 1.954 . . . . 0.0 117.985 167.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -70.23 110.5 5.25 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 115.632 -2.427 . . . . 0.0 112.968 -177.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 1.093 ' O ' ' N ' ' H' ' 29' ' ' GLY . 0.0 OUTLIER -122.7 156.97 33.29 Favored 'General case' 0 C--O 1.207 -1.145 0 N-CA-C 103.511 -2.774 . . . . 0.0 103.511 167.314 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.642 ' N ' ' O ' ' G' ' 28' ' ' LYS . 13.1 tttt -34.51 49.15 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.905 0 CA-C-N 122.721 2.509 . . . . 0.0 111.16 172.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 1.093 ' N ' ' O ' ' H' ' 27' ' ' ASN . . . 101.26 -52.22 0.9 Allowed Glycine 0 CA--C 1.563 3.044 0 N-CA-C 109.234 -1.546 . . . . 0.0 109.234 -177.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.526 ' HB3' ' HB2' ' I' ' 30' ' ' ALA . . . 129.35 115.38 0.0 OUTLIER 'General case' 0 C--N 1.377 1.799 0 C-N-CA 125.946 1.698 . . . . 0.0 107.977 177.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.46 HD13 HG12 ' B' ' 39' ' ' VAL . 72.2 mt -126.54 128.13 70.95 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.115 0 CA-C-N 122.056 2.207 . . . . 0.0 114.793 -178.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -111.67 110.51 32.47 Favored 'Isoleucine or valine' 0 C--N 1.353 0.754 0 N-CA-C 108.015 -1.106 . . . . 0.0 108.015 175.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.424 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -116.46 105.4 1.35 Allowed Glycine 0 N--CA 1.465 0.602 0 N-CA-C 107.215 -2.354 . . . . 0.0 107.215 178.269 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.583 ' O ' HD23 ' I' ' 34' ' ' LEU . 73.8 mt -140.65 148.86 41.51 Favored 'General case' 0 CA--C 1.508 -0.66 0 CA-C-O 122.832 1.301 . . . . 0.0 113.376 -176.069 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 4.8 ttm -113.86 112.36 23.23 Favored 'General case' 0 C--N 1.318 -0.791 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 175.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.644 ' O ' HG13 ' H' ' 36' ' ' VAL . 5.0 p -132.39 102.55 5.54 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -177.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.752 ' N ' HE22 ' J' ' 15' ' ' GLN . . . 122.52 -163.29 15.97 Favored Glycine 0 N--CA 1.467 0.702 0 N-CA-C 111.075 -0.81 . . . . 0.0 111.075 -179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' I' ' 37' ' ' GLY . . . 128.28 -54.57 0.78 Allowed Glycine 0 CA--C 1.547 2.06 0 N-CA-C 111.655 -0.578 . . . . 0.0 111.655 -178.291 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.842 HG22 ' CD1' ' N' ' 31' ' ' ILE . 14.6 t -109.7 165.99 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.294 0 C-N-CA 123.681 0.793 . . . . 0.0 110.127 179.63 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.528 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 2.5 m . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.658 -179.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.36 133.67 52.23 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.772 0.32 . . . . 0.0 110.509 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 54.6 tp10 -75.35 122.57 23.96 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.245 179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -139.51 160.86 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.548 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.609 ' ND1' HG11 ' H' ' 12' ' ' VAL . 21.8 t60 -145.73 100.25 3.39 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 121.253 -0.179 . . . . 0.0 110.724 179.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.557 ' CG ' ' O ' ' J' ' 14' ' ' HIS . 45.3 p-80 -165.52 169.57 15.34 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -179.613 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -89.84 158.95 17.24 Favored 'General case' 0 C--N 1.341 0.215 0 CA-C-N 115.811 -0.632 . . . . 0.0 109.829 178.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.765 ' C ' HD12 ' I' ' 17' ' ' LEU . 83.7 tttt -139.97 111.12 7.0 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.752 -0.833 . . . . 0.0 108.752 177.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.765 HD12 ' C ' ' I' ' 16' ' ' LYS . 10.5 mp -127.95 128.64 45.43 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.247 0.546 . . . . 0.0 110.332 178.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 71.4 t -112.76 120.77 63.66 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 177.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -114.0 106.42 14.4 Favored 'General case' 0 CA--C 1.532 0.287 0 N-CA-C 108.409 -0.959 . . . . 0.0 108.409 179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.58 ' CD1' ' CD2' ' J' ' 20' ' ' PHE . 1.9 t80 -115.52 129.14 56.43 Favored 'General case' 0 N--CA 1.481 1.11 0 O-C-N 122.342 -0.224 . . . . 0.0 110.451 -179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.411 ' N ' ' CD1' ' I' ' 20' ' ' PHE . . . -150.18 130.57 13.79 Favored 'General case' 0 C--O 1.245 0.847 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -178.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.8 tt0 -95.65 119.42 34.12 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 106.84 -1.541 . . . . 0.0 106.84 176.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -118.64 46.3 1.86 Allowed 'General case' 0 N--CA 1.479 0.997 0 N-CA-C 115.352 1.612 . . . . 0.0 115.352 -175.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.572 HG22 ' OD1' ' H' ' 23' ' ' ASP . 23.7 m -92.74 173.55 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 175.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.32 27.82 65.12 Favored Glycine 0 CA--C 1.529 0.936 0 C-N-CA 118.244 -1.931 . . . . 0.0 109.908 -177.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 4.7 p 166.66 146.68 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 -179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 17.2 m120 -53.15 136.93 35.11 Favored 'General case' 0 CA--C 1.54 0.558 0 N-CA-C 117.416 2.376 . . . . 0.0 117.416 -173.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.469 ' O ' ' HA2' ' J' ' 29' ' ' GLY . 37.9 mttt -60.84 51.06 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.074 0 CA-C-N 110.704 -2.953 . . . . 0.0 114.293 173.825 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -108.07 51.94 0.69 Allowed Glycine 0 N--CA 1.495 2.609 0 O-C-N 120.494 -1.379 . . . . 0.0 116.148 -172.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.526 ' HB2' ' HB3' ' H' ' 30' ' ' ALA . . . -100.31 147.09 26.17 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-O 123.685 1.707 . . . . 0.0 114.993 -177.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.751 HD13 HG22 ' C' ' 39' ' ' VAL . 13.7 tt -132.29 135.88 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 CA-C-N 112.959 -1.928 . . . . 0.0 112.248 -179.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 89.6 mt -106.28 108.6 25.49 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.581 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.01 111.0 3.63 Favored Glycine 0 C--O 1.24 0.496 0 N-CA-C 105.305 -3.118 . . . . 0.0 105.305 176.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.583 HD23 ' O ' ' H' ' 34' ' ' LEU . 0.3 OUTLIER -148.32 141.07 24.6 Favored 'General case' 0 C--O 1.237 0.429 0 C-N-CA 117.68 -1.608 . . . . 0.0 115.073 -174.462 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 81.6 mmm -103.13 114.65 29.12 Favored 'General case' 0 CA--C 1.503 -0.828 0 CA-C-N 112.233 -2.258 . . . . 0.0 105.134 175.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.413 HG22 HD22 ' I' ' 34' ' ' LEU . 58.4 t -122.57 131.75 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.664 0 CA-C-O 120.809 0.337 . . . . 0.0 111.047 -176.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.509 ' O ' ' N ' ' H' ' 38' ' ' GLY . . . 80.44 -111.22 3.24 Favored Glycine 0 CA--C 1.532 1.132 0 C-N-CA 120.629 -0.796 . . . . 0.0 114.807 176.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.55 -70.51 0.22 Allowed Glycine 0 CA--C 1.539 1.583 0 N-CA-C 108.54 -1.824 . . . . 0.0 108.54 -175.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.456 ' HB ' ' CD1' ' O' ' 31' ' ' ILE . 2.6 p -134.61 137.07 51.82 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.383 0 N-CA-C 107.936 -1.135 . . . . 0.0 107.936 173.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.558 ' OXT' ' ND1' ' L' ' 13' ' ' HIS . 27.5 m . . . . . 0 C--O 1.218 -0.57 0 CA-C-O 117.814 -1.088 . . . . 0.0 111.284 -178.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.25 0 N-CA-C 109.484 -1.446 . . . . 0.0 109.484 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -106.54 137.67 44.12 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 110.135 -0.32 . . . . 0.0 110.135 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -130.67 139.02 50.32 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 120.899 0.381 . . . . 0.0 110.843 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 41.8 t -123.24 125.29 71.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.423 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.56 ' O ' ' ND1' ' K' ' 13' ' ' HIS . 3.3 m80 -120.96 121.92 39.05 Favored 'General case' 0 N--CA 1.468 0.429 0 C-N-CA 121.018 -0.273 . . . . 0.0 111.166 -179.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.557 ' O ' ' CG ' ' I' ' 14' ' ' HIS . 0.3 OUTLIER -152.45 156.41 39.4 Favored 'General case' 0 C--O 1.221 -0.438 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.19 176.478 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.752 HE22 ' N ' ' H' ' 37' ' ' GLY . 83.8 mt-30 -90.37 160.22 16.2 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 110.378 -0.23 . . . . 0.0 110.378 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.617 ' C ' HD12 ' J' ' 17' ' ' LEU . 68.5 mttm -139.7 97.21 3.22 Favored 'General case' 0 C--N 1.315 -0.894 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.27 179.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.617 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.1 mp -122.8 121.49 36.41 Favored 'General case' 0 N--CA 1.483 1.182 0 CA-C-O 121.703 0.763 . . . . 0.0 109.549 176.406 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . 0.506 HG13 HG13 ' K' ' 18' ' ' VAL . 21.9 t -110.67 116.23 51.89 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.564 179.716 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.432 ' CZ ' ' HB3' ' J' ' 17' ' ' LEU . 33.9 m-85 -112.58 104.46 12.55 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 107.633 -1.247 . . . . 0.0 107.633 178.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CD1' ' I' ' 20' ' ' PHE . 4.5 t80 -115.09 131.02 57.06 Favored 'General case' 0 N--CA 1.478 0.939 0 O-C-N 122.449 -0.157 . . . . 0.0 110.882 -178.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' K' ' 21' ' ' ALA . . . -168.38 171.82 8.85 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-O 123.631 1.681 . . . . 0.0 115.464 -179.117 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -111.62 113.84 26.49 Favored 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 113.164 -1.834 . . . . 0.0 107.426 177.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -172.82 49.81 0.02 OUTLIER 'General case' 0 CA--C 1.543 0.707 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -176.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.754 HG22 ' H ' ' J' ' 25' ' ' GLY . 13.2 p -154.81 -179.75 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.879 -178.636 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.754 ' H ' HG22 ' J' ' 24' ' ' VAL . . . 61.59 29.74 72.72 Favored Glycine 0 CA--C 1.539 1.543 0 N-CA-C 116.905 1.522 . . . . 0.0 116.905 178.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.626 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.7 m -145.32 -120.8 0.08 Allowed 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 105.64 -1.985 . . . . 0.0 105.64 -179.736 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.626 ' O ' ' O ' ' J' ' 26' ' ' SER . 1.3 p-10 -53.51 -156.61 0.0 OUTLIER 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 176.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.486 ' HZ2' ' CE1' ' F' ' 13' ' ' HIS . 99.0 mttt -63.36 -39.9 95.79 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 119.573 -1.954 . . . . 0.0 107.084 -173.103 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.505 ' N ' ' OD1' ' J' ' 27' ' ' ASN . . . 92.5 -65.69 2.09 Favored Glycine 0 N--CA 1.473 1.112 0 C-N-CA 119.732 -1.223 . . . . 0.0 114.966 174.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.402 ' HA ' ' O ' ' I' ' 30' ' ' ALA . . . -169.56 155.36 6.03 Favored 'General case' 0 N--CA 1.44 -0.93 0 C-N-CA 116.759 -1.977 . . . . 0.0 115.346 -179.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.509 ' HA ' ' O ' ' K' ' 31' ' ' ILE . 0.8 OUTLIER -135.3 124.96 42.69 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 111.065 -2.788 . . . . 0.0 109.628 177.417 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.425 HD13 HG21 ' J' ' 32' ' ' ILE . 44.8 mt -108.22 117.12 53.1 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.968 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.93 100.73 1.2 Allowed Glycine 0 N--CA 1.462 0.404 0 N-CA-C 105.785 -2.926 . . . . 0.0 105.785 175.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -127.86 129.79 47.5 Favored 'General case' 0 C--O 1.238 0.472 0 N-CA-C 114.87 1.433 . . . . 0.0 114.87 -175.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -99.58 109.92 22.4 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.293 -2.484 . . . . 0.0 104.293 174.185 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.417 ' N ' ' O ' ' K' ' 35' ' ' MET . 2.0 t -125.64 153.19 33.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 121.095 0.474 . . . . 0.0 111.497 -175.386 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 57.47 -101.89 0.2 Allowed Glycine 0 CA--C 1.526 0.747 0 CA-C-N 115.653 -0.703 . . . . 0.0 113.172 178.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.561 ' H ' ' N ' ' K' ' 37' ' ' GLY . . . 99.29 -76.66 0.51 Allowed Glycine 0 CA--C 1.537 1.408 0 N-CA-C 111.008 -0.837 . . . . 0.0 111.008 -177.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.852 HG11 HD11 ' P' ' 31' ' ' ILE . 28.0 m -131.46 161.11 41.75 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.841 0 CA-C-N 118.362 1.081 . . . . 0.0 110.482 178.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.446 ' OXT' ' O ' ' J' ' 39' ' ' VAL . 44.8 t . . . . . 0 C--O 1.221 -0.417 0 CA-C-O 117.907 -1.044 . . . . 0.0 111.33 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.76 131.83 54.7 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 120.759 0.314 . . . . 0.0 110.584 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -101.84 107.59 18.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.42 HG23 ' NE2' ' K' ' 14' ' ' HIS . 2.5 p -144.63 149.68 17.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.86 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.56 ' ND1' ' O ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -143.2 94.8 2.67 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.049 178.753 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.667 ' CD2' ' H ' ' L' ' 14' ' ' HIS . 46.8 m170 -119.94 167.57 12.01 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.948 179.113 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.808 HE21 HD21 ' K' ' 17' ' ' LEU . 34.9 tp60 -89.76 157.74 17.82 Favored 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.804 ' O ' HD23 ' K' ' 17' ' ' LEU . 16.3 tttt -140.93 95.41 2.84 Favored 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 120.074 -0.651 . . . . 0.0 110.797 178.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.808 HD21 HE21 ' K' ' 15' ' ' GLN . 2.5 mt -131.87 129.62 40.6 Favored 'General case' 0 N--CA 1.477 0.875 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 176.378 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.506 HG13 HG13 ' J' ' 18' ' ' VAL . 3.5 p -118.6 119.33 60.81 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 178.186 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.476 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 29.9 m-85 -106.05 105.73 15.9 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.46 -1.682 . . . . 0.0 106.46 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.635 ' CE2' ' CD1' ' L' ' 20' ' ' PHE . 6.0 t80 -113.59 120.31 40.51 Favored 'General case' 0 C--O 1.226 -0.177 0 CA-C-O 120.66 0.267 . . . . 0.0 111.679 -177.352 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.597 ' HA ' ' O ' ' J' ' 21' ' ' ALA . . . -150.66 120.49 7.08 Favored 'General case' 0 C--O 1.245 0.858 0 C-N-CA 119.704 -0.798 . . . . 0.0 110.547 178.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.563 ' CG ' ' N ' ' K' ' 23' ' ' ASP . 54.5 tt0 -178.18 163.54 1.69 Allowed 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 116.988 2.218 . . . . 0.0 116.988 -176.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.563 ' N ' ' CG ' ' K' ' 22' ' ' GLU . 19.9 t70 174.05 -74.13 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 CA-C-N 112.03 -2.35 . . . . 0.0 106.978 172.681 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.611 HG22 ' H ' ' K' ' 25' ' ' GLY . 3.2 p -67.7 -113.26 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 104.679 -2.341 . . . . 0.0 104.679 170.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.673 ' H ' ' HA3' ' J' ' 25' ' ' GLY . . . 134.7 -37.79 1.9 Allowed Glycine 0 CA--C 1.541 1.7 0 N-CA-C 121.421 3.328 . . . . 0.0 121.421 171.426 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 30.5 t -71.81 118.09 14.21 Favored 'General case' 0 N--CA 1.482 1.167 1 CA-C-N 125.935 4.867 . . . . 0.0 107.28 177.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.689 ' ND2' ' H ' ' K' ' 30' ' ' ALA . 0.5 OUTLIER -103.77 160.58 14.66 Favored 'General case' 0 N--CA 1.487 1.406 0 CA-C-N 120.36 1.436 . . . . 0.0 113.127 179.271 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -44.45 -39.85 5.07 Favored 'General case' 0 CA--C 1.535 0.378 0 N-CA-C 114.529 1.307 . . . . 0.0 114.529 174.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 67.67 0.04 OUTLIER Glycine 0 CA--C 1.55 2.231 0 CA-C-O 118.939 -0.923 . . . . 0.0 113.484 -174.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.689 ' H ' ' ND2' ' K' ' 27' ' ' ASN . . . -71.04 156.18 39.94 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 119.82 1.81 . . . . 0.0 113.607 -176.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.629 HD11 HG13 ' E' ' 39' ' ' VAL . 82.2 mt -122.92 126.53 73.92 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.92 -178.781 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 13.0 tt -130.96 118.0 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 O-C-N 121.245 -0.91 . . . . 0.0 110.51 178.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.81 111.62 1.87 Allowed Glycine 0 N--CA 1.466 0.699 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.62 HD13 ' CE2' ' L' ' 19' ' ' PHE . 82.1 mt -122.92 117.3 25.23 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-O 121.165 0.507 . . . . 0.0 110.728 -178.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.417 ' O ' ' N ' ' J' ' 36' ' ' VAL . 8.0 mtp -108.3 114.41 28.25 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.468 -0.787 . . . . 0.0 109.404 178.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 46.2 t -119.65 144.76 27.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 N-CA-C 107.726 -1.212 . . . . 0.0 107.726 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.561 ' N ' ' H ' ' J' ' 38' ' ' GLY . . . -136.51 102.68 0.41 Allowed Glycine 0 C--N 1.32 -0.31 0 C-N-CA 119.825 -1.179 . . . . 0.0 111.104 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.427 ' O ' ' N ' ' J' ' 40' ' ' VAL . . . -61.28 -67.13 2.26 Favored Glycine 0 CA--C 1.54 1.652 0 N-CA-C 111.265 -0.734 . . . . 0.0 111.265 176.83 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.485 ' HB ' HD11 ' Q' ' 31' ' ' ILE . 16.7 m -143.44 112.86 2.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.2 0 N-CA-C 107.31 -1.367 . . . . 0.0 107.31 179.375 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.752 ' OXT' HG12 ' J' ' 39' ' ' VAL . 2.5 p . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 117.88 -1.057 . . . . 0.0 110.882 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -111.74 130.96 55.62 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.743 0.306 . . . . 0.0 110.305 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -93.56 142.05 27.78 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.631 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.3 t -115.94 126.24 73.38 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 110.044 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.558 ' ND1' ' OXT' ' I' ' 40' ' ' VAL . 10.8 m-70 -130.86 104.59 7.24 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.214 -178.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.667 ' H ' ' CD2' ' K' ' 14' ' ' HIS . 83.2 t60 -160.61 164.57 31.77 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 178.187 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.501 ' O ' ' CD2' ' L' ' 14' ' ' HIS . 88.0 mm-40 -89.76 158.57 17.46 Favored 'General case' 0 CA--C 1.516 -0.335 0 N-CA-C 109.17 -0.678 . . . . 0.0 109.17 178.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . 0.728 ' C ' HD12 ' L' ' 17' ' ' LEU . 16.7 tttt -140.4 93.93 2.68 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 177.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.728 HD12 ' C ' ' L' ' 16' ' ' LYS . 10.0 mp -122.72 118.15 27.4 Favored 'General case' 0 CA--C 1.509 -0.609 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 177.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -102.81 108.06 23.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.801 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.62 ' CE2' HD13 ' K' ' 34' ' ' LEU . 79.7 m-85 -100.32 98.14 8.83 Favored 'General case' 0 N--CA 1.445 -0.725 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 177.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.635 ' CD1' ' CE2' ' K' ' 20' ' ' PHE . 39.7 t80 -108.38 105.15 14.69 Favored 'General case' 0 CA--C 1.504 -0.789 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 179.748 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -165.95 171.51 12.53 Favored 'General case' 0 CA--C 1.484 -1.567 0 C-N-CA 119.126 -1.029 . . . . 0.0 110.634 -178.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 72.9 mm-40 -75.94 104.71 6.6 Favored 'General case' 0 C--N 1.307 -1.241 0 N-CA-C 106.965 -1.494 . . . . 0.0 106.965 177.066 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 54.1 p-10 -147.0 48.01 1.15 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.422 -0.808 . . . . 0.0 112.41 -176.242 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.563 HG22 ' N ' ' L' ' 25' ' ' GLY . 7.5 p -65.23 169.75 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 179.78 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.563 ' N ' HG22 ' L' ' 24' ' ' VAL . . . -92.2 -42.53 4.6 Favored Glycine 0 CA--C 1.52 0.399 0 C-N-CA 118.709 -1.71 . . . . 0.0 113.819 -176.689 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.51 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 4.6 m -67.72 109.49 3.35 Favored 'General case' 0 C--N 1.33 -0.271 0 C-N-CA 117.861 -1.536 . . . . 0.0 111.906 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.68 ' O ' ' N ' ' L' ' 29' ' ' GLY . 21.4 m120 -145.21 158.68 43.76 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 173.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.537 ' C ' ' O ' ' L' ' 27' ' ' ASN . 42.0 tttp -18.2 -43.51 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.288 0 CA-C-O 121.936 0.874 . . . . 0.0 111.312 175.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.68 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -178.45 63.33 0.08 OUTLIER Glycine 0 CA--C 1.553 2.411 0 CA-C-N 113.885 -1.507 . . . . 0.0 112.381 177.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.463 ' HB1' ' O ' ' K' ' 30' ' ' ALA . . . -88.94 163.08 15.74 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.13 1.465 . . . . 0.0 110.019 179.418 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 22.2 pt -141.15 135.49 32.41 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.196 0 C-N-CA 119.252 -0.979 . . . . 0.0 112.027 179.073 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 96.2 mt -118.53 121.09 66.2 Favored 'Isoleucine or valine' 0 C--N 1.34 0.18 0 CA-C-N 114.73 -1.123 . . . . 0.0 111.227 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.11 116.3 2.41 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.371 -1.091 . . . . 0.0 110.371 179.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 59.6 tp -126.42 125.65 42.51 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 16.3 ttm -129.3 130.3 45.98 Favored 'General case' 0 N--CA 1.469 0.502 0 C-N-CA 121.152 -0.219 . . . . 0.0 111.099 -179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' L' ' 37' ' ' GLY . 55.7 t -124.21 131.87 72.21 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.191 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 178.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -42.56 -111.62 0.0 OUTLIER Glycine 0 N--CA 1.468 0.82 0 CA-C-N 115.483 -0.781 . . . . 0.0 112.631 178.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 56.99 64.93 3.96 Favored Glycine 0 CA--C 1.532 1.116 0 CA-C-N 114.706 -0.747 . . . . 0.0 111.455 -178.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.649 ' O ' HD11 ' R' ' 31' ' ' ILE . 41.8 t -115.9 157.91 16.52 Favored 'Isoleucine or valine' 0 C--N 1.346 0.456 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.412 ' N ' ' CG1' ' L' ' 39' ' ' VAL . 11.6 m . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.119 -0.943 . . . . 0.0 110.616 -178.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.407 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 94.7 m-85 -107.42 131.04 54.71 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 120.758 0.313 . . . . 0.0 110.662 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.07 166.87 15.49 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.598 179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 53.0 t -113.65 128.61 70.45 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -113.31 162.67 15.77 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.711 -179.343 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.519 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 3.4 m-70 -83.33 168.71 16.39 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.652 -179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.9 mt-30 -129.2 150.86 50.4 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 178.477 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -97.26 111.81 23.89 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.353 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 86.6 mt -125.69 114.04 18.14 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 178.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 58.4 t -128.88 132.88 67.1 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.357 -179.31 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -133.25 134.83 44.46 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-O 120.86 0.362 . . . . 0.0 110.919 179.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -128.26 131.82 48.74 Favored 'General case' 0 N--CA 1.47 0.544 0 CA-C-N 116.144 -0.48 . . . . 0.0 109.766 179.467 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.6 111.14 7.55 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.108 0.48 . . . . 0.0 110.25 179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 17.7 pt-20 -159.1 151.13 20.95 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.372 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 51.96 46.43 26.61 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.818 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.809 HG12 ' H ' ' M' ' 25' ' ' GLY . 39.6 t -80.45 179.89 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.471 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 -179.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.809 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -71.44 -33.75 63.99 Favored Glycine 0 CA--C 1.526 0.763 0 C-N-CA 120.622 -0.799 . . . . 0.0 112.878 -178.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . 0.594 ' O ' ' O ' ' M' ' 27' ' ' ASN . 25.5 t -162.51 120.61 2.13 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 113.606 0.965 . . . . 0.0 113.606 -178.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.594 ' O ' ' O ' ' M' ' 26' ' ' SER . 13.6 t30 -22.03 153.22 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.98 0 O-C-N 124.424 1.078 . . . . 0.0 111.976 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 67.3 tttt -163.17 24.54 0.09 Allowed 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 114.638 1.347 . . . . 0.0 114.638 -179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . . . . . . . . . . . 89.28 106.15 1.11 Allowed Glycine 0 N--CA 1.471 1.004 0 C-N-CA 118.539 -1.791 . . . . 0.0 114.913 175.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.727 ' H ' ' ND2' ' N' ' 27' ' ' ASN . . . -111.48 80.24 1.29 Allowed 'General case' 0 CA--C 1.555 1.168 0 CA-C-O 124.098 1.904 . . . . 0.0 109.999 178.334 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.599 HD11 HG21 ' H' ' 39' ' ' VAL . 59.6 mt -130.36 130.01 65.14 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.58 0 CA-C-N 110.974 -2.83 . . . . 0.0 108.419 -178.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . 0.447 ' O ' ' O ' ' N' ' 33' ' ' GLY . 47.1 mt -103.94 106.18 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 N-CA-C 108.323 -0.992 . . . . 0.0 108.323 177.952 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.92 97.43 1.14 Allowed Glycine 0 CA--C 1.506 -0.476 0 N-CA-C 105.055 -3.218 . . . . 0.0 105.055 176.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -148.95 152.92 37.2 Favored 'General case' 0 N--CA 1.463 0.213 0 C-N-CA 118.308 -1.357 . . . . 0.0 113.826 -174.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 91.7 mmm -110.21 110.31 21.11 Favored 'General case' 0 N--CA 1.445 -0.691 0 CA-C-N 112.946 -1.934 . . . . 0.0 107.177 178.251 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.63 HG23 HD21 ' N' ' 34' ' ' LEU . 96.4 t -104.29 122.88 57.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 178.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 150.32 -113.24 0.58 Allowed Glycine 0 C--N 1.309 -0.94 0 N-CA-C 108.419 -1.873 . . . . 0.0 108.419 -178.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.68 -69.57 0.22 Allowed Glycine 0 CA--C 1.533 1.179 0 C-N-CA 121.438 -0.411 . . . . 0.0 112.413 179.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' M' ' 40' ' ' VAL . 3.1 m -137.57 166.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 122.649 0.38 . . . . 0.0 110.373 -179.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.544 ' OXT' ' N ' ' N' ' 40' ' ' VAL . 21.6 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.888 178.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.431 -1.468 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.88 135.67 49.69 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.845 0.355 . . . . 0.0 110.395 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -140.71 146.42 37.76 Favored 'General case' 0 N--CA 1.466 0.355 0 CA-C-O 121.023 0.439 . . . . 0.0 110.721 -179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.458 HG22 HG22 ' O' ' 12' ' ' VAL . 70.2 t -126.98 133.66 67.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.4 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.706 -179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.553 ' ND1' ' CE1' ' O' ' 13' ' ' HIS . 77.1 m80 -102.97 97.66 7.74 Favored 'General case' 0 N--CA 1.471 0.62 0 O-C-N 122.093 -0.38 . . . . 0.0 110.509 179.777 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.636 ' ND1' ' N ' ' N' ' 15' ' ' GLN . 1.7 t-80 -159.95 168.53 25.47 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.941 -179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.636 ' N ' ' ND1' ' N' ' 14' ' ' HIS . 81.9 mt-30 -156.0 142.27 18.38 Favored 'General case' 0 C--N 1.34 0.166 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 178.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -84.73 120.64 26.64 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.822 179.156 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.484 HD12 ' O ' ' N' ' 15' ' ' GLN . 4.8 mp -129.11 124.03 33.71 Favored 'General case' 0 N--CA 1.471 0.585 0 CA-C-O 120.755 0.312 . . . . 0.0 110.192 178.274 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.21 131.58 69.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 91.4 t80 -129.37 115.58 17.77 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.147 -178.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 44.8 t80 -111.9 126.17 54.83 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -146.0 147.56 31.79 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -177.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -132.46 133.0 43.31 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 114.436 -1.256 . . . . 0.0 109.016 178.178 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 59.7 m-20 -158.05 46.62 0.35 Allowed 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -178.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . 0.54 HG12 ' N ' ' N' ' 25' ' ' GLY . 20.8 t -91.79 169.18 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 178.003 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 0.54 ' N ' HG12 ' N' ' 24' ' ' VAL . . . 77.16 34.8 40.24 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 -179.008 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 4.2 p 169.51 -114.59 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 -176.461 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.727 ' ND2' ' H ' ' M' ' 30' ' ' ALA . 28.9 t30 -61.89 170.88 1.87 Allowed 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.358 0.599 . . . . 0.0 111.782 -177.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.561 ' HD3' HD11 ' N' ' 31' ' ' ILE . 81.7 tttt -54.15 -39.36 66.44 Favored 'General case' 0 N--CA 1.456 -0.144 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.474 -176.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.34 -63.51 0.53 Allowed Glycine 0 CA--C 1.531 1.04 0 C-N-CA 119.639 -1.267 . . . . 0.0 114.107 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.86 99.52 3.81 Favored 'General case' 0 C--O 1.239 0.512 0 CA-C-N 120.319 2.059 . . . . 0.0 115.529 -176.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.842 ' CD1' HG22 ' H' ' 39' ' ' VAL . 96.3 mt -122.59 118.94 56.72 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-N 114.162 -1.381 . . . . 0.0 107.304 173.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.561 HD13 ' CD2' ' P' ' 19' ' ' PHE . 74.8 mt -107.71 108.32 24.95 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 119.041 -1.064 . . . . 0.0 110.28 178.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.447 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -109.08 98.66 1.18 Allowed Glycine 0 C--O 1.234 0.138 0 N-CA-C 104.641 -3.384 . . . . 0.0 104.641 175.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.963 HD23 ' N ' ' N' ' 35' ' ' MET . 3.0 tt -145.25 147.84 32.84 Favored 'General case' 0 CA--C 1.506 -0.727 0 C-N-CA 118.352 -1.339 . . . . 0.0 113.065 -174.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.963 ' N ' HD23 ' N' ' 34' ' ' LEU . 12.7 mtp -112.0 115.67 29.31 Favored 'General case' 0 N--CA 1.442 -0.836 0 CA-C-N 113.215 -1.812 . . . . 0.0 108.786 178.073 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.675 HG23 HD22 ' N' ' 34' ' ' LEU . 51.4 t -114.59 111.63 36.71 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.293 0 N-CA-C 107.83 -1.174 . . . . 0.0 107.83 179.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.768 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 135.21 -131.75 5.95 Favored Glycine 0 C--N 1.316 -0.562 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 179.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . . . . . . . . . . . 86.74 -63.69 4.05 Favored Glycine 0 CA--C 1.536 1.374 0 N-CA-C 111.021 -0.832 . . . . 0.0 111.021 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.52 HG12 HD12 ' B' ' 31' ' ' ILE . 11.4 m -104.52 161.06 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 122.952 0.501 . . . . 0.0 110.384 179.859 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.56 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 47.5 t . . . . . 0 C--O 1.218 -0.602 0 CA-C-O 117.852 -1.071 . . . . 0.0 111.58 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -109.29 139.43 44.24 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 80.2 mm-40 -102.05 124.28 47.39 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.566 -179.543 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.458 HG22 HG22 ' N' ' 12' ' ' VAL . 1.4 m -125.49 125.91 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.573 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.553 ' CE1' ' ND1' ' N' ' 13' ' ' HIS . 21.0 m-70 -121.48 122.17 39.15 Favored 'General case' 0 N--CA 1.47 0.555 0 CA-C-O 121.193 0.521 . . . . 0.0 112.208 -177.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.524 ' CE1' ' O ' ' P' ' 12' ' ' VAL . 0.6 OUTLIER -150.27 175.95 11.32 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.69 -0.687 . . . . 0.0 109.576 178.38 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.628 ' NE2' HD11 ' O' ' 17' ' ' LEU . 39.2 tt0 -152.74 139.75 19.19 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.587 0.708 . . . . 0.0 109.107 175.593 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 61.3 mttt -95.68 108.64 20.95 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.592 -1.185 . . . . 0.0 111.043 177.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.628 HD11 ' NE2' ' O' ' 15' ' ' GLN . 5.0 mt -124.03 109.64 13.77 Favored 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 119.293 0.951 . . . . 0.0 108.729 175.678 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 85.9 t -107.39 116.4 50.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-N 114.773 -1.103 . . . . 0.0 108.877 179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 44.5 m-85 -110.99 103.31 11.77 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 179.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' P' ' 20' ' ' PHE . 2.7 m-85 -110.38 133.92 52.81 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 122.354 0.262 . . . . 0.0 110.303 -178.726 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.77 136.56 29.0 Favored 'General case' 0 C--O 1.242 0.672 0 CA-C-O 122.99 1.376 . . . . 0.0 114.128 -179.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 26.5 tp10 -93.12 163.79 13.5 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 113.263 -1.79 . . . . 0.0 106.986 178.202 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.437 ' OD1' ' OD2' ' P' ' 23' ' ' ASP . 54.5 p-10 -172.93 52.36 0.02 OUTLIER 'General case' 0 C--N 1.323 -0.577 0 C-N-CA 120.106 -0.638 . . . . 0.0 111.091 -176.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.605 ' HA ' HG13 ' P' ' 24' ' ' VAL . 13.5 m -74.5 142.17 15.07 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 C-N-CA 117.981 -1.488 . . . . 0.0 112.47 -174.796 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.501 ' H ' ' CG1' ' P' ' 24' ' ' VAL . . . 98.97 38.14 3.93 Favored Glycine 0 CA--C 1.535 1.313 0 CA-C-N 112.488 -2.142 . . . . 0.0 110.233 179.623 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.993 ' H ' HG11 ' P' ' 24' ' ' VAL . 2.7 p 72.74 120.16 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 117.806 -1.092 . . . . 0.0 108.11 179.021 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.472 ' O ' ' OD1' ' O' ' 27' ' ' ASN . 54.7 p30 -83.62 156.24 22.8 Favored 'General case' 0 N--CA 1.467 0.414 0 C-N-CA 115.968 -2.293 . . . . 0.0 109.956 178.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mmtt -48.66 -42.53 34.82 Favored 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.874 1.435 . . . . 0.0 114.874 177.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.443 ' O ' ' CE ' ' N' ' 28' ' ' LYS . . . 160.19 67.37 0.02 OUTLIER Glycine 0 CA--C 1.546 1.998 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.117 -176.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.67 132.22 30.65 Favored 'General case' 0 N--CA 1.488 1.442 0 CA-C-N 120.305 2.053 . . . . 0.0 114.155 -175.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.456 ' CD1' ' HB ' ' I' ' 39' ' ' VAL . 9.8 tt -137.36 131.88 45.24 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.932 0 CA-C-N 114.57 -1.196 . . . . 0.0 112.18 -178.675 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.569 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 71.3 mt -108.25 114.36 46.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.378 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.445 ' O ' HD22 ' O' ' 34' ' ' LEU . . . -111.97 94.9 0.77 Allowed Glycine 0 N--CA 1.468 0.792 0 N-CA-C 107.236 -2.345 . . . . 0.0 107.236 177.099 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.461 ' HB2' HD12 ' P' ' 34' ' ' LEU . 1.3 mm? -121.32 134.6 55.14 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 122.476 1.132 . . . . 0.0 113.264 -176.181 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -113.0 104.41 12.36 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 173.809 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.576 HG11 HD13 ' Q' ' 17' ' ' LEU . 2.5 t -113.6 103.46 15.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.507 ' N ' ' O ' ' N' ' 36' ' ' VAL . . . 136.85 -153.53 21.77 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 120.409 -0.9 . . . . 0.0 111.663 177.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.724 ' H ' ' H ' ' P' ' 38' ' ' GLY . . . 137.79 -56.29 0.67 Allowed Glycine 0 CA--C 1.543 1.796 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -178.011 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.433 HG22 HG23 ' O' ' 40' ' ' VAL . 5.0 p -133.15 154.78 40.05 Favored 'Isoleucine or valine' 0 C--N 1.342 0.243 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.486 ' OXT' ' CG2' ' P' ' 40' ' ' VAL . 17.3 t . . . . . 0 C--O 1.219 -0.542 0 CA-C-O 118.025 -0.988 . . . . 0.0 109.999 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -109.07 135.54 50.06 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.579 0.228 . . . . 0.0 110.627 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -73.61 133.19 43.43 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-O 120.946 0.403 . . . . 0.0 110.653 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.524 ' O ' ' CE1' ' O' ' 14' ' ' HIS . 43.9 t -136.81 166.29 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.635 -179.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.537 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 12.3 m170 -44.22 110.77 0.24 Allowed 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.658 -0.417 . . . . 0.0 110.946 -178.324 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' O ' ' Q' ' 14' ' ' HIS . 55.4 t60 -152.62 154.43 35.35 Favored 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 110.121 -0.326 . . . . 0.0 110.121 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.768 HE22 ' N ' ' N' ' 37' ' ' GLY . 81.9 mt-30 -98.47 169.81 9.28 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.743 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -158.26 103.99 1.84 Allowed 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.976 177.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -134.05 133.28 41.0 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.521 0.677 . . . . 0.0 110.861 178.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 64.1 t -123.55 120.94 61.35 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 115.337 -0.847 . . . . 0.0 108.935 179.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.561 ' CD2' HD13 ' N' ' 32' ' ' ILE . 5.5 m-85 -112.73 112.3 23.71 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.441 ' HB3' ' CD1' ' O' ' 20' ' ' PHE . 26.4 t80 -125.2 122.47 37.11 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 112.382 0.512 . . . . 0.0 112.382 -176.768 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.9 122.09 29.54 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 178.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.521 ' CG ' ' N ' ' P' ' 23' ' ' ASP . 69.6 tt0 -167.45 158.97 11.95 Favored 'General case' 0 N--CA 1.486 1.356 0 N-CA-C 117.695 2.479 . . . . 0.0 117.695 -176.925 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.521 ' N ' ' CG ' ' P' ' 22' ' ' GLU . 1.7 p30 150.64 -70.05 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.647 0 CA-C-N 111.643 -2.526 . . . . 0.0 108.386 175.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.993 HG11 ' H ' ' O' ' 26' ' ' SER . 4.4 m -57.05 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 122.099 0.952 . . . . 0.0 109.336 174.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.4 ' H ' ' HB ' ' P' ' 24' ' ' VAL . . . 141.57 -36.25 1.73 Allowed Glycine 0 CA--C 1.525 0.688 0 CA-C-N 113.641 -1.618 . . . . 0.0 110.621 179.606 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . . . . . . . . . 4.8 m -70.33 114.49 8.51 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 115.916 -2.314 . . . . 0.0 105.18 171.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.75 ' ND2' ' H ' ' P' ' 30' ' ' ALA . 50.3 p-10 -119.98 154.6 34.27 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-N 121.212 1.824 . . . . 0.0 111.926 176.435 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 77.5 tttt -34.52 -39.46 0.09 Allowed 'General case' 0 C--N 1.326 -0.455 0 N-CA-C 112.879 0.696 . . . . 0.0 112.879 173.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' Q' ' 29' ' ' GLY . . . 140.07 74.52 0.05 OUTLIER Glycine 0 CA--C 1.553 2.447 0 N-CA-C 109.723 -1.351 . . . . 0.0 109.723 -175.295 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . 0.75 ' H ' ' ND2' ' P' ' 27' ' ' ASN . . . -70.55 170.14 12.74 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 116.099 1.888 . . . . 0.0 116.099 -173.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.852 HD11 HG11 ' J' ' 39' ' ' VAL . 0.9 OUTLIER -149.14 143.7 18.33 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.965 0 CA-C-N 112.739 -2.028 . . . . 0.0 114.907 -176.103 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.461 HG12 HD12 ' O' ' 32' ' ' ILE . 3.7 mt -113.12 113.06 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.925 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 174.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.38 101.8 1.2 Allowed Glycine 0 N--CA 1.462 0.402 0 N-CA-C 105.82 -2.912 . . . . 0.0 105.82 176.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.54 ' C ' HD23 ' P' ' 34' ' ' LEU . 9.0 tt -144.49 132.08 21.06 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 122.866 1.317 . . . . 0.0 112.397 -175.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . 0.485 ' N ' HD23 ' P' ' 34' ' ' LEU . 74.0 mtp -120.86 119.59 33.11 Favored 'General case' 0 CA--C 1.495 -1.153 0 CA-C-N 113.163 -1.835 . . . . 0.0 107.512 178.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.437 ' CG2' HG22 ' Q' ' 36' ' ' VAL . 0.0 OUTLIER -95.67 113.85 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.797 0 C-N-CA 119.014 -1.074 . . . . 0.0 108.604 -178.521 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.551 ' N ' ' O ' ' O' ' 36' ' ' VAL . . . -65.64 -123.29 0.01 OUTLIER Glycine 0 CA--C 1.521 0.408 0 CA-C-N 113.871 -1.513 . . . . 0.0 110.799 177.205 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.724 ' H ' ' H ' ' O' ' 38' ' ' GLY . . . 66.64 60.86 5.79 Favored Glycine 0 CA--C 1.532 1.125 0 CA-C-N 114.301 -0.95 . . . . 0.0 113.641 179.261 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.598 ' O ' HD11 ' D' ' 31' ' ' ILE . 0.7 OUTLIER -84.71 124.14 39.65 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.029 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.082 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.505 ' C ' HG12 ' Q' ' 39' ' ' VAL . 3.1 t . . . . . 0 N--CA 1.478 0.943 0 CA-C-O 118.341 -0.838 . . . . 0.0 112.428 -176.482 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.361 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.4 m-85 -108.29 131.07 55.09 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.141 -0.318 . . . . 0.0 110.141 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . 0.434 ' H ' ' HG2' ' R' ' 11' ' ' GLU . 96.4 mt-10 -141.23 138.23 33.14 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.542 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.448 HG12 ' H ' ' R' ' 12' ' ' VAL . 34.5 m -125.28 129.92 73.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.435 179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.56 ' CE1' ' O ' ' N' ' 40' ' ' VAL . 14.2 t60 -136.4 132.98 36.23 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.912 0.387 . . . . 0.0 110.811 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.583 ' O ' ' ND1' ' P' ' 14' ' ' HIS . 3.7 m80 -145.48 162.58 37.04 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.515 178.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.496 ' HG2' HG12 ' O' ' 36' ' ' VAL . 17.6 mp0 -89.95 157.26 17.93 Favored 'General case' 0 N--CA 1.452 -0.352 0 N-CA-C 107.054 -1.461 . . . . 0.0 107.054 176.619 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . 0.42 ' HB2' ' NE2' ' P' ' 14' ' ' HIS . 87.9 tttt -141.66 102.34 4.16 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.174 -0.676 . . . . 0.0 109.174 176.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.576 HD13 HG11 ' O' ' 36' ' ' VAL . 5.2 mp -131.37 119.47 21.73 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-O 121.389 0.614 . . . . 0.0 111.143 179.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -107.44 111.8 37.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.569 ' CD1' HD13 ' O' ' 32' ' ' ILE . 88.3 m-85 -106.63 103.44 12.88 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 179.015 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.58 ' CE2' ' CD2' ' R' ' 20' ' ' PHE . 26.1 t80 -110.01 119.34 39.01 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 110.029 -0.36 . . . . 0.0 110.029 -179.174 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.47 128.34 21.91 Favored 'General case' 0 CA--C 1.518 -0.286 0 CA-C-O 121.424 0.63 . . . . 0.0 111.349 -179.445 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.432 ' O ' ' OD1' ' Q' ' 23' ' ' ASP . 38.9 tt0 -91.29 109.96 21.25 Favored 'General case' 0 C--N 1.328 -0.333 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 178.202 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.432 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 99.1 m-20 -141.96 48.27 1.6 Allowed 'General case' 0 CA--C 1.533 0.303 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.212 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 30.0 m -72.86 160.56 5.27 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.481 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.82 -30.04 8.42 Favored Glycine 0 N--CA 1.466 0.668 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 175.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 3.7 t 61.46 109.96 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.336 0 CA-C-O 118.903 -0.57 . . . . 0.0 112.157 177.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.744 ' O ' ' N ' ' Q' ' 29' ' ' GLY . 14.9 t-20 -129.41 159.74 35.27 Favored 'General case' 0 N--CA 1.474 0.744 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 64.5 mttp -29.53 48.82 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.154 0 N-CA-C 117.641 2.46 . . . . 0.0 117.641 -178.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.744 ' N ' ' O ' ' Q' ' 27' ' ' ASN . . . -171.93 52.61 0.18 Allowed Glycine 0 CA--C 1.536 1.399 0 CA-C-N 120.552 1.524 . . . . 0.0 112.34 171.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -92.04 95.06 9.57 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 119.819 1.809 . . . . 0.0 111.295 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.485 HD11 ' HB ' ' K' ' 39' ' ' VAL . 49.4 mt -133.36 123.98 47.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 CA-C-N 120.66 1.573 . . . . 0.0 112.687 -178.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.0 mt -126.97 121.97 59.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.636 179.409 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.75 114.05 2.01 Favored Glycine 0 N--CA 1.467 0.76 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.387 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.688 HD22 ' CZ ' ' R' ' 19' ' ' PHE . 89.8 mt -124.98 119.73 29.57 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 120.504 0.192 . . . . 0.0 110.576 -178.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.421 ' O ' HG23 ' P' ' 36' ' ' VAL . 82.1 mtp -127.93 124.4 37.27 Favored 'General case' 0 N--CA 1.471 0.616 0 N-CA-C 112.812 0.671 . . . . 0.0 112.812 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.437 HG22 ' CG2' ' P' ' 36' ' ' VAL . 64.2 t -115.93 146.9 19.75 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.152 0 N-CA-C 109.503 -0.555 . . . . 0.0 109.503 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.91 102.29 0.41 Allowed Glycine 0 C--N 1.315 -0.634 0 N-CA-C 109.047 -1.621 . . . . 0.0 109.047 176.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . . . . . . . . . . . -48.99 -71.09 0.65 Allowed Glycine 0 CA--C 1.535 1.292 0 CA-C-O 121.559 0.533 . . . . 0.0 111.945 178.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.507 HG12 HD11 ' E' ' 31' ' ' ILE . 2.4 m -126.2 119.01 53.07 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.273 0 N-CA-C 107.351 -1.351 . . . . 0.0 107.351 -179.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.468 ' CB ' ' O ' ' Q' ' 39' ' ' VAL . 61.1 t . . . . . 0 N--CA 1.487 1.403 0 C-N-CA 124.34 1.056 . . . . 0.0 109.882 -178.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.764 -1.335 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -115.22 140.57 48.98 Favored 'General case' 0 N--CA 1.464 0.256 0 N-CA-C 110.178 -0.305 . . . . 0.0 110.178 179.726 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.434 ' HG2' ' H ' ' Q' ' 11' ' ' GLU . 97.1 mt-10 -73.48 129.99 39.16 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.458 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.448 ' H ' HG12 ' Q' ' 12' ' ' VAL . 72.0 t -126.07 131.86 71.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.115 0.483 . . . . 0.0 110.343 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 98.0 m-70 -132.84 95.72 3.64 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.711 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.502 ' ND1' ' OE1' ' R' ' 15' ' ' GLN . 84.8 t60 -155.36 161.93 40.93 Favored 'General case' 0 C--O 1.222 -0.349 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 178.489 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.57 ' CD ' ' H ' ' R' ' 15' ' ' GLN . 0.2 OUTLIER -90.17 159.8 16.57 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.867 0.365 . . . . 0.0 111.452 179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . 0.694 ' C ' HD13 ' R' ' 17' ' ' LEU . 57.7 tttt -139.96 107.12 5.47 Favored 'General case' 0 C--N 1.318 -0.761 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 177.224 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.902 HD22 ' N ' ' R' ' 17' ' ' LEU . 0.0 OUTLIER -126.82 121.3 31.53 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.694 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.8 t -104.34 111.31 33.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 N-CA-C 107.143 -1.428 . . . . 0.0 107.143 177.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.688 ' CZ ' HD22 ' Q' ' 34' ' ' LEU . 80.1 m-85 -103.44 103.77 13.78 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . 0.58 ' CD2' ' CE2' ' Q' ' 20' ' ' PHE . 62.3 t80 -114.07 109.2 18.07 Favored 'General case' 0 CA--C 1.515 -0.398 0 CA-C-O 121.352 0.596 . . . . 0.0 109.58 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.47 125.08 33.49 Favored 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 82.6 mt-10 -81.98 114.38 20.52 Favored 'General case' 0 C--N 1.323 -0.585 0 C-N-CA 118.911 -1.116 . . . . 0.0 109.719 -178.394 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.401 ' O ' ' OD1' ' R' ' 23' ' ' ASP . 67.0 t0 -150.24 46.27 0.9 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.671 -178.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.658 HG12 ' H ' ' R' ' 25' ' ' GLY . 24.1 t -96.02 175.93 0.74 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.658 ' H ' HG12 ' R' ' 24' ' ' VAL . . . 70.96 26.97 72.99 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.186 -1.165 . . . . 0.0 110.186 -178.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . 0.48 ' O ' ' O ' ' R' ' 27' ' ' ASN . 28.5 t -153.37 120.29 5.71 Favored 'General case' 0 N--CA 1.463 0.18 0 CA-C-O 121.101 0.476 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.48 ' O ' ' O ' ' R' ' 26' ' ' SER . 16.3 m120 -42.07 178.78 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.175 -0.92 . . . . 0.0 112.663 -179.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -72.58 45.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.923 -179.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.416 ' H ' ' C ' ' R' ' 27' ' ' ASN . . . -92.08 59.53 2.74 Favored Glycine 0 CA--C 1.537 1.458 0 CA-C-N 115.571 -0.74 . . . . 0.0 111.525 179.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.37 165.86 33.69 Favored 'General case' 0 N--CA 1.45 -0.452 0 O-C-N 122.545 -0.385 . . . . 0.0 110.33 -178.38 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.649 HD11 ' O ' ' L' ' 39' ' ' VAL . 93.6 mt -109.95 119.01 58.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.261 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . 0.5 HG23 ' O ' ' R' ' 32' ' ' ILE . 18.6 tt -130.37 124.07 56.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-O 120.921 0.391 . . . . 0.0 110.223 179.594 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.43 120.3 3.66 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.978 -1.249 . . . . 0.0 109.978 179.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 42.9 mt -121.48 121.57 37.81 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 -179.371 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 75.4 mtp -128.95 131.03 47.46 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.45 0.643 . . . . 0.0 112.175 -179.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 p -134.38 142.67 40.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.935 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.63 -102.31 0.2 Allowed Glycine 0 C--N 1.306 -1.097 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 -179.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' R' ' 39' ' ' VAL . . . 109.06 -71.85 0.2 Allowed Glycine 0 CA--C 1.534 1.247 0 CA-C-O 119.11 -0.828 . . . . 0.0 112.055 -179.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.508 ' HA ' HD13 ' F' ' 31' ' ' ILE . 94.1 t -29.95 123.03 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.353 0.722 0 CA-C-N 118.492 1.146 . . . . 0.0 111.657 179.215 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.446 ' H ' HG21 ' F' ' 31' ' ' ILE . 91.7 t . . . . . 0 C--O 1.22 -0.463 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.974 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -112.7 137.63 50.7 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-O 120.812 0.339 . . . . 0.0 110.444 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.5 134.17 33.69 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.458 179.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 6.3 m -123.05 131.41 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.389 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 75.1 t60 -137.67 141.01 41.13 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.257 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.625 ' ND1' ' N ' ' A' ' 15' ' ' GLN . 0.4 OUTLIER -84.58 166.62 17.02 Favored 'General case' 0 CA--C 1.532 0.267 0 CA-C-O 121.248 0.547 . . . . 0.0 110.681 -179.174 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.625 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 83.0 mt-30 -157.45 143.09 17.36 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.071 178.615 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 62.7 pttt -81.07 134.36 35.65 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.334 179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.7 mt -124.92 116.56 22.39 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -125.26 133.68 68.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.054 -179.323 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 29.5 t80 -140.33 139.52 35.43 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.016 -179.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.526 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.1 p90 -126.46 127.81 45.97 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 109.581 -0.526 . . . . 0.0 109.581 179.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -113.65 116.22 29.11 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.302 0.572 . . . . 0.0 111.018 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 62.9 mt-10 -142.4 120.9 12.46 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 98.7 m-20 58.44 46.43 15.16 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.995 -0.282 . . . . 0.0 111.14 -179.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.789 HG12 ' H ' ' A' ' 25' ' ' GLY . 40.1 t -75.96 179.71 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.789 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -88.96 27.71 7.16 Favored Glycine 0 CA--C 1.53 0.977 0 C-N-CA 120.637 -0.792 . . . . 0.0 112.047 -178.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.438 ' O ' ' C ' ' A' ' 27' ' ' ASN . 7.8 t -170.19 -136.4 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 177.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.438 ' C ' ' O ' ' A' ' 26' ' ' SER . 99.5 m-20 -32.48 133.96 0.11 Allowed 'General case' 0 N--CA 1.472 0.664 0 CA-C-O 119.304 -0.379 . . . . 0.0 110.662 177.312 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.436 ' O ' ' O ' ' B' ' 22' ' ' GLU . 52.3 mtpt -118.36 -38.34 3.19 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 120.123 -0.631 . . . . 0.0 112.271 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.432 ' O ' ' HB1' ' B' ' 21' ' ' ALA . . . -80.7 -78.59 0.93 Allowed Glycine 0 N--CA 1.468 0.792 0 C-N-CA 118.951 -1.595 . . . . 0.0 112.919 -177.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.56 93.64 0.2 Allowed 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.938 -0.705 . . . . 0.0 112.114 178.788 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 92.7 mt -126.28 104.73 13.38 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.44 0 N-CA-C 107.764 -1.199 . . . . 0.0 107.764 177.399 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.413 HD13 ' CD1' ' C' ' 19' ' ' PHE . 96.5 mt -110.57 112.01 38.66 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.099 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.609 -178.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.6 92.66 0.5 Allowed Glycine 0 CA--C 1.508 -0.383 0 N-CA-C 104.356 -3.498 . . . . 0.0 104.356 176.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.686 ' O ' HD12 ' B' ' 34' ' ' LEU . 91.5 mt -151.79 177.95 9.88 Favored 'General case' 0 CA--C 1.51 -0.594 0 CA-C-O 122.969 1.366 . . . . 0.0 111.985 -175.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 31.4 mtp -140.38 119.38 12.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 113.096 -1.865 . . . . 0.0 108.902 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.483 HG21 HD13 ' C' ' 17' ' ' LEU . 1.7 m -131.97 113.56 22.42 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 107.297 -1.371 . . . . 0.0 107.297 178.193 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 154.38 -124.64 1.58 Allowed Glycine 0 C--N 1.307 -1.058 0 N-CA-C 109.106 -1.597 . . . . 0.0 109.106 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.62 -67.03 3.6 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.977 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.521 HG22 ' N ' ' A' ' 40' ' ' VAL . 2.4 p -115.56 166.49 9.44 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.287 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.521 ' N ' HG22 ' A' ' 39' ' ' VAL . 9.8 m . . . . . 0 N--CA 1.472 0.646 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.58 -179.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.395 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -106.27 133.21 51.33 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -93.17 106.02 18.03 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.85 0.357 . . . . 0.0 110.788 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -128.9 130.81 68.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 N-CA-C 108.805 -0.813 . . . . 0.0 108.805 179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 81.3 t60 -134.16 105.76 6.83 Favored 'General case' 0 N--CA 1.47 0.574 0 CA-C-O 120.814 0.34 . . . . 0.0 111.166 -179.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.635 ' ND1' ' O ' ' C' ' 14' ' ' HIS . 4.5 t60 -157.12 167.37 30.59 Favored 'General case' 0 CA--C 1.537 0.443 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.584 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.591 ' N ' ' ND1' ' B' ' 14' ' ' HIS . 84.3 mt-30 -154.75 141.84 19.33 Favored 'General case' 0 C--N 1.339 0.127 0 N-CA-C 109.627 -0.509 . . . . 0.0 109.627 177.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -85.53 131.5 34.36 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.271 -0.422 . . . . 0.0 110.624 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.467 HD23 HD23 ' C' ' 17' ' ' LEU . 33.4 tp -122.16 120.97 35.79 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 118.121 0.419 . . . . 0.0 110.117 177.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 59.2 t -124.61 131.97 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 -179.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 16.8 t80 -131.14 123.29 28.24 Favored 'General case' 0 CA--C 1.537 0.463 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.616 -179.069 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -112.79 124.85 53.52 Favored 'General case' 0 N--CA 1.478 0.944 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.352 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.432 ' HB1' ' O ' ' A' ' 29' ' ' GLY . . . -124.15 126.28 45.89 Favored 'General case' 0 N--CA 1.48 1.039 0 N-CA-C 113.162 0.801 . . . . 0.0 113.162 -178.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.436 ' O ' ' O ' ' A' ' 28' ' ' LYS . 79.0 tt0 -115.07 162.98 16.27 Favored 'General case' 0 N--CA 1.48 1.07 0 CA-C-N 115.205 -0.907 . . . . 0.0 109.912 179.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 68.5 t0 -178.81 48.71 0.01 OUTLIER 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 122.337 0.255 . . . . 0.0 110.443 -178.24 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.522 HG22 ' O ' ' C' ' 23' ' ' ASP . 2.7 t -72.57 161.05 5.03 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 CA-C-O 122.363 1.077 . . . . 0.0 112.749 -174.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.402 ' N ' HG12 ' B' ' 24' ' ' VAL . . . 107.07 -34.71 5.52 Favored Glycine 0 CA--C 1.535 1.309 0 CA-C-N 113.051 -1.886 . . . . 0.0 112.588 178.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.577 ' O ' ' O ' ' B' ' 27' ' ' ASN . 89.2 p -162.46 120.07 2.08 Favored 'General case' 0 N--CA 1.473 0.678 0 CA-C-N 118.831 1.315 . . . . 0.0 113.851 177.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.604 ' ND2' ' ND2' ' C' ' 27' ' ' ASN . 18.0 t-20 -22.37 153.41 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.357 0 C-N-CA 123.362 0.665 . . . . 0.0 111.644 174.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.461 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 56.3 tttt -165.45 26.5 0.05 Allowed 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 115.772 1.768 . . . . 0.0 115.772 177.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 81.72 107.93 0.38 Allowed Glycine 0 N--CA 1.47 0.944 0 C-N-CA 118.239 -1.934 . . . . 0.0 115.7 174.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' C' ' 29' ' ' GLY . . . -120.47 105.23 10.66 Favored 'General case' 0 N--CA 1.474 0.732 0 CA-C-O 122.363 1.078 . . . . 0.0 108.136 177.582 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.47 HD11 ' O ' ' N' ' 38' ' ' GLY . 2.6 mt -133.49 135.63 55.67 Favored 'Isoleucine or valine' 0 C--N 1.346 0.435 0 CA-C-N 114.746 -1.116 . . . . 0.0 113.163 -176.036 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.654 HD13 ' CD1' ' D' ' 19' ' ' PHE . 94.1 mt -113.15 110.78 33.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.383 176.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.01 102.33 1.07 Allowed Glycine 0 C--O 1.239 0.462 0 N-CA-C 105.327 -3.109 . . . . 0.0 105.327 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.686 HD12 ' O ' ' A' ' 34' ' ' LEU . 12.2 tp -146.67 144.42 29.46 Favored 'General case' 0 C--O 1.237 0.446 0 C-N-CA 117.828 -1.549 . . . . 0.0 114.765 -174.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -107.43 114.81 29.06 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 112.277 -2.238 . . . . 0.0 108.299 178.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.732 HG11 HD21 ' D' ' 17' ' ' LEU . 17.0 t -133.21 123.2 46.98 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.472 0 C-N-CA 119.916 -0.714 . . . . 0.0 110.938 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.7 -113.74 1.02 Allowed Glycine 0 C--N 1.317 -0.476 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.719 ' O ' HD12 ' I' ' 31' ' ' ILE . . . 86.7 -72.72 2.58 Favored Glycine 0 CA--C 1.536 1.348 0 N-CA-C 111.64 -0.584 . . . . 0.0 111.64 -179.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.585 HG12 ' N ' ' B' ' 40' ' ' VAL . 47.6 t -134.31 164.56 33.98 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 O-C-N 122.463 -0.434 . . . . 0.0 110.946 179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.585 ' N ' HG12 ' B' ' 39' ' ' VAL . 53.1 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.886 -1.054 . . . . 0.0 109.961 178.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.142 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -81.93 140.28 34.14 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 110.027 -0.36 . . . . 0.0 110.027 179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -139.08 139.36 37.71 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.785 0.326 . . . . 0.0 110.871 179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 57.8 t -126.46 130.96 71.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 179.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.602 ' O ' ' ND1' ' D' ' 13' ' ' HIS . 33.2 m80 -145.7 101.43 3.56 Favored 'General case' 0 N--CA 1.467 0.384 0 C-N-CA 120.107 -0.637 . . . . 0.0 112.183 179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.635 ' O ' ' ND1' ' B' ' 14' ' ' HIS . 27.0 p-80 -155.89 155.0 32.12 Favored 'General case' 0 C--O 1.222 -0.362 0 C-N-CA 118.415 -1.314 . . . . 0.0 111.95 175.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 42.4 tt0 -90.48 161.19 15.63 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.355 -1.293 . . . . 0.0 111.416 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -139.32 112.65 8.22 Favored 'General case' 0 C--N 1.313 -1.019 0 N-CA-C 106.539 -1.652 . . . . 0.0 106.539 175.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.49 HD12 ' CD2' ' D' ' 17' ' ' LEU . 3.6 mt -116.24 111.48 20.22 Favored 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 120.734 -0.386 . . . . 0.0 110.475 -179.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 21.6 t -111.08 110.12 31.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.413 ' CD1' HD13 ' A' ' 32' ' ' ILE . 96.0 m-85 -110.32 113.09 25.48 Favored 'General case' 0 C--O 1.237 0.423 0 N-CA-C 107.394 -1.335 . . . . 0.0 107.394 178.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 t80 -112.32 124.88 53.45 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.676 -0.238 . . . . 0.0 110.505 -178.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . 0.554 ' O ' ' NZ ' ' C' ' 28' ' ' LYS . . . -131.78 136.77 47.8 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-O 121.508 0.671 . . . . 0.0 112.724 -178.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.442 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 15.5 pt-20 -163.81 133.2 3.98 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.3 179.795 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.522 ' O ' HG22 ' B' ' 24' ' ' VAL . 0.2 OUTLIER -150.02 -60.3 0.2 Allowed 'General case' 0 C--N 1.353 0.758 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -179.56 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.669 HG12 ' N ' ' C' ' 25' ' ' GLY . 35.9 t -94.15 170.55 1.23 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 C-N-CA 117.378 -1.729 . . . . 0.0 112.579 -178.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.669 ' N ' HG12 ' C' ' 24' ' ' VAL . . . -81.51 27.83 3.2 Favored Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.404 173.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.405 ' O ' ' C ' ' C' ' 27' ' ' ASN . 4.8 t -170.56 -138.65 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 118.947 1.374 . . . . 0.0 112.75 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.604 ' ND2' ' ND2' ' B' ' 27' ' ' ASN . 66.4 t30 -34.52 127.69 0.46 Allowed 'General case' 0 C--N 1.349 0.547 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.178 -179.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.943 ' HZ3' ' HB1' ' D' ' 21' ' ' ALA . 71.2 tttt -104.94 -42.16 5.41 Favored 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 113.536 0.939 . . . . 0.0 113.536 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' B' ' 30' ' ' ALA . . . 81.18 60.88 2.18 Favored Glycine 0 CA--C 1.543 1.812 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -174.955 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.622 ' H ' ' HG ' ' D' ' 26' ' ' SER . . . -110.21 112.39 24.34 Favored 'General case' 0 C--N 1.361 1.101 0 CA-C-O 123.237 1.494 . . . . 0.0 114.077 -175.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.556 HG21 ' CG2' ' O' ' 39' ' ' VAL . 1.1 tt -134.63 127.19 49.22 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.513 0 CA-C-N 112.218 -2.264 . . . . 0.0 109.228 179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.417 HD13 HG21 ' C' ' 32' ' ' ILE . 29.2 mt -106.56 116.32 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.213 -179.749 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.97 106.36 1.62 Allowed Glycine 0 N--CA 1.466 0.695 0 N-CA-C 106.551 -2.619 . . . . 0.0 106.551 177.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . . . . . . . . . 90.9 mt -133.05 134.63 44.61 Favored 'General case' 0 CA--C 1.497 -1.062 0 N-CA-C 114.128 1.159 . . . . 0.0 114.128 -174.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -113.02 98.94 7.48 Favored 'General case' 0 N--CA 1.432 -1.338 0 N-CA-C 101.591 -3.485 . . . . 0.0 101.591 173.058 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 2.3 p -130.02 132.22 65.61 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.283 0 N-CA-C 114.76 1.393 . . . . 0.0 114.76 -172.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 89.09 111.97 1.25 Allowed Glycine 0 CA--C 1.521 0.461 0 CA-C-N 114.267 -1.333 . . . . 0.0 113.194 176.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -97.9 -60.51 0.92 Allowed Glycine 0 CA--C 1.54 1.609 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 176.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.662 ' HB ' HD11 ' I' ' 31' ' ' ILE . 10.0 p -145.06 150.5 15.93 Favored 'Isoleucine or valine' 0 C--N 1.342 0.269 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.497 ' OXT' ' ND1' ' E' ' 13' ' ' HIS . 9.8 p . . . . . 0 C--O 1.218 -0.577 0 CA-C-O 117.999 -1.001 . . . . 0.0 110.534 -179.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.429 -1.468 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -115.59 138.01 51.49 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.014 0.435 . . . . 0.0 110.745 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -71.97 140.61 49.21 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.136 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.583 HG23 ' O ' ' D' ' 12' ' ' VAL . 22.0 m -126.23 109.99 22.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-O 121.433 0.635 . . . . 0.0 110.594 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.602 ' ND1' ' O ' ' C' ' 13' ' ' HIS . 2.5 t60 -126.83 127.87 45.66 Favored 'General case' 0 N--CA 1.47 0.532 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.694 -178.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.461 ' HB3' ' H ' ' E' ' 14' ' ' HIS . 1.5 p-80 -134.19 164.39 27.46 Favored 'General case' 0 C--O 1.221 -0.396 0 C-N-CA 120.887 -0.325 . . . . 0.0 110.165 179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.415 ' NE2' HG12 ' B' ' 36' ' ' VAL . 44.4 tp60 -90.1 151.51 21.58 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 178.093 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 94.1 mttt -150.33 97.13 2.5 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 177.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.732 HD21 HG11 ' B' ' 36' ' ' VAL . 7.4 mt -123.29 121.56 36.15 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.07 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -114.89 106.54 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 177.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.654 ' CD1' HD13 ' B' ' 32' ' ' ILE . 91.4 m-85 -107.78 106.0 16.1 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 177.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 t80 -116.76 129.38 56.08 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.787 -175.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.943 ' HB1' ' HZ3' ' C' ' 28' ' ' LYS . . . -133.86 128.73 35.26 Favored 'General case' 0 CA--C 1.537 0.444 0 CA-C-O 121.54 0.686 . . . . 0.0 111.295 -179.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.629 ' N ' ' NZ ' ' C' ' 28' ' ' LYS . 98.9 mt-10 -95.13 139.4 31.51 Favored 'General case' 0 N--CA 1.469 0.487 0 C-N-CA 119.804 -0.758 . . . . 0.0 111.381 179.979 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.501 ' O ' ' O ' ' D' ' 24' ' ' VAL . 9.9 m-20 65.36 47.92 2.22 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 114.223 1.194 . . . . 0.0 114.223 177.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.501 ' O ' ' O ' ' D' ' 23' ' ' ASP . 5.2 m -52.45 -175.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.516 0 C-N-CA 119.215 -0.994 . . . . 0.0 108.433 177.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 165.43 19.46 0.02 OUTLIER Glycine 0 CA--C 1.523 0.548 0 C-N-CA 118.252 -1.928 . . . . 0.0 113.342 -177.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.622 ' HG ' ' H ' ' C' ' 30' ' ' ALA . 5.2 m -80.33 -130.37 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.534 0 N-CA-C 108.131 -1.062 . . . . 0.0 108.131 -179.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' CG1' ' P' ' 39' ' ' VAL . 9.7 m120 -100.48 149.78 23.33 Favored 'General case' 0 CA--C 1.516 -0.332 0 C-N-CA 119.048 -1.061 . . . . 0.0 109.745 -179.583 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.498 ' NZ ' HD11 ' F' ' 31' ' ' ILE . 95.8 mttt 37.78 42.54 0.41 Allowed 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 114.346 -1.297 . . . . 0.0 110.887 -177.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.56 -66.42 2.32 Favored Glycine 0 CA--C 1.545 1.947 0 CA-C-N 116.514 -0.312 . . . . 0.0 113.245 177.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -170.21 165.41 9.06 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 107.246 -1.39 . . . . 0.0 107.246 179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.525 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 11.9 tt -129.59 129.92 66.84 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 C-N-CA 119.453 -0.899 . . . . 0.0 112.733 -179.447 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 75.1 mt -113.52 112.68 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.761 178.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.64 97.01 1.39 Allowed Glycine 0 C--O 1.239 0.409 0 N-CA-C 104.226 -3.55 . . . . 0.0 104.226 175.2 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.427 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 64.9 tp -117.09 121.54 41.59 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 115.371 1.619 . . . . 0.0 115.371 -173.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 89.6 mmm -112.03 97.93 7.0 Favored 'General case' 0 N--CA 1.433 -1.3 0 N-CA-C 103.796 -2.668 . . . . 0.0 103.796 173.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.628 ' CG2' HE22 ' E' ' 15' ' ' GLN . 14.3 p -119.09 120.84 65.14 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.268 0 C-N-CA 119.714 -0.794 . . . . 0.0 110.454 -177.202 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -99.51 121.88 7.37 Favored Glycine 0 C--N 1.332 0.345 0 N-CA-C 110.766 -0.934 . . . . 0.0 110.766 179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.498 ' O ' ' O ' ' E' ' 39' ' ' VAL . . . -119.24 62.07 0.47 Allowed Glycine 0 CA--C 1.532 1.149 0 CA-C-O 119.035 -0.869 . . . . 0.0 112.532 178.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.63 ' HB ' HD11 ' J' ' 31' ' ' ILE . 49.2 t -84.3 130.04 36.61 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.896 0 CA-C-N 119.324 1.562 . . . . 0.0 109.742 179.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.431 ' O ' HG12 ' D' ' 39' ' ' VAL . 16.9 m . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.284 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.339 -1.504 . . . . 0.0 109.339 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -110.79 134.79 52.2 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.655 0.264 . . . . 0.0 110.302 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.433 ' O ' HG11 ' D' ' 12' ' ' VAL . 73.1 tt0 -105.54 137.59 43.13 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-N 116.373 -0.376 . . . . 0.0 109.994 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.553 HG11 ' H ' ' F' ' 12' ' ' VAL . 4.2 p -139.52 156.39 26.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 120.916 0.389 . . . . 0.0 111.42 -178.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.497 ' ND1' ' OXT' ' C' ' 40' ' ' VAL . 7.7 p80 -74.19 125.06 27.55 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 115.957 -0.565 . . . . 0.0 112.194 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.461 ' H ' ' HB3' ' D' ' 14' ' ' HIS . 52.6 p-80 -154.05 166.36 33.28 Favored 'General case' 0 CA--C 1.533 0.295 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.339 178.229 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.628 HE22 ' CG2' ' D' ' 36' ' ' VAL . 16.8 tt0 -89.84 151.71 21.63 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 110.266 -0.272 . . . . 0.0 110.266 178.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 72.0 tttt -149.57 105.27 3.43 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.858 177.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 10.4 mt -117.59 117.06 28.38 Favored 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 116.153 -0.476 . . . . 0.0 109.893 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 60.1 t -117.45 103.88 15.57 Favored 'Isoleucine or valine' 0 C--O 1.236 0.35 0 N-CA-C 109.938 -0.393 . . . . 0.0 109.938 179.221 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.639 ' CE2' ' CE1' ' F' ' 19' ' ' PHE . 3.7 m-30 -106.54 109.12 20.94 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 178.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -129.72 130.9 46.05 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 120.058 -0.657 . . . . 0.0 112.521 -176.24 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.441 ' HB1' HG13 ' D' ' 24' ' ' VAL . . . -124.47 133.18 53.43 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-N 116.32 -0.4 . . . . 0.0 109.936 178.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.454 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 92.0 mt-10 -127.18 170.64 12.19 Favored 'General case' 0 N--CA 1.493 1.683 0 N-CA-C 116.982 2.216 . . . . 0.0 116.982 -176.007 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.454 ' OD1' ' O ' ' E' ' 22' ' ' GLU . 11.4 p30 48.18 46.31 19.77 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 110.722 -2.944 . . . . 0.0 116.167 177.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.677 HG23 ' H ' ' E' ' 26' ' ' SER . 15.7 m -72.12 -168.79 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 C-N-CA 119.247 -0.981 . . . . 0.0 108.947 174.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -101.42 36.81 3.96 Favored Glycine 0 N--CA 1.467 0.725 0 N-CA-C 105.815 -2.914 . . . . 0.0 105.815 172.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.677 ' H ' HG23 ' E' ' 24' ' ' VAL . 21.3 t 61.63 111.21 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 113.339 -1.43 . . . . 0.0 107.844 -175.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.481 ' O ' ' N ' ' E' ' 29' ' ' GLY . 98.8 m-20 -130.0 161.1 31.7 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.433 ' C ' ' O ' ' E' ' 27' ' ' ASN . 98.3 mttt -28.63 -40.27 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.294 173.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.612 ' O ' ' HB2' ' E' ' 30' ' ' ALA . . . 107.68 -63.45 0.28 Allowed Glycine 0 CA--C 1.54 1.611 0 CA-C-O 117.096 -1.947 . . . . 0.0 115.968 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.612 ' HB2' ' O ' ' E' ' 29' ' ' GLY . . . -179.75 168.89 1.34 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 122.903 3.351 . . . . 0.0 115.915 -178.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 91.2 mt -119.53 125.09 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.189 0 CA-C-N 111.18 -2.736 . . . . 0.0 106.087 175.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 89.5 mt -130.49 128.76 64.04 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 113.205 0.817 . . . . 0.0 113.205 -177.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.94 106.28 1.01 Allowed Glycine 0 CA--C 1.527 0.814 0 N-CA-C 107.493 -2.243 . . . . 0.0 107.493 176.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.675 HD23 ' C ' ' E' ' 34' ' ' LEU . 7.3 tt -115.61 122.75 46.55 Favored 'General case' 0 CA--C 1.512 -0.518 0 CA-C-O 120.926 0.393 . . . . 0.0 111.672 -176.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.457 ' N ' HD23 ' E' ' 34' ' ' LEU . 8.2 mtp -118.76 126.07 51.04 Favored 'General case' 0 C--O 1.237 0.42 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.635 178.482 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.474 HG12 ' N ' ' E' ' 37' ' ' GLY . 59.1 t -90.68 156.38 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 CA-C-O 121.142 0.496 . . . . 0.0 111.052 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.474 ' N ' HG12 ' E' ' 36' ' ' VAL . . . -102.13 102.5 2.33 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 115.551 -0.749 . . . . 0.0 112.299 -179.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 48.56 -73.56 0.0 OUTLIER Glycine 0 CA--C 1.541 1.676 0 N-CA-C 115.567 0.987 . . . . 0.0 115.567 177.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.498 ' O ' ' O ' ' D' ' 38' ' ' GLY . 6.6 p -129.05 153.85 39.2 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.074 0 CA-C-N 118.577 1.189 . . . . 0.0 111.64 -178.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 67.8 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 118.037 -0.982 . . . . 0.0 110.695 -179.305 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 47.6 t80 -72.47 129.52 38.52 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.842 0.354 . . . . 0.0 110.611 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -141.43 140.26 33.58 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.56 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.553 ' H ' HG11 ' E' ' 12' ' ' VAL . 67.9 t -124.46 127.5 73.06 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.46 0 CA-C-O 121.952 0.882 . . . . 0.0 111.439 -179.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 5.8 p80 -126.51 103.29 7.52 Favored 'General case' 0 N--CA 1.462 0.154 0 CA-C-N 114.903 -1.044 . . . . 0.0 109.981 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.444 ' CE1' HG11 ' F' ' 12' ' ' VAL . 0.3 OUTLIER -148.08 169.38 20.08 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.423 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -89.58 156.88 18.32 Favored 'General case' 0 CA--C 1.515 -0.384 0 C-N-CA 119.227 -0.989 . . . . 0.0 110.65 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -141.21 104.71 4.68 Favored 'General case' 0 C--N 1.309 -1.174 0 N-CA-C 107.92 -1.141 . . . . 0.0 107.92 177.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.585 ' H ' HD12 ' F' ' 17' ' ' LEU . 0.0 OUTLIER -124.76 112.31 16.56 Favored 'General case' 0 N--CA 1.472 0.655 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 179.727 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -107.13 107.16 22.1 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.383 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 178.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.639 ' CE1' ' CE2' ' E' ' 19' ' ' PHE . 13.1 m-85 -118.89 108.78 15.22 Favored 'General case' 0 C--N 1.323 -0.567 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 179.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.525 ' CE2' ' O ' ' F' ' 21' ' ' ALA . 57.7 t80 -148.76 163.32 37.7 Favored 'General case' 0 N--CA 1.468 0.425 0 CA-C-O 122.33 1.062 . . . . 0.0 113.234 -178.428 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.525 ' O ' ' CE2' ' F' ' 20' ' ' PHE . . . -137.62 138.34 39.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 114.246 -1.343 . . . . 0.0 109.582 179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -77.94 112.67 15.07 Favored 'General case' 0 N--CA 1.465 0.287 0 N-CA-C 107.882 -1.155 . . . . 0.0 107.882 179.092 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 51.2 p30 -174.18 48.88 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.395 -0.366 . . . . 0.0 111.244 -176.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 35.3 m -71.86 160.57 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.387 0 C-N-CA 118.587 -1.245 . . . . 0.0 109.043 -177.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.5 -34.66 5.26 Favored Glycine 0 CA--C 1.521 0.409 0 N-CA-C 105.724 -2.95 . . . . 0.0 105.724 -175.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 40.5 t -80.55 120.12 24.1 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 112.25 -1.975 . . . . 0.0 109.524 178.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.618 ' O ' ' N ' ' F' ' 29' ' ' GLY . 64.7 t30 -87.43 -175.8 5.38 Favored 'General case' 0 C--N 1.328 -0.336 0 C-N-CA 120.872 -0.331 . . . . 0.0 110.59 -177.559 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.505 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 99.0 mttt -49.58 49.59 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.72 0 N-CA-C 115.44 1.644 . . . . 0.0 115.44 -176.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.618 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -101.75 51.42 0.92 Allowed Glycine 0 CA--C 1.545 1.921 0 C-N-CA 120.516 -0.85 . . . . 0.0 111.222 177.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.523 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -130.2 170.19 14.39 Favored 'General case' 0 CA--C 1.516 -0.359 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.498 HD11 ' NZ ' ' D' ' 28' ' ' LYS . 97.1 mt -119.73 124.68 73.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.294 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 33.7 pt -135.79 137.18 49.47 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.25 0 CA-C-O 121.215 0.531 . . . . 0.0 111.218 -179.596 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -134.96 120.31 2.34 Favored Glycine 0 CA--C 1.523 0.543 0 N-CA-C 110.035 -1.226 . . . . 0.0 110.035 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.584 HD23 ' C ' ' F' ' 34' ' ' LEU . 6.2 tt -118.54 121.98 41.55 Favored 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 -179.524 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.576 ' N ' HD23 ' F' ' 34' ' ' LEU . 4.8 ttm -119.25 120.37 36.81 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-O 120.958 0.409 . . . . 0.0 111.101 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.472 ' O ' ' O ' ' F' ' 37' ' ' GLY . 22.4 m -87.12 131.8 34.11 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.076 178.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' F' ' 36' ' ' VAL . . . -46.97 -111.82 0.01 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 121.918 0.732 . . . . 0.0 112.103 179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -104.64 -71.36 0.83 Allowed Glycine 0 CA--C 1.535 1.319 0 N-CA-C 110.866 -0.894 . . . . 0.0 110.866 179.364 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 58.3 t -102.5 128.58 55.11 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.473 0 CA-C-O 121.339 0.59 . . . . 0.0 110.751 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.219 -0.544 0 CA-C-O 118.107 -0.949 . . . . 0.0 110.585 -179.982 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.181 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -80.54 143.16 33.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.832 0.349 . . . . 0.0 110.805 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -122.68 164.56 18.04 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.268 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.5 t -117.08 131.4 69.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.25 -179.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 37.8 p-80 -143.69 161.09 39.46 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.509 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.41 ' CE1' ' CD2' ' H' ' 13' ' ' HIS . 72.3 m80 -150.22 173.48 13.89 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.154 -179.607 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 29.7 pt20 -92.33 150.27 20.94 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.772 -179.441 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -101.31 151.16 22.22 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.131 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.0 tp -137.45 124.83 21.92 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 121.561 0.696 . . . . 0.0 111.681 -179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 65.8 t -124.82 129.97 73.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 114.99 -1.004 . . . . 0.0 108.819 178.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -134.27 130.63 37.37 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.198 0.523 . . . . 0.0 111.285 -179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.508 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.6 p90 -135.67 128.37 30.91 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.752 179.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.6 138.37 54.56 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-O 120.801 0.334 . . . . 0.0 110.898 -179.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -81.96 -168.78 2.07 Favored 'General case' 0 C--N 1.333 -0.112 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.593 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 95.9 m-20 -36.38 -60.46 0.57 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.862 -0.608 . . . . 0.0 112.406 -179.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.437 HG12 ' N ' ' G' ' 25' ' ' GLY . 4.1 t -72.73 160.68 5.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.499 0.666 . . . . 0.0 111.72 -178.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.437 ' N ' HG12 ' G' ' 24' ' ' VAL . . . 110.29 -35.21 4.97 Favored Glycine 0 N--CA 1.466 0.671 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.077 177.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.438 ' OG ' ' OD1' ' H' ' 23' ' ' ASP . 38.7 m -80.71 119.36 23.22 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 178.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.506 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 15.4 t-20 -88.38 178.91 6.44 Favored 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 119.52 -0.872 . . . . 0.0 111.618 -179.725 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.506 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 77.4 tttt -56.09 -36.55 68.27 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-N 114.869 -1.06 . . . . 0.0 111.685 178.799 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.65 82.15 0.45 Allowed Glycine 0 CA--C 1.53 1.018 0 CA-C-N 114.127 -1.397 . . . . 0.0 113.508 -174.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.498 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . -101.95 102.98 13.59 Favored 'General case' 0 C--O 1.242 0.698 0 CA-C-O 124.132 1.92 . . . . 0.0 109.775 -178.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.506 HG23 HG23 ' H' ' 31' ' ' ILE . 53.1 mt -126.45 132.54 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.656 0 CA-C-N 110.506 -3.043 . . . . 0.0 108.868 -177.459 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.505 HG22 HD21 ' H' ' 34' ' ' LEU . 33.5 mt -103.66 110.79 31.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 176.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.81 104.98 1.44 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 107.524 -2.23 . . . . 0.0 107.524 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 50.7 tp -163.0 152.79 15.67 Favored 'General case' 0 C--O 1.241 0.654 0 C-N-CA 117.976 -1.49 . . . . 0.0 113.64 -177.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.43 ' SD ' ' HB2' ' H' ' 35' ' ' MET . 45.4 tpp -100.03 116.87 33.07 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 112.572 -2.103 . . . . 0.0 107.953 178.036 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 39.6 t -123.09 112.1 32.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 N-CA-C 108.261 -1.015 . . . . 0.0 108.261 179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 109.53 -131.88 10.75 Favored Glycine 0 CA--C 1.52 0.4 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 -178.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 106.47 -62.66 0.31 Allowed Glycine 0 CA--C 1.54 1.648 0 C-N-CA 121.436 -0.411 . . . . 0.0 112.442 179.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.674 ' O ' HG23 ' G' ' 40' ' ' VAL . 12.6 p -116.22 160.47 15.59 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 C-N-CA 122.542 0.337 . . . . 0.0 110.936 -179.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.674 HG23 ' O ' ' G' ' 39' ' ' VAL . 24.7 t . . . . . 0 N--CA 1.471 0.588 0 CA-C-O 118.099 -0.953 . . . . 0.0 109.401 177.04 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -83.21 139.76 32.95 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.727 0.298 . . . . 0.0 110.509 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -138.34 140.76 39.62 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.913 0.387 . . . . 0.0 110.891 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.5 t -129.96 134.51 62.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.41 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.636 179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.41 ' CD2' ' CE1' ' G' ' 14' ' ' HIS . 20.6 t-160 -129.58 100.46 5.54 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 120.825 0.345 . . . . 0.0 110.843 179.644 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 0.1 OUTLIER -159.3 171.98 18.84 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.128 179.851 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.645 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 84.6 mt-30 -152.2 141.31 21.3 Favored 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 178.092 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -88.08 114.53 24.79 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.79 178.006 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 70.8 mt -119.55 112.99 20.04 Favored 'General case' 0 C--O 1.237 0.442 0 N-CA-C 108.94 -0.763 . . . . 0.0 108.94 178.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 69.6 t -120.77 131.12 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 120.792 0.329 . . . . 0.0 111.441 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 t80 -133.15 116.15 15.92 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.585 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.447 ' CE2' ' CD2' ' I' ' 20' ' ' PHE . 10.4 m-85 -122.65 134.84 54.48 Favored 'General case' 0 N--CA 1.472 0.67 0 N-CA-C 109.098 -0.704 . . . . 0.0 109.098 179.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.11 127.83 23.33 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 113.593 0.961 . . . . 0.0 113.593 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 80.3 tt0 -95.02 117.38 30.06 Favored 'General case' 0 CA--C 1.522 -0.101 0 N-CA-C 106.003 -1.851 . . . . 0.0 106.003 176.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.45 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 84.5 m-20 -136.05 46.99 2.26 Favored 'General case' 0 N--CA 1.471 0.61 0 N-CA-C 114.135 1.161 . . . . 0.0 114.135 -175.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.66 HG22 ' HA ' ' I' ' 23' ' ' ASP . 17.0 t -99.88 162.98 2.97 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 C-N-CA 118.013 -1.475 . . . . 0.0 108.386 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.459 ' N ' HG12 ' H' ' 24' ' ' VAL . . . 70.99 28.58 70.27 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 107.611 -2.196 . . . . 0.0 107.611 -178.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.532 ' OG ' ' N ' ' H' ' 27' ' ' ASN . 20.0 p -170.53 -132.65 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.548 0 CA-C-O 121.801 0.81 . . . . 0.0 112.467 -175.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.532 ' N ' ' OG ' ' H' ' 26' ' ' SER . 1.6 m120 -30.7 143.67 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.502 0 CA-C-N 114.1 -1.409 . . . . 0.0 113.713 -177.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -132.53 -25.14 1.95 Allowed 'General case' 0 CA--C 1.539 0.529 0 CA-C-N 113.609 -1.632 . . . . 0.0 111.224 -177.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.498 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . -78.83 109.37 2.83 Favored Glycine 0 N--CA 1.47 0.913 0 CA-C-N 116.187 -0.46 . . . . 0.0 113.376 -176.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.86 111.99 12.61 Favored 'General case' 0 N--CA 1.471 0.623 0 CA-C-O 122.385 1.088 . . . . 0.0 112.621 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.506 HG23 HG23 ' G' ' 31' ' ' ILE . 14.9 tt -140.34 137.99 36.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-N 114.515 -1.22 . . . . 0.0 111.124 178.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.439 ' CG2' HD12 ' H' ' 34' ' ' LEU . 95.5 mt -106.19 113.88 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.609 179.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.74 100.67 1.13 Allowed Glycine 0 N--CA 1.466 0.663 0 N-CA-C 106.631 -2.588 . . . . 0.0 106.631 176.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.505 HD21 HG22 ' G' ' 32' ' ' ILE . 90.7 mt -141.76 153.45 44.59 Favored 'General case' 0 CA--C 1.51 -0.564 0 CA-C-O 122.844 1.307 . . . . 0.0 113.586 -175.467 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.43 ' HB2' ' SD ' ' G' ' 35' ' ' MET . 4.1 mtp -116.87 117.18 29.02 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-N 112.498 -2.137 . . . . 0.0 105.939 176.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.557 ' O ' ' NE2' ' K' ' 15' ' ' GLN . 58.9 t -123.56 102.42 11.17 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 O-C-N 122.469 -0.144 . . . . 0.0 111.35 -176.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 131.64 -162.37 23.76 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 111.535 -0.626 . . . . 0.0 111.535 178.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.437 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 146.71 -55.64 0.52 Allowed Glycine 0 CA--C 1.547 2.093 0 CA-C-O 119.572 -0.571 . . . . 0.0 112.561 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.613 ' CG2' HG21 ' N' ' 31' ' ' ILE . 3.0 p -142.44 162.51 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-N 118.498 1.149 . . . . 0.0 110.248 178.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.432 HG23 ' ND1' ' K' ' 13' ' ' HIS . 7.2 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.854 178.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.306 -1.518 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . 0.514 ' CD1' ' O ' ' J' ' 9' ' ' GLY . 97.7 m-85 -99.28 132.59 44.49 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.723 0.297 . . . . 0.0 110.572 -179.637 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.5 ' N ' ' CD ' ' I' ' 11' ' ' GLU . 2.0 pm0 -154.4 141.25 19.14 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.054 0.454 . . . . 0.0 111.446 -179.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -126.81 129.35 71.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.291 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.968 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 18.7 m80 -116.25 138.88 50.93 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 110.35 -0.241 . . . . 0.0 110.35 179.867 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -149.85 167.85 25.4 Favored 'General case' 0 C--N 1.33 -0.25 0 C-N-CA 120.216 -0.594 . . . . 0.0 110.351 177.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.413 ' CB ' HE21 ' J' ' 15' ' ' GLN . 44.2 tp60 -139.22 141.07 37.91 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.015 -0.735 . . . . 0.0 109.015 178.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.456 ' C ' HD22 ' I' ' 17' ' ' LEU . 99.5 mttt -129.8 104.3 7.32 Favored 'General case' 0 C--N 1.321 -0.664 0 C-N-CA 120.44 -0.504 . . . . 0.0 110.394 179.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.463 HD12 ' CZ ' ' I' ' 19' ' ' PHE . 3.6 mm? -111.9 113.29 25.53 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 t -109.08 107.48 22.95 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 178.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.463 ' CZ ' HD12 ' I' ' 17' ' ' LEU . 57.7 m-85 -109.05 108.45 19.16 Favored 'General case' 0 CA--C 1.546 0.821 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.447 ' CD2' ' CE2' ' H' ' 20' ' ' PHE . 5.4 m-85 -117.5 130.42 56.43 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 122.184 -0.322 . . . . 0.0 110.917 -179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.29 134.22 30.69 Favored 'General case' 0 N--CA 1.476 0.856 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.563 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 85.5 mt-10 -92.4 -161.33 0.82 Allowed 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 115.399 -0.819 . . . . 0.0 109.217 178.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.66 ' HA ' HG22 ' H' ' 24' ' ' VAL . 0.4 OUTLIER 95.12 54.2 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.3 0 N-CA-C 107.181 -1.415 . . . . 0.0 107.181 -177.689 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.458 HG13 ' H ' ' I' ' 24' ' ' VAL . 1.1 m -81.3 133.49 29.18 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.973 0 CA-C-O 125.133 2.397 . . . . 0.0 116.264 -169.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.707 ' H ' ' HA ' ' J' ' 23' ' ' ASP . . . 94.5 -41.99 2.5 Favored Glycine 0 N--CA 1.443 -0.869 2 CA-C-N 107.471 -4.422 . . . . 0.0 113.594 172.516 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 94.6 p -68.39 110.85 4.31 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-O 115.976 -1.964 . . . . 0.0 112.039 174.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.888 ' ND2' ' H ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -147.66 124.47 11.23 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 123.313 2.778 . . . . 0.0 111.566 166.739 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.408 ' HZ2' HG23 ' A' ' 39' ' ' VAL . 94.0 mttt -18.11 -52.86 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.708 0 N-CA-C 115.638 1.718 . . . . 0.0 115.638 172.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 161.61 52.77 0.02 OUTLIER Glycine 0 CA--C 1.563 3.08 0 CA-C-N 112.584 -2.098 . . . . 0.0 109.661 -175.25 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.888 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . -41.98 141.64 0.84 Allowed 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 117.26 2.319 . . . . 0.0 117.26 -171.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.719 HD12 ' O ' ' B' ' 38' ' ' GLY . 55.0 mt -143.19 147.79 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.033 0 CA-C-N 112.831 -1.986 . . . . 0.0 113.701 -177.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.429 HD13 HG21 ' I' ' 32' ' ' ILE . 27.3 mt -110.58 111.61 36.91 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 N-CA-C 107.937 -1.134 . . . . 0.0 107.937 174.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.09 104.57 1.96 Allowed Glycine 0 N--CA 1.466 0.643 0 N-CA-C 107.267 -2.333 . . . . 0.0 107.267 177.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 1.3 mt -141.14 144.56 34.91 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 114.438 1.273 . . . . 0.0 114.438 -175.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 49.2 tpp -112.85 115.67 28.84 Favored 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 104.644 -2.354 . . . . 0.0 104.644 173.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.51 HG12 ' OE1' ' K' ' 15' ' ' GLN . 47.5 t -123.44 102.62 11.61 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 118.055 0.389 . . . . 0.0 111.874 -175.767 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.737 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 107.31 -161.93 13.54 Favored Glycine 0 N--CA 1.467 0.714 0 C-N-CA 120.486 -0.864 . . . . 0.0 112.803 177.557 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.822 ' H ' ' H ' ' J' ' 38' ' ' GLY . . . 148.15 -55.35 0.5 Allowed Glycine 0 CA--C 1.542 1.75 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.746 HG21 HD12 ' N' ' 31' ' ' ILE . 18.2 t -114.43 130.46 68.7 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.306 0 C-N-CA 123.409 0.684 . . . . 0.0 109.217 178.554 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.492 HG23 ' ND1' ' K' ' 13' ' ' HIS . 2.4 p . . . . . 0 C--N 1.322 -0.62 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.898 179.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . 0.514 ' O ' ' CD1' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 86.3 m-85 -117.13 143.83 45.38 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-O 120.675 0.274 . . . . 0.0 110.434 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -73.68 108.58 6.61 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.86 0.362 . . . . 0.0 110.677 179.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -139.7 136.64 39.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.31 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -145.87 126.07 13.85 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.948 -0.301 . . . . 0.0 111.159 -179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 11.2 m-70 -140.41 157.57 45.33 Favored 'General case' 0 N--CA 1.47 0.553 0 C-N-CA 120.245 -0.582 . . . . 0.0 110.012 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.413 HE21 ' CB ' ' I' ' 15' ' ' GLN . 3.4 tp60 -90.31 158.85 16.95 Favored 'General case' 0 N--CA 1.454 -0.272 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 174.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 44.1 tttp -141.18 113.55 8.09 Favored 'General case' 0 C--N 1.31 -1.116 0 C-N-CA 119.973 -0.691 . . . . 0.0 110.163 177.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.429 ' N ' HD12 ' J' ' 17' ' ' LEU . 2.8 mp -136.61 127.94 28.28 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-O 121.755 0.788 . . . . 0.0 110.84 178.603 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 61.0 t -112.95 112.23 39.55 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.355 0 CA-C-N 114.464 -1.244 . . . . 0.0 108.76 179.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' K' ' 19' ' ' PHE . 18.5 m-85 -106.98 106.33 16.8 Favored 'General case' 0 N--CA 1.462 0.162 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.598 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 20.4 t80 -113.79 114.8 26.81 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -179.598 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.53 122.59 22.62 Favored 'General case' 0 C--O 1.246 0.9 0 CA-C-O 122.153 0.977 . . . . 0.0 111.829 -179.615 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 96.5 mt-10 -83.89 125.46 32.01 Favored 'General case' 0 N--CA 1.455 -0.178 0 CA-C-N 113.824 -1.535 . . . . 0.0 107.861 179.251 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.707 ' HA ' ' H ' ' I' ' 25' ' ' GLY . 61.2 m-20 -166.45 47.29 0.07 Allowed 'General case' 0 CA--C 1.545 0.751 0 CA-C-O 118.158 -0.925 . . . . 0.0 113.393 -174.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.563 ' N ' ' OE1' ' K' ' 22' ' ' GLU . 9.3 p -98.6 161.31 3.04 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 CA-C-N 121.419 1.918 . . . . 0.0 109.286 -176.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.741 ' H ' ' N ' ' K' ' 25' ' ' GLY . . . 73.23 28.87 65.3 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 106.662 -2.575 . . . . 0.0 106.662 -178.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.502 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 8.7 t -104.5 -120.75 0.21 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 116.927 2.195 . . . . 0.0 116.927 -173.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.415 ' OD1' ' O ' ' I' ' 27' ' ' ASN . 2.2 m120 -81.8 163.75 22.14 Favored 'General case' 0 C--N 1.343 0.316 0 N-CA-C 114.827 1.418 . . . . 0.0 114.827 -175.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -47.47 -36.82 10.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 112.661 -2.063 . . . . 0.0 114.504 178.075 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.8 77.84 0.06 OUTLIER Glycine 0 CA--C 1.532 1.104 0 C-N-CA 119.147 -1.501 . . . . 0.0 114.859 -174.089 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -51.21 169.0 0.05 Allowed 'General case' 0 N--CA 1.473 0.68 0 CA-C-N 118.847 1.324 . . . . 0.0 110.555 -179.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.63 HD11 ' HB ' ' D' ' 39' ' ' VAL . 68.8 mt -127.39 135.64 62.79 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 115.212 1.56 . . . . 0.0 115.212 -175.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 53.7 mt -106.49 105.75 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 172.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.18 101.17 1.94 Allowed Glycine 0 CA--C 1.508 -0.398 0 N-CA-C 104.849 -3.301 . . . . 0.0 104.849 176.354 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.752 ' CD2' HG22 ' J' ' 36' ' ' VAL . 6.5 tt -143.33 125.74 15.7 Favored 'General case' 0 C--O 1.243 0.738 0 CA-C-O 123.081 1.419 . . . . 0.0 112.618 -175.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.7 mtp -104.68 118.07 35.66 Favored 'General case' 0 N--CA 1.439 -0.978 0 CA-C-N 112.582 -2.099 . . . . 0.0 107.875 178.226 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.752 HG22 ' CD2' ' J' ' 34' ' ' LEU . 1.8 t -105.91 114.09 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.614 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' I' ' 36' ' ' VAL . . . -64.78 -123.24 0.01 OUTLIER Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.071 -0.812 . . . . 0.0 111.071 178.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.822 ' H ' ' H ' ' I' ' 38' ' ' GLY . . . 64.99 61.05 6.15 Favored Glycine 0 CA--C 1.533 1.21 0 CA-C-N 114.278 -0.961 . . . . 0.0 114.573 178.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.466 ' HB ' HD13 ' P' ' 31' ' ' ILE . 1.0 OUTLIER -92.52 130.17 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.99 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 177.817 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.652 ' OXT' HG13 ' J' ' 40' ' ' VAL . 7.4 p . . . . . 0 C--O 1.221 -0.431 0 CA-C-O 117.84 -1.076 . . . . 0.0 111.859 -177.604 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 93.6 m-85 -104.69 133.41 49.57 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-O 120.75 0.309 . . . . 0.0 110.609 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -142.9 133.29 24.8 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.666 -179.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 95.2 t -124.97 123.8 66.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.462 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.492 ' ND1' HG23 ' I' ' 40' ' ' VAL . 6.4 t-160 -145.04 112.98 6.4 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.044 0.449 . . . . 0.0 111.305 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.673 ' CE1' ' H ' ' L' ' 14' ' ' HIS . 19.0 m-70 -140.41 159.22 42.68 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 108.546 -0.909 . . . . 0.0 108.546 177.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.737 HE22 ' N ' ' I' ' 37' ' ' GLY . 77.0 mt-30 -90.18 159.35 16.79 Favored 'General case' 0 CA--C 1.512 -0.492 0 N-CA-C 107.154 -1.424 . . . . 0.0 107.154 175.713 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.711 ' C ' HD12 ' K' ' 17' ' ' LEU . 99.2 mttt -140.03 101.0 4.06 Favored 'General case' 0 C--N 1.31 -1.118 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.45 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.711 HD12 ' C ' ' K' ' 16' ' ' LYS . 7.7 mp -125.89 125.91 43.57 Favored 'General case' 0 CA--C 1.506 -0.73 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.785 178.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.405 HG13 ' O ' ' K' ' 18' ' ' VAL . 5.2 p -119.49 118.33 56.96 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.519 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.503 ' CD1' ' CD1' ' J' ' 19' ' ' PHE . 53.2 m-85 -107.03 105.98 16.28 Favored 'General case' 0 N--CA 1.447 -0.586 0 CA-C-N 114.728 -1.123 . . . . 0.0 109.69 -178.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.598 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 40.1 t80 -106.24 108.09 19.43 Favored 'General case' 0 CA--C 1.515 -0.391 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -148.36 155.11 40.86 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.94 1.352 . . . . 0.0 113.38 -177.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.568 ' HB2' ' H ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -93.06 117.58 30.23 Favored 'General case' 0 C--N 1.311 -1.066 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.908 -179.273 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.427 ' OD2' ' OD1' ' L' ' 23' ' ' ASP . 13.6 m-20 -67.4 -51.25 54.18 Favored 'General case' 0 N--CA 1.47 0.55 0 CA-C-N 114.418 -1.265 . . . . 0.0 111.547 178.867 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.568 HG22 ' N ' ' K' ' 25' ' ' GLY . 2.3 p 158.8 161.84 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 N-CA-C 106.835 -1.543 . . . . 0.0 106.835 -177.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.741 ' N ' ' H ' ' J' ' 25' ' ' GLY . . . -63.29 30.41 0.08 OUTLIER Glycine 0 CA--C 1.532 1.116 0 N-CA-C 118.509 2.164 . . . . 0.0 118.509 -174.225 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.575 ' OG ' ' O ' ' K' ' 25' ' ' GLY . 5.2 m -169.96 -127.8 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 121.293 2.546 . . . . 0.0 114.104 175.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.437 ' O ' ' N ' ' K' ' 29' ' ' GLY . 60.2 t30 -48.13 152.29 0.85 Allowed 'General case' 0 CA--C 1.52 -0.203 0 N-CA-C 113.577 0.955 . . . . 0.0 113.577 -178.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.449 ' NZ ' HD11 ' L' ' 32' ' ' ILE . 85.0 tttt -70.33 48.84 0.11 Allowed 'General case' 0 N--CA 1.455 -0.214 0 N-CA-C 107.524 -1.288 . . . . 0.0 107.524 174.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . -82.47 51.1 4.46 Favored Glycine 0 CA--C 1.527 0.818 0 C-N-CA 120.27 -0.966 . . . . 0.0 112.707 -176.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 173.58 7.13 Favored 'General case' 0 C--O 1.237 0.428 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 179.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.529 HD12 HG13 ' D' ' 39' ' ' VAL . 42.2 mt -125.46 127.75 72.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.743 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.424 HD13 HG21 ' K' ' 32' ' ' ILE . 33.4 pt -132.63 127.6 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.664 0.745 . . . . 0.0 111.753 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.608 ' C ' HD22 ' K' ' 34' ' ' LEU . . . -117.34 110.93 2.15 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.709 HD22 ' N ' ' K' ' 34' ' ' LEU . 1.9 mm? -121.64 116.16 24.08 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-O 120.902 0.382 . . . . 0.0 110.066 -179.443 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 4.1 ttm -107.81 130.28 54.99 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 178.445 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 54.0 t -125.64 131.84 71.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.275 0 CA-C-O 121.915 0.864 . . . . 0.0 112.352 -179.509 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.03 -111.41 0.01 OUTLIER Glycine 0 CA--C 1.527 0.827 0 CA-C-N 113.722 -1.581 . . . . 0.0 111.085 176.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' OXT' ' J' ' 40' ' ' VAL . . . 105.91 -70.55 0.23 Allowed Glycine 0 N--CA 1.473 1.101 0 CA-C-N 114.518 -0.841 . . . . 0.0 111.758 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -155.58 97.21 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.195 0 N-CA-C 107.557 -1.275 . . . . 0.0 107.557 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.403 ' CA ' HG21 ' Q' ' 31' ' ' ILE . 2.3 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.946 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -108.79 132.64 53.79 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 110.059 -0.349 . . . . 0.0 110.059 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -144.54 142.63 30.35 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.271 -0.422 . . . . 0.0 109.921 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.533 HG12 ' NE2' ' K' ' 14' ' ' HIS . 2.1 t -110.79 115.93 51.13 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.034 0.445 . . . . 0.0 110.462 -179.335 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.516 ' O ' ' ND1' ' L' ' 13' ' ' HIS . 1.5 p80 -147.19 101.5 3.4 Favored 'General case' 0 CA--C 1.539 0.527 0 CA-C-N 115.734 -0.666 . . . . 0.0 111.975 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.673 ' H ' ' CE1' ' K' ' 14' ' ' HIS . 97.6 m-70 -156.55 164.92 37.64 Favored 'General case' 0 N--CA 1.467 0.42 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 178.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.449 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 96.5 mm-40 -89.97 159.36 16.94 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.851 0.358 . . . . 0.0 111.104 -179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -139.78 104.18 4.83 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 121.605 0.716 . . . . 0.0 109.494 177.701 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.663 ' CD1' HG21 ' J' ' 36' ' ' VAL . 1.8 mt -122.69 115.48 22.14 Favored 'General case' 0 CA--C 1.505 -0.75 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.338 179.98 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 77.1 t -101.64 97.76 6.06 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.93 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.327 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.565 ' CZ ' HD12 ' K' ' 34' ' ' LEU . 85.2 m-85 -93.87 98.93 11.39 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 106.368 -1.715 . . . . 0.0 106.368 178.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 59.8 t80 -122.38 127.02 49.22 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.746 0.784 . . . . 0.0 109.996 -178.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -147.11 150.96 36.03 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -64.45 107.79 1.46 Allowed 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 118.549 -1.26 . . . . 0.0 108.758 -178.026 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.427 ' OD1' ' OD2' ' K' ' 23' ' ' ASP . 13.8 m-20 -153.89 50.0 0.66 Allowed 'General case' 0 C--O 1.231 0.122 0 N-CA-C 113.336 0.865 . . . . 0.0 113.336 -177.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 95.8 t -82.8 149.3 4.67 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 178.095 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.93 36.25 5.83 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 109.086 -1.606 . . . . 0.0 109.086 -177.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 18.1 t -76.45 102.35 5.96 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 121.706 0.765 . . . . 0.0 111.487 -176.616 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 86.7 m-20 -97.48 -167.61 1.56 Allowed 'General case' 0 CA--C 1.533 0.304 0 CA-C-N 114.543 -1.208 . . . . 0.0 112.188 -179.175 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -49.13 -40.55 32.93 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 114.042 -1.436 . . . . 0.0 114.38 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.31 68.79 1.86 Allowed Glycine 0 N--CA 1.477 1.432 0 N-CA-C 114.971 0.748 . . . . 0.0 114.971 -175.09 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.444 ' CB ' ' O ' ' K' ' 28' ' ' LYS . . . -141.74 141.71 33.26 Favored 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 177.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 96.5 mt -120.6 117.69 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.125 0 CA-C-N 120.443 1.474 . . . . 0.0 111.577 -179.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.449 HD11 ' NZ ' ' K' ' 28' ' ' LYS . 95.4 mt -119.57 122.18 68.21 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.12 0 CA-C-N 114.812 -1.086 . . . . 0.0 110.205 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.4 106.72 0.91 Allowed Glycine 0 N--CA 1.464 0.547 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 48.9 tp -125.17 123.9 40.61 Favored 'General case' 0 CA--C 1.516 -0.343 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 94.0 mtp -132.77 133.58 43.61 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 121.436 0.636 . . . . 0.0 112.217 -179.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.5 t -128.87 132.35 67.55 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.135 0 N-CA-C 106.781 -1.563 . . . . 0.0 106.781 177.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -83.6 112.19 3.53 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 119.182 -1.485 . . . . 0.0 111.736 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -63.34 -63.51 4.46 Favored Glycine 0 CA--C 1.534 1.235 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 177.158 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.506 ' CA ' HD11 ' R' ' 31' ' ' ILE . 0.8 OUTLIER -125.65 -169.5 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 C-N-CA 124.229 1.012 . . . . 0.0 108.355 -179.111 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.909 ' N ' HD11 ' R' ' 31' ' ' ILE . 0.7 OUTLIER . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 118.348 -0.834 . . . . 0.0 111.734 179.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.629 -1.388 . . . . 0.0 109.629 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -110.2 138.54 46.45 Favored 'General case' 0 N--CA 1.467 0.403 0 CA-C-O 120.728 0.299 . . . . 0.0 110.487 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 42.7 tp10 -141.67 110.41 6.13 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.89 0.376 . . . . 0.0 110.048 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 70.4 t -125.87 131.6 71.67 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.327 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.814 -179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -107.43 107.81 18.86 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 121.058 -0.257 . . . . 0.0 110.695 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . . . . . . . . . 42.8 p-80 -152.66 165.94 33.68 Favored 'General case' 0 N--CA 1.462 0.148 0 CA-C-O 121.212 0.53 . . . . 0.0 111.728 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 52.7 tt0 -170.75 147.99 2.87 Favored 'General case' 0 N--CA 1.447 -0.613 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.271 178.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -77.9 120.41 22.74 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.063 179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -128.31 113.81 16.1 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 178.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -130.19 130.07 65.55 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.354 -179.847 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.0 m-85 -133.56 141.88 47.91 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.44 179.51 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.408 ' CD2' ' O ' ' M' ' 20' ' ' PHE . 50.9 p90 -134.8 129.28 34.31 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.714 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -111.53 116.59 31.11 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 121.326 0.584 . . . . 0.0 110.339 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . 0.581 ' O ' ' N ' ' M' ' 24' ' ' VAL . 67.3 mt-10 -150.9 -139.06 0.09 Allowed 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 115.329 -0.851 . . . . 0.0 108.918 -178.568 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 53.7 p30 -53.05 50.99 0.0 OUTLIER 'General case' 0 CA--C 1.544 0.734 0 C-N-CA 124.694 1.197 . . . . 0.0 113.226 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.587 HG12 ' H ' ' M' ' 25' ' ' GLY . 2.7 t -101.02 -141.73 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 -177.886 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.587 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -72.59 -36.99 58.29 Favored Glycine 0 CA--C 1.524 0.615 0 C-N-CA 119.161 -1.495 . . . . 0.0 113.273 -175.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . 0.425 ' O ' ' C ' ' M' ' 27' ' ' ASN . 93.8 p -162.27 117.26 1.88 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 118.873 1.336 . . . . 0.0 112.134 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.529 ' ND2' ' O ' ' N' ' 25' ' ' GLY . 99.1 m-20 -23.33 144.83 0.0 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 114.769 -1.105 . . . . 0.0 113.194 176.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -120.24 -36.6 3.21 Favored 'General case' 0 N--CA 1.469 0.503 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 173.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . 0.437 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . 80.14 -70.2 2.98 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-N 112.275 -2.239 . . . . 0.0 112.584 178.762 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.437 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 179.46 74.73 0.01 OUTLIER 'General case' 0 CA--C 1.539 0.538 0 CA-C-N 117.533 0.666 . . . . 0.0 112.022 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.6 HG23 ' O ' ' M' ' 31' ' ' ILE . 19.3 tt -128.58 108.94 18.23 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 CA-C-N 119.243 0.929 . . . . 0.0 109.313 179.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . 0.572 HD13 ' CD1' ' O' ' 19' ' ' PHE . 96.6 mt -114.48 109.55 28.89 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 C-N-CA 120.89 -0.324 . . . . 0.0 110.592 -179.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.25 98.36 0.69 Allowed Glycine 0 N--CA 1.461 0.308 0 N-CA-C 106.154 -2.778 . . . . 0.0 106.154 177.021 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 82.5 mt -145.93 164.6 31.5 Favored 'General case' 0 N--CA 1.474 0.73 0 CA-C-O 123.269 1.509 . . . . 0.0 113.888 -176.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 88.9 mmm -113.77 110.19 19.77 Favored 'General case' 0 N--CA 1.443 -0.823 0 CA-C-N 111.771 -2.468 . . . . 0.0 106.859 177.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -118.04 111.78 35.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 179.757 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 134.69 -131.52 5.92 Favored Glycine 0 C--N 1.314 -0.648 0 N-CA-C 109.371 -1.491 . . . . 0.0 109.371 -179.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 99.02 -63.08 0.75 Allowed Glycine 0 CA--C 1.536 1.398 0 N-CA-C 111.348 -0.701 . . . . 0.0 111.348 -179.261 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.449 ' O ' ' OXT' ' M' ' 40' ' ' VAL . 2.1 t -114.04 160.71 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 CA-C-N 116.992 0.396 . . . . 0.0 110.05 179.64 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.449 ' OXT' ' O ' ' M' ' 39' ' ' VAL . 21.8 m . . . . . 0 N--CA 1.469 0.48 0 CA-C-O 117.836 -1.078 . . . . 0.0 111.918 178.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.113 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -85.51 137.9 32.57 Favored 'General case' 0 C--N 1.329 -0.319 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -100.77 141.95 32.92 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.487 -179.8 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -124.72 132.78 70.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.528 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.376 -179.833 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 51.0 m170 -116.98 99.79 7.31 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 178.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' N ' ' N' ' 15' ' ' GLN . 23.1 t60 -154.01 165.82 34.96 Favored 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.594 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.705 HE21 ' NE2' ' O' ' 15' ' ' GLN . 13.4 pt20 -160.34 143.52 13.58 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.217 178.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 63.0 mttp -80.0 112.2 17.06 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.977 -0.556 . . . . 0.0 111.457 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 6.9 tt -120.98 117.92 28.53 Favored 'General case' 0 N--CA 1.47 0.568 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 178.63 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -125.72 131.83 71.52 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 121.09 0.471 . . . . 0.0 111.094 -179.376 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 87.9 t80 -126.94 119.12 25.95 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 178.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 87.5 t80 -118.21 126.32 51.95 Favored 'General case' 0 N--CA 1.474 0.766 0 N-CA-C 109.996 -0.372 . . . . 0.0 109.996 -179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.32 129.49 43.27 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-O 121.292 0.568 . . . . 0.0 112.355 -178.572 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 94.9 mt-10 -88.65 115.99 26.58 Favored 'General case' 0 CA--C 1.515 -0.379 0 N-CA-C 107.519 -1.289 . . . . 0.0 107.519 177.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -87.04 47.6 1.53 Allowed 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 113.446 0.906 . . . . 0.0 113.446 -176.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -110.48 151.64 12.63 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.781 0 N-CA-C 106.266 -1.753 . . . . 0.0 106.266 176.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . 0.529 ' O ' ' ND2' ' M' ' 27' ' ' ASN . . . 63.39 29.83 75.73 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 178.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.496 ' O ' ' O ' ' N' ' 27' ' ' ASN . 4.7 t -155.65 111.24 3.04 Favored 'General case' 0 N--CA 1.463 0.211 0 N-CA-C 113.854 1.057 . . . . 0.0 113.854 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.496 ' O ' ' O ' ' N' ' 26' ' ' SER . 7.1 m120 -49.7 -164.75 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.178 176.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.59 ' NZ ' ' CG2' ' G' ' 39' ' ' VAL . 81.7 mttt 78.38 -41.17 0.3 Allowed 'General case' 0 N--CA 1.483 1.193 0 C-N-CA 124.543 1.137 . . . . 0.0 114.012 177.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.96 -68.28 3.45 Favored Glycine 0 CA--C 1.545 1.96 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.731 -179.094 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -179.98 107.85 0.03 OUTLIER 'General case' 0 C--N 1.346 0.448 0 CA-C-N 117.576 0.688 . . . . 0.0 111.853 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.746 HD12 HG21 ' I' ' 39' ' ' VAL . 0.2 OUTLIER -123.89 122.09 63.78 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.931 0 O-C-N 122.208 -0.307 . . . . 0.0 110.489 178.755 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.595 HD13 ' CD1' ' P' ' 19' ' ' PHE . 60.5 mt -114.36 116.15 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 177.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.73 110.39 2.22 Favored Glycine 0 N--CA 1.468 0.775 0 N-CA-C 106.179 -2.769 . . . . 0.0 106.179 177.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.639 ' HB2' HD22 ' O' ' 34' ' ' LEU . 76.5 mt -144.67 143.58 30.81 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -174.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 1.7 ttm -110.11 106.66 16.22 Favored 'General case' 0 N--CA 1.441 -0.895 0 N-CA-C 105.176 -2.157 . . . . 0.0 105.176 173.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.585 ' C ' HE22 ' P' ' 15' ' ' GLN . 29.6 m -126.31 123.33 63.3 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.487 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.595 ' N ' HE22 ' P' ' 15' ' ' GLN . . . 138.18 -113.58 0.99 Allowed Glycine 0 C--N 1.308 -1.011 0 N-CA-C 109.222 -1.551 . . . . 0.0 109.222 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.47 ' O ' HD11 ' B' ' 31' ' ' ILE . . . 73.08 -72.78 1.09 Allowed Glycine 0 CA--C 1.532 1.109 0 CA-C-N 114.57 -0.815 . . . . 0.0 112.052 179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 52.0 t -113.34 132.61 61.72 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . . . . . . . . . 98.8 t . . . . . 0 C--O 1.221 -0.422 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.363 179.896 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.185 0 N-CA-C 109.119 -1.593 . . . . 0.0 109.119 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -112.85 138.4 49.74 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.993 0.425 . . . . 0.0 110.571 -179.743 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . 0.548 ' O ' ' CE1' ' P' ' 13' ' ' HIS . 98.3 mt-10 -140.92 162.93 34.3 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.714 -179.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.675 HG12 ' H ' ' P' ' 12' ' ' VAL . 5.0 m -118.53 126.87 75.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.467 ' C ' ' CG ' ' O' ' 14' ' ' HIS . 10.3 m80 -129.92 136.23 49.24 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.329 0.585 . . . . 0.0 112.028 -178.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.708 ' CE1' ' H ' ' P' ' 14' ' ' HIS . 5.1 m-70 -156.97 176.0 13.35 Favored 'General case' 0 C--O 1.223 -0.307 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.294 179.241 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.705 ' NE2' HE21 ' N' ' 15' ' ' GLN . 59.0 tt0 -152.96 140.11 19.38 Favored 'General case' 0 CA--C 1.517 -0.321 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 175.267 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . 0.557 ' N ' ' CE1' ' N' ' 14' ' ' HIS . 88.2 tttt -94.45 110.89 22.64 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.167 -0.469 . . . . 0.0 112.106 179.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.82 HD22 ' N ' ' O' ' 17' ' ' LEU . 0.7 OUTLIER -117.73 109.8 17.05 Favored 'General case' 0 N--CA 1.469 0.509 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 176.102 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 74.5 t -110.11 113.89 45.49 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.433 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 178.538 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.572 ' CD1' HD13 ' M' ' 32' ' ' ILE . 77.9 m-85 -113.36 106.88 15.12 Favored 'General case' 0 C--N 1.325 -0.466 0 N-CA-C 108.847 -0.797 . . . . 0.0 108.847 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.77 125.03 53.23 Favored 'General case' 0 N--CA 1.469 0.49 0 CA-C-O 120.789 0.328 . . . . 0.0 110.553 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.58 122.73 28.04 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 108.54 -0.911 . . . . 0.0 108.54 178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -149.32 -176.77 5.5 Favored 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 114.446 1.276 . . . . 0.0 114.446 -178.283 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.431 ' N ' ' OE1' ' P' ' 22' ' ' GLU . 96.7 m-20 66.22 50.32 1.39 Allowed 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 113.365 -1.743 . . . . 0.0 112.298 -179.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.447 HG12 ' H ' ' O' ' 26' ' ' SER . 67.0 t -82.45 146.43 7.16 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.262 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 176.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -70.91 -39.12 64.65 Favored Glycine 0 CA--C 1.523 0.54 0 C-N-CA 118.682 -1.723 . . . . 0.0 110.57 179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.721 ' O ' ' O ' ' O' ' 27' ' ' ASN . 39.4 t -174.15 124.78 0.33 Allowed 'General case' 0 C--O 1.221 -0.436 0 CA-C-O 118.525 -0.75 . . . . 0.0 110.185 178.411 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.721 ' O ' ' O ' ' O' ' 26' ' ' SER . 22.5 t-20 -2.62 145.99 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 N-CA-C 114.602 1.334 . . . . 0.0 114.602 178.422 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.417 ' CG ' ' O ' ' O' ' 27' ' ' ASN . 93.4 mttt -159.03 30.93 0.21 Allowed 'General case' 0 N--CA 1.468 0.44 0 O-C-N 121.805 -0.56 . . . . 0.0 112.413 -179.914 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.71 88.28 0.72 Allowed Glycine 0 CA--C 1.526 0.728 0 C-N-CA 119.49 -1.338 . . . . 0.0 113.028 179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -110.63 134.41 52.45 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.949 0.881 . . . . 0.0 109.873 -179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.715 HD13 HG22 ' I' ' 39' ' ' VAL . 4.5 tt -149.23 140.54 17.23 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.504 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.744 -175.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.56 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 73.6 mt -110.57 109.86 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 N-CA-C 108.077 -1.083 . . . . 0.0 108.077 176.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . 0.817 ' O ' HD23 ' O' ' 34' ' ' LEU . . . -117.54 101.85 0.96 Allowed Glycine 0 N--CA 1.469 0.855 0 N-CA-C 108.489 -1.845 . . . . 0.0 108.489 179.076 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.817 HD23 ' O ' ' O' ' 33' ' ' GLY . 0.3 OUTLIER -141.92 158.83 43.32 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-O 122.962 1.363 . . . . 0.0 114.175 -177.052 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 1.9 mtp -112.16 112.71 24.51 Favored 'General case' 0 N--CA 1.443 -0.787 0 CA-C-N 111.618 -2.537 . . . . 0.0 106.315 175.724 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.449 HG22 ' CG2' ' N' ' 36' ' ' VAL . 88.6 t -119.68 111.68 33.89 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 -177.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.745 ' N ' HE22 ' Q' ' 15' ' ' GLN . . . 136.01 -131.67 5.81 Favored Glycine 0 C--N 1.319 -0.397 0 C-N-CA 120.783 -0.722 . . . . 0.0 111.567 178.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.431 ' O ' HG23 ' P' ' 39' ' ' VAL . . . 98.96 -63.26 0.75 Allowed Glycine 0 CA--C 1.541 1.66 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -178.42 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.556 ' CG2' HG21 ' C' ' 31' ' ' ILE . 55.9 t -126.95 133.34 68.65 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 177.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.407 ' H ' HG11 ' P' ' 39' ' ' VAL . 96.6 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 117.918 -1.039 . . . . 0.0 110.723 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.265 -1.534 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -108.79 135.69 49.6 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 121.078 0.466 . . . . 0.0 110.793 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -89.7 116.77 28.06 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.11 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.675 ' H ' HG12 ' O' ' 12' ' ' VAL . 34.7 m -136.31 159.86 38.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 121.185 0.517 . . . . 0.0 111.455 -179.359 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.548 ' CE1' ' O ' ' O' ' 11' ' ' GLU . 80.0 m-70 -147.48 104.62 3.65 Favored 'General case' 0 C--O 1.232 0.173 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.024 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.708 ' H ' ' CE1' ' O' ' 14' ' ' HIS . 40.0 m-70 -148.74 159.43 44.14 Favored 'General case' 0 CA--C 1.519 -0.246 0 C-N-CA 119.53 -0.868 . . . . 0.0 112.734 178.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.595 HE22 ' N ' ' N' ' 37' ' ' GLY . 7.5 mt-30 -90.31 159.89 16.42 Favored 'General case' 0 N--CA 1.448 -0.542 0 CA-C-N 114.215 -1.357 . . . . 0.0 107.822 175.111 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.34 99.21 3.6 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 176.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.542 ' CD2' HG11 ' N' ' 36' ' ' VAL . 4.6 mp -127.37 122.63 34.18 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.116 0.484 . . . . 0.0 110.525 178.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.44 114.31 45.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.595 ' CD1' HD13 ' N' ' 32' ' ' ILE . 59.4 m-85 -112.36 108.01 17.03 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -112.78 124.11 51.85 Favored 'General case' 0 N--CA 1.473 0.701 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 179.318 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 137.05 34.74 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 113.837 1.051 . . . . 0.0 113.837 -178.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.431 ' OE1' ' N ' ' O' ' 23' ' ' ASP . 78.9 tt0 -81.6 116.94 21.58 Favored 'General case' 0 N--CA 1.462 0.149 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 177.057 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.404 ' H ' ' HB2' ' Q' ' 22' ' ' GLU . 99.7 m-20 -138.34 50.28 1.89 Allowed 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -176.66 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 32.8 m -81.85 148.4 5.41 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.625 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 179.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.485 ' O ' ' CB ' ' O' ' 27' ' ' ASN . . . 93.72 36.16 5.92 Favored Glycine 0 CA--C 1.525 0.681 0 N-CA-C 106.412 -2.675 . . . . 0.0 106.412 -176.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.549 ' OG ' ' ND2' ' Q' ' 27' ' ' ASN . 21.9 p -76.05 102.62 5.75 Favored 'General case' 0 CA--C 1.514 -0.405 0 CA-C-O 122.443 1.116 . . . . 0.0 112.498 -174.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -96.87 -164.47 1.15 Allowed 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 112.823 -1.99 . . . . 0.0 110.889 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 76.7 tttt -48.74 -40.25 27.93 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 114.895 -1.048 . . . . 0.0 111.877 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.77 70.08 1.88 Allowed Glycine 0 CA--C 1.543 1.809 0 N-CA-C 114.937 0.735 . . . . 0.0 114.937 -174.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.36 111.04 6.81 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 104.969 -2.234 . . . . 0.0 104.969 176.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.466 HD13 ' HB ' ' J' ' 39' ' ' VAL . 57.6 mt -135.42 136.18 51.14 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 N-CA-C 116.915 2.191 . . . . 0.0 116.915 -172.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.471 HD13 ' CD1' ' R' ' 19' ' ' PHE . 3.0 mt -106.05 106.07 19.9 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.665 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.26 99.38 1.18 Allowed Glycine 0 CA--C 1.506 -0.488 0 N-CA-C 106.482 -2.647 . . . . 0.0 106.482 178.523 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.502 ' CD1' HD12 ' O' ' 34' ' ' LEU . 2.8 tp -128.43 123.59 34.11 Favored 'General case' 0 C--O 1.241 0.63 0 CA-C-O 122.419 1.104 . . . . 0.0 112.821 -176.277 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -98.47 104.35 16.38 Favored 'General case' 0 N--CA 1.435 -1.191 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 175.422 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.623 HG13 ' O ' ' P' ' 36' ' ' VAL . 8.7 p -119.18 113.76 42.43 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.521 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 -177.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 164.22 -123.85 1.21 Allowed Glycine 0 C--N 1.309 -0.958 0 C-N-CA 118.95 -1.595 . . . . 0.0 111.79 -179.678 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.525 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 81.26 -67.72 3.57 Favored Glycine 0 CA--C 1.536 1.354 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -178.087 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.439 ' CG1' ' OD1' ' D' ' 27' ' ' ASN . 67.9 t -136.09 155.61 35.5 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 177.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.419 ' N ' HG12 ' P' ' 39' ' ' VAL . 11.2 p . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 118.03 -0.986 . . . . 0.0 110.651 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.873 -1.291 . . . . 0.0 109.873 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -108.56 134.77 50.85 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.751 0.31 . . . . 0.0 110.313 -179.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -88.87 117.96 28.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.878 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 29.3 m -127.98 135.51 62.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 120.949 0.404 . . . . 0.0 110.991 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.488 ' CD2' ' N ' ' Q' ' 13' ' ' HIS . 2.0 m-70 -136.18 118.29 15.44 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.628 179.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.692 ' CD2' ' H ' ' R' ' 14' ' ' HIS . 22.7 m80 -147.23 159.6 43.45 Favored 'General case' 0 C--O 1.219 -0.534 0 N-CA-C 110.171 -0.307 . . . . 0.0 110.171 178.29 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.745 HE22 ' N ' ' O' ' 37' ' ' GLY . 0.7 OUTLIER -90.25 159.59 16.61 Favored 'General case' 0 C--N 1.334 -0.084 0 N-CA-C 107.838 -1.171 . . . . 0.0 107.838 176.145 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 66.5 tttt -140.2 104.34 4.79 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 120.313 -0.555 . . . . 0.0 109.697 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.415 ' N ' HD12 ' Q' ' 17' ' ' LEU . 4.3 mp -128.88 126.23 39.29 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 121.724 0.773 . . . . 0.0 111.006 179.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 84.8 t -114.3 113.63 44.32 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.466 0 CA-C-N 114.721 -1.127 . . . . 0.0 108.837 179.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.56 ' CD1' HD13 ' O' ' 32' ' ' ILE . 59.5 m-85 -110.76 103.65 12.21 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 178.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 26.4 t80 -112.45 125.09 53.84 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.888 -178.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.68 143.61 35.2 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 112.886 0.699 . . . . 0.0 112.886 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.404 ' HB2' ' H ' ' P' ' 23' ' ' ASP . 93.7 mt-10 -84.64 137.37 33.31 Favored 'General case' 0 N--CA 1.469 0.478 0 C-N-CA 120.166 -0.613 . . . . 0.0 109.619 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.531 ' OD2' ' HB1' ' R' ' 21' ' ' ALA . 35.8 p-10 -177.75 50.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.491 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.159 -177.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.473 HG22 ' O ' ' R' ' 22' ' ' GLU . 61.5 t -81.8 149.27 4.89 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-O 122.904 1.335 . . . . 0.0 113.828 -174.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.415 ' O ' ' OG ' ' Q' ' 26' ' ' SER . . . 93.09 36.7 5.9 Favored Glycine 0 CA--C 1.532 1.132 0 CA-C-N 111.784 -2.462 . . . . 0.0 112.887 178.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.415 ' OG ' ' O ' ' Q' ' 25' ' ' GLY . 3.2 p 72.65 120.18 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.34 0 CA-C-O 118.621 -0.704 . . . . 0.0 110.546 175.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.549 ' ND2' ' OG ' ' P' ' 26' ' ' SER . 1.6 m120 -83.11 160.99 21.77 Favored 'General case' 0 CA--C 1.529 0.152 0 C-N-CA 116.824 -1.95 . . . . 0.0 108.057 176.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -48.74 -39.79 26.23 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.573 0.702 . . . . 0.0 111.381 176.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.23 67.46 0.04 OUTLIER Glycine 0 CA--C 1.541 1.711 0 CA-C-N 114.767 -1.106 . . . . 0.0 111.075 -177.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.96 152.18 43.89 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 118.449 1.125 . . . . 0.0 112.002 -176.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.443 HG23 HG23 ' R' ' 31' ' ' ILE . 6.3 mt -113.3 129.19 69.47 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.328 -177.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 99.8 mt -124.69 116.06 46.27 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.587 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.866 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.72 117.02 3.16 Favored Glycine 0 N--CA 1.47 0.951 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -179.244 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 29.2 tp -124.55 120.64 32.53 Favored 'General case' 0 C--O 1.238 0.497 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 -179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 93.7 mtp -135.17 144.94 47.3 Favored 'General case' 0 N--CA 1.472 0.64 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -178.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 2.9 t -118.82 164.05 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 178.016 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -168.68 93.68 0.1 Allowed Glycine 0 C--N 1.311 -0.812 0 C-N-CA 120.056 -1.068 . . . . 0.0 111.119 178.627 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.417 ' H ' ' HA3' ' R' ' 38' ' ' GLY . . . 164.45 -81.86 0.11 Allowed Glycine 0 CA--C 1.536 1.347 0 C-N-CA 120.473 -0.87 . . . . 0.0 112.465 177.674 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 2.5 p -157.68 147.57 9.91 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.158 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 178.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 7.3 t . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.552 179.554 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.275 -1.53 . . . . 0.0 109.275 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -105.95 133.09 51.23 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.876 0.37 . . . . 0.0 110.609 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 21.1 pt-20 -77.99 150.65 33.88 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.762 179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.4 HG12 ' HE2' ' Q' ' 14' ' ' HIS . 52.9 t -123.69 131.62 72.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.537 0 CA-C-N 116.308 -0.406 . . . . 0.0 110.105 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.428 ' ND1' ' N ' ' R' ' 13' ' ' HIS . 0.0 OUTLIER -152.22 112.67 4.11 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.487 -179.656 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.692 ' H ' ' CD2' ' Q' ' 14' ' ' HIS . 75.0 m80 -149.81 164.43 35.35 Favored 'General case' 0 C--O 1.22 -0.472 0 N-CA-C 108.763 -0.829 . . . . 0.0 108.763 178.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.441 ' OE1' ' OE1' ' Q' ' 15' ' ' GLN . 60.0 mt-30 -89.94 159.5 16.88 Favored 'General case' 0 C--N 1.332 -0.191 0 C-N-CA 120.317 -0.553 . . . . 0.0 110.401 -179.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 61.8 tttp -139.55 115.19 10.02 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-O 121.456 0.646 . . . . 0.0 110.332 -179.852 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.448 ' N ' HD12 ' R' ' 17' ' ' LEU . 1.2 mp -135.46 125.54 26.04 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.796 179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 3.5 p -112.96 116.48 52.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 N-CA-C 107.338 -1.356 . . . . 0.0 107.338 176.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.471 ' CD1' HD13 ' P' ' 32' ' ' ILE . 55.3 m-85 -105.17 104.77 14.57 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.604 -1.628 . . . . 0.0 106.604 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 28.9 t80 -123.73 124.37 42.58 Favored 'General case' 0 CA--C 1.517 -0.323 0 CA-C-O 121.997 0.903 . . . . 0.0 112.099 -177.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.531 ' HB1' ' OD2' ' Q' ' 23' ' ' ASP . . . -120.65 130.2 54.03 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.473 ' O ' HG22 ' Q' ' 24' ' ' VAL . 97.8 mt-10 -70.21 110.15 5.04 Favored 'General case' 0 C--N 1.322 -0.613 0 C-N-CA 118.813 -1.155 . . . . 0.0 110.377 -177.421 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 54.0 p-10 179.57 48.62 0.0 OUTLIER 'General case' 0 C--N 1.342 0.277 0 N-CA-C 112.7 0.63 . . . . 0.0 112.7 179.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.519 HG12 ' N ' ' R' ' 25' ' ' GLY . 69.0 t -72.85 160.34 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 C-N-CA 117.324 -1.75 . . . . 0.0 108.644 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.519 ' N ' HG12 ' R' ' 24' ' ' VAL . . . 110.35 -33.27 6.06 Favored Glycine 0 N--CA 1.465 0.593 0 N-CA-C 108.485 -1.846 . . . . 0.0 108.485 179.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 6.3 m -72.2 129.57 38.77 Favored 'General case' 0 CA--C 1.517 -0.301 0 CA-C-N 113.028 -1.586 . . . . 0.0 111.806 -179.463 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . 0.67 ' O ' ' N ' ' R' ' 29' ' ' GLY . 98.6 m-20 -90.86 -161.91 0.86 Allowed 'General case' 0 C--O 1.222 -0.388 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 178.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -48.22 47.58 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.015 1.487 . . . . 0.0 115.015 -178.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . 0.67 ' N ' ' O ' ' R' ' 27' ' ' ASN . . . -99.28 56.9 0.9 Allowed Glycine 0 CA--C 1.541 1.686 0 CA-C-N 119.301 0.955 . . . . 0.0 111.997 178.184 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -166.97 168.61 13.73 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.751 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.909 HD11 ' N ' ' L' ' 40' ' ' VAL . 15.9 tt -116.15 110.28 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 177.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 74.5 mt -117.11 128.63 74.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-N 115.667 -0.697 . . . . 0.0 111.542 -176.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.14 115.07 2.44 Favored Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 tp -122.46 117.4 25.87 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 8.9 ttp -141.19 124.38 16.46 Favored 'General case' 0 N--CA 1.472 0.646 0 CA-C-O 121.364 0.602 . . . . 0.0 111.126 179.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 93.6 t -99.32 111.68 29.57 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.156 0 C-N-CA 120.125 -0.63 . . . . 0.0 111.753 -179.409 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . . . . . . . . . . . -96.8 132.17 10.9 Favored Glycine 0 CA--C 1.518 0.273 0 N-CA-C 108.793 -1.723 . . . . 0.0 108.793 176.845 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . 0.417 ' HA3' ' H ' ' Q' ' 38' ' ' GLY . . . 109.49 63.24 0.53 Allowed Glycine 0 N--CA 1.474 1.18 0 CA-C-N 118.201 1.0 . . . . 0.0 112.95 179.618 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.412 ' C ' ' O ' ' R' ' 38' ' ' GLY . 41.4 t -32.17 151.75 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-N 117.285 0.543 . . . . 0.0 112.287 -179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 28.0 t . . . . . 0 C--O 1.219 -0.509 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.765 179.682 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.097 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -108.23 137.04 46.88 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.706 0.288 . . . . 0.0 110.76 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.45 ' O ' ' OE1' ' B' ' 11' ' ' GLU . 95.7 mt-10 -118.28 140.02 50.45 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 121.029 0.443 . . . . 0.0 110.419 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.4 m -137.27 162.13 33.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.966 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.461 ' H ' ' HB3' ' B' ' 13' ' ' HIS . 80.2 m80 -145.13 135.53 24.17 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.583 0.23 . . . . 0.0 110.785 179.331 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.572 ' CD2' ' N ' ' A' ' 15' ' ' GLN . 20.8 t60 -158.06 165.18 35.7 Favored 'General case' 0 C--N 1.327 -0.387 0 C-N-CA 120.01 -0.676 . . . . 0.0 110.972 179.518 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CD2' ' A' ' 14' ' ' HIS . 68.2 tp60 -158.97 142.45 14.89 Favored 'General case' 0 N--CA 1.454 -0.233 0 CA-C-O 121.027 0.442 . . . . 0.0 109.97 177.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -82.51 124.16 29.85 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.473 178.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 80.0 mt -127.18 119.52 26.63 Favored 'General case' 0 N--CA 1.471 0.623 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.3 p -141.49 146.45 23.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.506 -0.316 . . . . 0.0 110.363 -179.042 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 85.1 m-85 -147.52 141.2 25.61 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-O 121.11 0.481 . . . . 0.0 111.427 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.476 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 49.6 p90 -115.34 132.64 56.55 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.05 126.93 46.15 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 -177.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.472 ' C ' ' H ' ' A' ' 24' ' ' VAL . 96.0 mt-10 -128.14 -140.53 0.25 Allowed 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 105.791 -1.929 . . . . 0.0 105.791 177.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -68.49 50.44 0.07 Allowed 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 177.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.791 HG13 ' N ' ' A' ' 25' ' ' GLY . 3.9 p -93.21 -142.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 114.748 -1.114 . . . . 0.0 110.761 -177.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.791 ' N ' HG13 ' A' ' 24' ' ' VAL . . . -82.78 -36.98 14.28 Favored Glycine 0 CA--C 1.526 0.744 0 CA-C-N 115.373 -0.831 . . . . 0.0 111.037 -177.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.663 ' H ' HG13 ' A' ' 24' ' ' VAL . 28.9 t -81.28 118.34 22.53 Favored 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 179.581 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 56.5 p30 -88.23 -179.31 6.12 Favored 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 115.159 1.54 . . . . 0.0 115.159 -174.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.439 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 96.0 mttt -55.86 -37.48 68.83 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 112.081 -2.327 . . . . 0.0 112.409 -179.055 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.05 77.72 0.4 Allowed Glycine 0 N--CA 1.47 0.936 0 N-CA-C 112.079 -0.408 . . . . 0.0 112.079 -175.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.39 141.67 41.43 Favored 'General case' 0 C--O 1.243 0.746 0 CA-C-O 123.736 1.731 . . . . 0.0 113.012 -177.132 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -126.76 127.63 70.22 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 111.739 -2.482 . . . . 0.0 108.406 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.452 ' O ' ' O ' ' B' ' 33' ' ' GLY . 80.8 mt -100.9 105.66 18.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 178.381 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -106.07 96.39 1.15 Allowed Glycine 0 CA--C 1.505 -0.589 0 N-CA-C 104.385 -3.486 . . . . 0.0 104.385 176.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.932 ' O ' HD12 ' B' ' 34' ' ' LEU . 51.6 tp -148.2 159.21 44.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 123.002 1.382 . . . . 0.0 112.969 -174.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.487 ' CE ' ' SD ' ' B' ' 35' ' ' MET . 17.0 mtp -119.52 117.51 28.59 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-N 113.433 -1.712 . . . . 0.0 108.482 179.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.487 HG23 ' O ' ' A' ' 36' ' ' VAL . 27.3 m -119.24 111.85 35.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 N-CA-C 106.436 -1.69 . . . . 0.0 106.436 177.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 124.22 -131.99 8.14 Favored Glycine 0 C--N 1.315 -0.602 0 N-CA-C 107.543 -2.223 . . . . 0.0 107.543 -177.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.486 ' O ' ' CG2' ' B' ' 39' ' ' VAL . . . 87.05 -63.72 3.99 Favored Glycine 0 CA--C 1.533 1.186 0 C-N-CA 120.126 -1.035 . . . . 0.0 111.608 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 2.0 m -108.26 179.89 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.225 0 CA-C-O 120.847 0.356 . . . . 0.0 110.106 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.455 HG12 ' CD2' ' C' ' 13' ' ' HIS . 85.9 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.852 -1.071 . . . . 0.0 110.959 178.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -109.17 132.13 54.41 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.783 0.325 . . . . 0.0 110.31 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' O ' ' A' ' 11' ' ' GLU . 80.7 mm-40 -124.63 122.77 38.46 Favored 'General case' 0 N--CA 1.471 0.592 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.483 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.439 ' CG1' ' C ' ' C' ' 12' ' ' VAL . 3.6 t -112.92 100.27 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.983 0.42 . . . . 0.0 110.52 179.514 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.461 ' HB3' ' H ' ' A' ' 13' ' ' HIS . 12.2 p-80 -138.82 145.19 39.76 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.747 -178.216 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.548 ' O ' ' ND1' ' A' ' 14' ' ' HIS . 2.9 p80 -146.33 160.35 42.14 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 121.482 0.658 . . . . 0.0 111.98 179.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' OE1' ' C' ' 15' ' ' GLN . 85.9 mt-30 -90.3 159.67 16.53 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.178 178.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -139.97 108.05 5.75 Favored 'General case' 0 C--N 1.313 -1.008 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 176.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.49 130.84 53.48 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 120.875 0.369 . . . . 0.0 111.021 179.013 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.84 130.88 70.13 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.463 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.713 178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -127.26 129.64 48.11 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 179.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.3 t80 -128.68 124.19 35.05 Favored 'General case' 0 N--CA 1.467 0.375 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.05 134.37 54.78 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 120.674 -0.41 . . . . 0.0 111.173 -179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.484 ' O ' ' CB ' ' B' ' 23' ' ' ASP . 81.9 tt0 -161.74 159.8 27.65 Favored 'General case' 0 CA--C 1.55 0.969 0 N-CA-C 114.953 1.464 . . . . 0.0 114.953 -178.463 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.524 ' O ' ' O ' ' B' ' 24' ' ' VAL . 19.4 t70 112.83 -70.27 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.286 0 C-N-CA 127.055 2.142 . . . . 0.0 110.854 177.205 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.524 ' O ' ' O ' ' B' ' 23' ' ' ASP . 9.7 t -58.77 -122.59 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 N-CA-C 107.242 -1.392 . . . . 0.0 107.242 173.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.46 ' H ' HG12 ' B' ' 24' ' ' VAL . . . 139.12 -34.94 2.02 Favored Glycine 0 CA--C 1.52 0.394 0 CA-C-O 118.089 -1.395 . . . . 0.0 116.262 172.651 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 17.5 m -80.43 119.52 23.23 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 121.355 2.578 . . . . 0.0 106.59 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.439 ' ND2' ' O ' ' A' ' 28' ' ' LYS . 3.0 m120 -89.78 157.7 17.83 Favored 'General case' 0 C--N 1.344 0.368 0 C-N-CA 116.11 -2.236 . . . . 0.0 108.181 176.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -48.31 -40.53 25.39 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 122.394 1.092 . . . . 0.0 110.983 174.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 67.64 0.04 OUTLIER Glycine 0 CA--C 1.549 2.21 0 CA-C-N 112.956 -1.929 . . . . 0.0 110.5 -174.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.07 141.89 52.74 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 120.09 1.945 . . . . 0.0 115.168 -172.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.895 HG23 HG23 ' C' ' 31' ' ' ILE . 19.8 mt -136.23 134.09 50.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.924 0 CA-C-N 113.159 -1.837 . . . . 0.0 113.106 -175.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 55.2 mt -104.92 103.0 14.62 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 174.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.452 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -103.69 103.88 2.4 Favored Glycine 0 CA--C 1.507 -0.446 0 N-CA-C 104.309 -3.516 . . . . 0.0 104.309 175.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.932 HD12 ' O ' ' A' ' 34' ' ' LEU . 17.8 tp -146.12 147.66 31.79 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 118.272 -1.371 . . . . 0.0 113.538 -173.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.487 ' SD ' ' CE ' ' A' ' 35' ' ' MET . 3.9 ttm -113.13 116.37 29.74 Favored 'General case' 0 CA--C 1.511 -0.543 0 CA-C-N 112.815 -1.993 . . . . 0.0 107.824 178.585 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.406 HG23 HD21 ' C' ' 34' ' ' LEU . 37.8 t -118.95 123.73 71.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -179.129 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.76 -114.15 2.03 Favored Glycine 0 C--N 1.315 -0.591 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 178.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.535 ' O ' ' CD1' ' H' ' 31' ' ' ILE . . . 81.02 -72.65 2.7 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 111.163 -0.775 . . . . 0.0 111.163 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.486 ' CG2' ' O ' ' A' ' 38' ' ' GLY . 24.8 t -124.54 163.53 24.53 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.532 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 20.7 m . . . . . 0 N--CA 1.473 0.689 0 CA-C-O 117.782 -1.104 . . . . 0.0 111.694 -179.198 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 95.0 m-85 -109.97 135.59 50.59 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.783 0.325 . . . . 0.0 110.362 -179.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -138.83 144.9 39.46 Favored 'General case' 0 CA--C 1.531 0.244 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.801 HG21 ' C ' ' D' ' 12' ' ' VAL . 27.6 m -138.19 164.43 27.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-O 120.963 0.411 . . . . 0.0 111.807 -179.029 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.455 ' CD2' HG12 ' A' ' 40' ' ' VAL . 4.2 p-80 -129.48 132.92 47.04 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.301 0.572 . . . . 0.0 112.131 -178.552 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.538 ' CG ' ' O ' ' D' ' 14' ' ' HIS . 17.7 p-80 -157.26 169.52 24.56 Favored 'General case' 0 C--O 1.22 -0.474 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.066 178.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.418 ' OE1' ' OE1' ' B' ' 15' ' ' GLN . 99.5 mm-40 -89.67 156.61 18.45 Favored 'General case' 0 CA--C 1.519 -0.23 0 C-N-CA 119.354 -0.938 . . . . 0.0 110.112 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -141.36 115.41 9.25 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.993 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.453 ' HB2' HD22 ' D' ' 17' ' ' LEU . 4.6 mp -135.24 118.8 16.96 Favored 'General case' 0 N--CA 1.474 0.737 0 CA-C-O 122.018 0.913 . . . . 0.0 111.029 178.153 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -106.76 117.51 52.7 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.571 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 178.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.402 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 54.9 m-85 -109.93 99.73 8.81 Favored 'General case' 0 N--CA 1.447 -0.582 0 N-CA-C 105.995 -1.854 . . . . 0.0 105.995 178.053 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 23.2 t80 -109.79 126.67 54.01 Favored 'General case' 0 C--O 1.241 0.626 0 CA-C-O 121.41 0.624 . . . . 0.0 111.058 -177.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . 0.638 ' HB1' HG13 ' C' ' 24' ' ' VAL . . . -128.17 113.26 15.49 Favored 'General case' 0 C--O 1.244 0.778 0 CA-C-O 121.884 0.85 . . . . 0.0 110.806 -179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.424 ' OE2' ' OD1' ' C' ' 23' ' ' ASP . 0.4 OUTLIER -86.17 103.3 14.68 Favored 'General case' 0 CA--C 1.515 -0.392 0 N-CA-C 107.675 -1.232 . . . . 0.0 107.675 179.065 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.474 ' H ' ' HB2' ' D' ' 22' ' ' GLU . 35.5 m-20 50.84 50.15 19.61 Favored 'General case' 0 C--O 1.214 -0.793 0 CA-C-N 114.837 -1.074 . . . . 0.0 108.47 -177.417 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.939 HG22 ' H ' ' C' ' 25' ' ' GLY . 9.9 p -160.1 -174.22 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.359 0 C-N-CA 120.148 -0.621 . . . . 0.0 110.094 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.939 ' H ' HG22 ' C' ' 24' ' ' VAL . . . 59.78 26.82 63.27 Favored Glycine 0 CA--C 1.522 0.473 0 CA-C-N 115.584 -0.735 . . . . 0.0 113.777 178.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.513 ' O ' ' O ' ' C' ' 27' ' ' ASN . 62.8 m -166.19 -145.94 0.08 Allowed 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.513 ' O ' ' O ' ' C' ' 26' ' ' SER . 10.6 m-20 55.48 142.25 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.475 0 CA-C-O 120.906 0.384 . . . . 0.0 111.797 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.745 ' H ' ' CB ' ' D' ' 26' ' ' SER . 71.1 mmtt 62.47 46.06 5.96 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 111.747 0.277 . . . . 0.0 111.747 178.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.98 61.08 0.79 Allowed Glycine 0 N--CA 1.474 1.204 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.083 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.456 ' O ' ' O ' ' D' ' 29' ' ' GLY . . . -101.87 119.3 38.56 Favored 'General case' 0 C--N 1.341 0.235 0 CA-C-O 121.567 0.698 . . . . 0.0 109.66 -179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.895 HG23 HG23 ' B' ' 31' ' ' ILE . 3.6 tt -137.07 136.34 47.41 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.862 0 C-N-CA 120.021 -0.672 . . . . 0.0 112.438 -177.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.414 HD13 ' CD1' ' E' ' 19' ' ' PHE . 63.5 mt -107.09 107.42 22.71 Favored 'Isoleucine or valine' 0 C--O 1.233 0.216 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 176.687 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.06 100.95 2.01 Favored Glycine 0 C--O 1.237 0.327 0 N-CA-C 104.89 -3.284 . . . . 0.0 104.89 175.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.756 HD23 ' O ' ' B' ' 34' ' ' LEU . 0.8 OUTLIER -133.25 138.08 46.33 Favored 'General case' 0 C--O 1.237 0.401 0 CA-C-O 122.99 1.376 . . . . 0.0 114.314 -174.75 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mmm -109.14 110.75 22.07 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 175.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.417 HG22 HD22 ' C' ' 34' ' ' LEU . 25.0 t -122.98 123.16 67.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 118.429 0.559 . . . . 0.0 109.529 -177.02 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.5 -113.19 0.65 Allowed Glycine 0 C--N 1.315 -0.59 0 C-N-CA 120.228 -0.987 . . . . 0.0 111.964 179.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.488 ' O ' ' CD1' ' I' ' 31' ' ' ILE . . . 74.05 -72.98 1.32 Allowed Glycine 0 CA--C 1.548 2.122 0 CA-C-N 114.863 -0.669 . . . . 0.0 111.641 -177.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 43.3 t -131.51 136.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 109.144 -0.688 . . . . 0.0 109.144 178.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.405 ' OXT' HG12 ' C' ' 40' ' ' VAL . 73.7 t . . . . . 0 C--O 1.22 -0.484 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.373 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -107.02 134.03 50.78 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.915 0.388 . . . . 0.0 110.652 179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -75.78 146.69 39.8 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.582 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.801 ' C ' HG21 ' C' ' 12' ' ' VAL . 68.4 t -132.94 162.07 40.6 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.266 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.553 179.627 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.566 ' N ' HG12 ' D' ' 12' ' ' VAL . 2.3 t-80 -63.35 103.86 0.55 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 108.828 -0.805 . . . . 0.0 108.828 178.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.604 ' CD2' ' O ' ' D' ' 15' ' ' GLN . 12.6 t60 -146.72 159.76 43.08 Favored 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.536 -178.158 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.604 ' O ' ' CD2' ' D' ' 14' ' ' HIS . 36.1 tp60 -84.65 157.97 20.98 Favored 'General case' 0 N--CA 1.475 0.788 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -178.635 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.84 ' O ' HD23 ' D' ' 17' ' ' LEU . 88.1 tttt -159.56 100.23 1.47 Allowed 'General case' 0 C--N 1.315 -0.913 0 C-N-CA 119.428 -0.909 . . . . 0.0 112.39 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.84 HD23 ' O ' ' D' ' 16' ' ' LYS . 6.2 mt -132.8 136.13 46.1 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 175.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 53.8 t -120.59 124.23 72.02 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.492 0 CA-C-N 115.469 -0.787 . . . . 0.0 109.955 179.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.503 ' CD2' ' CE1' ' E' ' 19' ' ' PHE . 37.9 m-85 -117.82 106.18 12.74 Favored 'General case' 0 C--N 1.327 -0.397 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.485 ' CZ ' ' CD1' ' E' ' 20' ' ' PHE . 1.1 t80 -122.17 129.45 52.31 Favored 'General case' 0 N--CA 1.476 0.863 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -176.604 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.19 114.35 9.08 Favored 'General case' 0 N--CA 1.475 0.808 0 CA-C-O 121.952 0.882 . . . . 0.0 110.624 178.58 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.474 ' HB2' ' H ' ' C' ' 23' ' ' ASP . 95.5 mt-10 -92.65 -174.74 3.74 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 114.422 1.267 . . . . 0.0 114.422 -178.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 54.3 t0 31.17 52.23 0.16 Allowed 'General case' 0 N--CA 1.477 0.913 0 N-CA-C 115.823 1.786 . . . . 0.0 115.823 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.56 ' N ' ' OE1' ' E' ' 22' ' ' GLU . 86.6 t -64.96 145.5 13.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 C-N-CA 118.734 -1.187 . . . . 0.0 108.172 177.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -132.84 -24.35 0.73 Allowed Glycine 0 N--CA 1.467 0.761 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 -178.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.745 ' CB ' ' H ' ' C' ' 28' ' ' LYS . 4.8 t -72.09 160.17 32.93 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 122.311 1.053 . . . . 0.0 112.785 -177.334 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.711 ' O ' ' N ' ' D' ' 29' ' ' GLY . 97.8 m-20 -91.68 -130.06 0.11 Allowed 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 113.384 -1.735 . . . . 0.0 110.159 -178.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 68.1 mttm -48.49 54.94 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.333 0 C-N-CA 124.931 1.292 . . . . 0.0 112.317 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.711 ' N ' ' O ' ' D' ' 27' ' ' ASN . . . -110.28 -48.79 0.74 Allowed Glycine 0 CA--C 1.546 1.971 0 C-N-CA 124.529 1.062 . . . . 0.0 113.808 -176.53 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.411 ' HA ' ' O ' ' C' ' 30' ' ' ALA . . . -82.71 113.61 20.5 Favored 'General case' 0 C--O 1.241 0.609 0 N-CA-C 114.941 1.46 . . . . 0.0 114.941 -174.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.73 HD12 HG22 ' O' ' 39' ' ' VAL . 96.1 mt -130.56 130.0 64.69 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.71 0 CA-C-N 112.453 -2.158 . . . . 0.0 111.339 178.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.483 ' HB ' HG23 ' E' ' 32' ' ' ILE . 47.6 mt -108.22 109.77 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.271 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 175.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -102.54 104.06 2.54 Favored Glycine 0 N--CA 1.462 0.395 0 N-CA-C 104.145 -3.582 . . . . 0.0 104.145 174.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.57 HD12 ' O ' ' C' ' 34' ' ' LEU . 25.0 tp -133.88 128.18 34.07 Favored 'General case' 0 C--O 1.246 0.881 0 N-CA-C 116.477 2.029 . . . . 0.0 116.477 -172.573 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.1 ttm -104.38 111.54 24.22 Favored 'General case' 0 CA--C 1.508 -0.644 0 CA-C-N 112.793 -2.003 . . . . 0.0 107.377 174.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 17.3 t -109.43 143.9 18.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.004 0 N-CA-C 107.195 -1.409 . . . . 0.0 107.195 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.792 ' H ' HE22 ' F' ' 15' ' ' GLN . . . 168.31 -101.95 0.18 Allowed Glycine 0 C--N 1.294 -1.766 0 C-N-CA 118.818 -1.658 . . . . 0.0 111.462 -179.387 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.445 ' HA3' ' N ' ' C' ' 38' ' ' GLY . . . 42.48 72.16 0.32 Allowed Glycine 0 N--CA 1.466 0.658 0 N-CA-C 109.901 -1.28 . . . . 0.0 109.901 -177.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.831 HG21 HD12 ' K' ' 31' ' ' ILE . 92.2 t -36.2 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.462 0.146 0 N-CA-C 112.85 0.685 . . . . 0.0 112.85 -176.556 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.534 ' N ' HG12 ' D' ' 39' ' ' VAL . 19.7 m . . . . . 0 C--O 1.222 -0.386 0 CA-C-O 118.078 -0.963 . . . . 0.0 110.593 179.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -107.73 136.59 47.22 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 120.817 0.341 . . . . 0.0 110.436 -179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.31 120.88 41.22 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.792 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.507 ' H ' HG21 ' D' ' 12' ' ' VAL . 33.8 t -112.08 95.32 3.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 CA-C-O 121.189 0.518 . . . . 0.0 111.241 -179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.412 ' CD2' ' O ' ' D' ' 13' ' ' HIS . 5.4 t-80 -118.65 109.97 16.76 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.26 179.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.634 ' CE1' ' N ' ' F' ' 14' ' ' HIS . 43.0 m-70 -138.13 165.04 27.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.213 0.53 . . . . 0.0 110.7 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 3.4 tt0 -90.26 151.62 21.43 Favored 'General case' 0 C--N 1.325 -0.478 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 176.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.819 ' C ' HD12 ' E' ' 17' ' ' LEU . 88.8 tttt -149.68 107.46 3.68 Favored 'General case' 0 C--N 1.315 -0.931 0 C-N-CA 119.345 -0.942 . . . . 0.0 111.526 178.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.819 HD12 ' C ' ' E' ' 16' ' ' LYS . 8.7 mp -129.07 120.59 26.22 Favored 'General case' 0 CA--C 1.508 -0.649 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.15 121.21 60.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-N 116.001 -0.545 . . . . 0.0 109.95 -179.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.503 ' CE1' ' CD2' ' D' ' 19' ' ' PHE . 30.5 m-85 -116.34 100.77 8.13 Favored 'General case' 0 C--O 1.237 0.4 0 N-CA-C 106.41 -1.7 . . . . 0.0 106.41 177.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.485 ' CD1' ' CZ ' ' D' ' 20' ' ' PHE . 14.3 t80 -121.68 134.9 54.97 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -177.281 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.599 ' O ' ' HB1' ' F' ' 21' ' ' ALA . . . -160.3 -178.36 6.89 Favored 'General case' 0 N--CA 1.469 0.495 0 C-N-CA 119.167 -1.013 . . . . 0.0 113.691 -179.299 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.56 ' OE1' ' N ' ' D' ' 24' ' ' VAL . 34.6 tt0 -68.07 159.98 29.79 Favored 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.454 -0.794 . . . . 0.0 109.94 -178.658 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 67.4 t0 175.65 60.26 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.798 0.839 . . . . 0.0 109.472 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 4.7 t -81.44 -113.36 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 116.956 -1.497 . . . . 0.0 111.305 -171.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -72.73 -42.12 47.69 Favored Glycine 0 CA--C 1.536 1.36 0 C-N-CA 114.839 -3.553 . . . . 0.0 115.4 -171.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.401 ' O ' ' C ' ' E' ' 27' ' ' ASN . 35.9 t -156.7 110.39 2.67 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 121.376 2.588 . . . . 0.0 114.298 175.156 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.401 ' C ' ' O ' ' E' ' 26' ' ' SER . 28.7 t-20 -55.69 162.83 1.55 Allowed 'General case' 0 N--CA 1.472 0.63 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 172.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -58.53 -42.65 88.25 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 122.127 2.24 . . . . 0.0 110.265 175.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 170.72 64.27 0.04 OUTLIER Glycine 0 CA--C 1.551 2.305 0 CA-C-N 114.104 -1.407 . . . . 0.0 111.856 -176.537 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.876 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -72.25 161.29 31.06 Favored 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 119.344 1.572 . . . . 0.0 112.461 -176.759 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.481 ' CG2' ' OXT' ' Q' ' 40' ' ' VAL . 97.9 mt -134.08 136.63 53.28 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-O 121.421 0.629 . . . . 0.0 112.472 -177.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.483 HG23 ' HB ' ' D' ' 32' ' ' ILE . 98.0 mt -130.6 129.98 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 O-C-N 121.929 -0.482 . . . . 0.0 111.702 -179.362 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.95 114.26 2.47 Favored Glycine 0 N--CA 1.473 1.162 0 N-CA-C 109.452 -1.459 . . . . 0.0 109.452 178.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.452 HD13 ' CE2' ' F' ' 19' ' ' PHE . 20.4 mt -124.75 124.01 41.22 Favored 'General case' 0 C--O 1.238 0.469 0 N-CA-C 110.183 -0.302 . . . . 0.0 110.183 -177.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 88.5 mtp -130.3 134.34 47.14 Favored 'General case' 0 N--CA 1.475 0.809 0 C-N-CA 119.9 -0.72 . . . . 0.0 112.553 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.469 HG22 ' HA ' ' F' ' 36' ' ' VAL . 0.8 OUTLIER -91.85 155.35 3.1 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 177.468 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.502 ' H ' ' HA2' ' D' ' 37' ' ' GLY . . . -102.96 102.8 2.3 Favored Glycine 0 CA--C 1.529 0.968 0 N-CA-C 112.256 -0.338 . . . . 0.0 112.256 -179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.525 ' O ' ' O ' ' F' ' 39' ' ' VAL . . . 52.58 -73.8 0.0 OUTLIER Glycine 0 CA--C 1.54 1.639 0 N-CA-C 115.009 0.764 . . . . 0.0 115.009 178.063 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.416 ' N ' ' O ' ' E' ' 37' ' ' GLY . 40.9 t -129.89 138.14 54.82 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 CA-C-N 118.211 1.005 . . . . 0.0 111.222 -178.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.525 ' N ' ' O ' ' F' ' 40' ' ' VAL . 77.2 t . . . . . 0 N--CA 1.472 0.638 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.177 179.572 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.445 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -109.6 134.19 52.23 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 120.676 0.274 . . . . 0.0 110.461 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -79.07 154.28 29.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.334 179.692 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.482 ' O ' ' NE2' ' E' ' 14' ' ' HIS . 2.7 t -108.21 111.01 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-O 121.163 0.506 . . . . 0.0 110.503 -179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.545 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 0.0 OUTLIER -145.23 117.72 8.54 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.209 -179.689 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.634 ' N ' ' CE1' ' E' ' 14' ' ' HIS . 79.5 m80 -156.97 169.4 24.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.593 -0.731 . . . . 0.0 109.447 179.401 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.792 HE22 ' H ' ' D' ' 37' ' ' GLY . 3.3 tt0 -89.67 155.78 19.0 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 179.174 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 75.0 tttt -141.39 116.32 9.84 Favored 'General case' 0 C--N 1.316 -0.876 0 C-N-CA 120.681 -0.408 . . . . 0.0 110.557 178.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.448 HD12 ' N ' ' F' ' 17' ' ' LEU . 1.6 mp -137.06 121.75 18.56 Favored 'General case' 0 CA--C 1.517 -0.305 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 19.7 t -106.11 117.11 51.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.081 -179.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.539 ' O ' ' CD1' ' F' ' 20' ' ' PHE . 11.2 m-85 -116.05 98.2 6.5 Favored 'General case' 0 CA--C 1.512 -0.501 0 N-CA-C 106.396 -1.705 . . . . 0.0 106.396 177.768 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.539 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 58.1 m-85 -152.08 173.65 14.66 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 122.806 1.288 . . . . 0.0 112.315 -178.235 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.599 ' HB1' ' O ' ' E' ' 21' ' ' ALA . . . -152.11 155.18 37.36 Favored 'General case' 0 N--CA 1.435 -1.189 0 CA-C-N 114.101 -1.408 . . . . 0.0 109.897 -179.13 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -75.52 137.78 41.1 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -176.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 60.15 50.12 6.73 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-N 114.112 -1.404 . . . . 0.0 113.599 177.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.562 HG12 ' N ' ' F' ' 25' ' ' GLY . 82.2 t -54.93 162.92 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 C-N-CA 118.832 -1.147 . . . . 0.0 108.734 179.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.562 ' N ' HG12 ' F' ' 24' ' ' VAL . . . -156.62 -26.06 0.03 OUTLIER Glycine 0 CA--C 1.523 0.586 0 C-N-CA 120.495 -0.859 . . . . 0.0 112.023 -179.059 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 10.8 m -71.5 130.19 40.65 Favored 'General case' 0 C--N 1.326 -0.421 0 N-CA-C 113.784 1.031 . . . . 0.0 113.784 -175.695 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.767 ' O ' ' N ' ' F' ' 29' ' ' GLY . 13.9 m120 -90.9 -156.2 0.43 Allowed 'General case' 0 C--O 1.22 -0.475 0 N-CA-C 105.909 -1.886 . . . . 0.0 105.909 176.371 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -49.15 50.39 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.053 0 N-CA-C 112.972 0.73 . . . . 0.0 112.972 179.226 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.767 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -100.2 -51.09 1.27 Allowed Glycine 0 CA--C 1.539 1.582 0 C-N-CA 123.762 0.696 . . . . 0.0 111.947 179.338 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.876 ' HB1' ' O ' ' E' ' 30' ' ' ALA . . . -101.65 178.22 4.69 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 -179.142 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.55 HD11 ' O ' ' R' ' 39' ' ' VAL . 90.6 mt -121.13 131.84 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.975 0 C-N-CA 119.812 -0.755 . . . . 0.0 112.601 -178.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 96.5 mt -122.61 117.82 53.17 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.127 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.331 176.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.66 126.81 6.98 Favored Glycine 0 N--CA 1.469 0.851 0 N-CA-C 111.49 -0.644 . . . . 0.0 111.49 -178.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 54.3 tp -131.83 114.45 14.71 Favored 'General case' 0 CA--C 1.512 -0.488 0 N-CA-C 107.73 -1.211 . . . . 0.0 107.73 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 90.6 mtp -122.01 135.49 54.84 Favored 'General case' 0 N--CA 1.468 0.43 0 C-N-CA 120.617 -0.433 . . . . 0.0 112.104 -178.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.469 ' HA ' HG22 ' E' ' 36' ' ' VAL . 51.2 t -108.28 132.69 55.4 Favored 'Isoleucine or valine' 0 C--N 1.341 0.208 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.803 179.612 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.542 ' O ' ' N ' ' F' ' 39' ' ' VAL . . . -92.6 112.4 4.23 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.533 -0.627 . . . . 0.0 111.533 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.98 -70.41 0.0 OUTLIER Glycine 0 CA--C 1.538 1.484 0 N-CA-C 114.011 0.364 . . . . 0.0 114.011 177.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.542 ' N ' ' O ' ' F' ' 37' ' ' GLY . 46.3 t -123.97 132.68 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.585 0 CA-C-O 121.586 0.708 . . . . 0.0 111.885 -178.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' E' ' 40' ' ' VAL . 11.6 t . . . . . 0 C--O 1.218 -0.571 0 CA-C-O 117.785 -1.102 . . . . 0.0 110.381 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.519 -1.433 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -107.58 138.42 43.82 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 82.8 tt0 -156.99 116.82 3.47 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.89 0.376 . . . . 0.0 110.894 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.552 HG12 ' O ' ' H' ' 12' ' ' VAL . 12.3 m -131.52 132.22 62.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-N 116.022 -0.535 . . . . 0.0 109.911 179.792 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.538 ' O ' ' ND1' ' H' ' 13' ' ' HIS . 51.7 m-70 -145.31 130.31 18.34 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-O 121.3 0.571 . . . . 0.0 111.965 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 42.2 p-80 -152.74 172.4 16.75 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.51 -0.768 . . . . 0.0 110.478 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 57.3 tt0 -128.97 151.01 50.15 Favored 'General case' 0 N--CA 1.455 -0.2 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -95.22 128.7 42.27 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.73 -0.668 . . . . 0.0 109.688 179.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -126.96 117.92 23.48 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.955 -0.387 . . . . 0.0 109.955 179.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.2 p -133.95 134.27 55.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.582 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -144.77 146.9 32.36 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-O 121.46 0.648 . . . . 0.0 111.452 -179.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.521 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 54.6 p90 -129.23 129.61 45.22 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.046 179.059 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -114.3 120.81 41.67 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 121.131 0.491 . . . . 0.0 112.085 -178.536 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -157.98 151.72 23.83 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 57.01 46.45 19.35 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.78 -0.368 . . . . 0.0 111.812 179.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 34.1 m -80.29 -179.8 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-O 120.933 0.397 . . . . 0.0 110.338 -179.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -71.15 -32.39 65.69 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 33.3 t -152.55 125.83 8.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-O 121.341 0.591 . . . . 0.0 109.576 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -38.93 134.14 1.04 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.814 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -110.59 -39.21 4.96 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 107.025 -1.472 . . . . 0.0 107.025 175.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.412 ' O ' ' HB2' ' G' ' 30' ' ' ALA . . . 79.96 -69.41 3.09 Favored Glycine 0 CA--C 1.532 1.121 0 CA-C-N 112.415 -2.175 . . . . 0.0 111.702 -179.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.435 ' HB3' ' CB ' ' H' ' 30' ' ' ALA . . . 179.78 87.61 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 117.59 0.695 . . . . 0.0 111.239 176.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 96.7 mt -133.32 113.71 19.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.541 0 O-C-N 121.765 -0.584 . . . . 0.0 109.702 179.461 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.534 HD13 ' CD2' ' I' ' 19' ' ' PHE . 66.8 mt -108.21 110.72 33.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.277 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.308 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.13 97.54 0.63 Allowed Glycine 0 CA--C 1.507 -0.434 0 N-CA-C 105.298 -3.121 . . . . 0.0 105.298 177.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.752 ' O ' HD12 ' H' ' 34' ' ' LEU . 56.8 tp -160.63 159.41 30.4 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 118.18 -1.408 . . . . 0.0 111.89 -175.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.448 ' N ' ' HG ' ' G' ' 34' ' ' LEU . 23.8 mtp -122.75 121.91 37.46 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.418 -1.264 . . . . 0.0 109.19 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.599 HG12 ' CD ' ' I' ' 15' ' ' GLN . 2.0 t -118.32 103.1 14.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 179.14 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 153.69 -153.05 24.57 Favored Glycine 0 C--N 1.314 -0.678 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.305 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . 0.445 ' O ' HG23 ' H' ' 39' ' ' VAL . . . 111.82 -56.2 0.48 Allowed Glycine 0 CA--C 1.542 1.779 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 t -112.86 160.8 12.21 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.756 -1.116 . . . . 0.0 110.395 179.316 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.388 -1.485 . . . . 0.0 109.388 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.5 m-85 -113.61 135.65 53.68 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 120.739 0.304 . . . . 0.0 110.364 179.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -109.11 116.02 31.15 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.497 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.552 ' O ' HG12 ' G' ' 12' ' ' VAL . 6.6 t -116.14 95.01 3.44 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-O 120.916 0.389 . . . . 0.0 110.092 179.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.538 ' ND1' ' O ' ' G' ' 13' ' ' HIS . 17.9 p-80 -147.84 165.68 29.86 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.077 -0.511 . . . . 0.0 109.871 -179.408 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.653 ' HE2' ' CG2' ' I' ' 12' ' ' VAL . 0.1 OUTLIER -107.73 161.61 14.73 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 109.484 -0.561 . . . . 0.0 109.484 179.361 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -89.87 159.64 16.87 Favored 'General case' 0 CA--C 1.515 -0.382 0 N-CA-C 108.36 -0.978 . . . . 0.0 108.36 177.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 mttp -140.0 101.27 4.13 Favored 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 109.766 -0.457 . . . . 0.0 109.766 179.406 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 56.8 tp -127.97 121.9 31.03 Favored 'General case' 0 N--CA 1.476 0.861 0 CA-C-O 121.115 0.483 . . . . 0.0 110.611 179.078 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -124.32 126.59 72.28 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.201 0 CA-C-N 115.498 -0.774 . . . . 0.0 109.625 179.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 21.4 t80 -131.07 123.0 27.72 Favored 'General case' 0 C--N 1.332 -0.193 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.44 ' CZ ' ' CG ' ' H' ' 22' ' ' GLU . 19.5 t80 -119.5 126.11 50.5 Favored 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 109.357 -0.608 . . . . 0.0 109.357 -179.95 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.34 121.56 38.87 Favored 'General case' 0 C--O 1.245 0.865 0 N-CA-C 113.826 1.047 . . . . 0.0 113.826 -177.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.44 ' CG ' ' CZ ' ' H' ' 20' ' ' PHE . 58.0 mt-10 -116.82 98.06 6.3 Favored 'General case' 0 C--N 1.344 0.346 0 CA-C-N 114.052 -1.431 . . . . 0.0 107.348 176.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 96.8 m-20 -112.38 51.5 0.81 Allowed 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.261 -1.014 . . . . 0.0 108.261 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.549 ' HA ' HG13 ' I' ' 24' ' ' VAL . 84.7 t -75.44 144.58 11.87 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.709 0 O-C-N 124.118 0.887 . . . . 0.0 110.61 -175.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 105.61 -38.31 3.37 Favored Glycine 0 CA--C 1.527 0.825 0 CA-C-N 113.84 -1.527 . . . . 0.0 110.562 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.46 ' O ' ' O ' ' H' ' 27' ' ' ASN . 74.8 m -120.48 -112.18 0.33 Allowed 'General case' 0 N--CA 1.475 0.814 0 N-CA-C 114.003 1.112 . . . . 0.0 114.003 -179.516 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.466 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 51.1 t-20 52.13 152.9 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.921 0 C-N-CA 124.327 1.051 . . . . 0.0 110.908 -176.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.466 ' N ' ' OD1' ' H' ' 27' ' ' ASN . 67.6 mttm -140.48 -28.88 0.7 Allowed 'General case' 0 N--CA 1.477 0.907 0 N-CA-C 115.189 1.552 . . . . 0.0 115.189 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -161.01 88.08 0.11 Allowed Glycine 0 N--CA 1.474 1.216 0 CA-C-O 119.471 -0.627 . . . . 0.0 113.74 -170.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.435 ' CB ' ' HB3' ' G' ' 30' ' ' ALA . . . -79.07 128.46 33.3 Favored 'General case' 0 CA--C 1.545 0.787 0 CA-C-O 123.308 1.528 . . . . 0.0 112.682 -175.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.535 ' CD1' ' O ' ' B' ' 38' ' ' GLY . 30.7 mt -137.32 139.66 43.43 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 112.638 -2.074 . . . . 0.0 113.399 -176.067 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.413 HG22 HD21 ' I' ' 34' ' ' LEU . 80.6 mt -109.48 112.23 39.58 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 175.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.37 99.3 0.82 Allowed Glycine 0 C--O 1.237 0.308 0 N-CA-C 105.573 -3.011 . . . . 0.0 105.573 176.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.752 HD12 ' O ' ' G' ' 34' ' ' LEU . 8.4 tp -142.4 140.89 32.16 Favored 'General case' 0 C--O 1.242 0.669 0 CA-C-O 123.007 1.384 . . . . 0.0 113.251 -174.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.1 mtp -107.47 111.75 24.2 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 112.315 -2.221 . . . . 0.0 108.387 178.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.585 ' CG1' ' NE2' ' J' ' 15' ' ' GLN . 2.0 t -117.77 122.99 71.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 -179.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.66 -113.18 0.6 Allowed Glycine 0 C--N 1.313 -0.731 0 N-CA-C 110.241 -1.144 . . . . 0.0 110.241 -179.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.571 ' O ' ' CD1' ' N' ' 31' ' ' ILE . . . 84.67 -73.28 2.66 Favored Glycine 0 CA--C 1.533 1.171 0 N-CA-C 111.14 -0.784 . . . . 0.0 111.14 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.563 ' HA ' HG21 ' I' ' 39' ' ' VAL . 34.9 t -133.86 157.1 41.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 N-CA-C 108.846 -0.798 . . . . 0.0 108.846 178.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.479 ' C ' ' O ' ' H' ' 39' ' ' VAL . 70.1 t . . . . . 0 N--CA 1.471 0.577 0 CA-C-O 118.181 -0.914 . . . . 0.0 111.295 179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.349 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -112.16 136.04 52.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.858 0.361 . . . . 0.0 110.534 -179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 3.0 pt-20 -99.6 109.19 21.71 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.379 -179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.653 ' CG2' ' HE2' ' H' ' 14' ' ' HIS . 2.4 m -139.75 162.44 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.905 -178.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.518 ' NE2' HG13 ' H' ' 12' ' ' VAL . 2.8 m-70 -138.86 97.29 3.29 Favored 'General case' 0 N--CA 1.473 0.7 0 CA-C-O 119.264 -0.398 . . . . 0.0 110.432 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.61 ' CD2' ' H ' ' J' ' 14' ' ' HIS . 7.2 m170 -122.36 156.91 32.95 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 119.827 -0.749 . . . . 0.0 112.28 179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.599 ' CD ' HG12 ' G' ' 36' ' ' VAL . 2.9 tt0 -90.44 159.59 16.47 Favored 'General case' 0 C--N 1.341 0.22 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 175.609 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -140.66 106.45 5.14 Favored 'General case' 0 C--N 1.312 -1.047 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 176.393 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.458 HD21 HG11 ' G' ' 36' ' ' VAL . 80.0 mt -117.21 114.97 24.41 Favored 'General case' 0 N--CA 1.479 1.015 0 C-N-CA 120.316 -0.554 . . . . 0.0 111.045 178.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 2.8 t -114.29 103.26 15.09 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 177.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.534 ' CD2' HD13 ' G' ' 32' ' ' ILE . 14.5 m-30 -114.42 113.87 25.08 Favored 'General case' 0 N--CA 1.475 0.824 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 6.1 m-85 -116.76 131.3 56.99 Favored 'General case' 0 N--CA 1.484 1.255 0 N-CA-C 112.063 0.394 . . . . 0.0 112.063 -178.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.19 138.76 50.76 Favored 'General case' 0 N--CA 1.488 1.468 0 CA-C-N 117.81 0.277 . . . . 0.0 111.184 179.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 87.6 mt-10 -76.67 176.38 8.46 Favored 'General case' 0 N--CA 1.506 2.34 0 N-CA-C 119.237 3.051 . . . . 0.0 119.237 -174.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -72.49 50.11 0.23 Allowed 'General case' 0 N--CA 1.499 1.985 0 C-N-CA 128.892 2.877 . . . . 0.0 114.132 -178.096 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.662 HG12 ' H ' ' I' ' 25' ' ' GLY . 1.8 t -74.77 -143.02 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 -175.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.662 ' H ' HG12 ' I' ' 24' ' ' VAL . . . -95.97 36.7 3.72 Favored Glycine 0 N--CA 1.465 0.573 0 C-N-CA 129.274 3.321 . . . . 0.0 107.706 -173.433 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.1 t -74.25 104.62 5.1 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 109.975 -3.113 . . . . 0.0 109.995 -176.854 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.708 ' O ' ' C ' ' I' ' 28' ' ' LYS . 86.1 m-20 -93.0 -149.23 0.26 Allowed 'General case' 0 CA--C 1.493 -1.219 0 N-CA-C 101.107 -3.664 . . . . 0.0 101.107 -176.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.708 ' C ' ' O ' ' I' ' 27' ' ' ASN . 82.3 tttt -32.64 -42.66 0.08 Allowed 'General case' 0 N--CA 1.483 1.193 0 CA-C-N 124.173 3.17 . . . . 0.0 106.235 -170.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' I' ' 27' ' ' ASN . . . 91.29 -61.42 2.9 Favored Glycine 0 N--CA 1.472 1.074 0 N-CA-C 121.583 3.393 . . . . 0.0 121.583 159.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -123.22 117.11 24.58 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 116.144 1.905 . . . . 0.0 116.144 -171.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.488 ' CD1' ' O ' ' C' ' 38' ' ' GLY . 3.5 mt -127.28 117.12 46.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 107.601 -1.259 . . . . 0.0 107.601 174.239 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.421 HD13 HG21 ' I' ' 32' ' ' ILE . 25.2 mt -100.22 112.93 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 N-CA-C 109.381 -0.6 . . . . 0.0 109.381 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.03 100.12 1.07 Allowed Glycine 0 C--N 1.339 0.733 0 N-CA-C 106.548 -2.621 . . . . 0.0 106.548 177.197 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.462 ' CD2' ' HB3' ' H' ' 34' ' ' LEU . 98.0 mt -131.79 145.04 51.36 Favored 'General case' 0 CA--C 1.501 -0.926 0 N-CA-C 115.291 1.589 . . . . 0.0 115.291 -175.454 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -118.93 102.43 8.77 Favored 'General case' 0 N--CA 1.445 -0.682 0 N-CA-C 104.735 -2.321 . . . . 0.0 104.735 174.248 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.498 HG23 HE22 ' K' ' 15' ' ' GLN . 8.0 p -123.07 122.9 66.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 121.616 0.722 . . . . 0.0 109.88 -178.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.29 -113.59 0.75 Allowed Glycine 0 C--N 1.31 -0.876 0 N-CA-C 107.57 -2.212 . . . . 0.0 107.57 -179.499 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.77 -72.37 1.05 Allowed Glycine 0 CA--C 1.535 1.303 0 C-N-CA 121.214 -0.517 . . . . 0.0 113.533 177.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.715 HG22 HD12 ' O' ' 31' ' ' ILE . 21.4 t -132.55 160.95 42.24 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-O 121.01 0.433 . . . . 0.0 111.698 -177.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.587 HG22 ' O ' ' I' ' 40' ' ' VAL . 10.9 p . . . . . 0 C--O 1.219 -0.545 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.4 -179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.401 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 37.0 t80 -71.02 127.32 32.16 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 74.0 mt-10 -142.97 156.07 44.8 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 120.967 0.413 . . . . 0.0 110.608 -179.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.591 ' CG2' ' NE2' ' J' ' 14' ' ' HIS . 2.2 p -130.78 134.62 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 179.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.498 ' O ' ' ND1' ' J' ' 14' ' ' HIS . 97.6 m-70 -120.83 124.85 46.04 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-N 115.609 -0.723 . . . . 0.0 112.46 -178.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.636 ' CD2' ' CE1' ' K' ' 14' ' ' HIS . 51.3 m-70 -151.58 169.82 21.18 Favored 'General case' 0 C--O 1.222 -0.382 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.585 ' NE2' ' CG1' ' H' ' 36' ' ' VAL . 8.5 tt0 -137.69 150.17 47.11 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 176.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt -115.7 113.89 24.1 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.692 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.534 HD21 HG11 ' H' ' 36' ' ' VAL . 89.5 mt -108.84 107.34 17.71 Favored 'General case' 0 CA--C 1.509 -0.61 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 176.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 t -110.96 102.53 14.11 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 N-CA-C 108.494 -0.928 . . . . 0.0 108.494 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.456 ' CD2' ' CE1' ' K' ' 19' ' ' PHE . 12.4 m-85 -113.05 112.0 23.1 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 107.465 -1.309 . . . . 0.0 107.465 178.772 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 12.9 t80 -114.98 125.98 54.23 Favored 'General case' 0 N--CA 1.472 0.632 0 CA-C-N 116.636 -0.256 . . . . 0.0 110.873 -178.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.49 129.54 33.28 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-O 121.666 0.745 . . . . 0.0 111.862 -179.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 94.7 mt-10 -82.32 116.89 22.03 Favored 'General case' 0 C--N 1.331 -0.215 0 N-CA-C 107.235 -1.395 . . . . 0.0 107.235 178.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.533 ' OD1' ' N ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -124.96 51.78 1.63 Allowed 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 113.513 0.931 . . . . 0.0 113.513 -176.138 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 48.3 t -75.07 143.31 13.47 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.82 0 N-CA-C 103.047 -2.946 . . . . 0.0 103.047 175.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.58 37.57 3.7 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 105.768 -2.933 . . . . 0.0 105.768 -172.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.434 ' HG ' ' CG ' ' K' ' 27' ' ' ASN . 5.3 t -69.48 105.11 2.51 Favored 'General case' 0 CA--C 1.515 -0.377 0 CA-C-N 113.522 -1.339 . . . . 0.0 107.94 -177.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 13.8 m-20 -117.85 -151.88 0.49 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 113.149 -1.841 . . . . 0.0 113.522 -172.302 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -37.54 -40.81 0.41 Allowed 'General case' 0 CA--C 1.551 0.999 0 N-CA-C 119.736 3.236 . . . . 0.0 119.736 -171.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.421 ' O ' ' CE ' ' I' ' 28' ' ' LYS . . . -171.29 69.47 0.12 Allowed Glycine 0 N--CA 1.484 1.844 0 C-N-CA 115.193 -3.384 . . . . 0.0 119.44 -174.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -73.39 140.73 46.81 Favored 'General case' 0 CA--C 1.551 0.99 0 CA-C-N 120.307 2.053 . . . . 0.0 109.172 177.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.506 HG22 ' H ' ' K' ' 31' ' ' ILE . 10.1 pt -146.62 153.6 12.73 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.066 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 -177.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 96.4 mt -114.56 128.47 71.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.305 176.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.36 112.55 0.97 Allowed Glycine 0 N--CA 1.462 0.42 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 177.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.651 HD12 ' C ' ' J' ' 34' ' ' LEU . 3.6 pp -164.65 165.63 20.78 Favored 'General case' 0 C--O 1.241 0.612 0 C-N-CA 117.588 -1.645 . . . . 0.0 114.986 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 70.6 mmm -113.87 117.56 31.75 Favored 'General case' 0 N--CA 1.45 -0.449 0 CA-C-N 112.746 -2.024 . . . . 0.0 110.653 -179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.601 HG12 ' CD ' ' L' ' 15' ' ' GLN . 15.3 t -111.5 102.51 14.07 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.153 0 N-CA-C 109.246 -0.649 . . . . 0.0 109.246 178.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.7 ' N ' HE22 ' L' ' 15' ' ' GLN . . . 125.09 -162.31 19.41 Favored Glycine 0 N--CA 1.465 0.585 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.386 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.441 ' C ' ' O ' ' K' ' 38' ' ' GLY . . . 137.84 -55.38 0.68 Allowed Glycine 0 CA--C 1.542 1.745 0 N-CA-C 110.053 -1.219 . . . . 0.0 110.053 -177.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.908 HG22 HD12 ' P' ' 31' ' ' ILE . 43.5 t -125.29 134.04 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.853 0.861 . . . . 0.0 108.798 177.672 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.695 ' HA ' HG13 ' K' ' 39' ' ' VAL . 74.1 t . . . . . 0 C--O 1.216 -0.685 0 CA-C-O 118.088 -0.958 . . . . 0.0 111.711 179.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.44 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.05 134.54 53.54 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.482 ' O ' ' NE2' ' L' ' 13' ' ' HIS . 97.8 mt-10 -144.56 169.48 17.88 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-O 120.859 0.361 . . . . 0.0 111.276 -179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.471 HG13 ' H ' ' L' ' 12' ' ' VAL . 19.6 t -104.18 128.26 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 179.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.528 ' CE1' ' OXT' ' I' ' 40' ' ' VAL . 81.7 t60 -138.93 114.81 10.06 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 113.115 0.783 . . . . 0.0 113.115 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.636 ' CE1' ' CD2' ' J' ' 14' ' ' HIS . 7.5 p80 -155.22 165.29 37.14 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.498 HE22 HG23 ' I' ' 36' ' ' VAL . 58.3 tt0 -129.48 149.95 51.04 Favored 'General case' 0 N--CA 1.464 0.27 0 C-N-CA 119.699 -0.8 . . . . 0.0 111.179 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -99.96 109.15 21.51 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.397 -0.82 . . . . 0.0 112.004 177.266 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.568 ' CD1' ' N ' ' K' ' 17' ' ' LEU . 0.0 OUTLIER -103.95 105.12 15.2 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 176.557 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 21.8 t -114.1 103.89 16.08 Favored 'Isoleucine or valine' 0 C--O 1.233 0.208 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.445 -179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.456 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 5.1 m-85 -114.39 108.26 16.65 Favored 'General case' 0 C--O 1.234 0.239 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 178.207 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 m-30 -106.69 120.8 42.95 Favored 'General case' 0 N--CA 1.474 0.726 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -178.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.461 ' HB1' ' OD1' ' J' ' 23' ' ' ASP . . . -132.42 131.36 41.7 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 120.556 -0.458 . . . . 0.0 111.415 -179.261 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.533 ' N ' ' OD1' ' J' ' 23' ' ' ASP . 97.4 mt-10 -87.09 104.61 16.5 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 108.005 -1.109 . . . . 0.0 108.005 178.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.465 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 0.5 OUTLIER -135.13 48.66 2.25 Favored 'General case' 0 N--CA 1.47 0.549 0 CA-C-N 115.905 -0.588 . . . . 0.0 111.733 -177.322 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.546 HG12 ' N ' ' K' ' 25' ' ' GLY . 55.0 t -71.92 161.38 4.82 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.553 -178.614 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.546 ' N ' HG12 ' K' ' 24' ' ' VAL . . . 110.26 -28.35 10.43 Favored Glycine 0 CA--C 1.529 0.94 0 N-CA-C 109.756 -1.337 . . . . 0.0 109.756 -177.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER 74.57 119.73 0.05 OUTLIER 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.051 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.434 ' CG ' ' HG ' ' J' ' 26' ' ' SER . 93.3 m-20 -83.24 162.79 21.08 Favored 'General case' 0 C--O 1.23 0.061 0 C-N-CA 119.432 -0.907 . . . . 0.0 112.832 -177.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -47.19 -37.28 9.97 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 114.038 -1.437 . . . . 0.0 112.294 177.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.78 77.35 0.07 OUTLIER Glycine 0 CA--C 1.532 1.147 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.597 -174.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.53 153.7 29.35 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-N 118.217 1.009 . . . . 0.0 110.01 -178.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.831 HD12 HG21 ' D' ' 39' ' ' VAL . 57.4 mt -133.78 141.24 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 N-CA-C 113.874 1.064 . . . . 0.0 113.874 -175.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 97.2 mt -127.02 118.36 50.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.169 178.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.16 109.56 1.72 Allowed Glycine 0 N--CA 1.471 1.002 0 N-CA-C 108.256 -1.938 . . . . 0.0 108.256 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.418 HD22 HD11 ' J' ' 34' ' ' LEU . 29.3 mt -127.84 125.27 39.43 Favored 'General case' 0 CA--C 1.512 -0.499 0 N-CA-C 112.811 0.671 . . . . 0.0 112.811 -175.7 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 1.7 mtp -106.94 106.01 16.32 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 176.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.623 HG22 ' H ' ' K' ' 37' ' ' GLY . 9.9 p -97.26 173.23 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.518 -0.261 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 179.827 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.623 ' H ' HG22 ' K' ' 36' ' ' VAL . . . 159.64 -95.39 0.14 Allowed Glycine 0 C--N 1.3 -1.45 0 C-N-CA 119.705 -1.236 . . . . 0.0 110.458 -178.107 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.441 ' O ' ' C ' ' J' ' 38' ' ' GLY . . . 98.13 -80.53 0.61 Allowed Glycine 0 N--CA 1.47 0.95 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 -176.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.695 HG13 ' HA ' ' J' ' 40' ' ' VAL . 0.0 OUTLIER -85.05 94.08 3.79 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.014 0 N-CA-C 103.961 -2.607 . . . . 0.0 103.961 176.416 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.635 ' C ' HG21 ' Q' ' 31' ' ' ILE . 13.1 p . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.799 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.441 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -106.49 136.2 46.67 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.544 0.211 . . . . 0.0 110.526 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 98.9 mt-10 -139.34 155.51 47.64 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.931 0.396 . . . . 0.0 110.503 179.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.471 ' H ' HG13 ' K' ' 12' ' ' VAL . 58.9 t -128.76 134.34 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.376 -178.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.482 ' NE2' ' O ' ' K' ' 11' ' ' GLU . 85.0 m-70 -135.12 84.65 2.11 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.7 178.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.486 ' O ' ' CB ' ' K' ' 14' ' ' HIS . 85.2 t60 -162.7 168.51 21.48 Favored 'General case' 0 C--O 1.222 -0.346 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 178.141 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.7 HE22 ' N ' ' J' ' 37' ' ' GLY . 78.8 mt-30 -100.35 151.33 21.63 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-O 121.345 0.593 . . . . 0.0 111.788 179.54 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -112.63 110.21 20.22 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.745 177.341 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.467 HD22 HG11 ' J' ' 36' ' ' VAL . 0.1 OUTLIER -104.77 109.88 22.0 Favored 'General case' 0 N--CA 1.47 0.548 0 N-CA-C 109.43 -0.581 . . . . 0.0 109.43 178.863 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 42.8 t -117.21 102.38 13.4 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 N-CA-C 109.481 -0.563 . . . . 0.0 109.481 179.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.424 ' CD1' ' CD2' ' K' ' 19' ' ' PHE . 5.0 m-85 -115.72 107.11 14.66 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 107.093 -1.447 . . . . 0.0 107.093 178.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 66.2 t80 -113.96 119.71 38.15 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.099 0.476 . . . . 0.0 111.515 -177.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.23 127.17 52.17 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 178.248 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -78.04 111.25 13.73 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 119.612 -0.835 . . . . 0.0 111.329 -177.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 56.9 p30 -178.39 48.66 0.01 OUTLIER 'General case' 0 CA--C 1.521 -0.157 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.618 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 33.7 m -72.62 160.32 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 C-N-CA 118.431 -1.308 . . . . 0.0 109.449 -179.619 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 111.05 -33.19 6.01 Favored Glycine 0 N--CA 1.462 0.433 0 N-CA-C 108.649 -1.78 . . . . 0.0 108.649 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 4.7 m -72.09 129.56 38.79 Favored 'General case' 0 CA--C 1.519 -0.246 0 CA-C-N 113.824 -1.188 . . . . 0.0 111.102 179.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.645 ' O ' ' N ' ' L' ' 29' ' ' GLY . 98.7 m-20 -90.98 -162.51 0.92 Allowed 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -48.28 47.59 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 115.127 1.529 . . . . 0.0 115.127 -179.145 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.645 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -99.17 57.08 0.9 Allowed Glycine 0 CA--C 1.54 1.608 0 CA-C-N 119.483 1.038 . . . . 0.0 112.016 178.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -167.07 171.73 10.74 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.416 HD11 ' CG2' ' F' ' 39' ' ' VAL . 94.5 mt -121.27 121.73 65.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 N-CA-C 108.665 -0.865 . . . . 0.0 108.665 177.108 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 16.0 tt -125.43 133.58 68.9 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.864 0.364 . . . . 0.0 111.57 -178.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.99 117.98 2.06 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.4 tp -115.21 123.53 49.1 Favored 'General case' 0 CA--C 1.517 -0.303 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 179.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.3 mmm -124.83 128.03 48.07 Favored 'General case' 0 N--CA 1.468 0.448 0 CA-C-O 120.659 0.266 . . . . 0.0 111.552 -178.172 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 10.2 t -97.4 152.24 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.196 0 CA-C-O 121.353 0.597 . . . . 0.0 111.929 -179.407 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.527 ' O ' ' N ' ' L' ' 39' ' ' VAL . . . -80.79 102.5 2.13 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' L' ' 37' ' ' GLY . . . 11.46 -73.04 0.0 OUTLIER Glycine 0 CA--C 1.539 1.588 0 C-N-CA 123.459 0.552 . . . . 0.0 113.92 -178.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.527 ' N ' ' O ' ' L' ' 37' ' ' GLY . 74.5 t -129.95 136.07 59.7 Favored 'Isoleucine or valine' 0 C--N 1.346 0.42 0 CA-C-N 118.221 1.011 . . . . 0.0 110.073 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.446 ' H ' HG22 ' L' ' 40' ' ' VAL . 13.8 m . . . . . 0 C--O 1.219 -0.543 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.336 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -112.52 133.8 54.39 Favored 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 120.792 0.33 . . . . 0.0 110.344 -179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -71.71 144.26 49.37 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.029 179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -139.49 139.5 38.63 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-O 121.159 0.504 . . . . 0.0 110.4 -179.612 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 96.9 m-70 -89.49 166.73 13.5 Favored 'General case' 0 C--N 1.333 -0.127 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.229 179.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.594 ' ND1' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -82.26 171.42 14.28 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.0 0.429 . . . . 0.0 111.212 -179.342 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -128.8 151.03 50.04 Favored 'General case' 0 CA--C 1.517 -0.32 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.47 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -96.3 106.77 19.04 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.704 179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 87.2 mt -128.22 114.41 16.92 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 121.005 0.431 . . . . 0.0 110.057 179.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 69.9 t -126.61 130.8 71.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.715 -179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -128.18 131.23 48.9 Favored 'General case' 0 N--CA 1.463 0.207 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 179.193 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.619 ' CZ ' ' CD1' ' N' ' 20' ' ' PHE . 1.6 t80 -134.38 128.84 34.42 Favored 'General case' 0 CA--C 1.536 0.419 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.204 -178.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 118.46 31.86 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 120.935 0.398 . . . . 0.0 109.949 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . 0.566 ' O ' HG23 ' M' ' 24' ' ' VAL . 94.5 mt-10 -110.53 -148.59 0.43 Allowed 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.773 -178.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 36.1 t70 -59.57 50.13 0.01 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 CA-C-N 115.399 -0.819 . . . . 0.0 112.855 -179.515 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.59 HG12 ' H ' ' M' ' 25' ' ' GLY . 2.3 t -71.72 -142.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -178.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.59 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -111.48 38.75 3.14 Favored Glycine 0 CA--C 1.526 0.777 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.904 -177.022 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 1.4 m 61.76 111.18 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.113 0.482 . . . . 0.0 112.082 177.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.45 ' O ' ' C ' ' M' ' 28' ' ' LYS . 91.2 m-20 -129.85 -161.55 1.13 Allowed 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 115.65 -0.705 . . . . 0.0 109.193 179.393 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . 0.45 ' C ' ' O ' ' M' ' 27' ' ' ASN . 73.6 mmtt -30.95 -41.31 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.748 0 CA-C-O 120.914 0.387 . . . . 0.0 110.996 -179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' M' ' 27' ' ' ASN . . . 91.35 -64.92 2.54 Favored Glycine 0 CA--C 1.535 1.342 0 CA-C-N 115.733 -0.667 . . . . 0.0 111.794 -179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.473 ' O ' ' O ' ' N' ' 29' ' ' GLY . . . -170.37 70.1 0.05 Allowed 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 117.616 0.708 . . . . 0.0 112.483 177.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 82.0 mt -130.89 115.09 29.06 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.638 0 N-CA-C 108.084 -1.08 . . . . 0.0 108.084 177.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . 0.52 HG22 HD21 ' N' ' 34' ' ' LEU . 4.0 mt -112.89 116.16 51.85 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 C-N-CA 120.062 -0.655 . . . . 0.0 111.107 -179.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.16 105.0 1.18 Allowed Glycine 0 N--CA 1.461 0.315 0 N-CA-C 105.389 -3.084 . . . . 0.0 105.389 177.108 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . 0.578 ' HB3' HD22 ' N' ' 34' ' ' LEU . 47.1 tp -161.02 152.34 19.02 Favored 'General case' 0 C--O 1.237 0.445 0 C-N-CA 117.548 -1.661 . . . . 0.0 114.354 -174.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 3.8 ttm -104.26 115.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.916 0 CA-C-N 112.56 -2.109 . . . . 0.0 106.856 176.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.517 ' O ' ' N ' ' N' ' 37' ' ' GLY . 36.5 t -116.91 103.87 15.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.383 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 108.29 -153.22 16.88 Favored Glycine 0 C--N 1.337 0.633 0 C-N-CA 120.026 -1.083 . . . . 0.0 110.952 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.586 ' H ' ' N ' ' N' ' 38' ' ' GLY . . . 147.65 -54.64 0.52 Allowed Glycine 0 CA--C 1.539 1.551 0 CA-C-O 119.721 -0.488 . . . . 0.0 111.93 -179.402 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.48 ' O ' ' O ' ' M' ' 40' ' ' VAL . 10.0 p -114.73 151.89 16.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 117.963 0.881 . . . . 0.0 108.787 178.411 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.779 ' OXT' HG13 ' M' ' 40' ' ' VAL . 8.5 p . . . . . 0 C--N 1.324 -0.533 0 CA-C-O 117.854 -1.069 . . . . 0.0 111.151 -179.727 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.437 0 N-CA-C 109.653 -1.379 . . . . 0.0 109.653 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.64 134.33 48.93 Favored 'General case' 0 N--CA 1.468 0.438 0 N-CA-C 110.542 -0.17 . . . . 0.0 110.542 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -151.38 135.77 16.89 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.999 0.428 . . . . 0.0 111.245 -179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.412 HG12 ' CG2' ' O' ' 12' ' ' VAL . 34.1 m -137.03 162.09 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 115.887 -0.597 . . . . 0.0 109.624 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . 0.51 ' C ' ' ND1' ' N' ' 14' ' ' HIS . 83.4 m-70 -143.34 104.86 4.31 Favored 'General case' 0 N--CA 1.468 0.435 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.489 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.51 ' ND1' ' C ' ' N' ' 13' ' ' HIS . 20.0 m80 -152.08 167.05 29.71 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-O 120.701 0.286 . . . . 0.0 110.67 178.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 83.5 mt-30 -155.7 141.17 17.76 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.032 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -89.82 107.39 19.07 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-O 119.215 -0.421 . . . . 0.0 111.666 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.432 HD23 ' HG ' ' O' ' 17' ' ' LEU . 33.4 tp -123.78 115.57 21.57 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 177.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.2 t -121.49 131.13 73.79 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.828 -179.175 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 90.1 t80 -129.97 112.35 13.42 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.522 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CZ ' ' M' ' 20' ' ' PHE . 16.5 t80 -113.81 130.37 56.47 Favored 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 109.234 -0.654 . . . . 0.0 109.234 178.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.44 133.14 40.16 Favored 'General case' 0 N--CA 1.468 0.46 0 N-CA-C 113.232 0.827 . . . . 0.0 113.232 -178.049 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -92.38 120.83 33.27 Favored 'General case' 0 C--N 1.34 0.168 0 CA-C-N 115.161 -0.927 . . . . 0.0 108.547 177.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.57 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 70.8 m-20 -148.39 50.39 1.02 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.981 -177.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 37.6 t -81.41 148.65 5.32 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 C-N-CA 118.951 -1.1 . . . . 0.0 109.719 -177.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 93.57 37.04 5.66 Favored Glycine 0 CA--C 1.529 0.944 0 N-CA-C 109.317 -1.513 . . . . 0.0 109.317 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . . . . . . . . . 2.9 p 73.18 120.21 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.114 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.617 ' ND2' ' N ' ' N' ' 27' ' ' ASN . 0.1 OUTLIER -83.09 162.44 21.34 Favored 'General case' 0 C--N 1.341 0.211 0 C-N-CA 118.262 -1.375 . . . . 0.0 111.499 -179.098 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.418 ' H ' ' HG2' ' N' ' 28' ' ' LYS . 72.5 mmtt -47.22 -37.17 9.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-N 114.663 -1.153 . . . . 0.0 112.955 176.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' M' ' 30' ' ' ALA . . . -178.96 77.99 0.06 OUTLIER Glycine 0 CA--C 1.539 1.579 0 CA-C-O 118.766 -1.019 . . . . 0.0 112.199 -173.387 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . 0.525 ' O ' ' HA ' ' O' ' 30' ' ' ALA . . . -79.26 107.51 12.07 Favored 'General case' 0 N--CA 1.481 1.098 0 CA-C-N 119.848 1.824 . . . . 0.0 112.835 -175.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.571 ' CD1' ' O ' ' H' ' 38' ' ' GLY . 18.4 tt -153.32 133.83 4.34 Favored 'Isoleucine or valine' 0 C--O 1.238 0.46 0 CA-C-N 113.627 -1.624 . . . . 0.0 111.336 -177.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.553 HD13 ' CD2' ' P' ' 19' ' ' PHE . 85.0 mt -106.96 108.26 24.76 Favored 'Isoleucine or valine' 0 C--N 1.341 0.198 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 177.226 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.807 ' O ' HD23 ' N' ' 34' ' ' LEU . . . -114.67 100.46 1.0 Allowed Glycine 0 N--CA 1.46 0.269 0 N-CA-C 108.04 -2.024 . . . . 0.0 108.04 178.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.807 HD23 ' O ' ' N' ' 33' ' ' GLY . 1.4 mt -146.59 157.91 43.81 Favored 'General case' 0 CA--C 1.5 -0.952 0 CA-C-O 123.665 1.698 . . . . 0.0 112.478 -178.047 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 8.0 mtp -113.79 108.53 17.22 Favored 'General case' 0 N--CA 1.426 -1.661 0 CA-C-N 111.156 -2.747 . . . . 0.0 104.604 175.088 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 2.5 t -87.25 100.96 10.73 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.707 0 N-CA-C 106.144 -1.798 . . . . 0.0 106.144 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.517 ' N ' ' O ' ' M' ' 36' ' ' VAL . . . -73.23 163.0 54.86 Favored Glycine 0 CA--C 1.52 0.353 0 CA-C-N 112.724 -2.034 . . . . 0.0 113.383 -178.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.586 ' N ' ' H ' ' M' ' 38' ' ' GLY . . . 114.92 60.72 0.37 Allowed Glycine 0 N--CA 1.471 0.972 0 C-N-CA 121.389 -0.434 . . . . 0.0 113.681 178.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 1.038 HG13 ' H ' ' O' ' 39' ' ' VAL . 57.3 t -71.09 130.91 34.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 119.442 -0.903 . . . . 0.0 109.501 178.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.519 HG22 ' CD2' ' P' ' 13' ' ' HIS . 10.8 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 117.999 -1.001 . . . . 0.0 111.3 -179.031 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.487 2.053 0 N-CA-C 109.236 -1.546 . . . . 0.0 109.236 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.48 132.97 52.64 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-O 120.759 0.314 . . . . 0.0 110.364 179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -123.58 121.83 36.61 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.131 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.412 ' CG2' HG12 ' N' ' 12' ' ' VAL . 2.3 m -131.43 155.27 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 179.826 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.594 ' HB2' ' HD1' ' P' ' 13' ' ' HIS . 86.7 m-70 -149.07 102.96 3.3 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.478 179.793 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.507 ' N ' ' CD2' ' O' ' 14' ' ' HIS . 0.1 OUTLIER -149.27 176.44 10.53 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.412 ' CG ' HD13 ' O' ' 17' ' ' LEU . 0.3 OUTLIER -149.25 140.0 22.7 Favored 'General case' 0 CA--C 1.535 0.385 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 174.616 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . 0.654 ' C ' HD12 ' O' ' 17' ' ' LEU . 54.1 mtmt -95.05 110.24 22.19 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.227 1.566 . . . . 0.0 115.227 -178.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.654 HD12 ' C ' ' O' ' 16' ' ' LYS . 10.9 mp -124.13 115.09 20.57 Favored 'General case' 0 N--CA 1.484 1.229 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 174.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 90.8 t -112.74 115.82 50.88 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.271 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.643 179.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.429 ' HZ ' HD23 ' O' ' 17' ' ' LEU . 48.4 m-85 -112.22 104.97 13.19 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -111.86 131.75 55.15 Favored 'General case' 0 N--CA 1.478 0.939 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 -179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.9 136.61 32.46 Favored 'General case' 0 N--CA 1.465 0.309 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 -177.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -95.2 113.86 25.58 Favored 'General case' 0 CA--C 1.52 -0.175 0 N-CA-C 105.824 -1.917 . . . . 0.0 105.824 175.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.446 ' CB ' HD21 ' N' ' 27' ' ' ASN . 18.1 m-20 -133.99 48.62 2.33 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 113.435 0.902 . . . . 0.0 113.435 -175.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.542 HG22 ' O ' ' P' ' 23' ' ' ASP . 18.6 t -72.88 161.09 5.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 C-N-CA 118.218 -1.393 . . . . 0.0 109.664 -179.406 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 108.27 -29.89 9.56 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 108.323 -1.911 . . . . 0.0 108.323 -178.71 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 1.2 m 92.83 114.21 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 113.66 -1.27 . . . . 0.0 107.791 -178.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.697 ' OD1' ' HB2' ' O' ' 30' ' ' ALA . 2.7 p30 -73.96 164.39 26.68 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.935 0.874 . . . . 0.0 113.071 -178.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -48.08 -36.28 12.84 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 114.041 -1.436 . . . . 0.0 112.862 177.211 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.38 78.5 0.07 OUTLIER Glycine 0 CA--C 1.532 1.119 0 C-N-CA 120.663 -0.779 . . . . 0.0 112.354 -173.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . 0.697 ' HB2' ' OD1' ' O' ' 27' ' ' ASN . . . -79.19 109.73 13.8 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 123.286 1.517 . . . . 0.0 110.955 -176.496 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.715 HD12 HG22 ' I' ' 39' ' ' VAL . 77.8 mt -133.15 142.21 42.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.713 0 CA-C-N 113.483 -1.689 . . . . 0.0 112.802 -176.859 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.499 ' CG2' HD12 ' O' ' 34' ' ' LEU . 52.9 mt -106.78 107.9 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.124 0 N-CA-C 108.042 -1.096 . . . . 0.0 108.042 175.799 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.05 104.97 2.23 Favored Glycine 0 C--O 1.239 0.437 0 N-CA-C 106.413 -2.675 . . . . 0.0 106.413 177.25 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.499 HD12 ' CG2' ' O' ' 32' ' ' ILE . 53.7 mt -140.35 144.0 36.06 Favored 'General case' 0 CA--C 1.504 -0.815 0 N-CA-C 114.546 1.313 . . . . 0.0 114.546 -175.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 3.0 mtp -116.42 109.22 17.02 Favored 'General case' 0 N--CA 1.443 -0.8 0 CA-C-N 112.212 -2.267 . . . . 0.0 105.038 175.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.426 ' HB ' HE22 ' Q' ' 15' ' ' GLN . 1.8 t -105.86 101.8 12.94 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.812 0.815 . . . . 0.0 111.05 -177.119 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 56.77 -179.11 0.65 Allowed Glycine 0 CA--C 1.538 1.5 0 CA-C-N 114.112 -1.404 . . . . 0.0 115.303 178.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . 0.69 ' H ' HG22 ' N' ' 39' ' ' VAL . . . -116.3 -58.3 0.32 Allowed Glycine 0 N--CA 1.481 1.638 0 CA-C-N 114.253 -0.973 . . . . 0.0 111.788 179.282 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 1.038 ' H ' HG13 ' N' ' 39' ' ' VAL . 45.5 t -115.84 124.92 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 N-CA-C 108.525 -0.917 . . . . 0.0 108.525 177.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.664 ' CG2' HE22 ' R' ' 15' ' ' GLN . 12.3 m . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 117.978 -1.01 . . . . 0.0 110.451 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 39.9 p90 -148.65 158.73 44.34 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-O 120.832 0.348 . . . . 0.0 110.768 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -86.31 123.8 31.97 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.839 -179.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.533 HG23 ' HE2' ' P' ' 14' ' ' HIS . 2.2 p -130.04 132.3 65.53 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.801 179.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.594 ' HD1' ' HB2' ' O' ' 13' ' ' HIS . 7.5 t60 -144.98 134.25 22.9 Favored 'General case' 0 CA--C 1.518 -0.263 0 CA-C-O 120.835 0.35 . . . . 0.0 111.091 -179.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.688 ' CE1' ' H ' ' Q' ' 14' ' ' HIS . 18.9 m-70 -147.45 156.42 42.85 Favored 'General case' 0 CA--C 1.531 0.249 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 175.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.515 HE22 ' CE1' ' P' ' 13' ' ' HIS . 3.1 mp0 -90.42 160.35 16.1 Favored 'General case' 0 C--O 1.225 -0.237 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 177.021 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -140.09 95.52 2.9 Favored 'General case' 0 C--N 1.319 -0.752 0 C-N-CA 120.116 -0.633 . . . . 0.0 110.725 177.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 4.4 mp -136.22 130.64 33.43 Favored 'General case' 0 N--CA 1.476 0.846 0 CA-C-O 121.142 0.496 . . . . 0.0 111.122 179.03 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 24.1 t -119.94 115.21 46.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 115.517 -0.765 . . . . 0.0 109.489 179.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.553 ' CD2' HD13 ' N' ' 32' ' ' ILE . 19.3 m-85 -109.09 111.87 23.73 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 178.879 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 12.6 t80 -127.01 123.45 37.1 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 113.297 0.851 . . . . 0.0 113.297 -176.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.18 121.85 43.31 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 107.178 -1.415 . . . . 0.0 107.178 176.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . . . . . . . . . 77.9 tt0 -93.86 152.41 18.91 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 117.843 2.535 . . . . 0.0 117.843 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.542 ' O ' HG22 ' O' ' 24' ' ' VAL . 93.3 m-20 27.92 51.52 0.05 OUTLIER 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 111.238 -2.71 . . . . 0.0 117.807 175.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 65.1 t -81.69 141.23 15.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.391 0 C-N-CA 117.13 -1.828 . . . . 0.0 106.181 175.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.441 ' O ' ' O ' ' Q' ' 24' ' ' VAL . . . -71.53 -41.54 57.51 Favored Glycine 0 C--N 1.334 0.444 0 C-N-CA 117.584 -2.246 . . . . 0.0 110.809 -179.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.422 ' O ' ' C ' ' P' ' 27' ' ' ASN . 42.3 t -156.63 112.3 2.93 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-O 118.355 -0.831 . . . . 0.0 109.452 176.15 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.642 HD21 ' HB3' ' O' ' 30' ' ' ALA . 7.4 t-20 -48.96 157.78 0.38 Allowed 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 117.75 -1.58 . . . . 0.0 108.127 178.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -69.65 -47.88 61.83 Favored 'General case' 0 C--N 1.316 -0.881 0 C-N-CA 119.367 -0.933 . . . . 0.0 111.665 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . . . . . . . . . . . 179.82 61.21 0.08 OUTLIER Glycine 0 CA--C 1.536 1.405 0 CA-C-N 114.261 -1.336 . . . . 0.0 109.768 -176.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . 0.485 ' CB ' ' O ' ' O' ' 30' ' ' ALA . . . -85.09 158.43 20.43 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 123.668 1.699 . . . . 0.0 115.377 -172.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.908 HD12 HG22 ' J' ' 39' ' ' VAL . 65.1 mt -145.05 148.3 17.96 Favored 'Isoleucine or valine' 0 C--O 1.236 0.355 0 CA-C-N 112.342 -2.208 . . . . 0.0 113.482 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 52.9 mt -106.19 107.64 23.17 Favored 'Isoleucine or valine' 0 C--N 1.35 0.625 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 175.159 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.89 101.38 2.27 Favored Glycine 0 N--CA 1.463 0.462 0 N-CA-C 104.215 -3.554 . . . . 0.0 104.215 175.292 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.419 HD23 HD22 ' Q' ' 34' ' ' LEU . 26.4 tp -133.49 130.25 38.3 Favored 'General case' 0 C--O 1.239 0.544 0 N-CA-C 115.979 1.844 . . . . 0.0 115.979 -173.008 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 40.2 tpp -111.27 109.27 19.22 Favored 'General case' 0 N--CA 1.45 -0.465 0 N-CA-C 105.793 -1.928 . . . . 0.0 105.793 174.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.644 HG13 ' NE2' ' Q' ' 15' ' ' GLN . 10.6 t -100.13 102.8 13.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.91 0.386 . . . . 0.0 110.573 -177.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 58.0 163.48 0.06 OUTLIER Glycine 0 CA--C 1.528 0.868 0 N-CA-C 110.835 -0.906 . . . . 0.0 110.835 -179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' O' ' 38' ' ' GLY . . . -94.57 -58.03 1.22 Allowed Glycine 0 CA--C 1.536 1.392 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.241 179.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.674 ' HB ' HD13 ' D' ' 31' ' ' ILE . 24.0 t -151.28 138.89 13.82 Favored 'Isoleucine or valine' 0 C--N 1.347 0.479 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.666 ' H ' ' C ' ' Q' ' 38' ' ' GLY . 31.1 t . . . . . 0 C--O 1.214 -0.789 0 CA-C-O 117.49 -1.243 . . . . 0.0 108.435 -177.299 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.471 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.9 m-85 -107.08 131.07 54.51 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -149.43 137.58 20.6 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.978 0.418 . . . . 0.0 110.348 179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -127.58 118.44 49.35 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.571 -179.688 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.522 ' NE2' ' C ' ' O' ' 40' ' ' VAL . 12.0 p-80 -158.47 121.05 3.7 Favored 'General case' 0 C--N 1.332 -0.156 0 C-N-CA 119.393 -0.923 . . . . 0.0 112.868 179.674 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.688 ' H ' ' CE1' ' P' ' 14' ' ' HIS . 4.1 p-80 -148.8 165.62 30.9 Favored 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 176.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.644 ' NE2' HG13 ' P' ' 36' ' ' VAL . 9.8 pt20 -99.75 149.93 22.84 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 119.921 -0.712 . . . . 0.0 110.454 178.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -114.74 98.61 6.95 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.637 -0.256 . . . . 0.0 110.951 178.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.447 ' HB3' ' CZ ' ' Q' ' 19' ' ' PHE . 6.0 mp -123.2 116.98 24.3 Favored 'General case' 0 N--CA 1.474 0.768 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 177.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 90.7 t -107.88 111.14 34.58 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.272 179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.485 ' CE1' ' CD1' ' P' ' 19' ' ' PHE . 37.1 m-85 -107.21 107.34 18.25 Favored 'General case' 0 C--O 1.234 0.264 0 N-CA-C 106.518 -1.66 . . . . 0.0 106.518 178.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.632 ' CE2' ' CD1' ' R' ' 20' ' ' PHE . 12.9 t80 -122.52 124.92 44.66 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 113.12 0.785 . . . . 0.0 113.12 -176.27 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.36 118.31 27.21 Favored 'General case' 0 C--O 1.243 0.711 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 177.44 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.409 ' OE1' ' OD1' ' P' ' 23' ' ' ASP . 82.7 tt0 -82.77 146.24 29.09 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -176.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.492 ' O ' ' O ' ' R' ' 22' ' ' GLU . 64.2 t0 63.87 -52.13 0.25 Allowed 'General case' 0 CA--C 1.535 0.396 0 CA-C-N 113.878 -1.51 . . . . 0.0 112.089 179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.54 HG12 ' H ' ' Q' ' 25' ' ' GLY . 0.8 OUTLIER 50.51 -153.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 C-N-CA 120.22 -0.592 . . . . 0.0 111.302 177.842 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.54 ' H ' HG12 ' Q' ' 24' ' ' VAL . . . 143.39 19.03 0.22 Allowed Glycine 0 N--CA 1.464 0.544 0 N-CA-C 108.844 -1.702 . . . . 0.0 108.844 -177.026 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . 0.568 ' OG ' ' HB2' ' Q' ' 30' ' ' ALA . 0.3 OUTLIER -63.13 129.9 42.3 Favored 'General case' 0 CA--C 1.537 0.452 0 CA-C-N 114.691 -0.754 . . . . 0.0 109.342 -178.22 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.477 ' CG ' ' H ' ' Q' ' 28' ' ' LYS . 45.3 t-20 -126.98 -130.62 0.23 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-N 114.353 -1.294 . . . . 0.0 112.186 -174.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.477 ' H ' ' CG ' ' Q' ' 27' ' ' ASN . 74.1 mmtt -38.79 -46.87 1.32 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.041 -0.982 . . . . 0.0 111.483 -176.591 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . -101.19 52.44 0.9 Allowed Glycine 0 CA--C 1.547 2.058 0 C-N-CA 120.929 -0.653 . . . . 0.0 112.786 -177.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . 0.568 ' HB2' ' OG ' ' Q' ' 26' ' ' SER . . . -128.8 127.43 41.95 Favored 'General case' 0 C--N 1.355 0.842 0 CA-C-O 120.915 0.388 . . . . 0.0 110.103 179.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.699 HG23 ' HB ' ' R' ' 31' ' ' ILE . 28.9 mt -142.81 153.25 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.222 0 CA-C-O 121.821 0.819 . . . . 0.0 113.064 -177.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . 0.491 HD12 ' CD1' ' R' ' 32' ' ' ILE . 86.5 mt -136.22 123.34 33.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 O-C-N 121.795 -0.565 . . . . 0.0 110.34 179.113 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.4 110.66 1.29 Allowed Glycine 0 N--CA 1.468 0.77 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . 0.419 HD22 HD23 ' P' ' 34' ' ' LEU . 28.4 mt -119.34 121.2 39.03 Favored 'General case' 0 C--N 1.344 0.339 0 CA-C-O 120.634 0.255 . . . . 0.0 111.444 -178.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . 0.4 ' SD ' ' HB2' ' R' ' 35' ' ' MET . 95.3 mmm -111.33 127.61 55.7 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 177.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.425 HG13 ' HG3' ' R' ' 15' ' ' GLN . 53.6 t -122.79 131.73 72.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 CA-C-N 118.69 0.677 . . . . 0.0 112.103 -179.311 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . . . . . . . . . . . -55.82 -111.52 0.01 OUTLIER Glycine 0 CA--C 1.528 0.882 0 CA-C-N 115.214 -0.903 . . . . 0.0 111.743 178.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.688 ' O ' HG23 ' Q' ' 39' ' ' VAL . . . 95.86 -72.92 0.87 Allowed Glycine 0 CA--C 1.537 1.436 0 N-CA-C 111.962 -0.455 . . . . 0.0 111.962 179.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.688 HG23 ' O ' ' Q' ' 38' ' ' GLY . 14.2 t -164.1 121.34 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.274 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . 0.52 ' O ' HG21 ' F' ' 31' ' ' ILE . 58.7 t . . . . . 0 N--CA 1.475 0.795 0 CA-C-O 117.841 -1.076 . . . . 0.0 110.992 -179.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.198 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 51.5 t80 -82.69 131.06 35.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.811 0.339 . . . . 0.0 110.93 179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.526 ' N ' ' OE1' ' R' ' 11' ' ' GLU . 56.3 mp0 -118.98 148.43 42.98 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.154 -0.476 . . . . 0.0 109.815 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 20.1 t -106.97 98.05 6.44 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-O 121.494 0.664 . . . . 0.0 110.885 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . . . . . . . . . 18.8 m170 -120.25 93.5 4.07 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 114.462 -1.245 . . . . 0.0 109.901 179.004 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -153.88 164.02 39.08 Favored 'General case' 0 C--O 1.222 -0.392 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 178.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.664 HE22 ' CG2' ' O' ' 40' ' ' VAL . 90.4 mm-40 -89.85 158.41 17.47 Favored 'General case' 0 C--N 1.326 -0.444 0 C-N-CA 120.668 -0.413 . . . . 0.0 110.417 179.672 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 13.5 tttt -140.4 90.13 2.33 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 177.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.464 HD21 HE21 ' Q' ' 15' ' ' GLN . 4.8 mp -134.37 120.14 19.48 Favored 'General case' 0 CA--C 1.51 -0.568 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 94.2 t -104.89 113.5 42.1 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 -179.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.408 ' CE1' HD22 ' P' ' 34' ' ' LEU . 25.1 m-85 -104.9 98.05 7.83 Favored 'General case' 0 CA--C 1.513 -0.449 0 N-CA-C 106.028 -1.842 . . . . 0.0 106.028 177.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . 0.632 ' CD1' ' CE2' ' Q' ' 20' ' ' PHE . 42.0 t80 -115.22 114.28 25.02 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-O 121.58 0.705 . . . . 0.0 110.847 -178.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.405 ' O ' ' N ' ' R' ' 23' ' ' ASP . . . -128.37 125.11 38.0 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 107.228 -1.397 . . . . 0.0 107.228 178.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.492 ' O ' ' O ' ' Q' ' 23' ' ' ASP . 81.0 tt0 -71.5 85.13 0.84 Allowed 'General case' 0 C--O 1.223 -0.319 0 C-N-CA 117.414 -1.714 . . . . 0.0 106.958 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.405 ' N ' ' O ' ' R' ' 21' ' ' ALA . 51.2 p30 -132.72 51.89 2.12 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.459 -176.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . . . . . . . . . 69.5 t -74.82 143.29 13.55 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.739 0 N-CA-C 108.064 -1.087 . . . . 0.0 108.064 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.19 37.56 3.8 Favored Glycine 0 CA--C 1.528 0.86 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -177.037 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 42.5 t -75.53 101.93 5.06 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-O 121.47 0.652 . . . . 0.0 110.201 -179.426 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 85.8 m-20 -96.44 -163.15 1.02 Allowed 'General case' 0 CA--C 1.542 0.654 0 CA-C-N 114.6 -1.182 . . . . 0.0 112.965 -177.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -47.72 -42.14 24.51 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 114.225 -1.352 . . . . 0.0 113.701 -177.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -93.99 61.68 1.92 Allowed Glycine 0 CA--C 1.54 1.652 0 C-N-CA 120.301 -0.952 . . . . 0.0 114.187 -175.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -158.09 135.02 9.89 Favored 'General case' 0 N--CA 1.455 -0.213 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 177.55 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . 0.699 ' HB ' HG23 ' Q' ' 31' ' ' ILE . 96.6 mt -118.01 128.45 75.11 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.265 0 CA-C-O 121.399 0.619 . . . . 0.0 111.965 -178.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . 0.491 ' CD1' HD12 ' Q' ' 32' ' ' ILE . 48.2 mm -120.4 123.34 70.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.082 -0.963 . . . . 0.0 108.894 178.634 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.66 118.05 2.8 Favored Glycine 0 N--CA 1.468 0.786 0 N-CA-C 111.46 -0.656 . . . . 0.0 111.46 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.401 ' CD2' HD12 ' Q' ' 34' ' ' LEU . 67.8 mt -116.54 114.9 24.81 Favored 'General case' 0 CA--C 1.518 -0.269 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.238 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . 0.4 ' HB2' ' SD ' ' Q' ' 35' ' ' MET . 85.9 mmm -134.27 136.23 43.43 Favored 'General case' 0 C--N 1.33 -0.257 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.042 -178.455 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 p -136.63 155.84 34.43 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 121.33 0.585 . . . . 0.0 111.006 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -52.93 -102.27 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.149 178.312 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 49.24 71.06 0.66 Allowed Glycine 0 CA--C 1.529 0.939 0 CA-C-N 115.148 -0.526 . . . . 0.0 111.807 -178.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.572 HG12 ' N ' ' R' ' 40' ' ' VAL . 59.9 t -112.29 165.69 7.03 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.644 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 179.471 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . 0.572 ' N ' HG12 ' R' ' 39' ' ' VAL . 15.5 m . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.048 -0.977 . . . . 0.0 110.101 -179.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.321 0 N-CA-C 109.814 -1.314 . . . . 0.0 109.814 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 99.1 m-85 -112.91 133.69 54.77 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.22 -0.289 . . . . 0.0 110.22 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -128.08 132.17 49.04 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.141 179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 13.3 m -136.23 140.34 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.476 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 30.2 p-80 -142.11 158.37 43.82 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.069 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.614 ' CD2' ' N ' ' A' ' 14' ' ' HIS . 0.0 OUTLIER -89.26 169.56 11.34 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.934 0.397 . . . . 0.0 110.642 -179.021 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 59.0 tt0 -129.42 150.71 50.65 Favored 'General case' 0 CA--C 1.519 -0.232 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 177.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -97.14 118.92 34.63 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.691 178.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 93.3 mt -124.77 114.9 19.88 Favored 'General case' 0 N--CA 1.469 0.488 0 N-CA-C 109.139 -0.689 . . . . 0.0 109.139 177.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -132.83 136.4 55.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-N 116.351 -0.386 . . . . 0.0 109.977 -179.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 88.6 m-85 -128.03 130.52 48.42 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.456 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 72.2 t80 -123.6 120.49 32.97 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.21 -0.45 . . . . 0.0 109.999 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.04 127.43 48.77 Favored 'General case' 0 N--CA 1.475 0.803 0 N-CA-C 110.19 -0.3 . . . . 0.0 110.19 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.404 ' CD ' ' OE1' ' B' ' 22' ' ' GLU . 83.2 tt0 -147.95 149.14 31.66 Favored 'General case' 0 CA--C 1.533 0.327 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -178.327 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.0 t0 51.68 46.38 26.62 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 115.531 1.678 . . . . 0.0 115.531 176.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.734 HG12 ' H ' ' A' ' 25' ' ' GLY . 41.2 t -102.45 -177.87 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 176.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.734 ' H ' HG12 ' A' ' 24' ' ' VAL . . . -70.41 -32.83 68.06 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 109.406 -1.478 . . . . 0.0 109.406 177.733 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.497 ' O ' ' O ' ' A' ' 27' ' ' ASN . 46.7 t -152.36 123.27 7.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 114.013 -1.093 . . . . 0.0 108.25 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.732 ' H ' ' NZ ' ' B' ' 28' ' ' LYS . 9.9 t-20 -40.88 166.61 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 120.051 -0.659 . . . . 0.0 110.246 -179.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.581 ' H ' ' ND2' ' A' ' 27' ' ' ASN . 68.1 mttm -78.66 40.42 0.38 Allowed 'General case' 0 C--N 1.326 -0.436 0 C-N-CA 119.418 -0.913 . . . . 0.0 111.961 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.422 ' C ' ' H ' ' A' ' 31' ' ' ILE . . . 119.57 78.37 0.56 Allowed Glycine 0 CA--C 1.533 1.167 0 CA-C-O 118.362 -1.243 . . . . 0.0 113.938 177.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -81.68 43.41 0.75 Allowed 'General case' 0 N--CA 1.491 1.619 0 CA-C-N 121.011 2.405 . . . . 0.0 110.9 178.628 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.422 ' H ' ' C ' ' A' ' 29' ' ' GLY . 54.9 mt -150.47 126.94 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.005 0 CA-C-N 113.148 -1.842 . . . . 0.0 106.866 178.871 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.432 ' O ' ' O ' ' B' ' 33' ' ' GLY . 50.7 mt -105.89 110.2 30.46 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.341 0 N-CA-C 108.987 -0.745 . . . . 0.0 108.987 179.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.56 93.7 0.57 Allowed Glycine 0 CA--C 1.508 -0.368 0 N-CA-C 105.614 -2.994 . . . . 0.0 105.614 177.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 89.5 mt -147.17 168.04 22.67 Favored 'General case' 0 N--CA 1.473 0.691 0 CA-C-O 122.998 1.38 . . . . 0.0 114.133 -176.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 86.8 mmm -120.22 110.64 16.84 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 112.224 -2.262 . . . . 0.0 107.229 178.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG2' HD11 ' B' ' 34' ' ' LEU . 2.9 t -97.92 113.44 32.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 C-N-CA 119.968 -0.693 . . . . 0.0 109.498 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 157.68 -125.03 1.49 Allowed Glycine 0 C--N 1.315 -0.596 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.24 -62.89 0.37 Allowed Glycine 0 CA--C 1.546 1.987 0 N-CA-C 112.561 -0.216 . . . . 0.0 112.561 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.552 ' O ' HG21 ' B' ' 39' ' ' VAL . 2.9 m -134.73 159.9 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 116.999 0.399 . . . . 0.0 110.009 179.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.473 HG21 ' CA ' ' H' ' 29' ' ' GLY . 42.9 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 118.019 -0.991 . . . . 0.0 110.336 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -108.94 146.06 34.42 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.644 0.259 . . . . 0.0 110.358 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.45 ' OE1' ' N ' ' B' ' 11' ' ' GLU . 58.5 mp0 -72.68 119.31 16.73 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.963 0.411 . . . . 0.0 110.263 179.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.457 ' CG2' ' NE2' ' A' ' 14' ' ' HIS . 26.0 m -134.89 161.01 40.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 CA-C-N 115.884 -0.598 . . . . 0.0 109.835 -179.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 86.2 t60 -131.32 96.15 3.94 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 121.075 0.464 . . . . 0.0 111.704 -179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.561 ' CD2' ' NE2' ' C' ' 14' ' ' HIS . 24.6 p80 -156.89 169.15 25.43 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 177.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 47.6 tt0 -129.51 150.45 50.85 Favored 'General case' 0 N--CA 1.461 0.121 0 CA-C-O 120.956 0.407 . . . . 0.0 110.128 178.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -98.37 119.94 37.93 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.843 -0.617 . . . . 0.0 109.722 177.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.606 ' C ' HD23 ' B' ' 17' ' ' LEU . 7.0 tt -122.76 122.79 39.55 Favored 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 118.194 0.452 . . . . 0.0 110.537 179.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.53 ' N ' HD23 ' B' ' 17' ' ' LEU . 69.3 t -126.22 128.76 71.88 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.239 179.832 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 t80 -124.6 114.06 18.88 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.872 0.368 . . . . 0.0 110.022 179.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.643 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 32.7 t80 -115.34 119.98 38.08 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.978 -0.556 . . . . 0.0 109.647 -179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.452 ' HB1' ' ND2' ' A' ' 27' ' ' ASN . . . -132.13 128.28 37.76 Favored 'General case' 0 C--O 1.24 0.566 0 CA-C-O 121.718 0.771 . . . . 0.0 112.219 -178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.404 ' OE1' ' CD ' ' A' ' 22' ' ' GLU . 87.8 mt-10 -96.73 111.98 23.92 Favored 'General case' 0 CA--C 1.517 -0.307 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.055 178.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 55.4 m-20 -104.17 46.42 0.92 Allowed 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.06 -178.736 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.726 HG12 ' H ' ' B' ' 25' ' ' GLY . 20.7 t -82.33 176.07 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.537 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.629 -178.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.726 ' H ' HG12 ' B' ' 24' ' ' VAL . . . 91.87 -28.27 8.84 Favored Glycine 0 N--CA 1.465 0.622 0 N-CA-C 109.713 -1.355 . . . . 0.0 109.713 -177.993 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . . . . . . . . . 2.1 p 166.31 131.52 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.416 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 60.1 t-20 -45.84 130.84 9.54 Favored 'General case' 0 C--N 1.326 -0.43 0 C-N-CA 120.39 -0.524 . . . . 0.0 110.607 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.732 ' NZ ' ' H ' ' A' ' 27' ' ' ASN . 98.7 mttt -89.28 -46.61 8.64 Favored 'General case' 0 CA--C 1.538 0.518 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 -178.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 130.36 60.92 0.1 OUTLIER Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.588 -1.291 . . . . 0.0 113.28 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.86 113.95 8.44 Favored 'General case' 0 CA--C 1.549 0.909 0 N-CA-C 114.968 1.47 . . . . 0.0 114.968 -176.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 93.0 mt -127.66 130.1 70.28 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.749 0 CA-C-N 112.696 -2.047 . . . . 0.0 109.702 178.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.515 HD13 ' CD2' ' D' ' 19' ' ' PHE . 94.3 mt -110.06 116.33 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.246 0 O-C-N 121.578 -0.701 . . . . 0.0 110.551 178.443 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -118.97 96.17 0.65 Allowed Glycine 0 C--O 1.238 0.352 0 N-CA-C 104.924 -3.271 . . . . 0.0 104.924 176.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.483 HD11 ' CG2' ' A' ' 36' ' ' VAL . 20.5 tp -135.9 136.74 40.74 Favored 'General case' 0 CA--C 1.502 -0.889 0 C-N-CA 119.268 -0.973 . . . . 0.0 113.099 -174.375 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 13.4 mtp -106.39 108.75 20.42 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 176.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.59 ' HB ' HG13 ' C' ' 36' ' ' VAL . 2.5 t -102.1 103.33 14.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 108.455 -0.943 . . . . 0.0 108.455 -179.456 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.99 -153.61 25.11 Favored Glycine 0 N--CA 1.447 -0.622 0 N-CA-C 109.438 -1.465 . . . . 0.0 109.438 -178.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.501 ' O ' HG11 ' C' ' 39' ' ' VAL . . . 115.44 -55.79 0.53 Allowed Glycine 0 CA--C 1.538 1.49 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -178.193 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.818 ' C ' HG21 ' C' ' 39' ' ' VAL . 27.8 m -124.05 137.02 58.44 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 C-N-CA 123.449 0.7 . . . . 0.0 111.279 -179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.523 ' O ' ' CE1' ' D' ' 13' ' ' HIS . 40.2 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.651 179.171 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.409 -1.477 . . . . 0.0 109.409 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -105.35 135.37 46.86 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.934 0.397 . . . . 0.0 110.468 -179.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.412 ' O ' ' OE2' ' D' ' 11' ' ' GLU . 80.1 mm-40 -138.24 139.53 39.27 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.384 -179.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.432 HG13 ' H ' ' D' ' 12' ' ' VAL . 3.4 t -106.7 91.22 1.71 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 N-CA-C 109.291 -0.633 . . . . 0.0 109.291 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 8.3 p80 -104.39 131.17 52.04 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.2 0.524 . . . . 0.0 111.997 -177.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.561 ' NE2' ' CD2' ' B' ' 14' ' ' HIS . 1.0 OUTLIER -151.0 165.23 34.4 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.492 -0.776 . . . . 0.0 110.534 179.285 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 95.8 mm-40 -90.02 151.94 21.42 Favored 'General case' 0 CA--C 1.52 -0.207 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 178.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.0 mttt -148.4 99.12 2.99 Favored 'General case' 0 C--N 1.31 -1.151 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 4.9 mp -131.28 128.99 40.95 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.447 0.641 . . . . 0.0 111.399 -179.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 59.9 t -117.99 114.56 45.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 N-CA-C 108.425 -0.954 . . . . 0.0 108.425 178.185 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 65.2 m-85 -109.05 107.83 18.32 Favored 'General case' 0 CA--C 1.538 0.492 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.643 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 17.1 t80 -113.77 124.86 53.27 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 122.009 0.123 . . . . 0.0 111.114 -178.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.82 131.83 21.67 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 120.262 -0.575 . . . . 0.0 112.516 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -116.04 112.43 21.77 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-O 121.179 0.514 . . . . 0.0 110.711 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.452 ' OD1' ' OD2' ' D' ' 23' ' ' ASP . 13.6 p-10 -124.86 46.56 2.3 Favored 'General case' 0 N--CA 1.472 0.668 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.559 -178.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.765 HG12 ' H ' ' C' ' 25' ' ' GLY . 21.8 t -73.38 179.74 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.979 0 CA-C-N 114.962 -1.017 . . . . 0.0 111.774 -178.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.765 ' H ' HG12 ' C' ' 24' ' ' VAL . . . 99.26 -35.38 4.73 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-N 114.329 -1.305 . . . . 0.0 113.413 179.115 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.489 ' O ' ' O ' ' C' ' 27' ' ' ASN . 28.6 t -162.38 117.53 1.87 Allowed 'General case' 0 N--CA 1.472 0.626 0 CA-C-N 119.6 1.7 . . . . 0.0 112.548 175.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.794 ' N ' HG21 ' D' ' 24' ' ' VAL . 67.2 m-20 -23.23 151.39 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 CA-C-O 118.976 -0.535 . . . . 0.0 112.232 175.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 39.5 tttp -167.55 31.36 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.447 0 N-CA-C 115.168 1.544 . . . . 0.0 115.168 173.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.412 ' N ' ' OD1' ' D' ' 27' ' ' ASN . . . 81.01 80.81 0.85 Allowed Glycine 0 CA--C 1.535 1.328 0 C-N-CA 117.886 -2.102 . . . . 0.0 114.097 175.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -101.93 119.49 38.88 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-N 119.447 1.623 . . . . 0.0 109.669 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.607 HD11 HG23 ' P' ' 39' ' ' VAL . 82.9 mt -123.14 132.53 71.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.845 0 N-CA-C 112.998 0.74 . . . . 0.0 112.998 -177.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.423 HG23 ' CD1' ' C' ' 34' ' ' LEU . 2.8 mt -105.79 108.45 25.06 Favored 'Isoleucine or valine' 0 C--O 1.231 0.117 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 174.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.412 ' O ' ' O ' ' B' ' 32' ' ' ILE . . . -123.64 106.76 1.01 Allowed Glycine 0 N--CA 1.465 0.577 0 N-CA-C 109.135 -1.586 . . . . 0.0 109.135 -179.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.423 ' CD1' HG23 ' C' ' 32' ' ' ILE . 3.0 mp -139.27 143.36 37.91 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 122.702 1.239 . . . . 0.0 113.434 -177.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 96.3 mmm -113.49 103.66 11.49 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 103.942 -2.614 . . . . 0.0 103.942 175.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.951 HG11 HD11 ' E' ' 17' ' ' LEU . 2.4 t -111.72 102.91 14.64 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 -176.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 165.09 -151.78 20.89 Favored Glycine 0 C--N 1.31 -0.879 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 -178.427 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . 0.687 ' O ' HG11 ' D' ' 39' ' ' VAL . . . 102.91 -56.81 0.6 Allowed Glycine 0 CA--C 1.54 1.618 0 C-N-CA 120.459 -0.877 . . . . 0.0 111.725 -179.183 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.818 HG21 ' C ' ' B' ' 39' ' ' VAL . 33.6 m -135.81 163.71 34.14 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 123.037 0.535 . . . . 0.0 111.095 -179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 96.5 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.987 -179.434 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -149.34 158.15 43.93 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-O 120.844 0.354 . . . . 0.0 110.439 179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.412 ' OE2' ' O ' ' C' ' 11' ' ' GLU . 83.3 tt0 -154.96 131.5 10.55 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 121.037 0.446 . . . . 0.0 110.488 179.715 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.432 ' H ' HG13 ' C' ' 12' ' ' VAL . 2.4 p -139.4 137.43 40.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.237 -179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.811 ' CD2' ' HD1' ' E' ' 13' ' ' HIS . 5.7 p80 -133.52 119.44 19.53 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -149.07 164.86 33.42 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.528 0.68 . . . . 0.0 112.144 -178.449 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.568 ' CD ' HG12 ' B' ' 36' ' ' VAL . 85.1 mt-30 -84.49 156.59 21.64 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 107.71 -1.218 . . . . 0.0 107.71 176.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -159.26 105.87 1.73 Allowed 'General case' 0 C--N 1.306 -1.293 0 C-N-CA 120.043 -0.663 . . . . 0.0 109.237 179.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.453 ' CD1' HG11 ' B' ' 36' ' ' VAL . 3.4 mp -136.67 127.85 28.01 Favored 'General case' 0 CA--C 1.515 -0.382 0 CA-C-O 121.434 0.635 . . . . 0.0 111.695 -179.334 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 22.6 t -109.72 115.43 49.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.347 178.46 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' E' ' 19' ' ' PHE . 35.2 m-85 -108.55 106.95 17.26 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 47.3 t80 -111.87 119.01 37.1 Favored 'General case' 0 N--CA 1.468 0.474 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.851 -179.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.73 138.57 28.93 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 119.569 -0.852 . . . . 0.0 112.968 -179.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.431 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 97.3 mt-10 -120.15 133.45 55.5 Favored 'General case' 0 N--CA 1.477 0.9 0 CA-C-N 115.485 -0.78 . . . . 0.0 110.776 179.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.616 ' C ' HG23 ' D' ' 24' ' ' VAL . 0.0 OUTLIER -149.41 59.78 1.02 Allowed 'General case' 0 CA--C 1.541 0.609 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 179.878 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.999 HG12 ' H ' ' D' ' 25' ' ' GLY . 4.4 t 91.3 -169.67 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.51 -0.572 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 176.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.999 ' H ' HG12 ' D' ' 24' ' ' VAL . . . -76.98 -33.82 44.36 Favored Glycine 0 C--O 1.214 -1.146 0 N-CA-C 109.953 -1.259 . . . . 0.0 109.953 178.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.449 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 5.3 p -147.3 118.4 7.74 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.289 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.412 ' OD1' ' N ' ' C' ' 29' ' ' GLY . 17.7 t-20 -59.93 169.03 1.59 Allowed 'General case' 0 C--N 1.333 -0.113 0 C-N-CA 118.49 -1.284 . . . . 0.0 110.884 -179.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -55.25 -38.06 68.04 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.839 177.693 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.58 71.42 0.1 Allowed Glycine 0 CA--C 1.533 1.215 0 CA-C-N 114.489 -1.232 . . . . 0.0 110.829 -174.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -71.49 135.27 47.05 Favored 'General case' 0 C--O 1.245 0.832 0 CA-C-N 118.785 1.293 . . . . 0.0 112.694 -174.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.565 ' CD1' ' O ' ' P' ' 38' ' ' GLY . 77.9 mt -139.28 134.62 40.64 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.645 0 CA-C-N 113.845 -1.525 . . . . 0.0 114.09 -176.29 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 3.6 mt -107.48 111.22 34.83 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 174.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.55 103.45 0.92 Allowed Glycine 0 N--CA 1.46 0.297 0 N-CA-C 106.557 -2.617 . . . . 0.0 106.557 177.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.504 HD23 ' N ' ' D' ' 35' ' ' MET . 6.1 tt -140.8 146.63 37.87 Favored 'General case' 0 CA--C 1.513 -0.463 0 C-N-CA 119.055 -1.058 . . . . 0.0 113.171 -176.051 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.504 ' N ' HD23 ' D' ' 34' ' ' LEU . 17.9 mtp -120.21 115.25 23.25 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.194 178.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.784 HG11 HD11 ' F' ' 17' ' ' LEU . 0.0 OUTLIER -115.97 102.83 14.26 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.201 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 178.675 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.45 ' HA2' ' H ' ' E' ' 38' ' ' GLY . . . 166.27 -151.31 19.53 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 119.66 -1.257 . . . . 0.0 110.561 179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.426 ' H ' ' CG1' ' E' ' 40' ' ' VAL . . . 99.7 -57.4 0.84 Allowed Glycine 0 CA--C 1.544 1.88 0 C-N-CA 120.62 -0.8 . . . . 0.0 111.484 -178.382 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.751 HG21 ' C ' ' C' ' 39' ' ' VAL . 27.7 m -134.93 159.92 41.33 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 C-N-CA 123.356 0.662 . . . . 0.0 110.773 -178.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.986 -1.006 . . . . 0.0 110.53 -179.603 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.809 -1.316 . . . . 0.0 109.809 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 92.5 m-85 -105.48 134.76 48.06 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.803 0.335 . . . . 0.0 110.385 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -142.07 146.0 34.96 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.173 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.503 ' CG2' ' CD2' ' E' ' 14' ' ' HIS . 3.3 p -139.83 148.69 22.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-O 121.065 0.459 . . . . 0.0 110.716 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.811 ' HD1' ' CD2' ' D' ' 13' ' ' HIS . 0.1 OUTLIER -143.27 119.26 10.66 Favored 'General case' 0 CA--C 1.532 0.259 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.755 179.763 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.591 ' HE2' HG12 ' F' ' 12' ' ' VAL . 90.1 m-70 -143.9 164.35 30.81 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 119.973 -0.691 . . . . 0.0 111.014 178.313 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.619 HE21 HD21 ' E' ' 17' ' ' LEU . 64.4 tp60 -89.98 151.93 21.45 Favored 'General case' 0 N--CA 1.451 -0.385 0 N-CA-C 108.691 -0.855 . . . . 0.0 108.691 177.526 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -148.74 98.8 2.91 Favored 'General case' 0 C--N 1.315 -0.907 0 C-N-CA 119.88 -0.728 . . . . 0.0 110.782 177.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.951 HD11 HG11 ' C' ' 36' ' ' VAL . 37.1 mt -122.8 119.33 30.26 Favored 'General case' 0 CA--C 1.509 -0.615 0 C-N-CA 120.573 -0.451 . . . . 0.0 110.081 178.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 40.3 t -107.62 104.32 16.89 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 107.654 -1.239 . . . . 0.0 107.654 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.571 ' CD1' ' CD1' ' D' ' 19' ' ' PHE . 73.9 m-85 -103.67 105.69 15.99 Favored 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 179.662 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.421 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 2.7 m-85 -107.49 114.57 28.66 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 110.379 -0.23 . . . . 0.0 110.379 -179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.47 138.43 31.0 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 119.096 -1.042 . . . . 0.0 112.623 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -84.59 141.85 30.39 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-N 115.131 -0.941 . . . . 0.0 110.624 -179.251 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.58 ' OD1' ' N ' ' E' ' 23' ' ' ASP . 0.6 OUTLIER 172.64 47.07 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.066 0 N-CA-C 112.759 0.652 . . . . 0.0 112.759 -179.095 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' D' ' 25' ' ' GLY . 3.5 m -73.43 175.28 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 119.08 -1.048 . . . . 0.0 110.307 -178.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.504 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . 100.14 -29.75 11.56 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 115.669 -0.696 . . . . 0.0 112.165 176.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 0.9 OUTLIER 92.01 114.67 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 107.65 -1.241 . . . . 0.0 107.65 -177.796 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.468 ' O ' ' ND2' ' F' ' 27' ' ' ASN . 78.6 m-20 -73.92 174.53 8.4 Favored 'General case' 0 C--N 1.329 -0.313 0 C-N-CA 119.441 -0.904 . . . . 0.0 111.754 -178.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -51.11 -36.69 41.78 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.205 -0.907 . . . . 0.0 111.559 178.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.79 77.08 0.07 OUTLIER Glycine 0 CA--C 1.532 1.094 0 N-CA-C 111.17 -0.772 . . . . 0.0 111.17 -177.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.28 155.4 27.3 Favored 'General case' 0 C--O 1.241 0.64 0 CA-C-O 121.946 0.879 . . . . 0.0 111.673 -177.598 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.879 HD11 ' H ' ' Q' ' 39' ' ' VAL . 75.0 mt -131.44 133.34 62.11 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 114.554 -1.203 . . . . 0.0 112.248 -177.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 96.3 mt -122.43 115.35 45.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 178.289 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.49 113.42 1.6 Allowed Glycine 0 N--CA 1.466 0.679 0 N-CA-C 110.134 -1.186 . . . . 0.0 110.134 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 46.8 tp -123.37 121.38 35.64 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-O 120.825 0.345 . . . . 0.0 110.619 -179.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.1 mtp -109.57 105.72 15.14 Favored 'General case' 0 CA--C 1.519 -0.231 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 178.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.65 HG12 ' H ' ' E' ' 37' ' ' GLY . 21.6 t -91.84 174.33 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.373 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.65 ' H ' HG12 ' E' ' 36' ' ' VAL . . . 167.99 -95.15 0.11 Allowed Glycine 0 C--N 1.303 -1.27 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 -179.112 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 92.64 -82.64 1.12 Allowed Glycine 0 N--CA 1.474 1.193 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -178.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.442 HG13 HD11 ' K' ' 31' ' ' ILE . 64.4 t -72.17 101.89 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.329 0 N-CA-C 107.649 -1.241 . . . . 0.0 107.649 177.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.548 ' N ' HD13 ' K' ' 31' ' ' ILE . 8.8 p . . . . . 0 C--O 1.222 -0.37 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.793 -179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -112.98 138.18 50.26 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.815 0.341 . . . . 0.0 110.792 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -110.01 113.47 26.21 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.895 179.572 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.591 HG12 ' HE2' ' E' ' 14' ' ' HIS . 2.5 t -112.82 100.67 11.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.466 0 CA-C-O 121.165 0.507 . . . . 0.0 109.757 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.622 ' NE2' ' CD2' ' E' ' 13' ' ' HIS . 68.8 m80 -140.16 114.6 9.28 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.588 -0.733 . . . . 0.0 111.954 -178.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.534 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 77.2 m80 -156.21 162.1 40.21 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 109.583 -0.525 . . . . 0.0 109.583 177.31 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -90.06 158.23 17.42 Favored 'General case' 0 C--O 1.232 0.135 0 C-N-CA 120.716 -0.394 . . . . 0.0 111.678 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 31.9 tttt -141.16 98.28 3.34 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.814 -0.81 . . . . 0.0 108.814 175.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.784 HD11 HG11 ' D' ' 36' ' ' VAL . 7.9 mt -119.06 110.75 17.45 Favored 'General case' 0 CA--C 1.502 -0.895 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 83.1 t -101.29 99.26 8.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 N-CA-C 106.371 -1.714 . . . . 0.0 106.371 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.4 ' CD1' ' CD2' ' E' ' 19' ' ' PHE . 92.6 m-85 -96.51 95.08 7.76 Favored 'General case' 0 CA--C 1.505 -0.767 0 N-CA-C 106.768 -1.568 . . . . 0.0 106.768 178.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.421 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 67.8 t80 -107.4 109.25 20.93 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 179.585 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.548 ' O ' ' N ' ' F' ' 23' ' ' ASP . . . -148.82 135.41 19.61 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 -179.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.584 ' HB3' HG12 ' E' ' 24' ' ' VAL . 63.3 mt-10 -74.98 79.53 2.18 Favored 'General case' 0 N--CA 1.436 -1.127 0 N-CA-C 102.807 -3.035 . . . . 0.0 102.807 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.749 ' O ' ' O ' ' F' ' 24' ' ' VAL . 53.0 p30 -120.71 54.34 1.08 Allowed 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 112.472 -2.149 . . . . 0.0 113.729 -173.304 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.749 ' O ' ' O ' ' F' ' 23' ' ' ASP . 13.7 t -52.64 -123.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 177.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' F' ' 30' ' ' ALA . . . 139.76 -35.84 1.89 Allowed Glycine 0 N--CA 1.469 0.837 0 C-N-CA 117.428 -2.32 . . . . 0.0 116.648 177.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 41.5 t -65.44 111.51 3.11 Favored 'General case' 0 N--CA 1.447 -0.598 0 C-N-CA 115.142 -2.623 . . . . 0.0 109.372 -174.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.703 ' O ' ' N ' ' F' ' 29' ' ' GLY . 71.5 m-20 -149.45 175.19 11.69 Favored 'General case' 0 N--CA 1.44 -0.946 0 CA-C-N 111.235 -2.711 . . . . 0.0 106.97 179.116 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.46 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.9 tttt -8.95 -45.31 0.0 OUTLIER 'General case' 0 CA--C 1.549 0.916 0 N-CA-C 114.55 1.315 . . . . 0.0 114.55 176.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.703 ' N ' ' O ' ' F' ' 27' ' ' ASN . . . -170.03 60.66 0.18 Allowed Glycine 0 CA--C 1.551 2.304 0 C-N-CA 120.151 -1.023 . . . . 0.0 115.165 179.432 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.447 ' HB2' ' O ' ' F' ' 25' ' ' GLY . . . -85.57 160.86 19.54 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 118.936 1.368 . . . . 0.0 109.965 178.161 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.691 HD11 HG22 ' R' ' 39' ' ' VAL . 96.5 mt -134.97 136.92 51.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -128.54 124.7 62.26 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 178.81 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -138.82 129.05 4.31 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 120.902 -0.666 . . . . 0.0 112.663 -179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 60.4 tp -123.6 125.34 44.66 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 178.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 95.6 mmm -131.47 133.28 44.98 Favored 'General case' 0 N--CA 1.472 0.663 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.609 -179.084 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 14.7 p -141.48 149.77 20.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-O 120.815 0.341 . . . . 0.0 110.788 178.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -135.12 102.04 0.42 Allowed Glycine 0 C--N 1.322 -0.216 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -44.22 -71.95 0.4 Allowed Glycine 0 CA--C 1.539 1.584 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.077 178.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.455 ' O ' ' OXT' ' F' ' 40' ' ' VAL . 5.6 m -79.31 167.91 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.111 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.609 ' H ' ' CG2' ' L' ' 31' ' ' ILE . 27.2 m . . . . . 0 N--CA 1.47 0.569 0 CA-C-O 118.133 -0.937 . . . . 0.0 111.502 179.329 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . 0.527 ' CD2' ' O ' ' G' ' 11' ' ' GLU . 86.7 t80 -73.19 139.84 46.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.776 0.322 . . . . 0.0 110.405 179.934 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.527 ' O ' ' CD2' ' G' ' 10' ' ' TYR . 79.4 mm-40 -70.73 150.32 46.04 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.535 -179.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.403 HG11 ' ND1' ' H' ' 13' ' ' HIS . 65.1 t -120.94 130.54 74.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-O 120.953 0.406 . . . . 0.0 110.018 -179.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 74.3 m80 -82.16 160.77 23.01 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.643 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.421 ' CB ' ' O ' ' H' ' 14' ' ' HIS . 33.9 p-80 -99.5 169.49 9.27 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.083 0.468 . . . . 0.0 111.356 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.442 ' H ' ' HG2' ' H' ' 15' ' ' GLN . 67.1 tp60 -129.69 151.38 50.35 Favored 'General case' 0 CA--C 1.522 -0.117 0 CA-C-N 115.567 -0.742 . . . . 0.0 109.036 179.038 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -95.63 130.57 42.47 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 121.13 -0.228 . . . . 0.0 110.59 179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 84.1 mt -126.19 112.43 15.77 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.218 0.532 . . . . 0.0 109.783 179.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.456 HG23 ' O ' ' G' ' 18' ' ' VAL . 21.2 m -125.65 132.49 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 115.665 -0.698 . . . . 0.0 111.179 -179.227 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -127.0 113.32 16.32 Favored 'General case' 0 C--N 1.331 -0.209 0 N-CA-C 109.637 -0.505 . . . . 0.0 109.637 179.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -111.82 117.51 33.01 Favored 'General case' 0 N--CA 1.469 0.514 0 N-CA-C 110.297 -0.261 . . . . 0.0 110.297 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -117.04 107.39 14.48 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 109.257 -0.645 . . . . 0.0 109.257 178.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -151.36 138.96 19.63 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -179.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 55.18 46.41 23.91 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 119.985 -0.686 . . . . 0.0 110.857 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.784 HG12 ' H ' ' G' ' 25' ' ' GLY . 37.0 t -80.42 -179.86 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 -178.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.784 ' H ' HG12 ' G' ' 24' ' ' VAL . . . -71.27 -31.82 65.84 Favored Glycine 0 CA--C 1.525 0.677 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.371 -177.246 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.697 ' O ' ' O ' ' G' ' 27' ' ' ASN . 15.2 t -173.93 127.53 0.38 Allowed 'General case' 0 C--O 1.224 -0.283 0 CA-C-N 118.35 1.075 . . . . 0.0 113.656 179.554 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.697 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.6 m-20 -2.56 150.74 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.169 0 N-CA-C 115.021 1.489 . . . . 0.0 115.021 175.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 97.4 mttt -158.88 17.48 0.19 Allowed 'General case' 0 N--CA 1.466 0.333 0 O-C-N 121.942 -0.474 . . . . 0.0 110.326 177.08 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.33 169.53 0.66 Allowed Glycine 0 CA--C 1.524 0.651 0 CA-C-N 115.892 -0.594 . . . . 0.0 112.898 176.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.414 ' H ' ' HB2' ' H' ' 27' ' ' ASN . . . -130.83 87.31 2.47 Favored 'General case' 0 CA--C 1.544 0.715 0 CA-C-O 121.346 0.593 . . . . 0.0 111.588 178.38 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.463 HD11 HG12 ' A' ' 39' ' ' VAL . 42.2 pt -138.83 127.12 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.223 0 N-CA-C 108.451 -0.944 . . . . 0.0 108.451 177.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.462 ' O ' ' O ' ' H' ' 33' ' ' GLY . 57.8 mt -107.73 111.12 34.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 -179.624 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.29 95.14 0.65 Allowed Glycine 0 N--CA 1.463 0.458 0 N-CA-C 105.347 -3.101 . . . . 0.0 105.347 177.056 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 93.4 mt -142.71 161.34 38.34 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 122.462 1.125 . . . . 0.0 113.861 -175.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 54.9 tpp -120.67 115.02 22.55 Favored 'General case' 0 CA--C 1.514 -0.433 0 CA-C-N 113.041 -1.89 . . . . 0.0 107.843 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.61 HG23 HG22 ' H' ' 36' ' ' VAL . 0.0 OUTLIER -131.57 111.76 19.62 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.503 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 179.728 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 137.61 -131.49 5.52 Favored Glycine 0 C--N 1.315 -0.585 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.55 -63.18 1.13 Allowed Glycine 0 CA--C 1.535 1.333 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.718 -179.682 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.404 ' O ' ' C ' ' G' ' 40' ' ' VAL . 11.9 p -120.47 153.34 23.59 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.436 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.531 ' OXT' ' CE1' ' J' ' 13' ' ' HIS . 22.7 m . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 118.06 -0.971 . . . . 0.0 111.069 -178.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.447 -1.461 . . . . 0.0 109.447 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.62 134.75 52.98 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.727 0.299 . . . . 0.0 110.289 -179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -138.73 137.96 37.24 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.4 179.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.479 HG22 ' O ' ' I' ' 11' ' ' GLU . 2.0 t -123.78 107.63 19.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.48 ' N ' ' ND1' ' I' ' 13' ' ' HIS . 81.0 t60 -126.63 120.9 30.66 Favored 'General case' 0 N--CA 1.469 0.475 0 CA-C-O 120.92 0.391 . . . . 0.0 110.579 -179.342 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.645 ' ND1' ' O ' ' I' ' 14' ' ' HIS . 11.7 t60 -155.59 170.28 22.36 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.094 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.595 ' N ' ' CG ' ' H' ' 14' ' ' HIS . 82.5 mt-30 -156.0 141.95 18.1 Favored 'General case' 0 N--CA 1.453 -0.289 0 N-CA-C 109.193 -0.669 . . . . 0.0 109.193 178.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -82.38 120.41 25.4 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.362 178.723 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.4 ' HB2' HD23 ' I' ' 17' ' ' LEU . 5.7 mp -120.54 114.5 21.84 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 109.483 -0.562 . . . . 0.0 109.483 178.978 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.42 HG12 ' HB ' ' I' ' 18' ' ' VAL . 25.6 m -133.98 131.79 56.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 CA-C-O 121.364 0.602 . . . . 0.0 111.195 179.471 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -122.26 120.14 33.24 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 115.342 -0.844 . . . . 0.0 110.201 -179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -117.34 122.17 43.15 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.736 179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.61 115.73 22.62 Favored 'General case' 0 N--CA 1.467 0.389 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 178.44 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.551 ' O ' ' N ' ' H' ' 24' ' ' VAL . 95.7 mt-10 -115.8 141.84 47.56 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 112.86 0.689 . . . . 0.0 112.86 -178.025 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.432 ' H ' ' HB2' ' I' ' 22' ' ' GLU . 88.5 m-20 54.38 -59.71 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 114.668 -1.151 . . . . 0.0 113.789 178.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.551 ' N ' ' O ' ' H' ' 22' ' ' GLU . 16.3 m -93.48 172.04 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.82 0 CA-C-O 122.005 0.907 . . . . 0.0 111.616 -177.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 73.97 27.93 65.65 Favored Glycine 0 CA--C 1.529 0.948 0 CA-C-N 113.841 -1.527 . . . . 0.0 112.762 178.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 46.6 t -98.38 110.83 23.35 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.392 -0.595 . . . . 0.0 109.392 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.475 ' OD1' ' N ' ' H' ' 28' ' ' LYS . 5.4 t-20 -77.19 172.81 12.66 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 118.062 -1.455 . . . . 0.0 110.562 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.583 ' O ' ' N ' ' I' ' 28' ' ' LYS . 68.7 mttm -52.4 -36.46 54.16 Favored 'General case' 0 C--O 1.218 -0.575 0 CA-C-O 121.988 0.899 . . . . 0.0 110.821 176.055 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.473 ' CA ' HG21 ' A' ' 40' ' ' VAL . . . -132.12 79.48 0.35 Allowed Glycine 0 N--CA 1.47 0.901 0 CA-C-N 114.497 -1.229 . . . . 0.0 112.466 -175.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -72.61 132.53 43.87 Favored 'General case' 0 C--O 1.238 0.492 0 CA-C-N 118.829 1.314 . . . . 0.0 111.132 -176.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.421 ' CD1' ' HA ' ' B' ' 39' ' ' VAL . 87.5 mt -140.84 147.55 22.65 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 113.954 -1.475 . . . . 0.0 113.544 -174.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.588 HD13 ' CD1' ' J' ' 19' ' ' PHE . 65.3 mt -106.86 107.25 22.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 174.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -111.56 98.59 1.03 Allowed Glycine 0 N--CA 1.462 0.398 0 N-CA-C 107.178 -2.369 . . . . 0.0 107.178 178.2 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.647 ' O ' HD12 ' I' ' 34' ' ' LEU . 2.4 mt -135.18 139.09 44.29 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-O 122.584 1.183 . . . . 0.0 113.392 -176.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 0.3 OUTLIER -106.21 108.66 20.29 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 104.15 -2.537 . . . . 0.0 104.15 175.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 1.001 HG11 HD11 ' J' ' 17' ' ' LEU . 53.1 t -127.94 131.26 69.77 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.247 0 CA-C-O 121.184 0.516 . . . . 0.0 112.159 -175.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 104.88 -111.11 3.68 Favored Glycine 0 C--N 1.32 -0.339 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.749 178.444 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 80.7 -74.22 2.42 Favored Glycine 0 CA--C 1.534 1.254 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 -177.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.429 HG22 ' O ' ' N' ' 29' ' ' GLY . 18.2 t -110.43 135.93 48.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 C-N-CA 122.902 0.481 . . . . 0.0 110.475 179.08 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.472 HG12 ' O ' ' H' ' 40' ' ' VAL . 69.9 t . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.322 178.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.423 0 N-CA-C 109.453 -1.459 . . . . 0.0 109.453 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -82.89 136.71 34.5 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.869 0.366 . . . . 0.0 110.533 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.479 ' O ' HG22 ' H' ' 12' ' ' VAL . 80.2 mm-40 -78.6 155.39 29.63 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.424 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.587 HG12 ' N ' ' I' ' 13' ' ' HIS . 74.0 t -138.4 166.91 22.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 116.085 -0.507 . . . . 0.0 109.931 -179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.587 ' N ' HG12 ' I' ' 12' ' ' VAL . 11.0 m-70 -54.99 143.0 27.89 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 120.777 0.322 . . . . 0.0 111.46 -178.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' O ' ' ND1' ' H' ' 14' ' ' HIS . 16.7 t-80 -153.9 154.31 33.64 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 109.119 -0.697 . . . . 0.0 109.119 178.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.601 ' O ' ' ND1' ' I' ' 14' ' ' HIS . 64.2 tp60 -98.76 169.3 9.58 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 118.315 0.507 . . . . 0.0 111.208 179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 82.2 tttt -159.73 104.29 1.57 Allowed 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 109.864 -0.421 . . . . 0.0 109.864 176.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.4 HD23 ' HB2' ' H' ' 17' ' ' LEU . 11.7 mt -123.89 123.29 40.1 Favored 'General case' 0 N--CA 1.477 0.914 0 CA-C-O 121.236 0.541 . . . . 0.0 111.472 178.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.42 ' HB ' HG12 ' H' ' 18' ' ' VAL . 60.3 t -115.91 112.08 38.16 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 177.593 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 75.1 m-85 -112.54 107.36 16.07 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 109.524 -0.547 . . . . 0.0 109.524 179.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 4.4 m-85 -114.74 126.93 55.41 Favored 'General case' 0 N--CA 1.475 0.792 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.77 130.09 25.35 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-O 121.817 0.818 . . . . 0.0 113.114 -179.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.453 ' OE1' ' OE1' ' J' ' 22' ' ' GLU . 58.5 mm-40 -95.6 120.23 35.48 Favored 'General case' 0 N--CA 1.461 0.096 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 177.892 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.455 ' H ' ' HB3' ' J' ' 22' ' ' GLU . 90.6 m-20 -125.72 48.64 2.04 Favored 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 112.038 0.385 . . . . 0.0 112.038 -177.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.565 HG12 ' N ' ' I' ' 25' ' ' GLY . 81.2 t -72.39 161.11 4.99 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.419 0 C-N-CA 118.447 -1.301 . . . . 0.0 109.896 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.565 ' N ' HG12 ' I' ' 24' ' ' VAL . . . 108.39 -30.05 9.34 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 106.845 -2.502 . . . . 0.0 106.845 -178.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.481 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 22.9 p 93.28 113.59 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 112.573 -1.814 . . . . 0.0 109.619 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . . . . . . . . . 99.8 m-20 -74.19 161.95 29.44 Favored 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 117.916 -1.514 . . . . 0.0 110.649 178.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.583 ' N ' ' O ' ' H' ' 28' ' ' LYS . 72.7 tttt -48.65 -39.5 24.5 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 174.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.33 68.82 0.04 OUTLIER Glycine 0 CA--C 1.551 2.327 0 CA-C-O 118.826 -0.986 . . . . 0.0 112.421 -174.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.25 150.62 46.22 Favored 'General case' 0 N--CA 1.478 0.938 0 CA-C-N 119.775 1.787 . . . . 0.0 114.587 -174.325 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.55 HD12 HG12 ' C' ' 39' ' ' VAL . 77.5 mt -141.44 152.32 19.53 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.204 0 CA-C-N 113.517 -1.674 . . . . 0.0 113.996 -176.237 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.454 HD13 ' CD1' ' K' ' 19' ' ' PHE . 6.6 mt -106.93 109.08 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 N-CA-C 107.089 -1.448 . . . . 0.0 107.089 174.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.42 106.03 2.04 Favored Glycine 0 N--CA 1.465 0.617 0 N-CA-C 106.323 -2.711 . . . . 0.0 106.323 177.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.647 HD12 ' O ' ' H' ' 34' ' ' LEU . 26.6 tp -147.54 140.25 24.79 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 122.837 1.303 . . . . 0.0 113.969 -174.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.548 ' H ' HD12 ' I' ' 34' ' ' LEU . 42.8 tpp -110.04 115.08 29.13 Favored 'General case' 0 CA--C 1.514 -0.426 0 CA-C-N 113.033 -1.894 . . . . 0.0 106.799 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -131.79 123.13 51.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 N-CA-C 109.653 -0.499 . . . . 0.0 109.653 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . 141.06 -113.55 0.86 Allowed Glycine 0 C--N 1.317 -0.527 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 179.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . 0.46 ' O ' ' CD1' ' O' ' 31' ' ' ILE . . . 86.24 -73.01 2.58 Favored Glycine 0 CA--C 1.536 1.405 0 CA-C-N 115.48 -0.36 . . . . 0.0 112.211 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.437 ' O ' ' OXT' ' I' ' 40' ' ' VAL . 39.7 t -123.19 146.09 29.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 178.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.472 HG13 ' ND1' ' L' ' 13' ' ' HIS . 52.9 t . . . . . 0 C--O 1.221 -0.413 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.651 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -112.84 134.33 54.41 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 110.263 -0.273 . . . . 0.0 110.263 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.41 ' O ' ' CE1' ' K' ' 13' ' ' HIS . 98.9 mt-10 -74.57 130.79 40.2 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.483 179.898 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.589 HG23 ' O ' ' J' ' 12' ' ' VAL . 32.9 m -138.38 88.09 0.59 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-O 121.601 0.715 . . . . 0.0 110.904 -179.721 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.562 ' H ' ' CD2' ' K' ' 13' ' ' HIS . 6.1 t60 -129.03 128.14 43.01 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.433 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.569 ' O ' ' CE1' ' I' ' 14' ' ' HIS . 0.0 OUTLIER -140.67 173.64 11.29 Favored 'General case' 0 C--N 1.328 -0.343 0 N-CA-C 108.309 -0.997 . . . . 0.0 108.309 178.426 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.489 ' NE2' HG13 ' H' ' 36' ' ' VAL . 10.2 tt0 -124.64 142.45 51.37 Favored 'General case' 0 C--O 1.224 -0.248 0 C-N-CA 120.211 -0.596 . . . . 0.0 109.465 177.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 93.2 mttt -112.82 112.16 23.45 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 119.168 -0.444 . . . . 0.0 111.078 178.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 1.001 HD11 HG11 ' H' ' 36' ' ' VAL . 24.0 mt -118.43 114.36 22.76 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 118.613 0.642 . . . . 0.0 109.984 177.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 15.5 t -110.13 105.83 19.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 N-CA-C 108.107 -1.072 . . . . 0.0 108.107 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.588 ' CD1' HD13 ' H' ' 32' ' ' ILE . 65.5 m-85 -106.36 106.67 17.3 Favored 'General case' 0 CA--C 1.534 0.34 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.454 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 22.6 t80 -115.24 122.48 46.11 Favored 'General case' 0 N--CA 1.475 0.786 0 N-CA-C 110.053 -0.351 . . . . 0.0 110.053 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -141.77 138.3 32.19 Favored 'General case' 0 C--O 1.253 1.26 0 CA-C-O 123.091 1.424 . . . . 0.0 114.479 -178.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.455 ' HB3' ' H ' ' I' ' 23' ' ' ASP . 24.0 tt0 -79.89 90.99 5.33 Favored 'General case' 0 N--CA 1.449 -0.496 0 CA-C-N 113.526 -1.67 . . . . 0.0 107.614 178.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.685 ' O ' ' O ' ' K' ' 22' ' ' GLU . 84.3 m-20 -89.98 60.04 4.76 Favored 'General case' 0 C--N 1.31 -1.116 0 CA-C-N 111.773 -2.467 . . . . 0.0 110.42 -178.944 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -62.7 -112.65 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-O 117.109 -1.424 . . . . 0.0 108.282 -174.209 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.608 ' HA2' HG12 ' K' ' 24' ' ' VAL . . . -103.82 44.51 1.47 Allowed Glycine 0 N--CA 1.472 1.081 0 CA-C-N 121.707 2.049 . . . . 0.0 112.078 -172.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . . . . . . . . . 29.0 t -71.82 100.64 2.44 Favored 'General case' 0 N--CA 1.453 -0.278 0 N-CA-C 107.514 -1.291 . . . . 0.0 107.514 176.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . . . . . . . . . 73.9 m-20 -109.67 -150.81 0.46 Allowed 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.176 -175.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . . 99.2 mttt 34.96 42.07 0.07 Allowed 'General case' 0 C--N 1.329 -0.301 0 N-CA-C 113.36 0.874 . . . . 0.0 113.36 -178.12 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 111.55 71.82 0.63 Allowed Glycine 0 CA--C 1.536 1.369 0 N-CA-C 117.297 1.679 . . . . 0.0 117.297 177.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -104.33 120.27 40.82 Favored 'General case' 0 C--O 1.241 0.646 0 N-CA-C 106.131 -1.803 . . . . 0.0 106.131 174.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.471 HG22 ' N ' ' J' ' 32' ' ' ILE . 42.3 mt -145.12 155.45 13.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 N-CA-C 116.417 2.006 . . . . 0.0 116.417 -174.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.471 ' N ' HG22 ' J' ' 31' ' ' ILE . 40.7 mt -111.89 111.23 35.25 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.818 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 173.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.27 103.88 1.64 Allowed Glycine 0 N--CA 1.467 0.75 0 N-CA-C 106.872 -2.491 . . . . 0.0 106.872 177.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.432 ' CD2' HG13 ' J' ' 36' ' ' VAL . 12.2 tp -137.33 137.31 38.79 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 122.205 1.003 . . . . 0.0 113.663 -175.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 3.7 ttm -111.39 114.22 27.21 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 113.677 -1.601 . . . . 0.0 107.543 176.419 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.432 HG13 ' CD2' ' J' ' 34' ' ' LEU . 1.3 m -121.23 103.21 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.519 0 CA-C-O 120.399 0.143 . . . . 0.0 111.11 -178.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 147.39 -153.43 25.33 Favored Glycine 0 C--N 1.318 -0.468 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.016 178.053 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.479 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 126.15 -56.4 0.71 Allowed Glycine 0 CA--C 1.541 1.71 0 N-CA-C 110.014 -1.235 . . . . 0.0 110.014 -178.294 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.657 HG12 HG23 ' J' ' 40' ' ' VAL . 55.0 t -136.5 137.17 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.657 HG23 HG12 ' J' ' 39' ' ' VAL . 61.2 t . . . . . 0 C--O 1.219 -0.551 0 CA-C-O 118.093 -0.956 . . . . 0.0 110.433 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.469 -1.452 . . . . 0.0 109.469 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -110.98 143.81 41.07 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-O 120.754 0.311 . . . . 0.0 110.644 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.489 ' O ' HG12 ' J' ' 12' ' ' VAL . 97.0 mt-10 -129.41 149.87 51.01 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.434 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.534 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 34.2 m -140.37 161.45 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.498 -178.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.562 ' CD2' ' H ' ' J' ' 13' ' ' HIS . 28.1 m80 -70.17 118.15 12.64 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.546 ' ND1' ' O ' ' L' ' 14' ' ' HIS . 65.9 t60 -148.23 162.82 38.71 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 120.306 -0.558 . . . . 0.0 111.107 -179.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.435 ' HB3' ' H ' ' L' ' 16' ' ' LYS . 41.3 tt0 -90.2 152.28 21.16 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.53 -0.304 . . . . 0.0 110.819 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -150.39 93.14 1.94 Allowed 'General case' 0 C--N 1.319 -0.731 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.616 177.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.438 HD22 HD12 ' J' ' 17' ' ' LEU . 2.0 mt -120.93 115.31 22.96 Favored 'General case' 0 N--CA 1.478 0.94 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 62.0 t -111.47 105.41 18.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 178.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.481 ' CE1' ' CD2' ' J' ' 19' ' ' PHE . 52.1 m-85 -104.28 103.67 13.45 Favored 'General case' 0 C--O 1.235 0.305 0 N-CA-C 107.15 -1.426 . . . . 0.0 107.15 178.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.454 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 31.9 t80 -113.07 119.3 37.37 Favored 'General case' 0 N--CA 1.465 0.294 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 -179.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.546 ' O ' ' HA ' ' L' ' 21' ' ' ALA . . . -156.74 162.71 39.76 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 122.626 1.203 . . . . 0.0 113.604 -178.83 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.685 ' O ' ' O ' ' J' ' 23' ' ' ASP . 97.0 mt-10 -82.05 118.81 23.31 Favored 'General case' 0 C--O 1.206 -1.22 0 C-N-CA 118.344 -1.342 . . . . 0.0 111.347 -179.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.908 ' O ' HG13 ' K' ' 24' ' ' VAL . 65.2 m-20 -62.09 -50.41 72.04 Favored 'General case' 0 N--CA 1.479 0.984 0 O-C-N 120.251 -1.53 . . . . 0.0 110.016 179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.908 HG13 ' O ' ' K' ' 23' ' ' ASP . 0.3 OUTLIER 159.6 171.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.597 0 N-CA-C 105.447 -2.057 . . . . 0.0 105.447 178.626 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.56 -33.27 76.14 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 177.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.608 ' O ' ' O ' ' K' ' 27' ' ' ASN . 12.3 m -162.68 120.94 2.1 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 114.186 -1.007 . . . . 0.0 109.872 -177.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.608 ' O ' ' O ' ' K' ' 26' ' ' SER . 39.7 t30 -22.25 152.33 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.148 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -179.628 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 72.9 tttt -164.69 29.82 0.07 Allowed 'General case' 0 C--N 1.327 -0.388 0 C-N-CA 120.467 -0.493 . . . . 0.0 111.528 -178.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.91 88.04 0.82 Allowed Glycine 0 CA--C 1.529 0.923 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.685 -179.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.36 155.95 45.51 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 107.208 -1.405 . . . . 0.0 107.208 178.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.548 HD13 ' N ' ' E' ' 40' ' ' VAL . 6.9 mt -127.1 146.93 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 N-CA-C 113.657 0.984 . . . . 0.0 113.657 -176.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -128.13 114.88 36.42 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.366 -0.834 . . . . 0.0 109.318 178.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.75 113.89 3.21 Favored Glycine 0 N--CA 1.465 0.623 0 N-CA-C 109.868 -1.293 . . . . 0.0 109.868 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.409 HD21 HD13 ' L' ' 17' ' ' LEU . 20.3 tp -122.84 124.36 43.11 Favored 'General case' 0 CA--C 1.513 -0.476 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 17.8 mtp -129.24 131.09 46.98 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 120.582 -0.447 . . . . 0.0 111.409 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.593 HG12 ' N ' ' K' ' 37' ' ' GLY . 57.8 t -100.84 166.28 2.37 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.106 0 CA-C-O 121.003 0.43 . . . . 0.0 110.568 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.593 ' N ' HG12 ' K' ' 36' ' ' VAL . . . -75.01 -102.91 0.1 OUTLIER Glycine 0 CA--C 1.527 0.837 0 CA-C-N 115.718 -0.674 . . . . 0.0 112.151 179.378 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -117.55 -77.16 0.59 Allowed Glycine 0 N--CA 1.474 1.217 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 -179.523 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.422 HG22 ' O ' ' L' ' 39' ' ' VAL . 45.5 t -115.26 132.05 65.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.497 0 CA-C-O 121.428 0.632 . . . . 0.0 110.585 -179.352 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' L' ' 40' ' ' VAL . 15.1 m . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.991 -1.004 . . . . 0.0 110.547 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -115.31 140.8 48.8 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.816 0.341 . . . . 0.0 110.104 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -70.53 137.91 50.56 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.529 -179.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 55.1 t -123.84 133.82 68.19 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.402 0 CA-C-O 121.533 0.682 . . . . 0.0 110.942 -179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.492 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 2.5 m-70 -131.33 127.24 37.24 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 114.627 -1.169 . . . . 0.0 111.181 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.546 ' O ' ' ND1' ' K' ' 14' ' ' HIS . 94.9 m-70 -155.01 165.46 36.68 Favored 'General case' 0 C--N 1.327 -0.396 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 177.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.423 ' OE1' ' O ' ' J' ' 36' ' ' VAL . 47.5 mt-30 -89.69 156.64 18.42 Favored 'General case' 0 CA--C 1.518 -0.282 0 C-N-CA 119.521 -0.871 . . . . 0.0 109.635 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . 0.435 ' H ' ' HB3' ' K' ' 15' ' ' GLN . 52.4 tttp -141.99 95.66 2.84 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.221 177.542 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.409 HD13 HD21 ' K' ' 34' ' ' LEU . 0.1 OUTLIER -117.65 108.19 15.14 Favored 'General case' 0 CA--C 1.512 -0.495 0 N-CA-C 107.748 -1.205 . . . . 0.0 107.748 178.299 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 76.3 t -107.11 103.93 16.26 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 N-CA-C 109.11 -0.7 . . . . 0.0 109.11 179.058 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -101.23 102.13 12.97 Favored 'General case' 0 CA--C 1.51 -0.586 0 N-CA-C 106.73 -1.582 . . . . 0.0 106.73 178.13 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 63.7 t80 -126.52 129.7 49.15 Favored 'General case' 0 CA--C 1.511 -0.529 0 CA-C-O 121.35 0.595 . . . . 0.0 110.231 -178.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.546 ' HA ' ' O ' ' K' ' 21' ' ' ALA . . . -144.84 149.09 34.8 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 120.059 -0.656 . . . . 0.0 110.66 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -74.24 120.98 20.55 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.833 -0.622 . . . . 0.0 110.657 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 1.4 t0 -163.52 51.61 0.16 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 120.372 -0.531 . . . . 0.0 112.067 -178.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 34.4 m -76.15 143.24 13.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 C-N-CA 118.119 -1.432 . . . . 0.0 108.51 179.349 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 103.52 -37.52 3.7 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 108.701 -1.76 . . . . 0.0 108.701 -179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.42 ' HB2' ' H ' ' K' ' 27' ' ' ASN . 0.3 OUTLIER -80.6 118.26 22.02 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 113.379 -1.411 . . . . 0.0 112.057 -179.267 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.536 ' O ' ' N ' ' L' ' 29' ' ' GLY . 57.3 p30 -89.01 -177.95 5.58 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.957 -0.386 . . . . 0.0 109.957 178.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -51.98 49.66 0.0 OUTLIER 'General case' 0 CA--C 1.543 0.7 0 N-CA-C 115.089 1.514 . . . . 0.0 115.089 -179.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.536 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . -101.58 51.35 0.93 Allowed Glycine 0 CA--C 1.549 2.182 0 CA-C-N 119.698 1.135 . . . . 0.0 113.515 179.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -130.38 174.47 9.83 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.609 ' CG2' ' H ' ' F' ' 40' ' ' VAL . 0.6 OUTLIER -106.91 119.91 57.3 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.927 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 176.214 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 95.0 mt -123.62 128.66 74.61 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-O 120.876 0.369 . . . . 0.0 111.7 -178.073 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.51 116.24 2.22 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 109.899 -1.28 . . . . 0.0 109.899 178.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 34.3 mt -119.64 124.59 46.67 Favored 'General case' 0 N--CA 1.465 0.297 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 -179.56 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 6.7 ttm -124.04 123.54 40.57 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.857 0.361 . . . . 0.0 111.468 -179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' L' ' 37' ' ' GLY . 72.8 t -98.33 131.52 45.24 Favored 'Isoleucine or valine' 0 C--N 1.34 0.17 0 N-CA-C 108.953 -0.758 . . . . 0.0 108.953 178.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -34.6 -111.51 0.0 OUTLIER Glycine 0 CA--C 1.531 1.089 0 O-C-N 123.543 0.527 . . . . 0.0 113.257 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -111.68 -71.65 0.62 Allowed Glycine 0 CA--C 1.535 1.298 0 N-CA-C 111.556 -0.618 . . . . 0.0 111.556 -179.762 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.422 ' O ' HG22 ' K' ' 39' ' ' VAL . 53.2 t -125.33 129.93 72.97 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 CA-C-O 121.165 0.507 . . . . 0.0 110.998 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' K' ' 40' ' ' VAL . 8.7 p . . . . . 0 C--O 1.22 -0.458 0 CA-C-O 117.899 -1.048 . . . . 0.0 110.724 179.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.327 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -114.09 139.14 49.55 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.711 0.291 . . . . 0.0 110.593 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -71.17 127.64 33.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.874 0.369 . . . . 0.0 110.119 179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . . . . . . . . . 54.9 t -125.48 131.93 71.58 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.334 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.349 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 78.9 m80 -106.28 160.71 15.15 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.022 -0.536 . . . . 0.0 109.633 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.592 ' H ' ' CD2' ' M' ' 14' ' ' HIS . 8.5 p80 -83.43 166.91 17.96 Favored 'General case' 0 C--N 1.332 -0.153 0 C-N-CA 120.392 -0.523 . . . . 0.0 110.617 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . 0.423 ' HB2' HE21 ' N' ' 15' ' ' GLN . 86.2 mt-30 -129.95 152.07 49.82 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.927 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . 0.59 ' C ' HD12 ' M' ' 17' ' ' LEU . 63.6 mttp -94.38 112.3 24.08 Favored 'General case' 0 C--N 1.321 -0.631 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . 0.59 HD12 ' C ' ' M' ' 16' ' ' LYS . 11.1 mp -116.88 120.61 39.02 Favored 'General case' 0 N--CA 1.471 0.622 0 CA-C-O 120.879 0.371 . . . . 0.0 110.124 179.454 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 61.4 t -129.61 132.54 66.14 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.049 179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 33.2 t80 -142.25 134.23 27.3 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.989 0.423 . . . . 0.0 110.828 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.448 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 52.8 p90 -123.31 133.11 54.18 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.732 179.707 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.91 125.66 41.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 121.145 0.498 . . . . 0.0 111.543 -179.264 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 18.7 pt-20 -156.33 126.34 6.47 Favored 'General case' 0 CA--C 1.529 0.153 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.586 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 99.2 m-20 54.24 46.41 25.29 Favored 'General case' 0 C--N 1.329 -0.284 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -178.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.831 HG12 ' H ' ' M' ' 25' ' ' GLY . 21.6 t -76.7 -179.8 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.349 -179.303 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.831 ' H ' HG12 ' M' ' 24' ' ' VAL . . . -88.88 28.15 6.77 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . 0.443 ' O ' ' C ' ' M' ' 27' ' ' ASN . 4.7 t -169.74 -134.53 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.865 -0.421 . . . . 0.0 109.865 -178.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.443 ' C ' ' O ' ' M' ' 26' ' ' SER . 3.0 t-20 -32.04 134.19 0.09 Allowed 'General case' 0 N--CA 1.472 0.671 0 O-C-N 122.985 0.178 . . . . 0.0 111.141 -179.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . 0.452 ' O ' ' OD2' ' N' ' 23' ' ' ASP . 68.7 mttm -118.23 -38.5 3.18 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 112.559 0.577 . . . . 0.0 112.559 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . 0.587 ' O ' ' HB2' ' M' ' 30' ' ' ALA . . . -81.04 -76.99 1.02 Allowed Glycine 0 CA--C 1.53 0.969 0 C-N-CA 118.794 -1.67 . . . . 0.0 112.178 -179.363 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . 0.587 ' HB2' ' O ' ' M' ' 29' ' ' GLY . . . 171.05 99.12 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 117.386 0.593 . . . . 0.0 111.31 178.284 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . . . . . . . . . 3.2 pt -127.9 116.63 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 177.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . 0.436 ' O ' ' O ' ' N' ' 33' ' ' GLY . 96.5 mt -113.49 108.1 24.64 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.235 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 179.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.26 96.87 0.78 Allowed Glycine 0 N--CA 1.462 0.393 0 N-CA-C 105.45 -3.06 . . . . 0.0 105.45 177.365 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . 0.623 ' O ' HD12 ' N' ' 34' ' ' LEU . 91.3 mt -142.63 163.5 32.64 Favored 'General case' 0 CA--C 1.51 -0.562 0 CA-C-O 123.12 1.438 . . . . 0.0 114.163 -175.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 1.4 mtp -117.62 110.71 18.24 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-N 111.824 -2.443 . . . . 0.0 105.977 177.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.895 HG11 HD11 ' O' ' 17' ' ' LEU . 74.6 t -117.92 131.61 70.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 121.334 0.588 . . . . 0.0 110.15 -178.312 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 82.54 -111.42 3.36 Favored Glycine 0 CA--C 1.523 0.549 0 CA-C-N 115.032 -0.985 . . . . 0.0 110.924 -179.417 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.1 -73.03 0.97 Allowed Glycine 0 CA--C 1.532 1.153 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.424 HG12 ' N ' ' M' ' 40' ' ' VAL . 56.0 t -99.17 158.42 3.61 Favored 'Isoleucine or valine' 0 C--N 1.339 0.149 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 179.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.424 ' N ' HG12 ' M' ' 39' ' ' VAL . 11.7 p . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 117.957 -1.021 . . . . 0.0 110.567 -179.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -83.07 139.41 33.25 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.78 0.324 . . . . 0.0 110.614 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -140.63 128.06 21.29 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.765 179.918 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -127.46 130.27 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -123.71 104.37 8.95 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-O 120.913 0.387 . . . . 0.0 111.667 -179.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.62 ' CG ' ' N ' ' N' ' 15' ' ' GLN . 1.0 OUTLIER -158.31 170.57 21.94 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.985 -0.552 . . . . 0.0 109.864 179.151 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . 0.62 ' N ' ' CG ' ' N' ' 14' ' ' HIS . 51.7 tt0 -155.44 141.46 18.28 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-O 120.897 0.379 . . . . 0.0 110.355 178.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -87.04 117.51 25.81 Favored 'General case' 0 C--O 1.237 0.415 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.801 178.424 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . . . . . . . . . 18.4 mt -118.69 124.4 47.26 Favored 'General case' 0 N--CA 1.473 0.692 0 N-CA-C 110.198 -0.297 . . . . 0.0 110.198 179.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 75.1 t -129.02 126.84 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-O 120.994 0.426 . . . . 0.0 110.968 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -130.85 130.27 43.39 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.861 179.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -124.29 128.49 49.21 Favored 'General case' 0 N--CA 1.469 0.479 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 178.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 118.6 26.57 Favored 'General case' 0 N--CA 1.47 0.557 0 CA-C-O 121.013 0.435 . . . . 0.0 110.458 179.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -127.22 128.69 46.48 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.504 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.463 ' O ' ' ND2' ' N' ' 27' ' ' ASN . 34.4 m-20 -162.47 51.26 0.19 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.164 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 89.2 t -63.21 150.81 9.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 121.041 0.448 . . . . 0.0 110.668 -179.188 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.06 -37.37 3.8 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.508 ' O ' ' O ' ' N' ' 27' ' ' ASN . 51.4 m -120.49 -112.36 0.33 Allowed 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.794 0.33 . . . . 0.0 111.588 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.524 ' ND2' ' OD1' ' O' ' 23' ' ' ASP . 16.3 m-20 52.31 153.08 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.69 -178.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' O' ' 28' ' ' LYS . 68.8 mttm -139.7 -29.57 0.73 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 113.712 1.005 . . . . 0.0 113.712 -179.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . 0.429 ' O ' HG22 ' H' ' 39' ' ' VAL . . . -161.73 85.02 0.11 Allowed Glycine 0 CA--C 1.531 1.048 0 C-N-CA 120.421 -0.895 . . . . 0.0 113.935 -174.547 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.86 123.64 28.44 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 118.824 1.312 . . . . 0.0 110.627 -178.818 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 0.432 HD11 HG23 ' I' ' 39' ' ' VAL . 70.0 mt -129.98 134.53 62.76 Favored 'Isoleucine or valine' 0 C--O 1.234 0.285 0 CA-C-N 114.65 -1.159 . . . . 0.0 113.515 -175.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . . . . . . . . . 68.0 mt -105.0 104.93 17.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.161 0 N-CA-C 106.87 -1.529 . . . . 0.0 106.87 174.323 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.436 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -110.41 109.44 2.64 Favored Glycine 0 C--O 1.235 0.202 0 N-CA-C 106.274 -2.73 . . . . 0.0 106.274 177.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.623 HD12 ' O ' ' M' ' 34' ' ' LEU . 15.8 tp -151.55 139.13 19.62 Favored 'General case' 0 CA--C 1.511 -0.535 0 C-N-CA 117.432 -1.707 . . . . 0.0 113.379 -175.412 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . 0.528 ' H ' HD12 ' N' ' 34' ' ' LEU . 0.8 OUTLIER -105.25 108.88 20.63 Favored 'General case' 0 N--CA 1.43 -1.434 0 CA-C-N 111.756 -2.475 . . . . 0.0 106.424 177.401 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . 0.653 ' CG1' HE22 ' P' ' 15' ' ' GLN . 8.7 p -132.8 142.6 41.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 C-N-CA 120.809 -0.356 . . . . 0.0 110.141 -177.687 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . . . . . . . . . . . 122.74 -102.02 0.75 Allowed Glycine 0 C--N 1.32 -0.307 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 179.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' O' ' 39' ' ' VAL . . . 77.01 -80.76 1.21 Allowed Glycine 0 CA--C 1.531 1.064 0 N-CA-C 110.738 -0.945 . . . . 0.0 110.738 -179.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . . . . . . . . . 9.8 p -149.49 149.51 14.66 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.375 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.574 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.411 HG12 ' CD2' ' P' ' 13' ' ' HIS . 33.3 m . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.873 -1.061 . . . . 0.0 110.256 179.452 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.816 -1.314 . . . . 0.0 109.816 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 51.4 p90 -148.93 159.94 43.73 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.729 0.299 . . . . 0.0 110.484 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -134.55 160.22 38.74 Favored 'General case' 0 N--CA 1.468 0.434 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.619 -179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . . . . . . . . . 60.3 t -118.45 131.04 72.38 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.281 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . 0.545 ' O ' ' ND1' ' P' ' 13' ' ' HIS . 37.3 m-70 -140.13 123.6 17.08 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 179.754 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.715 ' CE1' ' HD1' ' P' ' 14' ' ' HIS . 30.9 m80 -147.58 174.09 12.08 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 121.25 0.548 . . . . 0.0 111.152 179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.4 HE21 HD21 ' O' ' 17' ' ' LEU . 67.0 tp60 -137.69 140.8 40.98 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 108.056 -1.09 . . . . 0.0 108.056 177.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -129.96 104.55 7.42 Favored 'General case' 0 CA--C 1.501 -0.924 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.333 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.895 HD11 HG11 ' M' ' 36' ' ' VAL . 12.7 mt -116.61 116.3 27.32 Favored 'General case' 0 N--CA 1.469 0.486 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.006 179.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 2.9 t -110.89 106.34 20.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.22 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 177.891 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . 0.436 ' CD2' ' CE1' ' P' ' 19' ' ' PHE . 13.6 m-30 -112.02 118.07 34.42 Favored 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . . . . . . . . . 46.9 t80 -119.62 127.24 52.75 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-N 116.789 -0.187 . . . . 0.0 110.933 -179.184 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.39 124.83 26.35 Favored 'General case' 0 N--CA 1.478 0.95 0 CA-C-O 121.944 0.878 . . . . 0.0 112.053 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . 0.438 ' O ' ' OD1' ' O' ' 23' ' ' ASP . 80.4 tt0 -96.09 141.79 29.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.316 -179.504 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.524 ' OD1' ' ND2' ' N' ' 27' ' ' ASN . 65.3 m-20 -162.75 47.22 0.15 Allowed 'General case' 0 CA--C 1.537 0.473 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.87 179.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.621 HG13 ' OE1' ' P' ' 22' ' ' GLU . 25.0 m -62.77 -179.49 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-O 121.716 0.769 . . . . 0.0 111.535 -179.031 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . 0.475 ' O ' ' CB ' ' O' ' 26' ' ' SER . . . 91.25 -29.01 7.42 Favored Glycine 0 CA--C 1.527 0.801 0 CA-C-N 114.22 -1.354 . . . . 0.0 113.358 177.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . 0.475 ' CB ' ' O ' ' O' ' 25' ' ' GLY . 0.9 OUTLIER 167.63 127.85 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.325 0 CA-C-N 118.385 1.093 . . . . 0.0 112.798 179.467 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . 0.515 ' ND2' ' O ' ' P' ' 27' ' ' ASN . 39.4 t-20 -36.72 138.48 0.24 Allowed 'General case' 0 N--CA 1.472 0.626 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 176.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.452 ' O ' ' O ' ' N' ' 28' ' ' LYS . 78.1 mttt -150.56 34.82 0.62 Allowed 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 121.077 0.465 . . . . 0.0 111.684 -176.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.35 80.39 0.95 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 115.27 0.868 . . . . 0.0 115.27 176.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.01 110.99 23.1 Favored 'General case' 0 N--CA 1.465 0.315 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 176.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' O ' ' I' ' 38' ' ' GLY . 42.8 mt -121.93 130.72 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 N-CA-C 112.416 0.524 . . . . 0.0 112.416 -176.545 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . . . . . . . . . 81.5 mt -107.44 103.64 15.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 175.281 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -103.27 102.41 2.21 Favored Glycine 0 C--N 1.335 0.505 0 N-CA-C 104.146 -3.582 . . . . 0.0 104.146 176.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.557 HD12 ' O ' ' N' ' 34' ' ' LEU . 13.0 tp -140.19 135.87 32.85 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 114.937 1.458 . . . . 0.0 114.937 -172.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . 0.428 ' SD ' ' CG ' ' P' ' 35' ' ' MET . 89.5 mmm -111.64 108.73 18.3 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-N 112.369 -2.196 . . . . 0.0 106.185 177.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.597 ' CG1' ' NE2' ' Q' ' 15' ' ' GLN . 21.4 t -115.67 131.51 67.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.199 0 CA-C-O 121.447 0.641 . . . . 0.0 111.94 -177.069 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' P' ' 37' ' ' GLY . . . 75.39 111.71 0.1 Allowed Glycine 0 CA--C 1.526 0.737 0 CA-C-N 114.767 -1.106 . . . . 0.0 114.222 176.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . -94.17 -60.1 1.14 Allowed Glycine 0 CA--C 1.542 1.762 0 N-CA-C 110.013 -1.235 . . . . 0.0 110.013 176.153 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.45 ' N ' ' O ' ' N' ' 38' ' ' GLY . 5.7 t -122.02 131.12 73.85 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.542 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.442 ' H ' ' HB ' ' P' ' 39' ' ' VAL . 91.4 t . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.922 -1.037 . . . . 0.0 110.476 -178.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.285 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . 0.436 ' O ' ' OE1' ' Q' ' 11' ' ' GLU . 93.5 m-85 -106.94 138.71 42.6 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.878 0.37 . . . . 0.0 110.31 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . 0.509 ' O ' ' CE1' ' Q' ' 13' ' ' HIS . 96.2 mt-10 -71.8 152.06 42.99 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.478 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.461 ' O ' ' CG2' ' P' ' 12' ' ' VAL . 1.4 m -110.46 119.94 60.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 179.822 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.545 ' ND1' ' O ' ' O' ' 13' ' ' HIS . 9.2 t60 -146.39 134.15 21.17 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 120.511 -0.475 . . . . 0.0 112.115 -177.846 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.715 ' HD1' ' CE1' ' O' ' 14' ' ' HIS . 1.0 OUTLIER -145.96 156.01 43.22 Favored 'General case' 0 C--O 1.23 0.068 0 N-CA-C 109.774 -0.454 . . . . 0.0 109.774 176.314 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.653 HE22 ' CG1' ' N' ' 36' ' ' VAL . 53.1 tt0 -90.56 159.71 16.32 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.661 177.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 51.5 tttm -140.91 105.65 4.92 Favored 'General case' 0 C--N 1.318 -0.796 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.115 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . 0.647 ' CG ' HE21 ' P' ' 15' ' ' GLN . 39.6 mt -115.25 119.76 37.42 Favored 'General case' 0 N--CA 1.478 0.973 0 CA-C-O 121.202 0.525 . . . . 0.0 111.166 178.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 48.8 t -116.75 98.29 6.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 N-CA-C 106.931 -1.507 . . . . 0.0 106.931 176.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.489 ' CE2' HD13 ' P' ' 17' ' ' LEU . 16.9 m-30 -112.86 110.35 20.39 Favored 'General case' 0 C--O 1.237 0.395 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -112.51 128.7 56.42 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.925 -179.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.5 158.13 40.86 Favored 'General case' 0 N--CA 1.466 0.356 0 C-N-CA 119.067 -1.053 . . . . 0.0 112.953 -178.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.621 ' OE1' HG13 ' O' ' 24' ' ' VAL . 99.1 mt-10 -85.83 112.21 20.9 Favored 'General case' 0 C--N 1.324 -0.515 0 C-N-CA 118.851 -1.14 . . . . 0.0 111.405 -179.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.482 ' OD1' ' O ' ' Q' ' 22' ' ' GLU . 9.8 p-10 -112.44 52.07 0.79 Allowed 'General case' 0 N--CA 1.471 0.623 0 CA-C-N 113.511 -1.677 . . . . 0.0 108.847 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . 0.565 HG12 ' N ' ' P' ' 25' ' ' GLY . 96.4 t -41.35 161.66 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 CA-C-O 122.169 0.985 . . . . 0.0 112.249 -175.087 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.565 ' N ' HG12 ' P' ' 24' ' ' VAL . . . -93.14 32.61 5.57 Favored Glycine 0 CA--C 1.527 0.836 0 CA-C-N 113.077 -1.874 . . . . 0.0 114.218 -173.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.429 ' HB3' ' H ' ' O' ' 27' ' ' ASN . 11.9 t -92.57 -112.91 0.1 Allowed 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.575 ' O ' ' N ' ' P' ' 29' ' ' GLY . 15.4 m120 -86.27 156.58 20.2 Favored 'General case' 0 C--N 1.326 -0.439 0 C-N-CA 118.097 -1.441 . . . . 0.0 110.893 -178.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . . . . . . . . . 50.1 pttt -49.16 46.27 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.713 0 N-CA-C 115.628 1.714 . . . . 0.0 115.628 -178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.575 ' N ' ' O ' ' P' ' 27' ' ' ASN . . . -99.38 58.17 0.85 Allowed Glycine 0 CA--C 1.545 1.915 0 CA-C-N 118.875 0.761 . . . . 0.0 112.322 179.065 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . 0.576 ' O ' ' HB1' ' Q' ' 30' ' ' ALA . . . -152.72 108.06 3.27 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-N 117.811 0.805 . . . . 0.0 110.856 179.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.479 ' CD1' ' O ' ' J' ' 38' ' ' GLY . 14.0 pt -145.04 147.86 18.43 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.876 0 N-CA-C 113.387 0.884 . . . . 0.0 113.387 -179.702 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . . . . . . . . . 85.9 mt -114.4 115.89 50.93 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.952 0 CA-C-N 115.509 -0.769 . . . . 0.0 111.341 178.949 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -109.46 98.31 1.12 Allowed Glycine 0 N--CA 1.464 0.538 0 N-CA-C 104.739 -3.344 . . . . 0.0 104.739 174.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . . . . . . . . . 22.6 tp -127.49 132.43 49.98 Favored 'General case' 0 C--O 1.238 0.48 0 N-CA-C 115.32 1.6 . . . . 0.0 115.32 -173.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . 0.428 ' CG ' ' SD ' ' O' ' 35' ' ' MET . 90.6 mmm -111.56 112.83 24.82 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 174.756 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.494 HG21 HE22 ' R' ' 15' ' ' GLN . 0.0 OUTLIER -121.32 102.35 11.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -176.001 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' O' ' 37' ' ' GLY . . . 141.55 -161.34 27.0 Favored Glycine 0 CA--C 1.509 -0.339 0 C-N-CA 120.4 -0.905 . . . . 0.0 111.802 177.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . 0.565 ' O ' ' CD1' ' D' ' 31' ' ' ILE . . . 148.16 -55.8 0.5 Allowed Glycine 0 CA--C 1.544 1.87 0 CA-C-O 119.234 -0.759 . . . . 0.0 111.229 -178.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.607 HG23 HD11 ' C' ' 31' ' ' ILE . 73.3 t -144.72 139.85 23.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 CA-C-N 118.355 1.078 . . . . 0.0 108.805 177.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . . . . . . . . . 86.7 t . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 118.074 -0.965 . . . . 0.0 111.321 178.705 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -81.46 139.37 35.24 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.835 0.35 . . . . 0.0 110.609 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . 0.436 ' OE1' ' O ' ' P' ' 10' ' ' TYR . 95.9 mt-10 -85.36 110.0 18.8 Favored 'General case' 0 C--N 1.333 -0.142 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.632 HG12 ' H ' ' R' ' 12' ' ' VAL . 34.4 m -141.13 165.27 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 N-CA-C 112.374 0.509 . . . . 0.0 112.374 -178.535 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.509 ' CE1' ' O ' ' P' ' 11' ' ' GLU . 3.1 m-70 -132.93 121.13 22.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 115.542 -0.753 . . . . 0.0 109.785 178.326 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.588 ' CE1' ' N ' ' R' ' 14' ' ' HIS . 32.1 m-70 -144.82 161.83 38.29 Favored 'General case' 0 N--CA 1.469 0.524 0 C-N-CA 120.797 -0.361 . . . . 0.0 110.626 178.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.597 ' NE2' ' CG1' ' O' ' 36' ' ' VAL . 58.1 tp60 -90.09 157.81 17.6 Favored 'General case' 0 C--O 1.223 -0.34 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 177.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -141.52 102.34 4.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 176.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.594 HD22 HD12 ' P' ' 17' ' ' LEU . 77.7 mt -116.14 117.11 29.17 Favored 'General case' 0 CA--C 1.506 -0.719 0 C-N-CA 120.317 -0.553 . . . . 0.0 111.06 179.083 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 41.1 t -118.01 99.28 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 N-CA-C 108.207 -1.034 . . . . 0.0 108.207 177.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.403 ' CZ ' ' HB3' ' Q' ' 17' ' ' LEU . 7.2 m-30 -110.57 107.64 17.32 Favored 'General case' 0 C--O 1.235 0.297 0 N-CA-C 106.496 -1.668 . . . . 0.0 106.496 178.17 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -120.49 138.84 53.6 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.989 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.432 ' O ' ' HA ' ' R' ' 21' ' ' ALA . . . -147.62 151.79 36.79 Favored 'General case' 0 N--CA 1.468 0.454 0 N-CA-C 114.483 1.29 . . . . 0.0 114.483 -179.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.482 ' O ' ' OD1' ' P' ' 23' ' ' ASP . 80.5 tt0 -80.27 121.8 26.09 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.217 -179.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.458 ' OD1' ' O ' ' Q' ' 23' ' ' ASP . 67.1 t0 -136.22 52.08 1.99 Allowed 'General case' 0 N--CA 1.47 0.56 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 -177.381 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . . . . . . . . . 66.8 t -74.7 142.43 14.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 N-CA-C 105.251 -2.129 . . . . 0.0 105.251 177.435 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' P' ' 25' ' ' GLY . . . 100.4 38.05 3.61 Favored Glycine 0 N--CA 1.468 0.83 0 N-CA-C 106.082 -2.807 . . . . 0.0 106.082 -174.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 37.2 t -69.71 104.03 2.3 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 123.003 1.382 . . . . 0.0 114.568 -172.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . 0.505 ' O ' ' C ' ' Q' ' 28' ' ' LYS . 10.8 m120 -118.82 -153.33 0.53 Allowed 'General case' 0 C--N 1.333 -0.116 0 CA-C-N 111.824 -2.444 . . . . 0.0 105.036 178.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . 0.55 ' O ' ' HB2' ' R' ' 30' ' ' ALA . 99.0 mttt -35.42 -41.15 0.17 Allowed 'General case' 0 N--CA 1.484 1.244 0 CA-C-N 120.354 1.434 . . . . 0.0 109.9 -177.713 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . . . . . . . . . . . 91.02 -65.42 2.59 Favored Glycine 0 CA--C 1.532 1.148 0 N-CA-C 116.95 1.54 . . . . 0.0 116.95 172.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . 0.576 ' HB1' ' O ' ' P' ' 30' ' ' ALA . . . -171.01 174.95 4.53 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.981 -177.017 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . . . . . . . . . 63.6 mt -121.12 118.08 54.99 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 CA-C-N 113.347 -1.751 . . . . 0.0 107.015 176.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -120.38 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.24 0.543 . . . . 0.0 112.282 -178.04 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.81 114.34 2.07 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 109.191 -1.564 . . . . 0.0 109.191 178.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 32.0 mt -120.9 128.91 53.22 Favored 'General case' 0 CA--C 1.514 -0.408 0 N-CA-C 109.928 -0.397 . . . . 0.0 109.928 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 57.2 mtp -132.47 132.14 42.4 Favored 'General case' 0 CA--C 1.514 -0.405 0 C-N-CA 120.163 -0.615 . . . . 0.0 111.314 179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . 0.445 ' O ' ' N ' ' R' ' 37' ' ' GLY . 69.2 t -115.65 135.58 55.25 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 178.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.551 ' O ' ' N ' ' P' ' 38' ' ' GLY . . . -139.44 103.32 0.38 Allowed Glycine 0 C--N 1.306 -1.095 0 N-CA-C 109.213 -1.555 . . . . 0.0 109.213 -179.616 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.448 ' O ' ' C ' ' Q' ' 39' ' ' VAL . . . 148.56 72.5 0.01 OUTLIER Glycine 0 N--CA 1.479 1.524 0 CA-C-N 119.76 1.78 . . . . 0.0 114.635 -178.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . 0.879 ' H ' HD11 ' E' ' 31' ' ' ILE . 37.2 t -18.63 125.23 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.045 0 C-N-CA 123.601 0.761 . . . . 0.0 112.699 179.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.219 -0.516 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.639 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -81.96 140.16 34.17 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-O 120.889 0.376 . . . . 0.0 110.589 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . . . . . . . . . 78.6 tt0 -113.53 128.04 56.3 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.711 -179.603 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . 0.632 ' H ' HG12 ' Q' ' 12' ' ' VAL . 78.5 t -135.28 156.71 39.37 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.125 0.488 . . . . 0.0 110.982 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.437 ' N ' HG12 ' R' ' 12' ' ' VAL . 3.2 m-70 -144.06 132.42 22.03 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.591 -0.731 . . . . 0.0 111.252 -179.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . 0.588 ' N ' ' CE1' ' Q' ' 14' ' ' HIS . 64.2 m80 -151.73 161.73 42.18 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 177.016 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.597 ' NE2' HD23 ' R' ' 17' ' ' LEU . 52.3 tt0 -90.13 158.45 17.27 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.89 0.376 . . . . 0.0 111.486 179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -140.6 100.83 3.95 Favored 'General case' 0 C--N 1.318 -0.778 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 175.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.597 HD23 ' NE2' ' R' ' 15' ' ' GLN . 0.3 OUTLIER -111.64 112.78 24.73 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-O 120.958 0.409 . . . . 0.0 109.948 179.313 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 87.6 t -117.83 101.64 12.18 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.465 ' O ' ' CD1' ' R' ' 20' ' ' PHE . 4.0 m-85 -119.43 116.83 26.96 Favored 'General case' 0 CA--C 1.518 -0.263 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 179.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . 0.465 ' CD1' ' O ' ' R' ' 19' ' ' PHE . 80.1 m-85 -150.8 160.03 44.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 122.08 0.943 . . . . 0.0 112.384 -179.142 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . 0.432 ' HA ' ' O ' ' Q' ' 21' ' ' ALA . . . -129.36 145.94 51.31 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.129 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.77 153.87 40.63 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 122.095 0.95 . . . . 0.0 113.49 -175.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . . . . . . . . . 61.0 t0 61.98 47.93 5.54 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 113.581 -1.645 . . . . 0.0 111.676 -179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.638 HG12 ' N ' ' R' ' 25' ' ' GLY . 45.4 t -59.68 171.12 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 120.326 -0.549 . . . . 0.0 109.911 178.181 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . 0.638 ' N ' HG12 ' R' ' 24' ' ' VAL . . . 161.12 31.41 0.02 OUTLIER Glycine 0 CA--C 1.521 0.412 0 N-CA-C 110.695 -0.962 . . . . 0.0 110.695 177.289 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 3.3 t 72.73 120.75 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -179.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 95.7 m-20 -83.04 162.3 21.44 Favored 'General case' 0 C--N 1.325 -0.457 0 C-N-CA 119.428 -0.909 . . . . 0.0 111.508 -179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -48.08 -39.67 20.89 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.407 177.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.38 66.89 0.04 OUTLIER Glycine 0 CA--C 1.539 1.557 0 CA-C-N 115.115 -0.948 . . . . 0.0 111.829 -178.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . 0.55 ' HB2' ' O ' ' Q' ' 28' ' ' LYS . . . -71.81 159.32 34.52 Favored 'General case' 0 C--N 1.345 0.409 0 CA-C-N 117.837 0.819 . . . . 0.0 110.117 -179.735 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 94.9 mt -107.42 116.14 50.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 109.303 -0.628 . . . . 0.0 109.303 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 90.1 mt -124.25 125.44 70.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 CA-C-O 120.803 0.335 . . . . 0.0 110.566 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.15 121.05 3.24 Favored Glycine 0 N--CA 1.463 0.478 0 N-CA-C 109.894 -1.282 . . . . 0.0 109.894 179.33 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.905 ' H ' HD23 ' R' ' 34' ' ' LEU . 1.2 pt? -123.15 128.26 49.81 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 121.433 0.635 . . . . 0.0 110.471 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . . . . . . . . . 91.3 mmm -123.56 120.03 31.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.628 -0.714 . . . . 0.0 110.022 -178.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . . . . . . . . . 96.2 t -100.28 115.42 41.51 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 C-N-CA 119.859 -0.736 . . . . 0.0 110.33 179.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.445 ' N ' ' O ' ' Q' ' 36' ' ' VAL . . . -115.25 122.97 5.78 Favored Glycine 0 CA--C 1.508 -0.384 0 N-CA-C 107.494 -2.242 . . . . 0.0 107.494 177.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . . . . . . . . . . . 113.92 66.48 0.46 Allowed Glycine 0 CA--C 1.536 1.389 0 C-N-CA 120.366 -0.921 . . . . 0.0 112.428 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.691 HG22 HD11 ' F' ' 31' ' ' ILE . 26.8 m -53.89 152.59 1.22 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 117.43 0.615 . . . . 0.0 110.574 179.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 21.4 m . . . . . 0 C--O 1.221 -0.432 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.756 179.685 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.505 0 N-CA-C 109.761 -1.335 . . . . 0.0 109.761 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.416 ' O ' ' OE2' ' A' ' 11' ' ' GLU . 95.2 m-85 -84.14 140.03 32.03 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.726 0.298 . . . . 0.0 110.792 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.416 ' OE2' ' O ' ' A' ' 10' ' ' TYR . 43.9 mm-40 -136.94 114.23 10.83 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.709 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.774 HG13 HG13 ' B' ' 12' ' ' VAL . 73.2 t -138.61 87.22 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.563 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.6 m80 -148.54 143.66 26.79 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 121.05 -0.26 . . . . 0.0 110.339 -179.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.592 ' CD2' ' N ' ' A' ' 14' ' ' HIS . 0.5 OUTLIER -111.94 163.14 14.56 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 179.144 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 87.5 mt-30 -89.91 158.74 17.28 Favored 'General case' 0 CA--C 1.518 -0.273 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.9 tttm -140.62 106.86 5.24 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 178.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 87.9 mt -136.11 120.09 17.54 Favored 'General case' 0 N--CA 1.474 0.734 0 CA-C-N 118.917 0.78 . . . . 0.0 110.772 178.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -133.34 136.01 55.44 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.703 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -125.46 119.38 28.08 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.907 0.384 . . . . 0.0 111.203 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -108.39 118.73 37.53 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 178.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.16 117.5 30.21 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.215 0.531 . . . . 0.0 111.2 -179.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.73 -162.56 0.33 Allowed 'General case' 0 CA--C 1.518 -0.258 0 CA-C-N 115.294 -0.867 . . . . 0.0 108.897 179.399 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -39.8 -60.54 0.98 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 120.635 -0.426 . . . . 0.0 110.697 -179.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.442 HG12 ' N ' ' A' ' 25' ' ' GLY . 16.8 t -73.15 160.77 5.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 177.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.442 ' N ' HG12 ' A' ' 24' ' ' VAL . . . 110.26 -34.97 5.11 Favored Glycine 0 N--CA 1.467 0.731 0 CA-C-N 116.36 -0.382 . . . . 0.0 112.203 177.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.452 ' CB ' ' HZ3' ' B' ' 28' ' ' LYS . 5.3 t -80.45 119.5 23.22 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 120.431 -0.508 . . . . 0.0 109.807 179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 15.6 m120 -90.04 161.23 15.93 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 122.016 0.912 . . . . 0.0 112.869 -179.767 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.441 ' O ' ' O ' ' B' ' 28' ' ' LYS . 99.3 mttt -46.77 -38.87 10.74 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 113.666 -1.606 . . . . 0.0 112.331 176.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -110.09 70.47 0.21 Allowed Glycine 0 CA--C 1.532 1.139 0 CA-C-N 114.575 -1.193 . . . . 0.0 114.335 -173.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.517 ' O ' ' HA ' ' B' ' 30' ' ' ALA . . . -95.21 117.0 29.48 Favored 'General case' 0 CA--C 1.538 0.519 0 CA-C-O 123.86 1.79 . . . . 0.0 112.071 -177.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 32.0 pt -149.59 147.78 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.753 0 CA-C-N 112.457 -2.156 . . . . 0.0 108.589 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.406 ' O ' ' O ' ' B' ' 33' ' ' GLY . 97.8 mt -105.74 114.03 44.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.536 0 N-CA-C 109.944 -0.391 . . . . 0.0 109.944 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.26 95.04 0.72 Allowed Glycine 0 N--CA 1.462 0.376 0 N-CA-C 105.639 -2.984 . . . . 0.0 105.639 177.141 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 92.3 mt -142.95 151.78 41.3 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 122.664 1.221 . . . . 0.0 113.901 -176.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 89.5 mmm -106.99 108.98 20.76 Favored 'General case' 0 N--CA 1.447 -0.606 0 CA-C-N 112.634 -2.075 . . . . 0.0 105.616 176.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.41 ' O ' ' HA ' ' B' ' 36' ' ' VAL . 24.3 t -124.14 112.05 31.1 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 N-CA-C 108.893 -0.781 . . . . 0.0 108.893 -178.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.486 ' CA ' ' NE2' ' C' ' 15' ' ' GLN . . . 115.48 -132.09 10.09 Favored Glycine 0 C--N 1.321 -0.296 0 N-CA-C 108.868 -1.693 . . . . 0.0 108.868 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.436 ' O ' HG12 ' B' ' 39' ' ' VAL . . . 92.06 -63.34 2.46 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 120.996 -0.621 . . . . 0.0 111.579 -179.756 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.4 ' O ' ' O ' ' A' ' 40' ' ' VAL . 1.1 m -96.03 177.86 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.614 0 N-CA-C 109.611 -0.514 . . . . 0.0 109.611 179.057 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.537 ' H ' ' HB3' ' H' ' 28' ' ' LYS . 7.3 p . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.893 -1.051 . . . . 0.0 110.746 179.245 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.322 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -107.06 132.41 53.0 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.736 0.303 . . . . 0.0 110.243 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.519 ' O ' ' CE1' ' C' ' 13' ' ' HIS . 84.2 tt0 -151.35 128.37 11.08 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.474 -0.33 . . . . 0.0 110.398 -179.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.774 HG13 HG13 ' A' ' 12' ' ' VAL . 0.2 OUTLIER -127.05 109.93 21.78 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-O 121.438 0.637 . . . . 0.0 110.358 179.703 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.444 ' CE1' ' HD1' ' C' ' 13' ' ' HIS . 22.6 p-80 -151.21 158.97 44.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.726 179.21 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.52 ' CD2' ' ND1' ' A' ' 14' ' ' HIS . 2.8 m-70 -143.04 163.89 31.58 Favored 'General case' 0 N--CA 1.464 0.229 0 C-N-CA 120.18 -0.608 . . . . 0.0 110.63 178.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -89.96 152.01 21.42 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 177.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.3 mttp -149.16 100.98 3.1 Favored 'General case' 0 C--N 1.307 -1.262 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 178.229 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 69.8 mt -122.78 121.91 37.44 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-O 120.789 0.328 . . . . 0.0 110.41 179.676 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . 0.722 HG22 HG22 ' C' ' 18' ' ' VAL . 60.6 t -125.79 125.88 69.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.552 179.939 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 68.1 m-85 -124.17 120.88 33.57 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-O 120.57 0.224 . . . . 0.0 110.695 179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 85.5 t80 -122.58 121.06 35.58 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 116.697 -0.228 . . . . 0.0 110.967 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.98 130.15 55.53 Favored 'General case' 0 N--CA 1.481 1.08 0 CA-C-O 120.655 0.264 . . . . 0.0 110.611 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.452 ' CG ' ' N ' ' B' ' 23' ' ' ASP . 77.0 tt0 -66.73 154.87 39.61 Favored 'General case' 0 N--CA 1.475 0.818 0 N-CA-C 116.68 2.104 . . . . 0.0 116.68 -175.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.452 ' N ' ' CG ' ' B' ' 22' ' ' GLU . 65.8 t0 -67.15 47.79 0.04 OUTLIER 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 111.216 -2.72 . . . . 0.0 113.833 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.739 HG12 ' H ' ' B' ' 25' ' ' GLY . 1.9 t -60.73 -179.5 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 C-N-CA 118.388 -1.325 . . . . 0.0 111.527 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.739 ' H ' HG12 ' B' ' 24' ' ' VAL . . . -99.71 28.91 13.33 Favored Glycine 0 N--CA 1.471 0.999 0 CA-C-N 114.809 -1.087 . . . . 0.0 115.681 -175.173 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' B' ' 27' ' ' ASN . 42.8 t -162.18 116.14 1.83 Allowed 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 120.089 1.945 . . . . 0.0 113.869 -176.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' B' ' 26' ' ' SER . 10.5 m120 -22.71 164.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.848 0 O-C-N 125.311 1.632 . . . . 0.0 112.636 178.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.452 ' HZ3' ' CB ' ' A' ' 26' ' ' SER . 98.8 mttt -155.39 -20.71 0.11 Allowed 'General case' 0 CA--C 1.53 0.185 0 C-N-CA 119.826 -0.75 . . . . 0.0 112.646 -177.192 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 71.38 97.8 0.06 OUTLIER Glycine 0 C--N 1.334 0.462 0 C-N-CA 117.497 -2.287 . . . . 0.0 109.603 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.517 ' HA ' ' O ' ' A' ' 30' ' ' ALA . . . -120.05 119.08 32.32 Favored 'General case' 0 C--O 1.238 0.472 0 CA-C-O 122.66 1.219 . . . . 0.0 112.505 -176.085 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.655 HD11 HG13 ' N' ' 39' ' ' VAL . 97.3 mt -127.45 132.29 69.48 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 CA-C-N 113.971 -1.468 . . . . 0.0 111.097 179.406 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.602 HG22 HD11 ' C' ' 34' ' ' LEU . 23.1 mt -102.72 116.63 46.77 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.102 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' A' ' 32' ' ' ILE . . . -115.63 98.56 0.84 Allowed Glycine 0 C--O 1.237 0.287 0 N-CA-C 105.818 -2.913 . . . . 0.0 105.818 177.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -137.68 135.14 36.2 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 122.495 1.14 . . . . 0.0 112.558 -175.459 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . . . . . . . . . 4.4 mtp -104.05 110.36 22.5 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 113.311 -1.768 . . . . 0.0 106.842 177.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.566 HG23 HG22 ' C' ' 36' ' ' VAL . 1.4 m -131.21 123.09 52.69 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.637 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . 146.84 -113.4 0.66 Allowed Glycine 0 C--N 1.311 -0.84 0 N-CA-C 110.261 -1.135 . . . . 0.0 110.261 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 71.61 -72.62 0.82 Allowed Glycine 0 CA--C 1.532 1.103 0 N-CA-C 111.316 -0.714 . . . . 0.0 111.316 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . 0.564 HG21 ' CA ' ' H' ' 29' ' ' GLY . 3.7 p -144.58 157.48 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.165 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.455 ' C ' ' O ' ' B' ' 39' ' ' VAL . 20.4 m . . . . . 0 N--CA 1.473 0.686 0 CA-C-O 117.965 -1.017 . . . . 0.0 111.921 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 109.431 -1.467 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.2 m-85 -107.94 136.16 48.11 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.314 -0.254 . . . . 0.0 110.314 179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 83.4 tt0 -122.12 100.99 7.26 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 120.862 0.363 . . . . 0.0 110.323 179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.529 ' CG2' ' HE2' ' C' ' 14' ' ' HIS . 1.5 p -145.1 137.55 21.2 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.281 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.345 179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.519 ' CE1' ' O ' ' B' ' 11' ' ' GLU . 2.0 m-70 -147.22 135.31 21.47 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 121.15 -0.22 . . . . 0.0 111.116 179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.653 ' ND1' ' N ' ' D' ' 14' ' ' HIS . 32.8 m-70 -142.23 161.08 38.92 Favored 'General case' 0 N--CA 1.472 0.646 0 C-N-CA 120.243 -0.583 . . . . 0.0 110.977 177.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.486 ' NE2' ' CA ' ' A' ' 37' ' ' GLY . 22.8 mt-30 -85.41 157.16 20.56 Favored 'General case' 0 CA--C 1.523 -0.09 0 N-CA-C 108.258 -1.016 . . . . 0.0 108.258 176.109 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -159.22 91.94 1.05 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . 0.421 HD12 ' N ' ' C' ' 17' ' ' LEU . 5.2 mp -128.82 122.35 30.26 Favored 'General case' 0 CA--C 1.505 -0.761 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.968 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . 0.722 HG22 HG22 ' B' ' 18' ' ' VAL . 3.9 m -124.48 120.79 59.97 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 N-CA-C 108.314 -0.995 . . . . 0.0 108.314 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -113.47 108.16 16.82 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-N 114.889 -1.05 . . . . 0.0 108.317 -179.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -110.59 122.01 46.72 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 110.245 -0.28 . . . . 0.0 110.245 -179.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.41 125.72 33.32 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.914 0.864 . . . . 0.0 112.406 -179.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' C' ' 23' ' ' ASP . 94.9 mt-10 -98.72 110.14 22.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 107.327 -1.361 . . . . 0.0 107.327 177.699 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.41 ' OD1' ' O ' ' C' ' 22' ' ' GLU . 99.2 m-20 -140.45 49.26 1.72 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 114.618 -1.174 . . . . 0.0 111.2 -175.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.556 HG12 ' N ' ' C' ' 25' ' ' GLY . 53.8 t -71.44 161.39 4.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 C-N-CA 119.339 -0.945 . . . . 0.0 109.901 -175.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.556 ' N ' HG12 ' C' ' 24' ' ' VAL . . . 109.46 -29.87 9.09 Favored Glycine 0 CA--C 1.531 1.031 0 N-CA-C 107.315 -2.314 . . . . 0.0 107.315 -174.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.489 ' CB ' ' O ' ' C' ' 25' ' ' GLY . 1.1 m 93.21 114.58 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.587 0 CA-C-N 114.194 -1.003 . . . . 0.0 110.583 179.257 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -73.58 164.05 27.18 Favored 'General case' 0 CA--C 1.53 0.181 0 CA-C-O 121.551 0.691 . . . . 0.0 112.266 -179.187 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' D' ' 28' ' ' LYS . 98.9 mttt -48.01 -37.01 13.84 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 114.109 1.151 . . . . 0.0 114.109 178.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . -178.85 77.21 0.06 OUTLIER Glycine 0 CA--C 1.536 1.367 0 C-N-CA 120.384 -0.912 . . . . 0.0 112.971 -175.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -80.0 138.27 37.01 Favored 'General case' 0 CA--C 1.541 0.633 0 CA-C-O 122.547 1.165 . . . . 0.0 113.478 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.574 HD11 HG22 ' O' ' 39' ' ' VAL . 94.1 mt -142.42 144.89 24.22 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.747 0 CA-C-N 114.328 -1.305 . . . . 0.0 112.656 -178.763 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.551 HD13 ' CD1' ' E' ' 19' ' ' PHE . 75.6 mt -106.71 111.4 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 174.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.72 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -118.94 101.66 0.89 Allowed Glycine 0 N--CA 1.465 0.592 0 N-CA-C 108.534 -1.826 . . . . 0.0 108.534 179.213 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.72 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.6 mp -141.9 148.01 38.02 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.954 1.359 . . . . 0.0 113.329 -178.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 92.2 mmm -104.4 111.52 24.21 Favored 'General case' 0 N--CA 1.44 -0.925 0 CA-C-N 112.097 -2.319 . . . . 0.0 105.692 176.113 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.98 HG11 HD11 ' E' ' 17' ' ' LEU . 55.1 t -124.81 123.22 65.32 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.741 0 N-CA-C 109.827 -0.435 . . . . 0.0 109.827 -178.028 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . 143.07 -113.31 0.77 Allowed Glycine 0 C--N 1.312 -0.794 0 C-N-CA 119.75 -1.214 . . . . 0.0 111.958 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 81.78 -73.01 2.68 Favored Glycine 0 CA--C 1.533 1.196 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 -177.738 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . 0.652 ' HB ' HD11 ' I' ' 31' ' ' ILE . 13.6 p -172.79 132.92 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 177.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.555 ' CG2' ' NE2' ' F' ' 13' ' ' HIS . 21.4 m . . . . . 0 C--O 1.219 -0.55 0 CA-C-O 117.776 -1.107 . . . . 0.0 110.043 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.711 -1.356 . . . . 0.0 109.711 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -105.87 132.68 51.69 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.774 0.321 . . . . 0.0 110.63 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -97.36 113.77 25.47 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.622 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.482 HG23 HG23 ' C' ' 12' ' ' VAL . 20.3 m -133.86 134.68 55.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.231 0.539 . . . . 0.0 111.218 -179.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.498 ' O ' ' CG ' ' E' ' 13' ' ' HIS . 7.6 m80 -140.07 135.6 32.76 Favored 'General case' 0 C--O 1.225 -0.194 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.032 179.339 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.653 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 1.3 t-80 -136.88 156.0 49.04 Favored 'General case' 0 N--CA 1.466 0.345 0 C-N-CA 120.151 -0.62 . . . . 0.0 110.649 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.665 HE21 ' CD1' ' D' ' 17' ' ' LEU . 54.8 tt0 -87.55 157.15 19.23 Favored 'General case' 0 CA--C 1.516 -0.362 0 N-CA-C 109.332 -0.618 . . . . 0.0 109.332 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -162.45 92.93 0.83 Allowed 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.221 -0.991 . . . . 0.0 110.674 176.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.665 ' CD1' HE21 ' D' ' 15' ' ' GLN . 23.3 mt -122.39 114.17 20.37 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 178.315 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.9 t -110.64 109.18 27.5 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.534 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 179.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.407 ' CZ ' ' HB3' ' D' ' 17' ' ' LEU . 66.0 m-85 -109.62 107.37 17.42 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 107.269 -1.382 . . . . 0.0 107.269 178.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -122.24 131.58 54.0 Favored 'General case' 0 N--CA 1.474 0.726 0 CA-C-O 120.737 0.303 . . . . 0.0 111.544 -177.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.06 140.01 32.44 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 122.033 0.921 . . . . 0.0 112.998 -179.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -82.03 113.87 20.21 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 122.039 0.923 . . . . 0.0 111.372 -179.159 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.546 ' H ' ' HB3' ' E' ' 22' ' ' GLU . 54.4 m-20 50.17 46.42 24.77 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 113.551 -1.659 . . . . 0.0 112.267 179.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.707 HG12 ' N ' ' D' ' 25' ' ' GLY . 96.4 t -111.62 177.64 1.44 Allowed 'Isoleucine or valine' 0 CA--C 1.497 -1.078 0 N-CA-C 104.719 -2.326 . . . . 0.0 104.719 174.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.707 ' N ' HG12 ' D' ' 24' ' ' VAL . . . 63.02 28.69 72.49 Favored Glycine 0 N--CA 1.442 -0.922 0 N-CA-C 106.91 -2.476 . . . . 0.0 106.91 178.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 48.9 m -108.67 -120.01 0.26 Allowed 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 121.794 0.807 . . . . 0.0 112.498 -177.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -79.94 174.05 11.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.338 -178.496 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.422 ' O ' ' O ' ' C' ' 28' ' ' LYS . 99.1 mttt 58.32 39.91 25.01 Favored 'General case' 0 C--N 1.323 -0.557 0 N-CA-C 113.998 1.11 . . . . 0.0 113.998 178.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 100.11 70.99 0.95 Allowed Glycine 0 N--CA 1.477 1.422 0 C-N-CA 119.031 -1.557 . . . . 0.0 116.346 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.0 109.08 15.08 Favored 'General case' 0 C--O 1.238 0.454 0 CA-C-O 121.365 0.602 . . . . 0.0 109.917 179.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.565 HD11 HG23 ' P' ' 39' ' ' VAL . 2.1 mt -133.57 141.95 42.94 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.782 0 N-CA-C 114.101 1.148 . . . . 0.0 114.101 -177.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.578 HD13 ' CD1' ' F' ' 19' ' ' PHE . 6.4 mt -108.69 113.9 45.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.91 102.97 1.27 Allowed Glycine 0 C--O 1.24 0.511 0 N-CA-C 107.025 -2.43 . . . . 0.0 107.025 177.469 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.459 HD23 HG13 ' D' ' 36' ' ' VAL . 10.5 tp -133.93 134.51 42.69 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 122.181 0.991 . . . . 0.0 112.877 -176.725 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 1.6 mtp -105.17 112.36 25.46 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-N 113.445 -1.707 . . . . 0.0 107.304 176.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' E' ' 37' ' ' GLY . 0.4 OUTLIER -114.17 177.06 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.544 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 -179.165 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.414 ' HA3' ' H ' ' E' ' 37' ' ' GLY . . . 131.53 -96.29 0.33 Allowed Glycine 0 C--N 1.31 -0.877 0 N-CA-C 110.184 -1.166 . . . . 0.0 110.184 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . 0.496 ' O ' ' C ' ' D' ' 39' ' ' VAL . . . 38.17 75.92 0.08 OUTLIER Glycine 0 CA--C 1.533 1.207 0 C-N-CA 120.565 -0.826 . . . . 0.0 112.056 179.651 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.563 ' CG2' HD11 ' J' ' 31' ' ' ILE . 60.4 t -6.35 123.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 N-CA-C 113.053 0.76 . . . . 0.0 113.053 -178.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.509 ' O ' ' NZ ' ' K' ' 28' ' ' LYS . 55.3 t . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.455 179.608 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -81.81 138.98 35.03 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.993 0.425 . . . . 0.0 110.489 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -136.28 140.61 43.55 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.029 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.434 ' H ' HG12 ' D' ' 12' ' ' VAL . 70.4 t -124.35 124.97 69.66 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.28 0 CA-C-O 120.902 0.382 . . . . 0.0 110.465 -179.855 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.607 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.5 OUTLIER -156.4 134.75 11.44 Favored 'General case' 0 C--O 1.219 -0.513 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.058 179.387 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.607 ' N ' ' ND1' ' E' ' 13' ' ' HIS . 34.8 m-70 -143.52 167.38 22.35 Favored 'General case' 0 N--CA 1.469 0.516 0 CA-C-O 120.73 0.3 . . . . 0.0 110.464 179.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.63 ' NE2' HG12 ' C' ' 36' ' ' VAL . 34.4 tt0 -89.64 151.3 21.97 Favored 'General case' 0 C--N 1.332 -0.185 0 N-CA-C 108.042 -1.095 . . . . 0.0 108.042 177.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 14.3 mttt -153.35 98.73 2.29 Favored 'General case' 0 C--N 1.317 -0.824 0 C-N-CA 119.399 -0.92 . . . . 0.0 111.011 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.98 HD11 HG11 ' C' ' 36' ' ' VAL . 2.9 mt -121.84 116.13 23.88 Favored 'General case' 0 N--CA 1.47 0.566 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 178.39 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -111.21 101.54 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 108.666 -0.865 . . . . 0.0 108.666 178.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.551 ' CD1' HD13 ' C' ' 32' ' ' ILE . 41.2 m-85 -106.75 102.65 12.01 Favored 'General case' 0 C--O 1.235 0.337 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 178.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 9.7 m-85 -122.49 132.99 54.59 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-O 121.229 0.537 . . . . 0.0 112.225 -178.357 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -138.77 145.34 40.08 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.42 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.546 ' HB3' ' H ' ' D' ' 23' ' ' ASP . 79.5 tt0 -68.73 147.16 52.21 Favored 'General case' 0 N--CA 1.471 0.589 0 C-N-CA 117.574 -1.65 . . . . 0.0 108.804 -179.795 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.534 ' O ' ' O ' ' E' ' 24' ' ' VAL . 21.2 t70 -128.05 61.6 1.44 Allowed 'General case' 0 N--CA 1.476 0.827 0 CA-C-N 115.449 -0.796 . . . . 0.0 113.083 -174.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.534 ' O ' ' O ' ' E' ' 23' ' ' ASP . 4.7 t -33.64 -110.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 113.725 1.009 . . . . 0.0 113.725 -175.318 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' E' ' 26' ' ' SER . . . -113.4 46.49 1.16 Allowed Glycine 0 N--CA 1.485 1.952 0 CA-C-N 120.173 1.351 . . . . 0.0 115.421 -174.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.515 ' CB ' ' O ' ' E' ' 25' ' ' GLY . 1.8 t 91.56 111.5 0.03 OUTLIER 'General case' 0 N--CA 1.472 0.633 0 C-N-CA 122.318 0.247 . . . . 0.0 111.378 176.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -75.35 163.88 27.0 Favored 'General case' 0 C--N 1.325 -0.484 0 C-N-CA 119.4 -0.92 . . . . 0.0 111.644 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -48.88 -39.41 25.76 Favored 'General case' 0 CA--C 1.533 0.311 0 N-CA-C 113.959 1.096 . . . . 0.0 113.959 177.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . 171.31 68.13 0.04 OUTLIER Glycine 0 CA--C 1.544 1.849 0 C-N-CA 120.159 -1.02 . . . . 0.0 113.312 -176.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.76 145.17 50.6 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 119.333 1.566 . . . . 0.0 111.727 -177.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.499 HG23 HG23 ' D' ' 31' ' ' ILE . 1.3 tt -131.72 141.75 44.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.872 0 CA-C-O 121.675 0.75 . . . . 0.0 111.968 -177.814 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 94.5 mt -124.98 131.43 72.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.78 -178.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.56 117.2 2.72 Favored Glycine 0 CA--C 1.533 1.182 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 179.654 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 36.5 mt -123.55 122.81 39.14 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.236 -179.417 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 95.0 mmm -119.73 129.18 54.39 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.468 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 54.2 t -94.15 135.05 29.65 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 C-N-CA 119.478 -0.889 . . . . 0.0 110.985 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.518 ' N ' ' O ' ' D' ' 36' ' ' VAL . . . -99.9 -103.42 2.51 Favored Glycine 0 CA--C 1.52 0.364 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 178.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . 0.493 ' O ' ' N ' ' D' ' 39' ' ' VAL . . . -63.27 75.12 0.04 OUTLIER Glycine 0 CA--C 1.534 1.229 0 CA-C-N 113.891 -1.155 . . . . 0.0 112.48 179.591 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.505 HG11 ' H ' ' F' ' 39' ' ' VAL . 8.8 m -46.12 159.65 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 N-CA-C 112.803 0.668 . . . . 0.0 112.803 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 39.2 t . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.822 179.819 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -111.98 136.97 50.61 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 120.685 0.279 . . . . 0.0 110.707 180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -102.66 140.79 36.47 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.6 179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.481 HG12 ' NE2' ' E' ' 14' ' ' HIS . 2.6 t -108.22 106.02 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-O 120.839 0.352 . . . . 0.0 110.471 -179.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.587 ' ND1' ' N ' ' F' ' 14' ' ' HIS . 17.1 t-80 -152.97 139.89 19.12 Favored 'General case' 0 N--CA 1.463 0.202 0 N-CA-C 112.499 0.555 . . . . 0.0 112.499 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.587 ' N ' ' ND1' ' F' ' 13' ' ' HIS . 81.0 t60 -150.52 168.64 23.61 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.833 178.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.49 ' N ' ' CG ' ' F' ' 14' ' ' HIS . 51.1 tt0 -89.56 150.35 22.46 Favored 'General case' 0 C--O 1.231 0.13 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -151.82 96.35 2.22 Favored 'General case' 0 C--N 1.317 -0.82 0 C-N-CA 120.563 -0.455 . . . . 0.0 110.195 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.431 HD22 HG11 ' D' ' 36' ' ' VAL . 0.3 OUTLIER -116.84 109.74 17.47 Favored 'General case' 0 CA--C 1.517 -0.313 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 178.273 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 2.4 t -108.58 106.27 20.38 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.074 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.578 ' CD1' HD13 ' D' ' 32' ' ' ILE . 44.3 m-85 -109.04 107.35 17.66 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.343 -1.354 . . . . 0.0 107.343 179.016 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.475 ' CD1' ' O ' ' F' ' 19' ' ' PHE . 9.2 m-85 -146.63 140.69 26.21 Favored 'General case' 0 N--CA 1.465 0.294 0 C-N-CA 118.29 -1.364 . . . . 0.0 114.063 -178.256 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.517 ' HB1' ' HB2' ' E' ' 23' ' ' ASP . . . -114.86 119.34 36.26 Favored 'General case' 0 N--CA 1.45 -0.448 0 N-CA-C 103.649 -2.723 . . . . 0.0 103.649 174.836 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 99.2 mt-10 -95.09 134.49 37.74 Favored 'General case' 0 N--CA 1.482 1.127 0 N-CA-C 117.533 2.42 . . . . 0.0 117.533 -172.614 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.472 ' CG ' ' H ' ' F' ' 24' ' ' VAL . 24.4 p-10 174.25 -59.82 0.01 OUTLIER 'General case' 0 C--N 1.348 0.525 0 CA-C-N 113.406 -1.725 . . . . 0.0 110.598 173.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.472 ' H ' ' CG ' ' F' ' 23' ' ' ASP . 31.1 m -117.19 173.09 4.51 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.808 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 176.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -60.35 -34.69 86.02 Favored Glycine 0 CA--C 1.533 1.18 0 C-N-CA 121.005 -0.617 . . . . 0.0 111.872 176.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 88.9 p -156.84 114.31 3.16 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 114.994 -0.603 . . . . 0.0 110.835 -176.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.439 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 95.9 m-20 -51.44 171.43 0.04 OUTLIER 'General case' 0 N--CA 1.466 0.347 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.648 -178.584 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -61.69 -39.84 92.88 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 114.99 1.478 . . . . 0.0 114.99 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -172.06 67.03 0.13 Allowed Glycine 0 CA--C 1.537 1.461 0 C-N-CA 119.094 -1.527 . . . . 0.0 114.809 -178.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -88.12 174.95 7.94 Favored 'General case' 0 N--CA 1.463 0.19 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 178.027 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.525 HD12 HG12 ' R' ' 39' ' ' VAL . 14.6 tt -129.61 137.83 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.451 178.845 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 16.2 tt -132.66 140.45 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 CA-C-O 120.994 0.426 . . . . 0.0 111.57 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.47 124.43 3.68 Favored Glycine 0 CA--C 1.525 0.698 0 N-CA-C 110.375 -1.09 . . . . 0.0 110.375 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . 0.432 HD23 ' C ' ' F' ' 34' ' ' LEU . 9.3 tt -130.69 127.15 38.27 Favored 'General case' 0 CA--C 1.514 -0.44 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 92.8 mtp -139.33 145.4 39.02 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 113.187 0.81 . . . . 0.0 113.187 -178.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 6.3 p -144.59 146.07 20.65 Favored 'Isoleucine or valine' 0 C--O 1.232 0.149 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.11 177.436 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -137.45 102.11 0.37 Allowed Glycine 0 C--N 1.319 -0.368 0 C-N-CA 120.446 -0.883 . . . . 0.0 111.172 178.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.6 -73.56 0.3 Allowed Glycine 0 CA--C 1.536 1.381 0 C-N-CA 120.454 -0.879 . . . . 0.0 113.96 176.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.598 HG12 ' N ' ' F' ' 40' ' ' VAL . 99.1 t -146.82 163.31 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-O 120.998 0.428 . . . . 0.0 110.443 -179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . 0.598 ' N ' HG12 ' F' ' 39' ' ' VAL . 8.0 p . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 117.896 -1.049 . . . . 0.0 110.334 -179.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -113.05 134.05 54.7 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-O 120.807 0.337 . . . . 0.0 110.377 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.4 tt0 -150.9 154.0 36.35 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.833 -179.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 99.4 t -120.96 133.96 65.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 121.174 0.511 . . . . 0.0 110.967 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -103.89 158.52 16.35 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.742 -179.596 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.618 ' CD2' ' N ' ' G' ' 15' ' ' GLN . 18.6 t60 -85.62 166.97 15.78 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.718 -179.569 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.618 ' N ' ' CD2' ' G' ' 14' ' ' HIS . 83.6 mt-30 -155.29 141.81 18.74 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.169 0.509 . . . . 0.0 110.357 178.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.629 ' C ' HD12 ' G' ' 17' ' ' LEU . 99.0 mttt -88.03 110.16 20.4 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.743 178.335 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.629 HD12 ' C ' ' G' ' 16' ' ' LYS . 11.3 mp -120.42 112.91 19.58 Favored 'General case' 0 N--CA 1.479 0.977 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 177.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.404 HG22 ' CG2' ' H' ' 18' ' ' VAL . 61.8 t -125.74 131.32 72.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.155 -178.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -129.68 128.25 42.17 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.469 178.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -128.29 126.78 41.49 Favored 'General case' 0 N--CA 1.468 0.459 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 179.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.75 122.61 38.52 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-O 121.706 0.765 . . . . 0.0 112.012 -178.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -121.56 133.25 55.01 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.536 179.192 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.718 ' H ' ' CG ' ' H' ' 23' ' ' ASP . 98.3 m-20 53.49 55.03 9.17 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.337 -0.847 . . . . 0.0 112.181 -179.963 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 5.1 m -67.71 134.53 30.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 N-CA-C 108.688 -0.856 . . . . 0.0 108.688 177.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -114.1 -31.62 2.21 Favored Glycine 0 CA--C 1.532 1.156 0 C-N-CA 120.652 -0.785 . . . . 0.0 113.357 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 19.1 m -93.24 -130.25 0.13 Allowed 'General case' 0 CA--C 1.541 0.628 0 N-CA-C 113.648 0.981 . . . . 0.0 113.648 -177.882 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.522 ' OD1' ' NZ ' ' H' ' 28' ' ' LYS . 71.6 m-20 -82.91 -167.64 1.74 Allowed 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 114.5 -1.227 . . . . 0.0 111.541 -178.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 67.9 mttm 51.12 39.22 22.92 Favored 'General case' 0 C--O 1.232 0.142 0 CA-C-N 115.869 -0.605 . . . . 0.0 112.24 179.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.25 -66.67 1.59 Allowed Glycine 0 CA--C 1.539 1.565 0 C-N-CA 120.158 -1.02 . . . . 0.0 110.68 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' H' ' 30' ' ' ALA . . . -150.7 62.32 0.93 Allowed 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 119.593 1.696 . . . . 0.0 114.605 177.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 80.6 mt -136.45 113.44 13.45 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 N-CA-C 106.601 -1.629 . . . . 0.0 106.601 176.246 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.445 ' O ' ' O ' ' H' ' 33' ' ' GLY . 96.4 mt -107.87 106.2 20.22 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 C-N-CA 120.349 -0.54 . . . . 0.0 110.606 -179.054 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.03 97.17 0.94 Allowed Glycine 0 CA--C 1.508 -0.357 0 N-CA-C 104.95 -3.26 . . . . 0.0 104.95 176.393 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.833 ' O ' HD12 ' H' ' 34' ' ' LEU . 52.4 tp -155.63 154.39 31.54 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 118.188 -1.405 . . . . 0.0 113.361 -175.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 8.1 mtp -112.11 122.47 47.83 Favored 'General case' 0 N--CA 1.446 -0.629 0 CA-C-N 112.989 -1.914 . . . . 0.0 108.655 178.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.704 HG21 ' CD1' ' I' ' 17' ' ' LEU . 35.9 m -131.32 112.07 20.64 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 N-CA-C 107.896 -1.15 . . . . 0.0 107.896 178.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . 105.69 -132.07 10.94 Favored Glycine 0 CA--C 1.519 0.303 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 103.53 -62.64 0.42 Allowed Glycine 0 CA--C 1.536 1.37 0 N-CA-C 111.656 -0.578 . . . . 0.0 111.656 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 2.2 t -92.78 164.41 2.08 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.46 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.552 ' N ' ' CG2' ' H' ' 39' ' ' VAL . 8.5 p . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.991 -1.005 . . . . 0.0 110.585 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.196 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 44.3 t80 -71.38 133.5 46.0 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.906 0.384 . . . . 0.0 110.587 -179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -94.29 115.62 27.89 Favored 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.388 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.15 136.09 32.98 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.338 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.501 ' NE2' ' OE2' ' I' ' 11' ' ' GLU . 81.0 m80 -113.4 149.54 33.98 Favored 'General case' 0 N--CA 1.465 0.304 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.557 ' O ' ' ND1' ' G' ' 14' ' ' HIS . 9.6 p-80 -86.82 164.15 16.82 Favored 'General case' 0 C--N 1.332 -0.167 0 C-N-CA 120.304 -0.558 . . . . 0.0 110.983 -179.376 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 97.3 mt-30 -100.81 152.6 20.32 Favored 'General case' 0 CA--C 1.522 -0.098 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.837 178.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -110.84 107.86 17.49 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 109.948 -0.39 . . . . 0.0 109.948 177.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -123.16 117.38 25.24 Favored 'General case' 0 N--CA 1.472 0.639 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.404 ' CG2' HG22 ' G' ' 18' ' ' VAL . 12.9 m -132.14 133.76 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 121.132 0.491 . . . . 0.0 111.033 179.098 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 8.7 t80 -129.91 129.65 44.14 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.559 -179.097 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.408 ' CE2' ' CG ' ' I' ' 20' ' ' PHE . 29.2 m-85 -127.43 131.57 50.22 Favored 'General case' 0 N--CA 1.471 0.575 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.465 -179.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.19 122.38 31.73 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 178.309 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.45 ' O ' ' OD1' ' H' ' 23' ' ' ASP . 82.6 tt0 -147.17 121.67 9.73 Favored 'General case' 0 N--CA 1.472 0.662 0 N-CA-C 114.621 1.341 . . . . 0.0 114.621 -178.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.718 ' CG ' ' H ' ' G' ' 23' ' ' ASP . 1.7 p-10 156.24 -74.5 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 114.211 -1.359 . . . . 0.0 109.379 175.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.741 HG22 ' N ' ' H' ' 25' ' ' GLY . 3.6 p -67.53 -112.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.446 -0.65 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.713 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.741 ' N ' HG22 ' H' ' 24' ' ' VAL . . . 126.39 -38.76 2.14 Favored Glycine 0 N--CA 1.454 -0.128 0 CA-C-N 113.866 -1.516 . . . . 0.0 111.133 176.545 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 16.2 t -70.4 112.7 6.89 Favored 'General case' 0 N--CA 1.446 -0.668 0 N-CA-C 106.241 -1.763 . . . . 0.0 106.241 174.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 28.4 m120 -113.68 168.54 9.69 Favored 'General case' 0 CA--C 1.507 -0.683 0 C-N-CA 119.268 -0.973 . . . . 0.0 111.815 179.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.537 ' HB3' ' H ' ' A' ' 40' ' ' VAL . 99.2 mttt -39.39 -38.42 0.55 Allowed 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.618 -1.173 . . . . 0.0 111.091 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.564 ' CA ' HG21 ' B' ' 39' ' ' VAL . . . 179.72 77.08 0.06 OUTLIER Glycine 0 CA--C 1.535 1.314 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.909 -176.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.464 ' O ' ' HA ' ' I' ' 30' ' ' ALA . . . -51.49 91.14 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 CA-C-N 119.131 1.466 . . . . 0.0 112.157 -177.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.402 ' N ' ' O ' ' H' ' 29' ' ' GLY . 96.8 mt -134.21 138.63 49.73 Favored 'Isoleucine or valine' 0 C--O 1.236 0.37 0 CA-C-N 115.409 -0.814 . . . . 0.0 112.135 -178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.571 HD13 ' CD1' ' J' ' 19' ' ' PHE . 96.8 mt -108.32 104.95 17.88 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.243 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 177.867 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -105.13 97.09 1.29 Allowed Glycine 0 N--CA 1.461 0.3 0 N-CA-C 104.565 -3.414 . . . . 0.0 104.565 176.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.833 HD12 ' O ' ' G' ' 34' ' ' LEU . 15.2 tp -143.09 136.43 28.29 Favored 'General case' 0 C--N 1.323 -0.553 0 C-N-CA 118.731 -1.187 . . . . 0.0 113.044 -174.081 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.8 mtp -105.18 118.82 37.52 Favored 'General case' 0 CA--C 1.51 -0.573 0 CA-C-N 113.176 -1.829 . . . . 0.0 106.845 178.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.576 HG12 ' CD ' ' J' ' 15' ' ' GLN . 10.9 t -130.03 102.62 7.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -177.346 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . 112.43 -162.49 12.38 Favored Glycine 0 CA--C 1.519 0.323 0 N-CA-C 111.225 -0.75 . . . . 0.0 111.225 179.58 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.16 -55.44 0.52 Allowed Glycine 0 CA--C 1.542 1.747 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -178.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 1.085 HG12 HD12 ' N' ' 31' ' ' ILE . 1.8 m -127.99 161.57 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.444 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 177.389 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.45 ' OXT' ' O ' ' O' ' 28' ' ' LYS . 46.6 t . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 117.942 -1.028 . . . . 0.0 110.012 177.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.28 0 N-CA-C 109.482 -1.447 . . . . 0.0 109.482 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.93 135.45 48.46 Favored 'General case' 0 N--CA 1.466 0.342 0 CA-C-O 120.793 0.33 . . . . 0.0 110.367 179.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.501 ' OE2' ' NE2' ' H' ' 13' ' ' HIS . 97.3 mt-10 -74.35 109.4 7.8 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.895 -0.409 . . . . 0.0 109.895 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.475 ' CG2' ' O ' ' J' ' 12' ' ' VAL . 23.2 m -139.27 159.79 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.942 -179.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.477 ' CD2' ' OXT' ' G' ' 40' ' ' VAL . 78.0 m80 -69.78 114.25 7.8 Favored 'General case' 0 N--CA 1.469 0.499 0 C-N-CA 120.682 -0.407 . . . . 0.0 111.611 -178.116 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.645 ' CD2' ' N ' ' I' ' 15' ' ' GLN . 13.2 t60 -161.9 169.98 20.24 Favored 'General case' 0 CA--C 1.538 0.507 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.273 179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.645 ' N ' ' CD2' ' I' ' 14' ' ' HIS . 57.9 tt0 -156.27 140.28 16.34 Favored 'General case' 0 C--N 1.341 0.23 0 C-N-CA 120.191 -0.603 . . . . 0.0 110.4 177.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -97.92 113.94 25.9 Favored 'General case' 0 N--CA 1.469 0.521 0 N-CA-C 113.089 0.774 . . . . 0.0 113.089 178.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.704 ' CD1' HG21 ' G' ' 36' ' ' VAL . 58.8 mt -121.98 114.22 20.66 Favored 'General case' 0 N--CA 1.475 0.804 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 87.4 t -116.41 109.68 28.88 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.444 ' CD1' HD13 ' G' ' 32' ' ' ILE . 74.1 m-85 -108.01 106.44 16.67 Favored 'General case' 0 CA--C 1.538 0.498 0 N-CA-C 106.316 -1.735 . . . . 0.0 106.316 177.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.408 ' CG ' ' CE2' ' H' ' 20' ' ' PHE . 35.3 t80 -120.6 132.97 55.4 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -176.316 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.66 ' HB3' HG21 ' I' ' 24' ' ' VAL . . . -149.7 146.5 27.27 Favored 'General case' 0 CA--C 1.547 0.844 0 CA-C-O 121.63 0.729 . . . . 0.0 112.651 -178.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.422 ' OE2' ' OE2' ' H' ' 22' ' ' GLU . 77.9 mt-10 -103.88 151.55 22.99 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.837 178.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.602 ' N ' ' O ' ' J' ' 22' ' ' GLU . 71.4 m-20 57.47 48.79 13.93 Favored 'General case' 0 CA--C 1.541 0.634 0 CA-C-O 121.14 0.495 . . . . 0.0 110.405 -179.525 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.662 HG23 ' HB1' ' J' ' 21' ' ' ALA . 0.1 OUTLIER -137.4 -173.92 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.983 0 CA-C-O 121.66 0.743 . . . . 0.0 110.824 -177.23 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.71 28.2 67.67 Favored Glycine 0 CA--C 1.531 1.078 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -177.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.538 ' HB2' HG21 ' J' ' 24' ' ' VAL . 71.3 m -143.56 -128.18 0.09 Allowed 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.548 ' CG ' ' H ' ' I' ' 28' ' ' LYS . 50.5 t30 54.38 -159.48 0.17 Allowed 'General case' 0 C--O 1.215 -0.727 0 N-CA-C 112.536 0.569 . . . . 0.0 112.536 178.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.548 ' H ' ' CG ' ' I' ' 27' ' ' ASN . 64.1 mttp -64.46 -39.61 94.14 Favored 'General case' 0 C--N 1.321 -0.637 0 N-CA-C 115.46 1.652 . . . . 0.0 115.46 -173.309 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -162.31 66.31 0.25 Allowed Glycine 0 N--CA 1.472 1.067 0 C-N-CA 118.52 -1.8 . . . . 0.0 114.616 -175.127 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.464 ' HA ' ' O ' ' H' ' 30' ' ' ALA . . . -82.7 131.95 35.19 Favored 'General case' 0 CA--C 1.541 0.631 0 CA-C-O 122.156 0.979 . . . . 0.0 112.111 -178.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.652 HD11 ' HB ' ' C' ' 39' ' ' VAL . 50.5 mt -144.05 143.4 23.71 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 CA-C-N 114.447 -1.251 . . . . 0.0 113.585 -177.036 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.421 HD12 HG12 ' J' ' 32' ' ' ILE . 54.1 mt -105.15 101.99 13.17 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.594 0 N-CA-C 107.345 -1.354 . . . . 0.0 107.345 173.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.423 ' O ' ' O ' ' H' ' 32' ' ' ILE . . . -103.62 98.5 1.61 Allowed Glycine 0 CA--C 1.507 -0.452 0 N-CA-C 104.913 -3.275 . . . . 0.0 104.913 176.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.596 HD12 ' O ' ' H' ' 34' ' ' LEU . 23.7 tp -140.13 135.12 32.17 Favored 'General case' 0 N--CA 1.45 -0.461 0 CA-C-O 122.287 1.041 . . . . 0.0 113.281 -173.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.408 ' N ' HD12 ' I' ' 34' ' ' LEU . 5.9 mtp -109.43 117.66 34.61 Favored 'General case' 0 CA--C 1.512 -0.484 0 CA-C-N 113.612 -1.631 . . . . 0.0 107.205 177.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.565 HG11 HD11 ' K' ' 17' ' ' LEU . 4.4 t -130.42 111.82 21.68 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.442 0 CA-C-O 120.624 0.25 . . . . 0.0 110.736 -177.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.759 ' N ' HE22 ' K' ' 15' ' ' GLN . . . 138.33 -131.07 5.23 Favored Glycine 0 C--N 1.318 -0.434 0 C-N-CA 120.395 -0.907 . . . . 0.0 112.144 177.681 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.05 -61.76 0.39 Allowed Glycine 0 CA--C 1.543 1.828 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . 0.746 HG21 ' HA2' ' O' ' 29' ' ' GLY . 4.0 p -146.21 151.25 14.59 Favored 'Isoleucine or valine' 0 C--N 1.344 0.339 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 175.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.506 HG23 ' O ' ' I' ' 39' ' ' VAL . 58.6 t . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 118.026 -0.988 . . . . 0.0 109.753 179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.238 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -105.62 133.04 51.01 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.928 0.394 . . . . 0.0 110.732 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -85.18 125.29 32.71 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.912 -179.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.483 ' CG1' ' NE2' ' J' ' 14' ' ' HIS . 96.0 t -125.82 108.64 19.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.621 179.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 58.3 m170 -111.78 124.38 52.22 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 113.283 0.845 . . . . 0.0 113.283 -178.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.883 ' HD1' ' H ' ' K' ' 14' ' ' HIS . 47.1 m-70 -148.67 162.9 38.8 Favored 'General case' 0 N--CA 1.463 0.221 0 C-N-CA 120.29 -0.564 . . . . 0.0 109.735 174.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.719 ' NE2' HE21 ' K' ' 15' ' ' GLN . 85.0 mt-30 -100.69 147.17 26.31 Favored 'General case' 0 N--CA 1.45 -0.442 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 174.114 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 13.8 mttt -118.34 92.37 3.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 174.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.895 HD12 HD22 ' K' ' 17' ' ' LEU . 6.9 mt -117.24 115.54 25.5 Favored 'General case' 0 CA--C 1.507 -0.69 0 C-N-CA 119.734 -0.786 . . . . 0.0 110.693 -178.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 98.7 t -113.5 102.38 13.81 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.571 ' CD1' HD13 ' H' ' 32' ' ' ILE . 64.6 m-85 -104.05 107.09 17.83 Favored 'General case' 0 C--O 1.236 0.37 0 N-CA-C 105.84 -1.911 . . . . 0.0 105.84 178.222 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.567 ' CE1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -121.95 124.07 43.17 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 120.99 -0.284 . . . . 0.0 111.622 -176.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . 0.662 ' HB1' HG23 ' I' ' 24' ' ' VAL . . . -136.27 115.48 12.52 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' I' ' 23' ' ' ASP . 98.0 mt-10 -120.18 177.74 4.9 Favored 'General case' 0 N--CA 1.495 1.777 0 N-CA-C 118.333 2.716 . . . . 0.0 118.333 -174.85 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.441 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 41.5 t0 28.62 46.31 0.02 OUTLIER 'General case' 0 N--CA 1.477 0.896 0 N-CA-C 119.946 3.313 . . . . 0.0 119.946 175.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.656 HG22 ' N ' ' I' ' 24' ' ' VAL . 0.2 OUTLIER -80.57 -179.81 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.724 0 N-CA-C 106.209 -1.774 . . . . 0.0 106.209 175.105 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.408 ' O ' ' CB ' ' J' ' 26' ' ' SER . . . -71.05 -29.23 69.18 Favored Glycine 0 CA--C 1.533 1.21 0 C-N-CA 118.126 -1.988 . . . . 0.0 112.274 -178.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.421 ' O ' ' C ' ' J' ' 27' ' ' ASN . 1.5 t 168.16 127.24 0.01 OUTLIER 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.813 0.807 . . . . 0.0 112.079 175.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.506 HD21 ' N ' ' J' ' 30' ' ' ALA . 2.0 t-20 -37.21 133.94 0.63 Allowed 'General case' 0 N--CA 1.474 0.765 0 CA-C-O 119.138 -0.458 . . . . 0.0 110.733 174.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.441 ' HB2' ' O ' ' I' ' 27' ' ' ASN . 67.6 mttm -109.27 -40.27 4.98 Favored 'General case' 0 N--CA 1.478 0.967 0 CA-C-N 118.969 0.804 . . . . 0.0 111.118 177.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . -164.45 64.35 0.24 Allowed Glycine 0 CA--C 1.541 1.718 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.924 -178.482 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.506 ' N ' HD21 ' J' ' 27' ' ' ASN . . . -83.7 143.26 30.15 Favored 'General case' 0 C--O 1.245 0.855 0 N-CA-C 113.533 0.938 . . . . 0.0 113.533 -177.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.563 HD11 ' CG2' ' D' ' 39' ' ' VAL . 79.9 mt -135.78 131.0 50.03 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.662 0 CA-C-N 114.832 -1.076 . . . . 0.0 111.677 179.015 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.425 ' O ' HG22 ' J' ' 32' ' ' ILE . 3.0 mt -106.22 110.36 31.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 N-CA-C 108.066 -1.087 . . . . 0.0 108.066 176.275 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.6 99.0 1.06 Allowed Glycine 0 C--O 1.239 0.441 0 N-CA-C 105.624 -2.99 . . . . 0.0 105.624 177.018 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.546 HD12 ' O ' ' I' ' 34' ' ' LEU . 24.3 tp -134.93 123.59 23.62 Favored 'General case' 0 C--O 1.24 0.597 0 CA-C-O 122.414 1.102 . . . . 0.0 113.697 -175.612 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.43 ' N ' HD12 ' J' ' 34' ' ' LEU . 2.2 ttm -98.29 116.69 31.05 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 106.209 -1.775 . . . . 0.0 106.209 176.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.518 HG21 HD23 ' L' ' 17' ' ' LEU . 0.5 OUTLIER -130.11 103.3 8.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 C-N-CA 121.365 -0.134 . . . . 0.0 111.049 -177.434 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . 144.22 -153.72 25.23 Favored Glycine 0 CA--C 1.509 -0.283 0 C-N-CA 120.035 -1.079 . . . . 0.0 112.358 178.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.493 ' O ' ' CD1' ' P' ' 31' ' ' ILE . . . 138.73 -56.31 0.65 Allowed Glycine 0 CA--C 1.544 1.898 0 CA-C-N 114.24 -0.98 . . . . 0.0 110.787 -178.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.53 HG12 ' N ' ' J' ' 40' ' ' VAL . 87.8 t -135.93 157.89 38.72 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 177.059 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.53 ' N ' HG12 ' J' ' 39' ' ' VAL . 17.3 m . . . . . 0 C--O 1.22 -0.495 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.528 -179.629 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -108.85 146.54 33.52 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.854 0.359 . . . . 0.0 110.561 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.8 mm-40 -70.32 128.81 37.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.14 -179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 23.0 t -111.94 121.05 63.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.325 0 CA-C-N 116.11 -0.495 . . . . 0.0 109.785 179.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.628 ' CE1' ' NZ ' ' P' ' 28' ' ' LYS . 6.6 p80 -151.59 113.72 4.51 Favored 'General case' 0 C--N 1.332 -0.189 0 C-N-CA 120.377 -0.529 . . . . 0.0 112.027 -179.729 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.883 ' H ' ' HD1' ' J' ' 14' ' ' HIS . 13.4 p-80 -153.34 160.31 42.65 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.389 177.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.759 HE22 ' N ' ' I' ' 37' ' ' GLY . 88.3 mt-30 -90.12 160.08 16.46 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 178.213 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.2 tttp -139.42 109.38 6.37 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.457 0.646 . . . . 0.0 109.902 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.895 HD22 HD12 ' J' ' 17' ' ' LEU . 1.1 mt -118.55 122.41 42.58 Favored 'General case' 0 CA--C 1.513 -0.477 0 CA-C-N 114.992 -1.004 . . . . 0.0 109.865 -179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 16.7 t -113.49 101.05 11.92 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 25.3 m-85 -100.79 102.67 13.8 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 105.232 -2.136 . . . . 0.0 105.232 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.574 ' CZ ' ' CD1' ' L' ' 20' ' ' PHE . 1.4 t80 -113.4 124.96 53.66 Favored 'General case' 0 N--CA 1.474 0.762 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 -177.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' K' ' 23' ' ' ASP . . . -160.76 162.78 32.51 Favored 'General case' 0 C--O 1.237 0.406 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 -177.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 48.6 tp10 -72.36 136.83 46.25 Favored 'General case' 0 CA--C 1.515 -0.377 0 N-CA-C 104.612 -2.366 . . . . 0.0 104.612 176.163 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.729 ' CG ' ' HB1' ' L' ' 21' ' ' ALA . 6.4 m-20 -152.5 61.03 0.82 Allowed 'General case' 0 C--N 1.323 -0.564 0 N-CA-C 114.987 1.477 . . . . 0.0 114.987 -173.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.669 ' O ' ' O ' ' K' ' 23' ' ' ASP . 34.4 t -44.16 -110.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 178.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.539 ' O ' ' N ' ' K' ' 27' ' ' ASN . . . 162.82 -46.51 0.33 Allowed Glycine 0 CA--C 1.506 -0.519 0 C-N-CA 116.707 -2.663 . . . . 0.0 115.781 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 15.9 m -65.99 101.56 0.69 Allowed 'General case' 0 CA--C 1.519 -0.25 0 CA-C-N 123.605 3.702 . . . . 0.0 104.373 178.539 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.539 ' N ' ' O ' ' K' ' 25' ' ' GLY . 28.2 m-20 -130.04 161.4 31.08 Favored 'General case' 0 CA--C 1.517 -0.312 0 CA-C-N 114.847 -1.069 . . . . 0.0 112.455 -178.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.509 ' NZ ' ' O ' ' D' ' 40' ' ' VAL . 61.3 tttt -28.71 -39.47 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.833 172.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' K' ' 27' ' ' ASN . . . 141.75 73.81 0.04 OUTLIER Glycine 0 CA--C 1.545 1.914 0 CA-C-N 114.702 -1.135 . . . . 0.0 111.103 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.44 150.03 46.63 Favored 'General case' 0 C--N 1.354 0.777 0 CA-C-O 121.804 0.811 . . . . 0.0 112.681 -177.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.418 ' CG1' HG22 ' L' ' 31' ' ' ILE . 2.6 mp -136.42 138.26 46.96 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 CA-C-N 114.689 -1.141 . . . . 0.0 112.78 -177.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.8 mt -117.68 119.99 63.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 178.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.46 117.41 3.31 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 111.131 -0.788 . . . . 0.0 111.131 -179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 67.7 mt -123.47 129.18 50.86 Favored 'General case' 0 CA--C 1.518 -0.257 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 73.2 mtp -137.61 136.68 37.75 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 119.365 -0.934 . . . . 0.0 113.061 -179.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.495 ' HB ' HG13 ' L' ' 36' ' ' VAL . 10.8 t -113.31 155.27 14.56 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.149 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.433 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -52.25 -102.34 0.01 OUTLIER Glycine 0 CA--C 1.524 0.599 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 179.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' L' ' 38' ' ' GLY . . . -138.03 -74.6 0.06 OUTLIER Glycine 0 CA--C 1.527 0.792 0 C-N-CA 120.823 -0.704 . . . . 0.0 113.177 178.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . 0.74 HG13 HD11 ' Q' ' 31' ' ' ILE . 6.6 m -73.81 130.78 35.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.428 0 C-N-CA 120.599 -0.441 . . . . 0.0 110.428 -178.698 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 14.6 t . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.04 -0.981 . . . . 0.0 110.29 179.967 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.679 -1.368 . . . . 0.0 109.679 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -103.94 133.04 49.58 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.795 0.331 . . . . 0.0 110.583 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -126.88 134.24 50.52 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 91.1 t -111.91 101.41 12.49 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.21 0 CA-C-O 121.265 0.555 . . . . 0.0 110.877 -179.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.481 ' O ' ' CG ' ' L' ' 14' ' ' HIS . 5.0 p80 -147.2 90.82 1.92 Allowed 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.639 179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.481 ' CG ' ' O ' ' L' ' 13' ' ' HIS . 69.3 m80 -158.19 168.31 27.42 Favored 'General case' 0 C--O 1.223 -0.295 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 179.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.461 ' OE1' ' OE1' ' K' ' 15' ' ' GLN . 94.8 mm-40 -89.84 158.45 17.46 Favored 'General case' 0 C--O 1.232 0.164 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 178.71 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 73.2 tttt -139.92 105.27 5.06 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-O 121.465 0.65 . . . . 0.0 110.492 178.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.518 HD23 HG21 ' J' ' 36' ' ' VAL . 0.2 OUTLIER -116.16 113.9 23.73 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 177.695 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.2 t -106.79 103.85 16.11 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.547 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 178.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 39.7 m-85 -99.78 101.71 12.94 Favored 'General case' 0 CA--C 1.518 -0.279 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 178.197 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.574 ' CD1' ' CZ ' ' K' ' 20' ' ' PHE . 15.1 t80 -110.04 103.13 11.83 Favored 'General case' 0 CA--C 1.508 -0.664 0 N-CA-C 107.548 -1.278 . . . . 0.0 107.548 179.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.729 ' HB1' ' CG ' ' K' ' 23' ' ' ASP . . . -132.87 137.31 46.64 Favored 'General case' 0 C--N 1.314 -0.978 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 -178.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.525 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.9 mt-10 -78.62 102.77 8.15 Favored 'General case' 0 C--O 1.221 -0.43 0 C-N-CA 118.879 -1.128 . . . . 0.0 108.636 -179.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 44.2 p-10 -155.77 46.62 0.48 Allowed 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 112.786 0.661 . . . . 0.0 112.786 -177.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 32.9 m -83.22 172.69 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.649 0 C-N-CA 118.819 -1.152 . . . . 0.0 109.788 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 96.02 -28.68 11.86 Favored Glycine 0 CA--C 1.533 1.165 0 CA-C-N 115.824 -0.625 . . . . 0.0 111.545 179.531 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.9 t 91.68 119.22 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 -179.679 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.533 ' O ' ' N ' ' L' ' 29' ' ' GLY . 15.4 m-20 -71.95 150.3 44.24 Favored 'General case' 0 CA--C 1.533 0.298 0 C-N-CA 120.291 -0.564 . . . . 0.0 112.221 -179.013 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -53.17 47.45 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.732 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.533 ' N ' ' O ' ' L' ' 27' ' ' ASN . . . 101.77 63.38 0.75 Allowed Glycine 0 CA--C 1.543 1.799 0 C-N-CA 119.928 -1.129 . . . . 0.0 114.088 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -119.63 169.46 10.06 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 106.478 -1.675 . . . . 0.0 106.478 178.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.418 HG22 ' CG1' ' K' ' 31' ' ' ILE . 12.6 tt -139.8 151.03 21.97 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.16 0 C-N-CA 119.008 -1.077 . . . . 0.0 113.626 -177.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 15.0 tt -135.48 134.08 52.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.014 -0.994 . . . . 0.0 110.152 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -139.64 134.22 6.52 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.315 -0.469 . . . . 0.0 111.971 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tt -127.25 124.72 39.51 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 108.145 -1.057 . . . . 0.0 108.145 179.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 92.4 mtp -140.86 146.58 37.7 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -177.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.495 HG13 ' HB ' ' K' ' 36' ' ' VAL . 8.8 t -139.33 132.13 37.03 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.461 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.463 177.662 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -106.97 112.42 3.76 Favored Glycine 0 N--CA 1.468 0.794 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 179.023 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' L' ' 39' ' ' VAL . . . 112.52 71.25 0.58 Allowed Glycine 0 CA--C 1.541 1.67 0 CA-C-N 117.522 0.661 . . . . 0.0 112.477 178.804 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . 0.547 HG12 ' N ' ' L' ' 40' ' ' VAL . 66.2 t -27.33 158.84 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.956 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . 0.547 ' N ' HG12 ' L' ' 39' ' ' VAL . 92.9 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.942 -1.027 . . . . 0.0 110.788 178.594 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' M' M ' 10' ' ' TYR . . . . . 0.491 ' CE2' ' O ' ' M' ' 11' ' ' GLU . 88.6 t80 -73.06 132.67 43.62 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.8 0.333 . . . . 0.0 110.535 -179.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 11' ' ' GLU . . . . . 0.491 ' O ' ' CE2' ' M' ' 10' ' ' TYR . 79.7 tt0 -74.08 152.38 39.95 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.154 179.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 12' ' ' VAL . . . . . 0.42 HG23 ' O ' ' M' ' 12' ' ' VAL . 29.0 m -114.9 130.13 69.9 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 CA-C-O 120.95 0.405 . . . . 0.0 110.714 -179.6 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 13' ' ' HIS . . . . . . . . . . . . . 75.6 m80 -95.06 165.8 12.25 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.366 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 14' ' ' HIS . . . . . 0.481 ' CD2' ' N ' ' M' ' 14' ' ' HIS . 0.8 OUTLIER -86.47 168.0 14.15 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.498 -179.36 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' M' M ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -129.17 150.72 50.44 Favored 'General case' 0 CA--C 1.518 -0.251 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 178.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -97.62 120.91 38.85 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.595 179.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 17' ' ' LEU . . . . . . . . . . . . . 92.2 mt -125.29 115.3 20.14 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.098 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -140.34 140.59 34.39 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.383 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 19' ' ' PHE . . . . . . . . . . . . . 30.1 t80 -143.18 141.32 31.11 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.095 0.474 . . . . 0.0 110.674 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 20' ' ' PHE . . . . . 0.484 ' O ' ' CD1' ' M' ' 20' ' ' PHE . 53.1 p90 -127.4 128.38 45.73 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 179.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.66 127.41 46.24 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.329 0.585 . . . . 0.0 111.378 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 22' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -138.67 146.34 41.5 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.94 179.572 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 23' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 58.47 59.84 2.81 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.231 -0.44 . . . . 0.0 112.173 178.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 24' ' ' VAL . . . . . 0.765 HG12 ' H ' ' M' ' 25' ' ' GLY . 4.1 t 70.59 175.29 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 121.514 0.673 . . . . 0.0 111.732 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 25' ' ' GLY . . . . . 0.765 ' H ' HG12 ' M' ' 24' ' ' VAL . . . 100.65 -34.72 5.35 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-N 114.717 -1.129 . . . . 0.0 111.948 -179.202 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 26' ' ' SER . . . . . . . . . . . . . 6.1 p -82.92 -121.47 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.299 0 N-CA-C 107.81 -1.181 . . . . 0.0 107.81 176.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 27' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' M' ' 31' ' ' ILE . 8.9 p30 -92.42 161.21 14.74 Favored 'General case' 0 CA--C 1.517 -0.297 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 176.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 28' ' ' LYS . . . . . 0.413 ' O ' ' CD ' ' N' ' 28' ' ' LYS . 72.8 tttt -45.29 -39.2 6.32 Favored 'General case' 0 C--N 1.329 -0.309 0 C-N-CA 119.139 -1.025 . . . . 0.0 110.517 -179.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 29' ' ' GLY . . . . . 0.445 ' O ' ' OD2' ' N' ' 23' ' ' ASP . . . -146.9 -76.18 0.02 OUTLIER Glycine 0 N--CA 1.473 1.11 0 C-N-CA 120.951 -0.642 . . . . 0.0 112.893 177.784 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 30' ' ' ALA . . . . . . . . . . . . . . . -159.76 87.81 0.82 Allowed 'General case' 0 C--O 1.234 0.283 0 CA-C-O 121.129 0.49 . . . . 0.0 111.611 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 31' ' ' ILE . . . . . 0.658 HG23 ' O ' ' M' ' 31' ' ' ILE . 14.3 tt -138.33 115.56 11.73 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 N-CA-C 108.801 -0.815 . . . . 0.0 108.801 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 32' ' ' ILE . . . . . 0.42 HD13 HG21 ' M' ' 32' ' ' ILE . 43.1 mt -107.09 109.37 27.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.485 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.88 92.46 0.55 Allowed Glycine 0 N--CA 1.463 0.46 0 N-CA-C 105.886 -2.885 . . . . 0.0 105.886 177.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 34' ' ' LEU . . . . . . . . . . . . . 91.8 mt -143.56 167.16 22.87 Favored 'General case' 0 N--CA 1.472 0.664 0 N-CA-C 114.927 1.455 . . . . 0.0 114.927 -175.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 35' ' ' MET . . . . . . . . . . . . . 90.7 mmm -123.45 106.58 10.75 Favored 'General case' 0 N--CA 1.446 -0.641 0 CA-C-N 112.108 -2.315 . . . . 0.0 107.062 177.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 36' ' ' VAL . . . . . 0.551 HG21 HD21 ' O' ' 17' ' ' LEU . 43.9 t -112.46 111.97 38.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.66 0 CA-C-O 121.264 0.554 . . . . 0.0 109.835 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 37' ' ' GLY . . . . . . . . . . . . . . . 125.42 -131.7 7.74 Favored Glycine 0 C--N 1.315 -0.63 0 N-CA-C 109.013 -1.635 . . . . 0.0 109.013 -179.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' M' M ' 38' ' ' GLY . . . . . 0.492 ' H ' ' HA3' ' N' ' 37' ' ' GLY . . . 94.47 -63.27 1.66 Allowed Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.786 -1.325 . . . . 0.0 109.786 -178.289 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 39' ' ' VAL . . . . . 0.436 HG22 ' H ' ' M' ' 39' ' ' VAL . 4.7 m -96.65 173.51 0.95 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 N-CA-C 109.34 -0.615 . . . . 0.0 109.34 177.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' M' M ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' N' ' 40' ' ' VAL . 26.8 m . . . . . 0 C--O 1.219 -0.537 0 CA-C-O 117.97 -1.014 . . . . 0.0 110.938 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.664 -1.374 . . . . 0.0 109.664 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' N' N ' 10' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -106.42 134.8 49.0 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 120.764 0.316 . . . . 0.0 110.333 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 11' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -114.97 119.71 37.43 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.796 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 12' ' ' VAL . . . . . 0.415 ' CG1' ' HE2' ' N' ' 14' ' ' HIS . 58.8 t -126.96 131.4 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -142.32 130.27 21.83 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.443 0.64 . . . . 0.0 112.63 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 14' ' ' HIS . . . . . 0.513 ' ND1' ' N ' ' O' ' 14' ' ' HIS . 33.0 m-70 -153.1 172.39 16.97 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.218 177.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 15' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -155.18 141.0 18.15 Favored 'General case' 0 C--N 1.327 -0.405 0 C-N-CA 119.821 -0.751 . . . . 0.0 109.741 177.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 16' ' ' LYS . . . . . . . . . . . . . 70.1 tttt -88.53 113.66 24.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.937 -0.574 . . . . 0.0 111.161 178.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 17' ' ' LEU . . . . . 0.418 ' N ' HD12 ' N' ' 17' ' ' LEU . 8.3 mp -111.24 113.1 25.36 Favored 'General case' 0 N--CA 1.472 0.65 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.245 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 18' ' ' VAL . . . . . . . . . . . . . 61.1 t -128.12 132.16 68.71 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 CA-C-O 120.891 0.377 . . . . 0.0 111.35 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 19' ' ' PHE . . . . . . . . . . . . . 7.2 t80 -141.23 127.45 19.69 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 120.956 0.408 . . . . 0.0 111.835 -179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 20' ' ' PHE . . . . . . . . . . . . . 31.6 m-85 -117.23 131.58 56.81 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.254 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.29 133.23 34.75 Favored 'General case' 0 N--CA 1.475 0.781 0 N-CA-C 113.151 0.797 . . . . 0.0 113.151 -178.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 22' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -122.02 145.31 48.26 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.359 178.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 23' ' ' ASP . . . . . 0.445 ' OD2' ' O ' ' M' ' 29' ' ' GLY . 51.6 m-20 -160.94 46.68 0.21 Allowed 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.918 0.39 . . . . 0.0 111.161 -178.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 24' ' ' VAL . . . . . . . . . . . . . 5.0 m -73.35 -179.79 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.74 0.781 . . . . 0.0 111.99 -178.232 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 25' ' ' GLY . . . . . . . . . . . . . . . 99.17 -35.33 4.76 Favored Glycine 0 CA--C 1.53 0.99 0 CA-C-N 114.306 -1.316 . . . . 0.0 111.95 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' N' ' 27' ' ' ASN . 84.8 p -162.56 117.04 1.79 Allowed 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 118.061 0.931 . . . . 0.0 110.874 176.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' N' ' 26' ' ' SER . 55.6 p30 -21.63 161.73 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.813 0 N-CA-C 113.515 0.931 . . . . 0.0 113.515 178.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 28' ' ' LYS . . . . . 0.454 ' CG ' ' O ' ' N' ' 27' ' ' ASN . 60.5 mttm -158.61 -10.3 0.07 Allowed 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 120.389 -0.524 . . . . 0.0 112.405 174.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.36 118.12 0.64 Allowed Glycine 0 CA--C 1.537 1.408 0 C-N-CA 120.122 -1.037 . . . . 0.0 112.631 178.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 30' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' O' ' 29' ' ' GLY . . . -102.91 113.33 26.7 Favored 'General case' 0 N--CA 1.475 0.807 0 CA-C-O 121.599 0.714 . . . . 0.0 111.98 -179.735 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 31' ' ' ILE . . . . . 1.085 HD12 HG12 ' H' ' 39' ' ' VAL . 81.4 mt -135.5 131.05 50.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -179.853 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 32' ' ' ILE . . . . . 0.608 HD13 ' CD1' ' P' ' 19' ' ' PHE . 92.8 mt -107.08 111.04 33.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 177.01 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 33' ' ' GLY . . . . . 0.406 ' O ' ' O ' ' M' ' 32' ' ' ILE . . . -116.0 105.6 1.42 Allowed Glycine 0 C--N 1.322 -0.234 0 N-CA-C 105.217 -3.153 . . . . 0.0 105.217 176.672 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 34' ' ' LEU . . . . . 0.633 ' O ' HD12 ' O' ' 34' ' ' LEU . 7.0 tt -152.77 140.75 20.23 Favored 'General case' 0 CA--C 1.504 -0.8 0 C-N-CA 117.953 -1.499 . . . . 0.0 111.747 -174.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 35' ' ' MET . . . . . . . . . . . . . 45.3 mtp -114.29 116.02 28.32 Favored 'General case' 0 N--CA 1.44 -0.972 0 CA-C-N 113.664 -1.607 . . . . 0.0 107.825 178.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' N' N ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -93.65 102.84 14.06 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.96 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 37' ' ' GLY . . . . . 0.492 ' HA3' ' H ' ' M' ' 38' ' ' GLY . . . -35.38 152.74 0.01 OUTLIER Glycine 0 N--CA 1.465 0.572 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.121 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 38' ' ' GLY . . . . . 0.563 ' O ' ' O ' ' O' ' 39' ' ' VAL . . . -85.28 -57.55 2.21 Favored Glycine 0 CA--C 1.541 1.676 0 C-N-CA 120.837 -0.697 . . . . 0.0 114.326 -179.021 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 39' ' ' VAL . . . . . 0.655 HG13 HD11 ' B' ' 31' ' ' ILE . 6.1 m -52.85 140.97 7.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-N 119.42 1.61 . . . . 0.0 110.812 -178.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' N' N ' 40' ' ' VAL . . . . . 0.429 ' OXT' ' OXT' ' M' ' 40' ' ' VAL . 7.5 p . . . . . 0 C--O 1.221 -0.438 0 CA-C-O 117.904 -1.046 . . . . 0.0 110.552 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.333 -1.507 . . . . 0.0 109.333 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' O' O ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -106.53 127.24 53.16 Favored 'General case' 0 N--CA 1.464 0.25 0 N-CA-C 110.024 -0.362 . . . . 0.0 110.024 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 11' ' ' GLU . . . . . 0.472 ' O ' ' NE2' ' P' ' 13' ' ' HIS . 97.4 mt-10 -146.7 158.96 44.02 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.809 0.337 . . . . 0.0 111.01 -179.775 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 12' ' ' VAL . . . . . 0.473 HG22 ' H ' ' P' ' 12' ' ' VAL . 55.2 t -129.53 118.3 45.0 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-N 115.956 -0.565 . . . . 0.0 109.659 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 13' ' ' HIS . . . . . . . . . . . . . 16.1 m-70 -134.36 137.56 44.23 Favored 'General case' 0 N--CA 1.474 0.742 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 -179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 14' ' ' HIS . . . . . 0.698 ' ND1' ' O ' ' P' ' 14' ' ' HIS . 66.2 t60 -151.12 153.2 34.57 Favored 'General case' 0 CA--C 1.549 0.94 0 C-N-CA 119.027 -1.069 . . . . 0.0 112.278 179.906 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 15' ' ' GLN . . . . . 0.548 ' O ' ' CD2' ' O' ' 14' ' ' HIS . 15.2 tp60 -87.83 158.8 18.65 Favored 'General case' 0 N--CA 1.474 0.753 0 C-N-CA 123.263 0.625 . . . . 0.0 110.791 177.472 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 16' ' ' LYS . . . . . 0.602 ' C ' HD12 ' O' ' 17' ' ' LEU . 71.5 tttt -159.09 95.21 1.25 Allowed 'General case' 0 C--N 1.309 -1.169 0 C-N-CA 119.616 -0.834 . . . . 0.0 110.252 176.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 17' ' ' LEU . . . . . 0.602 HD12 ' C ' ' O' ' 16' ' ' LYS . 8.2 mp -116.45 127.16 54.34 Favored 'General case' 0 N--CA 1.475 0.802 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.283 179.242 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 18' ' ' VAL . . . . . . . . . . . . . 48.4 t -127.23 107.04 16.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 N-CA-C 107.769 -1.197 . . . . 0.0 107.769 176.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 19' ' ' PHE . . . . . . . . . . . . . 75.8 m-85 -111.91 113.23 25.43 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.501 -0.555 . . . . 0.0 109.501 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 20' ' ' PHE . . . . . 0.481 ' CE2' ' CD1' ' P' ' 20' ' ' PHE . 45.8 t80 -111.77 121.53 45.32 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 179.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.19 136.91 47.38 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 122.065 0.936 . . . . 0.0 112.492 -178.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 22' ' ' GLU . . . . . 0.498 ' HG2' ' H ' ' O' ' 23' ' ' ASP . 51.6 tt0 -65.85 179.59 0.85 Allowed 'General case' 0 N--CA 1.444 -0.758 0 N-CA-C 106.725 -1.583 . . . . 0.0 106.725 178.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 23' ' ' ASP . . . . . 0.498 ' H ' ' HG2' ' O' ' 22' ' ' GLU . 1.8 m-20 167.59 58.8 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.574 0 C-N-CA 119.638 -0.825 . . . . 0.0 110.978 -174.68 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 24' ' ' VAL . . . . . 0.46 ' O ' ' O ' ' O' ' 23' ' ' ASP . 18.4 t -62.92 -114.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -177.237 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 25' ' ' GLY . . . . . . . . . . . . . . . -104.01 43.51 1.66 Allowed Glycine 0 N--CA 1.47 0.922 0 CA-C-N 121.71 2.05 . . . . 0.0 109.677 -176.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 26' ' ' SER . . . . . . . . . . . . . 19.4 t -74.37 99.93 3.64 Favored 'General case' 0 N--CA 1.451 -0.38 0 CA-C-N 111.479 -2.36 . . . . 0.0 108.724 174.101 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 27' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -94.72 -161.73 0.88 Allowed 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.617 0.722 . . . . 0.0 112.045 -177.263 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 28' ' ' LYS . . . . . 0.587 ' NZ ' ' CB ' ' K' ' 13' ' ' HIS . 70.5 tttt 38.38 40.54 0.37 Allowed 'General case' 0 CA--C 1.544 0.717 0 N-CA-C 115.592 1.701 . . . . 0.0 115.592 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 29' ' ' GLY . . . . . 0.746 ' HA2' HG21 ' I' ' 39' ' ' VAL . . . -177.72 62.34 0.09 OUTLIER Glycine 0 CA--C 1.541 1.672 0 C-N-CA 118.974 -1.584 . . . . 0.0 115.221 173.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.45 90.4 3.29 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 118.05 0.925 . . . . 0.0 110.883 174.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 31' ' ' ILE . . . . . . . . . . . . . 71.3 mt -140.96 132.94 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 CA-C-N 120.869 1.668 . . . . 0.0 113.826 -179.125 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 32' ' ' ILE . . . . . 0.6 HD13 ' CD1' ' Q' ' 19' ' ' PHE . 78.1 mt -109.88 109.0 26.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 174.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.1 99.28 1.06 Allowed Glycine 0 C--O 1.239 0.414 0 N-CA-C 105.547 -3.021 . . . . 0.0 105.547 177.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 34' ' ' LEU . . . . . 0.633 HD12 ' O ' ' N' ' 34' ' ' LEU . 10.3 tp -128.23 130.56 48.14 Favored 'General case' 0 CA--C 1.508 -0.661 0 CA-C-O 122.458 1.123 . . . . 0.0 113.507 -174.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -104.94 104.24 13.95 Favored 'General case' 0 N--CA 1.439 -0.999 0 N-CA-C 104.729 -2.323 . . . . 0.0 104.729 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 36' ' ' VAL . . . . . 0.559 HG11 ' CD2' ' Q' ' 17' ' ' LEU . 8.0 p -131.48 142.55 42.98 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 C-N-CA 120.343 -0.543 . . . . 0.0 109.81 -176.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 37' ' ' GLY . . . . . . . . . . . . . . . 120.97 -102.04 0.82 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 38' ' ' GLY . . . . . . . . . . . . . . . 64.46 -80.17 0.06 OUTLIER Glycine 0 CA--C 1.534 1.28 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 -178.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' O' O ' 39' ' ' VAL . . . . . 0.574 HG22 HD11 ' C' ' 31' ' ' ILE . 3.4 m -148.44 167.66 3.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.689 0 N-CA-C 108.295 -1.002 . . . . 0.0 108.295 176.308 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' O' O ' 40' ' ' VAL . . . . . 0.774 HG13 ' HE2' ' Q' ' 13' ' ' HIS . 1.4 p . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.377 179.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' P' P ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -109.35 136.85 48.11 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 120.74 0.305 . . . . 0.0 110.299 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -103.14 114.93 29.62 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.438 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 12' ' ' VAL . . . . . 0.473 ' H ' HG22 ' O' ' 12' ' ' VAL . 2.4 p -141.87 135.64 29.7 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.495 179.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 13' ' ' HIS . . . . . 0.514 ' O ' ' ND1' ' Q' ' 13' ' ' HIS . 86.3 m-70 -142.48 118.81 10.84 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.437 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 14' ' ' HIS . . . . . 0.698 ' O ' ' ND1' ' O' ' 14' ' ' HIS . 0.0 OUTLIER -146.9 170.74 16.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.472 0.653 . . . . 0.0 111.821 -179.552 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' P' P ' 15' ' ' GLN . . . . . 0.495 ' OE1' ' CG2' ' O' ' 36' ' ' VAL . 47.7 tt0 -107.45 149.8 27.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.448 179.709 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 16' ' ' LYS . . . . . . . . . . . . . 71.8 mttt -139.91 110.64 6.78 Favored 'General case' 0 N--CA 1.472 0.663 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 176.146 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 17' ' ' LEU . . . . . . . . . . . . . 6.3 mt -126.88 116.67 21.19 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 178.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 18' ' ' VAL . . . . . . . . . . . . . 43.1 t -110.11 105.54 19.01 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 N-CA-C 107.719 -1.215 . . . . 0.0 107.719 177.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 19' ' ' PHE . . . . . 0.608 ' CD1' HD13 ' N' ' 32' ' ' ILE . 92.5 m-85 -106.59 107.19 18.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 107.44 -1.318 . . . . 0.0 107.44 179.192 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 20' ' ' PHE . . . . . 0.596 ' CE2' ' CD1' ' Q' ' 20' ' ' PHE . 31.3 t80 -116.06 124.29 50.05 Favored 'General case' 0 N--CA 1.473 0.686 0 CA-C-O 120.469 0.176 . . . . 0.0 110.73 -178.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.41 138.25 30.97 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.75 0.786 . . . . 0.0 112.432 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 22' ' ' GLU . . . . . 0.504 ' O ' ' CB ' ' P' ' 23' ' ' ASP . 20.9 tt0 -76.81 -174.54 3.09 Favored 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.146 -1.428 . . . . 0.0 107.146 178.172 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 23' ' ' ASP . . . . . 0.504 ' CB ' ' O ' ' P' ' 22' ' ' GLU . 10.3 m-20 142.99 50.02 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 p -82.78 149.46 4.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 C-N-CA 119.341 -0.943 . . . . 0.0 111.404 -177.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 25' ' ' GLY . . . . . 0.406 ' O ' ' OG ' ' P' ' 26' ' ' SER . . . 93.23 36.81 5.83 Favored Glycine 0 CA--C 1.529 0.947 0 CA-C-N 113.614 -1.63 . . . . 0.0 111.848 179.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 26' ' ' SER . . . . . 0.59 ' N ' ' O ' ' Q' ' 24' ' ' VAL . 3.4 p 72.65 120.23 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 N-CA-C 112.219 0.452 . . . . 0.0 112.219 175.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 27' ' ' ASN . . . . . 0.868 HD22 ' H ' ' P' ' 29' ' ' GLY . 10.4 t30 -83.2 161.75 21.44 Favored 'General case' 0 C--N 1.338 0.084 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.809 175.24 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 28' ' ' LYS . . . . . 0.628 ' NZ ' ' CE1' ' K' ' 13' ' ' HIS . 75.4 tttt -48.54 -39.38 23.26 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 113.461 0.912 . . . . 0.0 113.461 177.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 29' ' ' GLY . . . . . 0.868 ' H ' HD22 ' P' ' 27' ' ' ASN . . . 171.59 68.85 0.04 OUTLIER Glycine 0 CA--C 1.544 1.863 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 -174.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 30' ' ' ALA . . . . . . . . . . . . . . . -70.22 145.76 51.17 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-N 119.062 1.431 . . . . 0.0 114.673 -173.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 31' ' ' ILE . . . . . 0.507 HD12 HG22 ' J' ' 39' ' ' VAL . 75.2 mt -136.08 133.94 50.44 Favored 'Isoleucine or valine' 0 CA--C 1.55 0.968 0 CA-C-N 113.46 -1.7 . . . . 0.0 113.651 -177.505 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 32' ' ' ILE . . . . . 0.423 HD13 HG21 ' P' ' 32' ' ' ILE . 55.0 mt -107.67 117.06 52.59 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.016 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 175.614 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.77 102.02 1.06 Allowed Glycine 0 N--CA 1.466 0.657 0 N-CA-C 106.746 -2.542 . . . . 0.0 106.746 176.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 34' ' ' LEU . . . . . 0.612 HD23 HG22 ' P' ' 36' ' ' VAL . 0.3 OUTLIER -126.25 132.36 51.72 Favored 'General case' 0 C--O 1.236 0.36 0 N-CA-C 114.154 1.168 . . . . 0.0 114.154 -175.571 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' P' P ' 35' ' ' MET . . . . . . . . . . . . . 1.8 mtp -109.17 99.71 8.97 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 104.2 -2.519 . . . . 0.0 104.2 174.306 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 36' ' ' VAL . . . . . 0.612 HG22 HD23 ' P' ' 34' ' ' LEU . 1.4 t -114.06 103.15 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.344 -0.389 . . . . 0.0 111.719 -175.32 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' P' P ' 37' ' ' GLY . . . . . . . . . . . . . . . 148.31 -153.77 25.46 Favored Glycine 0 C--N 1.319 -0.39 0 C-N-CA 120.284 -0.96 . . . . 0.0 111.813 178.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 38' ' ' GLY . . . . . . . . . . . . . . . 118.43 -56.03 0.57 Allowed Glycine 0 CA--C 1.545 1.946 0 N-CA-C 111.287 -0.725 . . . . 0.0 111.287 -178.461 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' P' P ' 39' ' ' VAL . . . . . 0.565 HG23 HD11 ' D' ' 31' ' ' ILE . 0.9 OUTLIER -153.24 157.55 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.261 0 N-CA-C 108.866 -0.79 . . . . 0.0 108.866 177.566 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' P' P ' 40' ' ' VAL . . . . . 0.602 HG13 ' CD2' ' R' ' 13' ' ' HIS . 7.0 t . . . . . 0 C--O 1.219 -0.51 0 CA-C-N 114.659 -1.155 . . . . 0.0 110.459 178.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.284 0 N-CA-C 109.346 -1.502 . . . . 0.0 109.346 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' Q' Q ' 10' ' ' TYR . . . . . . . . . . . . . 95.5 m-85 -113.56 135.1 54.28 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 120.805 0.336 . . . . 0.0 110.468 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 11' ' ' GLU . . . . . 0.411 ' O ' ' OE1' ' R' ' 11' ' ' GLU . 96.5 mt-10 -87.26 119.61 27.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.984 -179.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 12' ' ' VAL . . . . . 0.482 ' O ' HG23 ' Q' ' 12' ' ' VAL . 33.3 m -118.32 126.1 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.075 179.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 13' ' ' HIS . . . . . 0.774 ' HE2' HG13 ' O' ' 40' ' ' VAL . 0.1 OUTLIER -152.74 140.55 20.03 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.989 -179.525 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' Q' Q ' 14' ' ' HIS . . . . . 0.608 ' N ' ' ND1' ' Q' ' 13' ' ' HIS . 1.1 p80 -159.68 161.7 34.96 Favored 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 109.489 -0.559 . . . . 0.0 109.489 177.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 15' ' ' GLN . . . . . 0.431 ' HB3' HD11 ' Q' ' 17' ' ' LEU . 75.5 mt-30 -90.02 158.71 17.22 Favored 'General case' 0 CA--C 1.516 -0.349 0 C-N-CA 120.5 -0.48 . . . . 0.0 109.747 178.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -140.81 101.9 4.17 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 176.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 17' ' ' LEU . . . . . 0.56 ' N ' HD12 ' Q' ' 17' ' ' LEU . 1.1 mp -119.06 113.42 20.91 Favored 'General case' 0 CA--C 1.51 -0.561 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 179.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 18' ' ' VAL . . . . . . . . . . . . . 61.7 t -110.92 106.63 21.11 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 19' ' ' PHE . . . . . 0.6 ' CD1' HD13 ' O' ' 32' ' ' ILE . 72.2 m-85 -107.04 103.05 12.37 Favored 'General case' 0 C--N 1.328 -0.349 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.296 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 20' ' ' PHE . . . . . 0.596 ' CD1' ' CE2' ' P' ' 20' ' ' PHE . 37.3 t80 -108.79 118.32 36.47 Favored 'General case' 0 N--CA 1.465 0.295 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 -178.747 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 21' ' ' ALA . . . . . 0.471 ' O ' ' OE1' ' R' ' 22' ' ' GLU . . . -140.79 138.02 33.78 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 121.85 0.833 . . . . 0.0 112.967 -179.106 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' P' ' 23' ' ' ASP . 94.7 mt-10 -85.03 122.34 29.11 Favored 'General case' 0 C--O 1.22 -0.497 0 N-CA-C 107.748 -1.204 . . . . 0.0 107.748 177.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 23' ' ' ASP . . . . . 0.417 ' CG ' ' O ' ' Q' ' 22' ' ' GLU . 35.4 m-20 -162.44 52.15 0.2 Allowed 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 112.496 0.554 . . . . 0.0 112.496 -176.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 24' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' P' ' 26' ' ' SER . 93.2 t -74.45 142.25 14.98 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 C-N-CA 117.923 -1.511 . . . . 0.0 110.069 -178.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 25' ' ' GLY . . . . . . . . . . . . . . . 100.46 37.49 3.75 Favored Glycine 0 CA--C 1.53 1.02 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 -178.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 26' ' ' SER . . . . . . . . . . . . . 92.4 p -64.57 106.44 1.16 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 121.698 0.761 . . . . 0.0 111.576 -177.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 27' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -149.85 -161.25 1.3 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 114.429 -1.26 . . . . 0.0 110.173 -179.604 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 28' ' ' LYS . . . . . . . . . . . . . 68.9 mttm 29.5 40.82 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 29' ' ' GLY . . . . . 0.682 ' HA2' HG11 ' K' ' 39' ' ' VAL . . . 110.53 70.91 0.63 Allowed Glycine 0 N--CA 1.481 1.641 0 N-CA-C 116.36 1.304 . . . . 0.0 116.36 175.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 30' ' ' ALA . . . . . . . . . . . . . . . -108.53 114.14 27.72 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 175.632 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 31' ' ' ILE . . . . . 0.74 HD11 HG13 ' K' ' 39' ' ' VAL . 66.6 mt -130.29 135.33 60.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 CA-C-N 119.108 0.867 . . . . 0.0 113.238 -178.177 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 32' ' ' ILE . . . . . . . . . . . . . 96.7 mt -121.59 114.71 44.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 176.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.14 114.84 3.29 Favored Glycine 0 N--CA 1.467 0.748 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 34' ' ' LEU . . . . . . . . . . . . . 14.3 tp -117.63 117.18 28.69 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 122.251 0.221 . . . . 0.0 110.429 -178.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 35' ' ' MET . . . . . . . . . . . . . 10.2 mtp -121.76 124.28 43.84 Favored 'General case' 0 C--O 1.233 0.19 0 N-CA-C 110.066 -0.346 . . . . 0.0 110.066 179.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 36' ' ' VAL . . . . . . . . . . . . . 67.1 t -110.81 131.48 61.88 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.166 0 CA-C-O 121.108 0.48 . . . . 0.0 111.087 -178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 37' ' ' GLY . . . . . 0.461 ' O ' ' C ' ' Q' ' 38' ' ' GLY . . . -72.81 111.68 3.63 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.229 -1.148 . . . . 0.0 110.229 179.833 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 38' ' ' GLY . . . . . 0.5 ' H ' ' HA3' ' R' ' 37' ' ' GLY . . . -6.09 -67.23 0.01 OUTLIER Glycine 0 N--CA 1.477 1.428 0 C-N-CA 123.608 0.623 . . . . 0.0 114.224 -178.049 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' Q' Q ' 39' ' ' VAL . . . . . . . . . . . . . 14.0 t -86.09 120.63 36.27 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.337 0 CA-C-N 118.351 1.076 . . . . 0.0 109.68 179.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' Q' Q ' 40' ' ' VAL . . . . . . . . . . . . . 29.1 t . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.883 -1.056 . . . . 0.0 110.272 -179.312 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' R' R ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.479 -1.449 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' R' R ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -148.29 160.75 42.65 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 11' ' ' GLU . . . . . 0.411 ' OE1' ' O ' ' Q' ' 11' ' ' GLU . 79.2 mm-40 -114.74 151.32 33.92 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.154 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 12' ' ' VAL . . . . . . . . . . . . . 57.4 t -107.09 105.97 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 121.043 0.449 . . . . 0.0 110.705 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 13' ' ' HIS . . . . . 0.602 ' CD2' HG13 ' P' ' 40' ' ' VAL . 63.0 t60 -148.82 130.14 14.68 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 115.584 -0.735 . . . . 0.0 112.224 179.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 14' ' ' HIS . . . . . . . . . . . . . 42.0 p-80 -154.03 162.8 40.94 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.833 176.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 15' ' ' GLN . . . . . 0.592 ' CD ' HG12 ' P' ' 36' ' ' VAL . 5.5 tt0 -89.86 158.29 17.52 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 16' ' ' LYS . . . . . 0.545 ' O ' HD12 ' Q' ' 17' ' ' LEU . 68.9 tttt -140.82 103.15 4.44 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 17' ' ' LEU . . . . . 0.612 ' N ' HD23 ' R' ' 17' ' ' LEU . 0.1 OUTLIER -115.51 109.29 17.6 Favored 'General case' 0 CA--C 1.512 -0.484 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 178.702 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' R' R ' 18' ' ' VAL . . . . . . . . . . . . . 59.7 t -106.28 104.09 16.46 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 178.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 19' ' ' PHE . . . . . 0.431 ' HE1' HD22 ' P' ' 34' ' ' LEU . 51.2 m-85 -100.25 100.95 11.84 Favored 'General case' 0 CA--C 1.509 -0.599 0 N-CA-C 106.724 -1.584 . . . . 0.0 106.724 178.252 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -110.77 110.33 20.93 Favored 'General case' 0 CA--C 1.511 -0.525 0 CA-C-O 121.299 0.571 . . . . 0.0 109.949 -179.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.6 130.29 45.48 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 106.548 -1.649 . . . . 0.0 106.548 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 22' ' ' GLU . . . . . 0.518 ' OE2' ' CZ ' ' Q' ' 20' ' ' PHE . 52.2 mp0 -77.86 108.99 11.5 Favored 'General case' 0 C--N 1.321 -0.65 0 C-N-CA 118.597 -1.241 . . . . 0.0 110.686 -177.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 23' ' ' ASP . . . . . 0.573 ' CG ' ' H ' ' R' ' 24' ' ' VAL . 22.8 p-10 -178.83 -69.79 0.01 OUTLIER 'General case' 0 C--N 1.347 0.463 0 N-CA-C 113.986 1.106 . . . . 0.0 113.986 178.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 24' ' ' VAL . . . . . 0.573 ' H ' ' CG ' ' R' ' 23' ' ' ASP . 42.9 t -147.28 120.59 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 -177.518 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 25' ' ' GLY . . . . . . . . . . . . . . . -66.75 -43.73 91.09 Favored Glycine 0 CA--C 1.53 0.987 0 C-N-CA 119.546 -1.311 . . . . 0.0 110.659 179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 26' ' ' SER . . . . . . . . . . . . . 44.1 m -139.56 -111.03 0.15 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 117.231 0.515 . . . . 0.0 111.283 177.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 27' ' ' ASN . . . . . . . . . . . . . 7.1 m120 55.69 152.67 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.859 178.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 28' ' ' LYS . . . . . . . . . . . . . 82.0 tttt -70.41 48.79 0.11 Allowed 'General case' 0 CA--C 1.531 0.243 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.465 178.301 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 29' ' ' GLY . . . . . . . . . . . . . . . -98.35 -52.06 1.38 Allowed Glycine 0 CA--C 1.541 1.664 0 C-N-CA 120.705 -0.76 . . . . 0.0 113.859 -178.424 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.4 176.44 5.15 Favored 'General case' 0 CA--C 1.514 -0.436 0 CA-C-N 117.454 0.627 . . . . 0.0 109.972 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 31' ' ' ILE . . . . . . . . . . . . . 85.7 mt -110.45 116.97 53.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 177.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 32' ' ' ILE . . . . . . . . . . . . . 77.4 mt -113.63 127.44 70.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.039 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.85 113.13 1.7 Allowed Glycine 0 CA--C 1.529 0.952 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 179.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' R' R ' 34' ' ' LEU . . . . . 0.646 ' C ' HD23 ' R' ' 34' ' ' LEU . 6.9 tt -118.05 121.43 40.57 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 -179.594 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 35' ' ' MET . . . . . 0.549 ' N ' HD23 ' R' ' 34' ' ' LEU . 93.9 mtp -140.01 143.16 36.31 Favored 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.567 -0.453 . . . . 0.0 111.075 -179.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 36' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' R' ' 37' ' ' GLY . 3.3 p -122.83 131.56 73.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.693 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 37' ' ' GLY . . . . . 0.5 ' HA3' ' H ' ' Q' ' 38' ' ' GLY . . . -34.05 -111.41 0.0 OUTLIER Glycine 0 CA--C 1.529 0.933 0 CA-C-N 115.102 -0.953 . . . . 0.0 113.591 179.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 38' ' ' GLY . . . . . 0.41 ' H ' ' CA ' ' Q' ' 38' ' ' GLY . . . -111.52 -71.68 0.63 Allowed Glycine 0 CA--C 1.537 1.42 0 CA-C-N 115.563 -0.319 . . . . 0.0 113.288 -178.292 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 39' ' ' VAL . . . . . 0.525 HG12 HD12 ' F' ' 31' ' ' ILE . 6.8 p -138.49 142.71 34.27 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.522 0 CA-C-N 117.618 0.709 . . . . 0.0 112.254 -178.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' R' R ' 40' ' ' VAL . . . . . . . . . . . . . 70.8 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.965 -1.016 . . . . 0.0 110.455 178.629 . . . . . . . . 0 0 . 1 stop_ save_